<SEC-DOCUMENT>0001739614-22-000023.txt : 20220228
<SEC-HEADER>0001739614-22-000023.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228160702
ACCESSION NUMBER:		0001739614-22-000023
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inhibrx, Inc.
		CENTRAL INDEX KEY:			0001739614
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				824257312
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39452
		FILM NUMBER:		22689359

	BUSINESS ADDRESS:	
		STREET 1:		11025 N. TORREY PINES ROAD, SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(858) 795-4220

	MAIL ADDRESS:	
		STREET 1:		11025 N. TORREY PINES ROAD, SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>inbx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:8eb0955a-77e8-4ec9-9bdb-5f279743741e,g:91526847-18eb-416c-96d8-1d5c48d93616,d:e96bda597eaa4024845d6498a1c78657--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:inbx="http://inhibrx.com/20211231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>inbx-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N180L2ZyYWc6NTQxOTFiZWQ2MDg1NDUxNzhmZjY4ZmNmZjFhYTE3NGMvdGFibGU6MjRkNjFjZmNmYTEyNGJmMWE5ZjM2YmQ1ODlkNjI1NDAvdGFibGVyYW5nZToyNGQ2MWNmY2ZhMTI0YmYxYTlmMzZiZDU4OWQ2MjU0MF8xLTEtMS0xLTI0Mzc2_8a26b592-5baf-4c34-8022-a7f1a8d4a2ac">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N180L2ZyYWc6NTQxOTFiZWQ2MDg1NDUxNzhmZjY4ZmNmZjFhYTE3NGMvdGFibGU6MjRkNjFjZmNmYTEyNGJmMWE5ZjM2YmQ1ODlkNjI1NDAvdGFibGVyYW5nZToyNGQ2MWNmY2ZhMTI0YmYxYTlmMzZiZDU4OWQ2MjU0MF8yLTEtMS0xLTI0Mzc2_919ce106-8354-410c-bf71-6aa105f1494a">0001739614</ix:nonNumeric><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N180L2ZyYWc6NTQxOTFiZWQ2MDg1NDUxNzhmZjY4ZmNmZjFhYTE3NGMvdGFibGU6MjRkNjFjZmNmYTEyNGJmMWE5ZjM2YmQ1ODlkNjI1NDAvdGFibGVyYW5nZToyNGQ2MWNmY2ZhMTI0YmYxYTlmMzZiZDU4OWQ2MjU0MF8zLTEtMS0xLTI0Mzc2_28f5fb87-dcc1-4a22-9b96-3a859e26b528">2021</ix:nonNumeric><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N180L2ZyYWc6NTQxOTFiZWQ2MDg1NDUxNzhmZjY4ZmNmZjFhYTE3NGMvdGFibGU6MjRkNjFjZmNmYTEyNGJmMWE5ZjM2YmQ1ODlkNjI1NDAvdGFibGVyYW5nZToyNGQ2MWNmY2ZhMTI0YmYxYTlmMzZiZDU4OWQ2MjU0MF80LTEtMS0xLTI0Mzc2_589d44e8-1db9-4b55-aac4-a0c241f5230d">FY</ix:nonNumeric><ix:nonNumeric contextRef="i7ab52899837545d286948af053bb22a6_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDIx_fb18bef6-4644-4d4c-b39d-3e7398424521">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i964a81d9b0a74c4191f65b0b105bd98e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDYy_22f664cc-88d9-4893-a2bc-e342d557a1d4">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i796767f501ce49c3aa17f0da608f9877_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNTAx_ac274eaf-b7f7-4024-9d85-68b4306ca0ff">P4Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i2d96c21dec494881b4a6b19595e76848_D20200811-20200811" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTcvZnJhZzpjYWVjMDc1MzIwNWY0OWIyYmQ1ZmRmZjZmNzk3MTVmZi90YWJsZTpjZGI4YmViNDM2ODA0NWQ1YjY3MDNmODAyYjIyMDlmNC90YWJsZXJhbmdlOmNkYjhiZWI0MzY4MDQ1ZDViNjcwM2Y4MDJiMjIwOWY0XzEtMS0xLTEtMjQzNzY_53d67076-3cc4-4aeb-a4dc-02c4a9a23424">0.5753</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="inbx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i506355bc91dc4a3382f883e168444b20_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1db365e9d856446db31cae19f9e0e5db_I20220221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ibd9dfc54d94543ba8698368d96961d03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i11f52d64e8c349e58d874face32a65a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i250f7e2f155f413297fef8b19d430be2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd1e8d9a53a428686d8938f450e798b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f5f2867b4374b8392c13581eb930e33_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25366f43bada4f5b9d53d088a682e118_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie64d22ae265b44358c9e947a1a1b1c0c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6373c936330246fe88c309a40939f56e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c545895ca04258955cb754430080ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id881f495b72943148f25b6840685d537_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ec9949e1e248ccab71a11e6c1074bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50251df3c1c54c87b2d175fa7d628143_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bb7bb32c3f343c8a327751ee96ff5a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e88fbcb34b14703a4c85b9f232b78bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id726b7dd9036485d8c990a47cc6bd3d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida37a3d3907b43bd835289673510cd62_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0952c59ab2f14ce9a7f5f4f4bab1f608_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ceb6a7800114c0f80544f3e11e04a59_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72afbdbf0e414c5caaa6e4ab484a62f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f6557dde914ba196b748270c390563_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e858246ea634ea3904ae0efa91f93ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dfd538e45ac47328f0a920dcb4c0614_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db515ef6fb84613872d16729bbfc6bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c768226360e440e85d40981d2a3a347_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaf0841293054a07bd73deb9e8af0344_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932ae73c06e44acab39c531ada30fa22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i722a3c1036664a1db19bf1f1b8c8ef4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d39a168fc3a432aa5b6c0e2880ae017_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782f77ab577843fa872a7b5b9541a230_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43e54c84aae74e828b9b94427b981d3e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5392c3f3d956465e9c4f2e9ee08ac5b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc6061b1a5654bd1a013f69ed4b79e27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b6686e2594645e0b104bd30c79c6ce2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c90406be53b4899a32eb757c4b6aa8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f87c3827874f3ca0e19457894ec414_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inbx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d258a97d4684eaba513930d94729cd8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inbx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c9a266f60c4664bc65b6877237a861_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79c55f122bda4d359fc762cce6002cc9_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8177b8ffee4c4ea998a952b70d65e0ef_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6cea0c2ca9441f79fe37eb6f7844b1d_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad4a6f2ea563431298cac685298bcd91_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if28c89b4ce594ec18c2baa17251f5398_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64129936be0b412b8e1d86243a3cc9f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inbx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90dfb0c9e29b4454ae5d3269b190a197_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inbx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93fd390c8a614c1f8ea8dce7fbd6bbd1_D20200511-20200511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-11</xbrli:startDate><xbrli:endDate>2020-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09e02f53cc2d44b4a25de925c223563e_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39dd7198616e4871a04691df5d501376_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f3cbe060eb4e03859e4a074152ce82_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:WuXiBiologicsHealthcareVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab52899837545d286948af053bb22a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc73af7586ed4a7893d2827190cc61ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i964a81d9b0a74c4191f65b0b105bd98e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb2b71a468364db0b76d16dcc40554c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i796767f501ce49c3aa17f0da608f9877_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie74f508386624bc591b2098160a4640a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>inbx:lease</xbrli:measure></xbrli:unit><xbrli:context id="i71b075ff878e44c4922334a3be94c8cf_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icc9931e7028244ecadfcd288d792171d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd205c8ba4b4294b112ca3f590109b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa5894f258e64ee787243df2040ca6d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibca4cb805a4d45438e207a1536816957_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">inbx:WarrantAndDerivativeLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iead2791fae4b4da59253032bf7b42e47_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb4707fb2959449d9321c8c1488e1c19_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab110f9486a46d7bc11aaaf0bf87703_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b34f949eb8d495c9c9f5c2ff130ba51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">inbx:WarrantAndDerivativeLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18dec53bcc4c412abadbaa5a71931d50_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cbc8f3cc82e45b1b819d385f0420fab_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37602c9d5ed8495cb15a8ef8ddaa15dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i170482e872e54fa3a75fd05af40e0ac9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd52f475273e436dbd8c13baa139f7ff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c0b54c2dda34749b9b0940bc4d42110_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>inbx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2d96c21dec494881b4a6b19595e76848_D20200811-20200811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-11</xbrli:startDate><xbrli:endDate>2020-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1710f2bbed1f4858b4386673f448cffe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i020ea95670924586b00a510e94318bdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ee0abef7874f9db4990a4e94b36a2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53e4b677a5742fd983bfb37b3aa7e80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6a2d5f0e3c440ef8d989fed722504af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377f66a6d4c54b4ca81d7975dd8a5c8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7242126f78fa4a8a8b9c857fce023330_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia33ae29820054b0db7fce225cab20805_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife5ab90e2a7d472080cd923e5b5db3b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3c6503a73a4cb9beb9b3b8e12d0fc5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9a2ae527c6442f69033f87496c9e149_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad61546aa39a46a6ab37a1278118f591_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfda6bf472bc49e48b735e5c112a0531_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d71b0c7c95e4b21a9fd208c7d3fa8c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bbe9a1a4e50490a8f0a1b8d2384b65d_D20200715-20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansTermBTermCTranche1OfTermAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-15</xbrli:startDate><xbrli:endDate>2020-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d0faac086f48b49f67f4291eb50af5_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe5a8c4c13b647ba8a99cfbad3d44b0f_D20201112-20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f1dd4556c84be1903e4fccae311a27_I20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i822a1c2899dd422882f0c3c6958c8b78_D20201112-20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>inbx:tranche</xbrli:measure></xbrli:unit><xbrli:context id="ie0e9b67a1f98416d947e940d51019a13_D20201112-20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4dee1f4dab044b5904819f8b2634e06_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanJune2021AmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7b1a7a708534f06a0a7d794a7a27a80_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanJune2021AmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a0d6e3138bb4cb6ba9620a8eee4bbd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23f05621867b46ba85b04d8f1e06e75d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i921b6c207f2a4f428b2e98a2c7602eaa_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida7de870e3734f6f8e5b74fa33367059_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i546e91723e584f938387442db9ab32f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea06729df7364389bb97b7cac1e9cfad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ddad33eb12403ab966960a6f430d69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e8046ea9e74b1c96aee8f24c431683_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic890278d955442b5a665ca0900a0a5e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cfb99837e104069a050c050a6a0e015_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idde9aa5844664a6f8c3890232bb1f19a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbed81cbbbc44ceca46d67906a40279c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0171f114a2a6466ebf29d4bf342dc328_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanJune2021AmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd8bb82f3c443ae89d9b90d7796e52b_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsIssuedConcurrentlyWith2020LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80af9778e30f4d7c8c60c10f21011485_I20200715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsIssuedConcurrentlyWith2020LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id95bef5f495646d58a4ab12c5852afc4_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsIssuedUponConsummationOfIPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d74b118fa384d7ebae249afc60e4626_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsIssuedUponConsummationOfIPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f93dd1e5494e218459effec8912900_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsIssuedUponConsummationOfIPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51d5eb374e764a38a5a2883487e16341_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dec658dfa294ef580b787eaea9c9e61_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd2ea5f3b8d4063b55ea5ac924b3bc2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2015OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i903596dda51b4295ba537cb047cbe3ee_I20190520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice2d978f42f647d0b34ffd2d606a3b23_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b2c31362ca6456e9fa354eb0012a302_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9912d0eb770b4de0a793e3fe42d493b4_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if68d1087bb6f4d22995e04dde84541a0_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09b542f567974ce98531ed6d78bdcb08_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie129391072864eaa854b90a526c15513_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0784cd66e4954bd983b5bf6086ef67c6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39de78949fa4338b856a1bf1a370fbf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c0a33aee14452581d9c884594cd5aa_D20190501-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9c4b992959d4ddb90aad9b4d5df22bb_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c9b6bfda5d34fbca767a5fbbe17acf7_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8eef267ef1c487289aaf7cbf76447dd_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61137fd603eb42ea8e17d095c0e1c8a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e02f9252cd34ce2b7cec9630fc0647c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c6895eb15134795b9d0e82c56053e76_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06da7c90c85744e885809060c5d6303c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f544045b0fb4204a60d3d67976ede93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48c28eaf2c8c46e5bee554a6274ee022_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a6aef8263df4b4394e27acda74d8862_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d9970bae2c434f937ba92ef27c5adf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341109abd16e4f10b4e1e65b6337432b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c3275369d04c28ab7b49526e64a396_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i142ace6beb0a4e0cb0a31bdafc6073cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec1fc7e08a643bf8e0ed329426540bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9873f9e3a544e59ad94ffcbdc43d0e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b7601189b5477d86501a51b482aa63_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if36de08aad5f467f9e693d3ede931b29_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a51291642f448ec8cd027ba449ffffc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcea0ecd9c6b41f78dbf074f597078d2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd518d0ffae4538a37e20dd37eef51e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff19098b1d84316ac86ea37db136e01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d0d09c00524dfa9503fde259f37888_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14792fc3ee614e638bfb3b224a160754_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia67376928e9f4157be200ec20b14f188_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6590e8fbc4694172ba86e9ff761b35b1_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4809a9a893f4d2c8042ea8a8edf9689_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a40dcc9d78543888f5c69df6b043678_I20181220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i698dae32d5a249e4b3a18d5a9465c4eb_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2018OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271fbcd059344d279776e92017e48fd9_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2018OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09040213ce284863b236dce6b9e77648_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2018OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia212ff07ac3d4e76acd885a467fdf19e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2018OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2033a7016a444c9b438b2366300cfe_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>inbx:program</xbrli:measure></xbrli:unit><xbrli:context id="i1083dfcb25d248699e857f5dda8cb53e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementAdditionalProgramsAuthorizedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcfc29d4ec6340358e01e8204eb73565_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedProgramOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c1b2eab0714268ae2f91d921ac33bc_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedProgramTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37061eba67bd4d3d915360e78477ab20_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67acf789baa649c0af5372276d8d64e9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="performanceobligation"><xbrli:measure>inbx:performanceObligation</xbrli:measure></xbrli:unit><xbrli:unit id="license"><xbrli:measure>inbx:license</xbrli:measure></xbrli:unit><xbrli:context id="i26036eb0b6df49ce9df831623f43f4a3_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ce3eba7b0a49238928411c43819b44_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic67e70a01a3247d0a701bceabea7050e_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c3132dfaadc4bcfaee034b1b2617d1c_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c3843a1089489cba9c3e221a109e69_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i029f0471f2e849158f5ea613d5e42420_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8577557b2c0f4aff994327f2da3dcc87_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie48c123d39ec4759bab8a2b5f5a6d11b_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7901dde9ee1429db2a92db83900b165_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6ad83c5ab34b7fa1f535c9d4959c05_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafffed7f22504c3dbc95651d314d0c59_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="compound"><xbrli:measure>inbx:compound</xbrli:measure></xbrli:unit><xbrli:context id="i8db766ee7ea14809bda578860b7d5f45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3960dc6272747bc82dddb1552b4d038_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65490e5c0be44ba79b6d213cefb118a6_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52cdafa4cb7a4f99adc30a5a1c93624f_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i232e3ecd8bfe4c2aa8c2c245ad98b7c9_I20190819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dfab9b39f19493b85149f07e9d3107b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd1fc01bfe349e38bce8388ae5742cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b51a3f85ef8434cbdc45bc15a773289_I20130630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29ef6bdd06234b22b93dd43c5eff449b_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fbcce74ea2b42b78bf1705bd1403dfd_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad2111df94964e5485832ec9af0f84c0_D20181201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04bdb4d1a6f84aaaa9f1469326060cc7_D20210201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bf66075080045f5ab3fa12625764cd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:LAVSummitLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98668daa4f54447a8199b989b8876b3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if065b432564046c9bfb0a597fe817533_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ebe67fc2c1e4f268cfb5159168b291a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d04a4699dc49db872fde8657a661e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">inbx:CostSharingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1308cbf39e914b3390c47254ceff94af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">inbx:CostSharingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cfee3e7350642afb89fae53b611c85e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">inbx:CostSharingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72fe4742bba4cdf9802783a4d7a8394_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">inbx:SaleAndPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5a16567fbac48168a3ad10ee9c58f87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">inbx:SaleAndPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2035d7358b324a5489bcf06a61d764cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee515f8958047ef8b35c147f98db98e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd2cf3902be24fe99f49b14a22a00695_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61def5f79b3b4943a515f38e57f56fa7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83fc42be157249d68dc8368a8c9862be_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i521b2e3a6dc44d48afe6adc72a12b794_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8432517eb8a474aa5bafe8e02511ce5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i272efd5ba40f48b3a36b628d2290dacc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6069ad52bbd94a97b38f0c5021430f66_D20220101-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcbf97b5335e41168d1a299751595d81_D20220101-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacb6213d02d74a88b77cba676df9265a_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20fe34380fca42f098a2db8d31b3286a_D20220218-20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13753df759a242849113e207322baf72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e7f4a47cd94673bc773402b7a5368e_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id785c7ea3a28479b8b1ddfb99f5cb605_D20220218-20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b78bb8be854db5b78e268e11b79ddd_D20220218-20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e1a737421844578b29281dfff09e84f_D20220218-20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec65463072474a72bf5be2ef264db82a_D20220218-20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b61d2e608d24c2eb1c1116a2a66abe6_D20220218-20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39dc64f1760d475e9b12a1ab87444d97_D20220218-20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c6633104ca543ebbacf87abf6aea7fa_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic510443d218e4b0ab9d522e8d0b425fa_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693b3d23e36049d1b4d15aeac78e1972_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739614</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie96bda597eaa4024845d6498a1c78657_1"></div><div style="min-height:18pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.932%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549 </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6NzZhNzE3YTIwMjg5NGY0YzkwZTIxOTk3ZDhiMzg3NDQvdGFibGVyYW5nZTo3NmE3MTdhMjAyODk0ZjRjOTBlMjE5OTdkOGIzODc0NF8zLTEtMS0xLTI0Mzc2L3RleHRyZWdpb246YWU2NGQ5ZTUxMDk2NDE0Yjk1ZTM1NWFiODQzNjQ4NjNfOQ_9afbb0b1-a80b-4365-b5da-eaf03b1839a9">10-K</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark one)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzgy_4e969822-086d-4c16-a420-8c5fd5b84e97">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8xMzc_a8bf092b-a46a-49ea-abce-ea1b86cdce46"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8xMzc_395fc878-69e7-4a8b-88c1-71df42413678">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzgw_be59fb4d-5037-4547-bfc5-5e06ef71eff3">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160; </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzg0_62bd804d-3cbe-4970-945d-64c7b99aa9e6"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzg0_b45bd50b-c011-4a49-846f-47aa6e7c13ee">001-39452</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.932%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.993%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl8xLTAtMS0xLTI0Mzc2_86640cf1-71c4-4d75-ab0c-1900e4301100">INHIBRX, INC.</ix:nonNumeric> </span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) &#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl81LTAtMS0xLTI0Mzc2_c2ed7d89-e103-48ca-a7ca-8ce8d6029708">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl81LTItMS0xLTI0Mzc2_fa0e5c84-55ee-4740-a530-79fd6e004f8b">82-4257312</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl84LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246ZDY2YTAyODViYzljNDQ5YTk0Nzc5ODQxZDBjZTUxZjRfMTA5OTUxMTYyNzc4Nw_68180893-38b0-493b-ba63-10f2a6cb13a3">11025 N. Torrey Pines Road</ix:nonNumeric>, <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl84LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246ZDY2YTAyODViYzljNDQ5YTk0Nzc5ODQxZDBjZTUxZjRfMTA5OTUxMTYyNzc5MQ_68b00ca3-083e-4b4c-99b8-4ec77346ffdb">Suite 200</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl85LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YzFlNGQxZWUxM2FkNGM5ZWFmNjQyNDI2YTYyOWI2MDZfMTA5OTUxMTYyNzc4Nw_14a1c26f-ae09-4748-92c6-eded3a57350f">La Jolla</ix:nonNumeric>, <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl85LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YzFlNGQxZWUxM2FkNGM5ZWFmNjQyNDI2YTYyOWI2MDZfMTA5OTUxMTYyNzc5MQ_6f526b4d-795b-4dbf-9ef2-96d7f7eeeca0">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl85LTItMS0xLTI0Mzc2L3RleHRyZWdpb246M2E0MjNlZGQxNTcxNGI5ZWIxNmQyOWI1NjZlYTdmYTBfMTA5OTUxMTYyNzc4Mw_c240a835-67fc-48d2-bcd9-b394c43d0c8f">92037</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl8xMi0xLTEtMS0yNDM3Ni90ZXh0cmVnaW9uOjM1MGU1MTljZjRmNDQwM2FhYmI2ZWZiMGIyZmU0NTUxXzEwOTk1MTE2Mjc3ODY_c34e7f7d-e48e-4728-b0e0-e811a988e87b">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl8xMi0xLTEtMS0yNDM3Ni90ZXh0cmVnaW9uOjM1MGU1MTljZjRmNDQwM2FhYmI2ZWZiMGIyZmU0NTUxXzEwOTk1MTE2Mjc3OTA_410bfcc7-8b66-4310-b9d8-1612162e1b35">795-4220</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></td></tr></table></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.218%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.943%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6Y2Q0ZTVhNzhiMGUzNDRkY2IyNzZhNTJkMmIzZmUyZDIvdGFibGVyYW5nZTpjZDRlNWE3OGIwZTM0NGRjYjI3NmE1MmQyYjNmZTJkMl80LTAtMS0xLTI0Mzc2_d632f5a1-77b7-4a56-aeb9-f137a7a6026e">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6Y2Q0ZTVhNzhiMGUzNDRkY2IyNzZhNTJkMmIzZmUyZDIvdGFibGVyYW5nZTpjZDRlNWE3OGIwZTM0NGRjYjI3NmE1MmQyYjNmZTJkMl80LTItMS0xLTI0Mzc2_e87fe2de-9732-4728-b11f-31715e340b92">INBX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6Y2Q0ZTVhNzhiMGUzNDRkY2IyNzZhNTJkMmIzZmUyZDIvdGFibGVyYW5nZTpjZDRlNWE3OGIwZTM0NGRjYjI3NmE1MmQyYjNmZTJkMl80LTYtMS0xLTI0Mzc2_ec4a0304-ec41-4201-b838-c1b721646b04">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8xMDk5NTExNjMxNDcx_095d852a-9da0-4530-a2a6-896a224b11b4">Yes</ix:nonNumeric> &#9746;  No &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#9744;  <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzc3_4d530756-e69e-4867-882f-dffdab06a997">No</ix:nonNumeric> &#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzc4_a56b5eac-f3e9-4c2a-a8d7-19f2917e13d6">Yes</ix:nonNumeric> &#160;&#9746;  No &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzgz_71a5d61c-7a75-4f59-bcbf-a3b8a2a5b544">Yes</ix:nonNumeric> &#160;&#9746;  No &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:564.75pt"><tr><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:24.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:265.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:24.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ZmUwMThhZWY2Mjg1NDMxZDgwZTQwYjVjNDNiMzUwZTMvdGFibGVyYW5nZTpmZTAxOGFlZjYyODU0MzFkODBlNDBiNWM0M2IzNTBlM18wLTAtMS0xLTI2MDU5_62faa36f-bd2c-4306-8bee-e84372d5fc8a">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ZmUwMThhZWY2Mjg1NDMxZDgwZTQwYjVjNDNiMzUwZTMvdGFibGVyYW5nZTpmZTAxOGFlZjYyODU0MzFkODBlNDBiNWM0M2IzNTBlM18xLTQtMS0xLTI0Mzc2_fc31fdab-028e-4548-83b8-4ebdb19a2daf">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ZmUwMThhZWY2Mjg1NDMxZDgwZTQwYjVjNDNiMzUwZTMvdGFibGVyYW5nZTpmZTAxOGFlZjYyODU0MzFkODBlNDBiNWM0M2IzNTBlM18yLTQtMS0xLTI0Mzc2_a37a9ca8-3e30-4451-bed5-6033f6b369e6">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;      &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes &#160;<ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzc0_0aad8f27-edb6-4e52-8be8-076bc8cf94ce">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;No &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;&#160;&#160;&#160;             Yes &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzg1_2311ae9d-79ed-4215-9d0e-5f28f83508fe">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No &#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="i506355bc91dc4a3382f883e168444b20_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8yNTk3_3baed7e5-9d6c-434d-8bed-159cc0234edd">764.3</ix:nonFraction> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Market of $27.52 per share. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;21, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i1db365e9d856446db31cae19f9e0e5db_I20220221" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8yOTUy_89fa544b-7a3b-4769-a9c3-f8f680c91ebd">39,025,644</ix:nonFraction> shares of common stock outstanding.</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Documents Incorporated By Reference</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzgx_f736fd59-8e9c-42df-9c3f-905eb32a5f6d" escape="true">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission.</ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INHIBRX, INC.<br/>ANNUAL REPORT ON FORM 10-K<br/>For the Year Ended December&#160;31, 2021</span></div><div style="margin-bottom:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_10">Special Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_10">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_13">Part I.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_16">Item 1. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_103">Item 1A. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_103">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_103">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unresolved Staff Comments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_2307">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_127">Item 2. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_127">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_127">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_130">Item 3. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_130">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_130">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_133">Item 4. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_133">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_133">96</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_136">Part II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_136">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_139">Item 5. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_139">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases&#160;of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_139">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_142">Item 6. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserved</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_142">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_145">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_145">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_145">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_187">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_187">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_187">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_190">Item 8. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_190">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_190">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_259">Item 9. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_259">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_259">149</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_262">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_262">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_262">150</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_265">Item 9B. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_265">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_265">154</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_2428">154</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_268">Part III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_268">155</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_271">Item 10. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_271">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_271">155</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_274">Item 11. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_274">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_274">155</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_277">Item 12. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_277">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_277">155</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_280">Item 13. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_280">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_280">155</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_283">Item 14. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_283">Principal </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_283">Accountant</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_283"> Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_283">155</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_286">Part IV.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_286">156</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_289">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_289">Exhibit</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_289">s</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_289"> and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_289">156</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_292">Item 16. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_292">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_292">160</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_295">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ie96bda597eaa4024845d6498a1c78657_295">160</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, or this Annual Report of Inhibrx, Inc., or Inhibrx, or the Company (also referred to as &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) contains forward-looking statements that involve risks and uncertainties. Except as otherwise indicated by the context, references in this Annual Report to &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; are to the consolidated business of the Company. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;design,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress and results of our research and development programs as well as our preclinical studies and clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to advance therapeutic candidates into, and successfully complete, clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our interpretation of initial, interim or preliminary data from our clinical trials, including interpretations regarding disease control and disease response; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approvals; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercialization of our therapeutic candidates, if approved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing, coverage and reimbursement of our therapeutic candidates, if approved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize our technology platform to generate and advance additional therapeutic candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model and strategic plans for our business and therapeutic candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully manufacture our therapeutic candidates for clinical trials and commercial use, if approved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into strategic partnerships and the potential benefits of such partnerships; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, capital requirements and needs for additional financing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the impact of the COVID-19 pandemic on our business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our third party partners and service providers&#8217; ability to continue operations and advance our therapeutic candidates through clinical trials and the ability of our third party manufacturers to provide the required raw materials, antibodies and other biologics for our preclinical research and clinical trials in light of the COVID-19 pandemic and the ongoing political unrest in Hong Kong;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section titled &#8220;Risk Factors&#8221; elsewhere in this Annual Report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report to conform these statements to new information, actual results or to changes in our expectations, except as required by law. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report and the documents that we file with the Securities and Exchange Commission, or the SEC, with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this Annual Report appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_16"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_19"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, developed using our protein engineering expertise and proprietary single domain antibody, or sdAb, platform. With the goal of addressing unmet medical needs, we leverage our deep understanding of target biology and innovative protein engineering technologies to create therapeutic candidates with attributes and mechanisms of action that are superior to current approaches and applicable to a range of challenging, validated targets with high potential. Our sdAb platform allows us to pursue validated targets with clinical promise where other antibody and biologic based approaches have failed. Highly modular, our sdAbs can be combined with precise valencies and multiple specificities, creating therapeutic candidates designed to be capable of enhanced cell signaling, conditional activation or combined synergistic functions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical pipeline is enabled by our protein and process engineering capabilities, and includes therapeutic candidates in the following categories:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INBRX-101 seeks to maintain the natural function of Alpha-1 antitrypsin, or AAT, in a recombinant format, optimized for less frequent dosing and greater potential therapeutic activity as compared to plasma-derived AAT, or pdAAT;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INBRX-109 and INBRX-106 utilize our multivalent formats, for which the precise valency was optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INBRX-105&#8217;s mechanism of action is enabled by a multi-specific format that we believe enables programmed death-ligand 1, or PD-L1, targeted 4-1BB agonism.</span></div><div style="margin-bottom:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.00pt"><tr><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:109.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:115.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:112.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:134pt"><td colspan="21" style="padding:0 1pt"><div style="margin-bottom:9.5pt"><img src="inbx-20211231_g1.jpg" alt="inbx-20211231_g1.jpg" style="height:165px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-109</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-106</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-105</span></td></tr><tr style="height:38pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AAT-Fc fusion <br/>protein</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tetravalent DR5 <br/>agonist</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hexavalent OX40 <br/>agonist</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PD-L1x4-1BB tetravalent conditional agonist</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.749%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Program</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Therapeutic Area</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Target(s)/Format</span></td><td colspan="24" style="border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">STAGE OF DEVELOPMENT</span></td></tr><tr style="height:11pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="6" style="border-right:1pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Phase 3</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">INBRX-101*</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Orphan/Respiratory</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Neutrophil Elastase Inhibitor<br/>AAT-Fusion Protein</span></td><td colspan="24" style="border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="9" style="background-color:#80a035;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="24" style="border-bottom:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#ededed;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">INBRX-109**</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">DR5<br/>Tetravalent Agonist</span></td><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="15" style="background-color:#80a035;padding:0 1pt"></td><td colspan="9" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">INBRX-106***</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">OX40<br/>Hexavalent Agonist</span></td><td colspan="24" style="border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="9" style="background-color:#80a035;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="24" style="border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#ededed;border-left:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">INBRX-105***</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">PD-L1 x 4-1BB <br/>Tetravalent Conditional Agonist</span></td><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="9" style="background-color:#80a035;padding:0 1pt"></td><td colspan="15" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Commercialization and development rights outside of the United States and Canada, subject to an option agreement with Chiesi Farmaceutici S.p.A., or Chiesi.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Third party partnership with Chinese biotechnology company, Transcenta Holding, Ltd. (formerly Hangzhou Just Biotherapeutics Co., Ltd.), or Transcenta, currently in place for development and commercialization in China, Hong Kong, Macau and/or Taiwan.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Third party partnership with Chinese biotechnology company, Elpiscience Biopharmaceuticals, Inc, or Elpiscience, currently in place for development and commercialization in China, Hong Kong, Macau and/or Taiwan. </span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div id="ie96bda597eaa4024845d6498a1c78657_25"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Leadership Team </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a team with deep scientific and clinical experience in discovering and developing protein therapeutics. Our in-house capabilities span the disciplines of discovery, protein engineering, cell biology, translational research, chemistry, manufacturing and controls, or CMC, clinical development, and commercialization. Members of our team bring experience from multiple organizations including Genentech, Inc., Gilead Sciences, Inc., Merck&#160;&amp; Co., Novartis AG, Pfizer Inc., and the Takeda Pharmaceutical Company Limited. Our board of directors is comprised of individuals with proven business and scientific accomplishments and significant operating knowledge of our company. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_28"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biotechnology company with a differentiated and sustainable product portfolio by focusing on the following: </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rapidly advance and optimize the clinical development of our lead programs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on rapidly advancing our four therapeutic candidates, each with key clinical data readouts expected in 2022 and during the first half of 2023. To augment our U.S.-centric clinical strategy for our oncology therapeutic candidates, we have formed collaborations in China designed to provide access to patient populations for clinical trials not readily available in the United States, including treatment-na&#239;ve patients, and to facilitate rapid patient enrollment with the goal of generating more robust early clinical data. We believe this harmonized clinical strategy may allow us to accelerate our development timelines. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Apply our sdAb platform and other protein technologies to create differentiated therapeutics in focused disease areas with particular emphasis on oncology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed an sdAb platform and other protein technologies that we believe can be applied to meet the specific challenges of complex target biology. Our current pipeline is focused on oncology and orphan diseases. We plan to focus our internal clinical development where we believe we can create solutions to address the challenges of both validated and novel targets and generate differentiated therapeutics that can be advanced efficiently through clinical development.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maintain our culture of innovation, execution and efficiency.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last 12 years we have successfully built an innovative culture that encourages scientific risk-taking within the bounds of our data-driven philosophy. This enables our research and development team to discover numerous promising preclinical candidates cost effectively, from which we select what we believe are highly differentiated programs for clinical development. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maximize the potential of our therapeutic pipeline by retaining rights as well as selectively entering into additional strategic partnerships depending on the therapeutic candidate, indication and geography. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a disciplined strategy to maximize the potential of our therapeutic pipeline by retaining development and commercialization rights to those therapeutic candidates, indications and geographies that we believe we can develop and eventually commercialize successfully and efficiently on our own if they are approved, while also seeking to enter into additional strategic partnerships where we believe partnering will accelerate our development timelines and/or maximize the worldwide commercial potential of any approved therapeutic candidates. For example, we have granted Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada following completion of the Phase 1 trial. In addition, we are currently party to license agreements for the development and, if approved, commercialization of INBRX-105, INBRX-106 and INBRX-109 solely in China, Hong Kong, Macau and Taiwan. We otherwise possess the worldwide rights to these candidates. Where appropriate, we plan to seek to enter into additional strategic partnerships with the goal of maximizing the potential of our therapeutic pipeline. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selectively enter into additional strategic partnerships to maximize the potential of our protein engineering technologies in non-core areas or indications ancillary to oncology.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the broad potential of our protein engineering technologies, coupled with our strong intellectual property portfolio, can lead to the generation of multiple additional novel product candidates addressing a wide range of therapeutic areas. For example, we licensed our sdAb technologies for specific binders to 2seventy bio, Inc. (formerly bluebird bio, Inc.), or 2seventy, for use in cell therapy. Moreover, we have several preclinical programs focused on non-oncology indications that we are actively seeking to license. Where appropriate, we plan to continue to seek to opportunistically enter into additional strategic partnerships in areas that are considered non-core or indications ancillary to oncology to maximize the potential of our technology platform.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_37"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our sdAb Platform Technology </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antibodies are multifunctional, Y-shaped proteins, made up of a pair of interacting heavy and light chains to form a symmetric, dimeric molecule with four total protein chains. Each arm of the antibody contains an antigen binding region (also referred to as the variable fragment, or Fv), which consists of both a heavy and light variable domain, or VH and VL, respectively, held together through interaction of constant domains. The Fc (Fragment, crystallizable) portion of the heavy-chain constant domain extends the half-life of the antibody in circulation and has the potential to modulate the function of immune cells through interaction with various Fc receptors found on the surface of cells of the immune system. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that antibody Fv domains are not optimal building blocks for multispecific and multivalent therapeutics due to the extensive protein engineering required to ensure the correct pairing of the appropriate VH and VL domains to construct functional Fvs. To overcome the limitations and formatting challenges of conventional antibodies, we developed our sdAb platform to enable the streamlined production of protein formats with multiple antigen specificities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sdAbs provide a small, simple, modular target binding domain that can be combined in a variety of ways to meet the unique needs of each biological target. We have deep domain expertise surrounding discovery, humanization and optimization of sdAbs and their incorporation into unique configurations enabling the generation of therapeutic candidates with favorable drug-like properties and differentiated mechanisms of action. We have created various multivalent and multispecific therapeutic formats that are each designed to achieve unique functions specifically tailored to the requirements of a given biological target, including the ability to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively cluster receptors with precisely defined valency; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">simultaneously engage multiple antigens or epitopes; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">combine synergistic functions in a single molecule; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrict therapeutic activity to specific micro environments in the body; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be readily manufactured at high yields with established processes used to produce therapeutic proteins.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also developed a series of patented modifications to our humanized sdAb scaffold, which are designed to eliminate recognition by pre-existing anti-drug antibodies without compromising affinity, specificity or stability of the sdAb. Previously, the presence of pre-existing anti-drug antibodies in human serum limited the broad use of these agents as therapeutics. We believe our improvement, combined with our extensive knowledge of the structural nuances of sdAbs, will enable modernized development of therapeutic candidates with favorable biophysical properties, and will greatly extend the utility and applicability of our sdAb platform. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_22"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline </span></div><div id="ie96bda597eaa4024845d6498a1c78657_52"></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INBRX-101 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein therapeutic candidate that we are developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency, or AATD. We believe INBRX-101 has the potential to be dosed monthly, while maintaining patients in the normal range of AAT exposure, which would be a significant improvement for patients currently receiving weekly infusions. Through our proprietary engineering capabilities, we were able to overcome the challenges of producing AAT recombinantly and manufacturing at commercial scale.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of AATD </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AATD is an inherited disease that causes an increased risk of developing pulmonary disease defined by progressive loss of lung tissue and function and is associated with decreased life expectancy. The pulmonary manifestations of AATD include the entire spectrum of emphysema and disorders associated with chronic obstructive pulmonary disease. Patients with AATD harbor mutations in the AAT-encoding gene Serpin family A member 1, which causes AAT protein misfolding, loss of activity, and retention in the liver. AAT is a protease inhibitor that primarily targets human neutrophil elastase, or NE, an enzyme that is released by white blood cells in response to infections and has the capacity to degrade normal tissues, especially in the lung, if not tightly controlled by AAT. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unmet Medical Need</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This disease affects roughly 100,000 people in the United States, with a similar number of patients in Europe. Since AATD must be diagnosed using laboratory testing and cannot be diagnosed by symptoms or by a medical examination alone, it is believed that many individuals with AATD are likely undiagnosed or misdiagnosed. In April 2017, the United States Food and Drug Administration, or FDA, allowed for the marketing of direct-to-consumer tests that provide genetic risk information for certain conditions, including AATD. We believe such tests will lead to earlier diagnosis and an increase in the number of patients identified with AATD.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approved standard of care for AATD has been augmentation therapy using pdAAT and has not been substantially improved since 1987. Plasma-derived treatments are highly dependent on human donor blood supply, which is costly and can be limited. Due to the short half-life of pdAAT therapeutics, patients require weekly infusions to achieve and maintain serum concentration above the protective threshold, presumed to be 11&#160;&#181;M. However, even with frequent treatments, the AAT serum concentration following treatment remains considerably below the normal range of 20 to 50 &#181;M. There is clinical evidence suggesting that maintenance of higher AAT serum trough levels may better protect against lung function decline. The graph below is an adaptation based on published data that depicts the pharmacokinetic profile of pdAAT. The published results from the RAPID trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revealed the correlation of serum AAT through levels and lung density decline in AATD patients. Additionally, there are other significant barriers to treatment for patients with AATD, including under-diagnosis, high cost of chronic augmentation therapy, difficulties associated with administering intravenous infusions on a weekly basis, and plasma collection practices that may not be sustainable. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG. (2015) Intravenous augmentation treatment and lung density in severe &#945;1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. The Lancet. Jul 25;386(9991):360-8</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><img src="inbx-20211231_g2.jpg" alt="inbx-20211231_g2.jpg" style="height:190px;margin-bottom:5pt;vertical-align:text-bottom;width:552px"/></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Solution - INBRX-101</span></div><div style="margin-bottom:18pt;text-align:center"><img src="inbx-20211231_g3.jpg" alt="inbx-20211231_g3.jpg" style="height:424px;margin-bottom:5pt;vertical-align:text-bottom;width:396px"/></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INBRX-101 is a recombinant AAT protein that is comprised of two human AAT molecules covalently linked to the Fc region of human immunoglobulin G4. AAT has proven difficult to develop recombinantly, often displaying loss of activity and experiencing accelerated degradation. Fusion of AAT to the Fc region allows for production using a standard antibody expression system, which, when combined with our proprietary AAT-function preserving purification process, generates substantial and scalable yields of active recombinant AAT protein.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Data </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we initiated an open-label, dose escalating Phase 1 trial which is being conducted in approximately 10 clinical sites in the United States, the United Kingdom and New Zealand and will enroll a total of approximately 42 patients. The trial is designed as single ascending dose, or SAD, administrations of INBRX-101, with doses of 10 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mg/kg, 40 mg/kg, 80 mg/kg or 120 mg/kg, followed by multiple ascending dose, or MAD, administrations of INBRX-101, with doses of 40 mg/kg, 80 mg/kg or 120 mg/kg. These doses are administered every three weeks intravenously to patients diagnosed with AATD who are either treatment na&#239;ve or previously treated with pdAAT therapeutics. The primary objective of the trial is safety and tolerability. Secondary objectives include AAT serum exposure, immunogenicity, as measured by frequency of anti-drug antibodies, and NE activity. Exploratory endpoints include biomarkers of AAT. In addition, we will measure pharmacokinetic and pharmacodynamic biomarkers in bronchoalveolar lavage fluid, or BALF, for those patients who received MAD administrations of INBRX-101 at doses of 80 mg/kg or 120 mg/kg.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we announced initial results from Phase 1, Part 1 (SAD) of this trial. Interim functional pharmacokinetic, or PK, data were from 21 patients with AATD, all with the ZZ mutation of the SERPINA1 gene. Interim safety data were from 24 patients with AATD. There were no drug-related severe or serious adverse events at doses up to and including 120 mg/kg single dose and 80mg/kg multi-dose. Drug-related adverse events were predominantly mild with a few moderate events and all were transient and reversible. No signs of neutralizing anti-drug antibodies were seen.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dose related increases in maximal and total INBRX-101 exposure occurred across the entirety of the tested SAD range of 10 to 120 mg/kg. </span></div><div style="margin-bottom:18pt;text-align:center"><img src="inbx-20211231_g4.jpg" alt="inbx-20211231_g4.jpg" style="height:259px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14pt">The shaded region represents the normal range of functional AAT in healthy adults.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14pt">The dashed line at 11&#181;M indicates the functional AAT goal of the current augmentation therapy with pdAAT.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14pt">Day 21 data from the 120 mg/kg cohort are from the first 2 enrolled patients with available data.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14pt">Results shown are from preliminary, unaudited data announced in October 2021.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from the first MAD cohort of INBRX-101 at 40 mg/kg IV every three weeks showed the expected accumulation of functional AAT levels with observed trough levels exceeding the goal of the current standard augmentation therapy with pdAAT. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><img src="inbx-20211231_g5.jpg" alt="inbx-20211231_g5.jpg" style="height:320px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to announce additional data from this trial during the first half of 2022, including BALF data for those patients who received MAD administrations of INBRX-101 at doses of 80 mg/kg or 120 mg/kg. The end of Phase 1 meeting with the FDA will be planned after completion of this study, and based on the feedback from the agency, a potentially registration-enabling Phase 2 program will be initiated.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_43"></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INBRX-109 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate targeting death-receptor 5, or DR5, a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand, or TRAIL, receptor 2. DR5 activation induces cancer-specific programmed cell death. The valency of INBRX-109 was selected to maximize the therapeutic index. In patients treated with INBRX-109 to date in our Phase 1 clinical trial, we have observed signs of single agent activity in serious, life-threatening medical conditions that have limited treatment options. We initiated cohorts with INBRX-109 in combination with standard chemotherapies in several indications. Additionally, in June 2021, we initiated a potential registration-enabling Phase 2 trial for the treatment of unresectable or metastatic conventional chondrosarcoma.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on DR5 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apoptosis is a critical process for maintaining healthy tissue homeostasis, but this process is frequently altered in cancer patients leading to the accumulation of malignant cells. Apoptotic signaling pathways are tightly regulated by the balance of pro- and anti-apoptotic factors, and their therapeutic modulation has the potential to be exploited for the treatment of cancer. Targeting the anti-apoptotic proteins has been a clinically successful strategy. For example, Venetoclax, an inhibitor of B-cell lymphoma 2, or Bcl-2, was approved by the FDA for the treatment of chronic lymphocytic leukemia in 2016. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, we believe therapeutically targeting pro-apoptotic proteins such as DR5 is a promising oncology treatment strategy. DR5 signaling is induced by clustering of multiple receptors, which initiates an apoptotic signaling pathway resulting in cell death. The strength of apoptotic signaling is proportional to the degree of DR5 clustering. Importantly, although DR5 is expressed throughout the body, cancer cells have been shown to be more sensitive to DR5 signaling compared to healthy cells of normal tissues. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promise of inducing cancer-specific cell death has led to extensive efforts by pharmaceutical and biotechnology companies to therapeutically exploit the DR5 pathway for the treatment of cancer. These initial efforts centered around developing recombinant versions of the DR5 ligand, TRAIL, and agonistic bivalent DR5 antibodies. Despite </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demonstrated clinical safety as single agents and in combination with chemotherapies, these first generation DR5 agonists failed to meet clinical efficacy endpoints. We believe these failures were caused by insufficient clustering of DR5, which is necessary for activation of this pathway. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unmet Medical Need</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently investigating INBRX-109 in chondrosarcoma, Ewing sarcoma, malignant pleural mesothelioma, colorectal and pancreatic adenocarcinomas. These are some of the most aggressive diseases, some of which are also orphan oncology indications that have shown signs of activity in preclinical studies. These indications and many of these cancer subtypes do not respond well to currently approved immunotherapies and represent a significant unmet need. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Solution - INBRX-109 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INBRX-109 is a tetravalent agonist of DR5 that we designed with our sdAb platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. We believe INBRX-109 has the potential to overcome the limitations of previous DR5 agonists. As shown in the diagram below, INBRX-109 is comprised of four DR5 targeted sdAbs fused to an Fc region that has been modified to prevent Fc receptor interactions. In preclinical studies, we have observed that INBRX-109 has the ability to potently agonize DR5 through efficient receptor clustering, causing cancer cell death. Based upon experience with earlier generation DR5 agonists, hepatocytes appear to be a non-cancerous cell type particularly sensitive to DR5 agonism. We have engineered INBRX-109 with our proprietary sdAb modifications to reduce recognition by pre-existing anti-drug antibodies in humans, which can lessen the potential for hyper-clustering and thereby reduce potential hepatotoxicity.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Primary objectives of the Phase 1 trial are safety, tolerability, and determination of the maximum tolerated dose, or MTD, and recommended Phase 2 dose. Secondary objectives were serum exposure and immunogenicity, as measured by frequency of anti-drug antibodies. Exploratory objectives included clinical anti-tumor efficacy, based on response rate, duration of response, disease control rate, progression-free survival and overall survival, as well as evaluation of potential predictive diagnostic and pharmacodynamic biomarkers. </span></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-109: Tetravalent DR5 Agonistic Antibody</span></div><div style="margin-bottom:18pt;text-align:center"><img src="inbx-20211231_g6.jpg" alt="inbx-20211231_g6.jpg" style="height:326px;margin-bottom:5pt;vertical-align:text-bottom;width:357px"/></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Data </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IND, or Investigational New Drug Application, for INBRX-109 became effective in August 2018, and we initiated a Phase&#160;1 clinical trial in the United States in November 2018. This Phase 1 clinical trial is designed as an open-label, three-part trial in patients with locally advanced or metastatic solid tumors. </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.233%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="background-color:#80c9ff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 1 INBRX-109 Trial Design and Status</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">First in human Phase 1 trial started November 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#bbdff9;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Part 1: <br/>Dose Escalation </span></td><td colspan="3" rowspan="7" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;</span></td><td colspan="6" style="background-color:#bbdff9;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Part 2: <br/>Dose Expansion Cohorts</span></td><td colspan="3" rowspan="7" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;</span></td><td colspan="6" style="background-color:#bbdff9;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Part 3: <br/>Combination Studies</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#bde782;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Completed </span></td><td colspan="6" style="background-color:#bde782;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Ongoing </span></td><td colspan="6" style="background-color:#bde782;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Ongoing</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="5" style="background-color:#e8e8e8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Dose Range: </span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">0.3 to 30 mg/kg</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N= 20</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Result: </span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Maximum tolerated </span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">dose not reached</span></div></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=34</span></td><td colspan="3" style="background-color:#e8e8e8;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Chondrosarcoma</span></td><td colspan="3" rowspan="2" style="background-color:#e8e8e8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=20</span></td><td colspan="3" rowspan="2" style="background-color:#e8e8e8;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Mesothelioma with Cisplatin/Carboplatin &amp; Mesothelioma with Cisplatin or Carboplatin and Pemetrexed</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=10</span></td><td colspan="3" style="background-color:#e8e8e8;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#160;Synovial sarcoma</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=22</span></td><td colspan="3" style="background-color:#e8e8e8;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Malignant pleural mesothelioma</span></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=20</span></td><td colspan="3" style="background-color:#e8e8e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Ewing sarcoma with Irinotecan &amp; Temozolomide</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=20</span></td><td colspan="3" style="background-color:#e8e8e8;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Colorectal cancer</span></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=20</span></td><td colspan="3" style="background-color:#e8e8e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Pancreatic adenocarcinoma 2nd line with mFOLFIRI</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=10</span></td><td colspan="3" style="background-color:#e8e8e8;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Gastric adenocarcinoma</span></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=20</span></td><td colspan="3" style="background-color:#e8e8e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Colorectal cancer with FOLFIRI</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part 1</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part 1 of the trial utilized a traditional 3+3 dose escalation design escalating INBRX-109 as a single agent from 0.3 mg/kg to 30 mg/kg. Twenty patients were enrolled in this portion of the trial, which was completed in August 2019. INBRX-109 was observed to be well-tolerated without significant toxicities observed at doses up to and including the maximum administered dose of 30 mg/kg. No MTD was reached. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part 2</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we commenced single agent dose expansion cohorts, Part 2 of this trial. As of February&#160;1, 2022, we have enrolled approximately 112 patients in single agent dose cohorts in the following tumor types: colorectal and gastric adenocarcinomas, malignant pleural mesothelioma, chondrosarcoma and synovial sarcoma. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part 3</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have initiated chemotherapy combination cohorts in malignant pleural mesothelioma, pancreatic adenocarcinoma, Ewing sarcoma and colorectal cancer cohorts. We expect to announce initial data from these cohorts in late 2022. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Initial Results from Phase 1, Part 2</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INBRX-109 Chondrosarcoma</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chondrosarcoma is a rare malignant bone tumor composed of cartilage matrix-producing cells. It is reported to be the second most common primary bone sarcoma with an incidence of 1 in 200,000 per year globally. The incidence in the United States is reported to be about 1,400 cases per year. There is currently no approved systemic treatment for patients with unresectable or metastatic disease. The placebo arm of a placebo-controlled trial, which tested the hedgehog pathway inhibitor IPI-926 in this indication had a progression free survival of approximately three months. In this trial, IPI-926 did not result in any partial responses and only a small subset of patients had minor reductions in their tumor size.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stable disease or partial responses were observed in 16 out of 22 patients with chondrosarcoma based on the initial data from the chondrosarcoma cohort of our Phase 1 trial. Two of these patients&#8217; scans were still pending and four of these patients were still on treatment as of October 1, 2021. In January 2021, the FDA granted fast track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. On November 24, 2021, the FDA granted orphan-drug designation for INBRX-109 for the treatment of chondrosarcoma.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;text-align:center"><img src="inbx-20211231_g7.jpg" alt="inbx-20211231_g7.jpg" style="height:592px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we initiated a potential registration-enabling Phase 2 trial in this patient population, which will enroll approximately 200 patients in total, with progression free survival as the primary endpoint. We expect to announce data from this trial in mid-2024. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Primary objectives of the ongoing Phase 2 trial are to evaluate the efficacy of INBRX-109 as measured by progression free survival, or PFS, as measured by an independent radiology review. Secondary objectives are to evaluate the overall survival, PFS by investigator assessment, quality of life, objective response rate, disease control rate, safety and tolerability, pharmacokinetics and anti-drug antibodies to INBRX-109.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.520%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#80c9ff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Phase 2 Trial Design</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="5" style="background-color:#e8e8e8;border-left:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Randomization 2:1</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Key eligibility criteria:</span></div><div style="padding-left:9pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8226;  Conventional chondrosarcoma</span></div><div style="padding-left:9pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8226;  Unresectable or metastatic</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:9pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Stratification by line of therapy and IDH1/2 mutation status</span></div></td><td colspan="3" style="border-left:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="5" style="border-right:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8680;<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8680;</span></td><td colspan="3" rowspan="5" style="background-color:#e8e8e8;border-left:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Until progressive disease (PD) or toxicity</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Including </span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">interim analysis</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#8226; </span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"> Primary Endpoint: </span></div><div style="text-align:center;text-indent:4.5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">progression free survival (PFS)  </span></div><div style="text-align:center;text-indent:4.5pt"><span><br/></span></div><div style="text-indent:4.5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">&#8226;  Secondary Endpoints: </span></div><div style="text-align:center;text-indent:4.5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">overall survival (OS), quality of life (QoL), overall response rate (ORR)/duration of response (DOR), disease control rate (DCR)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#bde782;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INBRX-109<br/>N= 134</span></td><td colspan="3" style="background-color:#ffffff;border-left:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">&lt;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Placebo </span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">N= 67                     </span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(allows for crossover)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:47pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INBRX-109 Malignant Pleural Mesothelioma</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mesothelioma is a malignant tumor most often caused by inhaled asbestos fibers which accumulate in the lining of the lungs, abdomen or heart. The epithelioid subtype is the most common histology of malignant pleural mesothelioma, reportedly comprising about 70% of all cases. It is estimated that as many as 43,000 people worldwide die from mesothelioma each year. There are currently limited approved therapeutic treatments. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We observed signs of single agent activity in the Phase 1, part 1 malignant pleural mesothelioma, epithelioid subtype cohort. Time on treatment with INBRX-109 was equal to or greater than 24 weeks in seven of the 19 patients (~37%). </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><img src="inbx-20211231_g8.jpg" alt="inbx-20211231_g8.jpg" style="height:518px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the single agent activity observed, we initiated a chemotherapy combination cohort in malignant pleural mesothelioma with Carboplatin/Cisplatin and Pemetrexed, which is currently enrolling. We expect to announce initial data from these cohorts in late 2022. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Clinical Development Plans </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to investigate the therapeutic utility of INBRX-109 through a broad clinical development plan across difficult-to-treat cancers. Other future clinical development of INBRX-109 may include combinations with additional chemotherapies and potentially synergistic agents in several solid tumors and hematologic malignancies. We are currently conducting preclinical studies with INBRX-109 and various rational combination agents, including targeted therapeutics and apoptotic pathway modulators, aimed at guiding our future clinical plans. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_46"></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INBRX-106 AND INBRX-105</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INBRX-106 is a hexavalent OX40 agonist, currently being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-105 is a conditional 4-1BB agonist that is currently being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors.  </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on Immunotherapy</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A notable recent success in cancer treatment is the approval of checkpoint inhibitor immunotherapies as therapeutic agents. Immune checkpoints are key mechanisms that fine-tune and control the body&#8217;s immune response. In the cancer setting, tumors have developed strategies for hijacking these checkpoints, preventing an immune response to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the cancer and allowing the tumor cells to proliferate unchecked. Checkpoint inhibitor immunotherapies were developed to overcome this phenomenon by relieving immune cell inhibition, resulting in a potentially long-lasting amplification of the anti-tumor immune response. Therapies against checkpoint proteins, such as PD-1 and PD-L1, produced impressive results in clinical development, resulting in marketing approvals in a number of malignancies. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unmet Medical Need</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite unprecedented clinical response rates, the majority of patients fail to respond to therapies targeting PD-1 and PD-L1. We believe this is in part because T-cells require co-stimulation for full functionality. Thus, checkpoint inhibition alone is likely insufficient to fully enable the immune system to attack a tumor, and we believe further benefit could be derived by the addition of immune co-stimulatory agents. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe INBRX-106 and INBRX-105 have the potential to combine with the fast-growing immunooncology market, which currently has annual sales of over $20 billion. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INBRX-106 </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on OX40</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OX40, a member of the TNFRSF, is predominately expressed and is a key co-stimulatory receptor on activated T-cells. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death. The natural mechanism of OX40 activation is via the interaction with its trimeric ligand, OX40L, which serves to effectively cluster multiple OX40 molecules and facilitate downstream signaling leading to nuclear factor kappa-light-chain-enhancer of activated B cells, or NFkB, activation. Based on the capacity for OX40 signaling to enhance anti-tumor immunity in preclinical studies, there have been many efforts to therapeutically exploit this pathway for cancer immunotherapy. Most previously developed agents were bivalent OX40 agonists, the configuration of which we believe to be poorly suited for efficient receptor clustering, evidenced by the lack of clinical responses observed for such molecules. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Solution</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor. As shown in the diagram below, INBRX-106 is composed of six OX40 targeting sdAbs and a functional Fc domain. </span></div><div style="margin-bottom:18pt;text-align:center"><img src="inbx-20211231_g9.jpg" alt="inbx-20211231_g9.jpg" style="height:341px;margin-bottom:5pt;vertical-align:text-bottom;width:341px"/></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a hexavalent therapeutic candidate, INBRX-106 is designed to bind six OX40 molecules on the cell surface to mediate efficient receptor clustering and downstream signaling. In preclinical studies, we observed that INBRX-106 elicited superior OX40 agonism when compared to the bivalent antibodies, 1A7 (analog of MOXR-0916) or 1D10 using an OX40 expressing NFkB reporter cell line, wherein clustering of OX40 receptor mediated signaling culminated in luciferase expression. We also observed that INBRX-106 can mediate T-cell co-stimulation and reduce the suppressive activity of regulatory T-cells. Additionally, INBRX-106 is able to exploit IgG-mediated effector function via the Fc domain.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Data</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a Phase 1 clinical trial in December 2019 for INBRX-106. This Phase 1 trial is designed as an open-label, four-part trial in patients with locally advanced or metastatic solid tumors. We expect the entire trial will be conducted at approximately 12-16 clinical sites in the United States and enroll approximately 145 patients. Primary objectives of the trial are safety and tolerability, and the determination of the MTD and recommended Phase 2 dose of INBRX-106 as a single agent and in combination with Keytruda. Secondary objectives are serum exposure, immunogenicity, as measured by the frequency of anti-drug antibodies, and clinical anti-tumor efficacy per RECIST (version 1.1) and immune RECIST based on response rate, duration of response, disease control rate, progression-free survival and overall survival. Exploratory objectives will include evaluation of potential predictive diagnostic and pharmacodynamic biomarkers.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.717%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="30" style="background-color:#80c9ff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 1 INBRX-106 Trial Design and Status</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First in human Phase 1 trial started December 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#bbdff9;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Part 1: <br/>Single Agent <br/>Dose Escalation </span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;</span></td><td colspan="6" style="background-color:#bfe4ff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Part 2: <br/>Single Agent <br/>Dose Expansion </span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;</span></td><td colspan="6" style="background-color:#bbdff9;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Part 3: <br/>Combination <br/>Dose Escalation</span></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;</span></td><td colspan="6" style="background-color:#bbdff9;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Part 4: <br/>Combination <br/>Dose Expansion</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#bde782;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Complete</span></td><td colspan="6" style="background-color:#bde782;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ongoing</span></td><td colspan="6" style="background-color:#bde782;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;Complete</span></td><td colspan="6" style="background-color:#bde782;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ongoing</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:93pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Dose Range: </span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0003 to 3 mg/kg</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">N= 20</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Result: </span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Maximum tolerated </span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">dose not reached</span></div></td><td colspan="6" style="background-color:#e8e8e8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">RP2D Two Dosing <br/>Schedules<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">N=24<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><br/><br/><br/></span></td><td colspan="6" style="background-color:#e8e8e8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">INBRX-106 + Keytruda<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">MTD: 0.1 mg/kg<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">N=21<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Durable responses observed in tumor types responsive to immunotherapy</span></td><td colspan="6" style="background-color:#e8e8e8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">INBRX-106 + Keytruda </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">CPI Refractory (N=20 each)</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">N=20  PD-L1+ NSCLC</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">N=20 PD-L1+ baskett</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">CPI Naive (N=10 each)</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">PD-L1+ melanoma</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">PD-L1+ ocular melanoma</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">PD-L1+ head &amp; neck</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">PD-L1+ nasopharyngeal carcinoma</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part 1 of the trial utilized a traditional 3+3 algorithm for single agent dose escalation from 0.0003 mg/kg to 3 mg/kg in twenty patients. INBRX-106 was observed to be generally well tolerated in humans. The most common adverse effects, or AEs, reported for INBRX-106 were Grade 1 and 2 rashes or dermatitis, cytokine release syndrome, fatigue, and infusion-related reactions. Notably, cutaneous toxicities are common immune-related AEs associated with immune checkpoint inhibitors. These mostly mild or moderate and likely immune-related toxicities were in line with the mechanism of action of this candidate therapeutic. The maximum administered dose was 3 mg/kg and the MTD level was not reached. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part 2 of the trial, single agent dose expansion, administers INBRX-106 in two different dosing schedules to patients with tumor types responsive to checkpoint inhibitors. Utilization of extensive biomarker data guided the determination of the optimal dose for Part 2 of the trial, which we believe to be 0.03 mg/kg. Key attributes leading to the choice of this dose level included OX40 occupancy data, evidence of peripheral memory T-cell activation and proliferation, and sufficient drug clearance to allow target recovery prior to the next dose administration. Part 2 treatment cohorts of this trial, which are still ongoing, are in the following tumor types: non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Parts 1 and 2 we have observed stable disease, per investigator assessment, of greater than six months in four out of 10 response evaluable non-small cell lung cancer and melanoma patients. Three of the four patients had previous exposure to checkpoint inhibitors and one uveal melanoma patient was checkpoint naive. The longest duration of stable disease as of January 10, 2022 was 95 weeks and ongoing in a non-small cell lung cancer patient refractory to Keytruda.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Parts 3 and 4 of this trial, INBRX-106 is being evaluated in combination with Keytruda, a PD-1 blocking checkpoint inhibitor. In the all-comer Part 3 of the trial, INBRX-106 was escalated in combination with Keytruda and enrolled 21 patients with locally advance or metastatic solid tumors. It was observed to be well tolerated, with predominantly mild or moderate immune-related toxicities noted. The MTD was determined to be 0.1 mg/kg dosed every three weeks. Two durable partial responses with duration of greater than six months and ongoing were observed in two CPI-naive patients, one with nasopharyngeal carcinoma and one with uveal melanoma. Additionally, there was one double-digit reduction in tumor size with duration greater than four months in a cutaneous melanoma patient who had been previously exposed to checkpoint inhibitors. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Clinical Development Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part 4, INBRX-106 combination expansion cohorts, which initiated in December 2021, will enroll approximately 80 patients who are positive for PD-L1 expression as determined by immunohistochemistry and possessing adequate hematologic and organ function, to qualify for enrollment. Forty of these patients will be checkpoint refractory with non-small cell lung cancer and a basket of other indications. An additional 40 patients will be checkpoint naive, enrolling 10 patients in each of the following indications: cutaneous melanoma, uveal melanoma, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. We expect to announce initial data from the dose expansion cohorts in combination with Keytruda during the second half of 2022. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_49"></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INBRX-105 </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on 4-1BB</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4-1BB, or TNFRSF9, a member of the TNFRSF, is a promising co-stimulatory receptor that we believe can synergize with checkpoint inhibitors to address the insufficiency of checkpoint inhibition alone. 4-1BB is expressed on recently activated T-cells but is largely absent from circulating T-cells under normal conditions. Agonistic 4-1BB antibodies have exhibited anti-tumor activity in mouse models of cancer, especially in combination with other immunomodulatory or tumor targeted therapeutics. These observations motivated the clinical advancement of antibodies designed to agonize 4-1BB and co-stimulate tumor reactive T-cells. Most recently, urelumab, a 4-1BB agonist, showed initial signs of single agent therapeutic efficacy, but clinical investigation was halted due to dose-limiting liver toxicities. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Solution</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INBRX-105 is a precisely engineered multi-specific sdAb-based therapeutic candidate that is designed to agonize 4-1BB selectively in the presence of PD-L1, which is typically found in the tumor microenvironment and associated lymphoid tissues. PD-L1 is a validated biomarker for tumors with the potential for anti-tumor immune activation and thus we believe represents an ideal anchor antigen to drive 4-1BB agonism. The image below illustrates the unique structure of INBRX-105: </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-105: A PD-L1 Targeted 4-1BB Agonist </span></div><div style="margin-bottom:18pt;text-align:center"><img src="inbx-20211231_g10.jpg" alt="inbx-20211231_g10.jpg" style="height:337px;margin-bottom:5pt;vertical-align:text-bottom;width:374px"/></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe INBRX-105 can overcome the toxicity issues that have limited the success of prior 4-1BB agonists based on its potential to selectively activate 4-1BB + T-cells in the tumor microenvironment, and thus alter the T-cell population, and enrich for cells with anti-tumor capacity. We expect to achieve the maximal therapeutic benefit of INBRX-105 in combination with a PD-1 checkpoint blockade. Our preclinical studies demonstrate that acute exposure to PD-L1 dependent 4-1BB agonism is sufficient to derive maximal anti-tumor activity when co-dosed with another PD-1 blocking agent at a target saturating dose. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Data </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a Phase 1 clinical trial for INBRX-105 in the United States in February 2019. This Phase 1 trial is designed as an open-label, four-part trial in patients with locally advanced or metastatic solid tumors and is being conducted at approximately 14-18 clinical sites in the United States. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Primary objectives of the Phase 1 trial are safety, tolerability, and the determination of the MTD and recommended Phase 2 dose of INBRX-105 as a single agent and in combination with Keytruda. Secondary objectives are serum exposure, immunogenicity, as measured by frequency of anti-drug antibodies. Exploratory objectives include clinical anti-tumor efficacy per Response Evaluation Criteria in Solid Tumors, or RECIST (version 1.1, or v1.1), and immune RECIST based on response rate, duration of response, disease control rate, progression-free survival and overall survival, as well as evaluation of potential predictive diagnostic and pharmacodynamic biomarkers. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:4.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.962%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="30" style="background-color:#80c9ff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 1 INBRX-105 Trial Design and Status</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="30" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">First in human Phase 1 trial started February 2019</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#bbdff9;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Part 1: <br/>Single Agent <br/>Dose Escalation </span></td><td colspan="3" rowspan="4" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;</span></td><td colspan="6" style="background-color:#bfe4ff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Part 2: <br/>Single Agent <br/>Dose Expansion </span></td><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;</span></td><td colspan="6" style="background-color:#bbdff9;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Part 3: <br/>Combination <br/>Dose Escalation</span></td><td colspan="3" rowspan="4" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8680;</span></td><td colspan="6" style="background-color:#bbdff9;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Part 4: <br/>Combination <br/>Dose Expansion</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#bde782;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Completed </span></td><td colspan="6" style="background-color:#bde782;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Ongoing</span></td><td colspan="6" style="background-color:#bde782;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Ongoing</span></td><td colspan="6" style="background-color:#bde782;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Planned</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:62pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e8e8e8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">INBRX-105<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=32<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Dose range: <br/>0.001 to 3 mg/kg</span></td><td colspan="6" style="background-color:#e8e8e8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">INBRX-105<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=32</span></td><td colspan="6" rowspan="2" style="background-color:#e8e8e8;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">INBRX-105 + Keytruda<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=15+<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">No pre-screening, all-comers</span></td><td colspan="6" style="background-color:#e8e8e8;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/><br/><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">INBRX-105 + Keytruda <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/></span><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N= 80</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:57pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=8<br/>N=8<br/>N=8<br/>N=8</span></td><td colspan="3" style="background-color:#e8e8e8;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">PD-L1+ NSCLC                <br/>PD-L1+ Melanoma           <br/>PD-L1+ Head &amp; Neck Squamous Cell Cancer     <br/>PD-L1+ Basket                 <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><br/></span></td><td colspan="3" style="background-color:#e8e8e8;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">N=20<br/>N=20<br/>N=20<br/>N=20</span></td><td colspan="3" style="background-color:#e8e8e8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">PD-L1+ NSCLC             <br/>PD-L1+ Melanoma        <br/>PD-L1+ Basket              <br/>PD-L1+ (1-49%) NSCLC, CPI naive     </span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part 1, single agent dose escalation, was completed with a total of 32 patients enrolled. We observed dose-limiting toxicities, which were consistent with immune related adverse events, such as hepatitis, arthritis and myalgia/hyperthyroidism, at several dose levels and determined the 1 mg/kg dose level as the MTD of INBRX-105. Patients in this part of the study were not pre-screened for PD-L1 expression. Eight out of 18 evaluable patients (44%), who were dosed at the 0.1 mg/kg dose level or above, achieved stable disease, with the greatest reduction in tumor volume observed to be 20% by RECISTv1.1. The longest duration on treatment with INBRX-105 was 41 weeks, or approximately nine and a half months. Notably, seven patients with stable disease tested positive for PD-L1 expression, with a minimum of 1% positivity as determined by immunohistochemistry (Range 1 to 95%), and the results of one patient are pending. Four of these eight patients were refractory to or progressed on prior PD-1 checkpoint inhibitors.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part 2, single agent dose expansion, began enrolling during the first quarter of 2021. Part 2 will enroll 32 patients in expansion cohorts in each of non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, as well as a basket cohort of gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma. Patients in the expansion cohorts for Part 2 of this trial must be positive for PD-L1 expression, as determined by immunohistochemistry, to qualify for enrollment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part 3, dose escalation of INBRX-105 in combination with Keytruda, will enroll a minimum of 15 patients. These patients are not pre-screened for PD-L1 expression. We expect to announce initial data from this cohort during the second quarter of 2022. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Clinical Development Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part 4 of this trial will consist of INBRX-105 in combination with Keytruda, enrolling 80 patients. Approximately 60 patients will be positive for PD-L1 expression and be refractory to or have progressed on prior PD-1 checkpoint inhibitor in each of the following indications: non-small cell lung cancer, melanoma, and a basket cohort of gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma. Additionally, we will evaluate an additional combination cohort of approximately 20 checkpoint inhibitor naive non-small cell lung cancer patients that are positive for PD-L1 expression with a tumor proportion scale of between 1-49%. We expect to announce initial data from the Part 4 combination expansion cohorts during the first half of 2023.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_58"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various license and collaboration agreements. The license agreements discussed below pertain to intellectual property that we own and license to the parties identified below. We retain ownership of the intellectual property subject to the license agreements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elpiscience Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into two different license agreements with Elpiscience. Each agreement is a standalone license to Elpiscience of a distinct and differentiated protein therapeutic candidate with a separate biological target. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2018, we entered into a license agreement, or the PD-L1 and 4-1BB License Agreement, with Elpiscience, pursuant to which we granted Elpiscience an exclusive license to our bi-specific therapeutic candidate designed to target PD-L1 and 4-1BB, also referred to as INBRX-105. On April 30, 2018, we entered into a license agreement, or the OX40 License Agreement, with Elpiscience, pursuant to which we granted Elpiscience an exclusive license to our multivalent protein therapeutic directed to the biological target OX40, or INBRX-106. Each of the PD-L1 and 4-1BB License Agreement and OX40 License Agreement provides Elpiscience with the right to further advance the respective therapeutic candidate through clinical trials, as well as to manufacture and commercialize these therapeutic candidates in China, Hong Kong, Macau and Taiwan. The PD-L1 and 4-1BB License Agreement and OX40 License Agreement also require us to provide Elpiscience with know-how and materials specific to INBRX-105 and INBRX-106, respectively, including process development and manufacturing data and information necessary to develop INBRX-105 and INBRX-106. Additionally, pursuant to each of the license agreements, Elpiscience granted to us a royalty-free, worldwide, non-exclusive research license to intellectual property created by Elpiscience that incorporates intellectual property we licensed to Elpiscience. In the PD-L1 and 4-1BB License Agreement and OX40 License Agreement, we also agreed to negotiate an agreement to supply Elpiscience with INBRX-105 and INBRX-106, respectively, for their development in China, Hong Kong, Macau and Taiwan. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As payment for the license granted in the PD-L1 and 4-1BB License Agreement, we received a non-refundable upfront payment of $2.5 million and reimbursement of $3.0 million for certain costs we incurred. As payment for the license granted in the OX40 License Agreement, we received a non-refundable fee of $2.5 million, payable in two installments, and reimbursement of $3.4 million for certain toxicology study costs and chemistry, manufacturing and controls costs. In December 2018, we received the first milestone payment of $2.0 million under the PD-L1 and 4-1BB License Agreement. We are also eligible to receive specified developmental and commercial milestone payments of up to an aggregate of $100.0 million under each of the PD-L1 and 4-1BB License Agreement and the OX40 License Agreement. Additionally, we received reimbursement for specific supply-related costs in the amounts of $1.7 million and $1.5 million related to the PD-L1 and 4-1BB License Agreement and the OX40 License Agreement, respectively. Further, each license agreement provides us with the right to receive percentage tiered royalties on future product sales with rates in the high single-digits. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the PD-L1 and 4-1BB License Agreement and the OX40 License Agreement contains representations and warranties, insurance, indemnification and confidentiality provisions customary for similar agreements and arrangements. The terms of the PD-L1 and 4-1BB License Agreement and the OX40 License Agreement commenced on February 28, 2018 and April 30, 2018, respectively, and expire on a country-by-country basis upon the full expiration of Elpiscience&#8217;s milestone- and royalty-based payment obligations under each license agreement. The royalty obligations expire upon the later of (i) the expiration of the last valid patent claim for the applicable product in the relevant jurisdiction, and (ii) 12 years following that date of the first commercial sale of the applicable product in the relevant jurisdiction. Each license agreement may be terminated by (i) either party for the uncured material breach of the other party, (ii) either party for bankruptcy or other insolvency proceedings of the other party, and (iii) Elpiscience at any time upon 90 days&#8217; written notice to us. As of December&#160;31, 2021, and based on current plans, the last to expire issued patent (assuming the issuance of a patent based on our pending patent application) licensed under the PD-L1 and 4-1BB License Agreement is projected to expire in January 2037 and the last to expire issued patent (assuming the issuance of a patent based on our pending patent application) licensed under the OX40 License Agreement is projected to expire in August 2039.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_61"></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chiesi Option Agreement </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into an Option Agreement with Chiesi, which was later amended by the First Amendment to Option Agreement, dated August 19, 2019, or the Chiesi Option Agreement, pursuant to which we granted Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada. In August 2019, under the terms of the Chiesi Option Agreement, we received a one-time, non-refundable option initiation payment of $10.0 million. If Chiesi exercises its option under the Chiesi Option </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement, then Chiesi must pay us a one-time, non-refundable fee of $12.5 million upon the effective date of the definitive agreement granting Chiesi the exclusive license. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option period under the Chiesi Option Agreement began on August 19, 2019 and expires 60 days following the last-to-occur of (a) our delivery to Chiesi of trial phase data for the first Phase I Clinical Trial for INBRX-101 (including the complete clinical study report); (b) our delivery to Chiesi of the finalized minutes from the definitive FDA scientific advice meeting conducted following completion of such Phase I Clinical Trial with the use of the full clinical study report if required by the FDA; and (c) our delivery to Chiesi of the finalized minutes from the definitive parallel European Medicines Agency health technology assessment, or EMA-HTA, scientific advice meeting conducted following completion of such Phase I Clinical Trial with full use of the clinical study report if required by the EMA. The Chiesi Option Agreement may be terminated by (i) Chiesi upon 30 days&#8217; written notice to us, (ii) either party for the uncured material breach of the other party, and (iii) either party for bankruptcy or other insolvency proceedings of the other party. The Chiesi Option Agreement contains representations, warranties and indemnification provisions customary for similar agreements and arrangements. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_64"></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transcenta License Agreement and Technical Services Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2017, we entered into a license agreement, or the Transcenta License Agreement, with Transcenta, pursuant to which we granted to Transcenta exclusive, non-transferable rights to develop, manufacture, and sell its products containing our mono-specific protein therapeutic candidate, designed to target DR5, or INBRX-109, or a derivative thereof, within China, Hong Kong, Macau and Taiwan. We also agreed to provide Transcenta with the know-how and materials, including assays and cell lines, necessary to develop the therapeutic candidate. Additionally, pursuant to the Transcenta License Agreement, Transcenta granted to us a royalty-free, worldwide, non-exclusive research license to intellectual property created by Transcenta that incorporates intellectual property we licensed to Transcenta. As payment for the license we granted in the Transcenta License Agreement, we received a non-refundable upfront payment of $2.5 million. In August 2018, the Company achieved the first milestone under the contract for $0.5 million. In June 2019, the Company achieved another milestone under the contract for $1.0 million. Additionally, we are eligible to receive certain developmental and commercial milestone payments of up to an aggregate of approximately $100.0 million, as well as percentage tiered royalties on future product sales with rates ranging between the high single-digits to the low teens. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Transcenta License Agreement contains representations and warranties, insurance, indemnification and confidentiality provisions customary for similar agreements and arrangements. The term of the Transcenta License Agreement commenced on June 21, 2017, and expires on a country-by-country basis upon the full expiration of Transcenta&#8217;s milestone- and royalty-based payment obligations under the Transcenta License Agreement. The royalty payment obligations expire on a product-by-product and country-by-country basis at such time that there is (i) no valid patent claim for the applicable product in the relevant jurisdiction, and (ii) no Generic Product (as defined in this Transcenta License Agreement) of an applicable product available in the relevant jurisdiction. As of December&#160;31, 2021, and based on current plans, the last to expire issued patent (assuming the issuance of a patent based on our pending patent application) licensed under the Transcenta License Agreement is projected to expire in July 2036. The Transcenta License Agreement may be terminated by (i) either party for the uncured material breach of the other party, (ii) either party for bankruptcy or other insolvency proceedings of the other party, and (iii) Transcenta at any time upon 90 days&#8217; written notice to us. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2018, we also entered into a technical services agreement, or the March TSA, with Transcenta pursuant to which we provided reasonable assistance with the drug substance transfer between our contract manufacturer and Transcenta. We were reimbursed $0.7 million in April 2018 for the March TSA. The March TSA had a six month term and expired in September 2018. On October 6, 2018, we entered into a second technical services agreement, or the October TSA, to provide reasonable assistance pertaining to the transfer of the drug substance between our contract manufacturer and Transcenta. We were reimbursed $0.4 million in October 2018 for the October TSA. The October TSA also had a six month term and expired in April 2019. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_67"></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Celgene Agreement </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2013, we entered into a license agreement with Celgene, a Bristol Meyers Squibb Company, or Celgene, as amended on November 23, 2018, or the Celgene Agreement, pursuant to which we granted Celgene an exclusive, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">global license for the development, manufacture and commercialization of our proprietary CD47 binding domain, or the Celgene Licensed Intellectual Property. Per the terms of the Celgene Agreement, Celgene is operationally and financially responsible for the development, manufacturing and commercialization activities of Celgene Licensed Intellectual Property and any additional related antibodies covered by the Celgene Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As payment for the license granted in the Celgene Agreement, we may be eligible to receive development and regulatory milestones of up to an aggregate of $934.1&#160;million, assuming the achievement of all potential milestones in the Celgene Agreement, as well as percentage tiered royalties based on future worldwide sales, with rates ranging from between the high single-digits to the low teens, subject to potential reduction when and if comparable third-party products attain certain levels of competitive market share (on a country-by-country basis) and, subject to certain limitations, payments to third parties for third-party intellectual property rights. Celgene&#8217;s royalty obligations expire (on a country-by-country basis) upon the later of (i)&#160;the expiration of the last valid patent claim for the applicable Celgene Licensed Intellectual Property or related product in a country, and (ii) 12 years following that date of the first commercial sale of the applicable Celgene Licensed Intellectual Property or related product in a country. We are obligated to pay 2% of future amounts received under the Celgene Agreement to advisors who assisted us with the negotiations and other matters in connection with the Celgene Agreement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Celgene Agreement contains representations and warranties, insurance, indemnification and confidentiality provisions customary for similar agreements and arrangements. In addition, Celgene has the sole right, but not the obligation, to enforce the intellectual property included in the Celgene Agreement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Celgene Agreement commenced on July&#160;1, 2013 and expires on a licensed product-by-licensed product and country-by-country basis on the date of expiration of Celgene&#8217;s applicable royalty obligations.&#160;As of December&#160;31, 2021 and based on our current plans, the last to expire issued patent licensed under the Celgene Agreement is projected to expire in 2033, absent any extension of term. The Celgene Agreement may be terminated by (i)&#160;either party for the uncured material breach of the other party, (ii)&#160;either party for bankruptcy or other insolvency proceedings of the other party, (iii)&#160;Celgene at any time upon 30 days&#8217; written notice to us, and (iv)&#160;us, upon Celgene&#8217;s, or any of its affiliates&#8217;, legal challenge to the validity or enforceability of a licensed patent.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_70"></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2seventy Agreements </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The 2018 2seventy Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;20, 2018, we entered into an exclusive license agreement with bluebird bio, Inc., or bluebird, pursuant to which we granted to bluebird an exclusive license to use our proprietary sdAb platform to research, develop and commercialize chimeric antigen receptor, or CAR, T-cell therapies. In November 2021, bluebird assigned the agreement, which we refer to as the 2018 2seventy Agreement, to its affiliate, 2seventy, in connection with an internal restructuring and subsequent spin-out of 2seventy. Under the terms of the 2018 2seventy Agreement, we will provide 2seventy the exclusive worldwide rights to develop, manufacture and commercialize certain cell therapy products containing sdAbs directed to various cancer targets. As payment for the license granted in the 2018 2seventy Agreement, we received a non-refundable upfront payment of $7.0 million. We are also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. In August 2021, we received a $2.0 million milestone payment under this agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 2seventy Agreement contains representations and warranties, indemnification and confidentiality provisions customary for similar agreements and arrangements. The term of the 2018 2seventy Agreement commenced on December 20, 2018, and expires on a product-by-product and country-by-country basis upon the full expiration of 2seventy&#8217;s milestone- and royalty-based payment obligations under the 2018 2seventy Agreement. The royalty obligations under the 2018 2seventy Agreement expire on a product-by-product and country-by-country basis on the later of (i) the expiration of the last valid patent claim for the applicable product in the relevant jurisdiction; (ii) the date on which any applicable regulatory, pediatric, orphan drug or data exclusivity, which provides 2seventy with the exclusive right to market the applicable product in the relevant jurisdiction, expires; and (iii) 12 years following that date of the first commercial sale of the applicable product in a country. As of December&#160;31, 2021 and based on current plans, the last to expire issued patent (assuming the issuance of one or more patents based on our pending patent applications) licensed under the 2018 2seventy Agreement is projected to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expire in May 2040. The 2018 2seventy Agreement may be terminated by (i) either party for the uncured material breach of the other party, (ii) either party for bankruptcy or other insolvency proceedings of the other party, and (iii) 2seventy at any time upon 30 days&#8217; written notice to us. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The 2020 2seventy Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, we entered into an option and license agreement with bluebird, pursuant to which we granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing sdAbs directed to specified targets, consisting of two initial programs and up to an additional 8 programs. Inhibrx retains all rights to the specific sdAbs outside of the cell therapy field. This agreement, which we refer to as the 2020 2seventy Agreement, was also assigned to 2seventy in November 2021 in connection with bluebird&#8217;s internal restructuring and subsequent spin-out of 2seventy. We received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and we are entitled to an upfront option fee for each additional program. We also granted an option in which 2seventy may acquire an exclusive license with respect to all binders and cell therapy products developed under the 2020 2seventy Agreement, which entitles us to additional fees upon exercise of the option. 2seventy may exercise its option on a program-by-program basis during the option term. Additionally, 2seventy may extend the option term for up to six months in the event that there are additional bona fide development activities that 2seventy desires to undertake. We are also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 2seventy Agreement contains representations and warranties, indemnification and confidentiality provisions customary for similar agreements and arrangements. The term of the 2020 2seventy Agreement commenced on June 9, 2020, and expires on a product-by-product and country-by-country basis upon the full expiration of 2seventy&#8217;s milestone- and royalty-based payment obligations under the 2020 2seventy Agreement. The royalty obligations under the 2020 2seventy Agreement expire on a product-by-product and country-by-country basis on the later of (i) the expiration of the last valid patent claim for the applicable product in the relevant country; (ii) the date on which any applicable regulatory, pediatric, orphan drug or data exclusivity, which provides 2seventy with the exclusive right to market the applicable product in the relevant country, expires; and (iii) 12 years following that date of the first commercial sale of the applicable product in such country. As of December&#160;31, 2021, and based on current plans, the last to expire issued patent (assuming the issuance of one or more patents based on our pending patent applications) licensed under the 2020 2seventy Agreement is projected to expire in May 2040. The 2020 2seventy Agreement may be terminated by (i) either party for the uncured material breach of the other party, (ii) either party for bankruptcy or other insolvency proceedings of the other party, and (iii) 2seventy at any time upon prior written notice within a specified number of days before the termination.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, pursuant to the option extension terms in the 2020 2seventy Agreement, bluebird requested to extend the option term for one of the initial programs by an additional six months in exchange for an option extension fee of $0.1 million. In August 2021, pursuant to the option exercise terms in the agreement, bluebird exercised its option to exclusively license one of the initial programs in exchange for an option exercise fee of $2.1 million, the payment of which was received in October 2021.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_76"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect the proprietary technology and information commercially or strategically important to our business. We seek to obtain and maintain, patent rights intended to cover the technologies incorporated into, or used to produce, our therapeutic candidates, the compositions of matter of our therapeutic candidates and their methods of use and manufacture, as well as other inventions that are important to our business. We also seek to obtain strategic or commercially valuable patent rights in the United States and other jurisdictions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To cover our proprietary technologies and our current pipeline of proprietary products and related methods, such as methods of use, we have filed patent applications representing 37 patent families. As of December&#160;31, 2021, our patent estate, which is solely owned, included 20 issued United States patents, 23 United States pending non-provisional patent applications, 9 United States pending provisional patent applications, 9 pending Patent Cooperation Treaty, or PCT, applications, 188 issued foreign patents and 317 foreign patent applications currently pending in various foreign jurisdictions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we own more than six patent families with claims directed to various sdAb and/or multivalent therapeutic antibodies including, for example, our INBRX-105, INBRX-106, and INBRX-109 therapeutic candidates, and related methods of using the same to treat diseases, e.g., cancer, inflammatory disease, or infectious disease. Patent applications in these families are pending in multiple jurisdictions, including, for example, the United States, Australia, European Patent Organization, Canada, China, Japan, Korea, and Russia; as well as PCT applications and several U.S. provisional applications. Patents in these patent families, if granted, are expected to expire between 2036 and 2039, depending upon their respective filing dates and absent any patent term adjustments or extensions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own two patent families directed to protease inhibitor fusion proteins including, for example, our INBRX-101 therapeutic candidate. Seven United States and 61 foreign patents (Australia, Canada, Mexico, Europe (validated in 39 countries), Hong Kong, India, Israel, Japan, South Korea, New Zealand, Russia, and Ukraine) were granted in these families. These patents are expected to expire in 2032 or 2035, absent any patent term extension. Additional patents in this patent family, if granted, are expected to expire in 2032 or 2035, depending upon their respective filing dates and absent any patent term adjustments or extensions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we own two patent families relating to the Celgene Licensed Intellectual Property that are licensed to Celgene. Two United&#160;States and 67 foreign patents (Australia, Colombia, China, Europe (validated in 39 countries), Eurasia, Hong Kong, Indonesia, Israel, Japan, South Korea, Mexico, Malaysia, Macao, New Zealand, Peru, Philippines, Russia, Singapore, South Africa and Ukraine) have been granted in these families and include claims directed to anti-CD47 monoclonal antibodies and/or methods of using the same to treat cancer. These patents are expected to expire in 2033, absent any patent term extension. Patent applications in these families are pending in multiple jurisdictions, including, for example, the United&#160;States, Australia, European Patent Organization, Canada, China, Japan, South Korea, and Russia. Additional patents in these patent families, if granted, are expected to expire in 2033, depending upon their respective filing dates and absent any patent term adjustments or extensions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following patents (including expected 20 year expiration dates) relate to our fusion protein technologies.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Number</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Expiration Date</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,986,688</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and method</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WAP DOMAIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,914,765</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WAP DOMAIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356433</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WAP DOMAIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,980,266 </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and method</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,920,109</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/6/2034</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,730,929</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,723,785</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,400,029</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,046,752</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2012275287</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition, method and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2017279724</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2015339507</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/27/2035</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition, method</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019202904</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition, method and use</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2839619</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition, method and use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe  (validated in AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SK, SM, TR)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2726092</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1197544</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373030</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366213</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/27/2035</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230209</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6674604</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6737781</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/27/2035</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2084944</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2231139</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356517</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381183</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619023</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2642310</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2698655</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2728861</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2727452</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use, method</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2746550</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/27/2035</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ukraine</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124083</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/28/2032</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following patents (including expected 20 year expiration date) relate to our single domain antibody technologies. </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Number</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Expiration Date</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,526,397</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/7/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-IMMUNOGENIC SINGLE DOMAIN ANTIBODIES</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AU</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2016209247</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/7/2036</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-IMMUNOGENIC SINGLE DOMAIN ANTIBODIES</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following patents (including expected 20 year expiration dates) relate to our multivalent therapeutic antibody technologies.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Number</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Expiration Date</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,308,720</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/18/2036</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,117,973</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11/22/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS AND METHODS OF TREATING NEOPLASMS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">EP (Validated in: AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3322734</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/18/2036</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HK</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1254433</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/18/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6807606</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/18/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and method</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RU</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2748620</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/18/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SG</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11201800223W</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/18/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018/00238</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/18/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,093,742</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/22/2036</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and method</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,844,129</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/22/2036</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and method</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AU</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,016,297,249</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/22/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition, method and use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JP</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,913,682</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/22/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RU</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,753,439</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/22/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TW</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">I745296</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/22/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018/00410</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/22/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,501,551</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/11/2037</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and method</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MULTIVALENT AND MULTISPECIFIC 41BB-BINDING FUSION PROTEINS</span></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following patents (including expected 20 year expiration dates) relate to our CD47 antibody technologies.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Number</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Expiration Date</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,045,541</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,663,575</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2013217114</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and method</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL201380017900.0</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14171778</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eurasia (validated in Russia)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34778</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe (validated in AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2812443</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indonesia</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IDP00005873</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6273212</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2100388</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360772</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MY-169341-A</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628314</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/2014/501758</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11201404638S</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ukraine</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116772</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201405864</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HK1205195</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2013377886</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition, method, and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019200942</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Composition, method, and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105101997</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition and use</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eurasia</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">036963</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indonesia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IDP000058855</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240390</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6726238</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2170196</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2276974</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J/003573</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710695</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peru</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9897</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2015/05745</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/6/2033</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF</span></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess and refine our intellectual property strategy as we develop new technologies and therapeutic candidates. As our business evolves, we may, among other activities, file additional patent applications in pursuit of our intellectual property strategy, to adapt to competition or to seize potential opportunities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the laws of the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing of a non-provisional patent application. However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the United States Patent and Trademark Office, or USPTO. For example, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension for FDA-approved drugs of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our therapeutic candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those therapeutic candidates. We intend to seek patent term extensions in any jurisdiction where these are available and where we also have a patent that may be eligible; however there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets to protect aspects of our technology and business not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect this intellectual property, in part, by requiring our employees, consultants, outside scientific collaborators, sponsored researchers and other service providers and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advisors to execute confidentiality agreements upon the commencement of employment or other relationship with us. In general, these agreements provide that confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements further provide that inventions and discoveries conceived or reduced to practice by the individual that are related to our business, or actual, or demonstrably anticipated, research or development, or made during normal working hours, on our premises or using our equipment, supplies, or proprietary information, are our exclusive property. In many cases our agreements with consultants, outside scientific collaborators, sponsored researchers and other service providers and advisors require them to assign, or grant us licenses to, inventions resulting from the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we expect to rely on data exclusivity, market exclusivity, patent term adjustment and patent term extensions when available. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek trademark protection in the United States and in certain other jurisdictions where available and when we deem appropriate. We currently have a registration for &#8220;Inhibrx&#8221; in the United States. We intend to file applications for trademark registrations in connection with our therapeutic candidates in various jurisdictions, including the United States. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_79"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry is characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. While we believe that our platforms, technology, knowledge, experience, and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any therapeutic candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our therapeutics, the ease of use and effectiveness of any complementary diagnostics and/or companion diagnostics, and price and levels of reimbursement. Our primary competitors fall into the following groups: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing novel therapeutics based on sdAb or alternative scaffold product candidates, including Alligator Bioscience AB, Camel-IDS N.V., Crescendo Biologics Ltd., GlaxoSmithKline plc, IGM Biosciences, Inc., Molecular Partners AG, Pieris Pharmaceuticals, Inc., Sanofi S.A. and VHsquared Ltd.; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Antibody drug discovery companies that may compete with us in the search for novel therapeutic antibody targets, including Regeneron Pharmaceuticals, Inc., Adimab&#160;LLC, Genmab A/S, Macrogenics, Inc., Merus&#160;N.V., MorphoSys AG, Numab Therapeutics AG, Amgen, Inc., Xencor&#160;Inc., and Zymeworks Inc.; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing therapeutics designed to treat AATD, including CSL Limited, Grifols, S.A., Kamada Ltd., Takeda Pharmaceutical Company Limited and Centessa Pharmaceuticals PLC; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing cytokine therapeutics, including Alkermes PLC, Altor BioScience, ImmunityBio, Inc., Medicenna Therapeutics Corp., Nektar Therapeutics, Neoleukin Therapeutics, Inc., Novartis AG, Pandion Therapeutics, Inc., Merck &amp; Co., Philogen S.p.A., Roche Holding AG, Rubius Therapeutics, Inc., SOTIO Biotech, Synthekine, Inc., Sanofi S.A., Xencor, Inc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors also include large pharmaceutical and biotechnology companies who may be developing therapeutic candidates with mechanisms similar to or targeting the same indications as our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our therapeutic candidates. Our competitors also may obtain FDA or other marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These early stage and more established competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_82"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those we are developing. Our therapeutic candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States and will be subject to similar requirements in other countries prior to marketing in those countries. The process of obtaining marketing approvals in the U.S. and in foreign countries and jurisdictions, and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations, require the expenditure of substantial time and financial resources. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">United States Government Regulation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates biopharmaceutical products under the Federal Food, Drug, and Cosmetic Act and the Public Health Services Act, or PHSA, and implementing regulations. Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval, may subject an applicant to administrative or judicial sanctions brought by the FDA and the Department of Justice, or DOJ, or other governmental entities, any of which could have a material adverse effect on us. These sanctions could include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of an approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a clinical hold; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seizures or administrative detention of product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production or distribution; or </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions, fines, disgorgement, or civil or criminal penalties. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLA Approval Processes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a therapeutic biologic may be marketed in the United States generally involves the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of nonclinical laboratory tests, animal studies and formulation studies conducted according to good laboratory practices and other applicable regulations and guidance; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials according to good clinical practices, or GCPs, to establish the safety and efficacy of the therapeutic candidate for its intended use; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of a BLA; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the therapeutic candidate is produced to assess readiness for commercial manufacturing and conformance to the manufacturing-related elements of the application, to conduct a data integrity audit, and to assess compliance with current Good Manufacturing Practices, or cGMPs, to assure that the facilities, methods and controls are adequate to preserve the therapeutic candidate&#8217;s identity, strength, quality and purity; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the BLA. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a biopharmaceutical candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">animal studies. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Additional nonclinical testing continues even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include a study protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Clinical Trials in Support of a BLA</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must be conducted under protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol, and any subsequent material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must report to the FDA serious and unexpected adverse reactions in a timely manner, such as any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator&#8217;s brochure or any findings from other studies or animal or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk in humans exposed to the product or therapeutic candidate. An institutional review board, or IRB, for each institution participating in the clinical trial must review and approve the protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each research subject or the subject&#8217;s legal representative, monitor the trial until completed and otherwise comply with IRB regulations. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1-The product or therapeutic candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and elimination. In the case of some therapeutic candidates for severe or life-threatening diseases, such as cancer, especially when the product or therapeutic candidate may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2-Clinical trials are performed on a limited patient population intended to identify possible AEs and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3-Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These trials are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A pivotal trial is a clinical trial that adequately meets regulatory agency requirements for the evaluation of a product or therapeutic candidate&#8217;s efficacy and safety such that it can be used to justify the approval of the product. Generally, pivotal trials are also Phase 3 trials but may be Phase 2 trials if the trial design provides a reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need. Human clinical trials are inherently uncertain and Phase 1, Phase 2 and Phase 3 testing may not be successfully completed. The FDA or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product or therapeutic candidate has been associated with unexpected serious harm to patients. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a new product or therapeutic candidate, sponsors are given opportunities to meet with the FDA at certain points; specifically, prior to the submission of an IND, at the end of Phase 2 and before a BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share information about the data gathered to date and for the FDA to provide advice on the next phase of development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trials that they believe will support the approval of the new therapeutic. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as &#8220;Phase 4&#8221; clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of &#8220;Phase 4&#8221; clinical trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product or therapeutic candidate and finalize a process for manufacturing commercial quantities of the product or therapeutic candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product or therapeutic candidate and the manufacturer must develop methods for testing the quality, purity and potency of the product or therapeutic candidate. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product or therapeutic candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product or therapeutic candidate does not undergo unacceptable deterioration over its shelf life. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Clinical Trial Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors of clinical trials of certain FDA-regulated products, including prescription drugs and biologics, are required to register and disclose certain clinical trial information on a public registry maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. The NIH&#8217;s Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and the government has recently begun enforcing those requirements against non-compliant clinical trial sponsors.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketing Application Submission and FDA Review</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with detailed descriptions of the product&#8217;s CMC, proposed labeling and other relevant information are submitted to the FDA as part of a BLA requesting approval to market the product. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for prescription biological or drug products. Fee waivers or reductions are available in certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the applicant is a small business submitting its first human therapeutic application for review. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the goals and policies agreed to by the FDA under PDUFA, for original BLAs, the FDA has ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification and the sponsor&#8217;s process to respond to such inquiries. This FDA review typically takes twelve months from the date the BLA is submitted to the FDA (for a standard review) and eight months from the date the BLA is </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submitted (for a &#8220;priority review&#8221;) because the FDA has approximately two months, or 60 days, after BLA submission to make a &#8220;filing&#8221; decision.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of a submitted BLA within 60 days of receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission whether the application is substantially complete to permit a substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission, and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, whether it has an acceptable purity profile and whether the product is being manufactured in accordance with cGMP. The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers these recommendations carefully when making decisions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA likely will re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. The FDA also may require the submission of a risk evaluation and mitigation strategy, or REMS, plan if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the biological product. The REMS plan could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS plan is needed, the sponsor of the BLA must submit a proposed REMS plan. The FDA will not approve a BLA without a REMS plan, if required. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically inspect the facilities at which the product is manufactured. The FDA&#160;will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements and to assure the integrity of the clinical data submitted to the FDA. To ensure cGMP and GCP compliance by its employees and third-party contractors, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval process is lengthy and often difficult, and notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval or may require additional clinical or other data and information. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve a BLA, the FDA will issue a complete response letter, or CRL, that describes all of the specific deficiencies in the BLA identified by the FDA. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the CRL may include recommended actions that the applicant might take to place the application in a condition for approval. If a CRL is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter to the applicant. The FDA has committed to reviewing such resubmissions in response to an issued CRL in either two or six&#160;months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product receives marketing approval, the approval may be limited to specific indications and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as &#8220;Phase 4&#8221; clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and/or testing and surveillance programs to monitor the safety of approved products that have been commercialized. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Companion Diagnostics </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA issued a final guidance document in July 2014 addressing agency policy in relation to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companion diagnostic tests. The guidance explains that for some drugs and therapeutic biologics, the use of a companion diagnostic test is essential for the safe and effective use of the product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test. According to the guidance, the FDA generally will not approve such a product if the companion diagnostic is not also approved or cleared for the appropriate indication, and accordingly the therapeutic product and the companion diagnostic should be developed and approved or cleared contemporaneously. However, the FDA may decide that it is appropriate to approve such a product without an approved or cleared </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic device when the drug or therapeutic biologic is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists and the FDA determines that the benefits from the use of a product with an unapproved or uncleared </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic device are so pronounced as to outweigh the risks from the lack of an approved or cleared </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companion diagnostic device. The FDA encourages sponsors considering developing a therapeutic product that requires a companion diagnostic to request a meeting with both relevant device and therapeutic product review divisions to ensure that the product development plan will produce sufficient data to establish the safety and effectiveness of both the therapeutic product and the companion diagnostic. Because the FDA&#8217;s policy on companion diagnostics is set forth only in guidance, this policy is subject to change and is not legally binding. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track, Breakthrough Therapy, and Priority Review Designations</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation and priority review designation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the BLA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor and the FDA agree on a schedule for the submission of the application sections, and the sponsor pays any required user fees upon submission of the first section of the BLA. In addition, fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging in the clinical trial process. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, with the enactment of the FDA Safety and Innovation Act, or FDASIA, in 2012, Congress created a new regulatory program for product and therapeutic candidates designated by the FDA as &#8220;breakthrough therapies&#8221; upon a request made by the IND sponsors. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies are also eligible for accelerated approval of their respective marketing applications. The FDA must take certain actions with </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect to breakthrough therapies, such as holding timely meetings with and providing advice to the product sponsor, intended to expedite the development and review of an application for approval of a breakthrough therapy.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, the FDA may designate a product for priority review if it is a drug or biologic that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten&#160;months to six&#160;months for an original BLA from the date of filing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accelerated Approval Pathway </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a drug or biologic when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Drugs and biologics granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long-term clinical benefit of a drug.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a product or therapeutic candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post-marketing studies, would allow the FDA to withdraw approval of the drug. All&#160;promotional materials for product and therapeutic candidates being considered and approved under the accelerated approval program are subject to prior review by the FDA. Lawmakers, FDA officials, and other stakeholders have recently been evaluating the accelerated approval program and have proposed potential reforms to improve certain aspects. In addition, over the past year, several oncology sponsors have voluntarily withdrawn specific indications for their drug products that were being marketed pursuant to accelerated approval, and the FDA&#8217;s Oncology Center of Excellence launched an initiative called Project Confirm, aimed at promoting transparency in the area of accelerated approvals for oncology indications. Scrutiny of the accelerated approval pathway is likely to continue and may lead to legislative and/or administrative changes in the future. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Restoration and Reference Product Marketing Exclusivity for Biological Products</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our United States patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product or therapeutic candidate&#8217;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product or therapeutic candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant BLA.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act, or the BPCIA, enacted in 2010, amended the PHSA to authorize the FDA to approve similar versions of innovative biologics such as ours, which are also known as &#8220;reference biological products.&#8221; The pathway authorized under the BPCIA allows FDA to approve, under an abbreviated application, a biological product that has been shown to be highly similar to a reference product notwithstanding minor differences in clinically inactive components; there also can be no clinically meaningful differences between the follow-on product and the reference product in terms of safety, purity and potency. Follow-on biological products approved for marketing using this pathway are commonly known as &#8220;biosimilars,&#8221; and companies seeking approval of biosimilar products must submit in their abbreviated BLAs data from analytical studies, animal studies and a clinical trial or trials sufficient to meet the statutory standard in order to obtain FDA approval. In addition, an interchangeable product is a biosimilar product that can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product, although to date no such products have been approved for marketing in the United States. FDA approved the first interchangeable biosimilars, including an interchangeable monoclonal antibody biosimilar, in 2021. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA bars the FDA from approving biosimilar applications for 12 years after a reference biological product receives initial marketing approval. FDA also cannot accept an application for a biosimilar product that is based on the reference biological product until four years after the date of first licensure of the reference product in question. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA is complex and is still being interpreted and implemented by the FDA and by federal judges. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation and legislative amendments. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation and Orphan Product Exclusivity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to a therapeutic candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects either (i)&#160;fewer than 200,000 individuals in the United States, or (ii)&#160;more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a product or therapeutic candidate for this type of disease or condition will be recovered from sales in the United States for that product or therapeutic candidate. Orphan Drug Designation must be requested before submitting a BLA. After the FDA grants Orphan Drug Designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. INBRX-109 has been designated an orphan product by the FDA for the treatment of chondrosarcoma.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product or therapeutic candidate that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the approved product is entitled to orphan product exclusivity, which means that the FDA may not approve any other marketing applications for the same drug for the same indication, except under limited circumstances (such as showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues), for seven years. Competitors, however, may still receive approval of either a different product for the same indication for which the orphan product has exclusivity or for the same product but for a different indication (which could then be used off-label in the orphan indication). Orphan product exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same drug as defined by the FDA, or if our therapeutic candidate is determined to be contained within a competitor&#8217;s approved drug for the same indication or disease. Further, if a drug designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, an orphan drug credit is available for qualifying costs incurred between the date the FDA designates a drug as an orphan drug and the date the FDA approves the drug. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Exclusivity and Pediatric Use </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. Under the Best Pharmaceuticals for Children Act, or BPCA, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor submits information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the product or therapeutic candidate in children. The data do not need to show the product to be effective in the pediatric population studied; rather, the additional protection is granted if the pediatric clinical trial is deemed to have fairly responded to the FDA&#8217;s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product or therapeutic candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. The issuance of a Written Request does not require the sponsor to undertake the described trials. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric trials for most therapeutic drugs and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original new drug applications, BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. Sponsors must also submit Pediatric Study Plans, or PSPs, to the agency for review within sixty days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The initial PSP must include an outline of the pediatric trial or trials that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric trials along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials or other clinical development programs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The required assessment must assess the safety and effectiveness of the product or therapeutic candidate for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product and therapeutic candidate is safe and effective. The sponsor or FDA may request a deferral of pediatric trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The FDA is required to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation, and the FDA publicly posts such PREA Non-Compliance letters and sponsor&#8217;s response. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although FDA has taken steps to limit what it considers abuse of this statutory exemption in PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Requirements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new product, the manufacturer and the approved biological product are subject to pervasive and continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (i.e., &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or a BLA supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product or therapeutic reaches the market. Later discovery of previously unknown problems with a product or therapeutic candidate, including adverse events of unanticipated severity or frequency, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences of non-compliance include, among other things:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated modification of promotional materials or labeling and the issuance of corrective information;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any therapeutic candidate manufactured or distributed by us pursuant to FDA approvals will be subject to continuing regulation by the FDA, including, among other things: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">record-keeping requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reporting of adverse experiences with the therapeutic candidate; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing the FDA with updated safety and efficacy information; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sampling and distribution requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">notifying the FDA and gaining its approval of specified manufacturing or labeling changes; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complying with FDA promotion and advertising requirements, which include, among other things, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in-patient populations that are not described in the product&#8217;s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Therapeutic manufacturers and other entities involved in the manufacture and distribution of approved therapeutic products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMPs and other laws. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP requirements. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the BLA applicant and any third-party manufacturers involved in producing the approved biological product. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of quality control and quality assurance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or the PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. More recently, the Drug Supply Chain Security Act, or the DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10&#8209;year period that is expected to culminate in November&#160;2023. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. For example, the FDA released proposed regulations in February 2022 to amend the national standards for licensing of wholesale drug distributors by the states; establish new minimum standards for state licensing third-party logistics providers; and create a federal system for licensure for use in the absence of a State program, each of which is mandated by the DSCSA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Outside of the United States </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we will be subject to regulations of other jurisdictions governing any clinical trials and commercial sales and distribution of our therapeutic candidates. Whether or not we obtain FDA </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under European Union regulatory systems, a company can consider applying for marketing authorization in several European Union member states by submitting its marketing authorization application(s) under a centralized, decentralized or mutual recognition procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The centralized procedure is compulsory for medicines derived from biotechnology, orphan medicinal products, or those medicines with an active substance not authorized in the European Union on or before May&#160;20, 2004 intended to treat acquired immune deficiency syndrome, cancer, neurodegenerative disorders or diabetes and optional for those medicines containing a new active substance not authorized in the European Union on or before May&#160;20, 2004, medicines which are highly innovative, or medicines to which the granting of a marketing authorization under the centralized procedure would be in the interest of patients at the European Union-level. The decentralized procedure provides for recognition by European Union national authorities of a first assessment performed by one of the member states. Under this procedure, an identical application for marketing authorization is submitted simultaneously to the national authorities of several European Union member states, one of them being chosen as the &#8220;Reference Member State,&#8221; and the remaining being the &#8220;Concerned Member States.&#8221; The Reference Member State must prepare and send drafts of an assessment report, summary of product characteristics and the labelling and package leaflet within 120 days after receipt of a valid marketing authorization application to the Concerned Member States, which must decide within 90 days whether to recognize approval. If any Concerned Member State does not recognize the marketing authorization on the grounds of potential serious risk to public health, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. The mutual recognition procedure is similar to the decentralized procedure except that a medicine must have already received a marketing authorization in at least one of the member states, and that member state acts as the Reference Member State. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drugs in the European Union enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product, the marketing authorization holder is unable to supply sufficient quantity of the medicinal product or the marketing authorization holder has given its consent. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom left the European Union on January 31, 2020 (commonly referred to as &#8220;Brexit&#8221;), with a transitional period that expired on December 31, 2020. The United Kingdom and the European Union entered into a trade agreement known as the Trade and Cooperation Agreement, which went into effect on January 1, 2021. It remains to be seen how Brexit and the Trade and Cooperation Agreement will impact regulatory requirements for product candidates and products in the United Kingdom. We are currently evaluating the potential impacts on our business of the Trade and Cooperation Agreement and guidance issued to date by the United Kingdom&#8217;s Medicines and Healthcare products Regulatory Agency, or MHRA, regarding the requirements for licensing and marketing therapeutic drugs and biologics in the United Kingdom.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the regulatory framework in the United Kingdom covering the quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from European Union directives and regulations, Brexit could materially impact the future regulatory regime as it applies to medicinal products and the approval of product candidates in the United Kingdom. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, Pricing and Reimbursement </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. There may be significant delays in obtaining coverage and reimbursement for approved products, and coverage may be more </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. It is time consuming and expensive to seek reimbursement from third-party payors. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States, or U.S.. In the U.S., third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but they also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of therapeutics have been a focus in this effort. The United States government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic and biosimilar products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If these third-party payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement for the pharmaceutical or biological products apply to companion diagnostics.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in some foreign countries, the proposed pricing for a product and therapeutic candidate must be approved before it may be lawfully marketed. The requirements governing therapeutic pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapeutic candidates. Historically, therapeutic candidates launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product and therapeutic candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product and therapeutic candidates that obtain marketing approval. The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of our product and therapeutic candidates. For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and devices and to spur innovation, but its ultimate implementation is uncertain. In addition, in August 2017, the FDA Reauthorization Act was signed into law, which reauthorized the FDA&#8217;s user fee programs and included additional drug and device provisions that build on the Cures Act. Furthermore, the next FDA reauthorization package is currently being negotiated and is due to be finalized by Congress in 2022, while several other FDA-related changes are also being proposed in Congress, including within a &#8220;Cures 2.0&#8221; bill that is likely to have bipartisan support. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. Moreover, among policy makers and payors in the United&#160;States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted in March 2010 and has had a significant impact on the health care industry in the U.S. The ACA expanded coverage for the uninsured while at the same time containing overall healthcare costs. It also included the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program. As another example, the 2021 Consolidated Appropriations Act signed into law on December 27, 2020 incorporated extensive healthcare provisions and amendments to existing laws, including a requirement that all manufacturers of drugs and biological products covered under Medicare Part B report the product&#8217;s average sales price, or ASP, to the United States Department of Health and Human Services, or HHS, beginning on January 1, 2022, subject to enforcement via civil money penalties.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA, and as a result certain sections of the ACA have not been fully implemented or have been effectively repealed through Executive Orders and/or executive agency decisions. However, following several years of litigation in the federal courts, in June 2021, the U.S. Supreme Court upheld the ACA when it dismissed a legal challenge to the ACA&#8217;s constitutionality. Further legislative and regulatory changes under the ACA remain possible, although the Biden Administration has signaled that it plans to build on the ACA and expand the number of people who are eligible for health insurance subsidies under it. It is unknown what form any such changes or any law would take, and how or whether it may affect the biopharmaceutical industry as a whole or our business in the future. We expect that changes or additions to the ACA, the Medicare and Medicaid programs, such as changes allowing the federal government to directly negotiate drug prices, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the health care industry in the United States.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA that affect health care expenditures. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, which was signed into law on March 27, 2020 and was designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030, in order to offset the added expense of the 2020 cancellation. The suspension was subsequently extended through March 31, 2022, with a reduction of the suspension to 1% sequester through June 30, 2022.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another example, in December 2019, President Trump signed the Further Consolidated Appropriations Act for 2020 into law, or P.L. 116-94, that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019, or the CREATES Act. The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. Because generic and biosimilar product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic and biosimilar products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221; Whether and how generic and biosimilar product developments will use this new pathway, as </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. The HHS has solicited feedback on some of various measures intended to lower drug prices and reduce the out of pocket costs of drugs and implemented others under its existing authority. For example, in May 2019, HHS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified an HHS policy change that was effective January&#160;1, 2019. As another example, in 2020, the FDA finalized a rulemaking to establish a system whereby state governmental entities could lawfully import and distribute prescription drugs sourced from Canada. More recently, in July 2021, President Biden issued a sweeping executive order on promoting competition in the American economy that includes several mandates pertaining to the pharmaceutical and health care insurance industries. Among other things, the executive order directed the FDA to work towards implementing a system for importing drugs from Canada (following on the Trump administration notice-and-comment rulemaking on Canadian drug importation that was finalized in October 2020). The Biden order also called on HHS to release a comprehensive plan to combat high prescription drug prices, and it includes several directives regarding the Federal Trade Commission&#8217;s oversight of potentially anticompetitive practices within the pharmaceutical industry. The drug pricing plan released by HHS in September 2021 in response to the executive order makes clear that the Biden Administration supports aggressive action to address rising drug prices, including allowing HHS to negotiate the cost of Medicare Part B and D drugs, but such significant changes will require either new legislation to be passed by Congress or time-consuming administrative actions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate PBMs and other members of the health care and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future business operations are subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we research, and, if approved, market, sell and distribute our therapeutic candidates. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, physician sunshine and drug pricing transparency laws and regulations such as: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or paying remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is broadly interpreted and aggressively enforced with the result that beneficial commercial arrangements can be penalized in the healthcare industry. In the past, the government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on a variety of arrangements, including sham consulting and other financial arrangements with physicians. Penalties for violating the federal Anti-Kickback Statute include imprisonment for up to 10 years, fines of up to $100,000 per violation and possible exclusion from federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, prohibit, among other things, knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the U.S. government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government. Actions under these laws may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government uses these laws, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the U.S., for example, in connection with the promotion of products for unapproved uses and other allegedly unlawful sales and marketing practices. If an entity is found to have violated the False Claims Act, it must pay three times the actual damages sustained by the government, plus mandatory and substantial civil penalties;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The U.S. federal Health Insurance Portability and Accountability Act of 1996 and its accompanying regulations, or HIPAA, created new federal, civil and criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Physician Payments Sunshine Act, enacted as part of the ACA, among other things, imposes reporting requirements on manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to HHS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors and certain advanced non-physician health care practitioners), teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The law carries penalties of up to $1.15 million per year for violations, depending on the circumstances, and payments reported also have the potential to draw scrutiny on payments and relationships with with physicians, which may have implications under the Anti-Kickback Statute and other healthcare laws; </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous state laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws which require the registration of pharmaceutical sales representatives; and state laws and non-United States laws and regulations (particularly European Union laws regarding personal data relating to individuals based in Europe) that govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in November 2020, HHS finalized significant changes to the regulations implementing the Anti-Kickback Statute and the civil monetary penalty rules regarding beneficiary inducements, with the goal of offering the healthcare industry more flexibility and reducing the regulatory burden associated with those fraud and abuse laws, particularly with respect to value-based arrangements among industry participants.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant civil, criminal and administrative penalties, including </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monetary damages, fines, disgorgement, imprisonment, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. and European Data Security and Data Privacy Laws</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as well as a number of other federal and state privacy-related laws, extensively regulate the use and disclosure of individually identifiable health information, known as &#8220;protected health information&#8221; or &#8220;PHI&#8221;.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA applies to health plans, healthcare providers who engage in certain standard healthcare transactions electronically, such as electronic billing, and healthcare clearinghouses, all of which are referred to as &#8220;covered entities&#8221; under HIPAA. State imposed health information privacy and security laws typically apply based on licensure, for example, licensed providers or licensed entities are limited in their ability to use and share health information.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, all states have enacted legislation protecting the privacy and security of &#8220;personal information&#8221; such as identifiable financial or health information, social security number and credit card information. These laws overlap and apply simultaneously with federal privacy and security requirements and regulated entities must comply with all of them. The California Consumer Privacy Act, or CCPA, that went into effect January 1, 2020, is one of the most restrictive state privacy laws, protecting a wide variety of personal information and granting significant rights to California residents with respect to their personal information. Regulations under CCPA have been modified several times. Additionally, a new privacy law, the California Privacy Rights Act, or CPRA, was approved by California voters in the election of November 3, 2020. CPRA will modify CCPA significantly, potentially resulting in further uncertainty, additional costs and expenses stemming from efforts to comply, and additional potential for harm and liability for failure to comply. Other states in the U.S. are considering privacy laws similar to CCPA. In dealing with health information for the development of our technology or for commercial purposes, we will be indirectly affected by HIPAA and state-imposed health information privacy and security laws because these laws regulate the ability of our potential customers and research collaborators to share health information with us. Additionally, we must identify and comply with all applicable state laws for the protection of personal information with respect to employee information or other personal information that the company collects.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Part I, Item 1A &#8220;Risk Factors-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face regulation and potential liability related to the privacy, data protection and information security which may require significant resources and may adversely affect our business, operations and financial performance.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, increasingly stringent data protection and privacy rules that have and will continue to have substantial impact on the use of personal and patient data across the healthcare industry became stronger in May 2018. The EU General Data Protection Regulation, or GDPR, applies across the European Union and includes, among other things, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances and significant fines for non-compliance. The GDPR fine framework can be up to 20 million euros, or up to 4% of the company&#8217;s total global turnover of the preceding fiscal year, whichever is higher. The GDPR sets out a number of requirements that must be complied with when handling the personal data of such European Union based data subjects including: providing expanded disclosures about how their personal data will be used; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal basis in place to justify their data processing activities; the obligation to appoint data protection officers in certain circumstances; new rights for individuals to be &#8220;forgotten&#8221; and rights to data portability, as well as enhanced current rights (e.g., access requests); the principal of accountability and demonstrating compliance through policies, procedures, training and audit; and the new mandatory data breach regime. In particular, medical or health data, genetic data and biometric data where the latter is used to uniquely identify an individual are all classified as &#8220;special category&#8221; data under the GDPR and are afforded greater protection and require additional compliance obligations. Noncompliance could result in the imposition of fines, penalties, or orders to stop noncompliant activities. We may be subject to GDPR if we undertake operations in the EU, offer products or services to individuals in the EU or monitor the behavior of individuals within the EU.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be subject to evolving European Union laws on data export, for transfers of data outside the European Union to us, group companies or third parties. The GDPR only permits exports of data outside the European Union </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to jurisdictions that ensure an adequate level of data protection. The United States has not been deemed to offer an adequate level of protection, so in order for us to transfer personal data from the EU to the United States, we must identify a legal basis for data transfer (e.g., the European Union Commission approved Standard Contractual Clauses). On July 16, 2020, the Court of Justice of the European Union or the CJEU, issued a landmark opinion in the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maximilian Schrems vs. Facebook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Case C-311/18), called </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schrems II. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This decision (a) calls into question commonly relied upon data transfer mechanisms as between the European Union member states and the United States (such as the Standard Contractual Clauses) and (b) invalidates the EU-U.S. Privacy Shield on which many companies had relied as an acceptable mechanism for transferring such data from the EU to the United States. The CJEU is the highest court in Europe and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schrems II </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decision heightens the burden on data importers to assess U.S. national security laws on their business and future actions of European Union data protection authorities are difficult to predict.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the United Kingdom&#8217;s decision to leave the European Union, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, while the Data Protection Act of 2018 that &#8220;implements&#8221; and complements the GDPR achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the European Economic Area to the United Kingdom will remain lawful under GDPR.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Laws and Regulations</span></div><div style="margin-bottom:9.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our present business is, and our future business may be, subject to regulation under the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations. See Part I, Item 1A &#8220;Risk Factors- </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div id="ie96bda597eaa4024845d6498a1c78657_85"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities for the production of any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We presently have relationships with suppliers for the manufacture of supplies for all of our required raw materials, antibodies and other biologics for our preclinical research, clinical trials, and if and when applicable, commercialization. We currently employ internal resources to manage our manufacturing relationships with these third parties. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_91"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are a key factor in our ability to achieve our mission to discover and develop effective biologic therapeutics for people with life-threatening conditions. We believe that our future success depends on our continued ability to identify, recruit, retain, and incentivize our management team and our clinical, scientific, and other employees. Our ability to do so depends on factors including our Company culture, compensation and benefits, growth and development opportunities, and prioritization of employee safety.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Profile</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 112 employees, 106 of whom were full-time, 97 of whom were engaged in research and development activity, and 25 with a Ph.D. or M.D. None of our employees are represented by a labor union and we believe we maintain good relations with our employees.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Conduct &amp; Ethics</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx adopted and regularly reviews corporate policies, including a Code of Conduct and Ethics and Whistleblower Policy, which apply to all of our employees. All employees attend a mandatory public company training session and are required to abide by, review and confirm compliance to the Company&#8217;s Corporate Code of Conduct and Ethics and Whistleblower Policy, as well as our Insider Trading Policy governing trading by Company personnel in the Company&#8217;s securities. We have established a Whistleblower reporting hotline to enable our employees to anonymously report any suspected violations of these policies. In addition, the Company requires employees to complete Anti-Harassment Training, with employees who work in a management capacity required to complete additional trainings in Harassment Prevention and Diversity, Equity and Inclusion. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Compensation and Benefits</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation programs are designed to reward and support our employees in order to continue to attract and retain top talent. Our compensation includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employee base salaries that are competitive and consistent with employee positions, skill levels, experience, and knowledge;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation awards which help to align the interests of our stockholders with those of our employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bonus award plans at the senior management level and discretionary awards for other key employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retirement savings options and matching contributions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fully covered healthcare benefits for all full-time employees and their dependents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unlimited vacation benefit for all full-time employees; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Parental leave and other leave options available to all employees.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Growth and Development </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx is committed to fostering and growing talent within the biotechnology and life sciences space. We provide internship opportunities for students interested in biotechnology and science within our research and development departments. Many of our interns have continued on to join the Company in a full-time position after graduation. Our hiring process is transparent and we are an equal opportunity employer. Many of our employees hold Ph.D.s or M.D.s; however, the Company equally commits resources to advancing all of our employees with a range of educational backgrounds. We offer tuition reimbursement aimed at growth and career development, as well as the opportunity for employees to attend relevant conferences and symposiums. In addition, we offer in-house coaching opportunities to refine or develop professional skills as our employees become managers and plan their career growth.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Wellness, Health, and Safety</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are strongly committed to the health and safety of our employees and strive to maintain the highest possible level of safety in our workplace. We require annual workplace safety training to reinforce workplace safety procedures that may be useful in the event of emergency situations and to assist our employees in helping to prevent workplace accidents. Our Environmental Health and Safety Committee, which is comprised of numerous cross-departmental members, meets regularly to review workplace safety and adherence to safety policies.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we created a COVID-19 Task Force, which, since March 2020, has been continuously implementing changes in our business to protect our employees, support appropriate health and safety protocols, and comply with government regulations. These measures include implementing a policy for employees to work from home to the extent practicable, increased physical distancing in workspaces, and regular testing or vaccination requirements. For our essential employees who remain onsite, we provide personal protective equipment and enhanced cleaning protocols. We have implemented a policy and protocols to address COVID-19 cases and potential exposure. As the COVID-19 pandemic continues to evolve, we adjust and tailor our approach based on applicable regulations, public health guidance, and local community case rates. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_97"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware on November 17, 2017 under the name Tenium Therapeutics, Inc. In April 2018, we changed our name to Inhibrx, Inc.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_100"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internet address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.inhibrx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to which we regularly post copies of our press releases as well as additional information about us. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through the Investors section on our website as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the SEC. The SEC maintains an internet site (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. We include our web site address in this Annual Report only as an inactive textual reference. Information contained in our website does not constitute a part of this report or our other filings with the SEC.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report, including our consolidated financial statements and related notes, before investing in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results, financial condition, and prospects could be materially harmed. In that event, the price of our common stock could decline, and you could lose part or all of your investment. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_106"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the section of this Annual Report titled &#8220;Risk Factors&#8221;. These risks include, among others, the following:</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Need for Additional Capital </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate product revenue or become profitable, or if we achieve profitability, we may not be able to sustain it.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotechnology product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from product sales and may never be profitable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding in order to complete the development and commercialization of our therapeutic candidates.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Development, Clinical Testing and Commercialization of Our Therapeutic Candidates </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our therapeutic candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability, and the results of any preclinical studies or clinical trials may not be predictive of the results of later clinical trials. If we, or our collaboration partners, are unable to advance our therapeutic candidates through clinical development, obtain marketing approval and ultimately commercialize our therapeutic candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct all of our clinical trials and certain of our preclinical studies and for the manufacture of our therapeutic candidates and we intend to continue to do so. If these third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Organization and Operations </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the therapeutic candidates we develop, our commercial opportunities will be negatively impacted.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials, marketing approval prospects, access to capital, performance of third parties and our business may be adversely affected by circumstances and uncertainties related to the COVID-19 pandemic.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not able to obtain and enforce patent protection for our technologies or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The marketing approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our therapeutic candidates, our business will be substantially harmed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not know whether an active, liquid and orderly trading market will continue for our common stock and as a result it may be difficult for you to sell your shares of our common stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect that our stock price may fluctuate significantly and future sales of our common stock in the public market could cause our stock price to fall.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our executive officers, directors and holders of more than 5% of our capital stock own a significant percentage of our stock and will be able to exercise significant control over matters subject to stockholder approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div id="ie96bda597eaa4024845d6498a1c78657_109"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Need for Additional Capital </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate product revenue or become profitable, or if we achieve profitability, we may not be able to sustain it. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company. To date, we have financed our operations through equity and debt financings, license and milestone revenue and grants. We have incurred significant recurring operating losses since our inception. Our net loss for the years ended December 31, 2021 and 2020 was $81.8 million and $76.1 million, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $227.1 million. We expect to incur additional losses in future years as we execute our plan to continue our discovery, research and development activities, including the manufacturing of and ongoing and planned preclinical and clinical development and commercialization of our therapeutic candidates, and as we incur the additional costs of operating as a public company. We are unable to predict the extent of any future losses or when we will become profitable, if ever. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biotechnology product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from product sales and may never be profitable. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted substantially all of our financial resources and efforts to developing our therapeutic candidates, identifying potential therapeutic candidates and conducting preclinical studies and clinical trials. We are still in the early stages of developing our therapeutic candidates, and we have not yet demonstrated an ability to successfully conduct or complete any clinical trials, including large-scale, pivotal clinical trials, obtain marketing approval, manufacture a commercial scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Consequently, we have no meaningful operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had more experience developing therapeutic candidates. We previously entered into the Chiesi Option Agreement and the Celgene Agreement. Our ability to generate revenue and achieve profitability, including any revenue we may receive pursuant to the Chiesi Option Agreement or the Celgene Agreement, depends in large part on our ability, alone or with license partners, to achieve milestones and to successfully complete the development of, obtain the necessary marketing approvals for, and commercialize, our therapeutic candidates. For example, while we believe it is possible Celgene may incorporate the Celgene Licensed Intellectual Property into a multispecific format with another antibody for future development pursuant to the Celgene Agreement, this may not occur. We believe it is unlikely we will receive additional milestone payments pursuant to the Celgene Agreement unless Celgene develops a therapeutic candidate under the Celgene Agreement and advances that therapeutic candidate beyond Phase 1 clinical trials. Even if we achieve development or commercial milestones, generate product royalties or generate product sales, including any milestones and royalties we may be eligible to receive pursuant to the Celgene Agreement or the Chiesi Option Agreement, we may never achieve or sustain profitability on a quarterly or annual basis. We do not anticipate generating revenue from sales of products for the foreseeable </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future. Our ability to generate future revenue from product sales depends heavily on our and our collaborators&#8217; success in: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing clinical trials through all phases of clinical development of our current therapeutic candidates, including INBRX-101, INBRX-109, INBRX-106, and INBRX-105; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advancing preclinical therapeutic candidates into clinical development; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeking and obtaining marketing approvals for our therapeutic candidates that successfully complete clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining satisfactory acceptance, formulary placement coverage and adequate reimbursement for our approved products from third-party payors, including private health insurers, managed care providers and governmental payor programs, including Medicare and Medicaid; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching and commercializing products for which we obtain marketing approval, with a collaborator or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining supply and manufacturing relationships with third parties; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining market acceptance of any approved products by physicians, patients, third-party payors and the medical community; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting, expanding and enforcing our intellectual property portfolio; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementing additional internal systems and infrastructure, as needed; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring and retaining qualified personnel. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with biological product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA, the EMA, or other comparable foreign authorities to perform preclinical studies or clinical trials in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our therapeutic candidates, our expenses could increase and revenue could be further delayed. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect we will need to raise substantial additional funds to advance development of our therapeutic candidates, and we cannot guarantee this additional funding will be available on acceptable terms or at all. Failure to obtain this funding when needed may force us to delay, limit or terminate our development efforts and, if any of our therapeutic candidates are approved, our commercialization efforts. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had $131.3 million in cash. We expect our expenses to increase in future years as we execute our plan to continue our discovery, research and development activities, including the ongoing and planned preclinical and clinical development and commercialization of our therapeutic candidates. Identifying potential therapeutic candidates and conducting preclinical testing and clinical trials are time consuming, expensive and uncertain processes that take years to complete, and we, or our collaborators, may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our therapeutic candidates, if approved, may not achieve commercial success. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents will be sufficient to fund our planned operations through at least the 12 month period following the date of this Annual Report. However, changing circumstances or inaccurate estimates by us may cause us to use capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. For example, our current and our planned preclinical studies and clinical trials for our current therapeutic candidates or other therapeutic candidates we may seek to develop may encounter technical, enrollment or other issues that could cause our development costs to increase more than we expect, or we could expand our clinical trials to additional indications which could increase clinical trial expenses. Because successful development of our therapeutic candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our therapeutic candidates. Our ability to raise additional funds will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. In addition, our ability to obtain future funding when needed through equity financings, debt financings or strategic collaborations may be particularly challenging in light of the uncertainties and circumstances regarding the COVID-19 pandemic (as defined below).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or clinical therapeutic candidates, or we may be unable to take advantage of future business opportunities. In addition, any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future therapeutic candidates. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital by issuing equity or debt securities may cause dilution to existing stockholders, and raising funds through lending and licensing or collaboration agreements may restrict our operations or require us to relinquish proprietary rights. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate substantial revenue from product sales, if ever, we expect to finance our cash needs through a combination of equity and debt financings, strategic collaborations and license and development agreements. We do not have any committed external source of funds. To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#8217; ownership may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Equity and debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures or declaring dividends. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants therein, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely affect our ability to conduct our business. Additionally, during 2020, 2021, and 2022, we borrowed a total of $110.0 million in four separate tranches from Oxford Finance, LLC, or Oxford, with three additional future tranches with a total of $90.0 million, under our loan and security agreement and its amendments, which we refer to collectively as the Amended 2020 Loan Agreement, which, as further described below, also has covenants restricting our ability to declare dividends or incur additional indebtedness. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional capital through collaborations, strategic alliances or third-party licensing agreements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or therapeutics candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital through equity or debt financings when needed (including if we are unable to do so as a result of the COVID-19 pandemic), we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market therapeutic candidates that we would otherwise develop and market ourselves. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The expected phase out of LIBOR could impact the interest rates paid on our variable rate indebtedness and cause our interest expense to increase. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended 2020 Loan Agreement, our term loans bear interest at a variable rate based on LIBOR. In July 2017, the United Kingdom's Financial Conduct Authority, which regulates LIBOR, announced that it intends to phase out LIBOR by the end of 2021, or the FCA Announcement. In November 2020, the Intercontinental Exchange announced that it intends to cease publication of certain LIBOR settings by the end of 2021 while continuing to publish overnight and one-, three-, six-, and twelve-month U.S. dollar LIBOR rates through June 30, 2023. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, is considering replacing LIBOR with the Secured Overnight Financing Rate, or SOFR, a new index calculated based on transactions in the market for short-term treasury securities.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended 2020 Loan Agreement includes language to determine a replacement rate for LIBOR, if necessary. We are evaluating the potential impact of the eventual replacement of the LIBOR benchmark interest rate, however, we are not able to predict whether LIBOR will cease to be available or whether SOFR will become a widely accepted benchmark in place of LIBOR. Although it is not possible to predict the effect the FCA Announcement, any discontinuation, modification or other reforms to LIBOR or the establishment of alternative reference rates such as SOFR may have on LIBOR, we do not expect the effect to have a material impact on our interest expense.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development, Clinical Testing and Commercialization of Our Therapeutic Candidates </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we, or our collaborators, are unable to advance our therapeutic candidates through clinical development, obtain marketing approval and ultimately commercialize our therapeutic candidates, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are early in our development efforts, with only four therapeutic candidates currently in clinical trials (INBRX-101, INBRX-109, INBRX-106, and INBRX-105). We have no products on the market and our ability to achieve and sustain profitability depends on obtaining marketing approvals for and successfully commercializing our therapeutic candidates, either alone or with our collaborators. Before obtaining marketing approval for the commercial distribution of our therapeutic candidates, we, or our collaborators, must conduct extensive preclinical tests and clinical trials to demonstrate sufficient safety and efficacy of our therapeutic candidates in patients. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. As a result, we may not have the financial resources to continue development of, or to modify existing or to enter into new license or collaboration for, a therapeutic candidate if we experience any issues that delay or prevent marketing approval of, or our ability to commercialize, our therapeutic candidates, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our clinical trials, the clinical trials of our collaborators or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">therapeutic-related side effects experienced by participants in our clinical trials, the clinical trials of our collaborators or by individuals using drugs or therapeutic biologics similar to our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in enrolling research subjects or high drop-out rates of research subjects enrolled in clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in our clinical trials due to quarantines or other restrictions resulting from the COVID-19 pandemic, including further delays or suspensions in enrollment in our Phase 1 clinical trial for INBRX-101; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or the manufacturing location(s) for a therapeutic candidate; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate supply or quality of therapeutic candidate clinical material or other raw materials or supplies necessary for the conduct of our clinical trials or the clinical trials of our collaborators; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in the development or approval of companion diagnostic tests for our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight for human clinical testing generally or with respect to our technology in particular; or </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">varying interpretations of data by the FDA and similar foreign regulatory agencies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The therapeutic candidates we or our collaborators pursue may not demonstrate the necessary safety or efficacy requirements for marketing approval. Further, a clinical trial may be suspended or terminated by us, our collaborators, the IRBs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations, administrative actions or lack of adequate funding to continue the clinical trial. Clinical holds may be placed prior to a clinical trial even beginning, in order to address potential safety and risk concerns of regulatory authorities, and partial or complete clinical holds can be imposed at any time during a trial. Furthermore, while we perform certain similar functions internally, we expect to rely on </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract research organizations, or CROs, and clinical trial sites to ensure proper and timely conduct of our clinical trials and while we expect to enter into and have entered into agreements governing those CROs&#8217; committed activities, we have limited influence over their actual performance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators experience delays in the completion of, or termination of, any clinical trial of our therapeutic candidates, the commercial prospects of our therapeutic candidates may be harmed, and our ability to generate product revenue or receive royalties from any of these therapeutic candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. If we were to cancel the development of any of our therapeutic candidates, we may still be required to pay certain non-cancellable commitments to our CROs under the terms of our various CRO contracts. Our approach to protein engineering is novel and unproven, and as such, the cost, time needed to develop, and likelihood of success of our therapeutic candidates may be more uncertain than if we employed more established drug development approaches. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our therapeutic candidates. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of preclinical studies and early stage clinical trials of our therapeutic candidates may not be predictive of the results of later stage clinical trials. Initial results or observations in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical studies and early clinical trials does not ensure that later and pivotal clinical trials will generate the same results, or otherwise provide adequate data to demonstrate the safety and efficacy of a therapeutic candidate. Frequently, therapeutic candidates that have shown promising results in preclinical studies or early clinical trials have subsequently suffered significant setbacks in later or pivotal clinical trials. The initiation of registration-enabling trials for INBRX-109, or for any of our other therapeutic candidates, is and would be predicated on positive Phase 1 trial results and acceptance of our IND amendment by the FDA. Our therapeutic candidates in clinical trials, including INBRX-101, INBRX-109, INBRX-106, and INBRX-105, may ultimately fail to show the desired safety and efficacy in clinical trials despite having progressed through preclinical studies and despite any initial observations of single agent activity, stable disease or partial responses. There can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development, including development in registration-enabling trials, of any of our therapeutic candidates. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies or trials, and any of these setbacks in our clinical development could have a material adverse effect on our business and operating results. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our therapeutic candidates could cause us, our collaborators or regulatory authorities, to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or other regulatory authorities. Results of our clinical trials or the clinical trials of our collaborators could reveal a high and unacceptable severity of adverse side effects and it is possible that patients enrolled in these clinical trials could respond in unexpected ways. For instance, INBRX-109, INBRX-106, and INBRX-105 are all therapeutic candidates targeting oncology indications that are clinically evaluated in very sick populations, and INBRX-101 is a therapeutic candidate focused on AATD, a rare disease with a relatively small patient population. It may be difficult to establish safety and efficacy in these types of patient populations. Further, we intend to develop certain of our therapeutic candidates in combination with one or more cancer therapies. This combination may have additional side effects that were not present in preclinical studies or clinical trials of our therapeutic candidates conducted as a monotherapy or in combination with other cancer therapies. The uncertainty resulting from the use of our therapeutic candidates in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our clinical trials or the clinical trials of our collaborators reveal adverse side effects, our trials or the clinical trials of our collaborators could be suspended or terminated and the FDA or comparable foreign regulatory authorities </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could impose a clinical hold, order us to cease further development of or deny approval of our therapeutic candidates for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Further, clinical trials by their nature utilize a sample of the potential patient population. Rare and severe side effects of our therapeutic candidates may only be uncovered with a significantly larger number of patients exposed to our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any of our therapeutic candidates receives marketing approval and we, our collaborators or others identify undesirable side effects caused by a product or any other similar therapeutics, any of the following adverse events could occur: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component of the product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of safety-related labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients or to implement other aspects of a REMS such as a restricted distribution program or educational programs for prescribers; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adverse side effects caused by any therapeutics that may be similar in nature to our therapeutic candidates could delay or prevent marketing approval of our therapeutic candidates, limit the commercial profile of an approved label for our therapeutic candidates, or result in significant negative consequences for our therapeutic candidates following marketing approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of the above described events could prevent us from achieving or maintaining market acceptance of our therapeutic candidates, if approved, and could delay, impede and/or substantially increase the costs of commercializing our therapeutic candidates thus significantly impacting our ability to successfully commercialize our therapeutic candidates and generate revenue. Any of the above described occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to develop certain of our therapeutic candidates in combination with other therapies, and safety or supply issues with combination use products may delay or prevent development and approval of our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop certain of our therapeutic candidates in combination with one or more approved or investigational cancer therapies.&#160;Even if any therapeutic candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our therapeutic candidates are replaced as the standard of care for the indications we choose for any of our therapeutic candidates, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may evaluate our therapeutic candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market and sell any therapeutic candidate we develop in combination with an unapproved cancer therapy if that unapproved cancer therapy does not ultimately obtain marketing approval. In addition, unapproved cancer therapies face the same risks described with respect to our therapeutic candidates currently in development and clinical trials, including the potential for serious AEs, delay in their clinical trials and lack of FDA approval. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination our therapeutic candidates, we may be unable to obtain approval of or market any such therapeutic candidate. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our therapeutic candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, we have experienced some difficulty enrolling patients for our clinical trials for INBRX-101 since patients with AATD are particularly susceptible to COVID-19 and the physicians acting as clinical investigators for our clinical sites may be otherwise engaged with treating COVID-19 patients. For instance, during the second and third quarters of 2020 as a result of the COVID-19 pandemic, we temporarily suspended enrollment for our trial for INBRX-101. This trial resumed enrollment during the fourth quarter of 2020 but there is no guarantee that we will not have to suspend enrollment for this trial again in the future. Should any competitors have ongoing clinical trials for therapeutic candidates treating the same indications as our therapeutic candidates, patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is affected by other factors including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient eligibility criteria for the study in question; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the therapeutic candidate under study; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our payments for conducting clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for any of our clinical trials could result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our therapeutic candidates and in delays to commercially launching our therapeutic candidates, if approved, which would materially harm our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of any of our therapeutic candidates may be delayed, and our business may be harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have provided, and will continue to provide, a number of timing estimates regarding the initiation of clinical trials and clinical development milestones, and the expected availability of data resulting from these trials for certain of our therapeutic candidates. We expect to continue to estimate the timing of these types of development milestones and our expected timing for the accomplishment of various other scientific, clinical, regulatory and other product development objectives. From time to time, we may publicly announce the expected timing of some of these events. However, the achievement of many of these milestones and events may be outside of our control. All of these timing estimations are based on a variety of assumptions we make which may cause the actual timing of these events to differ from the timing we expect, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our available capital resources and our ability to obtain additional funding as needed; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress, costs and results of our clinical trials and research and development activities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of clinical trial clearances or approvals by the FDA, EMA and other regulatory authorities and the timing of these approvals; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts of our collaborators and licensees, including Celgene, with respect to the commercialization of our therapeutics;  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the securing of, costs related to, and timing issues associated with, manufacturing our therapeutic candidates and, if any of our therapeutic candidates are approved, associated with sales and marketing activities and the commercial manufacture of our therapeutic candidates; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">circumstances arising from or relating to the COVID-19 pandemic, including potential effects on the global supply chain, our manufacturers and the availability of raw materials needed for the research and development of our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to achieve announced milestones in the timeframes we expect, the future marketing approval and commercialization of any of our therapeutic candidates may be delayed, and our business, financial condition, results of operations, and prospects may be harmed and our stock price may decline. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial, interim, topline and preliminary data from our clinical trials that we may announce, observe or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect from time to time, to publish initial, interim, topline or preliminary data from our clinical trials. Our clinical trials are also conducted as &#8220;open-label&#8221; trials. An open-label trial is one where both the study participant and investigator know whether the participant is receiving the therapeutic candidate and where we (as the sponsor) have access to trial data on an ongoing basis during the trial.&#160;These initial, interim, topline and preliminary data from our clinical trials that we may publish from time to time or that we may observe on an ongoing basis in our open-label trials may change as more data become available and, accordingly, they are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues, more participant data becomes available and we issue our final clinical trial report. Initial, interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, interim, topline and preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for any current or future therapeutic candidate we develop, if and when approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer therapies are sometimes characterized as first-, second-, or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We expect to initially seek approval of certain of our therapeutic candidates as a therapy for patients who have received one or more prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but there is no guarantee that therapeutic candidates we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of patients who have the cancers we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future therapeutic candidates may be limited, if and when approved. Even if we obtain significant market share for any therapeutic candidate, if and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct all of our clinical trials and certain of our preclinical studies and intend to continue to do so. If these third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect to continue our current clinical trials and expect to initiate clinical trials in the near term for many of our therapeutic candidates, we do not independently conduct clinical trials. As such, while we perform certain functions internally, we currently rely and intend to continue to rely on third-party CROs, clinical data management organizations and consultants to help us design, conduct, supervise and monitor clinical trials of our therapeutic </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates. As a result, we will have less control over the timing, quality and other aspects of our clinical trials than we would have had we conducted them on our own. There is a limited number of third party service providers that specialize or have the expertise required to achieve our business objectives. If any of our relationships with these third-party CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative CROs or investigators or to do so on commercially reasonable terms. Further, these investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials. These third parties may also be susceptible to disruption as a result of health crises such as the COVID-19 pandemic or periods of societal unrest. For example, we currently retain CROs located in Hong Kong. These CROs may be negatively affected by, or subject to disruption arising from, the societal unrest and regulatory regime change related to China&#8217;s passage of a national&#160;security law exerting additional control by mainland China over activities in Hong Kong. If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy the legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines for any reason, our clinical development programs could be delayed and otherwise adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the relevant study or trial. The FDA requires nonclinical studies to be conducted in accordance with good laboratory practices and clinical trials to be conducted in accordance with GCPs including practices and requirements for designing, conducting, recording and reporting the results of nonclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our clinical trials could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on Celgene for the successful development, manufacture and commercialization of the Celgene Licensed Intellectual Property. If Celgene does not devote sufficient resources to the development, manufacture and commercialization of the Celgene Licensed Intellectual Property, is unsuccessful in its efforts, or chooses to terminate the Celgene Agreement with us, we may not receive any further proceeds from the Celgene Agreement and our business could be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Celgene Agreement, we have exclusively licensed (even as to us) to Celgene the right to develop, manufacture and commercialize the Celgene Licensed Intellectual Property. Celgene is obligated to use commercially reasonable efforts to clinically develop and commercialize the Celgene Licensed Intellectual Property. However, Celgene may ultimately determine it is not commercially reasonable to continue development of the Celgene Licensed Intellectual Property. This outcome could occur for many reasons, including internal business reasons or because of unfavorable regulatory feedback. Further, on review of any safety and efficacy data then available for potential candidates relating to the Celgene Licensed Intellectual Property, the FDA may impose requirements on a clinical trial program that would render the program commercially nonviable. In the event of any such decision, we would be unable to advance such program ourselves. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the terms of the Celgene Agreement, Celgene has full control and authority over the development and commercialization of the Celgene Licensed Intellectual Property. We may disagree with Celgene about the development strategy it employs, but we will have limited rights to impose our preferred development strategy on Celgene. Celgene may elect to discontinue the development of the Celgene Licensed Intellectual Property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Celgene Licensed Intellectual Property may not be scientifically or commercially successful for us due to a number of important factors, including the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Celgene has wide discretion in determining the efforts and resources that it will apply to its development, manufacture and commercialization of the Celgene Licensed Intellectual Property. The timing and amount of any development milestones, regulatory milestones and royalties that we may receive under the Celgene </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement will depend on, among other things, Celgene&#8217;s efforts, allocation of resources and successful development and commercialization of the Celgene Licensed Intellectual Property and the other antibodies that are the subject of the Celgene Agreement; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Celgene may terminate the Celgene Agreement without cause and for circumstances outside of our control, which could make it difficult for us to attract new strategic partners or adversely affect how we are perceived in scientific and financial communities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Celgene may develop or commercialize the Celgene Licensed Intellectual Property in such a way as to elicit litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential liability; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Celgene may not comply with all applicable regulatory requirements, or may fail to report safety data in accordance with all applicable regulatory requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Celgene were to breach the Celgene Agreement, we may need to enforce our right to terminate the Celgene Agreement in legal proceedings, which could be costly and cause delay in our ability to receive our rights back to develop and commercialize the Celgene Licensed Intellectual Property. If we were to terminate the Celgene Agreement due to Celgene&#8217;s breach or if Celgene terminated the Celgene Agreement without cause upon 30 days&#8217; written notice, the development and commercialization of the Celgene Licensed Intellectual Property could be delayed, curtailed or terminated. Additionally, even if the Celgene Agreement is terminated, we may not be able to dispose of the Celgene Licensed Intellectual Property in a strategic transaction without Celgene&#8217;s consent. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Celgene became a Bristol-Myers Squibb Company in November 2019. Bristol-Myers Squibb Company may again enter into one or more transactions with third parties, including other mergers, consolidations, reorganizations, sale of substantial assets, sales of substantial stock or other changes in control involving Celgene. These types of transactions could divert the attention of Celgene&#8217;s management and adversely affect Celgene&#8217;s ability to retain and motivate key personnel who are important to the continued development of the Celgene Licensed Intellectual Property. In addition, the third party to any such transaction could determine to reprioritize Celgene&#8217;s development programs such that Celgene ceases to diligently pursue the development of the Celgene Licensed Intellectual Property, and/or cause the Celgene Agreement to terminate. If Celgene does not devote sufficient resources to the development, manufacture and commercialization of the Celgene Licensed Intellectual Property, is unsuccessful in its efforts, or chooses to terminate the Celgene Agreement with us, we may not receive any further proceeds from the Celgene Agreement and our business could be materially harmed.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently party to license agreements with Elpiscience and Transcenta for the development and, if approved, commercialization of INBRX-105 and INBRX-106, and INBRX-109, respectively. We may in the future enter into additional collaborations with third parties to develop our therapeutic candidates, including collaborations with Chiesi if Chiesi exercises its option pursuant to the Chiesi Option Agreement. If these collaborations are not successful, our business could be harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently party to two different license agreements, or the Elpiscience Agreements, with Elpiscience, pursuant to which we granted Elpiscience exclusive licenses for the development and, if approved, commercialization of INBRX-105 and INBRX-106 in China, Hong Kong, Macau and Taiwan. We are also party to the Transcenta License Agreement. Ultimately, Chiesi may not exercise its option pursuant to the Chiesi Agreement. If Chiesi does not exercise its option under the Chiesi Agreement, we could incur additional expenses for the development, and if approved, the commercialization of INBRX-101. We may enter into additional collaborations with third parties in the future, including collaborations with Chiesi if Chiesi exercises its option pursuant to the Chiesi Option Agreement. Any collaborations that we are party to may pose several risks, including the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical trials conducted as part of these collaborations may not be successful; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any therapeutic candidates that achieve marketing approval or may elect not to continue or renew development or commercialization programs based on clinical trial results; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial or abandon a therapeutic candidate, repeat or conduct new clinical trials or require a new formulation of a therapeutic candidate for clinical testing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have access to, or may be restricted from disclosing, certain information regarding therapeutic candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our therapeutic candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">therapeutic candidates developed in collaboration with us may be viewed by our collaborators as competitive with their own therapeutic candidates or products, which may cause collaborators to cease to devote, or limit, resources to the commercialization of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our therapeutic candidates that achieve marketing approval may not commit sufficient resources to the marketing and distribution of any such therapeutic candidate; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may have disagreements with these collaborators, including disagreements over proprietary rights, collaborator performance, contract interpretation or the preferred course of development of any therapeutic candidates. Any disagreement we may have with our collaborators, may cause delays or termination of the research, development or commercialization of our therapeutic candidates pursuant to the applicable agreement, may lead to additional responsibilities for us with respect to our therapeutic candidates or may result in litigation or arbitration, any of which would be time-consuming and expensive and which would likely divert the attention of our management from our core research and development activities. These types of disputes could materially harm our financial condition and our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of biotechnology products is complex, and manufacturers often encounter difficulties in production. If we or any of our third party manufacturers encounter such difficulties, or otherwise fail to comply with their contractual obligations, the development or commercialization of our therapeutic candidates could be delayed or stopped. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have found that our sdAb-based therapeutic candidates can be readily manufactured at high yields with established processes used to produce therapeutic proteins, the manufacture of biotechnology products is generally complex and requires significant expertise and capital investment. We and our contract manufacturers must comply with cGMP regulations and guidelines for clinical trial product manufacture and for commercial product manufacture. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up, addressing product quality, product comparability, validating production processes and mitigating potential sources of contamination. These problems include difficulties with raw material procurement, production costs and yields, quality control, product quality, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if microbial, viral or other contaminations are discovered in our therapeutics or in the manufacturing facilities in which our therapeutics are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that manufacturing problems, including supply chain disruptions of any of our therapeutic candidates or products will not occur in the future. Any delay or interruption in the supply of preclinical or clinical trial supplies, including any delays arising from circumstances related to the COVID-19 pandemic or supply chain disruptions, could delay the completion of these trials, increase the costs associated with maintaining these trial programs and, depending upon the period of delay, require us to commence new trials at additional expense or terminate trials completely. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to experience an unexpected loss of supply of, or if any supplier were unable to meet our demand for any of our therapeutic candidates or future approved products we seek to commercialize, if any, we could experience delays in our research or planned clinical studies or be forced to stop our development or commercialization efforts. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods needed to switch manufacturers and suppliers, if necessary, would significantly delay our clinical studies and the commercialization of our therapeutics, if approved, which would materially adversely affect our business, prospects, financial condition and results of operation.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to supply and manufacture our therapeutic candidates, and we expect to continue to rely on third parties to manufacture and supply our therapeutics, if approved. The development of therapeutic candidates and the commercialization of any therapeutic candidates, if approved, could be stopped, delayed or made less profitable if any of these third parties fail to provide us with sufficient quantities of therapeutic candidates or therapeutics, fail to do so at acceptable quality levels or prices, or fail to maintain or achieve satisfactory regulatory compliance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to develop and manufacture our therapeutic candidates for use in the conduct of our trials or for commercial supply, if our therapeutics are approved. Instead, we rely on, and expect to continue to rely on third-party providers to manufacture the supplies for our preclinical studies and clinical trials. We currently rely on a limited number of third-party contract manufacturers for our required raw materials, antibodies, and other biologics for our preclinical research and clinical trials, as well as for the manufacture of supplies for our therapeutic candidates. To the extent any of our manufacturing partners is unable to fulfill these obligations in a timely manner, including as a result of circumstances relating to the COVID-19 pandemic or circumstances related to China&#8217;s implementation of its security law to exert additional control over activities in Hong Kong, our clinical trials may be delayed and our business may be adversely affected. In general, reliance on third party providers may expose us to more risk than if we were to manufacture our therapeutic candidates ourselves. We do not control the operational processes of the contract manufacturing organizations with whom we contract, and are dependent on these third parties for the production of our therapeutic candidates in accordance with relevant regulations (such as cGMP), which include, among other things, quality control and the maintenance of records and documentation. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our third-party manufacturers may be unable to successfully scale up manufacturing of our therapeutic candidates in sufficient quality and quantity, which would delay or prevent us from developing our therapeutic candidates and commercializing any approved therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing partners may be unable to successfully increase the manufacturing capacity for our therapeutic candidates in a timely or cost-effective manner, or at all, as needed for our development efforts or, if our therapeutic candidates are approved, our commercialization efforts. Quality issues may also arise during scale-up activities. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our therapeutic candidates in sufficient quality and quantity, the development, testing, and clinical trials of our therapeutic candidates may be delayed or infeasible, and marketing approval or future commercial launch of any resulting therapeutic may be delayed or not obtained, which could significantly harm our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully identify, develop and commercialize additional therapeutics or therapeutic candidates could impair our ability to grow. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our efforts will focus on the continued preclinical and clinical testing and potential approval of our therapeutic candidates in our current pipeline, we expect to continue to innovate and potentially expand our portfolio. Because we have limited financial and managerial resources, research programs to identify </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic candidates may require substantial additional technical, financial and human resources, whether or not any new potential therapeutic candidates are ultimately identified. Our success may depend in part upon our ability to identify, select and develop promising therapeutic candidates and therapeutics. We may expend resources and ultimately fail to discover and generate additional therapeutic candidates suitable for further development. All therapeutic candidates are prone to risks of failure typical of biotechnology product development, including the possibility that a therapeutic candidate may not be suitable for clinical development as a result of its harmful side effects, limited efficacy or other characteristics indicating that it is unlikely to receive approval by the FDA, the EMA and other comparable foreign regulatory authorities or to achieve market acceptance. If we do not successfully develop and commercialize new therapeutic candidates we have identified and explored, our business, prospects, financial condition and results of operations could be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of biotechnology treatments of any therapeutic candidates for which we or our collaborators may conduct clinical trials. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing any approved products, these claims could result in an FDA investigation of the safety and effectiveness of our future commercial products, our manufacturing processes and facilities (or the manufacturing processes and facilities of our third-party manufacturers) or our marketing programs, a recall of our products or more serious enforcement action, limitations on the approved indications for which the product may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to clinical trial participants or patients and a decline in our stock price. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by potential product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to commercialize successfully any such therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing or distribution capabilities. While we have marketing and commercialization agreements in place for certain territories with our collaborators, we will still need to expand our own internal sales, marketing and distribution capabilities to commercialize our approved therapeutic candidates, if any, in the United States and other remaining worldwide territories, or will need to enter into collaborations with third parties to perform these services. Any internal effort would be expensive and time-consuming, and we would need to commit significant financial and managerial resources to develop an internal marketing and sales force with technical expertise and the related supporting distribution, administration and compliance capabilities. If we were to rely on additional third parties with these capabilities to market our future therapeutics or were to decide to co-promote products with any of our current or future collaborators, we would need to establish and maintain or revise existing marketing and distribution arrangements with these partners, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. Any revenue we receive in connection with third-party license, marketing or distribution arrangements, including the Celgene Agreement, the Chiesi Option Agreement and license agreements with our licensing partners in China, will depend upon the efforts of these third parties, and there can be no assurance these third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The future commercial success of our therapeutic candidates will depend on the degree of market acceptance of our therapeutic candidates among physicians, patients, healthcare payors and the medical community. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our therapeutic candidates are in early stages of development, and many of our therapeutic candidates are still in preclinical development; we may never have an approved product that is commercially successful. Due to the inherent risk in the development of biotechnology products, it is probable that not all or none of the therapeutic candidates in our pipeline, including any that are or may be licensed to third parties, will successfully complete development and be commercialized. Furthermore, even when available on the market, our products may not achieve an adequate level of acceptance by physicians, patients and the medical community, and we may not become profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our products may require significant resources and may never be successful, which would prevent us from generating significant revenue or becoming profitable. Market acceptance of any approved products by physicians, patients and healthcare payors will depend on a number of factors, many of which are beyond our control, including, but not limited to: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care for the targeted indications for any approved product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">wording in the FDA- or EMA-approved prescribing information; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales, marketing and distribution support; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product liability claims; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians, patients and healthcare payors of each product as safe, effective and cost-effective; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience, ease of use, ease of administration and other perceived advantages over alternative products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevalence and severity of adverse events or publicity; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations, precautions or warnings listed in the summary of product characteristics, patient information leaflet, package labeling or instructions for use; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment with our therapeutics in relation to alternative treatments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which products are approved for inclusion and adequately reimbursed on formularies of hospitals and third-party payors, including managed care organizations; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our products are designated in the label, under physician treatment guidelines or under reimbursement guidelines as a first, second, third or last line therapy. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_115"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Organization and Operations </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the therapeutic candidates we develop, our commercial opportunities will be negatively impacted. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The life sciences industry is highly competitive. We are currently developing therapeutic candidates that will compete, if approved, with other products and therapies that currently exist or are being developed. Our primary competitors fall into the following groups:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing novel therapeutics based on sdAb or alternative scaffold product candidates, including Alligator Bioscience AB, Camel-IDS N.V., Crescendo Biologics Ltd., GlaxoSmithKline plc, IGM Biosciences, Inc., Molecular Partners AG, Pieris Pharmaceuticals, Inc., Sanofi S.A. and VHsquared Ltd.; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Antibody drug discovery companies that may compete with us in the search for novel therapeutic antibody targets, including Regeneron Pharmaceuticals, Inc., Adimab&#160;LLC, Genmab A/S, Macrogenics, Inc., Merus&#160;N.V., MorphoSys AG, Numab Therapeutics AG, Amgen, Inc., Xencor&#160;Inc., and Zymeworks Inc.; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing therapeutics designed to treat AATD, including CSL Limited, Grifols, S.A., Kamada Ltd., Takeda Pharmaceutical Company Limited and Centessa Pharmaceuticals PLC; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing cytokine therapeutics, including Alkermes PLC, Altor BioScience, ImmunityBio, Inc., Medicenna Therapeutics Corp., Nektar Therapeutics, Neoleukin Therapeutics, Inc., Novartis AG, Pandion Therapeutics, Inc., Merck &amp; Co., Philogen S.p.A., Roche Holding AG, Rubius Therapeutics, Inc., SOTIO Biotech, Synthekine, Inc., Sanofi S.A., Xencor, Inc.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors also include large pharmaceutical and biotechnology companies who may be developing therapeutic candidates with mechanisms similar to or targeting the same indications as our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products we may develop in the future are also likely to face competition from other products and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to&#160;in-license&#160;novel compounds that could make the therapeutic candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval or discovering, developing and commercializing products in our field before we do. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain FDA, EMA or other marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the therapeutic candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our therapeutic candidates obsolete, less competitive or not economical. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, the conduct of our clinical trials, results of operations, financial condition, and prospects may be adversely affected by the widespread outbreak of an illness or any other communicable disease, or any other public health crisis, including the coronavirus disease pandemic.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by widespread outbreak of illness or other communicable diseases, health epidemics, or any other public health crisis. On January 30, 2020, the World Health Organization, or the WHO, announced a global health emergency because of a novel strain of coronavirus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or novel coronavirus, which causes coronavirus disease 2019, or COVID-19, originating in Wuhan, China. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 and continuing through 2021, COVID-19 spread to most regions of the world, including California, where our primary office and laboratory space is located.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are, with our partners, conducting clinical trials and other research in geographies that are affected by the COVID-19 pandemic. Potential impacts of the COVID-19 pandemic on our various clinical trials may include delays related to patient enrollment, dosing and study monitoring due to changes in policies at </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various clinical sites, federal, state, local or foreign laws, rules and regulations, including quarantines or other travel restrictions. They may also be impacted by the prioritization of healthcare resources toward pandemic efforts, including diminished attention of physicians serving as our clinical trial investigators and reduced availability of site staff supporting the conduct of our clinical trials, interruption or delays in the operations of the FDA, or other reasons related to the pandemic. For example, we temporarily suspended enrollment for our INBRX-101 Phase 1 clinical trial as a direct result of the COVID-19 pandemic during the second and third quarters of 2020. While our oncology-related clinical trials have not been materially impacted to date, it is possible that these programs may be negatively impacted in the future. If the COVID-19 pandemic continues, other aspects of our clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient recruitment, further or additional delays in enrollment, availability of clinical trial materials, and data analysis. Some patients and clinical investigators may not be able to comply with clinical trial protocols and patients may choose to withdraw from our trials. It is unknown how long these suspension, pauses or disruptions could continue. FDA has issued a guidance for industry, &#8220;FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic Guidance for Industry, Investigators, and Institutional Review Boards,&#8221; which is being periodically updated to continue clarifying for affected stakeholders to ensure the safety of clinical trial participants, maintain compliance with GCPs, and minimize risks to trial and clinical data integrity. We intend to follow FDA&#8217;s recommendations in order to address unavoidable protocol deviations due to COVID-19 illness or COVID-19 control measures, as appropriate.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently rely on third parties to, among other things, manufacture raw materials, manufacture our therapeutic candidates, ship investigational drugs and clinical samples, perform quality testing and supply other goods and services to run our business. If any third party in our supply chain for materials are adversely impacted by restrictions resulting from the COVID-19 pandemic, including as a result of staffing shortages, production slowdowns and disruptions in delivery systems, our supply chain may be disrupted, limiting our ability to conduct our research and development operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have requested that our employees, including all of our administrative employees, work remotely and have restricted on-site staff to only those personnel who must perform essential on-site activities such as activities in our research and development laboratories. Our increased reliance on employees working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees conducting research and development activities may be more limited in their ability to access our laboratories for an extended period of time as a result of the rigorous workplace policies and guidelines implemented as a result of the COVID-19 pandemic. Additionally, it is possible that governmental authorities will further modify current restrictions. As a result, this could delay timely completion of our research and development efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health regulatory agencies globally may experience disruptions in their operations as a result of the COVID-19 pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced to continue to monitor our clinical trials and, as a result, review, inspection, and other timelines may be materially delayed. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our therapeutic candidates. For example, regulatory authorities may require that we not distribute a therapeutic candidate lot until the relevant agency authorizes its release. Such release authorization may be delayed as a result of the COVID-19 pandemic and could result in delays to our clinical trials.</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading prices for biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common shares in future offerings or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of COVID-19 could materially and adversely affect our business and the value of our common shares. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve. The ultimate impact of the pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the success of domestic and international vaccination campaigns, the emergence of new viral variants, additional or modified government actions, new information that may emerge concerning the severity and impact of COVID-19 and the actions taken to contain COVID-19 or address its impact in the short and long term, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued service of key management, advisors and other specialized personnel, including Mark P. Lappe, our Chief Executive Officer, Brendan P. Eckelman, Ph.D., our Chief Scientific Officer, and Kelly D. Deck, our Chief Financial Officer, who are all employed at will and for whom we do not have &#8220;key man&#8221; insurance coverage. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and technologies and the specialized nature of the marketing approval process. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations (many of whom have substantially greater financial resources than us), and we might not be able to attract or retain these key employees on conditions that are economically acceptable. Our inability to attract and retain these key employees could prevent us from achieving our objectives and implementing our business strategy, which could have a material adverse effect on our business and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a significant amount of debt which may affect our ability to operate our business and secure additional financing in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we borrowed $10.0 million under the loan and security agreement, or the 2020 Loan Agreement, with Oxford. In November 2020, June 2021, and February 2022, we borrowed an additional $20.0 million, $40.0 million, and $40.0 million respectively, under the Amended 2020 Loan Agreement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Amended 2020 Loan Agreement are secured by substantially all of our assets, other than our intellectual property. The Amended 2020 Loan Agreement requires us, and any debt arrangements or instruments we may enter into in the future may require us, to comply with various covenants that limit our ability to, among other things: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dispose of assets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complete mergers or acquisitions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur or guarantee indebtedness; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sell or encumber certain assets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay dividends or make other distributions to holders of our capital stock, including by way of certain stock buybacks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make specified investments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in different lines of business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change certain key management personnel; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in certain transactions with our affiliates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These covenants may make it difficult to operate our business. A failure by us to comply with the covenants could result in an event of default, which could adversely affect our ability to respond to changes in our business and manage our operations. Upon the occurrence of an event of default, including the occurrence of a material adverse change, the lender could elect to declare all amounts outstanding to be due and payable and exercise other remedies. If the indebtedness were to be accelerated, our future financial condition could be materially adversely affected. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur additional indebtedness in the future. The instruments governing such indebtedness could contain provisions that are as, or more, restrictive than our existing debt instruments. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against any collateral granted to them to secure such indebtedness or force us into bankruptcy or liquidation. Further, if our business is subject to liquidation, the right to repayment of Oxford and any other holders of indebtedness would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees and independent contractors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees or independent contractors. Misconduct by these parties could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish for our therapeutic candidates, comply with federal and state data privacy, security, fraud and abuse, and other healthcare laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, monetary damages, fines, disgorgement, imprisonment, loss of eligibility to obtain marketing approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance may not provide adequate levels of coverage against claims which may adversely affect our financial condition.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain insurance that we believe is adequate for businesses of our size and type. However, there are types of losses that we believe are not economically reasonable to insure or that cannot be insured against. For instance, we believe because directors and officers, or D&amp;O, liability insurance has become cost prohibitive with high retentions providing minimal coverage, we recently chose not to renew our D&amp;O policy.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that we may be subject to securities litigation in the future, including potential class action or stockholder derivative actions. Our indemnification agreements with our directors and certain officers, as well as </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware General Corporation Law, may require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Without D&amp;O insurance, the amounts we would pay to defend any such litigation or indemnify our officers and directors should they be subject to legal action based on their service to us could have a material adverse effect on our financial condition, results of operations and liquidity. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development and regulatory affairs, as well as sales and marketing to the extent any of our therapeutic candidates approach receipt of marketing authorization. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to integrate efficiently or achieve the expected benefits of any acquisitions of complementary businesses, therapeutic candidates or technologies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we in the future acquire any complementary business, therapeutic candidates or technologies, our ability to integrate and manage acquired businesses, therapeutic candidates or technologies effectively will depend upon a number of factors including the size of the acquired business, the complexity of any therapeutic candidate or technology and the resulting difficulty of integrating the acquired business&#8217;s operations, if any. Our relationship with current employees or employees of any acquired business may become impaired. We may also be subject to unexpected claims and liabilities arising from such acquisitions. These claims and liabilities could be costly to defend, could be material to our financial condition and might exceed either the limitations of any applicable indemnification provisions or the financial resources of the indemnifying parties. There can also be no assurance that we will be able to assess ongoing profitability and identify all actual or potential liabilities of a business, therapeutic candidate or technology prior to its acquisition. If we acquire businesses, therapeutic candidates or technologies that result in assuming unforeseen liabilities in respect of which it has not obtained contractual protections or for which protection is not available, this could materially adversely affect our business, prospects, financial condition and results of operations. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected as a result of computer system failures. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the internal computer systems belonging to us or our third-party service providers are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failure. Any system failure, accident or security breach that causes interruptions in our own or in third-party service vendors&#8217; operations could result in a material disruption of our development programs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our or our partners&#8217; or collaborators&#8217; marketing approval efforts and significantly increase our costs in order to recover or reproduce the lost data. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability, our development programs and competitive position may be adversely affected and the further development of our therapeutic candidates may be delayed. Furthermore, we may incur additional costs to remedy the damage caused by these disruptions or security breaches. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity breaches could expose us to liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain sensitive company data on our computer networks, including our intellectual property and proprietary business information. We face a number of threats to our networks from unauthorized access, accidental acts or omissions that expose vulnerabilities, security breaches and other system disruptions. As noted above, certain of our employees are presently and may in the future be working remotely as a result of the COVID-19 pandemic. We may face additional cybersecurity risks as a result of these circumstances and despite our security measures, our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infrastructure may be vulnerable to attacks by hackers or vulnerable to other disruptive problems. Our third-party partners, including CROs and providers of data hosting or cloud services, as well as suppliers, distributors, alliances, and other third-party service providers, face similar risks, which could affect us directly or indirectly.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States federal and all state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the collection, use, and dissemination of data. Some of these federal, state and foreign government requirements include obligations of companies to notify individuals and others of security breaches involving certain personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and follow-up actions related to a security breach could impact our reputation, prompt regulatory scrutiny and enforcement, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such security breach may compromise information stored on our networks and may result in significant data losses or theft of our intellectual property or proprietary business information, it may also subject us to significant fines, penalties or liabilities for any noncompliance with certain privacy and security laws. A cybersecurity breach could adversely affect our reputation and could result in other negative consequences, including disruption of our internal operations, increased cybersecurity protection costs, lost revenue or litigation. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business, or reputational losses that may result from an interruption of breach of our systems.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes, medical epidemics or pandemics, or other natural disasters. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operations are located in our facilities in La Jolla, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics or pandemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents, including the COVID-19 pandemic, that results in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations. Earthquakes, medical epidemics or pandemics, including the COVID-19 pandemic, or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. Certain of these natural disasters, including fires and severe weather events may be exacerbated by the effects of climate change. If a natural disaster, pandemic, including the COVID-19 pandemic, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or if similar events occurred elsewhere effecting the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could have a material and adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain and enforce patent protection for our technologies or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, patents and patent applications protecting, or seeking to protect, our therapeutic candidates and methods for treating patients using our therapeutic candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. Our patent estate includes various issued United States patents, United States pending non-provisional patent applications, United States pending provisional applications, pending PCT applications, issued foreign patents, and foreign patent applications currently pending in various foreign jurisdictions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we will endeavor to protect our therapeutic candidates with intellectual property rights such as patents, as appropriate, the process of obtaining, maintaining, and enforcing patents is time-consuming, expensive and sometimes unpredictable, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to any patents we may license to or from third parties. Therefore, such patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to provide meaningful protection from any competitors. Our competitors may be able to circumvent our patents by developing similar or alternative therapeutic candidates in a non-infringing manner. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and therapeutic candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which non-compliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology patents. As such, we do not know the degree of future protection that we will have on our proprietary therapeutics and technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions and has in recent years been the subject of much litigation. Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., due to a determination that the claims are invalid or unenforceable. In addition, there can be no assurance that: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not or will not be able to legally make, use or sell products or therapeutic candidates that are the same as or similar to our therapeutic candidates despite the claims of the patents that we own or license; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors, or our collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors, or our collaborators are the first to file patent applications covering certain aspects of our inventions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any issued patents that we own or have licensed will provide us with any competitive advantage; or </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others will not have a material or adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining valid and enforceable issued or granted patents covering our therapeutic candidates in the United States and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors or third parties may use our technology to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the United States. Third-party or competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biotechnology. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, could provoke third parties to assert claims against us, and, whether or not successful, could result in substantial cost and divert our efforts and attention from other aspects of our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally file a provisional patent application first (a priority filing) at the USPTO. An international application under the PCT is usually filed within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the United States, Europe, Japan, Australia and Canada and, depending on the individual case, also in one, several or all of Brazil, China, India, Israel, Mexico, New Zealand, Russia or Eurasian Patent Organization, Singapore, South Africa, South Korea and other jurisdictions. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that, depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate or technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a patent is granted by a regional patent office (e.g., Europe or Eurasia), the patent must be validated in individual countries in order to be in effect in those countries. We may decide not to validate regional patents in every available country or at all in any country in the region. In addition, we may decide to abandon national and regional patent applications before or after grant. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or any licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent. If we or any licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States and other jurisdictions in which we file patent applications could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. In contrast, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, assuming that other requirements for patentability were met. Furthermore, United States patent law under the America Invents Act allows for post issuance challenges to United States patents, including ex parte reexaminations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews and post grant oppositions. If our United States patents are challenged using such procedures, we may not prevail, possibly resulting in altered or diminished claim scope or loss of patent rights altogether. Similarly, some countries, notably members of the European Union, also have post grant opposition proceedings that can result in changes in scope and/or cancellation of patent claims. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Supreme Court has also ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non compliance with these requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO, the European Patent Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. For example, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO, the European Patent Office and foreign patent agencies in several stages over the lifetime of the patent. Some jurisdictions also require payment of annuity fees during pendency of a patent application. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaboration partners fail to maintain the patents and patent applications covering our therapeutic candidates, our competitors might better be able to enter the market, which would have an adverse effect on our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to reduce the scope of our intellectual property due to intellectual property claims included in the patents or patent applications of others. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may have filed, and may in the future file, patent applications covering technology similar to ours. It is also possible that we have failed to identify relevant third-party patents or applications. For example, United States applications filed before November&#160;29, 2000 and certain United States applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with this earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapeutic candidates could have been filed by others without our knowledge. Additionally, pending patent </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applications that have been published can, subject to certain limitations, be later amended in a manner that could cover any future approved products or our therapeutic candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies, if possible, or block us from practicing certain aspects of our technology if we are unable to successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If another party has filed a United States patent application on inventions similar to ours that claims priority to an application filed prior to March&#160;16, 2013, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. Similarly, if another party has filed a United States patent application on inventions similar to ours that claims priority to an application filed after March&#160;16, 2013, we may have to participate in a derivation proceeding to determine whether that party derived the claimed invention from an inventor listed on our application and then filed the third-party application without authorization. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our United States patent position with respect to such inventions. In addition, an unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Further, changes enacted on March&#160;15, 2013 to the United States patent laws under the America Invents Act resulted in the United States changing from a &#8220;first to invent&#8221; country to a &#8220;first to file&#8221; country. As a result, we may lose the ability to obtain a patent if a third party files with the USPTO first and could become involved in proceedings before the USPTO to resolve disputes related to inventorship. We may also become involved in similar proceedings in other jurisdictions. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors, licensees or any future strategic partners may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our therapeutic candidates, or put our patents and other proprietary rights at risk. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. We or our licensors, licensees or any future strategic partners may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries including patent infringement lawsuits, interferences, derivations, oppositions and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review proceedings before the USPTO, and corresponding foreign patent offices. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future therapeutic candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If we, our licensees or our licensors, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we, our licensees or our licensors, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give any competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, the holders of any such patents may be able to block us, our licensees or our collaborators from marketing therapeutic candidates based on our technology until such patents expire, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our technology. This loss of patent protection could have a material and adverse effect on our business, financial condition, results of operations and prospects. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under the agreements pursuant to which we license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose the rights to intellectual property licensed to us. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements under which we are granted rights to third-party intellectual property, and we expect that we may need to enter into additional license agreements in the future. License agreements may impose various development obligations, payment of royalties and fees based on achieving certain milestones, as well as other obligations. If we fail to comply with our obligations under these agreements, the licensor may have the right to terminate the license. The termination of any license agreements or failure to adequately protect such license agreements could prevent us from commercializing therapeutic candidates covered by the licensed intellectual property or otherwise adversely affect our business. Our license agreements may involve sublicenses from third parties which are not the original licensor of the intellectual property at issue. Under these agreements, we would rely on our licensor to comply with its obligations under the primary license agreements, where we may have no relationship with the original licensor of such rights. If the licensors fail to comply with their obligations under these upstream license agreements, the original third-party licensor may have the right to terminate the original license, which may terminate the sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property and, in the case of a sublicense, if we were not able to secure our own direct license with the owner of the relevant rights, which we may not be able to do at a reasonable cost or on reasonable terms, it may adversely affect our ability to continue to develop and commercialize any of our therapeutic candidates incorporating the relevant intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation related issues; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborator; and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain any licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our intellectual property agreements with our licensors, licensees, collaborators and third parties may be subject to disagreements over contract interpretation, which could narrow the scope of, or result in termination of, our rights to the relevant intellectual property or technology or increase our financial or other obligations to such third parties, or reduce the financial or other obligations our licensees have to us. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. For example, we may disagree with our licensors, licensees or collaborators regarding whether, when and to what extent various obligations under these agreements apply to certain of our/their therapeutic candidates and products, including various payment, development, commercialization, funding, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement. In either case, such disagreement could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable, generally expensive, time consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material and adverse effect on our ability to compete in the marketplace. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for certain aspects of our therapeutic candidates, we also consider trade secrets, including confidential and unpatented know-how important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. Trade secrets and confidential know-how are difficult to maintain as confidential. We seek to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, partners, outside scientific </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, even if relevant agreements are entered into, despite these efforts, any of these parties may breach the agreements and unintentionally or willfully disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. Moreover, a competitor who independently develops substantially equivalent proprietary information may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets or confidential know-how. Under certain circumstances, we may also decide to publish some know-how to attempt to prevent others from obtaining patent rights covering such know-how. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or biotechnology companies, including potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. Our trademarks may not be approved by one or more governmental trademark offices or may not be approved for use on our products by regulatory agencies, such as the FDA. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our patent terms expire before or soon after our therapeutic candidates are approved, or if manufacturers of biosimilar drugs successfully challenge our patents, our business may be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited duration. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our therapeutic candidates, their manufacture, or use are obtained, once the patent life has expired, we may be open to competition from competitive medications, including biosimilar medications. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our therapeutic candidates, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, and similar legislation in the European Union. The Hatch-Waxman Act permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner than we expect. Also, the scope of our right to exclude during any patent term extension period may be limited or may not cover a competitor&#8217;s product or product use. As a result, our revenue from applicable therapeutic candidates, if approved, could be reduced, possibly materially. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates might expire before or shortly after such drug candidates are commercialized. As a result, our patents and patent applications may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of biosimilar drugs may challenge the scope, validity, or enforceability of our patents in court or before a patent office, and we may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any potential sales of that product. Upon the expiration of our issued patents or patents that may issue from our pending patent applications, we will not be able to assert such patent rights against potential competitors and our business, financial condition, results of operations, and prospects may be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business nor permit us to maintain our competitive advantage. The following examples are illustrative: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others may be able to make therapeutic candidates that are the same as or similar to our therapeutic candidates but that are not covered by the claims of the patents that we own or may have exclusively licensed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not develop additional technologies that are patentable. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our collaborators may be unable to obtain marketing approval for any product that we or a collaborator may develop and the marketing approval processes of the FDA and other comparable regulatory authorities outside the United States are lengthy, time-consuming and inherently unpredictable. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product that we or our collaborators may attempt to develop, manufacture or market in the United States will be subject to extensive regulation by the FDA, including regulations relating to development, preclinical testing, performance of clinical trials, manufacturing and post-approval commercialization. Preclinical testing, clinical trials and manufacturing, among other activities, will be subjected to an extensive review process before a new therapeutic product may be sold in the United States. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays, including delays arising from the COVID-19 pandemic. The time required to obtain FDA&#160;approval, and any other required approvals for biological products is unpredictable but typically requires several years and may never be obtained. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product that we or our collaborators may wish to develop, manufacture or market in countries other than the United States will also be subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing, pricing and third-party reimbursement among other things in such countries. The foreign marketing approval process includes all of the risks and uncertainties associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in such foreign jurisdictions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, obtaining marketing approval for biological products requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process, and in many cases the inspection of manufacturing, processing, and packaging facilities by the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use, or there may be deficiencies in cGMP compliance by us or by our contract development and manufacturing organizations, or CDMOs, that could result in the candidate not being approved. Moreover, we have not obtained marketing approval for any therapeutic candidate in any jurisdiction and it is possible that none of our existing therapeutic candidates or any therapeutic candidates we may seek to develop in the future will ever obtain marketing approval.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our therapeutic candidates could fail to receive, or could be delayed in receiving, marketing approval for many reasons, including any one or more of the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or comparable foreign regulatory authorities for marketing approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain marketing approval in the United States or elsewhere;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon review of our clinical trial sites and data, the FDA or comparable foreign regulatory authorities may find our record keeping or the record keeping of our clinical trial sites to be inadequate or may identify other GCP deficiencies related to the trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies may fail to meet the requirements of the FDA, EMA or comparable foreign regulatory authorities; or&#160;&#160;&#160;&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the medical standard of care or the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner that renders our clinical data insufficient for approval.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of the therapeutic candidates we or our collaborators may develop will obtain the marketing approvals necessary for us or our collaborators to sell the products either in the United States or any other country. Furthermore, approval by the FDA of a therapeutic product does not assure approval by regulatory authorities outside the United States or vice versa. Even if approval for a therapeutic product is obtained, such approval may be subject to limitations on the indicated uses or appropriate patient population that could result in a significantly reduced potential market size for the product. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators fail to obtain the appropriate marketing approvals necessary for us or our collaborators to sell our therapeutic candidates, or if the approvals are more limited than those that we intend to seek, our business, financial condition and results of operations would be materially harmed. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be subject to stringent domestic and foreign therapeutic and drug regulation with respect to any potential products. Even if we receive marketing approval for any of our therapeutic candidates, we will still be subject to ongoing regulatory obligations and continued review, which may result in significant additional expense. If we fail to comply with United States and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties. Any unfavorable regulatory action may materially and adversely affect our future financial condition and business operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive marketing and commercialization approval for a therapeutic candidate, we will be subject to continuing post-marketing regulatory requirements. Our potential products, further development activities and manufacturing and distribution of a future product, once developed and determined, will be subject to extensive and rigorous regulation by numerous government agencies, including the FDA and comparable foreign agencies. To varying degrees, each of these agencies monitors and enforces our compliance with laws and regulations governing the development, testing, manufacturing, labeling, marketing, distribution, and the safety and effectiveness of our therapeutic candidates and, if approved, our future products. The process of obtaining marketing approval or clearance from the FDA and comparable foreign bodies for new products, or for enhancements, expansion of the indications or modifications to existing products, could: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take a significant, indeterminate amount of time; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the expenditure of substantial resources; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve rigorous preclinical and clinical testing, and possibly post-market surveillance; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require design changes of our potential products; or </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in our never being granted the marketing approval we seek. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences may cause our operations or potential for success to suffer, harm our competitive standing and result in further losses that adversely affect our financial condition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, as well as its foreign regulatory counterparts, also have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. Additionally, the FDA regulates the promotional claims that may be made about prescription products, such as our products, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. However, we may share truthful and not misleading information with healthcare providers and payors that is otherwise consistent with the product&#8217;s FDA approved labeling. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will have ongoing responsibilities under these and other FDA and international regulations, both before and after a product is approved and commercially released. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA and foreign regulatory agencies. If we or our collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, adverse regulatory inspection finding, holds on </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials, delay of approval or refusal by the FDA or applicable authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of marketing approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, exclusion of eligibility from government contracts, injunctions, civil penalties or criminal prosecution. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively commercializing our potential products and harm our business. In addition, negative publicity and product liability claims resulting from any adverse regulatory action could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted outside of their respective jurisdictions. While we currently have partnerships in China designed to provide access to patient populations outside of the United States and in the future may conduct clinical trials in other foreign jurisdictions, there can be no assurance these data will be accepted by the FDA or EMA or other comparable foreign regulatory authorities as a basis for a product&#8217;s marketing approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To augment our U.S.-centric clinical strategy, we have formed partnerships in China designed to provide access patient populations for clinical trials not readily available in the United States and to facilitate rapid patient enrollment with the goal of generating more robust early clinical data from patients in China. We may in the future pursue partnerships to conduct other clinical trials outside of the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the U.S. population and U.S. medical practice and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations. In February 2022, the FDA publicly rebuked an oncology product sponsor for submitting a marketing application with Phase III clinical data solely from China. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, any foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction, including any trials conducted in China. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our partnerships in China subject us to risks and uncertainties relating to the laws and regulations of China and the changes in relations between the United States and China. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under its current leadership, the government of China has been pursuing economic reform policies, including by encouraging foreign trade and investment. However, there is no assurance that the Chinese government will continue to pursue such policies, that such policies will be successfully implemented, that such policies will not be significantly altered, or that such policies will be beneficial to our partnerships in China. China&#8217;s system of laws can be unpredictable, especially with respect to foreign investment and foreign trade. The United States government has called for substantial changes to foreign trade policy with China and has raised, and has proposed to further raise in the future, tariffs on several Chinese goods. China has retaliated with increased tariffs on United States goods. Moreover, China&#8217;s legislature has recently adopted a national&#160;security law to substantially change the way&#160;Hong Kong&#160;has been governed since the territory was handed over by the United Kingdom to China in 1997. This law increases the power of the central government in Beijing over&#160;Hong Kong, limit the civil liberties of residents of&#160;Hong Kong&#160;and could restrict the ability of businesses in Hong Kong to continue to conduct business or to continue to with business as previously conducted. The U.S. State Department has indicated that the United States no longer considers&#160;Hong Kong&#160;to have significant autonomy from China. The U.S. State Department has recently enacted sanctions related to China&#8217;s governing of Hong Kong, and the United States may impose the same tariffs and other trade restrictions on exports from&#160;Hong Kong&#160;that it places on goods from mainland China. Any further changes in United States trade policy could trigger retaliatory actions by affected countries, including China, resulting in trade wars. Additionally, the biopharmaceutical industry in particular in China is strictly regulated by the Chinese government. Changes to Chinese regulations affecting biopharmaceutical companies are also unpredictable. Any regulatory changes and changes in United States and China relations may have a material adverse effect on our partnerships in China which could materially harm our business and financial condition. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives could harm our business in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing pressure on biotechnology companies to reduce healthcare costs. In the United States, these pressures come from a variety of sources, such as managed care groups and institutional and government purchasers. Increased purchasing power of entities that negotiate on behalf of federal healthcare programs and private sector beneficiaries could increase pricing pressures in the future. Such pressures may also increase the risk of litigation or investigation by the government regarding pricing calculations. The biotechnology industry will likely face greater regulation and political and legal actions in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse pricing limitations may hinder our ability to recoup our investment in one or more future therapeutic candidates, even if our future therapeutic candidates obtain marketing approval. Adverse pricing limitations prior to approval will also adversely affect us by reducing our commercial potential. Our ability to commercialize any potential products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments becomes available from third-party payors, including government health administration authorities, private health insurers and other organizations. Third-party payors decide which medications they will pay for and establish reimbursement levels. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize in the future and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval in the future. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any therapeutic candidate that we successfully develop. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Our inability to promptly obtain coverage and adequate reimbursement from third-party payors for approved products could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize potential products and our overall financial condition. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material and adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations, and other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for our therapeutic candidates, if we obtain marketing approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive or set a price that we believe is fair for our products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA was enacted, which includes measures that have significantly changed the way healthcare is financed by both governmental and private insurers in the United States. It also included the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The ACA continues to significantly impact the United States&#8217; pharmaceutical industry. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. As an example, in 2020, the FDA finalized a rulemaking to establish a system whereby state governmental entities could lawfully import and distribute prescription drugs sourced from Canada. More recently, in July 2021, President Biden issued a sweeping executive order on promoting competition in the American economy that includes several mandates pertaining to the pharmaceutical and health care insurance industries. Among other things, the executive order directed the FDA to work towards implementing a system for importing drugs from Canada (following on the Trump administration notice-and-comment rulemaking on Canadian drug importation that was finalized in October 2020). The Biden order also called on HHS to release a comprehensive plan to combat high prescription drug prices, and it includes several directives regarding the Federal Trade Commission&#8217;s oversight of potentially anticompetitive practices within the pharmaceutical industry. The drug pricing plan released by HHS in September 2021 in response to the executive order makes clear that the Biden Administration supports aggressive action to address rising drug prices, including allowing HHS to negotiate the cost of Medicare Part B and D drugs, but such significant changes will require either new legislation to be passed by Congress or time-consuming administrative actions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate pharmaceutical benefit managers, or PBMs, and other members of the health care and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, such as changes allowing the federal government to directly negotiate drug prices, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability, or commercialize our therapeutic candidates, if approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union similar political, economic and regulatory developments may affect our ability to profitably commercialize our current or any future products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Our future products, if any, might not be considered medically reasonable and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">necessary for a specific indication or cost-effective by third-party payors, an adequate level of reimbursement might not be available for such products and third-party payors&#8217; reimbursement policies might adversely affect our ability to sell any future products profitably. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biologic therapeutics. For example, on December 20, 2019, President Trump signed P.L. 116-94 that includes a piece of bipartisan legislation called the CREATES Act. The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products to deny generic and biosimilar product developers access to samples of brand products. Whether and how generic and biosimilar product developers will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on the U.S. biopharmaceutical industry are unknown. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our therapeutic candidates, if any, may be. Furthermore, the next FDA reauthorization package is currently being negotiated and is due to be finalized by Congress in 2022, while several other FDA-related changes are also being proposed in Congress, including within a &#8220;Cures 2.0&#8221; bill that is likely to have bipartisan support. Increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-approval testing and other requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our therapeutic candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we may obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors and customers expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind to induce or reward either the referral of an individual for, or the purchase, or order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the U.S. federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and the civil monetary penalties laws, which prohibit individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the U.S. federal False Claims Act; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to HHS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors and certain advanced non-physician healthcare practitioners) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant civil, criminal and administrative penalties, including monetary damages, fines, disgorgements, imprisonment, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations, any of which could adversely our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We received orphan drug status for INBRX-109 for the treatment of patients with metastatic or unresectable chondrosarcoma. We may seek orphan drug status for additional therapeutic candidates, but even if it is granted, we may be unable to maintain any benefits associated with orphan drug status, including market exclusivity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for a disease or condition will be recovered from sales in the United States for that drug or biologic. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received orphan drug status for INBRX-109 for the treatment of patients with metastatic or unresectable chondrosarcoma. We may seek orphan drug status for additional therapeutic candidates, but the FDA may not </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approve any such request. Even with orphan drug status, exclusive marketing rights in the United States may be limited if we seek FDA marketing approval for an indication broader than the orphan designated indication. Additionally, any therapeutic candidate that initially receives orphan drug status designation, may lose such designation if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, others may obtain orphan drug status for products addressing the same diseases or conditions as products we are developing, thus limiting our ability to compete in the markets addressing such diseases or conditions for a significant period of time. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We received fast-track designation for INBRX-109 for the treatment of patients with metastatic or unresectable chondrosarcoma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek fast-track designation for other of our therapeutic candidates. Even if received, fast-track designation may not actually lead to a faster review process. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to benefit from the FDA&#8217;s fast track and priority review processes. We received fast-track designation for INBRX-109 for the treatment of patients with metastatic or unresectable chondrosarcoma. Under fast-track designation, the FDA may initiate a rolling review of sections of a fast-track drug&#8217;s BLA before the application is complete. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the BLA is submitted. Additionally, the fast-track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. Under the FDA policies, a drug candidate is eligible for priority review, or review within a six-month time frame from the time a complete BLA is accepted for filing, if the drug candidate provides a significant improvement compared to marketed drugs in the treatment, diagnosis or prevention of a disease. A fast-track designated drug candidate would ordinarily meet the FDA&#8217;s criteria for priority review. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fast-track designation for INBRX-109, or for other future therapeutic candidates, may not actually lead to a faster review process and a delay in the review process or in the approval of our potential products will delay revenue from their potential sales and will increase the capital necessary to fund these product development programs. Without fast-track designation, submitting a BLA and getting through the regulatory process to gain marketing approval is a lengthier process. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates for which we intend to seek approval may face competition sooner than anticipated.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in achieving marketing approval to commercialize a therapeutic candidate ahead of our competitors, our future therapeutic candidates may face direct competition from biosimilar products. In the United States, our therapeutic candidates are regulated by the FDA as biological products and we intend to seek approval for these therapeutic candidates pursuant to the BLA pathway. The BPCIA created an abbreviated pathway for the FDA approval of biosimilar biological products based on a previously licensed innovator, or reference, biological product. Under the BPCIA, an application for a biosimilar biological product cannot be approved by the FDA until 12&#160;years after the original reference biological product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our therapeutic candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity available to reference biological products. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our therapeutic candidates to be reference biological products pursuant to its interpretation of the exclusivity provisions of the BPCIA, potentially creating the opportunity for follow-on biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing including whether a future competitor seeks an interchangeability designation for a biosimilar of one of our products. Under the BPCIA as well as state pharmacy laws, only so-called &#8220;interchangeable&#8221; biosimilar products are considered substitutable for the reference biological product without the intervention of the healthcare provider who prescribed the original biological product. However, as with all prescribing decisions made in the context of a patient-provider relationship and a patient&#8217;s specific medical needs, healthcare providers are not restricted from prescribing biosimilar products in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an off-label manner. In addition, a competitor could decide to forego the abbreviated approval pathway available for biosimilar products and to submit a full BLA for product licensure after completing its own preclinical studies and clinical trials. In such a situation, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its biological product as soon as it is approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If competitors are able to obtain marketing approval for biosimilars referencing our therapeutic candidates, if approved, our future products may become subject to competition from such biosimilars, whether or not they are designated as interchangeable, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our therapeutic candidates may have received approval.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face regulation and potential liability related to the privacy, data protection and information security which may require significant resources and may adversely affect our business, operations and financial performance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory environment surrounding information security, data collection and privacy is increasingly demanding. We are subject to numerous U.S. federal and state laws and non-U.S. regulations, including in Europe and China, governing the protection of personal and confidential information of our clinical subjects, clinical investigators, employees and vendors/business contacts, including in relation to medical records, credit card data and financial information. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act and CCPA), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators, and the privacy regulatory area is in constant flux. The state of California, for example, has adopted the CCPA, which went into effect beginning in January 2020. The CCPA has been characterized as the first &#8220;GDPR-like&#8221; privacy statute to be enacted in the United States because it mirrors a number of the key provisions of the GDPR. The CCPA establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for residents of the State of California, imposing special rules on the collection of personal information from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. In November of 2020, California voters approved the CPRA, which will take full effect in January of 2023. The CPRA modifies the CCPA significantly, potentially resulting in further uncertainty, additional costs and expenses in an effort to comply, and additional harm and liability for failure to comply. Among other things, the CPRA established a new regulatory authority, the California Privacy Protection Agency, which will be enacting new regulations and will have expanded enforcement authority. Virginia and Colorado enacted similar data protection laws in 2021, and other U.S. states have proposals under consideration, increasing the regulatory compliance risk. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, or EU, the GDPR, which came into effect on May 25, 2018, could increase our burden of regulatory compliance. The GDPR implements more stringent operational requirements for processors and controllers of personal data, including, for example, requiring expanded disclosures about how personal information is to be used, limitations on retention of information, mandatory data breach notification requirements, and higher standards for data controllers to demonstrate that they have obtained either valid consent or have another legal basis in place to justify their data processing activities. The GDPR further provides that EU member states may make their own additional laws and regulations in relation to certain data processing activities, which could further limit our ability to use and share personal data and could require localized changes to our operating model. Under the GDPR, fines of up to &#8364;20 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, may be assessed for noncompliance, which significantly increases our potential financial exposure for non-compliance. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be subject to the GDPR where we have a European Union presence or &#8220;establishment&#8221; (e.g. European Union based subsidiary or operations), when conducting clinical trials with European Union based data subjects (whether the trials are conducted directly by us or through a clinical vendor or partner) or offering approved products or services (if relevant) to European Union based data subjects (regardless of whether involving our European Union based subsidiary or operations). </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR sets out a number of requirements that must be complied with when handling the personal data of such European Union based data subjects including: providing expanded disclosures about how their personal data will be used; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal basis in place to justify their data processing activities; the obligation to appoint data protection officers in certain circumstances; new rights for individuals to be &#8220;forgotten&#8221; and rights to data portability, as well as enhanced current rights (e.g. access requests); the principal of accountability and demonstrating compliance through policies, procedures, training and audit; the new mandatory data breach regime. In particular, medical or health data, genetic data and biometric data where the latter is used to uniquely identify an individual are all classified as &#8220;special category&#8221; data under the GDPR and afford greater protection and require additional compliance obligations. Further, European Union member states have a broad right to impose additional conditions&#8212;including restrictions&#8212;on these data categories. This is because the GDPR allows European Union member states to derogate from the requirements of the GDPR mainly in regard to specific processing situations (including special category data and processing for scientific or statistical purposes). As the European Union states continue to reframe their national legislation to harmonize with the GDPR, we will need to monitor compliance with all relevant European Union member states&#8217; laws and regulations, including where permitted derogations from the GDPR are introduced. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also be subject to evolving European Union laws on data export, where we transfer data outside the European Union to group companies or third parties. The GDPR only permits exports of data outside the European Union where there is a suitable data transfer solution in place to safeguard personal data (e.g. the European Union Commission approved Standard Contractual Clauses). On July 16, 2020, the Court of Justice of the European Union or the CJEU, issued a landmark opinion in the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maximilian Schrems vs. Facebook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Case C-311/18), called </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schrems II. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This decision (a) calls into question certain data transfer mechanisms as between the European Union member states and the U.S. (such as the Standard Contractual Clauses) and (b) invalidates the EU-U.S. Privacy Shield on which many companies had relied as an acceptable mechanism for transferring such data from the EU to the U.S. The CJEU is the highest court in Europe and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schrems II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision heightens the burden on data importers to assess U.S. national security laws on their business and future actions of European Union data protection authorities are difficult to predict at the early date. Consequently, there is some risk of any of our data transfers from the European Union being halted.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where we rely on third parties to carry out a number of services for us, including processing personal data on our behalf, we are required under GDPR to enter into contractual arrangements to help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have an adverse impact on our reputation and business. Any contractual arrangements requiring the transfer of personal data from the European Union to us in the United States will require greater scrutiny and assessments as required under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schrems II </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and may have an adverse impact on cross-border transfers of personal data, or increase costs of compliance.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partnerships in China and our CRO relationships in Hong Kong may expose us to new and stringent Chinese data security laws. The Data Security Law of the People&#8217;s Republic of China, or the PRC Data Security Law, took effect on September 1, 2021. The PRC Data Security Law requires data processing, which includes the collection, storage, use, processing, transmission, provision and publication of data, to be conducted in a legitimate and proper manner. Moreover, the PRC Data Security Law provides a national security review procedure for those data processing activities which affect or may affect national security and imposes export restrictions on certain data and information. In addition, the PRC Data Security Law also provides that any organization or individual within the territory of the PRC shall not provide any foreign judicial body and law enforcement body with any data stored in the territory of the PRC without the approval of the competent PRC governmental authorities.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, U.S. and European lawmakers and regulators have expressed concern over electronic marketing. In the European Union, marketing is defined broadly to include any promotional material and the rules specifically on e-marketing are currently set out in the ePrivacy Directive which will be replaced by a new ePrivacy Regulation. While the ePrivacy Regulation was originally intended to be adopted on May&#160;25, 2018 (alongside the GDPR), it is still going through the European legislative process and commentators now expect it to be adopted in 2021. The current draft of the ePrivacy Regulation imposes strict opt-in e-marketing rules with limited exceptions to business to business communications and significantly increases fining powers to the same levels as GDPR (see above). </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may find it necessary or desirable to join self-regulatory bodies or other privacy-related organizations, particularly relating to biopharmacy and/or scientific research that may require compliance with their rules pertaining to privacy and data security. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The introduction of the GDPR, and any resultant changes in European Union member states&#8217; national laws and regulations and the ePrivacy Regulation, will increase our compliance obligations and will necessitate the review and implementation of policies and processes relating to our collection and use of data. This increase in compliance obligations could also lead to an increase in compliance costs which may have an adverse impact on our business, financial condition or results of operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any person, including any of our employees, clinical vendors or partners or those with whom we share such information, negligently disregards or intentionally breaches our established controls with respect to our clinical subject, clinical investigator or employee data, or otherwise mismanages or misappropriates that data, we could be subject to significant monetary damages, regulatory enforcement actions, fines and/or criminal prosecution in one or more jurisdictions. As above, under the GDPR there are significant new punishments for non-compliance which could result in a penalty of up to 4% of a firm&#8217;s global annual revenue.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable laws may conflict with each other, and by complying with the laws or regulations of one jurisdiction, we may find that we are violating the laws or regulations of another jurisdiction. Despite our efforts, we may not have fully complied in the past and may not in the future. If we become liable under laws or regulations applicable to us, we could be required to pay significant fines and penalties, our reputation may be harmed and we may be forced to change the way we operate. That could require us to incur significant expenses or to discontinue certain services, which could negatively affect our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon technology systems and data to operate our business. In particular, the COVID-19 pandemic has caused us to modify our business practices, including in certain cases allowing office-based employees in the United States to work from home. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies. A breakdown, invasion, corruption, destruction or breach of our technology systems, including the cloud technologies that we utilize, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including the cloud technologies that we utilize, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack. Likewise, data privacy or security breaches by individuals authorized to access our technology systems, including the cloud technologies that we utilize, may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches. Further, a data breach could result in negative publicity which could damage our reputation and have an adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.&#160;Compliance with these legal standards could impair our ability to compete in domestic and international markets.&#160;We can face criminal liability and other serious consequences for violations, which can harm our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.&#160;We may engage third parties to sell our products sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals.&#160;We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations.&#160;We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of net operating loss carryforwards may be limited and U.S. federal income tax reform could adversely affect us.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to utilize our net operating loss, or NOL, carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes. Corresponding rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from the initial public offering of our common stock, or our IPO, or other transactions, or any resulting limitations, if any, on our ability to utilize our NOL carryforwards and other tax attributes. Even if there is no limitation on utilization of our NOL carryforwards as the result of an ownership change, the utilization of NOL carryforwards originating from a loss incurred in a year after 2017 is limited and may reduce taxable income in any post-2020 year by no more than 80% of the pre-NOL taxable income in such year. If we earn taxable income in a future year, such limitations on utilization of NOL carryforwards could result in increased future tax liability to us and our future cash flows could be adversely affected.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New legislation or regulation which could affect our tax burden could be enacted by any governmental authority. We cannot predict the timing or extent of such tax-related developments which could have a negative impact on our financial results. United States federal legislation affecting the tax laws was enacted in December 2017 (the TCJA), March 2020 (the Families First Coronavirus Response Act), and again in March 2020 (the CARES Act). We cannot estimate how the changes in tax law from this legislation will affect our tax liability in future years, but we have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits from those assets.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we use our best judgment in attempting to quantify and reserve for these tax obligations. However, a challenge by a taxing authority, our ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions may cause actual financial results to deviate from previous estimates.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain quantities of various flammable and toxic chemicals in our facilities in La Jolla, California required for our research and development activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these hazardous materials in our La Jolla facilities comply with the relevant guidelines of La Jolla, the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Any insurance coverage we have may not be sufficient to cover these liabilities. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations which would adversely affect our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future growth may depend, in part, on our ability to develop and commercialize our therapeutic candidates, if approved, in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our therapeutic candidates before we receive marketing approval from the applicable regulatory authority in that foreign market, and we may never receive such marketing approval for any of our therapeutic candidates. To obtain separate marketing approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our therapeutic candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our therapeutic candidates and ultimately commercialize our therapeutic candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries. We may need to rely on third parties to market, distribute and sell our products in foreign markets. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_124"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not know whether an active, liquid and orderly trading market will continue for our common stock and as a result it may be difficult for you to sell your shares of our common stock.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our IPO in August 2020, there was no public market for shares of our common stock. Shares of our common stock only recently began trading on the Nasdaq Global Market and we can provide no assurance that we will be able to sustain an active trading market for our shares. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of common stock as consideration.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that our stock price may fluctuate significantly.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of shares of our common stock may be highly volatile and could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of our clinical trials and preclinical studies or those of our competitors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to our therapeutic candidates or development programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems; actual or anticipated fluctuations in our financial condition and operating results; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us, our partners or our competitors of new therapeutics or therapeutic candidates, significant contracts, strategic partnerships, joint ventures, collaborations, commercial relationships or capital commitments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of new or updated research or reports by securities analysts or recommendations for our stock; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement of, or our involvement in, litigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing disputes or delays; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any future sales of our common stock or other securities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any change to the composition of the board of directors or key personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expiration of contractual lock-up agreements with our executive officers, directors and security holders; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic conditions and slow or negative growth of our markets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or expectation of additional debt or equity financing efforts; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">circumstances and market conditions relating to the COVID-19 pandemic.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance. In addition, the stock market in general, and life science companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have on occasion instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit against us, the defense and disposition of the lawsuit could be costly and divert the time and attention of our management and harm our operating results. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and holders of more than 5% of our capital stock own a significant percentage of our stock and will be able to exercise significant control over matters subject to stockholder approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our executive officers, directors and holders of more than 5% of our capital stock beneficially owned approximately 46.1% of our shares of common stock outstanding. Accordingly, this group of stockholders will continue to have significant control over our operations. This concentration of ownership could have the effect of delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our common stock in the public market could cause our stock price to fall. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price could decline as a result of sales of a large number of shares of our common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 38,991,307 shares of common stock outstanding. In order to raise additional capital, we may sell shares of common stock under our Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which we may, from time to time, sell shares of common stock having an aggregate offering price of up to $200.0 million through the Sales Agent. As of December&#160;31, 2021, shares of common stock with an aggregate offering price of $41.4 million have been sold through our Sales Agent pursuant to the Sales Agreement. Sales of our common stock made pursuant to the Sales Agreement will be made under our $400.0 million Shelf Registration on Form S-3ASR, which became automatically effective upon filing on September 3, 2021. We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of then outstanding options or warrants, or the perception that such sales may occur, could adversely affect the market price of our common stock. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances, and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, or nature of any future offerings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, our stock price and trading volume could decline. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us issues an adverse opinion about our company, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to regularly publish reports on us, we could lose visibility in the public markets, which could cause our stock price or trading volume to decline. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Nasdaq Stock Market may delist our securities from its exchange, which could limit investors&#8217; ability to make transactions in our securities and subject us to additional trading restrictions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market. We cannot assure you that, in the future, our securities will meet the continued listing requirements to be listed on the Nasdaq Global Market. If the Nasdaq Stock Market delists our common stock, we could face significant material adverse consequences, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited availability of market quotations for our securities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited amount of news and analyst coverage for our company; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decreased ability to issue additional securities or obtain additional financing in the future.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. The Amended 2020 Loan Agreement, and future debt financing agreements may require us to have the lender&#8217;s permission before declaring dividends on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">financial statements and other public reporting, which would harm our business and the trading price of our common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. Pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning in the year following the first required annual report. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Securities and Exchange Act of 1934, as amended, or the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that there will not be material weaknesses or significant deficiencies identified in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. In the future, if we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by The Nasdaq Stock Market, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lost our status as an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act and effective December 31, 2021, became a &#8220;large accelerated filer,&#8221; as defined in the Exchange Act. As a result, our independent registered public accounting firm is now required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&#160;404. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions contained in our restated certificate of incorporation and restated bylaws, as well as provisions of Delaware law, could impair a takeover attempt. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation, restated bylaws and Delaware law contain provisions which could have the effect of rendering more difficult, delaying or preventing an acquisition deemed undesirable by our board of directors. Our corporate governance documents include provisions: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorizing our board of directors to issue up to 15,000,000 shares of preferred stock without stockholder approval upon the terms and conditions and with the rights, privileges and preferences as our board of directors may determine; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specifying that special meetings of our stockholders can be called only by our board of directors, the chairman of our board of directors or our Chief Executive Officer and that our stockholders may not act by written consent; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing that our board of directors may create new directorships and that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing that our board of directors is divided into three classes&#8212;Class&#160;I, Class&#160;II, and Class&#160;III&#8212;with each class serving staggered three-year terms; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing that our board of directors may amend our restated bylaws without stockholder approval; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring a super-majority of votes to amend certain of the above-mentioned provisions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a Delaware corporation, we are also subject to provisions of Delaware law, including Section&#160;203 of the Delaware General Corporation law, which prevents some stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations without approval of the holders of substantially all of our outstanding common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designates, the Court of Chancery of the State of Delaware, or the Chancery Court, or the federal district court for the District of Delaware, or the District Court of Delaware, or the other federal district courts of the United States as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation requires, unless we otherwise consent, that the Chancery Court will, to the fullest extent permitted by law, be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law (subject to the Chancery Court having personal jurisdiction over the indispensable parties named as defendants): (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees to us or our stockholders, (iii)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers or employees of the Company, arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws, (v) any action or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Chancery Court, or (vi) any action or proceeding asserting a claim against us, or our directors, officers or employees, governed by the internal affairs doctrine. If the Chancery Court does not have jurisdiction for these actions or proceedings, then the actions or proceedings must be brought in a state court located in the State of Delaware. If these state courts also do not have jurisdiction, these actions or proceedings must be brought in the District Court of Delaware. These limitations in our amended and restated certificate of incorporation will not apply to actions brought to enforce a duty or liability created by the Securities Act, the Exchange Act or to any claim for which the federal courts have exclusive jurisdiction. However, our amended and restated certificate of incorporation also provides that, unless we otherwise consent in writing, the federal district courts of the United States shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. In addition, any person holding, owning or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation. These Delaware and federal court choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Chancery Court or the District Court of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the jurisdiction. The Chancery Court or the District Court of Delaware may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs, which could have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2020, the Delaware Supreme Court ruled that provisions of a Delaware corporation&#8217;s certificate of incorporation that designate a federal forum for securities claims brought pursuant to the Securities Act, or federal forum provisions, are valid and enforceable under Delaware law, or the March 2020 Ruling. Various U.S. Supreme Court cases offer support for the argument that federal forum provisions do not violate federal policy. However, the March 2020 Ruling applies only to claims brought in Delaware state courts, and it is not binding on any other state court or the federal courts. Therefore, we are unable to predict whether a state court in any other state or a federal court would enforce a federal forum provision such as the one set forth in our amended and restated certificate of incorporation.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_2307"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_127"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters are located in La Jolla, California where we currently lease approximately 43,000 square feet of laboratory and office space under a lease that expires in 2025. We have an option to extend the lease an additional five years. We believe that this space is sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_130"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_133"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_139"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock began trading on the Nasdaq Global Market in August 2020 under the ticker symbol &#8220;INBX.&#8221;</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of Common Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;21, 2022, we had 39,025,644 outstanding shares of common stock and approximately 120 holders of record of our common stock. The approximate number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in &#8220;street name&#8221; or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital requirements, general business conditions, our future prospects and other factors that our board of directors may deem relevant. In addition, the terms of the Amended 2020 Loan Agreement restrict our ability to pay dividends without the prior written consent of Oxford. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 12 of Part III of this Annual Report for information about our equity compensation plans which is incorporated by reference herein.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 18, 2020, the SEC declared effective our registration statement on Form S-1 (File No. 333-240135), as amended, filed in connection with our IPO. Our IPO closed on August 21, 2020, and we issued and sold 8,050,000 shares of our common stock at a price to the public of $17.00 per share, which included the exercise in full of the underwriters&#8217; option to purchase additional shares. We received gross proceeds from our IPO of $136.9&#160;million, before deducting underwriting discounts, commissions and offering costs of $11.0&#160;million, for net proceeds of approximately $125.9&#160;million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The joint book-running managing underwriters of the offering were Jefferies LLC, Evercore Group L.L.C. and Credit Suisse Securities (USA) LLC, with LifeSci Capital as Co-Manager.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon receipt, the net proceeds from our IPO were held in cash and cash equivalents, primarily bank deposits and money market funds. Through December&#160;31, 2021, we have used a portion of the net proceeds from our IPO for research and development of our programs and for general corporate purposes. There has been no material change in the planned use of proceeds from our IPO from those disclosed in the Prospectus.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the section of this Annual Report titled &#8220;Risk Factors,&#8221; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_148"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, developed using our protein engineering expertise and proprietary sdAb platform. Our sdAb platform allows us to pursue validated targets with clinical promise, but where other antibody and biologic based approaches have failed. Highly modular, our sdAbs can be combined with precise valencies and multiple specificities, creating therapeutic candidates designed to be capable of enhanced cell signaling, conditional activation or combined synergistic functions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have four programs in ongoing clinical trials. Three of these programs are for the treatment of various cancers, and one for the treatment of AATD. INBRX-101 is an optimized, recombinant AAT augmentation therapy candidate for AATD. In October 2021, we announced interim results from the Phase 1 clinical trial. The data from the SAD cohorts revealed the potential to achieve normal AAT levels with monthly dosing and also showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events at doses up to and including 120 mg/kg single dose and 80 mg/kg multi-dose administered intravenously. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced therapeutic candidate, INBRX-109,&#160;is a tetravalent DR5 agonist&#160;currently being evaluated in patients diagnosed with difficult-to-treat cancers, such as chondrosarcoma, mesothelioma and pancreatic adenocarcinoma. We submitted an amended Investigational New Drug Application, or IND, to the FDA for INBRX-109 in April 2021 and initiated a potentially registration-enabling trial evaluating INBRX-109 in patients diagnosed with conventional chondrosarcoma in June 2021. INBRX-106 is a hexavalent OX40 agonist, currently being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. Both of the INBRX-109 and INBRX-106 programs are designed to achieve target agonism through precise control of therapeutic valency. INBRX-105 is a conditional 4-1BB agonist that is currently being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors. We anticipate additional data releases from all four of our clinical programs over the next year.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a diverse pipeline of therapeutic candidates that are specifically designed to leverage the power of our core sdAb platform and protein engineering expertise, as shown below:</span></div><div style="margin-bottom:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:467.25pt"><tr><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:109.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:115.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:111.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:155pt"><td colspan="21" style="padding:0 1pt"><div style="margin-bottom:9.5pt"><img src="inbx-20211231_g1.jpg" alt="inbx-20211231_g1.jpg" style="height:165px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-109</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-106</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-105</span></td></tr><tr style="height:38pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AAT-Fc fusion protein</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tetravalent DR5 agonist</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hexavalent OX40 agonist</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PD-L1x4-1BB tetravalent conditional agonist</span></td></tr></table></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.749%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Program</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Therapeutic Area</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Target(s)/Format</span></td><td colspan="24" style="border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">STAGE OF DEVELOPMENT</span></td></tr><tr style="height:11pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="6" style="border-right:1pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Phase 3</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">INBRX-101*</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Orphan/Respiratory</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Neutrophil Elastase<br/>AAT-Fusion Protein</span></td><td colspan="24" style="border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="9" style="background-color:#80a035;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="24" style="border-bottom:1pt solid #dbdbdb;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#ededed;border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">INBRX-109**</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">DR5<br/>Tetravalent Agonist</span></td><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="15" style="background-color:#80a035;padding:0 1pt"></td><td colspan="9" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">INBRX-106***</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">OX40<br/>Hexavalent Agonist</span></td><td colspan="24" style="border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="9" style="background-color:#80a035;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="24" style="border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#ededed;border-left:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">INBRX-105***</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">PD-L1 x 4-1BB <br/>Tetravalent Conditional Agonist</span></td><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="9" style="background-color:#80a035;padding:0 1pt"></td><td colspan="15" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Commercialization and development rights outside of the United States and Canada, subject to an option agreement with Chiesi</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Third party partnership with Transcenta, currently in place for development and commercialization in China, Hong Kong, Macau and/or Taiwan.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Third party partnership with Elpiscience, currently in place for development and commercialization in China, Hong Kong, Macau and/or Taiwan. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div id="ie96bda597eaa4024845d6498a1c78657_2301"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we completed our IPO of 8,050,000 shares of our common stock at a price to the public of $17.00 per share, which included the exercise in full by the underwriters of their option to purchase 1,050,000 additional shares of our common stock. Our aggregate net proceeds from the offering were $125.9&#160;million, net of underwriting discounts, commissions and offering costs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other sources of capital raised to fund our operations have been comprised of the sale of equity securities, payments received from commercial partners for licensing rights to our therapeutic candidates under development and grants, the 2020 Loan Agreement with Oxford, including $10.0&#160;million of gross proceeds borrowed in July 2020, and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from the sale and issuance of convertible promissory notes in May 2019 and April 2020, or the 2019 Note and the 2020 Notes, respectively.&#160;In November 2020 and June 2021, we amended the 2020 Loan Agreement which provided for two additional tranches of term loans, including $20.0&#160;million of gross proceeds received in November 2020, and an additional $40.0&#160;million of gross proceeds in June 2021. In February 2022, we further amended the 2020 Loan Agreement which provided for four additional tranches of term loans, including $40.0 million of gross proceeds received in February 2022, with an additional $90.0 million to be funded in three future tranches.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into the Sales Agreement, with the Sales Agent, under which we may, from time to time, sell shares of common stock having an aggregate offering price of up to $200.0 million through the Sales Agent. Sales of our common stock made pursuant to the Sales Agreement will be made under our $400.0 million Shelf Registration on Form S-3ASR, which became automatically effective upon filing on September 3, 2021. As of December&#160;31, 2021, we have sold 921,042 shares of common stock under the Sales Agreement for net proceeds of $40.2 million, after deducting commissions.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have devoted substantially all of our efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of our therapeutic candidates, hiring to support our research and development activities and financial reporting capabilities, establishing our intellectual property portfolio, and raising capital to support and expand these activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net loss for the years ended December 31, 2021 and 2020 was $81.8 million and $76.1 million, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $227.1 million and cash and cash equivalents of $131.3 million. Based upon our current operating plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months from the date these consolidated financial statements are issued. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting preclinical studies and testing product candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses to increase as we continue our development of, and seek marketing approvals for, our therapeutic candidates (especially as we move more candidates from preclinical to clinical development as well as study candidates in later stages of clinical development), and begin to commercialize any approved products, if ever. If we elect to proceed with the commercialization of any of our product candidates, we would incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We also expect our general and administrative expenses and losses to increase as we hire additional personnel and incur increased accounting, audit, legal, regulatory, and compliance costs, and as we incur increased costs from investor and public relations expenses associated with operating as a public company.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including strategic licensing and collaboration or other similar agreements. However, there can be no assurance as to the availability or terms upon which such finances or capital might be available in the future. If we are unable to secure adequate additional funding, we will need to reevaluate our operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our intellectual property on less favorable terms than we would otherwise choose. These actions could materially impact our business, results of operations, financial condition, and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future liquidity and capital funding requirements will depend on numerous factors, including: </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, costs and timing of preclinical studies and clinical trials for our current or future therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and when we are able to obtain marketing approval to market any of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize any therapeutic candidates that receive marketing approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence and effect of competing or complementary therapeutics or therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any strategic licensing, collaboration or other similar agreement that we have or may establish; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to repay, refinance or restructure our indebtedness when payment is due, including in the event such indebtedness is accelerated;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the valuation of our capital stock; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing or future effects of the COVID-19 pandemic and related uncertainties on capital and financial markets. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities for the production of any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on a limited number of third-party contract manufacturers for all of our required raw materials, antibodies, and other biologics for our preclinical research, clinical trials, and if and when applicable, commercial product, and employ internal resources to manage our manufacturing relationships with these third parties.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material cash requirements from known contractual and other obligations primarily relate to our lease obligations, debt, and services provided by our CROs and CDMOs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two leases for our laboratory and office space, which expire in 2025, with an option to extend an additional five years. As of December&#160;31, 2021, we have future minimum rental obligations under these leases of $7.7 million, of which $2.2 million and $5.5 million are current and non-current, respectively. For more information regarding these lease agreements, refer to Note 10 to the consolidated financial statements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended 2020 Loan Agreement, we are required to make only interest payments through 2024, with all principal payments and final fee payments beginning in 2025. As of December&#160;31, 2021, we have an obligation of $96.1 million of long-term debt, including interest, of which $5.7 million and $90.4 million are current and non-current, respectively. For more information regarding the 2020 Loan Agreement, refer to Note 3 to the consolidated financial statements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with CROs related to our ongoing preclinical studies and clinical trials with CDMOs for clinical supplies and manufacturing scale-up activities. These contracts are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately $7.4 million in our consolidated balance sheets for expenditures incurred by CROs and CDMOs as of December&#160;31, 2021. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While these contracts are generally cancellable, some may contain specific activities that involve one or more non-cancellable commitments, including minimum purchase commitments, binding annual forecasts, and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from the cost of work performed to date up to twelve months of future committed manufacturing costs. As of December&#160;31, 2021, the non-cancellable portion of these contracts total in aggregate, excluding amounts recorded in accounts payable and accrued expenses as of this date, approximately $2.4 million. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Collaboration Agreements </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Celgene Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2013, we entered into the Celgene Agreement, pursuant to which we granted Celgene the Celgene Licensed Intellectual Property. Per the terms of the Celgene Agreement, Celgene is operationally and financially responsible for the development, manufacturing and commercialization activities of Celgene Licensed Intellectual Property and any additional related antibodies covered by the Celgene Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As payment for the license granted in the Celgene Agreement, we may be eligible to receive development and regulatory milestones of an aggregate of $934.1 million, assuming the achievement of all potential milestones in the Celgene Agreement, as well as percentage tiered royalties based on future worldwide sales, with rates ranging between the high single-digits and low teens, subject to potential reduction when and if comparable third party products attain certain levels of competitive market share (on a country-by-country basis) and, subject to certain limitations, payments to third parties for third-party intellectual property rights. We are obligated to pay 2% of future amounts received under the Celgene Agreement to advisors who assisted us with the negotiations and other matters in connection with the Celgene Agreement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2seventy bio Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;20, 2018, we entered into an exclusive license agreement with bluebird to research, develop and commercialize CAR T-cell therapies using our proprietary sdAb platform. In November 2021, bluebird assigned the 2018 2seventy Agreement to its affiliate 2seventy, in connection with an internal restructuring and subsequent spin-out of 2seventy. Under the terms of this license agreement, we will provide 2seventy the exclusive worldwide rights to develop, manufacture and commercialize certain cell therapy products containing sdAbs directed to various cancer targets.&#160;In January 2019, we received a $7.0 million payment and pursuant to the license agreement, we are entitled to receive developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single digits. In August 2021, we received a $2.0 million milestone payment under this agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, we entered into the 2020 2seventy Agreement, was also assigned to 2seventy in November 2021 in connection with bluebird&#8217;s internal restructuring and subsequent spin-out of 2seventy. We received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and we are entitled to an upfront option fee for each additional program. We also granted an option in which 2seventy may acquire an exclusive license with respect to all binders and cell therapy products developed under the 2020 2seventy Agreement, which entitles us to additional fees upon exercise of the option. We are also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, pursuant to the option extension terms in the 2020 2seventy Agreement, bluebird requested to extend the option term for one of the initial programs by an additional six months in exchange for an option extension fee of $0.1 million. In August 2021, pursuant to the option exercise terms in the agreement, bluebird exercised its option to exclusively license one of the initial programs in exchange for an option exercise fee of $2.1 million, the payment of which was received in October 2021.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chiesi</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into the Chiesi Option Agreement. Under this agreement, we granted to Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada. Under the terms of the Chiesi Option Agreement, we received a one-time, non-refundable option initiation payment of $10.0 million in August 2019. Pursuant to the Chiesi Option Agreement, we are performing research and development services for Chiesi during the option period, which will continue (unless the Chiesi Option Agreement is terminated earlier by the Chiesi or the Company) until 60 days following the last to occur of (i) the Company&#8217;s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive FDA scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive parallel EMA-HTA scientific advice meeting conducted following completion of such Phase I Clinical Trial.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Chiesi chooses to exercise its option under the Chiesi Option Agreement, we will receive a one-time, non-refundable fee of $12.5 million upon the effective date of the definitive agreement granting Chiesi the exclusive license. If the option is exercised, under the license agreement, we may be entitled to receive specified milestone payments of up to $122.5 million, as well as royalties on future product sales.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaboration Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these contracts, we have entered into strategic collaborations with other third parties, including Phylaxis BioScience, LLC, or Phylaxis, Transcenta, and Elpiscience. For more information regarding these agreements, refer to Note 7 to the consolidated financial statements. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_157"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, all of our revenue has been derived from licenses with collaboration partners and grant awards. We have not generated any revenue from the commercial sale of approved therapeutic products, and we expect our revenue for the next several years will be derived primarily from payments under our current and any future grant awards and agreements with our collaboration partners. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our research and development expenses have related primarily to research activities, including our discovery efforts, and preclinical and clinical development and the manufacturing of our therapeutic candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. We do not track our internal research and development expenses on a&#160;program-by-program&#160;basis as they primarily relate to personnel, early research and consumable costs, which are deployed across multiple projects under development. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">External expenses, consisting of:</span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses incurred in connection with the preclinical development of our programs; </span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical trials of our therapeutic candidates, including under agreements with third parties, such as consultants and CROs; </span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with manufacturing our contract development and manufacturing therapeutic candidates including under agreements with CDMOs; and</span></div><div style="margin-bottom:9.5pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">other external expenses, such as laboratory services related to our discovery and development programs and other shared services, and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Internal expenses, consisting of:</span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; </span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">facilities, depreciation and other expenses, which include direct and allocated expenses for depreciation and amortization, rent and maintenance of facilities; and</span></div><div style="margin-bottom:9.5pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">other internal expenses, such as laboratory supplies and other shared research and development costs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that research and development expense will continue to increase over the next several years as we continue development of our therapeutic candidates currently in clinical stage development, support our preclinical programs, and continue to discover new therapeutic candidates, as well as increase our headcount. In particular, clinical development of our therapeutic candidates, as opposed to preclinical development, generally has higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Moreover, the costs associated with our CDMOs to manufacture our therapeutic candidates and future commercial products is also much more costly as compared to early stage preclinical development. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our therapeutic candidates due to the inherently unpredictable nature of preclinical and clinical development. Preclinical </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which therapeutic candidates to pursue and how much funding to direct to each therapeutic candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each therapeutic candidate&#8217;s commercial potential. We will need substantial additional capital in the future to support these efforts. In addition, we cannot forecast which therapeutic candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical development costs may vary significantly based on factors such as: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">per patient trial costs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of trials required for approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of sites included in the trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the countries in which the trials are conducted </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the length of time required to enroll eligible patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients that participate in the trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of doses that patients receive; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the drop-out or discontinuation rates of patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional safety monitoring requested by regulatory agencies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the duration of patient participation in the trials and follow-up; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of manufacturing of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the phase and development of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety profile of our therapeutic candidates; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties related to the COVID-19 pandemic. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expenses consist primarily of: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in G&amp;A functions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred in connection with accounting and audit services, legal services, commercial and business development and investor relations as well as consulting expense under agreements with third parties, such as consultants and contractors; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for depreciation and amortization, rent and maintenance of facilities, insurance and supplies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our G&amp;A expenses will continue to increase over the next several years as we continue to increase our headcount and incur increased accounting, audit, legal, regulatory, and compliance costs as well as investor and public relations expenses associated with operating as a public company. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense) </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of interest expense on our debt from Oxford and, prior to conversion, interest expense related to the amortization of the debt discount related to the 2019 Note and the 2020 Notes. Other income (expense) also consists of gains or losses on the change in fair value of derivative liabilities and gains or losses on the change in fair value of warrant liabilities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December 31, 2021 and 2020 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations for each of the periods indicated (in thousands, except percentages):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:39.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CHANGE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fee revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,231&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,888&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,657)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,795&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,331&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,202)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,191)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,768)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,124)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,644)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fee Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fee revenue decreased by $5.7 million to $7.1 million during the year ended December 31, 2021 from $12.8 million during the year ended December 31, 2020. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recognized $2.0 million upon the achievement of a milestone under our 2018 2seventy Agreement. Additionally, we recognized an additional $0.1 million and $2.1 million upon the extension of an option and the exercise of an option, respectively, under our 2020 2seventy Agreement. In addition, approximately $2.4 million of license fee revenue recognized was related to our agreements with Phylaxis, while approximately $0.5 million of license fee revenue recognized was related to our effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period under our option agreement with Chiesi. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, $7.4 million of license fee revenue earned was related to our option agreement with Chiesi. Additionally, we achieved a milestone under our agreement with Elpiscience and recognized $2.0 million of revenue related to this agreement. Additionally, we recognized $2.0 million of revenue under our agreements with Phylaxis, $0.4 million under our 2020 2seventy Agreement, and another $1.1 million related to other license revenue from non-affiliates.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue remained consistent, with $0.1 million of revenue earned during each of the years ended December 31, 2021 and 2020. Grant revenue during the year ended December 31, 2021 consisted of revenue earned under our grant with the Department of Defense, or DoD, which was awarded in February 2021. Grant revenue during the year ended December 31, 2020 consisted of revenue earned under our prior grant with the DoD, which was awarded in September 2018 and concluded in September 2020.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary external and internal research and development expenses (in thousands, except percentages):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CHANGE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, depreciation, and facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other internal research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,440&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,495&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,055)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.1 million to $71.4 million during the year ended December 31, 2021 from $73.5 million during the year ended December 31, 2020. The overall decrease in research and development expense was primarily due to the following factors:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial expense increased by $11.3 million, which was primarily attributable to increased CRO costs from the progression of our Phase 1 trials and initiation of our Phase 2 trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturing expense decreased by $28.3 million, which was primarily attributable to the timing of work performed by our CDMO partners for the formulation and manufacturing of our INBRX-101 and INBRX-109 therapeutic candidates during the year ended December 31, 2020;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical expense increased by $1.9 million, which was primarily attributable to the initiation of additional preclinical studies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expense increased by $11.5 million, which was primarily attributable to an overall increase in our headcount, certain salary adjustments, and the issuance of additional stock options; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities expense increased by $0.6 million, which was primarily attributable to an increase in depreciable equipment and an increase in repairs and maintenance expenses; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other research and development expenses increased by $1.0 million which was primarily attributable to an increase in the purchase of lab supplies in relation to our increased preclinical lab activity.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G&amp;A Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expense increased by $5.6 million to $12.4 million during the year ended December 31, 2021 from $6.8 million during the year ended December 31, 2020. Personnel-related expenses increased by $3.7 million during the year ended December 31, 2021 as compared to the year ended December 31, 2020, due to increased headcount during the period, as well as certain salary adjustments, and additional stock-based compensation expense from the issuance of stock options. We also incurred an increase of $1.0 million during the year ended December 31, 2021 in legal fees related to patents as a result of the Company&#8217;s expanding intellectual property portfolio and an increase of $0.2 million of other legal fees during the year ended December 31, 2021. Additionally, the Company incurred an increase in other costs of approximately $0.5 million during the year ended December 31, 2021 associated with expenses of operating as a public company following our IPO in August 2020.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, decreased by $5.6 million to $5.2 million for the year ended December 31, 2021 from $10.8 million for the year ended December 31, 2020. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we incurred $5.4 million of interest related to interest paid and the amortization of debt discounts related to the Amended 2020 Loan Agreement with Oxford. Interest expense was offset in part by $0.2 million of interest income. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, $7.8 million of the total interest expense was related to accrual of interest and amortization of debt discounts on the 2019 Note and the 2020 Notes through their conversion date, in addition to $2.2 million of debt discounts on the 2019 Note and the 2020 Notes accelerated upon the conversion in August 2020. During the year ended December 31, 2020, $0.9 million of the total interest expense was related to the Amended 2020 Loan Agreement with Oxford. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair value of warrant liabilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recorded no gain or loss related to the change in fair value of warrant liabilities since they no longer existed and were reclassified into equity prior to the beginning of the period. During the year ended December 31, 2020, we recognized a loss on fair value of warrant liabilities of approximately $24,000 upon the remeasurement and reclassification of the warrants into equity following our IPO.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair value of derivative liabilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recorded no gain or loss related to the change in fair value of derivative liabilities since they were already extinguished at the beginning of the period. During the year ended December 31, 2020, we recognized a gain of approximately $2.7 million related to the change in fair value of derivative liabilities upon the revaluation of the derivative to zero during the period.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense remained consistent with approximately $2,000 and $3,000 during the years ended December 31, 2021 and 2020. For the years ended December 31, 2021 and 2020, we have applied a 100% valuation allowance against our federal deferred tax assets since it is more likely than not that the deferred tax assets will not be realized.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Equity Method Investment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recorded no loss on our equity method investment since it was already written down to zero prior to the beginning of the period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, we entered into a joint venture with an entity affiliated with ArrowMark Partners, Phylaxis, and received a 10% equity interest in the company. Upon receipt of the equity interest, we established an equity method investment at fair value. The loss on equity method investment during the year ended December 31, 2020 of $0.5 million consists of our share of losses from our investment in Phylaxis, which reduced our equity investment to zero. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_166"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow Summary</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the net cash flow activity for each of the periods indicated&#160;(in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.794%"><tr><td style="width:1.0%"></td><td style="width:66.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(80,323)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(47,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(809)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">166,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,637&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">117,124&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $80.3 million during the year ended December 31, 2021 and consisted primarily of a net loss of $81.8 million, adjusted for non-cash items including stock-based compensation expense of $15.0 million, accretion on our debt discount and the non-cash portion of interest expense related to our debt of $1.2 million, depreciation and amortization of $1.2 million, and non-cash lease expense of $1.5 million. Changes in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating assets and liabilities also contributed to the cash used in operating activities, primarily related to increases in prepaid expenses of $4.0 million and other non-current assets of $1.6 million, as well as decreases in accounts payable of $4.6 million and in accrued expenses of $3.7 million, which are due to the timing of clinical and development activities which were paid during the year. Additionally, the operating lease liability decreased by $1.5 million as a result of lease payments made throughout the year. In addition, deferred revenue decreased by $1.7 million following the recognition of $0.5 million of previously deferred revenue related to our option agreement with Chiesi and $2.4 million of previously deferred revenue related to our agreements with Phylaxis, offset in part by the receipt of $1.25 million of additional deferred revenue under our Phylaxis agreements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $48.0 million during the year ended December&#160;31, 2020 and consisted primarily of a net loss of $76.1 million, adjusted for non-cash items such as accretion on our debt discount and the non-cash portion of interest expense related to our debt of $10.2 million, stock-based compensation expense of $5.0 million, depreciation and amortization of $1.0 million, non-cash lease expense of $1.4 million, change in fair value of derivative liabilities of $2.7 million, and a loss on equity method investments of $0.5 million. Changes in operating assets and liabilities also contributed to the cash used in operating activities, primarily related to increases in accounts payable of $10.4 million and to accrued expenses and other current liabilities of $8.5 million due to an overall higher volume of clinical and development activities, and a decrease in prepaid expenses of $0.7 million. These were offset in part by a decrease in operating lease liability of $1.3 million and a decrease in deferred revenue of $5.6 million as a result of the recognition of $7.4 million of previously deferred revenue related to our option agreement with Chiesi and the addition of $2.3 million of deferred revenue related to our agreements with Phylaxis, adjusted for $0.5 million of non-cash deferred revenue related to the equity interest in Phylaxis.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.8 million and&#160;$1.4 million during the years ended December 31, 2021 and 2020, respectively, and was related to capital purchases, including laboratory equipment and leasehold improvements for our facility in La Jolla, California. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $83.8 million during the year ended December 31, 2021 and consisted primarily of net proceeds of $40.0 million from the Amended 2020 Loan Agreement and proceeds from our ATM offering of $40.2 million, offset in part by the payment of costs associated with the ATM offering of $0.4 million. In addition, we received proceeds of $4.0 million from the exercise of stock options.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $166.5 million for the year ended December&#160;31, 2020 and consisted primarily of the gross proceeds of $136.9 million from our IPO, offset in part by $11.0 million of costs associated with the offering, gross proceeds of $15.0 million from the sale and issuance of the 2020 Notes, and net proceeds of $29.9 million from the Amended 2020 Loan Agreement, consisting of $30.0 million in principal, net of $0.1 million in lender fees, further offset in part by $0.8 million of costs associated with the debt issuance. These proceeds were offset in part by the repayment of $3.6 million of principal and final payments on our previous loan and security agreement, as amended, or the 2015 Loan Agreement. During 2020, we also received $1.9 million in borrowings from the Paycheck Protection Program, or PPP Loan, which was subsequently repaid in full with principal payments of $1.9 million.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_175"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates and Policies </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements and accompanying notes are prepared in accordance with United States generally accepted accounting principles, or GAAP, which requires management to make estimates and assumptions that affect the amounts reported. Management bases its estimates on historical experience, market and other conditions, and various other assumptions it believes to be reasonable. Although these estimates are based on management&#8217;s best knowledge of current events and actions that may impact us in the future, the estimation process is, by its nature, uncertain given that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate, our consolidated financial statements may be materially affected. In addition, if our assumptions change, we may need to revise our estimates, or take other corrective actions, either of which may also have a material effect in our consolidated financial statements. We review our estimates, judgments, and assumptions used in our accounting practices periodically and reflect the effects of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revisions in the period in which they are deemed to be necessary. We believe that these estimates are reasonable; however, our actual results may differ from these estimates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note 1 to our consolidated financial statements included elsewhere in this Annual Report, we believe that the following critical accounting policies and estimates have a higher degree of inherent uncertainty and require our most significant judgments: </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue from our collaboration and licensing agreements with partners, as well as from grants. Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those services. To determine revenue recognition for arrangements we conclude are within the scope of Accounting Standards Codification, or ASC, Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC Topic 606, we perform the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligation(s) in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (v)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identifies those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaborative agreements with partners that typically include one or more of the following: (i)&#160;license fees; (ii)&#160;nonrefundable up-front fees; (iii)&#160;payments for reimbursement of research costs; (iv)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (v)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, we analyze each unit of account within the contract to determine if the counterparty is a customer in the context of the unit of account, in which case we apply the recognition, measurement, presentation, and disclosure requirements of ASC Topic 606. If a unit of account does not represent a transaction with a customer, it represents an arrangement with a collaborator subject to guidance under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC Topic 808. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In applying the principles of ASC Topic 606, we consider a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. We evaluate each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees and non-refundable upfront fees are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, all collaboration and license revenue was within the scope of ASC Topic 808 and/or ASC Topic 606 and recognized accordingly. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 7 to our consolidated financial statements included elsewhere in this Annual Report for additional information on our collaboration and license agreements. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development and Clinical Trial Accruals </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on our behalf, pursuant to development and consulting agreements in place. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expense. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials and other events. If applicable, costs incurred related to the purchase of&#160;in-process&#160;research and development for early-stage </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock-Based Awards and Stock-Based Compensation Expense </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation costs related to stock-based awards, including stock options, under our 2017 Employee, Director and Consultant Equity Incentive Plan to certain of our employees and certain members of our board of directors. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of subjective assumptions to determine the fair value of stock-based awards. These assumptions include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Our board of directors determines the fair value of each share of underlying common stock based on the closing price of our common stock as reported by the applicable trading market on the date of the grant. Our board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of our common stock underlying those options on the grant date. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We estimate the expected term of our stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Due to the lack of company specific historical and implied volatility data, we based our estimate of expected volatility on the estimate and expected volatilities of a guideline group of publicly traded companies. For these analyses, we select companies with comparable characteristics to ours including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. We compute the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of our stock-based awards. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;For the determination of the risk-free interest rates we utilize the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected dividend yield is assumed to be zero as we have never paid dividends and do not have current plans to pay any dividends on our common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in these assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop. See Note 6 to our consolidated financial statements included elsewhere in this Annual Report for information regarding certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted in the periods discussed. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_181"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information with respect to recently issued accounting standards and the impact of these standards, if any, on our consolidated financial statements, refer to Note 1 in our consolidated financial statements in Part II, Item 8 of this Annual Report. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_190"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_193"></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_196">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTMvZnJhZzo3Yzc5NWRmMTc1ZGU0NjhlOTY0NzEyYmVhNmJmYjBjNi90YWJsZToxNDM1OTVlYjY0NTc0MjhhODY0MThjMmJhMDk3ZjI4ZC90YWJsZXJhbmdlOjE0MzU5NWViNjQ1NzQyOGE4NjQxOGMyYmEwOTdmMjhkXzEtMC0xLTEtMzQxMTUvdGV4dHJlZ2lvbjo4ZTAxNWI0NjQ5NWU0OTY2YTBjYjMzNzg5ZTM5MDI3N180Mzk4MDQ2NTExMjY5_d9609a67-e28c-4f41-99e0-27966197da2f">BDO USA, LLP</ix:nonNumeric>; <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTMvZnJhZzo3Yzc5NWRmMTc1ZGU0NjhlOTY0NzEyYmVhNmJmYjBjNi90YWJsZToxNDM1OTVlYjY0NTc0MjhhODY0MThjMmJhMDk3ZjI4ZC90YWJsZXJhbmdlOjE0MzU5NWViNjQ1NzQyOGE4NjQxOGMyYmEwOTdmMjhkXzEtMC0xLTEtMzQxMTUvdGV4dHJlZ2lvbjo4ZTAxNWI0NjQ5NWU0OTY2YTBjYjMzNzg5ZTM5MDI3N180Mzk4MDQ2NTExMjkz_b9e85f22-8f56-45fb-9635-a9229340f83e">San Diego, California</ix:nonNumeric>; PCAOB ID No. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTMvZnJhZzo3Yzc5NWRmMTc1ZGU0NjhlOTY0NzEyYmVhNmJmYjBjNi90YWJsZToxNDM1OTVlYjY0NTc0MjhhODY0MThjMmJhMDk3ZjI4ZC90YWJsZXJhbmdlOjE0MzU5NWViNjQ1NzQyOGE4NjQxOGMyYmEwOTdmMjhkXzEtMC0xLTEtMzQxMTUvdGV4dHJlZ2lvbjo4ZTAxNWI0NjQ5NWU0OTY2YTBjYjMzNzg5ZTM5MDI3N180Mzk4MDQ2NTExMjU0_cb6dc922-4d04-45c1-b5d4-518848ed755f">243</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_196">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_199">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_199">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_202">Consolidated Statements of Operations for the Years Ended December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_202">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_205">Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the Years Ended December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_205">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_208">Consolidated Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_208">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_211">Notes to the Consolidated Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie96bda597eaa4024845d6498a1c78657_211">121</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_196"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board of Directors and Stockholders </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx, Inc. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">La Jolla, California</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Inhibrx, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company's internal control over financial reporting as of December&#160;31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Accruals</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 1 to the consolidated financial statements, the Company recognizes costs incurred for preclinical studies, clinical trials and manufacturing activities as research and development expenses based on its evaluation of its vendors&#8217; progress toward completion of specific tasks. When payment terms under the related contracts do not align with the pattern of costs incurred, the Company is required to estimate the outstanding </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations as of period end. When evaluating the adequacy of the accrued clinical trial liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs, which can involve significant judgments, estimates and specialized knowledge. As of December 31, 2021, the Company recorded $4.5 million in clinical trial accruals.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified clinical trial accruals as a critical audit matter due to the application of significant management judgment over the estimate of services provided as of year-end. Specifically, evaluating the progress or stage of completion of the clinical trial activities under the Company&#8217;s research and development agreements is sensitive to the availability of information from third-party service providers and internal clinical personnel. Additionally, due to the duration of clinical-related development activities, the estimate of the clinical trial progress and the level of effort expended requires judgment based on the nature, amounts, status, and estimated progress of each key activity. Auditing these elements involved especially subjective auditor judgment due to the nature of the audit evidence available to address these matters.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary procedures we performed to address this critical audit matter included:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reviewing the Company&#8217;s contractual agreements with third parties and any change orders to assess the impact to the amounts recorded including changes in scope and timing.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing clinical accrual cutoff and evaluating the completeness of clinical accruals by comparing invoices received by the Company subsequent to December 31, 2021 to the amounts recognized by the Company as of that date and evaluating the Company&#8217;s documentation of trial progress and status, including consideration of measures such as patient enrollment and milestones achieved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing clinical accrual for completeness and accuracy by confirming amounts due at December 31, 2021 directly with clinical research organizations (&#8220;CROs&#8221;) including total expenses incurred for all services provided by the CRO during 2021, and by evaluating publicly available information (such as press releases, investor presentations and public databases that track clinical trials) and board of directors&#8217; materials regarding the status of clinical trials and inquiring of clinical staff outside of finance to gain an understanding of the status of significant on-going clinical trials.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ BDO USA, LLP</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2018. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2022</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_199"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data and par value)&#160;</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzQtMS0xLTEtMjQzNzY_f8d01533-86ff-43c0-b132-706f07f57404">131,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzQtMy0xLTEtMjQzNzY_3d5fa1fb-e413-4604-9614-d0a108217cb8">128,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzUtMS0xLTEtMjQzNzY_beb8e529-84f4-48fc-8065-9801196cc033">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzUtMy0xLTEtMjQzNzY_d98fba2e-2600-4cb4-a2e2-dd33d9890b8e">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzYtMS0xLTEtMjQzNzY_2e4f37f6-5ee3-4787-a07b-9e6a8a6ec75d">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzYtMy0xLTEtMjQzNzY_e4436b1f-ebba-448a-91c4-1849aff56d07">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzctMS0xLTEtMjQzNzY_1989006b-b3fb-422f-84f0-a3f3a7451c1f">6,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzctMy0xLTEtMjQzNzY_0e79f3cb-02b2-4a0d-ac22-adcfd247627c">2,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzgtMS0xLTEtMjQzNzY_4343ae53-a6ff-4532-8f58-883cb8d4638c">139,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzgtMy0xLTEtMjQzNzY_59ac1402-b3f3-40dd-b9b3-ebbcf8c4760e">132,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzktMS0xLTEtMjQzNzY_c97f355d-0bff-4bef-9416-57ac30911228">3,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzktMy0xLTEtMjQzNzY_7f44f5ee-b5cd-4e6e-b764-f407dbabbe8d">3,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzEwLTEtMS0xLTI0Mzc2_839207d0-8b71-414d-a282-59e7becd0351">6,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzEwLTMtMS0xLTI0Mzc2_285dba90-5f40-4227-a1b5-5c8a4837bd33">7,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzExLTEtMS0xLTI0Mzc2_61ff1d3a-82f2-4f56-b53b-29ce351d1c12">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzExLTMtMS0xLTI0Mzc2_6ae18112-6b90-4f1d-bdb1-56473f85815d">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzEyLTEtMS0xLTI0Mzc2_9abe39ec-ed86-45e7-9aca-7d61077d3aec">150,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzEyLTMtMS0xLTI0Mzc2_52434607-a90a-45c3-bc78-74b522602f48">143,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE1LTEtMS0xLTI0Mzc2_93060ed1-4565-4d22-b57e-8a3f94f129f4">9,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE1LTMtMS0xLTI0Mzc2_38ac31fc-a672-4f7e-b2e1-0ef713f9141a">13,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE2LTEtMS0xLTI0Mzc2_40af3288-461a-4fbe-b33e-171085e6c3d6">9,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE2LTMtMS0xLTI0Mzc2_40147474-47a7-4c46-9fe5-79aac10d0c83">13,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE3LTEtMS0xLTI0Mzc2_e9a7ecc4-90a8-42f8-ad92-3d661d59e7f1">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE3LTMtMS0xLTI0Mzc2_79495a16-6447-45ec-9146-e39f8e9297a7">3,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE5LTEtMS0xLTI0Mzc2_7e5b4042-401f-4389-abb6-8ebb0c02f1ba">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE5LTMtMS0xLTI0Mzc2_c22ae9fd-82fc-49a0-9a3d-b622f772d31b">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzIxLTEtMS0xLTI0Mzc2_9fae8799-7a54-4845-a606-08329cdb802a">22,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzIxLTMtMS0xLTI0Mzc2_f9896f00-859b-4f21-95a7-1cfe3c1eb7b5">31,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and including final payment fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI0LTEtMS0xLTI0Mzc2_2d70fb7f-29e5-48ab-a9a5-ba0f9d2a49ca">70,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI0LTMtMS0xLTI0Mzc2_631a498c-4a5f-436c-a409-db055b5551b2">29,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI2LTEtMS0xLTI0Mzc2_da44753f-11aa-4437-a73b-d0973f2e773a">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI2LTMtMS0xLTI0Mzc2_af39e93c-93f9-44be-b60d-fc71a8b2a0a8">6,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI3LTEtMS0xLTI0Mzc2_d10a9338-590e-42cd-9115-e1923e405c6b">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI3LTMtMS0xLTI0Mzc2_deb0041b-3636-4c36-a14d-241362568366">737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI4LTEtMS0xLTI0Mzc2_6b674a56-dff8-4de9-9e31-19d26d53a0a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI4LTMtMS0xLTI0Mzc2_e626bd40-ceb4-459a-a882-a3a521ecb791">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI5LTEtMS0xLTI0Mzc2_62c1a190-d800-4344-9397-6130546defe2">98,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI5LTMtMS0xLTI0Mzc2_b14f0d2f-f8cf-4e45-813c-e11d61122039">68,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMwLTEtMS0xLTI0Mzc2_94fe4402-b20e-4f3e-862f-9f68e876aa3b"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMwLTMtMS0xLTI0Mzc2_afd3d958-dcd5-4351-a381-3a8fb6f62492"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk1Mg_a7630243-f690-45fe-8935-7d650e879392"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk1Mg_bb48a573-2baa-4dec-a1d2-9d07fb7c6fec">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk1Ng_4fc115ca-7e5d-48d4-b71f-f4737d9ebf53"><ix:nonFraction unitRef="shares" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk1Ng_ac5a9893-a016-4c4c-9207-aa2dee16888c">15,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk2MA_271c0a9a-246f-4863-a398-0b239962408c"><ix:nonFraction unitRef="shares" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk2MA_e22ea9c6-04e3-4331-a40b-4d0540c1e7af">no</ix:nonFraction></ix:nonFraction> shares outstanding as of December&#160;31, 2021 and 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTEtMS0xLTI0Mzc2_a1d780d8-e480-49ac-8e0a-8d3057d050aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTMtMS0xLTI0Mzc2_307ab21a-ad40-4ebe-9bfa-0b88e88b4035">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODAwMg_5bc9455d-0ce6-45ff-9066-0e4b53fbc6c0"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODAwMg_856e262b-884a-459e-a8b1-bf16014de57b">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODAwNg_728a6f2f-b6e3-4ab6-b525-c9dbd895c21c"><ix:nonFraction unitRef="shares" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODAwNg_a89da7ca-ff8d-494f-86df-18539c274e69">120,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2021 and 2020; <ix:nonFraction unitRef="shares" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODA5MQ_46d15fae-6677-475c-a16b-d60a6a0742f7"><ix:nonFraction unitRef="shares" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODA5MQ_fe2a905b-0e40-404e-81e9-42dd41ccefd7">38,991,307</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODE2MQ_dedb2eea-16c5-44d4-b3f7-ba9623a4c237"><ix:nonFraction unitRef="shares" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODE2MQ_ff581712-f126-4949-a699-9064fc1386a9">37,712,390</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTEtMS0xLTI0Mzc2_1cb07c4e-f071-4e20-a13d-3f6e95f41fb9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTMtMS0xLTI0Mzc2_42630c33-c4b2-43a2-bb9e-9f0574d9abf7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM1LTEtMS0xLTI0Mzc2_c56642fe-4dba-4a49-988b-d8a435e17cc0">279,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM1LTMtMS0xLTI0Mzc2_8ff4d83d-c43e-47c3-b5a0-dbaad10bbb64">220,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM2LTEtMS0xLTI0Mzc2_fa881fff-1013-4421-ba6f-6e887ffe81ec">227,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM2LTMtMS0xLTI0Mzc2_bd321dd3-df03-4a3b-b186-58e3a384ea95">145,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM3LTEtMS0xLTI0Mzc2_6d436754-9106-42db-9581-a7b661fd5cd9">52,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM3LTMtMS0xLTI0Mzc2_35b40a06-254d-4ca5-acd9-2ea2c3de0c91">75,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities, convertible preferred stock and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM4LTEtMS0xLTI0Mzc2_20c1fa42-3a24-4ae0-b066-6813071bdf7d">150,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM4LTMtMS0xLTI0Mzc2_e0075662-d512-4955-8fc9-0d2351bec620">143,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_202"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER&#160;31, &#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License fee revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f52d64e8c349e58d874face32a65a0_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzQtMS0xLTEtMjQzNzY_20aa4f94-cb0f-4d48-9b07-aa24500f47ce">7,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i250f7e2f155f413297fef8b19d430be2_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzQtMy0xLTEtMjQzNzY_8d1f0308-fae0-4d97-8843-25e7383109f3">12,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1e8d9a53a428686d8938f450e798b_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzUtMS0xLTEtMjQzNzY_9fdef7c9-fe6d-41a7-bc12-a297c536ef3f">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f5f2867b4374b8392c13581eb930e33_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzUtMy0xLTEtMjQzNzY_b25842b4-a2ed-4e36-99d5-f5dd075aca7b">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzYtMS0xLTEtMjQzNzY_dd3f084d-06dd-4899-9817-70b82ab64cae">7,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzYtMy0xLTEtMjQzNzY_da170539-af5c-40d9-9221-456fc74b5d59">12,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzgtMS0xLTEtMjQzNzY_6caac2cb-646c-4717-98ad-8ae23646a30a">71,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzgtMy0xLTEtMjQzNzY_2328fb62-fd66-4b50-ad78-c73074731846">73,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzktMS0xLTEtMjQzNzY_d8898142-19f9-4601-a3f1-6d6208a1f437">12,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzktMy0xLTEtMjQzNzY_db28cd14-e0fe-4a56-9a08-410db238fc3c">6,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzExLTEtMS0xLTI0Mzc2_0f826bd9-d962-4beb-80da-656638239936">83,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzExLTMtMS0xLTI0Mzc2_123a699e-8747-418f-b352-08071d062bba">80,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzEyLTEtMS0xLTI0Mzc2_9746100e-05ce-4d01-ae5e-6c4c9b49cc04">76,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzEyLTMtMS0xLTI0Mzc2_86a06122-7d05-4142-ae1f-10b60693a8c5">67,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE0LTEtMS0xLTI0Mzc2_c145ca91-7800-4532-a148-1f7ba9af817b">5,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE0LTMtMS0xLTI0Mzc2_a4ec3bbc-525b-4624-ad03-65dbc5774bd7">10,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE1LTEtMS0xLTI0Mzc2_faf72f02-587c-4dd6-843a-0c28e0e253da">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE1LTMtMS0xLTI0Mzc2_b06011bd-973d-4c64-a64a-963e3ebb0a52">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE2LTEtMS0xLTI0Mzc2_ecd42d98-3c89-4157-9011-2833b584360e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE2LTMtMS0xLTI0Mzc2_8d9cec93-10c6-40ed-b9a3-a6c4d40c7e51">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE3LTEtMS0xLTI0Mzc2_4ce94d8e-1579-4188-8776-25531e689b5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE3LTMtMS0xLTI0Mzc2_712bfc5d-ff21-4bb6-a3b4-68df3dee6921">2,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE4LTEtMS0xLTI0Mzc2_aa757c30-b092-4297-b9c2-c3cf0330496a">5,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE4LTMtMS0xLTI0Mzc2_b1b73130-a961-4e21-a7f2-7fb5908a2dd9">8,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE5LTEtMS0xLTI0Mzc2_1f739c15-f2b9-4a54-bdc3-c9987051f59e">81,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE5LTMtMS0xLTI0Mzc2_499966f6-a4ec-4d95-b802-29409b1b2819">75,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIwLTEtMS0xLTI0Mzc2_b416fc1f-824e-432c-9ac2-506bb592a578">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIwLTMtMS0xLTI0Mzc2_abdee66d-f137-408a-989f-efa11d27c4dc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIxLTEtMS0xLTI0Mzc2_e43ffd13-000a-477a-b1d7-838a4f96e6ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIxLTMtMS0xLTI0Mzc2_8deecd1a-c684-4380-a4c8-d448eba3e153">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIyLTEtMS0xLTI0Mzc2_f1d3706a-3766-4b58-87ea-0ddafd0b29d3">81,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIyLTMtMS0xLTI0Mzc2_40b729f2-fa28-4426-a9f0-1050e6372bb6">76,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIzLTEtMS0xLTI0Mzc2_2bf21325-3516-4d9b-a757-ecb2668d8662"><ix:nonFraction unitRef="usdPerShare" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIzLTEtMS0xLTI0Mzc2_b1a8a90d-7ab1-45a9-9af7-d0b3dde573d2">2.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIzLTMtMS0xLTI0Mzc2_2048ec75-6059-40b4-9d0c-66ca44284d4a"><ix:nonFraction unitRef="usdPerShare" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIzLTMtMS0xLTI0Mzc2_c51184a3-5ed1-40bf-8833-74d71aee3a4d">3.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzI0LTEtMS0xLTI0Mzc2_67f50eef-1540-4c2a-8786-6360aece30ef"><ix:nonFraction unitRef="shares" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzI0LTEtMS0xLTI0Mzc2_7434fe73-a0ab-4823-911c-6b296718d0ad">38,010</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzI0LTMtMS0xLTI0Mzc2_6776022e-c6d4-491f-a25a-8835ec124c38"><ix:nonFraction unitRef="shares" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzI0LTMtMS0xLTI0Mzc2_68c990b2-0790-4e35-bca2-e1720de7a1c5">25,261</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_205"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"></td><td style="width:23.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.272%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.272%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Convertible Preferred Stock<br/>(Shares)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Convertible Preferred Stock<br/>(Amount)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock<br/>(Shares)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock (Amount)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity <br/>(Deficit)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25366f43bada4f5b9d53d088a682e118_I20191231" decimals="-3" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTEtMS0xLTI0Mzc2_56833aa3-5b31-4277-b7ab-0c53f674e8ef">12,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25366f43bada4f5b9d53d088a682e118_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTMtMS0xLTI0Mzc2_f2492fca-80b1-438d-801a-76bf271aac5b">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie64d22ae265b44358c9e947a1a1b1c0c_I20191231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTgtMS0xLTI0Mzc2_38a2c5af-1328-4b80-879f-316e27e54905">18,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64d22ae265b44358c9e947a1a1b1c0c_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTEwLTEtMS0yNDM3Ng_cec5aa50-2310-42c6-85c5-2ab475020a13">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6373c936330246fe88c309a40939f56e_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTEyLTEtMS0yNDM3Ng_359564b1-0f07-4f33-804a-67e8fa0c292c">24,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3c545895ca04258955cb754430080ec_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTE0LTEtMS0yNDM3Ng_43737e10-cbf3-4fe8-b63f-33b6276ca82e">69,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25366f43bada4f5b9d53d088a682e118_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTIwLTEtMS0yNDM3Ng_f7949cd4-ab87-47bc-beed-28fd21bfcd6d">93,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id881f495b72943148f25b6840685d537_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIzLTEyLTEtMS0yNDM3Ng_a7e92fc1-b62c-4687-9f35-3addb50676a9">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIzLTIwLTEtMS0yNDM3Ng_fe06f0ff-52a7-4633-82c5-b6842069b886">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Notes - beneficial conversion feature</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ec9949e1e248ccab71a11e6c1074bd_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI0LTEyLTEtMS0yNDM3Ng_e70152b7-15a5-422c-b1e1-fe4f4d9e9de8">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50251df3c1c54c87b2d175fa7d628143_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI0LTIwLTEtMS0yNDM3Ng_040cdc9f-1306-4d36-acc4-0dfab44357b6">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bb7bb32c3f343c8a327751ee96ff5a5_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI1LTgtMS0xLTI0Mzc2_88da687b-e502-4b36-828f-0747712edc1c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id881f495b72943148f25b6840685d537_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI1LTEyLTEtMS0yNDM3Ng_dbbe22b3-6941-4f02-9ff7-97a6bae064ae">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI1LTIwLTEtMS0yNDM3Ng_2c5f41ba-d9fa-448f-ba57-25477a44b67b">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in IPO, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e88fbcb34b14703a4c85b9f232b78bb_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI2LTgtMS0xLTI0Mzc2_608e21fc-19d4-4dcd-9d91-c3bd88ebf5ee">8,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e88fbcb34b14703a4c85b9f232b78bb_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI2LTEwLTEtMS0yNDM3Ng_dcbcc3ee-c3af-43b2-86dc-9c30bdc40f2a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id726b7dd9036485d8c990a47cc6bd3d2_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI2LTEyLTEtMS0yNDM3Ng_4e507d2e-c9c7-4822-9144-828f5b0269d4">125,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida37a3d3907b43bd835289673510cd62_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI2LTIwLTEtMS0yNDM3Ng_f47da7a9-3ae5-47b4-841f-8bc277b20262">125,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in conversion of preferred shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="inbx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTEtMS0xLTI0Mzc2_1c4425b5-d757-492d-a9e7-1cca7f6d3818">12,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="inbx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTMtMS0xLTI0Mzc2_79d57f35-046c-4c62-8661-0ce987738ff6">59,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0952c59ab2f14ce9a7f5f4f4bab1f608_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTgtMS0xLTI0Mzc2_78f7e458-a158-4051-8973-e7d00807d76c">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0952c59ab2f14ce9a7f5f4f4bab1f608_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTEwLTEtMS0yNDM3Ng_e8605529-c2ff-4685-89a3-a62e3b9acf71">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceb6a7800114c0f80544f3e11e04a59_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTEyLTEtMS0yNDM3Ng_bf8144cf-3ce8-4e24-9c7b-0eb30e576ab7">59,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72afbdbf0e414c5caaa6e4ab484a62f0_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTIwLTEtMS0yNDM3Ng_2befea71-8efd-4bc1-8750-51903ec5a4cc">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in conversion of the 2019 Note and the 2020 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9f6557dde914ba196b748270c390563_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI4LTgtMS0xLTI0Mzc2_87967b4a-9285-45fa-885a-3e0c49f04181">4,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e858246ea634ea3904ae0efa91f93ed_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI4LTEyLTEtMS0yNDM3Ng_ff41a2d8-28de-40d7-9fbb-5e9634678f18">59,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfd538e45ac47328f0a920dcb4c0614_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI4LTIwLTEtMS0yNDM3Ng_77148d2c-3acf-4376-88a9-5f8c94e7c444">59,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversal of unamortized BCF on the 2019 Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9db515ef6fb84613872d16729bbfc6bb_D20200101-20201231" decimals="-3" name="inbx:ReversalOfUnamortizedBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI5LTEyLTEtMS0yNDM3Ng_b933cb83-4e6a-42bc-8044-65f985288d9b">5,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c768226360e440e85d40981d2a3a347_D20200101-20201231" decimals="-3" name="inbx:ReversalOfUnamortizedBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI5LTIwLTEtMS0yNDM3Ng_7e47df58-d307-4ce4-ad11-5eeacfeaf5b8">5,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reversal of unamortized BCF on the 2020 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9ec9949e1e248ccab71a11e6c1074bd_D20200101-20201231" decimals="-3" name="inbx:ReversalOfUnamortizedBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMwLTEyLTEtMS0yNDM3Ng_93f8cd71-11fb-41b0-b54e-7e40016e2b6c">2,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50251df3c1c54c87b2d175fa7d628143_D20200101-20201231" decimals="-3" name="inbx:ReversalOfUnamortizedBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMwLTIwLTEtMS0yNDM3Ng_776bafcc-72b5-48f3-8bb4-131e0c25820e">2,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities into equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id881f495b72943148f25b6840685d537_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMxLTEyLTEtMS0yNDM3Ng_f21317d4-1d30-4c4a-965d-0007dc2b2c2e">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMxLTIwLTEtMS0yNDM3Ng_7cab7e6b-9382-4852-8dca-bba5fb30a4c2">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaf0841293054a07bd73deb9e8af0344_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMyLTE0LTEtMS0yNDM3Ng_033c1e07-3301-4cb6-8881-6fcc70b3ab6d">76,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMyLTIwLTEtMS0yNDM3Ng_5cd29707-8ae1-42c7-ad17-c1c82a01891c">76,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTEtMS0xLTI0Mzc2_cfb98f2d-eaf2-41d4-8052-9f633385e122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTMtMS0xLTI0Mzc2_608afdde-6c8d-459a-83b9-57cf1e345205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i932ae73c06e44acab39c531ada30fa22_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTgtMS0xLTI0Mzc2_1a5c54e2-9213-42f3-84a4-39bd92578e6b">37,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i932ae73c06e44acab39c531ada30fa22_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTEwLTEtMS0yNDM3Ng_7f3754cc-3828-462b-af20-095e26c4e74e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722a3c1036664a1db19bf1f1b8c8ef4c_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTEyLTEtMS0yNDM3Ng_fd96bac4-b55f-4e60-a219-f558dd870525">220,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d39a168fc3a432aa5b6c0e2880ae017_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTE0LTEtMS0yNDM3Ng_a7f3d144-b140-4324-9fe4-4e7f023edea5">145,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTIwLTEtMS0yNDM3Ng_86ebe2e6-43e4-494a-a81f-afd57930a5e1">75,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782f77ab577843fa872a7b5b9541a230_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM0LTEyLTEtMS0yNjA4MA_9ce46dd1-d9e7-4e96-baab-bb79b8e72a83">15,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM0LTIwLTEtMS0yNjA4MA_9c84ffed-0a26-4003-b2a2-d351e9cf7816">15,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43e54c84aae74e828b9b94427b981d3e_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM1LTgtMS0xLTI2MDg0_35f17b4d-0996-4e84-8e58-64be046f1aa6">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782f77ab577843fa872a7b5b9541a230_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM1LTEyLTEtMS0yNjA4NA_8e67f535-cf32-4771-97bc-8c2dd08a9e11">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM1LTIwLTEtMS0yNjA4NA_a4c349ce-630e-42ca-87e5-4a0ec9bc713f">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43e54c84aae74e828b9b94427b981d3e_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM2LTgtMS0xLTMyOTgy_1549baa4-9f9c-4f63-b225-7a6c1ac19b6c">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782f77ab577843fa872a7b5b9541a230_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM2LTEyLTEtMS0zMjk4Mg_448b4478-5b2f-485f-928c-bd13f980da8f">39,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM2LTIwLTEtMS0zNDE4Mw_41d94dbe-7128-49ae-b4c5-24e036e76f2f">39,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5392c3f3d956465e9c4f2e9ee08ac5b3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM2LTE0LTEtMS0yNjA4Ng_552eab86-162f-48ae-b47f-67b03569a651">81,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM2LTIwLTEtMS0yNjA4Ng_4281898c-aed5-4608-8523-5850efca2187">81,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTEtMS0xLTI2MDg4_53143cc7-8a5f-4084-8c96-12d870e7dd3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTMtMS0xLTI2MDg4_0b31d127-2103-4b44-b691-6238aa47f8ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc6061b1a5654bd1a013f69ed4b79e27_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTgtMS0xLTI2MDg4_fed5f7ec-ae43-4972-8cbc-7e2d0cd5a6d7">38,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6061b1a5654bd1a013f69ed4b79e27_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTEwLTEtMS0yNjA4OA_4cff8f8a-d640-4f9e-9d03-4c904b67fbae">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6686e2594645e0b104bd30c79c6ce2_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTEyLTEtMS0yNjA4OA_831339de-9a6f-4510-a8f9-13402776843e">279,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c90406be53b4899a32eb757c4b6aa8e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTE0LTEtMS0yNjA4OA_18017490-073f-4c95-b6a2-acb5bb730632">227,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTIwLTEtMS0yNjA4OA_12d50485-d5c3-4670-9f6c-a8936c2279ff">52,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_208"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands) </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER&#160;31, &#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQtMS0xLTEtMjQzNzY_2ab95fc3-1b2b-4164-98c1-dbf1befe0850">81,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQtMy0xLTEtMjQzNzY_c56c451d-ea05-4a42-b8df-2264e1e133f8">76,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYtMS0xLTEtMjQzNzY_89609c8d-57ba-45e9-bab3-e0e67dea1bc2">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYtMy0xLTEtMjQzNzY_b5d851d6-c18d-40cc-9b0f-8cb03e306ffe">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of debt discount and non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzctMS0xLTEtMjQzNzY_eeff1a96-1518-46a5-a3b5-6f786092110e">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzctMy0xLTEtMjQzNzY_11c5f1f4-6315-4230-a3c4-e83e76ba0915">10,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzgtMS0xLTEtMjQzNzY_bf3e2e16-0335-4377-bc91-19439f9aa517">15,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzgtMy0xLTEtMjQzNzY_c585d573-73aa-4852-8dfc-15fa91311816">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:NoncashOperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzktMS0xLTEtMjQzNzY_711e910c-60db-4e56-a8ce-c719c0f9feec">1,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:NoncashOperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzktMy0xLTEtMjQzNzY_2bfa7f53-d1a4-40d7-be29-63145d778eac">1,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on disposal of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEwLTEtMS0xLTMzMDIz_bf872b43-a409-4547-8bf9-fa1ff01216ab">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEwLTMtMS0xLTMzMDIz_57555ad7-992c-42c7-981e-d6e5d1da8e52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEwLTEtMS0xLTI0Mzc2_3cb84be3-19df-483c-9d34-f1143dfdf798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEwLTMtMS0xLTI0Mzc2_2520a3b2-63aa-4259-a41f-a21b907bc5a6">2,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzExLTEtMS0xLTI0Mzc2_b42b9f33-8042-4a65-92c3-677f13ac22f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzExLTMtMS0xLTI0Mzc2_5d663d31-430e-4e9e-b81e-eabd0eec38bb">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEyLTEtMS0xLTI0Mzc2_83e96c29-ac8e-48e9-9785-e21a56ae01ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEyLTMtMS0xLTI0Mzc2_7237506e-f82a-4f14-b7f3-074a97cd5998">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE2LTEtMS0xLTI0Mzc2_bf8439b2-6a9e-4dd3-9dce-69838a3bc19b">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE2LTMtMS0xLTI0Mzc2_4f81ea1f-c764-4449-8b42-4ca965aa6d67">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE3LTEtMS0xLTI0Mzc2_edac7f8e-90ec-4cda-8ec0-b65ce3a3b87d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE3LTMtMS0xLTI0Mzc2_5fb6719a-0b18-48ce-a43d-ca3f60de37a6">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE4LTEtMS0xLTI0Mzc2_b2f12c40-0707-489a-a4c9-e0c304c84cf2">4,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE4LTMtMS0xLTI0Mzc2_a7ad5230-99dd-4c44-a969-180e35b0a0af">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE5LTEtMS0xLTI0Mzc2_4ef84dc1-6d22-45d2-84c4-e514e7785dc6">1,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE5LTMtMS0xLTI0Mzc2_96c9338c-d856-4de2-9c87-8160c4679533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIwLTEtMS0xLTI0Mzc2_99faead5-9239-487a-8d09-bf90449a7435">4,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIwLTMtMS0xLTI0Mzc2_d5ef7f14-4de9-4946-a7e0-51d49dd431dc">10,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIxLTEtMS0xLTI0Mzc2_44a5ec9a-447f-499e-8c8b-53fefde5ffca">3,736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIxLTMtMS0xLTI0Mzc2_58fa5538-7eb4-463d-b265-5623a30c338b">8,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIyLTEtMS0xLTI0Mzc2_c937ea92-be41-4ad2-8164-fabb79795dce">1,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIyLTMtMS0xLTI0Mzc2_20d07a4e-1624-4601-ad5c-6f816399f124">1,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="inbx:IncreaseDecreaseContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIzLTEtMS0xLTI0Mzc2_f58fafc5-0088-429e-9198-9b45fec41126">1,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="inbx:IncreaseDecreaseContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIzLTMtMS0xLTI0Mzc2_65e6441b-52ee-4a68-81c1-73cdfe476a81">5,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="inbx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI0LTEtMS0xLTI0Mzc2_de158cb7-07c6-43ac-a6f6-28f16fc92538">627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="inbx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI0LTMtMS0xLTI0Mzc2_4173e6d9-93f6-405e-aa52-adaa5ea9a4db">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI1LTEtMS0xLTI0Mzc2_4981b0d0-19cf-4849-9610-3f418d80a83b">180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI1LTMtMS0xLTI0Mzc2_1a22cf35-da30-40b9-b0fd-7516aed91d19">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI2LTEtMS0xLTI0Mzc2_3bfb5f0c-32a9-43f2-88ca-37ab56f486a9">80,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI2LTMtMS0xLTI0Mzc2_89723bd3-081c-4ce9-9369-abb0f7c63dca">47,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI4LTEtMS0xLTI0Mzc2_d61b5b91-5f21-49c6-97d8-2b6f3a2999bd">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI4LTMtMS0xLTI0Mzc2_aa1bd5c9-5817-418f-803f-31650cc6c318">1,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI5LTEtMS0xLTMzMDcy_cda064eb-e539-4d3d-9dff-65c2f033cfed">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI5LTMtMS0xLTMzMDcy_90b3b821-c314-4822-81d3-5658e5f9e3c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI5LTEtMS0xLTI0Mzc2_74d57207-eb0c-43aa-bf8e-79572c242836">809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI5LTMtMS0xLTI0Mzc2_9931eadb-cd3c-4722-b505-9fe86e3c4108">1,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from ATM offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f87c3827874f3ca0e19457894ec414_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMyLTEtMS0xLTMzMTM1_802bac6f-027c-4412-bb22-5a3e8c1ab938">40,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d258a97d4684eaba513930d94729cd8_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMyLTMtMS0xLTMzMTM1_9fdd1108-0892-4131-af7c-f7dfd6a816c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs associated with ATM offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1f87c3827874f3ca0e19457894ec414_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMzLTEtMS0xLTMzMTM1_66545bc5-a8fd-4792-80dc-830a02d23fab">382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d258a97d4684eaba513930d94729cd8_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMzLTMtMS0xLTMzMTM1_b5df1e0a-e9f8-412a-85f7-4c248c2a2762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM0LTEtMS0xLTMzMTEw_9f78cbe7-d83d-47fe-a827-633db1bcd6cf">39,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM0LTMtMS0xLTMzMTEw_594a53b9-63ad-4be9-a966-459b2d0687d2">29,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of fees associated with debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:PaymentsOfDebtIssuanceCostsSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM1LTEtMS0xLTMzMTEw_2d73e8c0-9bb9-4ae6-b8de-e73498e3c402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:PaymentsOfDebtIssuanceCostsSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM1LTMtMS0xLTMzMTEw_6a48cacb-e2fa-467b-9a2c-46bd929d9d9d">786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM2LTEtMS0xLTMzMTE2_efeeefdd-7c1d-4128-bb22-ae35d012b74e">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM2LTMtMS0xLTMzMTE2_dbe586e2-d035-42cf-89c2-b43ee3210033">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from initial public offering, gross</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c9a266f60c4664bc65b6877237a861_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMxLTEtMS0xLTI0Mzc2_9a21cf2e-ea1f-4d47-8cf9-fb667783922c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida37a3d3907b43bd835289673510cd62_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMxLTMtMS0xLTI0Mzc2_b5ec95c7-2349-4f49-be13-64bcea298a1a">136,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs associated with initial public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c9a266f60c4664bc65b6877237a861_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMyLTEtMS0xLTI0Mzc2_bf54adde-0ea7-441f-85c3-b04ad690a5cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida37a3d3907b43bd835289673510cd62_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMyLTMtMS0xLTI0Mzc2_cb0770fa-9181-4398-a63d-efd139d1b4d4">10,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMzLTEtMS0xLTI0Mzc2_cb34b97e-56d4-4017-8b53-d19c83551b75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMzLTMtMS0xLTI0Mzc2_5ad32af1-4dfc-4139-a2bd-b4c1e43913d2">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of principal on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM3LTEtMS0xLTI0Mzc2_46f06023-0265-4914-a486-0bdc13705d31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM3LTMtMS0xLTI0Mzc2_f2d5580e-57e6-453f-9b21-9bc7100dfd54">2,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Final payment on debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:RepaymentsOfSecuredDebtFinalBalloonPayment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM4LTEtMS0xLTI0Mzc2_be2c43b5-c21a-400c-804a-9807e7a8fa4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:RepaymentsOfSecuredDebtFinalBalloonPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM4LTMtMS0xLTI0Mzc2_792baa91-fe2e-4bb0-b05f-3c2e04c6408c">1,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the Paycheck Protection Program loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM5LTEtMS0xLTI0Mzc2_e0c09884-906a-44dc-bd90-ee9371d36b1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM5LTMtMS0xLTI0Mzc2_e68f2e5c-1ff8-4e0e-8b10-e9a54808f383">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of principal on the Paycheck Protection Program loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQwLTEtMS0xLTI0Mzc2_4fffeb35-6607-41d5-a6b8-4c5a1a4ca273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQwLTMtMS0xLTI0Mzc2_ecff85e3-9862-4e28-867e-8cb1deac510d">1,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ0LTEtMS0xLTI0Mzc2_962ae8fb-2af8-4860-8c54-3b471bb811c9">83,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ0LTMtMS0xLTI0Mzc2_0ab98985-9972-4661-95ff-df7ccb006554">166,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ1LTEtMS0xLTI0Mzc2_ba2d2bdc-a059-4a04-9ba4-78af8a1366f7">2,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ1LTMtMS0xLTI0Mzc2_d0c00be6-dc6e-41c8-beda-7908aab804a3">117,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ2LTEtMS0xLTI0Mzc2_e1241bf2-27e7-40d3-bf8c-6516e3dcd451">128,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25366f43bada4f5b9d53d088a682e118_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ2LTMtMS0xLTI0Mzc2_e98534b4-6c71-4bf1-b5d6-66f0435f13bb">11,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period </span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ3LTEtMS0xLTI0Mzc2_c2dfc088-df47-46cb-90f8-6cd33322cdd2">131,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ3LTMtMS0xLTI0Mzc2_b8d2bf69-83c4-41c1-8ecb-47fa6aaa0c81">128,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzUwLTEtMS0xLTI0Mzc2_283b1dbb-366c-4edc-8f3b-8a7d3a69deea">3,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzUwLTMtMS0xLTI0Mzc2_0dba536f-2fe3-4283-9615-fadb575f29f7">504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzUxLTEtMS0xLTI0Mzc2_eebc3837-1212-4420-b408-7dc08a66defd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzUxLTMtMS0xLTI0Mzc2_80e96030-451b-48c4-8d2f-7123ff654081">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATM offering costs included in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU4LTEtMS0xLTMzMjc2_16330ade-d1d2-4cd4-b23d-03bda264f509">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU4LTMtMS0xLTMzMjc2_8552427e-8941-4ff8-8e8c-596b77f2dbdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATM offering costs reimbursable in accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:AtTheMarketOfferingCostsReimbursableInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU5LTEtMS0xLTMzMjc2_20a7d076-8f82-4f45-bb8a-1c0372bb6045">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:AtTheMarketOfferingCostsReimbursableInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU5LTMtMS0xLTMzMjc2_d0d21418-2588-4002-b000-6ad2ccf49f2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable for purchase of fixed assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:CapitalExpendituresIncurredButNotYetPaidReleased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYwLTEtMS0xLTMzMjQ3_85c1b52c-1647-4be1-92d2-e342f5723f72">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:CapitalExpendituresIncurredButNotYetPaidReleased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYwLTMtMS0xLTMzMjQ3_5c5e092f-f2c8-4c7d-8808-9e2d2159fce4">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU0LTEtMS0xLTI0Mzc2_a2a429f6-42b9-41fc-8d73-0331ed8c377d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU0LTMtMS0xLTI0Mzc2_f4b95033-127f-41fd-86bc-66a3ffeb0add">59,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of the 2019 Note and the 2020 Notes to common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU1LTEtMS0xLTI0Mzc2_4acbae8a-78e3-4e54-a069-fb1c51ef39e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU1LTMtMS0xLTI0Mzc2_1eee5565-d22a-45f8-a1dc-b15fdabb0aac">59,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount arising from convertible note beneficial conversion features and reversal of beneficial conversion features</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU2LTEtMS0xLTI0Mzc2_9aaf029e-d7a5-4488-8a4d-332245cc531e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU2LTMtMS0xLTI0Mzc2_ce35bedf-77d0-4b69-b85b-a6c6a54af0ef">4,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities arising from obtaining right-of-use assets </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU3LTEtMS0xLTI0Mzc2_92ea2364-c7f8-49ab-b4df-d589fef7bd1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU3LTMtMS0xLTI0Mzc2_5aef346a-695e-4d61-a93c-1ca0afe7c36e">1,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities arising from the issuance of the 2019 Note and the 2020 Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU4LTEtMS0xLTI0Mzc2_64799b1e-2d97-4ced-b599-f0943d199848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU4LTMtMS0xLTI0Mzc2_f85f4402-ff9b-44b1-99da-bd52783970cd">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:NonCashEstablishmentOfEquityMethodInvestment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYwLTEtMS0xLTI0Mzc2_6f1ad534-7992-4e75-b0fa-3bbeaa43cd02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:NonCashEstablishmentOfEquityMethodInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYwLTMtMS0xLTI0Mzc2_fce4f6f0-20a7-48d8-9540-9063a802d73f">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities to equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:ReclassificationOfWarrantLiabilitiesToEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYxLTEtMS0xLTI0Mzc2_91baf339-eb2e-43e0-aad0-2ce5080df2d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:ReclassificationOfWarrantLiabilitiesToEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYxLTMtMS0xLTI0Mzc2_91b597a2-d25f-448d-a667-e095004f9396">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liabilities issued to lender in conjunction with 2020 Loan Agreement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYyLTEtMS0xLTI0Mzc2_7e25fcdc-2c45-46bf-958a-e9c0d204c1e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYyLTMtMS0xLTI0Mzc2_86610053-567d-4139-846f-4e8470dfd10b">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_211"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx, Inc. </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div id="ie96bda597eaa4024845d6498a1c78657_214"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzUw_537f7010-8d93-464e-b8e1-b2c48d0c6661" continuedAt="i1ea198a6220f4ab6857fd428c21830ae" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </ix:nonNumeric></span></div><ix:continuation id="i1ea198a6220f4ab6857fd428c21830ae" continuedAt="i365ceb2758da454aba6bb5da7cf00f10"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx, Inc., or the Company, or Inhibrx, is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines target biology with protein engineering, technologies, and research and development to design therapeutic candidates. The Company&#8217;s current pipeline is focused on oncology and orphan diseases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, risks associated with preclinical studies, clinical trials and regulatory applications, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company&#8217;s therapeutic candidates currently under development will require significant additional research and development efforts, including clinical and preclinical testing and marketing approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;21, 2020, the Company completed its initial public offering, or IPO, in which it sold <ix:nonFraction unitRef="shares" contextRef="i79c55f122bda4d359fc762cce6002cc9_D20200821-20200821" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTM1MTY_0de8830d-07a7-4122-8798-f7573c8d89e8">8,050,000</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8177b8ffee4c4ea998a952b70d65e0ef_I20200821" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTM1Njc_694a5e6a-5504-4ab1-a635-29e660031745">17.00</ix:nonFraction> per share. Net proceeds from the IPO were $<ix:nonFraction unitRef="usd" contextRef="i79c55f122bda4d359fc762cce6002cc9_D20200821-20200821" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTM2MTM_63b8fe4d-7673-4b1b-a9e5-912f24250624">125.9</ix:nonFraction> million, net of underwriting discounts, commissions, and offering costs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, each of the following occurred in connection with the completion of the IPO:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conversion of the 2019 Note and the 2020 Notes (each as defined below) into <ix:nonFraction unitRef="shares" contextRef="ib6cea0c2ca9441f79fe37eb6f7844b1d_D20200821-20200821" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzIwMDA_4e4d48e6-e137-4314-aaee-bdbfc49fde61">4,294,603</ix:nonFraction> shares of the Company&#8217;s common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conversion of all outstanding convertible preferred stock into <ix:nonFraction unitRef="shares" contextRef="iad4a6f2ea563431298cac685298bcd91_D20200821-20200821" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzIxMDg_9e507718-a3cc-480a-b4dc-ed3918134c83">7,211,086</ix:nonFraction> shares of the Company&#8217;s common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adjustment of an outstanding warrant to purchase convertible preferred stock into a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzIyNTc_88f4ebdd-6741-486c-96ed-d70814645467">7,354</ix:nonFraction> shares of the Company&#8217;s common stock; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amendment and restatement of the Company&#8217;s certificate of incorporation, authorizing <ix:nonFraction unitRef="shares" contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzIzOTE_84b4e5ed-84b9-4d4d-8f75-13fdef2b72b5">120.0</ix:nonFraction> million shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzI0MjE_5a8e9640-3470-4e88-95f6-6fbf0f4fafce">15.0</ix:nonFraction> million shares of preferred stock.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;11, 2020 the Company effected a one-for-1.7382 reverse stock split of the Company&#8217;s common stock, or the Reverse Stock Split. The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion prices of the convertible preferred stock and convertible notes have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY1_371a2a47-9ab3-44fa-83b4-c94886d1c9cc" continuedAt="i2ee9d3bb6f7948ceaca5948d91dc1d95" escape="true">Basis of Presentation </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2ee9d3bb6f7948ceaca5948d91dc1d95">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzYw_f2aff4ac-9cf7-4011-97e5-8479cf27da13" continuedAt="ib02f39f871e244bf8771d689ef5889c8" escape="true">Principles of Consolidation </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib02f39f871e244bf8771d689ef5889c8">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP.&#160;All intercompany accounts and transactions have been eliminated in consolidation.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i365ceb2758da454aba6bb5da7cf00f10" continuedAt="ia9052b89c6b24fa6a619d85589847b41"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="inbx:LiquidityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzcw_b0d5cc82-0534-4c30-b722-a479c53ba6b3" continuedAt="if7f02a1773f24977aaa1ca40d2b10b16" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzM1OTA_58bd9d43-1bc2-4521-bc9f-3d18870a464b">227.1</ix:nonFraction> million and cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzM2MjY_8392cddc-3fb6-4ccc-b5e8-e16df61886c6">131.3</ix:nonFraction> million. From its inception and through December&#160;31, 2021, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company&#8217;s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, and other similar arrangements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5, the Company entered into the Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="if28c89b4ce594ec18c2baa17251f5398_D20210901-20210930" decimals="-5" name="inbx:SaleOfStockCommonStockAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MjE3Njc_9694dfcc-7e95-43be-bab8-04898bdd5b80">200.0</ix:nonFraction> million through the Sales Agent, or the ATM Offering. As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i64129936be0b412b8e1d86243a3cc9f1_I20211231" decimals="INF" name="inbx:SaleOfStockSharesCommonStockSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTkwNjg_f2b44f6f-e48a-4103-abd8-da74b7a24372">921,042</ix:nonFraction> shares have been sold pursuant to the Sales Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i90dfb0c9e29b4454ae5d3269b190a197_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTkwNzQ_4bf137b9-f429-4cb6-bad7-21c9d4a57c43">40.2</ix:nonFraction> million, after deducting commissions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#8217; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if7f02a1773f24977aaa1ca40d2b10b16">The rules and regulations of the SEC or any other regulatory agencies may restrict the Company&#8217;s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the global outbreak of COVID-19 and the World Health Organization&#8217;s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. The full impact of the COVID-19 outbreak continues to evolve as of the date of these financial statements. While the pandemic has not yet had a material effect on the Company&#8217;s financial results, it is uncertain as to the full magnitude of impact the pandemic will have on the Company&#8217;s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&#160;</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act includes a provision for a Paycheck Protection Program, or PPP, administered by the U.S. Small Business Administration, or SBA, and further amended by the Paycheck Protection Program Flexibility Act of 2020, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="ia9052b89c6b24fa6a619d85589847b41" continuedAt="i63b9a7dc52724f0f981cf97810f95ee1"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or PPP Flexibility Act, which was enacted on June 5, 2020. The Company was approved for a loan pursuant to the PPP, or the PPP Loan, in the amount of $<ix:nonFraction unitRef="usd" contextRef="i93fd390c8a614c1f8ea8dce7fbd6bbd1_D20200511-20200511" decimals="-5" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MDk2NTM_6f67a423-9850-4aef-b3d4-8d601471a260">1.9</ix:nonFraction> million and received the funds on May&#160;11, 2020. On October 2, 2020, the Company repaid the loan in full plus all interest accrued during the period outstanding. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also permits employers to defer the payment of the employer share of social security taxes due for the period beginning March 27, 2020 and ending December 31, 2020. Of the amounts deferred, 50% was required to be paid by December 31, 2021 and the remaining 50% is required to be paid by December 31, 2022. The Company began deferring payment of the employer share of social security taxes in April 2020 and deferred a total of $<ix:nonFraction unitRef="usd" contextRef="i09e02f53cc2d44b4a25de925c223563e_I20200430" decimals="-5" name="inbx:DeferredFederalPayrollTaxesCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTk0NzU_5a74df36-eac1-44aa-a072-98deafb2feab">0.4</ix:nonFraction>&#160;million of such taxes during the period. The Company paid $<ix:nonFraction unitRef="usd" contextRef="i39dd7198616e4871a04691df5d501376_D20211201-20211231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTk0OTE_cdbd9d68-2ea7-420b-a6d9-78d73f20ff0e">0.3</ix:nonFraction>&#160;million of deferred taxes during December 2021. As of December&#160;31, 2021, the Company has a remaining deferred payment of $<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-5" name="inbx:DeferredFederalPayrollTaxesCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTk0OTk_116b9f71-d205-4ba5-93a2-61cad54686c8">0.1</ix:nonFraction>&#160;million of such taxes which are classified as accrued expenses in the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to examine and evaluate any impacts the CARES Act and associated subsequent legislation may have on its business and taxes.&#160;&#160;&#160;&#160;</span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzcx_53df3dec-6d92-487d-be5a-603dbbbe1c8c" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The Company&#8217;s most significant estimates relate to evaluation of embedded derivative instruments and beneficial conversion features, or BCFs, within its previously issued and outstanding convertible notes, whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company&#8217;s operating lease, and valuation allowances for the Company&#8217;s deferred tax assets.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzgw_7a84e5e7-71ee-413d-b4fc-febb6818c3b0" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist principally of accounts receivable, accounts payable, accrued expense, its long-term debt, convertible notes, warrants, and derivative instruments as applicable. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and convertible notes approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#8217;s debt approximates fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company&#8217;s derivative instruments and warrants are carried at fair value based on unobservable market inputs.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU4_97ed807b-6eb6-4b1e-b3da-7ea8d559f703" continuedAt="ie8f4ce4b4ecf496e850b1dc2978ec2ab" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie8f4ce4b4ecf496e850b1dc2978ec2ab">Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking and money market accounts.</ix:continuation> </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc0_bc6429be-b570-4be4-a524-549b1e17d814" continuedAt="i1e44dc950e484dd19b460656be08ee0b" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#8217;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December&#160;31, 2021 and 2020, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i63b9a7dc52724f0f981cf97810f95ee1" continuedAt="i4eafe20a1bd34f5d9acdcc41d39858ef"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1e44dc950e484dd19b460656be08ee0b">The Company currently depends on third-party suppliers for key materials and services used in its research and development, as well as manufacturing processes, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. In August 2018, the Company entered into a strategic alliance with WuXi Biologics (Hong Kong), Limited, or WuXi Biologics, pursuant to which the Company agreed, for <ix:nonNumeric contextRef="ib7f3cbe060eb4e03859e4a074152ce82_D20200801-20200831" name="inbx:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4Xzk5MTc_a2c47cf1-896b-4e2d-8685-00fe020dab41">three years</ix:nonNumeric> and subject to certain conditions, to exclusively use WuXi Biologics to manufacture its therapeutic candidates on a project-by-project basis. In August 2021, the exclusivity provisions of the Wuxi Agreement expired, and the Company may use manufacturers other than Wuxi to manufacture its therapeutic candidates. The Company does not control the manufacturing processes of the contract development and manufacturing organizations, or CDMOs, with whom it contracts, including WuXi Biologics, and is dependent on these third parties for the production of its therapeutic candidates in accordance with relevant regulations such as current Good Manufacturing Practices, or cGMP, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation.</ix:continuation> </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU2_ea8c3a67-2d00-4290-8823-073defa8534e" continuedAt="i6898b511a1a0470c82a2ef964218f9ca" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has never declared or paid any dividends on its common stock. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6898b511a1a0470c82a2ef964218f9ca">Additionally, the Amended 2020 Loan Agreement limits, among other things, the Company&#8217;s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company&#8217;s common stock will be at the discretion of the Company&#8217;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#8217;s board of directors may deem relevant.</ix:continuation> </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU1_e735db29-0ba3-4025-9645-7f9e4c229023" continuedAt="ib7b593fa6452453db5b6192be6214a93" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">machinery and equipment: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDIx_fb18bef6-4644-4d4c-b39d-3e7398424521">three</span> to <ix:nonNumeric contextRef="idc73af7586ed4a7893d2827190cc61ae_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc1_a9148f36-9f05-430a-a345-96365c793fc0">five years</ix:nonNumeric>; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture and fixtures: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDYy_22f664cc-88d9-4893-a2bc-e342d557a1d4">three</span> to <ix:nonNumeric contextRef="icb2b71a468364db0b76d16dcc40554c5_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzgx_f4339934-75ba-4bdd-8ae2-1f6952460b90">five years</ix:nonNumeric>; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNTAx_ac274eaf-b7f7-4024-9d85-68b4306ca0ff">four</span> to <ix:nonNumeric contextRef="ie74f508386624bc591b2098160a4640a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY2_d992549e-3340-4341-a6f7-b27569ae68b6">five years</ix:nonNumeric>.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib7b593fa6452453db5b6192be6214a93">Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc4_8a4942ac-14d5-4cd7-ba5a-6e18c726ead1" continuedAt="i7b7893aa84674f7ebe6c21654a289f19" escape="true">Impairment of Long-Lived Assets </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b7893aa84674f7ebe6c21654a289f19">The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzcy_25808bdd-ff36-41bc-a4b4-bf298ee1c140" continuedAt="i0b6df2719b3b47be9104d1f4d65724ab" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="lease" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="INF" name="inbx:NumberOfOperatingLeasesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzEyNjIz_2b9cd6f8-347d-4396-aed0-6fb74d822910">two</ix:nonFraction> existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company&#8217;s facilities, which commenced in January 2020 and is accounted for as a separate lease. The Company&#8217;s <ix:nonFraction unitRef="lease" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="INF" name="inbx:NumberOfOperatingLeasesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzEyOTMw_e9d3fa37-bd4e-4ea6-b277-4dfac0f6a5ad">two</ix:nonFraction> existing leases are classified as operating leases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the long-term operating lease of its corporate headquarters, the Company recognized a right-of-use asset and lease liability on its consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. Agreements are reviewed at </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i4eafe20a1bd34f5d9acdcc41d39858ef" continuedAt="i50cf83ce23f64e3982fed491a9e68124"><ix:continuation id="i0b6df2719b3b47be9104d1f4d65724ab" continuedAt="ie2206b2a6ea74a8cb28dc47da548c6bb"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inception to determine if they contain a lease. Leases are reviewed and classified as operating or financing leases at commencement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to exclude from its consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.</span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie2206b2a6ea74a8cb28dc47da548c6bb">Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the consolidated statements of operations for all periods presented.</ix:continuation> </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzUx_29485b19-7eb0-429a-9d5a-83eb6376d7fc" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 7, the Company received an equity investment in the form of a <ix:nonFraction unitRef="number" contextRef="i71b075ff878e44c4922334a3be94c8cf_I20200731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE0NjA4_50302292-80af-46a5-80de-a2bdfb6cb7bf">10</ix:nonFraction>% equity interest as consideration in a series of agreements with Phylaxis (as defined below), which is accounted for as an equity method investment. The Company's proportionate share of the net income or loss of these companies is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#8217;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. During the third quarter of 2020, the Company&#8217;s equity method investment was written down to <ix:nonFraction unitRef="usd" contextRef="icc9931e7028244ecadfcd288d792171d_I20200930" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE1Mzcw_a4956a6c-b59b-4843-a070-17d5b2d49f7e">zero</ix:nonFraction> as a result of the allocation of the Company&#8217;s share of losses of the investee. As of December&#160;31, 2021 and 2020, the equity method investment remains at <ix:nonFraction unitRef="usd" contextRef="ibcd205c8ba4b4294b112ca3f590109b2_I20201231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE1NTA0_8c9b55eb-3c77-426e-b88f-97bcc4e6483f"><ix:nonFraction unitRef="usd" contextRef="ifa5894f258e64ee787243df2040ca6d0_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE1NTA0_a3664d8b-aa50-4afc-ab68-3109b7780260">zero</ix:nonFraction></ix:nonFraction>.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY5_3036ea53-0740-468f-98da-f9b1ba2b9b87" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the convertible promissory note, or the 2019 Note, issued in May 2019 to DRAGSA 50 LLC, an entity affiliated with Viking Global Investors LP, or Viking, and the convertible promissory notes, or the 2020 Notes, issued in April 2020 to Viking and certain other investors contained embedded features that provided multiple settlement alternatives. Certain of these settlement features provided the noteholders with a right to a fixed number of the Company&#8217;s shares upon conversion of the note. Other settlement features provided the noteholders the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction, change of control, qualified IPO (as defined in the 2019 Note and the 2020 Notes), or default of the Company. The Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 815-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and determined certain of the settlement features would be accounted for as redemption features meeting the requirements for separate accounting as a single, compound derivative instrument.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This single, compound derivative instrument was accounted for as a liability at its estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the consolidated statements of operations. During August 2020, the Company consummated its IPO, resulting in the conversion of the 2019 Note and the 2020 Notes into shares of the Company&#8217;s common stock. As of December&#160;31, 2021 and 2020, the derivative liabilities no longer exist.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="inbx:WarrantLiabilitiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzUz_335726a3-2310-43df-a931-bfc8195285db" continuedAt="ic7b3ce6116914dcea40c17f5d135ad1c" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, in conjunction with the 2020 Loan Agreement with Oxford, the Company issued warrants for the purchase of: 1) its preferred stock if the Company remained privately-held or 2) common stock upon the successful completion of an IPO prior to December 31, 2020. Upon the issuance of the warrants in July 2020, pursuant to ASC Topic 480, the warrants were accounted for as liabilities and measured at their estimated fair value as of the date of issuance, based on the potential conversion into preferred stock. During August 2020, upon consummation of the Company&#8217;s IPO, the warrants were deemed to be issued for the purchase of common stock and </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i50cf83ce23f64e3982fed491a9e68124" continuedAt="ie29aecc49fcf40c880bc77eacebd2d84"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic7b3ce6116914dcea40c17f5d135ad1c">were no longer accounted for as liabilities. The change in fair value was recognized as a component of change in fair value of warrant liabilities in the consolidated statements of operations during the year ended December 31, 2020.</ix:continuation></span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzYx_50a69ae5-a089-4641-9d7d-124296a5cd56" continuedAt="i738c02afb75b4e2da23a3b42fd14e3b4" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific&#160;to the asset or liability. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 Note and the 2020 Notes contained embedded derivative liabilities (see Note 4). The 2020 Loan Agreement contained warrant liabilities (see Note 3). Prior to the completion of the IPO in August 2020, these were classified within Level 3 of the hierarchy, since they were valued by using inputs that were unobservable in the market. Upon the consummation of the IPO in August 2020, the derivative liabilities and warrant liabilities no longer existed. As of December&#160;31, 2021 and 2020, the Company had no financial liabilities measured at fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU0_ea692b43-2596-4519-8356-beb30497da6d" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of the IPO in August 2020, the Company&#8217;s liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) included the derivative liabilities related to the 2019 Note and the 2020 Notes and the warrants issued with the 2020 Loan Agreement. The following table provides a reconciliation of financial instruments measured at fair value using Level 3 unobservable inputs for the year ended December 31, 2020 (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca4cb805a4d45438e207a1536816957_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzMtMS0xLTEtMjQzNzY_f7a17343-d989-4953-8beb-c7f075aba709">1,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of derivative liability on the 2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead2791fae4b4da59253032bf7b42e47_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzQtMS0xLTEtMjQzNzY_8636d464-e2d5-4e21-80fa-7af593dac92f">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of warrant liabilities on the 2020 Loan Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb4707fb2959449d9321c8c1488e1c19_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzUtMS0xLTEtMjQzNzY_3c99a96a-f71a-4704-856d-a24abf389300">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities on the 2019 and 2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ab110f9486a46d7bc11aaaf0bf87703_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzYtMS0xLTEtMjQzNzY_94ba3a62-286b-43b8-8e36-7800850d963c">2,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb4707fb2959449d9321c8c1488e1c19_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzctMS0xLTEtMjQzNzY_b9b6350f-9a55-4f2a-b5b5-76548cee03e4">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities into equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb4707fb2959449d9321c8c1488e1c19_D20200101-20201231" decimals="-3" name="inbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzgtMS0xLTEtMjQzNzY_61e98118-722f-45a2-8db7-cec94fbebe7e">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b34f949eb8d495c9c9f5c2ff130ba51_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzktMS0xLTEtMjQzNzY_117394da-0279-4d26-93ed-7413090fb468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i738c02afb75b4e2da23a3b42fd14e3b4" continuedAt="if51e169b557240aa806df4a932699fa6">The fair value of the Company&#8217;s derivative liabilities categorized in Level 3 of the fair value hierarchy during the year ended December 31, 2020 was determined, with the assistance of an independent third-party valuation specialist, using a lattice model. The valuation utilized unobservable inputs, including the discount rate, management&#8217;s assessment of the probability of various underlying events triggering the conversion of the Company&#8217;s 2019 Note and the 2020 Notes (as discussed in Note 4), such as an IPO, financing, or extraordinary event, and the current valuation of the Company determined with the assistance of an independent third-party valuation specialist. The warrant liabilities were valued using a Black-Scholes model upon issuance. As of December&#160;31, 2020, the derivative liabilities no longer exist as a result of the conversion of the 2019 Note and the 2020 Notes upon the IPO. Additionally, as of December&#160;31, 2020 the warrant liabilities have been reclassified into equity after the Oxford warrants became exercisable for common stock subsequent to the Company&#8217;s IPO.</ix:continuation></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="ie29aecc49fcf40c880bc77eacebd2d84" continuedAt="i78ce6e2147f04ac783aa7097d5b0451b"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if51e169b557240aa806df4a932699fa6">There were no financial instruments measured at fair value during the year ended December 31, 2021.</ix:continuation></span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc3_65983d85-2fe0-4b49-b073-4cb66d835f17" continuedAt="ib0415b262bfa4ab9af0091b407279cd3" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company&#8217;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal, accounting, and filing fees related directly to the Company&#8217;s IPO were capitalized as deferred offering costs to be offset against proceeds upon the consummation of the IPO within stockholders&#8217; equity (deficit). In August 2020, the Company completed its IPO and offset $<ix:nonFraction unitRef="usd" contextRef="i18dec53bcc4c412abadbaa5a71931d50_D20200801-20200831" decimals="-5" name="inbx:PaymentsOfStockIssuanceCostsInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzIzMDUy_a617999b-f14a-40d9-b06c-3744d96fdf28">11.0</ix:nonFraction> million of IPO costs against the proceeds. No deferred offering costs were capitalized on the Company&#8217;s consolidated balance sheets as of December 31, 2020.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib0415b262bfa4ab9af0091b407279cd3">Legal, accounting, and filing fees related directly to the Company&#8217;s Shelf Registration are capitalized as deferred offering costs. Deferred offering costs associated with the Shelf Registration are reclassified to additional paid-in capital when the Company completes offerings under the Shelf Registration. In November 2021, the Company completed an offering under the Shelf Registration and offset $<ix:nonFraction unitRef="usd" contextRef="i7cbc8f3cc82e45b1b819d385f0420fab_I20211130" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTk1MTI_b3ef59ed-50cd-48a8-be2b-62543298a150">1.7</ix:nonFraction> million of offering costs against the proceeds.</ix:continuation> </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY3_97170d84-db96-4845-950a-cc1867f57801" continuedAt="ibaa3fb408d2c4a19a24f23ca1bef072a" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet until all revenue recognition criteria are met. In accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or ASC Topic 606, the Company recognizes revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC Topic 606, the Company performs the following five steps: (1)&#160;identify the contract(s) with a customer; (2)&#160;identify the performance obligation(s) in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (5)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners that typically include one or more of the following: (1)&#160;license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether each unit of account results in a contract with a customer under ASC Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC Topic 808. The Company&#8217;s licensing arrangements are typically for functional intellectual property as it exists at a point in time, being the time that the license agreement is executed. The Company typically does not have an ongoing performance obligation to support or maintain the licensed intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i78ce6e2147f04ac783aa7097d5b0451b" continuedAt="id8f807c039d54148b2915f02e5006e11"><ix:continuation id="ibaa3fb408d2c4a19a24f23ca1bef072a" continuedAt="i87205acc1bd848dbb2a579795f1e62fa"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company estimates the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. The Company recognizes revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. In the case of an agreement which provides the partner with an option to license a therapeutic or therapeutic candidate in the future, the Company evaluates whether this option represents a material right at the inception of the agreement. If determined to be a material right, the Company will consider the option a separate performance obligation. The Company has historically concluded that the option to grant a license in the future are not material rights as they are contingent upon future events which may not occur. When an option is exercised, the Company will identify any separate performance obligations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may allocate transaction price using a number of methods including estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain, and observable standalone selling prices exist for the other goods or services promised in the contract. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been awarded grants from the Congressionally Directed Medical Research Program, or CDMRP, funded through the DoD. With respect to revenue derived from reimbursement of direct, out-of-pocket expenses for research and development costs associated with these grants, where the Company acts as a principal with discretion to choose suppliers, bears credit risk, and performs part of the services required in the transaction, the Company records revenue for the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the consolidated statements of operations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since there is no transfer of control of goods or services to the granting entities, the granting entities do not meet the definition of a &#8220;customer&#8221; as defined by ASC Topic 606 and therefore, these government grants and private not-for-profit institution grants are not within the scope of ASC Topic 606. </span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i87205acc1bd848dbb2a579795f1e62fa">Revenue from these grants are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses related to the grant which is consistent with the concept of transfer of control of a service over time under ASC Topic 606.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc2_016b09ba-07c8-44b6-a3ed-85ddd580da08" continuedAt="i5c4b41276dad4c4b9d6f81228e594634" escape="true">Research and Development and Clinical Trial Accruals </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c4b41276dad4c4b9d6f81228e594634">Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#8217;s behalf, pursuant to development and consulting agreements in place. The Company&#8217;s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company&#8217;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzcz_94c9389b-8196-4d28-a1d6-70bf1c178dad" continuedAt="i3030d72a12fe4f658b100f71d3c3344b" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="id8f807c039d54148b2915f02e5006e11" continuedAt="i7b602139a1ea4518852bb52ca2b2c3ce"><ix:continuation id="i3030d72a12fe4f658b100f71d3c3344b" continuedAt="i469f925920064fff81888c4efe068f1e"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i469f925920064fff81888c4efe068f1e">The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.</ix:continuation> </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU3_be8046ca-aec2-41e1-ae22-e2aff92ed903" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders.&#160;Accordingly, for the years ended December 31, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzYz_4dcaf22a-c598-4d54-9fe1-6c2d56215c95" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i37602c9d5ed8495cb15a8ef8ddaa15dd_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzQtMS0xLTEtMjQzNzY_f24ab2e5-1ea4-49ee-aa2a-c1f95f9e72fe">4,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i170482e872e54fa3a75fd05af40e0ac9_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzQtMy0xLTEtMjQzNzY_76716dd6-0894-44db-b81c-cf1eab62e4e1">2,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifd52f475273e436dbd8c13baa139f7ff_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzYtMS0xLTEtMjQzNzY_41faeab1-70f3-4160-870b-0a5452d5a46c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8c0b54c2dda34749b9b0940bc4d42110_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzYtMy0xLTEtMjQzNzY_23f6676e-2134-45b1-8c46-e3f0792d6f63">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzctMS0xLTEtMjQzNzY_f2f7b543-ca2d-48e2-abbf-79364da79e34">4,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzctMy0xLTEtMjQzNzY_51d74721-f1e6-434b-b473-ba411e99599a">2,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY4_3c38e8d2-5c47-4319-909a-1807d007d574" continuedAt="i324b232da2a24b9c82c07819110260ff" escape="true">Fair Value of Stock-Based Awards </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i324b232da2a24b9c82c07819110260ff">The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i7b602139a1ea4518852bb52ca2b2c3ce" continuedAt="i2acbc024886c456d90f218e784396529"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU5_243afb9b-0106-490c-93d6-aebf3a6342e6" continuedAt="i0f5f0d67abb14d55a16d529581818767" escape="true">Other Comprehensive Income </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0f5f0d67abb14d55a16d529581818767">The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY0_b8d90b67-b655-4cab-bef1-3b5ae1748d99" continuedAt="i83c8e7e9f5a548929a20d61d8620cd94" escape="true">Segment Information </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i83c8e7e9f5a548929a20d61d8620cd94">The Company operates under <ix:nonFraction unitRef="segment" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzM1OTg5_90723a50-e515-4566-b1f9-e2a8519e2c23">one</ix:nonFraction> segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.</ix:continuation> </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc5_c71268e1-55b7-4db0-a064-6ab2fedc5f16" continuedAt="i53600d0046fe43feb6fcee2cf3563365" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments-Equity Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 321),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments-Equity Method and Joint Ventures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 323),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 815), - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 was effective for fiscal years beginning after December 15, 2020, and interim periods within those years. Early adoption was permitted, but required simultaneous adoption of all provisions of this guidance. The Company adopted this guidance as of January 1, 2021, which did not result in a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU 2019-12 also improves consistent application and simplification of other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 was effective for fiscal years beginning after December 15, 2020. The Company adopted this guidance as of January 1, 2021, which did not result in a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or Subtopic 470-20 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subtopic 815-40: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share, or EPS, calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 under a modified retrospective approach as of January 1, 2021. As a result of the adoption, there was no impact on retained earnings or other components of equity or to earnings per share in the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i2acbc024886c456d90f218e784396529"><ix:continuation id="i53600d0046fe43feb6fcee2cf3563365"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company was a smaller reporting company at the determination date, and therefore the new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 260), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt-Modifications and Extinguishments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 470-50), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 718), and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Subtopic 815-40):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which intends to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods therein, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2021-04 may have on its consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div id="ie96bda597eaa4024845d6498a1c78657_220"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzc1MA_3407843f-9fde-42a8-a669-e59f003abd92" continuedAt="i7e808426053c41038b30ffa1192fc0d2" escape="true">OTHER FINANCIAL INFORMATION </ix:nonNumeric></span></div><ix:continuation id="i7e808426053c41038b30ffa1192fc0d2" continuedAt="i719e9597cbd6418a82cb63f0b04104cf"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expense and Other Current Assets</span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzc1MQ_d0f5474d-904f-4ffc-8958-3f936f904085" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzMtMS0xLTEtMjQzNzY_fd3a504d-b9d7-4efd-bb62-b1f012dedf83">6,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzMtMy0xLTEtMjQzNzY_2c7f3e08-4fa0-4b93-85f0-9591d618b5c8">2,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzUtMS0xLTEtMjQzNzY_4925266e-f90e-4ad5-b1d8-6ee259f2bf89">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzUtMy0xLTEtMjQzNzY_69279f02-3d38-416d-b6e6-903226f67338">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzYtMS0xLTEtMjQzNzY_e19db378-c10e-48aa-af0d-c44f1b923bc9">6,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzYtMy0xLTEtMjQzNzY_97e4b7b5-3bd4-41fc-a190-7e683b9ea614">2,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzc0OA_76778299-f793-470f-97d5-30e3c17c2af1" continuedAt="i3cd8933d713a42b794eabb7a1ccb557e" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1710f2bbed1f4858b4386673f448cffe_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzMtMS0xLTEtMjQzNzY_b6af7b65-d9b5-43f0-9f5e-ae70395a3b1a">6,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020ea95670924586b00a510e94318bdb_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzMtMy0xLTEtMjQzNzY_5816806b-a8ae-4882-a55c-91de2ac6ef79">5,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ee0abef7874f9db4990a4e94b36a2c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzQtMS0xLTEtMjQzNzY_1d5e345c-75fe-40b3-8be4-3af0889e4af9">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53e4b677a5742fd983bfb37b3aa7e80_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzQtMy0xLTEtMjQzNzY_051da001-bc45-4b8d-b39a-da2ec5551925">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a2d5f0e3c440ef8d989fed722504af_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzUtMS0xLTEtMjQzNzY_39ac0983-45fe-4f83-a5ff-af714ae23eb9">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377f66a6d4c54b4ca81d7975dd8a5c8b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzUtMy0xLTEtMjQzNzY_2c9a78fc-e2be-46a5-bddb-764e846ba1f9">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7242126f78fa4a8a8b9c857fce023330_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzYtMS0xLTEtMzI3ODE_d1694f30-e16a-4634-9a55-c0b294c8c4d0">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33ae29820054b0db7fce225cab20805_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzYtMy0xLTEtMzI3ODg_4eb4cec4-b562-4ae5-b8c2-2dd507979864">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5ab90e2a7d472080cd923e5b5db3b0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzYtMS0xLTEtMjQzNzY_cfda0ea9-01e5-4a7e-8c71-b7d1c07c3c49">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3c6503a73a4cb9beb9b3b8e12d0fc5_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzYtMy0xLTEtMjQzNzY_d31ccbec-c6a8-4a8c-9636-c48786e73112">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzctMS0xLTEtMjQzNzY_e92f0f23-a6da-43a7-9a52-c7ea30e0dcdd">7,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzctMy0xLTEtMjQzNzY_1e6e9541-fb7e-42c1-a5be-ea13c6efba19">6,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzgtMS0xLTEtMjQzNzY_a97c2be8-088d-4004-baba-0208c9457296">4,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzgtMy0xLTEtMjQzNzY_35ed2744-10bd-4037-82a9-935f7c24ed07">3,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzktMS0xLTEtMjQzNzY_110f46a4-5efd-48c1-aedd-174c2db000a6">3,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzktMy0xLTEtMjQzNzY_5936eff0-6485-4d6d-b416-bf3008574cdf">3,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i719e9597cbd6418a82cb63f0b04104cf" continuedAt="i545d00d97eaa445a854ad83726c39ea6"><ix:continuation id="i3cd8933d713a42b794eabb7a1ccb557e"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzE2NDkyNjc0NDI3NjA_a2591a98-6f6f-4041-af81-9da3ef414301">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzE2NDkyNjc0NDI3Njg_4d196c6b-7313-4d0e-8b8e-8ace728269ee">1.0</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively, and consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.286%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a2ae527c6442f69033f87496c9e149_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzMtMS0xLTEtMzk0MzM_141c3c79-3168-45ef-932c-ebda21996ed0">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad61546aa39a46a6ab37a1278118f591_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzMtMy0xLTEtMzk0MzM_deae3076-b7b1-4ca0-9732-7257d028fcdc">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfda6bf472bc49e48b735e5c112a0531_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzQtMS0xLTEtMzk0MzM_b8219c30-6ad5-44d3-aae6-f7c0b87e804c">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d71b0c7c95e4b21a9fd208c7d3fa8c9_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzQtMy0xLTEtMzk0MzM_ecf68af7-649f-44f7-97b4-f8769cdfa70e">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzUtMS0xLTEtMzk3NTQ_81cf97b2-1c79-46e3-85de-c6e0ecc63ca5">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzUtMy0xLTEtMzk3NTc_cf93535a-8295-457f-a6aa-69dd39cb8694">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzc0OQ_80fe7884-8215-4b33-82f2-59e19e2a3019" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="inbx:AccruedClinicalResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzMtMS0xLTEtMjQzNzY_2c187dd5-8499-47a3-9d74-9a2f237f42ed">4,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="inbx:AccruedClinicalResearchAndDevelopmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzMtMy0xLTEtMjQzNzY_e260c21e-d309-452a-8f89-3cf715c8cbea">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other outside research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMS0xLTEtMzk1NTg_fdbda561-74f5-4364-a98f-ac23953a98eb">2,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMy0xLTEtMzk1NTg_f45c3bd2-5379-4176-a84b-3709d0d51bba">10,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMS0xLTEtMzMyOTU_6dab7ba0-fe65-4d64-8b06-cba550dba49f">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMy0xLTEtMzMyOTU_2aa45776-2a75-4f9f-b11d-48ac5601ff56">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMS0xLTEtMjQzNzY_721dc026-80b6-4a9b-9f32-e5854a54ab6c">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMy0xLTEtMjQzNzY_df3a76cb-585f-4bad-a1b0-e876106de209">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzctMS0xLTEtMjQzNzY_161e983f-476a-47a1-805e-bfc2ef68dcb1">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzctMy0xLTEtMjQzNzY_d5187952-0d6d-4e59-b962-f74d2dd6bfa5">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzgtMS0xLTEtMjQzNzY_b68a492a-9659-4268-a6b7-207b53c7ff01">9,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzgtMy0xLTEtMjQzNzY_482e3bc9-8302-4993-91fc-8c6db96ff364">13,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i545d00d97eaa445a854ad83726c39ea6">The amount accrued for research and development expense relates primarily to the Company&#8217;s usage of third-party CROs and CDMOs for clinical and development efforts as its therapeutic candidates progress. See Note 1 for further discussion of the components of research and development.</ix:continuation> </span></div><div id="ie96bda597eaa4024845d6498a1c78657_223"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc3NzE_5a135957-e715-473a-ae2b-7d8abf48e2e7" continuedAt="i63a89226196240b8a2a20b414ff5d69d" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="i63a89226196240b8a2a20b414ff5d69d" continuedAt="i5adc1a5481a94abb8e532e3974c836e7"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;15, 2020, the Company entered into a loan and security agreement, or the 2020 Loan Agreement, with Oxford Finance LLC, or Oxford, pursuant to which it received $<ix:nonFraction unitRef="usd" contextRef="i5bbe9a1a4e50490a8f0a1b8d2384b65d_D20200715-20200715" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzI4NjY_99fb8208-4856-4fa6-beef-b7eac8335704">10.0</ix:nonFraction> million in gross proceeds, net of $<ix:nonFraction unitRef="usd" contextRef="if9d0faac086f48b49f67f4291eb50af5_I20200715" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzI4OTU_068c670f-fd4f-4ac1-a99b-7135dba0cf19">0.1</ix:nonFraction> million of debt issuance costs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;12, 2020, the Company entered into an amendment to the 2020 Loan Agreement, or the November 2020 Amendment, and received $<ix:nonFraction unitRef="usd" contextRef="ibe5a8c4c13b647ba8a99cfbad3d44b0f_D20201112-20201112" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzI5OTk_d1351b95-ebbd-4f6f-92bb-b4d30b90710d">20.0</ix:nonFraction> million in additional gross proceeds, net of $<ix:nonFraction unitRef="usd" contextRef="i51f1dd4556c84be1903e4fccae311a27_I20201112" decimals="-4" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzMwMzk_0b06d481-d962-4475-a3c5-2b79e42be8a3">0.02</ix:nonFraction> million of debt issuance costs and $<ix:nonFraction unitRef="usd" contextRef="i822a1c2899dd422882f0c3c6958c8b78_D20201112-20201112" decimals="-5" name="inbx:DebtInstrumentAmendmentFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzMwNjk_00c0b575-c5e4-47b9-ab04-afc986870307">0.7</ix:nonFraction> million of a one-time first amendment fee. The November 2020 Amendment provided for <ix:nonFraction unitRef="tranche" contextRef="i51f1dd4556c84be1903e4fccae311a27_I20201112" decimals="INF" name="inbx:DebtInstrumentNumberOfAdditionalTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzMxNTI_b0224d9e-6f5e-43bd-a22d-aea3527141be">two</ix:nonFraction> additional tranches of term loans, in addition to the first $<ix:nonFraction unitRef="usd" contextRef="i5bbe9a1a4e50490a8f0a1b8d2384b65d_D20200715-20200715" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzEwOTk1MTE2NDExMTA_99fb8208-4856-4fa6-beef-b7eac8335704">10.0</ix:nonFraction> million tranche, or Term A, for an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i51f1dd4556c84be1903e4fccae311a27_I20201112" decimals="-5" name="inbx:DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzMyMzE_4be4b100-b22c-4f47-b6fb-de93cd5bb73f">50.0</ix:nonFraction> million, as follows: (a) the second tranche in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ibe5a8c4c13b647ba8a99cfbad3d44b0f_D20201112-20201112" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzMzMDY_770f430f-d594-46c5-8f26-8809cf275dcf">20.0</ix:nonFraction> million, funded upon the closing of the November 2020 Amendment, or Term B, and (b) the third tranche in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ie0e9b67a1f98416d947e940d51019a13_D20201112-20201112" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzM0MzU_a06c1bbf-1bbd-4fa1-bc6e-2284d023bf8a">20.0</ix:nonFraction> million to fund on or before September 30, 2021, subject to the initiation of a potentially registration-enabling trial for the Company&#8217;s therapeutic candidate, INBRX-109, in unresectable or metastatic conventional chondrosarcoma, pursuant to the terms of the November 2020 Amendment, or Term C. The terms of Term A under the 2020 Loan Agreement were modified to align with Term B pursuant to the November 2020 Amendment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;18, 2021, the Company entered into an additional amendment to the 2020 Loan Agreement, or the June 2021 Amendment (collectively with the November 2020 Amendment, the Amended 2020 Loan Agreement). Pursuant to the June 2021 Amendment, the principal amount of the Term C Loan was increased from $<ix:nonFraction unitRef="usd" contextRef="ie0e9b67a1f98416d947e940d51019a13_D20201112-20201112" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzEwOTk1MTE2NDE3NTM_a06c1bbf-1bbd-4fa1-bc6e-2284d023bf8a">20.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="if4dee1f4dab044b5904819f8b2634e06_D20210618-20210618" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzEwOTk1MTE2NDE3NjA_c37d558e-9173-4b79-883d-4e0b4ccc9a0f">40.0</ix:nonFraction> million. All terms of the Term C Loan align with the existing terms of the Term A and Term B Loans. Upon execution of the June 2021 Amendment and based on the initiation of a potentially registration-enabling trial in unresectable or metastatic conventional chondrosarcoma, the Company drew the Term C Loan and received $<ix:nonFraction unitRef="usd" contextRef="if4dee1f4dab044b5904819f8b2634e06_D20210618-20210618" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzEwOTk1MTE2NDIwODI_40e7f2f3-1604-4fd8-bd72-d52214c88ecd">40.0</ix:nonFraction> million in gross proceeds, net of $<ix:nonFraction unitRef="usd" contextRef="ib7b1a7a708534f06a0a7d794a7a27a80_I20210618" decimals="-4" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzEwOTk1MTE2NDIxNDU_41254d49-5684-4abb-a108-72d2fe641f9a">0.01</ix:nonFraction> million of debt issuance costs.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i5adc1a5481a94abb8e532e3974c836e7" continuedAt="ieb75ae760e244403bc40416d2ce4618f"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 the Company has $<ix:nonFraction unitRef="usd" contextRef="i1a0d6e3138bb4cb6ba9620a8eee4bbd4_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQwNTE_cb8b386f-2817-4f32-a081-80eb0bec0e30">70.0</ix:nonFraction> million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement. The outstanding term loans will mature on November&#160;1, 2025, or the Amended Maturity Date, and bear interest at a floating per annum rate equal to the greater of (1) <ix:nonFraction unitRef="number" contextRef="i1a0d6e3138bb4cb6ba9620a8eee4bbd4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQyODk_c39cf755-69f2-4798-b539-d6abbee512f0">7.96</ix:nonFraction>% and (2) the sum of (i) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (ii) <ix:nonFraction unitRef="number" contextRef="i23f05621867b46ba85b04d8f1e06e75d_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQ1MDQ_8ebfc42c-121e-46bb-aac2-350f9410b5f1">7.80</ix:nonFraction>%. The repayment schedule provides for interest-only payments until January&#160;1, 2025. The interest-only period is followed by <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="inbx:DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQ3OTk_8d49400f-935d-4651-96b8-da9e6c64f197">11</ix:nonNumeric> months of equal payments of principal and interest. Upon the Amended Maturity Date, a final payment of <ix:nonFraction unitRef="number" contextRef="i1a0d6e3138bb4cb6ba9620a8eee4bbd4_I20211231" decimals="INF" name="inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQ4OTg_2c013ddf-6047-4385-9564-08afc9f9a898">9.0</ix:nonFraction>% of the original principal amount will be due to Oxford. This final payment of $<ix:nonFraction unitRef="usd" contextRef="i1a0d6e3138bb4cb6ba9620a8eee4bbd4_I20211231" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQ5Nzk_d74b9c84-9ecc-41dd-83b1-6164cb1e32ca">6.3</ix:nonFraction> million is being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from <ix:nonFraction unitRef="number" contextRef="i921b6c207f2a4f428b2e98a2c7602eaa_I20200715" decimals="INF" name="inbx:DebtInstrumentPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzUyNDk_857ee3fb-201d-473c-b7d9-0e9db9bccee0">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ida7de870e3734f6f8e5b74fa33367059_I20200715" decimals="INF" name="inbx:DebtInstrumentPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzUyNTU_fc364712-4369-4ca7-9ada-66f328b71f5b">3.0</ix:nonFraction>%, depending upon the timing of the prepayment. All other terms of the original 2020 Loan Agreement remain outstanding.</span></div><div style="margin-bottom:9.5pt"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc3Njk_653743bb-e993-4727-a2b2-686df035a8ae" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following (in thousands).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term A</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546e91723e584f938387442db9ab32f8_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzItMS0xLTEtMjY2NzA_651310f9-6334-428c-8844-f213e7707c30">10,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea06729df7364389bb97b7cac1e9cfad_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzItMS0xLTEtMjQzNzY_f40abc00-e26b-40b7-b08e-e1072b577281">10,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ddad33eb12403ab966960a6f430d69_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzMtMS0xLTEtMjY2NzA_062b81a0-5aff-4e55-8670-9486cfe80565">21,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8046ea9e74b1c96aee8f24c431683_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzMtMS0xLTEtMjQzNzY_7085de4e-922e-4e8d-b815-583a69b0c83c">21,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic890278d955442b5a665ca0900a0a5e3_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzQtMS0xLTEtMjY2NzA_00da06c5-3600-45da-800e-13ce5e386ce2">43,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cfb99837e104069a050c050a6a0e015_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzQtMy0xLTEtMjY2NTI_c1acc2d1-9282-448c-a4ca-f8a08a1b3061">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzUtMS0xLTEtMjY2NzA_c48eb7a7-aacd-4e87-abc9-5177c19d1e9a">5,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbed81cbbbc44ceca46d67906a40279c_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzQtMS0xLTEtMjQzNzY_88da62f8-8f25-43f7-9f48-8029ee4b2e22">3,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzYtMS0xLTEtMzQ3MDY_603db2f2-0639-43bd-98bd-a9b0b190f219">70,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbed81cbbbc44ceca46d67906a40279c_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzUtMS0xLTEtMjQzNzY_ac3708a4-30af-4a01-bff2-8acd31002965">29,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion, including debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzctMS0xLTEtMjY2Nzc_bebcc78e-c496-4bc6-83e1-744eb50accdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbed81cbbbc44ceca46d67906a40279c_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzYtMS0xLTEtMjQzNzY_9d82e81a-4168-446e-aea5-0ede2fbc228e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzgtMS0xLTEtMzQ3MDY_bb21f12c-7d4e-479e-b4d4-f10f6ca3b2ee">70,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbed81cbbbc44ceca46d67906a40279c_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzctMS0xLTEtMjQzNzY_eafc3cd2-a35b-4c9b-a319-85745a35114e">29,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc3NzA_c3c8fd1d-2333-49f4-ac1b-9da9f606efbf" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through 2024, the Company is only required to make interest payments on the outstanding principal balance, with future principal payments and final fee payments beginning in 2025, as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTphMjAzZGIxZDAwZDM0OGM0ODM0YWM5YTFhZGUxZDkwYy90YWJsZXJhbmdlOmEyMDNkYjFkMDBkMzQ4YzQ4MzRhYzlhMWFkZTFkOTBjXzUtMS0xLTEtMjQzNzY_0300ac97-7835-4a17-ab12-84283216c06e">76,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTphMjAzZGIxZDAwZDM0OGM0ODM0YWM5YTFhZGUxZDkwYy90YWJsZXJhbmdlOmEyMDNkYjFkMDBkMzQ4YzQ4MzRhYzlhMWFkZTFkOTBjXzctMS0xLTEtMjQzNzY_78f24d25-8576-450c-95d0-961d7bac32c8">76,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTphMjAzZGIxZDAwZDM0OGM0ODM0YWM5YTFhZGUxZDkwYy90YWJsZXJhbmdlOmEyMDNkYjFkMDBkMzQ4YzQ4MzRhYzlhMWFkZTFkOTBjXzgtMS0xLTEtMjQzNzY_4d4491d9-b584-417e-8c13-736c62333564">5,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTphMjAzZGIxZDAwZDM0OGM0ODM0YWM5YTFhZGUxZDkwYy90YWJsZXJhbmdlOmEyMDNkYjFkMDBkMzQ4YzQ4MzRhYzlhMWFkZTFkOTBjXzktMS0xLTEtMjQzNzY_ef8a7b86-ad1c-447b-bf46-c06e9557ebae">70,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 and June 2021, the Company evaluated the amendments and determined they should be treated as modifications of the original 2020 Loan Agreement since the terms and resulting cash flow were not substantially changed in either the November 2020 Amendment or the June 2021 Amendment. The Company will continue to amortize the existing debt discounts prior to modification through the Amended Maturity Date.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Amended 2020 Loan Agreement are secured by a first priority security interest of substantially all of the Company&#8217;s assets, other than its intellectual property. The Amended 2020 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company&#8217;s operations, that may require prepayment of the outstanding term loans. Additionally, following the June 2021 Amendment, the Amended 2020 Loan Agreement requires a minimum cash balance of $<ix:nonFraction unitRef="usd" contextRef="i0171f114a2a6466ebf29d4bf342dc328_I20211231" decimals="-5" name="inbx:DebtInstrumentMinimumCashBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQzOTgwNDY1Mjk2ODk_e55dfd95-7c4f-4d61-b96e-4d06cb200216">20.0</ix:nonFraction>&#160;million to be maintained in a collateral account. As of December&#160;31, 2021, the Company is in compliance with all covenants under the Amended 2020 Loan Agreement and has not received any notification or indication from Oxford of an intent to declare the loan due prior to maturity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the debt issuance in July 2020, the Company issued to Oxford warrants to purchase shares of the Company&#8217;s capital stock equal to <ix:nonFraction unitRef="number" contextRef="iabd8bb82f3c443ae89d9b90d7796e52b_I20200715" decimals="INF" name="inbx:ClassOfWarrantOrRightPercentageOfFundedAmountIssued" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzY4NjU_da59943c-d285-4c38-8d53-991c93c90856">1.25</ix:nonFraction>% of the funded amount, or $<ix:nonFraction unitRef="usd" contextRef="iabd8bb82f3c443ae89d9b90d7796e52b_I20200715" decimals="-3" name="inbx:WarrantsAndRightsOutstandingLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzY4OTM_b8dd018f-e290-41b7-9448-3b33d6107edf">125,000</ix:nonFraction>. Upon issuance, the warrants were </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="ieb75ae760e244403bc40416d2ce4618f"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercisable for preferred stock and were classified as liabilities pursuant to Topic ASC 480 at their fair value of $<ix:nonFraction unitRef="usd" contextRef="i80af9778e30f4d7c8c60c10f21011485_I20200715" decimals="-4" name="inbx:WarrantsLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzcwNDY_5aa71c7a-7fb5-4df4-875c-315233abd0e1">0.12</ix:nonFraction> million. Upon the consummation of the Company&#8217;s IPO in August 2020, the Company remeasured the warrants and determined a fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="id95bef5f495646d58a4ab12c5852afc4_I20200831" decimals="-4" name="inbx:WarrantsLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzcxOTA_e73e60f4-dde5-428f-8c4e-a432a6b6f77e">0.14</ix:nonFraction> million. The change in fair value was recorded as a change in fair value of warrant liabilities within other income in the Company&#8217;s consolidated statements of operations during the year ended December 31, 2020. As of December&#160;31, 2021 and 2020, the warrants are equity-classified and are exercisable for <ix:nonFraction unitRef="shares" contextRef="i4d74b118fa384d7ebae249afc60e4626_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc0NDE_04b21bc7-8bee-48a7-a29d-6bc42e425230"><ix:nonFraction unitRef="shares" contextRef="ie6f93dd1e5494e218459effec8912900_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc0NDE_1c4d5098-5115-42cf-8bc2-e5bb0c69a0fc">7,354</ix:nonFraction></ix:nonFraction> shares of common stock of the Company at $<ix:nonFraction unitRef="usdPerShare" contextRef="i4d74b118fa384d7ebae249afc60e4626_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc0ODU_17ba2199-e01b-4c3a-b12a-c886aea6da6d"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6f93dd1e5494e218459effec8912900_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc0ODU_64f96b70-992e-4e76-9957-159ab2d6b093">17.00</ix:nonFraction></ix:nonFraction> per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment. Interest expense was approximately $<ix:nonFraction unitRef="usd" contextRef="i51d5eb374e764a38a5a2883487e16341_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzE2NDkyNjc0NjAyMjE_0d4cdb60-57e4-4dd8-8ea0-6aaa05251051">5.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4dec658dfa294ef580b787eaea9c9e61_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzE2NDkyNjc0NjAyMzE_ed8b00da-6c6a-436d-bf71-db750946c422">0.9</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020, respectively, as related to the Amended 2020 Loan Agreement. Interest expense was approximately $<ix:nonFraction unitRef="usd" contextRef="i8bd2ea5f3b8d4063b55ea5ac924b3bc2_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzE2NDkyNjc0NjAyMzk_b1c93460-3f78-4416-892c-3e161727f20b">44,000</ix:nonFraction> for the year ended December 31, 2020 as related to the Company&#8217;s previous loan and security agreement, as amended, or the 2015 Loan Agreement, with Oxford. The Company recorded no interest expense for the year ended December 31, 2021 related to the 2015 Loan Agreement since it was paid in full in March 2020.</span></div></ix:continuation><div id="ie96bda597eaa4024845d6498a1c78657_229"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5Xzc5NjI_56518355-1834-4859-a7db-f890044014d2" continuedAt="i19b361921aed41e38877ab0091b8c96b" escape="true">CONVERTIBLE PROMISSORY NOTES </ix:nonNumeric></span></div><ix:continuation id="i19b361921aed41e38877ab0091b8c96b" continuedAt="i7aab063eb62e4837baf0afe9269860df"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company issued the 2019 Note in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i903596dda51b4295ba537cb047cbe3ee_I20190520" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5Xzkw_907e92ab-cdb8-4d56-b2e2-1b91fea7dd0b">40.0</ix:nonFraction> million to Viking in a private placement transaction. The 2019 Note began to accrue interest in February 2020 at a rate of <ix:nonFraction unitRef="number" contextRef="ice2d978f42f647d0b34ffd2d606a3b23_I20200229" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzE5Nw_995c1cc2-1402-44e0-8c40-492d343bd9ad">1.5</ix:nonFraction>% per month. In April 2020, the Company issued the 2020 Notes in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i5b2c31362ca6456e9fa354eb0012a302_I20200430" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzI4OQ_efce9fb5-a41b-4661-aa5b-5d412f3661bf">15.0</ix:nonFraction> million to Viking and certain other investors in a private placement transaction. Upon issuance, the 2020 Notes accrued interest at a rate of <ix:nonFraction unitRef="number" contextRef="i5b2c31362ca6456e9fa354eb0012a302_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzQyNg_66f0d725-51bf-4205-86d3-b4fe1361226a">1.0</ix:nonFraction>% per month.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion Upon IPO</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 21, 2020, the Company completed its IPO. The aggregate total balance of the 2019 Note, or $<ix:nonFraction unitRef="usd" contextRef="i9912d0eb770b4de0a793e3fe42d493b4_I20200821" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc0ODY_775fdabe-fc2d-4fd5-b87c-39ba4aaa5d7a">43.7</ix:nonFraction> million, converted at the fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9912d0eb770b4de0a793e3fe42d493b4_I20200821" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc0OTA_868a9daf-8fdb-42c5-a23e-3a4ace24791c">14.35</ix:nonFraction> per share, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="if68d1087bb6f4d22995e04dde84541a0_D20200821-20200821" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc0OTQ_abda2871-14ff-444d-98c0-bbe15e16c93a">3,046,467</ix:nonFraction> shares of common stock to the holder. The aggregate total balance of the 2020 Notes, or $<ix:nonFraction unitRef="usd" contextRef="i09b542f567974ce98531ed6d78bdcb08_I20200821" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc0OTg_b23390ac-d9ad-42ef-81c2-06971c2a14e6">15.7</ix:nonFraction> million, converted at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i09b542f567974ce98531ed6d78bdcb08_I20200821" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc1MDY_99af909d-2410-4af0-8ef4-82ee7a8060cf">12.56</ix:nonFraction> per share, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="ie129391072864eaa854b90a526c15513_D20200821-20200821" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc1MDI_9e984e0b-6ea6-4183-a1d0-8c440c5e5936">1,248,136</ix:nonFraction> shares of common stock to the holders.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of the 2019 Note and the 2020 Notes were evaluated for contingent BCFs under ASC Topic 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt With Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See discussion of debt discount below for evaluation upon conversion.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2019 Note and the 2020 Notes contained alternative conversion options to the IPO upon the consummation of certain events, each of which had its own conversion prices and terms. The Company determined certain settlement features qualified as conversion features not meeting the requirements for separate accounting as embedded derivatives, while others qualified as redemption features meeting the requirements for separate accounting which were accounted for as derivative instruments.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the 2019 Note and the 2020 Notes, the Company recorded derivative liabilities with corresponding debt discounts on the consolidated balance sheets at the estimated fair value of the bifurcated compound liabilities. The Company remeasured the fair value at each reporting period. Changes in the probability of each embedded redemption feature drove changes in the fair value of the derivative liabilities and had a corresponding impact on the Company&#8217;s net loss. During the second quarter of 2020, the fair value of the derivatives were determined to be <ix:nonFraction unitRef="usd" contextRef="i0784cd66e4954bd983b5bf6086ef67c6_I20200630" decimals="INF" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzE2NDkyNjc0NjA5Mzk_8dbfb45a-0c2e-4264-ac31-d948a9582550">zero</ix:nonFraction> based upon the expected conversion of the notes via an embedded conversion feature which did not meet the definition of a derivative. Upon conversion of the 2019 Note and the 2020 Notes in August 2020 upon completion of the Company&#8217;s IPO, the derivative liabilities were extinguished. No additional expense was recorded at extinguishment since the derivative liabilities had already been assessed to have zero value. During the year ended December 31, 2020, the Company recorded other income of $<ix:nonFraction unitRef="usd" contextRef="id39de78949fa4338b856a1bf1a370fbf_D20200101-20201231" decimals="-5" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzE2NDkyNjc0NjE0MTM_8881afe3-5f72-4af4-a0aa-1771e72ed1e9">2.7</ix:nonFraction> million related to changes in fair value of derivative liabilities in the consolidated statements of operations.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Discount </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the 2019 Note and the 2020 Notes, the Company recorded debt discounts related to BCFs, as well as derivative liabilities and debt issuance costs. Prior to conversion, the debt discounts were amortized over the life </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i7aab063eb62e4837baf0afe9269860df"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the notes. Amortization of the debt discount from inception of the 2019 Note until conversion of the 2019 Note and the 2020 Notes upon IPO was $<ix:nonFraction unitRef="usd" contextRef="i88c0a33aee14452581d9c884594cd5aa_D20190501-20200821" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzcyODA_01919c56-1134-4f31-b10d-20ab74dfa2f1">8.7</ix:nonFraction> million. At the time of conversion, the 2019 Note and the 2020 Notes had unamortized discounts of $<ix:nonFraction unitRef="usd" contextRef="i9912d0eb770b4de0a793e3fe42d493b4_I20200821" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzczNzM_a8bc06a5-b398-4f43-ae58-4d38249be786">6.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i09b542f567974ce98531ed6d78bdcb08_I20200821" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzczODA_aa28a7f9-f86b-4f7e-b39e-ed6583b4e420">2.7</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion of the 2019 Note and the 2020 Notes, the Company remeasured the intrinsic value of the BCFs which resulted in a reversal of the remaining unamortized discounts associated with the BCFs, resulting in a $<ix:nonFraction unitRef="usd" contextRef="ib9c4b992959d4ddb90aad9b4d5df22bb_D20200821-20200821" decimals="-5" name="inbx:ReversalOfUnamortizedBeneficialConversionFeature" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5Xzc2MTY_81433b1f-56b3-4c46-b0ea-41a670cf14ee">7.4</ix:nonFraction> million impact to additional paid-in-capital. Additionally, the Company accelerated the unamortized debt discounts related to the debt issuance costs and the derivative liabilities, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i3c9b6bfda5d34fbca767a5fbbe17acf7_D20200821-20200821" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5Xzc4MDg_64b4624e-997c-489c-ad00-c6f661d935f8">2.2</ix:nonFraction> million charge to interest expense during the third quarter of 2020.</span></div></ix:continuation><div id="ie96bda597eaa4024845d6498a1c78657_232"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzIwNzQ_0e1926cc-554b-4daf-8754-4e541f66907e" continuedAt="i127eb1a36cb547de85d7c179dd944f22" escape="true">STOCKHOLDERS&#8217; EQUITY (DEFICIT) </ix:nonNumeric></span></div><ix:continuation id="i127eb1a36cb547de85d7c179dd944f22"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Certificate of Incorporation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;21, 2020 upon completion of the IPO, the Company&#8217;s certificate of incorporation was amended and restated to authorize <ix:nonFraction unitRef="shares" contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzIwNQ_f3066c7e-dbf5-4389-a880-520bab0ed437">120,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzIzNQ_84f4eaca-fea1-4d63-9953-0f5676e743a0">15,000,000</ix:nonFraction> shares of preferred stock, each with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzI5MA_45c341f1-b253-4748-ae1a-a574828fa05f"><ix:nonFraction unitRef="usdPerShare" contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzI5MA_6e56c054-d02a-4c22-8dc1-f8c74457c1d1">0.0001</ix:nonFraction></ix:nonFraction> per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of the Company&#8217;s IPO in August 2020, all of the outstanding shares of convertible preferred stock were converted into <ix:nonFraction unitRef="shares" contextRef="ic8eef267ef1c487289aaf7cbf76447dd_D20200821-20200821" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzEwOTk1MTE2MzExMjM_0b172963-8648-471c-8887-b2cc8d950fae">7,211,086</ix:nonFraction> shares of the Company&#8217;s common stock. Prior to its conversion to common stock, the convertible preferred stock was classified as temporary, or mezzanine, equity on the accompanying consolidated balance sheets since the shares contained certain redemption features that were not solely within the control of the Company. The Company had not previously accreted the convertible preferred stock to its redemption value since the shares were not currently redeemable and redemption was not deemed to be probable. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No convertible preferred stock was authorized or issued as of December&#160;31, 2021 or December&#160;31, 2020.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into the Sales Agreement with the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="if28c89b4ce594ec18c2baa17251f5398_D20210901-20210930" decimals="-5" name="inbx:SaleOfStockCommonStockAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzEwOTk1MTE2MzIzNTM_de59d662-9414-43a3-aa22-3cd8a4593a4b">200.0</ix:nonFraction> million through the Sales Agent, or the ATM Offering. Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to <ix:nonFraction unitRef="number" contextRef="if28c89b4ce594ec18c2baa17251f5398_D20210901-20210930" decimals="INF" name="inbx:CommonStockSaleOfStockCommissionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzEwOTk1MTE2MzIzNjA_0d2379a5-5e8a-4f7c-aead-aa39a1c325cd">3</ix:nonFraction>% of the gross sales price per share sold. As of December&#160;31, 2021, the Company has sold <ix:nonFraction unitRef="shares" contextRef="i64129936be0b412b8e1d86243a3cc9f1_I20211231" decimals="INF" name="inbx:SaleOfStockSharesCommonStockSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzEwOTk1MTE2MzI1MjE_c809cbe9-338d-4672-988c-55b9e9d13da8">921,042</ix:nonFraction> shares under the ATM Offering for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i90dfb0c9e29b4454ae5d3269b190a197_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzEwOTk1MTE2MzI1Mjg_3edd3398-4d09-43ca-8b49-c45e74d0e6c9">40.2</ix:nonFraction>&#160;million, after deducting commissions of $<ix:nonFraction unitRef="usd" contextRef="i90dfb0c9e29b4454ae5d3269b190a197_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzQzOTgwNDY1MTYyMTY_0720c1cb-ad03-478a-84a6-a29277f3d169">1.2</ix:nonFraction>&#160;million. In connection with the ATM Offering, the Company incurred an additional $<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-5" name="inbx:AtTheMarketOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzQzOTgwNDY1MTYxODU_3e3c160a-bf34-4d57-9551-69447fde0416">0.5</ix:nonFraction>&#160;million of expenses which were offset against the proceeds of the offering.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, the Company issued warrants to Oxford concurrently with the 2020 Loan Agreement. Upon the consummation of the Company&#8217;s IPO in August 2020, the warrants are exercisable for <ix:nonFraction unitRef="shares" contextRef="ie6f93dd1e5494e218459effec8912900_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzE3NDE_c2994f25-5cb6-42f4-91d0-9a1b7388f15a">7,354</ix:nonFraction> shares of common stock of the Company at $<ix:nonFraction unitRef="usdPerShare" contextRef="ie6f93dd1e5494e218459effec8912900_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzE3ODU_7758aa37-db94-4ad2-ad1d-e80acc49279e">17.00</ix:nonFraction> per share. As of December&#160;31, 2021, the warrants are equity-classified and reflected in additional paid-in-capital at $<ix:nonFraction unitRef="usd" contextRef="i1b6686e2594645e0b104bd30c79c6ce2_I20211231" decimals="-4" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzE4OTE_57fa71db-8f49-4201-9a83-25fb05b649b8">0.14</ix:nonFraction> million. The fair value of the warrants was determined using the Black-Scholes model on the date of reclassification. No subsequent remeasurement is required for equity-classified warrants.</span></div></ix:continuation><div id="ie96bda597eaa4024845d6498a1c78657_235"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDQ_6c5a66fc-808c-45f6-8647-a5ce215da6db" continuedAt="ia2cdcccacdf145fb8bf163726721e3a4" escape="true">EQUITY COMPENSATION PLANS </ix:nonNumeric></span></div><ix:continuation id="ia2cdcccacdf145fb8bf163726721e3a4" continuedAt="i723cd1a765c94dbabcc0c50242407093"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, provides for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. As of December&#160;31, 2021, an aggregate of <ix:nonFraction unitRef="shares" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzM3MA_21ce5e1b-f989-43de-859e-e423d1dbc07e">4.5</ix:nonFraction> million shares of common stock were reserved for issuance under the 2017 Plan, of which <ix:nonFraction unitRef="shares" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzQ1Mw_bfd0b30e-cb66-4dad-8559-16e8bdacc2a0">0.1</ix:nonFraction> million were available. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. The Company grants options with an exercise price equal to </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i723cd1a765c94dbabcc0c50242407093" continuedAt="i1c43e1d8cdf046dcac7e612762f6bad0"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair market value of the Company&#8217;s stock on the date of the option grant. The options are subject to <ix:nonNumeric contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDU_65655ebb-e924-4eb9-9331-f61a9d142275">four-year</ix:nonNumeric> vesting with a <ix:nonNumeric contextRef="i61137fd603eb42ea8e17d095c0e1c8a8_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDY_2bc4c9e8-f26d-4bf3-ad6e-8f35880fe405">one-year</ix:nonNumeric> cliff and have a contractual term of <ix:nonNumeric contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzg5NQ_d26705a4-e319-4bb2-87e9-94c3fe4b74a0">10</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDc_27212925-7329-4ef5-9bb8-c2c2e74899ab" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under its 2017 Plan for the year ended December 31, 2021 is as follows (in thousands, except for per share data and years):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (In Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzQtMS0xLTEtMjQzNzY_074f77a8-db4f-40b9-b2ad-84a56f85e213">2,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzQtMy0xLTEtMjQzNzY_a6e09cb4-2eae-4bd8-a798-8e8cdb52b837">11.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzYtMS0xLTEtMjQzNzY_b0af60ed-4ea9-4456-a711-dfc856b1dff3">2,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzYtMy0xLTEtMjQzNzY_65f65072-95d2-4ec7-a037-65b907e23c68">32.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzctMS0xLTEtMjQzNzY_02130fce-a16f-47d4-987b-6010c8a5b356">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzctMy0xLTEtMjQzNzY_05e59064-50a2-4921-9936-5a93ba41195d">23.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzgtMS0xLTEtMjQzNzY_7990264a-5aed-480e-a9e8-d9157b83a2dd">358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzgtMy0xLTEtMjQzNzY_b0d5ee24-79b5-44d1-8aae-d75087d7f65b">11.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzktMS0xLTEtMjQzNzY_e146e4a3-898d-456e-b3bd-5c18eac324af">4,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzktMy0xLTEtMjQzNzY_ded9f0b0-7ff5-4c43-89b4-fdac39509c84">22.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzktNS0xLTEtMjQzNzY_5959c551-7523-4d12-ac0e-fb5f09c33ca7">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzktNy0xLTEtMjQzNzY_57aad947-2524-4ae1-bab0-bbfcf9692ca1">87,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzEwLTEtMS0xLTI0Mzc2_444b72fe-a4ae-4ddb-a51c-abad4f631b81">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzEwLTMtMS0xLTI0Mzc2_47b69c0e-9db8-428b-acf6-19fc4efa52af">11.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzEwLTUtMS0xLTI0Mzc2_5dbb088a-cb07-4e48-9baa-d93be514fd35">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzEwLTctMS0xLTI0Mzc2_ae0fcfdc-d4df-480f-b1f3-338b232f9e39">40,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzEwOTk1MTE2MzM4NDY_533f5912-5a5c-4e35-bfd5-4fb9036bb0a0">7.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzEwOTk1MTE2MzM4NTI_3e72fb8f-237b-463e-8cdd-4d6084d237c7">19,000</ix:nonFraction>, respectively. Aggregate intrinsic value of stock options exercised and outstanding is calculated using the fair value of common stock on the date of exercise and as of December&#160;31, 2021, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#8217;s anticipated stock volatility, and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. The Company recognizes forfeitures as they occur.</span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDg_01c838c1-847f-4e63-ab70-46537a723ecf" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the years ended December 31, 2021 and 2020 were as follows.&#160;</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzMtMS0xLTEtMjQzNzY_94771b3b-ac36-46a0-befe-a8ed8a6ed5e2">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzMtNS0xLTEtMjQzNzY_3c640895-81a3-410e-971e-bb2c96968056">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzQtMS0xLTEtMjQzNzY_793d1a83-0875-4d70-9476-759639b16925">93.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzQtNS0xLTEtMjQzNzY_564fe1fd-7412-4454-a8c7-83e64c43c259">97.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzUtMS0xLTEtMjQzNzY_a1940fe7-c666-42ae-abb8-dfc33457bb52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzUtNS0xLTEtMjQzNzY_d1a73667-bbca-42cb-a816-31d2732841cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzYtMS0xLTEtMjQzNzY_65cc1c1d-c945-477f-8f22-eb78fa2dcceb">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzYtNS0xLTEtMjQzNzY_750d293c-4602-4016-9f05-de7005afebe4">6.08</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzgtMS0xLTEtMjQzNzY_4e2670a9-7891-42e3-b104-7002c157a1f8">24.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzgtNS0xLTEtMjQzNzY_182ca280-fb19-4201-9f04-fa5153bc437c">10.82</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the assumptions used in the option pricing model in the following manner:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited historical stock price volatility data, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i1c43e1d8cdf046dcac7e612762f6bad0" continuedAt="i4de00b28a727457bad19e3363dd59bfc"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">selected companies&#8217; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s IPO, given the absence of a public trading market for the Company&#8217;s common stock, its board of directors exercised their judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company&#8217;s common stock underlying the stock options, such as: contemporaneous valuations performed by independent third-party specialists, its stage of development, including the status of its research and development efforts of its therapeutic candidates and the material risks related to its business and industry, its results of operations and financial condition, including its levels of capital resources, the prices at which its sold shares of its convertible preferred stock, the rights, preferences and privileges of its convertible preferred stock relative to those of its common stock, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable life sciences public companies, as well as recently completed mergers and acquisitions of peer companies, the likelihood of achieving a liquidity event for the holders of its common stock or convertible preferred stock, such as an IPO or a sale of the Company given prevailing market conditions, trends and developments in its industry, external market conditions affecting the life sciences and biotechnology sectors, and the lack of liquidity of its common stock, among other factors.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on its closing market price on the date of the grant. The Company&#8217;s board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of its common stock underlying those options on the grant date. </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDk_b437527d-9f5c-4698-b5f6-fe9c4fc1b2f1" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.286%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e02f9252cd34ce2b7cec9630fc0647c_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzMtMS0xLTEtMjQzNzY_65af8a3b-5d0d-4da2-92e7-5b64a9d47a45">11,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c6895eb15134795b9d0e82c56053e76_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzMtMy0xLTEtMjQzNzY_99809030-408d-4a97-89be-ebb6d2903534">4,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06da7c90c85744e885809060c5d6303c_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzQtMS0xLTEtMjQzNzY_0eeae1e4-1e4e-4eef-884f-c3d2f133f82e">3,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f544045b0fb4204a60d3d67976ede93_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzQtMy0xLTEtMjQzNzY_0963b788-b594-4df2-8f0b-749a10614a8f">723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzUtMS0xLTEtMjQzNzY_5d4030b5-4e27-415b-8321-ad3f27ddeb12">15,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzUtMy0xLTEtMjQzNzY_3ec83d5a-2099-4981-bafd-f3c7eabd9451">5,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4de00b28a727457bad19e3363dd59bfc">As of December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i48c28eaf2c8c46e5bee554a6274ee022_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU2ODk_6e6437e1-8780-4574-86f2-be4ff1531b32">47.0</ix:nonFraction> million of total unrecognized stock-based compensation expense related to its stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDI_857802e5-e363-436b-96f2-25e59a53815b">3.04</ix:nonNumeric> years</ix:continuation>.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_238"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="inbx:LicenseAndGrantRevenueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzIyNTAx_65abe53f-9954-4023-a987-27f08a010d61" continuedAt="i7405f16c499e433bb1fb97f123700af9" escape="true">LICENSE AND GRANT REVENUES </ix:nonNumeric></span></div><ix:continuation id="i7405f16c499e433bb1fb97f123700af9" continuedAt="i46f6c4b447844561a036662e9715cc8d"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzIyNTAy_baf0b5cb-ac79-4345-b018-577bc3cc65a5" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company&#8217;s consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.286%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elpiscience Biopharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a6aef8263df4b4394e27acda74d8862_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzQtMS0xLTEtMjQzNzY_23aa33ae-4600-46b3-be25-5874866cf0a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d9970bae2c434f937ba92ef27c5adf_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzQtMy0xLTEtMjQzNzY_f5a26ba6-f309-4e95-b7ef-e7f0e2b19649">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from affiliates</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341109abd16e4f10b4e1e65b6337432b_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzYtMS0xLTEtMjQzNzY_195658a2-6a05-4368-9e17-a031fbdf7fd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c3275369d04c28ab7b49526e64a396_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzYtMy0xLTEtMjQzNzY_0f3fc12a-eb7f-4d11-aa15-8acce6a7031c">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from non-affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2seventy bio, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142ace6beb0a4e0cb0a31bdafc6073cb_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzgtMS0xLTEtMzQ2Mzc_98251813-c8a1-457a-aa94-cb99468acb13">4,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec1fc7e08a643bf8e0ed329426540bf_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzgtMy0xLTEtMzQ2Mzc_93fb9713-8f7c-45b3-90ff-1fcf12ff3667">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phylaxis BioScience, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9873f9e3a544e59ad94ffcbdc43d0e_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzktMS0xLTEtMzQ2NDQ_bc52e2d1-62c4-4dd9-82cf-86d4851f22d6">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b7601189b5477d86501a51b482aa63_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzktMy0xLTEtMzQ2NDQ_0f4b29ad-d38f-4623-b8f4-a6259881741b">1,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chiesi Farmaceutici S.p.A.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36de08aad5f467f9e693d3ede931b29_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzgtMS0xLTEtMjQzNzY_f44ac1c8-2e20-41a5-a0e2-da12ff8ba9e8">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a51291642f448ec8cd027ba449ffffc_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzgtMy0xLTEtMjQzNzY_fe91061e-e53c-4d9d-80d4-a3514723bb8b">7,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license revenues from non-affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcea0ecd9c6b41f78dbf074f597078d2_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzExLTEtMS0xLTI0Mzc2_849e3643-347a-4681-8349-ab88cf131a52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd518d0ffae4538a37e20dd37eef51e_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzExLTMtMS0xLTI0Mzc2_fc707c1e-dc4f-4da3-a8ec-395e4fe556ca">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from non-affiliates</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff19098b1d84316ac86ea37db136e01_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzEyLTEtMS0xLTI0Mzc2_943250f6-5242-4700-a0a3-06027dd764a8">7,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d0d09c00524dfa9503fde259f37888_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzEyLTMtMS0xLTI0Mzc2_dfa1ff20-6bda-4805-9841-9af0a1acd0c5">10,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congressionally Directed Medical Research Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14792fc3ee614e638bfb3b224a160754_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE2LTEtMS0xLTI0Mzc2_544699e0-a9b0-499c-8922-548ea22ef74e">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia67376928e9f4157be200ec20b14f188_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE2LTMtMS0xLTI0Mzc2_88ccb47c-7b6b-4260-9993-845e52eff74d">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd1e8d9a53a428686d8938f450e798b_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE3LTEtMS0xLTI0Mzc2_622096c6-ec6e-47c1-817d-0f3870141997">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f5f2867b4374b8392c13581eb930e33_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE3LTMtMS0xLTI0Mzc2_f4f3d3a4-d10e-4812-b1d2-80eb08893f93">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE4LTEtMS0xLTI0Mzc2_7f5630a0-da8c-4d44-94a0-ff79acfe89e7">7,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE4LTMtMS0xLTI0Mzc2_b9ff9bed-37bb-4d19-a77b-88d00a5047ad">12,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Elpiscience</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into a separate License Agreement, or the OX40 License Agreement, with Elpiscience Biopharmaceuticals, Inc., or Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#8217;s multivalent protein therapeutic directed to the biological target OX40, or INBRX-106. This license provides Elpiscience with the right to further advance the therapeutic candidate through clinical trials, as well as manufacture and commercialize it. It also requires the Company to provide Elpiscience with know-how and materials specific to INBRX-106, including process development and manufacturing data and information necessary to develop INBRX-106. In the OX40 License Agreement, the Company also agreed to negotiate an agreement to supply Elpiscience with INBRX-106 for its development in Mainland China, Hong Kong Macau and Taiwan. The Company is eligible to receive certain developmental and commercial milestones of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i6590e8fbc4694172ba86e9ff761b35b1_I20180430" decimals="-5" name="inbx:CollaborativeArrangementMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NTk5NjY_856f485a-937a-40af-99a7-2dcb86697575">100.0</ix:nonFraction> million, as well as percentage tiered royalties on future product sales with rates in the high single-digits. Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company achieved a milestone under the contract for $<ix:nonFraction unitRef="usd" contextRef="ib4809a9a893f4d2c8042ea8a8edf9689_D20200901-20200930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NjA1Njc_4e7344b7-12c5-43d5-ba6a-e71f02a825c0">2.0</ix:nonFraction> million, which was received during September 2020. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="id5d9970bae2c434f937ba92ef27c5adf_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NzkwOTc_49aa6a38-0ad6-4bc6-afc0-7b503b7c8753">2.0</ix:nonFraction> million during the year ended December 31, 2020. <ix:nonFraction unitRef="usd" contextRef="i8a6aef8263df4b4394e27acda74d8862_D20210101-20211231" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NjA2Njg_f313c00b-f475-4a7b-8abc-3670ea1ebc12">No</ix:nonFraction> revenue was recognized related to this agreement during the year ended December 31, 2021.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2seventy bio, Inc.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2018, the Company entered into a License Agreement with bluebird bio, Inc., or bluebird, whereby the Company granted bluebird the exclusive, worldwide rights to develop, manufacture, and commercialize certain cell therapy products containing binders. In November 2021, bluebird assigned the agreement, or the 2018 2seventy Agreement, to its affiliate, 2seventy bio, Inc., or 2seventy, in connection with an internal restructuring and subsequent spin-out of 2seventy. Under this agreement, the Company is entitled to receive specified development milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i6a40dcc9d78543888f5c69df6b043678_I20181220" decimals="-5" name="inbx:CollaborativeArrangementDevelopmentMilestoneReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTAyNjQ_ff47a4b3-b40b-48cb-a61b-bc3880c39263">51.5</ix:nonFraction> million per therapeutic, as well as percentage tiered royalties on </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i46f6c4b447844561a036662e9715cc8d" continuedAt="i448fc9c203f544b3bf26538cc56bf107"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, a milestone event under the 2018 2seventy Agreement was achieved and the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i698dae32d5a249e4b3a18d5a9465c4eb_D20210701-20210731" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTA5MDc_33905dc9-cd46-4161-ad22-587056fc36a4">2.0</ix:nonFraction> million of revenue at that point in time. The Company received the associated $<ix:nonFraction unitRef="usd" contextRef="i271fbcd059344d279776e92017e48fd9_D20210801-20210831" decimals="-5" name="inbx:CollaborativeArrangementMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTA5ODE_93222f9f-01f4-4a2b-8c1b-4b164d4f2a92">2.0</ix:nonFraction> million payment in August 2021. During the year ended December 31, 2021, the Company recognized a total of $<ix:nonFraction unitRef="usd" contextRef="i09040213ce284863b236dce6b9e77648_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTEwNTk_55512117-2816-4501-9e05-d3daff42cf0a">2.0</ix:nonFraction> million in revenue related to this agreement. During the year ended December 31, 2020, the Company recognized <ix:nonFraction unitRef="usd" contextRef="ia212ff07ac3d4e76acd885a467fdf19e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzQzOTgwNDY1ODM5MzQ_a6e8c11f-32cd-4349-9d3f-6ac353b3137d">no</ix:nonFraction> revenue related to this agreement.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Option and License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Option and License Agreement with bluebird, pursuant to which the Company granted to bluebird exclusive worldwide development licenses to develop binders and cell therapy products containing single domain antibodies, or sdAbs, directed to specified targets, consisting of <ix:nonFraction unitRef="program" contextRef="i0e2033a7016a444c9b438b2366300cfe_I20200630" decimals="INF" name="inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE1MjY_2492a705-f625-4cd5-b5e9-8e7b7bec2c91">two</ix:nonFraction> initial programs and up to an additional <ix:nonFraction unitRef="program" contextRef="i1083dfcb25d248699e857f5dda8cb53e_I20200630" decimals="INF" name="inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE1NzE_f377a6e4-b39f-45b2-9274-ed2a02b2ab4d">8</ix:nonFraction> programs. The Company retains all rights to the specific sdAbs outside of the cell therapy field. This agreement, or the 2020 2seventy Agreement, was also assigned to 2seventy in November 2021 in connection with bluebird&#8217;s internal restructuring and subsequent spin-out of 2seventy.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company received a non-refundable upfront option fee of $<ix:nonFraction unitRef="usd" contextRef="ifcfc29d4ec6340358e01e8204eb73565_D20200601-20200630" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE5MzI_61b224b1-6aa8-454f-8f5b-e8c81c194f5e"><ix:nonFraction unitRef="usd" contextRef="i99c1b2eab0714268ae2f91d921ac33bc_D20200601-20200630" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE5MzI_d62aaa7c-91cc-4304-86d1-f9dd1a49cc17">0.2</ix:nonFraction></ix:nonFraction> million in connection with each of the <ix:nonFraction unitRef="program" contextRef="i0e2033a7016a444c9b438b2366300cfe_I20200630" decimals="INF" name="inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE5Njc_e1fa2eb4-e98c-434f-a63b-3225053f7158">two</ix:nonFraction> initial programs, or $<ix:nonFraction unitRef="usd" contextRef="i37061eba67bd4d3d915360e78477ab20_D20200601-20200630" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE5OTI_7a44f377-1a45-4e7c-bd5d-01a6c37abc05">0.4</ix:nonFraction> million in aggregate, and is entitled to an upfront option fee for each additional program, on a program-by-program basis. The Company also granted an option in which 2seventy may acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which 2seventy exercises its option, 2seventy will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions for each option 2seventy chooses to exercise. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i67acf789baa649c0af5372276d8d64e9_I20200630" decimals="-5" name="inbx:CollaborativeArrangementDevelopmentMilestoneReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTI3MDg_fe750441-c18a-409a-91e5-a83f5e45d2e6">51.5</ix:nonFraction> million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the effective date of the 2020 2seventy Agreement, the Company identified <ix:nonFraction unitRef="performanceobligation" contextRef="i0e2033a7016a444c9b438b2366300cfe_I20200630" decimals="INF" name="inbx:NumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTMzNDE_644b664e-84ba-432b-a25a-f0822681d50f">one</ix:nonFraction> performance obligation, which was the transfer of the exclusive development license to bluebird for the <ix:nonFraction unitRef="program" contextRef="i0e2033a7016a444c9b438b2366300cfe_I20200630" decimals="INF" name="inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTM0NDk_a28b331c-4709-4bac-ad64-0a768cae1eed">two</ix:nonFraction> initial programs. The Company determined that the option granted for an exclusive license in the future was not a material right. For the <ix:nonFraction unitRef="program" contextRef="i1083dfcb25d248699e857f5dda8cb53e_I20200630" decimals="INF" name="inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTM1OTE_3f4f45d9-b561-4423-a10d-da021f6538cf">eight</ix:nonFraction> programs not identified upon execution of the contract, the Company evaluated the customer option for additional purchases and determined that those options for additional programs did not constitute material rights nor variable consideration. As additional programs are identified, the Company will re-assess its performance obligations and transaction price accordingly.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the total transaction price of the 2020 2seventy Agreement at execution was $<ix:nonFraction unitRef="usd" contextRef="i37061eba67bd4d3d915360e78477ab20_D20200601-20200630" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQwNjc_576770d9-6243-4672-9b18-7936d5fe6165">0.4</ix:nonFraction> million for the transfer of the <ix:nonFraction unitRef="license" contextRef="i67acf789baa649c0af5372276d8d64e9_I20200630" decimals="INF" name="inbx:CollaborativeAgreementExclusiveDevelopmentLicenses" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQwOTU_f33ea29e-e6c9-4456-9322-3e87ce039924">two</ix:nonFraction> exclusive development licenses. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i26036eb0b6df49ce9df831623f43f4a3_D20200601-20200630" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQxNTQ_e29a8f4c-609b-4767-879a-c768e66541ed">0.4</ix:nonFraction> million of revenue related to this agreement at the point in time in which the exclusive development licenses were transferred to bluebird, which occurred upon execution of the agreement in June 2020. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, pursuant to the option extension terms in the 2020 2seventy Agreement, bluebird requested to extend the option term for one of the initial programs by an additional six months in exchange for an option extension fee of $<ix:nonFraction unitRef="usd" contextRef="i89ce3eba7b0a49238928411c43819b44_D20210501-20210531" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableOptionExtensionFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQ1ODQ_2a804a6b-cef9-49e0-875a-fdd764103ce6">0.1</ix:nonFraction>&#160;million. The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="ic67e70a01a3247d0a701bceabea7050e_D20210501-20210531" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQ2MTY_c63a80a3-8730-4413-8902-50853b95c139">0.1</ix:nonFraction>&#160;million of revenue related to this extension in May 2021, the point in time in which the extension was granted.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, pursuant to the option exercise terms in the 2020 2seventy Agreement, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i4c3132dfaadc4bcfaee034b1b2617d1c_D20211001-20211031" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableOptionExtensionFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQ4MzQ_bf8d115d-ae26-4d88-9c5c-df237bcb6b9e">2.1</ix:nonFraction>&#160;million option exercise fee for one of the initial programs and transferred an exclusive license for the program </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i448fc9c203f544b3bf26538cc56bf107" continuedAt="i040bdc9987be4d62b232359d91b18b0e"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recognized the $<ix:nonFraction unitRef="usd" contextRef="i53c3843a1089489cba9c3e221a109e69_D20211001-20211031" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQ5NjI_97e5bbf5-33b7-44c9-b572-603da8bb6258">2.1</ix:nonFraction>&#160;million of revenue related to this option exercise at the point in time in which the exclusive license was transferred.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i029f0471f2e849158f5ea613d5e42420_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTUxMjU_81bcba72-f12e-4c42-8c3b-f58a561d3a4a">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8577557b2c0f4aff994327f2da3dcc87_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTUxMzM_8007162b-e9be-4bc8-8915-2ca99908411d">0.4</ix:nonFraction>&#160;million of revenue related to this agreement, respectively. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phylaxis Agreements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a joint venture with an entity affiliated with ArrowMark Partners, Phylaxis BioScience, LLC, or Phylaxis. In connection with the joint venture, the Company entered into the following agreements: Contribution Agreement, License Agreement, Limited Liability Company Agreement, and Master Services Agreement, or collectively the Phylaxis Agreements, pursuant to which the Company licensed certain intellectual property and know-how to Phylaxis and agreed to provide services to develop certain compounds. Upon closing, the Company received a $<ix:nonFraction unitRef="usd" contextRef="ie48c123d39ec4759bab8a2b5f5a6d11b_D20200701-20200731" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzgwMw_acbdf286-38fb-4949-862c-8d25f2c68fd6">2.5</ix:nonFraction>&#160;million nonrefundable, upfront payment from Phylaxis under the Master Services Agreement, or the MSA. The Company has also received an additional $<ix:nonFraction unitRef="usd" contextRef="if7901dde9ee1429db2a92db83900b165_I20200731" decimals="-5" name="inbx:CollaborativeArrangementAdditionalPaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzk0Mg_eb27fa03-1e62-4e0d-8ed4-fe2c300aad63">2.5</ix:nonFraction>&#160;million, which was payable within <ix:nonNumeric contextRef="iae6ad83c5ab34b7fa1f535c9d4959c05_D20210101-20211231" name="inbx:CollaborativeArrangementAdditionalPaymentReceivablePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzk2MA_5f9bd769-9a04-411f-a669-2ddf64118046">180</ix:nonNumeric> days from closing under the MSA, in two payments of $<ix:nonFraction unitRef="usd" contextRef="iafffed7f22504c3dbc95651d314d0c59_I20201031" decimals="-4" name="inbx:CollaborativeArrangementAdditionalPaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzk5MQ_ad4b4938-a1e4-41ad-897f-3c8970c6670f">1.25</ix:nonFraction>&#160;million each, received in October 2020 and January 2021. Upon closing, the Company received a <ix:nonFraction unitRef="number" contextRef="i71b075ff878e44c4922334a3be94c8cf_I20200731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwNzA_81ad648a-eed1-44e0-a64b-9c05c58f8457">10</ix:nonFraction>% equity interest in Phylaxis as consideration for the contribution of the license of the Company&#8217;s intellectual property and know-how and is entitled to receive an additional <ix:nonFraction unitRef="number" contextRef="i71b075ff878e44c4922334a3be94c8cf_I20200731" decimals="2" name="inbx:EquityMethodInvestmentAdditionalOwnershipEntitled" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEyNDc_4aefa60e-dac1-49ad-bc2c-fc907a0ebba1">5</ix:nonFraction>% based on the achievement of certain milestones. Under the License Agreement, the Company is also entitled to specified development and commercialization milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="if7901dde9ee1429db2a92db83900b165_I20200731" decimals="-5" name="inbx:CollaborativeArrangementDevelopmentMilestoneReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzE0NDc_7fb5855d-3524-4606-89ab-2e3a222b3e59">225.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if7901dde9ee1429db2a92db83900b165_I20200731" decimals="-5" name="inbx:CollaborativeArrangementCommercializationMilestoneReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzE0NTQ_58bbc75f-24d6-4a6c-b4e7-e674db9b606b">175.0</ix:nonFraction>&#160;million, respectively. The Company is also entitled to share in a percentage of the profits of Phylaxis under the Limited Liability Company Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the fair value of the equity interest in Phylaxis, the Company engaged a third-party valuation specialist. The valuation report utilized a market approach to establish the total equity value of Phylaxis using inputs not observable in the market, including the discount rate. The fair value of the equity interest was $<ix:nonFraction unitRef="usd" contextRef="if7901dde9ee1429db2a92db83900b165_I20200731" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzE5Mzk_9c5e018c-4f96-4a13-99cc-4f727fe5dd5a">0.5</ix:nonFraction>&#160;million, which has been accounted for under the equity method. The fair value of the equity interest upon the execution of the agreements has been included in the transaction price, along with the $<ix:nonFraction unitRef="usd" contextRef="if7901dde9ee1429db2a92db83900b165_I20200731" decimals="-5" name="inbx:CollaborativeArrangementPaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzIxMzE_2b39443d-492c-48f2-8e49-cfd61e1ba4fb">5.0</ix:nonFraction>&#160;million of payments due pursuant to the MSA.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the transfer of the exclusive licenses for, and performance of, development services to modify the first and second compounds as <ix:nonFraction unitRef="performanceobligation" contextRef="if7901dde9ee1429db2a92db83900b165_I20200731" decimals="INF" name="inbx:NumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzIzMjM_27a74370-3236-46c5-8d84-6209b80cb4a7">one</ix:nonFraction> performance obligation and allocated the transaction price evenly between the <ix:nonFraction unitRef="compound" contextRef="if7901dde9ee1429db2a92db83900b165_I20200731" decimals="INF" name="inbx:RevenueRecognitionNumberOfCompounds" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzI0MDQ_4a6c436f-59de-4885-984a-3bfee5e53adc">two</ix:nonFraction> compounds. Revenue related to the performance obligation will be recognized over time as services are performed, based on the Company&#8217;s progress to satisfy the performance obligation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ifd9873f9e3a544e59ad94ffcbdc43d0e_D20210101-20211231" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzI2MzA_ffa02f7e-ef58-41c5-8711-d3716daf1822">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id7b7601189b5477d86501a51b482aa63_D20200101-20201231" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NzkxMDk_a19df6d7-faa6-4f61-b04e-c3f1f356dadb">2.0</ix:nonFraction>&#160;million of revenue related to this performance obligation, respectively. As of December&#160;31, 2021, the Company has $<ix:nonFraction unitRef="usd" contextRef="i8db766ee7ea14809bda578860b7d5f45_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzE2NDkyNjc0OTc5MTg_1adee84a-86be-4f30-8f51-01b30235b00d">1.1</ix:nonFraction>&#160;million of deferred revenue related to this agreement, all of which is classified as current. As of December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="ie3960dc6272747bc82dddb1552b4d038_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NzkxMTg_0853ffd6-21df-4933-945a-03b6208a3d74">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie3960dc6272747bc82dddb1552b4d038_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NzkxMjQ_d81f8b48-4660-402a-bb79-13457c581b46">0.6</ix:nonFraction>&#160;million of current and non-current deferred revenue related to this agreement, respectively. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chiesi</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into an Option Agreement, as amended by the First Amendment to Option Agreement, dated August 19, 2019, or the Chiesi Option Agreement, with Chiesi Farmaceutici S.p.A., or Chiesi, pursuant to which the Company granted to Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada. Under the terms of the Chiesi Option Agreement, the Company received a one-time, non-refundable option initiation payment of $<ix:nonFraction unitRef="usd" contextRef="i65490e5c0be44ba79b6d213cefb118a6_D20190801-20190831" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTg0MDU_bdf22fce-09e4-4428-9e3d-4bdae5db7f22">10.0</ix:nonFraction> million in August 2019. If Chiesi chooses to exercise its option under the Chiesi Option Agreement, then Chiesi must pay the Company a one-time, non-refundable fee of $<ix:nonFraction unitRef="usd" contextRef="i52cdafa4cb7a4f99adc30a5a1c93624f_I20190831" decimals="-5" name="inbx:CollaborativeArrangementAdditionalPaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTg1Njg_622f9ebb-15dd-4cf7-a25b-533fcd1d3cd7">12.5</ix:nonFraction> million upon the effective date of the definitive agreement granting Chiesi the exclusive license. If the option is exercised, under the license agreement, the Company may be entitled to receive specified milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i52cdafa4cb7a4f99adc30a5a1c93624f_I20190831" decimals="-5" name="inbx:CollaborativeArrangementMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTg3OTc_7d527fb2-1799-417a-a0f6-43d890e123e4">122.5</ix:nonFraction> million, as well as royalties on future product sales.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified <ix:nonFraction unitRef="performanceobligation" contextRef="i232e3ecd8bfe4c2aa8c2c245ad98b7c9_I20190819" decimals="INF" name="inbx:NumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTg4NzU_65e2f824-7050-452a-9364-299b974614f6">one</ix:nonFraction> performance obligation as of the effective date of the Chiesi Option Agreement, which is to perform research and development services for Chiesi during the option period, which will continue (unless the Chiesi Option Agreement is terminated earlier by the Chiesi or the Company) until 60 days following the last to occur of (i) the Company&#8217;s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i040bdc9987be4d62b232359d91b18b0e" continuedAt="i22d574be296944bbba32ab6919b45877"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration, or FDA, scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive parallel European Medicines Agency health technology assessment, or EMA-HTA, scientific advice meeting conducted following completion of such Phase I Clinical Trial. The Company has determined that the option to grant a license in the future is not a material right.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i65490e5c0be44ba79b6d213cefb118a6_D20190801-20190831" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTk4MTY_bdf22fce-09e4-4428-9e3d-4bdae5db7f22">10.0</ix:nonFraction> million upfront payment has been allocated to the single performance obligation. Revenue is recognized over time as services are performed during the option period, based on the Company&#8217;s effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period. During the years ended December 31, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="if36de08aad5f467f9e693d3ede931b29_D20210101-20211231" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAxNzM_15a77d3c-5814-4645-ac69-90310e5a8fb2">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5a51291642f448ec8cd027ba449ffffc_D20200101-20201231" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAxODE_83c8b7d9-06af-45a3-914a-135516f27669">7.4</ix:nonFraction> million in revenue related to this agreement, respectively. As of December&#160;31, 2021, the Company has $<ix:nonFraction unitRef="usd" contextRef="i9dfab9b39f19493b85149f07e9d3107b_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAyNjQ_db865b55-3860-43fe-bc91-84b3c5ba43a2">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9dfab9b39f19493b85149f07e9d3107b_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAyNzI_0ecf02b4-cc69-44d7-b56a-f31c242aa24f">0.1</ix:nonFraction> million of current and non-current deferred revenue related to this agreement, respectively. As of December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="iecd1fc01bfe349e38bce8388ae5742cc_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAzODg_e82bc5e4-0327-480c-adb4-17686ffd57c2">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iecd1fc01bfe349e38bce8388ae5742cc_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAzOTY_75ff469d-28e3-4712-ad4b-fc5a13dcac70">0.1</ix:nonFraction> million of current and non-current deferred revenue related to this agreement, respectively. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2012, the Company entered into a Development and Option Agreement with Celgene whereby the Company granted Celgene an option to exclusively license certain intellectual property rights relating to the Company&#8217;s CD47 checkpoint inhibitor. Upon grant of the Development and Option Agreement, Celgene made a non-refundable upfront option payment for the exclusive license. In June 2013, Celgene opted to exercise its right to license the intellectual property rights associated with the Company&#8217;s CD47 therapeutic. The Company is also eligible to receive certain developmental and commercial milestones of an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i8b51a3f85ef8434cbdc45bc15a773289_I20130630" decimals="-5" name="inbx:CollaborativeArrangementDevelopmentMilestoneReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzQzOTgwNDY1ODU3MjA_9758de76-2611-405f-b232-a43e73a78b46">934.1</ix:nonFraction>&#160;million, assuming the achievement of all potential milestones in the agreement, as well as percentage tiered royalties based on future worldwide sales, with rates ranging between the high single-digits and low teens. The Company is obligated to pay <ix:nonFraction unitRef="number" contextRef="i8b51a3f85ef8434cbdc45bc15a773289_I20130630" decimals="INF" name="inbx:CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzQzOTgwNDY1ODU3MzY_f5faf094-1c2a-44b7-81f8-7a54dfdd693d">2</ix:nonFraction>% of future amounts received under the Development and Option Agreement to advisors who assisted the Company with the negotiation and other matters in connection with the Development and Option Agreement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. No revenue was recognized under this agreement during the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue was recognized in accordance with the Company&#8217;s stated methodology discussed in Note 1.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CDMRP funded through the DoD </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During September 2018, the Company was awarded a grant by the CDMRP funded through the DoD by the U.S. Army Medical Research Acquisition Activity in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i29ef6bdd06234b22b93dd43c5eff449b_I20180930" decimals="-5" name="inbx:GrantValuedAwarded" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzIxNTk0_c2baffb5-22d1-4818-9238-e88efdaf09c2">0.3</ix:nonFraction> million for the continued development of multi-specific antibodies for the treatment against Acinetobacter baumannii infection by circumventing development of bacterial resistance, or the 2018 DoD grant. The work under this grant began in December 2018 and was completed in September 2020. In February 2021, the Company was awarded an additional grant from the DoD in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i7fbcce74ea2b42b78bf1705bd1403dfd_I20210228" decimals="-5" name="inbx:GrantValuedAwarded" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4NzA_6d85294d-77d3-4e02-9e50-8023b12a24f3">0.3</ix:nonFraction> million for the development of sdAb based therapeutics targeting SARS-CoV-2 Spike protein for the treatment of COVID-19, or the 2021 DoD grant. Work under the grant began in February 2021 and is expected to continue through February 2022. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from these grants is based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue is recognized when the Company incurs these covered expenses related to the grant&#8217;s continued progression. The Company submits requests for reimbursement to the DoD for only those expenses which have been incurred by the Company in each period, resulting in reimbursement in arrears. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="iad2111df94964e5485832ec9af0f84c0_D20181201-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4Mzk_f5c1ceed-5699-4005-99cc-178fb83b64f7">0.3</ix:nonFraction> million has been recognized to date under the 2018 DoD grant, all of which has been received in cash from the DoD. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i04bdb4d1a6f84aaaa9f1469326060cc7_D20210201-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4NDg_d9804741-44b0-4cf9-ad6e-8259f37c4f33">106,000</ix:nonFraction> has been recognized to date under the 2021 </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i22d574be296944bbba32ab6919b45877">DoD grant, $<ix:nonFraction unitRef="usd" contextRef="i04bdb4d1a6f84aaaa9f1469326060cc7_D20210201-20211231" decimals="-3" name="inbx:RevenuesCashReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4NTQ_f70f35e5-03ff-41df-b70a-78089a114852">86,000</ix:nonFraction> of which has been received in cash from the DoD. During each of the years ended December 31, 2021 and 2020, $<ix:nonFraction unitRef="usd" contextRef="i14792fc3ee614e638bfb3b224a160754_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4NjY_5bc85997-cf1d-49b1-add7-072aa8b4b3d5">106,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia67376928e9f4157be200ec20b14f188_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4MjU_750c6e9e-2593-45c9-9444-760ec2a8a47d">80,000</ix:nonFraction> was recognized as revenue under the grants, respectively.</ix:continuation> </span></div><div id="ie96bda597eaa4024845d6498a1c78657_241"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzMwNTU_337fe467-6dc9-4452-bc80-529e88b87df8" continuedAt="ia87bac59498b46e79d1942662937c8d1" escape="true">RELATED PARTY TRANSACTIONS </ix:nonNumeric></span></div><ix:continuation id="ia87bac59498b46e79d1942662937c8d1"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business. These agreements are ratified by the Company&#8217;s Board of Directors or a committee thereof pursuant to policy.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LAV Summit Limited </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LAV Summit Limited, or LAV SL, a limited company, is a principal shareholder owning more than <ix:nonFraction unitRef="number" contextRef="i5bf66075080045f5ab3fa12625764cd4_I20211231" decimals="2" name="inbx:RelatedPartyEquityInterestInCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzM4MA_acbf1da7-0bff-4c9a-8c0b-c67b2678351e">5</ix:nonFraction>% of the Company&#8217;s outstanding equity interest during the year ended December&#160;31, 2021. Due to this equity ownership, LAV SL was considered a related party. LAV SL&#8217;s General Partner, Lilly Asia Ventures, or LAV, through one of its funds, holds a significant equity ownership position in Elpiscience, and the Venture Partner of LAV is the CEO, Founder, and Director at Elpiscience. Accordingly, the Company identified Elpiscience as a related party. As of December&#160;31, 2021, LAV SL no longer holds more than <ix:nonFraction unitRef="number" contextRef="i5bf66075080045f5ab3fa12625764cd4_I20211231" decimals="2" name="inbx:RelatedPartyEquityInterestInCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzQzOTgwNDY1MjQ4Njk_acbf1da7-0bff-4c9a-8c0b-c67b2678351e">5</ix:nonFraction>% of the Company&#8217;s outstanding equity interest.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elpiscience</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into the OX40 License Agreement with Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#8217;s multivalent protein therapeutic directed to the biological target OX40, or INBRX-106. Under this agreement, the Company is entitled to reimbursement for certain chemistry, manufacturing, and controls, or CMC, and toxicology expenses incurred for which Elpiscience has paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="i98668daa4f54447a8199b989b8876b3f_I20211231" decimals="-5" name="inbx:ExpensesReimbursedToDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2Mzg3MzI_df1bdfad-7396-4a22-b497-6833f129ff68">5.2</ix:nonFraction> million to date as of December&#160;31, 2021. As of December&#160;31, 2021, the Company has $<ix:nonFraction unitRef="usd" contextRef="i98668daa4f54447a8199b989b8876b3f_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2MzkwNjM_ee5cb033-9a82-4460-a78c-45e5e8722dd8">0.2</ix:nonFraction> million recorded as receivables from related parties from Elpiscience for expenses incurred which have not yet been reimbursed. Additional reimbursements of approximately $<ix:nonFraction unitRef="usd" contextRef="i98668daa4f54447a8199b989b8876b3f_I20211231" decimals="-3" name="inbx:ExpensesExpectedToBeReimbursed" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzE2NDkyNjc0NTUxMDA_c11d72df-ed03-4fd4-9489-9b9090862427">38,000</ix:nonFraction> related to multi-year stability studies are expected to be recognized and paid upon completion. During the year ended December 31, 2021, the Company received <ix:nonFraction unitRef="usd" contextRef="if065b432564046c9bfb0a597fe817533_D20210101-20211231" decimals="INF" name="inbx:CollaborativeArrangementExpenseReimbursement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzE2NDkyNjc0NTUxMDU_91c82bb5-a6d4-4550-9d04-c9a7ec4eff6e">no</ix:nonFraction> reimbursements for expenses already incurred. During the year ended December 31, 2020, the Company received reimbursements of $<ix:nonFraction unitRef="usd" contextRef="i5ebe67fc2c1e4f268cfb5159168b291a_D20200101-20201231" decimals="-5" name="inbx:CollaborativeArrangementExpenseReimbursement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2Mzk2Njk_0b5a34c5-a530-4ce7-98b0-24e7561d5ce1">0.2</ix:nonFraction> million for expenses already incurred. During the year ended December 31, 2021, the Company did <ix:nonFraction unitRef="usd" contextRef="if065b432564046c9bfb0a597fe817533_D20210101-20211231" decimals="INF" name="inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzQzOTgwNDY1MjQ2MDU_4b95013e-551c-4915-8de4-e599865bb3e9">no</ix:nonFraction>t derecognize any expenses related to these reimbursements under the OX40 License Agreement. During the year ended December 31, 2020, the Company derecognized approximately $<ix:nonFraction unitRef="usd" contextRef="i5ebe67fc2c1e4f268cfb5159168b291a_D20200101-20201231" decimals="-5" name="inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2Mzk2OTk_26d599ee-8bf6-4023-a7dc-e5489eac0a3b">0.2</ix:nonFraction> million of expenses related to these reimbursements under the OX40 License Agreement, respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into an additional cost sharing agreement with Elpiscience related to the OX40 License Agreement. Under this agreement, the Company is entitled to reimbursement for certain formulation development costs. Through December&#160;31, 2021, the Company has received $<ix:nonFraction unitRef="usd" contextRef="ie1d04a4699dc49db872fde8657a661e6_I20211231" decimals="-5" name="inbx:ExpensesReimbursedToDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDA5NDQ_cd1b7565-3db3-410a-8989-102e7ff90af5">0.2</ix:nonFraction> million of reimbursements for expenses already incurred under this agreement. As of December&#160;31, 2021, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="ie1d04a4699dc49db872fde8657a661e6_I20211231" decimals="-5" name="inbx:CollaborativeArrangementReceivablesFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDA5NTM_226452a6-6297-4e5c-b653-2a569ddf8d56">0.3</ix:nonFraction> million recorded as receivables from related parties from Elpiscience for expenses incurred which have not yet been reimbursed. During the year ended December 31, 2021, the Company received reimbursements of $<ix:nonFraction unitRef="usd" contextRef="i1308cbf39e914b3390c47254ceff94af_D20210101-20211231" decimals="-5" name="inbx:CollaborativeArrangementExpenseReimbursement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDA5OTg_105628a4-420f-4dbe-9d31-2d15f5085c6b">0.2</ix:nonFraction> million for expenses already incurred. During the year ended December 31, 2021, the Company did not derecognize any expenses related to this agreement. During the year ended December 31, 2020, the Company received no reimbursements. During the year ended December 31, 2020, the Company derecognized $<ix:nonFraction unitRef="usd" contextRef="i3cfee3e7350642afb89fae53b611c85e_D20200101-20201231" decimals="INF" name="inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDEwMzk_71bad12c-eec1-415b-bffe-12934bd7c9d5">0.3</ix:nonFraction> million of expenses related to this agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a Sale and Purchase Agreement with Elpiscience, in which the Company sold drug substance supply to Elpiscience for approximately $<ix:nonFraction unitRef="usd" contextRef="ia72fe4742bba4cdf9802783a4d7a8394_D20210101-20211231" decimals="-3" name="inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDA2MTM_794cae29-8cd8-4744-bf47-76fd958f596c">37,000</ix:nonFraction>, for which it derecognized expenses during the year ended December 31, 2021. As of December&#160;31, 2021, the Company has $<ix:nonFraction unitRef="usd" contextRef="id5a16567fbac48168a3ad10ee9c58f87_I20211231" decimals="-3" name="inbx:CollaborativeArrangementReceivablesFromRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDA5Mzg_cc79fd91-1d0e-43d9-8ae1-2c4ce02cd178">37,000</ix:nonFraction> recorded as receivables from related parties for this purchase.</span></div></ix:continuation><div id="ie96bda597eaa4024845d6498a1c78657_244"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzYyMDA_83d91ff8-3c24-4078-b2f4-7ae861593137" continuedAt="i82285167e80e4b16b8d2b75782d04c2d" escape="true">INCOME TAXES </ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i82285167e80e4b16b8d2b75782d04c2d" continuedAt="i548a32c518234e4e9890aeafb831b540"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzYyMDE_6091fe51-2378-4b8e-bda8-70cf8d829be0" continuedAt="ie479cc1ec1214068a96a97ff903931c0" escape="true">The components of income tax expense (benefit) were as follows for the years ended December 31, 2021 and 2020, respectively (in thousands): </ix:nonNumeric></ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i548a32c518234e4e9890aeafb831b540" continuedAt="i0988530a2bec43049dfc1703a0296ac7"><div style="margin-bottom:9.5pt"><ix:continuation id="ie479cc1ec1214068a96a97ff903931c0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo3NDU2MzM0MmExNzE0NjJiYTMxYjc5MWNmMjVjZDExZi90YWJsZXJhbmdlOjc0NTYzMzQyYTE3MTQ2MmJhMzFiNzkxY2YyNWNkMTFmXzMtMS0xLTEtMjQzNzY_e4ca8968-2dd2-4bd1-b8ca-ed5af49a436b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo3NDU2MzM0MmExNzE0NjJiYTMxYjc5MWNmMjVjZDExZi90YWJsZXJhbmdlOjc0NTYzMzQyYTE3MTQ2MmJhMzFiNzkxY2YyNWNkMTFmXzMtMy0xLTEtMjQzNzY_ae610292-4f08-46f8-9452-c0b6a9c2ec9d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo3NDU2MzM0MmExNzE0NjJiYTMxYjc5MWNmMjVjZDExZi90YWJsZXJhbmdlOjc0NTYzMzQyYTE3MTQ2MmJhMzFiNzkxY2YyNWNkMTFmXzUtMS0xLTEtMjQzNzY_ad093a6d-f7ad-4cca-98bc-aa5041831529">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo3NDU2MzM0MmExNzE0NjJiYTMxYjc5MWNmMjVjZDExZi90YWJsZXJhbmdlOjc0NTYzMzQyYTE3MTQ2MmJhMzFiNzkxY2YyNWNkMTFmXzUtMy0xLTEtMjQzNzY_0b1c6eec-b270-4a9f-9a03-a0a0b0da2921">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for the years ended December 31, 2021 and 2020 was related to California state income tax.</span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzYyMDI_1ed1a2d9-3ca4-4e9c-af34-bb412eaf343e" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2021 and 2020 as follows (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzItMS0xLTEtMjQzNzY_45da2fdd-f6b8-4bf7-8866-4260252c1f8b">17,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzItMy0xLTEtMjQzNzY_55118da7-2a83-4d3a-b319-219141a4e988">15,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (benefit), net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzMtMS0xLTEtMjQzNzY_53413b0b-57e5-48c2-ad91-38450e377863">1,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzMtMy0xLTEtMjQzNzY_50b35cb5-5ebf-4080-95aa-bd33ebc31254">4,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" sign="-" name="inbx:EffectiveIncomeTaxRateReconciliationPermanentItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzQtMS0xLTEtMjQzNzY_f5b9cce2-c89f-4c45-ba06-7a24498bd5d2">207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:EffectiveIncomeTaxRateReconciliationPermanentItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzQtMy0xLTEtMjQzNzY_214a4ab9-2f6d-4bf4-86f5-0fbd713bdd49">2,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzUtMS0xLTEtMjQzNzY_9aeaa944-5926-440e-9666-41d6b18397fb">1,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzUtMy0xLTEtMjQzNzY_19d284c0-1444-4356-8980-87d535f9bfaf">2,878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (FIN 48)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzYtMS0xLTEtMjQzNzY_e11374b0-6186-4856-b938-33ab58a198ac">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzYtMy0xLTEtMjQzNzY_f230209b-a5e1-4e67-b5eb-f604c963be3b">707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision true-ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="inbx:EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzgtMS0xLTEtMjQzNzY_3c1d15d4-b8fd-41b6-93b9-aa4beb467c35">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="inbx:EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzgtMy0xLTEtMjQzNzY_3c5ff9c3-c218-4662-9a35-8651377a43a9">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzktMS0xLTEtMjQzNzY_6beda448-d930-410b-8246-1a1c75ee6b6f">19,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzktMy0xLTEtMjQzNzY_9f3eb08c-6f61-4e5e-8e24-5f996d92e5ee">11,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzEwLTEtMS0xLTI0Mzc2_202fcd9a-814f-4d90-930b-e550e8c5a07f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzEwLTMtMS0xLTI0Mzc2_be04df6c-99d4-47a9-9389-3047738aab8a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i0988530a2bec43049dfc1703a0296ac7" continuedAt="i57bccf46a4cb484fb24ca8c67108e521"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzYyMDM_40531215-6701-405e-a28d-89c112d1fd7d" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred income taxes were as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred income tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzMtMS0xLTEtMjQzNzY_c50b34cc-187a-4b88-8d10-3b1add6d3815">43,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzMtMy0xLTEtMjQzNzY_5c9511c4-3acf-4c0f-924b-f5b3163f9a33">27,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzQtMS0xLTEtMjQzNzY_af7c77ff-d5cb-4622-a91b-2a335268d919">8,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzQtMy0xLTEtMjQzNzY_6f694165-d0f1-4336-8901-54595d44792d">6,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzUtMS0xLTEtMjQzNzY_960ef664-7df2-4b4a-8ddc-f77a9fdff4e1">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzUtMy0xLTEtMjQzNzY_a68d6ab0-fbd3-4d50-9ad6-0c02d361b996">4,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzYtMS0xLTEtMjQzNzY_6a213a9f-bc25-4a60-92e3-dc8882c26d72">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzYtMy0xLTEtMjQzNzY_cab33b31-53cb-4485-9bff-85fb1908936c">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzctMS0xLTEtMjQzNzY_3aff59fb-fc2f-4724-80e3-6bc417351776">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzctMy0xLTEtMjQzNzY_e66e59d2-e04c-4f0e-b19c-ef2bc74b19f9">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzktMS0xLTEtMjQzNzY_b11ebf92-7124-482d-bbad-2248a3403a06">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzktMy0xLTEtMjQzNzY_082e5cc7-4267-4d44-a9f4-c790513e9b1d">806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="inbx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEwLTEtMS0xLTI0Mzc2_b4eedb08-3573-4010-b977-6d9a731da138">1,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="inbx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEwLTMtMS0xLTI0Mzc2_dd7862f8-2346-4e46-b5de-e00ea6b94a1c">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEyLTEtMS0xLTI0Mzc2_e18eface-5c79-4954-81a9-846b0f13840c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEyLTMtMS0xLTI0Mzc2_858e9d51-603f-44ca-868a-412cd0999cd3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEzLTEtMS0xLTI0Mzc2_59b8a16c-5595-45de-a932-4bc4dd062314">59,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEzLTMtMS0xLTI0Mzc2_3e163d52-045a-454e-beb4-af1bfa29f28b">40,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE0LTEtMS0xLTI0Mzc2_8d1422ce-7455-4ba1-8b1a-c79c85110eab">58,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE0LTMtMS0xLTI0Mzc2_cb664c92-1698-4d18-a5c8-a40ad7468c66">39,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE1LTEtMS0xLTI0Mzc2_194a77b2-fa06-48f9-886b-bf5552e36e24">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE1LTMtMS0xLTI0Mzc2_cdd3d410-92d3-405d-96d6-bcc9d832b778">1,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE3LTEtMS0xLTI0Mzc2_3b9d24cd-80e5-4c3f-aea1-5914899fb69f">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE3LTMtMS0xLTI0Mzc2_7892191d-8bd9-4f64-94db-7454e2d6dfad">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE4LTEtMS0xLTI0Mzc2_a781d38e-ef41-47de-a7dd-9fd2b1d247df">1,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE4LTMtMS0xLTI0Mzc2_b376f7d0-e575-43a1-84c2-647bcc14e35b">1,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE5LTEtMS0xLTI0Mzc2_06c83a36-d93f-49cf-889f-120c312c5918">1,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE5LTMtMS0xLTI0Mzc2_0c327f06-1a55-4312-ab4c-dd0b4cd8be5f">1,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzIwLTEtMS0xLTI0Mzc2_e8cf20d2-2a53-4f40-ba5f-d57a0fe80eb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzIwLTMtMS0xLTI0Mzc2_694516e8-4531-4313-a430-bf7ea22554cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had unused federal and state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i2035d7358b324a5489bcf06a61d764cb_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzEyMTQ_0c87aafb-63ae-401a-b911-8702006b5ad8">198.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieee515f8958047ef8b35c147f98db98e_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzEyMjE_c165439e-475b-409b-a0f1-1961843be273">24.5</ix:nonFraction> million, respectively. The federal NOL carryforwards may be carried forward indefinitely but are only available to offset up to 80% of pre-NOL taxable income each year. The state NOL carryforwards will begin to expire in 2038, if not utilized. As of December&#160;31, 2021, the Company also had federal and state research tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="icd2cf3902be24fe99f49b14a22a00695_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzE3MTg_41a44cf7-38c7-4148-8c9e-c5e25aa61e0e">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61def5f79b3b4943a515f38e57f56fa7_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzE3MjU_275e1966-7d74-46bf-922e-3247677f9c60">3.9</ix:nonFraction> million, respectively. The federal research tax credit carryforwards begin to expire in 2038, while the state carryforwards have no expiration. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of NOL and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a full valuation allowance against its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December&#160;31, 2021. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#8217;s projections for future growth. Based on this evaluation, as of December&#160;31, 2021, a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzM4MTI_dfe33e86-e36c-494f-9ce9-27c1e216d010">58.5</ix:nonFraction> million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i57bccf46a4cb484fb24ca8c67108e521" continuedAt="i140764e1cf8b465d8fef42f49ae98f11"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#8217;s projections for growth. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. </span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzYxOTk_0eff9abb-b06b-4c24-9e71-cfcdb56c3543" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzItMS0xLTEtMjQzNzY_b6c80a96-0e7b-43f8-aef8-a911e4047031">2,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25366f43bada4f5b9d53d088a682e118_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzItMy0xLTEtMjQzNzY_ad39db55-014b-4c19-acad-e49d3df7bcfd">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzMtMS0xLTEtMjQzNzY_8b7cf780-7399-4ce3-b39b-de28812262e9">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzMtMy0xLTEtMjQzNzY_dbecb5b3-0fa1-498a-b48a-d430418cb023">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzQtMS0xLTEtMjQzNzY_fed61c0c-31ae-4450-a85e-54ac7f3415b9">2,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzQtMy0xLTEtMjQzNzY_706d2497-cf7a-4622-8314-c5cf1633a6a1">2,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had gross unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzUyMTQ_28e8ba7d-44aa-45de-814d-ba6ded4a7abe">2.8</ix:nonFraction> million, none of which would affect the effective tax rate due to the existence of a full valuation allowance. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company&#8217;s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had <ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzU2MDY_a3e9f70c-84b3-4582-b374-c561ed1beb57"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzU2MDY_eb7d5e3f-d5fb-4685-9e1c-029e7826c5d6">no</ix:nonFraction></ix:nonFraction> accrual for interest or penalties on its consolidated balance sheets as of December&#160;31, 2021 or December 31, 2020, and has <ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzU3MTc_725b2379-9c8f-41a7-903d-50e35c3b1564"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzU3MTc_d51a3957-7fc2-4cfb-8dae-9fe82b362bbc">no</ix:nonFraction></ix:nonFraction>t recognized interest and/or penalties in its consolidated statements of operations for the years ended December 31, 2021 and 2020 as the unrecognized tax benefits relate to tax positions for which no cash tax liability has been reduced. </span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i140764e1cf8b465d8fef42f49ae98f11">The Company is subject to income taxes in the United States and various state jurisdictions. The Company&#8217;s tax years from 2018 and forward are subject to examination by the United States and state tax authorities. The Company has not been, nor is it currently, under examination by the U.S. federal or any state tax authority.</ix:continuation> </span></div><div id="ie96bda597eaa4024845d6498a1c78657_247"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NDk_12a99af4-2ed3-4cdc-a3b6-9fa6137e07ef" continuedAt="ia549fa35030a4acbbfce5f178ce51e8a" escape="true">LEASES </ix:nonNumeric></span></div><ix:continuation id="ia549fa35030a4acbbfce5f178ce51e8a" continuedAt="idb6a46cf3f984ca1b8a0bb664139acc3"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company entered into a <ix:nonNumeric contextRef="i83fc42be157249d68dc8368a8c9862be_I20170930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NTA_394741e0-6d0c-43c3-958b-fc4a506c490a">seven-year</ix:nonNumeric> lease agreement for approximately <ix:nonFraction unitRef="sqft" contextRef="i83fc42be157249d68dc8368a8c9862be_I20170930" decimals="-3" name="inbx:LesseeOperatingLeaseSquareFootage" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzExMg_7eb452c7-4d12-4fbf-aebe-c21ce67b1515">34,000</ix:nonFraction> square feet as its sole location in La Jolla, California. The lease expires in June 2025 with an option to extend the lease an additional <ix:nonNumeric contextRef="i83fc42be157249d68dc8368a8c9862be_I20170930" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzI0Ng_62991d84-055a-41e0-93b0-a1e087acbd5d">five years</ix:nonNumeric>. The lease contained an initial base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="i83fc42be157249d68dc8368a8c9862be_I20170930" decimals="-5" name="inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzMwOA_2ba2a607-77b2-4162-9864-f33ab57b7f0c">0.1</ix:nonFraction> million per month with <ix:nonFraction unitRef="number" contextRef="i83fc42be157249d68dc8368a8c9862be_I20170930" decimals="INF" name="inbx:LesseeOperatingLeaseAnnualEscalations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzMyNg_362d60d3-97f9-46df-b592-76a7c7088e35">2</ix:nonFraction>% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company executed an amendment to its lease agreement to expand its facilities by approximately <ix:nonFraction unitRef="sqft" contextRef="i521b2e3a6dc44d48afe6adc72a12b794_I20190531" decimals="-3" name="inbx:LesseeOperatingLeaseSquareFootageExpansion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzY0MQ_7e2ea18b-1d19-4909-a119-a3c3eacc9c0b">9,000</ix:nonFraction> square feet and began occupying this space in January 2020. The amended lease terminates coterminously with the initial lease agreement and contains an initial base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="i521b2e3a6dc44d48afe6adc72a12b794_I20190531" decimals="-3" name="inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzgyMQ_efb718ae-f84c-4c67-8ed2-72f6afa03e3d">30,000</ix:nonFraction> per month with <ix:nonFraction unitRef="number" contextRef="i521b2e3a6dc44d48afe6adc72a12b794_I20190531" decimals="INF" name="inbx:LesseeOperatingLeaseAnnualEscalations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzgzOQ_7f903673-8436-4091-8d27-0d79f359d716">2</ix:nonFraction>% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NDY_1fdf5b8c-d444-4179-8831-c573bc77d602" continuedAt="i5130ee241dc247bfb2686610324f44bf" escape="true">The right-of-use asset and operating lease liability as of December&#160;31, 2021 and 2020 are as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="idb6a46cf3f984ca1b8a0bb664139acc3"><div style="margin-bottom:9.5pt"><ix:continuation id="i5130ee241dc247bfb2686610324f44bf"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzItMS0xLTEtMjQzNzY_89ccbda6-3280-4154-accf-d2ee1b95e1d0">6,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzItMy0xLTEtMjQzNzY_c4975eeb-be87-41bb-b89d-80972703f116">7,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzUtMS0xLTEtMjQzNzY_8ffa465c-ec33-4e0b-8434-eccfab2325f6">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzUtMy0xLTEtMjQzNzY_52ad0dee-36a2-4313-bfb8-32b84b3ae056">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzYtMS0xLTEtMjQzNzY_4404742b-b045-4d6f-8a9e-9d0ade0327ba">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzYtMy0xLTEtMjQzNzY_5448cc50-7782-4f43-be7e-3ca2d23e48c2">6,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzctMS0xLTEtMjQzNzY_97e82be9-7857-4e03-9121-425b4fb750ee">6,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzctMy0xLTEtMjQzNzY_d041395a-4998-4e33-bbe1-94d01127b7b8">8,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During each of the years ended December 31, 2021 and 2020, the Company recognized operating lease expense of $<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzEyMTY_0a1c799f-917c-495d-bed8-bfa6abaad9f6"><ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzEyMTY_14beb00b-450f-4a6b-a527-c39252856a4f">3.1</ix:nonFraction></ix:nonFraction> million. As of December&#160;31, 2021 and 2020, the Company&#8217;s operating lease had a remaining term of <ix:nonNumeric contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NDkyNjc0NDMzODk_46f74853-4431-4a3c-8f1a-a98aa7f58b5e">3.5</ix:nonNumeric> and <ix:nonNumeric contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NDkyNjc0NDMzOTM_7de5bbd0-d0a6-4717-a169-2df3e133856b">4.5</ix:nonNumeric> years, respectively.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE1MTc_266eaf1c-fbd1-4100-95db-e2e0a7a9202b"><ix:nonFraction unitRef="number" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE1MTc_6ee16c04-7543-4a0c-b9f4-47251be528cb">8.2</ix:nonFraction></ix:nonFraction>% as of December&#160;31, 2021 and 2020.</span></div><ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NDg_bda360d3-9483-4c43-9e1c-9ba874f8b75c" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating leases are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzQtNC0xLTEtMjQzNzY_630e669d-be19-4e34-a45f-68d890bd1da2">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzUtNC0xLTEtMjQzNzY_689eef99-3a31-442c-9ce2-65a42f63b0b1">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzYtNC0xLTEtMjQzNzY_9c47bf0c-70df-4808-af80-ee8edac44e95">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzctNC0xLTEtMjQzNzY_41e7106e-5c40-40ff-9a8e-51e5b768745e">1,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzktNC0xLTEtMjQzNzY_f9981955-f465-4bea-8a1a-e68e2737824b">7,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzEwLTQtMS0xLTI0Mzc2_f1184f19-31f5-4bd6-9892-b1c176274e19">1,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzExLTQtMS0xLTI0Mzc2_6c2cb0fe-278b-4c36-911c-650b37c70fe7">6,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzEyLTQtMS0xLTI0Mzc2_2a250737-9995-4691-984c-2ec1dfff1ff3">1,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzEzLTQtMS0xLTI0Mzc2_cd767574-38f9-4e62-ba02-60a20de98317">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie96bda597eaa4024845d6498a1c78657_250"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzMzMjk_f11463cb-a4a1-411c-8093-1ef9c09ee431" continuedAt="i0309ed3525fb40ca88f8d0cc2542cee5" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><ix:continuation id="i0309ed3525fb40ca88f8d0cc2542cee5" continuedAt="i3635eafdf58442d48c52461cf0a9a1ca"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#8217;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i3635eafdf58442d48c52461cf0a9a1ca" continuedAt="i0067c311deb846b1a0d2c041abcef8af"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has several ongoing contracts with CROs for preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. These contracts are generally cancellable, with notice, at the Company&#8217;s option. The Company recorded accrued expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="ic8432517eb8a474aa5bafe8e02511ce5_I20211231" decimals="-5" name="inbx:AccruedClinicalResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzE2NDkyNjc0NDUxNzA_d8405fae-fa76-44bd-a9b2-4db3e8a5094f">7.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i272efd5ba40f48b3a36b628d2290dacc_I20201231" decimals="-5" name="inbx:AccruedClinicalResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzE2NDkyNjc0NDUxNjI_354a2009-2b7b-439f-8070-9b939d37442e">11.5</ix:nonFraction> million in its consolidated balance sheets for expenditures incurred by CROs and CDMOs as of December&#160;31, 2021 and December&#160;31, 2020, respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While these contracts are generally cancellable, some may contain specific activities that involve one or more non-cancellable commitments, including minimum purchase commitments, binding annual forecasts, and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from cost of work performed to date and up to twelve months of future committed manufacturing costs. As of December&#160;31, 2021 and December&#160;31, 2020, the non-cancellable portion of these contracts total in aggregate, excluding amounts recorded in accounts payable and accrued expenses at each respective date, was approximately $<ix:nonFraction unitRef="usd" contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231" decimals="-5" name="inbx:PurchaseCommitmentNonCancellablePortionOfContract" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzI3NjU_7afb86c0-a99a-4374-b75e-039a4438ac4e">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231" decimals="-5" name="inbx:PurchaseCommitmentNonCancellablePortionOfContract" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzI3NzI_56de8259-64a2-4377-b5dc-afdb80bcf22e">7.0</ix:nonFraction> million, respectively. During the years ended December&#160;31, 2021 and 2020, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" decimals="-5" name="inbx:PurchaseCommitmentExpensesIncurredRelatedToContracts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzI4NjI_f09a1d50-ee02-4e0b-95ad-1e9ba888ac19">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231" decimals="-5" name="inbx:PurchaseCommitmentExpensesIncurredRelatedToContracts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzI4Njk_f02cb7c6-d90f-4bf4-bc09-68ff7aed4732">30.2</ix:nonFraction> million of expenses related to these agreements, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0067c311deb846b1a0d2c041abcef8af">Additionally, as of December&#160;31, 2021 and December&#160;31, 2020, Mark P. Lappe, the Company&#8217;s Chief Executive Officer, Brendan P. Eckelman, the Company&#8217;s Chief Scientific Officer, and Kelly D. Deck, the Company&#8217;s Chief Financial Officer, and certain other members of management have agreements that provide for severance compensation in the event of termination or a change in control.</ix:continuation> </span></div><div id="ie96bda597eaa4024845d6498a1c78657_256"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzEyNzM_2f7770f2-dbde-4c9e-be54-2b2f1d821a6c" continuedAt="ic9bd542e5787417ebfc5d46bccdea71c" escape="true">SUBSEQUENT EVENTS </ix:nonNumeric></span></div><ix:continuation id="ic9bd542e5787417ebfc5d46bccdea71c" continuedAt="i9532a4f6a6cc4b1f906b09213e32bc43"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the audited consolidated financial statements as of December&#160;31, 2021, the Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these consolidated financial statements, other than disclosures related to those outlined below.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Issuance</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January and February 2022, the Company granted stock options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6069ad52bbd94a97b38f0c5021430f66_D20220101-20220228" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg4NjU_71634816-a26a-4453-9319-6d9ec294b726">0.8</ix:nonFraction>&#160;million common shares at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6069ad52bbd94a97b38f0c5021430f66_D20220101-20220228" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg4Nzk_a565dc93-a560-41af-a4fd-2354c8ccf05d">33.84</ix:nonFraction> per share to employees under the 2017 Equity Incentive Plan. The Company granted these options with an exercise price equal to the fair market value of the Company&#8217;s stock on the date of the option grant. The options are subject to <ix:nonNumeric contextRef="i6069ad52bbd94a97b38f0c5021430f66_D20220101-20220228" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg4OTk_6fecdc10-ba24-4d49-80c2-cb65f8532720">four-year</ix:nonNumeric> vesting with a <ix:nonNumeric contextRef="ibcbf97b5335e41168d1a299751595d81_D20220101-20220228" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5Mjg_e9d4429e-6ce4-4817-a938-3c80764087dd">one-year</ix:nonNumeric> cliff and have a contractual term of <ix:nonNumeric contextRef="i6069ad52bbd94a97b38f0c5021430f66_D20220101-20220228" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5MDM_52eaedf7-8ba6-45eb-ab68-56d2d07c003b">10</ix:nonNumeric> years.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to the 2020 Loan Agreement with Oxford</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2022, the Company entered into an additional amendment to the 2020 Loan Agreement, or the February 2022 Amendment. The February 2022 Amendment provides for <ix:nonFraction unitRef="tranche" contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218" decimals="INF" name="inbx:DebtInstrumentNumberOfAdditionalTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkwNjA_052b1f07-9772-4960-856a-b5946f3de9f5">four</ix:nonFraction> additional tranches of term loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218" decimals="-5" name="inbx:DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5MzA_e3db09a3-841e-4311-8fb3-fc5b5c0fb90b">200.0</ix:nonFraction>&#160;million, as follows: (a) an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i20fe34380fca42f098a2db8d31b3286a_D20220218-20220218" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5NDY_df5817cd-0daa-456d-b49f-ccff84c09af5">110.0</ix:nonFraction>&#160;million, which includes the $<ix:nonFraction unitRef="usd" contextRef="i13753df759a242849113e207322baf72_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5NjI_ad1b8778-935a-4986-a3a6-d6b0cb1f8f54">70.0</ix:nonFraction>&#160;million already outstanding; the incremental $<ix:nonFraction unitRef="usd" contextRef="i41e7f4a47cd94673bc773402b7a5368e_I20220218" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5Nzc_022e4323-1323-47cc-a000-22d624bd0bd2">40.0</ix:nonFraction>&#160;million principal amount funded upon the closing of the February 2022 Amendment, or Term D, (b) an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="id785c7ea3a28479b8b1ddfb99f5cb605_D20220218-20220218" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5OTI_abcdc14a-3812-47c6-88e7-e669544b91e7">30.0</ix:nonFraction>&#160;million, funded upon initiation of Part 4 of the INBRX-105 Phase 1 clinical trial, or Term E, (c) an aggregate principal of $<ix:nonFraction unitRef="usd" contextRef="i12b78bb8be854db5b78e268e11b79ddd_D20220218-20220218" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkwMDc_750a7373-c37d-4e09-82b7-96651af8005a">30.0</ix:nonFraction>&#160;million, funded upon the reception of positive topline Phase 1 data from INBRX-101 in AAT, or Term F, and (d) an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i7e1a737421844578b29281dfff09e84f_D20220218-20220218" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkwMjI_2e3dad3d-ddb8-4961-ac3b-c4f27f63be90">30.0</ix:nonFraction>&#160;million, funded upon the initiation of an INBRX-101 potential registration-enabling trial in AAT, or Term G. In accordance with the February 2022 Amendment, the Company paid a one-time amendment fee of $<ix:nonFraction unitRef="usd" contextRef="iec65463072474a72bf5be2ef264db82a_D20220218-20220218" decimals="-5" name="inbx:DebtInstrumentAmendmentFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkwMzc_a2399676-f1b8-4f9c-8c68-201b9bfbe744">1.1</ix:nonFraction>&#160;million, which is equal to the amount accreted for the final payment on the existing tranches at the time of the amendment. The terms of the <ix:nonFraction unitRef="tranche" contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218" decimals="INF" name="inbx:DebtInstrumentNumberOfExistingTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkwNTA_f4b35d0f-2870-4130-82b0-eda7724da624">three</ix:nonFraction> existing tranches under the Amended 2020 Loan Agreement were modified to align with the <ix:nonFraction unitRef="tranche" contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218" decimals="INF" name="inbx:DebtInstrumentNumberOfAdditionalTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkyNTI_052b1f07-9772-4960-856a-b5946f3de9f5">four</ix:nonFraction> additional tranches under the February 2022 Amendment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding term loans will mature on January 1, 2027 and bear interest at the greater of (1) <ix:nonFraction unitRef="number" contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MzA4NTk_e60cb30e-4484-416c-927f-d10d79501944">8.30</ix:nonFraction>% and (2) the sum of (i) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (ii) <ix:nonFraction unitRef="number" contextRef="i9b61d2e608d24c2eb1c1116a2a66abe6_D20220218-20220218" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzEwOTk1MTE2NDc0MDM_9555cd60-7f81-4362-96ab-fbd0c4b39619">8.19</ix:nonFraction>%. The repayment </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="i9532a4f6a6cc4b1f906b09213e32bc43"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">schedule provides for interest-only payments through February 1, 2025, with principal payments beginning on March 1, 2025. The interest-only payments may be extended by 12 months through February 2026, with principal payments beginning on March 1, 2026, if the Company raises at least $<ix:nonFraction unitRef="usd" contextRef="i39dc64f1760d475e9b12a1ab87444d97_D20220218-20220218" decimals="-5" name="inbx:InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkyNjk_c4a23fdf-e29a-45b0-8069-7c43ea9c215c">100.0</ix:nonFraction>&#160;million in upfront licensing or partnership proceeds by February 2025. The interest-only period is followed by <ix:nonNumeric contextRef="i39dc64f1760d475e9b12a1ab87444d97_D20220218-20220218" name="inbx:DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMzc_13e0df78-3f29-4af8-9765-d02ca18fba7f">23</ix:nonNumeric> months of equal payments of principal plus interest, or if the interest-only period is extended, by <ix:nonNumeric contextRef="i39dc64f1760d475e9b12a1ab87444d97_D20220218-20220218" name="inbx:DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkyODc_f9d76a7d-86ee-47a6-b21e-c2d31f6ec260">11</ix:nonNumeric> months of equal payments of principal plus interest. Upon the maturity date of January 1, 2027, a final payment of <ix:nonFraction unitRef="number" contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218" decimals="INF" name="inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMDE_1e17590e-f898-4900-85be-4cb873ccd708">9.0</ix:nonFraction>% of the total principal amount will be due to Oxford. The Company has the option to prepay the outstanding balance of the term loan in full prior to maturity, subject to a prepayment fee ranging from <ix:nonFraction unitRef="number" contextRef="i4c6633104ca543ebbacf87abf6aea7fa_I20220218" decimals="INF" name="inbx:DebtInstrumentPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMDc_68efaada-3904-4f18-8d44-8d3c6c909316">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic510443d218e4b0ab9d522e8d0b425fa_I20220218" decimals="INF" name="inbx:DebtInstrumentPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMTM_ce8d350a-75cb-4faa-81f0-8bbdb6ff99ca">3.0</ix:nonFraction>%, depending on the timing of the prepayment. The Company granted Oxford a first priority lien against all of its assets with a positive lien on intellectual property. All other terms of the Amended 2020 Loan Agreement remain outstanding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the debt issuance upon the February 2022 Amendment, the Company issued to Oxford warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i39dc64f1760d475e9b12a1ab87444d97_D20220218-20220218" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMTk_c3fe3940-5c87-4306-83dd-80078345cab9">40,000</ix:nonFraction> shares of the Company&#8217;s common stock at a strike price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i693b3d23e36049d1b4d15aeac78e1972_I20220218" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMjc_eccc7292-9f6a-4c98-9eb5-62e746c58e5f">45.00</ix:nonFraction> per share.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_259"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_262"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report, our disclosure controls and procedures were designed and operating effectively at the reasonable assurance level.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, as amended, as a process designed by, or under the supervision of, the company&#8217;s principal executive and principal financial officers and effected by the Company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company&#8217;s internal control over financial reporting includes those policies and procedures that:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the company; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-Integrated Framework.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our assessment, management believes that, as of December 31, 2021, the Company&#8217;s internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s independent registered public accounting firm has issued an audit report on our assessment of the Company&#8217;s internal control over financial reporting. This report appears further below in this Item 9A.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:18pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board of Directors and Stockholders </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx, Inc. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">La Jolla, California</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span><br/></span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Inhibrx, Inc.&#8217;s (the &#8220;Company&#8217;s&#8221;) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the &#8220;COSO criteria&#8221;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ BDO USA, LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:2pt;margin-top:4pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_265"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_2428"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_268"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_271"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Management and Corporate Governance&#8221; and &#8220;Code of Conduct and Ethics&#8221; in our proxy statement for the 2022 annual meeting of stockholders.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_274"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#8220;Executive Officer and Director Compensation&#8221; in our proxy statement for the 2022 annual meeting of stockholders.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_277"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our proxy statement for the 2022 annual meeting of stockholders.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_280"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Certain Relationships and Related Person Transactions&#8221; and &#8220;Management and Corporate Governance&#8221; in our proxy statement for the 2022 annual meeting of stockholders.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_283"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#8220;Independent Registered Public Accounting Firm&#8221; in our proxy statement for the 2022 annual meeting of stockholders.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_286"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV. </span></div><div id="ie96bda597eaa4024845d6498a1c78657_289"></div><div style="-sec-extract:summary;margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed in the accompanying &#8220;Index to Exhibits&#8221; below are filed or incorporated by reference as part of this Annual Report.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statement Schedules</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Index to Consolidated Financial Statements&#8221; at Item 8 to this Annual Report. Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.800%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filed Herewith</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporated By Reference File No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Filed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020012979/exhibit318-k.htm">Amended and Restated Certificate of Incorporation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/21/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020012979/exhibit328-k.htm">Amended and Restated Bylaws</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/21/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex41.htm">Form of Common Stock Certificate</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit42s-1.htm">Second Amended and Restated Investors&#8217; Rights Agreement, dated April 6, 2020, by and among the Registrant and the investors named therein.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#94;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit46s-1.htm">Form of Warrant to Purchase Stock by and between the Registrant and Oxford Finance LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000047/exhibit44descriptionofsecu.htm">Description of the Registrant&#8217;s Securities.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39542</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/12/2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit101s-1.htm">Form of Indemnification Agreement. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000110/exhibit102lappeemploymenta.htm">Second Amended and Restated Executive Employment Agreement, effective as of January 1, 2022, by and between the Registrant and Mark Lappe.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/09/2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000110/exhibit103wagneremployment.htm">Second Amended and Restated Executive Employment Agreement, effective as of January 1, 2022, by and between the Registrant and Klaus Wagner, M.D., Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/09/2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="kwagnerseparationletter.htm">Separation Letter Agreement, effective as of February 1, 2022, by and between the Registrant and Klaus Wagner, M.D., Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000110/exhibit104eckelmanemployme.htm">Second Am</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000110/exhibit104eckelmanemployme.htm">ended and Restated Executive Employment Agreement, effective as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000110/exhibit104eckelmanemployme.htm">January 1, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000110/exhibit104eckelmanemployme.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000110/exhibit104eckelmanemployme.htm">, by and between the Registrant and Brendan Eckelman, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/09/2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000110/exhibit105deckemploymentag.htm">Amended and Restated Executive Employment Agreement, effective as of January 1, 2022, by and between the Registrant and Kelly Deck.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/09/2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000162828020012466/exhibit1013s-1a1xamendedan.htm">Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex109.htm">Form of Stock Option Grant Notice under the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1010.htm">Form of Restricted Stock Agreement under the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#916;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit1031s-1.htm">Non-Employee Director Compensation Policy</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1011.htm">License Agreement, dated July&#160;1, 2013, by and between INBRX 103, LLC and Celgene Corporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1012.htm">Amendment to License Agreement, dated November&#160;23, 2018, by and among the Registrant, INBRX 103, LLC and Celgene Corporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1013.htm">License Agreement, dated June 21, 2017, by and between the Registrant and Transcenta Holding Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1014.htm">Technical Services Agreement, dated March 19, 2018, by and between the Registrant and Transcenta Holding Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.800%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1015.htm">Technical Services Agreement, dated October 6, 2018, by and between the Registrant and Transcenta Holding Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1016.htm">License Agreement, dated February 28, 2018, by and between the Registrant and Elpiscience Biopharmaceuticals, Inc. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1017.htm">License Agreement, dated April 30, 2018, by and between the Registrant and Elpiscience Biopharmaceuticals, Inc. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1018.htm">License Agreement, dated December 20, 2018, by and between the Registrant and bluebird bio, Inc. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1024.htm">Lease Agreement, dated September&#160;8, 2017, by and between the Registrant and HCP TPSP, LLC. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1025.htm">First Amendment to Lease, dated May 21, 2019, by and between the Registrant and HCP TPSP, LLC. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1027.htm">Option Agreement, dated May&#160;29, 2019, by and between the Registrant and Chiesi Farmaceutici S.p.A. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519225351/d636583dex1028.htm">First Amendment to Option Agreement, dated August 19, 2019, by and between the Registrant and Chiesi Farmaceutici S.p.A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/20/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit1027s-1.htm">Option and License Agreement, dated June 9, 2020, by and between the Registrant and bluebird bio, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit1028s-1.htm">Loan and Security Agreement, dated July 15, 2020, by and between the Registrant and Oxford Finance LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961420000014/exhibit1011-firstamend.htm">First Amendment to Loan and Security Agreement, dated November 12, 2020, by and between the Registrant and Oxford Finance LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/13/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000078/exhibit101thirdamendmentto.htm">Third Amendment to Loan and Security Agreement, dated June 18, 2021, by and between the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000078/exhibit101thirdamendmentto.htm">Registra</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000078/exhibit101thirdamendmentto.htm">nt</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000173961421000078/exhibit101thirdamendmentto.htm"> and Oxford Finance LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/21/2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001739614/000173961422000017/exhibit101fourthamendmentt.htm">Fourth Amendment to Loan and Security Agreement, dated February 18, 2022, by and between the Registrant and Oxford Finance LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/22/2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1023.htm">Amended and Restated Master Services Agreement, dated August </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex1023.htm">28, 2018, by and between the Registrant and WuXi Biologics (Hong Kong) Limited.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000162828020010679/exhibit1030s-1.htm">Amendment No. 1 to Amended and Restated Master Services Agreement, dated December 11, 2019, by and between the Registrant and WuXi Biologics (Hong Kong) Limited.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-240135</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001739614/000173961421000090/exhibit12openmarketsalesag.htm">Open Market Sale Agreement&#8480; by and between Jefferies LLC and the Registrant dated September 3, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3ASR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-259313</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/3/2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739614/000119312519164114/d636583dex211.htm">Subsidiaries of the Registrant. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-231907</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/3/2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231q42021.htm">Consent of BDO USA, LLP, independent registered public accounting firm. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q42021.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.800%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q42021.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q42021.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q42021.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document contained in Exhibit 101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#94;&#160;&#160;&#160;&#160;Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#916;&#160;&#160;&#160;&#160;Management Compensation Plan or arrangement.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*       This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159</span></div></div></div><div id="ie96bda597eaa4024845d6498a1c78657_292"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie96bda597eaa4024845d6498a1c78657_295"></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.75pt"><tr><td style="width:1.0pt"></td><td style="width:223.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INHIBRX, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark P. Lappe</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:&#160;&#160;Mark P. Lappe</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:&#160;&#160;Chief Executive Officer and Chairman</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February&#160;28, 2022</span></div></td></tr></table></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:34.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark P. Lappe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">principal executive officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark P. Lappe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kelly D. Deck, C.P.A.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(principal financial officer and</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">principal accounting officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly D. Deck, C.P.A.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jon Faiz Kayyem, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jon Faiz Kayyem, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Douglas G. Forsyth</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas G. Forsyth</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kimberly Manhard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly Manhard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kristiina Vuori, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristiina Vuori, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>kwagnerseparationletter.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i029ab20078144c58b9e418d3e1e229a1_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><img alt="inbxlogo.jpg" src="inbxlogo.jpg" style="height:66px;margin-bottom:5pt;vertical-align:text-bottom;width:219px"></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">11025 N. Torrey Pines Rd</font></div><div style="text-align:center"><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Suite 200</font></div><div style="text-align:center"><font style="color:#7f7f7f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">La Jolla, CA 92037</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">February 1, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Via Hand Delivery</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Klaus Wagner</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        Re&#58; Final Day of Employment with Inhibrx</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Dear Klaus&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            In light of your resignation, this letter serves as confirmation that your employment with Inhibrx (the &#8220;Company&#8221;) is voluntarily terminated as of February 1, 2022 (the &#8220;Separation Date&#8221;).  You have received or will receive payment on the Separation Date for all due and accrued wages earned through the Separation Date via the Company&#8217;s regular payroll direct deposit. You acknowledge that you are not entitled to severance or any other future payments.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            If applicable, you may apply for unemployment with the State of California by accessing this website&#58; https&#58;&#47;&#47;www.edd.ca.gov&#47;unemployment&#47;Filing_a_Claim.htm.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            Regarding your other benefits, your existing healthcare coverage will terminate on February 28, 2022, the last day of the month of your last day of employment.  You will receive information regarding your entitlement to continue your health insurance at your own expense pursuant to COBRA under separate cover.  If you are enrolled in the Inhibrx 401(k) Plan, shortly after your separation date, Fidelity will send you a letter notifying you that you are entitled to a distribution or rollover of your vested 401(k) balance, along with instructions to accomplish such distribution or rollover.  Please follow the instructions provided.  Alternatively, you may call Fidelity at 800-835-5097 any time.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You remain subject to the Proprietary Information and Inventions Agreement you signed in connection with your employment with the Company and agree to enter into that certain Release and Waiver of Claims. A copy of that Proprietary Information and Inventions Agreement and a copy of that Release and Waiver of Claims are enclosed herewith.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In light of your position as a Section 16 officer of the Company and your significant ownership interest in the Company, and in exchange for the Company&#8217;s promises and representations in this Agreement and in the enclosed Stock Option Extension Agreement and Mutual Waiver and Release Agreement, you agree that you will not sell or otherwise dispose of any Company stock beneficially owned by you prior to June 1, 2022.  As of the Separation Date, you are not subject to any blackout period under the Company&#8217;s insider trading policy, and the above-mentioned restrictions will automatically terminate on June 1, 2022, at which time you will be free to sell or otherwise dispose of your Company Shares with no limitations.  Notwithstanding the foregoing, you agree that you will not, directly or indirectly, buy or sell securities of the Company while in possession of material nonpublic information or engage in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">any other action to take advantage of, or pass on to others, that information, in each case, subject to any exemptions under law or pursuant to a trading plan.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            Upon receiving your signature to this letter, the Company agrees to extend the expiration date for the exercise of your vested stock options to February 1, 2023, pursuant to that certain Stock Option Extension Agreement by and between you and the Company. A copy of that Stock Option Extension Agreement is enclosed herewith.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You also agree to complete a D&#38;O Questionnaire to enable the Company to accurately report certain biological and other information for the Company&#8217;s Securities and Exchange Commission (&#8220;SEC&#8221;) disclosures. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You acknowledge and agree that from and after the Separation Date, the Company is not obligated to prepare or file any disclosures or documents required by the SEC on your behalf.</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Please sign below to indicate your agreement with the terms of this letter. </font><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Company wishes you the very best in your future endeavors.</font></div><div><font><br></font></div><div><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                                                    Sincerely,</font></div><div><font><br></font></div><div><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                                                    &#47;s&#47; Mark Lappe</font></div><div><font><br></font></div><div><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                                                    Mark Lappe</font></div><div><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                                                    CEO</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Acknowledged and Agreed&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Klaus Wagner                     </font></div><div><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Klaus Wagner</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Date&#58; </font><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">February 1, 2022</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#221e1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Enclosure&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Proprietary Information and Inventions Agreement</font></div><div style="text-indent:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Waiver and Release</font></div><div style="text-indent:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Stock Option Extension Agreement</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit231q42021.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i701e8b72337e4a15a5b86f0ae1278cdd_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inhibrx, Inc. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">La Jolla, California </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (333-259313) and Form S-8 (No. 333-252214 and 333-248138) of Inhibrx, Inc. (the &#8220;Company&#8221;) of our reports dated February&#160;28, 2022, relating to the consolidated financial statements, and the effectiveness of the Company&#8217;s internal control over financial reporting, which appears in this Annual Report on Form 10-K. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; BDO USA, LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">San Diego, California</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February&#160;28, 2022</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311q42021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8182f34d11514a06961c3cd07b09643c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER<br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark P. Lappe, certify that&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Inhibrx, Inc&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312q42021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9bc4cb57c8ea4d55a269ba1d6ccf2e6d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER<br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kelly D. Deck, certify that&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Inhibrx, Inc&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly D. Deck</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly D. Deck, C.P.A.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321q42021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i06467546c16249b79f134e6c4a0f759d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,<br>AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the annual report of Inhibrx, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Mark P. Lappe, Chief Executive Officer and Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit322q42021.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia2c555e95ce8409ca85629600888374a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,<br>AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the annual report of Inhibrx, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kelly D. Deck, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly D. Deck</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly D. Deck, C.P.A.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>inbx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8eb0955a-77e8-4ec9-9bdb-5f279743741e,g:91526847-18eb-416c-96d8-1d5c48d93616-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:inbx="http://inhibrx.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://inhibrx.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inbx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inbx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inbx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inbx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://inhibrx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://inhibrx.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://inhibrx.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit" roleURI="http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit">
        <link:definition>1004006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1005007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2303301 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails">
        <link:definition>2404401 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>2405402 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails">
        <link:definition>2406403 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails">
        <link:definition>2407404 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATION" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATION">
        <link:definition>2108102 - Disclosure - OTHER FINANCIAL INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONTables" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables">
        <link:definition>2309302 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails">
        <link:definition>2410405 - Disclosure - OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails">
        <link:definition>2411406 - Disclosure - OTHER FINANCIAL INFORMATION - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails">
        <link:definition>2412407 - Disclosure - OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONAccruedExpensesDetails" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails">
        <link:definition>2413408 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://inhibrx.com/role/DEBT">
        <link:definition>2114103 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://inhibrx.com/role/DEBTTables">
        <link:definition>2315303 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://inhibrx.com/role/DEBTNarrativeDetails">
        <link:definition>2416409 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTOutstandingDebtBalance2020LoanAgreementDetails" roleURI="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails">
        <link:definition>2417410 - Disclosure - DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTOutstandingDebtBalance2020LoanAgreementDetails_1" roleURI="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails_1">
        <link:definition>2417410 - Disclosure - DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTFutureMinimumPaymentsDetails" roleURI="http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails">
        <link:definition>2418411 - Disclosure - DEBT - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLEPROMISSORYNOTE" roleURI="http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTE">
        <link:definition>2119104 - Disclosure - CONVERTIBLE PROMISSORY NOTE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLEPROMISSORYNOTEDetails" roleURI="http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails">
        <link:definition>2420412 - Disclosure - CONVERTIBLE PROMISSORY NOTE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICIT" roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICIT">
        <link:definition>2121105 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITDetails" roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails">
        <link:definition>2422413 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANS" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANS">
        <link:definition>2123106 - Disclosure - EQUITY COMPENSATION PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSTables" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSTables">
        <link:definition>2324304 - Disclosure - EQUITY COMPENSATION PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSNarrativeDetails" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails">
        <link:definition>2425414 - Disclosure - EQUITY COMPENSATION PLANS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSStockOptionActivityDetails" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails">
        <link:definition>2426415 - Disclosure - EQUITY COMPENSATION PLANS - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails">
        <link:definition>2427416 - Disclosure - EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails">
        <link:definition>2428417 - Disclosure - EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDGRANTREVENUES" roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUES">
        <link:definition>2129107 - Disclosure - LICENSE AND GRANT REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDGRANTREVENUESTables" roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESTables">
        <link:definition>2330305 - Disclosure - LICENSE AND GRANT REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDGRANTREVENUESRevenueSummaryDetails" roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails">
        <link:definition>2431418 - Disclosure - LICENSE AND GRANT REVENUES - Revenue Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails">
        <link:definition>2432419 - Disclosure - LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEANDGRANTREVENUESGovernmentGrantsDetails" roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails">
        <link:definition>2433420 - Disclosure - LICENSE AND GRANT REVENUES - Government Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2134108 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2435421 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://inhibrx.com/role/INCOMETAXES">
        <link:definition>2136109 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://inhibrx.com/role/INCOMETAXESTables">
        <link:definition>2337306 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://inhibrx.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2438422 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>2439423 - Disclosure - INCOME TAXES - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofIncomeTaxExpenseDetails" roleURI="http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails">
        <link:definition>2440424 - Disclosure - INCOME TAXES - Reconciliation of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofnetdeferredincometaxesDetails" roleURI="http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails">
        <link:definition>2441425 - Disclosure - INCOME TAXES - Components of net deferred income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESUnrecognizedTaxBenefitsDetails" roleURI="http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails">
        <link:definition>2442426 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://inhibrx.com/role/LEASES">
        <link:definition>2143110 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://inhibrx.com/role/LEASESTables">
        <link:definition>2344307 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://inhibrx.com/role/LEASESNarrativeDetails">
        <link:definition>2445427 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" roleURI="http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails">
        <link:definition>2446428 - Disclosure - LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails">
        <link:definition>2447429 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1" roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1">
        <link:definition>2447429 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2148111 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2449430 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://inhibrx.com/role/SUBSEQUENTEVENTS">
        <link:definition>2150112 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://inhibrx.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>2451431 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="inbx_A2020OxfordTermLoansMember" abstract="true" name="A2020OxfordTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_Amended2020OxfordTermLoanTrancheThreeMember" abstract="true" name="Amended2020OxfordTermLoanTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_CostSharingAgreementMember" abstract="true" name="CostSharingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_DebtInstrumentNumberOfExistingTranches" abstract="false" name="DebtInstrumentNumberOfExistingTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_ElpiscienceBiopharmaceuticalsIncMember" abstract="true" name="ElpiscienceBiopharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_LicenseAgreementAdditionalProgramsAuthorizedMember" abstract="true" name="LicenseAgreementAdditionalProgramsAuthorizedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_CapitalExpendituresIncurredButNotYetPaidReleased" abstract="false" name="CapitalExpendituresIncurredButNotYetPaidReleased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_CollaborativeAgreementExclusiveDevelopmentLicenses" abstract="false" name="CollaborativeAgreementExclusiveDevelopmentLicenses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_Amended2020OxfordTermLoanJune2021AmendmentMember" abstract="true" name="Amended2020OxfordTermLoanJune2021AmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ReclassificationOfWarrantLiabilitiesToEquity" abstract="false" name="ReclassificationOfWarrantLiabilitiesToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" abstract="false" name="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_LiquidityPolicyTextBlock" abstract="false" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_A2020ConvertiblePromissoryNoteMember" abstract="true" name="A2020ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ExpensesReimbursedToDate" abstract="false" name="ExpensesReimbursedToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" abstract="false" name="CollaborativeArrangementAdditionalPaymentReceivablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inbx_WarrantAndDerivativeLiabilitiesMember" abstract="true" name="WarrantAndDerivativeLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod" abstract="false" name="DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inbx_SalesAgreementMember" abstract="true" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" abstract="false" name="IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_CollaborativeArrangementExpenseReimbursement" abstract="false" name="CollaborativeArrangementExpenseReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" abstract="false" name="LesseeOperatingLeaseInitialBaseRentExpensePerMonth" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" abstract="false" name="AccruedOutsideResearchAndDevelopmentOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable" abstract="false" name="AtTheMarketOfferingCostsReimbursableInAccountsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_CollaborativeArrangementPaymentReceivable" abstract="false" name="CollaborativeArrangementPaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" abstract="false" name="RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_CollaborativeArrangementNonrefundableOptionExtensionFee" abstract="false" name="CollaborativeArrangementNonrefundableOptionExtensionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_A2020OxfordTermLoanBMember" abstract="true" name="A2020OxfordTermLoanBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_NonCashEstablishmentOfEquityMethodInvestment" abstract="false" name="NonCashEstablishmentOfEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_RelatedPartyEquityInterestInCompany" abstract="false" name="RelatedPartyEquityInterestInCompany" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_WuXiBiologicsHealthcareVentureMember" abstract="true" name="WuXiBiologicsHealthcareVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_Amended2020OxfordTermLoanMember" abstract="true" name="Amended2020OxfordTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended" abstract="false" name="DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inbx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" abstract="false" name="CollaborativeAgreementNumberOfRelatedProgramsToAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" abstract="true" name="LicenseAgreementInitialProgramsAuthorizedProgramOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_LAVSummitLimitedMember" abstract="true" name="LAVSummitLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_CollaborativeArrangementNonrefundableUpfrontPayment" abstract="false" name="CollaborativeArrangementNonrefundableUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember" abstract="true" name="DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" abstract="false" name="PaymentsOfDebtIssuanceCostsSecuredDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" abstract="true" name="DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" abstract="false" name="CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="inbx_WarrantsLiability" abstract="false" name="WarrantsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_LicenseAffiliateMember" abstract="true" name="LicenseAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inbx_A2020OptionAndLicenseAgreementMember" abstract="true" name="A2020OptionAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_WarrantLiabilitiesPolicyTextBlock" abstract="false" name="WarrantLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_CelgeneMember" abstract="true" name="CelgeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_LicenseNonAffiliateMember" abstract="true" name="LicenseNonAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" abstract="false" name="DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_A2015OxfordTermLoansMember" abstract="true" name="A2015OxfordTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ReversalOfUnamortizedBeneficialConversionFeature" abstract="false" name="ReversalOfUnamortizedBeneficialConversionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" abstract="false" name="IncreaseDecreaseContractWithCustomerLiabilityCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_CollaborativeArrangementReceivablesFromRelatedParties" abstract="false" name="CollaborativeArrangementReceivablesFromRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches" abstract="false" name="DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_CollaborativeArrangementAdditionalPaymentReceivable" abstract="false" name="CollaborativeArrangementAdditionalPaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_SaleOfStockCommonStockAuthorized" abstract="false" name="SaleOfStockCommonStockAuthorized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_AtTheMarketOfferingCosts" abstract="false" name="AtTheMarketOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering" abstract="false" name="PaymentsOfStockIssuanceCostsInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_LesseeOperatingLeaseAnnualEscalations" abstract="false" name="LesseeOperatingLeaseAnnualEscalations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" abstract="false" name="OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_PhylaxisBioScienceLLCMember" abstract="true" name="PhylaxisBioScienceLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_A2020OxfordTermLoanAMember" abstract="true" name="A2020OxfordTermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_CollaborativeArrangementCommercializationMilestoneReceivable" abstract="false" name="CollaborativeArrangementCommercializationMilestoneReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_A2018OptionAndLicenseAgreementMember" abstract="true" name="A2018OptionAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" abstract="false" name="ScheduleOfLicenseAndGrantRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_WarrantsAndRightsOutstandingLiability" abstract="false" name="WarrantsAndRightsOutstandingLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_DebtInstrumentNumberOfAdditionalTranches" abstract="false" name="DebtInstrumentNumberOfAdditionalTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_DebtInstrumentPrepaymentFee" abstract="false" name="DebtInstrumentPrepaymentFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_A2seventyBioIncMember" abstract="true" name="A2seventyBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_AccruedClinicalResearchAndDevelopmentCurrent" abstract="false" name="AccruedClinicalResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_DebtInstrumentMinimumCashBalance" abstract="false" name="DebtInstrumentMinimumCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_RevenueRecognitionNumberOfCompounds" abstract="false" name="RevenueRecognitionNumberOfCompounds" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum" abstract="false" name="InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_GrantValuedAwarded" abstract="false" name="GrantValuedAwarded" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" abstract="true" name="LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" abstract="false" name="OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps" abstract="false" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_Amended2020OxfordTermLoanTrancheOneMember" abstract="true" name="Amended2020OxfordTermLoanTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_LicenseAndGrantRevenueTextBlock" abstract="false" name="LicenseAndGrantRevenueTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" abstract="false" name="ClassOfWarrantOrRightPercentageOfFundedAmountIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" abstract="false" name="ContractWithCustomerLiabilityDerecognizedDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_DeferredFederalPayrollTaxesCARESAct" abstract="false" name="DeferredFederalPayrollTaxesCARESAct" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_ExpensesExpectedToBeReimbursed" abstract="false" name="ExpensesExpectedToBeReimbursed" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_A2019ConvertiblePromissoryNoteMember" abstract="true" name="A2019ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_RevenuesCashReceived" abstract="false" name="RevenuesCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember" abstract="true" name="DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_LesseeOperatingLeaseSquareFootageExpansion" abstract="false" name="LesseeOperatingLeaseSquareFootageExpansion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="inbx_CollaborativeArrangementMilestonePaymentReceived" abstract="false" name="CollaborativeArrangementMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_PurchaseCommitmentNonCancellablePortionOfContract" abstract="false" name="PurchaseCommitmentNonCancellablePortionOfContract" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" abstract="false" name="CollaborativeArrangementDevelopmentMilestoneReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_SaleOfStockSharesCommonStockSold" abstract="false" name="SaleOfStockSharesCommonStockSold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="inbx_LicenseAffiliateOX40LicenseAgreementMember" abstract="true" name="LicenseAffiliateOX40LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_EquityMethodInvestmentAdditionalOwnershipEntitled" abstract="false" name="EquityMethodInvestmentAdditionalOwnershipEntitled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_NumberOfOperatingLeasesHeld" abstract="false" name="NumberOfOperatingLeasesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_DebtInstrumentAmendmentFee" abstract="false" name="DebtInstrumentAmendmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_SaleAndPurchaseAgreementMember" abstract="true" name="SaleAndPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_NoncashOperatingLeaseExpense" abstract="false" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_Amended2020OxfordTermLoanTrancheTwoMember" abstract="true" name="Amended2020OxfordTermLoanTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ChiesiFarmaceuticiSpAMember" abstract="true" name="ChiesiFarmaceuticiSpAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_CollaborativeArrangementMilestonePaymentsReceivable" abstract="false" name="CollaborativeArrangementMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_LesseeOperatingLeaseSquareFootage" abstract="false" name="LesseeOperatingLeaseSquareFootage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="inbx_Amended2020OxfordTermLoanTrancheFourMember" abstract="true" name="Amended2020OxfordTermLoanTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" abstract="false" name="AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_A2019And2020ConvertiblePromissoryNotesMember" abstract="true" name="A2019And2020ConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" abstract="true" name="WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_A2020OxfordTermLoanCMember" abstract="true" name="A2020OxfordTermLoanCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_OtherCustomersNotSeparatelyDisclosedMember" abstract="true" name="OtherCustomersNotSeparatelyDisclosedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_RepaymentsOfSecuredDebtFinalBalloonPayment" abstract="false" name="RepaymentsOfSecuredDebtFinalBalloonPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_WarrantsIssuedUponConsummationOfIPOMember" abstract="true" name="WarrantsIssuedUponConsummationOfIPOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts" abstract="false" name="PurchaseCommitmentExpensesIncurredRelatedToContracts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember" abstract="true" name="A2020OxfordTermLoansTermBTermCTranche1OfTermAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_CommonStockSaleOfStockCommissionPercent" abstract="false" name="CommonStockSaleOfStockCommissionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_LicenseAgreementInitialProgramsAuthorizedMember" abstract="true" name="LicenseAgreementInitialProgramsAuthorizedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>inbx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8eb0955a-77e8-4ec9-9bdb-5f279743741e,g:91526847-18eb-416c-96d8-1d5c48d93616-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_064a50a4-d064-4e02-ab4b-5c7759b0cfea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6b69dd8d-c908-4de9-bdb4-87ebc20f5280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_064a50a4-d064-4e02-ab4b-5c7759b0cfea" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6b69dd8d-c908-4de9-bdb4-87ebc20f5280" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6286df3b-8b07-47f3-9845-7ef7ab1ba337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_064a50a4-d064-4e02-ab4b-5c7759b0cfea" xlink:to="loc_us-gaap_PreferredStockValue_6286df3b-8b07-47f3-9845-7ef7ab1ba337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b674c2b3-f300-4c32-98ad-46f8f3bf52b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_064a50a4-d064-4e02-ab4b-5c7759b0cfea" xlink:to="loc_us-gaap_CommonStockValue_b674c2b3-f300-4c32-98ad-46f8f3bf52b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d3a98609-167b-4821-b68d-aff14046d4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_064a50a4-d064-4e02-ab4b-5c7759b0cfea" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d3a98609-167b-4821-b68d-aff14046d4ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c27fcfe5-a344-4471-8e28-0a9d5a8e112f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_165e6c10-8c95-4f60-b49c-b65ca5aa50fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c27fcfe5-a344-4471-8e28-0a9d5a8e112f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_165e6c10-8c95-4f60-b49c-b65ca5aa50fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9666c6cb-5572-4a59-9a97-ed351d43acfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c27fcfe5-a344-4471-8e28-0a9d5a8e112f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9666c6cb-5572-4a59-9a97-ed351d43acfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a144fdb4-2420-4b98-84a2-f84da50bbef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c27fcfe5-a344-4471-8e28-0a9d5a8e112f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a144fdb4-2420-4b98-84a2-f84da50bbef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ce75aa4e-672d-4db8-aa90-693ff90687ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c27fcfe5-a344-4471-8e28-0a9d5a8e112f" xlink:to="loc_us-gaap_AssetsCurrent_ce75aa4e-672d-4db8-aa90-693ff90687ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_05683e67-990b-4596-95fc-305fd519f951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1c195882-b0dd-4555-b11b-98b5de8e39a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_05683e67-990b-4596-95fc-305fd519f951" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1c195882-b0dd-4555-b11b-98b5de8e39a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_25ea0e2d-ce12-4608-ab8f-f5f49a248415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_05683e67-990b-4596-95fc-305fd519f951" xlink:to="loc_us-gaap_AccountsPayableCurrent_25ea0e2d-ce12-4608-ab8f-f5f49a248415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7d3e6eb0-9b21-47c2-9acb-081455d92913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_05683e67-990b-4596-95fc-305fd519f951" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7d3e6eb0-9b21-47c2-9acb-081455d92913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2eabd583-97bd-4135-944d-36c0e16335de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_05683e67-990b-4596-95fc-305fd519f951" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2eabd583-97bd-4135-944d-36c0e16335de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f71920d5-de96-4ec7-af28-e1c1259eea4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ae6943d0-9c58-45da-b7c1-db55d1db0373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f71920d5-de96-4ec7-af28-e1c1259eea4e" xlink:to="loc_us-gaap_Liabilities_ae6943d0-9c58-45da-b7c1-db55d1db0373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bac99bd5-00b8-4bce-a837-4f70238a9b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f71920d5-de96-4ec7-af28-e1c1259eea4e" xlink:to="loc_us-gaap_StockholdersEquity_bac99bd5-00b8-4bce-a837-4f70238a9b64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_484046dd-b798-4c3e-8aa9-88985868d6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f71920d5-de96-4ec7-af28-e1c1259eea4e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_484046dd-b798-4c3e-8aa9-88985868d6b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_38386d49-6ce6-4196-93f4-bb597ce79dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_06217bfe-3eb6-49ed-80ba-7a607203086a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38386d49-6ce6-4196-93f4-bb597ce79dd3" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_06217bfe-3eb6-49ed-80ba-7a607203086a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8bee431c-d85b-435b-ac6f-a5d54f8b1b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38386d49-6ce6-4196-93f4-bb597ce79dd3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8bee431c-d85b-435b-ac6f-a5d54f8b1b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_937f95f6-2b1c-4256-8065-d0b93779949a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38386d49-6ce6-4196-93f4-bb597ce79dd3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_937f95f6-2b1c-4256-8065-d0b93779949a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0830c4c4-2c8a-4ce9-94ac-9583843f7bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_38386d49-6ce6-4196-93f4-bb597ce79dd3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0830c4c4-2c8a-4ce9-94ac-9583843f7bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_70c23565-75d0-45b0-98be-45e2d89dd89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c7b198e2-4394-4a5a-b3e8-f4998d9be7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70c23565-75d0-45b0-98be-45e2d89dd89d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c7b198e2-4394-4a5a-b3e8-f4998d9be7b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7a85d0ac-03b9-4340-9cad-aa9d6d3edea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70c23565-75d0-45b0-98be-45e2d89dd89d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7a85d0ac-03b9-4340-9cad-aa9d6d3edea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0220b41b-1dff-475e-8a76-32ad782fc43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70c23565-75d0-45b0-98be-45e2d89dd89d" xlink:to="loc_us-gaap_LiabilitiesCurrent_0220b41b-1dff-475e-8a76-32ad782fc43c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_29c586f8-79f0-4050-a917-3991b3ce28c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70c23565-75d0-45b0-98be-45e2d89dd89d" xlink:to="loc_us-gaap_SecuredLongTermDebt_29c586f8-79f0-4050-a917-3991b3ce28c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b541ccc2-995b-4d1a-b80c-1f43af96c47a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_70c23565-75d0-45b0-98be-45e2d89dd89d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b541ccc2-995b-4d1a-b80c-1f43af96c47a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d75c8a20-8bc0-4b43-9882-e7fcbc29e76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_20abb156-e744-4793-85ea-98768742ed7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d75c8a20-8bc0-4b43-9882-e7fcbc29e76b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_20abb156-e744-4793-85ea-98768742ed7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7b439934-f813-42f6-991b-231520df3043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d75c8a20-8bc0-4b43-9882-e7fcbc29e76b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7b439934-f813-42f6-991b-231520df3043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_00a67770-b9c4-44dc-b49f-e194e8772a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d75c8a20-8bc0-4b43-9882-e7fcbc29e76b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_00a67770-b9c4-44dc-b49f-e194e8772a0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_9151742a-cd19-4c9c-b4f8-8df6c0e00f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d75c8a20-8bc0-4b43-9882-e7fcbc29e76b" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_9151742a-cd19-4c9c-b4f8-8df6c0e00f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e9068d10-09aa-43da-9782-0aed1f95d79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cc0b9c63-2613-45d2-84f2-f3299bd6d799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e9068d10-09aa-43da-9782-0aed1f95d79f" xlink:to="loc_us-gaap_OperatingIncomeLoss_cc0b9c63-2613-45d2-84f2-f3299bd6d799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_90d6cb2c-3d9b-46aa-bd5f-b4bbe3c63faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e9068d10-09aa-43da-9782-0aed1f95d79f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_90d6cb2c-3d9b-46aa-bd5f-b4bbe3c63faf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c64c7b89-ca48-4f09-9141-6bef2d83c8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d302a912-4a27-4187-b7c1-259e19412998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c64c7b89-ca48-4f09-9141-6bef2d83c8e7" xlink:to="loc_us-gaap_OperatingExpenses_d302a912-4a27-4187-b7c1-259e19412998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_85bbb693-1d67-413a-9d1c-49e89d8f44ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c64c7b89-ca48-4f09-9141-6bef2d83c8e7" xlink:to="loc_us-gaap_Revenues_85bbb693-1d67-413a-9d1c-49e89d8f44ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_97ff81e7-8ab3-472b-9af7-bca801af9e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_230922c9-f262-4044-80ea-48ef95ef0e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_97ff81e7-8ab3-472b-9af7-bca801af9e94" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_230922c9-f262-4044-80ea-48ef95ef0e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_79df192c-57b7-4b67-93a0-845f6b7e8bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_97ff81e7-8ab3-472b-9af7-bca801af9e94" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_79df192c-57b7-4b67-93a0-845f6b7e8bb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_366c5bd8-a08b-4c41-83f9-efd5e72895e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_97ff81e7-8ab3-472b-9af7-bca801af9e94" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_366c5bd8-a08b-4c41-83f9-efd5e72895e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_aa6657e8-7cfc-46e0-892c-eb48c067099d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_69c39476-c939-4187-9c95-f635856227ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_aa6657e8-7cfc-46e0-892c-eb48c067099d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_69c39476-c939-4187-9c95-f635856227ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f01fe9f4-92d3-4147-9c5a-ef50172a61a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_aa6657e8-7cfc-46e0-892c-eb48c067099d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f01fe9f4-92d3-4147-9c5a-ef50172a61a4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7d3ffe2d-ab7d-4615-91b7-d8e340414ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7d3ffe2d-ab7d-4615-91b7-d8e340414ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_53c4be0d-093c-4c0c-8430-449d1da24f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_NetIncomeLoss_53c4be0d-093c-4c0c-8430-449d1da24f2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_46e19d94-4817-41aa-85ff-448d49f36510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_46e19d94-4817-41aa-85ff-448d49f36510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_23fe49b9-68ee-48b8-9c77-55b80ccad014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_23fe49b9-68ee-48b8-9c77-55b80ccad014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_c29b67aa-5f35-4c3c-8899-a765da776b08" xlink:href="inbx-20211231.xsd#inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_c29b67aa-5f35-4c3c-8899-a765da776b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ce761acf-9181-4149-9dec-1f4cf8425eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ce761acf-9181-4149-9dec-1f4cf8425eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NoncashOperatingLeaseExpense_7d510560-97f2-44b4-9c45-5d5f7dc4969a" xlink:href="inbx-20211231.xsd#inbx_NoncashOperatingLeaseExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_inbx_NoncashOperatingLeaseExpense_7d510560-97f2-44b4-9c45-5d5f7dc4969a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_041f31d0-fce3-4e3c-8b70-241a7df50cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_041f31d0-fce3-4e3c-8b70-241a7df50cfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_532c4119-c778-4e1c-966a-cd88395b3856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_532c4119-c778-4e1c-966a-cd88395b3856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4eac65e4-3aea-4c5e-993e-f37b793206e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4eac65e4-3aea-4c5e-993e-f37b793206e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_da53f299-a3a4-4dfd-a998-ea7dff7b41a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_da53f299-a3a4-4dfd-a998-ea7dff7b41a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_51b04175-9586-4215-b15f-455bc6ea7647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_51b04175-9586-4215-b15f-455bc6ea7647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ad1072c0-5b80-4087-a4ad-d6c99f704fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_OperatingLeasePayments_ad1072c0-5b80-4087-a4ad-d6c99f704fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_04ab8dd0-e5b2-48bc-8c76-959b4e94bb50" xlink:href="inbx-20211231.xsd#inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_04ab8dd0-e5b2-48bc-8c76-959b4e94bb50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_50f36f69-b8e4-4446-b9b8-5b3f3d1d250a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_ShareBasedCompensation_50f36f69-b8e4-4446-b9b8-5b3f3d1d250a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e4713e39-06a6-4d44-8a1d-94d6f182c5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e4713e39-06a6-4d44-8a1d-94d6f182c5d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1103e87f-0cb3-4afa-8072-694149ada7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1103e87f-0cb3-4afa-8072-694149ada7f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5b06a226-fd13-412a-909d-7f7ba9ee695d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5b06a226-fd13-412a-909d-7f7ba9ee695d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9dbd9f0f-8562-49fd-bfec-579d2d1469b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e44f484-c91e-416c-9064-dc777270cbff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9dbd9f0f-8562-49fd-bfec-579d2d1469b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_5bf8270f-f378-48c3-8a9c-3ca8da0a5132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_5bf8270f-f378-48c3-8a9c-3ca8da0a5132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e95d4f20-19b7-41e0-a8b2-9ad1f6d2b4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e95d4f20-19b7-41e0-a8b2-9ad1f6d2b4dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_179f1942-f7fb-4d31-a450-187286fd3a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_179f1942-f7fb-4d31-a450-187286fd3a5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_1e020aab-022b-4536-ab40-1cb843be2e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_1e020aab-022b-4536-ab40-1cb843be2e64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment_a4aa7f59-632c-4652-b026-450a0436937d" xlink:href="inbx-20211231.xsd#inbx_RepaymentsOfSecuredDebtFinalBalloonPayment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:to="loc_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment_a4aa7f59-632c-4652-b026-450a0436937d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_dd0386da-9878-452d-9266-83abb6d697db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_dd0386da-9878-452d-9266-83abb6d697db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_cf91765c-1354-4539-8ba7-aa6d1572ced9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_cf91765c-1354-4539-8ba7-aa6d1572ced9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_782386d4-95af-478d-83b2-51331b46616f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_782386d4-95af-478d-83b2-51331b46616f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_be3f39e4-78c1-4137-9e81-89edc6fee718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_be3f39e4-78c1-4137-9e81-89edc6fee718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_e7e99462-c54b-4f45-811f-34636b56dd4e" xlink:href="inbx-20211231.xsd#inbx_PaymentsOfDebtIssuanceCostsSecuredDebt"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a2ededb-cbf9-4efa-adc8-6d99243d48df" xlink:to="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_e7e99462-c54b-4f45-811f-34636b56dd4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9ddb51b2-cc98-4d26-946a-4befe031b986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_575f364d-264b-4fa5-aaf4-eaf834d93d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9ddb51b2-cc98-4d26-946a-4befe031b986" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_575f364d-264b-4fa5-aaf4-eaf834d93d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b5ab6625-59c1-4d7c-857c-d191124bee4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9ddb51b2-cc98-4d26-946a-4befe031b986" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b5ab6625-59c1-4d7c-857c-d191124bee4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56a2d319-8ca8-4eee-9ce3-3d9db6b901a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9ddb51b2-cc98-4d26-946a-4befe031b986" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56a2d319-8ca8-4eee-9ce3-3d9db6b901a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6561a502-912c-43d9-a854-6cb7176eae1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c31378f9-f405-4903-8643-9e8eed2172dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6561a502-912c-43d9-a854-6cb7176eae1a" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c31378f9-f405-4903-8643-9e8eed2172dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_70726371-8cc2-4651-8e51-fd8bd0f8495b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6561a502-912c-43d9-a854-6cb7176eae1a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_70726371-8cc2-4651-8e51-fd8bd0f8495b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ab5f6f7-b0a5-4ace-87d0-64811440fb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_ed872000-03eb-44b4-8c31-d01f0e56dccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ab5f6f7-b0a5-4ace-87d0-64811440fb50" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_ed872000-03eb-44b4-8c31-d01f0e56dccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_95d88bde-5d37-4be9-9eaa-a3731f3b1f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ab5f6f7-b0a5-4ace-87d0-64811440fb50" xlink:to="loc_us-gaap_OtherAssetsCurrent_95d88bde-5d37-4be9-9eaa-a3731f3b1f3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5741d9cf-a7c4-4669-9e21-68b7b17c9610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_db0a4d5d-6ebd-4608-b9d5-1fd34a24fd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5741d9cf-a7c4-4669-9e21-68b7b17c9610" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_db0a4d5d-6ebd-4608-b9d5-1fd34a24fd7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_edd064c2-be10-4411-a87a-a37ff0464f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5741d9cf-a7c4-4669-9e21-68b7b17c9610" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_edd064c2-be10-4411-a87a-a37ff0464f20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATIONAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_876c5b04-e40f-4fd5-82f5-211d439402f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalResearchAndDevelopmentCurrent_1f4ea01a-215e-4447-baca-628dec040955" xlink:href="inbx-20211231.xsd#inbx_AccruedClinicalResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_876c5b04-e40f-4fd5-82f5-211d439402f9" xlink:to="loc_inbx_AccruedClinicalResearchAndDevelopmentCurrent_1f4ea01a-215e-4447-baca-628dec040955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_80f10dc4-8129-422f-b968-bfe108f34ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_876c5b04-e40f-4fd5-82f5-211d439402f9" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_80f10dc4-8129-422f-b968-bfe108f34ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_7ea1ca8c-3d01-4d79-a541-336fea289ce5" xlink:href="inbx-20211231.xsd#inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_876c5b04-e40f-4fd5-82f5-211d439402f9" xlink:to="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_7ea1ca8c-3d01-4d79-a541-336fea289ce5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_21c2ffc5-ea8e-4491-88fe-7688ee06e2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_876c5b04-e40f-4fd5-82f5-211d439402f9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_21c2ffc5-ea8e-4491-88fe-7688ee06e2a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_8b8e13f9-8443-45e3-a3d1-135cff8529e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_876c5b04-e40f-4fd5-82f5-211d439402f9" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_8b8e13f9-8443-45e3-a3d1-135cff8529e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTOutstandingDebtBalance2020LoanAgreementDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9edd4494-d1f3-45a5-9a87-aed4d6bbb950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_389b76a0-e13d-443c-9eee-291054f815cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9edd4494-d1f3-45a5-9a87-aed4d6bbb950" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_389b76a0-e13d-443c-9eee-291054f815cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d3295193-fac0-4223-a22a-26d6d725d0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9edd4494-d1f3-45a5-9a87-aed4d6bbb950" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d3295193-fac0-4223-a22a-26d6d725d0b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails_1" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTOutstandingDebtBalance2020LoanAgreementDetails_1"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4c35e5b1-a8bc-490a-82d7-3e543521aed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1ec76059-da1d-43b9-bafe-db097dcaac8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c35e5b1-a8bc-490a-82d7-3e543521aed6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1ec76059-da1d-43b9-bafe-db097dcaac8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5ffab606-9d43-4d7b-9fdd-7f4f1927a1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4c35e5b1-a8bc-490a-82d7-3e543521aed6" xlink:to="loc_us-gaap_LongTermDebtCurrent_5ffab606-9d43-4d7b-9fdd-7f4f1927a1d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7394e5ef-5b75-4b96-82c8-bf8d3d21eb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3bcb2d8f-b256-4ecf-a061-3ce5d7dff3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7394e5ef-5b75-4b96-82c8-bf8d3d21eb9e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3bcb2d8f-b256-4ecf-a061-3ce5d7dff3f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5dbe8dde-8b8a-427a-8d9e-df7c5fd8b9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_62192ded-bc62-4dcb-b92c-92db3007cc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5dbe8dde-8b8a-427a-8d9e-df7c5fd8b9d2" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_62192ded-bc62-4dcb-b92c-92db3007cc5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXESReconciliationofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9af8893d-8212-4d70-809b-855052c5ea22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1c1400e6-9af3-466b-ab12-5b573c680de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9af8893d-8212-4d70-809b-855052c5ea22" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1c1400e6-9af3-466b-ab12-5b573c680de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8212f366-96cf-434f-93e7-064f0f797495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9af8893d-8212-4d70-809b-855052c5ea22" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8212f366-96cf-434f-93e7-064f0f797495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_56676698-c256-4e0f-a063-e57dd7336d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9af8893d-8212-4d70-809b-855052c5ea22" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_56676698-c256-4e0f-a063-e57dd7336d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6deaef1c-2a77-490b-a131-88cf8fc27882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9af8893d-8212-4d70-809b-855052c5ea22" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6deaef1c-2a77-490b-a131-88cf8fc27882" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_c3a6a48f-ec73-4a4e-a9d8-307ee70a8dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9af8893d-8212-4d70-809b-855052c5ea22" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_c3a6a48f-ec73-4a4e-a9d8-307ee70a8dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_30d4fb1e-bf0b-4f63-a465-65c4872fc860" xlink:href="inbx-20211231.xsd#inbx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9af8893d-8212-4d70-809b-855052c5ea22" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_30d4fb1e-bf0b-4f63-a465-65c4872fc860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps_1d0b6cbb-6142-4a20-9969-94a8e7426f55" xlink:href="inbx-20211231.xsd#inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9af8893d-8212-4d70-809b-855052c5ea22" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps_1d0b6cbb-6142-4a20-9969-94a8e7426f55" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXESComponentsofnetdeferredincometaxesDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ba4d886b-fb4e-4f4b-9c9b-6907135ba061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3dbfc88a-462e-46d3-8209-8c389e8d9639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ba4d886b-fb4e-4f4b-9c9b-6907135ba061" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3dbfc88a-462e-46d3-8209-8c389e8d9639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_70ee17a3-274d-4c05-b951-c5a4b8f984b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ba4d886b-fb4e-4f4b-9c9b-6907135ba061" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_70ee17a3-274d-4c05-b951-c5a4b8f984b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3dda4242-ab4e-4a51-9597-575e7abac1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_93f92815-285c-477a-a779-61e7aa120e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3dda4242-ab4e-4a51-9597-575e7abac1d7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_93f92815-285c-477a-a779-61e7aa120e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2e688d71-bf8d-42c3-aeba-b414d3e26db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3dda4242-ab4e-4a51-9597-575e7abac1d7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2e688d71-bf8d-42c3-aeba-b414d3e26db7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_13ea882d-f724-40f1-8046-443de95d5254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_45a665c8-ab67-4fa7-a248-ca2f31091348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_13ea882d-f724-40f1-8046-443de95d5254" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_45a665c8-ab67-4fa7-a248-ca2f31091348" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0a604162-25e5-4ea4-a0a2-721127aa04a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_13ea882d-f724-40f1-8046-443de95d5254" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0a604162-25e5-4ea4-a0a2-721127aa04a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_bcc2271b-1f7e-473a-8fb6-4e5a2d049486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_feffe722-9109-422d-8d7b-aa1cb5e90609" xlink:href="inbx-20211231.xsd#inbx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bcc2271b-1f7e-473a-8fb6-4e5a2d049486" xlink:to="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_feffe722-9109-422d-8d7b-aa1cb5e90609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_5e8fdeec-463d-4130-ac88-4b72968afeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bcc2271b-1f7e-473a-8fb6-4e5a2d049486" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_5e8fdeec-463d-4130-ac88-4b72968afeda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_27d37471-c870-4455-9187-90c630eb03f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bcc2271b-1f7e-473a-8fb6-4e5a2d049486" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_27d37471-c870-4455-9187-90c630eb03f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_264e4b79-b18d-4d62-a98b-385c58c7a889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bcc2271b-1f7e-473a-8fb6-4e5a2d049486" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_264e4b79-b18d-4d62-a98b-385c58c7a889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d3854f6e-3d06-4708-8b80-59d14b734aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bcc2271b-1f7e-473a-8fb6-4e5a2d049486" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d3854f6e-3d06-4708-8b80-59d14b734aba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a66cc42a-e107-481a-bde6-dfe2ab1883a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bcc2271b-1f7e-473a-8fb6-4e5a2d049486" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a66cc42a-e107-481a-bde6-dfe2ab1883a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b4dd2e51-6995-4832-9f66-2a72dd0e6693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bcc2271b-1f7e-473a-8fb6-4e5a2d049486" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b4dd2e51-6995-4832-9f66-2a72dd0e6693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0aa248d5-00a9-46df-8bab-86043709b8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_bcc2271b-1f7e-473a-8fb6-4e5a2d049486" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0aa248d5-00a9-46df-8bab-86043709b8f1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ec424598-e21c-4d6c-bc6d-7e1d3ca5f1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6b81ce5b-7536-472c-9d22-dad6ede53494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ec424598-e21c-4d6c-bc6d-7e1d3ca5f1d3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6b81ce5b-7536-472c-9d22-dad6ede53494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3ace128a-18da-4fab-8091-16a4b4f0dbee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ec424598-e21c-4d6c-bc6d-7e1d3ca5f1d3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3ace128a-18da-4fab-8091-16a4b4f0dbee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da013037-68f0-44c7-9c0f-f98d4e089d28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d57b9828-c3fa-4f63-9ad2-94d2616266f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da013037-68f0-44c7-9c0f-f98d4e089d28" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d57b9828-c3fa-4f63-9ad2-94d2616266f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d6cc8d78-6a0b-4454-b07f-fcaf735df2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da013037-68f0-44c7-9c0f-f98d4e089d28" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d6cc8d78-6a0b-4454-b07f-fcaf735df2eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6b096429-d496-4e63-9806-122c58e1a6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da013037-68f0-44c7-9c0f-f98d4e089d28" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6b096429-d496-4e63-9806-122c58e1a6b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ad6f93fa-7fbb-4de2-9b47-1dbb7cd5f4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_da013037-68f0-44c7-9c0f-f98d4e089d28" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ad6f93fa-7fbb-4de2-9b47-1dbb7cd5f4b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="inbx-20211231.xsd#LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a6f1d764-b186-49cf-8568-027d097df5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c61914b6-c4f4-4e37-a723-68f98733296e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a6f1d764-b186-49cf-8568-027d097df5a7" xlink:to="loc_us-gaap_OperatingLeaseLiability_c61914b6-c4f4-4e37-a723-68f98733296e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_38d138a1-f3c3-462c-8e81-cc9c6b0f68de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a6f1d764-b186-49cf-8568-027d097df5a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_38d138a1-f3c3-462c-8e81-cc9c6b0f68de" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>inbx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8eb0955a-77e8-4ec9-9bdb-5f279743741e,g:91526847-18eb-416c-96d8-1d5c48d93616-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i3854c9729bc4424d9b544a2a5cec2dac_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_37ec8354-6300-4024-9975-e3ad879ecafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_RevenuesAbstract_37ec8354-6300-4024-9975-e3ad879ecafc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_92909d3a-92c8-439c-a251-68b5bacc5c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_37ec8354-6300-4024-9975-e3ad879ecafc" xlink:to="loc_us-gaap_Revenues_92909d3a-92c8-439c-a251-68b5bacc5c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6f3759b0-e1b3-42d7-b6f4-27c5e920e9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6f3759b0-e1b3-42d7-b6f4-27c5e920e9ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_923df297-e1a5-4b04-87f8-b31c8b75bc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f3759b0-e1b3-42d7-b6f4-27c5e920e9ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_923df297-e1a5-4b04-87f8-b31c8b75bc2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0c73c70b-8c93-491f-8a33-a3d82e31bae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f3759b0-e1b3-42d7-b6f4-27c5e920e9ed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0c73c70b-8c93-491f-8a33-a3d82e31bae6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8c54ae83-09a6-4b8b-a9ab-d786764f1d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f3759b0-e1b3-42d7-b6f4-27c5e920e9ed" xlink:to="loc_us-gaap_OperatingExpenses_8c54ae83-09a6-4b8b-a9ab-d786764f1d53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f7a44e15-47c0-4363-806c-ba9b67165e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_OperatingIncomeLoss_f7a44e15-47c0-4363-806c-ba9b67165e7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d3160d74-867c-49a3-8b88-1f1d32f5467b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d3160d74-867c-49a3-8b88-1f1d32f5467b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_070aa8d7-30c5-43c0-a05f-a659df446c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_070aa8d7-30c5-43c0-a05f-a659df446c1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_35785ce6-e8db-41bc-89f5-2a61bbbbcda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_35785ce6-e8db-41bc-89f5-2a61bbbbcda6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ba227711-e997-4580-a754-724951a67ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ba227711-e997-4580-a754-724951a67ff2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_66756dc5-93ab-4b1e-a346-0a448bf69e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_66756dc5-93ab-4b1e-a346-0a448bf69e8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e0e33a1f-4f92-4a8e-a9f4-550753afd94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e0e33a1f-4f92-4a8e-a9f4-550753afd94f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_741085b5-ba66-4630-8f69-9855c478aa26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_741085b5-ba66-4630-8f69-9855c478aa26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9e53eac9-3810-44d1-bfb4-8ffd12389a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9e53eac9-3810-44d1-bfb4-8ffd12389a67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4d47c3f3-8d7f-4835-957e-a96ca1f408b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_ProfitLoss_4d47c3f3-8d7f-4835-957e-a96ca1f408b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_036c130b-1cb7-4cef-93fa-b8d56a832f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_EarningsPerShareBasic_036c130b-1cb7-4cef-93fa-b8d56a832f99" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f1b1e03f-a770-45aa-9f98-7e5c2671ab40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f1b1e03f-a770-45aa-9f98-7e5c2671ab40" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_554d0629-0918-4fb8-b4b3-8fe4f1dc7183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_554d0629-0918-4fb8-b4b3-8fe4f1dc7183" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b6e4b107-ee5e-4b17-a8c4-2e51db64ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b6e4b107-ee5e-4b17-a8c4-2e51db64ca9e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_69ccb20f-8063-4e58-b959-a4dd090558ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_StatementTable_69ccb20f-8063-4e58-b959-a4dd090558ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d6bb2e6-07e6-447b-a4a8-64005691facc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_69ccb20f-8063-4e58-b959-a4dd090558ec" xlink:to="loc_srt_ProductOrServiceAxis_4d6bb2e6-07e6-447b-a4a8-64005691facc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d6bb2e6-07e6-447b-a4a8-64005691facc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4d6bb2e6-07e6-447b-a4a8-64005691facc" xlink:to="loc_srt_ProductsAndServicesDomain_4d6bb2e6-07e6-447b-a4a8-64005691facc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e718c704-5055-4803-8dca-06c283e5b6c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4d6bb2e6-07e6-447b-a4a8-64005691facc" xlink:to="loc_srt_ProductsAndServicesDomain_e718c704-5055-4803-8dca-06c283e5b6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_477258cb-46e8-47a0-b5f7-0abba15a1f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e718c704-5055-4803-8dca-06c283e5b6c7" xlink:to="loc_us-gaap_LicenseMember_477258cb-46e8-47a0-b5f7-0abba15a1f2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_0e65a262-d53f-4e73-aae7-6b6aeed84606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e718c704-5055-4803-8dca-06c283e5b6c7" xlink:to="loc_us-gaap_GrantMember_0e65a262-d53f-4e73-aae7-6b6aeed84606" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit" xlink:type="extended" id="if3c8deaf88a24b52b068a847fde8a0de_ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7631eb49-7a85-4b28-a382-47a0161aa28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7631eb49-7a85-4b28-a382-47a0161aa28c" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7827d1de-6779-4110-99ba-74dd1b20a625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7827d1de-6779-4110-99ba-74dd1b20a625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_eb57d6d0-9aa4-4002-a659-388a2260d0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_eb57d6d0-9aa4-4002-a659-388a2260d0ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_686189b6-72fe-437d-9655-39c27ef05456" xlink:href="inbx-20211231.xsd#inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:to="loc_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_686189b6-72fe-437d-9655-39c27ef05456" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ea0b81aa-cf86-448d-a9d0-c45cfb472477" xlink:href="inbx-20211231.xsd#inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:to="loc_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ea0b81aa-cf86-448d-a9d0-c45cfb472477" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_31e80012-89dd-4bff-b277-25f14f3a7ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4033c334-8aeb-4568-ad1f-f3d9971cc996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7631eb49-7a85-4b28-a382-47a0161aa28c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d7a51ac5-c6cb-439b-90a2-0311fbeeb1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d7a51ac5-c6cb-439b-90a2-0311fbeeb1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4309537d-0c62-4d49-9d88-c9eaa7746257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4309537d-0c62-4d49-9d88-c9eaa7746257" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_368c429b-462b-4298-83fa-7880391fb5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_368c429b-462b-4298-83fa-7880391fb5ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1b76afba-b47a-43f5-a84a-205bc7cf617a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1b76afba-b47a-43f5-a84a-205bc7cf617a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ca5100f-7fec-4e54-a36f-63afd0f152f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ca5100f-7fec-4e54-a36f-63afd0f152f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_36172810-15c2-4bdb-bd9b-bc254b78d989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_36172810-15c2-4bdb-bd9b-bc254b78d989" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f0e0b052-94a8-45b8-83b5-63520f8e63b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f0e0b052-94a8-45b8-83b5-63520f8e63b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fbdc0a89-384f-4465-a938-26f47dbc55d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fbdc0a89-384f-4465-a938-26f47dbc55d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e58cd95f-4d5c-46f7-b25f-82761aa236f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e58cd95f-4d5c-46f7-b25f-82761aa236f4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_7ceeb9cd-36a5-4ea3-a2ff-3d719b9b6555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_7ceeb9cd-36a5-4ea3-a2ff-3d719b9b6555" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReversalOfUnamortizedBeneficialConversionFeature_6d0043f0-4433-41fd-b40e-6983a7bccc02" xlink:href="inbx-20211231.xsd#inbx_ReversalOfUnamortizedBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_inbx_ReversalOfUnamortizedBeneficialConversionFeature_6d0043f0-4433-41fd-b40e-6983a7bccc02" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2fc876a2-b20c-472b-afd5-6e86131e767d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2fc876a2-b20c-472b-afd5-6e86131e767d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_54507c51-e2f5-4b50-91bf-8c4726034427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_NetIncomeLoss_54507c51-e2f5-4b50-91bf-8c4726034427" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e6131eb4-926e-4ce0-8c9a-dd9dcec95e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e07289c8-afcc-4761-83ed-2ca634031d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7631eb49-7a85-4b28-a382-47a0161aa28c" xlink:to="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_258c4529-ff27-4c92-bdb2-1c2286a0ab40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_258c4529-ff27-4c92-bdb2-1c2286a0ab40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_258c4529-ff27-4c92-bdb2-1c2286a0ab40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_258c4529-ff27-4c92-bdb2-1c2286a0ab40" xlink:to="loc_us-gaap_EquityComponentDomain_258c4529-ff27-4c92-bdb2-1c2286a0ab40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_72f4df31-1e9c-42a6-aa8b-98efdaa1d236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_258c4529-ff27-4c92-bdb2-1c2286a0ab40" xlink:to="loc_us-gaap_EquityComponentDomain_72f4df31-1e9c-42a6-aa8b-98efdaa1d236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f8c3c9bd-e8af-4eb5-a30d-39cd8d9cc695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_72f4df31-1e9c-42a6-aa8b-98efdaa1d236" xlink:to="loc_us-gaap_CommonStockMember_f8c3c9bd-e8af-4eb5-a30d-39cd8d9cc695" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a55c3e4d-5281-4396-a4df-8a3e888631c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_72f4df31-1e9c-42a6-aa8b-98efdaa1d236" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a55c3e4d-5281-4396-a4df-8a3e888631c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_447f2caf-122d-4f02-af32-f1d3072a664e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_72f4df31-1e9c-42a6-aa8b-98efdaa1d236" xlink:to="loc_us-gaap_RetainedEarningsMember_447f2caf-122d-4f02-af32-f1d3072a664e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bea3cb2f-acb4-4499-b714-a2fa954557c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:to="loc_us-gaap_DebtInstrumentAxis_bea3cb2f-acb4-4499-b714-a2fa954557c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bea3cb2f-acb4-4499-b714-a2fa954557c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bea3cb2f-acb4-4499-b714-a2fa954557c2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bea3cb2f-acb4-4499-b714-a2fa954557c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_510cdcd9-c9d5-4094-9c9b-d593289d3d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bea3cb2f-acb4-4499-b714-a2fa954557c2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_510cdcd9-c9d5-4094-9c9b-d593289d3d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_1304e05d-0c74-441a-a906-0c36532bf9e6" xlink:href="inbx-20211231.xsd#inbx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_510cdcd9-c9d5-4094-9c9b-d593289d3d90" xlink:to="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_1304e05d-0c74-441a-a906-0c36532bf9e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019ConvertiblePromissoryNoteMember_16285351-c4e9-4dc3-8bd3-6fd7034afa57" xlink:href="inbx-20211231.xsd#inbx_A2019ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_510cdcd9-c9d5-4094-9c9b-d593289d3d90" xlink:to="loc_inbx_A2019ConvertiblePromissoryNoteMember_16285351-c4e9-4dc3-8bd3-6fd7034afa57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020ConvertiblePromissoryNoteMember_d0f48a20-c775-472b-8701-a354fcba072f" xlink:href="inbx-20211231.xsd#inbx_A2020ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_510cdcd9-c9d5-4094-9c9b-d593289d3d90" xlink:to="loc_inbx_A2020ConvertiblePromissoryNoteMember_d0f48a20-c775-472b-8701-a354fcba072f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a55d5b58-62da-487c-9a1e-1c8cdf579420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a55d5b58-62da-487c-9a1e-1c8cdf579420" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a55d5b58-62da-487c-9a1e-1c8cdf579420_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a55d5b58-62da-487c-9a1e-1c8cdf579420" xlink:to="loc_us-gaap_ClassOfStockDomain_a55d5b58-62da-487c-9a1e-1c8cdf579420_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_18d6bc2c-eba8-4e5b-b30e-928f524036f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a55d5b58-62da-487c-9a1e-1c8cdf579420" xlink:to="loc_us-gaap_ClassOfStockDomain_18d6bc2c-eba8-4e5b-b30e-928f524036f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_b4c17553-9dcf-4ce2-8f22-43ed183eae6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_18d6bc2c-eba8-4e5b-b30e-928f524036f2" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_b4c17553-9dcf-4ce2-8f22-43ed183eae6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f646c514-010e-45d0-a59f-9e6a4593c363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f646c514-010e-45d0-a59f-9e6a4593c363" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f646c514-010e-45d0-a59f-9e6a4593c363_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f646c514-010e-45d0-a59f-9e6a4593c363" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f646c514-010e-45d0-a59f-9e6a4593c363_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46b0574c-5791-4e68-bda4-cd1b5bcf2784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f646c514-010e-45d0-a59f-9e6a4593c363" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46b0574c-5791-4e68-bda4-cd1b5bcf2784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_16bdfb6e-69d4-40e1-b72b-47f19df1385f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46b0574c-5791-4e68-bda4-cd1b5bcf2784" xlink:to="loc_us-gaap_IPOMember_16bdfb6e-69d4-40e1-b72b-47f19df1385f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i9989d21255664650acbd726d6493de1e_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a7825fb2-fd8a-41cc-8106-222a8756f02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e890530-c298-4c27-a824-a494070589a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a7825fb2-fd8a-41cc-8106-222a8756f02c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e890530-c298-4c27-a824-a494070589a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e890530-c298-4c27-a824-a494070589a6" xlink:to="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_db39b653-7b76-4992-9eef-7d8c0ba476b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_db39b653-7b76-4992-9eef-7d8c0ba476b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7ef86e39-f497-42d2-b7d3-20515b5abfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7ef86e39-f497-42d2-b7d3-20515b5abfa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cd8b511b-a45a-49dc-be65-00f41cfd3096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_ShareBasedCompensation_cd8b511b-a45a-49dc-be65-00f41cfd3096" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NoncashOperatingLeaseExpense_8d1a818d-e6bf-4487-bee3-9dbcb284cbb7" xlink:href="inbx-20211231.xsd#inbx_NoncashOperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_inbx_NoncashOperatingLeaseExpense_8d1a818d-e6bf-4487-bee3-9dbcb284cbb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3131fbc3-aa00-498c-89ef-4c9f22899dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3131fbc3-aa00-498c-89ef-4c9f22899dcf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_106fdc7d-9ceb-4afa-a3e9-09dabe6dd4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_106fdc7d-9ceb-4afa-a3e9-09dabe6dd4a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_0c2d173b-4c7b-4a54-b8a9-28efb76380c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_0c2d173b-4c7b-4a54-b8a9-28efb76380c6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ce20187-cfe9-4552-ba17-d2a1dead0fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ce20187-cfe9-4552-ba17-d2a1dead0fec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d6f508bc-14d7-452d-8613-a5e4369f376b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d6f508bc-14d7-452d-8613-a5e4369f376b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_e08f3164-0d6c-4aa9-914a-c329bf75176e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_e08f3164-0d6c-4aa9-914a-c329bf75176e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a08cd79e-7e89-488a-92af-5b4e58dd01bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a08cd79e-7e89-488a-92af-5b4e58dd01bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1cc11db9-9e51-4b03-bfb6-591636ef1ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1cc11db9-9e51-4b03-bfb6-591636ef1ca0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_47f53525-ecd8-4962-8f6b-64b87d9e4cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_47f53525-ecd8-4962-8f6b-64b87d9e4cca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_aed5afdc-8394-40fb-af34-58c53896558c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_aed5afdc-8394-40fb-af34-58c53896558c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_49cf1297-fe7a-4ce2-b44a-8e1073350ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_OperatingLeasePayments_49cf1297-fe7a-4ce2-b44a-8e1073350ea8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_8c9ad9a2-3fa5-4f82-aae8-f81f285f566d" xlink:href="inbx-20211231.xsd#inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_8c9ad9a2-3fa5-4f82-aae8-f81f285f566d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_9b156d63-0a19-4da4-bb88-057234f58ce5" xlink:href="inbx-20211231.xsd#inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_9b156d63-0a19-4da4-bb88-057234f58ce5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3dfafe30-3881-4ce3-b499-d05884792fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3dfafe30-3881-4ce3-b499-d05884792fa3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8895c9c8-e9fa-4d81-b15e-6b09b8e4f909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8895c9c8-e9fa-4d81-b15e-6b09b8e4f909" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0c21bbdf-24a4-48c5-bc57-670ced3c9087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0c21bbdf-24a4-48c5-bc57-670ced3c9087" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c08add23-90fa-4725-8fd2-ae6528189572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0c21bbdf-24a4-48c5-bc57-670ced3c9087" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c08add23-90fa-4725-8fd2-ae6528189572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94ff63a7-0cba-413e-a3cc-19962db519f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0c21bbdf-24a4-48c5-bc57-670ced3c9087" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94ff63a7-0cba-413e-a3cc-19962db519f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed13c4eb-f2a9-4644-850c-00e22d9d39e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed13c4eb-f2a9-4644-850c-00e22d9d39e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_55224935-6806-44ad-9eed-4012f881f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_55224935-6806-44ad-9eed-4012f881f8c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_075dc6a4-1896-4043-9834-f2beafe692bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_075dc6a4-1896-4043-9834-f2beafe692bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_608aeb70-23a4-4e46-82c9-e4678b011a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_608aeb70-23a4-4e46-82c9-e4678b011a85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_ae8a9f0e-6973-452d-926e-1f52c2b6c8d0" xlink:href="inbx-20211231.xsd#inbx_PaymentsOfDebtIssuanceCostsSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_ae8a9f0e-6973-452d-926e-1f52c2b6c8d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ee09142d-3ea2-4efd-9172-2f779f770be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ee09142d-3ea2-4efd-9172-2f779f770be5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_971ca757-8a43-4c4b-8b9a-4f6f13cf878a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_971ca757-8a43-4c4b-8b9a-4f6f13cf878a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_dbb19b0d-bb93-4233-9df7-129e3d6bf6be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_dbb19b0d-bb93-4233-9df7-129e3d6bf6be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment_adbec624-70ad-4a0b-bdea-43efc50ffd8a" xlink:href="inbx-20211231.xsd#inbx_RepaymentsOfSecuredDebtFinalBalloonPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment_adbec624-70ad-4a0b-bdea-43efc50ffd8a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_5d7cbbba-d156-4455-b7e2-1d8237e53be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_5d7cbbba-d156-4455-b7e2-1d8237e53be9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_b4191bfe-4db0-4a14-b450-efaff8ae6c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_b4191bfe-4db0-4a14-b450-efaff8ae6c82" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6683e18f-4f12-47f5-9410-f60075e566c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6683e18f-4f12-47f5-9410-f60075e566c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6dc8d92d-07d7-4111-bc67-b1dce522797f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6dc8d92d-07d7-4111-bc67-b1dce522797f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eec69795-a38e-46b1-8d0c-e872cbaf85ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eec69795-a38e-46b1-8d0c-e872cbaf85ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6282111-69f0-459e-8d8e-62ec7bdb885f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_d3eccf07-cb34-409a-b3aa-291ea375289a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_d3eccf07-cb34-409a-b3aa-291ea375289a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1915ff8b-d402-4f1e-9e28-8d13c94bbc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d3eccf07-cb34-409a-b3aa-291ea375289a" xlink:to="loc_us-gaap_InterestPaidNet_1915ff8b-d402-4f1e-9e28-8d13c94bbc93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_dc3b74db-f709-49ca-813a-709c3ca18214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d3eccf07-cb34-409a-b3aa-291ea375289a" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_dc3b74db-f709-49ca-813a-709c3ca18214" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_10c97189-a0b7-4493-a897-c5f6e65734f9" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_10c97189-a0b7-4493-a897-c5f6e65734f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable_611e123f-f65c-467e-85ba-69bab881a741" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable_611e123f-f65c-467e-85ba-69bab881a741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CapitalExpendituresIncurredButNotYetPaidReleased_c3240331-b750-4295-a573-554afdcf0bb1" xlink:href="inbx-20211231.xsd#inbx_CapitalExpendituresIncurredButNotYetPaidReleased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_CapitalExpendituresIncurredButNotYetPaidReleased_c3240331-b750-4295-a573-554afdcf0bb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_4224b8b2-e57f-4fcf-a542-bb2e92cee8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_4224b8b2-e57f-4fcf-a542-bb2e92cee8eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_00c690b7-2b69-4a38-9ef6-81b0a6ecacd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_00c690b7-2b69-4a38-9ef6-81b0a6ecacd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_3df9f593-b1c4-4d36-9d0d-d875459a459a" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_3df9f593-b1c4-4d36-9d0d-d875459a459a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4ac8354a-6fe4-4b70-850e-2dfbd5fe9d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4ac8354a-6fe4-4b70-850e-2dfbd5fe9d3e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_da8af555-e576-419a-ad16-5c4ba884a935" xlink:href="inbx-20211231.xsd#inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_da8af555-e576-419a-ad16-5c4ba884a935" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NonCashEstablishmentOfEquityMethodInvestment_b5fce2c6-4162-423d-b6ae-96654d7cfef7" xlink:href="inbx-20211231.xsd#inbx_NonCashEstablishmentOfEquityMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_NonCashEstablishmentOfEquityMethodInvestment_b5fce2c6-4162-423d-b6ae-96654d7cfef7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReclassificationOfWarrantLiabilitiesToEquity_dc67ab2a-85dc-4c3f-ae04-37596d62664e" xlink:href="inbx-20211231.xsd#inbx_ReclassificationOfWarrantLiabilitiesToEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_ReclassificationOfWarrantLiabilitiesToEquity_dc67ab2a-85dc-4c3f-ae04-37596d62664e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_049fbd59-a988-4f10-a0a5-6736d8e0ea8f" xlink:href="inbx-20211231.xsd#inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_049fbd59-a988-4f10-a0a5-6736d8e0ea8f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7c65133a-95e1-4bda-8619-f6ad0ecbfe7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a7825fb2-fd8a-41cc-8106-222a8756f02c" xlink:to="loc_us-gaap_StatementTable_7c65133a-95e1-4bda-8619-f6ad0ecbfe7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fef4c208-ff98-47e3-ac33-3450b33b68df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7c65133a-95e1-4bda-8619-f6ad0ecbfe7f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fef4c208-ff98-47e3-ac33-3450b33b68df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fef4c208-ff98-47e3-ac33-3450b33b68df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fef4c208-ff98-47e3-ac33-3450b33b68df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fef4c208-ff98-47e3-ac33-3450b33b68df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_062aa30a-242d-48f1-ac34-007c304430a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fef4c208-ff98-47e3-ac33-3450b33b68df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_062aa30a-242d-48f1-ac34-007c304430a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingMember_40bf2c32-2662-42cd-b22d-2ae065b0dc82" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_062aa30a-242d-48f1-ac34-007c304430a4" xlink:to="loc_inbx_AtTheMarketOfferingMember_40bf2c32-2662-42cd-b22d-2ae065b0dc82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9a12a388-ca92-4b27-ae4c-e84e69c23458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_062aa30a-242d-48f1-ac34-007c304430a4" xlink:to="loc_us-gaap_IPOMember_9a12a388-ca92-4b27-ae4c-e84e69c23458" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" xlink:type="extended" id="ibf95f2e6c89d4366b35dd1cb4cc8fc4f_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f72a1a1e-bda3-4bc0-9854-bc07a2797eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f72a1a1e-bda3-4bc0-9854-bc07a2797eab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_279db910-8456-4b6e-a708-64c20dc98b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_279db910-8456-4b6e-a708-64c20dc98b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5f6183e9-e640-4f88-8808-2ca6eb8c9adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5f6183e9-e640-4f88-8808-2ca6eb8c9adf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_44335f41-fed2-426f-908d-37450b7a6175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_44335f41-fed2-426f-908d-37450b7a6175" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d743e344-79cd-4181-99dd-80690bf7a17a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d743e344-79cd-4181-99dd-80690bf7a17a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_eff3e067-5d31-4700-b66e-59f6aa81d330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_eff3e067-5d31-4700-b66e-59f6aa81d330" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_33b70994-50e7-4117-a70a-f13517e43ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_33b70994-50e7-4117-a70a-f13517e43ecb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4bfc67cb-85bf-4911-b49e-0bb7967578c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4bfc67cb-85bf-4911-b49e-0bb7967578c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0bc27f0d-70e6-4788-9127-4d8f42010eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0bc27f0d-70e6-4788-9127-4d8f42010eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0bc27f0d-70e6-4788-9127-4d8f42010eea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0bc27f0d-70e6-4788-9127-4d8f42010eea" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0bc27f0d-70e6-4788-9127-4d8f42010eea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e16b4cf9-b41f-4347-9d64-f186afb831f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0bc27f0d-70e6-4788-9127-4d8f42010eea" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e16b4cf9-b41f-4347-9d64-f186afb831f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_69f31764-3ab8-44e1-ab57-e5e5089e7a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e16b4cf9-b41f-4347-9d64-f186afb831f3" xlink:to="loc_us-gaap_IPOMember_69f31764-3ab8-44e1-ab57-e5e5089e7a28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2fbf1829-8a93-46f4-91ac-8602fd261315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_DebtInstrumentAxis_2fbf1829-8a93-46f4-91ac-8602fd261315" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2fbf1829-8a93-46f4-91ac-8602fd261315_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fbf1829-8a93-46f4-91ac-8602fd261315" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2fbf1829-8a93-46f4-91ac-8602fd261315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_afd02317-3846-45a8-8d85-f42da5926739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fbf1829-8a93-46f4-91ac-8602fd261315" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_afd02317-3846-45a8-8d85-f42da5926739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_8405dbd4-367e-4e3c-a608-484a3e10fe8e" xlink:href="inbx-20211231.xsd#inbx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_afd02317-3846-45a8-8d85-f42da5926739" xlink:to="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_8405dbd4-367e-4e3c-a608-484a3e10fe8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bd2f7c25-ff19-4582-98c7-71212aeef532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bd2f7c25-ff19-4582-98c7-71212aeef532" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bd2f7c25-ff19-4582-98c7-71212aeef532_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd2f7c25-ff19-4582-98c7-71212aeef532" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bd2f7c25-ff19-4582-98c7-71212aeef532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ee52294-ea6d-4cfe-b108-4869eaa23218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd2f7c25-ff19-4582-98c7-71212aeef532" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ee52294-ea6d-4cfe-b108-4869eaa23218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_73bba405-c298-4b58-b5fe-51c3d5c89c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2ee52294-ea6d-4cfe-b108-4869eaa23218" xlink:to="loc_us-gaap_ConvertibleDebtMember_73bba405-c298-4b58-b5fe-51c3d5c89c87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c2844e9e-5018-49cc-b760-609da7664b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c2844e9e-5018-49cc-b760-609da7664b0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c2844e9e-5018-49cc-b760-609da7664b0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2844e9e-5018-49cc-b760-609da7664b0c" xlink:to="loc_us-gaap_ClassOfStockDomain_c2844e9e-5018-49cc-b760-609da7664b0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca72defe-443b-42d5-bfef-d9f8725dd106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2844e9e-5018-49cc-b760-609da7664b0c" xlink:to="loc_us-gaap_ClassOfStockDomain_ca72defe-443b-42d5-bfef-d9f8725dd106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_be9361e1-378a-48b1-8f33-ad75decadce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ca72defe-443b-42d5-bfef-d9f8725dd106" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_be9361e1-378a-48b1-8f33-ad75decadce8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_17d5693b-c421-407a-9e37-043ce0a1e0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_17d5693b-c421-407a-9e37-043ce0a1e0fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_17d5693b-c421-407a-9e37-043ce0a1e0fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17d5693b-c421-407a-9e37-043ce0a1e0fa" xlink:to="loc_us-gaap_EquityComponentDomain_17d5693b-c421-407a-9e37-043ce0a1e0fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c326117-fcfd-4643-ba5e-b0ccf266d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17d5693b-c421-407a-9e37-043ce0a1e0fa" xlink:to="loc_us-gaap_EquityComponentDomain_9c326117-fcfd-4643-ba5e-b0ccf266d7ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_12b9e9b5-690f-4c68-9abe-f741fc03fbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9c326117-fcfd-4643-ba5e-b0ccf266d7ea" xlink:to="loc_us-gaap_CommonStockMember_12b9e9b5-690f-4c68-9abe-f741fc03fbfa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="id7233bd256bc4b5e88a48e4657f1964b_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1860b3cb-5da8-4eb9-b97e-8401e398065f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1860b3cb-5da8-4eb9-b97e-8401e398065f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8154eb18-c405-4d0f-9eb2-c65c3a9b6169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8154eb18-c405-4d0f-9eb2-c65c3a9b6169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6fcf7dab-e7b7-4c6d-82e9-476c57c9c2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6fcf7dab-e7b7-4c6d-82e9-476c57c9c2d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleOfStockCommonStockAuthorized_df0f37c6-1586-4a75-ad35-5d29606e75ab" xlink:href="inbx-20211231.xsd#inbx_SaleOfStockCommonStockAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_SaleOfStockCommonStockAuthorized_df0f37c6-1586-4a75-ad35-5d29606e75ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleOfStockSharesCommonStockSold_ea80a444-59ef-459f-96e9-4b3d1151ce2d" xlink:href="inbx-20211231.xsd#inbx_SaleOfStockSharesCommonStockSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_SaleOfStockSharesCommonStockSold_ea80a444-59ef-459f-96e9-4b3d1151ce2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05edf5fd-1e9b-4eb2-a3df-7ef024450bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05edf5fd-1e9b-4eb2-a3df-7ef024450bf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_a21ac77d-ce65-410b-b9cc-323aba79e061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_a21ac77d-ce65-410b-b9cc-323aba79e061" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DeferredFederalPayrollTaxesCARESAct_c8c2e334-5a5e-4ae3-8de6-8754a89decbd" xlink:href="inbx-20211231.xsd#inbx_DeferredFederalPayrollTaxesCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_DeferredFederalPayrollTaxesCARESAct_c8c2e334-5a5e-4ae3-8de6-8754a89decbd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e09d86cf-15bd-4def-971a-e77bacbd47f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e09d86cf-15bd-4def-971a-e77bacbd47f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementTerm_4612260e-3ee7-42e7-a18d-fc3f1b2d2c5a" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_CollaborativeArrangementTerm_4612260e-3ee7-42e7-a18d-fc3f1b2d2c5a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fc924ed7-ea8d-4ccd-a762-ff288b54f165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fc924ed7-ea8d-4ccd-a762-ff288b54f165" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NumberOfOperatingLeasesHeld_589f5df2-d548-429f-b707-176af3655210" xlink:href="inbx-20211231.xsd#inbx_NumberOfOperatingLeasesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_NumberOfOperatingLeasesHeld_589f5df2-d548-429f-b707-176af3655210" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a4b1f3e4-72ef-4eb8-905e-61cfaaa37337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a4b1f3e4-72ef-4eb8-905e-61cfaaa37337" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d88d2c53-3199-4a49-8021-690249772f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_EquityMethodInvestments_d88d2c53-3199-4a49-8021-690249772f16" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering_e1e9ee82-15c4-4bec-bc35-a150dc416837" xlink:href="inbx-20211231.xsd#inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering_e1e9ee82-15c4-4bec-bc35-a150dc416837" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_9c2fdccb-4741-495e-9d0b-d5cd53f01b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_DeferredOfferingCosts_9c2fdccb-4741-495e-9d0b-d5cd53f01b25" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_18960330-773f-49cf-ace5-45232a67e1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_NumberOfOperatingSegments_18960330-773f-49cf-ace5-45232a67e1d6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ae6c9f9-bbbd-45a0-9e7a-cfbce543fbda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_srt_RangeAxis_9ae6c9f9-bbbd-45a0-9e7a-cfbce543fbda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ae6c9f9-bbbd-45a0-9e7a-cfbce543fbda_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9ae6c9f9-bbbd-45a0-9e7a-cfbce543fbda" xlink:to="loc_srt_RangeMember_9ae6c9f9-bbbd-45a0-9e7a-cfbce543fbda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_129671d7-0c02-4afb-a17c-b71ffa7777f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9ae6c9f9-bbbd-45a0-9e7a-cfbce543fbda" xlink:to="loc_srt_RangeMember_129671d7-0c02-4afb-a17c-b71ffa7777f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a7695830-e36f-4ce4-b037-2ca83b19caf4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_129671d7-0c02-4afb-a17c-b71ffa7777f5" xlink:to="loc_srt_MinimumMember_a7695830-e36f-4ce4-b037-2ca83b19caf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e5191dce-2659-4c5f-bed1-b0e3ee882867" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_129671d7-0c02-4afb-a17c-b71ffa7777f5" xlink:to="loc_srt_MaximumMember_e5191dce-2659-4c5f-bed1-b0e3ee882867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5f6ba61-d4b8-4f10-aa09-88fe1648795d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5f6ba61-d4b8-4f10-aa09-88fe1648795d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5f6ba61-d4b8-4f10-aa09-88fe1648795d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5f6ba61-d4b8-4f10-aa09-88fe1648795d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5f6ba61-d4b8-4f10-aa09-88fe1648795d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a8352b0-e51f-41e8-91bc-db2cd263ec32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5f6ba61-d4b8-4f10-aa09-88fe1648795d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a8352b0-e51f-41e8-91bc-db2cd263ec32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_628eef3e-cafe-48ca-af9c-f8a82d738780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a8352b0-e51f-41e8-91bc-db2cd263ec32" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_628eef3e-cafe-48ca-af9c-f8a82d738780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c81580ff-2f23-46d6-9eaf-1f2fafc263d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a8352b0-e51f-41e8-91bc-db2cd263ec32" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c81580ff-2f23-46d6-9eaf-1f2fafc263d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9e879451-c0a7-4c0f-8f2b-a725163e9514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a8352b0-e51f-41e8-91bc-db2cd263ec32" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9e879451-c0a7-4c0f-8f2b-a725163e9514" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ac1d3f0-74e4-46b4-9e61-8d9aa6e6b2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ac1d3f0-74e4-46b4-9e61-8d9aa6e6b2fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7ac1d3f0-74e4-46b4-9e61-8d9aa6e6b2fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ac1d3f0-74e4-46b4-9e61-8d9aa6e6b2fa" xlink:to="loc_us-gaap_RelatedPartyDomain_7ac1d3f0-74e4-46b4-9e61-8d9aa6e6b2fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7eea0377-5e2b-472f-9378-0d5c9ac9ae2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ac1d3f0-74e4-46b4-9e61-8d9aa6e6b2fa" xlink:to="loc_us-gaap_RelatedPartyDomain_7eea0377-5e2b-472f-9378-0d5c9ac9ae2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_050d5c9f-6d51-45ee-9983-916571bd5741" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7eea0377-5e2b-472f-9378-0d5c9ac9ae2c" xlink:to="loc_srt_AffiliatedEntityMember_050d5c9f-6d51-45ee-9983-916571bd5741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7583e5f3-17f5-4d74-a535-712d7012b898" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_srt_CounterpartyNameAxis_7583e5f3-17f5-4d74-a535-712d7012b898" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7583e5f3-17f5-4d74-a535-712d7012b898_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7583e5f3-17f5-4d74-a535-712d7012b898" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7583e5f3-17f5-4d74-a535-712d7012b898_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aa4fcad-3d9f-4dee-bb9e-f824647a9ea9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7583e5f3-17f5-4d74-a535-712d7012b898" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aa4fcad-3d9f-4dee-bb9e-f824647a9ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WuXiBiologicsHealthcareVentureMember_8c5ce4b0-00a5-4483-9532-7b042fb57cea" xlink:href="inbx-20211231.xsd#inbx_WuXiBiologicsHealthcareVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aa4fcad-3d9f-4dee-bb9e-f824647a9ea9" xlink:to="loc_inbx_WuXiBiologicsHealthcareVentureMember_8c5ce4b0-00a5-4483-9532-7b042fb57cea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4315960-455e-4f25-bafb-1c0c0fc9c38c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4315960-455e-4f25-bafb-1c0c0fc9c38c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a4315960-455e-4f25-bafb-1c0c0fc9c38c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4315960-455e-4f25-bafb-1c0c0fc9c38c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a4315960-455e-4f25-bafb-1c0c0fc9c38c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6aecf370-df9d-4f2d-8a3e-2609d230ea27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4315960-455e-4f25-bafb-1c0c0fc9c38c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6aecf370-df9d-4f2d-8a3e-2609d230ea27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember_f9001bbf-251d-44bf-9950-70b6af6a41a6" xlink:href="inbx-20211231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6aecf370-df9d-4f2d-8a3e-2609d230ea27" xlink:to="loc_inbx_PhylaxisBioScienceLLCMember_f9001bbf-251d-44bf-9950-70b6af6a41a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a2d0cbd1-129a-4af3-9fa4-4ebda681d1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_DebtInstrumentAxis_a2d0cbd1-129a-4af3-9fa4-4ebda681d1ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a2d0cbd1-129a-4af3-9fa4-4ebda681d1ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a2d0cbd1-129a-4af3-9fa4-4ebda681d1ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a2d0cbd1-129a-4af3-9fa4-4ebda681d1ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_afccf5db-4d84-4804-81fb-f129071d4690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a2d0cbd1-129a-4af3-9fa4-4ebda681d1ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_afccf5db-4d84-4804-81fb-f129071d4690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaycheckProtectionProgramCARESActMember_5b196d04-ce14-4d23-b667-c1378755adfb" xlink:href="inbx-20211231.xsd#inbx_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_afccf5db-4d84-4804-81fb-f129071d4690" xlink:to="loc_inbx_PaycheckProtectionProgramCARESActMember_5b196d04-ce14-4d23-b667-c1378755adfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_6af92d03-27c9-46e9-8663-a788eba6d358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_6af92d03-27c9-46e9-8663-a788eba6d358" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6af92d03-27c9-46e9-8663-a788eba6d358_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6af92d03-27c9-46e9-8663-a788eba6d358" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6af92d03-27c9-46e9-8663-a788eba6d358_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_d37219e5-c85c-44f4-bcd2-a9b0182f1bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6af92d03-27c9-46e9-8663-a788eba6d358" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_d37219e5-c85c-44f4-bcd2-a9b0182f1bb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_24e9b905-0d91-4c7b-af1e-4a5c8d09da5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_d37219e5-c85c-44f4-bcd2-a9b0182f1bb5" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_24e9b905-0d91-4c7b-af1e-4a5c8d09da5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e8d6b425-df04-4f0e-8011-bff691030e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e8d6b425-df04-4f0e-8011-bff691030e13" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8d6b425-df04-4f0e-8011-bff691030e13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e8d6b425-df04-4f0e-8011-bff691030e13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8d6b425-df04-4f0e-8011-bff691030e13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9fd223f-b3ca-4d3e-b0d1-f81730c2751d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e8d6b425-df04-4f0e-8011-bff691030e13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9fd223f-b3ca-4d3e-b0d1-f81730c2751d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SalesAgreementMember_1c2071aa-8240-48d2-b422-db88e66621e1" xlink:href="inbx-20211231.xsd#inbx_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9fd223f-b3ca-4d3e-b0d1-f81730c2751d" xlink:to="loc_inbx_SalesAgreementMember_1c2071aa-8240-48d2-b422-db88e66621e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="extended" id="i8bbfaf0e95fd4f35b8a7b39c232e3eac_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b75cf2a0-6f6c-4b58-84d6-3b08e719897f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b75cf2a0-6f6c-4b58-84d6-3b08e719897f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_984f5d0f-02fc-48e5-9e65-748e84841f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_984f5d0f-02fc-48e5-9e65-748e84841f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_05667c7f-a390-4a62-afff-812a4cabd6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_05667c7f-a390-4a62-afff-812a4cabd6f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ccaf14f6-b7a4-46a9-807c-d74dfec6ff11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ccaf14f6-b7a4-46a9-807c-d74dfec6ff11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_93278ff7-0776-4343-b76f-1263de74927c" xlink:href="inbx-20211231.xsd#inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:to="loc_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_93278ff7-0776-4343-b76f-1263de74927c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5ae50832-96c6-4274-8f3a-9451f83a8ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3c296c63-54b2-4532-b222-5717e57b8ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b75cf2a0-6f6c-4b58-84d6-3b08e719897f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3c296c63-54b2-4532-b222-5717e57b8ecb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39e0ed0a-b840-477d-b5eb-f0896b54a84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3c296c63-54b2-4532-b222-5717e57b8ecb" xlink:to="loc_us-gaap_DebtInstrumentAxis_39e0ed0a-b840-477d-b5eb-f0896b54a84b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_39e0ed0a-b840-477d-b5eb-f0896b54a84b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_39e0ed0a-b840-477d-b5eb-f0896b54a84b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_39e0ed0a-b840-477d-b5eb-f0896b54a84b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f5df0be6-d304-4237-89e6-3273c2ad2022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_39e0ed0a-b840-477d-b5eb-f0896b54a84b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f5df0be6-d304-4237-89e6-3273c2ad2022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020ConvertiblePromissoryNoteMember_4ad7510c-c9c7-4092-889d-4cf384c0ae9b" xlink:href="inbx-20211231.xsd#inbx_A2020ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5df0be6-d304-4237-89e6-3273c2ad2022" xlink:to="loc_inbx_A2020ConvertiblePromissoryNoteMember_4ad7510c-c9c7-4092-889d-4cf384c0ae9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_7eda5939-a26c-4839-98bd-3a439874e664" xlink:href="inbx-20211231.xsd#inbx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5df0be6-d304-4237-89e6-3273c2ad2022" xlink:to="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_7eda5939-a26c-4839-98bd-3a439874e664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_348fcc08-10a4-4880-b4f5-dd0e8322d527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3c296c63-54b2-4532-b222-5717e57b8ecb" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_348fcc08-10a4-4880-b4f5-dd0e8322d527" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_348fcc08-10a4-4880-b4f5-dd0e8322d527_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_348fcc08-10a4-4880-b4f5-dd0e8322d527" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_348fcc08-10a4-4880-b4f5-dd0e8322d527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0573d5f9-6792-49e8-8fc7-b2d9249b6dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_348fcc08-10a4-4880-b4f5-dd0e8322d527" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0573d5f9-6792-49e8-8fc7-b2d9249b6dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantAndDerivativeLiabilitiesMember_8ece5f87-0b99-4dd9-8608-ec684cccad7e" xlink:href="inbx-20211231.xsd#inbx_WarrantAndDerivativeLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0573d5f9-6792-49e8-8fc7-b2d9249b6dfb" xlink:to="loc_inbx_WarrantAndDerivativeLiabilitiesMember_8ece5f87-0b99-4dd9-8608-ec684cccad7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember_7ecad716-644e-4cb6-a235-e2d88d65f3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0573d5f9-6792-49e8-8fc7-b2d9249b6dfb" xlink:to="loc_us-gaap_DerivativeMember_7ecad716-644e-4cb6-a235-e2d88d65f3d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1a1e524d-27d8-4a90-b6b9-5449fd80c8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0573d5f9-6792-49e8-8fc7-b2d9249b6dfb" xlink:to="loc_us-gaap_WarrantMember_1a1e524d-27d8-4a90-b6b9-5449fd80c8e6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" xlink:type="extended" id="i1235f2184899450f8730bae5e5d12863_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc75adc3-eaea-4742-922f-be38160c06eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bd704507-b10b-442e-a520-0259a55b4175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc75adc3-eaea-4742-922f-be38160c06eb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bd704507-b10b-442e-a520-0259a55b4175" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3853d0e0-b286-4292-91aa-581fc0255632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc75adc3-eaea-4742-922f-be38160c06eb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3853d0e0-b286-4292-91aa-581fc0255632" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a67f1447-1186-48f2-aeba-490ab6d7491c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3853d0e0-b286-4292-91aa-581fc0255632" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a67f1447-1186-48f2-aeba-490ab6d7491c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a67f1447-1186-48f2-aeba-490ab6d7491c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a67f1447-1186-48f2-aeba-490ab6d7491c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a67f1447-1186-48f2-aeba-490ab6d7491c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b69ffbe5-d4db-4bcb-9d36-175db23c92dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a67f1447-1186-48f2-aeba-490ab6d7491c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b69ffbe5-d4db-4bcb-9d36-175db23c92dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a38fab4a-722c-4c09-bb20-a1dc5d439b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b69ffbe5-d4db-4bcb-9d36-175db23c92dd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a38fab4a-722c-4c09-bb20-a1dc5d439b6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_04e64ab6-380d-448c-9be1-3ab6873b1994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b69ffbe5-d4db-4bcb-9d36-175db23c92dd" xlink:to="loc_us-gaap_WarrantMember_04e64ab6-380d-448c-9be1-3ab6873b1994" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="extended" id="id372b64c1e254d4d81019634a1c69769_OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e19baa53-07bd-453d-98c0-18180c1f8061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e19baa53-07bd-453d-98c0-18180c1f8061" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d1f9ea7f-8fc5-473e-8d57-84451445bbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d1f9ea7f-8fc5-473e-8d57-84451445bbbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c062073a-7287-4d9b-bd2e-9f8713dda6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c062073a-7287-4d9b-bd2e-9f8713dda6e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6f416167-5754-4b77-b93b-80089a9d6588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6f416167-5754-4b77-b93b-80089a9d6588" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a187fc5f-05fe-4c9e-9354-477c1844bdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a187fc5f-05fe-4c9e-9354-477c1844bdc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7978a546-2351-4a69-80d8-583dbedbc0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a187fc5f-05fe-4c9e-9354-477c1844bdc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7978a546-2351-4a69-80d8-583dbedbc0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7978a546-2351-4a69-80d8-583dbedbc0d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7978a546-2351-4a69-80d8-583dbedbc0d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7978a546-2351-4a69-80d8-583dbedbc0d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7978a546-2351-4a69-80d8-583dbedbc0d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6e8e34bb-279b-4e90-94d8-91a2ae0d9ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6e8e34bb-279b-4e90-94d8-91a2ae0d9ecd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_81f00bd7-b17e-4839-b599-7c60d3bd5a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_81f00bd7-b17e-4839-b599-7c60d3bd5a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_17f6c512-f492-403b-9880-3a88e341290e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_17f6c512-f492-403b-9880-3a88e341290e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_f5ac7afc-492a-4a2a-b971-75f81c04a257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_f5ac7afc-492a-4a2a-b971-75f81c04a257" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_0f2d57b0-49c3-4a07-985e-9ed86095dc32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:to="loc_us-gaap_ConstructionInProgressMember_0f2d57b0-49c3-4a07-985e-9ed86095dc32" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails" xlink:type="extended" id="ic5b7ebf143b44a86980c87a81422cb56_OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e460a08a-b85c-4485-87b3-556c5f2a476a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_80b27604-6521-4326-96a1-217cfa13c207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e460a08a-b85c-4485-87b3-556c5f2a476a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_80b27604-6521-4326-96a1-217cfa13c207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8888074d-d4c1-4936-9d35-d459aa851a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e460a08a-b85c-4485-87b3-556c5f2a476a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8888074d-d4c1-4936-9d35-d459aa851a3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3f752f72-a77e-4934-a994-a5643992fdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8888074d-d4c1-4936-9d35-d459aa851a3d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3f752f72-a77e-4934-a994-a5643992fdc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3f752f72-a77e-4934-a994-a5643992fdc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3f752f72-a77e-4934-a994-a5643992fdc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3f752f72-a77e-4934-a994-a5643992fdc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6b5e7d06-e08d-43f9-967d-14546e05c644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3f752f72-a77e-4934-a994-a5643992fdc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6b5e7d06-e08d-43f9-967d-14546e05c644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_554275d4-383e-4038-8396-ef421d71f252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b5e7d06-e08d-43f9-967d-14546e05c644" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_554275d4-383e-4038-8396-ef421d71f252" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72d60d1a-57c4-4c4e-bf45-40779589d5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b5e7d06-e08d-43f9-967d-14546e05c644" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72d60d1a-57c4-4c4e-bf45-40779589d5a0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/DEBTNarrativeDetails" xlink:type="extended" id="id68be695b8c643c69894a6bae07361df_DEBTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_84335719-49a9-4c97-b16a-9833ad213c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_84335719-49a9-4c97-b16a-9833ad213c35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_4040c67e-e56e-42d7-8448-40d73582e249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_4040c67e-e56e-42d7-8448-40d73582e249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentAmendmentFee_accb0f5e-c494-49ce-ac44-01a472fa863d" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentAmendmentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentAmendmentFee_accb0f5e-c494-49ce-ac44-01a472fa863d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfAdditionalTranches_8e2ff7d3-ef81-4043-b347-fcb783d85121" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentNumberOfAdditionalTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentNumberOfAdditionalTranches_8e2ff7d3-ef81-4043-b347-fcb783d85121" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_60a9bea9-c970-479e-b26d-02c6f886a120" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_60a9bea9-c970-479e-b26d-02c6f886a120" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5bd1fe5b-c9c8-4b8c-84ab-6b9c5ddcaf58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5bd1fe5b-c9c8-4b8c-84ab-6b9c5ddcaf58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_78c3a26d-dabc-4cff-a86c-75660e0e2141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_78c3a26d-dabc-4cff-a86c-75660e0e2141" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5d45a072-6299-4282-ad18-a062ccb9f4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5d45a072-6299-4282-ad18-a062ccb9f4fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_4d033c7d-a4f9-4848-bf8f-a54bf20ecc64" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_4d033c7d-a4f9-4848-bf8f-a54bf20ecc64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_328f6351-6af7-4e23-8acc-24aa43932126" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_328f6351-6af7-4e23-8acc-24aa43932126" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_e77046d5-0a65-401a-841b-d8b9707f05bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_e77046d5-0a65-401a-841b-d8b9707f05bc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrepaymentFee_15610e0a-a793-42b4-9214-ea256f539329" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPrepaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentPrepaymentFee_15610e0a-a793-42b4-9214-ea256f539329" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentMinimumCashBalance_cac1eb90-bb10-431b-a80e-aef63114cfb2" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentMinimumCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentMinimumCashBalance_cac1eb90-bb10-431b-a80e-aef63114cfb2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_799b3647-91b5-4ed3-a8b8-489fc601a6a7" xlink:href="inbx-20211231.xsd#inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_799b3647-91b5-4ed3-a8b8-489fc601a6a7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsAndRightsOutstandingLiability_58f0f5ac-8d6c-4372-827c-573d14709f21" xlink:href="inbx-20211231.xsd#inbx_WarrantsAndRightsOutstandingLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_WarrantsAndRightsOutstandingLiability_58f0f5ac-8d6c-4372-827c-573d14709f21" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsLiability_00f0423f-2abd-44b6-ae39-5fb02d19b683" xlink:href="inbx-20211231.xsd#inbx_WarrantsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_WarrantsLiability_00f0423f-2abd-44b6-ae39-5fb02d19b683" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2285f378-df65-413d-b3c2-1000ba9de307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2285f378-df65-413d-b3c2-1000ba9de307" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_248f48fb-4ea1-4246-bcab-a319a294fa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_248f48fb-4ea1-4246-bcab-a319a294fa0d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_737f79b0-7d64-421a-a8aa-5525b1969543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_InterestExpenseDebt_737f79b0-7d64-421a-a8aa-5525b1969543" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eee05be9-7dfe-4f7a-9e48-acf21226228d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_DebtInstrumentAxis_eee05be9-7dfe-4f7a-9e48-acf21226228d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eee05be9-7dfe-4f7a-9e48-acf21226228d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_eee05be9-7dfe-4f7a-9e48-acf21226228d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eee05be9-7dfe-4f7a-9e48-acf21226228d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_eee05be9-7dfe-4f7a-9e48-acf21226228d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember_a73c7ce9-23bc-4b86-9b5f-f32d786ee686" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember_a73c7ce9-23bc-4b86-9b5f-f32d786ee686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_a013693c-60b2-4d6e-82af-f65e5a0c53ae" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_A2020OxfordTermLoansMember_a013693c-60b2-4d6e-82af-f65e5a0c53ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheOneMember_ea0fc3b7-fca4-4b7c-8702-ad899092da6f" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheOneMember_ea0fc3b7-fca4-4b7c-8702-ad899092da6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanMember_3c8bfeee-5d63-45b0-b617-e0e5bf98d88d" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_Amended2020OxfordTermLoanMember_3c8bfeee-5d63-45b0-b617-e0e5bf98d88d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheTwoMember_d770287b-63f1-4ae4-ac4d-1a0d7ae5e6c4" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheTwoMember_d770287b-63f1-4ae4-ac4d-1a0d7ae5e6c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember_f3603d8f-7cec-498c-818f-7bb8afa1430d" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanJune2021AmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember_f3603d8f-7cec-498c-818f-7bb8afa1430d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2015OxfordTermLoansMember_e9e25633-8125-41fb-8130-829974fdbf8c" xlink:href="inbx-20211231.xsd#inbx_A2015OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_A2015OxfordTermLoansMember_e9e25633-8125-41fb-8130-829974fdbf8c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ffa25339-c0fe-4b74-b0f3-50fbb6b80f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ffa25339-c0fe-4b74-b0f3-50fbb6b80f36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ffa25339-c0fe-4b74-b0f3-50fbb6b80f36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ffa25339-c0fe-4b74-b0f3-50fbb6b80f36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ffa25339-c0fe-4b74-b0f3-50fbb6b80f36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6013b155-da53-4005-99af-546935405c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ffa25339-c0fe-4b74-b0f3-50fbb6b80f36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6013b155-da53-4005-99af-546935405c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_054d64d4-f4da-472e-a221-6da3ee24e62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6013b155-da53-4005-99af-546935405c22" xlink:to="loc_us-gaap_SecuredDebtMember_054d64d4-f4da-472e-a221-6da3ee24e62c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1f6d432f-6370-4ef3-ab47-8baa9f2787f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1f6d432f-6370-4ef3-ab47-8baa9f2787f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1f6d432f-6370-4ef3-ab47-8baa9f2787f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1f6d432f-6370-4ef3-ab47-8baa9f2787f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1f6d432f-6370-4ef3-ab47-8baa9f2787f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_296abf6a-5fa2-4ef9-83ed-3bf7262f5bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1f6d432f-6370-4ef3-ab47-8baa9f2787f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_296abf6a-5fa2-4ef9-83ed-3bf7262f5bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_49a3e55a-61f4-4bf6-a163-08eb363dcebe" xlink:href="inbx-20211231.xsd#inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_296abf6a-5fa2-4ef9-83ed-3bf7262f5bd7" xlink:to="loc_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_49a3e55a-61f4-4bf6-a163-08eb363dcebe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsIssuedUponConsummationOfIPOMember_15b6135d-cd70-4031-a17a-c43ac49b1801" xlink:href="inbx-20211231.xsd#inbx_WarrantsIssuedUponConsummationOfIPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_296abf6a-5fa2-4ef9-83ed-3bf7262f5bd7" xlink:to="loc_inbx_WarrantsIssuedUponConsummationOfIPOMember_15b6135d-cd70-4031-a17a-c43ac49b1801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d5a75597-eb6f-4b8c-99cc-412837ec721c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_VariableRateAxis_d5a75597-eb6f-4b8c-99cc-412837ec721c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d5a75597-eb6f-4b8c-99cc-412837ec721c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_d5a75597-eb6f-4b8c-99cc-412837ec721c" xlink:to="loc_us-gaap_VariableRateDomain_d5a75597-eb6f-4b8c-99cc-412837ec721c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bf26af13-2b51-4624-a0bf-68946469e6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_d5a75597-eb6f-4b8c-99cc-412837ec721c" xlink:to="loc_us-gaap_VariableRateDomain_bf26af13-2b51-4624-a0bf-68946469e6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_34474050-e177-4bdc-8942-7e1b40a626fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_bf26af13-2b51-4624-a0bf-68946469e6f7" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_34474050-e177-4bdc-8942-7e1b40a626fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_929fe0ee-1eb8-48d8-9215-1e92de1235e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_929fe0ee-1eb8-48d8-9215-1e92de1235e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_929fe0ee-1eb8-48d8-9215-1e92de1235e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_929fe0ee-1eb8-48d8-9215-1e92de1235e4" xlink:to="loc_us-gaap_EquityComponentDomain_929fe0ee-1eb8-48d8-9215-1e92de1235e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2b4bd5fa-8e98-489a-b7fe-beeb78f301ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_929fe0ee-1eb8-48d8-9215-1e92de1235e4" xlink:to="loc_us-gaap_EquityComponentDomain_2b4bd5fa-8e98-489a-b7fe-beeb78f301ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_785d7d7a-b942-4575-a77d-def3d2a79ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2b4bd5fa-8e98-489a-b7fe-beeb78f301ca" xlink:to="loc_us-gaap_PreferredStockMember_785d7d7a-b942-4575-a77d-def3d2a79ca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb305789-bb10-4152-848d-d91cfd65a043" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_srt_RangeAxis_eb305789-bb10-4152-848d-d91cfd65a043" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb305789-bb10-4152-848d-d91cfd65a043_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eb305789-bb10-4152-848d-d91cfd65a043" xlink:to="loc_srt_RangeMember_eb305789-bb10-4152-848d-d91cfd65a043_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1066c629-af1e-4694-a37f-db104bdfcdaa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eb305789-bb10-4152-848d-d91cfd65a043" xlink:to="loc_srt_RangeMember_1066c629-af1e-4694-a37f-db104bdfcdaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_94459c97-59c5-46b6-a52d-4b1856d557c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1066c629-af1e-4694-a37f-db104bdfcdaa" xlink:to="loc_srt_MinimumMember_94459c97-59c5-46b6-a52d-4b1856d557c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5666ebd6-fb4a-428e-b31d-c924ae0c483c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1066c629-af1e-4694-a37f-db104bdfcdaa" xlink:to="loc_srt_MaximumMember_5666ebd6-fb4a-428e-b31d-c924ae0c483c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTOutstandingDebtBalance2020LoanAgreementDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="extended" id="ifbc3d706192b4f399af530f7227423cc_DEBTOutstandingDebtBalance2020LoanAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_62fa51dd-8f0c-43c5-88d2-d566e00b0975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_62fa51dd-8f0c-43c5-88d2-d566e00b0975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_02cc099f-bdd0-4399-a1ee-0c197476c138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_02cc099f-bdd0-4399-a1ee-0c197476c138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f1f19661-f5fc-4461-a1c2-964214377c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_LongTermDebt_f1f19661-f5fc-4461-a1c2-964214377c55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f042bf0d-328d-4254-be9a-227494c7ae81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_LongTermDebtCurrent_f042bf0d-328d-4254-be9a-227494c7ae81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f0daf8c9-1e08-447f-be48-fe2d39ac578d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f0daf8c9-1e08-447f-be48-fe2d39ac578d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d69a1631-2fd7-49b0-b60c-988a70ae270e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_DebtInstrumentTable_d69a1631-2fd7-49b0-b60c-988a70ae270e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a6ca3084-7189-4ea8-a563-b60ce968f623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d69a1631-2fd7-49b0-b60c-988a70ae270e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a6ca3084-7189-4ea8-a563-b60ce968f623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a6ca3084-7189-4ea8-a563-b60ce968f623_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a6ca3084-7189-4ea8-a563-b60ce968f623" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a6ca3084-7189-4ea8-a563-b60ce968f623_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_594336c7-2c37-4414-9896-1e9d69447ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a6ca3084-7189-4ea8-a563-b60ce968f623" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_594336c7-2c37-4414-9896-1e9d69447ea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_78d2d7ed-b822-4f79-bce3-8b4d79d5cb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_594336c7-2c37-4414-9896-1e9d69447ea8" xlink:to="loc_us-gaap_SecuredDebtMember_78d2d7ed-b822-4f79-bce3-8b4d79d5cb0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba0ca47e-fbb0-46cb-a7c4-ce8c112750f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d69a1631-2fd7-49b0-b60c-988a70ae270e" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba0ca47e-fbb0-46cb-a7c4-ce8c112750f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba0ca47e-fbb0-46cb-a7c4-ce8c112750f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba0ca47e-fbb0-46cb-a7c4-ce8c112750f7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba0ca47e-fbb0-46cb-a7c4-ce8c112750f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8de99fd2-3519-4099-bf51-b454c71e9a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba0ca47e-fbb0-46cb-a7c4-ce8c112750f7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8de99fd2-3519-4099-bf51-b454c71e9a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_af4836a6-5dc9-48db-876b-0a30cde0b77b" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8de99fd2-3519-4099-bf51-b454c71e9a3a" xlink:to="loc_inbx_A2020OxfordTermLoansMember_af4836a6-5dc9-48db-876b-0a30cde0b77b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoanAMember_c806a3ec-b7b1-431d-b933-913275522808" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inbx_A2020OxfordTermLoansMember_af4836a6-5dc9-48db-876b-0a30cde0b77b" xlink:to="loc_inbx_A2020OxfordTermLoanAMember_c806a3ec-b7b1-431d-b933-913275522808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoanBMember_bc527092-3df0-49a9-b56f-273f9390387d" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoanBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inbx_A2020OxfordTermLoansMember_af4836a6-5dc9-48db-876b-0a30cde0b77b" xlink:to="loc_inbx_A2020OxfordTermLoanBMember_bc527092-3df0-49a9-b56f-273f9390387d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoanCMember_6469e18c-9aae-423a-a427-95b8acd7b8dd" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoanCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inbx_A2020OxfordTermLoansMember_af4836a6-5dc9-48db-876b-0a30cde0b77b" xlink:to="loc_inbx_A2020OxfordTermLoanCMember_6469e18c-9aae-423a-a427-95b8acd7b8dd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTFutureMinimumPaymentsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="extended" id="i1e2eb45a7c5c43e491d1770e833ba2d1_DEBTFutureMinimumPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_679fc345-e5a1-4995-9c4a-22def39de894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_679fc345-e5a1-4995-9c4a-22def39de894" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0b4673c1-0f38-4a7a-979b-2427b622ea6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0b4673c1-0f38-4a7a-979b-2427b622ea6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_431ca8e9-f7da-42c7-a863-080d135dedb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_431ca8e9-f7da-42c7-a863-080d135dedb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cfd7466d-c4e0-4604-ba88-6ef5bf6a7653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:to="loc_us-gaap_LongTermDebt_cfd7466d-c4e0-4604-ba88-6ef5bf6a7653" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a402d526-eb99-4f5b-a389-9d09b7f1da0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:to="loc_us-gaap_DebtInstrumentTable_a402d526-eb99-4f5b-a389-9d09b7f1da0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d6777ae9-0b76-4e58-9414-bceb728580eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a402d526-eb99-4f5b-a389-9d09b7f1da0b" xlink:to="loc_us-gaap_DebtInstrumentAxis_d6777ae9-0b76-4e58-9414-bceb728580eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6777ae9-0b76-4e58-9414-bceb728580eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d6777ae9-0b76-4e58-9414-bceb728580eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6777ae9-0b76-4e58-9414-bceb728580eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_737b24eb-160b-4ab2-a746-e76c06bf2dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d6777ae9-0b76-4e58-9414-bceb728580eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_737b24eb-160b-4ab2-a746-e76c06bf2dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_0026d3aa-8b07-4ad8-8f9b-ff15e99f4406" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_737b24eb-160b-4ab2-a746-e76c06bf2dd8" xlink:to="loc_inbx_A2020OxfordTermLoansMember_0026d3aa-8b07-4ad8-8f9b-ff15e99f4406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_df8e6f7a-f1a2-47c2-8887-3f3b014ccf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a402d526-eb99-4f5b-a389-9d09b7f1da0b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_df8e6f7a-f1a2-47c2-8887-3f3b014ccf14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df8e6f7a-f1a2-47c2-8887-3f3b014ccf14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df8e6f7a-f1a2-47c2-8887-3f3b014ccf14" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df8e6f7a-f1a2-47c2-8887-3f3b014ccf14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_48afdbd7-0c50-4b3e-a6f9-925796fe6d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df8e6f7a-f1a2-47c2-8887-3f3b014ccf14" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_48afdbd7-0c50-4b3e-a6f9-925796fe6d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_fb69696a-dc1e-4918-89e5-d26fda8c350f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_48afdbd7-0c50-4b3e-a6f9-925796fe6d96" xlink:to="loc_us-gaap_SecuredDebtMember_fb69696a-dc1e-4918-89e5-d26fda8c350f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#CONVERTIBLEPROMISSORYNOTEDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails" xlink:type="extended" id="i2ca7ede3cebb4442998612436d62fb84_CONVERTIBLEPROMISSORYNOTEDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_91df65ab-825e-4a9a-9704-2fac16d6661d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_91df65ab-825e-4a9a-9704-2fac16d6661d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1f513288-1b44-4210-a31b-437e98bc109c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1f513288-1b44-4210-a31b-437e98bc109c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4b16f7ef-f5fc-45b4-978d-c8986181705b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_LongTermDebt_4b16f7ef-f5fc-45b4-978d-c8986181705b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_68562ee7-8606-404f-a25d-116688ba91ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_68562ee7-8606-404f-a25d-116688ba91ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_d27df92f-4c4d-4cb6-9fed-a01dbb11f633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_d27df92f-4c4d-4cb6-9fed-a01dbb11f633" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_e4d9114c-e450-430b-af47-a6607e84cf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DerivativeLiabilities_e4d9114c-e450-430b-af47-a6607e84cf10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_318cf3d2-7770-45e2-94b4-62f5e40460e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_318cf3d2-7770-45e2-94b4-62f5e40460e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_01d6a52f-6078-427e-9560-56a796c28487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_01d6a52f-6078-427e-9560-56a796c28487" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_98beb196-969f-4c09-9659-41ceec208108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_98beb196-969f-4c09-9659-41ceec208108" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReversalOfUnamortizedBeneficialConversionFeature_3f26ba20-5d23-402f-87b1-8cdb7d70b700" xlink:href="inbx-20211231.xsd#inbx_ReversalOfUnamortizedBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_inbx_ReversalOfUnamortizedBeneficialConversionFeature_3f26ba20-5d23-402f-87b1-8cdb7d70b700" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_bf56cad6-e9c4-4041-a789-a0f9cffd674e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_bf56cad6-e9c4-4041-a789-a0f9cffd674e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_121edac3-878d-43ab-a8c1-126decb052c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:to="loc_us-gaap_DebtInstrumentAxis_121edac3-878d-43ab-a8c1-126decb052c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_121edac3-878d-43ab-a8c1-126decb052c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_121edac3-878d-43ab-a8c1-126decb052c3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_121edac3-878d-43ab-a8c1-126decb052c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_951c6f09-fa37-4a6f-8e10-d9aa29fd3833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_121edac3-878d-43ab-a8c1-126decb052c3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_951c6f09-fa37-4a6f-8e10-d9aa29fd3833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019ConvertiblePromissoryNoteMember_bff331dc-3d86-4b25-9290-fd8f07c16d85" xlink:href="inbx-20211231.xsd#inbx_A2019ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_951c6f09-fa37-4a6f-8e10-d9aa29fd3833" xlink:to="loc_inbx_A2019ConvertiblePromissoryNoteMember_bff331dc-3d86-4b25-9290-fd8f07c16d85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020ConvertiblePromissoryNoteMember_a4db274b-5aee-4b51-9348-3e74e8253845" xlink:href="inbx-20211231.xsd#inbx_A2020ConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_951c6f09-fa37-4a6f-8e10-d9aa29fd3833" xlink:to="loc_inbx_A2020ConvertiblePromissoryNoteMember_a4db274b-5aee-4b51-9348-3e74e8253845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8d3b7134-f815-4f44-9469-becf86ef7ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8d3b7134-f815-4f44-9469-becf86ef7ffc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8d3b7134-f815-4f44-9469-becf86ef7ffc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8d3b7134-f815-4f44-9469-becf86ef7ffc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8d3b7134-f815-4f44-9469-becf86ef7ffc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_db562030-13a7-4e56-8e4d-4b5e6ab29370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8d3b7134-f815-4f44-9469-becf86ef7ffc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_db562030-13a7-4e56-8e4d-4b5e6ab29370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_76893a5f-a72c-436f-bba1-0e5f0dbbf4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_db562030-13a7-4e56-8e4d-4b5e6ab29370" xlink:to="loc_us-gaap_ConvertibleDebtMember_76893a5f-a72c-436f-bba1-0e5f0dbbf4fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e6984d3a-5851-47b0-9f79-e6918ad061fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e6984d3a-5851-47b0-9f79-e6918ad061fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e6984d3a-5851-47b0-9f79-e6918ad061fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6984d3a-5851-47b0-9f79-e6918ad061fe" xlink:to="loc_us-gaap_EquityComponentDomain_e6984d3a-5851-47b0-9f79-e6918ad061fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a6ee9aa-6b83-44fa-943a-c2facafb509a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6984d3a-5851-47b0-9f79-e6918ad061fe" xlink:to="loc_us-gaap_EquityComponentDomain_2a6ee9aa-6b83-44fa-943a-c2facafb509a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3f992377-f522-4009-b41d-e8a49555dae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a6ee9aa-6b83-44fa-943a-c2facafb509a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3f992377-f522-4009-b41d-e8a49555dae1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#STOCKHOLDERSEQUITYDEFICITDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="extended" id="i3f4941e314d546d09bddba03a255246b_STOCKHOLDERSEQUITYDEFICITDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_15e32a9d-0a8a-4e07-9ec6-f1a89c1b773a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_15e32a9d-0a8a-4e07-9ec6-f1a89c1b773a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_234d452e-dfcc-42fd-bb7c-b462b4284ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_234d452e-dfcc-42fd-bb7c-b462b4284ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d47dcba1-ce22-4f5e-84f5-8e17a8d54a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d47dcba1-ce22-4f5e-84f5-8e17a8d54a17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_92399b48-2567-4bcb-b564-00e7ade3ca07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_92399b48-2567-4bcb-b564-00e7ade3ca07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b589899d-328f-42dc-9949-ad786a268c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b589899d-328f-42dc-9949-ad786a268c11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleOfStockCommonStockAuthorized_f8123329-a834-4866-96de-0d56d1b4dfc6" xlink:href="inbx-20211231.xsd#inbx_SaleOfStockCommonStockAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_inbx_SaleOfStockCommonStockAuthorized_f8123329-a834-4866-96de-0d56d1b4dfc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CommonStockSaleOfStockCommissionPercent_d58de3c3-9e51-47e8-8621-22189cb8882b" xlink:href="inbx-20211231.xsd#inbx_CommonStockSaleOfStockCommissionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_inbx_CommonStockSaleOfStockCommissionPercent_d58de3c3-9e51-47e8-8621-22189cb8882b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleOfStockSharesCommonStockSold_b7af284e-3d65-43eb-b858-fcaa34924910" xlink:href="inbx-20211231.xsd#inbx_SaleOfStockSharesCommonStockSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_inbx_SaleOfStockSharesCommonStockSold_b7af284e-3d65-43eb-b858-fcaa34924910" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b045196d-0afd-4074-b234-5edb2b402247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b045196d-0afd-4074-b234-5edb2b402247" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fd7f5007-e5a6-4eb0-841a-8625f3cd95c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fd7f5007-e5a6-4eb0-841a-8625f3cd95c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingCosts_74b21b3a-e4b9-4707-9257-f3dcbb7156c7" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_inbx_AtTheMarketOfferingCosts_74b21b3a-e4b9-4707-9257-f3dcbb7156c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_367b63e5-7ce8-4101-872d-521ad2530a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_367b63e5-7ce8-4101-872d-521ad2530a62" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1d86f7c3-802f-42a9-8eed-9305d9ee1ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1d86f7c3-802f-42a9-8eed-9305d9ee1ff3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_b2ad8d9f-8372-4e77-a1db-a040e89b1ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_b2ad8d9f-8372-4e77-a1db-a040e89b1ea4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fe7e2f19-2f85-4591-9992-a1d696acac47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fe7e2f19-2f85-4591-9992-a1d696acac47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe7e2f19-2f85-4591-9992-a1d696acac47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fe7e2f19-2f85-4591-9992-a1d696acac47" xlink:to="loc_us-gaap_EquityComponentDomain_fe7e2f19-2f85-4591-9992-a1d696acac47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b84c091c-8c1f-402b-9f08-e526c5496d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fe7e2f19-2f85-4591-9992-a1d696acac47" xlink:to="loc_us-gaap_EquityComponentDomain_b84c091c-8c1f-402b-9f08-e526c5496d2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_42eb450c-4f1a-4650-9e5e-ca51a79aecf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b84c091c-8c1f-402b-9f08-e526c5496d2e" xlink:to="loc_us-gaap_CommonStockMember_42eb450c-4f1a-4650-9e5e-ca51a79aecf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9dda178f-d4f4-405a-94c2-9c62bfb0444e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b84c091c-8c1f-402b-9f08-e526c5496d2e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9dda178f-d4f4-405a-94c2-9c62bfb0444e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_bbd69231-366a-4deb-b6c0-67e251442d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_bbd69231-366a-4deb-b6c0-67e251442d3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_bbd69231-366a-4deb-b6c0-67e251442d3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_bbd69231-366a-4deb-b6c0-67e251442d3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_bbd69231-366a-4deb-b6c0-67e251442d3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_cb3e72eb-9f43-4e3d-879f-dddc9a4c9016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_bbd69231-366a-4deb-b6c0-67e251442d3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_cb3e72eb-9f43-4e3d-879f-dddc9a4c9016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsIssuedUponConsummationOfIPOMember_5668f925-2439-4801-ad38-7bbd4a0f7818" xlink:href="inbx-20211231.xsd#inbx_WarrantsIssuedUponConsummationOfIPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_cb3e72eb-9f43-4e3d-879f-dddc9a4c9016" xlink:to="loc_inbx_WarrantsIssuedUponConsummationOfIPOMember_5668f925-2439-4801-ad38-7bbd4a0f7818" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c2a486b2-06eb-40db-b1af-de4ddaaf6d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_DebtInstrumentAxis_c2a486b2-06eb-40db-b1af-de4ddaaf6d8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c2a486b2-06eb-40db-b1af-de4ddaaf6d8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c2a486b2-06eb-40db-b1af-de4ddaaf6d8d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c2a486b2-06eb-40db-b1af-de4ddaaf6d8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6e6af310-4f28-43e1-a0f1-6b6b799745b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c2a486b2-06eb-40db-b1af-de4ddaaf6d8d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6e6af310-4f28-43e1-a0f1-6b6b799745b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_df6f574c-c9a7-48ba-9787-a731f6b908c8" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e6af310-4f28-43e1-a0f1-6b6b799745b1" xlink:to="loc_inbx_A2020OxfordTermLoansMember_df6f574c-c9a7-48ba-9787-a731f6b908c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfb053bf-5d0c-4405-bfe5-f392166ea221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfb053bf-5d0c-4405-bfe5-f392166ea221" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bfb053bf-5d0c-4405-bfe5-f392166ea221_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfb053bf-5d0c-4405-bfe5-f392166ea221" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bfb053bf-5d0c-4405-bfe5-f392166ea221_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c89c61ba-a7a6-489d-bd44-a9f853f00b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfb053bf-5d0c-4405-bfe5-f392166ea221" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c89c61ba-a7a6-489d-bd44-a9f853f00b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_8b6212cf-3287-457e-90b0-5082667ca994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c89c61ba-a7a6-489d-bd44-a9f853f00b52" xlink:to="loc_us-gaap_SecuredDebtMember_8b6212cf-3287-457e-90b0-5082667ca994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b35980e1-87a0-43f8-a643-0eb2cc6ce000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b35980e1-87a0-43f8-a643-0eb2cc6ce000" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b35980e1-87a0-43f8-a643-0eb2cc6ce000_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b35980e1-87a0-43f8-a643-0eb2cc6ce000" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b35980e1-87a0-43f8-a643-0eb2cc6ce000_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cec13ed7-710e-45cc-98e3-8ea647f08f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b35980e1-87a0-43f8-a643-0eb2cc6ce000" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cec13ed7-710e-45cc-98e3-8ea647f08f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SalesAgreementMember_557651b4-2e3a-432b-a7c4-c8ebb7d411c4" xlink:href="inbx-20211231.xsd#inbx_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cec13ed7-710e-45cc-98e3-8ea647f08f0e" xlink:to="loc_inbx_SalesAgreementMember_557651b4-2e3a-432b-a7c4-c8ebb7d411c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#EQUITYCOMPENSATIONPLANSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails" xlink:type="extended" id="i675c06b82f8f4f6fbd79a10fff16445b_EQUITYCOMPENSATIONPLANSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44f9561a-4cbe-4175-bcbf-5ad9813b03b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44f9561a-4cbe-4175-bcbf-5ad9813b03b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_db1bfda7-d7fd-41c9-a793-b7823a1df28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_db1bfda7-d7fd-41c9-a793-b7823a1df28c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df47d95c-36b8-4046-a010-2b05a41d2fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df47d95c-36b8-4046-a010-2b05a41d2fb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_77cc80bc-2dba-40f3-8bfa-766cd431fd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_77cc80bc-2dba-40f3-8bfa-766cd431fd9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2a479ba8-2666-4837-bdda-fe4a4d9244df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2a479ba8-2666-4837-bdda-fe4a4d9244df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ffce32c9-4860-4647-9b57-a1b8072029bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ffce32c9-4860-4647-9b57-a1b8072029bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a21ee30-f8c9-4cd3-b904-e1e1aeedce33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a21ee30-f8c9-4cd3-b904-e1e1aeedce33" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6cb4ce0-a8bb-4944-adff-e1b34b13f317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6cb4ce0-a8bb-4944-adff-e1b34b13f317" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d204f295-4f31-4a9f-94fc-6ff7bbad6ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6cb4ce0-a8bb-4944-adff-e1b34b13f317" xlink:to="loc_us-gaap_VestingAxis_d204f295-4f31-4a9f-94fc-6ff7bbad6ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d204f295-4f31-4a9f-94fc-6ff7bbad6ed8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_d204f295-4f31-4a9f-94fc-6ff7bbad6ed8" xlink:to="loc_us-gaap_VestingDomain_d204f295-4f31-4a9f-94fc-6ff7bbad6ed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9f740c54-275c-4b77-9ea2-9065677cce7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_d204f295-4f31-4a9f-94fc-6ff7bbad6ed8" xlink:to="loc_us-gaap_VestingDomain_9f740c54-275c-4b77-9ea2-9065677cce7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b28cfb8d-4168-4a7b-a819-2719793947c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_9f740c54-275c-4b77-9ea2-9065677cce7e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b28cfb8d-4168-4a7b-a819-2719793947c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0ae45597-fe36-4ae4-98ac-ce89282edb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6cb4ce0-a8bb-4944-adff-e1b34b13f317" xlink:to="loc_us-gaap_AwardTypeAxis_0ae45597-fe36-4ae4-98ac-ce89282edb21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ae45597-fe36-4ae4-98ac-ce89282edb21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0ae45597-fe36-4ae4-98ac-ce89282edb21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ae45597-fe36-4ae4-98ac-ce89282edb21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b4a695-f290-4eb9-9014-dd7fa7a56663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0ae45597-fe36-4ae4-98ac-ce89282edb21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b4a695-f290-4eb9-9014-dd7fa7a56663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_17b11dae-b3d6-4fc7-ad32-2e1b01e2c842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b4a695-f290-4eb9-9014-dd7fa7a56663" xlink:to="loc_us-gaap_EmployeeStockOptionMember_17b11dae-b3d6-4fc7-ad32-2e1b01e2c842" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" xlink:type="extended" id="i642e6ebee2844ca8ad5fb37693daeb9d_EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f3d5ae9c-3ffc-4d1e-9fc6-f53bd70a1ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f3d5ae9c-3ffc-4d1e-9fc6-f53bd70a1ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_91c8b9f2-d01d-4219-8985-97f58160bc88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_91c8b9f2-d01d-4219-8985-97f58160bc88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5861f527-ec06-4024-8dbd-9ca4d7c2b09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5861f527-ec06-4024-8dbd-9ca4d7c2b09a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c494de23-6898-4d68-8dca-3a9b258c86e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c494de23-6898-4d68-8dca-3a9b258c86e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_292d4914-fd1d-44f6-9bd8-4161fc3770c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_292d4914-fd1d-44f6-9bd8-4161fc3770c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be235ee2-9c74-411d-b153-4a9c6c7292a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be235ee2-9c74-411d-b153-4a9c6c7292a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df577d5c-a58f-4675-a9b6-e0038fc85f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be235ee2-9c74-411d-b153-4a9c6c7292a2" xlink:to="loc_us-gaap_AwardTypeAxis_df577d5c-a58f-4675-a9b6-e0038fc85f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df577d5c-a58f-4675-a9b6-e0038fc85f10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_df577d5c-a58f-4675-a9b6-e0038fc85f10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df577d5c-a58f-4675-a9b6-e0038fc85f10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe3f3f77-c00c-4c0e-a69b-725208484631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_df577d5c-a58f-4675-a9b6-e0038fc85f10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe3f3f77-c00c-4c0e-a69b-725208484631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_577a8f9b-9f7e-4f1b-b79b-9f1a60b98451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe3f3f77-c00c-4c0e-a69b-725208484631" xlink:to="loc_us-gaap_EmployeeStockOptionMember_577a8f9b-9f7e-4f1b-b79b-9f1a60b98451" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" xlink:type="extended" id="ib3963c341e884d61995c2b0b4b0dbb3d_EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab1c4bdd-b421-4a0d-83d8-76397977f3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4fec83ac-6efa-4977-818d-b1ccc859f628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab1c4bdd-b421-4a0d-83d8-76397977f3dd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4fec83ac-6efa-4977-818d-b1ccc859f628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a226da2-2493-47d5-b377-f1a1adb8823f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab1c4bdd-b421-4a0d-83d8-76397977f3dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a226da2-2493-47d5-b377-f1a1adb8823f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a9bc447-610b-405e-ab4b-18423c474bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a226da2-2493-47d5-b377-f1a1adb8823f" xlink:to="loc_us-gaap_AwardTypeAxis_8a9bc447-610b-405e-ab4b-18423c474bed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a9bc447-610b-405e-ab4b-18423c474bed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8a9bc447-610b-405e-ab4b-18423c474bed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a9bc447-610b-405e-ab4b-18423c474bed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb6017c2-cec0-43e9-8988-2bdd08f29c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8a9bc447-610b-405e-ab4b-18423c474bed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb6017c2-cec0-43e9-8988-2bdd08f29c4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a07731fb-3334-498b-ae83-46142ded8e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb6017c2-cec0-43e9-8988-2bdd08f29c4d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a07731fb-3334-498b-ae83-46142ded8e7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b797c83a-97ef-4ee7-92a6-f5336924f315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a226da2-2493-47d5-b377-f1a1adb8823f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b797c83a-97ef-4ee7-92a6-f5336924f315" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b797c83a-97ef-4ee7-92a6-f5336924f315_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b797c83a-97ef-4ee7-92a6-f5336924f315" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b797c83a-97ef-4ee7-92a6-f5336924f315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dc33fdeb-5106-4791-b877-f04a81af9a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b797c83a-97ef-4ee7-92a6-f5336924f315" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dc33fdeb-5106-4791-b877-f04a81af9a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e25696a4-060e-482e-9a58-4cd81b173c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dc33fdeb-5106-4791-b877-f04a81af9a80" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e25696a4-060e-482e-9a58-4cd81b173c03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99be59b3-fe98-4be1-83be-b591d9fdfa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dc33fdeb-5106-4791-b877-f04a81af9a80" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99be59b3-fe98-4be1-83be-b591d9fdfa94" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LICENSEANDGRANTREVENUESRevenueSummaryDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" xlink:type="extended" id="id56021eb9dbd491487531bd1c5d40c77_LICENSEANDGRANTREVENUESRevenueSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e82c5f1-8563-49b2-9665-c01468bdc3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_179ccc50-5250-4254-b8ee-bf8b24e6ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e82c5f1-8563-49b2-9665-c01468bdc3ee" xlink:to="loc_us-gaap_Revenues_179ccc50-5250-4254-b8ee-bf8b24e6ec25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e82c5f1-8563-49b2-9665-c01468bdc3ee" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c990ac7d-2cfb-4b11-9c75-757918fd68e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:to="loc_srt_ProductOrServiceAxis_c990ac7d-2cfb-4b11-9c75-757918fd68e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c990ac7d-2cfb-4b11-9c75-757918fd68e1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c990ac7d-2cfb-4b11-9c75-757918fd68e1" xlink:to="loc_srt_ProductsAndServicesDomain_c990ac7d-2cfb-4b11-9c75-757918fd68e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3083177a-ecd0-48eb-a852-785b543b6e39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c990ac7d-2cfb-4b11-9c75-757918fd68e1" xlink:to="loc_srt_ProductsAndServicesDomain_3083177a-ecd0-48eb-a852-785b543b6e39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAffiliateMember_6d29fd44-816b-4a18-a55f-cc95f9abc025" xlink:href="inbx-20211231.xsd#inbx_LicenseAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3083177a-ecd0-48eb-a852-785b543b6e39" xlink:to="loc_inbx_LicenseAffiliateMember_6d29fd44-816b-4a18-a55f-cc95f9abc025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember_0ac4f8cb-987c-4e71-a01f-efb60ec7ead2" xlink:href="inbx-20211231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3083177a-ecd0-48eb-a852-785b543b6e39" xlink:to="loc_inbx_LicenseNonAffiliateMember_0ac4f8cb-987c-4e71-a01f-efb60ec7ead2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_0f286671-c078-49e0-b6ff-e2ba0edddc96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3083177a-ecd0-48eb-a852-785b543b6e39" xlink:to="loc_us-gaap_GrantMember_0f286671-c078-49e0-b6ff-e2ba0edddc96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_457779a2-d373-476e-9b39-572b938b9401" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:to="loc_srt_MajorCustomersAxis_457779a2-d373-476e-9b39-572b938b9401" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_457779a2-d373-476e-9b39-572b938b9401_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_457779a2-d373-476e-9b39-572b938b9401" xlink:to="loc_srt_NameOfMajorCustomerDomain_457779a2-d373-476e-9b39-572b938b9401_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_457779a2-d373-476e-9b39-572b938b9401" xlink:to="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_bfe4aa90-9aab-4144-b1a5-3ae9cbce2f70" xlink:href="inbx-20211231.xsd#inbx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:to="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_bfe4aa90-9aab-4144-b1a5-3ae9cbce2f70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2seventyBioIncMember_8cb6a73f-f309-4ff5-8551-b61f6f7b3c23" xlink:href="inbx-20211231.xsd#inbx_A2seventyBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:to="loc_inbx_A2seventyBioIncMember_8cb6a73f-f309-4ff5-8551-b61f6f7b3c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember_e4e3bc9f-f485-4ec6-a063-bfcc42d88a65" xlink:href="inbx-20211231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:to="loc_inbx_PhylaxisBioScienceLLCMember_e4e3bc9f-f485-4ec6-a063-bfcc42d88a65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ChiesiFarmaceuticiSpAMember_8f3c035e-2025-44ea-9213-1be49eb53d3c" xlink:href="inbx-20211231.xsd#inbx_ChiesiFarmaceuticiSpAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:to="loc_inbx_ChiesiFarmaceuticiSpAMember_8f3c035e-2025-44ea-9213-1be49eb53d3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherCustomersNotSeparatelyDisclosedMember_69bb991b-aac4-4a20-8d2e-0ec5a2d20427" xlink:href="inbx-20211231.xsd#inbx_OtherCustomersNotSeparatelyDisclosedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:to="loc_inbx_OtherCustomersNotSeparatelyDisclosedMember_69bb991b-aac4-4a20-8d2e-0ec5a2d20427" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a75d35d5-0f75-4835-bad7-a2861be62c00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:to="loc_srt_CounterpartyNameAxis_a75d35d5-0f75-4835-bad7-a2861be62c00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a75d35d5-0f75-4835-bad7-a2861be62c00_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a75d35d5-0f75-4835-bad7-a2861be62c00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a75d35d5-0f75-4835-bad7-a2861be62c00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38e3d872-bfb6-4c27-9e1e-a4ec616b743a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a75d35d5-0f75-4835-bad7-a2861be62c00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38e3d872-bfb6-4c27-9e1e-a4ec616b743a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_2639ccfb-deba-44f9-b53d-e9f3cdceb288" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38e3d872-bfb6-4c27-9e1e-a4ec616b743a" xlink:to="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_2639ccfb-deba-44f9-b53d-e9f3cdceb288" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" xlink:type="extended" id="i22e0464573d2467bbf506740e3149ee3_LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementMilestonePaymentsReceivable_c9cb78b4-0f72-48a5-ac73-98e7b63bd5df" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementMilestonePaymentsReceivable_c9cb78b4-0f72-48a5-ac73-98e7b63bd5df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_930649c3-c9dc-4275-822e-c629bac446ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_Revenues_930649c3-c9dc-4275-822e-c629bac446ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_6f023157-d932-482e-b03e-af3625912741" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementDevelopmentMilestoneReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_6f023157-d932-482e-b03e-af3625912741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementMilestonePaymentReceived_780d754c-6939-49e4-be17-e325df525613" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementMilestonePaymentReceived_780d754c-6939-49e4-be17-e325df525613" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_49bfdaf4-bd6b-4f82-bf1a-576a805bddbf" xlink:href="inbx-20211231.xsd#inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_49bfdaf4-bd6b-4f82-bf1a-576a805bddbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_c1aee4f6-6475-4a32-b130-40d165ba5f82" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementNonrefundableUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_c1aee4f6-6475-4a32-b130-40d165ba5f82" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NumberOfPerformanceObligations_15f7c5a0-6939-4016-86d0-b331e08d07fa" xlink:href="inbx-20211231.xsd#inbx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_NumberOfPerformanceObligations_15f7c5a0-6939-4016-86d0-b331e08d07fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses_6f93513d-6fcc-4b4d-a581-09ee96044190" xlink:href="inbx-20211231.xsd#inbx_CollaborativeAgreementExclusiveDevelopmentLicenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses_6f93513d-6fcc-4b4d-a581-09ee96044190" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee_f3ad4ddf-8c07-40ba-9e3f-a1e1eb32d2b6" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementNonrefundableOptionExtensionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee_f3ad4ddf-8c07-40ba-9e3f-a1e1eb32d2b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivable_f8e847fa-7b14-445e-a5cd-471ae0b46ab2" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementAdditionalPaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivable_f8e847fa-7b14-445e-a5cd-471ae0b46ab2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_746ab5fd-4505-44a5-b6d3-ce9b8b8663bb" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_746ab5fd-4505-44a5-b6d3-ce9b8b8663bb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f5a3226d-5746-4c39-996f-5bf03408c4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f5a3226d-5746-4c39-996f-5bf03408c4ce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled_229f1bd5-cf1f-4016-8ef0-2611fed27082" xlink:href="inbx-20211231.xsd#inbx_EquityMethodInvestmentAdditionalOwnershipEntitled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled_229f1bd5-cf1f-4016-8ef0-2611fed27082" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementCommercializationMilestoneReceivable_0d9b224e-e268-4147-9c68-dc9f271341ec" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementCommercializationMilestoneReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementCommercializationMilestoneReceivable_0d9b224e-e268-4147-9c68-dc9f271341ec" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9e4fa91e-20ef-4454-aefb-df49906b4b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_EquityMethodInvestments_9e4fa91e-20ef-4454-aefb-df49906b4b25" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementPaymentReceivable_e19fd7bd-a111-4f8c-aac7-a7336e3fe859" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementPaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementPaymentReceivable_e19fd7bd-a111-4f8c-aac7-a7336e3fe859" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RevenueRecognitionNumberOfCompounds_be1c29a4-d025-4db0-8580-f2269c08442d" xlink:href="inbx-20211231.xsd#inbx_RevenueRecognitionNumberOfCompounds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_RevenueRecognitionNumberOfCompounds_be1c29a4-d025-4db0-8580-f2269c08442d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c3e221a5-27a3-4fcc-8c49-cf0f54969790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c3e221a5-27a3-4fcc-8c49-cf0f54969790" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4773df31-8320-408f-8e87-5459c2e622fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4773df31-8320-408f-8e87-5459c2e622fe" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3b055e25-575a-4549-9bb1-3609fbe8c915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3b055e25-575a-4549-9bb1-3609fbe8c915" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_c1d30dc8-7f52-4ad3-9899-b8ab2529078a" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_c1d30dc8-7f52-4ad3-9899-b8ab2529078a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6ef13a28-64d7-41a3-9903-d5efe4d441f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:to="loc_srt_MajorCustomersAxis_6ef13a28-64d7-41a3-9903-d5efe4d441f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6ef13a28-64d7-41a3-9903-d5efe4d441f0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6ef13a28-64d7-41a3-9903-d5efe4d441f0" xlink:to="loc_srt_NameOfMajorCustomerDomain_6ef13a28-64d7-41a3-9903-d5efe4d441f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6ef13a28-64d7-41a3-9903-d5efe4d441f0" xlink:to="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember_071f14aa-5729-4ada-887b-5f79f05bd60b" xlink:href="inbx-20211231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:to="loc_inbx_PhylaxisBioScienceLLCMember_071f14aa-5729-4ada-887b-5f79f05bd60b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2seventyBioIncMember_c5d93c99-2e5b-4646-8860-4d2ea471420e" xlink:href="inbx-20211231.xsd#inbx_A2seventyBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:to="loc_inbx_A2seventyBioIncMember_c5d93c99-2e5b-4646-8860-4d2ea471420e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ChiesiFarmaceuticiSpAMember_a49f293b-08d5-411b-ae48-ec87a6e4e2c2" xlink:href="inbx-20211231.xsd#inbx_ChiesiFarmaceuticiSpAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:to="loc_inbx_ChiesiFarmaceuticiSpAMember_a49f293b-08d5-411b-ae48-ec87a6e4e2c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_baac9d64-d0c6-4907-a192-d439eecec6a8" xlink:href="inbx-20211231.xsd#inbx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:to="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_baac9d64-d0c6-4907-a192-d439eecec6a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CelgeneMember_e7d0b9fd-45de-4758-bf56-b03971b2451b" xlink:href="inbx-20211231.xsd#inbx_CelgeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:to="loc_inbx_CelgeneMember_e7d0b9fd-45de-4758-bf56-b03971b2451b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77a7e481-9730-44a2-9bd6-71c05b038b71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77a7e481-9730-44a2-9bd6-71c05b038b71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_77a7e481-9730-44a2-9bd6-71c05b038b71_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77a7e481-9730-44a2-9bd6-71c05b038b71" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_77a7e481-9730-44a2-9bd6-71c05b038b71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c927bbdf-1277-4115-8cdc-4600d2cf39e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77a7e481-9730-44a2-9bd6-71c05b038b71" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c927bbdf-1277-4115-8cdc-4600d2cf39e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember_87e550b9-0e3a-47fb-af2b-d384b3595141" xlink:href="inbx-20211231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c927bbdf-1277-4115-8cdc-4600d2cf39e5" xlink:to="loc_inbx_PhylaxisBioScienceLLCMember_87e550b9-0e3a-47fb-af2b-d384b3595141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_09a76472-d595-4e32-bb34-0ef384043625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_09a76472-d595-4e32-bb34-0ef384043625" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09a76472-d595-4e32-bb34-0ef384043625_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09a76472-d595-4e32-bb34-0ef384043625" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09a76472-d595-4e32-bb34-0ef384043625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09a76472-d595-4e32-bb34-0ef384043625" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_408136ac-9908-4f61-b39c-ef51425b0e76" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:to="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_408136ac-9908-4f61-b39c-ef51425b0e76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_d3d6a788-cd24-4483-b056-c3285edb84c2" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_408136ac-9908-4f61-b39c-ef51425b0e76" xlink:to="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_d3d6a788-cd24-4483-b056-c3285edb84c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_f6b4e4ef-945d-4ad5-8faa-a40ea668628d" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_408136ac-9908-4f61-b39c-ef51425b0e76" xlink:to="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_f6b4e4ef-945d-4ad5-8faa-a40ea668628d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember_7322ec52-878d-4d11-add8-73e3f43abb5c" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementAdditionalProgramsAuthorizedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:to="loc_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember_7322ec52-878d-4d11-add8-73e3f43abb5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2018OptionAndLicenseAgreementMember_f4e3652d-36cd-4e00-84cc-c027b0d5b734" xlink:href="inbx-20211231.xsd#inbx_A2018OptionAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:to="loc_inbx_A2018OptionAndLicenseAgreementMember_f4e3652d-36cd-4e00-84cc-c027b0d5b734" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OptionAndLicenseAgreementMember_34d3151f-9f85-4f34-bac2-91729b6466bf" xlink:href="inbx-20211231.xsd#inbx_A2020OptionAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:to="loc_inbx_A2020OptionAndLicenseAgreementMember_34d3151f-9f85-4f34-bac2-91729b6466bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c8218bc8-18ca-45c2-9636-8ed54ca1f9a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:to="loc_srt_ProductOrServiceAxis_c8218bc8-18ca-45c2-9636-8ed54ca1f9a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c8218bc8-18ca-45c2-9636-8ed54ca1f9a2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c8218bc8-18ca-45c2-9636-8ed54ca1f9a2" xlink:to="loc_srt_ProductsAndServicesDomain_c8218bc8-18ca-45c2-9636-8ed54ca1f9a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_01fcf5f4-5846-4098-8409-80006a981642" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c8218bc8-18ca-45c2-9636-8ed54ca1f9a2" xlink:to="loc_srt_ProductsAndServicesDomain_01fcf5f4-5846-4098-8409-80006a981642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember_ad601d60-5e0d-4fa9-8a87-abab608acd1d" xlink:href="inbx-20211231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_01fcf5f4-5846-4098-8409-80006a981642" xlink:to="loc_inbx_LicenseNonAffiliateMember_ad601d60-5e0d-4fa9-8a87-abab608acd1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAffiliateMember_1d93191c-01eb-4fb6-8eea-c177b5e50c4c" xlink:href="inbx-20211231.xsd#inbx_LicenseAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_01fcf5f4-5846-4098-8409-80006a981642" xlink:to="loc_inbx_LicenseAffiliateMember_1d93191c-01eb-4fb6-8eea-c177b5e50c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAffiliateOX40LicenseAgreementMember_4baab25e-a18f-4059-a08a-f35b950c9b38" xlink:href="inbx-20211231.xsd#inbx_LicenseAffiliateOX40LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inbx_LicenseAffiliateMember_1d93191c-01eb-4fb6-8eea-c177b5e50c4c" xlink:to="loc_inbx_LicenseAffiliateOX40LicenseAgreementMember_4baab25e-a18f-4059-a08a-f35b950c9b38" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LICENSEANDGRANTREVENUESGovernmentGrantsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" xlink:type="extended" id="ia882be109c4d428aacb29c140830730e_LICENSEANDGRANTREVENUESGovernmentGrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07e73192-c72e-4a2f-9b0f-809e083b4c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GrantValuedAwarded_9099e011-c99f-4e02-88ba-d3b50a9bdddc" xlink:href="inbx-20211231.xsd#inbx_GrantValuedAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07e73192-c72e-4a2f-9b0f-809e083b4c06" xlink:to="loc_inbx_GrantValuedAwarded_9099e011-c99f-4e02-88ba-d3b50a9bdddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f5600c92-d9a3-4d8f-9c4b-5e8faf9cf540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07e73192-c72e-4a2f-9b0f-809e083b4c06" xlink:to="loc_us-gaap_Revenues_f5600c92-d9a3-4d8f-9c4b-5e8faf9cf540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RevenuesCashReceived_db33f4b4-1cb5-4c2d-8bcc-94711247c26f" xlink:href="inbx-20211231.xsd#inbx_RevenuesCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07e73192-c72e-4a2f-9b0f-809e083b4c06" xlink:to="loc_inbx_RevenuesCashReceived_db33f4b4-1cb5-4c2d-8bcc-94711247c26f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cea0212-78a0-484a-9cca-8f87f367c1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07e73192-c72e-4a2f-9b0f-809e083b4c06" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cea0212-78a0-484a-9cca-8f87f367c1e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f3ab3d4e-7b30-4a64-9b06-18fb397963f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cea0212-78a0-484a-9cca-8f87f367c1e3" xlink:to="loc_srt_ProductOrServiceAxis_f3ab3d4e-7b30-4a64-9b06-18fb397963f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3ab3d4e-7b30-4a64-9b06-18fb397963f3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f3ab3d4e-7b30-4a64-9b06-18fb397963f3" xlink:to="loc_srt_ProductsAndServicesDomain_f3ab3d4e-7b30-4a64-9b06-18fb397963f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d4708a4a-f211-4da1-ac95-5a6919d35fa9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f3ab3d4e-7b30-4a64-9b06-18fb397963f3" xlink:to="loc_srt_ProductsAndServicesDomain_d4708a4a-f211-4da1-ac95-5a6919d35fa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_67132374-7a65-4f7a-8a70-f5240e1764de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d4708a4a-f211-4da1-ac95-5a6919d35fa9" xlink:to="loc_us-gaap_GrantMember_67132374-7a65-4f7a-8a70-f5240e1764de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4fa17e4f-2d1f-42dc-b339-f67c4b3648e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cea0212-78a0-484a-9cca-8f87f367c1e3" xlink:to="loc_srt_CounterpartyNameAxis_4fa17e4f-2d1f-42dc-b339-f67c4b3648e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fa17e4f-2d1f-42dc-b339-f67c4b3648e2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4fa17e4f-2d1f-42dc-b339-f67c4b3648e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4fa17e4f-2d1f-42dc-b339-f67c4b3648e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d0d2ab-c3c9-4c89-8af3-3211d74903ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4fa17e4f-2d1f-42dc-b339-f67c4b3648e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d0d2ab-c3c9-4c89-8af3-3211d74903ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember_f0a52c04-6e18-431a-8f14-dbff9bd3ae96" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d0d2ab-c3c9-4c89-8af3-3211d74903ba" xlink:to="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember_f0a52c04-6e18-431a-8f14-dbff9bd3ae96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember_be20f9a0-e973-4090-9dbe-29a7aaf6425a" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d0d2ab-c3c9-4c89-8af3-3211d74903ba" xlink:to="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember_be20f9a0-e973-4090-9dbe-29a7aaf6425a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_dfc4b45b-5c7a-48c0-a00e-05f46ae05175" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d0d2ab-c3c9-4c89-8af3-3211d74903ba" xlink:to="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_dfc4b45b-5c7a-48c0-a00e-05f46ae05175" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="if8c438fd5b4b445fbae3532c32c05add_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RelatedPartyEquityInterestInCompany_fcfe775f-d205-4996-ac66-bd5a307d9b48" xlink:href="inbx-20211231.xsd#inbx_RelatedPartyEquityInterestInCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_RelatedPartyEquityInterestInCompany_fcfe775f-d205-4996-ac66-bd5a307d9b48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ExpensesReimbursedToDate_2d987de8-a829-41a1-b7f7-a5bbe96e8261" xlink:href="inbx-20211231.xsd#inbx_ExpensesReimbursedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_ExpensesReimbursedToDate_2d987de8-a829-41a1-b7f7-a5bbe96e8261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_33fb68f3-1416-4864-b080-bf9eab36c87d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_33fb68f3-1416-4864-b080-bf9eab36c87d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ExpensesExpectedToBeReimbursed_c8a25093-797c-4358-8f61-c18abb35b193" xlink:href="inbx-20211231.xsd#inbx_ExpensesExpectedToBeReimbursed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_ExpensesExpectedToBeReimbursed_c8a25093-797c-4358-8f61-c18abb35b193" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementExpenseReimbursement_ebaa4bb7-e8a0-4829-a07d-7d573bc81eaf" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementExpenseReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_CollaborativeArrangementExpenseReimbursement_ebaa4bb7-e8a0-4829-a07d-7d573bc81eaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_4efa0176-8da7-434e-8336-ca9899ab3309" xlink:href="inbx-20211231.xsd#inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_4efa0176-8da7-434e-8336-ca9899ab3309" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementReceivablesFromRelatedParties_4d4c54ff-3dea-415e-8345-9f870d8e2b07" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementReceivablesFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_CollaborativeArrangementReceivablesFromRelatedParties_4d4c54ff-3dea-415e-8345-9f870d8e2b07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad45c263-e956-4e3c-9085-e4b59e2b31a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad45c263-e956-4e3c-9085-e4b59e2b31a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ad45c263-e956-4e3c-9085-e4b59e2b31a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad45c263-e956-4e3c-9085-e4b59e2b31a5" xlink:to="loc_us-gaap_RelatedPartyDomain_ad45c263-e956-4e3c-9085-e4b59e2b31a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7035af93-2970-4467-b78c-a9068f4d8a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad45c263-e956-4e3c-9085-e4b59e2b31a5" xlink:to="loc_us-gaap_RelatedPartyDomain_7035af93-2970-4467-b78c-a9068f4d8a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_71d5d0f4-59ab-4436-bcfa-216903f6db98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7035af93-2970-4467-b78c-a9068f4d8a03" xlink:to="loc_srt_AffiliatedEntityMember_71d5d0f4-59ab-4436-bcfa-216903f6db98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_21b68663-2baa-4fc0-a81a-f0db7fc04729" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_srt_CounterpartyNameAxis_21b68663-2baa-4fc0-a81a-f0db7fc04729" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21b68663-2baa-4fc0-a81a-f0db7fc04729_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_21b68663-2baa-4fc0-a81a-f0db7fc04729" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21b68663-2baa-4fc0-a81a-f0db7fc04729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fb9b3715-f6d1-4c0f-9f9b-f4ce7485b4e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_21b68663-2baa-4fc0-a81a-f0db7fc04729" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fb9b3715-f6d1-4c0f-9f9b-f4ce7485b4e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LAVSummitLimitedMember_cffbede3-ac5a-4df1-99de-f47212977be8" xlink:href="inbx-20211231.xsd#inbx_LAVSummitLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fb9b3715-f6d1-4c0f-9f9b-f4ce7485b4e6" xlink:to="loc_inbx_LAVSummitLimitedMember_cffbede3-ac5a-4df1-99de-f47212977be8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b6a643ec-569e-4106-a8f2-46f9a6b1f5e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_srt_MajorCustomersAxis_b6a643ec-569e-4106-a8f2-46f9a6b1f5e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b6a643ec-569e-4106-a8f2-46f9a6b1f5e5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b6a643ec-569e-4106-a8f2-46f9a6b1f5e5" xlink:to="loc_srt_NameOfMajorCustomerDomain_b6a643ec-569e-4106-a8f2-46f9a6b1f5e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_750373f7-98a5-4067-8a66-a8f278fb05d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b6a643ec-569e-4106-a8f2-46f9a6b1f5e5" xlink:to="loc_srt_NameOfMajorCustomerDomain_750373f7-98a5-4067-8a66-a8f278fb05d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_da4b9f30-c002-4758-8fe1-fb0e36c53daf" xlink:href="inbx-20211231.xsd#inbx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_750373f7-98a5-4067-8a66-a8f278fb05d9" xlink:to="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_da4b9f30-c002-4758-8fe1-fb0e36c53daf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5cd5357b-e510-4d63-8188-c251994d8223" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_srt_ProductOrServiceAxis_5cd5357b-e510-4d63-8188-c251994d8223" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5cd5357b-e510-4d63-8188-c251994d8223_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5cd5357b-e510-4d63-8188-c251994d8223" xlink:to="loc_srt_ProductsAndServicesDomain_5cd5357b-e510-4d63-8188-c251994d8223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_41b3bbcb-c99b-4b46-878c-708515513c15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5cd5357b-e510-4d63-8188-c251994d8223" xlink:to="loc_srt_ProductsAndServicesDomain_41b3bbcb-c99b-4b46-878c-708515513c15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAffiliateOX40LicenseAgreementMember_e5028f36-2110-40da-9029-1ed75f6d0bb3" xlink:href="inbx-20211231.xsd#inbx_LicenseAffiliateOX40LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_41b3bbcb-c99b-4b46-878c-708515513c15" xlink:to="loc_inbx_LicenseAffiliateOX40LicenseAgreementMember_e5028f36-2110-40da-9029-1ed75f6d0bb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_b99f0756-c59f-4d35-b1f4-eb86b4964776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_us-gaap_TransactionTypeAxis_b99f0756-c59f-4d35-b1f4-eb86b4964776" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_b99f0756-c59f-4d35-b1f4-eb86b4964776_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_b99f0756-c59f-4d35-b1f4-eb86b4964776" xlink:to="loc_us-gaap_TransactionDomain_b99f0756-c59f-4d35-b1f4-eb86b4964776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_5db6076b-9099-40d2-946c-6463ee7b9263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_b99f0756-c59f-4d35-b1f4-eb86b4964776" xlink:to="loc_us-gaap_TransactionDomain_5db6076b-9099-40d2-946c-6463ee7b9263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CostSharingAgreementMember_ab97ee67-f4af-4cbd-903b-6d5b34a8e207" xlink:href="inbx-20211231.xsd#inbx_CostSharingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_5db6076b-9099-40d2-946c-6463ee7b9263" xlink:to="loc_inbx_CostSharingAgreementMember_ab97ee67-f4af-4cbd-903b-6d5b34a8e207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleAndPurchaseAgreementMember_dd36aee1-d8e2-4ebe-b11f-5eb05d2ee388" xlink:href="inbx-20211231.xsd#inbx_SaleAndPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_5db6076b-9099-40d2-946c-6463ee7b9263" xlink:to="loc_inbx_SaleAndPurchaseAgreementMember_dd36aee1-d8e2-4ebe-b11f-5eb05d2ee388" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i7e838aec88ee4825a04e6d9361ea18b1_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_eeed669a-b147-4bd8-865c-d8abe6edb925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_OperatingLossCarryforwards_eeed669a-b147-4bd8-865c-d8abe6edb925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_f393f463-7989-43e6-9c85-59b6f3ae4a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_f393f463-7989-43e6-9c85-59b6f3ae4a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_805029d9-ca3f-4ae4-81a3-cd5c89ba53a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_805029d9-ca3f-4ae4-81a3-cd5c89ba53a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fbb631ec-616e-4fd7-8835-19bd964be21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fbb631ec-616e-4fd7-8835-19bd964be21a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5ae32d4d-b405-4be0-9a27-89b911354675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5ae32d4d-b405-4be0-9a27-89b911354675" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_50d1ec2b-768c-44dc-8424-bd9739c538a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_50d1ec2b-768c-44dc-8424-bd9739c538a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_c58b3046-4608-4812-8fad-932ec671895d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_c58b3046-4608-4812-8fad-932ec671895d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d288a416-6bfc-45ef-a0c6-07d954004e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_c58b3046-4608-4812-8fad-932ec671895d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d288a416-6bfc-45ef-a0c6-07d954004e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d288a416-6bfc-45ef-a0c6-07d954004e40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d288a416-6bfc-45ef-a0c6-07d954004e40" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d288a416-6bfc-45ef-a0c6-07d954004e40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_16ea0432-905f-48d9-8e4e-1ab7d3eee01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d288a416-6bfc-45ef-a0c6-07d954004e40" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_16ea0432-905f-48d9-8e4e-1ab7d3eee01c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_2239aedb-5af7-4c95-ad57-da12bca2519d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_16ea0432-905f-48d9-8e4e-1ab7d3eee01c" xlink:to="loc_us-gaap_DomesticCountryMember_2239aedb-5af7-4c95-ad57-da12bca2519d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3a94d40e-0c21-4333-9b8a-b63e31fab209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_16ea0432-905f-48d9-8e4e-1ab7d3eee01c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3a94d40e-0c21-4333-9b8a-b63e31fab209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_958713ed-c371-4b1c-985e-e95647b7574d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_c58b3046-4608-4812-8fad-932ec671895d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_958713ed-c371-4b1c-985e-e95647b7574d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_958713ed-c371-4b1c-985e-e95647b7574d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_958713ed-c371-4b1c-985e-e95647b7574d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_958713ed-c371-4b1c-985e-e95647b7574d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d4cef53e-e002-4754-8066-7890852ca393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_958713ed-c371-4b1c-985e-e95647b7574d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d4cef53e-e002-4754-8066-7890852ca393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_afaf938a-7536-4bfa-ae86-11b9b999b48c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d4cef53e-e002-4754-8066-7890852ca393" xlink:to="loc_us-gaap_ResearchMember_afaf938a-7536-4bfa-ae86-11b9b999b48c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="i75686a60682c41d38d4b7101f22d675a_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_2c9706d1-328d-4467-835f-49ea4d138118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalResearchAndDevelopmentCurrent_98444db3-e9e7-4768-9616-49ae96482beb" xlink:href="inbx-20211231.xsd#inbx_AccruedClinicalResearchAndDevelopmentCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2c9706d1-328d-4467-835f-49ea4d138118" xlink:to="loc_inbx_AccruedClinicalResearchAndDevelopmentCurrent_98444db3-e9e7-4768-9616-49ae96482beb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PurchaseCommitmentNonCancellablePortionOfContract_fceecc3d-43f9-4ead-8b87-f58abe31428d" xlink:href="inbx-20211231.xsd#inbx_PurchaseCommitmentNonCancellablePortionOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2c9706d1-328d-4467-835f-49ea4d138118" xlink:to="loc_inbx_PurchaseCommitmentNonCancellablePortionOfContract_fceecc3d-43f9-4ead-8b87-f58abe31428d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts_ff10593d-8ddc-41e4-90b6-3806e6ac402c" xlink:href="inbx-20211231.xsd#inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2c9706d1-328d-4467-835f-49ea4d138118" xlink:to="loc_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts_ff10593d-8ddc-41e4-90b6-3806e6ac402c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_6febd63f-a0a5-4db9-b54e-1d08ba448184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2c9706d1-328d-4467-835f-49ea4d138118" xlink:to="loc_us-gaap_OtherCommitmentsTable_6febd63f-a0a5-4db9-b54e-1d08ba448184" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_2a309266-826b-46ca-a0bb-cd0378a36931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_6febd63f-a0a5-4db9-b54e-1d08ba448184" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_2a309266-826b-46ca-a0bb-cd0378a36931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_2a309266-826b-46ca-a0bb-cd0378a36931_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_2a309266-826b-46ca-a0bb-cd0378a36931" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_2a309266-826b-46ca-a0bb-cd0378a36931_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_d3e41fa3-4aee-40a7-9b41-c024aeedc81a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_2a309266-826b-46ca-a0bb-cd0378a36931" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_d3e41fa3-4aee-40a7-9b41-c024aeedc81a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentMember_83a3c30c-668b-487c-bdd8-e6e89638d7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_d3e41fa3-4aee-40a7-9b41-c024aeedc81a" xlink:to="loc_us-gaap_PurchaseCommitmentMember_83a3c30c-668b-487c-bdd8-e6e89638d7e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="i0a6072b920114bf9a4ab1225e733aa88_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7af9f80f-d07c-4fb4-bb7b-741d579517df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7af9f80f-d07c-4fb4-bb7b-741d579517df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bc65c000-c22d-4bfb-a2f9-c77175afff06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bc65c000-c22d-4bfb-a2f9-c77175afff06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e2e3560a-870a-4a4a-93e9-f66f142313f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e2e3560a-870a-4a4a-93e9-f66f142313f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5476f849-2a67-450b-9613-a6b5b3849d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5476f849-2a67-450b-9613-a6b5b3849d14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfAdditionalTranches_5945ef17-3816-4021-aa07-fbb8f35d8d4b" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentNumberOfAdditionalTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentNumberOfAdditionalTranches_5945ef17-3816-4021-aa07-fbb8f35d8d4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_f3a9b920-4a40-49d3-9e4c-849bf15d3c30" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_f3a9b920-4a40-49d3-9e4c-849bf15d3c30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_c29655f7-7b18-4473-97ac-75d15d03f2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_c29655f7-7b18-4473-97ac-75d15d03f2f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2a880a65-170d-4d05-893b-d878329e9a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_LongTermDebt_2a880a65-170d-4d05-893b-d878329e9a54" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e7902b93-4dc3-4378-84f3-e905edab35ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e7902b93-4dc3-4378-84f3-e905edab35ad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentAmendmentFee_151f053a-137a-4a1d-97d1-cfb7916545bf" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentAmendmentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentAmendmentFee_151f053a-137a-4a1d-97d1-cfb7916545bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfExistingTranches_8862eaa7-264b-4dea-bea2-e10c9d8787bf" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentNumberOfExistingTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentNumberOfExistingTranches_8862eaa7-264b-4dea-bea2-e10c9d8787bf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_60e8a3a5-8164-4ba9-b62a-2dd7130ceaed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_60e8a3a5-8164-4ba9-b62a-2dd7130ceaed" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3924ceba-b3ef-4dc8-9e88-5653e16f9282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3924ceba-b3ef-4dc8-9e88-5653e16f9282" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum_13c2f68c-18d3-4510-bae6-84fd3b30f4a0" xlink:href="inbx-20211231.xsd#inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum_13c2f68c-18d3-4510-bae6-84fd3b30f4a0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod_b5105a90-3823-4ff6-b4f8-7f36a7b391fb" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod_b5105a90-3823-4ff6-b4f8-7f36a7b391fb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_0bf49fdb-2826-4c11-b480-f5579f9bb614" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_0bf49fdb-2826-4c11-b480-f5579f9bb614" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_36554573-f5a4-4adb-9e55-3d1ac5fcecac" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_36554573-f5a4-4adb-9e55-3d1ac5fcecac" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrepaymentFee_64bad060-fc49-45a5-863f-6574e6d78237" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPrepaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentPrepaymentFee_64bad060-fc49-45a5-863f-6574e6d78237" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_108e11fe-ecce-4592-8153-508169f1aa93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_108e11fe-ecce-4592-8153-508169f1aa93" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d9ffb4fd-5eb0-4b53-b8d1-56679f3024b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d9ffb4fd-5eb0-4b53-b8d1-56679f3024b5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_634e90ce-533a-4932-b73b-6179e93bb3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_634e90ce-533a-4932-b73b-6179e93bb3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_634e90ce-533a-4932-b73b-6179e93bb3e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_634e90ce-533a-4932-b73b-6179e93bb3e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_634e90ce-533a-4932-b73b-6179e93bb3e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_deddcfb8-2e1d-45dd-a80c-8b11b7e73b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_634e90ce-533a-4932-b73b-6179e93bb3e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_deddcfb8-2e1d-45dd-a80c-8b11b7e73b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_23278d2a-3a5f-4236-aad3-3dfd725c1b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_deddcfb8-2e1d-45dd-a80c-8b11b7e73b4f" xlink:to="loc_us-gaap_SubsequentEventMember_23278d2a-3a5f-4236-aad3-3dfd725c1b19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_62d249bb-471d-4707-a672-fd51ce23d9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_AwardTypeAxis_62d249bb-471d-4707-a672-fd51ce23d9b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62d249bb-471d-4707-a672-fd51ce23d9b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_62d249bb-471d-4707-a672-fd51ce23d9b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62d249bb-471d-4707-a672-fd51ce23d9b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ba9ce36-f470-4aab-b78c-f955dff1142e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_62d249bb-471d-4707-a672-fd51ce23d9b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ba9ce36-f470-4aab-b78c-f955dff1142e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4f201d81-d4ee-4bba-abc9-7370f92fe276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ba9ce36-f470-4aab-b78c-f955dff1142e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4f201d81-d4ee-4bba-abc9-7370f92fe276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_41a811b9-e92c-4526-ac99-1902d3a153d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_VestingAxis_41a811b9-e92c-4526-ac99-1902d3a153d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_41a811b9-e92c-4526-ac99-1902d3a153d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_41a811b9-e92c-4526-ac99-1902d3a153d9" xlink:to="loc_us-gaap_VestingDomain_41a811b9-e92c-4526-ac99-1902d3a153d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7ffa3f91-36ed-4d54-924d-be5e1aa3a037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_41a811b9-e92c-4526-ac99-1902d3a153d9" xlink:to="loc_us-gaap_VestingDomain_7ffa3f91-36ed-4d54-924d-be5e1aa3a037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_22ace9ab-7edc-4d3a-9c34-0e6afd9b681b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7ffa3f91-36ed-4d54-924d-be5e1aa3a037" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_22ace9ab-7edc-4d3a-9c34-0e6afd9b681b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ad8608f2-dce0-43b9-9fd1-8f601a272dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_DebtInstrumentAxis_ad8608f2-dce0-43b9-9fd1-8f601a272dcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ad8608f2-dce0-43b9-9fd1-8f601a272dcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ad8608f2-dce0-43b9-9fd1-8f601a272dcd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ad8608f2-dce0-43b9-9fd1-8f601a272dcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ad8608f2-dce0-43b9-9fd1-8f601a272dcd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanMember_733f02c1-5b9b-41f7-a0ef-985fc6d826e0" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:to="loc_inbx_Amended2020OxfordTermLoanMember_733f02c1-5b9b-41f7-a0ef-985fc6d826e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheOneMember_b2e3c895-5eed-4c50-ae14-8e1ea8ba87b5" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheOneMember_b2e3c895-5eed-4c50-ae14-8e1ea8ba87b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheTwoMember_ec7b2ea6-3153-4d98-81f0-dcd0612e182e" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheTwoMember_ec7b2ea6-3153-4d98-81f0-dcd0612e182e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheThreeMember_d059ecb5-fd7b-4da5-904c-ff117134de25" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheThreeMember_d059ecb5-fd7b-4da5-904c-ff117134de25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheFourMember_fbc9f38d-1c77-4a40-aa2e-e71ae55c630e" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheFourMember_fbc9f38d-1c77-4a40-aa2e-e71ae55c630e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ab3b5084-b706-489a-a878-5ca6782b2c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ab3b5084-b706-489a-a878-5ca6782b2c61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ab3b5084-b706-489a-a878-5ca6782b2c61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ab3b5084-b706-489a-a878-5ca6782b2c61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ab3b5084-b706-489a-a878-5ca6782b2c61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_05d96899-d23d-4c8b-bc10-6c4dcee08660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ab3b5084-b706-489a-a878-5ca6782b2c61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_05d96899-d23d-4c8b-bc10-6c4dcee08660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e0629045-e964-491c-84ee-b71a23defd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_05d96899-d23d-4c8b-bc10-6c4dcee08660" xlink:to="loc_us-gaap_SecuredDebtMember_e0629045-e964-491c-84ee-b71a23defd98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c733c12d-c644-403f-bbf9-a780fddb7554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_VariableRateAxis_c733c12d-c644-403f-bbf9-a780fddb7554" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c733c12d-c644-403f-bbf9-a780fddb7554_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_c733c12d-c644-403f-bbf9-a780fddb7554" xlink:to="loc_us-gaap_VariableRateDomain_c733c12d-c644-403f-bbf9-a780fddb7554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3eb8af06-5c5c-41d6-9ef2-3ec80a5d31b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_c733c12d-c644-403f-bbf9-a780fddb7554" xlink:to="loc_us-gaap_VariableRateDomain_3eb8af06-5c5c-41d6-9ef2-3ec80a5d31b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9f8e1ea9-431c-483f-8322-1ef86cbdaf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3eb8af06-5c5c-41d6-9ef2-3ec80a5d31b5" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9f8e1ea9-431c-483f-8322-1ef86cbdaf6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_faed9f32-c362-470f-954d-133f5a6be71e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_srt_RangeAxis_faed9f32-c362-470f-954d-133f5a6be71e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_faed9f32-c362-470f-954d-133f5a6be71e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_faed9f32-c362-470f-954d-133f5a6be71e" xlink:to="loc_srt_RangeMember_faed9f32-c362-470f-954d-133f5a6be71e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3e95aed-51e7-48ec-a266-13034c249789" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_faed9f32-c362-470f-954d-133f5a6be71e" xlink:to="loc_srt_RangeMember_f3e95aed-51e7-48ec-a266-13034c249789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7507604e-3dd6-47ac-86e9-3d49791816b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f3e95aed-51e7-48ec-a266-13034c249789" xlink:to="loc_srt_MinimumMember_7507604e-3dd6-47ac-86e9-3d49791816b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_78b54259-6eca-4d02-a365-3dd1350c5528" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f3e95aed-51e7-48ec-a266-13034c249789" xlink:to="loc_srt_MaximumMember_78b54259-6eca-4d02-a365-3dd1350c5528" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>inbx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8eb0955a-77e8-4ec9-9bdb-5f279743741e,g:91526847-18eb-416c-96d8-1d5c48d93616-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_0c85eed8-00f5-4808-bd99-3f901228912f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_4bc08a21-4f07-48fa-8f48-897e13f36c85_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_b9fc64b7-e51a-4432-ac9e-9be8477ad67a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_6ec277d9-4645-4fc5-b029-80f495409601_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_af4539fe-4dc7-44c4-8371-73f279c2291c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_NumberOfPerformanceObligations_541e8889-463c-497c-a726-a2dca93eb64c_terseLabel_en-US" xlink:label="lab_inbx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_inbx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_inbx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:label id="lab_inbx_NumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_inbx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NumberOfPerformanceObligations" xlink:href="inbx-20211231.xsd#inbx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_NumberOfPerformanceObligations" xlink:to="lab_inbx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_d0c841e4-b3d7-477f-a2b4-6fa4bdf8f1d6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_412d553f-92bc-4769-a3a3-405b4526749c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e1b99327-2af4-4cb8-a636-cd66fcf58e15_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6cf90f4b-f6d7-4ca3-958c-5e29da745e79_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ed118b72-8387-4c60-896c-9aa762a59c6b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f7fa1313-1121-42fa-8fac-f008b056ea41_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_7cdd7292-938e-43ea-b307-db359c1c57e6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanMember_a4fe0378-86c3-4d26-acb8-78b5fda19ba9_terseLabel_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanMember_label_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan [Member]</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanMember_documentation_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanMember" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_Amended2020OxfordTermLoanMember" xlink:to="lab_inbx_Amended2020OxfordTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d4cca3e8-1566-479b-97bd-be8954484e21_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses_7595bb08-1b64-4af6-b7a7-dd6322b140f6_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive development license</link:label>
    <link:label id="lab_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses_label_en-US" xlink:label="lab_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Exclusive Development Licenses</link:label>
    <link:label id="lab_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses_documentation_en-US" xlink:label="lab_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Exclusive Development Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:href="inbx-20211231.xsd#inbx_CollaborativeAgreementExclusiveDevelopmentLicenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:to="lab_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b61ccc9e-62b7-4c51-b5b5-fd1ada518008_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment_6f8da763-151d-49b9-b416-35bb145d52c6_negatedTerseLabel_en-US" xlink:label="lab_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment on debt</link:label>
    <link:label id="lab_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment_label_en-US" xlink:label="lab_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Secured Debt, Final Balloon Payment</link:label>
    <link:label id="lab_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment_documentation_en-US" xlink:label="lab_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Secured Debt, Final Balloon Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:href="inbx-20211231.xsd#inbx_RepaymentsOfSecuredDebtFinalBalloonPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:to="lab_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_619dc43e-6004-4445-8411-75ba167ef976_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_NoncashOperatingLeaseExpense_1f570ec2-c4b3-4f37-9bd5-4b16fb331f3a_terseLabel_en-US" xlink:label="lab_inbx_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_inbx_NoncashOperatingLeaseExpense_label_en-US" xlink:label="lab_inbx_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:label id="lab_inbx_NoncashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_inbx_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NoncashOperatingLeaseExpense" xlink:href="inbx-20211231.xsd#inbx_NoncashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_NoncashOperatingLeaseExpense" xlink:to="lab_inbx_NoncashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_82372008-2a84-423b-88a3-997fbf25cea4_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage due to advisors</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Percentage Of Future Amounts Received, Obligation to Pay</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Percentage Of Future Amounts Received, Obligation to Pay Advisors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:to="lab_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_9da69a16-a199-46a1-80b0-3fe1d2135ca5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6d00483e-1a6e-46fa-8a3b-cb5829332345_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheFourMember_844adfc9-9ff3-4e92-9c8b-684096e83aff_terseLabel_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche Four</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheFourMember_label_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche Four [Member]</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheFourMember_documentation_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheFourMember" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_Amended2020OxfordTermLoanTrancheFourMember" xlink:to="lab_inbx_Amended2020OxfordTermLoanTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_de92457b-03af-4a30-bc17-db826afa6d3c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5982bf05-083e-42dd-bff4-8b656f004d00_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_540cfabc-97eb-4d82-a734-5d849ea025d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e2ea124f-f4af-49de-87ba-b618762761e6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of fixed assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2b5e642e-2f6d-4d84-9db3-eae0e0280000_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_4d6fb3e9-76a5-4fbd-9434-65b01206304b_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_a04a86ff-804c-464e-8131-ff11e953889a_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_503bbcfc-a38e-4660-9a97-a0dd78c0369b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1f76316a-1250-4543-a59e-6e84793b6d5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7df24127-3aa7-41c5-b785-dce83b4f5043_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_db190d98-dc18-4d7f-b563-20b739ee5afd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_43058f17-a863-4784-a493-a5302decabf6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_335106b7-d460-4d33-952f-92db65be1a4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_710d3a4a-7e50-4291-8f38-ddc2825600af_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_31d049a4-e498-4fba-96ad-801cb224b567_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0e24a156-a320-44db-bc85-f2f4818ae2d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_d2a64214-f3f1-48d6-a9f2-96b58a76fbcf_terseLabel_en-US" xlink:label="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liabilities issued to lender in conjunction with 2020 Loan Agreement</link:label>
    <link:label id="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_label_en-US" xlink:label="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing And Financing Items, Warrant Liabilities Incurred</link:label>
    <link:label id="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_documentation_en-US" xlink:label="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing And Financing Items, Warrant Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:href="inbx-20211231.xsd#inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:to="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e8da1ca0-f3dc-4a72-a8fd-0f5f0fc36ad1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_30bd1682-2a0f-40ed-857c-e4a7b76166f2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fa6b58a3-998e-4bec-b48d-2d3ebb8fc30d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1dc29a6f-da00-475d-bb4d-e664c20607c5_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_8046cc99-c5b5-4d7f-a6d2-5454920604af_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember_2748eb73-7f87-4a37-a845-4016c7534e87_terseLabel_en-US" xlink:label="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Congressionally Directed Medical Research Program, 2021 Grant</link:label>
    <link:label id="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember_label_en-US" xlink:label="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defense - Congressionally Directed Medical Research Program, 2021 Grant [Member]</link:label>
    <link:label id="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember_documentation_en-US" xlink:label="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defense - Congressionally Directed Medical Research Program, 2021 Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember" xlink:to="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_PaycheckProtectionProgramCARESActMember_504468c0-a68c-49d5-bc8f-fddf803c2a0f_terseLabel_en-US" xlink:label="lab_inbx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan</link:label>
    <link:label id="lab_inbx_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_inbx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_inbx_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_inbx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaycheckProtectionProgramCARESActMember" xlink:href="inbx-20211231.xsd#inbx_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_PaycheckProtectionProgramCARESActMember" xlink:to="lab_inbx_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionDomain_9beb4f91-77fe-47b8-9af9-945e377ae572_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_TransactionDomain_label_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_RevenueRecognitionNumberOfCompounds_5a2d99c5-40a3-4c45-b7f6-87f2c1710f15_terseLabel_en-US" xlink:label="lab_inbx_RevenueRecognitionNumberOfCompounds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of compounds</link:label>
    <link:label id="lab_inbx_RevenueRecognitionNumberOfCompounds_label_en-US" xlink:label="lab_inbx_RevenueRecognitionNumberOfCompounds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Number Of Compounds</link:label>
    <link:label id="lab_inbx_RevenueRecognitionNumberOfCompounds_documentation_en-US" xlink:label="lab_inbx_RevenueRecognitionNumberOfCompounds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Number Of Compounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RevenueRecognitionNumberOfCompounds" xlink:href="inbx-20211231.xsd#inbx_RevenueRecognitionNumberOfCompounds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_RevenueRecognitionNumberOfCompounds" xlink:to="lab_inbx_RevenueRecognitionNumberOfCompounds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f7cbf159-e588-4280-90a0-b287c48bc3d8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_ced934a8-281b-47c2-978a-85c64222e7c5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_9db56a59-e24c-48b6-b790-f8f7ce2db6fc_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_72c8bf95-8ff5-494c-a59a-f2a98bb41ad2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bd75d797-6fc8-4f4a-a50c-bdc51e026a64_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from earnings per share computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_eac52250-872e-41f9-bb89-2600b82b5971_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember_057214ea-4704-4aa1-bb22-74a93ebd467d_terseLabel_en-US" xlink:label="lab_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans Term B, Term C &amp; Tranche 1 of Term A</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember_label_en-US" xlink:label="lab_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans Term B, Term C &amp; Tranche 1 of Term A [Member]</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember_documentation_en-US" xlink:label="lab_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans Term B, Term C &amp; Tranche 1 of Term A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember" xlink:to="lab_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3ae707fa-270f-4de3-962c-69921707f124_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2018OptionAndLicenseAgreementMember_dfc735d1-97a8-43e6-acb2-82cbfaa60b03_terseLabel_en-US" xlink:label="lab_inbx_A2018OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Option and License Agreement</link:label>
    <link:label id="lab_inbx_A2018OptionAndLicenseAgreementMember_label_en-US" xlink:label="lab_inbx_A2018OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Option and License Agreement [Member]</link:label>
    <link:label id="lab_inbx_A2018OptionAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_inbx_A2018OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Option and License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2018OptionAndLicenseAgreementMember" xlink:href="inbx-20211231.xsd#inbx_A2018OptionAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2018OptionAndLicenseAgreementMember" xlink:to="lab_inbx_A2018OptionAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_9da7965e-55d4-4afa-aea0-3aa88d68be7e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_5caf97c5-c3db-476f-9aed-6a3fff920122_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9a70c425-bd42-4349-b087-13250b4ef004_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_512daf68-1a6d-478e-b90e-60120704e911_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable, upfront payment</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Nonrefundable Upfront Payment</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Nonrefundable Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementNonrefundableUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:to="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_56f1d233-9ed2-4a49-87f0-c0263423ef16_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares of common stock after conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92805818-332f-4188-a9ca-8a9e6a707528_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentMinimumCashBalance_3e99d1fe-5669-4402-97cd-85bd504dd698_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentMinimumCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum cash balance</link:label>
    <link:label id="lab_inbx_DebtInstrumentMinimumCashBalance_label_en-US" xlink:label="lab_inbx_DebtInstrumentMinimumCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Minimum Cash Balance</link:label>
    <link:label id="lab_inbx_DebtInstrumentMinimumCashBalance_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentMinimumCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Minimum Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentMinimumCashBalance" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentMinimumCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentMinimumCashBalance" xlink:to="lab_inbx_DebtInstrumentMinimumCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_39aea962-f292-4e01-8fd9-491f19aaa4ec_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b3e04c1d-8e1e-4e49-ba12-0cec5a973f4c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_WarrantsAndRightsOutstandingLiability_6c253954-c4f4-4adb-baee-89830db182d8_terseLabel_en-US" xlink:label="lab_inbx_WarrantsAndRightsOutstandingLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued, amount</link:label>
    <link:label id="lab_inbx_WarrantsAndRightsOutstandingLiability_label_en-US" xlink:label="lab_inbx_WarrantsAndRightsOutstandingLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding, Liability</link:label>
    <link:label id="lab_inbx_WarrantsAndRightsOutstandingLiability_documentation_en-US" xlink:label="lab_inbx_WarrantsAndRightsOutstandingLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsAndRightsOutstandingLiability" xlink:href="inbx-20211231.xsd#inbx_WarrantsAndRightsOutstandingLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_WarrantsAndRightsOutstandingLiability" xlink:to="lab_inbx_WarrantsAndRightsOutstandingLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5591ad76-2e54-4991-9043-b99759292569_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2f8ad4fa-0392-4302-813e-d8be00379dfa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseAffiliateOX40LicenseAgreementMember_80f15496-47eb-4735-ad0c-090ece6b09a7_terseLabel_en-US" xlink:label="lab_inbx_LicenseAffiliateOX40LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OX40 License Agreement</link:label>
    <link:label id="lab_inbx_LicenseAffiliateOX40LicenseAgreementMember_label_en-US" xlink:label="lab_inbx_LicenseAffiliateOX40LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Affiliate - OX40 License Agreement [Member]</link:label>
    <link:label id="lab_inbx_LicenseAffiliateOX40LicenseAgreementMember_documentation_en-US" xlink:label="lab_inbx_LicenseAffiliateOX40LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Affiliate - OX40 License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAffiliateOX40LicenseAgreementMember" xlink:href="inbx-20211231.xsd#inbx_LicenseAffiliateOX40LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseAffiliateOX40LicenseAgreementMember" xlink:to="lab_inbx_LicenseAffiliateOX40LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d5ea0f51-5a2e-487b-9299-ac53c9607d5f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December&#160;31, 2021 and 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4edc2dde-513b-4567-a01e-631753baa0d3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f558798f-6e2d-4cb6-9702-bd7296fbc0c9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2ed1a57-059d-4cd7-abd1-e51a562c383f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_153ae765-d9a1-41b1-bf1f-32af33b903ad_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial conversion feature</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts_d5c79081-d565-4e6e-83f6-56ad576393e2_terseLabel_en-US" xlink:label="lab_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to agreements</link:label>
    <link:label id="lab_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts_label_en-US" xlink:label="lab_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Expenses Incurred Related to Contracts</link:label>
    <link:label id="lab_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts_documentation_en-US" xlink:label="lab_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Expenses Incurred Related to Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts" xlink:href="inbx-20211231.xsd#inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts" xlink:to="lab_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_460e6919-c430-4fd2-afda-4f58157eec2f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_397ad886-e449-4e9a-b548-8805122a2392_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_51b1e317-55e7-4a2c-bc91-1e23b12147aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d203e116-f4c4-41a7-af2f-6707b360993d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheThreeMember_f50141e7-e4b2-4698-96de-b21bc2c5814a_terseLabel_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche Three</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheThreeMember_label_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche Three [Member]</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheThreeMember_documentation_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheThreeMember" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_Amended2020OxfordTermLoanTrancheThreeMember" xlink:to="lab_inbx_Amended2020OxfordTermLoanTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ea0568aa-ec9a-4c77-ad1a-c42ff5e72f5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_44f9e682-f963-42f1-8a1d-1a18e072f3fc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e222a732-8cb4-4776-9838-bf16ed97a484_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in conversion of convertible securities</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheOneMember_e9562307-7eae-4c3f-888d-41ff1aeedc95_terseLabel_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche One</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheOneMember_label_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche One [Member]</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheOneMember_documentation_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheOneMember" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_Amended2020OxfordTermLoanTrancheOneMember" xlink:to="lab_inbx_Amended2020OxfordTermLoanTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0e6bc93f-2091-4429-95a8-276594af9b73_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_436f59e1-cb02-4476-ac1b-8c13bd09d3cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LiquidityPolicyTextBlock_3090afc8-a365-45bb-a377-0ba6e3f73f04_terseLabel_en-US" xlink:label="lab_inbx_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_inbx_LiquidityPolicyTextBlock_label_en-US" xlink:label="lab_inbx_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
    <link:label id="lab_inbx_LiquidityPolicyTextBlock_documentation_en-US" xlink:label="lab_inbx_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LiquidityPolicyTextBlock" xlink:href="inbx-20211231.xsd#inbx_LiquidityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LiquidityPolicyTextBlock" xlink:to="lab_inbx_LiquidityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ChiesiFarmaceuticiSpAMember_76f0a897-5d97-43fe-afc1-0aa5143bed2f_terseLabel_en-US" xlink:label="lab_inbx_ChiesiFarmaceuticiSpAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chiesi Farmaceutici S.p.A.</link:label>
    <link:label id="lab_inbx_ChiesiFarmaceuticiSpAMember_label_en-US" xlink:label="lab_inbx_ChiesiFarmaceuticiSpAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chiesi Farmaceutici S.p.A. [Member]</link:label>
    <link:label id="lab_inbx_ChiesiFarmaceuticiSpAMember_documentation_en-US" xlink:label="lab_inbx_ChiesiFarmaceuticiSpAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chiesi Farmaceutici S.p.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ChiesiFarmaceuticiSpAMember" xlink:href="inbx-20211231.xsd#inbx_ChiesiFarmaceuticiSpAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ChiesiFarmaceuticiSpAMember" xlink:to="lab_inbx_ChiesiFarmaceuticiSpAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_a062daee-acce-49e8-9e19-cb6683ea405a_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5276e445-0b49-4dc5-a5fd-0e121d4852d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_22bbf7f6-e4ad-4fce-95a3-1f57ce66c665_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6f0b1b04-151e-4ab4-a861-e3837cb6abab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_cbf8645b-111e-4a22-8745-e505e375ddf8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4403d691-4302-449d-8e3b-99548b297037_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_0dd9f48f-ce62-4d52-9fc9-23deb3beb353_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periodic payment terms, final payment amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_98316951-aa67-4596-b2b3-91c85fec0d91_terseLabel_en-US" xlink:label="lab_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Concurrently With 2020 Loan Agreement</link:label>
    <link:label id="lab_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_label_en-US" xlink:label="lab_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Concurrently With 2020 Loan Agreement [Member]</link:label>
    <link:label id="lab_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_documentation_en-US" xlink:label="lab_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Concurrently With 2020 Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:href="inbx-20211231.xsd#inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:to="lab_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_01994205-3546-4bfc-ac77-e169c3d1d4f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_d1f10cef-e01b-4c34-aff6-857c22c1c03b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_aa4a2c88-67e5-4911-8636-cecd8d3100f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of principal on the Paycheck Protection Program loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_129e27ce-df6f-46f2-a7d6-feec4eb11cca_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3fdbfd7b-1e12-4895-9d99-7226f5639a2b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_20b71139-4bdb-4707-8182-9ffafa7a6297_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bc72e811-33a7-4f1a-8884-1065c47364ee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember_9a074f4e-a194-4828-8139-9f6d3c8c53b1_terseLabel_en-US" xlink:label="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Congressionally Directed Medical Research Program, 2018 Grant</link:label>
    <link:label id="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember_label_en-US" xlink:label="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defense - Congressionally Directed Medical Research Program, 2018 Grant [Member]</link:label>
    <link:label id="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember_documentation_en-US" xlink:label="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defense - Congressionally Directed Medical Research Program, 2018 Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember" xlink:to="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_WarrantsLiability_9bf89d50-0c85-48ab-b798-8fff23668e83_terseLabel_en-US" xlink:label="lab_inbx_WarrantsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants liability</link:label>
    <link:label id="lab_inbx_WarrantsLiability_label_en-US" xlink:label="lab_inbx_WarrantsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Liability</link:label>
    <link:label id="lab_inbx_WarrantsLiability_documentation_en-US" xlink:label="lab_inbx_WarrantsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsLiability" xlink:href="inbx-20211231.xsd#inbx_WarrantsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_WarrantsLiability" xlink:to="lab_inbx_WarrantsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e7abcfb4-fbd8-419e-ab38-557acd85cbe4_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_54510e13-04d9-4cdc-9387-e45864bca3da_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f66ac42f-6ed6-4873-8171-086eb3835dd6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_1c33270c-1fa4-4095-9719-f9f23c614525_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside research and development services</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DeferredFederalPayrollTaxesCARESAct_1e567066-8aeb-4c73-9489-fb5fafa82de3_terseLabel_en-US" xlink:label="lab_inbx_DeferredFederalPayrollTaxesCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred payment of federal payroll taxes</link:label>
    <link:label id="lab_inbx_DeferredFederalPayrollTaxesCARESAct_label_en-US" xlink:label="lab_inbx_DeferredFederalPayrollTaxesCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Payroll Taxes, CARES Act</link:label>
    <link:label id="lab_inbx_DeferredFederalPayrollTaxesCARESAct_documentation_en-US" xlink:label="lab_inbx_DeferredFederalPayrollTaxesCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Payroll Taxes, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DeferredFederalPayrollTaxesCARESAct" xlink:href="inbx-20211231.xsd#inbx_DeferredFederalPayrollTaxesCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DeferredFederalPayrollTaxesCARESAct" xlink:to="lab_inbx_DeferredFederalPayrollTaxesCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_eda26ec5-7a9e-4599-a22d-40b8833ccff6_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_NonCashEstablishmentOfEquityMethodInvestment_a7e3e92f-b22a-4ddd-8b6f-f9033aae1437_terseLabel_en-US" xlink:label="lab_inbx_NonCashEstablishmentOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash equity method investment</link:label>
    <link:label id="lab_inbx_NonCashEstablishmentOfEquityMethodInvestment_label_en-US" xlink:label="lab_inbx_NonCashEstablishmentOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Establishment Of Equity Method Investment</link:label>
    <link:label id="lab_inbx_NonCashEstablishmentOfEquityMethodInvestment_documentation_en-US" xlink:label="lab_inbx_NonCashEstablishmentOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Establishment Of Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NonCashEstablishmentOfEquityMethodInvestment" xlink:href="inbx-20211231.xsd#inbx_NonCashEstablishmentOfEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_NonCashEstablishmentOfEquityMethodInvestment" xlink:to="lab_inbx_NonCashEstablishmentOfEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentPrepaymentFee_0e6a5046-b555-4cc0-87c9-24eb35d3b369_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee</link:label>
    <link:label id="lab_inbx_DebtInstrumentPrepaymentFee_label_en-US" xlink:label="lab_inbx_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee</link:label>
    <link:label id="lab_inbx_DebtInstrumentPrepaymentFee_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrepaymentFee" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPrepaymentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentPrepaymentFee" xlink:to="lab_inbx_DebtInstrumentPrepaymentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_739cc416-078b-4f21-978c-57cde1d8e93a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_f2ba1fc9-05f1-4797-9578-5bc94814a9d0_terseLabel_en-US" xlink:label="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease, by Balance Sheet Location</link:label>
    <link:label id="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_label_en-US" xlink:label="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset And Operating Lease Liability [Table Text Block]</link:label>
    <link:label id="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset And Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:href="inbx-20211231.xsd#inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:to="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7538835c-3db0-4615-bc37-da0836429cb4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_9e1acd12-c6d4-4f60-a742-aad3fccfd699_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development and Clinical Trial Accruals</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum_d815dfe7-61ba-446f-a777-961eca7318fb_terseLabel_en-US" xlink:label="lab_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront partnership proceeds</link:label>
    <link:label id="lab_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum_label_en-US" xlink:label="lab_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Only Payment Extension Requirement, Upfront Partnership Proceeds Minimum</link:label>
    <link:label id="lab_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum_documentation_en-US" xlink:label="lab_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Only Payment Extension Requirement, Upfront Partnership Proceeds Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum" xlink:href="inbx-20211231.xsd#inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum" xlink:to="lab_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ddaba493-bee2-4f91-abaf-455a36d03e19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_a27321a2-77e5-4755-b417-1942bf2c0f4f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_da7f3245-cd91-4df2-b3c6-7c11b0f5b7ea_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_beef2a8c-c9ca-4f4d-8ffa-eb651465ea87_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_4a3efaf3-cbf4-418e-988f-9f6aa752be27_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_be0a1416-b5a4-47bf-a061-36da04b025a6_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_de5dea7c-40ca-47cb-8843-48f8ee15bc4d_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_9d191c60-9892-4611-a6d0-89265abf48fc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dd469e2b-ee6e-4e5d-9f6f-a7c1e2b6b5b4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2b69dbab-5261-4444-b653-13e36cf62fca_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_76a71b5c-379c-4311-8503-17b59d8beacd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_3721d83d-2c89-47db-b451-10c44a681dd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax expense (benefit), net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_e4658af3-fdb4-400f-bfb6-2e533e92fa5e_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_2024b40a-c796-4db7-9c0c-b7eed75d64e6_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount arising from convertible note beneficial conversion features and reversal of beneficial conversion features</link:label>
    <link:label id="lab_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_label_en-US" xlink:label="lab_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount, Beneficial Conversion Feature (Reversal) Of Beneficial Conversion Feature</link:label>
    <link:label id="lab_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature Discount (Reversal) Of Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:to="lab_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f8b99c7c-1596-453e-a826-da9ec673b16c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_209bfa07-c7ec-499f-940c-010e2687dd9d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0d8ede60-981f-477e-b57a-c5c9750dc947_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_720f7d22-b1a0-4477-b094-356d542dc020_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionTypeAxis_1208045f-ee38-455e-97a2-db055c46a83e_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:label id="lab_us-gaap_TransactionTypeAxis_label_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6427c1c8-2144-42c7-b435-2500baaaf899_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cliff Vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_a591c7af-928e-4efa-8ee4-eb3971a3e250_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ca9c9c35-c100-4497-a6f8-34215b2ef28c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a751b3ee-8379-4ac0-a429-8d51bed1dbca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_704cae7c-a355-46f0-b0e4-91783bf343ee_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ExpensesReimbursedToDate_258c3f14-0bf0-4996-83a2-22e64c717748_terseLabel_en-US" xlink:label="lab_inbx_ExpensesReimbursedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement for related party transaction expenses incurred to date</link:label>
    <link:label id="lab_inbx_ExpensesReimbursedToDate_label_en-US" xlink:label="lab_inbx_ExpensesReimbursedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses Reimbursed To Date</link:label>
    <link:label id="lab_inbx_ExpensesReimbursedToDate_documentation_en-US" xlink:label="lab_inbx_ExpensesReimbursedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses Reimbursed To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ExpensesReimbursedToDate" xlink:href="inbx-20211231.xsd#inbx_ExpensesReimbursedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ExpensesReimbursedToDate" xlink:to="lab_inbx_ExpensesReimbursedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_54df3e1b-4d7c-47cb-90e4-ae053f11381b_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment receivable period</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Payment Receivable Period</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Payment Receivable Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:to="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ab56036-31b8-48a4-b4cb-d1130542a3f0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LesseeOperatingLeaseSquareFootageExpansion_dc34b114-8703-49d2-9963-b4a8ab136a56_terseLabel_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseSquareFootageExpansion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square footage of lease extension agreement (in sq feet)</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseSquareFootageExpansion_label_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseSquareFootageExpansion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Square Footage Expansion</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseSquareFootageExpansion_documentation_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseSquareFootageExpansion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Square Footage Expansion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseSquareFootageExpansion" xlink:href="inbx-20211231.xsd#inbx_LesseeOperatingLeaseSquareFootageExpansion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LesseeOperatingLeaseSquareFootageExpansion" xlink:to="lab_inbx_LesseeOperatingLeaseSquareFootageExpansion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_08b56d77-2f5b-4641-9afb-0871bee6eac4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2e4e11dc-80cc-4d9f-8dbc-327f79c5ea2b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Establishment of liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_SaleOfStockSharesCommonStockSold_2c0d9b4b-17bf-4418-9d4b-5162aeffbf29_terseLabel_en-US" xlink:label="lab_inbx_SaleOfStockSharesCommonStockSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares sold (in shares)</link:label>
    <link:label id="lab_inbx_SaleOfStockSharesCommonStockSold_label_en-US" xlink:label="lab_inbx_SaleOfStockSharesCommonStockSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Shares, Common Stock Sold</link:label>
    <link:label id="lab_inbx_SaleOfStockSharesCommonStockSold_documentation_en-US" xlink:label="lab_inbx_SaleOfStockSharesCommonStockSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Shares, Common Stock Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleOfStockSharesCommonStockSold" xlink:href="inbx-20211231.xsd#inbx_SaleOfStockSharesCommonStockSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_SaleOfStockSharesCommonStockSold" xlink:to="lab_inbx_SaleOfStockSharesCommonStockSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_c1459e36-b4a9-462a-9c00-644e0827d956_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_16ff262c-736a-46a6-9475-3642f98b0dfc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b87aa012-387a-4d39-9daa-21277302f065_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_50eff57e-3dce-4ae6-98b4-6331890b0859_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_25b7537d-71e3-4720-b1eb-441d5bf206ad_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_fdf5ef35-00d8-4352-bea6-796f058e3065_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_63273580-2561-4208-86b5-593c92cf70d8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_a1029462-a6ad-411a-b4c9-3b68ff09d13a_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ce955f1e-2de5-42ac-a516-66ff8f5dcc64_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_7c0c9b51-0c1f-491d-a5fc-406863470554_terseLabel_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_label_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Items</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_documentation_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:href="inbx-20211231.xsd#inbx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_36f91367-65dc-4053-b0ab-d7744566e196_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_b97e3f10-83b1-4cdb-b896-05a9fb1d15ca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_391c61fa-6bcf-4744-9dfd-e528c4d4fd9a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_148c2f6a-a2a4-4513-a7e5-9ebf15a61218_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_fab94316-fa5f-4b5c-b3c8-05751e7028fd_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c91a0c2b-5847-4b1b-9bf6-36924806a286_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_031b33d0-6104-43f2-8d41-67ecd13fa9bb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_70a35899-978c-4f40-9325-4ef66716a4c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_d7bda9d2-686b-4d5f-a32a-b06a28d57b42_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0e068a36-d0ad-4edf-9620-4290b1e782be_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2015OxfordTermLoansMember_0b1b7f78-73e1-42ed-abf4-31112649a590_terseLabel_en-US" xlink:label="lab_inbx_A2015OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Loan Agreement</link:label>
    <link:label id="lab_inbx_A2015OxfordTermLoansMember_label_en-US" xlink:label="lab_inbx_A2015OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans [Member]</link:label>
    <link:label id="lab_inbx_A2015OxfordTermLoansMember_documentation_en-US" xlink:label="lab_inbx_A2015OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Oxford Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2015OxfordTermLoansMember" xlink:href="inbx-20211231.xsd#inbx_A2015OxfordTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2015OxfordTermLoansMember" xlink:to="lab_inbx_A2015OxfordTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_SalesAgreementMember_02a00435-8d12-4284-8f68-ba08b1994d60_terseLabel_en-US" xlink:label="lab_inbx_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_inbx_SalesAgreementMember_label_en-US" xlink:label="lab_inbx_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_inbx_SalesAgreementMember_documentation_en-US" xlink:label="lab_inbx_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SalesAgreementMember" xlink:href="inbx-20211231.xsd#inbx_SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_SalesAgreementMember" xlink:to="lab_inbx_SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_SaleAndPurchaseAgreementMember_a0f3a496-f100-425c-858b-25ebfd0c6b03_terseLabel_en-US" xlink:label="lab_inbx_SaleAndPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale And Purchase Agreement</link:label>
    <link:label id="lab_inbx_SaleAndPurchaseAgreementMember_label_en-US" xlink:label="lab_inbx_SaleAndPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale And Purchase Agreement [Member]</link:label>
    <link:label id="lab_inbx_SaleAndPurchaseAgreementMember_documentation_en-US" xlink:label="lab_inbx_SaleAndPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale And Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleAndPurchaseAgreementMember" xlink:href="inbx-20211231.xsd#inbx_SaleAndPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_SaleAndPurchaseAgreementMember" xlink:to="lab_inbx_SaleAndPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2seventyBioIncMember_004b52e4-1718-48e4-82ab-e9d47930c436_terseLabel_en-US" xlink:label="lab_inbx_A2seventyBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2seventy bio, Inc.</link:label>
    <link:label id="lab_inbx_A2seventyBioIncMember_label_en-US" xlink:label="lab_inbx_A2seventyBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2seventy bio, Inc. [Member]</link:label>
    <link:label id="lab_inbx_A2seventyBioIncMember_documentation_en-US" xlink:label="lab_inbx_A2seventyBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2seventy bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2seventyBioIncMember" xlink:href="inbx-20211231.xsd#inbx_A2seventyBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2seventyBioIncMember" xlink:to="lab_inbx_A2seventyBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7a94db1a-c6f2-429f-9195-7fb7db8cd5de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8eb71b65-3610-4d40-85d2-529204908adf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_89162f45-7907-4545-a3b4-1522ed9d6fe5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_436827a4-9552-4df9-b3e8-28bcc0c12de6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in IPO, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_823745b1-b343-45a1-88ea-580073c01ff4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_cbc50776-50c6-4ab4-8cff-f7115d940a44_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_31a50fc0-27e9-46ff-9446-c7229f492323_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9a000184-67f7-4817-948f-cc2ec4b8ad66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_9498b4e4-886c-44bd-b2c2-fc8fa34b40b7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c1911313-0dee-4c03-9c73-5868a9b3bb16_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY COMPENSATION PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_02422cea-60c9-4fd2-bb4b-16a0c2ecdd1d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a95506e8-dc9d-489e-ae53-e1d71212184d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b3a15365-062b-45cf-b57e-28d916cd9059_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_a25cf610-a176-4b8d-bfcc-f7c2ca7ea502_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_b0b4e388-2cbe-4feb-8653-d00a643092f4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments associated with equity offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_77977784-4e6b-403a-83ec-1fc35dcbbb26_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in IPO (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_d8d17382-935c-4075-8cf9-6c0a5519edcc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_aa6a6c8e-4ee2-41bc-a0b8-a388c0b566c2_terseLabel_en-US" xlink:label="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Outside Research And Development, Other, Current</link:label>
    <link:label id="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_label_en-US" xlink:label="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Outside Research And Development, Other, Current</link:label>
    <link:label id="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_documentation_en-US" xlink:label="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Outside Research And Development, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:href="inbx-20211231.xsd#inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:to="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1626f770-f85b-4a89-9ede-c244bd18f2c4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e1ede1ba-aa51-45cf-844d-cb6b9389fcc7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember_f9986d98-5e4d-4638-93fb-8a2a2364e23b_terseLabel_en-US" xlink:label="lab_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Programs</link:label>
    <link:label id="lab_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember_label_en-US" xlink:label="lab_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Programs Authorized [Member]</link:label>
    <link:label id="lab_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember_documentation_en-US" xlink:label="lab_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Programs Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementAdditionalProgramsAuthorizedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:to="lab_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a756194d-4eed-41dc-a880-c3d366e6a0b5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f4c08f0e-72e6-4ae5-9328-8033bda2c5b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 120,000,000 shares authorized as of December&#160;31, 2021 and 2020; 38,991,307 and 37,712,390 shares issued and outstanding as of December&#160;31, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8b902968-6137-4d78-a5c7-d23383e5b1b6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_85a87af9-6a59-47f2-b75a-4af85c1bf184_terseLabel_en-US" xlink:label="lab_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in conversion of preferred shares</link:label>
    <link:label id="lab_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label id="lab_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="inbx-20211231.xsd#inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_PhylaxisBioScienceLLCMember_d41f3a92-cff3-495d-8bcb-e8511579bc3f_terseLabel_en-US" xlink:label="lab_inbx_PhylaxisBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phylaxis BioScience, LLC</link:label>
    <link:label id="lab_inbx_PhylaxisBioScienceLLCMember_label_en-US" xlink:label="lab_inbx_PhylaxisBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phylaxis BioScience, LLC [Member]</link:label>
    <link:label id="lab_inbx_PhylaxisBioScienceLLCMember_documentation_en-US" xlink:label="lab_inbx_PhylaxisBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phylaxis BioScience, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember" xlink:href="inbx-20211231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_PhylaxisBioScienceLLCMember" xlink:to="lab_inbx_PhylaxisBioScienceLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CelgeneMember_9b8cfbde-882b-4e3d-8a6d-3e80c10ed107_terseLabel_en-US" xlink:label="lab_inbx_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene</link:label>
    <link:label id="lab_inbx_CelgeneMember_label_en-US" xlink:label="lab_inbx_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene [Member]</link:label>
    <link:label id="lab_inbx_CelgeneMember_documentation_en-US" xlink:label="lab_inbx_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CelgeneMember" xlink:href="inbx-20211231.xsd#inbx_CelgeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CelgeneMember" xlink:to="lab_inbx_CelgeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_93615e7d-e067-4993-aa6c-c8097df9b740_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3256fcaa-ce4d-4034-9fbc-e81d28f9c635_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_71486523-9020-4ee4-b7b5-955a6cd5d35d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_6cdba821-61c1-4e69-b70f-09ea2e58f49a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_8bcc6e5e-5245-421b-9089-43cc056061ed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2d11a33f-6e29-4b70-9058-6cc34b4aa697_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AccruedClinicalResearchAndDevelopmentCurrent_3803d5c1-8121-4602-857b-aec6d400621d_terseLabel_en-US" xlink:label="lab_inbx_AccruedClinicalResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical research and development</link:label>
    <link:label id="lab_inbx_AccruedClinicalResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_inbx_AccruedClinicalResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Research And Development, Current</link:label>
    <link:label id="lab_inbx_AccruedClinicalResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_inbx_AccruedClinicalResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalResearchAndDevelopmentCurrent" xlink:href="inbx-20211231.xsd#inbx_AccruedClinicalResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AccruedClinicalResearchAndDevelopmentCurrent" xlink:to="lab_inbx_AccruedClinicalResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementExpenseReimbursement_a0d654af-7960-4dc8-949d-b32387bbd79d_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement expenses</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementExpenseReimbursement_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Expense Reimbursement</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementExpenseReimbursement_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Expense Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementExpenseReimbursement" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementExpenseReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementExpenseReimbursement" xlink:to="lab_inbx_CollaborativeArrangementExpenseReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_ecff30da-52da-4907-a597-b959924cea10_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_922bb887-5604-43b0-8db1-41558befc890_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_7309fe79-c65e-4921-b493-c99a4142e0b8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_aaf2f14f-0623-4f27-93c4-f1ae3db616b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used to Estimate Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ReversalOfUnamortizedBeneficialConversionFeature_c5de8471-75c9-4677-9d08-4cf08c1f47b3_negatedTerseLabel_en-US" xlink:label="lab_inbx_ReversalOfUnamortizedBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of unamortized BCF</link:label>
    <link:label id="lab_inbx_ReversalOfUnamortizedBeneficialConversionFeature_c2748915-0173-4fce-bebd-885b2b0f60f8_terseLabel_en-US" xlink:label="lab_inbx_ReversalOfUnamortizedBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of unamortized BCF</link:label>
    <link:label id="lab_inbx_ReversalOfUnamortizedBeneficialConversionFeature_label_en-US" xlink:label="lab_inbx_ReversalOfUnamortizedBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Unamortized Beneficial Conversion Feature</link:label>
    <link:label id="lab_inbx_ReversalOfUnamortizedBeneficialConversionFeature_documentation_en-US" xlink:label="lab_inbx_ReversalOfUnamortizedBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Unamortized Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReversalOfUnamortizedBeneficialConversionFeature" xlink:href="inbx-20211231.xsd#inbx_ReversalOfUnamortizedBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ReversalOfUnamortizedBeneficialConversionFeature" xlink:to="lab_inbx_ReversalOfUnamortizedBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3e79f407-6851-4332-b591-ef97c5ed619c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_0dea680f-c3df-46a7-a0e9-07316a5dd104_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_71dcef56-c09b-4e2a-8835-42baf5bb869a_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3769eeaf-1426-419d-baef-443e6bfdf269_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6b7a3cf8-7fcf-4b8b-b0d3-c106f8dc3968_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_f0aa8417-10d5-4470-b064-a6d074b885a5_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_db8e7818-39d6-4919-8cbc-a16456a62d0b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AtTheMarketOfferingMember_98cbaae2-445b-4c33-9f58-91e8561c78c0_terseLabel_en-US" xlink:label="lab_inbx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering</link:label>
    <link:label id="lab_inbx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_inbx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_inbx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_inbx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingMember" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AtTheMarketOfferingMember" xlink:to="lab_inbx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9b9e40b9-06e0-46f5-a43f-ed40f93d852f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_3c920cde-d1e6-48b8-8f99-8fbd7ce7e059_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_15b7e2d1-3ae3-42a0-b61e-23ab06b5a66b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a6f97537-12eb-4ac5-badb-bca68e9678eb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, proceeds received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_6a3b541f-b8dd-4dae-a901-edab5e9bb85c_terseLabel_en-US" xlink:label="lab_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities arising from the issuance of the 2019 Note and the 2020 Notes</link:label>
    <link:label id="lab_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_label_en-US" xlink:label="lab_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing And Financing Items, Derivative Liabilities Incurred</link:label>
    <link:label id="lab_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_documentation_en-US" xlink:label="lab_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing And Financing Items, Derivative Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:href="inbx-20211231.xsd#inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:to="lab_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering_1d2413b8-68b4-451d-a6f3-608e9525fc28_terseLabel_en-US" xlink:label="lab_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with initial public offering</link:label>
    <link:label id="lab_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering_label_en-US" xlink:label="lab_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs, Initial Public Offering</link:label>
    <link:label id="lab_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering_documentation_en-US" xlink:label="lab_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs, Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:href="inbx-20211231.xsd#inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:to="lab_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2020OptionAndLicenseAgreementMember_b2a9e765-a31e-4466-bbda-ffd7154f6830_terseLabel_en-US" xlink:label="lab_inbx_A2020OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Option And License Agreement</link:label>
    <link:label id="lab_inbx_A2020OptionAndLicenseAgreementMember_label_en-US" xlink:label="lab_inbx_A2020OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Option And License Agreement [Member]</link:label>
    <link:label id="lab_inbx_A2020OptionAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_inbx_A2020OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Option And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OptionAndLicenseAgreementMember" xlink:href="inbx-20211231.xsd#inbx_A2020OptionAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2020OptionAndLicenseAgreementMember" xlink:to="lab_inbx_A2020OptionAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_762c7669-a8fc-433a-93d8-748a7a435942_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_39833967-904d-49d0-be49-5271f6b3f70b_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c344a62b-18d3-4d77-805c-22c701e518ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_cd4daa43-9197-4074-bbc2-2e08ce28a1ba_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3edd08e5-1e69-4eaa-923a-43e3c3e41d9d_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b834fbef-e08f-4ecf-a444-3097eeac9e76_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of outstanding warrants to purchase convertible preferred stock into common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_422e73ca-0c44-495d-8057-b7f24b151b1a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c6addf25-9a9c-43e5-8b7c-1dfd1235dad9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_77968788-9422-4c8b-81f1-65c9aa7c5924_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_4b6ff32f-aab5-41e4-8e1d-709f09758fbb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_bc9876c0-5756-4223-8163-befa83566a55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_c9518f53-fefe-4a1b-841b-087200e88a47_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6fc0bae0-959f-4e2d-9c76-0b03476047ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMON STOCK</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_f72a93c4-4e50-49b5-91fa-79e844a0f168_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_7d29c7d7-52db-4446-95c5-87a286e5f394_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseNonAffiliateMember_8b026449-e692-427c-b2a0-8497fa658f09_terseLabel_en-US" xlink:label="lab_inbx_LicenseNonAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee revenue, non-affiliates</link:label>
    <link:label id="lab_inbx_LicenseNonAffiliateMember_label_en-US" xlink:label="lab_inbx_LicenseNonAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Non-Affiliate [Member]</link:label>
    <link:label id="lab_inbx_LicenseNonAffiliateMember_documentation_en-US" xlink:label="lab_inbx_LicenseNonAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Non-Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember" xlink:href="inbx-20211231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseNonAffiliateMember" xlink:to="lab_inbx_LicenseNonAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a6db09ea-e383-428a-92af-3c4082491cc2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_3773efc5-0591-4a7e-9cd4-6c464fa8fd38_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equal payments of principal and interest period if interest only period is extended</link:label>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_label_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period if Interest-Only Period Is Extended</link:label>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period if Interest-Only Period Is Extended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended" xlink:to="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5227867b-9cea-40b9-9b64-9ba16f275b5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementMilestonePaymentReceived_236cde9f-5589-4d7a-896e-eb7d17919388_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementMilestonePaymentReceived_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment Received</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementMilestonePaymentReceived_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementMilestonePaymentReceived" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementMilestonePaymentReceived" xlink:to="lab_inbx_CollaborativeArrangementMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementTerm_be12b774-61dd-4309-83f7-11813b93c41e_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, term</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementTerm" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementTerm" xlink:to="lab_inbx_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a1cf15f2-6380-4060-9543-599a6b772f33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_952acc11-a6cf-4a00-aba3-6261698b9fba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_7ad1a7e2-a9f5-4b1d-b7c9-a1a2cd52ac81_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8323c907-c8ab-45cd-bef7-34ebc9803155_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4c61e679-cb9a-42fe-ac28-7bf24f98f4da_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2019And2020ConvertiblePromissoryNotesMember_4c25fa78-f294-4798-be3c-7dff285173bc_terseLabel_en-US" xlink:label="lab_inbx_A2019And2020ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 and 2020 Notes</link:label>
    <link:label id="lab_inbx_A2019And2020ConvertiblePromissoryNotesMember_label_en-US" xlink:label="lab_inbx_A2019And2020ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 And 2020 Convertible Promissory Notes [Member]</link:label>
    <link:label id="lab_inbx_A2019And2020ConvertiblePromissoryNotesMember_documentation_en-US" xlink:label="lab_inbx_A2019And2020ConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 And 2020 Convertible Promissory Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember" xlink:href="inbx-20211231.xsd#inbx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember" xlink:to="lab_inbx_A2019And2020ConvertiblePromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6cbcbee1-80c5-4646-a5d3-c7c843bf5a20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_42402a7f-3fee-4929-a684-01df13c4b08e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0ffc1518-e414-4136-ab6c-edbb79f94371_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c7cb9d5d-2574-4676-8fbe-300de7353c8b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e4000e00-733d-4984-b51f-08d4dc8470bf_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_553912c7-3ffc-4304-a8ee-cf786e09b82a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentNumberOfExistingTranches_d2a8112d-318d-4f61-bc9a-948f99edef38_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentNumberOfExistingTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of existing tranches</link:label>
    <link:label id="lab_inbx_DebtInstrumentNumberOfExistingTranches_label_en-US" xlink:label="lab_inbx_DebtInstrumentNumberOfExistingTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Existing Tranches</link:label>
    <link:label id="lab_inbx_DebtInstrumentNumberOfExistingTranches_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentNumberOfExistingTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Existing Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfExistingTranches" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentNumberOfExistingTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentNumberOfExistingTranches" xlink:to="lab_inbx_DebtInstrumentNumberOfExistingTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51054960-7533-405f-812c-ae73540546a5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_5b7558e7-bb30-4baa-947c-9dffaed1809c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7107819c-9116-47a7-9d48-0c642ff4f666_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable for shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2019ConvertiblePromissoryNoteMember_7c45e0e5-63a3-4364-aea5-f8ea2ef84629_terseLabel_en-US" xlink:label="lab_inbx_A2019ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Note</link:label>
    <link:label id="lab_inbx_A2019ConvertiblePromissoryNoteMember_label_en-US" xlink:label="lab_inbx_A2019ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Promissory Note [Member]</link:label>
    <link:label id="lab_inbx_A2019ConvertiblePromissoryNoteMember_documentation_en-US" xlink:label="lab_inbx_A2019ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Convertible Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019ConvertiblePromissoryNoteMember" xlink:href="inbx-20211231.xsd#inbx_A2019ConvertiblePromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2019ConvertiblePromissoryNoteMember" xlink:to="lab_inbx_A2019ConvertiblePromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled_6ba1352c-9488-4c89-bfdf-21794ccb8608_terseLabel_en-US" xlink:label="lab_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional equity interest percentage entitled to receive</link:label>
    <link:label id="lab_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled_label_en-US" xlink:label="lab_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Ownership Entitled</link:label>
    <link:label id="lab_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled_documentation_en-US" xlink:label="lab_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Ownership Entitled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:href="inbx-20211231.xsd#inbx_EquityMethodInvestmentAdditionalOwnershipEntitled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:to="lab_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_62d602c3-0920-48bd-9f4d-14c758e67345_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_26abc070-2c4e-49e7-a329-4c3fe3cf2021_negatedTerseLabel_en-US" xlink:label="lab_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of liabilities into equity</link:label>
    <link:label id="lab_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_label_en-US" xlink:label="lab_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification</link:label>
    <link:label id="lab_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_documentation_en-US" xlink:label="lab_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:href="inbx-20211231.xsd#inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:to="lab_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fd773f2e-c035-47ce-92e0-13abfefbd37f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1fa17126-28c2-4709-9ab0-edcd3598bb70_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_43d36425-eed0-4786-b475-7c30c0ef07c7_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs related to collaborative agreement</link:label>
    <link:label id="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_label_en-US" xlink:label="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number Of Related Programs To Agreement</link:label>
    <link:label id="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_documentation_en-US" xlink:label="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number Of Related Programs To Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:href="inbx-20211231.xsd#inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:to="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_78883d63-d2de-416b-92d2-b1d2d6679d27_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_70d14337-7180-478b-b523-a26b6d237042_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_WuXiBiologicsHealthcareVentureMember_660491ba-3abe-46f2-9757-0e17aeb21246_terseLabel_en-US" xlink:label="lab_inbx_WuXiBiologicsHealthcareVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi Biologics Healthcare Venture</link:label>
    <link:label id="lab_inbx_WuXiBiologicsHealthcareVentureMember_label_en-US" xlink:label="lab_inbx_WuXiBiologicsHealthcareVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi Biologics Healthcare Venture [Member]</link:label>
    <link:label id="lab_inbx_WuXiBiologicsHealthcareVentureMember_documentation_en-US" xlink:label="lab_inbx_WuXiBiologicsHealthcareVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi Biologics Healthcare Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WuXiBiologicsHealthcareVentureMember" xlink:href="inbx-20211231.xsd#inbx_WuXiBiologicsHealthcareVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_WuXiBiologicsHealthcareVentureMember" xlink:to="lab_inbx_WuXiBiologicsHealthcareVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_30b318fd-7dd7-40e3-9d23-a7fe0e1595c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_38a3c69d-ffb5-4b32-9d1a-98bd011ca0ce_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0b7a7001-c80b-4da2-8c1d-33f572541e26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_99aed0ae-9f2b-4d73-89d6-1176ce730f88_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award granted, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad529ddb-707e-4b8c-9aaf-59b8bcc06a76_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9bbf0272-c28d-40e7-8ac1-bffca4f4b6ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGGREGATE INTRINSIC VALUE Beginning value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_66e7bd93-e9c2-4310-ba4e-d6a1916f8a5f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGGREGATE INTRINSIC VALUE Ending value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f6202452-fa1a-4e73-8969-de023a681f9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_6731ae1b-1454-4135-b10b-6529ea7f88ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fc484392-6b1b-44b1-870f-1ce5fa87390b_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c0268002-c23f-4963-9dc1-80fb1d8ef8ca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeMember_10b87329-3799-4dab-8ae4-2b7ff24848f1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeMember_label_en-US" xlink:label="lab_us-gaap_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeMember" xlink:to="lab_us-gaap_DerivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1674b3f0-2556-4615-ae44-7a51d0dc178a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_478d294d-d066-483c-89a3-8ebde0d8792a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_256fb824-899d-44ef-a400-7af36031ea8c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1db43cd7-b0c1-454a-857a-3b24e3a13b8d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_94a4d805-0491-4754-9fe3-7e8d243e72eb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_e2f24468-875b-4690-a980-e5d897a0c99d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of the 2019 Note and the 2020 Notes to common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_f4bd0a7d-18c7-4180-8579-594944c8559a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1410a510-620e-4018-9f93-440f234d8d87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_114d6751-88dd-4307-b2c1-a3f4fb033853_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized related to performance obligation</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d59a2694-e514-4eeb-bb6e-e4234d61a56e_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_90d7209b-cf5c-4a62-94ad-968c891b1945_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3a450fa2-724b-4988-9c7d-f51996bb4c7b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_1cf80e90-13e8-4aa7-a657-0f6a4cbe8fbd_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_RelatedPartyEquityInterestInCompany_f1d402a0-8b88-471d-8144-93930ed3713e_terseLabel_en-US" xlink:label="lab_inbx_RelatedPartyEquityInterestInCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest, more than</link:label>
    <link:label id="lab_inbx_RelatedPartyEquityInterestInCompany_label_en-US" xlink:label="lab_inbx_RelatedPartyEquityInterestInCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party , Equity Interest In Company</link:label>
    <link:label id="lab_inbx_RelatedPartyEquityInterestInCompany_documentation_en-US" xlink:label="lab_inbx_RelatedPartyEquityInterestInCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party , Equity Interest In Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RelatedPartyEquityInterestInCompany" xlink:href="inbx-20211231.xsd#inbx_RelatedPartyEquityInterestInCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_RelatedPartyEquityInterestInCompany" xlink:to="lab_inbx_RelatedPartyEquityInterestInCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_6612d18a-5e02-4e12-b821-e2a6dc17b506_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the Paycheck Protection Program loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable_821b4948-a6ed-4c26-9121-d408d5d54ac8_terseLabel_en-US" xlink:label="lab_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM offering costs reimbursable in accounts receivable</link:label>
    <link:label id="lab_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable_label_en-US" xlink:label="lab_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Costs Reimbursable in Accounts Receivable</link:label>
    <link:label id="lab_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable_documentation_en-US" xlink:label="lab_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Costs Reimbursable in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable" xlink:to="lab_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2020OxfordTermLoanBMember_defd7ab7-0716-4733-909a-dfe2888cd007_terseLabel_en-US" xlink:label="lab_inbx_A2020OxfordTermLoanBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoanBMember_label_en-US" xlink:label="lab_inbx_A2020OxfordTermLoanBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loan B [Member]</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoanBMember_documentation_en-US" xlink:label="lab_inbx_A2020OxfordTermLoanBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loan B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoanBMember" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoanBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2020OxfordTermLoanBMember" xlink:to="lab_inbx_A2020OxfordTermLoanBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1575669e-e5b2-4cac-b961-4cad436fb008_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_b769a95b-1540-4a2f-bdc6-535e8d607cee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d31dfb7f-7517-4eb1-b979-e63b4ff676f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_29856d38-9ced-4714-b5f1-ae0a80dce0ce_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0d289fa9-ef81-46d3-9ddf-4b9858507d85_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_38fc06ba-40cf-4e7b-a661-49ca852c0f2e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining term of operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_a2b9d2a1-4695-416a-b28d-0f15d7870472_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_WarrantLiabilitiesPolicyTextBlock_fd75d02b-07f5-4438-b122-cd7f73d029e5_terseLabel_en-US" xlink:label="lab_inbx_WarrantLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liabilities</link:label>
    <link:label id="lab_inbx_WarrantLiabilitiesPolicyTextBlock_label_en-US" xlink:label="lab_inbx_WarrantLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liabilities [Policy Text Block]</link:label>
    <link:label id="lab_inbx_WarrantLiabilitiesPolicyTextBlock_documentation_en-US" xlink:label="lab_inbx_WarrantLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantLiabilitiesPolicyTextBlock" xlink:href="inbx-20211231.xsd#inbx_WarrantLiabilitiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_WarrantLiabilitiesPolicyTextBlock" xlink:to="lab_inbx_WarrantLiabilitiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5423b8d5-9543-4c09-96b9-c09edf19ec44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_a3080be3-7aa1-4fec-93bf-e34ec33c3b25_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_2bf4717d-c600-49d5-9a53-800050b5ae41_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and including final payment fee</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9887aa0b-9b71-4e18-bf56-60ea86ddcc62_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2e62c4b1-5454-409f-ab0f-af04fa4e8437_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Notes Measured at Fair Value Using Level 3 Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_OtherCustomersNotSeparatelyDisclosedMember_237a0fb3-5425-4f27-9be9-b36faf87de12_terseLabel_en-US" xlink:label="lab_inbx_OtherCustomersNotSeparatelyDisclosedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other license revenues from non-affiliates</link:label>
    <link:label id="lab_inbx_OtherCustomersNotSeparatelyDisclosedMember_label_en-US" xlink:label="lab_inbx_OtherCustomersNotSeparatelyDisclosedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customers, Not Separately Disclosed [Member]</link:label>
    <link:label id="lab_inbx_OtherCustomersNotSeparatelyDisclosedMember_documentation_en-US" xlink:label="lab_inbx_OtherCustomersNotSeparatelyDisclosedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customers, Not Separately Disclosed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherCustomersNotSeparatelyDisclosedMember" xlink:href="inbx-20211231.xsd#inbx_OtherCustomersNotSeparatelyDisclosedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_OtherCustomersNotSeparatelyDisclosedMember" xlink:to="lab_inbx_OtherCustomersNotSeparatelyDisclosedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_cd28c47f-ed84-4e19-80a9-82d1c9c25a57_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_5bfad6b0-46e0-4a4a-a9ec-96aeb22b02af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits (FIN 48)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_68158bb2-1821-428f-87f0-546b8d4b3c11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_33066cce-6f7b-4ead-ba54-1e076e7c7f5e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11ab227b-682e-42ee-90a1-b5d09c35968f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8cc434a0-8c19-42d3-bf05-22307a139ae6_terseLabel_en-US" xlink:label="lab_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in conversion of preferred shares (in shares)</link:label>
    <link:label id="lab_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label id="lab_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="inbx-20211231.xsd#inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_68c5db23-5ba2-43ef-abf2-c0d05acd460f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_873a91b6-0896-4352-8c93-fe09b20a3616_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentMember_1f460fc8-452b-4e0d-b75c-f47f28dac6df_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentMember_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentMember" xlink:to="lab_us-gaap_PurchaseCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0b0c9ff4-5ba7-4eb7-80f5-ddabb723e0c8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_76c48287-345c-46b2-873a-6bebf13753cc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6a3a1f4d-d490-49ac-92f5-4346426071a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c64c0e93-1621-474a-bfd4-b3c7c4d63926_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a5f4a51-f5b6-4ea1-a227-18d405057eb8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f5565cbe-1b57-478d-bad9-ab69699115ae_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_07f90e9e-7a52-4529-8d5f-5a0378448a2b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_676fbcd3-5078-480b-8faa-c1a1a95f5201_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7e8f059a-f673-4155-b316-e60d1df6fddf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps_09fe1806-86f8-4297-aa33-e9391f348b52_terseLabel_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return to provision true-ups</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps_label_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return to Provision True-Ups</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps_documentation_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return to Provision True-Ups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps" xlink:href="inbx-20211231.xsd#inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps" xlink:to="lab_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e94c9e56-a488-4fc8-a223-d944b53a7b4d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c68df99f-9413-4e89-add5-e7063575b52f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Stock-Based Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_05949879-77a9-4be6-a32d-a21c0dd3a9fd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of warrant liabilities into equity</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d054e542-908c-45c9-8555-5f5ecd948618_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6bfe62d0-cdda-4afa-abcd-0792027042db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4d4ade69-cdba-48e3-a88f-078c2d654f03_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion, including debt discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7aa44089-00e5-43e6-acc1-52c0c61777ed_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3905959f-b655-400b-9ce1-2f8d3ca3908b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_852777f8-1546-4320-8b06-be9b5546e781_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_e353e2b3-7c3d-4fdb-bd25-236a70e4a492_terseLabel_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common or preferred stock warrants issued as a percent of funded amount</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_label_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Percentage Of Funded Amount Issued</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_documentation_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Percentage Of Funded Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:href="inbx-20211231.xsd#inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:to="lab_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LesseeOperatingLeaseSquareFootage_5ed4467c-221e-4570-8b69-d98e0c577eb3_terseLabel_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseSquareFootage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square footage of lease agreement (in sq feet)</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseSquareFootage_label_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseSquareFootage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Square Footage</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseSquareFootage_documentation_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseSquareFootage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Square Footage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseSquareFootage" xlink:href="inbx-20211231.xsd#inbx_LesseeOperatingLeaseSquareFootage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LesseeOperatingLeaseSquareFootage" xlink:to="lab_inbx_LesseeOperatingLeaseSquareFootage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_da39411a-5a86-4157-8dcf-c138022ac8a6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_46495561-2820-4109-83c5-a3edc961d49f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseAndGrantRevenueTextBlock_a5e91740-6284-4b66-8bf4-f95d8653eb8f_terseLabel_en-US" xlink:label="lab_inbx_LicenseAndGrantRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSE AND GRANT REVENUES</link:label>
    <link:label id="lab_inbx_LicenseAndGrantRevenueTextBlock_label_en-US" xlink:label="lab_inbx_LicenseAndGrantRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Grant Revenue [Text Block]</link:label>
    <link:label id="lab_inbx_LicenseAndGrantRevenueTextBlock_documentation_en-US" xlink:label="lab_inbx_LicenseAndGrantRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAndGrantRevenueTextBlock" xlink:href="inbx-20211231.xsd#inbx_LicenseAndGrantRevenueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseAndGrantRevenueTextBlock" xlink:to="lab_inbx_LicenseAndGrantRevenueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_b9b2f795-606a-4838-b83a-8cce1ad96ac4_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_PurchaseCommitmentNonCancellablePortionOfContract_655bf44b-0715-4fc7-9075-c493b9f364bc_terseLabel_en-US" xlink:label="lab_inbx_PurchaseCommitmentNonCancellablePortionOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancellable portion of contract</link:label>
    <link:label id="lab_inbx_PurchaseCommitmentNonCancellablePortionOfContract_label_en-US" xlink:label="lab_inbx_PurchaseCommitmentNonCancellablePortionOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Non-cancellable Portion of Contract</link:label>
    <link:label id="lab_inbx_PurchaseCommitmentNonCancellablePortionOfContract_documentation_en-US" xlink:label="lab_inbx_PurchaseCommitmentNonCancellablePortionOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Non-cancellable Portion of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PurchaseCommitmentNonCancellablePortionOfContract" xlink:href="inbx-20211231.xsd#inbx_PurchaseCommitmentNonCancellablePortionOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_PurchaseCommitmentNonCancellablePortionOfContract" xlink:to="lab_inbx_PurchaseCommitmentNonCancellablePortionOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fcedc601-6687-453f-9ec6-564c84c56f1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c0131027-c536-4006-a2d5-a8e6e6266654_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f26a9bc0-17cd-49da-a041-bf4b4c91da33_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c4dfb18b-cde9-4904-9bbd-b70f218bf92f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_af838682-eed7-4287-a29d-9079a920031d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d1a25b1e-cfd2-437c-900c-64321cf4f2fa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CommonStockSaleOfStockCommissionPercent_73140f62-e791-4b0f-8b13-00d51a47f1dc_terseLabel_en-US" xlink:label="lab_inbx_CommonStockSaleOfStockCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission percent</link:label>
    <link:label id="lab_inbx_CommonStockSaleOfStockCommissionPercent_label_en-US" xlink:label="lab_inbx_CommonStockSaleOfStockCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Sale Of Stock Commission, Percent</link:label>
    <link:label id="lab_inbx_CommonStockSaleOfStockCommissionPercent_documentation_en-US" xlink:label="lab_inbx_CommonStockSaleOfStockCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Sale Of Stock Commission, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CommonStockSaleOfStockCommissionPercent" xlink:href="inbx-20211231.xsd#inbx_CommonStockSaleOfStockCommissionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CommonStockSaleOfStockCommissionPercent" xlink:to="lab_inbx_CommonStockSaleOfStockCommissionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_e48cf4e5-4131-4eb3-a5f8-ffa12ccc160a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_a6dc7998-9ef9-48fb-a098-4a1d8ffbb68b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_834e120c-304e-4c9f-aaf8-531b84b011fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_88744a58-e508-4f8c-900a-79a7d28ff84c_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_31b10b8c-63b0-488d-9b14-927d2f4170f4_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_bbf62d7f-2b25-4d49-b59e-ea9141d213fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementPaymentReceivable_e906f1da-7d56-4298-b573-d518ff611129_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments due pursuant to agreement</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementPaymentReceivable_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment Receivable</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementPaymentReceivable_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementPaymentReceivable" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementPaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementPaymentReceivable" xlink:to="lab_inbx_CollaborativeArrangementPaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_81f8353e-aa08-4c36-93c3-ee6e54b53733_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6012c37f-75ed-4b1e-bdd9-2b61d9373af9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_87d54ecb-da25-4ed5-b9f0-18256b3f0a03_terseLabel_en-US" xlink:label="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Contract With Customer, Liability, Current</link:label>
    <link:label id="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_documentation_en-US" xlink:label="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Contract With Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:href="inbx-20211231.xsd#inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:to="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1fdda9a1-9916-4dd2-ac7d-58b556f8ce12_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f796e778-c713-47a0-a29b-138342b9ca71_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9671070c-8a93-4983-a1c9-d98707c01f79_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6cb59254-4e51-43d8-8f75-439c2d0f4b5e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_97763e97-9b06-4fe3-a3b7-003cd15849d0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_23b74260-b552-48cc-840c-dcd92e288406_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_6ccda876-41f6-496a-bbc5-9edeebe58c94_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_6496fbef-52f4-4b3a-883f-91f0e3f7ab10_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_73706f74-a9b2-4975-9d7d-a0ecb25f42b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_4d652ea8-c3af-44dd-8f79-18324df609dc_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income related to changes in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_216ba27c-972f-4922-9917-5a9aee74a25d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2020OxfordTermLoansMember_cc1bfe36-68c8-4ca2-a8d7-b1ced07f6301_terseLabel_en-US" xlink:label="lab_inbx_A2020OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Loan Agreement</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoansMember_label_en-US" xlink:label="lab_inbx_A2020OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans [Member]</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoansMember_documentation_en-US" xlink:label="lab_inbx_A2020OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2020OxfordTermLoansMember" xlink:to="lab_inbx_A2020OxfordTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_82390b31-cde7-46e0-abd5-c85699bb56a8_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_12f7ae82-ed24-4083-8e5f-97c5d23c31bb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_72a2b954-5000-46c8-bde9-d96349227581_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a5488904-889f-4e3f-8a29-a108b01527fc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_461a81cc-8f54-4a9a-9c07-f1070f93dede_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_99b12379-2582-49e0-88fd-c8e1657d6634_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_52115662-11ff-48de-9412-2d0dcef5a4a3_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AuditInformationAbstract_label_en-US" xlink:label="lab_inbx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_inbx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_inbx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AuditInformationAbstract" xlink:href="inbx-20211231.xsd#inbx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AuditInformationAbstract" xlink:to="lab_inbx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e2cdbce2-93a8-45cd-a479-7cb31cd1775f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheTwoMember_5d96725f-06b3-4ee9-abd2-dfefb3814a70_terseLabel_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche Two</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheTwoMember_label_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche Two [Member]</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanTrancheTwoMember_documentation_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheTwoMember" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_Amended2020OxfordTermLoanTrancheTwoMember" xlink:to="lab_inbx_Amended2020OxfordTermLoanTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5384bc3a-8dec-4d1e-af13-0c316e20fb64_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_0312cd26-8a84-496e-ad7d-a77cceeb16df_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9a979a7f-58f5-4c03-9cee-ba77e739e825_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_62b3ef54-355e-4d31-ad15-12938f6bcb55_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM, Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivable_218cad8b-587c-4031-be60-638ea8b7bb66_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payable due from agreement</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivable_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Payment Receivable</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivable_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementAdditionalPaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:to="lab_inbx_CollaborativeArrangementAdditionalPaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_bc95e83e-d8ac-49b4-808d-40d274d4faa8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_8ae7546a-1696-469c-aaed-25bf43c18042_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of principal on debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3737eeb1-a0fe-43c4-8ddc-09b0e7ff2afb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c62c4913-ec5b-4cec-ad23-6998f5661f14_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_836466ab-62d3-4ea5-ae77-2069efb01f26_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e6d6a059-106d-49a8-ac96-3f015af31298_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER FINANCIAL INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_560fe641-5622-4270-b9b9-288173ea3204_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_55dc860f-afd9-4d0b-9771-d51da4689073_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note monthly interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_23bf6433-a000-453b-88fa-d923f75c293c_negatedLabel_en-US" xlink:label="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of fees associated with debt</link:label>
    <link:label id="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_label_en-US" xlink:label="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs, Secured Debt</link:label>
    <link:label id="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_documentation_en-US" xlink:label="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs, Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:href="inbx-20211231.xsd#inbx_PaymentsOfDebtIssuanceCostsSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:to="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_467c4dd9-b85c-446c-8ad9-526ae4357467_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ElpiscienceBiopharmaceuticalsIncMember_feefdd0d-757b-42bb-9a70-5903dc8ce036_terseLabel_en-US" xlink:label="lab_inbx_ElpiscienceBiopharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elpiscience Biopharmaceuticals, Inc.</link:label>
    <link:label id="lab_inbx_ElpiscienceBiopharmaceuticalsIncMember_label_en-US" xlink:label="lab_inbx_ElpiscienceBiopharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elpiscience Biopharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_inbx_ElpiscienceBiopharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_inbx_ElpiscienceBiopharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elpiscience Biopharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember" xlink:href="inbx-20211231.xsd#inbx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember" xlink:to="lab_inbx_ElpiscienceBiopharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99084140-99b2-4d93-927f-56024bb1b67b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ac8a197-fdd6-45a6-9342-f766cae4cdb6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_fac49bc2-e072-414f-8c1e-783bad08bc83_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_9c184908-e5d4-4c21-ac6c-f7b5722b750a_terseLabel_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Programs, Program 2</link:label>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_label_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized, Program Two [Member]</link:label>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_documentation_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized, Program Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:to="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember_68765b12-435d-4fe5-b810-d57f1e967286_terseLabel_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Programs</link:label>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember_label_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized [Member]</link:label>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember_documentation_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:to="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementCommercializationMilestoneReceivable_aa839bf7-ec93-4ddd-81b1-5e3f1882c1b6_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization milestone payment receivable</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementCommercializationMilestoneReceivable_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Commercialization Milestone Receivable</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementCommercializationMilestoneReceivable_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Commercialization Milestone Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementCommercializationMilestoneReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:to="lab_inbx_CollaborativeArrangementCommercializationMilestoneReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d60481a9-e6da-4c40-b1bc-b61e07236945_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_f1035625-67b2-43ae-8461-fe1666930455_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_e575da80-cb08-474b-90e3-67bad78c81da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ReclassificationOfWarrantLiabilitiesToEquity_08b84bec-4355-4c4e-9649-7662d4202d29_terseLabel_en-US" xlink:label="lab_inbx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of warrant liabilities to equity</link:label>
    <link:label id="lab_inbx_ReclassificationOfWarrantLiabilitiesToEquity_label_en-US" xlink:label="lab_inbx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Warrant Liabilities To Equity</link:label>
    <link:label id="lab_inbx_ReclassificationOfWarrantLiabilitiesToEquity_documentation_en-US" xlink:label="lab_inbx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Warrant Liabilities To Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:href="inbx-20211231.xsd#inbx_ReclassificationOfWarrantLiabilitiesToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:to="lab_inbx_ReclassificationOfWarrantLiabilitiesToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_2d0fef96-2cec-4ba6-b366-a40ab299a41b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Costs and Other Debt-Related Costs and Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_a1ba7739-193c-4990-99ef-96c53298db82_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_d1cfc00b-215a-4e60-b05b-58bce0e0e943_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fa1072e2-a89f-411b-b607-0f5fb55cb9e5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares of common stock outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_be56210d-c0d4-4126-981f-eb57e5835c7c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_4bf15087-1487-42d9-9293-e1058cbb9965_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f123c4a7-03a0-45d5-8fbb-4cf5595f099b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount and non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_a90f303e-f6b6-4ad3-b6d4-370fdae7eba8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_96b887a6-06ee-4244-93df-201ee642b5f2_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_089eb2fb-50e0-401e-8be9-9f5a4cb3cada_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_RevenuesCashReceived_9ee33a82-6607-4f20-be9c-73b8361e2762_terseLabel_en-US" xlink:label="lab_inbx_RevenuesCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized, cash</link:label>
    <link:label id="lab_inbx_RevenuesCashReceived_label_en-US" xlink:label="lab_inbx_RevenuesCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Cash Received</link:label>
    <link:label id="lab_inbx_RevenuesCashReceived_documentation_en-US" xlink:label="lab_inbx_RevenuesCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RevenuesCashReceived" xlink:href="inbx-20211231.xsd#inbx_RevenuesCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_RevenuesCashReceived" xlink:to="lab_inbx_RevenuesCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0aab624d-5801-42f7-b241-8aed496ef630_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e2228ff6-1ca5-4713-9697-579efe8be262_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_3b41df92-7811-4134-95da-8673a90201b0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_601d6e1c-5785-4a01-bbe3-ee515069feb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_102baad2-0d52-4fe0-a438-252fb7e0a2b9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_3c80f75f-a947-4e97-a9d9-18ecbfe55d49_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_667aba40-3fe8-42d4-9f09-5ee121b4b1ef_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in conversion of convertible securities (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_WarrantsIssuedUponConsummationOfIPOMember_005fbc54-519f-4675-bd3f-046bde97a39a_terseLabel_en-US" xlink:label="lab_inbx_WarrantsIssuedUponConsummationOfIPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Upon Consummation of IPO</link:label>
    <link:label id="lab_inbx_WarrantsIssuedUponConsummationOfIPOMember_label_en-US" xlink:label="lab_inbx_WarrantsIssuedUponConsummationOfIPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Upon Consummation Of IPO [Member]</link:label>
    <link:label id="lab_inbx_WarrantsIssuedUponConsummationOfIPOMember_documentation_en-US" xlink:label="lab_inbx_WarrantsIssuedUponConsummationOfIPOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued Upon Consummation Of IPO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsIssuedUponConsummationOfIPOMember" xlink:href="inbx-20211231.xsd#inbx_WarrantsIssuedUponConsummationOfIPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_WarrantsIssuedUponConsummationOfIPOMember" xlink:to="lab_inbx_WarrantsIssuedUponConsummationOfIPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_1c00aaa6-9704-4f41-8422-bf1bb512a59e_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payment receivable</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Development Milestone Receivable</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Development Milestone Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementDevelopmentMilestoneReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:to="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_194ddf67-30cb-4915-ae87-ba934d70b34a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_45d09fa7-b66b-49d1-ae43-e95e972852e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_NumberOfOperatingLeasesHeld_7d334231-7cb4-4219-a2b2-b460667051dd_terseLabel_en-US" xlink:label="lab_inbx_NumberOfOperatingLeasesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating leases held</link:label>
    <link:label id="lab_inbx_NumberOfOperatingLeasesHeld_label_en-US" xlink:label="lab_inbx_NumberOfOperatingLeasesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases Held</link:label>
    <link:label id="lab_inbx_NumberOfOperatingLeasesHeld_documentation_en-US" xlink:label="lab_inbx_NumberOfOperatingLeasesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NumberOfOperatingLeasesHeld" xlink:href="inbx-20211231.xsd#inbx_NumberOfOperatingLeasesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_NumberOfOperatingLeasesHeld" xlink:to="lab_inbx_NumberOfOperatingLeasesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_092c9033-a3b7-48a2-9374-8506c2ae09b4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_GrantValuedAwarded_e8e07506-b367-4bc1-89e0-d7449639a4d0_terseLabel_en-US" xlink:label="lab_inbx_GrantValuedAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant award</link:label>
    <link:label id="lab_inbx_GrantValuedAwarded_label_en-US" xlink:label="lab_inbx_GrantValuedAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, Valued Awarded</link:label>
    <link:label id="lab_inbx_GrantValuedAwarded_documentation_en-US" xlink:label="lab_inbx_GrantValuedAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant, Valued Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GrantValuedAwarded" xlink:href="inbx-20211231.xsd#inbx_GrantValuedAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_GrantValuedAwarded" xlink:to="lab_inbx_GrantValuedAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_6b9143cb-7897-41b4-bc7d-266c3d584dc0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_e6146445-ca00-4f24-81af-3f581d911e94_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_bd344003-62d9-464e-93f5-951f7d467cf5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable for expenses incurred, not yet reimbursed</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_ed507f5c-3cf2-4222-9dc5-6b23fe32ce06_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6203192f-4aa5-4d0f-b2c9-3818b3c0f930_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e1ebad1e-c01b-478c-9f6c-5b4faec29b11_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7ca27bb0-0481-495f-9944-829bc8cf6f4f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43d2d0a9-3bd3-403b-be1d-a810f049f46c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_fc02fd7f-2bd4-4fac-8f8d-6974de1779de_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CapitalExpendituresIncurredButNotYetPaidReleased_e143c21f-3104-42b2-8f3f-68fea4fd87fe_terseLabel_en-US" xlink:label="lab_inbx_CapitalExpendituresIncurredButNotYetPaidReleased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable for purchase of fixed assets</link:label>
    <link:label id="lab_inbx_CapitalExpendituresIncurredButNotYetPaidReleased_label_en-US" xlink:label="lab_inbx_CapitalExpendituresIncurredButNotYetPaidReleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not Yet Paid (Released)</link:label>
    <link:label id="lab_inbx_CapitalExpendituresIncurredButNotYetPaidReleased_documentation_en-US" xlink:label="lab_inbx_CapitalExpendituresIncurredButNotYetPaidReleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not Yet Paid (Released)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CapitalExpendituresIncurredButNotYetPaidReleased" xlink:href="inbx-20211231.xsd#inbx_CapitalExpendituresIncurredButNotYetPaidReleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CapitalExpendituresIncurredButNotYetPaidReleased" xlink:to="lab_inbx_CapitalExpendituresIncurredButNotYetPaidReleased" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_feabfe85-13a4-4e1d-9acc-bc7b0f5f1065_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8eeb3836-d156-42fa-abb0-8cea8e1ea4d3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4f7a0866-d10c-4640-813e-dea42522d47f_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_941dbdf5-efd3-4318-9c7e-7a6b4a3c114e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_93aafb96-05ae-4b82-970e-02d8195be413_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6a79545b-6086-4287-acbc-ee797aff7f2c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d5fb7dc8-38cb-4e41-8357-f4d2382d3452_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_344c805b-d709-4a86-988f-74e4c43262df_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_221af539-0e14-41a7-8ece-c931421b1a54_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_2528ead2-7e9c-4ce8-b908-39396490a310_terseLabel_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Programs, Program 1</link:label>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_label_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized, Program One [Member]</link:label>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_documentation_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial Programs Authorized, Program One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:to="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_05a8a1e8-6124-48ac-bf0a-de5e77c6669e_terseLabel_en-US" xlink:label="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="inbx-20211231.xsd#inbx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2708d59d-1943-49d3-899e-7ef6f9d43f2b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6d7ff6fd-814d-432c-aee9-1176f3bb9edd_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_bbb9198d-6c1c-498b-95d2-c2d4207fb934_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_708c8bda-42b2-4a7e-8882-2cbcd7f11aff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ExpensesExpectedToBeReimbursed_be0d2ec2-ec91-48d0-b09b-719ccd899906_terseLabel_en-US" xlink:label="lab_inbx_ExpensesExpectedToBeReimbursed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses expected to be reimbursed</link:label>
    <link:label id="lab_inbx_ExpensesExpectedToBeReimbursed_label_en-US" xlink:label="lab_inbx_ExpensesExpectedToBeReimbursed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses Expected to be Reimbursed</link:label>
    <link:label id="lab_inbx_ExpensesExpectedToBeReimbursed_documentation_en-US" xlink:label="lab_inbx_ExpensesExpectedToBeReimbursed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses Expected to be Reimbursed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ExpensesExpectedToBeReimbursed" xlink:href="inbx-20211231.xsd#inbx_ExpensesExpectedToBeReimbursed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ExpensesExpectedToBeReimbursed" xlink:to="lab_inbx_ExpensesExpectedToBeReimbursed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_9e69e581-9426-41dc-9748-6ab4bd909629_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2ee8f7c5-7f51-4132-92ef-728d62ba9da1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_89de40dd-03d0-4f03-bbe6-8710eb0a06be_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c66cdbaa-2edd-4a36-abb7-45b04f6abb4f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CostSharingAgreementMember_d19fbf83-3f0d-4ff8-a008-5411a2fc5129_terseLabel_en-US" xlink:label="lab_inbx_CostSharingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Sharing Agreement</link:label>
    <link:label id="lab_inbx_CostSharingAgreementMember_label_en-US" xlink:label="lab_inbx_CostSharingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Sharing Agreement [Member]</link:label>
    <link:label id="lab_inbx_CostSharingAgreementMember_documentation_en-US" xlink:label="lab_inbx_CostSharingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Sharing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CostSharingAgreementMember" xlink:href="inbx-20211231.xsd#inbx_CostSharingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CostSharingAgreementMember" xlink:to="lab_inbx_CostSharingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_bd44bf26-27fd-4d59-ab5a-7dfe9c1b446a_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4ec699a6-2b50-4755-93e7-473fcd2040d7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AtTheMarketOfferingCosts_93f30e8a-796b-4101-8c69-3c185ee6ad08_terseLabel_en-US" xlink:label="lab_inbx_AtTheMarketOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering costs</link:label>
    <link:label id="lab_inbx_AtTheMarketOfferingCosts_label_en-US" xlink:label="lab_inbx_AtTheMarketOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Costs</link:label>
    <link:label id="lab_inbx_AtTheMarketOfferingCosts_documentation_en-US" xlink:label="lab_inbx_AtTheMarketOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingCosts" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AtTheMarketOfferingCosts" xlink:to="lab_inbx_AtTheMarketOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_WarrantAndDerivativeLiabilitiesMember_45082d27-9a15-4f1f-9b76-4e9e13cfacb4_terseLabel_en-US" xlink:label="lab_inbx_WarrantAndDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant And Derivative Liabilities</link:label>
    <link:label id="lab_inbx_WarrantAndDerivativeLiabilitiesMember_label_en-US" xlink:label="lab_inbx_WarrantAndDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant And Derivative Liabilities [Member]</link:label>
    <link:label id="lab_inbx_WarrantAndDerivativeLiabilitiesMember_documentation_en-US" xlink:label="lab_inbx_WarrantAndDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant And Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantAndDerivativeLiabilitiesMember" xlink:href="inbx-20211231.xsd#inbx_WarrantAndDerivativeLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_WarrantAndDerivativeLiabilitiesMember" xlink:to="lab_inbx_WarrantAndDerivativeLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_2fd6f9e3-bc5c-4ee2-b88a-8724b1d40a93_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8132363-d802-4a6d-a581-b0700aa65e77_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_003c7f65-8836-4c5a-9cfc-ab808d410ec6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_fef5682b-f208-41e1-a577-a97bbc0c0c19_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_507e7522-d125-4601-8430-96aa618caaed_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including debt discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentAmendmentFee_105f0ddc-950e-487b-9301-e94452f37c86_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentAmendmentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time first amendment fee</link:label>
    <link:label id="lab_inbx_DebtInstrumentAmendmentFee_label_en-US" xlink:label="lab_inbx_DebtInstrumentAmendmentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amendment Fee</link:label>
    <link:label id="lab_inbx_DebtInstrumentAmendmentFee_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentAmendmentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amendment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentAmendmentFee" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentAmendmentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentAmendmentFee" xlink:to="lab_inbx_DebtInstrumentAmendmentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d053fbd-ac91-4336-adf6-c8bcad3895b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8a9a6ee8-4747-4bd2-a3b2-91c927f770eb_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_76dcfc1a-4db7-4285-812e-bfa2baf9f325_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_602e834b-84f2-454e-9dc6-f7b90017c03b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_60705ee4-cd85-4e3b-88de-e23653ca95b5_terseLabel_en-US" xlink:label="lab_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM offering costs included in accounts payable</link:label>
    <link:label id="lab_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Costs Included in Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Costs Included in Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lab_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_7b13baed-c997-4179-bcea-392724433be1_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_b77aad25-cbbe-45d5-b8df-0440c3bbe347_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge of amortized debt issuance costs to interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d02aa04f-4417-4a22-a423-9a7d1bcb729b_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementMilestonePaymentsReceivable_b3fb12df-0376-4d87-8f66-b814439bf890_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments receivable</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementMilestonePaymentsReceivable_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payments Receivable</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payments Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:to="lab_inbx_CollaborativeArrangementMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_b7519c05-de6f-4f69-95b6-b3fcda802c36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGGREGATE INTRINSIC VALUE, Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_17c5610f-f607-42bc-8e48-0f3de34ef155_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_c1f1559c-31e9-48f2-8679-c93120813f68_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_72fa4255-8aa3-4ad1-a04e-c0e962e8f1fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0c6d5af-b0b2-4631-92cd-648f28c5dce0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16dc30e6-9f3d-49df-8777-1de3b58c140e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_7b1a3661-8dac-4165-9cca-682ddac94631_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_30ce12a3-7ecf-4f6e-9230-6b3f0ef1315e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9e1abb37-233d-4486-84f8-d1032395d543_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_42771688-a62d-4e53-bc27-e94745208560_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bbabbed2-5218-4240-a55c-12b0bef61d8e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2020ConvertiblePromissoryNoteMember_2f4b0e9e-8558-4f4a-ad09-ed4900d2debb_terseLabel_en-US" xlink:label="lab_inbx_A2020ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible Note</link:label>
    <link:label id="lab_inbx_A2020ConvertiblePromissoryNoteMember_label_en-US" xlink:label="lab_inbx_A2020ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible Promissory Note [Member]</link:label>
    <link:label id="lab_inbx_A2020ConvertiblePromissoryNoteMember_documentation_en-US" xlink:label="lab_inbx_A2020ConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Convertible Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020ConvertiblePromissoryNoteMember" xlink:href="inbx-20211231.xsd#inbx_A2020ConvertiblePromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2020ConvertiblePromissoryNoteMember" xlink:to="lab_inbx_A2020ConvertiblePromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_9802b38c-b7e5-4a6d-b309-832f93ba6193_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_36feef2d-d594-487d-a62d-83092fb399c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_a1e6296d-5f29-4dcb-b34e-94086ae57232_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_18660c15-89b2-4e07-92a5-953c867f5bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementReceivablesFromRelatedParties_da61aef1-d6a9-4a5b-8ef8-204de27b6ccc_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementReceivablesFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from related parties</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementReceivablesFromRelatedParties_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementReceivablesFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Receivables from Related Parties</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementReceivablesFromRelatedParties_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementReceivablesFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Receivables from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementReceivablesFromRelatedParties" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementReceivablesFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementReceivablesFromRelatedParties" xlink:to="lab_inbx_CollaborativeArrangementReceivablesFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_99576b28-bc9b-4814-80b0-f90f78d77ccb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10a41a81-17f5-493d-a40e-c9df09f935fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6a312f69-cbf4-4f36-8d21-5cdb141056f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f1118dfe-2da6-4289-809f-994f13ae1ae2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares of common stock outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_ffdf2c3c-b835-4f96-986d-ca6c408f3962_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember_344ea3b3-cbde-4fb5-8fc3-f03ad375d2f1_terseLabel_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan June 2021 Amendment</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember_label_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan June 2021 Amendment [Member]</link:label>
    <link:label id="lab_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember_documentation_en-US" xlink:label="lab_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2020 Oxford Term Loan June 2021 Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanJune2021AmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember" xlink:to="lab_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7b6d3b39-c9ab-472e-abc0-8712d7ac1e2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_28dcc002-3563-4289-addb-709389ac7c4e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_9362c9df-759f-45ff-986a-77ae4ed90613_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_63d2fdef-38da-4c83-bd08-c22206de0dd0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_de4abd0d-b6fc-4042-87f3-4c5e5e35ce7e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_SaleOfStockCommonStockAuthorized_3538edde-7754-4dcd-8af1-a312817078c9_terseLabel_en-US" xlink:label="lab_inbx_SaleOfStockCommonStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock offering price</link:label>
    <link:label id="lab_inbx_SaleOfStockCommonStockAuthorized_label_en-US" xlink:label="lab_inbx_SaleOfStockCommonStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Common Stock, Authorized</link:label>
    <link:label id="lab_inbx_SaleOfStockCommonStockAuthorized_documentation_en-US" xlink:label="lab_inbx_SaleOfStockCommonStockAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Common Stock, Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleOfStockCommonStockAuthorized" xlink:href="inbx-20211231.xsd#inbx_SaleOfStockCommonStockAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_SaleOfStockCommonStockAuthorized" xlink:to="lab_inbx_SaleOfStockCommonStockAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_f171e96b-842d-4d28-ab21-30c8cabe23db_terseLabel_en-US" xlink:label="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current portion</link:label>
    <link:label id="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_label_en-US" xlink:label="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Contract With Customer, Liability, Non-Current</link:label>
    <link:label id="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_documentation_en-US" xlink:label="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Contract With Customer, Liability, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:href="inbx-20211231.xsd#inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:to="lab_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_8a85568b-e9b0-4abf-9d87-58432d1f54fe_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of principal amount for final payment</link:label>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_label_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</link:label>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:to="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5b7758d4-e777-4b87-9026-de29750b126f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee_193de591-6de5-4860-ac39-f48f60bd9813_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option extension fee</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Nonrefundable Option Extension Fee</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Nonrefundable Option Extension Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementNonrefundableOptionExtensionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee" xlink:to="lab_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_11bf7551-c649-4e0d-85f6-b8dd9b893418_terseLabel_en-US" xlink:label="lab_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities derecognized from agreements</link:label>
    <link:label id="lab_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_label_en-US" xlink:label="lab_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Derecognized During Period</link:label>
    <link:label id="lab_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_documentation_en-US" xlink:label="lab_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Derecognized During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:href="inbx-20211231.xsd#inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:to="lab_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_df4d72b1-dc4f-4100-b3d0-aeb72179b282_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_f847d599-7d1f-4b50-8a9a-9df0a9ab37fc_terseLabel_en-US" xlink:label="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Congressionally Directed Medical Research Program</link:label>
    <link:label id="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_label_en-US" xlink:label="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defense - Congressionally Directed Medical Research Program [Member]</link:label>
    <link:label id="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_documentation_en-US" xlink:label="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defense - Congressionally Directed Medical Research Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:to="lab_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_b1fa5c69-2e7f-47bf-9567-2570e9ba0360_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_f4c61535-cfc3-4a55-ace2-084fcbdc1a00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5c796619-dbb8-4b62-b8a4-b25a0e5bb634_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b212812-fd67-499f-9957-a958f74c64ad_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_13af105b-7f43-4335-b9c1-2d06a12cb71c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3198673f-9161-4ac5-8bf4-4db417b8ea67_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac4dccdd-53a7-4a95-81ec-9db80aa0871d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_605ff61f-e1f4-4899-bd3b-ed82719a8ff6_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of additional tranches</link:label>
    <link:label id="lab_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_label_en-US" xlink:label="lab_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Aggregate Principal Amount of Additional Tranches</link:label>
    <link:label id="lab_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Aggregate Principal Amount of Additional Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches" xlink:to="lab_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_ce6d14ff-06cd-437a-b44a-2ac7cdfc411c_terseLabel_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial base rent per month</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_label_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Initial Base Rent Expense Per Month</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_documentation_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Initial Base Rent Expense Per Month</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:href="inbx-20211231.xsd#inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:to="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_96e6afd0-98fe-44a6-aee9-df1345b7bdf2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d160d4a4-037c-4d14-8cac-744bc423ac60_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e690416f-8e8b-48d0-9041-5127b4f32919_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9d9b0935-c210-48a8-ba5b-0fcaf69033cf_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b9fe5c41-ff25-4453-b064-3be8fb351d94_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dc517d33-1abb-4475-94e6-f3020cc3fe78_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6c74f488-df85-4a5a-b102-2ae7b686ee96_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_763330fd-0af2-4c1f-ba77-ca8d4f03fc10_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_f082bf9b-93a7-4914-977c-a2151817282f_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_e300d315-77b9-4688-a24c-1d45c1d04283_terseLabel_en-US" xlink:label="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of License and Grant Revenue</link:label>
    <link:label id="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_label_en-US" xlink:label="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of License And Grant Revenue [Table Text Block]</link:label>
    <link:label id="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_documentation_en-US" xlink:label="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of License And Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:href="inbx-20211231.xsd#inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:to="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2020OxfordTermLoanAMember_23452bc6-ccd3-4d9d-9826-acc13cee9c84_terseLabel_en-US" xlink:label="lab_inbx_A2020OxfordTermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoanAMember_label_en-US" xlink:label="lab_inbx_A2020OxfordTermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loan A [Member]</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoanAMember_documentation_en-US" xlink:label="lab_inbx_A2020OxfordTermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loan A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoanAMember" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2020OxfordTermLoanAMember" xlink:to="lab_inbx_A2020OxfordTermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f4084317-b9e9-42fd-88f3-49a168855f87_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f123b60a-cd11-4a6a-a4e9-a6408e6aea76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5560cba3-9919-4f17-99fb-c07e6b21891f_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_00e2564d-f905-4956-b1d7-a288b1983075_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseAffiliateMember_5a1d8274-2164-43bf-b2fe-a2c53d513ad2_terseLabel_en-US" xlink:label="lab_inbx_LicenseAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee revenue, affiliates</link:label>
    <link:label id="lab_inbx_LicenseAffiliateMember_label_en-US" xlink:label="lab_inbx_LicenseAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Affiliate [Member]</link:label>
    <link:label id="lab_inbx_LicenseAffiliateMember_documentation_en-US" xlink:label="lab_inbx_LicenseAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAffiliateMember" xlink:href="inbx-20211231.xsd#inbx_LicenseAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseAffiliateMember" xlink:to="lab_inbx_LicenseAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_0e25d659-e9a1-41f5-8827-5092d8cae8cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_d1793ab3-d950-46e0-9396-5df510ba6f2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5fdd1c07-6e7e-479a-a8bf-5bc0723db853_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10d6cf0c-e938-436b-bed8-4e369d66a4db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_078d0408-5706-4fa1-b4a1-3f4f92da477d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_109bf139-e258-407e-aa14-58c4b2104815_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_dc338f95-1967-4f84-b7fa-a4e140492689_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3cb91c1c-ce01-494c-b1ed-770742751e9a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentNumberOfAdditionalTranches_6220476f-f1f0-4a78-a067-fd80fab70207_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentNumberOfAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional tranches</link:label>
    <link:label id="lab_inbx_DebtInstrumentNumberOfAdditionalTranches_label_en-US" xlink:label="lab_inbx_DebtInstrumentNumberOfAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Additional Tranches</link:label>
    <link:label id="lab_inbx_DebtInstrumentNumberOfAdditionalTranches_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentNumberOfAdditionalTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number of Additional Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfAdditionalTranches" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentNumberOfAdditionalTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentNumberOfAdditionalTranches" xlink:to="lab_inbx_DebtInstrumentNumberOfAdditionalTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_924e5275-4d16-4f5b-9e18-85f75bffdf44_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod_577d46d1-c863-4ce4-8003-4bf598a0198d_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equal payments of principal and interest period</link:label>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod_label_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period</link:label>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod" xlink:to="lab_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_81e0e544-152e-4524-bffb-f833a4ddf97f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_58d29ec7-1a43-46cb-8899-e3d182c930cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected income tax benefit at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_154ae703-d23b-4967-8de9-4056e44c4eed_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_014e37a7-67e7-475b-b564-d2e8ee6fda04_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2020OxfordTermLoanCMember_4589d5d3-fd29-4d3b-a5c0-8428d9e4de0e_terseLabel_en-US" xlink:label="lab_inbx_A2020OxfordTermLoanCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoanCMember_label_en-US" xlink:label="lab_inbx_A2020OxfordTermLoanCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loan C [Member]</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoanCMember_documentation_en-US" xlink:label="lab_inbx_A2020OxfordTermLoanCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Oxford Term Loan C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoanCMember" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoanCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2020OxfordTermLoanCMember" xlink:to="lab_inbx_A2020OxfordTermLoanCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LesseeOperatingLeaseAnnualEscalations_fbe1d461-7f3d-4ad4-ac9f-b43d849eb709_terseLabel_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual escalations</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseAnnualEscalations_label_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Escalations</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseAnnualEscalations_documentation_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Escalations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:href="inbx-20211231.xsd#inbx_LesseeOperatingLeaseAnnualEscalations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:to="lab_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_50f5ec61-8181-4f65-a748-592dd91dc236_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_38e58a54-75a6-4f74-a309-6b15c9fcfebc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_bdd421d0-2e1a-49bc-88fa-8d2363ba6074_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f75bf300-7d7d-42e0-beaa-94fd645a470d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_e85744aa-0ad7-42e1-b290-1eee081372b1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONVERTIBLE PROMISSORY NOTE</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LAVSummitLimitedMember_bdeaa301-3947-4a93-a13f-efd2f2703ab1_terseLabel_en-US" xlink:label="lab_inbx_LAVSummitLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LAV Summit Limited</link:label>
    <link:label id="lab_inbx_LAVSummitLimitedMember_label_en-US" xlink:label="lab_inbx_LAVSummitLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LAV Summit Limited [Member]</link:label>
    <link:label id="lab_inbx_LAVSummitLimitedMember_documentation_en-US" xlink:label="lab_inbx_LAVSummitLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LAV Summit Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LAVSummitLimitedMember" xlink:href="inbx-20211231.xsd#inbx_LAVSummitLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LAVSummitLimitedMember" xlink:to="lab_inbx_LAVSummitLimitedMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>inbx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8eb0955a-77e8-4ec9-9bdb-5f279743741e,g:91526847-18eb-416c-96d8-1d5c48d93616-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://inhibrx.com/role/Cover" xlink:type="simple" xlink:href="inbx-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5d6e57ab-ca0e-4490-95ff-ba8725dae89d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_DocumentType_5d6e57ab-ca0e-4490-95ff-ba8725dae89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c42e20f2-2047-4f05-bcd7-1e842ea2cd97" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_DocumentAnnualReport_c42e20f2-2047-4f05-bcd7-1e842ea2cd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c47f7f42-85c3-4dc7-982f-eb24d21bb514" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_DocumentPeriodEndDate_c47f7f42-85c3-4dc7-982f-eb24d21bb514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5261a1a4-935d-46ba-8d13-6f1ba2288cd9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_CurrentFiscalYearEndDate_5261a1a4-935d-46ba-8d13-6f1ba2288cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_90fc7b9d-e5aa-4263-b797-1567cac6558e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_DocumentTransitionReport_90fc7b9d-e5aa-4263-b797-1567cac6558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0bc36129-d222-44f3-8781-0b5ef496ae17" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityFileNumber_0bc36129-d222-44f3-8781-0b5ef496ae17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_94f83e39-474c-42c1-82fb-cc731786908d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityRegistrantName_94f83e39-474c-42c1-82fb-cc731786908d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b5ceb01d-805f-4731-9ad6-64a70f473c4a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b5ceb01d-805f-4731-9ad6-64a70f473c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_452ffde7-6535-494f-84a7-9b3dc8d325c6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityTaxIdentificationNumber_452ffde7-6535-494f-84a7-9b3dc8d325c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f847d08b-aa75-4a2f-9181-c6b3672c25e9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityAddressAddressLine1_f847d08b-aa75-4a2f-9181-c6b3672c25e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_df1a0234-03d9-45d6-a032-9326e534ddbe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityAddressAddressLine2_df1a0234-03d9-45d6-a032-9326e534ddbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f79960f8-76b7-4b7f-a5c0-baf9d265f6c7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityAddressCityOrTown_f79960f8-76b7-4b7f-a5c0-baf9d265f6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_778724e2-4581-46a8-b56f-177150245b8d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityAddressStateOrProvince_778724e2-4581-46a8-b56f-177150245b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fb902883-58a2-4f6b-ae9f-48f002a179c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityAddressPostalZipCode_fb902883-58a2-4f6b-ae9f-48f002a179c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b99e9e85-c60a-4e48-9a31-bb41244e2433" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_CityAreaCode_b99e9e85-c60a-4e48-9a31-bb41244e2433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5698e741-8855-4f88-9559-b3f05f699324" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_LocalPhoneNumber_5698e741-8855-4f88-9559-b3f05f699324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_22bf8788-423a-4bf9-b80f-546474f7150c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_Security12bTitle_22bf8788-423a-4bf9-b80f-546474f7150c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1f1f6276-bc05-47b7-8d74-49ae6d3be7e6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_TradingSymbol_1f1f6276-bc05-47b7-8d74-49ae6d3be7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5f33da4c-4cd2-4f12-9bab-4ffc98888f91" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_SecurityExchangeName_5f33da4c-4cd2-4f12-9bab-4ffc98888f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_fe739c67-c69a-4262-8ab2-4057eeb95b8a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_fe739c67-c69a-4262-8ab2-4057eeb95b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_751f9a55-1f34-474b-ae54-5d0fc574ffec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityVoluntaryFilers_751f9a55-1f34-474b-ae54-5d0fc574ffec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a3165a53-6b78-44c5-abcd-13f4ef223ef6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityCurrentReportingStatus_a3165a53-6b78-44c5-abcd-13f4ef223ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_db956ec4-f542-4495-b9db-862317008634" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityInteractiveDataCurrent_db956ec4-f542-4495-b9db-862317008634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_468ee6af-30c8-40bd-a555-7d2812f2cb53" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityFilerCategory_468ee6af-30c8-40bd-a555-7d2812f2cb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dab8b4bb-378a-4a8b-863c-86ed96713fbf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntitySmallBusiness_dab8b4bb-378a-4a8b-863c-86ed96713fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_22a9fc36-64a8-4f04-9ed8-796e2e191699" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityEmergingGrowthCompany_22a9fc36-64a8-4f04-9ed8-796e2e191699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1ccb9df1-3088-4c63-9727-bbfedc9afe43" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1ccb9df1-3088-4c63-9727-bbfedc9afe43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8b8edb2b-d768-424f-b30a-a445ef27be8c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityShellCompany_8b8edb2b-d768-424f-b30a-a445ef27be8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f2c9e01b-6cfc-48a0-8eb0-4fb43a4941c8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityPublicFloat_f2c9e01b-6cfc-48a0-8eb0-4fb43a4941c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e5d1e763-553e-4b24-8213-233ff7947de7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e5d1e763-553e-4b24-8213-233ff7947de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f06275ec-054e-489f-8414-d98cc9b13b73" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f06275ec-054e-489f-8414-d98cc9b13b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9274c65d-f1d5-4f7c-b2b8-7b884b8ef007" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_AmendmentFlag_9274c65d-f1d5-4f7c-b2b8-7b884b8ef007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_632893f6-b4e2-4fb8-b904-726b3ab68d6d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_EntityCentralIndexKey_632893f6-b4e2-4fb8-b904-726b3ab68d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2961e45a-df00-473c-8931-3d335edff5e7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_DocumentFiscalYearFocus_2961e45a-df00-473c-8931-3d335edff5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bceea77b-2c1c-45f2-b09b-52060b491c6b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e616ddf-5e2f-4dd9-9815-f7d3e9e9a647" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bceea77b-2c1c-45f2-b09b-52060b491c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/AuditInformation" xlink:type="simple" xlink:href="inbx-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AuditInformationAbstract_e479f4f5-8e36-430f-afdb-1692d5a97604" xlink:href="inbx-20211231.xsd#inbx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_08465e34-b62a-4577-af08-d445215e37dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_AuditInformationAbstract_e479f4f5-8e36-430f-afdb-1692d5a97604" xlink:to="loc_dei_AuditorFirmId_08465e34-b62a-4577-af08-d445215e37dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_112cb2c5-2521-4c9f-b82a-1d7485bb76ce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_AuditInformationAbstract_e479f4f5-8e36-430f-afdb-1692d5a97604" xlink:to="loc_dei_AuditorName_112cb2c5-2521-4c9f-b82a-1d7485bb76ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_ba805816-6bd6-4ed0-a53d-4aec9c6c876d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_AuditInformationAbstract_e479f4f5-8e36-430f-afdb-1692d5a97604" xlink:to="loc_dei_AuditorLocation_ba805816-6bd6-4ed0-a53d-4aec9c6c876d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9824b25c-6415-4ef0-a674-226978818c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3988b231-6d6a-42f2-aabc-09938411b1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9824b25c-6415-4ef0-a674-226978818c5e" xlink:to="loc_us-gaap_AssetsAbstract_3988b231-6d6a-42f2-aabc-09938411b1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5cb36097-6185-4bf6-bb21-32de272dca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3988b231-6d6a-42f2-aabc-09938411b1f4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5cb36097-6185-4bf6-bb21-32de272dca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69d3c87f-b679-4e77-97a0-b04122a104e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5cb36097-6185-4bf6-bb21-32de272dca7b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69d3c87f-b679-4e77-97a0-b04122a104e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f4a8e934-ee45-4621-8c60-3b2afbfb44b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5cb36097-6185-4bf6-bb21-32de272dca7b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f4a8e934-ee45-4621-8c60-3b2afbfb44b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_ef4c7772-10d1-4cfb-a32d-efc33d99fb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5cb36097-6185-4bf6-bb21-32de272dca7b" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_ef4c7772-10d1-4cfb-a32d-efc33d99fb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_afacbf05-ca8f-424d-b925-757a5d769764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5cb36097-6185-4bf6-bb21-32de272dca7b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_afacbf05-ca8f-424d-b925-757a5d769764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3a3943b2-4836-4749-878b-17aae111a198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5cb36097-6185-4bf6-bb21-32de272dca7b" xlink:to="loc_us-gaap_AssetsCurrent_3a3943b2-4836-4749-878b-17aae111a198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0c11db55-895a-4c3f-8f7b-902f0c17a616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3988b231-6d6a-42f2-aabc-09938411b1f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0c11db55-895a-4c3f-8f7b-902f0c17a616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_93da8115-feee-4785-ad9d-8f22effebab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3988b231-6d6a-42f2-aabc-09938411b1f4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_93da8115-feee-4785-ad9d-8f22effebab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b26b03ad-957c-484a-9179-5a3b81de3281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3988b231-6d6a-42f2-aabc-09938411b1f4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b26b03ad-957c-484a-9179-5a3b81de3281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bf9591e2-5b8d-4b57-bcdf-2c6b4d02d62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3988b231-6d6a-42f2-aabc-09938411b1f4" xlink:to="loc_us-gaap_Assets_bf9591e2-5b8d-4b57-bcdf-2c6b4d02d62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9824b25c-6415-4ef0-a674-226978818c5e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_aba74f8c-885d-4b0c-ad98-e7f043e6fd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_aba74f8c-885d-4b0c-ad98-e7f043e6fd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6e7c2c88-6e36-4ee3-b079-539deabfe697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_aba74f8c-885d-4b0c-ad98-e7f043e6fd0a" xlink:to="loc_us-gaap_AccountsPayableCurrent_6e7c2c88-6e36-4ee3-b079-539deabfe697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_24f8a981-2c15-45f2-a8b5-7b8d985ca072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_aba74f8c-885d-4b0c-ad98-e7f043e6fd0a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_24f8a981-2c15-45f2-a8b5-7b8d985ca072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4dfe37c6-9e01-4c82-af1e-cd357a3eb0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_aba74f8c-885d-4b0c-ad98-e7f043e6fd0a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4dfe37c6-9e01-4c82-af1e-cd357a3eb0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_24a7f822-8b35-4c34-a614-f1095696047b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_aba74f8c-885d-4b0c-ad98-e7f043e6fd0a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_24a7f822-8b35-4c34-a614-f1095696047b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2ae7d6d5-0fb2-40a5-a101-80e549586b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_aba74f8c-885d-4b0c-ad98-e7f043e6fd0a" xlink:to="loc_us-gaap_LiabilitiesCurrent_2ae7d6d5-0fb2-40a5-a101-80e549586b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_19e2be67-a019-45cf-ac0c-31745968e79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:to="loc_us-gaap_SecuredLongTermDebt_19e2be67-a019-45cf-ac0c-31745968e79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5558a31b-f00c-46a5-9909-a40d5a477347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5558a31b-f00c-46a5-9909-a40d5a477347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b714b888-4f2e-48a0-b804-20251c1dfc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b714b888-4f2e-48a0-b804-20251c1dfc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_140191e3-f93e-4120-98bd-744ba2df05e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_140191e3-f93e-4120-98bd-744ba2df05e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d6b884d4-6de4-47cc-bcf3-7b521412804b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:to="loc_us-gaap_Liabilities_d6b884d4-6de4-47cc-bcf3-7b521412804b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_16032aa3-6ed5-472b-a139-ad5c576ca276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:to="loc_us-gaap_CommitmentsAndContingencies_16032aa3-6ed5-472b-a139-ad5c576ca276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8cd3c27b-a798-481a-bbd0-580f8792bea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:to="loc_us-gaap_EquityAbstract_8cd3c27b-a798-481a-bbd0-580f8792bea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ffb83e46-5b75-4bba-ba49-02a5ffee7d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8cd3c27b-a798-481a-bbd0-580f8792bea7" xlink:to="loc_us-gaap_PreferredStockValue_ffb83e46-5b75-4bba-ba49-02a5ffee7d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_acefefaa-ecfe-4ad3-9e11-40dab8c164ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8cd3c27b-a798-481a-bbd0-580f8792bea7" xlink:to="loc_us-gaap_CommonStockValue_acefefaa-ecfe-4ad3-9e11-40dab8c164ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9db292e0-73aa-4f71-8cd3-78cbe42d3cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8cd3c27b-a798-481a-bbd0-580f8792bea7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9db292e0-73aa-4f71-8cd3-78cbe42d3cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0d9e890b-13d9-49c4-a2a5-f623b9aaf9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8cd3c27b-a798-481a-bbd0-580f8792bea7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0d9e890b-13d9-49c4-a2a5-f623b9aaf9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_29e11dd4-e509-4037-bc00-13e69ece1885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8cd3c27b-a798-481a-bbd0-580f8792bea7" xlink:to="loc_us-gaap_StockholdersEquity_29e11dd4-e509-4037-bc00-13e69ece1885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8619be45-ff9f-4a26-85de-cebd17e122e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91813587-69b8-42ff-a665-311a2a58e958" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8619be45-ff9f-4a26-85de-cebd17e122e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a3581dda-701e-47d5-a02c-fed19f843328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a9d2929b-4bb4-4f54-ae0d-ee5e252aaeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a3581dda-701e-47d5-a02c-fed19f843328" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a9d2929b-4bb4-4f54-ae0d-ee5e252aaeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a6f62c25-b228-4bcf-9669-658c3bf6c904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a3581dda-701e-47d5-a02c-fed19f843328" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a6f62c25-b228-4bcf-9669-658c3bf6c904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_bce8f38b-f390-4ec6-aa58-fa0b7c4fc0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a3581dda-701e-47d5-a02c-fed19f843328" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_bce8f38b-f390-4ec6-aa58-fa0b7c4fc0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_47b668e7-505b-4616-ab30-ba4b0de9883f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a3581dda-701e-47d5-a02c-fed19f843328" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_47b668e7-505b-4616-ab30-ba4b0de9883f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ccc36073-d86e-4006-98b4-3ed9ece84113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a3581dda-701e-47d5-a02c-fed19f843328" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ccc36073-d86e-4006-98b4-3ed9ece84113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3b00e89a-265b-49e9-88db-2dea7dc4259b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a3581dda-701e-47d5-a02c-fed19f843328" xlink:to="loc_us-gaap_CommonStockSharesIssued_3b00e89a-265b-49e9-88db-2dea7dc4259b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_452ebd03-ed2c-4a25-92ed-8806e8e10ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a3581dda-701e-47d5-a02c-fed19f843328" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_452ebd03-ed2c-4a25-92ed-8806e8e10ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_dd67b44f-2ebc-460d-9073-9389c79fccc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_69ccb20f-8063-4e58-b959-a4dd090558ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dd67b44f-2ebc-460d-9073-9389c79fccc1" xlink:to="loc_us-gaap_StatementTable_69ccb20f-8063-4e58-b959-a4dd090558ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d6bb2e6-07e6-447b-a4a8-64005691facc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_69ccb20f-8063-4e58-b959-a4dd090558ec" xlink:to="loc_srt_ProductOrServiceAxis_4d6bb2e6-07e6-447b-a4a8-64005691facc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e718c704-5055-4803-8dca-06c283e5b6c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4d6bb2e6-07e6-447b-a4a8-64005691facc" xlink:to="loc_srt_ProductsAndServicesDomain_e718c704-5055-4803-8dca-06c283e5b6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_477258cb-46e8-47a0-b5f7-0abba15a1f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e718c704-5055-4803-8dca-06c283e5b6c7" xlink:to="loc_us-gaap_LicenseMember_477258cb-46e8-47a0-b5f7-0abba15a1f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_0e65a262-d53f-4e73-aae7-6b6aeed84606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e718c704-5055-4803-8dca-06c283e5b6c7" xlink:to="loc_us-gaap_GrantMember_0e65a262-d53f-4e73-aae7-6b6aeed84606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_69ccb20f-8063-4e58-b959-a4dd090558ec" xlink:to="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_37ec8354-6300-4024-9975-e3ad879ecafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_RevenuesAbstract_37ec8354-6300-4024-9975-e3ad879ecafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_92909d3a-92c8-439c-a251-68b5bacc5c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_37ec8354-6300-4024-9975-e3ad879ecafc" xlink:to="loc_us-gaap_Revenues_92909d3a-92c8-439c-a251-68b5bacc5c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6f3759b0-e1b3-42d7-b6f4-27c5e920e9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6f3759b0-e1b3-42d7-b6f4-27c5e920e9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_923df297-e1a5-4b04-87f8-b31c8b75bc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f3759b0-e1b3-42d7-b6f4-27c5e920e9ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_923df297-e1a5-4b04-87f8-b31c8b75bc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0c73c70b-8c93-491f-8a33-a3d82e31bae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f3759b0-e1b3-42d7-b6f4-27c5e920e9ed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0c73c70b-8c93-491f-8a33-a3d82e31bae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8c54ae83-09a6-4b8b-a9ab-d786764f1d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6f3759b0-e1b3-42d7-b6f4-27c5e920e9ed" xlink:to="loc_us-gaap_OperatingExpenses_8c54ae83-09a6-4b8b-a9ab-d786764f1d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f7a44e15-47c0-4363-806c-ba9b67165e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_OperatingIncomeLoss_f7a44e15-47c0-4363-806c-ba9b67165e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d3160d74-867c-49a3-8b88-1f1d32f5467b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d3160d74-867c-49a3-8b88-1f1d32f5467b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_070aa8d7-30c5-43c0-a05f-a659df446c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_070aa8d7-30c5-43c0-a05f-a659df446c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_35785ce6-e8db-41bc-89f5-2a61bbbbcda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_35785ce6-e8db-41bc-89f5-2a61bbbbcda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ba227711-e997-4580-a754-724951a67ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ba227711-e997-4580-a754-724951a67ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_66756dc5-93ab-4b1e-a346-0a448bf69e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9877f12a-ff36-4bc8-a3fb-8047cc7f7fe8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_66756dc5-93ab-4b1e-a346-0a448bf69e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e0e33a1f-4f92-4a8e-a9f4-550753afd94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e0e33a1f-4f92-4a8e-a9f4-550753afd94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_741085b5-ba66-4630-8f69-9855c478aa26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_741085b5-ba66-4630-8f69-9855c478aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9e53eac9-3810-44d1-bfb4-8ffd12389a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9e53eac9-3810-44d1-bfb4-8ffd12389a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4d47c3f3-8d7f-4835-957e-a96ca1f408b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_ProfitLoss_4d47c3f3-8d7f-4835-957e-a96ca1f408b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_036c130b-1cb7-4cef-93fa-b8d56a832f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_EarningsPerShareBasic_036c130b-1cb7-4cef-93fa-b8d56a832f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f1b1e03f-a770-45aa-9f98-7e5c2671ab40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f1b1e03f-a770-45aa-9f98-7e5c2671ab40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_554d0629-0918-4fb8-b4b3-8fe4f1dc7183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_554d0629-0918-4fb8-b4b3-8fe4f1dc7183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b6e4b107-ee5e-4b17-a8c4-2e51db64ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_700baea6-21ee-4aa5-88b1-dc65577a01a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b6e4b107-ee5e-4b17-a8c4-2e51db64ca9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ac2fc7d0-be5c-45f2-820f-cb6279f31a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ac2fc7d0-be5c-45f2-820f-cb6279f31a11" xlink:to="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_258c4529-ff27-4c92-bdb2-1c2286a0ab40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_258c4529-ff27-4c92-bdb2-1c2286a0ab40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_72f4df31-1e9c-42a6-aa8b-98efdaa1d236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_258c4529-ff27-4c92-bdb2-1c2286a0ab40" xlink:to="loc_us-gaap_EquityComponentDomain_72f4df31-1e9c-42a6-aa8b-98efdaa1d236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f8c3c9bd-e8af-4eb5-a30d-39cd8d9cc695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_72f4df31-1e9c-42a6-aa8b-98efdaa1d236" xlink:to="loc_us-gaap_CommonStockMember_f8c3c9bd-e8af-4eb5-a30d-39cd8d9cc695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a55c3e4d-5281-4396-a4df-8a3e888631c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_72f4df31-1e9c-42a6-aa8b-98efdaa1d236" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a55c3e4d-5281-4396-a4df-8a3e888631c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_447f2caf-122d-4f02-af32-f1d3072a664e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_72f4df31-1e9c-42a6-aa8b-98efdaa1d236" xlink:to="loc_us-gaap_RetainedEarningsMember_447f2caf-122d-4f02-af32-f1d3072a664e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bea3cb2f-acb4-4499-b714-a2fa954557c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:to="loc_us-gaap_DebtInstrumentAxis_bea3cb2f-acb4-4499-b714-a2fa954557c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_510cdcd9-c9d5-4094-9c9b-d593289d3d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bea3cb2f-acb4-4499-b714-a2fa954557c2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_510cdcd9-c9d5-4094-9c9b-d593289d3d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_1304e05d-0c74-441a-a906-0c36532bf9e6" xlink:href="inbx-20211231.xsd#inbx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_510cdcd9-c9d5-4094-9c9b-d593289d3d90" xlink:to="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_1304e05d-0c74-441a-a906-0c36532bf9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019ConvertiblePromissoryNoteMember_16285351-c4e9-4dc3-8bd3-6fd7034afa57" xlink:href="inbx-20211231.xsd#inbx_A2019ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_510cdcd9-c9d5-4094-9c9b-d593289d3d90" xlink:to="loc_inbx_A2019ConvertiblePromissoryNoteMember_16285351-c4e9-4dc3-8bd3-6fd7034afa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020ConvertiblePromissoryNoteMember_d0f48a20-c775-472b-8701-a354fcba072f" xlink:href="inbx-20211231.xsd#inbx_A2020ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_510cdcd9-c9d5-4094-9c9b-d593289d3d90" xlink:to="loc_inbx_A2020ConvertiblePromissoryNoteMember_d0f48a20-c775-472b-8701-a354fcba072f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a55d5b58-62da-487c-9a1e-1c8cdf579420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a55d5b58-62da-487c-9a1e-1c8cdf579420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_18d6bc2c-eba8-4e5b-b30e-928f524036f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a55d5b58-62da-487c-9a1e-1c8cdf579420" xlink:to="loc_us-gaap_ClassOfStockDomain_18d6bc2c-eba8-4e5b-b30e-928f524036f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_b4c17553-9dcf-4ce2-8f22-43ed183eae6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_18d6bc2c-eba8-4e5b-b30e-928f524036f2" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_b4c17553-9dcf-4ce2-8f22-43ed183eae6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f646c514-010e-45d0-a59f-9e6a4593c363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f646c514-010e-45d0-a59f-9e6a4593c363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46b0574c-5791-4e68-bda4-cd1b5bcf2784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f646c514-010e-45d0-a59f-9e6a4593c363" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46b0574c-5791-4e68-bda4-cd1b5bcf2784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_16bdfb6e-69d4-40e1-b72b-47f19df1385f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46b0574c-5791-4e68-bda4-cd1b5bcf2784" xlink:to="loc_us-gaap_IPOMember_16bdfb6e-69d4-40e1-b72b-47f19df1385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7631eb49-7a85-4b28-a382-47a0161aa28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ca1c354d-0497-4f90-abe1-f8011d87d476" xlink:to="loc_us-gaap_StatementLineItems_7631eb49-7a85-4b28-a382-47a0161aa28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7631eb49-7a85-4b28-a382-47a0161aa28c" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7827d1de-6779-4110-99ba-74dd1b20a625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7827d1de-6779-4110-99ba-74dd1b20a625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_eb57d6d0-9aa4-4002-a659-388a2260d0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_eb57d6d0-9aa4-4002-a659-388a2260d0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_686189b6-72fe-437d-9655-39c27ef05456" xlink:href="inbx-20211231.xsd#inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:to="loc_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_686189b6-72fe-437d-9655-39c27ef05456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ea0b81aa-cf86-448d-a9d0-c45cfb472477" xlink:href="inbx-20211231.xsd#inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:to="loc_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ea0b81aa-cf86-448d-a9d0-c45cfb472477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_31e80012-89dd-4bff-b277-25f14f3a7ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_31e80012-89dd-4bff-b277-25f14f3a7ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4033c334-8aeb-4568-ad1f-f3d9971cc996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4f3b7bcc-1055-4dd3-baf4-96e8e263c010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4033c334-8aeb-4568-ad1f-f3d9971cc996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7631eb49-7a85-4b28-a382-47a0161aa28c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d7a51ac5-c6cb-439b-90a2-0311fbeeb1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d7a51ac5-c6cb-439b-90a2-0311fbeeb1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4309537d-0c62-4d49-9d88-c9eaa7746257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4309537d-0c62-4d49-9d88-c9eaa7746257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_368c429b-462b-4298-83fa-7880391fb5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_368c429b-462b-4298-83fa-7880391fb5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1b76afba-b47a-43f5-a84a-205bc7cf617a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1b76afba-b47a-43f5-a84a-205bc7cf617a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ca5100f-7fec-4e54-a36f-63afd0f152f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ca5100f-7fec-4e54-a36f-63afd0f152f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_36172810-15c2-4bdb-bd9b-bc254b78d989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_36172810-15c2-4bdb-bd9b-bc254b78d989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f0e0b052-94a8-45b8-83b5-63520f8e63b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f0e0b052-94a8-45b8-83b5-63520f8e63b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fbdc0a89-384f-4465-a938-26f47dbc55d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fbdc0a89-384f-4465-a938-26f47dbc55d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e58cd95f-4d5c-46f7-b25f-82761aa236f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e58cd95f-4d5c-46f7-b25f-82761aa236f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_7ceeb9cd-36a5-4ea3-a2ff-3d719b9b6555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_7ceeb9cd-36a5-4ea3-a2ff-3d719b9b6555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReversalOfUnamortizedBeneficialConversionFeature_6d0043f0-4433-41fd-b40e-6983a7bccc02" xlink:href="inbx-20211231.xsd#inbx_ReversalOfUnamortizedBeneficialConversionFeature"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_inbx_ReversalOfUnamortizedBeneficialConversionFeature_6d0043f0-4433-41fd-b40e-6983a7bccc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2fc876a2-b20c-472b-afd5-6e86131e767d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2fc876a2-b20c-472b-afd5-6e86131e767d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_54507c51-e2f5-4b50-91bf-8c4726034427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_NetIncomeLoss_54507c51-e2f5-4b50-91bf-8c4726034427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e6131eb4-926e-4ce0-8c9a-dd9dcec95e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e6131eb4-926e-4ce0-8c9a-dd9dcec95e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e07289c8-afcc-4761-83ed-2ca634031d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2dc7d6a5-58d8-484a-98f8-6cf2b9429a09" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e07289c8-afcc-4761-83ed-2ca634031d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="inbx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2d43d632-2e94-4013-87e6-6b28d70b79e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7c65133a-95e1-4bda-8619-f6ad0ecbfe7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2d43d632-2e94-4013-87e6-6b28d70b79e9" xlink:to="loc_us-gaap_StatementTable_7c65133a-95e1-4bda-8619-f6ad0ecbfe7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fef4c208-ff98-47e3-ac33-3450b33b68df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7c65133a-95e1-4bda-8619-f6ad0ecbfe7f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fef4c208-ff98-47e3-ac33-3450b33b68df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_062aa30a-242d-48f1-ac34-007c304430a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fef4c208-ff98-47e3-ac33-3450b33b68df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_062aa30a-242d-48f1-ac34-007c304430a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingMember_40bf2c32-2662-42cd-b22d-2ae065b0dc82" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_062aa30a-242d-48f1-ac34-007c304430a4" xlink:to="loc_inbx_AtTheMarketOfferingMember_40bf2c32-2662-42cd-b22d-2ae065b0dc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_9a12a388-ca92-4b27-ae4c-e84e69c23458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_062aa30a-242d-48f1-ac34-007c304430a4" xlink:to="loc_us-gaap_IPOMember_9a12a388-ca92-4b27-ae4c-e84e69c23458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a7825fb2-fd8a-41cc-8106-222a8756f02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7c65133a-95e1-4bda-8619-f6ad0ecbfe7f" xlink:to="loc_us-gaap_StatementLineItems_a7825fb2-fd8a-41cc-8106-222a8756f02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e890530-c298-4c27-a824-a494070589a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a7825fb2-fd8a-41cc-8106-222a8756f02c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e890530-c298-4c27-a824-a494070589a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e890530-c298-4c27-a824-a494070589a6" xlink:to="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_db39b653-7b76-4992-9eef-7d8c0ba476b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_db39b653-7b76-4992-9eef-7d8c0ba476b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7ef86e39-f497-42d2-b7d3-20515b5abfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7ef86e39-f497-42d2-b7d3-20515b5abfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cd8b511b-a45a-49dc-be65-00f41cfd3096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_ShareBasedCompensation_cd8b511b-a45a-49dc-be65-00f41cfd3096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NoncashOperatingLeaseExpense_8d1a818d-e6bf-4487-bee3-9dbcb284cbb7" xlink:href="inbx-20211231.xsd#inbx_NoncashOperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_inbx_NoncashOperatingLeaseExpense_8d1a818d-e6bf-4487-bee3-9dbcb284cbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3131fbc3-aa00-498c-89ef-4c9f22899dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3131fbc3-aa00-498c-89ef-4c9f22899dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_106fdc7d-9ceb-4afa-a3e9-09dabe6dd4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_106fdc7d-9ceb-4afa-a3e9-09dabe6dd4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_0c2d173b-4c7b-4a54-b8a9-28efb76380c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_0c2d173b-4c7b-4a54-b8a9-28efb76380c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ce20187-cfe9-4552-ba17-d2a1dead0fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ce20187-cfe9-4552-ba17-d2a1dead0fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1d649b12-a5b0-46a6-97df-91224fbcf4a6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d6f508bc-14d7-452d-8613-a5e4369f376b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d6f508bc-14d7-452d-8613-a5e4369f376b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_e08f3164-0d6c-4aa9-914a-c329bf75176e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_e08f3164-0d6c-4aa9-914a-c329bf75176e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a08cd79e-7e89-488a-92af-5b4e58dd01bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a08cd79e-7e89-488a-92af-5b4e58dd01bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1cc11db9-9e51-4b03-bfb6-591636ef1ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1cc11db9-9e51-4b03-bfb6-591636ef1ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_47f53525-ecd8-4962-8f6b-64b87d9e4cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_47f53525-ecd8-4962-8f6b-64b87d9e4cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_aed5afdc-8394-40fb-af34-58c53896558c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_aed5afdc-8394-40fb-af34-58c53896558c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_49cf1297-fe7a-4ce2-b44a-8e1073350ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_OperatingLeasePayments_49cf1297-fe7a-4ce2-b44a-8e1073350ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_8c9ad9a2-3fa5-4f82-aae8-f81f285f566d" xlink:href="inbx-20211231.xsd#inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent_8c9ad9a2-3fa5-4f82-aae8-f81f285f566d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_9b156d63-0a19-4da4-bb88-057234f58ce5" xlink:href="inbx-20211231.xsd#inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent_9b156d63-0a19-4da4-bb88-057234f58ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3dfafe30-3881-4ce3-b499-d05884792fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3dfafe30-3881-4ce3-b499-d05884792fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8895c9c8-e9fa-4d81-b15e-6b09b8e4f909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4aa25567-ca06-4b85-aabd-4d16123a9f4e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8895c9c8-e9fa-4d81-b15e-6b09b8e4f909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0c21bbdf-24a4-48c5-bc57-670ced3c9087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0c21bbdf-24a4-48c5-bc57-670ced3c9087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c08add23-90fa-4725-8fd2-ae6528189572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0c21bbdf-24a4-48c5-bc57-670ced3c9087" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c08add23-90fa-4725-8fd2-ae6528189572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94ff63a7-0cba-413e-a3cc-19962db519f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0c21bbdf-24a4-48c5-bc57-670ced3c9087" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94ff63a7-0cba-413e-a3cc-19962db519f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed13c4eb-f2a9-4644-850c-00e22d9d39e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed13c4eb-f2a9-4644-850c-00e22d9d39e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_55224935-6806-44ad-9eed-4012f881f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_55224935-6806-44ad-9eed-4012f881f8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_075dc6a4-1896-4043-9834-f2beafe692bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_075dc6a4-1896-4043-9834-f2beafe692bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_608aeb70-23a4-4e46-82c9-e4678b011a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_608aeb70-23a4-4e46-82c9-e4678b011a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_ae8a9f0e-6973-452d-926e-1f52c2b6c8d0" xlink:href="inbx-20211231.xsd#inbx_PaymentsOfDebtIssuanceCostsSecuredDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_ae8a9f0e-6973-452d-926e-1f52c2b6c8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ee09142d-3ea2-4efd-9172-2f779f770be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ee09142d-3ea2-4efd-9172-2f779f770be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_971ca757-8a43-4c4b-8b9a-4f6f13cf878a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_971ca757-8a43-4c4b-8b9a-4f6f13cf878a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_dbb19b0d-bb93-4233-9df7-129e3d6bf6be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_dbb19b0d-bb93-4233-9df7-129e3d6bf6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment_adbec624-70ad-4a0b-bdea-43efc50ffd8a" xlink:href="inbx-20211231.xsd#inbx_RepaymentsOfSecuredDebtFinalBalloonPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment_adbec624-70ad-4a0b-bdea-43efc50ffd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_5d7cbbba-d156-4455-b7e2-1d8237e53be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_5d7cbbba-d156-4455-b7e2-1d8237e53be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_b4191bfe-4db0-4a14-b450-efaff8ae6c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9cefe3c7-d36d-4bc9-9dc1-a23cb34b5a58" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_b4191bfe-4db0-4a14-b450-efaff8ae6c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6683e18f-4f12-47f5-9410-f60075e566c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6683e18f-4f12-47f5-9410-f60075e566c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6dc8d92d-07d7-4111-bc67-b1dce522797f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6dc8d92d-07d7-4111-bc67-b1dce522797f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eec69795-a38e-46b1-8d0c-e872cbaf85ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eec69795-a38e-46b1-8d0c-e872cbaf85ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6282111-69f0-459e-8d8e-62ec7bdb885f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6282111-69f0-459e-8d8e-62ec7bdb885f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_d3eccf07-cb34-409a-b3aa-291ea375289a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_d3eccf07-cb34-409a-b3aa-291ea375289a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1915ff8b-d402-4f1e-9e28-8d13c94bbc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d3eccf07-cb34-409a-b3aa-291ea375289a" xlink:to="loc_us-gaap_InterestPaidNet_1915ff8b-d402-4f1e-9e28-8d13c94bbc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_dc3b74db-f709-49ca-813a-709c3ca18214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d3eccf07-cb34-409a-b3aa-291ea375289a" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_dc3b74db-f709-49ca-813a-709c3ca18214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLoss_6e0956a9-aa0c-4fbf-8cd3-71261cefe0fe" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_10c97189-a0b7-4493-a897-c5f6e65734f9" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_10c97189-a0b7-4493-a897-c5f6e65734f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable_611e123f-f65c-467e-85ba-69bab881a741" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable_611e123f-f65c-467e-85ba-69bab881a741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CapitalExpendituresIncurredButNotYetPaidReleased_c3240331-b750-4295-a573-554afdcf0bb1" xlink:href="inbx-20211231.xsd#inbx_CapitalExpendituresIncurredButNotYetPaidReleased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_CapitalExpendituresIncurredButNotYetPaidReleased_c3240331-b750-4295-a573-554afdcf0bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_4224b8b2-e57f-4fcf-a542-bb2e92cee8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_4224b8b2-e57f-4fcf-a542-bb2e92cee8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_00c690b7-2b69-4a38-9ef6-81b0a6ecacd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_00c690b7-2b69-4a38-9ef6-81b0a6ecacd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_3df9f593-b1c4-4d36-9d0d-d875459a459a" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature_3df9f593-b1c4-4d36-9d0d-d875459a459a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4ac8354a-6fe4-4b70-850e-2dfbd5fe9d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4ac8354a-6fe4-4b70-850e-2dfbd5fe9d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_da8af555-e576-419a-ad16-5c4ba884a935" xlink:href="inbx-20211231.xsd#inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred_da8af555-e576-419a-ad16-5c4ba884a935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NonCashEstablishmentOfEquityMethodInvestment_b5fce2c6-4162-423d-b6ae-96654d7cfef7" xlink:href="inbx-20211231.xsd#inbx_NonCashEstablishmentOfEquityMethodInvestment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_NonCashEstablishmentOfEquityMethodInvestment_b5fce2c6-4162-423d-b6ae-96654d7cfef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReclassificationOfWarrantLiabilitiesToEquity_dc67ab2a-85dc-4c3f-ae04-37596d62664e" xlink:href="inbx-20211231.xsd#inbx_ReclassificationOfWarrantLiabilitiesToEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_ReclassificationOfWarrantLiabilitiesToEquity_dc67ab2a-85dc-4c3f-ae04-37596d62664e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_049fbd59-a988-4f10-a0a5-6736d8e0ea8f" xlink:href="inbx-20211231.xsd#inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_61de0159-0460-422e-98d5-793d9f14afa7" xlink:to="loc_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_049fbd59-a988-4f10-a0a5-6736d8e0ea8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36804a4e-9607-4fd1-903d-137de6746c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_cb47e226-2d28-49c0-b0ba-5936d8e06b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36804a4e-9607-4fd1-903d-137de6746c92" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_cb47e226-2d28-49c0-b0ba-5936d8e06b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f7e4a9a2-046c-44ac-97ee-9a6740ff9f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f7e4a9a2-046c-44ac-97ee-9a6740ff9f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_868156c8-81e9-4ee9-83c1-c1f6bbeeeb47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_868156c8-81e9-4ee9-83c1-c1f6bbeeeb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LiquidityPolicyTextBlock_f1989611-e449-4bb5-a58a-f4f2b8c23180" xlink:href="inbx-20211231.xsd#inbx_LiquidityPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_inbx_LiquidityPolicyTextBlock_f1989611-e449-4bb5-a58a-f4f2b8c23180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_dff3e36f-f2f4-43e2-bbfb-d0aec0ca71ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_UseOfEstimates_dff3e36f-f2f4-43e2-bbfb-d0aec0ca71ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_101054a2-b537-4747-987a-98ff207426d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_101054a2-b537-4747-987a-98ff207426d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_910be0de-64ab-40f7-af36-56ea2eace60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_910be0de-64ab-40f7-af36-56ea2eace60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_fbafdf14-e4af-423a-9e1b-86e0aa5a9db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_fbafdf14-e4af-423a-9e1b-86e0aa5a9db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_81ae4cc2-229b-466b-a94f-af591d33a808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_81ae4cc2-229b-466b-a94f-af591d33a808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_821ab67d-6b22-4323-8571-269cc2d5ab22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_821ab67d-6b22-4323-8571-269cc2d5ab22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_97f42ce9-6adb-4d73-91c2-24610132d28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_97f42ce9-6adb-4d73-91c2-24610132d28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_86f885de-63d9-4213-8038-44045dfea3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_86f885de-63d9-4213-8038-44045dfea3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_1866b027-b416-45c6-a97b-7964d8178561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_1866b027-b416-45c6-a97b-7964d8178561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_71f6046f-c34c-4dbf-b976-6e0c4cad70f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_71f6046f-c34c-4dbf-b976-6e0c4cad70f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantLiabilitiesPolicyTextBlock_c7c78b68-c56a-4021-bc8f-47b406d56acd" xlink:href="inbx-20211231.xsd#inbx_WarrantLiabilitiesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_inbx_WarrantLiabilitiesPolicyTextBlock_c7c78b68-c56a-4021-bc8f-47b406d56acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e14322f9-a67e-4a2e-8fc1-7dd21899647e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e14322f9-a67e-4a2e-8fc1-7dd21899647e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_72a7d80c-aea3-45d7-9e2e-72a49ed8f431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_72a7d80c-aea3-45d7-9e2e-72a49ed8f431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_5c474335-5b8f-4cc8-98de-ab7d6a5a4364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_5c474335-5b8f-4cc8-98de-ab7d6a5a4364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4ab437e6-0cc1-41f9-8d03-961285f9a12f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4ab437e6-0cc1-41f9-8d03-961285f9a12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_961aa58f-0161-42dd-a3e2-d5a10f4d5ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_961aa58f-0161-42dd-a3e2-d5a10f4d5ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_89612e1f-e5d6-4b4e-8fd7-e13c597d0a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_89612e1f-e5d6-4b4e-8fd7-e13c597d0a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8711a981-d0bb-45b2-8b58-44188e484d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8711a981-d0bb-45b2-8b58-44188e484d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_30294f8e-d1b3-4b31-a2fa-e608a59a1bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_30294f8e-d1b3-4b31-a2fa-e608a59a1bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3a7ab100-1d6e-4ab9-9975-b7cc7bb1d1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3a7ab100-1d6e-4ab9-9975-b7cc7bb1d1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fe5de1af-dc5e-46a4-afac-7d397723d303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83046f6b-1325-4594-8323-6ec7ac30122e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fe5de1af-dc5e-46a4-afac-7d397723d303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f00f43c1-5862-4557-9b5a-2fcb5fe43999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_938692d2-99c2-4bb5-ac2d-310c741a44bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f00f43c1-5862-4557-9b5a-2fcb5fe43999" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_938692d2-99c2-4bb5-ac2d-310c741a44bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_325f2201-c6c1-4194-a925-498087199794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f00f43c1-5862-4557-9b5a-2fcb5fe43999" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_325f2201-c6c1-4194-a925-498087199794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1105b28e-ae8e-4787-8090-5431dc46785c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1105b28e-ae8e-4787-8090-5431dc46785c" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0bc27f0d-70e6-4788-9127-4d8f42010eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0bc27f0d-70e6-4788-9127-4d8f42010eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e16b4cf9-b41f-4347-9d64-f186afb831f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0bc27f0d-70e6-4788-9127-4d8f42010eea" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e16b4cf9-b41f-4347-9d64-f186afb831f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_69f31764-3ab8-44e1-ab57-e5e5089e7a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e16b4cf9-b41f-4347-9d64-f186afb831f3" xlink:to="loc_us-gaap_IPOMember_69f31764-3ab8-44e1-ab57-e5e5089e7a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2fbf1829-8a93-46f4-91ac-8602fd261315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_DebtInstrumentAxis_2fbf1829-8a93-46f4-91ac-8602fd261315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_afd02317-3846-45a8-8d85-f42da5926739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fbf1829-8a93-46f4-91ac-8602fd261315" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_afd02317-3846-45a8-8d85-f42da5926739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_8405dbd4-367e-4e3c-a608-484a3e10fe8e" xlink:href="inbx-20211231.xsd#inbx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_afd02317-3846-45a8-8d85-f42da5926739" xlink:to="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_8405dbd4-367e-4e3c-a608-484a3e10fe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bd2f7c25-ff19-4582-98c7-71212aeef532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bd2f7c25-ff19-4582-98c7-71212aeef532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ee52294-ea6d-4cfe-b108-4869eaa23218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd2f7c25-ff19-4582-98c7-71212aeef532" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ee52294-ea6d-4cfe-b108-4869eaa23218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_73bba405-c298-4b58-b5fe-51c3d5c89c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2ee52294-ea6d-4cfe-b108-4869eaa23218" xlink:to="loc_us-gaap_ConvertibleDebtMember_73bba405-c298-4b58-b5fe-51c3d5c89c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c2844e9e-5018-49cc-b760-609da7664b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c2844e9e-5018-49cc-b760-609da7664b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca72defe-443b-42d5-bfef-d9f8725dd106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2844e9e-5018-49cc-b760-609da7664b0c" xlink:to="loc_us-gaap_ClassOfStockDomain_ca72defe-443b-42d5-bfef-d9f8725dd106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_be9361e1-378a-48b1-8f33-ad75decadce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ca72defe-443b-42d5-bfef-d9f8725dd106" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_be9361e1-378a-48b1-8f33-ad75decadce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_17d5693b-c421-407a-9e37-043ce0a1e0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_17d5693b-c421-407a-9e37-043ce0a1e0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c326117-fcfd-4643-ba5e-b0ccf266d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17d5693b-c421-407a-9e37-043ce0a1e0fa" xlink:to="loc_us-gaap_EquityComponentDomain_9c326117-fcfd-4643-ba5e-b0ccf266d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_12b9e9b5-690f-4c68-9abe-f741fc03fbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9c326117-fcfd-4643-ba5e-b0ccf266d7ea" xlink:to="loc_us-gaap_CommonStockMember_12b9e9b5-690f-4c68-9abe-f741fc03fbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_261c946f-37ea-4a4f-81a6-b8c17c01b116" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f72a1a1e-bda3-4bc0-9854-bc07a2797eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f72a1a1e-bda3-4bc0-9854-bc07a2797eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_279db910-8456-4b6e-a708-64c20dc98b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_279db910-8456-4b6e-a708-64c20dc98b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5f6183e9-e640-4f88-8808-2ca6eb8c9adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5f6183e9-e640-4f88-8808-2ca6eb8c9adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_44335f41-fed2-426f-908d-37450b7a6175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_44335f41-fed2-426f-908d-37450b7a6175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d743e344-79cd-4181-99dd-80690bf7a17a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d743e344-79cd-4181-99dd-80690bf7a17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_eff3e067-5d31-4700-b66e-59f6aa81d330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_eff3e067-5d31-4700-b66e-59f6aa81d330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_33b70994-50e7-4117-a70a-f13517e43ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_33b70994-50e7-4117-a70a-f13517e43ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4bfc67cb-85bf-4911-b49e-0bb7967578c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2f4f1808-463b-4ae3-b6a6-edf99ac6389a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4bfc67cb-85bf-4911-b49e-0bb7967578c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b85768cb-e4d8-472a-aec3-4aaf17b9bb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b85768cb-e4d8-472a-aec3-4aaf17b9bb97" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ae6c9f9-bbbd-45a0-9e7a-cfbce543fbda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_srt_RangeAxis_9ae6c9f9-bbbd-45a0-9e7a-cfbce543fbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_129671d7-0c02-4afb-a17c-b71ffa7777f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9ae6c9f9-bbbd-45a0-9e7a-cfbce543fbda" xlink:to="loc_srt_RangeMember_129671d7-0c02-4afb-a17c-b71ffa7777f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a7695830-e36f-4ce4-b037-2ca83b19caf4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_129671d7-0c02-4afb-a17c-b71ffa7777f5" xlink:to="loc_srt_MinimumMember_a7695830-e36f-4ce4-b037-2ca83b19caf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e5191dce-2659-4c5f-bed1-b0e3ee882867" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_129671d7-0c02-4afb-a17c-b71ffa7777f5" xlink:to="loc_srt_MaximumMember_e5191dce-2659-4c5f-bed1-b0e3ee882867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5f6ba61-d4b8-4f10-aa09-88fe1648795d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5f6ba61-d4b8-4f10-aa09-88fe1648795d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a8352b0-e51f-41e8-91bc-db2cd263ec32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5f6ba61-d4b8-4f10-aa09-88fe1648795d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a8352b0-e51f-41e8-91bc-db2cd263ec32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_628eef3e-cafe-48ca-af9c-f8a82d738780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a8352b0-e51f-41e8-91bc-db2cd263ec32" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_628eef3e-cafe-48ca-af9c-f8a82d738780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c81580ff-2f23-46d6-9eaf-1f2fafc263d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a8352b0-e51f-41e8-91bc-db2cd263ec32" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c81580ff-2f23-46d6-9eaf-1f2fafc263d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9e879451-c0a7-4c0f-8f2b-a725163e9514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a8352b0-e51f-41e8-91bc-db2cd263ec32" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9e879451-c0a7-4c0f-8f2b-a725163e9514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ac1d3f0-74e4-46b4-9e61-8d9aa6e6b2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ac1d3f0-74e4-46b4-9e61-8d9aa6e6b2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7eea0377-5e2b-472f-9378-0d5c9ac9ae2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7ac1d3f0-74e4-46b4-9e61-8d9aa6e6b2fa" xlink:to="loc_us-gaap_RelatedPartyDomain_7eea0377-5e2b-472f-9378-0d5c9ac9ae2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_050d5c9f-6d51-45ee-9983-916571bd5741" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7eea0377-5e2b-472f-9378-0d5c9ac9ae2c" xlink:to="loc_srt_AffiliatedEntityMember_050d5c9f-6d51-45ee-9983-916571bd5741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7583e5f3-17f5-4d74-a535-712d7012b898" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_srt_CounterpartyNameAxis_7583e5f3-17f5-4d74-a535-712d7012b898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aa4fcad-3d9f-4dee-bb9e-f824647a9ea9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7583e5f3-17f5-4d74-a535-712d7012b898" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aa4fcad-3d9f-4dee-bb9e-f824647a9ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WuXiBiologicsHealthcareVentureMember_8c5ce4b0-00a5-4483-9532-7b042fb57cea" xlink:href="inbx-20211231.xsd#inbx_WuXiBiologicsHealthcareVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7aa4fcad-3d9f-4dee-bb9e-f824647a9ea9" xlink:to="loc_inbx_WuXiBiologicsHealthcareVentureMember_8c5ce4b0-00a5-4483-9532-7b042fb57cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4315960-455e-4f25-bafb-1c0c0fc9c38c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4315960-455e-4f25-bafb-1c0c0fc9c38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6aecf370-df9d-4f2d-8a3e-2609d230ea27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a4315960-455e-4f25-bafb-1c0c0fc9c38c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6aecf370-df9d-4f2d-8a3e-2609d230ea27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember_f9001bbf-251d-44bf-9950-70b6af6a41a6" xlink:href="inbx-20211231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6aecf370-df9d-4f2d-8a3e-2609d230ea27" xlink:to="loc_inbx_PhylaxisBioScienceLLCMember_f9001bbf-251d-44bf-9950-70b6af6a41a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a2d0cbd1-129a-4af3-9fa4-4ebda681d1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_DebtInstrumentAxis_a2d0cbd1-129a-4af3-9fa4-4ebda681d1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_afccf5db-4d84-4804-81fb-f129071d4690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a2d0cbd1-129a-4af3-9fa4-4ebda681d1ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_afccf5db-4d84-4804-81fb-f129071d4690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaycheckProtectionProgramCARESActMember_5b196d04-ce14-4d23-b667-c1378755adfb" xlink:href="inbx-20211231.xsd#inbx_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_afccf5db-4d84-4804-81fb-f129071d4690" xlink:to="loc_inbx_PaycheckProtectionProgramCARESActMember_5b196d04-ce14-4d23-b667-c1378755adfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_6af92d03-27c9-46e9-8663-a788eba6d358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_6af92d03-27c9-46e9-8663-a788eba6d358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_d37219e5-c85c-44f4-bcd2-a9b0182f1bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6af92d03-27c9-46e9-8663-a788eba6d358" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_d37219e5-c85c-44f4-bcd2-a9b0182f1bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_24e9b905-0d91-4c7b-af1e-4a5c8d09da5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_d37219e5-c85c-44f4-bcd2-a9b0182f1bb5" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_24e9b905-0d91-4c7b-af1e-4a5c8d09da5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e8d6b425-df04-4f0e-8011-bff691030e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e8d6b425-df04-4f0e-8011-bff691030e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9fd223f-b3ca-4d3e-b0d1-f81730c2751d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e8d6b425-df04-4f0e-8011-bff691030e13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9fd223f-b3ca-4d3e-b0d1-f81730c2751d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SalesAgreementMember_1c2071aa-8240-48d2-b422-db88e66621e1" xlink:href="inbx-20211231.xsd#inbx_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c9fd223f-b3ca-4d3e-b0d1-f81730c2751d" xlink:to="loc_inbx_SalesAgreementMember_1c2071aa-8240-48d2-b422-db88e66621e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58050c54-d7d8-421c-b1b9-6699d483b4d6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1860b3cb-5da8-4eb9-b97e-8401e398065f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1860b3cb-5da8-4eb9-b97e-8401e398065f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8154eb18-c405-4d0f-9eb2-c65c3a9b6169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8154eb18-c405-4d0f-9eb2-c65c3a9b6169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6fcf7dab-e7b7-4c6d-82e9-476c57c9c2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6fcf7dab-e7b7-4c6d-82e9-476c57c9c2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleOfStockCommonStockAuthorized_df0f37c6-1586-4a75-ad35-5d29606e75ab" xlink:href="inbx-20211231.xsd#inbx_SaleOfStockCommonStockAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_SaleOfStockCommonStockAuthorized_df0f37c6-1586-4a75-ad35-5d29606e75ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleOfStockSharesCommonStockSold_ea80a444-59ef-459f-96e9-4b3d1151ce2d" xlink:href="inbx-20211231.xsd#inbx_SaleOfStockSharesCommonStockSold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_SaleOfStockSharesCommonStockSold_ea80a444-59ef-459f-96e9-4b3d1151ce2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05edf5fd-1e9b-4eb2-a3df-7ef024450bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05edf5fd-1e9b-4eb2-a3df-7ef024450bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_a21ac77d-ce65-410b-b9cc-323aba79e061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_a21ac77d-ce65-410b-b9cc-323aba79e061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DeferredFederalPayrollTaxesCARESAct_c8c2e334-5a5e-4ae3-8de6-8754a89decbd" xlink:href="inbx-20211231.xsd#inbx_DeferredFederalPayrollTaxesCARESAct"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_DeferredFederalPayrollTaxesCARESAct_c8c2e334-5a5e-4ae3-8de6-8754a89decbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e09d86cf-15bd-4def-971a-e77bacbd47f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e09d86cf-15bd-4def-971a-e77bacbd47f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementTerm_4612260e-3ee7-42e7-a18d-fc3f1b2d2c5a" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_CollaborativeArrangementTerm_4612260e-3ee7-42e7-a18d-fc3f1b2d2c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fc924ed7-ea8d-4ccd-a762-ff288b54f165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fc924ed7-ea8d-4ccd-a762-ff288b54f165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NumberOfOperatingLeasesHeld_589f5df2-d548-429f-b707-176af3655210" xlink:href="inbx-20211231.xsd#inbx_NumberOfOperatingLeasesHeld"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_NumberOfOperatingLeasesHeld_589f5df2-d548-429f-b707-176af3655210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a4b1f3e4-72ef-4eb8-905e-61cfaaa37337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a4b1f3e4-72ef-4eb8-905e-61cfaaa37337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d88d2c53-3199-4a49-8021-690249772f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_EquityMethodInvestments_d88d2c53-3199-4a49-8021-690249772f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering_e1e9ee82-15c4-4bec-bc35-a150dc416837" xlink:href="inbx-20211231.xsd#inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering_e1e9ee82-15c4-4bec-bc35-a150dc416837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_9c2fdccb-4741-495e-9d0b-d5cd53f01b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_DeferredOfferingCosts_9c2fdccb-4741-495e-9d0b-d5cd53f01b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_18960330-773f-49cf-ace5-45232a67e1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0bd7f869-8795-4c88-badf-bc5811303dbd" xlink:to="loc_us-gaap_NumberOfOperatingSegments_18960330-773f-49cf-ace5-45232a67e1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_219ce53f-c7ca-45a4-8aed-cc2aa6f61675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3c296c63-54b2-4532-b222-5717e57b8ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_219ce53f-c7ca-45a4-8aed-cc2aa6f61675" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3c296c63-54b2-4532-b222-5717e57b8ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39e0ed0a-b840-477d-b5eb-f0896b54a84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3c296c63-54b2-4532-b222-5717e57b8ecb" xlink:to="loc_us-gaap_DebtInstrumentAxis_39e0ed0a-b840-477d-b5eb-f0896b54a84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f5df0be6-d304-4237-89e6-3273c2ad2022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_39e0ed0a-b840-477d-b5eb-f0896b54a84b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f5df0be6-d304-4237-89e6-3273c2ad2022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020ConvertiblePromissoryNoteMember_4ad7510c-c9c7-4092-889d-4cf384c0ae9b" xlink:href="inbx-20211231.xsd#inbx_A2020ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5df0be6-d304-4237-89e6-3273c2ad2022" xlink:to="loc_inbx_A2020ConvertiblePromissoryNoteMember_4ad7510c-c9c7-4092-889d-4cf384c0ae9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_7eda5939-a26c-4839-98bd-3a439874e664" xlink:href="inbx-20211231.xsd#inbx_A2019And2020ConvertiblePromissoryNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5df0be6-d304-4237-89e6-3273c2ad2022" xlink:to="loc_inbx_A2019And2020ConvertiblePromissoryNotesMember_7eda5939-a26c-4839-98bd-3a439874e664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_348fcc08-10a4-4880-b4f5-dd0e8322d527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3c296c63-54b2-4532-b222-5717e57b8ecb" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_348fcc08-10a4-4880-b4f5-dd0e8322d527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0573d5f9-6792-49e8-8fc7-b2d9249b6dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_348fcc08-10a4-4880-b4f5-dd0e8322d527" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0573d5f9-6792-49e8-8fc7-b2d9249b6dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantAndDerivativeLiabilitiesMember_8ece5f87-0b99-4dd9-8608-ec684cccad7e" xlink:href="inbx-20211231.xsd#inbx_WarrantAndDerivativeLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0573d5f9-6792-49e8-8fc7-b2d9249b6dfb" xlink:to="loc_inbx_WarrantAndDerivativeLiabilitiesMember_8ece5f87-0b99-4dd9-8608-ec684cccad7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMember_7ecad716-644e-4cb6-a235-e2d88d65f3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0573d5f9-6792-49e8-8fc7-b2d9249b6dfb" xlink:to="loc_us-gaap_DerivativeMember_7ecad716-644e-4cb6-a235-e2d88d65f3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1a1e524d-27d8-4a90-b6b9-5449fd80c8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0573d5f9-6792-49e8-8fc7-b2d9249b6dfb" xlink:to="loc_us-gaap_WarrantMember_1a1e524d-27d8-4a90-b6b9-5449fd80c8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b75cf2a0-6f6c-4b58-84d6-3b08e719897f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3c296c63-54b2-4532-b222-5717e57b8ecb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b75cf2a0-6f6c-4b58-84d6-3b08e719897f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b75cf2a0-6f6c-4b58-84d6-3b08e719897f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_984f5d0f-02fc-48e5-9e65-748e84841f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_984f5d0f-02fc-48e5-9e65-748e84841f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_05667c7f-a390-4a62-afff-812a4cabd6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_05667c7f-a390-4a62-afff-812a4cabd6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ccaf14f6-b7a4-46a9-807c-d74dfec6ff11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ccaf14f6-b7a4-46a9-807c-d74dfec6ff11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_93278ff7-0776-4343-b76f-1263de74927c" xlink:href="inbx-20211231.xsd#inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:to="loc_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_93278ff7-0776-4343-b76f-1263de74927c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5ae50832-96c6-4274-8f3a-9451f83a8ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_edaa541d-eac9-435f-a2aa-1b37c88062aa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5ae50832-96c6-4274-8f3a-9451f83a8ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f02c2417-d12a-4924-9714-2e1473b00697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3853d0e0-b286-4292-91aa-581fc0255632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f02c2417-d12a-4924-9714-2e1473b00697" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3853d0e0-b286-4292-91aa-581fc0255632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a67f1447-1186-48f2-aeba-490ab6d7491c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3853d0e0-b286-4292-91aa-581fc0255632" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a67f1447-1186-48f2-aeba-490ab6d7491c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b69ffbe5-d4db-4bcb-9d36-175db23c92dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a67f1447-1186-48f2-aeba-490ab6d7491c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b69ffbe5-d4db-4bcb-9d36-175db23c92dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a38fab4a-722c-4c09-bb20-a1dc5d439b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b69ffbe5-d4db-4bcb-9d36-175db23c92dd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a38fab4a-722c-4c09-bb20-a1dc5d439b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_04e64ab6-380d-448c-9be1-3ab6873b1994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b69ffbe5-d4db-4bcb-9d36-175db23c92dd" xlink:to="loc_us-gaap_WarrantMember_04e64ab6-380d-448c-9be1-3ab6873b1994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc75adc3-eaea-4742-922f-be38160c06eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3853d0e0-b286-4292-91aa-581fc0255632" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc75adc3-eaea-4742-922f-be38160c06eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bd704507-b10b-442e-a520-0259a55b4175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc75adc3-eaea-4742-922f-be38160c06eb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bd704507-b10b-442e-a520-0259a55b4175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATION"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8bcd7e0-6014-405b-b225-838e2c1d7169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_fd64c6a4-9869-4b3e-8901-68426cbb6d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8bcd7e0-6014-405b-b225-838e2c1d7169" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_fd64c6a4-9869-4b3e-8901-68426cbb6d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20efd357-5c03-40fe-aa8b-0ba549e2dcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_a10a1242-862d-4949-a8da-aa4771a627e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20efd357-5c03-40fe-aa8b-0ba549e2dcd2" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_a10a1242-862d-4949-a8da-aa4771a627e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_908727fc-d3e7-46de-be45-5133480cc7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20efd357-5c03-40fe-aa8b-0ba549e2dcd2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_908727fc-d3e7-46de-be45-5133480cc7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_36cb6015-9643-4b71-ac66-bd2cbab92e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20efd357-5c03-40fe-aa8b-0ba549e2dcd2" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_36cb6015-9643-4b71-ac66-bd2cbab92e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df138f09-fe69-4912-b400-0f24578f732e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_9f108413-ba20-4cbb-8e5a-b7475cd5527e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df138f09-fe69-4912-b400-0f24578f732e" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_9f108413-ba20-4cbb-8e5a-b7475cd5527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5f81d3e0-22da-45fd-9fa9-3edfc45829d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df138f09-fe69-4912-b400-0f24578f732e" xlink:to="loc_us-gaap_OtherAssetsCurrent_5f81d3e0-22da-45fd-9fa9-3edfc45829d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_961fd57b-6857-4025-871f-9771fa4cbd22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df138f09-fe69-4912-b400-0f24578f732e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_961fd57b-6857-4025-871f-9771fa4cbd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d753a6-d1e4-4b69-98fd-eaa78aac3336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a187fc5f-05fe-4c9e-9354-477c1844bdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d753a6-d1e4-4b69-98fd-eaa78aac3336" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a187fc5f-05fe-4c9e-9354-477c1844bdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7978a546-2351-4a69-80d8-583dbedbc0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a187fc5f-05fe-4c9e-9354-477c1844bdc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7978a546-2351-4a69-80d8-583dbedbc0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7978a546-2351-4a69-80d8-583dbedbc0d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6e8e34bb-279b-4e90-94d8-91a2ae0d9ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6e8e34bb-279b-4e90-94d8-91a2ae0d9ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_81f00bd7-b17e-4839-b599-7c60d3bd5a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_81f00bd7-b17e-4839-b599-7c60d3bd5a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_17f6c512-f492-403b-9880-3a88e341290e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_17f6c512-f492-403b-9880-3a88e341290e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_f5ac7afc-492a-4a2a-b971-75f81c04a257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_f5ac7afc-492a-4a2a-b971-75f81c04a257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_0f2d57b0-49c3-4a07-985e-9ed86095dc32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ae8b1c-29eb-4ca9-8c78-f1511e04e51f" xlink:to="loc_us-gaap_ConstructionInProgressMember_0f2d57b0-49c3-4a07-985e-9ed86095dc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a187fc5f-05fe-4c9e-9354-477c1844bdc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e19baa53-07bd-453d-98c0-18180c1f8061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e19baa53-07bd-453d-98c0-18180c1f8061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d1f9ea7f-8fc5-473e-8d57-84451445bbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d1f9ea7f-8fc5-473e-8d57-84451445bbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c062073a-7287-4d9b-bd2e-9f8713dda6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c062073a-7287-4d9b-bd2e-9f8713dda6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6f416167-5754-4b77-b93b-80089a9d6588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9aab8517-608b-441a-9402-b57eb7da0d7b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6f416167-5754-4b77-b93b-80089a9d6588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83bbe582-8ca1-41d5-a52f-3688fda9a9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8888074d-d4c1-4936-9d35-d459aa851a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83bbe582-8ca1-41d5-a52f-3688fda9a9c2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8888074d-d4c1-4936-9d35-d459aa851a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3f752f72-a77e-4934-a994-a5643992fdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8888074d-d4c1-4936-9d35-d459aa851a3d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3f752f72-a77e-4934-a994-a5643992fdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6b5e7d06-e08d-43f9-967d-14546e05c644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3f752f72-a77e-4934-a994-a5643992fdc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6b5e7d06-e08d-43f9-967d-14546e05c644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_554275d4-383e-4038-8396-ef421d71f252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b5e7d06-e08d-43f9-967d-14546e05c644" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_554275d4-383e-4038-8396-ef421d71f252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72d60d1a-57c4-4c4e-bf45-40779589d5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6b5e7d06-e08d-43f9-967d-14546e05c644" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_72d60d1a-57c4-4c4e-bf45-40779589d5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e460a08a-b85c-4485-87b3-556c5f2a476a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8888074d-d4c1-4936-9d35-d459aa851a3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e460a08a-b85c-4485-87b3-556c5f2a476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_80b27604-6521-4326-96a1-217cfa13c207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e460a08a-b85c-4485-87b3-556c5f2a476a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_80b27604-6521-4326-96a1-217cfa13c207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#OTHERFINANCIALINFORMATIONAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d6bbf1-1cab-44f5-96a5-f863118ff77c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalResearchAndDevelopmentCurrent_fa9264d0-1850-4ba7-a935-6b7afb63f5e9" xlink:href="inbx-20211231.xsd#inbx_AccruedClinicalResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d6bbf1-1cab-44f5-96a5-f863118ff77c" xlink:to="loc_inbx_AccruedClinicalResearchAndDevelopmentCurrent_fa9264d0-1850-4ba7-a935-6b7afb63f5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_bc6eb598-5bc7-4eca-a0ee-cdcfaae2f583" xlink:href="inbx-20211231.xsd#inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d6bbf1-1cab-44f5-96a5-f863118ff77c" xlink:to="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_bc6eb598-5bc7-4eca-a0ee-cdcfaae2f583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c42b165b-de4f-4045-b06e-6aa106663e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d6bbf1-1cab-44f5-96a5-f863118ff77c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c42b165b-de4f-4045-b06e-6aa106663e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_965b6b0e-4a14-4291-bae2-fd6c63e11bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d6bbf1-1cab-44f5-96a5-f863118ff77c" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_965b6b0e-4a14-4291-bae2-fd6c63e11bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a8b540fc-2d41-423d-9c0c-24185b032e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d6bbf1-1cab-44f5-96a5-f863118ff77c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a8b540fc-2d41-423d-9c0c-24185b032e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fddcb483-5909-417c-9746-468ef591b2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1d6bbf1-1cab-44f5-96a5-f863118ff77c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fddcb483-5909-417c-9746-468ef591b2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBT" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dae6491f-71f0-4782-afff-9ed5f3015302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_653d3463-e06b-4e73-8e62-1e41e3608ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dae6491f-71f0-4782-afff-9ed5f3015302" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_653d3463-e06b-4e73-8e62-1e41e3608ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTTables" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9fbb467c-7d28-40c2-b647-2ac28e7c6430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_53042614-20fc-4930-a01b-9cbf74b92cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9fbb467c-7d28-40c2-b647-2ac28e7c6430" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_53042614-20fc-4930-a01b-9cbf74b92cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f225bba6-ed25-4bc3-aca9-5e6f3a3232b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9fbb467c-7d28-40c2-b647-2ac28e7c6430" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f225bba6-ed25-4bc3-aca9-5e6f3a3232b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_19815331-0771-4a23-bb5f-9b0398102d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_19815331-0771-4a23-bb5f-9b0398102d4c" xlink:to="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eee05be9-7dfe-4f7a-9e48-acf21226228d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_DebtInstrumentAxis_eee05be9-7dfe-4f7a-9e48-acf21226228d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_eee05be9-7dfe-4f7a-9e48-acf21226228d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember_a73c7ce9-23bc-4b86-9b5f-f32d786ee686" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember_a73c7ce9-23bc-4b86-9b5f-f32d786ee686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_a013693c-60b2-4d6e-82af-f65e5a0c53ae" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_A2020OxfordTermLoansMember_a013693c-60b2-4d6e-82af-f65e5a0c53ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheOneMember_ea0fc3b7-fca4-4b7c-8702-ad899092da6f" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheOneMember_ea0fc3b7-fca4-4b7c-8702-ad899092da6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanMember_3c8bfeee-5d63-45b0-b617-e0e5bf98d88d" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_Amended2020OxfordTermLoanMember_3c8bfeee-5d63-45b0-b617-e0e5bf98d88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheTwoMember_d770287b-63f1-4ae4-ac4d-1a0d7ae5e6c4" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheTwoMember_d770287b-63f1-4ae4-ac4d-1a0d7ae5e6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember_f3603d8f-7cec-498c-818f-7bb8afa1430d" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanJune2021AmendmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_Amended2020OxfordTermLoanJune2021AmendmentMember_f3603d8f-7cec-498c-818f-7bb8afa1430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2015OxfordTermLoansMember_e9e25633-8125-41fb-8130-829974fdbf8c" xlink:href="inbx-20211231.xsd#inbx_A2015OxfordTermLoansMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25f99518-abeb-4d68-99a2-9ef295a52a6b" xlink:to="loc_inbx_A2015OxfordTermLoansMember_e9e25633-8125-41fb-8130-829974fdbf8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ffa25339-c0fe-4b74-b0f3-50fbb6b80f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ffa25339-c0fe-4b74-b0f3-50fbb6b80f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6013b155-da53-4005-99af-546935405c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ffa25339-c0fe-4b74-b0f3-50fbb6b80f36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6013b155-da53-4005-99af-546935405c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_054d64d4-f4da-472e-a221-6da3ee24e62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6013b155-da53-4005-99af-546935405c22" xlink:to="loc_us-gaap_SecuredDebtMember_054d64d4-f4da-472e-a221-6da3ee24e62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1f6d432f-6370-4ef3-ab47-8baa9f2787f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1f6d432f-6370-4ef3-ab47-8baa9f2787f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_296abf6a-5fa2-4ef9-83ed-3bf7262f5bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1f6d432f-6370-4ef3-ab47-8baa9f2787f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_296abf6a-5fa2-4ef9-83ed-3bf7262f5bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_49a3e55a-61f4-4bf6-a163-08eb363dcebe" xlink:href="inbx-20211231.xsd#inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_296abf6a-5fa2-4ef9-83ed-3bf7262f5bd7" xlink:to="loc_inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember_49a3e55a-61f4-4bf6-a163-08eb363dcebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsIssuedUponConsummationOfIPOMember_15b6135d-cd70-4031-a17a-c43ac49b1801" xlink:href="inbx-20211231.xsd#inbx_WarrantsIssuedUponConsummationOfIPOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_296abf6a-5fa2-4ef9-83ed-3bf7262f5bd7" xlink:to="loc_inbx_WarrantsIssuedUponConsummationOfIPOMember_15b6135d-cd70-4031-a17a-c43ac49b1801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d5a75597-eb6f-4b8c-99cc-412837ec721c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_VariableRateAxis_d5a75597-eb6f-4b8c-99cc-412837ec721c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bf26af13-2b51-4624-a0bf-68946469e6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_d5a75597-eb6f-4b8c-99cc-412837ec721c" xlink:to="loc_us-gaap_VariableRateDomain_bf26af13-2b51-4624-a0bf-68946469e6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_34474050-e177-4bdc-8942-7e1b40a626fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_bf26af13-2b51-4624-a0bf-68946469e6f7" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_34474050-e177-4bdc-8942-7e1b40a626fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_929fe0ee-1eb8-48d8-9215-1e92de1235e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_929fe0ee-1eb8-48d8-9215-1e92de1235e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2b4bd5fa-8e98-489a-b7fe-beeb78f301ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_929fe0ee-1eb8-48d8-9215-1e92de1235e4" xlink:to="loc_us-gaap_EquityComponentDomain_2b4bd5fa-8e98-489a-b7fe-beeb78f301ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_785d7d7a-b942-4575-a77d-def3d2a79ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2b4bd5fa-8e98-489a-b7fe-beeb78f301ca" xlink:to="loc_us-gaap_PreferredStockMember_785d7d7a-b942-4575-a77d-def3d2a79ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb305789-bb10-4152-848d-d91cfd65a043" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_srt_RangeAxis_eb305789-bb10-4152-848d-d91cfd65a043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1066c629-af1e-4694-a37f-db104bdfcdaa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eb305789-bb10-4152-848d-d91cfd65a043" xlink:to="loc_srt_RangeMember_1066c629-af1e-4694-a37f-db104bdfcdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_94459c97-59c5-46b6-a52d-4b1856d557c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1066c629-af1e-4694-a37f-db104bdfcdaa" xlink:to="loc_srt_MinimumMember_94459c97-59c5-46b6-a52d-4b1856d557c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5666ebd6-fb4a-428e-b31d-c924ae0c483c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1066c629-af1e-4694-a37f-db104bdfcdaa" xlink:to="loc_srt_MaximumMember_5666ebd6-fb4a-428e-b31d-c924ae0c483c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b58a89c2-bf1c-4750-ad0a-a301f45e83d5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_84335719-49a9-4c97-b16a-9833ad213c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_84335719-49a9-4c97-b16a-9833ad213c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_4040c67e-e56e-42d7-8448-40d73582e249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_4040c67e-e56e-42d7-8448-40d73582e249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentAmendmentFee_accb0f5e-c494-49ce-ac44-01a472fa863d" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentAmendmentFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentAmendmentFee_accb0f5e-c494-49ce-ac44-01a472fa863d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfAdditionalTranches_8e2ff7d3-ef81-4043-b347-fcb783d85121" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentNumberOfAdditionalTranches"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentNumberOfAdditionalTranches_8e2ff7d3-ef81-4043-b347-fcb783d85121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_60a9bea9-c970-479e-b26d-02c6f886a120" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_60a9bea9-c970-479e-b26d-02c6f886a120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5bd1fe5b-c9c8-4b8c-84ab-6b9c5ddcaf58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5bd1fe5b-c9c8-4b8c-84ab-6b9c5ddcaf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_78c3a26d-dabc-4cff-a86c-75660e0e2141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_78c3a26d-dabc-4cff-a86c-75660e0e2141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5d45a072-6299-4282-ad18-a062ccb9f4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5d45a072-6299-4282-ad18-a062ccb9f4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_4d033c7d-a4f9-4848-bf8f-a54bf20ecc64" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_4d033c7d-a4f9-4848-bf8f-a54bf20ecc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_328f6351-6af7-4e23-8acc-24aa43932126" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_328f6351-6af7-4e23-8acc-24aa43932126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_e77046d5-0a65-401a-841b-d8b9707f05bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_e77046d5-0a65-401a-841b-d8b9707f05bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrepaymentFee_15610e0a-a793-42b4-9214-ea256f539329" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPrepaymentFee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentPrepaymentFee_15610e0a-a793-42b4-9214-ea256f539329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentMinimumCashBalance_cac1eb90-bb10-431b-a80e-aef63114cfb2" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentMinimumCashBalance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_DebtInstrumentMinimumCashBalance_cac1eb90-bb10-431b-a80e-aef63114cfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_799b3647-91b5-4ed3-a8b8-489fc601a6a7" xlink:href="inbx-20211231.xsd#inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued_799b3647-91b5-4ed3-a8b8-489fc601a6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsAndRightsOutstandingLiability_58f0f5ac-8d6c-4372-827c-573d14709f21" xlink:href="inbx-20211231.xsd#inbx_WarrantsAndRightsOutstandingLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_WarrantsAndRightsOutstandingLiability_58f0f5ac-8d6c-4372-827c-573d14709f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsLiability_00f0423f-2abd-44b6-ae39-5fb02d19b683" xlink:href="inbx-20211231.xsd#inbx_WarrantsLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_inbx_WarrantsLiability_00f0423f-2abd-44b6-ae39-5fb02d19b683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2285f378-df65-413d-b3c2-1000ba9de307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2285f378-df65-413d-b3c2-1000ba9de307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_248f48fb-4ea1-4246-bcab-a319a294fa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_248f48fb-4ea1-4246-bcab-a319a294fa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_737f79b0-7d64-421a-a8aa-5525b1969543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_07bb4faf-19b5-4f0a-b5f0-ef9c3fdab7ad" xlink:to="loc_us-gaap_InterestExpenseDebt_737f79b0-7d64-421a-a8aa-5525b1969543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTOutstandingDebtBalance2020LoanAgreementDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a32e674b-1e00-43bd-89d6-411635469df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d69a1631-2fd7-49b0-b60c-988a70ae270e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a32e674b-1e00-43bd-89d6-411635469df1" xlink:to="loc_us-gaap_DebtInstrumentTable_d69a1631-2fd7-49b0-b60c-988a70ae270e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a6ca3084-7189-4ea8-a563-b60ce968f623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d69a1631-2fd7-49b0-b60c-988a70ae270e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a6ca3084-7189-4ea8-a563-b60ce968f623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_594336c7-2c37-4414-9896-1e9d69447ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a6ca3084-7189-4ea8-a563-b60ce968f623" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_594336c7-2c37-4414-9896-1e9d69447ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_78d2d7ed-b822-4f79-bce3-8b4d79d5cb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_594336c7-2c37-4414-9896-1e9d69447ea8" xlink:to="loc_us-gaap_SecuredDebtMember_78d2d7ed-b822-4f79-bce3-8b4d79d5cb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba0ca47e-fbb0-46cb-a7c4-ce8c112750f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d69a1631-2fd7-49b0-b60c-988a70ae270e" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba0ca47e-fbb0-46cb-a7c4-ce8c112750f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8de99fd2-3519-4099-bf51-b454c71e9a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba0ca47e-fbb0-46cb-a7c4-ce8c112750f7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8de99fd2-3519-4099-bf51-b454c71e9a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_af4836a6-5dc9-48db-876b-0a30cde0b77b" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8de99fd2-3519-4099-bf51-b454c71e9a3a" xlink:to="loc_inbx_A2020OxfordTermLoansMember_af4836a6-5dc9-48db-876b-0a30cde0b77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoanAMember_c806a3ec-b7b1-431d-b933-913275522808" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_A2020OxfordTermLoansMember_af4836a6-5dc9-48db-876b-0a30cde0b77b" xlink:to="loc_inbx_A2020OxfordTermLoanAMember_c806a3ec-b7b1-431d-b933-913275522808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoanBMember_bc527092-3df0-49a9-b56f-273f9390387d" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoanBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_A2020OxfordTermLoansMember_af4836a6-5dc9-48db-876b-0a30cde0b77b" xlink:to="loc_inbx_A2020OxfordTermLoanBMember_bc527092-3df0-49a9-b56f-273f9390387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoanCMember_6469e18c-9aae-423a-a427-95b8acd7b8dd" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoanCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_A2020OxfordTermLoansMember_af4836a6-5dc9-48db-876b-0a30cde0b77b" xlink:to="loc_inbx_A2020OxfordTermLoanCMember_6469e18c-9aae-423a-a427-95b8acd7b8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d69a1631-2fd7-49b0-b60c-988a70ae270e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_62fa51dd-8f0c-43c5-88d2-d566e00b0975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_62fa51dd-8f0c-43c5-88d2-d566e00b0975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_02cc099f-bdd0-4399-a1ee-0c197476c138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_02cc099f-bdd0-4399-a1ee-0c197476c138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f1f19661-f5fc-4461-a1c2-964214377c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_LongTermDebt_f1f19661-f5fc-4461-a1c2-964214377c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f042bf0d-328d-4254-be9a-227494c7ae81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_LongTermDebtCurrent_f042bf0d-328d-4254-be9a-227494c7ae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f0daf8c9-1e08-447f-be48-fe2d39ac578d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_45fbced3-52b8-449c-890c-f994dbec1dff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f0daf8c9-1e08-447f-be48-fe2d39ac578d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails_1" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTOutstandingDebtBalance2020LoanAgreementDetails_1"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#DEBTFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1fb030c8-8187-4764-ac9c-43ccbd353c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a402d526-eb99-4f5b-a389-9d09b7f1da0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fb030c8-8187-4764-ac9c-43ccbd353c84" xlink:to="loc_us-gaap_DebtInstrumentTable_a402d526-eb99-4f5b-a389-9d09b7f1da0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d6777ae9-0b76-4e58-9414-bceb728580eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a402d526-eb99-4f5b-a389-9d09b7f1da0b" xlink:to="loc_us-gaap_DebtInstrumentAxis_d6777ae9-0b76-4e58-9414-bceb728580eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_737b24eb-160b-4ab2-a746-e76c06bf2dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d6777ae9-0b76-4e58-9414-bceb728580eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_737b24eb-160b-4ab2-a746-e76c06bf2dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_0026d3aa-8b07-4ad8-8f9b-ff15e99f4406" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_737b24eb-160b-4ab2-a746-e76c06bf2dd8" xlink:to="loc_inbx_A2020OxfordTermLoansMember_0026d3aa-8b07-4ad8-8f9b-ff15e99f4406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_df8e6f7a-f1a2-47c2-8887-3f3b014ccf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a402d526-eb99-4f5b-a389-9d09b7f1da0b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_df8e6f7a-f1a2-47c2-8887-3f3b014ccf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_48afdbd7-0c50-4b3e-a6f9-925796fe6d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df8e6f7a-f1a2-47c2-8887-3f3b014ccf14" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_48afdbd7-0c50-4b3e-a6f9-925796fe6d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_fb69696a-dc1e-4918-89e5-d26fda8c350f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_48afdbd7-0c50-4b3e-a6f9-925796fe6d96" xlink:to="loc_us-gaap_SecuredDebtMember_fb69696a-dc1e-4918-89e5-d26fda8c350f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a402d526-eb99-4f5b-a389-9d09b7f1da0b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_679fc345-e5a1-4995-9c4a-22def39de894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_679fc345-e5a1-4995-9c4a-22def39de894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0b4673c1-0f38-4a7a-979b-2427b622ea6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0b4673c1-0f38-4a7a-979b-2427b622ea6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_431ca8e9-f7da-42c7-a863-080d135dedb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_431ca8e9-f7da-42c7-a863-080d135dedb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cfd7466d-c4e0-4604-ba88-6ef5bf6a7653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5a5db44a-be52-4ea4-9cdb-630577957b7d" xlink:to="loc_us-gaap_LongTermDebt_cfd7466d-c4e0-4604-ba88-6ef5bf6a7653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTE" xlink:type="simple" xlink:href="inbx-20211231.xsd#CONVERTIBLEPROMISSORYNOTE"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c0085d99-c457-40d1-9aff-ed0b4171e76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_7f54965b-5e7d-4abd-904a-5854ca11f7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c0085d99-c457-40d1-9aff-ed0b4171e76d" xlink:to="loc_us-gaap_LongTermDebtTextBlock_7f54965b-5e7d-4abd-904a-5854ca11f7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#CONVERTIBLEPROMISSORYNOTEDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0ebbe29e-4071-4f59-bb17-52986bff8e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0ebbe29e-4071-4f59-bb17-52986bff8e36" xlink:to="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_121edac3-878d-43ab-a8c1-126decb052c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:to="loc_us-gaap_DebtInstrumentAxis_121edac3-878d-43ab-a8c1-126decb052c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_951c6f09-fa37-4a6f-8e10-d9aa29fd3833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_121edac3-878d-43ab-a8c1-126decb052c3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_951c6f09-fa37-4a6f-8e10-d9aa29fd3833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2019ConvertiblePromissoryNoteMember_bff331dc-3d86-4b25-9290-fd8f07c16d85" xlink:href="inbx-20211231.xsd#inbx_A2019ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_951c6f09-fa37-4a6f-8e10-d9aa29fd3833" xlink:to="loc_inbx_A2019ConvertiblePromissoryNoteMember_bff331dc-3d86-4b25-9290-fd8f07c16d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020ConvertiblePromissoryNoteMember_a4db274b-5aee-4b51-9348-3e74e8253845" xlink:href="inbx-20211231.xsd#inbx_A2020ConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_951c6f09-fa37-4a6f-8e10-d9aa29fd3833" xlink:to="loc_inbx_A2020ConvertiblePromissoryNoteMember_a4db274b-5aee-4b51-9348-3e74e8253845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8d3b7134-f815-4f44-9469-becf86ef7ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8d3b7134-f815-4f44-9469-becf86ef7ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_db562030-13a7-4e56-8e4d-4b5e6ab29370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8d3b7134-f815-4f44-9469-becf86ef7ffc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_db562030-13a7-4e56-8e4d-4b5e6ab29370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_76893a5f-a72c-436f-bba1-0e5f0dbbf4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_db562030-13a7-4e56-8e4d-4b5e6ab29370" xlink:to="loc_us-gaap_ConvertibleDebtMember_76893a5f-a72c-436f-bba1-0e5f0dbbf4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e6984d3a-5851-47b0-9f79-e6918ad061fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e6984d3a-5851-47b0-9f79-e6918ad061fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a6ee9aa-6b83-44fa-943a-c2facafb509a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e6984d3a-5851-47b0-9f79-e6918ad061fe" xlink:to="loc_us-gaap_EquityComponentDomain_2a6ee9aa-6b83-44fa-943a-c2facafb509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3f992377-f522-4009-b41d-e8a49555dae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a6ee9aa-6b83-44fa-943a-c2facafb509a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3f992377-f522-4009-b41d-e8a49555dae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_168b8cec-b35c-4bcb-99cd-a098f90a6bef" xlink:to="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_91df65ab-825e-4a9a-9704-2fac16d6661d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_91df65ab-825e-4a9a-9704-2fac16d6661d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1f513288-1b44-4210-a31b-437e98bc109c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1f513288-1b44-4210-a31b-437e98bc109c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4b16f7ef-f5fc-45b4-978d-c8986181705b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_LongTermDebt_4b16f7ef-f5fc-45b4-978d-c8986181705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_68562ee7-8606-404f-a25d-116688ba91ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_68562ee7-8606-404f-a25d-116688ba91ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_d27df92f-4c4d-4cb6-9fed-a01dbb11f633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_d27df92f-4c4d-4cb6-9fed-a01dbb11f633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_e4d9114c-e450-430b-af47-a6607e84cf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DerivativeLiabilities_e4d9114c-e450-430b-af47-a6607e84cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_318cf3d2-7770-45e2-94b4-62f5e40460e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_318cf3d2-7770-45e2-94b4-62f5e40460e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_01d6a52f-6078-427e-9560-56a796c28487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_01d6a52f-6078-427e-9560-56a796c28487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_98beb196-969f-4c09-9659-41ceec208108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_98beb196-969f-4c09-9659-41ceec208108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReversalOfUnamortizedBeneficialConversionFeature_3f26ba20-5d23-402f-87b1-8cdb7d70b700" xlink:href="inbx-20211231.xsd#inbx_ReversalOfUnamortizedBeneficialConversionFeature"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_inbx_ReversalOfUnamortizedBeneficialConversionFeature_3f26ba20-5d23-402f-87b1-8cdb7d70b700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_bf56cad6-e9c4-4041-a789-a0f9cffd674e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_984402d9-9c94-4cdf-980d-8027835a2b5a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_bf56cad6-e9c4-4041-a789-a0f9cffd674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="inbx-20211231.xsd#STOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_10e92bf4-582b-4ebd-a822-e6e1eb957c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e9254996-d80b-49d1-9ad2-9779068d0132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10e92bf4-582b-4ebd-a822-e6e1eb957c7b" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e9254996-d80b-49d1-9ad2-9779068d0132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#STOCKHOLDERSEQUITYDEFICITDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8161887d-d9af-443b-95c7-2a59fd26f999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8161887d-d9af-443b-95c7-2a59fd26f999" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fe7e2f19-2f85-4591-9992-a1d696acac47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fe7e2f19-2f85-4591-9992-a1d696acac47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b84c091c-8c1f-402b-9f08-e526c5496d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fe7e2f19-2f85-4591-9992-a1d696acac47" xlink:to="loc_us-gaap_EquityComponentDomain_b84c091c-8c1f-402b-9f08-e526c5496d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_42eb450c-4f1a-4650-9e5e-ca51a79aecf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b84c091c-8c1f-402b-9f08-e526c5496d2e" xlink:to="loc_us-gaap_CommonStockMember_42eb450c-4f1a-4650-9e5e-ca51a79aecf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9dda178f-d4f4-405a-94c2-9c62bfb0444e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b84c091c-8c1f-402b-9f08-e526c5496d2e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9dda178f-d4f4-405a-94c2-9c62bfb0444e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_bbd69231-366a-4deb-b6c0-67e251442d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_bbd69231-366a-4deb-b6c0-67e251442d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_cb3e72eb-9f43-4e3d-879f-dddc9a4c9016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_bbd69231-366a-4deb-b6c0-67e251442d3e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_cb3e72eb-9f43-4e3d-879f-dddc9a4c9016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsIssuedUponConsummationOfIPOMember_5668f925-2439-4801-ad38-7bbd4a0f7818" xlink:href="inbx-20211231.xsd#inbx_WarrantsIssuedUponConsummationOfIPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_cb3e72eb-9f43-4e3d-879f-dddc9a4c9016" xlink:to="loc_inbx_WarrantsIssuedUponConsummationOfIPOMember_5668f925-2439-4801-ad38-7bbd4a0f7818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c2a486b2-06eb-40db-b1af-de4ddaaf6d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_DebtInstrumentAxis_c2a486b2-06eb-40db-b1af-de4ddaaf6d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6e6af310-4f28-43e1-a0f1-6b6b799745b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c2a486b2-06eb-40db-b1af-de4ddaaf6d8d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6e6af310-4f28-43e1-a0f1-6b6b799745b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_df6f574c-c9a7-48ba-9787-a731f6b908c8" xlink:href="inbx-20211231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e6af310-4f28-43e1-a0f1-6b6b799745b1" xlink:to="loc_inbx_A2020OxfordTermLoansMember_df6f574c-c9a7-48ba-9787-a731f6b908c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfb053bf-5d0c-4405-bfe5-f392166ea221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfb053bf-5d0c-4405-bfe5-f392166ea221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c89c61ba-a7a6-489d-bd44-a9f853f00b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfb053bf-5d0c-4405-bfe5-f392166ea221" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c89c61ba-a7a6-489d-bd44-a9f853f00b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_8b6212cf-3287-457e-90b0-5082667ca994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c89c61ba-a7a6-489d-bd44-a9f853f00b52" xlink:to="loc_us-gaap_SecuredDebtMember_8b6212cf-3287-457e-90b0-5082667ca994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b35980e1-87a0-43f8-a643-0eb2cc6ce000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b35980e1-87a0-43f8-a643-0eb2cc6ce000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cec13ed7-710e-45cc-98e3-8ea647f08f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b35980e1-87a0-43f8-a643-0eb2cc6ce000" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cec13ed7-710e-45cc-98e3-8ea647f08f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SalesAgreementMember_557651b4-2e3a-432b-a7c4-c8ebb7d411c4" xlink:href="inbx-20211231.xsd#inbx_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cec13ed7-710e-45cc-98e3-8ea647f08f0e" xlink:to="loc_inbx_SalesAgreementMember_557651b4-2e3a-432b-a7c4-c8ebb7d411c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_17e2da3e-3d49-4530-91aa-8a9013e72b62" xlink:to="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_15e32a9d-0a8a-4e07-9ec6-f1a89c1b773a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_15e32a9d-0a8a-4e07-9ec6-f1a89c1b773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_234d452e-dfcc-42fd-bb7c-b462b4284ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_234d452e-dfcc-42fd-bb7c-b462b4284ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d47dcba1-ce22-4f5e-84f5-8e17a8d54a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d47dcba1-ce22-4f5e-84f5-8e17a8d54a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_92399b48-2567-4bcb-b564-00e7ade3ca07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_92399b48-2567-4bcb-b564-00e7ade3ca07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b589899d-328f-42dc-9949-ad786a268c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b589899d-328f-42dc-9949-ad786a268c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleOfStockCommonStockAuthorized_f8123329-a834-4866-96de-0d56d1b4dfc6" xlink:href="inbx-20211231.xsd#inbx_SaleOfStockCommonStockAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_inbx_SaleOfStockCommonStockAuthorized_f8123329-a834-4866-96de-0d56d1b4dfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CommonStockSaleOfStockCommissionPercent_d58de3c3-9e51-47e8-8621-22189cb8882b" xlink:href="inbx-20211231.xsd#inbx_CommonStockSaleOfStockCommissionPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_inbx_CommonStockSaleOfStockCommissionPercent_d58de3c3-9e51-47e8-8621-22189cb8882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleOfStockSharesCommonStockSold_b7af284e-3d65-43eb-b858-fcaa34924910" xlink:href="inbx-20211231.xsd#inbx_SaleOfStockSharesCommonStockSold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_inbx_SaleOfStockSharesCommonStockSold_b7af284e-3d65-43eb-b858-fcaa34924910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b045196d-0afd-4074-b234-5edb2b402247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b045196d-0afd-4074-b234-5edb2b402247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fd7f5007-e5a6-4eb0-841a-8625f3cd95c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fd7f5007-e5a6-4eb0-841a-8625f3cd95c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AtTheMarketOfferingCosts_74b21b3a-e4b9-4707-9257-f3dcbb7156c7" xlink:href="inbx-20211231.xsd#inbx_AtTheMarketOfferingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_inbx_AtTheMarketOfferingCosts_74b21b3a-e4b9-4707-9257-f3dcbb7156c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_367b63e5-7ce8-4101-872d-521ad2530a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_367b63e5-7ce8-4101-872d-521ad2530a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1d86f7c3-802f-42a9-8eed-9305d9ee1ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1d86f7c3-802f-42a9-8eed-9305d9ee1ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_b2ad8d9f-8372-4e77-a1db-a040e89b1ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_2d88dbb2-7175-4321-af5a-e217df74ec09" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_b2ad8d9f-8372-4e77-a1db-a040e89b1ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANS" xlink:type="simple" xlink:href="inbx-20211231.xsd#EQUITYCOMPENSATIONPLANS"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3570bf18-b90a-4bbd-a75d-48df20b10c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1707e17d-9152-49de-b842-9dc1b7b1a39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3570bf18-b90a-4bbd-a75d-48df20b10c8c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1707e17d-9152-49de-b842-9dc1b7b1a39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSTables" xlink:type="simple" xlink:href="inbx-20211231.xsd#EQUITYCOMPENSATIONPLANSTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6c6bd80-106d-4c97-8311-6cc42a39999d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_3d2c4c1a-c990-4552-83a3-4ab2a41ddb40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6c6bd80-106d-4c97-8311-6cc42a39999d" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_3d2c4c1a-c990-4552-83a3-4ab2a41ddb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_abbe0d28-5511-4e37-b099-3ba4483d1c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6c6bd80-106d-4c97-8311-6cc42a39999d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_abbe0d28-5511-4e37-b099-3ba4483d1c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bf516b89-49f1-43c6-a11f-d273470d0a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6c6bd80-106d-4c97-8311-6cc42a39999d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bf516b89-49f1-43c6-a11f-d273470d0a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#EQUITYCOMPENSATIONPLANSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc9d1115-ad76-433a-aa00-b473e914f893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6cb4ce0-a8bb-4944-adff-e1b34b13f317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc9d1115-ad76-433a-aa00-b473e914f893" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6cb4ce0-a8bb-4944-adff-e1b34b13f317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d204f295-4f31-4a9f-94fc-6ff7bbad6ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6cb4ce0-a8bb-4944-adff-e1b34b13f317" xlink:to="loc_us-gaap_VestingAxis_d204f295-4f31-4a9f-94fc-6ff7bbad6ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9f740c54-275c-4b77-9ea2-9065677cce7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_d204f295-4f31-4a9f-94fc-6ff7bbad6ed8" xlink:to="loc_us-gaap_VestingDomain_9f740c54-275c-4b77-9ea2-9065677cce7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b28cfb8d-4168-4a7b-a819-2719793947c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_9f740c54-275c-4b77-9ea2-9065677cce7e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b28cfb8d-4168-4a7b-a819-2719793947c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0ae45597-fe36-4ae4-98ac-ce89282edb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6cb4ce0-a8bb-4944-adff-e1b34b13f317" xlink:to="loc_us-gaap_AwardTypeAxis_0ae45597-fe36-4ae4-98ac-ce89282edb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b4a695-f290-4eb9-9014-dd7fa7a56663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0ae45597-fe36-4ae4-98ac-ce89282edb21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b4a695-f290-4eb9-9014-dd7fa7a56663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_17b11dae-b3d6-4fc7-ad32-2e1b01e2c842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b4a695-f290-4eb9-9014-dd7fa7a56663" xlink:to="loc_us-gaap_EmployeeStockOptionMember_17b11dae-b3d6-4fc7-ad32-2e1b01e2c842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6cb4ce0-a8bb-4944-adff-e1b34b13f317" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44f9561a-4cbe-4175-bcbf-5ad9813b03b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_44f9561a-4cbe-4175-bcbf-5ad9813b03b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_db1bfda7-d7fd-41c9-a793-b7823a1df28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_db1bfda7-d7fd-41c9-a793-b7823a1df28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df47d95c-36b8-4046-a010-2b05a41d2fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_df47d95c-36b8-4046-a010-2b05a41d2fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_77cc80bc-2dba-40f3-8bfa-766cd431fd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_77cc80bc-2dba-40f3-8bfa-766cd431fd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2a479ba8-2666-4837-bdda-fe4a4d9244df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2a479ba8-2666-4837-bdda-fe4a4d9244df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ffce32c9-4860-4647-9b57-a1b8072029bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ffce32c9-4860-4647-9b57-a1b8072029bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a21ee30-f8c9-4cd3-b904-e1e1aeedce33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5745781-1d7e-4f60-8447-28f5339f057b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a21ee30-f8c9-4cd3-b904-e1e1aeedce33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0565adf3-1e16-46e7-b3ac-e1a0cdc2a9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38916d00-b30b-4b12-acf5-07155c3bcbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0565adf3-1e16-46e7-b3ac-e1a0cdc2a9d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38916d00-b30b-4b12-acf5-07155c3bcbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_43ab6c23-5015-4f94-bbc1-4917dc9ca060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38916d00-b30b-4b12-acf5-07155c3bcbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_43ab6c23-5015-4f94-bbc1-4917dc9ca060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75bd5d89-e88b-48eb-bc63-01fbdbf23b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38916d00-b30b-4b12-acf5-07155c3bcbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75bd5d89-e88b-48eb-bc63-01fbdbf23b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64582e4e-0a52-4297-b3d5-e3878d50d8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38916d00-b30b-4b12-acf5-07155c3bcbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64582e4e-0a52-4297-b3d5-e3878d50d8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b9738cce-031b-46e4-94fe-e6b3a99c8bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38916d00-b30b-4b12-acf5-07155c3bcbfb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b9738cce-031b-46e4-94fe-e6b3a99c8bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cb79de2b-464f-4c5e-afb7-adfffbe48783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38916d00-b30b-4b12-acf5-07155c3bcbfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cb79de2b-464f-4c5e-afb7-adfffbe48783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_088cb282-f984-455e-9d89-649febe930af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0565adf3-1e16-46e7-b3ac-e1a0cdc2a9d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_088cb282-f984-455e-9d89-649febe930af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3437a51-dfbb-4f07-b331-e16c6c8f8226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0565adf3-1e16-46e7-b3ac-e1a0cdc2a9d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3437a51-dfbb-4f07-b331-e16c6c8f8226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6f1c81c9-19b2-47d8-9180-65bcc8471ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3437a51-dfbb-4f07-b331-e16c6c8f8226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6f1c81c9-19b2-47d8-9180-65bcc8471ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5a781486-2c77-44bf-9235-1bf7f0c14abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3437a51-dfbb-4f07-b331-e16c6c8f8226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5a781486-2c77-44bf-9235-1bf7f0c14abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e62c558d-1428-4429-83f2-db79b24a39f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3437a51-dfbb-4f07-b331-e16c6c8f8226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e62c558d-1428-4429-83f2-db79b24a39f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e83da94f-d813-40a5-8d75-d9549ce766ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3437a51-dfbb-4f07-b331-e16c6c8f8226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e83da94f-d813-40a5-8d75-d9549ce766ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65f88d85-dbc0-497a-9822-2ca1e34f98ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3437a51-dfbb-4f07-b331-e16c6c8f8226" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65f88d85-dbc0-497a-9822-2ca1e34f98ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_033c2e21-f3f0-4cd8-ac62-568901247521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0565adf3-1e16-46e7-b3ac-e1a0cdc2a9d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_033c2e21-f3f0-4cd8-ac62-568901247521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_af5e8adc-9b9b-4ddb-a9b1-a24ebe9e693c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0565adf3-1e16-46e7-b3ac-e1a0cdc2a9d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_af5e8adc-9b9b-4ddb-a9b1-a24ebe9e693c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ff183dec-47b0-40af-9af3-fd49a48976f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0565adf3-1e16-46e7-b3ac-e1a0cdc2a9d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ff183dec-47b0-40af-9af3-fd49a48976f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5be85806-bdd9-4d5b-a235-39d0d874ff72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0565adf3-1e16-46e7-b3ac-e1a0cdc2a9d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5be85806-bdd9-4d5b-a235-39d0d874ff72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_11e0323f-6cd6-4b8c-962e-a8a1b0eefc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0565adf3-1e16-46e7-b3ac-e1a0cdc2a9d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_11e0323f-6cd6-4b8c-962e-a8a1b0eefc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_d18f3c26-cf71-42e8-a9ba-6affbc6b1591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0565adf3-1e16-46e7-b3ac-e1a0cdc2a9d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_d18f3c26-cf71-42e8-a9ba-6affbc6b1591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a472bb24-a3a7-4b17-b0e3-95f4ba4c26be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be235ee2-9c74-411d-b153-4a9c6c7292a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a472bb24-a3a7-4b17-b0e3-95f4ba4c26be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be235ee2-9c74-411d-b153-4a9c6c7292a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df577d5c-a58f-4675-a9b6-e0038fc85f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be235ee2-9c74-411d-b153-4a9c6c7292a2" xlink:to="loc_us-gaap_AwardTypeAxis_df577d5c-a58f-4675-a9b6-e0038fc85f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe3f3f77-c00c-4c0e-a69b-725208484631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_df577d5c-a58f-4675-a9b6-e0038fc85f10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe3f3f77-c00c-4c0e-a69b-725208484631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_577a8f9b-9f7e-4f1b-b79b-9f1a60b98451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe3f3f77-c00c-4c0e-a69b-725208484631" xlink:to="loc_us-gaap_EmployeeStockOptionMember_577a8f9b-9f7e-4f1b-b79b-9f1a60b98451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be235ee2-9c74-411d-b153-4a9c6c7292a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f3d5ae9c-3ffc-4d1e-9fc6-f53bd70a1ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f3d5ae9c-3ffc-4d1e-9fc6-f53bd70a1ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_91c8b9f2-d01d-4219-8985-97f58160bc88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_91c8b9f2-d01d-4219-8985-97f58160bc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5861f527-ec06-4024-8dbd-9ca4d7c2b09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5861f527-ec06-4024-8dbd-9ca4d7c2b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c494de23-6898-4d68-8dca-3a9b258c86e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c494de23-6898-4d68-8dca-3a9b258c86e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_292d4914-fd1d-44f6-9bd8-4161fc3770c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bd6624c6-91cf-4e9d-b79b-7abe93a3cc5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_292d4914-fd1d-44f6-9bd8-4161fc3770c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8de1ffe5-0914-405d-a256-61f1d66463b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a226da2-2493-47d5-b377-f1a1adb8823f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8de1ffe5-0914-405d-a256-61f1d66463b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a226da2-2493-47d5-b377-f1a1adb8823f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a9bc447-610b-405e-ab4b-18423c474bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a226da2-2493-47d5-b377-f1a1adb8823f" xlink:to="loc_us-gaap_AwardTypeAxis_8a9bc447-610b-405e-ab4b-18423c474bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb6017c2-cec0-43e9-8988-2bdd08f29c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8a9bc447-610b-405e-ab4b-18423c474bed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb6017c2-cec0-43e9-8988-2bdd08f29c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a07731fb-3334-498b-ae83-46142ded8e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb6017c2-cec0-43e9-8988-2bdd08f29c4d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a07731fb-3334-498b-ae83-46142ded8e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b797c83a-97ef-4ee7-92a6-f5336924f315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a226da2-2493-47d5-b377-f1a1adb8823f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b797c83a-97ef-4ee7-92a6-f5336924f315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dc33fdeb-5106-4791-b877-f04a81af9a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b797c83a-97ef-4ee7-92a6-f5336924f315" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dc33fdeb-5106-4791-b877-f04a81af9a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e25696a4-060e-482e-9a58-4cd81b173c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dc33fdeb-5106-4791-b877-f04a81af9a80" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e25696a4-060e-482e-9a58-4cd81b173c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99be59b3-fe98-4be1-83be-b591d9fdfa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dc33fdeb-5106-4791-b877-f04a81af9a80" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_99be59b3-fe98-4be1-83be-b591d9fdfa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab1c4bdd-b421-4a0d-83d8-76397977f3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a226da2-2493-47d5-b377-f1a1adb8823f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab1c4bdd-b421-4a0d-83d8-76397977f3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4fec83ac-6efa-4977-818d-b1ccc859f628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab1c4bdd-b421-4a0d-83d8-76397977f3dd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4fec83ac-6efa-4977-818d-b1ccc859f628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUES" xlink:type="simple" xlink:href="inbx-20211231.xsd#LICENSEANDGRANTREVENUES"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LICENSEANDGRANTREVENUES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_862d254e-8af3-4b16-bf8f-b5a86021bb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAndGrantRevenueTextBlock_a1d8cded-7374-4553-a0d0-b5b65165fe7e" xlink:href="inbx-20211231.xsd#inbx_LicenseAndGrantRevenueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_862d254e-8af3-4b16-bf8f-b5a86021bb01" xlink:to="loc_inbx_LicenseAndGrantRevenueTextBlock_a1d8cded-7374-4553-a0d0-b5b65165fe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESTables" xlink:type="simple" xlink:href="inbx-20211231.xsd#LICENSEANDGRANTREVENUESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LICENSEANDGRANTREVENUESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_0965d43b-99fa-4ace-84c5-e09d253f865e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_7bf722cb-80a3-419a-95a2-bbc71969442a" xlink:href="inbx-20211231.xsd#inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_0965d43b-99fa-4ace-84c5-e09d253f865e" xlink:to="loc_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_7bf722cb-80a3-419a-95a2-bbc71969442a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LICENSEANDGRANTREVENUESRevenueSummaryDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_ee8575c9-f1c3-40b8-978b-942201bbda60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_ee8575c9-f1c3-40b8-978b-942201bbda60" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c990ac7d-2cfb-4b11-9c75-757918fd68e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:to="loc_srt_ProductOrServiceAxis_c990ac7d-2cfb-4b11-9c75-757918fd68e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3083177a-ecd0-48eb-a852-785b543b6e39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c990ac7d-2cfb-4b11-9c75-757918fd68e1" xlink:to="loc_srt_ProductsAndServicesDomain_3083177a-ecd0-48eb-a852-785b543b6e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAffiliateMember_6d29fd44-816b-4a18-a55f-cc95f9abc025" xlink:href="inbx-20211231.xsd#inbx_LicenseAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3083177a-ecd0-48eb-a852-785b543b6e39" xlink:to="loc_inbx_LicenseAffiliateMember_6d29fd44-816b-4a18-a55f-cc95f9abc025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember_0ac4f8cb-987c-4e71-a01f-efb60ec7ead2" xlink:href="inbx-20211231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3083177a-ecd0-48eb-a852-785b543b6e39" xlink:to="loc_inbx_LicenseNonAffiliateMember_0ac4f8cb-987c-4e71-a01f-efb60ec7ead2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_0f286671-c078-49e0-b6ff-e2ba0edddc96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3083177a-ecd0-48eb-a852-785b543b6e39" xlink:to="loc_us-gaap_GrantMember_0f286671-c078-49e0-b6ff-e2ba0edddc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_457779a2-d373-476e-9b39-572b938b9401" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:to="loc_srt_MajorCustomersAxis_457779a2-d373-476e-9b39-572b938b9401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_457779a2-d373-476e-9b39-572b938b9401" xlink:to="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_bfe4aa90-9aab-4144-b1a5-3ae9cbce2f70" xlink:href="inbx-20211231.xsd#inbx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:to="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_bfe4aa90-9aab-4144-b1a5-3ae9cbce2f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2seventyBioIncMember_8cb6a73f-f309-4ff5-8551-b61f6f7b3c23" xlink:href="inbx-20211231.xsd#inbx_A2seventyBioIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:to="loc_inbx_A2seventyBioIncMember_8cb6a73f-f309-4ff5-8551-b61f6f7b3c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember_e4e3bc9f-f485-4ec6-a063-bfcc42d88a65" xlink:href="inbx-20211231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:to="loc_inbx_PhylaxisBioScienceLLCMember_e4e3bc9f-f485-4ec6-a063-bfcc42d88a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ChiesiFarmaceuticiSpAMember_8f3c035e-2025-44ea-9213-1be49eb53d3c" xlink:href="inbx-20211231.xsd#inbx_ChiesiFarmaceuticiSpAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:to="loc_inbx_ChiesiFarmaceuticiSpAMember_8f3c035e-2025-44ea-9213-1be49eb53d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherCustomersNotSeparatelyDisclosedMember_69bb991b-aac4-4a20-8d2e-0ec5a2d20427" xlink:href="inbx-20211231.xsd#inbx_OtherCustomersNotSeparatelyDisclosedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72cf3fda-1a74-4a00-9835-0c64e5025857" xlink:to="loc_inbx_OtherCustomersNotSeparatelyDisclosedMember_69bb991b-aac4-4a20-8d2e-0ec5a2d20427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a75d35d5-0f75-4835-bad7-a2861be62c00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:to="loc_srt_CounterpartyNameAxis_a75d35d5-0f75-4835-bad7-a2861be62c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38e3d872-bfb6-4c27-9e1e-a4ec616b743a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a75d35d5-0f75-4835-bad7-a2861be62c00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38e3d872-bfb6-4c27-9e1e-a4ec616b743a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_2639ccfb-deba-44f9-b53d-e9f3cdceb288" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38e3d872-bfb6-4c27-9e1e-a4ec616b743a" xlink:to="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_2639ccfb-deba-44f9-b53d-e9f3cdceb288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e82c5f1-8563-49b2-9665-c01468bdc3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2139fc3-e281-446a-8065-64dee6f57423" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e82c5f1-8563-49b2-9665-c01468bdc3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_179ccc50-5250-4254-b8ee-bf8b24e6ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e82c5f1-8563-49b2-9665-c01468bdc3ee" xlink:to="loc_us-gaap_Revenues_179ccc50-5250-4254-b8ee-bf8b24e6ec25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_21cb3033-1115-402a-92d7-2e2a1b422477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_21cb3033-1115-402a-92d7-2e2a1b422477" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6ef13a28-64d7-41a3-9903-d5efe4d441f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:to="loc_srt_MajorCustomersAxis_6ef13a28-64d7-41a3-9903-d5efe4d441f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6ef13a28-64d7-41a3-9903-d5efe4d441f0" xlink:to="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember_071f14aa-5729-4ada-887b-5f79f05bd60b" xlink:href="inbx-20211231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:to="loc_inbx_PhylaxisBioScienceLLCMember_071f14aa-5729-4ada-887b-5f79f05bd60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2seventyBioIncMember_c5d93c99-2e5b-4646-8860-4d2ea471420e" xlink:href="inbx-20211231.xsd#inbx_A2seventyBioIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:to="loc_inbx_A2seventyBioIncMember_c5d93c99-2e5b-4646-8860-4d2ea471420e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ChiesiFarmaceuticiSpAMember_a49f293b-08d5-411b-ae48-ec87a6e4e2c2" xlink:href="inbx-20211231.xsd#inbx_ChiesiFarmaceuticiSpAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:to="loc_inbx_ChiesiFarmaceuticiSpAMember_a49f293b-08d5-411b-ae48-ec87a6e4e2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_baac9d64-d0c6-4907-a192-d439eecec6a8" xlink:href="inbx-20211231.xsd#inbx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:to="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_baac9d64-d0c6-4907-a192-d439eecec6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CelgeneMember_e7d0b9fd-45de-4758-bf56-b03971b2451b" xlink:href="inbx-20211231.xsd#inbx_CelgeneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_545550ca-a758-4346-98f2-2a5aa1e39c21" xlink:to="loc_inbx_CelgeneMember_e7d0b9fd-45de-4758-bf56-b03971b2451b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77a7e481-9730-44a2-9bd6-71c05b038b71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77a7e481-9730-44a2-9bd6-71c05b038b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c927bbdf-1277-4115-8cdc-4600d2cf39e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_77a7e481-9730-44a2-9bd6-71c05b038b71" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c927bbdf-1277-4115-8cdc-4600d2cf39e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember_87e550b9-0e3a-47fb-af2b-d384b3595141" xlink:href="inbx-20211231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c927bbdf-1277-4115-8cdc-4600d2cf39e5" xlink:to="loc_inbx_PhylaxisBioScienceLLCMember_87e550b9-0e3a-47fb-af2b-d384b3595141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_09a76472-d595-4e32-bb34-0ef384043625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_09a76472-d595-4e32-bb34-0ef384043625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09a76472-d595-4e32-bb34-0ef384043625" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_408136ac-9908-4f61-b39c-ef51425b0e76" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:to="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_408136ac-9908-4f61-b39c-ef51425b0e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_d3d6a788-cd24-4483-b056-c3285edb84c2" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_408136ac-9908-4f61-b39c-ef51425b0e76" xlink:to="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember_d3d6a788-cd24-4483-b056-c3285edb84c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_f6b4e4ef-945d-4ad5-8faa-a40ea668628d" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_408136ac-9908-4f61-b39c-ef51425b0e76" xlink:to="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember_f6b4e4ef-945d-4ad5-8faa-a40ea668628d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember_7322ec52-878d-4d11-add8-73e3f43abb5c" xlink:href="inbx-20211231.xsd#inbx_LicenseAgreementAdditionalProgramsAuthorizedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:to="loc_inbx_LicenseAgreementAdditionalProgramsAuthorizedMember_7322ec52-878d-4d11-add8-73e3f43abb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2018OptionAndLicenseAgreementMember_f4e3652d-36cd-4e00-84cc-c027b0d5b734" xlink:href="inbx-20211231.xsd#inbx_A2018OptionAndLicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:to="loc_inbx_A2018OptionAndLicenseAgreementMember_f4e3652d-36cd-4e00-84cc-c027b0d5b734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OptionAndLicenseAgreementMember_34d3151f-9f85-4f34-bac2-91729b6466bf" xlink:href="inbx-20211231.xsd#inbx_A2020OptionAndLicenseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77d487d7-5660-41a1-b943-93181ece11e5" xlink:to="loc_inbx_A2020OptionAndLicenseAgreementMember_34d3151f-9f85-4f34-bac2-91729b6466bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c8218bc8-18ca-45c2-9636-8ed54ca1f9a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:to="loc_srt_ProductOrServiceAxis_c8218bc8-18ca-45c2-9636-8ed54ca1f9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_01fcf5f4-5846-4098-8409-80006a981642" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c8218bc8-18ca-45c2-9636-8ed54ca1f9a2" xlink:to="loc_srt_ProductsAndServicesDomain_01fcf5f4-5846-4098-8409-80006a981642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember_ad601d60-5e0d-4fa9-8a87-abab608acd1d" xlink:href="inbx-20211231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_01fcf5f4-5846-4098-8409-80006a981642" xlink:to="loc_inbx_LicenseNonAffiliateMember_ad601d60-5e0d-4fa9-8a87-abab608acd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAffiliateMember_1d93191c-01eb-4fb6-8eea-c177b5e50c4c" xlink:href="inbx-20211231.xsd#inbx_LicenseAffiliateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_01fcf5f4-5846-4098-8409-80006a981642" xlink:to="loc_inbx_LicenseAffiliateMember_1d93191c-01eb-4fb6-8eea-c177b5e50c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAffiliateOX40LicenseAgreementMember_4baab25e-a18f-4059-a08a-f35b950c9b38" xlink:href="inbx-20211231.xsd#inbx_LicenseAffiliateOX40LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_LicenseAffiliateMember_1d93191c-01eb-4fb6-8eea-c177b5e50c4c" xlink:to="loc_inbx_LicenseAffiliateOX40LicenseAgreementMember_4baab25e-a18f-4059-a08a-f35b950c9b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7472896-6705-488a-86b2-8c4e9f87bdcb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementMilestonePaymentsReceivable_c9cb78b4-0f72-48a5-ac73-98e7b63bd5df" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementMilestonePaymentsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementMilestonePaymentsReceivable_c9cb78b4-0f72-48a5-ac73-98e7b63bd5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_930649c3-c9dc-4275-822e-c629bac446ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_Revenues_930649c3-c9dc-4275-822e-c629bac446ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_6f023157-d932-482e-b03e-af3625912741" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementDevelopmentMilestoneReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_6f023157-d932-482e-b03e-af3625912741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementMilestonePaymentReceived_780d754c-6939-49e4-be17-e325df525613" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementMilestonePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementMilestonePaymentReceived_780d754c-6939-49e4-be17-e325df525613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_49bfdaf4-bd6b-4f82-bf1a-576a805bddbf" xlink:href="inbx-20211231.xsd#inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_49bfdaf4-bd6b-4f82-bf1a-576a805bddbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_c1aee4f6-6475-4a32-b130-40d165ba5f82" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementNonrefundableUpfrontPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_c1aee4f6-6475-4a32-b130-40d165ba5f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NumberOfPerformanceObligations_15f7c5a0-6939-4016-86d0-b331e08d07fa" xlink:href="inbx-20211231.xsd#inbx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_NumberOfPerformanceObligations_15f7c5a0-6939-4016-86d0-b331e08d07fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses_6f93513d-6fcc-4b4d-a581-09ee96044190" xlink:href="inbx-20211231.xsd#inbx_CollaborativeAgreementExclusiveDevelopmentLicenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses_6f93513d-6fcc-4b4d-a581-09ee96044190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee_f3ad4ddf-8c07-40ba-9e3f-a1e1eb32d2b6" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementNonrefundableOptionExtensionFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee_f3ad4ddf-8c07-40ba-9e3f-a1e1eb32d2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivable_f8e847fa-7b14-445e-a5cd-471ae0b46ab2" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementAdditionalPaymentReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivable_f8e847fa-7b14-445e-a5cd-471ae0b46ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_746ab5fd-4505-44a5-b6d3-ce9b8b8663bb" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod_746ab5fd-4505-44a5-b6d3-ce9b8b8663bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f5a3226d-5746-4c39-996f-5bf03408c4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f5a3226d-5746-4c39-996f-5bf03408c4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled_229f1bd5-cf1f-4016-8ef0-2611fed27082" xlink:href="inbx-20211231.xsd#inbx_EquityMethodInvestmentAdditionalOwnershipEntitled"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled_229f1bd5-cf1f-4016-8ef0-2611fed27082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementCommercializationMilestoneReceivable_0d9b224e-e268-4147-9c68-dc9f271341ec" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementCommercializationMilestoneReceivable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementCommercializationMilestoneReceivable_0d9b224e-e268-4147-9c68-dc9f271341ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9e4fa91e-20ef-4454-aefb-df49906b4b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_EquityMethodInvestments_9e4fa91e-20ef-4454-aefb-df49906b4b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementPaymentReceivable_e19fd7bd-a111-4f8c-aac7-a7336e3fe859" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementPaymentReceivable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementPaymentReceivable_e19fd7bd-a111-4f8c-aac7-a7336e3fe859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RevenueRecognitionNumberOfCompounds_be1c29a4-d025-4db0-8580-f2269c08442d" xlink:href="inbx-20211231.xsd#inbx_RevenueRecognitionNumberOfCompounds"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_RevenueRecognitionNumberOfCompounds_be1c29a4-d025-4db0-8580-f2269c08442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c3e221a5-27a3-4fcc-8c49-cf0f54969790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c3e221a5-27a3-4fcc-8c49-cf0f54969790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4773df31-8320-408f-8e87-5459c2e622fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4773df31-8320-408f-8e87-5459c2e622fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3b055e25-575a-4549-9bb1-3609fbe8c915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3b055e25-575a-4549-9bb1-3609fbe8c915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_c1d30dc8-7f52-4ad3-9899-b8ab2529078a" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f4020d3d-5c1b-4746-b4c2-7fcff33737d8" xlink:to="loc_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay_c1d30dc8-7f52-4ad3-9899-b8ab2529078a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LICENSEANDGRANTREVENUESGovernmentGrantsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_f9e427f1-c31d-47de-90ba-b44844c7fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cea0212-78a0-484a-9cca-8f87f367c1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_f9e427f1-c31d-47de-90ba-b44844c7fe5b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cea0212-78a0-484a-9cca-8f87f367c1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f3ab3d4e-7b30-4a64-9b06-18fb397963f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cea0212-78a0-484a-9cca-8f87f367c1e3" xlink:to="loc_srt_ProductOrServiceAxis_f3ab3d4e-7b30-4a64-9b06-18fb397963f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d4708a4a-f211-4da1-ac95-5a6919d35fa9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f3ab3d4e-7b30-4a64-9b06-18fb397963f3" xlink:to="loc_srt_ProductsAndServicesDomain_d4708a4a-f211-4da1-ac95-5a6919d35fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_67132374-7a65-4f7a-8a70-f5240e1764de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d4708a4a-f211-4da1-ac95-5a6919d35fa9" xlink:to="loc_us-gaap_GrantMember_67132374-7a65-4f7a-8a70-f5240e1764de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4fa17e4f-2d1f-42dc-b339-f67c4b3648e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cea0212-78a0-484a-9cca-8f87f367c1e3" xlink:to="loc_srt_CounterpartyNameAxis_4fa17e4f-2d1f-42dc-b339-f67c4b3648e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d0d2ab-c3c9-4c89-8af3-3211d74903ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4fa17e4f-2d1f-42dc-b339-f67c4b3648e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d0d2ab-c3c9-4c89-8af3-3211d74903ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember_f0a52c04-6e18-431a-8f14-dbff9bd3ae96" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d0d2ab-c3c9-4c89-8af3-3211d74903ba" xlink:to="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember_f0a52c04-6e18-431a-8f14-dbff9bd3ae96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember_be20f9a0-e973-4090-9dbe-29a7aaf6425a" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d0d2ab-c3c9-4c89-8af3-3211d74903ba" xlink:to="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember_be20f9a0-e973-4090-9dbe-29a7aaf6425a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_dfc4b45b-5c7a-48c0-a00e-05f46ae05175" xlink:href="inbx-20211231.xsd#inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d0d2ab-c3c9-4c89-8af3-3211d74903ba" xlink:to="loc_inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember_dfc4b45b-5c7a-48c0-a00e-05f46ae05175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07e73192-c72e-4a2f-9b0f-809e083b4c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cea0212-78a0-484a-9cca-8f87f367c1e3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07e73192-c72e-4a2f-9b0f-809e083b4c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GrantValuedAwarded_9099e011-c99f-4e02-88ba-d3b50a9bdddc" xlink:href="inbx-20211231.xsd#inbx_GrantValuedAwarded"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07e73192-c72e-4a2f-9b0f-809e083b4c06" xlink:to="loc_inbx_GrantValuedAwarded_9099e011-c99f-4e02-88ba-d3b50a9bdddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f5600c92-d9a3-4d8f-9c4b-5e8faf9cf540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07e73192-c72e-4a2f-9b0f-809e083b4c06" xlink:to="loc_us-gaap_Revenues_f5600c92-d9a3-4d8f-9c4b-5e8faf9cf540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RevenuesCashReceived_db33f4b4-1cb5-4c2d-8bcc-94711247c26f" xlink:href="inbx-20211231.xsd#inbx_RevenuesCashReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_07e73192-c72e-4a2f-9b0f-809e083b4c06" xlink:to="loc_inbx_RevenuesCashReceived_db33f4b4-1cb5-4c2d-8bcc-94711247c26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="inbx-20211231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0743a4e9-9ca8-445d-96f4-3b6863c95692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ecbc14d7-ba8b-4743-8c32-186aa10a0ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0743a4e9-9ca8-445d-96f4-3b6863c95692" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ecbc14d7-ba8b-4743-8c32-186aa10a0ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e8622dd5-9ba2-4a8c-8423-03154ccd84c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e8622dd5-9ba2-4a8c-8423-03154ccd84c8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad45c263-e956-4e3c-9085-e4b59e2b31a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad45c263-e956-4e3c-9085-e4b59e2b31a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7035af93-2970-4467-b78c-a9068f4d8a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad45c263-e956-4e3c-9085-e4b59e2b31a5" xlink:to="loc_us-gaap_RelatedPartyDomain_7035af93-2970-4467-b78c-a9068f4d8a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_71d5d0f4-59ab-4436-bcfa-216903f6db98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7035af93-2970-4467-b78c-a9068f4d8a03" xlink:to="loc_srt_AffiliatedEntityMember_71d5d0f4-59ab-4436-bcfa-216903f6db98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_21b68663-2baa-4fc0-a81a-f0db7fc04729" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_srt_CounterpartyNameAxis_21b68663-2baa-4fc0-a81a-f0db7fc04729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fb9b3715-f6d1-4c0f-9f9b-f4ce7485b4e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_21b68663-2baa-4fc0-a81a-f0db7fc04729" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fb9b3715-f6d1-4c0f-9f9b-f4ce7485b4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LAVSummitLimitedMember_cffbede3-ac5a-4df1-99de-f47212977be8" xlink:href="inbx-20211231.xsd#inbx_LAVSummitLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fb9b3715-f6d1-4c0f-9f9b-f4ce7485b4e6" xlink:to="loc_inbx_LAVSummitLimitedMember_cffbede3-ac5a-4df1-99de-f47212977be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b6a643ec-569e-4106-a8f2-46f9a6b1f5e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_srt_MajorCustomersAxis_b6a643ec-569e-4106-a8f2-46f9a6b1f5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_750373f7-98a5-4067-8a66-a8f278fb05d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b6a643ec-569e-4106-a8f2-46f9a6b1f5e5" xlink:to="loc_srt_NameOfMajorCustomerDomain_750373f7-98a5-4067-8a66-a8f278fb05d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_da4b9f30-c002-4758-8fe1-fb0e36c53daf" xlink:href="inbx-20211231.xsd#inbx_ElpiscienceBiopharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_750373f7-98a5-4067-8a66-a8f278fb05d9" xlink:to="loc_inbx_ElpiscienceBiopharmaceuticalsIncMember_da4b9f30-c002-4758-8fe1-fb0e36c53daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5cd5357b-e510-4d63-8188-c251994d8223" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_srt_ProductOrServiceAxis_5cd5357b-e510-4d63-8188-c251994d8223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_41b3bbcb-c99b-4b46-878c-708515513c15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5cd5357b-e510-4d63-8188-c251994d8223" xlink:to="loc_srt_ProductsAndServicesDomain_41b3bbcb-c99b-4b46-878c-708515513c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAffiliateOX40LicenseAgreementMember_e5028f36-2110-40da-9029-1ed75f6d0bb3" xlink:href="inbx-20211231.xsd#inbx_LicenseAffiliateOX40LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_41b3bbcb-c99b-4b46-878c-708515513c15" xlink:to="loc_inbx_LicenseAffiliateOX40LicenseAgreementMember_e5028f36-2110-40da-9029-1ed75f6d0bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_b99f0756-c59f-4d35-b1f4-eb86b4964776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_us-gaap_TransactionTypeAxis_b99f0756-c59f-4d35-b1f4-eb86b4964776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_5db6076b-9099-40d2-946c-6463ee7b9263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_b99f0756-c59f-4d35-b1f4-eb86b4964776" xlink:to="loc_us-gaap_TransactionDomain_5db6076b-9099-40d2-946c-6463ee7b9263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CostSharingAgreementMember_ab97ee67-f4af-4cbd-903b-6d5b34a8e207" xlink:href="inbx-20211231.xsd#inbx_CostSharingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_5db6076b-9099-40d2-946c-6463ee7b9263" xlink:to="loc_inbx_CostSharingAgreementMember_ab97ee67-f4af-4cbd-903b-6d5b34a8e207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SaleAndPurchaseAgreementMember_dd36aee1-d8e2-4ebe-b11f-5eb05d2ee388" xlink:href="inbx-20211231.xsd#inbx_SaleAndPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_5db6076b-9099-40d2-946c-6463ee7b9263" xlink:to="loc_inbx_SaleAndPurchaseAgreementMember_dd36aee1-d8e2-4ebe-b11f-5eb05d2ee388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35b1982b-1379-4e6c-a9ee-4f7aacd62c56" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RelatedPartyEquityInterestInCompany_fcfe775f-d205-4996-ac66-bd5a307d9b48" xlink:href="inbx-20211231.xsd#inbx_RelatedPartyEquityInterestInCompany"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_RelatedPartyEquityInterestInCompany_fcfe775f-d205-4996-ac66-bd5a307d9b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ExpensesReimbursedToDate_2d987de8-a829-41a1-b7f7-a5bbe96e8261" xlink:href="inbx-20211231.xsd#inbx_ExpensesReimbursedToDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_ExpensesReimbursedToDate_2d987de8-a829-41a1-b7f7-a5bbe96e8261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_33fb68f3-1416-4864-b080-bf9eab36c87d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_33fb68f3-1416-4864-b080-bf9eab36c87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ExpensesExpectedToBeReimbursed_c8a25093-797c-4358-8f61-c18abb35b193" xlink:href="inbx-20211231.xsd#inbx_ExpensesExpectedToBeReimbursed"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_ExpensesExpectedToBeReimbursed_c8a25093-797c-4358-8f61-c18abb35b193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementExpenseReimbursement_ebaa4bb7-e8a0-4829-a07d-7d573bc81eaf" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementExpenseReimbursement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_CollaborativeArrangementExpenseReimbursement_ebaa4bb7-e8a0-4829-a07d-7d573bc81eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_4efa0176-8da7-434e-8336-ca9899ab3309" xlink:href="inbx-20211231.xsd#inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod_4efa0176-8da7-434e-8336-ca9899ab3309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementReceivablesFromRelatedParties_4d4c54ff-3dea-415e-8345-9f870d8e2b07" xlink:href="inbx-20211231.xsd#inbx_CollaborativeArrangementReceivablesFromRelatedParties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_65657032-f069-4291-ae73-2999a60e8b7d" xlink:to="loc_inbx_CollaborativeArrangementReceivablesFromRelatedParties_4d4c54ff-3dea-415e-8345-9f870d8e2b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXES" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5271e182-e1cc-47d6-92c5-7c24c93fc7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2332a5ec-ad75-4c4f-b732-b19e7d0cd1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5271e182-e1cc-47d6-92c5-7c24c93fc7eb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2332a5ec-ad75-4c4f-b732-b19e7d0cd1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bdbd1d6a-dcbf-48a9-94b5-9c30b9840633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7024677c-5595-46eb-8a65-88bc1919e190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bdbd1d6a-dcbf-48a9-94b5-9c30b9840633" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7024677c-5595-46eb-8a65-88bc1919e190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f55ad4de-f20d-47f9-86a2-81f3d4195b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bdbd1d6a-dcbf-48a9-94b5-9c30b9840633" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f55ad4de-f20d-47f9-86a2-81f3d4195b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7874b009-cb8a-4097-a829-44357f8853f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bdbd1d6a-dcbf-48a9-94b5-9c30b9840633" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7874b009-cb8a-4097-a829-44357f8853f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_554a5995-01e5-4e13-bf19-d5019a7b5d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bdbd1d6a-dcbf-48a9-94b5-9c30b9840633" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_554a5995-01e5-4e13-bf19-d5019a7b5d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d179b17d-6331-46cb-bfad-6509886ef68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_c58b3046-4608-4812-8fad-932ec671895d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d179b17d-6331-46cb-bfad-6509886ef68c" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_c58b3046-4608-4812-8fad-932ec671895d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d288a416-6bfc-45ef-a0c6-07d954004e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_c58b3046-4608-4812-8fad-932ec671895d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d288a416-6bfc-45ef-a0c6-07d954004e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_16ea0432-905f-48d9-8e4e-1ab7d3eee01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d288a416-6bfc-45ef-a0c6-07d954004e40" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_16ea0432-905f-48d9-8e4e-1ab7d3eee01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_2239aedb-5af7-4c95-ad57-da12bca2519d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_16ea0432-905f-48d9-8e4e-1ab7d3eee01c" xlink:to="loc_us-gaap_DomesticCountryMember_2239aedb-5af7-4c95-ad57-da12bca2519d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3a94d40e-0c21-4333-9b8a-b63e31fab209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_16ea0432-905f-48d9-8e4e-1ab7d3eee01c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3a94d40e-0c21-4333-9b8a-b63e31fab209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_958713ed-c371-4b1c-985e-e95647b7574d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_c58b3046-4608-4812-8fad-932ec671895d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_958713ed-c371-4b1c-985e-e95647b7574d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d4cef53e-e002-4754-8066-7890852ca393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_958713ed-c371-4b1c-985e-e95647b7574d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d4cef53e-e002-4754-8066-7890852ca393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_afaf938a-7536-4bfa-ae86-11b9b999b48c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d4cef53e-e002-4754-8066-7890852ca393" xlink:to="loc_us-gaap_ResearchMember_afaf938a-7536-4bfa-ae86-11b9b999b48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_c58b3046-4608-4812-8fad-932ec671895d" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_eeed669a-b147-4bd8-865c-d8abe6edb925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_OperatingLossCarryforwards_eeed669a-b147-4bd8-865c-d8abe6edb925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_f393f463-7989-43e6-9c85-59b6f3ae4a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_f393f463-7989-43e6-9c85-59b6f3ae4a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_805029d9-ca3f-4ae4-81a3-cd5c89ba53a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_805029d9-ca3f-4ae4-81a3-cd5c89ba53a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fbb631ec-616e-4fd7-8835-19bd964be21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fbb631ec-616e-4fd7-8835-19bd964be21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5ae32d4d-b405-4be0-9a27-89b911354675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_5ae32d4d-b405-4be0-9a27-89b911354675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_50d1ec2b-768c-44dc-8424-bd9739c538a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e1c41ae1-cc99-4918-b00c-a6887d669c47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_50d1ec2b-768c-44dc-8424-bd9739c538a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d402d732-3153-4949-baf7-bead25917f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3f318818-d6f4-4829-8757-9c3a09a45db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d402d732-3153-4949-baf7-bead25917f38" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3f318818-d6f4-4829-8757-9c3a09a45db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e13a728e-e2e7-467b-99a3-30d8320cf603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d402d732-3153-4949-baf7-bead25917f38" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e13a728e-e2e7-467b-99a3-30d8320cf603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXESReconciliationofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8a147a-75a3-43dd-a7db-b154ef6a4fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6a49e9ac-52a9-4397-8db0-43cd46a9bf72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8a147a-75a3-43dd-a7db-b154ef6a4fd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6a49e9ac-52a9-4397-8db0-43cd46a9bf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_966dc1f3-0992-4c5c-ae0a-3c4a5e60c494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8a147a-75a3-43dd-a7db-b154ef6a4fd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_966dc1f3-0992-4c5c-ae0a-3c4a5e60c494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_64d01e4c-da1b-4276-8051-cba49b05bc26" xlink:href="inbx-20211231.xsd#inbx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8a147a-75a3-43dd-a7db-b154ef6a4fd7" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_64d01e4c-da1b-4276-8051-cba49b05bc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d9e8e7bd-6e8a-4325-b039-59d88fad50d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8a147a-75a3-43dd-a7db-b154ef6a4fd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d9e8e7bd-6e8a-4325-b039-59d88fad50d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_75eb33f1-e432-4504-9df0-d5e452cc981e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8a147a-75a3-43dd-a7db-b154ef6a4fd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_75eb33f1-e432-4504-9df0-d5e452cc981e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps_b2de6ca0-ba4a-4f61-a990-46bbc17b5dd6" xlink:href="inbx-20211231.xsd#inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8a147a-75a3-43dd-a7db-b154ef6a4fd7" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps_b2de6ca0-ba4a-4f61-a990-46bbc17b5dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_afa5570c-5b41-4d63-a484-f4292d9b6fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8a147a-75a3-43dd-a7db-b154ef6a4fd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_afa5570c-5b41-4d63-a484-f4292d9b6fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_47dab25e-0a95-4cdb-984c-92917be1a888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb8a147a-75a3-43dd-a7db-b154ef6a4fd7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_47dab25e-0a95-4cdb-984c-92917be1a888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXESComponentsofnetdeferredincometaxesDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_59b6706a-b512-4bb8-8355-3bd274a6e085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_59b6706a-b512-4bb8-8355-3bd274a6e085" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5784324c-25c7-4882-933a-cdcff8c31d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5784324c-25c7-4882-933a-cdcff8c31d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_61a3a894-72a3-427d-b5b3-9594185f8a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_61a3a894-72a3-427d-b5b3-9594185f8a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_818a5155-8b5e-4247-8b54-424b360c5865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_818a5155-8b5e-4247-8b54-424b360c5865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_b785ae05-6ed1-40e6-9e1b-9937aaaaf470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_b785ae05-6ed1-40e6-9e1b-9937aaaaf470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_fb92e651-94a1-4429-9c69-e514237feb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_fb92e651-94a1-4429-9c69-e514237feb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_5721cc71-ec0a-485c-a2b9-b683be9e2983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_5721cc71-ec0a-485c-a2b9-b683be9e2983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_2e25b966-1128-4108-86aa-ec985d62320a" xlink:href="inbx-20211231.xsd#inbx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_2e25b966-1128-4108-86aa-ec985d62320a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_612f84f2-2baa-47b4-9567-062438b87ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_612f84f2-2baa-47b4-9567-062438b87ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_61cda563-2e58-4b58-b393-41613122e1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_61cda563-2e58-4b58-b393-41613122e1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_637b0812-aaa6-49ac-8082-a704b419258b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_637b0812-aaa6-49ac-8082-a704b419258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e8741b9d-dd24-4056-a3c2-656369ff159a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_99109eff-ae21-4c38-924f-9f6c6e1c0c8a" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e8741b9d-dd24-4056-a3c2-656369ff159a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b651ad84-659a-4737-869e-49e59d4f42c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_59b6706a-b512-4bb8-8355-3bd274a6e085" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b651ad84-659a-4737-869e-49e59d4f42c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_54d48278-a48f-4003-89ae-2e025c249e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b651ad84-659a-4737-869e-49e59d4f42c8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_54d48278-a48f-4003-89ae-2e025c249e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1d0e29f4-6464-4f7d-871c-6743b1ac563a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b651ad84-659a-4737-869e-49e59d4f42c8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1d0e29f4-6464-4f7d-871c-6743b1ac563a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d94adbab-73cc-478c-aef7-fb82a171b27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b651ad84-659a-4737-869e-49e59d4f42c8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d94adbab-73cc-478c-aef7-fb82a171b27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_df0f6ace-3a0c-476d-8b50-6e885d28e9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_59b6706a-b512-4bb8-8355-3bd274a6e085" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_df0f6ace-3a0c-476d-8b50-6e885d28e9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#INCOMETAXESUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9629ae2d-3ac4-4f22-91d6-1409ef0104c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2062da74-1c4f-4cdc-b1e1-e06f52687677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9629ae2d-3ac4-4f22-91d6-1409ef0104c7" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2062da74-1c4f-4cdc-b1e1-e06f52687677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_14ddb8e6-b2dd-4802-989e-f3ce956da767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2062da74-1c4f-4cdc-b1e1-e06f52687677" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_14ddb8e6-b2dd-4802-989e-f3ce956da767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_705adbf5-638e-4a40-af0d-e7cf3d41ebad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2062da74-1c4f-4cdc-b1e1-e06f52687677" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_705adbf5-638e-4a40-af0d-e7cf3d41ebad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9541a022-7b15-4920-92c6-81d8e6e4345a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2062da74-1c4f-4cdc-b1e1-e06f52687677" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9541a022-7b15-4920-92c6-81d8e6e4345a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASES" xlink:type="simple" xlink:href="inbx-20211231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_71692106-dad0-44a4-94ee-db6d8439f72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_808515fe-eee2-4350-97d2-7798b977e5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_71692106-dad0-44a4-94ee-db6d8439f72d" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_808515fe-eee2-4350-97d2-7798b977e5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESTables" xlink:type="simple" xlink:href="inbx-20211231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_40287e99-451b-412a-8f3b-e1fc07d18d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_bdf6889b-f15b-42c2-87ed-77c7fd8780d9" xlink:href="inbx-20211231.xsd#inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40287e99-451b-412a-8f3b-e1fc07d18d5f" xlink:to="loc_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_bdf6889b-f15b-42c2-87ed-77c7fd8780d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_14d36a37-5109-4a7d-8d2d-b182ea5e128a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40287e99-451b-412a-8f3b-e1fc07d18d5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_14d36a37-5109-4a7d-8d2d-b182ea5e128a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a70e57b3-9884-488e-a47b-7e8328152e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_29bcd363-8119-4433-ba82-c017e1e0fa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a70e57b3-9884-488e-a47b-7e8328152e40" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_29bcd363-8119-4433-ba82-c017e1e0fa4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseSquareFootage_520a1a3a-1d02-4e25-bb86-fba093556f98" xlink:href="inbx-20211231.xsd#inbx_LesseeOperatingLeaseSquareFootage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a70e57b3-9884-488e-a47b-7e8328152e40" xlink:to="loc_inbx_LesseeOperatingLeaseSquareFootage_520a1a3a-1d02-4e25-bb86-fba093556f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7e1275f6-d370-4187-8b97-199ff8ec072a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a70e57b3-9884-488e-a47b-7e8328152e40" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7e1275f6-d370-4187-8b97-199ff8ec072a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_c3a2c025-e70f-458e-9b39-1a8ac52a40e0" xlink:href="inbx-20211231.xsd#inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a70e57b3-9884-488e-a47b-7e8328152e40" xlink:to="loc_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_c3a2c025-e70f-458e-9b39-1a8ac52a40e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseAnnualEscalations_54a83258-60e6-4adb-a566-d41523146009" xlink:href="inbx-20211231.xsd#inbx_LesseeOperatingLeaseAnnualEscalations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a70e57b3-9884-488e-a47b-7e8328152e40" xlink:to="loc_inbx_LesseeOperatingLeaseAnnualEscalations_54a83258-60e6-4adb-a566-d41523146009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseSquareFootageExpansion_211524bf-5574-49ac-aa12-962c419a8099" xlink:href="inbx-20211231.xsd#inbx_LesseeOperatingLeaseSquareFootageExpansion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a70e57b3-9884-488e-a47b-7e8328152e40" xlink:to="loc_inbx_LesseeOperatingLeaseSquareFootageExpansion_211524bf-5574-49ac-aa12-962c419a8099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_3d65b5b6-0fd0-4525-bb3f-7a237792fb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a70e57b3-9884-488e-a47b-7e8328152e40" xlink:to="loc_us-gaap_OperatingLeaseExpense_3d65b5b6-0fd0-4525-bb3f-7a237792fb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_73471009-c1fb-416c-9507-0473f3317317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a70e57b3-9884-488e-a47b-7e8328152e40" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_73471009-c1fb-416c-9507-0473f3317317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081a4b17-8ae7-4cfe-9a49-6bf06a8a5b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a70e57b3-9884-488e-a47b-7e8328152e40" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_081a4b17-8ae7-4cfe-9a49-6bf06a8a5b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c8cff745-23ac-4ea5-8863-490ad1a3f763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_05f7abe1-997d-4834-97ed-33c99d914de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c8cff745-23ac-4ea5-8863-490ad1a3f763" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_05f7abe1-997d-4834-97ed-33c99d914de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2a169a2a-7e8a-4963-8551-2b044c048747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c8cff745-23ac-4ea5-8863-490ad1a3f763" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2a169a2a-7e8a-4963-8551-2b044c048747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_943b1f53-9e47-448d-97b5-102725e922a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c8cff745-23ac-4ea5-8863-490ad1a3f763" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_943b1f53-9e47-448d-97b5-102725e922a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_83d8c18c-b52d-48fb-b12b-eda1e04e97cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c8cff745-23ac-4ea5-8863-490ad1a3f763" xlink:to="loc_us-gaap_OperatingLeaseLiability_83d8c18c-b52d-48fb-b12b-eda1e04e97cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7815c60b-cd8e-4291-a781-550b3dcb13e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a8f678b9-e313-4ce6-9cf2-5fc21962c6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7815c60b-cd8e-4291-a781-550b3dcb13e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a8f678b9-e313-4ce6-9cf2-5fc21962c6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c0c97cda-b4f6-4fb9-99bf-5097e95f3b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7815c60b-cd8e-4291-a781-550b3dcb13e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c0c97cda-b4f6-4fb9-99bf-5097e95f3b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bf5074fe-6acc-4515-b360-d5508bf4bcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7815c60b-cd8e-4291-a781-550b3dcb13e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bf5074fe-6acc-4515-b360-d5508bf4bcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2bdaf9e0-92c0-44b1-9ecc-e4678101f222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7815c60b-cd8e-4291-a781-550b3dcb13e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2bdaf9e0-92c0-44b1-9ecc-e4678101f222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_286eed13-c1cb-49ce-afda-e8283f749bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7815c60b-cd8e-4291-a781-550b3dcb13e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_286eed13-c1cb-49ce-afda-e8283f749bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4639051c-83f3-4cfd-b9f6-fb2552441ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7815c60b-cd8e-4291-a781-550b3dcb13e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4639051c-83f3-4cfd-b9f6-fb2552441ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9d735f6c-28f8-4969-a605-92173fc11877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7815c60b-cd8e-4291-a781-550b3dcb13e3" xlink:to="loc_us-gaap_OperatingLeaseLiability_9d735f6c-28f8-4969-a605-92173fc11877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_742301d7-9354-4534-8830-d5ae4441bc68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7815c60b-cd8e-4291-a781-550b3dcb13e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_742301d7-9354-4534-8830-d5ae4441bc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d981389b-b050-4276-9546-89e956aa3df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7815c60b-cd8e-4291-a781-550b3dcb13e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d981389b-b050-4276-9546-89e956aa3df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="inbx-20211231.xsd#LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="inbx-20211231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be027a4c-baed-4efa-bf4c-9dec4a6913de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c2b51b85-4ba8-4a5f-bbba-b985a4e548ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be027a4c-baed-4efa-bf4c-9dec4a6913de" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c2b51b85-4ba8-4a5f-bbba-b985a4e548ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ad1e240d-b53a-4fad-97dd-572448948571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_6febd63f-a0a5-4db9-b54e-1d08ba448184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ad1e240d-b53a-4fad-97dd-572448948571" xlink:to="loc_us-gaap_OtherCommitmentsTable_6febd63f-a0a5-4db9-b54e-1d08ba448184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_2a309266-826b-46ca-a0bb-cd0378a36931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_6febd63f-a0a5-4db9-b54e-1d08ba448184" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_2a309266-826b-46ca-a0bb-cd0378a36931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_d3e41fa3-4aee-40a7-9b41-c024aeedc81a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_2a309266-826b-46ca-a0bb-cd0378a36931" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_d3e41fa3-4aee-40a7-9b41-c024aeedc81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentMember_83a3c30c-668b-487c-bdd8-e6e89638d7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_d3e41fa3-4aee-40a7-9b41-c024aeedc81a" xlink:to="loc_us-gaap_PurchaseCommitmentMember_83a3c30c-668b-487c-bdd8-e6e89638d7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_2c9706d1-328d-4467-835f-49ea4d138118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_6febd63f-a0a5-4db9-b54e-1d08ba448184" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_2c9706d1-328d-4467-835f-49ea4d138118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalResearchAndDevelopmentCurrent_98444db3-e9e7-4768-9616-49ae96482beb" xlink:href="inbx-20211231.xsd#inbx_AccruedClinicalResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2c9706d1-328d-4467-835f-49ea4d138118" xlink:to="loc_inbx_AccruedClinicalResearchAndDevelopmentCurrent_98444db3-e9e7-4768-9616-49ae96482beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PurchaseCommitmentNonCancellablePortionOfContract_fceecc3d-43f9-4ead-8b87-f58abe31428d" xlink:href="inbx-20211231.xsd#inbx_PurchaseCommitmentNonCancellablePortionOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2c9706d1-328d-4467-835f-49ea4d138118" xlink:to="loc_inbx_PurchaseCommitmentNonCancellablePortionOfContract_fceecc3d-43f9-4ead-8b87-f58abe31428d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts_ff10593d-8ddc-41e4-90b6-3806e6ac402c" xlink:href="inbx-20211231.xsd#inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2c9706d1-328d-4467-835f-49ea4d138118" xlink:to="loc_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts_ff10593d-8ddc-41e4-90b6-3806e6ac402c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="inbx-20211231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_63214308-9338-4117-b83b-293851e8603f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_2b68500d-6389-4b39-843f-9dec6f018dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_63214308-9338-4117-b83b-293851e8603f" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_2b68500d-6389-4b39-843f-9dec6f018dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="inbx-20211231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8d720b04-f03f-4bd1-8d3a-c9df294c8438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8d720b04-f03f-4bd1-8d3a-c9df294c8438" xlink:to="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_634e90ce-533a-4932-b73b-6179e93bb3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_634e90ce-533a-4932-b73b-6179e93bb3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_deddcfb8-2e1d-45dd-a80c-8b11b7e73b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_634e90ce-533a-4932-b73b-6179e93bb3e1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_deddcfb8-2e1d-45dd-a80c-8b11b7e73b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_23278d2a-3a5f-4236-aad3-3dfd725c1b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_deddcfb8-2e1d-45dd-a80c-8b11b7e73b4f" xlink:to="loc_us-gaap_SubsequentEventMember_23278d2a-3a5f-4236-aad3-3dfd725c1b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_62d249bb-471d-4707-a672-fd51ce23d9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_AwardTypeAxis_62d249bb-471d-4707-a672-fd51ce23d9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ba9ce36-f470-4aab-b78c-f955dff1142e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_62d249bb-471d-4707-a672-fd51ce23d9b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ba9ce36-f470-4aab-b78c-f955dff1142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4f201d81-d4ee-4bba-abc9-7370f92fe276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ba9ce36-f470-4aab-b78c-f955dff1142e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4f201d81-d4ee-4bba-abc9-7370f92fe276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_41a811b9-e92c-4526-ac99-1902d3a153d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_VestingAxis_41a811b9-e92c-4526-ac99-1902d3a153d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7ffa3f91-36ed-4d54-924d-be5e1aa3a037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_41a811b9-e92c-4526-ac99-1902d3a153d9" xlink:to="loc_us-gaap_VestingDomain_7ffa3f91-36ed-4d54-924d-be5e1aa3a037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_22ace9ab-7edc-4d3a-9c34-0e6afd9b681b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7ffa3f91-36ed-4d54-924d-be5e1aa3a037" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_22ace9ab-7edc-4d3a-9c34-0e6afd9b681b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ad8608f2-dce0-43b9-9fd1-8f601a272dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_DebtInstrumentAxis_ad8608f2-dce0-43b9-9fd1-8f601a272dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ad8608f2-dce0-43b9-9fd1-8f601a272dcd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanMember_733f02c1-5b9b-41f7-a0ef-985fc6d826e0" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:to="loc_inbx_Amended2020OxfordTermLoanMember_733f02c1-5b9b-41f7-a0ef-985fc6d826e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheOneMember_b2e3c895-5eed-4c50-ae14-8e1ea8ba87b5" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheOneMember_b2e3c895-5eed-4c50-ae14-8e1ea8ba87b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheTwoMember_ec7b2ea6-3153-4d98-81f0-dcd0612e182e" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheTwoMember_ec7b2ea6-3153-4d98-81f0-dcd0612e182e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheThreeMember_d059ecb5-fd7b-4da5-904c-ff117134de25" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheThreeMember_d059ecb5-fd7b-4da5-904c-ff117134de25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Amended2020OxfordTermLoanTrancheFourMember_fbc9f38d-1c77-4a40-aa2e-e71ae55c630e" xlink:href="inbx-20211231.xsd#inbx_Amended2020OxfordTermLoanTrancheFourMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a44df42d-746a-4fe5-b444-2ac83fcf8c8a" xlink:to="loc_inbx_Amended2020OxfordTermLoanTrancheFourMember_fbc9f38d-1c77-4a40-aa2e-e71ae55c630e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ab3b5084-b706-489a-a878-5ca6782b2c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ab3b5084-b706-489a-a878-5ca6782b2c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_05d96899-d23d-4c8b-bc10-6c4dcee08660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ab3b5084-b706-489a-a878-5ca6782b2c61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_05d96899-d23d-4c8b-bc10-6c4dcee08660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e0629045-e964-491c-84ee-b71a23defd98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_05d96899-d23d-4c8b-bc10-6c4dcee08660" xlink:to="loc_us-gaap_SecuredDebtMember_e0629045-e964-491c-84ee-b71a23defd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c733c12d-c644-403f-bbf9-a780fddb7554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_VariableRateAxis_c733c12d-c644-403f-bbf9-a780fddb7554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3eb8af06-5c5c-41d6-9ef2-3ec80a5d31b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_c733c12d-c644-403f-bbf9-a780fddb7554" xlink:to="loc_us-gaap_VariableRateDomain_3eb8af06-5c5c-41d6-9ef2-3ec80a5d31b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9f8e1ea9-431c-483f-8322-1ef86cbdaf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3eb8af06-5c5c-41d6-9ef2-3ec80a5d31b5" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9f8e1ea9-431c-483f-8322-1ef86cbdaf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_faed9f32-c362-470f-954d-133f5a6be71e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_srt_RangeAxis_faed9f32-c362-470f-954d-133f5a6be71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3e95aed-51e7-48ec-a266-13034c249789" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_faed9f32-c362-470f-954d-133f5a6be71e" xlink:to="loc_srt_RangeMember_f3e95aed-51e7-48ec-a266-13034c249789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7507604e-3dd6-47ac-86e9-3d49791816b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f3e95aed-51e7-48ec-a266-13034c249789" xlink:to="loc_srt_MinimumMember_7507604e-3dd6-47ac-86e9-3d49791816b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_78b54259-6eca-4d02-a365-3dd1350c5528" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f3e95aed-51e7-48ec-a266-13034c249789" xlink:to="loc_srt_MaximumMember_78b54259-6eca-4d02-a365-3dd1350c5528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f489d15b-06ea-45d8-a8d6-cd7d02e42e25" xlink:to="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7af9f80f-d07c-4fb4-bb7b-741d579517df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7af9f80f-d07c-4fb4-bb7b-741d579517df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bc65c000-c22d-4bfb-a2f9-c77175afff06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bc65c000-c22d-4bfb-a2f9-c77175afff06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e2e3560a-870a-4a4a-93e9-f66f142313f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e2e3560a-870a-4a4a-93e9-f66f142313f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5476f849-2a67-450b-9613-a6b5b3849d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5476f849-2a67-450b-9613-a6b5b3849d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfAdditionalTranches_5945ef17-3816-4021-aa07-fbb8f35d8d4b" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentNumberOfAdditionalTranches"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentNumberOfAdditionalTranches_5945ef17-3816-4021-aa07-fbb8f35d8d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_f3a9b920-4a40-49d3-9e4c-849bf15d3c30" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches_f3a9b920-4a40-49d3-9e4c-849bf15d3c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_c29655f7-7b18-4473-97ac-75d15d03f2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_c29655f7-7b18-4473-97ac-75d15d03f2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2a880a65-170d-4d05-893b-d878329e9a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_LongTermDebt_2a880a65-170d-4d05-893b-d878329e9a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e7902b93-4dc3-4378-84f3-e905edab35ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e7902b93-4dc3-4378-84f3-e905edab35ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentAmendmentFee_151f053a-137a-4a1d-97d1-cfb7916545bf" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentAmendmentFee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentAmendmentFee_151f053a-137a-4a1d-97d1-cfb7916545bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfExistingTranches_8862eaa7-264b-4dea-bea2-e10c9d8787bf" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentNumberOfExistingTranches"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentNumberOfExistingTranches_8862eaa7-264b-4dea-bea2-e10c9d8787bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_60e8a3a5-8164-4ba9-b62a-2dd7130ceaed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_60e8a3a5-8164-4ba9-b62a-2dd7130ceaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3924ceba-b3ef-4dc8-9e88-5653e16f9282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3924ceba-b3ef-4dc8-9e88-5653e16f9282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum_13c2f68c-18d3-4510-bae6-84fd3b30f4a0" xlink:href="inbx-20211231.xsd#inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum_13c2f68c-18d3-4510-bae6-84fd3b30f4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod_b5105a90-3823-4ff6-b4f8-7f36a7b391fb" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod_b5105a90-3823-4ff6-b4f8-7f36a7b391fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_0bf49fdb-2826-4c11-b480-f5579f9bb614" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended_0bf49fdb-2826-4c11-b480-f5579f9bb614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_36554573-f5a4-4adb-9e55-3d1ac5fcecac" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_36554573-f5a4-4adb-9e55-3d1ac5fcecac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrepaymentFee_64bad060-fc49-45a5-863f-6574e6d78237" xlink:href="inbx-20211231.xsd#inbx_DebtInstrumentPrepaymentFee"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_inbx_DebtInstrumentPrepaymentFee_64bad060-fc49-45a5-863f-6574e6d78237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_108e11fe-ecce-4592-8153-508169f1aa93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_108e11fe-ecce-4592-8153-508169f1aa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d9ffb4fd-5eb0-4b53-b8d1-56679f3024b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c3027887-4b45-4ad2-a8bd-f3cb11c967f5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d9ffb4fd-5eb0-4b53-b8d1-56679f3024b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>inbx-20211231_g1.jpg
<TEXT>
begin 644 inbx-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHH[T47 **,YHI7 **#1WHN@"BBBF 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M167XN\5VWA#2FNKAF_NQHH^:5L<**XJR_:0L9YUBDTS5(Y>-RB/=LKAQ&986
MA+DK329,I);GI-%>;Z;^TEI3:J;74K>XTG>^V*2895O0G^[GWK>E^-'AF"\:
M!M9M?,7&<'*\^_2BCF6&JQYZ<TUZAS)G545GGQ+8_8EN?MUJ+=AD.90%/XUY
MSXT_:$GL[^:/1;>VN;>WQOGF8@-R,[?;W]Z,9F6&PL>>M))/;S!RBMV>K45Q
M_P '/BM'\5-!DG\L0WEHXCN8U^ZC')&#]*["NJE6C4BIQV92=]4%% HK0 HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4PRIQ7*UI;OYGI4I)JR-*BFHVZE&:^F-1:*!10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,<?\
MZZ4UE^,?$2^%/#5YJ##<+6(OC^\0.!4U*BA%REL@-(M@U#=W4=I \LCJD<:E
MF9N@ [U\W_$SXD>(M*TN;4[CQ ]G:W$9D9$D"+"G7&?T_&O%]&^/_B3QM-=0
MZ'HOC+6-/3,4DS#R8ISNZ+O.6!]1Z5\7BN.<#2TU\M+_ )'/+$Q1]"?'#]HK
M3-6M%TO3I9)(F?=-*#MS@\ >HZUYPFJV=Z+C4IC'###&VV-B")!WR/3O65\(
MV\._$3QO=Z5>23:9J5BVU[6\CV2K@9X&>>_(JG^V-X-3X?\ P"\3W=C=(DGV
M5D22-P7V$<D>AQ7P>=9]#$PEB6[\J>B.>K44E<\5_8YT[POXK^)/Q&\4:'#M
MU6?5#;!6.8H[?@ H,_*"4/3VKW;Q#\0/^$;MH[/4&M889G"JY?;EL#CDCL3P
M*_/[_@GUX_N/AMXV\62G[1)=:AI@^S1 $KN$B[2QZ#D]37:_\%&?@QXO^#_A
M+P]-K7C;4M6U3Q$3>W=@6"6]C@'B(XW#!?UR<>E?)Y=GE*E@_:U%JKWMZZ?B
M<M.I:-SWO1_!VE>-O&]K\1FNIDO;+6O[+M-DP:&.U(,1!4<9>1LEAT['BN@^
M/5[KVL_":ZM]!:&Z:"ZBG="=\<Z1R NAYZ\'BOSX^$GQM\0^&_@A;WS>(+N6
M'1M3\F73&D_=^7GB0K[N1T]<U].? /\ :D7QI^Q/\0(+2.PM]2LI))!*QV^2
MDBY<KZ$X./QKBHYI-5*E!4VXR3E?K?R%&IJ_,S?@W\0K7X__ +4&K-]A2S_M
M#3UM--9UQ(8XP7*GM@Y; [;17OVF^%];\*7]LL8DACL9!*DJ?>#KT-?.?[#.
MK^'])\4V^J7%Q8Q:DI,EOYDX7R0O)W#OTQ@<G\37UC=?MD>'=<TZ4KX/\16.
MFR;4_M:6%3"#RKDC<" &&.?6O2X2XPQ-2A*EB5]K3TO_ ,$UP]9\NIT'PU^(
M>M3:E-);ZQ>QR,I68R/N+9ZY!^G6O5?A1^T'<0^*)-&\27D9^T*7M[I\1J-H
M)()]QC%?.>D:W;0^/KAA-#;V^,,[L%53^)Z$?6NJ\7ZKX?\ $FG6_P!AUG2K
MJ\">8D<-RKN"OM7Z%3SRKA,9",IW4NC??R.CVK3W/JW0/BCH7B;4GL['4X9K
MA03L'&0,9QGZUT*-N'KZ5\6_"W58?$D+-=7#VTT(* J2&&*]G_9J^(.H:EXN
MU+0YKF6\LX;?[1$[G=Y/S ;<GGG/KVKZ_+>(/K%?ZM5A[WEL=,:E]&>VT4@.
M32U]0C4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2G5^EG8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M01TXKU/XH^%KCP=K+7_E>6S??4]67)Y_"O"/V/?@E;?LF7KC1;R\:&^!,L#
M_/,6W*8U'0;25P.P'I7TY=_"7QS\7X,R6G]G1S+GSKQMK,-V.%_7!HX;X7G@
MTJ6&IV75]WYCHT>5<J.*^%'C"+X=_&W1=79E6UOI?*F'3:KC:6_#.?PK[9MI
M5GB#J=RN RD=QBOC?P[^R-XXN_%J17UK"L,+@?:#(!&$!(RH_O8[>XK[$TVS
M_L_3X;=&W+;QK&">I  '-?KV3T:E*#IU.AWP32U+%%%%>TBPHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\#DJ7=3D/2O@-^QEHOPPL990T-_KNI.[WUXRC]ZV<[%'0*..  "0:^L/@/\
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M=PMCJFFR"XM958_NV!. WJO8@U]S?LD_MJ:3\:?#2V^IW,%AX^2,K<6+,/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **#30V/>@!U%-9\-2,VWD
MFE</4?130]"FBX#J*9NW4%B%I^0#Z*8&XZT;B!^% #Z*:C9%.H **:W!'/\
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M'-5]8I<O-S*U[;]>Q7MZ5K\RLM#T"BJ[78CC9F8*JC<2>@'6N%^"/[3O@?\
M:,DUM?!7B2Q\0'PY<BTU$VP;%M*=P"DD '.QN02.*J56$9<LGJ^@W4@I*+>K
MV\ST*BO"?B[_ ,%)/@K\"?'4GAOQ3\0=%TW6(2HFM\O(UN3_ 'RBD+^."*]?
M\%^-M+^(?A>SUK1=0M=4TO48Q-;7-M()(Y4/0@C_ "#FHIXJE4DXPDFT33Q%
M*;<823:->BHRS#;_ (XIQ?Y3C^=;FPZBH5=@.3_]:O-_AE^U;X9^+/QK\<>
M=):__M[X?O#'J@F@V0EI45U\ML_-PPSZ<5G*I&+49/5Z(B52,;*6ESTZBN#^
M,?[27@KX!W6AP^+_ !'8Z#)XBN_L6G+<;LW<W]T8!Q]3@5U&O^(HO#&@WFHW
M3.;>Q@>>3:OS%54L<#UP.E'MH:I/X=_(7MH7:OMOY=KFI17G_P"S1^T;X?\
MVK/A!IOC;PO]N_L752X@^UP^5,=C%22N3W%=[DD=:=.I&I%3@]'JF53J1FE*
M&J?4?12+UI:LH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDG'WEVL;Y-4DO8PA)R7+[WD?8"')IU-C7'UIU?8*_4^I"BBBF 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%+F0!1113
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HH)Q2$_A^% "T4@/O2C@4 %%(N>]+
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ</+M[J\AMU^9/FWA?P/7\:P_BU^V+J6M7W]FLNMZJ]O\L]OHEFTH5O^FA!
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MIJ @<FG5]F= 444"F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY%3U^RQ=U<[@HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MC'_Z]>#?'?QB-&^)#0ZHJR6JP!K1&)503U;L"1Q7O1&:Q_&'@31_'5@+75M/
MM[Z'.0)$R1]#UKS,VR]XV@Z'-RW[?D3./,K'SA;>-(O'&H6=O<3[;6,A,X^4
M+WR/?WK,\;?$>R\/?%A?#FDW\4-G]@,]U;PJ!+> G;]X#( 'H>];G[1OP0_X
M5)I7]L>'-WV.:8)):'[D>>X/7UKXS^-WQZD_9]^+_A?QG-:1RM<++IEW%.O8
MC<"#GZBOQSBC)ZF!I.HU=1M=+?E_ \^M%P1]6>!M?\(^(/B#JVDZ<D>DW=CI
MB3W.#A(SN/S,3U^4$YZ\5^;GQI\6ZA^TW^V9>>#YM0V6-G>&V26W/F*8 =QD
M4YZ;>?PKU[PO^V!H.O\ [/GCCQ-?#4[>36-2DMH0KK]H16!"A3R-H Z&O*OV
M*O@Q)'X?\:?$YH=QACFL]):;&[;M.]B<<'D"OA91IX^?U*A\.LGY69RR]]61
M]F> -9^'?[*/P*U+QM8#3KQH8#::(%CVQRX^7=M/(=F!)/7MTK\V_$TE]\:?
MCZNL7S74,=]?B]U2\@4D6HSPV1PI P 3[^];H^*FM_&71/"_A6U\QX-'B6U%
MNTH7]Z6.YCG@C)SGM^5?6>F_ S0_A)\$;K19"9KK4+%I-3NHTRS94G&/[H]\
MUCE^%K9ABO9T_P"'33^;#EYW;HC@?V0OV@=2\9_%^Q\'R:Y>7+37IM8KF:7S
M=EHC$[3G/!QG(]:ZO]M;XNV?A/XKVB^#=16[UK1H9K::\C):&-7ZHH.06XKY
M'_97^)=C\'=8\7?$)3OT_P +V\L%K*W62:7B-,>IP:]#_9#^,-I\0OBRMYJF
MGW%Y>ZM.9BRV^]$SR<H !T .:X<14QV#PB^KMN525]>EFK6_$SDVHZ'TY\)?
MA?>:=\&-!UN]5Y+C4D^U7DFWYYF.>6[YKZ,_97^)FD^ M=N+S4EO(0\*P0)'
M&&55/4MR/;UKG_AW^TAX&\1:99>'[[3]:T>X,;I97-W;".TO2"1M1QD9]CZU
M31+9/'9M4;-NPRR ]/J/\BOV#AS.JWU6$I:RBEK_ )GH4IM(^XM,U*'4[&.X
MAD$D,RAU8#J#5H'-?-WPC\;3>#?B5I>FPRS-I^J-Y30AOEW;?E//85]&HVY?
MO U^H97F4,;156.AVTY\RN244"BO4+"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:R9IU% ')_
M&6TEG^'M\L2[F !/L.]>-Z#-)?:2T._:P&U/I7T5?6JWUI)"ZAED4J0>]?/<
M>GMH?BF_MIE9'WML&.W;%+7H.^AQ.M_%@Z7J+:;8P+=3V+ 2LQVJ&'.!ZUZ]
MX=_:ZT*[T.'SK:^6^C0++"$!"D#KG-?)/QEU2[^%7Q6OK<MYD&J$W,))SU X
M_.L[PX]YJ&F?:$MY)IG!<R9Z'/2OAL?G&/PU>5VN7\CCE5DF>V^/?C'J'Q6\
M6R6YD:*U/RI"&RJC([>I]_2L#Q#XBC\+67V7P[:QZW>-&[-<>9Y=K9L 3\[C
MOD8P*\I\3Z=JW@GP1/?+?):W.LSK:1/(Y*QEV XQ_%@G%>UZ3X7TW1/!%GI.
MGQCR8(]K MN#D\EB?4Y/)YKX'.,=6QF)]E";MI=]OZL<]23DSS/5/B#XTO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW^Q!^T5X8^.FM:3<,FH:/=:\!<VEKJFGRV8NX@%(,)==DBC<H.UNI[9Y[_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR&9D+,2^[:K= 1@KDCC/U%\6O%6G67A_4-/UJ:'[9J&GS26UI("WGA "2<#
MZ@$DXYZGFOC_ ./6B6OP ^)%O>:#,UK)I]WE4D8%X)D;G(!R%)P 3U!ZE2*Z
M3_@IA^TWJ<VI^"I+.ZAD%YHA,LUDGEQRC*YD Z_-N''48-?CN!X@QE?!5ZGL
MTZBLK^7]7//C6DTT=Y^T!^V=X+^!_CNYNM'U*PU>Q\06HWVVE3I)Y5TBJ Q"
MY0;TSDCHP'!)XZKX)?ML>#_'?]E6WV35(%U.-!'>R64J6,DQX:)9Y$4,5;*Y
M P2!CK7P/\1_"%UXS^&'@WQ!I^CW*V>F"2WU/45R(YY9)'95&<'" @%@"#NP
M2,<_=O\ P2\U[1_BW^S]XH^&.M?9S#"IN+,NNZ2$/D%E^?<65QN# @Y8\DD5
M[&%SJM1E#")*TES)>=KVN7"4N919\Y>/_C3KOPO_ ."A&O:A&\<:SWL5J5=F
MVW%N8XP$? R6P >_).*_23P=\)5\<V5M>7%S+]ANH$N$:9]P"LH(!''//< C
MTK\T_P!MOX,77P>\6Z%XHO+>\EL/$D!:>:YDW,UQ PA=E&]G485#M/3=V.:^
M[OV5?B4?'WP'T>YM[F9H8;2,2,V 8]@VL"!@#&W/7@,O'-9Y#F%58RM%+367
MEK_P]QT9/F:9'XB?R?B/<>#_  ?IS:]K*PO,V)A'96?0*96STR>@&>#R#@'!
MUC1?B=X%O7NM2\/^$=0T=<O)%87<W]I1*!DJ4=0C,#D?*PY'09Q7H7PE\1W7
MA7[1!X?\%S7FK:E>R:@9VO4MFNX3)\KCS"0RJIQA2.W3)S1^/O[8?A72M=NM
M(CCOFURSS!'IZV,IFNYU4D)&40@X_O D#V[^E1S.5=<[K.+O9):+TUW--=[F
MM\/OB/HOBGX::?JVE[EDN LT%PC!6AP<$$#HZMP5]5KZVTP2?V? )C^_\L>9
M_O8YKYM_9M^'RZ58>$[#Q%I,=G>21S7YB#;D:XDD:X*D]#@L1CU!%?3*]?Y5
M^O\  ].H\(Z\W=R>QVX>+2'BB@#%%?<+8Z0HHHI@%%%% !1110 4444 %%%%
M !1110 4444 %%%% #9>G^%>9?$GXJ:M_:MYI?A]5BFTX;KFXD0-CC.U0>.X
M.:]-DYKPCXT>"]4TWQ[+=6[8LM<&Q6+8 E"_<;Z@$_\  37SW$V(Q%#!NMA^
MFK]#.K)J-T<MX@_; \0^$YXVU#4/#5C'&G'VH>2)A@_,VYQSGT('(Z5#XE_:
MAU[XD:/;R:7<0VL,:YD;3;@OY['&,,IR!UX!_&O+O@=^S]H/Q)5-4\8:?HWB
MK6KV^N)7DU.T2:"U<2&/RXHWW*BIY>!QNXR>M=[\7OV4;/3M*6^\!QQZ'XCT
MD_:Y!;-Y5O?X'^ID7<J@$# .,+UP1FORV?%F:\G,VG#[F<2JS:U,&V3783YU
MXMPJ3MERI,C,2>22>>_U'K7BW[?/[4%A\,?APOA>S58=3UR$QS"1L,L!/SR,
M.VX9 !XX-?5_AGXDV_BGP!I\NJ:;#;3K9I,RPG?M8@94$#D!N,C]:_*3]N^[
M;XH_M,ZHL4#R(UT+*VBB^:6X8,1Y8R!D [AC]>N?FN(<XE["*@K.IIYVW=OP
M,*U38_0?X<^'=/\ "WP^T=?#=G8Z=H8M8WM;9!@%&0,#P>^0*C\>_%-8M#FN
M/LL;:A$Z6EK:QI_K9VPJ#C YR"<9P.:\WM_AMX@^+GPDU#6&\6:I\._"7@>S
M6U:.Q:%KJXFAA7>C,2R*J?*,9.3G/H/A?X3?&3QXG[1^CP+JL.H:A?7K3R+=
M1*+4R %3-Y:D!?EQ]W!K2KG=&--44O?ELUVZ_P# #F21]^_ /X.ZC\%O%_C6
M;6-1@U2_O[Z"XGNH0\4.YXC*T:1$D!%,O##[P;U%=%^T+\;KGXEZ['X)T_7O
M^$9AT?2#?ZG=01HUV\+911&TBLB?,!\Q4]_6O"_V>/VO-0^+'Q.TG2=6N['3
M=0U[5HXM0@AM-ML5QY?!9F9<8YYZ#VK*_P""A%YI5]\7/^$<\/W+7%];VS6>
MJ3VDSC[2K$$6[;2"ZCNIXYQ@BO'CG^&I8%U'>/))^3>MR?:I0N2?LN6&O:-\
M/KHZOJNJ:P^N:K=7-O)?2I-*ENS*L2[U 4_*@/W5.6/&, ?=W[%WBFYL]6U#
M2I+AETRWLUGD+L-D4Q=0/ID;N!QQ7S[^S#\"[F\_9NT2WNX)+74+#S(^FY@-
M[,O;T:MF;PE-X#G'VM?-W/@NW?/0$=J_6,AXCHXBA2Q5*][;=_4[*-39H^^;
M>3S%RK!E/0@\&I*^6O!?Q$\0>!/#D;:?J:R6ZDL+:2)70$\D;L;OUKZ%^'7C
MJ#XA^"M/UFU/[N^C.05V[75BC#!/9E85][EN<T,;=0T:W3.JG44CH**;&VZG
M5ZUS0****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 UNHKYM^,'AW7O /Q#U75([&XO-,U*0S+<1KYGDY'(8=@,?K7TDXS
MZ_4=J\@_:G^(K:5I5IX?M;B..XU7/VA0W[Q(OZ9_I7CYYAJ-?".-?8SJ)6/S
MB_X*2?'2[^'?@&SO-*GDBOO$%VMFQB W)&>7YS],8]ZY7X%?#W5OB#\);S[/
M81K+=QH]M+=3>7['C!))/KBL_P#X*,_!+4/'_P 1_#=C97$MM8VRO)'Y*_O!
M-N !!]< <5L>&OCMXB^ EAH]KXLTNZO/W:QFYCQ'(P'<QXP2.,XQ7\X<3?V%
MC\TCA,TJN#II<JZ/KJ>/6C3G+EGT+/[#_AC6/V6OB]#X@\50V,"M//;Q6T8-
MQ<WVXX_=H ".WS'@<5[5XUU[7/B%\68_$VKVW]CZ?IV^*QTYGWM&C\&1R.-Q
M'&.U<MX2\7^'?B;\39/%6DW#7#:;8I:"&6$*;=G)+'/7/ KV;P;X'A\5Z?-/
M<?>N&+;>V.W\J^CX?RG T8/$T6Y4FW9=WW^70VITXK;8^?/VPOV)=)^.UHWB
MKPOJ7]E^)H8/,6+&8[EE!P..<_05\P?#?X\ZI\+AJ7A/4-#DNM0NHH;)9& \
MVTE$FYL!N>2..*_2SP3X,@TWQ#);88KT SQU_P 2*_.#]H_P5K_PW_:UU;7+
MQXY+RUOC(JIM*@[N,\@<<?G7@\5T<-@ZT*]+XVV[OS1EB(J+3B?=?P:^.UUX
MR\#Z?/I]O-+#=KY>\\ ,,AL^X/K6%\?_ -B/0/VG-)NK'6H88];,>[3]0V9>
MSD/0YZ[>F17I/[(&CPZU\ 4M[JS32=6TM/,FA8K\[NQDW#!/#;N_-;GAZXO-
M7\;;H[?S?LGRE1W(//3Z5]C0QD,3A>:$;)JS\]-SJ3YHZGQ!J7P)7X=>$1\+
M?B;J$,?B+0ITU/P[J$9+0W$.?WD8?OD ';U!-?1/_!/32R_@GQ=:ZZTMK)!J
M1GMHW<2$+(N5P1QR #QZUT?[;<NC:C\(KY[K06N-2W[=,D5<M:2D'D=\<\^M
M?&G[(O[0LGP=^(FL6&M37'V>^*0.^3LMF' )'8=1^-?EU*V&S^--RTLM?7<X
MG:-2Q]^VNL6^G7<B!9II8V( 0'C\<U]!_L\_%$>(O#L>GZA-)'J4#%46;[TJ
M#H0>]?*_@?XC_P!CZY;R2PQ-;W2J(9VQ)'(".#SD5[/;:O(?"]OJ]K)!'<Z3
M<"0+'& P7N>F.?2OVO 9C/ 5XRWC*WXGH0DXL^D <TM9_A37%\2>';.^161;
MJ)9-K=1FM"OU6G)2BI([@HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH :XKP[Q3XAD\1?$O5KR21H;?1U,,) W#(ZG\:]KU5U33IBS^6GEM
MN?\ NC'6OFK0-)O+>&;SKB1=/OKAR9F_Y:#)P:^+XTQ#CAE03MS&&(E:-CS[
MXJ?$BZO;M=.@/VB:9M^"/NCU-?)/[:?[2:MX.U'PCIN;J8H#J5S;/YD-GMZ*
M6!QN)/('%>J?M[^/X?@%X6OM0@F:34-2B^S6JH/G!)Y?V '7ZUX1!\/+CQ9^
MP;JWBJ\@TG2_[6U" V@2(1O<IO\ F8XZY/\ (U^.\2YLHX?ZCAEHXMREVMT]
M3S:T_=Y4>A_\$TC)H%^]OJ.E"ZN-5@,ME=S#F$8&0GUSS]!7UM\2X]0N=#M[
MY;:&UCAP$"J!G&,U\@?L@MJ_@KXM_#=H_LMU'=:3+(D<S[1"F\JS8/!Z<5]E
M^.]FE^&+C4M:U*WM;/:SI#NS)*,_P1C+'.>P]*\O@N:HX>2J/[5[_P"))_J+
M#)),@T2^L=-^'VI:]J$T/FVMLQ5&;:. 6Z_AC\:_*_\ :I\/ZMXX^*LUAJ<E
MO9K;L+N&.!P5@CDPX4G^+J#W/-?8GQ>U[Q!?>"K^^-E>:3X'TV$WLUQ?*8IK
MX _+&(^NPMC.0,Y'O7YN>(/$OBK6_$5]KEU<+,UY.\GDD']TF2 JGT QCTJ^
M+'&7*X5$M;HFOT/UB^%7@?\ X1C]F_PO97-U!J$S6,;":)@R[3T_SUKI[?X>
M6-OX<9QM#,GKWKY._P""=?QVU#XI_LXPZ(\;6]]X<O)+2[+MDA<Y5_Q_I7TG
M!XJAL;989[X,NWE5.>E?=Y3AZ\<%22EV9UPNHH\Z^,9LY/"5R=4DN%M]#9+U
M6C;$A\MAT/T)KS#Q9^V)=?$[QC9Z5X3TJ/R[K 2>\D+-TP20._3KUKT/]H:S
ME\4^#KZ5;.[DTR1HX;SR7,;I;LVUY <'[N0>AZ5\F? #X,76A_ML67A.;Q7;
MW%G(?,L-3L&$T<XP2L;$95)",94\BOG^*JV9T\3_ ,)LE!M6>G7O_P $RQ$I
MQ?N'1']E'Q18_M,Z+X@U.;6O[9N[M9WG=25,8STSP% ./;-?I1\ _'$'PN\7
MZ;OO$M=.U0B*X!Y4GG!/OGO[U+XB\%MH/PULXIH;JYND@VI>SJ#*ZX]>V/:O
M+_$4JP>$K7:=TB.!T[@UZ' =''X.C'Z]4]I-SN_3U-*$7%ZGW_ ZRKYBD,K@
M$,.XI]8OP[OI-2\#:3/(NV26TC9AC'.T5M5^]Q=U<](****8!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4&FN?2N+^+?Q@A^&EO;*L:W5Y=.56/=]P 9W']*QK5H4H<]1Z";2W*GQA^
M,DG@*[MM.LK5;G4KR,R+O;"1+D#)[]^/I7R_\3[R\U'6G_M"9KF:^E).6)!.
M>F#V'%=+K'C>Z^*WQ8?4)H8X62WCM_+A8E1@L1@GOS7*_&V#^P9X[B2XABFA
M<$)(X5CW[FOSG-<X=;&^R4O<MIT.2I4;E8ZSX5_ Q;:W;4#Y(C.=S2/C8?I_
M]<5\8_MA_ K2_ FOZIX@TVY\EKZ\FN@6("D[SGRV'4YSQ7J?B+QW;_&7XI:7
MX1O=1U%]-^RM=/86=QMC-PF&_>LIS]P,0I.#AN#7&_$;]E.W^+&FZEX4U*^U
M#1-8T5;B\T=HV8V]_"P+JGS$\H2,XQT]S7Y+QA@:^8NS?P/1K>^C_(XJT><\
ML^-'Q\F^.?["RQS:Q-?:WX+O(TN&D.3"K2*F!CDKM/!/H:XO]C/X-K^T!X.U
M2UU]GN-$MY6^PL3A?M#  L>_  Q^->!?!;7]2\(_&[7-#D:-])UJ&32]1@G#
M,$8?==5'.5/3/6OI?_@G/H=W\)OA]J4GBZ\?38-0Q=6AF&R-2@;(PQ'S'!X'
M7%3@:>#6*H.O-+F2C+NW9[DTU%R39CR+XB_8E^,=O-'++')ITF^!PV%NX,_X
M<'%>Q^-_B@G[6GB;Q;HEK<NZ^(O"]M?64;=(;P2LC87MVY]Z[/Q)\ M<_;CT
MN-K&SM['3K"%WL+ZYA+7%RP'RL%[)D<CN#[5\F_LR?$*;]EK]K>XT'QA826-
MTSFSN99QM^SJ#P5/]PG&".QKDH8&&$QKISUH-[B4>5V>QZ7_ ,$C?C#XE^%O
MC76_"*R1PZ=---!J"2L!Y4X^4MGKQM( %?37@CXB:'\-=9\?:3KFK-#'HMQ)
M?VLDL_F.QGRV%7J ),CUQ^%?-7[2OP'@\*_M%:3XLT'4#9Z7XHF^U1R0@+&]
MPJ[]HQ_>49SWP:Y'XZ?"3Q#\6?'FI>*M*DN637IK72$5T/[R<J@D]OO*QSZ&
MN2MC:N#JRH0T;?NO_%^FS!R:=C[+_9;^,>I:?\%[>34;Z0KK<TMVI<[3Y<CG
M;D>X&<^A%>U>!/@=XH^*\7]H6MQ'H]B0&BDN4+F;(R"%!'&".:\^^"7[-9MK
M'1=%D=6^S1P6OF2#. ,*/;&<5]R:-I,.CZ1:V<*XBLX5A7V50 !^0%?NW"N0
MX9TDGJHI)^IZ&'IQ:U.>^$/PHM_A9HDEN+F2]O+G#7$SC&XXZ =AUKKZ11M&
M!2U^B4:4:<%""LD=FVP4445H 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 $9IH7_(I37*?&+XA+\.O!5S>JZBY;$,()'#,< X[XZUC6K1
MI1=2;T0F[:LXK]JGX<V/BJRL;^1@EY;DQ*,X\Q#@G/T('YU^='[:?[&EQXZ^
M(GA+4;-KAHKR9M)N/*)Q&)2-I/.-N[KZ;J^O/%/C&Z\63K<SZHUU(?X"WRJ>
MX [5YO\ MO-J/PY_9<U36H;@"ZD:!(60_-&6E0<8YSR.E?B?&V.^N4*SC[J<
M?G=;,X,1+F1\5_$3X7B[\$:5X'D6Z6^T&Y_LRWCB<G?,TK9<CT"D5U7[7OQ\
M\.?LN?L[V_PX\-W5K)K,$*PW01@VPG!DSW^9B>O/;L*?X>T35O!.E>*_B?>Z
ME-J&J7(BA\,V?F9,]Y.@!EVG^XIZ>IKFOV<O^";FK>//$\GQ(^)UM?+?W-UY
MEOIMP"IF.XD22C/KCCICJ*_.>%8K$4?94I6E*W-+M;I\^IQTHJ2T.[_X)\_\
M$Y]8\:?!J;QUKEY<:!=2*DVF1* VT'#"5E8'@YQ^=>@^(/'NH^&=7D\-^*["
M2ZUR:$P:?-!E8-28@ 8Z[2#G/'0<=Z]RTCXMKX%\,_V/+NLUCC6,Q+\H*#@!
M1[<<=.:^1/VBOVCO"NC_ !%\37.I7FW6-/L('T*5&W&&Z5W,D?U(V9]LU]5B
MLOGE.&E4H/E;OKWT?XFTH^SCH?+?Q%^"WB7]G3PMXX59+J"/Q,D=C%>#Y@(V
M;S)$W8!!(&,C!Q]:]7_X)@_L\>'-?^%6N^-/%VFW%U8Z"Z06$&[:+N4<G ZG
M&%&#Q\U<OX-^%WCS]M'X@W>GZ<LDF@VEPMS<W,SXAB+(H"^[!1GCH&%?97B+
MX.#X*?!:S\,^&/(?4;54F 7"K=7$;!^<Y^]MQ7AY'A<7C:*]O'11YEYLQIQ<
MD7/%?PNE\)? K5=6U;2;:ZUF[D>[CAB"QM8LX"11QNH!&U=G/7);GBJO@S]I
M3PWX\M-#DO/$5GM6-8W9Y,R-(@ ?=[@]?K7H7CWXQ:+\4?V3?$%G'I]X_BR&
M#RSIXXFAE!SYB=-RC[W&:^#?V:/!$TOQ(U:TETV_M[)9T:9S;,H5F4GIU&:G
M'\1U\JYE@Z/,XPWL^]M;+<)5G#2*/TTN&L=<^'@NM/OK.\MY@562&0-M&.I'
MUQ6]\(_VBM:T'2--MI)+>XL+-5MVC:/&$7C.1SD5^9^I_M.WW[-WQ&2:QN&D
MTJ6X%I=6LC%4>,MMZ?PD$@@]?UK[N^#/B*TT/0$DN?)F6Z7S<EOOY&<@],=_
MI7UG!O$&(Q.!>*A%QGS;=SHP]:4H\W4^V= UZU\2:;'=V4R3V\G1E_E5T=*\
M3_9)N[O5)-:N$\U=)W(L&1A'DR2Q7\"/:O:UK]TP&(E6H1JS5FUL>E&5U<6B
MBBNPH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ;*2!\HR>:^=/CUXDEN?C+)I^J-,-.MX
MHWM(BP"-D9:0>IR"/;;7T6_\O>O$?VMO$/AV33DTR;35U+Q"L?FVQ&]/LBMP
M'9E(XSG"G(X/%>-GE%5,+).?+YF=35'SS\<?&6F^&)(;IKB.QTN%_.N'E;"H
MG]X]@.F3]*\[?_@HA9ZK:7&F^$_#<>I6\)5EO[J<QB4 '<1&!G;QPQ(SGIZ_
M,O\ P4^_:(<:3HOP[M-0AM[^\NQ)J<V\%4C7B.-\CY58L&+ K@1G)P37HW[,
MW[/>M>%]!*W>I:/!=O9M'Y4:M<*F[NO* J05(/!YZ5^"<60S:4(X;)(<TH/W
MG=?J>3B.?:F&L?MQQR^+XM+30[BT\1:W(MM!#%<"6!=QQYKL57:HSGD?CUKU
M+_A5]QI?[+>@7RZ/I'G:?!:W]U:VEG&5NX58/)C<06++N<\Y))ZYKYR\-_LO
M>*M&^-5UJ>N6^D/HL-W$GV^YU"&W@,0/0[FWKN)VC@\D=>H^O_VC/VGM'\1Z
M ?#?PYTV;4[J>&&UN+NW@:*PTI) @WEL#HC$J$SPK=,'/G8'%9CB']6S6/[R
M*LKK5WMMWML%.4Y:2/@;_@I]\(;'X(ZUI>J>'=6N;JQ\96;7MI#(Q9H\E<(N
M1G;AEP#V'4UY1\3_ (EW/C/X9_!UKJ"_;4WTZ6PNX&B;:QBG4(ZL"6)<, 2>
MA#5]<?\ !2[X,WOB[X ^&-=07%S#X;8181=ZQ1F,!7+=>"JC'3YO:O+/V5+S
MX=ZYI5D;ZQFL]0L;)HY[K[1\J,92WR#<H4D?*/F7)R>N37%FE2.6.>']G?FM
M?IJ[?J9R]S0^L/!_PIT?7?A%+X1ETN+3K2XTU8XX-OF&%RN_(R#\P8DX&,8/
M.,@_+'P#^*=Y^S;^T T=UYUJENTMA?F0[%50<%F[ <!@<GMZBOIKX&^$O%GQ
M^62'7M?OO#]MI;C3YK2PM_LNH2/&!AI9G9^'4JQVGD'@D')\=_X*^?LB1?LU
M:=X?\1:#%<7FBRHMO>))<--]GDZ1%MQ)PR@)DX'RJ,C@'T,\P[Q*H8K#4^7D
M2_K[S2K%NTHG _M3ZG?>-OV./"7B:%G#76M75S>7#Q$LHN'?G=G(R4 P ?O
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M>D;NQXQD]>..W:OUCAO*,7@:DE4=XM?B=U*G*.YK@YHH%%?8&P4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>LX&#22HO$=P@/5@/X01G'>OL+X$ZA#XUM[BXT"_CN+^!\W$#$Q7$38Y5HV
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MGX+^/I/%VDW,%W(K7VG.$E.,;U.=K?H:[5:_5<+B85Z4:L-FCOB[JXM%%%=
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MG+2W:ZNOP_,Y*VDDCZ0_9\_9NT3X/^$X].$QFN[BZ>ZU"\.XF:>3;O?'&.
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M11NHS0 4449R: "BBB@ HHHH **** "B@'-)O'J* %HHW49H **,T4 %%%%
M!11FC- !111F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!KFOBC_ (+( [/@GW4^.K08 Z\BOM=^M?//_!03
M]C76OVQO"GA6U\/^*[;PCJGA?5TU:WNY]/\ MJ[T'RC9O0=0.IKS<VI3J864
M::N]/S1PYE3G/#25--OR]49G_!7"[TVT_P""=GQ,_M)X8U?3?+@+?+F8R+L"
M_P"UFOE+]IZ^\9:/JG[%\VAZ=8ZEXS@5#:6FHSM##/-]FX61U!(&WT':O?/^
M';'CCXV^*=)NOCC\7KSXB:-HMREW#H>GZ4FDV$\B$%?.16.\#&<9KT[]H?\
M8VD^,OQ\^$7C*RUJVTFU^%]\]V;'[)YGVQ"A0(K!@$Q]#^'?QL5@J^)G*NHN
M#M%):-Z2NWY/MN>7B,+7Q$G4<7'X5:^NCN?)/CW6_B=^V1^VSX-^$/QMA\._
M#_3=!9/%%G;:.99QX@>%P0BSNP^[CD  \U[U^U5^PMJG[1?[6FB>,=!^+%]X
M'U#0=$DTR6WTA4_M***5LLRN6.P'IDK]#Q7;_MI?L52?M.ZCX*\0Z#KJ>$_&
MW@/54O\ 3]5-L9@8\_O8'4,I96'O@'GZ<]^T;^PWXL\>_&32?BC\.?B#_P (
M-\0K.P&FWUQ+IPO+'4X /NO"S<8/0Y./>J>6U(^T5:#J)RB[\UI:;;6V^02R
M^JHS52+E[R=T]6OO6QQW[$?Q'^('PB_;,\;? GQSXPO/B!9Z7ID&MZ-K%]C[
M:(Y#@QRM_%QW/'7%=_\ \%3/@GXV^/7[*MYHG@-Y)M4CO[>YN;".[^RMJEJC
M?O+<2?PE@?7M5C]D+]B'5/@E\2/$WQ"\<^,)O'GQ$\61QVUUJ M1:6]M;IRL
M440)"@'N/08 YSUO[9?[*D'[67PQAT5==U'PSJVFWD>HZ9JEDW[RTGC.5)7(
M#*3C([UU4<+6E@94IIW=[*^J3>BN=5/#U7A)0J)W;=E?5)O374^*?V7M"^$V
MA?M;> X;'P[X^_9_^(%A$8FT&\B/]G>*%*X,?F9*NQZY7&<=ZZ']DO\ 9L\+
M_M\?'#XU>-/BE:3>([K3/$,F@Z79W%PXCTJWC4CY$! 5NX/45ZAX'_X)\_$7
MQE\>_"/C+XQ?%*U\;)\/V:XT6RL-&3356<\"64JQW\#.#U(_*3QK_P $]/B!
MX-^-_BCQ;\&?BJ/ -IXZE6?7-,N](34(3.!M,T(8X1B.>G4_7/E4L#B(Q4IT
MKP3?NZ)O2RND[;_YGFTL#624I4[Q3>FBO==5MN>7_P#!+G4M%_9-^&G[2UTU
MQ(NB^"_$DTBM<2%F,<<!*J6/)/09/6OEBU^-W@'QQ^P_XVU#5K[6%^+WB7Q&
M?&-JXTJ=EBFBD#6\?F!<;1'QD<?KG['T?_@D)XCT?]GKQYX!_P"%G_;%^('B
M2#6M3U"?2R9IH%*^9 P64#<^#\PX'H:^RO#_ ,*M"\.^"[30K?2['[#9VB6:
M(T"',:J%P>.X%*GE&+JTH4W%044[)J^K=[K7IT)IY;B:M.--^ZHIZ/75N]]^
MG0^!_P#@H;\8[/\ :S_X)'^!_$L4S*/$6MZ+'=["/,BE,WER#V8-D^U5?VZO
MV,O!?[&7P \%_$SX=PW7A_QAX9UC35-^MW(9M225U61)=S'?NR?UKT+Q)_P2
M*U36/V:O%GPOM?B#%8Z#K7B]/$VDNNG,9=(C$AD>$'S?F).,-P!@\'(Q<N_^
M":/Q+^*OB/PQI?Q0^,DGC#X>^$;R*]M=(ATB.SGO'BQY8GE4_.%P.HR>?>G7
MP6*JN3J47S.*2::T:;UWV"IA*U1N52E>344FGLU<^RO"FI-K?AK3[R1=C7=K
M',PQ@J64$C]:Y/XK_L]:#\6KV&ZOOM%O<Q<-+"^TNG]TYXKM[&%;:)8D552-
M0J@#  ^E3D9KZ_V:E%1F?51BU%)G-_#;X6Z/\+?#ZZ?I5LL4*G+,?O2-ZFI_
M'_A/3?%_AB[M-4MX+BW\IFS*/N$ _-GMBMMA@?X5Y3\:?CK)X?U"Z\/Z7I\=
M]>-!B669L11[NVW'S<>X_&N?%5J.'HN4]$$K)'RMX\L=/M/#C+%"D<T;MMEC
M/^L )YZ\\#K7SQ\8OVTM-^&GAMM-T*2#Q-XLOV>#3+&QG$K>=C@.1]W&><UV
M_P ;8_$'B/QII_@F.XN+&SE#76K7-JC1O# 3@(IZ#<3C@D_2I/"?[#_@WX/Z
M>=5\-Z6BWZ?.9YV:>4GDGYF)P<YYZG-?G$L1S/V=-JS?Q=O)'&[O0^9M4_8@
MO/ OP6U+QQ\2-3MYOB)XRN5E\^9]RP*OS>4OOCL/3WKW3_@G)\"Y?"?PQU;6
M-4MVMI-8D_T9V.)'B49SCL":Z3]I+X57'Q[^(O@7P?+=+;Z?IVV^U&4-&S1%
MAM"?>X+  #Z&OH[6/@?<>%-&M]J>79QQB.-0<[5Q@ _A7YW0P<9YE4Q$YZ0=
ME]W4XU&\VS\L/#_C/5OA3^U#X?@M[KB;5IHBT?.8Y)",?D:^SOVK/ 0\1?L^
MZY!;QL]]'&+I/,_B,9!//7H#7R=>_P!A^'?VNM"749(I5MM6,5P/NA6\T[1V
M]ORK]#OC9<:7XV\$7FFZ7 RR7%L]L[ %\,ZE220.!S6/"DI5L-7PG+I)RO\
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M9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX7?#^6'4%\FZO9O/\G=GREP,9Y//7->H5]]@8.%",7V.B.BL%%%%=104444
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M7UE$BZI;+Y<W[L.O)S_7Z?RJMX9UXWLLD4C9DA^= >XR./\ ZY_PKP;]M?\
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M$U_->74EOI^E0M/-(H+,P49. O/;MVS7Y'4Q3Q>*J5J^B2=WY(X+W;;/'O\
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M$:Z:,K$,8)4(JXSWSD]*^SR_(986<6GL;TZ;3N>D)]WZ<4ZFJ:=7U1N%%%%
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M!HC)-70XR3U044450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCMH?).K?\$Y'\#_\$Y?&OPA\(ZA'J'B7Q79S/<ZIJ,AC%_>RNK/([ -M4X.
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M<=1E356,KQ;2OYMV/>I@60@':Q'!QTKX3^)?P_\ $'@[X@ZO#'8W4TEY<22
M+"S+*'?((Q]?UK[G68MG)'7UI5A2>3>57<.,XR12QF#CB(V9TRBI'S3\+/V2
M_$E[X5M;C4]672Y;@%FM/(/F6XR1C.?;/XUG?&;]E76/!U@NIZ?>2:[;QJ?M
M$<B!9$&.HQU[U]5A5Q_.L3X@W0T_P-J\GE^<([.5@F[;N^4\9/%<=3)<+R-Q
MCJ3[.-CX4UT2>'88;IM-:&&<?(VX$-T].E/T?Q)!#"U[(5:$ ER3S'CD_D*Q
MOB_\1=-\&^!HY+RZ%O%PBY!<E^R* ,DDYZ5\AZ_\5_B+^T[91Z#X;T+6/!/A
M_4G,6HZI=_*Y@)*Y5<#:2.1WYKXFI.*ARS3YV[)+<Y966O4XK]N/X_7O[7/Q
M+OO#O@ZUDN/ _A/_ $C5[Z),QW,JG@!NFU2!]2?:KO["WPD_X6=\8H3]F;^S
M]&Q?W1 ^1MO*J/J=HKZ!^)/PF\&_L7?L=V^D:#IJW:ZW<K'?RS,/,G;8QWL>
MN PSMZ$OTKL_V&_@A;_!OP8VN7RM_:?B14E,(&U+>$\JI'][GGTP,5^8XZC7
MQ^<1A5C[M.U^V^WJ<E1<\]3YV\2>.K/X5_M6:AJ4TGV=M+\10O*Q[9\N0_FK
M?K7VYXZ\=3?$#PM?P6IFFM;JR<"4,<,&4XP?H17YZ?M_:$=6^,6M-:P21SW>
MI('*GAR$3!X]BOY5]_\ PF\):E'\"=!EDA;:VEPHP*<L?*5<9]3UJN%8T(U\
M736CE)V3];"P\5[R/BC]GOX&:AXK^#5[JR:LMLUO;O!/!O+/,>>WL174?M-Z
M7]E_9=^&<VH6TT(2T6%B8]IC '''T45L>#_ VJ>%;SQ5;^&UW1Z;KLMC)O/^
MK$D<;_IYI'X5]%_MF_!^'Q+^QR^GV\]OJ&LZ?IT$N ,?-'C.#],BOA<IP]:5
M7'8:;?-%V7R=S&G%VDF<1\"? ?A']I3P38ZM>1?VM-<Q+8^49RSV$442Q!$Y
M^4G!8D8/S#G@8]=^%7PXF^&'B#Q!HMFEQ]CM_L]TGF9++'(' 4GO@H?SKP7]
MC@Z3^SOINFW6FWEQ?1W.DPMJUND6XV]QM#>8N!SG<RD=.!7K^B_M(:E\0?C)
M;QV.GZ@UKKUG)"KS1^6HD@^?;CKDJYK['!XK!3G2ITY)U(6N^NJ_S=C9-:6/
M>O@KX6_X3_Q^%OB6L])C$QC#8WN&&W/L.M?12<JV/KUKYZ_9B\=Q>'_$VH6N
MH+Y4FI%/+<C[K*"-OXDG\J^AT^85_0/#-.E'!KDM>^IZU'X14Z4M &**^D-
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T-TII.5]?ZT <C\8
M_B&G@'PO(RKYEY>!H;=1V8@]:^.?BIJNO^%_AA?:EI9M_/N&%M:)*VT32R$*
MJ9/<G/%>X_'K59;WXAWEO=_NTMH0;=<_>4C[WUX(KY@U'QS<?$;XY6?A9_,:
MS\'(=3EMGBW13SO\D#9[%,LU?D_%F85<17=&GLM%\]V<.(DV^4GC^(GBK7_
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M\'&3Z5Z%7Z-1J*I351==3L"BBBM@"BBB@ HHHH **** "BBB@ HHHH ****
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M_3W]FG]J/2_C'^QYH/Q,EGC6WDT;[9?DL%\N6)?WRGT^93@>A%<QX5_X)9?
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M^!6M>'];CCEAOH0(SLW21.!\KJ<'!%?GO\7O^"8_BY?M=Q(MCJEE]H*1?O\
M$C1] [[@,>]?@F,QV(P.9O%4*7/S/YK]3RY2E"?/%'>:?^W%X'NK;5(=!UA=
M6N[/;M2V#I]I9^%5 0"26QVZ5W'P)M%\-65Y-KVGV]QJWB4,=3:0>86#?\LC
MD?= P,5\&^&/V7/'_@[XO+;Z-IL=O;V\RJ+Q;A&CCP>H"MG(]:^\_"NI^+-,
M6Q^U2VMS-L6.;S5W-(<8W9![U]'E^)EC7)YA145TZ?TS:G)R^)'H?[/MGX9^
M!4>IV_AK2TM?M[LTP7+Y)SQ\V< >@K+_ .%B^&_BE\5=(TV\L9IX]%U=B\\<
MR\S&/E-AR=HX)/N*Q?C%/X_TB'3;?P[#H]BU]-B]U"Y1F:R@V\O'& =[<]^!
M[UM?"7X):'X;-G'81337UY.DE]J4Y_?2NQ 9@2,#/H*SS+*I5Y0HT8\L)--R
MOVVM\T*4;V2/2-(;3;#5[V8R&1)CLB)?JH]/3I7T5^SSX!C\/>%O[2FA*WVI
M_.68894[#VK-\&_LB^&?#NJ07TDE_JDD1WJ+EQL)Z@[5P*]8CB6-<*!M[ =J
M_2,EX?6&J>WJOF=ON.RG2Y7=BKT^M+0!BBOJC8**** "BBB@ HHHH **** "
MBBB@ HHHH **,TA^M "DXI#RU+U%&*G?5 <M\0/A!X=^)JQ_VQIZ7$D(PD@8
MI(OT88-?,_[0?P?T3P?XP;3K'3A=::ML&GMKAS,'W?[V:^OV&:XWXF?!;3?B
M7<QSW$UQ:W"+Y8DA(RPXX(/TKQ\YRWZUAY4Z:5W^74SJ4U*-C\[] ^'.N^$?
MB3%;^$[Z:T\*R!GN=)NHC)';.QSNA;J@))R.G"X YK:^(NF>(+'5([+^T/*C
M10V54;G/UP*^H-<_9&U#PAJ4NH:'?_VFK<M#=!5E]\,H _#'->,?%'X4>)/&
M'C:%KJSFTBVD!WSSJ S$''RKU_&OC?['Q>&G'#8>G:'?<YXTVM$? G[8W[*W
MCKQOXE?4K6^M;RVN,;H+MF3RL8Z, 1VZ5T'P0_X)J:IXNM(95U#2;96A&^5=
MQ<R8Z%< XZ\Y_*OM_P ;?LW:G8V,+:/>?VE'Y>9(KK"MG'\.!CUZ^U4/A%\-
M/$WA6YGN;FSA33X\F98I-[H/4@=J\'-. XR4I58/N[-V_,QJ87FU9TW[(/[.
MN@_LU_##4[*:2.77=03;<793!?'(11V4?K7JO[(4\,7CKQ+;JK^88HY-P^X%
MSC;7"3"X\8:]8Z5ILC7$MVZH=I&47NWI@5]*?"[X6:?\,-$>UL]\DTS^9/._
MWY6_P]J]S@G)94'[2"Y81]3?#TVM3IH^1_GFG;: ,4 8K]-U9UABBBBCR **
M**8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 US@5Y)^W;XHO_!?
M[&WQ.U;3F:.]T_PW?3PLIPRLL+<CZ5ZXRYK$^(G@NS^(W@G5M!U!/,L=8M)+
M2=<?>1UVD5SXJG*=*4([M.QCB(.5*48[V?Y'S[_P2-\#:9X-_P""?7PY_L^.
M%3JEBU_=RJ.9YGE<LS'N>@R>>!7EOP9TR'X=?\%O?B+IFCJ+>Q\4>#+?4;^W
MC^5//\Q1YA XW80<^C'UKG_@'J'[0G_!./PM<_#&'X5WGQ:\*:;/+_PC6K:9
M?1PND#L66.97]&/;W]J[S]CK]GWXC?#_ ,8?%#X^?$;16O/B-XOL_*L/#>GR
M*[6=M& R6P8L%+LRH#R,8/K7S=*3J1P]&,'&5-WEH]++779\Q\]3DZBH4U!Q
M<7KIM9:Z^9\D?\%:]3D_8I_:QU;_ (5OXHBT+_A<VDM#XJL(ER+#<X4W1 ^Y
MO5F.>#E7/<Y_1W]G#P-X&_8O_9 TF/2[ZSA\*:#I7]H7.J9&V\S'YCW)8==W
M4>V!7SU^R%_P3TU3XO:+\2O'_P ?-'5O&WQ2\ZS_ +.N=KOH-AR$C4@D*W Y
M4] /4YG_ &-/V6/&>H?!?QM^SO\ &;0-8U'X?Z3,8]!UU+I8UU.QW@K#N1MP
M*\8!&,$CH !SY?AZ]'$RK^SY?:)\J?V=>O:^^A&!HUZ>(E6]G;G3Y5_+KU[7
MWT/F?]JK0;S]K+]F/XG_ +1OBU3#'>/;:5X%TR8_-I^GK=HKW!7L\I![9P#[
M5[C_ ,%(9DU?]EG]F'2Y)%FL-6\2Z'!=KG@J+,N W_ @IYJ#]MG_ ((O^#-$
M_9DUI/A9H?B[4O%-N8%T^P;Q!<30D>:F\".5Q&0%WGGO76?&+_@F5.G_  3Z
M\/\ A7P#'>6?C+PW>67BBVMM4O7N=U_'&@EA+.QV@@,H .T'I7/_ &=BXRJQ
MJ0O>*O)-ZM2OM;5G+]1Q4'5A.&KBFY)O5IW[;FY_P7*TJ _L1QWGEJ+G3_$>
ME26[8P8V^U(N1Z'!(S7U]X8NY;[PQI\\W^MGM8W?_>*@G^=?G_\ &;3_ (Z?
M\%&H/!OP_P#$?PGU'X:^'-/U:VU'Q/JU]?Q31W(@(8I;*IW$%QD$\X ]Z_0E
M8/*MA&GR;4VK@?=Q7T&7R]IB*M:":BU%:JUVD[Z/Y(][ MU*]2LHV34?G;<_
M*CQ5\3-4^+G[5OQ0T7XO?&SQ;\&M7TO4GM?!VGP.UGI\ML&/ES^85VL2!&3R
M/O\ ?BO9OCE^TE\6OV6/^":5C)KGB#1=?^(VM:I%H.DZ]83>?%-'.X5)]P&#
M(%W<],@53^+EW\;-"UGQEX5^(/P,L_CMHNIW<Q\.ZQ9"VA^S6[D[(I@X#913
MU'/'6LKPM_P3)^(6I?\ !*^+P+J5U#;?$#3]:_X2;1[)YO,BTYD9#'9E\_=V
MJ1D'@M7@THUXNI&DI7M)MM.^ZLNS?:S/"IPKQE4C3O>TG=I]]%V;MM8X#_@H
M[^P]XT^ 7[%,GB'4OC%XT\6^;?::NOZ;J<JRVMY))=1@-%QE621@1SRH.:^D
M_P#@HY^T)-\!O^"<=E;V-T+?7O&FG6?AW365O+*/<1*KR*2> D>]N?2O$OVP
MO%_[2W[:?[+R^ 9?@/?Z#<0W5C/K-[-J$#K>M#*CXMDR."X!)/1<UZ'\;/V/
M_$W[77[77PMT#QIX7N_^%2^ /#:W-[)-*JP:CJ+1!/+P&W$IM49]"U"C).M]
M3B_>C!)N^[;OOJ7&FU[3ZI%KGC%)N^[;OOJ>7>%?#OA3_@G1^UI\!]0\.:QH
MLV@^+-%3P9XG%C>12*MX?WB3N%).#*S$M_=51G%=E_P4N\">(/BC_P %+/@#
MH?AGQ)=>$=3U#3-4C_M2V&Z>VA^3S?+SQN*Y SQD_3'4_MB?\$?/ASJ?[//B
M)_AIX1ATWQYI\ O-&DMYCYC7$;!U0;F &_&W.1P:X;XY>"/V@?$GQA_9U^)V
MC_#>ZOO$G@_P_=KX@L;RYBCQ-\B-$6W8#2*C,F,_,PZ4L1A:U&E+#UH>XY1E
M[MVK75^GS)J8>K1IRI586C>,ERW:M=7Z;]38N-/\=?\ !.K]M/X6:+)\0_$W
MCKP'\5KMM&N;7791+-97AQLD1@!C);)QCTZ<5^@T9^7WX)KX)TSP1\7/V[OV
MROA[XL\:?#N\^%_@?X63-J4-M?W4<]UJ=[@%2"AQY891Z<$U]Z1'K_LC%?09
M/&WM.1-0OI>_97WUW/<RE*U3V::A?2]_GOKN2,<"OFCXL^)M2^(OB[6M+N+Z
M2WTVUF\I;='VI\N.N.23GI7TL5W?6O)OBQ^S8?%>N76L:/?&ROKD R0./W4K
M 'GV)X_*GG6'Q%;#\F&=I7O\CTJD6UH?#'C7X3-J'[0237&V33?"MI'<6L#G
M=YDLN\;L'H5"'!]Z]*U+2=-\0>&FCB7,S)N0*G<]_P#/H*Y3XL:=K'A'XD/J
M4T<RVMKBPU>/9O:,!CMD'? SSZ FO6/A==Z+I6B>9=!;BUD@\U)5; =2N0X(
MSP>N*_,57E2;C5_B1;.+8\>^(WPTM?BUX[\.:5(BWVE>"X[:]U"VX?[0[2JI
MR/90Y/T%?2NO^ ]"L?#$<JS!)D7!CV<9QG].*^3/"_Q7\#R?M->)KZ'Q1;OI
MWB+38]->*$.OE3(YW;FXP2".GH:Z;XD_'6W\ ? *+6I+TFPL8)"9_,YD2-W1
M<GJ2<#WKY++\5"MF,X*HKM<TK;JWEZ&4*BYFT?)/_!0"\N+?X[WECI6EW%VT
MD\5Y')!"TFYB@3:-HP3\O05]S_"+XAZUXL^#'AVSDM)K1FTNW$L<R&,QN(E!
M^4\YR.G;-?!B_&76_B>NH>)+[Q5=:;;VMPKV.GV3")EQRK!\;B0>>O>O>_V5
M?%GB#XU6&K20?$2]MTLG$<5H LEXR!>97R,G)XKR,ES#!4\PJ_5HN3D[J]EU
MOU9A3DE)V-?QOX1U'PKXK\51Z8TEJVH6\<\GFVYV-.00LH.2#PG/T'K7K?[.
MOAV3XS? 62^U2;_4JUE<AFV^8R\-A??.?QK)3PQ-!X2U:SD\5ZC<:A=6[6T<
MUV$<6Y/H,<9_STKC/V6-<UKP[\-]2L)KH7UU)J\[-($V+%@(H7'MMSGWK; 9
M-F:X@J8JHN6G45_4UA"3J7>QC^-=2\<?LU^&KIM)LM)N/#L9:T>YBA#31IG$
M9?([$XS[UT>AWNK6/P;T'Q2%VZYHDZZY$TV4C(!;<K8^\ICSU_O>PQZ-\0/
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M0MEFAD26*0;D=3D,/:IJ_0D[JZ.H****8!1110 4444 %%%% !1110 4444
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MH\K,TDA'MO=L>U>G5]G@^=4(>T^*RO?O8^JPO/[&'M-[*_K8****Z3<****
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M_;!^%6O>*_$]IJ&GV-UJ5G):"V(M8FDDMRK,=Q"\G.X?]\U\G^*_@_X@\/\
MQ/'B:34/%&D:I'8?V8L;0(D(@\P2$!)XRH)8 DKM8X SC KX'B7 U\1B%4I)
MIP[=5U.:M%\R:/0?VD/VC?"?@WP%#X=U*^T_1M9UJUN([%YH9&$Q  .XHK#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT:;NFEJ1PIY8Q_"O J1>WKBDZ4H/S5L:#J***8!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5G^)?#UKXIT2XT^\C\RWND*,
MO^'O6A01FIE%-6>P'RKX_P# UQ\&_%]K8M<27&GW7SP2.NW;S]PGINKD?BVN
MJ:[HSP:7;RW\A7$@CP-H]"2<#BOL#QCX'TOQUIRVFJV<=U"IW*&ZH?4'J#7'
M>,OAOH_P_P#A9?6NEVJPJQ#LS,9'<^Y.2:^2K<*PEC/;Q=H]NIA]73E<^*/
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M)9XX@&Y]ZVP,4@&*6KC%)62$ .:* ,450!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% #3]ZFE-QZ?2I",TA7=2U 8T08C(^[ZTUDP.
M!^7:I@,4FW-*P$446#GO[TX)@>M/*Y-)Y8Q3"W0;LPW3ZT-_6GE U(4!I<JO
M<!JQ@MQ]:=MYZ4*@0<4NWFJ 84V'^I-&W^77-2$9I-G.: &%5=6W*"/?O0(5
M'5<G'4T\KD4N*7J!&%"C/]:"BD?K3]G-($"T]@&B)2* N/Y\U(%Q2%<FE8!
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M\A^U;Q')(SVR-U2(_='\_P Z[>H[<*B;5"A5& !V%25^Y8>C[*E&GV1Z:5M
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MWZK;CS-OE5OQN?$__!!X_P#&-_Q"_O-\1-6.>N?EMZ^X'49YYK\\OV</V/\
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MW8S@FOCN+]NNS^$/PXL_#]MX#M;B*Q3=/)'?M$SS9.YL&-PQ]&R. .!7\_\
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M!?%OPS\/_!CP$-2@OM9NYO$=OK-Y=I$P8+"(. <\@,JY*#Y@.&U_'5A#H?\
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MO_!,#XU>$/V+_BI\.(?%W@_4/$?Q*\4-J%UK,L]S MQ92.IN&D58&VSRA3E
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MA74K$S1_>3SUW+]1FOO?:15DWOL=1I44U)5D4,K*RMT(/6G5H 4444 %%%%
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M#3O+H%TGD>7C[/.6<J?9L]*9\*?@UKWA"TN-0GEM[RS@'^D101G,1.>3Z_\
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MNBW&L0L6E;R]IE8X^9@C 2'@??!(Q[UKF]&>.<5A:G*EOI]VJ"I%RTBSXA^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=5.2;M$_4;X-_#K3_AOX$L;&QC7=Y*--,/O3,1DDG\:ZP#%>;?LN^/;SQO\
M#M4U!8Q=Z6PM79.C@#@GWKTFOVC"SC*E&4=K(]%;!11170,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%?N65YG'%T5-Z2[?D>G3DFBUTHI%-+7J%A1110 4444 %%%% !1110 4444
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MUI#+<W"MAA"I V#'/S'.?I7R7XZU:XU7PU8Z;;Q1K=-<+)%(J@2L1_M9!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^;&,CMTKZ8_:XL_">N:AIANK=KCQM'DV\=FV^88&074'D<5\K_MA^ /&5MX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%#' H I>(=670=&NKQEW+:Q-+M!^]@9Q7YT?M<>)]8^,UEX
M@M[:^G\-WNKC-K>0XW6PXVGL#W')[]#V_0KX@:[IOAWPG>7&K-BQ\LI(H&6<
M,,8'O7PGXOT?^V?$$EKI\#26!G/D><!YB)GOBOG,\K13C&;5NWZF578^;]#^
M,,GP4\*0Z7=7FH:'X^M3%NG>YFNK34H=^#DNQQO )/&!VKZ+^*5YJEW^SY<>
M+M(FM;S3D"S7P@Q(TD9Y.P@Y7#8YX/ ]ZI?M(?L76OQ(\+Z/K"^?9WEB# [Q
MVY?S4QD*#UZ@U\?S_'Z3]CSQM?6%](FKZ--&;:_L2Y^2,]<)V?GN,=:_G',L
MVG',*N7.-H5-%+M?J>14J/GY6>?:LMG^TWX@O-/%TTWC*[U!'T^\N[AOWB<[
ME<X.0 !UZ5V?@#Q;\1?V*O%\-ROVBPE0%.<FUO8^^/4'\#7F>J>)](^!/Q]\
M.>+M-CM]8\*:Y/\ :M-DC?/RN?F1L?==22-IK[O^(6J6/B+X:V^GZIIUGKIU
MK9'IULS M*[J, '((V\YVGCVJZ>0.IAY1G/DJTOA?62_7U!4K[;GC7B#]IG0
M?VA?B!;V>HVY:R\?6G]DZKIY)#17*@LLZ#^'(R"<YZ>IKSO2_"GB3_@G9\:6
MN(=/DUC2+G TJY&X+L8@8D &-XST/'M79?M(?\$POB)\+/!.G^-/!TT=]-;Q
M&>6U@(CEM'7G]WUWX'&3R=O>N4^&G_!1S1_B3HUG\.?BGH\JR,/(DU&1&22T
M=5.V1E(SN4\\=:*>'J5,*Z.)ARS3NI?YL(QTLR_^U'JGBGXE>)KS5/#[&'1?
M$NF->7EB7 \F:-<,S 9.[KU'.?;C[0_9'^'^[X;>%+S5'^=[*WE9B-N0 I[Y
M["OE72_%^N?!SQ?:RPZ>/$6CZUI<]I8ZT5W6]^C)\O0##_[)K[&_9LUO_A</
MP TK7--:&SA@@$,]LI"^3*B[&3'KQG\:TX0QU6CCJM.<O>M%I]TM_P RJ.D[
M(^T=$\6Z5JL$7V/4+60, J*)1N^F.M:ZMS7QC9ZW)&ZV^GQ327BG/F*#F,^N
M>M>[^ ?C9?:=IMC#XBM8XXY (A>(WRY'=@>:_H#+^)J567L\3[KZ'J0K*6YZ
MSBBH[:=;F-75E=& *L#PP]:D!S7U"E=7-@HHHJ@"BBB@ HHIK-CZT #MC']:
MX/Q_\6I-.UA=)T;[/<7^,RM+_JXO3D=^#Q6A\:?'DWP^\#RWT$7G32.($'3:
M6XW?A7A[:U:^&?!\C+(MQ>7V6GDD&6C/.<'\Z^2XESJ>%BJ%'2<OP,:M2VB,
M/QQJ6M6VNW-]JR?:H[ISE^RCT7V^E-\.:''J6C7NJ27B6L=JC3%6;'RCKC\!
M7GGB'XHWFN>9Y*QKIMNV3)/($5NW4D>E?/G[3'[<EKI/A.;0/"M\MU?S7 M[
MJ11OC5?X@I[]0.*_-,\QRP>&>)KM<_:^K?30X:DDE=[G/^,_C!XR^/>L3:;X
M8T>UOK&^UV:XB4 )Y,$0"M,[@<#N>:XCQU^VQHO[(XFTGPE:_P#"5>,-2E_X
MFFIJOF*)3P$A !+(O3TS7LW[.7P/\=?&[P-#>V.LV_A3PKJSLM]'9VR"\N3G
M!B3M&I7J<<Y]C7L.D?L4_#GX):K<)X?\/JFI:BR^9<73>?,N!V)&%^B^M?G_
M  G@Z^)<L2]%.3;?7?H<]",GJCX]_97_ &&/B5^WK\1I_%7C2ZGT'1[AS<+]
MH7%T0/[B'[N#W.>HXKZ,\-?#ZU_95^)%YX3CBL?+UA =.U'RPLMUM^_'(V,L
MW0Y)Y'L*]8TKQZ_PCNY+#]Y$I4E7B7@9[<=_2OG?]HOXT:/\5+_5FN-<MXM/
M\+/!<1VR3(O]I7#. 5!()^5<@X[YKZ[&9=1RQ_78ZM:IO6_]=3:4(P5T?/?[
M<_C^]^)7Q^T/P'8_8VCMGW+J3G$&3DON<9"QJ!U]>.]4[O\ :MT67P[:_#/P
MG/#_ ,(WI+QI=:CMVG4)U)WL.,A<Y^N!6?\ M'_&GPW\09[I=%TV:UUYA)8(
M;9L1M;GAE;'7.!QCM7I'[ W[&&D>"/A_>>(_'^AQZE>:D_V;1]#<%&E<\JS$
MC'([\]#7RU/%5,RHU)J/+.>[[+_AC#6:=MSZ(_8Z_8VT/Q5JVB^(&,U\UJK7
M,"G:L<V,8;83N/)]*]0^(?@:\\,>*I9H=D,<GRDE?F'TKR_Q+\//^%-^%%\4
M7TD?AC68I8ETA-*!\O3VZ+ <?ZS<?O9X'%>K>(_B5=_$:"SAN")=2=(S<LHQ
MM? W#\\U]-P5EM7+H.G!;ZM^1OAXJ&B/I#]D[QEI+^%_[$M;66SOH%\^;>V_
M[03P6S^ XKV%>E?(VB:D? 4-GJ%E(]K>1LN2.C9XP1WZU]8:1<M>:?!*_P!Z
M6)7(QT)'-?MO#^9+%47&UN73_ACTJ<[HM4445] :!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(00RDMC(.X<5]$^$K.P7P1HZ6C;E6UC ##YB2H.>>><DY(ZL:X;QG^RC\/\
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MH![\JW6ODN(L&H5/:(ZJ,M#ZA6EIJ&G5\RG?8T"BBB@ HHHH **** "BBB@
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M3OS-:'O_ ,18/"*?!R#4_A\OF6,5XI\^WRLD2D\[BWS#!]>*]"^#_C*;XY^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFE_#'X8ZM=1Z=I>ZWO9;=PJW<JX1L-UR"K<YYS42E+ U99A=^RI^ZH])/O\
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MUX+OK3PWX^:U2XN/L\R/B1U&(KM$/8* K\' !QG KP+2?A#X@^"WAWQ'\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ8W1M;N8>,]#]*^*?V^_VB]#/A?3[C0;_5->U36_G2(3M$FG+C[IBB8(6W#
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MG8@_TK[O\._'O6O%9M9/$&BZQ/!'&L\6IZ=:-<VMVA'#?*2RMZ@X'-?F_P#
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MD79:Z<AB>21D_=QR$\G<QV\'CFL_]C+X975IXW\*^(IEL;BXU'4&,<4YR68
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M()P.I[GOU[X[5M>'=4D\-:K"%D6':=J28R%7OQ7F4LSE.5YZI%2CT/R,U1/
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M'2N[+\#+$U>5;=292LC/^(WQ'U3XTZS-J6M7DVF^'H79M/LW'RL %P& ^\W
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MCLMY;L5YCV_>_# )ZUY7\3?@#:_M"_\ !/G1XKR2'3]<2,ZIILENB[$DZK@
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M8Q@?I3J_5.AW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!G%?:7[%GQQTC0O"UQX:U?4[>QN8;EI+3[1)LC9'Q\@8\9W9(&>0PQ7YV?M
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MVD?.[;D<<X/O@<UY]\5? VJ>']0M_#_B"'1=;\*6+K%%J5N3'J5FA.%RN-H
M[A6.>#7RN<<.XJ=.5+"3Y>75*VARUJ<K>Z>8_%JZE_:RT7P_X-6&TT.RT^Q
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M<L+!OFW/4IPY4.HHS1FO:- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *",FBB@#FOBK\-;'XJ^$IM)O=T:R?-'*O6)O[P'0
M_C7G7P=_8]TWX:^+4UFZO/[1N;<G[,@@$:1\8!/<M7M17=UI-@]!6,L/"4N=
MK4!@'S?3UKQ/]M>:&Q\':;>&2/[5;7.$A\OS)) 1CCTQQ7MS *,U\R_&PBW^
M,.H+K7S1,%:UWD[0I&,#/&>?KQ7EY[B'1PDI./-TLC.I\)\2?$?X9Z?^U/\
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MQA6)&3@ G.:\/^/'_!0.<^+?$?@;5K.XU":U_P!$DO+6$6S+%(@^;&?FZYR
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M^@ZA"VVY,;^9O3 ) &!@YR ?:JOP%^#?A/P%\6I/$MK:V=M<W%N+)A$H3?\
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M<(SC*#]3N@7:*1JCGN!"5RV-WZ?Y_P *\97V-+I;DM%1Q.S%NX!Q3F<J1Q3
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M*]<>M0ZM\:/%&HM-?+>6FG"TY^Q<,'QR>=H./QKB/ GCG_A%+.WCL_+?350
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M[\U[!_P3)U;QUK/B.X6.SFC\/(C>?+<0LJW,F,#8Q^]CG..G%?;WBCX"^#?
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M:PW%CO5EWK'<0GY6]<,,\_TKTCX<:=X;^$6IW-UIVEV-BU]F2;[/ L99SW)
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M'))KYF,L/?#NEI*-^9^7*[\WS/G82H?N.3=7YO3EUOY7/"_B5\5?B%_P2O\
M&'CCX"^%K6;5--^)#B?X?7)E'_$J:YD$<B8/903U[J#W-?H%^PU^RMI/[#O[
M-%GHLDT3ZFR-J>OZG*V#=73 M([.?X5Y ST R>2<_#/A7]B[Q3_P51\*_$#X
M[>(KG4-"US5,Q_#FT,I1;"*W?=&[+_MD!<YSDN?3'L?PF^)7BK_@J)^P-X@^
M&Z^)$\$?%#1)$T+Q2\\!DDVHVUVV!E.)55AD'KGVKGRV4H8B<FF^:+]DGVN[
MKR;T^1CELI4ZKE)/9NFGV_1O\CY@_P""B_B+6?VW?#>L_&AIKJT^&_@[Q!9^
M'_!MOC:-2=KE4N+P@CE3]T'ICIR*^J?^"JFWX@7W[.GPYN)&70_&WBZSM]4A
M4_+<PJ@^1AW7)!YZXKY\_P""A/[)_P 9_P!G']A[2]#UKXG>&M8\$:)J6G65
MKI=EX=6SD5O/18W,@<DX;#$<Y)/X^N_MN?#+XB_"WX(?!'XC>*]07Q_JWPM\
M66^L:K<:78>218D# $2]=A )(Z_2N6,:T7656#3:A*5[=]>O;8YX^U3K<\6F
MU&4KV[ZK?ML:O_!5/X3>&_V=)O@S\0?".CZ?X?UGPWXOL[/S;*%83-:."K1-
MMX*DA>#GI7WP\RVUF9&SB-"QXY..O%?G+^V7^U-X._X*.>-OA!\.?A7J$GBN
M23Q/;ZQKES;VLHATNTB4[O,9E 5LG./8U^B\LS6UA(53S98X]P3.-Q X&?>O
MH\KE2=>M/#_!IJMM%T/H,O=/V]65'X=-MMM3X(T#]OK]H+]I"]\<:]\)_"G@
MF;PKX'U.?3OL.IW+_P!J:FT)P^$7.W=_#T_&O2OBO_P4JO?AA^Q)X>^(MYX-
MU"Q\;^*;A-)L/#5XKQ.;]F*[#QG8 K-G ) KY'^(OQ%^ OB#4?&FO:I=^*OV
M=?C-IMY<H;#3KF=?[1F7[LJQ*OER;S[=ZZ+XS:G\4OBI_P $Y?@C\6?%VBZA
MJVN_#[Q-#KVJP>05N;RR0NBS-'C[P#*3QT!/7FO%HYAB(*HG-RE;=:I6>]MT
M[=_4\6GC*L>>/.Y.U][I:[K2Z?J8_P#P4_\ &_[0]W^S[X;MOBQX8\'0Z#JW
MB"PGCNM%N':;3I1(&$4JMQCMN'.?PK[2_P""H_[0\WP _8V\03Z;,8?$GB1%
MT+1PI^<W-S^[#*.IVJ6; ]*^0?\ @JY_P41^&'[4'[/'A7P_X#U:XU^_N->T
M^]N_*M)%3345P=LS, %8M@ <@GZ5W7[;OAK6OV^_^"AOA'X4>'?$%QH.G_#'
M33XEU34;95E-M>. (!M/&\ J.<\2&DJWLY5XT)NHY*"3NGO=/7R_ KVW*ZT:
M$G4<E!=]7=/7^K%7_@G;\.+K_@G+^V7'\(]3NIFT?XH^&K?6;)IC\HU2%/\
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MIROL<!4G/#PG4^)I7/J<'4G.A"=3=I7"BBBNLZ0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH :U9/CGQEIGPY\'ZEK^M7UOIND:-:R7EY=3OMBMXHU+.['L  3GVK6D&1
M7Q!_P6N^$7QT_:*^%WA7P+\*/!Z^*/"VJ:A]K\8K'KUKI5Q/;0M&T=FKS,,+
M*2Y+*&QY0!!#5MAZ*J55"3LO/1&-:HX0<TKGQ';_ !<\<?M8?\%;OV>OC3KT
M=QI?@7QMXAO=-\"Z3/N$B:79&)3=.O0&>28DYY_=XY"JQ_;8OMYRN&.,Y[?Y
MS7XM?M:_%+X^:+^V;^RI;7W[.>A^"M2\'W%Y:^$/#=MXTL[F#5P%M4:(S(-E
MN(U5,%N6W_[)K[M\2_L%?$CXY^)(?&VH?'KXR?#/4->@M;Z^\(:+K$$NG:'/
MY,8EM8W"$.JN&!<'#'D8%>QF5.,E3;:2LUIKLWVN>9@:DHN:2;=T_30\\_X*
M^?LO?%CX@_"OXI^/%^.GB+PO\/\ PKX5N=1T[PAX?MUM&OIX;9G;[5>*1(\3
MLO,9#+@\;><^V_\ !+AS-_P3/^%+,V[S/"\99FY[,>O\^^:U_P#@J&/^-<'Q
MR!Y_XH?5A]1]DDZUD_\ !+A<_P#!,OX3-T/_  B\66[CANG^%<OM'+"*_2:7
MX&_*HXE^<6S\W_\ @F7^P#^S/^TO\%OB3XO^,TFGV?B"P\>:M:I>7/BJ32?L
MUH@BD5M@F5,!WD.\KTSV&*^C?^"+WC'6+KPS^T9X5TGQ5KGCKX/^#]7:R\$Z
MWJ4S78>,QS^=#%*1^\C7$/"X0 A@ )*\F_X)!_\ !/\ ^ /[4'P(^(_B+XI>
M#] UK7(?B%K%DMW>7\]K(ELJPN$&V5 ,,\G."??@8]"_X)1>*(?"'[0_[37P
MF^'^N7'B7X#^"H%F\-RR79OH-,GFBS-;03,26C,GV@#+L,PYY8L3ZF*:G[1)
MMM6>JLEJMM?\C@P\;.F]%>][/5Z==#Y__P""5O\ P3M_96^.'[ UKX\^+%]8
M:/XJ6[O!>:G/XMDTV2UCC<!'*&54&!SEE.>^:^Q/^"!7C[Q3XK^!_P 1-+OO
M$&M>,O GA?QA=Z5X+U[5)C//J.GQDJ")",L@ 0@C@%V QC ^=?\ @C3_ ,$Z
M_P!F_P#:&_X)Y:7XJ^)W@[P_J>O7%[>I<ZC=:I<6LBQHPV_,DJ!0HYR .G6O
M</\ @A%X^N)/$_QX^'_AW7[WQ1\'?A[XCBL_!5]/+Y\=O#)Y[26\4Q_UD:E4
M*X)&UE8??R9S*2G"KJW9]5HM>FY6"LIPM97[?KHCZZ_;+_;#\)?L,_ S4?'O
MC%K]].LW2""TL81-=:A<2,%C@B4D#<Q/5B  "20!7S[\*?\ @LO;ZO\ &OPG
MX)^)?P>^)GP=N?'TJV_AR_\ $-H!9ZA,Q 2)F&#&Y) QAMI9=V <UTG_  6-
MTOX.^*OV7+#P_P#&C6M8\+Z%KVN6]MI6MZ=:/.^DZCAVAE8JK!$ 5PQ88*DC
M()!KYM\>_%[XN_L&_'+X+Z!\4O&OP[_:3^'_ (XUZ#3='N[W1(+?Q'H[OM1+
MN$1AQ)MSS*2Q<@#<A8$<.$P=*I1U5Y-O>ZV71[?>=N)Q$XUK-Z?UN?2W[6/_
M  58TOX!_'^W^%/@_P"'WC;XN?$;[&-1OM)\-6ZLNE6YVX:>1C\A*MN P0,K
MDC>N?FW_ ()L?M!V_P"T[_P6U^,WBB'P[XD\)SMX#@L[S2->M?LM_8W$-Q:*
M\<B GOR#GD$' SSUW[!>OZ7\.?\ @L?^U/H/BNXM['Q9XF_LS4-#-VHA:_L$
MMQO$!;[P&8\A20?*8_PG&?\ LR?%CP[K/_!>+]H+7M/UC3;[2](^'T,=[=VT
MP>&&2&:S\Q2XRI*8PV#D'(QQ6WU>,*<X1A]E._F[&#J2G4C*3ZO3R1R__!<Z
MV\6?MM?'[PM^SS\/;HQW_A30[WX@ZTP#,JR0PR+90G;R"[[E'7:TL;8P*^R/
M^"=?[4B?MA_L(^$?&DDRRZK<:4;+5UZLE] OE3[AV+,N_'8.*_/[]@[4_P!J
M#XW_ !E^+/[1_P *?!_POU?2?BIJTNGZ=<^,+NZ@N8=.M6\N-84A88C*K&'S
MR9(6X'.?0/\ @D9KWC;]E#]KSXR? /XH:?H/A_6/&44OQ T6RTB9Y-,B:8R+
M/%;[_F*E0"!D[5MB/2ML5AH^Q]AHW"STW_O?FON)HUY>V]I*]I-^FVAYE_P2
M7_X*.:I^S;^S?XP\+^&_@O\ %+XIWVE^,=3U/5[C0+ -::;!)Y813)EMTI$;
MGRP 3MXK]//V,/VQ_!_[<WP.L_'?@N:Z.GSRO:75K=QB.[TZY3!>"502 P#*
M>"0593WKXW_X-\/BYX1TW]D'XB:5<:[H]KJ.A^--4U#4[::=(I+2V=8MLT@)
MX0['^8\?*:V?^""4L?B6/]HKQ1HZ_P#%%^)OB9J%SH+JI$,T?F2,7C. -I5X
MN ./Y89I1@Y59<MG%[]R\#6:Y(\U[GZ#J-W6B0X[T)U/O3B,FO!\SV#XL_;V
M-KIOQRM&61I+B\TU#-&RC;&/,?;@]\X.<_W17S+J/[/W@GQE\2[/7-7T.$ZQ
M8R"6"^A8Q3'[H&X@@28P -^<#IBOMW_@H9\)KOQ5X7TGQ#IEG/=7.DRM'<^2
MFXK"PSO8=2%9<<=-]?(\5\\]M#<;>85&Y<_-TZ?KG_\ 57UF2XZ=**E2E:2.
M>I&[U//_ -J?_@G-X'^*GP_\3:Y#X?NKK5-0MIEL+^[N))V@G\OY'5&D" [E
MSV')KQ7]A;]D_P 1?#?X?^!;GQ-J3+!X=AGOK/0DTA;-X+J?<'DN'W,\CJ&*
M@':,;3@D#;]O>'=6U[XDQ6FAZ1#>7O[P!4CC.R,G .['11N_D/2O8G_X)OW4
MVDVTG_"6)#JB(3.AM-UOOZ@*V0VT=,XY[!>E>AF.=*UISNWU)C3ZH^8[JZ\L
M%9FVOV7.0!]?\.*Y/XY_$JV^'7P1\4:U=74<=GINF7$SL3TQ&W 'KZ>^*]1^
M*7PSF^'&M7F@ZE:QQZEIO#3!G*7"'E9%[8.>@Z8.:^%OVW8_&W[1/Q!LO@OX
M2TV5-+O4@N_$FLXW1V,)=F1.H R()&(/+ 8'6N2GS2FI1V*/GOX0_LA:;HO_
M  3FM_'FOZ;=K<7VH/J N8Y<[80K)$2#R%>1G^;CG9D^GV)_P2;TIK+]DB&2
MW$A6^U6YE56&?+ V)@'H>C<]3GVX]B\-_#NU3X:2>![BWC;23I7]GHFP+'+&
M(@F,89><9Y.,GGFO/_\ @E=>S? GX0KHOBZUTU='DUN[M-$O'GR+J7?+YMO*
MO\$RNC$<!7SD=\_3T\0\7@W2CT>O<QY;,^>_^"LO[+$&@0-\1+2Q\NWN"JWS
MPC:(;C.%D?(*X8?*>5&0O.< ]5_P2B_:C\1>-_@]JVA>)EEC\.^"T$EMKT\@
M6"*(G<;=W8CE-VY2<@*2"0 !7UY^UGXKT&^\!Z]<:UIMI<>'_LLDMW9B/>LD
M*J25P!R2!TX.?3%?DMXF^)^F_$/1=4\1+9Z7I6FRSQ01>%;&0P6TB1 B%G10
MHF9>H8\# P!79A7/'TOJC^QUZV[$OW'S'Z!?$CXVV'[06HKX5^&^@:%XVFL7
M!N_$-Y$)M%T!B#\R28_>S!22%BY!R3P&QD>,_P!ARST[QEX=\::1KFH:EXW\
M.F.8Q7"K'::G(@. (XRICW9P#EMHSD.02?E?X#?\%5-<^!GPQTOPO#X)\/7N
MEZ4&6-X[R6&4AG+$G=NRVYNWI7WY\*/B'>^-_"6E:YJ&@MH=QJ$(F%H;E+G8
MCJK*P=..<G@X8=P,UR8^MB<%3]C'W8/\2H\L]1?AI^T;X>70KS5KZ^E\.WVA
MQ>=JVGW_ .[O=-(R?GC_ (L@94KN# @C/2N,^/\ \7O^%O>-?"^AZ;H?C%M7
M3Q'8:@;FXT&XAM5ACE#M-Y[)Y0&WJ"P;L0.16;^WOX7T/QS\.M/NM1TV,WR:
MK8V<=]$J+>6T<UU$D@C=@?O XVGAB5!!&17M$'B.XU$K"8B[[1\X(XXQSCN>
M3QZUY<<50I13IEJ+;.F\=C1K?3]T<;7EO);;+F*<+B;C# '/(XXXSWYYKPW]
MC#XR_P#"6?#"\T2'3X;73]),5SISB9KB:-+G>_DR2$Y;81G.WI)W! 7;_:%^
M)$/PC^"_B'6;M+Z^DAM6BBMK*-Y)'DDQ&@ 16(RS*,XP.2?6JW[(/P5M_@'\
M&] T>V 36O+2\U"98S&1<L S+]XX"9VD \D$]Z*>-4L+-/XFU9"Y;21]N?L,
M?!76O^$Q_P"$NU2S>STV&W=+$3KB24OQO Q]W;GGOFNB_P""A=O<0>'_  YJ
M&[-G%=/ Z_\ 31P"OX85AGWKU;]G;XG2?%WX8VFK74:I>([6]QM/RO(H&6&.
MFX$'';-;?Q'^'>E?%#PM<:/K%M'<6=P, -]Y#V93U!'J/Y5\3+%S6)]I/='5
MRZ6/SHN+BTN#=:E=7MOI]K:PM))-,WE1@ 9/)YSQBOGWX0?LVZQ\5=(UC5_$
M6MZE:Z;XPU>XU,:+I;BS^U1;EBC^T2Q.S/\ NXS\@8 ;SU.37M?[:OP5@72O
M&7@WPSJ3ZM']EDCA>5,?O@"PB8C <!EPW0'YO2O)OV"?'EYJ'P3DOI+66SDM
M-:U"+R1(9/LS>>7.&[D,S D=Q[U]YA<0OJ;JP6K:OZ'+:VA8U3X8:+;?M$>&
M? =OI,&B>'_ ^FOXA33;2 6]M<7DDODQN\:J"VS#L <Y9L^M>W>+M)M;6VM_
ML,DSM(H9SLVE6).0#WZ9_.O-?B1\*_\ A:'Q)C\66WBSQ%X8U%K(V-W+IS09
MNX/,5PI,L;E"&R=R;6&[[V.*XFV\>_$"[^+GB;X>Z)=6DUGI<5I/;Z_KZ;Y(
M8)(]I41H$^T,6C)#;@%/)+$T5)0KPY4UH"//_P#@H+\2_%_C_7_#?PR\-PZM
MJ6F:I"U_K=GIBF28H'6.(RA?F6$DNVXJ 2N 3BJ_[-'[,ECXM\96\?\ :FA:
MAI?A&[S>Z0S/%>13(A\OS;<J-H60AAO.#LZ$9KZ.\%_"^V^$=DL-G>7^J7E[
M*TMY?ZA)YEU>RL<[G/KMP-J@ 8Z9Y/(?'WX4^&O$EXWBD>*K/X>^-M,C_P!&
M\0PW,<,BCM'<*S!9HO\ 9<\9.".0?2P>;2]@\!&/_;R_4B=-7YF>MQ>.]'^%
M.@:E>:ZUK#IUA:O+//,VQ(8PN2_X8]P<>U?CY\=O%>J_MQ_M67FK:<MU=65Q
M=BSTM91Q#$6Q$I]-V-QQSV[5[;\;OVQ-4^/?P0\2>"_'FFVDQNKAH-/USP_?
M".S1X9@I>[3<^(207RN058?*,;J]5_X)H_L$2_![Q7?>(O$&IZ3K4<FT:%)9
M.9;:5&7/VGD8& 2H Y!W'T-;8*,,%"52M\7V?,B7O6Y3V/X.?!BP_9)_96O=
M/TFUAEUJQTZ>_OIE7<]U=F,DG"X.!P% /0 ]22?R>\/_ +/OB[XMVVO:A96,
MUPMI:7.J7,RQGD(&<]CCI@ ^O'0"OW3^-OP_7P#\-]4U2\O;-+%;.:62<S!8
MXU\MCN8G@ # )/8>U?#?_!*#X(JWP0U;Q/X@=KC3]6,MG96<T9C$*%2DDKMT
M.\-M'8#.1NY&>#Q#IT:M:LM7U*E&[5CM?^"2.O6GB?\ 8=\)F50MSIS75C*N
M<@,EQ)C@\\J0?Q^H'T*-*A>=FW,JD_P\<5\:_P#!/'Q7:_L[_%3XD?!>\OK;
MS-)U@ZCHOF-M-Q#,BYC /)=<1C'.>?>OLOP_:WVNR_N54C('+JBL3CC+8Y_G
MCCH:^2K6]IRI7OK<Z+'SA^WOX0\/:E+X;7Q5)!!X:O+/4K!+^X262WL-1FMR
MEM(^W*J<[P&;A<G!!KX7_8G_ &3O'7QR>;Q1HNEV_B31-*O6M)O*NXXV++G"
MIYA7*@8YSZ<#O^O7]DC6KC[-#;7%Q*TFPQ1PL^6] !R?P]>.,U>_9/\ A)X0
M^".B:CIJR:@UOJ-W<ZD[RR&0B:9LD 'A57 4*N -IXSFO<RG-G0]RFUH95*=
M]SX/_:&_X)>^*?$7BG28=!TF33K74K4R7L^I%4CLY "?X=Q?T&T'IR1GG[>_
M96^$%E\%=%\$>'[%?MD>CO;6J'R K3X89)1>FYLDCWYKHO&EZVKZMY+2M*K?
M+N;DE/0^WM6_^SYI5WXH_:!\,VNFR/&UK>)<.ZJ2$2/YV^@P",5EQ!G$\6G*
MJE:*TL.E34=$?>6A?"WPWX=UI]0L-!TFQOI%*M/!:I'(03D\@=SS70@8IJ#_
M #BG5^;RNW=G8,E/'TZU^,G_  7E_:0\3?M<67C;PSX(NMOPN^ ]Q8S^*[^-
MCY6KZQ<74=O#9*1PPA$CNV> RL",HI/ZA?MT7/Q.@_9:\6Q_!W2X-8^(UY:B
MUTB&6[AMA$TCK&\P>9E3,4;/( Q 8H%[U^1/[3W@/X^?LL?\$B=?^&OB3]GO
M3/"OAJ6]L[[Q!XQ?QQ9:E=W]\^H0.9Y;>(;V>618X^&.U2N6."3[63TX*HJL
MFKW22;1Y.95)V]FD[;NR9^S7[.GR_L_^!QAL_P#"/V'!&T_\>T?:O/\ ]MC]
MG_XG?M&Z)HNB^ /BW?\ PCTWSW;7KS3M/2XU*]@(&V*WD8J8&SR9%;(]#TKP
MWX1_L\_&#]M;]FSP%J7B;Q9\0/V;]0T"P2RMM-\(>(K:]CUZS-O;&&\F=5(5
MCAP$/S+SD\BOK3X!?"R^^#/PBTKPSJGBK7O'%]I:R++K>M2+)?7Y>5W!D*@
M[0VP>R"N&K'V52ZDKWVW_P" =5/]Y3LT[6WV/B'_ (-_M#O/"EM^T1HU]K.K
M^(IM!^(]YI7]I:I<-<7EVMN7A5Y7;EG(0$].6KR'XR_LL?"7]K3_ (+M_%#0
M?C!%;S>'=/\  MG?V@GUB33%%R)+= ?,21"W[MY/E)([XXS7M_\ P0U&/%_[
M4W_96=5_'_2)O\:\N\3?LR_#7]J;_@OG\4]#^*'A_3?$6B6/@&TOK:"^N)(8
MXK@36R!P493N".XY..37L1DUBZLM5[JVWV72Z//E'_9H)*_O=?4J_LG>%?"W
M[+'_  6&\,_#?]G3QIJ7B3X9ZMX=O)_&.A1:VVL:7H4J)(86$NYECD\P1C&2
MZ[BN0LA%<S#^QO\ !?\ :\_X++_M/6?QD@M;BST==+FTX3:U)IBJ[6-LK$-'
M(F[A<X.<>E=0? W@7]@__@L#\'?!O[-]^MC8_$*&Z@\?^%=/U22_LXH8@#%<
M/&[NT<@5IF'S J(B> 2KQ?#;]DCX3_M7?\%H?VI+7XJ^&])\16NE)I4MDE]<
MR0K"[6=JK,NQUZ@*,'D?E6][7J7?P+6WO7YENK_TC*6RA9:2[Z6MW-3_ ()W
M6.C_  (_X*S:]\,O@5XVU+QI\#QX3^W:Q:_VRVK:;X?U'S' C@FRRAN(^-V<
M2OG.W"_I?X_\>:5\*_ VK^)=<O(['1M"M);^_NI!E;>&)"[N<>@!-?F?\"]!
M\(?L=?\ !:?PS\,?V?=4;_A!?&&@W-WXV\.6FH2:A8:9<0Q3-%+O=I#%)D+\
MNX$95< /@_H%^USJ'@[1_P!F+Q]/\0H[B?P*-#NQKR0PO,YLC$PF(102<(23
M@= :\K,8J5:#=[-+IJ^]UW._!MQHS2T:?R^\^/Q_P7^TJW\.6WCB\^!OQAM/
M@W>7?V6+QN=/C:T(\SRO.*;N(O,&T-O.3P 6^6OH#]L+_@I5X"_9%^$/A;Q3
M-#K'C*Z\?20Q>%-'T"#[1?:^TR*Z&)3CY-CH2QY^=0 2R@_ NJQ^-_V'OV$H
M?B1\)OC9X-^,W[.-JJ2P>"O'FAPM+]GDGPUM'/G>\P9C^[8)@Y 0G KO/VD?
MBOX?O?V[OV'/BIKVGVOAGX<ZYX?G%E%.BQV.B7=Q;1&WB9MH1-K/'M;Y0!%D
M8 KJE@*,JD7"/N^]LWK9:)IK<YXXNHH2UUT^5]-#B_VKOVW=0_:A_;S_ &2M
M$\0?"OX@_"KQ%HOCRUO6LO$5HJ17<$DL2AX95.'(_B& 5R.N>/K+_@MW\=-2
M^&?[&DW@WPTTK>-/C!J$/@W18HL^83<\3,,<\1!P".C,OK7EO_!6/Q]X?U;_
M (*$_L<Z':ZMIUUK=IXZAO9K.&59)X8&E@578+DJKMC!/7;[5P/[7GB3XL?M
MA_\ !8&QMO@WHG@_Q-%^S1IZSRQ>)KF:'2_[4NADDF+#-(@\HH >&A>KITX2
ME2G9148MZOJF[;^9,JSBII.[;2^]*YZU_P $,O$^L?!;0_B1^S3XNO8[GQ)\
M%-:9;"0*8Q=:9=8EBD1"20NYMQY./M"KV->/>*_VL?\ AE?_ (+L?&2>S\#^
M,?B'KWB+PE8:?IFB^&[,7%S.X%M(S2$G"1JB,S.0<8/'-9?B?Q5\=OV0O^"I
M?PR^-GQL\._#WPQHOQ(*?#_59?"EY-);2!][0R7'G$D,K!&W X*P$=N?5_@A
M\1_#_@[_ (.'/C#8ZOJFGZ??:]X,L;?3([F81O>2K]F=D3=C+;%8[>I"DTYT
MUSSK634HWLMKW5]O,GF?LXTKM.,K:]CZ&_8=_P""F&@_MC^-?$G@N\\+>*/A
MQ\1O"*+-JWA?Q# (KN*)MH$L9'WDRZ<D*<.IQ@@U],(VZOSIT/7]/^*'_!Q1
M->>#[BWOK7PG\.#8>)KBS^:..X,TI6&1EX\P>9"2#Z ?PU^BJ+A>*\7'48PE
M'E5KI.W8]3"U)23N[V;'T4BFEKE.H**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=G,TL4"H\W?YB!EOQK1";1BEV\U7+L/E6QGZWHMEKEFMM?6MO=0;@WERQB1
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M-U>-$DDD%N21A"P.W.#D]>G->16GCO1_AUX]TV)M/F\3Z9I-TEP5:Z.Z]"H
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MG:NT=*DI N#GUI:T+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !73V_[%7P]A\4/J7]DR2;^?LSW#FW!_W<YY]#D<"O5H+:.WB5(T5$4 !5&
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M3BL7Q]\0M%^&'AFXUC7]2M=+TVU7=+/<2!%4?C7/_M)?&ZS_ &=?@OKGC"^A
M:XAT> R")3CS'/"C\3BOQG_;(_;]\>?MBVEJ^I+:Z;H,$C>3IEC*>O\ >?\
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MG=[JXGD$:RQ[2-I)P,$D8K]H/!WQL\)?$'5IK'0_$>CZI>6X)>&VNDDDP.^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#L'CI-.UU_/;3[C$AC5L*I]/_K5]^?L&:+/;>%]4O6MVAL[J15@9AC=CT]:
M/H!3S^E.KQO]I;]L#2?V?M2L=+^SOJ6M:@"R6R.%6-?5CU';WYJ+X-_MGZ#\
M3-1BTV^MY-&U23 5';=$Y..C#CGWYH ]IS12"EH *#THH/2@#YF\5_\ *3;P
M_P#]B\__ +-7TSWKYF\5_P#*3;P__P!B\_\ [-7TSWJF3$****DH**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/1HLZK-<$WBE<.9#]T>Z^GXU]5?"_P"$DNC7RZIJCB2[^]'$O2,8[T!'34]
MLK:.UMECC551   /2I2@(H']*6@ %%%%  1DT;:*,<TK7W  ,4444P"BBB@
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M^)OP>\-^++J&*2YM8$BGFB0#>A &3CO[UI_MY?!^X^*'A^'5FTU;62RE;>N
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M9]4A%O))&!M5P?0'M7NOACXEZUI7C..Y^)/V.31=0;'VFQ+,;5NPDSV/KVH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% #7Z?YYK\I_^"XG[3-]??&"Q\#:;J4T.GZ+
M;K/>Q12%?,F;!PV.>%QQTK]6'&:_&_\ X+B?"^W\$?M8IK$,WF-XFLX[J5 <
M[&4;/UV@T ?)UI>+)>1M>?:(#MRKD$_0@U^Z_P#P3Q\>:A\1?V/_  7J6HP-
M!<?8_(&[JZQDHK?B!FOPE\8_%CPA;:;Y>I:E;V]]:VD<=O'+(H(;(W9'7_\
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M+H?3/>BCO14E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9 \9:/\ $FZU[PMK&YKB3Y[)91]T9[9]R*I>+O!5Q9?$&+36N_[*WS>2[$8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\,CQ1;WBZ?:!HH[;][).3\Q)QG!)- 'K/[8QT=OV9?&D>O7$-KITVF3([R,
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M70^F>]%'>BI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ I&./\ #UI';;].Y]*_/;_@J=_P4I\9
M? _XM1_#OP;-I^BL]JLE[JES#YLB>8. G55XSSC/ICF@#Z7^*O\ P4;^$?P:
M^)\/A'7O%4-OJTA59?+B:6&U)Z"21057\<8QR:^+_P#@LA^VIX%^.'PUL_"G
MA/Q))J5UIM^L]S]GB8V]PN.,/P&P><C(K\^?$^H:C>:S=7U_<27DEY,\KW63
M_I#$@D@YYHNX9O&+R?V?9S;8X2\VU..!R>.@[_A]: /GV[NM*U6XOO$7B6QE
M\27']IMINE:4JK,J.IVC:C80L3DEFZ4S6(/",GA[6=4CT^\^'VO:&IEF:"-+
M:96'(^5?W<R$C'?O4?P BCUOQ]K6J7DVZPT:ZGFMXR<(#*^3)^2D?A72_%?7
M-#^(?Q!\-Q^3/=^"[N)K$KJ$(C,]POS*0?XD/( [T =9\"/BKXH^(_PPT/4/
M$DD?VE5)MA''L(BR-I.><GK@\<U^TO\ P1:^.%QXR^%NK^%;ZYEFFT-UN+=9
M&W;(GXP/QK\>-!:+5M0BTK31;R7%BBQ"VM@H:$ <#:.GXU^L/_!-SXD_!O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR,HR\! Y*^XKSGX5_$K3?CWX0UGPPMY+/=6ZM&DS(0SQ=49O>@#TCX->%9/
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M/.56:/<R'IE3U% '\Y]E>2:9*LD9VR8XXY]>@[4.TFHSEF^9G/;A>O-?KO\
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M$'4K;XBC1KZ\FN+&]A<+Y[%LNOW0,_6OL1!0 JC'Y4M%% !1110!\R_M%?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD ?,,>I[]>* -WP]93?"OXM6NBR37%OX?UX,RPEC_HTH.2 /1@>G3Y:_2/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?Q%T:ZU281V^H6X82VKGYHCGT/8YR*^=/CIX3T_Q'\;[+[1=QV=NQ:-FQD
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MD7BG4 ,1</T[4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "FN<#M]33JCN(_.@=/[RD4 ?#_[>G_!1G3X-)UCP/X5A:ZNY"UI=WCC]
MV@Z$+ZGJ*_)G]I?XJ+X>OET^&:.QE:W:ZN;QERUM !@[?5R>E?3'[0?AJ;PK
M\=?$VDL69HM2E7,GNQ8']>M?$?\ P4)\*2>)]!@GTGS&O+.007+H?E:(]=Q_
MN@\T <Q\.OBYX@\7:'?6?P_T>VCL=/&][J_RTEU(>I/N>M>&?$/XKGQ_\4(]
M-^)6AQ20V,;(R1+Y<B$G[P/<<5ZU^R;\2_#_ ,,O#6L:/J^J0OJPO L5G:+Y
MLEUQSL]_K7._';X<V/Q)^(K:EY=UHLDC 0Q7"_OI8!SO(_O$]J /HW]EWPK;
M6?P^B_LB'R]+N6\VSAC^8Q1< 9_(YK7_ &@_#.H0>(=+U3P:9;^'2HO)UJ^C
M(81;^JHO/S#G/'I7._L=G5/ GPAAC?[9%")94B>1#N\LYP/;/-7_  ;\0-1^
M$7C'7=!>1DL_$\IN;65N$=R!NC/OTQ^- '6^(/B[X*\,Z?I8MYEM8GMT24^0
MZM+,1\S.6 ^8GTST[5]C?\$T?V@8_@+XPGU"2QBO;'7A% TQ&&5<YW+^?/TK
MX!U;2)-0\36>HS0Q75G8H\DL4P&WI@,1W(.:^NOV [NS\>>(?#^EZE=006?V
MU"LTAVQM$.<;J /VJT^[34+2*XC^:.:-9$)ZE2,BIJ\)_:>_;*T']G+P1"FE
M7%EJVK2*L5K:1RAPB@ !F([#BO K+_@K3XCL8(TO/#FDS2R8<,DK8V^G!ZT
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M.:]I?C;X?W$5Z%U"Q:WM;^2&8L$BD;[V1_3UK]$/*4MNV_-ZF@(H)X'/7WH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L/
MXE>&K;QCX!UC2[RV6\M;ZSDBDA89$@*GBMRL7X@>/='^&?A6[UK7M0M=+TNQ
MC,DUQ</M1 /YGV')H _GS\3Z78Z'XV\06-XMY9O97<L-K%&F=I5R ASR!BO
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%!Z4 <[\6];A\._##7[ZX9
MQ#:V,KN4/S<*>E?S@_&'XWR^$_&&J6VBQ:AJ>J7T\DGD0$@JC.2'D;LO/?K7
M[S?\%&OC+9?"/]F'7C/,R7>L1&SM4'WG9NN/H*_%'PGK$G@_7KERL,*7^(I[
MDQY=%#>O?^5 'D7@4?;_ !)<:]KFO6]]KLB^2(XY\1V2?W%!//3K5K]JEO\
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M7<:KJQDM]J-MC[ '@5Y;K_Q@L- 73[I;=%=I_(EE=?F6-NGZYK0U/XA-,A,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .<=P0>1SS7QO^SC^Q/XV_:2\:1Z;I>EW%G;QD--=W,3)%$H(R<D<^U?M7\
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MBO+.X2^E=0T)B^=,D84#WSQ^->J?MM>![F;Q_P"$;&QL[OS+[3(HX+0CYR_
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M@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1N12T4
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MC_: \-_LOWWP;C^%RZI<6=E)IEOXC74HEM9[<$[6"%MQ<C@9(''?M]0?L4>
M]6^&'[*W@?P_KEG)I^K:3IBV]S;.P9H7#-QE20>,=#7J'EKZ>U. Q0 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".=A&N6*JO4DG %?
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M198W"_O$()//M@#@T ?I.M+7&_ 'QS>?$;X6:9JU\BK=7"8<@8WX_B_&NRH
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M[]G'XPZI\<?AT-<U;P?KW@>Y:X>%=-UB-H[K8H4K(59%(#9Z$=0: .^HHHH
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M_L7G_P#9J^F>]4R8A1114E!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>*** /'?VI/V
M*/!_[6%E;?V]#-#?6>1#>0';(J_W3ZCZU:_9G_8[\'_LM:)-:^'[1I+JZYGN
MY_FD?VSV'L*]8KRK]LCXY2_ #X(ZAK5M$TEY)_H\! SY;MP&_"@#I?CCH'AK
MQ1\+-8L?%7D?V') WVDN0I50.J^C>E?@/^TS\7?"7@OXW7_A/X?PWFOWK3$6
ML#-Q#'_>D/H/K7TAXD^-^N^,M,O(=6U35[ZXO'+/NNV\G)Y^[G%?(_B3X*ZI
M\*/CIJ/CK1;*'68=<B,4]M+)Y<D+GNIP: ,/Q6WC7P8UC?>)K[2+S3M0N$MV
MM8+<QO;%CP5;OCWKD?VB-9:#P5J.FV'[Z_NHW$2'.55<L6/TP/SKKOC/J_B?
MXA^ +J%?#R:?+$ZW$3378;:R=.-O.?3WKSG2_&VA:!X<74-0N9M0U?5@T;P*
MGF7&X<-&J#H 21GCM0!Q/[-'[9W_  G.H6_A?6K=X]2;]U%) /DEVKW'3/ %
M<3^S+!;VO[8_C.\F:.Q@M_,&V9MAW,W3FO'?&T&H? ;XQVVJ+:ZE90K<F[MS
M=1^4SJ221CIP#C%?17[)_C?0_%U[\2?'EYH]OJD,DR16]H_$DTC+A0G?.['3
MM0!]&ZG8V^KV+0RJ)89EPP.&#>X/Y=/2O$/VJ/'6I? 3X-ZH(7^W6VH(;2T+
MC,D+/P![\$]?2MSX>:)XHB\07.GZIKCV<;1&YMK6U4;85;C8&(W':3W/8UQ_
M[4WPVU'3?A=/+?>*+[4MDZ&"*>!&Q*#QSC@4 >$^&+K6+K]F/P[I\@DMX=9U
ML0A=F-Z]-WXD_I7[:?L+W<VB_!S2;"VC"Q6%LEOT^]A1G/ZU^*EK\>-06Z\&
M^&]2MK'_ (EFL1,&5,<E@3TXK]*/ /QVUWP#I\T&GSJL5QDX*YVD^E 'TC\=
M++3[VXS]G@N+P?,0(]V!QWK8TOX\+\._V?/$4ECNM;E;,G9$WELC#O7RGIOQ
MMURTU)KB6X^T22'^->]<_P#M'_';5-.\":E/+-;+Y=KC$ ^5RWKZT >Y?!2#
M4K*32/B)<W$DE]=RK)'&<R/<\Y9C7T)X6\0Q?$3QI<27EE>)/)#)/$NT+NPI
M;)';G Q7YYW7_!1:X^%?PS\/^'H/#[2:I!IJ217+$,D:MU('7(]Z^R/V-O&D
MGQ#^%5GKEM=_:IKY=\]RQ^;/=1CH!Z"@#WOP3K7ACP;\.)KY;"WU;Q%J4#Q7
MIN,E;=B#A=I/&,U\=:'\?]6\1>&]:6"P7R--U4&XAMH-JA$9O;'I7JWQY\1Z
MGX7DCFT>.*:[NL6SQ,<+(3GYL]<BOCGQ]+XN^"UUKEO'JEWY^H7.^XMD 5'W
M<L>GO0!ZW\/OB'K'[1/QEL?",E]_9VFZE="$-)\S2 L.",=\]O2OIGXA?"^'
MX _$VUAF:*UM[VS:Q1E^7#)@CZ9P<9ZYKYH_9!\ 7EU9P_$&\WV[:9('MX<_
M,X&<MGVXKV#XY^*-2^*UJLU]<><VH2HEKDG>7[-GVH ]2^ '[-/B3]H+P]JG
MB:SU*:WCMYFCT^ 1+LE /)8D=:R+;Q=XF^#/QIMX;FWDL]<TYBT<L)P)MIRR
MG\*]&_8R_:>_X45X>_X1?Q),;&ULEWVSA?W=T><'.."3UK6^+NAMKWC;1_$V
MEW&G7QU2X+W#$^8+.-E(.3V//Z4 >R:+_P %+M+U73[-5\.WTUVP5;@^:%C4
MXYQ7H7@WX3?#/XYQQ^+[?P_ILMW=-F<E 620=0X'>OECX3:9H^FZAKF@ZE';
MQZA<GS+"YD&V,]Q@^^"*];_8?O\ 4;SXCZ@MC#)'HMM&XOG#$PO-GY=GZYQZ
M"@#ZIL[6.QMTAAC6.*-0J*HPJ@= *EI%XI: "BBB@ HHHH ^9?VBO^3\_A%_
MUSGKZ:'2OF7]HK_D_/X1?]<YZ^FATIRV0D%%%%(84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ&I:6NBWU[:I/-8 Y^REAG9^&:LGP!H1UC^T/[%TO[?G/VC[*GFY]=V,YK7
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MRW:7# ='FEP7_M2&.1^<9\HG./K0!W7@[3--T[Q!J%]90*MO(([:! ,"67
MQ[9]/0USOQ4_8NUCP=\;GUJ^N%;7)+!;F&5'#0QJQZ(N1P!QDY)_"O6(_ \?
MA?QGX;TVXC:>T@N?/ A.Y9-JAEY QW/2O(_V\/VLM2T7XD9CMX=+DAM?+M)5
M&YI%/\/S<<''TS0 66H^,M.CFN%:UGM+52S2/*L6 /\ >;V]:M>"/^"A?A/P
M[X;U#1?%>ER6L6I*\,4][:R+'(<$928#:1SW]17AOCKXO2>/OA):Q37LEG]E
MB#W3F, WLN2<#'3OTQU%<+\(M.L?B1\1+%O&E[?6NFQ@10-MW.%YQPQZ?X4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZE,/FE,<+2,/<[17](6MZ+:>(=.DL[ZUM[VTN!LEAFC#I(OH000:Q?!7P?\
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MUOX&V:JEO-]HQ/AT.3'G.#CGFJOQ%^-7V#P/:>']+TUK#Q%.4M$A7[J+C#2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@X7<",J3U_\ UUVVI:M)::+;W%CYEK-I=J(8MA_URC)PWJ3GO7R+^UK\6/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /8O/_[-7TSWKYF\5_\ *3;P_P#]B\__ +-7TSWJF3$****DH**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M V\4;>:** &^4H_A'3'X>E+L%+10 FWCO^=!0$].E+10 FP8Z<>E!0$TM%
M!BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4WS%_O+^=*_(KPWXM_L0VOQ;\>7NN2>._'FCM>$$VNG:D8;>/ Q\JT
M>X^8O]Y?SH\Q?[R_G7S3_P .UK/_ **A\4O_  <G_"C_ (=K6?\ T5#XI?\
M@Y/^% M3Z6\Q?[R_G09%_O+U]:^:?^':UG_T5#XI?^#D_P"%*/\ @FQ9H<_\
M+/\ BD?8:TW^% :C/%39_P""FOAT]F\/28/K]ZOID')KQGX$_L4:#\#O&\GB
M)=<\3>(]8:#[-'<:Q>?:#"G<+P,5[*O_ ->@41U%%%!04444 %%%% !1110
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M9K>6RSILFB!R"CCLP8$&OR^_:JUO6M9_:C^-^C_&+P1^T!XJN+F0V_PWLO"
MNX]!EM&@VHTC02*@?S"2WF$Y Z<U]E_\$2/#>K>#/^";/P[T?7-%UCP]JNEP
M2VUQ8:G;/;W$#+(W!5P#]#WZT >_?M!7?]G?!+Q5/]E6\$>F3L867<LF(SQB
MOYT?$EI!KES?1W5M'Y-TS[XNT>XGCZKD<5_2Y=01W4#1R*LD<BE65AD,#P0?
M:ORS_P""J/\ P2]O-#\0CQE\-]!N+JPOV9M2L;5=S029W>8J_P!T\\"@#\H_
M"5AKOP4\=RW[K<ZMH^J1F*Z-G'NFBQD*Q7C<<9!^G-7-9_:1\-[YDCM=<W\A
M(GT]@[?T!S_.OT>_8@_X(ZZQ\>_#VI:IX\&J^$[/ %@GECSYF/)8J>B\C@^]
M6O'?_!!3QU8?$L6F@ZAH]YX=DD!6^F(26)<\_)W(H _+/]EK]GB'P5K6L^+-
M3C\G6/$D[3>6Z_-;1DY"CT..OX5] :GJ,.O^']*T^PL96O+0.;AD3<TW/!PN
M3P*_430_^" _@.+3K,:AXFUR:[3!NC&5593W&,9'US7T]\#OV$/AA^S_  +_
M &!X7T];K8(WN9X_-FD ]6;/6@#\&?#FG'4H9-+CA9M6O)HX88MOS;BV#CTZ
MCC%?= _X(,^)K[X/6&I6GB.V'BFY199;&1<6\889"YZY'>OOL_L#_"EOBFGC
M >$-,76HY1,)!'\N\=&V]/TKV+8%&T=L<#H* /PN^,__  3!^(GP%GT]-6BT
M^\;4"5B2TN-S(/4C' S7>_!+_@GSI:Z;9WVO>=)JBN)'@W#RHN."?IS7W%^W
M/K,-W\5='MX9?,FT^T/FIGE=S9'\C69\%_%&D:/:7UQJD/G>9$T:IC=G((Z?
ME0!ZU\+/V)OA_P"'?"&F^;ID.I3^0CF>5M^XE>WMS71>'?V4_"?AKQ"NH6]M
M<?(P=(6E+1H?84S]FCXA0^(_"QTMEDBNM/)VI("-T6?E(KTU1Q0 (JH-JC&.
MP[4ZBB@ HHHH **** &NVW^>:YOQ/\9?"O@K56L=6\0:7IUXJAS#/.$8*>AP
M?6NF->=_$?\ 97\!_%CQ&VK>(-!M]0OV0(979@=HZ#@XH N_\-(^ O\ H;M!
M_P# I?\ &C_AI'P%_P!#=H/_ (%+_C7*?\,%?"?_ *%.S_[^-_C1_P ,%?"?
M_H4[/_OXW^-&G4G4ZO\ X:1\!?\ 0W:#_P"!2_XTC?M)^ E'_(W:#_X%+_C7
M*_\ #!7PG_Z%.S_[^-_C0/V"_A0/^93L_P#OXW^-.T0U/+_BWX_T3Q]^W5\)
MYM%U2RU2.!9ED:VE#A"<D9Q7UBO^>*\Y^'_[)WP_^&'B2+5M#\.6=GJ$((CF
MY=DSUQDG%>C*NVB7D-7ZBT444AA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %-<9%.I&SCB@#\<_P#@X#T"W\??
MM%6NAV,;#4K[0O)=G^XY9G"CT]:^(O#O@Z[\)^'--T^Z:)[NUMU@F1&W,K+P
M0<=#Q7VM_P %7_%EK\7OV];O2[6[CMQH=M'9B=3U<*7//L6Q7R7\0?@)8^%?
MB<NL7&N:K9WEQ;K<"6TDRLDF. 5/'Z4 >.?M4Z98:W\+[[1;R&*;4-0Q#90D
M9?S20 ?7 '6O%O@_X6?P!\(O'7PMUG2[5+C[/_:$$C8\R]D5<J5SS@$=OZU]
M7^+O!.BW?B>QUU6NM2U;[,!//<G)#]#M'0=N@KRWXLZ?:^/O$MOI_AW39-4\
M96,B?9YX_ECB&>5E8\$$=CZ4 =M\"]4L;WX.Z%Y.ZZF;3HHB2,-#*H"E?>I_
MB]\(XOCSX.;2-2C7_B6Q$P,1\\!YY%8OP1T8>!(KZS:X5]2MKUIKJU)RMI+G
M)11_=]#WKOKW5[C6M6EFVD2W'!5!@'V 'K0!^=WQ5\ ^+_V5M6N'MY)_L,Q*
MI+&3LN5Q]T]J\4\ >#8?'.J1PK?_ &;4KBX$=O"J$L['H<]OFP*_3[XD>(]
MDO9-#U:WCNKF,X:*2'>D;$=_0XS7S$WP!T7X,?M>Z+J FAFTG6 ]S;1X^5)"
MA)4'IP<8H ]7_9U_;<\4>#6TWX=_$=5TV/3[?['%=RIA;X#A<OTR.GK7H6H?
M!_PK>ZK=:Y#:QW#7$+!27$D2L1P1[].:P_VE?#OA$Z=I^CZT;&^:XMDNE6"(
MSO:DGNZ_Q5Y9\!/C+H?@#P]+X;O+_4/.6]<H;DL=JD_(O/*@C:: /2_'W[2%
MY\ O #:3:ZDUUJU]'@(S9^S1]![BO)?#FG_$+]I+581<ZIJ$.D2;8I9F=A%L
MR,D#OTK[,^'G[)GA%_AY;^)_%AT_4+O4('FV%P[G()4>O''%><^#?'.CV^H-
MHUC;BQAC)$8QM5L=: /2OV8OACI/PJ\1SZ+H-O+<6MTNZXG*[Y&POW@>PSVK
MU#X+SPQ?&'6M0U"\^RWD.+>QBN(MN\8Y(/3UKA?@Q\2)OASJ<\EGI\-]>WB"
M&,./E )Y&/\ /2NUU#Q58_'6PU"UBMH],UK2Y!#=S)S'%G/*XYW$>G3% &GH
M.BW'[6'QNO-)M]LEAH:-]HN6&U'D7MZ$@"O<O"_P9D\5M'9M>+!IFGJL?EVR
M8=\<;<^_?%<?^Q_^S]=:'I<?EWDULC%S(",27'/WF]S7TS\/-%\O4K>TL[=I
M&:3:(U&69_6@#Z._9 _9/M?@_8VNK/B.:6$>3 !GRU(XR?RKW36-#L_$.G26
ME];0W=O,-KQRH&5OP-5_!T$]OX6T^.YP+A($5P.QP*TZ /,-?_8Y^&_B"V:*
M;POIL6XY#0KY;#\0:['X>_#;1OAAH2Z;HMG':6JG<0O5CZD_A6]UHH  ,444
M4 %%%% !1110 V3[M?-'AK_E)CK/_8 7^E?2\GW:^:/#7_*3'6?^P O]*J),
MNA],]Z*.]%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 $9--,2G''08IU%
M#3$I)^5><9XZXZ4- KIM90R^].HH 3:* @ ]/I2T4 ($"]*"@(QC@]1ZTM%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^-'_ &$(OYFOIH=*J6Y,=@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_@KY\&_AS8ZY-;^"O$WA;6;_ %/3!#$4NIX$S$Y<KO4J1T# ')S0!]:J>?\
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MG<"",]?QH \<^$7[-.JZ+K]OJ'BBZL;S["<P00.\B ]B=P'3TKVM!M'X4[%
M&* "BBB@ HHHH **** "BBB@ H/2B@]* /F7]CK_ ).D^-'_ &$(OYFOIH=*
M^9?V.O\ DZ3XT?\ 80B_F:^FATJI;DQV"BBBI*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKOP,4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!7)^E%% 'S5_P6
M'0#_ ()?_'/M_P 4??CC_KBU?-W[>?AJ\\4_\&V_AV.R61FL_ 'A/49M@)VP
M6ZV$\I('\(CC8GL*_0'XQ?"#P[\??A?KG@OQ;I_]K>&O$EG)8:E9^?+!]I@D
M&UTWQ,KKD'JK CUHT+X0>&?#?PDL/ =OH]K)X/TW28]"ATNYS=0&RCA$*P/Y
MI8R+Y:A3O+%AU).: /@K_@LQX\T?XN_\$T_A?INA:E;WEY\3/$7AJ'P^L$@=
M[XM-%-A%!W-A%)('0\'TKMOVHOV/?V6?V[?^"AA\,_$E=:UKXJ:%X0CF.@MJ
M%[IMG<Z:9W*3!H3'YK*[-D+(>%&Y3MX]*^!?_!'G]G/]G+XKV?C7PG\-[6Q\
M0:2[R:;+<ZG>WT.ELS%BUM!/,\4)SR"B K@;<5UG[6O_  3I^#?[;MSH]U\2
MO!<.NZCH))T_4+>]N=/OK8'JHGMI(Y"I/.TL1G!QGF@#YA_X(J1?\*D_:&_:
M>^#7AC6M6USX3_#'Q)81>%_MMVUU_9+7$$CW5G'(Y+%$F0IMSU0M]YV->0_\
M%N/#?QA\9_\ !23X3Z/\#;BUL_'FI>!-?@BGDN%MY$MRF9Q#*?N3-&&5&P<,
M0<KC-?I/^S/^RE\/?V//AK'X1^&WA>P\+:"LS7+P6Y>22XF;&Z6661FDED.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  !BCK110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>inbx-20211231_g10.jpg
<TEXT>
begin 644 inbx-20211231_g10.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X27 17AI9@  24DJ  @    ( !H!!0 !
M    ;@   !L!!0 !    =@   "@! P !     @   #$! @ ,    ?@   #(!
M @ 4    B@   !!1 @ "    ,0   !%1 @ &    G@   !)1 @ &    I
M *H   "0     0   )     !    1TE-4" R+C$P+C8 ,C R,#HP-SHQ.2 Q
M-#HQ,SHT,@ Q,3@Q,0 Q,3@Q,0 (   !!  !      $   $!!  !    Y@
M  (! P #    $ $   ,! P !    !@    8! P !    !@   !4! P !
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M*** "BBB@ HI"RKU('U-+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M)L6H@XB02$%P!N([FGUST'BJ"XU86R*/)+%!(<C)]<]/PKH:[7%QW+"BBBD
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M6:5) R*\C;#&3D']<_Y-6O"QFNX9_F5PQ"J@.<'')/MTKA;#4!?:2D-M 3N
M9I(@1M3MGZG%=CX3U"+2K%A%$J,ZKC>.0,GMW//K0!Z#:65O90B."%(P!SM&
M,U8JAI>H?VA T@&5!X<# ;_]56KA9GA(MY4BD[,Z;Q^61_.@!ZHJ9VJ%R<G
MZFG5E7$>KPVTLHU"U)1"P!M#V'^_5S3KA[O3+2YD #S0I(P'3)4&@"S1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1165XBU>/1M&GN#*J
M3%"L ;G<^.!CO0!HS^9]FE\D@2[#L)&0&QQFOG/6]?NIKJY_M&YFDD=<S#/
M89 !';OV]:WM+\5ZCID5Q/;7VX2$[PV&!;.,_7.:\RGN_M6F7MY>NH^W7WWS
MU(W=3Z\ _E0!M(K1B,LJ,Z$*P[DG S^I_.NS_P"$RU!?#T>AZ99K%"08F=6+
M22$GYL'/?->9IKD%YJTKQRA=/@C"R2N#MR3V%:^E70:V6X20@2.0D3MN(0GT
M[''- '<^'OA_JVKO,;R-[!0.'FA.3SPH!P:;XOLK73(K?PS82F:2.3S;B8J
M6=@ %X]%]_XJ]6\)74MYX5TZ6=)%D\D*3)U;'&[\<9KE?$MG;W.NO>>4D=PO
MR$'JV._IGW]* .7L-/.GJ(+98T\Q0DBMDJ .XYZ\=A5ZVFCM$B8J=A;RR7Z
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M.QCSYYXXFB==C(1DL>N30 NDRW5NZV]O,987E(2)N58DY(/&1QC\CWKNP
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M! 4&!PC_V@ , P$  A #$    =_@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        HX.%
M.;:]+CT]=EO?9M_-0                              "CBUS<5
M                                                       >-$/Z
M&' N&QN<>F.:^W+L>LF^J9DB])+S0J
M\+:>%M/9=7RNJ
M         !Q1#7-PX[S$,H]C/FNYEX(AT$6#\W#CM].@YJ*;=+3VV71G?']U
MUW=>AY-BNZR?*I4                            !Q2GQPJ_>68F)ZV+)
M][=V.3)W702S+T<ODKS6BI6O%KFHH5X.:@
M                        ,(QK*J^2X4@\]%CVRN['H)?CFNP&"S(=1%W^
M!7L<&SI:L[Q6&;:[$MO?GO:Y-JNKR.;BH
M #BQ'>HBB+QO!^>VF34OR>ET+;.SM>QR<ZS+NYV%TL]!+[+GSQ4BOEX?"2LL
M=-+]%Q6H                                                  &+
MQ4HCP.'E.EM^B&SL\-A?02\QLNX'&^#E;(YK'Z]S?&]$[;*[O>RR;0>EYDB;
M*_FH                             *(EU4=:/.<3*-/'G.MM^R:F(5K\
MN5)TF4ZK85RW=RY_+=BO/P_3S$&/9U\D^L9L\[R7E4
M                                #U64UL<M!VNCMSK00>FZO7Y#JN5@
MQ+CXK&=ED1SFJO<5C6U]!RZW<C!./JV9?/OLSWS5Y
M           M=%!93?SO%R+D\:K7&Q=E*RS61Y7%?*/3S8#W,V,[.7-M'![+
M7PS5^:>LN>AYEDMQ)S4
M        H5<'C2E>>7@ACCL=;=.'-V8Y?9W$%U/^#P[-=_E>=;>JRKZ'>9X4
MG]!/)6QOD/IY,[V<EBO3LSL\BI7@Y %"X                         !Q
M:\:TJKRL</\ EV#A>/'GEMN!X=UA]C=$O(0])N&;=_F?5#3M<.W#-[-C.XNN
M_P!7DRIE%:@                                                #
M@P; LJGST6*:BRO,%MEN/Q[;W9L/QXE=]-%C&-'8;L\O,]9'C^5=%F);4'EX
M-E759&.9UW:8]/K[.>7^IFD?=S>=U.:.%57-7-0
M    '%*13RD,)\)CX=!'"W'P5\YJ&]O;9&;[*3OL95/B,.W':9N-9E,TBDBO
M;VXGN)95W<UI^RG]\@
M      #BC@I]Q>-%6OCQ/;34PXG&M+Q>/:'$K]76WQ3H8XUXV&R_J.3Z<R3Y
M[J?;BTH3Y7@VY[;)E7=RX!NK^NR;NVP[,XW$WHFKCFOIW&+;F)/?IF7WN;<%
M0                    '%')Q2BKBUS6JKJ\>V,M+'$_EV%[H+?BEK6?CX8
MQR5Y^FE[+&=9/6.8+8-X>&W?H&3.<.9"UV#77K9LPI7,.EFLCM[Y+VDOD
M                                            #@ZJ&D2Z6.OVKLQW
M5V8=NKXFX#%D;6Q_#SD-@>_RX\X>"3;*5[DNRWT2>7]/;W>%9JP\^P_IT%FR
MGUW/[^6[NZ,&N1=QN/CV);[=G=8CH)Y%I7U^B94[=]D\U
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M]-S^[PJ=Q!';SKLC/L^[MI[@HYN
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M,)VE<'Z"7,M)#]^QOF#OLJ7>@F\@
M       !1P0EJXZZ\!B=KKZ0GOI*!?.VIG+R+7R=K:5?[O(]6ROVE^GYV=;^
M2K7)Q0]GM>.OLL)1C?*X^S+VW:=IT$D3>3X5)O/<3HMY?LI]RV=(N Q<I\EQ
M-D_L.=7[116:GOH-R&+L*]=V?2UCZ?-NR#!?/EK5>S[#LIKN;@
M          '"D-\+!C'F^)VE+L(NCF&[*J'YUJY#]-R\%TT7<XUT6<>U+Y6/
MM$] RNEY:.K'G&%\T5=F'T#L\ [";77\Z:F1>\RJ?34E7SO%VV=YEQ'K[)P[
M?(J!H;,WW=W;>0X6;X5N9^EY6->G9TQ<?!EFMMBWK9KN>J9WT7@
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MC+F\>$:+B]'+'>XEK1XUKX7\JP,Z]+R]CWIN;\D]TZ^E9LZ;&_FI4
M                               !@N-;0OC\>4^0Q\9V<DH\U#W'G*A/
ME&JI7VM_>:^RUOK&PF3V+82;RD&=Z.S%]HZ/-DS7G8M0/EF!@4-EP=M-<_U[
M8?-D,GU5O5378OSEE.?,<6:H;*M\]A[./?MQX;=Z[[I,Z_(G_M\KZ9'-P
M                     #BCQMI7OR/#Q30P8)BUBSYUUU%NZDM]V<NLS30W
MK]6V%H=Y+]\%F/[.2I/FF'63SW$[/'MVN^W;/T;:_%MO)EVHCZ^>OOJAC@\7
M/.?LHSR&//7E^'*>JOQ_V2>=O?=MW&);@/3S;">UR>ZEJJ
M                         CC$MI1P^/F6DB]5R6.9C^^)46V+4ERT%G9K
MIG[O*M3T,W?ZRS)M79T&PO\ 76F:<3'JJ\BUD99-+6;>;8KZKL<'V%GS37>F
M^DC::NN?0P?9\_:O&>[R=J'L6RP/,IT>6[?7I']*S)K[3(YJ
M             XHP[5Q5J\MQ/DAIV6%9KC\@UWJT-+-[C,K_ -M??WM[^GS+
M_DGOZ?875M\^PZR^/:^*NDEW#=]EY!U.1U.9=('-P=)L9(E[";&>:CI/\T:7
M&LFMCN<LO1L]CGWN<D,]OD9/K+8XZ>6RG536*W$O(
M                   ."NVJLK;QT&0ZZ+O]?29-)=\TMNK'48\>Y=9\TUDL
M>J9V624RC4V?!.Q3<2YMHK(.\HPJ9>=872;&^_??9%XNHSHFSK(XZ23/M!'G
MVM=/SL>K[Q#4-U+L@]ZVG3;B[J<N[ZX6>;Z:U/H&5[9
M       "@8]AVUJ\;U_S0V_%+=,6LNUT>?874>28$5>F9VTOT[+Z;.8WLKNZ
MP[,BQ*URX3$UZ<7A]:NVB]?FR!Z7D8YLK\UT<72;"_%MQ=#VSDIC\^ZJO.PO
MN=+39UU65W!&6^DZ;,DZ;-I-/8Y%I-[-R
M           #@K=HHZW<[!\M]W>QVY;SD?*W#LJ[K=C=D^ML^F^[$-I?\V0R
M35V?'/7%LJ[5-X_K_HY*#I,^_85VV5;_ #+NNWLG=X5LHZ:/"YJP%XEKZ.ZK
M&ZN:78Y])[;M=E)E^FLD'46<R299ZED2_P!;D!4
M  M<$3Z&*N/GN'ZZW>2W+M12J/D6#7;B\*\'<YT^>F9GP92(NDFR/7V3YI*U
M&Y3#I5S>-A_'Q6#ZG+NM[)F17U\V1ZV/[(7BK&O22PMXO@8WL*URQJ[JMO=+
M4F9"DN+&_3S_ $1V]SV.1>#I)N:@
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M3W^9*W(XV/;._P"">_J\NO=X=G<;Z>[_ &.1]5P !1S4
M                         .**D<=!AG)XT9=1/@-R,]192;C\:W?)0X;R
M^/#N-2^_=9?R;B^OWSCJK+^OY]K/1,J/X::R?'M?;/H9:T<?BWF];V-#?$=;
MMO\ ;]II]X'#D/<2;.^[R9+P9,!EC\.WR+:^C9?E6JX
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MX;P=%E9UZ7/KHW$D#:"&9L^^ZW279UM9["[V22MC?)NRO\JU
M                              *8GC4J#Y9AYQSL-4=%#*?HN5V*[+]-
M;'V_O[KS[$HUQ.+L6]*SNIV=>KR:T&^:M56[?7;8/7,_,=W?6/#K''R;H,[V
M4]M_>=K2?E\6JVCBVJ>T[&3,&M:N(Q+$=YE>^VWX=[-9'TG+SK9R<J*U
M                   XI2(^6BQ_RC#ZR.WK5*5>2X/;]GD9-TLD.^28<20V
M7B]AV,!?.VKD#14A#Z)S[L>C9>+3UTY>/8$U\/B;8O>-G\N3)2;SC!A/GX]J
M/L.PA+T/,RO3Q]MK8JBX=)=K?93#L^.6LX>LYTP[6\
M                        >-*0;J+("X;&@#S[$EGT;*^FE<PTD?IOK!'F
M&%.L-UDNUS<8E0Y3&UP_.^KQ[H)=RWL>RQC+K1C95S7Y!TGI[/-O][CL=;'G
MVMC#NLFSD=USYY*S<3B3=W.3AVVNL7ZOG2'MI.:@
M   .*.AQ;:L>:X?V<S!\LJMG#P6BZ[(Q7=7Z]/'-?'6ECVV>T;&K?A^'@_F^
MNP7Z2VUY?1LG[L2FIGR7!R+@<;8)]#[7.=O)D.MMHKP^-.]&:>O9^::*/YY6
M&;N:#?+,"[.\GZ3/IG/J6?8SH)>0
M         !1XU5VT,-4_*\%@6S#M9)@U-T-SQ05S\,M<Y9,/<9/1YE:V:VW6
MAY?@2OU,^S?U#.^615S&9U\IZWMNQEGKV_+J1YSA9C6[M.:@DOU'+K[J;+1=
MGE=UT\ULO1\OFM>:@                       !Q1T.-2IWE6%D'/PQ%PF
M/:#L<B*\]K@P;8N\RPMTGI^?7_S^*O7C.HPOZ(VM\>YR96U#6SY=KX&Y3$O=
MZEL;#]AD2CCSP1S&%6;203[ZOG\YKKLR3H-E=#/G.)9SI9ONZF>W7;9/>35
M                                          \:*^:F.*O,,*O'G^+8
MONLGZ<&.M^OIY<=!D\:6O5,V+MQ=!_.11)QF/;+I9IBZ"?ML6VN/&8_S>&:_
M%-]?;_WO8UXTT60^9PY]Y5;$G>1?#Z;F6(]!ROLW$EO_ $S,^R5S=4
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M33[==9)7"X_PXS;)ZOLX=W%DO^I9T^[6_FH
M                         "'M='7_ ,LPL[T5GUPTZ>EL Q4J'J[*EJV@
MF7E].SN:.[AHOKZ=3%5'S7$D371V]]*S\?RJ93J[/'N<JSWH>5]LU5'-0
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MCT3+N%U^3S4
M !Q1%.#;7CRC!S#31X7UD_6SN,*/K;KXY@N[/%MSG68_2WS1[V\TBXUF0:^F
M>=')-?4Y'71I9V-?I55H5                        '!\L5*N>?8N :>+
MKYWHJC;SW&B/FX>L]/RY4ZS,^+&IW^'3-5/FI%[<Z[L:W2'S,.5ZAU>79A_4
MSVZ](S,OR+N:@
M   !Z[4":.'J]3;.O4S^F6D5:NW#\W)^2ZRO/'8.2<-!\T,G4]1?(%EF3::.
M6^^RYSZ_(YN*%0                         "E/71!6JMZ*.GRXEL2\;C
M\50EO+^[YA*>BQ,)V<WP+\XR[>TGM\5?BS+I/X^'Y)J_3Z5EVTZW(Y%0
M                                               XH"KFC@Q16O<<
M_?2Q]=BPPIR\/4R397U5DS8#(-?2:-_+]5]>:E"I1P8/E6Q;LJ2QK:YEBW<B
MH                  !0.*TYH*JE"KB@8+K+*T^2X/2;"N$[*7Y.5CR7"MP
M_J+<][_89%DSYGK,7+L^LOYTE?>.Q\;BI8WM,C,LJY4
M                                     ,;5KI'-EDL/UQTZN^2H7312
M1T^+T^%=<WB)Y+P[N;P X(BS+*=]E!G>QLPO6W7]X3*[ZPK4
M      #BCU5I'.=;W,5<RQ+N;@ 'A8@SF8<*@MZ3?70ASE?'3V2+UE9SZ*?#
MX,B5KXI8NL X.3FH
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M.LU\UR>6EG36W\U <457VL59^JCR/.LB:RLY\K-.F@R>X18[;-*:V1[K
M                                                     !X*5ZLG
MZ2J,-SB0-V6/E$JM6YMP2-8_3W9]I9<LVMOE!7&\6OS24QW=0X)N[;6Z*3'+
M+J.;2+9-JK\:@O0),TLEJN:F]BA4              !0.*.+J0AM[*I=YBT)
MVUO?QTR.^MI.+GMYSLTDX=V3X]57B4%Z>#!MW'QDTZB2_P H*2CQV3/VINP^
M.:8;K),NCY
M       "D=VR0=)?6#JL'HMY'"71P=KJ9)%UMU3.@LMES\F;7NTAN^+%NRC8
MV5'Z:"_.CDD#&NK_ +&RA^PMV :63+#K:UPO%7GX')D+'O
M 'B1]EVUYZ./',RSW;*V@6XBM=I[\LFK%&PCBNM)UY>?W0UE"&O49]/;@5B[
M)I W1Q=%EV6HU$GQVV>[FY[:\IF8];+8.Z'*;K0
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M$Q6636Y)S<_NUN1L6Y*>8;;.0
M                     <4<4IUTJJ^^CKCLHO@MOIMW&/<#3R?#!9UUMWPP
M2_5/'J^ZR"%-K#92EVQ[DYY=P)<.W<6>85>CU-VOWN8+E\?-DFJNFOG\B[&E
MN\JU4*@              .*,4D4!W\7R]!!)F33G.MJ;O+)5BI6C=V31RLUB
MM?)\%5:\V.O4B'\^STZZ^8%M@=5?D5*Q+TL<D\MD_!@2;+^3OF3"KRJJ
M                                                   '!BDU*C=?
MCX/F6]+;3TV5^:.ZMW98V8Z*?NXKN]L93#;VN5;@M]NH+L8\#V47?R5O?R<^
MTS4W:V-W9.>FOCCK\>/^5GM!Q61/^)=>332\U                #BBOF;;
M3[JH>SSK==O<XNP_B)\_RKH1Z**2>;D^"E*>]+#KJWL>%X==HG+3S3IYO9?;
MV,EG;9%:D;N.TG'Y/<X-)UANN=S4O9QW<U
M                             #BBI^_CA+KL;J<:_P!43PK;VV2Q#:65
M<EMMMJ)><!'5EU5=_%,&SMP_/L]UE:';B*,]++?O,I>?E)JF;:."=S;UO,2;
M/.1R9B67PX_*\J.*N0*@              (8R[:!;FSU;6W7OZUK]I?G.73;
M<Q7:Q;HU@KK+[/'KYFQ]7!)L<X^>\6IDZJEV#15\LNWJH;JX=1CWBY*;J]?7
MMMA;D6*DK&OL/SD\B8=>0
M               <$%9MM*^DA]-*>5U)%W%OWWHGMMHYTL<U7L3P*Z[<ZG?9
MT>U;53W5T5U(>@BPR&[7]%6&-]!<;9VV@YR;5?M(\YP*[K>(RLIRZ3'S,O>0
MW91C5FO47\UKS4              .**][B*G&_CK1+;2GU7"M5SLUI>>DQ7=
MV:R]E2$\^&VF-?)6/=GV-7"-==<SGINVQWT["F/WTK]TT5W>;EP; O\ OR+/
MEAKDVQIV6DOV!<9D>2H
M             '%J)\BE#]M;Z=K#E^XLG@@>M>FCMJ/T\?:8]=86UCQ7(LR;
M:VRQ'==_EIXSBI;#CIZC]!90WK(;"YEG8R4S[8Q[)?)L[VTK\\+L,EUN%=*^
MNNS6"ZS'.R]I'7FH          !0.#HY:1KGV_1;2N?50QODV:W<M27N\.^.
MFGE?.IKDSXH^T4FQ_%OEK84NGHI.UQZZF>@BI/(V%Z*^0MO' 652T?/2V-PK
M\FHCK KU>%?V>;21]+??CG)N:@
M                    %'%%0M['7'=1UZVUGQ]##+.LK(VCDJAVL-).NQ9
MXS)^3#NQ;>V1'NHO@C=EB76,YF?9-I[L&DK0GHHNQV%O<]+!:#SG,MGJ;^FL
MKUN-=]=;<ZV%/KM=7JK[G<A/FN-=S0J          XHC+/MC+860%M(_AW-G
MP8[W7U^JM->G8XT ]-%)NMDIG#3/M--L^Y#(A??0V"I2N'16TMW<&#XKI-=)
ML9U5UAZWY?JKI+U]TO2NJE1'J:X_JY;#:J2X&#7OJ5
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M1<E/[3D
M   ^*M-9/1Q8M#=Z(U1.]Q:/^@X<@QWV?U-\Y<A/J/ZV'(ZV[AO+<S*UU+^\
MQ=B^MOKE>H7C75<K3I>ABLWL[+9;6*JN;'(^EGV!\%E=MHI>IQ*_3)3(MK9F
M6=3I[*9OH);O\ID>ZCD        'JJJCO8(=ZZ*0*(VN?=2["]5=V.7;*>99
MJ[Z&*G7<8O:\;D["=))B4%:K==CU9CN^S(MDJ6VYVAGMCS<L5V5U,=YC>W.C
MVGZF^V/'Y=)=E%8C NHU<F/GYKKV5V1\I-Y
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M?$N^Z6S8EII9.QK@
M           %'!"F791#>1^%S/\ I(NLZ"&NFZCULYE(2U$GQ<Y-:'+C^?LX
M)"UEV4:&6_\ S.1D:WI<&3NLZ/U*Y?G6^U6OG8XVK3HX<+U4EH<&F%;&G2X$
MFR/S[)GS/IYUIFM]8\Q+KT\!DYYCU       '%J%]O'6?LH>MFM[&^D?:F_&
M]1)Z=['$U:5TZ_'IOT\&99]DM<I/:W22_;C7R5I),OU]\E]!%("ZI$T<(V5R
MB^FI'I8K%:B2U>GOI!Z#B^O>Q=K<V9>;YDA</E\0V=QM:7<Y6:;,*X
M                                                 !1X&O\ ZB*-
M\JS[,RR7M@K]L(]=O30V2YR:"=C;K[BMRC8VV>S*8GN([T^<Y5=X;KU\9/WV
M53+-Y'UV'=[Y*??ETZ+*MUC^CX71XTG1Z>^]F#)JYW$/P9%-AU5Y>$R_= ZS
M#NV(\)D9-%<       .%-?7:8^:;V/!+7U*Q[J[J1;^*OO7P^O+IA^K8IO:7
M&MMV7^:9OU58IAW==C4^+%O[;.C]LM:P9%M+NMQ_@Z2&.^*R>UTLM>]Y%('2
M0; ;K[*8BPG$Y4<<_?\ #BW3OA7WCTU_N5
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M]#K)._6[#N3R,BCJ
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M&.XW(9$YZZ[D
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MX\HV]OW:._81Q>1[%50
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MH[T>/06VFQ7BLJ;+;N\V$7LON[GG[]A/(S^=Q6H
M                                 $19D=*.TQ^DP+OKVUNFCUS S_=Q
M89JYI$\UR[+XU9DUEV;:B7(=E;]^59U&ON^J>E=^CLT^]!#UV$[C84M'K[MO
MO.39=%=#<5--O3P9CWV-.-+IW\[R9CU=^H3JX=DO,R5T]-Q/JV,5H?*]C&T5
M.RP;[/8%>++MBG"Y/?P,*RZ=]%7N8:\W !Q17;=Q5EZ^#KL>[,\Q2W=0X16R
M[NHE@.50W,MKKU^-LKY3)PJEM9NRQYHT$\_8=TB8U< 5Q;57^O%4JZ2+!.LQ
MYEENVG<3/FG/RXOII/CQKOJFMK;W./:VK4#WV'">!=G_ $,=[.-GV$\EE8'K
M[I<YJ^Y.DF["RJH
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M-;8CGI;7Z&7FH
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M2O-U.5>*.*.:N:N% HXI7E0JK3@YJY5   4IPH5YK52G"G%;N:45<J@
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MGT#D=T?&=-*N'DZ"/0.0[6V[?%P'75OVF#K/Z;0[O^%ZOFKR"O-0
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MEXGIM ?H'(R7CS^)@<\>[7A^GUD]1H]XO!]9^?#T+C-V?%=3,.'DJU
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MOILN]%]N*S09+#-YW%CZ;9.:V_+=12OC6W&)[<MQY/;;7FM>:@
M   !Q1S4%'"BE>:N%!RJ.% 55*45KRHI4<5!0K;S2[@'(JXH5%%*CFM.#E4
M #Q*W;"V/,BMI-6S*.H6O&M*A;F.NV^BIMO[+?\ -2^NRN6[J/.<BVI5;=?/
MH6/BNULF+SS*J1@7;-M/+VF1;J*[''LGB7;=^+RM?&SAUX]#%[YW9S-KGG.=
M)V59V$])JRX^MQ:SMQN1;W67E.:U4<45-W<=;-W'UT#ZYZ>1TF+?]DEN [>F
MO;<PS1HYKH:&3WT40[#'I9Z'B9KSLN/;B/!,"NR3SW.M=L(HFZ.*5-1?%D=]
MC-+=V.1;\T5:37TM5KI9-QJ[$.;E^ZVJKBBMN7;2W<V>V2V;M=??#3R>52H
M %%"CBYR%5!3A7D'%"KE15Q2H"KD6N*E0Y44J4X"I0J4YH5<*JE YJ
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M5
M *%0"CY*TUT];%UNUB^*"L+9E(PW4>>8=;#:JZ*L^VLV?22^<EG?4R3/@W7)
MU=]3]I2(^HQ_GV]E$.F@@_8V6QYG(R_ALK*%O895DN\YER3KI9;F@GS'=A95
M4 H5*/$IOOHX1Z:&%H).YK'Q<J3'?0'L<3[>AL^2*MM,%*./6A%:[2>!R; :
MN3Z=M'KMZJ"G_60=QGQRUS&1N8Y.?RN8?I9>NNMJIV$-[]1=\$=]M>%GG?!O
MY %' .:@
M          HXHQN2D09;M[*19FT@3H88GW<=2XZ3?KY+!X-W9S6VUYB>Q>ON
MY5BN>E$NOQI0W%F1UK&M:1G%)%^GER&Z+*=;6YG-YOICNL]+![P   <'S6TK
MWL:5SBFZJ:V)^DQ/@I;@\$T=]GC5([7&Z^-?_EYIWT-V2<[DW?YR2MVPLA/:
M6UMVED!='%9>!9W32]+-97'=6X]B+5:N_*YJ_'C5NAQN1-&'<
M                                                       %'%7)
MP>HU=]'%UDU/C@IEL5T_XU^6Q4L7K[_;4/&E-?W1QXUTV/VD[YS 8[\)TE]L
M^=EE##N^".7O;4_21<@X .0*%7 H@1)B5LM<][A1-O<?&HLC(MA9.6;%WE])
M+BK V,EKDLBZVGDX4B3(4:ZR#X*(4V$<;Y=.ASJ78UU,KYS(F[5W_-?7-\>Z
M?\"OLJ
M              4>-5%-W%#FQMG?677)TLGWTJ.;@ CR6E*>B@QS+>S86XMD
M/OY^:T_*7016:9:6R#9=/<D?)X%#3 RRA9PY  (RMDB&R[OYHX3SHH!VU.NZ
M**<,FSW5>VQAFGOO]QV3(,11PI738VPWG6QK2N!34]N19W%*WTYV:9L6H"X
M
M       %'!ZJTQN1DT;S5YH 5*%7!Q1U=ZK^SMKYEUEO23TGBA[%7OU9_I)8
M:L4K*1J:^R6#"3929<#@'P$46W=!5\%+^SK9!&UBKQVD4J76==A5]<*?.?EN
M'II?*X%*<5JHZRM*L;6RM&XB^U)L.Y>3-XJA0%0
M                                                      XHQVE:
MVV3ZJ9()^K2RQ7\R@R8@@^4MH5N+Q%HSR/A-:A'AGB^7J))M=W?9A=;Z?=)%
M+E\5IM'+)F+=DD=%U>0 #@\5(MR*=W97.8:\U
M                                                      !1\E%7
MK)Z,2PQ^I)1T*GUJU@(6(L+ ER3/38X2H8,:<"63'11?H[ZK$;9L_I;,U\?-
MKFX    .#D4*@
M                              ."$+)=>];:RW62H860,0*9B2 0F;82
M?3Q+G$.FHLLB8Z>1>8STQ2V:7UDB76
M                                                        ?#16
M"E^JU7TW1=(K#YBY@Q*!Z#8N66.X(#(>(-)(,Q,L-@AZ;6-I[(UA[*M
M
M              . <@     'A17NDOSK?NNMU7*TT5K4MM:IWQ"ILF+*&2E9
M2,20#S+CDBVW]2OF2MF>5C*\@
M                                         '!TY3DA C8VZF1
M X6X[22#E]&:M?"W[%L5*9N9>1<61-EYZ2CQ@ZN7'T+;"+[96RV&K%D-;.0J
M
M                 .#4R47/J/>;="Y)R     #KC1^I7=7YCQ*QEF#V'?EH
MS[C+C$BO171==I7/UVR.VLRW0\G(
M                                             !UI^>@P@]ID)?<V
MA'(     ("4T,'=JXT5Y,U);.W)_)')5,L-7AD1GA.:N4FRZE,@JX/$\SD
M \3UGB<@  Y/8>0
M                      !&Y^>\\262-"VY8TG LN<@ X/E,,,Z/(B\H^:S
MCU%5"&"6BW1Y&5DSDY'@5-,C,Y)()(-C96PP(\R4RPYR  #@U"FM    ZL_5
MZ<@
M          'B:*2O9(AY&.G3GN/T+F9'(!ZC1R5I+<ES36"8@=<1F8>>H^LZ
M8E8S0[LG\P4C0F4^PS8GH[@[PS@DXC0R@L>>0 !P#D   _*<?JP.0
M
M#UFA$KX5^/8>1.1-I[#9X70.08L?G).\.M.T.C.#[RII8XKB>9[#XB5BRAZ2
M/R3S-"(RU!W!8(R$C,[XSHCXV"'U       _*<?JQ
M                                                .#Q.3K#\XI5D
MG\Q<S0JJ3.2H3H;VCZP<&@4A4]Q[S!R'SYB8#- <@ATALN,?07")*(G.@)2.
M3V$EF+F&DJETB5SD      'Y3C]6(
M                                   ."!C3V3L0:1$5Q/A,M/85A+UG
M:$EFYTGDX(O-"9UQ[2HY9,^LX/I/>;6BEQ68I:=H6,+#EK#[B"3UF:&='5&0
M&8$_%ECL3D       _*<?JQ
M                             /F-=YKV,).U.T,**M&7EIBL9G!)!U98
M8W;F3'PFB,@8X*M%Q#MS"C@[@S4W_'YXR%S$2<B<B*B\1()"I Q,Q@1.18DP
M ^,M@3F<@      'Y3C]6(
M                           !3HTUF:&*G5GL,M-:Q>@Z @TL@#+38*6Y
M*@E%##S[R*SY"3S+#$C[B438,3>:*R)#)R[A]!%1FY]Y]QG!WQFA6<N"=0=,
M?.6>)2)(/(      _*<?JQ
M                            ($-#)YGL/D/>=P:_2W)CQGI6DP(V!'4G
M@?&0L9P=.1L6M/C+]ERB1B3CP-")!IP="2D6Z,R(6(C+#&+G>$]D-F*$M$V%
M<SO"0#/RTQE(     /RG'ZL0
M                             #Q/SN'UG0FNTS0QPFL[0D8[ \"MA;DP
MTAPL$8^8&=L9J<F;'Z"#)3DX*HFDP\03<6),./88@3&2,5W/<=89J5^+FGSD
M5$O&.&?EJR;      ?E./U8@
M                           X/$\CD'B:GB@960[TZ8A8M*240:3J8^8$
M6$*E%L#[SYCV%Z3-25RR9G!R#$C\\!TQ[#P+ADC'D0H9F9D9(0^8F6S,)*'E
MKC[S*B.CT$X&Q [\     'Y3C]6(
M                              !P5+-<!:4V6GD>)7,_+05>-J9TYK'+
M4%MSY"$2=RKQFQB1=8QD^ DH^PWP&3'( .I-#Y")VY+Q8 [(CXZ8\SYS/BDY
M-A.)')2@N$1,26369.9:; #(B/RLI+Q-Y]IR  #\IQ^K$
M                                                Z(T1'2'PER2\
MA))I3-.Y*9:X@$JL6D)_(M*:ER242'2E!8(R M"6/*ZFPPVE@ '!%)I-/O)J
M.T/<?<>)@IT1])4,SPLJ=45--E)3PCDOR=J2V72.D-69WQV1,Y=XY  !^4X_
M5B
M    #@USFNDY.S.].^.I(:-3I*AL%(Z*&EY"4RL9"I/)YDQD:&/EDR#"020B
MV1N@.0 <$%%8B$#H2<2+2&B2SZ#+SHRE!V9<HA<JP7B/$J$2X6@.P/:1*=T6
M>(P/N-FYR  #\IQ^K$
M                    'B::BMAR=^=B#&RKIKS+5%P"OI5$V6GB4:(-.\-E
M)[S6^6M+!'T%:RVQ.!NC,E .# 2KA@)A)\A\9F!K^/<9H7;(H*LDK$U$7&N0
ML@65-=A8PV.F5$1$1F9%@SI3##9J?2  #\IQ^K$
M                                         X,8-!YXGI.[,J.@(X*1
M%7"^Q/QKR/C+OE-2M!\A>TF$B,IH;5R6#'RI98T&Z$N& <%13%CH#)# #%C)
M2N14@F$[$RDK^9$7I/ UM$>&Q8HJ=J72+TD6$'&3'O,P/D+=DS   _*<?JQ
M
M!P5A-11X$?$;$^G8G4&"FO P$V<G:&L(CLZ@')/A?LU;G1$V%P#(B/#(B5R>
MS>@=T "/2E9P8*?6968\1(5[*R%WB'C,B"RUA+A!Y6 LD1^84346&+)D"F-F
M$%JR&S9(28  #\IQ^K$
M                    '!K_ #5Z=J1H5X)2)(,I( *)F=ENR%RLQ-A%!$QG
MQ;<ATA(&R<^\Q@R\RXE\W!E@CD 'B5X*['QD'DE'4$,$"$9DA'5G4G=%TBTA
M4LA@[DR<C P8]!L$*P%ES#3.C#2^Q8,  'Y3C]6(
M                                         .#"S\]9GQ7,ZHZDR0\S
M#BCI,YML*5%"S$CI2P9A9T9=0I"2F;"CZ#T MN;I3WG(  / H4= 1V2D8\04
M= 5K._(W,D,J)@)C(Z(?/:6M/A*N&!%V#"CZB.B=CUFS8SL  'Y3C]6(
M                                                         !U!
M^>PZ B$GHPX])P:_2)"SIM3*+&M ^<V5F"%(2WQV93\O>3X9H8@?87'-Q9R
M  844Q/H(8/08Z8V9Z5?,2,U(G.\.\,A/$B(G(V %>2BI$)L1!8 Y,I+.$V'
M(  /RG'ZL0
M           #@HP:]"%#OCH",B-""3&B?2Y!1 J47\+,&KLZTVBFL\Z@V@G8
M&8'5G1E_C;*<@  X(7*XGJ/:8:1.1X2N0R52+)GWD$F/'V F<ZXRTO@:MBO1
MN1(P,$)8/:;&R1#D  'Y3C]6(
M                          /$B0U?E6RNYGQ\9+I$QFQ2\^PJP8P2*;'3
M7@8$6>)[->A8TV&'3G2G)]Q? VR'(  ."H)CAU(/O+3&I R\KT5/,M+_ )58
M]A+)2H\#OBQ1FIUY"Q-1WI 1*)9HLL65,L  !^4X_5B
M                                            #@_/D1X=<0R=L6".
MS,#.G(U->!T))!F)[R##.BUQ6\CTV)EAB1BS!KS/K-D1LL.0  <$&%?CL"5R
M8BMA4<C8C I^9P7W(?*Q&Q<@HHB3"7I,;,B,\(Q,,(\+)%OCZR>R4P  ?E./
MU8@
M    X-$97@ [H^,^$$&E+3!"XID150PTR0S0MF5*.@-EY+)R?H"-9I)Y?$^@
MY   .#HSLSZ3@H<1 8*=45=,@+"$ D?F7ERRE1T)+Y*!A!G9E!VIUA+YFY]9
M=4\P  ?E./U8@          X/$ Y.3D
M                   BDT3F$@ ]A]1K;(=+1EM"KA5LS0L"1:; RC);$EX]
M9[C?R2 <G(      (,-?A]AAAT1UQZCYR+#'RWQ\1@AFAUY(1GICIU9F9TY*
M9>8[0   _*<?JQ   /$U;%+06Q-M1Y  ^(_/L>@&W0IP40/T0'YO3:$;/CD
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MZAM_-01^E0_*6;DS;*>X
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MX !R #@          '(
M!CQHX/>8X5!(>)R.V,$.N/:6I/:5B+ 'QG3F2EP3<$12:MCL#KBV9< S@\@
M #U%0")R5RX)XFNHJL9T9":]"V1-QWIZ21#5P?80F9>2N1V6Q+CD;G1&P<D0
M   _*<?JQ
M            /$U)E?R)#Y#7,8R;.CY#H"0"13&"/B-26SUGP%KS-CK#%#[S
MT$:'M-D!=XY /$C\KP?$49+?'4$L'J*/&4'T'0%?C*SD[8SPM 0"0R58( .P
M,Y-I)W!A!+1LO/,  '!^0@V!  ^\W@F3
M                                '!$9K+*EG1%72S9+QFA4DR$D Z\X
M*\%@#[CTDJ'=DAF%&5F)$/$G'2EX2<2S9P5]*5'U$?DAGRG;GRF$GI,;,S+/
ME;3TF'')6 Q<R0EXRP[DJ(6N)M!>@S$R4Y  !P?DW/T'@'!]1:P]IXF!&,&=
M&5')$I+)Y   %:C+":00\8$6=.0 "'C BSIR
M                     #UGY[SH#X2N!9PKP:]"3S8@9>=&0Z6;)$.Y,2.T
M/L,T/,B$^,D8B\]Y.9MG,2-7!FY]Q,9B9'A+QC)!!C)*ACI=LIN1(2J4[.N,
M7)X)=)#/H(S)A/J.I-K)Y@   X/RGGZL0  #@_/.?<8D6<-S!IM-R9Y'!R<G
MB#DU$DW&P@%#2LQN* .0<%#"M)N+
M             !P0B:-2?C%"NY8@IF5"(F)C-KIJ:,H-HA]9["LH(W+;E@2)
M3#SR),.Q/C+;& G;EI3!#%"<2*B*#%RL9*A9PA\E8U[D7DIGB0"3<;'#I#JS
M 3NC"CW%Z2V)R   #@_*>?JQ   .#\\YN5+ GYGS]"AI:-[IH#,--B9=$T4G
M4&XLJ6:^3LS:H9$5G-AAH\/D-\A7HU GQE[C<6
M                       #@UF&N\[DKD9T9B=\4]*B'>&:D9%]BUQ[3"2%
M#/"PY]!\QCITQCQU!/A]9Z"PY)1 Y\I\AEQ)Q$Y5@RT]Y<$Q<R,JV0 =.=.3
M*0^3$3N0V2"9">1>,M =B<@   X/RGGZL0  #@_/.;EBP1HB-EIHN/T+GYWS
M] 97$LL080^5++'DBFQ,_,*;IBLQ5,V*$<$1%.#]+Q1H@LW%@
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M.*TGW'!$Q60GPLR5W)J(#++DQ%>#Y#.C8(:_BO!.1,I*!8(    X/RGGZL0
M
M #@HB:USS+VEGB:31:8@>\^XP(ZD]Q6 N$>PU8$B%VCU$.$SG6E""TYU)MN,
MM*A'D2:7U(5-;AL1/28F=J?,1 ?>>@EPA QL^\L4=4?(<EF2ZIX%:"BQGAL7
M,R    .#\IY^K$
M                 'RE+S)RV!Y @TU*D1%;SN"8SJBE9-)-11@RLN">1TY%
M1B13\L<9\;:3/S'"(S,BPIK:,C+&G>&>F*%K"FY%1A9CATI>XA$STCPSL^([
M,V2F7'M/,^T[$Y    .#\IY^K$
M                              X.3@'B4O-'9BI<$@ R8B\@\JX7 (@)
M-+-GW@\362>9+98<V2$EF%D7GRDMFO,V(D5F2$SG2F6E03!@1"6A-HY0@QDO
MF2N4/(R,@,@,]+_&6G(    .#\IY^K$
M                                    ]9KB(K(O-5IL./81$0H92=6:
M^"3"6R=#JS!C,3#" 23CK"X1/IEA%!FIW9&9!QL'(J.\)W/8100$1:=H?$3F
M7.*]$5&TPFXIV1R?(6$,/.Q+X'L    !P?E//U8@
M                                            %8#6>=N=68,5B/([
MHA\G8K^5I(W,B-GY6XS(FH\"J97\P8V1DA@ R<Q(KV=H8";42>@0 1J8 006
M(+F&-G7'QF4ENR0BFY(AD!W9%ALG/H    !P?E//U8@
M                                               $/&N0CD]!YD='
M4'2$2E4RZ!\)JR,9-@)8<BDSPR(KJ57(P-@Y/0!])\Q@1#QC9WA=<N<8X8>2
M,040B6/,H,(,9)O,F,/)7,V,O(+.M-@Y+!R    #@_*>?JQ
M                                                    !XD&$#EE
M"E!KE.E(*,0,0+Z%)"HIMP/8045A+W'>&M,P<N\6/!]9])U9#!'!Z2U98X[P
MS@QDS,IJ2T2B184O+6$T'@9V9<>9G))Y#QL;.0    #@_*>?JQ
M                                                        . #Y
M3\^164Q4DDH*6[*#F+&U<SPB$I@326_*^E!2PA?@Y/L/C/:8\10?";3SN"FI
M'1*Y/!&!9LR@IX1R3"6)+EE%3[#+#XC)B3B]!R     <'Y3S]6(
M                                                          ,*
M/SP%4BSAR5G*V$,G<%\RPQX%,")"QQ9HU;&!FT0LT=&1N5U+OF"DGDVF#FOP
M^,V'$0&1$B'P'4$CGR$T&S4\#469@>)R6H+=G(    !P?E//U8@
M                                                          @$
MT,D D_ \"A1#!LZ*X%O#TF7FL0CTL00L0H2@;Q3&RE!@)+998ZLBT@\CTV2$
MCE?B]!@)6$L^=L8R61-BYW)%150Z@QPOD22     #@_*>?JQ
M                                                       !'A^>
M BDE@]9P5R*YEYR#"XYTQ\YUI1LAPPTSL^D[XV'F5'7$:F2E-C&C.C8:?$26
M8F6'*VDJ$BG9D^%I27#D X .0     <'Y3S]6(
M                                             *X&C DT@4F@@@BH
MD(@H[$M.9F8R9>8&5#*L&,EY#[2LQ<TF$Q8J^8T3Z3Z>PE8S\A@S(@DVA& D
MMEABQIR         <'Y3S]6(
M                               *QFDX[T@\RTRXQ\Y(S(4+,F=G5'H.
M#Q(=-=YL^,D(]*IEU#$2QIEY"1V!ZB=#(#+"K)G98HF([8GHLD<@
M'!^4\_5B
M               <&L0H.64*WF.GV'0D:$>$_F.F8@^TQ@@4E@K,3D3(5N(;
M/H+D%XRM14TD\S@]IG1CA8$STL*=$=\6L)8.0        #@_*>?JQ
M
M.#1N5D/L/6?.#@K>61/<5O)S.W.H(Q),)2*>$;%MSO#J2J)$QG9V@,C+='PD
M7EK"VYC)D)F);XF4Y         !P?E//U8@
M                                         '!6LI04H,>,G.E/B(7/
MA)U/40*6 (-*BEPS/#%R/BR9Y@&'E+S)SN"K!LX,O.Y-KQV9B9().)*AR
M       <'Y3S]6(
M                      . 160>6O/G-*164PXBPGP@8E\URD3G>E]S%BLY
MM&.#P!Z"@)<0CDKL;!CS+.E\#I#)SK"RY)P          .#\IY^K$
M
M ' .3@UP&KHY(I(D+9F'&M8Z4QHSTS4N<2N?66:*]D:E'B0R*RVQ*A)A=HE@
M]1]1\9>8[@          '!^4\_5B
M                                      <& &D<A,^$I47C!BA2LK<9
M<;!270#/#"SXRMAU1.)VI@9;$NX?26A(@+,DJ@          '!^4\_5B
M
M       1$: #Y" 3O"Q9CAX&M\F@MX9L8(>9W1T8 .#@[0N$2J98?23H61.0
M          #@_*>?JQ
M                     !P<')R     "*3\_1X$<$-EK ?(4C+LG=F>D7'U
MF1ECR9"IIC!C1:$G$N83$>)U!W)R           #@_*>?JQ
M                                            !P0\:X#;L?":73P-
MT!3@H"96;MCDT?&\$&O IV3:;5#LP  ".S0 8\#YR)C%#TDX&2'D=N69*MF1
M'Z%CNS@K"5?,\,M+$DFG(            !P?E//U8@
M                                       \35P:VC]+AKM/@/L/A*OF
MUXD\R<Y/SK&_HI(4J-MY6HJP;;C5Z6*+ZG(!P5Q-(9TQ*98LIZ=,7&,Z)M+C
MF6$8'V$AG)P4_(N,D+5D6%E3D         X,+,:   /S2'ZM#D
M                                               '!^>8_00:FRX)
M]920QDC P(_1F>P_-\>XW8FJLV_DN'YP3:.9 :93]+)W8 /$I$4K-E98<CDQ
MHFL '( !P42,/,E,V,4+4DB@        'B:LC7N   3V;VSD
M                                              _/*?H(-7!/)]Y6
M8N.6?/SR'Z 3OC\NYV9^B(TZ&W\^TT:ED#U%"C]+YDX .  <@     X*#'3'
MN._,U)*)O         !P<@  ' .0
M                         <&@4WTD4FA<]AO6-=Q#9T)^@4\S\^QN9-*I
M*A'IT)NG*(%6RJ!^G<DL          BXI>#[C.BZ9[@
M                                                       <  ^<
M'T ^0^L')P <'( /B/M!R          <$0G!BI+1EYR
M
M                  < '(
M
M
M
M                          /_Q  ]$  !! (! @,%!@4#! ,  P $ @,%
M!@$' !$2"!,4$!4A-V 6("(P-E 7&"- <#$T-20R,S@E)D%"D+#_V@ ( 0$
M 04"_P#\*TF1"$X/)@E9_P ?9Y-67TKJ#YEW+K\HM*1^JW(Q3;%?D5EM?O\
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M'1YM;2I!??$$DDME/R#2N5&QM-LUJ:(FD&1[8392>Q]'XFS4]"*"8M3?TAL
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M:N)R[C)/3E@/6Q#1DS+%$5JV2CW)3+DD=9%X#K:R5()8?5B.M@RF)_72_03
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MU=53HMC;\^I7*Z\#$&1VVIT8RJ>^;CB7J$T1G,'M,)IZI[!E^.!4[7;5EO\
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M$NE.L/HY"VPZ(<:OT.\P:4\:9*3(<.(V/*;+DP01HT6X2?NNO14J\ 3[_3;
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M"388@UUY"M412@ZBRGIQIQG(ZU9:7'/9(!^AY^PP]8C*OL>F7,G[ECO=1J2
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MD8[*'QLIPK$8[F$F:;8C#18[*77+!"+C<R&.N$X0EUCR^A3R$MTP,4.#??\
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M=C-%,?JM_%8"V%:H\V #C\#8E6V$04.QA#4VDV8<Q7!6;+Z<QA2C36N,RSG
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M!YH"$;)KD:EE4[<H&'%%4W2$"G;FF$TK$":3NY7RE-I]D)V8&RH.<6EKM"B
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M*O3$6">XY0#P5$D.50 L$W1&5RJEARY1!XK"W6L]T*>R54^5W?S5)S@_5 "
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M!QY:<T"DI.60/+S72JI2&RZS'1UAR]7I,SVC[IX<ET(:Z<8Z3U?8R^N^%TL
M_*@G@:?V-6SK8+#Q_P!)G^D)T92#>?K6W\-^3]L4\12&3,X.!\=?O"PE48C#
M4:FI-,$GQ%_KE R$>WI:%CC_ /$-4?\ UM>?:3  T=X&]F'HTW%S*; XZF!/
MO73'LXS#1W?ZELO]0PW_ &QOJU11IU*C_98TNGP6)VUM+;.+.&P!<QK7$ #C
MJL1LSI#A&?""YPRW=#@[[UT;Z0U,56^!8J34((8X\QZ\S"VACZ>S\'6Q%7Y
MMXG1?E#:VV:^2D7/IDG+EME]R^#](-E4^LA[@9[^?BNC]5U;:^&?49E=G?/B
MAI;1=*MH##[/-!OMXJ0!R#/5O-;!V.,5L7$NJ 9ZX[.DRTR/>8\I71C$OPFT
MGX)[H;5);'\,PC]FJZ<!SO@('_U#[E@L3MG'X:G@,"US64[9AI$R;^96*P^W
M-D%U5Y>&V,SFG[5T=VT<?2-.H9K4P,W]O^8^O4J9\?Q^-Z^U<1YKIBX,QS7D
M26Y8]P5#I3CZ&&I4Z>%<X 0#'#_*JO27;%1A%/#O&8<M/.%L?8F+VCB_AF.!
M !FZKM#,)48T0UM(@>35T9_X[_BK?8Y!5G!E*HXZ9'?Z2MA0_I"TCY3ZA'E*
MVETC?@<4_#=3F MFNF],/SS:(PI[6KNTMNU65]@UJD1F8QU^9@KH2?USE A<
MM]7^KJ?]NI_I71W_ .8*?\5;['+EN]%=,,'4Q+*%6DTGJLTQWK872*A@L&S!
MXQF0TI$^+B;CC[_L56ILG;U 4BYKQR-B/?\ ^>Y8/ X?9N&?3H-[,2;\I3_]
MZ;:R5-:E0 3\D-/+P5%C:=.G3IC*UC0+ <ETOI!V +@T=9^]:?>NAK7C NSZ
MR.7]I;3Q;<'@JM9UH:0/$V717#'&;2J8NJ1%)SG7/[QMKWK;.%I8K 5Z)ATM
MS>U^Y?GW+HKC/@V/=1(R"L2UMYNW3\/-.NWR/V*G2;5V\VDX]DU;CF)38:UK
M&B T:0%TQPM.KA16MUC)OQ70ZJ3LXTW&]$_ZY_ (:7^-$IU.4VGE19*=366-
M4XP%7>Z49XIE+.4S#EJ:W*+I[[B%5>Y,)BZS)W#S3S:$WVCWIH6(]@^2']4Q
M,;)0$?.M3V2H[13-5_SD\Z^N:K0:7KFJ#>P@84BR<V0G4I<++J[!: *H^%4?
M)]Z%UU;G:)M!Z;3=%UU<E-H(,#0LT:(25E*R%!G/=.[I3'Y"QT_NT_\ ^5BV
M-M:OLKK/@M(U>MC- G3R3NE>U'6IX8B?[/\ _E51MC;=>CUS'BGVI'#W66Q-
MDLV5AFL%WU+O]>N*Z6?\3'C3^Y;._4L-_P!IG^D+V@/7%=,LKL3AV\0//VBJ
M&T?R;L2A7-(O@1%^)/U+_;671\#/_N6Q-LG:XK.ZHTLD"+\0[GX+&?\ S!4_
M[W_Y)OLCP^)TS_7,+Y?ZELO]0PW_ &QNF+\EM"@[$X/$463F+3$<_:C[ELO'
MOV-CG==A[2X.FQUYPJ&WMF8UKA4J"GF$%KK@\Q]WJV#V+L]E9F,P@&=I)D&<
MT^:Z;UNQA,/,,JY^LORB)\_M713!TL/LNE5 &>M)GC <1'U*ME?3<QX!!:X1
M',+8K?\ ?U*#8U*GE$J;-'<9]RZ1XHX_:G44X?3HN:UMQ']OQO*P-"CAL'1H
MMRB& $3QU/O,K;]+\F[7^%4+ N:YL<C[5N0N/)8/$#%X:EB6>Q58/>+'_P!T
MA=.0YWP!K#!.>_<NC-"E0V5A2V.LJ!Q<Z+R'$+%8>EB*55E3MYVG4:6U\EL.
ML["[=I4*8[+GO#N\&0$'9@/C\%TMC\H4NU$D3:> 6RJ.'=@:'YJF3D%S3;?Z
ME\'HC_E4[_V&_@@ ! $!8H$T*G(4W_Z2NBN9VVFNCY6(D^ <A-P?(KI#CV8'
M9[Y/;>(%[WU,>OM71*CU^+?B@W^KS97&?ER#]JK8#!UGYZM%KW'4F4-FX!K@
M1AV \-5TCIM_)&(:+-&6WFNA.N,;-AE^W?X*N3U-61EBF_\ TE='"UVWQE?<
M/J\/%<!X;HGC"QFT=G8=WP;$U!F=\DB5B.CVR\:SK640WK ":C23;7V5M?8M
M?8[!6PKW!NLR;7_=E='=HNVCL^HRH<SZ0 +N>8'[(3'C!=(!4J6#:EQQ@ICI
M:R(RD3*Z7@'9Y@QKX\/-=# &X"H&W,MU_P 2Z88TY*> #NU4G../,>^RPFQ-
MINHBI08YK7C@Z)O"&P]MAI;EJ0>;Y^]5<)C]E8K#OJ#JW%\L,@VGM>\+#5QB
M<*W$,@MJ,MX@0[ZUAQ_\0ASGAA%6TZ:H.&4%VL:+I;58,&UN:'5)@<HA=#6?
MT2L2T]MS>UP.6?L^]3<_;^C="<8LJT2A3%0#NU5.DT7A71[TX!/;Q*:^9"D+
M4A5W 0&H4^P'1=4WG15LWRM#P3#( X#^:IF)68'YUB4^F ;*(^M-O71#273H
MJND<%1= C102;(&$'.RSZXKK'%YOHFO)U3KJHPE/IENO>LP%E2J/;_X5)Q.J
MN4&( IS)75=R8V/C])O^#8L<"UD_YVKH4QE0XD%C:F7+&8 QX2%\%H SU-/_
M "-_!-8Q@AC6M'< N,Q)]>O-=*I_*_:%II_Z0MG&<%A_^TS_ $A%S:;7./LM
M!)DQ]:VMB/RQM@TJ33F#VAL7@"Q[M J&$9\!HX6LUKV-8UI'> %^3<#PH4P6
M]RH8>AA<PHTPS,)='&%C&QTCJ39O7>/RDUS8;!X#[$'"W,HV4QYKID/Z9A>U
MY?XRME?J.'_[8MN-@3R6*Q=#!4.OK.R,&IB4*6Q=N-=48UN()LYS9:6:Z]YC
M58SH<P4WOPCRQPNT3_-='=HXO![19@:E0O8]Q8Z?</#7U*Z<,']"=E+F?G,Q
M\(C335=&7A^R<. 1-(.#V6EO:)'O!]_@G5&EE3N:[7P*V&X?EV@V<SC5JSW7
M*VCB1@<)6Q+B&@,CS(@>[58'9N-VK6K5,."33>3FG]\V7Y V]82^VG;_ )K'
M[#VIAJ#L1B&N>RGK)G4QWKHEC15P9P0-Z$&.)S22/+@NG&6=GDMNWK.*Z.=G
M8N$AV8P_D8EYMKWJO5ITJ=1S[M:QSB>4-*V(XXGI#2K4Q#.LJ=^DJ9^/P72U
MCORA1(I&H)&DVL/%;+(& P_9R]@6]?>A,F=V-=&'JB\NIN CP6SJV)V7C3B&
MTG6=4X'1V8)_2K:#P13H.S'1V73WBZIX';&VJH=BLXI3J=(\.2V;L[#[/PXI
MTF@.^6Z/:/X#UJC<2M5TD)_)6(&0GV=)Y]RV1M2OLEU4T\,]W71-G?)\D[IC
MBQ_Z1WN/X*ETMQE2K39\%(:XP3'\DTY@".2K'-AJG$EC[<^R5T=:ZCMSM4'7
M?5O?O0TW6XKI+L5V( Q6&!?5:)(GEI]BV?TDQ>SA\'K4'U"VV5P-O K:VV,=
MMHLH8:@YHF[?YE='=G?D_#$5&Q4K &H.4:?:NDVQ:SJXQ^&:29)<!S&BP72S
M'X.FZAB<,Y_5P&F\_8MI8G:VTZ;L6:;O@_\ T^[EI*Z)=G!5GN8:=@8,W+0Y
M5>LVKMUQ?2?#J@RV,#*8\%18RG28UGLAN7W"$.X+I;@G5Z%.NP&:,P!?7P71
M/$.JX:K@WAS.HTD&^;77\%BL/B*NTJ@P[']:U\A]^!5+I-CL%EH8K#NJ/IB,
MQG[E7=M'I!CV.+'MHSIR6SL&S X2E0: "T=H_P!HK01^CJ.1NJS3*H]D7XIK
M@B86JRF951P(A"F9)64A9H64O,H'LY4\=6Z55>'!D=\JF+*86<JG5C5 S\Z/
M*+DT_G_7>G.]I,&?7^:9+7N"&B(D3R0J6A,:<STU-4!/I->-$^@&E6M$2J1L
MJ?'R_2=)B!L?%RTNLVPX]L<O6JZ#,OC'%KJ7L6(/WJ>T1N)A=+@]VT2]E-SL
MN30']T+#=*L5AJ%.DW".=E:&Z&T"!J%B-J;<VFPT:=-^6I\D#+$]\!='^C_P
M%HQ6*O7%PTQ+2>_CKY%-G*9U662#Z*?:PN8*VN<11VU6J]2YXZR6D#O\$WI?
MB6/#/@CC Y'EX(=,\620<"X7M8_@MC;2J;0H]95I&F9(@CD 9T[UQ[ETR<XX
MS"BC0+]+B;=H]WH+9;2,#AYL[JQ(Y>COVAA:>+PE7#N;FS-M?CK;^2PM3:/1
MW&%C:+NJ<3;4.'CP]0L1TNQ55KZ;,,:)(C,,SC_)='-EXFICORCB6%M-IF_R
MB=/"%M;9C=H8&K1MUD32<>!%X\U@\;M78-9P=2>YCG0]MX.68MZA5NE&/VA3
M#,-A74\P<UQ@W]X]<5T=H/I;8P[J])S7YGF8/&?)=,<14-&C@F!SQ4)+\H//
MLZ7]:+HK@O@N SD0^M=P.O9D#[_%7YK$T65L/5I5;L>P@VGA;Z[K9!J;*VR&
M]74ZIM1PJ&':.) GPE=-:?6? "UKGYNLT!M/-;,QFU=B-H#JWU<._-V3H MH
M=)L=C\^%I84L:^Q(XKHIL9^%'PG$-BH^2P'Y,S)]:KY3I_0/H4:CBY]-KG'B
MX _:@   + :#XAPF&.M&G_D;^"&$PPTHT[?V&_@@UK?9 $<ANX1P4:=R<UKV
MECP'-.H(D%?!,-$=33M_8;^"^"8;_H4O\C?P7P3#?]&G_D;^"CB@ +>/UIE"
MC3=G938UW[P:)OWQ\3*)E/P.%J',^A3)YQ'V)F$PU/V*+&]X%_>N$<% ((-P
M=04[9^#<<QH,D]R^#T SJQ29D_=@0F4:5,96,:T<@  FT*+'9V4F-<?E!HGW
M[W-:[V@'=Q$JG1I4G.=38UA=J6@"?<AAZ+7%PI,#C><HGWJI@L+5,OHL)\%2
MPU"B"*5-K)U@??JHG]&=%45.[ARXK',:T M&J%5W/1,K5.:-5YBZZZH#<V76
MRWLE4V9SV[K)$PBTIS&ID"RRWD6YK$7%U2;F]K@@(7BNQ&B.7,(3/9^<GORH
MU'<T7N*XA"&UYX*H[M@-T.J #&]E/!F1YIE01WK.\EP!LLI5*TYEDXA"5'>H
M55LA%N63Q*9:G/%4W6',Z_I'-:]I8]H<TZAP!!]Z;2ILG(QK,VN4 3[OB/HT
MJAS/IL<3Q+04<)AC_P BG_D;^";2ILLUC&^#0% *))UW=Z=AJ#W%[J3'..I+
M6G[D,)A@[-U%*?X&_@CA<.?^12_R-_!-:UEFM#1W #<^E2J1GIL=&F9H*#0W
M01OCZE5H4J_]:QK_ ! GWIFSL%3G+AV7[I^U-8UH#6@!HT T6ODJF%P]:.LI
M-=',)F%P]. RBQL:0T(4*+7BHVFP/&CLHFZ=0I/.9]-KCS<)^U!C1H /"P4(
M@$0=$:%$R32IR=3D;/OA/HTJ@ ?3:X#3, 8\)3L-0>SJW4F%HF!E%IY<O)4]
MGX.D064& C3C]J@7[[?/-0P$XRJ;@V256=U@A.IY>"F$RHJLJE4@P>*:X!J#
MQ[T;IS5E[D3E51V9V5,9E [U*F4!*;2*:($?.50F5&E]?JW.,"549V.L5&7&
M3S]>O!.T30W*Z=4RF)60#1!H52GI"%0-"=6Y+KCZ\TZN1Z\4ZNXJD#5JM;S6
M(I]7E:.2:8LF&1]*7B0GB-T(M:=4</3.@7P< V"-,G5"AV@8T0 B"LKE!"[9
M3ZH9JG5NLT3:;LTE:@#DG;J;1\Z5&<81+N/D@58]ZJ>QEX<DR:9,V:@[K;-,
M#]Y9?DZ]_--;"R@Z("$3'@JSFWYIA)GZD7PG5%))6&EKL_$:)[A4&9WM!?*5
M-WKW_2I[$[=$H61<"I"#@$.:-460=*J2(A.:7:IE"#*#0 LD+(4*<^OYIK8^
M=")51B=(0$IRK-<2#\GY2#^K]CV.(3:C7"0@91G@H<H,054H.<3R75Q-D:1<
MFX7FA1:#=90-%/! *D/I4[1.W4V:IS2LJ%.4:4)Q@)US;S3%(1#4,H3 "?7!
M91R64?/%2GR"#2)659 9D)U(-,M%T&O#B>:ISQ40NM:%FG7R1=[D0PIH8$XB
M$0$(\-S1*: !]*W4I0I("$1*ZNZ;3C@J@"J-31$H"=Q15(>O?\]0$6K(G"$8
M60% 1W)SK0BTS*:>:B46(@H HMW#54A], KPGHM!U759C9"DP"X1#0LK4VFU
M1'QR86<(&?G1XD)UBFN68%$RB2F@\/-4F-.J--G).IH4PH')5*0ME";1C4(-
M#=/I@-Q,[A#=4^HB937)I^.XI]XX*_/ZDTD<4-/FLO:$'3^@=2G1-I1,K(U=
M5R1HIE++*:F]Z</IJ-5P1U0 58Z191WHB$$T_'<X(N"E6LFZ?-3CN:XA S\>
M850J2J;R%8J_%!2G_38:%/1,!.=*D+7<PZJ5(4A%RS)SDYQ)0:5"'%,>LP4C
MYG.B<>:F%-TTP$T_&)1,[N 3'HC10FI_TUXCS3"83A*J'=*S'A924TJ5F*#B
MC?50$\\DT(S:%*=;1- 6;DLQ3'<_F9[DY %VJN-$'.'M%,?WK-S4CXCNY:;K
M(&$UY*&J"=]_TV8GNRCQ3W2IL4773 H3K('<W<2JG!-L-V8*9^($W3YB+H76
M>O01<N!4W0$;G-Y)I@HWA!%RSE!Q*-D72INID;F%-&YQGZ; PJKBZ.Y$!.*
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M<P\$ 252IZRM$#*)A/,H-DIC859 94VZ 4'?Q"-@JKB[3@@80J>O00KKKLR
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MV#G.D(: \_CF^J=OG<&PI.X7U4! !.30$X<D=0FZ+7<YLPLBS :*2XH,'!
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M8]S65&N#.4+9V"&#I1Q?!.[^SQ(LMH;/KX>O\*HS,S94]N5FLRNHEU2(!O\
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MLST'B""#KMO5@I"$IUF:N&CE2J 0J>5/96SH!--.!TE+@ ^S3F'A?:2-*M;
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M:POKGZSS9!\@170]M1PQ;P]I3BY[_6*KIA<J<N6K%*OU,EWOG44C24\3]U=
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MKF+]*+F\7VVK7)U8.H&=&M.-H6A*4C4S3CZ;1DMGVJ3>Y5R35OB 4 )JZ6S
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M84=5$TXM3SZ.SXZ<A13<7V,HM6D$-LSF5N!*>7X>^GQ<X4ZI%PSUMNGV' (
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M]T'^=85TG.7+=(ZIPZ9N!CF(^/P-6U[97:A*AF\:RH"4AM:9/LZBG4,EH^L
M=&^DS5Y:+2.M2O56W^584\6GVYWG6DDJ"3L(]]9OW8>7U+*SW&L7NE+?43J
M3%"Z(52L:] 95<+V2G0<SJ!\:P%"\=6O$\022X#ZFW5(!$QX;:U<N]4I2<@
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MV&G(5A_2@8I:=E/4NMREYKCIH#PWB:?OEZ@& -JLKIQ"TJ"SO6%7)N+<29(
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M/\V:\S:SD^='A]#S#3X =0%@<#3S3;=L\E"$I3U:]  /JFNB@R])$ ;9WO\
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M*3V2TC2/X!74.+<@#C71:S4@%2QM0_:F)O!FT=.QRF*?>)>6)[.>?C24"[1
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M;Y\6%\1UL0V=)TU,Q]_<*Q6_1AED]=.$0@".\GA[Z.)8WT@>+=N5J2DJC+I
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MD($<)S>&]=*+Q6)8R+=B%M,*2D:B-8S?&36&L-VEC;6X4@9$:IS#<ZGCQ/\
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M8:S72H).!W",HB$ #: #%= $E*KY1XY.,\:TTK-J.^N<>0JX_4.C_P#I+_\
M::Z+RGI*CLSVWN/<JAM]&^DP:O<3PIA1M+M\)4N 4J22#3_13!\1;"VT9<VH
M<&;6==O=6-]'+G V_3;)U1:0>!(RZ\JZ*XNYBF&J0[J64Y5.<\T[CR_,4'?0
M.E"77M$I=[0^UFT\J2ZE38)V(!TUF=M173501A93OFVY\.%= TQA[FG%,F>\
MQ73N^(;;LD+U<]M'NBK'HYC+S"'[7,A"Q.ABO]'^D/5]6I3A'(J_G3UI?8'>
M6[[PRK4OL*[OK>\59W2+NQ9N4)[#K1)@SJ!!^(-6A'^E $AL)>X\=:$'+IK
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M(@:"H_:KJ$K;6A0D*$16)]'G,ZEMI[.]-86Z"83JFEVA/9=VI.'6SJ<JDAQ
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M.K:.AT53H"CF.L_.L(9]'MW[UT9LGL)]].W]S=PXO-"BH(1X&*27K=LN+=R
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M;C*>^KBWA$BL&D 33:P6Q659)3P4#5];P^XFL-=]%4DDP)H9;NT"T:Z4;3K
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MS H@'RKHW_MWN_\ E72K_:VO[JO_ (T-CYUT4,,O<M/F:N<=M+>XN&UMI5!
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M[415Q:=8P1&L4ZV6EE!X?2)!D&K:[5F".>E-$H?2$>R(/Y\ZL<UTFT?^LV'
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M_)^!7'_<X'T&D_1 _P#*PBA_NBJ3_P"5YTVH?[D:&N__ )8G3:A_N!H:[_\
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MS9D];;V=7K!3N =\!5&IW(55ZEF-@/K(Q>6QJZCMSMT'S47P4'Z[_P!G]O\
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MYQRVLGT^SZV*^=B0LM190=KL%N6]XU:2.A7Y(PVH:\PHU[/AQ)/_ ),4E!4
MZ310<)_;@F5/1S ]&4_6NW+%5DF8-HJ:%G #'8</UEN;=A@5>/Z+6&PQ-!%5
MQ3548629$:Y16-K_  L>5\#M ??X7^KXXVL?O[SBOC)O RTR_D'@("/=?]&(
MVL98)1PY8QOQ([]/[8OL?5B&IB[44RAU]S>'0CD1T-^EL:42^-3Q[8:69TBB
M'-W(11\6V_7W XTTL,U8S>J5!CC;\@V+O\(\--'D[M$%O_4E;MX'J3XA;8%-
M71M03W O)?0/RP^F2(>+!N?+GA'4AD-B&!N"/ \CA0H ?PQ4T]^S)%Q0/I*;
M$_$,/J_L@\% BR,G9:=_Q8;J%06+V^=J ]^-0J@!\W@QZ;_R+_YQQ_5EO 0P
M_P#S)? XPAJU^DO"D/YR'3_F'&V7JK\MZ@E1X_B1?W;8:>>;5(?G#U1O90+[
M+[K8TR(#W,G]'W\<"S:;]+V^S&J1KGZ\*%"QQQ)VF.VXW+$].7N&^.%!?S6G
M;3!?WV>HT^)_%]=-\0J.V_!C-AWZ%W/=?I?%^&ONU;_'#1GT4C+I[5B#X VY
MXW[_ +_'[,199E&E\WKR(X^=XDD.FX ]M^2DV5$!E8CLXS:FKE1JI:- 94&K
M_P!XDU:'/;L2=^^PYV&+>.)6G.F.-&D=OFJ@+,>70;^Z^*J/+ZO\%Y)32<-Y
M[M>1B+Z>'&5,\A2QTM(D"AK6U:L4%+25E;59K75"QAG:&* !GCA3]KB/4HDE
M<;\9AV6[6,IH(W=A1TD%/J<W=^'&%NQWN;WON<+\,15,+:98&62,\NTN]O<1
M<'P-NN(9?X2)'_E*&_7_ !@DGF<)%&I9V/0#!\P1((0>RTBAY''>0=EOS'7$
M354W$X ["Z0J[\VL.9/ZL;"Q',8;QP0%)7IB[#?J<9=26LJI)4D]Y+</[-&P
MPTW:XA32D :PDW#!Z@<BJ&S(C>WO;%$^7WX6GMAMY!/SEXOTRQ)-][$8K:RF
M4<>"(-'J74M^(J[CKZV&\]\U04\RSMI!20LB.J]GD!Z3"4R9;.U2D8C4"12C
M:$MKL!J"66Y[@#B2K:T,DP16$'9U*O974PW:RFUSO:U[XCK:,++6O&U.(WW0
M\:VFXZLKV8>/6UQA\\ES9_/&42KE8<ZVB];AZAZ)7T>K%IWY$W./-JOT.807
M6:,C1Q=.Q;1S1U(]*G/J-L9JWS)A#_T2A?K]WAB/CBZ@]A[:M/=J&*64U?G
MJ0)QV%58M0%XU"@<B.N.)<<L268"-$9Y7/)4526O[AOAE5Y*;**=E-NJKS0Z
M>3U$J@, ;B,'EOB-:6EC,J(OIG423$@=7:YO[L%2ML.E921EV]6=$5:B-NCI
M(+&X\3:U\9CY*UDC3+1ZWI)&._"%BI%_9D1T:W??&^*K,'4A&M#!<>L 27=3
M\TG;X?V/G=3I=[1(?%^?^;?%IN[KW[_[?CAN%RQKK:B. 'U59KR26Z(@[;G?
MV5/N.&$<-1(M[!B]+$&]PGGB=?ST!VWQI>5J4\O3KZ(?_I$>JG%^0'%OW ]
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M'S!V?MMB7,.%>.CI6(<])9CI# \[A%DY=_,8S7-:L RZ=";DZ'J9GFG4[VW
MB)7>Q .U\5KQL!(\?F\/]\G[-Q^2FIOA@_;[^>*2FI](DGETL95U0E-)+<<?
MP=A;;M D%6!&)_)W-HVBDI)H7I'YA>&"HA,G)XG1]=/+_!KH>\@OAD&]CMTV
M.]_CSQ70OV0]&K'_ )N3;ZM9OBDS%&?SZK?AR@R$QF&! -84W*MNJJ%[)[1.
M]SA5&YO\/T<N[QQ^#HH \L47&:Y52 #8/=K==@-KXJ<MFD2*:G/$,,KKZ,DD
M2HNY&E7WVN+. + 8>S1,>MM_T=<.4Y=/]F 1T887QQ\,4]9IOYO,DMKZ;A3N
M+]+CKC4M0*9'MICAC3;\Z16+>^X!Z 8'G1%;!?M]E4F5?H%5521SL1=N\82H
MIW#QR"X/4=X8>RPZ@\OXK.KWTI3P</W%=1M^=? //WX]55]P&(VZ!L*]7)>5
MAZ&F3>:8^"]$W';.V"M%%#1Q>SJ'%<CZ5]K^X8+>=1M??>!2/=UQ;,:$2?VV
MG.EO>5;;ZL2Y%!3SJU71UD8G8KH#^;R60J!?<7^K$\>]H:ME&UN:*Q_3BLID
M%Y0G&A_OL/;  [WW3\["4T]F>DO1S(UF!0 :;@\[KV6/*]QTP8*(VBJH?.Q#
MTI]3LI1?HDJ6'=?!M]]QAXY)/3451%1,.X++JA4_\SI.+LX]:.*_]\))/\A&
M&(6"V\[=JM]K=F1KQ)^:@"#P48&$S&-;09BMW[EG39QMU8:7^. PYC[_ .K&
M:I(=34=.]..\PUOH(O@G%*^Y,%^235$A3Q5 (@1[]-QC,X&!6-*V41Z^>EG[
M+>ZVXQ2QT,O#I8IH7F7HZQN"WQ;>^%([*L@.W74/Z.6,]HENW!J'7<CUDJ9E
M;ZAI^L8NPVQDT*N#70RS-8>R'5!$C_ERZ2B]"K'"':_#75[].]_&^''CBXQN
MUCA9D;=""XZ/'[0/?M\<)(.3JK#XB_\ 8ZYV WOT '4X&@^@AO%%]+?M/^<>
M7A;!&VR8!S&C261?4G0F.=?#BI:Z_1>Z^'/"2^9-4F/EYS432)^=$'6%QTL\
M;#PP.*(Z>!!H@AC58U%MR%50 J+\ZWA9F*C$.8YB66E]:FI);KQ0;%7F7V8?
M[5ZT@'I-B4&I]&NF5=+C8\/6%TDC<:;\5-^R1=;;XI:N%];E.'):V[Q'AO\
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MRBIJI+FNKZ>:4=5;7Q>'[AITX(<+X;>%K8D*^KO;"'PQ;%10DW2PFB'1=[2
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MVI?#+>SOV%_61C,G"G4]> &^<%@C_0U\7]48SN2UR*/3;\N2-3^G!$:%WD<
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M2*5=#H8,+$,.8(/(WOA)6B6=5=2\3"X=+V9#U[0N+@AEOJ&XQ'FV0_[XT%5
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MVDA4:>_SB(_JQ2SD#UB?MVQ.T,5V,952@ZL+=,9GF,J6DJJC@(3M>*"][?\
M.%A\,4M)<<!(#4JI7]\8E6WZ[(/ =V^!6S*C21DR1AOX72>&1^2^EOA@YYF
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MJOVX2HHJF"K@?U9J>5)HS^?&66_A>^&DD;2B*7=CR55%V)MW#']=5#_(JO\
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MU.W$IZS*VJJ=_G0STO%C;\Y&!Q19!5U,])!4PU<C34XC,J^;4TDZA1*KINR
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M3H4A$Q!'_6HQ_P#>CA9*J.3,9+B15JFU+J'(\&(1K:_20R>/BH<Z44!54;
M<A86V'=C2?5(V/W_ */JQ5Y@X*K5LL<-_:CAOV_<79@-A<#4-F^7RF]^2_\
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MV'34TD03^5K ('SA<>_!JJIEGKG%KJ/1P+\V.X!)/M/87L+6Z_LO*7WY+_\
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ML"GZPF+   =!M^P:.:-)8VV:.10Z-UW5@0=QUQ_P9E__ %.G_P#IX_X,R_\
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M551LJJ-@!L!R_8<*KIH*F/YD\22K]3@VP9(,DRR-SOJ6B@O?G\S; 55"A18
M"P [A;D/D"YAE])6 <O.((Y2/BZD_;C_ 'ORVBH_&GIXHV_E*H/VX\X2BI4G
MU,_&6GB674U]3<0+JU-<W-[FYO@25%'2SR!0@>:"*5PHN0H9U)"@LQMRNQ[S
MA8XT6-$4*B( J*JBRJJK8*H&P V ^4S/04;RL=1E:FA:0M\XN4U$^-[X7SFE
MIZC1JT<>&.71KMJTZU.G58:K<["_+ I9J2FEIE&E8'AC:)1:UEC*Z5 '*P%L
M<:ER;+8);WXB4D(:_??1S_LUE]/>R3U+LX^=PE73_P!\X&-[;?<8ERYS:_:A
MDZQR@'2WY/1QW>X8>&LA:*S$*Y'HG%]BDFP[7,+?5:V+E?LVQQ%6R-O[FZX+
M>X8BFKH4D:8Z%,FXBF?U)0.1-]N79U;8U1'3^CX=PQ>VXZXT2@CQZ8W./7QQ
MZEQ%2P^D>20V6PZ_ZAOW8AIJ65XHEJ%4(PL)7YB><?,559HDYC9B-\4=,W\#
MJ;OUMN]^\DF]^OOP4_>P<"W(8W.%@IU8KJ DF]B)>I)Z]=@;XB@3U8D5!\!;
M^R51(Y_&U$FY]E=5@ON%ML+JE_1@I3\E&_CBW<<:HRPEI&UZH]G$+;2,I&ZF
M(Z)M7LK&]NTPQ%/769\HI5,Z7N%J57S6#V-XI%2HJ=)NP:52#?DX]WVB^"Q(
MXEOOMCC52S4\]_234C*CRJ.CAU=-7(<33JMLQ86L*'+(>#"#J<DZI99#ZTDL
MA]=C_) L%"@#!'ACSRE/!S*GL\+H='%T;JK-8V=?WE^0)TMV3V3E6:.T&;P7
M30XT><K'L6 :VF46]*G0]I 5[6!#ET GD@D3CO-VXW/M0JJD-V+V=EMVMEN!
M<_M>GRQ+C9'BG+7[]YH_JT^Z^ =&5*3S_:T[?_\ 5MA9)J]5BZQP4\"K;WNL
MCC^4#B,:YZJ6IKH$U2,\A02&U[EMDC':LNP )Z8I*: !!2P1P@<]D4#Z_'K@
MXJLM.ST4QD'C%4%G^Q]:_#^-*U$*EI:"3CZ1S,36$UO$  _ X!&  <7QPYXH
MYDMZLJ!U^WE[QOAECA:EON. UE#=6T$D,<.V56S&$;Z+JE4/S-@WP[O'!B.5
MU_$U:2OFDYL??H*_&_NQ#4YIJRR%&#B.]ZN6VX 0?BP>]M^ZUL $/H50MWYV
M46%^\]^.U-&/#'8='^(./57ZL25M:\<,$8YGFS=(XU]:1VZ*MV//D#C5-(M#
MD].X*1,=32,-KM&E^/-\R.QBC)[>*;S6)Z3*,O:X+?C9V-M<DS#UJB8A04W$
M,6V.TVRBR^X#88UGF3>QQ;[_  P0Q*TD!],R^TW2(>\>MW8$4$:1(HM9 %_1
MS/B=_P"R<DEOVO4N98GZ*3NZ>&ECM<[COQLU_C?Y-:@E6.X[O' !&KB;:>8(
M(W%NOCX7Q5RR.D=/(9DDC?G44T,DFC0Q_?*?5>.Y])&Q!NS!E2LH)TG@:ZZD
M-^1/K6Y%#=64[BUL>M@[CZ\$D_;C5I;3BP&A>_K\/Z<05H9J?-S(.%+%V2RQ
MBYDE*V96C_>YH^WJL+,/5"EC)I6VICJ9OILW-F;F2=[]V$ 4$FP MUPD:7VZ
M^/7'(]V_WZ^X^[ SFL30.T*.)A8DN-+5&_)0+B+O4L=P58ECOMA_CB)%]2M2
M6&0=^E#*K?FZ&M^5_&FQW'7W8CJJ;L4]:S>B]F.86)MW!KW Y<[8'R$G!"W"
M=^+J[ X[4NW@-S\<67M3??G_ $<L'B-\.F-048O&60CE;E\<9?1Y1ES5-96Z
M]5087F2$(=(540-JE/,AAI"[[8AK?**L2E06,5.Z:; ]4@C[,;$<G:[>[J.(
M6J-/L[1QG;?4!N^_7"P4P2*->@ "(._QQZW'(Z#U1[M_T\L7((Q>G7ATVK2U
M3(++M\SY[?YN%IXNF[OU=^K'^RC0SQI+$WK(XN/]1[B-QTP*RCU&B)M+$26-
M.3UN;GA'D-[@\SC?NP;=<*>L9M;NMS^SZ\09FL7G%)^+K*>]E8,!&RZMN'Q$
MTM"]QIJ8UN1?!S3)Y3799*W[9IV.D[_O=5$>U35T8LJ3E1%4"PET'1P_.J)_
M":*^B:"3JDL?0COL W,;;G<'ZV_IQ<@?&Y_2;8]9/K&-B/>/O:V/PA0VK*6.
M$(U-"#YQ#HYD)SD0^N=(+#\FUF612C<BK@AA;;<&Q^JX^.!'14514MRU)&QC
M0'VGDMH0;;%B!SWP'KJJ!";>CBC:<_2&HO JL.5UXJ_K67@&JF4W$E6PEM[H
M@J4^W,$Q,R_/QMTQIOAOCB*9?Q= K32-TU.IBC0^_63^;_&IWB75)22K4V'K
M%%NK@?!K^Y3@;C'PQPZ6"6HL=^$MQ\3R'+ @JZ>2FDYZ)5TW]QY'%\$D[\E%
M][^[!+-VFQ?D,;XM;E]N)& W&XV]4\KCNN.[]9P 5/PQ91;QQ:I42A8'D",+
MAF!4;]]M7VXN*;S9OG4[&.Y[R+V. \G&J+>S*_9^(%KX6.)%1$%E518 ?#^R
MSQ2#4DBE&'@P^^_?ACH::CN>'.H+:%[INJN._P!4\^_'K8O&^A_'U3]^_'#E
MC5TD!7HZ.#S4^!ZCZ\/+1S-2NZE6C;4R%3^]ZT82"/IHEX\8]F+GALQR9#,L
M2^E2&9)^-&#<Q24_HI:@ <F6,3)=M'-KPY1F^5OET]1+P(YXY3+#Q^B2JT<<
MD(8]E25;MD(UO6P4B<QQ\NSZS>_J/@<:F>;^4W]..R;^#=J_OO? #C@R="-@
M?CSP7J<LRVN;EQ*JCIY);=VMXRQ'QP(:>"GI(ARB@B2*,>Y4"C[,=KM+U.!8
M_+%14V\U0_#2^P&UR3X*MV/@,"GA[3MVYYCZ\LG>>Y1[*C8=UR?XU$$7!!!!
MZ@]#X8>?*YUA#DL::0'AAO[6W-1[]N5L 551#%'MJX=Y'/Y(Y ]QP*>G7LC=
MF;=W;J6/7]6.'60B2WJOZLB?DN-_U8)6OJECZ+9&M^<1C@TD(DX>SS2^D9VZ
M^M>P[OLPPFIH[F^ED4*Z>(*V/^L#$E'-NM]<+_PD1]7WGH?'"]^#OB1^\@?<
M8'+'W^_ZL5%<1V/Q$1^=O=RIZKZHOW_V:*L RD6*L 5([B.N&FH9O,RVYA*<
M2&_T=P4'/;M#NM;?]LYCZ/JD$/:/_..>S_T;W\.J24;2ZEF5&XTFO7KZC954
MC2?547OX8LX-NA^3SZ7+Z5ZN'>*J,"><*?5OQ=.O8':Y-N8WPEQL,=.6+CZL
M<]\:&(XB;>_Y.U]N 5N%;OY?;@'!PTVF\='3NQ;HLLME3XE=?POW_P <)&38
MFR7\#\FCK@)-=)$WBG3UXS^M>\881-!.@]5]?#:V_LF_QWPTE95PTJ#G;M_;
MRQ&U=6U5;=M16--$1WVN19B-MQ>V.-DE=YN?:@]=1XZ#VE^!M@-5UC3(+>CC
M&@-[SZUO '"Q1($C0655V '[.U1)JF/JP1[R'^CXX_J"71?GJ%_JQ^UI?2#U
MH7[,@^'4>[^RDX5=30E9P/[WZWU(6/PQTMBY&)5'O^K P/=@X2KS/69)%UI3
M \,(IY<0BSEK6-@=OJPOH7@Z-)%)*2!_SCNK?$7\1C525U)+"UBC2\2-R#WA
M$F6X\&W[AA*C,IQ6.ANL"+:G#=YU=J2W0$*/ WVX,]/$\>G2 47LBWL&W8(V
M]6V":-36T_LZ2!.@OLK*3VQW,O=O;&CS-J=3LTE21&%'?I]=O *I)QP(SQ)7
M.N>8\Y)".FPL@]E>F_7^.$Z]0NH?F_ZL6[\>/7Y.&NY/=TP:1'(IZ<V(!L'D
M]J]N=OJP&>0*XC%E[]L+44LA1XVZ$V:W1OJQ8>CK(U'&@//N+IWB_P"S,,5I
MJYQV8QRBO[<A_0.>QPU14.SR2-=F)OS^;]'NP9"_I>["5-.Q62)M0L>8','O
M!\<4]6O[]$KGP:W:'P-_[%%F8*JBY)-@!WDG'#:JXC V;@HTB@CZ0VQHIJI3
M)_!MV'^ :U_A^SL=P0;@]1_1AILKD10QU&GF) !_M;@';P/+OQIF>FI8O:D:
M3B$#Z*)>Y[M10'YPQII,_IQ4%-,D=6RA7?J5:/48[]$8-;J^&T\"I4$CT,ZG
MZM?#O\/MP5&7UEQ_:9+?RM-K>/+QQ'5YII54.N.D!#,S\P96%U"CYH)OU P3
MX>[!.)*5B64#6E^GA_'6;^]/_P!W /TL7&+#UCAH87#UM0+"Q'HE/4\^U@R;
ML;ZF;GN<1V8[#2?A\E+51DBTJJ]CZT;$!@?"V%;YR@_6+_L99R?3N.'3)U:1
MNON7#SS,7DD;4S'G<_J&]ML:JFIA@'?+(J?83CATV8TLK';2DZ$D^Z]S\D27
M[4,DB$=W:N/L/]BI,KIW*4U/M.5-N++U4]2J\K7L>N';6%T@G?%XV*R1M='4
MD$$=Q'W.$H,PD"5H[$;M8+4#IOL.(>[K^S:65@D:"[,QL !XX:CRZ5DHT.EY
M4[)J.^W7AWY;[\\22ZP-/>>9_IP^EB8#+Z6(W*$-UMT(W-_KPKJ;I*H93[Q\
MA4XTXGE^:H3Z^?\ '6HMSX3_ */D)O\ #$DR?CVM'#^6W^K"FHE:[M<L3<[G
M IJ<*U_6?VCCAR;!]P3W_P"OY-7=O]6^('B=>*D:I+$3VT=5L=N>]ML>DFB3
MP9U'V$WQ>-U<=ZD,/LP6J9UU=(E(,A_-&"(Z&5OFZG ]Q../4MV0;1QCU(QX
M#J?'PPN29!&M5F\O8OZW U#V5WNPYG5LN!6>5>:U51*X!-+!(VA;]H@O]FWC
MCBY#4566U\*DPOQW:-G -@YO?M&VXQ4>3GE"_"\H,OO&NOG.L?9\+G:^KV@=
M0VQ)J4RTLUN(H.XML'7X<Q[L!Z:IC:_LE@KC\T_V(9OF@L?<!BIE/-YY&N?%
MCUQ96(!]^"=0/N. RW# W4CF".H[CX[8:BJG!JZ8"Q]J6'H_BP]K]E#E$3Z4
M*\>HM[?\&AZVYFW+E?D/DTJQ Q*QW[1^K'X+JF"LM_-)">9Z1W_1C0_P/R#O
MMOB7OXV_U?QU(/(@C!ZQ2-=#[^GPQ;HQQ1+?M&8L!X #"%KV!WL+XNQD"]Y'
MW^O'X.R:%LTKO5M'=EC/7=>9^P8$^9^3AEH1S,8(D5>^^_>.8QYQ1RZ6&TL$
MNTD3=Q&+T]28W_M<FD_9C7)+)(W5G=B?M.#P:J:.^W9D;#2S2-)(?:=BQ^W'
MOQ55O.14X< ^?/)V8Q\/6/< <3>4N91EZW,F9J=G&KAPDGM GD7._*X738VQ
MNI_U=U_KQIQY)YS2>CGJ:I*6HT[<4!U6[CVNQ)IOW =PL"&]-I&WC;&I2Z'O
M4D?HQ>.KJNS_ &QL1TN:-Q87(3CV[<9/5N\<KX#*;J=P1R(/*W]A9J&EE66L
MF4QMH(*PJ?69CRO;8?'NQ69IF$ZPPT\9?M'\8_1%'4DXFKAF$N19 LSI3".X
MDF5#;L:-)?;VF;3J]7''R'RJJ:B1#J\VK&==?>O::6/EWJ+\@=5L?@7RMHFH
MJP=E*P"T3[BW$&Z@':TJ$J-Q)H.V(:VDDLZ'4I':1U/,&VQ5AW81JLO3S^W&
M$9UOWJPZ'N.^/VI4QR'YE]+_ ,DV/RW)%N_NQ520/KC31"&%['AC2UOS@>7R
M'YS"R=Y)P4J$OKVOU4X5XY>S?4FDV([M^\8>DJVO- NN-S<&5+VW]V#I-B!?
M%S]]\3]W$'Z/X[1M\V7]../.XCC7J>MN@[R3RQK TPQC1$OAU/QP,19)EEWK
MJTK&UO9#=/#;M,;; 'EC4VF>OF[514D=HM\V.^ZH"2!U.#M<'U@>5NMQBAS:
MB71EF;/PJR$ B,2DV<CH-CK'+ZL++'M<!@1W'Q&##)?6!L>\?)OR&+HEP,91
M3#LI-7^D_-TA=_#6<45,R!XXJ:%![@@& -(2^)*BMJXXDM=5N.(Y^:D=[DGW
M]<9?6Q4[0Y!D<O%6253Z:4'O[R0NWLV\< H;?T8LXWPZJJ]H$89N5^[%!)*;
MMPK7[PIL/[!#4.-4R"\4"G<CEJ8]!@M'P(4OLHCU >]FYG&B2KE"MS6+T0/\
MCM?;@RRG2+$W;K]?Z\>3?DFLK+25,O'J=!/;36=0\-*1O;Q(]JV(:2FC6*"!
M%BCC4=E57;3X\KWZWWWN,!K$C[_?_8,2+%$!F5*AEH91?5Q$%^$VG<I):UR#
MI:Q&^)<KS#4,QRL\-UE)XCP;B-F#ZG+*59"S6/9QOC5#*\4J6(=#I;ZQ^O'"
M\Z'=Q.&.)]=K8XGX1J]7/\8?^[ZMOA@T\E8W#TE6T*$9A:QU.!??PMAG=PHW
M9F8@6',DWZ#?<FV^&IJ*.?-JA-F%&MXE/=Q=[VW!TX2*O2;+I&;2GG M"#>U
MM70GZ5@?G#JDJ3Q;V92&4W'?<'QQ&%F23L]&O;%/O;4LH]XT\L:>K#[,!5&I
MB; =^%5_QC=M_ GI_':2%O:'9/<W3[<3TNH\&CDX07H2OK,>_?EC4,5.8'\7
M31,_U#8?$XKO**N';EDDBH]7LIJ[3KW7V4>&(ZG(IY!1)%>2.  R"1;WU*=V
M6PZ;X,,YHYW6_HZD+#(]N@O;?D+=>M\&DSO*98)XYHWC<=J,,-FTWOR!'7?I
M:V,OJ8'5@]+%>Q%PV@7![B,()$;B;V93^D8L@P!@\KZ-\+51"_X/K5E)',1/
MV&/P;2=\4>8U4J#ATJ\=M0[#(MFO\186YX$/DEZ.CX@66K>ZE=_G_J7?;?%+
M+Y1SR9G4)Z0J6*PZ^>XW+6\3;PPM-0PQP1+ZJ1J%'V<\=M3\L=%2H7DD:UQR
M1=KL_<!BFHTY01+'?OL-S]=_[!5LLA]69HT%[Z4C)4 =W+!B,0,GS^N.(?MQ
MPH^RMNFV/)_RNB@>I@R]S!6!?8C8GM&V]B'?\[2#L<1U&7U*2WTEX]0,D9(Y
M.E[BW+J-NF(^.5W%\,8UUGQY8EB@ 2#,86O&G93TL0EO;E?4K&_/M8)L;=^-
M0)MW?(S,=@.7ZOCCUBJ=%7L^/2V*'R;RQG\]S615E?4;QP,;=^VK=F^BIZVQ
M'34L$9GTCCU3*&FEDYLQ<[C<D@"P4&PZX:.I@C$]O0U2(!/$_>' N0;=H'4#
MM<' \GLY:\1MYE4-("A7DFEF.T9W!4MJ1S;2HMCI\/O^H?'$%0FYBD##Q[U^
M(OB*JIVO<69?:0]0P]]\1[7L&/\ K_CO-*QLL<4CD_DJ<3SH?2,\AO\ .U,3
M^C%F!4XROR?IW*_A.H7C:?X(G3:W7VC\,101+I2)%4 ?;\;\\>&+UE''Q>D\
M?HY0>_4MNN(P<VKO-5?5P&L^W<KF]O?[L)+E%55-E36"D=H1,.DHY;[[^_"O
M4B&J"CU731?O[2^&(X9<JE1GM=HY0WOL#O\ ;AZBF+JL+\.42C3I>UR+\CAD
MC;$L$ZB2&96CD1MU96%B#^KQWQ!2997S>:YA/P4I'9K(;@A2P/JAFZXB@3,*
M2"D2SZ!>]COVC;<^)W\< 4.:4A6+][-QK/=C\!>4M.M-F'[W+R23;8]Q#&]K
M8*C\9TVZ?)%30B\L\BQH/%NON',X18UUU+*./4,.VS'<@=RW_L'4%AZ&J<SP
M/[!$AN1?O5B1\NPP\57"LD$JE7CD4,K*1;K][[C<8CS'R>KYLME!N:74Q@:_
M0,K:UW'(AUW]GK'19_0/-2%A&M9':W/9C(OHSV?8(5CTWV/G--5+,MB3I/JL
M.:L1R*\B"+C%1.F\.6QRC4O+T2B!>>^[Z_Y/7!UZ;GKAU&XOC2WPPO%FT=JX
M2URUACP^_P!N,QKZ^H4ST$1B@CLTIN-$8TH-M0M]I-B>4CT.45E2JL1Q9+(G
MT3<<3GST\_HC%/!3Y- 8I)422-.+)(J,ZJS%[*JZ =1U?JP:F)/]\* <> I?
M5V=Y(=8WWZ=-0%M\1S$$STPX-0.H*;!B+GUN>^/=A)H'.@'TJ7[#CK<=_CA<
MR'JSQC@^X\S]>W\=FEJ)DB11<EB/T=?=AZ"@!6F?:28[&07Y#N'VXLN"KB^_
MQ^O&51S_ (J.,"$MWNKV/\K%CZWR;8LJW;Z_T8DIJB,>;S#2^I=OAU!&^D]/
MC@V4RY;.=5+4VL/[U);DZW^.%D5=UW'W.-*:9*21M4U,_)CR+*>8:WC;PP#3
M2Z*@#TE)+V9!^3WCGRQ?KW=<19A NM\JG%45M?L>T?S2%/NOB*2E*ZE01S@6
MUQR*+,&MN/#OQWXRJNA8I(E-J1E-CJBE8_'XXR_,%-^/3(7\) -+@_G#Y'S*
M0@QT.T:^T9FY'PL!_80TU6E^J2#UXF^<I_2O(XDH9CJ'K02#E)&?5/ZCX_(?
M.--E%QJZF_+#5=0]AVA%&MM4C 7L.X=[6L+COPLV7>34C4!:Z2S:AK0\F&OA
M@[;W6XWVP>'Y-)4PSQ%94-B"K#=3VR#B?*((FRV;,06%/.RJL:[L-+N2?5VZ
M]GNVQ4SSRBJS*NDXE54V[B=,4>JYT+<F][LQ-SRP4)LOOP\Q<+&H+N['LJHW
M8L3L !WG&FHS!6/3@(\P/N=%L<!<MI:BI*-M)+IA0_\ SGW:1A*'*Z2*&:H/
M#C$8DEDN?:Y*!I%R>=AOB/,TKJ&66H])4K5!FX<CC>X9)%G N2&-AJU #88C
MESW-IJL);]JTWH*;:]A866V_1 <<&@I8J=.O#4:FM\]_6;WDG&_=;X;[??;'
MX,156ASN[H+>I(WL[646=6&&(&G5_3@W%HPVYY7\!BGC%OVN\L5AT4.2H^H_
MQT:JFW/JQ1]9)#R'N[\,PJ'@CN=,</9V\2.>/VQ42RVW[;L1]6.X8.#XM^O&
M69\B:9:258I#UL6XD1^M6'YUL4M6H;3/"DBD>*_TXWO[K?ZL#APF( 69F//
MLB^\C>^-R /J^WEB?+JP)+%(IL;J3&_LL"#L1\-[8JLN>&681ZI8I$B9A)3=
M)+B_(;-T4]-\;+<CG<=WW_U8CJ*:5Z>:.Q5T.D[=-OT<L4N6YW99IV$4=8@V
M9M]I4Z'Z7+GB4[/%/'^4KHX]W=]6)L]\G&>?+I)3+6T&[\-3?6=',H!>Q&ZV
M%ML+)"PCJ H,U,Y](AZV',BX.,OFD)\ZT2JG=L;_ *]\5V7LUVRZL?0+_O4O
M;'POBW3].! OXNIA<..FI=U-N_<_V%CS"!=4M#ZX W,#6O[]!%_<6Q]_O[L<
M\4F5QREZ&BS"FI>%[,DG$3S@GKS4KSVW]4W4(H 4!0 HV M[L:)QKCYV]V^V
M//LOL:7+8"DDB;H6":+:N3;D@?DX.&<LJHF[2.VE .\DXJ,ORM%KVE1XI9WV
MIE5ULVCK(UC[AA+JPT"P%OOMW82&&%Y9)7"(BC=F8V %N\V%OZ,1UU721R9A
M41#6?7-,&W,:'H=]SX#QQV@5_IP !\ESW8R"K4>DBK2%MU0-&3MXM^G$<\HN
M70.%Z"XOBW2^)(YP6HZ@@L1>\3\M8'<0>U[A@34TJ2QGJAO]8YCW'^.=!3G\
M5PFD'<6+6^P 6Q;#'Y+#EWX0VOI-[8KXZ^2&EADAT1O)LJS@7A^)9<3956U<
M$;T,S"!I90J/"WS2_0$'[,:X)()1WQLK_P#=O^K!Q#E]970TU5/'Q(TE;3=2
M0H[?(7Z7Q+Y+Y7F#4&7447$J*B)MWMIU-=3VMSI6QML=L<:D\IZ@W%^WKW;I
M?0W+ DS*A7.:( PO4:>/Z+J+E3)'>^V]COA\Q\GK95FF[343V6-WOOV1R+="
MMAB3+ZZ)HI$)':&Q\5;D0>F*2L50WFLO$"L+KW;_ ']^!2U*+)E;;-![<:]\
M1_\ EOTP*RAE6>)AVU]J,D;JZ;D'G?IB+RCRB7S*=Y=,M*HM%,WK,RVV4GJ"
M+$7-KXRQ8XY*>NI2_G<+>IJ9!<HWM+<'W;8K\O8]FNIG(_+A-]O$JQ^K /?B
MEDE(56UQZCR&H;?;_85DBN&K)!3ZAS"^LV_2X%ML>&*ZN?U*6EFGWV_%H6'V
MXIJNJJ CMF#57:YNVII,278".,$ESL !]]K[8/D[Y)HTTKEXJFN7U(TY-H<>
MHMKCBGG<:0#OAZ,D5%7+VZJJ(L7DZ@$W.E3< <_:ZXUYA/H>2_"IUWGFTV%D
M7G:Y%V.P%\- G[3R^_\ 4R-N]CL9W%M1M[([/>+X[OO?_9CL[[_[.74[6'CB
M+/\ -(E:ME7520.H_:R-ZLAN3Z2W(\QBW,??ICM1CWKMBS:N#?U@+D#'H3J2
MVQ;;'/X8R_+!VH*!EDEL+V$5II3?8;MPX^6"H%K"RCP_U?)WCNQQ*&IDAOZR
M@]AO>ANI^J^ 9.!.O56CTW_.7E\!@@>BJHQZ6 FY_*7E=?A_'&.JI5UU%'<Z
M!S>([L/$@C;!5NRP-F5MF!\1SP1? 7QPJ.VD8[)NO?AJ+,81/3L02IN-QUN+
M$8ILTR^.4Y0957,:='/$A4GM.K WT6)WZ&W?B',?)7RBK*6-E&I#*95C8 70
MZ3>X/CR/OPTD=5%G-/&"S@MV](VW63?Q-FQ+7U0T-<(J"]HPG(#NWZ8?,:$H
M[R)HD$HUZTO>U_6^-\1TV97RVH-E[;7IG/@_LWWYX+6AJ(9%YKID1U;OM<;X
M?//(]VI98=<LU%%L& W+1*/'UDY':PYX>FSFG5<T@6TI]6="-N)&W/UO64[?
M9B2=%-9EMR5J8UN8QS F4<M_:]78X D-M]^\8A3+>S,-+R2$]F<]5D'=X],5
M67G3!F8A+I"Y&I*@*VB2$^TC,+,.X[XFIF0+.DKT\BGHVK&1U;&[2U:QN%'L
MR]@[#\K"GPPR2H;^Q(IL48<CA8*R U/#LJRJUF*COOS/+'H,O;_G)!^K @J8
MS22,;*S&\;'NOTOC;?\ L#1QW[9J"P'T0F_Z1\E>H;3)6/'2)XZSJ?\ S5^W
M&55554)3TT3.\LLKZ8U'#?KO[AWFPO?D<A\GZOA9:"/.*P]CC*C#B2+UE2]^
M$@];1J;G@0T,5FYSU+"\\[>T\DG/W#DH&&I*1$S"N]5@IO%3^+,-F;GV1\W%
M%6JKK.HD,S,Q-]9V"CDJ\]K#"]2UK ^.$K:A?,,IL'>KF'K+S(B4E=1L/6]4
M$B]\0Y+D62?ARNCE23SQT>5FJ(Q[/#[4I[/J!1#<&X',ZZ9$R^!AI2)O-:<H
MENS9#K<"QN;G5TMBFK?*&2+,<MDJ%@ET%7:._/DL;*VD$KJ[)MM>V*6IXT2)
M5I$\.MU77Q5NJK<[WZ=^&ZC;G^O&\*_H_7BJKY$C"4L#S'5ONJG2/RB=AWDV
M\<9KY2U=FDK*AHH0=-^'Q"\C!;W"EB$&UK* .MU:!-'9&I?&PP>Z_P C#I?%
MK;XH94OVYDA8#JLITV^LW^'\<F;ABFJ;&T\0T[_3 V/OM?GB:CF]>-[!AR=3
MZK#WC?XX0]^%; 9"-6G#+U%\/%*H=)%T.I (93S!OL1[\"LH^)/Y-9E+^V(-
MSYK*Q[2@;A0.:'ES'=B>&@JQ-69C3:8@@OPUEMJ,GS6"DKWWM;$=9)32>;SC
MB1U"@O$P/TUO;W'<&^%OSM?Y!YE62<(6O!(2\)'=I-]-_#"PYLGF$_67UH&-
MC>_51[^=_?B#RP\GI(I<NJ)4\[%.^I(Y&];5IO:*<=XLK6Q#5H$FIJR"S1OI
M<#4.W&PM;;EA\T\F@(Y>T\N7\HWZ^A^:;WVY<K8:FJHI(9HV*M'(-+;;<C^G
MD>F(\UIYV0QL"G#;MJ0;VMU'O[/2V^(JZHIQ#6-9:P 62=D( G ]EG'K\NT+
MXRO/J);K25-+4M^2'&K$;D:HY8TD%N8U*#C;Y;#OZ<\14JO&>$H42.FI[= =
MNF%7,HDDA-@9(UTNOTK<B._"STTJRQL.:_H/<??_ ,<XM9.L2]+^LWY*\SBW
M[9"_PG!.G^G!,<[S-;95C;<]V_+$M;5R%?8IJ8<D3I?Z7>>OR91E$9%W>:I=
M;V_M:7V\&P*5HBAY7OV64<_KQ/Y3YB>#!!Q(Z1I#H6UO2S:CM]!?G'G<XGRV
MFF:&D(>)ZR/LRRWV]!U5+@[\S?$NB?C1ERZL6N;'J_.[6YXC@I()*B:0A(XH
MQJ8GGR%_K.%SKRK=-4"\?S+5Z&(+N#4-[1V]0&V_7I_N>R*$4V04K+#/4 6C
MX:[$M;;?][@'/L,<:X*:-ZL@<:J=096:V^D^PNYY=Y&&DJ*BFHXU%NVPNW@B
M^LQWY ?7B;*:"DD>%YXY#53'AW*<M$7/J=S8^ OBB>6LJ)31\+S=7=N'$(K<
M/3'ZH"V]]L00Y)DE1659B032%69%F*6O9-E&L-?6X]7 5ZFCR>%SN1PBZ#\S
MBM_G7&(/)RF\HJS.GJ;-5]N7S:EO^,UW8J50=KU0"=*CF<&H7,*JKE>'A-&]
ME@4G<E4Y_'IZHM8X"CJ<+(Q':'+'A@L>_P"2"0*?-Z-Q-*]KK=?52_*]_P".
M= XMK: ZN\Z7VOBW=O\ 5UOCS*B3\*YF=O-Z8Z@&Z!F6]_$#!K#Y-::*VHK9
MA($MJO:]^7@;=V)-(\WKX@#44CF[#O=.]+[7Z=<??ZCX_9RQ'D,E#HRV=4DE
MJF77YPO]I)V0)ZOS]77 \Q)X9'(FY'/$GD_FBQ34%6'\V\XL5AG*_BSJOI5S
MR[CRQG$JS&AJZ.J$4.@:HM!W(9>X-<7[L%GI#54PWX]+Z1=/CU'U8TL"&'LD
M=KZC8XV.)J=)W$%0NAX=5TD&_-3L#>Q#<_'$M!F?%,,M1Q8I%[8@O8%=/.W7
M;;G@/05D-0#OI5QK'@5._0],%:F,05FGT-;%LX/,<3EK&Q\>["K6*]5E3-V*
MA 33R(;@:N80^_;ZL+F].R)&>T5U;@]1]G/'X/@)!6-D8^(%Q\>[ H9R!F&5
MJL,JWWDB79)4ZGN;N-[X)1+@;G!Z$=,6ZX%@68],+YURVNN+TB].0QKII"$U
M>D@;\6PWOMW[\\">/L2+V9HNJ/\ T'I_QGA&]15?P$5NS^6?9]WOP=>6]CPF
MWM\4'QM?$E35&P)]%#[$*=%7QMS;GX_)<?)SU.=@!T\2>X>/UC%#2T\6KS&A
M5IY I]:5F>S'P!%OT6L6AADEX:J52HE(N$3UI+ ;LUKZ5]H[;8BRO)HGI\JH
MX5CCIA?7-HW,U01S+6#:?5]KW,')$@:WN\/]0MA(Z6-HZ35>HKI581(I^;\]
MOH"YP%I8A-6M;BULH#2N;#4$_@TV]4=2+D](?([)RTA=E%6T?+7UXAWM% E]
M?35SY8CI9:J" 1KJE8D><5,^Q=V5>TY8\NHV5=E%GIL@AX*$:?.ZC=_>D&^G
MPU?%<-49A5SU4I)-YG+6\%4[+[E '+'/J.>  I.]K#<\^[%9D5?(M,^M*BE6
M<B,EI/6C56':-]+>M?M83R?\GQYQG5?Z"\9U&F63L\Q?2=^?L"Y[L:IY/.LT
MJ5#UU8V[NYW**QW6)3R7P!._R<9QV1WXX2M<+M@+WG&CXXCK<RD:FIGLR0+^
M-D0]2?94BQ'O\,+34<*Q1KW>LQ[V;FQ/\<Z,+(#,L!$B7]3MW6_OWQ64*S/3
MM54\D2SH;-&6&QN/MQ+F%;E<6>4;2']O &26-+GM*3?0YYEB+$#P&(9?/H:5
MYEWIJIA%*I\0_P!0/48RG/LEG@$57*$JXJ65"IO(@FU*I(*LC@G:UUOSPCJ;
MZPK;;^L >8\+8D6K*+*%9Z>4;O$]O^Z;"X[]\55#6HR212$*6&SIS5T/)@PL
M=ML"2Y'(@[[6W!]]\55%*]_/X6W)YS0FX^)U_9C2UO$'E[L,:FB2&9A_5%/:
M&0$]>S8-\1A:N#,4FI))N&(Y1IG%P3M:X-@.=NZ^-<E%410LHX+M%(%:,\FO
MIL01O>_7!TFWV<L++%))&ZD6DB<H^U^[GB-:K37Q@BZS#3+;PD'7WX-%7LE.
M9AIDIJ\#0>_3+ROOV3TOB2J\DZHUU UW:@23B-'L=7"*DAUZZ>8N,24=9')"
MYN=$@*,&',:6W_V8CKJ?U _I4'JR0/\ C$/Z??B&MHV5HJF$-WZ2PW0]Q%\,
M_?\ )J2P;&IFN3O? ,B:@=L&6C6]]RHP9J9]#7])&?4<"_K+^OGO@3*-$R=F
M>+YK>'72>G_%B2;  DGNMB2CRGI='JR.O(B+[>U[K8U3%CK>[NW,D\R3A!3,
M&-@"/'':!4XLV+#EWXU:3;$]74,(X*:-I9G.P5%%S<_?>UL9OFDRJ*:JG98"
M?6$$0TH?#O\ #ES!)GEI_20\0MMRM?\ HQ'EV4*9*Q_12:5U$D[!54;WN;6M
MA,U\J+PQR$2)0+99I=R1QOX-=ENO-K^&$@I8(J:");)'$NE%78?'D+D^MBL4
M5T1S#S>44T*'7(9BC</4$U$"YY^[E;%?4TS@9A67$E8R:JA$U%F$#'4JAVW8
M^L;*-AM@RU,\LSD[O*[2-W<VO;W?((Z>&2:1N21H78GNLM]OABJS2O49?34E
M.U48YK\>0)O81BY%^SZUMK]V!GK4*3YS4SU-/1^<#7Z57*B1$;94CMJ+VN"+
M7MCSF69N/--K::]FU$WU BUK=+<N0Y8BJJI3F3UL:QO5#MSTK/ZS+J/:U7TM
M[7<<)*M],BAQ>_)@".>XVZ'?OZ8>>>18HHEUN[[*JCF2>G]-ML2T>64%;F*Q
M:@TU.@T'3ZVGFW?9K$6W(Y7\VF:7+JQVMPJP:0S?-$G*Y^:;&_7%^8Z$<M_C
M[L4$3#4DM3$KCO75O\,*BBRJH51X 6'\<YIC^]1._P#)4G$]6Y+/)*[7^.P'
M@!RQ8X,4JAU(L0P!!'4$=1A,\R^G5)*8!*N.)0JF+8+( O5>1]X[L$ZFVB?3
MVCMRW'C?N[L*:7-JR,+R4REE_DMBARNOS"G:DF;1(TX2,V"D[/\ ./+N[\ Q
M%8\Q@!---86EZB*1@=P;=ENGQQ-15L+PU$+%&1]C<'I?F#SOW8@JXV[4,RN#
MX@^K^>+J?Z;8@KZ8@QSQJ^QY'VAMW&X^2DR"F-Z++FM4D<NS9JDD>-A'\,+2
MR4\$D$<:QB.1$90JK8  @],.$I6H)C8\6E.E>O..]B+^%Q\<.V5UD%=%S6.2
M\4W7\UK>X8TU>45BA=RR1M*EAUN@/V[XT2*RL-BL@(8<_"_UX6JBEG:B%A-"
M6:2.WS@#>Q'A@5JPTPKT36*B$K%/K OZ5;C5UOMB"2M4&+48F^/(WOAJ>@D,
MN6._:II#V1T)C[CW &V$K:*4.CJ"R^W&>JN.EL$X[(QVL C!*X9SS:^+SRB*
MFJ$*2%MEU>Q^O >-@Z-N&4W'U_\ %"['2J@EB>0 ZG$U!EG9AW22IY,XY$1]
MPV-_AA=B 3ZQPL,1O*!N1WXOJ]V%215U+MKZV^7@<,%CUZX/DUE\A]8-F#(;
M7;V*>XZ#UB._3\T8&F^IE"@#GJ87/V7.#3Y+!(>(#Q9F!$$2G8O)+N%M<=_/
MEW',LWJ*:?,SVY:VK*+'"3V[0"3ET[>DL;"Q&&BR[5F,B_OH/"I@>5];=I^O
MJKO;?IAXTJS30G;@T=XR1TU2'MD?%1SPY9CVCN;EF/Y3$X##F#MU^'QOB.GR
MJG,S2IQ#[*QV.E];-IL QWMOA9<_KK\B:2DV'BKS-OS'LK\<</+J"""PMQ-(
M:9O$R-=_T#N&*\\GK66DC\0V[_YBMB&)F/#I]:P1^R@9R[$#YSDW8\SRY8!!
ML1]_O\<09_FD/$1/2T5-(M];#U9V5O9N+IX>_#(18KM]7ZNGAC*O)*B9D6MD
MBEK-&S,K$A%)^8JB23QVOR&$HZ:.%+(.-,^CB3/:Y:1C<D=U^73!H<HR]Z[R
M@#:(JK+8PFF78!)2J_M@WNMA9U(M>UAAO]TTDG;930P3G5/# %Y.?6W^:QNN
MXL-L9<NK235P[WMMJ!._B/XZ21'E(CH?SE(_7BHHZA=+Q2, &]I+W5E[P5M:
MV+X'OP]/*@>.9"CH1ZP(M;W]V&CIAJHJI#+3'N!;>,^()PH>,[_;@%@4<;@\
MF'N[CB*#,"V8Y<I"E7_JB%?[6YOJMMV3?D+8\^R6IA7-X4U+R28]FYBJ$YGE
MV7L>9'+$M%51M#402&*6-K@JR]?$=S8\UKE,^7S-J%O7C+7[45]N?-.7=C,,
MTR^MAF>&G?1'>TG&;L*"GK>N>E^1Q6>4-4-55FDS\)VW;@JS7-ST=[GO^S =
M>6%919K;G'QQVE!!YW%\'SW*Z.?5S)A4-]:KB2&EIFI990;\-]5K]P;EB:7+
M,\DC<ERD;QZ!N#V2Z6QYIF"ZG2%7$\=VC?JI#=_?A9NNU^\,,&?+IG!47EBW
M:)UOS=-QX:NESA/PKETBMM>2!P4=NI ;<+\;X$;R34M](5IH^PVKZ2WV'Q^&
M!/231U$3;AX6#BWO4[>((!&"N#'>VQ.^"A[[8XB=JXWPD<CL]'K EB8WT [:
MT[K7W^&$E0W210RGP(O_ ,3,$+VEJW$6Q 81\V\=^6-_C@0JBJ1[77!).+7Q
MR/R??[VP^6Y8Z25Q)B>>X,=.?5-N89P;^&V*:L>M:KJJIN/4$FY/5B3[SB*H
MS>6445/+_4\0 ,QMS,AV51L#923JVMU7*/)&FI*,HJZY8%5FC%K%F)4ZI?RK
MX+UU;55;_P!ND?0/ )ZHM[AA6%V]FR@GW<A@"@RBKE!Y2-&8XO\ I'TK;[[X
M1\[S"*E#<X*0":3F-M9*QCQM?"2KEPK' OQ:WTOCZAL@_D?$XR_/Z*,14%5(
M..L2JJ1G9*B*RK94>,+* FG=,15$3:HYHUD1A>Q5A<?9CPQ'E4#]BC4A[7WJ
M7MK\/11VN3R9F P;_?[C?$>:YA'IRB&34JN/ZL9#NH&UX@W7V@+=<4GF>7K4
M)4@QIZ3A1PB-18;+\WU;=-COAFIX**CU7WT-*_UM9;_FX.93UTOX05T$=1$%
MC9$",++IVMIVY?;B"CFS/,7A'I*N5JF<K% NY'K6U/LJ#YUN@Q)-14,4,LGK
MRD%Y&.WMN687(!;?=NUC4<*RDKH.H-W$<M^>())3JFAO!*3U,>U_B/XZ-4YB
M>#.B$02(0)G(]5;>T+]_+!L=K[:O6^.+'  &^*6M8!5HYBSM_:W7] 91]>$S
M.DJ*=Y+ZHZ:1@$>,<O2\E8V]7]&)8ZRG%/(-N&K*RV[P1>^#A*G+JF6FF0WO
M&Q6^XV9>3 ];]V%\_$-%Y3P1@15EM-/F04'L3'V)6&RFV[D>.)151VX7J*W>
M/9_)[CRQ'G^6R3T\XJ(Z2NH"UXDETGM#F54E=0'*[8RY\RIO//)VHCB:*2,:
MN!'+N>VMM)WO9MC;OQ3UU(^N"HC5T/OZ'Z0Z_#K?Y OC\FEL<-2.74[8LS G
MPL<)*D2MYNP25K=KAOL#[@WZ<9BU/$\G 'G.A5U>A;UR/[V>>(YP@D13:2)]
MTFB/KQ,/'QY'$6=>3[ 4LO\ 5M >VU,_MZ+;L!?W^_#T\5529C#9EDI*F*^D
MVTD"X#HRVL#<:<)59<LM-2,Q\YHC*9H+-T346(VM;NQ'4457 970%Z<NHE1O
M:&@VZ]<7C)'NQ=[ZO'!1NXX8]]\9<9#=O-UY\[=/L_XD*2D >L=;EF]6$'E?
MZ7=[M\&:=Y)G<WU.;^.PY =UL:#CCLO8.#B[8U5]=2TH _?I40_43_1@N,TC
ME(]BG1Y2=NFD,#OSW'/$U-DL;4D!NK5<GX]UO["_O>H=>?VXN6+$D\S<[G<G
MQ/.^&MJD6,"",;MO??;Q-AB5(0V6T3.Q5:B;S?4#:Q[-W*V[N_QQ-'G>8TZU
M$BG4\ >5@>N[A 3XX?S@U>9-K.\DG"0_FQ6_[QPJT63T,12UF,"R2=GKQ)%+
M?&^   !W 6PAD]4$8$$'JVQ74=KU$:&HI>_C1;A;E6%G%U/?MB7+*D_MG*9.
M#OSX)OHZWLI!0DCH<304TT=3F3(P2.,AEANNSRM\19>9/NQ(U0[--*S.S/S.
MLESJ[B;W_)VPN9YCJ@R2!KW/9-6P]B,\N'>^IN1MMMA,KR6.&MJJ9>&E/3D"
MFIM-K"60?&Z>MJ%SO; FS&H:723PH%NL$5]NQ'RZ>L;DX"A&)/A@0K YDE>-
M8UL;EFV%OOROCTV]?5A9*EOF]1$O@O+Y>F%ED!!JI6G6^UT]53;Q _CG[L5+
M,Q,,,C10I?8*IM>WCW\_DO@R2N 5Y#O\,'R8HJ8YCF>:H8(J2,[QK)V!*Y&Z
MV/:&*?)/*K,J_**"1=<30.7I]4K!K:^5NUVS[)%N5K+/Y[65HDL5G%7K4COV
M)V^K"YCD9GK:<?U1"1JEC'SEMNPZ'!C="C#F&!!'P/+NWWQ%-8,$8-8\OO\
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M.XPT$EY:*1BU+46LDD;'9#W.M]\1I42B**U[GKA:*E&IA;1;J;8;R<K7U20
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M^CH\JA<BCRV$[A34!>"-[E>/+?5VL>4]+31K%3T_D]50PQ( %2..'2JJ-A8
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MTCW7Q1T5_P 13J'MOV[7?[<35-9Z5Z9@JTQ/9L1?B,.OATYX6*&-(HTV5$
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M)$9-F^T#%'F=(D,>:24L3K5][J@!64C>^H%0W-;^["Y/Y2PM3-<1T];N8VZ
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M@VQFT:02CR?GCE<SG5P'NP:#2=E,HU:"-)MV^X8LWR=XPWY)_0?UVQY2;?\
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M $$?_EQV((4_(B1?T ?+_4M/_P!!'_Y<?U+3_P#01_\ EQ9451W* OZ/V!#
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M+M(RCM,FE6"[BX#6_9&2:1(HUW:21E1![V:RCXG'!3/LH:6_XL5]+J^KB_#
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MZ:O:$8[(\;M[7R&EE[6W9;NMC[_?].(Z:D@EJ:B5@D<,"-)(['HJH&)^H>)
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MZ>HJ3)%<05#$W0'GI;XX2HK)FGD::559K:M"$ ;V[[[\^8O;!)L%ZWY?T?H
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MJ.G/?'G8GACAX8DU.V]BH('Q&_QQPXVUJ2P7X'G[L90D9N&I$E)[WFO+(?\
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M[7!C8^EJJ@[$N>>F_:D/JA-AN1B6MJY"\DK%K>R@Z(@V"JH]4 ;>^^  "22
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M84(H6QN?$^/?@,JA++8V_3]>./41G\'4KZI+^I/*I[,/TEZOTM8'8FX518
M #D -@![OV>4_P"4*/\ GC^/T^5U=DDLTE%56U/2584B.9?HWL)%!&M+BX:S
M";+,T@:&:,W1B#PYXKD+- W[[$VDC4.3!E/:! _8]K[_ '_1?&8%6U+"R4P\
M.#&J.OP?6/K[\??[_>^%SJO4/ LA%'#LRR-&UC+*.Y7V5#W:R+:<<27F>S#
MGXR5_9C11XVW]4?85GJ.SFDBL:&D!NN6Q/MYR_\ ]T-^]WN1HUG?3I:4W(OV
MCX]<1TD0TQ+Z2IF]F*$$<_I/LB+WF_('&7QTD0BA\UX6D;;Q-S/>QU;GJ<1T
MU.G$ED:RJ/M)^B!NQ[O?B.EA +<YI;=J67VG/4C;2O@!X8JH8$,DE;YF\4:@
MDLTE/&E@/&16/</=B\EI*^I534R#DG,B&/Z*ZMV]IM^5@/D^^WC[N_'D_4S
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M8?LII1N8XI) /%$+#NZCO&'49'Y(V5V4?M7-SL"0/_WR-["_3KMW?\!>2/\
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M<*&NF1KZC>TW 27S0E1/I/%X6:^8H:B?*)J7RAITCW,B4:RI4,MO6TT%743
M<FT#X9OY%9M504)S:LBS/*)9VX:5%>88Z.HH=;=A99(X*5J56*\1A+'^-:%3
M-6U]3!1T=-&TM1554J04\,:[EY)9&"(H'5B,4ODQY)4>55>05WE!!04<TU%.
MU9)E:3**RN+><Q[>:)45@]'=(U T,5(/ELJC4?\ <[F#FWS8XN(YY^RBLQ/(
M 8\IZ5Y42HJ<EIW@B+ -*M/5GC%%.Y*<:,MSLK X\I_)^)=51F&62>:*3I#5
MM*Z5U&FJQTAZJFB2YZ'?%;EWE#(N797GL2Y;75%0K1^89C12R&CDJ+C5% &F
MJ:>;4OHVF668QQPR-A9TEC>%D$JRJRM$T1&H2+)?24T]K7?25W',8RS(<@J(
M\QRWR<2>/SJE])'5YK7O"M4L#C:>&)*>GAC>/4CRB5H7:-M3>3.35:LE:M&U
M;6QOZT57F<TE?/ UOX!Z@P]W8VN,99_C9G7_ (>9?Q6K,SG!:.DA:4H-BYY(
M@/TW(7XWQ)5YA4/*68\.*YX4*=(XTY*J\N5_G$X^W!;NN;=^/*;RHK )*OSR
M6,%N80:>' IYZ6D:-2![*KW8:HK)FD8WTI?L(#["*+ 6OT'3#YO,H9RSPTHM
MZNGLO+[[]D?DX;B0B*H([-3"%$E^A;YX[[[_ %X\UJ-)M*C1R+RDC8/I:W-2
M;&ZG?"21L4=""KJ;,".US&*N:0O)FH*^<2RM<O"Q.CAWY#GKY'9>F.' A=K7
MLO.PQF-3*%7@0R.=0]M5.D'\XC"^4-4%J\TS &IC><:UBA>_#5+[+J3M<NSK
ML-C;$[9*$FIGD+299.2JHPZT[]/"VG;;?$$!\GX8GIM2K42U"VT'D"!+J.EM
MQM??"B:?+S*=/[3ACXCGESLMU[]WV%\4LS1\.26)&G4>K$Y4%UZ\NFYVPL8Y
M* /?;[_I[\55+(Q9:*I417Z1S)KL/ .'L.0_XKF=!$>PDRRQ@<ECJ8UJ$7\T
M26Q5GEJX+#W<"+]8M\,'0MAR!/Z1AR3=VW9K7Q/FF3-JA9N)5Y:PU*0-Y2G1
MQIN=  <#U3A<PBR^E[2,TGHDNLB F0&UN5B0W4$6\9"%TCSEBENG83U?UX]=
MM'ASQJ65_K_3[\%'NRFXP4U'T+RQQ[\D5R!^:]M>GEVL)2+&9)9FTIPK:KV.
MY4V6P':YKRYX2GJJ5X\T8_C:M1>Y.PC4C2H/)6&H,VVHV&$A,D:R'=8BZ!R%
M]:R7U6%K'KL;\\257#B0E66I/*[Z2==MAZ2Q!MS(WWQK!M1O.T<A/LQMV;^X
M=C[C 4_B8[&WLMMMM]^> H&W<-K8&G\9U\/'$F3U\W!"R T4LAM$%DO>$ORC
MLWXL'L]HBXV'[CE/^4*/^>/W'*LYR"JR*&EHLAARR9<TJZR"8SQYAF-66C6F
MRZK0QE*N,:F=6U!QP[6?'DQD%>T#UN39'EF6U3TSO)3M44E)%#*87DCA=X]:
MG0S11DK8E%Y?+'1YD6H\RH];97G$"!ZBC=[:D=&(%12R:5XD#,NX#QO&_:Q+
M_N?S6@GA;LI54.;U672O'?;CQ/$F@]61)9P 059SMA<P_P#:#G,"TO%XDU#E
ME1-4UU;OJ*5%?-'&*7B&XDX2U$C(;K+%(;I2Y;EU/%24-%!'3TM- @CB@AC7
M2D:*-@%&W7O))W^2>); RPRQ@GD"\;*#R/4]W]!>2/,_));R,RD9IFH8:B>[
M).=C8[]XY;G_ (9\EO\ MC./_L7'_#/DM_VSG'_V+]^\8DR/R@J*&IKGS6KK
M0^7SU%1 (9DA5%XE334LFOT;$CA:1?9CC-/*K**WR=BRVN_!(BCKZVNBJQYC
MEM%1RZXH<KGC!,E,Y2TY[&G5I)-HU-KK&BFW*X4#;EM\!CRB\G,L>FCK\UHE
M@IGJW>.F#K4P3>E>*.9U73&PNL3[D;8\IIO*&IR:=<W@RN*E_!5555)4T<E>
MTIF\YH*+1<5,>C1Q-5GOHTC7BH\H?)BK@R+/*HF2NIIT<Y7F,QYSGA*9:&HD
M.\TD4<T4EM9I^*[.9,OI,QI8:)[JZP>453%12@W!U1")25.Y-XO5*]DFX%+G
M_EQ7TV<5E))'44V4T8D?+HZI#K2:LJ9PDM=PVT-'%P(4$@U/QAIT%+ H1I*;
M%=-K:2O*UN8\>[%3G/D!7TF6FID:>3(\P,T5'%*S:G-!601S201L2Q%-) R1
MWTQS)%I18\MKLQHDR]&6WG>?U4])&O+5'!'#*2RKZJ\->BE@.39E-/\ AGRE
MJ(N#+F+PB*&DB8W>GRZ'5(T*/MQIGD::8J#>.,\(5N6UL8FH\PI:BBJXCREI
MZJ%H)X[_ $XW*XEE\D\PR^MH>,QH*OSZ3+,QAC?D*A!%H1D'8>2":3B#MA8]
M7"6CR3RFJ8:O-8ZNOGEE@JIJQ-%55/-$O'GCA<L%8!AP[!N1.)_*+R:JX<CS
MZI/$KH)T<Y9F4O\ #R<*\M%5OL99XTF20C6T/%9G)RI:VA&7LURG^Z"I&7DB
M_:, AUW/,6I[Z;>*XI?*#ROK:?.\VI&CJ*'+Z9'_  90U:'4M0\DVF2OFA8!
MH2\,$<<GI."76-DQ2>6E96^3K913YYF.8O'!6USUWF]4E8(@(7RR&'B@SQZU
M\XT@7L[_ ,5LV6(FZ"GE<#VHXJF)Y!\%&O\ ,^0'Y,UR<?U'F-?'F<##8!+3
M$Q>X.ZZK;^B3'W\<4>W\+UZ\5\<.,7:QY>[&5Y;%(*S-\QJIJR=NL2QHRQPG
MYH_&N3M8+CA*MWOI Y&_*Q^]L)3O="\4T,BG;DO$!/Q'/X<L,\&S$:=76V,Y
M523-)2O)XGALLQ'Q5"/?;&5RT<BZ%HZ>"1/FRP1+')&?<R^_KR(QQ-"H^E0;
M6Z8JI4NTB02L@'S@AL?AS^&#6U\9J*NIA>05'K,)B3V;GEIY6%L!'/[6G<*]
M_9WLC_"]CX>X891TPC2_U17L*N3Z*,@$*?!.U^?\ELPS"GICST.UY.5_Q:!W
MY?1WQ^T<SI9SST!]#_R)0C_YN.&:VD$AVT&HBU7]VJ^+@@@[@C_B"U96T>84
MD#*W?) /-W7WA$3ZQBEK%M=G2FD'?<.ZGX:&!]XPMAT^29G;3&D;LY^B%/\
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M7$;_ /PDFQTN>BMT]Q/3 (Z\K=?]1[_]N*:&=EB>=X(KFVAG8I%N3:UR=1W
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MX57E!# E3+D_E759A%!*Q2*62ES"21$D906"%E&K3O:X&Y&/ZTLD_P"N5O\
M1^K']:>2?]<K?Z,?UIY)_P!<K?Z,?UIY)_URM_HQ":WR0RMZ76..M-7U,<YC
MZ\%Y8Y(Q(/6 9"'L5[-]:Y9F\"21PYI04F811S*4E2.K@2=$D4[JZJX##H=O
MX]R4@""LA/&HI7Y+*.:D[G1(NS6ZA>[$E,V45;'=-<:<2(ZKJ")4[ ![[BPY
M[XDA<6>-VC8;;,IL1M?D;XEIIUUPS#2Z_KOT(Z8S"OAJ:B0TT?'CA.@#1&X9
MU)TW-EY?;?%!.*.#55TT<<M65UR1S+Z.1U8[J"ZD^ZPPR<83HMM+IZI[O]>)
MZL6$DS<)F/)0O:Y]/?AA-7)-+UCI_P!L$>%T[%^_M8;S&&=C1Q><MQD 1AJT
MFUK[CG8_TXFG8 %VO8=/A\OE5EUAIEFCS".W/TA.O;_GD^2R1EOL&$KH;>>Y
M=,E2)!\RX$D9^CIY^[WXAJ8KF.>))1W@.H(OXCK\D5'I.M"=SW8!'?B-6B1+
M+I!"VO:V))#[*D_'H/B;#'W[\,G:6&0:R#L#SQ3YI0,%J*<VL]S'*AV>*4<V
MC8<P"I]H$,!<R4E/34H73JA9#*P_.//78]!;?8;$QT.:1I35,K:(IH[B!V/J
MJRL2R.QV!OI);I\L])1QFOKHKHUCIIXI?FR2;ZBIV95MN/7&'S'-*@/*>RB7
MTQPQ^S'%'[*=?$DDDX9(8TFJ74K&/65&.W%DMT7;;G>W=C5)=Y'[3N^YOU]W
MAX6P]3%&2D(](]MA[\/!<]QL?JPL42M([\@,<*>/0ZV;3;I]^>+/S'W^XY8O
M< 7OBEC6Y@I=37]G6]KV^"X>0-HEDTP0GYLDE^W^8JL_YM^=L)#5(O$J5UN3
M8NH8=@$\^RIW^D6Q7PQOJ2MID:%FVN0%NH^,;+;P4=<,UO!??TQKF!E)WLVR
MCX"V&EJX9$F;\0D$I5I&MLMB2-/>UMOCCSNGS6LRZ$7;B"3]KHB\P8[*6(]]
M_KPU/%F,&9Q1L4C=T-Y5'4J>V/Y8PGGU.8)+6UQDM%S^;S7^4<25!(X8CU+O
M^,+V$?P9B!WB^#/+VIJN5IW8\ST'U[O\<:ZJF F'_O$7HY/SB!9_S_Z,*:',
MU*7]6HA[8W^=&=)^*XISG-3%4Q?O4*(5'&YQR.[7V5K; ;[XF7D4;>W)UOLW
M^OGC*.)^*.9Y?Q+\M!JX0P/A:^#4SY;")W]>2&\)?Q;AE;GQM@P9?2QTR&VK
M3ZSD=78W9OB3^XTN69C3I54-?Y<M25=-)?1-3U&:O%+&VDAAJ1CVE974V9&5
MP"/ZRJ#_ *WFO_K\?UE4'_6\U_\ 7X_K*H/^MYK_ .OQ_650?];S7_U^$FC\
MB<L+QMJ42RU]1'<?/AGK)(9!]&1&4]1A4151$4*JJ JJJ[!5 V  V &P^5*7
M._*+(\GJ98A/'3YIFM#0320%FC$R154\3-&9(Y$UJ"FI&%[@@?U\>2/_ .L>
M4?\ K,?[U9QE>9]G5_O?F%)6=GYW[7EEV\>7R_[F?]TF4_A[BF#\&>=Q^<><
M $FGYZ/.!8@P:N,&!31K%OW'+LPS>BKZV/,JJ2DB2@$)='CBXI9^-+&--MA:
M^^*?RERRFJJ6DJ9ZJ!8:SAB<-2SO Y;A,ZV+)==^7RU?E-F5/4U5)1R4T;PT
M8C,[&IF2!=/%9%LI:[;\L9E69/19A1)EE3%33+7B ,[2Q<56CX$L@TVV-[&_
M?^SJ_*;,J>IJJ2CDIHWAH^&9V-3,D*Z>*R)8%KMORQF59D]%F%$F65,5-,M>
M( SO+%Q0T?!EE&FVQO;?^+UN_;[,9K3GG#6U$>V_JR'[GQQ&H@<F4:D[)[2]
MXQ)3U4-@Z-&\;CUE92K+XW!.,[\GG)8Y36DPL;]J"8N /"S1:S_?,=A&(&Y-
MKVQEB19@PR^MC;B4T3$#SF-M]=M[Z"MM^_O./O\ '#RT(C)D%GUBX9#ZZ> 8
M;'KU%K8AKZ9KQS DCK&XV>-AT*MMXVOR(Q<]!<^ '/X>-\/,M;2O'$C22&.>
M-M*H-3;:KW Z$=+#&;>5$BE%KI/-:..Q_J>)U)9C;>^A%Y^LK=#@8C+*I6]C
M?V0?:MUMXXJTII"T<M+,.U\XQD_IQ3J\8DM%- "WT7;3]0/V8.X%R>9 _7;Z
MC[\;;^(_IQQ18K'VBI[ATV.$&@)H[-AB.'IIUGZ5S8?5I.(UF<(M[DMRZ?T8
M\SI[<.,:-0Y&VV'>&,NL>[&W+ ?N-G2]KCJ#^KQMTQ'/$W=(C#:QO<$=Q!Z=
M/AC+:IMVJ*&EF;\IX49OM/UWQF-7&_#GX7!@;5I99)F$0=3SNFK5L#:U\<.*
MXO\ C)=]1ON;'GOW\\ :-3'XG';CTGQ%CB2>,?MR.3M*>L=OZ<2TT;E8I?77
MH<<0^USQ+)PE>1HR$8^R=]QAGG;6V_=R^JV&96T@;]<!B787YMW>'3<<L!=&
MGP^S&1T"=I.(TTB#KJ=$&H>")*/<YQ*U1,JLD18\K(!<FYZ6Z_1OX8BFI*CB
MUE+4!E:,,0(R>V.)L#8A6V)'/O-XD2EO=EU%Y+7/4V [Q8#ZL>>N=,7FXG^#
M(&4+?F6OI [\/4RBP]6./V8XQR4#ZBQ.Y^ Q+ 92$?V/$X$@0G4P"_'H/?C^
MH9=OH;VM_0<93D^DQ.\<3U (L0L2H@!_.XC>],+&!9$ 5? *+ ?5@^[!<\L1
MRQMI=+$'N(P\TS:I&%O?C+8$U<66KI431Z^IIEY>[GW#F=@?W/*?\H2?SR?W
M'R?_ ,3Z7^>L[_V?'87-QD7E$GEK!1?AO*J'-%I&R%YS3"MIXY^"9US>/B</
M7IXG"35ST#!S[R<S1<Z7+@:@OD[567YQ3B-27F@I.(W$T+?^I:MZGYD+;Z:3
MR)\MZD35=1>')\]G;1//4+ZF7YB2 CS2"ZT]22)))0().+-(K8^_W]W/'^ZT
MY[E_X _W4?[H]8FJQG5ES#\(BE,7F_ ULXX3U/GH++>81*Y"I^X>2O\ AJK_
M -$7&5?X1SG^<9_ESW_E>4_Z?#CRO_PM1_Z'^SSS_E>4_P"GPX\K_P#"U'_H
M?\7JC,$T&NE_:^7QOR-0X_&$<RL"7D:W.P'7!9BTM14REW8^NTDC:F8^))WQ
M24-5&+I'HC8KN.6V"7/:VVZ=_P!_#'E5F997B:>*G5U("N\9DUV/> JM[I!;
M#P44"-K327;<]WNQQ&))I*M)N_2D@:)_AJ>,_#$573VJ4D741'OI/<<-'(I1
ME.ZGF#@)/=\OJ2L<Z7_%78#C*/H^T.HMUL159J:^&*'S.:4$[W!0Z"&Y,&U"
MWO[\*D=6LZ3HT@>)MBM^3#X]<4&6Y?7S1Q2S(IC/I(4B4ZI&X;AEV4'ISYX/
MT5O_ +,:<537V6GF)^$;8RK(\GC67.<P,[WD]2C@XC#CR#O]<H>0T;@ZA@U_
ME)Y19I-,=KP2V#NUR(X4*L3?DM[#;H,*WD[_ +IE%]2&<W5EY]I%2Q]VIAB;
M+<[HIHRL.M:SA<%7(91HD%@NI@?9%]M\: @O\ZV_OQ&X.X305[K&]_CJ.+BX
M/ACQQP- T2&TGCB"HI%(,GK[;<L.AWT/=3X$7M]E_CXXGR\+YU7"15RP27*1
MI(&XO$_M4! TIU,@'(6QQLTJYJN1S?2[>C7P2,61%%ME51;"W6PVQ2U>I&5A
MVM=MCU&.)!IT,@/8Y=,.*HGAL+$=^^&DBG1;V-B1W[C'H?Q1Y86)CL6 O[SC
MS*D05-5HU278"*#;M<5[@7!&XU*/''G.99[3T<;'T=)331]A3ZNMD.GB>!U:
M.C;G$=12YHN8Y=Q%2J5WUF-7*IKV8C\Y=.]KWQ"\,J3QS1K*KQFZV8#KC+W
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M+?#>_8J:',TOL)ET.?B$5O\ /./09=ET!Y-:1NU_*E?]6"IARR#5?TQWT?2
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M'J)6YZ1Z-!>VN63U447[77NQ2T (9XTU3R 6XD\AURMX]HZ5/S M@/W/*?\
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MO]&Q&GH+'KB3SFLBCFJ:N24J=5PJJL:7(!')-6Y'K8UT\T<R]\;AOLYCY;$
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M-Q<,.?=8XAKJ<VUBTL1]>"4>O$_=I:]C[2V/[KE/^4)/YY/]P0L38*"6)Y
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MY4WII&VUHVP'OOR^E=>HP,O0-4UTDT,ZT\>_#2-KL9F%^'V;V[+$W!%E[6.
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M@<;-X85'-E/ZEC6^"N:9_4SPD=N&G40JPL=F8EK@]UA^G$V65'9H\P8/05+
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M_:D/M,Y&VHM<GNZ8X4;:^]B>R@N+F_SN["4KJ"8TL-N?C@E1[6P'B;;#F3W
M8X]0G[>J -?7@IO:(=+_ ,(1S.W(?\9RG_*$G\\G^XAF65LBM.T)GH7/..M@
M[<!4\QJ8<)K<UD(Q)#*I26)VCD0\U=&*L".A# CX7P]-_P#$(\)MW2*5/V7_
M $]-ZWR)SIEAKJ>27S5V[)=78R05$+FUY$=KZ0.U&4&[%L57D_F]FK\E<+K_
M /B:,_BI+'J R_\ -E+[WP'IT=+CM"]QJZV^6I:/;SBGIJAQ]-DT-\6T:SXF
M_,XJ\XF4KYT/-J8':\*L'DD_(=]-CUX=\*HYL=OB;#%-+)*K/.NHQCFOWO\
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MKA/+SRZIJFFRQ*Y*Z9JM&I7KI*8AJ:CHZ=@'6EB*H"38"*/3U& JBRJ %'0
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MZO-*Y:_SAOI!]P&"]+75=+"W[SV) G@CR*7_ )1;!BI0Q9[&6:0ZI96'SB+
M#?90 !<[?_VKO__$ "X0 0 " @(! P(%!0$! 0$   $1(0 Q05%A<8'PD:$0
ML<'1X2 P4&#Q<$" L/_:  @! 0 !/R'_ /A5R_'^,G$CHUONA?$B<X)%&9Z
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M20XT?)V1$X9_VF]T/#=0^YO'3(/+'669ZE(XK-C:WM=8!SA#KQ#7K5X(H,<
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ME)J3>VMLEXSU TV&%G:^KTRIJ=AQ@!I%IJSUG"!$UO?$<S&LUAJ$OZL;8($
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M\<]#RI<># X*PHU/@C?0(-09?-,3[JCD/8</"O54P\E/"U21)DU05QI##Z*
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MG<$LNGNW->K(LT,(]!D^FL)#7A(D,_5(/G).&Y;4;V*F""'&QE)2(^C.!B3
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MA2.^%Q%V+E2U<BHG#%-Y<09=P=FL@*JJX+Q^WC#8V^,(_<P]#P;,003NX%P
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MM:Z3GF]-Y!2!CQE7(S0-X?,LV\P_\P=ZUDSZSOWR?S2=Q"%RD)$]B<G>RF)
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M4B"0E1A540)P"KG!FX6OYSB5(+Y+5'Z$G@,=5B)=8-Z>3<=1 6)H2@AXB"P
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M[8456I/,?QQZ[7/KCA1ZS>)@R$I8U36>+KZ?ZSRR7P5/)R BKQM5N*Z5(OU
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MI*.U[(LY-6=$328VU$83CV:]SD<Y=@DQ",8>@7>6=1_*>#T*_=O!RT*!5RC
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MD4FD\3)&F*DAC4(;Y+G031@2#!"!+_4G$3\R>DT/M/[7E/R"3 A.!!GN?/\
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M+(HF\G"CVE*UPQQYC.3'2#,D*8@2,HP4Z2N6(G7ZF84V 01HR'W?GODPD?4
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M*8<9FH8:X,_5O/J?EUQ^*F%!MGBD9 !X&D, (?&PMC8J(F1409C#%#6NFR%
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M-TCH=MP/Z/;/;.!>=$Z<MMPD<=$H8$L\D/;+W-X H>E$]S6HJ<IK&V;%"4Z
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M "0;N(=;\L[<U]7!B-O)2B^R<"J&%E45G,]!#DX853J\5'I#X^2X@S<X?O\
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MN9*)Y--H$:J<%"Z20$B/RY_R;Q\_;.N5KL)).8-,*P9@>@NAM\03KCSB$)
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M4 0$L2N&U9F<)0B#   'XP=F/%J>4-P.O)#1B]>D398YIAJ+#K(?5/!4
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MD7QZ8BZ^>&)6IUV/VCUR4<&Z23GYO)Q.\XH]C]F)\V16\FT8:(O3RFKXYR9
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M,DK7 &A U?&%I"2<O:_O@GUHEV=H"0@1GTR&>"A8VRW_ (I(&P."W0 =M8_
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M##4J2\-U6P 7\""!(;SG-R%3MO4KO@@B( O7VIJHP41P,90UL,V&#E:QD!A
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M;I/!2H:*W6O?!IW@R_<$B/3",&9^?4R2;)T<XKZ2DR$3ZH^HF". /1J>6?\
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MD7MHAMGBEN5^ J0IJ48!);8X<Z(^C\X-CVQ,_%*@8+4+(QN$]IA)$3V5$T)
M160R+N) NA,:'E8!4H_8X(T.DT&,DY4X5,!$JFB.?4S3Z?E_N?,ZU9#,G)AI
MM1 1=MR]0<F3S?PR"#8/O3[=Y8^YHEEJ[>16.:T5,Q^=">\IX0D<G41N!-_J
MXW";RP[$.B$AQHZ MYEIBWPE",E-%+1&2MHT#*(&!NUA8>8,HH%D7O#;$DZE
M.T%%@BX)A.LB(23V$0>25K%I!PH@=\)ND+&$V;2A1'7YX9 OE.M]\[P%\_\
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MO8I*2:(052I"RZTI*LBS*Q@-E(UBY?Y&K!09R# )G)))"&"4:26@(&%E(=E
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M*;]C?#QXQO[88-D&*V:+$3DA&<DY&"?=05)C155#I$! 1(90.<7"B;)NB]I
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M6CX=L0'RLF)H&T!I)K"!%,@Q<1"% 2PR!DH4,7WPH\@9(.SH&<'P")!2<GQ
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M3R=$F5"/,9?[62H:"=0[F%5@++ >*01^_IUA)^5)"2_,B6&JO-N'-%64DUB
MM$,.;[P$ MQMLAYP!"G+^/\ NYR5%'<?F?G6L@V2)S)94DZ;2S#&(6I@]T!I
M\?W5IV2@0;;>Z-8X_H3LR0*">=YJE_[[\\^^0EW2@EO02U1'.2PYDJF&W!VT
M]!A<?$8A\%Z-;!(+7,@9#$D2<!22SQ6'NDLD%NW"@,O\+@:<-&73MHXJ!"UL
MQ/3$G#H@R*>G^!42>6RG8PD$Y-]A!AM1IIBC@$*!WK:U]8@HCSD[)+<.7"PE
M6;O+3NA27 CLF,TG1!Q._)H&&5JN<<:LQS^BN;)E"=T5F3L(I4#.(:#<[9HE
M)1D5*#54GMO0NF.V9(=E4<*NF*##N5M/!%QT#HC!E"_0$1S%J+LIF!0$((B\
MD?X(/I V;X!SD3Y_DK!"GZ[R-8\AM-W)Q+1M2^D]$=6*"PB:PF*@B1&M*MES
M<*6S>TU7Z928]7SDQ)'P_H5]<GFPS1V:"T&3=P?4G]?]Q/RL*$$GP&1#]:O.
M8<.QFG$Q:%@IKT!QG22/,^/:7UP:>F%A'5%C5"4SXQ";+M'M+!,AX",V C7N
M*^Q#6L+@0&^H8#N0CCO')(5VE7 _6<")P@\^T(SS; *D0H $A4 ]"B/%5^!#
MMK  NOMA("($/0[90NO6,+^ .P2(,K/W([G*[KR@7\+A>/"7LPH4U!"5Q!E<
M<W(**3 RP]F\ACW# R@'"""+:P;R<FAW&D@%XHCI<R91$QXR/'QI0<F4)4+"
M8G"+']N8!0F:V9E#"YRRV7"E/;74C#+>X4'\5U52(0+FY7X$6.HD@<$1O$.7
M&HSACB;.1/4982LC15%R&E?:(9-^Y90Y+U(8;UCID3'3MQ8N!&KP.I>2-4;M
MFR>>,PKH%_4"L'@4QNEG: 5 I(K& !'AZ?/=9%N4GTR &IP(ZA,S"-KQ@?)L
M$/P]_P"PH)6#EZ.V:@YPV*A(TK0"F&9N1$F21L1I9L1J$R<&I["O.$:9#JWK
M1OOM@N)Q&! 7*O<L2")R8LYLE0H2VTE?44\#,AM.)6@QR9B$0)D321, K4)Y
MIY&=2X$O"DHEH=/ !=R7%UJ4<XP%06%AP[V9!0((; B048*0L@B2." T[:FQ
M#? 6A,98MPBDES/%.*C!A9A!$U:0+%8X*7(2?9UY/M@P*'D -6G?8^R/(^*8
M%Q 0+!O(&<X2E80:8TK-&&MJ"F9*!  S $L(\"9TO8T'H3-:OO"62JQG>4(@
M-Z;(A"(- H0@C0>#'IFM/KQ^7W<C?NSSH87EAWRQIZ8J$ 3H9Q*H(<XXH!,7
M2@GP 5LWN\!@/D66$DLR3,$3CX6%BH0;2%V<?#/0Q*1JQ9OHP"%-\O)XB1]1
M.I"T& ZQN[O\I^M8H!(2;\B@)\STP !P4>U?[B<H^B$_(..!U3^OOD<@U+VQ
MYWSCDQ=L5M?*1]8YQ@4N*(RX"@ '!@D%B>/5W 'GVR*#0NTNEAC7Z930WFA!
MHI4A0DL0?/K$3:)N52"PX7@'(\G%;;4""C)@P##&!PR5)WD,78_E^_)SB&/H
M-7F#\4$"Y8.#>'YY(I,^S]IKUYQ178(G+)?VPLTT@ C6(ZP01B%UR*R2-H21
MI(:C)T50 X3D9K T"M6A=,@EF04+.RD,@Q 0:[<7Y-)<F1Z="&\$E$(#8 VR
M-L:R]&S&ZUV2PE4"*9,5$$ZP4;$&"2BDXD?=?#=#5,[N,C^33":Q9T4-D<,.
M]"U(F48V)'<Y10(2"3* QLZB'GC(T4?LDA!,!$8IDV(M#%0(X0+F<#"/$8AB
M9-&5A%G&)6&/GZ^.L06#5]<$^";QC$?;P%?3"*@"U, '*M!ZXQ*2""_,I)S&
M0$_<,CF@Z8J-_P!<Z @0_  F(2$A$-Y"-ZRJVG;<]O/.431##^,0YJ 8*RX
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M70;L"(!K&,4& JE>""SNP*C 'T&BV4CI!EC4(*9A%GY B)"+.\'?3FDP00'
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MH-+"<>_[U\N-LY'@DUFW4*>!,:Q RA#JZ 65Q(F:FW2"A1K28AU<(VT^TG0
MB8!DJKSB6G91)$<<?:PVA$RN0! _7?\ 6]L:D:$L9-9@!0EI@[_,KK1^Z:WQ
ME7HHAV7R6P>7HA1ZY(1C8!."1_\ ;!D&1_DN7K/I#/3@2CC=@IBY<WE!+K^S
MB../WC(QSKS\^?ED[^1./6F">(DL;LF2^Y3]OVQU_'Y8\=&@2=<_GZJV,<<?
M@SU(UYT4B,#;GHD'3H,!$,*F@TTJP(F>2?:M8TFB#IB0)@2);,Z3)H>@@%DF
MS#A*/@))]LBM*R34]B;/=-\9S%_6\-D':VFTL&CGTR7O()0 7>EO,RX\G5OC
M5@HK$;&EM[T9"*-D0B]D%]_YZJ!&.BQQ!"]@$V0S.M3"@7*F6#"H18.08+8&
MXJ@&7%2I-*9RE%A9M!D-RP:;*VY4N7))5&0K*TMMMJQ"'1J:R/GVPSL!@P%E
M.R7$,&E2B'AD1@;%EK+^R_.:2,S :6S9R/N,S2*A!>!(_B1ZN33^2DCF9EX/
M6+<C !EG*SYXG^NVZZX$>#ZA2I#(&B3KK76HGO.L1N?K\A/IE!A&^_TQ!'5D
MS=$V5SA4[!0"9F*P]@!@59P04  4!QD82,P)+@MRHCGSE: J(V/LE3ZWDR3U
M_7\A^N"T*>6:+RO<4I=Y'OR8PZ$=5MX"5N0+!DOYQ[?D8J\7TAF,97$D%)(Z
MNR-2:K#U",-:=CO$5Z*<1X/!7"HE#> ,,_8PB"P!$:]&4P<5HNY1*9M5PZB"
MM7$I%W;*F(,TC%05H.>]\SBJ9A :$-OD7>1)(T>77ZR_3(D:"W#Z<,GH.?6@
M$,@!/+;-Y2CK(;?N_3G-D"LT9AT)*A[UC5+/"81Y'J&"U]IAC5;<C8D\_ECU
M4@ Y@[,=%NL,\.<@]D DXF#62C\QB1/2YU>$: #:2^G2OQ?^?; M^:) /01;
MUV9+T;B?H>2BOK@8#B$X 23=$$0 'RNB#78E")VB%B8F'<?IUPQZY*M#ROG.
M=8R4[**8 J*[0;K$P$TDV$)@*AB5=JI0GY_R6.IK)H7Y\V\\XN2!V>*(#HGV
M.=\(AX *1G1X1()(J8M6T ML27K)N#?.-"W"2$MM 9'U.^PIA[QI),(T.59T
M;,B4L\L1P1 )==<NTKLCG'YL'%>X(U+UF*C!:_9H0ED4=MC>*C.'8B5S+R()
MCF@5,3#=5#$U@ ^%6I_@::><<V6?W\X(/#9)B-@IKB@(VD;!CUI)KI[QZ>27
M/*9)YXR(2*H*ZX2[:*UD'Z@%@^E'=LK@J?%KO#W16- &%(X57V*OKD/A<#DT
MB5E]<LI3]A_W)\/;$U0!+@#K0FKQATZS!#)CRS^?]49&/S[>/GMA4^]PZIC0
M#PG 2'SY\O#\?SAK7O[B:8.,%\5*^)X%$@1>[N,E_/\ +]XN'TR=AN+@CLI+
MKV2YR%F@P)1RX/)1E&.PW'M$Q(Z%C$'&BVMB2IG,4K%(?WJ#A;].2IW;<+ C
ML'$ 3HP=.TH9T2.0D>IM6UT3 6>1(B=,T'5'S07_ !C!YG\'ZJN'$<_-1..H
MV3_";JM8M#$AOS8KLUG (K (>@>&B1K1C",:!;]%>K$3J!9 5/:JZ34HV;)*
MC )'\D^1O7904_&';=5K*[BL44GB/NFQ(-"33;"&DP7V"MC.HX]PDY_6_GTQ
MX\3\_+%6>6!_1 M;.:[.!""595JI S1!1$85>;J@C9%6NA*\8SPS)VFCQCC:
MEG0])S!#B94"9.@6#E D HB#5?\ W)BLCG-R CTB8KL1KYV1:]OK_0X$#(":
M4P+ E7U7EP0(1   % !1!CCIM5TF5$4652K./<8BH/.!CV(1D&P^:_C+^R4O
M3#"D@[B<-656D9I8^H89T4 'T(,"/P@^F%DM$$.Y,?;$YY*-;N>FUGN]X*.1
M00(Z%&1X^?/TZ,0]385%$6L/0Y7)41RM?)<(($J95)?Y"7*<+%Z!\2L"T6L3
MM7"*<J"P, 4  X_!Q8[I4CM=)&UR&!W)*B& "0!C8 UBA/GI/%K#<0(FMY*,
M9/F]??,_GD<?2#K\L/[$?D)A1Y2-C3T^6"4D*V*2H?/?.;!?X]\A32BTY@[:
M?1GSY]/Z"*+&*UAYGO4]@P]](^J'ZX#BVR,IZ'5CZKB.R#"+<5;E%=2>9_YE
M6PF%#P6!W.&=E*A)7+'@'33 @Q#)P0$KG))H:E9-_P#_ %>EQI;B] &$<DP-
M0M;M$L'"(C(R&.,@D-3KK M4%/"G[?3!&'T$U&8E#5@R?30;L[>^.O3'[+%
M/H"+/CK.0"WQERB"5N 2JLU]/.AR@T<E1) <^!6'>/*92<,AS6)L)J4<WCU]
M +Y%0ZB",*9,5J"=K(X57.#[&Q*L[^2F_?$1JN*P9P_3$H[FS>@%ZEGP8&R\
M1'8/-;-V<'# C?H<!Z]_C,4;ACUB3)</U&-_I^P81=A?K@B-Z^W+A2]=93&O
MF2')S' X5P00OB MUXF8>2,EU-5&+*#L],@[RE!U58SL]L8=%-*#WZ7@C?MS
MK!++A[<U=*!5DEQT63CB2_8M.AEB5O! I:(AZPU1OTT5[=Y)5#06</KDR&YI
M@F"'@NM7K$.)YU(JI>: 5*9]OYWO].?&,A0!B DKHD)IH!8W19+$IJ@DA($>
M8*UG$H&6TF97:9Y1"%!10 \;]H\[1(GTF3ZQ-[RRS1;Y6)"A@A0L(["K)3JR
M2B9HCTP4%0KJ):PJ>#]N?6#%-#B(94\ZD!2$P'X,;Z\3\WG%SH9=&;C,98UA
M-P*!BB4<:8*=8H%3,[%CXOU,M!'CQZ^N1.2!2ND OIZQDUK:"U!TM5H;B;_L
M[Q>1? WK];'G"OQ<FCC*AQI3HXKSB1C2OS$2A%BI=%?@HD BES="2"A2D[RZ
M<FU-Q/(=Z3YWD!B B2)#6QW,Y_TWX^<Y\-]\> )$^@,.?P<'*\# Z#(GB(PV
M/1@_6C3R]48*$8BF]5%<9!E)I@+Z$#U')3O)Z6'YKF=SMQ&BTJ>JI)@UD31T
MV((YD#2D$T0-HGBFCA!1.BC*R,%Y*VUO03S%O.)G01)1M)#'2;:\895X Z)4
ME%W.\[Z8H>250N9HZ,-AH&H0 ,-&C( Z/\!']R/PC^Q']$?C&1^$?VP"1)0=
M(['L>3G&6:VIJILIV$:086DRWB$F(#TF=W.!U(6:.TXE,($F/Z'7R,G,'<["
MP;0N$-FL(!=KUVJ_>'!^N!4YUVH%I/9D3*V8>Y=#QUC$"%=^#_N)^A!_.&E.
MA$E&'@-S]-+D=D@EYHB?%!N\17-D(B2) 22"(P6YY$<BQ2W);;!5*B4X>6+-
M"U+! $TL-M$AY"8Z2,IT:(0IZA;949.]9VYQ(W=G!L>5)AF.SOA[<14RW:#(
MX?\ $9>@PM!7@!SHC!CE-P5B$&G@B2V7@ISXDI>6Z19AIR3H\G/K>#L'6B01
M<J ^%762N4+DB%\BQ[9!OG!YPM5.FO4?-Y < P<NOUR(+B^<8 )8/0]1 TN7
MQD?T/SY\WB*B> ,QE$E@<,-A'0MTP R;CS%QE\V/0LX4T^.N, \JMW[)?_7M
MR]QSS\,9D4X3(9QFQ("V^OVB7A(R+ZV+)-W!$@(N?#.$$);Z(#10E,,8K(#K
M $*;%1K*@D:$(AD'92PC5*"G"\#'<)]&1R!\@19@>KD#S41K(<'<\PKQ&/#L
M4@L#Z&F5G,I)(4I10T>Q1:<DI@I%_7VP+9!WI7#GT=W"]=30XGSX"I1Y9UL9
M6RJM$S"]G@Q0J+LZTE(OA@;/R1[2UC<*0V,*FA*;US@<E.1D^1@FX0V)5"QT
MQO>3!FRB/32^OOED*7K]'2)T\Q@#@H*T'UW[_P!$\)0HI,<$$8@S-:<T=_/V
MB^>\!B(\Q]_KWWC:1"W+#@G<IXPCCC_G\?\ P1_8C(_HC(_KC(_I@R/]3 Y8
M)W&%/1OVQ%%8#)B/;+?IA=DVGY\\8"?=<5'IS.:N#*%1)."9!JC 2($9P:<.
M?/VFL?J89+W4+1/O'UQ%)@E_8$Q'9V@%3O&RE0+3<#,E&6DET&60@<V[D!$%
MX9;X+25@<) *$B# *S:RA-\FUD7UQ MD-B]=+GE*R'$+";2VS2@EE 0'%(GL
M.:^2@-)6-&7&BGL.0@DIG6$HZ#Y7!&E)/1QJPMW-NVY5*<_.B":Z=H>M<%YN
MZ(AOFH]6HXG&@^=@2*1!:+66)A!@BH9BIY]8\X3(#L_[QB1(=?#\O?-NZ=R!
M]5UZ9?GCLN2MVQE5<. P=2!X >TO-_U1A@Q0]0I!8S2"I;F@B&D>@-;+'M,T
M8ZB0?#$/U1V6X])XP]2E-J5^N J[%)Q-V1<4>N(FRRHXQY,*9%*\+>)O>,$I
M5"9J+F=#3O=XP+74R@<K0"U%3%< $EQ8@9#+84\!,CU!PCA[;)3C]LEF1/0I
M(GH4XVSNT D0:!V L<H&2DEE@2Z44LA2&*)Z!/"Z,#?Y)"99BZ#>4SFGLE$8
M:'^M!/$V%%("#FIT170N$:(-CV9.R"ZW&7(1(*4.H!2 *B.(8%Q$0&0&*;36
M0#GQTG7UO+Z)G;K;'M7OE"222I(D,(Q%,.M<NF%N<I:7U7/<,F-K0%L-@*HX
MS"3$@XCXWX/ ?(_2/Z)X/C"VHA"$^XUEB[70C;J)2O@!S&<!$JBLDE4)P(9I
M\L2X!!P!<JO_ (!IQ!NU-EZ<8JD0?KD(" TJ=Y"-Y;'T,E!-V9-8J06H@5,0
M._K:,A707(+1&1'X1M(0#7@>3(=@A,[AH4R1$,GU9'V(<L +FLD"CX<YG,:0
MC'  =2L!CX)+JN!V;P=9WE!S'JT:(UCL9$P+VTDF.:LPY"&EH1.AL#$F,M.Y
M .J!4!J*&#$DX\-T-PBD&"02V!.+@3I[U,\S= ^50<IU$-3M#&_8C!M*D=UN
M53 6,:,H*E&:VXAINKPNC(XE$ )Z/$N.S9!G;E-K<=M+OC$730QL*(6E2T9-
M9SM8IY F42B3DDD=#(122$1LP[9 84<L;>67^P)/K?7$SQ2Y5PA %P*(SR!G
MY !K3'V*/3SX<%:[FWYEF=X"N(@DWBU /M#26:PEW6XSH &PF\ C")52[28-
MZA1K%#@S" 3Z2XQ %X<'.WG<=<87<<@:Q)BALL,"3).4Y6XY;5+CTPV6T4P%
MDY24 '4YHAR,2(S1EE":A+,FF;FQ)F])+H9'JLIT1>$<&X1)-E8:$QD=T2*:
M6/A<!QGG0FT&R*H(V$#+P-3'/B_7?PR :-95#C:P>R$3D<'*6"$@HP22M#R'
M4UY;^N!J*+@^_B/?)A&E"R]D.G;=P&813F@$(#+(:5=>HX\<>B(.,-[AJDTS
M\O&LRVRP7EA$6H$=?U0?^!0*XH6[01-8$&"LFMSZ'J8P]\U3C',^$Q..A<2@
M"NC<(D&KUX$>0/UR; ;*&=S@I$CO(<4;_P %#6:L%KD#6]7) :T>D%)R 31#
MQ]#@H_3*8@^[J3NXKGC.F!!SCJI9).H8,  CP?3]LC(M=A$J@?K+U9G2LNIF
MB/6C+IV48G&KRN4H5/IOW]LW5H37D]\8WQ$(XOC]<]@,""#KC\J7ZD<X'FT
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MS*+2+028>D?T1^"U FA=MW/E''6'3 LR8FLLOC-%S&2 R21".E74)8V3E[+
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MR.-(?0Y#4 K=NG=T28I,;]L%;4SP@F&=BM%ZI"4^4D*1V(Y 4 11'!U@1_6
M@ @$AJ$9$>G%G\J:F6QS-C7<D07(  CNZ*O87T/_ !^$]C>[Q[@P:1&?8"/5
MPPI %Y7QG*X2L$7YJ!'N\G)TDS4L/ KR#FX7E@ 341M\$^8Y-D"Z57N]6YZT
M;8&L4T8! MB7$2B79JFR0%=9+L!JC*<(";+)K=9.TE%"Y&F2C* %-BDQYC:/
MU<?@O%7 C^H1D.MR 5,L054@2  0X!$7X0!QZZ%_Z_J8ZCS2EH*'&D0$=<9
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M!R)XQ,$.1W&W94M522()*R?%@# 27N0^\D@LP-<V-$$RH[>:*W@=)$Y9&'H
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MP1-&0)]"CVS[9';S)FV*2+63"2P#,ET(F[!%!*O,W9 $2SDL9-1+I^$([:)
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MA_+IP-730)N5 XI8G]8!2ME:EAXMH9N]*2C5Y61GAA<"5,AY>P6Q- HJ1!/
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M$],>,"S0]&FB"UV*BKK+4+N]+?7<MBQTK".+W/[F<=3.#[MPC3%$P5]6G3T
M):W+NYXC ':?/!SGDS#?/"5)RI&HYR=4;(9H( #WT-&#'8<WS,K*7V=DQEVG
M S5&U;BD#<Q$4=G,1A<D&/+>-R:&IC*C2?PXTQ%@0SON7NG%5>0@ 3X-/&CC
M%0^1H-UR$H\A1J<^W'[%"UP%$QR!6>240@8D3EB#0,3S2P.9V#O93_J"#39R
M.F1(R-Y+0PS%X\HAQ7;VR![V2ZA)]0ZQU@3A!O$(%0)P8,&PH4D%;,84?7@)
M YHAO25X]?&7SM!3HW:9\,QR5I1# /($_-M^920^CZ6'0PM62S!@J2N$!SV_
MJG88@N@&P<F":4)/.IR^M@ZGPN])XR9EU@/U";;X]W X>-Y6Y^^^\&/UQPRW
MQ1$[^N216JZ)=<.'(5JD*? 0"9*^/.!&D(C2K??M9 *YYIHO4$]CD8XE4810
MRR8U%/&%O':)_@"T_"C( ..R?($>YW8")- X&*.:=&R2&;A17,BBF%*I(#$'
M(FSJ1D8 "L&0)@<6:/82\A6;D6($8MI()G9BF=>BG9$M+(*/"=0I-P!,5A11
MWG2QU^@XWA= $M=#X:!' _J^9[_[\;)T,H"T, $Z EAC?<=\7_U]6P*1!9=
M>)\9HI9FQ?NM,\># 4(93!?0#F! VR$'3DC+D9<4@)S5RF-\J"4*->+H[U+S
M LHGP_EA[D>D+ F,?(CO(\ :/9'S9]&-GLD .I3)=\-5CP-!B>2[%59<D""/
M)/4@%ZGF7%12+*N?O,JV\49=.Y.L@37B$$6"$DS8<T"2AO4P'%2$S$KZ)+E
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M7\0. 3NG,I&TXFM"Y$Q4OA@V?4XGC=.3$J9$2D<ABU"+&H01 =(C7];YGO\
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M/%27FD?3&^HY$AYU$KP2%/HQER3I(U62H+F+T6G8+J>X-%L:+B1NM#]PX(D
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MXW)@YHO5G[LBZ0O,@2&JT&+&>^7U$ G"S4_CTNRF 6Y9W:X9-9M>Z%@:>5#
MU!S$H(9#D9U-30!"K8IAAC _P[UF$4Y"P$(&5<3>ND=E0=6N<!A$E<_X:""%
M&3 E]B=E08@R&X87N'TA QGL$BI%X>CGP2T%)T(1Z,I$;VIE53\0FZH(8!AR
M[.,%+8R,>?$P(U0P*6IN@$& ']E@O$((ACF:X:@]%\P2EAF1)SF B?$48JFX
M&#Y'IMX*R=1&S1*JK' Q+!.IT6M&O]6F],&8D.E<FI!)&*7" AE'G@;Z\RW
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M?%D40AMV3--)# T;/46A=0W7I9.=!>":I0INHSI )%A@<0E'P;UDL ,HX#G
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MV[K+F0-X44_4]S![#[5\/IA8\52>MT!,45-<X>8P&O2D2FQ;#<U07+!#$I(
MH!;B!;N.!$Y#B$!I9'(Y!'W^VOA7!D=D(LE)'2?9Z.04BL*,(E-P@MD)J;QU
MY;*IT53?*JR:[Q0$AE6<I&%-J<XR%DI.%P1"4& JSH!+IIK<'0&!$[L.JZ>0
M&DW"\]]8E(.B$FH!V,A-0>4U%FC,+ZHT&&W#$4)#H/3%ERPA&TUX)Q&N,.O"
MX*3%1# G364_/>GDZH8O2?V/F>_]A^?/GTG#SM4Z$%+D0B"Z5)0I]6V; 4_A
M!0?B&>&461GJ"&HC3&OM-44Y$:$65BJ4KCLYF?U3E87AH"4Q(%8R<DY)B2@"
M>EDQ@MYEFB2YB3!!F!P_,O/W7GK'#!'$S;2U4_6<.J75<8.IC+<.<E [D,TF
M2C),4E"2E"DDHI]0-#=5;3Y=><@U6'$< I!@I$ H6%\]Z_-KEO.7>%4B@TH2
M=AV.'/44G%AO!D%0%EP,'D(?QA4')A(2Q+:0(2D4Y;E=U,8H,($,=,-[8N7:
MH)A G,MV4FQV@S JY%01B-9$A+5L-1 A_P!W6&,"5B(JN/<9OP!GNDH2(FE_
MB.U"HDT#<DC?A*K)B0-A3!$*<$43/8,7HLW:*KZNYV=W?+M<:6A-V@)\LZ1H
M^?GT>EW_ *J:('$KL4H,<0Z:478\Q\]XC(\V 9%&JADYUQW[^,WB7 A HF-R
M046V? ]SW2L[L]HYG""(66F\G\_7G)>U4A-C37$A7.&WD)8(*==)0E(9+EP[
M 02%LEFTE5@8AAJ: ;8E-XVL8_D_!4DB'MA]TD2I#9M+P;<)P#X?KFM7N$[:
MN8[?;(*0.K6[;/?)O_"Z@(B;:\.'#ZG"-LT\V!!8S@!QVNMIVMV)V:K>%3<7
M&OK]YXC!V@0OT#*.,RIQFH\_/'KKLUB0OB$QB3702/H<3'3<-#I)S<OD80>D
M _!.P]/7", " 1'2(LG3IX_MOSYW.7\_*?V/Z+JBZ[T34I@BFVS@RA#C03]"
M7Y1!2 4Q"@*OY_.21D::45EN5#+*Q8!X=AFH5;(8[]82U&-R!685>8XLGJ#)
M#W;U5X!!2F%^^35<DXFB5$4;.(U.4$$0:DA%B,A[\9O%'<&G)(.TH(22S@.B
M99&!BZIH<BI37,JE; :Z$G(Y@AZA-:L4[1&IR,NT/F9N-;9]HU63*<H8]2V#
MUVRWDP\1[9RKP?K@\R@\P.O35:H=@Y-"(U1-V4^LO)7^Q\SW_LP?/?[LLNWG
M^A!V#Z^D?DIZ9\^?*XR/ZX/GSQD'XP?/GC(R#\8_HC(^?;(^?/DWO(R/P@R#
MY]/K'/\ JT ^)"9@LY" U)=97=:M>AS7F\"(0)[1X^F$T6P\:_,UZSD#&@D3
MJ(F\HHU3>/W*BJ7YTFN:C(Q1HDZ4)LE,&#4I^X265;3&$S7!@RQ'4$O:64BI
M#"  68+"2I4H@6%0V'#IL !"TX,'(#6Y)H_/QU@)R\ KR (;];K+3M+#/:W
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MI#4E67;7S<HRO-BA_%%28"//(YG8,LT*$2R+.'P*@7)7.9+G^P^^;1"SZ]Q
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MI*_]!QXMH4 ]MP!48<RY6Q9U8'@N4(%@WB^KBHD4;Z7$Q<[5(0%NQS"Y:E!
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M[=+E@1?+">AX4XN9N,7.K9SSB2S8,3TO;?GA%]$H618YP!5ECG)]T5R!V )
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M2386F#,4QUU$0V4;8C*J#%8M8W>&,.#>+#9AM^.- TZUOS@ZKRF(&MWY^SC
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M3,("6@ZE.=)(W1%; B0%P6*)I"!,TDEEG&\A]U$HR,OEYCM,M!T"1:V@I Y
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M@AIXSV)#2WN2-9G39/& *PCA5I<9J\K+M9'$M.HA& L6R#-9T$3S)."B'B.
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M@HCP9SZS&@!E#)<DF"B2'A%;)+X^N6%P^YE@)*<0/#BQ[1-$E30"7R2_ Q9
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MF0C#Q@ 1!8$0%-&3*9/Q!U8A$!%7PD7B9+PAIB*F.A0G)R0#&/'0TW"*(""
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M%FI"@A5;63-%K,-+L"A)%Q 2-R(9BK!@Z^%"@1<$1W%H.8_^C^/_  -)/O\
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MOX1;F(K8X >64F)%!44N)N\(Q(*\$$JR?UJ; TV>;_/(/U_O.,"V2B1.PO\
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ML6>2(!$+4L  M?J#\HA !+S0'_H,'X0?_NO_V@ , P$  @ #    $
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                      M4.                                (
M
M,58(                              !C@
M                                  "N#6XN$,
M           !Q@1'F1@Q@
M           !P*NBW[/$@                            !O[7(CI%J0
M                                                 !.VX+C-3\
M                            'K7P+-J70
M                           !Y#@<S-"8
M      C#83PV.'@
M     9"00%]5/*!D@@                         !C@'YF]_,P
M                                          ! -F8M_P!",O=J0
M                       %B M,FK!(
M                     *<]9]^G?NRTR)9(                     8(?
M#]-ABN@[X\X                                                2
M*?"@"U7/#;$EL                      ,Y1Z+1_K&%*1K
M                                   $/[057[9P"AQ@":/
M             <+:G$5D(R:@S,OP8
M             .XC@7)ZN1UFEFAWD                      4+%>H ;;&
MFCXDWC0                                          !1,B[=@6NGC
MC*[#P=P                      "#0\1-@\!'VEX1?*8
M                           # ^"8X!LOW#SE8K^&B
M       !(*5B.IB>&B7*^1:G
M     (.]FKER22%W#5G.&NGH                     1'I?1>M)?HG>F:+
M8>\                                         &K;9,.?$$*"2Y,SX
MZ                      'Z0WDW#9)*(#0L<TS
M                     !;U=U1/<LG'+-7HOG;0
M /U'VF?J8XLY/F'TU1D                                        "
M+? Y?L2]W8C1A[2=8                      $,P'KB,K(MP^BZM24T
M                                      Z[;$#\LD:FYB)1Q((
M                 '=D(T\PHVSM5(N?,!U
M               8/^TTXGMO%QZBISA                          .!&
M $:%];4;<.RM!(                                       #OS +(B
M\M!";RR=[8                         3@"*ES[)S'$M73A?H
M                               ="*3;K6297VU3'X1
M             1A8$XA#T0;C)Z,500
M        "95<'G!4\W"Q.*=-\(                        ( RD*["-WV
M.OEA4O>0                                      "9K&* CO!Q0G<6
MM*"A                        (4ATG&Q(U2I:>C,;!8
M                          H7D!AVUO21$G0HT!X
M      ;+KS#Z4O\ &JF%G0YKD
M    $P"_?@D3HI+.>@_OYB                       &TT6DFCGG "VM!M
MP\%                                       #& -%E)CN]VH=UP9X.
M                       'TR39FX!,5F.;[@DD&
M                       7\\)@3V/&;L+FSR
M #_U8(J0-*256W=#
M %\.(FG%[&&[N*:C                       %H;'))P8KR9(+^/*
M                                     #VLGI8?-A$0<9SZ)
M                 "YORI4]4Z1:?^$A)
M                J=73KDN#]X%0UO0C                       'AX(*
MV6'B]0/*_FT                                           M%+$?Z
M8#W(92YNZ                        &QM4#1-&LDI%$NU7@
M                                4J^E _2\XP<VZ:4
M            TR6[![Y:<&W5A"R
M          %&]_*@L$!1FNL9S                         "2!9*354X=
M,8T#@                      #.M(Z5%@Z%A# II$@U>60& LV;)U[Z6)R
MD*F                         "N.%D\K<UK\8FM!"=1!W_P"?ZFP '1J,
M[)$20 !'IC]982CSR0'W[\]Y]/< 7&GQN$DUL"8K=S
M        OCA".!P"UU#N)W!C)YFQT2_C0(;X]U99]2P  =E%=0/Z7*>P:!B"
M$/GPX1G?,%_2"=-00MCKP                        !0ZB'K("6OF.'4"
M0]$OJE3 BX1$LV!0<\9R   5]#Y0XD7A>PW]MS7'370 @@(P$W7OT)^\T_@
M                       !^(#:F#T-UNJ80 @7@'#)RH M JDQ4MBJDN
M 6G-4GL[B#P1>3];4[-3NP !/@3!*-4 +FGKP@
M  T;]VBU)_B8=V%$1-'P[M/DI3Q9&K[2ZI/&P !)-P,_,*^;P 7>H!(8$E^0
M    MI_,M57%"CP                        !P1.8E%P"V'8$  !/P@OX
M\1E-PX58.G3:&1P  ,W!MTE.OPK :]N32],/Y      66N%Z\-F>.
M                 *%8J=//#HXJT @ !$Q7R)<F\A0J:0LB\E)(
M                   !S8CI?[VWX=:                        >S F8
M9-T_TA@                                                  !V.
MZ#-L G%8Y                        N)9)A:GZI3N
M                                   !WE'Z<( \Y1
M           L'!^+ ;8VU>@
M             !-X/T"5\@;00                        )>#?[F5R1C1
M@                                                   ,=FD&0C\
M@                           TWXUE<:#4P
M                              ,X-XW5C; @I80@
M   A6 AMQ47TW<BT
M          !2=KH, !$Y\P                  !N @  )>=JNI%@
M                                                 )PVL]@-53N4
M@                 !V%D@!HI!79P6@
M                          !:KEP@%07K]8P                  @5G
M !+,^C:
M    !- \1+*%6PGPD0               %"''B1OHHM;C
M                                           9&L)/AN1&[QV
M          !)CPH0?XZIC0H
M                     !.-QH?=S2A?F@              !9ESU!S8C$)O
M<                                                          $
MZ*L5(E%M^,$@               >TN;K -XUFF
M                                   !-8U[F(.P;O#]0@
M    !E+0>0'%(#CHF@
M             (_R\D,[ULT%YU@                -Y]DI6R#S&O8@
M                                                   (4 &^.UY*
M8O<&DD@               -C1+8L4N)K34
M                             (=PD5".^*&6C2DS               ,
M*Y'H*>EYE/$F@
M        JK.*W*"]K*!4HN7            D C-R)V,=5J0'0W
M                                              I &1\H</#FFH8<
MC8@          LCK+] !<#"ZK!_H
M                        +DN7<@<W?%\ES^(G          =<.^3=![9@
MTP.8@8
M  -4D5@/.S1:'SQ0Y:H         &UAIY7$SB*!WE7,
M                                        CXU#@<!+0SIK!K-!*
M     IB%$G9@<TA"6()#OP
M                  ,1>!(M- DZGQ&R]!L        L,2!$_8'@LQ7:-!:P
M                                                        H%WK
MC\;^X'=1= QEJ        8:'_)-1H9G^ ;@Y\P
M                                 !D,P5(XP:.I@_N4CDQ        L
M&>Y*RLMO1K1PH[B@
M           !''W:)4'>J1%<JO.!2'@     DTK!,$HBL&U7^4&C0P
M                                                 !)8'LUIJ9)G
M]](B$VE;X@   ! %A!SIZLE"ZLLJI%8L
M                           !HB%.@XSI^VHH/-X$P9XH@  %_>MS"@"4
M"/PY -&@;^P
M     !7;YDO\5RRM0.XB_/M_MXH !*G5<P/(_750V5+.R.$X@
M                                           AREJ>6QO,!!+M*;V/
MXV-Q8I$<-[3\SK=;(_?3RRWTHI
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M8=,N\-%R2C;/]J0  K6C(HY!Y5Q0MO0*</$@J =L*'?G638'ZH^]'2Q.U70
MMQS)3<M4%P?$ YIE@[K@             '/ -HV?#G-GH'S_ +"]DD  (JIY
MG5(\U@%^/AM,@)^29BAP][& 9"TD*KL>!NA#0 "#ND8S2\4 ,6S25]2LP-D
M            +7C1Z$[ASM%;Y-)!RO\ #   8YUUB"0?:!C>E&<N&*GUK=[@
M6JS+AZ=H3]%WV4)( '"3,L-V*1&>/%ZWG5NV[B             $[_&7E[>7
M'))\V5QX-L   ",+0 TA4*]!Y65;/,SG5 /*[F<2#OK6&EL\N4_R:0 !@I%G
MUTT1/OM6HTEXT WS             "6'NIR3>0K;$46=0/09B  "LX4 ;!:N
MF++.VTG5 1Y"I:*ZFP[D:MPM(W[GN])8 !/P9^W4A]-9#Q;WJ]ZN'*
M        &4$HS2/=4.[Q@J-"*X'   0VX @G/=@'=76GHR) ."2V7%D3Q'&L
MY@R!>T2(]P  #G$ D]JK)9!LSWI=2'B*               @"^'Z7\FA2D/6
M0$-F,    P "L!>-,EZFR_6E6<7 0QO/$DVJ93AR3P]0< ^0  !;I".2V9SD
M" A#L\K,&@                                    "&P"$OA&.C)F'6
M)<*@  FQ'FFMZNY7>W!S; '"2
M                         " "LXWJ*T<$)&&*EJ " 6[1J:VR^PLKV'!@
M 2P
M      W"@"Q$\WO_ -N-0   (V&O<0#FXV-SR'P
M                                             % %96, "Z2S'? (
M( A $Z-8_5X14G?-@
M                         !YWL  JM2@H  (  !".JH#@C$1,$D
M
M   L%X@@A%#62Q!!) (!?EAIYP'(Y<0 @
M                                                -H 29!!((('2
MNC&  !))@
M                          $Y +)))())48OL    ! @
M
M    !(P!  !!!)  *
M                                           /61( ((!(!/$
M
M              !      !IH!1(() !HK
M                                                  !! (     !
M4A!0!! ;9%0
M                             !!)      )1 ()!)8*+
M
M      !)()      "0 ! ( *)I(   !)   (
M                                             !  (  !!) (!))(
M( ) !
M                      !! )(( !   ))!((!((((   !(   !
M
M  !))! )(()(!(!! )()(!
M                                      )))  ( !((()(!()())!!)
M
M              !!)))! ( (!( !) )( ) ! (
M                                                    (!((! !
M! ) !) ((   )(!(
M                              ((( (!)(( (!!!)  ))!!)!
M
M        ())()! )))(( !((( !(!!!))
M                                               ()))!!    ((!
M !()()! !!
M                      ( ) !  ! ! ( ) )((! !  ) (
M                                                           !
M ())(! ) (!(!   )!)!! ( !)  )(
M                                      )( (((!  )!!(  ((!) ()
M   (() )
M               !( !()! ))( !!   (!((!!! !))  (
M                                                    !)! !!(!
M ))(!(  ! ()(!()((())!!
M                              !(    )) ) !(      )()!! ))!!
M(!
M       !   !(()!)!   )(  (!(  ( !)) )!)!
M                                              )!  ))!!!  ())
M)  )  )))!)    (!(
M                       !)! ))(!()(!(!!(  !! )!  ) ()!  !
M
M  ))!!)()!)()()      )!)!((()(( !)
M                                        ()!!!))!( )!      )
M)!!( !!(() )
M                 !( !))!!!((( ()    ( )(!) ) (!)
M                                                         ( !
M      !)     (())))  ) !)) !
M                                   !( !! !))!((!   !()(!!  )
M))(( (               !(
M            (  !()((())))       ))  ( ((! ((       (!)  ( !)
M(    (                                            ))! !!!)!(
M)         )( !  ))   (       !((( !  !(  )()!!!(
M                             (!)())  ))!        ! ( )!!! !!
M       (!!(() !(((  ( ))
M        )    ( )!(        !!! ( )!()(        )!   )!( ! ))((
M! !(                                          ! !) (! (
M    !!!((!!! )!        )!!! )) )!)!((! )
M                       ))))))(  !          ))(!!()( !
M ( (! (((!)(  (!((
M () ) (!)!)(!      !!()() ( ()((        (!)( !()!!)))))((
M                                       !!(!  !!(!(!)(   ) (
M! !!! !(((
M                 ( !!()( !) ) ) !() )(())) ((! (  !)) (
M                                                       (! !)
M! !   ) !(((()(()()!) (!((  !  )(()(!    (!)   )
M                                  ! ((!))!   )(!!)()) ))!!)!
M)((   !(   !) !!(()(!(! )
M           !(!)((!!) !)!!!   ()(!))()!))(   !(   ))!!)()!!)
M((!(                                              )))(())) )
M)!!(!( )()!)(!) )     !(   )( )!! ! !))(!
M                            (!!!)) !)    (!(  )))   ) (!(
M!(   ))  )!!()!) ( (
M     !  (!!)!!( (!)) ((!)))  )) !(    !(   ( )!!!)(!!((( !
M                                            ) !)) ( !!(() )(
M!!!!)!(!(!!((   !(   ! ! (()) ())()
M                     ((!((!)!   !  (!!! !)!( )((!)    !(
M                                                           !
M !!  (!(!  (!) )!! !()!!(!      !(
M                                       !())! )!!! () ( ) !!
M(!)(!!    !(
M                (( (() ! ( !(() !  !!)(! !!     !(
M                                                          (!
M(!()) ) )( (!()!) ! ((    !(
M                                 !(!  )! (!!( ! () ))())!!(
M    !(
M             ))!)(!( )( !!!! ( ()!)))(    !(
M                                                 !)(  (!(()
M!!( )) )((( !((     !(
M                            )))) !))! !  ! (!!(! !( )     !(
M
M       ! ()!()!)!!))  )())!()))     !(
M                                             !(()())!(((! )
M!())))!)(     !(
M                       ! (((!))!(!)(()!)!!(( )(     !(
M
M !!) )! !!  !(()((((          !(
M                                        )!(() ((!! !) )(!
M        !(
M                 )))()! (    ) )  )!)         !(
M                                                        (!!
M(()( !!! !)! )          !(
M                                 ) (!   !))( ((( ()(
M  !(
M           !)!))() (   ! )))(           !(
M                                                  !()( ()()!
M))(! )!(          !(
M                              ((! ()(! (!((!            !(
M
M         ((!!!!(  !(!!(           !(
M                                       !       !(! (! )))!()
M            !(
M            ( )! !)) (     !!(!(!) !)             !(
M                                                 !) )!) !) )
M(  )!( )  )   (              )
M                             !!!! ) ))!  !( )!)  !(!
M  !))))
M      ! !)((!(!(!  ! (       ((          (   )
M                                               )!!!))()(
M      ())
M                      ))(  ())!(!(          !(!
M
M                      !(
M
M
M
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M:S65:==>D?/6@@1F8OLO%+*N]-Q#\?U2QGG;\<TAA\NDEM@=<S%&9/,^O_-
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M1=>&?'&*:2.I-BQ<W^F@[D>65=U@NM[$[4X)Q1TMF;0YVK06! TAF-+>#>C
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M%L?#VI!+20] L7V&.G>FF,I=N^311<EUNF\<588M-TWO/:/J*3.)C#,9S:*
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M&7'F(TFNP!GNUO,V;3US,>UZX/G\5"1VF2)GU*0(69X>68L,>2!!MC[=C:@
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M;!R+?&I'6)T2FBW@L#LAM9YXB*5L1 QWB7LYZYFL X^W^"!"R21/9H&EB,=
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MW2I=9[G[TV*2<X1SQG^^*",77GK]U-UL:1O.M!((9NEWOWC:G3K!DWACS^Z
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M04>DZ9H,>Q :HI$R#&6 6:BB$@JDK!L0L7R6'5(E1^PVKL2!<6+!&*$HJ:+
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MWUVB@8.6UQCI!J363,;V&LHWGT8R5(#77LOS0+8Z^EL?5 *AMJ\U>6UM.?\
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M:97N.??8I)#P!\Z3%0O")P_.U3HY]IM]=>UZG@&]Y>76E@QX[O-/*+[_ %1
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MOU/+^.*,X&FUWB\^U+-O7?U*BC49^Z,$[_4_]HI2&UX]OX29Z,%3&8OM+\U
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M>YM0+@IRFT>:4AB/(G\TJPVCOF.:(,M9MTY* N_WGFT>]&6=ON: ;ZZ[9I$
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MH" W^*[<M?F\Z2?-0"(F[WI0M[Z>]9Q8B+=9QYFD9B(S=:6;MG/UBM9+._\
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M_M/C^128U([5$K%UENY_E9S?L>:?S&.*52'&UCXH (+!_(!<MW?C%"E-?O\
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M !@D=L=Z0;- %B@"Q4$KOGM_, SK2S?^4FU!&/SGK2&7M;XH!<,?Q,QQ_P"
M1WY7Y_B GG-03.M3[8HH91C3XJ;!H8I!LT 6*@F8OO\ \MF[?)4&$_L_5"-R
MFA!,3Y\U#;QR[6BDXZ??8VK1W^OX5LOYWU#R*$S<6GM;<:19"(YG,\T[,Z1]
M[-$-RQ.N,\WGVH L5)KGVB*=2,;[VZQ[]J!2KMICYWIW'X^OJ>:4F7/G6L'X
M=HJ)D9M#'FY/>D+#.-';ZWI[A_5NEYIACR>:'J3S,?=3*,7ZEO?UUJ(EQMZZ
MS_X*R[Q/$1S>:F'.N^/X,L[?<T8A/2V,SI>G<FF;9-MXG6*8DD)8=R^3M:D(
MR;\<T$L]L<S23ESYLGM/-#U8XB?JFNR7XW\Q44L3O>/N@V#UZ[\4!4,S'OS/
M>)YIE&,ST];[T7)>^-](...2I)"R3.I[Z^O6],)+',3-GBT41':9-Y](B/X4
MQ.DWWFBSZ<9*""3?XHUGOF,=;T")=].>E%/7)ZZQWH1P_P""#DI5MIK:^.:E
M+3/3\]/2KB\S_P#@"#9ITHCUOGG3K0"P^W[J=S5FVW>M$7^;]J0@L=8_'I0G
M+&*X/?\ "E6&V^_L4P-RW$V]HZS:CQ"-[XSC.:A 6+/;%GF<4U9,<O-<7N_F
MIRWSO49D3FV-J"+>9U\L;5"J(F\>OG&U+A-KZ'Y/JHRB6WLO7SO.!!%6LWS'
MMPT17(YE='IM0)DQ%O7UW>>]1L8Y:"K8QFT[4 6/_%D$]8F,SZT"8GO:AB?P
M_=-)BWQYZE"M@YMM1UC?O;6U7)B<ZX&-M#?7FC.1M:77.:1JN:?V6I198^_:
MND,^,5(@L1.@YF@$;FOZH L40S?'W;3K1HH9\_ITM>H;Q,]ON*28B?0]IK.P
MM./OSBH"^F6WP4!1F,\6MY^Z!$Y)M?>CSH>V.+S2G>YIF@  P4PAZ<9GK2&4
MX^__ ,(0<E<7N_FD*):._P!U<2^W/6KFSKK]U!&GO/O4AI'3\TV8SDGJ9FHG
M%WG$=V9FA(V=.V] #),Z[YTF@"Q_&;M\E%8@W^J4,M$0SFT?=$2QG7S\=Z +
M'\(-XOYKOO2JW8]9UHW<Q/JUF[?)2E7S;_R0;-1E]B]O>@F"TYUWH&0:,=IX
M?FE3!:?,QZ>EL7O$9>\TX#.GJ:OXZUM>OR?5IH4QUQQ#KSW[4-%KNL\;33)"
M]K-GYM9-*0;$<3,V>;46?3C)48C7?]32KCOSIJFU>%_S16@F9.??KOVJ 7SY
M3X.2B1;XOY- B#[.]$JQ9';/SK3( W\XBE<[XQ>.YM0$*W\YC%7%XBD66T='
M(\U$^MLZ_P#X8 P]L[$X_@4,NOUGO06!SV_K%!0E!,Z/\$&S1$!$Y]9]L<$4
M!8Z$M %B@$8QRTS"&+RN](H+[&U0;%]<[O3]44C%KZ]3>F2,;9=Z)078?;%H
MO_ZJ9F\1'>?Q2 Z+_,:WU:*G;3F(^_72B-V=.('UI,CGC\TY4<'V$TV)-_/?
MUH#!$=:5<M2DACG.E6G9IM,[>7_@ QYG\M$A=L>U)F'3I]4FR[V^*D277F^.
MF*P5C0M\N:BN@C;7@?<CVH)(OQ<TZU (81KUYI;9/<_-3F$\\KIM1>!'G[M_
M^&E;#R"N+W/S2LS;'.] +A_G'Z?D^XII8\]SVS4;6ZDX]Z43>YI^YH+,&WW2
M9;1KUG2:"HR.'H3B@@L6/NA)2V/--J0&3(Q_[8R$F]OIH88S,_'TTLSY\E&!
M%STWZ^-+ NW^$B:SITFH (Q^_+]M/YLR=)^2K+"/-?SVKPM^:<F7;3KS2&=W
M7]?QB[_#6+O\O_X@A93W:XO=_- $P9[_ #_YJY/=\_<5-"-9^7T^J"(#W:!H
MQCN7JS$V[4DL=OND,%OTY],5!C7SSY_]$EC$Q]T[6>P1ZT8Y$QX=6D*+-]>F
M?JN8]#S2A F'FU,+ ]\^N*7[%OS2R)QO'[J<@B(U.=VE7/GGYW_F"9B_A6?X
M0;-9(M$?6]0S,VVC[JZ#??2: ,'_ ./8N_P_QF[?!_ IAJ4Q-^G?:E7+_P"F
MD3C[I0RT&&&UIMZ:4LJ[U#7;VNF9UJ6;>>;9LYI1LF_Y,SP:&,4,)MZL9V;T
M%R9-$G1UMU2@"Q7U_F'T:ZO;]T'V?_Q\81VJ5D67\[UDGRW\P3,7\/\ U%,/
M\2W-\]OX=T6Q][TQ/8+&I?\ _+G0.W1)737VJ!(QY^/?_P"35V^Z5XYGT#\_
M_EPKAB@D+&(YF?US1(@B9^9^X]*)EG%H^_\ X46[/,!&?6@!\OZOO3(S/_Y?
M,(3"X[<UZ:(XG.T]Z>1B[F_A7%[GYK+#I?\ #7%[OYHA$&_U_P"FL1$?=,(M
MW>Y^=ZQ#3\O'7-R:DE-L]_\ \OE,,WCVWI;!L^WM5V<.8C?%3_8J"(1[_/6N
M;V/Q2KE_\",R;?=$(@W^J9DC%Y^J=?!OGFT4.@6+='OISK2K"V/T[>1?2@#!
M0!D/=_\ S$%@S'&__H*8:R91C3/2-JC)[E[^],)EV^Z% (]]SC'XI99__,D&
MS0!@_P#44PUS?'XI39?8_P#]7R__Q  N$0$  @(" 0,$ @(# 0$! 0$!$2$
M,4%187&!D:&QP?#1X1#Q(%!@0#!PL-#_V@ ( 0(! 3\0_P#\*E0VY,E/O'\E
MX;*LM":](EYZ.LY(F8M#VM/WZI(UHBSQVB-^3XR=2"A1]&^?X[RU118Y>^H^
MLS/'_@$5(1'!$/KB39DK3FQ">LW\A_[P&H LK'[_ !R8&=)%DW$5)&YC>J:%
M1T1*-)9)LZ[CP8/RB=DG1U?%7&M&0%S=T>:4&O?)4+,FDR/:YYCYXDZ&I;HQ
M)#=;Z\)@S9@,KN(]C_OD@B&Y /N_ZPE$9[#9-_/66,0/J]+^_P#[12)@%E&@
M[=>N;AIN7CPS/H^WAN-,$=$Q["];]=/$E%T%+A6_'<1/*"!!H$ACXW[>T.&2
M@EF(^?\ > (WVP'B?;YXQ?.]!)4,3)>F/,>TL8+;B+H5K]O$M,K2)V]^?C#H
M9N0!\:O]6<6,9E=.$BN"^-Y;&@95^%:[IPL%FE?NOYP/F*0O0QW^[Q$AJ%=3
M,_7"99U-:X7]O_O&H9@)G\9".8K5,*7YUT;<C"$L 'S(H>KA.+,RH>-K>"J1
M=*5J89&/;(!O8:G?00UW\8V<"$V:4.M1_.%$X"7Y_BK2;:Q-#-80DCUD^W64
M3,CM/\B A>Z(^^2\P/6?H7@C,<;W@%B(>/WC+EOT.O\ U#'(=PPE8E)'9RO\
M'U\8V9-'LK80Z=8P#LZ!;BJ([.)PGWAU%.N_IO AUJNFNCQ;XRVU"R>&>8/K
M]L,DB-:-?[/VQG<:F0AN_P!^V [S?Y$>7[V4UI"HE=V^SO6 1"PR)W/#7[ZX
M".Q-SN1;QLH"_P"2WV\_PPPH3JZ=M1'\8(],?G]?C#7O]S_WDF.F*^3(W8('
M>O'K_K%!:]$\CUTL76(VS[E[3OL^V')J(T$U?<FXXQ4L=DA]_69@A,9A5A;-
MGX'^?&#15@='AA='CZ1CX,T*I%\5KBOK65-59R]XKR:P.P)D^DW;W1'EU@X@
M%M&NK):B,;@I$&=3T=^?J.*"6("NSP2$OI_.(0 $3S\;.(KFYA*7\][XX_\
M4.- JO9UTWOQC;H,4.YCOQ,Y.(,E00-T1Z&N(]3(\)"" \>/ZWD.B2X0\O<]
MQKZ7EZD)9'F>/KARCB1E:.O,1/'6,"2(E?T-%PV._5PDT660DT1(L [\2SLH
M (2A&U#C4\T#R(TD'0(*_;Q9^XZD[0*G7OO(RJ:4)(@$$A[W!DJCB2)WZ^KK
MS/&40'<^9K1/X+[@E>6)]M9^_/\ WBJ.71@$:Y(DT^'^\G !TG.WXG$I;3!Y
MN*?4^6=[D%%%(@IVNNR>7O'7F,I</"S)?DUD=*"4'<T7^O3 Y7Q0I?QX\?.,
MU*'!>G4_?VR%K$0D^S?@*^^$EJIOR=?K?G)EL-26WPEWX\=F# 6D((EM(T/]
MY.I-F6=RVE]:\D7&(Q#4C"S<1(>;.^<01$P)J"I[UKA\_P#J2*6 7/A_G[8'
M63WZ^8].^L-3++VGZ63'$X*(E7/'=<?>.,G6.:ZC]_;9C4U?3N9W[^WAYX0E
MLGH7,(F!RN;XPE8DN\V$[WHB,0  5%Q!^,,"DH JB6*_._D(6T#7E"4$C"8$
MK9B)9932)Y8HGF8S2J/0I%-A*<'KO+"B D*]^[Q?:+:8FXZYX_-_]ZZO#]9_
MC#H&4[XK[=/$"QB=@NP0)1Z."+DYKZ;4<XPU@)3Q0)"2AOQA@@3 I=*[]OI@
M(%:J&)9(.D2OYP6*"44)F>B0UQB@*21ZX&DOI//$9OC!#+SULY_:RDX0JD$<
M]XT;2C^D??;XYP\!6A#W]CSQXPH T9VG[RS[X&V&;$\>-S[OP-(-6=:)K?IZ
M?2Y>H(^O\?\ I-'RU^?\<EU<]ZKZ^3$D.$F%(/#<\<7WBZB*4$\[]_[T8M+Q
MFRR3[!&M_C(@"[5)(.UDAGSHB=*HK=JII68_K%6$HEK-,>'?^\&O+>B L;CA
MU]\5S(1*E&*H1W]<A& B$&E @%KO@O-SLA=:4U$??7C RT834$?61YB^L X6
M=0>D*"1&[GG%0Q3BHFO@MYCSA5R@K4W@H]^^$B0WF@?#N(^N*%4(@ (Y;>IG
M\95Y2DTJ>;]/ ;94+#/CK]]\),1#^SQEAV]CC^?ODO7U]?X/GQA/)'O.(ND>
M@=1_?KDA+EJHCZO_ &R DMF'K?[[X!%J+H$#F8J'33*<QBZ8,@[;F// \8HI
M$ 212RHLIOQ]4N22W8C:5#Y^F18P)P)G,O$!/I?G&-9ZB)AH'Q7OD:,AE-S,
M*+S]IPNVU6IQ+FE1$8Z]S@F[!"9":GVR,XR) F*:.JGC?>.LPLLU>B=3SBB!
M6$,7[;[?6<(0&%CL++_?[6EB&KGSQ]:XWA-P>]KLWZGQ@C9Z?'^__3,T!,U2
M]/[U.(;+,,\7\7]?7':02072>/1N,5;/J$OKCUZ.I-<@@DIJ)\>#?G#-1;++
MZWO5=>V3%U2;2.]U7U>RPVNJI+2KJ&=?>L9E=##"$MM^GC 0JG%4D=N_WDS:
ML.6VI[^< 0JY9XU_4?%8\@E6'0R)U=?I&.,J5B1"8B&@VBU 5E44+&F1K]]L
M:8MBDXF.#SZZU>"I0F4][(OG'Q Q;JIU7GCW.H S-IVNX&*OB?Y%""#3.WOG
MDK$J3^D]/XR0W=V^3&Z>(>@PP S,2+C97-^._.+5Z=#[3??&_? DRO5Q_P!L
ML 2H4O$>8JO[QM< *&"O984VE%2SJ$HM!0U?S'RX@Z2>$0;\R=_;+\IE$$ B
M2:/+?>(;!AI,L5P*N]E&3O\ +0RI=[O6YUD5B_Y@]_[C$FEH0.Y$L^\E7BBB
M%<0)1I>-\]HSV\FH!2Z1/3U4X1&I!>IG=M^?),SD3-)1^'SH\T][PPG+K;Z>
MGVY],V 6*:JSGS^[R+H0+9.;(>_?[X,J$H-R,_WY_P#27)=19'/%X@3(D?(G
M3YR0Z6)$2;XOV_G!%4-)S^'<3GJXX1*Z)S/MA#D<L A%R2Q+,L!<4<J+@@"B
M)!4(WZ8/B5V55FG'*#L;=/<X2\5I+^]^HR5@M*",5YAYPI!0%'!PE)5E27IG
M#4*B#8L.4QSIG%1-C,*,QNR"JWXQ8(Q2%;&_K.$ >;;:IX^'JMXB!)#8%E,H
M$$S:'.2J*D ES,-PM'\8W&%3(@CG^/\ 6,!(Y4"4NSSMY8G&P5!04\T)Y+XQ
M'3"4-&=;]V.4& (R)YW#Z77I@T.ZC^4G?UR0HIVCWO7+SUW@ D23F;2DDUKP
M[GG)U8 $JW7IQOXQ1)@C;87[\6^>,)N6>JU_.7+?H=?]9<E^IWD%;>NL6P"*
MS<5[^_O'&,#:;J;=18X@VAPC/?1Z<5SA)B*[G\9*+%>*]OT\283$ ;!F)Z%G
MDJ'NL$*JD0 CHB]'/Q@(5*59$,ZF>Y]C)+0*6E-=4!K)LW"%S,3'C<?UB80P
M-RGJ$F!>89Q!$FQZ45+M*>B9[RP22 *CR,E1J]=[\,]N'63%<[?,I(?UAT!I
M:,!!%[=O6<((88@VK&Q#4FLO8N ,B8GU?Y\@@53)!!C7F(HF\#$<A2(7)"./
M6(EVQ582IK)"K7U=XI7A)B=3W.ZCSE)(TA-4WOVZRD %;B4F9G6NN?&,36OW
MZ]\3JO\ T0AHED[?'Q\2^IH&4&?*?OMYPLP"CW/Q_JL.7);U7YZ]N<> 213]
M=]?L:POR2$4L%<?6<(SU-+1#B9$?&&SZJ4@T56GS[Y-6"#6X1-GKO" ):X](
ME^<-R%&6LRDI$6H^V3?&;)@%A!$E6/!L2L@>U*A$..'Z1B$)IJ;5EY]J],$.
M0"LBI0?4[_O!H\^+%" U1 'TY,6D*K!")!( S.FS=Y!%N0I41^7Y<%6"V1=]
MEUYR&4!N'76_F^/0P4*:D#0M"R]-8+B*(0$D7!<A?K6-28*%GR02M#?&29AI
MU$18=;3 %R &9-G<,4S^<LMBMJNQ5:A^C+@\@]0%6GJ#CWQR.N3Y_IP9L_ZQ
MG@G\8VL(9F#]ZLN-DX?4"6PO B="^ZY+"0O8]]1^<04W"P;WK\OMB8]3=H8;
M#KTJ^\KL2"4&*09AZW^,6*(04 >+;C?\8SA ,R0ZB4_'Q%X.01Q[VQ)?K'>.
MF4;01?&M!ARB@TQ*3<<?L77*JCJ!,FQ/(4,28JW[B)J>&TG7WR5 A <D$?ZB
MM1JT(#:T;.GY?0P&#.+ZJ?7]\1D0GL<@(N&I'PL<XLH!=0L:-W$GKDT26%Y-
M>>O%;QD*2K2<>LNXY;AAQ?B# JH'8?ZQ)&R3"6&2PLR-0P[O(XZ%C-W-V'YP
MDP!O,:7]O;[F$A'"3&T_WJ<==%-#O5GM_?\ YY4:EYD(W^^_^&C!3(C/CPS5
MSRQT9 A)-(]>:\.2+52)69G4<<ORX%H*DL[EG?''CZ&,=9 J[GS_ #.<7 \\
M_8OSS3CU$[!H@8T\QUIQM)0)211A[\3JO9I7]1@MB6EM/D*7?=]P$G:S)Y],
MES@(.TT(GVGS>.7:&DG(] [O61?F"U<1H&*3[)QD.X59:$(($ >K$8DE%8*+
M8*B:%X7'X(A)$,$Z A+?\%"QPI))M ,V1Z8EH% *ETGLCVP@E%RAV#9<[!#"
M01*3@!FHHLM2^EQ61*[DEDRBWP\9.I60@ V:MB/?:X" 9$BNE"0&=[ZPE B)
M:B9(0B_=<(1&:H!24B$!!U^8$'A1(RDDTJD9]>,1JDXA$,I6XW/6;O\ 21F6
MPJ">C_>-K(X(JXT U_$;Q!(;,"*/^L:-M%>N":1"2KA6OIDT_.FHM*EQ1\NC
M&5()IBY*FR((^?=B\3(H4X 5+T$>H1C4! $%V+?Y?RA&6!*7$:W+,?$8\1A!
MHC>Y>../?)F. H$3ITZX\S@B2]K?WMQ9 E$"2&6CC?<2X;,+18(BITDF0C*E
MVL60LK:24&I)(%#:04@:(UO\9?&010IBALCY]LJ"T P N-L?I&/6,H2 TI=S
M?^B7 UHQ*.RL ]SLGYL *7F8N?7C (B9UEB5OWQ?JL-H(@]V]XY FD,:;"A&
M)WQSCX5 3!60E")??LX@E,+@*OC35:S0TRM),OUOT^N1%OELMOF=/.-@9B'J
M(HW-/@]IP[+)8$\P3,_3$:4/=0^:P&3)/"C]_GO$0F=I*]K_ /-6$)R'@_?S
MEFH_%O-DIXN8C?> S 42+@_A_.!'1CM8F?AUXXQS!+'HZF/WVC*QA)$^]^W[
MWFD2)"OI/MSBB>BFTXED/IKVD@H>&9!8\PY9]8EE09?1$S],/6$0MJ68;6>7
M:MN19)#T+.D+$MP$4>FH50R[4U'.R9IOL'2) 0X]$P\?T8/2-"02X0$(@Z5/
MC!"GHT,A(!S*D8.3(N$I)0T&$P@L9L-B1DB0'0Q4!L60$Q=[(QO*%L)DB!<7
M[Q<P GR65P2IDCCU"8BTA*W8ABFEG2:BD<D1+(;,1QK777G @&6QXDWZ5_;6
M'TW(9+6JTIN*8G(QV53+JLBG!2-RSB46PJ2Z=3N_,W49+V!!24G0G2QU'IAY
M8'\O34SI,2%3CD3<>J1&KUW#0"-G$SU^,'" "#5 ?[^E?]<DQ>F8[R[O@>D3
MN/X[M%MU&QWN/-/MW40TTKTBKSY1NHC#=*4@9D$0:-C\8 'Q$O&ME_EU F(H
M"%0*@(D,+$K%9$-PBR RR)6IB-]/<$D9F5(@PS)SZ>2H:CH*F?K14^/?!, "
M$G(7VZ\9&1>28*0JH$257%N)0VNU$*R,2" L<-W*L2%J  MS)L_&&#/"PB(4
M2/$\Q.'6 @NQ7:&B-Z*EE)+6ZJOV1,G$IU7,$;2!1("! @7T[UC G))!E5(I
M?IO'(1(WT9JMQUN3(P#(D( +["W4><2*!GDQ:61%19"!B,)33CO00R4C8;J"
M6,JL798'Q<C/SYQ\-)6F8J(??ZW&,-A$6'W/6/O&&*9F4N%B/6]8O/9#)S?G
MS%]UD$1&@N8&&(_;R<$ I()Z'/\ 7R)("(BXB9G^/K_Y<5H_H^=XJ":;5T27
MQ^<@EB4F1'N[\3Q6*:V(OD%Q)SS]L%\4[8Y72UOYCSD]"((38SKUT]^,4&%E
M?>_3KY-SD! S($#,\_Z]L\<U@BO9\P.Z\8^A [?!Y=1=OH>)%YEE;-4S\1D+
M&^A6R&) @K:KZE\IFB3830<@,##W6HE\TS]$PW;($B#2:Y21)DWN6E!U]C1X
MI[^6<!(9E3Q(K'!7K';8ME@$@9?18Q34R8MYJHJU%I0N$&%E$A!%T*&FUD19
M6X176]VZF*M9%H\I->G.&$L&NZU.R5KNYG#'5;:7@)NX)]/!A$PMH 0%5V(B
M)I:MQR$-EF%1)QMYY]\B/81@(&H._IZ9./L,DA*P*=\:,00ELK)DN":?0XPD
M?J22( R;%RDQD)"1!N%(IU5O3&08!"^0V1]_JS2$<60AJIE#\^@9 L%>2)EY
M&/3UPEB8L[F9:?[_ ,$RRSJ&CU_ZR4,?W_64!RA&]CXY\=QE%,E!2&Z=M_SD
M)'25SN.!OCO)!]ILH$DT ]?&" %VR179ZO=;][:)33:=!+(5JI336#;2% T0
M9@Z+V@<-9&(H KF;>4]#6%1G.=(7HK4<IUXC>(N=03?EG[<0%DK)EA8 021O
MSNC'R0R($.5M@6!) PLB9E+0*!["7,M97ZT%H-)MF8;VQ>V6%< )8 .NRD4Q
M<(;HJ:E!"QK2"5A=$&@:V>FLLB;T=,<Z;9@C0P6OOK@[M)DAT7 *P\S9ZICY
M$'*J3&9SM)= O&3,@X<@RB<J2F8VLBX)TG%;W!("45!VK3.H)RP7BFH_4Z8D
M&1IVN.2;G6-LT;J>+5_OWU:X3)YT?S]L<U-HB2(7=QQT23K"ST?HVU*>G^L?
M3 !"M'[\^F(S)X(';SN]^)],18$^8!]J]\.@)T=>_/\ OT_\I0N(P HPG!RA
M$0=>L<\8'2:R2TOK^WDDE);*K?[U4=QC)$H3Q=/IK]YR0]0,?2G5U[&,U=O6
MYOGUGSCUJ1VXGG7[SUY]C!,ZR1JH[!JIB]XR'$Z-!(.NLG$@+EW(G1MYWIR'
M-U, +O85UQ'>)D4D"24P3#;)147E:TY0$(5LO [K&TD6*F0=QP_[P6&8IN4Q
MP,*"K$++$<2D(W6VUDE9D"H Q.S2U$T^$XJ,3DPR[&WL?"3*.(^H,DDH-:@8
M]'P88[35I9S?A?M./482'4"$>H,:KA#$J(PI0+B=ZB?0G!E#@1 2"Y5!(2A"
M7#:E%;@PLD6QL^,1=GA(%F;!-B$C>[!*LB>*1$3!OXN2B(,%;%C$L!$*6@YF
M!EDU6#84?5WN9*-K;*-N?#^P;R1Y4I4L)KU"HO6G":R"@\'Z]HR,Z\&48"7C
M=4YH.DF/:-_]:V)WC$KA3\3-?ZQX !+-EUMY#QK>\AB2!I2$2QL[_C%OVQB1
M#-$ .7YC"$4'LF$*'CUO53'Q() N 0 6'CG"[:0*:$A-PE3BXQP'14#8 4LU
MI\X>T"7H9YWJ-MXW\ &;H40^9T]X1&6R3PFDBPIJ^L U4 $2:@*Y3%Q=&0"*
MXC< J1(;'C5XA(%4VH2,<BM>_>!><PLVKN]KZE]8G"8$RI D!,)ED-I#APE4
M"!>.4D$K2ZFF.R *2)22A' %S.R1,*"4SC=%[K4\<^7 )AVEE3Q/<>N\KBE
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MQEAFP+$C0]+QU]%:PZF*TZ],D*5""*N 05$SK*Q1=N98FU.:"2)K)(&+$"4
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M3?Z"5BB,1#X*1$^O5Z<MQIXT)Z2>,+)W#CN=$5QSWFP<5^^O7QS@_P"?J4A
M".7GCRZ']("B@B*@V2$00)8@F3'""DPIMD^KD4)-2 /TB #QZ3AFF2\3E94;
M@XR[>69Y9@]:(Z^XN%=5()$Y@UPGG%LL%"\MW%LCJX8PB3" E1I88$DD>7L-
M/FT&&1,3?9]W#L@BQ+U)*N3K+_L^GH4"S20RL!<80(XBXN<L!!Y*)60<!D.Y
MWRSK 340O$$ [YN![GWPC A,T,'D-M<]3@)G(9RPUZ?O"WFB8 I2N =:.<>D
M!3P$"/G]FLGPE25%% +#U>^++H7(G)*IWQ!P381+(F 8!(ABO9+J@" *F+$2
MTC,^B=E.#KE(H2(DH1<IK<BX6L 4D0;.+K0OKE)$ M3LKQX,+(R@3W>TG?.1
M (VD-<:WY^M?^3FP[ZW49.O:HLF_LZ]_&")-D0U,K#M]OCG%0,A,W,JL35<:
M\\&,""&)H],6/[Q((&@AUX3Q[$>,9=7"DE$F (XWZXAC"$SHVP<<?&\/1/HL
ME.BQQKO5.*6D&)."0N7-^V:\V>)P+@DQZ+[P\P!@,!101WQSG*P(F)A^*C(8
M!"@_03+Z^\8Q$60$@@8:-;U]MEEI9BE+;$3HV[G6213L24$AM=FT(N7 5),S
M!) &XC94!P8?@W[2(U)-$5*]<J>I(J8$%5U.]8L$D1LM&$7WQ7L1CC'(D+4>
MC\'SU@'VH2 $!6BC8<ZO&G"@L-(T 9/+V@A&Q"H)V#ELCU,=6RD)"RD9V4KX
MUC.!$$6JH8(F93_63-P.0NTJ4! 9L.A2?UA$)0DEOS?G-F4%PN^N-8:I*&HV
ML?1\>MX(!$!!!%8D_L?;_ 1K[K]_^NXCA_?S@!HWB0J)I@G&P%;(,0+$&3DS
M7O@(9-ECLBOV'O$Z0-F$HDI^?=W>%%XS!.0!HFYW)K)6O8])' )6&0$@8N2R
MN$4$J1"(45@K'I7&VN^::\QS&TR>PP.H6 JG7[%ND O*:$ZY(R=BQ-%*J&AD
M%BQ%1AC1P)Q0K)0=G]I9712JB:( ZEZ,*FZ!@\+#Z^-&29R-.(&2*'4"PFI%
M)$\@2!1%:#XG($1&4@:VMV&J&ZG*\E@+A#PNR&376Y(RX!*H(FPO7'TP08PA
M;&2/[YX\XNUL4$0HELB*"?5R;$P]GRGE(8Z[/9=$A$:@N?7$X$@!2$I30CQS
MDOV$AHK4POIWUA/$1$D+68:OZ8J(-$!2V!J?Q>#H42 \EU(T(%6$265 X3H-
M@92)%B;D[PQ(KU7+&H'4Z]>##&1@*!_,\WW@+-M:36O=^A],4-O_ )%!: &^
MOJ<QECK)4ZCF^[_G )&9IZG7,GY^N# ";GJD/7],6IFFU2@>U[YG";<+ILDH
MQ-$Z7QSEJZ%/6:]-,??!_.AA7B"?#F)@:R2YKT92IB7A:VS':)0%& Q0(;YU
M4<Y*ZZC<<7P?QYR'L0[WS^OS@=@4CB5\0SK$Z&:7B+?VLA2 0>6?]^8ZUCD"
M%+R%G#'\^*R)?4AC8:BY)OD+ZP1B]&%<"@$DX$EEAB\S+5@*#9'5UZ16$@(#
M7 :YJ]SBM8+@BX\2>FGVP->%/#?7\YK.*5S#YYF/;G%G(2L5:B3/,%\M/31-
M U4!5/:SQYUDG, MG4A$14)<D#Z8YBT$S'9T0"K- JP.$0$3 F4-OZQZU:\
M1/(A#6L25JI^_P#>>L0="+'<K^_&QQ)@W]N>:UEBYG_M'@VM'I^_CO!^O0-O
MFNKFHTWCHD(5A86>>C^W&#VX!*(=UN7Z8!-5GU(/86PUL6!E.HPK (+X"@U&
MN, XA*A%2SJW]8N<>\$*[YKYX^^+:;4B0#$(L)HJ3 W@94,J@!@^AMWN>Z6;
MH0*B?%,^G)&*46)UY6F_3XC%0I;ZEP\5SCC"+@D(BT3IE> R5S-!  "S-E$E
M+ZX#5H@2B60*T1 L(8D(\ 4@2:LU#(P<ZG:R90 , 8?/FXO[8YB3?^+'?O&3
M1S1@61R7_6&RI-Q4Q*CYFMQZXHEDD1W";E4_[=]*$D!8!N"")]<7NB0M2)X]
MH^-EP)VB"A:)+<Q=W%98"E3:$:;CSZV8R2A:4;@@'3J]VMKEA526%;NU8EGF
M'6.4()1QS^7FC'X@!W3OR<?NL) @$\\?7^UP!)ZGT?FOPX(Z?_(.X@HF*"S9
M<6.=5[3/C)O2WCPO:$QDN3MXOZZGZ69RS*%@1+XC>_\ 5!70P@."I!O1)[X2
M(7823N0B#?CSD-<[AS$$A$!8*L8DQ<9MAL 00$&I9$!."=$R72PG@U:C$XJ[
MF$2R1RXUHFDJ3V]'B,% LIG]GWO>% 5FKL3?X^_EE+8!+.OPW]JQ9'3-%)RC
M@YO!@!$1!!!8D]$\R6$&XAY*2YIS,3[KS@=E-O,61 G/%SR**$(T,/K_ 'C9
M;<KN6JT8OG>2?7T^W6, M4SZTSQ]L*5V9.(YOZ>"2S!:G.*L/N"$$?:L<"L[
M( 2.VW'9Y%*ZP(H-99")%HP0I&/1=K(63KKG?NV<.EGEWZ]?:;PK$])Q?Y^)
M-X+Z&#5/MZ^L5A^:8AX.IU@21DJ/K?\ VE@*.Z&B._C-*45+<(^L^<+4.\@$
M+HJDUJ9RPDA6'45#_'IE. 461DI+;/'62=)'1F.&F=-25$9!@")8,@.YD$Z,
M26H])NL*;1X)OUQ@)??L(U8JC93HC$%8@ZO<"K@02Q148(<NDH(/$\U%-6S@
MD@48I_=S\\Z04B%0JSO8[DY]<>V8J$0H.@=:.]/&-0J0RBY*BRK(H3NZP"HX
M08+1$*%A@$#PNP5OG\UT<%7HQ=G&]''SAN!0RWJ=GM!\9/1D8:-3^8]3!Q""
M)2=)QZ^/O@,2+;>6FTWLXG)1*[I0>3IVVO7E)B$=L0M8^DC[8$")!*B3&32R
M4L1SEG4V54G^._Q&0B38%A VY9?MZQ41\PPPA3"D%#*/.$#*Y!(8GS+\5@$N
MT:+8GGS?UQ+I++R#'[>%%F">8HGF-^^!"P0(?-_U_P"0(-)G[+_GXC!#,2CT
MWSV[PQ8D4V3S=Z_'6'* (B'I-5\?G'2@V):7=;AY]>,AB W(K-;0RG>YZC*4
M.8FCQ(HQ$RY?;"(M1DE% 0 ! C&(Y99*F2$+UETR,9>W-1-C/9%\T8PPLH-]
M5?.YXB?I&G<=]UX[Q*DYQLGTWK[SAA&AD?M[?Q&M H T][U=?OA3(/NL_E;Y
MQJ(LMHLK= $J9B<8E,9*B HAY1'<L>< T@+0!+6JWS[1BS&6=AX@/2/3CK),
M32;[IOZ\Z+C+L*;?Q^U],/0(!W2]>=^DX0-R#W_'TJ<;([$F$#H)"V@:0<%J
MV&0I6) 842,QC7(F&"2/";K*,O.C#/WX@E(1$<O7G#":%9V2^9ZOYZQO=Y#M
MO[X4D*$^?4PDBIH\+^IN(P#P%_/['M_VDA@3NOC&0R"4V0*G)=?))B))K/HQ
M/T^_G#])(O7?[\;Q8 )$ZA'IS'K\9%)2\6WT@0.RR!;D@*#=AP$ZC^&YQGY9
M!1MO%EB8@P! XD6DTH'/+IMC(A00O4DDUS6_]8@ZZ)6; ?CKWQ&$4<K)'C_3
MQA T0&2;-/IKUP-8]#F4@)Y?N:QFV.)Z10)N 4L2PY8&!6 ":X*#2@:49&VP
MRT!1Z'][R06Q7/A_DR.5_P!B_>O:\G[;:E\S#,_C63A4#>[OO<>/7>-F) ->
M&]?M=9'4#EFR( OK^L@5#F48"FE!3 Q1!BE5$LTP5(! @M)PZ,3*:QM9)>IN
M8[[.,5X@82,D*(1\.'21V."PMDU-:E!YP?H(@S6[WRWY]=*1(6_;ZUELV%1^
M]>?7'=2&IN[[U?[QG[\?^0:-@A&+C7KO]G 765?JL/B(^=W@*:6!NF_WUYR-
M;#:^:U'I7Q@Q1X%)@GD2/WN,'8$S$@(%P 2I,5>KQ21!Y7,32UFT(D@8<2D$
MC9(JV95SZSEUNB*"0E!DX#4>N#3#K.H2F=RS;Z;T12+5$Y6V/><D-TB]QY_6
M,&NB^8 <<@O0^WU^OJXM)*1F0)'CGW97ZI)=C2%] DQ !RIVN,8B(N*$:HHM
M))^C_3&DJ#8U.C8DSS&$P)8T 6EVS^(<%+D%90F 3[5]Y,D95$ZBW7M/[.15
M@J,_NM_?<Y.Y#1T3/J>?T,8:= B=PL!+#U>VY7<#0"2X NX>>G3D$J !H4FU
M35)93+ G2* *FKEV@EB>@K#,V/WR)G?W^N,R@:9GSZ5S F QN+;U#U_.^\B8
MWD!1)0W>UP*A6#+<)XJ6[O"8ZR'WW[?G_LD73'M.0*6S=?QD6%D$PO,/R8Q5
M2(Z+%%(>G'.-@HT(U,OK+_!D39A.O5F?;ZUO%%(! P DW.VW7%D7FJ"""+*'
M"(81$>DQ/LN1(2#;I%+3YYQ*97QO!K="J$ (*,2@($ 8667L[G9K#4*!HYMN
M_;K \* >@E3^]LXL$4\7J,"M-3M(S.I8UQNL2;$(< )G,D[?&!#(&*%A(*6
M4D*J+9,C- )#; %$.Z5+!Q,!DKM0L3WT]?1"Q2BK+)!$WOVOQDE"L==2,OY^
M/.3RNT3[_!P[ZR(0!"?L>L[O7.3U7@N^6=^&+QC ZJ(D/Z:37.*,)D@EW$0I
M,\5>U8@P/J-))2(G$EHQS"=%A;&" .K @@6M:!)CL@+^[O)S2:0 \[BG[^V3
MB00$DN-5/G'<[:_P?'C)!H6"/;Q^_AJ,(&3,LO\ OYG/WY_\@/2@4?,Q^^GL
MJ PQ#ZISZ:]<1"M7ZOORG6/1R;K=0>:GYXXQRD8]$[LKZX@B"S7&N2;O7\8H
M@A<!FMG7[[IV )"CG02/?%9Q94&ZNXV\=?>,20Z>M?I)SWG08"1@T[W^]9%
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M<S!4]DX+H)1*%GR@F8@AN^DI 6\%1"MT]>KB:@*<1$DR;F)],"0<#+W600)
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M.6/&GY^<@1)5\)]I2_S>5H2JPD5PV3.6P&:._/C^_0+"@_3\S7YRQT:_9?\
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M6J0\]>?WC_)P0RB221BR^?;G%& 6&;<T(=]QI@B,+I44$E)++CIJ2=,..5Z
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M;-8A&$C7GWG&&"PB-2A#$^Y_N#W,+JZBRGL9@.8R!10?20J1$MJ@$U50B>7
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MX*1$<%E,0K"3=U6QQ^1U?07894*L!8VX2Z0( ,%]R0P:7T($-(B9B*NW^_\
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M:@)DQ]..!_:PSD)*O''[X^,4 D/LM-?ZS?"1,:V1^//Y( 2#)"29_>9[N<1
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M2 '??;XPS"2$TQ%C'UQ@,0K1Q[?2?3$B,AJ][?S/^.'O^,Y>WY_]L0B#O\8
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M1->_6ZQ@(T%3!+W^ASDR-B9G;'K_ 'UB)LF-',^(-/B?+@;7;QU'^ #1_P!
M@TX#2(XE[U-_6N*,2!F&E25KPG)+"/6;O*,_7]]\;J!2 HW,S0$W2F65DJ6
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M_$<3C".0?ZOT^DUBCMC24!9L$KH"#E6<-LF;B=<GF?/:8RF3A4 ,[F#1!/\
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M*\77$SN[?3BOMW'11KZS@!HR4/ZC7U_UO*A 81]X\HC'^LF( &>/6._SNW"
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M9(%=S+!B@B%0A?SS^^D2*X!F+E\<[Q."05'<6?7Z9, %D#%".0(B/KZ-TP7
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M)$<OGSBKM7URZ8OU?/\ -_\ Z@&C_P#CZ"H5Z_KO')'7YG_Y.'O^,Y>WY_\
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M% ]^NWWLXJ2VK)(*53!5AP7U 5*SI(GPB/BG&&C2ZT@F"RI6>=G.R52MEIZ
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M'OK%7D<3*DL9;BS*.ZVC#@]LP8JJ42  9#,^CDGL0154.PD[)&!<+2I.L7$
M7JR" >( %\SN>CDZ@D! *0L3LK6%=TWYJP)'#%[398'"#\^(K#M@,]B!X3O
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M-<F\Z11R0M9@"$]LPO$ZY#%6X%$$,:V-;#H ME$):3-,)\QI2$L*5]C&@"G
M/TYI@:B98\88!OR3_-*S (>&UAT@+H( 1T&A7WQ][WXI1AD(P3>0V2EJ58+I
M< ]=>/Z?^;\'Q]+WSKCO"1T=J%X(-P:'ASD1!@N(%X<)=DNB20#R]*L9B [0
M&*-J#KWV6')ABVC GL^![X%;VQ,Y NE(R9;*<;0H=C;+.NQZ!FDX!:3.JS2=
M-+$3/"P'=X*X1@F().#Y6P"?WQI(CRZ% C:+4%L13I4BX%5'%G;0"W2T3@QH
M$7NH!ARRH>(V[\D[P> NJ$4V"A#T@FTKBB2>?X0,RMK@.3HL6:/=9M"\*H4$
MH8)JD>#K  !V>=8;5QZ35B$$,5A<+'!1#D,*[=-KQ-+*,$\MFF]K) 79Q46J
M0M)@VD)0L34(08P5G*\*9OITOH+!JQ$!@##6DF8SH/DD7RO*JV& &"DRD"J"
MDE,&EP%K8V \&JTZH$2!["%K3-#Q.?#*PR=PNF5G!=OM_5GY3Y]_\:VD^;?R
MX#OO,TZV&WV)T=Y3&@8N1W!1+Y.R"@D$@7 )0;8R+JIQ8>W2"Q3#F&KW@8?S
MJ[ KY@J5Q%LK!5!N0G$!.)GGJP4G6@Y*SUQ#'*G9E0 !WV-> PUQ %F-#V[T
MOSO73P5A "4JD Z.*X-DT*JDU$,$@B%9,(3 K2.9VTX;V30*2MH@Z,J1M(4N
MB_)*":9ESUQ4TI<I"L%8T!"<*(1WMT(N=P(@J7B[8?Q<.94.K,QT"]%%/9H#
MB=X4FB6@]6V^#P-Y67L9I2(#'$('8<1&<4M_B"HJ!R@)I"0<;GXY!.&-,JDN
MQ,0G3"@-3'\%%5[:GUV]V;.4LCN$S)\RQ%$(\'IB W*49% <%SE#R2D>G>^.
MS@U41)UZ_?[ZY"S?[<.W;]I/OY_II2,O?J_98?G_ )LD0" @X0$ITF(W8<5B
MB,P!(G6=QLBRC5-Z=7M(%JB"@. (Y8(%)/,9OB'JJ\4V34)1@VSI,96=O-ZP
M(4-*#F5J#Q>N1:05.U[3YZ]]<=:!1B%52305AV)+Q0%K[N@:&KI5(12^M%T&
MXE( I$!XD :05K'3%[;XY%>08ME%7O$2F<ID8U!()U)7@5GA(C0ADZC"@(:A
MKP"B 2\):<#CJTX>==D&":7SR%X2T 5@1L, 0 2$+$'U.Q@4;5-57J",A[[F
M@  #@2Y-*@H+M>H08*(8@9"R#@JA .QF.'<8'6@!/5")2P)QPP<9'R[FX/>*
M*Q*809 7@("HAF',@@J"O4%\F*VU9Z@*,/(A6D_=<C"L( @=2@SI/N1S]@]=
MQPZ"=D%YC1L-N,$:H+E0 !@/&P-%6I502)>3_'X?\:EF]-GO@U@35 K"J*18
M ->"@B (5(6=A5.A " 44@./ZKZ.79MT8-2LOIEN'E$8+O,^.1Q,1? O:CI+
M ^UI%[*1W")<IZ+6-L\",48 KH$1 N .=H&T"=D[M-#I";>)D] @G$)!5)15
MOX@030$1)60G -52!6*NLC6:*IJ<(R6Q[81@2)@I%(%*,WW@37CD55$'HF5(
M,CSZ-%"<)(\":[A#8Q=.G+8$G(H]+-5/9W+$FB$Y!6SDI@L0 % -CBQ*(%_I
M<+1 (\'<H0G626(V D@Z/)UWU4*4BKPY 3> (TD0I:*S8$JZ9,E%4Q$-[]:/
M,@?24:$--LIH&G3C*R">L1\+@M''@(']*(8WD8K=QG<N7G&L+6C 2UCQXU2@
MR09E12T7B!?/<+IBFGO,=[O],*^"_OZD_/Z<<[Q<A"F"!*KE&<//&-%#45"9
M%JN #&)E(ITH<=3JG&S7=1;>H52$K $8(7*0TJC*[XL_(X7@I1EP)=\_C]..
MVZSQ&F/I"]_;B'1"? @JWY$[;G7*@? \$*+M11C(#$>4404PIF<(+QJ!IL^"
MQ!0 &)L>GECD1#T ;*S@]R5(;Q&W;A%):2OB2L$BX% ;CA_Z16^Q2HBN^AZ.
M8%KQ5?MO4M4WA0C((YODVLP%*,1.FL(D : $$-<$D\1# 58!"0/'77( IW"K
M0:9#(VDDDTDARR)-%/!N*UM4%@&&!("]+%./1 P <=!"#J6Q#PH)HHU&(6T$
M0R-"EXNR9\?A\DM.CJ!I'%&!L(34FI8TSEXH\6D$^%<Y"!(3U5L X:XW58Y6
M@36SB 2@9;=57I[HB>0T ]1D%C,8EI1%6<)WY0NWK?;_ /7T_P".GGU_?AN%
M%2P^K*A$41,7#$^.E:HKY D(@%;0S%. ]FHN("9L4YZ8)$#0H4$@<FH GA"T
MAF09Y]3B<^W!PD@E!E.J@3N*1 U![E%M:O"S&>DMD@+@VT8.4#U M,@;[R(<
M8(@$KFYD)(D#"-3WE%[%0;H>25X'_J@4@W$$6#6M+G*Q\PK8%52NV(;D$"N.
M(\&MZ!&BJ*ET14 MT(\S4E566$A5*<XVW,B5]:#',AXJD#0UK-1'H>34,706
M@#  TMM1>4"N64CK.L'-<*64NV(2HA4QU,@%$EN_#+CT]@2\QI!$_'<1F'D*
M\QC8 N,A!'#%TU&/)W48O$>*YK.SY5M3$-RHDN%HTTT4OCBPI%L*P^Y0:VJI
M;DOFO72Q#R5*J_(70X"@2HCJ,::AKRUN-75@6!X>H3S'.#[>NZ3\I^?U]<&K
MH_3Q]_/]*K)]?UP_-#XO!;.+'0"M$D(R$G#3?%U !!50$!![I:"A0[I]$'R$
M.S7BHHR0WD (M"=:+\(TK#M;6M>FE P TXN7!]DJ&!6-FG=;Q_JH*:>!H*3>
M_ ^.0J P\*>$G7E*3)RE(=2TH[ 9: :@=7DUGA@+U2K 9 FTK5?! T(G#Y'.
MP[" !25\TFFAAWL]@1*MP";$$51 I$"D YD% HFQR%,C&G2' 5I #I\ ]4Z:
M-H%P8CM8"KE+P\8PM,QBLH'11#(7$MX#N8OG:/ ..L6DD $0B4(G@)#@',/@
M5"TP   4YB( +!#9%5:5P#@ 2T]FKJPSX&#3C",]BMN0G5<G9E@(;+&CN#33
MP< +,V]KUE5< ?#*Q&;NK,<G1=BE,[NB&6-!'=TJGPMW!AU4\ @A&I6X:,<#
M4&+00D1!!&6JAM@JME5:E. 2!KS.EJ"(P12<-J/P4$R+% @C  X-O[IL3>GP
M_7[?\;6/J_140OA4?J'&^$B=S/. 1-!'+P(2Q!*>0:,N Y&00INLV?90BY!0
MRVUV&(BB652(4&?1J55RQ4J#P[)SO#I.&#$'B=1+!;:M!+Y \4$N>P0!2V$6
MB[VO*P"8+U(@# AHEXA->("3-D+;E&H65;UKP;,**@RO(4-Z $8:S(@!<(Z!
M(@(-!5(I*$"+&2D]VU>RU"M.$_[9- \5=*.\([CT(C%$HG!HU-*@6<(5)5$H
M]$$4"!(J:'J @ ^.)'D8A3,N7/\ FHZUWOF&D+H &G7 J?@)*9;KO^<&MP;X
M]B[4CDF(%,9+@"6+$ZC0N'5@6Z\DQ=KZ:N.A9*B%]_'XYS0E!V<H7PA<]=>#
MB!K/*L 5ZD^Q?GB?6]!1364K4#HBR0M@!4>:U%F0KJO;W@<VCB%8XI^-W$=M
M[1055'"^3K\_W]#^E/;<%^I.KXV(FT]7CY@GP7=@1/-P+*<0T:Y$T(WNT.O7
M1R>>5BC$: LDAS9>4%0,*.G$)KBH0"2X(V\A-C#V0".*(XC8\'IW\HC!N1*H
MM#*+L8&$)0P$LXS-,90=H!  KJWI*7 %,3@"C9+SJ/2\HMV-(8*-$!Q*(':^
MZ,G34;6$(+WHF<!@\9D(7L4HK[T488!'D%BH0*J""+0@B:PKH3U'2FO"(K32
MBFB=+\-# C2W(< JRN7JP6( F$H:E5;7%@$%6AA@@1"]&\H::W&0 1U3'="6
M B!44HMZ80X6REX"Z=OB(!!@,.FJHXD4)9"D%N(  !UM&&XSP=:&BW"OSI9-
MM=":F$ '*]5T60L*9&P*>Q >5<"!J'0E! 5>%=!!L@&2R'8+-ZXREH,6L%/>
M-,^+OI6-"\("*RA=:NC+":1K*J>3' \5X%74< A^&;"?>)7@GNZFU 1Y,+"=
M*,'E6A,<;#J%6JNQJ^UHWK *? F6\%H]2??_ (QM)UY_?[^>+U)>$%C %4(\
M Q 547M(H! IV=C.2:)2 5A0O8QK42VA(B7.)ML:\EV0JFV0;(!B4:T%.6#1
M\##(W@5Q#BVQ"C4MKZE#<^\>K%5_UF @X<B8G(, (*0T;%1!^T(NA!'1!)PD
MA&7?X;D0U&-LU7HS<!\2&W#A+'$,CEZPI);$7@T,E//=N&$NDMFRP*"H@R.-
M;4@C.NH@Y2%.!Z()?]P&<MM$UZQ$Z;_$N0EJ"I#+ %JUIS6 :>0!1AD"4F3K
M>31AT-L&".Z6AMCQ$**%,%1#2@7.WL_NJQE*.J&%I%E;-)&-0XS1,NA@$UW<
M[,)1&>X<%93%#X*RH&TW&9]']F];SB>A+.G)^/7IK(L"P.R,"L]JWV(8 #$=
MA*(/F/>^ YWA!N6%74!2Z6E1:$->X#!X!04HB@C$FE=GX%88<D#EA2IP',&O
M4RH<&K52> ]]?#XUR:]O])/?;MSXCK]*'?GI9Q!ERQ6JTQQ)Y:J^+<\NA!4+
M@C@NZD!$320-0;:K3[PB/,,)2N(KY-(9^A'BHZ)LE7/2=/"0 0DABP1L!6@T
MI)O5$9W$Z%GQRPU(VA?0 @#RHK2-56IRPVL#: R<@],%#G5H:GN3G5BP:$$A
MMB-]:311AXEX.Z(+T%Y2PF_K3L]#EVAI4X<C0B\^D$ J=4\5S#@%YI3H@@X2
MT[!6PMQ "/M![0B2.0X=:+0>A.!NQ!XL( I?H@H< K18B@Z,6?:$/>IE8*B@
M($5G9 Y=^$P *9[/FZD)9".@/=!-((:+(8KA2)B'94G!&ADPNNE15)U:D55*
MG2V_ $IX1@'$!I*2%T)O.P5:. J<PGIB;LH4-".[QU#[2"MDN1R-6&R;Y%"A
M*N"8'0<-0'LBK5[6Y?>O=XI44Q3,N4\^L9X\O(F[1B=F"0#S"7XG J1Z8PN5
M+0(* 7"5W?):;L!7TOE!57O^S_C$@)[;^#/T<DYI(P;$U+>JE<6R(HJ"K:.R
MU%[58 JZ>@*'B5ZFMJ<$.QH>UKAV\.[?><6B8'TJ(0H4"&I/6G!R0?(F( W<
M@>< M?!!"-ERB(-34?;/H*E%901'@_ Z(=T5EYD2B,3!L9*44>D.KS5#@H-8
MK!.U1HP7].=K8%(8(EUX?:2/ O@U1 <.I"<U>;I?%N8B &1SL,D+-"#> WD0
M/$9D71X=B**?&@AR$-"#@"H=7+VJ@SG3T9Y-=/!.[@FB^HBH[J$7PGF,IA9T
M](.@X,W6[&A$N;O)(W1LQ9"0:(HMQRS1B:)@*P' R_F)!*$@3 +4&(J-\S11
M)":7VKC?4&? 1U_<1H0;](8]D8D=G:\$XHX?$A?>L;KX4%E@ W?<Y K;<\E:
M)%,W"#3P'3"*B1J$:$H"P63ZB+Y?0H28%&S$4I$5:ER1XG!Y. S!S &U'A(&
MXE@!@]%?1T!#^DT'O]_N< (K-^06>6 3Z#T*\(UB"T>GK*AB+!BEDZ (-D%@
MZ11:.611 L>S(R*#@W2@N>Q*"UY"G*HK/< -$J1A'R/ E Q+ DBH* 6P@R4[
M\PV.:0%!# "$&^(L P$: ;XLJ&CDK!>/9H5PBAR<K=+*(*#:(/&Z5R!%_2V@
M D'P)*P4$X02W1=ICP[A.>B(^ 8J% .:P1L-IH,>$"F@N&0EE&(Z"0#F&PD%
M0OP=EJ56^[6>*H1DJW;5;Q4JT),""E6(I ' P"$ H-2GBD9D N]T+=& HA>H
M<O8/Q%-?4"3P(,>+!YA<!BEHYB  O6AFYZAFVD=)H'>QJ*I:UNX%4N,"F6(J
M3%$L#57 YW7VX.Y&E-X;BUE:/E& *"XXZ#@87L@5D*%U>EPXJ.198<'"=!(C
MIPB[.J 492#.L'(X;>BP4 <P'1@-(9CB5)0[" )U@M'1,(QG5[S\=^;P L)?
M^,4F5C"P7)7P?WG!+.QB/1"/2@Z@%IMH#2!@5PU=.WJ@+LEL7VELZ.L^SCF5
M,-F*V])Y\.6YQP@4VD(@0"#"JC7,ZPTN>Z+TD! %23*D=.I9FF@0 KPD'FX4
M1VD4F\()M"#8ZL$$6BQ*E CBZ\$)I*P0TN)>2'%<(1GH!2A;R-@]"\ASHHUS
M7()#K33PI3!(!<4T_9I5R&&@)N74P-@SOP"TC1G%C>[B +*0(@5II)7.PJ(Z
M@YM<)HMR$_<U2PDHN%I(A>^J%:!Z>M002*KN)5A2"VE%^HBYR;<U;6A= G+A
ME8OM# U7K"6%223OPIAURN Q;G-H*$]7:@2(D/:IL&WI0>( *R9K2->(KL*L
ML_"X+NA ]5S=0!T:#7CM4$B= [4?7:9G7,KSN!$LD3ISH[$8>G1'=P13#!LI
M@3*HBB$$JE*UZX"""M! (AI+%;JBW@.(<@<4#<L :!:! _#@HA\T_I-I(A3M
M\1H18F@E*5D)B\@.2+8\T,-R>$MD1(&2+<3!:TV+BC;1^W%<E,X-\^5.VP T
MG$@8P\(18=7&3+I8JHO0);0 +8J\?@T<*.P,!\AY"3ERR&J B3 (@@*N&\$G
M"V&$ AH YF'D4Y\@%-@ M/1R,FF=9D)O"?6U\NA0P2&K(Y&H7P@24#/B*!P"
MYRW9X.ML;+*B#EZHV$OA2AV%J,WB.X1X60!@%C-?C(;\LQ]\9>%#D5"#EQ$&
M:7-56"EM&%%%Z$@P"#%X2)+\N* $KBM!J\66^=.D!%)1'NXEOOX9 .B=D"%=
M8/'V#%7E#$ $'R0,JCA"EY)$V%$W#I#"77I&FEK* 1U4T 0AK9-4D=Q'>0C<
MWEWOA7G4T8(@J8H5!MA4"7D\A$)!:B.+!A4PI)K=Y.=X"#(8RF2"!A%  \2!
MR?O]^?GOD;WI6O6_GO??_' ^4?#LN=^/$+^#R[U%R GT+Q## P555@"#2M4,
M0<EJ1%W)90@)>ZG@\%*(*V WL!OFKY/)KGW")&B(G3W-+.#[UH 1BA&TPBJB
M'/1]4?)JAW3L2S9906O5!0X28N^L H"$G6*EER& 8[H0 M-*\(D^*@\,)6EE
M1P3%]TB*E(%6= 3QF-Y@F\'B2G<96_G]<;5X>U05X !\@PW2R?ML$P**<$N9
M(/ CQ@R#FJ0 N$ E#NAKBQGPYI^7$M%NXBNP[=F4</,X]".Z6?0)&IR"-"25
M>2='O<9QVB>"1PE[H!BA?.;$ )A:A" -?5) @GN&B@ 9""&)TL[@_8TX(@3F
MQ#L<"0K*G:+$5(0=R<P4=U5O(=_()O.CZ&&.,"6@C@_?$C 1=,D(@F#E5DY,
MA4@QP:@?)^XKY!I*((S5X ;\OD^F(^9"'*D19X$7L"2A,H =$^GU7]5?Z222
M?/TH*7S,>OIP?@K5H)M*QO?%#CN<"D QB3Z!:)0 !%#D715Z ,+"L#7D1]M8
MV J$T%PLX?!@=)52!U Z6EO;F7+^42@#:S*"K>3F[*RKII'N"8\-VP@)PQ8&
M$!0NLO 6=]!4$7#P; (?ZM](V"!4H^'&#9F"4$P!DF3@%-A+0(6*D4W_ )G%
M+%V@$9@)8*]P+7>>/ &P[4G6>[=YBWP*<[+3*RQ'#I5DH"1 N!5LGG6@LJ2N
MJ8!+ N2D<L1;)%*Y<LF9K)C6JX*JK*JK0Q"H)LFF4<8WUG:\E-JE*(HZ!$*0
M5*.0& \@.[,V)M[5;\M,-Y6=5"!\,<85"L#,BR!I.6=LJ05"H1TO J:8 -@@
MV4FQ*!(01PDP&1:-81E."(Z)+K7W@@UA$E 317! J" "H<,G+OP/C D12:T8
M&/@4'B"50=>G/L#(= $\^_\ D(/?[_<XA(E/7A(D3I(](G3V$4(L?);@575@
M:UX&'B#&*8NE"\CRIM13@C8)0ILR>4FY-EB*\0*4@J<EHDT"E(J@)#Z!V\%*
M=,%A  M"IX%H.I"( @166#C#9/I@$L58EPW*I*9-60(*$%\QPA.%3D^@68;Q
M?%$E(A(IEDVA HY5M88EV0\GZ$ "6R$X4-3 " "' 5.<ROE8)+LM5)P[XZFM
M P"!F%'@8IP<,XF&J%U8TFBNY9!OS&< M<!R1 IR!6A'0I"= -^QEC21)$QB
M.GLA(EX%/%^,,*G*"*,!4B- =4[0D&ZMT:UD :N*<WV(.5YQF/0\Z#'3<D9>
MDQEA^'V0+B+#C1"<"H*%U.!6SSF R@ HCA84E3H-T0&'DX*QZ_9C037E+&O2
M_<-%O&9F_P -+(2(Z3VZJH(\,GD=K$(NM\Y9*G':*U&,DU&CUSAJUH."1U6G
MD5?1/Z2,D.H![("A%(%N<4X=VUQU.CA<%4B9;H[06BZNU59O K/CDV-)5TUL
M+$UX1F!@X(B%:)@N1FT Z0J]"KL0( '(1F5ZH +'2E)CEX4*.MC"@(B6B/2<
M7\X9[LG0>22M>V!?5&;3DJ+8H/?"%5050A!S $.$SA#(#I?D'=O,L1A:JPRN
M7P,/'$1H4[*XT1\=_?ZO%J(:5NMF$R#-]>#@=6@9J8-#-DHH@TO&D="3:B%7
M5%97DWFV1XE1'0!(B.0;>NJ"*,( 6U7$FTD4!D*+D@EK3EP+A0KTF@:6FQG3
MS#;MT^X>Z<=8$*\#".NRZHK8C('%+I-'N%8<0I*4- @,5FH,DI8"X 0L 'R?
M)"@*:/-U(<5=  )'0IP!Q<OEN:*-@6O!YF$B)00$!!-#7F\VQL6Y$!'4!B<(
MX"$@%H^O:52AAG)V^^_T^WV_Y2?X^-^.OW\O 4>F(?KX4\?'2QBD LG&'FU6
MDY&43G:1>R)#)5BYZ2"NY)Q8-(]< @<&A)?F# V+,_9RT,*)&)"6D6U."97(
M!2($15K8D(6<"ZBJ CK,<4"N04\_FA1(D]\>(2UVDRL# D76X+>50AV"[6Q6
MK7 D-@J+O>]=]@>N0P49?$2D"ZTHZKLXA"925A]I/.B06Z%!4T55O3D[X 1P
MCV2L@ $->D\8<>!N5 0CZB@JC0$"B8X(B6#I)AH&'1P91.I(@(FC:Y6#$P%:
M:VB( &-;&@Q"DXF+C@HC>IV2GB$KD54 :[<PPR076QDB*@@4T!5Y2K9=A<@9
M*413@" K+$(FZ4R)@N B0C %*,LE#($QR2 )F_4D10$+O$L-0"DI032,.Q*O
M&-IR8&)48#*+YD.Y<H8Y0@@Y12UOVLOKP&,H[JG0?TB=<L4H6").&*B!R!1J
MJS0J8VH*JPNUYC!6%[>$V?;\;R@R42D/"R@LLWIR.Z%\4BA**$4W3AP!(M %
M,G(($S&B,PHP-34@JZ@MXAE 1K30D \;YO!6(#+OCT"!Y;;>*O$Q4*1,-+0<
M J/6FLZ+=J)&BO=Y#V$$?%^;OE[<UAQ[8V)@R:?J=]]?')<8&S._(&9]/DX$
ML"4NWR^)]\IZ?LJDGC;KN5 $8<(W*O0<?!3JKB7T3.Z$T -NJ X$P91H3(?A
M!@O#G-=Z$0D BCA%SB^(<%JK"H)*YER;P2#O/95\^9YZF3R+#9B"R/SE+X*-
M%.7V\G<01* @@"N("H=E1'02CHC7!.3J,X,#^)3*H\;AQ::WB(%.D44B0NP)
M$&F@*T!JIQ@IF:/DI3S A=BUY*S% >5A<B"Q9Y=#FLL5#Z884"6E\"48<S]P
MLZ8AU 4!=ND(^_;_ ,HW/4?LGX_AP!\01OD")J^V^OOXLUW !(""T-TT%!
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M )?^<-I<Y ;121T:4Z(.?Z!#2IT@VZ2J&-W!V9"9-D7+?!VGT6L)0:V=]-G
MP' ZE5\25/-^."M=8=P@"]^'Q3XYEMDH+,HGIZ*1Q0)6X0SS:LT!J$@:YVJP
M\@.JUH."F=';2*#!50/%X.38/1.8K^/9W.[P0JK"CC/3;89/'7!;B;H&%)?;
M[+9[XJ & 905T1"%[ TH45D&P8D0970Z!3$KI!+HI/ ]X(5"\ I 41Z)@=IE
MBTR0V^B_05$UM$DAIKHGN9'Z/XZC9 IE )  $4SIW(<O@P50!Y?VV> XSFD
M+4LSO3?'C@9ZVQP@X8^1H;[Y)P0$@$^="F)#&)$'A6"3@RR/*^,!"6@JICV!
M418].'=54B*%1<@W"8W;PXZ7KUI1)KJ0@P9;M:PD_/. FZNMI QH"&0<M^CD
M4O#V-,!0RBT!\H-7T61?+NO7'W;5WP;C\42[457TR?>K?F]_T@_?[7\YR&H=
M]S%_39PBJ=YWX^GUFSN'HY"WS[\^4+Z*P\5G\!>E$^7RDU_3;U/'!^,&3A!0
MZ"QW!+7,+4%5V*D%(BM.*.L#Z&&$F'$+@@H NP&B @8K '!\<9$$1%+??8P<
MCWUOHBP+"*P:=^:3K]>$#TX;FT(L ,^!: NEW/)"#3S:<H8DL:1!* 3X#H\)
MA,D3OQ. !2LH< @11?B@UKU4:' &!PPT!&  L1)W]FN%KVV=LJ/A('+PI!7(
MBTH@ 9[ZY VPZI@6*P*"YNX)W)#0 BK)""+_ !,"NP>2@7[^>;V G"LW2A:/
M8'0,:5CFZ0 ]R$  48K%"^!0M8SVZG$IEWN1"2 (R \#>W,HK*4&8Q<"3,BG
M,\0VV!)T"*(31@.B'11;.O7$3L<142-;\>,'M'FL:H$ /0*)))'U@$08AU@D
M4+:12TB"'FOE_-P_!#_+S%/)/T/\?\@BHG@?Q3.2CKT10^-PNAJZ<9"2111[
MJ ;$A,U4-&Q23(/1BY_XEM$NE$.H$WX^?F"(  )Q<608H7H@M%OW14; 0N^J
M\FMQDV78"F,#GC$ ^BLU+%2\MA4'#6:&HFEM0@W50D&S:5&B<:*5Q6?V @4A
MX0WT8BG'!/'8KZ!"^(7:,PMN5,H @+82=&]/-2\6E$L.M$:2"" 8W<MZZ_9&
M-,]H!:HW29=P*T(?K V#0^T';%[5Y+HP3$GP0(& !*"(M4##$BAAZ_\ &P+<
M=!<0&@1[P!,,X#NF1)72&^N-E">\RTB^5HEE:]%53$RZ2S+7WKZXP4H*[T["
MWW(9F^.+#2,+:*7Z3)U]N3U.E4T](*6_/KSPI(S!7 (0,FB,)Q'U!#0CW15R
MHAQ=5#WDA4E8@4Z#P,+5I6SR2M;SY&+6F7A3%/XY\$U R +%;4P=!4=I(+GI
M73?>>B?GTY-.WH\WX_/^D$OO\4_3^ !T?Q0ME7OY,/IF/VX8@(:ED 0,@(#P
MX75QF ,.@H-OO'0 XQU\+ BI5"T"!BG &K:]Y%^TNY+E> ^%(:PP(A#L#R[X
M+[T1501$@#8M#,\!&V71("PO $2&C*"B&=R=$ '$K2<0.SV%"CWD&9QK[.RR
M;MUYC$A&KS@Z^LPL@*%2\J)J-86JK=.C- .)T P8Z H"#U.Z<"$*-F([4.1W
MV?':I:&/*AE1AC84\+#D*]4(>@%^B\HKN2 QK*$H@=C>##?%3*'2&VM'ED'N
M-15FYL![!P CMC8[895>[*[O$'E0& 28"%=%5&%"Q X6R$:%$%!&V %12M:H
MEEUQJ<H84;5@94#(CV<5BB%227R!N^?G[A.9"A0SI:/BU_)JZAA9A=0(".D>
M^*SO5M J OTRD^W BON?E_R"R8M\'U+^!OX_' (-172P$.T=%**\D0J1 Q(T
MS(*++2\*(<)ZK5ZV'I[-Y6B&+XHB;W?W=;R(K"J X$V,KC9-\ U(@7JK@ABA
MHDV2+=((/@HH 5B4. ()T0(9' @ITSDOEL-AMETRP-&J4]19U9QI$ JM2 *5
M6D?0"9QO>APIL"@&H ' %020SAR\!A.212TDH\BASWZ9^F41,RC,I!J$@'%8
M\30%R253;NS !59@N2B6$2G91LEC418#IZK0_$ $ H<F$6VS!7Y"@HQM(;P+
MDZ(EXO)#4PF52;<84$CEX1 1*D8-LZQ-MUXQ2$)!BAYM]N^O-X.*S>L*@#G;
M<N$W.+:E*U T="&DPRM6OK(DE 104X'Q]((5Z]**96!0+*F00E":*-48V8>2
M_7>NN_7$'L'IW=&C]1T?#UR-SN7YF;[S%>P!H'(]3Q!0FY#/.^\O1 .C]> "
MIYGY=9U_2JZ*FW)H=C?'N3U8HI6OL0LH3LB1<,)['5$JG3YMTA\'@ M8[@ !
M3:+R<@"T9R<)),\"2EZT;'K+816BJ*0[+E&2^R@@#U 8J@H.J<JIMW@+Y3.
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M"F80XE<[$$BO1IAH]'C@XZ@#!A!@@8O:JM<?+%;1"&- JNMX3E/4"-%-8^
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M ?ST<%:O1V= \2IK;\H:X2A,@A3 'HUF<*0M5"*K@[>NFT+6.#"=5WBH(+2
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M.3W*K%<"PFJ-@7R(9C40>1Y%W9]DBN,$LDI>7!0%Q1B#J,\CBYMB I.YC/\
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M2>E$!^F5X@* 155))[W)#K7 -KK&"6GHJYPA;NC7ER2NVCC38A +[>IJ"0T
M&:J$-$$!T)"&I,G"#H"@Z,/ [7AQ=,B2.> XR U)I7E).X"[M5:J]>F<7+8#
M"0DJ#*95*I\?3\%/I^_I_P H+A^X,&^-AXG8+Q\#.0/ @8!$  .2BFWZTJKW
M4J[("!"TTBO;4(..D."2(8E [JV6[9$ U#ELST$E1@7P3E3O;U,SSVR5\RTL
M)7!W?5;?EX%9P?J(16N.>55;"F]6?$'"F0HJ&TPT3)&)HDGP(G3%:T"^^VQ
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MO6.03F'2B& )#WHX*!0 2N OD9FH?A@Q"^='<.=</@>30 *$T.T"7(XYI$X
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MRR8X;PG >H+(E2QK2"H!15Z\_>?G]5_AT[GX>SW/U\\;I;N:>(VT;B%9PI
M1-*&F%7#DC06A8AN#8PWP$AM](@N0Z5B ,!$WH% \'.(PRJ0M)*02<7(Y6!R
M=<80L9-9Q@M:.E*0)#PP%O6=:(?/9&>'+SS-O@>*BPLV!XOB9YX!>$;VR#YT
M4-@(8<+RYA*[$@AAXG?9*D%?-7MT,E9AP*.$!84*G"+X)T'I?EH%2.!59^:F
M7<[/D3A>W/774_3H<W56='@3%'R*,74WJ?S>'W_MS]CZG,KV#IT#H/=YL3F\
M+V-54MG%1!X-$F*D P?LAZ\.D@#!DA?35/Q%&B\0BX3I(P 0Y/% >9^O%' 6
M$*4!Q&BW*52G'5M0\YPB_>>>M<93"!QD48%UQ K=BM'14<ZE5!EE!,.),4E
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MAYQS..C&P4E"H*U+A9II-DP2&\%UTSF%9,A>E,,:A!X?_P"8";;Q=EV@-<]
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MBO"6K/MTN[H/4M]9_5"#+X_?X?'7*A#? 2@T@@A(<#50 (;YC"!$0@+3AQ0
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MA 0Q!\[T+FR<4VME:U=64"+A42\&*15 Z/!LOE"P#B7LDX[\*[?3>^+%8XD
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MPGY[3.$9$5 UY"3!E<+U>;3=BK*17 V@DBBM&+Q> H0$0@2KPN#H@ >LT$0
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M%0HU\1BN]QGY3A!K \0T(24) I05565HB.2<*X^0M'0[N]I*]N:VF*&(EO\
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MXH$$L2J>9DZ;>!9,*0"-2&!]A.$PB'-P=*:4,TJ"3ZC$8'VQB08**2?C/N0
MD\'%$1&PB&[H02&\1\DMJG"6$*C1QO0ID+G0!$5AEA/ 2I PC0JIB6SJ*Q2+
M([G(&"14ZY9', B11$LCI>SD3#JU*1%12JJJ7MXJ,#"G27U!L&R^7KD.P26
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M6C"C0#Y57L(6S2-'DMFD/KQ&&C84268E1[I77@TE36\8P.U0$WE+.VW8A63
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MUSV7QX[]<FD+6 N3KX_>\570<S._0H_:^>)@/&5.V(=H @C!%0=L)*6*J 4
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M5%=#%;?LW>O[]]<4 <HD+$\EM^^9T9PA2K T.L\'S^]YW]/C[??QX??&LJI
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M[^=F0\&5*6K_  -3OUA?[GSQ85Z.H@^!%%%\&^,X)>R_@$T(DP*07FI^Q*Z
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M(!4O:2?25SVSQQ290%0!H4)@HA2U>)^6*\685'(?"0S%,[K(3!$.5W'Q6O&
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M#DE"R\B*P1"Y).GB6)8C559E<7TF8T6CCV>]Z:/-'T*$"PP)?O$5YBJ=%!)
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M)\O52L9^LX',5$*G:K75S&X=%> V(JP)(,P$5G8<$!-OU!C;.B>$VL, V#L
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MBQ09B+4(Z.NHF+26KIP73R3)6E*YVFDM*@H4T.RW&)]&Q^,R?5VN.W02I67
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M![R?/5H0S+.(Z%L.W6O0+044D' HT2E+DB*+M@HM$D0$%'@<.,#I&$=80F]
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M(BZ)>,W'07%NH"70'0' 5)U3541JO4ZN%6%X=/-XU.HBR\H71Q!080*AC0@
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MDH@J)!4D@( +5$IDUV+N>\.C[<6_&(P=XH8:)<G?% ],=972^-OQF<'_ #5
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M%*PF)(F-.*JBO)L0P$MY@A7U]B-" 1%%4"N'?NJBHCL"_P E0\&ZVB@)(L'
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M'4>/=N"Y\>\<]R?7FS%#SN/&MB $3. F5R !#D@@AZ<B18,F#V8@M6$NO*#
M@C911:6 &F:7-=VQ2_-W+8[XD1E;FRR"5$";+ ?>>$F3?+MW)!X3@3D4V@2S
M,LU;Z:9X](/$[D>21DEM=0CD( (0D.B7,PG77!JGJ?G_ -/:OW\/H>DQQ!*G
M'FC!&2\ ), 9T<$!4O89<&;?Q!7.N9$;;;#69@>OCEN\*"8J+&Q0 0,4:/,0
M:59I(#;0"N'GOM[^=I];]NH?ZI\^[C,-<U%\P3Q%+D #H@\$T #;VW@A,T9(
M$-&UZ2$U01\+Z$&\$ZD?.4&LS-A4>)4>*TPRT,WC#K8M.5\='HP+W PO;#77
M> P.14K7%0&$+@'02$1U"8/(QK0J@A1/:?5$RK-CO(2^="D*^!W?GOCG%O&K
M JH)*<^!$EF7.%,%SI0\CG!2\"M!BHK2"X  T52",4#4D1$"*$*)@40&D$+:
MO3HO+T8:HH#!"ED631L+&!VT9F')/67N'[#[F\H*.+-ZLOD YW#//9Q.+%$B
M^!"M^)WP:HS 81EOFU&8N'O9_.TD05<>W'HB^@IF@HLXB@[J"B9!@"-QP,H-
M,Z_V_+^<L6+%BQ9N+:BA1:-D5-K$5\8BBFX]BD$B )(>D/\ T4:\A+A[E44$
M48(Q+7$U)F8'!K=5W@6)EU%"%D\])-O7!G8_&WV)$H :T2<.8B._$V_@6)+R
M&0';5?5@IJJ7B^[GHX"I4QHV.)>TR  'TF01O*M+4=R2Z#\R,[%5I_*))(#1
M6X2"8C0"\LZC?WX;V&X!K*#CC/Y&8@-#0$4D*X4+M#8"T(BP(G&&>F..SR!2
MM :C1@J*07/+98$>U\8>=\H3:\Z2BZF_188! Z#0Q#8E6%B-.3Q>V!1R-9JN
M_*H4\MNF950L[-<?%N2N)V&B:$5PHI ?P^0)L0%@AQ08 'C3L3[FFJ@%2$18
M>!CF5(2^R>A3HY>6(&()Y(8.U^W '-%@;H?"(DAGJ\@*/X9P.HI.DNY4"&!$
M[MHG-KY*M:(@8Y5IX .X & %J#+31P6U?-)#3(R=8,F.0CWACX"0O">?Y?;L
M DC&-Y'F%5U3!$0Y&O'L1C"HK):]<%CB2=Q"ZE37FI )!7%(5C)4"))0)!4[
MR;-5(_*:">B7"MJKC4AOKX.HT>5HO\WAV;X7QZ';F$;HXHV. L*&\<M#BYR-
MVT;JPD]1]>_/\V+%BQ8NREE(M$=:3% *D7_ [GX\J]9/X*1W278-.W>@KVS:
MM7'_ **) H((-%!1Z"B] JIV=4K#&%" QG505S)%$Q=,3I!SS?8<==%H-&@*
M13\X$$#)4I  :-@;@ AH('4R]E*= '0U*C9><=5(@5(L>]XY"]Z@8PG0D6#=
M.Z"Q*(Q"87/!O8B3W-O3(]?4\A_(G@)0>JJ"'1(+$'+*2M1Z" 2-$Y1)U#XU
MA($MHXD)Q!QE%C%(2G2+<-H'!W<N:!,TAQ+6&#Q2W>=KR085/<("@V/$I10C
MXA G13Y22K32$39TH8>FFK@5"+@+@%BSE&K##!/@,*9/!:;S2D!V7$3-G" M
M!9!,XT$U&"'2)%5.87"*2T=7<P-7(*W%!I:KV:H"%5^F$?F01*E%Q&L4,0 ;
M!VJ(D C@.BU5Z'NW()^,3,'4(*+9H0L05EHN!0G(F-TC!@X4((B.<<HK9@.A
MB&D1X%)Z-M0*S*@.2&#-(BN\49K>- &M4X9(!VB7$P@H]A:\I$QJH3'B@5U8
M*DX12Q,?:B1>M2Z*O$4OL#80$"Q$=M<5N'XYHH"QP@6 ! Z2QA3?4T&.""XY
M.ASWH]@>(H_S0H^03MZ47]#]KR-[TF*>5O>*K4U\K"?S?O\ ?O[\Q#)H8KV*
M1HK5PJ! #K/CQY>NO.OGS_T40!-4%XA$M(R*@X\#ONA4$!9/N)'.HK$T@+0.
M8 .31ODN7 &G)1%(H:[UU&2FN"; .(2O'6@O!3'5XK(6W:5J[F@@;_ !>">T
M(H0BJ5ZAY"K&E22P$57F@XV!U91J]4$+!&_I:(Q2Y^9X<_BRPD49ZS0 3:\$
MVM2*%Z!1^0/0X0 .6++3(U(FP>*90 # (-(>Q'/KQ@$L>X22*$3*:!F*L$=2
M.AN>ZTRH#BP#W"8JBH0M&6TTP@S: JN)=$)36N=OH'B8KIDA< !916OB$[+"
M5(U!5 U0IF5/(?E>32LX?)$WW@3UH$5'BD8 7!!#!8APR6>0V>QX]EXZE#M8
M8+;=X_:JEQ#ZD#TKM%9%D "#@,"EH)T #&(]<9Q:2 '0I%$Q+[#ECJA8T PA
M(Q/3RLQY(]2T2-[#R&Z?-TBFD=0>3V^>E<$Y9AG8J;P38B*-;HO/;C)WJ.<D
M!X848[AR."(XI R'&>QO"5$RNHM@8:MT9 'BICLK7#=P/IY0QXZ DB&$/F#O
MO?K@/!YB<E;ID&%@')?BIP 64>AJK7_I<C@TZ6*,$KKTO=A=&G& GPD4\4F
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ME<K[0 VVYMO"'.*- 1OI V3RBA#G<^K&XP,6ET76?W8H[KHAG[5!C/!46'%
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MH93?2^A :D3DNYR*>QP "'"$JQH[V=50X0P.*%!2 045:)X2EL5AO)GAWK6
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MSS71604E!-YH<X 6*"U.!+!P)#?#V%(-\KWT&#WR7&K"$K%BE;ML.>!K0,
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M_5-#,$D+F=C:HGL'QT$(@JA?P<'X%/K,/SOVGF<7ZN9$7T"2U31S'E1&LE,
MRT%1XV&U9G4'+)N+B45>%(W1)G0B1N4&,Z=,' 21L@X$VT,)E$#$*C%=*CJ)
M$LJF*AX(0;"NHH7P=((%AL !3Y02$-?D04FP%R97E]1ZKM"ECR&9Q3PBK*&
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MA;0X>F,PJ(Q" Y&?IJV6W5Z,OVG#T'^Y22"3L)80X+R!O,3?L8M-1 M?7%K
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M\KGTRM/D90!'@9&^;CNL6 \7(J =?W_?P'@@8!_/L084@(2I%E\$B(8L?*$
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MK:<(PKH@M*R= 1&24;[DB(1ITY;*&ZA/%*@M,D(N.":KD8$-@(#/#IAU]0G
M+3"Z475:%WQ23AH&* "W0+DJB)*=0KT=G#!$T1!,%X*TPF(.B(&,4 J(^1>
M VD#$2#P2HV\\  8HBVH\7.K%FI\C!5#H, IX^#2)01M4;@/SG P-"YH;<1"
M*A0G2D]:8N"%:8O#>O315X2 :JA!!4C(_?+&@I42N*."-ZR,P@E%%/;Q1LK3
M5\&#S"1$!P'.Y'12!(4D0E.-12$ ?B7%-QF1X]6=@@MM4H"R -)QZ+2YJ<I:
MN'*T-\_Y/'0/78@TO.32D_<#X:-$(*4P ,M8BM"2,(@BB3Q(_EK&R2X@#HV
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M5F$4,8J45W(@@G$$$*="D*O#FW\(6U8@^"EL+> V4Z@U%A@+Q63^HD;L&7Y
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M!'Z@+XQ89B<<T?!!7@Q"E>15#$+!WA*1 ,"$82+5:+G1P'S=A613J>"?CWR
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M5Z*(#".:TW(HP%1[1!VZP/!1">NA*;"QIGD)A>1UM")PJB!Q H #K!3J80"
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MH4 /S@+W1M2,& )R"R9Z&D2,;E+?T3H6:.(,7.@@*;A'R1<#(XPBC D/2'V
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M&W+S9,HZ*(-( AZ"8+%<"?.JKC*7<$[2]%38D:$X^;U(04\Q3GI,?ET:-![
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M@2*T7X^D>@!%Y:;HT\]K]L#N0P"AA31"-C10DDQP!BN.*AKZ(4O9>6WB@9X
M1@5@ZD@8BO/V+ \J70*Y@#E^2/RF Y6B@MB2 0I4@3X*0D:]?IA90TV#6)(+
M,V638-'ABTG684Q%1@;@:-")WX,*]5=D,+4(1F<;$8 VYW2Y#T2")M/9L\04
M\)+A#U6T06@JY!J%53< :3D(:\Q3Q@K9J&NHC".(J=S?@Q%HG<F 2MG&T:O@
M# ?[,^3@ $$T$52#I$-&<$80; ]9GA )Z7C HE6I;;8$^P[L.C/KO3<8R"C3
M?ES?IV*=5I*TD.(VK2CR1:L%@7@XRMF0\)70H0G MJQ51P$ <L1=X@9CIV"5
M&ED"- (@!T!I<'Z# :M IE%UG2M0/ZHJ'<A#%P;_ %M?6)$@EA,#"1+G @2P
MZT@X9+:3(O!(,((J4I%!29'!4$G%LQ(KDMH,E9GF$Y#.C-*TP7D H%AB(4'A
MD&^  D!';$1 T!I6G@1KR!0<(#0%B+8%]B\!2)Y>&QI+3+@ZT1":1&F@9!-(
MA"A_UR+D*%IO75JTP!4-9:!!1T>XYJQ0 #R(Q<81@YY[OX(B@]_7]_3L],>P
MY,AH<"^<F/@<6(.(9'<A&F_XF"JADXD$NV"CF_T))T) A_!.HE.$($B/#3JC
M@,IB5Z%-4Y@:.(8!$H'4*H/$I@RJ]JJ$@504IT'@ !).F<AQZXB>.L:RQ&L[
M%,?*C4V$3A3PL((D,IF34/ FJF]#0U1:-EX2E]_>JB3%!>!L%2@(4/  JD!I
M$R(=^5..8!!'G+6J>;9R:6_14\#F;DQDE25K_1!R+>%(%F!9?)0ZPY)P?#O@
MA=D '/P1(W$B10N--*7VA(<L\&X.3EV?#8"CT4^ 487:<16TZ"<-(4,A)0+\
MA&BX0%SB1R<(>?OF))E(1$=,."% 0\0P<=#0X60982Z(*0 JT%T1:6H%(X8]
MR))IMX2C;1VQ[Z$2%B! *;7^E!L^WT<00&D)>4P%A1BH(X;\A6NA9.&HJ<RD
M-SHL_+P\ B&H+8)8\.E**>0/*=>;H=H1&P(X"Q?,$@U!V#4;V%:2 8"9)T@U
MNB"55"I4J+U04&.U0Q%F57F_NW%4"\%H<$3,K<$2@=".EJ!5+_Z,QQRM!%%%
MRM1"D484+EZ;YXNC"1.**5-$3H,EP52%(!NDU@I6GME0QDF2+HB*I @#AH[+
MF--)J"VSE /2==A.LI/-^@[1M3VN*'5.$YJ B%,*A<+G0H@BZTN:A1<)2#5+
M.0CI*P;# ?)\*B(BH6%\#2;&P%6"<"09?6;J0->X*9Q3\6#\H=D/$4-)1Z&$
MI<%,%$ 1K9_I))X/++\$^2)1(/QP4YT%28,]L=&T3IG!6WW\]_%"GI\_P=@^
M<[3Y\?3D?B[ N@4K=[3AC!2BF-UJHUA7@.@0"!@()ODBN7%]\(I0F@@]7;4K
M[#IO0"D-H,( [(5,)RSF;8L()I08QPO $0*P]0M!\1 I. ?8@L(I3>SKD!K)
M1X:.W&[E^_" >@K&"$),)E0X &\C4DH7$(I X]YP8!\I&BD0#G6B;:T[%Y="
MF[>M\=L8,H*P@N@P$,8 @0J H5!5**-%;RL8)"( GD1)X!-AL)0RI;KQWFJI
MJ"#8S;N-GK>2R! C0C_<CM'KR\$'"O"K9MJ:\R@C4N[H2#D.;>-Q_P!@10>P
M?K\(GX(/U!X%(&:7==.W[@#3P Z)U^1 ^@'7\8  60,J4OM#VDZ7@!3=5U5U
M7M5@K"P8  (]'X?-_4OUX 6 5K *^WV_+_"'K]_L/PY/W5^?/U_MT'\$'O3U
MX^YY^C]>?!Y&^5(5>U@*U0CG.S!O=V_6]G1&D Z#@!8=R^U *OE@%=@>CB#*
M6(_<T?LZ>D$T.!;-]U70'5N@NZE:[R/GNZO>?/6#.KLN\PDIG=>I.[U!^H/>
M\ACY"#6SZ]_Y[Y#\&FO9^]][>WD8)9U54=**T8I1L9> '7U[?\_;Z = $-^>
M]=[_ "W#H\<AZ^/MZ_?S[>(9WG44GX)]+Z4Z48]!],N=IV2$:8>B1;-]U]2=
M]>9UX.W(S.NBL\^.O/X@]A(_)(*&M6#VNWO7=> &!#XSK?'CXZ:WMYY)NZ8E
M[1-%\I%RN'%&IO8^F-'JB1&,LX ?O]Y\=?TJ4AX3:!QO"%$!HX>CAD"'H 88
M 3!QZG#^'8%T01? J3;HSCM;,KB;(Q.B(H PAGW"[1A4JH&1G@\&1FF"$J%:
M3"4APO@-C$!5(:H .4A:@@WA2H2 9R$7U\^9KYQY 4%Z"QU)+4%%I8X%D!=K
M2WN$"$[.*!8UT"DI@'RE5>>#98('( 2X%HMM$(#:D@M"5(,CTF9"P: E8![-
MHJ"*N(ZAJ:123V(]\2X6-&F%PZ=W% @#2U";DZ) 1&)X.8[BB8&XP6)P+U]^
M5%ML]XE 2[JU(NF-K"%@7<E'(0W%>+)"<!%&0U%E",@%.,(014+($E"@NQ"/
M<QX5=6@9MA+!&."IWVN]&4B*=JX:ZE$$QC!:3)  [;2?SL^5(?:=(1[,X*;T
M(G46R6SYS2@M"C?##/,4IQ2'Q^"%M(:_*:6[.$8"HB)4 IS"*/L!1LD>$L40
M:$'2BQB*&2T *0&1H<07-!HPXEFD=UIZ/4GRE=6EZ9ELDJB=X(5@BJB2HRT,
MAP W\FJEIFZYD1DAGDXH#8ZU8J%U>[Y,O-$2(JHBCXOP;QZ5Z+%JLV_2WSWR
M>R7L]4(=40C-Y6>$$ZQ\8%0H:$U6FS.L4@8,ROEY:RD:^?$(5:AF!B>2Q TI
MAA'(GF#CCN_6B2XHO+[8'2X\=9 -99##I8A(I-J'G;IR;7. =L PR!89Q;\J
MP \RZ7S^7'OC  ]S&!Q0IB+PRUA20J,+P! @0_Z'(D ((VTH0Z'LH^_!$4YB
M9QC5\U0XP@ -#2@9,-(E,C2* UXO]?N/% @8X'(>6_+V6,P'BH O%0-D,0T1
M6Z,WSQ:<D;!&7+!QLG%!MNVU:Z&*1$HY6>;SEH5)B64ESB,L+]O26"CP.1'#
M'T!QK"#R&\89*,0&6RV02LG+]:%"  D F*06T$+MY19) L*K@)B5HQD]&"1Y
M6,T!TH8V'?4JC=/?9N^1T9<2 @ <WT&C0LNR#I>Q-"8 JV!F=+7A[0B2"*;
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M@SXZBGVR484<?)Q'ZD8O?&&JA"7A1*$!D<M(D_ %S56]SH4(JQX#31,L!]@
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M@\@+A*N5#0"D$$0 XD+% 5@KA8 HD@=87CTEK "8F@6L1N25=L>DZ$5 5 )
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M!DN&"$4@B@-0=!4 W(I=-2'!435!6P6D&O@B/!&^TH!W5:<[[AC"&R  T*!
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M>@,"Q@5%$H\@J;RH$6HPX?&Z< W9!5 "%'0!2\4KB>;B]%6(WN0>2&(5Z5&
M/;# "JB]RQ+7M4BT*!8 0X"EU8-#J$I#6I.E[PFF'!;5!H),D6W:X6*'3I/H
M5CPQBEE**%JK=/CW^IS.IU0Q4:,Z0I41!%-GE!5%<9 +CZ;=#.!H3:G[N_A
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M68H%THO( T9P&)7N-4:@X%2BO MG3%NFI*UA'Q$FY4V 354E2)=1+'\>D [
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MA1F-$*>(J#YO)YF72!41FPS6J6_-S7+XWAJ"::5J+0R2D4+8:N\)4Q.?R("
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MV !RB)G?!Z589 DFC7[55P@K68XH@U9L30@Z\^43P*68R-D(4<@-+6K;+<0
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MAH*4B\&O,M$H4E0E\8\9-GZ!I&N+4!6*%-"J[%#4F@0X]S.,RQ!3-9,<IO-
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MJ0U+%94%#*@N= M\(5 QK:I/*8X9"TT R!6!B")1"\(;*8,P&6Z5S:('#(=
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M5^ @'*3'DJ.F#L<.+FI0?,E :U\O1(\"-2$<-I"2210H VU>J=THK2B @)*
MK9!Z)&<; BG*G7$H3C 5J44M:E>.]]/CQ^''>_4^WVY#%F-,M XC3Y!+#UP
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MD*&$\''/=&*G=KX$@URO;<4&9&% =R"PE$>CF>V1E=5Z!! 9"@5M)58]'1'
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MX>:,M?K67P-FHS7% M[#5@6DOR  JO4%4J7[B/E$>Q513A5 0%4\58=E>0@
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MW1#H-I),, X@ !Q^]JE3K(B1A88!$E&'YV<@\U=9/5HRGIR[RJ:J0R;DK'J
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M0JH$L((XZD?U!:4:.Z:UCR>?.GNEZ>*&W  3V9SJ" /&L%N,4(Z$PG :#>$
MG*?0B$&F-JKQ#*?AW/U":( A*5)W+W*Q^*1#LLT/\B#V7IWV(C/8@CX>N'2(
M]/6'B6X')+X <]54:#Z.'!7HN -FAP3LJ)&;O(R-;CK,E0[L>'[=)[%TBAR)
M )'7* 6"&'E)P&6FK2I[08D!3CJDRLR14&I17(B>2+#"?KT]A8X/A%\8(G@4
MVXU6IHH_0KL.VV$(K1&&-/0Z4.ABEE^>+0!KF_C(+7% !G(EZB2X: ;R 6'<
M_(@'H/1"JRJO%_? JK AZUHT-H7CZ=>80L)&DJ;05F4X56^7T/'S.R:D@!"
M(I$"SJ'GUZ.,\VA*&T*@ Z;8N^ GT4[JV\6V(7X&'OH<="5<#23?]HG(AWY*
MPZB/RTT0Q%A.]-#JG8"+T</CHI[I_P"OYJE2I4J+020TIMSLJ1"J \"<-*^Y
MF*#^4^7Z']_\?UI+Q#*665<Z;WV3.VHE:0AY1K*BL\6%G\$!9!I4.KNH!'$&
M( DXEB KZ=I#WPE!1-%]GG2J( 3.2Q-/*EMKTH9+0I,2=W +/(-*D0$0XTK
M<F]G^&E!*;#TK!7O;L>-VX&*@H$\_P ).83B6A6!*!>8R6H?,S( 04>6,+].
MV++7<MP" 3/_ +OZJ_5??\) KV( *G8@J/P^.>5HDK*M"5%)BKP=RA?\45/G
MBF-FAZ:\E,H,4KBJ(J^!,H5\N3DP4&>P&:.M7555_DA@W<Q>G2(V5)N44#RQ
M6+Z8#N8*"N$P*OV['6HHE<K3PXGFVERN_P 1*/7D;6TZ;?6/O2XYYZ;HVTD(
M:E%2A5*%'F&8,,2#@     @& ! @ ),_"/7_ ,]?3"]'UR/7Z_A]/CKD*OE[
M?I?\_P R=?#>Y/K[]>MOCD1H]2 $ I-5*)JF+BCU3N,MGC#\+T$P)2R-QTBD
M\GUX(\X0)0$\#IV\CG#*8M8[+L$!H6P ;W=5D(D_[0A'QFS'M*6T%Q/*>1;@
M*!9,+O'[ZF0:\7E=?J]NMG<Z^;O?\HD2)$B<$J(@6$[!E,6B1)4))(4.K'\\
MLV\JU:.8^"84!>5H"I1)_6YY 2(P5%J4(3Q!1)RE!@O:R:"J*04H*JPT@44*
MD;1$2G)/@!44 G6$VOXW:1O0>V+>)C%01PB"()## $A4K@VP%ZLS$;:VITM,
M/E7*!E155=D#A222*Y";;$BF!)>@I=*F\IRTV(A/4</4SP^X*/%53T[A5(8%
M# #"\4^<CMWT'Q:TD]=>;E)6)T#H49!(R'2["VQ9JC3)^VVEA'AHG <(V$5(
M!1)(L54-5D6Z-C39+,\SJ@&  8 '0!Y[7^5!E.K/B^3T^GLK'7B2!A3!G5*O
MO?.][RG9Y/+L1'[(3Z!T$ ,"?Y>U]KY75[_U5#I?*!5#P>*X1F624DF-4*%C
M#)85H,P2$:VA(&+Q<()58:4]WU.^[E2Y<Y@UF1G:!8X;^?%8\F6Q1I&X ""3
MBZ8RXI0KTA5+_M*7-^RG3>R/U]].<A_?%/T_3KKT<Z_G09;C2*=>XE/8T?(\
M .B9/@"P#P%R>(=!_6JGAFJ^@UP%5\ 5W3CHZ\+:2"=620X(S<D(06JVA1>S
MGC&R<6@.-E2XEJFUT"8J2KS./_"69VQVK6'&,BU/$"K52F(@95YHBA;L5.$+
MB8VR01O^1@.6>Z59BD!2@1B<&N#SF82='95$AG>!EU99Z+7T5XQ[E !,!KY(
M;40KX /]M(821)X(-J%H5>.S1JY1I0("FL$J@1)!Z>F3BY/"LHAHJG@,M"\1
M;"YX/34<_L;"K2)'Q$_ ['4H?-I\A++W3:T/P $Y5Q&PZSE1&&UXQLN1DD(T
MNT0@?[3]_O\ >^>5EF8H!P,#<8N<A4*1+JV9M!"5HQV0J"(E<<<U>$X+EJ]+
M'9Z@D1;D>!/ETA27$ K$%P%@P3A-E08 $G_2:#+XT[$^YOU]\ P /1AW<#I7
M5-7O@!U]^]GE^?;VY7#B#WX^7]YV>G3>$X2Q&T 5$76OMXBZO(DB#  )(4$%
M&G9<35>R+KW%+W%+.=F&M?:Y%>U,'LA'#CSY051EB 0U^Z?$=2NL6I78O98]
M). "H:]OGR_A59UK[X@SX:?7D59W+WL)4ZLQ>T >B ,,^[F!#<880\RKR/7W
MVGT>S[3@'0_(GAI5BI6=JFK($0T(-;+9WY>_<+8<BV5&BZC$I;,4R8IY>0>.
MI#P0A#HSU.+2AC?BV]=;IF@6A%$M7X6J5*- $*  Z/OVO1JZX!O@/7 "P[U?
M*P*O:P"O@#Q_MB$ %% $3H04#D[SB>0CC%A8M-R(@Y/+B84"4)X]HN%6J,R$
MT7L,RASM^^9/>6L+ *H!@0_0]'H/ 8>/^P/@/P_=Y#_SQY.NO/Z>CG1G1#L0
-\Q\7RD7+T?\ [K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>inbx-20211231_g2.jpg
<TEXT>
begin 644 inbx-20211231_g2.jpg
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M>'!A8VME="!E;F0](G(B/S[_[0!(4&AO=&]S:&]P(#,N,  X0DE-! 0
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M-1<E5$,V_]H # ,!  (1 Q$ /P#?P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M1OCFD6-J1K35E2JJBITZHA-GVML,1-M.%'BSUR<2T163
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MHHI(HH*Q61NIY)W1JUJM1416Z)HG>-WN,5(PS,5C72.XUN+):<D1K+? TC9
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MLLLUYI76&4OSH>_W_"&W_P#L^Z_]ZFS_ "W'RSY/L4NN7Y(/G0]_O^$-O_\
M9]U_[U'Y;CY9\GV'7+\D'SH>_P!_PAM__L^Z_P#>H_+<?+/D^PZY?DAMO@5^
MK,IP7"\GN$<,-?D=AMUTKH:='-A9-64L<TC8VO<]R-1SU1$5RKIUJII[UZ-I
MCDEL*SK$2ZPQ9
M
M
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MTK%ADNJ0W79:X45C[1R+<:2]Q557V:+X+O%9*.!FJIUIVW1WU+D]F3IP6X?
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MBNOY)6'8-U\"? U6#XD/Z0SK[:@
M
M
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M;'[N\UY&QQWZ=8E*A$S?S><I/[8VW_Z177\DK#L&Z^!/@:K!\2'](9U]M0
M
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MKHU7A<G=:NBIW4*-J36=)C1:K:+1K#HS%R
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M+BOS,]G?CJUY-4O/YO.4G]L;;_\ 2*Z_DE8=@W7P)\#58/B0_I#.OMJ
M
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MS)HX)&SMF;*R=B1J[A1%:U'L5R(J^&NI)FW5LM8BT<3''@C'.L+7E5,
M                                          !'>[6%77<?;C+\$LV3
MKAU;EEO?;79$E*M:ZG@G5&U"-A2>G5RR1*YB+VB:<6O3IH28KQ2T6F-=&-Z]
M*LPJORO\D-KY<LSO&;U6=)GEUK;6ZUVI'6GR<E$V61DD\B*M95\3GI&UJ+HW
M1.).GB+.YWDYJ]'31!AV_NYUUU7L*2RA[?C9^V;Z[7Y%MO<Z_P C^6.PEM]\
M2#QEU%54TS98YFQ=I%Q_4JU4XVZM<J:DN#+.*\6A'DQ].NBIVU_(QE6U>$;N
M8/8]^%DH=V;/#:ZJH\W%C6B>R16R3QM2ZNXEDII9H51%;]4URJO C5M9-[%[
M5M->+O\ Z$--O-8F(GC[SIN5_DAM?+EF=XS>JSI,\NM;:W6NU(ZT^3DHFRR,
MDGD15K*OB<](VM1=&Z)Q)T\1CN=Y.:O1TT<X=O[N===5["DLH>WXV?MF^NU^
M1;;W.O\ (_ECL);??$@\9=155-,V6.9L7:1<?U*M5.-NK7*FI+@RSBO%H1Y,
M?3KHA/E6Y3KIRR7#+GLW27-;)EM/3-J+(MF\G)%54CW+%4-D\>JOK)'M<U&I
MKJU57P40FW.ZC-$<&FG?1X<'N]>'5/.]NV?ZXMK<OVT\M^;GG730T_EKQ;QS
ML.RJ(I^+L.U@X]>STTXTZ]2'#D]W>+<>B7)3IUF$"\JG*)_=DN.9U_ZPO/?S
MOIJ*G[+R3Y-\7\3?,_BU\<JN/B[7JT;IIW2;<[KWT1P::(L.#W>O#JN<5%@
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M%-%P>,>49>'A[777LUUTZDU-AEWW3I->CY?T*E-KT;=+5I$:];
M
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MN\4U@
M                                                          QD
M](]M=N;G.\&&W/"MNLGS"VTN'04M3<+):*VX01SI<*YZQ/DIHI&M>C7M7A5=
M=%1>Z;?L_)2M)B9B.'E4-W2UK1I'<:C[%6ZX6C9'9RTW:AJ+7=;7@^/4ESME
M7$^"HIZB"VT\<L,T4B-<Q['-5KFN1%14T4UN:8G):8Y9\ZYCC2L>!*A$S
M                                              88WG*O24[<7*XV
M^BI<[N-!-5S1T4D5FI,J1(H7KP*E0E-<%:BM>G2KDXN^O#T;F*[6\=SQZ?8U
MTVSUY?.X2^X?S_\ ,AV%BS.R9E56A]5'VU%?*2+&;8U[$14FEIWQ4,3TC1-4
M5(W+KKPZO719*WV^'AC3SL9KFR<$Z^9J+RA\JM'RWXU<ZF[W&&^[A98V'SBN
M5,CO%::&'5T='2J]&N<U'.5SGJUJO73P41J&MW6Y]]/!Q0N8,/NX[ZXA43@
M                  ?A)(V*.25R.5L;5>Y&-<]RHB:KPM:BN5>\B)JH&$=F
MV<W=YE>;E,QW+VORO%,%NU\6YW.HOUGK:&FCLUK:GBM LE1%&U7S1Q1PJC5U
M57.?IUFZG+3#ATK,3.G+W6MC';)DUF)T;O(B-1$1$1$31$3J1#2MD_T !@?S
MP[.[NY;S+9[?L5VLR_)K'606=*2\VJQU];22K%:Z6.1&3P0/8[A>U6KHO0J*
MG6;O9Y:5Q1$VB)X>[WVMW&.TWF8B6^!I&R
M
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MHG:2V^H9*^)5^MFBU[2)W[E[47U"C?':DZ6C1:K>+<4NV,&0
M
M
M
M
M
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MB\:PD0C9@
M
M
M
M
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M9K>:MFS4+X
M
M
M
M
M                       %(^>G8W/]]=M\6L>W=%2W&\6/(F7&JH:FICI>
M*G6EGA5S'RJUBJUSVZHJIT=1<V6:N*TS;D5]SCF]=(4@Q38+TB."VJ*QX95P
MXM:(D3AM]KN5DI8U5$TXGI'P\3E[KG:JO=4N6S[:TZSP^-7KBS5XOJ=+^K;T
MG_\ QA6_[<M/NC'WFUY/)+GH9^4_5MZ3_P#XPK?]N6GW0]YM>3R2=#/RK<<I
MN+<V./WG,9>8N_272SU%%2LQNGFKJ.M<VI21ZRN;XJBJQ.#1%XE375.A=.BK
MNK89B/=PGP1DB9Z:[Q36      /!RFIGH\8R.KIE5*FEM=9-3JFNJ/9"]S>K
MIZT,J\<.+<3^>?E+VEWUW@IL\QS:K<--NL4C?;WY[<&U4U+)4N<VJ;1PHE(W
MMI4T[75BO;'HJJNJZ(;W=9<>/2;1K/<:O!2]]8K.D+(9EZ-?<C"K3<,VV[WC
M=D^96B.>NBHFV^>SUD[D8Y94IJR*MJG+-(U7(B.1O$JZ*Y-2O3M"MITM72/&
MFMM+5X8GA6(Y%>8;+]XML-P,6S6Y2WS,=O8&+19!/PK45M#70S) DSO^LEAD
M@<USU35S59Q<3N)RP;W!7'>)CBE+MLLWK,3QPA#T4BP>/;YHY%\9[#'.R7HT
MX.*Y<?J]?"3=I_J\_P!2+9=UL::E?8P["M<GI)-U/%^%L27++%J433I17KK]
M'C5%4V^?^5KS*&+XT\[9XU"^@;F*WUM_+S@$.>W+'JC):>:[4UJ2W4T[*=Z.
MJ(Y9$DXWM>FB=DJ::=TGV^&<UNC$Z(\N3W<:J-?.J8A\D%X_VI3_ - 7/RRW
MM*W7(Y#YU3$/D@O'^U*?^@'Y9;VCKD<A\ZIB'R07C_:E/_0#\LM[1UR.0^=4
MQ#Y(+Q_M2G_H!^66]HZY'(?.J8A\D%X_VI3_ - /RRWM'7(Y&CVV6Y>)[M8A
M;LRPZYPW.V5J)'4+"JN\7JD8Q\U,]5:W5T2O1%5$T-?DQSCMI*W2\6C6$@&#
M(
M
M
M
M
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M1S5T73H4L;7):<M=9E#GK$4G@<?Z-C]FUGZ477^# 9]H?%YG&T]3G7^**R
M
M
M
M
M
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M9AM/4YU_BBL@
M
M
M
M
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MH=Q\.4/>C8_9M9^E%U_@P$O:'Q>9AM/4YU_BBL@
M
M
M
M
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MHZR-8X51J/U='(O>7K(MSGQY*^C726>'%>EN&=87]**R
M   !6+G-_9@WA_,\?Y7 6=I\6J'<?#E#WHV/V;6?I1=?X,!+VA\7F8;3U.=?
MXHK(
M
M
M
M
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MD
M
M
M
M
M       #B;CMIMS=Y&S7; ,;NDK556RU=JHYW(KM-=%DB<O3HAG&2T<4RQFE
M9[C[;/@V$X\]DE@P^R6.2-56.2WV^FIG-55U718HVZ:Z'$WM/',D5B.*'4F+
M(                      K%SF_LP;P_F>/\K@+.T^+5#N/ARA[T;'[-K/T
MHNO\& E[0^+S,-IZG.O\45D
M
M
M
M
M                                                       *Q<YO
M[,&\/YGC_*X"SM/BU0[CX<H>]&Q^S:S]*+K_  8"7M#XO,PVGJ<Z_P 45D
M
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M+'=\*SML_O.">-;4[:M
M
M                                ,[N8GFDYA=K-T+IA^W^R#LRQ>CI*
M.>BR);9=JM)WSPM?*B24BMCT8]59HG3T=)?V^VQWIK:VD\RKES7K;2(0=_?H
MYN?_ ,VC_L._^[)NI8?;\L(^L9/9\Y_?HYN?_P VC_L._P#NQU+#[?E@ZQD]
MGSG]^CFY_P#S:/\ L._^['4L/M^6#K&3V?.M;RK<P.\V\UZRZW;H[4NV^H[)
M14U3::[Q"XT3:B661S'QJM:KD<J(B*G"NJ%;<X*8XCHVU38<MKS/2C1=4IK
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M+?X*YL?%/CB>[$KN/)%ZZP[@O,P
M              *>;X\V=LVNR&;#L=L+<FO]"UCKS43SK#2TKI&H]L2<#7.D
M?PJBNT5$;JB:JNJ)T[MSYMIL,ON<=>G>./ATB.]WY\RIFW44G2(UET^PO,K9
MMY:BLL-9:?-O+*&!:I*!)NV@JH&JC7O@>K6*CF*Y.)BIKHNJ*[PM+78/S+C[
M3F<=J]')$:Z:ZQ,=[[&6#<1DX.*5G#LZR
M                    !7GFBS*\81L[?[C8*I]!=+C-36R"X1+PR0,J7Z2O
MC<G2CEC:YJ*G2FNJ=*'7OFG>Y-KL+VQSI:9BNO)KQ^17W-YK2=&+L=1/%.RJ
MBFDBJ8Y$ECJ&.5LC7HO$CD<BZHJ+TZGBT6F)UB>%J&SG+'NN_=+;FF==:KQC
M*\8<VW9"]R_?)M$UIZIW\JQ.E>Z]KSV?Y8[6G?[6.G.N2G!;O\D\\>6);?;9
M>G7AXX6,.QK                                                '
M\[59)VM752^^3/?[+E4^=KSK:9:"4C[,Y])MIN3B^6<;FT-)5)!>HVZKQT-1
M]ZJ$T3K5K'<;4^R1#9=C;^=CNZ9>Y$Z3]V>"?M\*3#DZ%HENW%+'/%'-#(V6
M&9J/BE8J.:YKDU145.A45#W:)B8UANWYG(
M
M                                               _%[V1,?)(]L<<
M;5=)(Y41K6HFJJJKU(@%0LQY[>6;#;G/9Y\]7(*VE>L=2MBHYZ^G8J:ZZ54;
M4@?U?]6]Q:ILLMHUT06W-([JRF'YICV=8?9,ZQVL=48WD%"RXV^LEC="[L'M
MUU>QZ(YJMT5%1>\5[TFMNC/&EK:+1K#X\$W)P/<ZUU-ZP#*K?EEKHZE:2KJ[
M?*DC8IT:UZQO3H5J\+D7I3J4YOCM2=+1H5O%N*7;F#(
M   !6+G-_9@WA_,\?Y7 6=I\6J'<?#E#WHV/V;6?I1=?X,!+VA\7F8;3U.=?
MXHK(           (2YCY'1;'[CN:JM5;7P:IWGRQM5/HHII/F2=.SLWW?KA#
MN/ARP^/#VE7PY'MQ/)>37O;>OGX:/)HUN-D8Y>A*ZE9]^8U._+ G$O\ )H=[
M^1^T?=YK;:T\%^&/O1Q^./PKVRR:3->5I\>H-D
M                         !A)OA*LN\6YSG*KE3)KDS5>GH94/:B?01#P
MCMR==_G^_;SM)F]>?"\#;S-+AMYFN.YC;=73V.K9-+ BZ=M [5D\*KWI(W.;
M]$@[.WMMGN*9J\=9\<=V.>.!CCO-+1+>>RW>WY!:+7?;34)56R\4L-905#>I
M\,[$>Q?4Z%ZCWG#FKFI7)2=:VB)CP2WD3$QK#TR5R
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MHL6C-5ZU8X]D^4NT>M[**S/I8_1GP?JSXN#F;?:Y.E3P+/'9UD
M
M
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MD>;><ABCM%UD[!R<%'.[7B3N1N4BS[>8QVG7N3YB=_7D8 GS@UX!:'E,W(7
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M(;TZ$Z+>'+&2O2A])@E
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MG8Y>E:.I=]]8U.]',NJ_RAZW_;[M3WF"^UM/#3TJ_=GC\5OQ,;0ND>BL0
M                                           8D[D/[3<//9.OCR*Z
M.UUUZZN5>L^<.UYUWN>?_9?\4I(<6:X=_M?F]3MWG-@RJ!7.@H9T9=*=O_6T
M<O@3LTZE7@55;K]<B+W#:=B]I6[.W=,\<43P]^L\$QXN+OZ$QJVCI*NFKZ2F
MKJ.9M31UL3)Z6H8NK9(Y&HYCVKW45%14/HG'DKDK%JSK$QK$]Z4;Z#,
M                                        "H'.?)IMQCD7V>20N_>T
M=4G_ $CH/]Q)_P"CCC_V1^&S*K-0\=9/HJ:6II'LCJ87P/EBCGC:]-.*.9B2
M1O3U'-<BH97I:DZ6C3@B>:>&!*^Q^XK]M=P+5>9I7-LM<OD_(8TZEI)G)K)I
MWXG(CT]94[IO?EKM>>S=[7),^A/HV^[/=YIX>8F-6Q+'LE8R2-[9(Y&HZ.1J
MHK7-5-45%3K13Z B8F-81OR.0
M         >%E$G98SD4O5V=LJW>Q"]2MO9TP9)_9GS2,,CYH2/I;1U+Z2>O9
M"YU'3314\]0B>"R6=LCXV*O?<D3U3UE,XQVFLVTX(F(U[\ZZ>:?$/UPS2T\T
M51!(Z&>![9(96+HYKVKJUR*G4J*FIC6TUF)C@F!M+M9FL6X.!8YE+7-\9KJ5
M&72-O1P5D/WNH;IW$XVJJ?N50^BNQ.T8[0V>//W9CA^]'!;R^1'*0#:@
M                                         =?9O\B;]NXH;CUVYV7P
M^=ZI"M@
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MU_)';'7-I[F\^GBX/#7]6>;U>:.5A:%HCNK@
M                    <MG,G985F$NNG9V2X.U]:FD4I=ISIM<L_L6\TD,/
MCYL2+5;$X&W<';+>NQQQ))<G-M-58UTZ4K*1M;)$B+W./58U7O.4[O\ +'9?
MYAL-YBB/2]":_>KTICQ\7.XF55W-<URM<BM<U='-7H5%3K14.D3&CE=[DUSO
MQ2ZW[;VMFTANK%NMD:Y>A*B%J-J&-]5\:-=_@*>D_P!O>T^ADOM+3P6]*OAC
MUHYXTG_"QM#0H]78@
M !U]F_R)OV[BAN/7;G9?#YWJD*V
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M5LFD=$K5IIED=&YO"BZI(Y%U7H;ITU=WM8PZ3$\:;;YYR<$KZE)9
M             5BYS?V8-X?S/'^5P%G:?%JAW'PY5Q]'E^STW]);G_!@-GN/
M6:._&O.0,0           5YYIG\.RF3I[Y46YO\ IL*_2.I_.TZ=E9/#7\4.
M:\;)L\+9K$W; ?*/+OB.?T4&M78+I74=W>U.EU%45*MC<[U(YNA/MU.V9^R_
M>=B8MU6.&EK1;[LSP>*WXG&O"KL=3<M7>5_///+;2BMU7-VEXPYS;56(JZN=
M3M;K22+ZBQ^!ZJL4]R^2^U.N;"*6GT\?HSX/U9\7!S2PM"QIVYP
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M;)8GMDBD:CXY&JBM<U4U145.A45#Z$B8F-81OS.0
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M$-532MGIZF-LM/.Q4<U['HCFN:J=:*BZH?0E+1>(M$ZQ/$C?M,@
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M^PI]'[?/3/CKDI.M;1$QX)X4;T28
M            '7V;_(F_;N*&X]=N=E\/G>J0K8
M
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MXEU<^D5%6DD^@UJQ_P"!KW3V[Y)[6ZYLHQVGT\7HS]W]6?%P<S"T++G<G
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MG/9IKTKV<G&B]Y%:A['\@]I^_P!K;;VGTL<\'W;?9.OD8VA;L[ZQ
M                                    '7V;_(F_;N*&X]=N=E\/G>J0
MK8
M                         #D,UM.!UUG6Z;AVFQW"QXNYUW\=O]-3STU
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M':4=H;+'F_6TTM]Z."?'Q^"6$PDLW#@
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M&AG9545?#'44=2Q=6R12M1['M7O*BHJ'T1CR5R5B]9UB8UB>6)XD;ZC,
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M6.T_R_?TR3/HSZ-ONV^R=)YB8;$GT"C
M               '7V;_ ")OV[BAN/7;G9?#YWJD*V
M
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M\/YGC_*X"SM/BU0[CX<JX^CR_9Z;^DMS_@P&SW'K-'?C7G(&(
M*N\WC^':/3WR]43?N95^D=*^?IT[-_QU^MS7C9;GBC-KIRSLX-D,'3OLKW='
M[JX5*_3/>?DV-.R</^+\=F$\;L-V<(CW#P#(L8X&K6U-.LUHD=HG!60??(%U
M[B*Y.%R_8JIL.W>S8[0V>3#W9C6OWHX8^SP2XB6+\L4D$DD,T;HIH7*R6)Z*
MCFN:NBHJ+U*BGSO:LUG2>.$BYG)UGGDS)+O@-;-PTF1QK76ACEZ$K:9OWQK4
M[\D*:K_)H>A_V^[4]UGMM;3P7X:_>CC\=?PL;0T:/7&(
M                           541%55T1.M0,%WN5[W/7K<JJOT3Y?F=92
M+G\E;-<PS&3[&SQ-UT^RJ&KU_0/1/[=1_P!G+/[$>=Q9HR>N,%$N<?;WM(+/
MN3;X/#I^&U9$K4^L<JK2S.T[SE6-57OL3N'F/]P>R=8IO*1Q>C;_ ,9^KGAE
M65 CRUDULY;]PO/W;>WLK)^UON+\-JN_$NKWI&U/%YE[J\<>B*J];FN/=_E#
MM;K^QK%I]/'Z-N;U9YX\L2PF$_':7
M            !0'G;DUK-N(M?J(;J[3[9U(G_1/+/[D3Z6WCO7_\655$SS)D
MW0QN/LL=L,75V=NI6Z>M"U#Z8V<:8*1^S'F1O:+ J5S9[;^<V'PYK;:?CO&'
M(YU;P)X4MM>NLNO?[%WWQ.\WC.B?/?8_6=M&YI'IX^/OT[O[O'X.DRK+,H\:
M9-)>43<CR[C59@%RJ.*YXLG;VA7KX4EOD=TM3NKV,CM/M7-1.H]?^0NV/?X)
MVMY]+'PU[])_TSY)AC:%Q3T%B
M       B;?9_9[0;@.ZM;3*W]\K6_3-%\SSIV9G^Y+F.-C<?/C-I9R8,TVXR
M.3[/))F_O:.E7_I'L7]NX_Z.2?\ V3^&K&RWQWYBHESEX)VE/C^XE%#X=.OD
MB^.:GUCE=)2R+IWG<;%5>^U#S'^X?9FM<>[K'%Z-O/6?/'/#*LJ!'EK)K[R^
M9WY^;8V.LJ)NUN]E;Y(O*JNKEEIFM1DCNZJR1*QRKWU7O'OGRIVGU_84M,^E
M7T;>&O%//&D^%A,)M.R.
M   #K[-_D3?MW%#<>NW.R^'SO5(5L
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M&\/YGC_*X"SM/BU0[CX<JX^CR_9Z;^DMS_@P&SW'K-'?C7G(&(
M *I\XC^':BB3WS(:-O\ ["I7Z1T?^X$Z=G1_R5\UF568)XNR:_<N;.#9;!$[
M]-4N_?5<Z_3/??E&-.RL/@G\4L)XTV'8W#*7FBP/S.W+J[G20]G:,R:ZZ4BM
M31K:A5TJX_7[1>/UGH>'?.O9?4]_-ZQZ&3TH\/ZT>/A_Q,ZR@C';[7XQ?K/D
M-LD[.OLM7%64KNXKHG([A=WT=IHJ=U#K&TW-]MFIEIZU9B8YG+;7&K_095C]
MFR2V/XZ"]T<593:KJK4E:CE8[]TU=6JG?0^C]GNJ;K#3-3U;1$QS_8C>X60
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M/Y.[6ZCOHBT^AD]&?#^K/-/!X)EQ,-9CW5@
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M\%M=3HY\"]/5QM5[/556G=?D/M/J^\G!:?1RQI_BCACQQK'AT<6AIV>SL
M                                        #K[-_D3?MW%#<>NW.R^'
MSO5(5L
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M*G MRL%>VD5[6].BOBD>JJB]*-;KKHFFTW\1?'6_TX5+:S-;S5LV:A?
M K%SF_LP;P_F>/\ *X"SM/BU0[CX<JX^CR_9Z;^DMS_@P&SW'K-'?C7G(&(
M          *E\Y;^':VRI[YD]*W_ $.L7Z1T3^X4_P#\^G_)'X;,JLR3QIDV
M'Y?6<&S6 IW[>YW[Z>1?IGT!\JQIV7@^[]<L)XTQG8'"N_,W@?GIME<*REA[
M2\8BJW:@5J:N=%&W2JC3NZ+%J[1.MS6G4_G/LOKNPM:L>GC]*/!^M'BX?#$.
M8EDZ>%LVBO)QGGE"P7G;^MFUJK!(MPLS'+TK1U#M)F-3O1S+Q+_*'K7]ONU/
M>8;[6T\-/2K]V>/Q6_$QM"ZIZ,Q
M         >9>G]G9[M)]A1SN]B-RD.XG3%:>]/F&%!\RI%Y>29FMUW!D^QI+
M<W]]).OTCTO^W$?Q,\]ZOGEC9H*>JL0#/CG&V]\5N-HW'M\&D-S1MLR%6IU5
M$;56FE=]O&U6*O[AO?/*?[@]D]&]=Y2."WHV\,>K//'!S0RK*CJ*J*BHNBIT
MHJ'FK)L+L/N"FXVW-GNE3-VMZMB>3;^BKJY:FG:B=JO\JQ6O]=53N'O_ ,L=
MJ_F.QI>9].OHV\,=WGC26$QHF0["X
M           9T<ZDFN6X9%]A:)G?OIU3_HGDG]QI_P"SAC]B?.RJI:U%<J-3
MK<NB?1/.F3>=K48UK$ZFHB)ZR'T_$:(WY'( 5<YJ=M_/#!O.:W0=I?,+1]5H
MU/"EH':>,LZ.O@1$D3O(UVGU1TKYW['ZYM/?4CT\7#X:_K1S>MS3RN:RRX/%
M&;1/D_W(\I6:X;<7.HUK+&CJ['U>O2^CD?\ ?HDU]ZD=Q)ZC^\T]:^0.V/>8
MK;.\\-.&OW9XXYIX>?O,;0NN>C,0
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MW^1-^W<4-QZ[<[+X?.]4A6P
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M)]MM\E<D3-9T19LM)I,1+F_1Y?L]-_26Y_P8"]N/6:>_&O.0,0
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MUS7)JBHJ=:*A]$5M%HUCBE&_,Y
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MZG(38-]>]XK.G"CR[:M:S,:I0]'E^STW]);G_!@)]QZS5WXUYR!B
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M9>A.I']$B)]BY#Z&^7^U([1V=,WZW%;[T<?CX_!+"8T2<;EP
M                            !F?SFR<6YM@C[C,8IE^BZLK/:/&_[AS_
M -^D?^N/Q69U5>QV/M<@L47OEPI6^S*U#I>TC7-2/VH\[ENB?3",   *W<SN
MV_GS@$UVH*?M,@PY)*^BX4U?+3:)XU"G=75K4>B=]J(G6=/^<^Q^O;.<E(]/
M'Z4=^OZT>+A\,.8EE,>'LV@/)YN1V]+<ML[G4??:/CN.,J]>N)RZU,#?M7+V
MB)^Z>O4AZI_;_MCI5ML[SPQZ5/!^M'CX>>6-H7I/3&(
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MJ'T92];UBU9UB8UCP2C?O,@
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M&HN5WK'(KNSIZ:-9)'(U-5<O"WH1.E5Z$Z3*M9M,1''+B9B(UED_7>D#W_W
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M@QW"!%6/37H3M6:L]5R,0[U\A]K=7W4[>T^CDXOOQQ>..#PZ.+0TR/9&
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MJSN3Q>1>XG#*C455ZFJXWWR?VGU+?UBT^AD]&>?U9_>TYM7$PUL/=V
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MYTGZ7VS^8JS'L[XO,YW?J<ZQW*W^SGLK^B%K_F&D&Y^+;PIL/J1X$]$"0
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MWY(455^T0]"_M_VI[K<6VMIX+\-?O5X_'7\,.+0T=/76
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MAOE[M/\ ,-CCRS/I::6^]'!/CX^=A,)1-TX
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M5U165"-XG:O5.%O$G=XBIN]Q3)$5I&D0GP8K4F9M/&OB4ED
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M=YX+>E7[WZT<\</-/*QM#0T]88@
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MG:[E!'56ZY4DK)Z>H@E:CXY8I8U<U['M5%:YJJBITH<3$QP2YB=7V'
M                         .7R+.,*P^:TTV6Y?9,7J+]*Z"QP7>X4U"^M
ME:K$='3-GD8LKD61J*C-5\).^AE6EK<43+B;1''+J#%R
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MT<JH[_UAZS_;[M3WF&^TM/#3TJ_=GC\5N'_$QM"[!Z.Q
M                      ")]]7\&T&X#N_:)6_OE1/IFB^9IT[,S_<ES'&Q
MM/GQFTKY,&:;<Y))]EDDS?WM'2K],]A_MW'_ $<D_P#LG\-6-EOSO[$    $
M)<P&WOZP]N+M14L':WRRHMTL/"FKW30-7CA3NKVL:N:B?9<*]PZW\U=D_F&Q
MM6L>G7TJ^&.YSQK'AT<Q+((\#9KV<G&X795-XVVN$_@57%=,=1R_]8U$2JA;
MKWVHDB(GV+U[IZ;_ &^[6TM?9WGC]*OA_6CZ^:6-H7^/4V(
M                         9'\SC^/?#-M.IODYJ?0MU+K_P IX/\ .<Z]
MK9O\/X*LZ\3G=BX^TW>V^;WKO"[]ZBN^D4_EF->T\'WX<SQ-DCZ$1@
M,I>9S;?S%S^>ZT%/V6/YCVEPH>%-&15.J>-0IWM'N1Z)U(CD1.H\.^<^Q^H[
MR;TC^'D]*.]/ZT>/A\$LXE -GNU?8;K;;U:YUI;C::F*KH:AO6V6)R/:OJIJ
MG2G=.J[?/?!DKDI.EJS$QX8<MIMO\RH,_P /L>66_1L=UIT=4TZ+JL%0SP)H
M5^T>BIZJ:+W3Z+[*[0IVAMJ9Z?K1PQR3W8YI1R[(V
M                  4YYT9-,!Q:+7ZN_M=I]K2SI_TCS[^XD_\ 3QQ_[/\
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M7.;^S!O#^9X_RN L[3XM4.X^'*N/H\OV>F_I+<_X,!L]QZS1WXUYR!B
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M<FK7(J=:*BGT36T6B)CBE&_8<@
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MAL3N)VT;?WS&HGU1Z%\@]L>YSSM+SZ-^&O>M'<_Q1Y8CE<6AH\>O,
M                             "EO.H_3$<-B^SN\KOWM.J?](\Z_N+/_
M %L4?MSYF56<YY(R;2;0,[/:K;ENFFN.6UW[ZF8[Z9]$]@1IV=M_^.OFA'*1
MC;@    *Z<SV">>6V5?74L/:7?$'+=J)43PG0,;I51^LL?AZ=U6(=2^=.S.N
M;"UJQZ6/TH\'ZT>+AYH<UEE >&,VC?)SG?E/&KQ@59-Q5>.2K76ECEZ5HJEW
MWQK4[T<RZK_*(>N?V^[3][@OM;3PTG6OW;<?BM^)C:%SST1B
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M(2#QB3@\16H1*U7<2=/;=&FFG3KI9W?O>A'O-/K^Q#@]WTIZ&K1DH+0
M               "L7.;^S!O#^9X_P K@+.T^+5#N/ARKCZ/+]GIOZ2W/^#
M;/<>LT=^-><@8@           SVYV'ZWK 8_L:*N=^^DA3Z1Y1_<>?XN".];
MSPRJH\>;,F[=J9V=KML?5P4L+?88B'TW@C3'6.]'F1OO)0    %-></ _*V+
M6K.Z*'BK<8E2DNKFITNH:ER(QR_R<RII]NY3SW^X'9?O=O7=5CAI.D_=M]EO
MQ2RK+-\\A9-5^5O//._;6EM-7-VEWPQ[;94HJZN=3:<5(_UN!%C3[13W#Y)[
M4ZYL(QVGT\7HS]W]6?%P?X6%H63.X.
M       !"?,:_@V5SMW?IJ9O[ZK@;],ZY\W3IV5F\$?BAS'&R!/ F;3_ )/&
M<.U%:[WS(:QW_L*9/I'M']OXT[.G_DMYJL++5G>'      %>>9?;WSYVXK:N
MC@[6^XEQW2V\*:O?$UO^-0IW?"C3B1$ZW-:AU/YR[)Z]L9M6/3Q^E'@_6CGC
MA\,0YB639X6S:#<G.X7C-!=]M[A/K-;E=<\>1R]<$CD2IA;]K(Y'HG[IR]P]
M5_M]VMTJ7V=YX:^E7P3ZT<T\//+&T+R'I;$
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M[I]$]B]IU[1VE,]>.8X8Y+1QQX^+O:(YAWQM
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M:U['(]CT16N1=45%ZE13Z'B=4;\@
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M9AR+\]6?\I0XV'Q8YW.Z]1)O)K^S#L[^97?E,Q'N_BV9X/4A1CGH_:YY:/\
MY'_7[RYLO@WY_,K[CXE?IW4L^DMVLDR3:VP;I6J%4O&V=P1EQFC14D\F7)[(
MG.XF]*K%4-B5-?J4<]=4Z=8NS\NEYK/=9[NFM>ER)SV^YE+3<N4Z#?J]3LGK
M,=QZ7SDIU5$62]4*>++!IJG"M54<"L37JD:0Y-O,9NA'=GR)*Y?X?25R]&_@
M-SN-!N/S"Y8UU5D6X]TJ*.V7&5$XI(&3K/<)V+IKI-5*C5Z>N(L=H7B-,<<4
M(MI7CM/=<-M%_P"9CNI_)WC\FIS/+_*UYF-/CRU\-4O,9^05\B<V',!'$J^*
M.H;VYR-3P.)M]ITCZ?65VAMM]\&O-YE#;?$M].ZV8-2O@
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M/R;VIU+?UK:?0R>C/AGU9\?!X)EQ,-93W5@
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M:CV+["GT9@STSXZY*3K6T1,>"4;T"4
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M65+/<>)=7.9"U/%Y%[J\42M157K<UQ[M\G=I]=V%8M/IX_1GF]6?%Y8EA,+
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MV?\ 55L*(DJ:=Q':H]J?8N0^ANP>U:]I;.F;];BM'):./[8[TPPF-$EFX<
M                                4)YW7^%MG'KU)>'*GK^)(G_,IY=_
M<B?Y>/O_ /@RJH6>8,FY&(,[+$\7B][M%$WV(&(?2NPC3;8X_8KYH1NB+8
M   !S^5X[0Y=C=[QFY-UH[W1RTDKM-58LC=&R-3[)CM')ZJ%7?;2F[P7PWXK
M1,?IYN,8E7RSUV/7FZV*YQ=C<+/5S4=9'W$DA>K':=]%5.A>ZA\W[G;WV^6V
M*\:6K,Q/AA(L/RJ9WYJ;D16.KF[.U9K&EOE15T:VL8JNI'^NKE=&GVYVWY'[
M3ZIOHQ6GT<OH_P"+]7_3_B<6AJ<>VL
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MD6P^U&6;C6#=K(,3;<-P<7;3,L>0>.5L78I22/E@UIXIV4[U8Z1RHKXU7O\
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M15-&LR32/B<V6BJ^*2)R*U%UXU1>GH;H4]UMJXXB:SK$K&#--YF)CAA>0IK
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M?FOL_?:16_1M[-O1G[)YI8S";$77I3I1>I3L;@
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M#G_OXX_]<?BLSJJU8&=I?;+'U\=?3-T]>5J'2=K&N:D?M1YW+=,^F48
M  !E7S38'YH[DU%XI(>SM&:,=<J=6IHUM4BHVK9Z_&J2+]N>(?.W9?5-].2L
M>CE]*/O?K1X^'_$SK*O]AO5=CE[M-_MDG97"S5<591O[G'"]'HB]]%TT5.ZA
MU7:[F^VRURT]:LQ,<SEMKBV14.6XY9,EMKM:*]T<57"W756=HU%<QVGUS':M
M7U4/H_9;NF[P4S4XK1$^/N<W$C>^6@
M    !6KFR?P[.7-OOEQH&_\ M=?I'3OGJ=.S+?>KYW->-E4>(,VL_*VSAV3Q
M1WODUQ=_ITZ?2/=?DF-.RL7AM^*6%N-8,[6X        *B\W.WOG!AU)FM!!
MQW3$'*E?PIX4EOG<B/UTZ5[)^CD[S5>IT+Y][)ZQM8W-8]+'Q_<G[)X?!JRK
M+,\\<9-.>4K<+SEPB;$*^?CNV&.;'3<2^%);YE58537K[-R.CZ.IO!WSV;Y$
M[6ZSM)V]I]+%Q?<GB\7%X-&%H6Q.].
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M*^4R(BR+2RM<^/7J22/H>Q?4<B*=ZV?:&WWE>E@O%H[T\7ACCCG8NE+@
M                         9X\Z\FN0X+%]A;JMVGVTK$_Z)Y/_<:?X^&/
MV9\\,JJ1GF[)O#11]E1TD75V<,;=/6:B'T[CC2L1WD;Z3,       1+O?@J;
MA;;9!9(8>UNE-'Y1L6B:N\;I45[&M]61O%'_ (1HOF3LS\PV-\<1Z41TJ_>K
M]O#7G<Q+'!4TZ%Z%3K0^?&:]/)IG?8U>0;>5LVD=8GE>QM<O_6L1L=3&FO=<
MW@>B)]BY3TS^WO:>EK[2T\?I5\/%:/%I/-+&T- #U1B
M                   =?9O\B;]NXH;CUVYV7P^=ZI"M@
M
M         'PU=SMMO5B5]PIJ)9458DJ)61JY$Z].)4UTU.8B9-7Q^<F._'UN
M^%0^Z'1GD<:P^VCN5NN':>(5]-7=CIVOB\K)>'BUTXN!5TUT703$PYU?:<
M                   "L7.;^S!O#^9X_P K@+.T^+5#N/ARKCZ/+]GIOZ2W
M/^# ;/<>LT=^-><@8@           S(YR7\6Z=H3WO&J1O\ I=8OTSQG^X4Z
M]H5_XX_%9G56S$V=IE.-,^SNM&WI]6=B'3]C&NXQQ^U7SPY;E'TLC
M *^\RV!^>VV5SGI8>UO&*JMWMVB:N<R)J^,QIW?"BU5$3K<UIU3YQ[+Z[L+3
M6/3Q^E'-ZT>+RQ#F)9+GA3-H?R;YYX[9KWM[6S:U%E>MSLC7+TK2SN1)V-3O
M,E5'?^L4]8_M[VIT\5]I:>&OI5^[/K1S3P_XF-H7;/2&(
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M5713MZGQ3,1[')Z[513Z/PYJYJ5R4G6MHB8\$\,(WW$@
M                   Z^S?Y$W[=Q0W'KMSLOA\[U2%;
M
M        4>Y]=\,JV8VCH&X15NM>2YQ<UM$-]CZ)J*E;"^6HE@71>&5=&L:[
MK;Q*YNCD12YLL,9+\/%"ON<DTKP=U4O#_1EY5E]II<GW4W;GMF4WJ%E576J*
MA?<9X'RM1W!4UE34QJ^1NNCD1FB+U.=UEJ_:,5G2M>!!7:3/#:>%UGS5&._+
M/<?]BP_^]F/YG/L^5EU*.5:+EAY0+3RTWC*[S0YO5Y;/D]'3T2Q3T4=&R!D$
MCI%=X,LJN5RJG>TT[NO16W.ZG-$1IIHFPX/=S/"N.5$X
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M75KV/35KD5.M%1=3Z)K:+1$QPQ*-^TR
M     *K<X+^':>F;[Y?Z-O\ [*H7Z1TCY_G3LZ/OU\TN:LOCQ9FU[Y;V<&RF
M"IWX*MW[ZMG7Z9[Y\H1IV5A\$_BEA/&F\[(X         %*^</;WRE8K7N';
MX.*LQ]6T%\5J=+J*9_WEZ_R4KM/\/U#SK^X'9/O<-=W2.&GHV^[/%/-/XF59
M9TGDC)JGRM[A>>6WD-EK9^TO>%JRWU".75SZ145:23Z#6K'_ (&O=/;_ ))[
M6ZYLHQVGT\7HS]W]6?%P<S"T++G<7
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MNW.R^'SO5(5L
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M).MIGOI%PN2V/7.<LE^PL2-U^VJ8E_Z)Z!_;J/\ MY9_8_\ *'%FD!Z\P
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M.GDX9$1%Z-=-.\JGM_9W;.T[0KK@R1:>3BM'AK/#]2/1W9LP
M                     #K[-_D3?MW%#<>NW.R^'SO5(5L
M
M          !F[Z3C*[]8]E<:L%JFEI;9E^1LILBFC5R)+!2P25$=,]4Z.%\K
M6OT[O9IW-38=G5B;S,]R%3=VF*Z.EVZ]'9R\63&+3#FEDJL_R*2EC?=;S+=*
MZE@=.]J.>M-'03TR)&BKHWBXETZU53')O\DSP<$,J;6D1P\+O/[A'*;\E'_;
MM^_[P,.O9O:\D?8RZMCY/.E?:KEWV<V2K;O<-L<.3&:R_0Q4]UG\?N%:LL4+
ME>QJ)6U,Z-T5RKX.FO=(LN>^3UIU9TQ5IQ0FHA2
M*Q<YO[,&\/YGC_*X"SM/BU0[CX<JX^CR_9Z;^DMS_@P&SW'K-'?C7G(&(
M        ,J^;-_%O%<4][MM W_V>OTSQ#YZG7M.WW:^9G7B1+M8WCW.VY9]E
MD]H1?6\=B-#V)&N_V_\ R4_%#F6UQ]&HP        !Y5]LU#D5FNMAN<7;6^
M\4DM'61]U8YF*QVG>5-=47N*0;G;TW&*V*\:UM$Q/@D8E97CE=B.27O&;DW2
MMLE9+22NTT1Z,=X,C4^Q>W1R>HI\X;[:7VF>^&_'69C]//QI$H[ ;GT^U^<L
MN-VDE;C=WIWT5]2)JR.8WZN*9&)TN5CT373IX5=IJO0;OY5[:KV7N^GDU]W:
M-+:>2=.]/DF7$QJU:QS*<=R^W1W;&;S2WJWR:?XQ3/1W"JIKPR-Z',=WVN1%
M]0]QV>^P;NGO,-XM7O?7R3WI8/?+0
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MU.+3I$R,&CY@2+K\E+-<HS:7["UT[?WTZK_T3T;^W,?]C-/[,>=C9HF>M,0
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M[<[+X?.]4A6P
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M8-X?S/'^5P%G:?%JAW'PY5Q]'E^STW]);G_!@-GN/6:._&O.0,0
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MJF.3NM<B*G>/1MIO<.[I[S#>+5Y8^ODGO2Q>Z6@
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M7#&+[1WNDZ..2EE:]S%7J21GU3%]1R(IWS9[_;[RG3PWBT=Z?/W8YV+HBV
M                        \Z\2=E:;I+U=G23OU]:-RD.XG3':>]/F&$Q\
MRI%Y.2:/6[[@2Z?44=O;K]M).O\ T3TK^W$?Q<\]ZOGEC9H,>K,0
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M\%?K9UXD)[<L[7<+ XM->TR*UMT]>KB0ZWV1&N]P1_[*?BAS+;<^D$8
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MW.R^'SO5(5L
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M[I.G@951->Z-5ZUC?]4Q?5:J*5-YL-OO*=#-2+1WX\T\<<PJ1G/)M8Z[MJS
M+[)9*A=7,L]SXJBE5>XUD[=96)]LDBG0^T_[>X;ZVVM^C/LVX:^/UHY^DRBR
MG.;;0;A[?.D=DF-U$5 Q=&WFF3QBC<G<7MH]49KW$?PKZAY]VEV!O>S_ (V.
M>C[4<-?''%SZ2RB4:&G'I6J\7:Q5L5RLMSJK3<(/XFMHY7PRM]9[%127!N,F
M"\7QVFMH[L3I/D%IL&YO<YL/8TF7T5/F%O9HUU5T4M<UO5KVC&K&_1/LF:KW
M7'=^S/G[=X-*[B(R5Y?5MXXX)YXYW$U7'P;F"VPSOL:>BOS;-=IM$2S7?AI9
ME<OUK'JY8I%7N(QZKZAZ#V9\U;#?Z16_1M[-O1GF[D\TL9A-9V-P
M               /!RF3LL8R.7J[.UUCM?6A>I5WTZ;?)/[-O-(PS/FE(OAR
M1QZS[E2_8,M#=?MEK%_Z)Z=_;>.'<3]S_P F-E^CU)B
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M&X]=N=E\/G>J0K8
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MO[,&\/YGC_*X"SM/BU0[CX<JX^CR_9Z;^DMS_@P&SW'K-'?C7G(&(
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MWU%522-D:B]:M=ITM<G=:NBIW4/1-KO,.ZI&3#:+5GNQ.OT\#%[19
M                   4EYUWZ8[@T?V5RJW?O86)],\W_N-/\##'[4^9E5G>
M>3LFUNU3.#;#;EO>QBT:^OXG%J?1G8<:=G[?_CI^&$<N]-H
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MFJHYF3,1?L55BKHJ=U%Z4.\[;=X=S3IXKQ:O+$ZL7L%@
M    Y7.Y.RP?,I?>['<7>Q32*4>TYTVF6?V+?ADAA^?-J1?WDCCTI=R)?LY;
M2W]ZVK7_ *1ZE_;>/1W$]^G_ ),;+VGIS$
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MW+'KS1WJA?I_C-',R9J*OUKN!5X5[Z+TG>-MN\.YIT\5XM7EB=6+V2P
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MYSN7*I1SE5&9=<T8BKU)V%(NB?155)^T?B\R':>ISM!BBM
M               &0&&R2+Z4G+-9'+Q-K6.Z5Z6MQ^/1J^HFB:)ZAM;_ ,I'
MT[JC7X\_3N-?S5+P!Y&07RVXQ8;UDEXG2FM./T-1<;G4+IX%/2QNEE=TJB=#
M6KW3FM9M.D.)G2-6'^W_ #W<P'ZS\,R;/KZV'9K+<GGH9;5);;=#30T7:QLG
M;#6,IF5#_$654;E<LGA::.5=5-S?98^A,5CTHCZ>-KZ[F_2B9XFZYI6Q *2<
M\N_V4;(;=X]3;>UZ4&X6<7AM'9*E*>"KDAI:9$DJI(Z>HCE8]RN=%$B*Q?XQ
M53PD0N;+!&6T]+BA7W&6:5X..7#\C',;N/NE=-S=N-Y;JEPW PRH;54JR4M)
M13I3LD=25L#XJ.*&/_%IVL17<.OWS15Z$,][MZTB+4XI8[?+:VL6XX=US4?W
MR_.#%?[LG!YO^3YO.;3R!Q^.=K][XO+7A:=GU=GT=?%W##;>XTGWG'S_ %,L
MWO-8Z'U*([G;L^DEV;QZ#*]R+_YN6"IKH[;!7^*X=6<55-')*R/LZ.&>1-6Q
M/756Z='7U%W'BVN2=*QK/.K7OFI&L_4Z;%LG]*3FN.63+<9KO*6/Y%1Q5]FN
M'983#VU/,U'1O[.9C)&ZHO4YJ+WT,;5VE9TGCCPLHG/,:Q]31?EB_O!?J\K_
M .\GV?GYY<J?)W!Y,XO)784_8]IY)_Q?B[;MNKPM--2AN?=]+^'Q:=_ZUK#T
M]/3XUBBNE                    X?/-R\"VPME)>=P,JH,4ME?5)14=97R
M<#99U8Z3LVZ(JJO"Q5ZC.F.UYTK&K&UXKQRBG^]WRT?++COX=_N"7JN7V98>
M_IRO$R'G7Y9,=M=3<Y-T[?>%@:JQ6VTQSUE5,]$U1C(XX]$5>K5ZM:G=<AS7
M9Y9G3HN)W%([JH/(#77C<7?+F-WI@M,EGQ3*JF;LZ?3[VE7<*]U;'%Q:Z/DB
MA36143K?KT<2:V]]$4QTIW80;;6U[6[C6<U:Z       ROYCN9#,MZ\RGY7N
M6-LERN-RDEH,\SF!RL@9 Q49510U#=>SIX]5;//]=_%Q<7$G'LMOMZXZ^\R<
MT*>7+-YZ%%P^6SEOQ'ESPQ+):%9=LINR,FR_+GQHR:LF:G@QQITK'!%JO9LU
M[JN75SE4J[C<6S6UGB[D)\6*,<:+&*B.145$5%3147J5"NE8;\IV46KEBYKM
MS-K<^JX\<LUYDJK#2W6ND2&".:GJ$J+7-+([1K8ZBG<O"Y=.E[-=$U-SNJSF
MPQ:O#].%KL-O=Y)K+8O/]SL'VRQ&NS?,,@I+78:.F=4PSNE:KZOP4<R.E8BZ
MS/DU1&M9KKJG<-33':]M(CA7[7BL:RRT]'=8[QN%O3O5S!W:C?#25[ZVF@D<
MBK&ZY7RM;<*AL;T1$58(HT1R:="2MZ.E#9[^T4I7''TT4]K$VM-FQ)J5Y7+F
MBPS>#.MM8+)LCDLV*YDR]4M3+<X;C-:W+11QS-EC[>#5RHYSF+P]2Z>H6-M>
ME;:WC6$6:MK5]'C9X_W;/2+?+7</_O.X^T7^L;;V?(J^ZS<OE/[MGI%OEKN'
M_P!YW'VAUC;>SY#W6;E\I_=L](M\M=P_^\[C[0ZQMO9\A[K-R^4_NV>D6^6N
MX?\ WG<?:'6-M[/D/=9N7RHUW@V*YWL8VURV_;E;JUM\P:VTC9<CM,F45M:R
M>%96-1JT\B<,GAJU=%),6;!:T16O#X&&3'EBLS,\'A68Y!;Q/0["-@CB8]OG
M%<G:NUUZ6P]Y2OO<TTR:1R.,.UKDKK,RNOYR57O$7W7ME3K-N\EZA3EGZ<QY
MR57O$7W7MCK-N\=0IRS].8\Y*KWB+[KVQUFW>.H4Y9^G,><E5[Q%]U[8ZS;O
M'4*<L_3F/.2J]XB^Z]L=9MWCJ%.6?IS'G)5>\1?=>V.LV[QU"G+/TYCSDJO>
M(ONO;'6;=XZA3EGZ<QYR57O$7W7MCK-N\=0IRS].8\Y*KWB+[KVQUFW>.H4Y
M9^G,><E5[Q%]U[8ZS;O'4*<L_3F/.2J]XB^Z]L=9MWCJ%.6?IS,K>8.K=7;P
MYI4O1&NDFI$5J=7@4<#>[ZQX=\V7Z?:>:>_'X84LM(I::P^#8V5T.[.#S-:C
MG15ZO1KNKP8GJ1?+,Z=I89_:^J7&*D7M%9[K6'SDJO>(ONO;/=NLV[R]U"G+
M/TYCSDJO>(ONO;'6;=XZA3EGZ<QYR57O$7W7MCK-N\=0IRS].8\Y*KWB+[KV
MQUFW>.H4Y9^G,><E5[Q%]U[8ZS;O'4*<L_3F/.2J]XB^Z]L=9MWCJ%.6?IS'
MG)5>\1?=>V.LV[QU"G+/TYCSDJO>(ONO;'6;=XZA3EGZ<QYR57O$7W7MCK-N
M\=0IRS].8\Y*KWB+[KVQUFW>.H4Y9^G,><E5[Q%]U[8ZS;O'4*<L_3F/.2J]
MXB^Z]L=9MWCJ%.6?IS'G)5>\1?=>V.LV[QU"G+/TYCSDJO>(ONO;'6;=XZA3
MEGZ<QYR57XO%]U[8ZS;D@ZA3EGZ<ROFXNQ^"9ZZ:NI[9'BE^EU<MTM;$9'(]
M>[/3:I&_IZ55O"Y>ZXZIVO\ *^SW^MHK[N_+7BGPUXI\D]]SU&O<F5)LZV5S
MC!>UJ:J@\KV:/54O5 CI(VM3NS,TXX_55R</><IYMVI\M[O8:VM7I4]JO#'/
MW8Y^#OJF7;WIX$1F@5W2XOF&3X7<6W7%KW566M33C?3OT9(B=*-EC75DC?4>
MBH7-EVAN-E?IX+S6>]W?#'%/.+HX%SC/E;!;]P+5%3R]#?."@8]8U_=34Z*K
MF^JK-?4:AZ+V7_<#72F[K$?M5C@YZ_9KX$F.N.?6U6NL^?T604,5RLE7176A
ME^HJ::3M&Z]UJZ+T*G=1>E#O>W[2IN*1?%:MJSW8X5VNRQVC6)GR?8]3SDJO
M>(ONO;)^LV[SGJ%.6?IS'G)5>\1?=>V.LV[QU"G+/TYCSDJO>(ONO;'6;=XZ
MA3EGZ<QYR57O$7W7MCK-N\=0IRS].8\Y*KWB+[KVQUFW>.H4Y9^G,><E5[Q%
M]U[8ZS;O'4*<L_3F/.2J]XB^Z]L=9MWCJ%.6?IS'G)5>\1?=>V.LV[QU"G+/
MTYCSDJO>(ONO;'6;=XZA3EGZ<QYR57O$7W7MCK-N\=0IRS].8\Y*KWB+[KVQ
MUFW>.H4Y9^G,><E5[Q%]U[8ZS;O'4*<L_3F/.2J]XB^Z]L=9MWCJ%.6?IS'G
M)5>\1?=>V.LV[QU"G+/TYCSDJO>(ONO;'6;=XZA3EGZ<QYR57O$7W7MCK-N\
M=0IRS].8\Y*KWB+[KVQUFW>.H4Y9^G,><E5[Q%]U[8ZS;O'4*<L_3F/.2J]X
MB^Z]L=9MWCJ%.6?IS'G)5>\1?=>V.LV[QU"G+/TYCSDJO>(ONO;'6;=XZA3E
MGZ<RF7.'=I:^V8+%)&QG!55[TX=>GP(4[J^J>=?W!S3?'@B>6WFA7W&WKBTT
MUX5%#S%5;%;?WZIIL#PFG2"-4I[!;8T5===&4L:=_P!0^A.RL]J[/#')CK^&
M&PKL:6B)UEUWG)5>\1?=>V7^LV[S+J%.6?IS'G)5>\1?=>V.LV[QU"G+/TYC
MSDJO>(ONO;'6;=XZA3EGZ<QYR57O$7W7MCK-N\=0IRS].8\Y*KWB+[KVQUFW
M>.H4Y9^G,><E5[Q%]U[8ZS;O'4*<L_3F/.2J]XB^Z]L=9MWCJ%.6?IS'G)5>
M\1?=>V.LV[QU"G+/TYCSDJO>(ONO;'6;=XZA3EGZ<QYR57O$7W7MCK-N\=0I
MRS].8\Y*KWB+[KVQUFW>.H4Y9^G,><E5[Q%]U[8ZS;O'4*<L_3F/.2J]XB^Z
M]L=9MWCJ%.6?IS'G)5>\1?=>V.LV[QU"G+/TYCSDJO>(ONO;'6;=XZA3EGZ<
MQYR57O$7W7MCK-N\=0IRS].8\Y*KWB+[KVQUFW>.H4Y9^G,><E5[Q%]U[8ZS
M;O'4*<L_3F<CEEFQC.:7Q3*\6MUY8C5;%-,Q4GB1?>IV*V1G^"Y"AOMIM]]7
MHY\=;>&.&/!/''-+GJ%.6?IS*E9ERKTLKIJO!KTM(JZN;9[HJOC]9E0QO$B=
MY'-=ZKCH?:/R+6=;;6^G[-OJM'UQ/A87V7LSXU7,IV_S'"Y59D=AJ:"+BX8Z
MY&]I3/7N<,\?$Q57O:Z^H=(WW9.ZV4Z9J3$<O'7QQP*=\5J<<.--<C>U8LCO
M^+US+ECMYK++7,T_QFCF?$Y43ZUW"J<2=]%Z"QM=YFVM^GAO-;<L3H+5X9SB
M9C:F14F96JER:G:B(MR@1*6L]=S6?>G^LC6>N=X[._N!NL6E=Q6+QRQZ-O\
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MFV^)#3T]M;D                 '7T+THH$'9WL#A&9=M64=/YLWJ35WC]
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MGNE#-_%U5-(V1FO=15:O0J=U%Z4.][?<XMQ2+X[1:L]V)U7JVBT:P],F<@
M                  *<\VSM(,#9]D^YN]A*5/IGG?S_ #P8(^__ .*AOOU>
M=2\\X:YKIA[>#$L79]A:*)OL0,0]_P"SXTVV*/V*^:&]Q^K'@=$7&8
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ME^F>I?(<?]7)/[?U0V>R]6?"M*=Y70
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MT.Y[(WFW^)BM$<NDZ>..!!;%>O'$N.-<C?X!_J*J*BHNBIU*'+M+-N-GF/\
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M4D%"E-- V%T$CWK(JRU,R*NCM$T3O])6W.YC-$1$::)L.&<<SPZKJ%-8
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MO6^IKM]QPI^>?*#82SMX+1:F=7!1P-TZNJ-J'T+MXTQ5CO1YF_KQ0](F<@
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MI+-X\<:AH-RMLX=N:YWOE]J7?^PIV_2/6?D>--A;[\^:K:[+U.=9 [DM@
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MKND1#M/R;BM?M&LQ'!6+3/BT\\K6TC7)#1T]B;8
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MRUJ)3SM5$1JI*RED>WNZ.]<M;N.CAI6>-!@GI9+3'$U+-:N
M        *Q<YO[,&\/YGC_*X"SM/BU0[CX<J<<B7]A3?T@N/\&$E[0^+S,-I
MZG.N845D           &4&Y;N+<3.U[U_N*>Q4R)](\&[:G7?9_^2WXI:3-Z
M]O#*0>6]O%NI:E^PHZU?_8N3Z9M_DZ/_ .C7P6\R7:?$AH\>Q-L
M                    >-=\=L%_B[&^66AN\>FB-K((YM/M5>U53Z!7W&SP
M[B-,M*VCOQ$L;4BW'"';[RW[:7CC?1T=7C\[^GCH*ARLU]6.=)6HGJ-T.N[K
MY.[/S<-8FD_LS]4Z^317MM,<]Y#%]Y4;Y!QR8WD]'<6ITMIJ^)],_3O(^/MF
MJOKHTZWNOD/-7APY(MWK1-?-K]2O;8SW)0Q?=G-RL=XW5V)UD\#.E:FA1*R/
M3[)5@5ZM3[9$.N;KY=W^V];%,QRU]+\.OE5[;>]>.$:R1R0O?%+&Z*6->%\;
MT5KFJG<5%Z4--,3$Z3QHGX'#A^V&>:FE9/3S/@FC76.:-RM<U>^CDT5#FMIK
M.L3I+G71)UBWJW-Q_@92Y555D#/_ -&N'#6-5$[G%,CGHGVKD-WM?F3M#;^K
MEF8Y+>EY^'Q2FKN,E>ZF>Q<U]UBX(\EQ:FK4ZGU5NF?3N1._V4O:HJ_X2'9-
MK\^9(X,V*)[]9T\DZ^>%BN^GNPF>Q<Q>V-YX&5%RJ+!._H2*XP.:W7^4A[5B
M)ZJN0['M?G#L_/P3::3^U'UQK'E6*[O'/>3!:KY9;Y#XQ9;O1W:#359:.>.=
MJ>NK'+H=AP;K%GC7'>+1WIB?,GK:+<4O5)V0    *,<V#M<EQ1GV-LE=[,RI
M](\P^?)_[&*/V9\[6[[UH\"J*(JJB)TJO4=#4FRC6\+6M3J:B(GT#Z+B-&_?
MZ                                        '@WG%L;R)BQWVPT%W33
M1'55/'*YOVKG(KF_04J[G8X-S&F6E;>&(EC:E;<<(=OO+7MK=N-]!3UN/3.Z
M46BJ%?'KZL=0DJ:>HU4.N[KY,V&;AI%J3WIX/%;7R:*]MG2>+@0W?>5&_P!/
MQR8[DU%<F)TM@KHWTK].\CF=LU5]?A.N[KY#S5X<.2MN]:)KYNE]2O;93W)0
MU?=G-R\>XW5V)5L\+.E:FA1*QFGV2^+J]6I]LB'7-U\N[_;^MBF8Y:^E^'7R
MJ]MO>O'"-I8I89'Q31NBEC722)Z*US5[RHO2AIK5FLZ3P2B?K.'   T0Y8V<
M.V:.]\NU6[_DC;](]=^2HT[/_P <_4VVS^'SK#';EH
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MEI,5HT2KK;73VW'JQD%.C5<[MJ:F2:OCC:U%5[G*BM3ZIR%NN/:VGHQQ\_\
M\()OGCAGBYERN3WFSCYC[/>;5D-JI[#N%BL<4UUI*+C\3K:25>!M53I(KG1Z
M/\%\;G.TU:J.7BT;4W>U]S.L<4I\&?WD</&F+F$WWQGE\V]K,VO\2W&MED2B
MQK'8Y$CEN%<]JN;&CE1>!C4172/T7A:G0BN5K5AP89RVTA)ER1CC66:=EWC]
M)!O91+G&V%@CL.(5/%Y.BHZ&QTU-,Q'.3C@??UDGGTX5:KHW*W5.XIL9Q;;'
MZ-IX>?ZE2,F:_#'%S?6E7ETYVMPJG<^#8WF/QV.PY9753;;:[[XLMNFCKW-3
MLJ>NIE7LU2H542*2)&HJN;X*M=Q-BW&SKT.GCG@9XMQ/2Z-^-J2:U<
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ML17)'&QJ<+(T54:G=<Y7.=K<^><UM97,6*,<:0G4A2
M   *Q<YO[,&\/YGC_*X"SM/BU0[CX<J<<B7]A3?T@N/\&$E[0^+S,-IZG.N8
M45D           &3&X+N//LW?]G?[FOLU4AX)VM.N]S?\E_Q2T>7UY\,I0Y:
M6\6Z%*OV%NK%^Y1/IF[^2X__ *$?=LFV?Q&BY[ VP
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MO6CP*OTK>.IIV?9RL;[+D0Z12-;1'?4X;'GT2WX
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MO-GBQ^[K$.X-FD
M                                                   Y2\X+AN0\
M:WK%[9<)'_55$M-'VW3WI41'I]!2AN>R]KN/B8JV[^D:^/C86Q5MQQ"*+SRT
M;:7+C=0PW"PR+TM\3J5D9KZK:E)NCU$5#0[GY+V&7U8M3P3_ *M4%MG2>+@1
M1>>4ZYQ\;\?RVFJM?J*>X0/@T]19(EEU_>(:'<_(62/@Y8GO6B8\L:^9!;8S
MW)>CM]R99QD%TI*C*+G;K1B\4_\ C\]+,Z>JF8Q?"9 S@1K5=U<3U33KX7=1
M6V?R/NK98]]:M:=W2=9GP<'G\K&FRMKP\35>CI*:WTE+04<3:>DHH64]+ WZ
MED<;4:QJ>HB(B'J5*12L5KP1'!#9Q&CZ3(       9\<R?._4;6YT[:+:K"'
M;A[DQLC96M>D\M-35-1#VL%/'34J=M52<+FO>UCF:)X/%Q:\%[;[/IUZ=ITA
M5R[CHST:QK*(,5YVN:6V9=BEKW<Y>4L./Y/=Z&U,KDLE[LDC%JZJ*F<]DE?)
M41R*U9FZ-T3551->DFML\4UF:6X8[\2PKN,D3'2KYVGN;9IC6W>*WO-,ON<=
MHQW'J9U5<ZZ35=&IHC6L:FKGO>Y4:QK4U<Y41.E36TI-YTCC7+6BL:RRNK_2
M#;\;@7.M7E^Y?Y;_ &&W2.9-4U5MNE^J5;T<#I66I\$=.Y==5:KW]:>$;.-C
MCI'\2W#S1YU*=U>WJU2ML-S[5669W1[4;YX*NV>;7*HCH;;7,944],^NET:R
MEJ*.L19Z9TC^ABJ]Z*JHU>'ZI8L^RZ->E2=89X]SK/1M&DKL[RYI<MNMJ-P\
M[L]-35=VQ.P5USMM-6->ZG?/3PN?&DS8WQO5G$B:HUS55.I4ZRGAI%[Q6>[*
MQDMT:S+-:B](]FMWP#$[;C&WE#FF^^35%:V?'[12U\ENI((IGLIM*2.::JGE
MD8WB6-DJ:)X7$FJ--A/9]8M.LZ5A4ZU,Q&D:RN-RI[S;K;P6'+G[N[>IM]DN
M+W&&C;1MH:ZW).R:-TFOBU>^25JLT1%\)47U.HJ[G#3',="=8E8PY+7B>E&B
M/^6+FCSO>O=_=[;_ ">RV&W6; W52V.IM<-5'4O;!<'4C4J735,S'JK-%56,
M9T]S3H3/<[:N.E;1KPL,.:;VF)[BZ>37.:RXWD%YIF,EJ+3;:NM@CDU5CGP0
MOD:CM%1=%5O3HI3K&LQ"Q,Z0J5R6\QF;<QN*9G?,WM5DM59CEVAH:)ECAJ8(
MGQ2P)*JR-J:FI57(O=1R)IW"UN]O7#,1&O"@V^6<D3,N+WVYR+MLCS&XSMS>
M:&S0[7U%DANV3WJ6FJYKLQ9$K.BF=%4-BZ70QM:UT+M55?"Z4X<\.TC+BFT<
M>KC)GZ%].XK_ )%Z0G?Z^0W++]J=@T=M?:GR)4Y+=[9=;FQL<2HBOGK*&6GI
MJ=?LFJK^'73B7359Z['''!:W#S(IW5YX:QP)8Q3TENV=;MC=LIRZP5-GSRT5
M$='#@=#+XQY1?,USHYZ:H>UB,B3@7M5>FL?0B<:N;Q16[/O%](G@Y6==W7HZ
MSQH7NOI">97'Y*'+<@Y?Z.S;:7*1JVZ>NMUYI75$;V>"V&[RO2F>Y7=*.;3K
MT=&G=)HV&*>"+</-YD<[J\<,UX&H.S&[>-;W[>6/<3%DE@H;LU\=9;:C3MZ.
MK@=P3T\O#T*K'=2I]4U6N[IKLV*<5IK*YCO%XUA*9$S5XYIMW,BV/V7R+<7%
M:"W7&^6JJM\%)375DTM(J5=7%!(KV02P/71CETT>G3HO2G0L^VQ1EO%9XD6:
M\TKK"CUS](;N)D5HPS'MF=KH=P=T*RR4]RSAM'07&NH:2I<U'34])0TDGC+T
M8BIQ/=-HQ?!\-454NQL*Q,S>=(UX%>=U:=(K&LK1X3S(YF_EDRC?#<;;I]IR
MG#O'67'#86U%N2H?2/CC:Y$JVS2P-<Y_A<2/5J(J^$5K[>OO8I6>">ZFKEGH
M=*85!3G=YR\E:VXX/RSI56;A2-TJ8YD5U19M.-=)Z::G8B*QS5X>'7NZ]*%K
MJ>"/6OY80=8R3Q5\DI9Y>N?6YYUN'0;1[SX&S LSNLWB5NKZ5M13P+7N3BCI
M:FAK%=-3ND3H8O:/U<K45$1>(BS[**UZ=)UAGBW/2GHVC25W]Y<TN6W6U&X>
M=V>FIJN[8G8*ZYVVFK&O=3OGIX7/C29L;XWJSB1-4:YJJG4J=93PTB]XK/=E
M8R6Z-9EFY:O25W:IV^QNGI\ I\QWMR"IJHY<=LL57#;*:)D[FT_WMSZFHEED
MC37LXW+]DKF]#383V?'2GATJJQN^#BX7DV;TB>\^#97;[5S"[*QXU:*]8W2,
MH[;<[+<H8%54?41T]TGF2H1-4T:BQ_;=/1S.PI:-<=M?%/F<1NK5GTH:YVB[
M6V_VFUWVS5D=PM%ZI(*^U5\2JL<]-4QMEAE8JZ=#V.14-7,3$Z2NQ.O"S&W2
M]()E=3G=TV[Y;ML%W)N5FDFAGO,U-6W)*I].]&3.I;?;ECE="S14259/"U1>
M%&HG%L<>QCH]+).BI?=3KI2-4%W[TB'-=BUWBQ_)]I,7QR_3]GV%DNEAOM'6
M/[71(^&":Y,D7BU331.GN$U=AAM&L6F8\,?8CG=9(X)CSM+N6'<C=[<W;^ZY
M!O7@*;<Y/1WRHHJ&TK;JZU)-01TU-(RH\7N,DLO3))(WBXN%>'HZE-?N<=*6
MTI.L:+>&]K1K:-%3=U?2%75<SN&WG+EMR[<^\V^5]/Y??#55U/4RQ.1LGB=!
M0<,T\:+JU).T:CEZ6HK='.M8MA'1Z62=$%]UPZ4C5R&/^D+W>P?(K9;>9#8Z
M7$K/=GZ-N%';KG9JN"+5$69E)='S>,HU==4:]G1U+JFCLK;"EH_AVU\4^9C&
MZM6?3AJ[8[W:LDLUJR&Q5T5SLM\I(:^TW&%=8YZ:H8DD4C571='-<B])K+1,
M3I*[$ZQK#U#ARR6]*7E-4^V;0;=4+WR+>+A77JLHVK]5)3,BI*/H[JJM3,B&
MT[-KPVLI;R>*&I6)V"GQ3%L:Q>DX?%,;M5':J7A3A;V=' R!FB)U)HQ#6VMT
MIF>5<K&D:/9J*B"D@GJJJ>.FI::-TM34RN1D<<;$5SGO<Y41$1$U55,7*@F\
MGI"=K,'J9,:VPI9=X\UED2FI8[2]4M+)W*C6M\=:UZU*JKD5K:9CVN^I[1BE
M[%L;VX;<$*V3=5KP1PR_WEKI><#.MQ_UL[[U:X9@JVFJIK%MBU74*++5+$L<
MCK8Q7O:D?"_PJV19VJNC4X7:HW$X:UZ-.&>7]/V&+WEK=*W!'(O<^S6B2ZP7
MZ2U4<E\IJ9]'37ET$:U<=/(Y'OA9.K>-&.<B*K4715Z2EK.FG<6-(XW[[A5T
M5!05M=<IHZ>W45/)/7U$RHD<<,;5=(YZKT<*-1541&KF6)/HT+7)<M^]SLHL
M]-)28Q;\;JZ9K$Z&QK<+E32T<+T15_ZNFD5/M3<=HSICB)X]6OVD:WF76>D0
MJZG..838K9]U1*RV5--0N=&Q>%$GO]T6B>Y%T75R1TS=%5%TU]<PV$='':_T
MX(<[KTKQ5L/;+;06:VV^SVJDBM]KM--%1VV@@:C(H*>!B1Q1,:G0C6-:B(G>
M-5,S,ZROQ&C'7TH&.LQ[-MG=S;.UM)>JZGK:&JK8V:.[6T34]31R.7J<Y/&7
MHFO3HU$ZDZ-KV;;6MJS]-5#>1I,2V#L5S;>K)9KPUG9MNU#3UC8_L4GB;)I]
M#B-5:-)T7HG6'JG#D KQS3;N9%L?LOD6XN*T%NN-\M55;X*2FNK)I:14JZN*
M"17L@E@>NC'+IH].G1>E.A9]MBC+>*SQ(LUYI76'0<O.X]YW;V9P3<7(:2BH
M+UD]'-/<*2W-D92L?%4S0?>FRR2O1%2-%T5Z^N<9\<8[S6.XYQ7F]8F4-\Z'
M,5FG+GAN(7_";59;K7Y#>7V^K9?(:F>%D+*=\NK&TU13.XE<B=*N5-.YW4EV
MFWKFM,2PW&6<<1,+48?>9\BQ+%L@JHHX*J^VBAN-3#%KV;)*JG9*YK.)571%
M=HFJE:\:6F$U9UC5DOG]'2W#TGN/T%; RJHJZ&DIZNFD35DD4N.R,>QR=U'-
M544VE)TVL_3NJ5OC_3D?ARAU]5RZ<V6YW+E>ZE[;)E$TD>.R3:HCZBD8ZLML
MOA="+/12N1=.M_ G3H-U'OL,9([GT\[C!/N\DT;'&I7V0UF=_>JY^JR[.UK=
MN=AFZ47U\$K[3,K(53H5BK/<'NE1=/"B9IW$-K/\#;Z=VWT\RC'\7+WH?AZ/
M7^W[F4_E)OZUG&_^'3Z=PVOKV:(<R.+MS+83=W'E8DDM5BUQGHF*FJ+4T<+J
MJG[_ /UL3>GN=90V]NCDK/?6LL:TF.\J?Z,G+I[UL7?<8J97R/PO)JF*A8JJ
MK8Z.OBBJFM;JJZ??W3.5$[_?U+7:-=,D3RPAVEM::<C1PUZT     !7/F@W_
M */ETVT=F:VR.^WJXW""U8[9)9EA9-42M?(]\CFHYR,CBC<Y51.OA;T<6I8V
MV#WUM$6;+[NNJ2MJ,ER?,MN,/RS,K%3XSD61VZ.XUMAII'RLIF5*K) Q7/1K
MN+L58KT5/!<JM[A'EK%;3$3K$,Z3,UB95YYP>:BGY<L7MU)8Z2GO&XV5MD\W
MK?4ZNIZ6")422LJ6,<USFHJ\+&HJ<3M>G1KB?:;;WT\/%"+/F]W'!QL][?O!
MZ1^*RMW8927RY8?-#Y06*6QVU]-)1*B2=HE'' VI;#P)Q=HQ$\'PN/154O3B
MVVO1X-?"JQ?-ITNXTRY5>8^V\R& 3WYU#%9,NQZ=E#F%AA>KXHY9&JZ&H@5V
MKNQG:URM1RJK7->W5W#Q.U^YV\X;:=SN+>'+[R->ZL\5DP
M      "L7.;^S!O#^9X_RN L[3XM4.X^'*G'(E_84W](+C_!A)>T/B\S#:>I
MSKF%%9           !DCFSN/,\N?]G>J]WLU$AX#VG.N[R_?MYY:/)ZT^%+_
M "QMXMS%7["TU:_=1I],[#\DQ_\ T/\ !/U)]G\3F:'GKK:@
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M&N2L=^/.CKQMACZ&;X
M
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MG+'<>4Y*_P"SNM8OLSO/G_?SKN<GW[>>6BOZT^%-_*ZWBW'JU^PLE4[_ -M
MGTSLWR/'_?G[D^>JSLO7YF@YZTV@
M          !R]\PG$<E1WE[&[?<Y')HM1- Q9D]:5$1Z?04H[KLW:[KXN.MN
M_,1KX^-A;'6W'"&;[RP[?W+CDM$]PQV9?J&0R^,0(OJLG1SU^@]#KFZ^2=EE
MX<<VI/>G6/+P^57MLZ3Q<"%[[RL9C1<<EAO-OOL3?J8I>.CG=ZS7=I'[,B'7
M-U\C;JG#BO6\?NS]<>57MLK1Q3JAB^[9Y]C7&Z\XI<*:&/ZNJCB6>!-._-#Q
ML^Z.M[KL7>[;XF*T1RZ:QXXUA7MAO7CAPQK$3I<-ME7>,LQNV44+IZFKN-,Q
MC&IKT)(BN<OJ-:BJJ]Q$+G9V&V;<XZ5C69M'G9XXUM$0UQ/?V]
M
M
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MVSXNI?P+/: >2[9\74OX%GM /)=L^+J7\"SV@'DNV?%U+^!9[0#R7;/BZE_
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MVSXNI?P+/: >2[9\74OX%GM /)=L^+J7\"SV@'DNV?%U+^!9[0#R7;/BZE_
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M>]C'-HJJ!CM'2.T5R*O3IKIH3X]SDQQI6=(1WPTO.LPCG^X1RF_)1_V[?O\
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M (Y_%5;V7KSX&JIZJV8
M
M
M
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MT[I'DP7Q^M&C.F2M^*4N$3,                    !6+G-_9@WA_,\?Y7
M6=I\6J'<?#E#WHV/V;6?I1=?X,!+VA\7F8;3U.=?XHK(           /YW;@
M_M*^ND^SJ)7=/JN53YWR3K:?"T$\:['(BS7</,)/L<=5O[ZK@7Z1W;Y#C_M9
M/N?7"YLO6GP-2CU)LP
M
M
M
M
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M[,&\/YGC_*X"SM/BU0[CX<H>]&Q^S:S]*+K_  8"7M#XO,PVGJ<Z_P 45D
M        /\54:BN5=$1-54#^=1SE<YSEZW*JK]$^=):!>WD-9KFN<R?8V2%O
M[ZI:OTCO?R''_8R_=CSKNQ]:? T_/4&R
M
M
M
M
M                      "E?/A3[4W'9);/NCD4F*NN-UB7"+['1SUW87B&
M":2/M(Z=CW]D^))(WKIT([5/"T+FRZ<9-:QKR^!7W/1FOI*N; ^D=Q3'\!H,
M6WGHKO69#C+([?;\CLU,RHCN5'"W@BEG;++"YDK6M1'+IX?U70JJA9S]GS-M
M:<4H<6ZB(TLF_P"<OY<_Q3+_ /9D'_O9!^79>\DZW3OIVV+YJ-L.86Y7^U8%
M'>8:S'*:&KKVW6D93M=%.]T;5C6.:7545O2BZ$.;;7Q1$V[J7'FKDXEDBNE
M                    5BYS?V8-X?S/'^5P%G:?%JAW'PY0]Z-C]FUGZ477
M^# 2]H?%YF&T]3G7^**R          'RUK^SHZN3["&1W1ZC54QO.E9GO.)?
MSMGSLT"_/(6S7)]P9/L;71M_?3O7Z1W[Y"C^-EG]F/.O['CEIJ>FMB
M
M
M
M
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MS6+W>!'LU^V0]#^0L%X][EF/1G2([\\,SXN#QK^QK/#+10]%;
M
M
M
M
M                                        *B<Z6_5WV#VB6[XJ^*/-
M,IN#+-C=3,QLK:171OFGJ^R>BM>L3(]&H[HXW-54<U%:MK:8(RWTGBA!N,DT
MKP<;.O-=@N<RU;8W_>O/]\+E;G6VV>6*[&%O]U6OCA=PN[%8X6MIHGHK_J&.
MX6]71U%^F?!-XI6ODA5MCRQ7I3)AG+#S:9]M79]T,9WUKJN*_6I;K:L:DR"\
M1UDJ>%I CE^])([AT35W#KIJJ=8ON<-+]&:^2"N'):NL2L=Z./SCN]/N+?\
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M2_APTPTBE(BM8XHC@AG$1$:0](D<@
M
M
M
M
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M+5#N/ARA[T;'[-K/THNO\& E[0^+S,-IZG.O\45D
M
M
M
M
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M^6:HG<B(Z:HFD5TDCU1$35R]":-;HU$1(,F6V2=;2EI2*1I"0R-D
M  &(G+1C=LYK>;?<W='/J:/(<:QF6:ZVRRU6L]-(KJCQ:T4\K7(K7Q0P1J[A
M5='.8W5JM5R&XW%IP88K7CGZ2U^&/>Y)F6PF;[<85N)B5;@^6X]1W7'*RF6F
M90OA9_BR<' R2F7A7L7Q]"L<S16JB:&JIDM2>E$\*]:D6C263?H\KG=]N>8#
M>38NXUDCZ."*X(Z!RIP+<K!7MI%>UO3HKXI'JJHO2C6ZZZ)IM-_$7QUO].%2
MVLS6\U;-FH7P     *Q<YO[,&\/YGC_*X"SM/BU0[CX<H>]&Q^S:S]*+K_!@
M)>T/B\S#:>ISK_%%9
M
M
M
M
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M.B(J\?9NX>A>CK.8XW$\3(;T4BP>/;YHY%\9[#'.R7HTX.*Y<?J]?";7M/\
M5Y_J4=EW6QIJ5]C#L*UR>DDW4\7X6Q)<LL6I1-.E%>NOT>-453;Y_P"5KS*&
M+XT\[9XU"^     !6+G-_9@WA_,\?Y7 6=I\6J'<?#E#WHV/V;6?I1=?X,!+
MVA\7F8;3U.=?XHK(
M
M
M
M
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M'SCF_P!\A5N^#77W0ZAC]KS'6K\A\XYO]\A5N^#77W0ZAC]KS'6K\A\XYO\
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M'SCF_P!\A5N^#77W0ZAC]KS'6K\A\XYO]\A5N^#77W0ZAC]KS'6K\A\XYO\
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M'SCF_P!\A5N^#77W0ZAC]KS'6K\A\XYO]\A5N^#77W0ZAC]KS'6K\A\XYO\
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M[VJDBE\291]LV&)S)97N<KU5WA-[A4W6U]SPQQ+&#/[SPKF%1.
M
M              _154M-74U315M-%64=9$^"KI)V-DBEBD:K7L>QR*CFN151
M45-%01.@SNW$]&ELMEERJKMB%ZO.W4U8]TDEKI.SKK<QSEU7LH)T25B:Z^"D
MW"G4UK40OX^T+UC2>%5MM*SQ<#E<8]%OMC;ZZ&IRK</(,EI(G\;[?204]M;*
MB::,>_\ QE^G7KPJU>\J=9G;M*\\41#&-G7NRT;P[#,6V^QNV8CAEDIL>QRS
MQ]E;[72HO Q%57.<YSE<Y[G*JJYSE5SEZ7*JFOO>;SK/&MUK%8TATYBY
M      "IW,3R>[9<Q$U/>[O)5XKFM%$VGARRUI&KYX6_4Q5D$B<,S6HJ\*HK
M7IT)Q\/@EK!N[X>".&$.7!7)X52+!Z*G'::XQRY1O+<;S:6HG:T-LLL5MJ'+
MQ-5=*B:LKFHBM1R?Q76J+W-%M6[3G3@KY4$;*.[+37;_ &^Q':[%+7A6#V:*
MR8_:&<-/2QZN<][NE\TTCM722/7I<YRJJFNR9+7G6W&MUK%8TAV9@R
M               8X^E;_P!8;'?YOD7\.VFV[,_6YOK4-[W.=L%;O]7T/^;Q
M?P$-5*_#[#@                                                B
MK?;^Q#>3]!LA_JVH)</Q*^&/.PR>K/@4.]%E_9AN9^E$/Y%$7>TO7CP*VS]6
M?"U&-:N                                                 ,9,T
M_P#-+LOYPL__ (=B-O3^4\?G4+?'^G(V;-0O@
M                         * ^DG_9M?\ I1:OX,Y>[/\ B\RMN_4YTP\F
M7[,&SWYGD_*YR+=_%LSV_P .%G2LF
M                  8R>CC_ +?M]?S=4_UJTVV_^'7Z=Q0VOKRV;-2O@
M
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M]8;'?YOD7\.VFV[,_6YOK4-[W.=L%;O]7T/^;Q?P$-5*_#[#@
M                                     BK?;^Q#>3]!LA_JVH)</Q*^
M&/.PR>K/@4.]%E_9AN9^E$/Y%$7>TO7CP*VS]6?"U&-:N
M                                  ,9,T_\TNR_G"S_ /AV(V]/Y3Q^
M=0M\?Z<C9LU"^
M  H#Z2?]FU_Z46K^#.7NS_B\RMN_4YTP\F7[,&SWYGD_*YR+=_%LSV_PX6=*
MR8                                                !C)Z./^W[?
M7\W5/]:M-MO_ (=?IW%#:^O+9LU*^
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M-;U.G^ZUR7Q&YH[73A;3S<*RZ:ITQ*]OJE++MLF/CA8IFK?BE/Q E
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MF;Q4$$+7HO!W>+JZ%)=[@ICB)K'&PVV6UYF+-,37+8
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ME33KZ5,M]@IBZ/1C377ZG&VRVOKJT>->M
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M2.DJ:.KHY5<Z*9C&N>BMT14:J*U%1%=#NMI6E>G2=82X<\VGHVXVCQKUH
M &7?/+S![Z[8;I[<8+L_D[+"F4VB.5:-*&VU3ZJNJ:Z2EB:LEP@F:Q/ :B:*
MU.E5<O>V6RP8[TFUXXE/<9;UM$51[+5^E?H(W5M1"^I@I4[66G9%A,SGM;TJ
MU(X$65VO5HSPN\9Z;.?I+'_L?31ZVVGI"<[Q',HMO^:'!%QJ7M^QJ\BIJ.>@
MJZ%)'>!)5T$JN26+I^KAX? 35&R+U\9-A6U>ECG5S3=3$Z7AK/1UE)<:.EN%
M!4Q5M#70LJ**L@>DD4L4K4>R1CVJJ.:YJHJ*G6AJYC1=?2
M                                                          CG
M<W+MK,6QVI7=F\X];L;K&*R:BR%T#X:I.[&VFF1RS+^Y:UR^H28Z7M/HZZ]Y
MA>U8CTF!?,I?N5#)+NR/EUPW(Z+(YJEJ>4:-[J2RSN<J:>+VZH9+4JY=-&HS
ML$1?K7&[V]<T1_$F-/*UN6<<SZ$-&N0"W\RM#09,F\C<C@PA:*E3"J7*'*M6
MV?M'K)V3*E5JV1I'IT/T9U<'J4-].*9CH::]W1:VT7_6XFD!KUL
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MZVBD<4(-I32.E/=:9FN6P
M      @O>;EZP#?BKP=^X+:ZMM>#UE36P6.FG[""M?4LC8L=4YJ=HK$[-%TC
M<Q?W6FJ+-ASVQ:]'NH\F*+Z:]QFAZ4"R6?&XN7^PX_:Z6R66U4.04]MM5%$R
M"G@B:^W:,CC8B-:GK(;'LV9GI3/>^M4WD1'1B&T9J%]X&4Y-9,+QN^99D=<R
MVV+':*:ONM;(NB,A@:KW:)W7+IHU$Z571$Z5,JUFTQ$<<N)F(C668G*IC-YY
MEM],OYM=P*%[,>LE8^V[5V6H1',B?#JV)6I]2J4<3NE431T[W/31S%-CN;1A
MQQBKQ]U3PQ.2\WGF<OZ.'^V7F*_P/ZQJ3+M#U*.-KZUFP1JEX
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M1%/# M!'*L4$JQU,U0]'/5CG)X>BMX53K.=SCKCO-:]QQAO-ZZRL$0)0
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MJJC=57NKTFKM:;3,SW5ZL:1I#WS%R
M               #'#TK7^L=CO\ -LB_AVXVW9G%;F^M0WO<;'FI7V4?/ONL
M[+\TPOE9LV36_$[?>JNBN&YF4W6KBHZ&EAD=VM-#433/C8C(F-\9>U5\->Q:
MWPNA=GL<71K.68UY%+<WUF*>-<S -SN6+;7"\;P3%]Z-OJ2Q8Q11T5#'YS6G
MB=P],DLBI4)J^5ZND>O=<Y5[I4OCRWM-IK.L]Z5BMZ5C2)CQLW.07</ ,-W8
MWYN.7YSC^*V^\<'DBOO%SI:&&JTKZA_WB2HD8V3P7(O@JO0NIL-]CM:E=(F5
M3;6B+3K+:REJJ:NIJ:MHJF*LHZR)D])5P/;)%+%(U',>Q[55'-<BHJ*BZ*AI
MYC1L'[P                                           %4>;#F:L7+
MO@\KZ>:&X;C9%#)%A>/JJ.5KEU:M=4MZ=(85Z=%_C'> GUSFVMKMYS6[T<:'
M-FC''?03R*<M5]Q%MTWZW6AJ';E9XV::UT5<G^,T=+7/[:>JJ6N1'-J:IRZJ
MB]+&="^$]S6S;W<1;T*\4(MMAF/2MQRTD->MOBN7^KJ__-I?X"G,<;B617HH
M?_X]_P#TM_\ K<VG:?ZO/]2ELOUN;ZVP1JEX
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MVEM=LB735L%)$V&/71$U7A:FJFMM:;3,SW5R(TC1[QBY
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M:C5T<B)PHO6O5W:NZW%,L1T8T3X,5J3.LZKO%-8
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M*>BA9!$B^LUB&HM:;3,SW6PB-(T>Z8N0
M                  <'NAG]IVLV]R[<*]JBV_%;;+6NAUT6:5$X8(&K]E-*
MYL;?5<AGCI-[16.ZQO;HQ,LO/1TX'=\]SW<OF6S3BK+C4UE3;[+5R<7#)<;@
M[QBY3LXE54[.-[(F]*II(]/K4-EO[Q2L8X4]K7I3-Y:_FJ7@
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M2):\;MM+:K:DKD=)XO1PM@BXW(B(J\+$U70T=K3:9F>ZV41I&CVSAR
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MIZBE7MH%1)&+%510RHJ:IUMZ>M.@U&3';'.EHTEL*7B\:P[PP9
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M'#7''=^GG<8/XF2;M@C5+P
M
M       !6C+^3KEISJ[SWW(=I[:ZZ53W2U4]MJ*VTMEDDT5\DD5NJ*:-SG*F
MJN5NJJJJJZJNMBF[RUC2+(;8*6G682;MSL[MAM)1S46W.$VS%65+(XZRII8E
M=55#(D1K$GJI5?/+IIKX;UZ55>M558\F6^3UIU9TQUIQ0DHC9@
M                                     <)N-MIA.[6,3X;N!95O^-U,
M\-3/;?&:FDXI8'<<;NTI)89/!7ITXM.^9X\EL<ZUXV-Z1:-)?5@6W^'[88M;
ML+P2R18]C5J61:*VQ/EET=-(Z61SY9WR2O<YSE57/<J]SJ1!>]KSK:>$K6*Q
MI#L3!D                                              "*]U-DML
M-[+?:K7N=B[<FHK)4/JK7%XW64;HI9&<#U1]%/ ]45O6BJJ>H2XLU\<ZUG1A
M?'6_&A+^X1RF_)1_V[?O^\";KV;VO)'V(^K8^3SNDP_DVY;<"R:S9CBFV[;9
MD>/U"55HN#KM=ZE(9FHJ(_LJBMEB<J:]'$U>_P!9C?=Y;1I,\',YK@I6=8A9
MTK)@"(MN=A]J-IKSDV0;?8FW'KOF#D?D56E96U/;JDCY4T953S,C3CD<ND:-
M3Z")I+DSWR1$6GB84QUK.L0ETB9@
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MNB=;NCJ3H*^3);).MIUE+2D4C2'>&#(
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MD>\R^\R3R1P,MO3HTCOK=E5.
M
M
M
M
M                                                        $-;F
M\OVT.\ETL-YW*P]F4U^,L='9G2UM=!%$Q[VR/:Z"FJ(HI$<YJ:I(UVJ="]'0
M38\]\<3%9TU1WQ5OQPF-K6L:UC&HQC$1&M1-$1$ZD1"%(_(
M
M                                 !\RUM&DZ4JU<*5*]5.LC>/][KJ9
M^[MIKI.B*<^.+='I1TN36-?$^DP2@
M                  'S2UM'!(R&>KAAED^HB?(UKEU[R*NJF=<=K1K$3HBO
MGQTG2UHB>_,/I,$H
M     !\T5;1S2N@AJX99F?5PLD:YR:=]J+JAG..T1K,3HBKFQVGHQ:)GDUA]
M)@E                                                 ?-#6T=2]
M\=/5PSR1_5LCD:Y6^NB*NAG;':O#,3"*F;'>=*VB9CDE])@E
M
M
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MFK=B
M
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M=5W6&F:L3$6B)C7CX7I$2R
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MDSF@=T
M
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MRU,T:Q%)M'#,<,6K'<\*ZYY\]L
M    #Q+_ (]:\GMZVN\0.J*-TC95C:]T:\3-=%XFJB]TL;;=9-M?IXYTE2[0
M[/P[[%[K-&M==>.8XO S\N$+*>OKH(DX8H*B6.--==&M>J)T^LAZ=BM-J1,]
MV(?/FXI%,MJQQ1,QY7QF:(      !,VR^.6F_P!\KI+I Z9]HC@JZ%6O<SAE
M;+JBKPJFO5U*:'M_=Y,&*(I.G2UB?!H[G\E]FX-YN+3EC7H1%J\,QPZ]Y<0Z
M(]B
M
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M^5/_ +/#X9_#*])YR]U
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M/,.R;SX%_NSYG1.R_P";P_?K^*&AQY<^AP
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MHIS'YE_EJ_?CS2D^0/Y^_P#QS^*JW1T=ZZ
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M>71T?+[_ *XR'_,XOYPJ?,_PZ>&?,V7]OOCY?NQYUJ#IKU0
M
M
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M'8/E3_[/#X9_#*])YR]U
M J%OW_OE0?FB'^?G.\_+7\M/WI\T/(/G[^?K_P <?BL]/8C&(:ZXU^2U;$D;
M:52"WM7I3MY&JKW^NUNB)]MZA#\R;R:4C#7];AGP?IGS+7R'V97+EMN;QZG!
M7[T\<\T>=:HZ8]515N_C,-^Q*KKFL1*^P,?6TLO=[-J:SL5>\K$U]=$-SV%N
MYP;B*_JWX)\/<\OG=4^<.S*[O8VO^OC]*)[WZT>+A\,0I4>@/%0   ]S&/\
M>3'OSG2?SS"OO/@7^[/F7NR_YO#]^OXH:''ESZ'
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MX^7[L>=:@Z:]4
M
M
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M\/AG\,KTGG+W4                                        "H6_?\
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M&Y?F:;\HIR'YE_EJ_?CS2M_('\_?_CG\55NCH[UT
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M_P!<9#_F<7\X4/F?X=/#/F;C^WWQ\OW8\ZU!TUZH
M                                  !1_FFYSHN6G*<:Q=-N7YK/?[4Z
MZR5:W9+:R!G;O@:Q$\3JE>JK&Y57P=.CK[ES;;3WT3.NBOFW'NYTTU5@C]*[
M&LD:3;#NCB5R)*]F3H]R-UZ5:U;2U%5$ZDU3URS^6?M>3]*'KO>\JU^R7/5L
MMO/=J/%TFK<&R^X2+#;K+?4C9%62*O@,IJN)[HW/<FB(Q_ YSO!:UW0JU<VR
MOCC7CA-CW-;\'%*Z!46      (UWAW(I=H=L\OW(K+7+>X,4HDJO),$B1/G>
M^1D,;.T5KD8BOD3B=PKHFJZ+U$F+'[RT5Y6&2_0K,HVY8.8NDYE,'NV708I-
MA]39;O)::VU25:5T:N;#%.V2.H2&G5R*V5-46--%[Z=))N=O[FVFNK'#E]Y&
MNBR972@
M                                             %)MY?[0;Q_)TOY/
M&>@]@_R=>?SR\2^<_P#[3)X*_AA&44LL,C)H9'12Q.1T<K%5KFN3I145.E%0
MV\Q$QI/$ZQ6TUF)K.DP[5NY6=MI_%DR:L[/3AXE5JR:?RBM5_P!'4H3V3M)G
M7W<?3O<3=Q\R]I17H^^MIS:^/C\KC*BHJ*N:2IJIY*FHF=Q33RN5[WN7NN<Y
M555+]:Q6-*QI#2Y,ELEIM:9F9XYGAF7Z3EB >DEYO"(B)=:Q$3J3MY/=$75\
M?LQXH6>NY_\ <MXY^U^,EVNLK'Q2W.KECD16OC?,]S7(O6BHJZ*<QAQQ.L5C
MQ0XMN\UHTF]ICPR[':O^T#&_Y:7^9D*';/\ *9/!'GAN/E3_ .SP^&?PRO2>
M<O=0                                        *A;]_P"^5!^:(?Y^
M<[S\M?RT_>GS0\@^?OY^O_''XK(315145%T5.I3L#I+M:7<;.**G2EI\EK$A
M:G"U)%;*Y$[R/D1SD]DU]^RMK>W2G'&OB\S=8OF/M'%3H5S6T[_#Y9UERE;7
M5MRJ9*RX5<U;5RKK)43O=(]WKN<JJ7<>.N.O1K$1')#59\^3/>;Y+3:T]V9U
ME\AFB /19=[M&QD<=SJXXXT1K&-FD1&HG0B(B.Z$0CG!CF=9K'BA8KO,]8TB
M]M/#+_5O-X5%1;K6*B]"HL\GNCCW&/V8\4.>NY_]RWCG[7U8Q_O)CWYSI/YY
MAAO/@7^[/F2]E_S>'[]?Q0T./+GT.
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M*<T/S+_+5^_'FEW+Y _G[_\ '/XJK='1WKH
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M<7\X=;^9_AT\,^9WS^WWQ\OW8\ZU!TUZH
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M^**R
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M(B)]:%;=J_[0,;_EI?YF0[9VS_*9/!'GAYM\J?\ V>'PS^&5Z3SE[J
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MIZ,>S/>4OQC_ 'DQ[\YTG\\P[]O/@7^[/F>+]E_S>'[]?Q0T./+GT.
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MW(B.Y/(X[8+_ 'QN7YFF_**<O_,O\M7[\>:6G^0/Y^__ !S^*JW1T=ZZ
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MSA)\S_#IX9\R'^WWQ\OW8\ZU!TUZH
M                       !CAS]?M4<N_\ FUH_KR0VVQ^#;G\RAN?B5^G=
M;'FI7T-<Q7BOZ@=[?'41:?S%R'B3H1>+R=/P::ZIKQ::>J3;?XE?#"/+ZD^!
M03T:]Y7&-C=Z\GK6NDM5AN\MP='JJ(OB=L;-,B+HNBJU&]Q2[VA'2R5CZ<:M
MM)TI,H?Y-=G;7S4[C;G[U;VL=E4%#<(G-LLLDC:>JN%8CY/OO"]'=C2Q,8R.
M+7A5%:B^"SA6;=Y9P5BE.!A@Q^]M-K-*L^Y1.7O/<;K[ _:['<5J*F)[:&_X
M[;:6UUM+,J>!*V2DCBX^%41>"3B:O4J=)KJ;K)2==9GPK=L%+1IHH;Z-_)+_
M (?NEO%L'=ZQ\]':65=QAIE_BX;A::V.W5;HT5=6K,V5FJ?^C3Z-WM"L6I6\
M*VTF8M-7@<]]L9CG-+MGN!N?CE;E&SL]#;:::FA5W9R14=1,^MHFJCHT21.T
M[7@5R<:.TXOJN'+93KBFM9TLXW,:9(F>)=?#<+Y'>8"P/I<)PO;Z]1=DCZRW
M6JWP6>\T[71JW65M,REK8TT<J<6NG$FJ*KFZI3O?/BGAF?/'V)ZUQ7C@B$G\
MS5+3T7+5O%1TD38*6DPNXPTT#?J61QTRM:U/41$T(]O.N6OA9YO4GP*\>C0_
M9SJ_TON?\Q2$_:/Q>9%M/4YU1N=_#:C<3G0P# Z6Y)9YLPLUBM"7-6J](&UE
M751/>K&JU7:-<O@ZIKU:H6]G?H8)MR:H=Q7I98AI%B')ORYXEB4>)NVPLN2(
M^G2*XY!>Z6.LN=1(K='RI5O3M('.7IT@5B-^M1#7WW>6TZZZ+5<%(C31GSRG
MV-VS?/7N1M38JJ5^-/IKQ;XZ>1ZOUI85BKZ)7ZKX4D3$1G$O3TN^R4O;JWO-
MO%IX^!6PQT,LUAV'I/:VLFONQ./WBLJ;?@5=4U]3=:B%-6I,R6EBEETT=J^&
M"55:FB_5+T=*F'9T<%ICC<[SCB.XN53[ <H2;9,F9@>!S8 VW-7SW>RD=(M-
MT:3NOBKV_$J]<G;Z]S7N%3W^;I\<Z\GZ%CW6/H\4:?3NJ#^CKQO#+SNQO%3T
M^+VG*L7Q6H@N6#9/=;9355?0R1UTK*&6"KFA[6%\D+>/1JM\)G$B(J%[?VM%
M*\.DSQJVUB)M+:,U"^
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MRTO\S(;+MG^4R>"//#0_*G_V>'PS^&5Z3SE[J
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M-".,?[R8]^<Z3^>8=AWGP+_=GS.D=E_S>'[]?Q0T./+GT.
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MN<VC7]J["-_MKX)MT>EIP\?%,3]2$_[O='_Q1-\%;_2G8/ZHM_MQX_T.D_\
MY[C_ -^?W8^U&NXVW,."06J6*ZON7E)\K'-?"D7!V2-77H>[77B-MV5VK.]F
MT37333NZ\;K7S'\N5[)KCF,DVZ4SW----._/*Z[E]_UQD/\ F<7\X4?F?X=/
M#/F;?^WWQ\OW8\ZU!TUZH
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M\7F8[3U.= O,7_YC&Q/_ -,?E]23[?\ EK<Z/+\:.9L$:I>8^[:?^9WN!_\
M-?ZLB-KD_E8^G=4:?'E[/I$\DIKQN9L5M)F5:N,;6W"IAO63Y;' DD\?:U3J
M*=8I%CD5JTU.CG*C45%61%>UW"TXV%=*VM'#+G=3K:*SQ(=?R6\LE1>&S47.
MQB$=AEE8L-IEJ;-)7=FJ)X"U276-G&J]2^+IIU<)+US+I\.=>?[$?5Z:^O#5
MK8':':S9O"EQ[:R2*Y4%14++>LD6IBK*JOJVM1O%43PHC-6-T1K&(UK4ZFZN
M<JZS/EODMK9=Q4K2-(3B0I
M                                                      "DV\O]
MH-X_DZ7\GC/0>P?Y.O/YY>)?.?\ ]ID\%?PPL1LU_9]9_P"4JORB0ZMV]_.6
MYO-#T3Y,_P#J\?AM^*4HFG=I    !'VZG]G^2?R,7\]&;3L;^;Q^&?-+KWS7
M_P#69O!'XH57VK_M QO^6E_F9#N7;/\ *9/!'GAY7\J?_9X?#/X97I/.7NH
M                                       %0M^_]\J#\T0_S\YWGY:_
MEI^]/FAY!\_?S]?^./Q62/L!_NO=_P Z._F(C5?,WQZ_=^N79/D#^3R?\G_C
M5.QUMWL    '-9I_N=EGYFK_ ,G>6^S_ .9Q_?KYX:SMK^0S_P#'?\,J+8Q_
MO)CWYSI/YYAZ-O/@7^[/F>%]E_S>'[]?Q0T./+GT.
M                     !G?DG^\5^_.-5_/./4MI\&GW8\SYV[2_FLOW[>>
M5[</_P!TL6_-%#^3L/-]_P#S&3[UO/+WCL?^1P?\=/PPZ,JMB    "!M_P#_
M ':LWYS3^9D.R?+/Q[_=^N'0O[@?RF/[_P#XRC[8+_?&Y?F:;\HIS:?,O\M7
M[\>:77_D#^?O_P <_BJMT='>N@
M     SEN_P#K6Y_YW-_.*>JX/AU\$>9\Y;OXU_O3YVA5H_U5;/\ -(?YM#R_
M/\2WAGSOH7:?!I]V/,] B6     5TYA/\CQ?^6JOX,1VKY7];)X(^MYS_<+X
M>#PV^IX7+[_KC(?\SB_G"Q\S_#IX9\RC_;[X^7[L>=:@Z:]4
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M4X51%1R+:RS[W!-KQI*"D>[RQ%9U;RFD;(
M
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M>&F^5/\ [/#X9_#*])YR]U
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M.G[3VM@O]\;E^9IORBG*_P R_P M7[\>:5WY _G[_P#'/XJK='1WKH
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M<9#_ )G%_.&O^9_AT\,^9N_[??'R_=CSK4'37J@
M                                                 !5KF$Y1]K^8
MF2BNN1K6X_EML@\5H\IM+HVS/@1RN;#4QRL>R5C5<JMZG)KT.TU1;.#=7P\$
M<2'+@KDX^-2E?11TWC*O3?65*/M=4@7&FK+V7%]3VGE1$XM.CBX-->GA[A<_
M,_V?+^A7ZEW_ "+F[ <GFU'+Y62W^PLK<ES*>%].N57AT;Y8(I/XQE)#&QD<
M*/1-%=HKU35./A54*F?=WR\$\$+&+!7'PQQK7%5,
M
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MF,>WZ'=M/DCAGZ=]C\D;&V;?>]T]''$SSS$Q$>>>9<8Z(]C
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M:)R;F8X-.C'?[MO%I"RYU)Z8
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M[T,
M
M                                                  !Y%]L5MR.V
M5%INU.E125"=*=3F.3ZE['=QR=Q?I$^VW-]O>+TG284]]L<.]PSARQK6?)WX
M[\*NW_8K):*>1UAF@O-&JKV3'O;!.B=YR/5&+ZZ.Z>\AW';?,>"\?Q(FL^./
MM\CR[?\ R)N\5IG!,7KW.'HVY]>#R\T.9_5!N+_P[_I=)_3%O\]V?M^2WV-9
M_1_:O^S_ )J?ZG.Y#A638K%33WZV>(15;W,IW=M#+Q.:FJII%(]4Z.^6MKVA
M@W,S&*VNG>F//$-=VAV)N^SZQ;<4Z,6X(X:S^&9<L7&K>U8L>O&35JVZR4?C
MM8V)TRP]I''X#51%7BD<U.M4[I!N=UCV]>GDG2.+NSYES8=GY]]D]W@KTK::
MZ:Q'!SS$.Q_5!N+_ ,._Z72?TQ0_/=G[?DM]C<_T?VK_ +/^:G^I[UDV-RVN
MG9Y8=3V2E14[5SI&SRZ?N&1*YJKZ[D*VX^8MO2/X>MI\4>7[%_9?(V^RVCWV
MF.O=X8M/-%>#RPM%C6-6K%+7%:;3"L<#%XYIG],DLB_522.Z-573Z'4G0=.W
M>[R;K)-[SP^;O0]1[,[,P]GX8Q88X.[/=F>67OE9L
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M7!V7BZ&/AF?6M/':?LY(^OA=<46W
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M-31$1#J%[VO:;6G69>GX<-,-(I2-*Q&D1'<A]!@D
M
M
M                               "OV_T,LUJQU(HGRJE7-JC&J[3P$[Q
MV?Y9M$9+Z\D>=Y_\_P!+6PX=(U]*?,JVZ"9CVQNA>V1WU,:M5'+KWD.XQ:)C
M75Y9-+1.DQ.J9]C:>HBS25TL$D;?)LZ<3FJB:\<?=5#0?,5HG;1I/ZT?6[I\
MC8[5[0F9B8]"?/"WQT9Z^
M        !$>]D<DN#R-B8Z1WCU.O"U%5?KNXAO/EZ8C=</)+J/SM6;=G3$1K
MZ5?K4VD@FBX4EA?&KOJ4<U4U];4[Y%HGBEXU:EJ\<3"3-HZ6ICW#Q]\E/*QB
M>-ZN<Q41/\4F[JH:CMR]9V=])Y/Q0[-\HXKU[4Q3,3^MW/V++LGGSVT
M                                          "J._=//+D]H=%!)*U+
M6U%5C5<FO;2]Y#NGRU:(P6UG];ZH>4?/N.UMYCTB9]#_ ,I00D$RR+$D+UE3
MKC1J\2?0ZSLG2C375T/H6UTTG59[E_AFAH\G[6)\7%-2\/&U6Z^#+U:G4/F>
MT3;'IR3]3T_^W]+5QYM8F.&OUK#G5GH@
M                  *?[X4]1+FK71022-\G0)Q-:JIKQ2=U$.]?+MHC:\,_
MK3]3Q_YXQVMVAK$3/H1]:&FP3/>Z-D+W2,^JC1JJY-.A=4-]-HB-=73(I:9T
MB)U6GV!AEAM&0)+$^)5K(E1'M5NOWOU3IOS-:)R4TY)\[U3Y I:N#+K&GI1Y
MD_'67?P
M
M
M  "N.>?VT8/_ "=!^53':^S?_K,W^+\,/..WO_O]MX*?BLL<=4>C@
M                                          %<=^O\OP?^4J_X=,=K
M^6O4S<W_ )/./GWXNV\-O/18XZH]'
M                   *XV/^WF^_R4O\Q&=KW'_U-/#'GEYQL?\ _I,O@G\,
M+''5'HX                                                "N.WW
M]LN>?R=P_+8#M?:G_P!;A_P_AEYQ\O?_ 'VZ\%_QU6..J/1P
M
M
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M:CUHZR"K2/3M%AD;)PZ]6O"JZ&%\=J>M$QX4N+/CR^I:)TY)B?,^HP2@
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MSF4=?3U3VIQ.9#*QZHG?5&JIC?%>GK1,>&$F/<XLLZ4M$SWIB7V$:8
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M.M-6JJ$=J6K.EHTE/CRTR1K28F.].K]YBS
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M2.E68F.6.%^TQ9@
M
M
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MVAVMDWE8K:(B(G7@;OL7Y;P=E7M?':UIM&G#I]40D0U;L0
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M=EX[8\=IGI3K.OB[FCL2@W(
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MT-1OM[?=Y.G:(B=-.!VCL?LG'V9@]SCF9B9F=9Y9TY/ ZHI-J
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
B                                         !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>inbx-20211231_g3.jpg
<TEXT>
begin 644 inbx-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &H 8P# 2(  A$! Q$!_\0
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M<[ ["_R@QD[< 8&,5^:9WF5/'58+#NZ2?D?093F&%PZ<*LG%M[VT^?\ PQ]
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M*'65TM6F:=+>2%'#L0 0202.!]*]W*)48QG5QBO&73MKK8TIVWD>?ZMXQL=
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M^A?]>$'_ *+6MFMJW\27JSFPO\"GZ+\@HHHK$Z0HHHH **** "BBB@ HHHH
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M2$3.,D=#D<&KLW@FYU>:2>'4%FCMV"^6[A0K-U;TZG&?:M%.C)<\)ZKMU_X
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M+E0-O&>K<<XZY]J\"_;HDMD^(_A9;N\41261"PD_ZLAV)./?Y?\ OFH/@_\
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M #E%8 ]/QJG\;+2^N->CT*/4TNM-MK55BDMHL211DD".-CT4D,QR,]/P\O\
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M:-"&:66_N5:Y"O'O/ QC;G '&[/6OLCX>ZFW_"O1;7,\>EPK;8BLH6$LDDH
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M(<<_*0.F1GG !['\/?V'_B)?11^180:=:70^TMJ6H:@DOG%@!N)0NQ) ';&
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MX>,^,/\ A(M6\7WMMK^H2:EJ\4K)<2M<B=58?> 925P#Q\O%>A6*VMK\*Y=
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MX>T^**XO=1D7=)MW%#W/L .<^@KZH@C,,,:%BY50I8]3@=: )**** "BBB@
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MDKGOA^NIKX/TS^V-_P!O:/<ZR'+JI)*JQ[L%(!]Q70T %%%% !1110 4444
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M/*D@S&I(X1 >!P.W0#WKLOA?J>HQW0\926T!M3Y]O*KQC+QOUDXZD$Y_#VH
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M* "BBB@ HHHH **** "BBB@"&&S@MU*Q01Q*3DJB  GUJ:BB@ HHHH ****
M"BBB@ HHHH **** "BBB@#,O/#]K?7#SR2WRNV,B&_GB7@8X57 '3L*A_P"$
M3LO^>^I?^#6Z_P#CE;-%:JK42LI/[SG>'HR=W!7]$0V5G#I]G!:VZ>7!!&L4
M:9)VJHP!D\G@5-116;;;NS=)15EL%%%%(84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>inbx-20211231_g4.jpg
<TEXT>
begin 644 inbx-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %# G # 2(  A$! Q$!_\0
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M=DKZKKY4^-'_ "D$_9R_[ _B/_TF2OJN@ HHHH **** "BBB@ HHHH ****
M/,OVH/\ DVOXL?\ 8IZK_P"DDM?/O_!(W_DS'1?^PM?_ /HVOH+]J#_DVOXL
M?]BGJO\ Z22U\^_\$C?^3,=%_P"PM?\ _HV@#[/HHHH **** "BBB@ HHHH
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M-?H[7YQ?LO\ _*6K]H'_ +!$W_HVQH _1VBBB@ HHHH **** "BBB@ HHHH
M_-[_ ()C?\G4?M7_ /8?/_I=?5^D-?F]_P $QO\ DZC]J_\ [#Y_]+KZOTAH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110!YE^U!_R;7\6/^Q3U7_TDEKY]_X)&_\ )F.B_P#86O\
M_P!&U]!?M0?\FU_%C_L4]5_])):^??\ @D;_ ,F8Z+_V%K__ -&T ?9]%%%
M!1110 4444 %%%% !7YQ?LO_ /*6K]H'_L$3?^C;&OT=K\XOV7_^4M7[0/\
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M3^.O$_ANW\.^']$M=42>=$AE\QY9[F/Y5D=<QJPY4-SC:"?,-:_9W^)'C!O
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M:W%RC.LNLF>*)0TY'\4:R%5QZ"N,N_V9O'-]\'9);/X4>'? FKZIXUT+4_\
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M,'.E398'D_O;*HE0<6E?<Z*6:TZL9R47[JN?II17*?VA=?\ />3\Z/[0NO\
MGO)^=7]5EW.?^VZ7\C_ ZNBN4_M"Z_Y[R?G1_:%U_P ]Y/SH^JR[A_;=+^1_
M@=717E7CKXF7O@A;-D\/^)/$GVDL-N@VJW!BQC[^YUQG/'7H:YKX9_M%)\5)
M;)M+\,>+[+3;Q9&CU74K!8;7Y"P(+"0D'<I4<=:[(Y5B94G7BO=77^O1_<7_
M &Q3M?D?X'O5%<I_:%U_SWD_.C^T+K_GO)^=<?U67<C^VZ7\C_ ZNBN4_M"Z
M_P">\GYTJZA<[A^_DZ^M'U:7</[:I?R/\#X(_P""8W_)U'[5_P#V'S_Z77U?
MI#7YC?\ !-FYEB_:<_:E9)&5FUS)(/7_ $V]K]#O[0NO^>\GYU$:#FKIG17S
M6G0GR.+>WXG5T5RG]H77_/>3\Z/[0NO^>\GYU?U67<Y_[;I?R/\  ZNOBS]L
MO]CGX5ZEH7B#XB7&@W#^*M1U73A<78OI@K>;=P0/A-VT9C)' ]Z^J/[0NO\
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MR...I)( H ]V\/\ [;'P+\5:]I^BZ1\3M!O]5U"XCM;2UBG)>:5V"HB\=22
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M[0'_ "?I^SM_V!_$7_I.E?0M>EAO@9\7G/\ O"]/\PHHHKK/ "BBB@ HHHH
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M **** "N;T5A_P )MXD&>1%:9_[Y>MK5=3M]&TVYOKIQ';V\;2.Q] ,U\Y>
M?BA-%\39]3OY-EKJTGDS*3Q&,XC/_ >!]":^(S_/<+E6,P-&N]9S^Y<LHW?E
M>2^5^Q]YP[P_C,XP6/KX=:0A][YHSLO.T7\VNY]+U);?\?$7^^/YU'4EM_Q\
M1?[X_G7VSV9\/3^->IU]%%%>&?IX4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7SK^V5\9]>^&>B^#_  WX(\.Z?XD^(OC3
M5#I6A1:JH-K;,%W2SR9ZA5QQD=<G@8/T57R;^UU9?#[XY> _#6MZ1\9O#_@3
MQ-X=UF2Z\.>*/[1A,*7L2@30,2V",,FX#)'RY!'! .'\+_$+XY_L[_%WP#HW
MQPLO!GBCPKXUU)-'LM=\-V:P3:;J#@F*-AL3*DC&<=B=W&#]U5^=GPQT+5?B
MQ\;/ FN?&W]I/X>^-D\,WRW6@>%_"=Y JW6H'Y8I9 %3+ D$ !B3@#:"0?T3
MH \=_:@^+/@'X#^ 8_'OC;2;36+O2YPNAVK6T<MY->O]R.V+ E';:"67H%)[
M8KXSUGX._$BY_9K_ &E?CA\3+0:3XX\>: !#X?MP0=+TV$ K')GD-Y:C(/("
M<\D@?:7Q^_99^'W[3,>AQ^/;"]U"/17DDLDM;^:V".^W<Q\MAD_(N">G;K57
MX1_LD?#KX)W>M3^';/4Y_P"V+3[#>PZOJMQ?Q2PDY*[)G8<\@\<@XH ^/_$E
MW#JUC_P3R@T>XAFOP;23; X+"%+.V$YX[#:X/NI':OJSXMZ+^TE>>-KF7X;>
M(_AYIWA0QQB"W\0V-W+=A]H\PLT9VD%LXQVJQ\)?V*?@]\#_ !Q+XM\(>%!8
M:V4DC@FFO)KA+-)"2ZP)([+$#DCY1T)'0XKW*@#\_CHOQAB_;P^!4/Q<UGPE
MJ=Q)I>OG3F\*VL\*QJ+9?,\WS>I)V8QZ&ONC_A'1_P ]_P#QW_Z]?-OQH_Y2
M"?LY?]@?Q'_Z3)7U76L:DH*T6<5;!T,1+GJQN_F8W_".C_GO_P"._P#UZ/\
MA'1_SW_\=_\ KULT57MZG<P_LO"?R?B_\S&_X1T?\]__ !W_ .O1_P (Z/\
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M7A%1I24X*S;C))W;;U_Q7:79GY]_\$T=,^U?M1?M4Q^9M\O72,XZ_P"G7O\
MA7Z+?\(Z/^>__CO_ ->OSW_X)C?\G4?M7_\ 8?/_ *77U?I#7Z'&K.*LF?"U
M,!AJLN:<;OU9C?\ ".C_ )[_ /CO_P!>C_A'1_SW_P#'?_KULT4_;U.YG_9>
M$_D_%_YF-_PCH_Y[_P#CO_UZ/^$='_/?_P =_P#KULT4>WJ=P_LO"?R?B_\
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M3YB\RP_MI*S3L]/^"R&XM(+M5$\,<P4Y D0-C\Z_G-^."A?C5X_50%4>(-0
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M/5FB4D_CBII;>*>,QR1I)'_<901^5244 ?F[_P $Q55/VIOVK@JA577L *,
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M3^56** *T^FVEU)OFM897QC=)&&/YD5851&H50%4#  & *6B@ HHHH ****
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M6FJT'3EL_P"NIY9^S9^S=J7P/UI;B3PQX;\^<S)=:W%JMQ/=I"S,R1QQO"%
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M-(?"7_HJ/@O_ ,*"T_\ CE'_  TA\)?^BH^"_P#PH+3_ ..4 >BU^<7[+_\
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M ()H/_B:]GHH \8_X8O^ W_1(/!O_@F@_P#B:/\ AB_X#?\ 1(/!O_@F@_\
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M['X<TW0_A5IDEGI2Z'=//)JUPT2PB>0,!Y8"HK8Z[ATYX^VZ "BBB@ HHHH
M**** "OSW_X*<?%[Q'XL\)^*_AEX NC!:^&]*77_ !MJL3LHMX2ZBUL0R_\
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M+-_P4)^"6I_%B_LK"35K?5GT[PMI$A-OIEND,@'F,"1)(^0S')Q@#/&!Z?\
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M"@#W.BO(?B-^T]X2^%'[/]I\6?$HN;31KNQM;J"QB DN9I)T#1P(,@%SGU
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MA/$/PC_X1Z^TW6M$T6VUFXNYI4:(B5(6\H <[E\X GIE37MU !117E?PB_:
MTGXL>-/B'X173[G1?$G@G5/L%]87;JS2Q,-T-S&5/,<B@D9Y&.>HH ]4HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\:>$]8UYHS=1Z#=I;IA$1 N0NXCY <$]: /%/@#>>,?!?_!0S4+3X]VUM?\
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>inbx-20211231_g5.jpg
<TEXT>
begin 644 inbx-20211231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &/ G # 2(  A$! Q$!_\0
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M:Y[XB?\ )/\ Q-_V#+K_ -%-0!^9O_!%W_D2_BC_ -A"Q_\ 1<U?I!7YO_\
M!%W_ )$OXH_]A"Q_]%S5^D%>M0_AH^ S/_>Y_+\@HHHK<\L**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .LL?^/.'_=%3U!8_\></^Z*GKQ);
ML_3:/\./H@KXX_X*P6M_<_LCWK6Z7$NE0ZU82ZNMK]\V8D.[\G,?7CI7V/7Y
M\^)O^"GVL)>:KHUU^S=XNU2S266UD$@9XIU#%3E3;D%2!TY'-2;'S!IK_"7X
MZ_$;XH_$+6-/GB^ _P ._!EOX>\.QWJSAUG,:Q6JC!W&3S#,P&?XE)K]!_\
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M+N=%!0E5BJK]V^I\4?\ !-#XZ:)KWQ];1;I&TN^O-,U*.R65MPN));W[7L!
MX*INZ]=IK]4Z_&O_ ()>_!:/6OVH'U34[M1)X4M;FZCMX#N$DZOY'S'LHWEA
MZX%?KA\0-<\1>'O#CWGA;PP/%VK"1%73#J$=CN4GYF\V0%1CT[UA0;Y-3TLT
MA'ZSRP['245X)\(/V@O'WQ4\1W5I+\(SHFC:;JUQHVJ:H_B2VG^R7$(^<")4
M#2#<5&5]<]J][KHC)2U1Y52G*F[2_-/\@HHHIF04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '66/_'G#_NBIZ@L?^/.'_=%3UXDMV?IM'^''T05
M\K_\%*OAGXC^)W[+^HV_AC3I-:OM)U&UUB728@6:]@A8F2/:.6X;=M')V\<X
MKZHHJ38_&RY_;\\'3_&SXB^(]/\  ^N33^)? UMX3L?#7V6,&*]7<K1NH8_N
MESQA2QQC:.WZ'?L!_"W7?@[^R=X$\->)89+36DAFN[BSD^];>?.\JQD=F"N,
MCL<UW_QBL;/PG\-?&OBK2-.L++Q'8Z/>7=OJ2V<1F25(697W%3D@@'FO-_\
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M(&3V%=;7$?&KPCH7C3X8^(K'Q!HUCKEE'93W"6^H6Z3QK*D3E7"L" P['J*
M/S6_X(SZYIMEX=^(VG7&HVEOJ%WJ%D;:TEG19I]L4Q;8A.6P.N!Q7Z6U^9'_
M  1M\'Z%JVE>/]=O=&L+O6M,O[06.HSVR/<6H>*8.(Y"-R;AP<'FOTWKUJ'\
M-'P6:6^M2L%%%%;GDA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M\8?\%6?%OC'PG^S?;?\ "+SW5EI]]JD=KK%U9LRNMN48JA8<A&< 'UX'>OL^
ML+QYX5B\<^"=?\.S>7Y>JV,UGNFC$BJ70J&*GK@D'\*B<>:+1TX>HJ56,Y*Z
M3/Q'_P""<WQGM_@[^TWHL^K:Q!H_AW689M-U&>[_ -5AE+19;^']ZL?S'@9.
M< YK]U$8.JLI#*>00<@BOYR-#^!_C+Q)J%_%I>A7^HV5A'<7-S?6MLTD<=M!
M)Y<T_')52.<<]J_H0^%;V$GPS\)G2]7CU_3AI5JMOJD3;END$2@2 ^^,URX9
MNSBSW,YA#GC4B]7HSS;]E7_CW^+/_90]9_\ 0XZ]QKP[]E7_ (]_BS_V4/6?
M_0XZ]QKJA\)X5?\ B,****LYPHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** .LL?^/.'_ '14]06/_'G#_NBIZ\26[/TVC_#CZ(*_/37/B[_P4"AU
MJ_CT[X1^%)M/2XD6VD=H,O$&.PG_ $\<D8["OT+K'\.^,-!\7QW3Z%K6GZTE
MK+Y%PVGW23B&0#.Q]I.UO8\U)L?G3XN\>?\ !0/QIX5UCP_?_"#PLMCJEG+9
M3M#);AQ'(A1BI-\0#@G!P:^H?^"??PK\4_!?]EGPOX3\9Z4VB^(+.>\>>S::
M.4H'N)'0[HV93E6!X/>OHVB@ KRGX]>#_%/C;P3J^D_#'Q1I?@SQY<A%;6)K
M=)I8[?/SKC!8;N &QQU'.*]6KX^^,W[%_CJ?X[:C\7?@K\2E\ ^*-:M!9:O:
MZC:"ZMIT  W*"&P?E0[=O#+N!!- 'R1X1\0:98?\$Q_CEX!L-";0O$?@[5%T
M_P 021W)N%OKAKE%:<-@8!\HKMZ (/6NO_;7CBM/^"9GP$GM0L6I6\VB26'E
M<.)OL4A^4#J>IQ7U?\'_ -A7PK\._P!G[QA\-]:U*[\37?C0RS^(M<F^2:YN
M)!PZ D[=APRYS\V2>N*\B\)_\$Y_'MW?^!?#7Q$^+:>*_A/X%OA?:-H,&G""
MXE93F-9I/[JC(^\V 2!C- 'H_P"V5\9OCI\)?"/@&X^#G@EO&E_J"RC5D.D7
M%^8 L<1C)$+*4W%GZ]<>U?(WB#]LK]N&]T'4K>_^"+06,UM+'<2_\(AJ"[(R
MA#-DRX&!DY-?K1TX%<_\0_\ D0/$W_8,NO\ T4U 'Y._\$F/C%X$^%_A+XC0
M>,/&&B>&)KR^LWMX]6OH[=IE6.4,5#D9 )&<>M?J/IFIVFM:=:ZA87,5[8W4
M:S07$#AXY4895E8<$$'(-?C%_P $F]*L=8_:BN[?4+*VOX/^$=O&\JZA65<^
M9#SA@1FOVCAACMX4BAC6*) %2.-0JJ!T  Z"O4P[;@?#YM&,<0VMV/HHHKI/
M$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** (;R26&TG>"(3SJC-'$6VAV X7/;)XS7S"W[2WQH7XA+X*_X4?9?\) V
MEG61#_PE,.S[*)A#NW[,9WD<?C7U)7ADG_)\D'_9.)/_ $YK6<[Z69UT.7WN
M:*>GG_F>V6,D\UC;R7,(MKEXU:6$-N$;D#<N>^#D9J>BBM#E"BBB@04444 %
M%%% !1110 4444 %*OWA]:2N9^(7PT\._%70X]&\3V+ZAIRSK<")+B2 [U!
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M%%%=9X 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX+>$+KPNGC1K"[C\2W>O:+837L&J746Z"2]AAD3RTE"#,;,N0N><YSS7T/\
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MQ47:=P\(Z%E>_P#KKOM6DN633.6C&K352+35E^J/=9-\5NWE+YDBH=BLV-Q
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MVS3(I"?Q*YK;WNYYW[J7V6OZ]#H+'4K35(_,LKN"\C_OV\JR#\P35BO$;_\
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MEL[E8?=Q\IKW2O$ENS]*I)QIQ3[(*J'5K%20;RW!'_35?\:MU^<'Q4_X)0_
MKP?IVO>-O%_Q+\5:!I"2O=WEW<7%JL41=\X'[@DY9@ !DG('-(U/T4_M>Q_Y
M_;?_ +^K_C5B&:.XC#Q.LB'HR$$?G7XI?\*%_88Y_P"+]>,/_ =?_D2OTP_8
M3TWP#H_[-GA^S^&6L:KK_@Z*YO%M-0UF(1W$K?:)/,)4*O ?<!\HX H ^@*_
M*3]N;Q5XX^-7[2\'ACQ)\,OB5K'P3\*3E39>%=(GSK%R%RTIE*;"F[Y 0<A0
MQ7!;-?JW10!\6JI_:_\ V2?B%\,O#/PJ\0_"%+#3X;/1M/\ $VG_ &&*5U/F
M1K&/[NZ,*S=M^3FOG/6-!^,'[3WPN^#_ .SSJ7PB\1>$1X5O[7_A)/$&J1&+
M3GMK:-HE\M^CY1B<*3\P7&0<C]7J* ."^(WP&^'WQ>L-)LO&OA/3?$]MI086
M2:C%Y@@W!0VWTR$7/T%>5>-OV'?@'I_@S7[JW^%'AN*X@T^XECD6TP598V((
MY]17TE7/?$3_ ))_XF_[!EU_Z*:@#\Y_^"'G_(D_%?\ ["%A_P"BIJ_3FOS&
M_P""'G_(D_%?_L(6'_HN:OTYH **** /GW]L7X06/BKX6^(O&>BZ3,GQ,\-Z
M9/>:!K6CRFVU&*9$+*@E3ET..8VRIZ8K\(_!?Q^^(OA/XM6WCRQ\5ZFWBQKM
M99[VZNV)N?FR4F+'#(<D%3P >U?TO5\A> ?@G\/X_P!O'XI3+X+T/?#X8TB\
MCS8QE4FGENUGD52-H9Q&@8@<[?KD ^J_#>KIK_A_3-2CE@F2\MHYQ):R"2)M
MR@Y1@2&7G@BO$M<_Y/J\*?\ 8A7_ /Z705AZQ\%_%?[-MQ>^)O@M/'>>$U+W
M6J?#35+@I9D?>>33ICG[+)U/EG,3'LM?$^J?\%9?#%Y^U5HGCN'P/J2^%;+1
M9=!D,UT@O-DLT<K3B, KE2F-F[D'.X=* /USHK \.^//#WBS2M.U'2M8L[RU
MU"!+FW*3KN='4,IVYST/2MK[5">DL9_X$* ):*;YB?WE_.E!SR.10 M%%% '
MSS^WM_R;/KG_ &$M*_\ 3A;U]#5\/_\ !3;]J'P)\.?AO)\/-0O9KOQ?JDUC
M?QZ=9Q[S#!%=QR%Y6)PNX1L%'4^F.:^G_@;\=O!W[1/@&V\7^"=2_M#2I7:&
M1)$,<UO*N-T<B'E6&0?0@@C(- 'H-%%% !1110 445R7Q+\(:UXU\/I8:#XO
MU#P3>B=93J6FP0S2E1G,>V567!R.<9XH ZVBOE;]D.Q^(GC6WN_%?B;XL:SK
MMKINOZOHS:+-86D<%PEM<R6\;LR1APV$#'!QGVKZIH **** "BBB@ KP&3_D
M_:#_ +)I)_Z=$KWZO 9/^3]H/^R:2?\ IT2@#WZBBB@ JMJ6FV>LV,]CJ%I!
M?64Z[);>YC$D<BGLRD$$>QJS10!\[:A^R9+X!O9]7^"'BRZ^&5\[&630'4WO
MA^Z;J=]FQ_<D_P!Z%EQDG!-1V_[4VM?"V>/3_CIX,G\%J6$:>+M&WW^@3GH"
MTBCS+;/'RRKCG[QZU]&U'<6\5Y;R03Q)/!(I1XY%#*RD8((/4$4 ?(/[>GQ]
M^'.F_!OPU#+XTT>275-?T74[);6Y%P9[6#48))9E\O=E%1&.[H=I R>*^JO"
M/C#1/'WANQU_PYJMKK6BWT?FVU]9R"2*1?8COG@CJ""#7XA_\%+?V4_$7PM^
M/VK^)-#\)&#P%K\D,FG2:-9XM;>9E5&@*H,1N9,D+@;MXQZ5]<_\$^_V,OB#
MI_P*5_&WCKQW\/[;4+U[JT\+Z/?+9;(651YDH,9='<@G:". ,C- 'Z-$XY/
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M:17ZK4 %%%% %/5]7LM TN[U+4KJ*QT^TB::XN9W"1Q(HRS,3T '>OCSP/\
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MAXHN/BU;?"SQ3!;:AI/BK4;V^MKRWA\N:VOIFDN),XX:-V+\8^7(QQQ7Z[T
M%%%% !1110 C,%!). .237SO)K%A_P -Y02_;;;R_P#A6LB[_-7&?[43C.:^
MA+JUBO;6:WG02P3(8Y$;HRD8(_*O$S^Q!\""V\_#'0]^,;O+?./3.[I0![@K
M!E!!R#R"*6H;.SAT^S@M;:-8;>"-8HXUZ*JC  ^@%34 %%%% !1110!\^?MR
M$CX*Z=C_ *&WP]_Z=;:OH.OGO]N7_DBFG?\ 8V^'O_3K;5]"4 %%%% !1110
M 5G:YXDTGPS;)<:QJEEI5N[^6LM]<)"C-@G:"Q )P#Q[5HUSWC7X=^%OB1IL
M.G^+/#FE>)K"&43QVNKV4=U&D@! <*X(#8)&>O)H \"_8%\7:#=? ^TTJ#6]
M-GU-]:UF1;**\C:8K_:$[;@@;.,<YQTYKZ>K@_"GP$^&G@/6XM9\-_#[PQH&
MK1*R1WVF:1;V\Z*PPP#H@(!'!YYKO* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,#QI\/_#7Q&T>32?%.@:=XATY^MMJ5LDR ^HW X/N
M.17YK?\ !3KX$ZG\"_@;92?#35?%5EX"OK\0:YX>&IRW.G6J!<PLJ.6:)-X(
M*AMA)7(SBOU(JO?V%MJEE/:7MM#=VDR&.6"= \<BGJK*>"#Z&@#\5?\ @CG>
M>,U_:2O+?1FNSX1;3)FUM!N^S @?N"W8/OX7OC=VS7[95\Z_L":'INB_LSZ
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MOGO]B'_DE?B?_L=_$?\ Z<YZ^A* "BBB@ HHHH **** "BBB@ HHHH ****
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M,GGWKF?^%&?#:/Y_^%?^%E*\[O[&MACW^Y0!S/[7C*/V6_BHV0%_X1R].?\
MMDU<'_P378-^Q/\ #/!S_HUQ_P"E4U>D_!7XT>%/VFO ^M:EI4%O>Z1;ZI>:
M)<VTTD5RDODR%-Q"EE*2+M=0>JNI[UZ+HVB:=X=TV#3M*L+;3-/@!$5K9PK%
M%&"22%50 .23QZT 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZO7 T_Q9;">V:2;:(KNW5B JE@/G1F!P"Q*1]A7[-U_+Q\//&^H?#7QYX?\
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M8JRLIY5@000>: .NKY"_X*C?'+_A3?[+6K6-HP_MGQ9+_8=KMFV/'&ZEII0
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M&DN"K.7($H&=W. ,>U?2]<]\1/\ DG_B;_L&77_HIJ /R7_X)/?LR?#'X_\
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M_P#!$/\ Y)7\2_\ L-6__H@U^E5 !1110 4444 %%%% !1110 4444 %%%%
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M_P *\T*71?[9\G[;YE]/<^9Y6_R_]:[;<>8_3&<UZY0 4444 %%%% !1110
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>inbx-20211231_g6.jpg
<TEXT>
begin 644 inbx-20211231_g6.jpg
M_]C_X  02D9)1@ ! 0( .  X  #_X2(017AI9@  24DJ  @    & !H!!0 !
M    5@   !L!!0 !    7@   "@! P !     P   #$! @ -    9@   #(!
M @ 4    =    &F'!  !    B    )H   !L!@  '0   &P&   =    1TE-
M4" R+C$P+C$T   R,#(P.C W.C$Y(#$U.C,Y.C(W  $  : #  $    !
M      @   $$  $      0   0$$  $   #J     @$#  ,      0   P$#
M  $    &    !@$#  $    &    %0$#  $    #     0($  $    & 0
M @($  $    !(0        @ "  ( /_8_^  $$I&248  0$   $  0  _]L
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M\*WM/T9=:BBN,1LD9#A6R 3U JC;F_MTDBOXU\]VPKH#A0/7_/>NRT33'T^
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MVD%L;B*?"2.<2L%* CH-K'C/O5%-)OH--TV%8[A=EN%D6%@2DG'/+ =O?]:
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M5-FTE<CY0PY'N&-)+ISS/(SSKB41EP$_B0YR.>![<T 3'4K,-(IG4>6&+'G
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M#"&+9!Y/X?C6[0 4444 %5T_Y",W_7*/^;U+(GF+M#LGNIYIL5NL+,P9V9@
M6=LG SC^9H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBP! ZC&,$\8Q5JW@2VMXX(\[$&!GK4M% !1110 4444 %%%% !1110 4444
M%%%% !1110!__]D _^$/<6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
M/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C
M>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@
M>#IX;7!T:STB6$U0($-O<F4@-"XT+C M17AI=C(B/B \<F1F.E)$1B!X;6QN
M<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A
M>"UN<R,B/B \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SII
M<'1C17AT/2)H='1P.B\O:7!T8RYO<F<O<W1D+TEP=&,T>&UP17AT+S(P,#@M
M,#(M,CDO(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(@>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C945V96YT(R(@>&UL;G,Z<&QU<STB:'1T<#HO
M+VYS+G5S97!L=7,N;W)G+VQD9B]X;7 O,2XP+R(@>&UL;G,Z1TE-4#TB:'1T
M<#HO+W=W=RYG:6UP+F]R9R]X;7 O(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN
M;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM;&YS.F5X:68](FAT=' Z+R]N<RYA
M9&]B92YC;VTO97AI9B\Q+C O(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\B('AM<$U-.D1O8W5M96YT240](F=I;7 Z9&]C:60Z
M9VEM<#HY839E-64T,RUA,V,P+30Q,#,M.6,S,RTS83<T-# Y83EA,CDB('AM
M<$U-.DEN<W1A;F-E240](GAM<"YI:60Z83!F,S!A,#(M-F,Q,RTT9C$X+6)B
M-3 M-&-F,&,Y838X,F-A(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM
M<"YD:60Z,V8V8C!F9#<M,#,X-2TT-38V+3@V9#$M.#8W93 U8V,P.# R(B!'
M24U0.D%023TB,BXP(B!'24U0.E!L871F;W)M/2)7:6YD;W=S(B!'24U0.E1I
M;653=&%M<#TB,34Y-3$Y,3$W,# P,38V,2(@1TE-4#I697)S:6]N/2(R+C$P
M+C$T(B!D8SI&;W)M870](FEM86=E+VIP96<B(&5X:68Z4&EX96Q81&EM96YS
M:6]N/2(Q-#DR(B!E>&EF.E!I>&5L641I;65N<VEO;CTB,3,V-"(@>&UP.D-R
M96%T;W)4;V]L/2)'24U0(#(N,3 B/B \:7!T8T5X=#I,;V-A=&EO;D-R96%T
M960^(#QR9&8Z0F%G+SX@/"]I<'1C17AT.DQO8V%T:6]N0W)E871E9#X@/&EP
M=&-%>'0Z3&]C871I;VY3:&]W;CX@/')D9CI"86<O/B \+VEP=&-%>'0Z3&]C
M871I;VY3:&]W;CX@/&EP=&-%>'0Z07)T=V]R:T]R3V)J96-T/B \<F1F.D)A
M9R\^(#PO:7!T8T5X=#I!<G1W;W)K3W)/8FIE8W0^(#QI<'1C17AT.E)E9VES
M=')Y260^(#QR9&8Z0F%G+SX@/"]I<'1C17AT.E)E9VES=')Y260^(#QX;7!-
M33I(:7-T;W)Y/B \<F1F.E-E<3X@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A
M=F5D(B!S=$5V=#IC:&%N9V5D/2(O(B!S=$5V=#II;G-T86YC94E$/2)X;7 N
M:6ED.F1B-&%F,V$W+6%B,S M-#DP9"UA9C(V+3<P.#DQ9#<W-3AE,B(@<W1%
M=G0Z<V]F='=A<F5!9V5N=#TB1VEM<" R+C$P("A7:6YD;W=S*2(@<W1%=G0Z
M=VAE;CTB,C R,"TP-RTQ.50Q-3HS.3HS,"(O/B \+W)D9CI397$^(#PO>&UP
M34TZ2&ES=&]R>3X@/'!L=7,Z26UA9V53=7!P;&EE<CX@/')D9CI397$O/B \
M+W!L=7,Z26UA9V53=7!P;&EE<CX@/'!L=7,Z26UA9V5#<F5A=&]R/B \<F1F
M.E-E<2\^(#PO<&QU<SI);6%G94-R96%T;W(^(#QP;'5S.D-O<'ER:6=H=$]W
M;F5R/B \<F1F.E-E<2\^(#PO<&QU<SI#;W!Y<FEG:'1/=VYE<CX@/'!L=7,Z
M3&EC96YS;W(^(#QR9&8Z4V5Q+SX@/"]P;'5S.DQI8V5N<V]R/B \97AI9CI5
M<V5R0V]M;65N=#X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F
M875L="(^4V-R965N<VAO=#PO<F1F.FQI/B \+W)D9CI!;'0^(#PO97AI9CI5
M<V5R0V]M;65N=#X@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X
M.GAM<&UE=&$^(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N
M9#TB=R(_/O_B K!)0T-?4%)/1DE,10 ! 0   J!L8VUS!#   &UN=')21T(@
M6%E:( ?D  < $P 4 "8 $F%C<W!-4T94
M      #VU@ !     -,M;&-M<P
M                            #61E<V,   $@    0&-P<G0   %@
M-G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H   'L
M    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)44D,
M  (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\    )&UL
M=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I &P
M=  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H    <
M %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #W
MP&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$6%E:
M(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D  !/0
M   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL=6,
M         0    QE;E53    "    !P 1P!) $T 4&UL=6,          0
M  QE;E53    "    !P <P!2 $< 0O_; $,  0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_" !$(!50%U ,!$0 "$0$#$0'_
MQ  >  $  @,! 0$! 0          !P@%!@D$ P(!"O_$ !P! 0 !!0$!
M           $ @,%!@<!"/_:  P# 0 "$ ,0   ![^
M
M
M
M
M
M
M
M \MOSY>/?=]
M                                          &+L4P5RS'8&CR0MTER
M)GKV?E5_KT
M                                       !#.$L13S:!D8_F^Q+FD3J
M9%Z=/F#-W@
M   !^?&!C413J<;9Y]<G;-)_OH                                5[
MUZQ$.EP]WQ%&\P+>J9"YHV8N2)G[TK;!(WS*7
M                              -0A41+HT+&:]:_L;SX7T[==R>V3*P
M                              !&4"BMW-,= .E1,OZW#$6YKVJ5K^=N
MX')UV3W29NDVK6,5;^/J2L[?^GH
M                >6GS4,?17738<B:A9RMA&F2:9E*YVWF;.6;O
M                    #P6:8VU^QZY]S<LC<S5[UX_)%^MQXAU2+#^.HP6.
MHQ6&M27G;OHT>QZ=GN:QOTW:L9;R=FG9<;;\5WV7^I9*6LK=
M                                   'BH\^WK[U>X:UY5S08.NXNWMF
M/HU' V=+QE&<S5S/;/?LMTG(2).N                            ?P@'
M0(/TT>-%^;K\>0JW[/2?+#MZM%I^^#L>JV_$7RC6D1LPIN1T.9M^/IJMJ466
MNES_ "7:L_"HU;(W/QZL_O<V7)]8
M              &B0+<'\SQ_NK?;.7])B4:62EJ<?0-%CZMLE>Y;'?@_!V96
MVZ39#;I4O[!?R%ZH >:GSY4O=<]                        'Y*M\^@X'
M3(E<,!8V[&T?N;7)F]2\?+J^57N]XFB-L/:KCBK5NMQD[!'?.I!NO1YYEW?+
MF*_U[[$^QWOWG[W0#8Y/W]
M         5NP-C1N>P?%>]]=OS6\A<\5U'O*L=97:I4:R?::\XA3OLU^8MIO
M[Q&I]N;N[_N$O:9U?XN50OKL?!X*QM6+HE7HTZ0,Y?
M      $-ZK%JOP_&2;MMV5(OOQ@R*E8+%W5VS+1G(B0)K]OG?R^+T=[/-D',
M7/[5[]J?*^:G&]7OMJ\U?V>B[7G:&0K]N%T*=GKU0
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M$S7;/D786U#.?D3?N\O<<7:L'G+UD]CD
M                  ?+Q7O!V*Z:E&U/&VKFX*_JLR/ <"WI.EV)PZ3*Q.<O
M[UAK,:8ZCDMQJ)T=R:]O3)GGO7ZNZ7C[C[ED_(HK[=CZMK]%INTY*6-IE
M                    "+\%8T#E,#'W//'6ER+*JWHV*E#=96)U3R0=KN<?
M>>0M?UFCHUM5^SV_9/DOQ? U'R%ZPNT>[/QR->+LTSX[E=YV\3@VGZY.W;J<
M_.0:)^V618W-7?15Z
M  ("UZ/5/$VXRJ]AC0H=B]3BV(WJ7BGFNZ38KC,JA.S[-LWS?['E'^:QMPQE
M'4/N^0RMWV.>01Y!S5_69-NO.9HNQF9WYRGDD]-F[QF+W]
M        !KD>FHFD0L#$\W/%6MOAJ1<LQMN.M9&M6H1;,W)/%W0HULMK]GN_
MYI^O6J5<[MR=V*9IV'LQ5JU/6;J<JE/$<?\ K7J;Z]YF^[I,W0<U=SL&F4<S
M<LIMLK*7J@                                           !_"K.N1
MX:U^QI>9NPGR^#Y-:CW*Z#+UO0HE=N:6*V;5<C'!>=5=LNSOFYU0-=QM)=$M
M7?Z7?NSM<C6=&\R%_P!_64M[1LDC7ZZ=DC^8J77,O7\CM$ZX
M          !X_$<1::TZG%U^'17[BF.G>S3@MINX3FMCFODJ^D/;I\.\O@5]
MYA'EW8;ET_HG*T:XYCX*PU-W>N3*S?->+O+,E6>Z#/W;>_(<RU&@YJ[*^M1_
M'GY%J.DS\C7Z                                           /X0Y@
M[->\#8CVY[M^+MQYR+'4SXM"M_U67)V0O<ON:PY-ZM)AC5*)#T^-U?[?DXTU
MJU0K!6<%*O\ :SHDNH.&A3!ODJ$.40+H]"R\0SH_AO\ HL]T[([C.K
M                  B'%VZC:K%@G#6Z=?.6*MMN5RN^EVY'Z?+N'ODCE9PG
M'[SB+?1CON1^6ZRZ>\;@0[>:1/K]W+(=Y]PJ_/GDI9F[,FZRM#S5V8-6C:WD
MKUBND3I!G5^BKT                                          ?'Q
MNGQ(TU>-I>1N;%!HDS"VM>YGY3+E$&NF;MV^^B\IS.XU#L=L]=G=\DTK^=,;
M)N>3ATN5I^PR:1<9@]8=QN:AF*K%PJJ;X6S:?K\_&WO=KVZ7-&3KEB=<_H
M                     !Y:/*L<JQL;U^T9^:,3LKW7\[,N-V&NGW*X=6I%
MSL?MUV (]O*[1(KSP3&Q!T&572/5T*N6[,99NFW2X$Q%J0NB3]\Q%F7]=L:%
ME+N"G5;UDKEI-\F^FKT
M#2(M-:N4XS8(E$/;3)EK6H_BP%5?='B1GCK5+,3Y._<\A ?.HENMFO6BZC-A
M7DN/I1RJ+GMXO=%NUY+F7Q:!;K4['ZWV[$NA1YO[SE9-W*3:[8;T^Y6[^@
M                      ?/QH.(LPKS+'^8ACDMBO&C6OIU>_K&2\H;C?>M
M&ZW+[Q)$)9>SSJYM"FC1+$$URJNYZGJQUV7C-6CVPS][G+RR#7^%58'1(DU;
M?>F7N^3UO/WI2UZQE-IDV5WR;Z:O0
M        !^?$,ZY'BW%V\?K$7/0Z8>VJ3Z(U,2Z-$V"Y[FXM/.C0K5?-QD3-
M>\LW@+5G>U9&-.8X^*M2MU @NG_1I&AVO("Y5:W*?8@F-7T7^D\K*5'EO.C9
M#,7?0                       !_""-*B:!IL/ S:]H@TTOY]$@GE$>R?2
M9?.BJF^/89]B9M6[8:S&4ZY &H183X7CJ][9*O7GO;/=AR%;]"A]()\OG1P?
M$TZL>7&YO$B'*5>'Z3RUZ.JS9GU./I.4JM)U/)[?(J
M                      _/B'<!8A31(6I9*Y)&!L>'3HU:H2%MHD;U@HUU
M]RE5JTR)&V4O\YM'MW-Q]4I82#I?3IEZ-OOSK#E<0\+!T'2+'2;KDRLO,*9+
MY[$W7?[MF.M2MJEUV#ZSD?O5Z                       !_".L'8K?ID3
MQ6O/O0E[!T48YI#P/((FJ]/R%X.H2/#M%2E%VR7X=PENH/SYBL50O?VJ=:+(
M51IGY&*@T8GEN/P4GW0MCD2WKEFNNBQZE;+(ZY=?FYV15)V?O6AV&1]O0
M                                    &DQ**[<GQ>UP/( W.7"?+<?&
MGS'BLY \JYTN7?;.57K[%D.>F*CS=NTSF5P3&^/&+*0X^7[-D+D;3(D?&40/
ML=[D]K5&T\^AVZRM<-<5A6H[9-L%ODCQ7&[9.[..[S-KR5P
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MQ-LTG2-/B?;3XU<,8^_(H6CQ/+.?5F9L_.]G3HT^8<K=
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M+62L>:[D*ZSZI8K=I]C7\)1U/RRP^SR(&W"_G(=$<;%(Z!;E+SMST
M                                #Y^*<ZS&^.E1(!Q=$=_'V'W"E3S>
M[N\W_+0_2V7W/.WYAU:-]//-%S%V2M0L\TN P89R--\.J7[H[%-@S9/=F@^;
M9CZ(MUB-4CBT2O.UW=]SMRXW9<A^,Y>G#3XTCX_W'=%DS_N4L
M          #5X%N).08_^Q[?@K<Z>?1*R8EUTZ#)YU\/QTY]@ES'JE%B>D3X
MDP-.G3(^TYZ[R?X="\D&G0]@O6H[7/NWL5W&WO?%>]]5OSX:S8@[7(]9K/O9
MC+W=MMUP1L7OPK:-F[]_MQE;)=]
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M@+-H[\C)9-6;D6.B#;[T5\FC75ZW+Y1Z#8Z,=PG6^BU?)1C<[=LQU3)>BKT
M                    >2GRJ>@P?SK%G2(%K7\5;VC;Y-9.'X^(<5;L?V*=
M!WS1C8AS=5U?IW+SI?\ :><2QT&:18N%]#Y+GKPV%J&3N2'W+(=9I=.O3;OA
MO>_CWS(V//MG+TSY*YI^.MQM7[@X%&S7U^-PE_?WT
M                    #7+7E#=,A[)BK6=A4S;A*XDNV*83+F\74S9*YX;W
MNLY"OZ4^?RVY;<E@Y#ED.3[E.NP/.LW<I\E2[L'XJC&>6X/T"+[>HS:I<'QW
M3#Z!R7-;E<2P6B6;]?0.3]LQ_:JI+Z_D-WRET                     "&
MM?CQ;S:#I^F19-SLB/\ 9+G,WCT#>K2W^[2->^9X-2]GIN_]3YADKG-WAN.]
M&MV>G7T#DN8O#<?XXOGRWB1*W39USY_NHY*[)>"L;)=]MGT*=F[GHU"S3!.'
MM2YD;DDS:P                                       !@[?G/[48F3
MQMOY7JMJQM'ZR%6IO<E&I\]SW[6_/9;\S4:CG??NU5X'C-ZP%J[?69-;^$0+
MG]CF6+W^53W&4U%X+CI!KIL_] Y6IG ,7:KI$G][9(PW/8EH.ES-DNUXK-7+
M2]+R&;OU                      1#@;, Z+!AG2HMC-BOP7KUBLM^Y/VO
MV+!3Y-&/G/$1WU.7T!^@LGY:7(7C<&?M4C],.^9*KNDQ8%Y+9O3V"5SIS=S[
MYV]9':+T\8FUM\FJX^_3OOZ
M      ^7BH>LQHGB4VAV2_)<FO9+GM?L9:A?2HNMS:L;=]V;'T0[;<QN<1-]
MYS$W.9[T.[GD*"?+^(DCI,JYG;\GH.%M5R^2</.,.K??J.?1OBT&;]DN7)[-
MD,)J<?\ M3:L]>E#HD^;]AO@                     :_$HJMS7'^Z%36+
M3(OLY!%V' 40UUN]:7H<W>=>JJK\TXJ./H_(WAWZ]FL53Q=XK L-13=CZ2R_
MJCT\[..P+P;_ ",;T.=777K4?X*Q:+:9$MYB[=S<968K]
M                            'S\>/SSWU>_T'R\4TYQC]8H\C'8I&F8N
MW1#GL3I=KUFFW-+$P[[7<GILWE5\]XW7.C2^K_4YF/B44#^7</8C7O;-?2<^
ME6FQXDVZ_P!*,W<D'&>1M L[)N,JQO4,CO61N                      0
M%H\.-]5B8[!4QPIC'A4#+Z_=Q?T+>LSN$J"N.1=!YWY]?J&;9Z>RN)M\@^$8
M^UDQ>?N61WB#56C$1X_P=J1.S93=\-8PLVNFV%MW S-S;??;'[]-WZ=6
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M$G'Z/F_G:_8#Y7 G[@=6B[E9\_9I-HMGDZ?D*K#]'G2%F;P
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MLYMV3      'PI\Y-\6U3K7VO;!4W2L3^ZEK]SRPY6<;U;IKUO9<])N
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M&)V^=>A'7X.LQ+=U]_S5BMIR(        %9-2QGU]<_>9X#K[W#;\W(K
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MV[5)M+L<BT/0)F=N-QEVZBZU8NU&I_6?O6?W>9N<NO9[WO\ 0
M          ?PU*-3K%OR'L%8PFK1H:O2I)WF5E;<>$M3M_R[>EB!%DK7XV@9
MR[8KH4^6,A<_H          !"FOPH9P,.<MBFR_G)@
M                       %:\!9U+G6/W7'V_+5[JV0N5\S\G0(54G8RS](
M[.PDM9*Q$NSR?=8IW+$V[1]-R&WS[@                       'FI\QE"
M+/;FK5,]58\GE6(ID;UCXT0Z=#V_8Y%CMAO_ +
M                                 !A+?E5=1B_'4HNT8^F,,Y>AVS>]
M:UMN:N:E[>VK4HTW51XXVB1N^4NR'?\ 9YV61]??0
M   !$VMQ].Y_#RNZ7_3MV1PGMK'>5YNJUC:),_5V?7X^OK^@
M                                            P5ORGO/X.=U^QD]_
MGZ?E)>2IL2ED_-4HDZ]AK$FTVI:S-[8+OH                    QUFGQ6
MO,[+K_H !JT6FH_/,?(&"M86U5K.TS)/Z#(]=Q\WOEHOV&N6/>
M                                                :S9\P$:G99U<
M#4W=@KC8SRY]#>_*\MC(^K82U)FT2,I(J                   &NQ*(-Y5
MC?%'\]>]3+ ;3(RUVH 1#C+=4>9PMGQ5&TXWS\W*]1Z5?G7>;^MVY&^>I>JM
M_P!
M  ,)XKM1?V*N-A_+OH]\PV#I\W/L3MV(\UW>I5H]ZF_7T
M   !#^!L1ES''ZW%IP4ZK:MJDV*VV5D:V0O5:ABK5:,53%?-X43ZG8E2OW?]
MID:GG[E@>DR\AD),P^T[E[2
M                      /*5\MWOE5:S55J*]5M?CET?(VZ,3F?-9S%RXG0
MIV[3*P!^?&B8ZW&VF0]GRUV7-NE_OT              (@U2+6KC&-T2:VW%
MV]8>29T&;AYE>PQJ=PPUF&ILBNV@Q)OW:3K6N6?5IMC?^B3-*RMZQW2YUH<T
M^H
M !&=-<;O,HM5CY9#D?5[7]QUJ,O'WV:1:;J\^;LA[]JO?SX^97W68T5ZE%D_
M!48B\FCK.2WS)7             !@HE$=Z[8P^AQJ7ZI"MGLTB08TB+=?M1I
ME8^Z[!(T_)5[KBZ/Q#4BT2/&F)HF_<+\MT>_G%>_OJ$B4-@JMMNDS(7/?[Z_
MH                                                          !
MK_GM=(54-Z#COGK-GQ:7'BFX^><N>BWY,FXRIOILY;9I.MQJ<?;\C73(NFZU
M'P\FJQF>D6!ZYDI$R]T            #7XM$$\DQV<QEO/5R:CPH/NP%$_7)
M6<SE=:,#"MOL^2A7(QHY@T5PT>/F-DNSEDI&)7MB@T0MK$67>SS<A&HVNVW2
M_5DIM4X[U-]]ST
M            ?GQ3K2HT+:=:D73+$5P+$6S/<A,]SN(IL'T.1GZZ=.REWZ^>
M??6K'RTVW-VWUZ#(JB'5;5G.IS)MZ!D,A>]_H           !H\*BLG,<=EX
MU&0L-[C7,#A8^+U:]$^K0-Y['+D:^KQI=CF-H5F8MWO='.G2\;>;CB*==F^P
M=HT.>]^GZ?/9:+YZK?GNL4R_U')2UEKH
M                            'X\:5BK7AL4Z!B+<'8JUX[2(>+Q)CW>1
MJ=ZN&-5AZ![1?3:[VS92O$7?9JQ%VI&K8ZV6P3MHOR:UV,=$\&B[N6R4<Y&+
ML^VRIIW:7]*O0          !^/%?<9:@K4(N^Z]'D#%7JH:;CK%[O+\>CLQO
M5-?,%:H!QB'I^6N=(.U3=PF5^_-7,U%IQL6FL'.X-V]\F_OVJ/,O7I^4NYB5
M[=7<)>SWO0
M      (PQ%F(>58WP7?<7*JU^?<R-BF(>90IHVB6O/9EF!@6^9W%(4[Y3WH)
MOTO?9==:\#'E+7Y/AN4:[G[6T;-=RM-7W-7F560ZYD]FE5            ""
M,7:KIID3#:_9P/'X,B]9F8[5;,K2I?%KG.-E&*M9MU4P927665:B6Y59N[3L
M^K4^O<KDZ9>[+,&_7'8;>A9R]=G<I<AR*@
M                              !"^*M5^T"%CI56?@V_10D?$^5 U:'8
M#H4W,P?-8G>[5!\I/J]BE/*(UOLMY>CL4_)Q:-5YQ3L>;KT6/'LSNV7@[(0]
M,R]S8,](N+MTGUU>@           #2XE-$]/BZ%@;.H?/>)VOH%^P^:N\S.1
M1H@V>[U&G+ YB7'T.US,YI @[/2.A&XU2=&HF'I4[9<)1%>OT1#OTB;I7MP^
MAS]OE5
M   #X>*GXFU!VO6)9UN--V"KB#)6J9<^B3++JV+>947WZM+U>QN&&LU]UZB%
M]-MV(W6[U!Z+.@#2HNY=0E5LY+ L-TZ;YLE7MNZ3+3;#(]?H
M#7X=%4N88ZK5^NBOS9BKG[[7K>@6ZG[1>OYV>=AM'A^G6K53>;6-?V:[*72)
M.O<AA6NNUV:^C<E6/4X^]['?I%+N7AV6]83,7;2YZ_\ KT
M                                           -*BT4_P">0?O9IL-K
M-W1)L?0Z_-?TNQ7.6H=H-J_&7]Z/;]EZ\Z'CJ_P+?-UYU9NWI"Z;5J^%M:5R
MN-G/I#*^_.WN@&WRMEO5            ##1J8[P-C1M?L8[6;$+>>5U^6,9\
MMUD5QR%5Z>P2<9*KHCQ;'_+7*)\V2NT?<\E2CE,*#-6HZF;I=VF3[1;GT3*[
M?>LY]!9CZVO)#QUN\W09WJJ]
M                     $#X>U4[58U#M3CW3UZ/N.2KW;8;T \&Q]:KU,.Y
MV1Z^?1K&Y*F[W7IT!XNW525=C7E<7J7LMRK.2\KYI=JZ/TKF)VIINIT?(9.Y
MZ           /QXT3$6:_P"JQ_5K$?!S:O11YH. LPI\U1(:Z5,L3U#WRZQ8
MYT:S1M,?RR&27"[;DM"S-Z@OS?B/YDZ[G;](JI\TXF1<?5<CZ E^+J^2Q4FJ
M:\U>MAL%_P#7H
M         #%6O*+:3#CZ?7H>+MZ/S&#F\?;O_M\NCG#<;2[Q.W3).P14&<CB
M9'(MOZ+(N;UK(T6Y;"TWG,>SV;I@C3Z+V?3>5L!"\F/IT_=LS>]=SW^@
M     'Y\0CJ,3&\ZB:W*1_E[F0L>37@:>;6AP(DYI:GOK4NI]BFJV3O78S'O
M6F[?AZB-7";<S\6GF'H=FU/29-6N;1K.:!%Z#9B?/W5K\9[-1&&P2-@LTVOW
MJ9OL^X
M  !C:/*5:/#TOQ]O/(5^?<17GE,:0]MN62[ED>7'*(UAL[[>KN.3U;G\.B'(
M8437J[=;C<NGOLFDW.K/WU-9O2;,A?4DS-RZ_)=\V*TD_?YLN;#(_?H
M    1GAK$8<M@YR-YJ<IHN7N?.I]]+BTNX=%D/"41MT&=\^A)UZ+,E^Q1,&N
M6XYR7O/[G4*1^=QH'VZ94[*52?@;5Z]JKQ&%L3MLTNR.=O07M5W88%&Z92NR
M_0)^0N>@
M   #!V*:BZI&B^U3*&N6-LYY'K5Q&U3V_%\O<LAL%[V%=(C])/H/*8S7[.<T
MB''D>OF?!27$MWMWF]!.H4XGCF/M_P#0^1LYG+^A9+WQ7O?=2D&][-W1I^PS
M*P       !C;?E4.88Z4=9MQ=E_8BV>1^+GN%PMFJ_S9B-0UJBZ?5)=G-_D^
M&?5J61KU;)7/WYY &!M??58T2\-A17L,F'-CKZG;[<_> L2)NLR&,-9FW:Y&
MM9B]+VKQ_P"T^3'U3)RKE+@
M                  'S\5SU*)$.NV/G5[.^LV]&P-=9M2QE,,7Y6_+WI$WB
M1[M'C7(BVL?N\J_6S7I%AW:=;%Y07%4QAS&'T.P%>(T>%@^@7N@?6ID6[!>R
M\:B1L-3F*/=*V>Y9+IF1R=WT       "+]?L1!S6!L4:F)]@O1C*JA_C>,C?
M4K<8V_)NU:UT [[D=LS-Z+<[<V+'T8&=5#4VND7#L;IT?S%X])^;JN]N=[4\
MY=L' HV"W3SMURU/?3Y\^1Z=[P]G1<S>L5T2?)^1N?WT
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ME96/383H$^4\Q=
M         $0XNU#',,?[[5,5;-(P]ZJ&N:8^ZN?OU[U:-F]QE4;Y3"KQADLZ
MA&F#K\OR9V1:/I\V1\'9V7'T?>GS?\91I^BV.5G(H."VB[*W0Y-G=XD_W=I<
MO:M&W[$6],S-RUG4LEF[]0      &.M^51Y?C<_@[7PQZFWSUC:;;5<Z?=6E
M5DX_'S&[>X'2H_0SN^6P-WS0<Q<W3%V_)KMJA^CQ:O:A3.>=]Z0]PR,1;+(Q
M4FK-Q:=.Y9C\5@[5+=:HL=R*'C(OGW[W/LQW_*RAKEC8-@OV>WZ;]ZO0
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MP^EQ:?<#QL1]1G=1.O39JU.-KTGVPW6<IO$VL
M                              #^%9M,AQ]K4?!3[D4\/Q<2_/F/T;+7
M8GVN[TNZ--C;*V]J[-E/[<]V"#1M6!L<C.*0?5AJ+G;7[T0Z%DHBS3$2?96P
M-'MBU<S^/8G$2:K [%)A:/:JMAO.H.P7+ =!E9+SS2\W<M/U?)^VOT
M>"WY5#FN.V76;,!:9&F;H$N,(5%+>$0)0WV]']^K>(-K<Y=V=<[?\E5O [!>
MYD\]CQ+A*<I%IZJ=9D[KN$G;\71L,&B+=COZYD;D:\HQLV=#G:%F+M>M;LUT
MT6-U*Z;+R='F?R-RWNYR\I7Z
M      !\:?!]JO0 /SX\]-/JKJ      TN#1 7*,9Z[/E?=RE<_/FS$3'R2%
M+G7IN%[-D&!L6 VV3Y,G<S,6GRW$GZ_8J;Q")3C5K$W=3D3QLM<K;G+RM+<L
M9;_M'E*N!8[9>HRJT\GB=#OH7)<Y>30YMU>U;KO&0STRO[;;(M=O<[^@
M &N0Z*ZZ+"T6'1'6K6)5MMGR5?-C VH=Y!#Z2]TG5>X-!PFLV8CZY-ZT=5ER
M7C?>=W-<?533K>)K]AO=I73'N^1EN1[MN,M92/3@IE<.XZFM'S1A\+-KWO%V
MXFM^Y/M^1Z(=+EV_W27(\RO[^@             /C3X/M5Z  /)13ZZZ@
M        !1[GN#BG"Q=JFW;8;IE9=S<S 1K?.;EFN_3U*68E75W_ #7MN5
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M?*=<EW.2[+[9DN=/+==Z+]2V+D[Q?5.O/;]N\]/G*'B^JY>17>;H>;L/M&1
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M/W;N[A+^_H#5+-.H1O)1G5^GT       !J4*SB+%$.8*'5+3,7U4[)M(
M                      &AXV/3'0L-LDN[<S?,SFI%8
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M8/#6LEK$>?I_NM[A+M[T&?\ 0
M                         _/C]>@!J\>FD&J1JOZE&LIG+LB8>SKTZY%^
MF1)PQ;R4T>#I,ZCO-(?JXS&CO,52KOURP^ZW]@W"5FXM.!U&+"^.HW^S5#.3
M]Z#RKE?[TC0^5PY0V:Y'>\2MQRE70+I\K)5^@ 81[3_5;<'ZA#QNO6:YS[EL
M-AN[Q<MZ].KK7J]C\VDN;+?W*957#28U/N'X^X'4Y6\;E)K9J=C6>:0\CHMC
M^;-<Z9]]R.VWO8JQM$7Q*;!;5?\ 375,6X2[!YV\
M                                          /GXJ)SZ#E-6C55PUF2
M]]G?JOR8]9LZ12AK7(_OU:WMO:\CRGY7#SO+XO[O^,;3M6X7KJ_1.6VROS-V
M/*G:9&M[M5_YW4=Q[VH1_8(XWBIUZK._&V3;C[17:#+5  #7?/::Z7:C#2HF
MD[3<\<7V3H=&<S/F/A4<\/GO%P+DKWORE5Z-GKL_7YRKY9'N1WW)66VJ_D,1
M:CJ#37S7[<DX>Q(N4K\5KS;[5.\]$R%E=OD[C(JR=?OZ
M                                              !\_%--#@Y75H\<
M6_(-C^3WLU^3L%:CZS3SKXCC\QS^SD.\SZ*YR_=K&6OS2B#D\.R??\E8GH,S
MY^^>2E7C7;-AMLD;1C[>H8VJ(]3L[-J47:^J3K#]#R=L<A:RP !\R+//=)HH
MB/"VX5UJSOFBV]^KM^C8&#E5T%UVW!7.XFSZ'%^$9->;OW!ZM.RO0KMQNA3_
M &U(@ATPMH\+ WO="N51S!HL'+JD'-WKE[-(_0
M                                         !JUCR(,5:TO'6XBU*+H
M^CPYOW&5AJO>>G(8.B5UV8W*[9;=)..S]ZD'.XE?.8Q.JG:IVM9:[1_0HVA:
M=8M[F5K.JS_C*]CNW>K7'HL-ZVC!43!NDNY^XW/8#134#:S7O&)]H_#S^FCQ
M%?.96=^NQ\MF+OZQ-G"7Z]5EU;3J$77-6L6-RLS+S_(*W&[=WH$[WU>B/X=&
M M>8SU$.%LZ-A[4Y[!?LKL4C^@
M                              'X*5:E%PNI1:8X>W*$NJ8\S>^<RK+9
M^]-$VOX^*S:/#J]Q&!(=JFH>%MZ9=KU;+W)NV&OI9UJ;N,&WAM8]C+(UU5W^
M1L7OMU\U(N#.\W'WS2CF09)Y,ZF?GG\ /FJP=F_,JQM=VJ*L?;K%I43\VJ=F
M@4[_ (:/]U>&D587?IEP=ME?H  ^/C7K5.PW:OMZ
M                                             'Y*0Z7#T6-3^)=>
MYS*LM#ID&=58W8Y/V]:A9\I_S?'SSJ]5-.?PH UJ%O\ N4CP]&FS?F;DHXRU
MB9-7LPM-7)4FLO69-UI?OF>^5[.)K;R.#=" 3HXH_9_2%54)4W9T]IN7[Y[S
M^&I6*=2C4PGS2!GL;;TS+U_;-W[*[A+D&74
M                                             (_AT1-B[<T9B[M\
MBK]  \/BEF@09ATR-]Z/,#?:!E[NJY"YZ[/DI[1(D/+7(HQ-$;3+] LU3.CS
M(/<8:(4V5::7--C>6_\ /;)J?Q[YRG7)F>;82^7G/T#^%==4BQC@+,M;A+GK
M,W?KZ
M                    %6]=L:;HT+.Q*,M&:-F;N>VF1MTZNPV=O>JKW\$+
MT7.-E5O<?:?"]BQY5]5F7F>/N]Z;'O\ /9ZIN;N<PZK=C_?-<,\=0ST@'\/-
MX]7H
M                    >?Q%,"B M2B9W5X^5V61:3?YWU] #SE ?/>>QF_:
M(:(U5:6\EM[GCI 2B84T,JR\D%[M)9LO&?T
M                                                    'Y/*>L_H
M,#:\C#'6Y0R%>=O5  #SD 47?E[;I4<R:D*O+$GR,8=02PA!1!I()]SI<;X
M
M                ?,H>5?((.Q18$     &"\<Z/*N;WM/B]1&;J;,1*=6#9
MC&%<SX&^%S"[A_0
M                               0<<'3[F5+UG4P     _AS".<A[3"E
M;2RID"QI+QF"O)%9J9>XG0OD?H
M                                          '-PY?FZFK%Z3J09P]0
M   !BSD 4O(]*N%A"83.$W$QEA"@9KQMY/1*AT,(^---N)*/Z
M
M   "EQQL)//2:D9,L^=A#]@ I\4?+]$F'&\BPUPK@:N8PF G(]1.A)Q4TF$W
M(V(LB;0:<3J84DPED_0
M                                !!!P5-+(_-A);-O+UG18VD'D/\_)
MI!\3(&M&R$7&G&A$AFOGD+!$^D8&$+ D-%MC>B?32#Z$AD;EX#8    "N<2J
MN<2H?PU&W[U'S5H
M                    #S'H*!'&@T,DP\Y Q8\W Z?G0@'\.(95DR)_2-",
MCT$\GX-8,D5>)P).)++:$:&D$W&+)5!IAMI9@M ?4      YSXFYT8RUL
M
M  5U.5Y-Y6$J6?@UTSY A<PV,M4=GC[FLG"<BXPA!9-Y[3]'J.A!7LK><\RT
MA+I=XDX@LQ!NQ(9KYM!+!:HD@_H      .<^)N=&,M;
M                                               'C.<1S_-/-K-:
M(6(S+G%?3;S=3ZG4DZ$&L'*DHN?DKN6\/&:X?4SIWE.(!6P]A9TP1/)90A,A
M4E4P9/9MI\B0"Y)]P      <Y\3<Z,9:V
M                                     (9.!9M9KICC:" S FUFM&SG
MZ)V.CQ$94LC\]I"!(QGC83UEERSQ+9Q$(M-A+^D.&>/,9 E$W$\1'I:DT$QI
M*!-!-YG0     <Y\3<Z,9:V
M                           ,(< C3C D7$M%.B?C'$HD*&B%LCQ&EF"-
M;/V98FXV8[Q&Y&8/P<(BOI_3<"2RY)!1$)9PB<W4WDA0V\G4C$^!OQMY<0VL
M     YSXFYT8RUL
M                   #BH5[-"*1&]&DEZ2%B8C5#3RRI3DM4>DP1N1\C?3H
M27E/Z?PYZ'*L^9]2X!*1#1D#;252#"/B7#0CTDZFA'M/*2.=!C9     #G/B
M;G1C+6P
M        ! Y"!<@SX(!/\VQ28Z/$*E63I4:L:B;T18;F?,MB0T>\MT=9C9CT
M 'Y.%!7,RQN!;L\Y'IL)K9*A5XEHE\K&0T2T2V#.DU%^3(FGGA-[/V   <Y\
M3<Z,9:V
M        !I1PP,*6V.@!,)S#/\\A*);$H8:2=%SSE-2TI^RMQ]20R12ZA"AT
MT+_@ $1G#<\Y:$W8UPP![R/#/%0"7R<B S[DN%8BZ9OY,Q=4T$YD&^DN%UST
M@  YSXFYT8RUL
M              #F 4,/N9TW(W\JR<MR9"YA4@T8O21D4]+$F<-W*@%U35#Z
MDH%M3M   :84;(9-8)B(N-*),/$9(H^;46=*RG]+\'-PDPM,;*9PKP2N;4:8
M=.#8@  <Y\3<Z,9:V
M                  /"<1B'3T&QGV,25U.8I=\M4<U2P!9@JX5$-O.BII)1
M@Z4&5*YEIB?CL^9X Q)5HB8CDQYF#5"A9+9;X\14(EHEPJ>53.DA24V@Z5FV
MD4D,EK3S& +Y$A@  YSXFYT8RUL
M                           #\D%G%4'I-E/61@4U*?G1\W4YA%T"+"J1
MBR\Y)A4TV\Z'GE*LDZ'[.\!8< B<K(?4\AI9^S!E,36#?3;"$#.E^B$CG&6X
M-?(/+SE]"&2.CT&T'K+ EGP  <Y\3<Z,9:V
M                                   !4PY &?*J$T'[))(J*#&C'24@
MPH684\!^RP)=8YA']+F&[GP,R3(7 .S9Z@#XE'3330#TFZ$7D2%*"=#QF;(E
M+O&Y%.S#$D$*DKDNE@B+#"&R&[EIRS0  .<^)N=&,M;
M                                            K:<3CTE?C9B-R>R(
M2E1N)=$K>0&365(-Y)S-:(>)6.A9XS^F5+X'2XWP  UTIB88A4D<T(B0J2;$
M?$Q1O)?LW$J81F3B8,KH90Z %1RTI&!FRVI<$  '.?$W.C&6M@
M                                                  :<?Y_3.%73
M/FVGZ(7*.%K3I.<RBGYY2[)5T^)<\H:7[+"'R/F36=[#[   ^124TLBDWXC
MU<C(C@_)JQ(9FB3" S5SI<:R5%(<+QF!-D-U,H=%3:@  <Y\3<Z,9:V
M                                                       !YSD<
M5&/$>8PIII7TK*65.AYS$*O'10D(Y6'1XK,1F=.S*$B$<$N'?@]@  -9*5G\
M-;(K- /8?<J@20> CD\ANQ]R23=2RYRK-+.L)7TG\W E4MR   <Y\3<Z,9:V
M
M!ACG$4C*P&\'A--/(5E)6(8(5+%%G#G.;D= SFH6/+YFM'U!84[LG]  !")
MQC3]F:-.*]GD**'K+P%53=B*2/"2S*%DB,R%BY1BB)B9"Z1:PV\  '.?$W.C
M&6M@
M    <;BG!YRN)(!;<BHR!7HHF:(2*3H5\,66'/45J.F)-A:8J6>4G([H'[
M!$17(^9OA/A2 KZ1:4P/T=&"OQ'1?\Y7F-+Z&Q&;,D1,:D8\ND6L,N6%  !S
MGQ-SHQEK8     &LE=P"T9ZP    #^'-4QA?4YU%G"X0
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MH32#%%R"B9TI*!%E"1SD,=$"AQTW.7IU]/4#DP=9RL9#Y?PYGEQCG8=7C/@
M                                  '\-=.-Q74C,])*)7TYTDIG2DQY
M\S &T&ZENR^!.Q_0       "G!1D\1&!+QD3W%;27B2#<R(B4#8C,GF.BQZ@
M   <Y\3<Z,9:V     !!17(Z! K^5Y.@P  .0I<0^Y)9LY1,Z4E BRAM!R]+
MJ L.<ISL  <F#K.5!/,7'*"$Y%(3K.
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M9@C937S)GM/B1(9(DX_A$YDB2#5S227C"$8DKF2-2-M
M                   !3XYL'Y*X%)BP99,H\1"7?+6%>"T96\CTM$3L=1R1
MS'&0/Z      "'3F4:R2L0:> M$?<C$KH0P6H/X6(*3%PC;3Q%OBQ(  !SGQ
M-SHQEK8
M        %>#DH>\B Y^DW$Y$(&KDEE@"%C=3T&NF_EY3JH5+*:F>)D+MFRGZ
M  !^2!B'R>28B-SED8HDXHV6#+$&UFKD2E/S$GY)N(L+]DH$=%CRV@  !SGQ
M-SHQEK8
M        &M'%PT(THI>5Q.@QL9AB:#YGG*RD['\/,6K)<(J/F>,U8^1T8+G
M QI6@\QSU+A&HEO"B1KYKYL15,D8_IL9-QM!4TJX0P?PF4Z=FKGC.E!)@  !
MSGQ-SHQEK8
M            J:<["N1$QA2X)[BG1.Y]C]D&$RF:/T28;*9P_1AR*#>3%EQ2
MU1/)H11(TXU@WT\!NA%)\353:R=2+#"&!(I(8/ 38;2;F54+UGQ+,$]$D'Z
M  *,8VNM<.K;[C*^^92ITCR]L      "F17HZ#DE@      ^) 98(
M                                     IT<D3:2HA;,J*<_B;#HP8 A
M,MD;^94UXULW4FPB$CDDHUP^!: Z=G.(TPW\V\PQ'9)Y&)7\E$]Q9 JN0:2B
M5.-9+*$R&>/4:(2D:N72+4@   '.?$W+:SJ-ON,K[YE*GK]       <BSKF?
MT      YLG28^!70LD
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MP<E#K6<F#K.4J)#*,G6H]P.3!UG/,<JR[Y78Z#E1#PD5%U3=#F$=4@
M                                "#3A@;F2D5K,$>XVLQYX3535B2S\
M%,2RA98ULR!@B.S53*&K$['0TCTU@W4UXEXP1&A*Q7\J*6(-A)W-B(?+$FG&
M]GW*WF]GS+"$7%J"=P   #G/B;G1C+6P        .3)UF(Q.;!84C(Z>G)@Z
MSE*B0S3"MQ.1:XYWDL%P#F@=3#D:6=*PG4\HL75-T.81U2
M                        !_#F 47,02 ? P1^#^F/-;-N*^GE)N.3Y:DM
M61N2<>4\A7<R!8DS!(I;@U(V@A0S!:PK\;>1N5M-K)T,02D0&7#-0/B:T6[*
MD$:EHCY%Z3W@   '.?$W.C&6M@        :D;:#43326SZFI&VF$/29(T UX
MEL\9%!+1@3;#'D3$F&=-;,V?8U@VH
M       'X.0Y5TE(O,6F./1$!ZCUD7GH(=-^)6.4!.Y:HT4R!MI34F0_1U@,
M*5A)1+1$M'*4NV9DU@\)MI30F DXA8U@D$EPU<RALQTU,>4U*XDXE]SZ@
M'.?$W.C&6M@
M            #1BJY:,WX$/'(DKD1"2(9\@,T(M04=)C+)GR(],$4"++$A'6
MXW$T(C@LD5=-"+)&6-N)$,V<\#[FLGC+C&BFN$C&O O.2X98&SGN    !SGQ
M-SHQEK8
M          'F-**E'"@ELGDJ^94C(HT3\8TE<G(SI^"KY6 L.3B=)C<"(S F
MT%5BWAK)E2<C!GC.>Y/Y7$L4=.CG\;"=1"!2CIMQG#>2^)N0    !SGQ-SHQ
MEK8
M      _)0$K"8,Y\E@CT%:S+DE'.8UTF\NL50-^/B:00L;66Y)R/D88W(PI7
M(O00663)7,80.5-/:9,LZ3:0Z9 Z5F)*CF;)]-'-A+MG]    !SGQ-SHQEK8
M         $*DAFS@   &"(G)U *]$\GL  !^2N18\
M                     P1QO->/Z>0KZ>8\1#I@CR%*ST'1TR)CB2"(RH9%
M9T))@ ,N>,JT>\TDZGEEC5"!C!E<"82W)JIJ)*A^B;3Z'N-"-K)?+5']
M!SGQ-SHQEK8         '/@M.0:6$).   (V*5G1T Y;'2PSH  /@<ICK
M                                      ?PATK*5G)R*?$1&"*BFV%C
M"E)6LZ0DC%8R0B5SGD0X7E+&@SIA3"E6C\DLERB7S9C5C#$8$B&&*WD]DGFT
M&UFRFZ'[(^.F9]0    #G/B;G1C+6P        (9*XD2E[CS$AFD%:">26BF
MQD"X9IISS)C)U)].6QTL,:5")3+,G@*='N*RG6
M                    _)X3W%?#A20P9,J:67*_E;SK$9TH>88O>0L4++7%
MQ#YGT/F8@A0U,Z@&W$)&MEAB.CVEK"GQ!!9 LV88QILY\R43<"YX     .<^
M)N=&,M;        &J'*XZ4G.\Z!E5BUAS>.F)_#;C12&2,BXAS2.DASA.E1S
M\.EARN+_ )1@Z!%/25S=BE!U@
M       !!I_G=-()H(H*7$>&$.F1*A%93DDLN6<UC03J>36:(1T; 9XS1: T
M@YU$I%V"KY.Q*Q!Q(IE"V9=TYO&C&6/$7%+3      YSXFYT8RUL
M5\(-+ZG/@M.56+6%?"OI;$D,H69@RY>HI6='2D)(95$Z2G%LL>8<N\<^CKN?
M$Y3'6                                           %(3AD9LVP_I4
MLJ4= C ED#)E:BEQ.)J!6PM:=<R"RD)(A:$V4BTKT8\Z&&)-M):*G$[FQ'T+
MG%TS5BCYKYAB_1)(     .<^)N=&,M;        $>G- ZIG,POB56+6&V'S.
M8A.Q+!E"K1>HYQG48Y='1PY_'2PY)G3<VLRIS4+;FSG/XZP
M                              J8<+ST&8/X1H4Q+HFE%FC!GJ*U%/S1
MC;S)DIE_S&&O'P*HFA$Y%Q"02-RV)#I["9S9BPA;0VH 'S/H      <Y\3<Z
M,9:V        !6(KL2R6=(J)6*>&I%R3:RB9()OI.A54BHL46:*M%EC0BF9_
M"^)^BBYL))I:                                           %&CE
M:N8 VPK@3.5F-@+/&\F",60R4T(<.B9K)#!<DR)"AJ1-I+Q^2V!I9HI%Y?XR
M))9;TE0         YSXFYT8RUL
M                               #FN4!/>:<; :0?(ADU4L>>X\1_3&F
M"*%E^38BOAYB12S9N95 VP]9))MAYC!EHR23*EIR9         #G/B;G1C+6
MP
M     !\3AN0\;N0P?H^1!YOAM1'1)I^CZE>"6"L9O9NIABO)[SH :*0R;F2H
M;(1475-W)E/P2R6Y,D         <Y\3<Z,9:V
M                                          /@<;2I)B#^'\/L5Z)K
M,T0<2Z94IZ62-X(9,*3N?DQ9 Y")JQEC]G10U G(OR8 S)-Q:@]P
M .<^)N=&,M;
M                 \QHIS6-^)F*%%3R"20C\'W-'.>!LA?XT@B$OV><'V**
M%E37BKIT2/F=6"72.3<R9B80         #G/B;G1C+6P
M                                                   !4$XI'I*_
M'T)^*,E=C6"224BQA-YMQL9&)1<WTCPF8GHFDO(>HVTPA<XW4          Y
MSXFYT8RUL
M                 :P<22NQ'Y%Y94QY4@J<?@OP6!/X9<VTCTKP1J3L;L:@
M= 2TAO)D#>2QQ_0         #G/B;G1C+6P
M                                           (R. 1I1 Q8DRQYBH)
MKY>XV TTS)B#S'H/T?H_AOQ=8D0]I(A:T]0          .<^)N=&,M;
M
M    C0_S['G(W(S)M,<5]+0&V&5-+-R-I.HY4<T4AHMT2T7T,L8T]9]P
M      #G/B;G1C+6P
M                         ,"</BO0/*:<8HW,SQL!:8G0HT=1BY *]E8#
M<21BPILX            .<^)N=&,M;
M                                       &DG"0C4ZT'B*.EYB?C?"0
M3^GP/N 5A*_F_DX&&+#G]          /P8VEBO&%H]YX8JYU3S=H
M
M #0C2B<#]'X/V    4;-),V;&>LMZ90          KK$J@6+5E:O,U4E6_Y8
M"52
M                   !#!4<^IL!)!:\_8
M
M   !YBMAXS#%GC8P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                            "J1.!OH-9(W/>2>9
M
M                              Y[%K"705**Q$H%>R]99L
M
M            %?2JI=\DTJD5E)&+_FC'.P%N2"RUAIQK)_#Q%PC%''0[-E*"
M$B7R]0
M                          *;D0EL25#E.==#GF6!/D1T7:!SV/L:(=-2
MJ9XBX0.2)U(,@:,<WSJ0;.
M                                          "AQ/ALY1LZ9%1SP&*(
M2+;EDCGL5]+U%H2I1XBX1C#CF=F3D.6/*GG6PW,
M                                                           K
M(4\)*+I'+LO 4N.F1FC4RB1:HA M&4-+PF@E;25RMQ>$LZ<<B]IS].N1N8
M
M                 !#Q@ 2V?TKX3"2, 4U!8@VL_1&IN1%AD"6#, C<BDDH
MD<]H
M                           !1\A<_ITO,P
M
M
M
M
M
M
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M#5==3=UVRE.% U=>6;/$1]56S<.:KO+P^NN%>PD5T)]#L*N UTB/^1V:<H4
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M:)7N+'+EAU6+GTM9+L->]@;9FSD\RLSKVF?,\O3"!IU&W1GJ;4A=J#=V8X+
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ME5L0X[0?;="8J2](V.U(7N@MIP&IM6(E77)UK 6<K:^>I.7 FAXF%C.L^O\
MR#$B(XJ_$";;H"8M8X'QC&>1,].MZ_*BV0+Y[1)'K >M"W#9C1.>/<RGC,*!
M(SQM8%%6P;?;#S:-;/YABG$Q"H6XE4!+/+J91@-?YJMG#RJ; 0C,,NZ6.-6@
M8 + ^XECI1<V"% 9\G*IMA?7^DG(?O@,6W+[<G1GASGRA5-??,E%F<2;>JQI
MH3GQ8:>(8E+V7>+6G%R/(<UE^,8>:XJ?U[KIYFK&5._8$';7/8BU;6$A/FDI
M\B).4*P1C!MDZD*%(Z_;@Y7ME\50G4E7EJ8C#QA&R%<\G0CQ*R](Z%D+,?X_
M:2LRFN&J]N3+&),&'A*G)'-FVN _"O4M-U<@I,10?84+*R^Z)U-E<@,YOY@:
MNH'>I6-,VT9MGIR*<R85>@!./GO''CY2Z8^64O1F_JKO6SVD!<M.VAL:1:J*
M)KO4U8QU^)D<>ZJ/I:B9BT+])GI@#^/A:0S-O:^U1Z\(,6S6*Q5,*;(6Q*C$
M7 Y1NW,:1Q%8WE\\82N'E29.SCA30W7/I4B&:JK&9<T-7/',*HCV>3'I#9\M
MU9$X#[EI!PAEK">):B]%RR(,Y/\ FS%5>OBE/G.0RKUA498E'_&SGB$2R?>L
M[\UUB'6YK@-'UKMF?V0BGUHJZR4O.Y<7C##:N'(I318./QCY;.+[L52</H@+
M36,5^NUF1\^M;#A8QD9$H+-V(W4DX\I%_FP53XQV,O%84CY5Y5&4S8:\*O-K
M>Z;3876%6LA9+,JTQ]JYI7+SU_I+96.0A8T9G'LV$YT4:Y*%B_8"PQ5.SJR\
M[)CU$&LAX7"VY]:= 6,P( CC =,<6,J_*NV%?9,M(?>GSU\5&ZDT"6*KK_2B
M)9F5L#Z_0]R+33N,Z)N=>.F&8(RI.'D=#$@#_P" 0FW-C6FV.4!ONA/\:5'S
MT9IG4</&=TF8&8<96_*:<N[,W:J.68FO&G%KM,,T4Z6YLFNSBRW,@Y^5K<*J
MC&UIMI_8#,@YAXF#\O;9HQK;Z)VMU>I=9#SQQ'PX??&.-BH]4C>=2-UZG45E
MC4Y#JT09$3H]N=C^;C&/1E/P,778N$_2,I8A'8W<CV&+,>ELR?+6E+K!3/+/
M6HACR_D%T[$1BI>5ZH04,XD-/'@1F/EAGPOQBJ0NT9!FS\M4" [:U=^6%5P3
M/PE)6+&7# O0SLV9"K"D]92]93&\]:Q)UPX2P-L*)=,4@0CPD9B9@FM71J,_
MQK8KVPBT7W6;_*)?=ZI,>PVDV$]>5W%M9DCH-9Q?$]ENL*XAZ00!8#6<O74.
M&S1Y0KZ_D;)V,*D6$U^J;8+QDOA93U&?&4)^03,CY9Y[V^7("RMRY0UM@&#9
MUA8D2MM>V1)G!=)X$:XL8<A9XT>3,RE5&1P_TBYGZ:VG.+"[,>%*[]^1%D Z
MMK+;2XU,OJFI]VQLUFR?IC8Q*O$Y5\O*EF-1?A;LKB(2'YEZG+VN/#57?VB2
M:UMM=L/);=?5*57*2LYL[#+%FJ5VV3UE+'PV'9*01*DKBL(VS_R+@:I^7WLJ
MZA[IQ8P_]/\ &;+">1EK'TZR;/4DX9%#JSSAKQ4434Q6VL:2M4UJ$K#=_P 9
MBNU9Q\J :=@EE0U'8*VZL,Z-4.R#/_CY5^%FTJ_95G?OX <0@:+&,7H=04?)
M*B-<\2Y*VV.;(8OS:M&,R"5@6JQE.R+ C$LU^%=(4\29U?VOTCL^9_*AOW6W
M3QZ*V.>#P)L@TIHA5LI=;-PLHU_5]90*;:A!K[!^>^JES%E,N7#>>7;+8@56
M$-=.BH"&.:AYESMII>&> G3A+Q.2K<4EKO;9WD2W(^LB>.HJ:*<.M\0TG(;R
MR1"M&.I:@KY4U<F/[FZ%. C:I1G7_C+Z8$5,A)+#?/G.'Q<P@-65A7+)@!6Y
M?XJ7!:O.$&V_48L6#:^<4#L*ZP;FE5_+]=&.C9S>&N;G]OEQ=L*_#'6BL>G>
MQHQ?#K/<,I&N+ZL0MGYY9OC7R)$<RF33&*Q8:W)NTB4(?9EIYW !2BWU+[^*
M Y6GUX\*_P!(MJHW+\0Q TG&<5K91\H[*JJK8[)%"+=)#KI6:N"'?ZM<L6TP
MG'V6<RL$LKQ Z(M.U/L[&]"C&58BF9 M494WZ67@A<X#"OXWH"6BJ]V$*#WU
MQ=*S3<YLU4XF=)RPGW2)TO%^>:Z'A-9ZHA82VST['-E4\H+96@_XW;!_/ ?P
MEC<**O8*%,*U+2R*[&PM+V1.C+YE,]P!]R$O(PD V<R)S9:'BM9.G(^-A;9M
M?TYF24O#QD#:E_MW")=DP[?NOR%<^MMX]U3;="J'GS.2L6G', C''@A4 T?!
MLG';4YT2^-B77:%7Z38__2)Q.L[WD9P$*LC+WUN>>5E./K8LLR+#.(XA#,L\
M&\OC;5B<>S]K@%Q8)C%8L?#"E5[34JZO&WKIKYJ[S,^':,R9K%D;+:&)%Y@F
MC49^SC@7'OX$&7J_L)3=2PUJ]+Q=.B ,;O+C'K'D "X$'_QNSF51HI)]+&X-
MLSR ?G VXW$-.;IKOR03K%5F:_;U=ORB!Q)-QHGGV&,I>!49^V:9S)LCHQ,^
MN<:QM[UN!%2$\,*Y?2*_6;QUZ0F*UKL"4*U#T)W &>>+[/1;5R\]?Z7G#%D=
M@0DBE97D7RUC5ZPQXHUL)8JKQ'8M2KG@4 J_AM-PLZB/XOWXYNFZT:RK4*FN
MTLK1\ASU9?)FT=CY'14D8Q9I#;%#<BVZZW:@LD)=$&$)YM*L*@+4AY8UYYZP
MQ^C[!"P^GQM(VY?9>KUBBR2*[&8QU,3PC_C61>!!B[9WS$6^>!8V&VQQ$;QG
M()H)%O>:Z U:>%BIBW\Z],"(0P"'P7M@ \;.-UWI!-1?*7K N9FY]3,<4^O5
MN*2U*QTRR'R!I9YY,.M1&'!M)=:OS6W]+.D VK#44D:VO],9C&7(BT0S\9^'
MELL\#65WFAXQX\W$37A* W'8;Q/K06K+7ZJJB_KE%;[QI3&T$RC-=NI7RALE
M>8XXUQ&Y7KD;*B(N:8C:Z/G*?LE7[8M2&7[/4CZRU^QGUS2ZDS]143=C/->C
M"*[_ !K\S)))</)QIL,5"K6!LQ#;MR%C*S?ID#A^OL1T%V84[4QR&*JNNJ4Z
MB';"89V:<,F_B"<7@DS3":2SJ _4Y6FSY.PU=%P/7%_HQ8B>#&L:-<3?3],A
M;<@>!KHW55>[7<1-?F5'Z<(CF5/G\A30JFBO9MF;'&@ZHZ>$ZLO 35=@WW5I
MEM1;MD'14M$E?ZE#BG-<M6%_^<H!S92>+G%2@24=I^2V0: R#$6=GA4DK=,N
M6JU8)52JXS98L(:KZD3IT75<1-I!RCG$L?XO/"9>5B9X60V$L@IK55F->ZA^
MC/5M0I,I#KJ'L!M$E7M]D"7U 5OM4*D@;-HL<Q:K;2!&.J,E5FBAGKVP1^,9
MPRS;%E(0\]W&I-L!$9$RE==7BVSW%NY0K^7I91PO*LAY=-S/-_Z;,-H!I8;4
M7=BR)$+&!A>RN04"^D<H".*TU,Y%]DWV1&ZYUC :^X"6.9%\O-E%AY-4S7AJ
M"716(RNKXQN^3;$_/Q1>O8S*&;#VFA!U"F9]37J@ B@KSC:L)'[&8I%5$<Y@
M@.]R-_C-N$C1*P_,:$E666RU9A+FXETE&#VXH'NOE"8K+$N.#BQM@4W/+UMM
MFT4\D\VJJ)6W;)::9?LC,B.[O0"5C6HF&#\5!ZY"PPO893,V, .%O&(U=>;*
M)PL9VY<,X6>T'H$9,Y)%,%8_Z'!V77VA/WF.QH5%T)QLA^'M9,IGCCP\NTX]
MNHU=;7 4*[]UE]7IK8P&E8OLVQ[J0T@0YR$E45FOQW4_.&*HFZEB"61>%[.5
MN-G"IMM<@0+#T"639%K(CU/=:@;<P&;++M,JLE-]5$U9JCZ1"\*/\I-9FEEC
M_%'OAQ,RVWRX9O[FDM@QBI+IROR)WNQWA6CH#538(+%N&2[TH^C/$CO;D/*V
M%55>2LVRD0(#1MNT"'L%3J4"-E.'-MU'9(TLF$\Q1C;3%>KJVDD9AKFTQ<57
M7RMX_;1"PM1?*Z-<U^94JZ*:OSI.S:\$9]YD\3IN"E#FC_A;LU,2:M5VGV!?
MS]K&^#93=X3]12W6O N=H;QL.L.(]F=C3C5W!NH=FF]G*]IN_&L_M]/?6GP[
M1W8W5J>KMV-VD?X=U_5JO_C/P]N7W8N'80\-DE(I-K!F/;UXE9<*N]3#(*5(
MNB$9BRBQFN=7E9Q$ICG/'&-/MEK+#6A+ =NU^7);2CC@AZD,XUN4T Z6W@/M
M1;+,\5VXG;M(-#%=I=-6!"1L64)<16[3$N$(ZR/,DK_$M;Y#!A!1,S:HKA&^
M$,WO!\2#L+"3:OJ2R1;;<BLP: &^2!'JE882J7#ZTI]_>:!Y,^\H7B;-L9CV
MZ<J!H@2R78>'95@_!M1@781927YI#PL/Q?+3K%JU5\U61JU@H9ULS0G'-6:U
MG!?=GVMO4R<]H]A4\6]WN:IZQN2/;*>=J;8ZU:FOL_L2V$>V]Z#GJ/;B]X3^
M/O/_ &C\-T?_ &:USK_LUVUV+X=[?WM ^C/PNS?H;HC^LX0LCM?6"%_1JKYE
MH&S1E&<>\/J/4/I0T )E1N*K&G[>"1[P)BU6J*OMMJ'/MMJ'!2ACA_N-M@2(
MHU=EZ-=(0T,^GC3>-336K-PUI]SI[ZT^#F^SL#L-$19H'8?P[K^K;-IU_7UJ
M_L#36=OX5E5=T6&H#D<)IM76D!WIV8GHVUKRXT\;L1<P5-%RK8=J*&($)(E,
M+;-AE3G6% 9=AF5(Y6I:ZN>G2U9>/P=:JCQVF!/!U-/6"VLMMMD*!/,319XH
M7/B]?<0:CG4[:)8"737F\;6#P1@??"<A9"S'^'9#9*%B1<)9(V^4;+/3O:SR
M2N2TFN[PP:Z[-IUJ;%8#NOR<1?#87P!+1G<R7VT!A'%^:,<8GG;-=KOHS[;&
M1"JP2Y*U30$?4D5TK=#02@9URME8ETU8KD4O"LQ=K5MN4B3".=-4K)Z?C.#/
MN]:?]B<>Z5K>Q5/4[GKK9-9>4[(C[V_L=5?0=X]!57:.M!:UL.GL;6NKWWTB
MT?;;4.?;;4.+G"IO'[AIX2T?/9NC8L6/4SJ/&^R(D. NQ-+87;S_ -H?#NM]
M[EGLVMFZ42A;4O4_.]O[VKOTR'1Q>R-(,MC.-D?P.S?H;HC^OP[I!J&VC12I
MF:AWA]1ZQM^KBZTT[0TU;3/YIV-M]%,!J.]"O ;6^H)/TG[".:\H^0I=V[09
M:N_1GS:IN-SOE:K6$1_9.R6](:YFO1M4LTY5VYN124?2NIY/P'W3,@J>GOK3
MG9#[Y!JG2*+U2^[4?HG]=/OM!JO.Z_JW7.H+VU&W]/?*@.GMP**L_#VX8.2^
MH6AB$G*N3-\QG7+L>+' P]L/'+FZ537<EBW7:7U[4\ XFG!6?5D(4>JGK&Z#
MO*2H2IY7[HCE =JS8X">,ETZ:XM9U^365H#6Q;.W6=BVM7[]6FC/Y0.+*R41
M3N!&FKKZK,6U_P"'V57"= OES%C1&61@(W@**P41U)-<2+V6;*C4B0LSWD1:
MMM&@31K;J+(.4X\].V?/WSQNFED"$$5F"2TR!6$*/5KVM%FC'<_9^17&P6\2
M52PEA;]@R,XGHUU5>-98V31I:U5'W>M/^Q/AW8#5=KG1Y4YH^]O['6^SZZNT
MP[LG2P*MH>G=@;/KZK"1)V65[32-%Z^ENE'[".:-I7V+&[#W0O31NO\ ;"=P
M4?#<3F6Z[Y3T?KN*-.ZWQI[W>=F^RFOZCI[;L)@=T<HD+8N8*-JX<90N"U(2
M_=]^[;1_-M5Z2?>H/SO;^]I_5IFS!;!TG16'U-MQBYO^!V;]#=$?U^'=)U9.
MT:,+,/4.\/J-=TT4R2K@P17VNZZAU\/G=Q7J;'K0OL==^#KK_6-@/!#H7!\9
M!5LETA-PZR<J^\OWIW"]\!V=/WG8%--8]-G]OI[ZTYW(^^8[!K':EFL)MI[2
MLVE-TT^^7ON=U_5JO_C,XQG&FXBO[*_#W NTLL8N0<]JRQDYJV5P5(E8U=4-
MM/<JKAD+XG-W6;EC ?JPP&8>E>V&-JG:=#-U.-9UTME97?; <&57DVX#)006
M\"TAQVT&7-E:U#+]0 N' V%+\RQ#:B!UJSRU@#3\I$&8^(L2X$Y6QS$+_#D4
MQ(J857*B;"H78',\M3W$ZC]7;X,A=,F'(V7>)/N+.0HE.)])&HMMBW5E[P/L
MMA7A'V,'/+G8$S5*HU+[3$W@1$%U2V-J_P"%P8Q'*1J1_P +K3_L3X=V'5TZ
MYT>+."/O;^QJW4]FS(CE,T+O3M;U12%SNHKT=4Z6%]'4_AL.JIMHK0:XJUD3
MX;]IS]%L:ON]M1C5=T2[=3WK?GR=6BU#:1S>?^T>=SOO8H]*W?.F9N[O)(JU
M1YG7MBC*-D>]O[V@?1G-@C!=V=^!V;]#=$?UYMG9"+6Z-71LM_VB,8PCWA]1
MZA]*=M:/\P'ZDWGRYYO76^S;-L]W6'8"F.J=H/D3"$X60+=I0+:K:KZOAG&,
MX[-U/6_LYT5==G';J^T+<];>#;$F8F"KP>GOK1TTI2J=!4SW#<_LCJG/LCJG
M-Y56:=NJ=G0Y5]U_5NOFBL$CYR)KZGJP"]ON_P"'MBRVN^4?6Y[$B.,#E<IA
M9/EM/EC";*B43S9Q)]>-F\N9@((N9>&MUGNC*!Z QOX9YJLG5QLYPO"TQ!B]
MAL: !V*DTYK[^CV<!,XCDK94V);"318/2NHE/ET/1CKZB14XQQ''^(:JZ6@Y
M6HL1K+4S >K*P9I!QKC% 2HWA8ZS[RK&2FX]6/F\^;5L9)9-EGK7TIO4Y0);
M7Q$"8R(U[6QM>4,*^:-+_P 7\7K3_L3CW:T&N5; Z;]B;)K*.K6T?>W]CJKZ
M#[,TG&SK>K=XRA-YV;J+O;:I=0;N+$7;-\T1CK[T/8U)C%>NB&>"QK^+S5==
M>T=:2D+V#WDNLM6].O1SM;YMQ@I_97-R87[IO(NE:H*+]D=4YW%J82SG53[Y
MUJO>W][K<T4O3BRQ@!DV+=Q[$_ WI8:XU07KKLL+DNN.RC,)>D#)S3I5B +G
M:FF;)LCK7!+P-?\ Z\W'JEU6[U2[8+4WP[L!%'?Z);9=IW8VB;6^VG6A" ->
MYL(93!%&'<J3ENJ]H[?=IFI"Z@IW73@]Q6TZOV=II5.H]D;J3H.A;%K>X]HJ
MME>J.KM0,U=7\.T]/-VA=U>KV1&G[*T?9-EV<G2^P]+,NUCL[<R=,T\+3UOX
M=E<;(_(5OGB+1&&01I1.T\>VQ?J=%,_9C^7 0T>;J"/(/:D7SS7EFNVT6:SK
M8B]4=>&#,[;D8T4FZ+W&6Y=NPNJ(^RI&.\\<&^G/#/QBU=?+*T[HR\QJ1"W@
MMF(8E+)=P=.*1O\ %[!9B 7HSIQ<?GTZM+72=T+/X"089LDNAF.PZC4?&CK\
MV-ZG3,3IHT .S"?70$DH&0D.?X9YHW[H?B_LT["H+SH/:5_%O2NQ$V:MI*34
MJN=L:N]V6KK]4>DU+G8O6)[!GH&-J'4?#N<$6[5NCK;)).U]9>;*)U9K[?7$
M7P;*>U4K8D;N#8JNN^N/LK-JK#=+F76FZ:PQD'W!LD;^I=D5N-F^:_(>M.NW
M:=_\-L21V+7NL=6W/5WG;&J/]FL(Z\WK4[#%':^V9T'01]/'_)C=M:C80P[9
MTP*HTEWV;M:T&E6O_P 1NUTN+J8RYO\ I<Q\&;*;$5E:23R=).<JKLBRT4M5
M1'. YRK#H\OLJN2R*!0449L;1.LL6SL,EGD+RKYZXC]I5_C' F2A)2]+)<Z>
M+ZX9Y",,5'?PSI,A',K:K<7!U>9=F0M@A'GCZF/+83F/"2)6YUA9-<'^7==C
M:_K[NWM+1JJ]]WR_=B.N]9MU?7/\0VZDU)J0/TEK%<TNO)M>'_Q.ZY_\Y9#^
M(RNFP'9=$)R7/338X:H[J:,5%XOU1(;"?HD2B#[OU)P(IY(+9WVP*PUJ@:W.
M2;EZ%?<(*H"$S_CC$H9N;=27656:JQ EDR='#O<&$*-6&C%GJ]4JR!S!>"AL
MB(J?6JQGP\IDY>9!K](=7YC9- US:;OV'ZWY]?T76M:E^E=UHG[D$G&(S,S=
M',8XP7FCRMI0ME6IINF,#33&W,8<71C*T@*.:R@\0F,'F7,51JPDC* '^1S9
M7RU<'=QN"+01#$ZIXSX\M'HMQ13#&2D42E]@;BOB/6R)D8QY<?K \&D\=FG*
M33%N\^,^;,6Y&*(S(KS/%^(8%6L38'@L ))KHROO+AB%V"#;:-::UP6:S;FR
M$<0C_D';G-,_;F2J4.;*KVU\;2<VUSC39G$Y2Q' \O-8+_8S7#.?UFQ$B:)*
MNQ85[^O,8H/>4GZV+?,'5AZ.0C&J)L*R>!Z?ZUPFH9Q(=6$-_B[BQZ.5L@K,
M_>;FX"$I*LNOB;;Y+\9LA09>).GT":ZJ<0X3X>4+^HT<QI_6IJD(_@^MKZ9&
MUQB'']]G+;?W^C'RHOX),75(68;)/Q%+J+K_ ,0R-B$/5ZS2PP7(DEVSW"S$
M,H,K^YM\X0!KOG+D,D68%\PN6T:K((BIU%YY=C.;4H<;)_K@_P#^M9GRYJSF
M4+*Y0LEBWR2>9!LAF5]I! TQU3?Y>9"<;(_X?;?-Z(E\JH'; OC*LU>7Q<RN
M4WTOP[:J6X=N;3AJH?:0;S;:]RQOO:4KA<;.VNL7;MB[$[22*_/8(0O:T%U3
MEXVIZO+1^N+J_5J-%S18-;X_!RTG&Q<MC?@BSV^9F1SB<XRGK]DK%?W,YQCC
M%\*%CYRSOR$_GBR,L2Q^>V.ZNWFYG96@*M''D/+11X5KV!(QEE7DY[CTY#D9
MLY'T?*?3ZIIU,F;VK-%4;Z5+6:MA<)>:+GR5V2CG5,R8YA"-<?UR[QY9#8_?
M=;"BNR_UBQF-4:BC@1*8OUQEA$81QI3>LD#SP^'CCDIPCAYL-ELZZY^=>173
MQE;&R>ND9(7_ )PE@.+PO8O4X*OO(L<9EG<Z,8LLBMYN2<2:S6BLMQ2E&(XQ
M3Y)C@SMQ>NKQQ]LH"EY>2W;V:]K<5/+PHE1I?180R+&,D)OL":"Z"(>./URQ
M%]U0P+PLPP:$&X$HXX.K$KIUTAA(W51(UHS[R8Z]BRN_SE5<^U!5,;MC.G*]
MLP+K-9#J^6W[6;R3K944Q;8-5NLQQ%;^;9E>S$$A[Z[% ]-Y;*%=>UH2&4T6
MPL:K<;0/?>S%Q:NT/_Q[3?3O')$\W#]B#3UM.PC2I!]<BMZ:-?!7T652A.C_
M -2*/:["?C.,!^>,*2+:)8:L9XH>F"S'(@35^MLYQC&U2@8RC59ZGJBC@@ 2
M]=Z[>+"@=P&+RJ"C-R,'91;85=Y;96SE0%?Q@7!6'KVJ6%9F-G,68-)0FDLI
MT'KC9K+J"J28_FMAJE:L&.\G/>>;,99MX*KSF!9ZI9:P)56U18L^  5KZZC<
M55[IM@ M;ISD@GKI00Y/G3+RUS\++A*/3Q*J,K<^]VAJKE&H:7IXOS'TUY7C
M$PB,H:A;*U?^L\YQ'!#T.F6=B$Q$[8[[L&3\.48Q=11.YFY(QC$;:*BHM-)*
MA#7(O]88K=I5&\+)C9P4?,I"+:_0W+&9MU4YC+O6ILK?/%RZ&@U66.;AQS:8
MCEUV!.;QK8RQ./YC,<2P]U#ULU8O'NHGZ>27\15Z<F&Q,%Y(]66]H9IMU?MX
M;#LHX%3@SWU] 591"&2[6$X6TJV,C+<> UMI$"RP@.*'=4]DF7(F.54I5F0S
M5&HCT(A5FM[E*^*T3]9[*?(6@6$)1+E55RN'FB;&.( AR]OK8U>#K0?/RI+Y
M.9GBOC8&ELO.MO0&ZSNY/G365,1R"?1I>!67'YVD7 XJ4XNRW2!K"O8Q!A29
M.G%;'TYLB\6<4SG,/\UMB3%M=3#QX_,EA7UNLG.IZPJ2U:-2249OI\0$A;PM
MH5KVGLGUWR*E9A9UI:5CL9(+J=M>^$Y/$>,FT&.N0&6:[KHBP<"KU+#<^@(P
ML\V2 [,VZXLI  _6FX"6VT#L<>4PK,Y5V2E' 4I9%L'I&$OC5LV,V1E8QQ6.
M/X6RQFN..SM7B1 6)0L].VXT20Y^"J[(_P A3KE1_#*"QQTCZ\)@9[6RB^7A
MF\WTLJ5AS:^BK%-/YI]B>5MHDL<V8GT5.A[7%?2,75N3MA?\C V3;&Q=^LK"
MF;2LVG3UNLTCC#;CV-0!#8'!+3,,S(OZ_P!A'5TQNNV-W9/PS4S%5UNNQKI\
MEO:HNV@B%]2.[UU_ZTLKA;#;-:]IP>4KL+/+RP6J8A$9>#I&T3M1'#-?5<W
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MLUO9VAVICI$.UX_DP&1"N+*R'E0V3F#^KME(]PP+\WI+B,>?;MML\P%.#.;
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M176XEREL-A=L\JV;6-<JN"1)NR!+V]6IADLG&<XK@5LZNC,]UIQE9L@I\O\
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MV'!$<>&+;8C4+:R-B=CV>[RP%P+/D+/3D/9:>Q66R5:AMK6]SL+0R^^Y?K
M$M=U4=EAUJ:JHG7$BD;$GM- 56(SI'&(%-FOL-'2EDI9ZLSQ=ET-Y+S+Z2:=
M:V4H2ZNR-L/QN_\ _0>_SMKU2%F8EDEU'9*JC59XYQQ6OD?=V17@8S1J,8%9
M/+Z[GZJZQ=KK6@I2'LR\\_ 61A]-[:6C:XT[R<V7N-B;NK\^;/!L1];<VD2R
M4J?Y:!&<JI8@P:\AK;NVT#I78BQ=(Z=I2E]E[2#KZ*5N;KS@3*2USCS&0.&'
M!MQ>?=$9H'5EW=36$Q(S&O S(75#!JR]_%&MN3%>T,RV'FM$'NMD5=.C*G=F
MU-:[=\7R%8BF1_$[_P#]!L0JV(6YJL)]C'#MOB3/V\ ]S2%VALZX<VEQDQZH
M&DK4ZZ/"=LL8G@[4*IWZ^OA'8)6V9C*<:H?/[(VM#-F+S6\V(;DWFQ$\0([A
MR:R)5\UU=ERZ3ZLG5C87 8SC&,8G.-<>S7=CC8O@MU_#/*P&]&73\GPN:.J9
MQ"!);E03TTBV^8 NL>%UI.P!%V;=&N$E1<CAU)<0,."XSM6XN(RM*PO,(OR&
M6E+D:O\ P^__ /0G<JL@-ZG/B)/87B:LA\H3>JN5X-4Z+[:>P'U575)2\ %<
M>$9&5Z:+B"W'LOEAQ1>RLE.:%8-L*;L^U]2RO4W4N3UG8(6"]:;<7SK?JV.N
M3^/:O97RV%EEE]O*\>:Q+1Z(N8#WTWTE!VBXKD IC7'A%L94MH8Q$*QBWLMU
MFT079!CJU&BWXD(59CA5$K,+CL 3.:1,)#C81)2-[,#\/O\ _7^T;XJUO@'<
MX)%ZYD(T'^'8*%8V1[IL\-9G4:<]<CHU?LMT)H3J=9*]HXKGYZ6:BIC!6P)#
MO<B9+ UMT.#1L#6D=;IZ_ :\N:ZL'QS&0]9-UF@[UE2SI!4&5PJKKQ\<_P!.
MTE!P&P_UY;"J-21381:)7C,";ZQ<MV5E\+/)0N7'YKE$OS0VO8Y57:DQHO$)
M=8S5NVS72I0%&W%G7GK+AMN%L%)'E;!(LK\XF<0.%EF5'&#Q:LX'LBHW.,XE
MC[_?_P"OG[6E0L=-+7C4JNC$^O=_GKM2+=U#ODK(0AVON\KKMP@4]V'5$XRF
M^>>;G@PUTG567-J*_1'-)]F(TVR19FOM9-Q6&O@&YVI3 (9-N&5>;MA<L.:D
MZB>6OH7A7/;,98=+;=<U&^[MNLK=@7/]?,4,4R8IB7;[!=$2P?-(@6691-,3
MS&57EKG3Y<^O976_\TVFJEQHMKQYI[IB%L-037%F[LC,"Q5*R$M7\6@OI>US
MJ"C#(K'EQS8'P24+YL4[,JS*J.M[650159BVO[W?_P"ONXMG(F7X<QCE</W
MV6A<(WW8KA=A+GD+#VX-GI)!35M&.9YW,H<9AJ4[#7O-M)P.I@4%,%2X"UU$
MMM/VP5;H A@SA8(G+4^%8+Y/DN.N;"297.J_PZ4B1\\^Z\*@, Q&&.KL*&!@
M"NQ(F*NCT<$D@\1[2+5:5>/?@8&5UC :$*]FIE@W7Q+LF&UY&QLU^(T:R^L
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MSGFBQLJ/L?26"=DWX:F""7FWZ;I]"BOM'8E(2;$;";-+1#J5^]-<GL5(N3&
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M@G63,&'OMDH(EDNN9""JK-9P8HL93AYNOQ<V9^_W_P#KYL%!@ \66J&; VR
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M_P!T#",)PV06X1BG86+C0RJS!]X0S/'\<CF::XID;+]V>?Q1^#$7-U1BV6,
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MJ^#[4D&RX'ZBTVBUCI.K-J1QZA!_]4[X-V")L%FV=MW82]8;3L)J\ 56%_\
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MT]VX 7E$9GS'E*[W.13IXS:4*>=23L(]R2IX&T* Z2GGHTR4XB.Q=KMO+%M
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M84 $J!C4.;GI +#W]^$-4;:0L#*?:8#O$=$HX<*!VC8W&L7G[WE/U?PW1O\
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M;S(( J:PO YMY3.842KXPX4[7AP8&IAPP[XJ4TVO>"IV,IUB\Y1]7\-_)O2
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M^(3#8W#XK2F]G_HW[+^SXW?E)MQ]%5^KI5'M?(CO;GE4FWT3^6\1_14?[_\
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MM+Z7OPG0E%@*M<BRM:FG?8W<^ -AWF_+T8D-B>D*J+;,]<TP3MV3DN; Z:<
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M,E"I\8,R>((O]!'TF=$MFP5,?):HO]\M_P#=^%K"XEK2HH=+&8>D*-0O8..
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M?JY;7S:VM:]Y1P.-RM7II4IO2895(:G4.AN4#6O;0$?&N1KM#TGTBHR%;/\
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MC#XQGH4:K*M05:;)3=E&N;+=1\4]DCEXQ3GIALI7,@.5A9A<7RD;@C8CG*.
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M)V=-+&(+"5VNV3EK*3YU\-(%@2Y$ L+??#>8BIE%N</:CT<_B-I0!ME/".I
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MM^_'#>:OE5;&+_WO*]W).R^7L/VXSKEU-1DM93V*RS!KC^S&?Y0LE$M2!VP
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M1]1O]F*ZGDEABDC_ %2&97('7L-<_P!6*W.>;2"64V:- MCY8X.EBS?,@(X
MI1]V'D?RXYZ0011)M9 #BC/I55''W$VQ#&(HUC'Q1;]M.(<SEC8T\)*VZD'
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M7CNORVIFA6!2B/I!N;G?'#?%E,*VKK*O2K3VL&WM[,4T\6:H)XK,K"X/=B&
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ML!'-"\NG!WO42]F/8^L$WD8=Z(V.&>+<PK<TCH\REC>*I1TB*Q1Q::@=M+E
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M:.-P!T4;8RFHB]'"E@K7Z8,L8ZL, AMQ^U%7!Z1 \?B,5N7/#,^M+=HVP*=
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MZIZS*,NJ96+224L?,8]6D0:'8^;,I)]N))(X8WEE=8XHU9Y)'(5411=F9CL
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M4\8"W8V%UBB47-AS'Z#4X&(XUBCCB7U8T6-?WJ */J&/=%FM#EE/\N2IF/\
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M&L$%41@-WNN0<%G,J9*[,)Y:>&<:H(H0O.DC/WUGD#*BOUC&ABRD/< C5F7
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MJ&9(5D)O35*@D(M_564@H8_\J5(L2^K](XM_Q=S+_-P_SJ#'N<_^N/\ V?\
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M(':^5$/^K /!/$5M&2UC['_ )6/?U-*2?'K!YWB'6)?>XBX5S?-\WGK(&I!
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M?#5)'-$=F_,XR5@U#&1Y_LRLG]'IWE^2,9G63S3N2[6U&V^"[LN^^$U, HV
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M/'QQF-#'6T\D<EG.DZ0=]\5=)F.4U;0T\LD*(=8MTZ]/^%L0\:5]%H21'FZ
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MW_CBGI([+R0O*L+$=/IP8UAI)VONL1.,PJ#4YY,XW 1E^>^.'LG>MS ,Z_!
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MM:A5!(]F,UJ%BRU]?74++W]<9'3D94IM^J1JP^C%92K-=)DUCI:V$X?HB]Q
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MCS&II:6EIIJ>GEY/,<R:W:.RS6TL%L) ZH;&X .]\4\\=5!#4PG5%/$DT9_
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M?EQ5?"U#&_K''N=<-DQK621]0"+CZ\%"E@NV()="MK]4 G''$YK7=D;L)=2
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MH][A0@<449) ',KMSL/\#JL-/"N[31*/%I$'VG'$G%&7TM#4TM+4155941/
MJP,)4A$JE&DDD4E 54G2ERY?3==-R. :"67,9LP*VIZ:%X@_RIYM/8'CIBU,
M]O5NE_7][-XY,UXHK*>$KS*C,321LY(0&(BG!8JK,$41W-E8V&P./^3[.?\
MG66?]M5?_9XRC@K-,OS.BK9JB@:*GF61UCEJ"Y !]4-2HI._>P]OO0<<TTU?
M%0B@G4RU:4@D,L=@7F$(<KIZ FY%_?XGS9\GRJ2IAMZ1+(M-3D[A))%=N81T
M.A$=E!V+!0=KC&3<-5_$@EKYZSE1&0H:B?74SS2* 6TJ72ZK< LT@WV4&QM/
M[GE7&-5'F4,KC=5FA>FZ>#I)4;^&P]HQE\4L%!0P3F\\-'313'5KO+'"B2'7
M\:[@]KOZXXDX@K<XKVRO+VD]$$WHR10FS5LP?06<C=HR^T49.C2!(XU'LT_N
M>5+Q!JG,8H)BM^5'3F<*?DM)SHMQT.E6%^A8=<ZRG-\DB6BJG:7+GG$L+QL6
MIC.J2 6#"\,VAWU)V=8W^$"!AP-^L$?\)J?]H>][H&9<RHILKC;LP+Z34 ?Y
M606A4^:1:G]DPQP]E"4W#T=%.F]=#)+5KWWJTL4/@R0Z(S^$E\9)42</<2"&
M<Z46>3+ZH] 8W?0)?WBN(Y[]Z#;K[S^H_P"];[#C*AF3U8BRGF^ESQO#>&RN
M(GMS#S#^HK8=J74FD?&%\1>YW4/'JGS2..<[E$IFF2Y\96FB8[]3ROIQ-#G7
M"&8(1)RRW:1XV+4M9$K;JZFVH=S(X62.X9=-T<Y5F$>:T%/71#2)D[27N8Y%
M)22,GOTNI -AJ6S6%_V1QK_C%6?YNE_FL6![V;S+3Y5F,S$ )15)%^]C"X1?
M:SD*/$FV.!(V?/0PZ0TE1(WL.B(?]Z08S7]:\R_@%9_-Y,91E%5G52]+2-"L
MB0-.3.S(FA7CC(!2.0ZKRKM:UK[^.<9!F&2&'TP1,DX.B6!F>/4O6-BR1D/:
MS6TV*GLDV:W"O#659M *RHJI)GADTST"@0A#OH$CAFDDCE4:@T?)N=27NC8B
MBB@C2&&-(HHU"I'&H5$4= JC8#!( ).P N3Y#'"P-;Q3#.>G-K*MOGCF9?\
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M=-./N8O^6/\ (']>/N9'_E'^A<#+8>]I#\Z__3A*.GC(8)<CH6);Y[=/J_\
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M7%S' \<+OF%"/5JRBSWD'>H-CN2X3W9I9$.0P\/P3GA7URO=IK:9&'+.G5C
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MBD[9WQ^"F;E.GB.[]=21V!)5#XG.U,"<-,KQ_6*%L[Z&;O$EM(.6/C2*@U[
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M51S[ZHMZX<ZMENSC/U5J^+<U@4L4^1;2 9(\VJ.XA5I+.XC676"6TZMQ5I'
M^^V>]@U'+-+-K7'RR105!W@.IZTOY5?149_RB_KJ%A\Q1^C\$BS; =:[,N.7
M;R8!KZ*UQKDQ$N?HKN1^C78YZY%,KC?!IU0Z0&/1B/U4;%93(C==;$]/"H>F
M5C _10=J%'XGYWJ:#^JB(<:?29(\]9I23W-8_77 VB.(9H5:0C^VEQ@AUVI0
M/.E4]36!63MEJEXFIRX)6FM/ELS$?11CD9G@>0Z]63I_\*Y]LV3IRWL-:"=B
M<4CKY@T&Q3PL<=T_O=(?E%>[332_*W-'E^%-.WJJ-3>X4]C;9$*'[XNQSY5%
M:#)).3^3FCW5VC ;;QTTTB@ -.QV]K5P9CTC@%%8FS)H&O;QIIKM@H"Y'CG%
M <(@7LKD@2#NMBN9Q&YN"1W]!8LONJ7DHD2!&7N@#?'LJ:1MR\DA^C4<5N*=
M3MD5<\,N7^]X2 $]:(KNBL 5JDS1@'=F4AU8=>[N-ZFX%?6$,W[G"[C6V@;#
M<]*LKNX1HH99.8 O323TQ^JH)#TD -:E- ^1KZ*C Z\Q?UU$A^:I_1^"5TV<
M8C.]2,3DLW7Z:/NHJPR&V--<6J@,5/HQL*F#VF$PW>%32;C$A!^NHUM(M;GJ
MWEM4D,OKPG2X/@12X\OC[WG4DVO3D%<^\5--+)GTLF"?:YHZ#FKJU)_9UJ!'
M;CY6P\*^P]VVB[M/0J#U=JRW@:&*4R[C(ZUI0@-D;"KQ]1([5(/HU&K:0[#,
MF?T5&EU%&AN8]:2%=Z@A@FS$[889VJ.2/Y;4OLKE8I2G4D4OY*_J_>WF#U44
MZJV\16OSHK8PB5]+<S\G%.);=5NBS9 &<FAQAK0&WUZ-9'34:EG@?4&"ZOQ2
M?"H@?&2K3\2&KNX^6(P8U/RCI%6[S0A8XVRR^#CR(J&2&-85QT385@]3M1MU
M;OM(/J-)^6!_UA5A-&G=DME9_>0*T@=:M;Y79464-(,[%?;5M>HP;G $@5TK
MI6U;5JDMT+?.(WI.<%!393Y>ZHX8VVC&!6"WZ:"CQ-8:H_$:U_74?\6G\T?@
ME<Z>F@YI3[:^B@U874%Q4_:(Q)B)SWO=4UE#$MO"9RC.HV]>M%E-%?<5N(T9
M-O2*Q R!4]W,I66\]+@^&=ZTN-JZBNHKN>=+PJ)CSS*AQXZ30#EM]S6Z@U R
M'3%))WQ4?%.&MV>Z Y@$769O;4<'$>&L0NSSOUV\:4I.@F8;Q^1H;^-,^3IQ
M5WG?]DO^NH.:X0:VW_TJ@N8,/)%;#1CKTK"*=<;X^KPJ$.1SXE&I?'--S .G
MC3<OI[*1Y5\0-Z4J<C2/U?O:T4@RK#%,!]ZD;N>7Q,P_=0R?6*[1>6D<LK2-
MZXWZT]J8$$&DGEX[N? U=<,:7*RN9 O@HSL*A\1K/]E1M_DJA:W5F0KW@.E1
MP.I1\XQ5IM@^->MTWKLVKT8B!QX5$?QU_7410>E6V33Y^K0C?U@2#[Q3#%'A
M'$W]!,RQ6Q<[#)\*#1L&1@,-]%;5YFLOM7A2A$9(,]Z0>%:H[MRP^36C$FGY
MU#G!F4GNDUX@5&D?>8,K'ZZ0>2*/T#\$KF-NA0U+'\QMOKH4M:<;XJ40>NX8
M;>VKEKR%7N99F<2,-QDYH3W#)/I/=0^ \J"K@(NRCR%':MJR&-333G2(HV??
MQ*[U)<KGE)Z,#P[IQFA4MTOJ0G#5J3JK9'T58ENJ1KJK,L:RAO"NT6<Z<->(
M%]MM>/DU$+R]3G:].6;<[[44BF/(9/#H:N5/C*YHLATE)6_0]6QN#Z+LRZB>
MGJU<F&59%>9CMT6K6]-V(HI"ID3IJ%0W5LZL)!\FLF@1C(Q2LWGC][H) /4)
M)H&K(:QEIP,4@# ?*J2Z<X1589/G4]TI/*1S'^FH)B#H0[^6]+%ZHT8J-&[X
MT8%6FV.;<J,?34$&.@'ZJE=3T0FI6/@ OU&K=,9R0?TBK6.094VXV/Y-7FD=
MWG.0/+>K=)4S#)(%<GH ?$TO$K,-R]7-BEC7U"!L0?*DX+QB;EW%N-II3O*>
M@ KKU&U9/C6NXQ)^*:BMHT5 V])%#&J84!B/$_'RY5&H>JQ'0UA+KNUK)$LW
MS\;_ ()W&/F&IW'SMZ*ML<>-%(E,F/FU@1,6\JUBTFQ[J*R=U@2"#6:P:V-;
M_%]AK)P;DMB32=]+5J8=X[GZ:*CSJ]YGKS$."?:*;V,:NK8G>'"K7>/2K9[:
M0KWCKQY5')N2K:A[P<T&<'(PN3Y#:I@?G-^JIU'C(_\ .JTX/9LRM<0(.:.B
M[#K7+!5+TCTDY\7\ZL%OKD75NQP1X 5 MJ-,..Z!T^);>+).H:B/+QI(AY G
MWX_>[D@AG.00/DT!UJP@&01=)GZQ4<?-^0OZJ'![/)=V5V==^[XBH8XACF(C
M2X\7\:EN2F#J!SBGGB]98\[4EK,Q;2=-6*#]QN48_72J@V"K^JKEC_B)/U5,
MQ'[J1G_2JRQY9_FU;#RB K[)6JCT2ZI5'RR:3G)W-7>\,4PN0LUI)%^QP<83
M:CQ3A#;*^L+&#W,;^%=DXQJEFA!R[G&=/A6NV=%DS]YSEMO&@&J!Z1O, _@P
M4;H=C4L\:&2*5LZ4&<"M$=K*I;;.D[5S;M0\DBX(-:UMQJK0%&G&,8I[RQ 2
M0;D>/MIH^:$*'2<^RM,G?_&'2@K=*RM29<-=3HT<: ]Y'QL2/?4_%+D/-,X+
M,2I[J@[?HHQYS@8J&VQL3K^HT88QZD87ZA4^>JR,*ECU??95'Z!3!<XJ77WN
M5$[?HH1W6-/M-!;&/Q'J[U,OJMWJN.8?W1B/=JJ""8[]$)J0KN-5-(5.8HR5
MJT+=<4?=1NSU;(S^]TCYP^GNTTLAR9>E&4C.D:FJ[MP.Y;IK0^ 85Z*[QC"A
M0,[?71O1J$ZK]]9=L5+)>Y$D<H0!A@L,]1[*CA&!S(U/Z*FBE.5*XQ5[(ZCT
M394^ J^'5(&!4^&U*// JYW!/(?I^2:F)Z]H/\ZK1L8PA_LI!Y+BG@E&J*3U
MA3Y![->2,8\;!![ZM8HCZD6]/ PU*W=8>PT\]DH@D?<DU]DH)]15N\B#?2.N
MU:LZ)H^XZ$]XD=3BH#+Z@ZU'RI4/=& &&?P9PP!]XK4(US[A]HV>FD_JJYY>
MPYK?KI@U=YA'\W5M3-)()92IY7+(.&]M<Z42& R QY!T+OU\B?U>-=GY8[=+
M$4>3Y)##]=/H()9BQP?$FAQ$KB%-2[C](J=<>#5Q(K\F>2K8$[/,*SCKC]57
MZ?\ ZL^/]4U-$N04+-^DUR9\O+D#S\:9@N%9O+SH2JN%9#GWFI.+60;59%>@
MZU:S'[\(U,X/75[JO% ]6$U'$67NJ=MJ&#U.*CT^)/[W) G2,E6I#Y5)I(YE
MU&T<?Y1&U'B5Q_A5SJ5C[#TIEC/=[K"A;7&Z^(4=XXJ)XXS#8)W71UTEF'C2
MJ%.$7 ]U2HF=>-JNKG?G7$61[ZFO9-YIE[U#4#D5<L6'WE^OY-2[_N['ZG-0
M(GR4T_50 K)Q162/5*J'DX\ZDLI\J0-*AJ(^26&*&U,K '6"OUTMW =-G(>\
M/QG-13?XU _U[T)+=R,>9)KO??8L<SW_ (.R ;'2?U5=@G?FM3SSMB--R,[G
MW4L=@DJVT3'21&W>'ATJ.>]SV8N#(')]7QP#26]I&O= W*C/UU%-;$"3F;GV
M5':KWWV:0_)TYW&:BMH%QW%U_E>-21^8/ZJXL?\ +.?TU8S'_'C_ ,_HI'P>
M@_54J#Y:E:XA:8_<N[[]_P#?0CF]7*M_UA45LOS5)IIHAEETBI;>_3[^ <8Z
M[5//:A^S3-K*XR=/L'A4EG%'*.T#EC4AQO5W8.<&$;#WT W2E@D/H#L/>:##
MH1G][;GF?XPXH@59</!RMO<KD>S-1QJ, !:%R1ZQ5:^R-^&];NK^D;4L2*%4
M;#;&U:'ZX_LI;>+>)9&##Z:T*GH@,4\L^CE./1@=?JKI]5300MAW1P,GS%-S
MU74SDC2V2=3$Y^FH9+B-EB*YZ'QH,I%!=LU:P3=[2^& _MJ#LO=2:X Q2NHW
M&#7I*TCIUI?,2Q^_K5GGPMX_YHHU=:?5U?@X9IVPHITLE70<C.,&I)WVU$LU
M1V,6H6<,ACN"N1XU#$((GY0QJ**2?>:]'&J8'R!BC'2V$6-1./K%"\F4&Z=C
MOUV-9*FC[C7$CT8LV*L0_A.OZC2KMNHQ]5$TO$\=RZD2'IYG%0WG17Y0V]N*
MC*'/=%/"PSG?ZJD20F.ZM7Y<2>JC >?G2\U_V2J8=1TU^-(L"J55AX5;<0.T
M-[<(KX^;D4)K8ZHV48^JL_-.?JK0Y]*IQCV#][8KF+J<EJ>5NB#)J]NW&800
MR'W&E/NJ'AR$,RR1N=.^V:BBB&%Y:Y&/'%:ZZ[X/ZJN=L\R9C'GWTA$$6\8T
MY_MK[W%[!G:CFWB-/;<N*.5-\,",T)&CMVE7!"^&U16O%+.VBC "ZXT[VD>V
MDN;9]2D OOXFGNL^HN:O;V0[:]<>:LT7?E7(U?76D^"C]5,@\J+1]!N?=4?"
MX>\NS,?#*G>H(O&.-4('LVH)"G<;SVH#]U<#F>_\".Q\.XSPZ]NM+/R+:ZBE
MDTIZ[!4)R%\3T^W6WXGQ?A]C.\8F6&YN8XI#$S,HDT,<Z"R. >A*MY4LB,&1
MU#HPW#*PRK ^((.1]T%IJ.C2#BAL.E74L8[PJZN=(YTW?SC?-:3U7K3 ]<5-
M<GYI/U5<J,E(8RZX\UKL\_K(YV/D*[^FGT],-4\0.!J?W'>K611MSU.WN-6Q
M ]9?[*!<FH+=Q][E5@<>.:6/)S&H;_5%"RSF0,VWL4__ *:R?*N=:NT-P,X6
M/NZC[<48K[4H<^C;)[WOJXE;?&,?14I?U[:)GC/XV*2QD8M,A;.>N,UO04>K
MCI^]>A"&D\J/<7/A2QR1JJ+L,>-76GUF@;%17)'I)E.30X18#FWDS<EAXKKV
M!%*_$6=KB0*VF0ZL!]ZC &^@5AAO1TY!'2K,2QKF.3#=W.??0B3"A-AC:MMZ
M-Q>\M8U&K?'A1FX5%'I! +JN#MUH27!TKBEDCP<+UJ/ALCX25MM]JNRIV9<K
M2I;LAGT8*DGK]5/?3Q(S.VH^./=7,C.&T[Z:QUKL4'?O9<+H\E;QKM<F]W,=
M8+=>_OC-"]O1@#U4ZAA]- 1QHF/FJ!^W3PZ[XSPZWO@T:&TENHEG#S!6B4QE
MM0:170J#N0RGQ'V\/V5XE9\/[1KY':YXX3+R]/,T!R-6C6FK'34N>M17=I-'
M<6TZ<R&>)@\<B'HR,-B/;]SXMQ3A[*EY:Q0&%W19%4R7=O"Q*-W6[DC8SD9P
M<&FY%RDVG&KE<)MI-.<XU:(#C.#C/7!H&X>V89]6YX6D:GV>C$#?4P-+'Q_A
M$8C) :ZX4[@Q^TVER\FL>)TW:D#HC&H^(<*NX[NUDV#QY!1AZT<L; 20RKD:
MHY%5QD'&"":L++@]S#!!-PT74@>U@G9I6NKB+UIE; "1+@#&^<Y\ ZR%E8!E
M9>#0%64[@@BVP01N".HK%VG#Y_.*[X>\!Q[.SRVS#WG(]AI>'W$/V*XJP]%
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M?V-T920:X;Q9<B&"Y"W*#?593YBN4_&(A=F3(^^*C=12NC!D=0R,IRK*PRK
M^((W!KX,_P 7Q;^=PZO@[^;8OUM\5PUN,"+X3V=VH'A))<V]V^/^==NGT?<>
M/_Q-I_6-G7PI]W!/[V^*>*"YAXEQ@*1#86[\U$E/0WLT>4@1/6:+7VAQLB#.
MM7FN]<D,EUV_C=YC2B1.Y<PH>B27&.1;1KZBY<+RH&P%4!54!54# 51L !X
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M!=?21-^/#)JB?\=#5M^8[/\ IG$*X7<V<\=Q ]E; 21G(U)"B.C>*O&X*.C
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M8V[B[?166ZUFNUW'J(=E/C04=!T_>EHI -6,*WE1Y;ZDSW<9HRRY(49Z5IN
M&8>J?;0XI8'4@;5(L8))0;XH6I'(O$&&20@/W?Q>M>KFM.C+'IBB5VZU)%<]
MT1L1'J&-J&^=Z$VGKN*]4CZ*CLU!:-F V4]W)Q0@5 9F&MG'XU/[ZN5_RGW;
MA'\?Q?\ JOB/Q&3BO$(87P=%JAYUY*?*.VCS)[-;A(E)&N11O4(M[9BTI%EP
MKA\>_)@U,^97]76<M-=W!PBJ/DPQ+CA_!XB'[+%Z:4#'.N96,MS+YZ6F=N6#
MNL>A,]VO@U_'<5_F6%<#]_$_ZXOZ[=8QC[-\-C8P:1WKZV&7DLF\WSF2TSTE
M+1["=F7[ \5D*\*O9L0R2G X;?,=.6U?>[:X;N3@]V*73-W!SRU<'@X2;01V
MDM[+==JG:'O2+;K;E=,4FK 6?5XC*^=%[>7A[MUT6O$98G)]\L%NF?>XI;3B
M4EZRIAGX9Q=WNH)H?5S;3L\A1-F"364W*YBG4),,AM.+V61%<J=43$<RWF0Z
M9H),?+C<$9Z.NF1>ZZTC\0OK.P21M,;WEU#:J[ 9*HT[H&8#? WQ33</O;2^
MB5^6TMG<PW,:R *QC9X7=0X5E;23G#*<8(^TF7BO#;1V9&S>B..&\AV/I$O%
M E71Z^&9HCCTB.N17#H;24RPM+Q.V+KTN+5;.[8.?Q?11SC\9%K@G%$4F.RN
MKJUFP,Z1?)"\3-Y*&LRF>FJ51U84.#%U%[P>6<<HL.9):7,[W,<ZKU*++-)
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M,8_HH2HV45/[0*Z]:T]1FMZ8_CI25DJ"?PTEMR/77:I(9UTH&Q&3XBL(VH^
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MB6)O5UC!Q43<31#;,W>,8R0OC27]OO'*/I]M(/')_;DDPZCI1DG<X8YZT,=
M:T1=:BO[#_"XI.:V?''ZZ6'BD1UI@91#C;VTMK&)%.!U7'Z:E8L#W">OLJ^U
M>KVM_P!==T#I1SW<?13<V7=1\ELUV>P_=3H7(WWZ5%Q3BY<7CMJ?2WTT%LUR
MZ^+C>O5/Z<5OOM[?]U6B1C2DQ+O[32>5#R-91VSY$[5@%:43XY9(%++&<@_A
MN2>@IN4>ZJ_1J%9<>.!Y4[NV)QLJU+>7F3EBT(.XP:#PP*;75G_1J(7?<?Q
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M2QQON%!VQ33W%R;G)SRY-Q0BAA$,:] NPK&=JU=:#]#J'ZZB+?,7'U?MOM\
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M[*!0>,Y1CW6'C5D^2.5.#4,A?UABCY^%=LNX\P#Y#>8H1PH$0> _;DX;Y2$
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MZ#;.V?.A?\8/,XBR]U0=8[WJ]VI(A+HB^0%R#CP]U<G1,Y9L#"OC'M-)=\5
M[/D-I4][%!+:%1I3JRC.WMJ8Q "XMU)A(V[WT5)P?B+:9K7Y3; _2::VA8-.
M00=)SUI;,*S<R0= 3C4VY/NH</M2#Q:<!]7K=V0;[^=/<7#,[2N7.<[9.=J2
M*09+';-(99(.7*H*C4,@>VH&BP04VQ1#BBOC0EA;21OC.VWLH,Y](NWU?AI+
M#_C%TU-!.,)JPE9'C6/"NWHOHVTKM6<,/;N*189F(+8P[&EE4J]VT (P<[D5
M*DOWV-BK>\4=1]?311L$>1Z4TL0T7 &1H[HS4D=UT7==/>]U:WZ*?U5%:3,.
M4H"Y]U8)1X9%WS@G?RH74,>JQF8OTSI!J*YC;9QEAG:K=[@KJ"9&,==Z@:'!
M0DUW<UG41[C6H2OD?C&NS7##7G"^ZNH^O]J\J)O3,<$>PUF3Q[V36F)ML>='
M?ZZZC>O?4DC/AV0Z-_&H^).VJ[EDU'Z.E-=7>]SH[HTZ@&'J[5)/;1$Q>JGK
M(.[TP*U\;R%ST1_"E6T@1R!U= 3179?8-A7+'E3W$[>C3O-D]10GX9J07$H&
ML#2#OYT[3RLTYC\6R.E3<5F16+*\::M\>6/;37$CEM\#)]49Z5#96JZI9/\
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M5J,CHQCC==6=+.H!9.%<1E>?@<MVMS:2PNTG#WNTBF4%5<:K2ZY4LW,B(3G
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M!O1'LH.-F&^:RQW4Z?J^X=CB8JOF*#;G;K1Y=Q*OL!K3<NTFG8:CFHN'VO\
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M5)=+-&X(.A2898P0X.)$R:CMY)KCA-S(0JKQ)$2!G/R5NHI)85SX&<P9Z=<
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MDM+I0.=;R>U"<HV!S(F24#2XKBRV<;37C<-OA:Q*0&DN3;2B!%+$*"TFD#)
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M U'/OG"@D4SC[^.@-2),5&C(QG>B8B#@[T.E6R/][,@U^ZK=+,CE!>GC]/\
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M*;YP/(THQC'3-6W,;8Q_V4]PBLRS-GN@G%*[Y7#97.U<]W#;>>>E&./<>0%
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M)B/]*>X?#2L%2)/O, L>$6YU+:18>7&DSSN3)/,1X<R5G8+DZ%TIDA17 O\
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M)<&L+J8]9VA"7#8Z!KB+1,P'@"Y H21?!^P+#<<]9+M?]2ZDF3_JTL<:+&B
M*B(H5%4;!548  \ -A4EK>6\-U;2C$D%Q&DL3C\9'!4XZC;8[C>N;_P?L]7D
M&N1'_LA/RO\ J5%:6T,<-M#&(8H(U"Q1Q*-*HJ#8*!MBNT6'!N%6-QI*<^SX
M=:6TVEO67FPPH^EO$9P?'XFMKRV@N[=_7@N8HYX6_*CD5D/TBN8?@_::O)6N
M43_9).(_HT5V?AMC:V,/4QVL$<(8]-3Z%&M_QWRQ\3\2/Q+A7#>(/$I6-[ZQ
MMKMHU)R51IXG*J3N0N 34<%O%'!!"BQPPPHL<44:#2D<<: (B*H 55 51L!1
M5@&5@0RD9!!V((.Q!'45VCA_!^%6,^@Q\ZSX?:6TNAL%DYD,2/H8J"5S@X&>
MGX'D>8(J2\9&-NR@<SPR:SFHX8XV[,3AY@-A4,DMP'T@:T*;$U]C!;1"'E<O
MU?9UJZ7EE+9Y2(=N[CV?&01OBB"/&LKUI"K%7QM)XK4-U<JMTTP#Y:M,,"QY
M\JNV^>U/)YQ_%VFWVF4[Z>ND4(W.B=.[H\3CQK?R)I+"W#)''(5DTG9L5PWB
M<>!)%'KF \3CQHPE#R5=?=BD0 8P*)PL<O428WSX5J;7>Q*<A3TI4%@RXVQ2
M/Q!="=>6_0U+&\D<+0 I&OF!Y5-,CD1<W*^1&:CN(VRT2:C79)"=,>PS\26E
MHA:8L,Z>NDTT(C=@_>Q[2*;GJT*<S.3[ZLN&QOKB>,<PCID>=+%$^GEC3M7:
MX6Q=Q@LA'K,U%IA)J:$Y<T+F0ZI7U9SUHK"Y7W>58+$G-=/"HGNM([YP[>%*
MZ'*L,@^8KEW,*2K^,,XI;W@\.&0EI(XQY5RYH&CD&VD]:2:XA>.!"'5CT.#2
MK\U0/J'W+X)_R[_<WX?M!>PI)Y%ATKF=HCY6K/+TGZNE"&S@1#\I@.I^-C>)
M&CQJ2)F'J^VKB!+E&@B.TH]4BC!8J+Z?IB(Y(KMD:W,477DX/05V6Y@,%VH^
M7ZQQXT5\JT0[R:>H\*CLKX;+A-;'9:62WF60=>[X5W2->OO4LOSEK<T1X5VF
MQ/(E'EU-3&[4QRQ@J&?;5MC-2W&2QDG)4^S-<-[Y"S0]\>=/=,/O@!6E/LK>
MCO6FD?.VFHXXSI#9U;]:B54*_C>=7-B9- 4:37>E4[[U'<PNLDDW="KU!H<5
MX@BO<ECZ_K8\*EA@MAJ75N/94L',9%UOM44<K8)SAS3K&_,;/R34(61F4N,I
MU^BI[7E'7%"?#V5R&V==61Y4EI:YY[N%)7J :6^-^Q)PVG'G1CND>91MK\*Y
ML#@-G.1\GV5V7B$ZHT>%1G..E;744A\E:B(Y4)(WCSFN9)8Q,_SL5RX(UC0>
M ^Y_!/\ EW^YOX C)*ZQH.K,<"F';H.[_E!1LN&OW>\LSJ<AA]%/PRUE9&,F
M@GSS2<0OEYMU)U)Z^?C10 8QY"MMCR33,>_,>D8];?V5=7=SO(W>B!ZJI\*N
M%^:YIX7G[FH!4)I)CZL[["K=!9ROYLHVKN]Q_&,^M76O7%#EH2I49=>E62$=
MV8ALX\*X=;8^]1Z:L)F73S%'6D.1THZF K1&V%H21GO5IF!&!U-6P4YUG^VK
M:5(BT_(!!7P.*[4TFCG[L#_;2QQ,)92<'2<Z?::@C9AVE#G_ ,BNQ7#'1X-T
M6I?',;G]%/&'Y8YK]??7;1,@FB7;S-&4[GKGSJU&>YSEU>ZGFU(XN!C QMM4
MK_\ LLQT(/!<GK6K(,>$8'PS4<$F&CT+M3=Q<,,_70M4!9)R6 %!3D'.W44'
M97<?34-Q!J5 V9!YBHYHV&LCO)GO#W_=/@G_ "[_ '-_ #D]!7V,X?(0NZ38
M/RA[JUW$I\V](:94W1O;FHN+Q(9(3.'8*,D*#G>HQM$P !5R =O96 ZGW,*7
MB%M&VZ"/7X9-)?WS"7;*X\ =Z:-B$720,[>%7,AD1DDD8KCRJVF4X7F M7!=
M!!9YAJ_10;B*#E)%JWV\*DE^#<4D46=/,QJ3V[]*[3/=QM&5QC\:B\5Y&%SL
M*E%W=Q-$/9Y5'S#D69T#;R\JMNXVM!N37#@-M$=:<D@5LY K=LBNZK'Z*[O=
MVWJQC???^VH(IIXNZF-)<9J+A_#&TM(^C7\G>A-.>9=..\XW%9.:V]=>]]5/
M!(K&XW1?=T%&XCE"NY+KGP!I+:\N ZMY5';1;L^VV]0SS[&4@I[*Y>2^.F*_
M974YY?@=7A2K."KYVD;8>S>D:24,@ .?=7)A!=@,;;]*ADTXF P!C>K>ZE4@
MR('W&.M2]#-R]O/-=GF7"ZL'.U<FT;,;LJD YP#]T^"?\N_W-^UK 7UK>71X
MAVDQ=E$/<%KR->LRRQ]>T+ITYZ-G&V;+BL$<D4-]")HXY=/,122,/H++G;P8
M_<K[B4ZN\-A:3W<B18,C);QM*RIJ*KJ(7"ZF SU(J\M[*SO;9K.&.9S=<C#"
M1R@"\J60Y!&^<?:1\-O+*_N9I+2.[UVPM^6$DDFB5?2S(VK,+$]W&"-SOB"X
M4$+/#',H;J!*@< XVR =_MR?($_52\*L['B$$K0S3"6Y[/R],(!(/+GD;)SM
MMCV_@E,(?OFDX^HU?<]7U<]]V!\STKK\3QS*K(1@Y%,RB49\F(%9'-^EC36\
M8W'>&>N1TJ6VXIG(8B+'S?DU(\#".R#8&H:25\,5(^H&95\_&I+:8=^%M-6$
M4C]Q;A N3L-ZX?PFP;-R6"7)C.>XP]E&U106"%]3;MDCSZT]L_K<QC]&?B>.
MW&01O@4"/OQ7O_E4JU;+XI'O]IK<9&,4[]!WC5OD]V-R/TU;\F5CKSJ <X_1
M4-PO53JS4,C^OIWKPIM)\*YLZY0+CV4AM8SZG@*URJP;ZJ[5.-H6RNJ@4QJA
M'H\5F4@2#UM5+:(1B!PQQTI5Z,H!4C;O"NS!P8?9N<49+E)#,2>J[;T.*3XQ
M%ZHZ;>ZN3$!BW70NWE7+8X5'P0:C:V![5+Y>=?9.^W:8913U'T?=/@G_ "[_
M '-^UO@S^1Q?]?#:^#WYO3^>]<%/!K&:\2VAO1/RI88Q&\KV^C(EECR6"-N,
M]-ZX-97\307=O:Z)XG969'YLAP61F4[$=&/W#X2?F3B?]$EKCO\ F-K_ $A_
MM+;\R6G]+XA7#O\ ,;3^CQ_;O^0WZC4/YOOOYB_@GSIT*O\ B8&:,_"06"C+
M!C7(Y#:\X]4XHRRA0[)W1G&]2VUU&1I^5CN_76E*+,>@R?HI(+ =R,=\CS3K
MO4'"9 $Y0$3D#&Z[=:61.\CC/G37A&D2DL?"H8$/K2J <[USV9Y)G49UG4![
MJ/M&/HINRD=**3$<[5L/931R*&!!Z[U*-PLKDKY8S4<:]6.*FMI?D)@?&9'Z
M;T<5))3WAVPY(\ZYVK5@Y&3FN3.K:(\:CC&U"&TSRQMO0T$;^VI);N1=.AL:
M6SO3RJ-Q(1T]M1=U6[GB,U$+=?2L-P%VS4:Q+I.GO>%-+<?>X]S[JDBX?LA;
M'3%=JD)[6R]_?:N6_3V5D8/OKU5'N%:#TH+)ZC'>FNK895B6VJ+7O':2AB/9
MGRH(@"JHP /NGP3_ )=_N;]J"*]E>XOG74G#[,))<A3ZKS:G2.WC/@9&#N-X
MHY,'&&^#<PASZXXHC2X\^4;%5S[.=]-?!R[X7*^81Q1;JUG7EW-J[_8XH)4!
M92'"MRY(W>-]+@-J1U7X/?F]/Y[U8K?6M[<F_%P8NR" Z!;<D/KYTT77GKIT
MZNC9QMFRXK;I)%#?0+/''-IYJJV=GT,RYV\&(I/LA))+=S(7M["V77<2J#IY
MC:BL<,6K;7*ZZL/RED*,HP/@W,8OGGBB"3_9=A*__%J6RM;:\M+V&V:[DAN%
MC:+DI+#"S1SQN=6'GC&'CB;<X! S5WQ.]+BULXN;-RTUR:<A<*NV268 ;@>9
M WHBR^#]U<)X-=7T5HQ]Z16]Z!_M#2IQ'@]Y8(VQF@GCOU0^;*8[231YE%=O
M)#4-]87$5U:3KJBFB;4K#H1YJZG*NC .C JZA@17PD_,G$_Z)+7'K[BMQRD[
M%;+#$HUW%S()G/*MXMB[>9)6./.J5T7>L0_!R>2'.TDO$TAEQY\I;*=0?9SS
M[Z%I$TMAQ$CNV5[H!GP,MV29&,<^D#.@\N; +"'0I85;?F2T_I?$*X=_F-I_
M1XZ:^XM=+;09TH-WEGDZB*")<O+(?)1A1EW*H"P(L_@_<W$.=I+F_BM)"//E
M1VUXH]W.-1V$L<W";^8A8(KID>WGD/2*&Z72.:>BI-%#S#A(];D+\4MU=S16
MUM ADFGF<1QQH/E,[8 _M.PWIHN%\+NN)JA([1+,O#X9,?*B!AN9BA\Y886_
M$KLO$K.?@S2@HD[S+=V88C $TRQP20@D^N8#$OK2/&N]0_F^^_F+^"F",CR-
M:NSPY\^6N?U5@;5<2<M1/;QR2ZP &.E<]:EB;JDCCZ :^QO#_27TFQ'4:&Z[
MU*\HU75QJE[VY!<9P#4TSKH9I"RD>6:-G<:2Z81-7L%26("A8G*[5:2Y]693
M4,_74!^JI58XRA ]].)=14Y(+;U'.N='0^6])/$<Y4:O>:[9;IEX$J/F]TQM
MWJ,*-Z^D?'C)'L^(@^I1T9 %):JI.IM)^NH^Z!.Z#F;>-''@.IIK*%@T^ZGV
M9\JTR2L03GUCX^%-CR8G;QJ6620B2)F0*/94=OU[Y S3Q,  "1365F VG*2X
M\*2-(P9 _E^NA$!B78,!TK3>;,XP,>9K*(S6!4-KW)R:']NWQ;'%2V\@5]2X
MRVY%7LBKW>OW7X)_R[_<W[3XCQ6096QM)9PO^,D"XAB_YV8I'GPU5<2\4N)G
MA&KB'%KH'TLFIPL=O&<:8VF;N( -,,$;\L>C1:[*OP=X28].G5):1RW&,8SV
MN0-=:OQ^=K\<YJQDX8\HM>*"[=;27O\ 9&MC;ZECF)UR1/V@:%DS(F@ZI9-0
MT_![\WI_/>O@U_%\6_G</KX/?FZ+];5=VW&+AX[6;X22<-DD+A3%9V]XUI%$
MKOW8O11JFKU59B^#XBW3X.<',8 7,MA;SS''BUQ.DEP[?C-(6]M2\5X38BRN
M9[5[258I9>SM%)+#,<0.[)&VNWCQR@BXSW=\U<\,O0[6MVG+F$;\MRNI7P'&
MZ[J-QX4$B^#W#) OC=VZWSGWO>\]C]?NQ7$.)\*LH>&7_#K6:]_8:\FWN(;9
M#+-#);+B$,8D<Q/$J/S-.HNO=KC/"&<M;=GBXA%&3M%,LBV\S(/#G+)#K_B4
M]M?"3\R<3_HDM7*<1EE6TX?#'<200]UKK7)H$1FSF*/;OE!S&&R/&>^.R_\
M!SA/*TZ=78XNT8QC/:\=JU?C\[7XZLU9S\+FG2QN\W/#Y"YY]I<VKH981*,,
M>27AEAE.'TN%)9XVD;A7%6^^W%MIN=L?LJW=[:Y('@K3PNZ#YC+5M^9+3^E\
M0KAW^8VG]'CK['6LGH>VMPKAB,?0PP1.5GNR!_C>7)=RMO(8PD>_+0!;4\(M
M.(/HQ+=\1@CNKB9CZSYD4K!^*L C"CVY8V=]PD-!8<2YI6 .3V.\MRC.L+'O
MK"ZR(\0+,8W64!@G+4<)XC,VJY>W,-TWBUQ:2/;2R-^-,8N=_P Y5I\&[>5E
MMX(4O>(*NPFN)2>S12>)6")><%]0M.K'+Q+IM;_CEC#Q#B=[$EPT-XG-M[*.
M4!XX!;MZ)Y0A7GO*KD29CCP@)>3LUC!P>]52T-UPZ".! P!VFM8^7!-&?E;)
M+\R9=\P_F^^_F+^"]S(QP;B.2%?I6IKI?7GFD0>S6>M'B-T>?<LYQS-R%/M^
M)Y8OOT:[ >-!V)1H'[PZ9/MJ>X^>Y-1S8('4'%6N^3\321KZ9?+K@4\,L7>!
M([PKLUP?0RMG)^3[*V(:*9<_HIW7U9W8BH+D>JLBE_=45Y"<ZUW \-J[5(QR
M 3CW4Q484;?51[P,WS:9;C"][ I8K?O*_4T)L!I7[V2-U/LK+= *>VL\,[ J
M3Y4T\S%F)ZDYI(H\Z?E'V4QC(SIW/CDBI(P6P[M4,XU8)U:J+E_3S+E-]]ZG
MO)TYDEZNI V^_LI[^91S)QE5\C[*+G=MLUI\$4-]5<JZA24:=/?4-CW9KM]E
MJ-F=VVV5F\,"@<^ K8TV#X5.2-R@W^G[K\$_Y=_N;]I\9T_*/#D8^2GB=GGZ
M_5^FOA(=N;S>%ZO/EZ+[1]&KF?%\&?R.+_KX;7P>_-Z?SWKX-?Q?%OYW#Z^#
MWYNB_6U3\:X!+ MQ=>EO+"X<QK+/\J:VFP45Y?6DCFT)S-4@E&K0!SVXO;V<
M.%S<JG%.'HOA&)V[7;Q*?DK'+&?FXIN%<4AAMN*K$98)+?4(+U(QF7$;EC#/
M&OI"NMDD36R\O1IH7$:)-Q&\=H.'029Y6M0#+/-I*DPP*5)56#/(\294,SI/
M=VM]Q.2VYA5Y!?GAO#5D&#RHH4DAB9D!7(BB=E!!D.6R;QY;KB,_#^R7"W@7
MC*7L(M#$XN-5M/<,VGDZ\M'#J4="#BN*_F9OZ;9U\)/S)Q/^B2UQW_,;7^D/
M\7! <<S[(SZ?/0+;TGT:C%GZ*M=707M^$_)YV?YY>K;\R6G]+XA5F4W8<-MR
MH\V%LF/TU#;<">1.*%9I(9([KL<H"Q-SBMQKC*DQ%P<."REEW!-?X=Q+_P#J
M4_\ ?:1;_G7JQDM&MWQR*Y"$[$H)KIPI(V)&,U'PWBL:Q727=U)H26.8".5@
MR]^-F7<ZML[5Q7G_ 'M9^&(P/3DCA]CGSV*Y;Z?H^)_R&_4:A_-]]_,7\%[<
MPY(68EL>ZD]D_P"JA[\?%ON/*GXA:KL,O*%\_;4%OCNO* Y\A7#QPX(;JWC+
M3E -1V\:[(_KQ Y%:U4E?.M-P0J:3UKMO#(QA%P50;'VT5/=D0_417(NO21]
M SGU15G<PL&#@DX\,_%'97AU6MRR0KK]5-1QM65NE[/)&-/3&6%/V%=0.>^O
MMK1('=F;QSXU#<$N$90Y7PWJ(/I&.K>51YD4[;>VHUM@N<;@'K4<45ORI,^N
MO5JC2\MW6V=@#,WD32=C<,<#,@Z[^%=GU]XN*[5+C5[:.@C4!L?*M.IBMH=/
MOI)KISIC7,:MTHYDQC[W'X$^5/=/$5CD&U:UR=MV^*2SN5!1_$C.#3=BGEDB
M8D[=%]E%XQ,[#Y-=FDL9%&=)?RJ.-OOI0:_NOP3_ )=_N;]I\7X4F.;=6C=G
M!V!N866XM03X W$4>3X#>IXN)\R&POE[)?YC;7:W$#MR)I(_OF('::*50"RK
M*[:&9 I%X.(V)M"NOM7:H.SZ<9U<[7R\8\=5</MN%2=IAX4EVLEXOWF>6Z:W
MRL'B\<0MQZ;U9&<\O**'?X/?F]/Y[U\&OXOBW\[A]?![\W1?K:I[>WXM827%
MM-)!/!VF)9XY8G,;JT3LLFSJ5U!=#8[K&IY>+7ME';\IP\,TD3M<*4.J&.VR
M7N&D7(Y2HVL'IC-6$UG$T=O#)Q*Z*]>SVAM+J-%<^^:*#/SG%?!V[&3#&_$;
M=_FK)*+.2/?SD6&7_9[>-6'#H[FWBON']HCNK1Y$27+W,LXN%1B&DBE6529%
M&D2:XSNM<2L#>17G$+VQNK.*SLY$FD1KF!X1)<,I*6\::]9YA$CC[W&_AQ7\
MS-_3;.OA)^9.)_T26KH<49H;;B5O';B[]:.VECDUH9U +<I\E3(N>6=)9=!9
MT[:.(V)L].OM7:X.SZ<9U<[F<O&/'55I:<)YEQ86&JVM-*-JO+RXD42S11^N
MRR:((8 5UG26 '-Q7"N%/CG6]OJN<=.U7#M<7 S\H)+*R*WBJCH-JMOS):?T
MOB%<._S&T_H\=/+#%_@%Z]S9!LB.ZX;<\P*FKRDM9'MI&7/+F$@]:.DFL^)V
MR2$+S+.YE2WNX7(W1H92I?!VYD7,B;'=<TTE[Q3A]JJ]3/>01_1AG!+>2@%C
MT J&\LYDN+6X02PS)ZDB-T89P?K&1T-0\:5#V7BUO$CR#HM[9H(61O :K5;=
MH\^OIEP/1FK6"XNXHN-6T,<-Y;3,L3SO&NGM5OJ($R3!=;B/>%R4=57EL\SW
M-Y#-=F-A;\.MY4DNII""%!12W(BSZ\\H"* <:WQ&T/YOOOYB_@OB4!C*SJH/
MAE>M/!$"S!WDP/*F#HV1(=O=\<]HV.=<IZ-/$^ZH.)JK_LCO],:*F:3.HVS=
MX^ZN)6]S* R1-IU>)IH@,C?XBNG6N^13W-D-$@SF-!U-&*XC*,-N]XT$8G3'
MLH\J>6:Y6,JN<&H[_AK-<E3K(C_<].^JHN'\3N6148 -(?'IBDY4@G3 .L$4
M)#"NH>-!">F ![*-Q)I#:<X-$\QN6A.@9VQ6E09&\!45S?\ HHE</I<;'?I7
M)M(U2- ,%<>5<N4:@,[FD@>810[;^'6HEMYPXY:YT^ZFB#^FD]7SIKEE8J^&
M;VYIH1<&,+L$KGWA$XZJ&K3$.SVZ[@@;&@D8&KQ?'7[7.!GS^[?!/^7?[F_:
MC\0MIVX3Q.3>:6.(36UTWSY[?5&1,>AFBD7/K21RMO6).,\,6'/KI'=/)C^*
M*1KGV<[Z?&K>QM>(20<02YY]QQ66U%RUPG+=#;+;"YMU@B#%)$Q*[ J=9DU!
MDX?PGG]J[!;B#M'*Y/-P6.KE<R71UZ<Q_?7#6^ROV-^QZW:X[#VSG=J-N?\
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M6:1>WK_9\>HHI/GI'VEK'D:B#^NE!\J4MTR*:#;U"!]5&R=M(R6&3Y_M?+$
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MGL;Z!+FUN4,<T,@RKJ?TJRG#(ZD.C@.A# &BJ,QDX+Q)&4@X-Q9/ID57Q_\
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MLLCC3KTG.XR!C_B/_P"9\8_^X4&3@%N2/\;/>W ^E9[F13](-<CA]G:V,/\
MBK2"*W3/F5B506_&.Y\3\:?9:P2:6/:.YC9H+I!\SGQ%7:/<GE2:X\][3JWK
MF/!?70#:N3<7K<KW?L=()"OL:0Y^5D;58V][PB%H.&I+'9102W5E' DQ0R +
M93VX;48U/I-9U9(W=]4%K;KRX+:&*WA34S:(H4$<:ZG+.VE% U,S,>K$G?\
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M<F_4BA=H,+EUT5'[2OO<5>9"3 ?^?:8IQ>>'?$K:<"=_6"C,F* 7:R(&QSL
MG*!OJH21I8P8M?(\1$IBW[R]SNM?6/*%@&%W=N("3@;*E]U_;JP-4:;K-,N;
MDJI^2YEV%/OR6R:7;/-T]('3P>!JW$OD4<\U&$EZ9R-AZ\8% 1M_"6H8#6;
M/5U,VYD-6]-XY@QF2W!'DPR IJ5%.1D^M38EHS^8IF.0FVO=F\3%> CS47.?
MIR,BZ"PZK6U+S8^*A4MFA2\Y#G\K$!)5'01[1P.RB^SPS 8ERVXS;S"J<!>P
M;C64%:BZ^?\ 4*"ZCZ4=4R"FW9/<!K[X@4N[BE'F9U'J\'-4K_7Z]S,,9;9I
M%_5=%T!V](C1;HTY.G,TCO %_4)4$LI@##?GF)Y*RV!:]"B8<%- S24]\>)F
M!;M];S\X#@@+II8EF=7^LZ&+-8C.H"VZ0$\6-J2ERI+)LY(.5?3?M$S6EZU!
MV-&MYCBHSB.KO'511LU],'B^9NA\KCUG"T:-O']N7C5#L<.YY89[S%EVU-3Y
M'<7IN#C<T@?&O_()"AL^8<P.8B%ZYZ,&K]4J=:C#>GB,O,L :WC-$KXL\DQ[
MRU#Q0 I-\:\0Y?$-KN6V!VMH$RA=I1'0 ;%;&:G*2RVT;RYE!HR$KO<U,XQ0
M'M@N9'S: S$*S!YY;(AD*M!]D6"J;<Q4BPNNN8\(-X-9S4R06?ZA*K9RQ^:7
M'@ .&G$:\RH$%W</:I06&C;PP6A*B7@/I91/2&$4K*FFN8EQ='32^6'&QU(+
M:L<YU,0'&+J@OYW*[W<O*(R]"9FVP8K,7%72W:FL\%XB(EKTTA>J/K+99% =
M@U5P82_/5S4MN& 6Y$SN("%-:HR;E-5PKK*S\KEHRP%E+:7'UE%QJ[7-ED]I
M3E>!1^4$%PICQ&=J"IZ$N-%AOGYQQD%$2KZG.V/[94"W ;6;6(;UYS"QH5X3
M7-$.MG@]-3G068ER.U:( Z*I$1.?K!-@JM1JE8706&@=,^(POJLG*4^I7@%.
MZS-ZH,P-_OF/N'81=?CWAO\ *U^"G<QHIAI'P>\N=5,H52*U,[-*CP76?E%(
M<-5W?YI?K6;NZ]IMJ%R=.;ASD"@0MA5PSV6G3+[I?4XG1[J";R#(O [@Y4E9
MXHG]2>D/:-$+-9=)59(M"@HP2][@/\J,0X8=<Q2P/)SBO.89B#50E13Q4=L7
M'79OGSU*AJ^)=W]DM/-ZE-HNOI,@?6>E%[UJ(L"TBBG>XLL\LYJ -\U@F];=
M,9$Q(XL:"JL->R,JJ&]JUJ_G"X']KV(L%\/I&0P]BL)-%F4RQ7I+VNX;.A-\
M.3[S4 0VN?/RCH.MV4/^<,PL9NDOY?VNOU/7@7 ^IN\C>G4<,C*[>E_:/E.L
M.7*JA(04\*C"($=,%-E>T)8730(#F;PDSC(LL0*\E;\&JJ%80R.QDH4^H8>M
M]?2$XDCK3*_I'Y""JI.)DC['0-M=8^<191(PQ$R-YF=GR*N7G!**TW"-9>T_
M[/M*-4U(LJ_G,<%ZEI;OWBGTXF%M82%+0R5ZB+<:UB'P_* 4]( B.1>8  !0
M%!T']2)4N(7RS %OKEL3(&)JN0:G)K;=&L3,>-F-8U"8SN6(YUXYE%7F@"K]
M4.2Z4]H>#IW\JF][B5 %OP77^I;/*HMF5+CUBR*+2YL4Z((97$76@WG<P]-\
M@"?M7$;<L$4X5C7'^YG9D9B]K!-NA1E2\:?I P$7N 5\!B0NFI0!QYN5*LR=
M<.<2_-93Q#UFRKO]R%$26TW'4,-D3B4I39?S3$J/1-:6H1,A$[K(^3^UGX2Q
MHUB"LX7/\X=\5!K=N8IC077&,RC7TA<$,P36GUSQ,M'#N331+N)8N<RB1M96
M0GJQZS->LGN)7K^\/T+6-N>I0]TBO.&"%B27)_Z,_K=YS>-=S/(MM=^FC4NP
MF3FJ>/G*/A5JL07KJ-"V@[NE_*9T!%DY*2G@.= 31\1;OUB"R/F_,",)R0ZZ
M:)\D   * T']3<D+:P<9*'5$_/I M:NV[7#56'[,H.B,\WWOUCG_ &T!8X8"
MVHM%\>9AYT)1I2MU%M1Q_P!0/5\1.=6J1W5QQ^T=:::KD*HG+Z-7B59+K2VT
M/K.&!4,@^;<26$TH_*#<;H'*U5-!PQ8N_5*[Z"S E9C?5J#Y8U%H;E@.KQDE
M_F3/4%SQ&QK;1]Y0Q3O5.V9+A*-*GHB/G K+2SH]RE[<2Q?9#68$XLNO[3<,
M!::"7%NI%X[_ .1AF*FBY=>JL:]8Q0U%1W$L(U85N-\4=K>OU2^UE'@G+Q%)
M1Q!JU;S>)M*%,V-_:6/PJJRCZ<^T5*/Y&O)S<R8%:&E\^NH7FK?*3AX8PXS,
MNT96$PIKIJ :6AT6*OZQ)X+=+=?K#'&W0;EKBHP62/6#\J1BHL#9KH+[5/(1
M?9$K>+B "D')"UX$L0A!0DY?ZGK+ BF:-])=$3*N_G-DRPI6!>&H:'9.LQ94
MNLMMN)4* :KGWOJ'&N!8,7]C[0%XA@KLXX8/9,071T2SIKN+5SR[53<Q'KKA
MM><PKIL:PUUX_"8I&IKTN*,&_,U>3.O+YN96)A(%550E@F%&8GWEL&&@ALDI
M:J4F\<_--3"5#EO_ ' *+&!KJ5=48'SF-?1*[)'FP7E>9E^2HA5+:#RP,2V$
M7X8_M)$X"U=!'1$6+SY:U'&;'(QV& Q$8@Z -QI0(BG#//$)+BVG'Y^TP<S!
M!IP[:AA:ER3+4 F/=THT^)0)0<6C7$OZ6Z[WM):@@O1-KB6@:J<"'K"X6/LM
M=T2Y2K3%U=,-8]8K\  :'**W"8(V;8)UO@JVUZ[S-&="@-HWZ]S)H8!9 U-4
MKW33S1!*IM?,BE5 Q)2NC4*N4U16'4'326_>!8/8G]26LN")VB+7SYF'%Q[!
MQ]/2&$)Z1C2>&9\Z+?M**M%SG1^=2IX*(,'GR3*LU]F:&FW4JBE>Q5V^C+MT
M?TE_Q-A\U%(,0EU5RN*6:\)N4YJZ;:ZZ743G7(KL^L(.&0PKS?/YU+TC8%%?
M*$+WXP?9_6WV(NK[S7[31AA"1&+K7E\1Y5,BN+[EC"P'A#/8%D#U=?F98_P"
MF[L]0@;:V&ZA8$&:M#VN-&$++$,^L*(*CH5_:5W)\!.R1#O,PFQRD58Q]0?I
M+N[#*' ,/ZGK,@%WFGHNZ/$O.#;/$*MM5]XIH3(^*U[W+@3)?##GJ%>3S@ R
MUJ'<7H'-*@\ZB_:MHMH!KA7F60R=%V,1[5WRMC[&%G+_ &G(7+'[1W0.?, O
M'\B:D^P:8>T8>ES:U1C_ $]H"6HF#74'QAQ.,LE&S::W,Z$J0VV<^8IG#K<L
MSM7B&/N^DP,E@9\/S_<(5R0S\N/ZB;W UWX0W+*U7F:F!62,JWI!RV1T3'<-
M5\2E@:<X?JEQ,SA-EN2HL.@@L.;<Q,&QRSJ9 X5\X&'XJ9O#E7F90(T%JQX_
M>&5H#1,OB"0\Q+*[<2M,5J5BOS4<.+:YB8%M=R_BW>NHE16.0M8=RSAK-Y9C
M$)5O0*.98!>PNO6,7A!TM#EF))"*17/6XATX)RU$?NE=8LRJZW!#F-JP4M/;
M^TUV'C\S>NA65M=2@!;@7<6)[=^D554LYP+]8:@'S)V%?69_-VFJ0W *8=PR
M3ZMQVY?IXC=B-[8XP8J <-0;+9NG4*T8/]2@IP%*\EF<3&+,^IZ<!]$;1AA>
MQ?I!%S:!6++Q6"(0'0BFC'2%4=,\,R-MD.>5.!@Y]YHDH%Q:/[H@<W2"B"EW
MXQ#W!]JJ KB7MH8V13=/K [F-R',J:+PN$T^3,M]K&%/HAX8EXJ>M?U!($L$
MYA,93<JS44FTOF7R*8QG<&.WH,=LV*%J72*74R'0R;RM]X=8@W77,8*S-YJ:
M-'1*$L1MF9-@S\H]QJMZ!<;]25XVCD^T)<+/JJE& +.7M*84=>H5*LA-)8:F
M$BK2OL9/B4T[!H:+13'=I!QB_P N K2"6H+UBWWG(<O<YR3\8:F)O J7Z4X]
MS(?NP(](/BCQ=_VI@*;*GN53+^&T/=*;ER\;3]841?)%N&6%_MK\+.=2L":J
MJ,0Z<U0F_6/BYA=$XI-ZEZ9@[";MG?-Q11H:ZOQ*3N["T6B.1P::( 6SF0$'
MTQ*MO2S0"O=B0+0+1$*6;Y+N.'C-)U+Q\YQ(CLM4OQ'-\2!9N)W3Q!4LP_1P
M?-Y@L\SH)J_TB-EJNLP9"EL6F=P0>5C*OBMG=&6$##R7_3MCH7M 8W\EO,T+
MX+\2NKO]R;&EK.B;(2,L+EAS+: ,'84%\&<?[CC@]5E^A-12:,@#/K$ZEJ;]
M+E0KQ4U<R8T:^4OO"CF&Q#P::)SD"90T'+AB&*PS#5K](1L'P8C,GR$PD5(J
MVFI= W+[NE+A'GB]_+Z16,.:TRU4LU8<O+Q,,DY<"(!%K>C)Q]_'FX'B@->T
MPO3^B)B,[8SK6I_S-1?[3LJ+WGK#+([UV7+>Y1P1POF$$"L%65,E6>(X5@!0
MP#>4EI,%,%Z_/^RPP>A:>B4@<@RH6W%:W;4.?0C/QZEOQ3F1XZ7,K]->N_Q#
M#' &1H/VA 0ZU5[*[W #QDCX+1B-Z-7<8;(-[:[E'!0)+>'%SE6 JBU-0567
M[JA3["4&F"QMX_/I"[0,:J)0')W#F"@987(.&O&8.6%L\,?I_3E/PL$LW.63
M//<#6RHI?O C;1CR0#HW5K(:B\[W]P!?3XXF+/%T6XO2I<P6_&/T4<0W<]J8
M).T5XE3(KP,31N-NG_)4&(+?$67+, A6DO*\-\DK\8@!)F&%QN%AL;O,::*\
M;Q5+*E?AMT]H+6ZNR  L"+E9?*A,:5<+B,Q+<!!8(T(%.<XKU@$+IYQ][_,1
MM2XF@K!G1%718AT[[B-GYN9#\8G2Q],S4V>^#_:3Q4[71"=I0N2Z_.Y<WQ.N
MB&9K.^^)?;\AA91P\8E2L,WX&$0LCU+Y$R1#M)O2^,=_.8%1D'=)>#ELN<6U
M'Z-,*P[XESP&=]4=.J@ ]C#-0!7R(72@95H</UEL\AX<)+'[HUS*+4@7CF".
M6ZUG<6WXB^&7B+[3&[()L??57I.(O,P<5>-H6T5X%#1!#L5;YGX$%01G3?RE
MF=@'5N/Z< 3GQR^S-[8\*RQ[2JM/2_*_0F;JC90PV(]IDW.!N[O>84 AQ'$-
MS!AB,59,)=AXU,8( C$+6EC$LJ">B0A67VEY:JOF[P5*@0(-O;"W#++P()>>
MD]J98</%G'O!8R-'Y^,U"=Y4K%7X>.8F%6?M+?)[3L!Q!S]JO$1]P!;XG(+.
MYB9&OO?0Y%,0H5Q#:P8KFVLQ%;OCY/,0XU*EPQ'L^49O40-5J3=:_.G^TJ'L
MI#8SE."VPU;EPA,1)R([F(\ BJ6ONQ=HZ%ZOQU$J9\7C*)OD*KJUG/=>9<UK
M9K42<_(Q^:(KK=1*\8!5X0:RA+EQ+*MI)7K*#9X>1X8U)V*XSY:+Q* R&C&,
MKN8!:),V2S7$ZC]>M=,)9U,5&GKN8P^!<?,<?G?# %ZIJ/V)=>"9JR_VW&X:
MQJ7R:J4R8!QKB&*E03+<*J6+ [72\Q6O;?1_31 JI3JY1E*H^LOT[7*O"!=)
M=:PF"%FL<K3S_K!')JUV'H7@E],(.';7PM9EKUOCY0"SI],$*\%.,!^I,PA<
M4'N!/',1950Y#?B)4$FRYS'PI6AS9N(I+7UUV?K"&AH"BPMXN7/ P71(0+J;
MK\\7F@8-%&)7*53.)>:5*BCQ,:H\4RG):N?/4H; H"DSZ)B\-]74O#JH0"VC
MYQ72D%E,A^C?[3H S+8DO=9<_G.MR_M%8.?UF%!X:U$(+%.1S Y+,#)UL)3M
M%4I107W#I"#<LA%;0<6]1%G-!TS,K'=%5YB,JD."Y:'5,/,Q!Y7+!@]<(\0)
M+ XQ?BN_UC?J::=G(K/F *,7=C9^V9A?(#*<9\RE=%/BX8Z_MQ*/FSOFTK@>
M9QB?I*L'T+6.JB&ZM%T[82\"=LCH^\()[J4YF(;VJ! 4^,SN",2FO1_30&60
M2Y?M@C0/$0I:!8GJ@2RY&Q:.#:16,%13/!6S<L0:3@X!T6'IXFBUKC4$</%P
MY^7=%&_$*R ^=L(IGHJIJ4%99,],W 5VV*^MS%@BU>V -0$< :E=S3=5LQQ!
M[9!"5P<P,HQ<"?GA9K1(C=L5+ITG0]$+4=#B+:X8B%[4;0X?E#HWTLME_/JW
MU<7J=VW,J!3>>*A(-<#-%EC);2]0G^TJ .6XAW<4_L2@W'/I#:L/_9B[HN7C
MX+O13]9CT1[V^BX4YN]K"^I6,2CKB"7(+K<*=47->B';'%U0P^DN68&W9U]'
MM%#&,2TO(@$&NX4:KYSE?^HV0W'>:+A)LXP@[($;,V#Y1]Q(FM*"+, 0>X_:
M9!E7ZQHF7GJ_:9>>5QCN_P ^\+0#&[>#K,>.D* FG[,R/8R'1X@V-#A66XD5
MG9$8M'ET:_IVYU"='I ZK/TC*(O]3&D%%/%#"DZUC!J+E=Z*U^Q$)M^; ACH
M%+UJ*'@:,T0D!2_5^R/X9E>L55L>>!?TC%6VM]IN&YB0Y6@M&OYJ(RC!U Z2
MI;'K$?8Q"CKW.S ['!B[F'2#-G;;>NY>0+8N[,1MIRH]]0\(_NS);-1TQQ ,
M:2,J_'9%,H\#[1@D;BC%/YS "E:ZG]IWY#(DGF#UA7E*9:A-?/E1 GB9O[2R
MP=;NE=Z@(L8(;-XE,IW+VAG;*^08%F(T,567@'EESC,K;&PT9S*BL[.^7ZPW
M&ZAYNOUC*P,S.S\XFZZ-S:_ O6./S4PUOJAQVX6R3)B-5)-;@&'REDNT3T#Z
MS06[;UM"*#8/%QD[L%I)*?O &K<&>SSN-U@79R;\0R@@=8QW-"TPGI%L.\?M
M\ 7_ $XT,7!:>_VF#UC^LNY7'1NJ"HN=+\+G$Z0V6:O&YH5&&RK/F[F",):"
M%?2KA+E:*::N%0C WUU*Z8 ]$V"<%&3A2?7%+?K'_<*!OZ3E# @K?((V"4%M
MV/QE;0!E20<WI)0O,) [#_N4VD79?GX'RE4. D%;\G7Z-P45,J:5PW7,<;1C
M])23=%5/^PY_; 66='B(GT.R<T8@]E4=%N=0E1(&:>[E1"UW?^I6[2=&1*SB
M8,:/*6U$>ZMCG:*7:*'D=Q[#)HA0/=]1A(=5U<QPXC=@0+QPX[,J,RE<.D]N
M8Y[.5ZQ)*1EI1UGZ05=(O:==D7O%%Q%SY5*26] 1M_2'F9:H#(T[89-RWY,Z
MA1&QY](F<A>'X<9F+(K@2B]\7<-YV*K3Z2V>?IQ1Q#&<MJ=3*=9?:&(LKQ[?
MTX&D$GE?$7*Z]L+XEV&44Z/M%?I/?1\R)P0O8 <,_GB64P; B6F;,\3#LOL:
MTNU,@+7K2 :U+PJ;D!+DK=^L/@%QE7V?6*%1L/R@A$'@JUWZ\\3R_-S9^V4'
M=%]DPCA&-XKGVB5CHW@K&KP7Z2CYJP;=3'4U8-X'<J_Y0J]NN6W$NA(C"MRO
M9R3%Q71G+;<("\2O&X+7=B!C57=_VR0A7" _>,1UF_\ 5_!P;9O56C]T=>KJ
M84K3ZSQ]L\_2]RI185(:J+SB66C8[0"^PLI>6!KIQ1J="_,^\$W@;,M=<<3/
M8LL+U8:=D?EC]!F%BO\ 6)&='?B%=#+V3"[A<WP1Z:66E9?N2N2/< $6*D\,
M2V?K?(-_.8C59%LEH!G$8F]<BA=[#,_FOCH@'PJ[#+* "6*Z9>T;#7M_O^G)
M US[P"6#>8GU&+N?<P)]U;L=/2!DRP+!M?K<K?JPYAT8R^DJG@4J,'&3$K!)
M5>A&?%X,VO@B: AJ;*<S**5N;N5ON2J)MW'EY>?]1Z0AAI7_  06*^L ,L$+
MT0.&Q9>&54MHV_[7#&@<52K1G,9@]H9J#5, P49*B'&OM&,7E[3F/7,$0[(>
MIL>LM)&=$?67H[(+5X77O_;K4EG;X42;/:OEAZ@. W:<RWF1C+0NEWVM2NZ9
M0Y'0-?7F8R<+EZSI>Y7[>S"#S$';1;:"II:<2KALQ!J<O6.A;&IL@@]Z8^1'
MH')_,N+35LX\-P?FE#PE06@&PK!_Q0I/IAX?TX7.72;HN5?!@WO,8D\UOH<R
M_P"\A!^)1+#M*-([3\S K-S5M>#WE07,]<RTE1VW8N*Y8A727_3+4UNFO7B<
M<7D<R[.::ES-99R&S]Y;<505FC@EA&$[53\KZ0*%2J75^I\O,UX_2D:OS$IE
ME](1C(MC'+Y$K"HP55B>CYE*3/11\VB/PW!T\2K+!+M%V-6*45EK,SXQ<73*
M$LI!TPR4I42#N0'HFU^8QBS%$Y\%UX)51@Z)0MC648?D2M#,'L#,+ (%1OMS
M])_;FM!NU>,1HK,\!QO<W\+K@=XC)< <?5B4+3&$>ZK6^XM"<0''P$R :2_!
M<1)!I?.+WOY3(7;'S=2PR&=1+Z_Y0%@5#5YE&!28*B]9(;BU@IZETU'.F/\
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MG8<QKJ(.#;O05;#>W27!,N_Q<X6##@P&JC@25(.^85(9?5!BPF+SZE+RT=;
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MF[&38'#O!2V!XT$ZHJ^&2LH _P #FX@  @"@I$<(F$<).(';A#BZVV&.&?\
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MI!#96@JI*@LYLEAQ&44C;96U3!86P!2ZLDU(DLH$:8I"5E]UA2AXXV:AH7?
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M-D2B5C<0;!2C+9DU_!E\/ 9VY)JPHPUNS:Y<7M %N!V05&ZP%&^D :R9)?\
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MRM%EA1%PGIMVVFDU+$'3FB8PX:_(?TI;Q47\R$ZFLQ#U:(@2MIG=H1AXQB/
M$+QRBWDDLM<3E"JZ&6C,.HS.9-?[B(8BL''>-H0EW5J\8]OPE:62TLHX^4QK
MX67RS9Q*2ZE56,J^L\0#.V9?5C+R5GSS*1AI:GT@!@*#@_IN\,87#*(LL'86
MT(Q+RJLQF];](87$4A>H$1.Q;M9])4L1M!R#Q< 2-JT++E-;,)^L5<$M!/3U
MZAJNX?V2NYE4=KB3+2J4Q$(0@B+=^Q[P *  T& _F,\L)$4+R6L- &(9!>!/
MWWOV$+G: 1P8+-V& K^U@6R1FPZB9&C%/A5;@>G'P17 GB,P!@.N=$K*7%N'
M?W0B!HU1CTFFH:TLGVI+F.?Q<=)RR<+]94)QXN55,0K+;B&*EG?6/ZE=OUY(
MCZ\3)J[IG^D>W^*(-<[@D[(8%88P\&*WZP7\4C5V9=J6 !=.'Y,=9CZKAY,G
M$I*K&]C.#S#TI#T%'T_O&E(&*%(II)<QQ4O)8!)L%JII!H1XZ5]!O[X@U5I0
M'*^D8+6C](V:#G)4)'E.E"_TB(PBNXPMR@WU+;?ZZ\2\?1SECJ#D" !6BOZC
M:*D6P#B\3/LV:X_7B6L-7D6:_#,V[[*I:!\F51R%Q.<M!Z(^56,2HM/W69^A
M/)G$MFL']YFJ;!)I\1O&=*@74:D*8^7J,U 5&QQ X*R%>HS2R-?6H6+0<&(F
MI8@R(A0*AP88]G$-YBAL]4+PFQSIS_2_D**"W5@+S]+@B"9'(_Q6&I9O5./,
M=YG&U#&8[K>/O% ;O ?ZE\$5QK@'51Z-SR>HJG)?E%C4NH*XC#U6^D!*D/O_
M 'L187<94$WI8X09_&E0=2KGHL^,3CVFTVN2 H2B[>+C]YGD1](RCYN//4D(
M52VT$8()8MOK_I*":V7-#B<;J<68WNR"[>^YH(.R@']D-A)A9;^$ESR#5^$,
MMS/D.?,(TKT;OLR];6K*JW=?GO*>TW7E'"\3C%U-FM<1=.D>(#8"L-5-?WPT
M_/Q$5@K_ #)9.97TF4-NI9. NW1#68W6BF27DOSK/<M2"=D8VA*]KS< \,1,
MF2_Z1LZ$&#$6NAW<UMPE7R7Q/4<J^0;B1+RT5;N,0P;1:?FY[B&!:E"P"V(;
M<T*^S%MCX&L:WG?B5:4V@"8'+XB;  L#D8B]HJTUT;K;,(WL3)3J5$MG'K!P
MR<*06+&BG-:BIF#AW_?)(\)ZI&TQ'C,ODU5:B9-DJ_;,O;AEV7'!ANSM>2X%
M^*U<'7+[RVAN<P_ W'-QLW"MS_"!0!M0!ZK"#@2D>0/,SY-]@(2S :TM=Y_6
M!V!8C?\ /U&$RJ-7XF"G4^0"9,PW9*D'+A*446==+JEEHZ]G"Z:6P@"#D-<5
M#((MRO1%!6CQRLT,$"],$WPD?:;(5='WF*DIPF;N6 [?37#O<%T*;RB8"ID:
M6%*OA^>T0I"K%*=!N.\\L8 V7GTE 9T']]"P 8QW^["[C N05+3=2Z+\LVFA
M0YXC%F0?7F-L6BBS?&<RE@0N_;]#!\1L@)>B_3U@^!7POZ_!#8>J$5AY: )6
M;9W+3L1ES>TU/K+%(4-%QYXDQ21+T1?C^=UZNF*>&9A-@>:,K"6MQ?@F0N(X
M)RQ\IG$!*,51 V507->T<:77.9O:8#V_)Z?F8-2(L02 ;O*G=0$!\[E4*,Z\
M/QZP.J1W*V!OU-08;TJ/HWAF[G&ZK8M!U1C&.1@F5CZI6..];G'MR1\8-B9E
M$(-V(>I<_P"X01TCZ9_O@:F[/-1?Z0\</-=I#$:<+C%^D4%Z*33C'WE=!O-S
M'?'< ZS6I9VU/E/"?M' $&@-8;CQ9WK<AGF 2# OJ^<M*132)CWC3R&!0<:Y
MFCSR6Q455U2B/SE)D)\C1SZP4RZ]!KOF%@D($;*:CR+M7R#;K,L2;1>=]?SB
M+J&O= QW8O5-M9@O1W<.("IPIXFD'*J$[!]FH?=:81B0F W+#/E+2O2JF7]>
M)>N])BKP6$*:HAI4[5@,RBBQCL)3I<\Y;'RY^4+[XT"AIC\\2N? S*&,+F B
MGMR3XQCTS4V <A0#9YAG\;6MCR8\_.5[Q^6IF%([YAL^V$_3#-0<W+0=LJW.
M)5@9[-?WNB5 JO1.K]AX-IK+_P FDU&ITL,_>_I*NL)<V5J60VJRY-ZXE_2
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M(S$SECE7](.@\8/0V<=19N@PF,854I&PP*&\PP\$!OP<P%5> ]\W+6<%NH\
MZKTEJH@WKLM)*.@#%CL(=;:*^2YH<"(+KCS N:!5.&O,]#KH\8CO;LCLJSQB
M;MF*_)'^-07:5"$6^LWS+43CLWY:U,DRUZDR>W]Z)DK@TY)*+E+<RL(Q?AA$
MY@>$K134^</G65CAF@EUWO\ 26E:M-+[R@N!HZ?ST@I4P5T_ZE9::61('#<'
M:-!<5Q>[[?/;%C)T#9FF:[*)1"+VSVCT@E?5MN>%;,.JEZ8<Q.-Q2;A1NUSA
MA@,HU'L1:7PJY<5$B?.5('#[BP'L=?S; E]"ON/$B2_-0P4]^MQ+9>:JW_:
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MR6KJL_K#!X%;:C(YC.1M!8<5=_*6PU$;]2[^\I0A "RO0,K$E$-F;0O9 V"
M0':,9X&@<C](@$F#W?[@H%Q@-E>B;4 4+J<?@9@]$9PVLW2.FE:7!IK]92%Q
M@I6*=;_>![=$W/.GC-4OVGO$_+_>IQ#S;#W-<+W*W-#G-2ZK#D#BN2G'O!"
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MF"(R*"<H!3(G-::Z6KC.^=-AYL#W*WLF3+A$YF>L:</[2HHG7_"/K4EGTC/
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M*04TZ_\  +%[-6CU<,<V#ECK#+YBH]!8YA(DZR0T [-C<!5X!H<GJ[%6G4&
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M>8S1A<-H_:JV:%=3EDL!5E5W#9%C==,<J2CE/$UN'M))3<>LH$L#!T=>D(]
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M6+,>);CT%W?K\!&F/[XA>M9G)9D7)A$;E #EZU+<=+VU%WO3^7I&L =Z'UA
M>[O/VE6;'(9/27%"[J8ILEH6.;K<5FCCQ'RC[-G8(/6E_&ZT\AVG:^9Z?4$L
MWKO">DP#SD+PYEV7:EWZ)<4*"L*:(8*Z_P "'4%0+$\PY!+CI?-$W+=#:A7F
M'2-;@\QLQ< F5MD#Q3"70"4O+KWE62+ EW!PJDYJ5R>(E?J($?**1=1"G#X@
MN):D!,^DW,73P3$&#KG[P.UVB$51@7$6=$8S/&-'&6,PBOVS-%(ZYVJ^*SXJ
M_?,<2!88]'YZSF\=2OSIHKP_M*X(7@%UGN4[-CPJH?>(H+6RUVF>KL_=>I&)
MQ2#(?[@,D)X1^TI(+ET$XEA4@+3P]IY!J<I@^E1&6K?((Y;>>?C5QF<UC,JX
MK8K'[^?EF5RM1:OCWG$-JF*AT+9E R_[EJ-S6UC"XC\+W%TS0"(950Y@HHN>
M[_TC)JF.%JX/  ^17\3-2V-D]U.M7W!6LAT'^!1:-6)\Y;;OU3+BY@/HZHL]
MDR?6IPP+MEI[2H*[?[0@AOV'O,(H0#@/@2UMTU(S-PN=D5&XJE]2X;66NWY^
M\I7,-"KW!"^&<;\]9:_+--U +D (*QH&0<U*.RQF ?HM&V&=RWN4Y7$LM_K#
MN;HZ8>IG>+XF_$9'0= *^>#G]XAJQ17FW#.,$'*%'4X12*R//F6^Y933AO)U
MS&]X8>$"2KLW5\H^ 7XFJ4D:/#->?7OW3[H%U3Q!W+:++K)?O\-XBAPZ_/YS
M+; <BLM3-!:=G*!>N(QLJ@VO4&.1"JG%^G.Y9W3'(&W^#S&5U!]#B)6ZY*]B
M,GDU_J@- #@*_BU71@P?.8)X:;AU,K'%PY>FP)=W/34,3R4]Y9X7P;>('>J3
MG!X?GZ2E5C9>.T&'-4*<U,GH5-4$.?,PV,$:!P)J.@Y13H0HI7$,Y!(9>'"@
M6]>L0XS(LW1;*9,BRN!;,0LQ\"Y!5>I_R6_"0V+79\HUE4(X!@@BN"#T8ZVC
MY6T6K(I?8@50 JN8YM.DQ;48[*[#Z'/K  T >B7\7..X+2=Y2]>OYZ]N2:'Y
M7,4*Q*><,+C:@%?X9MWZ;(-W6#WCS@NM8\,OC1]X]^2P)8 MM8D);*4U^\N<
M@>"GI^=2GO?6#X&58*/#* X:E0H:RI6G$VV ,0ENX1+FF_$O?D^2^\"/*LMB
MQU7(U!Y&5K9Y$M6_6T>S>25.>.TUWSJ;(X/5AE])1N+;=@I1++"UC84N?,,F
M7N8.7-(JV.C>1K+&YK=QU'J67C,.]4G-#<UQ$=L)]:?;7\"#A!.DN4L-[I^W
M^&VV  #AZO3 2,<O2=1:?%%<W'2&'3JERRL;;NG3J$\*0 Q05_";(5)XA8D5
M>KK>![TU^TIS-L-!;5XW C<*-:]B<IX/OZR,0\EJ^AN>)IT\!JY0W #/)G.?
M'$SPK- 7WG$T*1F1E1G<JQ ')7$"^5>U^T(IJ#"GK'N^U[_>->UCN946$[LF
M2>&P)AFL=?X= L#M ?6#U+U_29P1+&QY-?&M].H_>E(;;;[3'@=0_/\ QB64
MH++IJ9BJ Y51:>\:JJO4SH!A72\U4H-CL"GF^T-BZ%G+Q%YH>659P-SB5-*<
M%0 T:EA%,DN"_M'0WR$98P&/1>HM:[QT9Q+X8PFEZ('!YXUF73"CY1><17S+
M^DX.B%;!:/\ #CT"Y< %OT)F=X"T] >,D+:<FCT2I1W#8+I6%1GE@;;:C/S_
M /6Z]BH0!P[?0@BL+FL@*#G3%-3K_:Z%L=3  #DO,R9"AMM\0DZSCUAT[8'9
M'$GCKQ3FH[!3;-=_6%M)H,]:UJ;A-&'/);YE?VE5EG6D<BS9T-D=.&F^L %N
MRT>A]?\ #FU#0::$U](M,&S--M[Q85**NH:&\$VGX#H2J^__ *B,:*3883#%
MWJGM<K64\(S;'4@4,%=08H#)=#EQ* 0$ -8)F@A;KM,>9T /H^8FT*PH_M%2
MR;0I3&0E73%);YQ6N(X""Q--(&L0CITJQ:\+ K2 %A^86V-H(K3L'Z?X;5I:
MI:M+])?NV?*<!Y\6#0F!IJYESOY?K,3%*K'+-U^6(_+_ ,N5?@&\>LMK%40S
M)?KX@*5&KQN,>+K-II"HC<;K;?"^(TH.&AT.[$P<3(6*#T.Y0BUIS#D1R,I3
MP,Q AT.H+2/),), 8B'I-(Y/#-2GR$O0TW>16_:4S&V: ,S UI\CC$K:;W>D
M4B>YS\X(EF1_PO<<,K0]]42KG[DQ8,M&!R\1\B.BU)1&JS17&H58+90\Q3WL
M*-D.\P0-&^@']?X:'0Q..*.9EW\2V:^4SF)9*\O,(&<,4D<;XG4Y P!IYA8O
MC9?O$6N#Z'"8$>]^ #Q4M1-ZQ6'#0 NKTF#C[:CO]4]SO@49^74S8="X R\<
M<XAIZLR\P6!G%YL9(1V=13W7&*E3ZK 7JH@X@Q=KS'&\"M*V08&X\USN;;K6
MMO$*<J?5;](9G@YDY@ 2QR)S_A8NPS4RB/K'MM8]Q/:-TQ@*'3Q+.!U\D91[
ML9-M7GJ)L M\+YQ'YW@:;1^B(SC3B--G!*U4W5@6V\?$E;1!N[5+SXF;['$T
M1GJ>D:A9I-KPX@XS1,;U!:%5$1;1P,N&#. ,<>((5M>"+_66\/LV;SB-ER9H
MM=,.*E"-7SB7J'_8-E^L)1YN;E2_>!RL,(HI^C*I^E^7$4#KC&5:US")&-="
MQN^^EC7I<>H!7$%81DY]BGL0M*H%,*893;C XCW!AS%X'!>$H.V$<JX2Y^_O
MN_\ R_W0\WOHX-XF_%I>USP-K_3$?"Z/B#V=,O"\ ,MNBV]++_@7@7EP?)+H
MMUNY:CKO&F],6RTJK=B,"[3'N@]7&P&-G=QIS'"O,N7(G$Q97O)#=9AR&A4B
M1E0\8#NID]P[C=6;S\4LITX9W%* R[@M&I=)K]XGKS@AQ2\\33.%,;R(8,X@
M&&OVX8!EMTM&^FI4%T' T2P2%6+1V5;;44S5<<QX3%&K<:@-GD[75%;BFU?>
M'Q3(/KF40P=-;>(6K TR\Q"\GWGQ@1&Z;)+HVKK>;1\I2K&PW7A+BS\!4P%+
M-VJ.4RX%<X9D(0##/-5,!B%P'^$V&K0FK-K[,Q1GAHF%@KTBV&0<U*^D*4RG
M?+*)ZS$)6',2":V=S#%32$MT9F=UX@K?+>(](2V[,#F<1YRLN4SK'+*C8Y"\
M1_JA13]?@E@"J-P?NJ6M:I>_!YC_ $<9J5UF96CG:]RTMA<8IMOHA$!JJ7S8
M.IP AEX#])K0IIY:Q-\8* ;KS,9_S2<#B4."N<%$2)$@ :*$Q7UCM$6X8 NH
ML!;8*RGF/_+)M#56L\+O[><=0< N"#"DQ)X(M@16B0QR7U$YQJ"):9\3MU 5
M"#AU_9!C##0VP9@3*CDPO5<>L "@ Z,'^$F(^BG0/652@*T,&+/M'=*C8>'@
MB:I,<Y9;6Z@.>O/,NPP+[KEMW@L"K-<2M3E@&#Y0F-<H0NEI!=*!*-+Q&=%M
M:*T5!RL7V42II0&\@X/W@ !@ '@"-40+;5\0<7S);W>#*86URY7UEP:+G(@#
M%DK[(ZU!)TXAQ' 9!LSOS\&4'DJ6JG.ICL(8;"PH">IJ+XI6VO0XC\"#V!A[
MS+M#V*N<XN,J<J"\]OE*V;=2,PR3PU"Z.)<X$:$X=Q&I)+.6]1MJ[JA?TCX5
MMLJ1AL_27>;D2U:%MS=VIH.6B!O4!ANTLQ,;2^U7CS+GR,LH&#+JHQMA;>'_
M  DU<(5VUQQ4PUJKV9;O,HFK:7C%W06[AH!Z*0> -K5KUB-30,2_1&1TMIUO
M,;.2\:TY&IDT-,\W#MEJH.?33*-'5VIE;6.41:47/<Z8EJA#=\X/:,B.R)98
M..:C?+-JKY1K?: _G%AAN>.8[S7_ )D:@#'FL"\[, *CWC;3J+ $-HH\U*HM
M"CDY84(!BJ!T\PZ 1GLR>L7%![H'"&M3=&?>3 +_ '90Z\QKQG%X.>HA]$8M
MT'#;4J-S'%#MS4U@K#AN _R1D8RJ<0!E?@"&NVA=PE],!9C:;)2NEMY%XN5F
MV"HM<1334',PECK,97SXE76E6VF#OB5<BAQOE'A:X4^1?^$&,8;I+W 22S,8
M@279K9'?Y!6M*N_2 AJ#85<P0 6;6K@Q7=X:MRL19=.;[RFU VUNW'M \8><
M)Y&6GS:Y2@A42 2O@<WRUW,$8#)T/E*@L50#'AC?YUG>#=5![V1*=Z(@ 5BP
M77LRZ>7&%B_-2X7D=U[Z]I70.9?6I=-8+#J'BX%LV(:[9[=P&4: I((08 H#
MP$0R!   O;'\8)NYZ5\+[R=,195#"[74NXZ.U6JIO!*'%;5-JM-0M*NC9<TV
MF3-7C$%8A%%M&WS,^)DG%0'Y$!@EOO42$./HVBW& 9-L0L4XF;!$^1454<46
M9*@C&(#&8 KHHLL)X(^4H5W?#-U3B?L-I7^$&J>DQ1+N[U*21.GS*T$-33;$
MPR7FC+M<0?7U4>JB"X^%1AFT<G*H:!H)GL6S@=YU$P#.YW\H^H*.J;:@"VB&
MY;5NY7H(I=5LR,<PG.*0ITPU P/@ 7_9,0P6X ]>T+ZXH@;A*H[CE@SD5#?\
M8.50*V4/,)TCD"V(O-P  -!1Z'QM+%E9!$9BCP(VDVV\_#EVCYHV+%*UG,3K
ML!$(PE\CJ/%TEN.2&:#'-Y;<<S-%44"O65@#2US*M2Q.I=]M6K>&_::@'#'>
M-[E.757RHE%M'R-7/ CI^\;U;SXW#6.AE-YB]&)&K2WMA^H7O3_@MJ:!O!:=
M:8;ZQ[C1S4O^NM986^)?"25UP6S?-D4(TK6@26["U4/M@'3L+%R#CF$@2]SF
MT=S$4*T[_P"X331?T'[RH#";R6/K&8%'GQ5+Y9:Z@0;554?4/E' ;Q!IDPH&
MK^J )M;6#7M48YE.09^L7 V5+0OE?(;EP_%6W4V0]TS2QTB<P!QD(/X/H'[0
M-]>0$BGJ"41L=,%Z+S$72\#%6Y5$ 'R*E98$H>^":"9&Z6J]YO63>0?S]8A6
MN$'-A7Z09NB:AN_VA2'*J+UB"1SF9@HELPS84$C?,LUQ><COEF?30E:9XE"Q
MFGGTF8WT._G!X<'ZDNZ!LZP?"\Q!FY0KR0=D.&32-G^!F2$(%5VT//7F/, ;
M$I4YU4+]Y./[R$;223@!SB+6-87C5AI0.UWU+AN09_"7[=KB"S%:-PP=U +1
M5(.L8(U>%MC&F73B+OD1V/H\! <S:.T^51$,418*\Q?DI4/<N-3 3$'B^3J>
MD)Z#'KA-TC-*&3YP)%3JN(WW,N54QI*V0=FR+GL27VT_VOCV_B(#!>XN&!,_
MB&%3X5$R=DC2V;\0J]P#?&XU9/I"\1?5[)\KF)M-B?7JU UW$<TJ/PM=$!!K
MW]I8 T0^C'4$)GGQ+JV8:?G# !S'DN75U-<H59,Q;5CFS< 5FG@S&5XEY=1N
MK31QA#>34S=)@E3A0I6"6GB$B^L7H[E]/>%*N_R@-&D[>(WA!. XJ?3\P'^!
M6JX?#@=Z[A3C;;ZNYFJ"BES<2E"R\9F^'A6DJ,(1-VI;F6$ -8I9E<"0TI&
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M-O9_:$"Z X?$'5KFC]T%]HC6?*!D% %=72Y>$G&HVHZ\2YLX.QL+\LMVL _
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M:0PQK>PW$6Z8!MEHB7@+EUWJ%[? K\*F ]2 *%6\OJ_X#:V$R,WLCL!$T<^
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M?XRTXSQA]NLO<P@"^I?TI:L>9!7,08=J[AMRE76[Y@R%MLY" "F>P1=?2$F
MS9]HR9F\JK]8E,]H\)'&FA&ZP8- EF.2\0[D!'&'=>T),7Q)GE"K6,RA&D0M
M#F/5267;RP.J@%+JTKL*;.,3#(LE+NU5+KP)9@36;E\IA9[5,N7B5:# N2F?
ME_@-K-4LC:I"9\]5;=_-G80/JD0H\5M4M2NO! >Q^D$G-4XQ51@+5GZII53O
MBKJ)"<%BRVBXOEMWN:J*EVO&"IY@\<:=RO[+P-ID1J53*9,/:.I.[J!Q:N.H
M2K+;Z$+)A^P/,MRU*)^*E&18.M0K0BEH+'NRPFY+:0,:0B,"AZHD:*XV7:E*
MYH+]/XQ47%&+CFBYK!HA:36KY@2X3P/,) -$I J2\Y(A=ZU^L!4<;JXW/7!X
M(5'R^ J"7QJ<K3*XM\3,0!&FO,-'""F@_+@4[<&%67BH'Q"XM>CS<LYX0HVP
M0NHVN^\KY2H8RSYN5]6+YO<S1X<2L8X!<5L5<V9([Z5P>2HN40K;RF!R.RN9
MDQ2V8:U*JT;>J?Y5N9[>(U!8E$* %_@1HT>I#2,"DBGH(&RW?_IK+@-L6\ /
M+]#*T!+E8&AYF]E%081;6"Y4+D@15P:6 WC+CG)Y0-;RUN-()Q_@,&N!:,!N
M+_MG6 IDS[LJJG('T?"X'V(L)\XB5=OPSSB2Y9:$;:=K%8FRT;$@2A^J,T[E
MJ[$XG-1Z85OR.8_/R,P>3(^:74L$^#N#1U>9=4NA2,TT0DX$X!,DM#1;MB/A
M W#VG4&1U.U6]=S5ZH0S\_:(55#UG;)_XI%E;V9ZWP;?A06Q_.!<N+.\J&PR
MPCM66:Q3 @,,-G51?X11D?,;"F@]I9TR6K[5QQI9Y:'F'%;Y,6:*AVF52>5.
M8A?3*KLHHK53/K1(.<W$[I7:]ON#;E<+A#F!;@XBRV7*5AD+U". K"5-/G6&
MB;2$XUNGVA 3-G$9?Y9C)@'1U=FY_N!Z?#Y\V% ?"Y&#M1;FO_1CC+4K!P&C
MPQ]0[=X)ZJ_" G)AR&CD8N#NF/@@22/#=ZW_ )'9G\CK!$ %!117]H&#-TPZ
M/1#Z0 %;>&4T>8?3(C$')?!>Y3[-2K\Q8>IAS5&@'S&G)9Q$JE,*\BTA,:8L
M$JVM!S WOD+R?JX@&2*S5K_< 9F258*IEI,C+>&I:UX+7L2ZB<:Q:A8,97G"
M].H%]94-=.[8UF6I>Z+]:_\ 8$K!$['9&CO0XSI%O.-9:N=)P<6F!I@-IF<D
M?7,3@6H:)NRL+S*?MU63@N4EIL'_ &$.,J*IG$8B)F3,4WBN8\0G&9=,VDG#
MDM3' MKZ2YF7![(]@U!KF!%N2JN,((Y2?.+=" +2\\2C/]HBF??^78SG$*;!
M>>\_,OU@C0[T!?O\![=@) R+616'H-'8QTTE;6Y!*9"7E+9EV-"%1,R_P@6,
MFY3PC02BOX9*<L,K(4;JQ?PK8DZ5G,;E*P&$/9QQ;4 63=E ' L*0#4KY>T5
M46>"G8BF#RR^JH@V+,&T\V>:)0!UR%6/1(4&!J<P$?U=HS,4Y0M;>"E\!GGJ
M('^B;*_E#;*Y%T5 Q\:@70ZNVA55*V41@]MN%7=LL7J0VB'I8Q0J"$QM$B;S
MM!RL%#X.4,>T;(<LFY6-US1N(7Q^#GBDKY'G5P>_D4$R+C9L<P,N$JP  7.#
M21H0V V!','F5R!*Y4DJ0.8C'^Z)2)BA!-$'_+B%L9PIT0\GSB$<#>]7\O(6
ME)/W)[%]Q\=L)$01$2Q,B.D>H87=T.I=K<4A:$S A2BP! L^X&U,6*'+=P64
M@%O]D'(K2 "AHM(L\+BN.2PEI8*FY\^D1A$[N<^DH*^<L>K* VC@89JBLE*J
M8BT54<MD P%:L*@X J[.SEN+JEQD6P'RE&QAT^;6I;0%6B@J$YB\LE4:1"?
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M( \%7D]^7*@E7AU$M9[,91J*%29[/74%"-+9O%GS@)=&U8:R8E/F/U5A:;@
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M>W&SD,8K&QB?[4[HA)L+'U& U9-\EZP   - 4'H3=AAIF5;=2@?(;Y9N-?2
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MN&Y=)P\W* 8L>:8&/,HSH7#-;?$%.JH=!F($'A0NO$2=K0.?AQQ$Q6P=!/E
M0X0&0<YA"E0H J75W8^JH0FKAFH[T&C3L^L+M],]6&>I:@&\OD( HH\R E^-
M*M+.YX"&/25&T]6O/^&F#0 0JZIN!+BT<P2;$6S7.YNE?D&\7*,UL\(]Y4$0
MA */:+6:N ':S%+([Y0N[CZ0[1H;-!;J'@I@\!B<ISOX:=\<L]2!&SZQXEGQ
M02.06?*G%=Q(T:J+H%KB48P;"E.3I+GD-<.&+7*P9$S2ZO<#9?#V3,YND/;"
M\I. "QL$#]BTF!=7"Y9A6:Q#:I4^JY7EX5MO" JF2P\0PWQ,,0HJIS?I12XU
M%<79,^HV5>.8UJ\V*B9=IY>GSE0$]%OQ_AEMP;]+*.>6LL"8C[S1*/,R3QEW
M-R1*B^(15: ^9F7=UQG&S40,#K8Z%I7NR8*Q8#9Q,Y+G-XZ#\!;]7T(0JB&*
MX9[;F;@BK;,2PMFAZEF8ZC(KL/248X5B]+#CF(!U$M3LQQ$.JWDA?G?<+LC"
MEYN<8]8-D@%E<C9^D2)HE*E@:=S09QAEQ46@=:O++,B.A94O_9O$6&_,84.!
MXK)=]YY>&;(6@+1 "NTS379W?-M@=O:U9U, '84M]B7)>MGI-7*A^H_PRW#[
M5UA!_*#O3=#,MAP)?JFH#NO%Y/6(XRZR?E+_ %,5]X(!&H&L_P!$O%:BG<%&
M'&N=PRSKDX2/X>2--$3&_H5<V% -H-=PB"4[AY9@+5[:-'!N9AR2EBO.V(S(
MQD+=L&YA6..L^LVQ1X,$M@(?P0S'#M%MR,E3+\YU9._26.D6J7A-*B,?VX =
M$LT<451#T7-[-WZQC@+L;?$:##@$8TC\XRVFN!6G'B5 6:6^;FGFD#VL"LSY
M/SF'3*B@M#M#/^&V#\ $_6E#'$**&P,)/PKI?K@)0)>.*].YA J&0^I% =3$
MM6^,R\/@D@XVU$AXN*Y*U?*.P+.L&&!ED3('/7$#@C0ONX^D9[4F^9G,KMD[
M9E6VZN$L4MD[L_25^&JP*\6_-0U?>9,W+WU+Z=!B#]U?>)?SE]:S\=G/'QJ
M17!!ZR,/,,$\*W<!0,(X/O@F.34&S!DT.9?YM,^1"8P(&!7<$P=U#>DR.LW&
MF#(;ZOKQ'+ 3=>T.2[(^3_$+,O*3)LN'SF#M#9[L$]$/HZ2'\@>$T+!XN.8Y
M^U@K'M!H!L.A5RPMVLA#@+Z@&'#-N[A.V$.DBA;T%E.@2[X5E;44&\RAE@3R
M89BJYJ$O-3K0'-MSU ^DHNB8"SMZOE*R]J&X\$Q[3*7[7?@+XB[.KALI9M]Y
M=<8EGH$M1H+SEX\;E[M0:;8?2&I2RR-U3?!LF#&P'=D&ZWP#_B%GQLZUY:8$
MO5&JO3!B +-1IP\%TX/5F<7XIN79U+G(WD?$% B8E+*TQM;;.%<Z=0BO:.^:
MP0"@O%<I&4H:CG;46\!1H:/@>PA@:O,N$%&6:(@KV!]E1&J_Y'3F"&)=VS=0
M6=@@).U7<"@M*T]YFXP%10171^@M7DRYNN&P%):H" RQES&+T'3M\3PD"+L]
M8 8,'1_B)D6>KE/-]1+6EI[HBLJ!P+#W@'=*S5YX;!WJ#;@7>W8_69?E:\$L
M?4()D!4%L_>:_P"2B<D.ZW:>L JVTG&+^!E:+3TA6V+CT:F;?KA_:H R!XGD
M2I;U:,+G%*<J5UJ/N-(M6%2I49JX@U'N#FHQLS$W+L6#2!(*P?XC:EL]L*M_
M2-E-Y"^XNJ */T)L"#0!$][EB0-=R\O5RDT ]QLE;6 6J;B7=$0/1686^IX%
M3;-3AIXS-Z$-KT5$J%8:[BODB:WHBMOR(2\@'2&7'+[2R*]60U4V89B@.YFV
M;-)FKF+3=D*ESWNA0I<8\J9,TR_/X>ZZQ/$T2C_$C5*#YD'9F[!V"JM55+')
MKX>K9T5?K4>:2[R^\6LMOD_>(NX)4?6+6IQ9!UA0J)?."&B'*=RT.)X!- (6
M9MF6M1&4?8<PE>IADRKSBZ^-)=-!T05]%M#+#)908E[M,#.%@<]OZD/\4,'A
M/M.$>KF?_P "9,4K'K,M?IY]6T."XMZLM0$$<\U.PD0:-X\^\'XKI8:NZF/G
M@C<R#=9GL#E_T0?,4"@;7K&M?#RDTK\T_@ K$T-I<,JS]TXY&]H4MG8&VD-9
M8E1:P'F#8)IR?RQWDHA\U"66!W@O6N?B.'7#HO8OA^^&3*@,LF:)6K_@X.ZO
M_/(W%MBP'2H!(W9A[0$P  H T!\.3+^''_D,EKDTM*H./$-[F)D:^8()ZD[\
M4LQF;;M]^G^62X@2?EIQA@^Z?L\^L![U^#O>"7-O37!?7P-X0*:8 BF@$A_P
MYD!IIE^6XZZ!H8)Z\P_TY"OEMY\<0-SHO/?,PF"?04?XVNU(?8QN5U%5NB)3
M%E ^8S*;&WL;Y^D 3&2=JWG_ /:(<O(K8@@-U"199!5 41!T:U)?/Q*93-83
MNNP$$"_A&8/E#[4)>1(J;4< V*8LL/\ '*7[IE5JLL PB$JFR5"8#NQZ5^;J
MN\5E5KP5?,H"@@=] (!\[Y15E!>G_$] 8H?;R_"FTL0%EJ32%Z#JF32Q67 6
MLUNE&=K(W%"",! +^Z#J#5V1=PE_K0+G@E?+!676A<XIP%2N)CH*/#K L B!
MI,D$!M@:&W.5A!F_C@P I4E]R'K;!#%._C+]JQ$%&-5@X,76@$="/6K[E?'?
M?\&GRV *O*\  "L^HDK<=A@ Q:6,7 &Z*B/'()X8.XH3W=<YL0;)'@*EM5;V
M/F,Z[:V0:G+)$_Q&**R('DZV 6E!!I)SJD-50%)&R3#L9C*Q)TXY2-X,![V9
M5#251Q<(4@*=6(B\1#P  $%"> F4F.06O8E_M>IRIV/)BOA'H.$+1WH/:K5S
M4Q\(/]2@XM\OX)90EN3G/'U@ F.90]U9-6HKD24JD0?^N^1P-#@ '\-/EPC@
MO?O/T:G+>0WS/G*%A9Z&3(&C61'X,*#V,>HA,R9_AND4E*+MJ^DB+2NY1'M_
MQ*]F&JJ4-@(.:.C+=&95[>RD'VT*&;-/@6]K[%:O'-)J$UU7'#$V>,)T8VBX
M&@FU:7U<B/N(L#&1.(9'<M=%;MBT($P8J$^)TEZR]DJ:*S$"Y ,((O0V6AF[
MC^%0Z?*B#B^F4[11JKZ%C$6*&6&D>E'-0U038K(=4WH3('O@*QI<N='1UX"S
M7!X&P%-@ZKS7 S5 +5H.D?\ $9:H*18U^)<5^T(!9"("3N52:-[C"4H#75JB
MX&\NBU-4^G)4Y3:[+8@=4P#G=L=YX26II0"@*M=[63%D*%JI1O&9%*"YZ0=R
M&!"<E""5& OI14A QU(FV(H+U+[$LW@/-W"4'.B#4QEILP@$.P%9Y;<LRO@5
M+J"$J%EI8Y0B5+7G34 OHD-,UX8J<,-#SU^%$!3PF";F8Y5"PK=!/:;%T6CR
MHV]( :SBU0.2+)N82A8/7BF(2[4F&S8):&H]12 ;2##^T4R-C.N1U;A&*5%H
M\!:D': 40F=XVY6_Q&%K.Z7Q\YD?.,45X.R-2AP9K4@!FX(AK6U#RP<H*2PE
M( N#P,+?=<RN^FPE3JPN@4HKXXOD/;*M[W!!:DU5+UJM]UH!MQJ*S?R#Y80H
M5^JY*V>'?U<$:N0\P8B4UXVT!0-M/&[FAL^6)6M%S5&]O;KV3%FJGX"M7!"=
M.P"<MV3VC7(K6HK\:B]VSN!Z0(+08$ZG'H]@4YZ F5<7X>@LK] !PR/2FL;7
MZ!IV17^*2_%U!QFA3:8A!K#M3O&5K>EGF5,QHJPF':OQ("18'7M.7:Q"C/\
M]4/_V@ , P$  @ #    $
M
M
M
M
M
M
M                                        $
M
M             /I)@
M                                               S[L
M                                            !O$@
M                    ->7.@
M                  [M(                                 B7;("!
M                                                  *&5[0
M                       .\(@+A]SHKV
M                     !6$N:A^                            ) 5F
M_%VL  !P                                               7T0W
MLN !2                        ! +\^TB7"IV\
M                            *<D71&(84W<
M   !7C]H!/3<^%0
M !FNE5MGGCTW0                       !1Q&.O,VO&>&0
M                                   "5CM6 5W\!L
M          <H3%@Q[C VLT
M        (?XIQ"Y\#OU                        !0ZZW= J_R<$B
M                                          S*.4(E2T.>RX
M                !/'B^9(]W)Z@0^
M              !"C*C)Z.WV2$[0                      !,/KIOE-5>
M _VF                                           !$5A"QS;2;!YA
ML                        %:A-F@$P@ER=2
M                     #6*W4B$:%*-/"                         U
M) !$.LQ= RGN                                          %^^BMR
MHP0&JA8                         !? *#):/,QW_ &S@
M                            +#XV9BD8*P1A:
M      3>SY)39P*FF5N H
M *=.Q/LP.9(+06T                        2N*+F##.FPRU$W%
M                                  "/9V4FACB2RKY_H
M            !H;L*B0Y''=PGC%@
M        <]^F56K_ *E1F&9)                       'KAI=ZVV\D6:9
M^C                                         ":I'S.2[HGO\ =K!
M                      /?; -EN/MS  _A70
M                  .NV]<!X!Z:ZPQB&                      $K3%=
M"-22#Y7GS B                                        %9_#KW;_0
M/.GL#I                       \_QT>:>#E%:&]P,0
M                         GSQ'N2G^>BU58%W0
M  )Y76:>]<S9B/;B4:                                        .-
M@5;N7.#5VQ![H2                      9HRWS1!Z&3)Y)M#0
M                               !";^$(^*TTI6C[@TP
M          4T $'>)95$O.!7P
M     (?5W R5_;[(4/J9.                      ,:*[_ "EK=M80@
M                                        (]O'/P/[DHG,,CL
M                 #]K7V"7+#>82"@
M              9P# 5OJS7)@'HV,                      #\=U\[LHK
M1<TB                                              =YL&_\;XYS
MXE                      !%I4&#O\B3XH&H
M                       +#/DX8(&R?(F)@                     )V
M"-K5EK' 26F                                   1   /@    !42_
MF4 "LE?L >                    22]P2C.RV-?[.D@             (
M  (    #%_@U       #P!4 <     9?D/H_5P#5O=>P
M   "4/)G_%%?0X %]@  >T<7       !@< *@    %]HLI&;8 #-CV"$ !
M    -Q*P?XX^N3$5T$                   8*RJ%K@K), 8'4  ('\OK?9
M@ .\-<!WA;D    L MY>L:R!%]DP;: ,X     ,'^\W6+7H,<%R\
M           #CW* )&/J,2BG  ! %D[!K?8 'TR#[0*<@   %@&O$ $ 4))#
M>".8#Y@    1HM]$,*< 'XLX2                    DO*8T!O]P!L
M( TXH @4 ?ZX,1+E4<    N%%G 7OI :;J1+;,(0    "1[KH&EJ9^Y-"((
M                  !Z+V6X0K,@     ! KE\@&,< =F2"#"H2@   )\P0K
MH!!$8@#N1@,J1     #:G4E982!]42LX                    !47\>^AC
ML      --A<+@((@7]$?, O,(          G                    ",6T
MB:XR<                     "'(.P*22            1\
M       !0@                   "2N#C!79B
M0=Q;%XUP           +<
M   ;G3R'_P!U                        !0/'2\
M                                      1;WH]]QH
M         $+[)A4
M            JO\ "'D                     >  !V,UH@
M                                               (KI=IF
M             >X0 -[RKQ
M                     !RY'80                   -XT/#>1,+
M                                                       #V=9&
M@ ,-@               F-V&U+:90
M                             /5\SEQI7!@             #C^771NO
M+RD
M  !O$>;MN2<D             .J7Z2WPH/!0,
M                                    %*Q+S^5A8M             %
M1BDC\)]6GT<
M        ,*H48S4J\T?0P           $?VD@S8OY0%M@
M                                          <V'+9%1B2WK@
M      !4N3'\^5.#.P
M               'IF5)?%L55L<P            (M66+$,/V)$
M                                                 AKN*_#-"'M:
M@             -L^:3[>46)\
M                      !2SH<T_CJR_0            !24T/BQ(K-2JP
M                                                        !N@3
MV.6WK,             /G%-I&T;O'Z@,
M                             /73F]@E--7:5           NZ]N"SJ<
M!R4)<0
M   QD:-.$82N4/I@         '1"Q4=ST7^,#@J@
M                                    .SZ:]&;]6 I%)P        ($
M-*P\R2\-.87WH
M         ,QDKR*(H',.Y8W        !I;DG( JIYR8V:)$
M                                          !O!XHX?%@=TB?%L@
M     0U5<Y_BRBDZ>MK7@
M                "O.T_4W- CY[H(B       %%Y?M"':SY"5BM61P
M                                                 !3]+Y*BS#R4
MS:L=<      !'D!<JK;4V: ]]'_\
M                      !7"YAU"8E5(@,FR2P      ,<FBNTK#K7;=I&V
M#0                                          !L  -0      JL3B
M-DS]VUNYZH$8      (N.G&-9)+IL"\(X@@             !L   0
M      #A1]^0      #@-1.      )"3(3]62W>'F9>)#@     &L4Z9 Q(&
M"-L[X*9   &L0!40      #@-1J             1F6Z*#&  '1/L#8![
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M   -_KW4YPDZ#]:0EY?EJ   &5\%'2IP  _@'K9,D)0           96G0(
M4V \E/7^!8?F      +YT\'S)&CT2@NGNK   -N-M?%F;V7K< _P.<0   3L
M!@2@4" \]/7^!8PH                +S                 /1UGCC)H8
MT2-O(@6OP  #) ==G6AN^5&(0 #H        +S
M     !WL                 #@Y,M&F=;50K$>P%(P +P%"5M7I=Z%*&OP
M         !WL                                               8
MX ,QZ]KJ")F786P<  "Q*V)*^'J_F=)_
M                                 @ '-174MK/%?94%)@  #44=]U+-
M\W:*7@
M        %MU1(51,(Q,4FR0  %N>\A4W&;D)KIX
M                                          F^N*7R8GG^LX#"  !>
M%9- "WX(W.E
M               !M.2UP-S,EZ$4 0)*X/)>1_)SP.:VX
M                                                  (>NG;GL$D@
M:TU!"8!!CB'&48   <
M                       !(>V\)O0[.;O8 () !E! \[L
M                                                          Q(
M  (5%AFK+#0 4@"! (XT
M                                   !(\*.)T:0;)TG
M
M          &I@  \3*)()1)
M                                          ( KP  #5R )! )
M
M               (      /V )! ))
M                                               )!(     ()(!(
M !)(
M                     )))    ! )!) ))! )
M                                                        !(
M ) )( ! ))) !
M                            !)   )  ! (()!)! ((
M
M!  !)(!!)   )!!) (!
M                                 !))!!) !!!!! (!!( )(
M
M     !( !!!!!  ( !(!(  (!
M                                       (! ))((!(()! !) !!  )
M(
M             !  )( !!! )  ! !!)!)(!
M                                                  )(( ()(!)
M )) ) )!
M                 !( )) !(! !(( )()() !( )!!(
M                                                  !! )!!)  !
M))   !(!) )!!!!) )
M                        )!(())! !! !     ! !!(!) !
M                                                         ())
M !!) ()!)! !)) (( ! ))(!(
M                               (! !) (!!( (  )! ))! () (()(
M
M    ))!(!(!)!) )( !( )(! ())!))
M                                     !!))(((! )(!!  ! (( )!(
M()! )
M          ! (! ))))((()   !()( )  )(!!)
M                                             !())( )!((!
M!! )))))!! )
M                 !()(! ())) ((    ))(((!) !()(
M                                                      !!!  (
M!)(     !)!(!!)(!()(           !     !)!
M                         () ) (!((!)(   !(!! ()(  (((
M   ()(                                                     (
M )!)) (!!       !(! !!(())          !  )) !())(! !)  ))!(
M                                 !(!)!!!)!       !  () (()
M          ))! ) ((   )(! (!!)
M      ( (((!((((        )((!( !((          ! !    !(  ))) !
M( (                                     )!))(( )         )((
M!( )()           ( !!  ))   ( ((! !)
M             ()!) !! )        !((!!!())(          !  ()( )!
M( !)  ()(                                     !()(   (  (
M    )((!! ()(
M                    ! (  ! ()) !   !!!) )!(  !)
M                                                     !) )! !
M  (!)  ! )()  !() ()(
M                            ) ())) (  (  !(!)  !) ! (!    2'
M       !!       )
M  (()(( )(!!!!) ))()(!((  (    (0X       )        (
M                                  !(!( !)!( ( ( !()!() !!(!)
M              ! ( !!!( !!))((
M        )( )(( !!() !  !()  (  !                 )!!(!(!  ()
M                                         !(!(()( ()(! )!!()
M))!!)(!               !  (!( ( !  ((
M               )) ) ((  ))  () !( ! !!! (               )!!
M(!    !!!                                        (!  !))! !!
M!))!!! !)((!!(              ! )( (!((! )!!
M                      (!))  !)!!))!    ( )()!!!(
M                                                       !  !(
M ((!! (!()! )  !!))!
M                               (((()! !)!  ((! ())  )(
M
M   ! ( (   !)  ()!()!) (((                 !     )      (
M                                      !(!!(() (    !(()) !!(
M!                (           (
M          ! !!)!)((   !) !(! ) ) (                ! )!(  !
M!!(                                           ()!!((! ))() )
M )(!(!(               !   (!) )  ) !
M                    ()()( !( )!((!) (  !                 !
M) )     ))                                            !!(
M) !) (((! !!)!                (( (!(((!  )((
M                           !(  )((!(! !) ))!( !
M    !!(   ) !(())
M  ( ))))()!! )!!!(
M                                   )!!  ))((!)(  )(
M
M       ((!!() () (!(  ((
M                                        !()  !(!)()(   ( (
M
M               ! (((()!!  (!(((
M                                                  ! (!!(
M)  (
M                         ))! ) !( ( ((
M                                                          !
M)( (!)(!( (
M                               !( !)! !) ( (
M
M     ( !!!!!  )
M                                       !)()!   ()(
M)ZD
M             !        !          !-4
M                                                     !(
M
M                           )(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M ()
M                                  !!)
M
M ((  ! !( ))(
M                                 !(!( ( (!   ((
M
M         ( !(! (!(!!
M                                        !!!(!!(()!! ((
M
M              (!!  ! ( ( ))
M
M
M
M
M
M
M
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MWW<4)J(+D>SOGC?E/"PB69FK%]Y^O4Z2E3<3%692[XU;63S\P^?BM%R#]?\
M7!$<1OPG@SQZZ0E&&Y8JI/7' &D!/\>?RX=4XE,^3%$2,Q#$]YT56HBUN1SL
M87?HU$EP9G*YR<SMC)N1X P(D4MMA!O45.0U( A]4W,5G<WB8D-!(I3+-G*1
M&<[]3.H!NS SF/'._6VB%%#'DHGG$D/I<Z<I@&2EMA5S =<\Z@6$FMI[BG-<
M20[""7E([\[5?<][BH1!3MN"8J+EF^V%1[I/4X:)O[U$BA(H() E.H5VSA\
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MA N<4A;S15R$PQ=:!1(2$ZRJYYWLPSI90"13C'K&'.L ("MX8]ZN]\FA(JX
MRGM=1O@Y=(T(N,VI7O6[6]7HB86>A/R^5 ]-'!CI\9GNXXD(=)##U0;3/B.*
MNH LI28F_H5S\IPX64FDPP-#+)55E]]%+(H39:1E''D#RZ$L6"()M'WD=.6D
M&<&5NX221O6G*)^1ZC9C^,5I:0)?S@VC;]]!"%QP4U9;[D[&)TW,2YGM_/.)
M:_R>#X?IJ1M1<_.[AQ7$3LHCB:FC[^N-L2ZB:4;"SE.,D20[WG23 6 /?%R?
M7K4'8" )QO&_CLXU-WA29QAF+,1S)).I04-/!KBB'F+8?%H1,8"XIDP$[S Q
M,PSHYES$S%PL.&_I%Q(L,K%)[%KTS$1L(\ (97F[O;U&8LLR\$;3QG>J*(B*
MTE,&!,8YRD1Q.E$+B?Q8"?PXU,C$)OB*]RV#ZQHMO@A-F)MC!58M(C0 #,,M
MUS'[Q&DEB1]7U3VC-Z 2."(G8YOMFFI)-&U)F.I]&IYV@JK*H4D]YE7$T$05
M%;R.F09B@]($WS+#)S6G*18<9BE,$8SRV>&0+)ZYWKGY2K8T(DF/]6G1P_1^
M\8T%E<R%8F1K,BGO'>I*0J1!B/4MKT.9JJG8?4HJ"5/F-M,IR,QUCTF4\EP,
ME*8I-BA V-G3/=:G<$IC$/$ '59YTR-6O3&8>7N9\NE11F1<^>9B)V?;4V44
MM^,2!,UL-FE1 LA'L;BO6&C%8=I12=RW:\'[%+HY)M)%!O'I<=YK4*Q^REX]
M6$VS$83"14X[[OO&CEU"+M8;XF?/52(&$B PU81^WW,:4UL3CHG&V-O&G )&
M)*AD9WWQ@!TDUHT9V(&SE7$]:L>C@34 IX,X/?5Q+HZVF^\[S3OI9L*S;7[8
M^^34:!G>]FMC8^=\_P"4QIU(B2L&V<3UOI+@A+6=]J?')$C6H$G:(VS;B)8)
M\2Y@)#%C*F-GM\7BXT;0!5"(,U[3L^72V2)R?"5B-TXM#.IZK&"%&(KOFIA@
MV%@S-24LS)SM8X<$Y-I#@;YXFG&.=,8@[V6*&(GNENHNB5/H<Q@KAE'<<L:R
MP#",L73:*^LX&@0L-FZGDCC&)QH5 ,AB?.''CO1[@Y91&IK>6/1IJ=!49A#(
MI9T7S\Q!K<#YQ+XECN]5# 1!$RQ)VT[X#>M1*'.1A)GCULHC&A$"@H)A=LN>
M)BXTAFWA<9VWVH4BJ-1PB,2OG,;E7W[: 1P<Q$"IN?:9GK5#5]43Q?B#@VC"
M;2WLVGQ1MF288O2B)(K#U$[WOZU4UH9!Y)_U06S&)'S?DC#XF<2XR$;Q Q@6
M.<WI \B$;N:^PWMJ:"SV YB\HC>\W9.G 3'S]/R^#4Y#-^<)/$YLW.V)P30E
M*2??G;C+8L$0>N:FKXCOT:V )<F&!<CXJ'@T225&)*D=JW"''&H9.R3'!W$]
M'O6BT0UM41R7/SOHR,(29J?3XGN(#4E!"U>I\B[2:F@P-PW QPKCS,8*,HMX
MP.\XRMY-1"D?LG&,^N(=)![6U9=B9)>/C.44,VP/HST346XS&C=@9B%:D7N!
M@QW,&H+JS+J8(6XWVC?;1)2D$\_7C/$]Z1B*)^F6#,_$<$1VC>F>9,<S51F&
M(&W^4%)HS#$^IW][X$5**R7,F*ME-YR742B%OCUY*].YCDTJ%&@DM(.8;/KY
MTB\( 1+$W#C.T-D<UHPMJ@!HO@Q4\9Z=)ER!Q"<43D.3,&A,9HK*>ML08;F9
M'2+ O/H[LX]GUC602&8+VOT?ODSK)W&9")KYXN3G.A"0U?>_Q[5'!+$H59ES
M @Y6DP7M4Z=,3(P152XS.^*WQJ/#1(Q<UMB\S\1,WF 9ACG!6<]>M:O9"8GG
MO,]UZ[%)@JFQ"-R!BF2.-()#@@F)>PN9+W[TZ00D0\3QQ.T\RZ@Y>!-_S8/A
M>0=2DPN<XG3F*Q-^/I ^ TPLD;&W#X6<\\)HA7MU19WYT*MG,,,3$S=RLW!>
M2#3P%QAF=YV(W):[7HH3F#Z'YWG_ %,Q%K4FW-9DAG^S5\YY]H)]O)$SJ)(6
MF(VKZ;;$3I65!=XQ#&U,,3,\23IR!H>2')#G\K<<AK9-_5;)*SS&CFP2+)6?
M@XN,=Z&*0G!F!L<,7$2[AI.<7V9J(=CC=BYTBV04$S%XQ%Q=<'$NDUR2(ODV
MB:SUIC#!CS<A&+>Y(U*FB8'>L_'HN(K )(,1X5_:6:0!%$J8(G%L+LL$SI!$
MB!Y6RGD%/I&I8DD=I@WFY<V,PWHY2]AN>7-SB^N "R6)S<HP[@?:ZTV( (+#
M.!K;A[B\:5;,%.P_@S.7?(%QF"HOX]';>+UR@--DKLAF.IC:=.Z+FOC&8NM$
M]58Z5$U'BIV.A (R/^3HBUF8AP?/S6<Q:M25YF9[CU*@TQ(0[0_0_MC.BR7)
M;U?\[RG;I3RE6"-;$/;$KZ\DLH+&=GUPOOB#A-O,CI0\*5$L;=(H2P=K.,.W
M459H,5LA& E3F84K+/.J2Q1->O?B<Z819A82;"8)CY[R;@D-S%Q&V9X)\7Z:
M K;*BXCCJ/9]-*&999>XOGKOATS6%;)LXJOV#9SI;)*$VI@8]//OH:P )P$7
M\0^">.="BY_*]\[5O:*0'*.XWZ=\<R5I<D6RV9E2.,Y.=6; R,7&X6ME<&]M
M0-))+9+<$8BDP^-*0A=XWWEEJTNG;4D!DFJF3[=5"CR<1(=RA(8AG>/;5Y7/
M/']O;O.D!$KO'TSOMR1&B O4[YW.L[7.-8_U)J!C;WTTLN_(5)>-KCBVVDS)
MC+O!#E<,Y!F.=7!PO<?N1,>-.%(N5]/:U)RD8H24WWP;>?KQHT_-G\CSMJ!'
M1'5P^,?-ZR2Z6?69C:I_!<THCY"7//<71>G(1$^"Q)YP8>7)0!:"XM(QW]4]
M6?",J&<M<N?%Z;4@B1S7S 8B2ZBP40FS#YGVB3SG1@6ADY=^XN8WZO1,MAG]
M^\R<-YTB++FT@=2R\1/)HU#3&!CG9^USET+(+8 VCG.,S6Y#.F(+$HFT56Y#
M&"R*AB5D* ALJ@V&7;>^M!1 Q+>_I-[Y9YK4EBF O$+:CS*;G-Z0TN*8:7\)
MQXIG4!59B+6B.%O/Y&@PD@PRA0P[GPGOJ1%)D\,?AYVB?\@*&80\N-*ZIDCB
M/F<CE;T 8U 0$H40DR$[5PXT9AA "I]?<-SNM-EE,9K?\^FC**)C,>D.\A)&
M=#G-J)[JIM G!O=N@H2 Z;S!R$%HQ/&H$$X25*?6\9)WT1$)(A<$(S!<3[^V
M@V3"GQ+.WCD\Z&"+)+7EN]7'PZ01523<4[SQUZYSG$6+5F2,5'!XV=6F223G
M>VIMX\SHI3N][@Y82]Y<KII)R"I"3$*QL^U;1IY)/9O[O3)CK2$BR(5-9O+B
M*@@C??3D&HDQE\>U]9T T?5U'BCXW=$!R!H$T7J/%3S+H@Y@P[S%M_MF+C0C
M:\+QUB+?N[FCH;#$D[R'#OF7<C3C:%Q\=F,[V3>J'(FZWB>XC%YZTUH2ZF_/
M48#[Y$21D_U.:Y:04&^(K/M<=92KU#MY[]V:\Z@,QB[O*UM^;[-9)?/I[Q6^
MV5TK@>[C>HC>OMO!HE"@3:BO5(/$=SJD2 6D31P/'6-053K#).,"$IOF(U"@
M;(4J17-8)] TG9K6#CJ0BXSOEEA)BEZ:F(\>?G3-T2Q AN$D/JP2WQI9(-3O
MU@8]=EZO4B*@*Q4^WF,1&(T!HB"NJG>YKFX1VTW4L'5UUT^O%Z@6X'S7OUOU
MJ 56&,;^^=_1O2$-@7.(CJYA BZ]-4T8ILVS(WTQF<[:E(RCB><7DN=I-#Z(
MR8O^<3MO.D&1$87UJ*[S-5>CL\HFTVQ;?K-->1DA$I"2;S&_IOS[BD2/;7'F
M8^&8S:G5 8+>)^.<0=4""1$Z9_R" #>GCS'4I&]FHAR"#@FP=/5.VI"F9B)3
M+EX,++;M&IB63G!UO6:BO,RUM&)FPCUCZPQ44Q#M*)B&/FG^9T@J<(5/QVW9
MB#!"W%%)N;CJNXWVBYZ@IDP4#%F_K;C BE;YZGBH<UI0HX$XOT@O\V1&U3&?
M<BIX^FDG.+;9EQQ4<IG%[C1Z1,1WMSC'0MQL?7T=U0W\.#0J)MC,V1BML,-:
M$Y.1*Y+WV\3CG2.R*;^?+7O+&82D<H%;5Q5DYR0%3>,H7N>8WX2IN$U('BXS
MO.(L\Y@'&HH[PJ..>/S%.E0*"!%HJ)K)]"B0TNA J#YEDCVE.#2][S<<05"=
M;1F"M3O'J=J?W?5QI5B;;GB2+C9KVK&AL@W:.O>MO4'.DIE_?\\?ZHC(9G;Y
MT \Q](N+S>=[Q#J&$L<98%(]3$S68#40,+O=1(RNU3/S6@A%<V*SGTSXQ1I.
M%I<8GK%>L>VAD#GQ.R7%MGEP$*SG5%5,$5:QC  NHPQ98O:UG@^X9TD@@"B]
MA%^\YZ(J $3?I'QG>S]M2BYXCI@@_;GDA&)9VP#9XSC2";L;"HU':;8??4S-
MS%;1BLN#.(8XTY!<(3L[.S&<-IH1@A<6F]IP_OOI4I,2J'@9GMKHQH2$S(QV
M)]UZ-0_ 3)"(7<E*<-^K-P-B[3,2YLQC[&B$\"TD^L?$[>5E A'&4-]3QF^W
M)JX=YE9.X(HK DUQ&@@^+].)ZSC&F\$&F[-\X[X_>6M:M]I,R=3.(;T?7J5Q
MQ=+,T];D:+!Y_P >K($)CC/&\#,N$9=6JS!9YAD^FZ2SOHA\_B[S<7SRZ+KL
MXPQUC/?QIR6+"U#X9@,F9;N-&5J%E@K/SQL[:,!<,.*1AH\3,;3+J2,F%6(S
M?Q>&/,ZEC+&1C%;[<T&30*ID2B@UB90.<JTJNLHVSOB_&W,X*8B&84Q[.)>J
MWVK,Z9F6%;,S!*$^:QQ>B#,@HD'B8=UC<"FG60[7UYY[_BM6H49Q*[;5/QC&
MH11+,$8DFMH!/[-#8@V<8<\<^7;C0-MEANR(BHVCR6;P)%0558.?&Q/.K!9\
M[;YV\U%/< +*JF:B=L1>H8#NJ-K)R1/]M1TX2)2>#&;KBL:$I (LXP3!@+>(
MR3!J[8(@FY;+R2$XH>-14GN&LLQOM\3D )J&_/\ 8:=0+,9Q'K@,]9QH9!Y)
M_P!3DN48Q^?UI&4DJ^O?/=>J[2&@NHPLOF.O.ZFP3BX1YR2W)-3Q;IX.<)"X
M@.<..7B:T00Q)<C'NM767XG4:HB0@OVY)DX?<HA.Y@MB3PN]UYT$JV9Q:3AC
M:O2[WTT"8G;Z<S&P1@U-V02WYD6O:/C4HBN?F98EY;O8K4<-K/;TQ)@3-DN!
M-!B%R;SG;KT6HH4);)^5\.*\:>9!:BX^,W42V>R"O*7O>KB7:GREK F3BN?G
M'@]M1 YQ$QU?$WJ%*(.KNK7-<F I@-*S(A&)&8=RXSAEK;1!(R"\3QV<LD>=
M31W3VO)%_07&K\)220O>KC<^@L:')Y.9*\Y-BC&'4ID+B6#Y=R7TG$8A<DI"
M%\\\Q#.>2YK*$BZNW<QDVSG%P'1\?3CZ_P"."H,Q7G420D,3V>E[8CM*%G9+
M )J8G9JF.J3%Z55.!R!,^V\%)<UHUBT3O$!W$3'P: 0L6SS<N9@"JEQG1[R$
M#%S$2!O!%GGC602^Z5FQCLB0B^8 8F6V,D;^#LSB=8BA#$XKT...U=0A$D3,
M$W"U=9<HW-MZ!25%PCQG=X2I\$0XB[;,OE2;(:XG4J277NF9FRXXKQJ?%J!2
MU#FN*>KJHUX9EC9@NY@NR8[YF"%DN-X5#&*G&.]8$0&-V,[<K4[XDTAD$[O>
M?2<W89)=(28^D^-DSBGJ-)& B2H+[2.8^-M9S;,Y]&[=L]QQI&1$1SYG)Y\1
MJ "9!&""0O M[U"W>GBUH1L1G$$#WSG!9(DFP-^.)J)?%@8J)996-WD@%/J"
MZB0EN?;J-^(TRQVELYF(]F<9U#M%IB'+GWVGQI2'M_J6-788,QWWFN9\&H2%
M.STYS3$7$#!4:(!*W=\0OGO4;1E2,%*W%W$5J D S<V)OEX_8=*3%Q$6-Y")
MSZUOC1*2A3+-R8>)]=H(U1&:/?>O,UB\DZ)120K%BPU?/[SI%D*82:J63M'#
MM(TYU( ;1OF5PL6VKQ*3B9/.0GZNI'9%1S<2D[X"-L8-2H)4RT0X+,5;MXJ#
M*,%"3MQ/W]=/F@2XEXF\3U?EU @5 )D*)<M8E.])#.(CF /.T631,Z<8)@);
M/WG$T]["8%(@M<OG93Q$0RQHAC=8D=W?IN/&=5%& )^;SYX9T2G*#'N]X\';
MIF!!RZD8#>;J8+"5F93J#89@C<IYWAD9F8$U%)'M$//I94I185J'*8GP^GB=
M#$$B^B/I'KT,Z%09I8GS]G\G_'09F*N'WV?V=(LD)5??,S&P]Q:NE,2LVN)R
M9ZV]J-2Q"0O>@L/BXBH722S!QLN(KO/@FS1C$KB-^=_=[XTB>%H#9.%7,9]R
M]QQ&:#M>(CC=XXT\%Q9ZDV9P;D1\FF%" PB\3>2G%F QINH&,"\_#X^AJ&".
MQ*:P_P Y3-8OBR I&();>2WW,Z:8(4@5#4+41RS=Q/"K7FWGZ</GG44]\.-N
M-YQ3UPO[*_NO<%QE35,/%9,Q9_4X8G5!L3\YPE$UU?H#"P=0'BMYVF[U!;[O
MX?R-0"+,[7[S\^I<Z?NF9SC$[Q$X3F:#5!+  L*WP@E[\E<@ !M5QS_/Y)CF
M"7D6)O%1'*SXU/0"TN3;CBSF2628*5<,Q.:D9]9*J'0C#AQ<<QG:8]]&Q6%[
MVG[5YG6!X_U)PGKQK(AO.Y,\M=J.]9TQ(L6/:9GWK4(!A##BU&:[O]Y6"P0(
M!)9"9$?,PCSI2P*Q%R,W#U9! X[&0)>4='<;[+[2-0:.(4 WVGFZ<\Z<\* X
M*(ZQZ[9K2\"WUCKSYG+G2;C$^YB;-_KXSY7NM[L[;YASJ61C>7T??KU*'18@
MR.TX6/9JL56HPJ8%VR?;%NV\Z:EJ+;SU-8W3N3;4Z(2"0/<RO-/WK4:)HKA?
M,8"?QRCNXK\?[=J$TERHF>&2;:=OI)JP+1OD05A]I-RZ0I A13#F(#)>\S*3
M R$6(B,ED..=D7>3<T+%$01>PD^T7R>-"8% 3F1;_<U*0Z<:89"X#$;Y,;7+
M*:+# $ 2DS"#B-MIB[D++Q49IBG,%;W>^H 6JB9Q!WMD4K@9TT*=";%H[\U6
MSBM&"<P3_C56./?S3/1YT+I.4Q23<3(3FCTF:"IB+$+NM?3^^365D"A<I5EV
MM]6KA38DC$19-OAB\=CH 02BQ2U3$N",Y]DLAEB$AAI]PJ=[*D@8'$L=09/3
M^=@ *@#W/V8WYSJ,@T$"FY-L4G>9Q6A) +;'\;N<^-3RAD(9"MKWNJFZQI46
MA&$L,\#</O.R*X]F/=-3B2XCEC3DAL]^,"2G"5J;P 7H<7?E_FXE_'98>,;&
MA083K:CEFO4<<J$6^^"S+/WG!C2S:+Y!DYD>?[O2")&F&"Z#^8R1YU$?MOMG
M0**GB;/3'KS[U(C=9B:^L]$[!HR4,8FT.F$XZWAV7 +!9"4&'N'W:U% + RZ
MW",\QR1.MVZLC-;54OUEU.4)"/8[8]I_@0%[?G@Q[:,'@_U))!:D:5/,=^MZ
M[EH.*^/SSJ,EH!]#(UZQEYSI5F"Q#;K+!M<QF--8&%MBC<Y.(@CDTUR"1Z+C
M9:D]);+0XBD)C 99=H*%%9Z-(ZGH5$1',<5Q>K\1FXC\QS._$0.8!]8^WYQB
M(%HAL_6Q>3C.H*4.W[]\)/"1$.0QB0^6]_3U-2)3>+D/1\5->9-<X$%?-GS.
M8F)=&,V866SNE(WCN;U!( V6KBTSF39QX!J<,*9?F.L0Y\O6,7'#YE8SFSWE
MX5U*VPG.'WQW,'"B/L)29\F^2I6'.B>7C]:G:,]@(4))<1?S!$7-/6B#H"55
M&#$HWG8%J-&P$7/;GZKSW,(.* @S)%'.V,;\H,0(RLF7F;\W"#W !,53%.V'
M?=GE<:B0PR$FF:F8(9.+8Y(&0>0??_&H(B2.3G4B%+5;;'PG5.=#)6=QV?[\
M?;00S%DG;?DS&<R:+,%*]RRJO*7>()T!@C-DP5/4^MLRG*PR2L@<UL-5[1WG
M4EL 68,]?8]-M5FR-7<$]1$D>MN]C/#JMIDV^IMH"B0%&=GN<[&I>;+W-K+5
MN-\U6F[F)VVGOYS3MI4B(B>)#?UF]QK?017+3NUSOWS?&BD2X'P*/1YL-I=%
MD9 =FZ]K??/$ZE$;Q5Q7CZ\8F=")O%RXY])F-#")K;G[UG#H29;BY\_F;^S)
M6<_:G\]&-+,7ZQ^>_5:D#8<?G]_&EBN#?'!QCO-9VTL8RF7GNODC7XH_;OQ[
M:(Q,;+$9[JSF9=IJ("&)R-3U+BJ2)VO4B PSGBSZ?F=% <'^I&4=:"0HN/ZH
MW^CZYM3)WBYA_/2)"J)A2KPY!^LTGK97LB46"]X2N;WW705&Y$IELA(:YYQ(
MP0@K*[J +QM.^?324&0K8"=N3/&ZZ$(V/C>*K4".W[?GG.HW@B$+O$8;KK:P
MTHR"RSR3QZ=3WB3DI$IXXCUWYY+D6:S3]]MZ.XM8&)$PSCR[U\T;Q.@!%! C
M+ODYB#YTL)<D1W?!,>E.SAT+HA2F)CSU"MHZT<01B#CUF??::C39F@CE3CDJ
MX@^NF6=)"M\%LD7U[UJ<)J(0C=)J$*7QUHL! M?6_ ]DYFV &$C[3$1')+NF
M^C"1<+!P7/.W[ZBF +$^BLRVY"(XT3D$,L6SGQ)#WS IA6D;(N8VPS]-+M84
M]6STA_O1&()L;PY8MWPQ)C24SU'Y\?XZ%0LGU_KW]M2(=L7(@B*7\'C4HT4F
M-UM\8_:-$>HB7BVN;W8DPRZ!5@A9>1Q.\IM\;+$%$Q42J7]N3R#4REK,$V^E
M=Z4E"T=&-_&=M]M+5=OJ<[N)VMWT)B9I!M,1OBG?'1J+Z@\D!73"Y-"42K9^
MO./F;F]$L,3@\>C7R\2:&4&Q.K]";F>#8-$'9$0[D?$W'PYT2PJ6,8D9VQM]
MM(0&-U*N?O#Z,SC0"96G4DW+S[RH1F T5[=2;;P1XSH6'?GVC\J\:@'$19''
MGX-,($'0O6 K&=1 JKY]NJN(S@T   @BJQ^>GZF8<[/Y^?,RFZ_SC&T>/ 0!
M?/KQC\R_ZGFJ:F-.2*39SO\ 6_II8/*[V]X8VBO&H8@SSF?C;/-9U.A82]3E
M\L\5T:###):QEG'T6_;.C")KWWZYX\79J! 48G/3YS<_U#%)WS?[#O&;X(LA
MRYYKK;V#@C128F[KB_-'IIHD9QCN)Z)BYU$)MO\ >9(SAQJI.8EYO@_-\.DU
M7TW]8J/634&$"8F"\SN2>(W- %N8G#?O<T@R;YYWBJ1;N3QLLI#B,1IA8EG$
MF,S!'A@ K,::0&I9+,5DP(<A61=#/3#O%LXOQZ0#I)CM'/4[&7^:TI1S&Q#>
M7.\\C$>=2AS$N)&[B,;8SYA)U,4\B:4!O/L,U!.=WT!V+SC9S!6YIT6')"<%
M+C:YV9T$E /9)B]\WF$)M0A),=P0-2YHNM,  !GSCE4& ;Q/@$!M_C@6$M-X
M).]^_/FT8AV<3F<4I./6]& D@DZFF;+QO$,;1$ K J 6$JHG*\;3NXS%C";E
ML]WM4E6'14Q2'M'#S-9WN- -<+"F9@VQ\09:72;#85MBYGB1XS.=+0I3!5>W
M%D7$[8USU0Q,XFGW*YG>M4#&"=K_ '[WT (0ML9CACSZ1H(#:M]*\R77EVU*
M(48YG[=Q5?.G>!R76T-3&+C)Z5I0Q 6&[XC?K?C0  9?3$_4^=\:A50T&SOZ
M^-X[@!6075_?WS$Z$(0;[L9*AJV?V6B(EUQ&(OZ158-!D\M;X_-^3$+8,L_$
M=QGSXLT6#S_K*E\N(ER3BWF:C$Q&BZA)S5$QS41.-\KJ(RK\=ML3?QJ!M^?G
M[Y_2!-$\_/YY(-!%Y,U:N/W^FD#(K)7=$3_/II(J<,L->39B/LQJ90->=[K(
MSC'C&EC (E;)SG;\F- D88N0GY&'-X'-UI9829O;DV_K&A$,X!W/O[V5QH&Y
MH<8&_9FO&G%<S&-YEH%XS6^=$ZR<PD^\S$A*WH/M-Y_+\7MJ)!-?LQ'#/QIZ
M/+?#C/S?K,9.@HE"X8 9SE*RQ+.=-*5D[;05%8CFBHQIU+*,&&Y7'MWOYTX;
M@HO+.3J^)T2 MMMFT/YOXT4(P/!BLWS^5IRF&\D'GRQ#'4UHL101G#B+WCTE
MX31$V8#Q.?Y]_P#' V[;\V\Z94DE8G!C;PQ9&(THH$&6C!WTQ/I<8TI/ Y.A
M\;1>]MS&B@;4 MA^9B,M&_-!$3$YGJQ^%\:(#2%#>44!]&)S-3JP%!VXK,'6
M]SF'4<2@(%JLF-I,76\(7$,F/%QBVYATRMHHV97J(AWK?"4D$DL$XG=?KZ]"
M3$A2B,$E9W$:NPA-$E+@0EB.)NJ_@B9"'"JWES[YW9<^ LHVS^^G,)(TS$-=
M_.,>$92K,SW,.TG$8>[4J24R1.Z8N-HQG0!8R>GB/PT8C$&;@9_/.@4I&QN'
MCD.NPT0H(X1YQCSUH3@ 6: GB7\P<: X1G_6H# 'I_Q(((RRGGN?SWTB$8N^
M]OOQ6H,42R_$U]=,Y0OI/60^YSP@WLTAB'TVGS>\:",J2F8!=IQ)ZXU*(2,T
M_7%=:";VUWN@\]8G&A2&:2^;]2IV]M@!B#.U;K,J08/+>VD1C+Q?I[3'I4FI
MJD)CS/T@GK[RB$\#USS1>VGW!F+HF8\&\^Y%:24*M6S-CQ6(]=[TF&!)92OK
M%K5[03,("J""SS3-K5OC1OVC!/IA=R9XVT2"H"DV=.U;+,L8%B!D5129IVI/
MMQH("081G$%"3A#?>IU,D..J&B<.ZO?L0,;KO/SQ\<5_CL302,UCL>7\RH$;
MS"+,5!S-_P #@> 1R,]S.\[ 'B=1Q)G]I9"&YHLVTJAV!O;J]HF\KAU@)#!;
MO'SM[RL3BI$A4@(ZGVQ-Z(1LQ@D"8$Y3Q3QH=$"I(R9Q%AS7$S.CG !E[SN?
M8]742696QD88VG@]JC4LP389SL[Q>^6L6*#;2AF;+W@O!!2Z63T_'CXZ\63X
MW%1N',[-]S$X@K+( H\KFI)3FA322B$C0LE2PC'(BS/$0' %GB_,W5>(=;62
M,JQ%R?DY9XT  R#U^,T?QI2+.T1AXF/V].4F&Q$=1(6+*S,N9IVYIJG20(Y!
MFZ(SMM.Q4MPZ,ED5$3BX;,</LXU8;F?ZSB,Y_P!=;$Y'2GB)<[,_2A/.@VHS
M/ >;ZK/6G890V4W$8^9#SMIH;E:WM//]5OJA)C$G]L9GP.E55IFHJ\4S&\I"
M^9:6*UXOJHIA^70(4;NZ\]?GG3&4Q;$OO&*ZCZ:<2,BUCNGW.RAS<5-F7N*>
MB1ACK>QG*6%DCUQ&^\;$LNG43-,.T5PGWQRLNA(H]$VKHGVUQ@(G:(;[QF-M
MHT@,NYC-V%7F,7S>@!#9,4F#S[>N-1:I)@)(HMV/!B=XTI!.492]H7<"(WLC
M2"8P4F2/+!+M]-(NJ9C,K#MAQ6!D-2C%(.:5.+BMWT\,A"/O7T(Q\X_QS";@
M+P*^<;W-ZD!9?1BL\1.-XY@E"ZF&)?.\3?G4",1LG:G?&3QMH2,2)9C(E?8O
M+W)H9+ D21O)*!-.),YB9)"%$4%B48XW](T@U PEKY;F^)G<9--ZR39PO,V_
M'6A";I$3$V=9N?,K>H64J4&8Q<%61Q2IH@7CKE(_;?R:> !2+\5-=7],FC1
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M.QPB]![G=A0C.F9DCATPP<D ,(D*KN=N]'[3HD&4EF4-Q ?JM!4 V20RL8)
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M^OZH.W[^^= %'_:VC6A&Y1])_P"#IT, >6<OB8G8\?I)%.X:XES])$Q<2F1
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M28IB\]Z9N#!O/$>=^#SI(:CWQS&Y/TXPF0R[['\1\:2$P<5D:X<DR?2G303
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MX\[',$Z8D$F+,I-G4>PUPY#@Y$4S7GI^[JEL0V6)DWBV/X=;ZELX;MG'BP@
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MY"HM.&)S'!@+AU'F@8#*8Q=B-2U'G1DLAD&B(EQ4W=D"<:&B&5*(14F(Y3B
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M/>9-0KD N:DVWKGW#S@88<S0U7BBMCLSH.)0;X.\</I#&T:42W@?SG/S//\
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MB.9&I)X\<89XT""@ -H^(ZK5R;D^/>]H,;9U!HO?[8,9YNM.JRL&/7YNN=M
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M&A>39A+\DS5P[ 0Z02PS6"+VH9RV1B=+0D)*DOC==XCVS L;@]##N"QDCQ)
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MSH*!G(H?1U5&*I,%R&,I8H.IR4$<RIG9 "A+*_10B1D03>Q9Q>OQK[Z&0%7
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M3 -?6*E0G26H$AL=!7IXTA!;'L,&_P"2:D H+CPSLLV[[XMTDH DA1<YQO\
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M@@RLXTR^(?4!#@F7$JY7_P!,W \'TTB !4 #*K !NK&GYP:)>ZBH#%$J718
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M?4;Z,(A[^D_6_KH4&?XWQ@S&(.@U+,)"01N1O6<=XL#5O14)H,];QST>- ,
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M/U,UB$UWBW !3"E&B4.THQ*<F7)Z0T&_;)6RY6$2#QDE^1EA(K#5+,5*BM)
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M1_XIJI,(ZP8!2J#1NP(IP2:,?PR'32NA0A0*XKG0 D!GB.IA@+4@XI"##/\
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MC^]($3>K]_[WU!RA8EJ[FF0^=+H\I@SV5([3P9U/(,,P69[@OLPZ3@$8BQM
MR3<I7HK&G-JR+>$8G(!9$=\(!G/KC/QQ]-! '!'ZYLAY-=EY+^9^FDXM5A&,
M^)ZQHM199@QQ^R^YOJ%@YOFJ?WPS\Z;XDYYYYZ*X('_X*A3O4>OGGUIB<P&0
M->N".&MF.]"I(-SQ,8W]9O%%Z5"R<-S,]JY:'JDT*0 9(S6<=YF<[.FC K''
M@Q7?AU#R!Y_9<^:*YMX=_KG[?5K0,B"$^;_/;0 J8@-\\GISZZW0%@B"9F.,
M;3[3H$4R52[7UO\ ;TLD?57'WQ$1&>HT)#)[K69]-\=2&U>:WJ:]L73AT9T
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M*[9[OX)CKOMTQ)(W9(B^.>?J: 06[O\ \/$O-P^?S\K4%+ FZR#L#Q3B<TZ
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M6 -OH9[[V_C@JAHY)-'G_P ,_(ZR$,XKLDOM_''"\@S<QA[/O^P #  8^/\
ML%5:)9H=G7ZO]EK::H&9)UK6L^[S"T)!/N_:^YQ%6'19K5]_K]>*-""ND)7/
M4^FSUP3!>\B0*LQ(=\031L<P#60GRAG@@=(@)!7R@P$M?/%!!3CDA_B*9Z^1
MN?\ CX&0FE<H5;A'$.Q4)@ JGU_/':8)%O(]8S[F//(8!N\X&Q.L;/TQP@@
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M,:.QX+?, '@TS)@Z^G'200F :.YS(EZ\92'_ *<*:">O?$I27A2IXN1-O#R
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M(\80@3"8!,AA;PB#C6> %B=8'[O%@K4!\OG/Z9^5H,BS.1%^DW^>MJ2YI/\
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M[QQEB*#J]2Q]M.F',D$:$5+(WXA@N,O)ED4:[1'P$G\+P)4K1FS$)O;C:=<
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ML* T^7:0,PN79?$P$>QDO8=_?.0_0P!A"+@I%N^K.91>-,S.O=L>F\:RBZ
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M9?&B&AZ@PN?NY^KKFVJJ08(SMBFWQT<%+11465;E6/F:YD50!6_D$<WJ_7@
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M9QKCDT&'3[/CY-\ENC!:S[@N,>.28,:AXR.;G+MYK1)^'_B(,29 O[?GV6/
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M\$6;X'5 L%+EWF*X\#C@]V*B:&8^V)XOCF?*Y]Y[A?IP!(X!:JF,Z\^(OE(
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M0D<1C6B1\@X1J4"8O'*-5AP;K!X7B&B2*J5 ; CH:(]A#@, *("(Q$3^B_\
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M@.#K.3S/? <);U?H?/\ (G#DL8FBXS8^_H<@'8)K>LGVX4+4B4EMUY]J1_'
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MVX]]<I<\.#/0YN?..^MNM2R2W5\>/>_;S+<HE(;*@*5[YTUSLIJ!3>CX\\"
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M5&1PB5B.2-+CB4&U52UB1<T$8PO"XPL@HJB0&6C_ $&S2@L6:I[A$]"JJ/\
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M_P#O>I\_WX-XVS_'YX>E8%!LQN;_ $[Y*.(745D]9^VN+KMN%^S!UN^^^,A
M:##O81\_MVT!0'$OI1WC7$@":HH=R89B^-8EX3,C %H=+;:G]^48*^,WVO\
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MH)'J!T#F1M549/%21'J9-(<N'(?"U:".;B."8(XX=E2(!P>!5P3QS+H% /L
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M3 W6\;)YGTYG>P1,F<XUK[\:"E2I(8(I# '_ )Q<F^.V@#W'.[DZG,]JV+'
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M%]&TBUE+BQ*;GR\G!  R00P=/T[XW)H3K!OXQG'>>I#3&2+C64R3/W\' I8
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MN-$X AJ36\7^VB<:-J*BKYN+'8?&+QV/$84=FFDQ//QG#-"0W<ZR>56>$O&
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MUSQ[.4#)FGCPWW].!&:_%55&WW\_4>TG!++M#8DJ^^6AZ7!8.\ SO3[L$8V
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MZ*4%5\?KK,Y$<E(0!@%,?3%^KPH Q/8 V[B)C1%[Y0I<*Y_5^^IQ6@+!6&/
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MD4(=B*(_'&,&4<XFH D]D5HD8S5LN"AAMK_HP.I1R@E02B)3(C_3@.1$$D^
M$KZ/]2 ME#H&E,$3&1)OE[&TQWDQLC.L[_K$1*B(,40HX3*XG$1S(<@DH-(H
M_P!;8*!QN;,?2$FU4"B%)0"M -56M9+M-$RBP1%S%%3 2/\ 03GKBJA5Y#+Z
M:X M*16E0/E)_N()'(\495V #O>']NWFFS@P#D/!K'9.%D(Z&@K]G.,GSWQ'
M8[+W3SG&O6.^)3;*4TA&3 YN'6)#59/"-ICR>_PLO+0X"VRSN9IZR8Q'C&8:
M0PT=F8$7\O%Y&HM85SLW//QG@+=C#K0CGSV7/KAJE/KC]'X\8^G)( ,YU_X_
MN_2=(@\F/PGQ;O,<<<E%"S+G%[Q]<.^%^!;3OPF<9SGXY6H9$69U/&#>-6<8
MW *0(ITU%%U\DYC$L6*4$=J3TU/# @#D-MRYN)U_GBK[;3%321OK]>-"E$Q-
M$ BY*/F&K8FC&:*NQ0J^>8F: )P0F9C!/G/CD_%XI)8%R&CSQ@ E=441^H$/
M9G-)"*<H"^5FV>CA4O9[=HXQGV=9XM(@#AZ&5*YT[XN0#52GL&!IX/.3F+-0
MA=$\/D[IPEZ(A)T"UV^K[>"((T<B?[F1VJZZZUXWU@YY"#O=SWKX3UEZY"85
M"4HZ9=23QCKC(RA,C932& Z;)CAAB\Q1FB5[Q!?#:3RI)"JR@25\&<Y[JKD6
M=6(!%!F,/#M0!RP"T 3WE 2N."8#$0)E3>&?W>73<L;!Q%ZO7CC"$N -M;07
M?6G>KGF "CE@5?8SBF\YS!!  (0* 8.I7ZDG7$0NS:IGXU?J^N(26E"#"AM/
MKE^O"!;,9D"E-4=]6YXQ$2$\":&;\2?7#H81\:8=,6X[XM:F(W&_YUOKF%>)
M'.0-6^#/DEY6.Y/6/!_YYRSC39C?\R^I^B\4L$'Q\'I/K\\."L P]),0\7[[
M[2H;.BI68]*?<-3@!Q6@*G:XQU4QU,< \PSNIG/><S)[[19&FDMP8Z;^O<XK
M>@UDCA:O>8_4"$H*LK5P0^9\?H>$N1]9U]IYSZ@A$ "1B&@^F#7OOK_7_0CN
MUE9&*"BJJ\>3*@"0)=(UP1!0 X,PPCPKF;C#N.7DJA16:DV#//-?;JQ0D% &
M0> J9L&?D6/)+/\ DQ( DKX*MBE;FU4,4,+0L_I,#J4<H)4$HB4R(_TX#D1!
M)/@!*^C_ %"B.P1VDA%D)=42XX0?E&@*Q5AEACO^L1$J(@Q1"CA,KB<1',AR
M"2@TBC_6V"@<;FS'TA)M5 HA24 K0#55K62[31,HL$1<Q14P$C^NK^5\<(@E
M!(EP"7>*XF% -B7.XO\ Z@NA\'Z?T/@R)E-8J$N6DL0PLE\F@=^&QYOZ>VDP
MQ(+:5!8+-P?'$A^HD>40/:SAGQ+)4M-E'T-P/F&9$&Y+.6NVS^@[=D4E8@)#
M.$/(9P-M?"8H4#^G'5G\"J3@!@N!2XXB2BWC-8 ,< M!_JAH62Z,RT>@M',&
M9PH0,C".AY%7H[L5-(_]"7'7]"':H+"2!LA0 .1^J3/EI%V)M)@\I!!YX1CK
M<!)?ZTV\QE487E]/T17:8K.20"& C3NL0<H#,,+JMP<+V7]1,C(<:\B=$4PI
M><>WE\#QY[+E!MI%*2+*0A !Z4<S[58B"(R*"R2BF1_W2C04[^,!WV>YQ11L
M]_/T\W6//)0)(&RK@VQ%%T.]<A*$):N7&5?%NJ/31K<+K6)[R_F0<<ST100?
M2N\#VY6U%X! 0XFP$)VF'4\<U;1Q3'#F8!EA=NW%@5GZYZN<S_'#0)OLN<Z]
M?INYQIQ\#\9W].YP'%ELN-^M?KEIPHM08OC6QTF1\QG&^!79Q?J!,SO8^)X'
M&)<H8'#O)U],O?40)!9/-V\3C#&DK P%ZC7;>O4LPZ,H S#/?<?'.QTR.D73
M\VR!YZ.4&=%,(F QA^<.7,0.&H51=>JX,HWNMXR!1H<S+]''F=0HH"T QX@)
MTL)5WXY6 :E,SD- +#==($/EQ#H5C#>H9='"[H+@S:N]6_,(7B,9)0K"RWI%
MQ/7@]0-E<LXN!"N/?>AOD5;2)]L9VC^G(KG88A&='K@,#A&O@K=+YR'GH1!&
MB")I'(_7_8>&#*J'Z\2P<Y)W9PJD:1/[^_OR\Q0,UD7S=3X^I4R,RE N;UK>
MOB@O<)(=(AD%HV?J1OYB#0X []?VX::,M]YT]_EU),E$$( S2$M),N?CDX/M
M&X&D0B-PZ?/&B9U !-"K,N<_,Y45XNEV5L<'UC<*U>>SD.K#K A,F7A&\9*&
M,NIWJ"]XX_>D0&8Q1S)YCO7&#A7&SYO\.!YRH,88&[7$WF&.(:JY9:D1S=W^
M#Q'+4)@@8P;]]&)PA%$ ] F?SOKDF!!AX)7R_P#M<\1-G D*S[L(;TOT(A3+
M&?'>41V.O>!#%[4?WO?O]N$5^,M_F7P=W/+:R.=#+X/F?3@.I9U-^W?Q*_JJ
M3-!!U+K6OMUP:5L."+!IB?=>N,@0Y=V[RG<'UWXY"9ETM0W]/Y>N/88ND-N<
M9[QV^=<8"L 3K]O.S3>$T,,W$N.^O+\>\97==<36/A\/CW_M?X@O2="C,\:$
M!DA$'E:J"5#JZH3'TJ?T!4K(!1*J!5 SMG T0%0(&U1 .WKC0RPP#I^/&'SG
MB)80,"IVHK'@/Z#MV125B D,X0\AG VU\)BA0/Z?T7:>4> I!+<$%<_U#! F
M*PD5/I**T2&!JA X9'BY_8M<8UR,,*9)V4,F?E7LEAFSK-UEX0[5!820-D*
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M[_I&> RW1T7),,% KQ+IJ2F ,=C5RON">F8-%?-**& *1J=LKY<EC9XB0@C
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M HU<:6D7/G7 W-TE1Y<I#QZFDRH(7'3_ ()JGORV@\RQD,=,C\NUX9,4'<+
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M58M1V5Q*36WIY<I-05E,:"8=9^_+^":1?&3[VC.L8PUW' O0+,8+APA<[KF
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M+WWQP(&XVF*6[^FG9SHF!0B2=L^FIQKA[D%LU-KJBQ\1N6M2EBH#CS\\QO!
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M&IG;MSC:^0N^"56H:-8MGG\CR6: ]%Z3?C;XX<(0(X<,O[_=Q_\ 0..TJI2
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MCJ@@Z'%PEAG[GCD=Q"Q6)FWJ_KXL4S9TI]>OJ^,S'%XB(:&D/G\['SPT7?\
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M*#DZ<?\ )68TS"7PD7B-#\L0LY07UXLLYE>*V3.J$4-:(,UXMPL%#,9!G>P
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MWE88"#I@XW0+DB4%300'-*=MR07C]G"*$@ #RN PF^&8K@ *12IF[/\ B8P
MF;"%2%MO_CCC&=A&:R8(NSO.2'+8@DAV>EE/5?>*K U],11IM4[RG'F57<'0
M3  K<PMDX\(1NP"G@?E^W&P4""H,(Q>M\2#3QCF;7529SQX<*.EED$!';M;:
M8)*W"<G.:&"IS?\ H&B>D*&#9F:XLDW8ZQ1<XE-7M,\-WX%D$# KO#22'
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M6P\!(CE"&WCUI "P?F$'3\A7>*M<81090&0ZO?UMS'H L+XT/R=^;#((#O\
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M,8^. PXE6J)8PS<XMQ3,;K)1&/!I+ /WJB)F(MC0KPSE-3O)$/H3%$I"( 7
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MI_(=:ZZ>.AMV^E_XQ:'_ )"/Y;^3B,=2*R# 4,=WOSF:VA$E0.'OJ3?&2'2
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M#ZN:%*T.TXX-!G! <$@!@\!\\)20T5<@M63?K!P^F&#(@PF&X\PN<WB$29G
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M9%YI,JDL]?@@]KE*BS=N*^"D!_C,4!5 !56 &55P 95UR1N T$#BV6#1!Q"
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M$U +(S^2_BR(LINEJ=#X#"$4X-]X;FY2>Y=P)A:$@?@3L$$P//\ %: ZR6D
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M!>\?93P+9_S-9+9+N:E)C& "5E<AVF2IGPC"=P!@UWY0X\BF>#\!,*UX:5@
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M>^#.DUL-*N2KH>OT_P V<EPLY0&"[UD9Y $-1A4B*E*,<+N6RDA<L&& ,/\
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M,,P[\XO%WQR,[QB$!<NC0<8%/2F3B4A9#'?60# 0\'^V'KD!2T1D;'>W6-O
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MZ: .4\GZ/4XL48(B1@QN(^-R&*W'7.!JE-HU'+GDI:!T QAT09?63?&1G7L
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M!LQU\S-7;J#ITM,P[><?WOF$%AA@>0W24D]WBUD$40@*<C00@(3_ )H>-9J
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M4L%&8(WQ,VDA<!$A <Y\-M3Y9N!4 I$2"TL]<4WE=<[$,A1CTZX+X/#Z(,(
M,7?T*XZ"H *N/UK@N^&EV9 4@8B%,].AB3EB  !-JFS=0WP($9:9 4VDE=/"
M[277H?;'P]:_YJG:!U;M')#IU'+'0AM"5PFN!AVLJ9IW]/>]YPL0!:[+M^WJ
M'*T(RIE['Q\[SQ:Q[%!66C24SK&3%XVT3XF0 @F)4?5.'6;K.:0JI1%<*\O.
M0ZH4(1$3/K,."9%B-T2^S@T^.^$IEC5&8*!@4C\N7:O*F+G,T,D7URM-[-%
M4%5$J^&!'::6R280'HF,YXL<P'60PDRM2(RW9T4C$ '7('#@ CPKB$XG"](
M^\ 9$6D,*PI ?/5<.>^722D4I= V[/B9S5U.%S@F6]]PM4-<5KBHE,8"Y8P?
MIXSI"?D$U)G&ZOG$X.R8000OEG\_]8@"L!EC ]AW^,\:9,+&TS-SOSW"\DA>
M&RA\V./'%L=ATJE[ Z,2T-\.%+Z2T@4C AHP=<+U?SL*4&!\#4'2P[N,Z-)&
M@T&4!!31:)>LXC);[/?#K0NF4*6(UT(8N.19/;!DA&W"J&=/')H/*XRP(: )
M\M>$-75<Q9J$R'7?$!JP PD2K"UF:J\"BDB4N9 C$L9-X>=%V<08V@3!H[.
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MX$54P+(T='Z8V>#F9$!FJB]R^+[[O',B$'""(M627?$&84]PH8^G4[SS7UN
M*II1683)O@-O@N$)XA(FQUX397J;",L$(,+N@>#*V,D96P'TF%@#.=Q^488;
MVS@=YXH:U^+3XJD8#@:+Q*UB(DK@GP;,O%<D1 .X<8\=]Y J=PQ2!,>NB;[U
MP6GPI&8C(J;>D/#Y?X[,/3$1R=I> Y%M@@*HH&4 !@X/5@,NCE+;.]\*D%[
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M'<Z\C !N%#3MV\5+:Q?E$@R4'&PM',ZV-;@2@@PWE#.#@,(A=65MB1B^+H.
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MG"Z!A9%'6OFB(- E"]2Y+2RY%.!%6B,00KE?DN]'+?\ *\J 29'*EGHLAG.
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M4032,QIF@(G *=$16T@&563A!_P5-$1+!JIB0X78#VK$VKU:^;OC,AJ@L)%
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M,!Z9CU_QCS>&-O7R>@,&/#*^%9>&L3 4L(?XD#?,1*0.4 "J O#8D?W4"8(
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MVZS-BE?O6+^ P #0+$]9;OJ(4O(#CL6![$1X:_ 10YCBJ)*MZ:2 $!"2[?\
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M+PU6JSXDW/U.:/K:DEA4F6S>^QMQ,H(L!+0C!9)W>!QB#!H:C#QT=38\4#Q
M[,]7KUZTO*)5<Z<W[UWK7*54Q0"]'Q7Q^G/+'<*&4,UGWA8\GKE" *O6O/PI
MW)PBR$D&@Y]+GK:ZAF$LG@( A4BO7>.'AIL)"(!NKK#U0YYU+! *9>]NJ<9)
M"?6$F:W<GWKEQI<@:   S.A!IQAS*:>4$L=?JEY0K.X*"@F<GS]LP1T3$0JS
M@6_&9S%6Y-4V*PB6 @SA[/A+0>(4U-KMRT=8V #69$VJM]O*CK:E",:"1FX,
MX&<EC95HBZ,1QWCH/3"*)B!&)>OJ&#@640P1-@7<VF+BL<SA7,3LJC.TGHJ$
MPEF@!$?8_P"04M%0&#Q4O,E9(LRDO>\T)3+GBVJGGPX>.D5$0-(4:(OA1-\+
M"O5 #*F0E.IOCZ50!'1 +:G@>%83AC= &<N?*[>'S&49MNKGIT7ZY3L6KW*!
M5!1@PS$>,V0K/ !080HY\X@JZ-"+V:*HS;M.4%BQ@P5%MZ\[F0TS@TY0B@B$
M8$9*U(*$XD:B U H@N'I/I,Z\*NU[NSE4!0@4SCUW_7WRV!"H1,$CD MIRF*
MGI]CN-^ .Y"=\+JZD E:PN([;K2<BT'N $#0!@3;@./@;L+@H')-Y,/3U)XP
MB(B8!8.HXLS. &EPCM>@54 F>F3HV@BL=8A<[?,XH(8W$FQW\X_7X<F#[RQ]
M_P _WYWJRF:;\>OT\3/#<"#D$24\XF)T<TS\Y\PB!\)(.>6F8I <0)W[ /*9
MX]):(9#8CGS-S\<K!+JL\G>C_P!SP610J^!COS_9QERC7C#'']_GCGD,C! C
M?-CUB;<S_)[H1UQ&1',27(] B&4F'QE@[(I2@_AX7:*S?$D0%4$*8G7T(8%1
M !5#C;T7RXY'8Q-X:G.:(:(;X&"+_@,$4>VWI FH?X=V/YOQBMR-_CH7ARY?
M==HVFD2'_@ODX""'0R4(8#3MQ2SU=S#;.6#&9^)W R4FNBY1V6P<Z%3P+3WP
MW ,8VE\$:XUM8 3I5L_P073)]DG89%KZYWRPU:?W/$IQ3C$DY91]NCA]H'7*
MZ3A& ]ZH0"_A1'E0?P-"(AF N SJ'R@_!CP+@X&OSR1W#PFVOQ.!T/M$#!EF
M5_J,O]M\/X'LKWNQ8B%DN1&R[*JNND3F6#;^+;& "H*5"L>8L:@2>#;D,6Y>
M'/JU P.T0H^8<4;ALMGF#4E#E OCDO2PZ!>0>(VN?Y!6GN@B'^/VE$)+"@2!
MBS<XN)K%+<O\#V]?75@3E[98 A-,@TMK!J_X=2USK%'U>SY"Q[C;"_@\R(T*
M"HKW9F2"?"%R+_$TYE&#U+(F(RB1B.87-31?6E_PJ@@ 0  $ P $ &CA#B.4
MQ; 2:XE\SOID2\RK&  @0?Q"+<>Q*09O.')<GA2H=A * IB!0*?YB,;@=!$L
M4R.<8R8SP.@:2ULGLS\[ST<2$E(:3(Q,9QHRXX5XC3/9LW4!:RK1>EM I!)N
MWUMCB?A "E .U&?_ $09,Q%123W,M74R3TM :!%@VUN)0X1II6&%"88Z,SQC
MA(L Y?FZ]?GKAQ:*93/C/]]719# ,$W7,R"/JSJF5D(R5& C*+TY$-</<ST*
M 6QU-_'?)HBQO-U-NP4L7S(U9$.LF*A*.'(3&I8 T%6+"@YSUG;F6C5>1)$2
M!S.PQR<C**.1T[6:89SAN;PSK*@.G"B3$S6W%7:R6\X('.S"--V<01MJRN*C
MJUC%+G? 9P6P@!"IPI,;QT\F:5'+M1HPQHIG!YW]0F*8JEF/D8O 80%N8,4B
M*G""Y LYD>AV9(BMQO6B!"TL1),14,BK7-#@O)# JI 01O8:P  F!*%1R%Z.
MMW,P\Z#M'K"X9B;;K"\H3/9"39<F0Q^A/\88@A/@%?T.*123@R@<VMR&:,XY
M"]84@54N=V>"Z>$)RL4,80!)@)#6+FR'5 #84@A+WWF< H@E(8<T%<KGL3 V
M@R!+4,J9+7V1$YFS*: K15PJG4%O9>K=:EBI 6KF"X-AA^Y_1%Q5K=\-);*2
M;,S]>IQ/4@@IK1<&?J1X;S-(6JG5-A%;,' <DLBA"KD>[)FSBA?D)BAE"Q(7
M),:-6)Z"0&.,@ZS^G%(X>&G!7HTXP-+K@F"J"YH,B@]1,9X,HT^L*,RT:KW.
M39L<1FQ%1 6FW71OA)1,C(T8@@FO(1+"-O!J%- * $5]'&"M()&*#W+2ZQWQ
M&\=\%D, " HD!5"8"D9AVA) IU^_430?.3K/30S+Q]4UFBGJ/A_O7&1TLJ"?
M,=#YN3/'!,T"_KFP?[SQ,8Y<IA!*OE'QZX99,!!&, A)Z\SWQJ235.!FY;OW
M^G*U"+MH8?RS<ZSQ(%2?".<_FG]>(6IBT4@'ECR&2XY")@DFA%L3ZSWO_*[H
M6R_J:BA)(*B!R(\[RD'1438AL_@ND5F1_;FVELGP^@'R7!-ENEZ*$!/ Z>G'
M+861GK4B*R1:\N4"^.2]+#H%Y!XC:Y_D%:>Z"(?\'UHLN#I/TA!_@FXTLG"P
M-).386":0].7U20)H5 <RVM""E!R&%8;=7]/F1&A05%>[,R03X0N1?XFG,HP
M>I9$Q&42,1S"YJ:+ZTO^%4$ "   @&  @ T<(<1RF+8"37$OF=],B7F58P $
M"#^-%:> N(5FH,D;>#PN+(9K@-WR004/^HR_VWPXDY6*L/D&)1 O+H8V6J+Q
MJY5!AG_$5&.$+^-@1MQT]924.4_'L^0%5#,7$QS@=B8?R%=)!MP(<!4P,>5>
M,MX8O"*^TV]S!W/EG#[;*+C]65LU7BR32.3:?\5R3*]@K$3<3).4F2"JK5 7
MBMB'FJP<1EJ_(/E5,"H Y'BLFDB4T0" +!_A%&*2M@$B9=._PN>UDC)&NC!E
M/*D]MF\;D^KC%X]_D6Y-V$F@O:E!D+J0+F8@Q:88_@" -61W@JPKV_\ @QM0
M2#S&!B$DMCS?&KX@A$$#_,A.GX> MU[C53U2PSVG?,SPBS/]._'%6  NER77
MK^SF"6:%&8G[^Z^N-GLR2DRRI'Y?SCA-QK*D""J2= OMXG1PG18- MENU6\N
M%\0<TP<*M:. E RH7;XO\KX.^4EE,4UFD_M";X$"1F$)_P"_'J]<MH=X )"]
M$'OMLY2EK#(@0F%D28PC@4- F,2:'R;GYY"3TD[)8;9<]$Z%E(T4 "1=.BEE
MH+ZHT!)"'IACI-B\S"E\M5$&D/1C3@C8KPX'8=_/:9#C7F,XXN5<1T[JAC#Q
MUGI,F D%IQ<,M 1BD *A[F<8SVIR0BLJ9:;5B)*7LCQ0MTVAHJ9H^C5SQV.-
M2@@@":M1LSO+(75MZ7:M)JX/;P,T%H%?DD5$\F<:S>R:<0(>7Q)BS&."LW)!
M, %3+E7$FN(!/W7-A R[@-+3DD>XO80TNO$;]O$8) R2E^-8F+%N_P#&X&Q?
ME1^KR&3IL"H@<XR+'+P7@,RSD$FV('1\XX?'%1!1'0YP_+F;@V&QJJ4MR.T>
MVD?'* R6!@Y"!F9C&C7#K?V2X%Z \.*:XM>(#/R%!@,I@);F>(B_>BHKL'.+
MEU=00;VF7SZ,8\\S%C:Z5_OZUCF0D541ATRYRBL*=2?%X9<=0,JIE69(<5\1
M<BA'24B9BNL1KP$1=P"[P:R?CA9BY P%!RNM8ZO7%P!TA6E/8 /.?GBET0R6
M49TOH0O-QTVAJPR6B-*&WBD@($$'4KD\6?24^"S&J)C"&%W^>,(@<@9@@%2B
MKV] ,*]W*0H0852,BP,#E,TM@4Y) 9H]ICCA(K8>#R  01@"!KN" 2"X3O =
MDC&J%"&$)AN18TW?EYG"DA2(19MS/$]\8..D.5T&R27#@9,T*7))+6L[?+G$
MC%OE@;)H!UT5N,U84G!LOP 1.("MDBBK(/5^+NMS"H&!E0Q\;\3OTQYQF58#
M28729PB<,,@(*HXVJ+GXU_D]T)T'/#E   J( *L.!,D,RYXI;*I\H/7#P0M6
M5RL_B3D78G%H"<.RMFEDV+KGURC=<%(_5?==65>"_P"Q4P,>5>,MX8O"*^TV
M]S!W/EG#[;*+C]65LU7BR32.3:?\5R3*\&N@_%^8P'P(PXL( P@H@6U4><S$
M_4!5XY;BLFDB4T0" +!_A%&*2M@$B9=._P +GM9(R1KHP93RI/;9O&Y/JXQ>
M/?Y%N3=A)H+VI09"ZD"YF(,6F&/X** U#<9L# 8V_P#@$S30"]QA8=QI8ZW;
M3N#3,HX_]14Y*PW8:/(MS2"*D, P%Q@TIGGAJ]_22T<Q(XK,XF/N0TT5(%:#
M_$ V#P$     <<\5_6 5?U!3^#8Y'LO8PB&12'MMH<Z<KB;(2,G\Y;^( &")
MPO78S# $M(L2V(TK5\Z=2@W(55IM6C:Q (!8>8:BGD>;^,;3T6H"Z-PVTP7/
M!2M<3C-N!/06FE CHU:IG",N1?RNJD.9!2REN7@TCK83S^-9Y<P'';OP7)=D
M?FGQE3A@P"[TS&W@R+6! @"\MG18T!@A\\JZ98/@ZBD(R?X[6ZT^I''*3$;P
M#_.DCMDC,CGAZAP@['BKYC]*DL))0E8%!S0D+IM&E]H"7>"?R#* N*,"M$H
M?YJJ@08XSG.=-KAL-3E'*BKB9_\ 'QB5SP;I$+.L=_>^O'"+T%349=WI/Y.X
M[>5R"++YS?'].'?%P$&Q&&]SIEWPY1L0B*8>MM_3@9(02G6'UCW[XRV ;D#'
M;_/6>%0;H+*K^7??7+)/T&_QM]ZR\0)U^ZMM:@!GW:%:?$@+4)%@@;W'C;%
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M3C:-&*H!:_?7'6S(-KK.>S[N^-WZ_4'$44GQN4;:2 5[A+$45 OVUOC92N"
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M58(^@\[KKD+WC6I2H EBF%X*V*>Y F ,Y@/S0A-<9.@2!0N0T<+#5MP^TSD
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M& ;BQQK.![@7 3LF'-5$V\#"(M-B9>X?63.H;THD%@7+EWY3OWS!I-DF3(Q
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M]Z=*H@<83S X?18E07T8UZ"?*-%H(!. B@:"'G*,X$S(5"\@A\8QP%CT(CP
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MQ&([1'1\N/?&YM$!!< L3Q^>%:Q<%F2QIJ>#P<@2)6X=*8VE8]&>7X2&T)A
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MO%@+/7H%3@@'?=O*--^P(<"K,;S9U5X8LXI0UL29N-QX)]^N3<"C( T3@TR
M>;HG8<^/ZX7@3H(8Y8)9BZ[X4%($+A18.0^\\4TCI[#&EV1_L>-3%AL2K) E
M;K_$^'U(E11FQ])ON<I?TO9*++\[JRYP%$6=" 1%[GO9S"":5?*+4Z0U\77%
MRD2,C"#5=$+]XXF@T%;6PX9J?6WC!EQ66.VG:]ZWGA2,)0M>G,6.,]^CX%03
M(=W4N=!UXX);C)E.C#??G&L<M<TFMRS@NM-@'B*\W<(45HDSW<N]\FB@AA&5
MRGM_EOBT8.2_)=?MA3V]0BQ5$^\)1J&6NX0NF&FI@#EN_P#C$T@DP())!A'J
MK[X7LN;!4*9/;UV<PL[FEA7!/FC\>%@#! %\R(?/TX./D)2,*"[UT?$Q8<*D
MML'J*&O&]YX2+I8M0M#]KO')$L/10Y9V?U.9>E-1%R^7SKG=\\[;>\_]"&DX
M-:PO>>K)>81]HBO<2[;]OS)J,(40=89NWQP6ZW_\^8?TSDA$H!^G6/CW[XI8
MAF<H?O/[Q>[1Q[\N^_Y^^1!,EBKH_DO6=\$>KJYJV_H?CT\$JALRPC/CBA"H
MH0YRFC/]WD\K,2T.Q"F!WISS*HX:81.QISG1XY3?0U"F_@/G@H:ZC,3JCA(@
M]8[!\5:J=<F6^?/["FZW:!4E$0QJ&!HBHDI(!"JK7]'@<:I7;U863&;]<"\(
MC<S P%IZSQV BI@./A$R>>3E*4 C<='O9T\3E;ZIMCV=_%.+6"2C"*V9N8,.
MKWPR-#Q).H%MI^>  7 =16-2.C_ *,NSFL*WF7YZV3\)NT.2"'>*.<W9'&\^
M5),,[:3S)@X)(=#*4C#2:Q,GK/$8$HH#E6#QMNG'&?7B%":-)F0V+J0.9<.8
M6\ =BY_G3@IK74@!(]@^,O?!*ALHU2*"%PQSY5YFB@<Q0C-._MQ..$L4=W.>
MSV,NIUQFUDDJF2W/KO.H;;F86R-9E(R,D?'(>TE4(HT,AIKYO+,Q8J(7SE'%
MUZWP!%'@ (E4<2^9^MV$08 #IQ&8GYQQPB*HM&*>7&@V8#B!12QE!7+^<N%X
MLHM@:#*T#\^V)P@19:P[4:9I]^.+S.T8H<'>I[O'*Z)"!2[&-_',):99$*7I
MW^_*(H&("?H/[[XH#<0$[6%_H??"D<H!J:HXU/VS_P!!& LD:+:X#M4.2"O1
MQCD$TF?/:OQ5.THE?#YFZ9X252L0L*A58>=G#8AB9!%6CXC:_CP5#,5T#0;?
M?Y_/*LZ24R).YY\<1!$!!(NN&(Y"3)0E_?SKKBHD!!;U3[SLN^^#,K!(1^,9
MWJ779&$R%:!-G>C^G%% JK@>#CP3/GJ<!U5(L!$W=]-M[>/1%7+ ; <3)O>^
M5WGU.SD@WU/$QP$#<"0Y K6OC';0@PG$\NS-VZ]8XF$&,! L"BD,\K5!2I8>
MA%,5VO'Q0!$00I-E&V]=<M;ZC10S;]?.<'&JX,$H&E@9W)CB?C@P,)M6%B'L
MPU$*]^4'G^]>>2=D*HQ@R-U%S\<&QF22&D11B[W\_P 8D#,4&L!9!SZX(TIJ
M1"@<B)F]W$XY7L212-\-0PXF9$>+23" 92R1F&S^E]I$H%J4,_\ WF$M'*"K
MF9SE]O7GC0UX,:"(##/3EZYGJ$!!1%A-^68_/+S6!R*(R!G(8,DSQD"D#J$$
ML@*8+&ZXUHDV[*&.UQ/7%R:.001')+WAP"ZY:D\A8.T7[]/EPNO3_@D);99Y
MH\$+A@!(U;"W3WU>&RBU&JKJ)K+B7OA/T"#0@SK6NW&^!B$4" "SO0?'L.(
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MU$N77_FIZXY(,!I'(_XWFCZ!&EI@>S><GQ!RDZ*NG<_7/[$%?RS^O]GWQ2$
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M6*H)">O.!_''Z5(4R%-UA1?/'-K*E!H9$C,K_1HI%.\(B@N@F^N$#(QT(&\
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M(H@.,UZ5))LV"'_>$H+\[F.%47PR)E9IPBIKA?P[,U4D_P 9;"B.Y1&[V1U
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M,M'6_/)4P H*)G5NWX9R58BY!@#!<'>_Y<:J 4L"C!%*_7!XN9(4R2[F/[O
M*6($-$B2X7\+R0)W4 E M>^\><7Q&9ABY%'Q[^N*); 4H%<;;>_Z\LA8:$2-
M[A([^)R*X @*LMBK9O3Q2^Y5]']YT?/%KJKEI 4CO\G!AO$H2O N0ZV9R
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M[,;O@PD=T8!<NM\2$4"D*T(U'QC.6<GAP<@J'9/=W-N*C&PQB5@P><!P#[,
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MJX"48\,A8?\ $/)G)L>TK@LEQD00$CC;)YFFRGP=0Y'_ !_Z..]]2JFUIJ?
MCL.(!7*CC12T#M'^"&<XA;1@$@$@L&^\T6[3 A* @K_Q0C7)IE1)8650#8H*
M=XX4,5"@;D.QQ_3@O6U45#P8[>?QQB^%G\A+#<F1_-!%[* /GVL^O5LI\ICG
MHS/C7O/&4H(ADS?[G\N#;6"?&("S,.*580SYZ_OLWYY0'NAY2^<8_$X0$\";
ML0Z>_"F.I+0.1'&@KJ?#&.-M 9+:I99C/G[YF.B0Q%?7SYGSQE83VE%#(VC1
MZQQ1@G&S1P4[E_IP)S2P0\&@T,]^,\EJF@:(0<T^\!QH%A3+WGZ?Y<.,C0"/
MMT^.8-HNE79%3%IO7QQ%8QE!J#"HS+^KIN 0(4;V\&)_29<@D\0>AT8S3B46
M[:;OILLHS5G"/! 9V%?U(SQQ.F (LK(;4T>>&#%*@%#0<8('6[8$,"A #J3H
MQ-R4:.>V-$0#DQGIUP^ %^Q))I$;4GN<B-2B@=Z#'R'Y\&H0PTS^K&KY^N!S
M$-3#9E];[]<.)?0"U@8A'JXP<V#)(7D 0$*)>^5DL;2,2-M'-/%ZXZ\:4 MI
M1<WU='$P4374H^4S?SD0'!IT6D!HUFIO\4I,:)B11@Z)W6\'2)B"2(!WC+CX
MG +I"FH%"&;GI]N>81"0-8C'TU\8SCCJ/390*'.1?!^"<S9\"!%$\#]L:JG.
M&4CR$PGWDX2<PE3C#9ZN_6N3V^,(03M@Q?C%X<PPC,9$XJ,G6K"D(\+%H!9@
ML%>NO]@/DZL/AK&P4C^'P3(UJZ'XCE\$BX.5OV#FB@"XE=YD$Y$#\C5!_P"(
M/)G%A%H6&>,J\CHPHD>(X.0&FA8SI.JB,O<<^"0ADY,:1T>7=<4&O^CK0)7G
M%"<M$JFP_-=2+@,H:LSR W1B*QS'(#L&4>D2(4P \,ZQ_5>IQ0^.&$LP 1!H
MA"R0>1VA,%(9P+([+YL\?!2+JITW_$T!$:Y-,<NDCH"J_!RE/ID#@W,IF7/Z
MC@Q(QM0E=V_U\<CX&2*E#B'<<_VJ 35,0(HZUKS,\IDN@3-A$2+\YZXA1#61
M(FB"FN_GLYXCY,?W_>./),+)"&9^-=3F;E.3<Q]3!-_?*TX%*-$OC^^^,6K1
M**@<B([_ !A,U'>(=$!"DZQQ40\J(%T$CA]]<G3? :LJ$:B)-;WQY"2ZK6VY
M8_E\0B22).TGKX^.)2@BF; LS?U<XX<!=2@#)BMZXKIK!M6G>D_5YF/;WY]\
MV5!2@D)9O4'?B\I];='!@ E)>=Y?@G6L1,1,^QX] T83:!VKF=N#/-M%HQB1
MA?+WBX>.EAA%XF+##.(W&%NB:$'95BPU<GGKADQ8 ABG<5KXKO9LV%K4%HJK
MFOCC'N9$)W*M)GWOC!90= *HPW(]<'HP2=+KYGQU.(X0'IN.L=?,_GS/TA@H
M:1<;"FWV+RP!R4$BJ+$)#*)[X \LF)0B%IM7=SA>8!1L$RHX6L8'17A+<W1H
M"H8"CC3?$Y:+R=Z(P%,.X9:F."U2/1,ZF<W?\[<?>-%> C5,DQOAXS4S2.">
MB,QO'-.0_+8,?&9GO/'TBE (#OUYNR8Y-=.!(( 7 ;^^Y0_3WK0Q5,L1.]!<
M5,!D18>'?R7@-+$"C0S!T0+;'/$HJ&<.LL2+3YXPL[@&3P!.VT^] /E' @P8
MH.96AO\ UQI6LT:DM0JS5G\$20P8):F@U\-PUK.01[(@5LL*DX#R#M$%UES
M '\"WK^Q_P#H+&M_X6 [;84UM5TG>*1 2Q]&01N@Y/(GK;$'QZN<TAE=ED'7
M)0()(0I1TIH//%Y  '(YL72B(@PRNH' U%+;A+?#,28X8%4H ("@.P(UHDYV
MW @V9DB )P-;@=7EH9E$D /&[MFMT #+@!UD<I8,K*X366XJ%7@RB42@QR9
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MMS%T(BX#0]Y.Z<B3%35FL7C#RY>758$<03'HDY&S"LY?$"7/^*FX4/)\(-X
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M(:L+\0QZ LH)_@T:+*D+&$R"87BL'$]QQ9R"2UX0(7&JISTG!8$K N*%)'E
MP!8L CLB:J N5=I5Q +UYY;O\(3Z8UJK<FT\@VQJ#?\ #A3@WH;UQ6N6Z.2W
MA4#28G-:'"+>M/K-%>KQQ?\ B[-(0#X6L#*$+^'2!5]Q:\VY7(><!?<)R,(H
MA[IY@_KN$ZAD9F:_P#*T$WXIP"$8XR7$[B0@K6X&SCN71#/NGM6\LL W,)7J
MV%!D_P#&*46AO**H%A%3FYUYXPIUQ R,@:A-<1T!$U74"P7'QCBR10"$LZO
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MKEQ@:F*.XM[Z]&\X/B%F5CW]?@.#;FCB*O9F3O)C'%W,K&&P>$[-,3/ S9;
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MA<_?_49IDD2F:#,T0??QR[4_5#(G/1LX)@16%,NCA."$F@KED(%6/F]<.-+
M :E-FUX3X^TBIW19FZOID40%9BAYJXDN;C''=)%:")H (^-$X3,T@ 8#(]W?
MJSA *G$MD7WGIZX66P4#@3Z\8USTJXM_;C,D(H+29_OQ[X\B2!,1LCTXM18W
M.D(JUKVS4RNOXT1B"236L<=OD,"68=CN_CH^^5)%HD:S+J?6> OT'7U43R^K
MJ8'D%=!;AH#)B7S@UR^28*!RS:EQY_AG'%@=KLFG7#PE)I!#\?\ 4AK 7(CG
M "H1,#OD/:'MR%"JQQ. =M)35,)](XY9G4S?$XZ*VWB,39^NSQS*SF41\F09
MU^W =AIY0R:YA:K''2Y'+)\XX$9&J2OK <5LP,*ADX_NYX0S=*DY+4.A;K/$
MD5 51F% !+5\<*!4&F558'X<!R@"IL4 ?9<';_%<XM,"LU%DA+C&,M9&7*T7
M+!S9.#IO(PV; @C,X_3DOCF99;+*"9CU9C@)P5%1<H4VJ.[K_J@Q*8W4*PN3
M)UE(VRG74)*=.'K X.$<-(B;!*?C'*=$J"[@"$+,WXX"E:5F$'96 *LOIQ"1
MHU3M,3._'$,FVN%R =J8.G7$%T0R#P_^G!)XF$@ZCZ_/    ,   &  QK^ X
M5(;QMI:=-IUP    (!@ T!T'\1!!"(5B"EB,1>L9Y>@8G>7IUG]=< N+"I,C
M.?OX<>>%HXXPM#%<WB4D;E>V.50_KT" 0$-(E$](W_3+0;9/\_JCGX4PK>CG
MOE;!6X>;N'.[RK!K>C8'^S'C@<GOP*,\SF"DM_T=8)-!P%4!/+OB^##I PW0
M'?XX;$X0\      X@D01V.1^N9_LLWYRX $  T& ^O\ )M"-(*<KI/8?#+9C
M,C51(?7;GK\G&11 J0T#_P"_K-\MA$,A&1O#LV8]YX\IPC',"EVYQ?N%0F"$
M7L5W9O\ .?\ 3)66?@^\XD<'[,GF?J6'OD?[\WQ@??"4>$'7:BOP*S2BA4D-
M]79IY$[_ --IIH*25RQ4*&6ZGGA! FQ0I@^F+[N)R=#K()9?UZ\>J<G1&HLI
MF66=_P ^%TDT'$&.ET77ZBR!D(!,7P'_ %L%AT0?A(F-Y.N$JG#(KU![AGK
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,V)7_ /5&4'U[)?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>inbx-20211231_g7.jpg
<TEXT>
begin 644 inbx-20211231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MA>6QA($5G
M96QK;P    60 P "    %   $*:0!  "    %   $+J2D0 "     S4V  "2
MD@ "     S4V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]OI-W-"VV2.!W4XS@A217FZ^,-=/P5?7C??\3,3[!/Y*=/-"_=V[>GM2OO\
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M:A3+&T3DC.",87YNHZ9H Z"BL/4O&?A_2+.VNM1U*."*Z020@HQ9U(R#L W
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MHMO'+\>]=ED4,T5HI0D?=)6,9_+(_&NWO/#^F:AK%IJEY;>9>6?^HE\QAL_
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M#/X@^T7+:K<V_GSW)N'/F@MRC#."/KSGFF>)(GF\ ^ XHI&B>22-5D4X*$@
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ME1&LF/O8#@D'J1S2O:7%K#XG\/Z,)3!;K;S6\"L2423_ %D:9.>0C8'^U0]
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M/^^OYUY=11_;K_Y]_C_P ^L>1ZCYL?\ ?7\Z/-C_ +Z_G7EU%']NO_GW^/\
MP ^L>1ZCYL?]]?SJ.>=5B)610<CN/6O,J*/[=?\ S[_'_@!]8\CU'S8_[Z_G
M1YL?]]?SKRZBC^W7_P ^_P ?^ 'UCR/4?-C_ +Z_G1YL?]]?SKRZBC^W7_S[
M_'_@!]8\CU'S8_[Z_G1YL?\ ?7\Z\NHH_MU_\^_Q_P" 'UCR/4?-C_OK^='F
MQ_WU_.O+J*/[=?\ S[_'_@!]8\CU'S8_[Z_G1YL?]]?SKRZBC^W7_P ^_P ?
M^ 'UCR/4?-C_ +Z_G1YL?]]?SKRZBC^W7_S[_'_@!]8\CU'S8_[Z_G1YL?\
M?7\Z\NHH_MU_\^_Q_P" 'UCR/4?-C_OK^='FQ_WU_.O+J*/[=?\ S[_'_@!]
M8\CTV"=6A4M(I)Z\BI/-C_OK^=>744?VZ_\ GW^/_ #ZQY'J/FQ_WU_.CS8_
M[Z_G7EU%']NO_GW^/_ #ZQY'J/FQ_P!]?SH\V/\ OK^=>744?VZ_^??X_P#
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M/^$HTK_GLW_?LT?\)1I7_/9O^_9H]I@.\?P"]+R)_P"P=,_Y\X_UH_L'3/\
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MO^>S?]^S1_PE&E?\]F_[]FCVF [Q_ +TO(G_ +!TS_GSC_6C^P=,_P"?./\
M6H/^$HTK_GLW_?LT?\)1I7_/9O\ OV:/:8#O'\ O2\B?^P=,_P"?./\ 6C^P
M=,_Y\X_UJ#_A*-*_Y[-_W[-'_"4:5_SV;_OV:/:8#O'\ O2\B?\ L'3/^?./
M]:/[!TS_ )\X_P!:@_X2C2O^>S?]^S1_PE&E?\]F_P"_9H]I@.\?P"]+R)_[
M!TS_ )\X_P!:/[!TS_GSC_6H/^$HTK_GLW_?LT?\)1I7_/9O^_9H]I@.\?P"
M]+R)_P"P=,_Y\X_UH_L'3/\ GSC_ %J#_A*-*_Y[-_W[-'_"4:5_SV;_ +]F
MCVF [Q_ +TO(G_L'3/\ GSC_ %H_L'3/^?./]:@_X2C2O^>S?]^S1_PE&E?\
M]F_[]FCVF [Q_ +TO(?!H>FM I:SC)/UJ3^P=,_Y\X_UJI!XFTQ(55IFR/\
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MGM5C?S+=&5'5P>-K$D$%2.O/'3I5T:59"WNH#;JT=XS-<*Y+>86&#G/M@8[
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M-F)"1X)S]^O)S*>*BH_5[];V5^QC5<U;E+G_  FDG_/DO_?P_P"%'_":2?\
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M_P#?='MLU[/[E_D'-6+O_":2?\^2_P#?P_X4?\)I)_SY+_W\/^%4O^$4U/\
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M_,])HHHKQSV0HHHH **** "BBB@ HHHH **** (K;_CW3Z5+45M_Q[I]*EH
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M ._9H_X2G2_^>K_]^S7$_9+C_GWE_P"^#1]DN/\ GWE_[X->1_:^+_E7W/\
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M_P P]O/L=M_PE.E_\]7_ ._9H_X2G2_^>K_]^S7$_9+C_GWE_P"^#1]DN/\
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M1110!%;?\>Z?2I:BMO\ CW3Z5+0 4444 %%%% !1110 4444 %%%% !1110
M4444 13]8O\ KH*EJ*?K%_UT%2T %%%% !1110 4444 %%%% !11397\J%Y,
M9VJ6QZXI-V5QK5V*>L:-9ZY8_9;]&*JXDC>-RCQ..C*PY!%9MEX/MK:_@N[S
M4M3U1[8[H%OKC>D38QN"@ %L'J<UFZ?XN\1:EH\6J6WA.-[66/S%VZFN\K[*
M4'/MFK<_B^68:+_8>GK>G5XI)8Q/<>1Y80 D'Y6YYQ^%5LQ;BR^"8SJ%Y=6N
MN:Q9&\F,TL5M.BIN( XRA/0#O6OH^BV>AV9M[%7^=S)++*Y>25SU9F/))K-@
M\17\.M6FG:YI"V1O=PMYH+KST9E!8JWRJ5.!QP:V[R\AT^QFN[MQ'# ADD8]
M@!DTMD&[,G6K2:/6=+U>VC>4VSM!.B*2QBDP"0!UVL%/TS6Q+;PSM&TT,<C1
M-OC+J"4;!&1Z'!(S[U'87$MWI\%Q<0&VDE0.82VXIGL3Z^M8]_XCO4U.ZL]'
MT@ZA]A16NI&N!"%)&0JY!W-CGL.G-&VC#?5%W5]"M]8:WD>6>UN;9BT%U;.%
MDCSP0"0001U!!%.TC1+;1DF\EYIY[A]\]S</ODE;&!D^PX   'I6?-XL6:ST
MMM&LGOKG5(S+!"[B(*@ +,[<XQD#@')Z4U?%WE:=J4FHV#VM[IS(LMJ)0X<O
MCRRK\ AB1R0,<Y%&UPWL:+:#9RVNHP7'F3+J+$SL[?,01M !&,  #'^-0Q6"
MZ!8WUY&UWJ5W(@9FD :64J,(@"J!C\.Y)[FHH_$GEV6HOJ5I]GNM/95DABE\
MP2%@"@1L#);('('-:CS72Z69A:JUT(M_V<2\%\9V[L>O&<4GL/J5/#>EOH_A
M^VM)V#S@&2=AT:1R6<_F36I5;3K^#5--@O;4DQ3H'7(P1['T(Z&K-4]R5L1W
M'_'M)_NFGC[H^E,N/^/:3_=-<&WQ(N$<K_9T1VG'^L/^%=%#"U<1?V:O8Y\1
MBJ6'M[1VN>@45Y]_PLJX_P"@=%_W]/\ A1_PLJX_Z!T7_?T_X5T_V7BOY?Q1
MR_VKA/YOP9Z#17GW_"RKC_H'1?\ ?T_X4?\ "RKC_H'1?]_3_A1_9>*_E_%!
M_:N$_F_!GH-%>??\+*N/^@=%_P!_3_A1_P +*N/^@=%_W]/^%']EXK^7\4']
MJX3^;\&>@T5Y]_PLJX_Z!T7_ ']/^%'_  LJX_Z!T7_?T_X4?V7BOY?Q0?VK
MA/YOP9Z#17GW_"RKC_H'1?\ ?T_X4?\ "RKC_H'1?]_3_A1_9>*_E_%!_:N$
M_F_!GH-%>??\+*N/^@=%_P!_3_A1_P +*N/^@=%_W]/^%']EXK^7\4']JX3^
M;\&>@T5Y]_PLJX_Z!T7_ ']/^%'_  LJX_Z!T7_?T_X4?V7BOY?Q0?VKA/YO
MP9Z#42?\?$OT6N#_ .%E7'_0.B_[^G_"F+\1[A9&;^SX_FQ_RT/^%']EXK^7
M\4']JX3^;\&>B45Y]_PLJX_Z!T7_ ']/^%'_  LJX_Z!T7_?T_X4?V7BOY?Q
M0?VKA/YOP9Z#16#X7\0R>((+B22!8?)8* K9SD5O5PU:<J4W">Z.^E5C5@IP
MV84445F:!1110 4444 %%%% !1110 5%<_Z@_P"\O\Q4M17/^H/^\O\ ,4 2
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5M_Q[I]*EJ*V_X]T^
ME2T %%%% !1110 4444 %%%% !1110 4444 %%%% $4_6+_KH*EJ*?K%_P!=
M!4M !1110 4444 %%%% !1110 5%=?\ 'G-_US;^52TA 92& ((P0>]*2NFA
MIV=SSWP;H.KW_@?3<>)[NVLYK?'V>"VA!13G@.5+#Z]:N:OH_P!D\1^$]+T>
MZETY((;I(Y8U5V4!$_O@@Y^E=G;VT%I;I!:0QP0QC"1Q(%51Z #@4CVT$EQ%
M/)#&\T((CD9 63/7!ZC/>J;N[DI62.,M+>XL?'UM#XIOY]0D*.VDW+A(X\XP
MZ%%4?O ._.0>,5K>.C_Q2Y5CB)[NV67_ '#,@;/MBMRXL[:[\K[5;Q3^2XDC
M\Q VQQT89Z'WJ/5-/AU;2[FPN<^5<1E&(ZC/<>X/-+HO(?4SM=U37;">)-$\
M._VM&RDN_P!N2#8<],,.:I:M>:3KL5]H^K7EQI<EJBO,!<B'<K)G<"#\Z#)!
MSQD<BN@T]+J/3X$U!HWN50+(\>=K$=QGUZXIEYI6G:C)&^H6%K=/%S&T\*N4
M^F1Q0UT!/J<EIOBQM,\$Z.)XHGU&\5HK2$[8$=5)"R-T"+M"L?K@"M+2=#LK
MS2M0CO;^+4;S4&#WL]O(/E8#Y F#\H7'R_3-;-]HNE:FZ-J6F6=XT8VH;BW6
M0J/09'%.L-)T[2PXTS3[6S$F-XMX5CW8Z9P!GK3WNV&UK'&ZG"VG_P!J75G+
M+>G2U^TSSW.UC-=; $#!0HVQIAL #DCN#70:!=W;:EJ-A=7IU!+40LERR*K'
M>I)4[ %XP"..C#ZULI;01QND<,:)(Q9U50 Q/4GU)[U6%@FGZ9-!H=K:VK[6
M,4:H(X]Y'!(4>OM2V0;F1X)R-.U)!_J4U6Z6'TV^8>GXDUTE4=&TR/1M'M[&
M)B_E+\TAZR,3EF/N22?QJ]3\@\R.X_X]I/\ =->9OX"UIY&8+!@DD?O:],N/
M^/:3_=-/'W1]*ZL-BZF&O[/J<>*P=/%6]I?0\O\ ^$ UO^[!_P!_?_K4?\(!
MK?\ =@_[^_\ UJ]1HKL_M?$^7W''_8^&\_O/+O\ A -;_NP?]_?_ *U'_" :
MW_=@_P"_O_UJ]1HH_M?$^7W!_8^&\_O/+O\ A -;_NP?]_?_ *U'_" :W_=@
M_P"_O_UJ]1HH_M?$^7W!_8^&\_O/+O\ A -;_NP?]_?_ *U'_" :W_=@_P"_
MO_UJ]1HH_M?$^7W!_8^&\_O/+O\ A -;_NP?]_?_ *U'_" :W_=@_P"_O_UJ
M]1HH_M?$^7W!_8^&\_O/+O\ A -;_NP?]_?_ *U'_" :W_=@_P"_O_UJ]1HH
M_M?$^7W!_8^&\_O/+O\ A -;_NP?]_?_ *U'_" :W_=@_P"_O_UJ]1HH_M?$
M^7W!_8^&\_O/+O\ A -;_NP?]_?_ *U-'@/6B[*%@RN,_O:]3J)/^/B7Z+1_
M:^)\ON#^Q\-Y_>>9_P#" :W_ '8/^_O_ -:C_A -;_NP?]_?_K5ZC11_:^)\
MON#^Q\-Y_><UX-T.\T.WNH[X(#(ZLNQL] :Z6BJ.H:UINE36L6HWL-M)>2>5
M LC8,C>@_P ]P.XKS:U65:HZDMV>G1HQHTU3CLB]11161J%%%% !1110 444
M4 %%%% !45S_ *@_[R_S%2U%<_Z@_P"\O\Q0!+1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 16W_ ![I]*EJ*V_X]T^E2T %%%% !1110 4444 %
M%%% !1110 4444 %%%% $4_6+_KH*EJ*?K%_UT%2T %%%% !1110 4444 <#
MXBU"?_A*9!-J=Q:?8[NQ6VM8YC&DT<DBB21@/OCJO/ Q[UM^';\W/B'7(+>^
M:^L8I(WCD+[Q'(P)>-6]!A3CMG%9GBG4;2XDU87VB65_!I42(AN5#.]Q+MV(
MHQPO(R<]_:M+PI-<VTMWHE]9Z?:S62QR@:=&4A*R9_A/0@J<^O!HCM_7E_P_
MS"7]?U\SI**** "N-U#5-1OO%EYI4>OPZ"ELL?D(T,;R7>Y<EAYG& >,*,\'
M-=E7):S?LM_<6GB7PQ)JMCOW6<UI9?:1MP,AUR2K YY P:74?0AUO4_$>E>!
M[V6[ECAU"WN8X8;R*-")HRZ@2;#D*2"00>XXIVJ)XF\-:?+J[:]_:T%J/,GM
M)[2./?&/O%60 A@,GG(K$O-*OU\ ZNMKIE[#:37D,MCIK*9)HHPZ%OE&2N2&
M.WM6QK.M7?B72;C1M(T3589KU/)>XO;4P10HW#,2W4XS@#-/6VF__ 0E;KL=
MC#*D\$<T9RDBAE/J",UEZ#J$^K?;+XO_ *&T[0VJ #[J$J7SU.Y@?; 'O6E;
MP+;6D4$?W8T"+GT Q7)^'+/4;GX?6UCI>I?V5?6TLD,LWV=9MK)(P8;6XYZY
MINUW82O;4Z+6-432K'S=AFGD816\"GYII#T4?S)[ $]JYRTU_5H_AY=:E>RQ
M/J$,\L+2*@V1XF,>X#CA1SSV'-65\*:M+-:W=[XIN9+ZVC=%FCLX54ACDG85
M8 XP,CL/<T>"=*O+/1KN+59YYUFNIP(+F!$ 'FOEL!02'!SSQZ<4NX^PR/6[
MZTCU.Q^T_P!H745S';64SHH,CR(&PP4!3MR6. /E%=#/!>?V0T-O=G[8(L)<
M,B\N!U*XQR>H'X8KF+_19[BRU5M'L?L*6D$EMI\$48AW,PS)(H&,%ONJ?8GO
M5WPK;);W6HR6-G+8:6_E>1!+"T.'"GS&", 0#\O..2"?<FZ#9FMH>J+K6BVU
M^B>695^=,_<<'#+^# BK]<YX%4_\(P)^0EU=7%Q$#_<>5BOYCG\:Z.FP([C_
M (]I/]TUP3Z]J8=@+Q\ ^@KO;C_CVD_W36 ?!ULQW?:9>>>@KR,RHXFJH^P>
MU[ZV[&-6,Y6Y3 _M_5/^?R3\A1_;^J?\_DGY"M__ (0RV_Y^I?R%'_"&6W_/
MU+^0KR/J69=W_P"!?\$P]G5_IF!_;^J?\_DGY"C^W]4_Y_)/R%;_ /PAEM_S
M]2_D*/\ A#+;_GZE_(4?4LR[O_P+_@A[.K_3,#^W]4_Y_)/R%']OZI_S^2?D
M*W_^$,MO^?J7\A1_PAEM_P _4OY"CZEF7=_^!?\ !#V=7^F8']OZI_S^2?D*
M/[?U3_G\D_(5O_\ "&6W_/U+^0H_X0RV_P"?J7\A1]2S+N__  +_ ((>SJ_T
MS _M_5/^?R3\A1_;^J?\_DGY"M__ (0RV_Y^I?R%'_"&6W_/U+^0H^I9EW?_
M (%_P0]G5_IF!_;^J?\ /Y)^0H_M_5/^?R3\A6__ ,(9;?\ /U+^0H_X0RV_
MY^I?R%'U+,N[_P# O^"'LZO],P/[?U3_ )_)/R%']OZI_P _DGY"M_\ X0RV
M_P"?J7\A1_PAEM_S]2_D*/J69=W_ .!?\$/9U?Z9@?V_JG_/Y)^0I!KNIAB1
M=OD]>!70?\(9;?\ /U+^0IB^#[8RNOVF7Y<=A1]2S+N__ O^"'LZO],P_P"W
M]4_Y_)/R%']OZI_S^2?D*W_^$,MO^?J7\A1_PAEM_P _4OY"CZEF7=_^!?\
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MU^V:2"15&[)9" /E-=U16M+)HTZD9\^S3V[#C02=[A1117NG2%%%% !1110
M4444 %%%% !1110 5%<_Z@_[R_S%2U%<_P"H/^\O\Q0!+1110 4444 %%%%
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MHSWUB]M>Z<ZQ36GF!LLV-FU^A5MPYP._'%9HATW0?$7AO[-+&NFBTN+2*=I
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M9T^Q@_\ "&VO_/S-^0H_X0VU_P"?F;\A6]]JM_\ GO'_ -]BC[5;_P#/>/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% $5M_Q[I]*EJ*V_X]T^E2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% $4_6+_KH*EJ*?K%_P!=!4M
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M0HL(#M2)!T\S'WY/<]/Y=K7>:!1110 5$G_'Q+]%J6HD_P"/B7Z+0!+1110
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M5S_$0H_'WHZ!U,OP(3_PC3*/]4E[<K#_ +@F?%='532M.ATC2;:PML^7;QA
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M** "BBB@ HHHH **** "BBB@ J*Y_P!0?]Y?YBI:BN?]0?\ >7^8H EHHHH
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MCGD4H;R>:["D<A9)&9?T(KH:;\Q(CN/^/:3_ '37 /K>I!V O)< ^M=_<?\
M'M)_NFL$^#[1CN-Q-SSV_P *\C,J&(K*/L'M>^MNQE5C*5N4YW^W-3_Y_9?S
MH_MS4_\ G]E_.NB_X0VS_P"?B?\ 3_"C_A#;/_GXG_3_  KR/J&8]W_X$8>S
MJG._VYJ?_/[+^=']N:G_ ,_LOYUT7_"&V?\ S\3_ *?X4?\ "&V?_/Q/^G^%
M'U#,>[_\"#V=4YW^W-3_ .?V7\Z/[<U/_G]E_.NB_P"$-L_^?B?]/\*/^$-L
M_P#GXG_3_"CZAF/=_P#@0>SJG._VYJ?_ #^R_G3X=:U)YXU:\E(+ 'GWK?\
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M %%%% !1110 4444 %%%% $5M_Q[I]*EJ*V_X]T^E2T %%%% !1110 4444
M%%%% !1110 4444 %%%% $4_6+_KH*EJ*?K%_P!=!4M !1110 4444 %%%%
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M** "BBB@ HHHH **** "HKG_ %!_WE_F*EJ*Y_U!_P!Y?YB@"6BBB@ HHHH
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M %%%% !1110 4444 16W_'NGTJ6HK;_CW3Z5+0 4444 %%%% !1110 4444
M%%%% !1110 4444 13]8O^N@J6HI^L7_ %T%2T %%%% !1110 4444 %%%%
M!1110 4444 %%<8AU[6?%NN6MIXAET^VL)(5CB2TAD^]&&/++GK4VC^)9;*+
M68=>O4O5TNX2%;N&'!G+@$)L7(+@G;@>U '6T5CZ=XCAO[[[%/97NG731F6.
M*\B"F51C)4J2#C(R,Y&>E9UKX_TZZM[:Z6PU)+&>01?;'@ BC<G: QW9Z\9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/7I5>X>8^)M6AU)-OAV36%2]='P6<Q)L5_2/(&>>=P[9JK>];^MU_F3?2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ>K:A_9.CW5_\
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MP:;K7F-!:27)E81E)&F5,K\H/R]1^->@>//#=WK7Q4T^RU+P</&MY!X:@-Q
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MX.\6?#W5?#/]G:S#81WH:[T+5YG5]/D.UQ'&R[7$>X9&3DG)/4U;C9RCV?\
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MI<MI[,UO,DBEHW3=\PX!!!YXSWP.SI-6*"BBBD 4444 %%%% !1110 4444
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MXLN86N/)@AATAFEN%VAA,BY_U9!&&8C/84KVT[?KH+=+^O,W[7PO96GC*_\
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M@(W9 ) )8GUR>:6Q^%.F6GBBWUJ[U[Q'JQM)FGM++4]3:XM[=R" RJPW9 )
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MWN)O"VJQWZVS!9E$;QNF1P2K@'!['&.#Z&A:WMT!Z;G0T444 %%%% !1110
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MI7B[XA7>K6MOJGPQ_L^SDE"S7?\ ;]O+Y*D\ML49;'H*[VBA:.X/56"BBB@
MKPZPM/'U_P"*?B#9^##X;73[C57BN3JPG,H9H$!VA 5QM(Z@\^U>XU7MK"SL
MY;B6SM(+>2ZD\V=XHPIE? &YB/O'  R?2IY4Y7>UFOOM_D.]EIW_ ,SPQM \
M4^#_ (G:+HG@.72[[4-.\(>6[ZN)%29!<DMM"'(8MC )P!GFD\-PZSXD\"^+
M=3LVU"7Q??ZK&NIZ9I%ZNERV3Q838LK[QC:,D_Q=.H->Z?V=9'4QJ/V.W^W"
M+R!=>4OF^7G=LWXSMSSC.,TRWTG3K34;F_M;"UAO;O;]HN8X562;:,#>P&6P
M.F>E7=O?S_\ 2K_\.)VTMTM^$;'S_+H7C'3/!/C";Q/9>*+>T;0IU1M7\4PZ
ME$7RN (T12&P#\V>!D=Z[#1O"7COQ+?>%;SQE=>'8-*T5H[VV72DG-Q*P3"J
MYDX P<G'IC'<>JW=G;7]G+:7]O%<VTRE)89D#HZGJ"IX(]C4D<:11K'$BHB
M*JJ,!0.@ HOK?T_!M_J)JZMZ_C;_ "/G<>+?M'Q,\/:KX:\8ZO<P:EK9M;G3
M-0U=&*)ET8?84C CCX&UF;=R/E!YJ;4-!U7Q/X'^(NKZCXLU_9I][J,-II\-
M\5MS&F&VNI!+#C&W. N0,9KVY?"GAU+B:=- TM9IYUN)9!9QAI)5)*R,<9+
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M%:7A_P 6W<'PRO[;Q?X@U.ULY]6BLM/U"QU^TO;J+S!N*RW:955!!8L0&"G
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M,%;9]ZF> ]P-S!U_WB.U:D-U?0?$#QJMG\5-,\%J=8)-I>6MM*TQ\I/W@,K
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MO4V[ZL?5^K_,****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDO\ )G44444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3RVS)*VXF'<V"H7(.,8').NGPKU*'PI96KZI!?:Q+X@@UO5+R8&-965P65
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M\->!O%/B:V\*3^*]3TN30-*L%ELEL87CN9VDMP@$NXE1M#'E3SCH,\4_A_\
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M>%K/5]"/AJRU-+VU+QRBZD03^:8W."HP22",DD#) )Q>GM$NFGYH6OLVWO\
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M2_R7WDO;3^MO^#]QUU%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>inbx-20211231_g8.jpg
<TEXT>
begin 644 inbx-20211231_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MA>6QA($5G
M96QK;P    60 P "    %   $*:0!  "    %   $+J2D0 "     S8T  "2
MD@ "     S8T  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                       R,#(R.C R.C R(#$R.C4V.C(T #(P,C(Z,#(Z
M,#(@,3(Z-38Z,C0   !+ &$ >0!L &$ ( !% &< 90!L &L ;P   /_A"Q]H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG
M[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U
M+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(R+3 R+3 R5#$R.C4V.C(T+C8T
M,CPO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^/')D9CIL:3Y+87EL82!%9V5L:V\\+W)D9CIL:3X\+W)D9CI397$^#0H)
M"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO
M>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@
M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8
M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4
M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ_\  $0@"L +9 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
M           ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $
M$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ
M-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(
MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8
MV=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        !
M @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'
M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#
M1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66
MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F
MY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBB@ HKE?B7>7-A\
M/]0N+&XEMIT,>V6%RC+F10<$<UQ7C_6]9LO#G@^73-0O([BX@W/Y4K9F;;&1
MN /S<D]<]:/\[#M^OX'K]%>7>+?&,VK?">TUG2;N:SN7N8XYOL\I1D< [ER#
MG'?Z8J?XHW]];P>'8K/5[C2UNIC'-<13,@ (7YFP1D#)/)H=U]]A+6WI<]*H
MKQ#66O\ PW9+J.D_$QM9NDD55LUG\S?D_P!WS'!_$5TWQ,U35(?#6@21WL^D
MW%U.@N&@E:/9E/F!P1P#ZGM1TOYV#K8])HKQ+64N_#^ER:EIWQ3.IW,)4I:K
M<;_,Y Z>8V?7D8KMM;AUSQ!\/K#5=*NKJQU>.!+KRH)619CM!9"H.#GJ ?IW
M-'2X=;';T5Y"/%^K?$34](T?0Y;K2PJ>=J<\#E&4C@@$'./3U+#TKUR.,11)
M&I8A%"@LQ8G'J3R3[T[:"N.HKBO'OBG5=,BFTSP_I\TUVUHUQ+=CA+:/YLMG
M^]\IQG';KTIG@?6[B+X3C5]1GFNY8(YY6>:0NS[6; R>>V*F^C?8JVJ7<[BB
MO'C=>(D\!+XZ_M^^-[YV]K,O_HWE^9LV^7T_'^O-;GB;Q%?:MJ_AC1]-O)M-
MMM9B6XFN(#B3:1D*K=OK[C\:L[VZWL+I?H>BT5Y_X7U6^TGXAW_A*]U&?4K9
M81/;3W3;Y4X!*LW?@_I[UTGC6XFM/!&K3VLTD,T=LS))&Q5E/J".14MVCS#2
MN[&Y17CNG^&?$MYX,C\0CQYJ$):W,_DS2R;1C/!?S/;KBI=3\6:OJ'P3AU4W
M<UO?K=+"UQ;N8V< D9RN.O>F]+^7^=A+6WF>NT5Q5A\2-)3^S;6\BU&-;I$2
M._GMBL$KX .&/)Y[XQ6MKWC&PT&^AL'M[R_OIDWK:6$'FR;?[Q&1QP:;T8D[
MHWZ*P="\9:5K]K>30--:M8D_:H;M/+>'&>6&2.Q[]JR?^%I:.$6X?3]733V?
M8NHM9D6YYQG=G/Z9I=;#.THK&UWQ7I?A^Q@N;N1Y?M1 MH;=?,DG)Z;1WZCV
MY'K4>@>+M/\ $-S/:0QW5G>VX!EL[V'RI5!Z''/'/ZCUH#S-VBJNJ:@FE:3=
M7\L;R);1-(R1C+-@9P/>O,=&\2^(M4^+>GIJT=QIMK/;N\6GF0A=FUL%U[MD
M$\C/2A:NP/17/6***\,O/$VM:?\ %&\F;5+QM-L]2"S6[7#F,1L^W&W.,?\
MUJ%K)1[@](N1[G17D7Q;\0:K!K,5KHM_=6D=E;"6Y:VG:/)=@%!VGGH/SKLA
MXML]"\*Z))J1NKN\O;:/RH($,LT[; 20,\]>I/>A:QO\@>CL=717/:!XTT[Q
M!J$^GQ07EC?VZ[WM;Z'RY O'.,GU'YUQ'A_6+Z?P]XWDOM6OP+:9A%,LC2/
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M $?XGAOQ(T>Y\*ZE<V5H,:/JLJW4:8XCD7.5'I][\B/2NJ^+/V7R_"W]H_\
M'G]H_?\ 7_5_)NZ<],].:]*OM-L=3B6/4K*WO(U;<J7$2R 'U (ZTV^TG3=3
M2--2T^UNUC^XMQ"L@3Z9'%2M(I>8-W=_)_B>+>))/AI#H<TOA:2:/5D*M;-"
M;@$-D<Y?C'Z^E;/CM;J\\$^$%UM6:YFN(A<!^&)*\Y]#ZUZ/!X9T&UG6:VT3
M3H94.5>.TC5E/L0*N7>G66H",7]G;W0B;?'YT2OL;U&1P?>G_FOP)_R9Y'XU
M\'6O@?4K+Q'H>G1W&G1N%NK.X'FJOH?FR1GU[''KBNQ\5^/+72_!,.IZ5();
MC44VV*CDY(Y)'^SZ>N!77W%O#=V[P74,<T,@VO'(H96'H0>#5%?#NB)Y&W1]
M/7[.<PXM4_='.<KQQSSQ2W7*RNMSRG2K'5OA??Z=K6J.TUEJBB/4EQDP.22,
M^I&<Y_WAZ5W7B:S\9ZA>P3^#M:L;2Q: %EF4,7;).X'RVXP1WKJ+NSMK^V:W
MOK>*Y@?&Z*9 ZMCD9!XIT$$-K;I!;1)##&-J1QJ%51Z #I5;H6QC:VES'\/M
M02_D66Z73)!,Z#AG\H[B.!QG/85RW@JQDU+X'R64(S)/!<QH/5BS8_6O0Y8H
MYX7BGC62.12KHZY5@>H(/44RTL[6PMEM["VAMH%SMBAC"*,\G '%)Z\WF-.W
M+Y'C3:[9-\#4T-)D.JM*+;[%G][N\[=]WKT_7BNF\2VF@:?H/AG3/%'VRVGC
MCCB@U"U8(;9U5027/0=^AZ9[5W/]D:;_ &A]O_LZT^V?\_/D+YG_ 'UC-37=
ME:W]N8+ZVAN86Y,<T8=3^!XIMWU[NXEIIZGEW@S3;6;XLWUYHMQ->V%G;>7)
M?2S&4SRL!D[^YZ]./EKMO'O_ "(&L_\ 7J];=I9VUA;K!8VT-M"O2.&,(H_
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M<#W/N.E>A+HFE+IS:>NF68LF.YK86Z^63G.2N,=0*?<:5IUY9QVEW86L]M&
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MGM);L'$,>5)+$=.F<>U>G.B21LDBJR,,%6&01Z8JM8Z3IVF%SINGVMF9/O\
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M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGO;>!+L+Y!FD">9D9 &3R>1Q7F>J:-JG@KP]_;GAOQE+-I\2J8;2[(D1U)&
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MB1[9E#1J_P IQM/'\3<>WM57X=>&[+7/AIJT+VT(NKB66%;CRQO'"%1NZX#
M'%);.7E?\1];>=OP/5)[^TMK+[9<W4$-K@-Y\D@5,'H=QXYR*B;6--5[=&U&
MT#72[K=3.N9AZKS\P^E>.)J\WB;PGX=\&[F%XUX;>\7ND473/X'_ ,<-;WQ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_"+:I_SR3_OX*/\ A%M4_P">2?\ ?P4?7,S_ .??X,/:5NQO_P#"7:;Z3_\
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MNTWTG_[X'^-8'_"+:I_SR3_OX*/^$6U3_GDG_?P4?7,S_P"??X,/:5NQO_\
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M2#MM/]*DJ)O^/I/]P_TJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "FRM&D+O,5$:J2Y;H!WS3JJ:J]K'H]XVHDK:"!_/*@DA-IW<#GIGI2E
ML-;GDBZW\*'\0@_V),,S9^T%&%OUZ^7O^[[;/PKH?B)?^"[2^L%\4Z3=7SM
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M\:TJY;X:3R7'PZTEIOO+&R#G/RJ[ ?H!74UK/XF9P^%$5UQ;/GTJM_;6F_\
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M_"C^UL5_S[_,/;S['=_VUIO_ #^P_P#?5']M:;_S^P_]]5PG]F7_ /SY7/\
MWZ;_  H_LR__ .?*Y_[]-_A1_:V*_P"??YA[>?8[=]9TXS1$7D.!G/S>U2?V
MUIO_ #^P_P#?5<'_ &;? @&RN,GI^Z;_  I?[,O_ /GRN?\ OTW^%']K8K_G
MW^8>WGV.[_MK3?\ G]A_[ZH_MK3?^?V'_OJN$_LR_P#^?*Y_[]-_A1_9E_\
M\^5S_P!^F_PH_M;%?\^_S#V\^QW?]M:;_P _L/\ WU1_;6F_\_L/_?5<)_9E
M_P#\^5S_ -^F_P */[,O_P#GRN?^_3?X4?VMBO\ GW^8>WGV.[_MK3?^?V'_
M +ZH_MK3?^?V'_OJN$_LR_\ ^?*Y_P"_3?X4?V9?_P#/E<_]^F_PH_M;%?\
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MA/[,O_\ GRN?^_3?X4?V9?\ _/E<_P#?IO\ "C^UL5_S[_,/;S['=_VUIO\
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MQ_X ?6?(]3HKRS)]:,GUH_MW_IW^/_ #ZSY'J=%>69/K1D^M']N_]._Q_P"
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MBZ.#D?-1_JW5_FC^/^0?ZQX?^1_A_F>__9H/^>,?_? H^S0?\\8_^^!7@/\
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MJ_S1_'_(/]8\/_(_P_S/?OLT'_/&/_O@5%]GA^UC]S']S^Z/6O!O^$U\2?\
M08NO^^Z3_A,_$>[=_;%UG&,[J/\ 5NM_-'\?\@_UCP_\C_#_ #/?_LT'_/&/
M_O@4?9H/^>,?_? KP'_A-?$G_08NO^^Z/^$U\2?]!BZ_[[H_U;J_S1_'_(/]
M8\/_ "/\/\SW[[-!_P \8_\ O@4?9H/^>,?_ 'P*X_X8ZK?:MH5W-J5U)<R+
M<[%:0YP-JG'ZUVE>#B,-]7JRI2LVCW\-6CB*,:L59,C^S0?\\8_^^!3D1(QB
M-54=< 8IU%8J*6R.@****8!1110 4444 %%%% $3?\?2?[A_I4M1-_Q])_N'
M^E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SGC?P]=^)=$@
ML[&2&.2.[CF)F8@;5SGH#SS71T5#>7*65C/=2@E((VD8#K@#)_E2O9!:[.<T
MGPD\&K^)9=56VN;+6)598@2QV@$$,"!@\]B:?X.T#4_#*7>G7%S%<Z4LA:P.
M]C+$I/*,",8^A]?7CE;+Q[XWO[=-8L_#%O=:*TAPMN_F3[=V,</G(_W/PQ6O
MXL\6>(K'7=+TSPOIUM<S7]NTPBNU*N,<XY=0..QIK2WW!O?[Q^M1G3OBSH.I
M-Q#>VTEBS'H'&64?CG'X5M)X-T&/Q$==2PQJ1<N9_.D^\1@G;NV]#Z5SVA^)
M=3O_ !%#H'CS0K6VO6_TJR=%#QDJ,\99L,.3D'\N_4>)M;C\.^&[W5) &,$>
M44_Q.>%'XDBCX4GZ_P!?>'Q.W]?U8HW'AZ[F^(]IX@62$6D-BUNR%CYA8L3D
M#&,<^M8VK>#-=&I:P?#M]8Q6.N@"\6Z5_,A.,,8]O!R">O\ ]>NRTN6ZFTFT
MEU%8UNI(5:98@0JL1D@9)X_&N1UGQ+XLCNM6FTC2K.#3-)3<\FI)*KW6 2QB
MQ@8XQ^1SS@#26C\QIMZKR_X!-J7@N[MUT*Z\,7-NE_HL1@C%Z&\N9"NT[MO(
M/4\>M:7A'P]<Z%:7DNI7$=QJ&H7+7-R\0(0,?X5SS@>]9L_BO6]4L]&/A724
M:74H3-)<7BN;>V 'W69!R200/PXYXJ6WCS4GT>]CNK2U35K/4H]/D:,LT&7?
M:),9!P.>,]NHS@/6[_KK_F3I9?UT?Z$FI>&]6U+2-=O)(L:EJ$JI';&11_HL
M;C$6X' +C<3SCYL&GVT4_AGP3XBNKNW%A SSS6EF64^0A4!5PI*C+<X4D<U(
MGC"^?P\Q2"WDU=]1?3;=55A%*ZM@R8SD*%!)&3TZUK^+9)H/"%].EK:7LEO%
MYQANHM\3[2&/RY] 2/0XJ'\+[?\ #?\ #EKXEZ_\#_@$7@339-)\"Z5:3+MD
M$.]U(Q@L2V/UKH*J:5J,.K:1:ZA:G,5S$LB^V1T_#I5NM)7YG<SC\*(;L!K6
M0'D$8-8/_"O?"W_0)3_O[)_\56]=G%I(?05Q_P#PE^H_W+?_ +X/^-<U7,_J
M%O>:YNWD85X4)6]K%/U5S2_X5[X6_P"@2G_?V3_XJC_A7OA;_H$I_P!_9/\
MXJLW_A+]1_N6_P#WP?\ &C_A+]1_N6__ 'P?\:Q_UE7_ #\G][_S.;V."_Y]
MQ_\  4:7_"O?"W_0)3_O[)_\51_PKWPM_P! E/\ O[)_\56;_P )?J/]RW_[
MX/\ C1_PE^H_W+?_ +X/^-'^LJ_Y^3^]_P"8>QP7_/N/_@*-+_A7OA;_ *!*
M?]_9/_BJ/^%>^%O^@2G_ ']D_P#BJS?^$OU'^Y;_ /?!_P :/^$OU'^Y;_\
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M^@2G_?V3_P"*H_X5[X6_Z!*?]_9/_BJS?^$OU'^Y;_\ ?!_QH_X2_4?[EO\
M]\'_ !H_UE7_ #\G][_S#V."_P"?<?\ P%&E_P *]\+?] E/^_LG_P 51_PK
MWPM_T"4_[^R?_%5F_P#"7ZC_ '+?_O@_XT?\)?J/]RW_ .^#_C1_K*O^?D_O
M?^8>QP7_ #[C_P" HO/\/_# FC TI,-G/[V3T_WJD_X5[X6_Z!*?]_9/_BJR
MSXLU!G5BD&5Z?(?\:=_PE^H_W+?_ +X/^-'^LO\ T\G][_S#V."_Y]Q_\!1I
M?\*]\+?] E/^_LG_ ,51_P *]\+?] E/^_LG_P 56;_PE^H_W+?_ +X/^-'_
M  E^H_W+?_O@_P"-'^LJ_P"?D_O?^8>QP7_/N/\ X"C2_P"%>^%O^@2G_?V3
M_P"*H_X5[X6_Z!*?]_9/_BJS?^$OU'^Y;_\ ?!_QH_X2_4?[EO\ ]\'_ !H_
MUE7_ #\G][_S#V."_P"?<?\ P%&E_P *]\+?] E/^_LG_P 51_PKWPM_T"4_
M[^R?_%59\.ZO<:K]I^TB,>5MV[ 1US[^U;=>C0S*O7IJI"I*S\W_ )FL<)A)
M*ZIQ^Y'-_P#"O?"W_0)3_O[)_P#%4?\ "O?"W_0)3_O[)_\ %5TE%;?7,3_S
M\E][*^I87_GW'[D<W_PKWPM_T"4_[^R?_%4?\*]\+?\ 0)3_ +^R?_%5TE%'
MUS$_\_)?>P^I87_GW'[D<W_PKWPM_P! E/\ O[)_\51_PKWPM_T"4_[^R?\
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M]_/_ *U'/E/E]S"] F_X0VS_ .?B?\Q_A1_PAMG_ ,_$_P"8_P *A_X31/\
MGR;_ +^?_6H_X31/^?)O^_G_ -:CGRGR^YA>@3?\(;9_\_$_YC_"C_A#;/\
MY^)_S'^%0_\ ":)_SY-_W\_^M1_PFB?\^3?]_/\ ZU'/E/E]S"] F_X0VS_Y
M^)_S'^%,D\(6:;<3S\L!V_PIG_":)_SY-_W\_P#K4R3QBC[?]#8;6!_UG_UJ
M.?*?+[F%Z!9_X0VS_P"?B?\ ,?X4?\(;9_\ /Q/^8_PJ'_A-$_Y\F_[^?_6H
M_P"$T3_GR;_OY_\ 6HY\I\ON87H$W_"&V?\ S\3_ )C_  H_X0VS_P"?B?\
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M?B?\Q_A4/_":)_SY-_W\_P#K4?\ ":)_SY-_W\_^M1SY3Y?<PO0)O^$-L_\
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M_C1_:FG_ //];?\ ?Y?\:/[*P7\[^]?Y![&GW.+_ .$:U;_GT_\ (B?XT?\
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M?]^S7IM%']AP_G_ /JZ[GF7V.Z_Y]IO^_9H^QW7_ #[3?]^S7IM%']AP_G_
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MH **** "BBB@ HHHH *B_P"7P?\ 7/\ K4M1?\O@_P"N?]: ):*** "BBB@
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M^A_A1_9]G_SZ0?\ ?H?X4?V+5_Y^!]7EW/./M$W_ #UD_P"^C1]HF_YZR?\
M?1KT?^S[/_GT@_[]#_"C^S[/_GT@_P"_0_PH_L6K_P _ ^KR[GG'VB;_ )ZR
M?]]&D\^;_GJ__?1KTC^S[/\ Y](/^_0_PJ.:PLQLQ:P#YQ_RS%']BU?^?@?5
MY=SSS[1-_P ]9/\ OHT?:)O^>LG_ 'T:]'_L^S_Y](/^_0_PH_L^S_Y](/\
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M5_Y_&_[Y7_"C_A(M5_Y_&_[Y7_"NK_X1C2O^?=O^_C?XT?\ ",:5_P ^[?\
M?QO\:/[/S#_G[_Y,P]E5[G*?\)%JO_/XW_?*_P"%'_"1:K_S^-_WRO\ A75_
M\(QI7_/NW_?QO\:/^$8TK_GW;_OXW^-']GYA_P _?_)F'LJO<Y3_ (2+5?\
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M4 %%%% $4G_'Q#]3_*I:BD_X^(?J?Y5+0 4444 %%%% !1110 4444 %%%%
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M9!_S]R?]\"CV6:]_Q0<M8I?\)E>_\\+?\F_QH_X3*]_YX6_Y-_C5W_A#(/\
MG[D_[X%'_"&0?\_<G_? H]EFO?\ %!RUBE_PF5[_ ,\+?\F_QH_X3*]_YX6_
MY-_C5W_A#(/^?N3_ +X%'_"&0?\ /W)_WP*/99KW_%!RUBE_PF5[_P \+?\
M)O\ &FOXOO'QF"#@@]#_ (U?_P"$,@_Y^Y/^^!3)/!\*;?\ 2Y#N8#[HH]EF
MO?\ %!RUBK_PF5[_ ,\+?\F_QH_X3*]_YX6_Y-_C5W_A#(/^?N3_ +X%'_"&
M0?\ /W)_WP*/99KW_%!RUB30_$%SJFH&":*)%$9;* YZCW]ZZ&L?2O#T>EWA
MGCG:0E"N"H'^>E;%>S@HUXTK5_B-Z?,H^\%%%%=IH%%%% !1110 4444 %%%
M% $4G_'Q#]3_ "J6HI/^/B'ZG^52T %%%% !1110 4444 %%%% !1110 444
M4 %1?\O@_P"N?]:EJ+_E\'_7/^M $M%%% !1110 4444 %%%% !1110 4444
M %%%% $3?\?2?[A_I4M1-_Q])_N'^E2T %%%% !1110 4444 %%%% !1110
M4444 %<7XA\.63>)+.]N?$>L6<MU(T,%O;SL3N8#(3 )1?ER>W3IBNTKF?&*
M26J6FL6^I6.GS67F1A[_ #Y;+( #T.=WR@CZ8I/34:[&5X?30W\4(BZIKFH7
M-NTHM9-1E=H'=05D\LX 8@$@_C7=UQNC:7;K>>'K:UU.UFMM/LS=1H,B:X:0
M,IEQV3YB?J:[*J>FA(5R'BGQV^@ZO'I6EZ+=:S?M%YTD5OD;$SC/"L3S[=^M
M=?7E_C^?PZ?%>+[4M3\.:O#;#R=2@C)CE0GIA#N/\0_A[Y)P!4O=%+J=%I/C
MZ+5/#>JZ@VGS6M]I*,US83-AE(!(&['?!'(R"#QZX$7Q;OUMH[Z]\&:A!IK8
M9[Q79E"DXR"8PIZ^HJGHGB*_U7PIXML)]2;6;&QL2+;46@,3.#&?E(/)/'4Y
M/7).11:?$'PW:_"U-*>[,U^-.,!MA _+E<8W%=O?UIRTNUY?J"ULO-_H>IV=
MW!?V4-W:2"2"=!)&X'WE(R#7-Z9):3?$S66L8I1)%:0QWDHE'EM)U4;=N=P7
MON]L=ZM^!K*XT_P-I-M>*R3);@LK=5R2<'Z US/@^RFU.W\:017DEE?7&J31
M_:(\[HO[I&"#Z]Z<E:;MTO\ Y?J3%W@K];?Y_H=S;ZM976JW>FP3;KNS"&>/
M8PV!AE>2,'(]#7/>*/B%IOAS4K;38U%[?S2HCP))M\E6/WF.#S_L]?I7'Z5\
M/_$8\8:DK>)]4@6'R6-\8Y +T8SMSOYV].I_"MSXG:?:6VFV5U!;QI/=:Q;M
M/*!\TA"L!D^@';Z^M"^SYV_,;Z^GZ'1^)/$QT.6SL[.PDU+4K]F6VM4D$>[;
MRQ9CPH _SWJH/&-S'H!O+[0KJROOM:V8M)VPK2,P (DQ@IS]X ]#P>_/?$*R
MLY?'OAV77&:'29HY8)Y?,,:Y()VLP(P#D=^F:F\ V-IJFFZ[I9W7>A6^H%;!
MC(QV@'/R.#D8.""#WSGFE'5?UW"6C_KLS<_X3-1X=EOC8DWL=Z;!;-9<^9.'
MV[5?'([YQTSQ4_CD;_ NHF>&65!$&FBMY@C% 06 8J>V>W(]*YN[N;+2M4GN
MK&S\W3O#[>5%%YA)N+^=@"2[9)*A@"QR<L?2NBCUA=;\.ZY#?VRVTEGYUK<H
MLGF)PF<JV!D$$=0*F7P-_P!?U^C14?B2_K^OUN;.F36T^E6DMAC[*\*&';T"
M8&/TJU7*?#)I&^'&DF;D[' _W=[8_2NKK2>DF9Q^%$5T<6LA]!6!_P )G;?\
M^LO_ 'T*WKL9M9!ZBN2_X0Z__P">UM_WTW^%>3CYXN/+]65][F=1S5N0O_\
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M'WF_PH]MFO\ +^"#FK&C_P )G;?\^LO_ 'T*/^$SMO\ GUE_[Z%4/^$.O_\
MGM;?]]-_A1_PAU__ ,]K;_OIO\*/;9K_ "_@@YJQN:7XABU2[,$<#H0I;+$?
MY[UKUSVA>'[K2]0,\\D+*8RN$))SD>H]JZ&O9P4J\J5Z_P 1O3<G'W@HHHKM
M- HHHH **** "BBB@ HHHH BD_X^(?J?Y5+44G_'Q#]3_*I: "BBB@ HHHH
M**** "BBB@ HHHH **** "HO^7P?]<_ZU+47_+X/^N?]: ):*** "BBB@ HH
MHH **** "BBB@ HHHH **** (F_X^D_W#_2I:B;_ (^D_P!P_P!*EH ****
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MA7)?\(_JG_/F_P"8_P :/^$?U3_GS?\ ,?XT?VCC_P#GU^#_ ,P]K5['6_\
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M?<>;+Y:!=[GJQQU-7:BGZ1_]=!0!+1110 4444 %%%% !1110 4444 %%%%
M!1110!%)_P ?$/U/\JEJ*3_CXA^I_E4M !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110!$W_'TG^X?Z5+43?\?2?[A_I4M
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M_+X/^N?]:EJ+_E\'_7/^M $M%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^_7_P!>K/\ PF-C_P \+C\E_P :/^$QL?\ GA<?DO\ C0!6_P"$*'_/\?\
MOU_]>C_A"A_S_'_OU_\ 7JS_ ,)C8_\ /"X_)?\ &C_A,;'_ )X7'Y+_ (T
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MI/\ </\ 2I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=2]8?^^S_A1_PB.I>L/_ 'V?\*Z7_A(=*_Y_%_[Y/^%'_"0Z5_S^+_WR?\*
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MD:9.9M-TNRLY67:7M[=(V(],@=.!4EMI.FV=Y+=VFGVL%S-GS)HH55WR<G+
M9//-5>S^[\+DZM??^);HHHI#"BBB@ HHHH **** "BBB@ HHHH P?$GB*PT>
M2VL-3EN;./4@\*7T954@;'4N3\IYX.#T]J\PDB:3X?>+].TMOM^GV5\DL-\
M"\XW!G+,/OE0 =WH?3%>SW=E:ZA;-;W]M#=0,06BFC#J<<C@\46UI;65JMM9
MV\5O @(6*) JK] .*7?^NJ8[[' +J-IK_P 3O#4NCW274=G82R7#0MN"!EP
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MYB6SNKO3GMS*9&V[63 W%3@_+C.>U6-'UK6%UZSMI7U34;6YW+.]UH[6PMV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K'\4>'_\ A)-%:Q6Z:TDWJZ3JFXH1P>,C
MJI(_&MBB@-C#\0^&(M=\.II44YLQ$4\J54W% !M( R.JDC\:=JWAW[;]@GTZ
M[;3[S3LBVF6,.H4C!1E.,J0!W'3K6U10!SS>%I+[2[ZUUW5;B^DO=N70>4D&
MTY4QIDA2#SGDD]:ET_1=6BOX;C5M?DO4MU(CAB@$"N2,;I,,=Y]N!GG%;E%
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M.JB)KE;E9K8?>8,H # \;3S57P]\7[W4M<T2WUSPA<:+IGB+>-)U!KZ.;SR
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M!K]AJ]C#JDRV#1/$^<.DLI4!V9U)')^ZW2OJJBKB[23[6_!M_J*VC^?XI+]
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M7Q/J\=_/<:;=2106\1C@M$Y 1 3ECQDL>3QZ"NS^&WPQM/AS_:QMKYKUM0N
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MQA/J<^GV4M@46Q2U40LI5!%Y3#RRN?O?,3QTQ2U<F_+]'^MB7I%6[_JOTO\
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ME54@KG.0<>\?"B02_"#PPRN'_P");$N0<\A<$?AC%2](M]O^#_D#T:7]=/\
M,VK/Q5X>U&ZAMM/U[3+JXN%9X8H+R-WD520Q4 Y(!4@D=,'TI+#Q;X<U5K@:
M7X@TN]-LADG%O>QR>4@ZLVTG:/<UX=X T;3M,_9RUOQ#:^'+?5-6G6\5R$(F
MDC+["OF*0X0*,E5(R >YS6-\.CI]S\9O"]W83V$MC>Z?/$R:?HK6%M'((</
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MOZ_JPY>[O_7]7.NHKQKXF_$*^N/!?CVRTI;C2KKP[<6D*7MM=,LDOF,I)&T
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M/S([2!(67:BD@L?E!Y(]![GV*LC6_$^F^'[S2[74'D$^K72VEJB(6W.?4]
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M-I!'KDC\:X;PS\%M<T/5-/L9E\(R:+I]WYPU'^R$DU.X0$L(W+H47DXW [@
M,&O;:*%[K37]:W_435U_7:P4444#"BBB@ HHHH **** "BBB@ HHHH ****
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M $X Y]J@TWPMX?T:^DO=(T+3;"[E4K)/:V<<4C@G)!90"02 ?PIWUOY6_/\
MS_#[IM>-OZZ?Y?UN?,&A?V9X:\4Z7KBZC9Z]=SZT$74-*U6:#5&#2,K"YM)U
M8L&SC:BJ>.6.<UT6N^$=*UZ;XP:GJJ333:7,9[-!<.D<4JP,1)L4@,W;Y@>/
MK7OJ^%O#Z:T=830M-75"Q8WPLXQ/DC!/F8W9QQUJ8Z%I!6^4Z79%=1_X_1]G
M3%UQC]YQ\_''.:BSMYV:^_E_R_$IN\^;SO\ G_F>%:3H\6C^-?A5XAM+B[?5
M_$5I*=5N9[J20W?^C(P#;B0 "> ,#@<<"N"T_P#MG4=6/B*XU_PW8>*1JYA\
MVZO+TZFL@DVB+R(]RF,CY.$(VG!(KZS_ +#TG=8-_9=GNTU=MD?LZ?Z*,;<1
M\?(, #C' J(^&M".N?VT=%T\ZJ#G[=]E3S_N[?\ 68W=..O3BKYK5.9;7?W7
M3L)_!R^2_7_-?<>+P>!-'\9_$'XG'Q&D]S%:S0-# ES)'&DOD']YM5@&8=!N
M!QD^M<Q?:=HNN^!/A/J7C)UE2:X:RO+JZNFC7[,K-A6;<  ,#YN#[U]+PZ5I
M]O<7<]O86L4UZ0;J1(55K@@8&\@9;CCG-59O"WA^YT>'2;C0M-ETV!MT5D]G
M&T,9YY5"-H/)Z#N:BUDEVY?PW^_;T$TVWK_-^.WW$VGZII-U+)8:7J%I<2V:
M()8(9U=X5893< 21D<C/45Y+\14T/6?C18:)\2;W[+X6723<6D4]TUM;3W6\
MABSAE^95/ S_ #P?3=)\+6>D^)-5UF!84FU%88BD,"Q*D<2X4''WFR6^8]MJ
MX^7F]JNB:5KMJMMK>F6>I0*^]8KRW690V,9 8$9P3S[TWNG_ %M_3&M$U_7]
M=#YGO_.U#X=+I5A?W4F@P>.8;/1+SS#N2##@>7)R2JD_*W/]!]'^&O"VC^#]
M'_LSPY9BTM/,:4IYCR%G;J2S$DGCUJQ)H6D36-K93:7926MFR/;0-;H8X&3[
MI1<84CL1TJ_1TM_6R7Z7&];?UU;_ %L?)NHQ>%;SX;>+M;\4ZTT?C][RX@E0
MWSI-Q(JK"L.?FBV@#E2 ,C(V\>B>'6"?$RZ8W$ML!X#MB9X49WB_VE5>21U
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MTF;7?!NKZ19M''/>V4MO$TI(169"HS@$XY[ TI:TO/\ X"_X/]:FL;>U\O\
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M<:[;1)J5KJ8E:.&6--H>)T&6ZG[P'T.<"8_"K[_\#3_@^>FB*=KNW]:Z_P#
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M %%%% !1110 4444 %%%% !1110 445Q_BC_ (65_; _X0O_ (17^S?+7/\
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M!B-OO-FMOXO7=CK_ (B\0P:D+'^TM%L80)-:U62!%8Q%F6RMHPK.Y)!RY89
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M7]O%<VTRE)89D#HZGJ"IX(]C44FDZ=+I/]E2V%J^G>4(?L;0J8=@& FS&-H
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MH5S/CSQK!X&\/QWSV<NH7=U<):65E$VUKF=\[4SS@<')P?H>E><Q>,/$M_\
M%][;7M-U/PZ(?"]Q-+I:Z@LD3.)#ME1TRI;;@;MN001VYF4K)M^?X*Y2C_7J
M['L4&F6%M?W-];65O#=W6T7%Q'$JR3;1A=[ 9; Z9Z47VF6&J)$FIV5O>+#*
MLT2W$2R".1?NNN0<,.Q'(KR.#XN+X6^&/@Z>'3[K5+S6HY/*_M;6(X]JH3N,
MMU(JJ6Y &5&>GIGII_BFVF_#NX\1:[X9U+3K^&Y^QKI3@EIYR<((Y, .C9'S
MJ".N >,W)6;79V(B^9)]U?\ K_@G;:EI>GZS8M9ZO8VU_:N06@NH5E1B#D$J
MP(X-9FL^$[/4?!=UX;TR1]#MI8C'$VF 0&#G/RA<#&>H[@D=ZYNT^(NO0Z7K
MDWBCP-?:)=:78/?1*;D3V]RB@G:+A%VJ^1]WDXYK*B^--U#X+;Q3K?A*73-+
MN(HAIKRZA$6O9Y/X,8'EH""?,;'RC..U3))IIE1O=-?U_5R7P9\&YO#GB#3-
M2UCQ&FJ1Z/'(NGVEMI45C'$\BA7=A&3O8J.IYSR2:]'T_3+#2;,6FE65O8VR
MDL(;:)8T!)R3M4 <GFO)X_C5>:WX3\31Z9I%O;>(],L&NXH+75[>\B,/0S"5
M,H63EC&1SA1_%Q0\*^,=;U ?#,>([?5;6XU!YTCEBU=3'?(L",)IHPAW DG"
M$J5(SSG%7JW9_P!7?^?]:.R44E=>?X*_]?\ !U]>TKPWH>@R32:'HNGZ:\^/
M-:SM4A,F.FXJ!GJ>OK35\+>'TUHZPFA::NJ%BQOA9QB?)&"?,QNSCCK7"ZK\
M7]0BU#6'\-^#+O6]%T&5H=3U-;V.'RW3F41QL"9-HYX(Y]!@E^H_&!SXBTK2
M?"GAJX\0OK&D_P!I6;17209Y;Y7WC"#"G+$]<#!S4KHU_6E_R0VGK?\ KI^I
MV]_X6\/ZKJ,>H:IH6FWM[$%$=S<6<<DB!3D89@2,$Y%7%TVQ35'U);*W6_>,
M0O=")?-9 <A2^,E<\XSBN<^'WC@^-]+OY+K2I=(U#3;V2QO+*242^7(OHX #
M#!ZX'.>HP3UE/815M]+T^TO[F^M;&V@N[O;]IN(X562;:,+O8#+8' STJL_A
MK0I-<&LOHNGMJJD$7QM4,XP-H_>8W=..O3BM.BD!#=V=M?V<MI?V\5S;3*4E
MAF0.CJ>H*G@CV-9-AX)\*Z5?1WNE^&='LKJ+)CGM["*-TR,'#*H(X)%;E% %
M7^S+ ZH-3-E;_;Q%Y(N_*7S?+SG9OQG;GG&<54M?"WA^RU=]5LM"TVWU&0LS
MWD5G&DS%OO$N!DY[\\UJT4!N9L_AO0[K6(]7N=&T^;4HL>7>R6J-,F.F'(W#
M'UI;GP]HM[JB:G>:/87%^D9B6[EM4:54((*AR,@89AC/<^M:-%'D!E7'A;P_
M=Z1!I5UH6FS:=;G=#9R6<;0Q'GE4(P.IZ#N:G&B:4NB_V0-,LQIFSR_L0MT\
MG;UV[,;<>V*O44;@4],TC3=$L_LFC:?:Z?;;BWDVD"Q)D]3M4 9JY110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<VT%[:RVUW$DT$
MJE)(W7*L#U!%>=S:7XI\&2-I?A: :IIMX=EB9WYTYSR0Y[Q@9(]QCOSZ310!
MS_A3PG!X:MI9)9FO=4NSOO;^4?/,WH/11V%=!110 5S?COP;!XX\-_V;)=/8
MW,,R7-G>1H&:WF0Y5P#U[@C(X/45TE%)JX'DM_X(^)/C6R@T+Q[K.@0:$&1[
MMM'CE^TWH0@A&W@*H)&25Z$=,5TZ^#KR/XQ1>*HI+9=-CT3^SA#N;S0_F[@<
M8QMQWSGVKLZ*I.W]=U;\@_K\;GG'ASX46A\#WOASQO!;ZE;W&K3:@J6\\JJ
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M^H2V\BZQK,M_;B!F)6-L8#948;CMD>]=C111T2!N[;[A1110(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>inbx-20211231_g9.jpg
<TEXT>
begin 644 inbx-20211231_g9.jpg
M_]C_X  02D9)1@ ! 0( .  X  #_X2(^17AI9@  24DJ  @    & !H!!0 !
M    5@   !L!!0 !    7@   "@! P !     P   #$! @ -    9@   #(!
M @ 4    =    &F'!  !    B    )H   !L!@  '0   &P&   =    1TE-
M4" R+C$P+C$T   R,#(P.C W.C$Y(#$U.C,W.C4Q  $  : #  $    !
M      @   $$  $      0   0$$  $      0   @$#  ,      0   P$#
M  $    &    !@$#  $    &    %0$#  $    #     0($  $    & 0
M @($  $    O(0        @ "  ( /_8_^  $$I&248  0$   $  0  _]L
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M: SW$2^7%(T$VP\A^-N,]CD?0D5+DD*YLT56CN=K6\%QM%S*I;8G(&,9_ 9
MS[TR/4[>6;RUWXW,@?;\K,N=P!]1@_D:=T.Y<HJM-?10QPOAF\XXC"CD\9[^
MPJM<:F5N8(H4<AK@1.Y7Y1P21GUZ470KFE16=;:DT^I3VY5!$,B)@>6*X#Y^
MA/Z&C2=2^W6EMYJ,D\D"RG*X#=,D>V3^M+F07-&BBBJ&%%%% !1110 4444
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MOS;F^4G/\(_ UTE9>E:?:1VT$L6]B!P6;^E:E>U0@XPU=S5+0****V&%%%%
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MD8%3R?3(Q]/2KUG;20&9YI5DEF?<Q5=HX   &3V'K5FBFHI!9!1113&%%%%
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M(%A96B 'Y  ' !, %  D #5A8W-P35-&5
M        ]M8  0    #3+6QC;7,
M                              UD97-C   !(    $!C<')T   !8
M #9W='!T   !F    !1C:&%D   !K    "QR6%E:   !V    !1B6%E:   !
M[    !1G6%E:   "     !1R5%)#   "%    "!G5%)#   "%    "!B5%)#
M   "%    "!C:')M   "-    "1D;6YD   "6    "1D;61D   "?    "1M
M;'5C          $    ,96Y54P   "0    < $< 20!- %  ( !B '4 :0!L
M '0 +0!I &X ( !S %( 1P!";6QU8P         !    #&5N55,    :
M' !0 '4 8@!L &D 8P @ $0 ;P!M &$ :0!N  !865H@        ]M8  0
M  #3+7-F,S(       $,0@  !=[___,E   'DP  _9#___NA___]H@   ]P
M ,!N6%E:(        &^@   X]0   Y!865H@        ))\   ^$  "VQ%A9
M6B        !BEP  MX<  !C9<&%R80       P    )F9@  \J<   U9   3
MT   "EMC:')M       #     */7  !4?   3,T  )F:   F9P  #UQM;'5C
M          $    ,96Y54P    @    < $< 20!- %!M;'5C          $
M   ,96Y54P    @    < ', 4@!' $+_VP!#  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" 62!9(# 1$  A$! Q$!
M_\0 '@ !  (# 0$! 0$           <(!08)! ," 0K_Q  < 0$  04! 0
M            ! (#!08' 0C_V@ , P$  A #$    >_@
M
M
M
M
M
M
M
M
M
M
M           ,79H@36X&4O5SML4X17AXLLYJ6--@6?WZV^=>        %>M8
MQ^9OU39L$X19AXLI9B5_3XT^49YW@[V=&SH
M                      TG'V,+'HDW+R?W[[KT6WG)%?UJ]_GC68MK9Y=T
M        ?CSRH6CXBX&\Y@8ZU3_3(7:A3S1</</>LP   !IL"SR<XOJEMMUR
MVLQ+4':]!ZW=KVWEQQ_5[O\ 0LW,.=F<B.(:EU9[-M.VS;P        IEH>&
MVB7=M+N.4PUBCA=\ZZ-UO[;ML][)/\U'G*#C&J=:.U;8
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M><5. Z7-FP3=GF7>C'4MB]-?H
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MP_4.PO<MOH1S?!23E9%L-TRP
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MU+U2%9L-M&0O/T3.\H.,:IUH[5ME5=-Q6E8^S=_H6;
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M.S-5A6J^ZSCY6S4K;9MZ/L9'FK/S0(BP<23,O)CC%1HUQ,:4LQ*E#,2@
M                                         ,''MU.TO%8:/1:'<,G(
MN4DULU/&SWLL_,7Z_);IK9JF.S4BN/<7'K%J.,E/,RNAG3]@@+6H$)Z_"M/N
M.4D;*R:YZKCIQV*=FY%>'L44ST/#9F_7;K=\O_"GNC8?8I-S>LE?S=^O-R+D
MA920(ZQ4;$V:=>C6XWQ,;ZU>VZW?+?7WT        #FKR?6^E76-D
M                                            _A^///Z]_CSZ>^@#
M%1Z?-XSTFH        45YU@Y\V6=-VP3@
M                                              (TU:-%>GQ<W35K
M4INNVR/C&\WK.7OC%IB3G6/U.57:GJ.2V2[Z
M                      !B;/F(BT;9/N?WT!\_'X\\_1^_7Z]]
M                       K=H$'7-7C[[CJ-+N>_&[[BLC5H.8O;=BK7@D>
MZID[MW-ZF[I>]                                              '
M\*>Z'!S>GQ=VWN;NN?OQYA+/[K:AA;.U:_3KDGS<,E<G'H\[Z5>@
M                     "#<'8A[084,Z=%R556VV?/%&H]NX2=BR%S.1:8S
MSMZ8,I<L#M,G9;]7Z]
M   #\E M1B^O 6-DQ]O4,G=V*'3N&%M82)3)M+2<I7Y,E5:_JF3]M?H
M                         ^/BE.@08;Y_!C+ 6;D;S,V./37+6+$R[%?F
M^B32:5'C/:I4QR/;5[!>G'-7OZ
M          #7K%,/X.S7W7K&^86U^3'>HVT>'(5VY'<CS7'DW[!?VK>)EK=O
ME_KT                              (DU2+$.BPM=Q%-2,;:NGMDG(6?
M(0U^S]Y%<OSZJQXVUIV[S):R]S=_4HDC9*Y)6>OY.YZ
M                         /X:=&II3I4.-[U<9:E%Z9XV['<NQ7K4(T[[
M;(]$CVF6C19(V*]N.QR+J]-R&YS:P                            /YX
M^/GGY(6UF/!6NQ\KCJ- U6/%>)IM'O4F)\E7X=$B>F!3ON\RJ4<I@21[[9;K
M^0P\BKZ^)$P-CZ[[-W2[[ON>O[A,K^GH
M           #Y>(HP$?1<;;CJVCJWYJ-ZK7- @SGB*-HV:]7OGD2S?19GIMH
M0@48C VIYW*1NN3KL3TW(_7WT                           #&1Z8+T&
M#'%CS5,1;]]NF0:[GWM44*Y'!C#,7+2[5=IGJ%G4[?DK\]L7HZI,HURF!:6B
M7:KN$[ YJW#^Y2)CU>/AI5>JY&J0L+:RFZS++[I+_H
M                   !^?&MQJ(JURQB;WNJZ!!Q$JO6LC<RT:C6='BT)Y/#
MZ']_R>EZE8]CS1=ODS])]UG#6JQ:'&NMT^;IV1KW_*7;(;E+R%[WVU>_3T
M                        (XP-B-N58^L&(LS'1YEHM[4EJ;]AO<W^7P8D
MH=/MUR7-?F.(C[>Y>EZ];L%NLB*M)C3?3Y)6YW/MG+WOV61[>!XK"9"O9._9
M:=L+8]FVR[<[E+_0                                     !"V#L1]
MS*!J.0J\MZJ3,%:A':[^\Z_9V;7O8]Y-9Y]:9C;[]WR-&.-0=%Z)=C2![?\
MWZ1@[?E7N8QNNG:9NP2;T57K>JPJ=DS5W?K_ +-^[S-YSE\
M            #P6_*Z\XQ]=^=0[2YR3YM7\B#5(LA]4O<UN<Q-YQ_MK=TO<S
M>-0K8]TGQY3[73$T05<JZ;46Y7R?N2MN8O(HME.<1=6RU4$?0&4Z4]:FVCV2
M1/V=O_7T                                     !!>'LQ#SV#'N6NP
MOR+';/S6)C^TY'S9.K;H5$8Z+%J=IM-H>W3J2\CB6-Z%>B_D$3LSV?+T"U#&
MPGIMKKMW;(:YC?=?Q5O>\M<K98L6&S4C<=WD3SOT\
M       1CJ\:%.2P8>AQYQQ=[)9FK4\712O!4Q7M*38]JL?*H_1?Z&R6,S%V
MA7S]CM#G57-Z+?W>U3=OV]SJYK SW5)LF;9(HIH,;?JW0C;[NS[K,M/L-_U5
M>@                                    ?PB_&6JAZU'H7S^-B_GW%6
M*T.Q4S?)-S^AW;-=#EQ+KUCC]K]5@]SN['J5B]G6YO/OY=Q'0?J\O 8.GG_K
MMKL%VV;IW-;$DY"1N6U7JQ^1I1REZQO8<EMDRL
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M[#-CW.WMLQEK 3KD/\FQ]2>/0K"8_P!Z.]IR,:]$N8V15\]DD7LVN5]/0
M                                $=1*:::9#V7&VHSY-#C_ .=(,5?0
MTVV_4)D&8VU*E57GVN1*>NV.2G&H5I]6M>+J%ZR>?O0IJ=NLWBY73)=;/G['
MWD[%(WF7<B;3(MS-XR>HUVO?=33V')9J76
M-#@T:3:\4^5KP%G2<5:IK\Z8N:L/5GNJR*"Q:.B_6)TUT4Q!+KH[\W8?-92Y
MU/Z[-P.1KD#!VXVV"[ $+RL7-(7CGU=EMBD>6XA39;FO3[EX=PE[Y+J
M                               J[A;,5Z;$]%'DRZE9J)PJ%S^\HL-M
M%5F_I',[+ HQ$JK*QZ:J:'&B/FD.?.LS;WRJX?B.4'-(72#HM^IG'8VP;(V;
M T6([GDI3O\ F*D5[MBZ)XZID=URMT                           #4H
M-$ \HQNHQ*:?_-^/^G0I$=Y.OH%U.1Z[+Z6O*"<8QL!ZSYU?ZC-QO4I7VH\_
M=+1<Q>U?1H6L9R1/=-&PY:Y_-CDXZ)1<S9I.<N^@
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MH1G,9;PF#LPI0Q.!L;SM4G;+-/NL^8B55).F1^8?"(&NY#SIUVF?[<Y=\UQ
MFHV]2T.S"V@1+T=VGROL%R6.C3I2V61_0
M  5UT"#'6!L^BGR,N?1:,\7A=,^RS=CW>1JN1N8>3[57#VZ$<DB?;'4[+T*3
MT!ZG,G?&V\%+JUV?7(&&MV;Z%-DC(7
M        /X#\F@1Z:<Z-"_5M[+/FIY2O*1O,9?JI+R2!$?*H=L.BWND6SRHL
MV:O[4^[[@[?/'A./^5?G1?N^2T/*^S;N,N8]KE?T
M         \U'E:>8X[QX>B+=@NPAI<:I7$,=;*M>3MN4U[*(9QEO)WO>:W"<
M?N>5J@F'5J>^R;7=%E6TS]S&9:[(^%L2!D[EI=LE9>[5]?0
M                         QE'E1.;0(OR5>3BT[7CK<69F]1KGD6#.7P_
M=&\LYV";=/-U[-+JDS!V\7!M\^?G3&[EOE^Y7:9^N3*L_1[;/JV2]=?H
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M6S[?DOJ\_=/L,ZM&LY+KR.[R[7;C+_H
M       !$.*M0US7'Q7D+E?(-,4XVG"3Z[0ZO&B3FT>%JO+Q=>F5$^:L7TR^
M@<CMN0N:W@_?)$C4WUVS%>+ID?SV?_H3*R99IFC7:-@ZC-EG9I(
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MW>Z%/QF"LUXIMR%L5_;[_M>,39E7>YEK]]G[7?\ 0
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MS@X9 Z#=SGZ?JUF:K]R6-JO?3+5S_P!=R7[]]
M       TF#17CF6.C_38N8GUQ=R>%H^]7['[;*JK\QP),Z]?FKH5^K^K6X5Y
MC'C13+7T1E-0^>,5IV<NWKZW,]VYRIYR-R><U>D.94
M                   (6Q-FJ6K1X2U6/8B\J/SZ+(FG699Z=)_6[2ZZ:I8@
MS3K'2OJTW79M<"?)^+L)N$CW[VY[0Z.D>XR,-JMC;=JO^B15)&Z2IRVZ7_0
M                            #^%6=$A1=I$2,N80_/Q2W\/JB9=27?Y^
M_/6(FO9KV.ZS+U&)Y2#B\/(YJKQ=9R%S,AY(.\2Y$CTVDW69ODJH
M                              8JCR \%9@N)1I6JQZO\\BQ%R2%/'T?
ME:[<=@39JE&R= OV]WJ[XHWD"?-L*;^V2]:V+WS\VB[UM5S!Y:Y-NT295Z-.
MF#/W_P"@                              ^?GE3.68W6M;M:/.]@7DT&
MTO7YWAS-Z%\';W6ZV?.7J0\(Q4.:+:D#J4N[G;LE:#8K\X9.YD?7W]]
M                                   \5/E5=2C1]9ICC7+%9</1&/,(
M?CU&S/6]W[6=$D_G1+%=.(X^_GT7EX5V!"_S) WG.^Y;L,F1]YEW*Z9D<A<]
M                               ^?GE7>1XN*O$?PZ<WB;69SEZ6*?8O
MF^X_!V?YNDS5J_:^Z/%J7S")TO[CD+U]&GRK.K
M                   'X\?,C>+34O7H]1N80:W<-Q^S371+Z'ROORE=?=*C
M6+W*5G8ENKO$\;8GL60UW4K$I;5?L[T_([9D;@
M         BG"6:QZ9$B'68^/\;KA[<P[#?@;6[&-V>_NNWRM&LTX74H^E\EB
M=$^IS]$W>Y<3?)WK]                                          :
M_:\ICHD'E3P^!+>QUVIZ7-R\FJ5-8C1-C+4W9.]Y_?*UZE&GG<Y4&8JW::OV
MP?6\GMN0N                               ?+SR)L/:K_I4/5^:0] S
MU=@+M=8;-$];+?K=-NPQIT:F>BV95TJ+<K8Z^DO3\A"N<]LUU/);S)J
M                                    '\*OZS&^_.XE+.76<?LM#I<V
M0\E<R.*M1+SJ#9C+7M*J\T;'T21MLG5HE%K]^FV(VJ5^_0
M                $6:U'T[F,*/<JU3&T1[HUB9^D2]:RM>M3KGZ>58Y5!JA
M!]Z';77:J7[[:*=<W"7<'?9WW]
M       #X^*;<^@2KIEBMVL1N<G*8L!;A)G?9*[*]0FV7O(RUJQ.N+HC/+5^
M_1X^Y]#DR1N<NP&S2<U?J                               TW%VZ^\\
MQ['T1/[?U/F$6N]SR;^D7]\VF]D[%.;C4^6MY*ZLO<]VO7K&?WV;9O:I(
M                                       KIKL?4N=0,I80E,JY\:?9
M^>,IZ&=@G?.][Z:/-^P=K2M/M:MY1*6[R)9P?C;;U@.CSP
M             !Y+?D6:C$V+.7]XRMWZ>ABK7E?-'A5=Q-6OSZ\GK4:)I-VS
MN3MRO@K.I[/(EO99'S]]F[-7=8B4;9,K]U7H
M                  BS'VX(YACV3KT^[5]:*<M&IQ-^K"3*]*Q%N%N7Q]RQ
M-N:NDSY8G6/G+JF7=)<L[/)                            $-:]'T?F,
M#]U>Y'+W95Z1-W2=<'\(5L5Z36@OE>,CJJ[).1\DN+:FO?9LMY*X
M                                    !^368U.<O>QQ"HUR+3H&*M>/
M2XG]J4KS$N4=>L^7:I&,A>VIOQ[&;S,VN;<'X\:S"HC[5(TA;-(VC)W
M                     *WZQ&T+28>ZX"U])MS3-ANREL5^9-HDY&Y['OE<
M;*?'8HQ=%<YR?=O]I]/H
M       #!6_*P:-"PL7RNR1NV!BS_P!5GY:3?L?>M?7T,9;\@#G<#V:S;PWM
M/]VR_9WH,_\ H                      /YX']] ?/Q 6 CUCY5C?!9\R6
M%M2W?NX;=K^;S]^8<M=AG6_/!GKLF;17BJ;TV54;=[2
M                               !^/'E*[VZ_P 46/5?N[ JFWVC\>(?
MUN-$V L9+6[&4PUO6,U=\&TR+E;[._?H                     #S4>0ES
MJ#J/OFT;%?E#,W];QUK0=8C:=@;,/Z]9BR%3,.:N2%CJ(LFW//M\O,:]:_%#
M'YVY:+J4WS6Y%A;EG[@
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M\J?JT>J&L6NE_7IN/O5?2S34#FT:P&X2I4HO5QV?S==BE6PW.5*55OU
M                       &.M4_>KWU5^@           1;AXOON>R'E)(
M'X\\KAJN.LEM>2    U7SV'/*M2L1ZD:78E74K.0CTXK4;,N;E5E[E4>V_*U
M:K'NIMLC3LO<\USWZ8FUI>IQ\;)JGC*79(Z9/FW:9(
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MI&AQ]&UJST/Z=*D&U)K!JF/M=M.0BF3'B/7[5U.^9C=,I=
M    $>X&Q'G*<?\ WWWS>-?U:WZ(KSSE8:+-)N;6+Z;Q(FC-RN+_ #F!.6>]
MLUB*;#=RR%,=$BYG>)<K[E)EZSY=7=IG]    *WZIC:"<VP._9*_HV.L=.NN
M[-A[%%&N=X3J3V':-"QL?F9R76NMG:]L^GOH        Y'<2U+KCVW;1330\
M- NMP.HO8-H'.[EVO6QW7*S!G)@   HUSO!_>OV[W0<V.5?&]5O#T+.9N17S
MQY?KUI=QRF@XVQ?_ *7GQ!6NP9$RDC<9U[Y4^4^T?$:U$M7*WO,[#*N #ST>
M4ST3#8JQ1=7?\UHN.L52TS%:1C[-C=IR-I=QRE8M1QE0-'Q$@9*_T<ZIL?FH
M\X_<.U"S&VY*4LQ*M!M^4   $8XNW137K-*-<HLOSB)93:Z]?A6\;B[5=LY>
MWA3^<7:I/Q^/U<ZW)W[.W==YO1NF:NUYREB69U^4M]DS1T";Z;GH
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M.B+%6^=."][6[U)AF39_.,HGS8)>"S'FLY&Y-6S2;!;5)
M    \5'E)M#A53UVS5/YXQ=E\Q7JFY2)JSU5!^3Q;M[I<FSLF3HEQ;':+ME^
M*.?1^CF=\SF5KW*?7G=]F2UK%C#YF[.NX2I0SE[TU>@ :7 L<P>0ZSUR[;MH
M^5/G&7@^F]G^];G7_6<?1OGF#PUBCKIVW;OK4X\\,U#I[UW9_?=]Q-BBCG/,
M)TWZYLU1=(Q&(L4W)WO,?WU]ZO11CG>#KUK&/MMNN6BK#1+);7DIYV2?R.XE
MJ77'MNV\O.0:O'F+CYJ17'6*C]K^_P"Z<\.7Z_;'=<K,&<F<>^&Z?V$[EN
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M=3NH2I!S%ZT>U2<Q<]        J-I&)_OOEN-VRX
M &)L49:_6             !C:?*F\IQN7QUNJ>>D5J^.L!*>J6JO[])[ ==R
M5?\ -6MHW*5S[XI Q>DV+&=?DV+WJ9*UGRKN;O\ /SD6/NS$\ACE\3HY]'9'
M[92YL5?L[]$G[MEKH                  C3 V-(Y/C\%(]B78[V&U>-SU^
M<\;T8Z!*G3IDJ*]@N;-CZ=;PEGF)R&%FL]<Z7=HR.A9:[FHE&,E5P=J$6:]H
MD0%K]NCW-8G4OMN0M]M<F9LU>        'DHI'KKJ
M                  _A7S!V(-UNQ1O3[&&YQ#M?MU^.<Q7N^L1M@WV;E]@O
M;M@+'/'E\2&-<M74[GD9]R]S<,5;R^"HIKS"QK7-H5\OH2?CMNO^6XW*;78O
M?IV>F5@                #^%>.>0/=IUJOFUW--L4U.XSCM?TRS<[8:[,]
M:R$>9BO;X"-M7B\V^5Q;$6[ET?H:=XJO<K&HAC;I4$\/Q<"<]CV2T*W@<[[:
M3ZWS6Q9>Y<K>IOMJ]
M    U&+13[187,#EL24:UEND2_AK<?:-ED;%<]^]'GIM^0-RF!0[2+71_?KE
ME-SF:1E*]_Q%K'8.CEW\]XVQ/8I<X=BR,AX6U(6*I^>[R)]Z!/\ Z
M          ?&GRIW+,=L>#LP7MTFGG"<5+_OL(8&U/,BJXG9,CKLGR%Y-=<\
M/12CDT/?;[J3WO)?WUL,&C4LM>IER3'58U2CJ;%IM%T.9$6_7<9?JN%O<V0Y
M=8                                              %4M<CZEID.J7
M%8&]\(C4\WZK>L][:3ZCSDM:]9V&#;U7)7-$XU%YS<]A7/Z_(NWMDV&-CN2W
MKMJ+]5C4;X_$T3<KEI.K3Y$WB58'38_VD>V&[!D\A<]
MP<6B&^.8[SQ[4 X"CF3HD?ION\BM.EQ,W0O5U?)1MA:/CD*:2:G9KEH$>.-I
MD=)>Z9"6,E5Y;OOLM>:9I<2HL1TNO>RU<N03LM>"EU6\W:9*,VL
M                                     >?Q0+2X><P=G<,-;Q7+X_(.
M/1N.277[?DI<QMOPWJM:R5REO)(%9-"L3_TV5:?8*['2ZMC@6XSYE'IY!L[G
MDKD.ZE9ME])Y>R^!M>"M/O6<ENT^X                !K,.BO?)L9]+'E:
M>2PXGV:YG(U&,I]C+ VL;;74ZW-GOSWE5\^8O=NA2*J:?Y[^PSNJ.^W_ '6?
M/G[[Y+_OGJ;+CJ,U$HTG,WL;(]O+NTS<K]0
M                     \5*@.F1,UAK,GX*UMD>OD1$LV#N^3#N<K"S;GVI
M\_$6GDSQZ#NW.8NQY!U?[+/UG#T2??O5ST>!%V=JVO J_9'V2X-/0/I4O+T5
M['U&9*&S20                /X5TTV'K6DQ8@U.-)N[R^>W"\=+>XW?-S.
MQ&>NT68^NLQYHOE#_ES#W>^ELI0/BD'6\W<L;U^?=K+5ZQD*]UQ=&Z;)?L[L
M5_7K--:L5;\D&BZ6U2<E7Z
M        /X4!U&+\,1:S\&C(^>:3/N??U][7GY]9J+3SIB^U[X+C;597S4=*
ML=%^TS=LV>1R]XWC]DQU$]]:FQ'RZ+)O29/RYE&N)V6?D+B2.ESY<V*0
M             (5UR/$>@0M$U"/E<Q7SNUJWT,S%4*\8CU\M6;V?4&8KSBJ*
M0<$QW5SN\^IW-HFV8+V.>HW\/MTJQ6Q7INUN-9KH<^3,C<'Y'C]>@
M                                       !6; V(ABTVQV"_L]SV*H-
M$$:+#T/*W,Q$IB"'3S\Y?"]'/H_2'L\VF_%,?._5IME^D3*0_-F(G?GEO>OI
MN?13B$'I/]$Y/UZ]9V+(5>W:I%LNEY'[U>@                8>/35+FN.
MPNMV8+YQ%WGF%J&^N7+C])GU\^<H4;;I7<CK\N ])BT8Y%$Z/?3&4]EM1CE,
M*]?:<A5.BO3\)9M#LMZUVXRIZREW]^@
M                   /X#^@\5/E+^:8^+\M<K?CO(LU*-=?1(]1]8L=(.YS
M^:W$X'XZ--Z+[U?IAR2%L/#X5W_IS*\Q=*B6MWB18&NK1O/)/WN7:G?IWZ]
M                0GIL2)M1B0CJMGV4^01\_P &</I/(3C ]I?P"'M/=9M@
M]^O5JTN/5/C\+K)WG(2W'NT>TF!)W2YN6F^ZY-N0CK=BUTNJ2=^FSUL<@
M                                               ?PT2)32G3HE9M
M:L?2GVPVTWH8XSC)9VF_)NS7Z5_/6+\69KZ6]0FTEB^97Y5QMJOJO*50UJ'O
M7(+>*R%&P=>F2?N%^?\ ?)LF[!(                 @G5(L(Z=%@S&43)Y
MYH&OV94WN7\]1LUG^7L5+O<IF:W6_!D97W%6[X=*FRSK$;0-=HTW:+DMY2[&
M>P7]'T2%8/,WM\WV;8K8Y
M            T&%17CEV-A2!1\=BD3'C[6 G7(4XWC;T;K-Q$[WFIR>!'^4K
MZ-]>GQ)&IBSY1QMA>I7\UTR15_BT#.3*M]Z1(EC8[^_RZK+]3R?T]
M        #XT^:'C;<90:*P\TQ_MGW(GTV+8#:Y.9R-<53*]=T.',>T7L3B[=
M$>,1=@U>WA.Q2KF[1<TWE438^E2;$YB] \:WZ,S>MQT2?+F3K^_OH
M                                           T*'16;FV/C37;'SVZ
M5(T.C*P*8GU6/)]CS'] ETPU:QYM?M67V"Y[L9;UGYXA8_L\R=^L3<+!MQQJ
M=C;=SDZO'\L)LE^U70Y_[]               ")]5C:IS6'&^7]T[3XVF7&9
MEUY^?5)"J![%O;\]>P.0N4IX'BXDT^UM&PW*[[E)LY;MZKRJ--/3I%Q^C2XS
MQ5J<>BS[L;K,]'H
M      :E'IJEI\6$.;8^P6Q7]?QE%7.80Y4S-<*[[-B+YQQB55;KM<F3]ND^
M*!1"?GLZ9R[O>*MU TR)-&\S-"UN/9/HT^:,]>WO(7,Y)J
M C_$VH$YKCL)>JU#7[&N8VFQF>O4[QMK=+:'Z_;*;O*T?+7HQU&/1W@.,LYV
M*;9#H<S(XBUH%^N5[?D;RO<K+KWBU3>O>YN;N>@
M                             #^%5=?L0SSJ!I$*C7,512WCL3:<[57_
M *--FWG4/!8FC.6?+Y?0F3WS-7=$TF'-F4O>V\A_6K.B3ZI7P%K;>@2Y0PM/
M\V2]83J&0               _A7?1H6CZK&_N&IKGJ,>;.JS<'-KP\JJ!8%/
MZMO*31*]K9Q;'?W>Y/2OKF1FO*W<3'IT#&6Y1S-W^TOF;C(J
M                                        _)3O4(L21*-8];K"HP5#
MT^LE*JC#&4<]OG3%V?ZI,M#U2;L$&F/]=L??6;&DS/;GUU:=DZHBTB-+/2YN
MTXVW(6]S9WVN4               ,/:\J/JT;7(%$.<RQ_BG5RSO$O&U>Z)K
M]'-[C&.UNOV5=>L6QS<J^78)7MZ7,LOL,@
M                             8JCS#6?,I>]CK'49&MN$ZO6K/G/;G4&
MFO",7?OMF1@V57@X5/GOK$[#>V3'T9V#;B_4(\GZ_P"9CHLC8)'MI>HY+UU^
M@               ?DB/ V*W:=%A:55*=NG2,5<P=WRIF&MRQB[-B,1'L1L%
M_-S*\%TF;:7:)(
M            CF)17GEN.C/FOG._F>+BG.WM<R=5\MTD3[TV=M"C1<%9U'G\
M*<^M9'8\M>L[L=_?YE8                &J0:*UZ3$T"][*.IQ8#\E>;-^
M^&-1X[MR?HL7:(%&H9V]8;H,^3Y]8
M                           BB!;AKE.,D;&>UYQ,>$9ERKL^19K*U[?Y
M5*5ZW#.8KF"-3*^3KL_N\W^@                 'S,-;\BC!V(HO2-\S/N
ML0+.FV+^ZX"%A-:C35T?(3)E+@
M                        &)H\J?I$/WZE&^OBO68E8R+3LT[W68%=D<5"
MT39[^US:IUS\B5,[>                  'PI\A_18?WG5?C;)^I>T9!;QM
M-^?*K>/LT[+?J_H
M              ,%:\J7SN!L!B=YRGRHL27DT=0;\BXV)*^8N[1(J_0
M          /%:\UC'V]NR=S[5>@""L#8CCGD#T06O;7-D3H$GWW*<-;D6.N6
M?:
M   8RCSZ>H3\N_.NQB:;OO-WPT?5]+B2CT&=LTZL              #\^*Z\
M[Q_SU*SJ^Y7[);M-V:54!4#38T<\ZB;OC:/)-N^WK,J1=BO[)Y=F*JW_ $
M                                                           '
M\(+HNX>JU]GD>ZA9^O/HF4DV\?N$FWV\3?T ?GQIN,M9&[[L<^X
M  /EXJ[RK&UVTN)[(],A;S+WO/W]@O>^'7H]8HMR)])B[19234^6\R96WV=9
MO8KNV^T@
M         #3O*H>\]^$:/"_&H,AXKR,**?ONLB^/49N5J]'AH\K;J$3S:5&]
M7JPW7\GF;]0          Q<>F.=8C5_Y1!]F1]FFF[6O58NY]"D:Q/KW7%VX
MYU_RJ&O6=DD53#&9K8)'KWV]>?H4O.7Z@
M                                  !XRM.-]@GGN/R.E1XGP%KP;!<]
MDVJT>?KV_-7<'?\ <) MQ/SB#C9/LKY"];'M>4VF;<          QEFF >28
MW/8CS1*_(<UV-8F/*CY:EK9Y&F2+, X>U">OVYBW&3M'M_(X^F,H<?=^G39!
M@6MYO>[;L4F7]KD_T
M                  \M'E1M+BQ/I5KX\WAZ7MUV&M7LS=D:K+;O=U')5YJ.
MT/18EFLU-UR;9KSKUFT?0YTB[U*VS)7?[Z         Q=ORG'/H/MP]J3L75
MK^N1F,N1[BXLB=-DULY_&YP:7:Z5=EF2UL%W/1?-?O\ FFZ78V[>97RJ?.KW
M(Y&Y<7HL_P"OH
M            "/</9B_08.JU^Z1>JUG!VOMJ'F4S]W[2+<#ZU&^T1:/;+TX6
M[]:M7A3=)EQ59L8O8D]WI&!KMR#U?(25G+X         URWY4G2(>3UV/7?F
M$"?^B3<[I=-:KUJB_)8DY[G<L/N$B.L[=EF35A]'C9+.5VLR$B-,HB7:Y-S-
MHD2I,K
M      %:]6C:'ID3#RJLA8HS.M6XUO>2YD;FM3*O5#IY*<?A6#@T=!.Q3<%K
M=O,X'W%Y7R8]HFP]EK6L9:Y:+?)LCY"X         !7/!6:UX"Q"WS;AY-WZ
M_NL7WE;J--Z)]-NL]*BR!:Y2:G'M)N=RV,RJ1M[D[%JBN>SI3SMZ['09WIJ]
M
M&%H\HUK=C(:O&L)J],(RK5=-#C2?MEZ(LO>S&O6==UNQ6#2+4G[-=ZB;I-@Z
MNQK>+M[/L]_(;/(LYT&=)4JL          1#J46LNN6.6_ ,;:C->0MI_FV=
MFFRO9MX+0(M:])HR?4Y64U*Q;A[-7=,A7;5X\)[7*M9M$BZ6Q7Y=R=P
M                                                       "L&GQ
M*Q:]8ES1+6R;*C/ VXRQMKFMH]%YJ_.@70,C7/687+^%Y?>W[)&]UZ-SZ/\
M7N&2G;:Y%X=NE@         :=C;<3:7#T[%6OQ&\J_\ -D&(\W=R&_\ L^[1
M=YI\FB[]CZ+N=>F1U?JH7R:'U/Z#)KYR^%'\>BY'U9G?1[[8K,7;);)(
M                                                        &NQJ
M:'ZK%JKC*90U&)N=KS=]6HY]\IA^WL,S3N9Q=[LT33TZ5DMYFTXXG N',MTV
MUGR\_P!&92X>1KLGTJ?]/?0       !\_/(9T>)&.OV-?,S&H\F*IYR?.N-W
M?K<W 9:JI^L6KZYJY(TFC/=-R%/>70M8O^^3#6YEY#%NQOTWW]ND1;L-^S^:
MO3]L-_\ H
M        !'D&BG6E1-9R-</_ #[AXDYO&N?UV=S<U^W)66KNYU&94?B\"MNN
MV[=].DS1F*ZY<MIEK1(L]_24[=LK7F\G<D39;\O[3*_7H       0KJL7%\U
MB8:Y3&^;N9"SY!O'X48<KBX?HD_2.C563WZ7<;5K44R*:2Z!#T;1**Z=(E97
M6;-Y<S3)GMZU&W2(3VVYLL2FSO1)^[9*X
M                                !'.,MT\U:+E\=1)7,8U2N+1J5;/1
M*_9IT!<]C=,^ZY+1N=094L5\H\31MSRXF3]K]QR+;CK<BSVXRM%R57II\DN]
M[-72LAFY58      UF+37GDN-R46F#-MD8LBGG<*IW"8%W-INVFZY,UG-7<+
M)JU3)W( U2/_ #F4& ]*0KME?33H-_/0K?WV"\FUY3.WI@U:/[=UEV=W>8
M                                                         ,39
MIK%SF!&M?LN:[:BG6:8'PL.M&,]JMF[UI-?MS/'L3'U2=;N]<@?8KE6</1IO
M,(\R\YCZSDZ+G]]R&KYV[(^$HW"&U[:+ED>F9#TU>@    #\^(4T2%KVDQ?%
M=]JGF*X"X%C/'DJOUI5F['3Y,H[W+C?-W=LQMJ+/?>=_&8&FQUC-_D6[RU40
MY"N[D90WGD+0]@D76S-4DSZM?W:99[;9.Q2ZP
M                                   (>PUF,N6X[0,W>Q,GV,=-BREZ
MP>.M\ZL)[BM)M3K C[3VO(6/W^9FXM.R0+<E82B#]8L<\>(09*Z9)L3VW)9G
M+W)?U>/NF.\V3J$Z:MBD     #R4>5CY)C,MBZ-)U.SRDTRQ;G9*XJU&UF<E
MY?[>IV0S]<3[#7.&M4TET6!S_P!/IMWNUVU?7<AJ&2N8G&4;OS"'1KE<+S:E
M9D:#1:3ZSS.2VJ_+.3NV9WF;_?0
M                 Q5FC'VJ=EEW0 /YXTC'V-XR-\  >*WY7?5(NHZ;$]F"
MM4PUVB!M;L==NE3:5J9HS]Z"]/CTVTZUJ^%MWW[!,M/D[FLSJMH@T_W&6J1?
M/^-AC;;TDXKS;>NS;?;+?D'#6_ME[LV]6R&5D5     ?PJOSR!C=<LUPYM"B
M*_[-N<KK]SV-M]RJ]_59OXKN0=F$:8>W6K18^K\NC]0>RSL;T>1[;/FHY2['
MNLQO/EKWOT2)53AT#,_1^6Z'9/W.1*+!]=RFURZP
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M=NG7<'&HF'.S+N]!S8                     '([B6I=<>V[:
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MJ/-DEW/I[[[[GN3O5C%V:/%;\^?GF.M4X:Q1)^7E
M  "#==@SEL4X              #S^>4&U&+A8-,P9V]8W,W?;7[6[0H464>5
M*M^Z+BK?0.+;IWH$3H'T*7IV-M\IN&0;B]VR%J<E7&O.H<<<EC??Z2R<O[)?
MD?!V*VZA8P.<N2GJUO8>B3-WAV\]MM^S&^S_ .@\_GG.[GD?7=<M:EQW'[GU
MR?,%%B +-&#P5J:MEN^S9).@:[8K5R^'&.FT;7$3C]%Y"RN+L^2!YK>R7=YS
M%W#3JZZX.U:G9K]N-UF;'(J         %5-,Q4M9N7*.8E
M                                     "*,=1%\"W97/7LE5Z*]X"Q5
MK5(T#8"U9G8[N3QM$3\@@7LWJ;#N=4$UJS]=*LRYLM4O;G*^^6N0QKUFQTZK
M+X_R"L98E?/RJS<CBR7U.;L^/ILGU.3-NTR0!$$?VE.KVHPXMB?/G94B;Q>W
M&1;AO%42#DKGOEU:UB;5&/EC#93;KVDP/-[[9D;/\.Q>*S]R]O29N"G^Q%G+
MV.T6%8G)7=IZ3/L!L<@
M                       >6GRK&G1:IZC%WG,7I"AV_P!VT9:?$VW'4Z[T
MN?0CYFQ.9@^^;8%D^C29GZ=/WC78]/M4C3?E;V5R%?VMWX'YK"E7?)6M[3(Z
M0=)O[I*K &N*J+<QAQ]'MUOM^6=RUW=*[48Z]:IAI4>7=VDVKV2]SJXAC=HS
MMVYW4)D1Z!$K9S.+DH]'2KN>2\$*W'6.HFO?INZY2Y8399&QWJ@
M                                                      !ID6FM
MW)\7KF.HAW)7):R5R9=;LT(U6-C>3Q<+]&96B/+XMD[E&A<]CVH^@<G-71)F
M7L4P#@K4[Y^]Y8S0<%['O*,7,'<,M;'>)EFYE'] !'GE59M:L0;K]G*X"W)<
M*VV7VI.L6J#<VC;-@[5@[_LCY*Y,?9IMN^BS\''IB'"V?)A;468ZW\:/)ZV6
M1=S?9N7K]
M              'Q\0-@K&DXRW ^F1/WA;4L;)?H)RR%"> IL%OM^:ND38QP
M=JC7&X'5'O>3A2-Y5O0HUC)7EHNC3<;XJS#KF.S;W*$N?UK(S)(I&@'U/B\T
MU3\7FOVO*Y\TM;K$CYC*58R+3%%VKW<_A8O7;5VMOR<%[A1<7IF1SE?NGQ:(
MGQ5O#7?8DPUKWV:;O;O,]]7H
M                              _A3_5HL&Z?%BJPF6=5F\A<DK9I$PSZ
MZIZ=$K3Q.!K>M6:NXZC6\O<GW>Y'1;H<G,82B-(-VGG3)$F2*NA6>OSS53'A
MSY,LIN<I]0/X8"W(FFFULEQ5G6(\=X.QL6(M[QBK7\KJU3=95Q-XF_OT ,=1
MY\S*U^@
M             "L&LQX6Q=N7,[=W.[[M5^J3\C<_A3[3(<I<_M5SU6)J-5'A
MZ5.WRZVKWWPW/(=Q5ZHG5I-S[WD8O9$>PJ]V8P;RW*F9GFI%'/+TP*;N>I-/
MQXQ=/E8>98[%0+>?W&7.VRR=UDU
M                                      ?'QCJ?,O7Z !7C!6-1YK S
M$:G%2/8ZV21L<ZNW.XR_O6B*B[R1N6]V]\T@@HA\U\OD]G$N935&_JJGM._F
M]'1X_0-1B4ZQ8IE+(W/WZ
M                                    \%/D(82U$NG1,SB[=B.JY+<Y
ME?T]#RG-'RJGRG&>T5Q5:J;H]N&7F,"1,0>2@62+V
M                                                          ^9
M@3R&V@U&/3C+/D@3J_Z #PD%47(S]HXI>^PI[3/Y&ATA+?E33#&TG1LEH
M
M             \AQ[*S$KG<H^X   !4 Y)&DD+$QGY+7$OFJ%?222\I=P
M
M             A(X(&0,^?Z!S93^@  'X. Q%9 0)J)L)^)M.<9ZBS)9(OB8
M<_AFP
M                   02<%B5#5B="QATS/Z#^%)C6BY!RU*DD"D0G\)P)4)
MA)@*V$I&_EG39SY&S$P$D
M                                   &A'^>DAL\)O)-I>PZ4GJ,*?YT
MCX&9-5/>5Y,H>8PQMQ9\UHV\Q)/A+)/1'I(AA"\AZ0
M                                                      :P1R0N
M<)3ZF*,(;J38=PB=SY'^?0C4T0QQKI*!MI]C5RG1=,L\3\5P)3/6;*>PVDN:
M2:  #2K?L46/?R#Q>+#RJ<I4
M                              $(') A0]I IK1-Y7XL@9\[2%F"BQR)
M->/D;J8TRYT_*E%"C!D_%HB;BN1M1GB:#[D]EGS]     CFSZ)&O>
M                                                           8
M$_SX'B-:,D0L?TV$T0D$L>=*"G95(\Y7LGHV$RI/AT<.(!"1;0W4_1_#=#:C
M[&3-[,0323P28?8   $<V?1(U[P
M                                #Y'#$A4@X]!"1,INIKA$Y9\T0_IH
MY\25#>#O*209,Y+E SV$V%D".SQFYF(-U(9+$'\,,2$3H6>   !'-GT2->\
M
M   'Q/,>\'-TY>%<01D7--$-V-%-U!(QBRWQ(Y:LLV"M!PY/P2"7#-5,,2"?
MH@DL:5<)9-K->,L7A+'    CFSZ)&O>
M                                   ?@Y2$(G7<E,J*?Y0RV9CRH)TN
M(P/N88C$LP8HLP9@[D&9 (R.&AJQ:TW0CP])K)JYH)9\IH3H1:6F)/+GDQ%$
M3:"U9LH (YL^B1KW@
M                    %:SC.?4W(LL4^.3Q=DUP@TNZ4_/N2\8LB\L(9TV,
M[E%D0#\%#RL9_#:"-3<SYD+D)%ORII>LIP286 )I(>/.9HL<6S !'-GT2->\
M
M    Y@%&3WF?/(59.<YU%*T&[$X'.$\IT@*UGJ+8D#$_G4LOX 045X(Y-5-O
M.?YM!<,@(TTLP4(-N!KAU3-)(5+ F8-W+I  CFSZ)&O>
M                                               "LIRJ(A-Q-O(W
M*0$-G2@YQGD(U-(+P&!*^G2PD KF3F=##JR 54(Y-+,:9<K$59)F/H0P7V(,
M*QEF"L!T++4E?3$&W&<.C1_0".;/HD:]X
M                                    .)I!!6LVTV \)18WPETH^;^5
M[)++6%*2=RT!CB42U)VG-K -=*6D;& ,F044S)(-</<=#C%E1B32/S4RQQBB
M3#W&RG3D^@!'-GT2->\
M                      '-TY\D&GS-C-;.?)?<EPY+F$+($$%L"I1T0)?/
M 3^=VCT  %9"OIJ!DB&"(S5C0#:B6S<2K!=DRQ2HE$D8^Y():,MT ".;/HD:
M]X
M     (=.*9'Q^30"%"IY>0VTY=G1DB0C<E<@(Z4&X&O$_'=8_8 /X4Q-3-2(
MA-8/64\+%$(&',Z2$;&6D.3Q>$V$D$VLZ%FR  CFSZ)&O>
M                                                 ? YS'.DK$;F
M36:P5+(Q*]DW$NE0R\I54LP7.,.>4L6=R#^@ UDJ&8<^Y/QS:- *+%O0>4TX
M@,L,3>8PPIZ"-B]1;$LP?H CFSZ)&O>
M                                  :(?YZ3P&'-X,:88JL4T+)FAD:F
M^%H2EQT\)I.IYS$.E!>4  _!#1\R4BM)4<BPID6//V5_+OE""4R?SZ&R'Y,B
M6C-Q+8'] (YL^B1KW@
M                    '\.99S-/Z?H^I#QS<+LFU%'RP1KA<0@TND><[5EC
MSU@    A\Y]FK$>&1-9(V)1-N,";8;6;H8\W,WDNB94 $<V?1(U[P
M                                                        ?$I:
M1<4[(B*CFZ&SE.#?2Y1JY]B3#]%B3L4;0     #4#G25C(Y);) *T&WEDB+C
M?#=CY%D2V1^P ".;/HD:]X
M                          ,.<8" "$B<"D16DZIGQ,F:F2L=+"[YD0
M   #S%!"MAI9^3>3V$1DO$IFE'H-U-C.@1]@ ".;/HD:]X
M                                                 !^2JIS5*P$7
MF (>+ EFC:2L!:\U\O\ '0T^P     !!)S?/L0"?4L69\@DU@TXL">,R9*9T
M1)!  (YL^B1KW@      A<CD&[$\
M                       $:G&8\904T<O$<[38CI<1N;R5N)@+<'6DR9^C
MT'[    !IQR+/T?DC,L>?,ADJ$6I)H(C)')<,L=!3+  CFSZ)&O>      #F
M43";8;J3F
M    :H<3C'%+B)"RQ#A^2W!%IF#\F7+\G20YJ&')6+D$N'] /X?,J0:J6Y,$
M<LCWD:&HEMC8#-',4U,W8QQ<(L :8=)#/@ CFS[\R2KW@      YE%[R0C]&
MIG-H]Q?0E$
M   _)RT*1D3E'#HR; 84W4UX@LE8\18TW<P9ZB,3^G5LGHV(\!3PC<@,L6:\
M8PCT]1XS2#"&.)7-:(7( /V=-C92;RYI_0 ?CQ4.#5$=BK>;GFZW/)VD^;O=
M\    ',HTPRQ<PKB67)]
M              !A3EJ4O(,)]*JE83HL98B@L.2084R9N9XR(S>C4"SIU5.;
MQI!LIL1I9(I60^YMA88IN9$K":66.):,D>TVLM 6F  !I%KV,+/MA9=/]
M   .91?,D('+\OT2,
M           #XG$,\I5<G4I.5--_+!$#G44^Q70^!-A+I#QZ"7S ECC*%@"!
M2=2%"'2!BV!]B/BA9+9$Y)9T%(X,<>0E0Z&&W   CFSZ)&O>      #F47S)
M"!7$HT66+"DL
M      PY_GK(!-B)0(I*@F0,Z6Y)*-8,098F<Q)A"MYM),1*Q(A A)I(YKIK
MYX3Q$IGV,Z5>-^*^%AS^'L-T)L+<$A@  CFSZ)&O>      #6#/GH -.-));
M/8                                                     ",#_/
M:2(0D80^!+IZS&GH/@1J;22>;B8PU(AHC MP6/(B)+)R-P()-A-+*C%FB6C>
MC63.'B/R:";">TFTD$M$  ".;/HD:]X
M                                   *0'*4VX^QK!^C\FK'U( )V*8F
MXEGSTG[-/(J/.6<+1DH$>'M/P2@:@:^5<)!)X,L1T63,6?(^A Y.9O!;\VH
M $<V?1(U[P
M              <JBG!: NT<^"!C(FC'P(&+*E&P6T([))*TF8+IEDBLY-I>
M,YV$\&QF),J4X)<)$*]&^DT&I&2.J)&!0(W\Z&GK  !'-GT2->\
M                                                       &L$(%
MC3TD2'#X@P^9O)44V0\Q_2S1BR-BB1+1U,+;&C&FDH%0RQ!M9O)+9SE,>1T=
M"B-C&DK$3EO"1B:S83(   $<V?1(U[P
M                                    >0IF5R./!?,@@T4U<H<7#-I-
MD,T1D0(2&=$"P)%!F2,"0C+D@&[&JE%C=C13K.4X+1%T#G.>XDTVHNP>H
MCFSZ)&O>
M             "H9SX/T0>1D>8U P13XPQT"-")M-7*,&-.G)_3^&;(=/@:$
M=;#=2M9%) Q>XV4UTVXLR8TQ!(9H!T&,N   1S9]$C7O
M                                                 !HY4(K&2&4M
M--*F$B&8.;)T/)!(&+'%!B'CJ498RAC2!#3#?2_Q)YA37R,"3R#"1B7#821#
M>#0"TY8P   $<V?1(U[P
M                          ><^QR4.79ZRH)8@YWG5 V Y^ENCY'/\Z)D
MJ'V/P:"0Z=,S]%=2;3"DX&**JD^%S"$C,GJ-K+[FX    CFSZ)&O>
M
M#B2<["9B*2@!F"WA8$@\J&7G.>YNAUX(U*AEO3<B3RIA&I?,B4G<APG,]!T/
M)7.7Q^S8#J6>X   $<V?1(U[P
M                                <2B@Q)1^RC!8$QA9 \Q4HJX:N9$M
MV6X(S,6"JQ)Y<LV,FDC4W4W@F<OB;N8<UH\I(X   !'-GT2->\
M                                                         '",
MAHC\^!JY%)G2RQ[SYE;RCI(A8<B\MV:B0.2R3H2.2(:*:<7T-D+B$P@
M CFSZ)&O>
M                >$X%F9(>,J:B1:8,F\_9_31# $#%U2HQERSI8\I6;Z;6
M;2;49\M(9@ML2T      ".;/HD:]X
M                                   !%Y_GL-I-9/P:>8\W4C(E@UHP
M!O)3PLP9PK4:T;>8 F\ETU OZ;,;L67++'T      !'-GT2->\
M                                                         ^!4
MXH(80W<I\5_)2-$)9.>9L!;0KL6G,\?HATC$^Q'Y>TMB7F-:-[+9
MCFSZ)&O>
M                ?,_A]#AJ5H(0,D9@YQ&H$\&^%VC<3^E9",C7B?B<R]Q*
M)L9(!:D       $<V?1(U[P
M                                59.*Y#9X"9B%BC)M!T&,P94])H1!
MY*1D"8"^1,9Z2W!FP       1S9]$C7O
M                                         !_#BB5#*VEJCR%3R9RR
M!&IL9^3831#[DW%NRU1AR73>P     #^'@I82GW0;:.[/MAY=.S5@
M
M !^3BX4_/B1@8HSA*1F"PI7X[$%I2'"BI.A8 G$       &F6_8VL^YFKS?;
MOFS5@
M               -8.%YJYTW*5%DB<2P9NIK!LQ^R(BG9-QD2RQ[
M
M             #6SR&W@   %;RN9GC;BP9)H
M
M  ,44/,.207-/0
M                                         >(_!_3W@
M
M
M
M
M
M
M
M
M                                  $;FHD[ ^9JI]C9C]
M
M               %=B*R[H-*.0A/A&9;HN,
M                                                     "."K1:X
MWXI@0X6A+(D:E(#=2]97\BLMP5'+2G/4ZA'P.19TT-6*<$C%Z3T
M
M       '/PCHNF3J1B;T<A#L><CSIN5D/F2>5[(?.CAG#GD=0@40)*+!'J*)
M$TEG0
M                     4.)\)U!7@J8=.CCT==C3SGJ7 .;9:LZ!&E'/(ZA
M Y@%TBMQ')I)<<MF
M                                0J4L);+=%42H9?LG API>#+%NR*B
M-">R>3ET78(!-9.HIR:+[E/2?BV8
M                                           !6XU %B2!C'@L8;H"
MIIK9:(P!)I5XLB55/02<34"/2KI*Q)9(8
M                                                    !04CD\QT
MW,D
M                              #RGJ
M
M
M
M
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MC?5X/$@E0"GY@P 3A9$>:Q6MEJOJP@%\8RN)\K#*/_Q_76ZBAA3#,A[=P-S
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MZ6///+?_ %/;Z[8:PW(;U#B/G3LH/6'X_P /OMCRUVH%B/V&F#XU:0VAC)1
M=8&1-2QHMC?5]*LCZUPI&;F4W&MDVO$G7#"&1  %]8_^W-%&1-9'JLJ6K83F
MS&@-C7&U5VQ-)UP%T<7S89S"%22$H+_U^<XPBSV8>NNJRZ=X- Z-V*/ZC9+]
M>'?C,]3?9(S=6(O<(ZF'&KAX"#*-Q%RY9?C&CZN7Z_!\)#M<PS#7HV16_2NT
ML)&FJ%^)2WL;X)M=O9HN8B;@B,B$:*7$M_0MJUN[9;"%FPUG3?N_/EMBZA)
MZN7P'51KAT^O)9&1C'$<?K^RWV1KI540BP\-1#:FEN'J4/0X$<5PP>P\?/!<
M5BL6D:78(;(NY;K;HH[7M<"7X&MIQ"^?OBO&^(,ZX1JA]*68SF%\<U-P3H44
M[ZBNV"IFD)HD<%,>>HM& 52[7"/.4FXKPUU@TUNEU ==1M@DB1KS!&"7T_I!
M4S\@"(1XYU?Z^Y7Y.H)L-HS&B-U94\"&[-.VT>AR:OL#W#7[*HF9)Y6OMEF
M%?+ Z(<\FB.!:BX\D75BO5A+"#_I;< ZZ;1)9\-I&(\>AKF,=MTQG5?JZ)U
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M$2/C/P,X612(!,P69#NE82@7&4NT-FI5I^RL6<59'8QA.L046J$MN8-\ 3V
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M]ION8["['UZ_2NR%FV>S;-WWO4-C3-PWJSG9F_VZQ#KD_:G"O\EVO\B=&?\
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M\08G@X0HO[$[4KNK*J"F5,312+.6:0/[E.M#KI^QW1(9VH\-M.T:$M8%T=?
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MU_N>5=%<\60_%[ D5%*VNKA'U]-8[IZ8HLE)D9#5W5T C-M\5+6X:X0G=K\
M)7NS7&X'VL_.+BEY,_40N518U7:\YK;B?=W#Y2T_Y2_&V7>T>JE?QDU'G\9-
M1YK_ &)K^RL?J_;B;1=?\6;[IQ]_-@.N52U*BFYL3&-T-C6Y#:ZH98 V"R)Y
M8S:6=FV<)*=ED'55+65L4MXU$["E=<Z@+2**.0OILCC.)8_"?4^>J;C2M#3J
MX6U-EHN8IS_)R!KMM*XW7)#U-M>*]! <F\OPTZU#5-GL)(W=K,]FB)P2..7.
MOB9V8J8!%1-&^YN'REI_RE^-W9\Q(>JM58H_X/:?Q!UYKVML/J]Y1@E2=7Y!
MYF8B4[RMM96 7+M=;PW3UUQE6,2H \XWW650V,&^7 646PMX'KI#V?\ (Z_(
M%L<,'ZU8(^VIF]8_'G@.-5WPU:8!O.M,KONYG&,7W:0H1HFX;#+*9K4W"V?8
M5^O+V3&P^U+9.56\.<K0](JKKQ%WG/"7,V%1*XJ*.C)(+?87TK2M6V45>&2^
M@3G2_#$$^:ZNNB7J+U@WI ON;A\I:;*,M1_&[L^8M2E'[*^*//?C/'CH'7UA
M_8>[;4?Z'N,".F'M&FM?5><>_G9NK7+&C3-F9[1<=8F#U]DY;K=1HU-<9K@N
M:!L!^<UN_N66^;Q7'T6P9C+&<"6#E^M]7$'QF\\O'FD4XJFUMEF<,8%HTK>%
MIZ()J"P]A!- L-@W6XTHC;3UU0(,X7R<TU+56P-->SLCBW;>9OI&%#EZ(79-
M*NJ6R0^6/!>PG(UV0BFN[,$]-EBI8<JU4%XP<Z0V27ZUK[!K>MHRH%HUMJYJ
MT_3#:2_\?=E&,XNT6J:S9]O=OJX'O':-N*ML['EQ"<X8!_A=V?,0'5&T,0?X
M-[=SKC6&6JJ>[F=N3>N-?'1ZS]7&KPV-7<Z,!3.H FSFPUS6-H9,9<[,VUZN
M*2;4:O;+&U#P>TH0:0N,--FI'AF9( DU2+(V%=1E/B#$F1D_,:I5?\PUS>%B
M->"@):L[N&.A=&5.X;*8T9B+2Y5J$M)-UN8#T@8C AX4"5679>+8"%;9;;1:
M6WVTX:I(7LXM S!G\,71<V8N&67OS46MF+J$8WHJ&DLV5Z]:,!<_94G7]:YG
MD?[VS$WA:WI.K(*D/XW=GS%J7RK[.Z:9PV?43:V&L?5UD\5U]C[+9LNR+#:P
M9;,:#>ZFXK$K[ 49.-?(LJ9]?O2E;'LPY 3#1\LRG$:\8A;?[A1""G14T\CK
M=3KV-+8<7&_$XYC.J,_$,3\2!4V2IEG<&K<:A1Y45QJ483)E83,)EKK.3D6F
MH[<=G%2"KX18\UN(980PI<'>\U$7"DL966T,O' FNYI?K[.:>V3X-KKMK==<
M(#?05PRN-6==T1J]XE4#I0OO;A\I:?\ *7XW=GS%J7RK[.R=0LVE3J6].-'N
MM[O48KTO8[=I2?5A\X5A.K*/B1>RVF6*$/H,B#6%7=CEEVPO7-]J*CI&U 2!
MZT/OGKZ)?K]/JXQXP9>;S5U]5%^NW2".S9_*V7OY/''#8J]CK.V^^"%Y@Z*$
MG,;+=U%JGZMT])62./&I NA!@U*]Y*.@ZNFZ2ZO16==#O8']HK<W,B96=<HV
M2XW3*!IC:J*,J8ZP>*:G5F!"9U+-YO\ Z>$0*M"LXI<NU^-?>0<#_>W#Y2T_
MY2_&-2IF5E555%7M9Z\C=<JZ\TNF= ] M7U9N!.!-?9K\-[(:HB%BS1OE9-9
MFX4<]'LK7@0D%M%Q$[)9(A7B-L+,>/EK&M4QU*<39D@8];.6/?9=&/#V50U
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M03N.OF4+BS-D!'I^-4FW9]%/FRO<24Z#X<:]<0L5132C?,__ )UGQ2NVFEB
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MV\[*$44B7&,B*+AE*;4E)#0RG&-;(H8?%FX8GI>!68D9UY&,0]@2#O%TP&*
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M(^5%"1W9Q[R[?96"Q0QD1E"9+.4(OFU"JUP;#3M<JEECA1I)&RHNY^P <2>
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M_AT5?LN/&L1.F&B:5]EV'%F.RCO/N%SL*P\4O26++27RWSRMP5>"+ROZJC@
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MN61%=>3"_GW'O%-T1@VV61/JN?\ S9JCZ*P<9OU9<_\ 6,2/8+*?,&@
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M+V12FXO]"I33&^E-H+<:S:_C0U/USM\821PO3(;=U0JS.J<+UET'=1<#04K
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M^K)Y7TKCW4$//+2H]KAC1$HXFKR#];QH2+;L[\JZPWWJ!R=/H=F'.I6[-@:
MO]] 6%$4Y0<14D]^R-JN=Z"ES85ZIJ ]DB^]9F0V-[5KR/<: &:[;6UJ=NMF
MR#U%W/XY589[#87%88?&G,=366B=:#'?A43YE_3C"X-:AB 0-]30TO?G3=M3
M;E3*W:I57J>UOP\:A:TPY'2L1'D;,OC4DV95]]8<YC75]]8B'M&L._5ME/'>
MF 86-- RZKM[Z1RIL]1-PY[5(=:0ZU.,ISKYT #8U A&OT-E;*NE-(;W)KK
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MN-:9 :B@&9C>XN:*#NI@>%.A>8COI554RCE45R64;6UK:PJ+U!] 9(@VO&B
M 1QJ!MUX7I[.X V%[TAR.8SMP/"]-V1<T[M;L[?YU!E90.(JUJ+J-+U+.HT&
MM!NLD72UZE3JREMBH/@:B>Q^BY-A>I)+FI7(-ZAB$FKBW(4$5;6 MRHV TWI
MB=>=0$V;QHF_GIRI38F_"]*<TK&O\JA-@3Q-$$M4?J#Z M*HI];FA9'.8Z</
M.H=6<\+_ .=,F?AJ+ZTL;'LL;K^/92IK:VE&%=U[)J:5E&3CSXVJ]A3N#XU
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M;*0-3RXU!#\IMSM^/LJUA:LHYV/C4!(?+>_Z;)L+FCB;';2EE5N[\@@'0U)
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M DZ :D\A6(Q+S3R2YF 9NSJ191HGN \]:PD_PC#Q2\2MG^NNC>\7'<1Z#L?
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M8KJ6N%E/5LIX2"^4^-^R?'N'HBQF*.+B4SR%3B$4K?0J9 "+<K:>GIEV7"
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M6'':UVK$"[D_BU061KD>-ZC^#N#9K'7P]E$9"+'-FY4O:'?3MK4$AO;6W?\
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MO@?3TU!9X\0!HXZM_K+JI\UN/X*Z,GZ_"I<]N+XIOX?5/\MO,&NG=\-X2_\
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M/?M>("V_B]'3,"I-',NG7!LP_62W:\6##V7KH^0RX.!SJ<N4_P #%/?EKI+
M3XN2-XBEE3*<S$&^8GYIYU@H7P^&CBDMF7/?*;CM.S#6PX'TX67X%BPTJGL%
MT<?*6X*DB_+WCQJ/&X66V2=+GY+'(WA9K$^5_1TW(>LABX!#)YL2H]F4^TUT
M= L&%CT[4BB1SQ)<7 _A4@>WGZ( %Z5R@  8J0 #0 !G  [AZ.FY](\.#O\
M&/X;(/;F-NY371DN%P^'[<\:R2,6<%M0!HJ^S7^(UTI+A<1AP4FC:2-@R@'4
MANRP'N;^&NA9[B3#D[?&)X'1QY&Q\SZ.FOSM?W"?XY*A4+#&% 4!%T L-A4L
M:S1O$XNKBQ_S'>#J.^NC6:''HE]S)$_?H?\ SJI_0/2^&,T E07>&Y(YQGUO
MY;!O#-716.6*^'F.5&-XW.RL=U)X [@[ WOOI3NL:EW8*HW9C8"L=B3C<0HC
M!*+V(EXL6.K6YN;6'("^MZPD'P;#QQ<0+OWNVK>_0=P%=(XSX+%93\=)<)^J
M.+^7R>;<P#716#ZU_A,HNB'L7^7)S[PF_>UN3"L1 F(B>)]F&AXJW!AW@^W;
M8UAY9.C<65D&E\DJ_.3<.OAZR\Q<:7-*P90RFZL 01L0=C73.(SR+AU.D?:?
MOD8:#^%?>QY5T?A_@V&12.VWQDGUFX?PBR^()XUTI^?M_P!E_@7T=-Q$2Q2_
M)9,G\2$GWAO<:Z.G6?"QV/:C41N.(*"P)^L!F]HX5(ZQHTCG*JBY)_&_(<3I
M6%!Q72*O;><SMW -UEOL7T?"(+Y>OAS7RY>L2]]K6O>]]+?D,JL+, PY, 1[
M#72^&@A,3Q*$9RV9%T72W:"_)Y:6!Y7O719+8&'-^N!]42,![-O*L.WP+'+G
M_NI61_JFZ%O8<PYT"" 0;@Z@C4$'B*Z6=5P;J2 SE @XM9U8V\ -3_F*Z#_J
MI_WB_P"&NE9^IPK*#VYOBQ]7Y9_E[/\ %70^$202S2QJZ_U:!U#"_K,UF!&G
M9 /UA7P3"_\ NV'_ /HQ_P#XT^"PKHR]1"N92,RQ(&6XM<$+<$;BL%(<'C0'
MT[1@E\S:_@K -X"CL? UT4ZIC%SL%S*RB^@S&UAY\._3?T=-3KD3#@W8MG?]
M50#E!^L3<=R]XKH>(IA<Y_O7+#ZH 4>\'RM^3-J+4!VJQ$ D8$Z'[:G5GC6-
M%  T)&Y\:6)HQK3 96)MJ-!WU ;)5P:) JX85-H:.I'>=:DBS1*>0I00]0GL
M7XVH]K2L3$5:]0N253A>I(T 47N#O7:A<C@=CXT())W.8A1XVJ,JDF0:\+_\
M:93$<ZCQ%)VEN//QI<P/V4ANH_*Q#E5TKM:&^]+*QTJ23("UZAU[;;G;\?CA
M3$*3>DB,S%VV!TI1:ERA[OM6(-IF92<O"HI@W8/&@ $L*VO?R[J=KR5&.LF
M_&E6_P"53KE;QI4NMQQTJ!K&QJQX5XT1RH!MJ:-MZ[8[(8A3N*0<:&K5&-;^
MG%Q=?AIHANR'+]8=I?\ > KHO$##XG*_924=6Q/R6OV2?/LZ[9KGTX[$##8=
MWOVR"D8YNPT_E]8]PKH>$OB3+;LPJ3_$]U4>S,?+T8[$OCL0L<5R@;)$OSV.
MA<^/"^R\M:3HZ(8/X*=2W::2VO6_/'U=@/FZ'<UAYI.C<6R2>K?),O->#KX
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M;IB$=6.O(V%LLFG<_:(]HK#]%8B9^LQ5T4F[7:\K_;EOQ+:\A2J% 5195
MV &@'Y,M,"#3[ U'"TES>P7C4E]AK8CSKJ58"@H ]!!H7'A4S7;T(W9 [O\
MA4G8DJ*2QMP-9ZF3K8S;<4L3+X@^ZHV4+VFU[Z8)(+'Q'^=20.1:^G"U(,D@
M!&Q%7!WH?%&WR&^V@O&]+;**+J-S0(.WY$Z9A>A>^E!38\ZF]9%8=FE<WR1Z
MVXU(M@;F[&ET11S \;TK:V-Z= =J9,TG,4BQH^H(\Z5P1=3>F(RW/*F'$;UA
M4MF<[\ZSU* R]]0#3SM7576_'A22_(;>GVTI;DVI4 %$ T85-,O 4JVI18?D
M=)=&L6;$8=<P;62)1J#Q=1Q!^4!K?47!TPW2T\ $<J]<JZ#,<LB]V:QO;]87
MX7ING!;L8<W_ %GT]RZ^T5_I?2<VQ:VG**('W#WNUN-JPF&3"Q"-=3N[VL7;
MGX< . KI?&Y!\%C/:8?'$<%.R>+;M^KI\JNB<'U:_"9!VW'Q0/R4/RO%^'ZO
MUCZ.E,'U\?71CXV(:VW=-R/%=U\QN171&-M_HDAWN82>>YC\]U[[CB!734K&
M:.'Y*)G\6<D7\@-/$UA.E$PL*Q##EM2S-UELS'C;(>%AOL!6.Q_PT1CJNKZL
ML?7S7S6_56VU8;I88>".'J"^0'M=9:]V+;9#SYTZ++&R,.RZE2.YA17$=&8F
MXX7RL1V)4/XU%[J?(U_3D67^HDS_ #<RY?YM_P#<I4Q'2>)S'C;.P'8B0<!W
MV]4;L=>9I$6-%1=%10H\ +"NE,9B,-+&L+A0T>8]E6US$?*!Y5@)7GPL4LAS
M.V>YL!M(RC0 #8#T$V!/($^RH^G%M\; P/.-@1[&M;VFL3TR'C9(8F4N"N=R
M- =#91?6W'-IR-=#85U+8EQE5DR1WW:Y!+>&@ /'6NE,(<3$&C%Y8KD#YRGU
ME'?H"/ CC6"Z1?!WBD0O%<]G9XVXVOPYJ;:Z@C6\W35QEP\39SH&DMIX(M\Q
MY7/D=JP@D7I"$2@B3K;OF]:Y!)OWF]S72L_4X4J/6F^+'U?EG^7L_P 5="0?
MUF(/[I/<SG_"/;Z>FH+-'B -_BW\1JA\Q<?PBNBI^NPJJ3VX?BS]7Y!_E[/\
M)KIG\[3]RG^.2L/TK)AQU&*C9C'V;C206X,#HVFS7%^-]ZQG2QG0Q0H8T;1V
M:V=E/R0!< 'CJ21II71.":('$2C*[C+&IW";ECR+:6X@?6_1W2GY^W_9?X%_
M0$@N-*D&E'M+X5V@+ D7W'.DC)HJ1SH*>)H6HKRJ9LJV&]9/G<=>_P * NP
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M/"L.1EM;G3-Q)J8QR<,_>-*:*Q#*"!QK#+=0>%Z<VVJ[#?C04=8P/$TV>/\
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M$3)$XY;U$=#3,3V%@1]'-N3ZC,9*@^38@-'300T\4L*Q01)#&.8FR1J$7O\
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M<O/J90U@RBW.FDT&S$$II)VN3I6W]QO#?_W._P#TRO\ _JL?W&\-_P#W._\
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M#J1U:^[=-\<"2Q,\\#J%NUA_JXXORQFS20J.SVOUCCABDF226*"/F32FVO\
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M8TTZ%5JD ]95ZW)\^N.(9HZC-:&51<REV\NG?C@D,:B7PL1]N.(JB:;B"*(
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M\5SL>[%'(9($8^ _$K-9%LJ^'7%0WI$@4>S$\BT\?+'K?.QF%.E>DD$X#1R
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M^_V8X(J(<UR44LP$BI&J$-XVQQ!P_P#!,LD\=VIW8FUNA8]P\N_%)F HIE<
M21_.0]^,I-)G(YE/_%G!L>6+;CKOBERC,.5>FKIM8W[L5%+Q(LJ$SOIN 3<=
M.\^W"OFU-V[&L3YX=@+#V=^*;-J26-N2=,XN'CZ:3W_5B3,YB^SGKC(<Q>8<
MJ0ZO G\3C40*;&5 ?SAC-Z@&GM$X-_P=\04[2.2W3$:Q1*%U@';;%6B*P<NH
M[\5]?04RZFFCU#NU"^,YXGD>$QP*XB /;^:<35LTLKNQ-K'&69-49S4@HK"&
MYUN;V^ONQF\4-#5\B(_)J5>Q^<,<*S%,EBU=)(@"._IA*^IRN5@]VI)&+7_
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MGB!R6WQE^6^F$>'?@9%3JMA?5XX@R6&-];;VP$4+IL+>%L'+J4OKY8OA55
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MOY8ERBH=CV205Z>>*?):GF6Y9ZXRZB%)$!\X]?Q=>D@<ZFC6_L&%14%E4 >
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M%;.7B#Q]I2+>.->I[.+@XJLN92&4=EK?;C(*.1*F-K'8X[E]@P/QIS3,DRV
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M,\O?E2!%:5%_S@ZL3@\8T<:4L$BJ&+Z)C?U;=2?IQ5YRUN;24O/A'5@PZ?\
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MY(]/#%/#41Q&9TE"E.6KHA*2(QOVI%V94/7;;WLUXURO+I&@A5Z^=#9^0RK
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M?A%)@_\ J:2/_P )A. :):"6G-2S5LIC(K6ANL.A@S)%3\U>RXNK,TNK<&X
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MAGDEMSJB6QEDMT78 +&-RJ*.^Y+'?#*KJ58!E8%65A<,I%B"#L01L0>N,SX
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MG1I3,".7U)/ABHFJLSF>" F*DCNCR"ZL7'@>A!QE>1T5--S9R9I"?\X=8O\
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MTZ#\9M<KYXX>X0I,MT.T8DGVNUM[^?CCC^3DT-+"#INY4=W=A(!*ZTVG6TA
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M</U#2PLC-?1:USO_ 'V071P.I4C[,9O3NM2^KK?$:6!ON<9YQ=39%="&:<W
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MZY#=SI5Q\8Q\[VQ&>;"'MLPN/8>F*> LX]NV,IB:&C16Z]?L_ODDB1*6=@H
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MYS5B5$1W+NP4 EF)-^F.'VDI<CIFD%I9HD9O;88R&KO*5.]Q_ XFSZHSNM]
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M+I^PM7JIW4_,JZ<MR[^?RL/FSKX>_P ?_P".X?\ LZ#_ ']5BC_P2E_H\/\
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MMCI4XYJ2PN9 !H6]\>Z!5RU=4T0+<N-B .X[[?5CW-\A9V]-F39;%+CP_?\
MMQQ?"!G-E'4R'ZB,9+4CT@(+ #3:WCC+5C6BCD;\%?NP*J%FTZ1]6)/1AO8?
M5BHK *:6.$68H0"-L14D=9'F,,FGG--<E]B>\VOB7)Y:ZHGH(%5="CM>9VZ]
M,5/N99HM29=2.I.X9NE\<*^YW3T-8M75$R2*1ICV9 ?(?OMBI2T<4:C2JK8
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MC7HD2+&@]BJ !]7O2Y3E<TC2S9;E\LKG4\DM'3R2.?%G:,LQ\R<    "P&P
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MA#^BC_4'\V4_R$WZ*3]0X@^0A_11_J#^;*?Y";]%)^H<0?(0_HH_U!_-E/\
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M#NZMQY8N#<'D?P=-^77%1PCW>))?WZL6N0@ZXV:YQP](OTP-;6\B;# DF>,
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M26J'?^>)_P!>%X48%R-W +?;BHI1ZTL=A]F"DB-&R3'3J%M7?V(\L<6L*NI
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MM\<6FKJ>0N+A1("V.]-&KDW )W.!KY8&J0) XL;G;4V+=JA_RQC4C!E\1O\
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M\\\*Y9(K]'%C@GUIFYM[^=OP-CM?A\0:K?IPLL7JC%//4PWRN)(_2<_2*?#
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MF:DB?1!!^1/.LC2<K]G5-U=QBG^$&?4B5T]<IDHJ*J0/2PTNKT4\D+76>2H
MXB<75$L#H0FLZA*M#E]'E.91HS4E304\5*C2A3IBJHH52.6&0V5F*\6/9D?8
MJPR6IUQTV:2O055,_P"\YA%K%/)I]F43*:5[<UE[VHQI;&6TDN>Y@]-+\(J2
MFD@:7T3P/F4<3Q%;6T-&2EO#XXXH&9%KLVI:2I*FVJ#@5=5PS;HTM-%<<B 0
M>>*G-,PHZ7-*\5LE,8:Q4J(:2)$C:/[T?5&6FU,_%E1C8:8M.F344F^#^6QW
M]NB@&7R ^(DHN WVW!]H'$4"DQT.4T$<2ESK9*2AIP@+MS8K#%WCU.+32N@K
MIY)'<]X9?E4%V$<:^KZ*+3#&.4E3(&D-Y'?"TL>09;. FEIJZEBK:F3Q=YZA
M9'#,=_1Z%4^HJ* !39UE&NECJZU:*7+MW@1W@GG$U.[L9(Q][D/"=:W<&,Q*
MN@P?TA7_ />+\7R91WFCRUDRBDC3?BUSR 56D?3:J84OF*=#C+<HBL5HJ6.%
MV'*2:VNHEM_CIVDE/Y>'EI5*Q4.8IF%$HV$N75)XG9P?H\"26A<^*OBGJZ=Q
M)3U4,51 XY/%,@DC;^LC XE_FW_LG$&55-1)3T_!FJ9FA53*Z0:28HRW=C9]
M5N(5DT<]#8%*GP=RJ1 +:ZFDBJJAO-JJH62HOUOQ/=;%+F^3AX\MK)S3S4S.
M7%'5Z6EBX+L3)P)HTDLKEC$\1](5D1$II:J1I:V@EDRVJE?=IF@6.2&5CS9F
MI9H!(YN7E61B;D_N$54'4J J%;[\\:UZXFXL0.A6=3IW#*+C%7E%2H:)[Q1O
M:Y7O>T<0A7XH*IZAU6VY8FRV8)'2Z19FV;<7.^#DU-(H@1&52M[E8QXCWXDA
MF!5KV:_GCY&JHXM$^^HJ+':V^(LWH(TX,C7JH0!P^'Y(-M\1YE3):GJUX^WJ
MH6.P\!A*:=K<8B/Z[GECM*[*8[ACX$>.%J9)#VD2/WU8<P<0TTL22T9LO$TZ
MB+[#4<"JB@AN5UW5!?QQ?PP>-MMCLH<M$Y-KF]@/#^!SQ*=+GJJ@'#U67F\
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M11="PM>V^V%+]WC&-6\+8I\NC"Z-5XR!OIC(.^(T7DL:#;QMC4QT4R'O]&P
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M5MBIJ>G$(^I2<0U\2W:.--5N>YQI/+'9YI--%5OW[GNWY#"3BS+*H=3Y-N,
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M)%JK:!L;+L-CTQ2P* .!$$Q &"W,D8>W@<9;%"P:.GC97 -])Y[X5=N0&^-
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M8VWNUO/IA ? ?AYZ:-7MBT2!!Y8D/3N_J;%QX8[QLHZ831S#7^K;$<=,=<K
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MZE./M:GOWC_ZXX=53-30/LLSMW=^6!/ P:-MU(Q#FU%W)Z;2A ]I6/>/V85
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MW-K[7.YP*D@/F$B;$@%BW0>.!F><2.M._?AI@;H5.XU*>HPU(8U;CJ888K7
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MR"(-%X*_CA.WQ-,18%A8# C@=$E_B[][!0\[8D?@F35=2?*^-<>S#UDZC\.
MRWX>I=7VX[OACB*-QAH6)!8:<5=!(JJU9,TL<PYE?-O/':J5VIZY>\KQ]WB'
MH';PQ4?!WX0(IF0,B%N]KTCUN]B6:G#M2.YT-X<S;;IAJ![A&8=[>XMT&,M[
M2P:+M0+W-QI/CC+JK+Y42"2-S.J$!2Y\;8#1$2 CFO>'Z,&27ZKX!]DX:+2L
MD1'>5^5O=B:LBBCHZE 7/"4+J(\3YG%9$KD\*2PW\,1K4!I(;Z.1;3A7AJ I
M/)68 CZL#O:D]]QA)%)&+!1KT\[=<3T\AN(R E_W64#GPWM_DG$@;UU;?[<
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M%5Z"(DJ10PVBIHK[Z&[.BZR!\XSO:YPD47P;HTCB18XT6OE"HB *JJ.S;!5
M \L4$\N50T$]$DT7%BJ'F,\4K(ZQOJCCL(7#LG/YY\3Y-,]ZC)9O17.[4%67
MDB\SPIQ.AZ)&8%VVQ+_-O_9.(_Z-KOU1_%)*X[]+F-#-">H=V>G;[8YG^P>
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M\6IDGD4/4<,[K)5R:%1=B(8X0X#Z\9;E.QFAAXE6PW#UDY,M20>J+(QCC/\
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M1Z;ZF6[9H4^]\FII'UGEVJL1Z:!/?PC4R?B\,'G;#.[!44%F9B JJ!<LQ.P
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MHJR,:6[O<U>;'$B=UF52\$BV)#V[N^*C*:P$U-#Z,,W-_KZXX0J98DOZ@;;
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MD-/$D,2_DQQJJ#ZA\4E359!DM343-KEGJ,JH9II6^E)+) SNWFQ)P%4  "P
MV  Y #H!\:U,?P?R2.ICE$Z5"950+.DRMK6991 '657[XD#:@W>!OCM&89-E
M-?4:0G'K,NHZJ;0M]*<2>%WTK<V6]A<VYX_]V?@]_P#L7+O_ );'P?.697EV
M7&:;,1,:&BIJ0RA$H] D-/''KT:FTZKZ=1MS.,DJJS(<FJZF6&I,M14Y70SS
MR$5U4H,DLL#2.0JA1J8V4 <ABPV Y##4U?24U;3MZT-5#'/$3T.B1674+[-:
MXZ''$_N>H]7AKJ='_1<?A?YF%IJ&EIZ.G3U8*6&."(>)$<2JMSU-KGK\22YE
ME.69A)&NB.2NH*6K=$OJT(T\4C*NHDZ0;7-\)2T-+3T=-'JX=/20QT\":V+O
MHBA5(UU.S.UE&IF+'<GXS+5Y!E[2L;O)%%V5W/TG:E:$NWXS7.$EI<@RY9(S
MJ226+M3HPY,K533$,.AY@[C?X^+FF34-5-R-0T7#J"!R#5$/#F8#H&<@=,"H
MRW):*GJ%]2?09IX_..:H:62,^:,#CY3?*<M;,@RO\H-0TIKM2((T;M9BX^I(
MP$4Z[J@"C86Q%\IY9E^8\#7P>WT5-5\'B:>)PNT1R</7H37IMJT+>^D86FH*
M2FHJ9"Q2GI((J:!2YU,5BA5$!9B68A=R;G?XS35])2UU.Q5C3UD$53"64W5C
M%,KH2IW4VN#RQ+\F99E^7<?1QNP45-2<;AZN'Q>SQQ\31K?1JOIUM:VHXCK*
MS*<MJZR$((JJIH:6>IB$3F2,1SRQ-*@C=BZ:6&ER66Q.%.;951UKJ-*RRQ#C
MJOT5G33,%_%#VZVPM109'0PSH;QSM&:B:,CVHI*EIGB;\:,J?/\ @]\XS"&J
M:MDX&IHZMXT^]XTCC]&-O5C6_C_ #H1?4K#[1B>-5VOJM[SC=#?"54TFA6)&
MDWOMC3#&-7M,=]_*^")X5:XM<;'#01 <.4DI<7L,<N\3CL,4;354B,"R?O9Y
M6(Q)GV:PMK<ZHN)T-[CGBIAD^;*ZO"VD;8K&(]'3WX=_%7.-6@G$PT]^-&=/
M?A_XY'*_7CLU6D@C0LR2-L&'0#&J=UB &[-@&FA-94:K%H6PK4N7RHNGTAM?
M'#J&)?C. #S&._SOBS#9UM]N,TH*^/OR/][L&T6L/+SP:>?55Y8TO=9?WL%M
MM3'Z(Q15E&RZJJ[3%6ZVZX1T\1O? 6-MK<L78]V(:M_%3]P\;<G4C[<5,+@B
M$D\,]#XVP&U>8]^)6U+IC(]D8AJ+[O:7[;;8EI)B/2)I]V+9CF0GHT?T,*%D
M*J/5%_+$<.5SE8:YA'=KN([#F;X[3,XGK*COM)S U<Q8\L W%\+Z!II2FH,I
MY898)>RTQVLRJ;CZL:I)-8,FJ3;GOB!8P-2<V78\O$;X5+W-,5A!O?EB*GIN
M]657HT YJ?$C$TU4UZFHV>_/7(+6QW@1QGD-CX,;X*.-O''#CWOSQ)'$=JAI
M9)/RL=IB[P/S@\5&!+'L=M:_1/\ @N3)E"T[&BDK6G[1.(=IUI1'INIU?--?
MPVQE655XC%721SK,(GXB7>KGF72]A?N2+]>WX4\>,Z)_+;5[S@=J.B-6OW6!
MO;"01"R(/CBKA;1&NEO>3B:JN-21DI^4,-G>8DO),XEC0BZV.-$*B-479%Y;
M8K5D]D6_1B3-(0.R33O&^_JV;O&V!I"L"NV&&W?[MO?B<EGGS6IDXB0K'K12
M/9N.6.S+#!0K$NL/&Y5RO2X\<"KS#,Y>%L1&LNK4#XKBT4"DC]\*]XX,)75J
M%M)Y8O4J>P5)LA&X5W/Z+>.!,DJ<,[A]8_7CA&JCN/I2K:WVXF,+!A32V8J;
MKN/'![0BOQ-M)W&_7%'/2[PLQ.GV4'@!B)G<CU6M? WW!M[\/*!L;[_<J\R"
MZ7[X7O8M'*SAFVOX7P]7 29+7<>.-)>TT#B.U^\-/ESP]R67WXT@'"59'>I^
M_JZXI) YN8$O[[8[S'$R<)3(JEQ(1W[*.6"H<+H8BVKPQ)3@G7I9Q[@,2+ID
M#+?FIM^K%5E]>>&&9YE8_BB_,XFK+AUCT]F!W =>OEB"',_0TEP>YN&8'NW&
M$9-)AT )]F'T<NF))IB 4!87]8^X=<5>;3K;7,3!J&^AO?@\L5-K\/B?5R_D
M#>5]E07.'IXQII5-ORK=1BCC-^'),5?GR\\4:)O%PAOC3'WBVWNQ,/IHU_?I
MQ6Y%4]UKRN =CZ1ML?)]:?O>HNU,YY*@Z7ZXJ9^B1%U/^O#9A+9];LQU;\_?
MRP6ICHC*@;84T-8 H_>R+X2FKJ1Y9"=)=;67S-L7VTWVPU-,H*.I \5)ZWQ!
MD4529,NG8BRWU1JN]B_/$9I9W@J1$HXC2O:X'A?$S23":HEL99;\R/?@$MY
M>7CAH(W 6!@-Q?$/$/?T+]EL+3TX+R,X  Q!&?79%=_(D<ON9;_1PQ/-0P'U
M'!CD6Z\L"MRY[44H)EB OWV;?RP^I"18=,686.*FFGE3BRI94OO?'9:1_48!
M.1[@PD&:#AU'\:S +]F&>F=9(9$(NO@V*DP-9+AM'Z\7,9TI$ZN3RO;!6KA4
MAMN0&&J\DG6GF];3<DMY;>.&BJ**<A=N(%[I^TX@CEBDIH68%IY%[@%QU\\0
MTU+)Q(T4;@WWMO@(PX]7)\W3J>^;];>6(\PS5N'$K:TI?58>_P ;X1**G:*)
M18-;; 2:73'[5UZ86&(=!K;Z1\?Y ZG3_%M? OS'/$R( 98U9HORL"@G[M12
MVBTOM<CPOSQW\:;#6%W/Z\";+&O6 J)5M8%1YX3CZ5J(].AA?N@&Y%\7A?56
M3H:?3[EMA5E63?Z )Y_5A*N34O%8HH;]!Q=IK&WTL25\B*_$UH+]/,8OO?%R
M_J[VOBODYBFFLOUC&D[[X/#[OZ,33SR;K$Q&H]1T%\35\UQ S:A^-A:9G*IL
MMQ]EL12(HE>, EF'4C[H01]X[Z_(8:JI.9O=+V& *N+3KV!Z?;A;=;8>ZCEC
MT:B^.VTNHO"&,B^(\L:7C<-R.M6'^K ?<\C8<L*.-(T(_>7+:?=RQ.T-'HU*
MO?L=(Z7N=L%50/5S,.*Y&X<[$ ^&.-4D\2<&VP.CS&"<OG9QT#.%P8<TB#MT
MU[@_7@PM2PHAY,HW&.+E51),!OP9&TIB7,OA!!'JA9E@6^L:3UQ2JPO#Q1J'
M33X8BX"*J% 186_D%9'%U86(\L/-03+$'-RIN<<6_:+;E57':(AV.NAO;5L"
M?-1SPN79Q$T;DA8:L]V.0GD!YX)9_1L#WNA!PU5D]ZP/\Y'%WV7GO]N.!'EU
M3>]B2GJ^_?"U&>5"\/GV?=2/TX5*&G4:>ILV('AB++'+=M Y #GMB/OE8F91
MIWN0<0)?AH(U<EO=OAX(_OFH%QJC8=UO/$^N33#("$4@;7Y;XJ.U..TUC!M>
MJV^-0&JXN,-PDL/=BECBFX5.DJ/,+'O(#WAMXXAI(5T+&NF_CA)F:[:P<$MZ
MQ ^/A2U41DZH&W&/O699FZHAW&"L0X?FUL<[D\R>9_W?%PIE (]1N5L&*0%H
M_8?I:^V$$2EW;H.>.))1RK'](C;!]4GP._VXURT@+'FR@ ;XO#:)F',G"/43
MHT(;U1<7%\<*BA5%T6O8%C]>$0<VF3]>(8ST4?I'Q:7%I%]1_ ^=N>/2U"-'
MX6.+TLRA?HV-\:*B)OR[6!Q#%!$QLXUOT Q##_%H%^S^0A.SH%MJXEA[6 L"
MCML-WA8['B=.]B"/,JJ2!8UTD1R:M7OQHCC1W.S2-ZQP%IT J).6C"FJG9$-
MN3[V]V'A;TCL/G64:@1BJRJJ19(6#CO"]@VUQB2OR^'M%('$B>*"_@-\1TNI
MJ5D559(M0N +;W&"S:KL=VZGWX70C'\E2?U#$=94(\=-$00K;%O.QPNM;@"P
MOX88*N))WL%2,O\ 9AA3L535Z,)B&2H:1J8,NH;D6ZX@G295AT@."0#R\,6@
MG1SX:A?]>*B2)K54B6@\;];8-34:II)3K);<C5OB*6"1HXP1Q5&P;ESQ#4!M
M0DC5OK(^.Y('O.!$W!E)-K$@V4,#A=%+%<==..&T:E+6TVP]12IJIG]D>S[@
M,'5#(+=2AQY8'B,</5L,1(HU(NY/2ZG '@ /N?3PI)^4+X]!!''YJ-_Y">UI
M&98V#%[#D3@+% Y=C;;IA'GF55.Y0@W]V!P9!&W4F^.,Y$LH]4[V^P_'(#R9
M ?M.&AD"NA&X8 _KP9:2U.YW;P_1B\["4^1..''3 VZD C].!W46W(* N+4M
M,\@\5%\%*JGDC_*&*RGI8V9RCVMYWQ)!5"U1$_>#=#[L-3U4&MB#I86'NPPB
M9@A.PU&V%S.&MTRQ$,4:0[A=R-SB$5D#M%2D[J1I/V;8:.2"\90H'U"R-Y^[
M'%IF#0RD:2IVVMB.F,J\=+=TG>P'Q25K[VNJ_E6VP1'.%B<\K<A]6!7=I^^T
M8$ZF)U*-SM@%7 J$'I8[[_%9@"/,7P\9A2S \E -[8EIV&A >[?K?'=.YY#Q
MO@2R/P(V]EP;VQZ,7D/K/_L_D0T2*'4]#RQJBIXD;Q5=_NH:Y1[2JQ'.RX#(
MW/&H[X8C#,D;.;G<*<*HC*1W[S&Z_KPD42!2%&H@;DVWQZ>".3\I;X9X*>..
M.0#<+[6^*T@:-4V_3"M %>3P)Q>6G46^C<X["O%6WK:5/N(P:.G9H%.S2^H1
M]N$:.>2>F9UB<,>[J)W;"/<\)!=#S&^(*F-2L6M+NO/3B.174DC<$[_9B360
M )+BWC; :4]YK\^F^-"';%%'"Q]/+:0#VAY_<>D&A_XQ1WL"1V:>W)9 +8"J
M+ <@/Y&&AF74C"QP[T,HCZA3<X,%6#&R_2VO_P"N!''WG:PTCGA%,0U/WCJ
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M]S:_UX]V_P!6(LLRL&2.!U:1@=EOL<03U\YJ)"NIH'4%0?"^$6!5AIP2"B[
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M;%+FD]#P8Z=B1&#<$'%/5)*T=3 R/ITD7T^Q<X4OEL<MP Y+?5@O!97J3Q;
M>H\F_P"C%-3V>1:4GO?IQ-EIA':5U!06&W0-B7*JD%)(NZ&O?7?'I1WG&O[<
M6MCA:"88J?BL>@T<\&KIYKS2'O+;U;;8C$A+2U!5%\;.,15%2=,84L<,U:@2
M@]E;W5UZ-]8P&RA13Q4T@:0Q^W<=</6#U!<EK]>>)XZN-7DM9&;H<&B5>ZS
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MR!M2U\"3Q-T8<L"H[.DFEM00KL,)#$@2.,:41>2@=!\4KYVL7#C0Z)'%RIZ
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M$/ZM@WJG*<K:02MEN6T- TH&D2&CI8J<R!3R#\/4!TO_ "&D>(Q)FG"9Z&H
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M;1C;G<[XJ:R6NSU9*NHFJ9 E30! \\C2L$#98S!0S'2"S&W,GGC^_P#X0?\
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MG3"_7'P-"DMXRE,.KEPE S$WB2)?M5?EQ.$L\L(^E%U,2"C#SE)&(?MUE6Y
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M%:0(L*6K'.DL=I3V9/U $1) ,O'A/OC-&'(/RS_:_!_-_%)QC.Z8#Q/_ +6
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M]KZQ0$5-0V(]Q@)#50[?*R,BDB&_!&%2072R7(4Q^$38OS&%G*$:FAQALA(
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M<IB\("BM'C'E^$$%G^<9>!*N#QD"119@+S8 $F[(8FE#PQ1'\\8%A5G[L<J
ME=.D8\#:V6:Q0-'QH5EE&,A(AMF<1>D],I1N\? :,))"#LGG!@U?*O!Y/P&$
MNQC* -A(Y9\:P$:XY1 HC@CK)*Q"F._^V1A&'J=Z3=Y,J-VAU$N'"4&00I<!
M9B#K-Z&*A-UP<?/&3*!/4\3SUB$MI(6.?G-$]O<>\A%1(I/"-8 YH^%:R42R
MS<2).D$_G)$>$QA?3RP_HQGJ+(0(<)V6%,OS@B0H[:B,S>L372G&5R\E@4!@
M&8/;)L2!BAU#'3]QA$O*@&ZV6_\ .$96!9,"-<<F!TT&2,D.ICC>!80%?_$G
MC%YO\AD7/.F&@'Q8$0NMZ"][%XV/2?F- NLAFHXD[0R9)$V68(V]OX@R930"
M@O?B<D^QR(^91*_60HA W298Z6&W)1X]2<F=\,S_ #S:\0?NL,GPZU*XO-"1
MFCF*R*921R&-8H2 CQ0?IB>$ ,0<0MQ$L-=HR3[IR'CVN\F><="HE4C9?G+F
MV8P W\8206AS(_WD&DZ+"'[9.]4^2=0U$ZG'Y'?I:\+DQW1(X:B&\[$KYMK$
M1Q36A;HBN<$# &L+7XP/.6'--R9Y:,$ '7)+'\Y85J"&-)Y_HT+:!*P3HRN$
M3K0'?6L5_$QC?D*'9SD0!A=8YQJA#7[8\;/;Q/?6!W=H]H2<K1B'A$O/OB9U
M5 TK4-_NC+,0852X'XG)A CR]6^V&X\75+A,@<T3T9S>>O-1*CF*U;@FZ64C
M1-VAXA<F1!<-3\N<Y7C-#\O$ZQ&9RE CA,<8V :$@DO""?/RXXZI[M=8J)&:
M?;^>C'E-,%&)EYQ#.3,E]QD0.EXJ$_?!SFCR*A"=A> 6UHB1BPG2\IDI7:BW
M=\N3R&][6E\9&?U<4 8?WK , 4EA4OQ.7^/Q&/\ &(X4MLCCA>@-32'U#!ZR
M#P-:M?.(F1!&MX;C4,$I)@BL!R-NVLTI#%N119G5,%$1B. S.(NJ42Z:.\*W
M"1DD30X/Z-,L-1I'8X[&I H!?[RU1&FUE?>3)(/&4H[AM;^^&/E.I$S+Q7?Z
MY>$X4.(?#@3(H] '@PR1 7E,F2;@3PF/>+BGL3%/OHR/%(-.D<^L \D#\$J8
M$RC:T^1D#: 50L)]<9V@?3+H/6))G_)$6SN>\:>-:A(U!O)D17-)/Z88$VB%
M^,CYEE?#6"(B@/5C^>@;:1 AHG'G9",5YTY*CX:ZR6E;JH1X;R53*!14LF>Y
M,Y28=48QQO6IEE]O67M$6FVY*&8HECH?&3.20<6?'XR:U(>$91"8114SZ=Y+
M%PMAH&3_ -L(:D@: =^,-'SERO/O#-'JK X^8Q]J RPPB.;O7VRZ$]#03@/4
M(0&E##B<C8CPV[\SC(LT#Y/Z-.XM9!039RX@0[">HF[PO"%53@K,;?P+@34-
M5W/[<B7&C,H0&CXPS12P=#&DVH:C&H*$ CZR]NNF8%^+PZDHF7%8O74:Q'"B
M4UMC$Y$M$/KCQCQ_C& 9E\%1]LF$ Q2M&8Y_.2L<]<I$CP2?XR34$@U*93HR
M008Q6A[3"!LAY!QILPPX71I_K- .& D\HUG!HU?!_/H24$YK;0MZ^V( 8*1+
M0-]YJ="$ IU94Y2D!TXNT[R!0*H0D#Y.OCK)UV0I6"B*6?> V5M@F;QI].-1
M+^,BUBC (DAU?C-L1%VCH><<<$!K$>#O63_FP-9T:GWAYSRY L2BCSB3KI?Q
M"VS^[Q[8EDU#0-N\)/Q#)$&LQ<Y!<!;FA.)R:(,BM&G.1<+*P?>!'?OD(4E<
M?T;N.>H]/& 8A%8YP[E19!.U%U<X%9N]Q2$:/&2!:Y#14\'/&)'RZY9?>1!B
MI[989PB6!8\DSB63<@GW+G_O%K+A"1L++C'A&V1,?],E<E/LK"^W"9,Y-^><
M?N$3;%I]81<@+F2(^^#%J=(UI/C/%=9*:LFBD,24@*&;?RW2(Q0%*-MZK6#Z
M1G3;3[P( ZK^?.#N(.BQL^^0\"9?V:R2C=;.$Q<P3P\8J*(!H^"??'2[VV_V
MECA!R!,N:RCJ6Y_YWO(GK28-C_P8::FVA5\.3HX@HS9;'WAHY@GS:]36+T#F
M'?5Q,8C)9G)Z:?IK!23D69^%6\7,I Y\CD8D\>5C:V7YPP499*$CY_H^73AY
M21)B(K96/+=9!?E<!W*1K+9T$Q/X9'L8 ELG,!^^\%'(@<,X&'4F"/KO'I",
MO;-SXU\U! ,;R&3BBN)$WN3)R.L<O-IMYKUBTAQT6D[(7\8!=$0DX2T^<'TP
M\K-;G[XA**7,KXP4J_-P0/#.%8<4 )*^8W&'V#I"02F\WG3\@L&/^L@F(,]E
M4&!8)(Y(Z9'4?. "  - 0?;^?_L7;!#9?-*O^L6#U$!.\*$$C (Z.,3A%0KO
MQ1)QFI:<DF;KGSSCIHM-ZS@3?1"0>SOC)(\H\&+CUDIX-XD<N\A()0,"91&_
M/QSFQ,0RR'3D8+H]$"L3V1UU*JR0HF%'"8>,,!J1^ 9,\E&)<6VQ[RLS[@?Z
M28W\!,0B3)!0O3Q1[QXLZ,\\B%LK$:^:P[6&-Q1T6LH$S'Q#K&O5U"+M=890
MP@X3%<4F;[P+W;*GC&&49$V]&,KF H_51ZR3B";Q-Z)<W8^Q9$D_?]N)H.ZU
MOML8#,NJ(5-W83D">2%Z +%3K[^,@@,?Y"3CO:\Z@,BTB"-4 _G^@#)&T3Y6
M$VAXI(O-M,GDA/>2M#9Z8R+RR=J)($N,-)?>"8EA6FJQ4D"65$\O4TKY]SBP
M85>3L?#B@R1 CVKC>0<\\5EVY4^V GP><&T0LNB+7$UD6!Z6Y_Y_I4B!^B'Y
M'%1JZ56]4RU9&43^AD ]LY0,+?UP)I??+2;!XR7[@ W+4N &@B=;3AW^<BQ9
M3@V'-X %-21(<3DT8)BX9D+W]L@X( !H!!K$S:*/#L0\8)@LXMDZ3YPO9F$2
M0E>?>"^2\BXAP1H4_1<4J9\[Z_H$C9:X"9@.<."& )>3,G5"IW&&?CLWETM;
MC>1A:L8&WX)#@R&P5*O,TW&2;S":35-*IYPCE  ZEF1[P@4 4V ;E/&/ NCO
M$+FZ'0M)_DRGUIZ6$Y6W@-H(@(G0Q\M+X31X^^*>)Z&8C,?']+/_ &UV)Z_&
M5_-.Q=#XP6X\;3%4WC$=$Y8+R7^K63# <(]R88*O#F[9>Q?\'!20"-TWD- H
ME_[Q A?G#_&3P618H,E/PX*R8Z[P%%T/2E,X_P 3I=M& VE\/2U_0 )BRG&7
MHL*S@];R>F%MB1(_.?)(*4_G"50'&&X3_>.4K?9#[I9D<4P@@CM/!&$)0F0[
M#X7ECG1)GSZ.M9="NUDE&I.U9HRZFM;K6_&$R9 HC;@-OK#S"*8E&X;KC+X5
MQT$#E I1 W@(G)Y]C_2RZ=X];OUP,D]1 F_@P=&!2)S*M;A\,YI)6F#'S:\G
M7WDH"T $\X*H4?/2#97G)D@B$9%8G1WDX$L-G3EXRPAFM*C)0W.5?"5,) K@
MO+6)4R9T_P#3D%9NB$F^/#!MM%D)">?>!R  !!!_0""05+]PQ'2!4FQ+YS1*
M$1UAVR"!^0IZO+4BK +E_(P7D;"C6QO'0E+PL9=AYV1^< !AQ; ,9)"2=P/'
MKS.'E.4:VL8<Q-)%0DCR_&"DJ(0CT9((@P2S[4;/TPS8 =4(/Z5T$#[*C)I_
M<']^,8A=SO58S$ '5I?1ZR34@D"YA=QD^D3PAGPAC-(FT8@EVDC$"6BQ-D!3
M49!(:H:<:QM$8IA0)8?*0CB-)AGGDP^RR_<CXUDJ0*Y1!DKWC4#05:%K"ZN5
M:B@# 1*3H?Z *QL&G-TR14-Q$*&M9?C&G-ODE."R/TP[1KX GR&2UNIF_9#[
M#&J$!N6M@-ZP#\1)#\S."CC<<,>?< <07LBU\QDB@\N9R+?[W/LQ9*S@:>HW
MDUR1$#??]+@=-N,B#6*MI X&J$<R5@K_ ' .47BN1" _T'X,CRG<Q021,%??
M ' $&)0&\Y0-W.45$G#B)(K7AMQO<% )YV-Y:,XK+#FP!T?XQZ+%X87PPS%$
MQDP@^3#=&O\ ;_.SR(.X6.#SA>?2,GARH*V(%U4X;!>T)^/J7T0WIY(3DB]D
M. THWAX1A1"4M??.:_)"/T<LN3*1/. YPI5!3O2\:1AHJ #LC!=-?XP=4]F$
MX=:P+I[VO^LCKRRN&I'?G*8 T9/-6X\!4B!O.L'0R*!?8+_I>C! -R<@J>54
M$/&-P\NQ7<)DIUH%(3>]Y!5EX0?U,?G^@7[9PC:3'JML>OW^]80\$/&=0<XW
MF5X5MO\ $,@@:L(Y@8_3#^4!:<1!'?V^, T2*^8S;=")>&]9&D2Q2.9_G<0D
M8#L<* 0A]F$"/0J^,9(4)R#SAV"A+X/J0" C2.DQH<,/:&&/;ZQVO  =5QDJ
MNFE91JL<SFQ*^\B]"$\)JX^WC(NERP76XBL\2P0FY;^G $!-B2/L<CL3V@[L
MB\-F9$ 3[K%9KTRD\IM]-+$4D'947/4'[UE^:;SC!8^,L4N@$58^^,8&9P=?
M@Q)H!AR@]4P_MZ2")6$S0+$!IP&QH,?>0US]1Y(=J,A:AB4.*][PMK(PR@Y:
M<?1X1,-P>/YLVWZ2 G!6>_$>\[^O]AK8E"U/+Y\<OX2;IA;-!G\X0I2BE"Q^
MF\*8/"*NF.?I1[97B"K]IR[J?9RM::3"N#BFM"XN\C8<>$T>W Z"[ /W_J)#
M+#*2:&7PXA3U\07_ !QDP1"WV?O\9+E10R/KWE8#!+FNL,H1E!S9QA,*>CX/
MX<%:(   @U^OU5N"SPK\F$B3H5 Q/&]Y(%LCRWSCZJRUKYRD9CJK!D'L'[_R
M^3).S^!2 ]JQ@/F$.BL3*]R[$)\.%SLDQCIL+9$RI)\D.C!6 :(J;P2L^&0:
MPJ&[3@C:)_3%6"&IM]?? ;H4"EOV87D*3;VP_-L\.*QF ?9@1+#'I_J3\1X_
MK@D)K5-O&:!T(D".)UBR%2Q9'K">$'@\:P:8O&)_VPT8$Q9# !><>'@*ZKVR
M[^1; U/#@X0$J(@-L\<X[.W'(^3PXBE? ?IF'W#<<"E,$'HOL'\N5F49^-9=
M@V.10V8L)U9-R0_0,;[KD!F$S^)$X@;-8%Q_C)VLDBFXUD"=?*_[,9*E55$#
MH+BU\V)1D68.%")>\2+&\FJ;= 7!I79>-L.,>R)OVPO=;$".*G> %^V_+[8*
MK$\.@K[=8J":NSOQD7>_[VR8!N/ ?[P9H$?8W_4I0FV/[L62@)[*'7KG_6 I
M6A\QA25WE9#N(!.ID?D$>\&P,CX$^7/%!QG)W>3D1D_F_.+,HB28Z62Y,>=J
M),*FR<6P+2 9P;"SK-*@F6EM^,?Z4CXT,B"XFM_;^"0VA@]#/@/\I$Y[JZVP
M$CR5U"S.;@Y)CMT1^<T#*OR"P$YSD(5\C28R&1&XN3!B]VXP(B1PYF:2@ 1D
ML9X<:>>4XR$<QH.#XQ"H-(^<+18J+B,*IP$[NC)Y2)/)\XC0^+*XW>!"XZP@
MJUC@FB]'SCH3!<7BT^>N/ZGC':;4Z1\Q>,)=9#1@39A!<<9-P:T>>,N-:1&4
M>Q.-Y113=ZF3DE*A-I19_C)NL,!8$HD_'&2/I]4]=>\TOXC6$JA&$)^:FI!I
M?>'\(!5^<NQ@BD<=L40PI#)YPY)Q*J,="Y*P01S^$G)M"]F\,D(J$FVL(TS%
M7%3'G^4!L):/MA1<68973X\89_\ .C0+$.W+E!S36 2Q0S$DQ3Y9=L7^8)O"
M$B2P)@[G$P7/<+AX1]9/N0-J2#*P6@\YM?/A8(:^,?#M#(.+G%HZ:"A:)J8Q
M@JH_<%ZLWE<$(2P?[8>(#T+^<C1^"KD^2GR(%)-F<A3*RD0+28=U45D;YP:E
M]_SKQJ^>UYO&:6]R?KE'%_\ *%Q-*(-&AS PFP$BR5*WN[M=A_$,THK<%4>8
M,,E;(AM@$1">T_\ R,2@/:Q!ENR)H3-EZF)+TF!8.8$LE(AS3<8I[,5#O(%Q
M P\Y'^,B)TNL/B9-:,BR+7."FVIDHB R(HQ8#B7HQQQ@)D"\57-8%WC[9+/%
MFL)"!;59[&-H[1>FF(MF3*!I1\!-9)HIT2*7.,81?0BW\G4+6#MPT%C/G)X/
MG(Z?(A6^?>7Q"*CJ P/G(HH'0.]9MJJ]J'YQR$)-0P_#AP53Y;9_KD=R"+!
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M\7FC;XQ>3)S8RIK(%D7(TRD>9TX3"-3(50=WB6#[JR#[,*8 @D".:KU6GK)
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M4!*Y:Z<OF2?Z8E9,6A.+0XD(9)VE100ZQSN.6*G>/>7E5RB/"Y I$F_8X=*
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MD;%MW@UTTA57CU5X'QYG HGY9)1DA%U6W?&\*-[*OC'MP!GSD_ )3<$;R/\
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M:G^OWX01K;1=KA_PHYR>H-]!AVPL37#!QDH)J^Q[G0'G&QE3;_'"AT.M+N#
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M#8<BA83#XR-10%]#DKCLSQ!LPNP"?81_KJ."C![E-:S5\4.">-X]B/+8XIJ
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MY1\I;8#1@)V\@E^U8X.>*,%IBB3#?)BSXJ3[2G!$$TDGI_KKN.4P@(R'8NH
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M8[)QK2QGOYK*-O20A4[?#EZD+O@7),2AF6P$$.09L'LA$:3XPZB!L/MC8V/
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M08\:"99?09*SD'U!<_,>KTZX1I[+2X+E83D8W9K  D&@&4;B*51,.0KXWX7
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M;/\ MPCU./Q0RP]E8W:G(E(I"<?L[!@%L[^,F60G6H0\Y^!T<&0!2XUL47_
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MK3D]$%' F<Y]QT-62GNS E]*2=31ZJ2*8Q*G<\J0RIDC9 >@     " "@ H
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M"#AK#LWX/Q,!A@9@2$K9.'FF@X2-K_L'>%A <D?G"Z,$!V/GK#*!1W*C_K(
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M=+CD^;\X(!PCB<L/$YJS0G<%\.,C:!'P@\9'8#"E&8.7$R1 2>Q8:7I#&H0
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MX42/C/F@$Y0Y&DP%EU![XQ@0'P?(EGG)(5R?6+FYO:?\1>*KL[N/C%:PG/\
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M2&1H">1QMDBZ>^7*RUDT$Z&A7861E7]CT7W22X7U5G@;_&1X7*!9Z4<+&+G
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M(S*X89H0M9C"FO8 TCF>L" Q<*))K =$P*! =3&#&L)2@><%J%$&8ZP?>'2
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MG]G\N5@&=0SZR%618D.$<XC<1%H>0<"#%83S([%0HL8"'BJDU &U:<4A>'>
M,."!& +*Q+2$+1D;G>S'QZRDO,#>?MW;DH\-4[SB>!N86+!RPZUDR/=&1'@Q
M3Y9""U@L5?&2,_&9A//,?G(RC'1/ZS$%^),L/8I-9"0C5,SW]1(DHMQ/_P!D
M"4#M8/NY^[SNK!8&X-]RX>^\E.C/O%L?OP"'2>X1HI>24$QK@16)*H@K']C1
MY /N1@*'?2&@@EIS6%@FG6+P,04H34XFDW"#HG#:J?\ ;Q)..]30 DO#OJ,W
MF'Q&$O4 DGMABMJ63'DG"<S-> 93\X VFDBCX6YX6Q=O._S@<3M8@7K(9N8N
MZ+(68(1HB!AS"9M*;C_@DJ;@.[J=U;S,[C9NGP_WC_Y,NC;U8:A0?V0C\<31
M2!@[,1Z$5EZ^6!^(P.A60(8ICX"FC1,8BQE<!Z(W2<:@8K*2P=9]W$.3$$)\
M9%"0)2_+/DC. *:*I$1J(J,+'#:WV+OAQ' @!H H#H^@UT.DE3CXS:F8-80D
M)CBXO"Y20@4@$WA]4,IB$P^3^TA>C1*@]D/YQ(E9&E/:7[?_ "ZZ8<;+C):5
M_JLT[ H>,G<<A2,G&3X!>,6F>(_M?%&DD038TB[Q+B 0%:,0X.E<AB;JTC(Y
M<+ MJFO>'[- 10@^?[8: @(3GD0(_P" Q"H[#_\ @>45DPI0$E1',SH!KQFD
M)$--$FYX^J /F(E('* !5#Z A37IN]+.'$83$-(2(\)7]L?0Z($)'*N$?:IL
M68D;?)^!H@\3MM"\$L!>;A(-)G>[E,'% PAR05#^SY5@(;;:O"%G4A:0B0PD
MA<HI_4:"R8B9:4800A$V5NLP]I4?_.ID_)6P%/'KS;=]9 %1*_EQ2X+WZ18<
M1#RQ![W+FQD\R'3K*SJMF$MY8/J54($D+M1+ .EN%I:V.4"/U]#IIV:K&$K$
M8K*P:".E/+':B@&69Z":Y(49$RDA(4-?7(X\AE4"7B2D$< >&%M$^1DL*9R)
MP)H )+HA?:"2%T&5L"BR+.0C7B23'["EN^C!>[K/28/48-6ZN!;1PIBD E/]
MFB"?%!\T 6:5;.'4%D.P?<0A+!])C+5""ZG$U:+:JL#36VWZ0U;+Q R>8(RD
M =.I)?H@BS-8>6='FQ2$'%)3-G#BG28&5[I?5T[$EF),'?*R/>J-BTG]'U=+
M1A:HDM9@L=.RN8$QQO#1WG142'"NEDA=_AX&XF1D!!/+\-DSV9,C;/"7])GN
M<F!,'<5+$-$8-Y*:%5.$%(10# PTZ RM$1^D"PZJR61'*HMT+!C^SSV9#5^$
M3A$B=249D#.!S#GKMAMPCZ0,+/@&G,20)I%% -Z[ "78V,2A A#RQ#TERR;'
M)# VC@7Z#&)Z#GZ>B_\ P%/%!13/A@K;?04962)(%I_B1,A"E-F5Y3N)B@-D
MT:7$1V6\>A,)&/7>#!,/,1&#BIYDRB9:PE)W 32W'1)@  KL#^S:.]9_G!DO
M"L*Q!MM<&%S)NCY&#Y(I(TOY49D@('-?13['"$2%@SB4EQB!1$P(A&>DOK$Z
M':.%B+%G92PX-!H. @,%UDES6)V(P+$.)=XVRMXP*N&:ZT@Z/E1D*""=,T_"
M?9U:%="PE,FT#8%>%KL='T]6!UC1A!K&D0@M@L4+NZK0L5"05+]%41<#(FY6
M8A1!"9&#:"3R63%\7MQR^BY21%:%7!\ N#@DMZH4Z8>  ! 4!H.C'"59C*W3
MI:*0X66E$!4"<I%B>-)4U9V>=%V*S_9NC3*3[P7]%G,/ZAHT$NAAHT,%)A!3
M(Q!)[I#)!I!<KZ-&D02%^.6I4X B7]%=6>D&AKFA9+-J]*_4O]VT%F%63OV)
M6K,R*8R)KVW>BD,IN 2L>M5)6)BI:I!' .NTPPBP$ +"98R,DSJ9+8@S/T-$
M1N="/AEQZ1\XKSBU9,+["6]2/I+[=:, J%TL8V$?=V9\'^Z_&,XMJ@(L,&@0
MPP<9]R!8L<S*F"/[1%._,[C;YTE!M @T"M VC$/6I8I,W1C1-8$P6$4N"F&A
M4I!*0H(_M@I;IE/F9D%I9NY>_P#^1?\ _]H # ,!  (  P   !
M
M
M
M
M
M
M
M
M
M
M                  "D=X#8         $"0=
M                         '49A0        !L#(!    "1"IF8@
M  7 ,!4                                              ".C&88@
M        > /@<    6 4LE >AIX8 ;O'X'8)(8
M                       !@(#?L:@$T  5NOP4ICQ,   X!@* 4@%.# 9A
ME_"O!5S@                                             T"P.\#4
M'$> *NX& ^H%1   , %#!B$#<0  X.BX#-JCX
M                      -@' B 5WH-  Y+SP48#B<  !J',_,CO<$" 2%L
MC*B3OL                                              1>E\3#C4
M0= :Y5N& 8,4@  !I0T#$#T6H4#E!:B #2]
M                     "Q$+!H*2U\( $25WH!B*4         8
M                                           2@@ +         0@
M
M            "$)AXX
M     !1 #?L                               ?,:C7
M                                   6]9F:L
M            OZ4R=Y
M    #O80-6@                              "=O6U!6
M                                 /[2H9Q8
M          "%%,C5600
M ".H,H6N                              +EU#(:SB,7.
M                              ;U5&:L;+4
M       :3::I\H(K78<                                       9M
MWP$9<ZT[ 8                          #_&K&-T6SNKDH
M                           #AR4![%WPNB;H
M      :%'%TKMLD]]LX                                      >_\
ML8;E.?)ER@                          !$W8T<(N_P#W=[
M                           $MBT<VIA5W1,
M      "VZW<RV>1'+_9X                                    $KJL
MS(8/.AA7D                           E=/]JV]F%<8B!P
M                          F*5G#SADT02.S
M      &(OON:&Q,M,'"                                    %%M$,
M)FP (8!                              'R<LE. <>YSP
M                        !&;4+'B= 8?QZR
M      %"!%W:,*EZ00                                    784\?<
MOP^%(4                              23NX%BWO\8
M                        @@-YT\ZUA\+@
M      =E^,-H:<):                                       M/?\
MW_T+>:0                            !G6*XFA0>?OK
M                         /23P4()M$46
M     #U>HPGL^4 0X                                     (,]F8%
MU,U-50                             !K[@]WX@3]L
M                       !Z54:VY!$65Z
M     ^[1W.Q(&)V@                                     ,EKDR 6
M&_L]P                             -JEK_XKP\=#
M                      !]M=WY?LGN@2
M    (2+>&\_8I,                                      /4S2^0*@
M5[#                              !$_P^5M)B4
M                     !4]"3=2N-#D
M   *5$P)/$?2                                        &_\ _*)E
M\WP                               'U.@L?UX
M                       !!>OB16')
M    ![C8!PDP                                          +@H("<
M]0                               7T%&HOS[@
M                       2@]U_YBL
M  #D10RU;EX                                         !'O$#CR$
MD                               ;RA<HK_,
M                      "/>@7[X3                             #
MZ :&N0+KV@                                          6>'L8%A,
M                            "]L@# G!@
M                     "9X-]B-D#;8                          &D
M?@ O"                                                 93EX"$
MP@                      #8 0IF"J;$
M                       !,D6;Z\1                      "K,?CPU
MQZK0                                                  .LO[WW
M< +                    .S.Q(,Z-G@
M                       "2,D&([<O!@                  "TGBRTU:
MR*                            "8            !@  @    $6X857D
M-J,                  ">0^R?CYH*@    "X            !   -    1
M'QTB\        "X.0*@   "# >(@<X/\@                  ,+[Y_QI&=
M(    !PFE H@        ,#,!4   !  A]P" <5  *L^C 1A6T   #,9PLF?-
MZQ                  !4C;=,PQH[<@   [C4$,C@#U   T@J@- (<@  #
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M                   #&(*8)#/YT<   'F*T!0(VR#$!R-XW@)<.@
M  #@              2AXHF*Z%+B\                   5]I)E9YE*S8A
M        #$                      8              5?ZJ4OWQLZ^
M                 #MY%*B]G,"X.@        6@
M                 'H)]#5!#;6FP                 ">,[^2)L1X\L?@
M                                               WD'Y:)O,#<BP
M                ,%\F0Z#RB&75,
M                1QC@FMWI(>%4                 #WK*C#HA<VDF4@
M                                             !CU-VGUQY$@8D
M               .3HR=N@!KTG5T
M              !!_)'7L68B/ Q@                ",ISYL*T-SH\Q@
M                                            3[7O58ET]T+&,
M                6OQ":WM7@1
M              "#/INP/!.'55@                "6G1L"RU-8U
M                                           "  ]AW6CDTXA8
M             5LU_5@;',-$
M              "*-"(+$J_--@                #Y*IP1>&$F]
M                                            #X>&(>6#_'6
M           =MYI19LE_K]4
M             !O4O5:'9_ANX               #(%YCF)R\99
M                                           #;ULI^P8@C(@
M          8_BZKX"^#.<
M             2@#8UNO)A5M@              "5<AS12ICXH@
M                                          "(._DH)'3VM$
M          $E)A*[L
M            "(Z-PRXG-[/@                <"Q1&2
M                                             ,710"=B@
M         !9(7'PH
M              #O;\/ 6                  "!5-:
M                                            7;3.UW
M         <-5XN
M              ;8PB&                1, !@?QD
M                                            ,^KSH
M    :[( .&92
M              2%^R@ *@           "4(3!AW-
M                                             -$.@$CX
M  !GK-_B]$@
M             "\S4K#4R@         !Q?L9$<8[-0
M                                           ,5Q,L:S\H
M )3"OH(AM.,
M           "]B^E!IO,*@         ).EII]JGC@
M                                         8KC6$,@Q*$
M )/.3_(@ ,
M          "1=46#PAMT          !J);$57?"
M                                        !_(]WW"Y\          3
MUM$9!&PV
M         !6!J[P=G.4         X+JH)V4D:9
M                                       :06N[?8$3'        'NK
M^=E::?X\
M        "4'NE_;!MC'@      ;0-@$-7;:V44
M                                     "CA#";?^%[S:@     (6W*8
MQJ!XKM>0
M       :)B_)1RS161T      LU# CX"B[$_5H
M                            "\  )   :_R_!4:.T>->H     1>>T2I
M8I/5D85@                                    #)C8+         >
M5!4   4$F(FCPXL$3R@     +K=_\BNVBU)^\)M!<.@        # )@!
M             /=/C@L= .@  )WQP)X)V !?I)T5^S\G(!MD    "LL4;[7_
M -"@E&, >^)0C         # ( '                 * 7$. 4"GH %3_W@
MV_1*($4H#^&9P94 7C<    X%DRW\*R1;$G'@  Y \ R$:<) 42'HS8 1@
M             $X"XK(28J$$ *ZP\9ERHL $=!BXGO19]AF;,  "'L8&N5C2
M#+@\Z 'P (.@!0'!70PX#- Y8&W                Q<J6Z8O%&H0 _!\F6
M.0"0 !D[-0Q/4_S1,08  >G?]LYO_OZO92> I /N;/$:8P  1&8?TGX[X
M            "QJ80&.>$)# >R)@A ;0)  /)8OE=7BOD"/'2 "<)_Z^J1=B
M=B$ @ !BM@THY7D]P2QK)' [)^                      '
M    "NGEF*[[SAU8?#4 T,9=^4<G.. @QF  FHK I3:.8X [@ LX!1)
M                  P               IT='!3O1:VG'%-@%.U8?3BG6&-
MP          >
M    'H&V<'9(1"!I]P %7S,D;F$%T88
M                                   'E>S^NJDJ7I)  RZTE+]^]SVE
M
M     A TCO?<<37X@ #V*)<S\6#_ "
M                                   !NK-K[?FKJ.N ";O]HG=:#R&0
M
M      (;-J7XTRTN0(8 8F2U#@ '
M                                    %NZ! IFC)00+94@%.6@
M
M      B  +X,45B!#+81( @@
M                                      !5@\ 1H+)#0(
M
M       ( *( !7L!(()
M                                   !!)    !:  )((
M
M     ! !   !!())(!
M                                  !)    (( !((! )(
M
M    )!() )!  ()((!)(
M                                 ()(!(!(! ! (( (   !! 6
M
M !  ! !!(( !)!!!)(     $@
M                               )!(  )!())   )!)!     D
M
M( )(  (!))!()!!!!!    $@
M                            (  !!)(!!) !(!)!(()     D
M                                                         ))(
M(! (!(( ! (()( !!()  $@
M                           )) ( ((!    !  !   !((  D
M                                                        !!))
M!  ))! ! ()((()!)(  $@
M                         )! ))) ) )  )))( !)(( )  D
M                                                       !! !)
M ()(( !( (((!)!)(  $@
M                        (!  )) ) )    () ! ()    D
M                                                     ! )))!(
M))((   !!()) ((!  $@
M                        (!!) ()(!  )!())( (!(!  D
M                                                    )!( !  )
M)   !( ()( ) ((( $@
M                      )!  )!!!)     (!(! !) (  D
M                                                    !(!)  !(
M      !(! !)((  $@
M                      (!(!  !       )! !!))   D
M                                                   ()  (!)
M     )( !( !   $@      (!
M                     !)))  !((     !(  ) )   D      !!
M                                                  )  !!)(! !
M   !)()(!(!)  -       )!)!
M                   !(!)!( !!(( ))( (   !(   G+4    !! (
M                                                 !())!()(!!
M   )!  ))!   %H      ( (
M                    !(!(  ((  ()  ())  (   D      ! !
M                                                ! )!((!)!  (
M ) (!))(    $@      (  (
M                  ((()) ))!!(!) )(()))    D
M                                               !!)!!!((!(!))
M!!(!!)!!   $@
M                 (! !)!(  ) !!! ( ! !    D
M                                               ) !)! !( (()(
M)!( ()    $@
M                 !()() !! ! !(   !)!    D
M                                                   !)(!)))!
M())(!(   $@
M                !(!((  )  !)(  !!!     D
M                                               )))!))!!(()(
M(((     $@
M                 ) ((!!) ) !(((()     D
M                                               ) ) ! !))) ()
M !(    $@
M                (!(! )!!)!()!(       D
M                                             !))!((!( )! !!
M      $@
M               )(((!)  ((( !        D
M                                            ! !))(( ()!!)
M     $@
M               )(! (!( )(!(        D
M                                              )!)!  ))
M    $@
M                  ! !) !!       %KZ
M                                             )!!   )(
M !O0
M               !  )! (
M                                                  )!
M
M                    !)
M                                                 !)
M
M
M
M
M
M
M
M
M                                     ! !!
M
M         )!(
M                               !  !( !) ))!
M
M)   !( !(  ))
M                                ( !((! !) (
M                                                           !
M )!)!!() ) !
M                              )   )!  (!
M
M   !
M                                (
M
M
M
M
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MN.DZ'@X$$@FFA]GZE+>KB61!09)"\H !FN$QL&<^9QUKDF#  @,@.@.68O\
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ME('C'!F ^,@? )X$&S0,PL@CJ0Z0\U=,F9"'\FOE<_,=/ 1A[V<F "S8MCP
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MVS$V7 N4E<FC?,3.,A4,3EI:8@/T3K:HSP!8"LYF=1&V $%1$@5065<X* @
MT!].9N4%&4+C[ M#$#@95W 6[CZ<>GCP:A+HXJ%#1*5!6>-NU ( @F$+E7B,
M<>9(+%G9!$!4!9@"OT$A385(JA+&&GOCQ5; >!*:)%[7A,4S8/EAX1YTFI(.
M , 'WVLK*O$T,%$-(^;'(@B(/'*<K+P9HSW_ #QB+@I"Q&T<'>KDIOJ7!* "
M2B:0RY<./*/")N4(A2R9(D:F PXJK (%$RROZ''0+($HP0"4CI!X<>T*$35H
M!.U<0S)ED(L96G!@V'"1'%0$N9@E[!@ #@U$A!4GG6Q3+@#'      $ !0!0
M%!1_\CT94%9MF=F/ZID[/KR3ODCA'_B4+B?S&>8P?M/K\_9_^,>8DTLP3!B8
M8G,</,IT!*DB"2(V89_\6(QJM3/W=_SI$I<6\NG%P3])WUP9.B99KQW3VUX,
M<@BX4E&;AQ&+;W#7!1R3W?\ KQ/"4)'E'[_CK,Q-@GA>)((*A[P^3]_5\06D
MTS3 '\DPU,4W5<BA@&B8K,V5$$Q$^8"?Z@%E1^_TSS.A,76X[_XR&6.2=GU.
M2=GUY(X1_H!5!M9\D,%>A]]SC+"L9Q+Y<^KKK:(1F:Q4T0UHZ^:XRP*R1%O,
MQK,?M?%5/24GI[K">EQ? HRNX90C[W_'?()-!F>T^#^\_/ DDKVIXZ\:(O&+
M!L%H2<;R]?4V[$4-]2ZN6\%W7GD8!@(_/W_J!&L@4W5Q^Q-X]1'),Z"DN@FF
M"Y+D13=<@&2KFM7-U>/?S1/2:_COBH4>2:]C_OXYC,5<U'TW]L\G8D,S&A<=
M^O=3E,+ .DH_<F")^<3C%E$,Q-5,R? \/+2,I'OWF?.XP(DEC_WYJ$U"&7^?
MIOAP8[).ISC$3US)AQ$15QLM$YW$Q7(>95@8*9B!P?[Y!,%PI8/D3S2;>I4.
M$W!2@V]"]A#'+\46Y'%1UYAFIB^(2J;WYMS-3=5AOBLI),(IC<U6:C89>#0)
M@LN;+Z0HS\3R* HR4129S5?$&7@\4O6[Q]?Z?)4 K4,-VS-Z)JNN"PDDP:(S
M>/1_$<E7&9<)Z7GJHX E8DU55*.'WZLX0P!1:^^YK/D>M<0%YC9'G.34=W&!
M$+6&22S-"D/B^6FG#)-(W8IT^XX2 $HEJ&8MPW>+Z*KB(ET@N#X^,^Y\B ='
M_?L;QYX2D3)_R5%.O)?,3I2+F"4E],15KQ"2AGW#[ZZ]0<"")@+G?T-LZW/@
MI"69M#.D*J8RT=<@8ED#5:@\_4=1P6!W;4EQ +J8:UCA1(.F21<K*P=1J6UM
M":!5(0)$W-SG!NZY!D &<_ZY(F;U&H1K[YKC6*Q$3GS]_P#7].)0B>I)^Z<]
M@8GN?R9^+X.2B%VK&USW?W".,!*D  5>WK/TLF'@X!E"22L^<&8Q$XXCQ&2Z
M4T$F_@(]HFE%W-QAE5W&7Q9P!$"$D;RW9Y7< :>!72$DCS-QD^8]9 B(J9,U
MBH &<K7>YB_* ;\J\E%'W.8IEXM^?LW@NS^@("662&6\>=5#&8XI@6+VS(^:
MS_/+CK!-1!)>F\,3>GDD&80 9]GK.'"<1!)GMHFJ!J_R^!!4!820]W'?^?/*
M?5]W N/']NG@6% ^#1%2OE=%='&)(@ILPT;2V  V[*B*9,P9;7VP]3%6TC13
M>&8Z^WQCAC:J][^K(4PS%9EU0I%GF?YN<]<);(5K!]+^>[QQ ) E2VOC7#22
M?TQV8%>^31,72.9/*WJ*]\ (!1AW7?O=C,[XY3<RGV'1%^:2JYDU!52QF#.9
MB=W/!&0667^TQ+$^N^.A$HC(Q.4FSYEQ-\"1'9"BA&-RS/4@3/ @"%N;+V+'
MGM9'OCE<02^EX9]]8>6B4P7TQ,QXPC9J5=P Q$7E^1\S7QQT '1^_=^?^]D[
M/KR3L^O)632]?Q2:S=U<C'N)?AES*_M5QR!0FP69;8GQ,3@AF>/2-47L71G4
M9"2&'B8.[!-UH\VL5XX*D%Z?%/Q.-Y\A4%D%;V@MQXW=/+,0WUC%=;BJ(Q,2
M%J0O<,_!!&VOB04"5FOOCJ;QYZDU;HEIA!!,I!YHDJVJV2&8A5[2L3INP!XA
M2T?FNLUBY17<3R38O>\5MK?UQ7((DL)G$KZ\]?L\C2=0D5V&-+Z2IJ1?V4&;
M/K>/G,3R-"O;)/SKN_\ /!1!*%>_K_CDCAG^DL<:@%B9?MUWWLZX 0M=D_1R
M27CKR<D!0JC7\57^>0"H;CZ8SU,55<'.A!=QB \68@P2XX0%D1V[A'79X.-F
M(R':W3% =Q]#A0D2HGN*,Y_W?(#(X& S,]U)?LEYA3:=W>,=W"/DGF4W5G[J
M"XV[\7.RA#EH5.K**KZ04D08=!OJ(S,02X+2D'5)WD=R;M^[/ PD%Q#HZQ&<
M1]U!D$V3]?\ N@1:'[?GX2\4"B55L]T3]9DS7%1#Y5(,-G47(ICCZ 9H>(^C
MZ--UQFQ?=7K]YK/"9;*'N#XKKS-SQ5-&^[)I)YSYQQ]1K0'BNJS[F> .@KK)
M-Z+TU?7%( T F8N9O6 ;F71Q8&A/ /%1<1\1)Q,$RB43,7^(_%/$H)628F-$
M3^S!5SJL"P%EYC/^C&5RZDJQ>!H?8RL1,YC@"$826V&J]>.4%:!$YMF2&:\=
M\M"N#*&!6+VR^<3P6$NV[U_>=^.5,F9)@B"7=-(RDS-\D"RS4FI[O45X(S?"
M ;JXD-_&Z_8CBJI;[%FS(!CNIESQLB2O0N?7>IF7^D)"160R<F B$RMM?F"?
M?,T8-^M>_MY,<8L+9A,2>5^$O#OCGH><M1VL3<5!G( @ 8G<9J-C/?D]LY $
M@W+(_.75=]8!$6F5ED<14/<."F,A 0D*<F+C,W76<@#PB"@3<DC0BSN,]<<"
M5(,D!&;&M?ODMFVV+U8!FHT4V:X2&8B'P%S-Z7Q/;,%FA%!J/CH?5,^77#<
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M$HG81CI8[,XKE453*0Q$UD@G,4]89"RV2YB?!]+Q08.57* =;E^TKK$Y>*6
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MJ6!7(D)A$M27^^>^(Y2M)"8VL60^\&^$3@OK+KR=9\Y8DF@J""HCZ>NG,L<
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MW,9[\3GQ$ +$R!M-/F_WEY$4@HVW!#\Y<LD;Y(&,"=DR7K,SB["0XE' 1M"
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M,+N;3NBHC*P("04K1GHC%W-0-7R#>6@$1D$LMLSM8R\$0TR5$E,I]<&+F9
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MZ_G^C=DS,?9_9*WUR4IF1G=]Q_-5XXHRB;NLX+^[COD>&ED)!U9]H[ZX$-
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M=',,@8AP2]S3G7[SQ0C$B1CU]K==\D\09&;@E.TU6ZCDL*$S(UF3^8^KUPR
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M\8W/3$#7>)Z<44Y(+Q$@;0)^T1W@SPI,I2=AG)04#JUCDC$@<0 P3J<^^[E
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MFK_Y+ K@%^G!; +&1D14L^3S_P#E .FGU_C\)Y A$U=_YUOD9& ;R?MXSKB
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M8(OLH_)X:F1X(*F?!8HL7XXX DZB9_,S](;XKDEG+!OVV3^QU'_YJ J@%JL
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MCDM#O]$" %  $JK0!:M!;QJA4($?69I8K(+X7$+"Y/+0F6%8P+7)4(Q-290
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M+MX.I).F#QQ&[!.IA:[B;NNOTA>_C"J(+$.I0D0.$2U347E%93"29F@$PP@
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M2=B;-:]=HR<FAA81'>YS 9LJ6:Y,KHL4LNH#/A]SQ-X-@!+.VUM+SCKEX*&
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MD6R( W!!!D4(.%7-DF'E-B&2"(B"/ %)61!,8$@D"2!1]DT(@;$(]4* $?\
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M(/ "2J)&=  :BV]N&(>P+ZA<'8X(*LRA68C:LX3&.$1*&Z9E89H;25I:DYI
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MQ$LAN\&2.,C*!#0I@1F)[TWJN*1@P0L21+J4P1C!BN3'DB=X#W6Y9N^_^DB
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MC7_02X-"O/C6??': VK,PNV?,6F+Q3E@:;<R3'43<=F\\,F7"<DG;N OUU'
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MBI4DF,['>''#"I19CYF=Q5K,5OD'2 SLJ]3]>YZX&6!/J\:TWX,:D28P)?\
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M;( 6?KL\O^7BRYK\^J?ZXGL"7\S7]_7]?_Z/E_/CDR51?UO/8_X:Y.*PVL>
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M5>*/W$B+V^?[_MKS_P#,, DU+/;KM_-\R!Y.OC]X9N!J)0BD8 8A^\P6^O'
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M248)FD95 =S,LXH-Q(+F(9[/^4.S;=,78SC,M;SCD#*9N;'53.?<><<O*U)
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MGC&@LI7*(V;(%6"."$KH</D%]@>\4CQR+>?8X99$262^.@HH%"0HDLLHE0'
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MH[;]1%:EYC_BYX1#T@(^*<F0,S#D?!/$1XX)PN*_0 ?!^B4]ECNU$\JO
M   @ H * ,'ZB"5 PL"8#0&1L9Y2SB@:8HPE@F"6,_HV2VB-XP2@"6)F)8SQ
MWI[4!BO  $K !@YC'%+!EX=,"2:<FN=@=3PH#C@,]H 2[8EW^AAXL>%D4$JP
M,2KR;.5F!@82E0$JK:_JZ:65L[2:\R?/ AR2FQTBXII+&R/UPZ>5,# JH30H
M.N!1S8]Y,\H8K'&9LHB<H$G< #8 "N?3DV+X ")A.#@%_* *E4,%56"U5O\
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M&Y6ZO-Q1,OQLX3ER@\5>9^/ 3UQLF")1,YF8QN.^3&CUOWXU\Q.*X1 @FOY
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MP-]:+'G*)$&!6?8^EL5GD,86"_@J8,?Q/_ 89ZY,X@^;?,/>->>0<(WKQO\
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MO_F7YCLY^8[?_,OS'9S\QV_^9?F.SGYCM_\ ,OS'9S\QV_\ F7YCLY^8[?\
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M2Q'X6SHC/"IP 0"D4@DYK#@G,,-0Z]M>^03LDEHH+5 :1O("1(:R'=_A3FH
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M8A4+A>C"+6)$5(F$23'"@!\B>20B0<6J+VB(G*LQN8P )X*_>VE#J0\S:+R
M*;&94%28X""(GX,-SPA8$V9K*H9*08:J,9!-,B8,7Z29(HDRN/V$_5KS)<0*
MHJ+F!@II!'X+X%D&S0 50*%$QPM - J L%B,(T2SBH$N406D'R8:3L.AE#.?
M'M;_ ,E1(,^C4>0$+I6"$!(; =%]87F8?@2)T0U+2R>IPJ,&P"F%5)TSV#J
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MV)"B!444MYXAL(T,,"J)LBCTJ049\UJ+VTXB25@,H&B<02J1X$J0JL5<?%<
M, >&OEI-VH:D#14%*RGZ&$6Q8+&#$0.H.Z[8Z %D@@"<1&"#IY#-4TIO!UM$
MW"K+,"$M(!P!NL6I00$P;5G=VV<X'<3Z<2[K2)DMHP*%;@ HB(#*I 9)"AQK
MDAQ V@4(CHJA0K*AGD'RRE\SETU16HBC;J!IGO XA!O!QJTR.\ SLFP"&:IV
M0X!JG. P4%PE$& A$&.+N2NRN(A!9TC('X"L-QR(PF@IC']$=<RE$!BM#1%
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M9KB:8VXNKP]DZT&T+)U,G6>21L(J9;EMG7H-N>&R#3&11W#?F?KEX7M,R%U
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M!"-&;D?]\=43ZAH=O1\3KE)K-C**/<P12W'A 5-!)RM6J7)<&;PE P=&"$9
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MC##8<EWGC3.A(@.2H0Q.O;#0=^"8,KU[GYTG*N 5&PI'983*PWKE@,8]E?\
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M>G(0W(?"%D*9]:G$UQ. C[3[8\3'(%"2;KY2/E1QC0!& QI*BED7&=9YLN;
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MBXW)0:"]@QR%<*\$$& )N"XA2?7D22 YH%M^EW+KBV&:%N$6F/TFG><< :%
ML8V5OMQ2_%X(!-)3Z_V5&>L^3C_+].(J,FUPE3?E_AKSQE7?9LFWOD:\]$'
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M,4!3)+1P'),LR\U^I()MK2JZ'.+CEP$"%!<KV><7KOCY[@"#P)O3WYFMX A
MIO&OKYSGY>':BTP0;?'GS>YO@   # & _K2C!D!9PSQ_#B>)7H6>.J?SL/&
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M'VN.K[*\ D-!?._SGW7B2D.7O]O-37U<<(G&"+!(BPNX=;QQ=&:H S4 O?Y
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M1M?T]6V#!R-/EFK]^"1B^3]4L^6>N,$ 70!AOK.]>.S?(<0ITPWH)Z,;XEN
MF!51MUZ\^^9B:(2G3+84^V0-WBU@B+W\>YC^U]8 EQEV=?S#P3!*D.O.7R]&
M?]" J^!IONVXS#@9*92'$4+KZN''$AD4A,GI9;J!K!K@9I>6>N W/"4.$S3F
MX4#%U8W[IWS.S(!<&)O [36W-,<D!P8%7UM<^KX>,DMH*(&:Q.]P>\2\#JN2
M#HAY:I-=YXQ//J( 8*4P.(QCBXJ*B^R#],?!&/%JPIR=7]?\XY<B1*H5E!<;
MK?1V_P!; FPBA0*R]\RPT**WD:?RU\'1@[!KR'-\' : \C3\5E*5!2X4?/AY
MEJL!\!AO['MX<7 0RW=,-<H3[@/!,\I*(R*(G=SF=\5'BD$>###;U?C',[AJ
M<^Y@4UA:[MXC*")51:VVPF=MRYYGYRF]Y7'C9GB7$(*UCR/VZF^N8J([8OF;
M^W!*MJ ^-#OP:SOY1AE)@D^.6S/N #=UPRB0 !]C^U[\-@%7S^6C=F>/2I$C
MH9XU3,?RX^+0B43 4W/OBFA.',@3;I3\OSQCOD_D_%3NW/SGR3+PO*+R$'Y)
MKQ[RWCKL;%A.XX7W?IS9RR0R*8OS@[S<&>*!%L*Z5@;[/ODG&.8F<L)0:9M]
MZ&E$U/9""A6/>_; QQF,#KU[QC9Q)C%(ZPESAOY_GR2)(4._3'R./_<@814*
MMC21WB=V#_6R% H QC$V7Q/GC)A$N'S<L3?G[6\M9(B+]X/Y]?J]R@O!+V%-
MO6M\CR0'>(%?A?YB_P##+N+YWZ?YW\$"$&""&&=8;]?G@8NR5(E-8OK.>#8L
M:1(9@^G[=G,IT*BD"8!^9YC]9$3%88*;]2[WG6N(0Q?(H8NM^,76/[<0<)3P
M\#IA&K-&YQPJ;D !^7,\,$@:\^?GB;(^)/1D7[WAQ4VBJ.?R\:WIG(()EQ[(
M5G6[?KG"Y 45Q02CVW6CQ7!,R4(:)W<.YW,:Y'0+<EF^-I2R]^N#< @@:P$S
M'Z3=H^G9(/)D/TRYSUFXBHA%0.&9]3_; H@F*@+&:I3\4"K#R\)@#%KZIF?K
MZ>(C2L)8LWZXI<0' F5@=>?&#?\ 5CB+0(>KG\_\ZXP0/?[Z\%?KS/-05R^2
M]>=/ZF0C&&Y[]CO6-7@%$0NQ/$D]YN2 IPR(K,;:6]OJ=WX <$1$=EBF*=G3
M^"# [W/4OO\ UQV B#NY^?X9Y!VV6WEM/MCK/9R7*R7-9\'4^C-<262WI=^9
MP-H3Y /W#^X@IHV7LG$,6*B8ODUXW/K#C\BY>8ZN(E[']Z=D Z%T??<-.@O!
MSX*@Q9<'POU/7,(5<S-2@X37)."%@N$^Q?'VX  !  #P& _$>RS7M#!UMQP3
M-5!JXDWF>)\=!G<F7R.<A_N=/% +3QV;G7O[XP<H45!<*D/5K\7AD'S_ $]0
MVA\\HZ1^O_!P("JH'Y\L#FC)0_5XNMYLXP9]-P(CU&OCPO,O37':[!1P]X]\
M7(ZC0#ML08S]]\P!Y45&"29$LO=AC@$&^9DP).D\^YJ')*ZX% ++]IV_<XD,
MJ75"@]A<+/B]KR^PC \T(LSG/O?$ I@[7S7KOPSXX0#SGY]_ES=_/M_-WE0O
MT^/[D0=@_)>0DA/$)_,'VYASSH7KR19ZZO&)%KT/C!/)+GP\&LR6%RXF7X]?
M'CDL5)G'>=?;K]_P0%, 57H,O'Y)4J=R-GASG\D<4T]!X29_AYYGIS4(;O+X
M&=X=W@FJCR*1K;];ONI/@$TC<=7]IWCE4@LCUG]OUQ"\" > /R_IS0 P7&A9
M]9Q@J (."C4W]_;XX(2&&5_@Z\?'7'"CB0&/<OS^^.)K#"OA+);<:^NN:"S#
M".9\3O>O'),9"E@R4.;WH/ #<4$*5=YRX.TS@N,<(T@QHZ%ZQ\ZK#@@V%% A
MRVJL(WL.,3H\B< =%=:P>%;9"@#T(3L#O.<\=)RH@A5-J#;^?'F!$$0S+@QK
M!Y>NX#RU*YP9DVW\CE#U AC2%^.M/IT%@-@3$/G":QXZQS.3Q/FAF]_Q]\%0
M?[G=MW6_A+"P&,>\R]=D[Y9?68PNAW)3[<(@2"F)U%3"O9CJ<,(#0DW#ZD3S
MF@O$0\YS:#(W773EFL\0 I"%+0-R@+B?/+14$2]$=#)>M^EY#F U$&8-W&DS
M[X%VP9%-=^%M<^V06<G7%GQ7#GWYQS -AR*75-_E_P %#:'SRFD>MF_'])N5
M588P%>GEVG=. HOUZWJ6SEAL<(?2I'%R,OVXV!+9%+:#+#<'7J(,K:&&4**#
MZ]5SP6))I)&G8_SRXA P$H0/G.???-DVB&&$[D^;C54XG+NO6$*F"+X[Y7VW
MTD V%VF3&@;!E <: U,&)3AD&AT>?CZ W-/7"9R5'(E?[QXAP4XU1UG>\6/R
M[?=((P]+==8VX\F^% ',628)<? _Q*QZR2F__??EX!7['WQ^7Y<[OM_<Y,/;
MS"?5^G^.'@!@RACX_<_SEJ"X(@EC?Y^6.$$&"06IG/CY_3A\1&$ RG2V^;\W
MA\# IG'V<FA4W]()SD.BE@1P)DUKB,%6,1F(Z<F36)-"C52@02M&!F1,[)%-
MVL4%&2:*XC^_*. *E?RSC69WP'  M(LD81GP^'/#,D"<1[=?EX]TYN[#*"^W
M\]<#6>0#WSAL^V9-\ETH]E7X/,V8]\! !*A+DEGG$SXAS"4GJZ[G7>]_E_2
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M'?$@5BDM+W*.&?XT"3E"-=9K/R?&GIN9805 .05^Y]]<4H&>&$@.C&,],)X
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M\\= 59!SK'PW$ZCS/"YN 9*HEL(V:.1;?958!3$I4^<:X\8I'A3HF;WA\G?
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MBE%1TD9-+^(=0P)E$"SAA"5F--RBC6&/1EJ#@6^)#BY$*I!0P:["*?\ &=$
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MP6B84*% &3JZY:\A(-%:508//6N>3EM9RT[9[XJ#.)PL %4ZJ/C(A'TIAS'
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M3VDF=C-9@CI3,SBWE*K1"I(4QJ.1/9)'J%\VV\8[YP3&$_0NYP?JU*R_\/\
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MQ9\)Z7#@ %8S\6PCL=H$ ($9079G#(XG1,58032E.;Y2Y N-$,52 * F ,"
MP\_FRY$O[1K5^!:O.>;8V1Q &I1%-U]S69_0XR-HOK*,(@BA&G()G#
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M./4&Q((K-(L8-![_ $;R2":HL1*6MFU=[N$0E?6)Z=[^VIN"4,$%ESOU^6>
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M0J$'8H)W<S!W]^!AY@LR.9FMGGL]C4A@BK$+,X/BXX98) )FTX!SA\1X86,
M28"L569G?TU:M C@/&7>ODK>-"53++4_%#GK>9SMJ$=MNJ=[*YA:@(S1)FG!
M#1^WCF4=$"Q>COI^.GYF"J6&W*Q)G?[:XW%B5C. _G[<A5PG!2LQNRCU8$O$
M!@:#A2UU+.\\ZZ4OIJMS<*%<X4PA[ [@ T? F=<0^4H9)J6_;.UO+=;-4]G;
MGI]9UR>X!$]S\8.R\@: _N&TT!FMMJPW<G"'AB!@\#53ZGUO*K@ J'7S_/TX
M<!3P'#+"1!$BN)E\?;6BT1.>$=V=GY>IR'LB4*(0?AA+NSSQ=8L&7YSK[_7W
M,;\&LC@K+T=#\\L?BT0QV S#2NDX_1 ,LKD+/-+[?7,#R)*,M<^6]Y.^#A%.
MK,%8/C/7?,IP1'$7P;%)MUG/"=%6)W$V=Z_FAW417 NT?+3.Z.N8PS6UP1GT
MM]+U.-C1CKWGH&5Z_P \61N>J"V";M5 [(0!B",&" @UY/F>>/,CRZ1<59F2
M/3PLA1]$^.M$[GC'&3=*XQ1ZZ7YZ]CPCP  " !-?T13@%E0R'R.YQ!+F)83(
M:S_C76-#*0HK9;,F3S!.W%*4+2+#W@KVO':1O )8B(IA3&?/*(F#7II&,"@:
M-<(V:I9D3!D]YUGEXY@A$"CDGAS[W6<2VVRA*,KFS*>1+OAFDR#<"SX)UY]<
M@07-SA$B?'\P\H4Y=E<SO.Y9'#SF#,;6'I,=-EQCJO"C4V'08?F7O7 _&3 I
M(K]2&T=<<"@-=J.3.$N)'\N7"[@FEEA5F;O\U-(! 9,79MQ86'$*V)]0'3AP
M_I.6+K(;,Z5[T7Q\<$ H1TC3^Y8&B?BJGK]9R\"_'/=C;]=]<=D89!,9=XP'
MYS''?#"BKP(9;B]:WP8IN45D$-R)#QA[H\A8&">6=U]9ABDA'MH,/= 98"PM
M0(>&@#OPOO>OEO&,5*&#R&GN_'#BO!\1V'I?VUQ:@JZG>?\ SF2(R69 9O1F
M/L.L/#7B'638U4Q\9SA<HGX?GV,&,W7VU.=)4<P,7&"]0$R\-Q#K#;9A$PQA
MKQA >&8E!41<3N6_3BJ2HF'9(YO6&?7DU%B32B8IY3XR1MX(@FD$^'^B/BKH
M+E+\>Q[O7))71YKA<SLU\9Y<)%UE"?!<:;\9O%8B-"X+Q)$$@3&4O$TK(T4&
MNW=.6W>.'$D8H#JQ@A@Z?9P-)I/8V;()@_+CJQ@F"LG>%;)/GEX(F( (OHN?
M<U8L5CJ6JH^G>I\=U<2+<+V9@?I,Y'%X-)2>-J#IFJ%GGN@%@!Z@$\.+[Q,:
MXO85&"FQY]8U^_+0R9Q5R+W4[<N.BYV5[N!!5AO.2ZX^P'=2?GK%F^\\-,H9
M45LS3.?>1]\8R==1Q078MCXUU0*H8-73ZK.K.6^ -O1;WV2^S^Z*W:!1"B9V
MX:F%0""Q7HP;_/@Q_<84)0*Z]3.D]9,.1E&I>]7:H3A%J8AZ'@W]L<>+W=8@
MBTBI$8&<<,"68*9OMD;<9^.88KW.S]'+]II.&&BZL+% [<N-ABU1:\ R^07L
M4R>>O/)143],QOS<7K'&D8CJJ,.\3'U\<+2#",(-W, /K#Q9! %,A1N/*C_)
MQ%H6D3HT"!&CN.3PFR[H'*O9TSYZY%CA$L@N8P67WUP=4K :*R]VT,^=G"K.
M&&%B.^A[U]. ,]#5L0&=SK7H_HAH"4G=;H/H;'H<\=H299BL+OD>%@&9D\@[
MG4^>2T("5.;/+Y#+28X<-=08%@908 (!)K!*BHU>]=:/T^_%T3PJ4/(Z?77L
MX,^9Y%08,!$!VUO&D'K$**64<OL7&>*">M+!GNL?SQKD*-@#"ABCACER;^G'
M]MW ,&!91PG4,<"S"&F&DJ,!COYXQ@I$E!0/J>-V3%=S9",!4"M(9_\ >,4+
MLGAPC+_Y8\(0+%R71W7^3?$H"F:(1?AOM"\!%F)BR$3N[^RYG$C=K%7+[]SZ
M?'&K&!"1UDT:_P [W_<]PQ*SS'7E^>,$*(5'+Q?*RGUSP9JB5RMI>Y<?=P\1
M. YT5673^-XG HP-8'M3ZYT_2M"-(KIS3MPM_3/&8DHB[!61,F=ZO,4:R6&P
M,O7Q]3C#(X .<:\XU?6=<)!%;)%'IL%_/.I$O"TT4=_S&]G(@YN$[Z^QWKV\
M#22*4L%@+C<QWU.* (&P97#$S-A\^"E'7"Z'P 2^;J3DJP'"J*$FQKXQPS H
M $()MG-<]HM$1B&&9 ;(&1X]<;)#!1=XI_ .G9AH&^!2S/7T^<\=?P3(I29W
M7>E[KP &DO\ 00X&56@,\;4HQC]SS?IS'6 AKI$OS\=\,&%V1SMQM19%2XSM
MX:C(#3F]LGQK?% G]D1PT7IJWH.^"8 !CT&?/TGC/BXU6,S%?><#K.,;P+;;
M[)1T=U;Y[G"W4IJ*76B&&AC.^!8_FDW\!UXSCUP=M1.8D;FZT?\ C(13 +1,
M,N/4<OGDP=0*@4O;S%P&+D..82NH "51BTFZ9QG+9-&)!7;<=_GRZ6?$L'&8
M#*_/G.0FB4VT7+3E^&\OE$3?79K&/;].2V55AY74+3O1=<,2GA>^&@BZ<3JX
M*00*C2A2.&3L_P <!  " ?W.^_4RA?\ >OYD9:+-3"F_M_L;PPC1S"YF!O.S
M!^O&G%@3"94L3V?J\&<ITB7"^\J_YZ<.H\,F:0KY<^N :(5PU:ZZ?&L/7*$%
M%DN.+EL,R!=2<:LAL2-UPGAVWO)Q48<-(EKY3=R8KR U]CKH6>/TY=19-L7"
M2B'7FZY:2X !&IGV8F-<UI\C>$0#$HPV]/)$8E:!0T]^^^N"-@(%&WR^49ES
M]=H#4MT,I2&'?^Z&0V(5!E=EE:OWWS/]M140Q*8=9+]ML84 J@S)<=7).*T!
M,$VSAN<ESUZG  !H(?T&JB%H.Q!&Z&]?;@3J3VHVXUGZ7\^(+A03<30+UYNZ
M7C@P4PH([^F,XF?E@M9VN1=A<G+62Q *N!E_J#==\&AF9F(H"H@7/Z\A02**
MEQA:YUAO+YR @,E="9C,F'=."U&60#^[[S93BG$$U6%"!K6,Z>#%8Q:&5 [)
MA3H.$X 0@%F!2&#77?"<@-2"J(H@1F, <%PZ@Z=]+'P&?'#P*@)6.AEE ,N;
MKBC,CT3E6:^'!,N^[D5"$E=C):MW+T<,,P(#4P1[Z\G1GE/WJ TA*(9$=/@G
M'CE\\H:,.D_34X>= !\/]TE#B;TF//CN<Q4"+,'D]9^XXF>?G]!A)*43,WHG
M+I@@AU#[^_T<\5+%J&"+^6^SZ2H'+3"A:M'Q=-AR00@$VUH [BN=_0XZ]P'9
M(P[1^W!1%$1(,J5B]GCZ@@,<V JN5<5R=];XJPA$(V[=1-T>J\C2H8"3$NN]
M<"$JS#1!@6]['-W>),VP .T3,,#Z\\R@ FS8%]/RWG>N$[(NIUE//[9Z8\!)
M"('9RQ[/G1[^M6",3;M_-^>1I-9'3 %-6X^-%Y%Q<&]E[QH/&UY)K+L')^M_
M]ZSR#.;%4_UU?./Z!@].T6@+#Y9A_+9.FH1 [Q<&-=XUZX,:&+E8=D(OT\SE
MY8P9@YF9G/G#'&)A/G::BH6Z(&KR1YVF]F&6>==QF..H0(($@1RPS@RF8YXC
MDF1&J8Q=/@.WAPPY(39;)33F*&KPVD%:V?S%?OB\DQ,GH\8GCK'UQ"TP0PG$
M)W].G&UBDWP-"X\;_P#.%30J> AH5<+7>)CF)J1BSWHZLR3OBBX550_2&M_'
M6.FXU%P$SUC'G.#VO$9 @(.L&0&E#/U<\,,()W35Q?Y6ZX"C&L+X]#]_UWZD
M " &IHW/\X,)F"KY ?M_=5FPM6FQU[^.+T6P:S2GKJ2YSQO11U@H%<Z.M9P0
MY.,$;6,#N"*(XT).'1#8D+C,QB=I8NSE]T3!"VR WVA-^*)AB@*1W<^?G+OB
M#4J7$=D":7;>:<1$HL'M0JLK&)X[XQ)WM5'@T/T:)Q* $ 8, H>G6R@8XAI"
MP1S39T^5O#&QA;$BKF=LXF+Q0_P)A-+]69\EX:4E(>S=D_TY'D\*CRA)%PF7
M.G74Y+E JMETUMRNJ^GCE? J,+AX,7?7)XK)6Y9F?;^/ H".%!_9^-\:#"9)
M,C-;][+\_P! --,&D0S88[<LU[XG0B2ZW,$]_G/H78F!4# >?SP'G#>.%+5%
M%>TJ;UU>#Q0*BP4D]99GD'19@,[/4SU<[V;XY7)D,+AP3[8T>V\$(4I!.6PJ
MY8+;XLM11"BA.0+"Q'&VO%6B8(+[63JV:F.!J K2@W<TNK?N\#"BTTP4RBXB
MR^CA%L=Z:R;WB5Q7...V"98S%SO=O6.IO,H*[09^<<<%8@1'UFO7VF^#; T,
M>;&X]8/#B<@U""A7YYC6^2T^9>(*EO!3Z_S])_=+D3SR>F1\  _F=83BJXAL
M2[N)[<5\:X>1<ED]Z#^/7'R0\#-QM7WWG[:$A47;/'QGUR $]>WGQK9/3CA\
M8L$PCES'KM;YQQ$0U> D(4]?^2^RQU:HET6&B!4G#1951C$'JQ7MST<'0R3
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M]ZY*!!2H[(QK=I6^K$V!D:81V@SB5Q=\","%@"^"AGXZA[WAAT0&N3O>.!9
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M_P">/UZA2;PW&#%^3.#E"C 45(TF_I^9BB%%*J[S#[_S::@6^H@9^'_RF?Z
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M.">;.J&N8MF>EXV$"S<O?"<*7JH")Y)[,_1:6(IC#-Z!DLS/&:7Q)!K73_\
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M_P S9HY07%I,!RMQ"%2B'SRZ,DJ+T3IR\Y\9XK@,@2,0XV.&RLF0"R:8# L
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M631#$<B:<PQ$ X1; <"%28Q?=AP^F2W1Z9E;$I7#G65D(TQ(,1KFY[!U0KR
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M9$>S_P"J@5P J^@KQ$E!$R5XQ=F#U?7 Y3"WM=%M;.*@47!/<_7/^N8@ \#
MC*X2>/'KCZO&0+AGBM.*:IX<LC#.64!<0& BO' L(0PF.!EE7&O%0*H; <"L
MPV.8A\YX\H0CWW/Y^7?!V4A\,?N=6$2;Y4CW/G/SW[GKE9QD7*B4N9OWWU.
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M/E\LGT^??#1MAHZUJ]^M?GR#)57 !GSCW]/7(D56*)RQQ)Z'3R"HQ#"95O\
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MQP.0F$++ZK3K\T.(A4X!A0['N_6;L(@<4>KN.']#2]YI4-%1+393QMW](?\
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M!-.&&[\V->"%6X?7[^&'/6X_0_/S[_!D%[#"/OM_G>>,^\H+M]7/OQWQ!O\
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MV[=NW;MV[=NW;MV[=NW;MV[=NW;MV[=NW;MV[=NW;MU#-'%C.0T^1$?"3_\
M,D$1!$B.1'8G8\>7XAH<]M\ .@.+I!8."ZWVUCG8/T_)3B-_SN@\51C&&1$H
M%6C)EH?_ )<I,7MB1]$'DRNXH[SI4X@D_P#ZHMV[=NW;MV[=NW;MV[=NW;MV
M[=NW;MV[=NW;MV[=NW;J&S^0_?G\>D\CF^;Y+^(KAB=NCAES44 5DNN*TTF,
M"JSJR_\ Y<3@48(@:QP$69LH('^^_P"JYHUX[8YY?^:&??\ _;V__\0 +A !
M 0$  P " 0,"!@,! 0$! 1$A #%!46%Q$(&18*$@4'"QP? P0-'QX:"0_]H
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MHRXL9;'F$M@@Q%\B_11^CTHQ,P%*=MF(25:SX_+()12+?I N+%A;A92&J_\
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M$G_KS>NIC&R6$11560''@X4"B-MA:W'%9(_^4)6O.+!Y8>PU!Q"!R%PTH!)
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MT04CHTGXYW_XUI=<5RG,010JH$8D&BWP@0_J6SH\(N5N$<^SZ'*&P'UYCF.
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MU<@&V![HUNE['1KE:"#9G<<W^3A5'"H0!V,('GYG1P)#H]F!T^^LGG=.'ZT
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M7,)@98HGKK"9WY_F\32I"2!!CW&^QA2PI&<U&5<12B]'F<RX@Q88+$0^)Z'
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M5Z4CD@ORS7/50<'2HC(P8/@2^5@/R]05\2&GQ> WYO9*3W1?F)KF/)'@N<(
MS^*VO+:+-Z_)>[OG6?E:2(I"%-Z/$A)\<3(<S3/&_%,GO\0HU/(0PA>S/BWS
MB\Q'.[0WZ.VU)S86L RB *T(] #Q!6.XI&NC>O;]C(DKS@ =*,<'I![)O"\.
MK*<75E]@,'Y@!&<%5XJ>T/OZ8F1NU!8@ZH?>7C3(>2]8PMMO4^SBQIE1@4,V
MT$2N%G6NHX ;0+2TOIRQYP5W A6_M]<"D:*$8Q:YOU#SO$SPL\^R0*#2IGN\
M'&664:56%D9\S_.FZY]+:L_2404?S>!8TDE6QN=A,?>(46CHPX0:5EXW^7N&
M4@8$II*J\%U>"&#3-(,EOCQ"9WCX58*&&@/!1G1@!,$D@F_\\0IT4TZO\[_/
MWR]D;"-E1%*ORPLSAPRC1)2 "#7K>[R!^^E;=:P8?)\[QIO E3T*O70,DSHQ
MW3@?DIW31OOF,XD*P6O\4\^H>;& N52I;+^_UX_[C<22T9"$5GXU(/)B5OH;
MUK2=8&S.!C^/X"B(P$S*^4L#8!H*A < =TZ 8KN'T,C-U#$4IPE*"2"(&C>,
MCIQY0T.X(8D'!-.;?DW2>P(BI:VBUOC/Z)#^C[M I[IU[UQH"]U%L@.!#H&>
MLH4&P"4 @0_O^/7E=(%*5&/;[7W?V#A!34KR"$F&BJS..N0/D%"B86#TH< ,
M%O)2]$M! :B)9Q3=YH(V8#5?%0XH:#F1V7;O7X?QPV(@F&'_ "X9.16PBA6W
MHZ_B]]')+BF&07K#H<\[^N%4*H!;:*1 D-0Z>(;'6C58"! *]IF1'^J%$!DL
M-5N!6<  >"(^(*?W_P"/>&_LS PHSW7_ ![#=-4C<!) C=GO#%0[$9.L=O67
M[$$:&25"FNP[1)OBRY@RCO#P!AVQ>*H%H5%<E'DAMX1IP^:%A<%V]!*/9/VH
M= :*">5;Z<&)L HZ6'J)K(=\5A2>:-)40P0 F/V%%Q(%T!@'P?YT\HQA3Z.J
M8'SWG;)*J8*L)(!D@&ONIT!+52:GKGUWAGIC'*P(%ZK&H.]9#258X ",_(O9
M45WLBXR*=IE>^B. ]LT/.]:Z?GBEK *FQG:DS^UXL>=B"BD-M^^^DWF51A.E
M5,4J)(WLX+I&%@-+W/;KO-^M3@67:1\31)%DGHD!E!ZB.3I#A*".(>!U^?$_
MOR U;H5=IG3_ #5Y#!G2"F/;CW);Q<!P+4QXEIF?/\*N T5&&.L<[_G7A1P8
M6QH",<;U\<-=8C'X4/V>(E#$!#X1$?WX@JKVK/Y0O[_T4?)!N@0/TF/$ ]BH
M,IH7P(82'"<]9^"*%I%<LARH\24(8<1\2D+=IV7'JT&A@^=IUT\5T8K:L0**
M-&9?(UY#&NJ"$>QS\#,HR1 **IK%K;VR3AY;$0- 3?,OS\Z\!70K1Q[?%*_/
M[>/$7$&KL\;Y^:.]O#>KXIDRI6I9T6SLT"/@"]H["[JWY.+J66T34)41:9KY
M6L$R0] 54+>[$=7M11QV?'.]W^)G!2"0$!/AFE^?QP)Y%,QF!30A7Y>^'2_*
M59"K!T$/GJM;(VL:"B!W\O2\E7_%5$B"@*>3QQXL,$,*!UL^X0F3S;+3Q40/
MOR![M[.      '0& ?0?YX],^.$>,4HMB/.OB3.\Y;.,)^T4_GKLWA0@!5JG
M/O/]_#>,I%,1%A?]S_=.1;8NDR#WA7(UGU,R %4% Q @R),XZ&@-&!0"ID^W
M[^2VZ(E4U:4F-GM)[SX(("FIZZ-K'UG%S!X'@8,KT_Q>&QO"QHV^%@/RLG+$
MJ2F!]K^_GN2\&5&LF  "<-D V<-[>LY"L  E02&' F$$&$_"H_--3>";W68?
M/X['^T)QI_0A&C3ZBG]K.1":J0%(?7[%7<X(@#!%^B!$7?GK^CD @ ]B"/Y'
M'@\(^ '\ <- (Z"C\!0XBU17P0V*&J=SN,=CVE62.'1,^)F<F43):.^ O>9/
MK\@)4 0\0[[[^.PO*0F9^2]&?[Y_''9'1,J)EUV;CWE>&B##;;I$ KN?5>3X
M9A82/$RZ"0:"!&A^@A5:^JW7]N9P<GS@B"/SO^UQ0>J:I[Z!L^+TV%S#DBFL
MI^\@_)\\2/HA@4MP[\._9VG7G]&3H;!S]YP8J>!WB(I1H2]<3V"2>E"TK)W)
MAPL=9XF>"!(&+Z=7B)<($4XP%.N@XKM0B76-4&=URZ B"-$$3I'1_?\ SQ[T
M8R:@HKU4EWOGBMJLPN(&WV=]P$DL"22".^]MF\6]Q!&K F;H 'XYVF%DH)=I
M=@^_D>25BDT#CX224.YJ<-M[4;\H /7'EU$$!3,8C'SO7C4KB&4*JZO;YGMF
M&(14(F7O'ZG;AQ2^\& 23=EC^]/,.)*2OAI:N8XVBO9F@: Z$Z[>]69, FFP
M#<\$]F='&;X%%Z#"$QO:(7AS3&A:>1)<T#F,!G@$I1 W9^;UL >4:(74+5Q/
MH.\/ ,+<DRY&$F::$%'F,!AH+X;7V;G,83$H- :+*)^+LWG37%_5B/\ 1ZB>
M*P]U8J^?%EZXE>6E688!*E[V^["[&_Z*ZGH")>O!>;W *V^@]?&_QNYS&(J2
MNK<F=NY\^\&V,R0D"2;D%#4[INP+<PD6T("@./+AI"592NU5WSKJ<H/V"2X"
M_9<Z;YR(QZ'#9A9"J'W]E8LQ0SC1P8^L3!Q=0TAAW/';;\</T:DC"'HC&^?9
M>.L.XC"*$/S]RG=@$2<%(@AT&_+JL&#,0(E)58'G=O#V*55:8?+Y;[\]\]3!
M2E:3HFC]? \HT  8250W2:?(YSMDKY>%??SZ;[_GD[=>C.JX+-Q4'!3TWK[.
M_A$!0+U3W1O\_P![9WR:BKKX'Q>'G7N5881@$!/8*]6NL *2Y12Q_#BU2<"E
M +(J!%_9QXCP<9,5K[ D%P+1SL D2(*'L&1^$6?7+\GJ("AC\%H!ZLX6)9@=
M_9F\G_U"&1L=<)U]OT;\W"%>XVT.G0#>5:%,"\X5'C"+U%X&=KAK." K#[WO
M@820!],%+DA2KV#,C=C0@@ XP#X_++3U :Z:E[D7=-#TBR\"E'M$#P/E53!"
M0',U@!!\!X'#U%!!5CP)WFQ.;P&:P.6!D_Y*C0?D'^?Z,>@Y8 51P U7K@8&
MD*+.Q7O\?MR)HD$=R6C0F-*<(94033JDZ[]WK\\T!WW )M"82Q)YHQ'K5 8)
M2P_GLZX_X(8T60@7&(-3E&S-A6"%:(01%TJ1B_5%^^W7;B]^<+E.5L-- T+C
M(*UP_P N#4HKTJ7K[\)E]A&1 D$2Z?MJ&KOPT,?", 2' *%8WUJUVI=,?..Q
M[^@C?  ^9)^Z.)[B5: A&]Q 8UR<_P#(*SI@NYG[<&836'0?4V[66E.(\<4R
M"TZ^_P <8#:J$]'3R\S[;/ZQ*:D_#/>!!KS : @Z@1K>NO?\["4"+HA_X?\
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MPF>*KR 1L]'V3U4L*,<7*ZE &K\=&*Q 35/TP5DV_4D40.%+R=N^,W>DN;=
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MZVEPK=Z#T\XSMLTRL=0X. TSE^RX64YP@/%'N<6&0B2UH562+U^RF2]Q88J
M-="1G"(&PVL@@J[@_<EY-[Q5D755%I]/CB]RGJ"XABER$P>06ABB;I^ 9=GN
M.-]$KM0"]"2FKKTIS::#Y*I H-2>7@80Y800A).NBFD <*\]GW%Q"E3VKG%(
MJAV#J=O1K/.$P"R=3$SH_P#]_H!O[V  ?W>!+884N(,7L3YN%.;B6A;2GIDO
M3[>YSZ0<;"[YB$?CQO'NG(AZ.E-L+_?A+RK%1E(HB+$A,FZ]%TNG?6;]]7J_
M'! E;(!NCX_OL;.5-9R>AGU)L<*_D-?@XR?G +;]\?RL9=C83%K;/.N&'+,#
M3[KV$1Z?CD9@#K)?**8FS[X>OH0AY/8!5\Z]7ZMY63.X())V'X/Z5@"NOX.)
M_;A4@4M+$7A^W!M!" S*2%GSG[U&E8\Q%N@-J@[[P=0'$A$\T8$6G148NC9
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MLZ,5WFKW[X[7X0\=$4EK)@(D\42'T(RNC 0%E04#D\ZB(=EAA E%#J<))6A
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M0=($&Q@?L>W@U%,X06"]5LV#^W+)_9.3!A:G4@N[_G:,4-$*M<8^8?*<@=H
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M2C$7)';>NZ\5P4TR@/A2GA^=Z0SVB.M\?CL^I_/ _4Q8;U?C/CY@>CW9&X6
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M\-R[UQ5Q6 C@2K0Q36GO$T7K_0B?>SKUZ.<X+9A81N.G7@ 0(& =!\?IWJ_
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M0K'42*%0*'1>X]S/\F1.(4IZ91W#=X/Q)RQUI2VV>R\1"8A:-!;7/C]^7*Y
M&=C /E,B[SL63H(  E%]3^$_ILU!U($ P,\XO 58LZUH!?BOE0/0(Y9")HFE
M >-]N)_R:#LS;K7#6&],@)@)($TIH\8'<#!(P0M?0G:JRZ.I!3'$&/:@V<:T
MT:0)7) IZ/EWA:'K+(8$=$Z]I%3J)$J%3*U[ZZY3NN(B]]!4LDMD%%R*.W2*
MCZ!GF(\(4F)%O*G6 7YW:<AZS80A]84%M;F\  , !MI,;[3;[_XV;9;27L2E
M]C 9T9:(;95V%R.3<-15D&4)&S%K-)3R0XR*4A.@L3$I>5"!%]IKU@+F(NPG
MGB_;\1J[_I>>YGWZ$@-\A065_>&[$S7'!M8W\X_CY*Z7(/0'_K("[07%N: <
MW(GA9CW'*D8RUE_\J0GA_P"T(H,[P EGCG:K50'@CT/U(E-.Q@O?T5EEMP"D
MMV1\7C2]B.TARB5Y\FUV!*PD+<(')&+G3X$Q-^V:\GG)=F!"/91!0<K]6TEZ
M9%S1EBDX!^$0/\E&.ZR[6_'4_P Y/^)MW*0$/[)0+Q(!>(LP&804'E:\'*!*
MT'I .VP4Q;_X0$CP<@J_N;D>/^5"J",  8%[RB3LJ[ '5:B!PQ(( 1JB+K%8
MBKCB^X81(Z5PEP9Q\;T3@CB;RU(U6+4B<G'^N^TY^8_K$8J[%$D"EDY')N*8
M%D"PEXT9" 9W*BR(5?U*,A9I/*JM0)3D5&X:0!R2#= $2</ S8> '_A8W-?"
M;1&H<I31>FR>7@G7V#1-(&'T6^<IHR%^-+B&E"WHXG>+NG1J*W%4U.6$$12W
M]!4KK:/7%#PB1AI+B-V@;S?$62V2$73Z94LPL&D!S93$)>]N,/&6:SY ,"CU
MY.0K%M" =EE$(NB;R4.)BM9G 2()^3CYW)$_8*U#-GQX<#Q48W:(T"GMFF<T
MQ,#X%$VD\6^<%BU ?$!(P?W<)&^K0,0)D&@_D;K$1)BV5M!0L\86\NT 1%/"
M-">(%KD</D90<2E.RF[_ ),\T-.0=CA:8048]<.K"(F1(2![5_G.8)TNQE,1
MTGP@SN<F4>E$4![+Z/=R=!Q+R3]@ HA+V-<LSAZXT/BH6X=6]'5"T 6Q,PZP
M(6_<XF,8\..0+, >ENQA&7C!$!-U&L3,O!ZY"L-)[5!F?)QD\J1D<N]!3*I<
M0>#T,QT'$MTB5<2^L8+$( ,H%7N9>9#J>),A-UE!*#'B='1#O% :P509T6':
M$O2!/>@"3O>$W"Z,.,.NS>C)O*RR9)O1E?\ NWAUI%+4SLD?9VK-RSC @$\'
M:J? TD->J0;/9=.S'T^?C_P"WB.T)D(NJ$TG? +.WZK%(!7>5[B",D0;?]!/
M(>&%;]@[7/;<.3L(I"2T<O<M=_1,%BMB$^!Q\WR?CI5RO$9"2(@HX0=)A2Y!
MT+XAF6/(7U$24B/T&&P'Z\X8%0,%)!<Y5VBAU\K AW]5'PPOM(C+TY]<\G(I
M*)%<!(A%W?H(Q5T($>_Q'^T#1UM8[8^']2KS58W*+]2MRS@))'5;#6D'Z6TI
MZC'M6Q $'$L(+5[TWBD$(EP&RCD5^H_J2[V=ED(:#HB?8FEY'69;#PYU@A>(
MN3B&Y(7 18P8H7]0@I[+7 P35,5!S:<P.L";]Q [$$<6!C8$&=+_ !G%*6T6
ML/B8""&N-B,^C/A <3&P, S]4F6LO"(G)T84B/*8L5$8C-L,/T)S]P3T;CN"
M7H",%-09HSSEN0,&A#$F?8U '"A)"\L;)8:8<'V4Q6X\&',IQ-%UY.67>$P*
MS]%5&&13S=@N<]V6@76(@;@>"9$TB]=<=9<"K,3<A$Z"!&5%$OT!0I3)A3",
M7D$GZ4:JR[M3CT;0&2&IFD%[%U7(8OWTS(8(T9D"BR,4,Y0&.IF^/#(Y!<T?
MBGP@8EIYY\:N&:H<Q]5'BZ7EQ9_ZJM<NC* *0@.8"02)UT<;QJ"W"'@SB:=3
M61H\>9.H3Y+BYLNP%.PET_2BZ!&P<R3(E)P4#GZ"$%X#J0#EU-%CT+U"L5<A
M,&ZJ90 #$_QF$F9%HL4 -6XT8WBQS5HB(1!CER=_/7 N8W))# !O=,F/+G4$
MBRRS17 H=S@7U+I*!0J;^1,89M@88#1 >.;^>#'/#0*BS$4AO:</'<"R 9;\
MAZ]^1 \Y8M;:B&J5A08(>=3.K*@35WI<UYN9<2H,50,%X8@ML&YAP0N:U7-<
MD67O3!QQ-&=WF]!(0IDD1\)(6M"#F>@;$$1:JA^SKCWO3#"F[TTT.$RVEIVI
M$_;SX')Q<XMM"9;4?L;^.!D546 !SLPGG58-!.D'^?\ )03,@ #V((CZ)'E"
M45G[&/S4F_O5VMAS&"AJPE,U(=866E1BZXO65^^(]"#+$*+1"P5B54LA@8;N
M4VZ+/)Q2*HK/KH(VK.A6&\'\$RV)HV%LKJ>/PV! "70E'IMZJ3ITO!@+L BK
MH428LR2DJ8B0#04^"ESJ;R (V-*[?Q&T0/PHD#M;$J@TX[(@;@\A%"-;WAXN
MH[8?A0P :W=$Y:)BB1)2K0%&T-S@5K=.6!@BD#+!XFQGA1(01HC$LD>-#*DZ
M,%)(?#LSOUV^8H$^Z-_G.10N7&:I =(8U,> RH$^04?X?\;4@54#@@A)$A7G
M +;&_86.Y@+%"?K,V2C7)4 ;0=(\-UM ;?3S$"]X"?2Q&.#T1Q1JV:##AN#[
M9Q/U+!=S,4)E0G-PCG>GO;FPLLAC5X@0<0BP)(D L(-%(X_&#ONL;GI66$53
MT5(Z'[@$L.]%X[0%@\_&;LN,=[*IQB8C&CE3D5%J,"7@CS[E^G)7"D6?J54K
M$"=G.-'G!&E<5<BLJJ@"$5[=NS:;L.5DUT_B'I:WZUGQ<8[Y7<7TU\;1CPOP
M,C@:%S;DDIJ8?I3147ENLTGVVO0-1Q[_ 'BG@F(>T0(7E4H=H$2"BT!=3CO)
MEJB%G?:74?U!"S>1 "+UPO/BXZK)J,W)PP.X625'8A)0H_QND*,G1,#L8R%F
M"J!Q08PSP:4T[@\GZ,D"0FV;WT4"\K(Z7D$-QHX&-%QM-6"2 @)#].@'EM91
M/^S"Z0;HKEDJE@^#XMA7@2 RV2,(%?T@X7_=U#T!4BYHZO>F"K@(]#IXO!FB
M:,%/<41"K7Z6L^OJER3@Z)FNR\@6X@""B14P4+C/TO5.S03H]5P F2N ZH)W
M'   % !?U !BPSDQ\:LU)3PHD?RB+>2H6P9R2]UH)![BNI01:^G&20 O*CH0
M"H-J)E)L@O\  -.=GMC.LM (I)8(3RU3-?9'Z>T2@?M1F2FYI3P,P!NVC!83
M[!B#]:*U> ],=Y2FZ?><-OHN?'L9H*@$-?XC'&+@!J[\&YO#I75:!(Q[_,+\
M\3H0+ *=Q-',/Q?!: #I<ZGOB/G[7C51F7U$OK?VGXQ@&$/P@CU^?C:Z>Z(B
MV-#&@%KZE4"$I%#  4'V[YQ%FGJ;'C*)6Q>]O!%R6Z)H#IV&XZD6BG 5>%#%
M _%.%< !PM=M!*S7IX^0VE70%^C9F/:BP/-\Y +0-',>&#55P*2E46U6A/CE
MV%*K.!@04)]WJ<>YOP Q0I?OOSKLX_ ,8%SO0-^/_K4D=@9^/OZF]7KA&5B&
MZV)X/W\[$O'#<-0@ZP1^3IGT!"'1A_DY/ 7 (86.?AI':3B^^D;N@ PL'.]S
MB1]IM##380]^]. =66;90,90N6',KV9NND%J'7H]G*6Q[ HJH?8 V2@X#H0Q
M^B#"8'O":@7 )$TJ&BF%,V,=\9Z0A4F@$(IPQ0.10$4BS"69 DNYC*K@=J:3
MTEU5.V9YY0UVTHR$#>5-TK+]+J2KO=Z.6.X*@R,/ [:^\8,N@42!)(([9,^9
MD:#&CXSN4!47EV7,=4]W_P"OMW>0N9"E,J?']^\[O(;6+01LI8I>R?9;R4@4
MCH"!TL 48EXTS*:0 /PQ%/+_ (GG'IKYM=5"((A$>GMN^V])<N%;/T<[Y&SX
M#GS* O-Z;2/F*B!:=67)*^I,A^+A%5VQ+LG.T=POBT",9I5$#CW%GGTP2)#*
MR3!21'BE9;\Q"-^0@+QY1ZJB*7V5/B*35J!+TJX]T\1-Y6U$*7U3K@+Q>.IZ
MCWZ;,+JF"\D6D K7UB"@1FHE<D8;5BWF-(T)LI2569ID.E50\B^AR(_@.H%8
M (B &@<=Z16=+A'VDHP!^B&-U<,,V2\AX9#@$CQINE%2H-Z_II& S'$X3VW.
MG [6JV$6=DYNA?@C$VD3448 +]4#+@T>AI*M!7V'PNGUIUUD_H ,#'DT0G)6
M #,P5WB=7-41R70"RZ%LVJ)Y0B(_X GAJ3)9@6 7*PE4_P <K+-,89/#,'PB
M=U9OUC?DG9WNWU8%C\*T<QPL5MPDGU1/W!8+E>2YV7G1P4QM(L=9T"*<$  <
M^S8GB&O**.<P ,M%8OGA.2B9,H$.>!8=,^()B9)>JV(7QSE,MW>H@+0/GR5N
M*2M\%.I%6A=1P+-9*&JD*;^#$42YM$" 1CW^/HCETAWZ6K;"C=BJN6Z$G;Z4
M6N._CPV>03.K#"8'(# 8+X"/-%$Q(7Z#I3UAEJ/L&1/ZDP;M2-S1NQX=?(*)
M0:5HU *1_0_@9L'#QO9@Z0RX,NM;M!&EQO<JI+U.<G"%0SQM5"3@H_)T5=B&
M?K4?H?DFG.J^LB0=E>%CH&^L41EL4*K3[7@SLNZTW2H @] 17/+P2T2=1(*#
MRBQ4K-43N 7S>J7?!O)#+/Q*X[))AO>&E0?@D\D'=.TS&@@-_P 1JQ*'1HRD
M(A''7SCP$D*[5I7O[6UWO@9,$J.3#3(N8<1)-K$@HOVV_P <5SP. (2!71H>
MYP)\:-N,JL8*5_#PI<9#I$$@M)#/% (8Y-O=+G!7Y7@U3HC6# CH2'M+L9AM
MC'0R%?D1/[);@R=OQ 7"-3[5X>%'U"Z=/)>M#T+DILU#L-/#3B"!J*!0T%#\
M)Q!)[IU6,0A'7F0" KUT,M.\7QZ]>:NER0@KXQZ; +8S;&LK8?:R7J>N)31U
M,I?ES(ZKXARYL@9@J Q%!_#[P6LPQ.H,!^#_ "@4=T@QM4@$/>*HU8MT)FX#
M\@7.5M DJ Q%4<GQ[B"?&7L@922A-AH F4B!EL"J:0C#HV.J#:F*B$:6@1\J
MQK\TTI4'M.Y 4#D^^]EIP4  *ZJ5&3=[4I$A=D2>1>1PJ5SF630!$O0PS7GN
MV-LS%=GM;R8$/0*(=T$ TM[89Q! &6W4@E4V]PRG<F.*I1NB?=>'L/)M6T"9
M*.W=Z6\HGC)"=(I:7RO*]7 D11TED[_9U.IH2$X06O6'KEY0''#=5AI-&Q[.
M,)UT,D8(^:#GYZG#*@F%V$#U2=).RN />J(?8IGY_P 0V^98VJ.,FYWEE"/&
M*6A%W)R";O$.(.+%-&Z>&GM[3C4WBR&1KJ+!FNCG"'S'IH6@TIG"N5P25?,^
M._@H<Y>%B&'L*86RP(+VQLCZBP('WA3[9J'4/PC-$]>BRS/0S>J2E-?+@"!7
MCD-028^:&#>LN_\ N$"N?"/FQ?>O,H"Y\"+>Q![#1&4^3%[EA*@C#D&_21&F
MPIN&&YH#TV^,S(OAP822 )S6,V91%0(9Y%)@@EF83CEG-6CKJ;N3OZG:]-)/
M#%AW20@=A_B3/ (9P@^_$2_P0]\AA2N9)@DVDC*RX,\%]/D^/Q0ISKWA,FR6
MI45#AA(&Y=SEW)=IO*92])DL1D0I,B*FG0R/JFJ(9/Z_Q8L4+6I1*!JEXSRX
MX*"2FI4A;] 1@$BTL_@@^+X3!NB%8>B;9\ +UCU%94Z'>0*_QVN4!&5M_JOS
M*+'7B: P;26)XGM!D"O6>IKV(<'(TQ,WSHTX<X"E1]7GX@2M\5AP*+NG6#8_
M7U=/T'QE.DAWWSF;Q#$HNO\ 6Z$J.F2_N_Q/T+$J)!. Y$Y89(EZ!!\%*Q-:
M^FK6@S!HS@&C'KGD@N-=$L,C5$(M[\/\*T>$*MB\EA![7X'>=^0'\3F@@6[Q
MFHBW#E2N\;3.%RX;<5^"\%L$8(&*8 ':_BM$J"!04YYE*"_,;B &"'P3PZHB
M,\1"?A/^\G>8S\?"E37(9.KAV(KL\AC#,%7AKT&  ?J$UDPI7+7@4WXU:H3D
M91*@"8/F+_POCG_=E@'?AVVU*"8/L%CFJ0$"I_A 2]3:IV'&0 J/P KQ5?Q3
M^:1+?LFG$4EQ3LCA0+\HV*<*B1R^TOP=^7\/G#^!+7[7KX+]_)Q+8%["Y";/
M^F''M[I&R)%!A%Z[X2VVWR,0Q%,'0U-B\0XN!'8SX9'@;\4B>R2..QJ:D"6&
M2U$]$A51(%]QKSTR%*"(C<N:+W&3W"J#6@A"+X3CH?I,R;5%*6, J(W3A7M!
M9A\#Y/1S9H51+H  SJSJ\7WB-2][,H&13BE3R,"$D02:X9J<7'5";! BBD\;
M%Q:0BAJW -!V6SHOO(3$.@3(O;;Z]G7K_E N;0L&RSY4_P#L-XV\JH*5T#!(
MR=_*F=]-T65TOOOONO&HT$>B+<QRK^>MYI<%)3C+T<DGSMXSH 0<[. 3!,OL
M%=<R2H(+ LP(Q0<IV;TF,"$.NPMK5%8DPD (0_:D\\X0PV@5%G\AU\7:\'XZ
MWH!@ "^U,>N&MIYK(C"+'[? P0UQL%7I'Z%1/&SRB*ZHA%[L[$) 5W^0(5$C
M0J-GQS8K:HNP@7L,\9HMN#C\?<0P'7T5X;U%U,*[+U_*3[J$4,7J-G32QF[G
M'['WQ0+>H)IHCO#@6+(-!M[._P#[-Y)CJ%!DHC<DMW-7EH#Y[@+WU[7+[O\
MA0)[ ID/*&) =%6E*-[_ '!W8@/(DVL:IX) :Y$JUO 0H"N\Y;P@=D#PX#
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M)\/TF.?Y(#*(3X!5_8.14*:! @ M83JO=XU0D&\1WXE\^).3K6,$/L-/I_\
MDY1B8*TMP9QUC>V<2*@2H+I=!"J93@LU9Q%&95768XYLKJ^"[(M?F2_+. 47
MXB$?;\XOME0F)0Q.Z>B[GQ]WF<%Y!P[7]Z_/V'$]KZ$?$-#M"'77$1_9UHM
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M(/O,*:<@;=:;\>)UP!.($<A6SV]^G4^R.8%ZJ4)X-?0^\C%=<T(?. =>Z_\
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M\AW2*GJ,!&0M8_'6\<DD$6Z)42@!!0A.3! F()%$@TNX_4E=%>MQX:5_WSE
M%'54J"K7TEF$Y9: 241<L'M[1$[X-._46*FI0""A'#%68S\@ KY7\?7)9Q =
M!%Z^)#?G7)QT$DC"&=AK!&?B/]=M$$H%A@AKGA\]Y>2?KZE@1D10#M1F3C)
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M)V8\:I1>+*05IKKLT=XE<L0,J*1K?.F9_P"=4"VB:%B;9G[\:R47!(N@$,\
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M- ")](C_ %.)*G'R%[!;P [@RZ(1X/3")_B9,Y< *@@ 55 !5G!^'D/@GCV
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M1G]5%"7C$9('* !5 7B[Y* EM8B-"<C?H25@W<ESQR?X/)N'O_= .&P)ZZ1
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M0*@(8"+^>-6EOG*$"SJ%QS3/06, $Z+BD?B\7);+( -(@%7ZE/$L]U."2(D
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MBG%F0$3$HT+=9F36$/=S($53N!$J83:D@3O^<B.L5170U7Z/.2W]Q("8U/\
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MS)3[#<7;X8R=@@HPD6]R)1UU2K8JWB<!Q_5T%$\M3 !+_03O3UI=.' RD3C
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M!BH-#UW.^3Z&C(C:08(G7QOS9J(>16%=-_/\V)X\GX07- =F7^=Y+*6U0H@
M40/A0@<1[0IJ! (!+OP+P4 VH* NH9W?F3W>5%) A+H4B_6O4LXXSM R!1<P
M.[UWT\>4I::4$L."4*"!&5KI-E1TJJ.L=BCG*T(+YC$%-E,?. -=^@@@& _4
M==\X>>1Q$.D6MJQ+ITP,PB:C0"ZV7/$X$P2P/',[(.&>N1?6B2AT1'?C#*CP
M3(I4#+F.3'0/@./-$-%"'M\: ^*@N'O<_!0;"+CGC+2BK5#<_(0<_(=<$_X
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MO@"ZL*T%0D0492P 1E0(6 Z#]%41$2!EF? H  )=:B+1$\(  /U#9'U;]O\
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M@1C>6/[H,X9P.UMC]<*[9'=7:I! ]MZS+)4QPK'TS-[-X1*N2*EHZ18^FSJ
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M.WOT,2-X $"!@'0?')-_] 3C)A F.&( X_\ .>"UX<*1  ,<E^<X9B9>I)&
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MIG;>;_OQ!VWHG3% ,%OXX=1HR. Z$,*A5.N7J@*R]!"@N=O[TX*P@69T1/\
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M(M^2-_)WA17 7D/0CYWIX7BP0$=N"%3;U'J1:R)L;9 AK\.$0PD&BJ:'6?A
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M?@.@#^.N$\W&*E@R!$23M5X3%)[2BAG1EZY+,3Z&1_'+[ST024*=#KO\<.K
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M0Z)@;)??=X"HIH%*4!H16?@ZX+<Q%F:#O3Y9P+0?I,@"0TO228'.NJ&D* _
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MIW,A8!U"%JP/>9TV!", &PAF9^.3G [E"2BI^_QT+_R8GY9OD8_+T\/'"7T
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M;[E[H,F;*"R9=?VSDEW' L*0LESOM\_QN.LU!0M8.18$DRHB32R7*N;8
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M=[0#1&GHN>Y@<A*X< @6JAVG72-O1@"70 +*'NF <Z0R;'238;U\>H&M 8O
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MW>^8_"LM@';*::_MRIRXS  =:4\]',!6+A05#]0;Y.=UPPH"QSK_ +]X7-6
M34$2=?7U(\'M26H8.R:$E9GRL56$^HA18C_M>,!(*U2GWH-?EC'A-XW8;(,7
M$[WB(Y,T) ()(5]1Y6'&Q39 -VC'6><-E04@N9$8FD;'WBVC7@J$D#[?/8<>
M70DF,86(QW\#R9HS%5%$6>FVT.&5ZI7I&Q,[_NO)]LB3N?EJ?]]@K ,0L">C
M$-7(^IQM?%S"GHF/P>N?=HZXI(QQHN=]]"S<B/$JH1[L?CA6(-7*+6;U)W/!
MY9/YV=+D!1OO?1)/78@X'" 7?GY>6+R" (#$$2#]?6\0I DA%JJ%[8_?XXR@
M'1B,7I/IL[XU@Y"@A>KL#I$Y><1!5EW<45WLG% SQB)!2#V/JG"G-1I)C87H
M2/5MVZJM5QL,0R[/]"V+&<G *6W=Z8O?[\+VH49(!4,-.01)PE/(!\U^7]"W
MCN6&3@K#';YS*GSIK5$@8=^\*+9.4-:X $F7A"L0TP:>A^B<"HK"T5U#"^^?
MOR289?973$E.6-ZM"+@!8=_M\# (4JLDZ:)E^.*[@T VIN]P@S@:0T2?VNY]
M_/(2; JPL&X WLX+G4ZX4:P@O8<C=)DA0:(14-'5)P-U".#^BU9]]><L\MA4
M0W+E_A^YQPQ@)G6:SS_YI.&XI!@/)%'X9F?NHE,<(H:"K^;_ +\:+UC*VT]N
M]X/SC88Z5(M+P-[@3K@9@FO&H"!2F7?B\0**CD'L#M9B3#WA&/M3HQTB9]]_
M(J<Y#&\;$#O.'._"@P$-]/LMJ7BT2Z +UGLZOMO7&H^X!(J("DQ^9U'B(VS)
M3J+IB.]M\"*\(!,"BT>@?XYB,E7<^%#?BM);T1T_H'#'I_?Y[?/5MI,#"L%Z
M^'F5-EC68"P(G7T)Q9S#UT#4+#C+'Y)24":.!* '!7SRG&[ BE.$-;$R7<O1
M_H<Q8F@)\-2 Z1ZO)D5]FB#HEU4Z.2V1@H[3UV>]\ K.A3!;T?!_?E#EQ("4
M ?S_ +9PU"(DBJ2$EMB_V$!QS61W$M#=OO%$]HF34*[@6?CG2HM0%:[(#VG_
M #S1\/1LH;TD$^'WF(]XE)OVT9/V.3YPF%B09&'MYK]ZJ((:8I=S^W )+$24
M-BDPC?/L$?J<3@=1E_)Q;JG*("Z(P\LSD!8T)(T2$V?_ '@"232J*&I<GKWQ
M(;DT%;1!ZZF7OA61T-3002U[[O[O ,S.R WZSL=_CB0P\B2 "H+;4=D\3@*Q
M%Z%41L#B0!2?2,A0$F^O4F*@WT()%O,>\.!ZE&8MNDBJ,>&(9DB)- $W4^B<
MQW]AJEBK]O:/7K,_9^D?0F7+AWR7IU03 %*863XG.@M\0@B)5H_GKBW%CD!D
MHK>Q_,,:E(F.H59!C<^,()%(8*D2LNOG[@>BVY(] Q;]YL*'TQ#L<0,%VSZO
M,6^>85:GP!T=PY3A'(K8*4L[GO\ H<Q8G^;%1O@,L=#7[X;8D:*-K6JQ]O5X
M#= Q=M \Z/\ TYH#$(@UZ ["U_OQIN@#8Q0Y0_O_ !)F14[@$I=/6<"HV53*
MI57$::]-X1G8 TJ)C5C$Z=O ,,'AH(""DO\ ?>2U'&%V-?0_VSCE-'6 2HTD
MV/SPE!X0\A26*F]SDO2]100*RGS+^W'MXX-8(ZB?#Q]\);"$"2^GV^GQ0AHD
M)IU&5\XB] %[?).^3,PA: _+PHPNDB<"=YR += 5GU];PK39BE%T!*K"C<^^
M(]<ZN(+)\G;N"J\/"\6G0=M4[C\O &*6)D^E$ =>A"<6 ! "8Q/W_$?YY 7M
M7&.,10HZ?:\/45]+8PI$0K)DY5D@!#$="@_WCQU[!#H[+V@-DR-Y'Z0LOM[#
M D9Z'"32$I$ZKVM'^4RG_262XN0X$8[Q8RH#2).P:9=3B8M@V$3&IM$R3OAM
M!2A0!W4"F>[9Q\]!<4V( $=SWC-J6!2N@$/H+UG*H\%'5**:WIGQ_H<Q8RK@
M2I)1I"%B=<$NPWO)@\"%_M>($OF%0'JQOP7YXP09B.VA.!\_V=>HSI$4()U,
M_%X=T.S2??TF_GOFA1V0:SW: VV+O%[NI#I[1VBU7@J1L\$UB<.QF]\F MXY
M>U2DGQ>&TR <@R9B 1#A.%N"6%^'@=!APK5O#3II%GYZG.PVZ#73VK_]F'R$
MP"U+R"S&/&63"=R)M00LXVA:EOJ+O\]?H4HQ"=$4[1=/C[XB#OBOE!?VY5#6
MRR3(Q,()M\VB-.Q>V76#>V!Q0F([%^)5"]>$>+:1Y",W]">/,:;&84&*AY8S
MVVJ !P3[BXEAYFCQL R)).V*..&6V\<Z* +IZ SHXY"<6 ;@Y&$ PU.[M3A@
M]#C+_8YW?XN/1MT[8M^'?P<8;<9!-$6JF"-_AYV=B>B@!%NS>_.(76H&A(1'
MV/\ QE&B%DE)1^S-.\X9.;"^B1&(F?''?%S(4:J HBF#H_T18L5BW-C[7;V5
M[O=VWB<1#D"*!$3L3F>EVU7]0$H-#WR]M*H<JE4Z1$WC;MS&75$*P8==<NA=
M.C@R1/BW*O!@)D#8)%=-8X(&:'<SX3$IT"N_OWS-N%E$":^OV.+M, VQBF5F
MT^"]EP;5P9%VX=+_  3BO VP(A1L(#?DY$6F;]%D06W>*(+:B9]!\AGW9.#"
M>RH(!*O1?'AKW 4J P%[?CC214;\3L_?W@#3T: ""EEN72<!#.+R$8^R8G5V
M\!H>2BDBI;/K]^#O(*-08U6"/E>:YFZ*J+ H40'[.$_\.![Z8&F*^N:PAW)>
MJ5#K$W$IR7G]8*/H0F=;PO-8]H#L%IGW\X[4L0T*,8K[0.P'.!'UT/DM!:S-
MW.^/ES2"P$PIE_GCH8@J$"SCK"568D)6 O=02%9N?'"S7?0B8SS_ .?3>:Y,
M8$B+TG779_OQHEDX!%95K=6_WX&8S@&'$!".?Z)L6-FA@AIJG049"$^.'624
MD@%& %SSHXI8IJJK_/? ?CSGFH:,*HGXO*6Y2TH6!(=C/O1K+H"X$ E%>D_'
M$@*!=@1'IR3&^<D/8(HZ,\3I_?AHCA)8.I!VUVQXO25*(0F!)8$\.'2C0%*I
M$/1?YG"1 H"%RQP5Z< G7@<P1"%T1TE3@,ZXE\T@! T^?4!;P=3>BDRA^UG&
M,9^AQH) ^JC;.$"!LTFF4=5/-Y=(TA-"@"FB,G7V09A\3 )QGU/W.6Q>KV@&
M7;W]^)J?751 U$-J)C=%C@W7U 2+%U;M8BJNN B*=(>SW Q;M (A$[8G\(3E
M*\CK.U)IKZ[0QXB7<">INIW.VG'=D[EZ :'RD;AG$U5%"BT+=28?G.-7GO=+
M"-"8_ 3D0?#[909!!C8=/#UOUP#-0 -W_KS.+TCLUP$JY"UF<$T 42!*/DZ?
MO_1-BQSE?F00XJ__ #YY)"JHK!0*V]U/GB(HB)V)$_(\&.!Q2"R-R?;_ /S@
MC!2P.$TJ3,\O"Y\G3$G:P6_N\)SG4,>Z$^$&U^;Q=(@UIB]13SVV\D=0V*@)
M-E]_XT?$EFI6Q2I _%S@,?"K9HX-!%,_/"M4D"E!F:BNPKWS;[K5&-Z&)$3Q
MWA9Q'RD+$( (#+(B2LORUI:T8B]U_LJ@V-V#6XJ@YV=<<B>9TR:B(9_OPTJA
MI+Y+9RC\^TB;H[(6FFX_R^\24+]C:,PZI?Y.4@G"Z,""%[+GSQ' <"6@^ :&
MSOSLOTQ%.E58%:R?B\9.&$0Y/C<1G:^\+'@'"%0 T&C/SG!0):+0)U5/RQA7
MB:%"TRM&@/09!298^)L"E)B7W<A^>-.2@ %0A['YOG7)'2L?H-^^-SJ9&:-F
M\BBG+M_YWG77^B;%C2E(*1*#=G8'\\!< 0 H:IPLKSYR^,$Y1*#; I<^:#8)
M>[;U"5:/U(2* P^>*9\$2O?*76($ ^>ND,=N<R(N8(0CL"%?AXQE".@? @U?
M^>#!DDB1?MW^_7SPH^1%@RX%[/5O&F$&H7>\!7=^W@." U-(PRAU[=X,&#TC
M%J9@%!&?(AK.0$L">BE5N6\Q<3F-@ 5]9"'E0CM&H(1U&PT^3BWZHRM'V;I#
M[DUL9_<4[!43P%>^+74;5:3HSSN _/*A!0V/-94=POWR'T,5$,5Z9Y<W^$CS
M:_98#O['/QRFW+!D"BH2X'D)U+3R9*F%!#$^;A15I"("?H,*6B]O$6AEP: F
MA;42G3Y"=&*8T)T?E_Y_T88L81P@J4KD/OG5"9PPJ]?+Q]SBDV,,:$4GO<_/
M&*?OX,&A]GG\\;.H&;X$"ZCB9WBK* 0@ TN""S.(/$U:1O;3 J%]X:164%6H
MG8CGIQ5(# !%(0DPMG/M8K7^>.FQE=%+V'Q[H<7R4SDJT#+^7SLX(B6@T$-"
M%.[#E3E5$"% T$ZZT^&T-W@.+>LG@%.4GP;&+ F%M\^>#G D 06),(>KO CD
MW40S +G6=/SQ)2TE(H"UQM-G?7%SL9AL$2O%?GP,"QJ5!.J*N7^?Y3)F34*'
M#OG?&AG&]@U(VK!T^\:E6K+*19QHWK>2&3J"(F( 6?MOO!,C8KU 1*1V&C[\
MT^$M4>X&QSJ%\WDDO;<&H@="U-OY_P!&&+$J37:G/:,TWSUJQ)&S.B-O9J_Q
MR3)1&C!-"3Q(SK@,A9B%=\S4CJF?QP4Y*$0!V 9IUWG)@&&2,-!,>G'+5,$H
MI0A%']N-V<#Y(!(0?'=>+T2(/[__ +P4D43(1NU(_=]XD:>F<K*:<>H[RW")
M0:NA50O(;UQ4I.<HE8A%1Z?(<'%'* <60,9U3B_*I I8PB.$>]Y>Z'YF4"<'
M@ KPH=P_4W0.]8YGP<K3#:>W("-OX>9PT^8"$JO#IZT:>3AK>PP:!4\S(]YG
M&&0AV!A.D4/NSWC%N#S(11C )\A>09L.P%;"4C5]QF5>I 0TX/;"GXJ$G!%4
MI$6;4"PO+2H@1& @O*]R/!IZ   8 '6O;ZK_ *,,6)IQ!PX?0QXEU%"%6RV'
M#SIXLH 8:50P0,T.''<FJ"TUJ)U_''=1B1$$U05GA^:B\GXW*@BO:?'?+23"
MNC(J: Y,\XG0X:$I<G2MDF]/,#K[&$'X%1.N6*#P$!%%H#KWWE\=L ;I2UKO
M#V3:!N81%5?Z#\9P5/+O%" 1B>;);(!K&#UN4(@N%>BWB) )I1*7J_\ 7J]<
MHV ]B!_8/ A;) D#EZ'G?N\R!I4"M"G9(';R5S3CN(4I$BSKSEDH9SW0% @Z
MV#17@.!'WPI\Q59#/H\X8+]#"?+,(_9;Y2J9"E$3KP/(G+!0U"@AI-Z'/G[!
MCE &(B# +YKNY_HXQ8IDWMH\K83V<Z0GYEA_Q#B 44")\B1/W.)5:C"J)A2O
M_>^&"$H5?M\#$<>%4\K"/:-'YNN3 -(LVQN"*KC9./5/";A*:0SY2<5%$J0L
M +'2UO+:5 7A"@@QOR'"ABBU%H@0B>0\KA$ @E$(B==[*' ).A!L&8L=^_'R
MEWC4.L#O)U]^\-A5"+3+?K@<H6PB4?2@R_'[<+M#PR+"1@T2[P+LP3!JAP68
M6<'.[ A\?NFO@)P(U1M4,00+ZTX<ZCK?2!!+%J[YEXGIR4;8"SIOSCG)TN(1
M #4L9M?=S>*>26%S#%38VO7^C[%BH;4<U2  @"/:-0XK9?0]U 3)%[XTJ!A2
MP FU =]]G&4)4 Y(!TBG3-XG*]D&@335'TO$AM$WJL"Y._?QQS:K6&F:@?'X
MXP=%)V((PD9U^1XK?1UQB1$=MN_?Z.B0$EI-Q_O]^\%#!(Q@*G0?_P V<TS?
M++7H-?\ [\\98MJ9G>&(2]E;N\34D0"!%86OFTN3>!(G50 Z!FEZ#?-H>$-,
MX*I$">GX>,/HH(934BNZ^Z=\>=5<"@S]JCT?\<B&5!1AD!%VM[^>%@2.EJ?9
M>A]W_1]BQ:& B^@K_:\ PQ%AJ#MTMW8N/+ H, HJN@3LR.')T%F%30$?:;)Q
MN]?X@K"KX-4XKO@+)12B#.OV]Y+RSWL$3EOSEX-QC(.K(1HCC!G.XH3);/E?
M1Q"Y(J3J,I]3KC8.H41K];\?[<N>6[0#8 MZ+9Z,>%!4!5H&SOLCQ*74-H=4
M (6_'';PEE% !MK(;_OS!D.L#@#MSP[9T/N&6/Y(ROQT]O!H7X]S&"5IHOR=
M<0+!9'XD$'4F>[O)XMB PJ9K0%P"'O\ YFA;V8OR@'[O+^';DSNXY[>.Q@J,
MAVH(/5<XX.#0\P>&8)5U"I4I%Z#U''>CS"BSM)X/Z;V$O^AF_33^+5^UXNS?
MWR<+Y (<0BH5)*?AT_?F^C:Y%)V&4;P?JH/%13H?1/O@50@<KU#=][U[DX'4
M9>#JA+7*=^<ZI0(BHH:8= ?/WQ(R'N J!]W?]N$J1)$I31ID"FJ9AM<N F!@
M*T'[<0K&!7FBA0$B1O<!!T(" A0P2E@"U]>423(Y!2NI#/B\Z8[D*(%4^+1Z
M.W>5&@4"P4//E\[WA29'ZR1"P?EF:S?_ $$17VWUS^,L_3\>3S_G3]VWWA(\
MB!8=7[(%'V\0<44E[& =B(W;?]$'L-$]6A1FAV;Q(2M021DJ C/XX)B@QFAB
M158'?'NU,'<-!L5R=*;P!BBFK7@.R]G\(AO?%!T$NE,[+)Q01(GG!HCIO3QX
M*)=Z  52HNC>?P/C\1_A$F2<<-5K;Z2AVIWOSP6K2PH. ,  ,#] [.2!#AKI
M!9/^*U'4.T<?M,^#SCA4T@U!3]#KX^I(06RF@2$*=X$^^*.-AS;BRD3O_20Q
MG*^AL'C=F.+06/-12"J'8_C_ ,7<^LD0BZD&TB?1DM%%@(B!'AB+$OW>"C:D
M+"T;'^?S^. W@8" $554_..9QY<EBC(6NB?Z7@0015T!@L:%Y5\A3$' 4">,
M^.,@"!ZZ:1&VMQ6<.9DB( 8L$[+CG<X72)P#(@%05?5?],'P?70]UE?WO#(2
M $D"!429+/XY$N&-8J5:RO5F'Q__ ('D+M.:MU$?E=<VKY:*<@0D@LOZCX?S
M?,VLP#"G +%G!NE@))4 !5PW@%7DN52.10H:*?Z8HHJ\ ]AFX;ADD@,\(3&I
MD; Y8V8CR4"DV]^#TTW+#F#5C+L7:T.UO]'XC$BR4UB +-/)M@TT<*B95X:&
M R($JGO-90)"/T50+Q;."_X4[5C$\C/JB@8 8SQ-YI;LQ)7ZP;D>=6=UZ;6_
M,(61>C:H'DZ$Z!Q;#(%BX?$%LP^)JG#%[Z!Y6$?U11:3C!K!5U!)R&O=#(&\
M)0MRG*TS-G]8E #?2D?H53^#TM.J$-RA>GMD^Q2CO$U*0%'BRF@V0 N$%;&W
MFH2B@AVCZ7T):UF!@!&-&,QFDY3NBB*YGEG_ ),0C)\'=!_T:?)TA$M.//&)
MP%&)'Q$EAQ1K^MMW';Y 88&;5<IE+<MQ;UB0 ( 1.MW++4E0?HB@%NHX6KJD
M/GE0<(VE BX2LG<X29^H8>)MM$H6?-\ W,U1Q>!3^B=12JC"4?'H_)M-F\HB
MX&2)-/!D;XV&J$3_ (2(2!1>53@."6K/4+J#\W$,8K4 %*;: 7FU1.M=Z.!&
MC(?PK)D#9S)A#!  X@WL/JD&YO/+E19RL(H[C_H_?4,6P$^-GE .X]ED1-5D
M)*UY&1('Z(TK@AX.\<"/"7@G""3#"#B<WZ@A =_D6_F%N4^F3?0? "TZY_HB
M%! CU++8>!T'MK$"@NDI7^*&EY5+\I#&KPHX <LK+Z;\@EN#=  4K@0FQGX!
MS<C0,QDN"B%O#>24/LD3(@1DO]&\<BN^@((E("Q>:IZVRA),,:S7!ET\(LC@
MI&8_#!U.F%VC-"0@DB._T!QXFXJ1KF&Y+"TLR7 0)A5:%7 P2 '!'V'VT\-G
M*R8^-X  SRL:M5@VX-"=B0;F)?$.PTT1R91%^1NQ7+,#3 J48MK]$0!@HD01
M$T1Q$Q'$X!?8KDH:NZI\+\C0:I!**:@%^G7E#8([_P!7B=!U*T5E'7@5/Q;Q
MJ5@!G?76"\%6O;=?PJ8''<F$     $ (   ! PX+R0!#@G\('G/MMBLTH<+M
ML&XN]F>@+BCL6K_1HX@&3#RLW65C^I./&2P/S"D9(C6< S:O=KP0U2W]1CQA
MAYG(Q^N_JVY6A%:JM^S.BD\#N@947-0J<6%)<P]6UQ,?@ZN=E#%^0' ,A=WP
M-URT.U&V%W*%^2G@B5DE85+X.U(S=A!KXI6<QF#@*:!M+[I8G0=XDR=J("1<
MVXX0 0(& =!\?I8#&YMQH%"YA'6$>%?D?I?P)PT0Q#A,W%F<MR58';A@Y"G_
M *10=6B])X8B)3OBY%&\5F;J2 0$*B!P55R"G:<.$8]2?AFXX_\ 3!7#X01$
7$2(Z(]B>CSNX<-JMZGK1&JO_ /R*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>inbxlogo.jpg
<TEXT>
begin 644 inbxlogo.jpg
MB5!.1PT*&@H    -24A$4@   -L   !"" 8   #>ZJ/+     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  #L0   [$ 94K#AL  "/=241!
M5'A>[5T'=%;7D68W66]B.PFQXQ3'P3E)-KUGURF;7G:3M9/-QMW&):X@$" )
M$,T2*A0AA(1$!PF0:*)+PH@B.D+T(KI$;T("@401$FUVOKGO\;=[WWL"R;MP
M_L_G.[\/>G-?NW/OS-R9^]I0&&&$T>IH UC_'T888;0BPLH61A@?$#PKV_&J
MG;1Z4S:MVYK+S#-RS99)M&[;5#I??\J2#,3-FS=I5^4RJRU]&S9+MTZFM5LF
MT]GSQRUI9]RX<8-V5BQU;7LMKI%_S]8=LR0#<>/&==I]H(16;1K/QTT)D WF
MFLT3:<ON>73U6J,E[8S:NN,B9U^#B;CWU9MSZ%3-?DLR%(>.;^1KG,#/6]^&
MS35;)M*&'=/IXN6SEJ0/%8=+51LN[[4Y+.6VRK9/H_+]"^GXZ5UTI>FB=3;O
MN'*E@39L6$5KUBRATM*2%N7:M4NIK&P%[=JUE4Z?/D57KUZUSMJZ\*1L4)#9
M2WI1QX3[*&;((\Q/&QDYX$%Z+_,;=+)ZKR4=B,:F2Y0VZ7?4.>FC6GE_1J=\
MBCKQ<>^O&FA).Z/^8@T-R?DER_RSMCW%S\@U]A[V)3IX?+TE&8@KC1<H(_>/
M%,'M=.?C]>TH=DKZ"&5.^;-G95NW+9>Z#OP$=1O45MN>XF?X[WS,P+:T;6^A
M)1F(:]>N4EY!!^K0_S[JGNI\C9')#U#BJ._SH'74DE9H;+Q,HZ<_8[U7O>R=
ML$?JYZ0OI$_^#YJW]#TZ<&R]]"4O.'+D /7H\3I%1CY/45$OMPJ[=W^-XN,[
MTZA1@VC%BH545U=KG;UUX$G9T/G&Y#\OG3AVV.>IY]!'#?P<=Z2/T;!)?^"1
MZ8(E'8CJLP<I8>1W*6KP)S7RH>PB[?V>&@SM^>/8J1T4/^);W%$_SK+FZ^PR
M\$%*F?!S.E=WTI(,!#JENL:V6OE;3'N4.B=_A&:\WXT[D27L@@4KDUG9[Q<%
MT;;)C.5K[\K*UG?XO]#A$YLMR4!<O'26AN?]%[?U4==W@OL=-?UOK*!-EK3"
MF7-':/#XGU&7 0_(.?7R=\+/\6#UB P<N.?>PQYGI>M'%RZ=L:[ C$T;5U/7
MKB]2=/0KHA2MP9B85T7I(B.?HTZ=GJ5!@[K3YLUK^>P>7V8SX4G98!(.'O]S
MZ7R]A[6C7L.^H&7LL,=X-/XXY15VL"1#L8?-L]BTQZC'T,]HVPBFZI2?9Y.D
MV&K!C/+][W.[C[+,IUE6?YVQS*Y\C1-FOTS7KU^W) -1<7@M']>.V_JLM@T?
M^7ZY(RU?/]*2=,:-&]=H\KRW9 "!K+[-+\@S[LH#QM"<7].Y>OV 4%-[B!)'
M?Y^B4C[I_$[2E.+.+(ZQ)'V &=J/%1H6A.EYM21CAK"EDG@?C9_UDE@A3EBX
M<*8H0<^>KS/_WNK$+-JY\[.LX"_1LF6%GF?@YL"3LAVKVD'],K["G?@1?FC.
M+Q;FD9/9MWIS-L7PR\6HIVLCF&@3G7/6HAY6"V:LVC2.SX\9T]RVW?GFE_2S
MI$)1ROY45,K#?.RCVC9LRLB=^EGV09=8DLY !X-)!45RZ]R8C;)GMV=_XHHE
M'8B*(Z4R(& PTLG;Q/W"BM -"%OW%"ASSW50:1GV3F\GSPP6TEPV*YV0FYLE
M)J1.,5J+L;%OL+*](+/=UJUEUI6T'#PIV]8]\_FE/,(/RJ7S<>?$<9MVSK(D
M0S&7S0B8>>@$NC9"V4YFCT'C?TIGV>PQ >/0'/8K([F3.LT:>-E0I-6;)RA!
M#>8OBQ>%P RL:T.Q'<6D?HKB1GR3JFKV69+.@)F;,$J9T&Z#5M=!'Z,"O@X3
MX/M%#7[(]3GB?DV6P>*U:6Q"\O-RO,^69CN>21]B7^[K=.+T+NM* M'8V$@9
M&?'4I<L+6J5H34+A8%(.'=J7+EUR=UV: T_*MGCM4/'%] _/1XSRO3.^1(=.
M;+(D X$HWX39KWCHR/YD<XY';Y@Z&\IG6"V%HJ'Q(HV=^2+[!@]HVO"QAYB8
MC_-L5&))!@+F0_:<5T7!W4V]3U#:Q-]X\D$ S(#H^&X6 F:::!X0UFS.L22#
MP-<X?UD<*PJ_DS1]&S9C^%SP8X.CFM>N7Z6I19VMY]7Z)J0_$3B)&LSWMR7;
MNII 5)\^20D)D3+#Z!2BM0E?KENWEVG+YG76%;4,7)4-X?0IA1'BY^@>G(\8
ML1ZF0>-^0G473EO2@<"_IV;_4GP_?1MF1B;?3[D%[QJC?F?.*V<?2@)S1=<&
MB)DW8=3WZ/292DLR$)<NGV<%^BU%R^RC;P/$.1!8R)GS.C4U-5C2SEC%LRG,
M[)YISB8TKA'/<[?!/+W.BI+-@Y;R_9P4I9W,HKB?ABMUEK3"I89SE#GE26G#
MZ7D%$H./B;KC]81YCN>P8.4 ZVH"L6?/=JO3OQ*B"&:VG&^GHJ#/T;QY>=85
MM0Q<E:VIZ3)EYCTI#T?WX'S$2/]QB7HU&?R,PR>VB-D%I=2W8:+J-/U'?-MH
MLAT]N56<_9@A:-O<>;IQ.PCK7VF\9$D&XCB;>G%97[<ZO+X-FY@5"I?W]Q2)
MQ#%SEO9QG7G!:#8/$T?]@$Y6[[&D P%%0? DBLTQG;R/&! >I)RYKXF"^@,1
MUZ31/Y0 B]/S4F23F2T+#+AP 8*)&1[7K'QE=\6%Z8O^-+^DOW4U@5B]>K$5
MFG]5JPS^[-'C-3$WN[!_!Q\OD,_)W[IU>\E36S;M)8>\/&^!+Z]P5;:SYX]1
M\IA_E1 N1D S'Y<7.W-1M,R&.FQCAQPF!)QZ'*]O1T-Y@8^),IM\K6U["^0:
M$<+&\=IVF.@PD^>_94F%8L>^!6+BPI33R=OL*8&'AZEL^Q1+TAE8/AG'9BZ>
M49\,YWO'K#J<!X0&EM'A!"MA/ ]:,*]U\C;1\6'^P_<+'@\.'%TG?X>".#TO
M* =\]?1)?Z"\PG?DV?DSM^!MFCCW[VRQ_$K6).&WN[U;%;1YB!:7IEE7$XB"
M@JFB).CT\*%,1/B^3Y^W:>S8%)H\.8LF3AP>P$F3,FG4J(&4F-A5% [+")#3
M*9@_;67+S1UA75'+P%79$*K'*!29_%'^Q6*LGG#HWXUO0R7KAEN2H8!#_F[_
M?V33Y0%M&TZ,XFMXIW\;6<.[U'#>:E$!?E;1BB1Z)ZZ-**1.7I&OD=LH7)YH
M28:B>&T*=4CXD,LUMJ5.2?=)A]EW>)4EZ8RSYPZS^?H=.3_,:'V[H+K&G+FO
M6Y*AV+QK#G5.?D#6KO1M*$+1.B9\6#(Z@K%JXSC^&]\GGT\G:Q/G0-!IQ[Z%
MEJ0>YR]4\7--$#^RB\MU=>:^A!E^0_ET2]J':]>NT8@1R?366W_VFZ%"B:CA
MFV\^18,&]:"ZNG.6="BP^%]5=8(6+IS%BJ;\,9V"^=-6MJE31UNMM Q<E6WK
MGB(:/.X7/'+]FDV7WQDYA$>VE F_HOV'L2@8"IA1Q:M3*7GT$UIY=_Z>V_\E
M*]N?Z%1UH"EY_?HU?M%);!8]P?[)'S2RBJG9OZ6!XW[JV'$6KQW&,_F/*37G
M-]HV%'_/ONE/)?L"ZUU></I,!:7G/BGKE6DLKV]77>. ,3\193!A_8[I-&#<
MS_@:?ZMMP^80?EZI_'OXY!9+TH=EZT=2TIA_HZ$3];(V\<RQ>%Y=>]"2-*/^
M8C6-R7^!!H[]L>,]XAF,G/H_VF=W\6(]96</HZ2D*$I-[4U#ANB)OR4F=*79
MLR>)@GI!?OX$ZMP9:W=Z);-I*UMA8>A@<"=P5;:FJPU4=[%&(FY.K+\(UDB4
MRP1D@=3Q"[EPZ6R(O!?6LUS=A6I1KF!X:UO)7[VF]RF!*XT7Y3[T\C:Y'3[F
M\I5Z2\H=&&RD77Y.^C8M7D3;U9+69@+>B9>VY)WPK^YY(5_1R[M0;=1()-D+
M\$SPC,WMGI4D"2BF#C=OWI"0>WW]>;IPH<Z1]3RC-328GU,P-FY8S>;IBZ),
M.B6SJ3)+VM.F36LLR9:!B[+=I",G-M&NBL6TY^!RYC(#E]/.BD62D6!2-KS<
M_8=72_C;N2TG+I<(W=Z#*Z3#V8""[#VT@G8?6"K'F&1Q;N3GZ3H?T, =9?^A
M57P.M_ME'EC&][.2*H^LIHHCJURYYV")F.1N[>(>]O&]-%V];%U5(*[?N$8'
MCV_P_$Z.56VGFT$^]-5K37Q-I?(L];(^HHV3GM<1MU,Y6PU[#=>%^X)/;+)^
M@//G:R5!>/?N;1*5-''7KFUR#)3.*TJ6%GF:V1#V1\YD34V5)=DR<%2V2Y?/
MB9G1.5GE\IG8(_6S%)'P3S1NYDNL5/J1YB!W\EYI7Q0_ NMQNG:\$%')'JF/
M!F1M[#^\AO^&M9N'^%??-@(SR%S(S'M*E$J'RF-KJ1<"/>RC>+E&W'=@+J"9
M"+@@C4S7CC_A^R(266NH=$"EP@ V_^#SZ.1MXMHZL+^66_!.2"024<Y^F5^3
M**).UI\1B?=1X8ID2U(/5!-LW#F3XK.^R3Y96Y8+?79X_K@W)* O+<TPSI3+
MER^@B(AG;@4T3$2D$;]03"^ [S9Z]&"1<PZ2O"%I6PBNW+CA(<S<##@J&S(>
MXJP'B"B3D9*"\Q$J6!:'R5"+S3MG<3N?E$56;1M>R9T6'6W68E_ZUKIMDZ7C
MH$-K99B(@$'9IK\?*;.##IMVS9;%<RP?Z-H();(SFD%M&X%$M#)KZI^-RR>5
M1]=1GXPOR:"CD[>)9X%!$D&I8*#T)484W_U=8)EFU/2_LL(ER$+Z_&7OW6+!
M\GA)H\N:^A<^5D48\9S]Y;&FAGM'T*3KP+:T</7@D(1H&S AX5=U[/@W,>6"
M$X?]":7IW[\+G3ZMSQT-QJI5BV7=#K)Z)5.TDY-W[- G9MP)')5MQ_[WY>&I
MQ%[]F@F(AQF-,/BVT*B7C>+5*=8BK+X-'Q^3EZ3_&XCTK;:2OG6N[H2T/;\D
M3I1-?[PBPOD(^SLE#2]:.U2B:;AG71L?!'&-,Q9&2\?3 75I*,'!S*635T02
MM2J[0?YC,):M'R%K=,[/61&A>JPY8K:72"._0YNP4NQ?>QDBM V\S\]32O8O
M^-IG&)>%@(:&RU+N@IG%+42/I8'T]'@V(^MEE@PFDLSA^QTXL)=FSY[(?MK?
MQ0_3M643Y^S4Z1D:,6* 7$M+PU'95FX<+:,5E"GT(=I4+Z-76CNVU9=9DH'
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M;]5>CF]L:I0LD<Z=GM4>ZY4(R@P9THMJ:_5U=C!_L08(T]1$_!U+$5!6;.N
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M;=J[5[]^ZP^MLB'_#CX.,C5T#\PF1D",R"5EF99D*%!,BH?KM"T<% +! 12
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MRE]D%G"^7C6#C.:9"]L5Z( OV2";PRU@!48.^)C4Y04#VR@@6NBEAJTUB-W
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26[-J"=Q      $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242486680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 21, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INHIBRX, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4257312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11025 N. Torrey Pines Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">795-4220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INBX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 764.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,025,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001739614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242483176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242562696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 131,301<span></span>
</td>
<td class="nump">$ 128,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivables from related parties</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,933<span></span>
</td>
<td class="nump">2,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">139,112<span></span>
</td>
<td class="nump">132,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,153<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">6,338<span></span>
</td>
<td class="nump">7,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1,847<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">150,450<span></span>
</td>
<td class="nump">143,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,125<span></span>
</td>
<td class="nump">13,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,621<span></span>
</td>
<td class="nump">13,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,674<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,454<span></span>
</td>
<td class="nump">31,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Long-term debt, net of current portion and including final payment fee</a></td>
<td class="nump">70,470<span></span>
</td>
<td class="nump">29,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liability</a></td>
<td class="nump">5,033<span></span>
</td>
<td class="nump">6,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current portion of deferred revenue</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">98,067<span></span>
</td>
<td class="nump">68,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December&#160;31, 2021 and 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 120,000,000 shares authorized as of December&#160;31, 2021 and 2020; 38,991,307 and 37,712,390 shares issued and outstanding as of December&#160;31, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">279,526<span></span>
</td>
<td class="nump">220,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(227,147)<span></span>
</td>
<td class="num">(145,379)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">52,383<span></span>
</td>
<td class="nump">75,473<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity</a></td>
<td class="nump">$ 150,450<span></span>
</td>
<td class="nump">$ 143,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242497896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">38,991,307<span></span>
</td>
<td class="nump">37,712,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">38,991,307<span></span>
</td>
<td class="nump">37,712,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898241041224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 7,231<span></span>
</td>
<td class="nump">$ 12,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">71,440<span></span>
</td>
<td class="nump">73,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,355<span></span>
</td>
<td class="nump">6,836<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">83,795<span></span>
</td>
<td class="nump">80,331<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(76,564)<span></span>
</td>
<td class="num">(67,443)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(5,216)<span></span>
</td>
<td class="num">(10,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(5,202)<span></span>
</td>
<td class="num">(8,191)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before provision for income taxes</a></td>
<td class="num">(81,766)<span></span>
</td>
<td class="num">(75,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (81,768)<span></span>
</td>
<td class="num">$ (76,124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (2.15)<span></span>
</td>
<td class="num">$ (3.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (2.15)<span></span>
</td>
<td class="num">$ (3.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic (in shares)</a></td>
<td class="nump">38,010,000<span></span>
</td>
<td class="nump">25,261,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding, diluted (in shares)</a></td>
<td class="nump">38,010,000<span></span>
</td>
<td class="nump">25,261,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License fee revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 7,125<span></span>
</td>
<td class="nump">$ 12,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898235097288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>2019 and 2020 Notes</div></th>
<th class="th"><div>2019 Convertible Note</div></th>
<th class="th"><div>2020 Convertible Note</div></th>
<th class="th"><div>COMMON STOCK</div></th>
<th class="th">
<div>COMMON STOCK </div>
<div>IPO</div>
</th>
<th class="th">
<div>COMMON STOCK </div>
<div>Convertible Preferred Stock</div>
</th>
<th class="th">
<div>COMMON STOCK </div>
<div>2019 and 2020 Notes</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>2019 and 2020 Notes</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>2019 Convertible Note</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>2020 Convertible Note</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, preferred stock (in shares) at Dec. 31, 2019</a></td>
<td class="nump">12,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance, preferred stock at Dec. 31, 2019</a></td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of preferred shares (in shares)</a></td>
<td class="num">(12,534,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of preferred shares</a></td>
<td class="num">$ (59,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Dec. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">(93,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (69,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of shares upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of shares upon exercise of stock options</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares in IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares in IPO, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,211,000<span></span>
</td>
<td class="nump">4,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,507<span></span>
</td>
<td class="nump">$ 59,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,506<span></span>
</td>
<td class="nump">$ 59,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ReversalOfUnamortizedBeneficialConversionFeature', window );">Reversal of unamortized BCF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,332)<span></span>
</td>
<td class="num">$ (2,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,332)<span></span>
</td>
<td class="num">$ (2,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of warrant liabilities into equity</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (76,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,124)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">37,712,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 75,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145,379)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, preferred stock (in shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance, preferred stock at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 15,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of shares upon exercise of stock options (in shares)</a></td>
<td class="nump">358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of shares upon exercise of stock options</a></td>
<td class="nump">$ 3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares in IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares in IPO, net of issuance costs</a></td>
<td class="nump">39,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,768)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">38,991,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 52,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (227,147)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ReversalOfUnamortizedBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal of Unamortized Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ReversalOfUnamortizedBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898236782600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81,768)<span></span>
</td>
<td class="num">$ (76,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and non-cash interest expense</a></td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">10,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">15,048<span></span>
</td>
<td class="nump">5,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_NoncashOperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">1,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of fixed assets</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(167)<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivables from related parties</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,040)<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(1,602)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(4,642)<span></span>
</td>
<td class="nump">10,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(3,736)<span></span>
</td>
<td class="nump">8,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liability</a></td>
<td class="num">(1,503)<span></span>
</td>
<td class="num">(1,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="num">(1,047)<span></span>
</td>
<td class="num">(5,345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent', window );">Deferred revenue, non-current portion</a></td>
<td class="num">(627)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(180)<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(80,323)<span></span>
</td>
<td class="num">(47,968)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(864)<span></span>
</td>
<td class="num">(1,364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of fixed assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(809)<span></span>
</td>
<td class="num">(1,364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="nump">39,992<span></span>
</td>
<td class="nump">29,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt', window );">Payment of fees associated with debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">3,956<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from the issuance of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of principal on debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment', window );">Final payment on debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from the Paycheck Protection Program loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of principal on the Paycheck Protection Program loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">83,769<span></span>
</td>
<td class="nump">166,456<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash</a></td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">117,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">128,664<span></span>
</td>
<td class="nump">11,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">131,301<span></span>
</td>
<td class="nump">128,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3,889<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">ATM offering costs included in accounts payable</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable', window );">ATM offering costs reimbursable in accounts receivable</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CapitalExpendituresIncurredButNotYetPaidReleased', window );">Payable for purchase of fixed assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of the 2019 Note and the 2020 Notes to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature', window );">Debt discount arising from convertible note beneficial conversion features and reversal of beneficial conversion features</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred', window );">Derivative liabilities arising from the issuance of the 2019 Note and the 2020 Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_NonCashEstablishmentOfEquityMethodInvestment', window );">Non-cash equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ReclassificationOfWarrantLiabilitiesToEquity', window );">Reclassification of warrant liabilities to equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred', window );">Warrant liabilities issued to lender in conjunction with 2020 Loan Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inbx_AtTheMarketOfferingMember', window );">ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity offering</a></td>
<td class="nump">40,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs associated with offering</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">136,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs associated with offering</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (10,990)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At The Market Offering Costs Included in Accounts Payable and Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At The Market Offering Costs Reimbursable in Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CapitalExpendituresIncurredButNotYetPaidReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Expenditures Incurred but Not Yet Paid (Released)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CapitalExpendituresIncurredButNotYetPaidReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Beneficial Conversion Feature Discount (Reversal) Of Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Contract With Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Contract With Customer, Liability, Non-Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_NonCashEstablishmentOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash Establishment Of Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_NonCashEstablishmentOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Noncash Investing And Financing Items, Derivative Liabilities Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Noncash Investing And Financing Items, Warrant Liabilities Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of Debt Issuance Costs, Secured Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_PaymentsOfDebtIssuanceCostsSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ReclassificationOfWarrantLiabilitiesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Warrant Liabilities To Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ReclassificationOfWarrantLiabilitiesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_RepaymentsOfSecuredDebtFinalBalloonPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Secured Debt, Final Balloon Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_RepaymentsOfSecuredDebtFinalBalloonPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inbx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inbx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898241684072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx, Inc., or the Company, or Inhibrx, is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines target biology with protein engineering, technologies, and research and development to design therapeutic candidates. The Company&#8217;s current pipeline is focused on oncology and orphan diseases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, risks associated with preclinical studies, clinical trials and regulatory applications, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company&#8217;s therapeutic candidates currently under development will require significant additional research and development efforts, including clinical and preclinical testing and marketing approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;21, 2020, the Company completed its initial public offering, or IPO, in which it sold 8,050,000 shares of common stock at an offering price of $17.00 per share. Net proceeds from the IPO were $125.9 million, net of underwriting discounts, commissions, and offering costs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, each of the following occurred in connection with the completion of the IPO:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conversion of the 2019 Note and the 2020 Notes (each as defined below) into 4,294,603 shares of the Company&#8217;s common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conversion of all outstanding convertible preferred stock into 7,211,086 shares of the Company&#8217;s common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adjustment of an outstanding warrant to purchase convertible preferred stock into a warrant to purchase 7,354 shares of the Company&#8217;s common stock; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amendment and restatement of the Company&#8217;s certificate of incorporation, authorizing 120.0 million shares of common stock and 15.0 million shares of preferred stock.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;11, 2020 the Company effected a one-for-1.7382 reverse stock split of the Company&#8217;s common stock, or the Reverse Stock Split. The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion prices of the convertible preferred stock and convertible notes have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP.&#160;All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had an accumulated deficit of $227.1 million and cash and cash equivalents of $131.3 million. From its inception and through December&#160;31, 2021, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company&#8217;s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, and other similar arrangements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5, the Company entered into the Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $200.0 million through the Sales Agent, or the ATM Offering. As of December&#160;31, 2021, 921,042 shares have been sold pursuant to the Sales Agreement for net proceeds of $40.2 million, after deducting commissions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#8217; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules and regulations of the SEC or any other regulatory agencies may restrict the Company&#8217;s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the global outbreak of COVID-19 and the World Health Organization&#8217;s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. The full impact of the COVID-19 outbreak continues to evolve as of the date of these financial statements. While the pandemic has not yet had a material effect on the Company&#8217;s financial results, it is uncertain as to the full magnitude of impact the pandemic will have on the Company&#8217;s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&#160;</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act includes a provision for a Paycheck Protection Program, or PPP, administered by the U.S. Small Business Administration, or SBA, and further amended by the Paycheck Protection Program Flexibility Act of 2020, </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or PPP Flexibility Act, which was enacted on June 5, 2020. The Company was approved for a loan pursuant to the PPP, or the PPP Loan, in the amount of $1.9 million and received the funds on May&#160;11, 2020. On October 2, 2020, the Company repaid the loan in full plus all interest accrued during the period outstanding. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also permits employers to defer the payment of the employer share of social security taxes due for the period beginning March 27, 2020 and ending December 31, 2020. Of the amounts deferred, 50% was required to be paid by December 31, 2021 and the remaining 50% is required to be paid by December 31, 2022. The Company began deferring payment of the employer share of social security taxes in April 2020 and deferred a total of $0.4&#160;million of such taxes during the period. The Company paid $0.3&#160;million of deferred taxes during December 2021. As of December&#160;31, 2021, the Company has a remaining deferred payment of $0.1&#160;million of such taxes which are classified as accrued expenses in the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to examine and evaluate any impacts the CARES Act and associated subsequent legislation may have on its business and taxes.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The Company&#8217;s most significant estimates relate to evaluation of embedded derivative instruments and beneficial conversion features, or BCFs, within its previously issued and outstanding convertible notes, whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company&#8217;s operating lease, and valuation allowances for the Company&#8217;s deferred tax assets.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist principally of accounts receivable, accounts payable, accrued expense, its long-term debt, convertible notes, warrants, and derivative instruments as applicable. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and convertible notes approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#8217;s debt approximates fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company&#8217;s derivative instruments and warrants are carried at fair value based on unobservable market inputs.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking and money market accounts. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#8217;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December&#160;31, 2021 and 2020, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently depends on third-party suppliers for key materials and services used in its research and development, as well as manufacturing processes, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. In August 2018, the Company entered into a strategic alliance with WuXi Biologics (Hong Kong), Limited, or WuXi Biologics, pursuant to which the Company agreed, for three years and subject to certain conditions, to exclusively use WuXi Biologics to manufacture its therapeutic candidates on a project-by-project basis. In August 2021, the exclusivity provisions of the Wuxi Agreement expired, and the Company may use manufacturers other than Wuxi to manufacture its therapeutic candidates. The Company does not control the manufacturing processes of the contract development and manufacturing organizations, or CDMOs, with whom it contracts, including WuXi Biologics, and is dependent on these third parties for the production of its therapeutic candidates in accordance with relevant regulations such as current Good Manufacturing Practices, or cGMP, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has never declared or paid any dividends on its common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Amended 2020 Loan Agreement limits, among other things, the Company&#8217;s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company&#8217;s common stock will be at the discretion of the Company&#8217;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#8217;s board of directors may deem relevant. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">machinery and equipment: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDIx_fb18bef6-4644-4d4c-b39d-3e7398424521">three</span> to five years; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture and fixtures: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDYy_22f664cc-88d9-4893-a2bc-e342d557a1d4">three</span> to five years; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNTAx_ac274eaf-b7f7-4024-9d85-68b4306ca0ff">four</span> to five years.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company&#8217;s facilities, which commenced in January 2020 and is accounted for as a separate lease. The Company&#8217;s two existing leases are classified as operating leases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the long-term operating lease of its corporate headquarters, the Company recognized a right-of-use asset and lease liability on its consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. Agreements are reviewed at </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inception to determine if they contain a lease. Leases are reviewed and classified as operating or financing leases at commencement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to exclude from its consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the consolidated statements of operations for all periods presented. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 7, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis (as defined below), which is accounted for as an equity method investment. The Company's proportionate share of the net income or loss of these companies is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#8217;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. During the third quarter of 2020, the Company&#8217;s equity method investment was written down to zero as a result of the allocation of the Company&#8217;s share of losses of the investee. As of December&#160;31, 2021 and 2020, the equity method investment remains at zero.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the convertible promissory note, or the 2019 Note, issued in May 2019 to DRAGSA 50 LLC, an entity affiliated with Viking Global Investors LP, or Viking, and the convertible promissory notes, or the 2020 Notes, issued in April 2020 to Viking and certain other investors contained embedded features that provided multiple settlement alternatives. Certain of these settlement features provided the noteholders with a right to a fixed number of the Company&#8217;s shares upon conversion of the note. Other settlement features provided the noteholders the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction, change of control, qualified IPO (as defined in the 2019 Note and the 2020 Notes), or default of the Company. The Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 815-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and determined certain of the settlement features would be accounted for as redemption features meeting the requirements for separate accounting as a single, compound derivative instrument.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This single, compound derivative instrument was accounted for as a liability at its estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the consolidated statements of operations. During August 2020, the Company consummated its IPO, resulting in the conversion of the 2019 Note and the 2020 Notes into shares of the Company&#8217;s common stock. As of December&#160;31, 2021 and 2020, the derivative liabilities no longer exist.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, in conjunction with the 2020 Loan Agreement with Oxford, the Company issued warrants for the purchase of: 1) its preferred stock if the Company remained privately-held or 2) common stock upon the successful completion of an IPO prior to December 31, 2020. Upon the issuance of the warrants in July 2020, pursuant to ASC Topic 480, the warrants were accounted for as liabilities and measured at their estimated fair value as of the date of issuance, based on the potential conversion into preferred stock. During August 2020, upon consummation of the Company&#8217;s IPO, the warrants were deemed to be issued for the purchase of common stock and </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were no longer accounted for as liabilities. The change in fair value was recognized as a component of change in fair value of warrant liabilities in the consolidated statements of operations during the year ended December 31, 2020.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific&#160;to the asset or liability. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 Note and the 2020 Notes contained embedded derivative liabilities (see Note 4). The 2020 Loan Agreement contained warrant liabilities (see Note 3). Prior to the completion of the IPO in August 2020, these were classified within Level 3 of the hierarchy, since they were valued by using inputs that were unobservable in the market. Upon the consummation of the IPO in August 2020, the derivative liabilities and warrant liabilities no longer existed. As of December&#160;31, 2021 and 2020, the Company had no financial liabilities measured at fair value.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of the IPO in August 2020, the Company&#8217;s liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) included the derivative liabilities related to the 2019 Note and the 2020 Notes and the warrants issued with the 2020 Loan Agreement. The following table provides a reconciliation of financial instruments measured at fair value using Level 3 unobservable inputs for the year ended December 31, 2020 (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of derivative liability on the 2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of warrant liabilities on the 2020 Loan Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities on the 2019 and 2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities into equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s derivative liabilities categorized in Level 3 of the fair value hierarchy during the year ended December 31, 2020 was determined, with the assistance of an independent third-party valuation specialist, using a lattice model. The valuation utilized unobservable inputs, including the discount rate, management&#8217;s assessment of the probability of various underlying events triggering the conversion of the Company&#8217;s 2019 Note and the 2020 Notes (as discussed in Note 4), such as an IPO, financing, or extraordinary event, and the current valuation of the Company determined with the assistance of an independent third-party valuation specialist. The warrant liabilities were valued using a Black-Scholes model upon issuance. As of December&#160;31, 2020, the derivative liabilities no longer exist as a result of the conversion of the 2019 Note and the 2020 Notes upon the IPO. Additionally, as of December&#160;31, 2020 the warrant liabilities have been reclassified into equity after the Oxford warrants became exercisable for common stock subsequent to the Company&#8217;s IPO.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no financial instruments measured at fair value during the year ended December 31, 2021.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company&#8217;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal, accounting, and filing fees related directly to the Company&#8217;s IPO were capitalized as deferred offering costs to be offset against proceeds upon the consummation of the IPO within stockholders&#8217; equity (deficit). In August 2020, the Company completed its IPO and offset $11.0 million of IPO costs against the proceeds. No deferred offering costs were capitalized on the Company&#8217;s consolidated balance sheets as of December 31, 2020.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal, accounting, and filing fees related directly to the Company&#8217;s Shelf Registration are capitalized as deferred offering costs. Deferred offering costs associated with the Shelf Registration are reclassified to additional paid-in capital when the Company completes offerings under the Shelf Registration. In November 2021, the Company completed an offering under the Shelf Registration and offset $1.7 million of offering costs against the proceeds. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet until all revenue recognition criteria are met. In accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or ASC Topic 606, the Company recognizes revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC Topic 606, the Company performs the following five steps: (1)&#160;identify the contract(s) with a customer; (2)&#160;identify the performance obligation(s) in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (5)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners that typically include one or more of the following: (1)&#160;license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether each unit of account results in a contract with a customer under ASC Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC Topic 808. The Company&#8217;s licensing arrangements are typically for functional intellectual property as it exists at a point in time, being the time that the license agreement is executed. The Company typically does not have an ongoing performance obligation to support or maintain the licensed intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company estimates the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. The Company recognizes revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. In the case of an agreement which provides the partner with an option to license a therapeutic or therapeutic candidate in the future, the Company evaluates whether this option represents a material right at the inception of the agreement. If determined to be a material right, the Company will consider the option a separate performance obligation. The Company has historically concluded that the option to grant a license in the future are not material rights as they are contingent upon future events which may not occur. When an option is exercised, the Company will identify any separate performance obligations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may allocate transaction price using a number of methods including estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain, and observable standalone selling prices exist for the other goods or services promised in the contract. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been awarded grants from the Congressionally Directed Medical Research Program, or CDMRP, funded through the DoD. With respect to revenue derived from reimbursement of direct, out-of-pocket expenses for research and development costs associated with these grants, where the Company acts as a principal with discretion to choose suppliers, bears credit risk, and performs part of the services required in the transaction, the Company records revenue for the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the consolidated statements of operations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since there is no transfer of control of goods or services to the granting entities, the granting entities do not meet the definition of a &#8220;customer&#8221; as defined by ASC Topic 606 and therefore, these government grants and private not-for-profit institution grants are not within the scope of ASC Topic 606. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from these grants are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses related to the grant which is consistent with the concept of transfer of control of a service over time under ASC Topic 606. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development and Clinical Trial Accruals </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#8217;s behalf, pursuant to development and consulting agreements in place. The Company&#8217;s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company&#8217;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders.&#160;Accordingly, for the years ended December 31, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock-Based Awards </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments-Equity Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 321),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments-Equity Method and Joint Ventures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 323),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 815), - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 was effective for fiscal years beginning after December 15, 2020, and interim periods within those years. Early adoption was permitted, but required simultaneous adoption of all provisions of this guidance. The Company adopted this guidance as of January 1, 2021, which did not result in a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU 2019-12 also improves consistent application and simplification of other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 was effective for fiscal years beginning after December 15, 2020. The Company adopted this guidance as of January 1, 2021, which did not result in a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or Subtopic 470-20 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subtopic 815-40: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share, or EPS, calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 under a modified retrospective approach as of January 1, 2021. As a result of the adoption, there was no impact on retained earnings or other components of equity or to earnings per share in the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company was a smaller reporting company at the determination date, and therefore the new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 260), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt-Modifications and Extinguishments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 470-50), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 718), and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Subtopic 815-40):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which intends to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods therein, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2021-04 may have on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240612456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">OTHER FINANCIAL INFORMATION</a></td>
<td class="text">OTHER FINANCIAL INFORMATION <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expense and Other Current Assets</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,564&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,857&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $1.2 million and $1.0 million for the years ended December 31, 2021 and 2020, respectively, and consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other outside research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The amount accrued for research and development expense relates primarily to the Company&#8217;s usage of third-party CROs and CDMOs for clinical and development efforts as its therapeutic candidates progress. See Note 1 for further discussion of the components of research and development.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240754152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;15, 2020, the Company entered into a loan and security agreement, or the 2020 Loan Agreement, with Oxford Finance LLC, or Oxford, pursuant to which it received $10.0 million in gross proceeds, net of $0.1 million of debt issuance costs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;12, 2020, the Company entered into an amendment to the 2020 Loan Agreement, or the November 2020 Amendment, and received $20.0 million in additional gross proceeds, net of $0.02 million of debt issuance costs and $0.7 million of a one-time first amendment fee. The November 2020 Amendment provided for two additional tranches of term loans, in addition to the first $10.0 million tranche, or Term A, for an aggregate principal amount of up to $50.0 million, as follows: (a) the second tranche in an aggregate principal amount of $20.0 million, funded upon the closing of the November 2020 Amendment, or Term B, and (b) the third tranche in an aggregate principal amount of $20.0 million to fund on or before September 30, 2021, subject to the initiation of a potentially registration-enabling trial for the Company&#8217;s therapeutic candidate, INBRX-109, in unresectable or metastatic conventional chondrosarcoma, pursuant to the terms of the November 2020 Amendment, or Term C. The terms of Term A under the 2020 Loan Agreement were modified to align with Term B pursuant to the November 2020 Amendment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;18, 2021, the Company entered into an additional amendment to the 2020 Loan Agreement, or the June 2021 Amendment (collectively with the November 2020 Amendment, the Amended 2020 Loan Agreement). Pursuant to the June 2021 Amendment, the principal amount of the Term C Loan was increased from $20.0 million to $40.0 million. All terms of the Term C Loan align with the existing terms of the Term A and Term B Loans. Upon execution of the June 2021 Amendment and based on the initiation of a potentially registration-enabling trial in unresectable or metastatic conventional chondrosarcoma, the Company drew the Term C Loan and received $40.0 million in gross proceeds, net of $0.01 million of debt issuance costs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 the Company has $70.0 million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement. The outstanding term loans will mature on November&#160;1, 2025, or the Amended Maturity Date, and bear interest at a floating per annum rate equal to the greater of (1) 7.96% and (2) the sum of (i) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (ii) 7.80%. The repayment schedule provides for interest-only payments until January&#160;1, 2025. The interest-only period is followed by 11 months of equal payments of principal and interest. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount will be due to Oxford. This final payment of $6.3 million is being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending upon the timing of the prepayment. All other terms of the original 2020 Loan Agreement remain outstanding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following (in thousands).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term A</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,900&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,900&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,470&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,244&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion, including debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through 2024, the Company is only required to make interest payments on the outstanding principal balance, with future principal payments and final fee payments beginning in 2025, as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.586%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,300&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,300&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 and June 2021, the Company evaluated the amendments and determined they should be treated as modifications of the original 2020 Loan Agreement since the terms and resulting cash flow were not substantially changed in either the November 2020 Amendment or the June 2021 Amendment. The Company will continue to amortize the existing debt discounts prior to modification through the Amended Maturity Date.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Amended 2020 Loan Agreement are secured by a first priority security interest of substantially all of the Company&#8217;s assets, other than its intellectual property. The Amended 2020 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company&#8217;s operations, that may require prepayment of the outstanding term loans. Additionally, following the June 2021 Amendment, the Amended 2020 Loan Agreement requires a minimum cash balance of $20.0&#160;million to be maintained in a collateral account. As of December&#160;31, 2021, the Company is in compliance with all covenants under the Amended 2020 Loan Agreement and has not received any notification or indication from Oxford of an intent to declare the loan due prior to maturity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the debt issuance in July 2020, the Company issued to Oxford warrants to purchase shares of the Company&#8217;s capital stock equal to 1.25% of the funded amount, or $125,000. Upon issuance, the warrants were </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercisable for preferred stock and were classified as liabilities pursuant to Topic ASC 480 at their fair value of $0.12 million. Upon the consummation of the Company&#8217;s IPO in August 2020, the Company remeasured the warrants and determined a fair value of approximately $0.14 million. The change in fair value was recorded as a change in fair value of warrant liabilities within other income in the Company&#8217;s consolidated statements of operations during the year ended December 31, 2020. As of December&#160;31, 2021 and 2020, the warrants are equity-classified and are exercisable for 7,354 shares of common stock of the Company at $17.00 per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment. Interest expense was approximately $5.4 million and $0.9 million for the years ended December&#160;31, 2021 and 2020, respectively, as related to the Amended 2020 Loan Agreement. Interest expense was approximately $44,000 for the year ended December 31, 2020 as related to the Company&#8217;s previous loan and security agreement, as amended, or the 2015 Loan Agreement, with Oxford. The Company recorded no interest expense for the year ended December 31, 2021 related to the 2015 Loan Agreement since it was paid in full in March 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240652408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">CONVERTIBLE PROMISSORY NOTE</a></td>
<td class="text">CONVERTIBLE PROMISSORY NOTES <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company issued the 2019 Note in the aggregate principal amount of $40.0 million to Viking in a private placement transaction. The 2019 Note began to accrue interest in February 2020 at a rate of 1.5% per month. In April 2020, the Company issued the 2020 Notes in the aggregate principal amount of $15.0 million to Viking and certain other investors in a private placement transaction. Upon issuance, the 2020 Notes accrued interest at a rate of 1.0% per month.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion Upon IPO</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 21, 2020, the Company completed its IPO. The aggregate total balance of the 2019 Note, or $43.7 million, converted at the fixed price of $14.35 per share, resulting in the issuance of 3,046,467 shares of common stock to the holder. The aggregate total balance of the 2020 Notes, or $15.7 million, converted at a fixed price of $12.56 per share, resulting in the issuance of 1,248,136 shares of common stock to the holders.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of the 2019 Note and the 2020 Notes were evaluated for contingent BCFs under ASC Topic 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt With Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See discussion of debt discount below for evaluation upon conversion.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2019 Note and the 2020 Notes contained alternative conversion options to the IPO upon the consummation of certain events, each of which had its own conversion prices and terms. The Company determined certain settlement features qualified as conversion features not meeting the requirements for separate accounting as embedded derivatives, while others qualified as redemption features meeting the requirements for separate accounting which were accounted for as derivative instruments.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the 2019 Note and the 2020 Notes, the Company recorded derivative liabilities with corresponding debt discounts on the consolidated balance sheets at the estimated fair value of the bifurcated compound liabilities. The Company remeasured the fair value at each reporting period. Changes in the probability of each embedded redemption feature drove changes in the fair value of the derivative liabilities and had a corresponding impact on the Company&#8217;s net loss. During the second quarter of 2020, the fair value of the derivatives were determined to be zero based upon the expected conversion of the notes via an embedded conversion feature which did not meet the definition of a derivative. Upon conversion of the 2019 Note and the 2020 Notes in August 2020 upon completion of the Company&#8217;s IPO, the derivative liabilities were extinguished. No additional expense was recorded at extinguishment since the derivative liabilities had already been assessed to have zero value. During the year ended December 31, 2020, the Company recorded other income of $2.7 million related to changes in fair value of derivative liabilities in the consolidated statements of operations.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Discount </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon issuance of the 2019 Note and the 2020 Notes, the Company recorded debt discounts related to BCFs, as well as derivative liabilities and debt issuance costs. Prior to conversion, the debt discounts were amortized over the life </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the notes. Amortization of the debt discount from inception of the 2019 Note until conversion of the 2019 Note and the 2020 Notes upon IPO was $8.7 million. At the time of conversion, the 2019 Note and the 2020 Notes had unamortized discounts of $6.9 million and $2.7 million, respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion of the 2019 Note and the 2020 Notes, the Company remeasured the intrinsic value of the BCFs which resulted in a reversal of the remaining unamortized discounts associated with the BCFs, resulting in a $7.4 million impact to additional paid-in-capital. Additionally, the Company accelerated the unamortized debt discounts related to the debt issuance costs and the derivative liabilities, resulting in a $2.2 million charge to interest expense during the third quarter of 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240679480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY (DEFICIT) <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Certificate of Incorporation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;21, 2020 upon completion of the IPO, the Company&#8217;s certificate of incorporation was amended and restated to authorize 120,000,000 shares of common stock and 15,000,000 shares of preferred stock, each with a par value of $0.0001 per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of the Company&#8217;s IPO in August 2020, all of the outstanding shares of convertible preferred stock were converted into 7,211,086 shares of the Company&#8217;s common stock. Prior to its conversion to common stock, the convertible preferred stock was classified as temporary, or mezzanine, equity on the accompanying consolidated balance sheets since the shares contained certain redemption features that were not solely within the control of the Company. The Company had not previously accreted the convertible preferred stock to its redemption value since the shares were not currently redeemable and redemption was not deemed to be probable. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No convertible preferred stock was authorized or issued as of December&#160;31, 2021 or December&#160;31, 2020.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into the Sales Agreement with the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $200.0 million through the Sales Agent, or the ATM Offering. Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to 3% of the gross sales price per share sold. As of December&#160;31, 2021, the Company has sold 921,042 shares under the ATM Offering for net proceeds of $40.2&#160;million, after deducting commissions of $1.2&#160;million. In connection with the ATM Offering, the Company incurred an additional $0.5&#160;million of expenses which were offset against the proceeds of the offering.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, the Company issued warrants to Oxford concurrently with the 2020 Loan Agreement. Upon the consummation of the Company&#8217;s IPO in August 2020, the warrants are exercisable for 7,354 shares of common stock of the Company at $17.00 per share. As of December&#160;31, 2021, the warrants are equity-classified and reflected in additional paid-in-capital at $0.14 million. The fair value of the warrants was determined using the Black-Scholes model on the date of reclassification. No subsequent remeasurement is required for equity-classified warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240685048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY COMPENSATION PLANS</a></td>
<td class="text">EQUITY COMPENSATION PLANS <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, provides for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. As of December&#160;31, 2021, an aggregate of 4.5 million shares of common stock were reserved for issuance under the 2017 Plan, of which 0.1 million were available. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. The Company grants options with an exercise price equal to </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair market value of the Company&#8217;s stock on the date of the option grant. The options are subject to four-year vesting with a one-year cliff and have a contractual term of 10 years.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under its 2017 Plan for the year ended December 31, 2021 is as follows (in thousands, except for per share data and years):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.008%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (In Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.80&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,064&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2021 and 2020 was $7.5&#160;million and $19,000, respectively. Aggregate intrinsic value of stock options exercised and outstanding is calculated using the fair value of common stock on the date of exercise and as of December&#160;31, 2021, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#8217;s anticipated stock volatility, and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. The Company recognizes forfeitures as they occur.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the years ended December 31, 2021 and 2020 were as follows.&#160;</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.82</span></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the assumptions used in the option pricing model in the following manner:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited historical stock price volatility data, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">selected companies&#8217; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s IPO, given the absence of a public trading market for the Company&#8217;s common stock, its board of directors exercised their judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company&#8217;s common stock underlying the stock options, such as: contemporaneous valuations performed by independent third-party specialists, its stage of development, including the status of its research and development efforts of its therapeutic candidates and the material risks related to its business and industry, its results of operations and financial condition, including its levels of capital resources, the prices at which its sold shares of its convertible preferred stock, the rights, preferences and privileges of its convertible preferred stock relative to those of its common stock, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable life sciences public companies, as well as recently completed mergers and acquisitions of peer companies, the likelihood of achieving a liquidity event for the holders of its common stock or convertible preferred stock, such as an IPO or a sale of the Company given prevailing market conditions, trends and developments in its industry, external market conditions affecting the life sciences and biotechnology sectors, and the lack of liquidity of its common stock, among other factors.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on its closing market price on the date of the grant. The Company&#8217;s board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of its common stock underlying those options on the grant date. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,830&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>As of December&#160;31, 2021, the Company had $47.0 million of total unrecognized stock-based compensation expense related to its stock options, which is expected to be recognized over a weighted-average period of 3.04 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240652968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND GRANT REVENUES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_LicenseAndGrantRevenueTextBlock', window );">LICENSE AND GRANT REVENUES</a></td>
<td class="text">LICENSE AND GRANT REVENUES <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company&#8217;s consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elpiscience Biopharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from affiliates</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from non-affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2seventy bio, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phylaxis BioScience, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chiesi Farmaceutici S.p.A.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license revenues from non-affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from non-affiliates</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,125&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,808&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congressionally Directed Medical Research Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Elpiscience</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into a separate License Agreement, or the OX40 License Agreement, with Elpiscience Biopharmaceuticals, Inc., or Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#8217;s multivalent protein therapeutic directed to the biological target OX40, or INBRX-106. This license provides Elpiscience with the right to further advance the therapeutic candidate through clinical trials, as well as manufacture and commercialize it. It also requires the Company to provide Elpiscience with know-how and materials specific to INBRX-106, including process development and manufacturing data and information necessary to develop INBRX-106. In the OX40 License Agreement, the Company also agreed to negotiate an agreement to supply Elpiscience with INBRX-106 for its development in Mainland China, Hong Kong Macau and Taiwan. The Company is eligible to receive certain developmental and commercial milestones of up to an aggregate of $100.0 million, as well as percentage tiered royalties on future product sales with rates in the high single-digits. Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company achieved a milestone under the contract for $2.0 million, which was received during September 2020. The Company recognized revenue of $2.0 million during the year ended December 31, 2020. No revenue was recognized related to this agreement during the year ended December 31, 2021.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2seventy bio, Inc.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2018, the Company entered into a License Agreement with bluebird bio, Inc., or bluebird, whereby the Company granted bluebird the exclusive, worldwide rights to develop, manufacture, and commercialize certain cell therapy products containing binders. In November 2021, bluebird assigned the agreement, or the 2018 2seventy Agreement, to its affiliate, 2seventy bio, Inc., or 2seventy, in connection with an internal restructuring and subsequent spin-out of 2seventy. Under this agreement, the Company is entitled to receive specified development milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, a milestone event under the 2018 2seventy Agreement was achieved and the Company recognized $2.0 million of revenue at that point in time. The Company received the associated $2.0 million payment in August 2021. During the year ended December 31, 2021, the Company recognized a total of $2.0 million in revenue related to this agreement. During the year ended December 31, 2020, the Company recognized no revenue related to this agreement.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Option and License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Option and License Agreement with bluebird, pursuant to which the Company granted to bluebird exclusive worldwide development licenses to develop binders and cell therapy products containing single domain antibodies, or sdAbs, directed to specified targets, consisting of two initial programs and up to an additional 8 programs. The Company retains all rights to the specific sdAbs outside of the cell therapy field. This agreement, or the 2020 2seventy Agreement, was also assigned to 2seventy in November 2021 in connection with bluebird&#8217;s internal restructuring and subsequent spin-out of 2seventy.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and is entitled to an upfront option fee for each additional program, on a program-by-program basis. The Company also granted an option in which 2seventy may acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which 2seventy exercises its option, 2seventy will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions for each option 2seventy chooses to exercise. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the effective date of the 2020 2seventy Agreement, the Company identified one performance obligation, which was the transfer of the exclusive development license to bluebird for the two initial programs. The Company determined that the option granted for an exclusive license in the future was not a material right. For the eight programs not identified upon execution of the contract, the Company evaluated the customer option for additional purchases and determined that those options for additional programs did not constitute material rights nor variable consideration. As additional programs are identified, the Company will re-assess its performance obligations and transaction price accordingly.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the total transaction price of the 2020 2seventy Agreement at execution was $0.4 million for the transfer of the two exclusive development licenses. The Company recognized $0.4 million of revenue related to this agreement at the point in time in which the exclusive development licenses were transferred to bluebird, which occurred upon execution of the agreement in June 2020. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, pursuant to the option extension terms in the 2020 2seventy Agreement, bluebird requested to extend the option term for one of the initial programs by an additional six months in exchange for an option extension fee of $0.1&#160;million. The Company recognized the $0.1&#160;million of revenue related to this extension in May 2021, the point in time in which the extension was granted.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, pursuant to the option exercise terms in the 2020 2seventy Agreement, the Company received a $2.1&#160;million option exercise fee for one of the initial programs and transferred an exclusive license for the program </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recognized the $2.1&#160;million of revenue related to this option exercise at the point in time in which the exclusive license was transferred.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the Company recognized $2.2&#160;million and $0.4&#160;million of revenue related to this agreement, respectively. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phylaxis Agreements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a joint venture with an entity affiliated with ArrowMark Partners, Phylaxis BioScience, LLC, or Phylaxis. In connection with the joint venture, the Company entered into the following agreements: Contribution Agreement, License Agreement, Limited Liability Company Agreement, and Master Services Agreement, or collectively the Phylaxis Agreements, pursuant to which the Company licensed certain intellectual property and know-how to Phylaxis and agreed to provide services to develop certain compounds. Upon closing, the Company received a $2.5&#160;million nonrefundable, upfront payment from Phylaxis under the Master Services Agreement, or the MSA. The Company has also received an additional $2.5&#160;million, which was payable within 180 days from closing under the MSA, in two payments of $1.25&#160;million each, received in October 2020 and January 2021. Upon closing, the Company received a 10% equity interest in Phylaxis as consideration for the contribution of the license of the Company&#8217;s intellectual property and know-how and is entitled to receive an additional 5% based on the achievement of certain milestones. Under the License Agreement, the Company is also entitled to specified development and commercialization milestone payments of up to an aggregate of $225.0&#160;million and $175.0&#160;million, respectively. The Company is also entitled to share in a percentage of the profits of Phylaxis under the Limited Liability Company Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the fair value of the equity interest in Phylaxis, the Company engaged a third-party valuation specialist. The valuation report utilized a market approach to establish the total equity value of Phylaxis using inputs not observable in the market, including the discount rate. The fair value of the equity interest was $0.5&#160;million, which has been accounted for under the equity method. The fair value of the equity interest upon the execution of the agreements has been included in the transaction price, along with the $5.0&#160;million of payments due pursuant to the MSA.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the transfer of the exclusive licenses for, and performance of, development services to modify the first and second compounds as one performance obligation and allocated the transaction price evenly between the two compounds. Revenue related to the performance obligation will be recognized over time as services are performed, based on the Company&#8217;s progress to satisfy the performance obligation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, the Company recognized $2.4&#160;million and $2.0&#160;million of revenue related to this performance obligation, respectively. As of December&#160;31, 2021, the Company has $1.1&#160;million of deferred revenue related to this agreement, all of which is classified as current. As of December&#160;31, 2020, the Company had $1.6&#160;million and $0.6&#160;million of current and non-current deferred revenue related to this agreement, respectively. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chiesi</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into an Option Agreement, as amended by the First Amendment to Option Agreement, dated August 19, 2019, or the Chiesi Option Agreement, with Chiesi Farmaceutici S.p.A., or Chiesi, pursuant to which the Company granted to Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada. Under the terms of the Chiesi Option Agreement, the Company received a one-time, non-refundable option initiation payment of $10.0 million in August 2019. If Chiesi chooses to exercise its option under the Chiesi Option Agreement, then Chiesi must pay the Company a one-time, non-refundable fee of $12.5 million upon the effective date of the definitive agreement granting Chiesi the exclusive license. If the option is exercised, under the license agreement, the Company may be entitled to receive specified milestone payments of up to $122.5 million, as well as royalties on future product sales.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified one performance obligation as of the effective date of the Chiesi Option Agreement, which is to perform research and development services for Chiesi during the option period, which will continue (unless the Chiesi Option Agreement is terminated earlier by the Chiesi or the Company) until 60 days following the last to occur of (i) the Company&#8217;s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration, or FDA, scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company&#8217;s delivery to Chiesi of the finalized minutes from the definitive parallel European Medicines Agency health technology assessment, or EMA-HTA, scientific advice meeting conducted following completion of such Phase I Clinical Trial. The Company has determined that the option to grant a license in the future is not a material right.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $10.0 million upfront payment has been allocated to the single performance obligation. Revenue is recognized over time as services are performed during the option period, based on the Company&#8217;s effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period. During the years ended December 31, 2021 and 2020, the Company recognized $0.5 million and $7.4 million in revenue related to this agreement, respectively. As of December&#160;31, 2021, the Company has $0.9 million and $0.1 million of current and non-current deferred revenue related to this agreement, respectively. As of December&#160;31, 2020, the Company had $1.4 million and $0.1 million of current and non-current deferred revenue related to this agreement, respectively. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celgene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2012, the Company entered into a Development and Option Agreement with Celgene whereby the Company granted Celgene an option to exclusively license certain intellectual property rights relating to the Company&#8217;s CD47 checkpoint inhibitor. Upon grant of the Development and Option Agreement, Celgene made a non-refundable upfront option payment for the exclusive license. In June 2013, Celgene opted to exercise its right to license the intellectual property rights associated with the Company&#8217;s CD47 therapeutic. The Company is also eligible to receive certain developmental and commercial milestones of an aggregate of $934.1&#160;million, assuming the achievement of all potential milestones in the agreement, as well as percentage tiered royalties based on future worldwide sales, with rates ranging between the high single-digits and low teens. The Company is obligated to pay 2% of future amounts received under the Development and Option Agreement to advisors who assisted the Company with the negotiation and other matters in connection with the Development and Option Agreement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. No revenue was recognized under this agreement during the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue was recognized in accordance with the Company&#8217;s stated methodology discussed in Note 1.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CDMRP funded through the DoD </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During September 2018, the Company was awarded a grant by the CDMRP funded through the DoD by the U.S. Army Medical Research Acquisition Activity in the amount of approximately $0.3 million for the continued development of multi-specific antibodies for the treatment against Acinetobacter baumannii infection by circumventing development of bacterial resistance, or the 2018 DoD grant. The work under this grant began in December 2018 and was completed in September 2020. In February 2021, the Company was awarded an additional grant from the DoD in the amount of approximately $0.3 million for the development of sdAb based therapeutics targeting SARS-CoV-2 Spike protein for the treatment of COVID-19, or the 2021 DoD grant. Work under the grant began in February 2021 and is expected to continue through February 2022. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from these grants is based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue is recognized when the Company incurs these covered expenses related to the grant&#8217;s continued progression. The Company submits requests for reimbursement to the DoD for only those expenses which have been incurred by the Company in each period, resulting in reimbursement in arrears. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $0.3 million has been recognized to date under the 2018 DoD grant, all of which has been received in cash from the DoD. As of December&#160;31, 2021, $106,000 has been recognized to date under the 2021 </span></div>DoD grant, $86,000 of which has been received in cash from the DoD. During each of the years ended December 31, 2021 and 2020, $106,000 and $80,000 was recognized as revenue under the grants, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LicenseAndGrantRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LicenseAndGrantRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240751400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business. These agreements are ratified by the Company&#8217;s Board of Directors or a committee thereof pursuant to policy.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LAV Summit Limited </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LAV Summit Limited, or LAV SL, a limited company, is a principal shareholder owning more than 5% of the Company&#8217;s outstanding equity interest during the year ended December&#160;31, 2021. Due to this equity ownership, LAV SL was considered a related party. LAV SL&#8217;s General Partner, Lilly Asia Ventures, or LAV, through one of its funds, holds a significant equity ownership position in Elpiscience, and the Venture Partner of LAV is the CEO, Founder, and Director at Elpiscience. Accordingly, the Company identified Elpiscience as a related party. As of December&#160;31, 2021, LAV SL no longer holds more than 5% of the Company&#8217;s outstanding equity interest.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elpiscience</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into the OX40 License Agreement with Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#8217;s multivalent protein therapeutic directed to the biological target OX40, or INBRX-106. Under this agreement, the Company is entitled to reimbursement for certain chemistry, manufacturing, and controls, or CMC, and toxicology expenses incurred for which Elpiscience has paid the Company approximately $5.2 million to date as of December&#160;31, 2021. As of December&#160;31, 2021, the Company has $0.2 million recorded as receivables from related parties from Elpiscience for expenses incurred which have not yet been reimbursed. Additional reimbursements of approximately $38,000 related to multi-year stability studies are expected to be recognized and paid upon completion. During the year ended December 31, 2021, the Company received no reimbursements for expenses already incurred. During the year ended December 31, 2020, the Company received reimbursements of $0.2 million for expenses already incurred. During the year ended December 31, 2021, the Company did not derecognize any expenses related to these reimbursements under the OX40 License Agreement. During the year ended December 31, 2020, the Company derecognized approximately $0.2 million of expenses related to these reimbursements under the OX40 License Agreement, respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into an additional cost sharing agreement with Elpiscience related to the OX40 License Agreement. Under this agreement, the Company is entitled to reimbursement for certain formulation development costs. Through December&#160;31, 2021, the Company has received $0.2 million of reimbursements for expenses already incurred under this agreement. As of December&#160;31, 2021, the Company has approximately $0.3 million recorded as receivables from related parties from Elpiscience for expenses incurred which have not yet been reimbursed. During the year ended December 31, 2021, the Company received reimbursements of $0.2 million for expenses already incurred. During the year ended December 31, 2021, the Company did not derecognize any expenses related to this agreement. During the year ended December 31, 2020, the Company received no reimbursements. During the year ended December 31, 2020, the Company derecognized $0.3 million of expenses related to this agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a Sale and Purchase Agreement with Elpiscience, in which the Company sold drug substance supply to Elpiscience for approximately $37,000, for which it derecognized expenses during the year ended December 31, 2021. As of December&#160;31, 2021, the Company has $37,000 recorded as receivables from related parties for this purchase.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240569160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES The components of income tax expense (benefit) were as follows for the years ended December 31, 2021 and 2020, respectively (in thousands): <div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for the years ended December 31, 2021 and 2020 was related to California state income tax.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2021 and 2020 as follows (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(17,171)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(15,985)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (benefit), net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (FIN 48)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision true-ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred income taxes were as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred income tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">43,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">27,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,897&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,880&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(58,528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(39,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,369)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,793)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had unused federal and state NOL carryforwards of approximately $198.9 million and $24.5 million, respectively. The federal NOL carryforwards may be carried forward indefinitely but are only available to offset up to 80% of pre-NOL taxable income each year. The state NOL carryforwards will begin to expire in 2038, if not utilized. As of December&#160;31, 2021, the Company also had federal and state research tax credit carryforwards of $8.3 million and $3.9 million, respectively. The federal research tax credit carryforwards begin to expire in 2038, while the state carryforwards have no expiration. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of NOL and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a full valuation allowance against its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December&#160;31, 2021. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#8217;s projections for future growth. Based on this evaluation, as of December&#160;31, 2021, a valuation allowance of $58.5 million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#8217;s projections for growth. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,155&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had gross unrecognized tax benefits of $2.8 million, none of which would affect the effective tax rate due to the existence of a full valuation allowance. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company&#8217;s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets as of December&#160;31, 2021 or December 31, 2020, and has not recognized interest and/or penalties in its consolidated statements of operations for the years ended December 31, 2021 and 2020 as the unrecognized tax benefits relate to tax positions for which no cash tax liability has been reduced. </span></div>The Company is subject to income taxes in the United States and various state jurisdictions. The Company&#8217;s tax years from 2018 and forward are subject to examination by the United States and state tax authorities. The Company has not been, nor is it currently, under examination by the U.S. federal or any state tax authority.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898241675688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company entered into a seven-year lease agreement for approximately 34,000 square feet as its sole location in La Jolla, California. The lease expires in June 2025 with an option to extend the lease an additional five years. The lease contained an initial base rent of approximately $0.1 million per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company executed an amendment to its lease agreement to expand its facilities by approximately 9,000 square feet and began occupying this space in January 2020. The amended lease terminates coterminously with the initial lease agreement and contains an initial base rent of approximately $30,000 per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset and operating lease liability as of December&#160;31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,338&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,831&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During each of the years ended December 31, 2021 and 2020, the Company recognized operating lease expense of $3.1 million. As of December&#160;31, 2021 and 2020, the Company&#8217;s operating lease had a remaining term of 3.5 and 4.5 years, respectively.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of 8.2% as of December&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating leases are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.586%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,707&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898324092360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#8217;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has several ongoing contracts with CROs for preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. These contracts are generally cancellable, with notice, at the Company&#8217;s option. The Company recorded accrued expenses of approximately $7.4 million and $11.5 million in its consolidated balance sheets for expenditures incurred by CROs and CDMOs as of December&#160;31, 2021 and December&#160;31, 2020, respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While these contracts are generally cancellable, some may contain specific activities that involve one or more non-cancellable commitments, including minimum purchase commitments, binding annual forecasts, and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from cost of work performed to date and up to twelve months of future committed manufacturing costs. As of December&#160;31, 2021 and December&#160;31, 2020, the non-cancellable portion of these contracts total in aggregate, excluding amounts recorded in accounts payable and accrued expenses at each respective date, was approximately $2.4 million and $7.0 million, respectively. During the years ended December&#160;31, 2021 and 2020, the Company incurred $1.0 million and $30.2 million of expenses related to these agreements, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div>Additionally, as of December&#160;31, 2021 and December&#160;31, 2020, Mark P. Lappe, the Company&#8217;s Chief Executive Officer, Brendan P. Eckelman, the Company&#8217;s Chief Scientific Officer, and Kelly D. Deck, the Company&#8217;s Chief Financial Officer, and certain other members of management have agreements that provide for severance compensation in the event of termination or a change in control.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240732184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the audited consolidated financial statements as of December&#160;31, 2021, the Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these consolidated financial statements, other than disclosures related to those outlined below.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Issuance</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January and February 2022, the Company granted stock options to purchase an aggregate of 0.8&#160;million common shares at a weighted average exercise price of $33.84 per share to employees under the 2017 Equity Incentive Plan. The Company granted these options with an exercise price equal to the fair market value of the Company&#8217;s stock on the date of the option grant. The options are subject to four-year vesting with a one-year cliff and have a contractual term of 10 years.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to the 2020 Loan Agreement with Oxford</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2022, the Company entered into an additional amendment to the 2020 Loan Agreement, or the February 2022 Amendment. The February 2022 Amendment provides for four additional tranches of term loans in an aggregate principal amount of up to $200.0&#160;million, as follows: (a) an aggregate principal amount of $110.0&#160;million, which includes the $70.0&#160;million already outstanding; the incremental $40.0&#160;million principal amount funded upon the closing of the February 2022 Amendment, or Term D, (b) an aggregate principal amount of $30.0&#160;million, funded upon initiation of Part 4 of the INBRX-105 Phase 1 clinical trial, or Term E, (c) an aggregate principal of $30.0&#160;million, funded upon the reception of positive topline Phase 1 data from INBRX-101 in AAT, or Term F, and (d) an aggregate principal amount of $30.0&#160;million, funded upon the initiation of an INBRX-101 potential registration-enabling trial in AAT, or Term G. In accordance with the February 2022 Amendment, the Company paid a one-time amendment fee of $1.1&#160;million, which is equal to the amount accreted for the final payment on the existing tranches at the time of the amendment. The terms of the three existing tranches under the Amended 2020 Loan Agreement were modified to align with the four additional tranches under the February 2022 Amendment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding term loans will mature on January 1, 2027 and bear interest at the greater of (1) 8.30% and (2) the sum of (i) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (ii) 8.19%. The repayment </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">schedule provides for interest-only payments through February 1, 2025, with principal payments beginning on March 1, 2025. The interest-only payments may be extended by 12 months through February 2026, with principal payments beginning on March 1, 2026, if the Company raises at least $100.0&#160;million in upfront licensing or partnership proceeds by February 2025. The interest-only period is followed by 23 months of equal payments of principal plus interest, or if the interest-only period is extended, by 11 months of equal payments of principal plus interest. Upon the maturity date of January 1, 2027, a final payment of 9.0% of the total principal amount will be due to Oxford. The Company has the option to prepay the outstanding balance of the term loan in full prior to maturity, subject to a prepayment fee ranging from 1.0% to 3.0%, depending on the timing of the prepayment. The Company granted Oxford a first priority lien against all of its assets with a positive lien on intellectual property. All other terms of the Amended 2020 Loan Agreement remain outstanding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the debt issuance upon the February 2022 Amendment, the Company issued to Oxford warrants to purchase 40,000 shares of the Company&#8217;s common stock at a strike price of $45.00 per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898235003256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP.&#160;All intercompany accounts and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had an accumulated deficit of $227.1 million and cash and cash equivalents of $131.3 million. From its inception and through December&#160;31, 2021, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company&#8217;s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, and other similar arrangements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5, the Company entered into the Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $200.0 million through the Sales Agent, or the ATM Offering. As of December&#160;31, 2021, 921,042 shares have been sold pursuant to the Sales Agreement for net proceeds of $40.2 million, after deducting commissions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#8217; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.</span></div>The rules and regulations of the SEC or any other regulatory agencies may restrict the Company&#8217;s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The Company&#8217;s most significant estimates relate to evaluation of embedded derivative instruments and beneficial conversion features, or BCFs, within its previously issued and outstanding convertible notes, whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company&#8217;s operating lease, and valuation allowances for the Company&#8217;s deferred tax assets.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist principally of accounts receivable, accounts payable, accrued expense, its long-term debt, convertible notes, warrants, and derivative instruments as applicable. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and convertible notes approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#8217;s debt approximates fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company&#8217;s derivative instruments and warrants are carried at fair value based on unobservable market inputs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents are comprised of cash held in financial institutions including readily available checking and money market accounts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#8217;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December&#160;31, 2021 and 2020, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. </span></div>The Company currently depends on third-party suppliers for key materials and services used in its research and development, as well as manufacturing processes, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. In August 2018, the Company entered into a strategic alliance with WuXi Biologics (Hong Kong), Limited, or WuXi Biologics, pursuant to which the Company agreed, for three years and subject to certain conditions, to exclusively use WuXi Biologics to manufacture its therapeutic candidates on a project-by-project basis. In August 2021, the exclusivity provisions of the Wuxi Agreement expired, and the Company may use manufacturers other than Wuxi to manufacture its therapeutic candidates. The Company does not control the manufacturing processes of the contract development and manufacturing organizations, or CDMOs, with whom it contracts, including WuXi Biologics, and is dependent on these third parties for the production of its therapeutic candidates in accordance with relevant regulations such as current Good Manufacturing Practices, or cGMP, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Dividends</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has never declared or paid any dividends on its common stock. </span></div>Additionally, the Amended 2020 Loan Agreement limits, among other things, the Company&#8217;s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company&#8217;s common stock will be at the discretion of the Company&#8217;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#8217;s board of directors may deem relevant.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">machinery and equipment: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDIx_fb18bef6-4644-4d4c-b39d-3e7398424521">three</span> to five years; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture and fixtures: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDYy_22f664cc-88d9-4893-a2bc-e342d557a1d4">three</span> to five years; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNTAx_ac274eaf-b7f7-4024-9d85-68b4306ca0ff">four</span> to five years.</span></div>Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company&#8217;s facilities, which commenced in January 2020 and is accounted for as a separate lease. The Company&#8217;s two existing leases are classified as operating leases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the long-term operating lease of its corporate headquarters, the Company recognized a right-of-use asset and lease liability on its consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. Agreements are reviewed at </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inception to determine if they contain a lease. Leases are reviewed and classified as operating or financing leases at commencement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to exclude from its consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.</span></div>Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the consolidated statements of operations for all periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investment</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 7, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis (as defined below), which is accounted for as an equity method investment. The Company's proportionate share of the net income or loss of these companies is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#8217;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. During the third quarter of 2020, the Company&#8217;s equity method investment was written down to zero as a result of the allocation of the Company&#8217;s share of losses of the investee. As of December&#160;31, 2021 and 2020, the equity method investment remains at zero.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the convertible promissory note, or the 2019 Note, issued in May 2019 to DRAGSA 50 LLC, an entity affiliated with Viking Global Investors LP, or Viking, and the convertible promissory notes, or the 2020 Notes, issued in April 2020 to Viking and certain other investors contained embedded features that provided multiple settlement alternatives. Certain of these settlement features provided the noteholders with a right to a fixed number of the Company&#8217;s shares upon conversion of the note. Other settlement features provided the noteholders the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction, change of control, qualified IPO (as defined in the 2019 Note and the 2020 Notes), or default of the Company. The Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 815-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and determined certain of the settlement features would be accounted for as redemption features meeting the requirements for separate accounting as a single, compound derivative instrument.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This single, compound derivative instrument was accounted for as a liability at its estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the consolidated statements of operations. During August 2020, the Company consummated its IPO, resulting in the conversion of the 2019 Note and the 2020 Notes into shares of the Company&#8217;s common stock. As of December&#160;31, 2021 and 2020, the derivative liabilities no longer exist.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_WarrantLiabilitiesPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, in conjunction with the 2020 Loan Agreement with Oxford, the Company issued warrants for the purchase of: 1) its preferred stock if the Company remained privately-held or 2) common stock upon the successful completion of an IPO prior to December 31, 2020. Upon the issuance of the warrants in July 2020, pursuant to ASC Topic 480, the warrants were accounted for as liabilities and measured at their estimated fair value as of the date of issuance, based on the potential conversion into preferred stock. During August 2020, upon consummation of the Company&#8217;s IPO, the warrants were deemed to be issued for the purchase of common stock and </span></div>were no longer accounted for as liabilities. The change in fair value was recognized as a component of change in fair value of warrant liabilities in the consolidated statements of operations during the year ended December 31, 2020.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific&#160;to the asset or liability. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 Note and the 2020 Notes contained embedded derivative liabilities (see Note 4). The 2020 Loan Agreement contained warrant liabilities (see Note 3). Prior to the completion of the IPO in August 2020, these were classified within Level 3 of the hierarchy, since they were valued by using inputs that were unobservable in the market. Upon the consummation of the IPO in August 2020, the derivative liabilities and warrant liabilities no longer existed. As of December&#160;31, 2021 and 2020, the Company had no financial liabilities measured at fair value.</span></div>The fair value of the Company&#8217;s derivative liabilities categorized in Level 3 of the fair value hierarchy during the year ended December 31, 2020 was determined, with the assistance of an independent third-party valuation specialist, using a lattice model. The valuation utilized unobservable inputs, including the discount rate, management&#8217;s assessment of the probability of various underlying events triggering the conversion of the Company&#8217;s 2019 Note and the 2020 Notes (as discussed in Note 4), such as an IPO, financing, or extraordinary event, and the current valuation of the Company determined with the assistance of an independent third-party valuation specialist. The warrant liabilities were valued using a Black-Scholes model upon issuance. As of December&#160;31, 2020, the derivative liabilities no longer exist as a result of the conversion of the 2019 Note and the 2020 Notes upon the IPO. Additionally, as of December&#160;31, 2020 the warrant liabilities have been reclassified into equity after the Oxford warrants became exercisable for common stock subsequent to the Company&#8217;s IPO.There were no financial instruments measured at fair value during the year ended December 31, 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Financing Costs and Other Debt-Related Costs and Deferred Offering Costs</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company&#8217;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal, accounting, and filing fees related directly to the Company&#8217;s IPO were capitalized as deferred offering costs to be offset against proceeds upon the consummation of the IPO within stockholders&#8217; equity (deficit). In August 2020, the Company completed its IPO and offset $11.0 million of IPO costs against the proceeds. No deferred offering costs were capitalized on the Company&#8217;s consolidated balance sheets as of December 31, 2020.</span></div>Legal, accounting, and filing fees related directly to the Company&#8217;s Shelf Registration are capitalized as deferred offering costs. Deferred offering costs associated with the Shelf Registration are reclassified to additional paid-in capital when the Company completes offerings under the Shelf Registration. In November 2021, the Company completed an offering under the Shelf Registration and offset $1.7 million of offering costs against the proceeds.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet until all revenue recognition criteria are met. In accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or ASC Topic 606, the Company recognizes revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC Topic 606, the Company performs the following five steps: (1)&#160;identify the contract(s) with a customer; (2)&#160;identify the performance obligation(s) in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (5)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners that typically include one or more of the following: (1)&#160;license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether each unit of account results in a contract with a customer under ASC Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC Topic 808. The Company&#8217;s licensing arrangements are typically for functional intellectual property as it exists at a point in time, being the time that the license agreement is executed. The Company typically does not have an ongoing performance obligation to support or maintain the licensed intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company estimates the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. The Company recognizes revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. In the case of an agreement which provides the partner with an option to license a therapeutic or therapeutic candidate in the future, the Company evaluates whether this option represents a material right at the inception of the agreement. If determined to be a material right, the Company will consider the option a separate performance obligation. The Company has historically concluded that the option to grant a license in the future are not material rights as they are contingent upon future events which may not occur. When an option is exercised, the Company will identify any separate performance obligations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may allocate transaction price using a number of methods including estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain, and observable standalone selling prices exist for the other goods or services promised in the contract. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been awarded grants from the Congressionally Directed Medical Research Program, or CDMRP, funded through the DoD. With respect to revenue derived from reimbursement of direct, out-of-pocket expenses for research and development costs associated with these grants, where the Company acts as a principal with discretion to choose suppliers, bears credit risk, and performs part of the services required in the transaction, the Company records revenue for the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the consolidated statements of operations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since there is no transfer of control of goods or services to the granting entities, the granting entities do not meet the definition of a &#8220;customer&#8221; as defined by ASC Topic 606 and therefore, these government grants and private not-for-profit institution grants are not within the scope of ASC Topic 606. </span></div>Revenue from these grants are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses related to the grant which is consistent with the concept of transfer of control of a service over time under ASC Topic 606.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development and Clinical Trial Accruals</a></td>
<td class="text">Research and Development and Clinical Trial Accruals Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#8217;s behalf, pursuant to development and consulting agreements in place. The Company&#8217;s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company&#8217;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div>The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders.&#160;Accordingly, for the years ended December 31, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Fair Value of Stock-Based Awards</a></td>
<td class="text">Fair Value of Stock-Based Awards The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income</a></td>
<td class="text">Other Comprehensive Income The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU 2020-01,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments-Equity Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 321),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Investments-Equity Method and Joint Ventures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 323),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 815), - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 was effective for fiscal years beginning after December 15, 2020, and interim periods within those years. Early adoption was permitted, but required simultaneous adoption of all provisions of this guidance. The Company adopted this guidance as of January 1, 2021, which did not result in a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU 2019-12 also improves consistent application and simplification of other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 was effective for fiscal years beginning after December 15, 2020. The Company adopted this guidance as of January 1, 2021, which did not result in a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or Subtopic 470-20 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subtopic 815-40: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share, or EPS, calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 under a modified retrospective approach as of January 1, 2021. As a result of the adoption, there was no impact on retained earnings or other components of equity or to earnings per share in the Company&#8217;s consolidated financial statements.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company was a smaller reporting company at the determination date, and therefore the new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 260), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt-Modifications and Extinguishments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 470-50), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 718), and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Subtopic 815-40):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which intends to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods therein, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2021-04 may have on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_WarrantLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_WarrantLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898241649880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Notes Measured at Fair Value Using Level 3 Unobservable Inputs</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the completion of the IPO in August 2020, the Company&#8217;s liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) included the derivative liabilities related to the 2019 Note and the 2020 Notes and the warrants issued with the 2020 Loan Agreement. The following table provides a reconciliation of financial instruments measured at fair value using Level 3 unobservable inputs for the year ended December 31, 2020 (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of derivative liability on the 2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of warrant liabilities on the 2020 Loan Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities on the 2019 and 2020 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of warrant liabilities into equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898245432824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expense and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,564&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,857&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $1.2 million and $1.0 million for the years ended December 31, 2021 and 2020, respectively, and consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other outside research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240608632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following (in thousands).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term A</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,900&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,900&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,470&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,244&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion, including debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through 2024, the Company is only required to make interest payments on the outstanding principal balance, with future principal payments and final fee payments beginning in 2025, as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.586%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,300&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,300&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242494920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under its 2017 Plan for the year ended December 31, 2021 is as follows (in thousands, except for per share data and years):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.008%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (In Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.80&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,064&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used to Estimate Fair Value</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the years ended December 31, 2021 and 2020 were as follows.&#160;</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.82</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,830&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898241675688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND GRANT REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock', window );">Schedule of License and Grant Revenue</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company&#8217;s consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elpiscience Biopharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from affiliates</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue from non-affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2seventy bio, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phylaxis BioScience, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chiesi Farmaceutici S.p.A.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license revenues from non-affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue from non-affiliates</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,125&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,808&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congressionally Directed Medical Research Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of License And Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898234972488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text">The components of income tax expense (benefit) were as follows for the years ended December 31, 2021 and 2020, respectively (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2021 and 2020 as follows (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(17,171)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(15,985)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (benefit), net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (FIN 48)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision true-ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred income taxes were as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred income tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">43,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">27,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,897&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,880&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(58,528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(39,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,369)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,793)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,155&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898324150728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock', window );">Schedule of Operating Lease, by Balance Sheet Location</a></td>
<td class="text">The right-of-use asset and operating lease liability as of December&#160;31, 2021 and 2020 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,338&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,831&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Maturity</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under operating leases are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.586%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,707&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset And Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898243600392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Conversion of outstanding warrants to purchase convertible preferred stock into common stock (in shares)</a></td>
<td class="nump">7,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="nump">7,211,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="nump">7,211,086<span></span>
</td>
<td class="nump">7,211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2019And2020ConvertiblePromissoryNotesMember', window );">2019 and 2020 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2019And2020ConvertiblePromissoryNotesMember', window );">2019 and 2020 Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Issuance of shares of common stock after conversion (in shares)</a></td>
<td class="nump">4,294,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="nump">$ 125.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2019And2020ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2019And2020ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898235582696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2020</div></th>
<th class="th">
<div>May 11, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>lease </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>lease </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.5753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (227,147,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (227,147,000)<span></span>
</td>
<td class="num">$ (145,379,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,301,000<span></span>
</td>
<td class="nump">128,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_SaleOfStockCommonStockAuthorized', window );">Common stock offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from the Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DeferredFederalPayrollTaxesCARESAct', window );">Deferred payment of federal payroll taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments associated with equity offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_NumberOfOperatingLeasesHeld', window );">Number of operating leases held | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering', window );">Costs associated with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inbx_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_SaleOfStockSharesCommonStockSold', window );">Common stock shares sold (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_PaycheckProtectionProgramCARESActMember', window );">PPP Loan | Notes Payable, Other Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from the Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inbx_PhylaxisBioScienceLLCMember', window );">Phylaxis BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliates | WuXi Biologics Healthcare Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementTerm', window );">Collaborative arrangement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DeferredFederalPayrollTaxesCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Federal Payroll Taxes, CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DeferredFederalPayrollTaxesCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_NumberOfOperatingLeasesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Leases Held</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_NumberOfOperatingLeasesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of Stock Issuance Costs, Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_SaleOfStockCommonStockAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Common Stock, Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_SaleOfStockCommonStockAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_SaleOfStockSharesCommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Shares, Common Stock Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_SaleOfStockSharesCommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inbx_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inbx_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inbx_PhylaxisBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inbx_PhylaxisBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inbx_WuXiBiologicsHealthcareVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inbx_WuXiBiologicsHealthcareVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242356424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=inbx_WarrantAndDerivativeLiabilitiesMember', window );">Warrant And Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 1,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Establishment of liabilities</a></td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of liabilities</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification', window );">Reclassification of liabilities into equity</a></td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020ConvertiblePromissoryNoteMember', window );">2020 Convertible Note | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Establishment of liabilities</a></td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2019And2020ConvertiblePromissoryNotesMember', window );">2019 and 2020 Notes | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of liabilities</a></td>
<td class="num">$ (2,651)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=inbx_WarrantAndDerivativeLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=inbx_WarrantAndDerivativeLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2019And2020ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2019And2020ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898241011464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">4,071,000<span></span>
</td>
<td class="nump">2,532,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">4,064,000<span></span>
</td>
<td class="nump">2,525,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242040072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Outside research and development services</a></td>
<td class="nump">$ 6,343<span></span>
</td>
<td class="nump">$ 2,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="nump">$ 6,933<span></span>
</td>
<td class="nump">$ 2,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898235467720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 7,564<span></span>
</td>
<td class="nump">$ 6,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(4,411)<span></span>
</td>
<td class="num">(3,365)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,153<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">6,286<span></span>
</td>
<td class="nump">5,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">441<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240828280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 1,195<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898240886408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_AccruedClinicalResearchAndDevelopmentCurrent', window );">Clinical research and development</a></td>
<td class="nump">$ 4,496<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent', window );">Accrued Outside Research And Development, Other, Current</a></td>
<td class="nump">2,893<span></span>
</td>
<td class="nump">10,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation expense</a></td>
<td class="nump">1,322<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">649<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 9,621<span></span>
</td>
<td class="nump">$ 13,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AccruedClinicalResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AccruedClinicalResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Outside Research And Development, Other, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898236445848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 12, 2020 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Jul. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,992<span></span>
</td>
<td class="nump">$ 29,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended', window );">Equal payments of principal and interest period if interest only period is extended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember', window );">Warrants Issued Concurrently With 2020 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued', window );">Common or preferred stock warrants issued as a percent of funded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_WarrantsAndRightsOutstandingLiability', window );">Warrants issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember', window );">Warrants Issued Concurrently With 2020 Loan Agreement | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember', window );">2020 Oxford Term Loans Term B, Term C &amp; Tranche 1 of Term A | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt | Warrants Issued Upon Consummation of IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable for shares of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,354<span></span>
</td>
<td class="nump">7,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheOneMember', window );">Amended 2020 Oxford Term Loan Tranche One | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanMember', window );">Amended 2020 Oxford Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentAmendmentFee', window );">One-time first amendment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentNumberOfAdditionalTranches', window );">Number of additional tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches', window );">Aggregate principal amount of additional tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue', window );">Percentage of principal amount for final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Periodic payment terms, final payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanMember', window );">Amended 2020 Oxford Term Loan | Secured Debt | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheTwoMember', window );">Amended 2020 Oxford Term Loan Tranche Two | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanJune2021AmendmentMember', window );">Amended 2020 Oxford Term Loan June 2021 Amendment | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentMinimumCashBalance', window );">Minimum cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2015OxfordTermLoansMember', window );">2015 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Percentage Of Funded Amount Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Aggregate Principal Amount of Additional Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentAmendmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amendment Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentAmendmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Minimum Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentNumberOfAdditionalTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Additional Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentNumberOfAdditionalTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period if Interest-Only Period Is Extended</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_WarrantsAndRightsOutstandingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_WarrantsAndRightsOutstandingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsIssuedUponConsummationOfIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsIssuedUponConsummationOfIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanJune2021AmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanJune2021AmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2015OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2015OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898243629400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details) - Secured Debt - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">2020 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">$ 76,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Debt discount</a></td>
<td class="num">(5,830)<span></span>
</td>
<td class="num">$ (3,456)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">70,470<span></span>
</td>
<td class="nump">29,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion, including debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, including debt discount</a></td>
<td class="nump">70,470<span></span>
</td>
<td class="nump">29,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">10,900<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">21,800<span></span>
</td>
<td class="nump">21,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">$ 43,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoanCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoanCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898235530456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Future Minimum Payments (Details) - 2020 Loan Agreement - Secured Debt - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">$ 76,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total future minimum payments</a></td>
<td class="nump">76,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt discount</a></td>
<td class="num">(5,830)<span></span>
</td>
<td class="num">$ (3,456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 70,470<span></span>
</td>
<td class="nump">$ 29,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898234706920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">16 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>May 20, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Other income related to changes in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,651,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ReversalOfUnamortizedBeneficialConversionFeature', window );">Reversal of unamortized BCF</a></td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Other income related to changes in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Charge of amortized debt issuance costs to interest expense</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2019ConvertiblePromissoryNoteMember', window );">2019 Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ReversalOfUnamortizedBeneficialConversionFeature', window );">Reversal of unamortized BCF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2019ConvertiblePromissoryNoteMember', window );">2019 Convertible Note | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ReversalOfUnamortizedBeneficialConversionFeature', window );">Reversal of unamortized BCF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2019ConvertiblePromissoryNoteMember', window );">2019 Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note monthly interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 14.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Issuance of shares of common stock after conversion (in shares)</a></td>
<td class="nump">3,046,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts</a></td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020ConvertiblePromissoryNoteMember', window );">2020 Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ReversalOfUnamortizedBeneficialConversionFeature', window );">Reversal of unamortized BCF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020ConvertiblePromissoryNoteMember', window );">2020 Convertible Note | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ReversalOfUnamortizedBeneficialConversionFeature', window );">Reversal of unamortized BCF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020ConvertiblePromissoryNoteMember', window );">2020 Convertible Note | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note monthly interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 12.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Issuance of shares of common stock after conversion (in shares)</a></td>
<td class="nump">1,248,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ReversalOfUnamortizedBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal of Unamortized Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ReversalOfUnamortizedBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2019ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2019ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242654456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_SaleOfStockCommonStockAuthorized', window );">Common stock offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CommonStockSaleOfStockCommissionPercent', window );">Commission percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_AtTheMarketOfferingCosts', window );">At the market offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inbx_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_SaleOfStockSharesCommonStockSold', window );">Common stock shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Commissions costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsIssuedUponConsummationOfIPOMember', window );">Warrants Issued Upon Consummation of IPO | 2020 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable for shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,354<span></span>
</td>
<td class="nump">7,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="nump">7,211,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AtTheMarketOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At The Market Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AtTheMarketOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CommonStockSaleOfStockCommissionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Sale Of Stock Commission, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CommonStockSaleOfStockCommissionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_SaleOfStockCommonStockAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Common Stock, Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_SaleOfStockCommonStockAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_SaleOfStockSharesCommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Shares, Common Stock Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_SaleOfStockSharesCommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inbx_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inbx_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsIssuedUponConsummationOfIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsIssuedUponConsummationOfIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898235473832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS - Narrative (Details) - USD ($)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available shares reserved for issuance (in shares)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of recognition</a></td>
<td class="text">3 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Cliff Vesting | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242517320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS - Stock Option Activity (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">2,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">4,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares) | shares</a></td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">32.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">23.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">11.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">22.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM, Vested and exercisable</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">AGGREGATE INTRINSIC VALUE Beginning value | $</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">AGGREGATE INTRINSIC VALUE Ending value | $</a></td>
<td class="nump">$ 87,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">AGGREGATE INTRINSIC VALUE, Vested and exercisable | $</a></td>
<td class="nump">$ 40,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898244631432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value (in dollars per share)</a></td>
<td class="nump">$ 24.20<span></span>
</td>
<td class="nump">$ 10.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">93.49%<span></span>
</td>
<td class="nump">97.72%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898244632248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details) - Stock Option - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 15,048<span></span>
</td>
<td class="nump">$ 5,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">11,830<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,218<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898243561576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND GRANT REVENUES - Revenue Summary (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,231,000<span></span>
</td>
<td class="nump">$ 12,888,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseAffiliateMember', window );">License fee revenue, affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseAffiliateMember', window );">License fee revenue, affiliates | Elpiscience Biopharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,125,000<span></span>
</td>
<td class="nump">10,808,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates | 2seventy bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates | Phylaxis BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,392,000<span></span>
</td>
<td class="nump">1,993,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates | Chiesi Farmaceutici S.p.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,000<span></span>
</td>
<td class="nump">7,365,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates | Other license revenues from non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Congressionally Directed Medical Research Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inbx_LicenseAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inbx_LicenseAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_A2seventyBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_PhylaxisBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_PhylaxisBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_ChiesiFarmaceuticiSpAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_ChiesiFarmaceuticiSpAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_OtherCustomersNotSeparatelyDisclosedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_OtherCustomersNotSeparatelyDisclosedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898230796040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)<br></strong></div></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>compound </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>performanceObligation </div>
<div>license </div>
<div>program</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 19, 2019 </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Dec. 20, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,231,000<span></span>
</td>
<td class="nump">$ 12,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,034,000<span></span>
</td>
<td class="nump">3,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember', window );">License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,125,000<span></span>
</td>
<td class="nump">10,808,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseAffiliateMember', window );">License fee revenue, affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inbx_PhylaxisBioScienceLLCMember', window );">Phylaxis BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled', window );">Additional equity interest percentage entitled to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_PhylaxisBioScienceLLCMember', window );">Phylaxis BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable', window );">Development milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementAdditionalPaymentReceivable', window );">Additional payable due from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod', window );">Additional payment receivable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementCommercializationMilestoneReceivable', window );">Commercialization milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementPaymentReceivable', window );">Payments due pursuant to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_RevenueRecognitionNumberOfCompounds', window );">Number of compounds | compound</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_PhylaxisBioScienceLLCMember', window );">Phylaxis BioScience, LLC | License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,392,000<span></span>
</td>
<td class="nump">1,993,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized related to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable', window );">Development milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses', window );">Exclusive development license | license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc. | License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc. | Initial Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement', window );">Number of programs related to collaborative agreement | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc. | Initial Programs, Program 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc. | Initial Programs, Program 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc. | Additional Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement', window );">Number of programs related to collaborative agreement | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc. | 2018 Option and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc. | 2018 Option and License Agreement | License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc. | 2020 Option And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee', window );">Option extension fee</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc. | 2020 Option And License Agreement | License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_ChiesiFarmaceuticiSpAMember', window );">Chiesi Farmaceutici S.p.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementMilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementAdditionalPaymentReceivable', window );">Additional payable due from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_ChiesiFarmaceuticiSpAMember', window );">Chiesi Farmaceutici S.p.A. | License fee revenue, non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,000<span></span>
</td>
<td class="nump">7,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized related to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience Biopharmaceuticals, Inc. | License fee revenue, affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience Biopharmaceuticals, Inc. | OX40 License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementMilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_CelgeneMember', window );">Celgene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable', window );">Development milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 934,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay', window );">Percentage due to advisors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeAgreementExclusiveDevelopmentLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Exclusive Development Licenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeAgreementExclusiveDevelopmentLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number Of Related Programs To Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementAdditionalPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementAdditionalPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Payment Receivable Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementCommercializationMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Commercialization Milestone Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementCommercializationMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Development Milestone Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementDevelopmentMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payments Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementNonrefundableOptionExtensionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Nonrefundable Option Extension Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementNonrefundableOptionExtensionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementNonrefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Nonrefundable Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementNonrefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Percentage Of Future Amounts Received, Obligation to Pay Advisors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_EquityMethodInvestmentAdditionalOwnershipEntitled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Additional Ownership Entitled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_EquityMethodInvestmentAdditionalOwnershipEntitled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_RevenueRecognitionNumberOfCompounds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Number Of Compounds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_RevenueRecognitionNumberOfCompounds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inbx_LicenseAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inbx_LicenseAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inbx_PhylaxisBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inbx_PhylaxisBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_PhylaxisBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_PhylaxisBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_A2seventyBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementInitialProgramsAuthorizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementInitialProgramsAuthorizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementAdditionalProgramsAuthorizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementAdditionalProgramsAuthorizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inbx_A2018OptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inbx_A2018OptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inbx_A2020OptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inbx_A2020OptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_ChiesiFarmaceuticiSpAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_ChiesiFarmaceuticiSpAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inbx_LicenseAffiliateOX40LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inbx_LicenseAffiliateOX40LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_CelgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_CelgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898243560808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND GRANT REVENUES - Government Grants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,231<span></span>
</td>
<td class="nump">$ 12,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember', window );">Congressionally Directed Medical Research Program, 2018 Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_GrantValuedAwarded', window );">Grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember', window );">Congressionally Directed Medical Research Program, 2021 Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_GrantValuedAwarded', window );">Grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Congressionally Directed Medical Research Program, 2018 Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Congressionally Directed Medical Research Program, 2021 Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_RevenuesCashReceived', window );">Revenue recognized, cash</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Congressionally Directed Medical Research Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_GrantValuedAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant, Valued Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_GrantValuedAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_RevenuesCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Cash Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_RevenuesCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898234940696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience Biopharmaceuticals, Inc. | Sale And Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod', window );">Liabilities derecognized from agreements</a></td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementReceivablesFromRelatedParties', window );">Receivables from related parties</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience Biopharmaceuticals, Inc. | OX40 License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ExpensesReimbursedToDate', window );">Reimbursement for related party transaction expenses incurred to date</a></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Receivable for expenses incurred, not yet reimbursed</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ExpensesExpectedToBeReimbursed', window );">Expenses expected to be reimbursed</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementExpenseReimbursement', window );">Reimbursement expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod', window );">Liabilities derecognized from agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember', window );">Elpiscience Biopharmaceuticals, Inc. | OX40 License Agreement | Cost Sharing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ExpensesReimbursedToDate', window );">Reimbursement for related party transaction expenses incurred to date</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementExpenseReimbursement', window );">Reimbursement expenses</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod', window );">Liabilities derecognized from agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_CollaborativeArrangementReceivablesFromRelatedParties', window );">Receivables from related parties</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliates | LAV Summit Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_RelatedPartyEquityInterestInCompany', window );">Ownership interest, more than</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementExpenseReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Expense Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementExpenseReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementReceivablesFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Receivables from Related Parties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementReceivablesFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Derecognized During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ExpensesExpectedToBeReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses Expected to be Reimbursed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ExpensesExpectedToBeReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ExpensesReimbursedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses Reimbursed To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ExpensesReimbursedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_RelatedPartyEquityInterestInCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party , Equity Interest In Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_RelatedPartyEquityInterestInCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_ElpiscienceBiopharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=inbx_SaleAndPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=inbx_SaleAndPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inbx_LicenseAffiliateOX40LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inbx_LicenseAffiliateOX40LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=inbx_CostSharingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=inbx_CostSharingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inbx_LAVSummitLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inbx_LAVSummitLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898237016168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax asset valuation allowance</a></td>
<td class="nump">$ 58,528,000<span></span>
</td>
<td class="nump">$ 39,087,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">2,846,000<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">$ 1,499,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrual for interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Recognized interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">198,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242434664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242103032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at federal statutory rate</a></td>
<td class="num">$ (17,171)<span></span>
</td>
<td class="num">$ (15,985)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense (benefit), net of federal benefit</a></td>
<td class="num">(1,006)<span></span>
</td>
<td class="nump">4,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(207)<span></span>
</td>
<td class="nump">2,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">R&amp;D credits</a></td>
<td class="num">(1,912)<span></span>
</td>
<td class="num">(2,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Unrecognized tax benefits (FIN 48)</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps', window );">Return to provision true-ups</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">19,442<span></span>
</td>
<td class="nump">11,156<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Permanent Items</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Return to Provision True-Ups</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898230725720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of net deferred income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred income tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 43,440<span></span>
</td>
<td class="nump">$ 27,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">8,539<span></span>
</td>
<td class="nump">6,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">3,875<span></span>
</td>
<td class="nump">4,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock compensation</a></td>
<td class="nump">1,888<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">59,897<span></span>
</td>
<td class="nump">40,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(58,528)<span></span>
</td>
<td class="num">(39,087)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">1,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(1,349)<span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,369)<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898242535080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,155<span></span>
</td>
<td class="nump">$ 1,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,846<span></span>
</td>
<td class="nump">$ 2,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898243590024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_LesseeOperatingLeaseSquareFootage', window );">Square footage of lease agreement (in sq feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth', window );">Initial base rent per month | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_LesseeOperatingLeaseAnnualEscalations', window );">Annual escalations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_LesseeOperatingLeaseSquareFootageExpansion', window );">Square footage of lease extension agreement (in sq feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense | $</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining term of operating lease</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LesseeOperatingLeaseAnnualEscalations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Escalations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LesseeOperatingLeaseAnnualEscalations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Initial Base Rent Expense Per Month</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LesseeOperatingLeaseSquareFootage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Square Footage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LesseeOperatingLeaseSquareFootage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LesseeOperatingLeaseSquareFootageExpansion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Square Footage Expansion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LesseeOperatingLeaseSquareFootageExpansion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898244483320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 6,338<span></span>
</td>
<td class="nump">$ 7,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,674<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liability</a></td>
<td class="nump">5,033<span></span>
</td>
<td class="nump">6,707<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 6,707<span></span>
</td>
<td class="nump">$ 8,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898234942024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Operating Lease Liability Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 2,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">7,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">6,707<span></span>
</td>
<td class="nump">$ 8,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of operating lease liability</a></td>
<td class="num">(1,674)<span></span>
</td>
<td class="num">(1,503)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liability</a></td>
<td class="nump">$ 5,033<span></span>
</td>
<td class="nump">$ 6,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898234539816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_AccruedClinicalResearchAndDevelopmentCurrent', window );">Clinical research and development</a></td>
<td class="nump">$ 4,496<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_PurchaseCommitmentNonCancellablePortionOfContract', window );">Non-cancellable portion of contract</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts', window );">Expenses related to agreements</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">30,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember', window );">Purchase Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_AccruedClinicalResearchAndDevelopmentCurrent', window );">Clinical research and development</a></td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AccruedClinicalResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AccruedClinicalResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Expenses Incurred Related to Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_PurchaseCommitmentNonCancellablePortionOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Non-cancellable Portion of Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_PurchaseCommitmentNonCancellablePortionOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139898235634648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 18, 2022 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 12, 2020 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,307,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Award granted, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,992<span></span>
</td>
<td class="nump">$ 29,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended', window );">Equal payments of principal and interest period if interest only period is extended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanMember', window );">Amended 2020 Oxford Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentNumberOfAdditionalTranches', window );">Number of additional tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches', window );">Aggregate principal amount of additional tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentAmendmentFee', window );">One-time first amendment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue', window );">Percentage of principal amount for final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanMember', window );">Amended 2020 Oxford Term Loan | Secured Debt | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheOneMember', window );">Amended 2020 Oxford Term Loan Tranche One | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheTwoMember', window );">Amended 2020 Oxford Term Loan Tranche Two | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Cliff Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum', window );">Upfront partnership proceeds</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod', window );">Equal payments of principal and interest period</a></td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended', window );">Equal payments of principal and interest period if interest only period is extended</a></td>
<td class="text">11 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued (in shares) | shares</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 45.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended 2020 Oxford Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentNumberOfAdditionalTranches', window );">Number of additional tranches | tranche</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches', window );">Aggregate principal amount of additional tranches</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentAmendmentFee', window );">One-time first amendment fee</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentNumberOfExistingTranches', window );">Number of existing tranches | tranche</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue', window );">Percentage of principal amount for final payment</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended 2020 Oxford Term Loan | Secured Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended 2020 Oxford Term Loan | Secured Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_inbx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended 2020 Oxford Term Loan | Secured Debt | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">8.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended 2020 Oxford Term Loan Tranche One | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended 2020 Oxford Term Loan Tranche Two | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended 2020 Oxford Term Loan Tranche Three | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended 2020 Oxford Term Loan Tranche Four | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Award granted, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Stock Option | Cliff Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Aggregate Principal Amount of Additional Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentAmendmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amendment Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentAmendmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentNumberOfAdditionalTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Additional Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentNumberOfAdditionalTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentNumberOfExistingTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Existing Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentNumberOfExistingTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period if Interest-Only Period Is Extended</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Only Payment Extension Requirement, Upfront Partnership Proceeds Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_Amended2020OxfordTermLoanTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>inbx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:inbx="http://inhibrx.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="inbx-20211231.xsd" xlink:type="simple"/>
    <context id="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i506355bc91dc4a3382f883e168444b20_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1db365e9d856446db31cae19f9e0e5db_I20220221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2022-02-21</instant>
        </period>
    </context>
    <context id="ibd9dfc54d94543ba8698368d96961d03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1d11895fa0442ea81f055db5e18f8a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11f52d64e8c349e58d874face32a65a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i250f7e2f155f413297fef8b19d430be2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8fd1e8d9a53a428686d8938f450e798b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f5f2867b4374b8392c13581eb930e33_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25366f43bada4f5b9d53d088a682e118_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie64d22ae265b44358c9e947a1a1b1c0c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6373c936330246fe88c309a40939f56e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3c545895ca04258955cb754430080ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id881f495b72943148f25b6840685d537_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9ec9949e1e248ccab71a11e6c1074bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50251df3c1c54c87b2d175fa7d628143_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6bb7bb32c3f343c8a327751ee96ff5a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e88fbcb34b14703a4c85b9f232b78bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id726b7dd9036485d8c990a47cc6bd3d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida37a3d3907b43bd835289673510cd62_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0952c59ab2f14ce9a7f5f4f4bab1f608_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ceb6a7800114c0f80544f3e11e04a59_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72afbdbf0e414c5caaa6e4ab484a62f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9f6557dde914ba196b748270c390563_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e858246ea634ea3904ae0efa91f93ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3dfd538e45ac47328f0a920dcb4c0614_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9db515ef6fb84613872d16729bbfc6bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c768226360e440e85d40981d2a3a347_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idaf0841293054a07bd73deb9e8af0344_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i932ae73c06e44acab39c531ada30fa22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i722a3c1036664a1db19bf1f1b8c8ef4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d39a168fc3a432aa5b6c0e2880ae017_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i782f77ab577843fa872a7b5b9541a230_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43e54c84aae74e828b9b94427b981d3e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5392c3f3d956465e9c4f2e9ee08ac5b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc6061b1a5654bd1a013f69ed4b79e27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b6686e2594645e0b104bd30c79c6ce2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c90406be53b4899a32eb757c4b6aa8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1f87c3827874f3ca0e19457894ec414_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inbx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d258a97d4684eaba513930d94729cd8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inbx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1c9a266f60c4664bc65b6877237a861_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79c55f122bda4d359fc762cce6002cc9_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i8177b8ffee4c4ea998a952b70d65e0ef_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="ib6cea0c2ca9441f79fe37eb6f7844b1d_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="iad4a6f2ea563431298cac685298bcd91_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="if28c89b4ce594ec18c2baa17251f5398_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i64129936be0b412b8e1d86243a3cc9f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inbx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90dfb0c9e29b4454ae5d3269b190a197_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inbx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i93fd390c8a614c1f8ea8dce7fbd6bbd1_D20200511-20200511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-11</startDate>
            <endDate>2020-05-11</endDate>
        </period>
    </context>
    <context id="i09e02f53cc2d44b4a25de925c223563e_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i39dd7198616e4871a04691df5d501376_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib7f3cbe060eb4e03859e4a074152ce82_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:WuXiBiologicsHealthcareVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i7ab52899837545d286948af053bb22a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc73af7586ed4a7893d2827190cc61ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i964a81d9b0a74c4191f65b0b105bd98e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb2b71a468364db0b76d16dcc40554c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i796767f501ce49c3aa17f0da608f9877_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie74f508386624bc591b2098160a4640a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71b075ff878e44c4922334a3be94c8cf_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="icc9931e7028244ecadfcd288d792171d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibcd205c8ba4b4294b112ca3f590109b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa5894f258e64ee787243df2040ca6d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibca4cb805a4d45438e207a1536816957_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">inbx:WarrantAndDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iead2791fae4b4da59253032bf7b42e47_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb4707fb2959449d9321c8c1488e1c19_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ab110f9486a46d7bc11aaaf0bf87703_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019And2020ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b34f949eb8d495c9c9f5c2ff130ba51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">inbx:WarrantAndDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18dec53bcc4c412abadbaa5a71931d50_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i7cbc8f3cc82e45b1b819d385f0420fab_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="i37602c9d5ed8495cb15a8ef8ddaa15dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i170482e872e54fa3a75fd05af40e0ac9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd52f475273e436dbd8c13baa139f7ff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c0b54c2dda34749b9b0940bc4d42110_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d96c21dec494881b4a6b19595e76848_D20200811-20200811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="i1710f2bbed1f4858b4386673f448cffe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i020ea95670924586b00a510e94318bdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08ee0abef7874f9db4990a4e94b36a2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib53e4b677a5742fd983bfb37b3aa7e80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6a2d5f0e3c440ef8d989fed722504af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i377f66a6d4c54b4ca81d7975dd8a5c8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7242126f78fa4a8a8b9c857fce023330_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia33ae29820054b0db7fce225cab20805_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife5ab90e2a7d472080cd923e5b5db3b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c3c6503a73a4cb9beb9b3b8e12d0fc5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib9a2ae527c6442f69033f87496c9e149_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad61546aa39a46a6ab37a1278118f591_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icfda6bf472bc49e48b735e5c112a0531_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d71b0c7c95e4b21a9fd208c7d3fa8c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5bbe9a1a4e50490a8f0a1b8d2384b65d_D20200715-20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansTermBTermCTranche1OfTermAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-15</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="if9d0faac086f48b49f67f4291eb50af5_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="ibe5a8c4c13b647ba8a99cfbad3d44b0f_D20201112-20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-12</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="i51f1dd4556c84be1903e4fccae311a27_I20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="i822a1c2899dd422882f0c3c6958c8b78_D20201112-20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-12</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="ie0e9b67a1f98416d947e940d51019a13_D20201112-20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-12</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="if4dee1f4dab044b5904819f8b2634e06_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanJune2021AmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ib7b1a7a708534f06a0a7d794a7a27a80_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanJune2021AmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="i1a0d6e3138bb4cb6ba9620a8eee4bbd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23f05621867b46ba85b04d8f1e06e75d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i921b6c207f2a4f428b2e98a2c7602eaa_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="ida7de870e3734f6f8e5b74fa33367059_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="i546e91723e584f938387442db9ab32f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea06729df7364389bb97b7cac1e9cfad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66ddad33eb12403ab966960a6f430d69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0e8046ea9e74b1c96aee8f24c431683_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic890278d955442b5a665ca0900a0a5e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cfb99837e104069a050c050a6a0e015_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoanCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idde9aa5844664a6f8c3890232bb1f19a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbed81cbbbc44ceca46d67906a40279c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0171f114a2a6466ebf29d4bf342dc328_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanJune2021AmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabd8bb82f3c443ae89d9b90d7796e52b_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsIssuedConcurrentlyWith2020LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="i80af9778e30f4d7c8c60c10f21011485_I20200715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsIssuedConcurrentlyWith2020LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-15</instant>
        </period>
    </context>
    <context id="id95bef5f495646d58a4ab12c5852afc4_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsIssuedUponConsummationOfIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i4d74b118fa384d7ebae249afc60e4626_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsIssuedUponConsummationOfIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6f93dd1e5494e218459effec8912900_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsIssuedUponConsummationOfIPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51d5eb374e764a38a5a2883487e16341_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4dec658dfa294ef580b787eaea9c9e61_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bd2ea5f3b8d4063b55ea5ac924b3bc2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2015OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i903596dda51b4295ba537cb047cbe3ee_I20190520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-20</instant>
        </period>
    </context>
    <context id="ice2d978f42f647d0b34ffd2d606a3b23_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i5b2c31362ca6456e9fa354eb0012a302_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i9912d0eb770b4de0a793e3fe42d493b4_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="if68d1087bb6f4d22995e04dde84541a0_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i09b542f567974ce98531ed6d78bdcb08_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="ie129391072864eaa854b90a526c15513_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i0784cd66e4954bd983b5bf6086ef67c6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id39de78949fa4338b856a1bf1a370fbf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88c0a33aee14452581d9c884594cd5aa_D20190501-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2019ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="ib9c4b992959d4ddb90aad9b4d5df22bb_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i3c9b6bfda5d34fbca767a5fbbe17acf7_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="ic8eef267ef1c487289aaf7cbf76447dd_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i61137fd603eb42ea8e17d095c0e1c8a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e02f9252cd34ce2b7cec9630fc0647c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c6895eb15134795b9d0e82c56053e76_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i06da7c90c85744e885809060c5d6303c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f544045b0fb4204a60d3d67976ede93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i48c28eaf2c8c46e5bee554a6274ee022_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a6aef8263df4b4394e27acda74d8862_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5d9970bae2c434f937ba92ef27c5adf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i341109abd16e4f10b4e1e65b6337432b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11c3275369d04c28ab7b49526e64a396_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i142ace6beb0a4e0cb0a31bdafc6073cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ec1fc7e08a643bf8e0ed329426540bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd9873f9e3a544e59ad94ffcbdc43d0e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id7b7601189b5477d86501a51b482aa63_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if36de08aad5f467f9e693d3ede931b29_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a51291642f448ec8cd027ba449ffffc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifcea0ecd9c6b41f78dbf074f597078d2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9dd518d0ffae4538a37e20dd37eef51e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:OtherCustomersNotSeparatelyDisclosedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ff19098b1d84316ac86ea37db136e01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia4d0d09c00524dfa9503fde259f37888_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14792fc3ee614e638bfb3b224a160754_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia67376928e9f4157be200ec20b14f188_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6590e8fbc4694172ba86e9ff761b35b1_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="ib4809a9a893f4d2c8042ea8a8edf9689_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6a40dcc9d78543888f5c69df6b043678_I20181220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-20</instant>
        </period>
    </context>
    <context id="i698dae32d5a249e4b3a18d5a9465c4eb_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2018OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i271fbcd059344d279776e92017e48fd9_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2018OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i09040213ce284863b236dce6b9e77648_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2018OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia212ff07ac3d4e76acd885a467fdf19e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2018OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e2033a7016a444c9b438b2366300cfe_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1083dfcb25d248699e857f5dda8cb53e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementAdditionalProgramsAuthorizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifcfc29d4ec6340358e01e8204eb73565_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedProgramOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i99c1b2eab0714268ae2f91d921ac33bc_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedProgramTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i37061eba67bd4d3d915360e78477ab20_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i67acf789baa649c0af5372276d8d64e9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i26036eb0b6df49ce9df831623f43f4a3_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i89ce3eba7b0a49238928411c43819b44_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ic67e70a01a3247d0a701bceabea7050e_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i4c3132dfaadc4bcfaee034b1b2617d1c_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i53c3843a1089489cba9c3e221a109e69_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i029f0471f2e849158f5ea613d5e42420_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8577557b2c0f4aff994327f2da3dcc87_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:A2020OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie48c123d39ec4759bab8a2b5f5a6d11b_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="if7901dde9ee1429db2a92db83900b165_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="iae6ad83c5ab34b7fa1f535c9d4959c05_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iafffed7f22504c3dbc95651d314d0c59_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i8db766ee7ea14809bda578860b7d5f45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3960dc6272747bc82dddb1552b4d038_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65490e5c0be44ba79b6d213cefb118a6_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i52cdafa4cb7a4f99adc30a5a1c93624f_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i232e3ecd8bfe4c2aa8c2c245ad98b7c9_I20190819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-19</instant>
        </period>
    </context>
    <context id="i9dfab9b39f19493b85149f07e9d3107b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iecd1fc01bfe349e38bce8388ae5742cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ChiesiFarmaceuticiSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b51a3f85ef8434cbdc45bc15a773289_I20130630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:CelgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-06-30</instant>
        </period>
    </context>
    <context id="i29ef6bdd06234b22b93dd43c5eff449b_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i7fbcce74ea2b42b78bf1705bd1403dfd_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="iad2111df94964e5485832ec9af0f84c0_D20181201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04bdb4d1a6f84aaaa9f1469326060cc7_D20210201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5bf66075080045f5ab3fa12625764cd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inbx:LAVSummitLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98668daa4f54447a8199b989b8876b3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if065b432564046c9bfb0a597fe817533_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ebe67fc2c1e4f268cfb5159168b291a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1d04a4699dc49db872fde8657a661e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">inbx:CostSharingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1308cbf39e914b3390c47254ceff94af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">inbx:CostSharingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3cfee3e7350642afb89fae53b611c85e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseAffiliateOX40LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">inbx:CostSharingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia72fe4742bba4cdf9802783a4d7a8394_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">inbx:SaleAndPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5a16567fbac48168a3ad10ee9c58f87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ElpiscienceBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">inbx:SaleAndPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2035d7358b324a5489bcf06a61d764cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieee515f8958047ef8b35c147f98db98e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd2cf3902be24fe99f49b14a22a00695_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61def5f79b3b4943a515f38e57f56fa7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83fc42be157249d68dc8368a8c9862be_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i521b2e3a6dc44d48afe6adc72a12b794_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="ic8432517eb8a474aa5bafe8e02511ce5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i272efd5ba40f48b3a36b628d2290dacc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">us-gaap:PurchaseCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6069ad52bbd94a97b38f0c5021430f66_D20220101-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="ibcbf97b5335e41168d1a299751595d81_D20220101-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="iacb6213d02d74a88b77cba676df9265a_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="i20fe34380fca42f098a2db8d31b3286a_D20220218-20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="i13753df759a242849113e207322baf72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41e7f4a47cd94673bc773402b7a5368e_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="id785c7ea3a28479b8b1ddfb99f5cb605_D20220218-20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="i12b78bb8be854db5b78e268e11b79ddd_D20220218-20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="i7e1a737421844578b29281dfff09e84f_D20220218-20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="iec65463072474a72bf5be2ef264db82a_D20220218-20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="i9b61d2e608d24c2eb1c1116a2a66abe6_D20220218-20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="i39dc64f1760d475e9b12a1ab87444d97_D20220218-20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="i4c6633104ca543ebbacf87abf6aea7fa_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="ic510443d218e4b0ab9d522e8d0b425fa_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:Amended2020OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="i693b3d23e36049d1b4d15aeac78e1972_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739614</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="lease">
        <measure>inbx:lease</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>inbx:segment</measure>
    </unit>
    <unit id="tranche">
        <measure>inbx:tranche</measure>
    </unit>
    <unit id="program">
        <measure>inbx:program</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>inbx:performanceObligation</measure>
    </unit>
    <unit id="license">
        <measure>inbx:license</measure>
    </unit>
    <unit id="compound">
        <measure>inbx:compound</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N180L2ZyYWc6NTQxOTFiZWQ2MDg1NDUxNzhmZjY4ZmNmZjFhYTE3NGMvdGFibGU6MjRkNjFjZmNmYTEyNGJmMWE5ZjM2YmQ1ODlkNjI1NDAvdGFibGVyYW5nZToyNGQ2MWNmY2ZhMTI0YmYxYTlmMzZiZDU4OWQ2MjU0MF8xLTEtMS0xLTI0Mzc2_8a26b592-5baf-4c34-8022-a7f1a8d4a2ac">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N180L2ZyYWc6NTQxOTFiZWQ2MDg1NDUxNzhmZjY4ZmNmZjFhYTE3NGMvdGFibGU6MjRkNjFjZmNmYTEyNGJmMWE5ZjM2YmQ1ODlkNjI1NDAvdGFibGVyYW5nZToyNGQ2MWNmY2ZhMTI0YmYxYTlmMzZiZDU4OWQ2MjU0MF8yLTEtMS0xLTI0Mzc2_919ce106-8354-410c-bf71-6aa105f1494a">0001739614</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N180L2ZyYWc6NTQxOTFiZWQ2MDg1NDUxNzhmZjY4ZmNmZjFhYTE3NGMvdGFibGU6MjRkNjFjZmNmYTEyNGJmMWE5ZjM2YmQ1ODlkNjI1NDAvdGFibGVyYW5nZToyNGQ2MWNmY2ZhMTI0YmYxYTlmMzZiZDU4OWQ2MjU0MF8zLTEtMS0xLTI0Mzc2_28f5fb87-dcc1-4a22-9b96-3a859e26b528">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N180L2ZyYWc6NTQxOTFiZWQ2MDg1NDUxNzhmZjY4ZmNmZjFhYTE3NGMvdGFibGU6MjRkNjFjZmNmYTEyNGJmMWE5ZjM2YmQ1ODlkNjI1NDAvdGFibGVyYW5nZToyNGQ2MWNmY2ZhMTI0YmYxYTlmMzZiZDU4OWQ2MjU0MF80LTEtMS0xLTI0Mzc2_589d44e8-1db9-4b55-aac4-a0c241f5230d">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7ab52899837545d286948af053bb22a6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDIx_fb18bef6-4644-4d4c-b39d-3e7398424521">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i964a81d9b0a74c4191f65b0b105bd98e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDYy_22f664cc-88d9-4893-a2bc-e342d557a1d4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i796767f501ce49c3aa17f0da608f9877_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNTAx_ac274eaf-b7f7-4024-9d85-68b4306ca0ff">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i2d96c21dec494881b4a6b19595e76848_D20200811-20200811"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTcvZnJhZzpjYWVjMDc1MzIwNWY0OWIyYmQ1ZmRmZjZmNzk3MTVmZi90YWJsZTpjZGI4YmViNDM2ODA0NWQ1YjY3MDNmODAyYjIyMDlmNC90YWJsZXJhbmdlOmNkYjhiZWI0MzY4MDQ1ZDViNjcwM2Y4MDJiMjIwOWY0XzEtMS0xLTEtMjQzNzY_53d67076-3cc4-4aeb-a4dc-02c4a9a23424"
      unitRef="number">0.5753</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6NzZhNzE3YTIwMjg5NGY0YzkwZTIxOTk3ZDhiMzg3NDQvdGFibGVyYW5nZTo3NmE3MTdhMjAyODk0ZjRjOTBlMjE5OTdkOGIzODc0NF8zLTEtMS0xLTI0Mzc2L3RleHRyZWdpb246YWU2NGQ5ZTUxMDk2NDE0Yjk1ZTM1NWFiODQzNjQ4NjNfOQ_9afbb0b1-a80b-4365-b5da-eaf03b1839a9">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzgy_4e969822-086d-4c16-a420-8c5fd5b84e97">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8xMzc_a8bf092b-a46a-49ea-abce-ea1b86cdce46">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8xMzc_395fc878-69e7-4a8b-88c1-71df42413678">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzgw_be59fb4d-5037-4547-bfc5-5e06ef71eff3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzg0_62bd804d-3cbe-4970-945d-64c7b99aa9e6">001-39452</dei:EntityFileNumber>
    <dei:EntityFileNumber
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzg0_b45bd50b-c011-4a49-846f-47aa6e7c13ee">001-39452</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl8xLTAtMS0xLTI0Mzc2_86640cf1-71c4-4d75-ab0c-1900e4301100">INHIBRX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl81LTAtMS0xLTI0Mzc2_c2ed7d89-e103-48ca-a7ca-8ce8d6029708">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl81LTItMS0xLTI0Mzc2_fa0e5c84-55ee-4740-a530-79fd6e004f8b">82-4257312</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl84LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246ZDY2YTAyODViYzljNDQ5YTk0Nzc5ODQxZDBjZTUxZjRfMTA5OTUxMTYyNzc4Nw_68180893-38b0-493b-ba63-10f2a6cb13a3">11025 N. Torrey Pines Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl84LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246ZDY2YTAyODViYzljNDQ5YTk0Nzc5ODQxZDBjZTUxZjRfMTA5OTUxMTYyNzc5MQ_68b00ca3-083e-4b4c-99b8-4ec77346ffdb">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl85LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YzFlNGQxZWUxM2FkNGM5ZWFmNjQyNDI2YTYyOWI2MDZfMTA5OTUxMTYyNzc4Nw_14a1c26f-ae09-4748-92c6-eded3a57350f">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl85LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YzFlNGQxZWUxM2FkNGM5ZWFmNjQyNDI2YTYyOWI2MDZfMTA5OTUxMTYyNzc5MQ_6f526b4d-795b-4dbf-9ef2-96d7f7eeeca0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl85LTItMS0xLTI0Mzc2L3RleHRyZWdpb246M2E0MjNlZGQxNTcxNGI5ZWIxNmQyOWI1NjZlYTdmYTBfMTA5OTUxMTYyNzc4Mw_c240a835-67fc-48d2-bcd9-b394c43d0c8f">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl8xMi0xLTEtMS0yNDM3Ni90ZXh0cmVnaW9uOjM1MGU1MTljZjRmNDQwM2FhYmI2ZWZiMGIyZmU0NTUxXzEwOTk1MTE2Mjc3ODY_c34e7f7d-e48e-4728-b0e0-e811a988e87b">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ODc5MTdkMmQ4NzBlNGI5YmI2NTMyMjg3MWQ1NGEzOWIvdGFibGVyYW5nZTo4NzkxN2QyZDg3MGU0YjliYjY1MzIyODcxZDU0YTM5Yl8xMi0xLTEtMS0yNDM3Ni90ZXh0cmVnaW9uOjM1MGU1MTljZjRmNDQwM2FhYmI2ZWZiMGIyZmU0NTUxXzEwOTk1MTE2Mjc3OTA_410bfcc7-8b66-4310-b9d8-1612162e1b35">795-4220</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6Y2Q0ZTVhNzhiMGUzNDRkY2IyNzZhNTJkMmIzZmUyZDIvdGFibGVyYW5nZTpjZDRlNWE3OGIwZTM0NGRjYjI3NmE1MmQyYjNmZTJkMl80LTAtMS0xLTI0Mzc2_d632f5a1-77b7-4a56-aeb9-f137a7a6026e">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6Y2Q0ZTVhNzhiMGUzNDRkY2IyNzZhNTJkMmIzZmUyZDIvdGFibGVyYW5nZTpjZDRlNWE3OGIwZTM0NGRjYjI3NmE1MmQyYjNmZTJkMl80LTItMS0xLTI0Mzc2_e87fe2de-9732-4728-b11f-31715e340b92">INBX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6Y2Q0ZTVhNzhiMGUzNDRkY2IyNzZhNTJkMmIzZmUyZDIvdGFibGVyYW5nZTpjZDRlNWE3OGIwZTM0NGRjYjI3NmE1MmQyYjNmZTJkMl80LTYtMS0xLTI0Mzc2_ec4a0304-ec41-4201-b838-c1b721646b04">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8xMDk5NTExNjMxNDcx_095d852a-9da0-4530-a2a6-896a224b11b4">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzc3_4d530756-e69e-4867-882f-dffdab06a997">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzc4_a56b5eac-f3e9-4c2a-a8d7-19f2917e13d6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzgz_71a5d61c-7a75-4f59-bcbf-a3b8a2a5b544">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ZmUwMThhZWY2Mjg1NDMxZDgwZTQwYjVjNDNiMzUwZTMvdGFibGVyYW5nZTpmZTAxOGFlZjYyODU0MzFkODBlNDBiNWM0M2IzNTBlM18wLTAtMS0xLTI2MDU5_62faa36f-bd2c-4306-8bee-e84372d5fc8a">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ZmUwMThhZWY2Mjg1NDMxZDgwZTQwYjVjNDNiMzUwZTMvdGFibGVyYW5nZTpmZTAxOGFlZjYyODU0MzFkODBlNDBiNWM0M2IzNTBlM18xLTQtMS0xLTI0Mzc2_fc31fdab-028e-4548-83b8-4ebdb19a2daf">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGFibGU6ZmUwMThhZWY2Mjg1NDMxZDgwZTQwYjVjNDNiMzUwZTMvdGFibGVyYW5nZTpmZTAxOGFlZjYyODU0MzFkODBlNDBiNWM0M2IzNTBlM18yLTQtMS0xLTI0Mzc2_a37a9ca8-3e30-4451-bed5-6033f6b369e6">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzc0_0aad8f27-edb6-4e52-8be8-076bc8cf94ce">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzg1_2311ae9d-79ed-4215-9d0e-5f28f83508fe">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i506355bc91dc4a3382f883e168444b20_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8yNTk3_3baed7e5-9d6c-434d-8bed-159cc0234edd"
      unitRef="usd">764300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1db365e9d856446db31cae19f9e0e5db_I20220221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8yOTUy_89fa544b-7a3b-4769-a9c3-f8f680c91ebd"
      unitRef="shares">39025644</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xL2ZyYWc6NzE5OTAzNzBkOTM3NDZmMWFlYmM5ZDc5NmEyNTdmMDIvdGV4dHJlZ2lvbjo3MTk5MDM3MGQ5Mzc0NmYxYWViYzlkNzk2YTI1N2YwMl8zMzgx_f736fd59-8e9c-42df-9c3f-905eb32a5f6d">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant&#x2019;s Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTMvZnJhZzo3Yzc5NWRmMTc1ZGU0NjhlOTY0NzEyYmVhNmJmYjBjNi90YWJsZToxNDM1OTVlYjY0NTc0MjhhODY0MThjMmJhMDk3ZjI4ZC90YWJsZXJhbmdlOjE0MzU5NWViNjQ1NzQyOGE4NjQxOGMyYmEwOTdmMjhkXzEtMC0xLTEtMzQxMTUvdGV4dHJlZ2lvbjo4ZTAxNWI0NjQ5NWU0OTY2YTBjYjMzNzg5ZTM5MDI3N180Mzk4MDQ2NTExMjY5_d9609a67-e28c-4f41-99e0-27966197da2f">BDO USA, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTMvZnJhZzo3Yzc5NWRmMTc1ZGU0NjhlOTY0NzEyYmVhNmJmYjBjNi90YWJsZToxNDM1OTVlYjY0NTc0MjhhODY0MThjMmJhMDk3ZjI4ZC90YWJsZXJhbmdlOjE0MzU5NWViNjQ1NzQyOGE4NjQxOGMyYmEwOTdmMjhkXzEtMC0xLTEtMzQxMTUvdGV4dHJlZ2lvbjo4ZTAxNWI0NjQ5NWU0OTY2YTBjYjMzNzg5ZTM5MDI3N180Mzk4MDQ2NTExMjkz_b9e85f22-8f56-45fb-9635-a9229340f83e">San Diego, California</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTMvZnJhZzo3Yzc5NWRmMTc1ZGU0NjhlOTY0NzEyYmVhNmJmYjBjNi90YWJsZToxNDM1OTVlYjY0NTc0MjhhODY0MThjMmJhMDk3ZjI4ZC90YWJsZXJhbmdlOjE0MzU5NWViNjQ1NzQyOGE4NjQxOGMyYmEwOTdmMjhkXzEtMC0xLTEtMzQxMTUvdGV4dHJlZ2lvbjo4ZTAxNWI0NjQ5NWU0OTY2YTBjYjMzNzg5ZTM5MDI3N180Mzk4MDQ2NTExMjU0_cb6dc922-4d04-45c1-b5d4-518848ed755f">243</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzQtMS0xLTEtMjQzNzY_f8d01533-86ff-43c0-b132-706f07f57404"
      unitRef="usd">131301000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzQtMy0xLTEtMjQzNzY_3d5fa1fb-e413-4604-9614-d0a108217cb8"
      unitRef="usd">128664000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzUtMS0xLTEtMjQzNzY_beb8e529-84f4-48fc-8065-9801196cc033"
      unitRef="usd">373000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzUtMy0xLTEtMjQzNzY_d98fba2e-2600-4cb4-a2e2-dd33d9890b8e"
      unitRef="usd">82000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzYtMS0xLTEtMjQzNzY_2e4f37f6-5ee3-4787-a07b-9e6a8a6ec75d"
      unitRef="usd">505000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzYtMy0xLTEtMjQzNzY_e4436b1f-ebba-448a-91c4-1849aff56d07"
      unitRef="usd">533000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzctMS0xLTEtMjQzNzY_1989006b-b3fb-422f-84f0-a3f3a7451c1f"
      unitRef="usd">6933000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzctMy0xLTEtMjQzNzY_0e79f3cb-02b2-4a0d-ac22-adcfd247627c"
      unitRef="usd">2893000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzgtMS0xLTEtMjQzNzY_4343ae53-a6ff-4532-8f58-883cb8d4638c"
      unitRef="usd">139112000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzgtMy0xLTEtMjQzNzY_59ac1402-b3f3-40dd-b9b3-ebbcf8c4760e"
      unitRef="usd">132172000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzktMS0xLTEtMjQzNzY_c97f355d-0bff-4bef-9416-57ac30911228"
      unitRef="usd">3153000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzktMy0xLTEtMjQzNzY_7f44f5ee-b5cd-4e6e-b764-f407dbabbe8d"
      unitRef="usd">3492000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzEwLTEtMS0xLTI0Mzc2_839207d0-8b71-414d-a282-59e7becd0351"
      unitRef="usd">6338000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzEwLTMtMS0xLTI0Mzc2_285dba90-5f40-4227-a1b5-5c8a4837bd33"
      unitRef="usd">7831000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzExLTEtMS0xLTI0Mzc2_61ff1d3a-82f2-4f56-b53b-29ce351d1c12"
      unitRef="usd">1847000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzExLTMtMS0xLTI0Mzc2_6ae18112-6b90-4f1d-bdb1-56473f85815d"
      unitRef="usd">245000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzEyLTEtMS0xLTI0Mzc2_9abe39ec-ed86-45e7-9aca-7d61077d3aec"
      unitRef="usd">150450000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzEyLTMtMS0xLTI0Mzc2_52434607-a90a-45c3-bc78-74b522602f48"
      unitRef="usd">143740000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE1LTEtMS0xLTI0Mzc2_93060ed1-4565-4d22-b57e-8a3f94f129f4"
      unitRef="usd">9125000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE1LTMtMS0xLTI0Mzc2_38ac31fc-a672-4f7e-b2e1-0ef713f9141a"
      unitRef="usd">13458000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE2LTEtMS0xLTI0Mzc2_40af3288-461a-4fbe-b33e-171085e6c3d6"
      unitRef="usd">9621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE2LTMtMS0xLTI0Mzc2_40147474-47a7-4c46-9fe5-79aac10d0c83"
      unitRef="usd">13357000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE3LTEtMS0xLTI0Mzc2_e9a7ecc4-90a8-42f8-ad92-3d661d59e7f1"
      unitRef="usd">2034000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE3LTMtMS0xLTI0Mzc2_79495a16-6447-45ec-9146-e39f8e9297a7"
      unitRef="usd">3081000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE5LTEtMS0xLTI0Mzc2_7e5b4042-401f-4389-abb6-8ebb0c02f1ba"
      unitRef="usd">1674000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzE5LTMtMS0xLTI0Mzc2_c22ae9fd-82fc-49a0-9a3d-b622f772d31b"
      unitRef="usd">1503000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzIxLTEtMS0xLTI0Mzc2_9fae8799-7a54-4845-a606-08329cdb802a"
      unitRef="usd">22454000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzIxLTMtMS0xLTI0Mzc2_f9896f00-859b-4f21-95a7-1cfe3c1eb7b5"
      unitRef="usd">31399000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI0LTEtMS0xLTI0Mzc2_2d70fb7f-29e5-48ab-a9a5-ba0f9d2a49ca"
      unitRef="usd">70470000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI0LTMtMS0xLTI0Mzc2_631a498c-4a5f-436c-a409-db055b5551b2"
      unitRef="usd">29244000</us-gaap:SecuredLongTermDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI2LTEtMS0xLTI0Mzc2_da44753f-11aa-4437-a73b-d0973f2e773a"
      unitRef="usd">5033000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI2LTMtMS0xLTI0Mzc2_af39e93c-93f9-44be-b60d-fc71a8b2a0a8"
      unitRef="usd">6707000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI3LTEtMS0xLTI0Mzc2_d10a9338-590e-42cd-9115-e1923e405c6b"
      unitRef="usd">110000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI3LTMtMS0xLTI0Mzc2_deb0041b-3636-4c36-a14d-241362568366"
      unitRef="usd">737000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI4LTEtMS0xLTI0Mzc2_6b674a56-dff8-4de9-9e31-19d26d53a0a8"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI4LTMtMS0xLTI0Mzc2_e626bd40-ceb4-459a-a882-a3a521ecb791"
      unitRef="usd">180000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI5LTEtMS0xLTI0Mzc2_62c1a190-d800-4344-9397-6130546defe2"
      unitRef="usd">98067000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzI5LTMtMS0xLTI0Mzc2_b14f0d2f-f8cf-4e45-813c-e11d61122039"
      unitRef="usd">68267000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMwLTEtMS0xLTI0Mzc2_94fe4402-b20e-4f3e-862f-9f68e876aa3b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMwLTMtMS0xLTI0Mzc2_afd3d958-dcd5-4351-a381-3a8fb6f62492"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk1Mg_a7630243-f690-45fe-8935-7d650e879392"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk1Mg_bb48a573-2baa-4dec-a1d2-9d07fb7c6fec"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk1Ng_4fc115ca-7e5d-48d4-b71f-f4737d9ebf53"
      unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk1Ng_ac5a9893-a016-4c4c-9207-aa2dee16888c"
      unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk2MA_271c0a9a-246f-4863-a398-0b239962408c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTAtMS0xLTI0Mzc2L3RleHRyZWdpb246NDBjMzdiNGMwNzEzNDMzMzk2MDhmZTA2MDM1YTFmODhfMTA5OTUxMTYyNzk2MA_e22ea9c6-04e3-4331-a40b-4d0540c1e7af"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTEtMS0xLTI0Mzc2_a1d780d8-e480-49ac-8e0a-8d3057d050aa"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzMzLTMtMS0xLTI0Mzc2_307ab21a-ad40-4ebe-9bfa-0b88e88b4035"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODAwMg_5bc9455d-0ce6-45ff-9066-0e4b53fbc6c0"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODAwMg_856e262b-884a-459e-a8b1-bf16014de57b"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODAwNg_728a6f2f-b6e3-4ab6-b525-c9dbd895c21c"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODAwNg_a89da7ca-ff8d-494f-86df-18539c274e69"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODA5MQ_46d15fae-6677-475c-a16b-d60a6a0742f7"
      unitRef="shares">38991307</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODA5MQ_fe2a905b-0e40-404e-81e9-42dd41ccefd7"
      unitRef="shares">38991307</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODE2MQ_dedb2eea-16c5-44d4-b3f7-ba9623a4c237"
      unitRef="shares">37712390</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTAtMS0xLTI0Mzc2L3RleHRyZWdpb246YjA1ZWNhYTAyZTYxNDAwNTg4ZjljNjNiMzA5MGVhOTVfMTA5OTUxMTYyODE2MQ_ff581712-f126-4949-a699-9064fc1386a9"
      unitRef="shares">37712390</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTEtMS0xLTI0Mzc2_1cb07c4e-f071-4e20-a13d-3f6e95f41fb9"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM0LTMtMS0xLTI0Mzc2_42630c33-c4b2-43a2-bb9e-9f0574d9abf7"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM1LTEtMS0xLTI0Mzc2_c56642fe-4dba-4a49-988b-d8a435e17cc0"
      unitRef="usd">279526000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM1LTMtMS0xLTI0Mzc2_8ff4d83d-c43e-47c3-b5a0-dbaad10bbb64"
      unitRef="usd">220848000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM2LTEtMS0xLTI0Mzc2_fa881fff-1013-4421-ba6f-6e887ffe81ec"
      unitRef="usd">-227147000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM2LTMtMS0xLTI0Mzc2_bd321dd3-df03-4a3b-b186-58e3a384ea95"
      unitRef="usd">-145379000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM3LTEtMS0xLTI0Mzc2_6d436754-9106-42db-9581-a7b661fd5cd9"
      unitRef="usd">52383000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM3LTMtMS0xLTI0Mzc2_35b40a06-254d-4ca5-acd9-2ea2c3de0c91"
      unitRef="usd">75473000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM4LTEtMS0xLTI0Mzc2_20c1fa42-3a24-4ae0-b066-6813071bdf7d"
      unitRef="usd">150450000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18xOTkvZnJhZzpkNGZjM2M0Mjg3NjU0MmYwODRhZjgyNjZiZTA5YzcyMS90YWJsZTpmZjBlN2MyNDNiOWQ0ZmJjODg1YWYxMGJmM2QzZmVkYi90YWJsZXJhbmdlOmZmMGU3YzI0M2I5ZDRmYmM4ODVhZjEwYmYzZDNmZWRiXzM4LTMtMS0xLTI0Mzc2_e0075662-d512-4955-8fc9-0d2351bec620"
      unitRef="usd">143740000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i11f52d64e8c349e58d874face32a65a0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzQtMS0xLTEtMjQzNzY_20aa4f94-cb0f-4d48-9b07-aa24500f47ce"
      unitRef="usd">7125000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i250f7e2f155f413297fef8b19d430be2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzQtMy0xLTEtMjQzNzY_8d1f0308-fae0-4d97-8843-25e7383109f3"
      unitRef="usd">12808000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8fd1e8d9a53a428686d8938f450e798b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzUtMS0xLTEtMjQzNzY_9fdef7c9-fe6d-41a7-bc12-a297c536ef3f"
      unitRef="usd">106000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f5f2867b4374b8392c13581eb930e33_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzUtMy0xLTEtMjQzNzY_b25842b4-a2ed-4e36-99d5-f5dd075aca7b"
      unitRef="usd">80000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzYtMS0xLTEtMjQzNzY_dd3f084d-06dd-4899-9817-70b82ab64cae"
      unitRef="usd">7231000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzYtMy0xLTEtMjQzNzY_da170539-af5c-40d9-9221-456fc74b5d59"
      unitRef="usd">12888000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzgtMS0xLTEtMjQzNzY_6caac2cb-646c-4717-98ad-8ae23646a30a"
      unitRef="usd">71440000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzgtMy0xLTEtMjQzNzY_2328fb62-fd66-4b50-ad78-c73074731846"
      unitRef="usd">73495000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzktMS0xLTEtMjQzNzY_d8898142-19f9-4601-a3f1-6d6208a1f437"
      unitRef="usd">12355000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzktMy0xLTEtMjQzNzY_db28cd14-e0fe-4a56-9a08-410db238fc3c"
      unitRef="usd">6836000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzExLTEtMS0xLTI0Mzc2_0f826bd9-d962-4beb-80da-656638239936"
      unitRef="usd">83795000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzExLTMtMS0xLTI0Mzc2_123a699e-8747-418f-b352-08071d062bba"
      unitRef="usd">80331000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzEyLTEtMS0xLTI0Mzc2_9746100e-05ce-4d01-ae5e-6c4c9b49cc04"
      unitRef="usd">-76564000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzEyLTMtMS0xLTI0Mzc2_86a06122-7d05-4142-ae1f-10b60693a8c5"
      unitRef="usd">-67443000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE0LTEtMS0xLTI0Mzc2_c145ca91-7800-4532-a148-1f7ba9af817b"
      unitRef="usd">-5216000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE0LTMtMS0xLTI0Mzc2_a4ec3bbc-525b-4624-ad03-65dbc5774bd7"
      unitRef="usd">-10816000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE1LTEtMS0xLTI0Mzc2_faf72f02-587c-4dd6-843a-0c28e0e253da"
      unitRef="usd">14000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE1LTMtMS0xLTI0Mzc2_b06011bd-973d-4c64-a64a-963e3ebb0a52"
      unitRef="usd">-2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE2LTEtMS0xLTI0Mzc2_ecd42d98-3c89-4157-9011-2833b584360e"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE2LTMtMS0xLTI0Mzc2_8d9cec93-10c6-40ed-b9a3-a6c4d40c7e51"
      unitRef="usd">24000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE3LTEtMS0xLTI0Mzc2_4ce94d8e-1579-4188-8776-25531e689b5f"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE3LTMtMS0xLTI0Mzc2_712bfc5d-ff21-4bb6-a3b4-68df3dee6921"
      unitRef="usd">2651000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE4LTEtMS0xLTI0Mzc2_aa757c30-b092-4297-b9c2-c3cf0330496a"
      unitRef="usd">-5202000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE4LTMtMS0xLTI0Mzc2_b1b73130-a961-4e21-a7f2-7fb5908a2dd9"
      unitRef="usd">-8191000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE5LTEtMS0xLTI0Mzc2_1f739c15-f2b9-4a54-bdc3-c9987051f59e"
      unitRef="usd">-81766000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzE5LTMtMS0xLTI0Mzc2_499966f6-a4ec-4d95-b802-29409b1b2819"
      unitRef="usd">-75634000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIwLTEtMS0xLTI0Mzc2_b416fc1f-824e-432c-9ac2-506bb592a578"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIwLTMtMS0xLTI0Mzc2_abdee66d-f137-408a-989f-efa11d27c4dc"
      unitRef="usd">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIxLTEtMS0xLTI0Mzc2_e43ffd13-000a-477a-b1d7-838a4f96e6ec"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIxLTMtMS0xLTI0Mzc2_8deecd1a-c684-4380-a4c8-d448eba3e153"
      unitRef="usd">-487000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIyLTEtMS0xLTI0Mzc2_f1d3706a-3766-4b58-87ea-0ddafd0b29d3"
      unitRef="usd">-81768000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIyLTMtMS0xLTI0Mzc2_40b729f2-fa28-4426-a9f0-1050e6372bb6"
      unitRef="usd">-76124000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIzLTEtMS0xLTI0Mzc2_2bf21325-3516-4d9b-a757-ecb2668d8662"
      unitRef="usdPerShare">-2.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIzLTEtMS0xLTI0Mzc2_b1a8a90d-7ab1-45a9-9af7-d0b3dde573d2"
      unitRef="usdPerShare">-2.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIzLTMtMS0xLTI0Mzc2_2048ec75-6059-40b4-9d0c-66ca44284d4a"
      unitRef="usdPerShare">-3.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzIzLTMtMS0xLTI0Mzc2_c51184a3-5ed1-40bf-8833-74d71aee3a4d"
      unitRef="usdPerShare">-3.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzI0LTEtMS0xLTI0Mzc2_67f50eef-1540-4c2a-8786-6360aece30ef"
      unitRef="shares">38010000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzI0LTEtMS0xLTI0Mzc2_7434fe73-a0ab-4823-911c-6b296718d0ad"
      unitRef="shares">38010000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzI0LTMtMS0xLTI0Mzc2_6776022e-c6d4-491f-a25a-8835ec124c38"
      unitRef="shares">25261000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDIvZnJhZzpiNmY3YjVlOWI0MzU0MTM2YmU5NGMwZDJmOTMxYzJjZi90YWJsZTo3YzRmNDAwNmMyY2M0ZjdkODE4ZGM3ZTNlNzI0YWQ3ZC90YWJsZXJhbmdlOjdjNGY0MDA2YzJjYzRmN2Q4MThkYzdlM2U3MjRhZDdkXzI0LTMtMS0xLTI0Mzc2_68c990b2-0790-4e35-bca2-e1720de7a1c5"
      unitRef="shares">25261000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i25366f43bada4f5b9d53d088a682e118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTEtMS0xLTI0Mzc2_56833aa3-5b31-4277-b7ab-0c53f674e8ef"
      unitRef="shares">12534000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i25366f43bada4f5b9d53d088a682e118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTMtMS0xLTI0Mzc2_f2492fca-80b1-438d-801a-76bf271aac5b"
      unitRef="usd">59507000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie64d22ae265b44358c9e947a1a1b1c0c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTgtMS0xLTI0Mzc2_38a2c5af-1328-4b80-879f-316e27e54905"
      unitRef="shares">18154000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie64d22ae265b44358c9e947a1a1b1c0c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTEwLTEtMS0yNDM3Ng_cec5aa50-2310-42c6-85c5-2ab475020a13"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6373c936330246fe88c309a40939f56e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTEyLTEtMS0yNDM3Ng_359564b1-0f07-4f33-804a-67e8fa0c292c"
      unitRef="usd">-24316000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3c545895ca04258955cb754430080ec_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTE0LTEtMS0yNDM3Ng_43737e10-cbf3-4fe8-b63f-33b6276ca82e"
      unitRef="usd">-69255000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25366f43bada4f5b9d53d088a682e118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIyLTIwLTEtMS0yNDM3Ng_f7949cd4-ab87-47bc-beed-28fd21bfcd6d"
      unitRef="usd">-93569000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id881f495b72943148f25b6840685d537_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIzLTEyLTEtMS0yNDM3Ng_a7e92fc1-b62c-4687-9f35-3addb50676a9"
      unitRef="usd">5023000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzIzLTIwLTEtMS0yNDM3Ng_fe06f0ff-52a7-4633-82c5-b6842069b886"
      unitRef="usd">5023000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="id9ec9949e1e248ccab71a11e6c1074bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI0LTEyLTEtMS0yNDM3Ng_e70152b7-15a5-422c-b1e1-fe4f4d9e9de8"
      unitRef="usd">2656000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="i50251df3c1c54c87b2d175fa7d628143_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI0LTIwLTEtMS0yNDM3Ng_040cdc9f-1306-4d36-acc4-0dfab44357b6"
      unitRef="usd">2656000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6bb7bb32c3f343c8a327751ee96ff5a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI1LTgtMS0xLTI0Mzc2_88da687b-e502-4b36-828f-0747712edc1c"
      unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id881f495b72943148f25b6840685d537_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI1LTEyLTEtMS0yNDM3Ng_dbbe22b3-6941-4f02-9ff7-97a6bae064ae"
      unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI1LTIwLTEtMS0yNDM3Ng_2c5f41ba-d9fa-448f-ba57-25477a44b67b"
      unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4e88fbcb34b14703a4c85b9f232b78bb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI2LTgtMS0xLTI0Mzc2_608e21fc-19d4-4dcd-9d91-c3bd88ebf5ee"
      unitRef="shares">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4e88fbcb34b14703a4c85b9f232b78bb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI2LTEwLTEtMS0yNDM3Ng_dcbcc3ee-c3af-43b2-86dc-9c30bdc40f2a"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id726b7dd9036485d8c990a47cc6bd3d2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI2LTEyLTEtMS0yNDM3Ng_4e507d2e-c9c7-4822-9144-828f5b0269d4"
      unitRef="usd">125859000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ida37a3d3907b43bd835289673510cd62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI2LTIwLTEtMS0yNDM3Ng_f47da7a9-3ae5-47b4-841f-8bc277b20262"
      unitRef="usd">125860000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <inbx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTEtMS0xLTI0Mzc2_1c4425b5-d757-492d-a9e7-1cca7f6d3818"
      unitRef="shares">-12534000</inbx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <inbx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTMtMS0xLTI0Mzc2_79d57f35-046c-4c62-8661-0ce987738ff6"
      unitRef="usd">-59507000</inbx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i0952c59ab2f14ce9a7f5f4f4bab1f608_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTgtMS0xLTI0Mzc2_78f7e458-a158-4051-8973-e7d00807d76c"
      unitRef="shares">7211000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0952c59ab2f14ce9a7f5f4f4bab1f608_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTEwLTEtMS0yNDM3Ng_e8605529-c2ff-4685-89a3-a62e3b9acf71"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i3ceb6a7800114c0f80544f3e11e04a59_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTEyLTEtMS0yNDM3Ng_bf8144cf-3ce8-4e24-9c7b-0eb30e576ab7"
      unitRef="usd">59506000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i72afbdbf0e414c5caaa6e4ab484a62f0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI3LTIwLTEtMS0yNDM3Ng_2befea71-8efd-4bc1-8750-51903ec5a4cc"
      unitRef="usd">59507000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="id9f6557dde914ba196b748270c390563_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI4LTgtMS0xLTI0Mzc2_87967b4a-9285-45fa-885a-3e0c49f04181"
      unitRef="shares">4295000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4e858246ea634ea3904ae0efa91f93ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI4LTEyLTEtMS0yNDM3Ng_ff41a2d8-28de-40d7-9fbb-5e9634678f18"
      unitRef="usd">59393000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i3dfd538e45ac47328f0a920dcb4c0614_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI4LTIwLTEtMS0yNDM3Ng_77148d2c-3acf-4376-88a9-5f8c94e7c444"
      unitRef="usd">59393000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <inbx:ReversalOfUnamortizedBeneficialConversionFeature
      contextRef="i9db515ef6fb84613872d16729bbfc6bb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI5LTEyLTEtMS0yNDM3Ng_b933cb83-4e6a-42bc-8044-65f985288d9b"
      unitRef="usd">5332000</inbx:ReversalOfUnamortizedBeneficialConversionFeature>
    <inbx:ReversalOfUnamortizedBeneficialConversionFeature
      contextRef="i7c768226360e440e85d40981d2a3a347_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzI5LTIwLTEtMS0yNDM3Ng_7e47df58-d307-4ce4-ad11-5eeacfeaf5b8"
      unitRef="usd">5332000</inbx:ReversalOfUnamortizedBeneficialConversionFeature>
    <inbx:ReversalOfUnamortizedBeneficialConversionFeature
      contextRef="id9ec9949e1e248ccab71a11e6c1074bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMwLTEyLTEtMS0yNDM3Ng_93f8cd71-11fb-41b0-b54e-7e40016e2b6c"
      unitRef="usd">2107000</inbx:ReversalOfUnamortizedBeneficialConversionFeature>
    <inbx:ReversalOfUnamortizedBeneficialConversionFeature
      contextRef="i50251df3c1c54c87b2d175fa7d628143_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMwLTIwLTEtMS0yNDM3Ng_776bafcc-72b5-48f3-8bb4-131e0c25820e"
      unitRef="usd">2107000</inbx:ReversalOfUnamortizedBeneficialConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="id881f495b72943148f25b6840685d537_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMxLTEyLTEtMS0yNDM3Ng_f21317d4-1d30-4c4a-965d-0007dc2b2c2e"
      unitRef="usd">139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMxLTIwLTEtMS0yNDM3Ng_7cab7e6b-9382-4852-8dca-bba5fb30a4c2"
      unitRef="usd">139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="idaf0841293054a07bd73deb9e8af0344_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMyLTE0LTEtMS0yNDM3Ng_033c1e07-3301-4cb6-8881-6fcc70b3ab6d"
      unitRef="usd">-76124000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMyLTIwLTEtMS0yNDM3Ng_5cd29707-8ae1-42c7-ad17-c1c82a01891c"
      unitRef="usd">-76124000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTEtMS0xLTI0Mzc2_cfb98f2d-eaf2-41d4-8052-9f633385e122"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTMtMS0xLTI0Mzc2_608afdde-6c8d-459a-83b9-57cf1e345205"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i932ae73c06e44acab39c531ada30fa22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTgtMS0xLTI0Mzc2_1a5c54e2-9213-42f3-84a4-39bd92578e6b"
      unitRef="shares">37712000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i932ae73c06e44acab39c531ada30fa22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTEwLTEtMS0yNDM3Ng_7f3754cc-3828-462b-af20-095e26c4e74e"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i722a3c1036664a1db19bf1f1b8c8ef4c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTEyLTEtMS0yNDM3Ng_fd96bac4-b55f-4e60-a219-f558dd870525"
      unitRef="usd">220848000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d39a168fc3a432aa5b6c0e2880ae017_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTE0LTEtMS0yNDM3Ng_a7f3d144-b140-4324-9fe4-4e7f023edea5"
      unitRef="usd">-145379000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzMzLTIwLTEtMS0yNDM3Ng_86ebe2e6-43e4-494a-a81f-afd57930a5e1"
      unitRef="usd">75473000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i782f77ab577843fa872a7b5b9541a230_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM0LTEyLTEtMS0yNjA4MA_9ce46dd1-d9e7-4e96-baab-bb79b8e72a83"
      unitRef="usd">15048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM0LTIwLTEtMS0yNjA4MA_9c84ffed-0a26-4003-b2a2-d351e9cf7816"
      unitRef="usd">15048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i43e54c84aae74e828b9b94427b981d3e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM1LTgtMS0xLTI2MDg0_35f17b4d-0996-4e84-8e58-64be046f1aa6"
      unitRef="shares">358000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i782f77ab577843fa872a7b5b9541a230_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM1LTEyLTEtMS0yNjA4NA_8e67f535-cf32-4771-97bc-8c2dd08a9e11"
      unitRef="usd">3956000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM1LTIwLTEtMS0yNjA4NA_a4c349ce-630e-42ca-87e5-4a0ec9bc713f"
      unitRef="usd">3956000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i43e54c84aae74e828b9b94427b981d3e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM2LTgtMS0xLTMyOTgy_1549baa4-9f9c-4f63-b225-7a6c1ac19b6c"
      unitRef="shares">921000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i782f77ab577843fa872a7b5b9541a230_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM2LTEyLTEtMS0zMjk4Mg_448b4478-5b2f-485f-928c-bd13f980da8f"
      unitRef="usd">39674000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM2LTIwLTEtMS0zNDE4Mw_41d94dbe-7128-49ae-b4c5-24e036e76f2f"
      unitRef="usd">39674000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="i5392c3f3d956465e9c4f2e9ee08ac5b3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM2LTE0LTEtMS0yNjA4Ng_552eab86-162f-48ae-b47f-67b03569a651"
      unitRef="usd">-81768000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM2LTIwLTEtMS0yNjA4Ng_4281898c-aed5-4608-8523-5850efca2187"
      unitRef="usd">-81768000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTEtMS0xLTI2MDg4_53143cc7-8a5f-4084-8c96-12d870e7dd3e"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTMtMS0xLTI2MDg4_0b31d127-2103-4b44-b691-6238aa47f8ce"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibc6061b1a5654bd1a013f69ed4b79e27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTgtMS0xLTI2MDg4_fed5f7ec-ae43-4972-8cbc-7e2d0cd5a6d7"
      unitRef="shares">38991000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc6061b1a5654bd1a013f69ed4b79e27_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTEwLTEtMS0yNjA4OA_4cff8f8a-d640-4f9e-9d03-4c904b67fbae"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b6686e2594645e0b104bd30c79c6ce2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTEyLTEtMS0yNjA4OA_831339de-9a6f-4510-a8f9-13402776843e"
      unitRef="usd">279526000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c90406be53b4899a32eb757c4b6aa8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTE0LTEtMS0yNjA4OA_18017490-073f-4c95-b6a2-acb5bb730632"
      unitRef="usd">-227147000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDUvZnJhZzo5ZDk2MTc1Y2MwNjk0ODIyYjdlMWY3NjNhNTMwMjhmMy90YWJsZTo0MTJhOTU5MGQxOWE0ZDg5ODMzYzg2MzkzNWU5NTliYS90YWJsZXJhbmdlOjQxMmE5NTkwZDE5YTRkODk4MzNjODYzOTM1ZTk1OWJhXzM3LTIwLTEtMS0yNjA4OA_12d50485-d5c3-4670-9f6c-a8936c2279ff"
      unitRef="usd">52383000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQtMS0xLTEtMjQzNzY_2ab95fc3-1b2b-4164-98c1-dbf1befe0850"
      unitRef="usd">-81768000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQtMy0xLTEtMjQzNzY_c56c451d-ea05-4a42-b8df-2264e1e133f8"
      unitRef="usd">-76124000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYtMS0xLTEtMjQzNzY_89609c8d-57ba-45e9-bab3-e0e67dea1bc2"
      unitRef="usd">1195000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYtMy0xLTEtMjQzNzY_b5d851d6-c18d-40cc-9b0f-8cb03e306ffe"
      unitRef="usd">1019000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzctMS0xLTEtMjQzNzY_eeff1a96-1518-46a5-a3b5-6f786092110e"
      unitRef="usd">1234000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzctMy0xLTEtMjQzNzY_11c5f1f4-6315-4230-a3c4-e83e76ba0915"
      unitRef="usd">10189000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzgtMS0xLTEtMjQzNzY_bf3e2e16-0335-4377-bc91-19439f9aa517"
      unitRef="usd">15048000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzgtMy0xLTEtMjQzNzY_c585d573-73aa-4852-8dfc-15fa91311816"
      unitRef="usd">5023000</us-gaap:ShareBasedCompensation>
    <inbx:NoncashOperatingLeaseExpense
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzktMS0xLTEtMjQzNzY_711e910c-60db-4e56-a8ce-c719c0f9feec"
      unitRef="usd">1493000</inbx:NoncashOperatingLeaseExpense>
    <inbx:NoncashOperatingLeaseExpense
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzktMy0xLTEtMjQzNzY_2bfa7f53-d1a4-40d7-be29-63145d778eac"
      unitRef="usd">1374000</inbx:NoncashOperatingLeaseExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEwLTEtMS0xLTMzMDIz_bf872b43-a409-4547-8bf9-fa1ff01216ab"
      unitRef="usd">9000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEwLTMtMS0xLTMzMDIz_57555ad7-992c-42c7-981e-d6e5d1da8e52"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEwLTEtMS0xLTI0Mzc2_3cb84be3-19df-483c-9d34-f1143dfdf798"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEwLTMtMS0xLTI0Mzc2_2520a3b2-63aa-4259-a41f-a21b907bc5a6"
      unitRef="usd">2651000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzExLTEtMS0xLTI0Mzc2_b42b9f33-8042-4a65-92c3-677f13ac22f9"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzExLTMtMS0xLTI0Mzc2_5d663d31-430e-4e9e-b81e-eabd0eec38bb"
      unitRef="usd">24000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEyLTEtMS0xLTI0Mzc2_83e96c29-ac8e-48e9-9785-e21a56ae01ce"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzEyLTMtMS0xLTI0Mzc2_7237506e-f82a-4f14-b7f3-074a97cd5998"
      unitRef="usd">-487000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE2LTEtMS0xLTI0Mzc2_bf8439b2-6a9e-4dd3-9dce-69838a3bc19b"
      unitRef="usd">167000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE2LTMtMS0xLTI0Mzc2_4f81ea1f-c764-4449-8b42-4ca965aa6d67"
      unitRef="usd">-117000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE3LTEtMS0xLTI0Mzc2_edac7f8e-90ec-4cda-8ec0-b65ce3a3b87d"
      unitRef="usd">-28000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE3LTMtMS0xLTI0Mzc2_5fb6719a-0b18-48ce-a43d-ca3f60de37a6"
      unitRef="usd">294000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE4LTEtMS0xLTI0Mzc2_b2f12c40-0707-489a-a4c9-e0c304c84cf2"
      unitRef="usd">4040000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE4LTMtMS0xLTI0Mzc2_a7ad5230-99dd-4c44-a969-180e35b0a0af"
      unitRef="usd">-690000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE5LTEtMS0xLTI0Mzc2_4ef84dc1-6d22-45d2-84c4-e514e7785dc6"
      unitRef="usd">1602000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzE5LTMtMS0xLTI0Mzc2_96c9338c-d856-4de2-9c87-8160c4679533"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIwLTEtMS0xLTI0Mzc2_99faead5-9239-487a-8d09-bf90449a7435"
      unitRef="usd">-4642000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIwLTMtMS0xLTI0Mzc2_d5ef7f14-4de9-4946-a7e0-51d49dd431dc"
      unitRef="usd">10426000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIxLTEtMS0xLTI0Mzc2_44a5ec9a-447f-499e-8c8b-53fefde5ffca"
      unitRef="usd">-3736000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIxLTMtMS0xLTI0Mzc2_58fa5538-7eb4-463d-b265-5623a30c338b"
      unitRef="usd">8525000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:OperatingLeasePayments
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIyLTEtMS0xLTI0Mzc2_c937ea92-be41-4ad2-8164-fabb79795dce"
      unitRef="usd">1503000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIyLTMtMS0xLTI0Mzc2_20d07a4e-1624-4601-ad5c-6f816399f124"
      unitRef="usd">1345000</us-gaap:OperatingLeasePayments>
    <inbx:IncreaseDecreaseContractWithCustomerLiabilityCurrent
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIzLTEtMS0xLTI0Mzc2_f58fafc5-0088-429e-9198-9b45fec41126"
      unitRef="usd">-1047000</inbx:IncreaseDecreaseContractWithCustomerLiabilityCurrent>
    <inbx:IncreaseDecreaseContractWithCustomerLiabilityCurrent
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzIzLTMtMS0xLTI0Mzc2_65e6441b-52ee-4a68-81c1-73cdfe476a81"
      unitRef="usd">-5345000</inbx:IncreaseDecreaseContractWithCustomerLiabilityCurrent>
    <inbx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI0LTEtMS0xLTI0Mzc2_de158cb7-07c6-43ac-a6f6-28f16fc92538"
      unitRef="usd">-627000</inbx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent>
    <inbx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI0LTMtMS0xLTI0Mzc2_4173e6d9-93f6-405e-aa52-adaa5ea9a4db"
      unitRef="usd">-263000</inbx:IncreaseDecreaseContractWithCustomerLiabilityNonCurrent>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI1LTEtMS0xLTI0Mzc2_4981b0d0-19cf-4849-9610-3f418d80a83b"
      unitRef="usd">-180000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI1LTMtMS0xLTI0Mzc2_1a22cf35-da30-40b9-b0fd-7516aed91d19"
      unitRef="usd">180000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI2LTEtMS0xLTI0Mzc2_3bfb5f0c-32a9-43f2-88ca-37ab56f486a9"
      unitRef="usd">-80323000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI2LTMtMS0xLTI0Mzc2_89723bd3-081c-4ce9-9369-abb0f7c63dca"
      unitRef="usd">-47968000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI4LTEtMS0xLTI0Mzc2_d61b5b91-5f21-49c6-97d8-2b6f3a2999bd"
      unitRef="usd">864000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI4LTMtMS0xLTI0Mzc2_aa1bd5c9-5817-418f-803f-31650cc6c318"
      unitRef="usd">1364000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI5LTEtMS0xLTMzMDcy_cda064eb-e539-4d3d-9dff-65c2f033cfed"
      unitRef="usd">55000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI5LTMtMS0xLTMzMDcy_90b3b821-c314-4822-81d3-5658e5f9e3c7"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI5LTEtMS0xLTI0Mzc2_74d57207-eb0c-43aa-bf8e-79572c242836"
      unitRef="usd">-809000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzI5LTMtMS0xLTI0Mzc2_9931eadb-cd3c-4722-b505-9fe86e3c4108"
      unitRef="usd">-1364000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="ib1f87c3827874f3ca0e19457894ec414_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMyLTEtMS0xLTMzMTM1_802bac6f-027c-4412-bb22-5a3e8c1ab938"
      unitRef="usd">40203000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i4d258a97d4684eaba513930d94729cd8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMyLTMtMS0xLTMzMTM1_9fdd1108-0892-4131-af7c-f7dfd6a816c0"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ib1f87c3827874f3ca0e19457894ec414_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMzLTEtMS0xLTMzMTM1_66545bc5-a8fd-4792-80dc-830a02d23fab"
      unitRef="usd">382000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i4d258a97d4684eaba513930d94729cd8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMzLTMtMS0xLTMzMTM1_b5df1e0a-e9f8-412a-85f7-4c248c2a2762"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM0LTEtMS0xLTMzMTEw_9f78cbe7-d83d-47fe-a827-633db1bcd6cf"
      unitRef="usd">39992000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM0LTMtMS0xLTMzMTEw_594a53b9-63ad-4be9-a966-459b2d0687d2"
      unitRef="usd">29938000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <inbx:PaymentsOfDebtIssuanceCostsSecuredDebt
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM1LTEtMS0xLTMzMTEw_2d73e8c0-9bb9-4ae6-b8de-e73498e3c402"
      unitRef="usd">0</inbx:PaymentsOfDebtIssuanceCostsSecuredDebt>
    <inbx:PaymentsOfDebtIssuanceCostsSecuredDebt
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM1LTMtMS0xLTMzMTEw_6a48cacb-e2fa-467b-9a2c-46bd929d9d9d"
      unitRef="usd">786000</inbx:PaymentsOfDebtIssuanceCostsSecuredDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM2LTEtMS0xLTMzMTE2_efeeefdd-7c1d-4128-bb22-ae35d012b74e"
      unitRef="usd">3956000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM2LTMtMS0xLTMzMTE2_dbe586e2-d035-42cf-89c2-b43ee3210033"
      unitRef="usd">27000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="id1c9a266f60c4664bc65b6877237a861_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMxLTEtMS0xLTI0Mzc2_9a21cf2e-ea1f-4d47-8cf9-fb667783922c"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="ida37a3d3907b43bd835289673510cd62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMxLTMtMS0xLTI0Mzc2_b5ec95c7-2349-4f49-be13-64bcea298a1a"
      unitRef="usd">136850000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="id1c9a266f60c4664bc65b6877237a861_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMyLTEtMS0xLTI0Mzc2_bf54adde-0ea7-441f-85c3-b04ad690a5cd"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ida37a3d3907b43bd835289673510cd62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMyLTMtMS0xLTI0Mzc2_cb0770fa-9181-4398-a63d-efd139d1b4d4"
      unitRef="usd">10990000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMzLTEtMS0xLTI0Mzc2_cb34b97e-56d4-4017-8b53-d19c83551b75"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzMzLTMtMS0xLTI0Mzc2_5ad32af1-4dfc-4139-a2bd-b4c1e43913d2"
      unitRef="usd">15000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM3LTEtMS0xLTI0Mzc2_46f06023-0265-4914-a486-0bdc13705d31"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM3LTMtMS0xLTI0Mzc2_f2d5580e-57e6-453f-9b21-9bc7100dfd54"
      unitRef="usd">2183000</us-gaap:RepaymentsOfSecuredDebt>
    <inbx:RepaymentsOfSecuredDebtFinalBalloonPayment
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM4LTEtMS0xLTI0Mzc2_be2c43b5-c21a-400c-804a-9807e7a8fa4e"
      unitRef="usd">0</inbx:RepaymentsOfSecuredDebtFinalBalloonPayment>
    <inbx:RepaymentsOfSecuredDebtFinalBalloonPayment
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM4LTMtMS0xLTI0Mzc2_792baa91-fe2e-4bb0-b05f-3c2e04c6408c"
      unitRef="usd">1400000</inbx:RepaymentsOfSecuredDebtFinalBalloonPayment>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM5LTEtMS0xLTI0Mzc2_e0c09884-906a-44dc-bd90-ee9371d36b1b"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzM5LTMtMS0xLTI0Mzc2_e68f2e5c-1ff8-4e0e-8b10-e9a54808f383"
      unitRef="usd">1875000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQwLTEtMS0xLTI0Mzc2_4fffeb35-6607-41d5-a6b8-4c5a1a4ca273"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQwLTMtMS0xLTI0Mzc2_ecff85e3-9862-4e28-867e-8cb1deac510d"
      unitRef="usd">1875000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ0LTEtMS0xLTI0Mzc2_962ae8fb-2af8-4860-8c54-3b471bb811c9"
      unitRef="usd">83769000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ0LTMtMS0xLTI0Mzc2_0ab98985-9972-4661-95ff-df7ccb006554"
      unitRef="usd">166456000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ1LTEtMS0xLTI0Mzc2_ba2d2bdc-a059-4a04-9ba4-78af8a1366f7"
      unitRef="usd">2637000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ1LTMtMS0xLTI0Mzc2_d0c00be6-dc6e-41c8-beda-7908aab804a3"
      unitRef="usd">117124000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ2LTEtMS0xLTI0Mzc2_e1241bf2-27e7-40d3-bf8c-6516e3dcd451"
      unitRef="usd">128664000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i25366f43bada4f5b9d53d088a682e118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ2LTMtMS0xLTI0Mzc2_e98534b4-6c71-4bf1-b5d6-66f0435f13bb"
      unitRef="usd">11540000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ3LTEtMS0xLTI0Mzc2_c2dfc088-df47-46cb-90f8-6cd33322cdd2"
      unitRef="usd">131301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzQ3LTMtMS0xLTI0Mzc2_b8d2bf69-83c4-41c1-8ecb-47fa6aaa0c81"
      unitRef="usd">128664000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzUwLTEtMS0xLTI0Mzc2_283b1dbb-366c-4edc-8f3b-8a7d3a69deea"
      unitRef="usd">3889000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzUwLTMtMS0xLTI0Mzc2_0dba536f-2fe3-4283-9615-fadb575f29f7"
      unitRef="usd">504000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzUxLTEtMS0xLTI0Mzc2_eebc3837-1212-4420-b408-7dc08a66defd"
      unitRef="usd">2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzUxLTMtMS0xLTI0Mzc2_80e96030-451b-48c4-8d2f-7123ff654081"
      unitRef="usd">3000</us-gaap:IncomeTaxesPaidNet>
    <inbx:AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU4LTEtMS0xLTMzMjc2_16330ade-d1d2-4cd4-b23d-03bda264f509"
      unitRef="usd">271000</inbx:AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <inbx:AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU4LTMtMS0xLTMzMjc2_8552427e-8941-4ff8-8e8c-596b77f2dbdd"
      unitRef="usd">0</inbx:AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <inbx:AtTheMarketOfferingCostsReimbursableInAccountsReceivable
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU5LTEtMS0xLTMzMjc2_20a7d076-8f82-4f45-bb8a-1c0372bb6045"
      unitRef="usd">124000</inbx:AtTheMarketOfferingCostsReimbursableInAccountsReceivable>
    <inbx:AtTheMarketOfferingCostsReimbursableInAccountsReceivable
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU5LTMtMS0xLTMzMjc2_d0d21418-2588-4002-b000-6ad2ccf49f2a"
      unitRef="usd">0</inbx:AtTheMarketOfferingCostsReimbursableInAccountsReceivable>
    <inbx:CapitalExpendituresIncurredButNotYetPaidReleased
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYwLTEtMS0xLTMzMjQ3_85c1b52c-1647-4be1-92d2-e342f5723f72"
      unitRef="usd">38000</inbx:CapitalExpendituresIncurredButNotYetPaidReleased>
    <inbx:CapitalExpendituresIncurredButNotYetPaidReleased
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYwLTMtMS0xLTMzMjQ3_5c5e092f-f2c8-4c7d-8808-9e2d2159fce4"
      unitRef="usd">83000</inbx:CapitalExpendituresIncurredButNotYetPaidReleased>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU0LTEtMS0xLTI0Mzc2_a2a429f6-42b9-41fc-8d73-0331ed8c377d"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU0LTMtMS0xLTI0Mzc2_f4b95033-127f-41fd-86bc-66a3ffeb0add"
      unitRef="usd">59507000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU1LTEtMS0xLTI0Mzc2_4acbae8a-78e3-4e54-a069-fb1c51ef39e0"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU1LTMtMS0xLTI0Mzc2_1eee5565-d22a-45f8-a1dc-b15fdabb0aac"
      unitRef="usd">59393000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <inbx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU2LTEtMS0xLTI0Mzc2_9aaf029e-d7a5-4488-8a4d-332245cc531e"
      unitRef="usd">0</inbx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature>
    <inbx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU2LTMtMS0xLTI0Mzc2_ce35bedf-77d0-4b69-b85b-a6c6a54af0ef"
      unitRef="usd">4783000</inbx:DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU3LTEtMS0xLTI0Mzc2_92ea2364-c7f8-49ab-b4df-d589fef7bd1c"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU3LTMtMS0xLTI0Mzc2_5aef346a-695e-4d61-a93c-1ca0afe7c36e"
      unitRef="usd">1752000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <inbx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU4LTEtMS0xLTI0Mzc2_64799b1e-2d97-4ced-b599-f0943d199848"
      unitRef="usd">0</inbx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred>
    <inbx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzU4LTMtMS0xLTI0Mzc2_f85f4402-ff9b-44b1-99da-bd52783970cd"
      unitRef="usd">735000</inbx:OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred>
    <inbx:NonCashEstablishmentOfEquityMethodInvestment
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYwLTEtMS0xLTI0Mzc2_6f1ad534-7992-4e75-b0fa-3bbeaa43cd02"
      unitRef="usd">0</inbx:NonCashEstablishmentOfEquityMethodInvestment>
    <inbx:NonCashEstablishmentOfEquityMethodInvestment
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYwLTMtMS0xLTI0Mzc2_fce4f6f0-20a7-48d8-9540-9063a802d73f"
      unitRef="usd">487000</inbx:NonCashEstablishmentOfEquityMethodInvestment>
    <inbx:ReclassificationOfWarrantLiabilitiesToEquity
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYxLTEtMS0xLTI0Mzc2_91baf339-eb2e-43e0-aad0-2ce5080df2d5"
      unitRef="usd">0</inbx:ReclassificationOfWarrantLiabilitiesToEquity>
    <inbx:ReclassificationOfWarrantLiabilitiesToEquity
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYxLTMtMS0xLTI0Mzc2_91b597a2-d25f-448d-a667-e095004f9396"
      unitRef="usd">139000</inbx:ReclassificationOfWarrantLiabilitiesToEquity>
    <inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYyLTEtMS0xLTI0Mzc2_7e25fcdc-2c45-46bf-958a-e9c0d204c1e5"
      unitRef="usd">0</inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred>
    <inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMDgvZnJhZzozOTBkOWMyZjJhYTQ0NGFjODY3M2I4YWY4YjZhZjQ5MC90YWJsZTpiYjkwZjQ3ZWNkYTg0NDE2OGQ0YzE0MWFmNzFjZGQxYy90YWJsZXJhbmdlOmJiOTBmNDdlY2RhODQ0MTY4ZDRjMTQxYWY3MWNkZDFjXzYyLTMtMS0xLTI0Mzc2_86610053-567d-4139-846f-4e8470dfd10b"
      unitRef="usd">115000</inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzUw_537f7010-8d93-464e-b8e1-b2c48d0c6661">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inhibrx, Inc., or the Company, or Inhibrx, is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines target biology with protein engineering, technologies, and research and development to design therapeutic candidates. The Company&#x2019;s current pipeline is focused on oncology and orphan diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, risks associated with preclinical studies, clinical trials and regulatory applications, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company&#x2019;s therapeutic candidates currently under development will require significant additional research and development efforts, including clinical and preclinical testing and marketing approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;21, 2020, the Company completed its initial public offering, or IPO, in which it sold 8,050,000 shares of common stock at an offering price of $17.00 per share. Net proceeds from the IPO were $125.9 million, net of underwriting discounts, commissions, and offering costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, each of the following occurred in connection with the completion of the IPO:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the conversion of the 2019 Note and the 2020 Notes (each as defined below) into 4,294,603 shares of the Company&#x2019;s common stock;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the conversion of all outstanding convertible preferred stock into 7,211,086 shares of the Company&#x2019;s common stock;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the adjustment of an outstanding warrant to purchase convertible preferred stock into a warrant to purchase 7,354 shares of the Company&#x2019;s common stock; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the amendment and restatement of the Company&#x2019;s certificate of incorporation, authorizing 120.0 million shares of common stock and 15.0 million shares of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;11, 2020 the Company effected a one-for-1.7382 reverse stock split of the Company&#x2019;s common stock, or the Reverse Stock Split. The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion prices of the convertible preferred stock and convertible notes have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP.&#160;All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had an accumulated deficit of $227.1 million and cash and cash equivalents of $131.3 million. From its inception and through December&#160;31, 2021, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company&#x2019;s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, and other similar arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 5, the Company entered into the Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $200.0 million through the Sales Agent, or the ATM Offering. As of December&#160;31, 2021, 921,042 shares have been sold pursuant to the Sales Agreement for net proceeds of $40.2 million, after deducting commissions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#x2019; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rules and regulations of the SEC or any other regulatory agencies may restrict the Company&#x2019;s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impact of COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In response to the global outbreak of COVID-19 and the World Health Organization&#x2019;s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. The full impact of the COVID-19 outbreak continues to evolve as of the date of these financial statements. While the pandemic has not yet had a material effect on the Company&#x2019;s financial results, it is uncertain as to the full magnitude of impact the pandemic will have on the Company&#x2019;s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act includes a provision for a Paycheck Protection Program, or PPP, administered by the U.S. Small Business Administration, or SBA, and further amended by the Paycheck Protection Program Flexibility Act of 2020, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or PPP Flexibility Act, which was enacted on June 5, 2020. The Company was approved for a loan pursuant to the PPP, or the PPP Loan, in the amount of $1.9 million and received the funds on May&#160;11, 2020. On October 2, 2020, the Company repaid the loan in full plus all interest accrued during the period outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act also permits employers to defer the payment of the employer share of social security taxes due for the period beginning March 27, 2020 and ending December 31, 2020. Of the amounts deferred, 50% was required to be paid by December 31, 2021 and the remaining 50% is required to be paid by December 31, 2022. The Company began deferring payment of the employer share of social security taxes in April 2020 and deferred a total of $0.4&#160;million of such taxes during the period. The Company paid $0.3&#160;million of deferred taxes during December 2021. As of December&#160;31, 2021, the Company has a remaining deferred payment of $0.1&#160;million of such taxes which are classified as accrued expenses in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will continue to examine and evaluate any impacts the CARES Act and associated subsequent legislation may have on its business and taxes.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The Company&#x2019;s most significant estimates relate to evaluation of embedded derivative instruments and beneficial conversion features, or BCFs, within its previously issued and outstanding convertible notes, whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company&#x2019;s operating lease, and valuation allowances for the Company&#x2019;s deferred tax assets.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist principally of accounts receivable, accounts payable, accrued expense, its long-term debt, convertible notes, warrants, and derivative instruments as applicable. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and convertible notes approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#x2019;s debt approximates fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company&#x2019;s derivative instruments and warrants are carried at fair value based on unobservable market inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking and money market accounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#x2019;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December&#160;31, 2021 and 2020, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently depends on third-party suppliers for key materials and services used in its research and development, as well as manufacturing processes, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. In August 2018, the Company entered into a strategic alliance with WuXi Biologics (Hong Kong), Limited, or WuXi Biologics, pursuant to which the Company agreed, for three years and subject to certain conditions, to exclusively use WuXi Biologics to manufacture its therapeutic candidates on a project-by-project basis. In August 2021, the exclusivity provisions of the Wuxi Agreement expired, and the Company may use manufacturers other than Wuxi to manufacture its therapeutic candidates. The Company does not control the manufacturing processes of the contract development and manufacturing organizations, or CDMOs, with whom it contracts, including WuXi Biologics, and is dependent on these third parties for the production of its therapeutic candidates in accordance with relevant regulations such as current Good Manufacturing Practices, or cGMP, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company has never declared or paid any dividends on its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Amended 2020 Loan Agreement limits, among other things, the Company&#x2019;s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company&#x2019;s common stock will be at the discretion of the Company&#x2019;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#x2019;s board of directors may deem relevant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;machinery and equipment: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDIx_fb18bef6-4644-4d4c-b39d-3e7398424521"&gt;three&lt;/span&gt; to five years; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;furniture and fixtures: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDYy_22f664cc-88d9-4893-a2bc-e342d557a1d4"&gt;three&lt;/span&gt; to five years; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;computer software: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNTAx_ac274eaf-b7f7-4024-9d85-68b4306ca0ff"&gt;four&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company&#x2019;s facilities, which commenced in January 2020 and is accounted for as a separate lease. The Company&#x2019;s two existing leases are classified as operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the long-term operating lease of its corporate headquarters, the Company recognized a right-of-use asset and lease liability on its consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. Agreements are reviewed at &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inception to determine if they contain a lease. Leases are reviewed and classified as operating or financing leases at commencement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to exclude from its consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the consolidated statements of operations for all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 7, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis (as defined below), which is accounted for as an equity method investment. The Company's proportionate share of the net income or loss of these companies is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#x2019;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. During the third quarter of 2020, the Company&#x2019;s equity method investment was written down to zero as a result of the allocation of the Company&#x2019;s share of losses of the investee. As of December&#160;31, 2021 and 2020, the equity method investment remains at zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the convertible promissory note, or the 2019 Note, issued in May 2019 to DRAGSA 50 LLC, an entity affiliated with Viking Global Investors LP, or Viking, and the convertible promissory notes, or the 2020 Notes, issued in April 2020 to Viking and certain other investors contained embedded features that provided multiple settlement alternatives. Certain of these settlement features provided the noteholders with a right to a fixed number of the Company&#x2019;s shares upon conversion of the note. Other settlement features provided the noteholders the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction, change of control, qualified IPO (as defined in the 2019 Note and the 2020 Notes), or default of the Company. The Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 815-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Embedded Derivatives &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and determined certain of the settlement features would be accounted for as redemption features meeting the requirements for separate accounting as a single, compound derivative instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This single, compound derivative instrument was accounted for as a liability at its estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the consolidated statements of operations. During August 2020, the Company consummated its IPO, resulting in the conversion of the 2019 Note and the 2020 Notes into shares of the Company&#x2019;s common stock. As of December&#160;31, 2021 and 2020, the derivative liabilities no longer exist.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, in conjunction with the 2020 Loan Agreement with Oxford, the Company issued warrants for the purchase of: 1) its preferred stock if the Company remained privately-held or 2) common stock upon the successful completion of an IPO prior to December 31, 2020. Upon the issuance of the warrants in July 2020, pursuant to ASC Topic 480, the warrants were accounted for as liabilities and measured at their estimated fair value as of the date of issuance, based on the potential conversion into preferred stock. During August 2020, upon consummation of the Company&#x2019;s IPO, the warrants were deemed to be issued for the purchase of common stock and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were no longer accounted for as liabilities. The change in fair value was recognized as a component of change in fair value of warrant liabilities in the consolidated statements of operations during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific&#160;to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2019 Note and the 2020 Notes contained embedded derivative liabilities (see Note 4). The 2020 Loan Agreement contained warrant liabilities (see Note 3). Prior to the completion of the IPO in August 2020, these were classified within Level 3 of the hierarchy, since they were valued by using inputs that were unobservable in the market. Upon the consummation of the IPO in August 2020, the derivative liabilities and warrant liabilities no longer existed. As of December&#160;31, 2021 and 2020, the Company had no financial liabilities measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the completion of the IPO in August 2020, the Company&#x2019;s liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) included the derivative liabilities related to the 2019 Note and the 2020 Notes and the warrants issued with the 2020 Loan Agreement. The following table provides a reconciliation of financial instruments measured at fair value using Level 3 unobservable inputs for the year ended December 31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of derivative liability on the 2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of warrant liabilities on the 2020 Loan Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liabilities on the 2019 and 2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of warrant liabilities into equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s derivative liabilities categorized in Level 3 of the fair value hierarchy during the year ended December 31, 2020 was determined, with the assistance of an independent third-party valuation specialist, using a lattice model. The valuation utilized unobservable inputs, including the discount rate, management&#x2019;s assessment of the probability of various underlying events triggering the conversion of the Company&#x2019;s 2019 Note and the 2020 Notes (as discussed in Note 4), such as an IPO, financing, or extraordinary event, and the current valuation of the Company determined with the assistance of an independent third-party valuation specialist. The warrant liabilities were valued using a Black-Scholes model upon issuance. As of December&#160;31, 2020, the derivative liabilities no longer exist as a result of the conversion of the 2019 Note and the 2020 Notes upon the IPO. Additionally, as of December&#160;31, 2020 the warrant liabilities have been reclassified into equity after the Oxford warrants became exercisable for common stock subsequent to the Company&#x2019;s IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no financial instruments measured at fair value during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs and Other Debt-Related Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs are capitalized, recorded as an offset to the Company&#x2019;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Imputation of Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Offering Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal, accounting, and filing fees related directly to the Company&#x2019;s IPO were capitalized as deferred offering costs to be offset against proceeds upon the consummation of the IPO within stockholders&#x2019; equity (deficit). In August 2020, the Company completed its IPO and offset $11.0 million of IPO costs against the proceeds. No deferred offering costs were capitalized on the Company&#x2019;s consolidated balance sheets as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal, accounting, and filing fees related directly to the Company&#x2019;s Shelf Registration are capitalized as deferred offering costs. Deferred offering costs associated with the Shelf Registration are reclassified to additional paid-in capital when the Company completes offerings under the Shelf Registration. In November 2021, the Company completed an offering under the Shelf Registration and offset $1.7 million of offering costs against the proceeds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet until all revenue recognition criteria are met. In accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or ASC Topic 606, the Company recognizes revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC Topic 606, the Company performs the following five steps: (1)&#160;identify the contract(s) with a customer; (2)&#160;identify the performance obligation(s) in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (5)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research, Development, and License Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative agreements with partners that typically include one or more of the following: (1)&#160;license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether each unit of account results in a contract with a customer under ASC Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC Topic 808. The Company&#x2019;s licensing arrangements are typically for functional intellectual property as it exists at a point in time, being the time that the license agreement is executed. The Company typically does not have an ongoing performance obligation to support or maintain the licensed intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company estimates the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. The Company recognizes revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. In the case of an agreement which provides the partner with an option to license a therapeutic or therapeutic candidate in the future, the Company evaluates whether this option represents a material right at the inception of the agreement. If determined to be a material right, the Company will consider the option a separate performance obligation. The Company has historically concluded that the option to grant a license in the future are not material rights as they are contingent upon future events which may not occur. When an option is exercised, the Company will identify any separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may allocate transaction price using a number of methods including estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain, and observable standalone selling prices exist for the other goods or services promised in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grant Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has been awarded grants from the Congressionally Directed Medical Research Program, or CDMRP, funded through the DoD. With respect to revenue derived from reimbursement of direct, out-of-pocket expenses for research and development costs associated with these grants, where the Company acts as a principal with discretion to choose suppliers, bears credit risk, and performs part of the services required in the transaction, the Company records revenue for the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since there is no transfer of control of goods or services to the granting entities, the granting entities do not meet the definition of a &#x201c;customer&#x201d; as defined by ASC Topic 606 and therefore, these government grants and private not-for-profit institution grants are not within the scope of ASC Topic 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from these grants are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses related to the grant which is consistent with the concept of transfer of control of a service over time under ASC Topic 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development and Clinical Trial Accruals &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#x2019;s behalf, pursuant to development and consulting agreements in place. The Company&#x2019;s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company&#x2019;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company&#x2019;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an &#x201c;ownership change&#x201d; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#x2019;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders.&#160;Accordingly, for the years ended December 31, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Stock-Based Awards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Adoption of New Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued ASU 2020-01,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Investments-Equity Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 321),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Investments-Equity Method and Joint Ventures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 323),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Derivatives and Hedging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 815), - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 was effective for fiscal years beginning after December 15, 2020, and interim periods within those years. Early adoption was permitted, but required simultaneous adoption of all provisions of this guidance. The Company adopted this guidance as of January 1, 2021, which did not result in a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU 2019-12 also improves consistent application and simplification of other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 was effective for fiscal years beginning after December 15, 2020. The Company adopted this guidance as of January 1, 2021, which did not result in a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or Subtopic 470-20 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subtopic 815-40: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share, or EPS, calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 under a modified retrospective approach as of January 1, 2021. As a result of the adoption, there was no impact on retained earnings or other components of equity or to earnings per share in the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of Credit Losses on Financial Statements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company was a smaller reporting company at the determination date, and therefore the new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU 2021-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 260), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt-Modifications and Extinguishments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Subtopic 470-50), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 718), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Subtopic 815-40):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which intends to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods therein, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2021-04 may have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i79c55f122bda4d359fc762cce6002cc9_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTM1MTY_0de8830d-07a7-4122-8798-f7573c8d89e8"
      unitRef="shares">8050000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i8177b8ffee4c4ea998a952b70d65e0ef_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTM1Njc_694a5e6a-5504-4ab1-a635-29e660031745"
      unitRef="usdPerShare">17.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i79c55f122bda4d359fc762cce6002cc9_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTM2MTM_63b8fe4d-7673-4b1b-a9e5-912f24250624"
      unitRef="usd">125900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ib6cea0c2ca9441f79fe37eb6f7844b1d_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzIwMDA_4e4d48e6-e137-4314-aaee-bdbfc49fde61"
      unitRef="shares">4294603</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iad4a6f2ea563431298cac685298bcd91_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzIxMDg_9e507718-a3cc-480a-b4dc-ed3918134c83"
      unitRef="shares">7211086</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzIyNTc_88f4ebdd-6741-486c-96ed-d70814645467"
      unitRef="shares">7354</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzIzOTE_84b4e5ed-84b9-4d4d-8f75-13fdef2b72b5"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzI0MjE_5a8e9640-3470-4e88-95f6-6fbf0f4fafce"
      unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY1_371a2a47-9ab3-44fa-83b4-c94886d1c9cc">Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzYw_f2aff4ac-9cf7-4011-97e5-8479cf27da13">Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP.&#160;All intercompany accounts and transactions have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <inbx:LiquidityPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzcw_b0d5cc82-0534-4c30-b722-a479c53ba6b3">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had an accumulated deficit of $227.1 million and cash and cash equivalents of $131.3 million. From its inception and through December&#160;31, 2021, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company&#x2019;s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, and other similar arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 5, the Company entered into the Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $200.0 million through the Sales Agent, or the ATM Offering. As of December&#160;31, 2021, 921,042 shares have been sold pursuant to the Sales Agreement for net proceeds of $40.2 million, after deducting commissions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#x2019; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.&lt;/span&gt;&lt;/div&gt;The rules and regulations of the SEC or any other regulatory agencies may restrict the Company&#x2019;s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.</inbx:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzM1OTA_58bd9d43-1bc2-4521-bc9f-3d18870a464b"
      unitRef="usd">-227100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzM2MjY_8392cddc-3fb6-4ccc-b5e8-e16df61886c6"
      unitRef="usd">131300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <inbx:SaleOfStockCommonStockAuthorized
      contextRef="if28c89b4ce594ec18c2baa17251f5398_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MjE3Njc_9694dfcc-7e95-43be-bab8-04898bdd5b80"
      unitRef="usd">200000000</inbx:SaleOfStockCommonStockAuthorized>
    <inbx:SaleOfStockSharesCommonStockSold
      contextRef="i64129936be0b412b8e1d86243a3cc9f1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTkwNjg_f2b44f6f-e48a-4103-abd8-da74b7a24372"
      unitRef="shares">921042</inbx:SaleOfStockSharesCommonStockSold>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i90dfb0c9e29b4454ae5d3269b190a197_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTkwNzQ_4bf137b9-f429-4cb6-bad7-21c9d4a57c43"
      unitRef="usd">40200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i93fd390c8a614c1f8ea8dce7fbd6bbd1_D20200511-20200511"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MDk2NTM_6f67a423-9850-4aef-b3d4-8d601471a260"
      unitRef="usd">1900000</us-gaap:ProceedsFromShortTermDebt>
    <inbx:DeferredFederalPayrollTaxesCARESAct
      contextRef="i09e02f53cc2d44b4a25de925c223563e_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTk0NzU_5a74df36-eac1-44aa-a072-98deafb2feab"
      unitRef="usd">400000</inbx:DeferredFederalPayrollTaxesCARESAct>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i39dd7198616e4871a04691df5d501376_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTk0OTE_cdbd9d68-2ea7-420b-a6d9-78d73f20ff0e"
      unitRef="usd">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <inbx:DeferredFederalPayrollTaxesCARESAct
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTk0OTk_116b9f71-d205-4ba5-93a2-61cad54686c8"
      unitRef="usd">100000</inbx:DeferredFederalPayrollTaxesCARESAct>
    <us-gaap:UseOfEstimates
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzcx_53df3dec-6d92-487d-be5a-603dbbbe1c8c">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The Company&#x2019;s most significant estimates relate to evaluation of embedded derivative instruments and beneficial conversion features, or BCFs, within its previously issued and outstanding convertible notes, whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company&#x2019;s operating lease, and valuation allowances for the Company&#x2019;s deferred tax assets.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzgw_7a84e5e7-71ee-413d-b4fc-febb6818c3b0">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist principally of accounts receivable, accounts payable, accrued expense, its long-term debt, convertible notes, warrants, and derivative instruments as applicable. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and convertible notes approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#x2019;s debt approximates fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company&#x2019;s derivative instruments and warrants are carried at fair value based on unobservable market inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU4_97ed807b-6eb6-4b1e-b3da-7ea8d559f703">Cash and Cash EquivalentsCash and cash equivalents are comprised of cash held in financial institutions including readily available checking and money market accounts.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc0_bc6429be-b570-4be4-a524-549b1e17d814">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#x2019;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December&#160;31, 2021 and 2020, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. &lt;/span&gt;&lt;/div&gt;The Company currently depends on third-party suppliers for key materials and services used in its research and development, as well as manufacturing processes, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. In August 2018, the Company entered into a strategic alliance with WuXi Biologics (Hong Kong), Limited, or WuXi Biologics, pursuant to which the Company agreed, for three years and subject to certain conditions, to exclusively use WuXi Biologics to manufacture its therapeutic candidates on a project-by-project basis. In August 2021, the exclusivity provisions of the Wuxi Agreement expired, and the Company may use manufacturers other than Wuxi to manufacture its therapeutic candidates. The Company does not control the manufacturing processes of the contract development and manufacturing organizations, or CDMOs, with whom it contracts, including WuXi Biologics, and is dependent on these third parties for the production of its therapeutic candidates in accordance with relevant regulations such as current Good Manufacturing Practices, or cGMP, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation.</us-gaap:ConcentrationRiskCreditRisk>
    <inbx:CollaborativeArrangementTerm
      contextRef="ib7f3cbe060eb4e03859e4a074152ce82_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4Xzk5MTc_a2c47cf1-896b-4e2d-8685-00fe020dab41">P3Y</inbx:CollaborativeArrangementTerm>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU2_ea8c3a67-2d00-4290-8823-073defa8534e">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company has never declared or paid any dividends on its common stock. &lt;/span&gt;&lt;/div&gt;Additionally, the Amended 2020 Loan Agreement limits, among other things, the Company&#x2019;s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company&#x2019;s common stock will be at the discretion of the Company&#x2019;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#x2019;s board of directors may deem relevant.</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU1_e735db29-0ba3-4025-9645-7f9e4c229023">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;machinery and equipment: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDIx_fb18bef6-4644-4d4c-b39d-3e7398424521"&gt;three&lt;/span&gt; to five years; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;furniture and fixtures: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNDYy_22f664cc-88d9-4893-a2bc-e342d557a1d4"&gt;three&lt;/span&gt; to five years; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;computer software: &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzExNTAx_ac274eaf-b7f7-4024-9d85-68b4306ca0ff"&gt;four&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idc73af7586ed4a7893d2827190cc61ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc1_a9148f36-9f05-430a-a345-96365c793fc0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icb2b71a468364db0b76d16dcc40554c5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzgx_f4339934-75ba-4bdd-8ae2-1f6952460b90">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie74f508386624bc591b2098160a4640a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY2_d992549e-3340-4341-a6f7-b27569ae68b6">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc4_8a4942ac-14d5-4cd7-ba5a-6e18c726ead1">Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzcy_25808bdd-ff36-41bc-a4b4-bf298ee1c140">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company&#x2019;s facilities, which commenced in January 2020 and is accounted for as a separate lease. The Company&#x2019;s two existing leases are classified as operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the long-term operating lease of its corporate headquarters, the Company recognized a right-of-use asset and lease liability on its consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. Agreements are reviewed at &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inception to determine if they contain a lease. Leases are reviewed and classified as operating or financing leases at commencement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to exclude from its consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.&lt;/span&gt;&lt;/div&gt;Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the consolidated statements of operations for all periods presented.</us-gaap:LesseeLeasesPolicyTextBlock>
    <inbx:NumberOfOperatingLeasesHeld
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzEyNjIz_2b9cd6f8-347d-4396-aed0-6fb74d822910"
      unitRef="lease">2</inbx:NumberOfOperatingLeasesHeld>
    <inbx:NumberOfOperatingLeasesHeld
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzEyOTMw_e9d3fa37-bd4e-4ea6-b277-4dfac0f6a5ad"
      unitRef="lease">2</inbx:NumberOfOperatingLeasesHeld>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzUx_29485b19-7eb0-429a-9d5a-83eb6376d7fc">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 7, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis (as defined below), which is accounted for as an equity method investment. The Company's proportionate share of the net income or loss of these companies is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#x2019;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. During the third quarter of 2020, the Company&#x2019;s equity method investment was written down to zero as a result of the allocation of the Company&#x2019;s share of losses of the investee. As of December&#160;31, 2021 and 2020, the equity method investment remains at zero.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i71b075ff878e44c4922334a3be94c8cf_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE0NjA4_50302292-80af-46a5-80de-a2bdfb6cb7bf"
      unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="icc9931e7028244ecadfcd288d792171d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE1Mzcw_a4956a6c-b59b-4843-a070-17d5b2d49f7e"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ibcd205c8ba4b4294b112ca3f590109b2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE1NTA0_8c9b55eb-3c77-426e-b88f-97bcc4e6483f"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ifa5894f258e64ee787243df2040ca6d0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE1NTA0_a3664d8b-aa50-4afc-ab68-3109b7780260"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY5_3036ea53-0740-468f-98da-f9b1ba2b9b87">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the convertible promissory note, or the 2019 Note, issued in May 2019 to DRAGSA 50 LLC, an entity affiliated with Viking Global Investors LP, or Viking, and the convertible promissory notes, or the 2020 Notes, issued in April 2020 to Viking and certain other investors contained embedded features that provided multiple settlement alternatives. Certain of these settlement features provided the noteholders with a right to a fixed number of the Company&#x2019;s shares upon conversion of the note. Other settlement features provided the noteholders the right or the obligation to receive cash or a variable number of shares upon the completion of a capital raising transaction, change of control, qualified IPO (as defined in the 2019 Note and the 2020 Notes), or default of the Company. The Company evaluated each settlement alternative within the 2019 Note and the 2020 Notes under the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 815-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Embedded Derivatives &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and ASC Topic 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and determined certain of the settlement features would be accounted for as redemption features meeting the requirements for separate accounting as a single, compound derivative instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This single, compound derivative instrument was accounted for as a liability at its estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the consolidated statements of operations. During August 2020, the Company consummated its IPO, resulting in the conversion of the 2019 Note and the 2020 Notes into shares of the Company&#x2019;s common stock. As of December&#160;31, 2021 and 2020, the derivative liabilities no longer exist.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <inbx:WarrantLiabilitiesPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzUz_335726a3-2310-43df-a931-bfc8195285db">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, in conjunction with the 2020 Loan Agreement with Oxford, the Company issued warrants for the purchase of: 1) its preferred stock if the Company remained privately-held or 2) common stock upon the successful completion of an IPO prior to December 31, 2020. Upon the issuance of the warrants in July 2020, pursuant to ASC Topic 480, the warrants were accounted for as liabilities and measured at their estimated fair value as of the date of issuance, based on the potential conversion into preferred stock. During August 2020, upon consummation of the Company&#x2019;s IPO, the warrants were deemed to be issued for the purchase of common stock and &lt;/span&gt;&lt;/div&gt;were no longer accounted for as liabilities. The change in fair value was recognized as a component of change in fair value of warrant liabilities in the consolidated statements of operations during the year ended December 31, 2020.</inbx:WarrantLiabilitiesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzYx_50a69ae5-a089-4641-9d7d-124296a5cd56">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific&#160;to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2019 Note and the 2020 Notes contained embedded derivative liabilities (see Note 4). The 2020 Loan Agreement contained warrant liabilities (see Note 3). Prior to the completion of the IPO in August 2020, these were classified within Level 3 of the hierarchy, since they were valued by using inputs that were unobservable in the market. Upon the consummation of the IPO in August 2020, the derivative liabilities and warrant liabilities no longer existed. As of December&#160;31, 2021 and 2020, the Company had no financial liabilities measured at fair value.&lt;/span&gt;&lt;/div&gt;The fair value of the Company&#x2019;s derivative liabilities categorized in Level 3 of the fair value hierarchy during the year ended December 31, 2020 was determined, with the assistance of an independent third-party valuation specialist, using a lattice model. The valuation utilized unobservable inputs, including the discount rate, management&#x2019;s assessment of the probability of various underlying events triggering the conversion of the Company&#x2019;s 2019 Note and the 2020 Notes (as discussed in Note 4), such as an IPO, financing, or extraordinary event, and the current valuation of the Company determined with the assistance of an independent third-party valuation specialist. The warrant liabilities were valued using a Black-Scholes model upon issuance. As of December&#160;31, 2020, the derivative liabilities no longer exist as a result of the conversion of the 2019 Note and the 2020 Notes upon the IPO. Additionally, as of December&#160;31, 2020 the warrant liabilities have been reclassified into equity after the Oxford warrants became exercisable for common stock subsequent to the Company&#x2019;s IPO.There were no financial instruments measured at fair value during the year ended December 31, 2021.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU0_ea692b43-2596-4519-8356-beb30497da6d">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the completion of the IPO in August 2020, the Company&#x2019;s liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) included the derivative liabilities related to the 2019 Note and the 2020 Notes and the warrants issued with the 2020 Loan Agreement. The following table provides a reconciliation of financial instruments measured at fair value using Level 3 unobservable inputs for the year ended December 31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of derivative liability on the 2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of warrant liabilities on the 2020 Loan Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liabilities on the 2019 and 2020 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of warrant liabilities into equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibca4cb805a4d45438e207a1536816957_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzMtMS0xLTEtMjQzNzY_f7a17343-d989-4953-8beb-c7f075aba709"
      unitRef="usd">1916000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="iead2791fae4b4da59253032bf7b42e47_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzQtMS0xLTEtMjQzNzY_8636d464-e2d5-4e21-80fa-7af593dac92f"
      unitRef="usd">735000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ibb4707fb2959449d9321c8c1488e1c19_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzUtMS0xLTEtMjQzNzY_3c99a96a-f71a-4704-856d-a24abf389300"
      unitRef="usd">115000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i9ab110f9486a46d7bc11aaaf0bf87703_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzYtMS0xLTEtMjQzNzY_94ba3a62-286b-43b8-8e36-7800850d963c"
      unitRef="usd">2651000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ibb4707fb2959449d9321c8c1488e1c19_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzctMS0xLTEtMjQzNzY_b9b6350f-9a55-4f2a-b5b5-76548cee03e4"
      unitRef="usd">-24000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <inbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification
      contextRef="ibb4707fb2959449d9321c8c1488e1c19_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzgtMS0xLTEtMjQzNzY_61e98118-722f-45a2-8db7-cec94fbebe7e"
      unitRef="usd">139000</inbx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3b34f949eb8d495c9c9f5c2ff130ba51_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTozNzg1M2ZhM2E0ZjQ0YzkwYTQ5ZmZiNjEyZmM4NTRlMi90YWJsZXJhbmdlOjM3ODUzZmEzYTRmNDRjOTBhNDlmZmI2MTJmYzg1NGUyXzktMS0xLTEtMjQzNzY_117394da-0279-4d26-93ed-7413090fb468"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc3_65983d85-2fe0-4b49-b073-4cb66d835f17">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs and Other Debt-Related Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs are capitalized, recorded as an offset to the Company&#x2019;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Imputation of Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Offering Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal, accounting, and filing fees related directly to the Company&#x2019;s IPO were capitalized as deferred offering costs to be offset against proceeds upon the consummation of the IPO within stockholders&#x2019; equity (deficit). In August 2020, the Company completed its IPO and offset $11.0 million of IPO costs against the proceeds. No deferred offering costs were capitalized on the Company&#x2019;s consolidated balance sheets as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;Legal, accounting, and filing fees related directly to the Company&#x2019;s Shelf Registration are capitalized as deferred offering costs. Deferred offering costs associated with the Shelf Registration are reclassified to additional paid-in capital when the Company completes offerings under the Shelf Registration. In November 2021, the Company completed an offering under the Shelf Registration and offset $1.7 million of offering costs against the proceeds.</us-gaap:DeferredChargesPolicyTextBlock>
    <inbx:PaymentsOfStockIssuanceCostsInitialPublicOffering
      contextRef="i18dec53bcc4c412abadbaa5a71931d50_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzIzMDUy_a617999b-f14a-40d9-b06c-3744d96fdf28"
      unitRef="usd">11000000</inbx:PaymentsOfStockIssuanceCostsInitialPublicOffering>
    <us-gaap:DeferredOfferingCosts
      contextRef="i7cbc8f3cc82e45b1b819d385f0420fab_I20211130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzE2NDkyNjc1MTk1MTI_b3ef59ed-50cd-48a8-be2b-62543298a150"
      unitRef="usd">1700000</us-gaap:DeferredOfferingCosts>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY3_97170d84-db96-4845-950a-cc1867f57801">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet until all revenue recognition criteria are met. In accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or ASC Topic 606, the Company recognizes revenue when, or as, the promised goods or services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC Topic 606, the Company performs the following five steps: (1)&#160;identify the contract(s) with a customer; (2)&#160;identify the performance obligation(s) in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligation(s) in the contract; and (5)&#160;recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research, Development, and License Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative agreements with partners that typically include one or more of the following: (1)&#160;license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether each unit of account results in a contract with a customer under ASC Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC Topic 808. The Company&#x2019;s licensing arrangements are typically for functional intellectual property as it exists at a point in time, being the time that the license agreement is executed. The Company typically does not have an ongoing performance obligation to support or maintain the licensed intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company estimates the amount of variable consideration using the most likely amount, as milestone payments typically only have two possible outcomes. The Company recognizes revenue for sales-based royalty promised in exchange for the license of intellectual property only when the subsequent sale occurs. In the case of an agreement which provides the partner with an option to license a therapeutic or therapeutic candidate in the future, the Company evaluates whether this option represents a material right at the inception of the agreement. If determined to be a material right, the Company will consider the option a separate performance obligation. The Company has historically concluded that the option to grant a license in the future are not material rights as they are contingent upon future events which may not occur. When an option is exercised, the Company will identify any separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may allocate transaction price using a number of methods including estimating standalone selling price of performance obligations and using the residual approach when the standalone selling price of the license is highly variable or uncertain, and observable standalone selling prices exist for the other goods or services promised in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grant Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has been awarded grants from the Congressionally Directed Medical Research Program, or CDMRP, funded through the DoD. With respect to revenue derived from reimbursement of direct, out-of-pocket expenses for research and development costs associated with these grants, where the Company acts as a principal with discretion to choose suppliers, bears credit risk, and performs part of the services required in the transaction, the Company records revenue for the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since there is no transfer of control of goods or services to the granting entities, the granting entities do not meet the definition of a &#x201c;customer&#x201d; as defined by ASC Topic 606 and therefore, these government grants and private not-for-profit institution grants are not within the scope of ASC Topic 606. &lt;/span&gt;&lt;/div&gt;Revenue from these grants are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized as the Company incurs expenses related to the grant which is consistent with the concept of transfer of control of a service over time under ASC Topic 606.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc2_016b09ba-07c8-44b6-a3ed-85ddd580da08">Research and Development and Clinical Trial Accruals Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#x2019;s behalf, pursuant to development and consulting agreements in place. The Company&#x2019;s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company&#x2019;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company&#x2019;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzcz_94c9389b-8196-4d28-a1d6-70bf1c178dad">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. &lt;/span&gt;&lt;/div&gt;The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an &#x201c;ownership change&#x201d; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#x2019;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU3_be8046ca-aec2-41e1-ae22-e2aff92ed903">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders.&#160;Accordingly, for the years ended December 31, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzYz_4dcaf22a-c598-4d54-9fe1-6c2d56215c95">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i37602c9d5ed8495cb15a8ef8ddaa15dd_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzQtMS0xLTEtMjQzNzY_f24ab2e5-1ea4-49ee-aa2a-c1f95f9e72fe"
      unitRef="shares">4064000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i170482e872e54fa3a75fd05af40e0ac9_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzQtMy0xLTEtMjQzNzY_76716dd6-0894-44db-b81c-cf1eab62e4e1"
      unitRef="shares">2525000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifd52f475273e436dbd8c13baa139f7ff_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzYtMS0xLTEtMjQzNzY_41faeab1-70f3-4160-870b-0a5452d5a46c"
      unitRef="shares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8c0b54c2dda34749b9b0940bc4d42110_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzYtMy0xLTEtMjQzNzY_23f6676e-2134-45b1-8c46-e3f0792d6f63"
      unitRef="shares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzctMS0xLTEtMjQzNzY_f2f7b543-ca2d-48e2-abbf-79364da79e34"
      unitRef="shares">4071000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90YWJsZTo0MzBhYjY3OTY0OGU0ZjcyOWY3ZDViMjViNDNhMDZlNi90YWJsZXJhbmdlOjQzMGFiNjc5NjQ4ZTRmNzI5ZjdkNWIyNWI0M2EwNmU2XzctMy0xLTEtMjQzNzY_51d74721-f1e6-434b-b473-ba411e99599a"
      unitRef="shares">2532000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY4_3c38e8d2-5c47-4319-909a-1807d007d574">Fair Value of Stock-Based Awards The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzU5_243afb9b-0106-490c-93d6-aebf3a6342e6">Other Comprehensive Income The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzY0_b8d90b67-b655-4cab-bef1-3b5ae1748d99">Segment Information The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzM1OTg5_90723a50-e515-4566-b1f9-e2a8519e2c23"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMTQvZnJhZzoxNmJmZjk5ZDRjZDg0ZDI0YWYwMzU3NTZmNjc3Y2E0OC90ZXh0cmVnaW9uOjE2YmZmOTlkNGNkODRkMjRhZjAzNTc1NmY2NzdjYTQ4XzQyNzc5_c71268e1-55b7-4db0-a064-6ab2fedc5f16">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Adoption of New Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued ASU 2020-01,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Investments-Equity Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 321),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Investments-Equity Method and Joint Ventures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 323),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Derivatives and Hedging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 815), - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;addresses the accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The amendments clarify that: (a) an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method; and (b) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The provisions of this guidance are to be applied prospectively upon their effective date. ASU 2020-01 was effective for fiscal years beginning after December 15, 2020, and interim periods within those years. Early adoption was permitted, but required simultaneous adoption of all provisions of this guidance. The Company adopted this guidance as of January 1, 2021, which did not result in a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU 2019-12 also improves consistent application and simplification of other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 was effective for fiscal years beginning after December 15, 2020. The Company adopted this guidance as of January 1, 2021, which did not result in a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or Subtopic 470-20 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subtopic 815-40: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share, or EPS, calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 under a modified retrospective approach as of January 1, 2021. As a result of the adoption, there was no impact on retained earnings or other components of equity or to earnings per share in the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of Credit Losses on Financial Statements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 362), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as available-for-sale debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. In November 2019, the FASB issued an amendment making this ASU effective for fiscal years beginning after December 15, 2022 for smaller reporting companies. The Company was a smaller reporting company at the determination date, and therefore the new standard will be effective for the Company on January 1, 2023. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 may have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU 2021-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 260), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt-Modifications and Extinguishments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Subtopic 470-50), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 718), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Subtopic 815-40):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which intends to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods therein, and early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2021-04 may have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzc1MA_3407843f-9fde-42a8-a669-e59f003abd92">OTHER FINANCIAL INFORMATION &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expense and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expense and other current assets were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside research and development services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expense and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense totaled $1.2 million and $1.0 million for the years ended December 31, 2021 and 2020, respectively, and consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total depreciation and amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other outside research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The amount accrued for research and development expense relates primarily to the Company&#x2019;s usage of third-party CROs and CDMOs for clinical and development efforts as its therapeutic candidates progress. See Note 1 for further discussion of the components of research and development.</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzc1MQ_d0f5474d-904f-4ffc-8958-3f936f904085">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expense and other current assets were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside research and development services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expense and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzMtMS0xLTEtMjQzNzY_fd3a504d-b9d7-4efd-bb62-b1f012dedf83"
      unitRef="usd">6343000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzMtMy0xLTEtMjQzNzY_2c7f3e08-4fa0-4b93-85f0-9591d618b5c8"
      unitRef="usd">2204000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzUtMS0xLTEtMjQzNzY_4925266e-f90e-4ad5-b1d8-6ee259f2bf89"
      unitRef="usd">590000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzUtMy0xLTEtMjQzNzY_69279f02-3d38-416d-b6e6-903226f67338"
      unitRef="usd">689000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzYtMS0xLTEtMjQzNzY_e19db378-c10e-48aa-af0d-c44f1b923bc9"
      unitRef="usd">6933000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpiM2U0NjI1NGI1MjQ0MDU0YjM1ZTI2MjY0Y2E3YzY3MC90YWJsZXJhbmdlOmIzZTQ2MjU0YjUyNDQwNTRiMzVlMjYyNjRjYTdjNjcwXzYtMy0xLTEtMjQzNzY_97e4b7b5-3bd4-41fc-a190-7e683b9ea614"
      unitRef="usd">2893000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzc0OA_76778299-f793-470f-97d5-30e3c17c2af1">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense totaled $1.2 million and $1.0 million for the years ended December 31, 2021 and 2020, respectively, and consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total depreciation and amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1710f2bbed1f4858b4386673f448cffe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzMtMS0xLTEtMjQzNzY_b6af7b65-d9b5-43f0-9f5e-ae70395a3b1a"
      unitRef="usd">6286000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i020ea95670924586b00a510e94318bdb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzMtMy0xLTEtMjQzNzY_5816806b-a8ae-4882-a55c-91de2ac6ef79"
      unitRef="usd">5652000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i08ee0abef7874f9db4990a4e94b36a2c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzQtMS0xLTEtMjQzNzY_1d5e345c-75fe-40b3-8be4-3af0889e4af9"
      unitRef="usd">441000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib53e4b677a5742fd983bfb37b3aa7e80_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzQtMy0xLTEtMjQzNzY_051da001-bc45-4b8d-b39a-da2ec5551925"
      unitRef="usd">441000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if6a2d5f0e3c440ef8d989fed722504af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzUtMS0xLTEtMjQzNzY_39ac0983-45fe-4f83-a5ff-af714ae23eb9"
      unitRef="usd">514000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i377f66a6d4c54b4ca81d7975dd8a5c8b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzUtMy0xLTEtMjQzNzY_2c9a78fc-e2be-46a5-bddb-764e846ba1f9"
      unitRef="usd">507000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7242126f78fa4a8a8b9c857fce023330_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzYtMS0xLTEtMzI3ODE_d1694f30-e16a-4634-9a55-c0b294c8c4d0"
      unitRef="usd">42000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia33ae29820054b0db7fce225cab20805_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzYtMy0xLTEtMzI3ODg_4eb4cec4-b562-4ae5-b8c2-2dd507979864"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ife5ab90e2a7d472080cd923e5b5db3b0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzYtMS0xLTEtMjQzNzY_cfda0ea9-01e5-4a7e-8c71-b7d1c07c3c49"
      unitRef="usd">281000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7c3c6503a73a4cb9beb9b3b8e12d0fc5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzYtMy0xLTEtMjQzNzY_d31ccbec-c6a8-4a8c-9636-c48786e73112"
      unitRef="usd">257000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzctMS0xLTEtMjQzNzY_e92f0f23-a6da-43a7-9a52-c7ea30e0dcdd"
      unitRef="usd">7564000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzctMy0xLTEtMjQzNzY_1e6e9541-fb7e-42c1-a5be-ea13c6efba19"
      unitRef="usd">6857000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzgtMS0xLTEtMjQzNzY_a97c2be8-088d-4004-baba-0208c9457296"
      unitRef="usd">4411000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzgtMy0xLTEtMjQzNzY_35ed2744-10bd-4037-82a9-935f7c24ed07"
      unitRef="usd">3365000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzktMS0xLTEtMjQzNzY_110f46a4-5efd-48c1-aedd-174c2db000a6"
      unitRef="usd">3153000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTo1YmEzODVjZWFhMGM0NTM1ODdlZGRiYmNkNDY4M2M3Mi90YWJsZXJhbmdlOjViYTM4NWNlYWEwYzQ1MzU4N2VkZGJiY2Q0NjgzYzcyXzktMy0xLTEtMjQzNzY_5936eff0-6485-4d6d-b416-bf3008574cdf"
      unitRef="usd">3492000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzE2NDkyNjc0NDI3NjA_a2591a98-6f6f-4041-af81-9da3ef414301"
      unitRef="usd">1200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzE2NDkyNjc0NDI3Njg_4d196c6b-7313-4d0e-8b8e-8ace728269ee"
      unitRef="usd">1000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib9a2ae527c6442f69033f87496c9e149_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzMtMS0xLTEtMzk0MzM_141c3c79-3168-45ef-932c-ebda21996ed0"
      unitRef="usd">1003000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iad61546aa39a46a6ab37a1278118f591_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzMtMy0xLTEtMzk0MzM_deae3076-b7b1-4ca0-9732-7257d028fcdc"
      unitRef="usd">836000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icfda6bf472bc49e48b735e5c112a0531_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzQtMS0xLTEtMzk0MzM_b8219c30-6ad5-44d3-aae6-f7c0b87e804c"
      unitRef="usd">192000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4d71b0c7c95e4b21a9fd208c7d3fa8c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzQtMy0xLTEtMzk0MzM_ecf68af7-649f-44f7-97b4-f8769cdfa70e"
      unitRef="usd">183000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzUtMS0xLTEtMzk3NTQ_81cf97b2-1c79-46e3-85de-c6e0ecc63ca5"
      unitRef="usd">1195000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpjMzUwN2QzMjUwN2E0MTdlYTFjZjViMjFmNGJjNmRjYS90YWJsZXJhbmdlOmMzNTA3ZDMyNTA3YTQxN2VhMWNmNWIyMWY0YmM2ZGNhXzUtMy0xLTEtMzk3NTc_cf93535a-8295-457f-a6aa-69dd39cb8694"
      unitRef="usd">1019000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90ZXh0cmVnaW9uOjdjOTVmOTlmNDJlNDQxYTc4ZTEyYmZiYTI5NDllMGYxXzc0OQ_80fe7884-8215-4b33-82f2-59e19e2a3019">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other outside research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <inbx:AccruedClinicalResearchAndDevelopmentCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzMtMS0xLTEtMjQzNzY_2c187dd5-8499-47a3-9d74-9a2f237f42ed"
      unitRef="usd">4496000</inbx:AccruedClinicalResearchAndDevelopmentCurrent>
    <inbx:AccruedClinicalResearchAndDevelopmentCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzMtMy0xLTEtMjQzNzY_e260c21e-d309-452a-8f89-3cf715c8cbea"
      unitRef="usd">970000</inbx:AccruedClinicalResearchAndDevelopmentCurrent>
    <inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMS0xLTEtMzk1NTg_fdbda561-74f5-4364-a98f-ac23953a98eb"
      unitRef="usd">2893000</inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent>
    <inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMy0xLTEtMzk1NTg_f45c3bd2-5379-4176-a84b-3709d0d51bba"
      unitRef="usd">10559000</inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMS0xLTEtMzMyOTU_6dab7ba0-fe65-4d64-8b06-cba550dba49f"
      unitRef="usd">1322000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMy0xLTEtMzMyOTU_2aa45776-2a75-4f9f-b11d-48ac5601ff56"
      unitRef="usd">1165000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMS0xLTEtMjQzNzY_721dc026-80b6-4a9b-9f32-e5854a54ab6c"
      unitRef="usd">261000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzQtMy0xLTEtMjQzNzY_df3a76cb-585f-4bad-a1b0-e876106de209"
      unitRef="usd">282000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzctMS0xLTEtMjQzNzY_161e983f-476a-47a1-805e-bfc2ef68dcb1"
      unitRef="usd">649000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzctMy0xLTEtMjQzNzY_d5187952-0d6d-4e59-b962-f74d2dd6bfa5"
      unitRef="usd">381000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzgtMS0xLTEtMjQzNzY_b68a492a-9659-4268-a6b7-207b53c7ff01"
      unitRef="usd">9621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjAvZnJhZzo3Yzk1Zjk5ZjQyZTQ0MWE3OGUxMmJmYmEyOTQ5ZTBmMS90YWJsZTpkNmJhN2UyNTY4NDQ0NGYyYjcwYjBhZWE5OWJkZWNiYi90YWJsZXJhbmdlOmQ2YmE3ZTI1Njg0NDQ0ZjJiNzBiMGFlYTk5YmRlY2JiXzgtMy0xLTEtMjQzNzY_482e3bc9-8302-4993-91fc-8c6db96ff364"
      unitRef="usd">13357000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc3NzE_5a135957-e715-473a-ae2b-7d8abf48e2e7">DEBT&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;15, 2020, the Company entered into a loan and security agreement, or the 2020 Loan Agreement, with Oxford Finance LLC, or Oxford, pursuant to which it received $10.0 million in gross proceeds, net of $0.1 million of debt issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;12, 2020, the Company entered into an amendment to the 2020 Loan Agreement, or the November 2020 Amendment, and received $20.0 million in additional gross proceeds, net of $0.02 million of debt issuance costs and $0.7 million of a one-time first amendment fee. The November 2020 Amendment provided for two additional tranches of term loans, in addition to the first $10.0 million tranche, or Term A, for an aggregate principal amount of up to $50.0 million, as follows: (a) the second tranche in an aggregate principal amount of $20.0 million, funded upon the closing of the November 2020 Amendment, or Term B, and (b) the third tranche in an aggregate principal amount of $20.0 million to fund on or before September 30, 2021, subject to the initiation of a potentially registration-enabling trial for the Company&#x2019;s therapeutic candidate, INBRX-109, in unresectable or metastatic conventional chondrosarcoma, pursuant to the terms of the November 2020 Amendment, or Term C. The terms of Term A under the 2020 Loan Agreement were modified to align with Term B pursuant to the November 2020 Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;18, 2021, the Company entered into an additional amendment to the 2020 Loan Agreement, or the June 2021 Amendment (collectively with the November 2020 Amendment, the Amended 2020 Loan Agreement). Pursuant to the June 2021 Amendment, the principal amount of the Term C Loan was increased from $20.0 million to $40.0 million. All terms of the Term C Loan align with the existing terms of the Term A and Term B Loans. Upon execution of the June 2021 Amendment and based on the initiation of a potentially registration-enabling trial in unresectable or metastatic conventional chondrosarcoma, the Company drew the Term C Loan and received $40.0 million in gross proceeds, net of $0.01 million of debt issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 the Company has $70.0 million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement. The outstanding term loans will mature on November&#160;1, 2025, or the Amended Maturity Date, and bear interest at a floating per annum rate equal to the greater of (1) 7.96% and (2) the sum of (i) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (ii) 7.80%. The repayment schedule provides for interest-only payments until January&#160;1, 2025. The interest-only period is followed by 11 months of equal payments of principal and interest. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount will be due to Oxford. This final payment of $6.3 million is being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending upon the timing of the prepayment. All other terms of the original 2020 Loan Agreement remain outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following (in thousands).&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through 2024, the Company is only required to make interest payments on the outstanding principal balance, with future principal payments and final fee payments beginning in 2025, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 and June 2021, the Company evaluated the amendments and determined they should be treated as modifications of the original 2020 Loan Agreement since the terms and resulting cash flow were not substantially changed in either the November 2020 Amendment or the June 2021 Amendment. The Company will continue to amortize the existing debt discounts prior to modification through the Amended Maturity Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the Amended 2020 Loan Agreement are secured by a first priority security interest of substantially all of the Company&#x2019;s assets, other than its intellectual property. The Amended 2020 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company&#x2019;s operations, that may require prepayment of the outstanding term loans. Additionally, following the June 2021 Amendment, the Amended 2020 Loan Agreement requires a minimum cash balance of $20.0&#160;million to be maintained in a collateral account. As of December&#160;31, 2021, the Company is in compliance with all covenants under the Amended 2020 Loan Agreement and has not received any notification or indication from Oxford of an intent to declare the loan due prior to maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the debt issuance in July 2020, the Company issued to Oxford warrants to purchase shares of the Company&#x2019;s capital stock equal to 1.25% of the funded amount, or $125,000. Upon issuance, the warrants were &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercisable for preferred stock and were classified as liabilities pursuant to Topic ASC 480 at their fair value of $0.12 million. Upon the consummation of the Company&#x2019;s IPO in August 2020, the Company remeasured the warrants and determined a fair value of approximately $0.14 million. The change in fair value was recorded as a change in fair value of warrant liabilities within other income in the Company&#x2019;s consolidated statements of operations during the year ended December 31, 2020. As of December&#160;31, 2021 and 2020, the warrants are equity-classified and are exercisable for 7,354 shares of common stock of the Company at $17.00 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment. Interest expense was approximately $5.4 million and $0.9 million for the years ended December&#160;31, 2021 and 2020, respectively, as related to the Amended 2020 Loan Agreement. Interest expense was approximately $44,000 for the year ended December 31, 2020 as related to the Company&#x2019;s previous loan and security agreement, as amended, or the 2015 Loan Agreement, with Oxford. The Company recorded no interest expense for the year ended December 31, 2021 related to the 2015 Loan Agreement since it was paid in full in March 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i5bbe9a1a4e50490a8f0a1b8d2384b65d_D20200715-20200715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzI4NjY_99fb8208-4856-4fa6-beef-b7eac8335704"
      unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if9d0faac086f48b49f67f4291eb50af5_I20200715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzI4OTU_068c670f-fd4f-4ac1-a99b-7135dba0cf19"
      unitRef="usd">100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="ibe5a8c4c13b647ba8a99cfbad3d44b0f_D20201112-20201112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzI5OTk_d1351b95-ebbd-4f6f-92bb-b4d30b90710d"
      unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i51f1dd4556c84be1903e4fccae311a27_I20201112"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzMwMzk_0b06d481-d962-4475-a3c5-2b79e42be8a3"
      unitRef="usd">20000.00</us-gaap:DeferredFinanceCostsNet>
    <inbx:DebtInstrumentAmendmentFee
      contextRef="i822a1c2899dd422882f0c3c6958c8b78_D20201112-20201112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzMwNjk_00c0b575-c5e4-47b9-ab04-afc986870307"
      unitRef="usd">700000</inbx:DebtInstrumentAmendmentFee>
    <inbx:DebtInstrumentNumberOfAdditionalTranches
      contextRef="i51f1dd4556c84be1903e4fccae311a27_I20201112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzMxNTI_b0224d9e-6f5e-43bd-a22d-aea3527141be"
      unitRef="tranche">2</inbx:DebtInstrumentNumberOfAdditionalTranches>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i5bbe9a1a4e50490a8f0a1b8d2384b65d_D20200715-20200715"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzEwOTk1MTE2NDExMTA_99fb8208-4856-4fa6-beef-b7eac8335704"
      unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <inbx:DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches
      contextRef="i51f1dd4556c84be1903e4fccae311a27_I20201112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzMyMzE_4be4b100-b22c-4f47-b6fb-de93cd5bb73f"
      unitRef="usd">50000000</inbx:DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="ibe5a8c4c13b647ba8a99cfbad3d44b0f_D20201112-20201112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzMzMDY_770f430f-d594-46c5-8f26-8809cf275dcf"
      unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="ie0e9b67a1f98416d947e940d51019a13_D20201112-20201112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzM0MzU_a06c1bbf-1bbd-4fa1-bc6e-2284d023bf8a"
      unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="ie0e9b67a1f98416d947e940d51019a13_D20201112-20201112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzEwOTk1MTE2NDE3NTM_a06c1bbf-1bbd-4fa1-bc6e-2284d023bf8a"
      unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="if4dee1f4dab044b5904819f8b2634e06_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzEwOTk1MTE2NDE3NjA_c37d558e-9173-4b79-883d-4e0b4ccc9a0f"
      unitRef="usd">40000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="if4dee1f4dab044b5904819f8b2634e06_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzEwOTk1MTE2NDIwODI_40e7f2f3-1604-4fd8-bd72-d52214c88ecd"
      unitRef="usd">40000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ib7b1a7a708534f06a0a7d794a7a27a80_I20210618"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzEwOTk1MTE2NDIxNDU_41254d49-5684-4abb-a108-72d2fe641f9a"
      unitRef="usd">10000.00</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1a0d6e3138bb4cb6ba9620a8eee4bbd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQwNTE_cb8b386f-2817-4f32-a081-80eb0bec0e30"
      unitRef="usd">70000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1a0d6e3138bb4cb6ba9620a8eee4bbd4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQyODk_c39cf755-69f2-4798-b539-d6abbee512f0"
      unitRef="number">0.0796</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i23f05621867b46ba85b04d8f1e06e75d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQ1MDQ_8ebfc42c-121e-46bb-aac2-350f9410b5f1"
      unitRef="number">0.0780</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <inbx:DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQ3OTk_8d49400f-935d-4651-96b8-da9e6c64f197">P11M</inbx:DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended>
    <inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue
      contextRef="i1a0d6e3138bb4cb6ba9620a8eee4bbd4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQ4OTg_2c013ddf-6047-4385-9564-08afc9f9a898"
      unitRef="number">0.090</inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="i1a0d6e3138bb4cb6ba9620a8eee4bbd4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQ5Nzk_d74b9c84-9ecc-41dd-83b1-6164cb1e32ca"
      unitRef="usd">6300000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <inbx:DebtInstrumentPrepaymentFee
      contextRef="i921b6c207f2a4f428b2e98a2c7602eaa_I20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzUyNDk_857ee3fb-201d-473c-b7d9-0e9db9bccee0"
      unitRef="number">0.010</inbx:DebtInstrumentPrepaymentFee>
    <inbx:DebtInstrumentPrepaymentFee
      contextRef="ida7de870e3734f6f8e5b74fa33367059_I20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzUyNTU_fc364712-4369-4ca7-9ada-66f328b71f5b"
      unitRef="number">0.030</inbx:DebtInstrumentPrepaymentFee>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc3Njk_653743bb-e993-4727-a2b2-686df035a8ae">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following (in thousands).&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i546e91723e584f938387442db9ab32f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzItMS0xLTEtMjY2NzA_651310f9-6334-428c-8844-f213e7707c30"
      unitRef="usd">10900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iea06729df7364389bb97b7cac1e9cfad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzItMS0xLTEtMjQzNzY_f40abc00-e26b-40b7-b08e-e1072b577281"
      unitRef="usd">10900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i66ddad33eb12403ab966960a6f430d69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzMtMS0xLTEtMjY2NzA_062b81a0-5aff-4e55-8670-9486cfe80565"
      unitRef="usd">21800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib0e8046ea9e74b1c96aee8f24c431683_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzMtMS0xLTEtMjQzNzY_7085de4e-922e-4e8d-b815-583a69b0c83c"
      unitRef="usd">21800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic890278d955442b5a665ca0900a0a5e3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzQtMS0xLTEtMjY2NzA_00da06c5-3600-45da-800e-13ce5e386ce2"
      unitRef="usd">43600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6cfb99837e104069a050c050a6a0e015_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzQtMy0xLTEtMjY2NTI_c1acc2d1-9282-448c-a4ca-f8a08a1b3061"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzUtMS0xLTEtMjY2NzA_c48eb7a7-aacd-4e87-abc9-5177c19d1e9a"
      unitRef="usd">5830000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="idbed81cbbbc44ceca46d67906a40279c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzQtMS0xLTEtMjQzNzY_88da62f8-8f25-43f7-9f48-8029ee4b2e22"
      unitRef="usd">3456000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzYtMS0xLTEtMzQ3MDY_603db2f2-0639-43bd-98bd-a9b0b190f219"
      unitRef="usd">70470000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idbed81cbbbc44ceca46d67906a40279c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzUtMS0xLTEtMjQzNzY_ac3708a4-30af-4a01-bff2-8acd31002965"
      unitRef="usd">29244000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzctMS0xLTEtMjY2Nzc_bebcc78e-c496-4bc6-83e1-744eb50accdd"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="idbed81cbbbc44ceca46d67906a40279c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzYtMS0xLTEtMjQzNzY_9d82e81a-4168-446e-aea5-0ede2fbc228e"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzgtMS0xLTEtMzQ3MDY_bb21f12c-7d4e-479e-b4d4-f10f6ca3b2ee"
      unitRef="usd">70470000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idbed81cbbbc44ceca46d67906a40279c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTpjN2ZlYzEwYjY2Mzc0OWQ0YWE5ODI4OWE5ZTFmMDBlNi90YWJsZXJhbmdlOmM3ZmVjMTBiNjYzNzQ5ZDRhYTk4Mjg5YTllMWYwMGU2XzctMS0xLTEtMjQzNzY_eafc3cd2-a35b-4c9b-a319-85745a35114e"
      unitRef="usd">29244000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc3NzA_c3c8fd1d-2333-49f4-ac1b-9da9f606efbf">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through 2024, the Company is only required to make interest payments on the outstanding principal balance, with future principal payments and final fee payments beginning in 2025, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTphMjAzZGIxZDAwZDM0OGM0ODM0YWM5YTFhZGUxZDkwYy90YWJsZXJhbmdlOmEyMDNkYjFkMDBkMzQ4YzQ4MzRhYzlhMWFkZTFkOTBjXzUtMS0xLTEtMjQzNzY_0300ac97-7835-4a17-ab12-84283216c06e"
      unitRef="usd">76300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTphMjAzZGIxZDAwZDM0OGM0ODM0YWM5YTFhZGUxZDkwYy90YWJsZXJhbmdlOmEyMDNkYjFkMDBkMzQ4YzQ4MzRhYzlhMWFkZTFkOTBjXzctMS0xLTEtMjQzNzY_78f24d25-8576-450c-95d0-961d7bac32c8"
      unitRef="usd">76300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTphMjAzZGIxZDAwZDM0OGM0ODM0YWM5YTFhZGUxZDkwYy90YWJsZXJhbmdlOmEyMDNkYjFkMDBkMzQ4YzQ4MzRhYzlhMWFkZTFkOTBjXzgtMS0xLTEtMjQzNzY_4d4491d9-b584-417e-8c13-736c62333564"
      unitRef="usd">5830000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="idde9aa5844664a6f8c3890232bb1f19a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90YWJsZTphMjAzZGIxZDAwZDM0OGM0ODM0YWM5YTFhZGUxZDkwYy90YWJsZXJhbmdlOmEyMDNkYjFkMDBkMzQ4YzQ4MzRhYzlhMWFkZTFkOTBjXzktMS0xLTEtMjQzNzY_ef8a7b86-ad1c-447b-bf46-c06e9557ebae"
      unitRef="usd">70470000</us-gaap:LongTermDebt>
    <inbx:DebtInstrumentMinimumCashBalance
      contextRef="i0171f114a2a6466ebf29d4bf342dc328_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzQzOTgwNDY1Mjk2ODk_e55dfd95-7c4f-4d61-b96e-4d06cb200216"
      unitRef="usd">20000000</inbx:DebtInstrumentMinimumCashBalance>
    <inbx:ClassOfWarrantOrRightPercentageOfFundedAmountIssued
      contextRef="iabd8bb82f3c443ae89d9b90d7796e52b_I20200715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzY4NjU_da59943c-d285-4c38-8d53-991c93c90856"
      unitRef="number">0.0125</inbx:ClassOfWarrantOrRightPercentageOfFundedAmountIssued>
    <inbx:WarrantsAndRightsOutstandingLiability
      contextRef="iabd8bb82f3c443ae89d9b90d7796e52b_I20200715"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzY4OTM_b8dd018f-e290-41b7-9448-3b33d6107edf"
      unitRef="usd">125000</inbx:WarrantsAndRightsOutstandingLiability>
    <inbx:WarrantsLiability
      contextRef="i80af9778e30f4d7c8c60c10f21011485_I20200715"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzcwNDY_5aa71c7a-7fb5-4df4-875c-315233abd0e1"
      unitRef="usd">120000</inbx:WarrantsLiability>
    <inbx:WarrantsLiability
      contextRef="id95bef5f495646d58a4ab12c5852afc4_I20200831"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzcxOTA_e73e60f4-dde5-428f-8c4e-a432a6b6f77e"
      unitRef="usd">140000</inbx:WarrantsLiability>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i4d74b118fa384d7ebae249afc60e4626_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc0NDE_04b21bc7-8bee-48a7-a29d-6bc42e425230"
      unitRef="shares">7354</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie6f93dd1e5494e218459effec8912900_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc0NDE_1c4d5098-5115-42cf-8bc2-e5bb0c69a0fc"
      unitRef="shares">7354</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4d74b118fa384d7ebae249afc60e4626_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc0ODU_17ba2199-e01b-4c3a-b12a-c886aea6da6d"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie6f93dd1e5494e218459effec8912900_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzc0ODU_64f96b70-992e-4e76-9957-159ab2d6b093"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:InterestExpenseDebt
      contextRef="i51d5eb374e764a38a5a2883487e16341_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzE2NDkyNjc0NjAyMjE_0d4cdb60-57e4-4dd8-8ea0-6aaa05251051"
      unitRef="usd">5400000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i4dec658dfa294ef580b787eaea9c9e61_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzE2NDkyNjc0NjAyMzE_ed8b00da-6c6a-436d-bf71-db750946c422"
      unitRef="usd">900000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i8bd2ea5f3b8d4063b55ea5ac924b3bc2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjMvZnJhZzoxZGJmNzQ3NjNlOTg0ZDI1OTU0NjdlYzhhNWU2MDlhMy90ZXh0cmVnaW9uOjFkYmY3NDc2M2U5ODRkMjU5NTQ2N2VjOGE1ZTYwOWEzXzE2NDkyNjc0NjAyMzk_b1c93460-3f78-4416-892c-3e161727f20b"
      unitRef="usd">44000</us-gaap:InterestExpenseDebt>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5Xzc5NjI_56518355-1834-4859-a7db-f890044014d2">CONVERTIBLE PROMISSORY NOTES &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the Company issued the 2019 Note in the aggregate principal amount of $40.0 million to Viking in a private placement transaction. The 2019 Note began to accrue interest in February 2020 at a rate of 1.5% per month. In April 2020, the Company issued the 2020 Notes in the aggregate principal amount of $15.0 million to Viking and certain other investors in a private placement transaction. Upon issuance, the 2020 Notes accrued interest at a rate of 1.0% per month.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion Upon IPO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 21, 2020, the Company completed its IPO. The aggregate total balance of the 2019 Note, or $43.7 million, converted at the fixed price of $14.35 per share, resulting in the issuance of 3,046,467 shares of common stock to the holder. The aggregate total balance of the 2020 Notes, or $15.7 million, converted at a fixed price of $12.56 per share, resulting in the issuance of 1,248,136 shares of common stock to the holders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conversion of the 2019 Note and the 2020 Notes were evaluated for contingent BCFs under ASC Topic 470-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt With Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See discussion of debt discount below for evaluation upon conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the 2019 Note and the 2020 Notes contained alternative conversion options to the IPO upon the consummation of certain events, each of which had its own conversion prices and terms. The Company determined certain settlement features qualified as conversion features not meeting the requirements for separate accounting as embedded derivatives, while others qualified as redemption features meeting the requirements for separate accounting which were accounted for as derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon issuance of the 2019 Note and the 2020 Notes, the Company recorded derivative liabilities with corresponding debt discounts on the consolidated balance sheets at the estimated fair value of the bifurcated compound liabilities. The Company remeasured the fair value at each reporting period. Changes in the probability of each embedded redemption feature drove changes in the fair value of the derivative liabilities and had a corresponding impact on the Company&#x2019;s net loss. During the second quarter of 2020, the fair value of the derivatives were determined to be zero based upon the expected conversion of the notes via an embedded conversion feature which did not meet the definition of a derivative. Upon conversion of the 2019 Note and the 2020 Notes in August 2020 upon completion of the Company&#x2019;s IPO, the derivative liabilities were extinguished. No additional expense was recorded at extinguishment since the derivative liabilities had already been assessed to have zero value. During the year ended December 31, 2020, the Company recorded other income of $2.7 million related to changes in fair value of derivative liabilities in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Discount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon issuance of the 2019 Note and the 2020 Notes, the Company recorded debt discounts related to BCFs, as well as derivative liabilities and debt issuance costs. Prior to conversion, the debt discounts were amortized over the life &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the notes. Amortization of the debt discount from inception of the 2019 Note until conversion of the 2019 Note and the 2020 Notes upon IPO was $8.7 million. At the time of conversion, the 2019 Note and the 2020 Notes had unamortized discounts of $6.9 million and $2.7 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion of the 2019 Note and the 2020 Notes, the Company remeasured the intrinsic value of the BCFs which resulted in a reversal of the remaining unamortized discounts associated with the BCFs, resulting in a $7.4 million impact to additional paid-in-capital. Additionally, the Company accelerated the unamortized debt discounts related to the debt issuance costs and the derivative liabilities, resulting in a $2.2 million charge to interest expense during the third quarter of 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i903596dda51b4295ba537cb047cbe3ee_I20190520"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5Xzkw_907e92ab-cdb8-4d56-b2e2-1b91fea7dd0b"
      unitRef="usd">40000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ice2d978f42f647d0b34ffd2d606a3b23_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzE5Nw_995c1cc2-1402-44e0-8c40-492d343bd9ad"
      unitRef="number">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5b2c31362ca6456e9fa354eb0012a302_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzI4OQ_efce9fb5-a41b-4661-aa5b-5d412f3661bf"
      unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5b2c31362ca6456e9fa354eb0012a302_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzQyNg_66f0d725-51bf-4205-86d3-b4fe1361226a"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i9912d0eb770b4de0a793e3fe42d493b4_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc0ODY_775fdabe-fc2d-4fd5-b87c-39ba4aaa5d7a"
      unitRef="usd">43700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i9912d0eb770b4de0a793e3fe42d493b4_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc0OTA_868a9daf-8fdb-42c5-a23e-3a4ace24791c"
      unitRef="usdPerShare">14.35</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="if68d1087bb6f4d22995e04dde84541a0_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc0OTQ_abda2871-14ff-444d-98c0-bbe15e16c93a"
      unitRef="shares">3046467</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:LongTermDebt
      contextRef="i09b542f567974ce98531ed6d78bdcb08_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc0OTg_b23390ac-d9ad-42ef-81c2-06971c2a14e6"
      unitRef="usd">15700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i09b542f567974ce98531ed6d78bdcb08_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc1MDY_99af909d-2410-4af0-8ef4-82ee7a8060cf"
      unitRef="usdPerShare">12.56</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ie129391072864eaa854b90a526c15513_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzEwOTk1MTE2Mzc1MDI_9e984e0b-6ea6-4183-a1d0-8c440c5e5936"
      unitRef="shares">1248136</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DerivativeLiabilities
      contextRef="i0784cd66e4954bd983b5bf6086ef67c6_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzE2NDkyNjc0NjA5Mzk_8dbfb45a-0c2e-4264-ac31-d948a9582550"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="id39de78949fa4338b856a1bf1a370fbf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzE2NDkyNjc0NjE0MTM_8881afe3-5f72-4af4-a0aa-1771e72ed1e9"
      unitRef="usd">2700000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i88c0a33aee14452581d9c884594cd5aa_D20190501-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzcyODA_01919c56-1134-4f31-b10d-20ab74dfa2f1"
      unitRef="usd">8700000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i9912d0eb770b4de0a793e3fe42d493b4_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzczNzM_a8bc06a5-b398-4f43-ae58-4d38249be786"
      unitRef="usd">6900000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i09b542f567974ce98531ed6d78bdcb08_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5XzczODA_aa28a7f9-f86b-4f7e-b39e-ed6583b4e420"
      unitRef="usd">2700000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <inbx:ReversalOfUnamortizedBeneficialConversionFeature
      contextRef="ib9c4b992959d4ddb90aad9b4d5df22bb_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5Xzc2MTY_81433b1f-56b3-4c46-b0ea-41a670cf14ee"
      unitRef="usd">7400000</inbx:ReversalOfUnamortizedBeneficialConversionFeature>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i3c9b6bfda5d34fbca767a5fbbe17acf7_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMjkvZnJhZzplZDIzNjZjMmFhNDI0OTcyOGQxNzFhNzhkMTRiOTEwOS90ZXh0cmVnaW9uOmVkMjM2NmMyYWE0MjQ5NzI4ZDE3MWE3OGQxNGI5MTA5Xzc4MDg_64b4624e-997c-489c-ad00-c6f661d935f8"
      unitRef="usd">2200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzIwNzQ_0e1926cc-554b-4daf-8754-4e541f66907e">STOCKHOLDERS&#x2019; EQUITY (DEFICIT) &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated Certificate of Incorporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;21, 2020 upon completion of the IPO, the Company&#x2019;s certificate of incorporation was amended and restated to authorize 120,000,000 shares of common stock and 15,000,000 shares of preferred stock, each with a par value of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the completion of the Company&#x2019;s IPO in August 2020, all of the outstanding shares of convertible preferred stock were converted into 7,211,086 shares of the Company&#x2019;s common stock. Prior to its conversion to common stock, the convertible preferred stock was classified as temporary, or mezzanine, equity on the accompanying consolidated balance sheets since the shares contained certain redemption features that were not solely within the control of the Company. The Company had not previously accreted the convertible preferred stock to its redemption value since the shares were not currently redeemable and redemption was not deemed to be probable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No convertible preferred stock was authorized or issued as of December&#160;31, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into the Sales Agreement with the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $200.0 million through the Sales Agent, or the ATM Offering. Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to 3% of the gross sales price per share sold. As of December&#160;31, 2021, the Company has sold 921,042 shares under the ATM Offering for net proceeds of $40.2&#160;million, after deducting commissions of $1.2&#160;million. In connection with the ATM Offering, the Company incurred an additional $0.5&#160;million of expenses which were offset against the proceeds of the offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, the Company issued warrants to Oxford concurrently with the 2020 Loan Agreement. Upon the consummation of the Company&#x2019;s IPO in August 2020, the warrants are exercisable for 7,354 shares of common stock of the Company at $17.00 per share. As of December&#160;31, 2021, the warrants are equity-classified and reflected in additional paid-in-capital at $0.14 million. The fair value of the warrants was determined using the Black-Scholes model on the date of reclassification. No subsequent remeasurement is required for equity-classified warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzIwNQ_f3066c7e-dbf5-4389-a880-520bab0ed437"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzIzNQ_84f4eaca-fea1-4d63-9953-0f5676e743a0"
      unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzI5MA_45c341f1-b253-4748-ae1a-a574828fa05f"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzI5MA_6e56c054-d02a-4c22-8dc1-f8c74457c1d1"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ic8eef267ef1c487289aaf7cbf76447dd_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzEwOTk1MTE2MzExMjM_0b172963-8648-471c-8887-b2cc8d950fae"
      unitRef="shares">7211086</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <inbx:SaleOfStockCommonStockAuthorized
      contextRef="if28c89b4ce594ec18c2baa17251f5398_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzEwOTk1MTE2MzIzNTM_de59d662-9414-43a3-aa22-3cd8a4593a4b"
      unitRef="usd">200000000</inbx:SaleOfStockCommonStockAuthorized>
    <inbx:CommonStockSaleOfStockCommissionPercent
      contextRef="if28c89b4ce594ec18c2baa17251f5398_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzEwOTk1MTE2MzIzNjA_0d2379a5-5e8a-4f7c-aead-aa39a1c325cd"
      unitRef="number">0.03</inbx:CommonStockSaleOfStockCommissionPercent>
    <inbx:SaleOfStockSharesCommonStockSold
      contextRef="i64129936be0b412b8e1d86243a3cc9f1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzEwOTk1MTE2MzI1MjE_c809cbe9-338d-4672-988c-55b9e9d13da8"
      unitRef="shares">921042</inbx:SaleOfStockSharesCommonStockSold>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i90dfb0c9e29b4454ae5d3269b190a197_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzEwOTk1MTE2MzI1Mjg_3edd3398-4d09-43ca-8b49-c45e74d0e6c9"
      unitRef="usd">40200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i90dfb0c9e29b4454ae5d3269b190a197_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzQzOTgwNDY1MTYyMTY_0720c1cb-ad03-478a-84a6-a29277f3d169"
      unitRef="usd">1200000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <inbx:AtTheMarketOfferingCosts
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzQzOTgwNDY1MTYxODU_3e3c160a-bf34-4d57-9551-69447fde0416"
      unitRef="usd">500000</inbx:AtTheMarketOfferingCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie6f93dd1e5494e218459effec8912900_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzE3NDE_c2994f25-5cb6-42f4-91d0-9a1b7388f15a"
      unitRef="shares">7354</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie6f93dd1e5494e218459effec8912900_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzE3ODU_7758aa37-db94-4ad2-ad1d-e80acc49279e"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i1b6686e2594645e0b104bd30c79c6ce2_I20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzIvZnJhZzo5OGI2ZjExZDcwNzA0ZGM2YWUxMGNlZTY5ZTE1YTliMy90ZXh0cmVnaW9uOjk4YjZmMTFkNzA3MDRkYzZhZTEwY2VlNjllMTVhOWIzXzE4OTE_57fa71db-8f49-4201-9a83-25fb05b649b8"
      unitRef="usd">140000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDQ_6c5a66fc-808c-45f6-8647-a5ce215da6db">EQUITY COMPENSATION PLANS &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, provides for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. As of December&#160;31, 2021, an aggregate of 4.5 million shares of common stock were reserved for issuance under the 2017 Plan, of which 0.1 million were available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. The Company grants options with an exercise price equal to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the fair market value of the Company&#x2019;s stock on the date of the option grant. The options are subject to four-year vesting with a one-year cliff and have a contractual term of 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity under its 2017 Plan for the year ended December 31, 2021 is as follows (in thousands, except for per share data and years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (In Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2021 and 2020 was $7.5&#160;million and $19,000, respectively. Aggregate intrinsic value of stock options exercised and outstanding is calculated using the fair value of common stock on the date of exercise and as of December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#x2019;s anticipated stock volatility, and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the years ended December 31, 2021 and 2020 were as follows.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the assumptions used in the option pricing model in the following manner:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited historical stock price volatility data, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;selected companies&#x2019; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Company&#x2019;s IPO, given the absence of a public trading market for the Company&#x2019;s common stock, its board of directors exercised their judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company&#x2019;s common stock underlying the stock options, such as: contemporaneous valuations performed by independent third-party specialists, its stage of development, including the status of its research and development efforts of its therapeutic candidates and the material risks related to its business and industry, its results of operations and financial condition, including its levels of capital resources, the prices at which its sold shares of its convertible preferred stock, the rights, preferences and privileges of its convertible preferred stock relative to those of its common stock, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable life sciences public companies, as well as recently completed mergers and acquisitions of peer companies, the likelihood of achieving a liquidity event for the holders of its common stock or convertible preferred stock, such as an IPO or a sale of the Company given prevailing market conditions, trends and developments in its industry, external market conditions affecting the life sciences and biotechnology sectors, and the lack of liquidity of its common stock, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock is determined based on its closing market price on the date of the grant. The Company&#x2019;s board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of its common stock underlying those options on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for stock options consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of December&#160;31, 2021, the Company had $47.0 million of total unrecognized stock-based compensation expense related to its stock options, which is expected to be recognized over a weighted-average period of 3.04 years</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzM3MA_21ce5e1b-f989-43de-859e-e423d1dbc07e"
      unitRef="shares">4500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzQ1Mw_bfd0b30e-cb66-4dad-8559-16e8bdacc2a0"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDU_65655ebb-e924-4eb9-9331-f61a9d142275">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i61137fd603eb42ea8e17d095c0e1c8a8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDY_2bc4c9e8-f26d-4bf3-ad6e-8f35880fe405">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzg5NQ_d26705a4-e319-4bb2-87e9-94c3fe4b74a0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDc_27212925-7329-4ef5-9bb8-c2c2e74899ab">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity under its 2017 Plan for the year ended December 31, 2021 is as follows (in thousands, except for per share data and years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (In Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzQtMS0xLTEtMjQzNzY_074f77a8-db4f-40b9-b2ad-84a56f85e213"
      unitRef="shares">2525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzQtMy0xLTEtMjQzNzY_a6e09cb4-2eae-4bd8-a798-8e8cdb52b837"
      unitRef="usdPerShare">11.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzYtMS0xLTEtMjQzNzY_b0af60ed-4ea9-4456-a711-dfc856b1dff3"
      unitRef="shares">2307000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzYtMy0xLTEtMjQzNzY_65f65072-95d2-4ec7-a037-65b907e23c68"
      unitRef="usdPerShare">32.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzctMS0xLTEtMjQzNzY_02130fce-a16f-47d4-987b-6010c8a5b356"
      unitRef="shares">410000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzctMy0xLTEtMjQzNzY_05e59064-50a2-4921-9936-5a93ba41195d"
      unitRef="usdPerShare">23.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzgtMS0xLTEtMjQzNzY_7990264a-5aed-480e-a9e8-d9157b83a2dd"
      unitRef="shares">358000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzgtMy0xLTEtMjQzNzY_b0d5ee24-79b5-44d1-8aae-d75087d7f65b"
      unitRef="usdPerShare">11.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzktMS0xLTEtMjQzNzY_e146e4a3-898d-456e-b3bd-5c18eac324af"
      unitRef="shares">4064000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzktMy0xLTEtMjQzNzY_ded9f0b0-7ff5-4c43-89b4-fdac39509c84"
      unitRef="usdPerShare">22.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzktNS0xLTEtMjQzNzY_5959c551-7523-4d12-ac0e-fb5f09c33ca7">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzktNy0xLTEtMjQzNzY_57aad947-2524-4ae1-bab0-bbfcf9692ca1"
      unitRef="usd">87303000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzEwLTEtMS0xLTI0Mzc2_444b72fe-a4ae-4ddb-a51c-abad4f631b81"
      unitRef="shares">1253000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzEwLTMtMS0xLTI0Mzc2_47b69c0e-9db8-428b-acf6-19fc4efa52af"
      unitRef="usdPerShare">11.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzEwLTUtMS0xLTI0Mzc2_5dbb088a-cb07-4e48-9baa-d93be514fd35">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo1NzEyNDE4ZTUxNjc0Y2I4YTFlYjljNmIwNjQzZTJiMS90YWJsZXJhbmdlOjU3MTI0MThlNTE2NzRjYjhhMWViOWM2YjA2NDNlMmIxXzEwLTctMS0xLTI0Mzc2_ae0fcfdc-d4df-480f-b1f3-338b232f9e39"
      unitRef="usd">40468000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzEwOTk1MTE2MzM4NDY_533f5912-5a5c-4e35-bfd5-4fb9036bb0a0"
      unitRef="usd">7500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzEwOTk1MTE2MzM4NTI_3e72fb8f-237b-463e-8cdd-4d6084d237c7"
      unitRef="usd">19000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDg_01c838c1-847f-4e63-ab70-46537a723ecf">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the years ended December 31, 2021 and 2020 were as follows.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzMtMS0xLTEtMjQzNzY_94771b3b-ac36-46a0-befe-a8ed8a6ed5e2"
      unitRef="number">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzMtNS0xLTEtMjQzNzY_3c640895-81a3-410e-971e-bb2c96968056"
      unitRef="number">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzQtMS0xLTEtMjQzNzY_793d1a83-0875-4d70-9476-759639b16925"
      unitRef="number">0.9349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzQtNS0xLTEtMjQzNzY_564fe1fd-7412-4454-a8c7-83e64c43c259"
      unitRef="number">0.9772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzUtMS0xLTEtMjQzNzY_a1940fe7-c666-42ae-abb8-dfc33457bb52"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzUtNS0xLTEtMjQzNzY_d1a73667-bbca-42cb-a816-31d2732841cd"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzYtMS0xLTEtMjQzNzY_65cc1c1d-c945-477f-8f22-eb78fa2dcceb">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzYtNS0xLTEtMjQzNzY_750d293c-4602-4016-9f05-de7005afebe4">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzgtMS0xLTEtMjQzNzY_4e2670a9-7891-42e3-b104-7002c157a1f8"
      unitRef="usdPerShare">24.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTphMGUwMTJmMWI3MjY0ZmMzYmQzYTZiOGEyNmZlNTJiYi90YWJsZXJhbmdlOmEwZTAxMmYxYjcyNjRmYzNiZDNhNmI4YTI2ZmU1MmJiXzgtNS0xLTEtMjQzNzY_182ca280-fb19-4201-9f04-fa5153bc437c"
      unitRef="usdPerShare">10.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDk_b437527d-9f5c-4698-b5f6-fe9c4fc1b2f1">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for stock options consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2e02f9252cd34ce2b7cec9630fc0647c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzMtMS0xLTEtMjQzNzY_65af8a3b-5d0d-4da2-92e7-5b64a9d47a45"
      unitRef="usd">11830000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c6895eb15134795b9d0e82c56053e76_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzMtMy0xLTEtMjQzNzY_99809030-408d-4a97-89be-ebb6d2903534"
      unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i06da7c90c85744e885809060c5d6303c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzQtMS0xLTEtMjQzNzY_0eeae1e4-1e4e-4eef-884f-c3d2f133f82e"
      unitRef="usd">3218000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f544045b0fb4204a60d3d67976ede93_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzQtMy0xLTEtMjQzNzY_0963b788-b594-4df2-8f0b-749a10614a8f"
      unitRef="usd">723000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzUtMS0xLTEtMjQzNzY_5d4030b5-4e27-415b-8321-ad3f27ddeb12"
      unitRef="usd">15048000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12c7bfd9c8a8481288e1b5d2c5f10346_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90YWJsZTo0NjRjM2ZhYzUzMzA0OWVjOTBjZTM0NTZlOGJkMGE0Yi90YWJsZXJhbmdlOjQ2NGMzZmFjNTMzMDQ5ZWM5MGNlMzQ1NmU4YmQwYTRiXzUtMy0xLTEtMjQzNzY_3ec83d5a-2099-4981-bafd-f3c7eabd9451"
      unitRef="usd">5023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i48c28eaf2c8c46e5bee554a6274ee022_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU2ODk_6e6437e1-8780-4574-86f2-be4ff1531b32"
      unitRef="usd">47000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzUvZnJhZzo1NmJiNjk1ZGViYTg0NDFkOGNkYWU2Mzk2NmZkNTdjMi90ZXh0cmVnaW9uOjU2YmI2OTVkZWJhODQ0MWQ4Y2RhZTYzOTY2ZmQ1N2MyXzU4NDI_857802e5-e363-436b-96f2-25e59a53815b">P3Y14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <inbx:LicenseAndGrantRevenueTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzIyNTAx_65abe53f-9954-4023-a987-27f08a010d61">LICENSE AND GRANT REVENUES &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total revenue recorded in the Company&#x2019;s consolidated statements of operations (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;License fee revenue from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elpiscience Biopharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total license fee revenue from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;License fee revenue from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2seventy bio, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phylaxis BioScience, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chiesi Farmaceutici S.p.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other license revenues from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total license fee revenue from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Congressionally Directed Medical Research Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Elpiscience&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company entered into a separate License Agreement, or the OX40 License Agreement, with Elpiscience Biopharmaceuticals, Inc., or Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#x2019;s multivalent protein therapeutic directed to the biological target OX40, or INBRX-106. This license provides Elpiscience with the right to further advance the therapeutic candidate through clinical trials, as well as manufacture and commercialize it. It also requires the Company to provide Elpiscience with know-how and materials specific to INBRX-106, including process development and manufacturing data and information necessary to develop INBRX-106. In the OX40 License Agreement, the Company also agreed to negotiate an agreement to supply Elpiscience with INBRX-106 for its development in Mainland China, Hong Kong Macau and Taiwan. The Company is eligible to receive certain developmental and commercial milestones of up to an aggregate of $100.0 million, as well as percentage tiered royalties on future product sales with rates in the high single-digits. Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company achieved a milestone under the contract for $2.0 million, which was received during September 2020. The Company recognized revenue of $2.0 million during the year ended December 31, 2020. No revenue was recognized related to this agreement during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2seventy bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 20, 2018, the Company entered into a License Agreement with bluebird bio, Inc., or bluebird, whereby the Company granted bluebird the exclusive, worldwide rights to develop, manufacture, and commercialize certain cell therapy products containing binders. In November 2021, bluebird assigned the agreement, or the 2018 2seventy Agreement, to its affiliate, 2seventy bio, Inc., or 2seventy, in connection with an internal restructuring and subsequent spin-out of 2seventy. Under this agreement, the Company is entitled to receive specified development milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, a milestone event under the 2018 2seventy Agreement was achieved and the Company recognized $2.0 million of revenue at that point in time. The Company received the associated $2.0 million payment in August 2021. During the year ended December 31, 2021, the Company recognized a total of $2.0 million in revenue related to this agreement. During the year ended December 31, 2020, the Company recognized no revenue related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Option and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into an Option and License Agreement with bluebird, pursuant to which the Company granted to bluebird exclusive worldwide development licenses to develop binders and cell therapy products containing single domain antibodies, or sdAbs, directed to specified targets, consisting of two initial programs and up to an additional 8 programs. The Company retains all rights to the specific sdAbs outside of the cell therapy field. This agreement, or the 2020 2seventy Agreement, was also assigned to 2seventy in November 2021 in connection with bluebird&#x2019;s internal restructuring and subsequent spin-out of 2seventy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and is entitled to an upfront option fee for each additional program, on a program-by-program basis. The Company also granted an option in which 2seventy may acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which 2seventy exercises its option, 2seventy will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions for each option 2seventy chooses to exercise. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the effective date of the 2020 2seventy Agreement, the Company identified one performance obligation, which was the transfer of the exclusive development license to bluebird for the two initial programs. The Company determined that the option granted for an exclusive license in the future was not a material right. For the eight programs not identified upon execution of the contract, the Company evaluated the customer option for additional purchases and determined that those options for additional programs did not constitute material rights nor variable consideration. As additional programs are identified, the Company will re-assess its performance obligations and transaction price accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the total transaction price of the 2020 2seventy Agreement at execution was $0.4 million for the transfer of the two exclusive development licenses. The Company recognized $0.4 million of revenue related to this agreement at the point in time in which the exclusive development licenses were transferred to bluebird, which occurred upon execution of the agreement in June 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, pursuant to the option extension terms in the 2020 2seventy Agreement, bluebird requested to extend the option term for one of the initial programs by an additional six months in exchange for an option extension fee of $0.1&#160;million. The Company recognized the $0.1&#160;million of revenue related to this extension in May 2021, the point in time in which the extension was granted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, pursuant to the option exercise terms in the 2020 2seventy Agreement, the Company received a $2.1&#160;million option exercise fee for one of the initial programs and transferred an exclusive license for the program &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and recognized the $2.1&#160;million of revenue related to this option exercise at the point in time in which the exclusive license was transferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021 and 2020, the Company recognized $2.2&#160;million and $0.4&#160;million of revenue related to this agreement, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Phylaxis Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a joint venture with an entity affiliated with ArrowMark Partners, Phylaxis BioScience, LLC, or Phylaxis. In connection with the joint venture, the Company entered into the following agreements: Contribution Agreement, License Agreement, Limited Liability Company Agreement, and Master Services Agreement, or collectively the Phylaxis Agreements, pursuant to which the Company licensed certain intellectual property and know-how to Phylaxis and agreed to provide services to develop certain compounds. Upon closing, the Company received a $2.5&#160;million nonrefundable, upfront payment from Phylaxis under the Master Services Agreement, or the MSA. The Company has also received an additional $2.5&#160;million, which was payable within 180 days from closing under the MSA, in two payments of $1.25&#160;million each, received in October 2020 and January 2021. Upon closing, the Company received a 10% equity interest in Phylaxis as consideration for the contribution of the license of the Company&#x2019;s intellectual property and know-how and is entitled to receive an additional 5% based on the achievement of certain milestones. Under the License Agreement, the Company is also entitled to specified development and commercialization milestone payments of up to an aggregate of $225.0&#160;million and $175.0&#160;million, respectively. The Company is also entitled to share in a percentage of the profits of Phylaxis under the Limited Liability Company Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to determine the fair value of the equity interest in Phylaxis, the Company engaged a third-party valuation specialist. The valuation report utilized a market approach to establish the total equity value of Phylaxis using inputs not observable in the market, including the discount rate. The fair value of the equity interest was $0.5&#160;million, which has been accounted for under the equity method. The fair value of the equity interest upon the execution of the agreements has been included in the transaction price, along with the $5.0&#160;million of payments due pursuant to the MSA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified the transfer of the exclusive licenses for, and performance of, development services to modify the first and second compounds as one performance obligation and allocated the transaction price evenly between the two compounds. Revenue related to the performance obligation will be recognized over time as services are performed, based on the Company&#x2019;s progress to satisfy the performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021 and 2020, the Company recognized $2.4&#160;million and $2.0&#160;million of revenue related to this performance obligation, respectively. As of December&#160;31, 2021, the Company has $1.1&#160;million of deferred revenue related to this agreement, all of which is classified as current. As of December&#160;31, 2020, the Company had $1.6&#160;million and $0.6&#160;million of current and non-current deferred revenue related to this agreement, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chiesi&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the Company entered into an Option Agreement, as amended by the First Amendment to Option Agreement, dated August 19, 2019, or the Chiesi Option Agreement, with Chiesi Farmaceutici S.p.A., or Chiesi, pursuant to which the Company granted to Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada. Under the terms of the Chiesi Option Agreement, the Company received a one-time, non-refundable option initiation payment of $10.0 million in August 2019. If Chiesi chooses to exercise its option under the Chiesi Option Agreement, then Chiesi must pay the Company a one-time, non-refundable fee of $12.5 million upon the effective date of the definitive agreement granting Chiesi the exclusive license. If the option is exercised, under the license agreement, the Company may be entitled to receive specified milestone payments of up to $122.5 million, as well as royalties on future product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified one performance obligation as of the effective date of the Chiesi Option Agreement, which is to perform research and development services for Chiesi during the option period, which will continue (unless the Chiesi Option Agreement is terminated earlier by the Chiesi or the Company) until 60 days following the last to occur of (i) the Company&#x2019;s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration, or FDA, scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company&#x2019;s delivery to Chiesi of the finalized minutes from the definitive parallel European Medicines Agency health technology assessment, or EMA-HTA, scientific advice meeting conducted following completion of such Phase I Clinical Trial. The Company has determined that the option to grant a license in the future is not a material right.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $10.0 million upfront payment has been allocated to the single performance obligation. Revenue is recognized over time as services are performed during the option period, based on the Company&#x2019;s effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period. During the years ended December 31, 2021 and 2020, the Company recognized $0.5 million and $7.4 million in revenue related to this agreement, respectively. As of December&#160;31, 2021, the Company has $0.9 million and $0.1 million of current and non-current deferred revenue related to this agreement, respectively. As of December&#160;31, 2020, the Company had $1.4 million and $0.1 million of current and non-current deferred revenue related to this agreement, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Celgene&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2012, the Company entered into a Development and Option Agreement with Celgene whereby the Company granted Celgene an option to exclusively license certain intellectual property rights relating to the Company&#x2019;s CD47 checkpoint inhibitor. Upon grant of the Development and Option Agreement, Celgene made a non-refundable upfront option payment for the exclusive license. In June 2013, Celgene opted to exercise its right to license the intellectual property rights associated with the Company&#x2019;s CD47 therapeutic. The Company is also eligible to receive certain developmental and commercial milestones of an aggregate of $934.1&#160;million, assuming the achievement of all potential milestones in the agreement, as well as percentage tiered royalties based on future worldwide sales, with rates ranging between the high single-digits and low teens. The Company is obligated to pay 2% of future amounts received under the Development and Option Agreement to advisors who assisted the Company with the negotiation and other matters in connection with the Development and Option Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the uncertainty in the achievement of the developmental and commercial milestones, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. This will be re-assessed at each reporting period. No revenue was recognized under this agreement during the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant revenue was recognized in accordance with the Company&#x2019;s stated methodology discussed in Note 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CDMRP funded through the DoD &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During September 2018, the Company was awarded a grant by the CDMRP funded through the DoD by the U.S. Army Medical Research Acquisition Activity in the amount of approximately $0.3 million for the continued development of multi-specific antibodies for the treatment against Acinetobacter baumannii infection by circumventing development of bacterial resistance, or the 2018 DoD grant. The work under this grant began in December 2018 and was completed in September 2020. In February 2021, the Company was awarded an additional grant from the DoD in the amount of approximately $0.3 million for the development of sdAb based therapeutics targeting SARS-CoV-2 Spike protein for the treatment of COVID-19, or the 2021 DoD grant. Work under the grant began in February 2021 and is expected to continue through February 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from these grants is based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue is recognized when the Company incurs these covered expenses related to the grant&#x2019;s continued progression. The Company submits requests for reimbursement to the DoD for only those expenses which have been incurred by the Company in each period, resulting in reimbursement in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, $0.3 million has been recognized to date under the 2018 DoD grant, all of which has been received in cash from the DoD. As of December&#160;31, 2021, $106,000 has been recognized to date under the 2021 &lt;/span&gt;&lt;/div&gt;DoD grant, $86,000 of which has been received in cash from the DoD. During each of the years ended December 31, 2021 and 2020, $106,000 and $80,000 was recognized as revenue under the grants, respectively.</inbx:LicenseAndGrantRevenueTextBlock>
    <inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzIyNTAy_baf0b5cb-ac79-4345-b018-577bc3cc65a5">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total revenue recorded in the Company&#x2019;s consolidated statements of operations (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;License fee revenue from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elpiscience Biopharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total license fee revenue from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;License fee revenue from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2seventy bio, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phylaxis BioScience, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chiesi Farmaceutici S.p.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other license revenues from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total license fee revenue from non-affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Congressionally Directed Medical Research Program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i8a6aef8263df4b4394e27acda74d8862_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzQtMS0xLTEtMjQzNzY_23aa33ae-4600-46b3-be25-5874866cf0a1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5d9970bae2c434f937ba92ef27c5adf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzQtMy0xLTEtMjQzNzY_f5a26ba6-f309-4e95-b7ef-e7f0e2b19649"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i341109abd16e4f10b4e1e65b6337432b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzYtMS0xLTEtMjQzNzY_195658a2-6a05-4368-9e17-a031fbdf7fd9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i11c3275369d04c28ab7b49526e64a396_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzYtMy0xLTEtMjQzNzY_0f3fc12a-eb7f-4d11-aa15-8acce6a7031c"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i142ace6beb0a4e0cb0a31bdafc6073cb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzgtMS0xLTEtMzQ2Mzc_98251813-c8a1-457a-aa94-cb99468acb13"
      unitRef="usd">4200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ec1fc7e08a643bf8e0ed329426540bf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzgtMy0xLTEtMzQ2Mzc_93fb9713-8f7c-45b3-90ff-1fcf12ff3667"
      unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd9873f9e3a544e59ad94ffcbdc43d0e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzktMS0xLTEtMzQ2NDQ_bc52e2d1-62c4-4dd9-82cf-86d4851f22d6"
      unitRef="usd">2392000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7b7601189b5477d86501a51b482aa63_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzktMy0xLTEtMzQ2NDQ_0f4b29ad-d38f-4623-b8f4-a6259881741b"
      unitRef="usd">1993000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if36de08aad5f467f9e693d3ede931b29_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzgtMS0xLTEtMjQzNzY_f44ac1c8-2e20-41a5-a0e2-da12ff8ba9e8"
      unitRef="usd">533000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a51291642f448ec8cd027ba449ffffc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzgtMy0xLTEtMjQzNzY_fe91061e-e53c-4d9d-80d4-a3514723bb8b"
      unitRef="usd">7365000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifcea0ecd9c6b41f78dbf074f597078d2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzExLTEtMS0xLTI0Mzc2_849e3643-347a-4681-8349-ab88cf131a52"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9dd518d0ffae4538a37e20dd37eef51e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzExLTMtMS0xLTI0Mzc2_fc707c1e-dc4f-4da3-a8ec-395e4fe556ca"
      unitRef="usd">1050000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ff19098b1d84316ac86ea37db136e01_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzEyLTEtMS0xLTI0Mzc2_943250f6-5242-4700-a0a3-06027dd764a8"
      unitRef="usd">7125000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4d0d09c00524dfa9503fde259f37888_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzEyLTMtMS0xLTI0Mzc2_dfa1ff20-6bda-4805-9841-9af0a1acd0c5"
      unitRef="usd">10808000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14792fc3ee614e638bfb3b224a160754_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE2LTEtMS0xLTI0Mzc2_544699e0-a9b0-499c-8922-548ea22ef74e"
      unitRef="usd">106000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia67376928e9f4157be200ec20b14f188_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE2LTMtMS0xLTI0Mzc2_88ccb47c-7b6b-4260-9993-845e52eff74d"
      unitRef="usd">80000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8fd1e8d9a53a428686d8938f450e798b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE3LTEtMS0xLTI0Mzc2_622096c6-ec6e-47c1-817d-0f3870141997"
      unitRef="usd">106000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f5f2867b4374b8392c13581eb930e33_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE3LTMtMS0xLTI0Mzc2_f4f3d3a4-d10e-4812-b1d2-80eb08893f93"
      unitRef="usd">80000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE4LTEtMS0xLTI0Mzc2_7f5630a0-da8c-4d44-94a0-ff79acfe89e7"
      unitRef="usd">7231000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90YWJsZTpjMTcyYzU5ZmI3YTk0ODliOTk4Y2UyNWUzNzdkM2JiOC90YWJsZXJhbmdlOmMxNzJjNTlmYjdhOTQ4OWI5OThjZTI1ZTM3N2QzYmI4XzE4LTMtMS0xLTI0Mzc2_b9ff9bed-37bb-4d19-a77b-88d00a5047ad"
      unitRef="usd">12888000</us-gaap:Revenues>
    <inbx:CollaborativeArrangementMilestonePaymentsReceivable
      contextRef="i6590e8fbc4694172ba86e9ff761b35b1_I20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NTk5NjY_856f485a-937a-40af-99a7-2dcb86697575"
      unitRef="usd">100000000</inbx:CollaborativeArrangementMilestonePaymentsReceivable>
    <us-gaap:Revenues
      contextRef="ib4809a9a893f4d2c8042ea8a8edf9689_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NjA1Njc_4e7344b7-12c5-43d5-ba6a-e71f02a825c0"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5d9970bae2c434f937ba92ef27c5adf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NzkwOTc_49aa6a38-0ad6-4bc6-afc0-7b503b7c8753"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a6aef8263df4b4394e27acda74d8862_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NjA2Njg_f313c00b-f475-4a7b-8abc-3670ea1ebc12"
      unitRef="usd">0</us-gaap:Revenues>
    <inbx:CollaborativeArrangementDevelopmentMilestoneReceivable
      contextRef="i6a40dcc9d78543888f5c69df6b043678_I20181220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTAyNjQ_ff47a4b3-b40b-48cb-a61b-bc3880c39263"
      unitRef="usd">51500000</inbx:CollaborativeArrangementDevelopmentMilestoneReceivable>
    <us-gaap:Revenues
      contextRef="i698dae32d5a249e4b3a18d5a9465c4eb_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTA5MDc_33905dc9-cd46-4161-ad22-587056fc36a4"
      unitRef="usd">2000000</us-gaap:Revenues>
    <inbx:CollaborativeArrangementMilestonePaymentReceived
      contextRef="i271fbcd059344d279776e92017e48fd9_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTA5ODE_93222f9f-01f4-4a2b-8c1b-4b164d4f2a92"
      unitRef="usd">2000000</inbx:CollaborativeArrangementMilestonePaymentReceived>
    <us-gaap:Revenues
      contextRef="i09040213ce284863b236dce6b9e77648_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTEwNTk_55512117-2816-4501-9e05-d3daff42cf0a"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia212ff07ac3d4e76acd885a467fdf19e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzQzOTgwNDY1ODM5MzQ_a6e8c11f-32cd-4349-9d3f-6ac353b3137d"
      unitRef="usd">0</us-gaap:Revenues>
    <inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="i0e2033a7016a444c9b438b2366300cfe_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE1MjY_2492a705-f625-4cd5-b5e9-8e7b7bec2c91"
      unitRef="program">2</inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="i1083dfcb25d248699e857f5dda8cb53e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE1NzE_f377a6e4-b39f-45b2-9274-ed2a02b2ab4d"
      unitRef="program">8</inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="ifcfc29d4ec6340358e01e8204eb73565_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE5MzI_61b224b1-6aa8-454f-8f5b-e8c81c194f5e"
      unitRef="usd">200000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="i99c1b2eab0714268ae2f91d921ac33bc_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE5MzI_d62aaa7c-91cc-4304-86d1-f9dd1a49cc17"
      unitRef="usd">200000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="i0e2033a7016a444c9b438b2366300cfe_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE5Njc_e1fa2eb4-e98c-434f-a63b-3225053f7158"
      unitRef="program">2</inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="i37061eba67bd4d3d915360e78477ab20_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTE5OTI_7a44f377-1a45-4e7c-bd5d-01a6c37abc05"
      unitRef="usd">400000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inbx:CollaborativeArrangementDevelopmentMilestoneReceivable
      contextRef="i67acf789baa649c0af5372276d8d64e9_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTI3MDg_fe750441-c18a-409a-91e5-a83f5e45d2e6"
      unitRef="usd">51500000</inbx:CollaborativeArrangementDevelopmentMilestoneReceivable>
    <inbx:NumberOfPerformanceObligations
      contextRef="i0e2033a7016a444c9b438b2366300cfe_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTMzNDE_644b664e-84ba-432b-a25a-f0822681d50f"
      unitRef="performanceobligation">1</inbx:NumberOfPerformanceObligations>
    <inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="i0e2033a7016a444c9b438b2366300cfe_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTM0NDk_a28b331c-4709-4bac-ad64-0a768cae1eed"
      unitRef="program">2</inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="i1083dfcb25d248699e857f5dda8cb53e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTM1OTE_3f4f45d9-b561-4423-a10d-da021f6538cf"
      unitRef="program">8</inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="i37061eba67bd4d3d915360e78477ab20_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQwNjc_576770d9-6243-4672-9b18-7936d5fe6165"
      unitRef="usd">400000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inbx:CollaborativeAgreementExclusiveDevelopmentLicenses
      contextRef="i67acf789baa649c0af5372276d8d64e9_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQwOTU_f33ea29e-e6c9-4456-9322-3e87ce039924"
      unitRef="license">2</inbx:CollaborativeAgreementExclusiveDevelopmentLicenses>
    <us-gaap:Revenues
      contextRef="i26036eb0b6df49ce9df831623f43f4a3_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQxNTQ_e29a8f4c-609b-4767-879a-c768e66541ed"
      unitRef="usd">400000</us-gaap:Revenues>
    <inbx:CollaborativeArrangementNonrefundableOptionExtensionFee
      contextRef="i89ce3eba7b0a49238928411c43819b44_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQ1ODQ_2a804a6b-cef9-49e0-875a-fdd764103ce6"
      unitRef="usd">100000</inbx:CollaborativeArrangementNonrefundableOptionExtensionFee>
    <us-gaap:Revenues
      contextRef="ic67e70a01a3247d0a701bceabea7050e_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQ2MTY_c63a80a3-8730-4413-8902-50853b95c139"
      unitRef="usd">100000</us-gaap:Revenues>
    <inbx:CollaborativeArrangementNonrefundableOptionExtensionFee
      contextRef="i4c3132dfaadc4bcfaee034b1b2617d1c_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQ4MzQ_bf8d115d-ae26-4d88-9c5c-df237bcb6b9e"
      unitRef="usd">2100000</inbx:CollaborativeArrangementNonrefundableOptionExtensionFee>
    <us-gaap:Revenues
      contextRef="i53c3843a1089489cba9c3e221a109e69_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTQ5NjI_97e5bbf5-33b7-44c9-b572-603da8bb6258"
      unitRef="usd">2100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i029f0471f2e849158f5ea613d5e42420_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTUxMjU_81bcba72-f12e-4c42-8c3b-f58a561d3a4a"
      unitRef="usd">2200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8577557b2c0f4aff994327f2da3dcc87_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTUxMzM_8007162b-e9be-4bc8-8915-2ca99908411d"
      unitRef="usd">400000</us-gaap:Revenues>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="ie48c123d39ec4759bab8a2b5f5a6d11b_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzgwMw_acbdf286-38fb-4949-862c-8d25f2c68fd6"
      unitRef="usd">2500000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inbx:CollaborativeArrangementAdditionalPaymentReceivable
      contextRef="if7901dde9ee1429db2a92db83900b165_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzk0Mg_eb27fa03-1e62-4e0d-8ed4-fe2c300aad63"
      unitRef="usd">2500000</inbx:CollaborativeArrangementAdditionalPaymentReceivable>
    <inbx:CollaborativeArrangementAdditionalPaymentReceivablePeriod
      contextRef="iae6ad83c5ab34b7fa1f535c9d4959c05_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzk2MA_5f9bd769-9a04-411f-a669-2ddf64118046">P180D</inbx:CollaborativeArrangementAdditionalPaymentReceivablePeriod>
    <inbx:CollaborativeArrangementAdditionalPaymentReceivable
      contextRef="iafffed7f22504c3dbc95651d314d0c59_I20201031"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzk5MQ_ad4b4938-a1e4-41ad-897f-3c8970c6670f"
      unitRef="usd">1250000</inbx:CollaborativeArrangementAdditionalPaymentReceivable>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i71b075ff878e44c4922334a3be94c8cf_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwNzA_81ad648a-eed1-44e0-a64b-9c05c58f8457"
      unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <inbx:EquityMethodInvestmentAdditionalOwnershipEntitled
      contextRef="i71b075ff878e44c4922334a3be94c8cf_I20200731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEyNDc_4aefa60e-dac1-49ad-bc2c-fc907a0ebba1"
      unitRef="number">0.05</inbx:EquityMethodInvestmentAdditionalOwnershipEntitled>
    <inbx:CollaborativeArrangementDevelopmentMilestoneReceivable
      contextRef="if7901dde9ee1429db2a92db83900b165_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzE0NDc_7fb5855d-3524-4606-89ab-2e3a222b3e59"
      unitRef="usd">225000000</inbx:CollaborativeArrangementDevelopmentMilestoneReceivable>
    <inbx:CollaborativeArrangementCommercializationMilestoneReceivable
      contextRef="if7901dde9ee1429db2a92db83900b165_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzE0NTQ_58bbc75f-24d6-4a6c-b4e7-e674db9b606b"
      unitRef="usd">175000000</inbx:CollaborativeArrangementCommercializationMilestoneReceivable>
    <us-gaap:EquityMethodInvestments
      contextRef="if7901dde9ee1429db2a92db83900b165_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzE5Mzk_9c5e018c-4f96-4a13-99cc-4f727fe5dd5a"
      unitRef="usd">500000</us-gaap:EquityMethodInvestments>
    <inbx:CollaborativeArrangementPaymentReceivable
      contextRef="if7901dde9ee1429db2a92db83900b165_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzIxMzE_2b39443d-492c-48f2-8e49-cfd61e1ba4fb"
      unitRef="usd">5000000</inbx:CollaborativeArrangementPaymentReceivable>
    <inbx:NumberOfPerformanceObligations
      contextRef="if7901dde9ee1429db2a92db83900b165_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzIzMjM_27a74370-3236-46c5-8d84-6209b80cb4a7"
      unitRef="performanceobligation">1</inbx:NumberOfPerformanceObligations>
    <inbx:RevenueRecognitionNumberOfCompounds
      contextRef="if7901dde9ee1429db2a92db83900b165_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzI0MDQ_4a6c436f-59de-4885-984a-3bfee5e53adc"
      unitRef="compound">2</inbx:RevenueRecognitionNumberOfCompounds>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ifd9873f9e3a544e59ad94ffcbdc43d0e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzI2MzA_ffa02f7e-ef58-41c5-8711-d3716daf1822"
      unitRef="usd">2400000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="id7b7601189b5477d86501a51b482aa63_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NzkxMDk_a19df6d7-faa6-4f61-b04e-c3f1f356dadb"
      unitRef="usd">2000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8db766ee7ea14809bda578860b7d5f45_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzE2NDkyNjc0OTc5MTg_1adee84a-86be-4f30-8f51-01b30235b00d"
      unitRef="usd">1100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie3960dc6272747bc82dddb1552b4d038_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NzkxMTg_0853ffd6-21df-4933-945a-03b6208a3d74"
      unitRef="usd">1600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie3960dc6272747bc82dddb1552b4d038_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2NzkxMjQ_d81f8b48-4660-402a-bb79-13457c581b46"
      unitRef="usd">600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="i65490e5c0be44ba79b6d213cefb118a6_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTg0MDU_bdf22fce-09e4-4428-9e3d-4bdae5db7f22"
      unitRef="usd">10000000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inbx:CollaborativeArrangementAdditionalPaymentReceivable
      contextRef="i52cdafa4cb7a4f99adc30a5a1c93624f_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTg1Njg_622f9ebb-15dd-4cf7-a25b-533fcd1d3cd7"
      unitRef="usd">12500000</inbx:CollaborativeArrangementAdditionalPaymentReceivable>
    <inbx:CollaborativeArrangementMilestonePaymentsReceivable
      contextRef="i52cdafa4cb7a4f99adc30a5a1c93624f_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTg3OTc_7d527fb2-1799-417a-a0f6-43d890e123e4"
      unitRef="usd">122500000</inbx:CollaborativeArrangementMilestonePaymentsReceivable>
    <inbx:NumberOfPerformanceObligations
      contextRef="i232e3ecd8bfe4c2aa8c2c245ad98b7c9_I20190819"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTg4NzU_65e2f824-7050-452a-9364-299b974614f6"
      unitRef="performanceobligation">1</inbx:NumberOfPerformanceObligations>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment
      contextRef="i65490e5c0be44ba79b6d213cefb118a6_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2OTk4MTY_bdf22fce-09e4-4428-9e3d-4bdae5db7f22"
      unitRef="usd">10000000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="if36de08aad5f467f9e693d3ede931b29_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAxNzM_15a77d3c-5814-4645-ac69-90310e5a8fb2"
      unitRef="usd">500000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i5a51291642f448ec8cd027ba449ffffc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAxODE_83c8b7d9-06af-45a3-914a-135516f27669"
      unitRef="usd">7400000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9dfab9b39f19493b85149f07e9d3107b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAyNjQ_db865b55-3860-43fe-bc91-84b3c5ba43a2"
      unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9dfab9b39f19493b85149f07e9d3107b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAyNzI_0ecf02b4-cc69-44d7-b56a-f31c242aa24f"
      unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iecd1fc01bfe349e38bce8388ae5742cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAzODg_e82bc5e4-0327-480c-adb4-17686ffd57c2"
      unitRef="usd">1400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iecd1fc01bfe349e38bce8388ae5742cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE3MDAzOTY_75ff469d-28e3-4712-ad4b-fc5a13dcac70"
      unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <inbx:CollaborativeArrangementDevelopmentMilestoneReceivable
      contextRef="i8b51a3f85ef8434cbdc45bc15a773289_I20130630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzQzOTgwNDY1ODU3MjA_9758de76-2611-405f-b232-a43e73a78b46"
      unitRef="usd">934100000</inbx:CollaborativeArrangementDevelopmentMilestoneReceivable>
    <inbx:CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay
      contextRef="i8b51a3f85ef8434cbdc45bc15a773289_I20130630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzQzOTgwNDY1ODU3MzY_f5faf094-1c2a-44b7-81f8-7a54dfdd693d"
      unitRef="number">0.02</inbx:CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay>
    <inbx:GrantValuedAwarded
      contextRef="i29ef6bdd06234b22b93dd43c5eff449b_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzIxNTk0_c2baffb5-22d1-4818-9238-e88efdaf09c2"
      unitRef="usd">300000</inbx:GrantValuedAwarded>
    <inbx:GrantValuedAwarded
      contextRef="i7fbcce74ea2b42b78bf1705bd1403dfd_I20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4NzA_6d85294d-77d3-4e02-9e50-8023b12a24f3"
      unitRef="usd">300000</inbx:GrantValuedAwarded>
    <us-gaap:Revenues
      contextRef="iad2111df94964e5485832ec9af0f84c0_D20181201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4Mzk_f5c1ceed-5699-4005-99cc-178fb83b64f7"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04bdb4d1a6f84aaaa9f1469326060cc7_D20210201-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4NDg_d9804741-44b0-4cf9-ad6e-8259f37c4f33"
      unitRef="usd">106000</us-gaap:Revenues>
    <inbx:RevenuesCashReceived
      contextRef="i04bdb4d1a6f84aaaa9f1469326060cc7_D20210201-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4NTQ_f70f35e5-03ff-41df-b70a-78089a114852"
      unitRef="usd">86000</inbx:RevenuesCashReceived>
    <us-gaap:Revenues
      contextRef="i14792fc3ee614e638bfb3b224a160754_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4NjY_5bc85997-cf1d-49b1-add7-072aa8b4b3d5"
      unitRef="usd">106000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia67376928e9f4157be200ec20b14f188_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yMzgvZnJhZzpkMWIxNjJkNjM0Zjg0M2EzOTA2MWNjYTIwZWQ5ZmVjZi90ZXh0cmVnaW9uOmQxYjE2MmQ2MzRmODQzYTM5MDYxY2NhMjBlZDlmZWNmXzEwOTk1MTE2ODM4MjU_750c6e9e-2593-45c9-9444-760ec2a8a47d"
      unitRef="usd">80000</us-gaap:Revenues>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzMwNTU_337fe467-6dc9-4452-bc80-529e88b87df8">RELATED PARTY TRANSACTIONS &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business. These agreements are ratified by the Company&#x2019;s Board of Directors or a committee thereof pursuant to policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LAV Summit Limited &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LAV Summit Limited, or LAV SL, a limited company, is a principal shareholder owning more than 5% of the Company&#x2019;s outstanding equity interest during the year ended December&#160;31, 2021. Due to this equity ownership, LAV SL was considered a related party. LAV SL&#x2019;s General Partner, Lilly Asia Ventures, or LAV, through one of its funds, holds a significant equity ownership position in Elpiscience, and the Venture Partner of LAV is the CEO, Founder, and Director at Elpiscience. Accordingly, the Company identified Elpiscience as a related party. As of December&#160;31, 2021, LAV SL no longer holds more than 5% of the Company&#x2019;s outstanding equity interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Elpiscience&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company entered into the OX40 License Agreement with Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company&#x2019;s multivalent protein therapeutic directed to the biological target OX40, or INBRX-106. Under this agreement, the Company is entitled to reimbursement for certain chemistry, manufacturing, and controls, or CMC, and toxicology expenses incurred for which Elpiscience has paid the Company approximately $5.2 million to date as of December&#160;31, 2021. As of December&#160;31, 2021, the Company has $0.2 million recorded as receivables from related parties from Elpiscience for expenses incurred which have not yet been reimbursed. Additional reimbursements of approximately $38,000 related to multi-year stability studies are expected to be recognized and paid upon completion. During the year ended December 31, 2021, the Company received no reimbursements for expenses already incurred. During the year ended December 31, 2020, the Company received reimbursements of $0.2 million for expenses already incurred. During the year ended December 31, 2021, the Company did not derecognize any expenses related to these reimbursements under the OX40 License Agreement. During the year ended December 31, 2020, the Company derecognized approximately $0.2 million of expenses related to these reimbursements under the OX40 License Agreement, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into an additional cost sharing agreement with Elpiscience related to the OX40 License Agreement. Under this agreement, the Company is entitled to reimbursement for certain formulation development costs. Through December&#160;31, 2021, the Company has received $0.2 million of reimbursements for expenses already incurred under this agreement. As of December&#160;31, 2021, the Company has approximately $0.3 million recorded as receivables from related parties from Elpiscience for expenses incurred which have not yet been reimbursed. During the year ended December 31, 2021, the Company received reimbursements of $0.2 million for expenses already incurred. During the year ended December 31, 2021, the Company did not derecognize any expenses related to this agreement. During the year ended December 31, 2020, the Company received no reimbursements. During the year ended December 31, 2020, the Company derecognized $0.3 million of expenses related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company entered into a Sale and Purchase Agreement with Elpiscience, in which the Company sold drug substance supply to Elpiscience for approximately $37,000, for which it derecognized expenses during the year ended December 31, 2021. As of December&#160;31, 2021, the Company has $37,000 recorded as receivables from related parties for this purchase.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <inbx:RelatedPartyEquityInterestInCompany
      contextRef="i5bf66075080045f5ab3fa12625764cd4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzM4MA_acbf1da7-0bff-4c9a-8c0b-c67b2678351e"
      unitRef="number">0.05</inbx:RelatedPartyEquityInterestInCompany>
    <inbx:RelatedPartyEquityInterestInCompany
      contextRef="i5bf66075080045f5ab3fa12625764cd4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzQzOTgwNDY1MjQ4Njk_acbf1da7-0bff-4c9a-8c0b-c67b2678351e"
      unitRef="number">0.05</inbx:RelatedPartyEquityInterestInCompany>
    <inbx:ExpensesReimbursedToDate
      contextRef="i98668daa4f54447a8199b989b8876b3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2Mzg3MzI_df1bdfad-7396-4a22-b497-6833f129ff68"
      unitRef="usd">5200000</inbx:ExpensesReimbursedToDate>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i98668daa4f54447a8199b989b8876b3f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2MzkwNjM_ee5cb033-9a82-4460-a78c-45e5e8722dd8"
      unitRef="usd">200000</us-gaap:ContractWithCustomerAssetNet>
    <inbx:ExpensesExpectedToBeReimbursed
      contextRef="i98668daa4f54447a8199b989b8876b3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzE2NDkyNjc0NTUxMDA_c11d72df-ed03-4fd4-9489-9b9090862427"
      unitRef="usd">38000</inbx:ExpensesExpectedToBeReimbursed>
    <inbx:CollaborativeArrangementExpenseReimbursement
      contextRef="if065b432564046c9bfb0a597fe817533_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzE2NDkyNjc0NTUxMDU_91c82bb5-a6d4-4550-9d04-c9a7ec4eff6e"
      unitRef="usd">0</inbx:CollaborativeArrangementExpenseReimbursement>
    <inbx:CollaborativeArrangementExpenseReimbursement
      contextRef="i5ebe67fc2c1e4f268cfb5159168b291a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2Mzk2Njk_0b5a34c5-a530-4ce7-98b0-24e7561d5ce1"
      unitRef="usd">200000</inbx:CollaborativeArrangementExpenseReimbursement>
    <inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod
      contextRef="if065b432564046c9bfb0a597fe817533_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzQzOTgwNDY1MjQ2MDU_4b95013e-551c-4915-8de4-e599865bb3e9"
      unitRef="usd">0</inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod>
    <inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod
      contextRef="i5ebe67fc2c1e4f268cfb5159168b291a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2Mzk2OTk_26d599ee-8bf6-4023-a7dc-e5489eac0a3b"
      unitRef="usd">200000</inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod>
    <inbx:ExpensesReimbursedToDate
      contextRef="ie1d04a4699dc49db872fde8657a661e6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDA5NDQ_cd1b7565-3db3-410a-8989-102e7ff90af5"
      unitRef="usd">200000</inbx:ExpensesReimbursedToDate>
    <inbx:CollaborativeArrangementReceivablesFromRelatedParties
      contextRef="ie1d04a4699dc49db872fde8657a661e6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDA5NTM_226452a6-6297-4e5c-b653-2a569ddf8d56"
      unitRef="usd">300000</inbx:CollaborativeArrangementReceivablesFromRelatedParties>
    <inbx:CollaborativeArrangementExpenseReimbursement
      contextRef="i1308cbf39e914b3390c47254ceff94af_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDA5OTg_105628a4-420f-4dbe-9d31-2d15f5085c6b"
      unitRef="usd">200000</inbx:CollaborativeArrangementExpenseReimbursement>
    <inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod
      contextRef="i3cfee3e7350642afb89fae53b611c85e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDEwMzk_71bad12c-eec1-415b-bffe-12934bd7c9d5"
      unitRef="usd">300000</inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod>
    <inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod
      contextRef="ia72fe4742bba4cdf9802783a4d7a8394_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDA2MTM_794cae29-8cd8-4744-bf47-76fd958f596c"
      unitRef="usd">37000</inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod>
    <inbx:CollaborativeArrangementReceivablesFromRelatedParties
      contextRef="id5a16567fbac48168a3ad10ee9c58f87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDEvZnJhZzpiZTZjOTk2ZjU5MjM0MDUyYTI1NGFkZDVmMWY5Y2ZmMC90ZXh0cmVnaW9uOmJlNmM5OTZmNTkyMzQwNTJhMjU0YWRkNWYxZjljZmYwXzEwOTk1MTE2NDA5Mzg_cc79fd91-1d0e-43d9-8ae1-2c4ce02cd178"
      unitRef="usd">37000</inbx:CollaborativeArrangementReceivablesFromRelatedParties>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzYyMDA_83d91ff8-3c24-4078-b2f4-7ae861593137">INCOME TAXES The components of income tax expense (benefit) were as follows for the years ended December 31, 2021 and 2020, respectively (in thousands): &lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for the years ended December 31, 2021 and 2020 was related to California state income tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2021 and 2020 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected income tax benefit at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(17,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(15,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (benefit), net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits (FIN 48)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision true-ups&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net deferred income taxes were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;43,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;27,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(58,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(39,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had unused federal and state NOL carryforwards of approximately $198.9 million and $24.5 million, respectively. The federal NOL carryforwards may be carried forward indefinitely but are only available to offset up to 80% of pre-NOL taxable income each year. The state NOL carryforwards will begin to expire in 2038, if not utilized. As of December&#160;31, 2021, the Company also had federal and state research tax credit carryforwards of $8.3 million and $3.9 million, respectively. The federal research tax credit carryforwards begin to expire in 2038, while the state carryforwards have no expiration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The utilization of NOL and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an &#x201c;ownership change&#x201d; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change has occurred, the Company&#x2019;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established a full valuation allowance against its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December&#160;31, 2021. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#x2019;s projections for future growth. Based on this evaluation, as of December&#160;31, 2021, a valuation allowance of $58.5 million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#x2019;s projections for growth. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had gross unrecognized tax benefits of $2.8 million, none of which would affect the effective tax rate due to the existence of a full valuation allowance. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company&#x2019;s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets as of December&#160;31, 2021 or December 31, 2020, and has not recognized interest and/or penalties in its consolidated statements of operations for the years ended December 31, 2021 and 2020 as the unrecognized tax benefits relate to tax positions for which no cash tax liability has been reduced. &lt;/span&gt;&lt;/div&gt;The Company is subject to income taxes in the United States and various state jurisdictions. The Company&#x2019;s tax years from 2018 and forward are subject to examination by the United States and state tax authorities. The Company has not been, nor is it currently, under examination by the U.S. federal or any state tax authority.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzYyMDE_6091fe51-2378-4b8e-bda8-70cf8d829be0">The components of income tax expense (benefit) were as follows for the years ended December 31, 2021 and 2020, respectively (in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo3NDU2MzM0MmExNzE0NjJiYTMxYjc5MWNmMjVjZDExZi90YWJsZXJhbmdlOjc0NTYzMzQyYTE3MTQ2MmJhMzFiNzkxY2YyNWNkMTFmXzMtMS0xLTEtMjQzNzY_e4ca8968-2dd2-4bd1-b8ca-ed5af49a436b"
      unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo3NDU2MzM0MmExNzE0NjJiYTMxYjc5MWNmMjVjZDExZi90YWJsZXJhbmdlOjc0NTYzMzQyYTE3MTQ2MmJhMzFiNzkxY2YyNWNkMTFmXzMtMy0xLTEtMjQzNzY_ae610292-4f08-46f8-9452-c0b6a9c2ec9d"
      unitRef="usd">3000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo3NDU2MzM0MmExNzE0NjJiYTMxYjc5MWNmMjVjZDExZi90YWJsZXJhbmdlOjc0NTYzMzQyYTE3MTQ2MmJhMzFiNzkxY2YyNWNkMTFmXzUtMS0xLTEtMjQzNzY_ad093a6d-f7ad-4cca-98bc-aa5041831529"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo3NDU2MzM0MmExNzE0NjJiYTMxYjc5MWNmMjVjZDExZi90YWJsZXJhbmdlOjc0NTYzMzQyYTE3MTQ2MmJhMzFiNzkxY2YyNWNkMTFmXzUtMy0xLTEtMjQzNzY_0b1c6eec-b270-4a9f-9a03-a0a0b0da2921"
      unitRef="usd">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzYyMDI_1ed1a2d9-3ca4-4e9c-af34-bb412eaf343e">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2021 and 2020 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected income tax benefit at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(17,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(15,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (benefit), net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits (FIN 48)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision true-ups&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzItMS0xLTEtMjQzNzY_45da2fdd-f6b8-4bf7-8866-4260252c1f8b"
      unitRef="usd">-17171000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzItMy0xLTEtMjQzNzY_55118da7-2a83-4d3a-b319-219141a4e988"
      unitRef="usd">-15985000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzMtMS0xLTEtMjQzNzY_53413b0b-57e5-48c2-ad91-38450e377863"
      unitRef="usd">-1006000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzMtMy0xLTEtMjQzNzY_50b35cb5-5ebf-4080-95aa-bd33ebc31254"
      unitRef="usd">4548000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <inbx:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzQtMS0xLTEtMjQzNzY_f5b9cce2-c89f-4c45-ba06-7a24498bd5d2"
      unitRef="usd">-207000</inbx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <inbx:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzQtMy0xLTEtMjQzNzY_214a4ab9-2f6d-4bf4-86f5-0fbd713bdd49"
      unitRef="usd">2291000</inbx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzUtMS0xLTEtMjQzNzY_9aeaa944-5926-440e-9666-41d6b18397fb"
      unitRef="usd">1912000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzUtMy0xLTEtMjQzNzY_19d284c0-1444-4356-8980-87d535f9bfaf"
      unitRef="usd">2878000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzYtMS0xLTEtMjQzNzY_e11374b0-6186-4856-b938-33ab58a198ac"
      unitRef="usd">691000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzYtMy0xLTEtMjQzNzY_f230209b-a5e1-4e67-b5eb-f604c963be3b"
      unitRef="usd">707000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <inbx:EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzgtMS0xLTEtMjQzNzY_3c1d15d4-b8fd-41b6-93b9-aa4beb467c35"
      unitRef="usd">165000</inbx:EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps>
    <inbx:EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzgtMy0xLTEtMjQzNzY_3c5ff9c3-c218-4662-9a35-8651377a43a9"
      unitRef="usd">164000</inbx:EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzktMS0xLTEtMjQzNzY_6beda448-d930-410b-8246-1a1c75ee6b6f"
      unitRef="usd">19442000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzktMy0xLTEtMjQzNzY_9f3eb08c-6f61-4e5e-8e24-5f996d92e5ee"
      unitRef="usd">11156000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzEwLTEtMS0xLTI0Mzc2_202fcd9a-814f-4d90-930b-e550e8c5a07f"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTpiY2RlNGIxMjZiYjA0YzE5YWNjOTJlMTE1ZWRjZGY0ZC90YWJsZXJhbmdlOmJjZGU0YjEyNmJiMDRjMTlhY2M5MmUxMTVlZGNkZjRkXzEwLTMtMS0xLTI0Mzc2_be04df6c-99d4-47a9-9389-3047738aab8a"
      unitRef="usd">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzYyMDM_40531215-6701-405e-a28d-89c112d1fd7d">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net deferred income taxes were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;43,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;27,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(58,528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(39,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzMtMS0xLTEtMjQzNzY_c50b34cc-187a-4b88-8d10-3b1add6d3815"
      unitRef="usd">43440000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzMtMy0xLTEtMjQzNzY_5c9511c4-3acf-4c0f-924b-f5b3163f9a33"
      unitRef="usd">27055000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzQtMS0xLTEtMjQzNzY_af7c77ff-d5cb-4622-a91b-2a335268d919"
      unitRef="usd">8539000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzQtMy0xLTEtMjQzNzY_6f694165-d0f1-4336-8901-54595d44792d"
      unitRef="usd">6465000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzUtMS0xLTEtMjQzNzY_960ef664-7df2-4b4a-8ddc-f77a9fdff4e1"
      unitRef="usd">3875000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzUtMy0xLTEtMjQzNzY_a68d6ab0-fbd3-4d50-9ad6-0c02d361b996"
      unitRef="usd">4176000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzYtMS0xLTEtMjQzNzY_6a213a9f-bc25-4a60-92e3-dc8882c26d72"
      unitRef="usd">257000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzYtMy0xLTEtMjQzNzY_cab33b31-53cb-4485-9bff-85fb1908936c"
      unitRef="usd">233000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzctMS0xLTEtMjQzNzY_3aff59fb-fc2f-4724-80e3-6bc417351776"
      unitRef="usd">1888000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzctMy0xLTEtMjQzNzY_e66e59d2-e04c-4f0e-b19c-ef2bc74b19f9"
      unitRef="usd">409000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzktMS0xLTEtMjQzNzY_b11ebf92-7124-482d-bbad-2248a3403a06"
      unitRef="usd">456000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzktMy0xLTEtMjQzNzY_082e5cc7-4267-4d44-a9f4-c790513e9b1d"
      unitRef="usd">806000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <inbx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEwLTEtMS0xLTI0Mzc2_b4eedb08-3573-4010-b977-6d9a731da138"
      unitRef="usd">1428000</inbx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <inbx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEwLTMtMS0xLTI0Mzc2_dd7862f8-2346-4e46-b5de-e00ea6b94a1c"
      unitRef="usd">1733000</inbx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEyLTEtMS0xLTI0Mzc2_e18eface-5c79-4954-81a9-846b0f13840c"
      unitRef="usd">14000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEyLTMtMS0xLTI0Mzc2_858e9d51-603f-44ca-868a-412cd0999cd3"
      unitRef="usd">3000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEzLTEtMS0xLTI0Mzc2_59b8a16c-5595-45de-a932-4bc4dd062314"
      unitRef="usd">59897000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzEzLTMtMS0xLTI0Mzc2_3e163d52-045a-454e-beb4-af1bfa29f28b"
      unitRef="usd">40880000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE0LTEtMS0xLTI0Mzc2_8d1422ce-7455-4ba1-8b1a-c79c85110eab"
      unitRef="usd">58528000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE0LTMtMS0xLTI0Mzc2_cb664c92-1698-4d18-a5c8-a40ad7468c66"
      unitRef="usd">39087000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE1LTEtMS0xLTI0Mzc2_194a77b2-fa06-48f9-886b-bf5552e36e24"
      unitRef="usd">1369000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE1LTMtMS0xLTI0Mzc2_cdd3d410-92d3-405d-96d6-bcc9d832b778"
      unitRef="usd">1793000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE3LTEtMS0xLTI0Mzc2_3b9d24cd-80e5-4c3f-aea1-5914899fb69f"
      unitRef="usd">20000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE3LTMtMS0xLTI0Mzc2_7892191d-8bd9-4f64-94db-7454e2d6dfad"
      unitRef="usd">140000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE4LTEtMS0xLTI0Mzc2_a781d38e-ef41-47de-a7dd-9fd2b1d247df"
      unitRef="usd">1349000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE4LTMtMS0xLTI0Mzc2_b376f7d0-e575-43a1-84c2-647bcc14e35b"
      unitRef="usd">1653000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE5LTEtMS0xLTI0Mzc2_06c83a36-d93f-49cf-889f-120c312c5918"
      unitRef="usd">1369000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzE5LTMtMS0xLTI0Mzc2_0c327f06-1a55-4312-ab4c-dd0b4cd8be5f"
      unitRef="usd">1793000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzIwLTEtMS0xLTI0Mzc2_e8cf20d2-2a53-4f40-ba5f-d57a0fe80eb0"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTplNmNlOGY5ZGVjOWE0NDE4OGE0MDI1ZmViNjA3ZGFiMi90YWJsZXJhbmdlOmU2Y2U4ZjlkZWM5YTQ0MTg4YTQwMjVmZWI2MDdkYWIyXzIwLTMtMS0xLTI0Mzc2_694516e8-4531-4313-a430-bf7ea22554cf"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2035d7358b324a5489bcf06a61d764cb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzEyMTQ_0c87aafb-63ae-401a-b911-8702006b5ad8"
      unitRef="usd">198900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ieee515f8958047ef8b35c147f98db98e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzEyMjE_c165439e-475b-409b-a0f1-1961843be273"
      unitRef="usd">24500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="icd2cf3902be24fe99f49b14a22a00695_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzE3MTg_41a44cf7-38c7-4148-8c9e-c5e25aa61e0e"
      unitRef="usd">8300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i61def5f79b3b4943a515f38e57f56fa7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzE3MjU_275e1966-7d74-46bf-922e-3247677f9c60"
      unitRef="usd">3900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzM4MTI_dfe33e86-e36c-494f-9ce9-27c1e216d010"
      unitRef="usd">58500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzYxOTk_0eff9abb-b06b-4c24-9e71-cfcdb56c3543">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzItMS0xLTEtMjQzNzY_b6c80a96-0e7b-43f8-aef8-a911e4047031"
      unitRef="usd">2155000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i25366f43bada4f5b9d53d088a682e118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzItMy0xLTEtMjQzNzY_ad39db55-014b-4c19-acad-e49d3df7bcfd"
      unitRef="usd">1499000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzMtMS0xLTEtMjQzNzY_8b7cf780-7399-4ce3-b39b-de28812262e9"
      unitRef="usd">691000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzMtMy0xLTEtMjQzNzY_dbecb5b3-0fa1-498a-b48a-d430418cb023"
      unitRef="usd">656000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzQtMS0xLTEtMjQzNzY_fed61c0c-31ae-4450-a85e-54ac7f3415b9"
      unitRef="usd">2846000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90YWJsZTo4ZmFmZjdlNmU2Zjg0NGRjYTAyYWQyN2YyZGZmMDg0OS90YWJsZXJhbmdlOjhmYWZmN2U2ZTZmODQ0ZGNhMDJhZDI3ZjJkZmYwODQ5XzQtMy0xLTEtMjQzNzY_706d2497-cf7a-4622-8314-c5cf1633a6a1"
      unitRef="usd">2155000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzUyMTQ_28e8ba7d-44aa-45de-814d-ba6ded4a7abe"
      unitRef="usd">2800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzU2MDY_a3e9f70c-84b3-4582-b374-c561ed1beb57"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzU2MDY_eb7d5e3f-d5fb-4685-9e1c-029e7826c5d6"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzU3MTc_725b2379-9c8f-41a7-903d-50e35c3b1564"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDQvZnJhZzoyZTM1NjdmMjcxMjQ0MzFjODc0YmM0OTlhZDc0NDBiNi90ZXh0cmVnaW9uOjJlMzU2N2YyNzEyNDQzMWM4NzRiYzQ5OWFkNzQ0MGI2XzU3MTc_d51a3957-7fc2-4cfb-8dae-9fe82b362bbc"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NDk_12a99af4-2ed3-4cdc-a3b6-9fa6137e07ef">LEASES &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company entered into a seven-year lease agreement for approximately 34,000 square feet as its sole location in La Jolla, California. The lease expires in June 2025 with an option to extend the lease an additional five years. The lease contained an initial base rent of approximately $0.1 million per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the Company executed an amendment to its lease agreement to expand its facilities by approximately 9,000 square feet and began occupying this space in January 2020. The amended lease terminates coterminously with the initial lease agreement and contains an initial base rent of approximately $30,000 per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right-of-use asset and operating lease liability as of December&#160;31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During each of the years ended December 31, 2021 and 2020, the Company recognized operating lease expense of $3.1 million. As of December&#160;31, 2021 and 2020, the Company&#x2019;s operating lease had a remaining term of 3.5 and 4.5 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of 8.2% as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum rental payments under operating leases are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i83fc42be157249d68dc8368a8c9862be_I20170930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NTA_394741e0-6d0c-43c3-958b-fc4a506c490a">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <inbx:LesseeOperatingLeaseSquareFootage
      contextRef="i83fc42be157249d68dc8368a8c9862be_I20170930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzExMg_7eb452c7-4d12-4fbf-aebe-c21ce67b1515"
      unitRef="sqft">34000</inbx:LesseeOperatingLeaseSquareFootage>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i83fc42be157249d68dc8368a8c9862be_I20170930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzI0Ng_62991d84-055a-41e0-93b0-a1e087acbd5d">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth
      contextRef="i83fc42be157249d68dc8368a8c9862be_I20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzMwOA_2ba2a607-77b2-4162-9864-f33ab57b7f0c"
      unitRef="usd">100000</inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth>
    <inbx:LesseeOperatingLeaseAnnualEscalations
      contextRef="i83fc42be157249d68dc8368a8c9862be_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzMyNg_362d60d3-97f9-46df-b592-76a7c7088e35"
      unitRef="number">0.02</inbx:LesseeOperatingLeaseAnnualEscalations>
    <inbx:LesseeOperatingLeaseSquareFootageExpansion
      contextRef="i521b2e3a6dc44d48afe6adc72a12b794_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzY0MQ_7e2ea18b-1d19-4909-a119-a3c3eacc9c0b"
      unitRef="sqft">9000</inbx:LesseeOperatingLeaseSquareFootageExpansion>
    <inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth
      contextRef="i521b2e3a6dc44d48afe6adc72a12b794_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzgyMQ_efb718ae-f84c-4c67-8ed2-72f6afa03e3d"
      unitRef="usd">30000</inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth>
    <inbx:LesseeOperatingLeaseAnnualEscalations
      contextRef="i521b2e3a6dc44d48afe6adc72a12b794_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzgzOQ_7f903673-8436-4091-8d27-0d79f359d716"
      unitRef="number">0.02</inbx:LesseeOperatingLeaseAnnualEscalations>
    <inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NDY_1fdf5b8c-d444-4179-8831-c573bc77d602">The right-of-use asset and operating lease liability as of December&#160;31, 2021 and 2020 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzItMS0xLTEtMjQzNzY_89ccbda6-3280-4154-accf-d2ee1b95e1d0"
      unitRef="usd">6338000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzItMy0xLTEtMjQzNzY_c4975eeb-be87-41bb-b89d-80972703f116"
      unitRef="usd">7831000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzUtMS0xLTEtMjQzNzY_8ffa465c-ec33-4e0b-8434-eccfab2325f6"
      unitRef="usd">1674000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzUtMy0xLTEtMjQzNzY_52ad0dee-36a2-4313-bfb8-32b84b3ae056"
      unitRef="usd">1503000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzYtMS0xLTEtMjQzNzY_4404742b-b045-4d6f-8a9e-9d0ade0327ba"
      unitRef="usd">5033000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzYtMy0xLTEtMjQzNzY_5448cc50-7782-4f43-be7e-3ca2d23e48c2"
      unitRef="usd">6707000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzctMS0xLTEtMjQzNzY_97e82be9-7857-4e03-9121-425b4fb750ee"
      unitRef="usd">6707000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo5YWUxNzhjMzc3YWE0YTg4ODljNTI3ODY1YmQxZDhhMy90YWJsZXJhbmdlOjlhZTE3OGMzNzdhYTRhODg4OWM1Mjc4NjViZDFkOGEzXzctMy0xLTEtMjQzNzY_d041395a-4998-4e33-bbe1-94d01127b7b8"
      unitRef="usd">8210000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzEyMTY_0a1c799f-917c-495d-bed8-bfa6abaad9f6"
      unitRef="usd">3100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzEyMTY_14beb00b-450f-4a6b-a527-c39252856a4f"
      unitRef="usd">3100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NDkyNjc0NDMzODk_46f74853-4431-4a3c-8f1a-a98aa7f58b5e">P3Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NDkyNjc0NDMzOTM_7de5bbd0-d0a6-4717-a169-2df3e133856b">P4Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE1MTc_266eaf1c-fbd1-4100-95db-e2e0a7a9202b"
      unitRef="number">0.082</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE1MTc_6ee16c04-7543-4a0c-b9f4-47251be528cb"
      unitRef="number">0.082</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90ZXh0cmVnaW9uOjRkY2Q3NmRlMjliNjQyYjc4MDRhOTZjYWUzNGQ3YTFmXzE2NDg_bda360d3-9483-4c43-9e1c-9ba874f8b75c">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum rental payments under operating leases are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzQtNC0xLTEtMjQzNzY_630e669d-be19-4e34-a45f-68d890bd1da2"
      unitRef="usd">2161000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzUtNC0xLTEtMjQzNzY_689eef99-3a31-442c-9ce2-65a42f63b0b1"
      unitRef="usd">2203000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzYtNC0xLTEtMjQzNzY_9c47bf0c-70df-4808-af80-ee8edac44e95"
      unitRef="usd">2247000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzctNC0xLTEtMjQzNzY_41e7106e-5c40-40ff-9a8e-51e5b768745e"
      unitRef="usd">1137000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzktNC0xLTEtMjQzNzY_f9981955-f465-4bea-8a1a-e68e2737824b"
      unitRef="usd">7748000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzEwLTQtMS0xLTI0Mzc2_f1184f19-31f5-4bd6-9892-b1c176274e19"
      unitRef="usd">1041000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzExLTQtMS0xLTI0Mzc2_6c2cb0fe-278b-4c36-911c-650b37c70fe7"
      unitRef="usd">6707000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzEyLTQtMS0xLTI0Mzc2_2a250737-9995-4691-984c-2ec1dfff1ff3"
      unitRef="usd">1674000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNDcvZnJhZzo0ZGNkNzZkZTI5YjY0MmI3ODA0YTk2Y2FlMzRkN2ExZi90YWJsZTo2ZjUxMjE5Mjk4ZDg0ZTgwYmQxYmVmYjA2ZDE2MjQwMS90YWJsZXJhbmdlOjZmNTEyMTkyOThkODRlODBiZDFiZWZiMDZkMTYyNDAxXzEzLTQtMS0xLTI0Mzc2_cd767574-38f9-4e62-ba02-60a20de98317"
      unitRef="usd">5033000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzMzMjk_f11463cb-a4a1-411c-8093-1ef9c09ee431">COMMITMENTS AND CONTINGENCIES &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#x2019;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has several ongoing contracts with CROs for preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. These contracts are generally cancellable, with notice, at the Company&#x2019;s option. The Company recorded accrued expenses of approximately $7.4 million and $11.5 million in its consolidated balance sheets for expenditures incurred by CROs and CDMOs as of December&#160;31, 2021 and December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While these contracts are generally cancellable, some may contain specific activities that involve one or more non-cancellable commitments, including minimum purchase commitments, binding annual forecasts, and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from cost of work performed to date and up to twelve months of future committed manufacturing costs. As of December&#160;31, 2021 and December&#160;31, 2020, the non-cancellable portion of these contracts total in aggregate, excluding amounts recorded in accounts payable and accrued expenses at each respective date, was approximately $2.4 million and $7.0 million, respectively. During the years ended December&#160;31, 2021 and 2020, the Company incurred $1.0 million and $30.2 million of expenses related to these agreements, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;Additionally, as of December&#160;31, 2021 and December&#160;31, 2020, Mark P. Lappe, the Company&#x2019;s Chief Executive Officer, Brendan P. Eckelman, the Company&#x2019;s Chief Scientific Officer, and Kelly D. Deck, the Company&#x2019;s Chief Financial Officer, and certain other members of management have agreements that provide for severance compensation in the event of termination or a change in control.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <inbx:AccruedClinicalResearchAndDevelopmentCurrent
      contextRef="ic8432517eb8a474aa5bafe8e02511ce5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzE2NDkyNjc0NDUxNzA_d8405fae-fa76-44bd-a9b2-4db3e8a5094f"
      unitRef="usd">7400000</inbx:AccruedClinicalResearchAndDevelopmentCurrent>
    <inbx:AccruedClinicalResearchAndDevelopmentCurrent
      contextRef="i272efd5ba40f48b3a36b628d2290dacc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzE2NDkyNjc0NDUxNjI_354a2009-2b7b-439f-8070-9b939d37442e"
      unitRef="usd">11500000</inbx:AccruedClinicalResearchAndDevelopmentCurrent>
    <inbx:PurchaseCommitmentNonCancellablePortionOfContract
      contextRef="ibd9dfc54d94543ba8698368d96961d03_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzI3NjU_7afb86c0-a99a-4374-b75e-039a4438ac4e"
      unitRef="usd">2400000</inbx:PurchaseCommitmentNonCancellablePortionOfContract>
    <inbx:PurchaseCommitmentNonCancellablePortionOfContract
      contextRef="ia1d11895fa0442ea81f055db5e18f8a9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzI3NzI_56de8259-64a2-4377-b5dc-afdb80bcf22e"
      unitRef="usd">7000000</inbx:PurchaseCommitmentNonCancellablePortionOfContract>
    <inbx:PurchaseCommitmentExpensesIncurredRelatedToContracts
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzI4NjI_f09a1d50-ee02-4e0b-95ad-1e9ba888ac19"
      unitRef="usd">1000000</inbx:PurchaseCommitmentExpensesIncurredRelatedToContracts>
    <inbx:PurchaseCommitmentExpensesIncurredRelatedToContracts
      contextRef="i343101fd38eb4f69afa4738d406b4514_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTAvZnJhZzpkZGJkZGJiMDA1MWI0N2IxYjM2OTg3MWYxMDk4M2M3ZS90ZXh0cmVnaW9uOmRkYmRkYmIwMDUxYjQ3YjFiMzY5ODcxZjEwOTgzYzdlXzI4Njk_f02cb7c6-d90f-4bf4-bc09-68ff7aed4732"
      unitRef="usd">30200000</inbx:PurchaseCommitmentExpensesIncurredRelatedToContracts>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzEyNzM_2f7770f2-dbde-4c9e-be54-2b2f1d821a6c">SUBSEQUENT EVENTS &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the audited consolidated financial statements as of December&#160;31, 2021, the Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these consolidated financial statements, other than disclosures related to those outlined below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During January and February 2022, the Company granted stock options to purchase an aggregate of 0.8&#160;million common shares at a weighted average exercise price of $33.84 per share to employees under the 2017 Equity Incentive Plan. The Company granted these options with an exercise price equal to the fair market value of the Company&#x2019;s stock on the date of the option grant. The options are subject to four-year vesting with a one-year cliff and have a contractual term of 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amendment to the 2020 Loan Agreement with Oxford&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 18, 2022, the Company entered into an additional amendment to the 2020 Loan Agreement, or the February 2022 Amendment. The February 2022 Amendment provides for four additional tranches of term loans in an aggregate principal amount of up to $200.0&#160;million, as follows: (a) an aggregate principal amount of $110.0&#160;million, which includes the $70.0&#160;million already outstanding; the incremental $40.0&#160;million principal amount funded upon the closing of the February 2022 Amendment, or Term D, (b) an aggregate principal amount of $30.0&#160;million, funded upon initiation of Part 4 of the INBRX-105 Phase 1 clinical trial, or Term E, (c) an aggregate principal of $30.0&#160;million, funded upon the reception of positive topline Phase 1 data from INBRX-101 in AAT, or Term F, and (d) an aggregate principal amount of $30.0&#160;million, funded upon the initiation of an INBRX-101 potential registration-enabling trial in AAT, or Term G. In accordance with the February 2022 Amendment, the Company paid a one-time amendment fee of $1.1&#160;million, which is equal to the amount accreted for the final payment on the existing tranches at the time of the amendment. The terms of the three existing tranches under the Amended 2020 Loan Agreement were modified to align with the four additional tranches under the February 2022 Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding term loans will mature on January 1, 2027 and bear interest at the greater of (1) 8.30% and (2) the sum of (i) the 30 day U.S. Dollar LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, plus (ii) 8.19%. The repayment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;schedule provides for interest-only payments through February 1, 2025, with principal payments beginning on March 1, 2025. The interest-only payments may be extended by 12 months through February 2026, with principal payments beginning on March 1, 2026, if the Company raises at least $100.0&#160;million in upfront licensing or partnership proceeds by February 2025. The interest-only period is followed by 23 months of equal payments of principal plus interest, or if the interest-only period is extended, by 11 months of equal payments of principal plus interest. Upon the maturity date of January 1, 2027, a final payment of 9.0% of the total principal amount will be due to Oxford. The Company has the option to prepay the outstanding balance of the term loan in full prior to maturity, subject to a prepayment fee ranging from 1.0% to 3.0%, depending on the timing of the prepayment. The Company granted Oxford a first priority lien against all of its assets with a positive lien on intellectual property. All other terms of the Amended 2020 Loan Agreement remain outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the debt issuance upon the February 2022 Amendment, the Company issued to Oxford warrants to purchase 40,000 shares of the Company&#x2019;s common stock at a strike price of $45.00 per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6069ad52bbd94a97b38f0c5021430f66_D20220101-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg4NjU_71634816-a26a-4453-9319-6d9ec294b726"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6069ad52bbd94a97b38f0c5021430f66_D20220101-20220228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg4Nzk_a565dc93-a560-41af-a4fd-2354c8ccf05d"
      unitRef="usdPerShare">33.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6069ad52bbd94a97b38f0c5021430f66_D20220101-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg4OTk_6fecdc10-ba24-4d49-80c2-cb65f8532720">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibcbf97b5335e41168d1a299751595d81_D20220101-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5Mjg_e9d4429e-6ce4-4817-a938-3c80764087dd">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i6069ad52bbd94a97b38f0c5021430f66_D20220101-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5MDM_52eaedf7-8ba6-45eb-ab68-56d2d07c003b">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <inbx:DebtInstrumentNumberOfAdditionalTranches
      contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkwNjA_052b1f07-9772-4960-856a-b5946f3de9f5"
      unitRef="tranche">4</inbx:DebtInstrumentNumberOfAdditionalTranches>
    <inbx:DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches
      contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5MzA_e3db09a3-841e-4311-8fb3-fc5b5c0fb90b"
      unitRef="usd">200000000</inbx:DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i20fe34380fca42f098a2db8d31b3286a_D20220218-20220218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5NDY_df5817cd-0daa-456d-b49f-ccff84c09af5"
      unitRef="usd">110000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:LongTermDebt
      contextRef="i13753df759a242849113e207322baf72_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5NjI_ad1b8778-935a-4986-a3a6-d6b0cb1f8f54"
      unitRef="usd">70000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i41e7f4a47cd94673bc773402b7a5368e_I20220218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5Nzc_022e4323-1323-47cc-a000-22d624bd0bd2"
      unitRef="usd">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="id785c7ea3a28479b8b1ddfb99f5cb605_D20220218-20220218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1Mjg5OTI_abcdc14a-3812-47c6-88e7-e669544b91e7"
      unitRef="usd">30000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i12b78bb8be854db5b78e268e11b79ddd_D20220218-20220218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkwMDc_750a7373-c37d-4e09-82b7-96651af8005a"
      unitRef="usd">30000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i7e1a737421844578b29281dfff09e84f_D20220218-20220218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkwMjI_2e3dad3d-ddb8-4961-ac3b-c4f27f63be90"
      unitRef="usd">30000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <inbx:DebtInstrumentAmendmentFee
      contextRef="iec65463072474a72bf5be2ef264db82a_D20220218-20220218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkwMzc_a2399676-f1b8-4f9c-8c68-201b9bfbe744"
      unitRef="usd">1100000</inbx:DebtInstrumentAmendmentFee>
    <inbx:DebtInstrumentNumberOfExistingTranches
      contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkwNTA_f4b35d0f-2870-4130-82b0-eda7724da624"
      unitRef="tranche">3</inbx:DebtInstrumentNumberOfExistingTranches>
    <inbx:DebtInstrumentNumberOfAdditionalTranches
      contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkyNTI_052b1f07-9772-4960-856a-b5946f3de9f5"
      unitRef="tranche">4</inbx:DebtInstrumentNumberOfAdditionalTranches>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MzA4NTk_e60cb30e-4484-416c-927f-d10d79501944"
      unitRef="number">0.0830</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9b61d2e608d24c2eb1c1116a2a66abe6_D20220218-20220218"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzEwOTk1MTE2NDc0MDM_9555cd60-7f81-4362-96ab-fbd0c4b39619"
      unitRef="number">0.0819</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <inbx:InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum
      contextRef="i39dc64f1760d475e9b12a1ab87444d97_D20220218-20220218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkyNjk_c4a23fdf-e29a-45b0-8069-7c43ea9c215c"
      unitRef="usd">100000000</inbx:InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum>
    <inbx:DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod
      contextRef="i39dc64f1760d475e9b12a1ab87444d97_D20220218-20220218"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMzc_13e0df78-3f29-4af8-9765-d02ca18fba7f">P23M</inbx:DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod>
    <inbx:DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended
      contextRef="i39dc64f1760d475e9b12a1ab87444d97_D20220218-20220218"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkyODc_f9d76a7d-86ee-47a6-b21e-c2d31f6ec260">P11M</inbx:DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended>
    <inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue
      contextRef="iacb6213d02d74a88b77cba676df9265a_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMDE_1e17590e-f898-4900-85be-4cb873ccd708"
      unitRef="number">0.090</inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue>
    <inbx:DebtInstrumentPrepaymentFee
      contextRef="i4c6633104ca543ebbacf87abf6aea7fa_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMDc_68efaada-3904-4f18-8d44-8d3c6c909316"
      unitRef="number">0.010</inbx:DebtInstrumentPrepaymentFee>
    <inbx:DebtInstrumentPrepaymentFee
      contextRef="ic510443d218e4b0ab9d522e8d0b425fa_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMTM_ce8d350a-75cb-4faa-81f0-8bbdb6ff99ca"
      unitRef="number">0.030</inbx:DebtInstrumentPrepaymentFee>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="i39dc64f1760d475e9b12a1ab87444d97_D20220218-20220218"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMTk_c3fe3940-5c87-4306-83dd-80078345cab9"
      unitRef="shares">40000</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i693b3d23e36049d1b4d15aeac78e1972_I20220218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NmJkYTU5N2VhYTQwMjQ4NDVkNjQ5OGExYzc4NjU3L3NlYzplOTZiZGE1OTdlYWE0MDI0ODQ1ZDY0OThhMWM3ODY1N18yNTYvZnJhZzoyMzcxOTY2N2Y1OGE0NjIyYTEzZDM2YmIzMjAyYzg1OS90ZXh0cmVnaW9uOjIzNzE5NjY3ZjU4YTQ2MjJhMTNkMzZiYjMyMDJjODU5XzQzOTgwNDY1MjkzMjc_eccc7292-9f6a-4c98-9eb5-62e746c58e5f"
      unitRef="usdPerShare">45.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!4_(W$!<$:G(2":Q42_PWR_GBZ./KS&2M"!)ZY!\8,]DXD.TB:7P4J;(^E9
M#FBS2WM]UT%7N)!HQZW#<.C[BFM]LOM!;N$]\B4N]QT.Z3@=VB/3%GF0L/=?
MR R>:W(O&98AG2(#.+B&HXP?-K*4,0XY3P1$#52/&,$B.3BXJK\E.+)7$)(/
M<A.7DL/A;AGY),.08=R*3.'@ O^66[Y?9DH^B=@K7V\<<S3$J!6)PL&U_2VU
MF=0&,L8_8GUX$^.(9[3C]C%N1;)P<(5/EW (1XW#5'" HT%O<(Q1*7*$@PO\
MK;1Y=!;(&$L2%2#]LQZH",7BG19)@N+:_B ,)"RY) X]6AR3.?<2!?XJHU6!
M-))1!-HX-])[/"%K*!6>6)AP\K[3ZD!BP]@6>8/BR@[YWA?QBLQ?HH4,2TGB
M )/IU0^,29$<**[D.T>1ZV<O8/&*'TRN%4#3X7P\_!OC5*0#6BL=?(>C:?,Q
M!L&"Y60:8LTG$ZV3\F"KP/S)-<:M$'Y:2_B_R1!2.QS;TT))E9[;*I"F$B-4
M"#VM)?2[$C<K']/8 E5-RHGAB!6N*F2>UI+Y26RXRIH-MN!F.ZJES'#$"F:%
MRM-:*I\N'1E!\EE)52X5.,XM4[!AAI[' 0A@_ P2XUBH/<7%>LMQ'K$P)%>)
MMO5+^6KB.!7'.UIH/JUU,+B.N%K9^/H+$$P N2A:L[C<>SA@U8G%+<3?K2CL
M1S?W9)CXPD 1,32&0])."]R;D*W*F%7@5?C,+73>K74^F <@99BG*F J/57(
MO5OK+#!+%J'PP#V2E>W#\1:EEZ+81N;39?^TVW+/VT]EP^_U8FHI^^L4.P\8
M%%OD2V)@V>(T+QZ)F.CT]G$)O=%VE-,]>NX9U/NGW>X!AH6^N_5Z.WKO4 ?[
M>F'/GTL.NE5>G5:@/@2<+*%^EAL[.S\?XPCB%2H,^&4" )?+8P*3)N+-T&HW
M-#PQTKZ[AY;90^5C J&);<T2VV'Z0$9<&0:.%''6K,[ZQK\2H0 5[L_ D$PF
MD]SV52.)V.VS R/P]!6II9)1RJ,XE?_Q^X Z_3^UK>*?7[*B/FUNP.CIJ[8?
MN!OCCO,T2<'0:10$,O0AC1*8W0(F!RKJDXT >;&&VQI%0)! ?!25B@TCH6T_
M'#O-NT4J=?'$-P2Z?DKYH&[@ )7[M,B=;JW<.0(R"MPUB7W^3#[S<O' H6S1
MVG?/3ITNQJS(G2Z>\_*>U7XS[09NEB:G"K"J'F^1+=V:G;0MJVT3\C O'.[F
M9QFK]E[3WV;!]..))I[M\F3]__QN_H%FF'Z6:!>O9U]W[IA-HIJ$? FFG58?
M DME'TRR"R/7Z2>$A31&1NG/@#/8(_8%>+Z4TNPN[ #Y9ZO+_P%02P,$%
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M=0QE* _G48<;+3;F2.=9:"T*<YDQ"HO$R@#>KX30QYOJ \VIX/Q?4$L#!!0
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MPKN(@#GO)B1-"QL:? 5^4EZM:+0@:?;[;RZ"SI_@C"S#(&1@#+[<GH'GSUZ
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MF8];2E3ZU ;J]PU3H!V^Z!N,;W/?_ ]02P,$%     @ VX!<5(D6Y':=*@
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M2?WQ YXX0%X"3<!^0"<6V9/)V:.SR=G96>;7L&<^"Y8@8+3D7S(#QU2'F?#
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M_H2X@1@:]8O"PD3.(!*]R1F+<5J+MGAMVC!QW.HT>UN"B57@,G."'KQJNUF
M@E;/NF\ZK$U!V 4EN>D8WZBU<I87/YR?/Y[.@O0B+C%^'?] >P[$@154_3"[
MF$TO]/EI]AH- +9)D+1TCG;=N&ZU_C9L9):Y5G ,;(^&#5(J*KTES:RV&E!)
M:D(732>6!'#D;FC]HF51H^7%O+#GM_ &^ZX+V!<U$#F.V)BZ6QHT0LD.1K'
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M#+^\?7NY]RP]QYYH<"$V!DB5SZK<6&)$^/\$?&*@AV@2(+I["AL$&I-_9E8
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MUD> \PETVH0E!2^IKP0 95VR&WHAOC* ((8'5C=H#9B6=+'M&,(?&R ";#H
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M@#.Q$!?[?=B*&2D.Z-J2"P%&:#XM02;>ESHKN56Q"9UCCBAP8-%%<OT# ZO
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MN%1AH5UP7()@C/77>D>"E).TQ/ !6;'V+]RQ+5NY*Z*2FLI_*CXCJ^_\X#
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MH@2)FY$S\2\N(Z-O%7[CN%<OWL%X\B#$5_-QE8T<SQ#"'%-M$!@]'G&*>6Z
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M_+5)=0ENLK"U84/4)9$]/.T1@W4]#N= >O]2',GGS!6!:F&/R(CE^AGM-;]
MGII0!AQ)7I"@I-9FP1KO\W6CTG5P^]$L"%0MM?L+\I#:))$@OZ(F*)A+B:^J
MK((4DR2@V "5;O8?5)_&_-K &[)JXZ&T%<34,D?N@[DF@**WQ\K(64X*5@YO
M@].[Q/C[W\['H[-?/*TY6:JZTJE(H:#.(/] O/OM^LL_CT?)!<= ;9R"!RI0
M5"1NH2KI*\EGK+DC 3B,TB6<A)"7+K6%7(<"-AH,Z9]L\9L0S^VA$%F"_+@3
MHL0*Z2X*F^FYAK<IZ7.], &X@A\?2;5#D&' 5*/$Z+QQQEYHZ=+I3Z$,LR#R
MO5P]0DGFGN-.P:\L_%Z3T4M^A#Q;>#T?BL\;2F_A&LAL"UU:#RX)A%=(4>Q"
M ^<)3YPM'D?WX;2W,!17>;[N_CZ]GH_HE;I'&'/H/CIPQ4D8'4EG406^4TJK
M>Y2R)BUVF97.SECF" +_;S;]A9SHAU#FT'$^,L9:<9D^N5PF/Z^75VQ,M$D1
M9&*KM";3$KX]/-O!M0D-=.;0%6@!B^!U5S)ZV;DG'D-B]XGT**S %MUI11V7
M[1=X%O:TS9N&_D?:2CW,+2,7^UA)1WF)_*0:B7]B#N(<4Z6BNF3J0CA":O5'
M3?4O) 7DPYHC(QV-GHNSX<6+9P'UQ[$,X1B]U.%QDHA,/HCOPZ]#<8N,!=</
M[ZX_?0FDG2JMJQ@A6-_?$58"S1R-2>]M[2@Z8ASF"!TQJU&0%.Q,-&,4%]0A
MXQ=TT$6A,@0K(4)) 9(IW]L#)J';"G$==6=CRC1U-4Q3YK6'[)HT.T^>!2]
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M.Z=S_S&## M#&_#[4H->]1=RT+ZI._P/4$L#!!0    ( -N 7%0DEYL3VP4
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MV0;1SU7L] 6'#=-77$)>$\6M1>8IM98YD5/6S>.0P40NOG[E!6H8^:A[C*P
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M:U0TM,I2P0B;_H@5W:=V+1?%5^/XS/]IJ\4!7X!6YV-H#%*,QV?3 2Y218*
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M"%T-V LJ)J['SXJ@ &>X4#\BA@F--RN=J3"(L+B^"[D1\R[4A;]FX0FC7JT
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M)CF'GB?!P[@[3X51&W>:(4GUSE4',84&!2?XZ^K ?!C%:Q#VUSHT@\\2_/_
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M-=C*;0&LK'(%IBTE!=^<G/>7-*QK5B1<K)PD=P^KD5,X;%[WQBP6"T>/C:I
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M@6YV@-COX\JX7/A>457=#A_[O,J&)9_XP3MQX8>M/]/[ VSTZ)T@_-+&QB!
M7?D+"!W-^')T2VV&PL[97);U7$Q2+-#4M;(^%@B^O42FRG/)%0\6R)2XAR!4
ML2Y1&%4G-E;U]**0)U,^U.1VUK;#T<XXX \Z(=T=0/:9B:N:4D]8=+X$H7.N
M!:@\@78HZ!(<A4H6.0W<WPO;.PA5@JOKR>%OGW\<#3:5=4=WJ7(-?=C+_GZ2
MWM9.HDW:]KY;1&G2CR;0=4,E=@AF6XSHPUIM'AFK[E#[G4$LK!,E@'N%L#8R
M(F%PAW&IX+<54\_W-VV7@JCI&A/;4/NN(7&4!-KP[UE[>N31T=W^4?#PZ'DW
M\AS]V,CS,5'QZ?\R;A<J@SE0T331:+RS;'W9J0AM^!\;MSJPNZ:E_3M-.ZB*
MNGU9*-4^4*EU_50K[22>_;>0+BY/GR&>4\E7WX]8Z*FNBM+5#JUU<4;VH4,.
M O)+B6#WH3FK4*WUG>V>V*NA_TD#'>M]5RZ*/L-]IA";<_=G!W'ZICEZ"50U
MXRU;JF_?Y_K,1F7P^<EI(^H4])EZZ8U-I]Q)N>BJJ,@EM>'ZF9A6QK;/@$ZP
MN7XV(8Q4ND&9:%('8C+G<?NHVK%Y*X=/GU'K .^8#5(Z*]T,5XU_HI.Y[>62
MBF#1E8XF^'Y0^WA^[$Z; N9YO;"SBL:7;IIA 2<#_FJ6MS<%\9\\:$4#;CVC
M@/O@\,>-I/\#-Y*V7]OI&UGLWMAYV/4?B5\I#LIY-=_3-9WKNIUM=>Y&4&3K
M[F;72O&=[M15@FW82J7HFH_+,[@P*"/XM<OKFT^"##++OKW-R=);7/I )KXB
MU;TMQ,.^:\EWS:5S#MZ/[0+MWN$,8U(N[S<O'T]HWM38V_T3\L,Z4@W6?#9R
M5-'_QA$:9 !QP,G&L(S/"MM))M;RA=O#,!#=S&Y'<S9*5E:!YS1/70$3R'X%
MX4RH;SB5-<+)7&NZ(NKT'R=+=)G42^H9\S72]JYVJ;;#S+ YDOO1\<TBH@]3
MTMI#^D*,6-H<D>$3. 2,KG-A+<G5FOMSG%U89G?ON,&)OE73,K0%=["TU5^S
M.P=E)SS_%89T"$*#Z,ZU1&[5N/EX%L#)S>WA1?'[X5C<KO17%:Y';_()\"X^
M_O[N\C J';+"143]:TQ0U:5GBS*A]_AM%2;X0Y7!RW2\8MQD.YY.QFUA") ]
M)Q>GPE"[&V/W,WG<P#?TND\U.H&AM8EE,\LOK6F^4]'+=DN;/W-T29Q!(&3[
MXVV^SF1"K3WM2H\RRO$1MI3VHK>L?!<_9:4FQO!D#;9%CISZC,ELR_?6"]7*
MUNSYC".11]]#Z?9 ^#SQ]U<XG?;]BHU!*%!TR5&@G=JR2ETJO9QBTQ $>#FV
M,T(\+D&#BP$+WW@#'7S[JY<G.G?SY"X]!4ID7;AIV-F5+#A 2+J#N#4=:RE.
M<,+QP%%A*V^="U-!S#N]B!A$F!5(I%FTU'D70G2%GKY/8U]DH#Q]W[IR''W+
M#2*7.7^7#S$4]L-^X4WX-'Q=T,1^2T[SNOVNH6L8"+KDDJD9E@Z/GIT=V$#>
M_U$5*_[.G&E15<62?R5)526]@.>S F;$_4$;A"]1>OU/4$L#!!0    ( -N
M7%2XZI_\&08  .\2   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;,U8
M;6_;-A#^*P>OVR?7;TG:H$L"."]=,Z1MD*1=AV$?:(FVB%*D2E)UO%^_YRA9
ME9PZ2-L VQ=;HLB[YYY[[DCI8&G=1Y])&>@VU\8?]K(0BA?#H4\RF0L_L(4T
M>#*W+A<!MVXQ](63(HV+<CV<C$;/AKE0IG=T$,<NW=&!+8-61EXZ\F6>"[<Z
MEMHN#WOCWGK@2BVRP /#HX-"+.2U#.^*2X>[86,E5;DT7EE#3LX/>]/QB^-=
MGA\GO%=RZ5O7Q)',K/W(-^?I86_$@*2626 + G^?Y8G4F@T!QJ?:9J]QR0O;
MUVOK+V/LB&4FO#RQ^@^5ANRPM]^C5,Y%J<.57;Z2=3Q[;"^QVL=?6E9S=S Y
M*7VP>;T8"')EJG]Q6_/06K _VK)@4B^81-R5HXCR5 1Q=.#LDAS/AC6^B*'&
MU0"G#"?E.C@\55@7CJ[.+J8W9Z=T.;VZ^9-NKJ9OKJ<G-^=OWUP?# /L\ZQA
M4MLZKFQ-MM@:3^BU-2'S=&92F78-# &L03=9HSN>W&OQ5"8#VAGW:3*:C.^Q
MM]-$NQ/M[6R+5FH19$J7PH45W3AAO(CJ\/37=.:#P]W?]_C9;?SL1C^[C\+J
M]]JBE\[F%% C%&S\[U/())W8O!!F!25I3=($Z4@9S! H@H63$C45\#!D)%!7
M%2-%9$29:,"Z5!F4*"6V=![W<U+!TZSTP.;]@&XRB>'&F"?A)#D1U%S!UFS5
MAO'+3_N3\?-?/1U;X5*V=:H<:M(Z#T> D-@\5R%(R:N<Q(0"7DL!D !=6*V2
MU8 NIN_INN29=*'P"S]WA_IL,0Y?]&%9UQ.3"DF?%)!2X91)5"$T^0RX,ZM3
M,&271ID%Y=8Q#E"U]S-C_5H@Z&T^")/R?/FI5)$XL"Q]H+1T/,S+5E(XT(]*
M(.A8YC-X66MY0*=EE;4,F&HC@""=SU31KV.@I?  CPX(A#"SD:Z:E(L&V&\2
M!A 7RQM7, ,%K&CJE:#WR%,)B&N*6"K.EHN,K&DR/"]-BAE,"3/EU<(@I0FG
M8A,C$N-5;*P0S9DNE$^4- DD"&9B_+7'-1KVP7@1;R3U[&V?7EHX9*"\9BT+
M$J%M<$#3)(F*7.A55^"@Q=2::RT@X>\R-?51>9MY:)@VEK0U"SRJ@O]!'0PZ
M@,X-3:$Z#9?C_6X(L3P!,Q8H/WC[87>$O"78]R1-N^7:H7G)Q=(M-5J@HX5-
M-@S)VT2C=C]+5$1EN':V&5&.O4Q]%IH]%LX&634$)PI9!I50&E,$!_7ZF;+:
M+B 034&X!<X0##]*[/S-\=6'I^/1LP&]XQQ72F]:QD8B/1.A@JY,.ZGR&7>>
M&#I.'I1(%W#"(#Z3*/1I""$7IIRC7\>"JQ2$4@D.&V($</+ZI-:BO54)XP3;
MMP6'[T%W4CKFG8TO,Y5TR*4,$BJ$2CL@10%*;A5. A)%]61O,,&&K#67 #"G
M&&;E?4UE]\BO[8"]/AFUS()L")\+W_.U1&IF&NCGW/?; E?KP780'-K=@*M@
M,P$Q&!O0I +-I#1?.$^!-DUC:2.MG53$(#9HV-GOCT:C!@V8B")Z&KL?RF.F
M-!>&#V7**'FC8%!K%<UDC!)]YA^.TZ05[V6!\+EM:\E N%T^J*]V":TXPSQC
M-P/ID",TGV=7#4D/=3?:XNXN:9VT/HKOC5!3E<9\\D91TTFQOZS]M!(4XNZ]
M ;*LBW1;!_I.3EIXTDWIM#D!1X\&M8\%GB6&9&CT?K3?WTLXO(NNTWWY>/1%
M^(G%;LX'!(Y9;.W#&V"WDO>(/9#?Q$HX9=I2B1!M$><PXG@VJ[;U!S2;1K";
MJ?B68FG2T0[M&SK>'5'L_.?][\>:S?^^^KN)^K%6=Z>S/D:?Z(A@:V?HAM$J
M\O%]14[7.-[$C>:R= D$>/\I"_56*:9MT>.(2*DK%^3+&1\!H39?%@7<P\6F
M!C<WS.>\8?9;)P\5NN$WX3[X9>+AQXO*^S=6EJW+NZ@9&WSM%7G8^@B12QP&
M^5,+O[Z4)E3?(YK1YFO.M/J(\65Z]2GH-<Z2"N_D6LZQ=#1XOM<C5WU>J6Z"
M+>(GC9D-P>;Q,D,=2<<3\'QN<7:M;]A!\XWKZ%]02P,$%     @ VX!<5">A
M[4T2#   32   !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULG5IK;]LX
M%OTK1+8[2 #5\3.Q^P*2-)T-,'T@Z<SL8K$?:(FV.95%#TG%R?[Z/?>2DJ58
M3J<+-(DMB?=Y[E-]LS7VFULIY<7#.B_<VZ.5]YM7IZ<N7:FU=#VS407N+(Q=
M2X^O=GGJ-E;)C ^M\]-AOW]VNI:Z.'KWAJ]]L>_>F-+GNE!?K'#E>BWMXZ7*
MS?;MT>"HNG"KERM/%T[?O=G(I;I3_M?-%XMOIS653*]5X;0IA%6+MT<7@U>7
M8WJ>'_A-JZUK?!:DR=R8;_3E)GM[U">!5*Y23Q0D_MRK*Y7G1 AB_!EI'M4L
MZ6#S<T7] ^L.7>;2J2N3_ZXSOWI[-#T2F5K(,O>W9OL/%?69$+W4Y(Y_BVUX
M=C0Z$FGIO%G'PY!@K8OP5SY$.S0.3/L'#@SC@2'+'1BQE.^EE^_>6+,5EIX&
M-?K JO)I"*<+<LJ=M[BK<<Z_N_ET]?GCM?AZ\<_KNS>G'A3I^FD:3U^&T\,#
MIP=#\=$4?N7$=9&IK$W@%*+4\@PK>2Z'SU)\K]*>& T2,>P/!\_0&]7ZC9C>
MZ)!^16K62GR5#^*]=FEN7&F5^/?%W'D+1/SG&1;CFL6868S_3Q,^>YJ"[I7;
MR%2]/4)4.67OU5&+I/BZ4@)*;$RA"N^$60@=E/)02CT@/)T2QW-5J(7V)V*K
MH*!T8F%R1!S]M<*#Q*.2U@E%?A*PLEK/E:TM+621T8=^@DAS&\6QDC^*8UW@
ML"D=[KN35^)?UQ>WXOK3^^OWXOWUU?7'R^O;'0TZ+ZY*:R%G)=@K<>>E5^*%
M&.)G)+X:+W, N_70[B[DW%ASKSGF?TQRL8725N7@E@EOQ)7,-2@46@K'(NRL
MUA,7>#(U1:IS+3D[=%L59$@ N38EI"4GE$1]_BCD9I,_ZF+)]XE^Z8U]% N5
M*0L%&[0L\8Z$ #\XQ)JU0%:US-D)[6)*U/\%[1]4NN'H'_?5]0-Y&@P:XD8<
M">EK97;JV>#*X\%Y,C@?G/#'23*;3DZBFY]#9B(*%!D8NJ);L3H>)"@A)V*<
M3,93\44AV1+4A?9J#;6&_?,3,4R&LX&X_4FN-Z_?B]2J3",6<'(V&)[@F61Z
M/CT1OQ;DUF7!EFQH@R<_W'P28SQR!C+G_7-QJWQI"W+,#G#>ENIEN7%B<#;!
MSUC\)O,RX$.2C661*C&8)>/Q4 P&R6!R)F[V%:[ O+NEG) 4E&E*.(I.+N':
MX&KI' Q#+@4:YX"D?Q1K!5=F/;A^H1 K31=%:J2IS2K$*.0'BZHJ,KW "05)
M';3W6Z402+J Z#JZ4JW)N*FTE@$<P.V8/TG#9I-.<Z9AT5Q+-JU<0RQZNOLA
M*ME4>VNB!!['5DICB,X),$)!8#S6!CZN;U<Z7?&EIDZD>I.&5??*.D4A?=_A
M+:C!_B5#:<2XIRMK R*Y_D89SJ]D(0I#8@+RCFP,04" U&?F':IN->[3H3GY
M 8D&>.MU)&H"?-;IP:=9^FGP7MR)SQ\.Q6T'*"K)/E&(A=P"WW*^84_#NEMI
M,P!S/ )^^X32\Z0_F2 0'"P.2Y/_,E@S-YN D!ADTV0RFHFS9(R@N"F\+)9Z
MGD.%$6)N@J =G)^)BS2UI<R=&$[.Q7 T0CHPZ3>V!F(B.&603*=3,>[/=O*3
M\XI2B3$B:=H_$Y]WDBNT6BTX#9+Q<(K?YZ#^&8ZQ8C!&E/UL2<<N)TUFR71V
M#H;@VQ>_*.=>=0;T\00:#I$:CD>SI#]%L@E%JHOF(!F=S4B(V:C3"TV!/^@'
MW(P'D<7 8##&[Z=*6FH<7YK%R]*I^G$P&L_H1'(V&75*U&1US'+QXY#LA%'0
M)?YQXQ!E[Y_^-AT.AJ\;GRX8MWL%)^%0N(([9?$H5C)#^H*X69W+"3RAS'[Z
M_$L+<B&/;!"%#QI=-,7<B\%LVINAG<US=@7.OAB.>Y/J2KL)"8%5,=HGOY:/
M%(=T48=TR$C7R*](?)HYSDO/F<,4^"+OI<XE,$SYPRP6E'W+#7V9]O].TJ(1
M>TE\8#E^+#I8240)I:<@T2%U.3G,U5)S=4&NTI;SW+ _FB:4A"AQE%['K/&7
M+([0,FSV?7O;*G[)SR%F]^W_8MH;M>T]VCG@.7-_G_I!39&_R<2UI=K'5O)>
MP1+A%(=D8!P,4S=E9%Z2]_MR['RY*#TU^4^\%V'BROD?7)4,Z.)?@;2%6%IK
M'_,"2@QQPU1'_,VV0'E9Z8U(42B6B#6N$RR]2;F/S0@O]QJY&]A"[2!&?$MP
M3E=1GAZZ$ZKX=V$>1?Z<#EFUT714U9J;VZL$[%'8J9JS/,R.>X6EH?)7<*@.
M^Z^?2L:7!Z\[]-QI!RP4@G)ZU6;@;D0B7R;@!VID^%#2#>=:3B+>6XU(@AA\
M<:LI874$4[<#0.S4V%;N M@NBCT;4XGFV.7T2?8HUR7Z>L"S>@+VFE"LVE#+
MHZ%WA#;&Z:CP0J3*>HE''-6DE<EA2S H+7<_PJ("AT;>*O62PEL@06L3"_HN
MYSD.7"IIN:+F0PK>B5!3569LR@S7+89T15%.A_;1L]5^%:5=*UD08T@(OU>X
M:,&B!;.>N.'N!;HYS08G:/@G,LJ<=C./9/0 SGT9B#JAA!\1,LO85%!D_]$G
M"+XAM?;]17PK*5MYBZO*^>LVWES &D5VA$-G/$<<(Q2!.NKVDM@1HHG.*2'\
M65*Z:>I/S;S<#6&@_G3RHP94VEQSYPU5MDR+V3 Y;A)="2[-H.%FC9Q?=ZO[
MV("8 +MVJX",$C6@JQ^52R#1>;9 5X7.2@ZDLHB@Y?+.CD9LIGF9D?'""%FA
M+8!7^N\VMTU3Q2(EJLA=8E#BZ<Z5BX5.-36 3^*7FVWN=8.%@L0]\5$6<AF&
M"KI$_\)84V>&$(WWG +0$R]#*"OJRLDF5#N<Y^8@F+^6H#N15+)7,F?--$:<
MU8-VW&!U6)@&!:<Q(H*'!(N-1N7E3,_YD@3;EU %5X(0+1F(12,E<9.]"[?[
M.-7MY9-#PWQ/W)$Y=_QKMHS!:,Q= *6 I*9*$C)S3/2M@]$_G:&(1NR/J@31
MS!5MO+1FZU<]<2FIK>/" S"I&L,)T>MN5&0GTJGKF$QW31U'R9S&T7IR13C1
M!TM:(1OR:HX[-)(;%;!J KK'L #J3KA7"&G/9G&-<YA@95F>3.@DH2X1*[.E
M(3.)F8>B)ONC=#YDB^=P4Z5/U DN1&W0*-[]H ?*#;*H%;S_*\(FH)&5M[Q9
MKO+A$J>YW>KP>U([OHHG=EEW%,4"V)H. U!WNX#O8:<"33,9UAL8UQI1PLJC
M*L5D\UV-GE>8D\)OS4M8=D.L,.Z[V(UJBYS)US5W>E5 ULN%BACSB2+P]_EC
M*U'JX/QH4YI,ZBS5\%J&W."KQ/M7TFK-OD*> SXD=S"D5@EG)F1X)'"2 HXV
M>5G!NUI:8DA2-$-# S+:,D14-(1R2>PJXO1!^\NL:9,J@NHE3K7)"WD@EQ85
MW5=1$%2+>K%"U%!%!2'47 5!0P!A/H(HB!&?<Z;OB=_K[KYR_%RAKMXWK,;M
M" U^&ZM#:=E04->;GAT O/P&4,?>E'=%O)US[2'(JB7"Q]($UZPS&^,A$6VW
M3.D9VA!?/4AX/-9O8("#O/0K8P,<@<%V_:2@1@\@4]8^-,/-172SAXB@Y-4-
MGV;\U$O<F+$I-BEE-W;273%5'MY9_LA.Z)+&,-9E+G-.P"_$,!E,)O@[2,:S
M&>TC+2T<6EOR:A//=:H=E;0I/9N<T:N=IV2GX[.:_%_>&"QY4W-872H8P]YT
M-Y46IF!?AK8OM&HR+ NYRO-'RG_UFCUV3W4/H&(A.MR0M7-71B,6!7;8,'(/
MWVP6=&U"(")3U1>P) 4.J];H^@OUX,5@B+BC]V8M]KLT:W(-'(:PKFGR<72$
MBEKB>ML<IRI\D7E<N];.;2RF4 P\C3UAGJJ6E-VO/9XVMQG5*!DV?#$6HA M
MQC%\J8A"_HR%J$##+RC=H1:"Z#R]V$^X"E5C5\.R-?<]U76'!/7&FUDW7KO\
M^(L6>OJPCX/=&7ZM,"(^ <&P8BK=JCT!-]NBK$RI5^EZ)WG:>,6[5LCD]"*;
M5$4N#V][ZZOUN_*+\(IX]WAXT?X1A0 SB,C5 D?[O?/)4=A!5E^\V? +X[GQ
MWJSYXPHSI;+T .XO##)N_$(,ZO]!\.Y_4$L#!!0    ( -N 7%3(H<3^0 4
M /T,   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;-U7VW+;-A#]%8SJ
M=I(96N)%MA37]HQOF283MQX[;1\Z?8"HE8@)";  :$G]^IX%*5F2:R=][8MX
M ?;LV=VS2^AT8>P75Q!YL:Q*[<YZA??UR6#@\H(JZ?JF)HV5F;&5]'BT\X&K
M+<EI,*K*01K'QX-**MT[/PWO[NSYJ6E\J33=6>&:JI)V=4FE69SUDM[ZQ;V:
M%YY?#,Y/:SFG!_*_UG<63X,-RE15I)TR6EB:G?4NDI/+(>\/&WY3M'!;]X(C
MF1CSA1\^3,]Z,1.BDG+/"!*71[JBLF0@T/BKP^QM7++A]OT:_7V(';%,I*,K
M4_ZNIKXXZXU[8DHSV93^WBQ^HBZ>(\;+3>G"KUBT>Q-LSAOG3=49@T&E='N5
MRRX/6P;C^ 6#M#-( ^_646!Y+;T\/[5F(2SO!AK?A%"#-<@IS45Y\!:K"G;^
M_-/-Q</-P^G  XO?#/+.[K*U2U^P2U)Q:[0OG+C14YKN @Q 8L,D73.Y3%]%
MO*:\+[(D$FF<)J_@99O(LH"7O109H5A._'$Q<=ZB^'^^@CG<8 X#YO _9^M5
M.^ZL$U?+G,YZ:!U']I%Z'9CXI28KO=)ST3'^H,4#U9ZJ"5DD(QE%PA<DKDQ5
M2[T2I#U9F@JEO1%2.'HD?;@B:47)]D+.+1':Q@NTK)!U;<U20;Y4KD0VC.(X
MAO0;:4G,N.FE$\H[X4Q)HC2Y#+VBM/@DQ4=3EC(25[)4@-)*]L5G$&G=T+)6
M"(6W?FPT<=6.H%U?"*F%J0,,"-+2DYZ& #IZZ,3I5/&Z+,4,+2F8O-O&SJ$L
MS!,$*9D+-F,K]Q[& .(RL[VP#N)^@N8H2W:*=(J*I=FR2;\'B&X 0"Z798C/
M1:(N&X?L87,.2(P?1O5RB8@D^)I-41 G1E (-&\L)WZRZL)Q#@E&_*"KNR$3
M7/*J66BRKE!U@*NDAHNJ(\_KH \7?M76%K105%Y;%"HO.'$3PG#!RZK+ X=0
MKOJLCENY8EV\V]/%DO+&MSF3<#4-[H#$Y=V71JA,S=1X=29S52++B!+![>;V
MW7/%P&I"<RYSGC?UBK/D"P4-L<*#("386B:9QFU= R%P:WFT80'?(7?M@VD<
MG&W2MR[Z/F_VW:G#?:LXLCB$\'_0!9+\BC0XT9:_0H=F=MAPWISKZO7$N\UH
MJ>2$2[[B_@<\AF\[;]8#.%AQ_037'9MF& 9FX4[$!4;6>W%]<W5S>WES_V00
M-M\_=W\@CJ,L&^,ZBL99LC7O]JE<<1Z1BB0Z'@WQ>Q1GXF>C#_/N_5$49QG0
M1O%(?#8>I7LYK(-NWX$81VD2B^O&AJI)9+%+=1@[HM7ER_'O-IFEW,RU^IN>
MI[03!*,?9$_SJ"\NOI+A'0\_?#=.D]&/[AE\(5%J^.>#5N@XU)]QL_Y10!KB
M&B**L,G5%$X[:U6LZ4^5RTVCO=L:"K5<L0"=:!SC\@(D;8,JN;.,Q4>25T"'
M.KDPX=Q4V)+OJ#<@[KHL8+&M5K$(!R6:'LI'1(@&6Y-J'0!IW.?F_$K6^N)]
MXQMH$[BJ:JK0_>#[% X*:_?3Z/;D+-Z@3WV!Z0-<]_95=:<BC9+C<)OA-H4Z
M<3ODV^&H_?XE49*MM3G;I;>7;.Z&T7",;[Y#3ZFJ#J-;A6^[\^)-$L7#Y*VX
MX],"4O,HRR;DYF7%MWIO\=8=4QL;QL^KAF]"O[W=:;5O,CSH.O+?#E:#K2-I
M178>#MX\[E'H]G2Z>;LYVU^T1]JG[>T?@UMIYSSN2YK!-.Z/CGKMF%L_>%.'
M ^[$>!R7PVV!_R=D>0/69X8_,NT#.]C\XSG_!U!+ P04    " #;@%Q4Z?L*
MU+X&  !/$   &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RM6-MRVS80
M_16,FNF3HIN=)I/:GG'LI/5,[602MWGH] $D5R(:D&  T++^OF<7%$4IMMM.
M^V*1(/9V]NPNX).U\U]"2135?67K<#HJ8VQ>3Z<A+ZG28>(:JO%EZ7RE(U[]
M:AH:3[H0H<I.%[/9#]-*FWIT=B)K'_S9B6NC-35]\"JT5:7]Y@U9MSX=S4?;
MA8]F549>F)Z=-'I%GRC^VGSP>)OV6@I341V,JY6GY>GH?/[ZS3'OEPV_&5J'
MP;/B2#+GOO#+57$ZFK%#9"F/K$'CYXXNR%I6!#>^=CI'O4D6'#YOM;^3V!%+
MI@-=./O9%+$\';T:J8*6NK7QHUO_3%T\+UA?[FR0OVJ=]KY8C%3>ANBJ3A@>
M5*9.O_J^PV$@\&KVB,"B$UB(W\F0>'FIHSX[\6ZM/.^&-GZ04$4:SIF:D_(I
M>GPUD(MG%^^OKZ]NK]_>W'Y2YS>7ZN+]S>W5S4]O;RZNWGXZF4:8X(W3O%/W
M)JE;/*)NOE#7KHYE4&_K@HI]!5/XUCNXV#KX9O&DQDO*)^IH/E:+V6+^A+ZC
M/N CT7?T6,"NJDP$K6)0NB[4!=PU]8KJW%!0ER;DUH76D_K]/ O1@S5_/&'U
MN+=Z+%:/_R^8_X,Z]8N)9J6%]+<E(<*JT?5&F:!J%U6C?=RHZ!2O@=;DC;;*
MT@I_&^]RH@)XA(EZYUVE(BJ0-_/O6)D(B8W*2)GZSMD[*O#PK:QR7/;9GZ@\
MELVM-E7 SMP4P%W4P2_GL1F-0.6N]0'O2Y6U 9$&&/\(G;ZP>.9UV=[&W+$3
MH<W+0VN=B5S7JM1WA-B4+NZ(U1I$#S\ 1AR D5&NVV04-8PF0\*&0#%:8G;
MJQ##6!6&U3"6V.HIP-><$G4<%'JUA';GL9.7>(7$#6!4 ^, +NF:)6*I(S;?
M.:\SVX<34._6\FZ71?10*B;J"J53U69I\I3$J_KO\!KOQ0;OX3+PYB2O/%%B
MNSC Z4,B;%MP#O?M -,[PZ$"_P\PT>J4+ %\IVC?6%*8%&W&JG2V0 I\):EC
M2 3>@C/2VP-M$@LQ5!3*+0"&T"Z7P*[@;,+!UO-SMA%;WP@R1BH /D -X?'^
MKBX<E]EM&0C&N51ZBT0O@8^(X!<]M=N>:-;'.9'B0:LU55NIQD6L<:7HRK7
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MN$3+9RFMS1J'FW@R@&VU7%J\9;BRS"Y:71*^0.9=X?4Z2#=55Z=XN<S+"+<
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MJNBJ.C69)4]GPT][BUD#6_)[[J:1P*B:Z+FH+7X9,0!$0?&)*8K3D3LA+Y?
MF2B^L^A:NBAR3E3%A.T$#V[6SU5\;R77WNE-M %K#R2F/=OCRY9UW7+_A"ZG
MH6*<,\GLY-_\8^(Q-HVC?;%]R-[A)#4<Y0F77,57ZUUA0!XE#RE_=,D,!,M
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M+B/'[)VK<P]J+L)FJ4X[ 34GE9>]L4/@X%F=LT98",96@:BF- 1$#/?  6T
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MK:SH\P)#IV3_?61>QR'PB[ -VZC*A,?)M91]<')$<*_AL0:TB[!MTZ&MA-R
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M]">^ ,G6^ #\OJP ./(!%\!L6]K>S_\+4$L#!!0    ( -N 7%0.2MZ;G@0
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M97U4JQ^T*.WQ:"4T';;L[99.MRB- ;U?"Z'W#\9!>UX>_0-02P,$%     @
MVX!<5+TJ5 9Z P  ^@<  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
MC57;;N,V$/V5@1H4":!&LBPG7J]MP)<LML &#1*W?2CZ0$LCBPA%:DEJO>G7
M=TC)LEO$QKY(Y'#FS.T,.=TK_6I*1 O?*R'-+"BMK2=19+(2*V9N58V23@JE
M*V9IJW>1J36RW!M5(DKB^"ZJ&)?!?.IE3WH^58T57.*3!M-4%=-O2Q1J/PL&
MP4'PS'>E=8)H/JW9#E_0_EX_:=I%/4K.*Y2&*PD:BUFP&$R6(Z?O%?[@N#<G
M:W"9;)5Z=9M?\UD0NX!08&8= J/?-URA$ Z(POC:80:]2V=XNCZ@?_*Y4RY;
M9G"EQ)\\M^4L& >08\$:89_5_C-V^?@ ,R6,_\*^U4W)8]88JZK.F/85E^V?
M?>_J<&(PCL\8))U!XN-N'?DHU\RR^52K/6BG36ANX5/UUA0<EZXI+U;3*2<[
M.U\_+#=PO6%;@>9F&EF"= =1UIDO6_/DC/D@@4<E;6G@0>:8_Q<@HECZ@))#
M0,OD(N(:LUL8#D)(XF1P 6_8)SCT>,.S>%L+:VXRH4RC$?Y:;(W51(:_+X"G
M/7CJP=,SX"\T(WDC$%0!7Y3<_6)15^!<OE?*BUAN^B:F9AG. AHO@_H;!O--
MB;!25<WDV\\_C9/!_4<#-%K&,IESN2/^479;)IC,$!IJ@09+)@L:&VJ'JV%,
M@3$)BYU&)*F%3-%$&4NG%+13+I2@T71HUUR21#6&T,W-+2Q>X+=/L'Y8/3PN
M'Y[[KK2P&Y?J JY@$(<?XOBX\ =+2 ;AF';=SPM7D [#.]KY7)*/\ 6-F?AZ
M04XM4@W%=ST*Q\/X!JZ'83JZNX&-LDRTB=['87I/D!_")$T[XU6CM4NK5MJ-
M>0A<9J(Y%J?'/?CL???]<GKG[:X.;J\.CB\09]039_3#Q'EDMM'<<C0_1J.+
MR.=HI%6S*UWCTM WO2,5<'(JQ1O=KU\;KHD45M'U\HI4#@H"#166O3G>.#UO
M>4J_6E/5>$W]Z3@8TO5E2R@:ZV;M>-R#D"$47)*H0#R*M[CC4CI(HB!%.0J!
MF8Z9YG^\G%SBI?^,7-/NPJ'CG6=/%P_=G[QJJJ/;3JEE4B-9Y4CT#U4A?Y>2
M)U3L6?$>&:*3^[A"O?.OC@$/UE[-O;1_V!;M?7Y4;U_%1Z:I,@8$%F0:W]Y3
M]W7[TK0;JVI_NV^5I;?"+TMZG%$[!3HOE+*'C7/0/_?S?P%02P,$%     @
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M,_Y_V5[Z43R$*/1'X>B4DJWZ0LD]99;KQ$R()UARRA:7!W>8N2N@W#7(=%K
M6JN]9B7!7,"H9;!_ ?9"U&Z^(_=Q/Z(QBOW1: 2OE5OPK,^5J/=U-W>9>9"V
M:7G=;O=@S)H^^4.]>6WNF-YSRE>!.9F&O<NA![KIX,W"JJKNFCMEJ0?7TX(>
M/=1.@>2Y4K9=. ?=,SK]!U!+ P04    " #;@%Q4Z\<(^G\%  #3#0  &0
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M!'24$/45HGY1O#3']@57= DPPS7=NE#H!32_Y%SM7[2!YAXW^A]02P,$%
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MFDXYV=G9I^5\M5S!^3-;"S07D\@2J#N*\CW H@5(3P D*3PH:;<&EK+ XBU
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M[\4M/;&HG0*=ETK9P\(YZ![MV;]02P,$%     @ VX!<5'+Y>]8/!   P0\
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MYDYKQ9[:<//ZR?M%&CP$<T\EZ\7!=SY5B]-:NX:F;$:30-W&JRN6!Y0"].-
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M:W-H965T<R]S:&5E=#,P+GAM;-57WV_:2!#^5T:H#ZV4Q%Y#(%2 Q(\F9RE
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M$SNPHW(;[/N5M$VP7[@ Y5^ WK]02P,$%     @ VX!<5'KDZAH= P  > D
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MYZ(6@LMV84(45?#/E=D $HV%^G&"7K>EUW7TND?HQ<;>[-%;]>0M/J2L,H;
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MH;0!YOU6F'[73.P&[65K_!]02P,$%     @ VX!<5 L%"?>< @  (P8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULC97=;N(P$(5?913UHI6Z34B
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MIOH61V$"]/LEYVH_,1=%_5T(_P-02P,$%     @ VX!<5-\/CGC% P  D0X
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MZP#U?LZ8W$[T!N5_A>Y?4$L#!!0    ( -N 7%3*LJJF\0(  .X'   9
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M^YL4_3DM_7W*TCZR1R?(L1S[_G:&7K]ZTX R-:-\90^ XN0H5HDB.4[A06T
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MFX#OEU*:]\#>&-T?1/874$L#!!0    ( -N 7%1W96?V<P4  "<:   9
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M#V0>J&(3$7[A@=Y<=H8=%+ 534-]*[:?64&H9_SY(E39?[0M;-T.\E.E152
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M%]0+H[(+Z/U<2K,=V WJ[GKX'U!+ P04    " #;@%Q4%&7X1Q<$  #?#@
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M=C3<+447QS118/U&C59\N'+4':^EL?#ZV9YLU T])WWA-+7@XM222Y6WC+F
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MBXRO6X[O[ ;NZ6RNS(#;;B9DAB-4C\E0Z)Z;L80TPEA2'H/ :<OI^)<]WS,
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MX1RFD@6/Y[I((0Q8JKX<04SM1T]ZC' Z1$GB1)QM@^$N,P'G\# =PNG)&9Q
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M4VU3GC?.?")99GK/G$G5R<PP4C\;R'6 >KY@3&XG^@7E[TOW!5!+ P04
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M6EE4K9JH'KFBD1:F['VLRG$.[V;P5!Q?AEWB8=?5*7G93^:A'2:]7F_?\$.
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MMO9#B)F^E0D(?+.2*F8&AVIMZT0!"S*C.+)=QVG;,>/"&O2RN:D:].3&1%S
M5!&]B6.F7H80R6W?HM9N8L;7H4DG[$$O86N8@_F<3!6.[!(EX#$(S:4@"E9]
MRZ,?1JZ;&F0KOG#8ZKUGDH:RE/)K.G@(^I:3,H((?)-",/Q[@A%$48J$//XI
M0*W29VJX_[Q#_S4+'H-9,@TC&?W. Q/VK:Y% EBQ361F<OL;% &U4CQ?1CK[
M)=MBK6,1?Z.-C MC9!!SD?^SYR(1>P:T?<+ +0S<'PV:)PP:A4$C"S1GEH4U
M9H8->DINB4I7(UKZD.4FL\9HN$BW<6X4ON5H9P:S^XFWN!^3J3=;_$D6,^_3
MW!LM'AX_S<F[,1C&(_V>_$(^S\?DW4_O>[9!GZFE[1?XPQS?/8%/7?)1"A-J
M<B\""%X#V$BV9.SN& _=6L0Q^+>D06^(Z[CT"*'1Y>9.#9U&F<!&AM<\@7<?
M)5S['(0/9,AE$C(L+A\VAOLLTC?D0:"_;V3.(B">",ATH_P0ZXYX:P6 !\+4
MD&B6))H9B<:I782(&4!PILP+62@F-,N/R5\37$H>#,3Z[QI'K=)1JS;:"6=+
M'G'#0>-A4>#+M>#_HN>5DC%ANY#TL4+)D3L9<JHN3X-&QW%P#YZ.$&J7A-JU
MA&;@ W]BRP@)91Q4D8H$4X$LCQ')$=N7$>F41#K_1QT\_M%TR(3[*(27E4"W
M]-^];@G<E8[NSF2<Q\N-TAEQ@A?)JY2_$+/G&IZ3-%!-N/ W2N$:(TF BX]M
MR]W!MK3P,CJY,=2I),ZYL$8RN@>D;HB0AKS@G:EVL05'E<XY8%A+<$^#:7WM
M[!BEU'R3IVD)Y^C0PSKNGF;C5FS<-VSP+EM'&;@'#"KON1@72SJ7YJR275JO
MN_]%B0KH6MZ'2VIY5TI-F]?3"7PQDMJ0.5IQL;Y(0&BE[;1U70FAE6K3<[)]
M)1&AA^)>NV^5O--Z?7_#J>B\C4*E\+1[K9(?%="O;M\Z4M5M0,]=!V^_@ O(
M2\FXE=*[]4KOK5:8('2O\:1,O"]DCMT)-WB0\+?^Z[,2:Y=>]Y2XE1*[]4K\
MN!6@=,@3+'V#&Z[-#8FE F)")HXE]@Q>Z]9Q?C[&S-YK(&)0ZZROTL27&V'R
M+_-RMNS=O*QC^6%^B#U=WH%5,'E#^)&I-1>:1+!"2.>V@UJD\AXK'QB99&W*
M4AIL>K+'$/M24.D"?+^2TNP&J8.RTQU\!U!+ P04    " #;@%Q4&3(Q=(8#
M  #W#   &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6RU5]MNVS@0_15"
MZ$,+;"-1%UL*; .)G6X#;-(@[F6!Q3XPTM@62I$N2<?IHA]?4E(D)9988W?S
M8I/4S)DSA^1H--ES\55N !1Z*"B34V>CU/;4=66Z@8+($[X%II^LN"B(TE.Q
M=N56 ,E*IX*ZON>-W(+DS)E-RK4;,9OPG:(Y@QN!Y*XHB/A^#I3OIPYV'A=N
M\_5&F05W-MF2-2Q!?=K>"#US&Y0L+X#)G#,D8#5USO#I B?&H;3XG,->=L;(
MI'+'^5<SN<RFCF<8 854&0BB_^YA#I0:),WC6PWJ-#&-8W?\B/ZN3%XG<T<D
MS#G]DF=J,W5B!V6P(CNJ;OG^/=0)108OY526OVA?V8:1@]*=5+RHG36#(F?5
M/WFHA>@XX-& @U\[^,\=P@&'H'8(CG4(:X>P5*9*I=1A0129303?(V&L-9H9
ME&*6WCK]G)E]7RJAG^;:3\TNK^<?KB[0Q[,_+Y;H+;HF0A"S$^CU A3)J7RC
M5S\M%^CUJS<35^F(QL]-:_3S"MT?0,<^NN),;22Z8!ED3P%<3;7AZS_R/?>M
MB M(3U" ?T.^Y^,>0O/CW;T>]\71[CBQ9!,TZ@<E7C" ]Y$\H+F +%=HKI7_
MKN_QGH@,_?6'-D27"@KYMR5,V(0)RS#A(.T5"!T&*1V/2*G+R3VA.U+=/*KO
M/F$I]&UOA3LN<4T)N9]%<>3'GJ?%N^_*?F@8)%X\[AH^H1XUU",K]=\%EQ+M
MF("4KUG^3YW$'3!8Y4KV<:X 1QTJ?AR.#BGWV.$H.K!;1 >IX3!)!C,;-9F-
MK)F=I:G8$8KTGJ.<*1 @%2(L0[JD$ZIRZ$UN=$#Z>5HVBR=$QPW1L97H;2O]
M\3S'O^0Y/I!U@&?<\(RM/-]!!H)0RWU)&J3D):\E]MKBZUDI7^N;J%_AIN2R
M-:+FJ*>=@+W*UI!=:7$2F_,X=")QYV6 CY$0_4"W((&(=(,&M+"E[[?A_!?5
MN2VS.+#F90*E5:!T,(E:WN! WCBPB=L686ROPDM%%-C2:6LBCEY4M[9$87N-
M^E?G\[  ^6%D4[ M1-A>B4H%_^/A;*L)CE]4Y+;8X.1_.YQ)WVNV1UJWTQ$6
M(-9E9ZTWC^^8JIJM9K7IWL_*GO79^CD^G5<]> M3?1)<$;'.F4045AK2.QGK
M,RNJ+KN:*+XM^\X[KG076PXW^LL$A#'0SU><J\>)"=!\Z\Q^ E!+ P04
M" #;@%Q4*_MQQ6D"  "^!0  &0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6R-5,MNVS 0_)6%T$,"M)$MV4D1R +\*II#6B-.V@)%#[2TLHA(I$JN;/?O
M2U*RXCSL]F+QL3,[L^9NM)7J4>>(!+NR$'KDY435M>_K),>2Z0M9H3 WF50E
M([-5:U]7"EGJ0&7A![W>I5\R+KPX<F<+%4>RIH(+7"C0=5DR]6>"A=R.O+ZW
M/[CCZYSL@1]'%5OC$NFA6BBS\SN6E)<H-)<"%&8C;]R_G@YMO OXQG&K#]9@
MG:RD?+2;FW3D]:P@+# AR\#,9X-3+ I+9&3\;CF]+J4%'J[W[)^<=^-EQ31.
M9?&=IY2/O(\>I)BQNJ [N?V,K1\G,)&%=K^P;6-['B2U)EFV8*.@Y*+YLEU;
MAP- __(((&@!P4O X @@; &A,]HH<[9FC%@<*;D%9:,-FUVXVCBT<<.%_1>7
MI,PM-SB*;[Y,O][.X7[\8[Z$#S"5924%"M(@,[@1B2P1[MD.YCOS;C3"V00%
M9IS.X6R&Q'BASPWL83F#LW?G\ ZX@/M<UIJ)5$<^&84VCY^T:B:-FN"(FGX
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M2!15Y^#.>12NSZEP\U^^T6]02P,$%     @ VX!<5)>*NQS     $P(   L
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M<F]P<R]A<' N>&UL4$L! A0#%     @ VX!<5"Y7L)GN    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ VX!<
M5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #;@%Q4/6Q&7J<&  #"&@  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ VX!<
M5!@T0I 9 @  : 4  !@              ("!Z@X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( -N 7%2*#L[N\ 4  )D7   8
M      " @3D1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #;@%Q45JR;'< "   +"0  &               @(%?%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ VX!<5&>-<,,3!0  (10  !@
M             ("!51H  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( -N 7%00[%'_^@8  +DC   8              " @9X?  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #;@%Q4&H_^>,0)  #9
M+0  &               @('.)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ VX!<5(D6Y':=*@  +H8  !@              ("!R#
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -N 7%3*O")R
M300  #0*   8              " @9M;  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #;@%Q46]H76.T*  !4'P  &0
M@($>8   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -N
M7%1[GBV-#@<  +43   9              " @4)K  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ VX!<5"27FQ/;!0  5@X  !D
M         ("!AW(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #;@%Q4.!_))9H+  #='@  &0              @(&9>   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -N 7%0+-IMJ%!0  %!)
M   9              " @6J$  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ VX!<5+CJG_P9!@  [Q(  !D              ("!M9@
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #;@%Q4)Z'M
M31(,  !-(   &0              @($%GP  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( -N 7%3(H<3^0 4  /T,   9
M  " @4ZK  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MVX!<5.G["M2^!@  3Q   !D              ("!Q;   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #;@%Q4@D:WQ:L'  ">$P  &0
M            @(&ZMP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( -N 7%2.*V#6A2P  %V5   9              " @9R_  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ VX!<5 Y*WIN>!
M;@H  !D              ("!6.P  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #;@%Q4CU?TR7T$   ["P  &0              @($M
M\0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -N 7%2]
M*E0&>@,  /H'   9              " @>'U  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ VX!<5"^[9@G1!   %@L  !D
M     ("!DOD  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -N 7%0/(1<2N 8  * ?   9              "
M@;</ 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ VX!<
M5$SZ&DBR P  #@P  !D              ("!IA8! 'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #;@%Q4>N3J&AT#  !X"0  &0
M        @(&/&@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( -N 7%0+!0GWG (  ",&   9              " @>,= 0!X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ VX!<5-\/CGC% P  D0X
M !D              ("!MB ! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #;@%Q4L#NP3- "   W"   &0              @(&R) $
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -N 7%3*LJJF
M\0(  .X'   9              " @;DG 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ VX!<5*8I!KGV!@  VB$  !D
M ("!X2H! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #;
M@%Q46I=91AT#   R"P  &0              @($.,@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -N 7%0/[+9*>0(  "P&   9
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M970T,BYX;6Q02P$"% ,4    " #;@%Q4],PW=24#  "$"0  &0
M    @(&A2@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M -N 7%2JT V Z@(  ,H(   9              " @?U- 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ VX!<5(VW7QJ%!   $Q8  !D
M             ("!'E$! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #;@%Q4P='BT; )   G/@  &0              @(':50$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( -N 7%1ACE\&SP,
M *L1   9              " @<%? 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ VX!<5-:"BB[N P  ]0X  !D              ("!
MQV,! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #;@%Q4
M&3(Q=(8#  #W#   &0              @('L9P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( -N 7%0K^W'%:0(  +X%   9
M      " @:EK 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ VX!<5"9AST1U P  \PD  !D              ("!26X! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #;@%Q4C3:G:>4#  #W#0
M&0              @('U<0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( -N 7%31!0&SF@(  'L&   9              " @1%V 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ VX!<5.[T4_:$
M P  LPL  !D              ("!XG@! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " #;@%Q4LS$=BX@"  "6!@  &0
M@(&=? $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( -N
M7%3S2?U'Z0(  +X(   9              " @5Q_ 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ VX!<5,T^/4#@ @  X@<  !D
M         ("!?((! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    " #;@%Q4PGR69(4'  !%+   &0              @(&3A0$ >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( -N 7%0W==47,@,  /(3
M   -              "  4^- 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !" $( !1(  ,B: 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>224</ContextCount>
  <ElementCount>452</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders??? Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108102 - Disclosure - OTHER FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATION</Role>
      <ShortName>OTHER FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114103 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2119104 - Disclosure - CONVERTIBLE PROMISSORY NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTE</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - EQUITY COMPENSATION PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANS</Role>
      <ShortName>EQUITY COMPENSATION PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - LICENSE AND GRANT REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LICENSEANDGRANTREVENUES</Role>
      <ShortName>LICENSE AND GRANT REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2134108 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2143110 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2148111 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2150112 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables</Role>
      <ShortName>OTHER FINANCIAL INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/OTHERFINANCIALINFORMATION</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/DEBT</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - EQUITY COMPENSATION PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSTables</Role>
      <ShortName>EQUITY COMPENSATION PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - LICENSE AND GRANT REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LICENSEANDGRANTREVENUESTables</Role>
      <ShortName>LICENSE AND GRANT REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/LICENSEANDGRANTREVENUES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/INCOMETAXES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/LEASES</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - OTHER FINANCIAL INFORMATION - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails</Role>
      <ShortName>DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - DEBT - Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails</Role>
      <ShortName>DEBT - Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - CONVERTIBLE PROMISSORY NOTE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTE</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICIT</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - EQUITY COMPENSATION PLANS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - EQUITY COMPENSATION PLANS - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - LICENSE AND GRANT REVENUES - Revenue Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails</Role>
      <ShortName>LICENSE AND GRANT REVENUES - Revenue Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails</Role>
      <ShortName>LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - LICENSE AND GRANT REVENUES - Government Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails</Role>
      <ShortName>LICENSE AND GRANT REVENUES - Government Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - INCOME TAXES - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>INCOME TAXES - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - INCOME TAXES - Reconciliation of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - INCOME TAXES - Components of net deferred income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails</Role>
      <ShortName>INCOME TAXES - Components of net deferred income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2442426 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails</Role>
      <ShortName>LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2447429 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails</Role>
      <ShortName>LEASES - Schedule of Operating Lease Liability Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2449430 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="inbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="inbx-20211231.htm">inbx-20211231.htm</File>
    <File>exhibit231q42021.htm</File>
    <File>exhibit311q42021.htm</File>
    <File>exhibit312q42021.htm</File>
    <File>exhibit321q42021.htm</File>
    <File>exhibit322q42021.htm</File>
    <File>inbx-20211231.xsd</File>
    <File>inbx-20211231_cal.xml</File>
    <File>inbx-20211231_def.xml</File>
    <File>inbx-20211231_lab.xml</File>
    <File>inbx-20211231_pre.xml</File>
    <File>kwagnerseparationletter.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>inbx-20211231_g1.jpg</File>
    <File>inbx-20211231_g10.jpg</File>
    <File>inbx-20211231_g2.jpg</File>
    <File>inbx-20211231_g3.jpg</File>
    <File>inbx-20211231_g4.jpg</File>
    <File>inbx-20211231_g5.jpg</File>
    <File>inbx-20211231_g6.jpg</File>
    <File>inbx-20211231_g7.jpg</File>
    <File>inbx-20211231_g8.jpg</File>
    <File>inbx-20211231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="617">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "inbx-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "contextCount": 224,
   "dts": {
    "calculationLink": {
     "local": [
      "inbx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "inbx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "inbx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "inbx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inbx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "inbx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 559,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 4,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 8
   },
   "keyCustom": 77,
   "keyStandard": 375,
   "memberCustom": 43,
   "memberStandard": 32,
   "nsprefix": "inbx",
   "nsuri": "http://inhibrx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://inhibrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114103 - Disclosure - DEBT",
     "role": "http://inhibrx.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119104 - Disclosure - CONVERTIBLE PROMISSORY NOTE",
     "role": "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTE",
     "shortName": "CONVERTIBLE PROMISSORY NOTE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICIT",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - EQUITY COMPENSATION PLANS",
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANS",
     "shortName": "EQUITY COMPENSATION PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inbx:LicenseAndGrantRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - LICENSE AND GRANT REVENUES",
     "role": "http://inhibrx.com/role/LICENSEANDGRANTREVENUES",
     "shortName": "LICENSE AND GRANT REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inbx:LicenseAndGrantRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134108 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - INCOME TAXES",
     "role": "http://inhibrx.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143110 - Disclosure - LEASES",
     "role": "http://inhibrx.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148111 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150112 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://inhibrx.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://inhibrx.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)",
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables",
     "shortName": "OTHER FINANCIAL INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - DEBT (Tables)",
     "role": "http://inhibrx.com/role/DEBTTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - EQUITY COMPENSATION PLANS (Tables)",
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSTables",
     "shortName": "EQUITY COMPENSATION PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - LICENSE AND GRANT REVENUES (Tables)",
     "role": "http://inhibrx.com/role/LICENSEANDGRANTREVENUESTables",
     "shortName": "LICENSE AND GRANT REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://inhibrx.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - LEASES (Tables)",
     "role": "http://inhibrx.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details)",
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - IPO (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i09e02f53cc2d44b4a25de925c223563e_I20200430",
      "decimals": "-5",
      "lang": "en-US",
      "name": "inbx:DeferredFederalPayrollTaxesCARESAct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://inhibrx.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibca4cb805a4d45438e207a1536816957_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)",
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Measured at Fair Value Using Level 3 Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibca4cb805a4d45438e207a1536816957_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)",
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)",
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - OTHER FINANCIAL INFORMATION - Property and Equipment (Details)",
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details)",
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ib9a2ae527c6442f69033f87496c9e149_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "inbx:AccruedClinicalResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)",
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfSecuredDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - DEBT - Narrative (Details)",
     "role": "http://inhibrx.com/role/DEBTNarrativeDetails",
     "shortName": "DEBT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "iabd8bb82f3c443ae89d9b90d7796e52b_I20200715",
      "decimals": "INF",
      "lang": "en-US",
      "name": "inbx:ClassOfWarrantOrRightPercentageOfFundedAmountIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "idde9aa5844664a6f8c3890232bb1f19a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)",
     "role": "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
     "shortName": "DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "idde9aa5844664a6f8c3890232bb1f19a_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "idde9aa5844664a6f8c3890232bb1f19a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - DEBT - Future Minimum Payments (Details)",
     "role": "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
     "shortName": "DEBT - Future Minimum Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "idde9aa5844664a6f8c3890232bb1f19a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - CONVERTIBLE PROMISSORY NOTE (Details)",
     "role": "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
     "shortName": "CONVERTIBLE PROMISSORY NOTE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ib9c4b992959d4ddb90aad9b4d5df22bb_D20200821-20200821",
      "decimals": "-5",
      "lang": "en-US",
      "name": "inbx:ReversalOfUnamortizedBeneficialConversionFeature",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details)",
     "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i317e9ea6d1b24bc6b0976cc24e137ae4_I20200821",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - EQUITY COMPENSATION PLANS - Narrative (Details)",
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
     "shortName": "EQUITY COMPENSATION PLANS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ia1d11895fa0442ea81f055db5e18f8a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - EQUITY COMPENSATION PLANS - Stock Option Activity (Details)",
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails",
     "shortName": "EQUITY COMPENSATION PLANS - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ia1d11895fa0442ea81f055db5e18f8a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details)",
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
     "shortName": "EQUITY COMPENSATION PLANS - Fair Value of Stock Option Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details)",
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails",
     "shortName": "EQUITY COMPENSATION PLANS - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i7d35d6b2fdb647d49f734d8268986a51_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - LICENSE AND GRANT REVENUES - Revenue Summary (Details)",
     "role": "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
     "shortName": "LICENSE AND GRANT REVENUES - Revenue Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ifcea0ecd9c6b41f78dbf074f597078d2_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)",
     "role": "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
     "shortName": "LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i71b075ff878e44c4922334a3be94c8cf_I20200731",
      "decimals": "2",
      "lang": "en-US",
      "name": "inbx:EquityMethodInvestmentAdditionalOwnershipEntitled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - LICENSE AND GRANT REVENUES - Government Grants (Details)",
     "role": "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
     "shortName": "LICENSE AND GRANT REVENUES - Government Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i29ef6bdd06234b22b93dd43c5eff449b_I20180930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "inbx:GrantValuedAwarded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ia72fe4742bba4cdf9802783a4d7a8394_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ia72fe4742bba4cdf9802783a4d7a8394_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "inbx:ContractWithCustomerLiabilityDerecognizedDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://inhibrx.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - INCOME TAXES - Components of Income Tax Expense (Benefit) (Details)",
     "role": "http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails",
     "shortName": "INCOME TAXES - Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - INCOME TAXES - Reconciliation of Income Tax Expense (Details)",
     "role": "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails",
     "shortName": "INCOME TAXES - Reconciliation of Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - INCOME TAXES - Components of net deferred income taxes (Details)",
     "role": "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails",
     "shortName": "INCOME TAXES - Components of net deferred income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ia1d11895fa0442ea81f055db5e18f8a9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442426 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits (Details)",
     "role": "http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails",
     "shortName": "INCOME TAXES - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i83fc42be157249d68dc8368a8c9862be_I20170930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://inhibrx.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i83fc42be157249d68dc8368a8c9862be_I20170930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)",
     "role": "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails",
     "shortName": "LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447429 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details)",
     "role": "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails",
     "shortName": "LEASES - Schedule of Operating Lease Liability Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "inbx:AccruedClinicalResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449430 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "ibd9dfc54d94543ba8698368d96961d03_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "inbx:PurchaseCommitmentNonCancellablePortionOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i13753df759a242849113e207322baf72_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i25366f43bada4f5b9d53d088a682e118_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Deficit",
     "role": "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i25366f43bada4f5b9d53d088a682e118_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108102 - Disclosure - OTHER FINANCIAL INFORMATION",
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATION",
     "shortName": "OTHER FINANCIAL INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inbx-20211231.htm",
      "contextRef": "i61b691e0b8484bc381bc4d907228f4ea_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "inbx_A2015OxfordTermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 Oxford Term Loans",
        "label": "2015 Oxford Term Loans [Member]",
        "terseLabel": "2015 Loan Agreement"
       }
      }
     },
     "localname": "A2015OxfordTermLoansMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2018OptionAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Option and License Agreement",
        "label": "2018 Option and License Agreement [Member]",
        "terseLabel": "2018 Option and License Agreement"
       }
      }
     },
     "localname": "A2018OptionAndLicenseAgreementMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2019And2020ConvertiblePromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 And 2020 Convertible Promissory Notes",
        "label": "2019 And 2020 Convertible Promissory Notes [Member]",
        "terseLabel": "2019 and 2020 Notes"
       }
      }
     },
     "localname": "A2019And2020ConvertiblePromissoryNotesMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2019ConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Convertible Promissory Note",
        "label": "2019 Convertible Promissory Note [Member]",
        "terseLabel": "2019 Convertible Note"
       }
      }
     },
     "localname": "A2019ConvertiblePromissoryNoteMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2020ConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Convertible Promissory Note",
        "label": "2020 Convertible Promissory Note [Member]",
        "terseLabel": "2020 Convertible Note"
       }
      }
     },
     "localname": "A2020ConvertiblePromissoryNoteMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2020OptionAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Option And License Agreement",
        "label": "2020 Option And License Agreement [Member]",
        "terseLabel": "2020 Option And License Agreement"
       }
      }
     },
     "localname": "A2020OptionAndLicenseAgreementMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2020OxfordTermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Oxford Term Loan A",
        "label": "2020 Oxford Term Loan A [Member]",
        "terseLabel": "Term A"
       }
      }
     },
     "localname": "A2020OxfordTermLoanAMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2020OxfordTermLoanBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Oxford Term Loan B",
        "label": "2020 Oxford Term Loan B [Member]",
        "terseLabel": "Term B"
       }
      }
     },
     "localname": "A2020OxfordTermLoanBMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2020OxfordTermLoanCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Oxford Term Loan C",
        "label": "2020 Oxford Term Loan C [Member]",
        "terseLabel": "Term C"
       }
      }
     },
     "localname": "A2020OxfordTermLoanCMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2020OxfordTermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Oxford Term Loans",
        "label": "2020 Oxford Term Loans [Member]",
        "terseLabel": "2020 Loan Agreement"
       }
      }
     },
     "localname": "A2020OxfordTermLoansMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2020OxfordTermLoansTermBTermCTranche1OfTermAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Oxford Term Loans Term B, Term C &amp; Tranche 1 of Term A",
        "label": "2020 Oxford Term Loans Term B, Term C &amp; Tranche 1 of Term A [Member]",
        "terseLabel": "2020 Oxford Term Loans Term B, Term C &amp; Tranche 1 of Term A"
       }
      }
     },
     "localname": "A2020OxfordTermLoansTermBTermCTranche1OfTermAMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_A2seventyBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2seventy bio, Inc.",
        "label": "2seventy bio, Inc. [Member]",
        "terseLabel": "2seventy bio, Inc."
       }
      }
     },
     "localname": "A2seventyBioIncMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_AccruedClinicalResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Research And Development, Current",
        "label": "Accrued Clinical Research And Development, Current",
        "terseLabel": "Clinical research and development"
       }
      }
     },
     "localname": "AccruedClinicalResearchAndDevelopmentCurrent",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Outside Research And Development, Other, Current",
        "label": "Accrued Outside Research And Development, Other, Current",
        "terseLabel": "Accrued Outside Research And Development, Other, Current"
       }
      }
     },
     "localname": "AccruedOutsideResearchAndDevelopmentOtherCurrent",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_Amended2020OxfordTermLoanJune2021AmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended 2020 Oxford Term Loan June 2021 Amendment",
        "label": "Amended 2020 Oxford Term Loan June 2021 Amendment [Member]",
        "terseLabel": "Amended 2020 Oxford Term Loan June 2021 Amendment"
       }
      }
     },
     "localname": "Amended2020OxfordTermLoanJune2021AmendmentMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_Amended2020OxfordTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended 2020 Oxford Term Loan",
        "label": "Amended 2020 Oxford Term Loan [Member]",
        "terseLabel": "Amended 2020 Oxford Term Loan"
       }
      }
     },
     "localname": "Amended2020OxfordTermLoanMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_Amended2020OxfordTermLoanTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended 2020 Oxford Term Loan Tranche Four",
        "label": "Amended 2020 Oxford Term Loan Tranche Four [Member]",
        "terseLabel": "Amended 2020 Oxford Term Loan Tranche Four"
       }
      }
     },
     "localname": "Amended2020OxfordTermLoanTrancheFourMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_Amended2020OxfordTermLoanTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended 2020 Oxford Term Loan Tranche One",
        "label": "Amended 2020 Oxford Term Loan Tranche One [Member]",
        "terseLabel": "Amended 2020 Oxford Term Loan Tranche One"
       }
      }
     },
     "localname": "Amended2020OxfordTermLoanTrancheOneMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_Amended2020OxfordTermLoanTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended 2020 Oxford Term Loan Tranche Three",
        "label": "Amended 2020 Oxford Term Loan Tranche Three [Member]",
        "terseLabel": "Amended 2020 Oxford Term Loan Tranche Three"
       }
      }
     },
     "localname": "Amended2020OxfordTermLoanTrancheThreeMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_Amended2020OxfordTermLoanTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended 2020 Oxford Term Loan Tranche Two",
        "label": "Amended 2020 Oxford Term Loan Tranche Two [Member]",
        "terseLabel": "Amended 2020 Oxford Term Loan Tranche Two"
       }
      }
     },
     "localname": "Amended2020OxfordTermLoanTrancheTwoMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_AtTheMarketOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Costs",
        "label": "At The Market Offering Costs",
        "terseLabel": "At the market offering costs"
       }
      }
     },
     "localname": "AtTheMarketOfferingCosts",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Costs Included in Accounts Payable and Accrued Expenses",
        "label": "At The Market Offering Costs Included in Accounts Payable and Accrued Expenses",
        "terseLabel": "ATM offering costs included in accounts payable"
       }
      }
     },
     "localname": "AtTheMarketOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_AtTheMarketOfferingCostsReimbursableInAccountsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Costs Reimbursable in Accounts Receivable",
        "label": "At The Market Offering Costs Reimbursable in Accounts Receivable",
        "terseLabel": "ATM offering costs reimbursable in accounts receivable"
       }
      }
     },
     "localname": "AtTheMarketOfferingCostsReimbursableInAccountsReceivable",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "ATM Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://inhibrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "inbx_CapitalExpendituresIncurredButNotYetPaidReleased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Expenditures Incurred but Not Yet Paid (Released)",
        "label": "Capital Expenditures Incurred but Not Yet Paid (Released)",
        "terseLabel": "Payable for purchase of fixed assets"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaidReleased",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CelgeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Celgene",
        "label": "Celgene [Member]",
        "terseLabel": "Celgene"
       }
      }
     },
     "localname": "CelgeneMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_ChiesiFarmaceuticiSpAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Farmaceutici S.p.A.",
        "label": "Chiesi Farmaceutici S.p.A. [Member]",
        "terseLabel": "Chiesi Farmaceutici S.p.A."
       }
      }
     },
     "localname": "ChiesiFarmaceuticiSpAMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_ClassOfWarrantOrRightPercentageOfFundedAmountIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Percentage Of Funded Amount Issued",
        "label": "Class of Warrant or Right, Percentage Of Funded Amount Issued",
        "terseLabel": "Common or preferred stock warrants issued as a percent of funded amount"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPercentageOfFundedAmountIssued",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inbx_CollaborativeAgreementExclusiveDevelopmentLicenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Exclusive Development Licenses",
        "label": "Collaborative Agreement, Exclusive Development Licenses",
        "terseLabel": "Exclusive development license"
       }
      }
     },
     "localname": "CollaborativeAgreementExclusiveDevelopmentLicenses",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Number Of Related Programs To Agreement",
        "label": "Collaborative Agreement, Number Of Related Programs To Agreement",
        "terseLabel": "Number of programs related to collaborative agreement"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberOfRelatedProgramsToAgreement",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inbx_CollaborativeArrangementAdditionalPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Additional Payment Receivable",
        "label": "Collaborative Arrangement, Additional Payment Receivable",
        "terseLabel": "Additional payable due from agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalPaymentReceivable",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CollaborativeArrangementAdditionalPaymentReceivablePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Additional Payment Receivable Period",
        "label": "Collaborative Arrangement, Additional Payment Receivable Period",
        "terseLabel": "Additional payment receivable period"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalPaymentReceivablePeriod",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inbx_CollaborativeArrangementCommercializationMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Commercialization Milestone Receivable",
        "label": "Collaborative Arrangement, Commercialization Milestone Receivable",
        "terseLabel": "Commercialization milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementCommercializationMilestoneReceivable",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CollaborativeArrangementDevelopmentMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Development Milestone Receivable",
        "label": "Collaborative Arrangement, Development Milestone Receivable",
        "terseLabel": "Development milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementDevelopmentMilestoneReceivable",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CollaborativeArrangementExpenseReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Expense Reimbursement",
        "label": "Collaborative Arrangement, Expense Reimbursement",
        "terseLabel": "Reimbursement expenses"
       }
      }
     },
     "localname": "CollaborativeArrangementExpenseReimbursement",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CollaborativeArrangementMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment Received",
        "label": "Collaborative Arrangement, Milestone Payment Received",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentReceived",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CollaborativeArrangementMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payments Receivable",
        "label": "Collaborative Arrangement, Milestone Payments Receivable",
        "terseLabel": "Milestone payments receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentsReceivable",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CollaborativeArrangementNonrefundableOptionExtensionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Nonrefundable Option Extension Fee",
        "label": "Collaborative Arrangement, Nonrefundable Option Extension Fee",
        "terseLabel": "Option extension fee"
       }
      }
     },
     "localname": "CollaborativeArrangementNonrefundableOptionExtensionFee",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CollaborativeArrangementNonrefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Nonrefundable Upfront Payment",
        "label": "Collaborative Arrangement, Nonrefundable Upfront Payment",
        "terseLabel": "Nonrefundable, upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementNonrefundableUpfrontPayment",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CollaborativeArrangementPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Payment Receivable",
        "label": "Collaborative Arrangement, Payment Receivable",
        "terseLabel": "Payments due pursuant to agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPaymentReceivable",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Percentage Of Future Amounts Received, Obligation to Pay Advisors",
        "label": "Collaborative Arrangement, Percentage Of Future Amounts Received, Obligation to Pay",
        "terseLabel": "Percentage due to advisors"
       }
      }
     },
     "localname": "CollaborativeArrangementPercentageOfFutureAmountsReceivedObligationToPay",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "inbx_CollaborativeArrangementReceivablesFromRelatedParties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Receivables from Related Parties",
        "label": "Collaborative Arrangement, Receivables from Related Parties",
        "terseLabel": "Receivables from related parties"
       }
      }
     },
     "localname": "CollaborativeArrangementReceivablesFromRelatedParties",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Collaborative arrangement, term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inbx_CommonStockSaleOfStockCommissionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Sale Of Stock Commission, Percent",
        "label": "Common Stock, Sale Of Stock Commission, Percent",
        "terseLabel": "Commission percent"
       }
      }
     },
     "localname": "CommonStockSaleOfStockCommissionPercent",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inbx_ContractWithCustomerLiabilityDerecognizedDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Derecognized During Period",
        "label": "Contract With Customer, Liability, Derecognized During Period",
        "terseLabel": "Liabilities derecognized from agreements"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDerecognizedDuringPeriod",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_CostSharingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Sharing Agreement",
        "label": "Cost Sharing Agreement [Member]",
        "terseLabel": "Cost Sharing Agreement"
       }
      }
     },
     "localname": "CostSharingAgreementMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Aggregate Principal Amount of Additional Tranches",
        "label": "Debt Instrument, Aggregate Principal Amount of Additional Tranches",
        "terseLabel": "Aggregate principal amount of additional tranches"
       }
      }
     },
     "localname": "DebtInstrumentAggregatePrincipalAmountOfAdditionalTranches",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_DebtInstrumentAmendmentFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Amendment Fee",
        "label": "Debt Instrument, Amendment Fee",
        "terseLabel": "One-time first amendment fee"
       }
      }
     },
     "localname": "DebtInstrumentAmendmentFee",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_DebtInstrumentMinimumCashBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Minimum Cash Balance",
        "label": "Debt Instrument, Minimum Cash Balance",
        "terseLabel": "Minimum cash balance"
       }
      }
     },
     "localname": "DebtInstrumentMinimumCashBalance",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_DebtInstrumentNumberOfAdditionalTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number of Additional Tranches",
        "label": "Debt Instrument, Number of Additional Tranches",
        "terseLabel": "Number of additional tranches"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfAdditionalTranches",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inbx_DebtInstrumentNumberOfExistingTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number of Existing Tranches",
        "label": "Debt Instrument, Number of Existing Tranches",
        "terseLabel": "Number of existing tranches"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfExistingTranches",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value",
        "terseLabel": "Percentage of principal amount for final payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period",
        "label": "Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period",
        "terseLabel": "Equal payments of principal and interest period"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriod",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period if Interest-Only Period Is Extended",
        "label": "Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period if Interest-Only Period Is Extended",
        "terseLabel": "Equal payments of principal and interest period if interest only period is extended"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inbx_DebtInstrumentPrepaymentFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Fee",
        "label": "Debt Instrument, Prepayment Fee",
        "terseLabel": "Prepayment fee"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFee",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inbx_DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Beneficial Conversion Feature Discount (Reversal) Of Beneficial Conversion Feature",
        "label": "Debt Instrument, Unamortized Discount, Beneficial Conversion Feature (Reversal) Of Beneficial Conversion Feature",
        "terseLabel": "Debt discount arising from convertible note beneficial conversion features and reversal of beneficial conversion features"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountBeneficialConversionFeatureReversalOfBeneficialConversionFeature",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_DeferredFederalPayrollTaxesCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Federal Payroll Taxes, CARES Act",
        "label": "Deferred Federal Payroll Taxes, CARES Act",
        "terseLabel": "Deferred payment of federal payroll taxes"
       }
      }
     },
     "localname": "DeferredFederalPayrollTaxesCARESAct",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department of Defense - Congressionally Directed Medical Research Program, 2018 Grant",
        "label": "Department of Defense - Congressionally Directed Medical Research Program, 2018 Grant [Member]",
        "terseLabel": "Congressionally Directed Medical Research Program, 2018 Grant"
       }
      }
     },
     "localname": "DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2018GrantMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department of Defense - Congressionally Directed Medical Research Program, 2021 Grant",
        "label": "Department of Defense - Congressionally Directed Medical Research Program, 2021 Grant [Member]",
        "terseLabel": "Congressionally Directed Medical Research Program, 2021 Grant"
       }
      }
     },
     "localname": "DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgram2021GrantMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department of Defense - Congressionally Directed Medical Research Program",
        "label": "Department of Defense - Congressionally Directed Medical Research Program [Member]",
        "terseLabel": "Congressionally Directed Medical Research Program"
       }
      }
     },
     "localname": "DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Permanent Items",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Return to Provision True-Ups",
        "label": "Effective Income Tax Rate Reconciliation, Return to Provision True-Ups",
        "terseLabel": "Return to provision true-ups"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_ElpiscienceBiopharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elpiscience Biopharmaceuticals, Inc.",
        "label": "Elpiscience Biopharmaceuticals, Inc. [Member]",
        "terseLabel": "Elpiscience Biopharmaceuticals, Inc."
       }
      }
     },
     "localname": "ElpiscienceBiopharmaceuticalsIncMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_EquityMethodInvestmentAdditionalOwnershipEntitled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Additional Ownership Entitled",
        "label": "Equity Method Investment, Additional Ownership Entitled",
        "terseLabel": "Additional equity interest percentage entitled to receive"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditionalOwnershipEntitled",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inbx_ExpensesExpectedToBeReimbursed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses Expected to be Reimbursed",
        "label": "Expenses Expected to be Reimbursed",
        "terseLabel": "Expenses expected to be reimbursed"
       }
      }
     },
     "localname": "ExpensesExpectedToBeReimbursed",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_ExpensesReimbursedToDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses Reimbursed To Date",
        "label": "Expenses Reimbursed To Date",
        "terseLabel": "Reimbursement for related party transaction expenses incurred to date"
       }
      }
     },
     "localname": "ExpensesReimbursedToDate",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification",
        "negatedTerseLabel": "Reclassification of liabilities into equity"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_GrantValuedAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant, Valued Awarded",
        "label": "Grant, Valued Awarded",
        "terseLabel": "Grant award"
       }
      }
     },
     "localname": "GrantValuedAwarded",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Contract With Customer, Liability, Current",
        "label": "Increase (Decrease) Contract With Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "IncreaseDecreaseContractWithCustomerLiabilityCurrent",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Contract With Customer, Liability, Non-Current",
        "label": "Increase (Decrease) Contract With Customer, Liability, Non-Current",
        "terseLabel": "Deferred revenue, non-current portion"
       }
      }
     },
     "localname": "IncreaseDecreaseContractWithCustomerLiabilityNonCurrent",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Only Payment Extension Requirement, Upfront Partnership Proceeds Minimum",
        "label": "Interest Only Payment Extension Requirement, Upfront Partnership Proceeds Minimum",
        "terseLabel": "Upfront partnership proceeds"
       }
      }
     },
     "localname": "InterestOnlyPaymentExtensionRequirementUpfrontPartnershipProceedsMinimum",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_LAVSummitLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LAV Summit Limited",
        "label": "LAV Summit Limited [Member]",
        "terseLabel": "LAV Summit Limited"
       }
      }
     },
     "localname": "LAVSummitLimitedMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_LesseeOperatingLeaseAnnualEscalations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Escalations",
        "label": "Lessee, Operating Lease, Annual Escalations",
        "terseLabel": "Annual escalations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualEscalations",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Initial Base Rent Expense Per Month",
        "label": "Lessee, Operating Lease, Initial Base Rent Expense Per Month",
        "terseLabel": "Initial base rent per month"
       }
      }
     },
     "localname": "LesseeOperatingLeaseInitialBaseRentExpensePerMonth",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_LesseeOperatingLeaseSquareFootage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Square Footage",
        "label": "Lessee, Operating Lease, Square Footage",
        "terseLabel": "Square footage of lease agreement (in sq feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSquareFootage",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "inbx_LesseeOperatingLeaseSquareFootageExpansion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Square Footage Expansion",
        "label": "Lessee, Operating Lease, Square Footage Expansion",
        "terseLabel": "Square footage of lease extension agreement (in sq feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSquareFootageExpansion",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "inbx_LicenseAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, Affiliate",
        "label": "License, Affiliate [Member]",
        "terseLabel": "License fee revenue, affiliates"
       }
      }
     },
     "localname": "LicenseAffiliateMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_LicenseAffiliateOX40LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, Affiliate - OX40 License Agreement",
        "label": "License, Affiliate - OX40 License Agreement [Member]",
        "terseLabel": "OX40 License Agreement"
       }
      }
     },
     "localname": "LicenseAffiliateOX40LicenseAgreementMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_LicenseAgreementAdditionalProgramsAuthorizedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Additional Programs Authorized",
        "label": "License Agreement, Additional Programs Authorized [Member]",
        "terseLabel": "Additional Programs"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalProgramsAuthorizedMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_LicenseAgreementInitialProgramsAuthorizedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Initial Programs Authorized",
        "label": "License Agreement, Initial Programs Authorized [Member]",
        "terseLabel": "Initial Programs"
       }
      }
     },
     "localname": "LicenseAgreementInitialProgramsAuthorizedMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Initial Programs Authorized, Program One",
        "label": "License Agreement, Initial Programs Authorized, Program One [Member]",
        "terseLabel": "Initial Programs, Program 1"
       }
      }
     },
     "localname": "LicenseAgreementInitialProgramsAuthorizedProgramOneMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Initial Programs Authorized, Program Two",
        "label": "License Agreement, Initial Programs Authorized, Program Two [Member]",
        "terseLabel": "Initial Programs, Program 2"
       }
      }
     },
     "localname": "LicenseAgreementInitialProgramsAuthorizedProgramTwoMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_LicenseAndGrantRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Grant Revenue",
        "label": "License And Grant Revenue [Text Block]",
        "terseLabel": "LICENSE AND GRANT REVENUES"
       }
      }
     },
     "localname": "LicenseAndGrantRevenueTextBlock",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inbx_LicenseNonAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, Non-Affiliate",
        "label": "License, Non-Affiliate [Member]",
        "terseLabel": "License fee revenue, non-affiliates"
       }
      }
     },
     "localname": "LicenseNonAffiliateMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity",
        "label": "Liquidity [Policy Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inbx_NonCashEstablishmentOfEquityMethodInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash Establishment Of Equity Method Investment",
        "label": "Non-cash Establishment Of Equity Method Investment",
        "terseLabel": "Non-cash equity method investment"
       }
      }
     },
     "localname": "NonCashEstablishmentOfEquityMethodInvestment",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Operating Lease Expense",
        "label": "Noncash Operating Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_NumberOfOperatingLeasesHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Operating Leases Held",
        "label": "Number Of Operating Leases Held",
        "terseLabel": "Number of operating leases held"
       }
      }
     },
     "localname": "NumberOfOperatingLeasesHeld",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inbx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Performance Obligations",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inbx_OtherCustomersNotSeparatelyDisclosedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Customers, Not Separately Disclosed",
        "label": "Other Customers, Not Separately Disclosed [Member]",
        "terseLabel": "Other license revenues from non-affiliates"
       }
      }
     },
     "localname": "OtherCustomersNotSeparatelyDisclosedMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Noncash Investing And Financing Items, Derivative Liabilities Incurred",
        "label": "Other Noncash Investing And Financing Items, Derivative Liabilities Incurred",
        "terseLabel": "Derivative liabilities arising from the issuance of the 2019 Note and the 2020 Notes"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsDerivativeLiabilitiesIncurred",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Noncash Investing And Financing Items, Warrant Liabilities Incurred",
        "label": "Other Noncash Investing And Financing Items, Warrant Liabilities Incurred",
        "terseLabel": "Warrant liabilities issued to lender in conjunction with 2020 Loan Agreement"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "PPP Loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_PaymentsOfDebtIssuanceCostsSecuredDebt": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of Debt Issuance Costs, Secured Debt",
        "label": "Payments of Debt Issuance Costs, Secured Debt",
        "negatedLabel": "Payment of fees associated with debt"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCostsSecuredDebt",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_PaymentsOfStockIssuanceCostsInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of Stock Issuance Costs, Initial Public Offering",
        "label": "Payments of Stock Issuance Costs, Initial Public Offering",
        "terseLabel": "Costs associated with initial public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCostsInitialPublicOffering",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_PhylaxisBioScienceLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phylaxis BioScience, LLC",
        "label": "Phylaxis BioScience, LLC [Member]",
        "terseLabel": "Phylaxis BioScience, LLC"
       }
      }
     },
     "localname": "PhylaxisBioScienceLLCMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_PurchaseCommitmentExpensesIncurredRelatedToContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Commitment, Expenses Incurred Related to Contracts",
        "label": "Purchase Commitment, Expenses Incurred Related to Contracts",
        "terseLabel": "Expenses related to agreements"
       }
      }
     },
     "localname": "PurchaseCommitmentExpensesIncurredRelatedToContracts",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_PurchaseCommitmentNonCancellablePortionOfContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Commitment, Non-cancellable Portion of Contract",
        "label": "Purchase Commitment, Non-cancellable Portion of Contract",
        "terseLabel": "Non-cancellable portion of contract"
       }
      }
     },
     "localname": "PurchaseCommitmentNonCancellablePortionOfContract",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_ReclassificationOfWarrantLiabilitiesToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification Of Warrant Liabilities To Equity",
        "label": "Reclassification Of Warrant Liabilities To Equity",
        "terseLabel": "Reclassification of warrant liabilities to equity"
       }
      }
     },
     "localname": "ReclassificationOfWarrantLiabilitiesToEquity",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_RelatedPartyEquityInterestInCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party , Equity Interest In Company",
        "label": "Related Party , Equity Interest In Company",
        "terseLabel": "Ownership interest, more than"
       }
      }
     },
     "localname": "RelatedPartyEquityInterestInCompany",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inbx_RepaymentsOfSecuredDebtFinalBalloonPayment": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments Of Secured Debt, Final Balloon Payment",
        "label": "Repayments Of Secured Debt, Final Balloon Payment",
        "negatedTerseLabel": "Final payment on debt"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebtFinalBalloonPayment",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_RevenueRecognitionNumberOfCompounds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Number Of Compounds",
        "label": "Revenue Recognition, Number Of Compounds",
        "terseLabel": "Number of compounds"
       }
      }
     },
     "localname": "RevenueRecognitionNumberOfCompounds",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inbx_RevenuesCashReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Cash Received",
        "label": "Revenues, Cash Received",
        "terseLabel": "Revenue recognized, cash"
       }
      }
     },
     "localname": "RevenuesCashReceived",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_ReversalOfUnamortizedBeneficialConversionFeature": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of Unamortized Beneficial Conversion Feature",
        "label": "Reversal of Unamortized Beneficial Conversion Feature",
        "negatedTerseLabel": "Reversal of unamortized BCF",
        "terseLabel": "Reversal of unamortized BCF"
       }
      }
     },
     "localname": "ReversalOfUnamortizedBeneficialConversionFeature",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset And Operating Lease Liability",
        "label": "Right-Of-Use Asset And Operating Lease Liability [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease, by Balance Sheet Location"
       }
      }
     },
     "localname": "RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inbx_SaleAndPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale And Purchase Agreement",
        "label": "Sale And Purchase Agreement [Member]",
        "terseLabel": "Sale And Purchase Agreement"
       }
      }
     },
     "localname": "SaleAndPurchaseAgreementMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_SaleOfStockCommonStockAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Common Stock, Authorized",
        "label": "Sale of Stock, Common Stock, Authorized",
        "terseLabel": "Common stock offering price"
       }
      }
     },
     "localname": "SaleOfStockCommonStockAuthorized",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_SaleOfStockSharesCommonStockSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Shares, Common Stock Sold",
        "label": "Sale of Stock, Shares, Common Stock Sold",
        "terseLabel": "Common stock shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockSharesCommonStockSold",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inbx_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of License And Grant Revenue",
        "label": "Schedule Of License And Grant Revenue [Table Text Block]",
        "terseLabel": "Schedule of License and Grant Revenue"
       }
      }
     },
     "localname": "ScheduleOfLicenseAndGrantRevenueTableTextBlock",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inbx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of shares in conversion of preferred shares (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "inbx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities",
        "label": "Temporary Equity, Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of shares in conversion of preferred shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_WarrantAndDerivativeLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant And Derivative Liabilities",
        "label": "Warrant And Derivative Liabilities [Member]",
        "terseLabel": "Warrant And Derivative Liabilities"
       }
      }
     },
     "localname": "WarrantAndDerivativeLiabilitiesMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_WarrantLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liabilities",
        "label": "Warrant Liabilities [Policy Text Block]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "localname": "WarrantLiabilitiesPolicyTextBlock",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inbx_WarrantsAndRightsOutstandingLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants And Rights Outstanding, Liability",
        "label": "Warrants And Rights Outstanding, Liability",
        "terseLabel": "Warrants issued, amount"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingLiability",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_WarrantsIssuedConcurrentlyWith2020LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued Concurrently With 2020 Loan Agreement",
        "label": "Warrants Issued Concurrently With 2020 Loan Agreement [Member]",
        "terseLabel": "Warrants Issued Concurrently With 2020 Loan Agreement"
       }
      }
     },
     "localname": "WarrantsIssuedConcurrentlyWith2020LoanAgreementMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_WarrantsIssuedUponConsummationOfIPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued Upon Consummation Of IPO",
        "label": "Warrants Issued Upon Consummation Of IPO [Member]",
        "terseLabel": "Warrants Issued Upon Consummation of IPO"
       }
      }
     },
     "localname": "WarrantsIssuedUponConsummationOfIPOMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inbx_WarrantsLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Liability",
        "label": "Warrants Liability",
        "terseLabel": "Warrants liability"
       }
      }
     },
     "localname": "WarrantsLiability",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inbx_WuXiBiologicsHealthcareVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi Biologics Healthcare Venture",
        "label": "WuXi Biologics Healthcare Venture [Member]",
        "terseLabel": "WuXi Biologics Healthcare Venture"
       }
      }
     },
     "localname": "WuXiBiologicsHealthcareVentureMember",
     "nsuri": "http://inhibrx.com/20211231",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r302",
      "r444",
      "r445",
      "r447",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliates"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r62",
      "r64",
      "r117",
      "r118",
      "r232",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r187",
      "r297",
      "r300",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r231",
      "r271",
      "r303",
      "r304",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r505",
      "r508",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r231",
      "r271",
      "r303",
      "r304",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r505",
      "r508",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r187",
      "r297",
      "r300",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r185",
      "r297",
      "r299",
      "r464",
      "r504",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r185",
      "r297",
      "r299",
      "r464",
      "r504",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r231",
      "r271",
      "r301",
      "r303",
      "r304",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r505",
      "r508",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r231",
      "r271",
      "r301",
      "r303",
      "r304",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r505",
      "r508",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r63",
      "r64",
      "r117",
      "r118",
      "r232",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44",
      "r452"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r188",
      "r189"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r48"
     ],
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42",
      "r201"
     ],
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r31",
      "r335",
      "r452"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r332",
      "r333",
      "r334",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "verboseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r284",
      "r289",
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "terseLabel": "Beneficial conversion feature"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r305",
      "r307",
      "r338",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r227",
      "r284",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Reclassification of warrant liabilities into equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r307",
      "r328",
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r80",
      "r96",
      "r251",
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r77",
      "r96",
      "r251",
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Charge of amortized debt issuance costs to interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r96",
      "r251",
      "r263",
      "r264",
      "r426"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Accretion of debt discount and non-cash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from earnings per share computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r167",
      "r177",
      "r183",
      "r194",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r383",
      "r388",
      "r415",
      "r450",
      "r452",
      "r477",
      "r493"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r59",
      "r112",
      "r194",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r383",
      "r388",
      "r415",
      "r450",
      "r452"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r308",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r38",
      "r98"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r92",
      "r98",
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r416"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r109",
      "r112",
      "r137",
      "r138",
      "r139",
      "r141",
      "r143",
      "r149",
      "r150",
      "r151",
      "r194",
      "r213",
      "r218",
      "r219",
      "r220",
      "r224",
      "r225",
      "r269",
      "r270",
      "r274",
      "r278",
      "r415",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r291",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Conversion of outstanding warrants to purchase convertible preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants exercisable for shares of common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r53",
      "r209",
      "r483",
      "r499"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r210",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "COMMON STOCK",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r452"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 120,000,000 shares authorized as of December\u00a031, 2021 and 2020; 38,991,307 and 37,712,390 shares issued and outstanding as of December\u00a031, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r154",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r293",
      "r295",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Receivable for expenses incurred, not yet reimbursed"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r293",
      "r294",
      "r298"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r293",
      "r294",
      "r298"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Non-current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized related to performance obligation"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r231",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r261",
      "r262",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r365",
      "r373"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of the 2019 Note and the 2020 Notes to common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Issuance of shares of common stock after conversion (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued",
        "terseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r245",
      "r252",
      "r253",
      "r255",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r111",
      "r120",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r261",
      "r262",
      "r263",
      "r264",
      "r427",
      "r478",
      "r480",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r21",
      "r256",
      "r480",
      "r492"
     ],
     "calculation": {
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Total long-term debt",
        "totalLabel": "Total future minimum payments",
        "verboseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r230",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r228",
      "r261",
      "r262",
      "r425",
      "r427",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Note aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r50",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Annual interest rate",
        "verboseLabel": "Note monthly interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r51",
      "r111",
      "r120",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r261",
      "r262",
      "r263",
      "r264",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Periodic payment terms, final payment amount"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r51",
      "r111",
      "r120",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r261",
      "r262",
      "r263",
      "r264",
      "r285",
      "r286",
      "r287",
      "r288",
      "r424",
      "r425",
      "r427",
      "r428",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r241",
      "r257",
      "r261",
      "r262",
      "r426"
     ],
     "calculation": {
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized debt discount",
        "negatedTerseLabel": "Less: Debt discount",
        "terseLabel": "Unamortized debt discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Financing Costs and Other Debt-Related Costs and Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expense and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r43",
      "r241",
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r23",
      "r24",
      "r355",
      "r479",
      "r491"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r58",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r361",
      "r363",
      "r364"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: Valuation allowance",
        "verboseLabel": "Deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails",
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESComponentsofnetdeferredincometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r96",
      "r164"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedTerseLabel": "Change in fair value of derivative liabilities",
        "terseLabel": "Change in fair value of derivative liabilities",
        "verboseLabel": "Other income related to changes in fair value of derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r60",
      "r61",
      "r64",
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).",
        "label": "Derivative [Member]",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "EQUITY COMPENSATION PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r6",
      "r16",
      "r29",
      "r116",
      "r216",
      "r218",
      "r219",
      "r223",
      "r224",
      "r225",
      "r445"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Receivables from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r75",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r135",
      "r137",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r402",
      "r403",
      "r486",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r75",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r137",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r402",
      "r403",
      "r486",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r69",
      "r70",
      "r71",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r148",
      "r195",
      "r284",
      "r289",
      "r332",
      "r333",
      "r334",
      "r369",
      "r370",
      "r401",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r509",
      "r510",
      "r511",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r39",
      "r168",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r39",
      "r91",
      "r193",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r96",
      "r266"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedTerseLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r407",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r407",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Notes Measured at Fair Value Using Level 3 Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Change in fair value of liabilities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Establishment of liabilities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Gain on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r199",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r167",
      "r176",
      "r179",
      "r182",
      "r184"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r73",
      "r96",
      "r165",
      "r191",
      "r484",
      "r500"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Loss from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r203",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r347",
      "r353",
      "r360",
      "r371",
      "r374",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r133",
      "r134",
      "r166",
      "r345",
      "r372",
      "r375",
      "r503"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails",
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r343",
      "r344",
      "r353",
      "r354",
      "r359",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Expected income tax benefit at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Unrecognized tax benefits (FIN 48)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax expense (benefit), net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "R&amp;D credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedTerseLabel": "Receivables from related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r80",
      "r249",
      "r260",
      "r263",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Debt interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r89",
      "r93",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining term of operating lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease agreement term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r47",
      "r112",
      "r178",
      "r194",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r384",
      "r388",
      "r389",
      "r415",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r112",
      "r194",
      "r415",
      "r452",
      "r482",
      "r497"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r49",
      "r112",
      "r194",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r384",
      "r388",
      "r389",
      "r415",
      "r450",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License fee revenue"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r21",
      "r242",
      "r258",
      "r261",
      "r262",
      "r480",
      "r494"
     ],
     "calculation": {
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Outstanding debt",
        "totalLabel": "Total debt",
        "verboseLabel": "Total debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Current portion, including debt discount"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r120",
      "r211",
      "r247"
     ],
     "calculation": {
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, including debt discount"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "CONVERTIBLE PROMISSORY NOTE"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r51",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r66",
      "r67",
      "r71",
      "r74",
      "r97",
      "r112",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r140",
      "r167",
      "r176",
      "r179",
      "r182",
      "r184",
      "r194",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r403",
      "r415",
      "r485",
      "r501"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes Payable, Other Payables"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r167",
      "r176",
      "r179",
      "r182",
      "r184"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liability",
        "totalLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails",
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: current portion of operating lease liability",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails",
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails",
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r432",
      "r436"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedTerseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r438",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r121",
      "r160",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r48"
     ],
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r58",
      "r452"
     ],
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Commissions costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Costs associated with offering",
        "terseLabel": "Payments associated with equity offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r27",
      "r452"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December\u00a031, 2021 and 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r36",
      "r37"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expense and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r196",
      "r197"
     ],
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Outside research and development services"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from the issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from the issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from equity offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of fixed assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from the Paycheck Protection Program loan"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r84",
      "r331"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r66",
      "r67",
      "r71",
      "r90",
      "r112",
      "r125",
      "r133",
      "r134",
      "r167",
      "r176",
      "r179",
      "r182",
      "r184",
      "r194",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r382",
      "r386",
      "r387",
      "r391",
      "r392",
      "r403",
      "r415",
      "r487"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r200"
     ],
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r202",
      "r452",
      "r488",
      "r498"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r202",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r22",
      "r481",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r22",
      "r481",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentMember": {
     "auth_ref": [
      "r22",
      "r481",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments.",
        "label": "Purchase Commitment [Member]",
        "terseLabel": "Purchase Commitment"
       }
      }
     },
     "localname": "PurchaseCommitmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r302",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r302",
      "r444",
      "r447",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r442",
      "r443",
      "r445",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedTerseLabel": "Repayment of principal on debt"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedTerseLabel": "Repayment of principal on the Paycheck Protection Program loan"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r341",
      "r463",
      "r520"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development and Clinical Trial Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r32",
      "r289",
      "r335",
      "r452",
      "r496",
      "r512",
      "r513"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r195",
      "r332",
      "r333",
      "r334",
      "r369",
      "r370",
      "r401",
      "r509",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r72",
      "r112",
      "r162",
      "r163",
      "r175",
      "r180",
      "r181",
      "r185",
      "r186",
      "r187",
      "r194",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r415",
      "r487"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r437",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock, proceeds received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails",
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r51",
      "r120",
      "r261",
      "r263",
      "r285",
      "r286",
      "r287",
      "r288",
      "r424",
      "r425",
      "r428",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r307",
      "r327",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r308",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Assumptions Used to Estimate Fair Value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r352",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-term Debt, Noncurrent",
        "terseLabel": "Long-term debt, net of current portion and including final payment fee"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "AGGREGATE INTRINSIC VALUE Ending value",
        "periodStartLabel": "AGGREGATE INTRINSIC VALUE Beginning value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r314",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "AGGREGATE INTRINSIC VALUE, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r306",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockbasedCompensationExpenseDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Award granted, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Cliff Vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r308",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Fair Value of Stock-Based Awards"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r322",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSFairValueofStockOptionGrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM, Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r109",
      "r112",
      "r137",
      "r138",
      "r139",
      "r141",
      "r143",
      "r149",
      "r150",
      "r151",
      "r194",
      "r213",
      "r218",
      "r219",
      "r220",
      "r224",
      "r225",
      "r269",
      "r270",
      "r274",
      "r278",
      "r284",
      "r415",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r57",
      "r69",
      "r70",
      "r71",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r148",
      "r195",
      "r284",
      "r289",
      "r332",
      "r333",
      "r334",
      "r369",
      "r370",
      "r401",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r509",
      "r510",
      "r511",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/CONVERTIBLEPROMISSORYNOTEDetails",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r148",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r56",
      "r246",
      "r284",
      "r285",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of shares in conversion of convertible securities (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r284",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of shares in IPO (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r28",
      "r284",
      "r289",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of shares upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r57",
      "r284",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of shares in conversion of convertible securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r284",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of shares in IPO, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r57",
      "r284",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of shares upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r33",
      "r34",
      "r112",
      "r190",
      "r194",
      "r415",
      "r452"
     ],
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r70",
      "r112",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r194",
      "r195",
      "r289",
      "r332",
      "r333",
      "r334",
      "r369",
      "r370",
      "r380",
      "r381",
      "r390",
      "r401",
      "r415",
      "r417",
      "r418",
      "r422",
      "r510",
      "r511",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r289",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r423",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r423",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r423",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r423",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r453",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIPODetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "OTHER FINANCIAL INFORMATION"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r14",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r54",
      "r112",
      "r194",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Ending balance, preferred stock",
        "periodStartLabel": "Beginning balance, preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance, preferred stock (in shares)",
        "periodStartLabel": "Beginning balance, preferred stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction [Domain]"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r342",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails",
      "http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrual for interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Recognized interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANSNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationMeasuredatFairValueUsingLevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYDEFICITDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r136",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r135",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares of common stock outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125514181&loc=d3e34841-113949"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r522": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r523": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r524": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r525": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r526": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r527": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r528": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r529": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r531": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001739614-22-000023-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001739614-22-000023-xbrl.zip
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M(O8EG$O%KOAT!Z*+(Z,7@:[<MOB#AT<HCC(H:G['<$\"M"Q9H0*4H;*L^FI
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M_\U=UQ_O3_F3WZ&5R;EYKT+'6-B%65=Y\BNBE5__%9W[GN_T_U!+ P04
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M    97AH:6)I=#,R,7$T,C R,2YH=&WM6&UOVS80_KY?<76P- 6L5[_%<AK
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M8I&D.3'I>?">: N^_]F$S'%Z*WW?Y,$C_<ZSNN6R]VW'?P%02P,$%     @
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MIFW7G[[\TQ=?LU[_M!7^6O)%[ZAE3E]TNIT '2A.7J0;0SG\67@?.M5/N-X
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MM_3RS<J[[;4_GU\A\$/2>ZT#_'CZ&@A>FM9ZQX>3?X?3FKS?(^_I#?)JK%W
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M!A.I,%:1GU<26X3P\-P3>"9302YZ(VP$I6@=TX$I*RD/W(&L&L3I(I5EG8C
M;T,GE*8%]%WQ[:)3 /96R2)/6(:93XMLG'2:!V8)-CIZ,(&<]&E#EH6:!%X
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MB"[M/!N<H Q1K@+"01$$SJZD7/"1^A3C"%;-)=,#I-&9AR\84['+Q($M,9W
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M!M3+E7(XE]A'1ABF0JJEEZO!5;&T__UO+- ?*07Z*A8^RQ(EOFV S!10;M?
MW;(V&VZU]%.UHR*M=*M-AUM-A^,O-G =+?,Y1Q3DAC.9V^AXS@,2(4H<8J0C
MTX'-E^G0W%II;*]7-L($YD,V!?MA'F3IVQ9%_YSALV$\/XMEMYT-X6[RO_WN
MG8_<'3J;W]&I%NY7.V%D;XI6R(!]00>\>$AK:ZV:DTEO&[[LUX,6]$40ZQ4"
M:*'.!K"@),HUXSX7S$FKM3$Z/*P%51,!?;&,6\^1S1W"&.PBIG/%1,R9-$8$
MZ3 -(4U_XIP"<<A-A+^'*51/[\S'],X"Q<?G;[9BLOF:!T>QK;!7]))Z[Z==
M<182R8;AZTTXO]'TAQMMZ,_9JU;C[3K?::^31G/C=.-@CVY\_H#!(#O;_+Q^
M/7P-]Q^>-,B'T]U5N._M1[1ST"IV#G;PQMGZ*;1[LKL*YYH;? ><PG?-E2OA
MZR]*"(9<3"ZA8SGSDH-#CUR.-4*!48!'A)9>KC?^M?YJZY]GV7KC]?)U]/NY
MV:>;/+V(<C"9J?7;VHEQ_8I[LV[,RG.NS4POZQT%ES)J?%9TLJ+?R]R^*>$+
M?A]9FQ.,KIYC[+KYS,0T:Q?>M\*,:/;@V)4J));@?U<U9ZIRB*.RF*^[/MST
MR7OICJ.R^S6ULZ#!K$?%.GP#ZQP)7GJE\X 1S9ER)C<2_B@7E!>(@"U>1<-:
MYMB4X4XC;ZH"5 M#)0Q-<[(^2BUTE4 LL&_RV%R^?I7+HT&!.\5RS@,XF)*A
MW'"*<JFC%P$A%I5=>JE(S@B7%-_BW-S4-S_!Q7.39S'A7'.%P%FWS+K]_5!F
M!Y=*TH+.GEVP>[+N%Y>52?45Y9[I%&?5\>_WRQ5X\J1?7]Y:WE[.1M7G[IXU
MF)/^7@7*K-%=OHW MUN*&"^ZJ7@;<YWKQCF<UGYPU;GB?=K1>/3/.^@ KM7F
M]]0FNVX<7L_C@N\B.\V4#U:%$0\:JQ_X3O,0-<X<A^^&MEX=I!ROW8.MN-%<
M@>_\>++1W#EMI'$[_B(45DAIFE-E4<XTM;DU@N8816*$LY@:NO02G&O"L\9R
MUNR693C-W@/Q>L!TQM^<@IT!'Y&:CV;)1WSC _"11<@9FB-%P9BSS.5:6Y6S
M4-44$S%Z,.:V!P78+@2AZ28)UG@^0SQ_#3\WRV;WN';UORN%_'M2N'/V!MX-
MTO89I(N\.6R\A3Y_?M.&\3EMK*Z#A.Z<0A_(QNKN;6B.F<&.B)B;@'1RJ52N
MB1-Y\,%3P]..A''IY3N3_9VF;V:'W94/LUF^+[M?P2&H@TCSS5D5OD=.1$HT
MD9K;G'D;<QTBR;7P,LH0@C-HZ>5KP#T@9:>XP5MSX-G58-WKO>^"9+5VBZ-A
M[+:6JN]*U?HWI6J#P#<>-%J[(%F-ICM)_=C]O'[2:'](TH0;![NM'>C[3O/5
M#;S>./[B"$-&49ZGG=YSICS)K?,ZMU0SQZA'3@%>:X*HG$"@ICVM\3!341/&
M.D8,FZ:ACDI0$L61:67A)+A!O_B:9J=BX4+O]QD'NV<Z1"#&69+CWY_<S-L3
M">O-'OR3<;Y2!E/#_419!QM%@OIJX1P81="W0J/=?_:1:W_JF,]ZL'FP@:$-
MO-%L'8 CW 8G^1B,J?W4E]W/N\7&V_73W?9'U "8_^=L[7BS>0CWKI&- Y?&
MX8NC+("YY// 5)KR("JW** \*(R-5BHH"5[R;XJKWV\F+SP<EU1[V[W?[W86
M.=/N"7%*<^4+P\A&YV2NK! YHQCE5GN58X$)%B1@2_G22S#&<T;(E,,IBY'2
MHB=3DA>95__[WXI@^4<OZX=6.$K<GG4J=G^6@7TQW$PL,P"6\-&@5&_)%KIS
M'>H\E"?1>IE@]5,)E'09D<FJD_S8-4K8U/,GV3(:?N546\5JF?')LC(?I[./
M/[# !9K=)S%5S8>)^?-%&&;6N<E1F."?AV'X]AD9N%4AN*)?0(O#E,)4>34[
M&I2]0<HM['<SN*.:(\;D-_M[\OG2<I@5UY_ LYEKMIO/6Z<=*)@=9S6+?JM*
M50W&[6>N97J]:40$]'7<&"GB'ZG?,G=#59K*PNF=MFVW]=O,0R>S&XG&*+VY
MXIEPXO93@<<,T.=XOX S%Q#U(QEF/UGE9W9C\^C+>D=:X!036XGM GN9.^0#
MVFU^VF^<[8,G]_&LL;IUN$/63ZOB/LV_P?M</P/O#CS)ZU[FT<'NZE:K\7F-
M;KY=/]YM;J#&VZV#G8/U5-P'@]=ZNG/0:.^F-EH*W<@,]H*2R W.I;1IG3P7
MN0E6YQ%3::01B(@P7#$)[%SM3OHL.S)E]M6T!B'[GZJ X=T+Y*>)F+4@W"D(
M(R3>KH"XEH()I.!:YG!0,@;B0ZXE):,P&L8QIUAB'BA#5I.T%NC5/P^;&U^S
M^J28OS;2LL/5;]=G^Y,.7OB)_L>3AIUKTN"8012Q''[@G!$@A554Y0Y;2;!@
MPB(&YA\X5 W3\^8_V=M6UYI6EHJ6A?XD6?77<W-9[7+5WOQDWOS>][SY.:#-
M CDTMP-XH]L)#^/-W8O=)PR7T_-2X(\];NL=GQ8GA,R>9FX_N,.LG0HY%D.&
MO;3ZM>AE)CL.K59^V.D>0S^#Z<&8>[C0&Z0)!-/+?(A%9[@X=FO0"AE#?,SZ
MER0&I&#YKN(L#YX$]!F^X-_I [9'_5^ONK^02O<>]<96#WFCN7;2.-@X::RZ
MDR](<Z\X,;GV!N4LK4%+>VWE2@M#" /3TH("W0F]&W.RHYJ,6=;H9N=%EB8J
ML+,83-_I]N',?P9%0G@ ]ICJ[Y15,:[>[8A/TYJN\Z.J[.,%_M_)^3"VX\-J
M$+.'ST3]U&T-.GU35@5FRMZO)0-G<)U^81Y877*1!Z%#SI20N5(DYCY&;RP2
M1J>ZHXWN76R_J*Q^O!^JI9-7^?U%]AO^/=L')$]<[C/3:IVS^F49L&%T S1Z
ME>VOL/LES!\[/TD$TN54I2SS<+6S5]UZ5 87JM@L)EE5#+*7_0;M@9N4]09N
M/^OM=U.AA7%1L/Z^Z5\7UF/3NRFIU<.C;_C]C\QT?/8;&7ZC!6<+KML#^()T
M?W4K/)1Z,6HGE>#K59VH.FEZ_4RCS)O3WO(/ER2;M[\/#B^C\I_#PH4IV-,W
M_<$OB#+LB^'"\F!<'FG0.7.@9XWR,L<Z$HUEP-2+N[3KN4IX&CKV=N"IY!%$
ML5WT^R"\H04B678[R;-HG59">]3MI2O=4=F5T0+J !:IS7I%/SQ+VMMT3I]E
M 7R2TZS:Y-*X*E%VU?3-L&[>-1"[>..E5US6Z9>MV*VP-V@-E_%NY\WLMT0:
M^0>A9/G<S"VJ@C!'54&8!P:W8=?/^WT.7J'W^^R@Z1'JL)Q3-1%UA#"_'*3L
MG7V1V' OL,NED3QGD>O<.AMS0ZT"RYU;SNXTV">%E$4 CLHM;0'FA<PX!\"1
M4,%7DI!\TLZM9\&H[^2W7NBU 7'@+>58:0$3MX\J7 %AA>; )$CXNI?ME=WC
M_O[X\C(8.Z'J6^4#5P5,J\3]E'%'X#/OZ&%U&?\QONV[-]S9O_%]"1!&]][1
MU?&=8R<=$YN3L<EVV4Y;OH4A'C>?CPNV+$>)A+<G]%V)S%R]2- RX=^X_LV'
MOW61L(=J6/#QYTZYY?D8C'N$TG]TB<,3FT.ZJ -;O@9PV.N6IPNI](;31+OM
MC\<;T-[NYQVR<;"'&ZL;)[NK>\>[T,>=@T\'C=5&L7'V,4T#79\F:N\V5TXV
MW[YI[1[LG&ZN?D0;9V\.-U=?M1JKKXK&YPVT0=;/&FD_(*R.+Z4.D(W5C_R+
M(-$8*F)N/7$YHTCD"KS /"A&)?&I_KY):X/+"@ OH+@:^'O,H]["O65BG+EB
MW^L1C9E6'IK% %RB^-!&BD.R/T$RLTDJ53X98&[<9NW]"G3]I<1W>V@:#T7W
MW#X>'HY,WZ=&\P>W.*HQ?37HI5I'O:>X]\BC&B1@B'RX5O_149PF&G)$TF)(
MSE2N:%4RR'J+M2'>Q.]N>[;P:2J+@"YKMSO3-:+\(**,Q_%M-8ROAZ-8(\L]
MD>7T!K(8*HUV1N4T4)0SQG%N@^>Y0)1&8:FHMB[YSJY(/Y/',H[SI(Q0/+O9
MA_B-8%U:[#IA D":EZAF(\!L3)D _6XVZ T#?2 7PRT/;]FRJ%M6[VJ=II<?
M%_!J>&W6@6_KIMC=UZ)7F:$=TW&%::6X8"HG7BU-Z9N.-Z7O9:GT4^%O3RL;
M6C7R-_/[;^3WWU[=-N/ZK5R#2?YFU7]/=[9I-,,]BJ2FB:44.C7]?DB%MQ(Q
M8;C37!/TS>Q5,\'GJZ=-KP?V4#HU'O@08ZBF)3JC@BWIR2+-5G2 O@E&RVXK
MZP+47R+[11!W (QTD3/"$+NT!'#;E-9 L_GF22N<5A/HOV&>?5S>3GN*2R+2
M>L'?TX=??.4H'=&V ,,O,5<LRO9P=ND(WFW23<"/50*7KWIL!K[HC_IU+^Z9
MA[\[P%X//B^U[F*YDD:M6ZY<\,Z;EME[BDKM7O/@Z LRQJM(9!Z\%6#D<I+B
M;RI'4EBG7-3,A3O-W;O(_&3GQ*NIK=Y^:+7&BBO[[98DRSOG;[XQ$9Q=_N^2
MG,QP-\2']V732#YA@_->$\KX"XP9-D&GZH;!YXQ@GFN/0LXCC+&B'*D89KR-
MYNU"=3&%O0#I>"N5<?#WH!.&$D?1<,/>9Y7TFKT]D/\$$.UJ8<IHS6+WNEEZ
M;HBXX2K'7EKEF %_5QEYU>1V3(ELT%+OYM-5+HDY OORI  9"*W3[']&TO>F
M2JZ %@>=8BA[@YY?NBJ,' G*N74:>\<,I8I$I6C 0C'&+$%?UBMA%!0M 58Y
M>$6K]]=2SF]*Y/O*0'G3ZIJK^]J^Z S:N>_V\]'CX$J#>PR/BE]+,*&-0_J%
M6A.\#$D<19JT8CXI39]CKIU#A++@_=)+*=@R'8OEF(PO,V#A%OQXEEG3&Z9/
M)5YPK6XOV8-'(+L3L]?HV=L64*4F_H?(94Z2!P0Z"TS+Y9O[K,Y2Y-X$6PY,
M>3H4NR1PP*7DV4W/X'P+^YNR4'U7[YHX8 _.- ?@5%PP)N (.Q.PCCJ@P+VM
MQ"']#U\6A_7&FUL2)JOAKI8L;U>OVAST*W\0:#69@*!?3$ VFQ]/OR@=#0?H
MR:6A-F=2Z-QH1_.HHE (<"I8$!"JGR'"GP&-;DK)D+")3:YR_,7PW\R%&;/Q
M71447_YIR^<O)U=(MRRNJLX4G;2%R NL'D%GW6Z9C?<B[V47VZ !EKPZS4 "
MP-/LN##W>O<1MFKO71Z=5Z?G8].$%[UJ 3_]6K*9K,J3+U%2$3W7N0H:E!?Q
M,0?1A#^(!TN)X5& ?1$ OHZ2+)6#,%RF&[M@BA\G'>7/N2^ES!Z9M!8A>4NA
M&W]/I>JRXC)3@OE3C@<^Q5^Z%<!?M#9\?IRL^P8@-<,H__>+['4H^R9MZM@9
MXFP"_O-\6SC_'A[,UM?7SY]=Z70&H "WSL-'YXTEQ^U*IZH=S%,_;BG$]QZL
ML-.L*@9?Q9/&:PV2QAB_8R.$*GP#KZZ4PWZWY4/9N[(2HPHR7@L!IH#6N4-X
ML87XC4U!)Y3><4V_"=!M+'NIBN]1=Q@<?5&&E#[]-8R2^S"J!//24^,*0Q>/
M&-OKM@;]NQ_YL1Y>_IL:J>0Q:&&]X5H&8Q@B@ '<"Z:5P4XJP>47N31^9K^\
MF-39"[DM@SD$4QNP^H5I'9O3WM+SJ[V#KHV&0A(8BFE^Q9V/5X,^+W5]KVY&
MF[YEI='XN/(NVUI[O[G5S#8;V9O-K8U*;JK+;T;\OQ-,F:U5\?75X$*J43GR
MF(:F&YZ0:>\<C4>O3*FH_IG*E&H9,3WU2H>*+F,Q_6;Y,E.3;4/^*%6PYVM[
MX4KLFRNOWJUEFV^RUYN-YEJCN?VS"3LSK1TP[\7AJZ%^O_)V[?OE%L0TRJD_
MNE$[5"'F<=\X'!'P.4=[5R8;(BQE^V4RH__[^XH4HZ67VVD';;!I&MU^90^9
MLEH8!;!_##_S=]WN83H^-XAZ?SXWU_7?1-6(\)5:1.C;Y8A^HEQ^E;OQ^-[,
MPA(>WT'(AQ/*[WGH-=6^0S4*&%JY/<L_)(2UG,V28O1'Y.RGB38L]%-KODD)
M(\ 5 H66X106?SA9JLGRPV099S?7$+<P)*LA;AX)@^@8XU9JD)LWPFP5O</L
MC7'];EDCW0+1C>E'Q+I94&6(&*^6[[>08KZ^Z6.G#+UNZVOP*8X18S7W,HQE
M3/LC:WF;FKP1BN322RUJXV+^:(.)'$$%J6V+>:/+^[)[E$8QU);% E&M!KJY
M) U%(Z"C-=#-&UW>A3W32AD[+E3E_&J\6R#BU7@WGZ091XU8C7?S1I<-:#3;
M-C'T3[/5HI=6#0S*VLI;)!)^#_6N)VSR^:@74B<%S"]7B7%60)T6L$@TT[*V
M?^:1-'ID__#:_IDWNHP6-Z8E&;>LW!CM,+KVGT'1/WT&=[2JQ1Z75FAD&ZF<
M2#E<B#'<9RA[/RC=ONF--WOIQE$#E]9MU*BZ."Q2H^I<DH:1$:J*QT#569!D
M*\"#7Z_MSUU#Q!SRH5:/"Q'7GL_3S2_TN('1<N)<SV(I[H(2D8_ 1#ZHPU-C
M_(^39>-F;;84J!I4ZUPKLVNE8UJGO6)8 ^*\\MKK;L</*_:E>P!+!ZWALN#-
MHS#L3FV%+1 ;Z,?,DJHE=%+2J''2AERID7/.Z/(A510M^M6"_ H$X41K?'PI
MV)^MV.Z@/Z[SD])(:V!<'"IC3&IDG$/:Z'&6AZJC?O-&EPLK\6(1<H60VX.C
MHU9U;,K3:E/)&@H7AZP8U\N&YI VA(\G0'0-A?-&E]=5Z:A4S:H"0# +S5X9
M1I#X.56<6AD6%S?I!'C3*Q>UQM,#%U!Z85'6F+DX],>/NORHELU):2/&TQNZ
M=JSGC2ZON]5>#T.3L<H5]G72W&*1$'-4P]X\TF8\$:-?U;;BO!%FL]K"8OVB
M?&J->(M#/,S9HR#>K/:VNUAJKE\_P%+SF7[6A6MUM9X>W-/)_AZ41<\759WS
MWG#KI_=E^)HJ#:]W>D?##:?J=>ES+:",J DDM,[DKS/Y?Q#XU7DF_WJMK!>'
M9ICSVCV90]I(/"YG@VKW9-X(LUJ4H:I^]2Q;.PEN4.4Y;,98N'&"_NOQA@W9
MV[1/9XI<U\'J!:)P#8MS2ALVAL6Z^.G<$>8""]/.F*'3JT,W"T;!&O;FE#;C
MY%=<ERR;.\*,%EN>9IO'';#_]HNCE/P_W@/L5>@$, Q3WL+P>F4?7JPU&"T:
MN'.]9PV?B\,)-7S.)VW4.$,6UX70YHXP8Z"L,#!-( " ]JZ@8K.$'@ZW5P6/
M>Y@\-G3 L_6.#V!I^E#[UPM%]!HIYY0VYW7WZQ)J<T>8]V71<<416)(591;Q
M$RY2?!?V$[(W(8S6<(3R:^'J=+Q%HMYW%4\]]5U/??\@6YT7L?M4%[%;()IA
M7E?QG4O:C!=Q85XO2)@SNJR=[!>V6%#C#?K?6]B>7UL#=[Z<.-MV^\$/6K49
MNDC4K'7/?-)&CQ?#X4<I]E<3YD<(\Z9;IGRX_-_9]J#=-N5IC7B+0SPLOK,.
M[I=SO&OFF8QY^-++;1@[TZ^7OBX6U;XC\L_[QK;"^/RE,1_U0Q+HZ%&W5]56
M?%%6TX-?PQ_'A>_OCX?ETE-#ZKU %X\8V^NV!OV['P$=LE=T\M&3>IF?US%]
M^:<MGU_O^:6_J9'"_[4TR<ZK2^.']LL+QMP+N2V#.<Q-[(?RA6D=F]/>TO.K
MW8.^71Z+:7[&G8]C=550'BD6**\S(4E?N?U^[?7ZRKNLL=E<R[;6WJYLK:XW
MWF9O-K<^P\_\W>;FO]/Q=G.EN;:QUFAN7_W4B<;H$06K^J;F?M'+5CJ= 7AQ
M6^&H6_93L9-SV^99UBVS_BWWQ&R] \YW>?(,?KCEZK[S,]4SP[Q+TSG-?C.M
M7C<#80UE&7S6[V:FEZ6JI@3]<1R>5;_P'^,S@][YF>1DCLYV!^7H[.^ K9TT
M1]]+Y>N/3>GS5K=[F)8&]BZJ6E7K 8O.U[17;586O</A),F@XX83_*D:_7*V
M=N+"43]UIYO6^!X7O0 />4#A---O3ZO/2*\##GPV_((TMU^5C;EE5.#+OO%9
MW_RJS)0A/3]Z(4!%X8>=&/2 :+VJA.NE05W.5EJMRQ]<?4#Z[,Z5LS&#;O:[
M95(L630.SHV&#]J^_2M23^X>V64@<];KMJ&;J=;_L^RT.X"?'0 @N%S$TV]1
M!4;TN%OZ7M8;N/U+7) *-J:YQ/Z-8;.A582O-TZG;R@Z@UO.#UK^^LG0ZQ?M
M6]H.)VF5Z/6SP!NA<Z.-MCF]?NJH93HWSG5[O0+TR,WS_30ZIG7C DA$<;,3
M1V7WX):^^= #%+Q^MA?"X8US^[>-1!]P)]QH];AHW>C7\97'1P+="7O#*II#
M7@1A&5(3+@_9SR7F+),BS0"F06, BNT!KS:KF[_!&$7'M08^/ -V'S)@I]O/
M6D6[Z%> \>SRO2:5[7R1W0FN5ZJ#4S%6(./RX$FES ALJ^$4?XQ[_OA=^./*
MV& V5#R)M$4'K)3*N'J6@;3 /<\R8,*],D%/0JSRHI(TH%8Z#*9,0@S7/$AH
MJWM4!0"KATR[EZ3[. !&)7"%!X#1'72GPJ%>?^"+T;3U^<E^">+1^Z.FZ]3H
MFH;=V**5LH&3TO5?T\*O)+FE.0H#@-P$W+Y2-$D$DYPED@ X@X[KQ4&K=5J)
M="L >-:4>EA*);U3@I3T*RE,<C:4R=:SX:6BG7 6;DBPV$EU.H%N)HMEMUT)
MV#7R/!MA:@+:JTWW0'C'Q10\6#R@QBN;H.RVAM(\.@<B?@1WAYK0TX7:(;PF
M8K:*0Z#F?K?K$[F!*@/P*KM V0A"V]D; J0Y DC]6@O<U.D R-8.99J_*L[.
M92Y)TNT "0(51\0(OJ;%=&EQ! Y*97.XM$#9[(61S5&T[:#L#:<6:^K,@1$!
MPP[B$H:4"&Y_:.%GX OU4WFL=,M>Z(1JL7F%7B.C(S6=9"SIIUL)^$=-LJG:
M\^UQ0>_+R'8>3&AW?1AJ^[3U7S_L 2V2/UO%5*[>FFZJ2?:X4G;% H<7#E+D
M)I7!NAL *\)=LP&'#M:YFLL&O7 5)VL"/A !*WL::)8=IU+2_?VB]/F1*>%B
M+Y7:+\8K+R_1MCP7M>)*4T>AK)#5^/"? 5"Z=5JKM^EB9<]UCZJ8%DA%?U@W
M+CL.51AJ&,KJ9J&7IH>*WOZ(:D450JUD+CE7K18\ED*HT +0"PA73<_UAN9,
M9>W?*;@U-1],"JO)HBJP<5G-@1B.5D:?2UQV'I_-;+5">ACHJJ+4E^^O:35=
M6HTC\Y=#$BDJWZEF%IPY*OI DA* KR@O;5?2"<$/%=XELS(.LQ$[>S61IDND
M>)[F.5)%R:"O38?I"D(U%74C/#>RY),A,9[^V_RTOIIC#; $ ]H&/$O6_?]C
M[VV;V\:QM.&_PNK9F4IV:$7OMI*:KG)BI]O3B>,G=D_OS)<M2H(L3BA20XIV
MM!_NW_Z<%P $*5*6;=D6%>Q6)FE;(H&#@X/SANLR_'6[,-L]3<#<\-D-+IS#
M+IPZ$3A^XFMW>/+?^&/XJ:3K+'J#6*UT(LW!F0N.UWCUBVD<I=?34L\>]4&]
M12='LF'F?4OT)'F(]#UI4\=.[-TZ:()ETA@KL<-(5V>XK#?T,<KW1UET:%9S
M<J6@XCC!20I0S-7ZJV82A=<1ZOP\@@G1(](0'HU5?.=7^*7S&_R/U>ZG\I6P
M.D#] $*K:Z;<4KN^B24JT400":U6PTC7_ET']$_E[NAYQ@']'Z1AG/CPV-PS
MJ"'"+NNVEM6HQ>))@FUJ>)!$7"-")+2%CV"1VK*!*%/PCI>-&JY!M:>W2QU6
M=_0^8)R9I$/L]Z RK1.FLR%872P)8>.2F^]:XI,C2=+97&*09(6^Q32"=XU%
M,HK]H6KP@:?+H!96/A"Z^0@93YV/'D&'JD8/$23B%DR^*.\-:CB?HUA@3.MB
MA,S'&7W6<^"'2ZU@BGH5CC1_C%5DI-LB[SZ\\>,HQ)F[TI>_E?U9(([X6G!!
M$\(";H>"OQO.&1P"";6$J/X:?1#-,N@J.N&HF\;Q@D#)+L2TF,<!?9)@0C/O
M5.%')RR$HBNEVEY V>7S;Z<^G7-+^15J=8,Y#\%%5GE6^3 7A@;S]E)8$(^3
M ZJ% AXT]B<3$>N#%R3$TZ;URS5HT<NJE0>FA>^9>=\$=6:9AVTB-E0@G&3Q
M'82D+S.(?CQ*9_!2:GT;,PMY9?L8#@>7*AJ-I/]4F#[U:)5(0'I$X*R(O#RR
M[K QRAM3VWZFW'>TJJD#*-="1-V!NE7/D4UF9H->XH,I\&+S2[&88)J'502_
M,9%&= XN#[IT42A=JT" 7[=0FUJU/Q6V_-!#&:9S^):?48LXWHT'+Y9IIY3:
M:*3KA XA_[LH<]Y)H)SPK6PZG+XPGXW_@B?""+T$SEY\"8S"9[>./IV-T5W]
M.J[L4.BV+,I]9>TAZCPQILE-:*0-0Y2+Q\Z";+#D58#Q3KT;4OIQ.L+GPF85
MWZ>P<<B*^"$ZJDO9GA)AY]&-#S8CFKBT=W7F!C5(RTZO@3'^BG7P0[1WX0*^
MK[<)3<8/;T3"1V6,W8XI/D3P='!M8+SPG1B5E59Q47AZH_IT>LF>\A=HIRX_
M&%O5#>VUZ$U_2:?BGU%J[JY,"=?Y&8DZ']E:P5&54E&)33UV%(.]Q6#3L"&T
M1_D0S&4HR!1N8H1I\V0&A_P&.(]QU->I%\,>%<9;Y(CD4>$Z 7JS-%9$7+N!
M6,4ULU!H#RH/JOL,$EM@T49YHRE.FXP;'6 -YP^!6QWMPC=L2W6B(6P=-HAH
M!>9DEN<I_'1$A]C:XYIREN%2"L0AE;[#N,L$ E?7BP8,?H<.E&'EW.)QBTY,
MQ X8-ZX7\TTN_)=J@]=I@>'2";S;-29L)_<"'S$E+>TRQS".0#\R#P!4<4)G
M)A?IA"/!4Y63=/J=Q89-]S.? E9]N>'R](.;?9$T!!5/NN$>NPER*>ZIU7R6
M5NJU/(8-SXE]*?11R6NZE7/C1:[%&I9<0Y$MX;!4L3<6,%1T9.G?H3<3^>0;
M_9;%3O<HJ*-(5N(P=T%9K"B^]D+9Z@76[C(*R,\D#QZ.^M 7)/OL=:PVV1O-
M&RP55R?F<P%.(ZI%E+)%^\N?6H==?>FC>]1^YR3+V3#"9-N0/A-1KZ6^6J*Z
MW_D>@LBY3*Z*". ,=+4.D_'"KV" @]Z@O$>"[0.80)/Q"^DH#A$L%3E)L,%=
M;N:F8J54;6F)C<]%B!1<?(N#-3+U17XAS*-2>-79!>L+P3C;6[G<U[&7^QY\
MN8\QLTK4=$/9]W_:$0-;/CV&D6@X[V5NX^$3'=P]T2X,2?YD$<W?=EYLUE]N
M\(" 9]7@"/Q#=ISH$LH!'/C@>PS]R&BT',D[E>1Y>,[<GPM\%)YR801>A:[5
M5/;)R@0QYAX2U9E"C2]PM A,T@GN6$'O(5[X"2?R\#B-?;' >P?XM0"=J1F'
MRE0Q6M+QD8R/AZ[N!@7G63E(UQ&<DNCPC,=XI0A?D(8SL7!F&)' [ZBF3]$!
M>D?4 HPC&PLQ+WA7Z"73/38YUZ6,UF'^?#NM;#9:A.C;H3\,%G%1>1>&I;M8
MQ#X<T=+7F ET!OUDIATWBOFERY&D("U?^MII3,X8M=E!1*%2;MF)2FG>F%Q+
M>!8\%PYJRH^ZSHVG;G[R).5@IJ I6:ZCX7Q)6=A9YRT\([I-,&6$B= T3E)1
M]3!=I(/QS7"%.>7+;I):3QJSUB;.5ADSHJ3-Q /W>=QP?H718:=B-$X#+V:G
M D>74.IU*&2.%)Y [\?J(;X6A@<^C_*V9^ <^W.0#I)W^LA2@(ZXRTLEJ^%E
MB\67(ME1PE=Y<_9:)J  4W29P8'&BVCX*2^07>:A+DN1"RZSMW$VT&0)3L^U
MG^#+)FDXDEYC#0S)%_,RD#80X*L*BL IMC,WO=S>V'":VS(D2*P/TBKP'E,N
M>=45,AEGHRKR(Q;B.@*[D;RM875I1RM\9^?OO_[/0:O9<O#B+VUWW9!(MW01
MFX2B3M9:W G'P7SJ';1H<R_BY1P,,-GKX^,KCBD@ I%U#(PB*9D 'YCC7:7_
M Y7!*"E !9E@A@"-VS@B(XYJ<4VV-#::Z$S]4"$NIA?X?C!O53!<R<P[ ,ON
M8\*%1H(7W,;P+UOFW[JV#&BIU'_U<Q<YR/*2,59K#QL>EYSK71Q.FR8; ]#$
M4 _2(#YB#M"+CV'=(<H@U83S'4]:E930B44RUOCH693(LQ(\#+HW<AW!.;O0
M"FP[!)Y$(WJR4RG)7!O#L\F?%Q[KR($ZFJ6:Z!2$6E7^2J)N@</BP_'L+:8'
MF#,%_6O1'K\X.?@$_V*%@8]T#UKOW\MEGU5G"C8-X G))TL4Q&!B#D#@@3=/
MQ%OUCW=C/P$3M'SKAR0V^M*[_"OP!46D/'P?_UH&R=W^4:/99'@P!N:2;Y8Q
M=*.90_K*_[+5;ASVUOQ^[9?7__*)GML<J-G69<2M7NU&W-Y\Q!5X=9WN"F!=
MNU6)+7>G'^O/KITD'OWM)S\<?C]H-]LPQD[K?Z];C7_/KW^"V&-1]:O"N/J]
M^?>'[+)^NSO_CDFKNZ'Z#C> ZBO!8&/S48G"]B))&^7I:9.X563!>@EA8(4
M?IL5 C@N.2&46X'.T3:M ./COL2<(1@Z^(@9""P^.I1CEW'["VO"RXGD2BQB
M3T8K)U][+!09,_RP0OE5?%<R^?(_W:85"M5T,,[XSM'%PM":7/JO1$:["PBZ
M,P7+SIXT;SUOK B3 L^>)E81*_ZYRNEOMQO=WF'EKYN-5N7O7N*Q\,M6;_N/
M;1QV^_:I]JE/\M3!1D^MB#I;9?YF'-W*V%L?G]+&<$9NOG (Z=7YTWB(__].
M_A:KYJN_?"B >.GYT!T<3AYR/O3I&%I[0)"!N^ ,X#K?HUHZ>S#_*Z,$<@Q'
MX(\K",KRODI>O_E(.>-*0;2[Q=G'_)BM[9*'Q+1/+9[+J^-?3ITO'YV3TW^<
M?OIR@<#A&\2W)?9F(QJ(713!17:9N%(YZCNY*6)I5F?P:CZQ]@83NV,WUW+>
MG4WV:'NM3]#9T">XI[6?^>-Q(%Y*.CIE_=\;'7@/9D=YV5E^B>=3+WSS521S
M/R;(UGV>[3EX,7$TG_J!<QIXR0+UG[@>\"(YA=Z4I>04Y<4=V<G-3_EU!$AW
M[[1!]AIO].TZCM)P?"!%=M3TFIU>^0O,9[1ZSS/659FH#NDJU^=IQE%AG5;D
M)\;X_^^>+Y39#9LV^._[&K6[1+<'POD2CJ@)UTJF*)F3KSTRCF:]XOB.C+QI
M">Z0T*."HX?9!],>/MBHKC/,F\UP>\;V10;PP_B _?^^M\&LU3P?:/KJ-<?_
MZ3;)BAD%QOL8,>OB/:],MNK"U4I3=7?(_:U.I7AJ)8!M>V*UFCR5^IWOLI5X
MQ>_Z8%3\G\$'VRV[MH]N5E5WBJK4$T/LVCZ6Y_KDDP[X 0^W MR& "N[@_)7
M+O0-]Z>\CG*T4<?._Z[\WV97:G9I#O_]ES^U^LUWJ__[887+J<A+* 'YHW21
M( :NQ%3[/20HL\N%IZ[Y?O!";^RY.43&D*XZX4.O8\%@@W2/]</4%XGO?/3B
MF3>B4J_O7#;FC6/FP^5?;XBKN5-BKI3S50D,\M2?:W&$" )2>F/==:YB&!%6
M=#SGUR@8TT7<3XMQPWF%EXE$'"R=7[WP^O^F4>K\/4T6SGL_,BX2)G"(-_@;
MKTF\V?-<=>4Z0)PXO%DX8H1(4P'R7"A*3>#C.&QXA,88=IW/WLA+\0MO\#6>
M?^N%M5S%)UG&TV#N)R,"R\$5FD\S[2<$Z;-P1,MC?.XYUN<A-[/+^@8W1\)H
M]WZZ\VV[@X21QLXGX8WE0E\);U:'N^Q_2'1(Q!R:T65$SUG@V$E3"1R"=&Q!
MEQ)S .2$7\%J"DJ$J*6*B\4X&@AP7-Z#-VT- RQ@8VJ$ *[F57B'Y$!H8JC?
M<QPT04*H5RS=,@0*ET$()&0%P4R%2>#)F$1AJ,.GIF+F(QZS:P"XJU%+FDZ&
M:OKP^8-!RFIL);=\+S6<SP*!A36'+PERF(%]L+ (0DQC,>1 LPRDX5]$B+5Y
M'#'SO__B!PB^=LD[/E$__@Q#^"9-CS>;OV,C?A[=>(@MXAS_XCH7$U"(6'Y>
M(;5=>=_$V',N<M9%,\I_8@A27J5AY,5C7H!8,)"OSU?-8Q]!*XA)%;3;'Z<(
M62X1*&"EPCS)F:E((\(U]9-I1CJ"\!'X2[P@+W'\00[?PN@6U/):8Z2/%#_[
M@\W*4<W,RB53ZRSK8$]PO!+)#Y6$D)AYUYI6P1&3"4)FWP@#3@=!#C(0Q[F(
MY@HY,/ GXF Q)12$D& O5+9! ^2+FRBXD57S^#M3$GG&%MT$ZT>C_/D>P^0B
M4W."L _4PPXJC0"Z#@+132".CO#>]B0:292? C3'&O[T_&JU\ZK6?<JEHR>^
M1<X??[2!\GV5X.*:8Y+ F!F3@(D,2HRCVJ=DK119>2UP721 %"TIFK50HZNS
M !28TV0=2ZKP1E-6*"1SR 2$5-*(GHGQD02.9%R'=K/=YKW!QQ!ID1^#>S[U
M@@E*$S[1:3A7H-#I-4L8WO][X[*AH2 ,XG=I*A1\>R1SEI7C5?#0%")0B!YX
MPRC6YQ%[ASD,($5SXA&'(OT$/D[<]-$\#>17R^@2&4K7&_LY+&D)JY(+%7.@
M^\HR'(3>7_[4[@S>(085OU("Y\ 8X"!'!P+Q+6C9]*!$""=ZD 65)EJ6I%+%
MM\PB1!"-AA@8@:L0%!:/<&HST%X? 9KB6102/,>J_!%#E "C)%X4RBI@,']&
MW<KV"T+PDX^S\2;989-Q/)\'2PU/98!G::X;[0V6 X85C' N/B5"0-Z<BD/=
M0Z!?Z7*@QS-"?"Q'S"!J0MQU!.>1.Z N)HAV8X8AAV.XER0+@"$2'XRPT7C[
MSH1@!%*--:+PT=C-9L3Y[P4,.'8%%?*:B7IEV$MM;6B0U,.G5BJA#804N+19
M\3N2'64A8O302\\2QDTSIL/@UDI9Z'X?61O<8HQ\QP=3;D:PL%,#JHU8,0C+
M3X&V$<B28E5>IX$D7252/A7'Z,SXY-H&RU4Z*6,V%J)UK>YW:W[C<8>M\F<%
M7T8!%(2>1'4\T9B."+LMOHM1JC.[2J=':VB+=L=L(@PI[7OLGG5:;6<))WBB
M?9L<V_,P]0-,AIF EDHDM+UATB F#VV'$;$BT<O!PB.\>3QNI-,RQ*J;#OC1
M43@8(]Y:Z& [;Y1$\^D2>3$TVA-;O1RE6\X9P)2!&36%*40P49I(*$G.IV3<
M< 8XX AAOG1@%2Q=!5:.$&.W2%)$["I%G#!T>1'\TH0Y9\NGG/>\*V<:M#UP
M6#Y[W[-X)@/8TW1_F=>LS[SA4I*OX6+(L@<Z(9A^@K]9SK0$3)"+'^. -.-J
MJZ#+'8NYD""LK%^E;KNK\,K5;KT6N%*D:C78K3KG:"3XQIGK3'"+CUN4N]/>
M<MD(5QWQX:O"HTS024[29:Z6]$U4CD-S#*3$(6".H6"23(.+3H2DR8IN0R23
MAZ$M&;E8LLJ[DHD((JJ(("HE 9W!QGRWIJUX5O*W;-]0DS>(6%2)(+=>MU$<
MC&\Q0,RFG%]$S+FHR51(ON%\1.J1[Q[ZHEF4>DU\)F-5&"0F(P@3$S3BLH2(
M3'Q#R3%D_!:L ;(>DVTU%BB_*AGRYX9E3!.*E8F:)!XH?DG>3./@M\"5)>G/
ML[(-UXI@=&J@NA3*]I?RX7FU=E$[,J5857(8AV[:<@UH2A.H<H!.M."ZT9I"
MD*X"_2%AC&\1K!+9XI3+G2V[N;<$)?>S5?V#U,X HR11J+  E?G^FEP,ZJ4V
MJF3*1O9C'XZRR^+!LZD$[[2X=P)^P^_"*#P880Z%0W(B+S-MYPB,"H*;X_Y4
M(7D]#JL5JJ9A'&%N\[Y2PBV:S@,%TLU<;G'$W@$X#X+);#2QBDXTNW2N!)+>
MC51=YJUXD^MBDK'4'."JG+7A)AH \9[#^U7AI.=0A7$55ZVPM$[C+,63TP/B
MN5-IA:%/L/(XYG9")^$2LPE<N3*:$H9!*H98+]>_Y/X#]26&RL4R(0B7BGP\
MT&6!+9-]?0*W#W).LN'(ZE0%JJM.5YB:JDYU.G'5=C).62F!NTR9IJ0VS%HT
MQR5-0P(])Z?@7ML4CS3:6QH4'UZ"IU1,I'ER^VVR\3;PL;(JB28;>&C!K7-8
MLX(;Z?6%2KA=9:*H@;TZ-OC%01O(-"B<9R]PG7\>)%-OSM$=6BOB404CD,[)
M,P.-\V-.#8!FHOZ#UD^%=\->*K.?CJ;@7B6<Q\.,)!(NS016(EQPZ6%3@^;.
MP*N L%I6\+AD$BUX,Y*5Y(<TG%,LF'CQ3'E-FAY!LK2B"M,/K[&>['-T%,/N
M@$W\BEQ@DS;*8V?DQH,=232V$,ASR1[VQ<>;UZZ,AVGG)(LL/>BMS%(_@WDX
MZ G_^)4^\(]/+H;P\RS4GHH WW\M*#.KLH!:B&RG\:4+C[#=9SSY*QCKQY'S
MZJ,>YBA>PF<"].'@W:_I$#!\2AKD <FN^#BFH1JS +!V=(!UTQ6QXA>1[BS(
MPL>IE)J!+Q])K@FF\,A!W?NS60H!%QKBI'2FM.(H/4Q;P.S $HLYM0U,,%NB
M0MLDC2<><Y_SL^1(Y?,3D(.8U26@S?D(6M8?;]12:]8QJI^"A#$-1:H\#*+1
M-SXY:;/JXU-3=L@6^UPB>LPGBV9/3JIX633A(+G522K9V^"HP%X.VNZ*\V6:
M.\TR7==SX&,-3B=T*3*C M-,J#Z))S%$(?P&8K$U(F<&-"=[4JPW(#F<0@O4
MYHM.TZP.LEI2H@DQVPMJ$U8)9YQ*D%Z/U%<E%0F\S^J9N4S2LN0X46JA=<S_
MHHNQ3@)J!08^\=E9DUPQ61F'+:>T%68A0U.R,,VXAS1$1.N'F?5<Q0A<E_^
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M[1*ANF7+LI>=9E*[YV.T^,JLLD9C[3@=4B.&-)TS]2[:+JW!T6$#NXF2F7<
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MKPDF3F#X-QBE,LT#9?(#_4/7)%,5\(-4ORA31VP>]OF@D'<:[FZK?WSKZDL
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MB4>/08 9RS\*$87126:,[ M>(T'#:P'B",$OA&D0TC1#7_.Z(@T9*2:J?!V
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MZP,H%,(",; . NY4L8^$!J<2O2_+N:&F=5M,V4# /7DDJ1!YSQAHG0# F;?
M(''#A2U"6A6H3G!28KP>F]Y52HZ,4,B1AHOP9_4=Q&#;#+S^U5<LMCI48AWT
M_OPZPWZ"%Z4!<TDABX-B6"#4?!&B04&<^C3.8.IIVQI3PR7/TZM$L88B8DPC
MQOLKHMH9O QU@-NB*REWD+4-!8+_9U#Y!E[\A*Y#_B?%>X^Q1(QO:7(OD\_
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MR&<1)B%0O3F;#<_"$JZ3@)LFGZ:.#WKL%!XKZVO,(U\/(I[[.XG5RT.[&*Q
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M60V,^!<L,J ;)7-*1UGK6L'C7^BP)E%AS:KSS\^ZNCQ>\?3+'7WIR&*OBI>
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MEK.J;_AAX,_0T_"3P,B7G2QH=2-K1-II6,H#[EN.&DD?J5\=%LL][^ QQLV
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M9&PDP4 BFC^"8.672VZRG@9N;*MUF;(<BASUC@"F6>1CR'=UUB++;:'[-:7
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M'O:J,I,MA0PSC;':(%X">-2!1X)7>%OLP<2.G5H(/?T]6(PK! >/SUZ_AVI
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MI#M :M5;DQ/&^2(/F!NQD]H,G<0,.+8[D5E-?/._$M#YNP: FEG?#ZW0Z+'
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MEZ'*H:8I3)_*$BH3ZYX;D;%4L'C%!=/$A5_'3_I@&9MTXW"/C^+XBWXCG3^
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MV2Q=H4 X.-VTYD%<9-:34J=,^>MANS6#S"\GTI42L]X\K=!,$'4E1.K1F2[
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M_P1I5F:D<-[5EU$@[H'QE+:E<<=0AE$4P<^@RWE/;+F:PMB-"2W*]J;HE#3
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MS#B?, C[GUXU8Q<=<Y!V29FGQR#+3P%4L^-L%W?&SGV<&/_VJX'[2^@9Z/E
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M%YO#)&+2CL\$0B O41D8 X4?0?^;G@/&$> DHR8='1SAMQD??$%\-9B=59)
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M=G30N8D <YZ* ]96NBH[77@X4ZMB5P!E+PW,"8,6Q7N_'6RR,4A!./Z6 6I
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MAES:7KK\!CXJBX-K"]B>.5W!*D/"<?2G\_@_V/A_#^YO98B8(-:V,H%E;7P
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M'1Z@B!V\!S2K]=MA,O)6GY622409%;XJ%/GI@D3& 9V]C3TG2/0XZ4S(6 I
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M/,X#JA)_G@I+']EP"2/=)2O080V^C;#SE@]NCN]42 A]7R%\J^$+2S2LL%&
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MJ_.:>K@U5>5]S>S_P]!;")&CWV]LET>R8B*9X-VJ!<7U);7$TIV0?#%=(,I
M)6;$]%N9GII]N#43<[O[L327:3\1@U:;AY][Y./.Z^/AUD<Z(<A#<O4&9JB'
ML#'_VM< 31![4^Z,\-"U^IQGZ$.<"H(7C.>!UBK'5OWJ('3M90Y^\#!;3-8Y
MMO26"]W"_#JJ\/,L/MPLNFV56=L0_9O+G[K[N+](:RFE3U+N-$E)O9'KIBJ;
M\_P\W/RDN@F>MYDHA*GL<^CVQ;93)EQW'$'8ASA@BA54V-ZI8/GU>:;>->QD
MM6-L'I&ARDWXF'XB1:AR79(Y5(GYDR@B?U,(!IQ[K4P#9HY<,^^Z9EFB=HH3
M^*H$1G295U,%_\SQ<"KSB)3D0,\=<3#[<BNZ'?FVZ3DG$U5 N,$[0F($3I<Y
M:,PBWF"B3"8L*7@6T[ /YY7TES%5X'<_73*-"JHM=[2;$8Y'."/N2?-21L6L
M2(F>D)'&[+GB!>E)5-/LX'A07-YKBFQ#$NJ#')>3/3O6K6:#+? ;Q03Q@N>D
MJ-51UWV+T1*VBH\!QA(Q<;>>:\LP1T=(MYP W&CT[X%3"+^B(LIUGQ-2L2BX
M7#=![&5KWCCTFUI=-&R#HMUB%>3@9+E8?!_1658[#9>VZQ',C$\3[C=!OW$O
MT) PLQD#=;&PPK5)5Z<8<9@HGB2\#8*S.]<;+VSQ(X>$# K2DZN>A#6]%SKS
M#T_^_.3BSP;YI-V<=QN/Q4QV(0,S>0O^)DC,7Q-T&>ST T&,]HZU;<1%U!:#
M#N',<8@DAYYK1^8B<_Y&!]^1ZND.GF#A:CAG-4*-I]B%\#HY-V<P28^=44=[
MCP>HD%BA&L@S'H5TK=T.5&2 7M0CD#BC<A+;T"$:K*7.&F5HL_&JH'_0.-]
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M++?2RZPA(=TU+(.B96>,:[A<).92,''KKO+#HWWS:$7"*RX:8:L).98A)^_
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M!Z T^)%NX1M-Z!(H5L=*T4#($/W2&Q"OZQH\8FUXJQ=QHTO?>KH(_38Z"4O
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M&JB<]3;!!(X*0]B'TCB#EH'P6L)^"$+ VB2PR=G59=J1C" =Z,HV93V%F?!
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ME[O><@:-\P'A?</(G'J>A5$=A%J.<SLLS(JZR$&LKT^5=/V'PSBO>/T'3[$
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M0WD@C&4ISCSS^+LC:M+:CS&5\'YYW9&O87S\%XL?I?P@DJ_6P>Y&)#V=W;G
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M7&*RSX7]HX7]JY,K['\\QI\7[:0A)/LF74&V(TO?CI1&PDA+J8Q*ULID_J#
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M'0'8L 16UYP( S:ILC1"HH97HQ2?');C=1._>%I7@.IS3T+6,#MIMKI0N,]
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M\M)&-9H9^/'H:-SPOQ,T. %S$PJX& 37J%@NREO*"08+5RW5M_0'\P1$&K=
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M/&_1!"$8ECVSAU):=,UQPU$1KY3;==322/"")(*'E+B2F00&X!^"VRUI.VY
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M@'+#,V3T:.O_1;;"=8]N]2>V_NTZ^HTGO.IGSXW!BQC[PB6NOO[R2[0OEUN
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M&=\?D_6#5 1$T!2TR-@1M(4Y?6.R3XR=-Z!+TEP!Y(HL*8?((K8(\Q8YG]6
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MISN% LCSKA;<"M<3:6==[]=TJACG-AVO)0IZ4IR4445(/?WVLQ>3?V,.3R9
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M4=1O)XQ."9V$)/SM@BN6N1+IG-ENWS6SA#(GZMB.TAQ[G*Q"EI5F6^Z, M/
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MFZ[P>JTR$/L/;3PH[V%N5;9U$$S2RGD5-SZ!%6UXOR7\#!56FM,YI]QD.E1
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M1O!59[<@"2$.1O=KY0.Z-F%V>O;[JEC5!1^'82*-N')C&16\%$3Q&:@ZMT1
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M3@BBG'L@$?"4EMA!S+(4U"A6&7U5_(8\$+24,I(O<K-,&?+(0"S39EB%;0P
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MTQV'30E[B;J"X$M243;3" X:H4S-*0NY]SE?8\/7SNGB=(KY_7N8]">V?\5
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MJ)^EA!] ;\?,/,J= VY3-3X58+<]!P!X106'47<3VA:O%\UBMM+)OD@;<_G
MP$97C(>RF/A"M\>47V0;6K4O:V^Y(MW.9U:>,EH]NM:HMA1\(#B73^-!V "L
M2<DDHURICN1X%_R5^;+!%W0\:;0C[,C8.SBL6:1>1(.3*>OLY(VI"X':>"NT
MC=:=FZAUQ(_>!!5QJC'S4"F6[8.((-VR$ML?VU29[USA,.X!7KZI7"R:W-4Z
MSZ4K+;H/3HQXE(\@!JW%Z]T\NM5YV(BDGR%NJ%HDF1VR504MF\4L6X.Y$Q?9
M+<P[J)BI_F9(KHY[02V',YZ:X[EHMHMF)&/1$VJ[H2<5 HFU,E>!-T$1$>^L
M-TZUNGX&L< =<.QK>,;$59O->M%,O+-1,5-IO5G7\?#=_!<\0'Y<L 16 *6[
MJ])..#5?L[ZKX7-=%D-_CN\]=W9E'PR.Q19W_)=LNS&$D<3 KJ03IJUKGLVY
M;ATTO//2N5XT%+1&<OW#U5ES $E,>0Z>3WE@R'Z,HSH8X$<;2HHS#%S)RTE"
M7> +1H1)1WV?A7<U08;-[2:#QS^2/-@1@SN\\B8$G;#;],)@BL.+X_1&#RLF
M>".0AQXB3L#"O8Q>N;\V+EJHXHBPX*QH:0^)*J)&=/T7!N/ (KQ$&3R<Z9%/
MO2-](7V)W_?A12N_B<HK0 A#O'><&*05SJOV21! C-\='Q9Z&T+<%F^HE$ 7
M$JP.08WJA1"X<+E?H^+K>:/&78>1?Z>A8XXLCE7LG7PXW/K'Y7>;QWPM7U_7
MT77=]OSKNHVX>'M2L];7LL\P%3D[/!H6W_I!3OYS@?XE':F]_P7F0/L_K;;C
MW5.H07D; [H:2AA0.GHVC48V%(^3C*J8]A$C25@HCEY'8#/MZ_G.S*I3*?K6
MH2*^D2H-4A3S8QJ8I3/-0M!R9XCR#%P\1O+_UHO<)_;]=.PB3HA;TV&K  L^
MH>T4*[2'2=#)R?_"-89;JG,^F,;!+<CIVRC]I&EFWK\_HF2&_M OL/N@L7-8
M:98L/)U?<KKW335_R]9([&T0IPPZ$'#"Y6Q?6&B>,]M6L?G']8+1MS;A7%ZF
MNMC)[3#AX8,KQ3P@H-PMHX=H>#F$Q;Y-0_%AV#F\ *$W<UL?B:T]&KJ,+^WU
MZYQ*--->H@E'#*:?V\QC\?VJ<!3EH>*;$YHIYF@0&X_19#6,J)Z=;5)@/$-M
MA"PLNELPC",7:^-.E#^SJIDU%15V5BW4TJ68:RSM9P;-[$27TFW2I*K/Q84;
M]AX[8>\FG>GE $6E;)G+9>PA<.Y3G:(<U\(2(IS!3!=D=0VB9HNX"\7;Y2(3
M2A@7&^P6=>TUO(L[Y\/M#KWT*J'X,W#JI ,+FI<+04(6I9DVT^23CBB?<I6F
M(4%!F#0' _02:GF4+$#;)L!"JO2EUW,R I\^^T@9*65^2$-*ZR,Z15\-W(:^
M*+ICVE@?PM>BDD7%(A'Y(_\[58H0<N) 32M[L@P6@D^IEFGQM>C%3(92'DUE
MS9S5P6D@2'$ZI;)WHB(9@F&/1LQ.\X4Z6F<HG#:B#/UN<<-5B;"%QJQGVE^
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MC8N>W<7V@MXDR^"OSOF1+8'G1VGH++;>*CU[GOP1B%<>/:-SU?11*=TI(O"
MI'J[%J_3S(F2 QK..9JEQYS$HRCO10IW'0_-O/,/H[;"988W'D2Y?>+BXSWO
M<15#FSD'(/-V >\\KCXSQB1<_/JBY>@-=VGI4[T5>C1D"I(TV0KZ_2B.X,MY
M8TE17&/K_PMU\FZ0W><!6XD;!A&>CEX*NCX?TQZ3B!2LA"-4<II$"RDX$_BI
M/JGY7$\ !8?M>G$$RWH2>H!AQ6"LW%[1LVD"^,1C-0JRL;:HQZK/0&EIYAVG
MQV0$8/BH&(*;(,/W1@GX<=UL$F13>NW]1MM<<K0CT-NS8YX[LD]J-.;WD!>
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M>KM;P1A^WYTP!C5LF_W]T<496(T<P;-1J!@[.[T":=#\,HB&?SY *6D)YIB
M:4=CON8O?JG-7WI3R\"#R4!:A=51J5>]%^W]566!^&VB(3X2-O(FS;YJ5AQ^
M)&[MT?&',P_Y&A*5$<RZ'/QL.(D#PSU4')](Q>G'MQ?_VFHUF69"_^T 'Y %
M(S4!L^OUX*,H1-J19?58+5X/)EXCIV=\CGYI'*PN4D7]@"\6CJO1;(]ZO9L/
MMYNZNGI+L_[,M1D[JVTJ,HF)WZ ?A7X#GO&!"L(>.-]CW^N!(QW /^=!C/P+
M0?AEDA/+2^X;?K(HSR?,N%40C'R<]KX*\5/^9CYA3RT3*\J$5.#!09LC#,W&
M[LJRX,J +OK#3Y6N!10^JL(7,S4*HBP7:X%E! D)@KY7>(.?U!O_4!O/;%]W
MLYV4U;VE++N',) +.8'W!<Q & ==+Y^,1G%$;Q)N/0Y_4'G8E[N6 7\5(%EA
M-)X^!RZR_QT,1V\.-XAD1X^X6F/L6(U!86RK?>\P=O<^!*3G\\Q<69BW':;4
M9<<%TMY+A^#N:KZ_NZ@.)1BV;S8&T7TG<T'Z^/@;!5847W.'M2Q;QZTN/1Y'
M!Y/E8Z0WR,1OKGDMV-2&]X?R('Y++6.E>W;AZX6SO^QRP?AC=05#["M5X'$<
M!6/B-42J--1"DWBL">F.<'V3*>K-UMX;LDL8 \#KT"C$L8(H@GS%%%9M//5&
M:3;NIS"L&:N"HVXVVBX?GI <VC$M.9,RE:,ST.H50_>'WL41-+HS\UE+EY>^
M/,4">N3%1.(Y(]@X,U@-V'5X#*WI:-*-,7R2,=I$# 5>YV<XP,/)%<C4';1S
M&Z-'N?[P-($I*^^E:--7ZZ%.5YP*M?RJW)AAWTO4N/&DV<G*(?DSW--%U;_C
M'#Z=&5B&>+KIZ/TE?K>(=;IF3236Q+T-9TU<?UICI@LWM@!DOT!Q'.GSXQA!
M\V\0^80F! Z&8-"BOTQ^)%1=\!6BG)R&O,@VK+S#(0^'^$O?I[ ZAT5"X[-;
M.$$A,G87#S!Y[FF_GZLQV@+,X$G UZX<=T2*]=GQ4.^[D[5\WE'5:CE+'_1Z
M&7HA[@J1^[%X\X2DO=UL'7@?T[$RFT[;A_^2PU^S=')%7)41N@_)-3BTY"7
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M1I)0G)-W3KAX]_=)H@<!2%! 66B4:8QD/"ML 6I5RID%*.W@LZ!Z[:L0[[M
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M4]J<^9YKH$SG2<$T6<M$4].;2ZFF6[QOO:&TEC$/-D:G6%Q[=S1"% =Z;#%
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M+^9-E8[V)!>^!1>IP@+T#X-0H:=AC4"18J'X"G08,21Q^;F6WJU9FFOGJ"^
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M<]/6%'LS$;NRO-@,#7492QW3:UEOJ)%?7_^8J7B#HB+">@U>)_>.V6!!(6]
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MYY8#-GKQRTZYF-A[9V3N_;,3&_H'L2*]P<&5D<<$6()HM;'C;*UX(2-'"0.
M.4/ '#&@I!(@J$ FN$!1B"L>,.B!XV4LE6:&31DQ2QTQDE$6@Z1@D+' %*&@
M,4["RA(M)%8>F3R?JG8R\,]GU(4R$!?FZ_7+0RY3U&V,4WNF<IFBGI!P]J:G
M*"D0(0&<\ R8QA$,X2:K>!X<)BS-,"L>,&6*:O:(44YK9 D@J9.H"92#=89
MP)(@'Z3!N2\;X6TB'N#TK><457F-_QJ:=-WTM^]\V_YW^F-RV]>NY4+>73JZ
M>J?KT[]>8E5-4TOB_>J*+SO#]/7N_IF 5(6BCD++N.0(IKLY3V^EU>T-T_<E
M1"7OK]5)-W_8-\>M4],?9H]Q>!0&(8.]6IXU"7VMV.F:KNNDDQ+^AJ'*]WS1
MNC3H]+L9?[LDZ89/>X-.'@0O^^&X*MSVR_>.'QY-)JEKGQH;&EU]Q-AT"PG^
M=W[DQ/0/.]W)$-&YWL8O,X99_?Q;O76,Y<T7=/W/_ P5,P4MK#=<RV ,0R3)
M?>X%TRH!+#D17'XFB&]-/G74GSS$::)(L/U@OH*)Z1E?FN/OYGRP]:^;KR>]
MF_$]L='+F>-%CE_;]K]M/UWUEB>Y#PQ+?^?RUG?^IGO4L?T?[=:;KGMQY_!L
MRMV^N@ZQORZ!E3&8#E7<E#GM;3_$T.]7Y^0@3H[85#\=]8X3!0ZJU'[Y2VN4
ME]WZQVZ('=<9_O-N?-ZT-B9/@IK;W\D_WG03 ?7.TC7\X)\/?(+)>*VX^HI.
MJ@DBW?BQ.1V$EY,??O&=P>FQ.7_9Z59?7WWHEYL7S%"9#N[E%S0Z/$:1UB\H
MXAE(X]#B^(O'&'M186QJLAL=(_0%(OS.P^@%OO/8?9?5+X@DC[KJ_<>($$][
MK[=XBA,C)ID1'G7F"IZ_X6^UW&NYUV4@:TW1^I-WJAYFXY\L-<W1J/B>Q:>Q
MP_$TT::9>1N-M<Q=@J42D/\8>? SRW_E'5U[1SLGR0T>/N0=+0-Z\S31'FFK
MO CZ$M](Y+WN?#]# U9KJ654W_526G,,X6?[0G;2S>;PA3ENO34=#\FC>65.
M<[1FH]^*<V<G9\>5KSOV4)^(YYZ8.]?+;*,B\_>$&T8\.(DYW##I3[30NMBV
MG%G.7+<S"_3*F>7, KUR9CES<\XLT"MGEC,+],J9Y<S-.;- KYQ9SBS0*V>6
M,S?GS *]<F8YLT"OG%G.W)PS"_3*F>7, KUR9CES<\XLT"MGEC,+],J9Y<S-
M.;- KYQ9SBS0*V>6,S?GS *]<F8YLT"OG%G.W)PS"_3*F>7, KUR9CES<\XL
MT"MGEC,+],J9Y<S-.7-%W<B>M&S4K^;8=%UHF:J:]6YP(;=S:%'<;A&$=0V=
MQG[>1OQ9]FDAG H1&;7&&Q:YU9Y3CY0R0I& L?K\)K_?G[=G>1].3GM]TS\?
ME?%:V_X:?X_[:_3XI]VO9.^]PQ_)WO?]+U_39]Z<?_SBC_<^?*3[7_:/]M_O
MI>\^.MD[O^RO@?;>_^?H(-W;WN]__CA(W_5I]Y ?[.Y=?+PX)'L77R_V/Z3[
M?G_<^?C7='^-/W_LG;Q.Q[Y^_[3[FG]\_^[KP>Y7MG>Q_R7=V\7!^SW\Z?U7
M?/#A/T?_>_'F?*8%%!>*4I-;*EJ*@1$IP4IC 3E.HY LJ-PT#),VIZS>=AH_
MQ\T3MW1:+O[7N$_PW,^_IKQW-O"K(;U7IM_/_5!&-4O?=-WQ67YY;WO]?$,[
MPV&_8\^J]@#O>_N];KZE?N\X/<GAFURG,0R&@T*3]=+D5!NB2)@FT1E0*+='
MI\JGG[ !*6PD$AOCN-W:YKK-D5QOFER&^'Q\-[T'7&/!$M!%Z/U$Z 7!/"$F
M$,$M8Y0KIX-FTF"#+7;(/93S1N69JP*N1>0MF;T.;[(7588X;B)@2A0PJQ H
MJ2-0+ *1@3.=>SMAU<:\B+PB\C9<Y-5%>-=K58]TWF.476&_^5W<[V,W]WQ_
M=X_N'WYV(;&?X0B2S5!R<IT Q1T'8BR3'!%D,-W:)H7Z"O4]0^K[QQS<)ZBD
M3E-!*2),Q*"4HT@;AC35D8MP-_<-TG.FGY9%@D4?ULJ0YU,,2;GF@B77%D4D
M@45*DW_+# @95#3($4U<8DC63I)QAB9GFJP4ABP,^5P9,E#'&5>:.X,8R3]P
M9R5/0A$AA<(]ZK PY#HQ))IB2)9F1AF2?'0VTL2008$5-/G0U HBA3.*A*UM
MH=N$\[5ER.:M41<F+TR^)"9__&).8?(U8O(WT]& *#73SC,P5B6M*ZT#&X('
MHJ(GV$;GA=_:UK3-A5X#)I\[BR=6_VMH%L_ML*Z0!=8,0G[&D]/0'9@*WN%'
M_CFT'I7'<\N+6),5G*KU'?EESOC4[89?JH,U]96/6H4K9EH#E?=XTS_@&DM<
MXBV#JW! ,5,QTQQ^@U<*1Z:YE40SBIF*A%NA&!**)Q="?MXEB""$$8;\P\\7
M"G?\E[/!\"1TAX/WO:NFS;EG\YONN&-SE3)1":!7U_3/NY#<C$%G&/X*_6\=
M%]ZFA^_Y=\'U#KO55?YKCL]"\2AJ]"@N;HF>&QER=A@&*X@#)I);H2/E0!,.
M+$=""J.WMGD;$;KH&F,AAL+?3Q]_6X4N?)[#:8YYAJ;)!>'HJ0J61:%--$Q2
MY=-$8QG'K,PSSWR>F8U<!20BBA$X,3+-,WF5EC@.67T0)+152C1OGGE>V\QN
MAW4&8&N_-TQ7A)8-W1 [KF..,Z#3;0XRTF,PP[-^6&3'V1KRW>.FS]M'P%.F
M A0S/869&K%VV*S-"&5P%0XH9MI@,\T3J=+!:<UTP($PY9RQ$AN,@W 826;]
M4CR(5Y7D&7;L<=@-=OBA,SQZ=:F"?AN)H.(IU.@IH%LB4D$BS(F5@+GAP AQ
M8'' $ .++ T+[8-*JK4M^&PZ9R& 9A- 0WEZ?2-2FSV<YIA/."(<^T@==IPY
M)2WQ6/)HI!=$84;+?/),YI.9R!-BR'FG\PY2)(!Y*L XQP#Y:*I-<M**YLTG
MFY :]68P.*LJ'/5B:[1_NW5V6F5&A;[K#$:_S^E3K=YI-L>@I$HU8?VFK(NL
MA9F:M2164J564?!"6"NMI<312!EURE B)<<A:!%C<J?F5CE5]FKFZ>!WS_HY
M&[Q:/AM5P:@.'HRH^?68LWV1+/-)%CQ3\D(I;T12J!"2: 5FDV!11$5 DDF)
M2?!)P]:PY;O,$V6>*&9J5CK='71;I2@4MJV';6<"CM[:0(BE(#3#P&(B71VC
M!"V-L"8@P4R2163AXF@%R85PGSZ&6/+?UC'_K4P,RY\89B*'Q/'(L#7@=33
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M]G":9\*03@I%B* "!<904-PSI!7VQ%!#V</+Z9<)HP$3QFP,*3#I(U?@*9+
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M1<ZFZUOF)"=67%2_V+#"G4]93/BZ'=+/QZ%*;NGZG6OF*#-7?3/7QQE%K;1
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M,JH &@67.,D;4,$AL(*[0).\4-)O;9.R&WO=8/RD:4,%OLN"[_3:7;1"8FT
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MC1E?U=7?N9)67.76  W"-V#[XS4(>&:[G."/Y0KISM;#POW;:7@[O7O2GEW
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M7&8"-B:+'OU2P$8'?+-5KF=,O?^/RCL7JP9[MBZ=4K;.(TF8SH<E7;<T%HI
MES)0A8F 0:$CR20ZCM)"AD4@PB*[#EMU5\/U-Q#7QW\=<UF&<28+5O*H $L"
MS DI=,:B4('U*9),\?C1+SS8VT)970D7.3!A][RZ/JC9>A#U66-/O:[AT:BB
M;P=)<'S95U(W*,'?HTCWNEXS2ID@?6^@_^&;T/G?@,FPL,Y[L"$ZQ:'3D$EU
M.(6C"E=V2K&NT"VNIUU6!]Q]YD(-->:U].%+4%:ZN,2,O%^N=XK7-VVN!X)0
M. 5=:,K20-N-$FAH/,-A.*5[0K"0H%*NK1LM6;NQ4(,U7--]ITZILNI^!Q2"
M]B!< B\G( \JCVLHO1-4I:6WLP:(%DOQ#AZP@-,-%L/$!3RF"(= ]5D5 922
M!K8V%'CLF7A'%.M@$OS@P00S8 FB6H\@&)9'$H##TB[6EHE?02PP=* 0A*VQ
M"CN5WH]T^7Y?.O6]UU?=,A$+I]P:H&'84; V,.?(1K5I3_#7JTQ:9ZAX8 <8
MEA%GK5M>"[X!#/^DP2]M23=BLE0X*D)E 4(;@D_@F.=@<+5@ HGW,!,<B27)
M)2+7P+C/Z]7,&2;G>*+4:0V$:K68>G+B0-NM$4,1<W^WG3*F1@%U#)Y>#Y>>
M;#.RO.9XV;Q&I)=50X:9\ Z'B7@O8$4=O>"+Z1VK1>TQ#XA2.KIT=JG=P3-<
M5WRV>P@,P64>V+7<. 6$NN&'VF&M.(R0 8F@14MD4#ET%#0<[>X:VM6EM2V=
M@8N6PDS,':X)'1D0<<K><H8'H+'L%RUA]'$0_>+SB6I!X(L+"UM$DR<+"'T.
MN+ED1UH.@<O6&@I3XKHN:N#B,!<T6V=H_9#DG""B+"YD%TD$G0(,(I?1Y3C9
MD% \44TMJ77DNT:U/;[/IY&5QW#Q,4]%5X$>8!KKE*I@CQQCDZL6H:'P4'3V
M/WJ<7)FNS< CUCIP,5BTF1IYS4;I\7I0_%Z*NNU!OVM#0.36N3IQYNECVG\X
M 9:-#9&3P'!17B9Y/K[5FS-@ZL[[UW'FY<7"FM>#<]JYQJ:6E7>2BT0CTN:)
MK1'2'70/T XR"RO>I8,J6EHA8 5&[V_[)O-U#NP1P*2.HW\?/&%A,7D!"V3.
M*O405#7,.6V!<[>=*#B9U5)092=%TT<S\VK2'W4#C.!_C)@!VQOB[O7IOAL=
MYDA1\P^EK-R%6Z=UH!T;36T[501_G1N$8L+$#O1=BY4]+ AR-D?82[JF%:4A
MYZ#5_,X6L_K"N".&7+V: PE_-%9);%:+[AD#N="!=)4KS 7I-I=&Z)>AF\9H
MK.9]/7M/<M)=KUU=C/61;L<N_N.TFMG1^]6@& #*Z0LP%RD@V7%<EXGM,^'6
M3WO_!L=M-V&K>B%.\SL3)V!RHDJ+BV8G.QH+25+2DZY]YX#9S[KH,"Y]IR1M
MD0![D^=B+JQ3E5 .?>[S63U']#<?'["P<U1.2&;"J24]3X_]/F'L X6FHV(O
ME3P;(DE(+N8KQST=#'$ZE.L]3AZ^^KQNWI'6\!"L,B3J-WNO]B:E05M_-H2X
M _N $OSM#C>@4+VOFE4[V:_ -GJ)88?2SO@IK%:-A.$2.R\F^\KZT![OOWSZ
MRO[E'+S66,),]/I]1<:K3>^D/:6,=A 6I(N +M6 \@ZG_<-$@=Y5+<FQ#^:4
MKSYSAQFU>8W:D3U'?@Q.%VL=^$FGX<U W0+QU#07I&&YU'B8R0S.TYRRJ"Q7
M6)T-WNU&!M>=U;IC8=W!P5=X,]/;Z*A>H6TU1 E$Y8MB::IN&J/Z9\"+M$$N
M5EG>:#NRVW@+J+4S>"4ZY,]PW8Q7]RCLM;?6E^!^$UM'$3TIB)X8;'@)9.6%
M.C6P.2]ZF,875KLELGKQ C..->Y2:R,5H&0L/2F_.L.S_JL_Y/ON.E^!"/>_
M^G5_ZKA00WH4%3GVC[GB_9/?9N9#Y32H?<M>+"[<+H7OMBE\T0-.X;LV)6\M
M 2R-92$RK9(H@^N#LLA#5199'L+'Q)CPIL/\NW?)GK9UJO?L_!Q4!R\F8&7^
MN9I3+!$/Q#BBBQ=:?%",!=,AGV$_N'4/.9UL%WS!]V+3N*EW!ECSXM9.\KC4
M<1&H'+:(J[#,C<BU,EDI=2JE]I A2>@@0^##U4[R%\Y;CYD=KT[K9OD:1!)B
M >T<XM<ZQ)^\BPX1U*Q,,\&CF!5Y$C N3,EDK#G+=1J$'&N+T@#Q]2^'-',F
ML@U+.-UUKLF[]5Q<C.L6]R9'\\F16M826'VT#<<3$\$K^Q@B2R X4H47,]!W
MA,__1MDNE&JP'%"O.C74:A##XL 'D0@PEL9 ZS7.Y&Q@)36MQ=\&E<L9 !?#
MPO]>_<+@%WZ[KH*!5@/CU2MRHPW72AI8!,Q8Q*0"X"-1YBI,*3/'%ECZ..LD
M[K>Q'/"!UHZL04]]$OPWL1B')TR6G<0!5R33UQ\5=C9"8\[  L+7X2.J&S\A
M&K,WF ]BB--XR(OX:2L%9+>_:*I9OQ9^BL OES6Z2F_)_(+"!%&9Q$I%FG/)
M191H4T2)BJ(X26/CBN3YE4D+3]P@?K,VP@NKF+_&(1,! ?WL6-\-8H'!X<<W
MQXG(N"[CE!FA0L:Y$$P$602<4!M1RJ@T0C[Z)=C;1$:Q3,WS/R0B=*7Y,[;&
MCM82JI",;T,W<:%U%A9Y&J:&Y\"0 YX6H2X3G01AG*4VL@R,Y*:1Y1?.&G/1
M903<P@#"8X27W!'/38@'$3B4QOS@-&>1063A*)!,I+I@6:[1K1R496"0>#83
M4C>(I^,L(P+J^!SNZG49+^LYJF+ 3KO'#UCAWYD'O6-<=TM[[X[#,)5%F85,
M1T'"N!0)*V(1L3140B<\S5.LY0NV9,I?Q;BL'8%2T3N''3R#T[,H1MSV'2HV
M$20&2:92S"@JV9X:\S!0:T<V$KI5O=5(ON,/\,JYZVO@PY44_B3/9FL7I%?A
M, +3]^# 3'%09O#LS4#=:F?.L>1CW,[GV3M#YXX7.(?2YK\WN@Y]P9+D-ZTY
M*I^VRPK=W.UW=_RHU.S#<1*#J@#,B &3CQ@(8LVD201+@UA+*4VH<O5-E([!
M=B-CZ#;\H1A0MH1X&,ZZ4>+[)07'WOIH1Z+5YQZ8;G'PJ+Y=Z1/[,)M7U,=D
M+3*"T<-.*C;A (,97?N3:9>AXLHAD,]VAI'NFL=9J"Y"BR 4.)NZ@-<-'G89
M>]Z>]H^,:J/EY_8V.&>@(([ZI?2K8&$A;)"-F*/;!-15M*8J/4H:0X=^U6$R
MV]=+,Z?Z.!OJ\9@]H'M3,A*YH'Y]_%MKL]@KRREAK]]7]:K%%(?+,('64'S0
M3V9<I-ZN=6-4C>$U?)T"TP]#>(.TT3.SG [A.=!N'K7XJ9MW&^UXKBS6T0:3
M.JQ21L8S#/W,13E7K@;@S(C6ZG^4B<:DP!^HW=*\=6YSBJC-54-[B$&TNFDL
MK'I#>7EN6^AYUI5M^TU=44^"P1ALNF5]\?T>"@1L%Y0SY_T&F]UY>NW5D:03
M6R.S7)#F@!Z-CFK@^:=5BU%$Y5+0F@KS\Z:3=_/Z'(;<&/0C=94>3GFAV@?F
M\]_LEUTV&<P72! 3>D$L8W<J5XLS*,XA;T(#LZUMWI*M>B!HJ*I1JS.D(44]
MB?I3WGAC#H<Z0R_5^\J<VR6>4<H4'DW"3K$L9?BD*0VF[0ZWG>7>Y'%_O1F]
M"BFST3WHBW/5=#UKX#MT="A,0J*EVESP/L7$5F;YZ"[J'+K"],RN4*@=\C/7
MRHJN<#RFHU&;Z6F#L==E WU9E>0W4354-CGHMMECO;>V.OZ[U%1.SH\SD2,V
M9,:RT!ALJPZ:"B\5*XV4:1[F*I;!-Z&I(!5,B SP]/7=;P>4\%"4E\N%]5!<
MHC8##-,C11$G0HW"@Z!8)[R@!,;N2[#ZNV^&=MR4N/&LGI\P%$N4(3S=*C<M
MW+*KN;M,DK<#S"FK/RA7WSQ4?K;/RV<N?^I$ML/V49#K _$U9'-5TZ%7E4@X
M!%]H7>).-K880;*+,2?MH]<C!Z-=F]Q[3W_;9:-<#L?1#E[MW^R+:"FF(0V)
M<0LFB&N,8L6UT+2"CV1\Z[01N729K2Z'VB:-NN7PC'JK,G>%0N;WV[H"X _R
M RR'0[=:";F-:C!M&]HJ/\!JOEA]>K;H/>8W7QKZ:RM.P [IY?#C&WY<9$;G
M0299:A !0(8&PY2"91A"3I*BS((-I!<#*Z\,(B6KDA>IR9- AEI%198;%0FY
M+@0?^R)M^C#8@V\& .S:%>G78*-0G;@!<)&FHK-?VBM.S8P4TS%CKY8KGYGO
M:[I!X=85UMIT=064U]/U+JWGH-,Z#N)9_O49R5\<C _S<ESA7=6^>TP):/CI
MNSR'*CB6*N51@16^":),2\.92"+.$E[ F0PSG8=\LST[YUH526!@)[0."\G3
M($VPX#8WL$'?A#(ZHA4+(FBS%9%:'I@:.L'0$>8CHYY *6YDI+K$5'2Z4%*W
MOOS4@VZ&^>"D\FW<1:F8:ZW+?5)U;Q]K\J]CBJA',5&G8[R_SJ2W6=3N]KJU
M*0.CSKZX!\[+3FS+A2=&ZM^6E.,N4]RN A9WK$_46^18CM@M%O)*Y(P/)_MD
MG-Q/V^7C'-9MLT4W[S"MAXZWY6G5:+80B +3K3+EKECGETNF[Q ^:,>H0@ ;
MTZCA*2(AXU)^80,O\4J*M^28ZM^*<Z!X%V5_--;!:@NV2A_DLI.A"0SII!LP
M;"SLS.G66=MT)_(A3FFG>[1>T,%/X$L[:'8.YL3IQ5HG][[1.SYGD.,M:UVM
MN5[)G4;T3]ZIFG!VNL*^K89?7X;J?%0=0H>S(L0)5<G!<3M'& ^TNC"#2\PN
M',0S7CQPR[FWXG:@Y3'ULYT8GVK>FQK.$K-;AE[F5=N;4+1%?D.NCF?38VQJ
MV#IY;9LR@<IK+![UN4*8,7;1#=T:C=:;#J95W<"?6#KI?9O6F*I7<@GW]6^P
M64S6$[=^D#<4PEV.\;4YQO$#SC&^-F=X3>4!_;(T42!"J6->)KH02BO%0QT7
M>9*;\K[F&&^?_;4*W%B&6$X#!Q#DH7&9H$,&W=7KT,%[1WJ_+:"R3!$="M2Q
MP0=%*CKOKF![ S=MP,K&*&B$Y=%V:%%5.ZJZ=Q57MG)I@&MN,T_;=<ZU,78;
M#JD:&."@C)-^OQ@%#2W.NR^)WC[5O<F!;_2!75CS*T"@Q*"Z'EA811R,WO''
MZG^KR:\5RIE*M9,?_J>&1?B_\*\?IY-GJ'-A?B8,>WS==)3YW048>AF$=?EP
M(^[55?:6S,I8 46D@0'[,HCSI#!<!!D/DTB9//+]( /?#W(-V_9Q#P_PWNSW
M6%Z8TCU*#0+:5C_I50/B5;=F_MU98N^2YZ_5L8@4SU09LKQ()>,FTBQ/\X0%
M06E@>;4@,&+0!HR97,#)V7!B6/K;/!!#<4Z9+V#!M[;H#\[C.I%11-P?.G,%
M& ,R 2HOPO<Q><'<1_0E5FOT[S/:_+NIAJRO4G-*^1^K#]4 P0<4R:H98H7T
MQHP=^6"<>'PI7$CU]?2@&T]DK*$1> I:'J1UUC-Z\R5L:-"!AA3443C9 AT,
M[ZL'=;LV#O[XR?,C%PA'7/4SJNYV#QL!Z*V?<,?^+#^F%,#Y-JVLSPUO:E\W
M=R5H)#)GU)<:W7.A+@([K)KW'GZOA?Y>UQI+2P?3?4$ZNW(A?_7[\Q?KE8I3
MC"3@PKBMLY@J5)+GU?YZUG\Q@,9P%$%FK;$XAC OJ]Q91JQK12[P&\+"?UF_
MTZL!",U30MG9>8$//[Z)CHW(52S2C$4Z"!B/BH#E>12S((NU*46>Q-QLE'LA
M"%T2A@(SI[- Y9&(3%FD/ KSLE#BF_ ^/0$FJ4G7>@ .A]NE,L^QF18F%L^H
M000"4&$*/3'?;M;>MS. H;S.9+N72W.)]7$="?^RWP'MS"[L$NZ[.EJJ7\':
MO8&HM ZX[>ST&IB2A1@NNQ5:[TRG/#BH+5=A %8^[)+#%_ .H"X=:?RH2_ +
MQMWC'"R8PZ/"Q+C&#/UTZW?+6C04J] 5EGAC/A!%./$Y5A@2+-)X)5SFT-1E
M\&U!1;@$0\=C*+G405?RWDG[#M&+GM E^W;X.@-(VSYYZ49SHJ0>V-M.]GYM
M ?;"%<2_F,%@]N<:A1BI.3LY!G(L/#99G&@9%2R0(F8\B!(&ISEA60DVDXI
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M1QYTQ*[>_YBU]HAD)<Y79YV5^/UV1[PX?'OP\3B2A=)IF;.89QKLQ2)EPNB
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MF:(P977)%K7"GF,NT]M[N[R!,-=#)]7ER3&M<5,FRZPQ8X>1LHQ4(+7/5;7
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M-1**XF_4[MOI')V>,GXIY@R(IL.6<=.UQZ =K *1])ZK'^S.^IK*L7$J?*<
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MF3P#:N"EB$66E#I(1,D#$PA5N X4[O!O=%S>'?X'</@OQH<_2[,PU3IE05[
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MAALJ:A*G0:"#@*>EX7%I9%HJ \>HC),TCM/-VNR'J.>\-&A^3WHBFHRIZ$$
MAA!0"K5DKEVKYCD\>0!NN!C/R4)NM*L>Q_RW_5>_4FM;4IMM7[1& T]:TOVR
MMHCE;^8SA$;O$=,(DVJM=9XT,\2,]\WBL5TA_* &O9MPR;%[O!W"Y>,<X7(C
MKK>%=4&5O$.G=  ;G1G@WV6QX48=FGI^BAT/7,^AINN,/NK:9"'AA;8>MV^A
MH=N^FPO.$U_RH$G^8#[YIP")TUSTR"26B!U1[;]Z0[^ 3=[58=^/?<#F#:9=
MTE*SI_]9(<A-'R>>?.'!7CFT'VP/HC@*?WP B_;<P@"A;O)/:M'];_B5O,3W
M8@WC>[>&7W-98)?NV6H\,=0+KGKO4"3_Q^@39(;W@'CR,/EQ.F%?>BBW7+''
M,P%/NO"1*4*!%0XEUJ/;=PQDVGV,;0BLF]GTJZXPV5KW:UV_[KG4&ON@^C;B
M8SSLKEVGU96 Q]861G?5*7/&\N*SGA=W,-6*Z,5!4?OKJYYJJ-/F:N;:4KD'
M];!*TRW/'T%V6[IR&*L=PIKK\]A!WRTZK& /G;N\6%A@O2&4W6MJHF[FVJI
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M)+RMSK4VBR#&SRP\W:HHI-_FGE-O[5GQ,%<Q5&/=/ W%",N!C97P5>O@AX.
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MHBQ:F'*D'9;(.RL$#LYRDW)N#Z,/+M19O2!2K<V/W8NXUN9G0BRE-E-KN5"
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MD:,*]F?,L_6/Z<2S"IWC\5>LZW<[YX/KO[( U\_3W#P3TB>,SDS9Q,_#WI@
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M==.'5=+>,K6Q J<G[=/VR?G)"(,^)%W@8>:]-G-UA>=/LV;S\1>5FP$$*G+
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MM^K%_GFG(+'UMG^8*6TO&A>Q%QNGW4%F>,I'6H.V[70N&_[0GGXK"4ICN^2
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MG LJ- G&ZUST#.!?V"+Y/Z<DX\71[WD4,#D!NRG;UAG2AQH%7%,]<+F[M7D
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MI:E]\9RK"%JD_=+7I&R)LD?ZPJA5! 4"'"R2R%]_LZH;.[A )$5 ZHES9))
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M:7S*!DC)WBCF?.95!08Z[?-V'N]I>S#L]?/.7><V9W6.,^&:N32"G9><JLA
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M"R)V,+\WTWQPW=H.OV>#L@W*WAUE[UF9MD'9C4#9!7. 1:]9$!:6S!C$C29
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MTYS^[CO.5W7S:X[!O_%VQ)>(IDI",FPQ"E;G% O.D>'P*YCCQOH4M8DJ1[_
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MO3-&\ZCO@8S5;&]9^GN#L?P/EBX=CS6T0QEO87'MX0B8P;S(Y]?I7T,<G[>
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M?9SS81XQEVG=M!+DED.F-_Y8B_[DP-3D4R(TNJD-D;? L"N)67%M)!N663*
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M\/FA?7A^<!'%W+*X[^K<<ID.*A+@<\8#G7C,Y,1T(\,T,+'4/:8-P1I#SKO
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MZ60 XY?]G;/],VW*!C89J#K-?!Y^T_C(HM"EMLMB*PY\FU$S]*D1AJYKFU8
MF-BZ+YB2C!\%^SF/@NCQ?5+0=L(6.!RC4JZ2:-<A[OZ@JYWQ7B&%,;!H;]R
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M)+6@O6]V(L\/BY:PW+2+G.4NSL9P^6?&;(JW+X^WLRFD%GB83XH'NN<['IJ
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M)JH&:A#540+@K)X=^Z'GL,FL$:LI^#[W85LY0/ENTNEW1,HHD&<C<2=RR$^
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M)V4-#LI!]R&:',_3)(+4D*;Q(%UFG,L@3[')>$2 V-O]",_)V$H@W?Y,D)R
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M?7%?+XHV'L<C$_ZY?'<^S3A ]1O*&(6]@8M<WQQ=[5P8P.C-V/#TP/.(;@<
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M\V5]$C'.U2"E3VK"2D)$XV"^C\::JJ3Q<3QR'^I&%>W>X\HJ3O)V$]T=&M%
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M)4V*FW18F:W'TQ[6=X._PT%]%9!,,K$]DO]5XY]1YEKNL8R@&Y3$(.H45S,
M/BG2M^%:H:R3%N:JA #N0J=*81FF?<GSVLDU;R>M-(UJA=!D:NL*VR 3Q<4)
M19'G$95(H-<=5 ,3A TH"+V'9%6RBH1PDT22ZTB[3+&&JA1<2.2C^+]A$;:N
MG#0LP3&>(00HC=$DI?\=PY6'PQ7A)7^!M,!H7Y9_9R.=?]17==#P6F.L^D'$
MT2 @E['3:R>C:,)>"HP5B\Z)VK ;I*+4C"('%=?:K7.M$4L\K;C6&@B#<T&H
M0N0#F=:HX''L63)[5I:HBD;UKH#0,N2Y]U:\$D\+M%.5,4=X(40L\F/D[ED-
M: SD^1N4-_7C#S0>-_(-H,S#(5\<ZEMCP _QRB:1[,'"5)G,UPKB,:T@GJ<5
M2!6P4_K0X>^5DCP"#^% D.BH@W']J%%*J/%;HUE:ZCSMM%1'I73FY;&H!.SD
M=528@AZ*G#D"6,"*-,O'\(- .N(N64K@+F]+CQD)=V:"^9%N*_$^\/LP:>,]
M-PJ_&>M>2D!Y?9X-[3HSJUW($KCECO;Z&6"2TO0\$:?^^\[.R=@M_'#*B[.I
M6LHL+ <Q%%8SC#'OYYZ$'@*,[J7>YG'QWG(KZRP@'9C0>]WT7^UDX(H0]T,U
M\I<?PH>QM3%MR25Z577:M/06Q WK5IA9FI_R4KU-NG4:!/!!DW9#6(0R&<4E
MC$@TR00LC]M2T^ B%#.7UVYR.T'KJ$SN0XVY=+\8O\C]H#9Z:1M]'Q<10GY\
MFX10+POR F^M=!LAV'M83Z98B(7,818U*R-&_B6]HN2@]8+;X[0@AA1R4>Z9
M5MK?C.YI'QA(EMS1(7E-L-@A\QUI*)+8\-M%92Q>-"D27"()C@19:4DHJPX-
MK;EH4R@IK=^M-AF)DX&6G9=:I="8LCJ#F><:4O(;08(L[;>'J<PKU%I*\\KY
M;!9UKX/M^--(CTS$>2R-9NV1T:SQ""F-RBK:6*;-/9TDKZT,7@A=<38\@[62
M6%45S#$S'7"54EVN+BTFBE((>)/DU]6._9+R7&:H+JVD\S5F 91F:LWBQ2/]
M6]U-/W W[1CK$6^ZDF=X%K"N"S512V[>-<TLYK?X>1\O>*=59@%AS.O0:ZEX
M)'DY!FFTK@VM7PV+98E@JQIP7=0KX'"-E"3@1(4\@&<]+"@G+!3'V27MUL4X
M-C['J'H@"?E4GLM[G$S;/3X[;LRR_^CXP:4P'FN?,] 6;]+L>BWX=G5MA2:3
M.:L;@KH';+C"YW/V:G:1UD<H9OF(J$ISK)")J*55V[H.*SI;/95>YM(O&].U
MB4NZ7C\$IE^_=HZ3K".B64JO932M8]7(<IVF-^J7CQ[JT\-"CWA_(*K3Q_U,
M6 A$D<1A-<C*#>4)NS"+%<Y]$#'M7)GR0$]*#@HY:*ZY'+R7!%[:_>IT_^3X
M]%P[_JP='.WMG^S#CZ-S[73_]X.S\_W3_3WMY.NG+P>[VL[N[O'7H_.#H]^U
MSP>GAVO K#Y5IL*]H;:*NJNH*=I*VQ&:'*>F\5HVWU829K<-+'S7G%$]>^76
M]@O5_L#D1@UM%V@8P$@WH0L.>V[Y[D>QT94I G[<2[I"'=NL6XAOO%3FR[K.
M8Q0ZE,1O43P+4XGQ84)*BT_-#[_].E!NC!#3$ )ST),!7^0M>?<QM?)B%.8'
M;19TU=X2P[1^JV#(DC#T^%H EAX.MEH) ?@1X:229,9#N2IO2KR(09.<S$@G
MS2B@+*//">C<(Q2YS&45XZ@/>2UX$)"H<,VHTVECECE37%IAG"!%0WRYA2<2
MGU;+7_/Q/Q:A:O >34J0MU^[X@B(?'KY;]K;<I-/=G>./U6;6UV#U6IY5_'8
M0*339OEYNR)$%(8\-JK;*#I55KUF&T8?0NF])DPR3$;7":>77L9C+NZKR]BM
M;OE;*?O*@XH9$?"NZRU>);*D^$W:E1G-6UJ,=7R&J6Q%/3K\K:M5%X;E15@U
MRFY:E+=-(S==38YY%,Y8EDM#.W4F=6Z*(6.8ET$ZV);'0SJ9I-U%$?G*2 21
MO$ZL6BD;UN L/6 >$4I4CDQ1D!;.K>)78VZ3C^%*TEMZ&#<\KO)-F6 6[KAR
M^!MY:B,[$#/#UY9J7D.;X5;P!'^"IG8L*+U<&WEMG A;;$G?2-WI""/\FATA
M'+-H(,MK:L@&,[2ZS]&X:SKYD!L*UB5]"L4EU9B_?5VA%T^4XJ<R(0^#CZ<Y
MK<AZ&7-@+VCDQWS[H' "E;;I33[D%NC'ES!Q=S%RG(=1HDM\7<B>C9['%D._
MA9K,K;H4\UD' \HWZ<O6%RX.PTU\%($O+N'$HFCGPLHT^K;<;6F[OP$YT:9R
M(4&.8)R"W",Q+ Q&",7=]LS[)NDP>-/BPISR%": +IXCX#,7]\A3)L<T/-UR
M9)*52.^482:4Q_$+R7V&_A_#"Y+:/=8-I]>"$XF\VY439%G965RZCGNAELZ/
M<YS+Y_*T,4 V-$GCB.HK($#/<!G*7<,7B&"3TOME=,M"T>5= (@D$EQ@= ]=
M,DCIV(JKQ]!W]QNOK*(C)V?YYF'.Q3&7WG H[VK@=NVD]AYZ4B7#() QA_AX
MHU2[G2EOK4<9LF>XB*V'A]4E'+Q,NE(R+(G#QX*B2L^T-IZ 7UJAQ7VP1-+P
M%?4>&CIT8)KKU7%\670/'^,<PU[2.49[:SVPGDOSXFC,<>.8I&WEQO&\;AP[
M(*]%\.D+.W.H:Z3[KY'(FE\CO>99>EU'H:=8)Q]UN_":2_LN?Z=]VCO6OI[M
M-+0O7TY6Y(KJ#%ZYE_#+M'[ELPYFXBG+XW,3S]Q8&G6[OPA;MI:3@<51&5@>
MEX'E4U,[%K:#@U&ZBG6 =2*MT0Q&M""AV,1_LR+SNV]W=IOUO#&G0QWA<YIQ
M-#7]T0<P&"4EP!3B]J0$I@==8443T;-KL9]%S42LG((?8)?V<MBEOU[L<J5<
MJ$1Q[X.#@U_@0IZY!DS(-)HC7ZK&=!(-:6+93;.>@.G:[Z@["U/6.O =60U+
M7.25"2$2T&1PWOAOEU73$AXCXFZ=H^XBLJ,+S0;8<U]>2U7W@<*"#NV@MU'X
M+*-EOH72C>!PW'HT:_E*)P/Q_=#;1J:'V)6W2?*&#(;,*L>;*L@=U*C;P<A2
M,[S-%W?P5 92=S@O$T.->0C,V+5%R=E>!W(VFS4:QEM-WLW7!O:\,+E6=#<[
M<T[%%<96<24(T5L'0B3-ZK)[H!W?5#67\'27EP.?1%8;F9!(?"]6?8)SG)9>
M.#4'5VB"*8'6 O>]%O_]M96?P9KWI4-5_2AH)WC)7E.L5N%L^,8ZG VK.=P+
M0>"X=;!'^1C)G]>NGQKC'.E@Z,W"N#H%<T_!PVM\(A)JC"WU#.)_!)IY5=JW
MUH'V;8P!KA*FC))2:Y]Y>:%\AHE8V%HDC'TEO')0<V8['7G"E=Z_-:_?STG6
M>5;*5&:+NMG"68K9PG>5V>(7S1;__06KA1_,XJ)8M5"'.6*9B/<RT?+@PZJQ
M5@=UOU82)J5CR,B5ZVQXWL_*6L.KQ5[GI!@O)[-20YTO"7BU]FWDR+-=M6L<
M_!8E1C7%BDO+^%UTBY")P$4=Z'ERA.8R^Z7P@9G*<+Q2JS9[@]>'0.?<'W,^
MM:.[]:B6&1,< <Q".N[[0^0PD:%:WES-\$S2JH+AN?1J0H^=D//NR(&V\E^
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M5/A3X4^%/U5+U7+;6VX0_O04_MQ*_%FK\6J[;BV;@I7K)C5OJ02<M'L/_B0
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M$V$V-04Q%<14$%-!3-52M=SJEIL$,3T%,17$G("8W@,0<Z>7)6W-,A2^7 ^
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M:+DQR(<TS?^GH,\&0!]R_QW>;BOA\0/W=Q5@"0Q7 18%6!1@42U5RPUIN4&
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M%#?CU"U*,\Z;!V<W8K O>EAF[]79P>]'.^=?3_?/UF!OZK@&.25BN203PDV
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M9=IO@MXT(X>$79AG@SFOB43'YDC$?0SX-];[F#/0,AQ.J+];OD=]ESAL$_*
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MEFEN(]^5RHPK(#R.5U7ZQ-KF,23K5Z->+3.@"@<5%L;MM[FL@FW6M\2KV_%
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M[D980_)]=F#!95:W$T$S;K]9?L3Y>FBO9]-T3*9WNAQY8TPRB=:JM@)H&5/
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MIP/]=HK)9AHD1@8^DNR438*\,7+.F./$UNR%Y_( X=!E7$/R?AJ3HZ% &N8
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M!Y-NXUN1K^#>,$6/ER^01!4F56T?TY._??]]TN.C.G%%&AJ"(3]2257 2[3
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M?P?0<84DXMO4U<FGT4E*C8+\X,+WT]GPU'_I3_V@F5ZE2&W".5=R-9J4GP^
M@Y[TIS"_SIG9FA\@CC[/U-R8G3VA;41!EDLWCG]P9XDM$;W&6BH<3D:5ZZR,
MM4=VW.Q^5KRHD![=9GQWW*37$*;_[$\O;[VHM^"GUV/HL6"TS\$3]) \[C19
M$5\DS:D*T<2LF:ES6=_5"/[D<>=ZKN =/WJ\U/SR_$N3B/GF&XQC'^=D3T6T
M@2C-Q&2()2Y.HFVN,]$EB9)FIGBN<]>V.=;CYF!EW55(@GSL(&DU8('\YR4-
MCZF(9DSI%Q 2KNXA<B6#L<G9.E[SQE!?)-<ZTER%+,I')\=[^*/YU:27*=!
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M&P[%ATU$7C=*=)Z6GFT4T85$P/J2EAX4[J(TE<R.9).+4;LZYV\/H.S?">E
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M! ;EJB3$P*V,87F?6Q.8\MA37A03NI5YA7N(OZ, BREX/IP=EJ&0$.;T^\7
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MKH7@@&3+I9;&HTO>JA#)C\"51R[6#T65#:3?=:>E?U[_9_]5?S08?>['R7^
M'TPO([K9_T"TU^/%%:>-*H)$'YY2CR*09<=3@A,3J.0Y*!.7BTFN"<QN\[0]
MW^36T=*HIH@[MBQN]]+5>02K:O+>S XO!5-.4S2&2G9SYHJ$<@7.(HTT1Q>%
M;>5TM%HY=D%ZM);*WM378<&*@GL=KL5]9 MDG9LQCV/:O^VR/]V.JBJF8\/F
M"83:0\S"4)*R2P5A(M:+$EI#7>*"@N?=12$=@C*/F##/D3&;Z*-K^^;B\OO
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MHRJ3IHI"GLL=TMHAO?I^TVK .&.]DIIPH5@I)E3JH"1+E!4I0 J1ICIEJ%J
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M4/5N!\1-IYKS/*^&>#[^T/]\.;UU&'%;NRZVT^SPH5Q>H1UEG M"2T,<*Z*
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M7; T9"8\MZ6>WA#)T!QVC@J2%&2024J6Z[4J>-:] _<BP\.] _=1RF"=X[J
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M?;O]U;*#F!?4<;3P+=>!2!W12J<AD)BH,-8+[01KPJ.]H1XK_E:!'=,AM=3
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M-"K%.T5%NJGP[J.?H H/EMS.MW#'?-;5Q^5'F7/TO__7_P=02P,$%     @
MW(!<5$5;"ZQX*@0  J0$ !0   !I;F)X+3(P,C$Q,C,Q7V<Q+FIP9^RZ9U13
M7=3O&T2*5$&03E2:=.D]41$0$$%00%I$.DCO$!(% :D1D")5I-=([X2.H/02
M>N\UH082X/"<<>Z]Y\/Y<._[?GCO/?>9>_\R]AAK[:PYQ]Y[KO_<>UU-7"T
M;FNHJJL"B(B( .^N-\#5(N"!BH^=-0"@I040    Y-=M] #BZR.BZ^V_V]4T
M0!EP@XCHG_U_&#$)\3]&>O,F,0D9*1G9/Y#?HKQ%3DY!3D9&04U!04EU;62W
M:&BIJ6C^.?[G3_XY_9^SKG<J<C)RJO_'=M4"H",GUJ!Z1TST '"#CHB8CNBJ
M P"\]I6$Z+\;X'\8T0WBFR2DURY14%YWJ+I][3XQ\8UK9TENWKQN#;AN!]RD
M(Z&_+_:$],XK<[('K@SBGV(RR;F>EK4RZ@YAN"7>NP7>HKC+Q,S"RL/+]Y!?
M0%)*6D963E[YF8JJVG-U#;W7;_0-#-\:65A:6=O8VMF[>WAZ>?OX^@5]#@X)
M_1(6'AOW+3XA,>E[\L^L[)S<O/R"PO**RJKJFMJZ^K;VCLZN[M\]O<,CHV/C
MZ(G)J<6EY975M?6-S2WLP>'1\<DI[NS\G[B( ,1$_X?]+^.BNX[KQO4UN$GV
M3UQ$-[S_Z4!WD^2^&"G]DU=DYJYW'HA_(F=X&I-9UGJ+2T(7P_C>;8CB+K?D
M(@_VG]#^>V3_]P(+_ ]%]G\&]G_%-06@(B:ZOGC$=  PX(+P,_PAX%_^Y5_^
MY5_^Y5_^Y5_^Y7]KHH]>N5 \[+?-N?Z5]/ZY<2/\82Z1"H/.?QXK7$.GU]SM
MX>2MQ11\V4]$LGXWA6!X^46VD$W:^[@78UR)4;U<L^6UKBP)=S_7"6KQOLA.
M6,\>,G/.O1PVTK//1>O6U Y[-T]D)UD9#V;LK<_5Y."&%I-$64G'':&=72YN
MC?BCG]%6(46<?NY:?J'B-F]4;#+H)R["G&"S]L(3EG+?2,!1O@-18%OUG?TU
MA$I-=5U-3=?9VGMB-XF:Z?FY2&NKD+;N],I8;>=';N&SZ24JKE< ,I"@&E;O
M22Q<2-G7=DDA";V7Q1X3=%3:5E^@'_6\H-M:UWN,A(%"\#'%PY\?_^5?_K\
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M.KNQO3;Y^_#I.E6Q+.<R05Z?J1T2EJS]V>D*L'@3G2 ]+F.CEJXOKNX/N)G
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MJDXI-=8^K47^D"*6^7U3QHD]+BC?WDQDM%*NU*JQ(F1^ETXA;4[[+^E,NN\
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M'KC6SSRZ-._C+!8B<?IX(</HH+:=6(^:1%&H4EU4!KZM)X]UM<N: ]O,T^#
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M9$&Y%<EL);I;_O[^NA+K+[Q^>G9IHQG/;/#*,_:0VW#;NBI'8YW8@P[31T^
M?4EALJ^[;YK_(O'(J&;:'<KWF=>+:X'1B;HNIK#TC$HQ9P#M/<R_C(S>H-&&
M*6W'7"0TWY,NPROCG+KU1RP2> ]-=1<0@FZ97(@_"'M"35@>Y$Z2&F5(K.LT
M#$F(%MA/AN;C&TX<+Y+N/,8YRGR1/,NNJ$%G1Z]-,0(H;=O(1UUG=F8"9 SR
M[%&TG6-I56FC ]XGB-E?[E]]NKFPG68X82R?9N+)NR'AA7#F[%CJW5\8=@DG
M'5JP/WBXLI$C;]9LZ_86:Z3-3F:S:=9>$,0FX352DXR\9Y+'TN/IEC2($J>,
ME]G*J' F,$@8#NU(?A?V #-P[UJ)?GOAIB+T 08Y-0:U,V;A19H085*0'>W;
M=LX7F4U'39R#MX?Z'G+[]BL(Q#+'M"!SP<Y1G-O:E1AD!P??Z_!Q".D6Z2.K
M#[X)PP5OF3CP,4=(Q8N@1J4?!$T<WG5INVA 7)BWXZ=1(>##:ORO5M?6WJ ,
MY#!*I%^NS#?VC_->C:]4$RH1(R=@.KJB)+@@LV/UD_"H+$%G<'Z[/JYAWDP<
M,5?M7J;V."L: /CJL$W[\5I57V8LA!F_&;4(/#]8DCJ(B1.DCQD,&CTB%/V6
MHN6!JHA/FOBZ(/]F_^J&#,@B,V$W<><09EOZM[/NGKF%7,_).PK=@\XH+I:#
M+%3O&'KG)-8W(K1I8@>W\S#IW[W*BNL]4P.!M:P\]T&I;[;]?78S#9=5HJ46
M!"*)7A+SID&R'ZK8QXQ?3QFV_YEEC3<D'/.=]T!]-MSSAWV:L#=RVR;H3L1M
MS44XL9GI4Z:_[Q[HPC^736>,UV&EE-+XM<OO3)P5+9%%HKN2OTT%KRZ(:V:(
M2#G',W@0'Q1K Z<V0 HXNE);INJMW?PI=39U-(O>-+KVW$"KU$=!#;,;]_P*
ML"G1P_2]3JTW.S(9XQR6P<#4QDF.EK(^6*P8,?<ZO-7JYD-!YO92$)MJPRL>
M;U3%8QDW=GQ@DZ:D]^$L;V&N[@?T)78]!,H24&!BU\PQLK]05QN^^4=H@,[:
M91V4]6D7\I.I@#9<TO!H6_9R<'@ANP6C9[\[C3-8I0W^P(V!=Y:(+W?\^K(+
M52&;OA7\94KSMHL+R!P]LL9XNK_CC']BY'#.6;+(-B!Q22_,N3@^=+)KX53J
M5?/RB0XY*&H7$HM)E]E*"@U);.=-ACD3SMD][&5[N]T79ZVW%^'A5X#AE+^&
M*>2&+N3K9-OA9[27% 98C6T3S$ '99J4OE6TH_2#(N9WUH<L*>E9@$\#1GB9
MI72$>XZ/JFAY0(H.EK-4O;+*%[2$H4+."*S WC>"3PHOXB7G;UYV^[5+[GL6
M0'Y+:6Y'34=H-[I>;C 35],X'%%-TSW-89&/:0B'!Y2<ITD)C>>MW03Q8J/#
MO&V*[+PI+0KMRBDCWKY![$W<^3A7-!$$<8?U@*MSX[!Y[9K.!3.MYLLKD26=
M$8^N ,^YBF-.[AUW.W<U^B^NMVCCC#*H/)][9$>#Z6WY^A[%(:K;+M,W#!"G
M12V*ZI@335&&BRC+VB'/%./8GU86[%_%%.G5SI::C4-P@:40.UFDC5ZA7/ZH
MR[S%<<1+S)>XEUI/U:DJ7.;%+E_/&KR-9OD9_;PC5N(&$7BX60KCW8U S)=W
M9>39S4EBCKL[M,G-M9K+S%D<,BI2%Q*(J:-KN4 A]9O@A2P8\9C3<IU=E;]_
M0JVQA?WX"]YJ)Y -R^; ..IMJ[6AWQ6@R9,I9D-5/<,'UC]'53T*DK"C+JP4
MYGZEU%<IEO:G2?4QZ#-51EMSS2OT'$JVF>5RN%[[2X>;[7G>]R)#\=]<D4E[
MY++K%H )Q</P\_UV5-5N2 YUEIF=S+AKWR?)SB A9>*U[ER'[?(7O<'R[/&\
M-4/G*</)$R=*C=B7Q(S44;UFQFJ2CLURW^1E\KD>Y"+S9V8>_@S_\5_^W?I?
M_G^&Y.#$Z0^R5UHV[;H2CBO)!K2OCO24!W,C/F[QI]3H& ;GK1!OY)(NE[!]
M 08#0.'VTBKR'RGX2UK9KP#'FYF7D$;MQ<?TK[0&FDC*E1X2C>HIVS3)TOH!
M5'<-.65Q<5D$<"#?F$C"';D.6])U^(^2$4+1.F1*5[VX662Z+^#.%<"&S=+8
MCOS,VW*/A5#4UR?FWFZ^JI_<P.NV:L /NQ9RE5XIRP]W/91X,4VIGWM\ZQ\T
MA']]?0/.'GZFM\RT2[<8!7Y=4=&,KFR RRM3$>V]KEZ0,Z%)J\ 9:.)?V-)#
M]<:%">#L^32!NY]*G=?"W 5^R!H.GKQ7/[UG( ;'TQ(4L-U!]XP':"9G>ISI
M;@G2SK,O),ZGGFQIP>!Z,D7A^65BP5,CI@VV;O+1QIR^V.MDK;X _LRJD9,V
M.L<]OCQ+/V'WQ<KFG8MXAV/K\0 S,N$*8"<:#6="V=X,7.\T<O !MDVU.Y>/
M+/'8U*ET"ZU3J7$-NL_7S,R3PFY!E7!$B]1Z9K68DPCSO,G&6-^#9\4#VSW'
MVYN=/KQEBW!ZV/PY03ZX.O%N8MY4W.VF[U\"R=TT?EX!?#X^9EX.QS4__%OV
M>DM1!/A6\\SS6*ZHWYCS/EZ&0-2(0Y1<(#2JA*U+6=<6+O[8=NMJKYLUX#FA
MP HL9-<SKR0N[R0@94:2]D'@2%?FJ,PR>M,,BYUN.W?>2<,_[,G;H*0R"A[E
M?U]^K[U_[VGEYVL90RF3Q[@.Q&@YW[6K =-5E6B OU=J2E5_#IY-_!J9T?H$
M&(8,CS;03[ (S7NIU==L=^;KETHHT?(&_<"HM2H@/ET!Z >"G3/KZ@>K-,-$
MCK;7X_AM#QZY.YUMQIH4*)$MFG65JRUD)[>;);W=_&7]UOH=@()((;0*^@?O
M"!L_3;^%X0ANBJJ?MS?C;C#F?AM&*HO]#HRDJ^%0RR_E6H+L]A42]'&BV1M^
ML$2IDYK2C)V&+]F.(QR9I,=*+M[$1WH0Y>_6 Y3\YE:"?:*>G@U>FL?R/+H#
M\7NNJ&IP%R4\S ]45]@-[<G;1(=J5U1'[H5C>%\N[LED@G9(%"YO+2[Y0NFE
M'$FWQC4#GAXP'Y.?G:UKU?7B':W 418.5P *#V0XL)(V!,8Z9:)B9?/^U[2)
M!I/;GT=O[+*Y+G*)TX.<Y &"-EWI"F68C-T_#C^F[$[&:UBUANU.XIYV,DS'
MOR3O-UXQH;H"^$<'-JOQ1+T 61R'B=BY'Z"46.$8FN?S&=\SS*$RE2,$FS7)
M$74G"SX[I2<L[)>>N_,5JT%01:R%W4%Y'V?9W8V5_N7X'N(#WD:RA:JH=GMO
M/4FG7[,:+,I4M'\VPT_W;]V_ @1/9W7?5+$(F4Q^(?T:&II\T4ZB__KPN6K$
M\"84\9));_#TYH)>01D5A2?LE_=_]FL,F=\2V-;85P3&9$\*%GWT+:8F]0;C
M:$9W^.ZV:.<<1PW6)A3IL?T#-N!)%X4=M:DM_6 *ME/5,=5CJ 9Y8GN!MWV,
MM8S=V6,I Z*_R'&NSS7?NZCS-$8&H\BJS8P[MJ;"Z=B']M7=7M+(N[C *? 5
M[6:LERW#>\C[2;U3T%V*[-1$0$P<1!XVGWYCI#%@P9%7,TFD-"OZ+>?B X$?
M&C##[GO'?!N/',Y.E3HU*3\BE1.3S_T<'&E%LDON(C*@_HMX2#CDEW7H\JYZ
M3BU:TK_&\"V#XW.6MMU[7B3ZF16XC%*<31OL#BY^<?)!34@_799#,5D_MB@X
MN/DCZ-814A7#M[.]E!&* I02)(JT[*=,.[^5FVYJ4E1TE+Y\X1;)7OID>WO3
MS )/K^Z U6_O1%'/?)=L4NWKU:Z!?YML 9O0X4J@'S "Z0\8LM/6M8PNN.-'
M!E?L_\(15P!'44;1;B6)3CI$!0[6?Z @&#R9D-R7=)>G#'?)>"S3@632NAXY
MN2O-U8&G,^?X6PS&FU_?+.MHK=D;A\H,B%C,(P@V(']5E^5E/-!_[O5\)_\&
M^RD5C<\^PNA4=-*JM)D+>@^S6_2BYHZR;76<[-;>YZX6?(@N[7 ##BB>P+_T
MRV?;3,9Y/6_-(311PC4&"]QQP)847\IMUC!1C8_7!8#U=%S>:%/,!Q6N7P%*
M';;@4Q$GLB/-8CZQ0#K;Q%\3VZ[Y/!I.@?L48K%R/?<,^E!5B3LC?#M5>/4>
M+T/E'%RX=RU II>(R^<*\#&!M'GI(EJ* [P$:9_E7%LZX6<=4\GIB!@1PX"E
MIN"LXH@BC3=NR7]F#%PO/'E3#%9L(BY[KP#L525W.N5KVC,XC7KRYI[_3OX0
MVU[-%7SOXP4-S(1H'E2U,<> 8\MJ7=K5U5)3&]'?XC?<][?2=YRAIP%/ F)F
M#(I@0QG4C5Q+@K-W%<+NO9$Q>Z85R&WM875&OM$N1U9VHU9[$M&IMN2$0FZ
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M69<.O($;T$"+E"1"JX<2U,?<>R9:Z,E^%9N)!Q;LI*)E'+;>85^_T;9<J6N
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MJ'>]T?+!#24>_?XY[\DUAGK\2COU07/LML&(3/'VUV</[W5F/]ON+KX(M7G
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M^,NT;OBCK:MB^3_Y_<Q<9-HWVP_ #M\S'JGMH018H+% W#M5#CQ?D2V]H@S
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MZ=(\CM&Q*L([C%AN(IPP<0X(2H^H'.&JGKJX0NOV>S'U $$+OS8A^M2X8N-
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MB66\91%AJL5> RS9-"OBZ.\ICS@;IDKZRRYF]9N/J?(13+JYP;'(\LMKR5%
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MEO&)N _F"T4X[.MD3H:F;K&^_J,0=_WAJ>OPNR<EM$=9=P7X,,THS)@,-+'
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M[^:*G;M"%Q@0543*9K"D"EI"JKBFY;Y*/M]O75A>F\88$51V\JW8%29L3L\
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MZ;2TK-()D;(*TOXS&&(B$DH^3]1H6@J5MN@IF/MCI'EQ(94WX[TG6P; X'E
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M9"\R<YB!N=O%7( S)+?08X2(&!T5?G(2W,O>S1_F)37I_DWWHW/VVZN]ER_
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M6=6,RP[PVLPJY9<:_T#B6Z%K?*_NVRS_4-RKF"9SQY#921(D,81(SA6%JA6
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M0QQ72->$^(*08=<J':^9HZJG999H12C8^=_WVQE53]CM, TTE8V=6OP=>QL
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M'VM\7'E8W>%A\$OL+7^J-DFQ+2..F9WD^,7DF7ABME1JII[A[B 6R.W<S)7
M^Z,V#JL;1EN+2/I9F#VO^GXE<:]".9AZ-RRKQ!GV@VK0#ELU)2?98^HSNNX
M^#LT+_ELM[-*9V5A'O[S1088IP@>_6CRYNCS\/G3G76=HOY&=FW<)Q(<F63^
M\W5+^05'D0NX7,1O?-4\FA!TH6P^/[?5A^(&3.)!M_W87.L]E\=^D^R_ @F!
MO9%V?JS@FL W$GJ0B5OU5X@+*@JO/(9AI:*)(Z/JM:AMCIK;,VH,9N?,.6'8
MM'43G\(!?R#28E^*:G+  UFO^0:11.;Y3\,Y:@Y,JY-A20UAYBI?9]5>]]4-
M*@IEU55D-,H?2_F5:%+'O8O6DH_4__Z<Z\CVJ!N[5?.^@UF]KJ:<Z!/'+.2]
M"L*<Y(*=-X = 71D?'NFG)O^JI\MNK:AYL/WGR,)CT+]79D^=10^(Y>-TH-\
MZ-F_$H'C5>:G.Z*]:V:!;O,S%Q7U+;2IO*=7@\CAV(4X=/YJ%O]XN7LIW-X!
M5_VYNS--):E-4M.'D *@\.OY:_U#ZTA?D#35D>Q=_@WCIK>WXBJYX)0.Y2IX
M'E=ZY;75_0M9'V6#8&> BY)4Z4#BUGL0%^ZYE54[H9K%EC.@DSOFHN><GV@N
M/\C#96=PRFB7,%^7_Y)WC;MT_QJO<%Q@!0I>V&6$OSF;HP.\>Y@B(E*N!W-(
M$DQ6))QD'I8ATAH0/SP/9$ _R<%MF4!KJH;41_L1XFB9I,QXG(+<83BG&$;P
M)JTU4H&KBUFA&RP./T\M\#^6.QUBY,=ENB1O2(0=?EXW>?[V90-=RRO/P("H
M(^B"Q\?&E]N';R)L<%N-8+?\VM$EU,^:8\D<P:Y+/"\SLR.,2GVRU!8^>\)]
M3Z\>'M_6.)9UG@=N<X2R=RY%BTHT$77>C@9EZ<=SS.JTW[V2^&&GL'L!J*[2
MWO@T)ZK=^,^B[M%QOVAGPU.1\\?&J[[S<B=Q*G>(3B_;K:%F9O(IS"SBWPGX
MS*GNGD?WZ8Y;<!/9/W%83C)V_7R1N9,2@Q*B*J=5W%![L&;@M_\-[77PA!Q7
MXA#C]\;DM6>C&"<(5;C[F$$.ZI\W(]%NJ4[G'490;@M[_B"):Q# &K!?#FD%
M\L!MR<L4R6W-[$+-@XVWG]4*!._[=1B_89]NW+07VD76TJO6/DAR(I089X)#
M# \:Y\H.OUOJ[ IN#'["\.4A%_:4)BK]Y:(OCO\*2EN:"/JE)GA7M+([5^3;
M/CW?HD.3NC%'#809%=A3GJRGDQLS&W[<+]Q:&_]A-JO%,VAM-WVA9N-\&6+<
M]PCX<5]['1NN0N_L+/LGCZ5$:+?TC:C<PI5YDZH8NAB HL@Z)JSZ]":UK+@Y
M*7\2E:#!^77$X&;<_?20Y;KS2S;O#RJ*"#3,#62S,-N8:9182?46+2[J@>?8
M?IER1WN'J46 NA=C[-(7>:S8@5@W<'FB*9T0$:,5!Q?T@,_ %YX97SS.P5H%
M9^T3 ^37_8G:'H*[C7H%6+:2U&J+AJ_I7&TA[7Z#GF9Q025SM!L$2\A%J@]>
M#]43/@Z8Q0=H;F)CWNR3XN9*]N-X>Q_X\228\!-Q1%^C@KN;T-"TNVQFD[S_
ME>1B_.S06$/4;("2/'A6CE2\Q"PFJPP\O7:J/,^=:,FNI"7HR.9%\KKY/F8[
M [P[.@/$0T3\D$2K+"94[0A:2-?RV']F\,[;]>5RK@])>Z L]$[&2\OK/U?#
MN/#IP>H\(\XO^9(.UJ?*+&A/)U):3A]@R ,I)3:ZOK(9 :YFC^]E.ZS<]KF9
MRYJWD% @1+I=KZ?5/B^PG?TI+\IA? ,=)/N]:AR='IXL5<V.7#*_=!(U)587
M\I[]TU(!6:1S?/@.E!K;F-X*^-F#Y6Z]@(L&QE":F4]R]P,A["X<% 3WMA)O
MF2KECUW="PWO.V;-TB&PF+U.Q)V,5\Z&3\V_C$EMN6\L_YE1#_\1M7X@(=+F
MHY02XKTA_W0B)]F-2>M)8()ASJ=O\0P?$Q#6'1QK.Z&=B%>G/=,CU%'*!HP(
M-:A9#=#;[^RS./E9W-!:;S#7^VW3J*<V@-:(&Q=@HX829@;I:0XS)5H%[LW)
MBINH'7?>[@=YSF+W;LIO+SLOLB\NX/HA9'U\Q'TJDK05@P[DCDD.\,G\8V'%
MH'7KH4+WU""O22WC#/]:3])=XO:[GY53U@53$%K\QS+A[\B<8&?(]-+ ,85C
M^%T0<* &V>GYC,%(>U2[4)*O-X;&<?@KC^]DT\N&^5@2T<>!82U%@]E=8KWX
M?);7JUFQ#V)S,V)23[C*M1@_>WHR^H,J+Y41P5%DOW.*8+30:,42:C0N>Y>#
M]?< V[TS@-L@(HGB&ZYBZ$CV(%#2%_"LSO4U'^TJ(>+6+@_. +G6E7;)-R3-
M8*^P]-\W%O8*>\BHXJ6H'_>FV7!2B8=[F]?U^O$YVYBV6&ECJO&QXU\YI7:[
M%]8.<E^Z>EL_QOA*N[587>II^8?E926(<<'.,P":_I.LF"5P0_F3]TOQW'"A
MN664^VN&?/K?G>&:_H)U0HX%U'8RI^D8V,4/<=M/#MJOJQOQ_$G"7<G;QL)C
M5VYI,>'_G1I*GW'0LH.GBJ1\V&P$'T/_^NR*Z;FY!=[IG/VEZ=!^NPKX0WLU
M@%5,=-)56/3+3YD_P<$&S7U;MSIE[?;,",M8R*?J&B5$2H[>=ZKICILHWK@1
M/?XMZ/'2*Z"[_;1Q#S[A7(@V]I%7K!@F+B684T51$*)54(YFG)FRN7:/84B\
M4)-8 (B[O!"*2KBB"O5:D$ 7_$>GS!-^2+OLND!=MKOQ,L^%7(;"#%N,^ CO
MET44*Z(Q'OAS+OBJ0>Q,]X9[NEYEO$U@'U3'2LN?;5<E/<\0.0]H854*@SRE
MO*6NOI2]^P+F:5'R#F/GX;22-SAD0-<.+?Z;8%&VGVZE0><3.@!1U'R063=8
M(3OH'(#N2JRHCJLQXWTC;,[VM-U!7\>*C\F_>SEQI)G;#=2%(Y@T%_V8UV+L
M.@/LPQ1>7J=+0O B*R!EWOA*^@U8(=R FE[L!^W@[/,N=:(0B;T^1CP[?(1V
M.;F$[+MKM9N@+V\]N'1E.\9R[RH96/H,F</5$\&Z*M>V2<_)KJ:F(*$/:5,A
M'2EV$C?WI!)\'7'HP-?-T$5,V"G+>#/(1FNQ5.S[U&_!^EII2<+[@E?/?4."
M&R\I'.$FKHOTX5<#TDX.(EQ>+T<TBRT&?/$OV[IAJ.G_O?G]V/^UAK[_MRS/
M+NJP_?2J]#'$KX2B3T[Y^(:,B,Y=L\!&R];N^;T>RXN_Q4#ZLP0*F.#*>'+7
MV-OQUX,.LU@>]SR*U@B;6><1GL;&3,2OMY>O>-+>4:&YSB"6\?*$(6I$>WVT
MU8SSYO*59<'8%J -O<7*&< =/./5E7T>'DQN: ]F>O>?6<I&U%1/"J6L>%:'
M3? JO[E*T*=!(8$D[$F9VF-CWQ&<J>_XE)/G&<#E^1]/MQ*9M*KF!N"+80AG
MWS_F E"KCI5HFN3JE.T^PN:'W+\@*8RU',Z*?)IW($>IJIG5X5!K2/R0!>99
MP;AB9H!$K3;,M$@KA.&4BPII;Q;"-9K\L%IU]X:FWM(VX@#L1'P(G>4)GAY3
MY)O;0X]G[L_HM2Z],Y&7#Y+(1^/L5HO%VL'VP0)P[VVS2%GM4W$_K=9FOE&C
M.8LV:XY3W<@[*;#9<CZRW.Y(TX_=Y[IBSL()&MH$ZX'U5A,MJP2_3F_##LU\
ML%-Y2EKEN";*13W39MZELUB,OAW(L@?DU14*D*O+6QVD/VIU].5O1=;THS*,
MJ*%$IDC"M:]N^VX>NJ/NDG$W=4L*"?Z#QW2?)*BF6=,<2Q[J!LX"-M!TE%E_
M\$_PAB(Q>!K8B>$L4U&#064QH8W/ITW3%ULJ-]X++UP!^AVG$4]O_M,%+TAD
M>1H;6(<J?Y+H*!^Q>=4<#[7_*EM&BZR[-3C+?U]M.3XNJ6W72BF?IW]%Q'ZM
M$BO>]=&Y*R_S2V9RIH=[Q!2;V0"&;(2?UNW 5]&O[]H1#:[V>S#EPX@2ROI>
M,F*BA]+/6!_1<?7P'YO]\C,F^B")SJ2JFHF]]"8+!9,"5,BF?"JOD\A=KGAK
MEB[C)$<UL+_0Z?$_#/C5:>QMS;8_NJUDNF#6E<TGZU6*&.'ICE=!AYE>4%19
M.)\]T=P=9[U&17AO#V[HPIC"CA]#]- ?'[9R+%T[L*27778<\FQKX'DQ64+N
M:[<(_H2>2C=$ZVY)$O)KA&4=8AM8LM4AW,&M$+@4D9D>E%XH5\:X3 G;FBH3
M3Z#C;U<&L/LI=&DO?ZNH1##YG9*>I#F,;FQ6,+B_)<^@>CT#-X 62V< )_QY
M"YK)^+HL,YN3UVNY8)&-ZO37K]OY+O'[\8/;,'S]"IH*LP8U19H;EI#X5E%1
M:^84\!MDN,5R6U+MZ'ZIE8OOQ$HA?F;FM;:KMH)V7X6I8&)_D'6^7SF7^-C,
MK+B;R/SCEE<3P'#X ^@"KT'ERYG)J6F,0N3CS;]O_9?*U CI_%[&4K>%X%[(
M!JH=1G;S3UV0BB2W[3+*,H!3_^J#2N,.(*L(U>TDI\SZ]&A@8&Z3/ZG^XH5L
M,@VZ4]"!X9$=C#ZJ+BC66):G),V.1DIRT:)^SV@MB*TBJ?>T-L[-TXVD$^*B
M@_C2:CZ]YRR\="CA5I^QN[.)G6@,ICRF:LZ#M\/*$R;69)M*C725[;Z+\CGR
M/X02:Z?1BJ;YX?GL]\J"SZ>P2 5T'XE1Q*D]Q UC0E)YC0<45!18\$2F/V#@
M$J-08:/6V_?[K\ ?63)\*WXV7UB]3IV8)Y(>8>*(I_3]'0S/S%CD%$UCW[\*
M6*YI@B// !>PV[XT,8_8% OW[GG\BW SY8CY!PRD[8$'&S9SQ]XT=_#54WX#
MHA3S2XM8@V/-RWTY3FGW-]64/X=.PD:J>JM<DMX*S&>\BQUK+#51BNU:Q-2$
M-Y58.S=?&7%S10SZ"Y=_<J^!E^IPF^W_-2! 'L+/437 <<UWX89Q>J#1%_95
M"4]0F=6E%7PQ6H^9'@P*C =W8'C1@]."1.;V_8G<^E$+B9>"\65SC:GTDF6#
MFKT+9X"CU<%V"4V/,' -4Q,,F.K-/+7YHD7HZJ@TP"3HRH!JR:*HDGGQ%C='
MG;VD):71[(]'XW)2WF$*++NRH,N<9D^,K@ ,E-G*?@S1U76>^XI%?6[A$+EP
M76%EI/D,,"*3WL3;UL-84M8WKVE" DJ7JP9;4'UU3U)I:@OXR)IY!275#%UO
M+TH!BY5,PDJY.3#UH4KK@/8L8$^U>6ZH^:9LV>^ !"QKSV)(;V0E?_7NAP&Z
MM9@L-*5.7^3&^FF.A42QV\OFHO5WHXD&25FCQXI:,D!&-U)M[?&3/K'$ 7AE
M%B>Y?*?Q@.*+:@3Q-F)J->(DG@8KS6D=/, )_#M>TU5,SL/4I^9/W5T&NO=M
MR6%LAC8?U/Z+^.VEX*AWA[)!YS8G.%XD$(4U[(98%2K2/&A:WO;N[RS_F*3K
MIO3>5;@0FCUF-N:YB]Q-.T22?#!V!7!K3 +'KJ"]L2 3 LZ';(^#DOS:KUP9
MCC5KA"QX$6_7N0^F@ET@H6DU&Q(DWC7MYE;^S,Q&Y?+-1R<MJG:QCXX['+?.
M9XEAP5!5L G9H$65N=5WQ+GR1TI ^/C&&):2;O2PU.P'(8%)804"H2E2^PE
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M.:'MKM$FWG/[/NSVSPM\<9=5XN.ZFB5.,C'V@XS4P<ZC@_<J;Z+2?N0S).M
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M3N+M6+ICZ'E1X'D:?2^*%OV4-[%:]"=B+R3I4@47W-VT2:+!R4-\]3/SW3'
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MM,8'@4(XJ*(ZL3ANVOQWX>O.606<Q^O[E95YIK/!&N>-9[K#^D]06M25RI;
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M2]$#(7HJE92%EM'WLSS-=.VP+?G(1LF^,BU7VGE"Q\LRE! .,GT,B /59G<
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ME^_/TV>N4ZX /_P?PQ>A)SXOCO75L?$EULQ(Y%;TNLIL'Y6;B/D>AA7"^7?
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M2X0TIQ04ANG6CR.W!FHBRD?HOXKVF/,;GM3F8"*.[++KIQ29B??V=]16C-Z
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MVVS(YJ-O&MT2"^YO' QBS]*T%O\';><5U534[?M8$*4CTIL*BDH'Z4U$0$!
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M?*/C]=Q/R+N->:HOME]8D7!TDB]M6JJ]MB-MQ='BMC"]LT[?.2P3;);.]SS
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M\]_QK2&(4EL6=S=-P*[T*J(V53_RL1'_DU_'<LOSZ./G$7)+N12D\5 FB2M
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M#7V<9ZJ\X:;4^KHVRG(X_'?*5[^G>A:A^Z-X6K!^.['*75$*[(R09UKFM63
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M-HF&91\[Z8"7%19.C8_NY6I[3W/N\_GJ/K]TKJ*6;?]Y>?]_HC%(H76&&35
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M$*YLR0O&1%7>>@I4B)QC7!58H<E -.*G7>IKSG=<Y"C+).DJ6M1Y--H[EVR
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M5>.9P5K5=5A(==&2E<I-A)X YH'GQM"N\@@ML$\"JQZO^-#4G\<(/GYZ2#$
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M?U\3T_Z/7BVUCZ0"RL:DO>'@F-6F*\":%5AFW-N=7H586>KT^_9FVNU+CG4
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M2_M!-N6D'_K]KSB5T.,4PUW3/I_%7J.'9PX#P#I$=SDP$DB-Z,T((S9W:;1
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M=+P>'LLA13^I^TF-J83\FE*J0Y)%-WKFS?23G1_R^SQ[91(I3D "$U7CVLX
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M:65!B%2\Y+48D$?*C_LCQS&>GB6>DWMW%YP?_)^X/_-_#G)_PQF=J)HU(/M
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M=D DT[3P1FJAHF/[:H,8GI\%\G 6Z3%3*WCFG'_6P:? ,C\A[S$#.1'=;(Z
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M/7I/6TW_R"XTDJW2(407IT6^O1.0RWKD'J*+;VVVF90@QE'E-><C8-UUU1>
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MR2=3)O(N*:=$6 0EAY<C&I#B".0'4Q17W[S%^<WCJ\?)==&O@XKFLWH9>=[
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M\X/AC4^JZ?^>TQ-L8TG89"'X$N4("FV'8?ADB":!\8[W)<?&GT]_;:B)<-]
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M0A(W$:"-*-G>(7#\&KM0N="H."%_=Z?T!OG;\96FU_>'0\R+2"9$QO:S48;
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MKU\:(?SFV"\5?C+^&S'=QF.)[=$KGZOVA)M&H9YNS87I8[+=W[L;C$>_^>9
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MZZ\+!'54*?2^#HUDQ6J^/L]:!VOZ"J 5@K%M/>ST$2=SPBPZCK>RBEM\=6.
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M=$DQG[&;PJ<CBE5BY=S5K)!UR4Q=/LSC=#QP^;6(![CDE?O@W.7JMNY#+D@
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MN_!=O/,+9]2/,[_U(L_K;"BP !ADEUJ7H?S44],ZV]*S=6"Y^C"LIM6CP\=
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M_&2MBM6ECJ]WM]"X/1O#P#5 %*4,_HYIA1;'#.Q,.$F[&GH8F9R^7-<HC]?
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M/)3;#ZE^:=3#:_IC-&CP:B$3FGSY]-)DIW(!HCB^QY=A+.W"KL4,7>6]DX4
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MA'S21 ]>ZC(:='F&M"7MX6=6NA3NR'+]]P1=8$%>>1%\P!Y5CKA^@+E,'5#
M1#0]$U/28IYR^R<O,]R3(JB2HMN"#/Y+TO]%L'O^N)PH;QUZ7/V4>LWPQ0HB
M5MB-T".E '/ZPJEB.WXJ!D8:GWY4WQNH;.)?\A-O.45,N_7)E5GNH?9DQXY
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MR(>')QQKE8D*Y>_ GS8+9@^=]E4^7$1Z)"G2Z P%DRVEV-J5EZEPDQ0[V.!
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M0U=^K/ *7WRAI70@(UQ$''<.(%0*+P+_'3/DV==&8IL;GD%PN"$)L+#@L=R
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M2$R(-4F2U;TN?)]^_0HRB,H\/M/7JK"0)VD6&M4-RF!\%T?^,WD37_?LV@=
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M9+9*$=MVI[_QV=JYZ?X*[L@O%W>Q>)UBP;<I7B3$\CS\N!-(!^<CQ0B#KD+
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M\]\IP _E][J!%$1N@B"6*6IUP'RR"LN8FV_\24M8FXOU-?HW\7Z ,4\%]&*
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M'60TF!?G=CUR_GTBO94*Q.@O41'4+S,]@'>@4:I))K68Y$1SK3*SV6]K=3#
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MC%^YZM269.N2G)OP %HP!4FZN" ?Y:4K>D*"#J$6!%,#=/J]![V!1:GG?D3
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MYGC#]BM27\FJLU/-Q(6!AS6G]*/_++IT^Q]-_'$)TRP4'$55#M5Y3%ONRW3
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M6=5QXZ5T]<O1)L:2B='Z8L;2Q3!6(I+<10IIY[1D\$0$#Z++)MNE9G[/$*+
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ME+9KHD@MMF@NKF:!-@[K?[$'07;CJ S?*>Z%TA[DF;7KGK5W*Z=S?%C9+O=
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M^%1JO!@/,RZQNXE;->HI9U\Q<&<F@<B9(U[[+:#[@X1T4PLQIZUK,V\Z#)/
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M<<)X<-PN&ALDB7%KR8M @*E?B=#1!>>3C/L 7QZ2U;UW@\"K$"1GWP=ONT3
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M>,%/!&/ZB/QSV._,>&($QOT3>,]M2K[)>]Y4*K[9P\C(XEL^G/ 8%VF3VN^
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MW""<.J/_%"IP"<@7]^J+Y."'.\!P!NJ8N= CJ]V&ANLZO..7#TZZZSU<@T+
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M='$[\1$^,PS=!+P*D<1;38>+O9.]PD'2M4&J^B2$(DV@-+VN)G'DYY1\GS,
MHTO=(TJS:%J_U!Q64?*SESHG.2'D*DDTH+,+Q$FV?SU%\-9S+!BH=TWB%:G*
M7!G/Y :0]@GZ1"[A-D1DB9VOU" L4!@M3A\R*>1!5QN4X&W#H'ISCJR!6T=_
MC]LY:%OCP@Q!BOA*"OY#UOQRWPEX#<X$^_V/;S8)('&$*%C]_V_.OGJ:[J.:
MOJ_!MU%\[W]2RO"_7B) K$ED68O=,I^=;DN=1;_%MN+M)':N&Q>*8N=+;:+Y
M54:I7$3C??/I6@8K"=W*^#[9[L[=I[1_L]_TY0#7A[M.K1*C5MROF2Z*_?DZ
M:]7/5&I4Z)?B=8'WX+)(VPY$K&2["1[=HEZTV<\W.;BR63D_?"O"&I!K%MH^
MKZY,3_(F4(B[N'KL&6 76 J&,HZC0^36YH%U:DREWD/237J)C3=)-#8W3:&C
MYCZG3/'<!<>E+"&%VK8U55$##6X#T!WG5*&5;0J 11LGNL@V>@:H%E760&R>
M&J2JCCJZ/2KUJFBWU;%Y:!^ISW. B#D#@+.Y9HAI6-AL34KSF[>J0RCG+!V>
M $6A-%N_,T!"2"U>$&/2-5=V0VGW+DEW]-)<Y%B9*5W&D2>\AIWN-]/(^\:3
M04@GZ2FTS_PD%"FU!4)S</M5EE@^3O.OG+E@/-_TX5>C(AJU>-.0;D+@ LKQ
M#,"T1.UINEPF]\D3RZ=K(. *_OIWRJ=:\$>B0--/)3FID #$$)P/XHW$97>'
M/#$>$<]8,M:=%8I=$QP0%KJ@0D&F[,&N@Y9SD\Y;F3-X&4'W>#CPHB[?7BYJ
ME6$TEV%)L1V4X@&J1'3R"??".,1;=+%*/$XRI*=@/,UP,A>=TE=A5?+(96@E
M28$8"XPHP^OVOEBRM ;[JV/E%<7N!DH("F"/K">+2=+.C^I[N([%Q)5B:H8O
MSB+0OL'1!TE6W\-(99W?LX*N.2_5+NUZ_H2.^1.@+&-S?;A$N))*C=/[D +J
MYJ?*85=&TG0.L?=Y/9&.Q&*ZF2KZ<<M:\!?DS5NW^22M(O>>]\K>;<A+E<1>
MDE9GD5,01"Y( HWGO=<B=/TP*2ASI7@]@W)S%*)<X;1H]3/?T^S[SZX2,L S
M]J\!]6H,SD7/8?\%_OH%N3, 7-?_8WA"</7;3SM*TS/L\FG4*ZA4[3$Y2YD[
M7^@2D%%%00!XQR/><XX94S,'[KOH9^)OU"GR02IZ@.:FS[ LZ9CT$/H;!CP#
M.,(O_VNC$D.$&50W98R!E P/PJSF_ZCW:WO-K^<H(-IA$02C?KQPYX'-$VJ4
M7,&5CW;TO]]:3A_98.QC(/)%E&R*UFS>P1E@8492C0,?>V60U?"R>QRT7R#2
M/0//MON<3DJ$F7XE@TPE)E\\180?QP5S3N8VV':(AAS/:],NL1$0YSBU$#?<
MJ9NBP70W!SI0@-QZMZ4'20YV$BWG,OV6$V]W\(O\@[;O: '<*8)IS/OZSWA>
MABP%(_G@T;*7Y#3(_$""FV@[CBU#YA;U,K6V%JSJL\OH-0)X6> O8D_[U2E?
M1%%.99YE3VT'?K)_-8Q_K9DWD<@@ 'MB(V^0>P;HJ,'O-3K[!KK[H*TZ+;KP
MF:6_BB*->F"G$S0'L*B6*Y4NCOJ'$9\'6;KBM9ANXVA.L8U**C=G7)H@\F"I
M>=&D.S.2'Z_YM9^LE4$GLUE?UQ)CO$Z?E?:!?:J;'_^=&S)][9WUR*0Z ,TD
MCUUJ7P!U9P@]8-O]L.A93\NY +<%KJOQA^)L"(AFHF?1(&9!;FK)<,Q7X?$_
ML>UOC:C#MEY!)I_)KL1^SV(BRG+T:.&18BK6=,U,^'V,&Z='I_^?7A61!&(@
M#FZ(KX^LU84SNS!YELTT.M:*JEU?^;Z2B<_N:(1?A$[(HYB/U\9\-W;W:G59
M@ZVF/:X**37+:4HIL8R]5SW"H3KC+,X X=S0LI\,2G%6T-Y?@:I:8(_+G*'3
M-P]M."!Z>%@DE3\@5D&FOZ3LV91NQ<]_['8!(N\]:%1"MN=0=O $J"BN]+G+
MTJQ_1FKR_:1%I>#HEGX_QH<*[P#;OVZ:)$'\*-FU";I8O>Q$&<H%/A'MQ&.-
M[G!&(;19I)D1'6"E4H;F"!%?6]P2;+<\]\U@M\)\#JMDEC[@[F*F.3Z=&):8
MLF &D2%&_"2B#_1L=1-<QI^.?Q)])Y0H>UM*RN\S+Z%/446D'Q*,G];!PR-3
M%_<4,*0[33T5.]?Z&^E^/<//,QL(LX$)P93OM8A8@C%[D]NWZ>P :']2U[WV
M!UYMGN,J&[1[PT1A^,["#Z<U$,_6.'HWG<\5$YX*25(7U][M.8?C3;1L*["J
MD]A5W%*4S]*E+?-@Y].(;XATEICP$J]'U6]I$O-B";++AA=&_O/HH12UU^;
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MYP:OH NUMD"07U>,<!@T6?B8.)-C['W_ILIMGJ[5R(*B]:18 &B>7.&PN5C
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M5TW%D]_%BG2>*R6,-T3Z0?8PWH"B7A3N)>B:5<!PQSEOBB;&+G7>=_.UK;^
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MF\9JQ%3*UTPF;L48.^C+RTEY$C-6J;<ASR>.)>*O;YSZY=TI&,IU_+-@B1C
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MW7 ZO50\CZ\)V^70&K%+.9W>TM,(]N>+*$T>V.9]6.SOH$ /Z+O[7EFI\PR
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M9>;+H\\SC5AGGI%;R12GL(?GF-O7)T4/63E,A, NO#]K.S339 ><W3\"45.
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MYE@LT/YMK^P,0RVU/R\@)P>1W'RY/';E!Y&OV)>Y]YI!G=X1"/JK^1^3KQ)
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M?8R5KK\8<A5 5!U^. *]-@"3XMK6W0V&H>[2:W\EC9C1_)]XE%9C&TV2D$\
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M>5R^BVMF'285^@H"LK(T;:<P;04TV"<PUX1#98+3JP-J,<^!16*,/K'J:U^
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M9$/,&-4Y#@V2%%][FO9D$#8A;LCZ67>V</\M@E)!>AU;3M"T+UB1][YH5)R
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M1WGND9VK@%'::EZ^93<N,&].8EWVDA2S@'UPK"PEA&S0PM&1^:@LT9A/D&(
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M2NBEX8WRNJ[[]Q(1R]=U8)F,E'H'. Z(!1JGM9WV5 ZY:&9D>PCPLR7=/,?
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ML4R'"A[-0R.+9/[.P],/PFL#$PI)>R=5P?>,SSM?MF&/IU,4T"^[4F#^C"B
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M\J\-^11C&L>^*?6D7YJEFD6CY \2*W4/5A*QEV)&^SI:SDBRNIN_&'TOK/[
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MM7->OQKV1C@@OIIW-S0*'\*",VARQ>I7F?RR]H@6;5)Z^L+D$& 7IG,%\C9
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M01\E4Q:DE\F*[]EO?G.  0Q$7M*[D>XEG,PN).GQ)M:A/4-I+'5 ?YA^.4=
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M6'ESK>+')Q_V!#H,,"H[>TV;?_5P4>N'@..'@*>!4!/KHM=J-1D053? KO.
M%8 N2%K\XG?)<9@0D696GZIN'P/OJZ[DUM&,5X3Z JGB ^]*T$ +=[,,J4JQ
MRS7ZR=:"_'SD2$&.C!K1M<TR&@O],CS:C7 ,QZ7H5[!P[A0K4IX\5+G#D/U;
M>4+8X/D+S=, NCQUX!# VDQ]1^(+T5%Q+:=UC)ZR2!PF^(CO2HEP8H))1LQ3
MV[G%:2XA)4'#[M%X@_ 76SF$UZ%?,%/0*G 9UVR[K=B,(**KG*:WF!=DVY=
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M,X>K1B%^'ODWSKCEV[>\[13V)TC4 CO"KB&=.>1D6L%7R&.Q;A528_I3J@7
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M0MI3=NM.0P=!?#%+;0 #CX=:9-ZK>%Z^TO$VP1JX3SF'>\7FH1^VI >\\9@
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M'#V>'0X[4(N@2I)U5BRH#C^O#4#NNZ'W+5"<QNT%I8ERC3$3Y[J/&K9I,.U
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MD%+< =$[G>$(2G^K&,P5[_FR_>98;[[<RKF9Q-MVS3!!E%0ND2!<4?IL@KS
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M\TB7BT-ITP&Q$![RIX7<Z 4$*?Z4EX$>LA&A=DGNWJWDZ^+M@ %^-EMB%_"
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M_B#2O07-JP3A0;PC=DZQ="P2+T195G4-[/]R[J(B]W9N7.SLQ^NU)<X#*1B
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M4&'%:'])^[)ICK\6Z0[%J7EYN?1FH[9&\OYRD7$1%I%LF63L^A>B1OF2[HB
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M#DVEO&<C,!F6#G<@PAHN/(<7?1J\_Q'A.RW!T7"<7]@P$P&?MK).T1CR\&R
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MAKKKW84ZA"%W+8W7\YQND[FAMM;3ZFI@%$=!$8D%X^-5$Z#PMYF%D$TI46"
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M(ZO">#L^)^*^'[(3;(IOO8P^;ZT]_^8B3-NH?S][T ;6O2/ELUX9.6+!=:-
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M/I(\BC%'H:/Y/OV5_(.(N#^<CM:.,+GL36C/I[ZD$"5GVIO,E $[#UK%N.Q
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M7B$M$E(&*0\^ 4%&(#^(B5E:)KGQSQH %0$!@(#\Z@_@%X=R"JH&#C.:T1\
MC7V:OH7*"4[V.^Y^UM:RD!HO/O4FBQ0CUY _@.5*WE;[4T<.S8P33@)2N,T"
M/NF1N;)QCNU,:QIH@)A-!W_0 Q(:/2*M0*>D_62KV#!1(QFE\ON7[!A9II*(
M[:B<X33.&^",Q!S< \..\()_^90"3^,U)HKG>@S>06>KE;JJLN XFB,P1W9%
MD8)*TQ/AWE.MF.LC/R7#*N<;[0<J[2XU!6^NY[MB> <^VE9ADN21,'5QYS.]
MV#B<3CBI.9\\S]1,'[$]_F2^EH/2<U@@G(M5);J]N9+"V%1SB8#N>9!3NWG+
M/'D"GS_ .Y&.4M!<'\%=W"(G,5HMH>R83P=1Z!U5B;QX''E/*ST'P:?&8<+Z
M[/JAYT^:W^K]IZU6 _SWA"^V^RQD::245#F"N!,@-_1U!: _ ',Y]7%%*[\N
M(H]LQ*0]D'.QOX*G<K+GXHM6FQ6;H#(\'B^3RA7GUGL1')OH>;""K489;%W?
MA2P.$<BV(?SE2[TFBW)@^);\9>,=I.\GRM=,O.?;6*5D+' WF=*@5JHK,09F
MFA[&J\50UZ;.F+;N\(V4.&'[MLVP F]V!<(^T(P;6?*,-GQ4\!EC6N)3XPI0
MIA=TQHCT<"B LJ4,*<^,>*^_EA4L),I[P=0CT7=!)TGA\J:L46ZE.=BMSL(+
M'1/A"HKNV?01-P-.\W *\\@6+B6.?Z&K,*XU/&,PL#[F]^9'?+-VR%+5:<'1
MTJ!2]7C$6Q%K(39RA,P@?M"U46V'%_\'L+C@K3[,SV&;_0[$@B6D/UR_:XUN
M1VV P#"!>?<@ZI6;%4$>SNV%:#2C&U\.;/.9JD 0 IWH(G@LV]YQ)-30U0V:
MF#/4XL ^J4K)<9#!/KS/*-#ASEB// "4?3F."^$E.R::(7E-%)L5+8EM^HZJ
M7>AE#D3S^>-KKE*.!P-I33#9(++-L$'Y#6K%ANJGIXR)Z_S&\=*]J =A%HLX
M ENBAD$L(HS 0SIE[WK7LX"E.3!F*4E>*=M#R1J,5S9[-&N9IPS$-%ANIU84
ME3HNYEUIVJT:X"Z^@A^H1ES0J$XT(F)!;O1Q>QXH;2=V.$/S(*-.*%#HAM;:
MW'K$F)PX1Z[-UT'V@2_G=X> ZN:+_P*Z!<VTSGCC$A.95J?$-PJ#/0S0>R/B
MSZ9IN4FQ'@'$"78BJVQD8\X<^/%/L2V*R)5NI2S\\PF%K#+S)[CST+OONGPT
MYIU\=%@-A+NR/[27_-]-AG-:'9ZF_UQ&&G:!>S(*J+Z_D+EJPI@4>H+<7.%C
M\0ZX-*+H95KGR;K1I:0&-XN%,$]R5PST*"1__^AJRC:GRV5UL=#O-L/H$B"S
MD9<WRF^=?V&WRBTIL=9=EFHDUWV<K8B[>S-@I(@M'-GBT_R\O^\C2S;YN#W_
M6Q'8\$8H&QCIEO]*ERFJY];0"Q+).;F0BW2>)IL8B\_*.#3"_V*PX6MM\T[L
M4**0[C[*YJ/R<!?]U36E<=I*ZSNZ%*6)H<1S&/P7NV.#YD0NK3C&FZ-1.7*7
MO'WT>T,XEDTAT/0Q0*8H_E5V,S5VG;5N/(__0$:LXB6:+U+B&>MWF_<3$WS1
M'MD8/9_T5HJE]8%?F8O S'AJO&/'F683GEIDS@;G"V6?#%<JC(SWM29,DY-?
MO2'KDJL)-RHN-,A8'R,71=^;>Q'^OA1E<88UFGBUI0$6864AS/,X:%O_D1&&
MGLR>*,CT\&W3P.EPS+C8\75S%HX^U>#V-2$T,@_,)))>EZM+X1KK4<EPO-5Y
M^HY-V48-7'JBZ%C_05=:9*>1:"[% &*ZYRWD*<-JSWKOLUSV UA,7WM[>NI4
M/6AC;S=H"$PYJQ1>YF?+B.S_PDQN?8JRX6:DZEX=J;T.,6(W=BT(W'-N?#4Z
M#+DW]/D#8,/J+JO2RT-W&[\-Z;DG<_'K=VM*+*&/9JEV:?&/B@^MK@X #,O&
M#_ET$MR(DG%I2#0(D.T1K]O0S7[&"S FYUBH4R66K[#\EM>]8IK;/J$RNNNF
M2=EP1DJC1/D19[6(16*V^[N9)^^W4OK2/#01-3_BF%S?1/3Y]+#+@E?2"%FY
MWM^U6!+H1Q>X>Q;0H(VI09,Z4U<+\:ETT?T([#/ ^@K46A^S1'I.;S\J,.W8
M Q81V KMP'%.8M8EFXBY);U_'E\JU,"I.I/RR[<8\A+[>1I'AP"5LQ'O+1\2
MCR+SY=1Q[5Q-_<-O%VHF1[O2*Y]!Y9-G=-'L%E91^Z?= 9YA\@T+:B'?\L!B
M.?'#GNL2XAV.<]FN4J.MDSW!PY@+*>KC2;AT6L3,:"8!Z<G:%.DJL9R\F<Q!
M<Y6$159[VW3N<B5N'I _ +V5= S#N((0<?+:V2D6L*%L! [6PS4^8U[F03$L
MGZ"?)R+R!D.;$@?UG [MV)1/>BJ8SS(';J(R@%(E>V\Y#TQ4;$F$H)?SZ@3S
M6NA_4TM5(,8&B&J[X>*FX!T>^O7B_\KM&O=&)](_FG4ET["==GX4:&VA?\M/
MNH=!]CT >52ID#ZSJ,H>UU;?M*PT)Y';W-C&@\(^?=Q2'9HB9_2+?*M=G1>A
M3'M8SH%[L(&J^3S 76Z<7NK#^CD'['5^9*!?OW;++E=[76-H%X.EB+PVL&7N
M"TRIW;32GLO.DG4<,4.V.Z=[1X=0J:#%!-U[L]&]I@$1PJQBK2TU (8^GW=5
M,YG*P28<Y+CIT@EOT75/G(\46VLEJ0HHH+;:DLA(AT%!7JTBA[),^FS6BX(Y
M2H*Q.LQ\MW7E(\'%>/NET=DQ.K3]3Q$N<XUJ/#9J*:.N&1+<%T_^6&L2#KW^
M$R\+-M'P/"["5I6!LYQ'+0+MG\<I=KWZI5'!Y;T6IQ>6E+]$L?D15-@N-F K
M*?%ZG)%-6-;(:IHZ]C9TT^P6C&^TV%S&=]R]INBI&0>'W#"#_%VO5";1-<2W
MVWXV(;?7@I+6O0ORDGFV4H5E#%^Y?<82^;3YP<1*0QVV//PEW+"@&8?TS,;:
M."UN@T'Y-2F:0\"FDW>8G@-^0S+W=,[DB#U5@'38R=0\515HY&=I2JU6IEW#
M39<7G/%SQ'6-*U/9<^-X#<.M3*FP28&7/FWE^R/PW",958#+5X]:['MC<[[#
M2U]2'#K. *X?Y5RS[GG1&N?32C_4<]2S/%!2F6TZ#S]GLA,C.[TO!^,BV E/
MY#$T-=:S=*17)B-/^F$<7%6\_Q6Y%@*3DJ%KLEYS75& IGBZ0N,RX@.*28]Z
M< PX/*>QJ%JCQ^Y/(+3-&%9EVZAVVB/SFHVL.<_N<&/2-$]HSU/FS-L%ANR,
M:R.5#^&"^Q^?7:.EX3TKW-CA23_L:8A0Z'D%:QAZ74Q^CG(")=2X^P3!7UR=
MFQ"Z=4AMXO6!F^P)C*RU<*5//_%(C2)Y&?B:+@XP]-+95-K8'-3*RE+WS_AD
M.3N<VVB=4MKT-[,*Q3EL5'X5"3Y&KENFP'[,[$6X[)(JZ6=5P?'[G\:.*+ZK
MP"94@QBZYS^GW);#LRH[12=4[N&[MHRTS3U>K&2F[,'C[PPGMWP6J8V43X=
MV*,@2EZ?][A[SZBO/S94U?+^ NX2F>)C*F-C.:?&N+ '9_B.&8M)Y:WYYGT9
M?Q6"#"RSZ"GQ&W8CCETH)"UB(ESB;O+T%U5[63S*-(I_0!)!'_1O29D#J%'
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MKA6FUO[BE,U]?6V1D7$PN&N!"PFT>\KZCB>3*W"7\$BLQ^YI_U!DGJ>S,LA
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MS*C&S@ G4?!MZJQ)NZ6V=7EH(UI0@G7U7=\359_DVPD;9PZV1]TM%^6>D/%
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MPH:SB7 9<;VKY"0QF0DA\;>SL,OX39*)X%H*0] /"RKOY^VI) P\UU0E15/
M0R 5^VIA,'Q1%'!?J!DXP4]/5^MY%.=Q*!/:0$CS.>T\;FHJ<,PIJ2F*NZU4
MR;HCETO!48LDJH750V%Y=V'^3>6^ZUI73R=&'(9L9<U$>]+MQB].H-Z*48O*
M;)&6%)_G'Y?M/R,%GS1$\<<JO8PF@DFF!ZHT<D"?'V/53KD=G*5)]%QCGV!A
M&%M29?^%I:'+Z>]$AV 96I:NVT.>B<*7*SU42)Z\<.HQ.K;27#,)=4.);T>
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MJW@6VRTJ0X" :![Q>K-'G4H@H3*1DO@V^2FV3+61&B>8T*/)MM$HS8(]A./
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M"P2(?EK!6&9/GGX?2;L<>]YK*4EI<>YYVQ-/P,S#_?X4?51"Z&K2>6ZSODY
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M43%9,:?O.WBL) ,YF O$1S7B@MP+FIJU'38Q,CB?JM!Y&SD"8M1^V<O/O;5
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M5LS(H(:6=F$\';]!U?C?**V/S*QD!Z:CE:6*&'F'E>_N,B3H"0FK@$+93^:
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M!9^MW(F(Z\!YI7T'KW=F40'G9:@JN)-?ST)!8^@SA%U?@R_-I=Y@)\C;4+Q
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M(2/8WOI&QUL:3?=GU2K!5C]6*-=</-DE 6]U'YJ0:YJ5]\90B0-KZ0YAHN+
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MA$]<-99=\2.BA )M$'[NI:A*4IOT\?+,DD>K)'/S:@RO^NU0!H_ZY+ER4G;
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MEB%] % $IM7VV_6LR6?BAS(>N[]NQ?(9ON\]@SE'>.4;BC#L&T7.O#3VLSX
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M"2DUF;=N-WW.='@8A3G7?D[VL"#^S1XO9(^?&Y\\1E7P2?TE%L@+QY!MJ>-
M=.K!)V'EUN<&;B/O>MV[H1*-[ ^VE[TSLK2^?GZDW]<#XV :%'_14WR2&2K2
M;.8VTKZ8;\XK2[G7Q\P\L\.CS52KW(O36UNMJ;?7SWY?$%GA?WZL&(-H/O&
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MTC3NNDMET]U0!$/1EAJ*+UKF0RLX0)5#30F?6Z<)*2R 4BIW+RD,[+3"*VG
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M- ^W$\NCDU3G3U6KF2,;+M37(./3!HJ H#*%6+;3P\]J@GLD9U7>:YF8&:/
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M2>6XJ0#_C.@R=!X#?H,5T2$ %AQW.1U@602;)D+TT+:]Z/>*9HAZVO;K"H.
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M22!E5SL%-L$*@YF0%I"Y!^$AWTGHE[[@;DK8A;6JX2"%!"B._%0Q06"MVOT
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M.4_5,@X4"V=TG6H=;<ERS(VNG[U5?/ZK,PQRK4+/UL+@?*?.%[IK\U@>%OF
MD4RQPLG9K(%U5Z=N47F%.ZOS>G374&_72FS<58WVD])4H=G-@D$K X6M?M &
MNO(OA()A)VQ-^]0F1_*\=9O R#!U$Y&#AV6A&%M;JQF7:-[]^ES%7VI<_7KI
M'Y*Z[7RK#<W=\\&+O#[KL]#N_RRE\;)'U7YDP<\/P#M$LYUOVT?4C9SIH=3Y
M4<]!-7DV+=P>;E?KU_UE]+GUJXK7TDOZW)OR/X+9%IRC;,*LX2VQU(_L_QC!
M$+>I)I&_=1HI,EQD#\+RIWU3?FO+D!^8?S]NXIO</&CI+E&F1>S'O/9'(?H
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MIW)S6O:6/ <TZ@B05\$PT1U-.W]AOX+X)AO^A2_R-_!?!,-_T:?^1OX*.*
MMX_6F4*--V=E-C7?O!HF_?'Q,HF4_ X6H<SZ%,GG$?8F83#4_8HL;W@7]ZX1
MP4 @@W!U!3MGX-QS&@R3W+X/0#.K%)F3]V!"91I4QE8QK1R  ";0HL=G928U
MQ^4&B??O<UKO: =W$2J=&E2<YU-C6%VI: )]R&'HM<7"DP.-YRB?>JF"PM4R
M^BPGP5+#4*((I4VLG6!]^JB?T9T514[N'+BL<QK0"T:H57<]$RM4YHU7F+KK
MJ@-S9=;+>R539G/;NLD3"+2G,:F0+++>1;FL1<75)N;VN" A>*[$:(Y<PA,]
MGYR>_*C4=S1>XKB$(;7G@JCNV W0ZH ,;V4\&9'FF5!'>L[R7 &RRE4K3F63
MB$)4=ZA56R$6Y9/$IEJ<\53=8<SK^D<UKVECVAS3J' $'WIM*FR<C&LS:Y0!
M/N^(^C2J',^FQQ/$M!1PF&/_ "*?^1OX)M*FRS6,;X- 4 HDG7=WIV&H/<7N
MI,<XZDM:?N0PF&#LW44I_@;^".%PY_Y%+_(W\$UK66:T-'< -SZ5*I&>FQT:
M9F@H-#=!&^/J56A2K_UK&O\ $"?>F;.P5.<N'9?NG[4UC6@-: &C0#1:^2J8
M7#UHZRDUT<PF87#TX#*+&QI#0A0HM>*C:; \:.RB;IU"D\YGTVN/-PG[4&-&
M@ \+!0B 1!T1H43)-*G)U.1L^^$^C2J !]-K@-,P!CPE.PU![.K=286B8&46
MGER\E3V?@Z1!908"-./VJ!?OM\\U# 3C*IN#9)59W6"$ZGEX*83*BJRJ52#!
MXIK@&H/'O1NG-67N1.55'9G94QF4#O4J90$IM(IH@1\Y5"94:7U^K<XP)51G
M8ZQ49<9//UZ\$[1-#<KIU3*8E9 -$&A5*>D(5 T)U;DNN/KS3JY'KQ3J[BJ0
M-6JUO-8BGU>5HY)IBR89'TI>)">(W0BUIU1P],Z!?!P#8(TR=4*':!C1 "(*
MRN4$+ME/JAFJ=6ZS1-INS25J .2=NIM'SI49QA$NX^2!5CWJI[&7AR3)IDS9
MJ#NMLTP/WEE^3KW\TUL+*#H@(1,>"K.;?FF$F?J1?"=44DE8:6NS\1HGN%09
MG>T%\I4W>O?]*GL3MT2A9%P*D(. 0YHU19!TJI(B$YI=JF4(,H- "R0LA0IS
MZ_FFMCYT(E5&)TA 2G*LUQ(/R?E(/ZOV/8XA-J-<)"!E&>"AR@Q!52@YQ/)=
M7$V1I%R;A>:%%H-UE T4\$ J0^E3M$[=39JG-*RH4Y1I0G& G7-O-,4A$-0R
MA, )]<%E')91\\5*?((-(E95D!F0G4@TRT70:\.)YJG/%1"ZUH6:=?)%WN1#
M"FA@3B(1 0CPW-$IH 'TK=2E"D@(1$KJ[IM.."J *HU-$2@)W%%4AZ]_SU 1
M:LB<(1A9 4!'<G.M"+3,IIYJ)18B"@"BW<-52'TP"O">BT'5=5F-D*3 +A$-
M"RM3:;5$?')A9P@9^='B0G6*:Y9@43*)*:#P\U28TZHTV<DZFA3"@<E4I"V4
M)M&-0@T-T^F W$SN$-U3ZB)E-<FGX[BGWC@K\_J321Q0T^:R]H0=/Z!U*=$V
ME$RLC5U7)&BF4LLIJ;WIP^FHU7!'5 !5CI%E'>B(033\=S@BX*5:R;I\U..Y
MKB$#/QYA5"I*IO(5BK\4%*?]-AH4]$P$YTJ0M=S#JI4A2$7+,G.3G$E!I4(<
M4QZS!2/F<Z)QYJ84W33 33\8E$SNX!,>B-%":G_37B/-,)A.$JH=TK,>%E)3
M2I68H.*-]5 3SR30C-H4IUM$T!9N2S%,=S^9GN3D 7:JXT0<X>T4Q_>LW-2/
MB.[EINL@837DH:H)WW_39B>[*/%/=*FQ1==,"A.L@=S=Q*J<$VPW9@IGX@3=
M/F(NA=9Z]!%RX%3= 1N<WDFF"C>$$7+.4'$HV1=*FZF1N84T;G&?IL#"JN+H
M[D0$XH"2G2(A9G#BG2Z.*!*&Z=U0:+.%FDV*R3<H- W@2F 7^8WF_P 0BZ#I
MU\E(X;N*E!.4!-M*+W$PLHCQ1:$#&J$)IO\ 8J9]>]/, 1]-R@93A*J-B$T*
M966Z#4ZR:^%UGKT$UV;<1*<U-:X+M+,1JM0N::$!'S&YF\&$0LAE>RIF4=S4
M[<5H47H/E/;,0@M4PPG.F/IK*D)SD%)3[D( 0HY(-0CBG-:>">P<$1":[*FN
MYH)UE3=K/DB"JINV%3-EQNFCYE>T;R8T6=_ _4CF*&9J:WFH6BZSFC5:@\N6
M65E"R-Y(\D=4! ""'=;Z:3"<Y7W!'1/U3-%"D(WW$IP1$()CM4;Z++!6?@JH
M(@\U2/KWHA-/S*40CHB;P@VVB,!6<H6;*G/7M(-";3CS6595*C,G6*F0-S7Q
MJ@Z?IF]$IJ=NE%H0>1X(G1 A2&HE%IX+M!&#XJ'3W+AWK.05G!L4]D&6JKVF
MMC@L/?UXIQ*:3/S*5"? :4V[UFA&2FMRRB8"<X\2M5E)36 *8[U)\$.^Z+1R
M0  *=<H6C=9!Q&BZP\T#/TQ(E%BB$[>0BU %R%D\DH.A-JA&Z<U"-$6Y?-$7
M0G7DFU X1Q1XJBZ$3.X/*SGU_P"$'?,50Q"!54]GUWIGM>N]..8B$! E%\^2
MFR<)*#43>R[2;(U34X*47+4_$@[F(?3)T)W<H*RE$1N=V2(\UG;'>A-TYJA"
MH>::\$&4(FR/: 3FV6D@\4 !HG2J=G(1'Q&F%G[T*DH']LD+,LZ<[-Y(2JAM
M"XV\TV!,IU0Z3N )64#51-AHFB-47@)U24VH4YSC$%=OFA)30-XW94P#Z9OW
M.E%SDPDS.ZHH=*8Z)49DZG"B"C*&J#X76>O03FYM$6D*+%:%,,C<% 1WM<@9
M_:2Z%GE..Z41&ZJ=$$;H(-0$*I?12 GU)1DIH66$UT$J931*C>$U94!'TS>H
M*=(5N*>X",MN:$1=/ <HX<% Y)ANG .CS1ICDGB(0%D&A9837.$W4\T1RLG-
M37%J:90W.^(UY"!G]G>^-%)*TT0W&RE$V50W":U1R36\T"&IS[)SCS6;GN *
M 13BF&Z M:R)1+N!32>*(TA-)M]-"@9W1*J61-T*GKT$U\E99"(A--TVZ, )
MW:/@@U0LJ+$X(SP3\R;F,RF/A4W9MT<U$HB-['?LSW?$;N=NJ.L@9*:$$2C)
M/@H*(U0$E"DFL53LPB91;HF,3; HH"%" 0^FKFCANN$^"J@C<$QQB$YH,)S0
M-$RH6FZ+\P3(,SNU0W$(MTA.;9.!:4$'.'LVYH51QU0J2FN3A/Q&N*'[&\HH
M3QW!JRA048XI[N2<[FF1>RE"3Q4$\4UD*"LC8* @H285@%6=HH0$ZHG+I9&J
M5UG>FO>XZIK!"Y_4B4/IHY3>4>")E5&K*B(32@Z$YTIX-H39BZ;9#11>%"!O
M"(W2JHT6B81=&F=5<*G4]>_N1?HM4!&YJ&G[$7)SN_>U:(U876"Z>^5S42FT
MBLBA!&-Q*(A4WQ*?5X(=M-;"=95'*$+E4VP@ZR)0NA]-'[C(5DZ_DKRH9Q"+
M.6B*CEJK\4'.E"(T37\%V>2)W!$;G %IGAHF^U#D0 ;)M0Z<$YH,0LD+-&J%
M0RFG,-W@A^Q/WG40@851YM=$@H!RL$2' ]RI7/KO4[FJ2HE%J@ITJ8F%,FZ9
M92$YR-]5"8!*X!!  H!H^FCC 1<@B-$X)NI\D6(M/N0<-%DD%&RB5U<>OYIL
MW0-T';VIV[NYJH,I0;F:B(*8[FM4YA*%.$UV5"^BT3-/V)^NXBR+UUBU3:9F
M42 $>U9$91XJ@W>W=,* GNRHNE'<"KQWK+F75^O13K:)HW!<#Y(.0^F;Y7-2
MFWUX(M3VPA4/-2G  H>R$Y@-X64!%HA&Q\40(L@YU[IKE*:G;ZK9U"IN-Q/@
MG,M*F"@Y-B\[G-^I->-%=-,:K-^POUW.<;IS936&4&:)SH"<Y4F6)*><SHY*
MD( ]<]P1MINU6>%4=FA6CO5RH4<K)K95@BYR#,VJ@!"Z&JM"M*:;?3-PD(B-
MP=E1K0G5 ^W)!UT-)3]4!+1Y_:H43N>U$QN 0!;N<I"S0CV@G#*X%,>"V%5I
MZ%-,)CE%ES1:0937R%.YKT#/Z64YR)1,(W*#8\T6@768)SI3&9BJCL@A4FS)
M.]J=N)A.=*:)G<QNJ+4!!463C)0:B0-%.8H-CS65'<TPA],G/5B)*$*J^-"L
MY*IQ=$<E3<Z#)0EQ6@"GFO!$K4&4]M]S"I'%64$ZK*BT(N<.*<93#='M-1;=
M- 5QQ6>)E&H%_#YH.''>UW)#]$47(N)XJ"B GR=$UL+Q3RI39)NA#&VL4^7N
MO=,&0*0B>2!3HY(HW]I.B4'$)MS=-42LB=I93!OY*\=RJOTRICD*@LB_DK\4
M$UOTR?N L5%E4N=U-I3:2>V(36PB43"E"^J*<U1NS2FO0*MR^M$3HGLC<U,>
MBV;HG*4763W$II,JE<&4:9F4T[@AINS(&?CO,(F4 B83G+-EU6= S*>@+IC8
M51_!!UUGF(0NH0&[1/1"C1-:@@5F4JJV2TA%_9A'7<7D)CYW-0=E0,_3&IPW
M-<CH83Q<IK27)E(-X+1/)LAHH140FJ!:R($)\#1$E">",A,J&2$#*:#=.$JH
MR-$"04TPFD$)S)OR4'1.8!$!1"HNU4RHY(3Q1/)-<GNE24''FFF=\C>^5!G[
M5(1SR$6 -T50DGP37E,(A.=*IMUE.= 3S*LF-31&]SXT76$G6R!E7X)HGO0G
MX@:$=$6R4ZEI9/!:$;IAA4SF0&J=P33],:O#?*>-%3IKNY)Q3WIE2\+@$1*C
M=*)E/T1U34YLA $$JF[O]74[G,E/;"E4WJ;>*(E94ZEZ]?\ E 9$$U.')!W!
M9MXU3--SGJ4URS(ZHNCS64DH!5767$H,E"6^:%(S*@0GN3C*8V539$K+91">
MZ%FG<WBFB4&J(^(W=-U(51DI]/*FM5(:H\-S?H4)X_%T[_B^:D%"?T]YUT4S
MIO)C@2KG33X]03"R%!I"A/$0C4CBNN(XHU"B7%,L53?(NB"H*@KQ4-A/"*XA
M  M51H&B:FGFB@4]@(T3F93XH -0J.Y^":9&X(M:=1X(R#9 J>:?'!-* W#5
M,T1T3PA&X%.* +M>"T4IYE,I$DRA2(67FI@*H[+IQ3GRHS1"IL$;ILGN3G2F
M-3K+P\TSO0*S;H"@()[@WS4@E#*H3V3KY*!*;861*YH$S\?RW7DWW_7\6?B3
MR4=\?6O.?T,]V\E#OW$QPE SPCYBK5V4!F?HJ6-I8DQ3,[R[+P1C4JIBZ%,@
M%XDIKP\2THN:T',Z/)/VI@Z;H=6_]I1VI@'?\[ZBJ6.PU4Q3J ^:O:(@JO79
M0&9VB_*N$ O4R^4H;5P;C:O/^%4\51J_U;P^-?T)LTNY)FTP[%"C(UA?+'@N
M+AR53'8>@[*YT.Y)C\[<X]DZ;MI;0^ -:<LY_J6"Q?PO#]9EA-TO\> H1="?
MVE4L5<II0^U!LH=@IID*0I"<=%FX)Z<N(\TTIPD(F"B^(373N$*LT1/)/,&$
M#Q3#Z]Z A.7WIP3#,HB4X0FGDAIN&J9HCHGZ[HM.Z;H'*LUD7?6A3FZ\$25<
MZ\$Y\)QS#P0!)5*GK*T0,HF$\R@V2F-A5D!E3;H!0=_$(V"JN+M."!A"IZ]!
M"NNNS("4T(M4)K?BF;0G.#02[1?E"@7A@<)*)M(NA,7W&?+B4]]!EWU /-4J
M[*Y.2^77SW5L;A\/'7/R9O9M/V+\KX#_ *WU%-VI@GV;4GZDRK3J"6E/+*;2
MYSLJ&U\$"6NK7_A*&U, _P#YPMW$:JGC</4LQ^8_H9CA,K%[4^"U,CFZJA5Z
MZF*D0';J^(IX>#4,2J6(IXG^K,@(V:>Y8G$'#X=U6)A8#:7PX.[.7J_K0^8!
M[1G0+:V+=B*KZ5-W8I:^:Z/V>[NWW':^2 9"KX_'XJK4I4 6M!BPX+$4Z]&H
MSK7'-WK!",,P\2$=#X*LSX1M'J3[,K\@4@/;UX1_-8O9+L&SK:1-N];%Q#WM
M>VI)RQ%Y6V_U>W/\5LW9U+&-<:CRTB(U,I_1YM^JJW&DC^:;4KX#%"DYT"8=
MW\E1>'TP[@0N9YHSP1<T+,WF/?N!!1R_*=">6]6Z'AUKJ@UOY4;_ !'BM+\@
MG.:P.>[2#/N6*=4Q&(J59):QRV/B36P[6O=);^*^5W<%TB=%.EY_:MC.#<"T
MOL$',(EKPO/XY1U056D#P75'@A1*ZN(E#2RC-Y)L1=6X;CP4)]HE.A293-%"
MJ, X(7F>"IDRH5PIM#E4IM/!9%3F?7>C$"/-'<;A,%SY;B,VJLTH.D60"A#1
M%.W<$XPKRH<=5  6I\$# A-X[CQ3S=3RXJDP'4740(1NIA.<4XZ0F#<\SJCP
M5/U]:FRSJ>:[/J5957E%@U3@C9<5)'L\52T]=ZS1 ";?591\;Y0'BML8T4QU
M+#VSKW<EA,WPMA>=3HFV:!N'>MI8W%T#DHSV^056CBNJ=7KETZ\N*V"9H.=Q
M,3Y3NV_$T1FC5878]*O0HU,]W S95]A9&YZ522T$\EL[%U68GX.XWF%5GJ7
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MY"!*PDD>XS\*Z&M,?H5MPK2DI4[UB=B86=^585>VE[C8&BE,DA*I[N JU=2
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MINK%VS [+:=/=5VTMI]QE0B%'3N&U6;QMKAJX&F10]Q(%*RW&&J<;U0ID_\
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MH'E/QTKI.VKT]6F_X46EE9' ;=U(M3OQIQF!!&]97,G5)/8&PKIIACY93B#
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MC]T;P^H7X5=.9$*\Z:3UKGG5\_U0ZH4HYBJ1-01JD%)YG\*OF+,VX=N&TJ?
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MW17I[HMEVB%$!]0S#[0$1[M??705CUK*8D($K\3^%=/[H(PI-N%0I?W&L,6
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MK>=7B+[:M$@_.L8(M[YFZ08S+2J1XB:P"Z:O<-MWY!E ^ BG'4H&E.725G+
M.\@UTBL+7T1Y]*!EXG8MK)["TGF#MPW!KHMBQ7;JP^Y5FN+2,JCNL+U'N%83
M?)>M5-+.5Q(TJZ+A=.;F:MDG,*N%96D)&ZP8Y=]7BE87TA;2VC*WB&;,.'83
M[J6TI20O@=JMF24I\?OK &5-,&?K ?NQPK%K)#[)<R]H<:Z0VR7K13+:8<3*
MLW]SM?=71G&W[VT2E3OK&2I"QX'*/E5V\2#KVU;FD I)+FO*DW192\K+J$*R
M'EV3.E8$A-Q;7%RHR7G#K_=6:OCZ)TKM.(N<W_:C2FTJ65E7=E[J8M5.F-2H
M[>5=)6GV,(6DH*7'("CO(S0.X4+)+0&D9=9[SOXZUT?P9-[?-O:0CA2L([(4
M5 ::;5:V2$+U(,5TI5&$O-H3.9)!5]FGL,/Z15E$B5DGWFN@ED4XHT<LN)*P
M?,'[J-GV0G+J)/A73=E2',.X%Y:@3X$5==*F>C[;-C<LE22@=N2(E(/#QK#N
MEEDWC#MPVH"TN",R9TD"/G5IB^%724%%PDNG9/C6'X>EWI+>K5JXG(4JG[2*
M]"4,OG71^U:-R@*3J#I7&. VKY_M/C-73#;Z"%IS&#%8O:JMKE4B$2:</;GZ
M@KI62F]PNX5LVI>8_P!Z(IA276$]Z!\JMK@L(+JE94("LWNTJQ9ML:LKYT)
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M<:Z8NLN8H@(@NI4 0GF8&XJQ0M& H0Y[7HZY\P2/A%=#T@=($'^*XX_PKK<
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M#*(_PBAVIS 0>$</PKI/;'#\=2^P.K"EI*? Q/X59O=?:VSDR5(29\M?C-&
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M.^N<>0JX_4.C_P#I+_\ ::Z+RGI*CLSVWN/<JAM]&^DP:O<3PIA1M+M\)4N
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MTS+2,I$S5_T&90TX[8OE"TR<NOP,_A71J_O++$A9.N*4TM64@F=MOC^%?T@
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MN0$SPK$+/T9>;=+FJ5\*7(V.]7]F'IY\Z<L+A&L2GN_/WFCV3!!FMMS_ *Y
ME21S('QJQ9RM@ :5,1Q.NE6[3MP\EME!ZPG?E5K<MX<EMEYP+<CM#:#3V)-=
M7.8=K:L0Q)SKGFD'LZ3&E65NJ]@:[[DD_.K.RZM+23[*)FL:Q N.&S85L8TK
M"TIL<.6\K1S+VE'C-73ZW[AY9]A1.NFNL:;^-" E*1PGXU<1E--:.&NTL"NI
MRB2)INQ1<N*7$(;[MZPBS"+0O9,G6^R(U&72BVSU_K$9G9[*J](%FRG,)4X/
MEM3E\Z[*4#2@A9';T'?6(7;%JJ!VC3"W[I20)4E7_90LK6T/67*@[QR[?*KO
M%)S-6PZMH^T!N>6N]8:\OT@,DE;2]^[SJ^;0S<K2(RB(\QK5TZ,M-RM9I3:N
MJA/*L084VX%<#[YG_+]\\/?ZM<4R]G2#42-:=8S;"3PJWZ.W-ZL'*4)JWP!N
MQ*$N:I7[9\*NK(JLB&=4@:)XTOU:\B]%B9'OK"VSF%QP;2YF\P8J^7FN5K3Q
M4?F:1<Y>-&YSD4T Y!K!K@LOAM1["]#7H;8=*Q[*]10;[):)C[,U>NW%@\2D
M%;)/;'=2^IO4]:TH-D;I[ZNP^DE.4J',4PWVCV#WTVPK+^K-%JXS96VC!W-%
M2VH5EA2#5A>JQ+#PT1J@16,6)MW<R-%3-='\22\GT1T]H"$S3K8S!)K';))4
M5IWC7W5;Z+*>5:23Q&U6]RB]ME6;_M)'86??5RU<-.%)!B>SX4&U[FLJ%#*H
M"KW"4+!6CVNZG[=QDPL:<#%;?ZQ+:E'L GP$_GSJTL7,X4X".0_RTIB$H">Z
MD#4)2G,XO1'=6083;=:"#<N#NE-./*<45J62ZK4_=0NWUO--R8!J[M#UZ"@2
M7XGR JQM TT D0Y6*8HFPM"@*]<K3PK!K5R\N?2'-25372&Y2Q8IM&]%K&OE
M23#<'>30/UN=/*TJU0E2E$]U%.6,OY%6[+K[B&PGLGVCO1PMI(:;:/>N./&K
MRX#+090G+U8VJT2V\?2%_4DUB6+NKN5I1["=$TSBCR?R*?QEY3<<.=7SF@63
MF*C5@LVECUD:O#3NBE.J62IPDS7HJW"D(UZS8"H;P=A2E=IY0_PT]?J=[9,D
MS1>+ABK9F"2>- #+6*,I4B8VFE>V1RKB?+]\ E2E)2GCPYU:8<<P*Q/'E5O*
M'"WPTBA @<36#827U%;B<P$%-(LV6D ! &E8FSHVL#V)GSI@AQ*2CLP-?R:Q
MUBV5<H#:1UJCVB/SRJ[<1AMIU*(#CJ>UQIP2I1&Q.GWUU!4=J%L>56Z@C2FU
MY2%)WD5:W/I##>LE&]/%"T(/*9J\6VX@H@'A5U9/H6IQB1W"=:MKVX"LEP--
MM133K*94$ $\>=*Q!:=$D#_I%-8D\'!J"#N,H\*186MTC@!+0+2_L+8S*X35
MA9*LW &]&E[IK&,/0K,HIDD:4SGP^_2]J,I-6V(-7D*D9APK%ENH"W0G,W]9
M/=5JQ;7Q*K=SJG.*")U\Z=PN[1 @G/L1_*K; KE#*G7"<P$HYBFBU=(ZFZ ]
M)02,YTYQI5U:.6ZLJD]@[.</A3@R[>2N=!,MS6(VS3C(5E[0!UI:<JR#P^B1
M_J(*MOS_ #JUPYQTRL'+IIQ\Z;LK=E ]7VO&E:IA UX'E27%)1VTPOGSK"DI
M;MS=7$)T]6#NKG5W=.7#Q<R2URFG8(SH[,<3]7\:L6"^^@-]O7M*B*9MF\R"
MM,+: U/>*?>:L&UW#OM$=FKNX<Q&[4=3*M/"L%8#-MUWLAM,JK$[XWEZM0U2
MDPGNYTXK7+U1UW4)-!KLP![]*N$E/U:MW.V1E,\*MFEN1G3D3]HFD7J+<]5;
M>V=%*WFK5M74!Q?M[U>-J>'6*$K.G+NJ_*;*S#:.RXZ#3R3)S[[SXT7\AI=X
M,F4'?>EK*BC7LS0A6'L* EMH'K/^K:E&!EG0[5@5MF*G5(]CV3X[UB6&I?<<
MSIE2_9_RJZP*\MU^RHMSM&PIJQU^R103'9B(XTLY4R:Q&[3D(\:!E2C7Y^?[
MX6*<UPB@D) TX4I75O9C5LYU[J .8K#,K=LB-XUI!"QK6)/VR&RE9 ,&.^KK
MI*JW6XVS[(D36%WGIEUUSJI]H^$ UB5VNZ<42?85'E,4Y^O4GZND>[6F&@17
M5)U_.]+;*#-,/B8-89>I946U'VMJ])!0I/YUIMM3CD\#7HZ1!RS&XJ_PQNY&
M9M&4CD*<:<:]6L1EV/.B(W-&X#"DJB>ZL,Q/.I,F/X::0%LYTF28TY5=M]:S
M,>R*Q:QE77 :":MG%6JPZD\?9I9:Q"V2E*H<6-4\Z;PQQF[#38R.%7M5A]DA
MI@"X(<7 ,D;4IMMQ$IC*)D5T@3Z-?*ZL90HS([JML724>CW8SH.@-8K:]A+E
ML9;,F!]6K=Q0;RJJZ4.I/G3_ .M7XUK, 32;1]0D(-.,K;]M)'R_/C%1!_JG
M:L)M ZO,1,;4AI+8@"EZJ$TA 2$Y4YBJFL/MVVA=WNP]EOB:<M;W$6B^PDIM
MVOU:.8XT$/\ L%*LP/LQ2[!]U'K1U38U5WUA%PRA98MT=I.ZZ2K,$J<,9=2>
M=8_B NG$LM*E"-#%8/8!QX+*=!$=_.L19<9M0Q;_ /$$*BA@+80DN*RJU-7#
MS-KZE+87'UJ%XR8#C7@0?PIQ5BL:L_&GWK-C]4U"E;:SM2+N_NE=4E)0W]KN
MK#+5H+]9[0XGC6:8;1L*4IL*0E6R0K-\Q6*7/I-PO[*/9I]P* YZS3R"HZ4I
MAS?E66$#G6 W+:V5V3WLOB)/#+2L+2+@-+5IFD=X_/WBK5EIAA+:0-!OSI:?
M2+Q.74).M*M&'495H':'+:L8Z.]5+S&V\"E:$I(@HJY<D$5=6CC^HX32VRTH
MI4((W_EW?O>9X4=M*PEA2E=9X5D!3KO%7;$P8JR?=8N4C-I(K"[Y/5M2=".U
M]U7%^BV;4Z5@-QM6+XN[>W"B'X;23D'CO1 5.LYMZP-K+<%(&Z5:<]#5TM33
MUPTM!#@5I[R:+N<H.QJV<$:UG15PO<"E.*0J9I%\2M)GM"L.N77B23.U,(&4
M&*6X&0)^M3652,YU%8EA?I#0=2G021YU<>J6I"AM-.NE*AKX59/J0Z%SQK",
M621D*]3 H*!9/)58C;!31"4\Z>E#ZVLN77?_ #I%XY90ZA6J(S#G7IMOB=JE
M^U(1>IW'$FL.Q:X 2Q>M%2CIFS1I_P!-(6W$(T2KA,UTKM"2VZE4^U-#.WJ1
MISJSN^K5#YSMN_4/=WU>61 ](M3+1W0/JT4N.**5>R=A5QAPZWB >7Y-6F&%
M*U$B1I%,LH2B,HJZLF71JB=-*N6BP^I&PX?1J3 KJG(F%?X?IP8I0@'N%*6"
ME9%,9GWPS$J)T-(3;8>WE<@O1KKMRJZO'+QY" J0%" .4U8VJ4,(  $(&G>1
MK3V&,*"GDI3UO P/E6.)O4J*'"8)AN!''7:L%P\VS>=T1UFLFL6OEB;9A4$<
M?&K.W+B]B5$]H^=87:I;0DY?9XTM(4,T:BL4NT-P)C?-5[==<K*A0BDQE',4
M5*;]O4'859X2NZ<2ZH>JY&AAK2%!*4@)'YWI^U6R00>S]7NJT?RZJ.M7EYEZ
MSM>U3KASJ,[TKMJI# /"EL"-J>$&.%6SJV\F0P9^1J]?/HEM=A7;$YCX:5:]
M*D )8=.96R3]GQK"^K6>N2L*SZQ0@QISI_*MI:5:UC #-TL 0DT^XDJTIH2/
M'>L980DR@10V_>X[&D^R/SQK""D-#P%':GE @#QI;?K01SK"W%9-] *QW$[I
M;GHR"<FU$J285)JWZQ1&5LGWU8-W2'D.H94,A$]\UTDPP.9;]A';R^L2!W14
ME2I(@R=/?3,Q^>^I.M*UI3:3O3=NGK >^L."4 13*] *Q7_92H>T-16#XIG3
MU#AU!@3XTVZ%,=7P(K&[!N%.)&M*0KK2%;3I4)2!%6UXJW<0N= :P?%D7C:4
M3K$4\R%!,#QK'\)1U1=8'K.ZLEPHE"N'M4RTY;JS6R\KGP_"AC%ZS/7B5<%:
M?=5MTC>;@N=I)I^YM<3M.R1UI&@[Z=;6TXIEQ$"=*?0A(T/:3MW36&WKK:H7
MVFCHH&KW#TK0F[M_9.I2.%.MK5VHVIEQ.4 [UWTMP#RFL44EVY)'"N,>^L-P
MU*P%K&\'7AW>5'#[?+  FKW"R)*10LEE82=I^%,,EE(IE#SRLC8DJX\J4&,*
M:AN%W3FZOLTI]]\GK%$Q];G-8-;EW$&4[R9]U,+A'4G0J "3RBKN]&%I5G7U
MA.PKTC](7*7;I.6W1)D[5B.+!;BF+;]6C0*%+<.7K5:GB=Y_RK![4%GK([:X
M(TJT:2BV 5[57=XW;-J!/ UB]^75*RG>:;>*'.UQ--J)((V-89AIO5@NCL"O
M1TLI2TWH$B@$*5D"NU3J#JE6L;5>J-N":N\1*U@3SIR[JW7,DZTVH13JA5RL
M9J2[ERGQ'OK*]^B6TK^OF(\,TT&@E1^TK;NK#L4NL.=3*R43SX5A>-M7R$0=
M4CM:U<W"4))FNDMV%/\ 9/.F$*>726RD"*Q9I:DDQ6LF?W(\ZD'8T/'Z28X3
M259NZI%&> GX4)XB*F.^LP/&H[Z/C%9AXT#/#Z-?ZY,<*^%:CC1[OH@@^UY?
M3YQ0[S)_KV%T6R05;1%(OP4ZJI=ZB1\*+\J"N%85=9VW!.HB*;P<7:NL6B9I
MOHI9K 4IG7CK0P9BS(R-#2FEM)2/5I!YP*>6W!2L=ER92:Q_#%6-TIYK]0[J
M@#A]JK>Y 1KO1?;" 3N:7<#ZM+<6H2#M277$Q)K#%I6A)XG>FD=F:N0'+=P;
MD)TI+CMO<+7,0K2L'Q3TAM"7#)VK$FEKW]@\*Q"Q4E04@::S%)0I6G*ELC01
MXU88@]ASZ.K7E3.H_P ZPW%6KQE,*&>.T:?,/%,9TJIW!K-3-RL->M6 1KM%
M+24.K9X))S&?A3Y04Z:"D.]G+3-X^P\V4*(CCP'EM69C%+0OY!U[8[7,\-O"
MGL/9>;)0O*I7#[4?*F+5^W.5Q&9(VBL,=25JMWCV'1 2>!C\:O+0VCJVUJD&
M2/ [4L=61WS2%$B*N4$-DCE5S^M5XTB XD]X^!JR4GT<$;Q0B 1OK.M.$$0:
M4V,^>-$[]]6MJN[5"1(Y\J><:P]GJ&&QUVO6NS/A0>"W#UJRX2>_2BW*=-$\
M.ZNCUL&U"]?&3)[!/NVJ]Z0)95E;2%[RH'>KG'4NJDLYCWJ-7&)W-RRIE'JT
MGZHXCQIM:[>4D'+];C6%6R\1?2V$GJ@=Z8PT-9$-:=7O5Q<MM(*HRY!J>=8S
MC0?6IM"J)*CVC-/M]K6L)LW+C?V$Q6'LM,,!.6-*Q"Z3;-J7FV!RUA5PJX<<
MN%*)@Z?$4M0RAQ6ZMO*L2AU*IUJX82%G**]'"CK01U<127"!RHJ4K6>R-^^K
M@RN8TK"K%R_NFVH*FYU/A6*H*$MV;3<)93OXBG595J2$%)'&EO.#^+NK!\9>
MM;E( *$*]K69JXQ NM9OJ1-7I5<7*R?9G2K5 1M0C7OJ]0"VHD33P =6!M/]
M3E1KSH:;GZ?*OAY?U3/"IH*GA4SM4QO4]W^IGA7G]/G7A]'G7G/["9MW;E?5
MLIS*WCN_)%7.'75DF7FLOF/NKRCZ(F@23 %-6-T^G,AI>41*HT@\=8G_ *9I
M;75J*5>T-Z[1V%-8+B#P"F[<J_ZD_>:_0.+#_P#A3_C33V%WS S.VZD?X3\B
M:,"<\R#II'=5I;O7:LC*,RHD">$Q]]?Z/XP-K:0?XD?C2\%Q)'M6JO)2/Q^Z
MG;1UD^M;4V>&8&#X'4?'QHZ4!']8F"--Z]HQ3V!*;LC<RHZ3PCY3\:3[)YR:
M@0"?*F,,O+I!<::*D?:T^_\ /*E(4VM2%3F3N#P^C",(_2JW.UEZH#XSSK$;
M,6-R6 K-&L^_0^ZN)'#^MKPH/.1$TA2EN(D\:;8!;'A6&*]&O&L^C:U=JK0-
M+2VMD MP-:"4%/ <JN&TY20)JZN"G,V$P3L?#6G[T.MJ<.BDB(^%*0+RR=#Q
MS=3.4_WJ<MH4H(YF@RLI -)8UI%N,I[ZN+>$2*P:0!--K!;%95DE/!0-7UO#
M[B:PUWT5223 FAEN[0+1KI1M.L#B5#7A5S9^BK)(WJ$P5'RJ[2"OL\*P6\N&
M;EMH$Y7#KY5:LMY$+7VE$4^R4A:D;'A6-,=0^7>"O:J[=2#V?95M5LA2S75P
M-1Y\JPJX]&NH7HR]V8.VT5B=IZ,J$*E"NTGSUY]]6V)N6R^K4.M0=TF/G3"+
M*Z4AU"PAT&2CEYUTAME*<3<I,H(^0 I[.7-1IPIG0?GOJX(ZI7A5Y^N57(\J
MPM15;CPJ<J!2G)-(1];AH/?I3*$89AQ=(]8\.SW4]G<3.I69S>_2K:P<6=49
M.\U:88C.5+7+2-79VTU'RK$<6+A+;'89:T 'UN%%_K$"50:;1*]5TL):2AP'
M-E[OG6%X*WB=J7G1ED:>56ENWAH2PRD9U?6IIY#(]8K<=HUTDQ\+=-M;G02"
M1QI#!6HN*W.M*0L*S:PFD,KN5B!L:PQI;, #E-.W26;>>,5BF)KN7>KGL@F:
MZ/MD-K)]C_.EDN( 3LF:O>RA<U=/0O3OKKJ1< [T'$&EK3&\??2RY=/)9:3.
ML$U@UDUA]JA0 +[@'B*+++PE:!F/M&KW!+)]4 1W@4OH0VOUB'(\OYT_T95:
M01VH[J<>ZBS*%#M 4NY25*TV/XTFZ$TFZJ_O@$%-*.915S_JY5.*"4\P--S.
MD#G2L(O$-ATM*"0)F4_<:W,<!6GTM-/O:-M*5PTU]_+SBG[1ZUR=<(ZP2D>&
M_P Q0UJVPZZO,WH[1<R^UJ!'OBOT#B?_ -LK_$G\:7@V(M>U;*'FD_\ RI:'
M&E$.)(C<'0T IQ24MIS%1"=^)T'G/Y%# <2*<R;?0\<Z?QK] 8J 5>CF#_$C
MX2:=L;NW_7,J0.>_RD?&AEDQOQW_ -1 XUAV!^GL%X+B)T\"1]U7#74/+9F<
MACZ&+1Z[S)9259?:VTG;?PI^T=LS#J<I()U[M_G0DJ'(S\*L[07=VAG-&<QX
M0DG[JQ;!AA8:.<KZV>6D> HF/V = .)-='\,%M;^D/)AUV"F>$</SSY5TK_V
M=$]WS%#Z--N)V^^K7#,(LV6GGU)4L@'M&=1Q )TUY 5;.VEPRYZ/D4C*=4P1
MH"-_*K_6Z>G@NLP! G4[5;+]&PT/)U.2:_TK?.G5 '77/]V7[Q6&8XW?K]'N
M4 *5M/\ EO\ Y\#727#VK9;3K1'K)S "-MIY^/+RCHT,V(A(VR+^:#6-8P[8
M+:0VD+D*G6(B.X\Z9Z6+)]:SV1OJ#1:M<:LNN2WF.4E,:1S\_E3[>1Q;?%"H
M^/X?0-3,Z<N= YB0 =.-("X.;?@>%:A(G7G4&M3M(CND'PJ!F!UG;8U<DC 5
M$F92/H:07%(; DJ5E2/$Q_.L/;;L&&[: %*2-_K:=_=72*UZB^4XA,-NZC[Z
M/=71$2Y<^"?D:QY(5B+F76(]^NGRJ#RCQK7P_KL?K4^-6V4M#PI].Q'"L!Z0
MKMD!ETRV.!_&CTALG0D9^KR^.M/])+=""&AUGG%'&3=7*4EC(.UK,U>$E:DM
M)S3$ZTA26+125^TO<5F1G4!SHG>I$[4EP;4^Z%0GA6#H!5K[ $FK%9=<<3NE
M/LTV-CQ&::Q58])<YT71"1.IFNC&)=HVKZY"O9JY:+#H5'9WK%&$736= V&M
M/W(2HLQ!3-)1G5-,@L0XDY2G4&)CRK L4O7M% J0G_B'L_"G,69"^H#H4M?'
M['^==(&''&EJ"@M&Y(BB<Q*(T2>P?G5EF;]K442H F>RJG5 J;UV.GOJ^[=I
M:R9,&?NHL),F*846G,TD9=M35NRF[PU"'AF.512?C5PUE4H+'LDY1RKK<NG"
MKBX'5J@Q3ZRITD\Z&]88E MP12AV1.U0LO\ 9]D5:)4^\EG^),U?V*W5I2XH
M-6321VI!X:Z;[U>7V'V:%AA.=S0!SGY4FY<N]9@+(".$<#5^3863=KF]:ZF7
M>9XIH,9EYW!/*G&RE2E#8TV]"H)IA'7J2B)!WK"F2&$,1E2! -*L .UFU2/&
M:Z18FNT2IM(.NDS047',R]2HZ4TE*4]O6NK+G9 T.VFU6N'(MV@O)"SQK#F"
M>T=N-8Y==LL,F*+7;4.,B3XU8H+5J@(T"AK2"$IBL564H5RHMJ<>43J)TKT5
M$;:TXU&VE .C8U"RZVE<D&>Z*P*R#!6^[!RZ_A5G>*4I3A5V6YD<]XIC$>N!
M ;T,Z^%8>R'$I)XDT+?6,NGC5PP#F;&YKI&XAB6$1UIX_P J%LJ"IP2H[FKM
M:V5#*8KTVX^W\*<=6[[9G^MT=PPO+-RZ):0>S/$Z@^[;S\*Q I] 7DC*$Z:4
M=S^>='0*/&C)3V=]*P;"K*Y9](NE1D)T)T,$C3;EQFK2ZPT.BUMPWV1$ #33
M3PKI4,MTT 93"X'+V:3M[ZZ*CU%PKCIY[U>](W[:Y?8#0.0@ SW3ME\M^_NJ
MWZ52I*'V0 LP3(/W5C>'V[V'F[:2,XA0(T\?>*9'KVE),'K$?^X5B5RJQL.L
M0B2E""-><3P-?Z471RRV $]\_=5ABUOC3986VE#D<0/?6-V2;*ZA!E+@)Y0H
M'7AM!!XZYOHTK8Q[5=N3ZO3QHSR*:X=]95#C/=1S?8D<:Z,)(LG5SI!T]]8A
MK>OJG=?W4.,^5=&K9-O;KN70,JX)GE.G"NDMLE]CTEI(RMZJB-CIOPC?OBAI
M'G6#C_ZBQWJ,^XUTL$-VI[S\C4**9C6M8!.] S_OOC6!88;VX2ZM/J6=2>!/
M\OGIP-7N*G](6UG;_JT'*8\/Q'YFNE6;J6IX@?=],#<[C:EN.OZ+<40GA/W5
MT:CT%R-X7\U5??[6]_?-:YA D:2>6M %6$?_ -O8>%>CNYIZI?'ZJOPK \+N
MU7:+DH4EM!D9NR=BG;?:>7")%=*;II?4MHC,G?6:Z*Z8GK]AS_X5TH8<-PRI
M*5J';]E)(X;QMO\ "D6;[HR)9<)/\!'Q( 'F>ZL)3^BL-2EW<I<D>,D>Z?\
M*KE87<O.C92Y'O-':/&FD+6XEI/$@>\_S^^K;#K##;5NYN4!;D3)TU_/"F<4
MP:Y<ZI24IS:1E/SBL<P1AEI5U;"$>T>1'YU%6EJJ[N&V4SVMXB0/S_E7HN'8
M.R5.%""0#E(S9O,R9I-]@6)#JE(2%["4D2?AMW;5BC8;PAT)]B!E]_T=';3K
MKY#BA+;.I\3/Y]U8]B99Q"V#9CT<]KD4J@?*8[ZQRW%[AZ+A DM)S2.9X?=0
MV/<3\S71(@&Y.3/HF-8B9JX3A5HI=X^$AT_55J?#\[U;7N$8BDH 0%G81!K&
M\(]"]:V(;/N YCX?UT>VGQJU=[(%+6<N@F:;=RKU$:TV4$:Z^=:"DJ(<20>R
M/:X;UBZWK5*'[4R%#7:E7;[H!6>T=Q24J!FLP2#FKK$D[U,Q%05. 59@6]NM
M1W4!%87<(;S$_6I*ADS#D:Q!1<NW1WT6U%) ]KA5NMRV6T\#"DG6FKYJ^LT*
M/M!.M+)"5)3JDS]]8K:)2\E:=U$YJMF%J, 5;8:V/7W9RH;U"#]>KS'(3U%F
M TT--(UIVXD=8'"%;D\37Z4<)2RITK:5HH4K!VE-AYA68*$QRI+2FUY5B*;M
M''$3P[Z=PUY("Y&_=5RLI882H@Q/*I$&EJ]8.4U:7756=D.*\P/A,5CCC;=Z
MZV-@$G_$G6G'$ZF:NKB) -3)-3!]U8?<0P*Z[,U3"([1^M6 X9VU7A^HE1 .
MDZ'G\*Q&^>=+R'7#!) 0.X\Q2;<.9%$=DSI6'-(7<MM#V421Y":Q9UQV_*BK
M1,".4:4HA21%7!&0#CK2@0N:P-2W'<J4R 1)Y4Q>L--):5"51O5_BXLF4D)Z
MP*!U'#QK%+I>*N*(TUVHL9!_$BF'\QR+K"K7K7,Q'93M2D)<4EH5?O)PZR5P
M6H=FG+HNJ6ZHRJ33:P>T=R15ND&T;/=5QV$*7]FK_P#M%J5"DPCWT5B*7!-
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MM5AAX/)W1MYTV\7W"XYN=JS.=801V?E3JCEI9*U@>-%/5IFKAV1[ZN3V_?\
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M;J)@!>IX#0UTG<0NU;ZMT*,#01W5&@)W^@[&E:?"NC;C8L7DE800%;]ZE5B
M_M3\*GM:'GH#]])[64D:BK%*;C"PA3J$G+&I3^-?Z*V13F-VE/=(/WU;V6$X
M;+F=*W$\9)^^L<Q@7RT--_JQ.:-C&U='8&(H)( R*W\4UBF$VN).I4MY*"@:
M=H:S&_NH=&K!KM./!:?[\?(U<8G9X;;]5;% .6(3$^X?Y4\^;AYQQ6ZE2?SX
M5K-6EQZ+<M/#=*I\MC\/*:<=L<;8;#I3F"=]I]T12>C%FVH.&YS)&N4Y=?&
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M DMBDJ4C;ZN@&FLU8/OV]QZI)&<P1N*L<.8>BZ4@!PP5?Y5<M,K84SIM%7^
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MJW*9QV=-2;NU)?I')()$2_)^ 3ZV*Y#*%SCS?S"-#LYU=@S@>M<(=S_";#?
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M@VV-Q8@]VZV/QP]/57:@E.K4JW>&4]3WH0.U;>]C;<X62-@Z.H9&'(@BX/\
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M.$FTOYMEL#&A-["J:GD/I9%/[R6GU1J+,="D]P3:P'+[]_?@$XCA+:5=U5V
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M*LQ=;2U%5+(YMNL<J(*=>^VF(N.G:VYX=4;LR+I87YXS02[.8J8GNV:;'FE
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M?ZK?)JHZJ6'>^@-Z,]]XVU(2?R;^.!0URK'5$'AR+V8Y](OITG=9+;VO9M[
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MLHM=%.NUUFANBO;IJM[MR.AQ7421*NMGC(/, \O\VV*.H;^JZR%Y*9>1\XS
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MVL>>]KV PSTCQS!%U<-CH?W \C@QR Q2KS5MC?\ HQI;UA@7^1W8V 4L2>0
M&Y^'/?;#9!D503$3;,*N%MI/_N:)ANR?PCBVJ^GE>_%<=OF!W#[G$?B/U8JN
M'98:*EFJJB4\D"1LR)^5(P"CXX%ARQ7K;E7 C_H(\))5)IGA8-35*?C(F!U
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M&[3.DR#PNC#_9?NG9I0#7%&:_EZ"KSVW@FXKOLQ."1#6+$SE0!;W_O+9S!,
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M9S,(V'?2\ISX++K0GTVI5GO$7['J#%176TN[O[C:+)57L8>AJ,K]4407/>Q
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M5ZQBJ9^*G!BD$O(2=<\WLCS:Q/057T86@(@ <$3M?]8\'P#S0<V286,TK4^
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M+Z6(W*$-UMT(W-_KPKJ;I*H93[Q\A4XTXGE^:H3Z^?\ '6HMSX3_ */D)O\
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M:@23B-'L=7"*DAUZZ>8N,24=9')"YN=$@*,&',:6W_V8CKJ?U _I4'JR0/\
MC$/Z??B&MHV5HJF$-WZ2PW0]Q%\,_?\ )J2P;&IFN3O? ,B:@=L&6C6]]RHP
M9J9]#7])&?4<"_K+^OGO@3*-$R=F>+YK>'72>G_%B2;  DGNMB2CRGI='JR.
MO(B+[>U[K8U3%CK>[NW,D\R3A!3,&-@"/'':!4XLV+#EWXU:3;$]74,(X*:-
MI9G.P5%%S<_?>UL9OFDRJ*:JG98"?6$$0TH?#O\ #ES!)GEI_20\0MMRM?\
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M[H 1OX7!RVIJ2PED@TR7VUM'V"]OI6O?KSZVQ<X-N_Y$H1)^V:<N71N>EF+
MKU*]/#^.<.:0*7-+V*A1SX7/7^;UP,7QRP155 >H]BEA[<I/C;U1[\4U1$\M
M'3TS_M6-)#<6/XQK>T3;W8RRMKIDCXNFEJZCEQ5(L'FM8%N7:/YU\"="KHR!
MPRG8@CIWX_!E@U17U4:Q1^U9#SMS]8J/CC*Z0^O!1PJU^C:1J'UWQ8XM\@KX
M(M=3EC\38=IJ=K<1?<+ CNWMB]CI;M*+=>XXZV'WMB/(,QG2GS2@9_,)M8CG
MX?.,H?;TL5!7N&!E7E2DD^7\J3-HE+#2?56;E8@7O<]-KX#4%?33Z@#I65>)
MOR!0G5BY(MWW%L!*FMI8K]&GC!_3@C\(T9D/J+QTNQ\-\-I(X>_NTGQY'%4J
MK^UZW]M4W=VMRJGEV6_VX;)JMRU;EHTJS&YEICZI[^QZI^W!SNAB_:M0UJQ%
M&T,A_?=O98\_AB9E;::)X91T>.46>/QN.6'R"HDCAD1Y'H6<A1*CL28O>M[C
MZL$>.+! TC"QOR^.(O*2@!_ ]?)HKJ==D@9SVNR-E#7+JW*]QUQ'5T3J\4@N
M2-RC=5?N(Y8OUQOL<+#.354>VQ/I(Q]#^CPP)Z24..J^VI[F7]UO(Z(.]V '
MVVQ+14$JSSS@QNZ=J.-#LQU<BW2WR22LRJL:%W+&P"CF?ASQYE 7B\F\IDU5
M4R[<5U]D=[R^J!?L1ZVYD'$5'2Q+%3Q)I2)190/%>\[EN\DGJ<9I2TU%!#^$
MXY5JFBCTEWD4]HD6.S=H 6%^F,TI:Z58HLAK*I'DD[*1TZW>YOW=K;OV7<X>
M0$I00.T5!!W1 VXK]#(_K-W>IR&$,BVRZD<-52=)"#^*7Q.Q[K;8H?)++V6,
MU2H]2L1VCI4V2-P-QK8:K=VDG'X6K("*>DB7S4^P\KCF/R!R[M7?CG?&QM@W
MQ?!GF8=C<*=[XFK:YTCAC!T)R,G0)&OM,>X;]>0.&SK,J.5O-:62/*( % @=
MT/"G8.0;M>[,M[[J++MB6=S>6=VE/YYN3]9VOW=V(X^?"[**!N\A;GMVCN;#
MGSY@8CJ\]J?,*.P:.EAL]4Z_.?V(]7QM?U<63S]&(];CJWQWCPLQIY*Z5=U-
M;('0$7_>P%0_%3@(BJBK8!5%E [@.[$'D\9#^#,K4252ANPS *\MP.;%RL?/
MDN(Z>EA2&"%0B1QJ%5546 L+<L2U%1(L4,*-))(YV557<^.W3J>_!RO+%DI/
M)R"1/.ZTC^J I^=L#WJN^VECVL4]%3#1#31+%&O@H]W7F=SOSQ8?)XXHJB,V
M].D;_2CD(5@?LP#W@?QQ+N=*J"S$\@ -\2TN711O#VHWEF&H/T;2O*V'O878
MG86&_0#NP%D]7'X)RED\_F6\TO/S:,CX]L],-/.[RR/NSN2S'KS/W%\*]O4;
M"N#XXKX<Q&K*<OBUI62D]BU]46L\P !8=,3Y]4J?P1E<EJ6,WTM(N\:V_P ]
MS<[D#D!@CN^6QPT,RAXY5*.IZJVS#ZL2-!IT\7C0[;F*3?\ S>6+ +;[[X6:
MFE>&9&U))&2K ^!'+"Y-Y711R@^B6LDCU(QV51./9/\ ;!SWPE;E-3/ECR>D
M2:@G/"(.X*A6TV^%^_!4^5N8R06(T=K5]>!+55>95DJ\S+4, ?>!B2JF>;+Q
M1QE_.DED)C(&W9Y,;[!>K6P^4TV82BD1W7C<JB2*_9NV[!2.E_??:T66YH6J
M):-@:&L;>0)R:GE/,BUC&=[6:_/%%F\=Q%K"SK[,D+&TBM\.V#AH1(135].K
MI)'TU"ZG;GI.Y[[8:DK$VN>!4 >BF2_0_I'3"9?4U#T,U3V*.K1K-#5#>,?D
MONNW?@T?E-0RYC0AB(<SIP6]'?8L;?4&Z8XU)61D*+O'(P1T YZE)]^^!D]/
M3+F<$KB.N=MXA'<!M'>PZ'D+87.,HXE?Y.U)XDU,UR\"N ;-:^P]E^=E-S@5
MM#5H:C2&>F8@31L5!(*WN;<K]X.+]Q^2&H0GAEU69+[,C&Q)'A?GSPDB[JZJ
MP/@V_P"YM!2VJZSN4^BC\7?]0WPTM94,]SLERL:CN5.[W\[;X["[8W7%-Y+9
M W$KJZ41U+H;B) >T&MR  8R-R"#OMB/+U4++IXE1-[4]0X])*Q]]U ]E1IZ
M8<(;@<L5&95CJD<2$@7WDE-]$:?2+6_V7QF%#3MH_"U8U;6:3VGMZD9M[ ]8
M@[:MQR&*>AIEO-4, 3S6*/F[M;D #?X6PVXBIZ& RU$IMKFD [1/SF=ME'?:
MU@<5>:RC5+5U&FG3?92^F-+]^G0+#K]6*"AE=GD$2O-J_A' )]UN0'=;!;B!
M6[OO;&H.&WP?#':V\3L/OT^."&J!4UC;0T%.P>>1SR%EU:>U9;F_,;8E\I_+
M)_-Z.GB>>FRAB BHBEDXUR!=M^S?4VU^0&*RL;]_G=PO1%U=A!X*M@+6MZH
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M W(]Z\_V:9722&.21-=0Z\PAY)?IJWOUQJ/U]Y[\!/KP[:EC6-2Q9S86'?\
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ML%3KFRJ5[2QW)X&K]]C[M)]9>5N0VQ%6TLJS4\ZAXY%-Q8_K'(CH<6&)J"K
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MWWZ7Q6>4F?:VRJFJA7YD;DQ!%;]I93"=K+LH95WT!Y>;8:*-%CCC\KZ9(XU
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M_")MOXG;&GY+'IBU\??[W[L"KS-GIX)%O#$GXUAT8WY#E@^;9B.'N5$B'5X
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M/RCS]*PY,M8,PS+-:P.IS*5'#BFI68#BLS*JLR>BBB ^BN%10%5%"A1R4#8
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MO,?7^Y=HA?>;?[?ACUT_E#'KI_*&/73^4,>NG\H8]=/Y0QZZ?RACUT_E#&S
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M%]D9+G+RHW53BQ*A?2STEY](.2N/(,B(Z8:(T92%Q[!77W_9?A KV+RP-*Q
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M'ZT@WH\3PG#X@%H"IPCL)1:EWRXI"\,WIG.76):7G@WE+H0\R]+>N71I$#!
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M<=X>_Y]^L*0W@(I2O3[]G;IVJ7RN(:\<]<7JM67M;CBR!T%5_S20&[T%9=E
ME5Q!G&4%GE.Y>.)M) [2%0^F\J,W#16PS:'<@#]%):SWK+U3(/B\=5D95=1R
MDK:U]M-,K *'8[6O9I^F$?0/L2"1T'LNV%LZXXY\]';C*U.A:]?)RT]!D%_+
MP&L ]XG<<F79V0!K*BZ'EK,$>'B1F&"JSXRQ@OAIIIX]8D^:<[D5DL'DN=E-
M)ICW+7=9)]I=,&PKVXY#BUP-7=%-G"?QA)VE588@]#*TQ]KP2'-FANIR/Z*X
ML("RK$:U)!U^4O/F,##+/FX>6E1:)&,=V8P^C^IJ+C;YGI+#P2S;X [M<7BY
M(_058'@7Y5.,U2,GA]\H*OTY5ZM]J#;/5S\\9'A7BHE#U\9).5GY2]-X(OS-
M[H M6Q?3I:CO!GIC492.W(.4E^FQGS*!]6&@C;A P&<?S:?$CU\QQYD$GY*T
M4J[<5*W!SZT.7[S*;:G.NGU:W%!UJ TM5WV\_)R\6 Q%7O(/2)YSZ,+8 LHM
MU46?E+53$->45$H#:E0?8ZTS;].W@GE$?DOV?;E; OM3^X81;%[T*0 $?\0J
M/1'[JO$YJ7;&,<-HXWCR+U&^<?$O62%SB1I\C36N<NJR[FO"&L_]T\3\J' F
M:DQ(Y[EX%_9].*\M+FF*:DE;$YGMY<-#)Q\.+GW?_'/QT4G7"/>[N")[3Q-?
M$H^*T\;;D][ZT4#"K/ #2)4U:8 ":O9U<^\?12%5+IH71Z.Y98_3WGHUIE)-
M$9C%@ZFY]%-N\SGO]C<6A;Q*JGD'L8'10(PH[Y YY7E.SK2M[Q$V'Q^/2 /B
M-B<J27QMI8#WU2R8]XV/,>@L>@WN**A&A=\( #?A(E[%E=_Y<&W;@:5J"C0D
M>.BFS=LCFT%30\3\C6D6IH&1I"T(FV?\7#O78#G-$SE9LWIG=LDOWDN=J6(C
MN)'2OZ0@LCL%&TS[&QQ3@U_PJ06$!QI*[W3MAHFLS*MGZ@B'#DTO'5><-\-\
M/.1XI[Y_5/=LG%L^WF"-R>?8^/A6)G-P.2R=M:G+6;;C3;'5W9N NA%2>4BM
M_&@)1E5?_]*!<&]LT_[TFU(!+RE,"UFSW?4-(/'F1_A%DM<.V;3,@N.VW>9>
M]7/V_],LBYD93H+G!NZ/C/23:CTTY9]A>[F>3;XXHS]L9O:11>F$_;R3X4JX
MY Z2"DN-Q1UAS8T_=SO70S.TZ2NS[+P:*J=.+YLM)Q$W"WZ@JW[2N%;11CC#
M[PK5DJ]B_BI'8FW.]YZ4>+^@M?:7"]4Q3657W(M?]>A/@F,G4]-]FU*,WI;=
MHN<2S%(<XQ9":&.E^(5\7\71S[T(7I12895WJX]_ <BT00 "VDQ4!'AV2$G?
M07+YYFW=&._AY@/ZN6*E7050OO\O #5(#ABVM'S[]8\:3^VB5NV2HX#7(]#T
MROLLW&/7_T7)_I#OOBSJH6<Z7+'S+K[SF9S)VF;7V[B@K$0;JV)O 'OY.-#,
M]/2T9WIJ/-L#4M_P+3DX[A40:2#UQ;;_1RKT=K>%&&0).^N74DC[9*-3]P&J
M[@ :@_!V<M!^4P\9Q0G99DBJC\9C.LY0Z1+Z')=2W2\@=33ZOE2^O?[@MUS!
M9[!+^W\HJ?-MT!],.HI S.F8D6'YM.Q/EJ%65JBQ0#>VV@DFQ$XTW%A$%PN,
M]V6/,>FQ;V/*>4#O=5#B#44R*D9]90(\&13*:%A[WB%]](W8\^@*@W(&N,76
M6PDMO *^[#CQ7_<,A!,](O,S*A>T!7!:KLK<71DA-#)R,EDPV<X4E1N/3I<A
MD'ZYG*9AMCW3(*_HQQ<@,&Y=,BGNBGU^?G:BT2ED]G5TO%EO]M1=#%208WW4
M'3B5:ME+\ #%QBMZ%TJ=EFPZO;3*9^()>Y<\ ^.HIWBC!,P<RT"O@,]=2%?O
M/X+(OI6J09:*,6]'/'&IT#OB]1DU:\ U[V=HCI'L0V34<P_7E2?G\0THD1&
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M$'V^X*ON5&[S#.PRE'T%S' %OLQ3^+?^.PS!F^85H#[V"GBTQ7U1W;F"<Z=
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M4/K*LU4UU0^KR/ @K#X%8V+V9Q_^.NWC[PM?$&XM<>#D>;0N>"Q(\]^O@!?
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MN(F))-38)*+UPL^^HG;*64'=AK-'GR0]C,D[[NPM8VFI[4IB[P:U0([F[P_
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M&-^/8!0.:<(IHWJ#F;5CB0,AO%"137S\BPR-W\I3_)?X2'#^L.F/H,PQ/N&
M*FK01A1Q;J&Q_#@NB93A)N57O4Z5?%$O"U;&LA+$ Z9\A!W)P= QN#-8A&'\
MCC\E7(U.IRD:XT^6U,:%TW@IN9QZY/36>8UJ.36Z5_@L'2QA")>Z:0U1/2"Z
MPIR=9^W-E3JIM3WGTT4AF^&5AVAC3@$U:/-UT[P<P_T)$U"ND)'.A#C3DW2C
M,@Q1#Q9.Z&C9,G0+Z,E-D"$\\\+U!GF#W,]T'P1 3Z&9_I.JO"./_S#HX"P
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MKX:#IET;O1>*5B4R<N;K2%'!W=A=83UW#,:R2S)UD+W7'9N7?> T"EQW-R=
M?7V%F2V%WPC3HN,VQZM:L3LB'.]+3"&Z)1\,))X\U=9 9/!*^D3/;(O-('HM
M&\LB)2S0W@[Z-MV=VEQ4,!K85"1/@--I>5ZPN8W-RH;7.X^]M_QK@=Q&?SV#
M[K#G=^]<WPW%,\#E_T,K&7+^KV^$N*=N*=TH8^J-@9%K*[I_\VJ? 8%K_1TW
M7R\6.K&?M&W:,QE[$Z ZQF]F=#;<3K5D18:%4)M^ ;],_#XZ//K02# EH;EY
M"21M$AS8SF"6UMF$YWVP!&,%"UH-<H;'8U5%80Z4: 4?*B1"%>"6;PS)I!@-
M=5G')__ RT*^5SW\D@+^_CXZ0 ,QM6_C/6;C/;@&IA1P(I!614SG5().(!4M
M17!L'NL06+M0L'JOJ>PF=Z!ZMQJCR*H8>"?)G4YMF?KCU.OCJ2(QJD==I[O8
M>=>R2GG\17ST):_.5-ZGTN0M2VO^LA080K.?W@N7P#Q<#Q;@:'\<PW)&7)UC
MJ&68 .) M8_?0C'A"?.\0.6_0%;"=,GE#*W9&GOC:Y#3P3[?&1/$-O++PL W
M/XL2;SW_PP"Z3Z'M?D</6%N85CV0-$O0D[?N'WVZ[$(X(N7=<D4 O\I'2=WP
M,X'R-C;>DH$,423I'93%QC1!FAZF&$0&/M1;TG./__8KX!7O4!-+6F3S($M+
M4D((. 8;9)',LE9.*\ZK*(<DY6=KL9'U?@:P#?A/K/4F/ -6;;@N@'*P?=K$
M_L6R:/Y0RI%T2YY2GXF%G!HMK4]>!AA7K<=Q4$F%38?/[\?'/]FF:6SY**9U
M@/!TU-@PWTZ(2RO\+;;X\ XE<H$C[RR3J^0/RP_0'+.!<I<B6U:" ZPEGC4P
M1G6BZ_<LS4SAT;<8=F=!=_X>]GK^ +$K<"I(1D I.B4W9OC[TYF0:&4J)-A2
MBRF^IDUA_/T\_KX:Z*TJ/_45UOR>/&5U(^/!3/<KA82)7A7IQ DY%2PG9%G?
M3R)?:ANXM ?LS]&!?A@3 31*AM]9%R(2A%I#(%@S2IH25) .ZHX. _O-D^40
MR-(9T'']UY(E+R1WVT^]N?J#,RCUY;;?^I8+E]&$'@.DL5#?W,L^\FP+P TU
M7N,KS:=\<5 B]VALNY_OQ)9G-3US8:-_Q<%]/@<^FE2,GB5$KZH79)WE'NUI
M2GK+\<_E;$DJJAYYOQT^-N7^NB@[7I@7UJVC+R?:W;6:7T^:J"A?XHY*ENKH
MD-AAX:0MQWY(A!^ZX4?:(_E#\"#C\SUN<(1X!O%/JR2:<.GRR 66*3-3(4<R
ML[4XOD*KL=;ON$W'X'*5>L+=B*9)[6> ;^HS@!'6;F2=G1.0V9)K6WB_X R]
M7L\0K.-"_@*/,/P+MAT()"?B!HJ8SW-$FW":H-1^K65T-OIAOVXI \#T<'E7
M,55S32!BU^:-0EGW@WH ?2O*/SG<H/OQB0%\ZU<2^"L$U?"*RK]]KXV9U25T
M/H<M/+*67U[XNPVZH.=5NY7;[)R:LM:M#$SQ8JZ6OS(\E%3\C;XR.XG%Q!SC
M ')IU_LJ_MTHNUNI@ P=>Q@6NR*P$I\U3V]YR#5P?8(D2K# P,"ZXUOO.'N3
M([U-RYA]07,M<C%:_'XMO[+Y(P(]J? J'#ND:ZW);CH;(P?C2X$,J9[7WUX2
M0$TJE[K*B)AY@<3PWFYD#&.*%0,,I2!,I9U0M?@,\*.V7@RN:J@%MX8;)'NZ
M54P4\?#R&"]8&=J(!8)'3=1,=%7O2TNO7#O[PF8CW?L[0_-@Z.HE<CO79F&+
MB?^.^7H]49DHHMJ.T2A$>W)4*4E5PEP&OTF"GCYD[Z3[%6+"<ZE.4E3_]7^Z
MFZ0AB@8AZ]^$.'!9+>XBK9X!J0X-B@U0WCN95P]"A$V9XV(]-Q:Q?K<N:]SE
MF%;V0I()=I_Q;7#,ZH3_Y.BRS?H^ ^:^4RCC_D$Z9,M@Y\Y&E1]WB[OB(V&=
MFAFNN.X\XM\L3[!>//E+-(0CHXF%4."?QGTA6]C'?4\M1H]M#U0=[W)A3#F1
M<(*<=NLEXO34J4-W][8;RX%S8=:_4[5OZG'''ZZ->]4.+=Z8@$X*> M8!()R
M:!A ]37$"^!1URZMB7>FR:BP5$-+,I^ON(0;-WZ1<DRV 2I(EGY1^JA6RXE!
M@^CQ>K_%"CCGWEY9VQ81U9<C?;7;CVK;<?<Q<<^ -5^N\VF/&.KV;F#$;1M.
MW!!OR/F\#SPCL__.\GMM*<@C38E!%Q5'O^7LYS@;EZ7QBRH;'2.H4&PS>AQ+
MO_,>29JS]<_\*$:S6\U7$N05*YNRQ;=G=@+N]DD:D'@K$&DY=U$P/%U_&*8\
MT>(4[%)55APW2*"?#FQT4S6E"@&EW[(EC]>L67Z6'@%.(9FW,^;E;1H@B%]Z
MY]TRCK!E]<BAKNC336@\+;Q*YH/A)U %E2 TY1>M@IH2B7UD<1US2\!90!6R
MG77(V(;U4YDEO("IO"!<7U-X W[& <QG+/#2M=3;L)JG(5ZS&72.3(&RL+44
M9)21%%.;QTDGJO>BIW6_B9[D!2F L+QFKO.2'036J-B!)>4EYZR[VR1^GS^M
M$66(6N?F([SV$N62V.-Z'IAWA^QP"8:.NR>H$DCR*.6TV<Y&F,YM]A3#^-*6
M/R;PU_ -OTQ*J=%JS?W$8"P8>512.DAR?5/S#/B#_U_<H"/YI.'WZ*\W\ SH
MT!\YCWP&^+?^P<O_CLAF77DLX+# P6VJI?=3AX[!#,O"Y>>.!VW7Q9\!"9N2
MNR?K_]XYJ26ZHP3^A(/,*" 2*EHO*1I@?AC90>'GEY;A>E+UU0Z>64-%/@5G
MV09>=XI>#18*9^ZRX=D,"9BX">^T@QL6SWLO>S=U'SG_J>(YO?*A,Y\)D;)4
M[EQ%$?!01EBV_+@&9^ZYC:C.S%>TV8J)VLK/()-\9A;_JV1":S9%NR(91E\*
MYZ'AI:VR*I/>YB0W(1U X/+;]8MUX']_XMEI[_^!Y?:>9T#W0?<HLYXPOR[Y
M7%$VZ(LCV96#%U<P\SGI+7VA_ ^GWD_;5\BJN%V,J\8C[%ZVJ&"::.6FV&*,
M>XV 7/LA?G?J9T!Q\VO]C2<7PP^US%5?E9)IL!>%T-NN.4Z6'\-3R(>Y*I)=
M16Y^Z#P#@.NCD#E7]#@#V4-_5MU'/5:S0>HI?V6/L8MOAR]\U]_/S*AL)Y=^
MOIE"M0OW6/V$@VPI/R)<L+.S\^[I)6+R>VIG6CF26$'\9"K]A5A^1#4G1?;S
MLSNK4 2?*?$D)]%R\2HN+ U=2?4X;G)HJZ&ORN&.R5!7E]*^STOS%OT6W5E:
MZTR'AM$0BT_7(CPN-VD?OJ>P4:TU/6 >>8XK0FV_Y#9U^PS@/.!A'YJ6AZ6G
M_I9Y6M8YWFRM%'0TSI8K,F>!RTQ6_'K#/"YJO-AS1715B6VG_FL8J[CG#6E9
M(<.!$IEAUM15JB$)0N_N<U7)[V^QW]T#O&LL'[NS8]>%<\08K,YGT1Z]4]LR
M_[A3)0=GGIH]2BVV[W>UR$UA1,VK*&(PXR/:%EO>SAHTFCU6ZR?AOK]K85Z9
M-=1#:["UKRNM>#-Q91Y]1DF/."BPFI4,N@^1T"LL'BRRVBD, '[M9RU68"%;
MK ZV[ZL<=XW>W^MV )G@_3;$+^\<%WM?N%(Y?G6(+?@1?]8^O- \))KQ1P"B
ML5V6\D">6&]QY8ZG;JD$QYVXKF,A ]'CE#X]W!G!;9F5URZ!HH*=9^\W0$#V
MY@7]5&/7+7YEF"1Z.1YK:*J! NH0O?'G#\EJ$G_V[LOXAS"8'&:X<)<B1UC=
MG@'>7T)"B3+12B+Y_>Q2L.\3&_1:N=9NTC/[>[$R1G;$UE( 4E!&S&*W9AYT
MU<5K8%!Y$)2.Q:DO@LJ_]_7VQY-]TM[/XDX"0.[@O"3B >ZMD./CHV[=@E)U
M,S],]E^YC@<P-\N%9AUZT#"RU,7VG$KC*=+)!KEOHT:YX<1?BNB$?UN8O=>]
M=W+[:4Q=V?*K;V;'E^'PZB]T&!]OYU))MIYPLST8_Q,BFIH ) <!?0  1%'"
MC/4ZY?%/CD>/@UWV^W[3:4Q6CB/%^ID<R34^W .U*V0[KBOEI^1O#*_9"QZR
MF,[['WO[GP&G$HFWVZ+WC_6 =\Y43/Z+AJ"T.):L@8?CDYT?VJ2B5G_73R11
MVW&,HXPDV.;OI,G(!:4WIG4::76#O_7&EZJ"TZ?8BG#4"#ZH*)+[G[A6:N.Z
MK>W2DTIR/#04G$.+1M(LY@CD;/)L5$^W1&(7Y>B5H"R[Q/R5@YT(8W(8ZC^M
ML-+[3]FS_E/V]]]'6L!B9];T>C:VU I6#"Y6XTUP[<(\/#*A;(3\#:\@7$>$
MY-OD*S[E9OY^B)6-/NT?7L4E5SA1@>7?:0UMZWB6<2,YWI+)*6YA\5:>IH%&
M'/A49I"Q(*[$%UV<Y FEW'E=>?Q!G<KZ8],)V\J+B/R>Q$&O >N<_K,49,F
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M?'HZ=C5@L+Y&J=.+S8NB%5OWER#XLX*%PT'P51*F(3\AFN"M_A;QH8>3Y<Q
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MDB$#B1:@'@JC*1D9:%!Q<<YD' ]^A$L]X[7SG?4P9&\9D@ZV>;V!_]#\"-G
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M^5GLC@=Q-VS$#D]'W3F[T5QS\51D\.T2P29-<[\JH^BKAXY3;?';<O9KWBS
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MUR7T6B1&JO%J1@JP""9C>QG$7\*)FT"X7&TNY(1</A"$K*<_$&G/4('?IGE
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M1&.R3Z5+6W).906QJV;' V^RN6E^]D?%'?%K7;..B@+HT;7T = LJ>AG9[3
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M%?$69H7K-L!Q,D8C7_6-CM,)OGQ*PZCV.?0RV[!=6XFV%4?B9K;\%?#6Z7=
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M5Y4EF;"UH@/-R=;B*A-Q%O>7+<^%YORL(,@B"4L:<7:?:J^F(P)#'^5;(R>
M@9!%M1> 0).?XQ)979/,I6^#\$TQ<WQN[(L35;3 )O1/@UWJG[ )5^X*)#"\
MJ5Z)!/'TW2M ]9U:&CZ20)Y3:99D5 P1R:%-3WMG4_OTE>LXQ&8N3;*V<G)3
MF^Z9%R' _?YM>X^.B@Y7Z-L!O.S^,FR4^OVYS2@UB-9TX\,%];HMZ566X5E9
MOP[,(@5>\+[V.(4D.#4LD#X.<S8*].9/,NM9VRO E*:L3=]^*X52-)^!6N&%
M#Z-H\!6P-3V8^RE+58]E="!6I)^SN#!%X:PLAEA;,?Z@''\.@?"M&<5B8BK%
MS:G>*P Z?+V],_S<F?X*.'1[]KWG_,<6[X8\Y(:8BBF'P-O-7LK^_V>MITB8
MBUX!)V_HY:4^&A@)T!KH.X[)1EO4D\+ ]_1/&32O !!1R2L@5?(5\*7M0M_,
M*F=^8U,-':8JDEC7^KCP=0M$3V[XGI B_->SSER\V"_.7?,_W.5\YY=$;FFV
MIFH[Z1_ST#Y:?_0?5QY3UN)5;N169$-S@Z:<T/T.TL>?#]:=SAV.K)VPK9R@
M33>%2^_[QP.."7XO.8V@;UV(CZ-D+XSM5BMW<A36)!^*C!G 946=:&KTH^-$
M_$,M$W'M49=[;?C1$)"ZL%V#:U.,AWIL2HL*+\!"V5FKR\ H8F\?RT!\T"![
MBJGB((L?GD=KUNQJL0NI4ZDQG MXVXRDR5Z'4G$#;\;0@12.ZU&"N$5&DY"/
M*IIN,O,M:?CUK7:@SL6I_QJ_RG^-7^T=*MLK0$Y9_Q23<R/&#FID+!+X4J!^
M4[CPS_P;LG%]_NSQ(%(3P6*0;VA8ON^57:J[$B"%<J.AS=:CRT>9LY5!6U$P
M*E\1A9?(65G#PXN/KR,D3PP2>#+ XC93EEL@(&@;,LGS0]21L=N/RN#S'"MY
MKE7*DM0>&\M&+]S^H*DK.1[CHN>H_G.]:<YSIG47A,+YJ':<(SAJ&Y7!Z_7<
MB+<2*6HA@6^D&<6IY!1WP.3(#GZ;AG<U?82ZKSD_V$L9X6-*B.,$5--/2]&V
MV[!#POW9*-0MYF?@@(JA+B6:*7GBXLTZ<?S=K4Q@[*!BLJJ1ZZ!<;22/E2G8
M 8WE/ABDG%K2I,+7D44P=*N;EQM%O^!B4,7F3=$^QWJ&8:B")WTP,/R3Y"7[
MZ#Z"Q$+-^PTS6>M^5+E*H (\;L!H[8,P?__;*1>ALF"T!V_TY7>TB(_F^^8
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M "X0 0 " @(! P(%!0$! 0$   $1(0 Q05%A<8'PD:$0L<'1X2 P4&#Q<$"
ML/_:  @! 0 !/R'_ /A5R_'^,G$CHUONA?$B<X)%&9Z E\$X?\_\^]4'SYUW
MDL2*%MJ*L^@DO(4\@[Z-.A?IB=L61(>8>SKC&G=;==Y2X?%623<% C7#QE(%
M9_=6B?1)_P! 0) .V ^\?GBLMZ4UNB_VPY_W18^?/7"?VCOH045N3:BG"7-C
M"QW$3]#WR.AJ0D9X91ZE3O"?R^?'& J $JZ M745SHQ]_+$:T V)G0AN<8.Q
M)(R[%DUD=-2-Q$I $D@!N9J/4K#7MVW:KYR.OEK<]%#9)%9/9I%&O%9,NF75
M8DM@:G7ZSY]3+F*>LQ/N?>?3.O\ /2VEW@:/)'D&7W):NW,.<L#B9JS(*/J#
MTF'G"%A01P!Y462,P7VD#>#V'AUOJF<#4MI @C]0S;<XH)!(D0CIDKS3]/\
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MC'H"5$Z.+H,$&/QDU+" 0*I86U*C3+K;'KSD,+Q5&P2_5)%2'6#9!!+$>/\
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M-SRMHAW%N=+NY%\JKD- UI],\F!.O3Y&3C C-BHW$KH;@TN#VZ_HH>@75B*
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M$F(,AI02Q0@\R:8J&$Q)RK_.4,,UP$\N#!J2[ 5XFB$[! ,4A+=P3R.7 .G
M+THVUFI3MP:]@T 2#88:2S#!DR#,4H$/%@'H8F*PX33&_M0D]:1DB?&>[EJD
M)<^IQA(\X\#S(\'H(2/5PCZ.12<]"7UD"] TP@+K;2AEHUD[8*,X%6*6,U&)
MP>NR /*:3DD=)!DEY#JEQ, %XF-A=%:&02%+R1;9=RH"+4PP5;@ B)F QY0Y
MT TM25B#(,$&J\;1P!'!R#E""QKL5I!Q(2,WU>1#7J3,#X68VD%\,_#2=)PO
MF#&>C=[PY;XEM;K%-R)41SY]'XO^K\:8('8_)*CZMFGSB*7J#8$9]L#'1'U[
M^V)J&0U)^%<\CH@'V>C& @<H"IK/2U,^)Y^N\'7"&T1K39'?ME*B;X/4TRP:
M %LMEW:\(9X07MOY1.61LRJ$VF%F<P9"G/$224F\0:^><@TQT<RO'M,X7GP"
MDWXK@-09:5*_+;TOI@KX)$,=7RK+ZX.R09$VQB%?!S:5YH\Y0'XL3Q]5[(B*
MR#^(46M%#6V^\X4M/Z53P/#,1@^$ -T)?!JB,-\*-J8X !W*-5G+#C+3?UKV
MP*4"D*B(^X\8(-1P6/)$HH%18)9S8EQ^7\X). +5XY]XP<$9&SQH%PVS6L#'
MU!A[B<MIN0/\DXN!/&NE]0?U8FH7A7%?6)@U.L6H1LR2CE B-@!DL E3$-!H
M)V(5#I8PI>$\H$I,HA8N8@-9*J(F9@UFB#*I&%DL=!,,]B2PE0!E)8OV]-"%
MB!;D(DO4DEJD!<)6B,%5?PBZP2HQ)WZ,/=@92>0,\3D4I*.U[(LY-6=$328V
MU$83CV:]SD<Y=@DQ",8>@7>6=1_*>#T*_=O!RT*!5RC ?ND[\/4-+RN:@9H3
M+/L&DMRAG6.H7P"+4HF:SV!DV;:$\0:4#+!-<K*B0O2+N4/-RGI/>5LL-$1T
MG7C3I,8\X7T)0 #9=^5&3\W31@,+1, X,C!$@I)45@:TB8W#6%.'&_\ N(\Z
M3UQZ:CLWD^KH"XIA*2&T$K_J[AWP3T=^-<0EE)RFU-!!+[M-"W6*N%N@14:G
MT-QK I(7BPV"):0:YGHP:20&T)W,OI?>>J2E!KV9/I#[G@7M-+N&'5SM*8!2
M7Q*ZY/ !@&;.G2(ARC"[X21W=3B<_P!4R6Y%$Q"H'A@/5RL%ES24@X@%XIJ(
MC.,C=0(1GJAV[C"E !0""9C3 5K#UDK^S)7F%BPP>6=8Z?=X$\Z@!?KC*?I,
M(6B!H-B[G(7M2FBBLB$$"R0S^J!K%F!09DUH643%5 QJNOWM%M%MJ7D-<)"0
MMOQ76.5&>5(UD[6'8XLH%D7[Y\BWP'*M!Y<I?!RPPWQD5+;+>!'^3K7,+M3[
MT"Y0R>+(!1O0^2@9(H Y"18BQ]'<>$D9E<?R&ZK)P$'"WH2$!=I]6%QTF])J
M>M5[3YR0AMDX@->H@=WC$PY]FZ-1H&#GA1@8W<1#M-.FL% C H4&EG-T]*SP
M^I!^2D >I&&B(0& F?84[U.[Q7VH6P.,W<_6IPH9]9%HK?TO)U!UA2LYD@F9
M-84B4(W:>T M[(+R,;7-!/>SG%+EGY\<O !ED@4;"G@'<2'15(Q:,!F""^%T
M:UQ80S422A4\$:"FP@678%D]=X0FFH4B!WJ1^N#BD^0CD4FD\3)&F*DAC4(;
MY+G031@2#!"!+_4G$3\R>DT/M/[7E/R"3 A.!!GN?/\ K#L^=?EA4RD'+7WC
M6'N.'$L!<%PQ+O;R+P#/&P6-_#BAHXR.Z<_;]_KA/P4$V55<SG*/O8#P<J(Z
MR3*0"RD)="*/W+*B#.AB@G26ZM.5PEJ+0ST _EDW[$L_\S8QJ,K$T*=;(>?#
M-X;'/1VHW;BH2ENQ!6F.AQ-8FZ:>=ZWB5J4L#%H0SR)^*8%&</J+?C+L:8=&
MRY<1#J\/LW(\,[D"">2$_+ L^118(6K!*M R1@X#=I!<)(J"%;FBBJ")(L7C
M^O3(4Z6]5M%M"[!XQ^A1L$X[?2K ITU[%?/&3AF'T25(#]!)@0501'4!QX_R
MKA$D#:HB !M Y+_/K&AI<F^3M,SP'J#@@=K*H6)"\#"MQ %]/8@S-S.*>I(;
MY$5$ZXPSJA5#BY))DHVUBDHJH"%K:5*$N=PO!,HNA:'K%9HA7'8@KV3O(4(9
M+%"97$3*S=L2 NN;0PHE(/)>0.3S# 19.96/$N\X+QQ[?IE\?<HY$[V25'KC
M 0P@!:>_+#)2!GC$%[?;UA4013F2/,L[]" #&DJ_M[Y&+ \$;.M_EE3;Z@%$
M(D2KH!VO' V8JV/8147R5VQ9"Q(RYV)$2N=PE0QU @\3AD@ ["U20*<UUG&\
MVF@GK#F_I&("2,*P:^AVK6V<EQPJ<\:.0'(IGC-+^+-=""T OHM&-1AQ9>0
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MYOX&B"P$L&'+*<3_ %B$_;&)M1;WF'J\&05-77J'62_"/GM/K^#.$JR%'X%
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M"2$2%L'J(HJLH1K%H8@D,'?:[# 9*)#Z;4V30=7DLJ"8<R (!H;@X%$SQMW
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M#X):0),B'/I;?@7T]&3_ ,R:SY^?]!32Y)N4J5N/5>([SC"ZRE0):DC(V6!
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MP623&5(@PP(C(-+'#Y]<F&9/[ HDK5')WDCI\1YL<Q@W0I$<W[;DI@NTA0\
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M4*XXR/692C*X!B4HLL\C>OT0C#02,"01X2)&(M-.0@0D!E%.<5G)3(00@XU
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MP 0V;=3=*]LC>QBR9SP_Q6G0G07%1C 0<W,.YXX]\L4.VGZ*&-IYA=0)>&?
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MS !$.:)5I!@3,5DR0Z9FSN+\Q1[Y;>AG#^J)$L\8'!OP\GU0,381YY$L !Q
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M DZ<9!!!"TU#7F#P,X+P/9=2XZA)SP*>\."WHV,0[3O$/3)P4M-=$#9:\?\
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M;I(G@9KG=MF'5U5FV;,-DUKUSDE<6ZRT0)+TF)CP%.72:@2KNTSBT!2 8(J
M78Q+:]DV.:@A!#K'2B!DZ$,;45%1&GK:3@E%6!3*6C4F]-&L%U 2A "NAQ$D
M[@\ZQ8Q<19"!=#?<'G%*'%QP%;5ZX[PR"4D4(G""GV?[[(7<]H^V#C0H[%H^
M';$!\K)B:!M :2:P@13(,7$0A0$L,@9*%#%]\*/(&2#LZ!G!\ B04G)\0*2!
MB+"P;@@HK%&&]N!S92$@#0 (@4;</'!M@?5.-:;<G(4T!!,1LS;8JIR7=1LR
M"=K;4BF>\V8;&[1'TP4# #G?[8PS@_G@".>?3VYR0.B8F B?T;RJO^.,&!(
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M@85*E@D'5S"V>-X++ F$M126B#;R; DQ#4+Z?GOZ8P[Y$-KSB#)!@\^O[8Y
M2:I$;CQ]:O X1B M023T/&-U1<QHD>30YQG1*T$2>ELC#-H%*7(:2.H8BY58
M0\.*!L:D>9G B"]5TR["S2$(C&&>4KC"(LJ'%H0$85DA](DWV.$:J5*V[O\
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M"4GS27'"N4J1F.)*?7-2)6T[0\17.YR.XSJ(K*2((  AQ624#$SO$RV011?
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MPG'O^]?+C;.1X)-9MU"G@3&L0,H0ZN@%E<2)FIMT@H4:TF(=7"-M/M)T (F
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M 3RVS>4HZR&W[OTYS9 K-&8="2H>]8U2SPF$>1ZA@M?:88U6W(V)//Y8]5(
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M[1+!PB(R,ACC()#4ZZP+5!3PI^WTP1A]!-1F)0U8,GTT&[.WOCKTQ^RQ0#Z
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M6*>0)E$HDY))'0R$4DA$;,.V0&%'+&WEE_L"3ZWUQ,\4N5<(0!<"B,\@9^0
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MM5US3BZ_N]\(>2RP_'I' :9#LTNKQ5Q,W#O"[#ZG5!I^K@=J&HC*'1XP*X&
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M6SLOAO6N1K7WY.;8$86)NRW]'?IONQP2<'=Q%7*:'!:%-NPMF:*()L5+_=Y
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M&46\>.<H._94SDN]24+GJ!_K1S?TKOX*?*2X_*IB!/\?8)X5-*8Q3ICASAI
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MZX/GSQD'XP?/GC(R#\8_HC(^?;(^?/DWO(R/P@R#Y]/K'/\ JT ^)"9@LY"
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M*R.)@5J 8?-8OISSU^G"\25C@S-P] E/[,&E8*4P-DNZK@2(&L1V#E!25M-
MVZ,6;J6L,KPL@0 @287S$"Y;4^'UO*GJ@H3DF/E" *]K7!SZY,RJ5#2$#5[$
M?ICL IS]-57_  G*_0'&O#L@X_-S6>M(</@E#%XGSA,W2H(=GZ9Z"*3*<@5R
MVF6I.V0,$F X[2!#5:(8LR(4$2E/J(29D<U+I)(+B4,>3)J)=)D33"@B1.6;
M_%LA#$$66#> $4AFF#-O-T5K'2)-K 6I*45X> L:X<:T%)J5J!HD96RZ9DA+
MX9Y'Q(*:S0:=H0,):>9B!RCQ1PM+ <A-;XA M N)0J%AM#)61 DXTD*#PMK<
MZ,;XLKM&%\LHXF7+IZ"<W"=JM)Y6H2$:CF<A9)+#N/\ 8_C+L'NV&#EG]*-#
MA.D6'(1!%=!VU\W.!7!^-"0.!@* /P9X^G\\';#AR@,TX#PNC\H^:WZR^^":
MB5W..$G!,+8,_P#'Y\GG&OGZ6OM?662IY/H]!][B3*+^23J!/1OO^Q3&+3&V
MW&8E\5);N'+0)7(FS)_%257#Y$*<Q85EIE2Y:#.]#U(_J$%%R?8A'DG%C!FJ
M?)3DG>H[7'^NDG0_5!KTX/4N\@2;>A7K;/DK:<'7,2P-GTUWCF**MR!O[&K>
M.).QI_7]PMX@Q1K@:!:GZI],,;;-:7F! L+KL>2R\L[;GRMN?;1D8E@*;I;.
M" PJED]XBV229'FO5U+2P(SP):05A6"//$@M$"LA>^B*V%QE9W3:@B28#08#
M)\DL<GJS'F<F%BO@$:(+ $Q..2&O5468:K(,F 5D"FW0+U9Q<2H(AN:=!,6>
M!@1D!TDGFBS],D&84BIV$F^9?;(!1[ C1'$7(7MY<% H_=G]"%7+88:WRJ*2
M\>S+HCM](21WZ^F$/A-2"LSW3'UR.39,2Z@1Q,W[XP%@GC I/!^02)$('+$U
M'!Q2$ 4E;@GTA35U0GF0@$B<CCDUVE0]\LSE3A 5>TJ_GFA>BG:7._KCJD1<
ME31/ F8F]XDBF&A\GU].(R(S"A1Z1SK&>5QKD.";..#)&DV2E**0".,:$=8I
M%N^?+,E0/!<1%L$K@Q H6WD(P("+I%,;0!(POWR?969@Y  [4]> T(A4O EV
M+"0#7 +) I-0$ L@JD 8")[RA :&;!IM6I5(P6V><?O-OR%P6H2!(%2"G7$7
M?!&^-:.,CW> N* >76+18+LN3HT(_#!,O"P@5Q7B*<J"2-?1 #=WSD:-T]\M
M@G3S]<FK^2A1._4SE[/-KNHG+I@&T-$V2-DIS@@/0]?GK<S_ &?X_LI'\K,/
M\@^T;N(#.B8)Q8U"J)U6 ',@.BS<QLHEQ)0AG@^7!44+6M!%SO9CU@CZP;I2
M)ALQ)! E+M,BSI<JG6/3S-<?EQ8L7C\U]-\D_P 9\^>T?S^,_P#?GZY/SY7[
M^WXPW\N_?X(F. ZSY_/PP_;YO]#/B?E\YSX7I\];WDZ^?;UBC)^?#OB7)^?*
M]L/G[;WG_?AOG/CS\^F?'_E'U]36?#]?I^][_P!>4UWG%#Q6:U&C%MK!Q!Y5
MMH70&<UJV[5U<U=O;C@HRD 5)JZ+69L#*9UO#P!24)U)HX/R"$.3H:7]L?,Q
MHV!0Z"'CUYR*QW1,7-S]<@YG*FA8Y>-^ECJVBA)4, H)@,F3M1P(:1%!PG@Y
MD(C'H_1CX,(]6>P[-%<FV!$&K$&BI3R/ZY*55UDVL?IX5]R0]:P/;"6D8K95
M<H%@<3PZ?\*-U*Q*,=YW@@UQ6"^63BY>T$W6$A;R,AUSECEO>YOC7UP@U\ &
M'N+XBL+AV%#A)*JN[QK8+L#,R[-NDQ1%#BDRW]<EFBP:$SZ+7,M=LOCB;D5Y
MD1ZQ&9:W 1.TSR*$8;0@&&9-)@HA:5 8Y.)YR=344@MBLAYL3D0O[8.-@"(\
M:V8UZ^")!!$GV5"/GUR%4M5P07UH)X4Q&>QAR;)/>8#8PS(6-)TB7&FR&=R6
M\A%4) A0@8)@TK9%BN '(L/(EKDLN^D^+51H91RJ.20B(MS[:$&_$V[,9.2L
MV1/&<Y*V=J@.V7P@]XV:PAL")23&U"06)AFPQ?6)2S%\8+%#XP:J!^N10(ID
M15&I\[PVPF)38["C6#USY$<B!0/.2;RNF.2T.8CQ$=Y',U6?Q[9'83$Y+&[<
ML!YFX.UF)*EP4< D DS-->$$&%,:*:''=VP($@8?[3^/[*1_  #]4?\ EXUS
MO$-5#N;GVY=_K."(ZF(=0%-,!$"H.UV0_O),&^5SA@J&*9>Z:]$VE2!5P(D4
MH!EB@S@;82WJ\N\A&.2:>)^$%G2Y)K^$,YK.<P7/I#4E67;7S<HRO-BA_%%2
M8"//(YG8,LT*$2R+.'P*@7)7.9+G^P^^;1"SZ]Q ,#M7M(8VY^'@<((/;1BX
MH&:IZ"$&,#"--WR:OS/]X_I?3/@O@KZQEAFFY'7%XY5CM<6#I0&36RKRT>(Y
M#$IYAF<YSTE]QJ1RX;D:9,><D[$&-W]%DK2/H 4[S!24&#GP4X0'2)M4BS]K
M7Y[C4^L Q"!_UT<>Y&_+E>3/3%%J^DAQI'K1KK%ID*3%2:4 03">6BB%6&FI
MX<%LNQ#+BCTXMQTA:0L3A-SOT;R1UV/U![>ER G!,@C2IWZ9%Y7U-!%1QC!5
M8--5.I/YGB"@7*$5;"TNFS 8)(=G*OB4="I).\+$S-1*#6W0J 4L3ZK^SKSR
MSOSE[1-E,+UXRT57 PMP.Y<3B.)IV%B=0P.$[EA!EIZ  W$V; 4&C0 %(BH_
M9]<&Q_V,U EKZ5'S]\8+J^N$IXN?W^L8>X:I@*H>1D@H+(ACJ2QEC.AB1 $&
M/.)U$3U\05:8-$2J3(A0=#-KUR#I#-FRC6KB?;HQF@0Q'I1'%M:E7:X,A7!'
M 4<LWZ3F[A2V*\C.5908>;HD $VEA)#%$7"8/50WD]FSCDYXP(&@S+M) _-R
MRTR0QS*8'PT39@MGJ %X5EHW#)K 7(11F!*Y<)"8$FI$F(8G9VX)D'W_ *:@
M#)"BFI"+)TCJL%,3!P6X,NP$LS#BHS%WO!SF,'E9/RD?&463=)"FR(@,^&"%
MG@H 9"J$"$NZC(RA4R8%RK)+&%?+TQRB"1-%P0WBFD_LJ%A<$P!>(#%*+33J
M],;%-[G-)$+A-# D1G'7G(B!CFQ7V;QE&H0%2L T$<@N(+KL5NTNHTF$W<<C
M#D. &RH%CM:@]V,F6;T(AVA*'AA,4,H..?91FR:T$@@9T-[;A6^:$<A_:_C^
MRD?Q  WY\[S7_F07U%7A/2.A!<_#?&'X)DWC+!*U;8YA)&\2F42>37A/')!0
MZ)'<X\RA$C.-@':8W*/B"*X7(/Q DA0,:$4 R$Y5;,CAL.!%330>N<1Y HK!
MIQ>B&3"!2 0(RB)20CROW:GJ9Y%$G##:,.#:*2M+!8.#I^N11%@)%+$V+U:8
M-^KD@P$R7S?SY]\^2^.)\2\9;Y4AL?>RZPE!G<A_I*_]!QXMH4 ]MP!48<RY
M6Q9U8'@N4(%@WB^KBHD4;Z7$Q<[5(0%NQS"Y:E! 3?+X_!JSP?O]I^QT:J#_
M %U^?E^L^V#;I!LK]6M+APU@Q$)J02"4DLJ$">,Y52H9LJAE)N)%'64K.5FH
M1+K;W\/TCX57&%MO "1=#O6"-0*F+3R5D<6,E663K9Z0RV+L4C?2W0,NTBAJ
MLAN[)X& TSZ(SC4DU,0G)#B\!H\Y''<(W[C:-\LW#ZK^^\,BWQ^VLW%@O4&S
M]9\9(-*P:T<1)8F4P;SM)B1=A<HMTT"",%"32@2(UQH^S$$DTFCHE):D)K$)
MDOX2^;UH\]3H)$<D%":4,J(CLA%66+E$)'C;H A,1A[4:47UB0#=@, 8;!^B
M4*=3G2<D N9)99!;7E[R4B:%*+.:@A>I:R-T$@#0BIE$@L,F2C 0,+2G8)%F
M*J>65JB>RR2:HS$2*$TP\VE5RWZ8+AD@H-0^OZ8A9S&L382J78AR:U1+&UIV
M^7'(AGIN?F]M8QBDZHGB>XO*#'I@E;VYJ&>)2? HEEZNWF><X?SM!@M6)18M
M8('6B4Z2< B<HIDP2B"%V[+],!JDBI8)YJ(X[Q(9N 9%ADU+5[K-+>42%M0:
MLGR'89N2R&(=@HM>N[PE"84V)$MIIA48$X,:$ 4!!QSN8!H4F*)+;M-:*KJ!
MJ#(^.D F&"VR86)@QV $(3(M*5,Q(1$AIAU7J?T42^59L.JNF*.(1,%8\=Y$
M29-<H#Q1QO($@1XV= Y #"2I%RY<&D[>Z'I(C^S_ !_92/X@ >G\3]/,Q'>L
MC>#"G(#S)239>M<0/]'"N2R8_!-PL^T_CX"Z1C![. ==C2,D9P_!WA@AP(%2
M3PA U\3OC4I6!,GU0!SB$O@$EC[]V=;1D'00R&L:L&M8Q]@3CY'HUP5!=Q.?
M4>LFGG9-1)BH'"1S-K'E#EXAXE5B\/+1<] C?S4Y#-G:[QZ#-B+O/F?^T1GP
M7P=\]9;XC)8?+?(2P+,(X5NQ+2U)"4LXC<<7.OSI7=ZD:7#5+""(WBH,B%,6
M-5+PA]JF?*;@>!?V#F'F21Q$><^4]A),FB1VV#G\7@UUS6GPV_UUX^:O E#9
MVC&Y>1 %8 ]6^68$*825B12"U9&)1 0\Q71$)4%*[=+E@1?+">AX4XN9N,7.
MK9SSB2S8,3TO;?GA%]$H618YP!5ECG)]T5R!V ) ) A)"DL9L?J'VZOO$2<]
MJ_JR"[^ZWZ<^O&6==\V>:/A46HTUW=_4#\\B<;(R"\6-?<I$:R>\X<8?VZ6@
MPH5)A\\D4U7\E;>#NC9F8:<S(.I[<HA:RMC:3S95VC*[]?T_3#[G+$?B;,W#
M$2F(K=(<D<C( I4*A<C0@D,[3%I+8F$ H]02),@HPXRUPF$69EIHBONT0+4.
MRCV)><9:<(EV3&AE=<8AF.RH L%!%BZQI,:,$,DZ#N32H&\4Z1D0$K,NQE1P
MVU:*M@H7%@ER8691 -QIO<H+15-K8XQ[ :%/J!YQ1I\Q9<L(J%<[[(C%O\:<
M+5F %5Z")7^<8WO9YH!*2[)+&3%.ZDZH6"F0L&4<H@;;9MQQ#[9-I$R="*L!
M()K&*)-+J66,DYA&T@A1P\@2X=867%%C0L/62HL9T!4M;345[Y(V.*[&G\9%
MT$IBA<M<PZ-H</$/7$B 8#I ['@O2(HH*T*/TCZ\-X/SC!".:B6$DPXB$ NQ
M%%-&AI'&2O<!=(K &. L&/SC(P " $1KW7/%&>$M]S!8$Y[@H"BA\9K#YLF6
M4&5E"W^S_']E(S^?SYZ<F*9JV31SDV2"K"A$LD]JO_=,@<H:XF2Y<:'H"F4.
M%>>%$EW$TJD1$<_'0<^*B&-5%=Q,40SZ&_=M4!,V",1F885KHP")QD2DS5AC
MZ8#;15V"8SZ43XI$'3&M) L4%<W/NL*\B PC1!"W0J)@5*S-1UC68E\%E<91
M$Q #B7X(<NV';[%E,!,N20'(FMM_=%XI]0$[0FN/,\6G%'X*0%"TQ63\J^/8
MNTPE"171SD'INRWNB26:"$\+(9+GYB*\-QQ4ME@P4*)I,UTBC#BD]4I;0VAO
M3.+62OT;8LBE"\*S8L::)GH6:U69O##"8.84"2Q<F^C+"@[T<!D;8??>-SN-
M6ARKP9^PU?=J=S$C/^N2UDZ-*92:&6)SA?P"H@F@B\'T<4!,*1-6)K6".?&8
M2KR%GIEJ"7&84#$M6)D:?2G\GN,Y&&%%V]]?)_!X3%0Z?U,YPT!)HZ2Q)YP"
M3TV3+#K$K,:8CIT(],( 5*@DN&=HT'..17IZ#6.VVN TK-Y!QR,8E[?X8IX_
M1 $4+*]ZU(I)-4.0&%29IZQRQ()Y9?WT9:8241(\*P^E,FL;(R,]D]OJ8*C%
MY.;Y'<[ZY\N*(-=;KBY5&\HCY;ED 0IR+4QLV(M*'A@SP0PU:"YP^(XE4- $
M -5H)F.*$ZM1XF=L ($L[?2A*BQ 4A2'#::-25)"AJ()DCO3-A([CU&3=.-D
M-#YYCCB1,RF,"W&%F.')6F$P=""B1T0PM$);#DWS<.12(LK<0!"[R!(>FCE%
M?]R>1 L_?\.*$T^"6V?S$02&\2;$R"@2U9JW/B'3@><0GLM*=R;<G#,S=&AX
M$S!  5D5B$LC([WAP-+D5+:@6,C4'2"RAI%2GQ\0TXL9@PJ]YXWRDP#94406
MH'>COSU$D;DQ"'F?VQ$K  A3I?3[X2UWFI$[[R6E&TT> 6VD+U#,J<Z#V),W
M@(@=(QF2_9 #$BU;KMPG([9YQM"!%BD(7U,@ZW)J5D\T_;'!$R4#=,/GHRD#
M^S_']I(+X8E/_8; ^08]&]AOUOAH& 48@H0 "A)R#\%:PH3WK>1^9B18/GI&
M:P5%&[L@X&)W+XE@_4JV )"$&"8,KGAPF; 0  HQ!(2DA.(ZC'71:7WS>WT&
M(8:YL8-S4R6O%GBZW1%D#B=*. )TU;+2LB7QF*]1@ZD9XGA%:)L_KDAE0]"1
M$<-0Z\T0F,    Q,0,L<&I<(PO <7F>%1L #!C(^^"C.'6(-NH)"CECEKEEO
M<F#S@=F    : @/;%>@JS0!I PSOG.0;Z*O096$NDYZD;"$:L,U(\:_9=_/1
MJ!I,?Z[<MG(]O*R5:54*PE2DW\N7N\-%;7+[1D85457W:U/MC"@(C' F1^08
MG'8M"-[ @Q.9.EAX>/WOT?KPV8F#< S=OH:^NO?(A"0W.R/@^^;$=)60WK43
M<:F'C$NI %#9L U76EG;'?\ (3@(DD73D):=3'%A$=@61,X<],)*"07?#5E)
M)@WP$MH,>3/2I.(@S1!C@^>J$/KFQ]HY8W.^7X4"9.)Q.2$PMI<!_'2,Q!V"
M5Y@Q(3C-6R:/6H]+OGZ9%''@J$V6$2*N\2L3W(QZF0E(%I"%PNED-XRO(*+&
M4#O-GTA0& *4FU0UB"$*S0:(%!M=0\T%2!,B@W ((F.CU^8F<A,8&#%V+KO1
MDGR9X10K+H0;ED(;1#JFG-K</F%6,'8#?&6JP"[7'>Q+;(7 NZ"!5#&P!59$
MRNU XT%-&UPOAJ%>OC'$'*$>M?GZL" PNRYK-91Q\!H!QIV )5A=;R#X20;&
M!YA9]!QQ@.--SH9(B1;9 X18.Z26  E8"3.'.:^C2386F#,4QUU$0V4;8C*J
M#%8M8W>&,.#>+#9AM^.- TZUOS@ZKRF(&MWY^SC TUA&^*Q#J)E++U>\=L,V
MRA*20$+9A&=V&>AH+L>9DQCZZG;ML$A.:E+5= NN7ZD;1+#U8%1J'9JS*GC/
ML@-^2<5L)8(^C!'MX1#^S_'_ ("D?GS[9]_R^ B1J$@SB.*H-(_<IC4SN>+5
M )58(\USME*7$LPL 9HJ_00T#" PYY_LFG ;=9("R(P99!&SLJ8UZR<>^;4<
MNT"*RF2;D?E]=_?O+,!4ZFX.#W/UQ@0.$Q[#'&@AG<C)XC=!@8_<G$^EN B0
MD!JY)#)XQ?I"<-[+,V"E90L%8!X=2SSS@ABOC;](^H+"X$]Q(#(YW=U6W%.W
M7VM3\\&<U40IR$"ZY YQ3/DW\T*H>((H@:L7+, D T&$UA+R:2D6JNQ0,N,D
M581670!):)@F,)*XT@!:6T054SD$R W<P4#E & ( 11(:XOZQ@_@IPF)K;4$
MX-Y*1)%"G@BM1.B(Y2?XHQ0D"Q)$S)(9PX542VK0D"D4=,N0DC!"E,6&R."C
M%1<UT '06*92\K\M! DW9+>4S).X@H CD[>.],FXP Y**&B<3,PRCO))N/9"
M%4E]@5F$'N\LG+#:X])TR:]\%.Q@X>U\ <99%V2P"*@V1O7+)0 K8V[N1Z9?
MA)!T'3.7[M\9H_W([@,T,-N+,2C&AA0ZS*ZG0AA(#XC11)?,Z Q3/ELF:/&:
M&%J=W\_;)K)7#<%\:OTPPG6-B[CWK7C R9^6#P)P5*CFQ\^?EU6-(Z '0I(H
MIT<0J$"%% 0B>)<.)1Q0]:0;/! DU8FOP2"I.*Y"U*R.0(& D"$X)0(0"/[7
M\?\ @20  G%+22*(F2"K)$GI !$;LRO/]6=*H4#'@3@  0! #0"HC59!^$RZ
MV5"(P$;(#.,&GI='00[HL &@@35OV-.4VG^@DQGA5T1P05 SNLV X08(@ '.
M)GDQR8FNA$R/,$%Y9K/2]QY P1]7SK:85!>Q14$,0N3ZB)$*#  E"(;;6E&R
M1$Y7'&U09 K\F:5(/H1.2OSR]@RB+B#K=>2,1+,:T/7!B!MKVR9)E)$@=8\!
M(C>04&H(;WF4"93F;7&4#6B\/F6K2X0X5I?)H%+7 ;%.0#"G17+2 LA0ER&<
MGKHD_H!$)&3-Z)=:I]^<@9L!KCZ9$1+#Z_7\^^<F,1(#UXBCS_&,Q2=>8GG-
M;\"QT#1INU LG'U4TR0[DR8:)F2<A[+(BFF\1/*'=YV6]#2D(J827Q4GT,GW
M9XXW[Y7C6EB4VUHM0%8*^R@28%K)@EUT<"!#32P!KO M"$K)'2MPV1A O=X]
MPH0VU8DD6/!K#.2( 6#55>8.!.$:&HPA:"%Q$!1Y3-KF(QH"Q<2['3'P1Y*Q
M,N21+;1SD7Z4I)09TD7$)XS>TY+9XY8+8,V8Z+Y:3*H$B3MNQ_M0,_%DH" E
M;G&&G/6 DHL (PY0@=#YEAH1%5-DLY"H?W;C\ ,C(<(99"P.I)]K!.A9J>(Y
MKH > A;!+&D(VL=I8<2],@ [-^,2PDT7O(^?/S_M?Q_X,D:^?P_H8P)4#:Z
M2JRZ@W+Z0. BQL30*2=G009N353\3@'9VJ+DY8#_ #T)L(,<(A"%/]S1B!@D
M51Y.\9IE-@EWP3#X8C"<SX"!>;2V;0YQ F]=QETP3,("6@ZE.=)(W1%; B0%
MP6*)I"!,TDEEG&\A]U$HR,OEYCM,M!T"1:V@I Y F60L:(R\@:;D5$Q7+_.E
M39;3OKUS[_@X<!(!F34-0V1J^\AD=(D?QHZ$IXK.*>"@Z(VX8[:0R02CNE89
MMT^=11C=":U2:O=$:@,@XG(E],0 U#M6O:[>,JEL@<M \QSO#,14;?J\-F\*
MNZWV\*Y-7[XE<=&4AC'4A\F8Q$(<I*%H1):FU.,(4R^J49,$@*48,/J)E#<4
MX@94&C&E,FV"2 4&12&6-V/'B2B0D*0+%\1$=D <>8;]HUDT0FYV54\CU3UP
MBEA%&%UKD>HQ!5G05@!EF2X9 *YGW!68=3(=DAO%^D#.@!<*0V8J81PB5#SH
MQ?9);1=$P(V#Q9B7*TBKB;0BA3N<Y$CP"-C3[BIG&<B%;EV35E9:E="W%'T(
M2$%C/)X$C&@E%)51CM!$B;5$C6B9BV2D6(JMZJ?D/6&,RE#&742"#879E-AZ
M0X++(4U(7,'SQ_;_ (_\%2&SWBC(6@"5:@CF2E8J7D* P$)G42_ MDX&XT!^
MN)Y.3E,\NQ'N9F.0B@_&LSF-TA !4-PQ3\"(RK*!V9)9G+N_/L]\;$6-I80Q
MJ:B8]J!+["$DIHIFK*E&2/JVH780$M144HJ)+BLG"'35(":>)1Z>]]3R:8^O
M&5B@E4G#\MW;R%*KD*/V G1Z+-0T\( "R-B'D C)$0X/6?B12%!G!P,(VD62
MUI@+7E/;R9T&>;NJM\9-ZA>4!L*Y3@K@!0Y:@FRB$6LL9H!8!D2JI$:U1D=*
M-RE"W!I<S*WDY4KB',;U-/>1LJ$MBPUUCE (/KD&CZXS3G;1#P>3]&0BP((P
MF>PZR7A"[P<!7@>,DT0'";<%+7Y8,NJ-$R[YC/CD^T=S%%@T!E0EF+C3W0N%
M(QHTS2#(B5!NEE!% @.*A!,5<:!Q:&6*U&1*W+=LP]C+81D)R%P#Z,@)0@3Y
M XO7&%!5.^< *)*;)7RXZR $;$!PL0Z.=:!$"EQ8B4P/Z!J=CX99Y6=N')+9
ME4!3<'A)JJ8W1(#U/I!:Z7"W-11GH<);:8CIA2+D5GHK2!%J .+:G 6)5J'0
M.Q0L;7D 2B2$+ZM:^F*-ZB:64_?OG1AVB:(,A$75/;;9PYR#4.3)X#(+C#E$
MJ0T8GU^CNJO>JWOQK%)RZH*:13%V*9%L1M"D.Q&GD_M_Q_X*D%PC@*ZI-GQ*
M,6+,GZDR\G&C\\F.'B&.H)@S81(2^K-K3+=9ZBY$4:93!X=ZDC$%)HL#DI%;
M8WQ+E[C>/^&&'JRUI,W##@"1 #)#D23I)J'-TI)AJ$\H!I@# 54M[PP7  -T
M\A0H@E0SI(9ZC8"AF0<02KR-!JV)MRNM$?&3<.%4!""8D==*\A$HE.%8LL[)
M')25("(B!H6%O4!P)?HL2 I"Y<3UZ3D'(]@J=*\=SK'#5%$>:DDXB;=&,C21
M[SU;\"_IDZF]H1%;#<^)&L1(=%KB%?7U=_T?//MB>U2J].:Y?IFS$NM.?3(D
M6+,] +$^)=SK%$L-P,.L6Q7<X&!=K7R5::A/!B6((66@F*TY(G>""+R3$*_G
M\R?6'K"?0Y\AST6G#(!!AU0G7PP+EA3B2$)W0,:8#M11Y-N/[10(RK!9;DOF
M,5N9!FB%4$0\F$K,<-Z"6B J0E'%0892O%REX%V;R@MY@=&.="$J^&&T4E"@
M6:.7(J$HP?!^A)WHCHUJ(,_]?(ZCFF\(N31D&NX12*44A"L'&04E"%# P8['
M*8E 8A@4A]])CA@D):6Z:F6^LAGF1J1(,.0?;*592'T-2\R!,!#@FFAE+= W
MZ\_V_P"/_!4BA)#JDHOT8D+,DA6]"4'U*W+&)CLX)G:/ZX%S&6^?/USLNZ0I
M&B4@VU"LC(AD):0H)* 19UQS'*L'*T>N&E@53!ZMU&'HIH"FAA"2)@$ K!^
MJ/1 ES4*IP[JNQ8H@F9\A(YB1HB219>H.@2*8Q$!A*31"+#MNYO$D^,K!O+U
MFPD^V2K43*\)@;$(OA<WIH'F1:X1*1PP8O\ P=QW*Q3*RQAO$.H FJD-.4,
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M3"#%*$*3@%/1PC$T33DPO%%@$$QD<.!ZN6A$A#51@AIXSV)#2WN2-9G39/&
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M+-/MNB"PDAQ/2T1(1#I8$E/!OOYA'@87G5^,-))90P6D06C1LM@J@8%#):=
M3NO28H&!*#0$R842<"IK!@(#PY,L<X8:T% [%1Z#F?PD0+D?$ "E*56!O&(Q
MB;%0TO;!#3$\UP5Y0$J5".)J4FSY)^S-4BOA":,8/?6@+J#E7M&?[G\?^%))
M_" R1D&1[A9QM4$PO20CN>:,@9X-PD*6 S+OT%*"3^_TA+T\<_A\_36EO:Z)
MIR46!JV O *$5,!U-F-8#6.=R"1B3KB5RC%89H1#60B!^$95H%&  T%8H04@
M=S2#(-1SD$E1(FY8<7_&;^NN_'Y5BH\<U-@UP7!& 6C(JCO 0/=E.9H1GH Q
MG@-52?<2/E475][(-%04**QJ1(&"*!=JF  ]BD[+L*@)((PB1!GUD$&]=D,(
M<#,Q[1J"H3$ 2(J46![;-NF1Y3"-S$ ![Q %B2:4R,8;$9!5._*K^6%4&N "
M@0P!U5O$C;+(&URNV%X*OF$RBW4B7ECQ*1#$7!.L5*BOX0J=\9"IZ-$O:D6,
MYQ").V5C([EU4BU#LC<+DW_=+DI4@D(V%D 0PM%*PT%(N,MXO0V@EFE'P#U2
MW*B, LTY!9")5YP6:KY?):]%*W) B)#!E"J0!=:@[A@V;:J.<8T !LAAAZ%>
MHV2F*"0$[E99!E(&56SSB1[/Z8G?][^/_"DC4$_G)LC:;I&,DT$\1S)[N'Z<
M$[U&T3 '"(2EY&*ICYZYJR%LH U@5F06CH=C'*A(OUJVB810,X,T$A%P92R@
M[@699 A@R;("I1L W&(#1&D)C!:^F#J<0D1T#D=DJHN>"Q,FUM)+T3 9R4V
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M_ 7>.5$L(D$F"0)-EJ'N_"A-:C!1<)]$_*T$$21$>R,F+\+<0V>9H \8IJY
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M %!XZYRM('GPD@'UG(D0%% *LP(HI-1B>J#JN$GLQ,W8^@;(]JM85R#Y]/\
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M!92""F5!L8\D7+6V^;^?;V8?""0AA':R#([5E%2;#E(>9DVM"@N3R8J&C4,
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M?[;<(L7809,N^"\H0<AU2,*D7V'/,^==D/Q;(+S[!K1.6MM.54)%*IO?4\(
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MZ\BGQ.YV0$$04X*[,JT="Y5-3$YLC!:)NJR!VAM=9T3_@E('27*2 <:4.Q0
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M!"#&@\4AH+^V<1@ '*Q<0C#)>.") M,%Q/V:)$& 0 48(1X R@B8:F))* 8
M2A,<^0N4Y(% D D>E!C]=' ,//!A87%XOT )S# ZVT@(]+?#0(B @D;JYRE!
MP?020X $L$8 * 8>#$QX('@,$#]/"7T"X>"S$'][E8 ')43C_'S10=!/%R@)
M1RL  .8<W$?PT<"T_S0C#$FP<L',@-L'GFUT%:/;+5A]/TWI6ZKEP7_HC2-$
M@-S O8/^@BB!?(CEX>"_0 3Z99P"-! 7K#[HC]\I_@A8G"045$B,;VG! "G)
M V 3_X6S1 RF5Q(*UBSZ-((N3!X*@B!_2>*0OR7DVUKP%($',@X"C_L%Z8;
MP"Y #";GVV%(  _Y-V%!_@?M'PD8>CFHV[]K$3P.?$!<*,9O.H +IAT&=D#@
M!_[D ]PXM"&1_UW3P$(F1*/]OA"M> @T)?2Q_R<I1BK P,PD_'Z>03&!$TH"
MOU<<+A3M,>1A2)#G/V\!F@P2#_H[>;0NP<'Z_>U5' (\_R K.%KZ_K$[H/L(
MN/QW2N!! BG%_48)?"($6-?@LZ,U\!\"W"8%.*@D_WJ)E(0E_/$2B<X\C!BL
M: @,^4](@0C0W(*5\FTM!!HH#\< 6\SO HX&(0955 $.FHU_ () D6 7 /4-
MO=$@"'H?OV7XIP.)I@$0@\004) >>,+!YDN(B[89&/^X^,\![H@"NA^A<<##
M"2H VLG#T'G[9E?0GZ6 -F7_' @84N&;5$*@H#-!RXLD_ _+! <DOYD?Q \T
M8@B84AAH;,#N!J*!J\!N3HS.&!2)=F(@.)08_*P?L!F@S*(S XH_^-%@^U:
M$?]& %R+!^H5VK<DR/^(S4![$E! @-^Z +J$T5GZG1*H+9(@.'BH_AD(M*:@
ML0$O L0*Z+:+KCX$&@1-"1= "RFXL[@_\B>5\&][C2Y24"=!>L00&*'\[Y1
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M*3SK0N[.7##3272)MP*UGC+R$$[%H/PLT.Y-(<7DUJ%^6*E"L^=01W3)!X@
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M^?K:MFC#UI6;Z+^_B$^L?^U2U$:1]R1>=&AN47&8E\['ZY:.S%"FBS>.\I@
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MXO.^2B MF(Y@F\<Q4(-M+L>E7EOT-O\ 8)*,Q$^].S9;-XU-#@&_7FA">QO
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M3WOSA^:*9-..>&:9.96D)U_JK3&UL3"[4B,;],W#GI4C)35ZHZ=OK%,HYO\
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MDU9GV^Z19PTG628OSUJ=+ BV=?)MM3:$KI8^6I<:N.TSHFM2$\3I[/GJ<49
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MV_2@65E@NZJM3,T$"):E&+1*QIFIS@D)6!F]5B&;DB12,&$2$X D.?0(C-(
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M1$(\4M7:9LOFP6SN-$3&UI(F(B8,Y<M[T3&9NQ.9 !]*9S*D=SFPEGEM@@H
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M,1&(X_W,1NS]>=JG-^H]H_-JV*$CSI?MK:GO)"8.OLC]1B*57E*ZI:_,?'%
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M-<Z[\Z<&;'VGYZE>DZ>B),:^CFAD1[Y]*8EXZWGIF.:'Z<9G6G -[K>==:?
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MW(S:W2)J7<Z9:2#@GG,],4IS+M^ZL+S- F77.="U(2#MH<_Y*&6KR>]\1_7
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M3MKUJ2,NUHSWTBI(-6GKOT7XID22LZ]?Q'K2C+>?.]<_E_S[&U.J+VZ][8#
M4(DE7EOT-O\ 1J&=: (%"6?[_%*476?JI TXWO.S]S2;!-+.>6E)DVL=\3Q4
MB&B=-YXH!E$XVL??F:Y/FA$DJVSZ_JI 5\ZTU79C&L-0A&TQ'9O1$W)XQ3 A
MQWZT*D(YE:.2= Y,W\UI*)=_BB1.^?5J,AJB<]O;_M8)';'>LO-G\4)Z,O:8
MUM%$WE^^KL>15DFL>S4R)S[]_CB*@&<V[9^=>VU(9W=?U6'6>WYQ;UIXQT)Q
M=X_C5V^_XDL8^?Q3A?FM&S,SQB%QZU(L8C,3KC/G2DF/S^&H.9F.(WZ<T 6*
MDE-L]_X#,FG3[HI<>2_Z'SSSM1:LZ_J/)-Z4,-)<7'3;O%2LCML:TA6[IVWH
M/L_Q,",3YY:F@6(QZ+IVS4P"X3\N\;^U)(7/;^L4Y$'GI7A;\5-AI#I^"E!7
M3G[I5 X^^(M\XHM!V>VR5*QDP;2[N:)DC.GC3"QK':S4FN?:)_B1\]<>=>/^
MV24,,6\Z3206"6AJ3B@"Q/=WH!!<?<4<P8TGAUMBH6$9^YN^U#-W2(]Z4C1,
M.,^G-  7V-Z:S+M]T*8:4V7V*W]O4^IH%23&.\S0!&VM_P 4)N:7>T#'QGYH
MW'4L7R8GC[J 0WAF[Y/\,:$;WF:1?+5\C$1G69\YYH L?Z%0NTFK]6+'K\4@
MA)WGSOT/X)AC%I^J$E'1\ZZT<B_9Z[&;KCFI,(CK]TL#%S-S;S1I43J+^/BA
M%A]BFLR[?= 8GGZKB]W\TPO&(]YSP6IFFR[:9CZJ,6U3OGR+6H(L>3^_8ITR
MVMVXGRV]98+[WMG<^Z8@W+([7]_A[HD+:B2$3,^YYS?_ +=(*>7I$]H/6H'3
M3T^(I%"UW9"S@Y\Q36FT:=9I)C,3/,\1Q2%$2^FG6A"8DTTB_6<TEP>OHXOO
M5QI,:S]-==+[CS8_B'P9[XUXIAZ3'M\>]$N[?2>9F>M<OJA@8L_;D&@!2[>/
M6_MO0,K>([%2VS':9EWM%7%YG_1))'F:FE]^VU^D8>&DAAT_BXM,TCC33?%+
M!+!.IJ1O]T#DXXQ/K,S03#0QKAX/&LGJ_/\ &KM]UH[_ %_#2#>9]J%D<G.Y
MO4(7F-8YZ<[=Z1P/MUX-J@+"_6W6*<,;_4T;+SYK1_;C,:5:C!/FG_:H&&/>
M<;1_7>*0)2+.\O9_J\VJRPV^--"_K:FRNMONN3XI0'GX?BE C,ZN[2AY:6MZ
M]ZBBTCEWS%IK)Z,_52C9WW\^* "(-=_JD7PTBLV?.]"NK<Q&=B\U#0C<N[Q1
M%+;?7:*!@Y;7&.D&I-9,QO8:RC>?1C)4@-=>R_- MCKZ6Q]4 J&VKS5Y;6TY
M_P!&W(;E#!#?Y_?M20IM2#G[^J8)9'?,?%Z)(AV(=:,UXGIZ9L?JBR3 \&+\
MW/'@&XE,WWG-"6VF2UYQ2L]-\/3YIBZB\9^M"?BB"AB=7=CX/7FI4,3^74._
M:M2)GGMO2B+@TO\ ,T#RTOC\TX 6&;>_YJT(0WYVM[]:)1K/L_<U")")YG$U
M=.AG6?7&*)U9YQ_V;!UTW_JF6SWVQ\^Q%J%X?BD1OFF2F^/>LW;Y*4F,?I_%
M>'=H SZ<;]9KF]G\4BXO&>\12AEH&T=']4K+O$\1'-YI5.^>8.MH]Z;,;Y]&
MD+ETC;TW[=ZP91G3/6-JD#%OBSK04@=,\KI2.!P[$?=3%\E( C29?BU0:8]Y
MFO//7_2&2=ON*"8;QVS41['YFI'#B>GGK4@7+F->M,;W3+CGI<],M76 4S#K
M[=]Z$$A;KSZYI ><=I\UZ5.V;_ON'MI8I+IL$0>13()D<9MF=:.,7NZ.>=/J
MB86GF8]IIU3*8TSG6F*D8Y_5-B.8M_7-&.UB;=2/RT"%I/3.G%*%VA27#$./
MK&=*!0>674-OWO\ ]D[!Y>?P4PCF9GG$5J[?=:._U0HR4ILOL5%E,<_F?)I"
M!CH?,T*)=].=NVU)M'5OSI2*^7&=)\F@6VFN^*&2X;R9WYSMY*M=MO!S:)]N
M#:H(-[HW]M(VH"0QLM,\T V'A],59)@Z<3>*$ES3;WCY;416-<KIG]_W3,DR
MG>_?R*P3KY]:()-B(.L?GI0A+(Y(/U>A$(\_?Z[_ .C;8WF?:D+*>[0;;,6S
MS^"E)+)+\.9Z1TH@A[>!S39V['[HL%V+SUY:<"8.GFK3E+!]Q0*E+//CFB)%
MMRW;\YWM6<RS=T]_O5H%@^B(_,T,0-G?,].O6*L_H^*2K9//7\^QM4  1$>\
M^=:<(WS\3]TH'!?VQS2#DJ)JX,9[\UD45 F6ZG7B\S[%&#5>IA>GAU_[&/T\
MS^;4HL>>Y]G-#SUUW]W>M'?Z_E'&FF^*06/3]SWJ0OC@U]*E"'$WZU$1;-LS
MZVUIE>XY]]BDD/ 'SI,5"\(G#\[5.CGVFWUU[7J> ;WEY=:6#'CN\T\HOO\
M5$#*;&8@YN5J(->GB3:IE\VBWX]*G1D_O'2^CGFIGWOC2AA':KSMMSQ7![E'
M6^F<:]";=Z&2<?Z'F/&I+ED]LTR])'X_ I0GE^*< 3/H[Q5V%KQQF=;S1* M
M*;Y[]NM(5NZ=]ZU"(_!364C-YG?2:1&S7J;/IBBUB8[>:WI(XCCMTYDK5V^Z
M8B?)_JA$;&G[IRT9R3YY-#(YB([E_&I;&V.]21,V\/XXO<_/\)F)M_;00O\
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MFKI-(]VB,MC\5J$Q^7O_  1F3;[KB]W\T0B#?Z_E1"<3&+S/%HH;SS/!M_\
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M-!GEW)('R4DH]0([39%W=8E%)VE_ 8W!C+CZJ@&F'2O72#WU)>F71F"Y%.>
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MF$C0F/#%A0X$69Q#1^,+F.D&>_5\IW(?YEZ"ZZ3Z>K?M@N5S2EV+WXXP>W\
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M%!0T4'E&E:N]?Y+)[^6[,Z6SOR3)G_SJDI:9-O/2D7_>*_NECL%;N@MC96%
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MQ>($R)'R)T^<D.EB1$F^+]OYP15#2<_AW$YZN.$2NB<S[80Y'+ (1<DL2S+
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MR986 $$D;\[HQ\D,B!#E;8%@20,+(F92T"@>PES+65^M!:#2;9F&]L7MEA7
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M4_F/4P<0@B4G2<>OC[X#$BVWEIM-[.)R42NZ4'DZ=MKUY28A';$+6/I(^V!
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ME@K$@=X9660@83QU+SS.+8 B[01_KE^C>&% NYWMY^.JP8#DQU-/S!]?&(
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MD@D2M2\XC^)I!E%ITCN8>,?^8G"Y992&UY(+PEA%D"I5>W\X;0Z90"!702N
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ME#<12GB:GC%!$BRM03>_$><O[$S&&Q!.ZCMH%0R<5E0DF5@+ (14+EXPM X
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M(T4RQ#C0% .S>CQ]\4E $%9:@'3SU7GA^-^*@VU"]!J?3'STS E"B%0XHQ)
M0E62LKR"%3 XC_!92P75,V1?'TP+0;XA1VN?O@PY!8D@\@BWS<U.DG-#'AOC
MZVGXWD :'D./7][K_D_H\8VEW?:E)X?!D0RPD+"&.FOOAMH""/P_ZKK2J+ H
M+$]RQKWNG"F=V$0+@WMVLS&L)1"@:0NG,NUB.$29>4GHSBK+*,-2#,5P\FG
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M$FFI)7E$23O -HXH6)\ $"-D:Q7F*%NXHXJ)B7?MA0$$U[ /T?K@" J-SO\
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MP.,#/I*.R;CF\3 T < J((.#HB.,,Z"$*<)0#4Q+>+(SPLNSBW4 ])G>;((
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M_7UR2A: (0B2U)Z7WC+J) %,$JRT&CB,'9!<%%(EBW:$PQD#Q)(XM?<V8UV
M(;#T7<?B<FS">*^_$4^GU(C$,D :W+4A=W[ZF"NR-D,0N_'?I 5,QLMM3&%L
M4JX!MDH02B'@))B)F%&!+,/_ !*0.TDYO%5=8Z(AN6IIN#X\<XAH,4A CIR>
M#\ 6)A^ *_GCSCD1=?>_-<^>,7@P!FXY6[HW\UA&C@/7]K]K_P!0_H\8#"4#
M6I/[8I\8UA$"HFVO:N8CYR(9VFIO5:](XR!ZH\1-_/VJ<=@;;E.9K6K]:R8"
MF@(T_G_?5*(%ZA//!]/6YP8,;UYEGJCOWDQ@-P)4US\7\^N.'@PXE>NXL=5>
M(Z8 FV.99KC]C Q8"B3>E*YTN1!J7,\\=3X_C(*"R:(B;4X]==8C,] =$32Q
MJC]K'A* (#'<A_K?SA$0+,RWZ2Z\SA P- ''?>N<0LI/N_\ :GU32N=Q$\C_
M 'QDXPE $[5CQZ>O%I-VJL1/0^?&'^B@)C?)?[Z8J-1"P$5#A:KXC(1UJB\3
M +8NCS<Y.KD9,$(5\V G&+6!+1+, GF&@W$.4J +$1'K,_WD\I35$?ZGOQBR
M8DZ1WSM]ZN,$(: D[9D[U,^W$K1>0"P5 ($YCTR="FH"3?=]>V,J)$!!&=5I
MZG^Q?2JU[FM<=/QA*-F=\;J?VS".(?F9/-_6><G<D6VI?X^)R5)0\GB+V>?]
MX0R.=O?_ *E"K!'M<^?ZG'50)1B)F9_?& *@S_//[Q.'F*20%12>)UKP<XO
MPDI9.[\_ZP> QD7:^TB^KP.(Y&C\S]#QFNH>"YG5;@O\X*>#.@"-L5]/XQ;F
M^G4Q?/9UB@@EOYJT]XYU&,M&".ZG]?$8.1$\-M_F^L<6#![J?HAUUSA]$&9>
M98I[[^.L;(U!/3SY_P "R.HCW/\ MH&'K6(AD(L$"XWQNN;R"?+ F3\UJF^*
MQPG3NK_GY^3 SB[+GE#< TSNN<!#!19(E>=NO[P!B9,$8U;XG6$<GP),.J(]
MNL*T!,AF:>"8H//G#:8:-^?7^YP.*5+>E6SUY],($XG@?'CU?O.'E8D3LE9/
MWQ](-K(/+N'W[/6,:@)DQ]..!_:PSD)*O''[X^,4 D/LM-?ZS?"1,:V1^//Y
M( 2#)"29_>9[N<1 *A$>[EB]_P#J0-*_?.).Y^7$FL"*DWY:]+R SSZO\X@D
M/T4WZ8 L.^7G)B(G<<<>F- YB3*//[^-94WUCG?S]O[!$I:XC?2^OWWD1R$@
MNFY))_>\'Z 5*.+:WY@O>2GDC9D/HU'CIYP50( 1!^SS.YP1HU"/A/\ $$KW
MOV_PS)=$S^,0@;-\<QCJ#S%40V,55,6<1(SB*E!QIS/V<XY)1T H;)#8*S,I
MIDUB? ^O[]O?+EZJ/S_U$DAWKVQ&:AX@?\/0P_/TP),LV\1R_P"$'9_A!(9]
ME, :^[_.,<E"=Z:WS/TP<A0%$Y&S]OUQIWD23%E7KW*]\3>&H$-==_MN;UC+
M;W._M7.C$ B,U$[OGW^<(@92Q-/GCJ,.IH#=3)=:^O?L&&-<K,^FJ^N2<9/'
MJYF[T8G))'&OD[H_)-OB^  1]*\1Z98X78,W5/!SX]L%12S)&O2^M?6\6"22
MGPL?[U@-"/\ V($EQ$/S^_;%UI!\>M^.]95H-:3^/<QU#$B%#N_WZ\8B'$M@
M\3],5Q2MGM'3Z<^F"S*<*(D.XF2-"QA-!@^>]1^_7_CORH?UAATDHF[=D:KS
M)=$J@ R@+&H/2^M]T9")&C+6X01',K/$)%F((TN)F1\/-?&./I(*'@=:9)VQ
M+,S@CI_ZA#;Q/]Y)H& )5B6". GT%XQE( HLGP2[E%L],.I!+85PC#78,6J1
MB(!VW/Q5[K_D "$1.+(2+T7$^=XA")E5V2KQ76X^<?LB%)F;H)?8/B<0HB@H
MNG1.O/)K#1[I/J_?363:@GJMW9'\UEE,4A(<;^(]WC 87%E=U&NOC"A*UU/X
MU@B!\OF^9#ZX :U^OY<DK!)U77^\:BA<Z9\?[XR T![8"3*L]\?OM_[)37+I
M]-_CXP#D5&NO<Y-N+'"KA OU\S]-X9R"T*3\=:]-9(SU+2&-^;]?0C&W;>]Q
MP^G>+Q$)FYAW/T,9^P:38DO>)OSZX-V>IB.(?7O^/V3!F=O:(W\XP$OLB>O[
MPJB&76W]8YXR%00G<XNOD\3BQKHY X%$8F,BG5+!,">!OJ,DA* :#MJ[KUCO
M$28E!\>W3/UW9DJJ@1AZ#,/6>%@CIG_ID0.[J9U0=N,DPNUHX@Q>IO<\0 >@
MG E'K$U//& 1 8KXX/&7C1(60W!-Q$Q[+I$PYZ_=X-IU'UG^O^"I Q,_;%&!
M-#Y_@^/?.>["])8-:&%@F-< .-(B(DVS<0'4Q.O&.:8@V*7!\[]7",(*P(W'
M&OO[F41'A ]=>L?W@)[3[>.,=0!,\?SZSZY=5W_,X@[_ ,H._N_S@1K[K]__
M &4,.&WX^<>$H$_)X\0SV9#00:'!S7ZOMEJ2A-0<#\:Q%$LCKSQ7YWC:C]_?
M+OD<<*(WW,U$]>GIB^I64Z+N::.UIDYG 52%S*(V0H#)=3XR+ N)2!;\1_LR
M#@-D=ZJ29]>/E% ML0.=2DZM69QC%:01/B/5^OG'L3@"*R>'9Q.^#-'P&MK,
MR&KAK$CRBX+6Z/)KUX<$Z0$(YA/K=>GK@QVJ<E-C(UR\>;P8(F0'19(+-2S)
M'+P@;P3,2B]/,S^UDI*'9_TW59*/*$_7C6^,KTIX?KXCH3BL8. 5T]!\X!%G
M\<)KKS_&.E>6Y\ZD-3]]KDH$)#!YI_GV\HZCDW\O_!05MU\F0[#>V& >.IB?
MOQ@@ (!^+U//B#4X2 '??;XPS"2$TQ%C'UQ@,0K1Q[?2?3$B,AJ][?S/^.'O
M^,Y>WY_]L0B#O\8 NX^W[_/.#"-BD(COO\8U-D-.Y^NWCWXPP3M(DNP]NYXY
MC"D1@ 'J9DC?KWCXFB8;$Z'R</7C"9 B5@I7UZ>=X>RJK/J>_GYPI4%D+.-Q
M^S.%+;W7F>*W'K61"<1$!L.???)Z99KD4'YI_P!^F:%9+H6J(LD_K(R.4\H(
M6(X.YF\@50W>W-M/)^P^5594>R<Q]+XQYY"#)T6GMYUN\%K%EL%W/0S$V5>+
M_>*D,S3;KGZY(K)Z'GWCS. Z$3%B$P(8CS%(MUC&L**V),V?):)8H_\ 0T*F
M9_=9#,RQU4?:<&J3J)]_; L"O7*O41*O $O!C#'T#XF=23425,$BUX6$0D!-
MRTII+8I H8-X6R":&3?P]X<4*A@D[@0I7P8"G@X!!=K*1^EY/(R.PKV=D^GT
M.B,$O!96!(9B2SV5*NI6E"'EN0K: =]$TA$CS,^8_?;.66/1%>=3=Y2$L.@9
MG9!SK7/&\(B0 E.V5;C>^%YR2*<*F._,>A_.5 %=A?A_@F>=XRF@VCGK9YKQ
M\A> 9_98C]2LFR;5948F-KQU]:Q2GZ>/IK)+=OV,9R]OS_[;A[_C+^J)H[_?
MV<J9'%P35_;^G.&8MM3P>LUY,AFH@APR>="T^VL"0%9  '1*H>&<"]8V/IG;
MZW\<2A^1(.R=:H[OG&:A% A;4_'Y(V+56H .D(7\^O-85MIK_3Z_;U42WCYF
M?6_H\;86[(N/7X_K#+"P$YOB9UQTXX86I$< RA.S43Q -2:0YQL:+.O&XFLA
MY1HUY9!7^WP#0<@.W@*3?&,1#+OW?XCB_9PI$$SQTWK[9'@:9+=FM1/I/C F
M$\GH^)UUYPK"+7[E>I$\3_T,BF)8BX]8\U&DW6#1"1(C6P8L&EU(F DT+A+S
MJ9]TB8K6+"@#.OOPO/WP*<"(+:K03!-NH=Q@-3,HN6;/;GK);DET%B%">O>,
M8\4--#1Z+^QC,@80DCAF8V\'TQ:8+,A%:^K:[Q>RREI9+[&OKA2 M:CW^O'4
MX\(DP@8-SKNOUS="8CG=_'KB2X3,^)YV'?ERD=P'^OWTUC10<PN?7S\,QD4'
MDL_C4"MG6)GI-DIJ.)HUO)$X1CQN>#[ZR(C4M=S&O$?AQP7:Q[. _7N?XSE[
M?G_VJLCN9]C$@.KGTK'Q:"JS=\2X<F$:-!([_O6&9:0Z99(BBW*5Q%7*"S=D
M_IA,%@T8;\!%;[[V;:")%>6Q^OOX?B7"J(%DK+*_U>,JGTA9B213WW<1C0FQ
M"_*)+W)X\5BY!*BOKZ/OSWC.2,>9%RZ0-,FDAKF+0L9\8/S@:&U8#%<D><7$
M%=9+TAN52!43#E2><TF"*F"ZAUXP$V&7!"I@?'TUC,_F5>>M<S]<E0CW+Y^_
M]89! -'O<N])X_$!I^O#5:],,B$(C<:F9G5?1;Q9ALC20=>M+),J<8$>5V]]
M5_T$Q24:OM#\^V&8( *!DYKEVO+>!,G0D5'A:FM!,6K+$(G)?CE\><86"91-
MR11"2&%^I*X8F*8.8?;G$C5 Q,JU IN:Q=C!M@OJ!4$37A-X(!R Q63B6 C#
M4SZ7BEM8>PI>^ ],(.(H<D4W:^?IB=$.#T/$^WO=&3TB4&I]/QZYS"6J[D9_
MC#,5[%1+<USKZ890 IA 3:=6K>( "I*#)W!9\^M8"$W=2."[Y^NIP?T).W#\
M6U@KR3<RI*5Q_.':Q(YH;\^<!H'*'1ZU=W^,(DM$1]< -'_M7]'C*^F1W%0=
MO _M)V5[$_OY[,+3M)KAF(YXU\83XPR[H_=<<O>,-629L!?8_P!8)TARDC)Y
M-?.O5P<>:FN7-IB?VYP#V4C$-TX&]<9 X<6#+Z'$5^F.+&T&CNY?/'B\:QA9
M_4M>L'7<NGSP$5'I@#7/'6LF/Z:+&>=9 &524%< /'K^4:: 0*4J:*+]W>7>
M#06U*!+I9^[&,&B1B1<2REOXO'B1.TTRI.+&P-F3AP1/X^8_UBE%A'GJ?7K!
M94"T<S['GV]<"Q^[\U&22G6_?_H&D]?M]_ZR2-T,NH[COG93O(PB)7ON>-G\
M9 +JY^O1W[]F45T-<_7]^MH@J6,6%C4V;/7SQAH, %@9Z*1'?C@P@<TR&&"F
MH^YB,JZ@4.T"LOHDG3C>PCD2)^5QYN,;R(RU1"&^I:_.+$EP_P!<?'G#+S$'
MQ/\ $9"(=/M?YWSC] OWS,/C(H,4$D0+-V'#SAZSI$5$S**&]O\ >#B26QGI
MAR:QBED$(DOEYW\Y#0&0ZZ#FUCSY*SC8IB*/6HWR>O.'05)@]?B8^N;GL%^_
MQ_[1$A )DC>2)"O(4?I]</)O009W,(UZO1,X9#&630'1?U=IU0ZW;,MQJZZ_
MG$H;"".E/[ZX9$D@C<@XCJ#YW@340=EZYXGQSXG#6"J2<\_'IC&N:[[G<\:]
M)PRB8,R"D::N;]<FSF%P,_I/K/O@_P!)UN$-?;WR$,V(CO\ /VYN,+)(6>51
MX6#WQ<[9(B':IXGGCO2G-D10J*Z7:Z^F%@2B *9L\OIQZJS"+*+/D87%(?&-
M1 2XA;7QZ_G(B%;Y1->_6ZQ@(T%3!+W^ASDR-B9G;'K_ 'UB)LF-',^(-/B?
M+@;7;QU'^ #1_P! @TX#2(XE[U-_6N*,2!F&E25KPG)+"/6;O*,_7]]\;J!2
M HW,S0$W2F65DJ6 SV$^)3CK&8>0ND1LI]=;,M(BJ!.I.R);V=F1/A!BBTKM
M=KU[YMRF! "O&T;]HQ)',D2&-24(^O$8(I4P"1OB./C.?124YU,^OG.&_2$%
M],<3B$S$A4TJM,V^.?-<0!,* )J3H)CO"-$2LK)1'NMCWQ@N*L*A\3'[YQ/D
M$O,;"&5_KN#!KG(=P@'/%1P>V,$R:U:UK51&I[R!K8D/E:[]?OCO$*2]P_WC
M/#'G> FV?:/_ &1H(TB*X;Y]D-NS(74-CGN=OG<M\9 I #3F_P!Y[-QB1>AG
MQZ>*_8R@DI[&Z^GC6\B8F/)Y7C4]X(4T#'9]./V# NE##W/F^/'Q@.FR'V2M
MSJ>O[E*B7@\5W^/;)L,*0Q?S'7W*SH*X)?:#GOUQ4W,A%#S&SGZ3E2N-'?O!
MZ\&YR%-,N/AI[Y]-8V-, %C>JF<)4RYMJ0">IX^N4ZH=V@@LB2=EQLC#MS7I
M$\D34!+N#QCTQLBH+.S[7YYR!G#5N!4D_MF:A6>.T/W]"D+]5(?7G!STON'=
M5<^E8,J=1]?^CBY/?SUZ1B,*W'?K/[S."B?#\^]]9&P"CST45I;>-=YJ"4YE
MM*GQA((VRL@]<:ZA^'"B,911U*"-*.YXG)HQLB.$>M"'4&B<$M@G=VOF:T?1
MRW,0*<JN'?7TPU$J$%A\63^]8+6%!*LO4QU#;Q@]+A9L.?WG>MSWL+(N0F"K
MU[]Y"$0K/]CWQ=(14@F1FR#VMMQT_1\].4%4(>H*=[:S=8&+Q OL_P!34IKL
M>=?0T?7/.C'I,^(Y]>,!I(D![DVU\<YS4'D8DM%T<@DDA,84I[U>^O\ V(LC
MJ(]S$Z8E4K'"/6(CO#A#"'/ZFLW#91&.9\>3U],G&1SQ/=Z_$3SQB(/R..$B
M\B9=K:3U,?'.$PJ")"@DIJ4]N<;MB"9+'0G?'TS7F-S&FTY]L<)=Z(W4:_W/
M..VLR& )1XWQ@&:=GJ\S_>")R+A*R21RB)['G(*E45O>I"M==QB-9D!P@7:D
MP7:T6K&$9FJ@=]3W^W&02$M(M5^AKC!"E *\0)*&)8\ORD(;!$IY/RX&ZC"4
M@4BWN.?C-33$04)(WP_S4Y#K+W#\?7[91=FQN->G<G6(TNX)94UXF47C>\'(
M!A1ZFG27\1&$EU]#M?LGQBAMQ%TQ[#@)MGVC_H$>"X!3AX-^C]X@120P^8-'
M\Y).!2"PHR2$CWZN0.""((J8NC[1A&8: 935A('?K60 DA&3B=^QLO>))I5%
M$$M$U$!J;%B)=VP0028U\_JF0W4@I+"7O<N^YK!0C.!QTQ'7CF><*6K98$R;
MB;^)]<EB"5 3N9LK_4]X] GQ;2E(JH>3WPSD#> 3XO\ @*R\E;2 =H_9Q"3^
M.9YPC'88B+^"./C&7=#4V8$W?7XQX"D1NVORSWWO%-D"W/4Q/KZKU@P0LI!5
M>V]>^!!262'?7S^<"9H3"D0MF+&Y8:\9XJ"S4L!+OAY6(-LGQO\ O_V ,+ R
MY\W6BHY,C6T1OUK]W<-9%PW*;EM=PSS/O\P.:5^KS\^7SDL$B2!MCJ^=6E]8
M@@"4,(S<4BTG.(.%'<8]G[YP8RQ=-T2<..OI,[%L<%4)3=GT,AD;0WS,@ZFN
MKR8[2+ TNSP>VG%X@Z$-U,AKA]?6\UP%*$B5)Y'6BO2,$6<DI=:JBIM]7#&"
MT&4*0W)Y2+F?-ER1 60ERR]^,$"6FVL11^Z]<8U%'F:ZKX_C!% ,.N6P\=Y.
M&MB(!+Y>_F3"#=+!M!+OOOSD?4N\Q<^V_2+R(18E0U"_C(<94$^C_!K6$J):
ML0BW<+SSJ>[<6"I;4 #NHE:B-S+O&G2RB D*,)41,"-\EN2$A841!!(B12.Q
MN3US9\-?C_[Q'3E05$UMB7QXV[XPPB(6QSM]O]8HPD%'GZ\'J8=H4$3?P_:W
MQA0"J14RSN:&IILQ1Z209B*0R5KN<+A2**[3 B":8CWFS !H(\#L@F]/O>#/
M"6Z$7!,>6/?PY?0)9&422\MF(*))"4-E(_=V[Q%-29)'-2%^_..X"X5R5 Y(
M7[E!B;FI(ZEN8GC_ 'DJ+< W9[O/SZM6PLZ(Y_7_ 'FA@7H7^R?-\9JHT#4(
M3[KB/&1!<P*?V?67)(-3M-V[YK^<Y:!6]S$Q^^K@D.VNY?F'W,"L:,^D5Q]\
MYE!:%I*B']DO. 3IBR9"^_5?^P2&-L_0Q0*3J+@G21WW@3)$:;-G<5Z.^<"1
MDPJ_B[O?&YK#2;%0H]BOEP02A@5%R2&Z-]X@,F'IWKYX'QD^S5#KNXUN3S@C
MQ+@7:M'$6\^V2$3;&Q,!Q$UB**$BH:<I,P.GQX9FG M32#)^.V*<<T3"T!O9
MYOQ\"A&-E)7,7O?B\E*E0"R9"TUS.(H%(2)+/GC<U'O)_3?!50 JE.\EV:!#
MT<5SYO&#"@8$A%\/?IC$@?D3C1=_NL7,G:&RJR^>UCUQUB2+!H ^O^LB5(P<
MVR\>7?VP3IMK<L_OB?.=L/@[]9KOF7%1%=\V]R8* .QH6U\<^UXSH6ZD"Q$Q
M,30*>"<F11(2>)%BHXB9AXQ$0%!FD/;YU\;Z'VJOG_Z$73'M.*&W-DB]%3YU
MO]]Y,4L&QOP/O3&#1LHGH]QI/1]L&QA41:'$$!ZM-\ZQ4> LVH6O$K,T$Q08
M+(007B!G7>O%X#:001.YT_ OOUD4!-;BK_>,"N5N$H9053W<?$U8(H$J=F]\
MF\4E( 2D;N$ZJ?.# S;,N^S(2O+AL$AQ!]L9@Y5KM)%:&XCC&=LP"*0U"]02
MS>G %K*4@F9&-+7*^=QBSU)#U 7NIO?KN8QYFBI9OA/C6"O$3W"XI_CEP$4L
M(!9UN&IT7XP*B!>-:7W@89WCX" $$H:A!:.G5<8*86\JF9X'_>$BE<-)#ZQ%
M.P^^XP3!L37;O]UYRQH9]8_&_-68R"*'K^>X\QA#H!$[50/=/B<%2,Z?F5_'
MO/\ ["20[U[9/3S\UEC;$3K;KHXU%:K!7.C]XYZJ\$($& 1'4H_&#)Q2D!A8
MG6Z\5Z9 D0KB N6/.WHCQA).?1\/QSO&\4 L7E-G%?C$SD"B02+J9CT^#&F'
M2!1)TXX$_.2(ZLTD MCL[KZY-IE12Y3RCZ[_ )EX2S$1UX=_/WQ #Q1*&1JS
M<ZIWW@HF9A$MG >(CCQDV@=,@MP1+/7XG!Q&G '9TCQ7[+: H%1]>S>)9IW%
MW^?WM<V&7#Q+=Z_?ARD),)ZN?>:T3]C-3DY+7SW6 =89C?\ /OK -"_$\/-1
MZ9V*:^_('QC2%L274^O,84()CQ>O'UIR*4Z*CUB%CCECZXM4 $! O[\.IGGK
MGR(R59./A9$;X[?R^.9_P(Z?_FN0#<^T9.J"1A+%W$&*8L1*1QF V68E7Q$$
M)TCJ,#*(61,SM8M99>65Q!:&R"OQZN @*['45Z:V3Q&\M1%)?@Y_3U,3.[>-
M7]6_1@O "X+(GK'U[_DR@91#F@74?:]Y0BZ.0^9V1UU81C.4]'0@?&NG[86Y
M]QN?CS^;P>&%-(NM?UK6&B',TI"NVJ][P#="91#%$(0^,02(@(+Y>4DPL%!4
M#OTFXW].YY5 /5;$_P ?&1GXMD;J-[+.9AQJXIH!U%\_6\CV!09+)WW>N^8<
MCK-0$ &T$;0=>V,R3-W[_>'F[G)I::#E+H/>/3VP835*^LB]&Z\X:"U,_P ;
MY@^N!5M3-\3[?##O"PJMUN-]T1!YO63Y-S+#WQ[[W;[_ /L$974S[F*R#F9]
MN, \!OR2V5YKQ#C.9!$N/I^\^<&SQ#A.]HE:]Y]GBPB,G,S)+]<-($ZBMYA0
M?&\+WN84P2I\\W^,A1'10"8MRVL=752)&IE$MA!/!XK9B=IHA%"Q[\E?QE8J
M8;E(,DZ=QHK)9 P$,$,:F/[Q?'!W>GI^_64S@CH()5HMB-^>\!,($&UTN^S]
MK&-\M0M&4HJHZ]9R/%L0B=[0YK<3]ME @2K2ZB&_/IA$ N#,FZ&=G[QE3R"3
M:/;O?BO&1Z<R1"F;]=^^2]%B$W187:]^"\GS,R+%AI^F1H!AZ[%Q,=?QDBRC
M,SW[\1\3MP0D4[^N_P!^+4*ST?L<;Q5$Q4"4GGZ&/%-+9B7EB:EFL:& D%+9
MG6\)%) DT6E\USZ;W@M33$?6?K_\B!%MUB#9EJ"R7].M9.4&$V!GSLAV\PQ.
MB00#SJ?WO\E!%E80:&)4-I<<3$XB2(M4BM]=\_KBP5;Y_P!?CI\9*C#/C>YW
MZ9!!1%,>]U*/S_88I >7SKD$G?S*$(Z[C<^?S]"M)($[N^JW_6,@BAUT3K40
M>F,23$@R]/K\]SWEQM*05)\2L^>JP.@LUB"=ZB?QSAKO= 3Q!0J?%]!BC)(
M- C!_3>"%0:*^VYM]&?C#R0-,+K4[\X*@$46RU#QSHG[DEC9,(HLGG_6+@A
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MIKFL+ S3W%S_ '\X*%,)VI)4W?Q<]8=R0%8)"D\Q]L<5)8LJ,H1)H#<;]<'
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M+*H!R5("V<5"0*PC2);X@M%TJ2N2Q?-QK[==XJ4&8^3]?\$HQ;UW_JL6XA2
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M_/G&N!)"OD'V*>8ZP9YV%.B))E#?[S@AL"4PP++'U"+UQDX.N3L;/$//VQ@
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M$DE-+WLV<O!Y8;!MBD3%Z9UIP*0J$"#F=M+K?%JF+'(0R@-5 E)I("55B>Z
M90EZ,-.T-PCR+EF1$5+TR1'OOC [F!TAMQ2,#,6$TE8S$.2$E2@@ B+)#)O#
M8##:D"P1+%12,NAQ"5$0I+22S($6 @F+QZ2A$L:5)S!HP"(M1B5W4("B8'/G
MUQIN, 0$P%;5:W<W.&XDH/LGS2ISKO ?E$+T)UL4'U)9BDT09"2!J8-)TH,C
M)BRFPA#Q(D:3EV@^HHQ,*DQ6Q4;L-?X)%VRPR)(Z;, 08%@YL.,9B;$3R7B9
M<I2%,.AWFPA9J@F"#D11$1$61&R+(;*&YP(V7&_?_7M_]C!YT(;K)X"5U* ,
MH+HI!VE)C7!5@G;H7)MI2Q,J7+ F0:"J,:U(Y37@/Q:QB'T&H]*$5#9S[XR1
M!E'?4P,QOQA T^$#8&4VOLKX*6.0GSLRGK_NY_M/&!*0Q?LAGGO7G6(;$HC=
M [F8KOQ@FP%F!)F1;.H=B8Y.<I&PB21)*#(# VF115)NTQ:K"B#MJHPQ@++K
MF <[F;WQW<TQI(Q07:&A"D[!AP\5Q1 J!U=^W@Q@PA5' L$"1 @]"#BF.)G3
M=)P@0;' TANB:Z>=?=G)J@;(:0IYD2A"H M$(@J0!8%)" 0$@I,I&*@R6"9H
MB(@V0@B4A1)@A@&"$2@C1!J)B49_.N YF6:*@CLM250.Q)&M2!6T(J61#S:%
M"&1+\\><4*D#Q8OI)1R851*H]5MGU_N",*MN1(!U;( (N5VN#*PAO6AI"(#R
MJL.7%";*03(I630L+"K.3!HHU*(D\#%W6(Y834$OIXA#V[QR\1MD$J$4L!/1
M'9BHF&+)2RY E=I-+A>0M 2 ABMWZ1WD #<R_A_O_E9D R^@AZU,^=9$+&N?
M'^MIYC >4T=NXY<'2#.XYEZ]#YO!4W6-D77V_8P#?HK@#I=H]F@G$2$"AE)8
MS#GT,%PFB11,[E:AQ^4(,A=>B<>V,B#51OG=<?@@R\"$^$F9K?I/B<:9FG?5
ML?E\;Q<89$;6JX@ZQ>5JLFZ>9_:PJ 6/+OCBO;Q@2@01&RD]!K#7F!NK<+_;
MXR>9=XH2I\&/?SBC,43H&XVX&B7K$X#(<T[_ !J,5D-$FBTDZO;XR<XT N)/
M>^I?.$RQ PA#O9OSUC4LI!,,38_;WQB-0D 5D>7KQC50II/5S7/5?>?2:S)!
M&F:UXX^;P($M+/"0:X]OEP+L9PA!H76G7>$%:,K$]$<]=XF<4V,<Q8OBI_.+
M)6D##SYNYXUBN6LDLP0J0SZ\[\Y:$+6B/YW7SDP)%(X!/K^AC!+HS')TK@8/
M,[MID@@"0;#P'AK KB(@FPLKQ=<3.[M].*^W<=%&OK. &C)0_J-?7_6\J$!A
M'WCRB,?ZR8@ 9X]8[_.[<(""(+N ?R_7$'(T @;)(>'QAJ!!%"BA+:Z/36$!
MN:XD'EBN>))[Q3(!%5F53SS:>(Q 9T9D<6^Z\Z^N*K8! 2IUKPP3[X1"\I%[
MN.O;\1B %&U((OE!^^^*O,-%J060]N2\?V 0 A'%>QS[8]T"@*>$*6W#KWE\
M, SQN:)9WT>,9!,@1928J()O58K$(AHTZXWS'S&"B, 7(>GKQZSCIP,"^3SJ
MSB=U@$L*#8P!OF4_C$@DOU';XW'U\XD#56W9K5'[YQFLH#P)1\:CY\SD9B;>
M+E.[_P!5CC2R$O5L]ZR2$%14#MZUK[$F<YQOZ_QO?C(  !4L,[_U_$80@)'3
MYG=?UYPA9\!K?K[>ADZ5J2ER2&F;^6;P=LT"XK>&HY\XKZ[2,1 6BDOYPH&X
M*S]CCV\8U V98N.V,4$BRY;]>$_;QQECE>],<?O&'$--5*1KOE_WC2<A,D[G
M7P3\_P#%8%Z_?O@1 H@#MH%W!45OQ"KQ5W"P!#1&V97<0$I<L2B4% B*'9(
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M  @5&;9))$2F#&!8L !283:072A RKNV48@NYEB/%7DP"?*8$!0&H%1MB+:
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MSN/;]WB>&UI]6)[_ -^;AL$)-P'3Q_.&V7 PI!:;FF>L51*7RG0PT5+6/#I
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M8^A!-\;G?M\1E@$I.A[FWHG?>L&2>Y^__.)W''=G\8P$'!Z$H*.>5H66@GG
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M1LKOXB,C#07=\Z=6Q%Q$RF0+MK$LM\X 49^_OS_S -&+!E-7^/\ A!(]:]\
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M\[YO$ F++\=\;[O "8YMQA5J;KXXZJ/YR0J ;B)Y7HV]'>*&*B;)\7O^IS6
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MR&)9A.S53$_UUDZ:)!&K9X\1X_PK/1F?BL5(>#>O;>2*MP/8-3S/?&X36+(
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M-._CMO?_ ,2#3GB^K_/^'0=[]HPQ,21'+Y\XJ[5]<NF+]7S_ #?_ .H!H_\
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M1>)5K>@)QJ: -%#RDP  .-:DB(X=3MD+2<#0 KJ:(D1'%4*BUP7LG(4FP0O
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MU@>))@)P1L &[Q'Y8P8P@!S334,A"D:&"FJ=<[[<86I5.BE"#,=.+U:G1MU
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M) &@!!#7!)/$0P%6 0D#QUUR *=PJT&F0R-I))-)(<LB313P;BM;5!8!A@2
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MH'5Y-9X8"]4JP&0)M*U7P0-")P^1SL.P@ 4E?-)IH8=[/8$2K< FQ!%40*1
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M!3$X HV2\ZCTO*+=C2&"C1 <2B!VONC)TU&UA""]Z)G 8/&9"%[%**^]%&&
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MR:Y]PB1HB)T]S2S@^]: $8H1M,(JHAST?5'R:H=T[$LV64%KU04.$F+OK *
MA)UBI9<A@&.Z$ +32O")/BH/#"5I94<$Q?=(BI2!5G0$\9C>8)O!XDIW&5OY
M_7&U>'M4%>  ?(,-TLG[;!,"BG!+F2#P(\8,@YJD +A )0[H:XL9\.:?EQ+1
M;N(KL.W9E'#S./0CNEGT"1J<@C0DE7DG1[W&<=HG@D<)>Z 8H7SFQ "86H0@
M#7U20()[AHH &0@AB=+.X/V-."($YL0[' D*RIVBQ%2$'<G,%'=5;R'?R";S
MH^AACC EH(X/WQ(P$73)"()@Y59.3(5(,<&H'R?N*^0:2B",U> &_+Y/IB/F
M0ARI$6>!%[ DH3* '1/I]5_57^DDDGS]*"E\S'KZ<'X*U:";2L;WQ0X[G I
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MK=&M9 &KBG-]B#E><9CT/.@QTW)&7I,98?A]D"XBPXT0G J"A=3@5L\Y@,H
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M!VKHIXM]_P+:G0(A31R>IG<"19=[IV]<T*J308X'["6V6U+B=2S&TBXO3T7
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M/A+7@E3]7@?7%E^%ECXR:$E]&NS]0'[DM:IM94'K"W*,R6A.X$ 4AYE0J5K
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MS:45KU7R_F6TTO=P?E*34P+.8Y:6+4V\@=EW@&,Y'3[.?OUL;E0%#:]G)E'
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MI%JKKS]9>,>@LG,TDSBE5WGZ*;&^2;=>DB^:O%B';G703IM3GC5SMB0@^:E
M?AX;9J Z:V!_?%%(V3@P9Y$NGE8 %#@QZZ()<M-X87^!2\QVPJ25NR,U"=7Z
M!K&!/,@>M2UZ,OI<)H"6#IN9I<;R:^'-"#487T]- ^K-Y.9_$!>QZ:LB9.6)
M^-V;,2Y53:,4KRF6&MPQ;S*FQ33>3];JU(<<LE?O-PLJ=%25!J>$;Q^+#*0G
MA,*!O<01C=C:6A>XHOM[P  :GPVUK4 K/ ;=(9 ..:71UM%_ZZ.R7?=F4F]8
MW[-\:D%R]F$G7-U)SZ#X)RCV-)]&3XM:8\<?0/Q9#[>"+_-S#FRG<].>3+5N
MN.$>M\LU3ORY>31R]H+E7JDR?$'^<ZFS(\743G:GK9L58OGUT6?2.FKRJ$P%
MO]&?U<'B3M[L,HG#AG-CP=QB58X@19^7CT/HJMN?E(78YKC!&,=6O8V)9_RT
M%;)24L2>AGQ\A'Z]L:6ID@-/@P]"F"2Q'/8%?3R0YZ'L"#'A\3VLP IF): -
M8A2>_?HKJD?<=&4M<6>0 =QE"LD!XKH%&GJW#\J-I0<+OF85F'N#.I-J*"7Z
M]8C]=HX)"QF 3:$LGG@N@U+W7NPFYDHM/'X\H5?)?EM=P;A=%RF#?:MNX]2D
M5:=G@Q,PE6KR:GY?SARG/XLLZ+ W0[=!X]1A8*O>6'*C?>W-D J.J0=#=!#Y
M-5(FDP32RGI^C;>2_EA+=="64Z['UFG1Z\5\C@2(,U^\17)(._V2!A@MP"JW
MM#7_'W#K5-_L]R,U;@]7^'ZS#"\UY=LW$D[)1GHK?%5X%5!E:F4;!3\&R#TM
M:@.S,Y]B,B>I0\\FV-/Y0_",A^*K]31,8A,$*9T&6T,2(&UGD2.Q8?XK)U+D
MK!<  7B) '\,!H;+1O83B_2T7"P!!*^/!QF5<_0GR_%(\R%U:TG9W.^W]UX>
MT_P+%#LH,A!XD?VKH. R(V;Z-"1\\SLQU"1-YP/\\NY>H+-\9*:QCZ^>L&+?
MH-]=A)67'GF_98PMNO/Z4%V%Y&G%&_5>5;)]I/GPUGN\%EH;P<S-/4P_($,F
ML!X"(9M(7XK-XDO09DN<QPF0?>%HK+08_-;R$1Y2S>+&"'6(!_0S4"."6GI/
M,D^HGI^]N UC&\)5](N-?LQ=WNG;M.I(C8M5FGTX7QQAF'I7-M,JQR?6 0B_
MKC'K(5\7Q9)Z_[KPF@\[^ONNIO;HU[_EB%]$,H9HIA[Q*:L3-<UT=FPZ/T!C
M"6[F)#<4>F^-R=8>07&2+]7'PCI WK+#S$2LQ1#G-%U(ROJN.LC@2^5^'N_5
MP-OU""=$NKMUZ5XU!/R[Y1"^)[A1X#"(*#2&86A2K:LQ_M"]^K6(!?I>UI0V
M\?!T):9)V[NB55H/8+S?)$L\9<XN8H8U'13EB!?Z%.1P3<25B=XGE6(GY>D?
M[Q2I+"@S!"5]6^<'OQV/QP(-PC 71^T-P;+&$'8:5QHNLF8^[QDKOZ\.5-T/
M-+H^@VZO#C0(1,YRL*5H8_LH>(/+5AX;2&R'5!_KWWS'Q1LS.$J.-O>Q/'%5
M8L6E$)\OX]3M?6ETAJR\S)/J'K]A,MLO%8#K/[*Y4S1@J:>-@F,! "#%4_7E
ME2>]HW;F>G3KU/G=VL80YX32Y=7UA[[\TV,F Y8I%YA/-6%L .HXUSQM3=5"
M35OU/CDNLBZ4)."$JJL!%.;FXP&^+_F@XL4+V33CTQ<E-L\/L&P.( /1OFA?
M!2(:HRM2SY5E2X]"8W/?\HAL/Z]+M=[CXC<!W9P%6K?J>F%/A/SNC;-N8(QB
MZ8F<&7<"JT4MT8UQKUJ>:GQ6D"BU":]#=> MEK3LN9.3T&ZL7TK,=%M)V77]
M8[7&$2+UG%C'+!Y;W-24,%29/[LTU,HF/:-G51A<-P4#U[FMMQT@[SL-&6$T
MRXNA"2$R%)*335\"S3- H9I /9#FP7V&3D5MJ>&5P>]3]V4W*NH3Q(WIM?H2
M0%H:)/+J$MH&Z9!GKM;NQ.'07%"*6/OK.C53 @FYPJI4$^H9>R$5]Q7M*D@S
M2>E?H:K;UN=KXJ&SQW/BCIS7<$9BY5Z\.^%<V,B[^/ENI-:AF54\/2592AV:
ME&I,:./)B[M?1W,IP_DK0M7-7KIY5*^R3BOP3D[74+RI\IYY?6M&7:=CC]*@
M$8 ]OR7**%>MIY5_+[9AHC>PYFOFFQ6 !X/K=B\:4U[BH06RN#-G)91]$J&>
M"=N.57&H=03B^AA, SS77[2E'PQ*'$<.*($(D^!%$&O;-M,=!M4*\ZHT^XD4
MY<SDP2IDKLJ 8@_M*(4)2%-,%)6[4/B<\^% SJ%U]/5@2B7[1FI/)S%-SY3"
M4Y[DF':43(<(PJR?4J@JP05)&)+[/1LB,CQ1%-/9+M7PE&I#&M#&$L-6%MSH
M2(G?FY%BW10=24K:_GTJ.A!],W8N<%.M=_BI1=!F_9 ]\OI9"A5-FS\;<E8F
M%]AO8S2_27OGLS-M#JYJG[KB>)H@HQ=/6,2#H9A<XXB3R)Y![O?! 78=!OE0
M6^+*LV)M.HF,NX5D="TOE#V@+D /0_B6;?<?'1E>*+3D<3FEY@;2G[&?$]A@
M[G=2"5BF"D,W,+!^9Q#DLC-A%;$0*A<DX=4;3^<>D7F\R\?M232X3Z'] \K*
MP1R!C"G1S&B+Y_;_U*\M!,9R8\W<A++=+#,<6%5#988AU7_F*5"R%5M]V'+&
M4LG-9;"MH#1+!L6J['6):<#4Z+Y!HW3)@"N?*%A0-L"6;YU1MR?566UI3N1D
MA)F5>_5PXV4J-+MGYF/;D*7$:(3Z^DH7"\XL6;,[/M),ANQG9<WNQ7] %O([
M2A4 6SGFU&L7%R;]BO5/>M4MR\FY=IOYSQ?GP3^!ML8LCA!0)S 5QOP7KJXC
M$2M,SJZ<.SXSMM#6'[<S(:6E,"%\D![B54:B'*QZ?/:<[\]MD!CMW@=E)YXR
M[#;'8B4N.OEYC@I$NS>(2YIN>(GEI/>>RFLT17J2FY!Z.$XH^Z_"TYP9\5CR
MN=*(G1S9NY.M7WYO&MBLJ?\B^==7.R?>\7RS8UNU8?Y$#:>1+"7P\8V5'HDQ
MYNJ5+'[&Z1^;\7799<%I:6[00Z\/??\!?_Z%%>RME3WK%Q@I>Q5[Q1'XDPOW
M]]'$\+'@:>%(\+^U6H;UXAWPS>U?NX=$1BWD 8O9P$KYD"P,)0&")62462J'
M$U_2G:R=:<=)_E&KKA4!+[OPITZEG[TZ6GM6RZ^!Q[%"+0.)00S'YW)_&DMF
M&C,H!7D9YV(K.)>OW$*_G#/.>+V@.XS;W?UQ\[@35D-2GN\H-&0B[F*E;^,@
M70[[ 7L+IF(F&H-'\62:.SUB] HB>#'X5&*B'E(NEIN*JO35=HW03/[HN5)Q
M$@SAQOG9I:3Y5IX)/%&0V8\E?*G#)2NZ&L![@TP<*=?Y?P^W)P;3OLVNDUBH
M3%[9>^AGQ8N$%WUB?Y 5+U3J(<9'(HI,NN<?%-AL[T/W_JEG8SR"0%2X#P>G
MXI?H.G@ER;M#9@N9/;;-9%?U&;1@]Y-:J,!W)MO8$^HZ[[.9<J:)B*7ASUF2
MU8<D\X!]%YHM.EX!DAY>AQUM_OOP?@H]<#8>; DI;W+\*!QOOSBU>&D1>PZZ
ME)$FGFP[.Q'MJ:U@CC^46KZ7LO:73[&"Q^G46=DEO7NQ8@ J!"14IM[W]]&X
MM6?!KVY"9D/1[EW4+SLJW#=1ZFD1$I)2U4HCNF&*.W^O5NOQ)Y!\&C"0-+Q_
M'JDNY%9!<&NJ,H;)XZ*;MVM>>&>V())IJTU5S3R$Y9&$=5G7T"@Z:O)T"\.2
M,M2G]W3QC&2UZ/7VG*"/16'6I,8F-P:=M0@##R29,*N9WG\ ,ED(2B%H:\CR
MC%N\H,C^'%,LMI1T8#58=V1D,C1S.8+V<7D7]Q<$6%EJXFAIPZ< N_HA"F*2
M/H6$O6+[SL]8!9_RS$K0L(N8#4*$13]0EVY&/43048./)&A^I*+OAH5$N-8A
MK_S)D^9WA1/C Y/2%*CI'&8?N- ]:*X+K\TZA9N SZ!;@N;$!T>747@2V?2Q
M$(WX2?:(SD%576$$OOQ5K1+SZIRY.6M2B[EO/-.RS6=*X!7E-JIKSLO^)?D2
M:BM_4*[BI="F6NQG^8ICT)RBZGB3#7C -X,0G7Q'%AG!J?WUF4?J%O2EP6U'
M>M@P<US=)$_:4S=PWNOT_S\^%>ORIPLCC_^:=#_\T$).$9>8F)-1D]DU^FQ&
M V&#-\^ *_8L]%>J,N=M=EOZQ=PY6@ZJ;,G*W&WE<J[=&*8J#_7QV?U\=:@T
M&^CJ<BV408(_)>R:HV; 6!>,Z;;%YS_OOEPL?!#N^..P-?+PYT/'HQJUVJM_
M;+1]9%=K1_\BU,U1-"]<-R+K",Y5'%A!CU$)G;ICH<-F3LU@@2>Z']KH,JD>
M6Q;$HZI>DL&0"X+5-E:CZ;5AMQAW6#(:8XC>Y^]6;F:?UB4N4+W-%P<Y)(7:
MAYV^D#L3BF#D%(C\#]@]?ST<W+XN?'14EAS]22#@3]Y5OG(X23-_U'W;F,B3
M-<(ZY,,QDBZ6CY2[7"%Y>YU7.BLY(V@(^ ]P[['\C>KN:^W^(L5]?ATNGU2<
M\K=!/QGH9WAP\8:6K'N9 FYG5='N6PDU;G+Q:!\M-TW4\E2)I)%C[X2$+S[H
M$IP]+OR&GHP)(I85W<S^^JEV2XUS-!M*FKLLF^P?DC+\U9MI MH:2!+J)U0'
MY>*J%4H.?]CW3OC90YMY)2&%>HG("#@%/R<=&X.1(@_GK5H/)E2;MJ5OE89&
M6._5PT=9+^N7\RF4S%^]T!R;%YRZBKD1?*#;\C=XF5^?-6;.I-56P%%0=#5O
M<O;FZ[O4XHU&36C3<T;E]%@OV75</OVI(%NL\J9*-HI4!U>$&\C=9M9X:'?E
MZ>P/?I/4(NMW9QIC%/\9SR4GG1-L(JO.0T_S_MC.*??>\"[\)^?BM;8H>6II
M!?1'J+3.BW.W<(N](NF^WL?+F/-\+.'4J%2"LZ#",OFQ)=F@[Z=XTF%S@4G_
M*W(9HUAC<_L[-+(TMO^X71]UNSZHBVL+2V;JK^S<T@\!1^  ZLBBV<#(FI5#
M,PVR>(T!.+K+,CRC63!>7$,L =-PG !^3^L!2^N!] BH>[F,4EOR"7A_[R-/
MC$.T:03M[ 8J%MH9XTT1T3A9G41,*RTG95'7^FO?I'OXT7V^IIGRO>X[AK&<
M#!R"1_B[PQK3:K0.CYD1.^I=>X'73U'&L5APSZX"+0G-^'G/55+4YAFHLL8C
M+GD.IKW/,7#]+=:S^.F&)@^-D?Z^%NE^P288KVVE+] [1M5)E.MY3^:SUUC"
M?7=OH9"W95EAU@U)?OC=EXP28&F(EU$'364G5H\-4.'+]P:)A^%!(:.YBNL*
MHY3Z-1'ZRO@WG=8-O_=+'+L@9&1"%,^MA)YQF?:;UA[M_P=@Q+BZ)>YE)*4L
MBG-!%"%$ EX+@.2F!ES/-%R8MXS"D1TSPE]P<9G9Z[G<*=B?S8\/<X Y1?])
M=3X=V+&)Y=$]"^E)_X)?HB)\@6$QUFN%!+O^ZV1MO\P(*P?$/>MH]8%BA!";
MD8Q13DJE_C$Z9-@/V_?''RN9[O:S@:6<FA^,8A. Q6O@XBD"E0KB3, +G*?9
MKX+FXG+;,353\V_NJR%7YLT8]4TL\59D.1+*OL=?8!:ICO6SQ1QI0GC"SP;,
M?0AI.7\N;4L_"FCC!:WPL?YAA[.,!;MGL7V[S1E@5(#0.-"&0F1@#)*6L7@V
M6U3-\_ XT,M"JH30Y$8YB,?=+6%=H8Q41^P,;0)2X7.</CVU X2P?M%U*^GH
M/T#E$2!/2GO@K;R=RNM" \V21QAOV[W(6R6AK'$_5:N\B/WZZ$E#9+6;RL:E
M#:=D8_GJSN<["7&Q#2JBIYNL!'8%A;[2HV/K;KT+$#&Z$;OUZD,/N_<XT5Z5
M^Q:XO/-X[-O'^Q+^X.9OWTWOW-%14\F:'>&G]>&!!GW@4EQ[[T8:;QRRPE ;
M\5V+:&? H$PPN&$.+]%]U3>2J'CGT?J)A('HDY[F.<*A1WN:#%G8+6:]7.?\
M )YW!IQ_19ZEM9[$Q'/YW$K[\SW&6?'X/R![VO)$)6\,6Q:UY[8+<\J1B!I(
MLYOZ6A9NA%32"F!3,?P*,VHR47V25+45=75QOOD Z*UPZ3O.=KR]ZYCN+43)
MV"^,QMTIT.ST!5/2RX09W,^)MO"XOOI*.)M,_E-B46D?1*82>GJ;:3@[Q\.R
MC)YNS!$Y!X6=?D)PN7U-6GR^+<K9H_;VF.]K/44L#=ZV*"\M%5,A.CU=5T<!
M3S.*1\Q17B'UH4Z^MZ5:N!D.3GO3%LGX9,/=+NZ_>_;OT:-;'[<N_JW$QT!.
M[FT]&I%:=?LC>#Q$N\)!H*2K(JUN-7YA]V.]'U3:8B8LR @+K)&A,'!O&08#
M*OWK;M4&OSL$/K!8?\N8_?_MO*5Z+,T1L19[D?\!+\%__\T.SZW(TOP-%M]R
M+OBZV6@I+W.49Z%Q4U9-:7B  OK3<5)B!._J1I^"A=F/O3^D#@]O_M8.'",B
M>/^4J)21_B;]<[KH(M^%6^)T2_GD^$U""0#P '+7Z]-$5\W!Q)(;$HB(>??N
MV(CG /B<]V[R<"'Z27Z9N_BX8C$]L/QF;"FNO>@^VL1EF)!-T6$JPQ8QT>F6
M,4^96XO8[ ]\+)U? Z_#(9;^8E#]]2B9FS?V9E)FX"3#;@XJM,:]3!OUY>6E
M-WM[ET>R.XN:R*]AQ4*B[,N21L]M)45DN@.I>*?9,\L0O6,&PB_O38,_S$U2
MM[+[2@?1QE"]]X8*F=G*T NVD^4'!RA&120++G]B=9@!^&T1GLP$G]__ 0O_
M7XIK/6[M>YGN2/IL]0C]CG*O>[:)ZTRR"QEUI *&'C!8%\\IKGO(+$F^JQNX
MZZA&FH<%QT\=@ATS%:M-@/ %=[!FZ,/L%) 3+8E@,2!@Z?IMPKY ^_;L>U/A
MF5@$NP]BP-M55OT.ZQB^3F-^>> [2S-_Z!Q<=O?\SO>S-IB^WD>'!0TA_2;!
MI'3;2:'83>C'ZMGR9X%9]+)NGIKKA;D"/@\,6-)E!,$=L1;U,?GP+M\8R0B;
M1-8U86.E_*LFB?A$X(?MBD+!3A2JZYG9N"N3SIO;?#T2=89)^(6M1D?6P"+R
MIH,]^LHS.TH&V0:$M&: D <SJ=:!A$L'6*TTL 6RI\P20"6U3'LG!]JAA6EQ
ME]Y1BHS/#UMFB$7?:PO>'VB6FH+SQ.Y.4M0H!QX+/<N_4?D/&*=:^ C'(>T%
MC<LYD06(TE9HF,.A]OWL17E-!LUN)YF\/K!#$Q(J?)!FKT"[*$N.L%2-3><"
M6U!3;7K:OUI+4GE1)G3%K%C*$53JA#:L6/TI$?-675 &P@?IP !2M]E>UY,^
M7 PDUSN#ND9?L]0VAWW[(GU>ESJ%>C8P*J?)C#,/Q"L$#]]86C;0Q]88NN2_
M1YG76;_FYWE<GV(T*S2?/*R"U/24]R\R<V7SV?X;A#:J)*".&^?8R=5)"' &
ME4.]G\*ZMY D,W*DY*SJW=;9)(MPM_?3;K?/"]^O<P?@QW*1HO=^#F^WD;^\
ML$AR,L70P'_)@JZ.2)UU!/(H:4Y'WVMKQ"$):JF4Z&0(LGEJLT$]7DL$/KR2
MS#>INT#R3_C&[>EN\<-_;VY>PY2Y:$S^1*FC*?C'W.QE/AXT0=?/[]<F()ZK
M UFMBE1U21:.!H<M3^&_4  S0!(( $0) %"@'X.$**0/9YGZ14DLB^<,G57W
MTY ?G+;/L\22*./9:TT=5,]O'G&U8CX\=U(FGOR:ON$ I!>^GSYZ-)E&(VVJ
MJOI,AV6>!+<I\V+_YP2_PCTR8F3L:(&(GYX02/OVV[^[N[^=-V9?7T:I3BY,
MLM6\>1*>T7&7VVX@&]":22RR&LR584Q(ODN9+D_4"SA+%M.L<0.(6JL$[/']
MY$&A[([<;/WAT1V7X-#WR!=Y=N_)[97,LWE5)!A_EWHG37IX)8FK?.PC34TC
MER--V_0J X7KG(^JA> 6X:X#I]]HW]#"73?#EH34G66C0J2L78E5\; $1 GZ
M4D!]_Z$]3&_=RNO;<Z=/DSD*MU=^+UB<[=T/M0X)IZ./3I4,E:^_6>5Z=#BY
M>%TR?DY5"BF_B'BA^%;<W<I\:5B+DY+6K1I">I#42I4+].<RS5K>:+.*(]/B
M]WD Y/8)-N)9*WT@([(&-.3]2M"REL,!]ZL$_7>WK/.]!9S=PXP0.H3XFCH]
M;?:IQI+%$SJ8(JF/C;63UWI#K#V(#CSZ_F_D5"%LY_S??\" 3#VCJ<S@Y9^3
MP5LS_S?QE5R(9+()J3N$@TF11 *:FZ[>K;5=',K!9[M:$_@C.4^>X\!M#,7@
M )R@8^KJS4E-#)(D]Z&E]9\T F?:N?AKK5BO$O:V.S+ZL3_9IE)P/J/J(!A[
M:SQLDT(=%5"'HUR:Z.Q.E NDLGDY_+Z 1B^*56XLD& <\O9(4/=LWT735-BE
M! L:FZH$X*P*IQY:R!S873$J:A=]\Z/S@7EVU^^_G]E<G/_3H;69^@^87#TF
MM7WX[E%,&9-FO47LJX!(E08&E>K;O,/4/*$9^&RJX8"LS&MXP:?M%_MLFE7^
M!#+(IA936L9!"PUIC0Z?E>=;8T:>X^?T5;4N^TC\)]]"1"&\\2WMW;'R8KMO
M],$H"7/I7+-I+2H$1P:(3"6W)IY!?E-@=%J8 ;7PG83(5B/14!UKIU))JQS;
MWO/H"$IASXKZ3DMO^2KA;0LDZ25$GVW[+7,=/DJ X>CM+[7Q'K).!WR8=9W_
MZN.7OOV>S("^!#)S8QY3];PM$!#V8'A217^0OKS.X(?W]K<>34CR&0CVJDDA
M5H:#)$K&C'XC+WD?%"3F/B+ =9APWD0D:.!!1-;E?T!^>\9 (W8^L*AQ@9^-
M7JNN(*;9T 6/1R@F2%J*Z/67L0[3_ <8]W ;\30D4-$75R*ZLAT1+V$#MSG<
M1NV2QSTDJX%*U^,XG/1:>23(6(!>@BH;WCNGRN-4[V)GWTQ2ERPRRRGB6.\E
M)5JM,(/+7.A))X2RUXVZ0&/7+1.TT4(6% HD1!DMBR0EO>2'$ 9&47\9O_HP
M['T_)SI-M/^#I)+["GOO^_4URIL-$Y[XR!G1LO6'SBHF>(S>SA]DC>?D^@\H
M(NLZ>>!4+CN)I84+=4F6:WT/]FRV)OXLRB7U%0P4#:]P;7)2'I78)F#\G*P8
M)(7-\7G>L;*IH$U:+[$BS/9$BR4[G)KB6"!9J)Z=\.J3PNJ7 7Y'NCHM'(WV
M5U= 528!_ZS\(=/-WYO_ -#29R[*=YJE^_(ZH@EC%&I8K9Q !@EV*B2T<_8_
MH&VQ)*66N-U^KK*T[9PX=7/_EMW_G:?$.MXI?##Y]>3BA(AN1BZM-#YS+/GY
MYE5D?"E^1J'QHU@=W9'N/W?%C??O51-%:];S/RU4^[\V,Y6,,^,-I.#2GCB]
MU7@3^?#6J('=T8??D?>._AP?]GP+=Y _X,6Z5QD-%XGAB[=%/I8)GIM35,=O
M-WK\MF(2X!PWK!R6;;?PI@Y0&5(*30Q>J3L)EMJ)@<%_J@H%NMWQ%O)-/71I
M.$(W:#!U\YR?+BNFWY9K>V$@5/?-OT>(4;XHDUFE_\H2"/RHZ\&Q3GZ_>/5C
MYTM$/HCLT[J2%=)(=1P[#IZ->W'7Q\ORTT;(T2^:2NV@I"QZ#N@3B@'6LIDD
MB/ VR^]?QV'7?Q_E4[S9.C'^$QC*3W?Q3RV+[X.I K\NW8 7;3'84 ZT.4BY
M.!YO'U::].D8!9J="D?AN_,^E"<D.[N4,ZV@(O AD.. <X:;=YS=E8D<DASX
M<FLK3?XI67_XQ]>I]/&KL):DIW-PHU'?IYV3OFR:F?A%$Y@CV!UW=E"^]SQ=
M02FHPI$G)178_C[YY1_#>F5V:H0JV='@^AI[T^W6I^L/;CS^K=3Q,>R_SIM0
M>^=<IO1CFVIW_T))7%CDS]K?G@W#A[<,_TZNKR8L>&;R210W/.5XJY178ELT
MBM?$T*UE#$':LBL^1E$K,!QK\ZD)2OFX^BHS2;RBXU](+HE'@\W)2:,*[/:E
MK?)]%8BO*)J4A&WE">^)*T Z%5S+!8E0<KY3/<Q>W%U/TA"29_Q*QSR5Q='(
MG.-LCP3N@RU'3UIH6-!\C+=<W^6P,MHX?[R\2B5SDZAJP#+9P6YX8!:SQD=_
M]I$GQ0 Q?7I-\=VN@L<X.18/,=:?!Q_D&OWV^W$Q?3,:)?+_1M]LZTN9K(6M
M]0%[S[+4Q#_^'SA84\J3QUM7E:<5/TA,%.C5!*K;8#4*L>26WU+)P[<"]2S2
M:!URLT(=^+/HA97P(! >!OUJP)14Q*Q>)@%&DZ+I:'@AE03&G2HA&Y!WK6]%
MX6NG=$(D?C_P[ZO> T5^ZD8VZY_K!9P@XA&M<)JPYHMPO>>(TH&Q3A6_(22.
M-;NU+8*/H:;B,>9:6C:UCIU*-LWZ\?-2]@(&,]CW0+U-RZT[Y/$:?B_S<YY0
M!\"%OU-@C**LYFT;L[MF"GK*4VBY:?HIO0(?P(#=$&..GG#(E/.OW4<[M!-%
ME!VL/+[6Q[<%$[10&J:,B&?BB:@GPBK$N;M9CII2/]V8,!%D>D0D*YNYP9,/
M>-QS1-Z+LKNC16TQ3>;:0[OL)B7T/PG$ 43]OO30V%OUJ1O2=O8HCGN9$5-/
MR\U)1Q-R_+R3+6]YN)._]Z&MV,5K=WH&-2Z\?]&&\#3^WFA(+E_#HQC,)8@,
MHH^_X/:2^CNK^(5C"02A_)3J>@?B$CK:L(33V');])>_I\NK1US?X[]3,H/9
MH779BJ?0JJY4247#=QU;+.T%CT<AY5CB]H0")L/2PH1,*>/!VH]5>F[!26=C
MP_R\]]K=YI>D=^LYWM-\ZIN)#AOUZH<,78=NJ89O4C]JW"7<>O@N3>]*8-^T
M]F([VI4V&E+U1UN+?/2B#28QHV!4HJ")LSM(*%QT+F,6>&KUV^'5^&)$*_2Z
MXE3D5M"[A\*>*(>YK(DSI5\+J(I_KYP+53#/[U/\FZ]<$23-_G&[22F/630@
M7/>+E8CEQ,L</0(.*;_YJ$H5DY]W6\DLI:JW6\<<U3L0:/BLZC2L[SQ2/A,^
M?!XF^?V365(45_>M^X>?YCMW6YF^%)ZX_KGUZ-'Z+-7F9-#%R=J7J!WNW45Q
MH=0 EYX37C&%W@UG?6+!$UWFV_HI;UV+I;J_&!7F^-UF&0BP F\(T)++E%<_
M!![@S4NRJY^0:070'-L;S["CAONBK8Y=ZL(]IU ]%04/H Q#Z)B8O[U@JQ_W
MY4<EFY (@E9]>/CV"A0MTW\10#:L1>),Q>HN4:Y 7E?U8-Z'(V3Y)6G\D*0D
M&VCS94@)!#G376-X)<PN -6.U4QZ2/%V5/?VSTGA'V^:?RS\4HWY#S ;^AS9
MJ)*^8JLUO'9')037IL'S0[TZL9E^SJ1>W?4SYBZ86"S])OYX;>%C3/AE^Z7>
MDW1T\IQ'Y,%(;0LYM?1<PK*B6<\)4U._;ZZ1X_LSV\W.&JN$9(&X41:A$P]8
MQ6 _+-;\Z6<.AOB3U*:&1AKST6=^$\;VVPM843Z.AXHJ@F,\D:*Z//[."(!%
M8LQ0$AEXWK4TVI;:L/GL ;TEE1#*@,6%R" 4>[:?5_1=F8+V>\G_/?H*M&.+
MR]?70(^T;-_?K%*ZCJ"/D8<159S9F75DEA$HO4*G882$@L)URI% KZHF^==T
M0O\(S.GXJ(+$1H%/NN+3_Q@N#W^H'S^.?^[<<<ZZ.V>O._/,$+*J<\X>G3VS
M*RM15JCN.)R9G4+9*SLKH;-G94:47<D6BL:WW^]?>+\>S]?K^1;6GZ^T]*UX
M6C@RIME@ISK GIM?:)AJG#;0AFYU#UC<WA/_[G.H$\?KII,V ='!YA$>I<_W
MY5_#,:G<#U'WL%WBQ!ECSVL&W/KFVBE3["*O"DO 38JZW\ASNF_]D9S[7R%0
MI*H-7:=E7+Y"VD-J.U 43'9CSXVM< [0O2=EQ/)]QGZ,L.S_#/L'Q/\Z+[.V
M/9GS&O(J;4E1.6*.\<)>0H-?+7% /HA+*)1$39&PCTBISVBY0'N&O!:0?JV
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M=6'IF;6 *Q$NZ+B9((=$J1;S5]T7<6OA[NK2^$=0&Y=29%O3$7N%(WW\8PN
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MJ>1F*L4ZZ+A\<HFU])('MP8+2%N@O^2VA0%6T2I W'QZS)^_8.+#&Q?6TW^
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M_!!:80FO-%64*J# 9R#,(#%H[^I8LD@J#>G4?+5U5#I'J4[))+&(9V4?^UX
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M,EJ? N7Y$>$=ZJ+!)OHDL_';F]0VCE##1-BSBZ$DC2PQ-LT4)@>Y'BVUD9L
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MGIUPT==!.E%)+K!=]D%6%PV<1'7NW4L/H6I3-+>)%L'S#23J@O;X$(6V.?V
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M<.OB@_BAAK%U2OKO,%:S4BA:7<OE,Y!@T$%%WX(WY-DVS2"?O=NF4,.(P0
MA#9N>J0(7N#3P/VEP<-"J+==]E%R']H,+.2LP(3X7"%*_]S8^C7SV@AY+&LF
MHC%P59:7%TA%P&!0\[W?_OQ*( T\[R6\!/+[[.@JY=[3-IM1- !@0#!(J'<
MU".UAD52(YWS?E;3?4# H<(!-Z:2N_U9;3:XI0J! F#V]H   H7UPE9K"&7M
M+[S_+^RW]D_W]\=[>'.H*ZKX7B%"JR<<LQ:T8UB9>!!U$>1ASUHSOD[L([V?
MJT^!BW[*&QN!RI^(&^%5O_0<G95E;/\#OITV<??MW902[,,^Q@'US*!K0^/!
MT-'SZ].%V1'#>L0,)#^03\VO!=BDD?4ZP"ZPAXP1ALI(G:!P[AFN9R!Z?NQ>
M!=_"Q.,A%6_4-_V^)MY^7:]I+C2>Y2/]RS81=R13X5LD"GB4JBK.@*,2FS%B
M2I?I98#+<C/:/>U= _#%?.<X;J"2/7K(W=E55_1O*%S5T%3'!F9!0;0V6:*:
M":23"DB$\B)\31#6FK)1M -VO:/OP B\[S6U%R!R&%D5;MM82^"U1H&B<P#6
M:23I*A".<0-4CG(J&^*_P1@2^HF9_5MWGA5IY9@87+544Z[WC,>@^_SHD*YO
M)!X3?O$)?-0_3ITU:[%3H^DF5^6-[JD/Y:5Q1]"9D/QFN3WV^PP0& OZ&C6>
M7<XS"HR(W)O'9R7!R_P$]IOJ&8[/$W^TFMU8=,!3,\*8K\*F<@+;18<B#,D*
M'W.M$BJ"L%89^YQKKJ;/HG+;,PEZ[D\^F>*:^^:Q2N+$S?.3K)6<:K8'"YNA
MG#TO'H5B*-5WM/7$%($#':#CVHCQ0#0#[M4D)O[/R.)5&?+BZFGX;>[3S RW
M#:9=LQP16GCJWD;Z"OFB[J#!!S"#[ ^"1U<+YR>\(KR(J?BV>\-70R7LU_17
M+==Y6(W@:IJ?4X7,\YW9\QX\=*2D%?T,* TF6$&<WBH+FB/80E8<?2S0Y)%>
M/33EFI6]@5I T 9HF0S6A]?\T+G&PW"6J*-I[W"-8VBYL!'5"XF @3Q)F3TU
M_8[9L&E5S7] 2]>-F4NII51JB/9#\=;57]I!E5$V&"H[^I-F:Y]>SVYK:N0T
M%@V"K4 M/WZJ_O%C/ B<N."Z1_(7*1N_TP_X]_[2(2RE;[FJ%Z)3ZS\C^^\0
M:_30JP=%+N,K*X-67! __OJ^Y@5*344,'-(ON"45F #2$?X@[IDN [Q8"%$E
M4UUF.^V9R.9&\5_] \ZN.-855R #VL1B$X*^D'T@ (UA:5"I>Q-RVIMM67<9
M#J6M_R_RG<9"0A7&FN \$CL=E0'U'MD@  ><UZB[V=W=CJ\4UP2.%#63,A &
M$>O2SFDVVQP[33?#P0DZE3D.#UKN11IQJ:/?/M'_.>JU^G!U",,>#XD79' [
M!U6W,6*LH+W,@:*"=JW(T*K+%^4!C?F/T2@R$(E6@)XUDK\0"K[I>?=WK>7K
M)Q?5E\!I:+[=Z>T*_L6KLSQ)4I*Z7E5ZG81BR*=[QA-@#?4&O:0(W51A<A/'
M5+8^%A4)_Q-+6U!;AEL_:LP,-MQ$U!E1R#!.FQ0M=RND1+/8&?#JRD\%KDY)
M<M$XJ$AY,J^T3 -IC"Q+"@)"9,@S9=>$E^+= 98"HGI*7?=N;H0L"QX8/JGK
M@D7[%N$=#58&+_-=7NE@IFFA,=J2@#<L3YR\\^$&4X>L.[4O2)$ACPR%0)-A
M5A5H"8H.,&8=#)X>Z_TZ5#KD'[#Y-[P[FN=NV!GAQ9>KL.70W3.\_]K?T"A5
MR84S[/(MR]3J;W]1+$K[[R^#Z&^G%.R'VP'^HQSRO_U[J91/EQ$A?S5XPA/^
M/KT)[?FRQAIXJP=EN1S>1]%T0!9P>'6ZB><*AZ#/%4"E%W__ ?X;/-PI W4:
M!2KWEA>(Z#_+RZN7@-C1\A^X%F,A9<0[L+TC7\)J8[4_"U*4DLPN7^Z#,52I
M04%M1)A4Y;AB6$K"A:=7E;_N)9\/@W:K+D0PQ3TQ?.5,HE\)<F=L&5!G.Q#7
M8^M+H*Q3G8&"F7+(PW8(V0[MH4A4WKU/!5]B>Z,JWI^O$12ZR29>G1YQMY/T
M$Y.B0<QNP12=+U6L$>^:B5LVM%\\IJY#&5.]T=/"^NE\"2WPZ_0:$,9 3H7>
M;59M*^PCS)1Y( 9[7URV\.$KJ?O?N3!K((TB.6I:%MJUVA^XE)S>E0SKC@&6
M" M(0I*5E#XKWGJ&JKJ?(9O5+]-0H_=FIG.B'*/I @Y>#XU3(\^P'->MK:0"
M/^!DY)GH?.)J_.L,/?_IO7;V^X!/D8Q[T-,WU[C/TI<=-#YDI*H+FP8,"J]%
M\@G?<UK]0R8&Y>MMI_P4W^Q*5OE6,K\H'49CS(;&0Y:'FIH]G_=YKY!#_JHD
M#;J=W7A%2%:1_54TNQC92[TZ3+XV>Z@<82 ,VM0C]Z<20^B\$A&VJK!.%"K4
MB=^2K9JK%;52U;3BNZP0ZEY7\>V#"X&6Y<LO?6(:#@%P%;6.C[5_V0V&A&BG
M9 %R3KU8?6UC#5VT2:7$^&:&S(*R>L1/A0951N;J -S HO;4701JAM?=ZN#1
MG15N5UXKD,9(_/?T:F;3'!"%7?*YP7:KME8C.-(Y3U\OGSZ/]0;8*!,<7L*?
M&=(;QR&U4A;?EE7+41<?+_A>:="^4/PA'M3/;@ =!M/?_$%M[H/R?<7XCG>C
MMVB$^55;8::1Z;:-(RLC.XG;).13/PJIM_WA-FB]?OS%:M=6H/ C/=I@'LYD
MK=1H(NU:0E_>@P:S.0N!%L']F#</08"X#*;J.X)F' '6"8+B7GNZ&J@^#5E6
MS@H-Z_D3>G-0Z05WYZ7JW],W$KR->K2%+K4HHC 4 :8!!)'[X/K[1NC7T9:
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M+?)(C+X/9X(=4TA02F1V%RX$(I7N/\HQ:0+#IA$PO.LN>6@K:R;"E/0!:15
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MH.21I6H0- P1B8LWK7HZ%^\KM4+?%OR@Z"RP40H8@JZ1_U+:S!%-Y.--\H(
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MYF>\U&30GYO>,3)=&BM&_-OFV>>V%4,'[S6I\[^W!3&CS83:+AVO=H2@>;=
M*/E8ZP">P\HLE U#*,78'=CAK6H7BS%6S@578OVM+HZF4J]!JD7_ ^ZFK7<X
M$E!1WDVJ2/!NMH#J"V3T/%QG8G%GW4;"<ODFB_=?B6DL<[<H4BDN\*X[K@G4
M+,)F "9W6:4_=;.2F?8<3IQTK&>]NG'I?AY<0&#(8@8:),\8TQMV>2)U.VE5
MPD;%6C:SUT]67,0V2LNYF8MKO8BL7D,K&A3D;#M3A2(5:3WT"\'51&<P2JN;
M[D\NQT>:=/:9VC1:L_7A'TU*J0M?W-U]5:'^6SB"R15[:BY-IPQ'*VFO)>(3
M(G@I:E"D%H$UYY:<M,/N_!KMLFMXOIA46I9((/SV:P5="TK2_8Z:8J-#9JG2
M*9G=)L$6EL1_-.S#0Y]^\T%A^\$)#ANM#8<[$?5)G3K7_%4;,HTA>??J[A>]
M]<D<#!YAWGIDB;[=5H18ZTOH&WW7GF%+Y#CGY<$ DF7_0"]B]+[<$0XO&/8*
M(24[(OJCY"Y96^"=-+?.FE#3EZS'FX73;Q[NMX5']N>\K_K$5Y<!ZRC'U>*<
M7V,,D6R,]LNU 4%-3FU5=+X5,@*(1<8&6V?O-/FQI#9=L%?E2#'/NGCWH@KS
MJ]7WO=T2DU$]NUZ GZ(%AX4T_XN/^NG\22F!8"-O=H^2Y.B)+M[?D>-]FUHS
MEH/@W00(+AJ6#AD=#11P!U_\2[BK4)OI ,%^2HT^GRD#7:OD$_:7,YXTACF0
M Z3^]  !_KGYG^EW-^CSPT)YCRE/\*3<?O[I:*D\:]_7(AEG3++)U5G#'V_;
M4#/_F=?^_?L?T(.&7:@/;"[U/9WH8LM]A\[ELF 102X#/[H!N5)=!BI=0R_D
ML#EKW3X]6JBJU_2R21Z(  ,BG :I(&#'5@KDG6 LC::?7EPG @Y/ -% E\O#
M7]@L=C00&<UM;(Y#_Z*<0'#5&[B.I\^7+(318P$ D KC>\^7PZ[KJ/6AI)C7
M:KI2]^%<M$2JBGM4<OZ7H2R,HY>I]0U%F/A-=(U$&E.K9D[G^FY.65"<&U4^
M%*>>/"3^E<MC1I>4;(8YFTL$T XN3R;6$KU+RT+[#]WGOP'.-&:5=!*-UV.7
MSKIU#DX@&HM=-V'B 5,-8:L(A07VSV+0@TRPT<=/"2@=Q2->;>Y>(:.DJ.*.
M=%OIFPVJ.I;)&3%]H4Y0*I15:@40#;U 7J:JPI^W(9Z\?"M^X2_<?/CA+6'Z
MP=BLP[B.Q<Y:/7Q!DLQ/1 %&#3O2[F8%8A2XMWJ?_+6;%Q[2$L1SH0+9SD&$
MZE%;<K*4;++I(R>^SC%2/J,;;T*2HI428NJZV9E)[TWS2*./OK(RS>(X$::)
M"Y>0979G(&"2M*+!1C=YJ%A:HO"+,IYL4CQPZK5IO ([VY2+\(Q8(6"Q*.J#
MS.>5)H&GN\V)ECIOXOFWZI?<OP\(M(R+^Y][0\K!<EQU'3I;$^/&*46-_9:O
MB:VNSG!,0]7UGT'XH"K7H.4*Q2R?:]R=BL)9CLDZR\D#]-&=?2SBW.FBC]#N
ML]VVSM\9%#"F%G&OW2$635WQ"T8[TO$@+@8!8(V*370\S 15+R'('*98IG%E
MDF5J%&0FPX0/M3;*ME=APWZ4Q'7N(S\WB0.X?Z'0=5#_3\VH%6 $Q6)QV;+Q
M$<!DL+[?^4=XJ@K0A"AP(!I/4G>D@([;;16)+V-5[03@Z=^J=<C.ON9:_F=0
M:X_UTE]*P+2A6*MC9SDY:E3_:& P+U:<?8^XSH>[[#!%?XTSU;'J/?)UH]VM
MS$/P.>G9J+Q7B2Y<E\W7;R8Y-&$L;G1Y5=MBHI[CNJ>JT^\;TW'BOY!<H/*N
M(^DT*2X+9+J;Y8@3W'I.&N#WO^30_JPV ,);UUT$3W8P%"A\;4Y M1O[6WH*
M8#H?WQGB#L !SP(<A\L;+U4H BF^'0#N[K;F--V6F\CEI?2OJB6YAFUIA&N]
M)3QH\ HV(B@2L>XD/6RP/4-7<.9(TY-A  /G4U8?:8QLU0SIL'B_&4G (C()
M''DU*(E758EKZ1&W&.J[\:[1@.17M"F+T,33_5ND/\^+\OX)[-P6K^<F2/7P
M%=L\95:)XWD _EF$MDVK2=.["RQ/R3(-')*^WE7#[XU17))LK#L6M47P;GAC
M1R.7;DXY4P,7EG"-?=(4*P\J23:8&IT]>(;I\*:%S(W]T7U'/-U E<[AL-!"
M13P-T6SGS^1K:4!N<"H%)6W JU7;[B3..(AC=9F_/"*#=CJ,,9-9%5%F.WTK
M/652L/@XHS;><V]L;#+U4O$*C*LCDWP:2G2"M" %KH"*PCC5%T4M2BL_RG/E
M2GKVX7O? RYV4" EP !^S\_9YAGV4>XZ4P]-1K.MN)RF3#'T"YG.I1_BK^N<
MB?OW'/^1<M9\MK[5^_C1U^D76X& >4+>0)A^BSN/$+92_-:M=XPX-%ERMIT5
M2:$U"IZ#IB8KQM,!?8T<XD3Q(DXQG8+.9LB*8=<D:+S"=JD17R6P<VVL/"57
M>L34F03R8Z_%JM.A<<6VCNI,. IVOF5E6-QN6K$93,7'I7Z@T6%.T+E6'GRM
MCVV*_E_>NP)<7=^R  8-T5[/OQQ3EN;3TXGTDM-@HF>7@9SK+5<[]!_T[D^R
M6UE5+MQ+D_9PZZXDX?4GI*!'5@E"#L-1KUC59J@<>R%&31.+$M=>$^@*([:Y
M6X"V3Y8#<O[X1DPJ>%E,XP7E-7ZB5BF,'\0>MLQLTTG"MF$+S<YVKC#R:;(*
MW0UN4;*6Y ZX95.$W$=ISCCM=CZ%%*.\I#""5;0># 'Z= F$)<",*DSCO:T0
MP'QT^7>:!:W@A+:S^8\F=>>?S#A1(8TS]*I*#ZCJM-R&VTU1788D\)&_VBT\
MOG7EY5:EHX+LS7+6;R%'[^%69EU7:,':,OB\\Z!ZG\NJ%#X0!\Y?H:%?'.IL
ML$>IBLC-IUTSMA.F22O]P;>VH%C=Y*?/L[O$CH&-(\0%2':L!).$ NQF(4V(
M0ZC3+QGMC__'<L&'8D%NBOI!9!5$0GB=NYDGL6,Q'X5?F( F6+?<C,Q80 8]
MI:=BS/VNT4!4!N?IJ8AH[(&^YK#D/8E4IOI7^C#/36JUQ^! 91P:(W;IO%U#
M-H.&9KM[PIG?QIXB-4*Y/3=WN=55L? @Y5XI>T(EY-N-XS$*X-\I/F@R.R&H
MR%+.FCK<;*,[9 V!_^""=">0/U:Z3=@W':>^@QX.[FCG!6@J662?D0CA<#K;
M;=!4N'R_'C[\&-W9<A?$F^\PL)5*"WY1-"W:8(]L4%(W5M:1;<Y+X*)09KE+
M8KZQ,914'SO$> C%.]J)L.* 'L(C?&K^7>-^\7)5XAS"1HC:.>S'G9J026)/
M_2E$@01#>-&'5EE]AP"J2JGAZ'*S8$A\IH!))4-^<VU>!GK)H9?G>82JIG+0
MI5%C/%+.RM[#;RTI.&/DVM<Y-QHEI,&(Q6+R[_$XM9"OMYIZJB5SF,T4>7)D
M-OW";2CQF301!GJ^%>T(39(V=LHRQ0 W9<9.">=M+MZE<EQRI'0 \Y$[G8\:
MISUZHSI/S?XTB.;Q3M7LVYJ__1VR7DU$UZH"3]W3F?FJJ=@T XM_'N-3RFCN
M+$I_"\:U\KCY/\ XSZCH=.N@\.*?WWH^%UT"YI=!ASJ!K/HN;?9$]/F2JZ+Q
M7_P*[M+P#FL_=I(I"7G9K@T"OB.9@&$@U))PO?)ATMM,J'7A;Z\C'9?;!B)O
MV0Y[?)02((6?Z62N\FIMBZ''7'@M@:;E0ZC?*.N;!M<B09I)V]8P:"=!STT,
M7^HN>F!!,C9WKM\AJ\2!0Y</W&A7+I5'21>M_<P&:SZNX-\DMFV^[W>4GH@S
M#1&[7.=+&:YQ$$QJBOA6K.5'B:]1Q>GYL? + .X674%W7U @9C2+(%Y/X2J+
MVZ7IJE:U#9<??$?N?OE>Q/.*=J/=X:U'[),.L5<MIE%MP"SNZD:#T#-A0LZM
MJS,BZ7I!B.;&LQP4%'#EKHLS/'9%N_CGB[DW%Q;R-Q\4!V+U1]B0@MCZVT^=
M'E+/]Z.,PP+X&2BQ=@-BU,KI;>^R8Y] #\@0I#+?_>GKL^^D@H= T.MTZ5-$
M"7_/)#TK2\FU;*X+4\Y(SG1KM*W.#27^-#Z]SA6O.^41? ]POJ4"4/>X&PF6
M\AZ<EO2J':?B+0CNXWL75]I]N,3W-+)3=SM_(;3!'4UH:>$=5+N2>8O5K=)7
MU442L/C"V9* <KXCM7-LJJG3($BMSI(9/V31\3;QC MHSMZ'H0NRV2=FE.A7
MA^<J?= .4^7%447"KY\V_( 'NPPUC @)=-K^<K@W ,1R^R[*U*)$F6R_P  _
MK:K(/H(SF'_+[<JEFOFG4=8\89XE+M;V^*%"+X[]V N:YIN-3E1+WFA+^1>[
M:_51<JQO!VP.OYW\^5_]9-(<54<NJ3%9<K4"$:#<Y%?T+!$81)^"GB.P[>7N
M?XYB>HN+=SE%U\'B@@0^!*G^']-MX=7TXX;]OY>,41L,I!VC1LGHUFT,&-U(
MEZB4$H*$J&,,&-VB2&QTB8@8".H($3!H 8-6$1!)Q?P\W]\YO_.<YYS[/[CN
M\WI=UY>&67;]2F)!1C;>-1^=V-,H!\&3DI,69(2,EVND:?+Q9RF:!J?$K40/
MS741]#R/%];"]CS7M/C=%=Q%]',NFPQ\];K^T2I"QL##N=RS^"2Y3%A)T!(5
MA4[VM/Y*R/$*'J#IRI=F!$/(S7BQ./S=*\^KV]K3K:*5@ T1T"8"_CX&T#$[
M&WY8[0!%"7 O9=]3MXIT5?:6XI.S^E3@'400I\][P3/.S$N*-]YKXGQY>Y>8
MZET'LQ "GS)*)G+W(8]0;!)/L<VHM4,.AAC!99K$N_W=G6YQ\+."2QES,^]&
MI015"U\OMO<M@GH0ES8N<_0^&U\]0?,*,7X]D^WTV#!8_@S/_'6'XS(.2OK@
M-<$BQ]!';]\O'-N%.8]^//P\B@#-40Y@I%I_>%A$&MBTEWV3P)!U7U:X)^Q,
M.ZXIP]><=/I.+7B:JQ9Z#6>0T5@!_\[R*4_XLG7YGK+R!DPE"9OLH\(EV!P0
MT/?8KOU#OM@=P3Q^V6H!FIAV,WG&IES*(956,M84^?D\[F-RJT\HYH9X(4AP
M>M[)[LC,O6N:(IK83R)^R@X2)&!M(#]UN,V?!A)&T80<)-Q'PXO;6SF+:9^0
MRYS!Y= OV_RB7=0*AS$R#7US#AK1 CA'W]P$W R%K/#5QVS.WN444_'RB+&6
MGRURP=4H]2L*Q95T1(']J9H\T:)#7J5K9^AHJ,NZ*G,\-"JO+AC5-TXN /1!
M*.[_T0F]_4(\46CD,?S/K_E DQ^[4^<'7)>O<J6TP@=H_1R$%M,43Z+(U<S%
M<B6X!A0 QXX-F8VU+&GAU1YU4H%^-X->^7Q_MP",1F;QR6@L/0J*:B#GM_3?
MO(KP<L,>*H6K+>HZ-^J(B/(\"_I7;;XI=H68WR#0>.? FZ8DT@7KZD;VK&4V
M>\WVM?ON^EY7$?87LI$JJ-"/!.\K%AX(4AS>VI=$-Z>^T:[H/S [:]7N2NQS
M$M60)K>5;:;=H(+U&EZ56,+YCN,];I> _6)PA@/"1*NSU0. QO5TQ=6#F#4/
M5TN1[:B@7L*QS-_JU!UD9,7 ,\5,A>"3?K^I679'OJR*!N\S8)V-^;P?S_%Q
M+IB)I\(TZ94$E9,&XZ0I"';OMVW$=,O>GV\MQS0K\HKL&>8'S_BY6!YJD[&,
M-@J<*\Y35<45;N,S\>;8$]WT4).R%#73ZOR+&#DRGADMY]/WBQ>J &DF8Q5C
M4:S,2\OQ++VIX1%<"P\V5<[!'8:LK=EVD. JF;Y2&[UOZ8/0S[A(44C++RD>
MBGE(S^R2F'$T\CVDS[YH;M3%M\T5:Q6OA>LW)P<LD7&^I_\Q]\E.V=QNPT,D
MC>GGU1_6X$BCE$"6.C^(((&MC$"\J.;G#7:WCD/)==T-[>](29.1K*U2]+ZC
M.D8RD5LSRVB D.2G9/*)J@AY\O,4E;A?U]OA7&?!M9M7Y'A?R&.?<T%J$T6M
MY,-/ERWY2!*RY9TZXQ_=7AND9&,#6#WF]/#Z=!8H>MT#>&;3N'&/.;_873A=
M9*\?)D)CGEBCF MJ)6D8&1LDOCG9D+&P_,/]T/VTM H)U^F*<@<YP6SN+ %@
M+%D.\59LO/(U3 P'M;<U_@^X\:G CN&\/OKBMO&.UJA_]_R]/X?>0I$JPAQ[
MPM=MXQJG#V)F5H+63(*D3^OW.4:4K:( "]NNU$F]91'0F(!0X \/(1CBM;=G
M<P0X=N=Y8R2COR'SH2(N@\=Z:IQ^D>:.L*02B?H +;-)*H\R[@(7JG4 ',W,
M-E?0!$:JZ$7(K*IYZ[XB;RA;TB'O:?N;>ZLBV9\&044.5!G$XE'"253^/7)D
M>=E1'I!(UE.G\KK7P=S72[#-6?&VA@4I]+NA?9:8X37#]+!,?+E0WK"SW&&*
M?+E'7<07>TE1;I>IUJJ&\!?CXPMY*:RJURES"U<-9#<KQ2,7WV([+%&)6F+]
M9P7Y1_PC[TX'W09409?./%7Y^#,!>H6EGNU^1E%R?)ODRTLN677E)??."Q;\
MKU4'X*:#N\8Y21]2@YR;%JORDFAU_NA,0Y-O_N([IR\6AC_T9();.Q\3D7-'
MHZ&[$XATAWS!T1/4;J[44#W68JDG,9D:,_N0H$8Q?>)\-[G^QK5((?IQL!U&
MBL-B3!(_W7OF+/X&Q6\G7[AH]T74$/0B,.(8E]!4U\ZWKK<UAJ]8A;4BL=HV
MJ6X@2Z?CRCCGNO+3IUQPP1M#1_T0D<L>;GSR6N>)V<AMKI 0M\(YOPQ+7QDU
M'G=!Y1 8&7N;SXK);2MBGU@]$Z]50_9'I0>(N/=5*$K W0KK/R^[X/X#^D3'
MQHD WW] DIE<I7O'2L6^MI6>I3IOR7 RL&$-SD=*Q3YS;VXL @> L1X87.83
MIT;BP&QSFRP(<V::IW$P)M#6PRI+-,BUL)4O^<(0U'= SN8?N^K:O__YLV)S
MR?F3)B5=Q3^!5E]X:-Z$]29;X7*5$44PAW>^G@;Z6R>ZGB]\^7?BJC&2X:2<
M]V+C/^!X#S3E>DN:)HW7JC1 \Q\S/MQ:S R:DJ$!;3[2$< ?5)B)?;,9!#=9
M\_1%#ZRM#0Z>&S:TJ!1ZNQ%.-N=;&JFIFR*7R(S9<(]MRQ2PDHB[_+Q[+Y^+
MJR<.5!$REJ[LD*HS*0$Z5/VCMGPAS8(?8*E$@*BCW#)+-*A2&N@M]GUGFI]_
M7USX9(YC56C*;?_;V/"BY4AH RMKA<0G:V5(UE@^+2<09.-"<J[B:9)2*#0
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M1H%9W.EV'I\1?WNGS 0GP!CY.BAP8B+89//OPNV&YS+#%59#-A7Q!].&OOJ
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M_E(]6<WDE2V;C,9S7"Y1I!YQMAVY-]A*[7?J$[A35V,[<9'-V"@P#=**60\
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M(=8[QE:H.)QH5I8:,CT"_P_P\G,OP%X3@G +?@9#VS>H^D'WBW#;5 )=V:F
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M)\/'YCQ=*72X9]W)E'*W_,@RYMN>!!W#-;)9"8H97( BH[*8"(MD)#K4T^_
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M/H]:DBE\)/S<&Z-7EN><P1"J[[7NP:1V;A$^FU;=6:TB^/JDJ];Z\3]M3&I
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M&M7)E^Y^WNC+0'=?3$OLL/PC*;5D)__F#5[2AOCSC\I4M)R*D*A-&W_?P'\
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M>T!V+(>_(O7C]0_&Y8.R$. ;L)8\[IX$2]X6XNTCSSWY^^?X:+J^3]B&QW^
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M4?X53N"D*S^M](HH,KL/VW437IQ;M0R;@G83GVJ &Q_WE8W; 5[3%@X)H <
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M_LND?S!78U.K5SG2,S50$Z5ZUR=N*#\S-WZX._NJOS?#>VG67:& '#_5NJ[
MZQ9_=*&K(9U8.W)(PFXBUL=N>Z7FL* 0WWL!*98NRW1R=':\)P/M>LQA0"!#
M;+[.JU63D5N0ERB'K0T L%4M*L,PZ:L"%M1Q;0U101-XBC&\J^EAQQ2JO](/
MI+@5X@OV%$U?1I3(X+%0]W[WPTZ<UH:9PWLXOZ7N%U^@_ >V*JH:(^]N%LL2
MQY EE[*IV]#30@X*#IK!UV*68=G5_@>=S78>#?<K%!8D??<B;H\?.N+V+UR?
M+P@<M7?\W2G7!D0O)F<5B*>4./,?<_2!R2E W1K\FG3:80I8:*BNCA/HWSWM
M%9=3'S,^N!6IE>;#;GDC;!G;D\*GTJKPM#(1]A$N!@M[:2UV8Z5CQGG4KO)U
M@])$SR&/;6EJ\Z#=@M>>X_AZ]T#FT-4<8F8S6;BU,?'"CDU$G6/O%WKGX:X]
MKO(SI:>H?":I1^#9QB7B#GEL[?=IEH[WLW430%@_&^2'Y[4D%.1$IKSJF!TV
ML('HCX;Q>(W$"8S:T!+>G3_51].C7A[YN.+SR&%N7 (T5.ROW"_I+ HSW;/R
MVPS;?;5B/B\*_20S>,SAW.0VRA.>R449@U1&[P2IC_Z"*A]9]S<Z/<\TPC[A
MWXO3<_P)<PF^8S,-]X#'\1LPK9Z:MEX9:#(YJAR54[V($$YMAF>7C\IM9MOP
MD<^)Y>8^47&VC-/C<6B1M+"ZF9)"]'C!C'*E':2&%<U-QZ?*5I5GL5\YO;%G
MJR,*"I/H=KNVV?V4L99[_ +0IGT87>O7$MN:*Z&"\/GIZ3FC9(#_9@&@H;_,
M+7[Y]_% ARD#,%LHQC^;T0P$C61]EM^TO_W)DTR$LM#8@1J=%$T_Q^=O2P0_
MSD(O#_A.<#+4GTG _S9>E^=-7#EMHZ167I!=X"Z6:6%]A4P1AVGP%UE:6G:#
M )8@UV3>,I:)G-5FT! O+E47$U'K@G1OC+#-" F&M0HO=)SX,Q8R:C-@O>><
M_&+0'_K1W]]?TB45#:L*9-T-LR>BIV;UTOS7%LP  ;CV)1&63@WCKE"C8BJC
MB]Y'"BVRYO4(7 F]HL'M? J&D\YKEPVS,&Q^']/70FG"=_)[36P6]A"4?"GV
M_>I6(HO;OWZE?I0KFKPQ.)G48&_UJ'6^(?'0L:DN,#JD.Q39E,,.TA*Y,9U6
M3-^!OHG4R;,09[I(@'K[LAW-5=YTZAY&!!%KTNYN@[J^=6P"85L6L<%ZKGP$
M_CT&+889!H+G<9TU)'HXOA29'Q?&>#V7K"NF:_3 -%Y_6_V\)A>Q+=/KJN&K
MQ#JT[G Q6]6ZC7/1O<M+GAFFF/$,*[$01SM=\%R"LN>^/T]N<6^RV=)1!.)9
MK?_AZ+9%ZPK\]B%^)N/NN^GXPE#G!C>+$K[4I7=]RZ]][QQ0=C"#2;)$S64R
MSF3I>F-%89I$Y8+=4RWGQRV%5"PT('A=QM_8(R?_"1]3E5AY=0W4$4^F/>L)
MJ.%^,0A".W264MTE*@I[@T^K64*G\$)G]):LFY84Y'.;]Z(7PLH ;9,R3O)]
MCC"A](?1\_VM)G;CZB'6]I:@ LM+*R,)>9S5=CU;@$_/LAN_C'XLS(,K..8!
M<6F"I);LZ/AC#OQP&26 4!6H\>'>3Y8:2W>1(PWE*)"!88WKN_??!(9'9HN^
M:H?D%D\GN,07@$* FVWK.L]HGK[ H&,.V, 6T6Q>(*2G'?0>&U4>'_0Y3C-M
M1D!A1-(>IJ6$GJ)Q_7II'>PB$;E:O_N)M1EY+_4Q-;X^@>H SR$7%1&JGA3D
M$]"\BM1>?6=>H>AA&:<8LI2>JJ![59)#:[R"P'M'4<\_,N)=1\J1_3C0(9._
M]N[TMHSOD7[$(O5;&XUKAQ%Q,T>9K>"B?2DPO/"S;5Y$3=[HA(N45%8G7%I^
MQ*"#-X,9.9K:#L^)!<+,I!E='MS^N>D6@112M< N/$[F,<M5C9]?VJ>&$HLW
M+OJ6&',IV29RI7SX@LP-[UE'_*TU:7)]-_\[;'2[T2F S8HYBU2?T[[:SGPR
MIGLZ:*)5[$$@*7 #L=0DI>QTACVGI;]N)_TFCI%H=LN$6^AKR.M$H+V891L#
M%AU-@-60H^F'U46$47M8<DQ+:7;)SM.<3!RQ(B6C3_[.J!.IFY)AGGS,<=WC
MW#+AO68OOR/:R;+6MN%STP:_2P:[YTVQ;KJC"V=0P\,&A_[QZX058\X0ENKV
MY .+M+2^P)&ZN]["Q.%'D],M1?NVDW46+6L*.*E9_$T$/>_YDS<]L<O#+L(A
MF@EN9H3*I>[*3\,Q.V1'3 Y=4:#XV_Q:,5=%=:*Y5S6VNC P%>-C"5#/2<W-
MZ09" +)FYAH>@3%9HFA1&>+[@8 <[:"B>#2Y>?TJ'I*6G/FP7NMTWR;X0-&_
M9L1RU,BOVN7-'V3;36E899\5L(S_N0&SRB4#'P)P?AKHL=2(%"U<!]=<)'8N
M %C@+AM@Y>NZQ$!3\B#_2Z=-08I=1_9O40(5;S^/[9D):+1%%[E(D/-X'"F8
MO$QXJ':H\:9GL;F\BL[2K:,TB2-):D2WHIK7H8NG8(/EC:]R$>5RC4<*KFU2
MI@<FP[&GA#,INE<3&]*_(9(Z9T%"\GV0PC'3^IZYZ$UC(ZW;BU+2 G3-#%AK
M.=!><+==R,*PY,F<D6B6T6_@T+C"#3W9VM1^],RKZX]W*&!>0.AU\QYGV0%M
MTY.UH;K\4F/RGC)5 M$!G,+H+^G/+"TOKDC2/"T")O3]&815@'D?ZLDNE#H!
MM1='TV /9*"D1&YQ'U3+B$"L(26.EWM<4SJU'2]IT$9TB6I,"G#1N:EK/#FB
MJK5K,B.< ;W\RX)1<C6 3;$WFG&1FIU;GIG^Q XSEU\JQ1.JOX;)S]>YYMAB
M-5U)>5B#N'EL1$0M8>*15P;TR]P,K0.N%E\7T3ZFJWA:?[P$,;VKN;$GX+>!
M7BEF" /V/NKLTC67WB:KNF(%%O^6MG1U-%4XKWE[-;(;9)P,X2KR$83"\R'O
M<\]8 4W,$\R 8E)V;1DOC41K7LP!;:DE4R >S,7N^;)FX0%G&.-:RLRLP;7>
M'!.>XCH#DR2V<*=P>=L.O'CHH!*K03((D.0IR#0V^A#57Z<DO1]GC!BIX'Z'
ML#/< DQ%9H%3>!/DRQP"?& +G-.-83F$<B8JSQF<>MTZJM@,;;-K:<G+_\:2
MEQ-! 1 E\0$2$H#GE7YS!AJD!= !=7Y/5FT7NI"75.@_$4J:RY0,=,XQ,[@+
M&0G"@_B(S_GYKV"6\@PI6$3%_F#*L+F(@0\K%JL))6N.31IGL*8!'QSO^.B6
M^"^3/,SI(%5&TDJH16BHE<'I^\R!>JPA6X <!XCI+\(E%)N&$>%^HVAPV#@X
M&H ]X.Q=&T;*?9M\[H( X%#)SAD?$5<3MUN!]T"/OD4R&QV&FABDY#<%XJ9&
M\G@8)5' *!,<ZE_HURB+2YU 3R=N2LF6-\COY'Y274YQ>Q]8O_NJ\>IXJJVS
MS!^52@^8,?;7/DZ7!$;GI]^>A2W22R[DG2_/\QP-6K"0)M+BQI[GT3)><=+:
M?"NKQM^^D\>%G?883T#:#/K4];T=_#05GQ=YP3YU(MD_T%_'6G_1&?3\)3'-
M.]80L\4[81LT8U X+_@Z+;P585:"*;*]C;TP'%3]J-_Q36YU%>'Z'\61]J0"
M0DXI4"RU"*_2Q[A-7[9]1TNG+78M9LJ[/ MQ0B[T^F&QO8R-&J1:VL3#+?S7
M^/WY2?S>H8AT:0EXQOEER&:@*W $#1_(W1>1)^A&,EJ*AY<<LX?8\3M1X=4T
MDY]9%@/''&D9F(%NB[D2=6U4Z6K!7&9,Z9:/4,A>"+2%&)):Q^+"&M-,G+4F
M<W B*WG>^"L@E;J%8X[ ]%KAY@C;B9 O(;USKC>V6A-P"IM1CU=K[W*3I[\I
MN,B+KS#OZU0Q)VV]G#52YL=P-4PSVUH$2F%(9,+M^D)"7>Q"(N')]FPQJT7;
ML?6QQW@RXMV-&V=%TITXATOTI6?S[C-=C,U,T%FW7(+_MF "W3OSJ7JPL67[
MTE2A1\+T4'BO@V';BWDYA#[!\'ZQ^_*0J,XQAQ6Y"1[7]%DUN5-@\[YL;33S
M-SKE=6^.!6]13>L9UTHUV9"!79CN#+RV&9.86AQ-^:FR\G9^%//#4=C][EHE
M=W792+6X\<BT*?MBA>K7#))2H^_&I&+GK Z5/G,YGZ /A*?.UW!WX4Y.0D!;
M]*"!@9D99DGEQ ]\JV(,2[-5G Y'!+LX%R!*VGQ"GNWNC F??<ZF_'JQK*BD
MU\M.B4I6FM$J< \[;EZMB+,QSLZY,0&!RFM?_34WC,Y$'WEJAEU_&DS\:KDA
M>&L"=NFBK[Q]=WV&4<O!. ;GTV>*7S2^&=M,$4<YC[$%!1L"C,V[*UMS-(/M
M6,'<S0*%R?)"T^QA12!OH$P8KZU8VB/K')N/C)8'<^PILRO&MY>OOT\0A^43
M#.#"><\:<\F)^X(F;E,S3ZLKAB7/8D!?)N</ND.(W7.=N\$S$Z"R=R8+R8FU
M\KT=*IN]S=,NXM_D+\NIL!-<ZI_T],+[F1*,"7&MEU_A9M</.FC*$>.I!TDN
MA^W;K)[H<[=#'?_,R\[;FO\]+W-6Z=,)V%M KF>).:O8-J:-=VW 6#VV-;'?
MMCX2#!*#T^9!OR-%'FYRW?YB0CWFX(\.'Z[<A+G<F%&9FG(IPJ@<$!MJ*@WI
M5=<"#MJ&S7C7L3JW!"&_NJYL=MW@*QQ;IMAT6C@'1E.36.!L=XK'PY!GD3E;
M&V1H4YR8\&ZQS9)D\\A^)1S:Q[N/*5SBIJ2SCCF,U\1>N1:IRB;#%*ZMTE(_
M>TM)RR4+X$B6@Y<?S*#ZO?-Y>?!M,;ETR8>P^O-)YCU4L%U5@SF6=T*_)X'3
M $ A@#3;ZSK>*PMU-M7ES"<2IH*WL-"/GUM?6!M;C@36<7V:^30U/>4,&#98
M5LH)L7TQE\Q'%(7<#V3VZ]%&#-4R/6J^W9*?M)XJ_&,+2$^:9C4[3\,&\PWR
M<O # [='KG_,^FP^U0?L07'3BU:)F; N R_GX$I@[IJ$A*<*)K1FN]VH2W71
MELT^,]K]TO(>C$QGNI+ENPN2#*V-+W+'9D/$$>ZUU&&;E%'H^$"C?\6^RA*<
M(NL8&XQ0,<4==>L.;6T:F_$YVEL&=L@_*MQ+5QT8,G&6#:%808%KX)LQ>)5I
M'-59^.TPQ2F*CY.Z[>\?D-V96OUY('5RR:ZT'?/ MU;.+ZMLCV!0W>\R3::L
M]H7R!Q6^\E,&FE>RZ5K+3AE=1'6YQD\@_&J RG.8&O+,1/K]!,!;WPGK2O/=
M)^3K@B,V_39EW+UY!5% 8#Q *&8H/S]_GI*:3RGIC/[(SDDJ"*J#<_T6A*WU
MK5(0\+6HQF;3F .,/@>$GUI5<4G*B^C%I<<&!@%9TOX:P&OCUE'=@Y?]W:KL
M^W--$[/ALLMU(;:RI2!CD;OEB30MF.0$>8W_XZ)7P'(#\"<; ,(<?W?E:H-P
MB@XKF-<+)]SF6N^R/_&N2_>L*C9VQ)=/(,2DR""K>-+/+GTG(T,]!Z2XJ=$V
M+R/I]9 $<A%GZALX:&R8"Z(A7GP/V@4:WTZN0?=HR=$/O<M'.V*J+ .>>55.
M5>66.RR!!QT2'I:@KO_D!,WC&2<OKIUA.,R:EB)*TF)B$EN<!EM;LH>..1XV
M1YJ0]3 C\&>\L94!<BWQ^[Q 5\^83[7-'J1?4\F8/$3?I-7LGL?2.]\;/]8A
MP7'96I:U0:H[TU=3BD\%;A&SL(6\C]HF.G+C<UX0PG1,'Y(+X_)G7:@&!D8
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M>U@B#OK-"]:  E^!%CQI%J=<XWE8P1['3'@-C/F4#=K-D>."B.*VRU$W<X'
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M H+W1:6D/ 7VROB1G;\Y-XYV3;?&]\T-#-!25A17B'(1+\:7>'])CH)F)U2
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MOWC*5TGL8WM^TUT_?LP.-/1>U_PA][)G_65X)L<<$+#LUG \?:5MI=YOAWP
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M@7'2_?-1ND0&TT@D_&0UC U=4;C]EK<_<N1YR(LWKM_3.^63.7![ES,1^\C
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M/R?U8[-! ),(59QI!3,#[$%FVZXWX!'+F7%_3,04YQG'^ 5]&X[O4PIQ5.S
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MK*EV_YQ!X<#(8K_;X]L.DU0MQFK_Y/#_P=YWQS69KHDRXZ@SUD%!E.8("A)
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MG_@E(&Q"SCC(Z8RI*/LCQSVQ.432,WT=8+"<G\]O\;7][0UY+?E ,-$^P>%
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M^H.Y ^(A[J OLJ  GRFZ9XSI/JCS) @O"-HV[U::  P_UTC1EG.F/P "% 4
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M2J['38IU[,GJH"2EOSEA[ER;_4/0XW]:YG=^S(%-QED^1GRAP:M0J3OE"5K
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M^B<SAX_V@CL+4H82[WTWP[G!^A-.[J91!_9U=4V/"!<[)TQ455I([$INPFQ
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M]C*.<<=7]G9:@I,XUY>9 T@Z=/Q%CT]706%/.6-*38*2((P(B V0_/-C;WS
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M';/2-UT3IAZ-7= !;:[SZ,*#&2B%E-\%X=:YB&AWCY6<@X8JC@R8*E:1<%-
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MU=8A<*7#G9V'@HF=G=-#,>\\#/>G__H*';BF=2A+V76MQ]&-BF/(%*.<9O/
M29=\:OWLVU\0C4^3DX/&M\*J2<V;,]X$1=E/$FCWZ%=3IHF^@+NT_V;M,/%F
M&_STR6OLYO'F#7#@6*8<93UA4*\T2>9=?/L<@\;G&CZH^BPD,)@%-122:21V
MW+Y@.^8_L :QR]0C5?JN;:@'!VZNM*/I ]_J)A"'B-15ET)T,3P!A1AG'![
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M'7=%WPR2)^J^,OQ;15_<ZE<#^1'YJKICWI+Y!O476NY[F]LEL((3S6\,U:4
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M%.I0?DJ%;-?6J9S&G*E?'3,+  )\M0'!(3S P6' YY4:8PD$J+0W"&AEA5B
M:T*(9>!J7MYQI#0WT^T/X^!_O<8/RU@J"TQ!:BA'9/O*?UEDV"HYL%[%EP6>
MA0(\;/P%SFN9:P8/SU7JD'F+0SKW_+V.U=MT>7Y8?;G5$H4DK(DZT.\D;G#_
M=!^16W@P1UC3E(N>?#ZB69I)\$65KAC*PWP?6).L-,/X]1^#*$/.-AT#?LLW
M,U<UK07^\BM.SM.;'=52/9<JX(Z6U^-]D!OV5@Y.:6,#:7#)$/T$B?SX$%?$
MS2$GGN1\JV #.&^3N$]CPLQ$UH31J;"_@HXP#SWANI@!]6&\/' 2X??7>S7
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MORT\J/5*IY>M4U5VE;)/BT*D5R=."AJFU(&6%>:!DK(!J[@,D(8-KF[, 4#
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M'+;I >I.L7-1(U^3M:&9KL7IOL+F?KW59C"_#0>F=\;8=(UKW;8*MB)D$-H
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M*V -PL,4[))#(N%M/_=%N<G>ZQ+-+Q8UL&-"H-L4[<:Y6J%+9T4>96VX<!K
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MMPRP1ZR1X6S5DI$8&(O VS#QW*Q%^9XF[ZD#;G5+_ 17E5$NVU7H[%)!Q\8
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M)*'+$Y#+.OMI_<T#;ZO,7YXO35^,^Y9JO_MM]8FW$SH+/^FZIH"8?1+7F'\
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MHT3 1$-,#Y&_<7!(OA$YTA-9[XWI^O'WOZ;_A^LC%D[;;G %7ESIS+CE%$E
M0FM>OBH.Y&(@]DO2(50@#9%[5<4(4IS(? 7L,[=S*/-51*J4S"%W<4_O&L0,
MB[T;2TX\"#TZX0B_OK4XRDS6;18"B4BA73\Z$S^%M@W*Y_BM70)+^!7'0.UX
MB.BWY+!"LFX$Y]WI0%&L**6M&'VAYZL=U0P<4KF05HE8TR/==B^]670KBS2[
MH^&GH=;O.%W3;SR/Q2[UTH><51+[XM8+R)'N2>V%V%*#>7HDW8Q[Q"/?F]?
MAYLDJ"E/F6YP"RW-O3C,!9/;AJ*59*S!'FYLW"2]*W#5UI8:P<+66'\X<I2R
M$I744+^IR#9#312$?[CEODM/4:+YA6>;/4C7CA'+18U%D'!3\<3"8M=RP] D
MC61U6P)=M07#0"",0.9>]I.Q09QW\FLZ*X<ZKGFM536&+GQYOZQ=%<B4I\A
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M0-\<&$RWZ5: 3F\5V:K0' ,>.(AZ_HW3%]RP9+CJ%%!;.ND*:V&O\1D?/OT
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ML*F>M5_CZ98\FC[!;$FKC6<BK"7B4>RM>V<C>)4- EV#-7-C[7KK+?:KCBJ
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M7!Q+6Z]*9&Y7W8T>@O(\6,"3@&QK4]PPU(4 :=P"NK"%U&/6U2ZC6'X1^>N
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MK^"*2F/CO/:3G&<-KY9B(S %[IL;NA?RG-U0ZK).])6\E']J_"$]4O8D7%#
M\7FK:2#PK?()1T^IH&J"C<4L=\ML;C3N[<C24_>E*_6X-$\-^?F(W2@K5.V;
MU.7ON&K'OEJL-0 "Z5^(!I*]^FJXZ@?-OD-&XU!S0G>&V NU6]E'7@!Q]NQ+
MQ$I1[?=3(?# :/A-R\#BCQ;'?R FSZ!&8MZ]JG*5PI;JG6ZO_HN'AUS?UW]T
M0$F$K6PM36?J,X3JX/=VMREMQ2CTA;FMH\8D&L/&"9*%7IUG\X8SA29Z1M_G
M*$4.R3<IVJ"_HZI;-+6K3(FFF]MJK<Z+'9C-Q-M[ZS&+KHF#.5H@ZE;>)^PM
M!/8U6H9BI&?EDP?ZPJC21+V.V[R6.Z'B-S;W/WN+</4LD$#+^[(Q'Q6^X#[]
M$*!V8$T]9%:TIOZ^:2T:>:7#.RWU%%39#Z7^92QP:.AD]#D=WU-,9?D$R[/&
M7J ]2B[,S@->K27O*3_.C$V" "+#M6V9K;D48G"VPEGUZ&G#$PX 35(KQ=+I
M/5K^.5G]%'^L:Z!/\<=3KM)_F(NL[U8N=&8^VG1[$!#XB+[CI:XH/!D2*@'2
M_@ZJN$V;O;?-)A9.44[YKTQU%X65[6.B]/MIPNE.L8YC^46N?5%+DWZ<M&8N
MD)MV"L*S$4Q5>%M\;RR*CNI*^7PKIV3\$\>5GZ<3LK0\D3OM5:#ZJ81ZXZVQ
MY#R+[A,.P2-S8O?X1LD=5MJ_KNS_KHE=SO%26Y%/I:MKA]Z0=:H#$#X "U+9
M(W;;CJH+E!U13/Y85&W9*,!T=T*^W<4P8G-R5B^:HDB[!K_VJ<SI>C+DH2>C
MC1MC$^)AEC7OE0&BT\3H3L6HTM?H"\,/F%ZAMJS'#J7\\P3!M8Y=SYA=CT0>
M[Z:KC0/Y_^-+_6UFN&0[OM'YY2C=*/B%N19_BQB:VI@0^/,,:Z*3W[W$46N-
M:S9 -6[R#^>( 7-\W5I-0&-5U\K^07"O]3S;$&E/_=:S_!2XN#AVPD'(NU>A
M+&RA*'H)%M =P V.L*@R:3Z,D<?F+Y=?^N-RL<$6KW&:T+W(PE=!Z[P:NQJ>
MNIOZ>VYY,WJP-V$27*,17L,X/X%B,=)8GD5:@82IX9&.;7^^":$8\;T#^(2#
M#]-3_SSXT/$4=*\U?4$HWA7V3ES#S_+6?-7OQF*240:O\BBREO;U]\VOSI:3
MX#%QB!Y!LD6VKCAO$V2ML4;T^>UK6Z5!0$'Z*3C&.:$O(M#C7'GO:*3,M1IX
M4& NIFJ*3M]&13@NE/A2P[H-5")W?8RG[$(A4_LS3Z;4=7)8!YWH"6@$BK;0
MT=%(N\<7>WVR.Q(@X"M',H5/9_=%YANII:T9G0M1=ODZA<Q5:QF)=A:$^PJ6
MI0OY"=J^SA&Y%,15 MF,<_K?C85G!06CAW8N^@9E6)D/C F93-4];B%K**BR
M!_3$@FWF7\5Y;KW//_ !;X@;!?!"-Z657E*$,Q]?O?+QW4V@C::[5AY08GWZ
MT7*&MI6Z+O\-^@AC^\F\-7BQ5')L:MZ]K^:G[<JY/C!P25KN/S@*G)A!!BD^
M!>U<G]3&SJ;?':Y;OB!5WD>6QOZ"4--QL^!W!)HLB >AEF[0(:)2UVLBXS.=
M*]WCJHJ,7T8-%J+T#2MD8.]\C?+9UZKZ?7GO/TD[I7_Z.'Q5'RM@H?F^18*=
M%K&PT 0WF8 WL*MI0_3O%_WJ6[U-S'X3L''"L?K<+_NN5WQ&8(W.3)>NV^).
MIJT>I.CC,J^LH+6S]ZWJ0PMB,O ;#*AI7!H<>>]SE&]0)1V+!,L+6(=5[2B7
M!)A&W3R:\E\K5'BL/G9S>L,/J@P]- O I^GG-I<-3!E/5]OI8&>:D3;@\ZJ<
MSF*;8-ZB![*I>'O_QUG$WNL>K3<F'3S1Z>%'X@*#^C7- _9B'R=XM,$6"&0L
MS=Q<F;/+XJY(C(-4C@4/A*PN&V(QD7FSB4@[!8(1QP7&K:C#.TV=6P5@9XVA
M81ET]PNWB$2:V\?I5+HY<6B%*D><SR,$69<7E18"%^DR/):BR>(0F1KJQ:IA
M\_B "H)>$3+\YL0PP"SOJ5H^BO[IS\6(S!H-,NH _]AQ58]4ZYQ.;'4K'\3@
M7(EZ4"*=TM(>.2PS&Y5:V4<!EA@IO)ZRX"U,8 *=B4P88F""@10.N;Q' ,U?
MI]85KKQA[540HZCLB<6V)3J7H]*N=.9G?ML^_QH)J"J8&\5'DXS[BIC6GWN
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M+"MT$T?D34Y4H%I<M]L:OS'@'4=7=Y,*G8"5BT'9YW[RFFX&253#]<K<VHF
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M_<6;?=)&^&(9NHSZXS_W!OX3(?#4BS9Z;QZ*(:A/2_ITPS-!DF CG6"TFVE
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MTL!,S$+Q0Q/,L<EZ;,[]RN_;7M&C%SXD"&>?*W09MG7O^13=:>$#8M&G$Y8
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M\QYY"994KF=V,KQ\5M9'L5G M"/D>_<F-5%#\S0MX9I.L,YY@/*AW=S<W,#
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M-AZ:Y#B>DY,LK@0J4ED*4[-]'3G=":D"NC;'T)4@/RIWAB<4:7K-#O4GO+H
M38I1H@L6UGI47<:7MFNJAST\L22_5N;7LUZ? 2SY7*%T,U!6T[3,HY_6KN\\
MC?3S&W<T7XU?DPK;4=4(/2(!@V:9>GT/Z]Y'U J_@!74WR]@RGH22UF1%4.+
M B'R:65"-754$9IX(3HY]02V,-^1=5(W(8[/XEY;+!IK%Q[>][K?A>8=F)]K
MY"T96@.[L/+^+]W7Y9E6)MN!4WF^(1537TF]:J"<E>I?EJ[A I<A0&_:6E_&
M)!H.L,\]GQL5$-RD0Z%!!OX<93OKM.V4L<FGLEUA,;,TC3=3#6%J5Z?Z+ID
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M1&$'%2<TT#ZA;E\XJ*F>?OQQ:'F[9W!'PGB!6ZLKN0"0E;K(T,#,90F??I;
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M:RI%L*4<8/",$E5N3<9N*JMAJ5DRB$+WIW@.P3B5+5@6\ULJ;,"OSB!A_V<
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M\HQZR#K>LV?=B\[^?*](DD?YX&7$KVM$E9]J/,=L:N[_996%Q/\;+@;X>C;
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M6]..Q#9I#T*RY<"7L<WUYU<,LV>[2&#N^D!W_BBH^#/#^\\+"8$I.,J/ &S
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MK^KE3IB/@('LW,#Y;XPW7"#K.LB=DD]U.NX=3D#D*0Y;7J68; 1;SI-_A\;
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M!4O3[5'"+BX.1W]%\_OTK"CB#$EEY7BN-_GZ$TSWT*09VNJ5#/42;ZP&6]G
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M9F[GT->UPG9BF@L7NUMR,YW(JSX'PQX#>SN80V%MTGK\62^U)P;==H+W'<?
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M<=Y8$F@1:_ TQN]-LYGG&I^G'<*2.%5.@Q&9?XX:BL&+!E5BWWC!UJN#[36
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M<!&#87E-T A6B2U2#R2VJU_<]W[L\/WF*HG30J,?:W9WD3RT,2  %=W[ :.
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M2CY_ 8/QH===PO-LLQ=CT9\R\FG.%<&?=8+42"OSS\\I8[RHSV["M BT\LB
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M$8V[&5^GHQLS_9.0@>-<7:I"6"O@O)YEK;Z-4)$-4*L66D.8>WCMJ&>,L$]
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MSXGGC$"),48:I(GG"WJ;%WQ6G..[\5OC.C:[I[*-DC!B*JVNW6FU7+,&.HH
M*G<1=;)/K7NY6U+C^MM!)>_D\=(P^_RGAGS^,58RQ3/U7KC9WFB() 5-#L=!
M;YJ*4$ZW560%M!L)I<?Z'GM2[940Y,?>Z=:U$QOR+.6*4B[F TH1->K$1]&8
M@6-XEJ6D2-DOT7X2=RIV-6)>UU8='3S#<XQHR/DB4,>,LZX/IDU3HG]B2-%L
M*$_R$<)7!W1L"N"[;P*Z/3+FXF1?W#EU]KG,T1=D\YV'VK@^0<!<[R^*4SCU
MTK(-0YS"29*W[B^?'=C2!O%ZV5A7WY8P.E ,EY8N7M$%#/KK;!A<623I-K 0
MUM51H55*":>DHUMF7.S4NHWK;;B4("<4L+ 7"+?1$S1C^Z<B1,Q9V28EM#-D
MF<"]ITA/HGXQ(5R?VJREGWZJ2DRU?VYRHO7I#>5RS2/:*13^7%#M\5?QP)\*
MY@%T.@<KJN-'DB;'T_-588*('#.<:AF[[1G/N^EIZ\G]T"HGN4')Z)%OZ$:]
M\*D+>P7-_^<%Y81TI\113R -25'TF):IZ-#M^+H0B2^%YD2I59Y;WY.^GKL%
MJZ?IJTNX8<V6-Z#D7'HRUA4[BJ,J69.@]VGAY1!L@'\% K6X=L"WUC;AGHV'
M=CLDIC]"DJI$@])+*Z;B=JT&F<!!@4N48,E-4XT8I T!'GZ7,KH347&T3WP[
ML3;BAJ6HY%E8P= .%Q%B.LK=/9,3L4+3F(;%A[HGN TKPJXP^F1O"G#9N'0V
MN%UQ?FM_[PPOJOX;9R\3J$Q?&7U#NRNUE\3Y &G &8T,F ZWH=H;U#1$]'I*
M2]:^>FZ@;91T3K21PR5;$QV#?6==6PYMHX?-@.-/!3&!P[3+ \+Z=5*2U1ZG
M5A0MSL<>W8"X.3\XY]S>A)/!X03-.-N8P'XF<),)Q&FADQN$>TDJ'7;RL772
MQ'+18\3Z[%17&0V- V8&@NG>-':QDS?D BH"!G,JCK^*@%RC?.M@2'%2-1-)
M]!2"2@KU[N7=\H9KE#XF<(*#_@*[ B) Z7*LN@AN5O-_+3K=Y%PF\ A.><<:
M/;N4">2GX7JQ1,.I'15)848SC@GLJC?<HQ=!?XPQ3J%'"DN8P*),Y<8Z[9 &
MXTJ''A-X6\D$&$FYH \+_Z)G"AL)9!@3>%R)^@8E[\]D OHCN(55E#^JFPG\
M?(H9XV0T": 7QL4 NN2K^./ OQ3VC3 &5Q(3D#>GVC"!$21KV* MU$/<W#9-
M0)QQ-8^,80V]PP3ZEY?H1W/WQ!__GY<Z>_)32AE)!>^;D_N5.(X/Q KX*LD^
M47*.W[0/3[6ZEG?H8@_A.KH1/J8PD\./$"8W4DR+'* 1-'\\.GZ7_7(O;TRB
M(NHKFOO1PVQOU]^>]6BH)-^/!XCK"5,'T5Z@A$DMBC_F.^.K1LT5R(&A]@\2
M=T,SPE^OZ5F\$H#N/7I.^^&)B8[+U!1R "5I9CVN@:=ND'$,>?X1OJ%2:&.\
MK: [\/2!MP\NR7X'VHV59^@9.[M@?L8$2OFCO1 1TP(#&FF0PH [V][92\6G
MGD/:_&&&-%XB*($!INB'^4E0UI8)H-CUTQEKX?KP:U7QDI]S+W(8-;?7&HG^
M>"H_%G'^\-_$H*#09F-7F1*U%9:UIUG2TB&ZQ_/4*5^YGRX?/^Z_XE_Q3%LH
M$ZC2Y%1EVS!M3]DQE%^990(WT/RLV5&V&0HB*F+B&TY2\L@4RD$F(*C#FT^1
M0P36(Z_+I9>6,8$QP?'3/UO9/GCRI#AV]#?L_N4T@)3_K;)A<K%>H!UU; *8
M?&()NVNDB*0R 0Z6LCPZVX=>440S@3P/]I7=?]5V&H&>S@1F%6$5(/H].2;0
M5Z6VJPU[ 7O/!&@%I>1(5O>_3>VJMT= #3S^PF[2)EE&UP7=-8@:8@)D,'37
M,1R6K[93SQJZG35T$9VU>%8@Z,V:7:RAQ[^J\_]6P:A19J@7$<;D\/X*[5[!
MKW=<<6K' [.T>CZ#U</B?ARY<?H"=UZ:T71H&MMFR4X>N9\B3^(D7* $$YA
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MT,XMA14?K6%M1<CPI'A@1;Q(FFIU@O@QLUP.D16@ V]]'&,@^=SZR[EPS.A
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M#[Z9];X*8<_,#I+JL 4[H6.E\*,1MAVA1!,C)R21;WM7N[-$U%\$[OGD;(^
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M:9!A#, '__EG,+F3"1_\T@.X+M,Q?4)1M%>VK#G34.VB-.9"B\_.$6B"9QE
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MMY7X.3=O\VLCVX/L^SF+,?/$X'<<IC)-;G8DG,8L_@+4=S!6WVI5@9SG0.;
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MHE50.0)&20,?7D>'*3=(2+L-M[B49')?W2]:B_D@Z2>FU%\0@BW0C4R??<,
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M'EX^?HGSDE+2%Y155-74-32O7M,W,#0ROFYA:65M8VMG[W+/U<W=P_.^GW_
MDT!84'!D5'1,;%Q\0GK&B\RLEZ]>9Q<6%9>4EI575-;5-S0V-7_XV-+9U=W3
MV_>E_^OHV/C$Y-2/:10:L_![<6EY974-M[.[MW]PB#\Z_J,7!4!)\??VG^K%
M1M;K#!45)17M'[THS@3^.8&-BOK<)1IV/7-:YT<<HHK/Z#BOI!74=M"+*=W"
M<MU]/,+ +:Z,EL#]4>TOS?[W%(OXO]+L'XK]4R\4P$1)038>)1L !DXM$,SX
MB9,'H?QX2C^YEXFAGN[""![6XM7Y7[\JOE\<Z67I(A[(_*S:.>E$-H W)+&I
MW9JO(72S]X./9[]-V6<U%C85:$&6+KDQRUP$J3ZT9!FG6+<F 5C;H:=C]\'N
MZ0J<>KYOPJH;)J3W/S]O7H5>"^4YK6[G"!\6N(N%)&VHR.G6[);>,/TT+T@"
M!O@ E^$]FG;/#"*#[XEDO]>!^VB-\!SOCD,7G87PJU6G5"QRWG=CX>3&"I$+
MCYS/HW98&9VY+[H+&6\8<"D97';XKL<J>$]&VE]DBU9L71=D8W,9XQN7RXEU
M[+X(B^T^UHG6'FB7VM?"5T^/"[(7_&!7^FES%9H%;C)(J\#O'AP$[4,CPL7P
MG] @%OQ]+:.]*KJE"+Y?SYY_D31/DOFFUVLLDV1&N]H<T^::#QM%.>2QKF?[
MM/HR'CTV+?W5]S#NQ_=1L^<L+ \]LWU3M#6JO=3L#?(0JX''C:7A(\[>(8(9
M79&1[2IW!_ )A)-1HE*H$G:;P'&(.8PG4L'<%M#M"/H3;D1QOVRRGW/0.2,3
MGR<NQ.J42=[?_E3\.$0BB(J@<7(Q_"L<"->""6N]5>I+F[-U6FLI=/QR;YQ]
MB3O[FJNL#9]9/D S.OW=@_* /0%' I+S&@.[\J:GKF&7RG"T-GGZD4ZL!PH7
MOGJE]W#Q=>Q,U#X3W5_/W@'C@^<VIDC U9)M(MTV'#\!A 7I!QE^!J,BT7.;
M2B[OG$)U)L]/;.Z]%DO8+*W+GG$QXBT_HW_[M_3JJE/UA^#A,R/&'X)'_O_&
M?[VASPG8+!OV0/ 2H"@"N/J^L!+6O=NH33I ?/ A#M_9.7;KO8V;[+1B.67N
M:UJN8P5HC)/.:0[X?BH?P6BB$<X9JHYC[=9B;3+Y;8^/(-J)7 I*LO PB1+Q
M[KT(V\MG0=P^K=Y"NL-Y'%9RSV%]/\\EF;][97JU4]/?Y(+W@[-;M='L(-,R
M&J0YW!6<P WF;:==";\PUB8X>Z:Q+6C"7S79HE]:YMR=,U)=;!]"B[9MEONZ
M<O)08+1Q%,S]0!/K]O)]S6K!&,6'AYIN;F^:PG:A1?#ZOL2V@(74:$WK6ARH
M<P2OUE.O/>!7U&UL:W7/-6D',JM;/?4)"#8-S<%5'7S'!6[LXM)/C'"^G8Z^
M5G@_B?(PF>YVOFB$>.[C_*/'YSI+619%WB2=H:!IKRM\"E;482'V$W7PKT^4
MB*/!LV7Y)FC?LP3+=N+8" $,"_TH9N2:#HN,H!D3N_Y5*>59"D4-3S?J, EY
M?R@22@-W9P3'M%\8;M-#KY\8$2R"*FUY9:NKJUT\ NE9P8I-6U=V/@C40VN4
MS6A?$AQ/7Q/Y"<&C>Y?!?;-\J=U/6J1\W[]K5NKZO65EK1$_I4'WR6^TS;TW
M#VLZ-]UE@@UO#?'"?D?)Y(30+R7H5<P)U=366D3JJ(O83$X,A5XC >EPC.\)
MC2-\I32?]=L<7G05C(TFF'?T$6[(PO=N3QQ?_7"<]QVIAIQ/1.Y($,Q)P/OH
M5&)B-M)(9K*(H!S*XDX\!+_\+;^P!M=4 UD<C9H[Y-JVIE805GZ&09:-]8%_
M=427\<^]DOO&B?XOS,YLZ93M%CW:![^5X 3^_P7_71?0VKF2 .&')*#E0G!$
M'U$;30+\+?<Q)D_"7QOB'^WI.>F?0&"T&$@W//:2)Y11VQ/T3/MZ\\@-5''!
M^SL,'0M'5BWI967W]U$["JB0#C!'6QAV5DX-K9983>#!/ OC'*RX'=DP$^V-
MPZ;V2X0\J5#5N40&[HWE$Q^80@>JIM431V1^;*I#^]&+5\*C.(W-1'42=F49
MF&=7@MXB?@Y7G6P7"_]*9,7QQ(5:228%A&PWM!V_J7T1UAD(E7Y&^:+W6PK+
MSX2CQ!YX[=1FP8(OZ^Q*=E_?J?S"C4_)!1\B--P2!Y.?,96D P_U1))V'9"4
M\'M05#U:OF+^EQ*1AR62YZF_PP?M4X9>5<L0_>?*M5([M+)JCR$2=:9 >*0Y
M&=7^B,UE' ?1F 3$(S?X DA 878+_W*[*+P?C%,[C91'[EF8T2[Y$M@"B=>0
M">"#L[4D8,3/9I4ZW)<$=/# ?YO@BTB ,R/HE$<E_+E-]56\!YYIZ'0+KO!%
MJC#AYTYG@E3^F?]'PE+W#Y-3IQ*"NH@K%>O=61NGJJG8A96(=EZ<S<;+$_U0
MR4F%1O S$B!0UCZRE&L2A44FP<.?O[S;(Y:6.?[T)G#NHE;V26[Y>O;26_1;
MX6VKB>WJO4'%[THJ/;_&(]0+]29>IP*6.2" V83((*&8"-Y 4NO^I RU'R:J
MSQH2M? V<.S0@2E^$3/$YS%[ ;^ J]LUC[WQ*=$LLK.=^SRJ_W=2C-7KB-+%
M+XNJS^&?G XQVZB7:(6G>ZDL]W-%<,3$$EM8RB^?O=<U\A?ET7?H,@V4ZIET
M7)X-!CO&%'A7_IB9M;NM'^C^B'^ N9M%6.-L4HRUX%E#D02@5I_3C.*/W#[L
MAAQ)$L^3T<IUBIAP?\4K%Q]/ L1)0/?< 5,+V:"FNJ#72*S^W!$[48H$_+C2
M1P+T!Z'%7$=($D#E2 +2%#"IIU%_@T ]IT96=-&\$OCP(P$I4I@@XS? (%7X
M]/^5: Z \+NQIR,6X]Q@W#+K26$9@MVA?@\%[DHM9, O$!DZO.!^)V*SC2VW
M34JN5MN:5%4CYE3O7FW=\0,Y:=K\V#_:Q?CBI0_>O\RN20XX48.U6M8;NS8^
M-^+#O+W*I6'AHW>+]J:AROF^;_Q>! G\.DX D]HMYP+)57A* E@(?+[H;9:^
MX/I8NV]>7)5)0KV0B]\^N^-?9)_2DH (3_UW72=<!'7'!S?.7[RM\O[#]^UZ
M@=<W+L-CW7XA-S8160BDSR#M+:PVD3GO0'N2!* Y/V1*YABF#/=YB\>MB]:+
MS@!&KA9#)6&K)ZH$*W@RB'8/RHF,\B$PR3.]/Q\=W'JOV:C88]SE_OS9_&?/
M.C@I5O=WRS8'3FZ"ILOF-WLF4Y /<)/-[7VZM==V!0>;%31NKK(3^IJ>1$ZV
M)R(&6)-SY?$O20 S"&?1IR.+%UJ <GIF.Z6%D8.&[M>TO>8/SZQJP7BYU;M1
M2A<EFBD_N^WQ @=D2GKP 7<SA^P:FQ-$1?SL:9L5QE1Y[D'00@I(1S_OZS->
M@\HS6Z[?:1YE[S2>%H$]AIXY<>%M<&48GJ0]!">,H\\^ZBP4?_>RJA9\XX.D
MA;BO8*6:^X"UCS'PE,4O;1%*1;B*@ T0Z5UP:AW#,"7KYMH1YXQ;L=WLYU2S
MGZH5+*8HO-R^5FGR.%@X<Y(XX:0QW"X&[]"&NR-H\(%6C>/[I_>WKX^AZR)<
M/=.-JF>EU0QTG)NN5(;],*-=(]PJ'A%/>W_O(9^MO\B>2C2.CF,>Q $HPNOE
MX7L6-M_!3;$;(9A4%+QSEG),&[S@C[TW*\P15FB:_O[#;)H4I0OB*M]ZWB>H
M*"R22,^#4S(8#I"[XIL\,L15W9#1YJ0_];TR.HX$./QD ,CFC) G 5]>X@R)
MG=S@8_G[IR*(01* %]TFQ,,YX1OG7,APNX089=@OAS.#*%Z3@$]#BT?4G'](
MP]_1^;]#;)AQ@4XX1&P;V.O1O+>,WD2CZD=Z9:=SX_9?J>.J7#,G'.0^2/5J
M<JPZ#OJU:^(#T'GQ*$U/89D1[X#-2VYV/=48'ST1*IJ^<BJB?TF(AZ=IB?)B
M+094[]LW%#_'7_.@4<Z]<Y9MI$U.N?G)J(E+C?9AIZW0PI&S%,6ME:"A7TOM
M:8@D$C#_-H^6P$7;%:0-!<5L6'1/AHM.RGGOZX&V"^-NXJ)H+Y]A1UZ%NEE:
MM"9/CR69);OSRDB<!D5SFML+ZOT=R?XG0FOG\E\,]3E_&^JY3CR(PS8DH-[W
M\UN3'GZY)/O4N"T?Y]&]G*".2SD5.0S?*/@8*%45E9XJ#894PR0W&[%CG7">
M=FHGO$5/N$P]UKR]-?9$TK[]]=T4(3UC#SU9W:/W7PWT.M27N<[W?0GGP($W
MK4I@>0NLT0%#<5GDC.QLPS:M'2RE4RXM4495C6&GNU*,#OK5YL:"C]&RX!0J
MKP[41T\"/(:FESMUM#XUI8S=&A>!(9SCG*F[;RG?XA+*3/"A?/_ IJ/J1)(X
M?7R8TCAPI.V,?D$"HA(-8[L"B1<BED3=QXK4;YWI:[M$FP5<VD>,L$YOS[?G
MG%PF"&#[GBI7H+;F#)NE#F^VV@>]?;WX/&7F[:N%]R)/\EGU*S67$MTQIAQF
MHRIT;2>,)T%R/J(_;4)]2AP?TXF)Y!JJ!"< Z'!. CO6O0,:NSJ?2N^Q[HR.
M]LS9X!B4^-J<;?S\4N:K]QK:'"E>D5C6#2TL&)W:3;$ 80X%C^UMGRUZ+9+W
M+<MH\]5OGYCSC]-R(1>*A*I^E>>?^;@=E[<#(9B2@#L#B%/.B>&I?\\_GH*5
MX/^17^_"B72M)$ 4V@,ZH;,E 2L?J_8B/MT'=1E^=H-O^QV%DYW$>CF+TUP?
M^.\2+JZ9(:%WVU[\@X_+>Z5^>U=NI[[@[O@L*;B0D)49CLWW\MO-.9#"C^%,
M3(<5M&G1J;&SH$EYU*'5Y&#/89S]Q)6<,<'X9Y1ATRRTY<LIF<>2'F/&7I2W
M#6IO*TIG*7M_K4Y]19FBJ[&$U$'.YY* '1MYY 97-7SU]]2*E;,!H:SDU>,3
MM_3WYOI<'Y?(J*#[OQ(AUW]A.6N,_S(F3L7+31][@]!](]1!99OTV)#/4(%V
M_ED/$+M8$OZ^-#=N2[Q5M7!Z6-!DZ;?W9[?U/DF5U8!Y4-/A,Z(@?FS>ZC>2
MJS%GDZ>#7^6G?<G"Z@Y5UGS^/2-#JO1!$8#%N,>X]JA@80BD?R*"KQ-2.GAP
M6A"0*EC_4_9J1_5=5'+=CL'$<TJ.YY!K9F']B GXM&]?KB;^)=:P:_8</@W=
M@89R_XK7F2B-<Q*JK%/L/1',NK7"]1XBT&K338[2V,UG6 %T:G2;;R5,8#Z\
M!.TMV7GL6E,B7R3[J+_B_ME!35U!)=?:7=K^#!^*56A!'DN[R J<JXVU$-_:
M91-! JY.;&:M389Z2T#<A%X)1FB=U0?\_?]NV7^7[-7$M)& A:F4!GAL'CW!
MN'(]PY0ZPV[@ ?\LRB1F%E=7/L.?D7382QL,$#;^,U0?@./%MKO?TG9Q$Y6Q
MLP67NX.;FLNG$Z46&K*,YAY8N/LGE%@0J?3#B_]&D&5'5!(RX)//_GAL^G^K
MQR[--8#ZMIF(@TCF+8(K)E(YJ_9+T\'DDWR^FN4'F?&*NM\IV8T_,Y@&F\)
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M4&?AHZ5$PYO"A2762NDM-PB&9 ?Q"W5OQFN=F*[4KZ&Z^<&Q :_<Q@+XMDC
MA/.+!CM?].E:WZXPS<V'+%Z'YKR:5=),9<_UOH@BWR2SSL.3VHS+H3TE*S;'
MR9E1@3QJ:I--@^*/9O0D7RH3'EN1Z<X!8N4JVN&',7:HT]UD8F%J#UUB7]U>
MP>'C4,PFQ4ZYG30ES]>J7O_SNS,+;#QQ8F5(]303OC"'&3I]<=F=#.8IGWK;
MM ZL2$ J/!%\8+:?=\JB><B_%ML)(^^+ZTR0JM+X7Y4:_N?E .1EE:%$)-9,
M*J *O[<=%<Z9 S&)YT89>BCB:+3(- TBF);2B;RR#NIJOS@<"A4:6[&?S*N6
M>->NW^5Y:*P>HZM4>Y#1^"F5G"DN0Q+;@D@ -26N+#H@E76.((*M^[&6]7CZ
MYG"_CZ"A*.?=XKFS+/0='8AR^'P>G(%@@84>V&&1403W$M5$#*/&MG"(:K;&
M==H/:<-;R:]O6CV;/T04>>2?:2M;F(HD6"SX4JT=0[I G)[A3+C%+_K>=[W\
MLVTW=W=K+MKZS-/T"1FJ(ZP1J>U*X3U$S;R%IB)<X#RBNP3+FJ!2I>=:A5I3
MC5A#^0/,7^D>@#)9?K4I;E%QZ(+$88;=_*ZQ! [0PLNG#Y3/#[<9SF^:^Y-I
MK+%0_P>']9B/^IY==^Z I&IFGXKLUR /IE)D(/CS[I^--Z_T5#@,%AH[+S[$
M^-8:A9MIYI9Q[<,[2, /FTXD"PEPW^8-59MLE$%R..*'!\!QC?WMQC4^XH*:
M9V[^BF7Z.#28'HQI2^R$8V_"A7_-X7FZH&PZ<F4)1 X\-Q[J@6+B?QB!L;9X
M->D);BD2VU:E$'%1IE@A 4TVO;XI>?2A8O,"J9&Y]+[\T#5&J8GGJSP\2T!M
MMXOXE:\6C]S7IX0G=M3BP \0,S&'>N/5VT2Z!FXE!Q.A;B0V[CYCG6*4TKV!
M9\\R,J#50NI<0X2K)""-\E_513*06./4)"<J/!2M$#<,Z^KEEXPYW]9>'P+;
M]UK91+G:+C)9:O !:6^"I]9T7E>@O.P#:@J<_;@VD\>]E'G.JL,6#?BLK07/
MZGU1P?>0H21G]%U *BIA:\ZLK@D9262;Z=VI*;"ST;FGC7[&AT"I.Z?,<B;P
M3DH]IS9:,*O,]P=8(C[=T/*A[5H:27K$7/WC6*JP!7)6JC !^#^1F!UCYX:W
M\W$0S2+E1]PHH:=HOQG)I*EO<B<FH1[0.)-Y!-[\ (I]KIH5D,9*D+BX<2+U
MZFIK^#?W(,%PE7T)V+V\G=#G\&GU#!)PT\ON^['=6W^-L"V/LK*\H]QI%_%=
MVYE^/[JFC[")DBA5M,!S-?F0^=]N984)PXL,4H7/_@-9O7"*WB^N<<?P=$%8
M"%;#"R-MD+O',6_JJS_'RXL_W3;3U2IRO<R+>V-V<$&UY2,62N (N!IJ_/HF
MG:9!'9WV,O%\9WM4K?/)N=!KIIK6.^V,L+J]' V'4VB,B@;]>>[+[*-/^BU&
MU<0?\K=[DH$M@*"!W<_K99:TCNE))S*SVN1JA!Y=%+R?ZD/O^ /<HA4D?!J$
M* #/E_*S)A#T3\ZO'[1S180T.;1Z-FJ%N,J)9QGUY#%HB*C'IVA)7ZY*Y[=8
M6DL-9/.\>YH3;&+@#ZJ=2]Q38%?H*6]XZ]9E\1RV:_UQVO-Q.DCBEZKQT_#U
M.^@609L1+KS<"<4ZJBP*>1]..3>S!OV1?>_EG/.XSY9@WX,1HR3MUPY;BU\H
MK@:$?5H_+*U).L(\7E+WK9JH"_Q@;AK$K2*[P68H\6J>(3I QN .]4^J7( =
M@9_26\PB6Y?J_YK(X =/!(E3LZ*G;VB[3R7U\<8(PM58,YSVX2TG3\9S)D_X
MH')-W0OJ?&N:4QN#H;LG0L2O4^"ZR8R%$*T\-GT,!X:<P =X5-\0UG6E=*;.
M>;2  %W/<%F&XX/=4Y K/_[PO] A,EF>.)#<V,;YFN'1V*+KN/ *M D9'IUF
MC15UDBMH=@MV?M^CVK)2O],:*\1\GW #/S$/B0SV1.*:$Y41S#,+CQ/7,XU!
MS?V@63B>3GDN$LY+4,(M?WZ2JXB-_C:53?VS_BIU-U99=DF:7U7+X;F:=&_P
M,*WO/ZJ?D%X$EP>1 6^"V71Q&J_>>RL_=^.-28#_B;G).2OAW[4 1;\XA6-C
M:!GYG2[B93"0%%#=;%4IWB[+U-"X+=$N1/6Y)*H@6GSW++ON3\IM /O$I8*3
MXJB1',S)F6*G59+6 =9PEMD+-.JR@9T/+]^D #]#3*\1V$Z?^NR]53BHP>J4
M5..SQCH/N)7:>M=V(')NCZ.Y@5\4C^?]GB7M0C]-#XFE.67QG33I*&@D5Y7]
M(D>(H_O3_V-Z@$Z']^_HD8![&,BI1G7(VW\;L^;RL::@QI4AO\*$"]_O%"9(
M ?]>2J!M.@TO^K?NUD>8Q/^VO1-](]UHF:&2QEARF$)W<GEYBL Q1;RNDGJ:
MB.HCYLXBK\CLLAX(D&T%HL9O?5]VPL6D%CN41E=VCCK^DKVCM<XJ*@]Y'/OP
M8 EY4ZY&M*TY 29NYYQI;?3;XOE7 SWA;FM.^\7+VIV*5CD>1P,'87@X&LD/
M,UR Q#9^8NDS&PE@%5Z_>'NZ_\Q&&N5Y6LH(+;8OVDF6P>X)Y'Z?EC1K'FXC
M4S98(IIS1Y8?DN03G[Y\51PM%\"]-N)O^6'S<WAO"V3:AGB9*$L^_>HD?$]]
M':5R67'(?LRGX?3*I, Z8SF*;[/FK/;C(B;%NEPZL=HRWE_GFQ4K;+**DO83
MB0W2L$C=$3*)RODD:=78/*E\^2:KO(?@5@+F/+!/^]Q D_\(@@9O=&&KB/R&
MF.J7!!$4=#I4^UBN-Y-%L/I-,J71(.^O#OG*.3.9LO09^].D,L]-G2F,PC.F
MD]+& =,0M&RNO4ZUW/,AF8%KFO=L\@@4I[4Z'/CF@QK\:R]GS&UXI]FQ:WOR
MY<'6'J[?SZ^,M%1=G,\2\]GPV;20Y)Y27=JKF$@ZOZJZX)-;A:L]^,79OY0R
MR7<^6S]!:KRU7XS:RDS16#+_S$=GG-_GZ*NL K"'D<,DP,N!!. "1OQ3Y0QN
M30NY<O[X;2=F8\"2I/BN3"1R./)F_O/_S#'(0OFNELR\U.&_N"[K_;/,AI-H
M!9L6$=2/11!]J0+A<WE\1.U0^XEPX6G83!>4HJ%<WK71Z]?5;Q%7&[^B2^^Y
MV3BG 'I;,@?";7V8PXTA;-?"IQR]!3B-9_#XAW,*]@KR:]J'=ADL.J\[MIB-
M:X\<?$\$\2$FI\TZ;'BE7B?E/ PQ!]-*WWC9Y)97UO3CKQF95FGWW*1?O5A^
M8AK^&<;Z65B(/$@[@)AA%D9-PPTR$C*^+AZMYN2.&$\W%L\U5CGZA>,ATKN'
M8%V<FO&Q6!-,!3:\HF@K:R+42C1(]>A6,6-R,7#UXKGA%*\-Z(_EOEE9?":6
M]=HDP;=BY7@HGNG0>DH-Q5EKXJ66J=7[KII/ZN8$7U\H5M.,MND?I=:O>5@+
M;]K>]G.G:=KFOO// N2Z_?14RWQ=\S2]J,6_5=**N[M<%+)R: RSN4U.JD0-
MGX;>,*0]45PF ?HJ /QBBT%L^?HA>U?ICY_0?DY3[2IO#B.7> -[ Q0+EZ%$
MZAED8=XTL7/;!"\P+V.RZ207OB7$/B(^/O^<3-)V7BY;@V AASWA$!+0(>9B
MA[SOM5)LE2ZMK1*<0C9RJ9$BW=;EJCV9CGKCDPL$2!-68IT+;XX9:-+A;GW\
MQ*,E,GVH5(/(6ZSA8;QB(ED2Z#QU84D'JOJR\66M0W48I$2JY(*A><+U;1U+
MJ<*7M*-/V<FL^G^G-ON7./%)$O+$00<WQ4G 6/;4>U@1M!F;%Q,0YK/IN.D_
MH(%PL^VU+?9P?"K\P0*:: /"6K#&LX</=V'N/;&_ZU!2,,JC?W$)O+&K_J(;
MNAV4\U3K-,0EH?/=N)S?>(?S_;L:/[5 S9S6AI%MIKX+$+J5\',-*4;5*EZ\
M"N@4\UC++)4 VCDF&:=F[=[L)\[D]Q$ANS7%PS!IF=\D8,9OOCE*ODT^5]F+
M\0/!)!#AT<3AU%'IJ-]"K^ <<VUGU"SR4KW\E>4WR]I3Y#!B(?+ W-'RB:JI
M:$<=4ZV;Z4\^>!2W9O]^*7(F\/K6+V!!O?Q6Z*2FZTV&[.Q@I )>TD*?T^I-
MQU^#$;3'VZ3WV"W2AYS6+V5BPJX;$UH3+SOA4==$+DS?Z7"0U#+XZ7^^]7H"
M9F>VQVK+1[3YRD-^=SKZO?[B WF6T9M3.KRGS]JX,%H(BA_3Y.&5*53 #WU^
MO/&J_$?QVB&8! ][JNRUD9V"#K/ L&'FL"E!+P91T2A]"BO+.X F(+,\]"/0
MK-'WF>JPW#BSQF1C#)ML)13D^V:9;^CZ 6N<,,<G7%GLO3%9;9-*V$UTL2%_
M5HH+1SEMIO#=NOE#3'WIQSOOGMPM&7*Z;G\_Z.5&%1D*2  W?*-@'7PL&+"E
M@D8RPMT$\J+#Q<-N#F'@B?M:#F^O>-\Z,6D/\?,->235G7K^1^3CAS"Q3*XM
M*[-/C1<17Y=AK;G>)T8$M7$=!0(]KCG2/Z>D?GP_3&.^*?,[SS>JB]:7([E0
MD!,K?,;\]G05AC5*1TH#IQ;;"&%=S64=?U>CK5\I2V,U.N_)E>57+UXS;,LU
M1'F9.IP$3$41%)H3=@]>X?=]'[%#J&H]TOHY$_B$3(LBBH7IQ!I=K;,S;NQ=
MM.U'KWZ7=O3%%X?<4/0DBHZ8+X2$65QO;Z:^S94E\,HQ^)#I7=F*'B)+&?D,
MS.QP,#3E'XD][.PS3OU\\-+XKK\7_)R;6EW%\_.#!7& 3^]#Z@>K:K>(?3J7
MFH85BM,A$9JG<R^+YZ[WQ$8C[OG(2;B,CAI(#KAT/WB22Z<R[ G>"26>$TLC
MI_/4>>"#4SG5\>JP;\Y\MY8>!JN4[?\\C',V@=V22G-)4&&(*Z+0Y058.O/^
MU(.C_TZEN7:G^EA1)GUY-/O;%\"1:N$BV/W> J^2U>.?3F+U3QU_0AI$CV09
MR[Y?7_RPH-&!L,6[8GPY\(@N[Q#,'(WQO*/ES9%D><?K CLNP%V((NAENE&?
M>6IPIOBOY$4#\XB<QKQL39148?GGOZ<2ZW_GD6:V)*#O#7@K(;?-V&=HS(,<
M&#IQ,KN@[CFLA4("7*!=#$K0QG/,)RM QC%91C0E& %\:%?M5Z7*5G&76N"E
M3B_RILR20O(<.>V+@ O4R*L(Y+& &/$Q-DKP!_A'Q 'IYV^V_8'>Y<M?EX<3
M,EQV24 OLCZOQS<.W#C5!8DF 0VTW607/ OBM!\HAPAG^-^PCDN4"7I4)95L
M?#'%ZJ+2+-).AX$@@)WZ#(KEAT9H2S!W\PN_;>N6+U7\^FW+<?K5OL2K7$ 0
M2QW^&%]U0'M:2 0(U['+W?!8'?DF?+,?&C8KISH$3<M:DK*SNZ$GGN$E+Q[.
MK=]W__3,:7:X&*P5@^@4DNS6T<06YS+@;M1!J)>218UBSJ=8Z_YXR$O#P!N
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M(5@5X@>,8RV'54*$?$U?N6D-ZJ EX_OJSXE,5L-LXN$N>6<<UW;7VUG#(.C
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M^OR58IK4  (UCP%^3"[;GJLA0J)K2U($!I9?K2BL"?7971'DA"^IVS4<B ;
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M -NDU;2KIMW3%(_GX]]O_'38VG?+(LK2@7:U.(</457[JK.&&SV;LI-+LS\
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MW%V*GO9#52[DF&F:9]06!*WU!^9G%I-"T.]YEU4OA_<=,,H*_;*4P4#U+[J
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M5.(&23SI XB:OYWB5V0YZ1HP\?Q5=44:CL<MKOR6=>_5QS]$WS%'[]]$]T+
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MX43HNX=&2IM+5(TL,@/PWF>9,/94EG'@>+4@]G=ABG2@K8-V!-7:,*SNL=_
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M>4%4F[AH%59I_.372D/ADTR:5@@<KS.G-Y-G'M.RX7Y9DUM3-.HPR@4=H7F
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MTP'N    5, 3!!0  AS3@ /A3]P #K0(2#]P)#BPPA5@P;_A@@ V./X0_NT
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MCO&-,AJ*%7S]C33#=1T1/2L>SUQG5.EAZ?[KKZ%NIU<2=UVWP;KO@\+I8NB
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MU*VC?'!2Q!I"GH).D2CS6081B)7OTM^@+$]]CL4M[PNJUH]9,-'2>A!AU\^
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M,0SVE&'TI0R159E_VX'YV$Z8Q-]BL5=2H3$X8F,EN#(F1*/#VSHY>C(%/[!
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M$^H6O&\F #<+.';F#@ZV0&9FB#V3D0G4&,P$@MHPNQC9,K,RL3 #^(5<;(U
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MYK_G^F.-JCG4&?(/TK_R_$H7@3DX0V%6BC!%8TLPR.%OI/_,]6N-"GR^LG>
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MV9N;0RH  "T2 +@*N[FY^'AS<Y4* "!- P"?(+_)0S\  #S'<'K8;S3*%
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M><)W,>[PQ:_Y>*2^-\\MJZ-17=LZH_-YD6E]0[=V62< 6_#;C&BQ?C<TP':
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M-S=BUN[YSSPK2TOBGIT-+1J_W3FPF3NQH_WU*\$[M\V&N2SR8J_?*^WAP;M
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M"5KP[)3U2LM;HU@MJ* VN)V@BB[3+1:OFHV#<M0\^6WUUU/')'?EIL&^LFL
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M B7+,:0-K)_WRNM[XT&;+=' )V"P0G VGY)D5OO2M\F28STDQ]8J&$UKD]5
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M/$D$+Y5V]1DQW%< ;>)W)@PGJK91'0?4.D)[^_N&CA_/6RTL>G,MJ63R^8O
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M9GMNGZ7E*J9@E+OYI^4N;"+FYB:(XB?N>,D15)__&6.P*021P*A,K/[\/+[
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M%OX=< ]LFZ;"MU9IM]:YA3AUPDDDAOA'QDCU Y\']/H)&PN(OX5C>--;Y39
MONUB&/K:.P17XY%/+66A&7F^9V#5-=&* +!2FU[N[O<R(;BD!R'$/8O^9L6
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M>KO'DV1-5F6JJ[($O3LTL=\)\X&K_:OMQ/Y/E]^8])MV']1#KZ##%2C!SM_
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MH1;4H^I&4+QG0IP/$J>*'/HA$_ OP(AV:]RG,++^;ZW\WPZ^K^V E\\ L-\
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MM)G:-:SW$TI;I$/05R]Q/&IIA_;XQC'^3E*,,,7HH]>3/-'-L/(7<&B?[8U
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M>73<SS?^FS#: :6&U%W8LB1"Q@87LKD% OI'* CBM-3.1?9-]D1NN=8P&ON
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MRH#I[<"BK/P]N&#DOJ%H8A)RKDS?,9UR['BQP,/;#QRYNE4UW)8MUVE]>U/
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MAW5/9)ER)CE5*59D,U1J(]"(59K>Y2OBM$_6>RGR%H%A"42Y55<KAYHFQCB
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M+&SPO92E9SK5C7?KGOO+G#'',,*_"\F1.6X93TMB38O+UV_)!:-2&R'VC7;
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MB5*V;&W6-<B&E=/%Z#&S;\:UBM>'>CI;]>##UA_)DRR7#X$YNGJT[GGOK<P
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M?$(X%7O<>6JO;\];Y2D5L[OU62G'<Z'32@U!C"JLFJ=C\V"SJ?A>!G[9T9_
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M$RM%7$?XW7P(W7O[]GIQ1H#'%L&(-BB&$ZO6<GW")U>:T)KH:,&^;5L2WU9
M!Z<9+?D7KF"I,JW DG0:X.37L]B_AH:UN"6T]L*O;J8&[DGR4&XM,>CRR74Z
M7T#L-"I$/85X0R>\Z:..?+[WE"3L[Y?E)&3U&R%(]8QELV"XS&S.-O*6^G0&
M/B-W=]374I*-2$%4(/;"$.WF4GQD/=2:!DJR-SC5.75WTH\WNXW5O+1:%@3Q
MIMP(;K7&;38V%\V_)7=']SJD^WCX>I)U3*HXBR]1?)(6NYRABFE(I!YVIH$3
M,;#H1DVY]$9Y8)] ]A F@4$ZF?FEX]1[(!._P!1=2M_&&US#S]8RR5$55O^%
MZH.AQ[NP@BY-UC6I7L4Q2?*&KO'CM@]X=Q:+N$GE#_NY!>B\<SZZQBL)+]C@
MS\MQ\\ZIMDZGUJNZ)/?(^XY:<#$J[3:FKDO&C7NE1Y\S>J.WC&\G;6*57*"\
MI&>GG>-K$5XOP</H6O2,\;Y/2+,X_5?R$3;9TO.XDS9Z&1WSN],--CY]5RKE
MU<;VH.Z BDY+@D%U%0_;L[%)-'S%,26]2WOVLE.O2H9!ZJ;=4;[W_71H>\/"
M7+7CE<=!!MK8.EF@OI[_X'0EVE';W'L1[;J__%JV-Z8)6:HGM& +0/OHBE'P
M74+%2%:PP(\KECBF3!@C"-R2AUF.A,2AW8YF(@V:O^W7/4 @XHZ._,RJ%FW>
MJ_9]I]Z9-MOXJ&^PC%IN6NQXH) #79;HZ(3!W!SU1#ZKIF2VG_;K4)!\JZ'.
MSD9$1#J$@P2KP;9<G]\,YR3+)8"4E/<>0#)Q#,=LX23UIPT[SJ3R1"_2 FE%
MCY!LV95EN0 ZBDG<P4B2M?;CZRW!J&!MM."ET=V_L^7FD-\\D!_"Z0+<$QQQ
M3$GV2/9WS]O'7L>X3?@2W 25")2,4:&V<V(#83[>&3!I 3MD@QYNE A2L1LC
MM,@+&^'+_)^L-IJ+(&, P OGT/MHW7U,Q@?;P8R"=A.;SJ]5>:W1&(CW6282
MZH<M.?IV!:FCT--I].(Q"Y_Y25^-ST(,>=6?UXWB"T6\&/P$ MV\/@K)PJ%H
M\,K/WLEX)>S*+<LDCM\Y\;4;M[_XKAP6M.G7,;N1Q("O4BJ<O6C4\1AVAH*6
M<7Z'?+4S8*)E?EI[@WN\$ASR:#MUU*UM_RFHV;:8]B66QPHG52Q-P&#=X5;B
M >P#W2NH_@Q2/\?&#\F^PJ[R%1I"7;E-JV\!V1 HV^36BQ^5H<FN+^B W^!L
M:VRLH"C<%FC;E!7GS1^<2Y_:TJ7F2R:8Z1:OL<2*+F'VG8L+!L^L^VI-6-V&
M/4D>UKKOB32G)SY\T7I62JFR8Q+:>LB8LY*=-;G>,>%P\.!,##5HQ=#X](WP
M.PEC>U/H,_(') J;'&\"G.%+;6$6Y\ _@YM4.F*JW;$^+'6$&: [WAOP%3#E
M?Y@F;&;+;*;G8?/39EM+/_=)BP!0W_B#SOOD6J4H-,PMY:5-,V2"9\<Z@W<$
M8;;M%&X!H]1D<DXU%#O9)I^.#,VB"8B$.C?1LEU5_%N%ZA3[*SD,:Q>6GREE
MHN#-DM8T5;3 \5#& Y4)(Q[@D[G@KQ6;X#+AP?>L3=*1F9Z.ZP?9,30S..ER
M,,G8J=G!28L]:"K4QCJ*ML T.@_HC-]/V-F2T=62^E2N\)XPMB>,8(JOMS^S
M?U*Y'I_FMO]!57Y4&! @C)%^"/ATMI:#,#O5DA[PO]3;MSGV#\[P2"?PA^VN
MRL4#H;MTC-JZZLH*:R7NU@17L$:0-6F5@0A/0'6?6'X=D2)" ];0ADN\>4&G
M"U/_X# 1U##N>^Z15Q>6_76<ZO<*%N(]?']Y"YNQ)!9!&3Y\WX8Y:_)W)']?
MO+]T]MN?,%ECPK,.6ZPV&28T&Z?9XI.T+23U4V(_A,J*V-OFJM!0!&_K@,V7
MV^L8-D<S1A-"P%91#C>!<!U9%S2YKKT" _,HJE+0N*8[1!L![S1<LC,')I7Z
M61.:J=">-1>57LJ@OC<X4V<*0<5IXJ\*C?4638!RYWJM#)M%+1,>R03._+IG
M*;(:K[P;M7)2PB:1U"[4<]8_N=D76&>6:LN*-R_^WW?TL.L9K\@3^F^\OPS;
M>O,6@.TO #\Z^U358^RFV@%?G+9VA\2N]^-D9BD.XUMLMZ28:13I[X>;7LL=
M&G *9CIY2-6BZ4X<+XE-7/2TBY?T!E1 7?V^ SQ=;I2YT:1G/'CK/KHP'6]^
M$:52YC<XZ=T_*^Y,9Q?\MHOCWR2*:'T>;QL^EU5I"D7TWH6]=H/:U\P<[;TT
MW9JH.54D'PW-W"[#'D('2HV$$205F^RG HI'QE.:KC-0EOFWJB)1 MH..T-0
MF4_)X^45FDA1FI6DA=*?YHT+AN4[.,-;S#5J,C-L9V@'AYHI[!%7=5=$O%!#
MK^(?""?N8(/XFK:H'RX%R>Y5?+ULN@36&]%/TGF/"6366#0W$>+S1H'-KGDE
MP"#46CR$3<U?<O 4I\Y(5-1WG:]C[6G Q:K:YN)N#KR.I",>N]Y-AIZ_T5#M
MJ>E?_]0<&D-!_?CD%* [9E00&%'1N=K1 9PY835B_0XE479 KF^DKPM5/*F(
M4R+G-:)_#IH,*CZ/"0=QVK6<I)5@78W;RW9_K.U/Q=:/J@$JB'HW0]C03H!5
M;W#O>A3N+8DSA>H/4D!O<&9]K1R3@C:F^O=>Q!?;OVAGZL&0]W V]S&,UB;^
M^+.^BH;,)^R\=1RV*"W[XU%88(S;;G4NC+2AH0+;<8WM;2\CB _R&.ZMHPY[
M#G*?:+P RXFY=1=2+SR1PFW)H+15I0.!=LC9/^$/@,&^XN0%A@UFV\T_H.4!
MT=32G$V'>"V_:S?036@:,-92?7OW,IF=B5IF'?E^-KEW(!K+>^6./N%+#:OT
M%X."OX_/J7%7#1GS?QV4$[9*#B1=QDT9&-'(-I09CEKI@"LT*6QBM^/%MI;+
MRV8,1%_I9,MMLO6KHVG.IFD7BQ"6^#%Q;M,)#9S0WQGK+XLTH]ZQ,U@[ 7J^
M$NA4NS?8: 3>PB\R6.E3V4I^ZJS>;K;(RZBRX"-K>V?JZ?LM$L.^R 62)IN4
M ZF6G&NROOQOWU_F\6&3;,#H2Z;_3XVS1>"%TD.7SU:XR@@] D ]WUQT>/C8
M?J\I'0_G'MUNE M_U>?TJE4:)8L&QH3L<9MZ[5PL44!B>GXZ4=TQU^LJJ<YM
MJ3^AKK+1%E>$.E;K*N8T:7L;%1GT?%4K792L@66$DQ6A[EC8OU#8183$0UI=
MNI5FDVA-.ZJJ(+'/")KL3))U6%\B]"^)HT0_T\GAUF-_@[I].#8G2*OW([1+
M"^([<A7ZU3JM*Y3:1 *NT:O[5K. K9#P(P_[G8X$UJ\A#&M'^O%,)-0:^NQ4
M=Z4KLA07+#*+,4?+&293]O5_3!PYZ2MZG%!3 ]G=BE9<_:N_">:B7V*;3#AO
M7K,P:VY=_=+G?ZV9DDLZA'V%"NL.0=U>*(%.V\Y*OJ?RIQJQR=S3%/Y*6:,I
M5'K)02+MBB?W4B3(0$$!ZWD\*VL/X;-OF:.,O!]04WA5!WPP0ENO;W%@RG95
MQSZT'[]@_@0>G.J__DS,LQ)8NT'@TJMS\>3G520TV&_13ZJ%T.YI4G1.D$</
M5[294">,Q8"-'$N[""8);S_Z+,INNQ:+?=\ZZ#:JOUTLUY?XNEK7*H(4I.4,
MG854AOWGY0#+85+7KAY)#R73/*&D?<ZFG%(H,# 5U+GM9SZW<P?'.!]M0Z^P
M+X2@%-@3"[S3I&N^Y<MP;6Z,;Z[<0#\QRSK*//7&:XIUV5MK <R]TO&W..D5
MKC6MIC0*BPT-0=A=@16JI\A;7'LO2]Y'6?BQ#J?9\F8.='Z=N<L^SD*G#56.
MX6?0W"Z7^IQ;5XCWS#+K&:KC?)#U ?%(2-06OSGGQAV@=@I485'V\2 D4]>@
M.>ZI1%\#;%4VF737B#-RSA[[V=J^+LN93^^XL\#'DQE1&CUG/EBI889949V;
MXT.4**BU?D NH$09;UO%9.)Q?S"<A;/UQ:%0R;CF\BK)+H5GT96FW7'WV#?5
M)7MGAQ7@5$9OP5;!N[1A/$ABXGA7Q6#+@7"M3W;$!Q +-T^*-R>1O\.+_<F&
M4D*XB9O-O%?3DAJ '>T_NNGW!K?C:S;S.)*WX;)_XN:ZEP\QHF;-]+-S#-&J
M:+U<;KOWQ>P.G?Q:>SWRF-9+WCLUR+<@?&=&I=7KVJG[N^XZX,?5J9G2=<HS
M5'CZGP!U/3)V]+'JE.=D].3>UI5< 0V/S]8=Z95?+&QPUOU6'"H#>\FU;J:%
M7=(3;S#3I46J][VHR0CR_<='.D/G:(E\)8?-/W^\UI+X(RXLH)?H:K65#P26
MUFC6"GRU:6[.;3Y@0J:%'3D^OCRA;#648L,&U,WJYG<)'6W^U*%.9R(>7AD>
M-?QL6+B6,1P.^WZ:I<=K.:_3DE,:Q("CJ>2_3C1!  * <_BX*(9:,NDJGJNC
M->E>H#4?C#\>(8_?RP=7=>89'EF:>&:/R>)-@-7^;V]>B%]"R8N4SV8?158N
MO_0LIST*[YI(E&^8G;AI[+66T"U^6.G-/*1\J/?[^=KC=ZV[K#RV^'ANIM(L
M^ (X$OFO#$MMF#I7\UC6Q43_ U\>OUQS794.J_?J5FKXO>BM"J"#OC0\LDU0
M:0MC?$NBP!$-F!C%;HL/CPP_]P?6N]#16Y)YT_M:J2,PGHT(+ @WZ+998*MO
M'OD8R7X)XZ0D]NEE;#!XSE@&!J>%1$380MJ5 XB,X._%!SF*M 2^^BL.^HK_
MJLIWQK?]*COD[.[07U-)WBHZE#-A&OW'&1_7K0-L7%7 S=!</<4\Q?7Q_T6-
M'"\%3\RR%+AA\;'KU]ACF^U+U5(0U0YKD/%13]T9^$NLDX.,<(W&*;+AV/S9
MGZ68^'98>V)K"/O<EROC\R\O@><'M3LX(\LUH%F*FK.#P,]^X4OAF4&I0?Q*
MO$K:Y+/FVQ.=#I]Z;4=$0SIB5ZM5Z/YZ;%2BUZ74@HCO L]=/P5]M#T)CY7<
M7 M;>8,KSN$F5N]2L\Z#<:65Y3<!%C?+J1QWDJQ,LO:%)+[^6L43';N=0TSN
M%7/>];@L& CAT".W;T&G:JOI<%M);QSS%1\[/@.H67Z]&*,<NQ5Z$N6/"J/U
M305(!T9?(9(;><ZN?;KI<D9QP%#(<':5RYYMCY #?3JCE342CIRMO."6;Q'_
MGGO&;?B$TH[7=+E(;HB2]7\B99)\":DXDP[S4U0"9]HR--"D63^:RYGH XL#
MDF)9F$=&0X- ODE V7PJ CIJ777-$0J7SX^M<9V6S1U,<A%@YVD$"7*.]N#<
MC?CGR1WB_D#Z0I_$5@P+G3S;=*6<H9E6N(:M";V6"G*_LFW+F$\\?^VQ]<T.
MZM=['^<7=T<_O_@)E7.RJ/R^.\!N&/BM&+Q.J$@KR[47Y7V.MO8Q_)>%C9'7
M#ST**H3H#Y$%F5%.@J4.DE7R^=I*""K3WE]^CE[>)31[TEL%%7Z')][;K &X
M.I;@,? -#..:9?U2,FF;ZY%K8.U'D3 L9%:U#)914P07)F(LF1GAEZ2:U\*W
M<55_9TF6!Z["RGI:.GO?X,)>>T]2J179*3=R*@Y/<&IG#I5"_MAGPF$3NDQ$
M44]X3AZ)?Y"X[JR-%35U[M]0^<7S57R73)'J@SQ?A*NE:@EJ-F]*%%7OV9(9
M:FYOK\%J@:U0S*,Q^M?T##OB$8^[YCPKS+L;5.>?EKD^G6>+6BDQ8UN&OY1L
MB$T+WN!(79O%5%KO\D[%A>!)]^:G/CW]4H\%/3WQ@T]YFPL94XRM(WU^<%B<
M@Q0_9"C56W^JKH6X6R82JU*X]A'RV9W?O<$=[_5+A'\D,"S*170.W]S.7FOI
MK-5B3"20=GR<!IJ"W^7JJ3:9Z)2BQLGGS7]/ '!O+N78S:?0V?R@U'N9% W"
M)\0XO,3+/_,*P:'!?GFU?6^@'&/^JG$$'H=JOPPDE HI;EPQK[CI@#\MZ'MT
M7E -Y"YO$B2VV=A\[":2_?7GTV@2_D=*[PU^;&(G,=U0I$3VG%04S?TX/DZ'
M9CLJ+PG7!1D@LI,,@<T.CZ0RD8G@)_1(?4G\O>\I3$2$$*9 X'1&W=/+O_#Y
M;Q%F0X/ ):KF>:9\\T-6!=W8]AAD^:27?,PZ%59+S#$%M:_HNF$&_EZVL:7;
M28$E<QB9"M7G3N$]DM$$Y[+.&/T_4)<'<'XF@9L7VL4G2FGKX\7]7PJ'IAQS
MHU6;1E.&%&3[V]/.QCC#=1ZE&QN]S>YOLMW@Y#QF[/E;:=8_)M0*^6YW6[B+
M!@I KBP^N-\B:^MAJG<;[U@P>K?KG^!HR6YN"!@'R"36PF>OGQMJCQ/<G#ES
MR\Q*D3F5<)S/Z=19,P3FJ->-B'#>/0W+=6M_]CXK^4M^WN1)?CW_[1S61[6T
MEBR)((/81KY8L;"=[W59(:*'$014/ZE]@U.^X[-_XB'2XHZB_B2T*U/D'%G1
M^R3LF2M-F3.RZ9D;V5MB;W\M#3$^X)\:J6^01_-0WIB4A%=<2=4*J30C#I_U
M -DF82@\I#$3<MRQDF]+Q53/.U%,9*96-0YCL IH5*X;@[O"\0ULE:%[=/:;
MK(-F&HN*1Y]EBH6HORW9XD3%40S F1Q:3(IZS#QI'X%"DK34/MO2#Y)Q#HO#
M2&,:$T\<)4V8=F2Z]*BH^Q&_6:W9%6#5>Z_BQF/@)-^<':>ZWFY\W5C%;6@I
M[,!P,VGXIEW?*YG@]!RA/=SG$,IWT^HL[F8,(@+U.-4N.F&$*:N:ROM.33OY
MB4OR1'EIG!N6I;_O$SP%9IR\FT(&6TO"@2@4;@KZ.<Y/1H4.(=$R9;GU\:>$
M=@]>3J'4.*NFSS\(4CRT#^KLFQQB,!DSML?&Q8B3O%@B77:,7P73G>K3>=7,
MK<_A&6Z<E.4M;:Z^J6$XB;!1^0Z5_G;!CQ?\(+Z%ON^0JS58ILH$<3,5=X7O
M)#3268AMD]Q$CR\H0DC?W>%BM=>!'V-T$A;MQVX2J@O7%<%JDN,C, MFG!1%
M@87V0?R6OT46HGYY_R^S?EXJ<[TV,VEH:IH;;']QG?(&8W9 ,+-[H *JA\UR
M3>T?'83U&BU^.IX%E'AM>.\Y$26MA4);(JIJ"W:7@B)Z,SWH]A8F EL1N\ST
MS_=$P</-['_6G#J<&_A"77L:C94CSS;IZ_Q:*<N%$@_I"Z K/X_WN4X #?8]
MR4%&1@WU?O&G$:\I-$^D>52QN^3B^'C+&:.\J$P:,CKCRV>UFTQDW15HG[(!
M%TDFJ>(Y1CL5-8>296DN(X*1%ML'TSX 4>-M=?X@C!0"NP&MW>S+/Y>C4Z?(
M%E\<*W<,]_%F9KSTJ&E2E^3TR$MLQV:)Z\?)MHZ)$T:Z@TWWYRO 3FR&&?!&
M!M=+;'%V;3[M?*.M1=U9]74N*JP>"P.!A$>$[\%N:N%_ QJ:;C(:;*4/[C1)
M7HP;_-2I >P_\-W>FWPK[_*UD\7G*2I\@_OZ3XC2<%]7]KU"Z.:_*+CW/3GE
M_.TG\T5GCE8_NZP9?ZW**ROUO2)-AOFD41\[])(GOL%9_3T_N7D/$88QXSF:
M",3YL@6LR<?>YHN-#_JH7KS!_3A>A&->-,$PJ'JT]4Q>?A0=[OT._0,C_35/
M>N+.0!\G%;,A![\V'YL1%!E#)M>@[:%T07+9PUF29T>T_U,D/7N+7[%)2[5]
MMIHX)/:$>F(@?DK;UG@JP/F20J2&;7HIC8LHQ)R9J')Q1UH+$:TF8TXPFJPN
MJ!P)&<4.S^13-+XZ0;^)#@7+S\P?]02CKE<(7+(:RO/K"U,D=9I%15_!2FBD
M\N$NF#*X3+0\#FIG4N02OYJ9!L)!F>BT0:T5K4.Z? 1;S5\^3817^?X(;IRX
M"'J#^QL9!C,^,[832E%6%%P4]&[R<[Y2?(-K?EC;N A1N5:S&?EU-QM?VO__
M-D?TI_38G)# ^*6=<%[GX>*C9OR@R?G'!U'A0^Z^1Q/^&[^#UU]BS#/83V-(
M+8=X/KK&+<,2CQM4:.FT",3#ZE$NKQ1:.J7@_K9J<M]Y \$4P -3]DA=BOD8
MU_'MO7DO5[%WC=U7N6RL419V$7^(Y?OZ*7YHTSW8S&Q\&5 _)26LG%PB,(QW
ML<N(%RMJ//;T\B>%T3!^FX2TFH8YIN&W_66R1^,.,@^#D3,O[ST]S9JO*8%,
MF0D+C%-'U#H=UE7=*Y4>ZB[TG:'9&L]PDUL(F>FN%1_;+E[>^SJM<[MAR'O!
M\UU8_[^ .([R!N?BY2YU^\-TX1:2'_R[PA<E5:C-0'3PS,'L-DRXZ_5C56_\
MJ0E#9MKA6LZ@7F']N1')S4BS;TH[7AK!Y'O?V' (,#$J7^(FWG+&O9;0F=RA
M:7[M^*49]Y8-'-9 5V*JLD[Y-]!OSB[LNM/MZ'QV8SZ_IVGR:UW-].2 CFU=
M]4I4I.Z0UE:RO]=@M,X6:ET^CI%^S,JIP" /-+GS*UH;_X<W.)Q$56"?6!X[
MD,C4>LAF[_)/V>1 TL5MS//$R94M#K2U&4^B;"X)VN8@XYAM$ AAM-2VJ?KM
MV2Q-#@[,>4K_!E;Q:1A[@P,7)]I\_&$F#LA^)ZVAAT5XZ-"SVZ6POI:0N)UF
MD)H9A!!>915S/0//?^*[IJ*'M5K6XPML\CWE21MFX^8LZ(3"P&VM#XU]+__;
M-PL$ALP+VVCF/(W"PY(IK&B/709L=#T,PXZ\=^@<C#NB1B8>G"T8/ H#6/5(
M'Q@7[.JONY?%!Q,$[#4:NJ(_,+9,U%]W*",EIFL-_JBT8W(H#6Q.4H(OEN_<
MF)T;30K2$)3HNQK-&:DWG3+O8:CO&#72P^_J9,82>NU.%K0)==Q/&G%OGM];
MLP'N51(=,]N:QWCY4<+XCXG\I=[@H/"J2[4.!CX[%()A+=E>,0*U6-[@C)>(
M\5GF)+-CA)\HY9;U%QM-:=X-ZLU\%>- 1CF3*U%_@Q9C*T\J><C#WZ"@RJ8Z
M=&=)Y$(#&2XS];O(8/&8':&Q\%U0$V86VZ=W^FMR[-0#=JG!3+.N9)\;\YSC
M)="=^5UP\7]Y*I?D#%CEY'YXL+H7_>=)7E:0SF5? $AGV$XUWU(N5FYLW**"
M:V7L6E>BT?C,0+B6,=EVO^4&C#HH[Q_/S@_=)4?8R7\<!M6#:L8[!48""BA*
M1OF=<=ZA-^4#0,7G=90:@ 0V8UTO%!@S1[#7+E&?<MI( .L)_4PN/.'2B- @
MLX[LG /]E0,974ZU^-^>LP$Z)<05-+JD%256(V>*N:'BIB4 +UT)$V2+:<!7
M9R;K43@+GD;%:'R\^OFPR_\*KZ=*?,GT +FQV53-^8 DM>C>Y WN-1)T5!D%
MTIZ=>N@=&?=SJ8M0;B77C4"Z^1*Y'&AD1*_S%86UI6QW=%S/-->OZR1ZKA2L
M_MR@2GR=FX(94)1T:^UUNN T;#S8&/6MIH7*FBLM-&^T][$R/L:ZBP79&",M
M9F\MK,.=A=DT^9L\C2!)N]VR7MJ@$(LJY4]>9DZ77-Q6?'/+]U=>M6CIF#_'
MY-WWN-2WX#P\@#.=U;&KZO Z5(R-OE&QYM!D])--O_72*/"!,_O6/T_[^%[P
M8M3J3!-HH6&2RM7I(=IG](GPT\FQZ\?]3?\3,)62.8&Q]6F2*'F$]Y"H(! I
M^7H*I',X8\QE$MWKN29JA))')S8A;,*P=&K:NA6)"W+1X:TP8(=",_NZ&?*>
M@0]2DDS@(+R=01-C8X#=WI)%2P,90===.[-1#<T\*4M:SB@AINMT:NSM:?$0
M%(/&AO^IU\F15<U*CF\"O>0L=B%+071LQ7B@Y_MT]F49E%XPI<[%\!0!"_@L
M2?N)>8EO]#\(NZ"7M=#\(3"3;\.%P4_-LI6,QR[WOIU67ZX>E;@[\P2Q6Z\M
M@!UPT04C3!X( &*T^D&FR2YV%Q9]9(X83T#Y!B8BSEG,THCF X8US>9+M4YE
M..+6LK_B,9_0K"^V]M)X!L,;3+H$:G(!T>8(3B0\G&VC)*Q+K91#PMNB&6K$
M!6QW1K)KVI^,1<6=CV\%;+O$\MQ-FC(8C;3>"^-L.!OA_P6!\5E"!H.86VRR
M^[&%3@A^10\6"*B:TM08PNP; %%5OPGNVS T_C#P6SE2J<_RUE3%_@^LKNFG
MG/>S/0WUSA_CYA%8?1ON[BA+'[^\JNVLOL'I,O^+E4^0,+?*4. ++4Q>=7LM
ML]:3UT,<HAN]>!*/:ZEH2=/ /)$WP;4W;0RB3P0=28%^[DL%0)T*TR/-,^);
MQ_'W'[?F%2J$]8.N%"NT69.G\,)M? )Z7[MO'&HV>;'3;%[T31(0"*J>@#7
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MJ.$K]3C""KM1O><WCV\T /FN+2E!2%4''"^0= G?X!8_O@W!Z6##(< CO$-
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M([L;4*,JSRCN>3]N2;'0*,2M95D$+B%YOSF,41= 6ZS36KT2Z:^H/*[XHWP
ME0=,O1QCSFZ/D51EN@+O=7Y^JZ*_FCLN^?L=\^BL:7'Z..^3@"*JY_JC^U>H
M&27($B\A4W2$O9JZ":,6>?L-KO2=L:P^S-"!VQVG"%APX3_)<;)WGNWR+C
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M/"C6Y13#7+\<XZ>=V)CI=-.3BRN/P,;#/BS'UMP^DHV3AJ8LN+!\,CJR,4P
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M:YCC]4R\0\=EU!YL9+#WZK> $DAE'R8]^3?Y(1\V/<F*9-\R=I9?@E!*M'K
MEM&2+JT7.XY2.VAI0UN"NC10RFK]N^C9*RG"3\SK?WEE?O<_ X[^I;<'H6?
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MF-49 Q6E[E;!'97+'&LTK\UZA/9-N0-5"V?@@>'P?T?3^+&U9FSTB YV.J_
MB#\^I_<3U9PIW"E7+N+5?;8DZDLW4C+=ULFJ5Z'T)$:.'+PKN,?9YJ/&_%%N
MRW0HULBWH/*?N4C/KMI^0>NYTKXCDZT![_MREJ;("&LG@4]W3D#/%H(7B)W"
M];*DVAQ,"[BD_KZ4?D+EY\H.)%P\3^%W_:9FA#:K$'EYB? "A6Z(KLGC/P!'
M22A+(.9=(BBHTB=_M3<7U7][Q;*<,"YM1<?YS<7%\ZWMYPE+WTL"E5;N$EI1
M\?S9+#^Y-,XHQAQ3,W4;EO>MZ4P2BSQ3WU3+$K2/Z)J8*+.T[NX/ ?'%@Z:P
MVR'GM(&-0UIAC_*&[QL>/#W8HM?JTIQA:(]>]^&ZO2>/'HPIC@[<$O;]F<Z(
MOY.[<N\91/2HE@]K<AFCQ1SY]!^LOQPO:U3UH@ 6/5</2(,BUW3#5N<LB;SJ
MIC>GC=%W;YDO>*C]?QIUUH0&X804@\3\Q;S&E- (I7X>\<_<YD_HM<2L[67=
M=8C[3/R,+%<ZIT3WI2SE("V06+5Y8SR=3,TY>2(105V%J7F/:$HX:C)F\G6@
M:NS2H\Q /_?3]E4/ER;UCJ(&Z1[3**1P:%-S-J\7V7Q$+$YX^"A2\1-S/'G$
M]5F>J@@K?;C#WYMU(*1=T;IRD4WCFWMP"O MG?OZ)S.0D(Z@6NCHH>5(-&T^
M1)=HRA[V?B!2O.TD+"7I1HZ[+K;2(0U'OD_9?:3C!1TJ+.GQWXB?(\EVMI$F
M#_:HVR;M%\Y4,\;Z&[H,&@5J%J]"2KX%/0/48[O*U1(EJ 76-#;Q<DL2EW^
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ME=$Y)&@,Z6)H,_EG[II+TESJI6RD)'5Y#E;2:J%"R@ZK)^[S<D0$V!P\PL\
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MC(2ZZL)+Z!+GHM F9JO/$7<BL :^SM8:JZ&ZB';[_M;MN9S&1M% F*_WR1W
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M&CJ"J);;:GP@(OU:!/8,\@RFSLC3[.I6-S4)TI<"1;4W;?,H97V:SW\9PLG
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M]Y("S03$5Y\1Y3:Z3/^<-7[IQV- 8!3R>/)H T2?5YQ!^"&U-5B]:/F&64L
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M'2BA1:<C*J<ZC\!X_GGI!M4 X1)N';?&EV4JF)(R)]MQJK*%_%Q=>_1$/FD
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M"YI_##Q/UV,#^S@A'#7,)XB?VP$\]MUA3<3F^U0H,S'J<O6UT_9;N<AMPZ1
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M@Q^8990?!Z?3\:+0R2&<;RHK@B''D6"+QD5O1LAZ?][I&-;._"&>Q3>=M,/
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M?H!4"6>EQ94*XH$N5$@TI57QU4J%M9LND=5XUMO.B%)$8(:*Z*D_:<@+AZ%
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MO@-00)X,)N41''+VFU;A\!E]6E04EI'1M1,E?E7"T8=J@X)7XS?;3"-7)XV
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M]?E.QKP+L7P'],!N\OX?4]2>.X\!74]-XBABZ)RVS4_W*9Z&.E^"-4=HU=.
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MA"?IPP/%IBL";72<VS<VI<S@J&=@'&51;/!B%) </8^BKKR/F/5/KTNTEI:
MO,%Q(;QYQN&VG2T@H6,W,&:^L6(Z?;9_7DW<6)Z;1,XNW/WO=N^ KK);,>#
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M>=$R7VK\B 5A3XZXM5RXL")47OE#L/V'WH"&!.F\JOCBNQX]&<NU!..E8$F
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MONZ[]/?$[X5P')Z8REBA5M6$UEJS)+^DTTP@"Q_[Y<!(K%\/<  A]>CV\_B
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M.-4S$.K:3A:OD#J"=C$%+?GYOU[AU)PLQG*DKFG;N@Q[[9*_A]:$>[%&, 5
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M&_?'>;_EP16H>*[4[79CEC(A*9EG]@_<&:F#^L(93H8WA*\;N$>88SMU<;_
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MD:),^!-]6G"\FZC/O/P5SFW$@0ALD^R^-P<S4_M\TZ8'AGTR,-K3)?UX^Y6
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MF7D##!WFCS7 :7&>-'00YS41LG#,]V<F(U*X#JLG*A27;^ 1V@;&0H^&,]#
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MG8V-:.$D*ZWC8]EXD&H.Y8".!"+4R-IN(+ V7%I6RYQ9#L;Z^M+#!&GN<#/
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MBLV\ ;_<Q;&7YD +7U?8,MH!P#XZKMWWCW'G/TM0J.4=*%,7$#.="W]3M]4
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M3Q X&I_<=ZM9%&W/4[>XU;$#UE_LH%R:@MW'WN56!QXYI8\G,:AO]44++.9
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M/.G7]U"^D%2Q?XQ2M7EL^T87N^\FNOA7;"/1 $9_>IY%Z]/KIWE;+,V=Z9\
MA:"H!L:TR'$>GO'R%1-#(&8QMRO:V]'CU\N6E;NH^X72VQ%0W+C$?HD#?HQ4
M++U,:_JK4_3WU)=2D!$ZGWU?<1G7*M)KMR?%?96M>G7%/<R8RB%E'F10"R/!
M!S-XD8@,/]U:=J,$ UR;G3[/.F$FI#OM2S6S,K1MD.#@]:3AMS%H981'S/%M
MNIKUZ$:'O.<#&]6Z/-IN,=_S^FIF[0,I&S#W@5+=S-S-*,H1MQW>AK2OR6&!
M[ :";*\>%QYX'VTD,%W"QYL@2*/AEK(V%+;*.4SG2H]IP,D^-:I9% '7F\(A
M0?2>2A_32CBO"K"\AZ,UH9K*X_*R[W4+$?-$<8/34O6B_#+@BYC4-<6%P!'>
M0 [:BF666/.W.@>2,$@,5<Z?BX*W!IXH&O9;X3F2WBGR+=;7EA>:K!=YFS@9
M.V_F)(IN8C9P\?![=T.#@X9;<@X((/M&*!NNQR?Y.\X9R0W^Q:V?ZFJ'AO&+
M9>$WTV$AN%EUV%Q,3@1Y?$EJ\A.(UD:5&/=YX=D5ON]W^=.!_P!#X9\?$.*(
M5[4J""Q# $->W!Y<'=.SB+O7#I\J.%Q4'"^/7,$MO?Q2PVS+;06YCO0!)#EH
MD74)522 *>LLD>,>/Q?!G^+XM_.X=7P=_-L7ZV^Y\?\ XFT_K&SKX4^[@G][
M44D571MF5P&4CVJ=C4\UC;0\)XOI)AN;9>5;2R#HMW;1CE%7Z--'&LZDZR9=
M/+9X+P/' EUV'C=EG4K1HY0S(!W6EM\F:WE3[XF4#<J9LJZD,K ,K Y#*1D$
M'Q!&X-<+_,B?TZ]KX,_\G^#_ -7V]-:\0M+>\MW&&AN8DF3ZG!PWDPPRG<$$
M5<V_"Y7B2TFM;_ASZLR6^M8[F)=1R6-O)E%9LEU16?))JSNQL+JUM[C_ &T2
MR?\ ^5)/Q2^M;"&200I+=S)"C2E6<1JSD MI1FQY*:_]9.#?^\+?_P"NO_63
M@W_O"W_^NHKNSGBN;:==<,\+B2*1<XU(ZY##((V^U1N+\3M;'F?>TFD]+(!U
M,<"ZIG \65" =B<FM"<?@!SCTMM?P+_KSVD:8]NK'MH7-C=6]Y;MLL]K-'/$
M3L<"2)F7(R,C.1GXFM^(<;M(YT)$D,/-O)8V'598[*.X:)_Q) K>RGAX5QBU
MNI^6Y%N>9;W# +DE+>Z2&9PH]8HA"^-0_F^__F)\8@@8M:W5_'PZU9=^7PNS
M)YMPGL:)+F^Q\Z0BC;7#E;:WOY>%W;-L'X;=L.3</^*J-;7W_-CX[;\QV?\
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M,0&DB'?J/X,7\KM87SO%:I.6S87ZAF6./5ZD=RRF%H,8[2T;KI)EYGW#C_\
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M$V?+&]%UM9"/R,UJ[+(/]#_PK#.%]G0UW-+-Y8!-9[*Y7V1?^%:>R2Y_(_\
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MB FD=2$'3.L*K/!]C80M'L#.41_C_K;_.7VD]VOB@LJGU;UG:E,#@[YO:W^
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MY/#R>_,#P?0_WL[BM!]1M'[%L(N@C@H=#(WO**7+1/Z3KN^$F*4L?(A)@LP
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M$BR[M1=-CXIVIA";\'FGG) -_M\@-BF0A^^MO%#QF@+:%<^8YA5215N6H)W
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MX_$M%!F\N37_9Y8<Z4,.A'KKD'Q<^MP=H]O2'/] A,JM_?R0RJ+^88$D?>U
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MXJH_I\K^J:9B5<_L1X&KM!1\3)@%@ZQEX2LO"T5X_G\[C>N--W:>1,DWS90
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M5:X]PJYTB;L)A@A>L1U-+ZT4S*8ME;KEOO(=IS7:-"M:[HG]>L2E@M[PS2&
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M,K.'R+E"J\D:V[YVY)))/&V.AS40#S/_)4C?:1HW2R&.R=.*'*?QEPR96G5
M3:O?_[RB$>-K3E7,:FB^6N#3;V2:::7=LD[2%-UY5#:BGVOU:,EXEQYETA/3
MBQ:*89%-E_1OAX!;J31SNQMNVRP3R@,'BP)5T\2(HA;&%$)??$(D%7+*JZS4
MB[;M062*L84AVXBB0%J)'@@AIAT3;4#BF =L"AI41H>=1V?X..C1847;328N
MJLUD)$ I#D]:VD6H%-#5'9V36G[,Z1.^+>VGB"(J.R(]KX;;^'EYSRAL-M8-
M46G.H&*JNT9PV/"3:\BWYX+U:&WXSV[2(3+?>W%\H:4EK?X9-NE;AY*7T84,
M_3RTS#]:N$\,</6;QGX\;8,C>K\J9KHB5?OY2;LG9-&<=EFG%28):AB6,1*;
MI6?# RY=N0JGO.T7TBYCLMX["GZ"+VKU&S8Z"O8XK2W'LQYSH1!U!5D&W.KO
M2]KD7=95XN*V.F4SK%16=0_*!V0EPXTT%[H:]2EY)0/LICR44FNYHHUUI\(H
M]C<][XZ6*X'O7P$2R6-6,-&(T[, S/6XE83K57GP*R#D!ON>V!/C85KA](GX
M]U_:/_4!W>0,)\@]=PPLQ^'T1A<WT@0>["[P"$93$4@;9QP+<&0*$D.%OS3)
M]N4$(8IW80YVYG8.ZD<N.YA:&?6V3G(H[6-C;656B#/D91>U% 9_V !G_$[>
MLKOI",%IB]O1$<E)"JEJ[A$*N?6,Z]+4]KAE''Y^DQ"J:W NU1HO8('MCM+H
M=!CJSJLO-)Q#Y],=LQ[36X;,A<%33;RKC?_C;*UM&D]'Q0;I319?@L7Y=M<'
MARWV?2T#=#I$PV9P#N;Y US(*N&&U 3X"!?Z1<)5'[GM/XZ.2$3P>&NE[=%Y
M##<<F3"]E1*V$2KR)"D2!9R"!*M)/GZ.LW27.C737JH2=.$^0EXMDG F2+A0
MC)Q/E3/I%W($>>_%CK9;=:D;Z-]JZ2AJC%2BHCIOV2H&M_'S$.8U_B8EKFG^
M.:-,QO[#TX2[*0#"$$^LLLJ;5Z9HF6RE$=Q>[M7FG4&BZB_,')-[ D\?!G'9
M-O3NAC1QPX9*/45.*A(K.7,,M&?IC.Z$=AS!J?8U1*AU*;LXV7#A)A;ZCF/5
M+ -QXW8+P+_HN0;@GZ+&TUGU9)#DOM!TL<>B+Z,@EY?]MNK;$._:?IM?VRJ-
M;Q]ME8G//D>'S\2%2"5T>92@:.XXWG[Y_UU[S@J(H=X9F)78A+=05]]78XC.
M@">0>S4N^,$1+Z4L;?UV[R]83Q:N9<%#IJI#43K7N,OO#<!(K!I^[+;><;<$
M!@;&%Y&RY_KHWEX7CUT+./5;M\GSZJ-]26SY"4KBRE96=!UF_HZT"9G9-X)F
M6_&TM7&D&)3B[BPM"^KGMHHO'YV!SLIXT=L-+D-I;@3>3@7F7IY_4?6Z;9(?
MPKXO0?;K\P]93O1M0YWH0!S<LIDCF- V(9RD,<T1W?'@Q:$';*Z53<WKY;QD
M<TLM^M^]AS+P16MF#,&8)*+[$COO:7UGX9O_BZZW#(HC;/IWEQ L6+#@[NYN
M(>@&)[B[V^(.@> .08.[+L%W<5^<X.X6W-U.WO,^S__4.56G:CY,U<Q\F+OO
M[KY^75U]LT'%SW@2=0_9AP^K&V4=;/53'7XK9^M*TKE?_N3SN]!S*T<YR)O\
M[4$UOG#4); L/+GIQ\#AIJ+S"W2REKI'>$%A[.\JC]>+F/B9\.X;XN'Z)R8:
M30+6$)6)U1'R#W&*W;&-(:?%P=[*E* @#(S9:D]8SEZ4?FQO0 6G=$S! 5Y9
M3EBXM8KV4V6&PV2LOB+HTM2T$$:528I]Z;[=@IE;EU+4#+T:?[&I,CM3@#%V
M.(O$,@QP3O,ZC#K$!"XJ.T>-UO/YYF6IM>XZ+^J?Z-\Y+WOO%Q-LKWC#?<Z.
M-SBD]2#)BHD*VT0J)YIBJ@L+Y4E,S)I+\ABSEZ;A)'N.+?(=DW;ORT#SY5#Q
M+&YN-N"L6>GX;T/1]*;=.= I1H8YV<?^A!)RG;FU<X7V>UBKM4:.8/QAC+ 0
MG_P\^;@(_#D2?7Y14CC#'S'.B#^WAO/R.N2WOH.J*_6V7X>IW01:PT"LI&:@
MJ;>:H?.O0AN7%:6EE>%RW/"?%_JM##@T45R3)8^N3=S0<B>OQFE#_1I<:-#7
M(6PR-0G;X?10:H-,6<'I[,?K^[00=KQ$+ZMG^H;?Q\&HBJ2)9R:A!?.#>W>%
M-)_F:_P.)_K[E3]!?D6>WT_@!*_UFS7^8#GB/,Y)I)35GD\;]K@.-?-PU(]!
M$-U'_9>K$UF'2,2T[Z7S]'..^=7&[.]TY;K-0-SP35K%K,V$J;?^1 IS)":Q
M79G8_EYL(\+W',#-[.TY9/=D>5I=D##?O(/O.V4L80XT?EDR3&(+&C*,HF]&
M:SXZ^I=5QY/!(Y[B8VH2DT08S]-X5+SG-D0":W)>4FFUW],^9>&AMRP/>"#:
M-?:MC;FNO&<_9$HN"9TF$V<J]0N#QL?&!(A",N\/8-7I3YW11N]/7S%EO9=K
M[+'W8ZJS?[K@9LH+,[YK<Y5F#'(UA_38>_1:*<JSD^##Q^$W[D5')#'>5'%$
MZ_=%_*/V\,\H:P3T-$D!=S#Q.X/2EZDJFO89]M<!W?9USB^==L=E5G-!")K[
MMC-Y (R%HKJM+#7Y5LVZUI\]?W0'VOI0\NO1L)H]Z1VT[TLVC1 R!::0.,;Z
MW6@N%9FRV9H8-C<_AJSNU\E-Y5P+X;(D>=RD;;(%PX>*:"]#T3OFT+UQ.__>
M^K>8MB+U?&<]J9 ?A')W46VETBJE"K-8^B-Y4T&^<?ME:!$I:/%=LOSY'W%4
MYDZ3*)<_.7-?R?A>"SD\Y *I+LY7/M(2!;TM"Z:3HI[,PT4:_IF#GQ<3[9[:
MQM7I+]5^>P,SZW4=KI)O!L>%]C)-484<H1Z!9[;[9?)Q/%;;]A^)<G>%9Z!7
M;(-YSID0#[0U[".L]4 5+_W'2@+3UGH$<G+T@@W799J4I^;$JGR*0@*8G%&(
M_9_&_<.0G)K[_>H-@$=_A:[O,IX/5K@_RV0'L>'Z)2R_J-M##(OKZ16J%K]=
M$TUU!B3XF'J>^?Y%(%Q+FD]+0^[:=/%1;=1(SE@?G/*S:Y2$3[^QFA'S!H_A
M"HD34&H^_G7E1^H??P.4I.Z!?B5VIE==5^$8I*Z[M )/*U>[2)*WVQ7J'JO2
MWS_D.K@?=2Y)6%A]!WFNJKV"_6](]"T*^DX_41.^]Z?+S]B1^>'99)^E-N*4
M?7N@+>:&+0MH#O,[DOYE>0JJ$''K+MOI8%S<.R-Q_W<G5O4K"I/0H;E*L0R"
MNQ2YVQP$=@.%=$:,B6 7L&%UR)'A]FNG/\3/!Q+Q<WRO$+?0VPG6I)S*1 U]
MS]DUF"_TCM>1PR8?J?6/D[*K"]?H#_;.GARY%._/9#GJNI2'P)!KHC@D<@IX
MN3F+=LJ18"5&DY:YY&OZ@OWUS\MCA-'+%..,=,2CX5KI@T7RH8;:78M^#(HH
M=_'DT/]EN9>R]<OQI\>![:WPJ['<:]^EW*NQ_6L[\LC W>RTFY_DN/I"+VA-
MR1=Q--/2V2+=CNQL4O8^?SU#-3]S?/T$*!=$P96KA1']B.-1B?B?*;"5H1JJ
MOU4X$'L@I*<I^[+>((<:TFV2/Y%NR5OY>8-(^69Q)1!M<2I'JN@'T8[--X >
MT1-I%JSGQ"$OC/-5Z%+@=#=P)$'^O=6%Z=?ZS=3)/.LMF=:?&#=CVPPG.*WN
M#LH)&?12$M2&A_%Q=_>OJ"_PX<]J;X!/;X Q7O*]H[-94E#K@G91SXQ>W]$1
M35J]K#F-$5U\[BA2KY+M7=1*7J(7BPJQUZHDNUT;-_+>NJEQ',I7AY3$[9\?
M!SOQPGL($FB'5VHP6IGR7+=2&2V:DR2W_O"P?J2GJ1J&]MDRUW_MCT?MS)D2
M.7LBG6(N&PC$*TW!]4O1@#<&;!CMX8M/?8+(+WTN9\>J;>QL3]\8$;G[6%6J
MMRU$-5^ >V,F<96Q""DN&JXFA6&V1H:@Q5UCP-V5]\+/?$1>43\4 G:#9]OS
M]'4$7IC$W[,3"UQCOP%X9I\G[W9/<!!F.X=Y^;&V$+:QAGY(.1[HWT?-.MA@
MTM&>"< ;_:TR"-.\Z"'BPM[74L@O5R+," <I^%H6=T(C6+CB-J:;_&<<-.>0
M%._,R<2EL9O.8Z\./YR6&7G">().*S-;VS/J#+F4:HXKRY.?2:<_^!VBELD6
M<[-5>5L66CY4B,LNR:3NM]O>L_#!IH$L&52BD]$6Y44Y-H1)= *SF=KU!W .
ME6K@I<ZF)#G"&Q:SUNRFLE-#CKUU"+PC7YF7_[-M)?WH.D%9U8;CLZ2LK]FW
M*W]WI;..7_#C#9D'1K6OCZ.(HF%Y\F$P0=Y<[T(XT2'/TLUZLI,92+@XWV\A
MNZ4D[HT&67V2DW:$ <9]>QN*:H)J$YEF#TN:ARF61'8OJV+9Q4W-7J^H2#"U
MML@2:^R7U+K!\T+/NOUBJJ$CKTE(5JQ"$:8_\%WR\-2.M__(__9!GLB\ 5(]
MU^?XR7$#QCDME5L3O<1U\%SR3K,<CSDNQXI#,*O(YR_@R3;\>)N-;D74>)(/
M&=;Q:O8->5^((Y[UJ:\J Z4R(8$/L(^OOWA!P(@C>HR6<"U953.;-X ZD!CV
M^AT/8;4UD@(:)KB9Z(F)6T9*X#L3<K'V!B#O#LQS?@/\]Y#<5?_'0C#71^Q)
M5,9S,7/^VS'&.Q;=]1>B>PGCT0(M/51(VFZ+E*-)UD-*S(C3Z9YO +.=VLAX
MVU:"M<)=C,?Y!$T=W%;9 *[9AJ61T!;W[YZ)_A79^QYB/6-M7UY!(Y_,_^S*
M#O17\\W<2:K*B2N]^"?ZTN=)[S> @\T])4_,DOLNTA23I4G"5+W3"<^<=1X*
MNO*2EA:/!;Q3(Q!'MS=AX0;IJ?(,ZPU0P:QE%?TBH:OZA3W(,/=3Q("RKO<7
M6PN!_O<M?0H^IFDI:_.',XD*/&$$//8G.P+QE+]]XAUH?/"^LLECE!1Q&5]N
M6^H_1+DXMYA; +SA#>QL$THNL5;Q:-X +4.M^_9$68.RA9$1Z[QTKB,I'\H>
M#^7E8ZH(3A^P[>10#FW/"S[X\$8VWVF,<GL:I3_ZSXKNI+NBE<J T\L$LJR^
MY+-3@7N@EP+7Y6K6JR+,>)U!)4'H<E3T![B&"G'?4I 6T&6HA/M:;,>F*;J>
M$C\/=21#>0O#V86<6ZNMMYK*RKFKS(1O>,@H $RE3NX>[I;=HMSR/$>A]J0Z
M5V6K'/MIVYM2Z0,:'0YP6;[,@DO0\ZSA"IWPEM!RR]4&A'QW@;Z)G [94Z/W
M;X"T0&BG+?]S?<=K+>0>$OY![=.6E(X#:0MJJP?.%Y0'9D9#A=A+L\2(M9HJ
MIRJ:)!0:]2T2(<T=9;0+<Y9S3K3\:[XG@E.SW<TNK$$:0_0></]1OGI:!,$G
M9(+X#I>-)$O(E \E1]B%O>?79[H.'5_TG]/ZT1F!MZ<T#UU?ECL95\%T*1[8
M!;+9"FZS_S_;56+@7ITN@-($*WAOCC/#\;B7\&-/)YN=E0TFB^=>W!<<=A(0
M9%-?9A82C_ZCKI<,K+@;.:<S2?@STFQ&[X]B<4(635GT2.$"A/:Z;MO$'830
M9ORD8% >09[$/<T\!['ZE$H3+']DD;$5DRIE*D<I[Q3;%JC(3H"\FA;9[30"
MT3_0JQ1(0HJ,'TR0)>%B'U?[NE-X$ ,2P_)PFN.HXRU*(/8N@D>4&+5>^_C:
M%,OU=QR>@[#2D"&1ASG0N%D>A\,R1OY3-4(07.VT .%EV1N WRB@['!O>%<P
M]<Y9WD&(/ 5WT QT74GZ+#2EWYU E:34[3-YV+#U*3Z%\RN2YS<9MQ6]0QU3
M/R A69A9QCWIW]8I;A+^C[SU?,)K&3W#T3DA"3L81?=]"<NVQH*:3;56=>='
M:@\VCG34+XRGY.C,"'+)9QRH9%B.[JQ%VMZ@H@GA9)HKK,W1E.S@G;\&C$FX
M6N_> !S0UX3&<Z<K>K372#S#P,R5P$51\;WHB2<[Y6[$C<GF@L_D9MN&2[.[
MBHXR2CSEZZO*?9FSL=#KK%&R7)O,F7"D8MP.#3=CUQK_OTNR/^(VZED*[S@W
M$.1MRHMWATKXQ+Z DR2*K^_T8,6&A9SVG$=*43ZR:FS N6+064E]P!9)YY1=
M31_9@48AN5CF?-C2W\B5,LZ31 G'4ZLH[EGN6C)U] :Z+1&'73F:'WKZ8:2;
M1^1,L9F7UAA=)G&O7SK-81D30+TY9AGK=I(?SSFEO&/<(JY?OW==+;72]F]&
MYA-Q7KW<T+8.CMDKI6M?P^H*H)JSHW@IY3PQ.3HO&OP$4#6>P:'.%*%^$MO'
MVL2YDA:3>*SKF7G7U[]+VQ-I=86;"=DB!X+VVV4%\J[I[-Z_JN4%UW@H?[K#
MDVE$YGY6?]%X(E.4\/.?H3H(0G3=55T8&*,>F@JW)MI+=-G)&Z[%O>PB6&[%
M+D(/ G\CG7?X6Q3[MPC.V<<TSXMCT#*^M"._"U9HT!'_7[8I7YX//D_T'^<G
M;7 ^XO1<(HQN>"E-'M_G3AHP\!G!!DX,=%IX661?*";N?R=2)P.R"9:)]$#(
M>$?C-UZ^&[L>I,JG##[+1](J%RHQJO&J2\%I?$3XQS?_+O@N] Y*7Z=N+P7\
M_.S^%1&A<>:\2T1L@6Q*[+ $X7 ''>-1#)< FNA(;1T0\K8#".9KAS!%_4_G
MZTS.Z@&I50B[^UD;8ZL;4^H^,3O9O-<\+W<MC^K_4/!N5)X3%2HH_"QC2-M=
MQ58B:F7]19]/"!$2+36*%,3V.9_&".D8%1TF:MYJ=,-6E"%^. 4C8K$.8J)B
M4-<@1M @ & "^/!HJW?;^#6G8H (?38L2N*$)'@"AWP+I_Q@IV?R^MD=HAW9
MUT'EX3= N:JNGB0)WY\!RBCD&1;5OL*O!7D+#,2FK=+AB)N:_$1?78_OW8L;
MEO3F#.TY"@^<L++(R2.K:UCS6IL##5'3"W,^/9?M:$I>1^V1A]QFMJ6 5<47
M:;;$"Z4] HC-[,PPOY%68?407,\\XMH%POQJ+\2QQ;$W]?DC1+YJ\G?4-K5:
MSV2ER.30,Q6=?MG 4>UVPG66^,#BW/N!!21-A,Y( LI#CJ@ :*C@R72I:L*E
M?$<K,O_H01%2^]X=;TD@$&E3D_LOYU75O7]Q0PLQ0G(&FMPC01FM:\CWG-SO
M.][!3/(#,GS'>:XB7':"99MQ?,=]FWOP)BI#K%W^%'9??N$8F2$T?"'38I^]
M=:\LWOW9Y"T7[G@JFDOXWBF*(IYH^*:(J=^(&+C5B#X[7#VM +];J<#!XGU9
MV?1PHDR?%8AOT[QD(7QP5*02.QXYW5K8MSW0?$F7U+/")4L2:C[E8:^%O@7:
M .+Z[,'_>Q1#BTEKX+]0]!F1@R&+Q>4&V\SO7K-DWA<[*U24446;:]M>3?RC
M <I\Z@NZ//$0"2N D>CA^^XWA3@I_96:1,*R4VK[!F#9O'E"-N<Q]P5M<<&G
M]-_C.2V*/%3\QB_'OG(E^Y5?LD9WG@Y'P@8>M[Q@''$99&ZU4H_>9DJS2YOV
M!@.HE&3UO)_2@>7Y@JY?]B0KM&:S;@I^0XT\4XQKZ7FG>PI\JZD[G$\VO_YU
MJ>+"3 <;C#(RO7*,,SIYB0B8TQ;%<>[J0_.L=XAM1&WH(*';WY'=S?YL3-6,
MJ8CE_Z=(M1Y^@G#,2)]H,@7-+A#3K+J\SJTL1K;?D!)G##H,X../)!*QE<L(
MKSRIC,#>)4*.FXI7C^+0+NO(+:$2I&HUMW/%-? 6$$7PT$M'P[<5,ZH";4O[
M54H)#Y66G9<=UX2-_)B#610GK5DDN)_>:[G%^CS-U#WO5H]A;1J4]%W2DADH
M*CC.P%B,RZR6-1?&Y$%) \"A;\=CSFL/J#RB%_O*;KUG07C%8L-K<3<EB5=-
MF7$"XPF+LYVZD1H?7OFS]1<R>!"(%#V+OW7<D(ZRU0'YW9AN$,/QMI!K7+0?
M7YM$F+2-FXC2-+<7U;I'S0V<&J5)JH-=PWF.B*^(Q6EF*,TMU;89Y_^6GWC+
MZJOD8EJX$%L9Z)"IIZ9"]UM#:7V";)QBG["=ET#[,L)%WC\=:GJ@OP70LW;\
M<BT\#"F%"F5#95SC4AIGU,AI;:D$59+XXP7!YJF<W,_'6FS(<SQD\*>!_Z&+
M(&H:<&W>X:@S8[AC2.NKBFK=9LWJ&<MX*67XI'(OJX6Y&5VPWQ6PCSWMESN]
MFL_#_>1G1,X=9H=XFFG.LU$?&5&'EQ1W3]>VV+4(LHK2'C#^'K0T=/_4%DXE
M$QA?*7S,M(J05;,WS <^ SV;B36ZU^BK[.8SJ5O,%^M0DBY&V&_W0-R;Q&[(
M,G]GI"ESRNI*)D[%E;QKD%G0Q9;QG2TQED'ZIMFMY)Y[4FFC1C5]"8?@A\'<
MR),I^/1;?%F>1('V9Q8IO9!_25YLNL=/P3? (+C?&28;XJ:;!N.$ON!>A._&
MV=W<S3O@4&32+H]._CSUV1^OEO'-VIT]+?VE)@ AZ!I85J]Y ]2-NE&<Z^<T
M5E+ ?AC[<:MVTQ&)HC;R@YQ[Q0U0U1&27+3A))0DQE>ED2P\R14E08C%GQ<3
MO*/BK!?LJ-LRSC #5_^?<36"H@C^,9N7'UN+%L09?"L-^DK'VBE+U%>)ES.C
MH_O"Y!0V%QB&/F!XE@U,<@#P7."6%[4Q2E=ZTB+T9);SXHW"%&E?KE \AK>[
M2 \*3;'<$KB;0_4'S66 -*:0RTJ;GYO>08W.!N\_>8?53$I HC#4I"O]VYB
M >C]-*I6RMQ$R<N=7T^X5P<F4P;$B:+[O0GTCYE4/3UQI$1S-,@Y=G2RX9W8
MF9I.^1J(D_4%T!MD=5WD\.H3F#T&P8>UC\RMJ\L^M;%WZT^VR"4Y;(=F0%!F
M=/CYP-246&P@O0^.DG>:DO X/UYRYO*\X=VL\ONH@6TW(T\)F2W!+ZU)1[D
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MXOD06WKM=73L7I43WM3\83,"]J?WO9*F;QW2_9I^FDO3)4&/;"<K0.];#ZM
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ME&EK87G0838N\ETV<:Y0' %%DDQBL*<,*#/^>+64ZU!F-KGV@ZWLAG7J=.R
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M<H)W/\@W7.2K?.S,:3EUB2W_D9;LO%3Y(7/C1#+RBF\_ BD _O 5/9.>4(N
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MV#MI_*YAN0%?@C=%UM=;\C)[7G[CVDG]7MU5JBA:)\>1G.<[E.1+CT(A-=X
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MVZ05I6S;E'J 55\7Z<ZA;>KQ,SPKB.Z7^F,1$RZ#.1Q@%8*_YTCX\@%S(RJ
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MIJ :6AT6*OZQ)X+=+=?K#'&W0;EKBHP62/6#\J1BHL#9KH+[5/(1?9$K>+B
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M81S&"/:8168QIHIS@B/<_G@U\42'N<,I<,FKKMRY*Z-K C"G#H0#QH=!9>
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MRVAN<P_ W'-QLW"MS_"!0!M0!ZK"#@2D>0/,SY-]@(2S :TM=Y_6!V!8C?\
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M@B4 BDBKX'SB! ,A+LV*"=!I?D(1*@8</^YO^:(Q0"#GN;),\X@K++W>?O'
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M,0PF6Y823'\8>%-CS%PXAS+NZ:P]1CXAV-962S#.3P!O#\]$*(_/VYF,KH8
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M]CPM^T!I#7[<DW6SYM))=3;XL [CC4>5[[_^ 5 CPIB+IXF96H%&G.^!U+/
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M1@@YQI4B=KV-GN_3IX0R%TIG=5B%H^)"'98BNZS;7$CD0DK"L$U0@7TRW @
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M5+F]/L\L]V)7KP(#G/@LGJ6NB.9/"UBR<E5B[H[G,+QQQIG%T0RQL>TW5G2
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M>VPC6"B*/P"+HZ>F9SQ1"#"<8\BPXM?5L?:;(+[T/UGL QH[!/"=B&M0:XZ
M+K)G:%DT:&KWY]IH/@U1"DZ&FF5U8815>IB%GZK\;<*#-_E]\V)#O&H0OKAA
M PP3Z7>Z!T5L,2^G]('3G-<"?\3^6 %#C1[/2EE@DV/%5#;A)'UW5DX(A[,B
M'ZK;".:+-R9%\14"Q#\O&QAXI9?KK!%>&E0QNC&>C+&6DY4RXQ\A'K6T-HU^
MP-(*7%EHPB=55>$C5*XH8Y0C:T+CO4'I=^WN*^$OU!YS[T+HTM1]4BIA_T"Z
MOA8,$L+O.KL.VV3&J(-57Z<_+&5U_D@!"&1_+@UGW2VY)S%<^;K ]5P#VH22
M&NK3]JB 8:IRL;=.S+#,,HZ@6*>?7Q0CK-&E3.I]AUG7$;<)?PUP%.FVNSB[
M5K5@(415Q3>/3A"JS4S;&^EGV-=F1NO5I5]/ )\YLG)<W+R9-%I3U-L ]A3B
MF_S-_P#X"X.B2A(#WK\(2U,1T0O2!GH$=MI)R)*2&PR[+'0T+>DYJ*T2Q?;G
M(-5!UXWU('O7V'A3G_(8%1KI.V8>O6*G)G/&2CFW"?@NMKI++"Z<<A0@DX%B
M@PS/Y(<Y%;U\MG-^+38'8D _Z%OAWT$NCT7=,] I#:5LS'V.!""0K%$[D>A/
M8W5,6N+Q#2MJ?*0O > U' RG)QZ2)$K=]*'=V*(LD3$1[51YLB*%!>;U 6$2
MU!F40K)#-T X\X!&.W8T[ZM-^7V&3*@38HRS/-:F:U)Q!# =:J/#*8\L4^?+
MY<!!FN(HR>L+]>\F86U32T(F:WS@\''LC*\/FK>R$R%T^'1U$Z#,WEJ9H2$<
M=CQPW!$=09-/^QQ&]NWE^[1 0IT ^"C3=&PAN,^QY^#!@&/&7G3#0JY)U:A\
MS H.QUU%V232-I33<CL/T6-GF.LCD9-V%<@XM:R*.;M']HK9#;ZXJ@X?MS%Z
MN9&<DN'KEZX#7R?[I _3O47F+[V6?%!S6:FJ S\&)K'L,LH;_%Q*^IL.C!X[
M<IM8\_UL@2RM4#(NI[T?]8ZEGMQM)6;AX0;ZLT#=/$WL!3CU7J%UY P$!$_+
MAW<&*TFI'U9D&AMR3R%, ,3$[8C[IP=Q!-Y]\U5*"@E'T?WX7JY><N8VSI92
MQ6^@6QZV&J<8:3/(<[)63N&4X#X!<W*Q P#2HQ4A,$1#UT\8F33C4L]_'VPC
MT0F,&J+0VT]: ]U'+P046N##&1JR&^&Z5JPD=BOE"HJ0H5U#O>JQ^@Q*ZV/_
M 2QLA7HD\K2Q'C%"5'YBKF1\5FR80$=GEH7RS[4@T'C*&>-<N#\D1'$75V!,
MJ0=9@1I_8ZTP6L6RG/"DX5RSK'X>YZO7B.4=\NPJQ'>YPJR@5_JS;<V\D&7Z
MQ.DXO!?D_A%I7:(QKLZ'8+"@% J>[6@\;D'$L<>^"<C25=-;K6J@^J2Q8!N;
M$ZL;ON8:C(A8O/1M4OD#-B^C"[!N1[EB/I#:X02O.J>T\QX68QEH740<V;++
MZY.Y$Y:_-A"I:;*75O5$"@LF+9EOTD1?3,8T,BN*)+IE\(;[!^#A,"'LZWG,
M7ML1C?0$BY+&=R": '1K,E,ND/2%N> .".#BOV;YRRK]5(W@=(G5BK-%YZHY
M%<!QRD)<MHGQ0<LT/"9JZZL;* /.A3!J=O?4/6+4?/L]?IK8)S,]&7+0GHBT
M5S/&1Q+9>.<*&L6/4HQ1 *RT8C^RM?">^"4HF,MS?&:P,G6+U ?_4&=)\VY&
MWWHK=#+ [[(OOHNLD!5D)5H12!XRQ>8+2=!F0T;05I[ 9ES3'U*#2^8U7)T+
MO_')/CC$C.OP"%-=M8KE]C- 8"*H;6)G4Z=!=G#Z5)=&-2IW+Z8\R?^W(YC]
MRYX)HL38W?^P]]U!42[+V^\N2TY+SK!$R3DGEYR5G'/.(@@"@BPY(R 918+D
MG*-(!DF2041$! 0$)(FHH-_B#>>>X[WGJ/=6??_\NJQBW^F>9WMFNI_N>:'*
M"*R!Y*6GDWW%RUJ?.#_WCATJ;B[9X)PS!73A' ]FJF,_X\WN<RR]I\^\S<CM
MOT%REW5(%+83KH-'\@F"UZ;3UKPV[KC+B29$CD$),NDKI$WSO.9*'Z9X?P"!
M"U)59W&R"G;-DUV<T^5YBXJ[9R2I.FV.FOKZ#.-I%U<77TOS:E4CZF[4G987
MX_I6CQX7HWU.IYB0GNU^Q^DB 3+YE'.XK>0"BL@0E!'?,JUZ3-%!W]5/1[C^
MR"SZQE%4T^:R[X+J?$TIV5A@[FCGJ^J/?$PQ1K5W5/P6^'L./61P>T&2(W$"
MTZ8,H6Z]&3A$LYS%FL[=<IOJ%2BF(R+WUJ/+5%VG.P4@P-!:4%S#:TFKD[<\
M7AC@3^G'A>6TMB2C,I'.>U2>J=[M&SCA3>.R %M.-YF%L@IB[('CD\R.LL>&
M*4\=]Y,&L@C:ND/A:3;)!WAKD.N1WKN8? $J.9KEAJ-YE/)<>#:S*G;/1U#*
M$-K;4^U8KJ^)<&*9N7?UN#LP[2%S[A9LX3FS_.NK>KE=K6P/TD]Q*V8YX\MD
M'9[JN;T<NQ^&7R;/>F"BV\A1#4&O_21S2>@*GQXYMO[MTD+==S%MT9C=UB..
M+9TF-UO+8M)=!K!R+ \&[@]_&>E:M%4LU&&[B^^X?64O][KSZQ+5NN>;LD\B
M=_#YEQI9'\2DV!J*SW#(LCERWJKK<5=S0J&4901'EC$Y5@F;E:INA)Q?CM,U
MU8I-<&RMH*1W$BK?@+1<11EE0I%_B)5\E$Q_L_)V#0FU>Y6(E(<OO=;A*5:(
M!>6]2OZ6YKY1.$%11Z\2!EON60OQ;G>XD6\)';2E<?/(<]Q7-KY&=ENX_1W'
M.COYB+2[P6SLQ@<!I4C"V@30=1,2+WOE=X4>?NS<6EC/ART])3@R[Q(W656J
MEBLNEW[1:\U99M0T3)%%D)T2%"B5XC*"D]DV8:[-09]<N%%<3;KP>2:&)PC7
M+1W]LI\IR(29&'+K<BL3&*"EH?B.)'CZP><.YUXK7Z);X74)=NQRY_GL8(AE
M^[2=O<P3?7*_A<Z:\](X@][S_:>BR>MI86[%+B31=9.U,%6Z,H$KZ^6UHO=F
M_*U,#L7N/!T:I56_DV6F!CF5"%4RR/16RU,>$Y2] EDA8FH0-&EB?(7B<7)?
M)FEF5__]TNQVF,#1292>YOO[=4&K27;7[/U?HKT,1ZT]6S%MJ>\H<>7OD= W
MJM !H^ (>VL%A6DE'5%A.4H5WN<W[IP=I#1:S]N@UO_(9Q\3Z92JLG[%FFR:
MO9TUOU%'ND%9;*QO+W7QY'.HNP%VF%BP.Q[#B-VP/@7V#".B@EE#VCLBNB'L
MM4GQ(I1(^#I%4)H-"VAR]EGKEQ7_ .F !4TZ[*301M*-Q\<V<8T<Z*""7CK-
MW67,[>H>L*?5D..:]<I>QBE,A;'W9N57(.G9@Z&W$#@J*K'!27"HB+JX%/03
M'&3B:R?H%SG-P(?.O&^^+CVF^IC/:MMJ3"N7CJ^8^9Y\F0[6(1<]7Q$G864E
M.J](I^SA[2H8!4.]_N,E4&:R7DAIVEU&KE>E+N;8YGUMT0.USJ0X=GX]Q]NH
M[U-Q;^PMS-F5WLH_=_D*6*IV$]4^HY28>"VNT/':R/F-2G=_$5H&;I$#4Z 7
M4; S)<M.!0__@V:]NR'KS$7=7P$K//[\TGN*#"RVHSJ^539]ERC2U1=5>I-G
M!L&+G]0RT]'KI$(U73((W%7+XV )V@&K+S# 4T=]!9<7&3(_?#&+>P,MZO9[
M=YG_W#(>[QCU\QEZLR433JP1263NY,*@!K.;NPQ;8GI*D]W"1+C\Z.,>U+CL
ME/UX2/[C"%7/7@YZQ>W^,P[K*ZGW!M8Y0&%2]ZZ[P4DUGL&IL;'@0ASKNR1:
M#B'WHXKP.3O+HH0YNQN.'+*8 >\AO3ORX6AHQ;P$YV8% L3KV":^; %H?MNP
MH'S7ZG7<NE8R!?C@0*X97M4BB1Z''4'H<W>2FZZU_HF+]%LVQ.P8ZFZ$+$<-
MU!7$TGB:@PVND9S9J?'S@N[T ;?Q?!]6)[TQ0'^<),//+>SJA<)-6 & O$)5
M**$+N,'4W1L&,-5U%7;X!B/=7K1R1AYD$OVL);SV'MLD_J5Q>FK<=P:'AZ0I
M=S]<J@T<''1EDB<@X%2/VJ+-"W\QL6U6V4_OJ-X5SEH#P99><5,WS!NYB9J"
M,#E/].10!O+RISCW6ZK$.)D+0XK>/'VH2"#1^O1A;O6]VNUA%,<5JZS\.NTR
M:RX2K1%;%)!Q38DHN&I\W"2VS-36!'28XFHUO3%7V(!JS,I.E-%1IT<I?ZF+
MG38@@=]S&G>!]6U4!&A[AB&DCH9+K1O35J9+O(KH(\ *6H $9I!V9YAM0F#W
M[5Q];J6^RJU0U2V;6!RP'N6A[XV>2R-*5&UQRS<B'X$1;A/IA;L^5S-3-<F5
MBCM?O\&YMA>&Z!<M2(H9/O5_G[*J?E.KCE-?<IC)("G0SDFW2<.^,Q%1>T5.
MDFZ4+QW/?"2(CIU"&BTB3JBQ\8V3_JH. CR0"CU)3V0>_@I0N-TT#>^J:.Z[
M;6>&,!:*%-67+;>=O+JW84JV_P2E@%!MB8UE\\,CUGZK;MV8-UC6G]AO?T$;
M,_)FW]+:6J]]$2L9H-!Z]M@"4GD:\:6(A&ULYE&O^CQAX $V'<1XL)OW 1US
MZ:-'\R4D!#WC2EO\P_=C76$3A1HJAD-!N0=Q80@ _U5'?3N[\.=MF1:ME!NF
M>&YZH#X]SNN2.*YR,O7^?1U5B\OF?AP<9!'A)U8\:&HX\A-0@EQ#%OC!>4IH
M&-'H=(YI^K;XZB&M\B;FU8>$O;" 6:U6K&DT)X?K4U^"\XE028!'+<'YW(,<
M=QIQG]ULZ+3ZQ":;59J!Z6Q*'$XF;/\,O3VKCB$=X2/=(FE>*$P6[E-RZUFB
M\+[8$<!+?".(28D5A!DH*^ARF7,X,9LP-8L;/2>?GDW--N!-!.(^O,#M"FWH
M07"<,_G*#*,K=54'@T[3WL'\JBMO$9>Y'5%>=O4D=>U7(#K['>OLAI[J[H!?
MA/:MEC 64NBGKP OWX.AFP=97\QKPXDMHI8],&C3!K.>/SWM)GL<+L1@$@,K
MAO(LU6-HJEG)[3OIHQ)@;4]S6?9[G8&7OEA4A^AKT4:_\,RZ]PK''">X/J>%
MJY+CP'$"+02#2S6DC5KQK$:[GBS\]MO3:NV62)GEV8^(U$:E&^MB-0N7T:A1
M.SKKT7A9)E_5*D@O*^^]*+M<KVP3L,;)O8'MCNKL307)+<U[(R#:MC U/<I8
M@$)>#8MF+.*%@:7*K0LD'3+ULLJU1 Y3T9+5^Q\:]G%TNVK)YX80V!WBY5/U
M>8;J=33VB3AUXM(F#TT50<(Y29V;OEP5Z-+LEY#L+=1TJ\HPI]\5)8O)MCSV
M)FPS4?F0/ W<90XXS+HGG_E$"SLXHXQ8)N]-2D=6"OT]ZLK85:'(4OC\W93>
M9J(/AIEE-9(?.YE#\&AY3&"2X4E4P9_'NISL)\9T,DHGR/E>6HQ^V]+U7#[3
M^^2#Q1F,8U>._+0P*$ET"*X"&@U UU+[>VOWYQ37XH78G!(/V?JH51)!(;,M
MR8LB?7Z&!#$"*6UYDHZV3-%5 L<+#S,HFE@=V/%RN!\VLP\Y>[CH:CCO81.=
M@=R#>.:[V9Z(KJ"">K 8P\(Q[D@G<D5T,1%BJQC;#7HMA0]1&((2\OW;E1P,
M"\+=,#6#\1Z2&<C?L)5G;CMB)],@5V18P$IJ=QYEW5X.*-*7Z]'5K%\)IR[-
M2,Y3(,W4I@O6NEJD'6.V<]-IH8PP^'$&D.%!7D9"WBB%=^VEXZ+S@6]]J#NI
MC:N\%G-P[<:=HG'C15\R+&SU@L^\(1Y[YWG$]O8N:'<Q;U)K$S6=C% +:BJ_
M"O$-U9L,&]?@K\>M3^$QBE>3C[?>V)3/(D#L-6/8D?A'[J&[]);8UE3X+EK-
M?U28*KTG'[!/3";G2[9%R:O&#HI(%7;V6:<HNFNPKJX[S2KVO-3B$^4LZOE7
M(-E#F&!AH(#&[C&KW WIQ+F>>9Y2LPV.M_Z3J'&9.[?,ELP."2=\CK@2*#S3
MEU:#^S<$&)QGOO#)EXF:?UPJGM(AITGGN1J=+7*462%<F?"N#]O5Y,GUT4&#
MN_B\H;1D/=XX26QN75P)Y 2XC$E?C&(<"4J*;'C1<Z\.,>\Y?-"_#<L4,R]Y
MY5<\JAQ21[\Y+ZL$ @O9A'MMR(!HKD"#Q,F%:+DLFR07Z7D][E]KN'KWM:D9
M[CF>""9% 7]O>\_TSIUC!@(39U9H(,B/<@2JH0SP(;.27]G*64,>[5#/2 W]
MU4=%J=$OXR-:;=>8<^I(P?,K=RP0$^2D)-S*!ZI3(QU^4[$;6E0Z"LF/1#6O
MWP4 +!Q0[N:__(<8W,G9TDTUHS7;^=URO6_6;-Y[!=!9&79,6]J8*@_'%/#<
M]R8XP&6'GMI+T0\*]DE=(=4;L9H26Y'*:%--EU!/<IU;XZPKWS^!CA=FL.#F
M/ZZKP2QTI68$B[*/;"^!="SV)-3*@Y4+A4QGS<C >:BF.8FN;_#-.?,EV>9'
M=&J+,H;N#4AX)2]*66<=$2\=<4+(.NS>1,EI[O EIT[,C+ILLKX3(5R26WS[
M!E)!O!>,JS]-,U'<N\MYOLZ^4_6.[O,<\!'4NHG^OH# %<NN-)0'K(4KC'XO
ML^9\Q 9_SKPW[>VP*)L!2@G/8(W]GCWK4I**QR?"4MCURW1S^+(NUYX>];FK
MN:WC]8XU";MC  $1+)RU6CZ:T8;B+9^$"(SQ]P7X'PJ0Z=;<>%"K;4PI.<*#
M:!U"<#XR!&]OF!_!T,_""UGK3SZ-H%P"4W(]?>BG:6#T.3'%</TYR2[.HR^)
M U(^S[K?!Z]6M1;@TR,2Q*E5:[DB> ;XHSZU(F0L3Z^L\-#&"$LKKJ!;;NS@
M>(L03 9XF41*3N* )O';!828OP*"D!!2EKNG+T2Q#60(']<B3B5:(^UJYECF
MI#R/ V]_!2#3*0-:SK>36OPL^R^KP-=XL54=\G1<,>.>5<Q4G%676U2T6D#$
M*XJ6G]3.3YC5MI_9K@UN1V#Z!%*/OD?;P5ZUW>X.;;(0BP\I@UGA?<#=;&[K
MA7)%41N()>BEV?0Y59H&!6>LT[\43-0P!O0)&%"XI+70+.--33G"!*UB</I6
M#DD#U(! .;Q7>\\_@UCO4'AAEFIHM"KI=D14>$&Z(J8&MZ UH5K.4?H-W@"V
MQ*>;9)GW']N.HM:\T,'U7+.]KGF4%3YGVC56OGG$^L&N<P7E+@?'(@]<?\&@
MPTCF,UIM4$]0TWS^6XA^)6NN^#5OB%Y20T'WTE*&P,WM+ CJNH#"6,GQR8"H
M,]'0Y!G*",WK*).M7H+W'3SZQ*J$^)%WM43\9[NGO!#D+K=B^OO*<\/AY>T)
M<]@^JZ8'W5)4X7VDVCRN+H';V>5? :V"3L-;$AFMG,%>&W8>TV;-%!L8BN[7
MA\]M\I,2Z";2T9K],;IUWX'?+ KI)I22T7_X"J#4F5IK)8I4K=C)A4A[H6P;
MU LWO+W%G-P^'1D;0WH?QT4C( ][]*3:+S**6EP@*>1X]?5;M8V7W696D^.&
M*6(?\_"XS0\SZC6)&Y?*LE\%">[#B@ND9[N(FH1)H34^:A_"'S7TZ:3E23_$
ME:NY;J!#B-&T^7H9#8<5G[ 3;24#7JWA308PEGQD;AP9:JCV;7G4K7#C:2!A
M!F'BHD6#5%13S/C&:*$J*)*W*T=_8R6AH_;X7C.J1_F7-P7^75*?^H2O"-KK
MA_<<S.03#WN/];FYX&0.XA.9O9U9UY0JL7(<)3UKFG+;)^AMB\52*.$7P9FI
M.<CH@SMW&)?'9Y\61SU2>,2?L.A?'Y2% ,&!3=Z@5[NZP.G5HZO4$\%DR5,\
MH$ ^U'?$9S<KR![=EOX0^N'ILS?S'\&CT$'M]RR]WD]<QLH"7M,^F44EMBVK
M)S..,YVY?-*>9,GUV&C$CGI,+=OQ8Q8V=M/+YT8Z(9KCGVW2VM'K;.U9J>I'
M6P()3-.V;1=3IHGYEA9TLAS4*UXT?;RZS)IEH0=>SD^<>\'A/:HE7%\\ANB9
M!=Y0U&FY]OE2,%(3:L?=96V\'U8U3GHO@X2;%3U:ZWG+PMH.+3?!R /2J[Y?
M 6^'.>W #,Z:""%:E0<?T3.@O NP='[LP-R%QQV5"WNMCLT9P)5SMYZ#:*=&
M-G2R7OP%\*"ZZD(-2K%F0(55XD?%!$],<)N=0DTJE7S=A_4-:4S&F0_@1VKJ
M%AFY"V=^#"Y";U(9GAW8A!VW]JL9A3'D^AQ"VD[--[@_IO6<HQ!Q9;E[SJSF
MW; V-9=AG\4\T<YO\!3BEZ]LJZ/8'JAOSG=VLU2K#_JXOY&&>>#Y$<JUL>=!
M53W)UF/^6+885;P[X/&:8!;#06< =0\ $).CR$Q^!6I>[?4O-C=O<3F#V;BD
M.5%<.#D-T\5K^EV*,RMY;,[K,+>J%2T<!3,-R&:HR7+;CC.>:,=*\*I1#3&W
M3B0)=Q_JH4G9,S1X1CBE>8PI\A [L'-'1%7L/<7N]R#A(L9BT(DEU\7WT?2\
M8EVHNE;)WYY)D[1?Z%#H;.\I>LUCF3&JQQBF=(^[C.JZ5W:F%IS%F%^(YJU!
ME.6M#MJ*<F&MY-J6%LWWXQWRLU2L(_7/B<#$:J%U:!/\CZA&]\I+2JS?%UH_
M8J:D\"JQDK%E\T]-&6)_K+R%Y\J;,LC[3D/3D U]0# CT&6V]UGM#>GU7N82
M:$&08YF*,2V]?Y"F7Z422W#W)<^C$*CSI[PMN*_YQ%H>K_WK2_=9]G!CI+3N
MX>6Y6?>$ELX2I4/;4D65EZ <KD1DJ^)]\]YL\Z:JER?P]$->6KPQ%/L*2.<3
MB\VY]F/-8CLSU@VOB<%)A94,["TQ'!Q3-#Y(N766)1"#K)R*/U.5>YA<AV.<
MQ^R0<FZU'S+RA)=L!'XY0C&.<?2S.;A1KR[V=K(P:\-B8NK.=;M;UI>2PBL?
M>;%4@50%Y\VM AA['#LN9\B%/:SB+L7<^C*BT)S8B-7J:HB^D= N>J_'K%?%
M^MX3*2I3K)M=X0$$R6>WB]U;0-H+:STPU$; +NE4.'G$F#!<=&<,'<LRLQK"
M0C:0E>MP;X43LJ6=PW#EFN_DZ96/A# ]3%!\>O000RWC"%%#(P]SB2_1C*B]
MX'*H.-I&U.523K)*7/3SW&EAG'>*1LF%J8=^D9(&G977,N1U(V_>3N<3*Q&>
M6;Q=,DNT'5WIO5X5&T&Y93C;\I+_F01690ZN#%L9!7"\M,QK[/%^V/0P9&G\
M2PT[3-!1"H^A%3WHA&2Q.(7L89E'!)J%D=DHWJ("V))M<WALQ,ANGBB!#3UK
MSL:$9J6T $020XP%M+20[=0/L:44K9^O@'-9.UFX5[ 0?GY";\DML4^D>U>Q
M.>EQK.ZMA+J.+: NFLE1A'-5GAZG#:Q]WBL:A=4Z.*><\G%Q[6K=L,;%?9:1
M@<;2:_J>3[Y/*-"\,,-*->$TC73=[?E,P:%:_83-M08Q'>,#'%S[9K^\YO'J
MK)+/T?6$NV"NAVKX#I-L4@(@>:78&]'O&?&6=2=?/GS^ 3O6ZX[%9N43\H2\
M,&AWG%L<]:J"7*LQ RXN!L#L*R:F8RE4..95SVY*52&2IYRJZN4L=+<_3K*]
M'G@U@).L#9^A_L+6^UBJK"[3H'Y1SS9=> C=S^.C;4Q&^)PRD?&3G<.4^_)[
M+R)TIE=F",%OWJ*O&HBO\?NN\?>TKD;;9>#(0I,/K/&<&[\"CMYJN'-V^142
MK+%ZSNH'W649#3UG5;K&#Z5\K!TR)GBUC*/*^PON/(RFRPU=N\[^T#G[2,[9
MNLOG)63$WZ<,M=&!IN0M#[XA.Q>TWX+;AGII6/BC&M>3"&T14YE/23D-]RN$
M(66H? 1X0ZD[!.LD?M?'=NR.X0M07Z/[..6!M)8#_M1P0VM'QT69=@-R"?R'
M Y;OZ$=(2GKXT62];V6JY99/.4I*TL\(#FN;B*>7E'%0\TQ92-@ZI.^-CBWQ
ME/4]V3/OE#$HC1,<NYU<517Y2'U\@MF=2S^[3J\Y5:RA4N-EX@%W7JNXST?9
M)0+#(G&AM9MKYRLMN.]NN</L="\]-M)RR'#.6))=19]\_0G%4P9;4LOH(X^O
M.ZT'1W!;EY],[[Y9%?K39G[3\*\ L=<U0A?[51KSKX BQ.KV2N%K#)WYTS=X
M9ZN))]3[=_N,ZO9 G!/V%0'"F?94NTIUSJ ;L8VV.66#$K->&E\!IX?-6X4G
MM]A-AC^-LG,(NKJ#?9ML+L?A46\7J&W@4.@WQGI%5K^7<YJ./+&2>\%.VT>[
MT%DGV-;=*N=S57*Z1'IV(G!9ZC56Z&/;QJYB30WJ&S3 ,YY0A?E*5A?4-"'$
ME#5:XEFTRSBS[P?/]6K^0!@^JOG5VZ8ES.8T\HTYHW:4,20LMZ2\43&FGG48
M'2'2%6<CZJQU-B[K63FU ,'C/CQ>TAW9;KP1&_G:Y$%+.\^<,PWPW_*4)YV,
MXNBZ#^]_ZIDG=TM%F+/>,2^HL!6X[E4FU-[Y!/&*XVDZGW=4NYSAJ+%*I'9(
M[V1&Z^QDMDR(/C=V@,;4RG !L-Q I5\8BY84V*/]&0='HT%C#U3A9%AXOEZ+
M[[0X><=P%!7QNO?V@PFJ-.Z3[C$?CK*\(4:F7&J">11O19$R60.T(K7/0N0S
MM@_2J66:+^&O"GI=HVA4(<EFM-:9R!J@K*(('&3MEQTXB3L:0<4VB[%?$;+<
M6-Y0N='08)U4DY\7W(P+&[C5UC:AQZF2KZ#[1KVLQ0+#32/@,A474^OGARAV
M<DQU;ZEY9_@+M?GXNQ^PAA%0U,5H77=+WKK]I&O%)_=I^_7:/=?#1E*Z12>N
M3XZY!H#)IL)ZIBM5'W6;7(.3V2=5-?!82$,?$8&#PI%73./@=$:W[[$7=5U3
MKW8$;Q2GU=,T6B8?#(Z500+7PAM&K;=JXV_X$=G _#M&\=B\V;R;I-AA0WL3
ME3-M3;V.IZDKL0N[*1I^4;@($?AJ%0XT?-8T-F6QK(A6^5RA$.K1EI9&Z5>!
M+P#-3G(]VD!):32+?RU"FQ842=@GO/)H8;/G\97^A?EABX?I544.-Z'1$7='
M.>L5QM]M"4C"UY8M#(52TZB*/Z>NQBZ/^ 0'WM!H:0_]-/N">V_%;+S.WO<Z
MWV?<UPGU6!.OBIU?UW6#3'4.<%*Q2Z]TY]L!CR3B[X"U?*L)AIL$;]<>Q1&1
M1'A+4AKS:&%I3<T]?BK4<[-"&[IH%).^ZBSAK/="VWW&6#8$FUJ#F7/NVM!:
M":JQ6D.4!P!"G$+=.L4HM2V4VQSRC1[GK>F]U4XR"8[,)T5PU_+TY"B9])2<
M'O,28%9A,-H4BG? <DMBIAAC '+,T:M^'B;]C-90%$(.BH_$-IM@W=#WKP7T
MM,O0)*%"-Z)R7Q=2GFIN7V>\BVN:-GV7/T'8+/DEREO $NR C<C1_JP_?>^,
MS3>"P[E$#98.6O/>QF@Y10"19YAT<L08(0S16FV+#Y[=/^40U;)XMD26\9Z=
MJB<U0(V^9][#99?@]CTU$\]CH_+2^AKZ9K7;DUWQKG8GLO54S#O3W?2Q,Y7Z
MNKX)>R=R9/:=\M-T?%[$.F(A.U:#HBG1LF'#)OF[&Q0M=CB'Q0^A#54'2_D\
M5Q.YG1^IX]7WU\*Z+&\],-Q[[;XCJV74JZ1Y; 4/>B))D,561\T:R<W+QQ!Q
M:I5CMW>Y*_G.)%XG"RE#(HW&"_-72CNH";E&SS^$/#/)HK]IJM[@ETI*YVG*
MJ5XC(X YXW\+[J?#[%@R*C2R66B_X?@"=RMEV>HCJ4 4P2-_YK:*[#M!'!99
M,;XTD ;4+M;KQUG*R\GP)6_>>XHSPUFO$)@=Z(S0][1N?9.W$_&[Z&IN/UA)
M:V"]1F(86'0SG[OJU15.JZS2P"^,=1;Z$K7:BMV9O0%JJ[BO)R8WA-$/GY6;
M)L4:UA,LW^<O&[N[3MT8;**EP^%$V6634<<B2R-61$EZ2<>AHCF^<.03[C!>
MG[8/GVXKOH![>TQ<1#-*8(W#]8TTDE5!,CH5''4LXTL9,KZ!1>Z&"HYD;2DB
M_5]J[O?45K$DPT@XWIQWH\%(WB^Y^4F@:#&'9KW.O>0;)P!$B8HM&ES7KM#*
M&$(M#Q_<L'_O=\.>5BE\C2JE)(^:E'V;TNVV$!I*B@_7ZF5&!Q3]^0KJ.XDU
M9%KO8T90HN0;#$>H&B40(:T[6&^BW=\.&)BD:HLJ/TIJM//H1-#0K<P-X<CB
MZ\5P-@2]I36"$R><*L9CJ^4\\D,P&;A<0LO-#<_UN,X?<<;">Y\@C##N:6LC
M;?)[XVR$X>,*A;DT+<TZ3'%N)H.KZ[*]*#:1E1HNX[SO15BM"J;4P=>T[/1[
MR<:4+)2;XNLA3Y10_.]@U/5;=)!V%TLSK!.,D$9N*K0HV#['&^V5*8NLC7CG
M&3G1Y.1K[WC+\8%\RTNJM'Z4N(%YG[=)JQAZLQ]Y(8W+1'OM:0S\6QTT%L^T
M)4K0Z]ISK-ON,!KYI8D&?C;)9$-1I^*_\:F;^XO8J%#@"'UPH6/VM&7_0O!9
MBZ: !5LV)W_^ P*-K%H9-@V_4].[40D;"4JG0L&)(+T)JMA-$5?YY>0#EV#4
MDY;2<L7W_GT<@T-ID)L,(.5BII+WTSY\1V%JLMBB(I4#TK SJ(;1=6I55&.S
MD3>%5ZYJ!:;B,_>'PC':*-+KG^N_MT_CZ.!/2\F%E<L/JEQM&?%8OV_.+);V
MCGT$>XL,@2K"^QYNS%M$1AF?CY4K&NF"Q<ZG::E;+]4?BI]8OP$=PL&\@K&5
M&AD'/V,([MJR>N]Z%?5U%##2:KV6[WMRG!9\5;[77XDJ%.U:<K.Y7>VUN**1
M(\UI5(;\A/5' ;>$)(1@/'XM@A(X\>*9,G93@3O#MKL.[-H3XKKB>>4/FNS-
M"%]5I3,:DINUF2>MA1'+F%#3N/.;ATV=#=ZP2PLY9X&?7LZM&TADG^"<G2:K
MG:.]]<Q<LKGTS5> 0:**3/8H$T=[=(^E0#(#2\')8H6GQDT::^"N!NE#K2>$
M3\4=F8G;"R_'W9\F:2/MBJVBM"6T#L'[&.3$.-.Y'S$_JRGM0"!.\([DS5N"
MW$W2^[-'W*S94C4$7*&-G#8/"E0/EU<X0LO8[DS2"KFE>AIV>/'(Z3V*^]PW
MRK X-++K@N&C-U"P7K9NZ'G0:C&SX=YZ$C\!,A=GV*@:2; ,Z'_LY"(#[7PK
M92?2K3FPX'2&Z8G+?N*-;I=[_3DGW&@/T<#7:3QW;)CY7I?9>SV6>>YEMU8V
MXU(8?,KQ@/.<,MSPH-0Y"\X1M7+NW._.87@+O7-5*9V$JBI^>(6JKG5UPQH_
M$^70CE&4.<[8ODJ4S+A8>?P],4VPTH)OI&6 4%+=2EAN*EJ$]-2,)Z:RKWU!
M_,ZHIE\8-@-%)%9=D+SEYCNSX<1MOHAPK:C6JSELK\WK'()>D(9=H3#IW-_*
M+AA&7.4N8/'>.H'E.7"OSVVS%8H590RLW^]$:0JLT%,?W$2SZ[<=OS0\>;L7
MV68;?=%]_V+M64M+8=G^E9M+ Q1S6D\C2&VS;J6LO>APH7HAG=1]H[PG;$2W
MM5XBVJH\!,0L2BW9UT7G1Z(3*?D5J-LEEKLMS=X%#M\X9_8/B1SGO9=&TI$\
M;LM<)E*2-1XLA6T#E!)N]O*A!7<R)(1U@!FXDPP%M;!5\([IT66L=CO<K1UY
MC5 G,1()(Y2]-"^SBI'UMJ 1/Y?AB6YDZHQ/94.5T^="!%\SN:TQJ)N5 &:8
MU2^)*WW:4Y_IFS/UP'PN401D"VBBAWY"T23#0O7W>-?-8!^C84\ZY(Z3$ANS
M)Q)\W;QBYXS*/*IGNB:J-;?-^IE0<'0(%H)=>KD15_V\S;!XRRI%\HQ)ED@O
MO"0-?#S*J8-!J+Z0X29&A8N(!>G7M^@NXVO;>LN%-O7RW%T6\3)(4HR/O,7&
MA?JA_YKLQ*PU]-@@2O:ZV3'L9CJU]XZ.+)]14Q#H$HYXVX(J;!7;T3<(XG>E
M[]+3$\P7)8YO,X>Q7H;>? 'HETBA-B%8J6:\>$M(SNZA4F7<NEZ?.,!!1?Y@
M]\IF6#8VG19B]FY >@4 H, U_8E\R)TR]5^HH@]=2W,7.D:L=)4.:;QJ;878
M<F6%7O-I]GR8;=LB_$EA?G>0=J(BUOZT-6?_YLT23:SV=HQ ZUW'2Z@ZG/:;
MLN/CN:5U3Q62;9VY:^^/Y]I,N=NM6Q^XW/'U.)6>X(%85$*D=3R7LS;J,VK@
MDW;#']H8%;/GQVF#(=B]+6_KVD1W4_3I7_"2+(UN]608.Y2.)0^'JW]>4NMB
M8:O'2&C4M6AX;517*Y!#*+U*KE9=UY&GX@Z!%5ZE#X" O8G1C NBC04S9%R.
M[=(VK#AZ>%=(SO?-\QY.+>E]!>#6IK/+QMUE),%F<,,^ (8=2O]P]KFH'T<&
M/V]UB6EAU-FJRYIGN=#5%7KJQSZPF!E>M9$D;GS%;EC!B-Q)Y1Q;FEWNEQU4
M WO%A^]02N+3ZNR4-PCVJ\6R7RP[>T!C6] RX<J&$89-ALG>_ 0O#J@+*Q[8
M<2^5ECO=E3STDMV7B+-'H%!9HU3T"A!L/R \)=Z;'&2($#BXQ^L=ZBFLQ0"
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M[^=,\ '$W9:U5^0D"0&E+N>]RL'% \%1\XGO[_ <9F,T,U#=:*7=ME_>M0<
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MCJ A'*/6TI6;]+HE<KLV ;SC=D")(PJQ43Y[S5740E),RPPW*NQT=]I(E*K
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M)-M2@V@.2!!,:O\LK9$@)3"2-W7;ZB[[46QU//.TS"1J(.G$"$Z:IK7Y+J]
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MFNCZQPC!^<-089YUD!OBQU'0A:F;%!29FJM^&])MY3O[J!/Z?9'Y$Y0B.Y4
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MV%*2!XA%@MXC[64_6/X#A93,GLH1!9%384HZ<?T;I^!<4J:_"B42Y7$?O(0
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MY!-C_E,HR.-_H46OJ\Y(1)R-K+0F.8<D(A2MF%4Y/XF"V=E2>&CM]Z4>T0,
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MM(^5R-DEOLXFLP5J5(ED"_E01=ES%$(4SS!&+S-')<[>GEF_'UCQ.9C?03(
MNI%>SDIB"%EMU(H 4NR)W R$;#-,XT$I EIF(##,)Z062,- 9O#'K?Q%SCV8
M P1Z\P\+Z.W8 Z&9.@A#?X^DLFIR*]?RMHV]=&PJS$]238"M)3CDEE$2>_V#
MTCI=2-FG.<F(\><&XB*H$Q B3Z^%A(P4!W1$4GOQN"P2LQ<?Y( JP&C*%F%$
MWABKK(W,3IX3:%=XS<4<!QU6@@( *F:J?&\%SN0.EH9J#80]Y/I>^HM0+;S@
MX_MD;!Y'-/UD\R[1G429@8@/-$V3&Z9Y(E1D@ )X(+G<]_%MZB#! NU9VGUQ
M.AI"5VJ>CS9OG1'0,"#STOO<T,@.E4@VW/6.[7%2Q.B,Q*3D/+S>3)53I"\+
M=".]^/51QI60&0JJ3FO24V[AT4(V8QNSO$=O>B(Y)&U3QYOIH@L31! PI50Q
MC0X3%EASS>+SZ56@!Y@CSGK/.(SPH(22.7QMD[\NC(>IQ_KZ@2XT @N6LV>_
M%16_C35&J>U>(Y.Y;F-5*R(3!$R[U6W=Z@$&20B<BU>T9J(WY,&XEN&&?V,I
M_.ADB*I$/6]3OZ^="9!B=IAMQ/<1%3*Z9;,46M32LSFJ>%SH"&($]L3^W7*:
M4R3 WS$O$;U<;Z>'5:<;A8GT\I9N32"F$>)?+MD]M!0-,P-]_7>[)JFD4:J"
MT<F_94[G<Q,F4"&$I0=.ZSL;NE%I0-H-S-7GB-LZ#XC%G6<IQ^41Q !EB\97
M$U;'#+IP)0;QG*SOO!2S[@G*F3'?I9%>O^1-S8WTR)@F@QCB,.59Q6BYE"9.
MY@[P>+C,Z.((4S4#)5;=Q[:BI1NBLW<Q&&KTB0-SA.,2BW(8C.73"%A+PX5Q
MCG/>S>BLDU<N9\Y/MI+#$&=SPJ\3PS<CI>$"[@8:N*N!QPQJ,%#NR7&W,\P;
MN'(UT&+B6J+BN>S9T850@ T0%6@;$P<\ZR."H3",(%]UBLU3,I5IE@)SST/C
MQIW$J2[W9EQNJX70YL,*,!O"HG40 PDPGVNC>#0*ME>>)AXC/]:EJ&4KP0ML
M1*M_0R)T$$1@RG&[WD]M01&8^V?"WXU&1/,4?:J:Q#'O(4W]3G!SWZSG_79#
M+&KZ>L_WZ#&WH:8V)96)/.9S6-$ ,6$%>U<Q-3'N(. A0J"9KZ!=7>F S9-P
M('TEQWWH21:"?KQ3F)Y]&-(G)+%TS>",R>D&C1C+ DS&^':'-"C'<4%S"F^W
MRU3IF.'$*,\I&[-[\$Z+98 \U6Z'9&8<5ITPC/\ /%1SYQC43*&UQ [1Q\<0
MNBQR%W4'QS+O.].@ KB,$C.''6Q.C2)DB):]\^WK&DFQ)$9'@K8OU#QJ\$"&
M8,V1'!OFL2FIN E;9Q&S2P;XB9DF")!64$G@U70\A8;>22Q[1N^F(Q_D9(<'
MZ->OKC&N;H9=HG9CAH$QT:BDI&=JC$%D^M9:-=0BS)9S"PNVY1C&@)@*$[[$
M.[/.*T8;*R8F+<;5.;YX4)3 A29A]?9E]- ?. 0>Q!7O7<ZN]8P)23?&V-O6
M9,-@:0D!1>^%^7M%5H*\3?!Z_@I<1:*C,3$/!RL,5N4( 4(R$F7O!>,&IM6)
MQ.;F0=NR9\ZB!+*LBF'X OQY%744C6"C<MS?K.=$D52J>]^:[ZET(]"=VLKD
MZRXXFVCD@1D6NX(VMDXC0(%O(6DV!B&#%>-.(R7N9XXZZ<5MHL#31B?AWK:Y
MJ-,140P7^?M;Q$,(%RR6F^WU\<HCA'Q?^NQ!O^W7\1R7J#<UO&V9Y3[<:90#
M*$SC?-;0\-U.I A3#?B<WB-_7.F2<B7/,Q&),%FU)H)$) KRQ%XQX<'$N>2B
MUR%>U[4NV=$6TI;*09.Z,YF69T21RA@(L,Q7FY^DZM$(X"H(,>KU32+:G5JP
M.^L,]=+PF09"&(%Q*8]B.LR@E8EC.)^CL;QI*GAN.#:/2GWQ8BI*1OMG$YR5
M.SC2%$SD;"TN58S;,U&"89$4?7+>!,E3I)<I-&+NA!''U;U"+@<R(&WC;O#&
MC".0$I!OO1R[;8@8,(F2)0K$[8>3$CEDKE*.9E).,3FF\S);F!F:OQ^W)FW_
M "!*N&//Y^1)I01]7I-MQOGLT $(>(OZ?&_*ZVGTQ$H^^8IFJU?*B&K.$\0%
MP*KC>#LE"-><RVC!?#6^B2#)QYGYG:+K;Q?1,4?FY!+3HGFL43=CFBS84KP7
M:IG%P9=I]+\8/)#)$D,DW]W]XEU9867,->6<E!X8TUP%VG$2BX7*5&@ARU/\
M?GF##M(2HI7QN]F9S,Z2(Q$. :CKWF7IT!(BM^2_%$.V\Z4- Q,;8J\,+AS/
M,+&'*-IF%X, /IP:)R@!!U[4VD0UHR AE$ZF5A'?=Q0FH@N1[.^>-^4\+")9
MF:L7WGZ]3I*5-Q,59E+OC5M9//S#Y^*T7(/U_P!<$1Q&_">#/'KI"48;EBJD
M]<< :0$_QY_+AU3B4SY,41(S$,3WG15:B+6Y'.QA=^C427!F<KG)S.V,FY'@
M# B12VV$&]14Y#4@"'U3<Q6=S>)B0T$BE,LV<I$9SOU,Z@&[,#.8\<[];:(4
M4,>2B><20^ESIRF 9*6V%7,!USSJ!82:VGN*<UQ)#L()>4COSM5]SWN*A$%.
MVX)BHN6;[85'ND]3AHF_O42*$B@@D"4ZA7;.'P /*A5<S$T;UM!.:AL4+*M<
M;1M_4)\P%R#$@T>(4Z/481DL;"=Z:,V6#-Y-&T6;)U]A\X.M!)D;2U V?:;@
M\!5$KO\ /W_R)T(>0U+D+6MCB<O?K95Z85!XB%NOI[UWIU$S!%$,=Q-G5^H:
M2I1J,3%3U)&[<C#H@03(\"-U4N[VWJY;%;3@S,4&2#+*J\X @+HP\DXYY<)B
MW1!+4U5,+.-]B*<WH0EF#O8@)C>5\870A9M;6=V%]\D>NVJ!,967!:#W\KHR
M (#:+.T#MY;T"3(*4 ,+M&TC&+O4@1*+!F+8%K.D&<P'/&Z[37/$FK"1MYPX
MF\;G&A8"B5!F9F"*^WIJ9),JH![<QWL5MJ 6()$(89V,"09S.1R1S$1FT8\P
MXZN9FO,F#N9[GCTTA",]Y)3AB]B8)WG0V2RC>?)7C:0<5@9!Y_UH'$%]^'KK
MWGQX)GT+ZS*W_6B0RO&WR9V^1YU 0W#.-]L;'>)E-3@-0,YYE@G-4?SI&VB;
MLEW+FK*@KLP#%CD8;#CZSZ:,!F!&'.\P&<SF/+IDLED)<>W#$1'\!,R81@4Y
M"]D\::-*)#UY/9NH\:<HV5YS'JM5#DTZ!=RF.)3U,W<QDT+MV(003%T7D3<?
M.FD!.!9SGQ_/: VI9WY8)C+'QN_GE9)519'/#;[NF@,M4??][]-S0$JR!=MK
M6OR-( $"D)Y]ZHW][U P!$P,X,5DB+KYT&(JB/7$$4L1C>5C43-,U8>(4[JS
M5!<K#+-3F0>,\-VZ5PAS'Y_'C_)%:+-!9.'%(>_E_LTQA*$\;8GAKIZATK19
ML9BK\DS4X>*T!$"(-KJ8L9<?6M!$@A.*MK;\Y#0F7 3/#F(]%X[G2XFB##-U
M!,S?4&UZ3(TRT%9+O..Y<[Z&("42S+3!C$>\DE&E2<L&P9WR6<&/.=1FVD2U
M,=YKZ[7L7$3 #:UL,[<'/&K$*N<3M%;9P.+QI*2XN)CN*]NI[U,PW8Q7YM@G
MWT%(0A9(20N6Y<']:9 4VO.(C*Q>:(>- K)PLK#-09<1EVB(O3"B!P5[9\Y[
M<L:I%B829ZCS?UC44%BUCYS!,1 WMB< 3+?.<3]):#VC0@C%6?Q^V@$C)_J[
M0O&G2^<9-_ICG=Q6EW(]S+/S6=^5-]7$T?G&;^V<)(%C&[6-MK"B<,;:D 4J
MN'[+.];&G ' N:*G,8J"WU72J 48$$<-=.9RS>B$"YQ2%O-%7(3#%UH%$A(3
MK*KGG>S#.EE )%.,>L8<ZP @*WACWJ[WR:$BK@#*>UU&^#ETC0BXS:E>];M;
MU>B)A9Z$_+Y4#TT<&.GQF>[CB0ATD,/5!M,^(XJZ@"RE)B;^A7/RG#A92:3#
M T,LE567WT4LBA-EI&4<>0/+H2Q8(@FT?>1TY:09P96[A))&]:<HGY'J-F/X
MQ6EI E_.#:-OWT$(7'!35EON3L8G3<Q+F>W\\XEK_)X/A^FI&U%S\[N'%<1.
MRB.)J:/OZXVQ+J)I1L+.4XR1)#O>=),!8 ]\7)]>M0=@( G&\;^.SC4W>%)G
M&&8LQ',DDZE!0T\&N*(>8MA\6A$Q@+BF3 3O,#$S#.CF7,3,7"PX;^D7$BPR
ML4GL6O3,1&PCP AE>;N]O49BRS+P1M/&=ZHHB(K24P8$QCG*1'$Z40N)_%@)
M_#C4R,0F^(KW+8/K&BV^"$V8FV,%5BTB-  ,PRW7,?O$:26)'U?5/:,WH!(X
M(B=CF^V::DDT;4F8ZGT:GG:"JLJA23WF5<301!45O(Z9!F*#T@3?,L,G-:<I
M%AQF*4P1C/+9X9 LGKG>N?E*MC0B28_U:='#]'[QC065S(5B9&LR*>\=ZDI"
MI$&(]2VO0YFJJ=A]2BH)4^8VTRG(S'6/293R7 R4IBDV*$#8V=,]UJ=P2F,0
M\0 =5GG3(U:],9AY>YGRZ5%&9%SYYF(G9]M3912WXQ($S6PV:5$"R$>QN*]8
M:,5AVE%)W+=KP?L4NCDFTD4&\>EQWFM0K'[*7CU83;,1A,)%3CON^\:.74(N
MUAOB9\]5(@82(##5A'[?<QI36Q..B<;8V\:< D8DJ&1G??& '236C1G8@;.5
M<3UJQZ.!-0"G@S@]]7$NCK:;[SO-.^EFPK-M?MC[Y-1H&=[V:V-CYWS_ )3&
MG4B)*P;9Q/6^DN"$M9WVI\<D2-:@2=HC;-N(E@GQ+F D,6,J8V>WQ>+C1M %
M4(@S7M.SY=+9(G)\)6(W3BT,ZGJL8(48BN^:F&#86#,U)2S,G.UCAP3DVD.!
MOGB:<8YTQB#O98H8B>Z6ZBZ)4^AS&"N&4=QRQK+ ,(RQ=-HKZS@:!"PV;J>2
M.,8G&A4 R&)\X<>.]'N#EE$:FMY8]&FIT%1F$,BEG1?/S$&MP/G$OB6.[U4,
M!$$3+$G;3O@-ZU$H<Y&$F>/6RB,:$0*"@F%VRYXF+C2&;>%QG;?:A2*HU'"(
MQ*^<QN5??MH!'!S$0*FY]IF>M4-7U1/%^(.#:,)M+>S:?%&V9)AB]*(DBL/4
M3O>_K536AD'DG_5!;,8D?-^2,/B9Q+C(1O$#&!8YS>D#R(1NYK[#>VIH+/8#
MF+RB-[S=DZ<!,?/T_+X-3D,WYPD\3FS<[8G!-"4I)]^=N,MBP1!ZYJ:OB._1
MK8 ER88%R/BH>#1))48DJ1VK<(<<:AD[),<'<3T>]:+1#6U1')<_.^C(PA)F
MI]/B>X@-24$+5ZGR+M)J:# W#<#'"N/,Q@HRBWC [SC*WDU$*1^R<8SZXATD
M'M;5EV)DEX^,Y10S; ^C/1-1;C,:-V!F(5J1>X&#'<P:@NK,NI@A;C?:-]M$
ME*03S]>,\3WI&(HGZ98,S\1P1':-Z9YDQS-5&88@;?Y04FC,,3ZG?WO@14HK
M)<R8JV4WG)=1*(6^/7DKT[F.32H4:"2T@YAL^OG2+P@!$L3<.,[0V1S6C"VJ
M &B^#%3QGITF7('$)Q1.0Y,P:$QFBLIZVQ!AN9D=(L"\^CNSCV?6-9!(9@O:
M_1^^3.LG<9D(FOGBY.<Z$)#5][_'M4<$L2A5F7,"#E:3!>U3ITQ,C!%5+C,[
MXK?&H\-$C%S6V+S/Q$S>8!F&.<%9SUZUJ]D)B>>\SW7KL4F"J;$(W(&*9(XT
M@D.""8E["YDO?O3I!"1#Q/'$[3S+J#EX$W_-@^%Y!U*3"YSB=.8K$WX^D#X#
M3"R1L;</A9SSPFB%>W5%G?G0JV<PPQ,3-W*S<%Y(-/ 7&&9WG8C<EKM>BA.8
M/H?G>?\ 4S$6M2;<UF2&?[-7SGGV@GV\D3.HDA:8C:OIML1.E94%WC$,;4PQ
M,SQ).G(&AY(<D.?RMQR&MDW]5LDK/,:.;!(LE9^#BXQWH8I"<&8&QPQ<1+N&
MDYQ?9FHAV.-V+G2+9!03,7C$7%UP<2Z37)(B^3:)K/6F,,&/-R$8M[DC4J:)
M@=ZS\>BXBL D@Q'A7]I9I $42I@B<6PNRP3.D$2('E;*>04^D:EB21VF#>;E
MS8S#>CE+V&YY<W.+ZX +)8G-RC#N!]KK38@ @L,X&MN'N+QI5LP4[#^#,Y=\
M@7&8*B_CT=MXO7* TV2NR&8ZF-IT[HN:^,9BZT3U5CI434>*G8Z$ C(_Y.B+
M69B'!\_-9S%JU)7F9GN/4J#3$A#M#]#^V,Z+)<EO5_SO*=NE/*58(UL0]L2O
MKR2R@L9V?7"^^(.$V\R.E#PI42QMTBA+!VLXP[=15F@Q6R$8"5.9A2LL\ZI+
M%$UZ]^)SIA%F%A)L)@F/GO)N"0W,7$;9G@GQ?IH"MLJ+B..H]GTTH9EEE[B^
M>N^'3-85LFSBJ_8-G.ELDH3:F!CT\^^AK  G 1?Q#X)XYT*+G\KWSM6]HI <
MH[C?IWQS)6ER1;+9F5(XSDYU9L#(Q<;A:V5P;VU TDDMDMP1B*3#XTI"%WC?
M>66K2Z=M20&2:J9/MU4*/)Q$AW*$AB&=X]M7E<\\?V]N\Z0$2N\?3.^W)$:(
M"]3OG<ZSM<XUC_4FH&-O?32R[\A4EXVN.+;:3,F,N\$.5PSD&8YU<'"]Q^Y$
MQXTX4BY7T]K4G*1BA)3??!MY^O&C3\V?R/.VH$=$=7#XQ\WK)+I9]9F-JG\%
MS2B/D)<\]Q=%Z<A$3X+$GG!AY<E %H+BTC'?U3U9\(RH9RURY\7IM2")'-?,
M!B)+J+!1";,/F?:)/.=&!:&3EW[BYC?J]$RV&?W[S)PWG2(LN;2!U++Q$\FC
M4-,8&.=G[7.70L@M@#:.<XS-;D,Z8@L2B;15;D,8+(J&)60H"&RJ#89=M[ZT
M%$#$M[^DWOEGFM26*8"\0MJ/,IN<WI#2XIAI?PG'BF=0%5F(M:(X6\_D:#"2
M##*%##N?">^I$4F3PQ^'G:)_R H9A#RXTKJF2.(^9R.5O0!C4! 2A1"3(3M7
M#C1F&$ *GU]PW.ZTV64QFM_SZ:,HHF,QZ0[R$D9T.<VHGNJFT"<&]VZ"A(#I
MO,'(06C$\:@03A)4I];QDG?1$0DB%P0C,%Q/O[:#9,*?$L[>.3SH8(LDM>6[
MU<?#I!%5)-Q3O/'7KG.<18M69(Q4<'C9U:9)).=[:FWCS.BE.[WN#EA+WERN
MFDG(*D),0K&S[5M&GDD]F_N],F.M(2+(A4UF\N(J""-]].0:B3&7Q[7UG0#1
M]74>*/C=T0'(&@31>H\5/,NB#F##O,6W^V8N-"-KPO'6(M^[N:.AL,23O(<.
M^9=R-.-H7'QV8SO9-ZH<B;K>)[B,7GK36A+J;\]1@/OD1)&3_4YKEI!0;XBL
M^UQUE*O4.WGOW9KSJ S&+N\K6WYOLUDE\^GO%;[972N![N-ZB-Z^V\&B4*!-
MJ*]4@\1W.J1(!:1-' \=8U!5.L,DXP(2F^8C4*!LA2I%<U@GT#2=FM8..I"+
MC.^66$F*7IJ8CQY^=,W1+$"&X20^K!+?&ED@U._6!CUV7J]2(J K%3[>8Q$8
MC0&B(*ZJ=[FN;A';3=2P=7773Z\7J!;@?->_6_6H!588QO[YW]&](0V!<XB.
MKF$"+KTU31BFS;,C?3&9SMJ4C*.)YQ>2YVDT/HC)B_YQ.V\Z09$1A?6HKO,U
M5Z.SRB;3;%M^LTUY&2$2D))O,;^F_/N*1(]M<>9CX9C-J=4!@MXGXYQ!U0()
M$3IG_(( -Z>/,=2D;V:B'((.";!T]4[:D*9F(E,N7@PLMNT:F)9.<'6]9J*\
MS+6T8F;"/6/K#%13$.THF(8^:?YG2"IPA4_';=F(,$+<44FYN.J[C?:+GJ"F
M3!0,6;^MN,"*5OGJ>*AS6E"C@3B_2"_S9$;5,9]R*GCZ:2<XMMF7'%1RF<7N
M-'I$Q'>W.,="W&Q]?1W5#?PX-"HFV,S9&*VPPUH3DY$KDO?;Q..=([(IOY\M
M>\L9A*1R@5M7%63G) 5-XRA>YYC?A*FX34@>+C.\XBSSF <:BCO"HXYX_,4Z
M5 H($6BHFLGT*)#2Z$"H/F62/:4X-+WO-QQ!4)UM&8*U.\>IVI_=]7&E6)MN
M>)(N-FO:L:&R#=HZ]ZV]0<Z2F7]_SQ_JB,AF=OG0#S'TBXO-YWO$.H82QQE@
M4CU,3-9@-1 PN]U$C*[5,_-:"$5S8K.?3/C%&DX6EQB>L5ZQ[:&0.?$[)<6V
M>7 0K.=454P15K&, "ZC#%EB]K6>#[AG22" *+V$7[SGHBH 1-^D?&=[/VU*
M+GB.F"#]N>2$8EG; -GC.-()NQL*C4=IMA]]3,W,5M&*RX,XACC3D%PA.SL[
M,9PVFA&"%Q:;VG#^^^E2DQ*H>!F>VNC&A(3,C'8GW7HU#\!,D(A=R4IPWZLW
M V+M,Q+FS&/L:(3P+23ZQ\3MY64"$<90WU/&;[<FKAWF5D[@BBL"37$:"#XO
MTXGK.,:;P0:;LWSCOC]Y:UJWVDS)U,XAO1]>I7'%TLS3UN1HL'G_ !ZL@0F.
M,\;P,RX1EU:K,%GF&3Z;I+.^B'S^+O-Q?/+HNNSC#'6,]_&G)8L+4/AF R9E
MNXT96H66"L_/&SMHP%PPXI&&CQ,QM,NI(R858C-_%X8\SJ6,L9&,5OMS09-
MJF1**#6)E YRK2JZRC;.^+\;<S@IB(9A3'LXEZK?:LSIF985LS,$H3YK'%Z(
M,R"B0>)AW6-P*:=9#M?7GGO^*U:A1G$KMM4_&,:A%$LP1B2:V@$_LT-B#9QA
MSQSY=N- VV6&[(B*C:/)9O D5!55@Y\;$\ZL%GSMOG;S44]P LJJ9J)VQ%ZA
M@.ZHVLG)$_VU'3A(E)X,9NN*QH2D BSC!,& MXC),&KM@B";ELO)(3BAXU%2
M>X:RS&^WQ.0 FH;\_P!AIU LQG$>N SUG&AD'DG_ %.2Y1C'Y_6D922KZ]\]
MUZKM(:"ZC"R^8Z\[J;!.+A'G)+<DU/%NG@YPD+B YPXY>)K1!#$ER,>ZU=9?
MB=1JB)""_;DF3A]RB$[F"V)/"[W7G02K9G%I.&-J]+O?30)B=OIS,;!&#4W9
M!+?F1:]H^-2B*Y^9EB7EN]BM1PVL]O3$F!,V2X$T&(7)O.=NO1:BA0ELGY7P
MXKQIYD%J+CXS=1+9[(*\I>]ZN)=J?*6L"9.*Y^<>#VU$#G$3'5\3>H4H@ZNZ
MM<UR8"F TK,B$8D9AW+C.&6MM$$C(+Q/'9RR1YU-'=/:\D7]!<:OPE))"]ZN
M-SZ"QH<GDYDKSDV*,8=2F0N)8/EW)?2<1B%R2D(7SSS$,YY+FLH2+J[=S&3;
M.<7 ='Q]./K_ (X*@S%>=1)"0Q/9Z7MB.TH6=DL FIB=FJ8ZI,7I54X'($S[
M;P4ES6C6+1.\0'<1,?!H!"Q;/-RYF *J7&='O(0,7,1(&\$6>>-9!+[I6;&.
MR)"+Y@!B9;8R1OX.S.)UB*$,3BO0XX[5U"$21,P3<+5UERC<VWH%)47"/&=W
MA*GP1#B+MLR^5)LAKB=2I)=>Z9F;+CBO&I\6H%+4.:XIZNJC7AF6-F"[F"[)
MCOF8(62XWA4,8J<8[U@1 8W8SMRM3OB32&03N]Y])S=ADETA)CZ3XV3.*>HT
MD8")*@OM(YCXVUG-LSGT;MVSW'&D9$1'/F<GGQ&H )D$8()"\"WO4+=Z>+6A
M&Q&<00/?.<%DB2; WXXFHE\6!BHEEE8W>2 4^H+J)"6Y]NHWXC3+':6SF8CV
M9QG4.T6F(<N??:?&E(>W^I8U=A@S'?>:YGP:A(4[/3G-,1<0,%1H@$K=WQ"^
M>]1M&5(P4K<7<16H"0#-S8F^7C]ATI,7$18WD(G/K6^-$I*%,LW)AXGUV@C5
M$9H]]Z\S6+R3HE%)"L6+#5\_O.D60IA)JI9.T<.TC3G4@!M&^97"Q;:O$I.)
MD\Y"?JZD=D5'-Q*3O@(VQ@U*@E3+1#@LQ5NWBH,HP4).W$_?UT^:!+B7B;Q/
M5^74"!4 F0HERUB4[TD,XB.8 \[19-$SIQ@F EL_><33WL)@4B"UR^=E/$1#
M+&B&-UB1W=^FX\9U448 GYO/GAG1*<H,>[WCP=NF8$'+J1@-YNI@L)69E.H-
MAF"-RGG>&1F9@344D>T0\^EE2E%A6H<IB?#Z>)T,02+Z(^D>O0SH5!FEB?/V
M?R?\=!F8JX??9_9TBR0E5]\S,;#W%JZ4Q*S:XG)GK;VHU+$)"]Z"P^+B*A=)
M+,'&RXBN\^";-&,2N(WYW]WOC2)X6@-DX5<QGW+W'$9H.UXB.-WCC3P7%GJ3
M9G!N1'R:84(#"+Q-Y*<68#&FZ@8P+S\/CZ&H8([$IK#_ #E,UB^+("D8@EMY
M+?<SII@A2!4-0M1'+-W$\*M>;>?IP^>=13WPXVXWG%/7"_LK^Z]P7&5-4P\5
MDS%G]3AB=4&Q/SG"4375^@,+!U >*WG:;O4%ON_A_(U (LSM?O/SZESI^Z9G
M.,3O$3A.9H-4$L "PK?""7OR5R  &U7'/\_DF.8)>18F\5$<K/C4] +2Y-N.
M+.9)9)@I5PS$YJ1GUDJH=",.'%QS&=ICWT;%87O:?M7F=8'C_4G">O&LB&\[
MDSRUVH[UG3$BQ8]IF?>M0@&$,.+49KN_WE8+! @$ED)D1\S"/.E+ K$7(S</
M5D$#CL9 EY1T=QOLOM(U!HXA0#?:>;ISSISPH#@HCK'KMFM+P+?6.O/F<N=)
MN,3[F)LW^OC/E>ZWNSMOF'.I9&-Y?1]^O4H=%B#([3A8]FJQ5:C"I@7;)]L6
M[;SIJ6HMO/4UC=.Y-M3HA() ]S*\T_>M1HFBN%\Q@)_'*.[BOQ_MVH327*B9
MX9)MIV^DFK M&^1!6'VDW+I"D"%%,.8@,E[S,I,#(18B(R60XYV1=Y-S0L41
M!%["3[1?)XT)@4!.9%O]S4I#IQIAD+@,1ODQM<LIHL, 0!*3,(.(VVF+N0LO
M%1FF*<P5O=[Z@!:J)G$'>V12N!G30IT)L6COS5;.*T8)S!/^-58X]_-,]'G0
MNDY3%)-Q,A.:/29H*F(L0NZU]/[Y-960*%RE67:WU:N%-B2,1%DV^&+QV.@!
M!*+%+5,2X(SGV2R&6(2&&GW"IWLJ2!@<2QU!D]/YV  J /<_9C?G.HR#00*;
MDVQ2=YG%:$D ML?QNYSXU/*&0AD*VO>ZJ;K&E1:$82PSP-P^\[(KCV8]TU.)
M+B.6-.2&SWXP)*<)6IO !>AQ=^7^;B7\=EAXQL:%!A.MJ.6:]1QRH1;[X+,L
M_><&-+-HOD&3F1Y_N]((D:88+H/YC)'G41^V^V= HJ>)L],>O/O4B-UF)KZS
MT3L&C)0QB;0Z83CK>'9< L%D)08>X?=K44 L#+K<(SS')$ZW;JR,UM52_674
MY0D(]CMCVG^! 7M^>#'MHP>#_4DD%J1I4\QWZWKN6@XKX_/.HR6@'T,C7K&7
MG.E68+$-NLL&US&8TU@86V*-SDXB".337()'HN-EJ3TELM#B*0F,!EEV@H45
MGHTCJ>A41$<QQ7%ZOQ&;B/S',[\1 Y@'UC[?G&(@6B&S];%Y.,Z@I0[?OWPD
M\)$0Y#&)#Y;W]/4U(E-XN0]'Q4UYDUS@05\V?,YB8ET8S9A9;.Z4C>.YO4$@
M#9:N+3.9-G'@&IPPIE^8ZQ#GR]8Q<</F5C.;/>7A74K;"<X??'<P<*(^PE)G
MR;Y*E8<Z)Y>/UJ=HSV A0DEQ%_,$1<T]:(.@)548,2C>=@6HT; 1<]N?JO/<
MP@XH"#,D4<[8QOR@Q C*R9>9OS<(/< $Q5,4[8=]V>5QJ)##(2:9J9@ADXMC
MD@9!Y!]_\:@B)(Y.=2(4M5ML?"=4YT,E9W'9_OQ]M!#,62=M^3,9S)HLP4KW
M+*J\I=X@G0&",V3!4]3ZVS*<K#)*R!S6PU7M'>=26P!9@SU]CTVU6;(U=P3U
M$21ZV[V,\.JVF3;ZFV@*) 49V>YSL:EYLO<VLM6XWS5:;N8G;:>_G-.VE2(B
M)XD-_6;W&M]!%<M.[7._?-\:*1+@? H]'FPVET61D!V;KVM]\\3J41O%7%>/
MKQB9T(F\7+CGTF8T,(FMN?O6<.A)EN+GS^9O[,E9S]J?ST8TLQ?K'Y[]5J0-
MAQ^?W\:6*X-\<'&.\UG;2QC*9>>Z^2-?BC]N_'MHC$QLL1GNK.9EVFH@(8G(
MU/4N*I(G:]2(##.>+/I^9T4!P?ZD91UH)"BX_JC?Z/KFU,G>+F'\](D*HF%*
MO#D'ZS2>ME>R)18+WA*YO?==!4;D2F6R$AKGG$C!""LKNH O&T[Y]-)09"M@
M)VY,\;KH0C8^-XJM0([?M^><ZC>"(0N\1ANNMK#2C(++/)/'IU/>).2D2GCB
M/7?GDN19K-/WVWH[BU@8D3#./+O7S1O$Z $4$",N^3F(/G2PER1'=\$QZ4[.
M'0NB%*8F//4*VCK1Q!&(./69]]IJ--F:".5..2KB#ZZ99TD*WP6R1?7O6IPF
MHA"-TFH0I?'6BP$"U];\#V3F;8 82/M,1$<DNZ;Z,)%PL'!<\[?OJ*8 L3Z*
MS+;D(CC1.00RQ;.?$D/?,"F%:1LBYC;#/TTNUA3U;/2'^]$8@FQO#EBW?#$F
M-)3/4?GQ_CH5"R?7^O?VU(AVQ<B"(I?P>-2C128W6WQC]HT1ZB)>+:YO=B3#
M+H%6"%EY'$[RFWQLL043%1*I?VY/(-3*6LP3;Z5WI24+1T8W\9VWVTM5V^IS
MNXG:W?0F)FD&TQ&^*=\=&HOJ#R0%=,+DT)1*MGZ\X^9N;T2PQ.#QZ-?+Q)H9
M0;$ZOT)N9X-@T0=D1#N1\3<?#G1+"I8QB1G;&WVTA 8W4JY^\/HS.- )E:=2
M3<O/O*A&8#17MU)MO!'C.A8=^?:/RKQJ <1%D<>?@TP@0="]8"L9U$"JOGVZ
MJXC.#0  ""*K'YZ?J9ASL_GY\S*;K_.,;1X\! %\^O&/S+_J>:IJ8TY(I-G.
M_P!;^FE@\KO;WAC:*\:AB#/.9^-L\UG4Z%A+U.7RSQ71H,,,EK&6<?1;]LZ,
M(FO??KGCQ=FH$!1B<]/G-S_4,4G?-_L.\9O@BR'+GFNMO8."-%)B;NN+\T>F
MFB1G&.XGHF+G40FV_P!YDC.'&JDYB7F^#\WPZ35?3?UBH]9-080)B8+S.Y)X
MC<T 6YB<-^]S2#)OGG>*I%NY/&RRD.(Q&F%B6<28S,$>& "LQII :EDLQ63
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MR 0#EFDB:J$D>6+UFP'9CJ.(9KVT,QU.Q$WL\Q^.H%01$,+CK",A._!J+,#
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M.$E"R.V Y@O#.'1SM,Z,T$;  #H #6#X?IK\YP_2\Z'#":NX=V U*:?5A#3
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M#;SJ5$I>RI3XI Y='XWG4I9,U8,GE822PD0J43/0#=?@,J@"H:)5"MU.!;)
MGA0&0_Z8:[+61H,(T8@N#6TB<H,%,2Q.)8RZM!68%VA\8Z( J+.3<6+L/[6\
MT0M0"R5P2BP 0 -1DRH(UCEB02XF1-7!M2P:$@)*1R*7K.=)9#C,'+O3:U,N
M)-##.F$ 6+ PR,0 #]#I1("%+RBE\P#;3JS8/#^<O66) ](0.$2P.TFK@VI8
M-"0$E(Y%+_1IQ"J(THN2Q.VB%%4A7P0HA&!2&Q&B]C9-D& T8EF9HT7G,@11
M$"X/NEH 9S8DS  I" 1&0+@Q'!0N+@@PEIDL +)V$% Y2Q4"@IF$D&H(-Z5,
M301#"A-,-,536J K28TPF4DD0&4,2+!HY) @P/T!4@$P2MR)#@QMNX:/=E1H
M-I2N%A@2,\S$C3Q)).)-:280$%-K8@(DA@2@WC*G%8$$LU,Z%E:8O)&D(" M
MDHRLJ6H_[+YB_3SF)^= -C4'![:P=9GB_3\K2TG$?>=K'&<:@X/8U!P>QH%N
MYU]\[?3UF0$MQ>6,GYO.72:LM]S)3QV\7J$@;BWO!!-8ZM=HT5*!B2POU]ZQ
MGO2"*9VY<$6DE_!&=3>Y&P[MCFXL21XB.;"3HQB'P7H8C@!JY(.(CX^NMA',
M%3/YR;QJ6&\;Q'CHB+FS2R)Q^WO-&5G-Q.N7 EIA2IW8X?NNL0*A8)8GCC;[
M5JJ!$ \%,_+\=ZJ#CJ?G;W]+P8@Q-TWTN(8,=LVR0#8#X_QDQ&7\;VJ=G0*(
MR=;/'Y6>8 [/'[S]^-C5(@^F^U71!XQIUD8!E*&L&^>,)BM&"1EB.IJ?<KZ2
MFKMO6W>]^O?.CPBI4P6Y^U?1Q#HCS]"9W]WW>4M<GX$Q*Q'%QH;2I;!3 )ER
METNX:$5(2C""IMN,LRK^\N<F2<AB/27PFJ[IE3B%4^GR.\ZE*>3Z'YYG_NBW
MRCXD, B4CBE'.D,/&D(C%F+19X&]#)/*?#I3*6((J4(!*3&3!-@_H13T"H)W
M">1$7$DSI-W^H.64HF&$0T%$FI[LE<-@[$34,Z2D7"A)B,H3YI?T' &16 $\
M &8D.VG-:@X&^/YMPDR% 521E6Y(N-9.#XD.#I%"C4Q"+^D?+@LX4HDE3Q+&
MFR5)$:B)R!+<DZG(2-+#0$&P@@%$1F4:>$L47!A88 PQJ;2JGF:IIHH(J9 Z
M!<%-VZ4 -P?(#2"+@!E)VA!0D,U+5;!,#Q!D&@)$H 5!7D$0YHPB#=P25'Z!
M%DQ;%F>6($DDL,+I(I5&5FA:$*!J 2/$<.4+G$\R(N))6>1@1%AR.22+024!
MX8#I)%#B6$@;IA   !BHW@D!83* /_(T$.LB24T,36%ETJ4/) JV(X<LD)@6
M!.U0$5),QFP07 .CUS="@!8W8E;JO^)@CZ]^BUM,1M[0*6"67*RQ'4\_)>F@
MI&@2N5$]:SW.=0TH Q4U../%1OLZA$J@V88KC?:=#PH5,L]%UEJ,3GSN$1CV
M>"')S-Z<9'#4$F#>**^+=($C):E&S28<YXO$*V(O&(,=U--0&=2)(O.%C;:<
MQ6.]3R2 E)8HX[_.EMK4O:8GRAR[T:!"L6;'BL_09F= &!'<?3K%2>*T*42S
MYK-?S\WHHQ>=JYVW^3IC_&QS>&/XFKTG1D8$_=GS5UZZ.:5B?.<]E;UI(QB8
M-YR'W]SF=.@1!$[3(.]Q9!S;,$ 1&"$<\5YHEESJ10)7$76W'&+YEB$&&2,I
M[!D\^L:\$[XK/F?XWG0D"F)QSX<20P4]3J8Q.&VN5"][1ZMNKX(21)$/M^+B
M:="LH+&^'%W(3=0\R2:>*W,%>D^ZY?I$G,/YG:-_;'_H,HC0"%81JD8DO$$[
MP>%UZ)CU!J0>Y,LEL$$@Q12#0EP"R&&)#,)!3.1E_P 081]A9B5!DLUG8TL(
M@[J.'Z#0P;(D2N$"A<N) E@)_P 5?T*^+GWQJ+(^/977<[DZ:P&952@V+QFL
M<.()1TL2P3C$WS-STAJ6VC$&QPQ%1,QO[:)P!>SOV!7OQ4:I%EPBY5CO]IT
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MLMC>;ZEB2L75:4#*,$>)J/)F%SMI'"J-?>?=WQ,W'^)\F\]YC[]^;UMBQ"O
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MXO@F-,I.UR&3,#FOCTJ:0F\SN^KEQZE1_NRA.J\_G&D$, ^,5=_U,Z"Z"FV
MLB/6><QXTITA(<L2']F7),:B&$Q--ZF"%FI66\UR4P;D8*397 WH@4I8YS!&
M9O. <L:>M'>;*D=I^F]XT%"W-I-TS>];YC?14WR2"6[C@S,D%80DN9@$!-%[
M%*XJ>(T#<F)ISEJ8(-G/G5,X03#,+DPPDXCF=*6,Q>"1AP^(!TJDPVGB8-[M
M])O0Q1().$S%3X\DQ53MB:%Q62[O?W-Q8-:(I_+9OQJ\ET3AV@F3;DS.L',^
MF6O6.-SPP1'\^OIS_P"M<A5Q)+X-(L3>$:Q-TUJGD$41]4-O)O8.@@42YB9E
M)2$7%G>78%%,* <3!XWQ-?&E9!3L@#5L/&)MYE=71 LM2//../FX-83#$OJQ
M.(Q$SK/[3X,Q9SQ&;[<*'@Q<'EQ&T[!.L%LHDZ7Q[QP%W*(X"5ES,'IF;B9N
M8:4BI0@3_?;3'2)Y"_WCN)I]- I1U72B [=5[:001,I$F\G7MA[TZ;8AJ3 A
M4DQ.UP3>CI,3099Q;.WP&YH8UEL7/5^*#!5C&I%,9:- PO2PW.VV8L-065=X
MSA(B<N8Q('YU['DQLWJ:0Q09Y^?=CY#!X.OC;_=<03N[M_C1M8A>_P"?IUXT
M]$$1-0[A,?SYT%- 2:-O9K/QN++"3.:/D$W9.V=<9209KCA98S[UH;32IWQO
M!D;<;8- B9 )G*XHDWA)9@XU(VOLJH)&)J9MYXM9S&1QGR9SMG&-"I.%$R$4
MG$6]BV.DK0B"[F"PWAR-];Z9,ZML!12%WSYF:8TP6<LWS!R5L3,3)J2(6>>_
M3S%Y%-(M L"LPYGD\;YNU(FE5%&:1%&GEWVTB69DMWHX]Y]MW4/ (B^:SQ]/
M.@(',G\5O1RK3OH@(Q _^IR%F]D]WKXU*DZSMM<1F\1,NN0MH4AXX/=T-LQ%
M?S-F,Y.]+) U?CO\%C$F>!).\D /JYHC??1<$@SL;^T.,U,^ XR.)1G@D?Q9
MT5H%*':;F'<OU>A/BC* QD)QBZB]W23WR0[UW'36V^H3 ;I+F'V^P\FH("H'
M2=UH@GSFXG0P,:5!](O=2#-Y-(5TNT[?;]N="CIE#$7N9B,OCSH6O7?,Y[9,
MR0[:A,505!A+WK%=YQIS>;/&7@;KKSH2C5:B,S=[FY]M!-;$R7$^[&V[G?#P
M39Z2/3<>?M.IT%WZB,5)S[1U&BW)(._>7VZXWC_=5(\&DE.;)WN8S/X0SH.1
MN.6-ZV?OC.-7>94D5+-3&#KXTQZ2$<3N%\^G#-NIHI#[/AP1L4[92D:&58\!
M.)6]V -*D<S*JS#AN;XB(J-4&DL6_$8#/G4&FE;]W?NWZ[.KX'<;FT?;9I@@
MLDH,-R!]]L3#,9T#9!VQ'$<?3S>FU2 NP0N,-4]9B-,R!&8[B/YZT>8"JQ,0
M,'FYM&+G44&).9BF-]XW+T,$PD7!-7ZN?,XU&%PD7J8C$R;OK)H@2P0>Z3$>
M<7]961%8#R\K7P<Q41H,+"4,D5!]?XXUT.<G_GQJ,O[7/M,=5FJ)5UX)06L\
M2['WE*TW,15"T[KRK><3WHA1(<USSM%^=F]11^[TF,3[,1OH5/ O8N7%5XTB
MFE#OC;%9XK>72""5(D)!OS9]5VT$'HF"3RLS%S6*'0T5\T%XWAFISQ$Q L9F
M&8S/#F)RDWCM(%N?O6=M@CC,*L).&9>68ZS4G<Z@I! A#3%W<<F<^NE-"E+.
M-MF1>82+Y!G,0=MX[C[=28'+VB6D5YPAQSH+EC.<#?6P>T$FE-$6(/ZX,\E=
M: ^2(,>O&P[>^EJJ0(4,9VG.V-@TIA@"T,A4\GQE;4<EDC]LG4QZE#1(+WL!
M^;F9=*D33].+]_BM)*Q) Q^W^Z)(G)I@PA-11S&T]Q$^SI"1FK/7SZ^<8DU!
MY<$N*_.O70$1@!L.&WOM+OVSV+RR'L^T&,[P$RR5.)^E^F]ZK*!%YO,++N[1
M%,@&E:-%4F\)VD7CPZ$M$PXB5,[Y'K,YTZ$$L>NT1]"^>PG+A9#%9\8;LO!I
MG40IA+)N<3^53H-<CWDX6[-MMG=:4K,EIQC8J8X2HTA01-ZY5X?I+QH'8+R3
M9\X9MZP=%'81QMP45CGK8-=(%14#[XC#F,:9:DBI.'$=4SWF34*Y +FI-MZY
M]P\X&&',T-5XHK8[,Z#B4&^#O'#Z0QM&E$MX'\YS\SS_ .48QM8=\^&9_O;4
M6GD27 ?-[%P^LHRT)>U\/-\676=1("G:\UF^]HSOC0A1]</'/?$;8"HQDQY_
MC]ZT0 YZ)5C$C*G%P QN:N3N4:Z\65?CI-@FX4P>I'K;6VDB$"46(#?MHY:B
M7&I B"2J:E@\9HJ:-##>L^"-^>)]M2688FLUAV#J0C+&D#0K92:Q1#FG#R8T
M8KP*LM]]P;@?1;P(A#$*5W?-]7J\51)M@XHSRXU,J4,%Q.+B,1ZQ .E@=Q9Y
M]3B2)[WT1AE=J[<Q/1/R!JT0,V?*S$*S"R8)C2H(4-U7#CO>!TL!4%5&TDPG
M=\0LNG$@%N",3XJYS$[S &1DP5BLX=XWI*VC4J!(-WYO&(]8Y-.$AE%(S,1C
M\Q.T@ P_[F:+4](("N?G'VMFM$=TW_7[)?&-#(&(*QD')=8FK[)T,17<DK<\
M+BE^D6;2P(E1FI"/3Q.^E ;M^L&/2-,KO -HQ>;<P37.HD1%EO):<+"MGTG4
MQX%MB"9AFI3VE[B#!$JI>*^S%WPZ=R(VGVXF3'F@J*SR(#<SAWW28G>L*\(1
MP\<R8O,]SHX#,YWKBPA[WK$@V XV;[12;^[1J' &,EDCLQ2+!+S=QJ5B+B$S
M(;Q-*&,VS)H)2M$9 QQ[T<Q+IDD.4[JR\)B^)Y"&&*A"?5A1[*JR&M";\$F#
M??.[#O\ (6*QZ>C[8N(IX5PUQOM4PC^3#!)Y@<7U&YL5WC0H9@D\\=?3#?\
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M<L;U>\O9H4HY:V$[S=GDT4)U VS!3[=_9THV"6$Z<;_8]03*,I'KM/O^3/\
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MDHJ-E1A-Y8C$$XXHWO2XM%%5/-#[<;Z*2D*61*1CSQ>+MT!(@5^;3A9C-]K
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MQ4CO)O.IP@J%-S:=1D3)Q"3M&"(B39<7 PNJ)88<X^6<A+.G#V#!E9;"&LK
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MOH5$^$*K5X8^\^+=% ';>(R2[=XZS#1RK6,!%,;1NV3'L*!8R#N\Q_&VS.)
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MPF?J=6AOHD0;2?A/ BV"'%F)**2([0*),!3B-)WW"&S*K!&S10HQF@L9*@,
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MUH"+*%D6U+XWJ-^]3YP8%)<694AS/O6F<DY5F5EO?,G'KH8( /I=S]\E:)%
MYHE05/?$X^A$BXJ,'OCGC%&D&C,37[!/4_=-5\C+^QQR?D?]#30Q1).<D8C?
MS43<\2JC,X]1J3P7G0K(%5, 31S1F]TWC0R6("B\8Q$8)Y\0:20@@5S?/WE#
M6))25A(8!FI\=1)J"D&4IZV_C=EQHA("E)Z@D]<$<;T:;!5PQ<P^X\2=Q=:D
M29_*G]\^D:<\0@=SZ8-L3W&@8;35,D[UMWBWK0A)N<O+YS5,[3.B0;03P;[6
M>R(WA'3R")>[USY.>VHT9S(Q@A9F8X';%\VPR_.,3B<UEU&Q!O4\W63GJ9LT
M1PL(]JVGVYQJ$C!AS7/]<5H9#5;8D0\8AYKO4GE&2.>*B99,2$M:AXB,L1)_
M>>@@=3N/9=UJ9BCSJ3T#^7S[D;)I(8?R'$>P\4-5=$ED_.YK&-+,(P_&<STF
M'Y HB?R_?]]'L$H9#"^/?'B-2(A-ZCZ3WQM.-5(6.K;]_/C9U) AF\5@_!^9
MTBBFKO>_>O@GFR@./^G7>QG3WB$%F'"$&-5HWTGR*DR6)5P")2'M^C8+;KMQ
MW'9(!8 1!TQ-,A&:A$@9)#$!5"R=P6"(QYA(J"40!HH48S06,E0& )=]1=9<
MMBP#%EX%,:5D% NRA$T2Q@W-%7@BK/"=NR"%4((O^,O+ *R& ( =#2BUBZ)
MJ6QA5(&8#1)5D.*G*65@)LKRT'2"QH'-]R!N)O\ H!() $AP,HC10@Y-?G.&
MJRH8&QS#9/PP+!-,%#N(3AD2FYAJ$LZ@GX; Y@<IJ!,A"0FJ?H(X"1$XKNX/
M&OS'#HC0(10L(3E@6"X%P/Z#)J(. 9>$#+<F6B<2=,S"#O(_] "\4F D'D(C
M#2(V:GJ+^)F/UK24J(I<V8-&8EX%TER@)2EB2#O<D2$UC&@?/L@$ 5"  JL!
M.DY [FT D0@&4%B!_0H).*ARJ[6-42+T> .(2(DL*"* $;GZB>I.X<([( +
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MQ,1Q-NU;SNL\_P R';)D<\"LXP8B0-)"R8XEFJGRT>4FYL"44AM@4]KWM9Y
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M)W-*!>Z^O.VVD8,U$29;O'8P.VL$R@P_=*VV_C1(< <7'89CG^DJKR_D;?\
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M.!N;.LYO:^5TPCJ(,5\S.>L6L'V@PY+GF;,?8W@ZCAN=^YAB,Y-+)#,17O\
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M/33N?@__ ([G,S,S,S,S,S,S,S,S,<*0W%[$3GS]=*\GA_>==WP_;4>7L?\
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MT,1*@#2X8GU_?OEN -O5,]G^/G@%GURK%I\8=WZ\0&Q<0WQ5W@_<G )C4[N
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MMUQAD6#@)@ QF=*^,(#AC&CGOZ-WJ"+L\+WKSK&\9KR49>T^\Q^/FWE!H1[
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M1P6HM WY'1XS?'!)/3P&W YSX]ZX9WPZ0IA9[^>^IS!L,3ML-P_GR7E#V+0
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M(&6+ @/TR_6G'^B?%.CG*.^^\91 $8,;W.O>/I+G2*0&8!IOO]3UP+4RP.R
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M$"BC#3"=BGG5ZY+@4&T(J+]<+ZQ>!Y\=#7,ZB&4\027;LB%Q$[ NW;QRR<*
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M-39D&, 4$I1N= /CBZ 2?80NL[FL:X T.,[7&^W+[WUR= +0,SC4^G^.).0
MTA/KG5 N&\[BDJ+\S^?;+_R#, YK%C$\SN<4 J6+]_U^G5G%UN+?6.]SYO7
MY\QC#&%[[UYG?%,6$,O5OT_EY"\RL%TC]>G<U>&SNPY37L)F?3&>$'-H,)$K
M#3;]"S3M=<*0&,8?MC+[DAN0G68X^+F[XL!F;.\=YQJ=;<;Y3NSG^.;KT8>
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MYEC!X-'S?>>>)91A6EU5D.L!+F=2Y B=+F1D>[##> F-0$4I$H1HVWK0Q>A
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MC8I&M*S":P^#[<"5+5< $QSH3'U7@<UI.F&'ROC\<E$%PBJ"YN[Y\\ 8G:P
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MBNJA^L_GUX943R?\1[A$^09K[?7UPB0*IHP6.*.']IP,J"(S*I\SY_QS-O
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M=%\*!)DSOY,0> S* HC@I<SWCA]@\!H=&,2?WW>*P13;)Y;F!-_3K@;%C""
MX.LY/,]\!PEO5^A\_P B<.2QB:+C-C[^AR =@FMZR?;A0M2)26W7GVI'\<
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M\M/7.*"Y(R@&5)<6X%!"(IJDH L7FUY:2/!LCD4 ,( B&'4J4M64(!=!8?\
M<X"()[XI>BW1O[?MP4$&L']N*BI.\'Z[YAKR.IGQJ/;T\$8%I43=/M\IZX$2
M8$USZ4TQQ<@&5KO^3'ZO$,1*K)@;]LWPX^"6=YP;;QX,8F>Y7F*,E%8"I</;
MCWURESPX,]#FY\X[ZVZU+)+=7QX][]O,MRB4ALJ I7OG37.RFH%-Z/CSP( $
MX 4F7V?GW.+")5AED7S^,SW<Q8 A(_I[_NGQQU2 6Y/MZK]SI>"I%4!;$PPY
M\'K-,+6V:G6JUC2/[<M@QLU0"8G>SP'F&*"Q,9S_ !,>HR<.::%F\]PF,[UK
M@C 8X2@!_/G/_%H.P?GEZ!1#-0OV^SECP%S4EP;H_$SKWUR[4&(RA@RGO?T:
M<.C(%II=8-J]9O$!)0HCG$LQB_7L:<"9@O9X^R8_%+#E!B.]O8F+C#X_*8FU
M:@H(PCFY_/E =JIN/:B.L[ZUP4DMB5A5N<?*Z^V3*-V-E??G23P/0410I 9D
M,2>C/7 E8J/T'UZSW_ZU&K^$UB]_S..*#1@YS@_C_O1 RR%9DV@4@(IQLB!4
M9'")6(Y(TN.)0;55+6)%S01C"\+C"R"BJ) 9:/\ 0;-*"Q9JGN$3T*JH_P#]
M@"Z\X$.&3+@(5F<,2P"G("RZ !)R*RT/]>A-DD.ME9+<7<%2XAK9%/R*@[S!
M:]T@>C1.E$R4 B^<I]PP2G49@A_H+/YB))^VG2!'BI UF8$@;+*J3C+$3WB9
MB *6$'"O*ZF#)",E(L\R<-T-B4"S:Y";"!?96DS+=1<@=(!P3[+P2%^M)=<-
M5\BVK$'L9(0"-><B;Y9*FEJ!8?T0@H @X:IB$3,9!65*^DN%)"9*06X%<NP1
ML>M]D)KLO)A^J1"2YC;SQC6@,05A*RH7!P,E!6A*]L@__P :*U[^? Y! V"I
M62!O:!:[&HA!(:+8&*YC0BD( ^I5@ 6C$[^V-6_\2TD!^AWDQ_GEG?@NZ)D[
M]33\\G:CAU4:Z\OK'R' G&:;&1,F_H^'.K3 1& [D;_CZ\?-$P2GD5\Y\GSD
M!APJR&&ECL1<LU>+ @!*T0=DDLLLRH')@TKIR7]GEIQQ(RR,#I)_[P$;"^VO
M9BWEFQ H,WBROO>,WBW8"T*9 !&&*SJ<90@20"K.#\ QS./8H9*AG@[U)];P
M J@6DRYS&/\ )7F\/D4[3UO&<&W_ (V&Y8?-$^N]<;MT&&;PCCKIU^!\6!N@
M/$;^V?C8(BD'>H?K?I]PC(11W;@MSWK_ #Q0);,^_P!;?)Q<7DZ%^IUYU-?-
M$@#R(Q+G4ZF?UX;B 6E68S]OM\D"3*N"C0A7.;%QKR3G6A+4)MI\W#X]1KY\
M_'FY3^_UQS#Z;U?GQ38WZ:8^QR9E^E#PN,8,S+RA (*&<S7P:^^]_P#T&@Q!
M@ #6@*D5&(>")L+Z)EV_,^^=%!*5& DR<4O-(8]CA(I;DR07_$24/P<.&HKM
M6!;Q\J6A/AE/FR]FN/,1S$4#NN 2$,_XK MJQ])^C_)QIW\$ZS_8_37"+*C<
MHB0W!_6?'!#2@318[QWD.BYT.?*&*QWN3Z^Y=<O%DA+6(NX;[[*YXLE0#@8;
M-=,KD&+RTS@!(C"P7 V8  G.^#HE,*X?4\3BL-"L&USG';W<TX=!J;!\_>:D
M9F' F&"<0]A/P?4WR"6X4*\X6VYN]:YC*DRX!#WB?C>IQD. J"V:J=/C&-9X
MO1OF+_/YYO\ QS57R!7Y2?G77 2Y$L+_ (?>/>.)^67<=?'VP3KQQ$XL@8R)
MC'G5>^IP96')20\%\_KG<6<,LBQ^H_R8NBAA( !5U\'V</.PHE)DS_'9?B)(
MQ9 ,+^/S4\9.2>CF2Z<7;\?5UQ-(ADGQI]><_><$C583X_FN+PR"4&*9#&OO
M>W_Z=[N8U@DX8#3 3'#*7O$D^' _(. 5 (/- )*AC*DF?]6B-2@"YPF/YT/#
MAKEZ[/%WXGZFJ"'"SU/!F>,9&'!HZ!,=-WX/\]YR-2D5K8=_A? 4WPBDXQ2+
M<Z[^/5@\5R"P@>M!UYX[ =FL:UAQUQ5E;A=E'SB_7\YY+("FY]+L_F.DI>PR
MWJ3O&*&OQQY0X]KC-KM)OQYO,X [GK[^>N[#B<TA"I5Q\;V?3W4?&^4=;]?\
MDE2ST]FA+<_'$%>=J%3YX "]<G#7C\<"*N!.WXE_SRIKOFR#RGZ^>_CWGFX'
M!TMWT=OWS\<2NB@%4!E[TZI[XQ!UAA<?(2_W\\OP$P.NM.?QWZ#@0AHP?]Q(
ML"9+_/Y.*SPJ@8NAZ-[=PLO"JD1FMMGUGS^KPH#9_-UY_P =\&(8C*CG(F17
MXG1WQ*ZM[_S\3.[DXP,JPTY>O'\^W *2$@=NQPZQ^FWCL0',F/<^;Y?UW1-F
M>P;W-WW\</!:!F?'CY@&?N\P9!&9Y,.34KUU\\&/,( 1=[W],?7ET5 92GGK
MS]\\!   !C 0_P"1D'IA@$M)DZ;\3/&<3"5,+3?N/GZ\P@E;0@3?3C[X\(H,
M4$1$;\7?[:Y1\-_3XX\I:&OIC^C]QG[?T@[!^G_=!=$4;\)^_&5+11DS$\W'
M>X;X:2N C<XNM_IZX+I1U4?;>IY-?04$WLSX_3N^;XYDSF0@'\?XXY!!("-8
M_G7B\ I#D#_XF/A[[Y:#U4*WD\8]9W]>+M1%TMA;/Y)>%DP!":[?^+\!%SFM
M^\<UJ8@]O6<7U[X-*:<G^J[Y]E&/YUS)YJ5:XQZM?[&N+(9J4 GS+,/(L10R
M.60C^KJ<8)B@4HZDG&5;%%S;MF?H9NB&H1L)D:&[.Q5!NA2$ 922&+H;I+L;
M1%*Z>T 0E(8!1D*&[GBN^_T+[_H'YW:NM1_[\66U;F1(WVV2?ULF&)3R7EJ!
MT:\]H(+U'F6/M^4ERGL+I.+8];,_HJZ[@& P(4#QW_13 1S9^[<C8F.T[3)7
M_K<G]<DS(.C?6#B^/!IM0/N@E!?T\S8^F7#'Z'P@1)BRSS+M+FBHF#JR_07"
MS3##3+]6X[-,)MN0( B@P1L0>_=AS[-!SI"CW,3;,E6:\ ]%#;W^3>^^A$WR
MYXKUIUP%L(05'=B2>OW=A8><WDO(VN62(=Q5B?^USI='S@U&WS:EJB^&N(;<
M]V=;)1@N[%Z'R%$"U?\LH*=<MN!^L&VD5^SI;/_F<V\%EMWFK'^N4K!W8L52
M- 5#4O#E*2JM 4/-HNQ+5M8(NX_M&\W94*&>TQ7P6=./B;?_%?)$2PLT R=(
M19"F>_Q)"DZ:[@VLV,=MR =6;%A( :_*O]NS8TTJ/!0:\19EO/57C%#_&_$G
M,E!HN"X+6)Z_]B% Z1?E*\21[_2#!9>Z%1O\%ZH!E4 /H+1SAYK_AYC!(4]I
M[/75C;:]DVC!MT*L]4?=&[F*H9@Q)YA_M/T=3N_F^"0X,,G,'$VG4\5_F_+9
MF]/47$G%\#8+M[&.CNH9?E^[MQ1)E(>AX99X3TGE['ZS6WOY#(C.02 *<IXN
M6.^"I,Z&CF29YL4"XN#_W"Q\RO7E]=\B9-SK&QD2^9,:"I&&C T"/^1>[U'M
MUR,D^W!47D21]%3\7$"0%NX.\\FD/OZ_BCN2# RQ\47]]8=4IC(HX$M(7+=D
MWHFS!T>5X\X?K7_QP<7 T-KB?@:LLVQBZ7]B3KW=1Z:<V=J$@M_=WT'IW-7
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MQSL\4I=@F]D>GE;$QK^85'GZCV=/8^3M EZ<B)"D)#ST+"QO%).4'!N9P#-
M%]% KY"DC%Q^-%UW/Q;DX0&7)6LXO^NWL-V,?CD/_.2XLK45#F8GCRG4[D5?
M\%FXQ@L%:[2)2^0-1JI@NGXH^Y[7_@BI?)?8['/E3+"(XFX51:]$,95?_K8Q
M(+<298%Y#=S^P\IC*1IV@M5@)DM]O?&CLIXXJ-R:?G4JHZ@OCINV!"_!QF!6
M8FNEC7!;=T71ZZD4>Z]+ZP97N:G2[),I&DQO^3\@>?.'KYJ,+@8O1X$L=8LB
MJ]$%*&08GM-PNT#0L-0<Q%1K?\!QQ"+4[=^4-R#\0X9D#G1JYL0C0NG*KW<#
M_K@F9QR<[AL=Z[+W(D<R[Q*20- /MG9]$:1;SM/LQ#QL-'U:9Y/KDUBK1\-2
MQ$4M"IG@EI.#)!/XI<300\^#Q<AD&2\>'$473^JT$([9" E(,!@=_6V6IX-+
M3WML:9NC7]@#4[F/G;E'NVCT,R _J\<)1FHUHQL4D+C9S>,NQWYHM-A6E_1>
MUWQ63X"J]NC8Y2X$N T($G8+J2;%5'(P[:WM@; 1S#;STPK;8A\.$X"5ZQ2.
M0?Z9/8(,;Z,R_OFJ:C\##LBI<"2S3KMLXP6BIKV;W\$M6L\),0X)[Z>6+"UP
MC4*Y#^'=/A4XROLFEJ<)SP#5%WJXZKK?!*[/MX9HN#;?.&E?-K0!,)Y@RDX)
M\JDC<<^ .%*^D*H65_-F6-'T"GK+3&+7;0,#H%S];TTU0K"^W3[$BO0@;=I9
MI S.@]-$(KC^0'_$FP 6)"[T>61N0WU9LTM,(?SXX"H6K7K I6WI>[<J(-62
M]I,PPY-IRCN+#:F'P(WL:3F/?Y,0_([!WW=A'D%/Q\XK[$6&9-2RL M1W?]<
MI9O8ZC,MYX"^%$KGHJ+3SO&&;D@ESZP@4D(QL[/\U1]BV<3[0DPPA4_U0BC(
MR2U=7J^( $%[^(",[<3BM8WAZV&3[2Q*6:E&B$<(R8@GI#$;91+_P=%?@6!7
MHR9QO.XD!T6&U:SD87T80T2=4L/IVZ2V=N6B]PA_S1\KS*M^K_^N*\M4%J4I
M;"I6]%#S)N%%M6;P?<_3291KW54L@B_-/-'^QOIB29>.$NJVLIZ"B1VCZ%"!
M"3Q&SIV&SD1=OC?ZPG*-&)RPB#@,8BGS(2$LM.W\RWNG=7FZXZV#SN/Q819I
M);0FAKG[$^#OL0'-H^GI@C?K5APY=J?=5-#VRWZ^OE9=NG7+KZFF'I6I8SM!
M=WIJ.[XOOPD2U#JOG1=\0<RCI?B<[O?>QA21C(=R<!"OQ.EIT^DEIBXV\6'N
MG((%NGB,26RK=G>@+;8B?QUO#Y.#9EG4)ED>CG&GJGPWY5O]Q0LT?3C6&[%=
M,O!/?)I^V*WDZZQU4.Y!I+"QTFB-ZH;EVC+?!F?BD'M>W\+IE/'^.AV@^C-.
M1\,<Q]M3.;P36K(F^@@%_[M*V%].^W)@6_21,\I'&SH^8-7"0B50)H.Y#3+D
MXV]&;3L[V=@!3,8USHG/N^NW85:L0;+K7P1.A..4SY=^7<TSBG?KF:*S=QA=
M:#N39>]@USXF(E4?9Q4&,:)F.;KVOKD+?2CS;]BHF3J9W=S/S'/J+?$E7GC%
MU/-P=7-;ZOZ7@&9=QN\F Q9 (_J!<?6Q*<<G&C?8"H/!Z@[;7RZ,BJ5?R%70
M^>WYE.:-4G>4_/&&:%97_I;1D];BNX?/D !%4BXM\^N#"$AM)5FS\I>1]PXK
M)FD3M5D*'8V'=$OUN6#[Q/#QFJPKV%61L./44R!DHXK*U,,AU+4QV7.P+$ 1
M%CJ$HAI/P/5B'7-S!!Y;0SXH*[Y<X?T8*(J4PA,"$S5BR>3U;8)4%DT1G(F)
M2Q\B(Q>> >+W=XCR_F#R.S<D@EY3.+0 >'?P]%^6'D:/U6X$Z7+^& :8-[]B
MN,S+N\PG>*L"O.G-7!098\^D@A2VHP9T;F7G%"5ST8TY6]URHG$-7MF%N3?D
M.\Y-@6D5CP.$Q<BB) DKZS<;_-S+C'&"<S<'I9-8:ZKKBMCM2I<%ZLPWX?@1
M#M,=%U_6S_4VZ>PRK3A(DX-/NKM"7L8EAH6DWS>ET@M]SE))@OMX$\><U3RJ
M5X8VFNH(RD+TY5!XAQ<0W<A+ZHC?YEJ[2W@[ KW4@5].'GTK3\PA"P\Y.?V(
MN#MMWY7'1-W^03!+)17XX3\#T+VO-C6PFJYWU\T_\?]#3IKV\N!NZ?.H.5"1
MK?FCV!5P="@W$#;SL$HU0K1[C(RR4> AIEN4TOZL&GZ+>]'AKUE[ *5<'!,Q
MZ3F6++2-5)MH>--SMA'XX^]1NM9*P(=#JOT!<#0E^YTO\7E.7T?+]S&G;ID<
MOU*%IO?"A#'4I-G7^08;Z-^Y+N/F.CSSHKX$BRNE@P]MD5(NGS%86=7G/DF[
M[QP<U1Z=+V'H2[[]XQL8F=.#:2Q,],86ZU[T;RY8LRK"B]CA?-$[*18#;,XR
M$M!<WTHOV)8WO5T[\%WHCXP06@#>1MNFN.$P?<Z#H:8V%-J/WN=S^0Q8'&13
M3@T(9._M!>$VF>LD>MGUZK !ATIC9%\_ R#+#MD1,)H[@N5#=N '"O(ZX,+(
MBNU@-61V6+[=AFZ1'Q$6-^L7^OH(2(8^_@-C20%_V1=$F]#!EHT&M*,HY"DZ
MS\@\"(K&MZ\2VL@[70Q^10 CT<AR[Y:BM";8_+13ZTYMRU"5E:0_WGIKG>NS
MA4\&*!PZ\R'ZW7IJ4(030CR<BNF.'EG!A?Z65%OS.L\CQB<*X.P[>-'#B8,X
M*I=1Q?J1+#8PLYW#4=;\+^LP#4LNQN!^?^'V<OA3#'$E]M43ZG$!C1R:Z)]K
M"":;>-1]Y^HU0<9%N)IEFN@6ME];:]>,E/ZT-!-PFL3/R:/:P+0Q/4_.U]6X
M\O!G<,1XUJ'F_6=O-_2*6:MPDXW6'WA*>N+8I$N?A$Y#>TB"<=@Y%98/BV[V
M3+(';M0NMZZ[HEQ2!K9K@[]:_\J5@W#Q%,8IJS)[T6U^/&D5"]=**_FX*.XO
M2/X9])?A-T$;O7S2)Z48@N%GP'R4247+*A\IU7H ]*-<G/[7MTG7I^U$R4"-
M$F&G1=J;+0&CK1W59P"QS_; )P!3(EG+4,>F0V!HF]B]Q>$2 !R\] RPNOHM
M.=+S)PC.I.^&S;#$-":QE1(?N_ Z*,NMA_D/45(FU&^IQ-XG\0_M\+>9TM.$
M!'7BU_><?8/@*EIOPF!Y-3+<='A]EB,7=-8_?KDA#TX/U:PEJ"ZW_A:Y[0Y3
M2,&0-R2(B7"Y'#:\ZV@R0&<."I*2Y:V+T+:K/7Y/&SNB4\+V5I-'D.P\0:6)
M)\2=-1DW(121OJM,H>_Y\_?E^>B;-*U9^YGEO6;QS%T<, @SY-V[QZ8INB2?
M:?</"$OT>M)X U6)9=R;7E=N"8H\$#Q:\ADPB*-03./ ><K$B17B9=G[N.BW
MK?@JM=?_TX*G55TW?"]Z!,15Z6,KC%SO\0$(Z]'H%:ID9TRF-N(TA/]T"<I;
MO<G<4!TS/+2[SQW^;:(1$=XOH$7OD\C&3:.9[O#JT'VG:X8;@ON)E&>\;TA0
M(863A6,8VMPCT1X;I:$689;G>^RGE=XAS,7Y'CW0!UCM))8N)^JUF;7 RDRT
MZT<#LK/>\;G/$L;":"\3=.FY(='H@]F3@)>TYT?^H,V0-\^.2#Z8.@GP8?$X
MN%UD3_DT?FCZY^S^8WP ^)@JX7#: Y8KO15]!BSAR"M%Q!/#-Z+,HQHW'A\"
M;H;"_N(DWWJ+=;M%"=9.+M\4^!\*W,Q\0>.P<(RS>9QE+^RD7,Y0H5S1RK$0
MH;57I#!3V!E(2Z5GKZ0&<FEUYSDSA]?BR,\:MIPCX+QS?64$T1];KR7.1!AE
MF'%_HB&U=S\9V6=8\SRV><8.7)/,?,;S_DI<IMD_1JX@@1'1DTC!S?KF@WI1
M:%4@DB&9A;X>Y57O@8H:B^3+PJ+@(8.ZSQ_Q /"2 #5[PO;CY4[%5.*X2AL?
MAP5\XSYG@>-XA/,=>*M5@+AJ"I\EKQY<<XO#A%V$-N(?OZ6&2;<PH-D^ QP$
M7/J"TF2/RUML@.,1>E/S>U TM@;_G$5.PYJX-$);HW) 9C'RQX;H!3E1J+'\
M1H'\L!U.4Q&IODHAY^3@+PXOJ[8ZU3/;9#\BI[%@RW74UYQ#D5&.JA/:0FQ,
MV#G.X)13;Y0TE(FG@[DM8'Y&D+.0)K,0G/6:( ZW;8S *;N66>L?!]&4U;9U
MS9LH'%,RP9%.K#])O&;82\#<>8V@--P0A6Q5[PV\0FHEYM=^(N?YMS;E&6CY
MF"X>UNOM-&I$!KQA"OS^TQZS48FUMMTB<$Z\8MX6ZG6!BJ<3N7S#+MF"BF>
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MA\ZUD=OBEA1F'<'>R1%NS"QK%QR K7"(+;=I,L(9!U_B_IAB\TP(5&GH:K6
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MKCY2LH,[Q-=H@&;BD?G=(0PV[ACG\N70D:Q*\^)1!7(=?_KJQ<Z=+,&T"=1
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M)/&PZM!9QX4_"Z]3BJ*)I@L_1>":N']\A4N,Z25] [6EA<W35!A\R3EW("(
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M=[S<^+5!5]MB@^M-XAPI17T4DB;BT YC]!KABC":]#U@]%[+6SYK_]G$52B
M>SCM:^WT1>'/?.[;NV%Q;[DZ+8( N[D+Z(F2//4KXD4\WSOH+/HF\=-1#71<
M)P;3[P57BYZ"=IJ&=VY0W9AV1?-G(LD1R6? H>R3)UX_MR!?V13>[DP?4S>\
M>4S]9;47B'U3L6P:\+%_A(*UEZP9?^ABOO#&3B]"WE#J&?!KCY-B2_;'G13V
M'::I)_=C6W!A"<MX=1I#PM\=W2>9Q?6?_9O,M"#2;OHEN_+&PD:@!M[X,V"
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M% 86&LP2QP.5)QM"(@!JZ6JK/*YM_=/U[6>V<2403$1-4UT8B4@-_4<77*K
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MF6,.K@9!['PZ'F/-;<WC!,O5_RAR!!H??:5IKEVSWR+ZA1F6]$H!ALUZJ5[
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M=>&/SQ$B0FIG'C_4^JUDEQ[V?1N7UP1U$:@$,?#U_P"\- JE")]":KG-;X2
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M(\^=Z3$S2_\ ?U!? OV.-=,8*&&9+,?EQ3@9*E89S^/DF.582)KE+7J?^\O
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M!1"KY3&.&1# @@*KT?,Z#G<4]0!IH>(UF7#P$!UHY!,94Y,%?/%5 5$B9\%
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M<];.8&_L*FQZDR8^<<.ZWE;)&7\[.L7@.P0P<:4(++#3JG$9X'8@X!$8D/\
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MFBJM 0?T#Y3(4*.BLDGB./\ WB-RJ*$##;U^F^N(3!D*$1E8%XGO/%J$M$H
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MCV6 U<F<R3.C)ODY)029 (:KO7<XS\,$!! F%5)YMUPV6:^&#KNH9^37 U1
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M"-F(9"/5Q,[-<2AA818HV%";&3)6E\LBE):J9Q@\\#G,?Q&JBB:.VF0!I@B
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MFG5JY&[Z:$>7]Z'=I![BXC2U)-5T]C28+ O'S#D"&=%>4B %482!L$V@C'\
M$HRK.1#(C82/AQ1.?J\(%0R'FP2R"D0*#'T"9,2MH-^NQ"/^C".ICYOMQ-;I
M1/".242ZFZ_7P9_T!(J#.5@N!G-F-8F)E<'Q$3L 3$ C7NU2< 9A"8"LG?WF
MNIR])"6($E+)GSDQ#B&SX5(N_?QV3C"<P&E1]JNH_1PD%0.$GC&869^3K,@>
MX0S+7:#,I4EQF+ 8).LNAC8^J =3-EX>I$ZN;R+7%VP11!@CG]<<IIG&$B89
M2TIRA98E@#M-%19CR\=6=5 , "PS DZAD/OSS$,>&,)ZAG%*F%5K@=ABZOB:
M)=Z8"D2H5!#[879VM(R.$SL6C,VYEXLF5I#)GB;U=IE.4DYK=.8]W^QYD?;+
MAT0(BYIGQOAK3+(C4#++#!O6#$50DTP#!.\,B:WGCH*)<LN4*OJNJWB:?!6#
M*)T80WFN+3D7P6RQ%8*N&(]$0X  ! ('K_:;FTP*H=A^7](Y)E;S M85Z7UL
MFKRY8PHO1C\6#>)UP2$!W9+^.]9XTQ4XI,@DA4+AF8ZK8&8-8P4P$\."1X*5
M^$YA8\AQ$ZO!9A8J(L,T!@Z?C*% 3 TF2F#UPQ@"143RT79LVF^63-A9"72J
MJ/[<+G4-V8 (W$)+O@'DN !J,DUIN?9Q>V_*P'*E]+G/,\LS#)3#V0Y<B6J
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MHA>%CV'PQD,148'>O\H_O(/C)8Z<[.8-##L\ &6 5GRO$<[*AD%R%C]^<)4
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MX-]X;FY2>Y=P)A:$@?@3L$$P//\ %: ZR6D ?QL6'?/BM@0&P8(/^$-ND%Q
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MHF2D@%2*]0NL9Y;II*:4F3+5ATBV5.>$@7)*W-A\3AA04WFM8<J,V8\:X 0
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M ;GP_C7$D,B5-2IL5A,8D>+:X"9%#EK1S6W#W J6YQ8$%(],5:=IX"'7"+N
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M&*W'7.!JE-HU'+GDI:!T QAT09?63?&1G7L .2;>V)\0J+FLBT2K)UT9^@
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M"XK"QMH?[3,,N83)$J^,_P!0WDUZ!K..IV?FG#HS'*Z$R29_'>);(2Q. WK
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M"!]Y\[;CH>/"FTB>)9_?52;!(S"4$>QSDUQ+@@42/-BD$(C0C9P E)>7A$0
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MA%1CZG!9,KA&$UB!XGQ. F4QD.H4.0-N,UXT1\@:HQ0N<CC[H;#Q3DN(J1Z
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M]UV'010G^<59K8 2K0W"+(%&\VCY16.LVBO&J1ZAQ?I3DWQDN)S>BFAMGY'
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M"C!64#G\?)A)RL"6$F<7WALJ=/K EL>#;>U->U>.KB^:,+-F(%UW6R6,<HZ
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M]Z=*H@<83S X?18E07T8UZ"?*-%H(!. B@:"'G*,X$S(5"\@A\8QP%CT(CP
M!]'_ #]Q-D]9!SUOBK6HLL+$+;Z[%PBA0(1==@Q9F8^>$V*TD)1WNX(_#PM$
MGY!-R#G+@UB\6+V)0 5,YUJ?K'R1W@FI,$^W4<YX<F'4-466UP$ *G?,1[]H
MY@*QD)$#/(8CM5) <7!OQ>.[?8!,X*@HF"F73Q-Q1"<W4#0C*LVX,^^5!!JI
M$'('>+R#O6]>$F9"6?SYGMS*P ]>QR_%X7T'L$*8&"#>WXXCOF[X!=8G][X)
MEL>O46?^3E?Z5V :;O#'SW>&(]U+,[XR%,!<UG#:'ARE<%Q.L^>I9#AR%%UF
M5QV9/?PQI 6E;.?23O)MZBR.- R&5(13]N!T#  IDU$.S)F=O*Q+XXR6#P)(
MX9.N4#+?=)"]@VB]NQ40(\?U;\;U_B209)#!XN_Z<7F$M"*@"*5= @W3D[M*
M9#O8%_'*'AU9T 4 U@-:QQW/499%4.@YICYRM:(08NYK(YQT^#A)0[2:$=,5
MVC[]B0*LO>%F]>?%7&7C6$DV.5@BL%PTU3?'??;5,48,X%\W#BK48]P5R:8*
MR7/%(8P9IX*AN,?#DB<-)BHTR4ZQ\2>6K&\FE06#2#I9;P:T.'),3$% GNWB
MQ9!F->HB.2/>,X$^B=92++MBSL8XO8U.I>[&=V):Y\@)U0'!0&9& 2$-40,$
M@H4U %HMIGC3/+5:!V'6\>#3OD=@ 4E @J[2IEP^ W@5;M47!@66L>(/H0%H
M,C$&%[SWLXD>@A7 'Z4VM+S_ .-Z/\_^@FJ("BD@%_"1SOB4JB("T!$^-?NL
M#FJ0)WB83L<#UGD>,!)%CL4$:;"J<)FU^0*@05U[,B/? )58 I5A'Q[RGHHT
MP#0-D=XUP2' C1BF0$,29"\0 "7RQAFA4,>W#RV4Q\9,93-4RY-*>89JQEH%
M/%H+.$\/((1 $C&=8KYB 1UB"J""5!7![,\$M ^FX$$;HQ-T9QFF6D PLEWG
MUC'"+]2@J% J"AU*;,* &7%"(X%L DJG"O+!",+*.%N-1ZXHR)1*+052U[F6
M7@1(C",8$*8[?,R7E(@"M1_3>^]X>-M*+3-XSZRO<+EQ M& RD(@,A>[V'>'
M)  H4S,[QGIXD%= T,9>KU']..8 ,1VG830E'\N> ?I&[^7\4TPA!PL0<*PA
MG\3F=M"[&9GLRV7Q%X4!!91I1GT=>'CCVWL<16*LAJU<SDLD%MJ.56*V5<J7
MO^&S#[Q\<-&?PHW$:NF\PAXOJ1<F20N\?#=%,]H!@C<"UWZ>7Z* @#4?-D>O
M-9>)3,0+$+5=.+H8L57TKM:D9[1%ICA(*953G-]YO(8+7--@Y89<-^[R0A9*
M1;--$AL[KY$"3D"'G%1$B9P.E$X0"TPFFY+7!U@DXFS; 4!&NX93N*"8X>L/
MDF_ZF>Y>_P"&^6@)4VJK#7;:^2O)Z%%5(=-6_/UH.2DR1TI(BD,N9ETZX(,;
M6$!25'&O<,MX;F8.ZF 3RAWOQQLA[L(9*=ND<=+$X !H ? 0_P"A&"8 *; X
MG[;Y"]4/9X =/D9X,B!GG#PL7)ZR=/?!244MX(T(R;-XT3_RSF6M!UEU@,\D
M9&0I(ALN$I;=SBHHPIM!H;6F/4\\P6P*NP =*W!/)%)E8B@J",ES99[> A!+
M+N$E>5%/$X(,S 88*B>F?N#9(1#:"D3:0;T+$D/R=05>\TUP(O!B\A.1@A0A
MFUX,6HP/@:T'G-X1NIQ0<.9G.?/HC$X\(@D:@JH%09J.ARJ9S-045@SQV/0&
M2<, $43&(.CWN,X\B% "89-!CP2ZXZ,50%@(E4UG>[A\6[ Q!&Y%/I[G'IZ0
MN;ECJ5G!%VPIW#-&"OE)WP++,A(C"J/2P<W7"O91'F5)^O$>QOD,;F2)C-;Q
MOVLG+-O8#7R]\B0B<-D*4HBCNO"*8D6)C'H,!<\O(.2+L>SQ3^(E KR684F!
M7UD_?OD)FG'2$O856 30BA(#\ *@F=J^! ;S A\&=4C<<$M@CGH3.9!]AE.)
MT[!H.T1J=9M?7,/H]4@RY0%>I'>YP3:$/DF_Q7QXY@H,'_J_G\YX7+()9KIU
MWT_TY@4D<G"!!S_\EYHKPE(D]$(*Z*)Y?_FEG\G^(*^I41PX]G/8$#B#,&[0
M=]<^(94(P? ?C_H5"VC'PA+]7G9<'I5V9M%F,ZFG20Q$J()%QWGSYXM,6(VF
M6Q;,0RV8P\2F5DGH&CG-]?H/L<$3*9HB28MT^$'5N0 &@!LI+I-:@\3, % Q
M/X*FC@!6#YGGR9WCA:TU?(W,(AVZ[O,PD GU)M(Y7ZN;#[N(5Q 4MZ<]Z<AB
MLDCL"#)E8P'>+%_MR&"D LF4*;H8X0-E0U*MP.5[89TYY'V+2Q6P<Y)L^> I
M4"AB2?WEOWQ&C+H\=]$G1,X>5MD\1VF'Q,#C&8O%[7IR0B#ZV[ZYT[?Y3X.7
M\O7 @B",I!XP]8N7ZA++.U5-ID^>!7D  7*820'##3A!<SRMJG$ER$>:ICF(
MP!"H'1O(O+K1T#*,F1[.;OA)CDHU81TGH)G.%>;9"M!$)'/]C7D>WJ5?+?X6
M2P"JZ %_EQX=J811&L::>5V)>0#BPV%P3WPN5DZ,2I& 8W( (;"><-C$!N1_
M! **(B.D2(_)QC UG6MK"V"MX9[*R@IIN5=AJ\,Q89!0F#DNTWKWQJ/*4,NO
M7J?.IP^;5E<<('*LQO !$>+%\#QE4D#2='9>&J.!C+%<LLRW=F _Z.\CS4!E
M<E&K_P"O%YO>9/D+ASX,;X9=X=UN ++YROK8G3(0/H _PX!'");8S]/Y<<DK
M%X #D('A,+&;V(@@"@WV6;GK'?%-6$H.1.[VN=Z\3B)O5Y)T(6'7[O,SRD&#
M)2 &N_O>)P03E$89;7.O<\L>$]P@@+L3T,OF-0YC>N&CNC-S71+A5R#@0T,$
M *A30!&3@66J,2&-:B+<6&^)PJDQ1X"Q1 'HP\@A:I)?Q$)[XRC"4 @;CU_]
M.$=WT04+E$G,4F$+BN-W7OUK#*1)_M%"'HT_7)I0Y*F#9G],\G*/Z0,407-]
MT7A:R$@PM$S)V5BDVG16P=@638>S)V<$/I$$*GLU_9P&T!NPHGD^/KSRJLL=
MK8/CQPUM\M40+-$(0[NRA27Z(V)AQ@P>M\?QX8J(:1ZF/!@XB:*H0*[(U"J^
M.,E4PR(@WX3^( HH$1TB1'Y.)QLUC) * A[QN'">+8L+)9D&/6LS'%#+!I=_
M0+3+LQ@W: @AJH5?;_TRS:<Y"X3HOV>S@Y#2 \ *"9KF/26<6I*9AL]CE-SU
MCJY54.O[[_\ N\K>M&@@9,A3/4^*IZ*Y.@1C@0XR6PB4C6 B-@J;#,FX(<,H
M80'2L"OO^!#DRT@CPTGBH#@J@@HMP#S=N!2L& W'FX/J&U7B;!Y_7[G?-B&<
MV+K"9S,\O&B=B,A6[U.(QPDUWJ)B]3KA;F*JN2RJ8_/V*"=00XN9=5^'?,9"
M04802 7PW=B#&9* (D/DJX=W'&5):)"=;HB8*0>9]9X9 A6(AM?'"8Z*099!
ME2?7% M1#4FZ#C-:NS'&CT<4%']L_&J-C-BC>'\]8\\(*DE.HYGLR3RWE\B7
M.F+.?Z'^ =4M@#\B(\8M#@QN<G27'CK_ *;98!$A&@X-)^U.(45K"A4) #TS
MYR\(&  # G(CL:#<&VSR6NGI%>\>?'+[A.Z:*#D:?>73P14? !"$Q@K[SP P
M$/!_@4"Y06A$%&4?#Q\AK#$2GMD4;8YX%B(ETT"-*IVX3I(*(H1&Y*>?DY H
MQ&([1'1\N/?&YM$!!< L3Q^>%:Q<%F2QIJ>#P<@2)6X=*8VE8]&>7X2&T)A
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MO%@+/7H%3@@'?=O*--^P(<"K,;S9U5X8LXI0UL29N-QX)]^N3<"C( T3@TR
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MH\$+A@!(U;"W3WU>&RBU&JKJ)K+B7OA/T"#0@SK6NW&^!B$4" "SO0?'L.(
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MU$N77_FIZXY(,!I'(_XWFCZ!&EI@>S><GQ!RDZ*NG<_7/[$%?RS^O]GWQ2$
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M6*H)">O.!_''Z5(4R%-UA1?/'-K*E!H9$C,K_1HI%.\(B@N@F^N$#(QT(&\
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M(H@.,UZ5))LV"'_>$H+\[F.%47PR)E9IPBIKA?P[,U4D_P 9;"B.Y1&[V1U
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M,M'6_/)4P H*)G5NWX9R58BY!@#!<'>_Y<:J 4L"C!%*_7!XN9(4R2[F/[O
M*6($-$B2X7\+R0)W4 E M>^\><7Q&9ABY%'Q[^N*); 4H%<;;>_Z\LA8:$2-
M[A([^)R*X @*LMBK9O3Q2^Y5]']YT?/%KJKEI 4CO\G!AO$H2O N0ZV9R
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M(DYYHN\/"FZ^AI?:!].<-%]W.=(-^)^O'M+O$5J=PKK&'-7#R$2=B'U7X_\
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M(/#$A!F9+_Q 7+;J"E'IZQ^O'Z67'2FJLLD8?KRA8CM"WMP--.VXSBS: @&
MBMS2X[%6^$, [!YOZLX_L"$H+!/?K'>N XW+R<* %2X<=W@]^68*B**$KWW>
M/$ -M"=@>N^UYU_'HL@CYQG1^=4?!'J\ ]_M]F9AR56'K?\ ?X(XH]*,_>3'
MSKEI0FH@-F;\QUPS46Y[AMP.FZGC@8*K:!":PG7Z[XY4&2S$(+@5OC/)0]E;
M -P9N_OY;'H_7Q_YWYY1J'CKNVZ]_IP0(15.A?KO?XZ7U2<OX0G[%_/!,Q5
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MN=N]YSPP)E&<TF0V1PC^JPN@VT: E>__ )_L!\E')LZG7I^9'+J ,6'I!-@
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MRQ$[T%Q4P&1%AX=_)> TL0*-#,'1 ML<\2BH9PZRQ(M/GC"SN 9/ $[;3[T
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M&.Y+>,0%N1B1]NYDS,Y#KY+8<9S+?1P!.H,*. L_\UR^ NQZJU9T7?:ZR\3
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M3ZN,)09BN'_YM^9:$W3:CYV2]IM^S@!,5EQ%MQUCE^$,Q) =JYG?A=0,ZSJ
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M/U8""J8%%MU'J<4<-#*0%#SB?/ T+ B4"_WZQ_!@0: :E0R=SF1[V1:ON?\
MW@Z!H*+&/B_S/_;)AG*#\C_,XMM[[X*"".GKB)B#5E'$P)W\9OGF'JO(V11E
MOE<ZG,'R?Y%! QL_3QP8O9:FB/H)9>_-XT$Y4A020S+C;]\68T'0 7ZQE.@U
MPJA(!&6%S]_]1FF21*9H,S1!]_'+M3]4,B<]&S@F!%84RZ.$X(2:"N60@58^
M;UPXTL !J4V;7A/C[2*G=%F;J^F11 5F*'FKB2YN,<=TD5H(F@ CXT3A,S2
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MC=0K"Y,G64C;*==0DITX>L#@X1PTB)L$I^,<IT2H+N (0LS?C@*5I680=E8
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M;/S*Y!*9[/3&O!-4;@>IO.,!;]9QF$OOI2X_FRIFW<500H%%)*H1*R>L#L
MG\>^[-$>;7DT.V2^",8<VZ2C2',6-NHGE9)PKO:(DC/$N#TDHZW %9R M-_
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M02>(^!_8E?\ ]490?7LE_]E02P,$%     @ W(!<5%V& S>J^@  /T<! !0
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M5P_=^_U%1:]D^"?03R$_A?P4\E/(3R$_A?P4\E]+R!_)KK$-.L-U1:>RJ$E
M"L##P<'%P<;#Q<&]@H=W!9^$ )UCX),37[]&0DE.345)3GF3AI[Y%@W=';J;
ME+<Y;]]AN<?&SD;-P,7+Q<K#S,K&^F,3#+PK5_"OXI,1$)"QTE+2LOZ'"=4
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MM8*P=^L3"JB6UQ\L<RXD6I>X7:[!G\"R$TGTW)ZUZ^BE),CW"TQ_T\"=ECB
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M?BK@VH,S=01;"8%_,BLBE,U5J-CMNX%U;P(,,L92> O]4L#0T>03NJ#[]DM
MB-N$'9%$(\_T]PIVMRQ00#<,=" $+<^!LB' W<<;;!W0>:XQZ!HC\^4!#!VT
M[ISO7F(;H1U7'<&";"M$=.VC Q1R(A51B/8VWK&<?U-"^@4U[)"K'>%_81%T
M &M&].FEU08A22]=D7[H"HKM1[30+T !_3(J%\OH./>;.L3;7T#HK8@/Q3V"
M#T!PQ>/9\RN=Z'JB\!=?]T&'.$ET&1'S(T@5YZ( '@2T _S/ O!K2>PN^.>-
M[^&]<VYH#4R]JZ(?\Y<X?/[+X?CO;X@"Z##H-.XL^,#VSXH]$WSGW*8CD'H+
MM(/6\C)4_RQN$2EY629UIC^/-"T<T)/ZEYK_6<D3?NB*?O@9WLD(\3(TZ"RY
M3MJ=^,^*LZDW2S"-[-;*FUN[>AP\W'*]!Y@N,Q>=Y'Q^/_J:=BHV_A@%W%Y?
M.;)0DI3>V!Y"],FG!;.UBT?\1>V)R68+/U7)5'RJ#6VO]F;5 M"5[+_:?OW*
M=_CY\3MD-7[L/]XU84L49>]9F-XS8,P&1P4KZ6J8CT_-B]'-<5R#ZRNEJ/4;
M7D#?7VM:X:UQ49EY?BEMYA8NY:^ZKQZ45CT4,/+ZG@/3<XJUH27=JBT1^Z."
M@N"LG1T%-5DJ\U1F?X0V;;7$!Y#B"-B5*QIWM32ZN(/JH,_.#2^93;:==7;O
MG5B#C:+E&^8(:%%4KN 2!CC Z45G6MC"S4 C8MI@U9% *:Q&LK*O!_1QW,<]
MO#K#)H%*Q"W0<6Y6@Z&M>^ /W@[MP>VO^N9MKV^23IF[5K_VB PSVV'?1C1U
M7V=CQ#AUI\+>/Z2WS"TNU2:X8LT8)4]*=B7_7M=+I\[==G+#T'+"4VXQQJPI
M<PFRTM):2=H-NHG[#HQ3R^6FDT*(>\E$I6Y>)-D3L]I?[[_*B^C^(*Z"HV3[
M5-9.:/*2PO,=AVJI)Z@H,X-4VWQ/FC+(\7YW% MEHVUU]O?D8\^F\ER<F;03
MBN<:ZU'N>H](F_KGFY*V2%XQ@KF$EOR\^^2?ZDJ>Y KG(\9O'3[)_DB"$<=(
M1847ST_8#<*^9\UZO@;]4C-<8!ITV7P+0 HQ[Q>$I965!7[KI='6:+%K\A/J
M=U+% EZ4(OR[?_^ DF&6B(/N'<U9X&)*)5OAK\4CW]6T";!;RFE_OKFAQ1-8
M24R!XVCS8*&M12$D'.TDUN8H 'R(SKTPP^%JHRGH'OARCZWX, T%)+]%9TWX
M8FNPU33H[,,*Y& +>G+)$068&H"C#X5V_^!G^;N-:D B7&=K:(GIO>^0'LR7
M1RR_+@6-?U=90O2*(LG+LA$HH _M<&CWT=:"]J%'IPT%[;_Q_R$=7%H,[D/[
MD\N-,S!OV']$W_!M=I5#M.<FO4:J="_"_A"3_F?Q6UZ_L?^F\X7B#?1D!/2_
M!L@/,"+K:P4PVX3E]CW\[=^PI<FG73R"U2J_0_P]S"5TJ?'?$^=_LC$56&&E
M]OI]9\07@E<1*1];T857>>F/_]H$7>#XRB+8+%70O10DG'SBJ>Q)&-O9CYNG
MIPG*O&(/W<O/!Z\BH1=SS^_ '<UI/0,0[1$2<\<%,W_Z='>@%?KCP"I_')C4
MOW9@@\'@7W3 .['Y<3[O_D[#_'4]W/+!,CE;2&VLS.LH\O<OET@N+3^G96D@
M'J<MK*8?T3H@^(PR*2WJ'@:S%#!6_N4E,(D4'UI_-JPVN[^3HO 7E\!_J/"(
M/,6V?D71#IP/#MV5C9IY%"Q%%I+!_@JK:-'?O[&5N6AT-7Y"AZ.;^4*]M3HV
M>N'958'3YY0,\CPN.:%QD&SECQV[VB);@F/(.WNC":XYNEI4VZN6A5N;<6]$
MO]R;"S$R%>K(5A$,SAZ<51A&\%M^ENM<YI^O"9%DIISID)G??"41@]/[+F]M
M3.]F;%/KL7^FEB+V,K-<)_N73Z%+]HV(+S&P0G31!RBC@+&.TI<U>]EO^$K?
MO:BO'SJ^%UI:K/_8Q"S%W-@8T@&ZAPW2FMJGR#F7\'5TQP]*>B#WXLB<,D 2
M_?J1:))H64HPC.5Q\8?R\^5R\$^8S5D&Q,MGLI7>J @ ;DPECA322#$ED\=K
MO*\JBV5+^V3*1AN\?8ZEF 4;1!80>(.S+S6^%Y5[BDL0N)M&+<CUX\7*=(FZ
MHH.Y:?M-K2.*U*-UQI*BM_,\O7E>XXH*N<7VIS)$\KM#HZ7.*<3,;^)G5L0=
MU8LD0=_X-F'WC/ B5/#N)BV$"JR@@&9B8Z-\L1DC;%P[ IR8JTR)1*_BO6TN
M@I1P]LGS1P8;I!'E6E:WEFH%\IK< 1#KYR=R5+WVG7/X*UO\ENM>-PL4L_6F
MIIIM'2!EL9#J%:%ZW>6@&6SCCBE!"/G0)E?>I*Z6KCD)Q]+5*ANK"E:^5XN6
M;()4.O17 7_56O%L_;OY7RRIWQ.8<GZ"$%@4T+85?P9*B AH3]: I4%=R2,>
M#GYSB@GDD!PL:H/@78R_<G4LA+,?@JM.U!+[XBQ,7FP_>61HDC\Y.^V#T[;L
M]O4S$Q)'G-X3[&NF;F#/>L?XCI%2T6V+6<TH58WL6-S28IF7#\+]6B(3;0W\
MMV[.Y)NIQ7%OB(2ENYI>IM!]:\FUZ7T=&BP)*8I9%=H<D!T,'4TMZ4]IUDJL
MSGH3I0O9?M)Q<DI)B2OW/1?43H6PU*J:Q6Y3?F?O(4F0HZ_B2@F><A5560#
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M]NS Q8 V(OCSXY42-9&1QV3J1S<JR6W*8PV%PD]A49>#FI"]#R!P0_2!P!5
M#:SR.VRA!MKV<;8\-A.!JBMM$@SU5X;)G]2MF:C9^>4X)>Q]6(<<#B-ASG7
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M6C'AQ)E6\P(S(QKPELG,W(/:[R_LM^/*Q(*7/YK7C;FYS7S5968(4;)=<C4
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MM_W#Y\R/NZT7VX&;@8PQ.B%7 *&*^D8?%P!N8]7MYKWNE,I7_%JO(LJ#)IS
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MR&R6?6H;:_"-:ROSRY:LN.?)(L?!D[KK/06*H!7T3CX^*R\_X.M5U#I*-?,
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M8>!,^DH'D1?MR_NG-VY:#SIO,/Q93;$KY0J@,?M2]_//&Q89_<4+7):)'5<
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M?CI]_MY2^!W)ACR$5R\EK@"ND(]_;XS\GZ^/AKSN<)!T9T@D6@^2.SQP&5D
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M,5Z*-8:?2EHB_[P &80SG?L;7:>H26QM?-F%K5RS6X4(AU-'J-QJJ-:!"A;
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MQM4)(.!+"Q(ZTX&&HA"SQ]3%CDKGX^')>B.KCYS3-D:5LL$3W24E@>1/2PN
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MO$V"/D0S8/Z+%Q%4T9OJ)QW YRFZUSY6G(#$N#$R<)8!ZS\S0%(P/D',9I"
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M0/,V(6QQJ(0V;,I1YU3SF[KS"PD60)"+LE1 1YG0;XP$QQ).%5^OE9PUQY>
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M[1UANU=S!WY-O/LF]#'O/6Z,B52WKA^1*0"I,%$$05A./VM>^UI&%+CX!D:
MG>B32TUXXJQ9DKJ/P3<%?$F')C0I<$9B0WHL*5\]OXAOZ S]"!WU5KIDP_<M
M'OZ4[F2.!F?QC+;9WL2SI? 6YWW/VT_+:O<^ -Q_SL$9BB*.O/0]7]@MG-N?
MWB5T)=!K/BFL6CD)PN0QX[B1K)IIAA\SMB&GPH;SX62=R I$ ^.@:]]O)1S4
M0#[,@$%7XW]1$/M_0N#/07* I;NGAGNDCZ%%9C6**C01DVX<$EE,O:>*3AQK
M"U(Q;YE>'S$ZT>'*CEH:V/W ]S96"#M*N<GP!M+6^3WPX>('T/'MQGH6"XX2
M[_I*J$Y3-IE_H%1YF5C@A?V#:R/3SY:B2 'P<18M(SMQG+0WH?D^29B;[#M=
M$I/O5SFODFLL_1RYB4_PMA U/3L8):]'^>^W7XI-S]>#Q*T*[+3?/$\+)!GC
MS:+?&AO*EZ/;=V42^+%3(?_@#H#DFFY^H@!TIJ4<R]?J_:DC^%SOWF[F_^O)
MW/]?!4<VM!C\:>?2X Y@U=CR5])&\Y=1SY8ZCTS8,V:N $[(>"L'V&%ONHX!
M&8R>&SHDB[P=\\F[<NE)OLR"9[(?V1DW,?IR9AW^ RV6YNCM3F//@U3?B&A!
M$[5B$\<$S>*WD(@_)8ZA)K"-6W)D9?CY'8#<_TU&MS%K1N  E/]QQ6'BG. )
M,PL>,X<86PC?=%'&$CP9G'857_3/G8#]YR[_4><IJ,1#]E:7MW5)$2@@1Z.L
MQX\WZENH/;1V2_R$#LOY7VM!.<OM?FHNN0D$81VX\W@>4X&&.MM(*O&BEC4;
M&J<WJM.5R]>MD]Y[G6QYX &?/#T*&/>A>ZA3FZX&;=TNPI#H6#11+JO=/KL#
M<%X'](UY&$2BYWM;7XT+10G%$Z/+_LHKUTPQ31QS68U;*C,EN^'&;7F?4D4Z
M;@DQTDN;&OBA9+I]X\.;&7_9U70Y^_GY/(PU,"!HE+#B=#HUI"<>&Y6TI1I5
M-6C6-3-KXPRXE)]3EX[^YW)%@>K<9G!W(",J(D3RZ=J+$O30NZES KS:))IB
MI[SH/?(D/0.R^:#WKZCF%I*3=SBV8YN5*A9 ^_K(HP@H+/;5ZBO>/SWX$DJB
M:5C!O0=?5]R#,]<%1>Q.>64Z3(M[X#?>:N=2.M&K@40])4K(',4,@RD:G:2U
M1=NHI2?A[+.RI$G25[28ON1LX(A@/*W_FY@.8UX(;[.V;;&12DD,31S-7VE!
M^Y1"NTN?F-%O6#CL@ \/W$?V-R\; F3H9/B?7HK= : 9F,0S(@/([8C)5?G'
MIN"C%04?I^DWG^),)-1XM8B)'^]'HQ9M>[*%)]E0D)9<=&J7TD0SFP>2B E(
M_G7I4=#'<>4^-[R=)M^+#JI7/NMFZAF]OEN9B;N7?&CC(2TXZSBO\"LZNJK?
M!KR0CBCL*JKRA?+DVSJG@ N.N?E-=/X=0&!NIY(:/B7]0G9-2N#=E+^>$R^&
M)?UE3S<3D=#3O\(><<\I-KZ_-D%#2"2).=U7^/=&D:6]I\93&Y/IJ(WT%URR
MY@#3(YVKWU^J;!86,#.'QFXMSC<.B!V;_.SEZ:C;(OLR4%'7-2&JJP+8^#F#
M*Z:!N;D90NF:^0F7F0F&C:LU^&^GU36#5X\CF@768HZIS$%M&A/G4JY")>M-
MSU L\4[XJ"=:LS,9LAUT+C[K$'#G[0O$!V1KV*K%H[V!(A.'],.;BHQR4SD>
M_S)1E4_X%2X]D/>V5>O59#"U)I6;BSN S&]X7J!Z9>,=8/.*X<V8.<$Z*PHZ
MW!;.Q=#GQ;^HL&9QL%M16T_:)2WR]I(46<9$(1:3LJGAQJEFB!*!\!YAS$IV
M;CFJQAV;&9>,)@JJ5-11$*F#\6J)/&*W/.?5$'ZU,HOKNO1;SNN6&(F3\W]6
M$+'=&-^V"Q$(E-!)FK4[OS5WK3O%^\8\(G(XXK4=>S9L6$GL!P7WW $HSOY6
M$@.?H#^>ZB!CG_%R3<>X,V'S?8R,?2.9K3*"Y]#;@FY:Y[P#D* =NC224$*<
M>1YP[VOAI+23A2N2*D&7:KVY99_(W=[7HC]WKLRO;XDJ_TA>VZ/S1W.+*TGO
M %^ZUBA_D037SAQ]0BZ5E*L$./N\/$K]^?WC&QWGE[?[5EMSQ O9Z]'G,2V<
MVHW(H@O;BX4_R[6/R=/SM7+[38*.RB[U,C*MCI+[5)T$*^@J$9@#\]I)1QBV
M:%4SO%%XO/;I%7_9E0YQ\8SDZ_Y^R:GHD]%@2M)=7Z48+D:?3Y#Y;K@VY^^_
M62'E5EQ^R1!U7[PHP7DSVR[JU*QBLR%;>T]'E*;KTU)!U\3P%]^>B(ZRZ.0T
MT50,W.RMPYLGCIV[ U/6B&C,GM*1Z%=/?L'A:K-J4&FN\<6=TQ"GK[5OO(TO
M'W:EC"\S7!YPZ/A,-KWY\G5R8CB^QD3'_@ZPN[S63S<77=8KC3LA4WUF8D&L
M660_WIW]/CV9_67%]S?/_];KR_#MN?ZQ P$5QCV6J4'T) 0]1-%[V90YAR>S
M#_43O=[JZ*\3S@]<?:.WOP9;/,7DH:_(%MO^V?2>L^)[F!8IZ*2I55\U ?.C
M:1K24>AI?O:*)6%EY4C+K1DUZEN5=N'F0&;X<H'(A_RC"G=W4'^D"E;T.2#!
M):"L3Y)HE9OLM,_8Z3*8^V%=S&HD#S?+]&#E][(%\4/&%.S?[S?2)"E7013@
MU:.06WKTXEJ,29SJOEYCLAHL>^OD,/SJDXUC AY^\P?V%0">@[$Y9\L=P."*
MMYMN"@.]!G_?_ZHC[)55OP@1V#?G6\TA0V]-]"7:M\I,'PLB6OD5G&U90TEK
M?&A>DA'4;[!488NZ_GGBTU$PW35K>A'-N9U#!#3G1BZ'>'*;G_;HF-6V<D%Z
M+<3'I09Q5EG=^MB(ZVG 03R43;R4_O)3'B1DH"DNV^@MNJ?R(5L$!G&J?2X'
M[:G,A(KX9 (3$X*9*94W_I++R0_+@-?+::=2_.IR(S1H+INF$(FF,)OPQ8('
M*G(W:V69"?P"D.]E%*O:1B"8-#M(G\ZVYZ*QYV8Z#BR4M4&IW3G]&\4JK?W5
MH_^A8?'H</;,$E*IF\BBUYP1>9%!\0>B1B1MWZP80_UI@=.'DVI]XV5*#C:M
M%<S>*<WBI&W325FG95GS5.56Y,^Y+V<0.JQB?W?-F1BMVT5=T!KE"J5:/!=;
M,8H%DH7/),('?\\>SU"O5=PR@J;GU<0EQ6$%O=5%Z)IYQ0 ]IV<#S1 %-A(&
MA0\NSU_@6 $@,+[+6HOIDD#'\67$0-L _:X"J'9)&)46<G8'H)_;3Z^E?]'T
M!PK]S%4QG-01+\,9_G;=(=LWN6.[JBJ;#17Q!:-G7;2_Q )#L<C,B*3GQ?B)
MKO@8 =CS>4 K8=:]!YD0?EW[^^0W$;DF23G\IT(LZ$=D\*OMUZ2EO<??>IX\
M%6IA$ LQQ>3JU\0%^D>'YF*YH*;>.1\D.-*SC<QPWQ@<?92TL$LY_8IA!O-'
MV6X#S_V@E\;+M5],<LI/\RDH2U"=>K[+.]4X8*1H;7Z>RN* U"=0RUZ,_:=;
M%\VO!$.(RD"I?='G)O^CE#9RA:G*TRNC.T#BT3VQ+X".>Z6ID45Q7#!NFPG=
MJ=H Q>F1>;WT*<:W)D$Y$KF8/)N#R^T*)8H_("L]E$T.RE.2;8V73+;"I.\'
M;%^-XJO7P0E59\A@0P>^R^LWS'A46YD&PLO3F<L)%O>NP&3^5$H\FKWD^;^H
M/?R?C_?G3OI#<F-','5]9Z:1<0&N\0.;F;R2SA#-E7^TFHB_U/0YT$Q #867
MX^/-'OV\M<>E:283*S46"YU.6=%/'WUP_&]G/(9-!Q* L+NIIT:@93L,=JV-
M8'[[P%GQ8V=3SB!Q+XI%@Z$E9FEL&*HM[ACCL[+H;G0",RLI-BP/60)8O2%=
M4(U^7GU$HJT];%]Q ?ZI/W%]*K5OCG9>)7EJM'N1/A+F)-3ZO2=3I?'E%]>3
MH"_^S21?47VJ(:>KMJ&\&.'TAR.1$:J0PTIFF,JF D1_1#7EPWO_ODT<]E'5
M4\[X2.,[0.=H^-*3,2&QVAU81K^U5],4-3"2>T5_\,5K7%NG\M)'*Q]AK.B!
M2@O_UQ/^"C_MZ^B!"T/.Q<OJ1+^GO7(95=(<':P?89XH7[F'9L/RRRL_Q]_K
M3OYGFOMY-SQ>(F \_X<!I8M[!N9T8<<\2.MOFAR9(45NJZV*@[$U*]EN/F)[
M0G'/-%"X\:X%0/W$)<.%P@'+Y#R22BTE+27&$\[A0G3:FHH_YZI:UA.0N\$D
M;.C4EMEXE'=6J?\W#1=VKR*6]0?E#CKE8H:UOBC!##IW981'@+@SQ2["J\YK
MWYHS1BW\GLS?SX*_82W0VLY+$HD<W=-\\*V=*]@>W 76EZ#C774..7,FWJ.F
MS_HA2Y]3 NY;T#AF5H-\]_K81:=(@L?R(7-L]3ALB0@)'5JPHZ;U2FKY-2?Q
M.#\ )?#9VNFWMSM$4Q1@2VOP6OH%&BX; %9"Q:7&W<"M<P?*#8<+OQO/O3>M
MZ#-X$4PHI2A[&)L*\EMCB+-&R80SHGB2\WJ*0+F#*@?C@RKO4.)R-:0OP&EX
M;$'$_&*B&U/[FVA@T<J?<[7K$V^,KL0H 5I>'FF>=&T;[AB7DC=HPT>5G[;-
M^,#M0'E'=-?4(B@0?T>:KFK<V5\V?\8,':_I\]S\S9%6,F>-\$30;VQ" 1Y9
M;+Q@HZ5':.@:G6TOV6[KJWO:!ZO-DR>U)NQ[X^8! #7Q2S\@NK6?OC S'JT0
MZFN&RMC1Y)"!MC4FCM*4_^*62<@2%=0L$ S)C_2F?/<OPGO^@@2%/1/MVI14
M=WR++^><2B355GDJQ6R"-EC)(45'"2T"NRXNC:-36'5&<N5:1'*K#,ZN@OL!
M]*)0SF-<.^K8QORT=% B#/C^5TMW1:LC9U994-=G$7H#W.K;%^@R,^3&$@,,
M.9R2LKE461P0;[W/GQM*(WPX".J@DJ0->D/%U$!P'&N\'>XOLQ8I:52XNXQ,
MV-&9[X5^.@F 6-02]F(VV[63NDIZ<05Z?84^Q]SB7:5 [P"5^S]W1U>A+\_5
M);3]WBW:NTBUY&=;W1Z) /C711W#:!,T*?#",%0_0/Q+>\M=P@]Z.4N:KQ)4
MCZA0L7&_7?LL@\V5BC"^4SP8@C6_F=X8<.E.=8>@[DR/2UTR2](7#AVS)%QS
MGQTW*2+?X[!-%,NUQ/ :^FSF\T9"K;9]KUQU]YNY"HND]<P$P%F9]Z^T\X4O
M*:W@I#L ,V?W\F,,Z3J1P5^U;G$<$9$,N=H!KH1?P1/>J4/UZ[&9F:[&U*/!
M_GQK)$1=/QP:A6H;31^^$^XGE"-K$29GK'3MH,*!?$$,B:M7?F%HKZMBP 46
M]5S'CG<4[IM;R=J_'$CY8LUBG\+?QB[#JXU&_ "==GG[(GK4I8=TD"XHZ 8]
M==#"FT;XS /EEQ_&G?L71Q2E3E6G+_WO (KW_^R]:6URF^:IVO69U$?GL$#\
MG$X^T$=U7(8#D,WI^*)UHN;WT1%3X1,7UR1?UW?3TD]!#!;3C%.>8!)9=Y\'
MN5QQ+$&BFDTM\EAL )),VN#01/, Z9B;K-4V?)!4LXSKRK!,-_7ODN*9CE*:
M)%3DP.SVQHH*3%;+]P%GQ7@@C9TTWB3,J)D[P-W*R;6P+2,WH" _*B-G>77
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M@NS/)A9,FP*W#*Z8XKC]'<#X)/V6#QV "UL%/S6VDU: %%66"O7T=/J,#>X
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M0X3WGWU[1B,.X&M_CD<U[/2T5[PS/B)-/ LQYX11^6#9A,MB:N8C]S[A":Y
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MNG@OUVRXTZA_HH_TYP4K&HEML<.E%OUH^WDDAJ*M4DK!^NJ69YL41=,5R(Z
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M2JMGCH]]P5K,HJ7B'F"M&3TF\%K_Q?8SXK80V:-&0:7EU7FD(_JAO'H-(>^
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M]74;"Q\0C"8P<6.%"&GT_3R.M'].\LV<6XL_["A_2F=9G_7:[$UN9&:#DRQ
M=$^_+RVBU=/[9*>;84$W,&H3OZ1AO1 %YN35>!9K2I3$1.[(426ZYFRX_":X
ME84K=_X4923CVY\\)DQ8TFO.G7FT#'U?.^8SAU"1">3N$KSYN5*YO'B[/ YH
MKT:F9EFMR>.0=L$9$"VI4!62_0X8$_W'V]/N7$3_(8"/T!85VH/AFFA]MY%
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MZ.U2[Z@TAO!A TE?I^[BXWQ31L<OW@,ZC2##<4WSCBCN!UAB^BO^'@D2N <
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M]I7K-<X:UR9H)JN,9@V=I5C$,=O'(E9GB"+PBGQ&4YH:IA&(10?3*%7$7N<
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MY)?\ORVBPJ*B,L(_?CE$1&4D;LB(BO^[]W!9"& &> -/<7\Y $7 !K#"U1V
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M][L+I!U270?L:<YL[$-"N3M'D0OU@[#&\N27.OR17(U5D$I2,K<5XJQ]4[[
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M/X9E_]NH[(]WY37"=K]G&. :8W!Q+A<:C0).X;%K[C1H+MQ2":SMX!Z*R#
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MZ'Q5E8%1^?3W/5>RK^E$2>D"4V?>;.A#6]!R!/2H,7.C%PIG^/'NS@0?"UR
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M$=#>KJDOWYJ^*<[-JUBF_^GRZ]=2_KT#Y4<SZ/)$P((K])\N"SU517:C5BP
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M<%21(7S0 ;D Q9Y/NL&\ & P HK!T,P=WR*T2O1YA@^& :#Z%'":NA4AFS\
M_RJ/E^BA> 3RZ00_;0.<(?B4=*M\^3_7IOR_-7G.06WC!8!HS@"BW2'*A?XF
MXQ#R#^$@T[<!]V_Q2]+^6N^N?@$NADAZ]8/G)\ ^3<"[.R#AQ^A?@,,%; L>
MYP+5C#D"21X'Q9B&8A\6(W'+[(1# 6\M3J+)$>@EV7^2@##L_7FAA04>;6K_
M4O@?W>N_L27U\9"/%3V5%/9;5WD>2G8@?Q.K]X\JAO\T&G](*Y43=03B![S4
M@/^?C>E_AX ?.Z<IHIRAQ8T8L\*,/VHH 3<</(L6NB!%+XJC >SZ_XB^OO]L
MWK<,-L>8*$I,E(W27.[&#C5J]._J&:AT'++>=7>;B&K6G\4];=N[TYM&_E#
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MM&^/N?:*L9\L4(5.I_$S7GAP6 %A'M2B^WRC#])US]64+?JZXHK*P[;_X)M
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M==R^(M0OZ0DV@3H5GE[KFL:3,$\7SYH9Z7[-2F)'TMX@RB[Q]I96(%>5,5W
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M<:K][Z)?;+:06# '[&P.#NK6E0%-_CNKQSH^+,/K$H+)W5FH^"\RY+X85N9
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MS1;T9K&6<U1^UNF3G[1=1U;NOB?]BOO]6@&0;5ODR,0A=_#0.1FUMF772Q#
M2D)GZ;.]?OCZP*/%+&&24CGO8:LF4X/Z?]?4!''J.6$^'$"7N*:<!/RY&8KP
M(/=]QNZWBOK8F\VJ,V;F-MK^;;^O"=*FQ#_)430-YO-K$\9[(RZ*$XB:0%OD
M?O#()8!/$7MW=W@OA7WX\522!]X=<Z!-8"DX^S,H4UG)8S>^Q7Y=.G:Q/;9Z
M,?X*[OESLAV+76HV+@&%\/W[$8.90:K"\)[>1\M[";)G.>%8S]1:$,Y09P+\
MNJYQXD<CR)3%];;"*Y;]6U3\2Q$KQ8JL?'=)7BZEOIH'71F:G^D_8^VCJ?-K
MTXR:/F(>MV?5L]U8Q0$2Y88U]6<#9=$2@;)8&@8F(N; M&4:J/=#__@'.]"0
MQVB!"^)TY!2J2<6]3B[$GY]K]K8?+\X&7X&7[&.#YIW3<X.TS"=QBP_\-[(,
MQ[?73IO)K/<PPQAX,G+%(YEH[(4]1T1;RG+.GSE-)RY4&$9A[#Q=&^.L%GXG
M0)S"Y@F6S5+]+BZ"XUF"CA91/"']",5&O#AR^<*C.U@ ?Q+M#,1.Y?D-??)_
M8ZZ=?NUQ54%6/;7<*X#'L%L&SI/]B&DY2$'USJ_!4B[MZ<.0Q^,[7.1=*O-#
M;)[PSOA6\CGNRJ/V@:8ZB^7P7!+?'[P$GV]O3\Y3XI.R[1J(PG->YK8DHQDC
MR,V=ES4EIGRJ M??QM+R?>4-RRG'&G0'^;3[\&I^(7/5A4Y/R\R5S2LAV>('
MM.]J7!,+@?5L7B\5](BO:B7>+1E9;D;1FA+W]^<Z#1ZE3>C)W$4E]J@1(;*4
M2<$G@_O[ZKCA' 3>&7O>U32<5T3\M?'J%[K2:-&P[G_6 *O^PF4;^,7R4PGW
MP<@KU1J'2T#['.)PH*FM#9[Q=ZU%"PMG(Z;TH&CK>*C.9:87WR(#F@-T2^UL
MF/RT_AQX+SVF_C_^H\29TIO+_3]X(T:O"1C0!47/[O5Q.J4;2%]TE%KL?8W1
MHE:,O_'U0UC[IL6+C0[=X[' >ZQ)V*()+P.:Y_CVX";_@5_EXA-?OT51 3Q2
M%N._#DRJ7)_'F&PWO4/%[@)K+<PV$2^B)K!6-6E&\_L;@=&/71LMY_$>QB]U
M?[D<@ LO 94Z"Z+'8 2)8E(Z^PU,MN.DJ3+U2_H$:+:URR@I-\..IH'_MU).
M-IV?2\=>3,9)[-$V"/::).T!]6'*;K+9HQLJB,ZK[Z?=X50/BQN+^$_+G,*R
MTJ>(:X'20A)4'D5;O\[D87\OXKFB6RL[X]OX?,2*)?P'27#R.Z$H!<O XMMS
M)61Q7%I6B.+>&_D"%$/?=/S4;F3)OO'(T;Z/5&Q;Q%\"T%M "U75[;,+2E/2
MJVEGE3N^Z=T&,"N)VLSRK^]C-<F&U']OSE]IGE\[RU"<;G?Z)8 S8Z_#*,-P
M*[V-I39-:](F";A\LY,O51*7$V(?NYHC/]U*Y"H9*MYNDHZ,=]YI42V?U_'T
M7/L9-_"R&_1-9[X_]3S?6<MP,IMK\=-L"4&*\PKC2+8R<26@S3N;;BW^@1Z/
MJ#77;;WOA5V;B.7FSK*J"9_*W&DC&^6N?-!1K&VY!!P6H)<],J9: H0_DYXN
M]TLO,/[9JE=Y'/:J-3P'+,XQFHOI>C=YTD=KXA\V74[L/(YH&FOY4#H# ?\M
MM2_0?Y\V>^&L-W3PZ)14'$<+6= \F+3!N[W9;J-J&@5WJ#"-54C#[ @D=59D
M&10&K:>$#:T_;5@&Q8:/O'+7X=B6Y@M7*"8)*A1NA)-<X,L7BF99YHXR1L=]
MN_MPKA=/[OT04PS1]UM]3P-ZT(QJ&R-)!.<*:,%0Y9;@PJ@ZU:BV>^A ]<)_
M5P11V]O8/&YHG+%M*DF='TY\VP67V=>^!-"O9!##RDDO&I%XOESKHG_H$\XR
M+>4LI#A!Q[W@"W"MFI(I;DY'C%YA17J>F+G<C<G'TJC>\37N0JOP3E=6WHQ9
MD&["B!V?#J--&8#-5&ZJ$7XLTB[A/K,)X5(@=I)U"=QI4[;C0CJ@+WQ"Z:_\
MQ9S,]8/]*E? 7G^^;E'SE>(3D\IC+,'%IQE7J+;K-:<:KC TG"!=RUD@([;W
MR/Z=&ILD^P"I/62A]FQ%^K<OM"=88ESIVE(N V3:[,5&E'1SX.:>P !PJ39>
MRD42CI4(5:?I\;?/.\K6?:'0^\G94^\E;A7:_* N9^V.Z!.;V6&V[THI\:F_
M-? ^A@F=34H,*SH]R.53AF/-2OI<3AJ'ER+L9L N[0;#?OF-K-A046%17/'_
M('LM.!\C,K=]YD(D4RY^#+2M=,P@5U]A@*GI'+1)+5XK75\<5G4_T=94EM3)
M0ZUZ\6$>?6\)<5TV?,\+"#::6D=[X=XBYJ1O?3#1$*&]7P#M #R97R5K(/)_
ML!DQOWYQ+_S_UT7*%UX^+M80X-0. 03J"%_+L*=.*EE-[@VA*BV%_@E6G-7S
M6%J0,:[+.="IG<+M2OORO^FN9!/JIRB+OT4ZMTO_4.A1,D7R*ICUY3,B/(CT
ML:]2+WJV+SFSD"\J&;LCWAR:=7>NU624]"%_^_7?CJ:X6+/"J0(?83TVAXD>
M'HJ+8?80!G-Z>830I+0$P!%S@X#;Z(QC=;BOH*Z;_0PSA:M8>R\79RVDB:?7
MH993]EM+)W..U2I*?,J(2"T&S2[..[*6N_EQ?[#+#92'[<H[Y9J5E#?#PX-P
M/X1$14]5.T;.R$D[)Y8/1\6\' [+%SSTZB=M101J,G:EO@UR/Z36US?0ER]H
M)1A$'LZ(6T]Z+<B,X62"\NQ;XF@5R>MX@\'F>O]CQ)>V^Q:@K?\UIH7_,(-D
MM%:5"M9L;A;HNOF(*8[Z[6.T00/Z7]_.%KNR=QJ7$^&=9FR?R<J^/3 ?O=HI
M(QZ9SGZVUV(ELAV-[^DU@U^/6+;5/?$)33^JNP0LP8VD( ](J"&)R:.9NJ$'
M<UJ<K3VE]JP9?542-@TO/I5;0S#Z\]RQW <9NCP!VI,;=S:O9'>UB*7A[MR\
M8-R:[$(@Q8F!]2AZ2,$,U(Z/_&T\>U&;'LPZX;6=4MJ[5EO*^8U=<SA?7JUK
M]?V&W%Z8,PBD#.I2O1/9"90$:4NTR-*F58-FI?@<WFRW_H@)I7C(3TM[!-A(
M:K9 J%X(9YZ1*PK9V.PQBZ>R$B2F?]E/NQ3$D5($A]G6B#RAZNN>M8TZKYYO
M<(6FQ$<B\LIXI0CFP0QX(DJF9W\=&E4) ][(I#W0GGOG\WZE49@J!-H13&\"
M.4'=J=4=HNIR!P_:VEP"G$-'.N^:]%[_=6W-_%5%\YPKNUS@%V&!%,M4@N<-
M=##?D.M3NQS!3SH]:N[%'U3C'>>=L,VU**Z[/A!%I]PUCZ;)EA?Y#K] W95;
M9\'9TB-W>KT\D[Y1_[[G<[<Y6<$_>AR1'OS0%(CJ1C .8A>@YP\P^QB)G1K5
MR!3#<S-JO'5X[H4AI7">)4@P7G2VY5&Y*=&^4X497U]9LD!G1^ZK3+:<E=3E
M?S',_<CK69D:/\JYJ!!*[[*-6+/*25XC-\&_C<[[-G=ZIQM[HX/YQ[_G]&LL
MO #N.(Z*JPV&SKQ.>YURL;QM-C#PCX==\F<?_^I=L("C*CYFCL2,EH*!-3U6
MMKF*TLX@8B9#'+(4)W$JC^^47XN;3QG=D#ZL+(Z5$M4-'W.6J'=DS7BSQ=2Y
MVCCC#+AY<K/]C"+74:H&/HWF,IOQ@>Y"2<-IO]*[5?B"'/YM5FU6EE&*.+U8
MM0O\F*S4LCLLOVGHD#&=BP6RSAF-%9_KQ8V[1%C$9O:XC84(),T;#QI> FS^
MY8BRSDHW;37UH5G?XLGE/UKK"YTQ=KA^'XK "W?9^H4&)[<^!(Z9[ZB,C.HS
M-H_7/1O+?>U(%A@EJ:[!7: *P=\V[ ?.8>,:Z]8</=BGL?$Y=4+KR$+(GG/Z
M679VN86H%(UT1]Z7A_/=[L'OJ81YJ*2QP?S-^.+(-@GBCQ/L>L:#^DG@$B>P
M>R'%O,/Z;5=2;_A[1$.\[U'?B)R"<<2N4,*R> +V0D6#-GTVK##N;-<V[#8A
MOY3G,=5 @!ONN3-NPZ6WN-1HZA2,-SYOXCW#2.%_09*V)+ 6]YQL$[MYQE!1
MSW<I7T8NA+K-R9=G5+46.,@01JH<ZQ6<)&6ZDO>7[QD[V0.J 5G&(Q.^&IV+
M,Y< ]L5SSD&R4&%;1]LS[.BI4,V=WCYWJH4>5RK'3H(8O01)J-0W'\2IF20;
M#K.N:VL98WOW::B6+6'0]5GCTFZ/6^]+XY:WS7,$/7)NPJ*HSP&)$UQZ]-9=
ML+HB2:%)CK:B^-['?^I5\"Z,S!A)UK;DEL2.W110;+5)[TG5F/#7^VR_+4$W
M'FU035>3Z2"_(.#;A\W>.6<.\:?\LL?E,)&>X9<)8HI+'DD'G@(?QUOLWZ5T
MS,(2NI0%>CEU%WQ[MO9WL1TZ8IR0@DB[?P7Q:JC[#V\F_*&\MCT>G;,-\8:C
MC_Z6>:=F[J*6+U3_G PI]IP];Z,;5]*HPLPX)#FF$?[$^'E'Y7WS<:*?\[FC
MW.Q9EO.8F)KGJZH]OK<K_KXIX5U#/)<AR\!-&ZNG,ECX5(F\V--)__466>.V
MVN21=@7+<ICM^Q2BY<V:*1?/4B_-Y#?&)X]!J]TM>!K)E%!Y[G<..+'T8P]\
MX2["+OE!.A:&1 #KC^L__2%;-;2+%*\-G"AJ,K!XZ&87%J$BI5&(S12>U',X
M#JF2W$J 1]3VP>PF6S0*S5[X\64Z'6!Z.8>S OMT SN3^HXJ7=N_2":J<]S@
MK=OO33A2Y@(3*.L@A3,FD/('J2X/8CLUTHY7WH0\ZS8"+ I5O+=/?<=?Y9'H
MML=W6Y"1Q(_O_%^'W\].NHD>?>9WB=8L$MK(.3+#*<58X87G)>"IXTBW)>^D
M<U[]Q!%.<@N[;+H<3=.WL/I.\,E_]-HWM04]VP\+?A)<(J6-&CC!45+-$TX1
M.MVM.^Y^V@HU,&&'$^EE#&"L%O?TV'V:I %='@PR-,IV8>E[]B!9\OSV:;3&
MI]N2[[3[J!J'K ,5%()&>EQH%OX:? #&[>8JO<H(CIYF'>N[U_F[ZA*@W,[-
M^$=GU7^)QGB@&8QW.237\KSHAQNUK:<?70(87 JXNLSNF\U8J%2_KS_9%:CY
MNL"OFZ;,^C1+7CEDR("^^(-;R;R)>H +$%=BE#,C9"AX+^+MK[#4OLV<NOTC
M=.11W+-M(WQJ0Y+A,M9B\:_DDS\5^X(_*?9^RE"=\J+P[XK14JW0'O2HGR$Q
M^:(PS@ #\NU-Y]R8HSN=B"NHJJ\C@R1R+@%N$EI7UE%^:K;H-^^($1[UY,B/
M,9\^7)#1T?PWOK\KIQO_[5K4D,I)EX),INNHHT)K>$'_M4:'C<;GME'<'-3"
MNQMQ"Z(;?#'&,F>Y<21PT;R9&60V8Z['J7.3<8O-/UGLE4':SBMOPL=D4X
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M7GS!GJ;[+O55260^\[":2D-9;Y?__4TD9PR4T_=776*WF[MSRF!X.Z!<QK6
MD9)!7GJ=CZ/*1>ENY29&90PV:SH['G3_'W^_RQ-=-8-? U0;"2]7R?Q$F>T.
M.'W@S0_*,[7C4J<+1P$]$]V'KB/\?6G:H'N33Q4.)@1*?Y>VI1\@5\A&YT/
MRC:X^]7>O;MGW97!,99BS#F<XSG#Y6AY4:J4IEB_I.*=TAS?ZEL1@^">R66$
M*-C%B7\K[?9SDVZ='-L:+9]M<>1RB%$L</9[M^:?<7J\H1-)9LZ-KI):L%IY
M,WY$9S;T(>M??S&H.?+V'JWCHB?I.ZETP$<>\8J@'U9 #,!&=G(!&?3J)G!D
MM.\03X4HN]W^'6<Y[JQK_1O1Y8ZM;TA,%_#ESV8+?K(G8-+G0N(2VE)XNG:1
MWJ$IN-"VH&?X9)\8BIFQ[=@0J5!9Q[(%:_,0QEMO@YD@_MZ1MJ70L[B(%)[Q
M>W0>?IR]K>G>4XF)E8M)D[3H,,R_C'=I,80<767)X06<C<E[A\JI5]I]MU[P
M!Y9IW_C87@:^ ^-49?0U.^]2:/&7"<5PA7)!YRKO>FFS!EX?.WU%;<Q/T4"[
M9%T$E1O8]-<BO($7HBH-I_7G A;#=(_(34'W?,HWZ_]W>_\X#PK[4 ?">>B7
MLG)QZ>^[A27%^PVY,P;JFI+4*S<S>+/IRYJ<XYL*6[O8OA>N>WQZP_QQ8L_F
M0K1?>#Q_C,Q%O'T)Z%*=54CX!//R<W:Q;IGXI&+^!E[F$\YS"?!FKZ90BNR1
M!QR"Z9P#G[H1RKME<QA_GK/&B,?01K%.5:Y\L;$=8Z=]U/O]1FC08.K1*?EN
M&TIU<+H;QWRA>E@.V2>-?,!/HR#8!-K-,TQV;LVB6LW]ZAM%6B)N\]QANZ+Z
M+7-+-]Q[\=8Z!\QE2ND,U )\][X1+%/,AH2$WULB;S_\\?W_Z3/T__O!DE#F
MB^HT$]J8D4;<V33S&AXEZRWLN*E,C.+LJ+AY'2BLHH>OF.#']K:H@T)K1-'/
M1$$9XT>/G_G;0^2&Z1Q&KRJL+?)Y0>/XVLW>CCJ>S"I)0F4(%A8F^H27/U.#
MB*+]2_;L2A_;"Q:BHU$K1-&<_!>^\(]>$C?!OAU32M($U1Y+_LE\4\$8O4D)
MNWWQQY'W3CK*XTDYWXV9+@&W#+IT*I2\L,:1(,VZC "9=^A\UEE[M6>=R U/
M]FN3L;M]&QE<OUSZJX7@;8OHH](C:99E\O7FR<,A>+N,_\7(9[WU<JB?]S8<
M$5,2_<FB<%+X#_6U+\XW9;E7T1J%)(LIK_*^/4_$M2V?8-8T_.R#ZAN#@I%4
MD)2==MT=NJPL/*4_J<Y98>X,L_CMMD[1): 2<<H#C@ND*?3=>X6LG;)IKD\>
M]VJL:Z[.',C J)->_A4XH$*7W%!?6HS,L \3W]N#[1WI&;^>E*&)N3#;'OF6
MJLDB^]Y5Y=O)DG4V8:][\!)PTU'V7J" ]'"ZPVNA2>>]E5^,C5S1OY-I1SY>
M8);B9\K]%[NYHHZ4)5[B72*JE%Z4.7+Z;]G]71 J:W=:X,C^)6OS,0$];;53
MA:I4[0_J5MZY!" VR<)Y1EJ?2=+6V"%*"U%#R0+]S?NZ%#>3A35IJPI"K]WP
MYUP[7/R,9%,8B7#R M-9.JQ8QMM0'GT31#;&I-Q]%N:>--"F&733B6C80]7M
M7X1BJ8N*,1AW">ZFV\MNQKUY>+'.YC#+G/@T)=?1F]S*=SIW0(<DHRKU4S69
MK^N^]U+>A X=N41S3JHH3 <"EU$WYJ%(?_/__MC$7_#')4T^F;=P+; !4&+_
M*C_1N030I W ;VSZMWW[ ;;8:BJ<,P']FWG[Q;S*I[QZ^:UU6N^S6Q19>KN(
M"V_2(9=YU<C9^/_IX7X3WVD^4%ZZ/;;YU"*H3(].@F"%2W2UGLNR8<".M/J#
MNIL6?L1EB)6^<R!\6>'@8,>VS$K$3,Q!R/<CNRS9,[70AZ),)3+?A+ OD7=6
M(G2^6%==6UH10,@E&!#;2V3R\E!12BP!^0Y-!UIT\85"\^XIHB4B",;8'\GZ
MM^3Y*3X.<QJ_I'$Y& LV8O(_4+X$%)_-'^H)Z]:-264&*;2;PG 35GM6?P*2
M=;9T^H4;I=T;8*I8@SF2[ J=\;GHU:I_LMM:7QPXUP^>6*W"S<SMVT]0\1Z-
M_ L61Q&H>@SHYV\YPSPO=#N>7=0NNXXP]HT?]5[[2B]K+>5\":@JK3ME&1@/
M!J^G;_D/L:SNDV"-OP@1F85;Y#L-$Q72NNTPJ)M'$.="XI_7-E#)&U'AD89S
M22DAKJN$D9A"0F\72%E7KT5/0F^BSQ!6IL5D<K];0"#OMOO^T4*H88A'R,/-
MH=7%^=L*<Q,$;^7QZ /V8('! J)J!ZN_>%R);Z3%=.UAQNP =.K@ML@CGXSE
M+[1+%[A\M\,B\T"'<[;0%O72+16>M D0_G"L&YZOXUWL\G5)0*RL0#+1([M5
MG>>Q;G(-%$EZ\N2DTKFX9,S2JR#P]:1S(*SPG_\E(&SW4#'(D4-H0GR].=XH
MTS&BL^?;_O#$PF<J"MXT%=%MXVDSRY@?FVQ,9AC?L'>AG;@[\CKWHK+')9/Z
M%#4EE1UJ)D8,>A:_5M7!52?W'!# *VVA:67J90MF&U42.5OH_O3P(*Q4Z\:X
MLQXQXL'-]7M^IWXCSI\.DXD[PK&!TGE5Z0IT_L.@/*'V)SJP:@TGA^@-'SFE
M6.M6&@L48JLSO1EU=&&^78+@)&82;I^MM <K_QI/6WG9A,=U%SP*@'D."K99
M/Q*$ 8HYV/N'H0'/B=DELM&>0PS=*DPMH]936(_"A1$?[J+5LHC.'Y> ,BMJ
M.<&LK(!QL_(K$C7GC2:C/OX[-(Z[\NCL] @R[=]M'V@)9MX2/ 2!T!>75OS2
ME?CZE\%U(#KJR4E41X+9Q%B;_"9;, ?:"VC79VKAX)#@ ;4/8-GO^\6MM3;(
M,=N513$!41J[@(/]](&ZZ<.+<0FO?[3LZ1##L-NK33&&1 ]XT8)TF,4FL54G
MK^&]I(#?L_#P!':&O2RW'(D.57:O!:XETM6B1'M^]KJUZ\4$L_<0SV.&>N_K
MW(-UQ:I]KD4(<-,"Y.GG+@$63B^G+.!FX'UE;/1J"]6*Z"6 S<R\OGQY+H[1
MX;8DGYSYW'S/=JIOU9T;B?ZX8;GU'U-M]SKSB,BW8T>Z%+0R9D\=\0NG,VS4
MD?29WJ0";A_YH4<!5YA\59'Z? YN]G>G!"$QUB89Y]&IPH>J'8V:E*XTV2PV
MD V<P_7[T3B=AE9QL?/XH[F64#'!_/B3CKD@\!L\N12Q.8U,[BW99EHL<?B8
M>?LN6$*<XMJ,^HJR*ZX2596['I&ZXG7A0GYU=CMZJ46#</\,W?5Y^8K.?2U7
MNF:39RO7!F)JZZ*I,W?7YOF^'LU];!^IA!'Y>HR"Y?%+4V)+&>,F:]" 9IW>
M/6"104ODP0V^9W)4(4(!,6<7^M'1!S PMJB2[[.TA6I'#G4;@:4H:I WWX=N
M_'G?JDW%Z\17!?2=6838]YEF>UV#?[W*+9@Z>)E;T$=^3N/D %-[T#THC:M2
M3Z+K*?GZM=+6\:!+P'+[OYUA<O3^-B*N?I0HJS^-.^3ZMELTE:[=.J&T5&,V
M,KQ&Q>Y.O;*[(2#D=_TFL1,K$%#N@,.O'YS#7\4YVU1;Z+,F[*S:]-GU/.WK
M>&@%IX@X)+?!4U!%^37D5MCIYI9_-\O:"9CC6^TE@'K>(8>C<<J.\-R0'9;?
M:()Y)$"Q*A1Q>U=.3/OWS9_^1@QQ*@^V,M([&=AG1HH6?0VZ9B5!+8F]?BUE
M.B(PW_57]@+\*^C2'Y:X#M%OW3Y(;( 7RUJ.*+&?+5P"YZG+HT!G^%KWX:YS
MW"[B9JAFA=RU-57%G&8M*U5:."?IS70=C^+OL^*0P]-=J0NK4]GBV96/&TDF
MEX ?]1Y((7T3;K>P1,@1,AN%V!YT=RDD(<YRT&^/@N2]XE@/])*Q 3;-X<N0
MRK^W[CQN%]'FY^9MD%[#"!*/7+YOH\T"S02-'Q7!.#,'R^?F^IF6GE8\D5^0
M?YVTOR)HW2!=5QGX-N4<]&J\A6'Y5.EU"?@OG797^F?':I",3+7/#9N4B>C,
M1Q+"%T&8 .;,5[C#.!&TQIC38:4\K7?]?P5W2N7OO7UO<Z+D59ZZ#K]YM* !
MKB-8#!<#3Q]A:3Y%T&S2*/_ZH!US([%A1,U55!@;D5XU*Q$5:%!)G#U_-KY3
M^<7!.T-O6V-]J)8@N<,U*,<.R'G:=SVK8*K@K/QB:YE]>Z )0OQ[+"+*U"&;
MD8W^>)@YPBB<4JICRYT.13KS.>MK66\I&K/ED\RGO.8&00NRO_VS>\.K]N@J
MS+J8*I*]1->YO-ZT4U"D#0,V$(-ZB( O7_9XK2?^(13Y6/,B?Y/O3Q\!17?0
M9W0K?P>+:;+)3NTAL:([5 P-[W$K.0WY9L3TBEFH41/EQZ7^NDJ?<V6)/1SC
MQ;WX(5!<&U1B>&:%G8-=H($I2.("!A\$BQ>"0' SQ6#['Z\M#4J(-:^G@OD#
MI3+DCBQ8>71Q**<)<61'=YI$\WUN9\!JJ%8>CV,E&D=7.$<,-8GXQN3@:G&1
M9J&V]1/X^_V<;F6>BO6#G<#%A?Y>]K+Z4B\?$L^G8]01FI1@]:.EI@O.454[
MPFU)=.DD,P>Y0ZG'-N9*7_Q/Z#?Z0D(//LB?^AUS,VVF^>CZ%;=[5^LQ#C'V
M"63<3^87D+-5BN!I7^6T$.=29!JS-)#HF<N48(<T62*6:>(4.M^VL$XCV63'
M*F=HNUDU:_BUHTR\E!LYY&Y*J#S=OF_ 1,?VVT<ARY*K.8UK\&-)+[.5(-4&
M5[J;RY?D:'I*^0UF3]31Q.X"0RIF$7VECG;1!]F&V+$G1&\&:E__%?"4U[D!
M4L/*^<U<?YBSKF*]FOR2MR"OOQVJP^6.8\:5]"JYGI5, KLX8R$L<8?-0\5]
M/O=C4RD$5"6HPEYDS^+@[06ZWLC<4]DSWNP7?JS%V)&[$#CWT2 =DQZ*0$/'
MB]$- KH\OR/@<KHJMN'([0-(=E76_EM-K'0K)RDCT8?@VV#,UIN%NLQ-*/\[
M9.HMC$U67$D(0YO:ZL>/PXS);JBCULCIQ6FT,FOT?BO?2E&FWU(KW&*JMM-6
M//+^"V!=W:H/Y*GJW:@U@]1?OLJ1I17%!$2,M&J,RLV:Z4,>C8Y^5[2>4,DD
MJZ^$P+Y[8?1[UC<, X-)B0$$'4MSU#2:/NZ,3%4[9I(CAMXE*?ZX*-<;DY!N
M[A<R>5]3QSX_M+!X0S.L&7F]I6E[Q:B\BJ1,\#P3CZI7P'SF/(U8?!.Z]3#?
M2WC85&UVS=4]A'=^@U_#7W;NC-Q,/\<[\\*#C]X+"#(BP@L6MJ<E;+VG^YX(
MC6876>0[%49Z\\DP""BA<WS!V ]X1,>%A@GA9O=PJ8]PE+A317Y#4\_QPOZ]
M-(VH48"[P>UK*W7FK3,-5Q9=>);$8?GHY/^T'=28+4'(XQ.ZSUT8-\]&<@M:
M_'-2J'-TZ21WE;6'(W=/#1CH9]A%_R9EA'7DLE5YY7+)AI,TEA$[H /GB9XD
M1S?+N[4V%=$A[)G<.*7SVQ:P YY#5-_AK.B TCU"U5[W[.0MR-)YPH[?+BV?
M2WV;[C?8OHF @7-(BXAWCLF25S_W.$F%X!/CA8CA!4[458H\G\ ):4]F_IUQ
M<BWX\>D_V6^2)C]771G4]8>/3\G@=;JYO>JM26.>%0->@^4AD/Z8%) 2?@?:
M%-WR<^:%PN]R3FN/EKC$_!RYU5BW;H_T7*[\"1)+A2,2PYLS9S*Z=[]VTM-/
MW-C33K/C5Q]SY!M)]=_##$Z,:<UPL[F#41>-J8<(Y7$58?#0BD.+*A9^:YX8
MY (K;/K9D+$K'SM6+.Q??%:#S+)9*6Y]#P'7BJ>7^D:,4XZO1&JV-;'6HR\!
MLXG*[>[>Y3H.#-\X&1G^!+P_*4J=U4609-=%RV7GR'S[RA'1#PL>_]_]Y%<1
M9-C!RSF]IX*N] UX.>GL_>F@:B<_]3@^S..1W"H!Q/P?I7?2,HY-S=18?5Q,
MJOMK&/^O>FV-I E%M6%)J.95A2H!;/$GKUQV7[A>6&?RW^Z@#V4:P447V58N
M8K)45BF3"?I/A[R/DK!P)@CF[JCM5%UD$BS?5DW@V9_=7L<2WH)$^=]']U,1
M'XJAI&&/%Y> \)J+.MA5<&4CW<N=R;P$C >W'Z,4G57#X(-9*Y76B$Z@;2#-
MRA#S_-^+XB[_N.ZI?+^$:D:]!GIO&UYZ5SK_1'F.'Y\%)V*V*D_F2!]EZBQ1
MN:=9M_"\/S"/\<XE!V9<,!K=M&&<;/V&?=Q_S%RNFNI;6N/5@8I+$E$YS-$,
M=/]4!,9P)(F;<[H\,_7V*.UO,;7J)NQ-R;)>&ZH[Z(K7QG_VX-L!9)N'A;SO
M+DQ!^TJRW:HW6C0JB9'=3^?FB=[817,5)^/9[-H4R]E$%9-\56\I,L\*$%G-
M;W1X"6!H 1<XFDE$*?$%Y3^H@>6_*%B<W5*!F@U$/6TU!3A%<-O0*ROPO?V_
M:/NNL*::J.LH*"!->B\*B$KO'12D25-46H"(" @10B?4( @HO0@H5:5+B=30
M([T)2)<$"!WI"36$D'R\SW__/]_-=W%NSYF9O6?66K/WV?M[4?"/(<(8?.#3
M<0!L&K,*C>DQBIMG6<I+=UJ&W=0X3;0YEO+-K*FY)(5^_+8.ECP/TKC"@%5:
MT6U*O^RY^9FPBE\*JN?593R:0M+6C3=\$]*VNF=T=>5W\O/_N]B>XV\X("&7
MVJR7KV)Z:D+"<),+5*WCR\U&1FRI]!;WN+DH]*31R7L6MKR>#^=\;+R(?%.^
M&.I_+OK3NWVQOG%G?K?\O!C<-[) Q]7)UU\P4@BZ)$:J!ZVQW;.YYT\&J"6:
M95F2&A!K9WE"RTG7MK%0R]X%65S/2;YFK<^WMGA%@HTR O$^I.\:R5DD.G!S
M5%3=[)(U4D#[NILA$1/=-KV?2-QCXS-/$.?BLA*K>REEC]*\[@,&KGTZH#+.
MT\B++43! I8"SEI2CXDP'JD!?H50[%!?QO[RA5A75D,,?]2R]493H.2XHQ^+
M0<[7&XH LZ&65"KE4;;*I?WHK-[T97>J)XUM=09U^[3TW!81^K(T")<@IP?H
M/0/-J<VCY[/ 3,(L?"#S/SO[D@'R(61 ,9$:IU%RHCTL&E5;L#6V4+0J_5A*
MZH^!=>OF9V8&F2A ?%X!( \.Q <L-[4Z+:.'N??U5,UBY<F VCF)V727J.GK
M"8J[U[P:(PP'>CUE58YM[ATAX,NI%Y39<<VDBKW UQCZ5L,2UW:FR5:9,M>?
M^*0NE.?/5+4>_[IF[:_2XE^5.R@CJ#2G=,SQNLM\CAWM8NYFYA-%./V/18C
M+"U9-0-F=KO2PHB^-:I4#:JFD_O]TT2S8GS8H5'])/]#S4K?AHS2#T"?_&=_
M "HJ1#E3TO$Y<AB#>V66:8\I.1.BM<?Z?_L!/>UHGF^='G+_&I=45U!+!9.5
MCGQYX^&J3ZK8I>RN:#BQY\6)Z_B&"4R_;&Y>44:(OD[ OQ8H!H^5?C\/5",I
MT4NXH# S"X%2W;!HD@C.N3)0\[.ZV(^_&*"X@4*++()=F0S(8^ELZ1?..$NB
M2GP_42\5S7]GXC;VQ4;D<1QM@F47._P-!K5]N\LS,=OP8L'*\2O(V*=/LUI7
M9*]2JY(,&(Z<@6U##M3-]Y<XXNH%Z/#+,^93OE^.I9CG@&:L ^OZO,Z*USXE
M%(:K2BJ]OI+S8AO)"$WMLIEH?8K3LAN_'K5TMS!UMN[O'69;F2<1AI\VJ#B5
MC0^\QMM$NYLOX%&M"J%5;DS#(O7Q>M;,UZ[U\X<GR^%C(XUPZD$-97R%W/8E
MO.9_]4,R:]#+\Y%'\<JBLG2K\&VC4*$+5Z<SBOH*(AG #B?PRRTQQB#L%?#7
MOH9F[_P!S;H]<V-W+0/N(QJ?"1%3)6G^_CH&S!BY8H-.GV,A'WQ'F?(970-L
M&A,<S!A=75D5O\MRF2Z7"W]Q2.7$_8V?J7IJUH:L1/)=1WNO!^_C,<?*(%I7
M$#-#<=**'40/2!OL>,-F4UI&R51/?<#^8;I0%0L@#<U[@%+JTN+=A#'LJ=]'
M)46O(NJ;6:R$IYV7U29EU5H#C&XG?TU]SWG&J9Y7O^/[]"),B7G,&F;'*(\'
M8E>>8\.:*K=5^TXT/C5_3=#+_28>]R;;.V#95(?9 *7,2UC46I[I,L((D &.
M X7S'2X:%<-L$[]WVITJPFENNE.)O@OWU.@)(&04@ LOYY7X32H=[,IB(I]M
MY*[+)4HAC%6S4,B,KSQFQ1(;5"W*-1K::/+$/N]&ZKJU4#!JO#N3RV%HDC]%
M9!Z38,G @+G5(_C[0U<D5U7(LY-2AMC2@UFK"/2W)NBX4H@CY_U<G[P@K^??
M\2^J],\U%_"L_[4*0@4PUU9TZA\\4+IJ:CH\3W4:1/+;]GV.-@H$XIJ>IL4U
M[^7/!1:7+<(X7#4E(<SXJV2 /H=EPQ.4&WM0JW>@I".G-5O!66VB=.A%. ;O
MMXC FL7<J6]M/P\K" T0.3[N-XD]-$Q 6_[DI,!PK2CS.;$9UL.T#I'KN@VD
MYDLT:-[_15+[TVI4-4?4FO8%AFIU<PBX-I+&WOV>-D^)AD9$5)F!\N/#92:_
MU(,H\$/&N.?VHEC[^F([MTQVIK];AI7: VPC(X^Z!K@L1K'OX@4ZF\D )FA-
M7Y=2ED(]T9)9LSJH07&=S9SM+S/MZW@IOIK0<N\B";9F6.:9#,)_?^;2#8?Y
M+V'T!NQY7!?*6*P,->\6V5V]C:HX\$A4>INZ?1-PM$BWH@']I_I!G:=4%R?0
MO2#H6IE07%G<Y7KU.D3&[@KE3W2XRHZ)?]U3D=\59$!Y>9A."ZD-<I:O 8*:
M@; -Y=C\KFG$M S80IL,>'W.#_1W;SE).:@V9QB'"@DGIO]Q ]$0+9<%&*#-
M*]W<&:D+PC@Z?^QMF[./+A!6R8KKCS.%%X^IB!IFW:IKB.A6%5@EJ+ &:/5K
M8C YW/9'?/(509<M7:OQ8^IZ]]NC3QLLK3P6#5>L 71LGZ2I*.,7"1-AQ_L7
MMH8'C>B233* (= R+HP%K&0OP2^(74-&U=-450C5M=3CV+YDR?L"Q*MO%N[]
MZE/F#=B%V>-=JP2H\!8370%9^B>(F/V,4[^>KPWUN5@T,N!J>('$'X;@G$/[
M;T\6[$02XD^]HV4Z6!YWZ O?'>A#LN945%W >*+@3@=$B3-^F1]$/IP0-.D9
M<GP%Z_X[:$7XU'L+Y8(2^9D3_]C]]!Y=X5IXF.I5U;0_V_P G&3Z<JY:MQ:C
ME#QT;VE\QJBY8>K6F\54$;7T*0<*L,M/ ,-".AH*ZK;(D\#V)+84]\E;(*K/
M4@JW*-ZEJ@!2T)/3]2]R?'?) /JS-\*3Z:=(H@89\"P&[[ X[]@Q';2%CR!,
M$S;,IYS:68#WGG1T'CQ/^K3*?T4P*&LMQ %+!BPSM."TM9AM!I:"=[7,>'Q;
MZ&V,H@T8KCO=C;V2)IB3ZM5W^I"_QYH;\_$(P[C@ZM\<V2\Z594Q/L5$Z^&S
M%02@$M6*=O4S&Y,:8#@Q);F3WN8;QSW-?A MQ12G4ZJNYM&3L2]<O;B#.73<
MMO=:0EXEZF'K+,)XQEL-"[J6@M52-P-/G$,?=%HUQ8$C.8331Y^HD '.;?:Q
MP6JQ*"NLR\0E,>(FC1WT+9T/5,EG*\:>VL<,^'ZP1[,GB@Q0B"HK\]XLJ5+>
M#3%:W&='0T] [$0MY#CSULFP^+Z$PONTP9?OTU-L- -\.=7]ML?+R(#.XPD^
MB$@M-B >XOYV+?6>QZYO?>K-)TOM7G>D9?+ .A;XOF^N8V^22ER;1]HNFCQ.
MV<&%-C0Y/QS]G]?\%%*/]XK,BG+A1!.:8<5Y'\JT C$$!%&@^P.>I1MA+X+5
M@U>"+5"YO3$GQ9.BT&Z)>^G2W^4?H:,V1QBN!^%L<^$=]"ZF4^L_:Y(ZF?_)
M@;)38(&%PH1/3YDY.UO^].J_H%P-]Y;I3+P<)H:E+I]UR]+&?)/0D%:.UMW(
M5;*H.U<_T.\;*1!F2DML(JI4(FFA&5T]"WP-T[YP!?>-.?6FB;<I-=46>ES*
M@A&J*?],0$#X-NA0NVTJO^3X- ^"$UB"?22^^+%%9<;/.OD6\M+@N_NK@8+F
MB8:3Z#>67EQJ[:_TWS+E$!0COPY\ATKV/51]/\-L,RL!1U-W5=,BH+PK?WW0
M:4"ZCN>UGH"!*AG2?6@(U,5X9M%H*([^V3-NI]J^FW2O)?MYHQW>#[)L1RCO
M&D$;+S5=M,XT<1X)_W.HH;2H_W%7JX;=55TB5\ B\5CJ5L33P+ ([>$-XU_)
M7O%W*5\?<U*>!IEU75ATZ>#?.2GT9!LN X>:=@9;7BED:/P0/H.J;,>3%/[5
M/3FV(-4CSF[UFDIN-\/\R(#?!V9XBS#Q,?<0H3*\^>7);0+3F="JE5QI9U:H
M['[D$OU$('K54VXWGC]R:332;Y_.;>'.I+H1S"G4J])>9'#@37RX@X%@F8"D
MW+LA3Q65JKW84. QT8X,D.4V70"M0?I7Q=5%0\&X8 O<\U1T-L^\HIC!B@5$
M7E714(BS;P5OF;] Y,#QYK'5UL;NZS4UU<Y4*3QT#'$*%ON43/S^Y =G>I_Q
MR]7XY;;VV"C62H_\C>&SI$OB4MD$$^IYJTGM!L,F0;L>3T)\RQVJ#"%^KG<R
M*73X*L:(Z$=6G5_? G28]46OUXL3V7"TSW$;EX)WA4^_:Y__@XL%8L+"21S.
M_^?,ZU!&0W\0\#1^]=W65-12/H<5M/+8:>)[8_RFY8&5V<:/A/$[LI:4:X%;
MGJ$_)@*:+P](>I*!1,GQ9 >^<C'!K)? GWL]22,SUS$D4V_4'',"_-ET)CQ[
MZ)BS@C0]XVV(PP;8U%;C*MOF"'P(HC JQ$LORZY%A[[B&R<;T\J>4_N)=Z#P
M52_[[X2%4=:^[S!G-XEUF^Q\1&6[NR4]8DC6)68?P2=F6CPX.DKB.>*;GTE'
M_MX(H2G9)IB]%S_:9U/,FLGX(*@W81PMQUSZ0A1*%<"+BSV<)=%N6<(8089Y
M^R:JN0UMDM4NZP4F[G>6O5B_EJH9*+^EP,_46*CA"TS,N'270@\42T2R[=.I
M_0L?1JPBRH07Z8Y4^K@@"YE*(+P+P?9SS]W9M\A%^'1?#I!X9\:#R+$<+':F
MKE+@9M-->ZTUC'\B8X'ZJ>?CNFS*"MYX:>%PN7"?V+B.2\T9HO,-OZV+N[8,
M=>Y54[M7L8$8DUC@=3(P#%!-$\LA]C2L\&W/WBVN"R UPR>YFVM)#62 ,#2
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M"J$UWHF@4,Q&R1H^M>&,#,A<@R\U68 2$(KVTA.^;:!.#FZ_Z#*H1*6')*0
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M/>5Q,!;7(*DH=1FI#\531T63%2BQ[G V<>BKH2B>Y[G=QYTK.=.@#V$:.M_
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M%%$=:IPG2^-5MFLV I"<]P8M]:[AZ*<G4;VCO1=<.3M2P?T#T"L ,WS%;C9
MC28A7-)7ILUJCY+_Z89&J^F;L=R5J';OQV2!V\ZB@@CP>KU).F[O((R!S3FV
MA3B!:\GID ^RUAH<\!49E9N.A?<X?U%RA3 O.\=590I6.OL$?QEKTH3>%HM6
M9#YLV^*X?Z##VY%&FYR,](E3I2GB5-TW[5@HRQZ[7%C@2_<H44Z!FHA4>S]B
M-2XJ^HBJQ%<L^_2WI]_V[&*=:]['>T<.M3V/M@H9[;NQU4.3FGE2Q5=/LBDO
MX )S=>#]G14Q_Q=IXX6 U>ZAD4T."Z&=J2W$V@PKRBIS4P>:QR(]:=0NGJIW
MFN;"F0.0G=(Z4VA(PO =][>/7NZHW;.A<JTZO,FY7]",3V[0@.QG!Y?UP)8%
M%O)>GD\+?[^SLEH:'9C\SK;F-W=0=IJGB&2JO!%>O.-Y'?Z)[0/];TD\%1UM
M[[0:7+/Q4E&_BN^"I1J/4S9;GF:Y5YCZO('AB#9YO6#R;<Q.@LR_=S8VC\Q=
M[$A;!*0UAS'%5R6)<>V=TY%#6?6.2I;G]"E1NE^OB2G?+*<S]6M6'[M;K@Q9
M87;+(XXBS]%-_'Q('=YP8!J5K]4)33@=)V]/HK2U@Q_ST6K<SY&.S<Z5ROS)
M &)F4!'=Y/0QXJ8:3D#CK*U3'^_H_DJV>,YY+':CS[WL1M UO3YZB.ZDXJ!=
MW=(5P *T0W0[>&]B80>*[L9= 2CL[68ZY$MVI0T$XTM1%YZ3Z;*?T29W!)6\
M1<A#B[J:YS'0^%DKI3XW*X^]V&1VI"L+F/\E^ %[4YH2C+*&8#_'.R<;CT'$
M2. ZF1_GE,SA9#O3N,5G/VKZ?A$T*"NZL3/U,F]/C84#G_QD)EP869M.U]58
M?@5PMVRVT",/\<DY3[G;5]CX\/5]?Y,V6:([:)2ZLNX*4 ^N7D'@K?LOZLNX
M2FK<K(#H@\>:0?),OJ.\UQ597,A2[F1:,!LT&ACC!+Y"K<]3U,_5!4XL249,
M\*,V)RD;WR?CX0JJ\C-'6VTSD!E9:KDS??9Q80'ZWWZ296])J;B^<>Q4]3YT
M?OC.##IS^D?_3\&^-;N;Q.$9L6)#P<RIP*WOZ*7T(@?5:<TDLNZ6P6M/R5(4
MNJ::S)[=]$$*==GYA[79M$Z%.B5A$NJU3RW$PM:\,ZS-RE.(0)P335IEE4@P
MW^*"07QTN"C$7B<,@G?5^=J6+*B(/N!-G>6CH*JYL9YI_=[HNOW!.&D-]=,E
M:V*'UE9RMW X0E)QJ9MUI<BWT$S?_F\5&[>(,!]7GP7B6"D?P+5<V9X.=F$E
MR)^%G4QX3#_R=IE$=M+LOTBW^#[=_+OE7N,O^*A'JK1C!4=J/[>5-9C6#=I6
MZA&4_S!V\$+;P?H[T!AB>C>Z9&2$Q85ETG_?2L9XB]QL.+9#+:C\,<36S<IK
M.>#[&G5AKF^S%%>(*1]I]:YR?J%;OLEN]Q+ITR8VETG) _4UE4^=@0=#JV$.
M#<;:Z\]G95+E-9O^"*96+J/.5I)#Y#+$]++__6CU^/7?C2XALY";LEL>!P;1
M&Y#5F.BN^7VF-=(*65VV3PIGY7./9'KKD0]$+CFX1K[94<G8Z7CIE.Z;1K@P
M8""9Q#_O>QWLL6PI\+$A0+^IZ^S2^.0'/&9:YY7M];]+VR#2".P4:2KRQ *!
MV<75?FF;);AV5#[<2=$"@#N\,;*.8YPQUJN-VH)>WL!G;UK?DY'DVE<B8Z-S
M"FN=WLQ#RY?<X&$/OE6<F651PBEEJX17.E9+,0ZN$1;/,TC7O/Q)=^@CHU;P
MC<.1W1>A>%;_,ZD<30PR)\1<$+Q#AN-5&:RX2>%X_R&,]9[Y.5OS<C2DX[CF
M[43..'5JYD\=PSH3K'W?Q*-EU((J90MF[6>ZJ]?9?CD^:;XBC7KBVSA##VL,
MUX>UM <PQKWWIGZU]RXB;R$RQ#F)(&;_8>OURTYG3.7CJ>8ZDUY<!+>9@?'U
MR8]G1KT?4YYHV[\4GSL.016)JT5U\2P%_[P"V$WAU&@U!+M=@4QU9PD[/DUC
MB2WY:]KR)*.V6Z'<5K@D$?@_D_X7[DL@VZ/?19(5!!ZL=CR2]F9K9K6[YP:(
MVL:F ZCVX:QI6)ES;.">[W'F5&BZNHS,)/6>*N.<BO,&(DDI-T\\KM&1+$B[
MCS5PH ;"&LC(7[4*4.3'W7W3\*+T?8,H8A)+]J^G=*X2=A:)(0XH<>XD-&SG
M;]ED.D(FE+Q 7]1UTU.HR/G!X;>@V"+V\70Z_#5Q"92X)+LU\<>,UK:(W(^4
M>FT=!VG1^:I2JY4Q1$SWYN],(-L1:-BPYU@-;[I\GG2HHE4=KCEW.C_78JOX
M9MQIAL__^N<G?8^N !W]#WR,7ALVJ+S]BB=%5G26>IX%P7E;,!'-5A&-27=*
MW76;UA1MNYR^=KQZ'P7^_E:? PN;WRV[^&=C^!YG_L_[-DT9Z?I.LH-V75?&
MUD3?W=LD!.+:ZN+$L_KEUWN.];3YCUB^7E4>K%P)T+],,@XGZARU'J$\8*Z\
MF0*U=,AA_F%^ER0E:B@45OIWSQVJN@;^*9*_ MP*LON"=T=.2.K,_TU.ZZFX
MD<=K8MF//_<<!CY$L4;$^.Y4[RA,WJGL!['M*<$26T#T'E9BT%#XVV4OWZ5$
M$^40VL<GUYX$K15N@7,[ Y-\K!$7;= M@3(#D!7B1,5<+5Y5AHT[_M2'Q3-?
MB, +YW1K$,C]J1@[U_5D2WOI]Q/2S&\O,TB&@C_[4.,-5(7Q?$-'%<^^#$9L
MA 10BQQNKWZ B*:6U]*8;E5OIA31W&@HWBW96P'-M@41Z&:_ZH&>3%AC77.#
M79&!Q4#<(-:V(?;T""U*_B4-T6_EH%Z5INI.E1*M/IR>IQQI%)D;SH,$)2J)
M+3_+K Z.T;*G05'^*ENREFKK3-6^S4]_K4HJY;WB)JOB1*@9PQ$19/>YP-UG
M_V)J/9P224L?;#@(YY.79S.]Y)[W<9GCE?H=C7;VZQ8E/;X.N+^>7<C]*G2E
M3_X+P:D3ZS_JY54Y0S]()W5B-E"0.+0*'.Y&VL8R"'F&N..MC]D7SO<O@U2>
M_%FO;Z%-:#$N;7CW:Z;%<S/XO*T^%RJ_8+TBD4FNK6VG0+T7&E /ML:H)39?
M 3BT-NSC86V:TA,O\R-^M=;>^:TN<[=VB'?X!P5[,/?L=%7UDU$)Q"^?$:XZ
M*.R2^T0U% ..#@ QA=_O;IT-$/6M<[>3S#]C3WXO3'4\U$/?ZV?*D1T%-@S=
MX\,[;DS2X=N-%U2"JG;17)#B\?)1IO=?H[PMCV_=I/@A=4*OJZ@P1.X)<ZN<
M@=M7BA)(Y+H;E"]=T_'L2.W.XOUEZ_W[>'5E:IX76KX5*-&SE1GRVY#,V:U7
MYXD:6<'\N,]H_W584@LZ(G(M )GME?^VW3:44A Z_X7F@%O<7(ZOPEH-OC\8
MELIP> A9N>0P-W=;%U?AWC 0W90KV[!5W='/TUS@B5->W#FY_L/EWEBZ)*G[
M:"]_T;L4WVS'X2[J!=E/CEI8H7<-:*#L&F,Y'>3X@?6JSEV2Z3-"?U2&-HBF
M#%J:.RHP57&X-LDQ=TF/+[#'#"=+R'8:/LT>N.1+@W.V7CI8KNA05M\JC][A
M\=/C##YOL/GZ]F\M.=OQ=D@T0J-ZAAD?,GA]?H=#7*P0,K?@O'B+NKT+T(""
M>'TSSN?.I*? QRR=:U),:W 7NLV2(?E(QFE/..5<@"$SGL\,FC__$O/GJ7?.
M6HPJ/H>\AR%FY% K\-2H&9K334UW='&I7.34?>N0>=,2:]P>V_QP".=%R=F'
M+TX9A7I+-;LJ_@PS%_HOE=O9: 83/?X\GWU"UWK7)0CVFWAPC& /EX>U:,TB
MI[+[+C[%ML0OIH$;W&NJ;_:0OW"*TA@: ,A5F[&,H).D";PPM.H=O/^C&9PG
M:TLJK4FZB78'?<2'+RX^]V[G+<J_]LU.1TYR]6J9(39!0U> #]T-?8C,+8LK
M "W.WWF3:#C(I35\=IGG7<')RF;)Y%;2?Y!ZMN7S2_L@<R[&+@ )9MZ[5%T@
MD$(FJI?VY)6>E7#,6+U8_)%*)55,;IW( 80KO5*UR1X=&9XS-?H$F4#AO>C/
M2V=/"&;=&CO$H'7YQ!9#O&Y=V7?,W/2>?%V$3XWMRMA%E,.8IH'@C53 R-B.
M NJ$(XCYD@Q+2=!/MVT$/P%*_WEB(&D:O3ZZ_?EEUA ]^4W%]5;5'!2#:?E[
MTU#)8^@6K<4_"W/7%-I85;GOF"TNLKD -*\A>:\(N'F8*L8HBS%B@U=M/BUX
M1+&'HBAG.=BS%YHO.=# @(]V%\^?M$B;%\^2<^2]D5'K/0+PGR6#N6J9 $'V
ML)<HG_WO(^%Z&" BY0VEZ8PD[]?YYO%%'.7-"IOA[>%"BJ%GLT5EQP]%/WS%
M<*?)TG*.;_@PV>\:\K=Q++O%/+,TYG5QL&#O%5/.TKU;2!*5O3=GJE"1'PE*
M@FY9/+"'N8)^'+OBW3?"?.(BV:8.*C$X]$(:B\VBQYG#]M!NUNN5I) D4ZE>
M&U=^+I&X'(R&20P27@(QJ%YROZ@;JLEO*7VA?>3N*!TQ%6U8&$W!?[H9DQ91
MFM2Z L2!ML';"4F_],3S"/)[(2,8Q  P2 .&)MA_WJWQ:5[RJA.3&;&Q3F35
M/2G/G!LM\FUV<BQT*86I,JWN@\A/[6]U3A2&5J1S=F2,8#\"X6YY["_H;FJ/
M4J3][D79Y6E)Y)X2)"^=A7R&L5> .!5H/X@*%_SW;J.[ OAH(($2.Z:S6U^@
MR?UM5H,<(GN/ _U*M?DW?_U$Y"&2[+CPP$W1,/"U3Y$[&E+!)I89$4EZ4#U2
M]2IP2$A$;].YME02[D(8UUV)O +0, ="&S8^3_*UX?TW4T5L07J8P):R8>01
MW:J^KV)WTO, IUE?R>RF7]Z*[ D[:4J?(BB0Y9><V,OXZA>K_8+9D&#0'U'Z
M!R%'0A_;(^70O1<XM%VRED E;FN&P&(/4CLQ/-'A7%>[@<#;&V&?7KQK/99H
M_#P.\K[K(N#H]5+.]-4W=.:1;2J#\?1=;W07\B_"O/M_ZU7^__A_'J172_\#
M4$L#!!0    ( -R 7%3#Z4Y[@QP' .EQ!P 4    :6YB>"TR,#(Q,3(S,5]G
M.2YJ<&?LNW=84]L2-QP$0:4I@DJO4J7WT%4Z2"=TA"3T!$CH5404Z1WI"-*;
ME-"+2N_2.RA5NG3I7_#HO>?>J^?<]WO_^I[O#L^0R5HSOS4S:];:*_O9^WST
M_!/@NH*,O P  ^,20 C]!SC_3"<N[6)I!@#(R[,"K@   &P &<9E  9:TD8S
M^0_9",W,&)C?94PT<Z,!\-&?:$, #UHF1G\ZH-GR!=9W'7\TQZ/9!AL H/S3
MIZR\LBH-#P<W%P<W']J2BX<+R"4(Y!:FX>8'\@H"^;G1UABI?XQSP1>$]@KC
M#]2+?QA_DB^A/<+\(6/^\ [[@O\DD_S):XQ+?]AB7]C^D#EI?XYR\7?^YQQ=
MX*+_G4\ '@"N8&/C8%^^@H.#<_7JE6MXQ/AXN+AXI$0W"8DIR:BI*,DH*&@8
M.)AHZ.[14U P"[+<X^+FX^.C9A(6$^(1Y>#EX[D P;AZ]2H>+MX=?/P[/+04
MM#S_QW3^#G#CRH5/F!AT@$LW,#!O8)PW :C1?E[&^$X_,H8.%!/K,C;.E:O7
M<-$*J.L7F<*\A(5Y^3(6%KK7$]T/P+IQF8B66PK[IIH)#IT],8]/^.LK]/>+
MWY.H]WUEX#5%/+UZ[=;M.Z1D=QF9F%E8^?@%!(6$@0\>2LO(RLDK:&AJ:8-T
M=/7 $*B9N86E%=+!T<G9Q=7-]YG?\Q?^+P,B(J.B8V)?Q<6GI;_)R,S*SLDM
M*2U#E5=45E5_:&QJ;FEM:^_H'Q@<&AX9'1O_/#LWO["X]&5Y96M[9W=O_^#;
MX=%%7!=Q_J1?QG4#'=<E+"Q,+)R+N# N.5\HW,"Z3,N-322EAF-B?Y..Q^<*
M\?WPU\7OK]+SJG\E,47T7;O%P/?Y[M9%:-\C^^\">_K_*K)_!/;/N,8!>)@8
MZ,G#O &0 !P<L28U'6!OL<-.4")X(=N7['B? +#,10_6-5/TW"WP#FYPQA('
M8TT0TGZ;"-H7IKXOK1AQOZI46CMDR5K_O7V904=&.1,-F/0$6[*WCD?LT;1N
M+6HFN,MG_R2_,^D=M9KO(9GS@RI$0 '_KFHK[N>$'J$@YOFMY+,/>0964/CC
M &($V:>'&Z %"B(93S<U![9X36W'\C<#*QH3T5+7VU[Z+ 1\$O=Z=O8\F$G]
MV#&C(CXHLOU2!Z(2?X#!'7)65A5FT)<6P/J<6$T:\%O6!L\8RE5HZ,O>E(8W
M"]0[RX$V'^]OX!A%15B5X&:OIS_CJ\ PFHS<CIJS%_?S-@A(AK#%1VGBNUY*
M".[V@6.$%[^;D^@\#(#H!=<&=2BVK&@2A\M)"#X26YXB6,AEK3%Z6"$SL\A!
M+')=2!49E/)NR&)/9SXN(:I<WUNDRY$M/+E!Z2(N/FT^MZ9>DR51*H-.>PK;
M.YT>^8U8[NLFWX:3ZKJ<F;L2?&18.QHOJ[PF9F&\35]5NK,HWV])&X>ANNP;
MYGY="B?C8;QTR1IAM9;J?/X+VKCZ'6J-07=,T)>TMGL0E?3.^MM/-U2_@#5J
M+ ])2@=#SP%&V%9-0 ,[Y;J[D8^=P^GGKFTF-=DG+X6Z-4AS:-Z2UL_C1.GA
M.D<7!_&2J.N'V@>\.+Z+%=!ISR4=ID#_*?@=6+C%6^]C6E*83F^@=)D?S /%
M=K<&3A1:VXI%V5J/0#XJ'B!J[6SJ5UR0GF]MH&;=:@6X$784:;GGK;H+C66$
M7<)V6HI4Z-/S"S<-F#/6M<XIW#"-D5/@DDQ24;AU-&^84156#,6OG?_DO"1>
M.3?]-H:198P621E-/'@<V+,!/!K(>Y.:%L ,^#-GFU4'8%^;GP]Z<AEH.5L1
M5%M(XFD=N\61@15#-'E?W^:*?"1<:C\_3TLUT'E0>?2+!,IF/W()+V3T?1Y7
M1^2'DM<=;]N*))35N_GOL#OGR:,T7ZAC+KW&R3#^Z)B07: N3PKQ&?6[+\FV
M8Q_P(9E=03N<55:1XQ6#Y0>#3F*-Q$XR,-8<#@XI*:6](F,T5D@_T0>#''D<
MG0^[F!-%(XQ)UCE2#L?$T9'5X3/]A2#UA9CL/'J&92+R&'PD_81"R6&NW54.
M&1&GUL\^VJ_?6F2X!G>%\J[CS7.R5GV8N[/A#:R2%M>\Q3*YO.R(I"CA_N"@
MFIY<:UXHO*R*3\9[.YJ]J41V(5]?A["2P,YE2>A] 9!Y00H,5*::+.5CF-@8
ME7LI21Y=P=("',K35[,I,9,)GT=LK =%#E2\Q?R:<U$EZ+7 [4>L)GD9S:3Q
M4T>Z8T+3']1KGAA5DKP?7ZD8T9#L"9?&%;EU#]&&D[WA66S8O1_+<)"YIE2I
M^4Z6PG[3X.&MK\M%2"3?ZXIB5[S@)V]&L!EYHT8>/BQ"4NEN%NXEY-T-:R1O
M*]S.76>:_P0N\NXO_#+"?!222/I&W# _O.TN0_#G*.JNV;@W1M*YWY[K5Y+)
MI3_GE_MV/&]^#BC2J(^\/D(V5DC03_;I\]O.RAP:Z@.?D]6>$H6MS:,P)S+;
M9%O:ZUVS^ T"BX?RO5]#WXW(Z[IIIUA2EA$UU_E3W+)=UHM>5_4-XG?F5Y1,
M"V S^1GJ!1/SN_3K$Q4&3>ZIM17>;HK]I#,YQF4K(*?P>BPH#&-I[Y2MWSIH
MRR:@SX!-AJ)D/8C@JICPB4LA'DRD-0[^L*_-0'8_S_#^F7,H=T]V2)VF#/85
M:B/6H9#DN<:P^^^6K-H77S?B1;@=?)I%T5PW^K*,QT94ZZ^6[G6%*<*[:,Y@
M(SAG9H)!&V0O^C%*7#/,YQTEB'+K< 3/E2-R+(U/4)0;R<>)]+19*(BYGR:,
MT9%\#O IDGFNE7QE0:5ZY0Z(^G.[0WOM4#P%W[/K9#SI ^&APS4,T@'\#U5S
MTP$$0RLFC^=PC1;#]0C04?_GFD$S)GE3Q"'0Q%:D4S3(;<M JR4\:T:DF:$O
M+%4TJ$?']POO@?Q<_&Y.:L!G 66RZB.N;CLCKJ]3275O2G5I==]2[C .80I=
M+A[T1/97;MG!.0RO1/ X["=/C^O"+LEP<-R7?,USOPC3]]N9(W]TV0$PK HN
MT-77R;)B!R1LE<A@C.3#M[9(L7JJ@>O10P#"%//$41CJ!SL-J?-/KE:%$$KR
MO/%TZ7;=RN* ;M.UFF?EZ$LS?7LIX:>7%K _1Z49_E9-FO@=<UH X">SQ6W=
M#9"+2_"/:WQ.J?F4<+<POKA6)DT1DZQ8]XJ(BHF.*5V&\J3ZZ&=PV24I^\82
M0V("'"UAH=XBQK2 [0&EVJJ!>;\,V=AN7PN&%A6AO2.R0:;KE('DX;0>D*=9
MPN\IZU$)Z?IUBZB[N^4(O4/]YXNV>_5Q1G/3M=D#ED;'<3HS'_VFUJ<*/@Z,
MD6!3=\&!(=ZT\>O+Q42F]S596'EPK!S=B7.V94;X%=Y+$VO[7F-.>_*=69.F
M)ONZRO?+5_G6,MI<!5@+[=O?GVD9K-HWWXF9I2>6+$.4(Q?:)%[,B(5ZB5D*
M,["EJP<\94M\(X[PSX@BHN]1*=K.+#C-FT15=^$%)@91V ^:9\K:CP>^CK'(
M9JI].LT0(2\.$E).+=_@?4?IDCM"EL]M* 4CQXF0UQ:X(V3PU&VW%X7_ABV>
M1.'XD>(LKK!Q5,Z<,+%4]KV#@UMI/&FTVU6BXMPUU/<E,Y?UW@"3WJBS7-(.
M-HS$ HO'K8@U*R[$!/&9\]I_-GG3R#MZ_ZIM8C3%K<T6[VB]/H?.6//X#2W
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M&!R-?TGG#QER(7M<R# ;1_#/%R/0C >%:VE<M*.9 B +D <H U0!- !3@"/
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M?='NZ')XN'')<*UNYV3U_%96GB)OG4$"$*^:9*><S:1[B,6!Q=$\>G2M\!S
M1I5^^.) L4/WL*=&;&,[\RQ.]%>9#)F)KH@ \XW7GKTB3QX2)PT)66 0X<2>
MHC=HTN^"@8Z<H\+EH7I/#^?E,L4\!==XP9/KZZ6DUAC >8GVXCVFT/MO7YT#
MW$3&$=Q%#ZN"PT&]D'!W@2KC7R[NG^4RJ&"9&4<(;1D/.N03.@<LR7&#/@[
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MGNE;L]3#<P]'<4G9X2T:^+8ZW89?83P<VL<B!_\1J>B@ZU5D-C"T'D9.<OB
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M>UJC<&\4:3>YLTBY6YH8I^(4+/-<!-[*8K[@NC&H[VSKG(@&FW U-N<E@MC
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M-O I?#SR0._8A=Y_X+Q5A*%9;TD)=WID2]4X0=!'J(.E^XTA+L]B:01*P';
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MW2HUB_IH4\&NQ?V>?*7,SI$XK-\-ESVH=-YW$5EB, TA<QC,AU>*:F9;U(.
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M?5M(/E(TN+[V56!0303*'GK0?>_-!\_1SOE]1RYS >GSO.RRK<5=)]<S+)4
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MFJG1^/Y35_ZK@[$/?]1Y6?8S&OY1Q^[_C!M))]31PE#WCC?:;Y.7U/%>+ZV
MPB)Z,6EF.5YAGS^&KPSR[6JIVCW,F#4)S%/V[Z)GY'4/*:A;G/WUY!& ?S]I
MG=F$]<&5>,ZO+Y^+Y9@O"6^"WAO>',HQKP4R*+,94\9U!<A.OK_5M4M#P 2)
M:UT?P\],N>3X:W'()1P??&R*]NYXJ$U,KH/5I9X&IT1%<(Z#;G8UO\DG<@-W
M!R<^'YI2G$WH_ 9:I!X)8V5\_;]@YA#\[L/I(27J;L) )RUF47,G-)+>N*T&
M:9'V:+Y$R2_T^;M J^9=P2??B'_\3MROF]%5Z7I")"UO5MJSK-NPWO$S_J>
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M53SGQZQ5VY0L:,/X:@>$SDB<=9 73*((:6N09Y5?=ARX%HV]#A<Q-13SFQ*
M<]?="7$\31VGB3J,VY,)%-N6B8^&'#SG=W05O=?1.U]=]J23#LY6$<*^K]%(
M96H^+A'$GIOPL*0%=R/;\7W<?H7WO8I[<@'5-\M:!=VKY4L9QC(*XNM7=D*H
MA?J6KS*=>R^:DV-(M;A<OX::"O7V$3S?#9XW?!X>JTP2WZ!JW_ VBN%S#'7S
M4=[E-HKPTWDUR3$YWNW1^#TLN_2TTJU4(,M4D]VH^(@0:7(UKP#-F51<>6@*
M(4XTT)UCU#]3+[@3&3M%8>)XYF&G94Q.3#Z'-2%N96V6FX\G0!XE(DA28S!?
MFW8O1LE.2Y*M8:T[P& LB[_2P)LG29Y.R7)JT]R;':)"1BC62/Y9ZZ3DY@XR
M]NVC"!A)HUQZ'H='81?+&L:-<6Y*9FW$U?/&7+M9G8[^B0DO:)^2=?=[\N%.
M((/[H+$A_B+CH>(-Q_&G&ISR-IQ[]$HZ]:I6=A< I3M]A*[H5Q@WAV&3!I+%
MR3O7BY,[[^$]ENT\:7^F&-ZLN[?(KZU9'M'^N;-\03,6Q+-YYF/\_P$E0-J_
M.GC)=5>(,EM!*W0TK$EEB^&9E3HEC::YE#:F+()7EI:* !-?A3JHN/1AR\G*
MML2%=1LS*NS&UTXR*7295]+O39 KF-MMU;1G<N4ZGO!)'$_D>@-+Q"QGL<MH
M*7>6)3;GQSW(:2U^Z9^L5"TW4AHO)PO_ %S-E<>9NJQASLOERFQLLM&MQ*>]
M/O2+.LV'G5V4U1P>Y"5$:V=4V>#G5@MJ(Q.IVL>2TKK>7BD6ECG.5]@T ;\9
MLLQ796B;14VYVR?B!>!FPC*,L?2,YQA$C::HVL-E-MDP=,"!YWXLJ+#E>OU.
MY98GTQI;\&(LQFA$$0F.IS758211XMU2VNE?6R_&5M5>(D+RLA&1E&<?UDLF
M M)31F1RVTN<K6PM6:KP2< )?.C)1F%G:/FQNZQ-R"Y.^-[2TW()PL/U<AGZ
MD79+Q):(^"M0-R[#FNH 5CU_'==JIO9JF&+)>$P*N<\,P<\$)S*4%_\ ;3-+
MPC_\_1V<XQPAL$-BS:[YS8[/ZH,&O%4&=]>,#CVD\J21Q/<H?#DJ_P =1:Q5
M$0!HY%L#;9IAK >WKS,"Q'SC:"HK$W73N0YAA%5W)E68XLV$D7@S,4FK!8^<
MXE'/ZOLGBP)$Z$A#22]@:@ZDIQ4VTD+(NOMV*HC++QQ[+\91NG@_$#=$!B$L
MWDKUKC4U9TRWL[L&]8FW#D-G=<G&J;,R+(3J:"&Q,(('-NPK*;H[V;'-W9!4
M9JG0C2W##,:D8U[-GC'NQ]&[4SL'X.#BV!\\!X7CYOG<-.NIEG.+Q"AA*ZMR
MU>[+Z8K0=E#TAFO[!BC2S-I\7&WQ**E1@B=WV6V#6P^P7,2T&GXLPR&7RN'M
M1>&B[(0F<N@?%3;$F(<V4<*&>2X_JI(\"J;E<UY841T>U+RZJ)%/J\',FGQ!
MI&/FU=EL/"?U;8)5!7L/C1,K?4':0LC0JW9,,71I37"Y^=?+X]U# '(>JTXO
M+W!#<6"0.2M,UR\4S#P7$9HWI&NO:V%3*A!L(H],)QLC]&[>MONC0PSX79M=
M<<=BR\7VY;SA9MP9'#F<&DW:56,J;&-D2,U_*ZQBVLOT2K,L7GJ69>OJH^GF
MCS!SINV*)15ZY#%C!8PE$-_L)--"#4,V6&:PHJDY67:[8G:PF&AGFYE^K;'G
M'E[/J0S4,/67=\R#0D- D@1:=7=56F=TU*;2>JB+8&D.XK,QE9<2FE12C.!J
MO6UZY92TV55(4OJ:5H:Y6YSK+E>W3F"/-38&G:QI\%V"PP.;Z#5,_K\TM:3Y
M==E*C;+5]E-T+Z_HQOL8P/"[\^K[&VN30A")/-9F!!5IUEK0GK[62;./A(6+
M;)CW: ZMQ*QBY\C2M(3CED3#K-6%5>G)T=U*C66S*@O4DYT16ZFNRP!B5*!4
M]A(S20W$NIW!C1$0-5Y(:E76MH_599Q'!UUIYQQF+*56:_.["N]%8H(K?BJ*
MI#;/V.J$ECJNO.'?9RH.J6D+IO6S/KNJN+X%[KU7Q"F"I^?<P8]?*)!(V H]
M]M*!7QHA8!0U1EEI1M>Q1!L6:[>UP'IY@;&$\TVL:/Z-)=RG#Z+V/;/33HQY
MF.P&-U0H2PD-L#2!&#5&$>*/HI8>==8JDVO[5MU1N#JK1=/I \;!CJY1/-*6
MC4@B$CC<V>OPM$VQ8#6;/991IFB8$I>.7(JY&E/&DJH<4!%/=6MMMUG3*?6A
MXQ0V_5KXYG3@W(-Q1\?%27_)E;6=1-VPT<ECN1?VBW:J[8*.L@\BL>VCQR,]
M&B>"U@9211OU-\ZMH?)2PM:6Q:[1>5Y-<(6$WS7SE"=DJ\/+YJ>,6<+9Z3M-
MV>!2Q:&P'SB7F>HI0VX!<1EB4?HG9&N5@(>)E$$V9JP_UVUAD[2;PJUSRU0P
M(-&'4*E[1];)"IJA6$(+*P*!JIV/>G>(7'] T69[I9U\-*?:FJUHJM+%"/<=
MAC^5K.A +R"=MC""D(.(RE0UF^V-E91(< G ]A7FYM )P4/^K,T C+E6CK_$
M1I(<N&J21"G.O1<A":S=0QO#.0VZ=C%+#<,F-'NDJ;D"BYG9"+XDFQ>R36Q!
MT%_Z%GFBDJ@2N,;9>#RRJ(VSVD2<@B]#8L@-#V#.NNTQ A=;3 W(SC @B?F7
M:Z5,E;]$[V;7.P2/IJZ*YDVBXHC1NKU@LCAK @K7CB&4J[,0Y0!.?#@YQX 7
M9&/;*OU/-<;+!VBDJ3_:51%=,^T88<H-'+I!<[A.!NMZNA)I8;EM!!+B[=6;
M>Q"'6D']7B4('Q\?Q3^PBJG6%^LM%HYE-@T:N,U@9W-D<$MH:&N,RHT323&F
MP%U1KLN%JNJK5T7B;?7:LDI"KK*UDP(I,79Z:R!LK(>.,8^#U1!&LD#R$U '
M$5UF%PWA8F9/T]O56OUQF1->'$$7Z(MEX*W-MES.9$9TJO*Q@FP/ _:VWUQA
MKV@-&4-87>F)'%C' O@\+#$/<"'&4>S]AC5C7ELW5VFUETY%96\.\XNG9$!J
M/8J2,&Z*/YUL=CUC*^6HZ;)./E?;.2G3*)#VZ:ILB#JJ\.>,8CC]9:'UA#VW
MWV26B2(EV)KY 3BUW<N3];B%+=?:C9KQ4;GBK-'I]CJ&((L/J'FIW._7#Z6X
M^P4>;$:J>2",CQQ7"S$L\EY-->EJ/,SBNO'LQ&./HK./?C8-6*R0#IK0JXE(
MU566$D5Q*UU7=P35;O!-;2%2+?&=7GRJY@O-]N"!0 ]NP,S-US-]-Z-+0(NI
M$JC99C$B>S=*M=+]84RLTK7R2M<XF&P75B%<YHU8^(_KNP$8BPN-KS@-AFK&
M[EV97+W$YLECD$X.JJPVQDOC7.EC*F!1MK2V*^4[)J8SAK&S&::6KV);LD**
MH^59_*=I&93K$']'K)%-P'T?G&,\V%3!@OH_MY\N/CSG^F5%L9TE>_EW_%GN
MG8/QLW#6OW:ED7X0LLHBG**\B:Z&;KF(\I")C#T1(R8IN]M50&"CYO->:>['
MZY;9BFLVJQP3-;135=?75/<VT1P1:<4M R:D!TI#>CA3<7/9"HQMIU+"E!8-
MBDYJCL%$M&A*R-#4 C7>X[81%?*3J)7U0D$5F6$;"(#/XD!R$XV8^CB[JQQ_
M^(5>3G(]\9>9&J$,UMBQ%F=M[&(>1$45PA8LAB.J5DC:NE=Y+4C49OLM!Q15
M)C .&[O:6!_7S @PFYEF4:3/!RLR$[:,YS5^ML__ ,)7*V=9N90Y5[KR74).
M7FX)_22HC-TAT)C::(8WI3+%5 7O+*K)'=BP]?IQP[ #=-0(3SUF$L,3NN->
MV.#'JUHDE#6-Z-MQ7L^O#HFM>Q<K7Y\O7VMXQOT9_CEC4"J6VN*+H778JK(.
MH\Z+=>'4^[=$6\8%;-L=M0E5=:%.0T(;"TTD]>)*R$=85NFL<AY\@"4+)[@V
MIO;[72..1J1WPQCZJ&)+QA[Z\J<PRF.]8-^MG5><*H\4;&5>?';5:+QFVG!G
MZ ,_2-.9P':-LWZUL.R;*P.KZX<E5-<,Y0EO)&5S[5SLC/3@@V(;W3"5G-+V
M:\-RX'G94JIQ*EAB/@:!84%5LJ[1M?%M8,_HS:6EHE-8/FQ>^2IJK/?[):WT
M/9_5"]>.W%RGJK7$E&\U4\U] 4Z8&4AZ>DKQB[.ESK"3-)A'1UU]5X]A+@&
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MI<S71*S(]4L3'YM9D\E==)+C74<0YV$162RBD4?!]+2PM,W N3!DF.7ZP@8
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MJ2YK=/\ 56M:JC6(V*FU?DVM<#AQ,E:GTNJTL$M9*B.)YJN56>IV2QC'&-4
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MT?S[Y;(VBNV_,CL6U\?56F*-55>!<$"-<*U&V#7F VN$7J=:MN!>7'SG'/\
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MF'/7773UM=8"'^5WJN5D(RLIQIVR4+W=I5.XM]AVB>H+]G=F;(VTU<%K:U
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MMS-L&LH3W:P!\(4)\NMB7D5U1VW9?AZ^5%K%@U7^CM*IK^(KAO&MKKKAB/\
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M+N=M!K_F/)5I@6]<]8+7N(</'&YXWYXLB0+?>#@:QT$&8N.9-[0,5QXUC:O
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MNZ>_[\\L11PCF 9/];.4GH&$7?I 2X&UYHE*;$.47,EKL94-(^>(:P-EP8)
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MV_L(/I,,WTET\'VLQ)W.:F&#2#K2U]\GPX0+V"BN$7)+O@?_(AG>AH8=)3O
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M!2>($70ZS2$D?7+.&F&ILJ Y.^R9S%FC@$JGXJ\UDO-IA,.(R<)A[;^ ??X
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MY<\MZ+J27#?O,)Q/NZZY7H%YE9>B]EC\K[8A9TT%1>>7H2UWW][Q-S9]C#X
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M!S]S1*G-:7M/NG^C]A,CE+32(IAKF\8[#BU"L^IV* YLTA 0.]ASA!TML:B
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M( 77:.6K]<[HB@+A#*&_5\-526R"2^XS5&ALE9ES(<7:!R"+]6 Q](_0>M7
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M 22RL^A-(1EI:\<=[M^7-##>T:91 PN5='?EE+&T2N'WIUMEU'YTM$M4&ZC
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MK!9=S8(WXK"I$_*=O_#+^/=T?>\^=>:N3M1._\_J,? 23X&%6N?(T7MA2)3
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M8Z-';RQX!?(0K_U'FH7S_I'/#>\V<LSO1O+J!D6'3TXFTA(2>C"D9S4>NT:
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M0,M.3:N($?.\.CD<BV@9O\:-<_KYU4<5.S(4I1RC&+M"HPZ^W1)[GD"DD*P
MO5V<<B#X%;FXG@(6G+AQPKT')72)M$>IVPQ465!'RWZ4;L#.(<;+BSCFJGXP
ML/F&(@30@@>KPX5+9$N1D<J?O\0Q_)1, ,9B@OHY8% 0S X$O\,[8_$2+HI>
M0!)P5)%] ;[U#S-BX>>/#(&N@)XZ]<O"T3]JGZ(]?K9S3@A6K!&2]G5P8CDU
MXI"?#UTD'\Y5IMGF"+W6[GMI4**D6^EH[!343KJ>UK[<8K/_"%&('V1+7*^^
M&]\R,TVY,.*BXEA6^F]2IA5@&>PX46OW>[&[>%?- %B SDW90:R1G$(#P$XF
M*\C;^B0-.SQH53M!<>(A:T+CG#\YFS@T?L52]K/.[ L +'MO=V[34M"F$#?N
MB&Y$1@F.+#I!P,UB(&9_65*\":M^ (;6%PA!)AFQDQT#KDI.Z-"R\$2^ '"=
M<8?BI%OZQ&RJ]WX7&%%[N[7)IP+LG+AQ3+1Y7X"*W*?H3T()$F5(%ID D43>
M-7,">V,M.]8]).)+::E5V?<3Z8[:&X_*?,LQTIV16>%L@8[8Z3O]P-!I#P'H
M#L+_278Y#4CX0SPZ5_T%4..-LZ%%]A>/#'?V*M)LV2:8OE%=)3"]M6PWE=T;
M&TH_!$6X2Z-2].7_.4;(F2A'8\<"3V&5T0W*K_\G6-UO<TAX-$)Y*QQEES@N
M>_K:#W,.M,(+DJ3#-\]OQTSQ![B97BOT_GXTZF,L.92NJL,96,(;@99[&TK\
M66USC'W?6E)QYT14F^^L<5FB"?9DSU3.^007.G]@L\VRXM]7]2)*A$07=GN<
MY[W#L=#7X.@&$8*HWLT\><!:&WW4)A]WAHH?7&JZ%I+-Z7TY:?HI[$]2%]_M
M507$MU1;WI3(EBKLA_)-J 3F'6QMA*O/,%[6@QM.A.E\RU?6A+YA-*#N*:.1
M8&]48+6_QP0PW[@\,!M6(*9@!G;9KC$?N9XBZ5S:(D[/A"'^)$__ GB4C'8-
MAE?YP1+PSKEI? O[(2ZH;>;[!?@]SI^WR K% +4H;J+*:2*\8FY<AFB?E0 D
MN*@LK,^%CV[]</- [F?_T(3H7GT*K2/YGW-:DVWB4>#P!<@,5&_A \7!_3<.
M7<[I]M'48]3Q8[V[>HK(7^,@?]L?GS%F<@LJYE'IW9J0>FAD^U>@[NF2Q/8G
M(I8G(3X55(^R%^7FQJM?PD<BXZON%R K[=WQY$1;@12+6%Y, R3)C1>S^5Z^
MVSRCDLXL#W%,WH$ZJD;)^&E^0SHW9YA=>XG^[J)FN##\@/Y.>D\HSWXC\QN-
M_+&16>#,EQ8RF"G=G? \(2XZYN+*].2D" 8A;I"<8$@UT$OG6(+BF^;AF/.[
MC.#[OQ)#OP"K>W@_>GVQ%-^K][WGY".'<(@HN85(8UQ[1DT'5GM;)W1SDQ6P
M$=JT-,BW/!U_';D^(0DA*\KN\JP+!;-K-=7MT3J>8QGL9=9Y!88:[T4?Z+(^
M==IL3JEY@AV?\&GWBV&Q6INWJ=ZI^4SLE<'O*L+UWMN:_,G4-(]),F'W1GR3
M.-R&7]?;/ HSZ< A,[^>/%?3*THE"^Y6J>AX0JWE.8XQM7RF [D3/8B])[)3
M;TL4)F#AOI*>>!NB)+@KKY1H77ET11_TQ)46'?D)8"1S6.-(X$:M,Y-YKDC!
M!'-6P4C$J'PW3TAAQ81+'9=J'J'8=OR;M#'XBH8FP&"-\=FF2;"= N>N-/B=
MDWDH4I$O"NOS](1/=XJ[7S*@&I="_?-6=GDK.ZNA,+T'G_A8["_"K8 +N]9M
M4->2N=WB4>FF<Q?P6<R:U.7ZF. C%=O8KM_R>\/%T$8VHS[,A]J_\V5X_<IC
MXT_:']HS)+W-)GSH2DC./J/DSJ5N>B;GT__@(?S>5;O+_E,U>#A5/F5@YI9J
MZ,6/W^SV?V>YX'@QM1767[.'AVL?G.9S6$"B9U&-W#:ZX@VU'LA.QYM?C%$'
MV"9HOLC4?P%\ZKFL.WC4S%U-JUQJLARJN.^ E1"[T,BHUU4\LGFF3MM.[M-O
M_L;KDOO26/:VY2TEV6Y\%1SJY)D_;CA'W\H/8PQU^O_R+&*OJR)2Q6*$9"#R
MD3MNB87-IGH8(I%4-2S'\FAJ)G12*JM(G3Z-ZPX5Q_-GF="0$+!$I.C2HO[]
M%-S3LEA7QN:6[$[;W:>>O&_%G>4RXOX"5&;_M(&S?YSC3KPIF_M9)02+R:7[
M?K9]"XE6CO#[Y]**/.V^>DO7 H*W3(B=KL\@4GZ3[;I*R"6?#=G?YGS@(JGJ
M916=)W<<7+R?K6Y&$<\L .O=EHG-9<9A!#P9(N>S^0LP&96T IXG39QY7C'J
M?4J[?3SGGEJW76@[9P?848HF)%00$,5"\\3='^73^]&3:KLD*D*(<IL04.SV
M>N6$?!M^MS07&:D(F4"86H1TN*&8I+4D+F4Z1'(=SV9_/BZXJ<3W\7_T"&2N
MJS>!1>&)21OK]_:!VL%"5]E +<5)X5(6EVQ?C>,J0KU_QI:LC_+(>+O_LK'#
M>67K0CH7-_".C32)/,1I(ECE]06 ;3_PA>AR4VNK$DZ4+J8'/F*@%%RZ4XH3
ME'T!L$N_S\YB,QNS*;D\I(Y/>IP;;#.2FBCL+BRX#7:,[=IW=5P$OGI?':1^
M+(2<6$-$UNN4<_NL09GQ>EP8:6;4D;H&BK65$1')TN23;.->--]#%R:0"Y/9
M?0<^&@\-#6_R<TTFY4C+X<@&X1*9ZXZ0.H]UA3W6M6\^<M24ED@Z/,<A=2F^
M95MV+,PT[&[5R&G9#B\<3&9\F\AY7;9XD.C^L$6-E&.3ISUG@XAF7I'T?H+/
M#L.SE#(UHX5VQ]V/:$P.:#SV&P/S#UIMO&]!WB,[TX:I7F3*H'\=8,6\Z7A>
M1'V=3(B5U:W*SEEOQ++U-IR)3!=&2,R-+XI]7)',0J$M*&#=XUE:JOQ=I?@=
MY]'O4C80T:U($CGF3%6A8;8<#X]@*<<XZ[GBF]CU,-6+#7+PB^A(#5\7/OO+
MZN>.X# Y@J34'EV;N1L(8!A-S$%(HYIZL0Y[O2?/*+W]E^5WWQ?@ K=:=,-%
MW_\'@7KP, ,S4K"YHCZ7)\MG^4%'-C)XH)#;[!I&]9]\0RL+F,LJW(@^X^7
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MB*!2D2BT7&4MMD-F/66M+\E,S>_(Q.G\GQQ$1KAH@GR9M#X9V,??G9,9,D%
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MI<\8?B45SZQX0FU?$43$F@9)\2^:%)X<M;8('D1 <<XK9TLCU56YS$.8U+6
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M2W7IIWC^UX%/''_JYT<&XO]72PP_6GSC8WP^TI8DF,HV-\S6,,R^+%QW?&/
MC0.2;?W_JM3_8XFP.%)M19KF9C(O1*O/L>"6A8SV1=.I?_OO^P7X&@#8H@+
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M,9XVSS^%!@&P<,'J(/)P]M9+",2TFY@KY"BT:**"N,N)'/3B'&IB.]A]QFO
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M'$\?%7#6EWEJX8-0576;TFC)[E9"9(E)L;+(B,1>PQPOGWPY1N955*RE94J
MFR.'U&.5!<E0X5@RGHRFW9( XK:W%%:TG19:,GO[ I:8_J^\WJM[#]V.!?\
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M9(P&D6F4@+"EV47$2K$#J%O6WP./<C4!5AKP   !3P  #8 #TG8#NQ\)T_\
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M8^DYC%01M>.A3M@=#4S@,WMT1<M1^"S2#;?'#F7?!>44E,RVF9.?4>//F[;
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M' >54LBRU,LU<5-Q')IB@/Y\:7=]^XR:#T96&  H"J JJ %4"P &P  V  V
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M!>,W%[DWVQE%?1>B01/*#5"-%TGQM;K[<5)E!-B/&P(^[&9S?^;YB=FLPO\
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MH,NI*",K31 ;>L0"?KZXSA'J(9X?PQ;$]%+"M5#*I':<I?O7%$S5U?1TLO\
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M+/*C=;[7PD#)*UQW&QQF&LLV -146(/?X8S6H,\+T-.H8VTRO;5R[]Y/=CX
MB, $TB"%0':^UV'47QP/DL$-96UT:6A5@T).]]K&Q[\5%2SNX]N*G5J.*$L#
MBKJ7UZ;XXKS(9A-'E<;[&SO8]-![6*Z659H,KINLO9N-].."H%HJ 4DENUVB
M?RK;WQ4Y?%Z^I=)\\4R01Z@"-U()VM8XXG6G@><)'>^ZGNOUP:H560'>YC"I
M[-L9C+R$C>XNC,03C)!FG$&;<B%2:8/\:S+==C_9C)<NHLGIDC55,UAJ( Z^
MS$5296"(FHGP%[8@RN%D5Y5[?4CI@T%,5TZ,1Y92Q-K";^>.G\M9A614<#,[
M ,00HOWXD,<TSS&Q+F^V*F?ED*HQQQ01U4*NZBS79OV;^VV,O:KEK*;)YY-,
M"3J\98];G9?JQ04$='2H ?FC]F*"6[6/3I]&)*0?*K8CKBHOSM_''H$=3/F(
MD6^L[?5BJRR4U,Z"-K)*X7;H =L<+I)35:!E*D-O?O.*%4C@$EQ<K]XQRVJ)
M-O5PH@AVV+XG)D:_=B-@O07.+RRN-NS?&5TP1-9 \!?%AX?B;6Y8SRF:'J3>
MW3$&7N_RRV[K]^*_(W9B8QJ!Q-E$L/K):^U\4F54<0GNBL]1ZY(WVQ4<.N93
MJJI/1]6KE6[-O#V6QE8AI8O1HU"):UABIA99+]QQR5DZ]<&FY,>L>&,]KQ14
MTLS>L%.G#5T@KI)]1:21B5)/JJ>[%&]1Z5Z6L?-=2#J.VCV>.,LF>.FB-[/(
M%8^5^N)JJ4HJZB<1L5@+7WOC/8S/$=(NPNQ_9C*,T97J,LE:US))N?FB^,XJ
M),US!<MH;V64B1E\"?WZ8X2R*+)J)"@!F= 2]M[VWP\DBJ3<ZOIQP]1)'2K.
MXU2. 03W"W\O<3":6I""^D!=N[$5)(""<5-'K-QOCCNG>'+E<7THA+>W%7"Z
MF.9#:>$">.0>L6M<+C@C._AK+Q%._P#&:8!) 3VM?A^XPSBG'9Q15C'9O5/C
MB6B1CS5L1ZQQ24R!\QJ&-T4BWATQFN9JE7/R@ .8^_3?4<1YR\;K(ILR]^,F
MXFG8()7)386)Z8RZIBJ*8O$PO87Q-(W,/7KA"2HU=^(X J$_3B:JE,^F,:(@
M>H^=C+95EIHRO<H!]H_%&IB$L3+8=,5<4B2'1W=0,<UM':& -]2X6:)ETR=;
M6Q-36^,C.W7",DD11C;;OQQK<_%IVK7TV[[X.53W+Z#=O+&698L62:F2TKQB
MYMWXA4B* 6W")]V*>FYR G8 =3BM811Z4W]F B5 8-WXXYC;*LS22AD FF4I
MH!L=+&S&WEC@[+!Z9&\EFF8ZI2=[W\/9?$$Q4I'W+V<.(R-\9#F<3)Z*S ,/
M5N>X?R[(XC1G;HHOC-<Y,]2^PLIT]/#"ULTCBW3$4,DBAE^F^/="AC.1RQ-(
MBRR)9 =M^GWG%;12T*TAG[5C&Q:VQ6W0X@DGX<S"DSF$-Z!7'54!;V5VLJD]
MP\/+;%%51YA%%41-KC=0Q[[$B]L%TA&W7PQ5YW(!Z)27>5^RY&X53X^&(':*
M@DA)O(R]L^)Z^W%9(K9C+'(=O2V#=W9+;_9C,>'IX8(JZF5I()1J.G?2/&_[
M,153I&NB]U;[L</\23TQ4$.Z_. W&*+-:&M<$RHI/4$BX/AA$25U","OD<:5
M]4D#:V*NDTW*XR*9D?0QLMN_ICGP].8G^L, @[C\3W8(C,>@!QF-3-Z6\D![
M.K=;]<0VGBU6 )%B//#+H8KAV</B*14I6>0V4+WXSGB Q%TIVT]=P<5V>3SR
MGF,3I/><19JY< [COQEJQ5V0,Z;%(@1BAI$E@B-QV%53[1BHFY$?+C[N_"U#
M2-I;IC.*R#*J">L9@.6A91?UK8DJ9LVKI,PJ26U2,*9&WM&YV(QP73N^:E =
M7*9=7L(O@47QE_/$M+J]4XHZ>:&JC92?6'U7PE]"WZZ1]W\N5O\ @TOYN*M;
M3O\ GG[\4H#%<2MZ+2W&UEU$XX\S6HKI&LYTP3H$7N8%OV8XCIDDR*GG8=MH
MXU]EUMC)J:GS_ARJRY[&2GC$2]Y! N;??C@;.S0SS\/U=^9 \FEF^=VM*V^B
MV,TGDHZ>2;3=MM-^Z^VWUXRJAY,1G8AYYQKU=X5Q?3]&%B8Z@1W$?8<<3(]#
MF\H(-I"S_P"U^_V8X(J(<UR44LP$BI&J$-XVQQ!P_P#!,LD\=VIW8FUNA8]P
M\N_%)F HIE< 21_.0]^,I-)G(YE/_%G!L>6+;CKOBERC,.5>FKIM8W[L5%+Q
M(LJ$SOIN 3<=.\^W"OFU-V[&L3YX=@+#V=^*;-J26-N2=,XN'CZ:3W_5B3,Y
MB^SGKC(<Q>8<J0ZO G\3C40*;&5 ?SAC-Z@&GM$X-_P=\04[2.2W3$:Q1*%U
M@';;%6B*P<NH[\5]?04RZFFCU#NU"^,YXGD>$QP*XB /;^:<35LTLKNQ-K'&
M69-49S4@HK"&YUN;V^ONQF\4-#5\B(_)J5>Q^<,<*S%,EBU=)(@"._IA*^IR
MN5@]VI)&+7_ )Z;]UN_$56DX#7U*_0]V)U"W==E&['R&.)LRFXDS2'(Z(L:>
M![U3KZG*(.Q(\6'WX$ >O2BA4 4R^CFP[Q8*3C@2C2@SRMAJ9H^;)RBH)L=Q
MX'ZL-3.;FX('ABKFFBD[%[8AS-XW5K;@CKC*JWTZE20^M;?^7*A.9"Z^*G&9
MIHG9?RF^_%$X&DGN_MQ.R5E#,B,.9RF 'T8SVFJ?39895-HI5[O6[0Q74;U7
M#Z+:_+&KZ N.!:AJ3.?17N$J&9F!Z; +CC3)SE.:TV=4HL%=&FT_.2]_IQQ%
MQ/)4Y;0O R:9E^._"'ATZ?3C@BM]-30\FNR ;F^/@]>H9;VQQYPVSU(D ^;>
M_MQP+F@RVL.7N;%V[_(6Q/3QURM',NI'!M].,YX&E0M/0&PZZ-VO_9^^V.&*
MDY55FDKXVA9O58C2I)-OI\[?LQE%3'JT!KZO5-]C[,9E.PET_5YXH6;5?J.\
M'IC/X#23KF-/V;R")P/5LQW-AB.$SZ95Z,!C(*%T;F,+ ?B;FU4::G)7UCMB
M:OFYA8NQ-\1YM#!!KJVLGGO=L-45]>NJD4TU*W2=39F'CI.)LNSF29>172E0
M!VMKWQ\!YD8R]7F$Q'AM;[,9C0T]%&]1,WI&BY"OO>V^*_._30$BB6GB!/97
MO&,JH3FLXIT!"[%VMW=XP*.ER'))>2%5EBW<"Q-L5M2];FS!;GG5(^IFMC**
M1H<JI4'4+AZ998'BF *-?KW'QQECO'4U.7"SI!;EO?QWQQCQ!\"9<T=M51-\
M6HZFS[8X9RU,IR*MSFJ_PJJC,VINH[P+GP&.%DCK,UJ)[ \TM-?VVM]@Q433
MP<6U4R.5,4<0CMWXX>KVK*6,N=5D"O?\*V,TC"3&PV_X8-F?Z<<,BU)] _EP
M[@CQ!QG-'RIV,@ZF_P!>)>S;1]F&KVHZ6>8OI*1,>O@,57$?IV:R%CK629?/
MH;'[L0567OEZP:]+R1 6*V%ROB<9A)\$YWSTV$<@4$=+.1?ZNN,WBBSS(5=;
M.>2M^_?3_;C,%J:2>6EE=EB5B%4]%MX8]S;,G6K,&KYPM[+XUR$BQQQ3%S:'
MFW[2D7]@_>V,T<T%9!FM.=E>[V[@6L<9'6P5V705*$->- WYUA?%15!.F.)*
M:FJJ,2:1'*)!ID4=I6[F&.'*^>$PTE2YU&PIISUDMU]F)IE(!FL7 ZGOQ254
M.JP %\<2O"F7!=0U/.@'TXR.B=HZ6-QMW_3B*-8D5%%K#\3<VI344YT[D;XG
MHF$AN+'?"QMF&:BF-_1X$$ENXNI[\2;4R*@TJHM8;?=B*9UD&_SL5U2L=,JD
M]MAT[\<59I'RO0Z<&:IDZ*G:M?8W'EWXRG@NKK662K[$9ZI8K]M\4.3TV5Q*
ME.ECXV_;CC;.?1,O%)?M3@QVOXXX=R U5;!.1N9%?Z-5\4^6I'%'&6 L!]V.
M)"E'02$,!;>X-CC*,]DBSNXE')9R96=K[6\?V8E+<8<1PCUJ:D:S#YK,K;>V
MW[?+''S+09;2Y=!MKO$5&VS#R^G' ^72)&U0RFX1E!/AW8S."?X7GE3UP%W/
M?VCCA*#T/*Q)4,-3V8#Z,9A4+*Y883>4;=3C((>71(WX7\N\7'9;==M\1FS#
MO\<9G0/F%+)31MIYJE"?)A;&2<$T\>9313L7-)+V>T1?OW\?IQ-E=-54/)T:
M7065D[)! L+D8SS+ZB"OEAE[2*QTMU^LG'!$W-R8PNVK>0&YOM<C'&^4\N>>
M15]<G00,<(5?H6=TVIK:Y50W]N'?3212+\]+_9BLD:J@E@;YRM;VVQ7TC135
M5#*#I'JW^DX]S>NEABFRRH<]EG=-1-]))T#ZL2J^O<7QGB-Z 3;Y]\14X^!*
M:LZ34P+*>G4X662MI(IE!-D56(\;;XI%=3OC/RU344U,#LK1R6]AQDE08G2^
MZJ!]PQ#/'.MT-_$>'XG9S1VD$B"VJ]\904ILZJ()F[31LPOX$XJ*B&)-/7]_
MW_XXCJ86?91J[O;CB#,)8 J(>94S@B!? ]_LVQD%*GPE--4MSIB&8ZQZAOZ@
M\@<0U@N%Z+W#!ECY3.U@$4L3Y#'$5>,[XC>)&U4M*P)/=O>^.#8XWGU@]B-=
M ]JX=G)N";8]T;,&I\N9=5M2@=<1R2R&T<C"1V/3KUQ[G65>ATWI<R[V+N3W
M^>.,,S^$\\:%#JCA967PONO_ #QDD]#0T2)(W:D0-8"_4>6.+<V2FS*0PC2&
M"V-K$[G'"F??">5VYERA"^>V+L7W)M??%+"LLJJHN;C&70&GI8XVZ_R[G66>
MGP]GUU^W%1E<M,;.ECA+1VU8EF2CSU?"K+-]6*:K990+=DG[,5>7T6;OF%K<
MU#MMTVQPHTE)4U='<D1O*MC^=>^.*Z#TC*9YQ'>2)=C;?? CF2N@G0%3'4+>
MWBIZXR1AF&0T+L>V(1?SN!A,OCYFYQQ7D%YUFI4$DDA.KNZ>>.&\D=*D5<A$
M6DV< CHIW&_7"OEE4YB2=>;TT[=1[<9UE;>B3(!>RLZ^>VV)^-*2AH9,FD Y
MZ JXWN#?]N,HXVG?D4,<1"O.@U7^:3;P_?QPLL"0)(SJ-2W.XOTPZ+F-;&](
M#(ZV#$K:P!\<1P>C1'5ZY&,C:3FL#ZIO^)KNJ*68V QG-;SH_BO5'?BKO#G,
M55>VI4C^W%5=UVQ3Q2*Y>QLG:/T8IP,PS*KFDW]%^2\KC&3(S9E5_G2_?@(Y
MM8=#UQQ%7G+\FFWM)(IC'CVUL/MQ102T\$C$,U1,Q+,=R26V^_Z,<-TS9=0+
MUUOVKG\H7.,OE,I4-WX]UFN'I4=(K;VN1]F.',N-14J"M]9&G;Z_W\<0HM!D
MK*.S\20>[?1CT>:>H:2*[2/*^YW^<>OL&.',FBI*2.>=3)*T=^WVE%QX''&/
M#M%6I+6E=,H4Z2NW3IMTQPKPW\#TL<B/J6H42D$][8F/08R#:M7O'=@=![/Y
M>KJ*.KB92!JML<5U)+!*R,.A-L9_ECF.*O0'53$ '\XB^*O,\MRVC$M1.BR\
MA3HU -J*]?KQ3>Z-%15U5'!'([5,H <+J7?LWOC)8",^,Y'9JJ5)"/-S?]N.
M(*NCH<JJS,C2)IW"XJLPI0LTL:]9Y"O3:Y-A[<>YQQ74YG329>5M%3635;Z>
MN)LPIZ=CS*J,;^J7L<9QQ>8OBZ6FDE)V$A35'_K=V,PSKB&2HTT\Z0Q-VFMJ
M'7NQ19A7^EQ.:F4S1L+V=M#>T7WQEV9Q5V6*:DZ75 I+;; ?;CBG*HJG/JF2
MF0,K%=UWOU\._'#G"%3+(CF-E (-[>!&*3A: ,#4RRFWS>8;?5BEI(XE6.DA
M&VVK2+_6,? \LUC(P'E?%)1I2II7KX_B;F^OT7L>/=[,0@21F)SN=O9C.<OD
MAJ$J&CU0+8WZV([[#%/7T4VPD^A@5^_'$_$]3D]84I_C(GB86#6&,O\ =!6@
M>8S0"]1ZQ)Z=V.$:9ZN)ZTK8U#EU'Y,FXQ,,NRY1Z7,JN>XV..(Z*CSF'F0S
MC0BBR C<KN+_ /+&4</S2UD#5$2^CECVNNP\K?MP]!3JB(K"R*%Z>&*.GB@1
MI+WT@G[,<=-/7\1U#[E(V<#OV!OCW/<N,PFJ'BVB :/_ (8XAGD@RN4#LW;[
MQTQD&44M-DIKYP"S)KW&X-[X-:&I8.4++RUZ>S&>U>HTE)WU$A1O9UQ3V6F@
MA'S(POU8BH7G:RK>^,ER,TSB>9;'N'X@9Y)&]85%M@+XX@JQ\'SQ#8 K]AQQ
MCP[/G&41YC2WD>(6:/?U47KBD#Q3QJ\.DAQJ-MP0V.%Z:6HA3,9UT$4ZPJI\
M%&QQ64_I:2T]0FN.2X(QQ?PU)ELQCIXR8Y':0[6"W/C]..!LASF.!FIF>EBF
M +3)N2.XVQ2\*0Z>973M6OU/,'?UQQ!%04.7RVB2.R'3;RQS)*R73!?46L!B
MGR'.5=.52J[.1OJ_X8RWAS-&HU%;(T"D;HIN.F*/ANC20?$JY\2-SB++>13V
MIH0#;N&(,OK990&U==\4M.M/&J@;]Y\_Q/D19%*MT.V'R1=9:-K>TG$U)+#\
MH@E3V:A;Z<9CD5!6$L+PO_U;:/L&.(N#&>+7#JDMXDL2/;]V*GAZ2"=>; =*
MNNK4O@1?&15M%3Y7&8BI9(%&E2/6"^6.+,QJ:FO><RRJ%;LHKD#ZOV8%5G@D
M22GK/BB1=&=CL>NU_#&4<3YC2E(I(/2(QU:%-17S/AB+/J2IT@R"!]KK*VDW
M]F.),\GRO):BJHW673$22.T/[,19YZ=/-/4+=Y-;GROOCW.,XI9J.6F2%@44
M!I"O9._<<<84ZU%##''L&J(22/SAMCB#C2?)'FR,Q%H1&@5D2]M77?'"W%F4
MU]+'3RR:91I4!V W\+' R_X0SN5AVHZ31(EORL14[Z](&]_VXR?+131"207D
M8=_=^(!Z'V8KI;5[ZCU)'VXSVE8T<T@N5)7[\9'"GP<%D *-LRGI8C?'%O":
M4F<0YC2@<B64/*EK]"+;= 1]V,M1TI:=572.4EQ:P]7 HHY.U<:O#&?\-4V9
M44NK0'52=1VM8>/7'#N3)2Y931B1#9+$@WZ'%3&((^R+V'7'%C9O73U,:4TS
M4\9[#*-C_P L0S>AD*JDU%^EMU/F/+'"?$=:)$I:J%3&U@)-._TD]_GBG[:1
M@FX>WVXI\L@CLUM^N B@6 'U8L/ ?5^*3 ,"#T.,SRJ;67@!L>X?=BFH:G2]
M]5<<3-#G.X00@@;(X.[N$MQM(.@PN 1WE^ :'(;@#L&9P3U L. >W-W=-<CF
MV7ONN_O+]ND_H+M/]:>^5=VGRBU>$$]%V"*=E"?&'0Q#'D8,4Y1]":46GQ5)
MFB>OLK,DX<R-*I$MP9%5'AOM6/9_@OR9WHFS/A4ZQNCCIZO,*-!W**M<U]YT
M(!VVF:X)PE&Y#JDZN]N*\+3DNE:(@-F:9V0G'990USFBFS\@@2V*L_JZO+*:
M 6M*8UOS"'V*B3))JOWHV$@N0@Z"#T:X;G1U;,R3\@/Q ;"?Y,K\O8?D?+F9
MA!\:NLY/Q93YT;X=VA[Z8Y=&YI=$<+,;#)UB_+I(F+4:*:N84F#M^&0GQ71%
ME;"BXWBS2:\52^B-2QZ!G'=+8G$QT!#GO*JR%.N[2)@7[V[?\%23U&SW:]Z[
M3O!9>U/-KGG'48?G@%1%+],DJH9NF"*%;5M#],_/X'9E1["=%@2OH+3F%?"/
M;1Y<NNF]0-O2>43'*J 1R3>EQ;=?G_EMF/0XM@L8CQJY*U&&M47L>1@:B+,!
M"&4=KG\?OFAIJ&EY\]0OIV#8-Y'ZQ-8DSSY)8RJ-)@)Y%<%8%+>!R_[,VI[H
M2B#TU=JSJ%+-#"6TAC[^5L'2?+G@9($$WM/9&4>AS<J68I"V9@'IUT]-DMX(
M_L=FTP*_N(C@3%X*;U ;H"GX@+_."?6)8)DQ27+Q#\YK]A>\;Y6)3GF^.[KN
MQ(2'EFY55)33TM#E/1(O=;^+HFRF\$M+U\OW;N/K^]K=+[ 9&A-870!U:FA
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M_T>H!%[5JF ,G\-TV:4['V>EGJMM7:H4$!,5GP$+@<M3V-JGN_]^#O$\Y#.
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MP^M\/<NP-HN)W;YN'(TI\4<,:3G_O-[V7V"%&,1W6N!5C#ZN4&LX6'[^ZRN
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MX-.G^"EI2OW:!'%\D'>$NI=>;P8(DK%]MC")<",.0.C3%Y!*[L4SEH+C9OP
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M3%,@XY=X\Q&F6(LP=(I8 =5,1VN0I1?P#G[Y-/AN'O#?8 ', P0!0H%]/MU
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MC8SJ$A1MMR+.R?@\SK9')??@J6X(6I<:CA)ZB&(_!7JY2/@OTBYB&"#X?6]
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MUKJ, O<F53\XGR[\5>6U<\'ITL2)R>V%"V;4HOTQ%,\U' YU E>_]_+$3:7
MV/LPGQE-[!BAL%*CKB@0I3I?P_%\]#C,#JYK#Q/WXI3\;C.8(JI6AF021M>Z
MG%?[FU!7N9()/1F)N$3Q^F^(^'_@F9*%_CBT9(8C?;"\/1T\1K'&EQO$/I^_
M%.&ERBCMU6GC'V#&][,/KQ&D2L#B:F2>/L6QQEEK;-IW]6_[]V(LOIH4O,X\
M;$8X:>AKJ1\N:1;GMIY:1V;?3BBEBH6]$KFLR'L.WSK]!BJJD<[$%!L-^[!Y
M3@Z>N/='5QER0@[.T6WM<#'$5"D/#^626%UD1C] &,EY.<\/U-#+9S>ZW[M
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M(XE.D#[\!))NS<[]V^(^':B9=6DCPVQ79;+2J5(/3PQ% X75;J_[,9;3RN
M#OB?(ZESL#C*,I%"NIOE#]G\CLP52QV %SC,^*)(I2E.+ =_6^,EX@-8_*GV
M)Z,=L'J/#!V]XX(#"Q%QA:>%#J5 #^/4L:RHR,+@C&:99,DC64VOM;&3Y1-+
M/VP0FDWOMX8.74FCEZ!TZVWQ#E-)$VO3<]1<8V L!88JJ.*K72X'M[\+P_3
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M/$]6[$ E0?(;?3BKYE8_-E?6>[RQ&&C8LVP V&.)VYW%+RWL5+=GV';$$/I
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M/:&X(_LQEM3RW&H['#3Q7U( ?;C+<UCD*T[ *W06_'NO@,],Z#K;$?.I9"K
MVOB6H BU="!?'NCQ2K,F81,R! VLJ;7U6O>W[VOB@XDS'+R/1YKK?=3<G?SO
M]^.%\R?B2%X:E3U*V:V[6ZC&<Y3\#5;1:.S(U]5MNT;V_;C@V009W#$6^4#-
M;[,9YDU/F"%*B(,&7K;QQG?![94)*R)OXLN^FVP\O'% QYC2]I&Z*O3?N)&W
M=C*>,!%$M)F2&(+I6.5R MO+QN?IQFV64^?T?I%,X=U&H2+Y#8#S&*K+RK&*
M92E3%M&_2_[]^,X5C64C2M9DF7KX#&3.U3E%'O8B(6\\)3FX<[,O?YX&=UE*
MH1)+@8R;/&JSRJ@=KN;I]'^1<0YGR8^1$XU'UK?=B5VE>YWN?IP*;5ZO7%-"
M\48O?%53ZQK/2VIO9CB?/XC,V7TS#2@[;WZ@[??C+*R:GS62:FIGJ9;NJZ-]
M(/?[!BBH\WS \VL=F#6/+ *%1YVZ[8R;(A$\;NVUAV</3T\,!$$8!T[G$B2<
MPD=^QQRXHZ60U-A%I.J_AALPK%%;2T4GH]*^MT<]I2JCNQPR[BKJ\QJ9+P:W
M&MKD$HQU6N=M]\+Q":L<I!\2JV!%K-X6MB5)\SJV@C!ZC4UN@/3[L19%+DU.
M]2*A$=OPT!N6'08R>&MHA)F%3$;5&I&:P " ^M[+8IGYFB2/=&%_+%,-4!+=
MPPE8E/.'ZD'NQEV815T09-F W7O]OX]9CF"42>+-L,&L$K&1E&YOC,JQ;:$V
MQQ@GI&3SBVKM*+_LP^5U$*++RFY9-@0I[L<,U-70U44L+,%!&I;V4[BYVQF<
M$&?T2RJ!Z1&H)VL3I&WGB-'R;-::NE)1(_BV_K,.[%/FE)7TZS(Z&/0+FXVL
M-\9H\F>YCZ+'<9?3$I.>YV&X\CBLR2DJ+<M!'ILHTC3N-K_3BNR"5H.6\7,4
M>JRC4R^!QE;UW#R%^8\U,>J2'=1W]D8K9,NSN#GPLL-2!WV3?OZ[XXOI&B]&
ME(TE:@"XZ,!WWQPCF@J,KB4'M1HJ#Z+7Q3U+E]+;@X%*"=;'LXDJXZ?Y'9AW
MC8XH>(:J.9=;%UO\XXI:J.JB61"#<"X\#_?ZR7DT\L@-B%VQF4DDTC-<M<XI
M8M1W&^*.ACBCYLOT#$]?11W61HT7Z ?JQQCQ13T=$T&6$SU$NUEW(4['IT Q
M/V55I26F=F:0GKN;@?1TQ[F]%#-+65,L:M:H=02.@_?PP8X%;XM0I\A;%*FA
M=;= -OV8I*CF3:3NK;'#Y8K'4I%CYXXAJ*6FGHZ!W4\V70Z@@BQ%['R]N..:
MV++N2M+:S(8[1^!]GMQEM-42TR1#XNG5VE;NU:MR",9;VZB.DIEU,38GYH%]
M[D=#X8GH8<D@,VF\SIV=KW:U[>.*&BJ:V1:S,7;EGM1P7NA'==?'&:5%.E":
M8*.9.IBBC&]FML;=V,FRB2&CA$@[3*"?R?9BHTT\/+!%\2+JDZ]_3'#*.KMU
MMH_'F>9*>-I'-E&,SS9*N?U; ';$%GB9E[L5@<N>MK[^S%8)<TCEH*925!)9
MAN Z] ?/&7Y=55$39;65,4;QEB(V0:C<V'UC%;DM1DYUJ=<8.^WJX@S>6EIX
MY$!U=_GY8X@K!GE%(("!4*-3J.IMN?IQPU75\.3:J>H+<PR0M3DZGV-CVCXX
MR-X)J+1&NB>PYRG=B_?AH7U:1TOTQER 1D2J"OF/W_?QQG>54U1\E:/^W&9Y
M#4JSF!V4K<ZQ?3?S VQQ%49L*=:7,('E5'NLX6R^0N/ 8X<SDY8E*]RT6PD7
MON;"^,K,%=#'50,"C6O;N;J1]&#&SJ46^V):-D<E[X=>6UUQD.9F"959^PQL
M?VX5E=0RFZGH?[[TQQ%GEM5+#TW#'\+'.+7N-\4;L)!?'$.=)E.5B<VUE0 +
M]-7?]&,WSVIJKA"]14SW$7*8@K]7E^]L4V6G(\G:LS!S+6U YJK)ZP5QT[5]
MA_;CE--2YE7.OQ21&2$GV]WGCW/J)(,H:4BS3N)/]88$46J]]\/%>F&GI;NP
M"*>[7WQ+G,D$#$O8]![,9MF#U/$!4%I"NE[@[+?$]$<VS2"C6\I]9][Z;'SP
M_"=HEC#A%T@$6QDN1T^6O>.,&4FY?S\=\<4I9<M9^GI O]6&D]33NMMK>&,Y
MS_T3/4CW8G1RO!&N-SB/W48: BEKHR6Z!]@NW4_O;%/Q509R-5-/&6.^@-J/
MV8@[<@.*/,H\M0#1JU=2/#%'615D8DC(\Q?I^/&=H[T;!<3)ID-_'&7RJMD;
MHV*C+N;JT]''7PQ06RBOJ*.I 4U$C2QR?DCQ/[,9KE\=:>9"3#4C=7CV+^ 8
M^&,N+U;-EN8*#*ILK==87YV^.)*%\HD T%J9K6*BY4GJ3;H,2TLA_C-$^^DA
MD!V:_>0._P ,<-U;4V:144@*Q\TL;^K=C?\ ?_CA,PH:/-:&)"JBI1B^GU2P
MMU^O RZ*32ZLI5@#<$=^*\K3($C/MM@$5$1_"&)517(D%_$8XOHX)\EG*Q+=
M(I&]7I9<97I,4".-M+!OMMC@K/YLFG:EK;G+V^3F-SNQW'@-([SBESW*I;>C
MRJU^][#[<&."MCVMJML1_;BLIN464X@5E<'I;OQP_4-+"R,U]%K7._\ ?9!=
M' ZE2/LQF].ZU+ZNM\1I8&^YQGG%U-D5T(9IS<!=.U_;A>)JKB%BDP+*39(K
MZO9M^]L9-PX*1_A.L4#1VD4]!Y6/3]N.(<XES/,4IE)($O(51TTN0-AY"^.*
MJ-,IX8I:&(6GJ?B3XV?_ (8X:II(,HI$L06AC/V86!]8/=C4RTA&)6)=BY(4
M?O?&?5E54J[TQ*4]->-V]74W<1W'%!41I4RU-01S&4*#UZ>>.#.745=17:=T
ME9 ?+%.JU WQ%10QG42-O9C.J-<RH98>CA3RF'56[B/#VXI:JMI9)<KJ5^."
MNE-(;V9 .I;N;Z<5>79N,X+UD4C'F$JZJ[((RQ([5NMNN.));U>D_,N#?&45
MM515*3TTC+9@70&RN!?8_P!N.%I?A.AIY_GZ%U^TXKU5 JGK88X=JDCD,1:P
M;SV_&B>H@I8FGJ98X(4MKEE8(BZF"K=CL+L0H\20,4M=1URL]'4PU*H=+M#(
MKA6(N =/0VW_ (=-FV65DO(I:ZEJ);%N7%,CMI7UC92=AX_PY)%B1G<V51<X
MJ<^69W@1;IN+['&8J%D)'M^O$^=4N6)S:J9(PN]F-KXF]URE1O1J2-G8]D.M
MF7Z\9OQ5//4TIG.\SH5<"V@%NC>>*><RQPNIU!@O:'2]L46F?B"F";E(Y ]N
MX^>,YHDJ@T4Z:TM]6(>%($<\FR*>['$^0_!55!6!3H>15=EVV\=L9K4-#Z).
MFMH]48#:CV=3 =?OQD^='D)"LE_BEMO<W(QZ1S[K(V^*.'UCW6Q5I#S3?&80
MQ62]95 <3-BE/0DD! T0(+CKX.X27((SN 09W-TUV "#>W ;!G<+DB"#$UP3
MW-T=]GF_^K9JM[:J^W_WW=7GOD[_Z,-GHH-? W^/U-V!Y\Y*Z_,3)SZN^ >M
M)TFP;,TRE-C6?SC7OAT&;\IB'%JX]$(Y$,#1<;[V3P'Y[X899]EX8&?)O@*Z
MH0(,T<2EEH6Y$@\$APR>SY\/!IRHN,3RR&JKA\N(5)QX\7K/"$]$7)2%9J23
M:F21#E\>^X0P#6(!P9P,X'?QM1X#3LF(?MXI(#L0S7-V_(#VX -%"Y$J2FR8
MMFF@;66(>Z!JU'/KALB_-VFV<<&[3#)OESD(UYY2&PQ7ITF-"4/:3N:J7 -'
M71J3M<_)#=)_+<FDX!8%'KH_/VQD-(G2\>CSRZ>J>GTEODML'*(NN.P3S'GS
MO6@&<;U1BA;;/^J^9U[\"A 6'[.X."7<6)S[\-Y(OC,8D(J0U+KN-CK3D$N,
MN"&[6WL0DT%]!50"5XTIQ>+)'L_<"&9G-E!V^F[%^8EN#!NF'A1A>OD64Z^
M9)<@1Z;UD8,]\R3O)#D@=D[(@@&IS(E3RB[G"!V+&5JR*^U!T&9TJQ+'T&$<
M[U?E,E"2DB['R?(Q C -8:EJ>EC6]3;GLDJ,1MZ(&JXO^'=+6.3IZ[W8OD\1
M[7-*TBM#,[4=3::UYSZDMI5EO>"A]4%*I;> *HW#EXC_C5L7YV@-';>. I'X
M QGV-GN"][KXL:  J6J_GD6P-E&05(;Z'N;57H3FLQYG@@N(WN,<JRO&D. I
MPJZXQW=,Y9&@13LNV(,DSK:REV@>^YQ +HN0/HVH7"DZOU/$EJ&$_<)WUH,9
M]E,#V^,]\4"_TQ>#]^8*[\#<MA#W&7%45;FX)W*^=[K><=4L 2>L&SK#!$!%
M E75M"EAKDCL+W\]1'-<<U)(%I%X6Z2@!.7CS+ Q3SM@2NZ_:-Q>4KDT=I\%
M>)@-UF3\+R._2,T7N8&@*]?N9857P,#TYLKI$SKG2^KGQYJ@:.\.CJ(Q<-$(
M.(ZZ5 NJ,2G'!H_75_K\_A<OBT4@,1\7R\BZ?75:;>*8Q:3:^SE8?!W;*@\G
M:3_9X.'I__Y,\>TK(#[]@4[N%<!P=KG4",DIG%T*B.KG9N!QY#^,G2/7TM"B
M4/^DLPCE'H7;'>Y*[DX6NA:\.6H)&+PXZ2?-LJ7AV^LMW7U4 =8?+"WL$^>B
MZJ8:D&&"'3?]'.S5%#*VB:3QFBB(#,3->%<6)U1Y;S;#7<N9<"J +? ?E\2/
M%T,'<'^.R7ZAFQN!K%P!K?I-",C6==\#L)(PSM[M-1UM9PH;F7K?PO'NX8.X
M)1=#I0W&Y.#$WIR5TI&Z/TK $Z>R&K!03V,]ZEU_I^9Z;%N>%-*=0$5XKJ0L
M;3BDWF.FW2$6*BZSR3*0Y"P(LFB*5U;DB?%R?\X8+TB.O.SH0QM Y!;;\S90
MP-?6-.7ZB2QD7@&_<3F[ YZ[!.!77:0HYG@0E<SW2RGN;>?/ UPF[O3EF8R'
M"7_'4UW.8_U/[65]:B.;1]E$(TN9UE@VEYNY,K*(>;0/YX]>[FFC<=,\T0"G
M N-T5UF1B:(&Q_8N[RQFW)=H[A5RS"^G'HT7ALWQW.LDY*RATUXY!J?7F_RI
MWT8L+$63(IV$'6)'.&#ELK&?2LAB[79=^1#H4XAD"U;.Q6UC\-."T_4/=4ML
MU;XFGW I= T.)C_WMNYY>W$\?W[Q@NDGC<-[K?:FG]!/=.$2/D"Z=+N_MR?]
MHLBHC,*UG4>]':12_8718A\+*77]+9,=ATZ7)Q"H60]*B0+(Y)=M-QN1]/KP
MB1CBQ*IFKE%8+P9CA0-0N$Y/!<0:@G0X8)RF4?83PR7<=GOQ:TRME_?QIIG7
M@'+&I)P"GJ86?8WA3>1XGT^U)I[O4J'PQV&#S6@WD3SN,G!DVBRJIS;!K,MT
MD*. -JI^C-MZ$ 8&;"* Y&XCGO+;>C&!FG,4C5I8/L%MSA2O56(JSAM+KV]P
MN%":^3? *>TR_@^7)(TZ^2S?N?=]T[*"9JO7R3Q?(D-BA7(W[1G:R?55!]3F
M8-V@+<&6N-CHVQ_@S!.=; <9C2K&S]:DA&5(/R_^]?><6E_G/['[\6[8=S/
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M#.TSBM)PF.O)/=*8F](N4I#3Q%1DMK:*D$D$56(E:6638#NL!3RLG#*-9,N
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M5=R5Q!NS-'>R?WK.IW8_KCWS)P%(G6K[#;/^9V)%&4ONL0U-L,JOQK2E7:)
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M<0;@49EC^M2,:+ 8G@-XOCV^!.!-+?G_F#V+DN$BAY4'(PF*T!9YO$>#C*U
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MCE68+-J#61/.4;BDJ L2#"1JI[OG.,\LM!K5J_AM.4*WO-830K5__Q,8:V"
ML:9,>N:D9BF@2$_/.G+^FB0LM]E8W49+"FB%5>OBFQLW]UL:J&;(VVIN'.BX
M6Q#0=;0,&*G3R;#\47)CY?[0<N 0FYLX)N'*I_%Q^0EMM*G$P843^9J,4R$E
MQ?F2T\[+ Z'<'::3 DY%@(PP>4Y?$C>,K5XHWRKYV#9_"K_X,%XRO#]TN+PC
M+SZ;N!@88X C@\=($R&P$>=+*U^7?P,,1ID]54K9=I.?&DO;OAC>U1QB)1-)
M$CRWLA[AO&0   !O>^P!>RC!M_-,PTE?N+8S?8>K:?6T(1GR]4@P>5(YF(#C
MGV\>2)VGT1<K[>7W35IX(*X%=BY?7?H FL+#1*)*-GMV4W]_U.2@6QJ65\ %
MVG]7!@05+2@LBF?A27%O+)6#S]GL;X09IX:I5.NS5?'S=1Z[.;:NQU8PPP;K
M[\M&K.E3-U-^UD].#]$DJC,2YVRRS $P)R10.D5%\-4SX*80[WC=G3@+5<=T
M9$,O\J(.BI66CP>S9Q:?;T;*GE4LXQNPO[SC,0-ZFX72[9,R_L^6 :*ERX^S
M>'CX]C4Z,@I:PSP56II2W,!_#UJ#L1)=-R0FV+\P>>PP13B_H*U^51M(E&V/
MMIR*PI=92.,C25)8>;P6$4^:K?.Y6-)V:[-04>(\-T>-K;OD%RA;/TI*35T?
ML9$J;V\HXTVY"^-T<UGQA9X&-M /7[Z?UY-2Y<G;1[-)"?E#I/GU.]::_D+1
M8#T$!7?JCV8_X[7%E$5B$.\VV[#_3%C8%\E9\K09K8CJM0>%LN\S1CJ*N2XJ
MX-_!^0>+,A$+Y86%E9/[[BE-AIV&W0JA3%>VS56DLPY"C=45^@\R#QA?D/$F
MHVP*(+ET;;KY<=2Q!/RTU._4W=J6W;J[_RL;9P;\6T0A]1?."6(E(AIG17DB
M1ZRU97M-=?7)PRM%15MCRURKHB]XQ%>K*ET:U55"V<JG#K)_5>CS"V"I5KF0
M))]I>872L@@%-1H"92ZAST8L2JS04062C0;@2 ,Z\9( D! =Q9VT1P0Y=!PE
MP<XLG6IH[X>2<OJT'/5)/3Z7$ 6>CU(]!2_E*X!AWGD E#''ZZ'XU98DW369
MB[T?"/>4_8MG@K@'G'SH]^>\-.9;[MWOTRKD:W6Q_Y+R"U@9^YZJ#/)NFGCY
M(ZY  Z/ 1/TUU$'RP< /*;;!W.[&Y<?NU;W\]L.E/ M$:+5,U9'+OMGWGZ6I
M<4N:P<7,TV3@Q&+L$E1,ZY"1C.2(;&%M26"NL+["W*88?;M@^47@ZOG\AV1F
MLQY(9>,5@/<04&P&#8&-3"FT_UZ2BX^B\!20#7KZ!SOG:E_YVS71T($/HN9C
M9PFE)3N>)M6A!^5,=W)I\IF*CUK'P_^^NSE!W.)GJG%I-^+2RG^9=NCI5MK\
MSM369LA%-J/_\H?3A)U>F/[W0FA=<0!*T8WJ=+RL?$,[W ?OXJ"$V*&IDE-K
M]EZQ7 @.\R0+N3"V]UW :O6%S8L4P,L2\,HMN1C%#) @/DT1VC%FJ <NA3D_
M3DMJ#NXV(ZWQMW>]V/^)!TM0AOVY'G!*H=;J8*PU=]F%P'4X$XI<II>$_\,Q
MKMUI4-< BG90!Z;J6%%9DM@<;#;NIX._C-2^BX@&TXK34=\] Z>TVT@U'0!8
M3MWCWI>HM0VJTU0_P)GM9M?T#-7UX#^Y,<MCNE*-$VW;.B82NCZT!S\=#]P@
M<'8C&>42-WQDCBW(A-O-N3:'B+XZE\_\=;H,+(JN>*9^.DDZV2PYA<C/0=WH
M4+U''N;,'SE_\7KP+GX-A3^G317?O7G\X8*O-%U6.!WT?2:9V"  ^3818@@G
M+6+SV>&'PV@RCE\2^^.-,X;RH1 (JW%7L]-U2R]\)F'/ZZR?Y2VS OW<B>A=
MQ,\O.2*V8FP:1_]6-':5,#I\6U9\S+(*@.:X5(<W04GG@0I&.71O)S]$E_F&
M,7"I&$]]D%PV#U);)<+$6PQ4EY%3+U9^*T\A96O0."70X'6C&\@S]X=.K5N.
M;+,;>VO;H(6J]L$9CB,)#5N=8/HZB4+!_YG'?7I8!E+ '(03Q75=\2)NY.5%
MM:Y]#"C[_<RIG/%A4:.'?N2HF?M1H/W*>R6O@LA_>JMREKE\W];60@'%6'?&
M@[<.(T;$CH56Q!4][!]GNOJET$.W\.^_=Q-,]1@=4U9I6EACE0^=<IXTFWIT
MT87#ZT:,H^U#3,Y\K<N/G.G@6;U&!74C'>H*3%G: *5NEWX"Y2\J^5+(_^'5
M1WD,5>AG%BB(N@1_XU1[Q<QW/6$.S5MCT;^8$2BJ1U+=VVH&+R%GL\PW%_[W
M: ;Q%:0_$F@5W?+><$W:->QA8UIV%7+DW(^F95?I$?C64^'(F4>KQ^<DI0%=
M(AOB>.J[P0!?'](J+'Y.PI:[CJ#3$Z6L[39T_ITGC257*;:Z-J%,NC%>^,(W
M8".#R?Q>0\BW2V!32+#R.@7G!GJ9O[1&@556*F#":;-'C26L'BXG]==T'>+V
M]68*X'@^C2J=Q$E[[&_5R.$K]#7&LJS#MODN0@S,*XQ-?,[4=MY,_4X41#A6
MO^1[H#>E.],<2;FT<\/WZ&+R(;\Z%Y7:+IK$-8]?O9G+$)HN7IA(30"75/1?
MU?+>R&:L+*VX\CW0-F)UL(W5_K=L3@,K*LCGB,;WG&T#''$.D&JJM3V,2 HF
M:M8&C%4[.:TNQZ9'TVPHPG [XT1<V&TY_-BI3U"[\P(9CFVV_3, K'7IMMJ?
MNYC+(G+?PU)_%[+EMWP6GSWO1];44M;,X* BE_QV_N>?KG1 D(J CZ'$4HU#
MU=.OAG?OH#V.+IF[,95]:5.8\;G</T<;\88[R0W$&["C#I@HT;]I<Z#D8HJ%
ME3]2>M^N[T;X#?SEJ8^OP'-/&;6]:#MN]:H[M!+]1R'+U9=,.TK"GI%6FA-=
MUG:-$V@CX*"VS:LA=?$CG=FQDV_ ]1H_>9@9(Y;HUNBK$,7*<RM4-[_1N3I8
M"/H$7C$"I7<SA@T34,C]C0V+H1N%"[Y%E0>0@R-RGG,VL>AX\H.]"-.B9HV9
M=-3LXCG]+;6:W)LXP%$#BC;7AA_UWEXA;[!$O/MC/D\2S,_BNP:V^QK/4#WE
MB/B9>Z2A(0^>6PL_%9U[67$)$"^='QGAU^=_VSNZ25.4H2$Y]5:,E37H5_-"
MV8C/>,MGVJM^,J%I301NC)[,<_?OB8/M.RD%6N"Z36%E@Z>C;YA3!YZ_,/X[
MJ:]DTDZN(W_=PLM*620%,!U:?B-$:/=I-\4W@(K$>N4'F3Y);*D&"ZO[I_WL
MQ#HS[\J""?.A/=QQ4<9KOJ>Q-1!J>",^!HVI:54EDA_'M=J;15-6!*BI!8%'
MS#=.!_&6P,*C.6)96!O-_Z4Q->!$U%DU_4GS"RT=.)IP&:;V\6_L?&1:F4E1
M>GC< _?'6N]-SC7XGR,?E<VSJGDB*TQ17@O9^JL_$9B51VP?:I<1V#)OIP<2
M<*@!PE)^QY"C8>"[/T6&1\(X-95!V['M$2W\Z3E9@SXZ/]T?*SZ.MZC;:UA,
M<7PH+Z1;]+QOC8E,X6"1J<-@0C;C(0 $<7@$-_'\\MT3J(J^CZL[A,"9@.46
M,O?2&N9/1\[7]FZ23&!'(Q![?ZVY@[0'];-+)E\=6)2CG('KYA2!O^.NYP)M
M1M75+L)TJ>JP[>:Y-ZN):1#IY2ZKL-A&X(75$^;^<G@9!?M<8QIK5(+)6K];
M^.ROFL?>LMN4BH4A?1U7><#*3M[@1$%[HD@3,\\JK!RO?(OUA^"S$90^E2Z
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MKPIY=3O^?G#^0$!;]S/'W0D.6"NP%RA#J4SZ;"[[TE1"B\Y^I^*D].VGYTL
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MI- \A9;*3.R]^^-FLCC:IU5L0UFW2<1DC&U2+[<);T]Y%=I75C(NT!=9 RW
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M&&#-B1D_LC37=/^E>^6/+@]TIKCJ_$;7H;00(N(M;U*]((DE=WH?=13KIH=
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MI.>VYP*Z:-&FN2M^F^)YU/>=](3\H8FSEHS8C5'Y6;% 9&[QIX]STV&,MR^
MZ^-+I?R'/$$1_>XPI^K 2.Y<\@,"LK%*J/54]?P 8Q"QTVN,54I&H]T^[?"5
M[Q"5HV*D'H%&)*.*D07YOUVQ\KU"<.*W"1.EU.Q^O!6<*;KU]V)EF.F,C6O@
M06.V$;*E[+&5[\Z<SYV.+U]0U6W57&%ABHX>VRI:F^D#UM@222$,>OAY8XMG
MD5N1&]\"6H7LR:O7L";7\\*:DK6NH]M<%<NH1#3+STC8V^K @@IN\=K^&$O&
MO'/>=B-P?#\#V@F%U8?9AA!*NCV0Q.&CGIN)'OW^'=,>I*A_Q1T#]&/E'+N)
M40E>_'O))?F< 2<2%NH-U/F,14T"O)4LB^K8C61S/UX,D\I E/J@D #ZCA"9
MY!/(!\W,P%V'47Q#31Z:VDO;0B\251Y<\)=UIY2!J29@K:NNV%%*4>"7Y_3N
M=/E;$<$'< F2XY7-\1  BU]^F(J2<FVI&'@2,5&6FE!HTC 4K'N+[X6E8/$\
M5@"QL.[B>61M45-H:._NP3S+':WGCME2H:1_5!Z?5^ #>X_JQ.>9#M^O%9&+
M:N[<'&G9@\C:NO/GA)T7T%0X8V]G<8IT0!?1(=MM].-.^G KI0ZSP=[4IT]U
M,4T<*$!4L;=<-*_L N0?+#SM%-V6G8\-BK: /'PP68Z81]5\)!4&.6B<A7UV
M9E^LXIY:7:.IT:"O*S\N6(YZUV<D:M*MM]>!%#"BJ/Q5O]>V+B- ?$*H_P!7
MX)-%*H96!&_GAVAAXM,Y[OD,<5*7T?MCQ'7!%5011S=6*F]\=HR^77U$6G;%
MC 49/L..SE^^O/?D<&BS*))FJ2%IY'Z'K;!9($@<G:1?UX,T=2]73(+M WJV
M\,1TT2"*7M*)PQXZ['%/ Z+QM&YZ[X;LWSL)XPMX1[VQ+#4TX+$:'5NEML2S
MFF544.^K\:U\9I-HV"#?PMA ^X61?T'$;IR*C\ &_)/ZL3H^QU-S]^*CAM:X
MO8>6)$9KLE3*/L.#J/I#IX8Z^L.6()#]%5M]6 ^W>&*SB#N\"3]6$;2+:=OM
MQ:+:^QMU&.#-3H4?UE/7!;)I"@&YA0;8>*;69E]96\<4A:_$B$96_P"*O+ @
MDVG@ #^?X*]X ^\7Q;AI;PTBWZL%]!BD/\7W1^C!IKEE'>YWVOALEH^$KKW:
MB0@:OJ//'&AEU27NUVOBGJ*6&622F?46C4[8IYVNDL:(C!MFU6WPVI&*6-\5
M&:O&^J*9PJ^S>][VQI4'PY8])S;G?SQ-!3K:,E-=AL 1Y8: "P2!@Q\;+C-4
M##0RV'CS.#*>5]L0_7^ +U5.=$RK<CH;=+8GA?UE5@1]1Q64W*1:B=[?UL46
M7UMVI8#(CKTY;7P]!(;4<G>AD]C4YV%\&LJ9+TL8YWV-^5L334%/_P 'R1LE
MN'>0@CF#[L0T!/9ZF-=+),;%C?H,&21AXWZ>_#2S5T!\%$@O@\-))6U>S9AB
MB[)$D99[.-(!-_&W/;%&L:6(IHM=AUT[XBG7:-F]+A)5Y.H;[?P6DJ'MW1L/
M'%75/>[1R</KL?5Q7O(K7>7GU.(ZNKF>*FYZ+;.#OO\ 5C33P(FH69@/6QIM
M:,F]NE\2V4>IBOX8&H5D@QI;F<2$;: QO[L5RS&S2%%BO[1'@<53$_O4G]DX
MFJ&;:1F^NS' 4>0&(0W/?\ "S&RCF<214GII;%?<</),MGFO<8FJ:E^%3U,6
ME-MN*QQF-;%WDBG[K#K<8(J$&M1=9>J-T(]V$H'S":3* W?O;3I!N-L1TJV,
M4<2I;QTK:_UX-11-V.J7='CYDXDRZO@*/8A:DMWG2UAM^G#@RLQOM<X4<^OG
MBGS"2-D@A(;?V\<-P-ETC#6\=OMQ#Q.=A;\FVWX+"AC/HX3:3SOA=2]S8'!K
ME5>!Q-80CNFP\.6!%54YT!=(X2@#&GC"%NG%<#&JGF24#;5&VK]6&$TJNQ!M
M"I](=N5L54F6Q+!2O.\Y%3&;LO/;WC$U,?15U(!QU]7GX#"9=2MQJB610_#[
MVE";/>W*V,ADHA:I29FG<>U??<]<=KE;>:#QZNN(I.5VD_M8%767T@]Q>5^H
MP% L!^ $<"'2)>9Y=<"21TW%^>^-:;HIPT!-F5248&QUVVWQF%+6W4AP%F?8
M-_6//#)'*"-Q<';!TW.-/)?/%W-_KQQ:>+C0Z H6-26PH2DEANV[RHP48B:J
M])4675O=+_7A5B554=%%L=WPQ#!)Z@;O#QPL:^JBA1]7X*N!S*FWV8JQ)SUC
M<XL!O@5$(O-"&.CZ5\-$Z,A&Q!Z8;4_NQV>B0SO,;*-5K%MM7U8[?G,C2U/K
MI"_[V?(XT(H2VVWACY1RFODHFG8=I$8]8#E?!K7;M-8?7G;UKGGB23GV?O#&
M7Y3!)JJM,#.!T"VU#$5)&-@-O?C@5<>J+V7/08UP/J\1X?@!W/G4]3]>.'4H
MR ; X))OC2?FA;;S.$EHM@%]*JV[QQJ*O-'?O= OCTWMA>U3B";Z)4[GZ\#L
MF\; %6'4'&J8D^_&]K>&.Z0ON Q?ECBI$6I_I>6-_#?#U>DB*,@J?'\%X:N/
M9W)U^> ?B*R1BY]J, &_OQQ:->/3$]U%NSCWX@;@- $=6)D5AL""<(LA])8
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M.TU3!0PCAT$#L2=30Q+#&-0X-.C</>-(S'#"BQ11(L44: *D<:*%1$4;*JJ
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M";V1507\;*!O\<^=_!^6!:FJ]+6Y?4.8UFJ/:FI9K%%>;UI(IM"<35()1KT
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M5;9.U3GJTU1EM(]//,N5\1:V:3@F2H$7RA#V8,\9;@ZIM.NVON[_ /O5_P#
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MU,>?3#5L8^^(078#G(JC9=L-"\7"8'2P/0XJ<LDM)$L;.H/BQP=5(LB^%O\
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M&6$E-^N*AXG<]IJ1)IN=]72V(\P^$0[)04OI8T/=:?Q#(_/"TF4*$I85X08
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MX>61@D<:-)([&RHB#4S,>@4 DGPQE]1$"1+FM=F!.^T82JJB3?ZAOS)"\S_
M-CB7,?@Q+!222MKERJ>\=(6/K&CF4-V>YW[.Z&$$G1)#&%CP::CA^$,,*;+%
M15!K*4><4<$L\(!_%4>>XP@S.+,G0;B3.JWAP0]+K#+(SCS$%.S<[C KZN1<
MRSG385&C33T6H6=:-&[VM@2C5,EI&3NHD*O(KNRH9&56*QJ5#.0+A%+LJ L=
M@795N>\P&^/E#/,O&7TM54*CS?*&6U"9=EZ$Z888H*R660I'<+ICM+4.99=
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ME)DDAA'K55+*%[33)XS7CCE@!YE'B7O38DRG,*22LRP2R-P!Z&LH)RWIA'Q
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M"IEB2_J!ML!Y6N#[9.^%A60M$]A:^VY^XD%K_P#I@QW]75]?EB\3D7]D'%)
MNH:7.IQ<$7'CA:=44U'M2V[Y\=_/%-*;A(=W]V*.7C1*#"EKR <QBYD1[\]+
MAOMPN7Y?Z2LEM?3R"<FN1R/EA8)HE%1[;VW-]^>-,M/&Q/M%;G$M7E-;,F@:
MN"7T1^[$_&BAK41VADBF<GO^[KB89R&RVJFL(4@C]%K_ "CB"CC8,@5=#_3
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M=X&^.T9ADV4U]1I"<>LRZCJIM"WTIQ)X7?2MS9;V%S;GC_W9^#W_ .Q<N_\
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M9>>_VXX$>75-[V)*>K[]\+49Y4+P^?9]U(_3A4H:=1IZFS8@>&(LL<MVT#D
M.>V(^^5B9E&G>Y!Q E^&@C5R6]V^'@C^^:@7&J-AW6\\3ZY-,,@(12!M?EOB
MH[4X[36,&UZK;XU :KBXPW"2P]V*6.*;A4Z2H\PL>\@/>&WCB&DA70L:Z;^.
M$F9KMK!P2WK$#X^%+51&3J@;<8^]9EF;JB'<8*Q#A^;6QSN3S)YG_=\7"F4
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M5(BCTM2W'7D;>/\ (WWF5?RB!^O!FJ:J%$'XZD_9?!:@JDFT\Q<:OLO\=Y4
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M4+VB5.Z&C.H X5YU(ETWL<5D+L0MD 4_ZOY&LPD/K302Q)^45P\Q]:5M1^W
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M+4&(CN^\\L5=;R[0[$7^O$Y:G>>.1G?6J\@>E\-62LHG2Q2)CW@?,''"B1F
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M,'3Y7K]L_)<(2\]2A<O_4&VG2)UXVCIU165)A[)1R8N8+J#/Q\!*.&,5\E?
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M'?)/8B).MMH.I"SHRW[Q,^*F*U8YEBANIFW>()@=^(9*^9AW\3^ >&I)IHA
M;K"Q86/Y12@EU^^\+?EG]?;-%BF,GJD@33A7@$X_Z[V67MOI%+XF8VWNOC>2
M %=W/V5@O.4<\3KL>R\IU5;[N;\< G5F3XK4HY1+[&):#=#F)V!)XCHVRC2
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M @$# @8# 0$!   !$2$ ,4%187&!$)&AL? @4&!PP=% X?$PH)#_V@ ( 0$
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MZ<*2IA#C7/KO";H--Q P>4=T!:D^IQ9,X(@-B[ED!AI:-S4^%P24.<%8X@*
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MM5FZA;DG=7D(19YG@U@*8AQZA]L)2B&=$*Y!AADYPGTW0()7%/@%E1 P]83
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M#)DD399@C;V_B#)E- *"]^)R3['(CYE$K]9"B$#=)ECI8;<E'CU)R9WPS/\
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MTR5R4^RL+[<)DSDWYYQ^X1-L6GUA%R N9(C[X,6ITC6D^,\5UDIJR:*0Q)2
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MHES=C[%D23]_VXF@[K6^VQ@,RZHA4W=A.0)Y(7H L5.OOXR" Q_D)..]KSJ
MR+2((U0#^?Z ,D;1/E83:'BDB\VTR>2$]Y*T-GIC(O+)VHD@2XPTE]X)B6%:
M:K%20)943R]32OGW.+!A5Y.Q\.*#)$"/:N-Y!SSQ67;E3[8"?!YP;1"RZ(M<
M3618'I;G_G^E2('Z(?D<5&KI5;U3+5D91/Z&0#VSE PM_7 FE]\M)L'C)?N
M#<M2X :")UM.'?YR+%E.#8<W@ 4U)$AQ.31@F+AF0O?VR#@@ &@$&L3-HH\.
MQ#Q@F"SBV3I/G"]F81)"5Y]X+Y+R+B'!&A3]%Q2IGSOK^@2-EK@)F YPX(8
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M"&:TJ,E#<Y5\)4PD"N"\M8E3)G3_ -.05FZ(2;X\,&VT60D)Y]X'(  $$']
M()!4OW#$=(%2;$OG-$H1'6';(('Y"GJ\M2*L N7\C!>1L*-;&\="4O"QEV'G
M9'YP &'%L QDD))W \>O,X>4Y1K:QAS$TD5"2/+\8*2HA"/1D@B#!+/M1L_3
M#-@!U0@_I700/LJ,FG]P?WXQB%W.]5C,0 =6E]'K)-2"0+F%W&3Z1/"&?"&,
MTB;1B"7:2,0):+$V0%-1D$AJAIQK&T1BF% EA\I".(TF&>>3#[++]R/C62I
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MY+EQ3< H,[G&NY& DR\-MXJ6:KU_I+1$0DQML)D%!F!J.J<11!B)G=A&]!R
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MB#1$8<QS*!<*%6\[)2!B@ $'TD'%"80I*V@N35*O%(S!E2#@926.!X#ZX,G
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MIXLHCAWM_L=O?D["Q6;!>2OLX@DRY]/RH"R +7(9%$HS*=NA)F4M#.):^H"
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M;@R$GYRKT*T#]U@3"0+$_B1RL%*VP#A$(,0+!K (R:-S*64<G@XBK'S31)"
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M[X<(&:X_9B(. )ZX!^OJ5($ILC+,53PQ,L^,7RBOU%H"\E0$KQY=U^)F\O\
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MBP@8K#<J/?9EFI(;2H4RHR4JV%IYSS!B%TKJ_>1B"47B@_&/2V8"G0:-#QB
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MG@'(!=)N8O\ J" $J'H-GG$,A-3[1_G%R:4:)@F!@)O)D*G(<M>LF&F9X/!
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M) Y\93I\28&_,0X+@L0A($TZQ7(B<@*(WG<D&]'62<2(4\Q;R;R )W'G-I=
MF&@%X+LP"#I4< B[&I_./:0F6V0#F><17[5:%]X$4X0"L+T3<1D-R@4ZD"UX
M<-25A'$;3]' >N2B>DK^I0#0'H^NIA6#.VD.H65)$$!:]<9#P;L272V<Z#0
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M'[3BO;A8'N.OO"+,"I)^+ R3\LA%6DCJL@3D&<(E#>V2CHR%N)?\LEC$0GG
M$\T@<3?K"6W17\@W7>-8PB*(2K\X3)TM7C#4VJ7$1 ($62)C;6'2@[AA(24U
MO.H=FL+"3:V_7%JHP59QNS;)58$*PI[6X2+N1'".O\9&JU_&$E^</0)P4,U
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MX^^'A-YT@(:5)$97\9[(+?? >4W"5$IW<XO",)91VZR604ZTH,S$3QQAPF!
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ML]'!ZC6.IQ@&:0P(C*+1X8%E!]I24ZI_7#N:$LG32B?&*:39M1G\&( G4@.
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M,2Q*+Q#GB $@0%B@,A=%E6*>$J^'\A$/V'3QV*RZBF-8)MHCV (WH,. 9RP
MD"0#(E)9BD#B7<SPO*>. 3V7X+X4%D*GXWHD_H=.=3*#(R<<D//Y "!TON-J
M7S2HDN&5<.\'7#*92(C6"FYP0342! )P71G!E1X5'[:NG-B<84.$B$A83U=!
M=(P<@9J/?Y]%XG0M9B'U9=$PI6_:I,)BL)2EQ+*5"NLTIB'"0I+49S>AX"7"
M/I,N FJ&L0B2AK_@H\V2W6_;LSRXG&"U6:GFDNJ?#+T+J7!BL0,/U='#2JCR
MC('%Z%IR#3)A$<%DT>MOEJ\%0YK]G[9>HHP4V4NU&<H(OIKTT3T$$V8>%)I?
MT*6U$0Y8&.@A1"??$67T'!8#;UU) AEOTTQMGHC9,%[[,Y9--D\1P?D0W_#&
M]A&769I%G3'VB)K 9:=[S;Q4A%=!4^#&AE5*9.'O"B0,A="BXB^L"JID2/5U
MD66><;$I[G)7 I6@E+B)$"UDX?A88@KB;X:&:1;BX0^41B3.:&&PD_C)/5FW
M/OO-];-:P.[W@Y$;(AOAOJHQ^4-MB!9UYQE*(0G_ )+O6#X03;"01^=>LE[R
MT-)OH9G_ ,P]D1R C#9QA=CV-# :2UTXL?+!WI/=F/C+ %%22DWZS4>:]H+_
M (DE+:(TDR(R9,)=SE%>[7'4=98WHB4,>VWC#"4Y#4YUE1QD1\5"CB@"R^\E
MQ(A3N$G!IF ,$>*PDV&B>%XOH2.ED=R+(Q'QX4*1RWO&B.+DG1=$U.-1-B$@
M/\9)BLC"(8.\9$%Q(I ?KE*X$()E8KB/J0B?OB3'+8$C3]CESZTDV<5)+/QA
M(E( AHJI)QY,*Y88MO-OSDL%SI%.N,E2XE!&["@,@-5"//C"J[&+WA;5Q(D%
M!U-HG7UI'A\10:CO&],/O,C.IE AJS#WT1%&($D+55(EA'B:\V"8_P"H6>\J
MB>( V8B4@<H %4#+"GJ@$*!6A>UTUYC+4:1(ZSXP.Y<7/Z [01.\A]&+31@N
MVT.#8Q5V@U4&NBRXS?\ =B"LO:^JU#CZN^XQ@TEE"H$PKE#,]0B:"E%6N(BW
M=**<G42<,C0+Y "3:":^D%T0YZ4@N18C3ATCW"'W&)A?V!_ ZV(LSK4JDPO#
MUD*%.D^E+ 5>F#G.\%9(L6"E3WLA<CT!Q1C@JS9<)KPL*0?ILQ!)[805E*@H
M"YQT3XB&05E4G_3_ -2.JC^!Y.!_(2K2%Q*EP%(B?5S<#WX9U6TJ:@*Y'ICH
M3P[ AR^&+_($ @(B(DB-(CL>3%],F YXS(08X.V>+0:!T=MT$@%H2)9\RZX7
M9BM5=;9Z(65W8&C'(^#*&X#3!%!DQ:4[BY%@S%:83Q\,?_D.R-8).%_I*VXS
MLM2$X:83T-^V'C")&=^(V.6>1B4>!=E^$GV$_&>%*X<,C1[I&'J=1U=VQQBC
M",O"MW7@HD?FX[!L @)I$BV":HI^60=&%5"% "ZGBD2"(4%]+A]Z["!/-6ID
M\/K>P\B*]WCV]&LHVEXD3]]\A>\D_<'NY%C:6R0768DP]@OEVPR\*6(7!:1$
MY3G:<C[9K&%1&YQ/0Q6@752R8,V>A>GV( _8K9P"7-16%(Q+FB&CL"4'&TIJ
MV"'ZO(U+B@3ZT;:P(!@XED5S5C,>IFF!&S$'FN6K@N$Z+A,J6C1(W' [;%1O
M9,D'LC(C9[1HVB[:!_#L>:88^8N)/*<>(Q]7[.SYP8&4<$2K@,0J+$2"9)7Q
M'WQXG6$4=:QB3>..LY H%9!20=O$9JHT%CM_#$/5G7$_.0ZT/FT_.,.!=G;$
M3P?YQ;1;)A%W^!K(<F$D\;,G-B#9!R8ZE,\9I$]H!#T19P@*7M&M8?:7!HEV
M+0Z<0H T@EVV:K)L9B3@NW3E/ E)WY54XBDCY)H2>IUEDV&@DRCXP6TQ:1VR
M#9S(UGFW[/\ !)B4XW'+]L@Q0;L$;SD63:"9Y,8-UC@)^&0Z X=V3WNOCC&/
MF2F<#T4B,][5JQ^<?@.7'D!D^G$?.$MXBFH%K/C*!'0X \'5?;[0:C$2A';A
M;U=;+G;67D4Y"0X4]?\ E85Q2D5 _&021N8QD\E8V6/F.\JRS*M[NB\'Q=/K
M?JVS+="20LCX!KW%90P839TG>&S_ +<(]3C\4,L/9>R[9U137;NPFX00(+2$
M&CJ$T'L/O85>I L(2 E5I"N@**&WT'N5#@I(1T!4>@=I4A21*B H14"1XGGV
MM]]QOK''?MKO,\[](YEC7G->][V2M;+F7&/$Z7X5TH2/9&A_'T'8_ :?B^6Q
MCE387@WPP0+U$CV-0[M7/.>>ZZ0U#!5%>^.71 VE9\A(H#84E67\-4%T3V@@
M=UJ[9TG">, ]7(8&D0'ZDND6$@Q<)."?9(UT7XZ3V@2S=XKTI@6HJ.+2U"OE
MQK*&N9JH&0$F8;AG/3-Q=N80SH24[MT*L71ALA(I^IH73*#:/<W^6M@KMR>)
M^\YTR]+2"38E96!GGDD&;%B J>K8NZO64)Y3O[CA1Z!4S]5]*_+NCI$9, U)
MZJW,TOO.&#PLT\2>K=^>HVAV71(;*)0DJX;(TQ>;5QD,5\[++]%KWUGE62+P
MDLX? ^#,BAK,!6)B96P$OJF5IL/'B>F^B>G1::A[\D)7ABTFZ]0&2BL> ,KO
M_9015TG-WM$"TV?RPY?EFCS"E)&@'>&R/4_[* S_MU<D_H#G@WP0]I9437_5
M2Z!6?PN U()L-J#6R AF6^"3HDB*:9E8 #<Q)%^QD#'-4:G6-S]_:#;XQ^?_
MU$TQ8]XWG"OK3I'\B';?/=NPKI WY1S'.2L8KWMG ZG1<]$>=UX4?\@';$CG
MS5_9K%ETT/*!?P.ZHM<<!4MO,V\ZDP&J(U@Q8$A8P&!G@F<CQQ?Q+4:'"IGE
MRQ]1:1Z$W)=##/3^^DFW^3D+&BW">(-\_2_P<1Q3:9P\,=Q80\XW>)H^W X3
M[.7%UE9C+XED(L+.'&.8*OH$[]EKR2DX%C9_;Z?$>VXSN,CX]?%&MDY HW8@
M6X^<"C1_*Y1!EWUX?J+SZN>P@]_:K?I)"A[.,/:('RO&V&<HR6 ];LF9=1WJ
M7VOB=]+9PU>.'=H707)2Z4E1C?MRKF[]L#@1QRTV_'JIF6OZI Q+R*E^WLDO
M&NZ(JNO5Y\L@4RX5G]HU/C*26<?,4>Z/C]OK?(TX2JS%&^/F;#F^AR';RTIZ
M#M<"WI*ZG:$VW:ORCG4^-WP^3'P+(%!A\RZV 93UJN='9 '%R_*W&>OU59FX
M[ ^A\25$AS]H\H.2^8@$XGC0YWM9M\_C=Z,M9D'7+9C9^E+J]5%<LPJ$E]XR
M@#E(#H # %2,3Z4.ZV058<;=N9./AM0M=!\V@V[KZLQ-?RF/=Z*J\A]-&<WE
MQ!(5_]__K28A-@-(H$ ,3XK_6-RY,L$ >EY?.8LEEB!V14?O)#/?X7XZ,[20
MY"8LIO617U70 .**\7YN3>O2Z!MA:JJ:1<#=?"N LI6@/1C+3[^G/3%_+WA1
M0@^9*0"BAAMG0H;6P]F:@ZFX?]ZW0E(Q.KN!=JFN[K_DDVZM92F7O;B7ZAB:
MC9UU/*&A::_LK[/^>OI#.$))KYM+\Y8V(H3NZ>VQ7_L>70-BG\5?7JM0@/D-
M^QA7 Q2>%,1J[G[V4?U:38]GCB!_.1+>-(PE^ ;AI8,XS.F%.9+@<<&#3VWV
MOLV]"9#K7=++4GNC/4K;)JU+E.B;-"]>?KR]HB268;@<K6VF*IB :-8VBQ1-
M+,RER7M+,)[1M?R*Y-<DQAX=>>PD]E5'*QGLA"2WWU&2NGCAW+2US111N;K1
M@)0L%S3V%6DA'N*%$JYQT55C^%W&&8OLF*OK-:\_$]WK\\@\^ DB<3J,F^3I
M/$KG01-'QO&T,O3W>49"G1A <,4Z^[2E]ZQUMR&WI1B55I=E5J#4O$+#'<.:
MN_L17-P?79%%3#U06]$R[7<. SH9 3//&\.&#/7X[9]]HKNM(K&-HNU,X_-Z
M-W+__JES")Z"YPNO>LV]L%I]Z6;E!V/IIP@R0@F?!(Z!EX!T0%[(9H?HL+-F
MU&QF1I:SZ8U+R]5/)(+8+*F0'$8Z7"^.@12L%W-JX"[OH*.ER1%+!XBQF00'
MX8BSLU[^^MX>$<"[S6^#VI=: =$RZXCYY8BZDM)@+GQP48Z*-VZ?)W8(]%+^
MJC5H2LWES-E&B4GLGAUE"U )^<P%>9,5[92OASG.^+@Y,K5\5))*96'E6VG8
MR6M9#._"D@T2B.C2/$2*JOBP:R<Y(\328$28&TN(<KB@5$,Z9:(^&MW7)5[>
M48J43'AR.?*A'ZH>C "0%+E\0C\R6GX=&KD;WTBE>7P9SJ&;@O#(</(Y]0ZF
MHA DXVB+V("#^D<?^\#>^N2@&,X)HW^D>BYZJ*[<]C2S\]C+9NP)\HT4]9'6
M,5ATJC.VJMRT-(LK?Z\@ZOQ\D3$Z+@]_%]2021RWUK#-?M_ 1THJM(R'91"D
MK:RXB8@3"HQ4!=(>9A_V6])RL U/<E35FH?K?.WK.[J*"-KZU)/0DZ,EQ9$4
MF9^CWZ5YA9Z"TU_[KI?HRONM+N2#<L5EAVHT4JOF'-H$3"!I6^E#?>0Z;>+G
M>IS$-:#JY\<]<YDB7%@)0OO9_L9ZA%E7ATYD!?!E_^T&Q-,-FGD6 $::<U!;
MD$=FZ>X!\^R9@N["'RGX#;!KEIX9$9IIH;-$S#@JWMD$9*O):^96BU_-$C=3
M7<B0<*[0)\I]?=)X&:F(_E3+A'6C#'S!AE903_!)?1O'T[3\A(VN&-(*LTG6
M=%OJ1DNWEC')+ZY'R0]-5NMXU#GQ++WP-Q*)\Z8N[JH]$0ZJY;X*EEL9(4_2
M&+IT6BWB:,N>#A!J>Q)0-SPIP,/Y:>D=Q.%8WW3NP:^)N8'XZAC%4N:HKD 0
M6M]2DQA]AV+BIS(U,!IBKZV[A ZNC(A,K+\@"K)4\=/:)BT#$SEMUXJ':?F5
M73<!M#O%/Q8-VI!:95=9+DYBP-U^I_$_3;(""E=^ [QLQ%)UPE6I+_SR&PLS
MLCZ[%CA(NJ(^-#PZ%HJ2U# ,WQBDMW?#+11D(Q9'L<?!O7#.&4I\Y'I:LVV.
M^P=F"$DY/WG7?),NHW6P@R*\7IJ'KU#3DIT>5V)X+9Z*^TA-1M1] Y5XN:I*
M2$AT>&1?;YM^<;'>(T'OD/DC7?'9G1O\$\[B&II6*B0>>Z@I78QP8 8ABW0J
M@7?/(#^W490F@]WR9:XKGYH#G0.O&+%^+*"F_A1GS4LHQFOR-%1)K%-%YI5^
MDREA"+#(6_!PD;/[46??3<129]:U,D+'(W'GT3J&KN+0K@E@=7E)6NYM9:'J
MU'?&0)^4+>!]1H<M^&8A#"A*^PVH9X"J2UK+'ZYA5?@\&4%VAY,$G-5LZD'Z
MH'H-J"P3RR?S;#FN);;JZ7G<6FG(>M->8'Z%M=]Z0&00I>"ZM2CNMG#A&CVX
M"9(^"*>HF3</!D#*)8V_GUVN#S:/V*8J=_0WM1GQW/L^"(\"RG!6;5-8@-9"
M9;7NP!VO\4D/H \%VHX98'-.J?@OCI.GUZ\;CBVY.UT79)7)S%[OOT/%DU\X
M/W)LS:I$)<C&N3TI9S<EUCT>I)%W9(^ESA1PO8,RM"OVNC-(X:8&.$&*[7&_
M#2'S>ZC^Z/'//LA P.J-=-YZNX:C)Y.>VSO,RXZO^TX@?$EQY/M])D<@[0LG
MZV/L8]L-D-Q<QSPT#7;#/?3M^8!JINN;?5FPYF!Z,UQ?SCUK<467Z59.B-'
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M9?VX-#!@-R?T9W8%&.C+K AU;>G#-L&[1B7M^GBA<A6V/E(,"#9S.SC@U9+
MR"U":%J<)/_;02\?50,+[DH7.#Q<1==<$VY%\#)!@=O]=(W:S\*56J4H4O?U
M]^\9Z0H$Y;., WM>O6X5C/JR>E-&T?>'"6/'2S3'>2*^K99)'A!26Q$![_2N
M*SB&Q:8YU=?.#D;;K30>?#/6;OS9O1H$!H2Z4#"I3J3T]>'OQHDE1"3_B#U,
MP2"[8S[B$:N->F3VCJ=N>./OLA=KDQ%?/J6?,TOFWT12]IG#ZYP+CY"8*BO"
M!I>P3PA'Q4^0M5O6(Z[A#/K]ID3W6<<Y/C<'#2:QCJ8[!T:.M7B2_EPA,7<<
M*;7G)NU1!5N:+J,'=^B*/8Y1T5RY11NL04]+1,*N\BE1]T4VL0>%M@Z"UINO
M4227/+=KM7^P'+VHE3/?/AON!D!!!,77U'3.1$5^+L3&?'49-8]>S4M'!06S
MCASE*<6"(V,7*G5FUN*+(W1Z\,QD55=-%U\1J^[;7?FZ3KUTU/K@7!/%I+O/
MFS M&_YPZ HM7V."SWWJL$^@!X/RZG%"E0<7DN%!NK*W/6.KJ]6X2[=7O,+.
M8QZX)IW(T?KY9M)!4G0?_0:<:[9-I=!0^X9%.+?4 \6.(F%&Q?$/!OV?KH<S
M&P8O*,'32D88J&.#7@U2"VBZJ;G,Y$R:%[MYII$[G#<^XBT8(RPTMDT+6+EY
M7TPO[LZ*P=/8OMWZ_5E:RL>3M@FOOFPS7T]O=M="Q=1D(KVHF,L-B=.0]_^X
M:GHBXS3GR0,3[_D'$)\RM%X_(,V] Q O5?<#4F*&#'LT1$LHB'PC[L?^_)X9
MJG]XM"(JQ\MSE."BHTI-X2%*492>\CU+!?6^*&2S>JW""XJU@=2],RFP;RB:
M4OI&7$'>%UIPZ 9[K-RTK2:T)18K4^<P\TQ(Q<8E#,,!C[)Q;UA0,>;9%LBS
MQU"])C-5PDEOOK>!$6CS5%X_(S2"OB+LD+F,BZQJ6H%7G:NN9N07IU[#1@S:
MX<]-QS+-U=\R'DSZ,$306%"-%MQ-G 9[IHW%<#5L51'_!E"'/YXI*Z98P.<H
M"N;!I7X,'^NY+--LQ3XX14?^@%C?/4T<E$%5C43!AT]&@=O$B-$XLA1HNC3:
M5OO><O"(M"H?]+$/XDM.^*:^O6W_*I?YAPO!>S01?IE._26\M]_,TIN-H/5R
MZM$/8K@?JPR+D" *4:?1T@0RULP&G\4+BF)[>HFOB'82]*(K?5[QUBAG;+!.
M\&@4R"HR(ZU4A32<5:\B"G#A$$W/..^>R%FH"O0&CZ6Z(87U0_I!FMX/R;W?
M7VM2F@1+!_<S: FH9*WVV5LIR+FN>)^J')AI\C!X=&<I[P_9HPXEB'^$;4;C
M$7=&A_VN61%Q]OWAP&AM.,&\)%*(FV?0G(H>+$"UTWGS,0[K=%WP9C_7TUV7
MRNI\HC1HE<N!EL&K_'.#ZMT#F89@Q@;#(2C BH!* 2+=#!2IG!W4!+_?YDJ2
M="H 'Z5HG+3/(F_,QTYTLXC3E)P_0B?+UPBM\W"]?N._IN1S-AW%?P2-XC2R
MK8C4=M0>/OZ*#QL33'96R-5H,SI_^-@0'-JJS<T5C2^4B YHXZ%.A5"'0HQ=
MGR86\/6W0R&Y02-9LY;RC#Z3--5I]Y5Y:#H99V$<]Z[%3C!E'A67B#D.6?-;
M3)Q2\?>CU(-B6@V/-]$HSJ'4R(:X,\;8ZFM1U,.*!3GYVO&K3O-?@S^CHDYB
M]^*'_>LY-U1WDAI_8#6[%W)[X-BQ5&79$X1.YI-%GU4A<GV!^_LCDBP_46FS
M+V7#3U)+0S[O]&LVRQ0LK*UV"'@,--4,=;TZ0X/0O)K^P-U\RG'QJHT-,.?M
M A^1?!E,F+JDIXHH<6+^-F&:O,KEIE6[<ZS:<3U]3@R?D*\_Y5YS==,B,()A
MKKFAWY[A<?H[I/M;F4&MCH?!(XL$"'M;"R9%3K)RE9:C0!9#R0@<%'\0)HMR
MDU3UB:M5Q@*<TJD/V"F%">&B&;&3,^H\_KCR<,/WAL)B]JI>ZN2=FGIZ )"<
MV!EH?3S^B64(@$V@%!TSV4B5 O*3NQYQ'A,@>^0%#A_ 05.U2A+2 LXT^@/Q
MX5J^S\:^(CO1HJ5YOIX%V8,M%Z]$*0CXV ^0$*G/KGZSN6*VO7Q5>/ZX>,V6
M2.;U6T)DJ9;U$,.B>)3C.G,GKC'RH P8U8CKQ?P:% 66GYAWYW8R$A@5R(U,
MD^D^<4*2SMQ9L]XH**-Z%5N?U,#881-M<$R)+TT=9D)M33!N-?DMF#(0E@JO
M<#JA'/DM.:KWJ&)?ICR<O %7E4]JS)$ (MN?'"5O,A73/-2UEPI:5LNP$/"&
MENBNB=G%Z0I&3.I=YZ0ZR,;U9IFEC9+:05RY4;UK=QH4DL_4A8W]VCJDT05$
M&.HP)C$ (;RY08RTD3QH=97<RN3SLL]6T]W^3KET*A.YA/8CB2A\[M5->,.;
MX!OZC.67\?0NG-SIP7_L#&/2> .@QC1U6'=^6(I;0(\Q(?V*[\ZGZ'>,GOJ1
M=G06N=T)2+ XAU87DZ"ZG=[[A?$-65&4SL=U7 W08XK5WRLZ8U4\3BJ%QC@]
M8[@5*@*"9HKTE4HD.(%TF(RELD*1$JJ)6!;,3<,O(4X1']3S\,)^SEQWS5)'
M*MNIV5\0D2/]'(F4EMD.4HB$G<W]$/JFDJGGO=W&4[%$QK(>H[30F5 GOZV5
M\ +6!44X2&GCBYJ7\'MAW!LK.:YA-H.Y&K885F6WZM.XI(, SZ/I09/F5&T.
MTDL'>N;[JQ'XC31!PX\LSLFCP59VR\["N[6/;:K%4ESF[(Z]A-/(2QKJ+*0W
M[$UR$[^]8=")KTMO[>8['?EN-"N%_NSI_LV%[;G[>D2<.+L]]]MG-ZS]S*H6
M-YZS1+6OIM<:4_M6S1-D76%3MKL"N9AX\( B,IN=3RX<)::43AGM2\9*&W1L
M7,;$]584*J9^7$WH_@5QDDWGJR/_:F"3G'\B0.\(8$?)I8,4$_^>8%3]ZJHA
M]#,9UZNM.U]YV9+/)(1-5^_C( O,OP$ORNG4T;M?7WJH=G0,4SRL\HM[90\B
M<20NHBIX..32F]$?01\8CW3GIM=5;*?I%HTB%K(B'=C@4X@Z /EVY5JY#@:T
M;YZ_0;,S<\:-45+G-:L%$AYN<+K!#R,&M>Q%*Q@BLJE1*CK[ENX/U!DC 1)R
M*W:J(,(;9$4VPXW'/D(8P]#])ZOMJ0QM0A_R;F\$<Z5H>_CNM$ @2XYDI3J^
M+-('P"-V]SLN#\BGKS72:@:^WOZQPFA%'"2NX=QOV@RM%PJ#773/O&0]A(5+
M9CJ6PIQ0WYY4:GVBK.+5#T<+ZMS)I@"H<2^8H+MT:CYBDR>)1VE0+TUK5R9V
MH>##G-,CUG06B?!V)?.]"WBV<#+;W=;]$#L!8UUG_=H#X)RV+'I%/,Y@#*F
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MOKG5=H.]/PA:EL[Q0-0=#>#_AOR.;P>IT#2;IEQZR-*M,&X-.=9I)Z6]"")
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M7Z\PN$RI/-V:93)S>]5<LBQ'=B9G)&JB??T\9"5!M)8@*9P':[!Z-%R%7#:
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MS:#W9*,Z[;)V+PZ0(6D31]R%@=3B2\X"&G^D, #/UR,=[T" F@>;>7[%;9
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M0EUVQV-%IP4<L?>:=*6 &0.F4^,D<V5X=B/\B8>N3RXWS"'*);[&AE]WME]
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M:%]Z[JTGQK)KUSH='\LD=UM/7)?Z/L+KJ(IE/LUVL&N:V=$FJZ/H9Y^PW[7
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M9:6W Z28:O:$O%./K"X@BAURF+87 O6#4V1C'*\,82\(6EQX@QF,0O/E=4?
MO;!=C^!T%&G9JV[.!DVF2J3R=]D7,#U[RY@SCP26U[_(WQ9H-IB)<YSLFHH7
MWKI!=?IUK<*;"VVQ>/?A@N%4A$)P+ 0&D1UIB]66@C0CVNFM*(9WYM*;<TE?
M,&+PS;JOWW^9K>@H%^5,5]!>;V$B P.]P;D10<,,+6S!#();5YM)F'-OI29X
M!WBGGXL278KPYKT5K&[.KU=IHV8XG>] RW !NC3UG&3:J87:KY+97SRD-V>$
MFPDP>-DEM>4BKCI(RKGK*"JFN!0E#02\'Z=M;>UOH^'WGO--$-N+4!_Y$IU5
M0U^X>_C#)XE/=6CM\T^ S0_.!=ATT4]G?)#Q#K!"I;"<T>]^<[G<;T\\,L"8
M/.]FQ[$+/[R!C*O\I6<8E;X4G9676&N3O%JY7'8$[F*!+&3HW8Z7+W<SVJK
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MV3*D<7:=S?PB>;%B\<$=+)=EQG[JO3=P'(2IZ>*J[.VAB5-"K!]4GVV%;:3
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MXF[KK](7OXPJB"Q#J4)$#A$M4U%Y164PDF9H!,,(   *   * C]##+-0!4=
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M/'ATS&6=$DPR1F";:GB3R"P*:9VBDT*3TO W*E;98)"JCK>+F _Z=!"$?E\
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MFT@(C>8X)(DV1%"08"D@I(%% &#DXH&?" (>0+-D<\L:DCTU>9UXXB)V*)6
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M7#L..D(0V!$=CQ0* "JL !*KH"UX51#2$WUCJ!UD&SB%OG> @A:"RKK:\87
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MCA@!F3  VL")<%@X'":P$\4"/_\ !%A$*A! ()  (B "KA%Z$LQY(OO].02
M1*4[!AX-O1R%XPD99A%Y*")F(QS3YYJ0'-$A! 60A7(&$1+*SC)4!6!/U.[-
M((;9+U!8SH5+BI"&^1#.6%$'*N/T &'C?>_D7Q=N?"TR[TXI1,S)$+J2'RBD
M1_V-D)Q+-61!\$R& 2&6XTQ5L;DX&!)MA=N$86R&1RVT^ I '/II2#GHF,B,
MRQ^L-U?(PJHD2II-\I$RI$#T(8U/WOC!( FHN$+.0EM13@      0 4 % %
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M*'S@@6#)M$@--C^G88#2@^218A)/!O@2E[,Y*";PB&8\<>;7^T)U%KC8X&\
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MD(%9G$WT1[,<B#@-/E<T3@FK)J>$/&"SXA+F<L;Z39+,)9C\^L[S_P!0H"M
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MQ,GO/Q/%H;6\:76:BJQ=\2%E2/3:N7H]5\\[2'MO77R5QE$D,1DS6?745[Y
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METF'FC 3,SU7?Q@KEH2L(RX\VU!=YWR,I&QWU_/G7?(DN#ARE?=S"7AWQJZ
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M3.%Q]\^S@ 591*E2QWGK/J0BX!9C_1?>>$").V+K$MOK^'^J6A?#XXA4RO\
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MX; 8RRW&G(!#C.2XXLHC)7W+YU/)5$-P@$1X D6S>(P\>$"19&FKHHC,PCD
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M3H8B(EKP/=Q&N3)RP%/A,34C'VC,<"!9)GQ.^Z]>)X2'R=/_  @(K- -B[G
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M5+E ^I3,>=1LXK.[:U^V/,G5UQDD@$1QA(GQ?A/,O,H,C%2RKYKS#L8E6%6
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M;L8EHE4H43!%$K*/2@=I+56L_P#1K4>0H<D:49I!@0\7E;,Q"),H#"-3D
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MH6;P1Y$^8?APE(GU%_4D"J@>C3\H^.*-D#N(Z>IE':N_T^D%>H!O"?%GQ)
MR*42EA*$!D.**A&)"0G\4"X1E%?T1HV=E2-98HMA&7A0A&2=*S91-_II_!!R
M<ASW*(0LQX")I + ! D$Q2@O$F.>)%AB(2,R ,",(:-E&@6XZ*Q ,3BS)R((
MHI80,XA=1^KAC<P=;H06 6',7P6,0LLP"8%41PXZI=.D:#B98S#CCAA.""6
MV"R!N'C8P<QF- &!N()F#A-C!*3VE; *T2'!8XA(&$@B9! DR#A^([?I'?G$
M.Q9XD1PQ+.1*B]%B/:(0Z2X<$!F)!]++X5N>-/(?L'H8;--<_,=/ T@Z0T9"
MX8A%0%PQ(5=P\0">Y/CCUR,ZY1D @DKN1R!!@2J&0DRA0%4,JS_P-P!=C^Q'
M[8W47/H=O\1B9_?SQ!AH4XUB"=>OC@-BBQ-F[QEZUC ')J@XZ?'F)KQ/*YX^
M)]Q$]Q.?GD9A"!R+D#4FSYUP*4B/CU<M?:,;XK*)9I]^+TIC'T%D+8@/I'76
M8\,$IQQ4,B35CWGY,QYCEPBQV,Z)Q+DT>">"(AK,QI.R_P"^8>1$/L9]951@
M<94G!, D95(^:J&!M^>3BM,CUTICIKB PP$=%11<Q<7F,.2(B$0>5FN\&JWO
MCF3+!;83-TH[?!GDE%U#'3)W^Q^.6;6WUMB86S5OP<EF%1D4!FV?,U,S%8.*
M86!M2K8>YDB(NYH" E!D<R&9W%UX)\<,)@$76 ^_94?1?_Q6!>B>+PG,!F"F
M=_NP+5\0WHVFXM_FHOQQ&BR0HIF10%J>V?-,P""6+<)1H4,8FY(.*/G#7*(M
M4QC?SQ,$5H:Q+K8S7F4GDH"X;2'L@DIB7R;XQH)F9F)TW<Y74?/(\F_AF,:9
MQW6RX(!6EB:>M%'0#,IKDK?JP]G\XU9/%/>&"Z @Q3-?O"YAQJUQ,F"8([Q,
MY*.1 )E+*"5Z^MX) KAD:J)0E;B/<^HC/!*P"G--UXU%YX,AA@];9E&OOZ%E
M@A@))TGK$SC=RXKA%"Q(Q&1ZL]C=?$;@*8M+*FXO#+%5*''4AUK7;469ZB)C
MAF;BCR5@F&Y1/EF.*$"(@@AF(J*VSAYU0& H2)ZD_.^,*K"D#;U'3UN86?U=
MA'+&$$ATR!U$\B1!9X%^&@]0%A^I[C:(HV\)!ZNN.Q0<O,I3LD-"\_IGZ8OH
MCXCW7R3T 4*(@A1 JK+;/AE8NB;&RI;19<MF=^C0TA6,&M61#M% $<',\"T:
M8RLDDE.8?U9XF!$K((0:P&I24]4\']_Q$/"@D%  "-9#4C'&_.G2A>@2)<8>
M9=2)$B*0:09"S]4-H@H4P21$8A50&A=<F?4H^%-AR%C%8BRP9*8K<JMQN]+8
MEOCBK" MG' )2<2P(Y:%3L#A@) (\" 5F$-,!AQ60U2R)@,$E$P3$P?I!_!A
MJ2/QP>)ICG:0)/8OM?+*%UZ&(>!/T\\C_AT,8_AE_40' #@@D2N1$I8)$['\
M%!%'MO1-"EHSR:H-$JAI;:DBEL"/_0](ZT'L4^#[N,A/TK_2-^O2TSR!\*>&
M&0!.Y2G@8SV)I_28F&69$C&5@;F,!?%Y<\-D),"<)8?' 9"*X"X&]\S*A8!R
M.I@MZKRBQA8< \D!;EI)*]VDV!KC W6HW# ;U5Z_1@S C4I/;(*=#7#: -2!
M34;93M5<_H@Q %  5* *LA'C]!W9#0#23$ ,)#AK]5[ P4+I.HU-$T"49Y&\
MT2(H@&4B&.34J"GKOXM&;JR:(+"@J$ C")8S"7,<*[I4W*5[4+V/T^[Y_P 1
MVX@ !0P )5= $KR)#:S"1SXM8!DPE> E@ 0" #4 #B34KZ\(" E#E>MEVULC
M,212"JG\QT\_%]?I!"W^DI^(^8X[H ?;7V_XA1=W\']YCD_#! 9N9[_,41Q.
M(M\)2OI'E\,(A0%BX=X3K<_!Q5$V"M/4R/6)(AKN ,DR3,)%]S.@EZ,0/0%=
M7;&8HUXN=2%DD9(^^8_?SYY*$@LUUG]OW[V\"H8/@]O7[=XX:B6(W86W&:BH
M-&.-5C5!1XS]_IZY!X"2>KQZ\?QP EL1-*TDNI:F;B4F9U2RPK,^M=/C3.JG
ME(W-X;V+#;7TX@2D@%SZGW#/F;3@04-"2 3!Z))+UP0,%LSA]?#/R>."@ 2"
M2V#<4TRR]\=E;O>:B#ZMR>^09KE$Q!J\)4H(W\%2(H99'WKU2=$<BT0A7V?J
MU>W"1PB5:+N<?:(]PV/_ .%T73$+%_/&(EPD_'"46;KZE6)C27#T:I,T"5G,
MW]NZ7A IE*1*L7[->\SP"^&L6E]*(N<QG,%X$N"3<T%RYNDY8),$%$U%EOP7
M<52AK!<KMOI(E7Q>.,!4-N["\+&ED[@A84"%E)*,PO>\#,/E T90*D?F>X]C
MR%#<CU=_0Z9F,<$"[[F29UFZ-1&^1 %HK!WTD$P;;@HQP<L*N9].?S[<0"6C
M/I7->:Y&FR:]W;^_.PV8\/UN/%<4$I(J_P")CR>HX )">X]A_.?CGD*U&;=P
M,;W#+]&0K#+0FK^WB)FCERUHI:+BEK[[RUR %RV/H]ED[>34#'COWCY:WQ84
M1,OB;C[/>L1^I5S"O3^0.*#V7X$^C/U/^$4XI(Q:K-?L_0JAYB*B N<Q0PJ2
M<104$$@J22)M("JB;A>(HKNLY:;24F4S51^DV8%U (FZ3RDJT&2BE[J@46DK
M#H_1UT(I2+J.D8Y$(N. ,(D@A;"X6'NTA^A($$0 O-1HCVM*KQ066SE2E=H"
MNU59G@$+^B0 *0+DN:X[S>1,+$C3-$,GG]9FT;%@"A*F=,H/&O$BR.D\,,/!
M2']'#8<G:4^A'" P1OH#G, 3 B+2H(B"(B)(C2(TB4CG@@3_   @*   H"#]
M(;=3'271W)7L217ZR@HN]!CD0X<.YZ\#>E/CS.\XUZB=$&&5]/ZD(MI8@EF
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MLXH-Q(+F(9[/^4.S;=,78SC,M;SCD#*9N;'53.?<><<O*U) P4$XK2=S6,U
MO!,6^'69C7>.$3*UJ-+I<!HP1!Y-D<!M9G'N3H> >C (WU-R!1^UV6PH(HQ
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M) F<GQ]<1Z.&>4M)U*K=5.,'QR5%34Q9U9.\*S[XZ#@)U>)^?R>8$/'Y^.N
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MB"5 PL"8#0&1L9Y2SB@:8HPE@F"6,_HV2VB-XP2@"6)F)8SQWI[4!BO  $K
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MKNYXK"9BFBKUJ_J\5(M!B99N(]SAX!M_21B%D^#$$2X@%J"D'O$??I(*V&=
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MRO08V#.^)XJ_NC_1L]@KV]%5$8+ I^DF1E_:5$N<PQGCGHX4/\&OX_]GFN"
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M,-DG/-:I?;%.H1C49P%/\CJ;A9[571C8'(\/]WN%W:=E6HEV<'7FK=PE%^-
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M-3]DY 9G,[0*AJ[\'N03 *G; MRNF$OQA5RRK,G$SX_J!Q&BBAK4!Z<SX;X
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M\%?KS/-05R^2]>=/ZF0C&&Y[]CO6-7@%$0NQ/$D]YN2 IPR(K,;:6]OJ=WX
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MAYYGIS4(;O+X&=X=W@FJCR*1K;];ONI/@$TC<=7]IWCE4@LCUG]OUQ"\" >
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M2&V0T)5KFO$KALBH&?\ &)X,;#*APR7MQ'!GU\PXS)%5A!H5,DS_ .<=01>
M@:H+&H-,;3C3H$&;3ZBV?7B] .E.LD7'B];LNS+7EUF!X*U@S[P<LL@@?('M
MS9\9CS-JTW/3G=UG^M^L7W6O:Z\\^I-A-83/S_VC!.6@6GH.I 2%X&PH3@B-
MF#L\A_R)FQ%-P*SW#A42$G6$' PHW7_Y"GQDX^WT_<_GODVI2LVX\3.JV;WG
MC8"X".'OU/6<'?$@5BDM+W*.&?XT"3E"-=9K/R?&GIN9805 .05^Y]]<4H&>
M&$@.C&,],)X !!<B?E^G^\<C0 "Y8/1;_KWQ(J\Y%D![# /9J<*PD*(11=K,
M9SU-P)B@U;G;@Q1>\?KQB!]N?MH'WB7DUB7*J+HK7ZEP77,82S(BN@":,=?4
M*:5 03,&4,R;];X(T:#2,#:]]YZUPR)<:J(L-$GYF?']&4,K#R\>N4 P1&/;
M\:\B<ZM$DRU7]?MQ[9,54 @ .'$[^70WF:I@LVH0SEUDE.6.H1J4L$JPG6)C
MFZTI$&9IM#G6. Q+HX4HZVX$,5EUPIC?-$V;Y3K,I5%7AX!&@&(8"6HY)R#+
M8-(HH%.Z8E['@T9TV(J+Y<#C[Z9O?#!6^0!RI<8\<Z[18@7#LF\>MF.,SV2B
MF$PACLZ_+.4JO FQ"=Y_/V\#4J9(T2R/8>NG,2C< 2/:XQ,?H^.(BBHF"A0J
M&?E*]Y_^B(0*H >58!\\:$[$4?"P/R?]O-4V1J4XQH80@/\ S'#@A0@5F5.:
M%4'&RW7\Y@-,P>__ (ODD.EL]"%VN@5#A$I4!BA2VUH#SP>RAD4%!DHY@A&
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M(]![1QCQF_'*KY&$KJ !\&(P>$(:JNAD#ZZF,XTU$1AV0N<9Z_;*V_WE*)4
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MWK L,O@O5TWA0H#V,[\/G+^IRE(I'L$D_/K/"^ P7J'9O^=S@I*TH1/..O\
MX5E5NG0^4_3@@*F:*DK : *59RFC.^ZZPL C@7#)HI9* !LT')UY1.$Y=$0/
M1!OX*G*-)*!!K*DVA08R1G APN6I6I<:]1\. VX(R4:[GTMEY '&"@R97X8]
M8DXI)Y8]''Y"BE%1TD9-+^(=0P)E$"SAA"5F--RBC6&/1EJ#@6^)#BY$*I!0
MP:["*?\ &=$ 76V;8NPX2#HO]2'\OQE.7=8#%,'05"$_@AR1) D[>070T:$P
M!RL&%!DE VP<5LN".0'-1X1^%1/..%=6,S&49PFTNX.V2O@EU:\[7H B;C$\
MFB?BO.JYFW"FMS%G+Y!%B'SB6SU/R]K-*12!#A H@B/^<5B(:V11.LJ*=DZX
M0X>C?+ZA]K\12+S,B6'H74<,=AQ[+)KC$YTI9F8&9CCP ,P8\5S; ^ )H<!J
MS4)E3(>("]#0L(@,    A^"2E#C9GI9.@7E VK,UN+E!42T:2X$X9+T,.@/P
M8BOL0I&XSR$*A<;T D''&P:* 1>## DIT;0 N89:T1@FW%,^!7X0O,G%=.*D
MA"H3\58T#<N,ARHP"",X00CI;EO/( 8MS(#MM.A;3<2:!3BWG<18*EF%0LKQ
MBN8 &:7L=MVJ :0L\,"6=J(<8"$KZ#*@S!*(OQ9;R-=/:P%<@9B)!7AGHO(1
MM/(Y-KF1*IP;3%;PF927A3-8(S^AGS^&J,T= 6U7"2R+20B+"BD"IUNABL5P
ME0C=[A<NO %S2;>VK[C#ABEJK_\ "8M SVZ9^6?/IB<(1:S=,/7<]_9BK/J*
MG(%$J]R=3AG$P6B84*% &3JZY:\A(-%:508//6N>3EM9RT[9[XJ#.)PL %4Z
MJ/C(A'TIAS' YBUN==< ,4D!L;"5,,RO4G'&2.@*< I7.1L<Z2T$" 8!BH04
MS\]4@@W 8"A0@&%]^7B+QK+((SVF/KT<?D(H%$?@@&8/1VTM ;N0%$5:JCYL
MJ'Z'.4 %!B#,YQC7%"YT2GT\GW[>,ZD.F4?I@X*MJ6J(A*X]F/>\_P!&OVJ(
MJ,WZ?SZ'(*(14 ,L,X^>\T,<"U$%&9?K+W[] \R$*P),$-*"#X]CS!H72H_)
M[@XIK$>8CBP,("0TOG:XDX^S32 M-M,3MFMB&)E,H.5GMS_C;?7JLQ11M="P
MVGCA3=J 7N@1R^=W0P<T#)@(/5N<U\\BV=0O;$G>@Y]O ,U JP,!89:?3YX6
M/6A2H'3(UVYTW5!!2:!6*GQN1X,\(<FL!VC,8<=S/#H"86X7O XZOMO$,&%;
MGI(-WGK[S@Y$9<PW[8^+P@+PVL5)%[#\KYYO_G9T5Q:#S&2(KT9X XY;OVJ@
M/Z7G_@:C@[829&"A$"8A/P#7Y)!68'!V*<S ,EF^9.D84\:PD= 4DEF08Q?Q
M+):C:!$LSZ:2]\ZL&T1"+$"21$3\.A@-=B2&'90QE.3*H3&J,AH1 7A Z.,A
MP5$EIZ9(#BO5-4-63HJ"I#,  "8@,"1 "  <*"35*C%48"%:V$C^XC8L&(HV
M/XT[#BI:I-*ZHJM(B2Q80?<:URUS"*4%6$^- 04UR\#_ $M^ 14*@?)294"P
MVP<,307)P>;BT:Z!@>X9#"[R18ABKP0A^%L6=&"[[[P$1$>90H(PT)Z)+P;Z
MA0,4*I;BQ4V#.9*+HRE/N+?&6S"'X+[8^R$#J 8:8 UR(Z.XV6ZFR6;PD/VB
M7AQB4<! HJ_Y3BX9F-Y:\;>%TG"_@YP:?#W#XA^-XI'R*<=*5EA6$;IITIFN
M[@L'>J#/NFCI[> P!2 H%MG[2X)2"A*DSS(A)3D-21/$ C%\N9Q'#:V!N$%<
M3FY=NEPI9!B!75<P,,D9S>E@%Z3L<:N%G8)1R"ZA0D7C8ZEE=Q/'0\U[YFI;
M/)/\G\!HHFP0A-:9E U9G\ 01( ,!H!0'(C1SO\ %\FA@WUJ%5!#3"Q\4'9A
MPM+ U@:*28 S1+,@5&7A2@HF70P[M.M,@8R6X0L=%TVG*IT9K/Q:6V/A=)I-
MMP0*#D7$(&FBS;F*3BTXK:3U P'P!JY 4'-"QRK68RA& @BX'X:OY7Q^! YA
MULRIAS&LQ<RB[%AO&5'O)^G_ " *@#*O+/P,RO$?KZQA*,YGC^VYJ>Y>_!US
M>HF7*YGHGVSYQS%97EQDSG&M.)]0X)F)8X!HEJ[?&\KJ8&RT"X%*4Z)E&MRL
M)9T-&',B';QGQ&UDAA&"Y3,&I7.,<?H]Z1*63'N?5X;R@B*-(] GD8^$S\$M
M$(@>E(V/G'$[?&C!Z8:&F80KOCEHFE(@4OW:;IB1BGVIQ'/GQ)YNI)XM9B@;
MS' =;R\*DZ(%TZ;Q57H&XY1"F@Z'#1VD?UYFM"%W^V]9G<U."A&Y(.YZKWZ^
M,\Q"E6V@W\?>XDR_T@T6")]/&+HB]B_;IWV.N8F4-0%7MQ]YCN!K.;!PS-T$
M,*;^F#N.:2HK:FTZUV\3V#*84 &X;$Z!^%0'!6ERXQ6O0-U./.*M2V*T,K-Y
M'KF'=A]:0!Z#+05P\/=B0+&YO!=MS\<N]."WA()MKO.3,')[4]" H><.7WMR
M\(0F/RK:S\Y7WO*!1A C($880][<A-6G4&41'(B5]<4LMS:S<#^39UT@ @$3
MJ=;\XFWV<C@YE'N^]8_QC,C*Q!0V&>?F=<*H4!$]S)"=\.@,0[$H_4_Y%=2:
M7KSO/$R]9X*<!<0]9+!V6WXDWA"+RR "BP!7'+!*,BHB@:DD9I&4XQ/(J, 1
MHFA",%7D8.M%336#T&5P1:ZDY4+,A$@[,Y,K%@K(4'!A0G'\(>#U! !4H *X
MX-L@!=R)D.O7K3@=(<0"3*@$^0#F)JAC-(U.QI"93/1N9^\BSLQRG:D>[^S[
MW\&M%_JT08SDTQJ]3B9*PPZ%AY\%D/EN" #I!2=I#+"S<XL2FDJ J %@%W .
MOQ3PRGCA@1<B3VDF=C-9@CI3,SBWE*K1"I(4QJ.1/9)'J%\VV\8[YP3&$_0N
MYP?JU*R_\/\ 3RBF00&$:-R(C:LJ80AA(=5 $ .8.%\SF!J$1CA'/)9@[YV.
MSW$X1X   @*"B%$1$1B9/P7_ ,+Y_"!C-!:=F#2G':JY?^3&3@07)9-"H3-.
M4,= JM4@E^+50K@A#"QZ&3 *,4+QL(*FQ8ELJ:R*<#L_K=OD@I N'@S/.R F
M@8O:84]\L@UE!@'10*@L(X/"!A5P=*F#%B/(KT1$FB"(BH28$0'F*H8"IC%6
MM(70<JDFK89*% "@'4E09;A_.&EF.9J[T*Y34I9=,KP_-C0/Y98&>,AP73(&
M49@@M%KL,1@?Y !%'@Y-JPG:59[(R4N%&\6I+5I#GB'")CJH&9C(..^.9G%2
M6L"IW!+#S_$%!@2]E//1$R"@XV@9:M4Y>FQX^K@48I\*=F-*<-$4%F,#L)ZG
MC:!6C JL"$;PN$6:"$##0DN0,0JD0*:?3@C_  .VWT0+6QCM-KM(2)[=/!*1
MV,600\[>2A'++:1=FX9=I.,'I."LD[ +\-2K\:&0B*^VP',??U"-'9Y$E(@@
M>M&@KKT5*EI#R0F@-!T@.@GI1?\ BL8(6@UB4C/]9ZY8OHT1\^(=>/AYIQ,&
M/5KC?A,D^@E13![AYS\SAR7PC2J**BSYGCC-H%!*2C#U2+IX0LI1,C10SH?E
MC6/!J89714-.\S&.\D2)9[2 7<:&=OCN"IU@D&XC:O?_ *0WW%$H+H1$$NXN
MX4CG6@H)BR=&I-3@1MX0+B_?.?/''2H""UAD&,O>/&"S[>4#$'H6X_6\759$
M'>FE;:7QW.+;%?+K@,II&WQ,H6"Y20"!_K&3ZN PC1E))1][^H\(K  Q<7N7
MOSP ( !H,!]/Z0 5 &56!]>$Y0:15AIY\]1F<\;=5O:$B'GOJGUX21,5] @!
M:ZF#KIXT18 &VC<6&KX&&(HG%H69@94QD\8.N5:)49H9A*AT18<#$B;Z<D&!
M,!)NM;B^<AC<N0])(7)VT%)#IT.""L)#. G'%B[0"3*@5@>6[>9$.-"0KX[)
M-B]5X-%^CJCH.3ZMSSQI7V$"++2I'QO9R(P"F$P)O;BOF+[E@C"2Y@*G6Q\L
MTJ2XAT)CJ#<11TO=/6TETN8"CG[6<;!DQD4,*.*)(W.?HV5H:.O#AIOTY#OC
M'7-64T&^@RZ^JS@E@"!HC[_Y3088HTXQE2$+0/(V< %.;LB/!4IC@EGT*< 4
MI %0Y9>AB,&AZFS@'(5&J%$H0-H,T\H1AULJ04"^)G+PY^]O] T^K[W@* WI
M<B,%]0V<.;O#L40!EJ<JS#./_<;D+[KT\&0(4HV;]0B9%+@B#E-*\37S E%2
M-I1P"AE@PB"BG$!HKP '+!E$!48#\E/N<J2@(C&\,L?VUI6!"H7!> (%/JH0
M&P ! (&J)#7"NP*\D<)1UI)&1LS7,.  ]!J:%@ $1"X@4?MO"I")&$4! "_@
M9N/Q"?T 6BD..Q-"E%J6UH44G@L.YFR/.,GX.+^,8H-"J8@C,<#MK>'3\&3V
MCG32WKS**+ !Q9:<.CM$.C!""K9I1EX+6)1;<$45,"O @G)*1:."\D U$_CB
MR@# Q/><W ^^9$+G<ST91 W=*,XO/B<G*7]Z(N<EX[F#ON&.D)@F4BYUN6HI
M%K0W2H #_P"#K80P6"#@$?'9S('\_3 H&J,VE081B.6O)!QI7>G%-X7R:"+4
M64Q(0CL6*1 -^(E0/#NBD-(E% A);\1+UQ!G0YT*8-Y0>$1U@(C7$0$$5#\5
M47[/X'$X?Y\/Q9\)Z7#@ %8S\6PCL=H$ ($9079G#(XG1,58032E.;Y2Y N-
M$,52 * F ," P\_FRY$O[1K5^!:O.>;8V1Q &I1%-U]S69_0XR-HOK*,(@BA
M&G()G#          $XJ.B7-DUA@'# Y%DJR#=,C4V4&A=\+V?0HP86X.%+C]
M1(Q'IV,R=NC@&N+.C?O4HS<C\2H#@#   ,  ?BI%P$I=DV3HZ\>/H;,&\I/A
MU*!!3!!K\ 0*/$ )*O U(2,*%L%1@;:K-@^05LR%_P 0L%=&7B:D(V(_;/G'
M7TH\Z)%4$5Z/9_G@)% >&EK\[_3E-6BFFX#!YOV=^B2&A%K1DV_?]K9'\K=
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M.:] 9N&9SNTXTIQ&J$F&\DP35?CB72!6A !N&8GYSC\K>K 4,(DQWLA=U)5
M;*/!R^KU3OC#0(4L 1,K?U%X.\Q4O';#F%7&<\9A--%0!#RNW.?.N21$"5'V
M<P<!C7F\N%H$[7*0R$SD/DX$M366DD41!@%-22@_,2CF0)C;! RC-MIIE4HA
M0P=>"8ZG63:"0:!D/+NZQ#7$Q4<]=W'J=27<X :J JAA!IZN[?Z04Q9' !E>
M)9QDRV,PZES.^X<'J(*K7LU_U9].ZDI:-*>3QUPYH;H@4<^#?C'7$<@U%+,Y
MNK#AMQDPH(!>8YJ4,7+WT'*HF LK:0)B>?.<1XBL"@SIAH?'^>8552I4D2+Z
M\]OM4^@9""<F%UA[WRM(1HP,TZ&D)+[L91M4T8_1K23T\"BA2"(&V^_?QPVH
M(JC6L/1/"=';PTM AA.P4K'>\]<1^Y 3-LNB!$S,<?>U&:)7*6H"]XUP^.$5
M!K&M>V%[P;XFI"7L6!I(Y!/5<"F8:@6FHS+4SJTX$F!IA&S7S>]<4@"C'8YQ
M\X?C&9@@X0&#]/O\J]_V"O+?O.2_<AW,V_\ >0?L3YYB\!/(5 _?(GQQAS[#
MYUU]L'U>/R-C<C:'5%^/RCSZ*L <&E[#UB/$L@,,)@#I;F;L0O3%A30*,>LX
M]7>7F6#E=0"]GF9=\S/-#=@5I.MF7$SQD"5YUSZM,W#F\V(>#@ALA1)7#A"\
M'YW:&Z,;,=Z.H<D7&ZT B/4T&+W,\'Q3=Z.&LYNG/A[X84%%F<+[P&/1B[Y.
M  @HJ###TSC&=O*4IE"PQ@Q$U5+K)RT#Q*!>@P],MC,\!M3,:H4F,)UFX1X*
MLI^$@^)]./,YS"PW7'Q[/&-%AY*<B;%='RGSPY=IV8A1B5\ >L_T<XZ6)B4G
M[XU^>%'IE4NQ;K=Z<LOKC\B4@6S>8]]=^?/+CQ9>\V/?T?G. HUAAA,QGK77
MQCC*5RY(%"(6>>TN>9!D' Q1,=8W+)"9!J$+B"4OWQ_'@,7!9,BDZI'SB9QT
M*_T&LZIWC3YUAD1F0]L@L[WDOL/''_S4UQ 8&<..O&H(- 8<.C[7%>4,11UL
M!3-_R/ET)!!M9O>KG\N\QXU*(W;SJ_&[5ZUP- ("")H:8$O?>_ #KB > ,P%
MZQGT<63-<@P/AWC&,9>23B2I4AD7,[CA=/)6(BU;JB=Y\M-/#! 3@RA$S[>2
M$QP;L _+Y[/?_3F> !T"&$ H,H*#EY<\)+J <H !94 7!_9KT=$<#7+3.?A#
M.,XEBTR&3Z\_EXSQRT,R5'(&T2S;%,C@6O8R.UR=SZFWR^U2@P1@J^"Q^,\'
M"4EU%TDI/'TUPBB;TEP>!.\U^_"Y#5.)V6Z0_P!<CJ,L>>\FY7^8>,(EM!'5
M,LRY/O*\4LP0+"@$PS&WT.")-)< J!J,AAU@E9P=#<0SMZ9KO/%"@4DIY3.W
MS^F^)A**U\%<J>G6/C:(Z"A<G$7.0)\6CMIBZB3R[J#ZEOHZA;>D(+FF[:WA
M($0HH@Z.]9WX\\>4B@^6 ^/M_F)1&&UPZ;W3-FS.G$;J8)64J!XV>;S:B1MI
M.YY_U_1=<=Q-0V,!AGNV?/RU?(?;XKZQ_P"<>#IP/:.?JFC9RPH,2CTABAVY
M]<2U(:(;!2$+./4&Q((K-(L8-![_ $;R2":HL1*6MFU=[N$0E?6)Z=[^VIN"
M4,$%ESOU^6> 9H>->F&M9D^9P8A'\0P(CB=1/\<'(")@)T$#66R.\\H9[AT#
MMUN#<6PPNE%0M-+_ );XU2X/P/3J>^Q.GETU*6U[.V9Q^5;CDJGZS&/KKTXZ
MY8RH)#)0&,PKOS<<G*!2-7R/VQ"[W @4,4S&;W[>XSGO'[PI%%VJX!6+..I8
M(MU"+3>OR7UPA5$S.!WX,(/OK/$9H4?[@C]00/<,X\0XT^%B_P R>#''R=T7
M"B=8?MXZ#W-R@44:>U\)EF571,.R@9-_DH^. 1"@&AO7AC'F7-YH\D- 5?;G
M]X[A,"(&2XW+X^77&(T:Q[])@ QC\K'T 4^7X^F/6NN"1+<7,,STXSL^W 6,
M1V@1\2OOJ9X"8^J.*'IZ=-[QPUD6G;]!<>_!>%O@7IZ3?Z>=PO#AHK S<_I/
M:YSOC#"*6DK+A>]Q^T.(7=T#(^.3,ZH@X)RGYSJ4A18S*,P)"F.)J59QDS8]
MW=*_KPS5)?.=9EQCYW]>3+=9VI'Z^.\=_ 'W?+I"'W?;WU'F_P"B=/>+[/"1
M6SE\N^][3^)@M8W]+G);J<F=4QQC>]1MNLG7!Z5ITL$&!E&N2;#D)"0I8KO8
MAPGGALWD+TI!?6.$K%63&HLQJ'U9EG=DV/WA]=TK]^4.(AM AV*DT2!YF^#T
M,ABXUI4BZDYNO'>LHD\ 8&ZY?BIS,&,^L!F 9M.8& #0(T$\.!^?GDXDCF2P
MR_89]7QQQ!-XU.][G6QR<6RCHED[^F^6D0#+6$\^(4^O@?:L7RS>J2:?UG#T
MMM$18(0P2YV>,<>G@@L04'>C=N9DSR%?@QHF3;MKE\'##RJJ_P \;.O&.5=8
M&?\ .?KK6#!PD",G[*?.S_?]P.OA5ZP-6_;.\>."Q8YYT9U/66W]'AJ#M68
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MDOODJ.7P1C&NIEK^W%7"K80! GYR8SP80$$CA&IVZ,_I.($PF\QPGGP3_&N
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M<C55NLOKQYYF#L%&AC'FOKQ@X?AT,$'.]H8F#7-+R'T)_<%W1Z9:.=YMQO\
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M'MH,/= 98"PM0(>&@#OPOO>OEO&,5*&#R&GN_'#BO!\1V'I?VUQ:@JZG>?\
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M-@(%&WR^49ES]=H#4MT,I2&'?^Z&0V(5!E=EE:OWWS/]M140Q*8=9+]ML84
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MG]!A)*43,WHG+I@@AU#[^_T<\5+%J&"+^6^SZ2H'+3"A:M'Q=-AR00@$VUH
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M/RX@BT@!=YGVXWD=+(3!@ZF)#7Q4A;'!@@GKT>IC^CP\<; TF!_7\OIQ"KT
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MY369G/-YQI%I0JCHS*IDK.$R,9#D7,_-,X\<T>CCE?;^O]^G (9R#^W) O@
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MS3YWUQT;+ZZQDO8ZO@@7Q$"H=JR2@]D^:C?< ZF1PXA_/9@-()#P$,&<X?\
M8QRTF4PR74SK&YO@!"2*DO5._P"0>" 1HE$['_J:W/N@G[\7J4G2SGT]V;M)
MB\Q("7S]FZ_+E7H%7M"X'UV>O/!P\G8$2A,O=^_ TH8"4@1'&QNL]<J358&9
M"3#F[N&<<D,H0#-K, $\N//*VE!%T"<$&['K/"G&W0Y&W.,UON<<$M,H4RM[
M7\GQQ$/.!FE\^=?0>,B%#]R%'U\Z.%@DK%$/KX#['7*R6J38#!\F2=8[>2-(
M45$4(M<^S?[E">"Z9?WEZ_0XU@UF#M,YV KLTEZ>$<Q-1 G7S.]^=G! >@?8
M_OH'( "E!)%_;BZ'5A 5I"@0OY[')'?L')G%D?\ '!RH$#-[;=^?;NG!V*8Y
M* W)HJYG?'K0P9>&1;O;X\<1+%K9E][HXWC=ZX3=I2&,-5Y]_'#7H+,;< @P
MX8+U'A."HCE,*JE;-(V6@XQI43 8R-%PYS,<N981"H+Y==>.\Y7E(H& WD>I
M;^G?!95-$)@ @/T7P<F90S1]@SG\MS/'$QZJ?4?O3%XHC2H"U^4\\$H'*<!-
M3/AG7&YNR5P0*_"SWX_ZK$RDR6?'$K-V+ 7![0]8[W>9K"%?LY?%\ZQQ5]P1
MB@L,I66^[S>XQ2T335G7YM<6>!,1 7#(,J3QQIP;=I1Q#!;7&)OEN59UKE0P
M.50WDKQ>E<[!L J45275'!0NH.T%3*,AVGAXO)+BBF+GLO2XX&9&?+@W"SK6
M^'845; (+.X%P\(IZU#R Z!:&)"[O+H4G"9S/'F9<G%"]C+\]^^_)W=IA1 H
MHF(F7]/H\%IU*C./'^/[[9,#D+B&R>?D:3OCZ<ER.&_J>CZ;Y/& E! L?_>O
MK>1\BX.J9#XS\X.64 JU6X%9@]W.VY 511*AW<GY8=\D1&AMYV MF-[X\6HJ
M*AIIV6L-:QQISC!IPRR=G!-W0("()@RT?>'$X6.M-E50$QJ"8-.%I,0@AR!5
MJ32E\UY3V^"8T,+'WYU)P16 !'95![G=W":5EF'"P*CO(AK/-=1@=@J>)<&7
M%EEN!EB":T-S_HM.([4F2L4^7WU@WVS?&_40WY[SY7_K([4-1[DS\_SHY@LH
M1<%6_3UUUQ7;(2"!BZHD"4'SB7>5V(,HSY'%?C@]M20)BCLNKH/LN+V,+E9O
M8)[DYE^PS P8.]M*A<$!4=4,+JJV@KT5Z5RU@'GVT8-WV@8G'XM12 #B#Q5U
M59CBQL@UD6EFN#%Q9KB Y7(FPDLC=)\')\Q, (=H'@S)I9@.1@16K<%S,ZZ\
M;X"(*!&GY18X[;GS&26$.,B)25/U^. ;H"?WV-($1]\;D$%F$#K[_7VQXKNS
M(#N&Z^7^6+:X %9'?_F3.GC(DIZ0B+N;\S,XCI-4W6MQ4<J>*>!6>B%\E 3*
MWOT\:.((3!C!UX\W7;:O1L0K8,$!\7/! AEC1( K M;WP6PVUE;3,F9LU+.-
MW*X:$F( N5I3+P5R>203!8X,6%.[QF;.WE,JN@U2BTV,(QT-A4)?'G'D=*$F
MS5<Z;SM/M)YXY H-)#YS?"OM<[/4@QY7Y]=?Y_Z\@!H:A9D'9+/#7'# QBGR
M-[]^-^\<0$^%D"8PT*:F67JYW09ND!:&#:^]\CE1D"%W0<S1M#LX:BP)DCL>
M%,.)>+8.2 @>"R,9=SE"B(3,L2.6;B/3;MB$,(*E3>WR8Q)@0O%&3N8\A^5X
M,VM,  6"P1-'@UP#+*4@Z3"],QO?*O1LPBR9<9V3X.3]2!#DC1H![X4:% A8
M1?IB^>!KD ?31K>W'ZLY5Q8PT)NU?GKPS^_"J10(N<]?1+U[X YBC#)H]]0[
MSKA((ZT*"'55)=IEXY> JRB[]4S\<FX-89=T.$A&UC\<K._+)2B*^SA%P\"E
M/)LRB<Q,-4[R<.J?'!LVE<0PD/9AQI!](T6"F5;E)Q^5 3&_)(C:SO9R3O9"
M !!E-+X<F=N69A30W-N>$$B37"QR]:T2DPPW/SCA>D1M4"@1!*X]3;P0D#(S
M@&'C.>M=\/!W0#2@M;CZG<P#_P!8 ;C)CK'P&8[^-I7)#!%W!)];[Y%@Q8N%
MSBG?I^O*S)/F0?%P3[_?A3H$RJITVY(1>@XH;(*I 2 193#^O![:SS(!,RP*
MU2&VNG<4!D 7)D \>1X<4M"8B$XCT63\Z  A !JA11MI@IO(*9K5PC;C%:F@
M<$G(:,P99D ""_&'&%Y0>$,N65C!DO\ X\::R 4J?;EKSB7C%KH@P" 8\8S7
MT:>(\*>+ 6I%O6HTPPA"+'7H=1,W])8*M);'H^CY9B>E04I1,L+W9'.,SY_O
MO*DNCRGGU_,\.":(6)=0ZD\X^9R<]7Y$86:3P7QKF>W> :@+#1&4OKBN$4"X
M@[T$ QA?'")V V;F"VG?SZX+.Q\UD/:THXW%Y&T&@-R7>P;S??/)]HI (1)%
MM+V3% W%$"OB#'\4USQU%BD;!F&X8]+PEDH %09=ASWNIY.$84$A(N!1@XL9
M59$H]MT+,&!2Y'V:\.P*,J40^"5#S;KDY&&?1@AFS_7+OE6@4]K&O?KQ11(2
MBA$>Z?\ 3,,!40 "JKQ$"J(::2@>O#/GF81T?D.WQY]<E 313[^[_-\.O8B]
MB,V?=^>R\($(K"*"P9E\Y71YN?SB"4?3!W9IF)DYTL< C05;HLW;S4N7644@
M[,)SA8-,A]K4/9 !2&7!X(G-!EA%=NFM^F,<5+$>!J1FMW8]I>-;X9;@OD&T
MOSPYNB$%4W"Z!EH^,#Y8A#)@((VL;,!U>+0>)3(*3P3)E=3?-I I&1:P)@J+
M!ZN>(H[%7R#:BO+[MQPP"OG([QJ'S.$"&"H QES!F,A^_#;H8@&8SGU]W/-_
MWUF5;AFOK'#GH",W8_6>M2G*OEO\)26P=_><5I6\4Q1F3YVV-6NSK0*H+#9$
M/U-&*A%XQP#J(;O28XA[%'168\5<+*LUP0!$2S)H/B=>;V\P(.($C-AD[1)]
M3EM2,7-L*K3XS+KQ#F*-8$0$(QNBMUPK$11PS#A#P.X0,:U4%2P-^38BC11N
M[%(L&5 =IHN$SN\1L/'"J!)=]VJ-WEF0,K>AJ9,7XU\[$00,@DSMOT-7B100
MPN#YR]5>8W&94"J #QU7/?>1'2/QG_HT@ &A3KVLKO'GE 0I*M7-MM>MEG'@
MK2[N?Y@\7N\;&@.Z!Z/_ #-FCE!<6DP'*W$(5*(?/+HR2HO1.G+SGQGBN R!
M(Q#C8X;*R9 +)I@,"P"M,L.K0EF8Q,.\CE]JVO9$@U $7):XN?G-QGG?2D1@
M9I)V-ZNCUEH9=7)8H>>NO7%"F-T5B6@F"8UOIZ.<X9!8$("S)YYO!T0(9+8)
MYZ1T<92#8+4P[ROIXMY0'B#! !&4Q]7B8C ,PF!1*X,'OAIK0(J--&L/K<9O
M$PI9;J S_2.2[X>C!53PN=?7.,3&(H V:(!7B^.G^^A*A4#H9V4?C6N09=4H
M7*IL\^9CT(:@3.@R?'7_ +Y>\.UF"FWO3WZ.3"7D"[5"'61IP&(504$,+,"?
M#NA_&P@B/)N2=?.8(C)8&+5,:+H%6&>$Z4Y%[ +)G+C;OC91,*(X3!NF8N"9
MX(V F"<)(GELK7V%.0%9-$,1R)IS#$0#A%L!P(5)C%]V'#Z9+='IF5L2E<.=
M960C3$@Q&N;GL'5"O(!RHP-UIO=MEY34!Y0K';L;MAO>.1Z5%LP&,]_?&]\!
M1 <2"4E#K'M]"\P\U14F"I9W_'EGX 2PR3>&]?\ W0024^=7Z;QQR,1VX%5#
M.CWC' 2"L'?KV=]>'DHBRP'9>_6-XOEH)&B)2A=)HX_QGA']DY%&V@;FAD[+
M2N.Z@9B@RX&:DO'A)8*F@Z P3MY6\B$+%!+B7O\ -_/A9<@]L#AYJ+/_ !4S
M@MH+A-Q'.O;P[A1:'#YU@-^"]XY!2:H*Q<&#]Q5VA'F@:$;1J)\F<\KE?#=[
MJ"5;]7>QA_ "K  )%84=V%>-@C(A39 K>._CL[1S+SFO ,0F'SQ.43"F(<U=
M[7%!)A_$NHE,,'6<ZN3BS D<CLVQZ8??BNF5N5V]'?VRZXM$;NC>0ZW\8)YO
M]\"6#VRL87VX_P!<551"OBG\QWWCAR5$,WRQW<'FYSG51H).9^K&^L;<SA/1
M' B@2U"/C.G(@D"P2"]PE8WR7@-QU!(LP[89R:%]<AT<@=0Z8%[-9Q\ I5%&
M#:- "4_8>9SU8JV0Q1!F!Q.8N<FX"I[H9?S5G L(ZPR-SY/*;^\Y@$.P[ VG
M?YN9AQE1;.,BBOJJF_SG&?<"!4I563#!R?'%L4&$ A!5"KW+!+R\8!=EH\!2
MUFV\-DJ2I"AO;V?EP $!*%V4Z_?:>>"(A7S9HP_IF9??$&A,UU=^,8^GZ<C,
M$2J"LR;@,TSG.!X88HAD1[/_ *J!7 "KZ"O$24$3)7C%V8/5]<#E,+>UT6UL
MXJ!1<$]S]<_ZYB #P,",KA)X\>N/J\9 N&>*TXIJGARR,,Y90%Q 8"*\<"PA
M#"8X&65<:\5 JAL!P*S#8YB'SGCRA"/?<_GY=\'92'PQ^YU81)OE2/<^<_/?
MN>N5G&1<J)2YF_??4X!7 :BTLS%B#2Q-<H^ LL"MK%92E^)%UE,Y@PS.=UN9
MJ\'&B(HJ#L?C+B!HIFH0>@"E>H(;IA\5Z'!2 $9$ZD_QZXD\Y 1*$W$*W"[P
MI>3(\T7@#6'S6-><FY(H715-]=$\\:YY/9L<?2[\OOC'<"P,L]GWQB>>(R$$
M0K>G^?G_ 'Q0S8H7H=_I]C-Y4/:Q]7QG+C>^IPY!*9SE)_K<VXG!\N89:\37
MA-O? 4)1&T 7 KZ>C)Q&]<<P%!R^1]=WE+Q<%K*>W?C;VVRPTI%= 9W8.?AE
M+1A".=H!8AWGOB<27A0>&;:6-14PXJ%.@  N2F48[D-912;""[-;D_7AKDF>
MU*&=S_<X+.M;[Z*^\W?4..0-R%'<WLWO]&<9P P+4F2M,99#IJ<5,Y04M%1#
MUDZQ4S9N7 12F+P!,F+;0<)F0508)F#&+G';Q.@T0B.,;>_,<OOD7E'&L46Y
MR7QK,Q.7["T?>Y_G'Y<5AB9 M7O2^.V]_P#U1Q 3X5'K]>'(F48[KN^#HU&8
MY:C):F/HN\O\Q*ZFDV9C'!?DF'51INALV[] 3XRNE$3""()>A$"KE>"'#R]=
M4%70!JS!<QX-%D26%!\T1*M?,>(94<0@1R_/OQKE-I0W/C]-SA /".< 2N,_
M#C$SS/*"J0+E/7W^.6$4*@,Z )BF->N)R1AHF%1\YZT7@D#'850&KYOBM\-D
MGF;HL-7K7?5^'AJP*&6?C'?Z>>/#JHP44D1C#]>'1"C64-(C,'!6ZEV)I (0
ML,2DXZ6%BPK[&>AQBW9R_OML41'>XUD,%5,*7A=0M?RKC]DZ(HX\1[[3UWKE
MNIP(A#$S#KO@B"9$H^1_N?N>G&A40M6B*H</7^B4&D3 .S/_ "4!5 "JX -J
M]!S8&<G"+#0HH4;_ ,R"4!\<3.E0TZ&]#>IO;;PA8*GW0GV'.^-S,09F<5 [
MC]^[O(E *H-()9BN"37*Z110^:VJ9*6^UF<62J#.VOY@\$-]"2NAOH76YP"*
M*"1ISE&>,>)ZXLU^6+A7'@ZN^LY> O#,688/@Y7"7Y5 #"2)]A W&$-3'%M(
M<N)3=6XSC$9=(XI:A=C]3S^?7F"&2EJ/R:SC)C[\;VQ=/SY3[7]>/P JS)1\
M=YL]<P5[J $ .  O_DT*?>-<Q%>D;GU5F#9%J69C%E48,KGA#@;BG2SE%%K'
M;D@\*11G$WCYGVKN)R*W"W&?I^_GSQ'S!FP=$O6<E/OS:R">$"GTOQX_^N
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M, "N*.L.[#1E"L9W/'(-=KA,6S#/U]^.2*P,P/.?>=-_/A<Q/(&@OGS^F'A
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M&$'M P 22TLTRT@*U'BACF*  ,JD ,JSB:942)7O @Q9;H"GY0Z9:9!KY/\
M(W5KTJ -BOZ=_F/Z UV2;/3/Z+CCM08[Z\9\NC-XD\D$=AE4\]YZ!IQ&(5B9
M*'4\2>3W.1(C+F&/@;\]\4D04D)+NI)H7>^7Y%R4-]-K]_OP[7'0K]1U?\<&
MY'I;\./77U'C1LB-A@32 PN+)&< 4B\ZV4R9:MJ_,-Y2#K%9K0UE19B!P20$
M.-$#=QN;^'L0P_$8W,*8ZTOLQMX7Q8,IXT=L8,;RZ7!6 6S CZ,D>+\!TNB1
M'/A\9Z<%W!EDTJ63*N]S+G@.8H "-2AXSJ?D$,@"J,2GQU_L>9;BU39DLO\
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M$T@=4#62ICEHD*P /(/CQOZ\AU*"I-2JRPEW*:HR(%PPM+"F'-',QHE(P++
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M@QX.5*%V<4SN=.>N]9X,V%1&QI\^KZ@P38V'M?\ ??WX4&$(&'.6(:GUT:X
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MS3C<X>-7]=]UCYX_RC CJ:LO_]D;7Q:#S 64#T37OL_T\[13.W&M;!H#TU1
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MO'=J,W<$(+MF0VO;?!C-PCNG^14>%"28@4--]YEU42IL9KV66W(60OY_ "E
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MQ?"HK0]>C]\)3B 4:-C.LAE^)Q05YE4Z"^#P\/QQ_2MOAX^5S^13KBJ?(/\
M;[X8#P0%2JAT9\N<CFT@$U*U,(:,-TX=45V85"TZ;TR"$X""#\(H3([--3OD
M7S@8SC28$E[Q>R;$DT;TFC*7/>(JJH.BD%OU, Z=XJ?;?Y$]9V>?Y<?M!2 H
MDIRLAQ]4:P@1'%,IE=6MX=IFO/X5VB_OWWP+IQ<B]L6&[T)5B<7E)G]%^T=)
M\Y]\,UDBE44CV0GJ?FD>!)8*3168_E[D (706STU?]WS1WB*1F54@1  4:9O
M<)^E _Q. LB%QYJ<65-5$T1&,ALG!KS:^5L"GN]+'BJ3.$#W$&%1W>+^&"I.
M(U\CV."WG;$?8?2B'8'@WKK3UD1LMR"X("R;YQ3$S,8+\NK?WN=!FT.^TQJ[
M;GJ?SPVP +NP!E;V/0_'"VDX 5 J2KZ_U+N6&/EZ/WZX.0RY9*O9%4B+0>G$
M^-A?'!_#^UW[X+DB&>!)=38P^^SBV\>1-$S:,(0;"<)<M.5 14F'1./,@VT&
MAVG+LN3D1'8[26Z_9=-,X+BH%.JMQ#>NTZY>*DJ^0@0/3UZ\-N&M&CPT!&D?
MA:JSA?LR7!BKDZZX=4'JC*QC$M&8G>KS# &* ?%;3V4]%-_P(% .U0"=U6$X
MK]+)?P*_Y3G7O9LG2#2=_77%))C@%6C 1[[^]@@3S'@/M0Z1%<>^$L,.)[4E
MGU6(,[19E(AF#+[2CF6<1!UJP'S5.]].N_$O@$W\7K_O>]<C#O, E&O76TR>
M<;P9,>\H8-"Q2AWPP*VH,MEI#0'PS9(K0B0," P!S_GCF5:F/JG\_P#W>!^E
MR$C2X_DW9W3@G* 1K0#<?Y\S.3RN,P+H#S?QX3ASCIJT5K/Q^&<2Z%&PQX8O
M\]!>*'4+H%@] 6: -X'8&X-#A1$Y2H%FG]3((B4<1Z3X>&E2$$5&/)1_+? #
M9(15D>MPF=,Y/M\U TF ^9OG1Q.WZ>HT%V'X%\>V".62T(0 &"7<##E1:(!,
M)+ A6G[79-2Y#(%%9[V,4FKQ?F*$Z'<A(B]4!U4DCLX^F/@/+RTK0@GHA224
M#KT%-D(@$0II!!+-Y"**N.B(\??[=< ,5??B-@=H[:>G"3R#PNU)1#'I? 0X
MO-M>E80JS#?S<Y1##YW5X )$KWG7%/C,GKVA)9![/;& 4,(L$^BSTV?4ZHT!
MW,VE"U-'Y_R@"J*B3OV]=\%L=RR<9.R_@WWC[H8-=5"FMUUO6</,R<C8042F
MJ=+P13PTH<J!!?MIP@W*5(# L4KNH;\\0=AX27#R=QV=_+ K!G5&HF:ZR%PX
M L91T)GDC0C>U5K>-&")'0@CH!WU&C=R-GT4%7/O[X1H2RK)( AU#Y.&T8(;
M60FSOIWPI^L4$ J9CIC/AXJ%5D(A<&MW-,NX!P90%$@JI";]J_7)%X JVZDC
M&!>\CQI NT6P)? "0J6@$#R '2@*_P"WG^=0=X1H'8=/^3SB,GT%Z:SP7TC+
M'_VD$YY5;((&YH(VY:#,MI&%(W0_Q7G P%2DH-$%!84[YFIDBY,0,) 0"_\
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MXON&$2.E<)<&<?&]$X(XF\M2-5BU(G)Q_KOM.?F/ZQ&*NQ1) I9.1R;BF!9
ML)>-&0@&=RHLB%7]2C(6:3RJK4"4Y%1N&D <D@W0!$G#P,V'@!_X6-S7PFT1
MJ'*4T7ILGEX)U]@T32!A]%OG*:,A?C2XAI0MZ.)WB[IT:BMQ5-3EA!$4M_05
M*ZVCUQ0\(D8:2XC=H&\WQ%DMDA%T^F5+,+!I <V4Q"7O;C#QEFL^0# H]>3D
M*Q;0@'991"+HF\E#B8K69P$B"?DX^=R1/V"M0S9\>' \5&-VB- I[9IG-,3
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MF @AKC8C/HSX0'$QL# ,_5)EK+PB)R=&%(CRF+%1&(S;##]"<_<$]&X[@EZ
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M3W%$0JU^EK/KZI<DX.B9KLO(%N( @HD5,%"XS]+U3LT$Z/5< )DK@.J"=QP
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MQH^,[E 5%Y=ES'5/=_\ K[=WD+F0I3*GQ_?O.[R&UBT$;*6*7LGV6\E(%(Z
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M,DJ""P+,",4'*=F])C A#KL+:U16),) "$/VI//.$,-H%19_(=?%VO!^.MZ
M8  OM3'KAK:>:R(PBQ^WP,$-<;!5Z1^A43QL\HBNJ(1>[.Q"0%=_D"%1(T*C
M9\<V*VJ+L(%[#/&:+;@X_'W$,!U]%>&]1=3"NR]?RD^ZA%#%ZC9TTL9NYQ^Q
M]\4"WJ"::([PX%BR#0;>SO\ ^S>28ZA09*(W)+=S5Y: ^>X"]]>UR^[_ (4"
M>P*9#RAB0'15I2C>_P!P=V(#R)-K&J>"0&N1*M;P$* KO.6\('9 \. P
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M^=N?,[!*#'2DE55N_CIW^G^N^!08,J>](09]U\L2 83N_@_W#\<-N\YD,[%
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M#JD:+ TJR_CK@X6M"Q4-=)&-^56<H6I0JV"58'&,$P"9<R:E&PYX8K\0B"P
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MJ"-[!W1TZL,40P G* ;X$\X]T P:+1T==4PO7L9[60B;8TM;N/\ <D*QQ-
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MQQH&0JK/CO\ '(Q7MPQ$)%G=SVB\!PEDMWTW$:>)-X.#8-0-;JFOWPR1] #
MIT8?]VMM%,_="NWDWNUYUU_5.X3?^*5^UXF+WU<*G% 8W!"/7#\VT (4$'CR
M[?GE9#OV@(  N@1MI\OD#<90@BB>J/WP1XM,9$R=7;U?C>'8D2Q85%T[!YF&
MA2:%P!-6E)V_19R'W7RI0\5*&Q0WBD]'FK2H7<.@#^"24+T,H -"E* X8+]
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M3Q ,3.)ZJNQT%O=(SUVSN(ABV6:1>YQT3FHB "8U/A<)';04:SULJTWKYO%
M&]H2# 70 ++B\4=1"AT"N[]_MPY (G&LQ TG2GS-<_(! B0J:7X1CY\SYP:H
M&7-5[\?&\!A0$.D2C^X_UXAT4-CV OG)Y,)0K8A6D-=?CA18KH#I:$P3/:H7
MCF!K5 6(,-6]IV<OK"R2R@JP*]O8U.#EXR,>B4"O;[YP]$FH*PHMM$8B&\-L
M3B(^!7P&[<^YS04@@>SL#_TW\(N"*0Y?;"&AY-[XXJK*"5R"!:D^,WA[,NH
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M1=M+ !62SRN%&I8#$$40,O;O!R1A8HD@!2%.G%Z[=Q:1=E(!( \-U*/#&Y@
M"^2]<"3W!Z+T"]%^/QQF2$@_J$"7(:/U.#,A:1!1$B(G;N><@F%I $\SS]OZ
M[-:K!V/0'-QPTG'?$:56)@TO?8' + M,,)/R_'WKTOLMVI!>C2=>^O($>&,$
M%\JG7<F/#C>TP4H*4$"X;PMI?I!HQ!(1D:=9#JZ9 5Z 5[$0?.V KQ!F1H,K
MVO*@\V6JG",Z*KLXJ4Q05&S).>J+$"5K4G6[D%3 ->ZJ2G@$] 01UN/23E M
M?,*U@H((9G0/@(90FD0"$:./8/$$X#V+VUW[Z=]G HE(GMY*!>T99@<!/8 >
MA(J%?*GR\ZZ_]:@485$ ;T&.[U2<;(HB5" R=3]K^>GH=I/)Z$/8Z9W>)NMC
M&0#+".[?E)PKXQ5&EBV8';N'!S#/L2#'&[7)APX9Y)=-D)\1D/ CQM.3(Z'&
MO5>FQ-0)I=,J59ZH#+&5P9XCB*M@J'AP6  &Z&$5(4:F-HS]$\[YC4(;JS.$
M!---D (<5DZ6W.7&UY=BHX 'P_2<'L44JDR0G2.G7._^*G@11/94]D@C68"(
M92LL\]-(A3^NP3E-2@3I8XJ+;*\+'EA;YH8",,=ZY<55R4V#7>&[!&<4'<6B
MS$8(/RI25[9O&81BW4$%1.^W@?OG1(82I^?WO)FO1%-54M%(NT^.#+DR,F(A
M!&&?1P8TQ:>'0*->_.G$M$PC@./$'I->/! 6(!JK81T2E(\O3&XP'1H 18-"
M4YL-/ .*648U"NF\-##K;*Z0/T(O>@)H)9B_83 OW_)QAYAQ,RAHBZG?UE_]
M4RP\.P@!\'7.N28A>\.@2%GP2]=:@NB&B; +BWP*WXX;;I4 POX?OV4KQIGA
M1WZNT]9UO6&"8H-GK72 2LZ0XYB - @N@6-\.^!I4]%;5!4-@[O:'+!AGK4
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M# P<=OX[/M^.-<RS 7I2H0/;>Y$G\8F%;%CM'<@C-$F70 QM49A52'L6%5S
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M!4H"E2.@""!SA S4#*D[1)]@ZX-9_J8L2QK<[5I0.2%C$$1 D9OP]F<*"6E
M\[2P)YNKF,#F@I1W0U^S&+>^(YG[W48LF@JUGF\6,(^JG5HU+Z))QV-A!F\Y
M%1^!=VI%VP^W>I^;^.#%Q]3%C.N[AWTAQ_)N W8V?E_O>=_("8\OUOT^O*<
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M(*]Z <'WUM&7-RD?'-^3P^(EFA!JD_H/0:"3-IC)C6<+-<C!3M)A) . F<L
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M0 !45$#:Y3WI<J&A"2P$$ G$\-4+6H2PZ-. .P,1&11PF2(MKFMG:?GC*)+
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MN"T!Q0(@](Y!7)W^KE<U#[@D1S1#A8 H779CU7ZYWFC*A+K8E9,;G)K;[@$
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MHUN_K\JH6<&I N=QG(\V U)ZR@NXVIHC:Y 1"FD(CO<J)C=:=4:M,(!ZMXB
M!- U\?\ 'A]>.LK+-X=[.ULLP+QM^AM*@>GTI+?DX7UZ (AB@RZUF\=/ULZ
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MSP""SUOR^WA950,E%KBK\:>:AE,+)0OZF,^EG""876QC%3O1KBO&\4(!D.!
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M$7>@AUOKU^E<9:^F%(*^P?-XC(I1]&$B;/BG6]\0PQ@T"0"[@P?M06$+$X@
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MB<OX[<) "C32GS\\5-,$NTFC]GZC !474 *AL8F\)'LQT]"U=8YG7 QU*#(
M'P?Z,*H),@L,.'IOWPUB9O@P4OP#4PG%.U&+@K\#>GV:TP#0(0%\77R\T05S
M&X0"J&6AH<P!?CZ']IGZA@1@R"Z*,[WYXN[40 !,$P*A$<,1!'@:#Q1[O[\
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M.;3@#[*:.B28![<^LXQ64QEB@BE'?W+RK-170508)T^QTG 2@400^1*)^/\
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M+$Z(2:(FY,ZY>+!I1P3+W#]^&2+Z1J" P_?_ #V)K1C!!<L0^NN*W)GHN$^
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MM125K6=E[X)UIJF(- 07$SK@]Q'$X6(7=:_/H:L;@&:)=)G[:=E?Y/\ 5Y'
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MF7_?AB##, .S1"ZW>S.9]56(3P,D%B]AWR:B0&$+""@V&#_H.Q8AWX8Q-NQ
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M@L#V,?\ D&(1/94@>V=<BC1&1SV/1[W)Q<P&7,PHU1_D1KSI3T@?L!OR]O\
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M?QR)C2 (@=(5RKOD$U_THW# !@%/B1X"!4&T51%[,/\ [&\O5BB.# KY=O\
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M+)<JYM@     @!    (&'_I?PC4%Q6C1P!+![3Y/VFH2W;<"<(S^K_="3/\
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MCELQ*!:S0!-/VYB8>0.1;:CT&4V;5B6*:H#HT4A]3C5>X^'@L%,>U[SH2AE
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M5GWUYRSRV%1#<N7^'[G'#& F=9K//_FDX;BD& \D4?AF9^ZB4QPBAH*OYO\
MOQHO6,K;3V[W@_.-ACI4BTO WN!.N!F":\:@(%*9=^+Q HJ.0>P.UF),/>$8
M^U.C'2)GWW\BISD,;QL0.\X<[\*# 0WT^RVI>+1+H O6>SJ^V]<:C[@$BH@*
M3'YG4>(C;,E.HNF([VWP(KP@$P*+1Z!_CF(R5=SX4-^*TEO1'3^@<,>G]_GM
M\]6VDP,*P7KX>94V6-9@+ B=?0G%G,/70-0L.,L?DE)0)HX$H <%?/*<;L"*
M4X0UL3)=R]'^AS%B: GPU(#I'J\F17V:(.B753HY+9&"CM/79[WP"LZ%,%O1
M\']^4.7$@)0!_/\ MG#4(B2*I(26V+_80''-9'<2T-V^\43VB9-0KN!9^.=*
MBU 5KL@/:?\ /-'P]&RAO203X?>8CWB4F_;1D_8Y/G"86)!D8>WFOWJH@AIB
MEW/[< DL1)0V*3"-\^P1^IQ.!U&7\G%NJ<H@+HC#RS.0%C0DC1(39_\ > ))
M-*HH:ER>O?$AN305M$'KJ9>^%9'0U-!!+7ON_N\ S,[(#?K.QW^.)##R)( *
M@MM1V3Q. K$7H51&P.) %)](R% 2;Z]28J#?0@D6\Q[PX'J49BVZ2*HQX8AF
M2(DT 3=3Z)S'?V&J6*OV]H]>LS]GZ1]"9<N'?)>G5!, 4IA9/B<Z"WQ""(E6
MC^>N+<6.0&2BM['\PQJ4B8ZA5D&-SXP@D4A@J1*RZ^?N!Z+;DCT#%OWFPH?3
M$.QQ P7;/J\Q;YYA5J? '1W#E.$<BM@I2SN>_P"AS%B?YL5&^ RQT-?OAMB1
MHHVM:K'V]7@-T#%VT#SH_P#3F@,0B#7H#L+7^_&FZ -C%#E#^_\ $F9%3N 2
MET]9P*C95,JE5<1IKTWA&=@#2HF-6,3IV\ PP>&@@(*2_P!]Y+4<878U]#_;
M..4T=8!*C238_/"4'A#R%)8J;W.2]+U%! K*?,O[<>WC@U@CJ)\/'WPEL(0)
M+Z?;Z?%"&B0FG497SB+T 7M\D[Y,S"%H#\O"C"Z2)P)WG( MT!6?7UO"M-F*
M470$JL*-S[XCUSJX@LGR=NX*KP\+Q:=!VU3N/R\ 8I8F3Z40!UZ$)Q8 $ )C
M$_?\1_GD!>U<8XQ%"CI]KP]17TMC"D1"LF3E62 $,1T*#_>/'7L$.CLO: V3
M(WD?I"R^WL,"1GH<)-(2D3JO:T?Y3*?])9+BY#@1CO%C*@-(D[!IEU.)BV#8
M1,:FT3).^&T%*% '=0*9[MG'ST%Q38@ 1W/>,VI8%*Z 0^@O6<JCP4=4HIK>
MF?'^AS%C*N!*DE&D(6)UP2[#>\F#P(7^UX@2^85 >K&_!?GC!!F([:$X'S_9
MUZC.D10@G4S\7AW0[-)]_2;^>^:%'9!K/=H#;8N\7NZD.GM':+5>"I&SP36)
MP[&;WR8"WCE[5*2?%X;3(!R#)F(!$.$X6X)87X>!T&'"M6\-.FD6?GJ<[#;H
M-=/:O_V8?(3 +4O(+,8\99,)W(FU!"SC:%J6^HN_SU^A2C$)T13M%T^/OB(.
M^*^4%_;E4-;+),C$P@FWS:(T[%[9=8-[8'%"8CL7XE4+UX1XMI'D(S?T)X\Q
MIL9A08J'EC/;:H '!/N+B6'F:/&P#(DD[8HXX9;;QSHH NGH#.CCD)Q8!N#D
M80##4[NU.&#T.,O]CG=_BX]&W3MBWX=_!QAMQD$T1:J8(W^'G9V)Z* $6[-[
M\XA=:@:$A$?8_P#&4:(624E'[,T[SADYL+Z)$8B9\<=\7,A1JH"B*8.C_1%B
MQ6+<V/M=O97N]W;>)Q$.0(H$1.Q.9Z7;5?U 2@T/?+VTJARJ53I$3>-NW,9=
M40K!AUURZ%TZ.#)$^+<J\& F0-@D5TUC@@9H=S/A,2G0*[^_?,VX640)KZ_8
MXNTP#;&*96;3X+V7!M7!D7;ATO\ !.*\#; B%&P@-^3D1:9OT61!;=XH@MJ)
MGT'R&?=DX,)[*@@$J]%\>&O<!2H# 7M^.-)%1OQ.S]_> -/1H (*66Y=)P$,
MXO(1C[)B=7;P&AY**2*EL^OWX.\@HU!C58(^5YKF;HJHL"A1 ?LX3_PX'OI@
M:8KZYK"'<EZI4.L3<2G)>?U@H^A"9UO"\UCV@.P6F??SCM2Q#0HQBOM [ <X
M$?70^2T%K,W<[X^7-(+ 3"F7^>.AB"H0+..L)59B0E8"]U!(5FY\<+-=]")C
M//\ Y]-YKDQ@2(O2===G^_&B63@$5E6MU;_?@9C. 8<0$(Y_HFQ8V:&"&FJ=
M!1D(3XX=9)22 48 7/.CBEBFJJO\]\!^/.>:AHPJB?B\I;E+2A8$AV,^]&LN
M@+@0"45Z3\<2 H%V!$>G),;YR0]@BCHSQ.G]^&B.$E@ZD';7;'B])4HA"8$E
M@3PX=*- 4JD0]%_F<)$"@(7+'!7IP"=>!S!$(71'25. SKB7S2 $#3Y]0%O!
MU-Z*3*'[6<8QGZ'&@D#ZJ-LX0(&S2:91U4\WETC2$T* *:(R=?9!F'Q, G&?
M4_<Y;%ZO: 9=O?WXFI]=5$#40VHF-T6.#=?4!(L75NUB*JZX"(ITA[/<#%NT
M B$3MB?PA.4KR.L[4FFOKM#'B)=P)ZFZG<[:<=V3N7H!H?*1N&<3544*+0MU
M)A^<XU>>]TL(T)C\!.1!\/ME!D$&-AT\/6_7 ,U  W?^O,XO2.S7 2KD+69P
M30!1($H^3I^_]$V+'.5^9!#BK_\ /GDD*JBL% K;W4^>(BB(G8D3\CP8X'%(
M+(W)]O\ _.",%+ X32I,SR\+GR=,2=K!;^[PG.=0Q[H3X0;7YO%TB#6F+U%/
M/;;R1U#8J DV7W_C1\26:E;%*D#\7. Q\*MFC@T$4S\\*U20*4&9J*["O?-O
MNM48WH8D1/'>%G$?*0L0@ @,LB)*R_+6EK1B+W7^RJ#8W8-;BJ#G9UQR)YG3
M)J(AG^_#2J&DODMG*/S[2)NCLA::;C_+[Q)0OV-HS#JE_DY2"<+HP((7LN?/
M$<!P):#X!H;._.R_3$4Z55@5K)^+QDX81#D^-Q&=K[PL> <(5 #0:,_.<% E
MHM G54_+&%>)H4+3*T: ]!D%)ECXFP*4F)?=R'YXTY*  5"'L?F^=<D=*Q^@
MW[XW.ID9HV;R**<NW_G>==?Z)L6-*4@I$H-V=@?SP%P! "AJG"RO/G+XP3E$
MH-L"ESYH-@E[MO4)5H_4A(H##YXIGP1*]\I=8@0#YZZ0QVYS(BY@A".P(5^'
MC&4(Z!\"#5_YX,&22)%^W?[]?/"CY$6#+@7L]6\:80:A=[P%=W[> X(#4TC#
M*'7MW@P8/2,6IF 4$9\B&LY 2P)Z*56Y;S%Q.8V !7UD(>5".T:@A'4;#3Y.
M+?JC*T?9ND/N36QG]Q3L%1/ 5[XM=1M5I.C/.X#\\J$%#8\UE1W"_?(?0Q40
MQ7IGES?X2/-K]E@._L<_'*;<L&0**A+@>0G4M/)DJ84$,3YN%%6D(@)^@PI:
M+V\1:&7!H":%M1*=/D)T8IC0G1^7_G_1ABQA'""I2N0^^=4)G#"KU\O'W.*3
M8PQH12>]S\\8I^_@P:'V>?SQLZ@9O@0+J.)G>*LH!" #2X(+,X@\35I&]M,"
MH7WAI%905:B=B.>G%4@, $4A"3"V<^UBM?YXZ;&5T4O8?'NAQ?)3.2K0,OY?
M.S@B):#00T(4[L.5.540(4#03KK3X;0W> XMZR> 4Y2?!L8L"86WSYX.<"0!
M!8DPAZN\".3=1#, N=9T_/$E+24B@+7&TV=]<7.QF&P1*\5^? P+&I4$ZHJY
M?Y_E,F9-0H<.^=\:&<;V#4C:L'3[QJ5:LLI%G&C>MY(9.H(B8@!9^V^\$R-B
MO4!$I'8:/OS3X2U1[@;'.H7S>22]MP:B!T+4V_G_ $88L2I-=J<]HS3?/6K$
MD;,Z(V]FK_'),E$:, '+"C3U30D\2,ZX#(68A7?,U(ZIG\<%.2A$ =@&:==Y
MR8!ADC#03'IQRU3!**4(11_;C=G ^2 2$'QW7B]$B#^__P"\%)%$R$;M2/W?
M>)&GIG*RFG'J.\MPB4&KH54+R&]<5*3G*)6(14>GR'!Q1R@'%D#&=4XORJ0*
M6,(CA'O>7NA^9E G!X *\*'</U-T#O6.9\'*TPVGMR C;^'F<-/F A*KPZ>M
M&GDX:WL,&@5/,R/>9QAD(=@83I%#[L]XQ;@\R$48P"?(7D&;#L!6PE(U?<9E
M7J0$-.#VPI^*A)P15*1%FU L+RTJ($1@(+RO<CP:>@  & !UKV^J_P"C#%B:
M<0<.'T,>)=10A5LMAP\Z>+* &&E4,$#-#AQW)J@M-:B=?QQW48D1!-4%9X?F
MHO)^-RH(KVGQWRTDPKHR*F@.3/.)T.&A*7)TK9)O3S Z^QA!^!43KEB@\! 1
M1: Z]]Y?'; &Z4M:[P]DV@;F$157^@_&<%3R[Q0@$8GFR6R :Q@];E"(+A7H
MMXB0":42EZO_ %ZO7*-@/8@?V#P(6R0) Y>AYW[O,@:5 K0IV2!V\E<TX[B%
M*1(LZ\Y9*&<]T!0(.M@T5X#@1]\*?,560SZ/.&"_0PGRS"/V6^4JF0I1$Z\#
MR)RP4-0H(:3>ASY^P8Y0!B(@P"^:[N?Z.,6*9-[:/*V$]G.D)^98?\0X@%%
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M*V7T/=0$R1>^-*@84L )M0'??9QE"5 .2 =(ITS>)RO9!H$TU1]+Q(;1-ZK
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M TP*E&+:_1$ 8*)$$1-$<1,1Q. 7V*Y*&KNJ?"_(T&J02BFH!?IUY0V"._\
M5XG0=2M%91UX%3\6\:E8 9WUU@O!5KVW7\*F!QW)A     ! "    0,."\D
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M4*0I8E&0!AE+NG+0EMN0OG4WXL3=^M">)[R;)LI5<9G4VU#KN6X^-(%^O/?
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MV!VD7@)D[Y'JH >/=[AZB=T[QZP7/6AH"M>*% O!NY;&;;0!2@.1XA!#AN(
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M/);]Y):M/K6 +(LZ$T._*Z"LC=1_O3C_Y9*A-#P"'F> ?)\)=T#_JOMV:4-
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M77#DOLW$\;, =H.?6Z*\4*=QN=,-@ =TZNBQES06K9O\5?OG7$&$HH@) M.
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MQ^ X^J:28Q".(]_F!->PVDI6+8^KLN0"QI[>DM/-_:CI736.3[_:U%?E\JF
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M[O/'ITW ]T/RUU59@_2*SN=2?/K5U&^L+RQF61AD."2:9,(PA2BCF:8;A&'
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M3XVI6ZEDLIJ MNNW</-A/DH@:^O!>MDH$#M0D'L?65"[5^0_:*I_ 5K=L7$
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M>N#\\1;-RY-HGG_.^#@^?@\5'VCW8T\0'P?BY''ACEM[)NR^LB(7.5W]:FG
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M[2$$TJ=/+/:)/"/M?;;3LGXW9[6%?S.(;5WPC+O##I)G_$?:2QJ\']RVELX
ML7.3J<]SQ]MN.L/KG8VG<Y[3MPJF9F ]K)D:\T9@DG&22!Q+*##58P=A".(
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M)*7^21"(*LF9DGDN,)G,Y5=C]3^Z.F!<Z-QJ I-F A^)$&\R&ZF!^7*T6>;
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M!MAE@EYLA 6S6EKP38OKL(/L0]=BGQX(L\BDT,)UK\!63M ("OX]'%P.N^I
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MT[1D+($)KA#$)%>0$(QAI9'F%5>%PJK%^VXN7@/M3;?QL+YKOM!Q@;9=/,-
M%WWEK,FA+26VB<_NR!IRV;R,2. ULZ?#@1?,RZH?KY86[WBGTED:=Y%WLOG[
MP_Q1/CTOEG3YLTF)\7DQF[U?+,V5R 1G(A4)U6LE$QG$2<8@DTA 6J%$)9@H
M7#B5>G?I?&Q+Z49V\,M&^E]-^HFM IMD,'\:'4"KA&.^7*?!L>.B6)!'YJ;
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M<].7H0H27DI8TH)AFG&$L-.A>!PQQT:]NYP:S37M0,7F^H?2CG%??X BDW*
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M5&0X=ZJO[MC_V AJ(U<]IT0GU3VO=;C6!+HP&)XV43B(7\-(,C^W$;![\M^
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M5_I3C"M9;Z\GQ0WXU(-<.-^)6 EY>SL<A[]$3T)>JW?\.'K+_7=MHNL)T\R
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M>C]=/GT0$X84S7E!8"I+;?>5QC,S+TJ8YF4B":-)5EB%S1^U/#;KK14.&.G
MAW?VU5OV\>J?_%>A$'FFVP+@5)/EI++>95CV6QNL\LI));K%5DX_X+FTF$OZ
M-Z:T0;<"0N=BY<W/W2.M-UE=^Z!-@/^'7)E,T'-Q]^.Y7@8?%^:C-B^^N8QI
MTD-/%.8%RK,<<I-6%=,\A_J+D<*DPHHSP1%-G!)B#"7XV(BCD;O.8RQWLEY1
M&F2H+X"EG3+"88UM\P0L0]+Y=FP  .M%_?&V1HD!X:;-S1_0FAIXX,):9D,)
M/ZR5-_"0'%F,0_=_997!]J^/T[E$DYR7I"@0@8*Q"F)6I)!5%$.6YC21.6-%
MAKV*#'9[&=OB<G=0.*_] 1AAP?W<M\C@'K"73=8@<$4F;6^D_&L,GD(B3(G!
MO99?I\+@*>7.%A@\^;"?_?M)KLUN]F&Y^#X54KSY^;OFH@_S#_/OFFFF\Z^W
M?#W]7ONL3'*6FJ0B*51"[T@QJ<LMY26D)*]4J<U;3,5DO5C3F9T%:]^U$TUL
M!8CWY=>2 VX.9UZ,+:(MS^E&9D"W0KN9H0[C8&=(QD$W,JL88.M3KXW8QN[[
MY?<&Y5_!5GAP>QEF9PO.';&@-IA#]X-:4>ZP'-I!'BV$LV32"<JH0DG.8*FP
MWGEG>@_."$<P%4E!4<I9B:SN4GM[^4M9,H__6EQOR:176#).<+VF)=.'5!!+
M)HUFR:2O;\FD+I9,>J4E<YB2X</\_ED:/^GYU[?T>:JM@NV5489(5929ME]0
M@2"F/(=577M7,(Q*5DE:E(YU*RR['AM-O/UF]J)UT=;%1F1 5RO9E@J;[7R6
M_\VYRH7M<-@9-'% CDPNIU*_:*RWDH-6]"@7?.Z(A2Z08=O]T.4R'&$Y43S#
MM04_3KOE_.7II4[?_TX^+R6?UD=(^N>9K,^2YN+VR:31^L_Z<VUA:3G6/Q_T
M=W!MSHW^XV7Z;$Z5)I1CP;D0,,^HWKOI+1NLD.20"%8EE"95B81'C?%0\EG-
MV.$KCW_42]._Z2W=5DD@.EK6!$D[ZKD19+"QM://08=JH"O4SL!T=3*A!*U6
M]1AU];H!&\WT3T:WF^:R8*->./8-#7A0;@XFW*#,'1K20UX/WO[5:;YNOWY=
MUGSWL,D^=5LGG[I7VG*>KFL7K,<EG?-O<C4IDERI BDHD3%F*T(@$QF#4E1I
MB0BM]&\]TWJYR#$V&W<K^W$*KX4"="L_6+<*>.=_<AJM?MH>< PBL_11/J?=
M>&P5 ;?;\=CI AX''0_O_%NQQN6U\FV%&Y]K\FKYH.J01\NI^=?*F^6#04^>
M+*_F/)8P8S9+N=T2?6RV2%.3E<E<=7_6HI@;[?E*/LCE;XOY^MN$RT(@K!1,
M"BX@SDH*&<84IJ8VH% <([LS6L_^Q[9DM=("X^P"FF3)<@F>C*@.9.@Q#A:+
M4EQT(R]&C? WG0.86OX;L$'<J ",#J!5HLX@]5M\Y!V6G[@C,-"R$V4DW!8<
M?QQ[%QJ/9H=;8/QUWEM8KFC&M_!<DTK^[6*U7K6';";,_&$IG^G4.$G=K[_)
MY6U]='VJM! I9$&52""IE(1Z;2D@E9) H5"&<U8RH9S"PZ\5:&Q+3BOW=K*9
M4Y%: ]#FK@:-*JXUZZX<-KO#K2$'(_IVJ:V94.MR SK:F+.K6I^;SN@T.NU7
MD8J7Z# 4T($KY%TIU,"5\\) >%Q1+U"[01W)MDO$SLEC>^\G4)$(3#%,LI)#
MK#< L.*4PQ)CQG&:46X7[.0OPMA(N/9]4G7$7YT4JG,G&]:OK&]8["@W+MB1
M2?:"G]G.)MUI$>6&UA_$(5S/^L08@PN:!4R6KF@V+?G1XM_D7#<],S<'XFDZ
MGYI&3>J^ULQJ$P[(@B08%0I6LF(05\9,U1_ '*4EPRI+";(JX^?4Z]C(KQ6Z
MN5;=$]N-\NP@MV.YX$!&)K8NAOL2;PW[BVDUG%G,":2@Q&77\Z!<Y03&(3VY
MO>S'2&\7\]5B-A7-%6:=\*BS2Q:$)<1$J:8HT41$*\AHSF"B.%6:I+*,.Q4?
MZ.ML;/S3GHK/]%IODB]T)7<CH%Z$[7@G%&Z1Z69/S&%RH=D@$Y1C>CL<E%IL
M5#]D%*MW?+WMOWR3LYF);:3SGQ-&E,RY-EJ42G.(<9Y!EA089DQ6BF4Y$L0Q
M8+#;_-C(HO4:KT4$K8RN/O5[\/7SPO6@1&8")SP\/.=/J7VER_Q>DP/[RI]2
MY]A)_N135^2Y8)=CD=EA+/(V8^+M:O7RU 0F;^.1Y?()303/42FR#"+*].8%
MESDD6!9094F:<)XI65IE^HXOZNA(9)NB0$OGD;8BSGC:62CC&*7(K!8@-44G
MB6Q'X9M=>HK'OK'W2T,1=5C")YZ((^[PJ2:BPGXRN43<'OU6FDZ9@TW5YX*7
M6.&J@D)5N<E]1"%#20I3*DM65(64I'")'#_NPHG9!X@0?S1]@$VE\TX4E1O+
MG\#2CIVO0R@RJW:$NP'!*EQ?5CTH<YWH9E#&.:_F(5/T/.EY@C2CJ]6]^K+6
M>\AWBR<ZG4_*(LNR1 F84)5"S)'2JV%90DXK@562*8Z<KO*.NQB;[59+: Z*
M:AG!GXV4ELF*>Y"T/!^Z"I_8IT*.T+B? 9W5/NS)SW$WPY[WG%7SZ)3G_)-^
M4_Q1/CTOEG3YT\2TK']^G,[EA[5\6DU44J5,$09)'4A($(:D+#FD*<I1A<JT
M2IT.B,]U-+;IOI43-(*"/XVHH);5<=*?Q=9NZH= +#(!^('E3 .7D A*!F<[
M&Y02+JE\2 P7G_=P[]_51OTXY>9:ZG8N_J:W'>O/\KN<O\C:_6QWX2&S)!$9
MRF%9,@)QH;<!-,4<(H%SCD2"T\J^"*E;WV,CD6Y9XU;^^J:VU@"T*CBXF3N.
M1#^_1,8W]DG-!MK[';2WA]"ZN$9>C;:#0W\\U =RYK="/Y#7OA]8O1[[CDT.
MYZWOI^N>I[YG$Q[KPJT&-KG_H?0+YASIXX+.;UMGFS3#><IX 3D7&<2""$BJ
MM("4<Y1Q*0FOK.X&+_0S-KXWXH%;!XKI@=""O,, $YFHC8R@$;(^^@9&3'#K
M4^VG!RT'\@V#VD!$>P:]0-1Z&8I>&NUY?3C*O*S#'CU:/.[N'=$>L[V?KCB=
M_4/2Y=U<O*-K.5$XJ7"&2LB(U+9PJ@2L*J49D5"D#>,\5Y55XK&^3L9&@IOP
MH4908"0%6E1@9+7WF#@+:3\OA@(J]HF9#T9.7A270/#VI3C;\& >%9=4Z_I5
M7'S6-SJQ&V?_^[S-"B6%B;,Q(?8/2_DT?7G2ME?]Z&KU0K5>=:C.)[F>*$VD
MK$@HY *9A(0%A11KAJ"%)@Q94$G+PB,]UY5B64V0U\K*5:>M$*T>KD&)UXU6
MGA<)9S2#A"#-XDKS.2&*09Z4LF IJ@A2F]$:ZT -,D8O.T6 >+WQ2A*9Y@46
M4)$DUVMM7D"&1 EI6E4,D2I+RMPM]#?^: VX0/]^;I2<8WVO&R:[X^\!P8^\
MZ!\EWND.Q$8;\$NKSZ_U26'S3JO3)D18JQ4RPC<(OH$#?*^3:>#XWB  'H?W
MAFG6)Y]/>W"DU'0VU8M'N\?.*3*)Y3!,48$ASIB"+%52TRK/,Y&CC JKC H]
M?8R-*C=GFTJ:M#SU^=D-H!N971*5G<'4XI3G>J0B\UHKX W8BNASN',&()<T
M.5<#-50JG"/ 0B6XZ46@/XG-Z5<'3%33*_M^,IK^1T-LZ3[IX6L==(PQ*8J<
M0$FHWJLAE<-*TR#,$Y**BE-9<>%O3>XZ&AOW'9DK1E1/OZ>SX/K8@'Z0#6W<
MV:%UI;EV#$5$.ZS3V2L:6,<J]UM.)Y[W(XA.-I6-;ZY )<DHRZ @>0)Q(1-(
M,E+ 7*@<)8P6*J4NU'#<Q=A(H9;0;>Z?P,UNUE^'1N3YWDW&%,&I^;SN02?X
MB6X&G=KGU3R<U#U/>@;(;<J[UQ?BDUP)@7A2PD*6$N*24$@KO</)F?XPS02K
M<BNOI=/-CVT:;Z5K/60<E_,#[.RFLS\BD:>R/1CNT5DG=0X;4;7?Q;!14"?5
M.XI<.OV4Y[3=NK>\7<ST+Q9-PHQ.'-3J=BX^:?G/_-HD/%Z9[%J+^:KY^J)$
M%%PE7!OX605Q5C#(I- _R:P@HB@H%LQIZ@<7<6STL:?77FQDG8>F\^]FF5Q_
MHW.P_Y(?[X0??$ON>M4AC<Q_ XRF.W%& SPL^887<U@"CP;ST2(0KR??_)7_
MNN7U0?IT_O5AN9CK'WDC2),VY3"13U)6(L%)!?,R*2!6%$&&]1^9PHJD@N*R
M=#H'<A5@;(O 9\GKL/>M#F!?"=>\E8[#84?<,4&.3,M:]//@#I-[R1>]P,DJ
M'848.%6E'T3'B2H]V[DNO?HC_=%LJNNE79O"A"F4$2C37!O B=X*4XHPS"N.
M68H27"%'SXE3W8R-R3P.M<[@9WN<?2TJT0^SVYSD6L+M&5<_2MZ9Q4^#$"5?
M^$%7KY(%_+2ZYW)[GWDZ6,%DTZJQN9H3M::KB>!95BF20T2*4ALZ%8:L5+6'
M(L())FE1$0_G1,ONK:;!\$Z(S=9GOIC#39(/ZE$>P78(['@D)**O6QZY!G<G
M]Z72$R$J(_<A%;LL\LF^7[LF<A\@%@61>U_W(ZR[I^?9XJ>47^3R^Y3+.KW1
MF\,,2+K/[W*E6:!.=K2J$_%T?V\<HCXMUO^0:[UA67R=&Q>J2<8901QQR*4>
M,$PPAPQ) <LR*7%:YD@2IXN[:)*.S53Z?;[<R@96)OU$FP6-=[.ER29]L1LW
MQAMM.S8=Q1C&ONHXE;=N=\9R [;Z;=+9&87TIVOP4YK WHU.-VV%R' 4'1W^
MH*0>3]I!EX'HH!\N'/$[O+H$\Z<7XTUVNN!RFB:X+!142"40T[*"--$VLA)5
MHB@KDS2Q"N=SZG5L2T C:>A2RCVH]]-W-"RC[[$/'<:VN(8LB=R#JW<!Y##X
MOE:Y8S^<KREM?!DOAT+&/8V]5MGBR_KU%"FV>-F-TE?+]>2SL6AN?TQ7$Y)B
MF6N+WI0;,[<V.8-$H@I6N2ISII10V"H3Q5ZK8Z-DXV$Q7:VG)I;X-[T?>UFV
M_BQ&6,L[]GW8^CG7&XS8YJT?#M9S^Z3>?7:E?J%C4^I_'=J3^RT.,H%/*K&9
MH*=_>;5-]2"7TX68\G;/83(OK.[^XX7.V@]6]VI7HWPN/LSUK-$68//:)"]+
M@0N!(*^*#&(N,:RTPA SE9.*)HA45C>OH04;&PW4@H/G5G*SPCUO9*]=.::M
M]*:XN!;?VZ:X;C2=S;G!QFAHBV^CV'8K7JMV YIQ?.B,X\/>.&XT;!MXI7'T
M-A\'&\_7LC!CC^LUMF@0\!W,U>OZ>RV+-@A*/49OF/8]/6A?V$K^QXONY>Z[
M_J.-LZR03&2.,41Y*B'.4PRU=<R@JK*,8B$4*9WR_)[L96P+YDY(4$OIZ(UZ
M$DB[P^:KX8EM21\@$Z&*9"\$8;TT3_8TK*-EG[)'OI*]#WM?_B^>Y"/]88Y,
M-;&8P%F]*FX_;BM.OI%SJ:;KV_5[*4QE2K.C>M'C^'/WODG"E5<B)9*7$%&L
M[?"",UA5A$"9"52EG&0)YRYL$52ZL;',MO+/M)82K.D/P!I- %T#U>@"5AME
MP-(Z4UJ<T;7V/GB=,8M,?7=*25Y[M3<2UDY01D:PKZ@9NU8GL%7J\)WP]V11
M8 _M\!!0PJ'=(L*#>\)Y(D(G?LO"P[+U-*M+2;0F#,HQE66209%F#&+C!58)
MD[\RR0N),<=2.GFZG^ID;"2]E;$I8N)&OR=1M&/1:[&)3(8'L$0P _L "$I+
M)SL:E%WZ5#TDB=YG?0NU\5U1\4F"L,Q*6L*BE"7$9<X@RPNLY[RLI"R4H(G5
MQ<C)UL<VNT_D<7(MS-;%SFYJ>R,2>4YOP @_ET]J'+@*6[>'@0NPG5#NN/;:
MJ8?")-=_VW[[<%X1D8L,*KT)@UCH-9KF/($53BM!)!8RD=<DUW\[SCE<IS]_
M>UVZ^+=6$S@@,)&G\NGT\&\#)=??H'5=<GT/U%XUN?[YK]C5R?7?GF)&^^3Z
M;X>D/4L=+B77/WS<)QVE7*VDO'^6)B9X_O6C<3B_G<]?Z.S.9/6NOR2KB6(2
M"5P@6*I,0$P%AI03!1G.1(6)9&5"[+-3VG0Y-H)L! 1R)Z%+^D4KD"UX,SAT
ML:VA6MX;L)48U"+?@!;.NXAPNB2W# WK4+DN \#KF 33!:G^G)A6+0V8(M-%
ML_V,F4YO^FTOZR)3FU3!B<HEUV1<H0I!K(H<TA)7,">I$ 0)GF:%R^:RT_;8
M6+<I>>:UJ>PB9K>E],0A,H4V$(3?3I[0-NAFLMO^H%O)$XH=;B1//1+DOO]1
MMU*[>&:5S"N:8UCFU'C&EMI@RA(""X9R;3AQ)9G3'=Z9?L8V7X]NMHV@3IZR
MEX"UF\H!X(H\K;V0NM8-X!"'F(X V[Y>TQ7@4.$+S@!'C_N1PF<Y,Y'S#W2Y
M_MG-K&2*"\P6QG%ZEVF'"8%3)!*82D0A)HR;(F845D*OXAFC15(ZG10[]#TV
M\OA\]_'V\>X=>+C]_/@/\/CY]M.7V[>/'^X_?7&C#A?X[>@D$JB1*::5&M1B
M@Z[<8"<X^#-*<B,/Q(*2D4O_@Q*4!S"'I.73A!^1!<@F]W%3)'U2AP1E20)+
M40J(4YE )BF%!"M1X)SB,G&Z^ XIW-BH\&S6R%5="?I0O;T\DGL3W6@(:A7=
M.#3HR-N1[&N-9V06#I$ =#>* 2DZ!MY!.3RH@(.2? QH#U>!*'UX^CXLYE_-
ME81QP]^95K+*2XPUP2=4E(;O$60I22"24B85RLJ4(2<?B%.]C(ZX[S_]<??Y
M\<.;CW?@X?/];Q^^?+G__ _PZ?[QSM$GXB2F=DQZ-5*Q;P6T?'!M[@3KZ)XX
M%F@O"&'=)D[V-*S[1)^R1VX4O0_[W"'>_O'EY>EINOXXU7](T9ZZ,J'-N\S@
M1; F $HR2%&FH%0B56F99-2. 'KZ&-OTUU*"1DS0RNERK74:QOXY'PB<V#/^
M"!>O*G:G 7*YZ+L:J*%N]NR_2(X7>+T(]-_8G7YUP"NZ7MGW[^3Z'SU'<EV0
MM77TS__Q7S:?Z#],9J__\5_^#U!+ P04    " #<@%Q4#*F@I6JS  #J&@@
M%0   &EN8G@M,C R,3$R,S%?<')E+GAM;.R]V9*;27(N>'^>HJ;/[7A7[(M,
MTK$D66S1#HNDD2RU=&Y@L7@P,8T$* #)(O7TXP'DOA$)_)%_D#-M$BN9F43X
M\H6'NX>'^S__KZ\GLU^^X'(U7<S_Y2_\K^POO^ \+?)T_NE?_O+'QY?@_O*_
M_O5__(]__K\ _N/9^]>_O%BDTQ.<KW]YOL2PQOS+G]/U\2]_S[CZQR]EN3CY
MY>^+Y3^F7P+ OV[^T?/%YV_+Z:?C]2^""7'SI\M_<AB9USJ M>A 8?+@8XZ@
MB[#>*FD5Q__[TS]YKH5QR@*G?P"*FP3>9 <\ZZ1<]M)PL_G0V73^CW^J?\2P
MPE^(N?EJ\]=_^<OQ>OWYGW[]]<\___SKU[B<_76Q_/2K8$S^>O[;?SG[]:^W
M?O]/N?EM[KW_=?/3BU]=3>_Z1?I8_NM__/[Z0SK&DP#3^6H=YJDNL)K^TVKS
MS=>+%-8;F7^7KE_N_8WZ-SC_-:C? BY \K]^7>6__.O_^.67K3B6BQF^Q_)+
M_>\?[U]=+#F='T_C\NM?T^+DU_JS7Y\O" E$Y>9?K;]]QG_YRVIZ\GF&Y]\[
M7F+YE[],Y_$KK28X%]NU_N?V'_YZN>3G):X()1L67],WSOY]7>51R^/7-<XS
M;KDY__#9(EW[I5F5Y>+B7\Y"Q-GFNY.,T\GF4X_B:KT,:3U12$C)N8!&44#E
M3'AS7$.Q6:)''XRRU[FMU*Z(W(WH5YC^^FGQY5?ZX%^K!/Y+U2]A^^5&%+>6
MW(IE/]K/=]M'^MV)S@:U#1%28 A*>09>EP(Q."MT#NA\/ICTJRM>I_RJ2H^6
MZ9?%,N.23,;YDF&9KJGW-ES/?N/7SV%)'P3I>#J[(+C:CB%TMEX,(+VM:HC<
MO_Q"7!=<+C&_WFKF7N8VG*W)D.+F-X?0^M%\?AIF[_'S8KF>)"50L")(860&
M56$:8LID$-'13X)(V1\.W+M6W@D%HG\4["W-3M#P#I?31?YMGE_0N4L,V&*+
M$N!TDB2-9$D:)!>,0F7!8]1<#0:':TOOA ?9/Q[VE^?(@'A^NJR2>CE=I3#[
M3PS+<Q[(1>*!!P5>Z@S*Q  N<PFF\!B$<(Y0??C9=L_J.\%"]0N+0:3:B:GX
MN SSU;3*_LS<>5:2C3X#ZA! "2,ADGL-7!N;0C):.QS.=;BQ^D[(T/TB8Q"I
MCHR,W^;KZ?K;R^D,WYR>1%Q.6$P4,PD/60A![E"1X*SCP*+&HKP)R ]W)VZN
MNA,23+](.$B*72#@/7Z:5B',UV_""4Z\*DZB]*"L2H3@Q($./?*1DY7<.N.9
M.SRDN&OEG9!@>T?" =+L @VOYFFQ)%.V$?P'DC\^7YS.U\MOSQ<9)U$GC(QG
M<$R3;(@'\"$;,"I85NCO286!P/$@(3MAQ?6.E>%DW05T/H:OKS*);UJFVT36
MF4546I22T8+14H.B+0&.>  ?94XN2Z&3&0@T]Y"P$UQ\[W 90KY= .4H9U+!
MZNP_KZ=SY)/BE,W,10C!$A.!Y.,Y'9O)1&FL2$+CX8'*O<OOEM9BO2/D4,%V
MB@XQR84')J0")DDB2I,9#$P*BK^$02U)3O'P8.7>Y7=#1\=9SV$$VQ,ZGM.7
M;Y<?%W_.)\5Z;UAQ8$VTH*(M$'1B$$/Q61A=3!HJ;+FU^&[(Z#@3.H10>\+%
MQHMZNWRW7'R9SA-.K'56**1 3)/-4R8XB-H4X-9RS832<;!HYFX*=D-(Q[G1
MP<3;$TS>+5;K,/L_T\\;3[M$SX1S$K0+Q$HQ=%BB)R&YPI@(W/K$A@7)M?5W
M@TC'>=*!1#MV#KWRL,2P#;X\\8M.DYO$ BA4CH(OBL!B5%PH0KR2\F!(7%UQ
M-Q!TG!+=6WPCJ[U67<S>'2_FYPD\;;Q#JS@XI\EA+HYHU]I#E(4"<>/)-3K\
M&NWFJKNIO^,\Z$%B'!D"'S"=+@F^7,2/T_4,)T+$XBQ1K(0D^,9"9#M&,E'$
MO2KU;$L'0^#FJKM!H.,$Z$%B'!D"'Y>AUK=]^'82%[,)+[P880W$Q B[EEQ@
MEZT"Y0.:+"-:/#QC=6W)W93?<49S?P%VLOE_^YJ.P_P3;M+VNDB90\W8IUS=
M%DX1<0R1OBK)._I?\7PP W!UY=UPT'&J\F!Q=A$F_!UGL_\]IT#X X85G6GY
MU6IU2H=:02M],I;\&K^YWA7@0B26F+:(T5.\,]3]QSTD[%9ZU7VF<@@!=X&4
M?U_,3DD!R\T5\'(UL9H7'\CCX46J>NM7 QZM0&=6DJ93K^#AKL.=2^^&C.ZS
ME(<(M M$G%4-;0M"ZI%(2CA=32C\,3IH"29:\HA4TA!BRL!E45B$D%B&N@6[
MFX+=\-%]KG( \78!DU=S^C02Q_0+O@CK<,;6)).-,Y@4%*UJ^8C7$'V.X(R0
MW#+FC#P\^GR(@MU@TGW"<@#Q=@&3C15\'M;X:;'\-E'&(9I00+)$*&<Q YE&
M#38+QT41*>K#TU)W++P;*+I/4>XOS"ZP\.$DS&;/3E?3.:Y6DQRBBRI&D-:1
MJQ1<1;%,] =F;RP9OE@&PL*UA7?#0L>9RD.%V046?CO!Y2<Z_OZV7/RY/GZ^
M./D<YM\F0@1?DMP4";GZAD&!Q^S >H,"N>?&#U5%<2<!NV&CXS3F4,(=&2.O
M4ED>G>8I_<;1>HVKK0Y>SL*G"4^)3KS"R>K5S%PR$KP5%F(LF),/!=7A1\C]
MZ^^&D(ZSG .)M@LC\N&8PO!S>+OH,$<1(5M34[:J0)0L0%!*DP=M([JA(M>K
MZ^X&B(XSGP>*L@L@O#N-LVEZ.5N$]80<'X^,1S"I)% N,*@OLLG@126#\HHG
M-Q .KBR[&PPZ3GP>)L@N4$#P/:F%R(OTCP_')+;5V]-U?:9>$_L3U)FC)9.F
MM41042AP@DL04I9BO;(9ARJS>HB.W9X:=I__'$S4G3PO6UW6LF-^]NU]I03G
M"3_BU_4S^N5_3 HSPFI,P+0BIIRO5<I<0?8N)1^YC/9POV-G<G:#4<?)TC:"
M'QE-1\11KEQMW"DO+/E0.D/AN580V 1TII*_'9U3=,(6Q@ZW.->6W T5':=(
M]Q=@'P<04;X,LU?SC%__-WZ;&"F<E\5 W-08%J(]>@J[K#!1AFA<-D-5;]Y8
M>C<D=)\%/42@G9PLEZ^O7])W5A/A#4>E V2";WT6E8!8HI@K2ZDQEZ('\$/N
M67PW5'2<!AU"J%WA8MNQ8<M$3(C!V@@B<?*W=1$0F8^@!3,L*L^3B0,CX\KR
MNV&CX[3H,((=#!W__.LM0;ZF;^S1PFJ3K7DU+XOER>9CKI.Z6S>K6Y]Q:&.K
MAXDZL,=5I7]R<X4+@*"ROJBB*1J5!I1D!4+)$;CQ(NO@K6'J>_)X<(6#7,!M
M:NWE='GR*D^84T:C5!"-"(0\:XE4YB KI06GG]A\N -P;<EQ&EP-I[!KWN#>
MLAP[#M@2OJD=(\RE*)(&052"2A2^1$<,\&R5TS%:DPY_^G=EP7%Z6S4%P*/E
MV(?Z7Y_U0YS$X)AVW(")F=C'S"!HF4$%3#Z9Y.P 8<"-1<=I:=44!GO)L\/S
M_/EBOEK,IGF3\0BSVD;SPS'B>K7/P7[_AQW>NG(G,@\\ZD]7\"F$SY/-R[SJ
MOKTM+Z=S6FQ*/MQBVYOH D#>"16%3F 4.80*"RG>6 5"&&^=XR[IAVQI":NX
MT?+9HIO=]"O.UJOS[VQD"XR?-1S]GX^A;E^+<;[&T6I%PKW@57KG(FD93#:U
MDI2<UA!B N:]=(KSR,M#A53[\WJ=CG'\B6:H.#<K PA]Q$/F.O5GM6$73.@4
MI6'>@N%.UV<K!F(D54N145B14[ /Q9&'(N<&.>,"Z!#]W@F50X3= 6*>A]7Q
MT3S7__SV7Z?3+V%6<_!'Z^=AN?PVG7_Z]S [Q8GQ6=(I2AZ6L9YV%+G:W@9&
M4;/B0@3.U(,YJOT1M!-Y/2#J(!@L6NND Z =I51[0:W>8T)B*<[P#:[/JUB+
M"@X]A7*(BJ1E2% N&08RBE!BB4I%W<9"/4#5.(%3.U@-IH$.T/3B%%^2R-[C
MK'JC[\)R/<5S84VPJ&2M%<!9KI%AB1!(0( E29F]+]$_5/BS/YH>HFJ<^*L=
MF@;30 =H>K?$SV&:?_OZ&><K)-/[=GV,RVLRFX024JP]M%-PI99 98A>:+#:
M!ITM>9:FC?N] W'C]"5NAZVA]=$!Q*X3+X/T2M9G@*XF/JSRM:=J!&Y#0,YY
MX/ZADK2!//)QFA8W/.#VEO'^ %FLPVP@&[3XC,OUMW>S4/OXY^KY?:Z1+AW2
M$Y8XSU%K<%Y3F))D 5=L!,]$H9_98/A#;^T.,3[W4]6#?S1((#>8Z#NP,V^)
MDU"?$;[&L,+W=2K1V_('&=$JKHF7.3A>[TX1D?8$;;&0?2:.A,!2,(;8)HY[
MD*P>7*-!@#2<\'M TN69^V8Q3V=6-0H3F0P9O+:U!E@%\)SB3QUD=#RC%.ZA
M1A('(.@N<GIP?(9!SL'"[@ Q6_HGL7CM.0JHS?+H"->VSITI()*)*C.1C6@3
M?FW7[\&K&3"_^"AQ=N#'O)Z&.)U-:S1(1^FF(/QX,2.AK^JQNOYVF:7GCDOM
MR-/SL;XI*06",9J4RH,(VJ'7;7S@72D<U[]I?M/11%$=6*$K?-T,+D(,5A67
M:@NWNI58JB>P [2%*8FF9/90MYM!(-?5;4@;#-P/M$,4T@&TSC.H[\*WFCX]
MCS0-VB22<V V90R($B*KQ[3T&4,L:!X<6W=X]OHZ/=U ZB!MWY.\/D#T?0!H
M>4JKWI+11)!@@G>\EJ3J;4EJ<%'7IPTD(IT"LZ(5ANXF:=SCKQV,!E! !TAZ
MOIAOI/'WZ?KX^>EJO3C!Y3E7YRV%)BH7E#89J,\V025'/!6.D++4-DB,+#_4
M4>. :]L=J!LWZF^$K\'5T@'4KF<U;G$C5+#%"0$NUFDM22IR#;B"PIG7QANF
M&E67/$S7N*F!1O :4!4= .LN*QS09I,UL+)IDA@T!$ZJ=PRU(A_3Q/9!81>W
M(XT =*#(.\@O;/JQTJJ+^:>/N#QY@7$]X1Y%1&,A,%Z'OB2*3A*)17*KM#<.
MK6\3U]U!3#=N4[N [E 5=&!Z[C&D5W*O6FL7)(]0&+&A#&T+[YF'H%C605DK
MU5-<E=Q!6C>.4SN$#:N>#O#VH%]X->-ON8JN-ELJ K<M5J)CJF)%\\1S268$
MC[V7"Y<GP5X+576 P,T-TQ4!7N&$*[+9'"447]NS<,' NYC!*A6#R(5I;)-[
MN)^F;IROAC9N&(5T *TK3$RRJ;TXL@*3L7:W3@EB*A)LU((3)[1#VD2#5X@8
M9P3W6#GU1XF\ P>^=HJ:KC>M?FJ1.UE;.N=QGBHKW# I0I!@L#9XL2)2+"+I
M5,\Z:6M2$+9-G=,#1(TSQON)C[QA5-*!+;HA%9>R3,(2S98B9.5X@!@S ^U8
M<=93R!+:>/%[7"4/WA+R23%T@. [@,V[\W4WTMD^L"DE.HG*@(YUT'",Q$)0
M'AB)HA1$FUF;4J<[B!GW3N\0W=XN[3Y(T!U@Y4JKPRW](1$A)03 5,A="UF"
M1\Z!0M$07>)&E59!VW5*QLT]#8B2@T3< 42.<MX4ZH39NS#-K^;/P^<I^4\3
MGZ/P AE82;S4B7%0Q036I8A*D, :U=_>0]"XJ:0! 3.$P#O S7M<A^D<\V]A
M.2<7;'64TNG)Z>:%U0LLTS1=3UCVZ#R+P#<#SGU24,]F*$;(Z$,H/K;)=7^?
MMG&30P.B:6 U= "LVT[?1%0#FBEL1,V( R9K72ECQ! :CPFY<VW>W-ZF9=QL
MSX# .5#,'43GWXL5)LYP'^L;X5+JV.L@##B=$1+&S"UR(; -;+Y'V4X@&KS?
M^EA9G\.5,QC8GJ 1TKN-#HYQ/4WDM%QCX,"N2-<_N5F+I <8>,I^28&01\8H
M@&6\/D'*&@(3"0IF[HM34HHVY15/T2_I>FA)$G^[W"R;-R'$.UQN&M-/@L_D
M$OI8 TU%+J&FDQM9!D2-0HL0,+1QH':C[P?HK_08%#T<_P^BI [<J^M<;0<@
M')VNCQ?+Z7]CG@1#;F$2&J(09/-C*N"-\6"T2S(6D_S-!J5-('>3KA_@@<MP
M4#M(*9U"[.J,C9C0%>DB%.D9*$P& KD34 *+-JF26&ACVK]#V+@IAE% MJ]:
M.D#9E<3;O;99V6AJ01=HILE &TXL1<EJSC:RC-XYV3S=>=#IV2P%T1QM0ZNG
M+\3=,M$I)6F8E9"=(5$Q9FH=A *)N8;.]0'M0R-V!D':7H=FLUS%4R+L('7T
MB*Q7J]4IL2$C8^A\ &'J!O'HP;D<060,-B<EM&]3HG(/0>.6JSP]HO900X]H
MNGK**RTP9B8!,TE%!?(JO<!,##&##CG+^8D@]5C/JUGARM/C:E^%=-X1_$*0
MJT4YJXNFGQZ:!+OG4X=,@.U"^$#)KSHS[@0O%KS 5\[&1J4*$!IJE3C+X.L!
MYJ7SR?I")UJ;$HY["#K\&N?L S_61] 3XU.*@A4@5$L*+G2=?J5K$7S.S#.M
M';;IM'*=CG%35D/H_O8]SMYR'O&H6BW7M9=9/DUK"@UP^66:\.CK=#51V<0H
MT "S](=2]7*KCOPVY,-IXWD):2><T )7,$)_NXF/^RCH)*FYAS87 XJV#VAL
MKHZV'*Q>+$["=#Y!RUVR3-6048-R=&ZZG (PDX23J*-).Y6E/ 8?M\D8!R3#
M:/8V3 X4<P<>[VLB?;["W_$DXG*BK!7:I9I10$>N6GWNHHL%%F(,7 =>1*O>
M.5?(&!TCAZKUUHWNOC+N "!_6X;Y^HQTAD8'801D+4OM1B\A!+1@H@F(V='Y
MVZ9R_PH1X]QGM /'OO+M !H71RY%#OB*OEQ-+&,Q8# @>&U_&8*F:"QRR,EH
M;0GK/+2Y!+M-2R<77_N[(P.)N0.@O,<O.#_%*QT3+28GM0(CZ^16)A1X;S6@
M#-E9CRF4-C'-34HZ\5GWU.RMBL8#Q-P13"9>>.:S#.!%HB-2^@1!: [&11W)
M(].I4;>9<PK&A<5A>KP'%(\2:@=@N.@.<#8@X%(:IDBK?62 /)(M%=E"-$6!
ML$FC%PP]/C18<8"F#3=)ZN2H&<:*#"/X#A#TGM1 !-0I2R]H$\P6FW;O9US1
M=I"Y"&^)F5#?(Y'WYFRA8UGRY*+5,8E6-N8!LL8U/ .I_I8%&DH/'8#J;S@G
M&<V(EZ-\,IU/JWS6TR]XS@Y+5E(H$,$E3X+RG%R^(,F/E]D)E)RV9:,0Z6'"
MQC51;8 UI"XZ@-8M(4U<TBJ@D\ \V7(5783@0X1LG;%&%4YQXM.<=.,6>+6!
MSV'R[N 9QP4#V]N1UXO5:E)L4 IK<U.;R%64%&U2R)D@!A^-Y4:C;3,L]PYB
M.JD*'-@MVE/8/>"E-J/9DE\'X-S<2]Y96[@(4$IMLQPI2@BRD/5DM=V(+;9@
MF^+2A^GJI-IO(!0-IX(.3JQ7<_HL7*VW#)UQ\V8Q7YSOE3I;*4MN6+;DUIDZ
MW\0'VB31.>!D3J4H6IE&P?PNU(WL;P^(AD5CU70 MXVXKO)PC;D)LRP$1QZ
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M& 0CLI+92 $"?7VSQR4XBP9,%"Y;%JW'5G=D]U,U\%P@FXSF4M).T\CK#5(
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M(\GVN(-I!:'6.G_P%N8Q"N@#/3O*ZOEB3M\XI>^=_7 QOY0?ST;YR 4$<OQ
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M15Y*L/2_W6;;[8Z*,:L+#E#93:7O(;^1U?[[=#X].3TY(SQ8X[63#%":6OR
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MY35OU(9Y5Q+'+3AKC;DVFNH @N]Q%M:8WP42WI7"N=6S;U=_LO$U;$@\R\+
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MO2F.,Q/ M)59%P_&DHE7'AV0A"S).WNA?#2W&I7U%][>S5HG$<7A,&P7QPZ
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M^^LG:]KH=&J;^CA7MQORAK]7BXOYQ3GFF1"^\)@UI,++-N[#PD 8S@MF8=G
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M7J,;).RCN>7X8IP:#1_#.=*)_?[^%>AU&)BE"4AQ7R:JR:9&I&W""VBL$:9
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M)7LERZ4Q1$Q4X_**TJ%G5"+'<A>Q5D:"3@:W(=,%=H\?LAV.CN-,HE>!-A*
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M              "  0    !E>&AI8FET,C,Q<30R,#(Q+FAT;5!+ 0(4 Q0
M   ( -R 7%3^R6AS+ @  "HH   4              "  6$#  !E>&AI8FET
M,S$Q<30R,#(Q+FAT;5!+ 0(4 Q0    ( -R 7%2H^"XD*P@  #0H   4
M          "  ;\+  !E>&AI8FET,S$R<30R,#(Q+FAT;5!+ 0(4 Q0    (
M -R 7%1C>\0[)04  ,H3   4              "  1P4  !E>&AI8FET,S(Q
M<30R,#(Q+FAT;5!+ 0(4 Q0    ( -R 7%12-H;#*P4  ,<3   4
M      "  7,9  !E>&AI8FET,S(R<30R,#(Q+FAT;5!+ 0(4 Q0    ( -R
M7%1LB6;%=U,$ $^A)  1              "  = >  !I;F)X+3(P,C$Q,C,Q
M+FAT;5!+ 0(4 Q0    ( -R 7%3M^]O Y!4  /[J   1              "
M 79R! !I;F)X+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    ( -R 7%1-&(O3/A\
M )HU 0 5              "  8F(! !I;F)X+3(P,C$Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " #<@%Q4_S=M?^2"   ?I 4 %0              @ 'ZIP0
M:6YB>"TR,#(Q,3(S,5]D968N>&UL4$L! A0#%     @ W(!<5$5;"ZQX*@0
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M              "  9(=%0!I;F)X+3(P,C$Q,C,Q7V<T+FIP9U!+ 0(4 Q0
M   ( -R 7%2D9#' -VX  &Y^   4              "  ;B$%0!I;F)X+3(P
M,C$Q,C,Q7V<U+FIP9U!+ 0(4 Q0    ( -R 7%2Z/3%!U(X& $_C!@ 4
M          "  2'S%0!I;F)X+3(P,C$Q,C,Q7V<V+FIP9U!+ 0(4 Q0    (
M -R 7%1=A@,WJOH  #]' 0 4              "  2>"' !I;F)X+3(P,C$Q
M,C,Q7V<W+FIP9U!+ 0(4 Q0    ( -R 7%2_B]S,OR0! )9P 0 4
M      "  0-]'0!I;F)X+3(P,C$Q,C,Q7V<X+FIP9U!+ 0(4 Q0    ( -R
M7%3#Z4Y[@QP' .EQ!P 4              "  ?2A'@!I;F)X+3(P,C$Q,C,Q
M7V<Y+FIP9U!+ 0(4 Q0    ( -R 7%2E-4E)#@<! /O^"@ 5
M  "  :F^)0!I;F)X+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #<@%Q4
M#*F@I6JS  #J&@@ %0              @ 'JQ28 :6YB>"TR,#(Q,3(S,5]P
M<F4N>&UL4$L! A0#%     @ W(!<5 +PE4W_"0  (BT  !L
M ( !AWDG &MW86=N97)S97!A<F%T:6]N;&5T=&5R+FAT;5!+!08     %@ 6
+ +(%  "_@R<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
